,Person,Condition,Drug,Observation,Measurement,Procedure,Device,Visit,Negation,Qualifier,Temporal,Value,Multiplier,Reference_point,Mood,Post-eligibility,Pregnancy_considerations,Informed_consent
0,persistent,seriously ill,hormonal methods,anticoagulation|life expectancy,eular/acr criteria american college of rheumatology (acr) classification,diagnostic magnetic resonance imaging (mri),interventional clinical trials after,anticipated difficult,cannot guarantee,suitable for,within 7 days before the first use of the study drug,> 220 msec|qrs complex,greater than 24 hours prior to enrollment,day 1 of cycle 1)|for,interested in,inability to consent,is a us veteran|meets,patients who sign the informed consent form and are willing to complete the study according to the plan;|aged from 18 to 80 years old;|ecog equals 0 or 1;|not receiving lung cancer surgery before;|confirmed to be invasive
1,2.|pregnancy,recurrent breast cancer,confirmatory antibody testing,surgery|life expectancy,months.|acceptable organ function,pharmacological treatment,implanted medical device,wageningen university & research,other treatment.|patients,resective,within 30 days after vaccination with the trial vaccines;|a serious,> 1.5 mg/dl)|chronic,multiple,age|history of,likely to be needed,inability to consent to participation in research.,children with,the following exclusion criteria are in addition to the exclusion criteria specified in the master protocol (
2,institutionalized,cerebral palsy (,anakinra,unable to communicate with the study investigator or research,pain visual analog scale (vas),supplemental observations,metallic implants located,nursing home,previous,insulin naïve patients|bmi,for 4 months after stopping study treatment,above 40°c,>1 year,,unwillingness to comply with the study,written informed consent.|male,"additionally, a subject who did not speak english may not be able to easily communicate safety concerns",provided written informed consent;|age
3,outside,allergy)|chronic kidney disease,immunomodulating medications,unable to feel vibrations from the device on their wrist,total bilirubin≤1.5×normal upper limit (uln),radiographic imaging obtained,implanted devices relying,outpatient stage of rehabilitiation|followed,intention of,rome iv diagnostic criteria,in the 3 weeks before the first study day|presence,=< 3.0 x uln|eligibility criteria,more than one month or more,,planning to enroll,willingness to provide,absolute contraindications to,"refusal to sign informed consent|paediatric population|asa physical status iv|emergency tracheal intubation|independent predictors of difficult videolaryngoscopy (neck extension < 80°, macroglossia, interincisor distance < 3 cm, anatomical alterations of the neck, cardiac surgery, ear-nose-throat surgery)"
4,pediatric,criteria may apply,ro7247669,unable to complete follow,screening);|body mass index (bmi),revascularization procedure,contact lenses,screening).||,not available,thalamic,at the time of screening||☞,120-160/min,greater than 10 mg daily,,prepared,r patients:||english speaking adult,a female,willingness to provide
5,patients|male,mixed sclc nsclc,atropine drugs,native english speakers,less.|human immunodeficiency virus,physiological substitutive doses,urethra,psychiatric hospital,no witnessed,non-hematologic,for at least 5 years from treatment end will,> 30 ml/min/1.73m2.||,≥40|no,,require,able to provide written informed consent prior to any study mandated procedures.||able to lie comfortably on back for up to 90 minutes,aml)|women who are,preventing patient's inclusion according to the investigator's opinion
6,pcr);|complete,archival tissue,relenza®,participated in other drug,virtual coaching sessions,irinotecan.||chemotherapy,coronary artery bypass graft surgery,study institute,able to understand and give his consent|patient affiliated to the health insurance||,pharmacological dose,within 5 years prior to breast cancer,≥11 g/dl,≥2 times weekly,,likely to shop,inability to provide informed consent (,the presence,refusal to participate in the study;|portal hypertension resulting from other causes than liver cirrhosis;|more than 42 days after index variceal bleeding;|bleeding from
7,teenagers,structural brain abnormality,vulvar,unable to complete remaining study assessments,cfs score,enrollment|participation,mechanical circulatory,university of wisconsin hospital,a:||cohort 2,american|unable to read,before first-line induction chemotherapy,above 35 kg/m2|polysomnographic,fewer apparent,,can be measured by,patient has given,"additionally, no abnormalities of clinical significance in vital sign examination",willing to sign informed consent form;|chinese healthy
8,meeting the,hereditary optic neuropathy,3rd grade atrioventricular block,enrolled in other clinical studies;|mixed lung cancer,hbvdna,acid suppressive therapy,implantable hormonal contraceptives|hormonal,emergency cardiac,nment-,inhaled reliever,within 6 months prior to screening|history,<50%|subject must,≥3 mm,,at risk for,written informed consent,the children,provision of signed and dated informed consent form (icf)|healthy adult
9,mutation;|patients,hypertension|bell's palsy,injectable cyclophosphamide,genetic test;|written informed consent||,hepatitis c virus antibody,bariatric bypass surgery,implantable loop,criteria|life expectancy,not to,potentially unstable,newly obtained,less than or equal to 75 years old|pathological diagnosis,≥ 4.||,,"weeks,|willing to discontinue","written informed consent to participate in the study;|age 18 and over;|clinical diagnosis of one of chronic respiratory diseases (copd,",is not able to commit to the 6 weeks of intervention and the one-,the parents will be excluded if they cannot understand and sign a consent form and are not willing to follow the the clinical trial procedures
10,gender,brushing,intravitreal,precludes,ast)(serum glutamic oxaloacetic transaminase,liver cell-specific contrast agent disodium gadolinium cerate,know hematological disorders|difficult,"community mental health center regularly,|being able to read",does not currently,femoral condyle graded,at least 2 consecutive standard of care ct scans,<50 ml/min.||for,2 months or laxativ 3 weeks before,,planning to become,able to consent and agree to participate in the study.|3,fallot patient,the patient to be cared for has
11,persons,peripheral neuropathy|hepatic,aciclovir,render the subject s participation unsafe,pro,pulmonary hypoplasia,interpret study results.|active infection,emergency department nurses,assault-,glutamic oxaloacetic aminotransferase,within 5 years prior to initial administration of xzb-0004,<37.5°c,≥ mg,,incapable of,"subject should understand, sign, and date the written icf prior to screening.|male","additionally, it is not known","refusal of the patients.|associated entropion., 3) severe ocular surface disease.|previous eyelid surgery.|associated lid laxity.|lack of adequate follow-up"
12,months|mild,or|inflammatory bowel disease,neck operation,cockcroft-gault (cg) equation||,cockroft-gault,intravitreal,aortic valve replacement,outpatient status,no visible,mri|pregnancy|acute,within 6 months of the study treatment,"2, 3",at least five,,prescriptions for,≤8 (cut off 10.5)|patient with mental fatigue: mental fatigue score,monophthalmic patient. 10,the diagnosis and classification of patients with fgids were in accordance with the
13,texas children's,hyperthyroid diseases,heart assist device,unable to take fuquinitinib,creatinine cystatin c-based chronic kidney disease in children,choose peritoneal dialysis,mental illness.|confused,neonatal intensive,except for,fuchs spot,within 2 weeks before first dose.|body mass index,<3.0 g/dl.||patients,maximum tolerated medical therapy,,scheduled for a,patient refuse to participate.|the anatomy is altered due to severe,women of childbearing potential not,patient older than 18 years.|definitive diagnosis
14,pregnancy;|those,malignant tumor|hiv,5-fluorouracil,etcetera,gina,edentulous maxilla,contraceptive pills,pediatric cardiac icu (pcicu),patients|patients,low ovarian function,for 30 days before screening,≥ 100 × 109/l;||d.,first or second line,,managed per local guidelines,ability to comprehend and willingness to sign a written icf for the study|male,the forms of,refusal to participate in the study|history of neurologic deficits or neuropathy affecting the brachial plexus|infection at the site of the block application|coagulopathy|pre-existing respiratory dysfunction|allergy to local anesthetics|uncooperated patients who cannot reliably answer verbal pain evaluation
15,estimated survival,physically capable of pregnancy,prilocaine,cessation,speech impairment|cognitive impairment|had dengue before|healthcare staff,health maintenance,potentially curative,neonatal intensive care,no other clinically,"criteria:||include known pregestational diabetes,|known",within 5 years prior to screening,"< 50 mmhg,|paco2",edema.|at least 1 sign,,unwillingness to swallow,"untrained|any response of ""yes"" on the par-q+|physical limitations",is between 18 and 40 years,|the patient is
16,old|patients,"iv,|chronic gabapentin",cockroft-gault,situations that would limit compliance with study requirements.|new york heart association class iii of iv congestive heart,bone marrow aspirate (bma),organic gi disease|suspicion,vascular compromise,university (ohsu),must pass,pcs-typical,within 30 days prior to study procedure,ranges from 3 to 5,2 years to 4 years,,imminent risk of,"ability and willingness to participate in the study, give written informed consent, and comply with the study specific requirements and all protocol procedures|sex:",women who are,the subject himself/herself or one legal guardian/agent of the subject is required to fully understand the study and voluntarily sign a written informed consent.|ages 5 to 35
17,unl)/dl,systemic immunosuppressants,supraclavicular,allogeneic,"criteria of sepsis-3 (2016,",substance abuse|a medical condition,implanted electronic devices|patients,university of michigan|must,plan|active,mount sinai west.||,between the time of screening,38%,once every 14,,plans to start these,"lack of compliance with any inclusion criteria.|anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the registry procedures",participants who discontinued the tv48574-imm-20036 study,subject must provide written informed consent prior to any clinical investigation-related procedure.|subject
18,weight,headache||,drug free,situations that would limit compliance with study requirements||other medical conditions,creatinine ≤the upper limit of normal;|patients,preoperative ekg,intra articular injection)|systemic steroids,u.s.,breech position|scheduled ecv||,danish digital postbox,within 3 months prior to dosing.|subjects,scan);|5-18 years,≥ 4,,likely to be,written informed consent to participate in the study|age,includes patients,patient of childbearing potential must have a negative serum pregnancy test
19,adlult,liver conditions unsuitable,steatogenic medication,remain on this background therapy,t)|total bilirubin,immunosuppressive therapy.|known,cochlear-implant,west haven grade >,no dose changes,self-reporting,for less than 1 year,> 2x upper limit,women)|at least one,,higher;|patient with,"inability to understand study procedures and provide informed consent, such as those with gross cognitive impairment (",for women,the subject will be excluded if he/she has one or more of the following criteria:||children with a history of
20,ytologically,non-epileptic psychogenic seizure,doctor,sexual activity to decrease the risk for inclusion of a woman,abdulhamid han hospital physical medicine,oral mucositis|ulcerative oral lesions|hypersensitivity,implanted heart pacemaker,nursing undergraduate,must measure ≤24 mm,period.|tb,less than 6,< 30 ml per minute per 1.73 m2 of body surface,more than 24 units,,"schizophrenia,|no access",willingness and ability to provide signed informed consent prior to any trial activity.|women,female participants,the inclusion criteria of the study were determined as being an
21,outpatients|age,end-stage organ failures,hormonal contraception|irregular periods,sleep aids|diagnosed sleep disorder|history,platelet < lln,small therapeutic window|the patient does not take any drug or product,toric contact lenses,interventional clinical research treatment,pump,g/24 hours|medically,within the 2 weeks prior to screening|active tuberculosis,less than 6,maximum dose,,suspicion of,capacity to provide informed consent|participants must,positive;|pregnant or lactating,adult patient or representative of the adult patient who has read and understood the information letter and signed the consent form. 7.
22,complications|women,infectious diagnosis|admission,type,psychiatric history,hcv-rna level,standard stup treatment,aortic valve repair/replacement,"university hospital ""fondazione policlinico universitario agostino gemelli (fpg)",assessment.|agreeable to,site of surgery|periodontally healthy,within 12 weeks of screening.|a participant,less than 24 hours|another family member,long term health,,can accept,patient inclusion criteria:||patients must,young adults,refusal to participate in the study|body mass index < 18.5 kg/m2 or > 35 kg/m2|history of neuromuscular disease.|history of allergy to neuromuscular blockade|scheduled to transfer to the intensive care unit
23,mandatory.|participants,age:||amenorrheic,equivalent|steroids,living in westminster,preserved ventricular function)|no change,gc)/gastroesophageal junction (gej ),gh secretion,evaluated,without,type,within 5 years,≥18 years|patients,2-month period,,likely to become,not able to consent for participation|includable participants not longer living in norway,a:||signed written informed consent prior to any study procedures,the patient must be a member or beneficiary of a health insurance plan|patient admitted to the icu with at least one positive
24,female|age,autoimmune antibodies markedly elevated.|patients,abuse drugs,unable to provide fully informed consent,age|infants,stool routine examination,implanted cardioverter-defibrillator (icd),pediatric endocrinology physician,cannot quit,3-9 months of age||,one month before enrollment;|the risk assessment indicates,18 to 35 kg/m2.|volunteers,≥2 for rhinorrhea,,precludes,hours|lack of informed consent,a male participant of,"the subjects in each experiment will be recruited for a distribution of gender, ethnicity and age"
25,patient.|age,autoimmune hepatitis||liver cirrhosis,alpha-glucosidase inhibitors,unable to fill,endogenous creatinine,sl|positive cytology,peripherally inserted central catheter (picc) line,condition;|pregnancy,cannot,hypertonic,for at least 84 days following investigational product discontinuation even if,< 20ml/min/1.73 square meter,at least 5 years,,attributed to a,"able to understand and speak turkish,|who agreed to participate in the research||","inability to obtain informed consent from the patient, family member or legal representative,|the presence of a focus of non-sanitized surgical",patient of legal age
26,riteria:||families,iv|uncontrolled hypertension,anti coagulant therapy,render the participant ineligible for the study.|immediate family member,lsu health,diseased knee joint|knee osteoarthritis|any musculoskeletal problem,central venous catheter inserted,emergency department visits,discontinued,extracranial,prior 2 years,≥80 g/l,tissue wax blocks,,reproducible,written informed consent is signed by adult participants themselves，and the minor participants is signed by a guardian;|participants should be,women whose,the patient will be according the following criteria:-||males and females
27,pathology|age,motor impairment,litigation regarding,remaining life expectancy,hospital stay,medical condition|history,patch,labial bone plates,with the exception of approved treatments for cognitive impairment (,diagnostic criteria of scd,for at least one year|controlled ad,<5 years ago,repeat,,commitment,willing and capable of complying with follow-up examinations for the duration of the study.||15. signed informed consent or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment.||,the child,cured;|the patient's
28,ib:||male,ischemic optic neuropathy.|no,psychostimulants,risk of harming self or others,instability.|baseline ecog,upper abdominal surgery||,iliac artery,pediatric emergency clinic,not,allogeneic,during the last 12 months|assumption,=< 14 days prior to registration)|serum,once daily alone,,conditions;|pregnant,informed consent signed and dated by the patient and the investigator|age ≥18 years and ≤ 75 years,"inability to obtain an informed consent from the subject, family member",the patient will not be included in the study in the following cases:||inability to read russian
29,procedures|women,and|difficulties,oral corticosteroid therapy,willing to take,serum amylase/lipase,catheter intervention,punctal plug,study,pathologically,mild-severe,within 1 week of neoadjuvant ha chemotherapy,≥100 x 109,≥3mm,,equioxe proximal,able to understand and provide informed consent.|age,have an,parental refusal|minor parents or under judicial protection|newborn who already have been discharded home before inclusion|hospitalisation after the first 48 hours of life|only palliative care
30,is,neuralgia,systemic immunosuppressants,nsclc.|no driver,lutx|age,small enough for the standard-of-care resection,device implant,pediatric endocrinology||,no significant,dsm iv (e.g. psychosis,in the past six months,≤ 12 months.|uncontrolled,25 mg daily,,negative).||,written informed consent is signed by adult participants themselves，and the minor participants is signed by a,a child with,refusal to give informed consent
31,hypertension)|women,respiratory acidosis,allogeneic,signed an informed consent||,epworth sleepiness scale (ess),cd113;|major surgery,aortic valve replacement (avr),pediatric rheumatologist).||,|recipient,criteria|50-90 years,within 4 days after hospital admission,score of 24 or higher,more than one clinical symptom.|18,,concern for,unwillingness or inability to participate in the study|currently own an apollo device,a child,"willing and able to read, understand, and sign the irb-approved icf.|between the"
32,chinese,hydatidiform mole,vaccine component,unable to have,floxuridine (fudr),mild trauma brain injury (tbi),implanted electrical devices,university hospital of vienna,except the,ses-cd>6,prior to injection,lower than 1.5 before screening × 10^9/l；||4.2 mds,"≥ 100,000/mm3|hb",,cessation,agreement to participate in the study,pregnant participants|presence of,patient does not object to the processing of his or her data||only for
33,volunteers|age,ccna,chicken,signed informed consent obtained before,new york heart association (nyha) class,baseline ecg,artificial cardiac pacemaker,hospital staff,irradiation)|unable to,haidian hospital,within the month preceding infection treatment,<50 mmhg.|those,more than 10 years,,interfering with exercise performance;|concomitant,inability or unwillingness of a parent guardian to give written informed consent or comply with study protocol.|parents who will not include either a puree or some form of bottle feeding such that the infant,yo|pregnant women.|breastfeeding women.|consent not given|claustrophobia|incapacited subject or,patient refusal to participate in the study;|pregnant or nursing;|allergies to
34,h|age,fetal abnormalities|inability to communicate,lactic acid bacteria products,breast feeding|patients,aspartate aminotransferase (ast)/ (serum glutamic-oxaloacetic transaminase,namzaric,bypass surgery.|able,permanent,precludes,topical use of drugs,"at screening or baseline which could, in the opinion of the investigator",more than 1200 g and less than 1000 g,vas).|at least one,,potentially causing,written informed consent obtained before any trial-related procedures are performed|male,participants who completed the end of treatment visit in study ins1009-211 (nct05176951),not willing to participate|history of
35,angiomas).|male,"risk breast cancer""||",anti-pd-1 monoclonal antibody,cohort study).|art restart,human immunodeficiency virus (hiv) antigen,complete quality of life questionnaires;|patient accepting study follow-up visits;|patient having,orthodontic appliances,neonatal intensive care unit,unresponsive,that may affect bone,practice at least one,≥ 200 ml,stroke|at least one,,immunotherapy for,written informed consent by legal guardian|paediatric patients,is japanese|for,the subject is caucasian &
36,|hospitalized,cancer navigation,iodine agents,life expectancy assessment,tsh,factors.||good general health|fixed orthodontic appliances patients should,hymenoptera venom,university hospitals (hus),unless otherwise,icsi|major,for at least 1 month||,greater than 4000 milliliters,more than 3 months prior to enrollment,,changes in pharmacotherapy,"inability to complete follow-up questionnaires|declining operative management|no desire to return to golf postoperatively|medical problem that affects the patient's ability to play golf (e.g., angina",inability to obtain,refusal to sign the informed consent form.
37,2）life expectancy,diffuse carcinoma in situ,rad52,unable to be reached,residual neutropenia,hospital stay,biopsy-proven,university of california san diego health cardiac,other than,clinical-related,within 100 days of visit 2|presence,≥ 1.5 x 109/l|platelets,≥4,,signs of progression,ability to understand and willingness to sign a written informed consent in accordance with ich/gcp regulations before registration and prior to any trial-specific procedures.|confirmed diagnosis,not caring for a family caregiver to a person with dementia,the patient is pregnant or breastfeeding.|the patient has
38,female|adults,alveolar hemorrhage,components of study intervention,artificial valve|life expectancy,uln)|absolute neutrophil count,surgical therapy,primarily interhemispheric,emergency department/urgent,not emancipated,african ethnic backgrounds,at least five,three times weekly,> 1 month,,early,availability of a documented biopsy-confirmed,is under,the subject has a history of
39,years;|histologically,root canal retreatment,agents used,understands infectious risks associated with fmt administration,sedimentation rate,therapeutic radiation,metal worker,action plan,with the exception of patients with,physician.|bilateral,7 days prior to admission to the clinical trial unit until completion of the final onsite follow-up visit,60-90,2 joints|at least one,,able to use,patient requested to physically come,"being a 1st, 2nd,",r parents and their children
40,include:||are,inhibits the,devices;|patients,histological evidence,pizz genotype,-eclampsia,mri conditional implants,er,not opposing,under guardianship|non-cooperative,medical university of,"between 18 and 65 years,|ambulatory pwms with definite diagnosis",less than a month,,anticipation of,incapable of participating in the study based on the assessment of the nursing staff|toothless or,female subjects must have a,intellectual retardation)|addictive behaviors|current major depressive episode
41,||female,biochemical-only,deoxycholic acid,close contact,modified allen test;|patients,re-transplantation,heart pacemaker,inpatient,not enough,muscle-invasive,within 200 µm of the fovea|if,"≥10,|identify",≥ 37.5 °c,,willing,unwillingness to fast,chinese males,refusal to consent|inability to access internet
42,minors,selected into other clinical trials,hydatidiform mole,invalid address|participant,absolute granulocyte count,allogeneic,aortic valve area<1cm2,pediatric hematology and oncology outpatient clinic,immediately,index,within the normal value range can participate in this study,>75 years,2-6,,potential for pregnancy,ability to understand the protocol and to agree to and sign a written informed consent,female subjects must not donate ova,"refusal to further participate in the study;|non-compliance to the therapy regimen.|poor quality ecg,"
43,dementia||men,infection;|unstable cardiac disease,medroxyprogesterone,situations related to covid-19 pandemic,hepatitis b surface antigen and hepatitis b virus deoxyribonucleic acid,deterioration of clinical conditions,venous blood collection,university faculty of dentistry,uncontrollable,non-medical reason,within 28 days prior to the enrollment,evaluation;|the patient is,more than 7 days,,low risk for,capable to understand the study and the questionnaires,participants provision of a signed and dated informed consent and/or assent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.|participants who is willing and able to comply with scheduled visits,refusal of the patient to participate in the study.|minors under 18 years of age and over 79 years of age.
44,parkinsonian,gastroparesis 9,full-dose,life span,points;|calgary schizophrenia depression scale,world health organization (who) definition.|any,intra articular,adult egyptian,with the exception of alopecia|prior palliative,preclude administration of,for three days,≤ 3 x the upper limit of normal of the,>5 mg daily|daily use,,evident,inability to consent for services due to,pregnant patients,"refusal to participate in the research,|diagnosing metastatic breast cancer ("
45,metformin);|women,heart failure decompensation episodes||if,components of nutridrink compact protein,participated in an allergic rhinitis study,pcd insertion,chicken,allogeneic,pediatric emergencies of,system|able,bnct||pregnant,admission history,≤ 80,more than 1gm,,criteria:||refusal to,ability to understand and the willingness to sign a written informed consent form and hipaa authorization.|stated willingness to comply with all study procedures and availability for the duration of the study|male,being a,refusal to sign the informed consent|subjects having previously been treated with car-t therapy.|subjects with clinically significant active bleeding
46,infants,decline in functional status,molars,unable to conduct the follow up visits per protocol,hiv test results|as applicable use,macular laser treatment,developmental delays,emergency department,cannot lie in the,3-4,within 14 days prior to registration)|step 1,more than 1.5 times of the upper limit of normal,greater than 350 mg/m^2,,psychiatric history,gvhd.|pregnancy.|inability to provide consent.|need for vasopressor,pregnant and lactating,the patient is between 18 and 85 years old|providing crps diagnostic criteria by using budapest clinical criteria [16]|the patient has had
47,a,problem wearing knee,antibody,remain on the,efw,chemoimmunotherapy,implanted electro-medical,pediatric adverse events,with the exception of the psilocybin used within this study),third trimester of pregnancy,within 4 weeks of first study agent,between the age range of 17 to 20 years old,10mg iv bumetanide challenge,,likely to require,informed consent obtained before any study related activities. study related activities are any procedures that are carried out as part of the study,the women,the patient has any history of active autoimmune disease
48,genetic,left heart disease,full combined pharmacogenomic profile,speak and read english;|provision,test result,adjuvant radiotherapy,implanted pumps|metal,emergency surgery|egfr,except ≤,clinically significant abnormality,after all standard therapies,between 18 years and 55 years,more than 3 months|having,,scheduled to have,able to provide informed consent for,the participants,"provision of free and informed consent in writing, signed and dated;|age according to the indicated population (18-65 years"
49,systemically,depressive,ajovy®,criteria||fully dentate,required;|total bilirubin (tbl),tsh,sponge,outpatient clinic of neonatal unit,"acceptable.|any prior surgery,",er,within the study;|history of oncological disease,0-10 point,ucsd|age 18 years,,indicated for,not being eligible to participate in curriculum research|have any previous training in blood transfusion|have clinical experience in the subject|not volunteering to participate in the study,the persons selected,refusal of procedure or participation in the study.|american society of anesthesiologists classification (asa) class iii or iv.|coagulation disorders (
50,≥iii;|obstructive,myelomeningocele,dopamine therapies,emergency life support.|patients' body weight,gestational hypertension|gestational diabetes|primary ovarian insufficiency,"gastric bezoar, achalasia",ic,pediatric intensive care,with the exception of the oberon,clostridium difficile induced diarrhea,in the last 3 months|systemic,> 6 weeks,at least 1cm,,stated,any other condition that limits the eligibility of obtaining informed consent or may affect the volunteer's ability to participate in the study;|pregnancy or breast-feeding;||severe and,the patients,"patient does not understand, sign, and return consent form|patient is pregnant|inability to perform regular electronic reporting"
51,participants,"cancer diagnosis,|no communication problems",immunosuppressant medication,nursing mother|foreseeable compliance problems|neoplastic diseases,er,mutational hotspots),noninfectious,outpatient clinic of assiut university||,absence of,reproductive organs.||(2,in the 7 days or,≤ 90 mm hg,greater than (>) 6,,need special,agreement to,pregnant and,a:||able to provide informed consent and comply with requirements of the study;|≥18 years and <70 years of age;|confirmed diagnosis
52,days|patient,hepatitis c.,intravenous (iv) diuretic,move from the study area,measurement of hba1c|class ii,first trimester abortion,cerebral vascular accident,university hospital basel|hospital stay,with the exception that,german language,previous 48 hours prior to the surgery.|patient,≥100 mmhg);|corrected qtcf interval,"≥nci, ctc ae",,relevant,unwillingness or inability to participate in the study|unwillingness or inability to provide written informed consent form|wocbp with positive pregnancy test,females with childbearing potential must comply with using highly effective methods,willingness to provide a written informed consent or witnessed oral consent in the case of illiteracy for participation in the study prior to all study-related procedures|be ≥ 18 years and <70 years of age|having a diagnosis of
53,excluding,clinical conditions|acute illness,sitting,unable to acquire ecg,modified melasma activity and severity index (mmasi) score||,imaging evaluation,irreversible toxicity not,pediatric primary care,a:||cohort 1,full-dose,within the last three months|participation,< 1000 iu/ml,large amounts,,is prescribed,written informed consent and authorization to use,pregnant or,"patient's lack of consent to participate;|presence of abnormal liver, kidney"
54,female;|age,tanymremvi (+),parenteral cs,noncompliance to medical regimens.|patients,american congress of rehabilitation medicine criteria,nerve root decompression,cardiac resynchronization therapy (crt),university hospitals,facility,first-generation antihistamines,within 4 weeks or five times the half-life of the investigational product,< 30%|platelet count,once a month or more,,requirement to,informed consent of the parents or patient.|after surgical resection,if there is respiratory disease,refusal of the patient from surgical treatment;|presence of contraindications to surgical treatment;|severe forms of diabetes mellitus (
55,1.participants,retinopathy,anti_platelet medications,cockcroft-gault formula).|positive test,european country|body mass index,mgb,intrauterine adhesion,university of cincinnati hospital,irradiation.|patients,treatment|prior,at 52 mmol/mol,<10 years,dose,,clinical routine,acceptance of the mother to participate and sign an informed consent form|a,"ftx-6058,",willing and able to sign informed consent form and comply with visit and study procedures per protocol.|male or female
56,years.|both,extensive small cell lung cancer,medications known to modulate skeletal muscle metabolism,situations that would limit compliance with study requirements.||exclusion criteria,months|being,ventriculoperitoneal shunt placement,pulmonary vascular resistance [pvr],pharmacorefractory,can,with curative intent|age,within 3 months prior to enrolment,<0.5 x103/μl|platelet count,more than 3 months||,,esophagogastroduodenoscopy.|information available,written informed consent obtained.|age,if the habitual residence,months：during the periods from four months to one month prior to the date of initial use of
57,mutiple,communication barrier|having problems,intravitreal corticosteroid implant,unable to follow,dbp ≥110mmhg)|excess alcohol consumption,index,allogeneic bone marrow transplantation;|14,neonatal intensive care unit assiut university children's hospital,healing touch,interfere with cooperation with the trial's requirements.|is,less than five months ago|at least 2,less than 20%,≥ 12 weeks,,refusing,participants exclusion criteria||- voluntarily requesting exclusion from the study,genetic male,"refusal of the patients to give informed consent,|preexisting coagulation disorders,|known"
58,patients):||age,cardiac illness,injectable glucocorticoid therapy,speak indigenous languages,lvef（left ventricular ejection fraction,er,arterial hypervascular focal lesion,ambulatory basis,no opposing,low ovarian reserve,within 3 months prior to study start,20-degree,10 mg/ml,,biochemical evidence,able to comprehend and follow the requirements and restrictions of the study,the male,patient's refusal|poor compliance
59,workers,diarrhoea,oral,unable to follow vocal instructions).|inability for,women.||body mass index,positron emission tomography (pet),imaging examinations;|the,pediatric oncology departments,record.|pregnant,non-inclusion criteria||patients,within 3 months before screening;|the,from 4 to 14years,<3 x uln,,unable to have,"period|able to understand written/spoken english - all study participants will be provided with an overview of the study goals, research activities and tasks",the diagnosis,signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).|the decision to initiate treatment with commercially available sogroya (somapacitan) has been made by the participant and the treating physician before and independently from the decision to include the participant in this study.|male
60,enrollment;|males,gastrointestinal obstructions,opioid substitution therapy,living in areas,response criteria in solid tumors (recist),clinical assessment,intratumoral injection,hospital stay;|age,unless,secondary to breast cancer treatment|the participant,at least 3 months prior to enrollment.|participants will be,"18-50,|demanding",>1 cycle,,managed for a definite osteoarticular infection,patient admitted to the room|patient spent ≥1 night,if the patient's signature,the patient has previously received stem cell or gene therapy|the patient has received
61,reminyl,hemopericardium,midline closure site,turkish|able to read,expected risks.||,institutional trauma code for trauma,pva,university hospital,condition||healthy,n3 rank.|full-time,continue for at least 4 weeks,<10.5%|body mass index,chronic use,,excessively,"any other condition or behavior that in the opinion of the pi would affect the ability to participate in the transmission study over the next several days.||presence of immunosuppression or any medications that may be associated with impaired immune responsiveness7.|including, but not limited to,",impossibility of collecting data related to the surgical procedure|impossibility of contact with the patient to obtain the informed consent form,patient older than 15 years and 3 months admitted in adult emergency department
62,mpox|age,events of pneumonitis,atkins],render the patient unable to comply,bprs,months|being,dementia||men,university hospital inselspital in bern.|patients,no dose,sampled,within 1 week before day 1 pre-enrollment:||tcs|tci|anti-pruritic,between 16 years and 40 years,≥2 in one system,,rely,the unborn child suffer,if the parent,refusal to consent|lost to follow-up
63,biopsy.|age,duct carcinoma in situ,psychoactive substances,plant sterols,spleen assessed,instrumental delivery,parkinsonian,pediatric brain tumor|patient,protections.|tattoos,electrophysiologically,during the 4-week period prior to screening.|uncontrolled hypertension.|severe,<95% or presenting,> 2 time,,proportion,patient relatives',is pregnant or breastfeeding|5,the patient has been diagnosed with
64,old,peripheral vascular surgery,hormonal drugs|in,setting,hemoglobin ≥60 g/l,intestinal surgery,dental prostheses,hospital intensive care unit||,with the exception of,sacroiliac joint,within 24 (urine),>1.500/mcl,10 mg daily of,,operated,able to provide signed informed consent (,adults unable to provide consent must have a,patient refusal to participate|age <65 years.|emergency surgery|pre-existing
65,major,skin damage,feverish,ceiling of care,cdr,chemo-radiation therapy|unable to give consent|pregnant,delayed dental implant,"ambulatory nyha class iv, and||documentation of the following",do not,high grade bladder cancer,in past 3 month|patient,2 to 5,daily for at least 1,,initiation,"subject unable to give voluntary written informed consent,",is a concerned significant,"refusal of the patient to participate in the study|contraindication for performing the regional technique (people with infections in the area of the skin where the puncture must be performed,"
66,practice|reiki,h. pylori.|prior surgery to the esophagus,walk,participation into a clinical study,structurally normal hearts|age,left ear|fecal calprotectin,implantable contraception,participants:||(1,angina;|unstable,sitting,within one year before enrollment in the study.|the treatment area,<institutional uln,≥1 g/g,,sleep aid,patient unable to give consent|patient on,suicidal|currently pregnant,current patient in the university of
67,≥2)|male,ketogenic,decitabine,limit compliance with study requirement,total bilirubin x1.5 uln,mental health triggers,urinary catheter,outpatient hematologist agreement to screen,by,accepted operation of eye||sjögren's syndrome||-inclusion criteria,at the time the subject,>110 ms|second-,changed deliberately.||,,appearance,the informed consent form signed by patients and/or legal representatives must have been approved by the irb for the current study.|patients must have the ability and willingness to comply with study procedures.||,is unable or unwilling to provide informed consent,the patient is age 18 or over at time of study device implantation|patients who have undergone primary triathlon total knee arthroplasty in which simplex hv/simplex
68,ria:||men,cushing's disease,thyroid,cockcroft-gault formula);||adequate coagulation,car t cell treatment,quality-of-life questionnaires,er,absolute,failing to,study coagulopathy,at the time of written,> 37 u/l,2-3 days of the period|stage,,low risk,inability to provide informed consent due to cognitive impairment|inability to provide informed consent as unable to understand sufficient english,"additionally, patients must have fully recovered from all acute toxic effects of prior therapy.||note: cytoreduction with hydroxyurea","willing and able to give informed consent, can communicate in english|age between 18 and 65 years inclusive|live in england|bmi ≥27 kg/m2 or higher"
69,hours|pacemaker,metastatic repetitions,values.||belimumab,change usual diabetes regimen,recist v1.1 despite,ferromagnetic metallic implants,larger implants,pediatric neurologists,with the exception of the cancer under investigation in this study and,ridge,for 7 months after the final dose of study treatment|if,< 3.5 × 109/l,1.5 x or,,anticipated use,"patient informed of the implementation of the study, its objectives",unwilling to follow the study protocol|self-reporting usual engagement in activities that have a,signed written informed consent|subjects diagnosed with vulvovaginitis|presence of at least two subjective symptoms and two objective signs (
70,aging,alpha-interferon,mycophenolate mofetil|patients,special diet,eular criteria,imaging scans,auxiliary appliances,sedentary,compromises the affected,lower extremity.|prior history of surgery in the lower extremity.|neurologic or,in the last 8 weeks|children admitted to any,"7, 1997",more than 2 months,,enjoyment,"lack of demographic information, clinical history",being a nursing student|getting,the subject must fulfil all of the following inclusion criteria to be eligible for participation in the study unless otherwise
71,palsy|children,human t-lymphotropic virus type 1 (htlv-1) antibody,anti-resorptive drugs,breast cancer|patient,interferon-gamma release test,insulin therapy schemes later,screws,university medical center,applied to,stage iiia,during the above mentioned,8 mm||group 2:||with upper scleral,dose-expansion,,vulnerable persons|people,able and willing to give consent for the study prior to participation|be,unwilling to sign informed consent,hours|provided written and informed consent (patient or carer)||australia only||•
72,however,type 2 diabetes,ascorbic acid,family plan,hads,donor lymphocyte infusion,ibs,metatarsal bone .|fracture,ability,"study.|non-healing wound, ulcer",in 6 weeks before enrollment.|received attenuated,40 mg/day,two separate occasions)|creatinine clearance <50 ml/min,,likely to be pregnant.|6,inability or unwillingness of research participant or legal guardian/representative to give written informed consent.|current use of,"additionally, it should be noted that periodic abstinence (e.g., calendar, ovulation, symptothermal,",unwilling to give informed consent/ assent
73,fudan,enrolled.|bilateral hydronephrosis,alpha-receptor adrenergic agonists,fbss,painful arc test,thymomectomy,metal clips,skåne university hospital in lund and malmö,"in addition to the primary,",cervical,during the observation period|patients,≥18 years|superficial,80 g/day,,symptoms,availability of written informed consent of the patient to participate in the study;|patients,females)|pregnant or,the patient is known with
74,menopause|female,cases might,investigational immunoglobulin,signed the informed,ecg qt interval corrected,sle soc therapy,septal myectomy|restrictive,participate||study exit,lack of treatment for a major psychiatric disorder,requiring dialysis.|immune system,at least once|does not,10 - 15|volunteering to participate,more than 1 glass,,intention to become,inability to speak/understand the dutch language|severe psychiatric problems (history)|neurodegenerative disorders|substance abuse|severe cognitive comorbidity,"anemia|pregnant or lactating women|in addition to the above, those who","the patient is at least 18 years of age;|the patient has a confirmed grade 1-111 osteoarthritis of the cmg joint on clinical examination and x-ray;|the patient agrees to abstain from enrolment in any other clinical trials that will conflict or interfere with the interpretation of the results of this study, in the opinion of the investigator, for the duration of the study;|the patient is able to understand the aims and objectives of the trial and is willing to consent;|be willing and able to return for all study-related follow-up procedures;|if female"
75,consent|adults,her2-targeted therapy.-,angiotensin receptor blockers (arbs),risk calculator assessment a,bone marrow blasts,cholesterol-lowering,pacemakers,outpatient,not of,inclusive.|good general health,in the past 12 months.|having,≥ 60 to ≤ 89 ml/min/1.73 m^2|hemoglobin,≥ 7 days,,management plan,patient cannot have diaper needs)|significant medical,"additionally, patients of childbearing potential must continue",written consent to participate in the study|for women
76,patients.|both sexes,middle cerebral,anticholinergic agents|spravato,care for condition,promis-anxiety short,quality/quantity control criteria,implanted defibrillator,university hospital grenoble alpes.|living in france.||,not excluded,similar,for at least 6 weeks,more than 2 times the upper limits;|not well,≥1 episode,,progressed after,written informed consent according to ich/gcp (,"additionally, the",refusal to participate|patient under legal protection
77,both,limb ischaemia,lovastatin,progressed beyond first line,alt increased,reviews,ae associated,unclear,active,non-compressible vessels,their partner(s),<6years.|has access,power,,consulted for,months|ability to give informed consent||,if pre/perimenopausal,capable of giving informed consent|stated willingness to comply with all study procedures and availability for the duration of the study|male
78,ia:||male,peripheral vascular disease.|the participant,anticoagulation used,limit other interventions,"forced expiratory volume in 1s/forced vital capacity (fev1/fvc)<70% predicted, fev1<80 % predicted after bronchodilation corresponding to a global initiative on obstructive lung disease (gold)",optical coherence tomography (oct),ssr pet/ct|patients,completed weeks,new diagnosis,walled-off,within =< 28 days prior to registration).||,< 3 x institutional upper limit,exceed 140g per week,,unable to comply,university of michigan students,hypermagnesemia|women who are,agreed to participate in the study via the study's informed consent/assent process.||operational definition of latent rhd borderline rhd
79,excess,donate ovum,stimulating medication,unable to travel to the nih.|have,rv/tlc ratio,mitral implantation,left ventricular assist device implantation|patient under ecmo,skåne university hospital.||,acceptable,environment,at time of consent||inclusion,18-75;|subjects,≥2.|people,,unwillingness to discontinue,completed informed consent process|male,pregnant women|postpartum,provision of informed consent prior to any study-specific procedures.|male
80,hypotension.|has concurrent,js006,panic disorder|a,lose weight,aspartate aminotransferase (sgot,rsv mat-009,allogeneic bone marrow/hematopoietic stem cell transplantation,outpatient department||,permanent,vitamin-calcium therapy,prior to the first administration of ip.|excessive intake,= 0mm/5min,more than one year.|signs,,3.agreed to,"able to speak and understand turkish,|conceiving naturally,|at the end of the gestational week",pregnant patients.|patients,patient does not approve sample collection|usage of antibiotics in the month prior to clinic visit|usage of any vaginal preparation
81,invasive,palpable abnormalities,myorisan,signed informed consent|age≥,oral,surgical treatment;|preoperative cranial mri,inhalation,psychiatric university clinic,months;||,rocket,3-4,"6-10,|the",>14 drinks per week);|history,,plans to,written informed consent obtained to participate in the study and health insurance portability and accountability act (hipaa) authorization for release of personal health information|age,methods.|male participants agree to practice true abstinence,signed written informed consent.|age
82,institution|women,transverse colon,components used in the formulation of the interventions,diet,criteria:||• mild,puncture biopsy,criteria:||uncorrected visual,changes||,"over,|able",hormone receptor- negative,within 24h prior to the first dose of imp,above 6,80 mg qd,,need treatment;||tumor related,unwillingness to participate||-,female volunteers cannot be,patient's parent/ legal guardians are unable to provide informed consent
83,women,lymphoproliferative disorders,prescription treatment||,admitted to the neonatal unit after delivery,inclusive.|body mass index (,kidney graft biopsy.|comparison (control),allogeneic bone marrow transplantation);|severe infection,up into the throat).|the,allowed per institutional,oral,post-completion,less than 65 years|non english-speaking|unable,nasal,,wanted,capable of understanding and complying with the protocol.|18 years of age or older but less than 60 years,pregnant and lactating women's|patients with any co-existing,the child is 7-12 years old
84,preschool,hemostasis disorders|renal function,serotonin reuptake inhibitors,close in the next 2 years|been,hepatitis c viral infection,permanent treatment discontinuation,peripherally inserted central catheter operation peripherally inserted central venous catheter,allogeneic bone marrow transplantation,non-,admitted to duke university hospital.||infant inclusion criteria,within 1 month before the screening;|human immune-deficiency virus (hiv),> 12.5 mg/mmol,≥3,,interfering with the,"ability to understand and willing to sign an informed consent form (icf)|male and female patients, age",is a,willingness to provide written informed consent. for decisional impairment
85,inr≤1.5×uln,clinical peripheral neuropathy,peanut,risk of reflux,fibrosis score,mechanical circulation,implanted csf access device,outpatients,other day,mid-qrs,within 4 weeks prior to the first administration of the study drug.|use,<60 ml/min/1.73 m2|urine protein,only for,,reduced risk,capability to understand the objectives of the research and to fulfill the term of consent||,not pregnant,agreed to participate in the study program
86,ranges,atypical parkinsonism|life-time,cumulative 1+ pack-year smoking,hypertension;|serous cavity effusion beyond clinical control,serum immunoglobulin m (,local resection,nt1,outpatient clinic surgery,not exceeding,site of epidural puncture,starting the night before each scheduled study visit.|agree,>2 × uln.|alanine aminotransferase (alt),≥1,,candidates to,"inability to give informed consent e.g., due to significant",a male subject should be instructed that,refusal to give informed consent|contraindication to venepuncture
87,infant,hypogammaglobulinemia,cah,screening|able to understand the nature of the study,edss below 4||hat start,impairs cooperation,spinous balloons,university of virginia,"in addition to oral anticoagulation for 6 months,",between consecutive lines of therapy,in english|patients,>450 msec,"100 x 103 /cc and 100,000/μl);|hemoglobin",,unable for,patient less than 17 years,"additionally, individuals must provide",provision of signed and dated informed consent form.|stated willingness to comply with all study procedures and availability for the duration of the study
88,admittance,esophageal pathologies,olive oil,partner;||using a combination,thyroid,target knee,nonmalignant,university of massachusetts,no abortion|not,new onset of tonic-clonic seizures.||,during screening/initial,"cvc,|over 18 years",1 mg/kg/day or,,cohort a and b,written informed consent must be obtained from patients and ability for patients to comply with the requirements of the study；|patients must be a man or woman,"pregnant patients,|those",provision of signed and dated informed consent form|stated willingness to comply with all procedures in the vns-enhanced stroke recovery program|aged
89,youth,pth,pth,any other,immunohistochemistry [ihc],cumulative dose of doxorubicin,sunless tanner,university of westminster;|a first generation student (fgs),excepting,history)|current,during the 6 months preceding,">=100,000/mcl c",≥ 50%,,requirement for,"inability to lie still,",gadolinium.|male and,provision of written informed consent|male and female patients|weight
90,influenza|adults,infantile febrile seizures,drugs targeting another kind of stimulation,entry into the study,odense university hospital|age,express testing,implantable hormonal methods,icu stays,with the exception of:,platinum-refractory/,at day +60 after transplant,≥ 480ms,≥ 100 mg/dl,,potential risk of reactivation evaluated,inability to give informed consent to participate in the registry,is hiv-1,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|aged ≥ 18 years|documented history of dry eyes
91,aged,aian)|female|live on,monkfruit,risk of,serum rsv antibody titer assay|participant,non medical therapeutics,corneal implants,gradual,prolongs survival,walk,in the next 3-months,≤ 1.5 x upper limit of normal (uln),2-12||,,preventing ability,not willing to report their symptoms using the,age-matched,complying with the study protocol；|no medical comorbidities
92,competitive,lack of,xanthine-containing drinks,prevention of contrast,alcohol + stimulants)|min,permitted.|investigational therapy,infusion pumps,outpatient settings,not eligible.||*'consider,might interfere with the ability to give true informed consent,within the 28 days prior to and including the screening,30-70 years,14-consecutive-day period,,interfering in,be willing and able to comply with the study schedule and all other protocol requirements||9,females of childbearing potential should have a,the subject is
93,form||,cerebral artery territory).|severe allergy,anti-psychotics)|if,cooperate with treatment;|judgment by the investigator,ankle-brachial index (abi),share,aneurysm clipping,moment of inclusion in retrospective cohort study|patient,does not,ankle-brachial index (abi),etc.);|within 2 weeks before the first administration,≥ 10 packs per year.|subject,more than 26,,consent to receive,written informed consent must be obtained before any assessment is performed.|healthy,subnasale that,parental refusal to participate|known allergy to local anesthetics|american society of anesthesiologists (asa) physical score
94,symptoms.|participants,bleeding;|habitual constipation,gastric tube,living with hiv,esrd).||participants,bone marrow blasts,nitinol alloys,ambulatory category (fac),no approved,histotype,within 15 degrees,3-4,higher than 3 ml/mn/year|a,,impairing the,anticipated life expectancy,"additionally, you cannot be involved in another investigational drug study during your participation in this study",willing and able to give written informed consent for participation in the study.|healthy male
95,21|male,metastatic lesion|on combined adt,topical retinoid,uterine cavity,prostate mri,teaching hospital,cochlear implant,pediatric rehabilitation course for the first time in the fall semester of the academic year,meets,non-surgical,during the 3 months preceding randomization,> 65mmhg,two-year,,intent|absence of current,inability of the trial subject's custody holder to read,the parent,patients who died during the treatment period
96,5/10,functional asplenia；|presence,supplemental corticosteroids,risk for bleeding,left-sided colitis,intra-arterial thrombolytics,implantable electronic device,study period.|test,fertile people,multidisciplinary team,at the time of starting atezolizumab,er,2 mg or higher,,likely to recur,not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation.|unlikely to be able to comply with clinical investigation procedures according to the principle investigator's/co-investigator's judgement.|unable or unwilling to return for recall appointments for a period of 5 years.|severe non-compliance to clinical investigation protocol as judged by the pi,"inability, for whatever reason, to provide informed consent.|language barrier|mother is from a refugee camp|mother has no access to phone",capable of signing informed consent.|histologically-
97,youth-caregiver,severity covid-19 infection,fine reticulin,risk for pregnancy,weight of,unresectable reconstruction,implantable contraceptive devices.|negative viral serology test results,university hospital of amiens||,excluding,platinum-containing therapy,3 months prior to inclusion,minimum of 18 years,none,,etc.|in the,inability to provide informed consent,if you decide to participate,"the subject has tumor,"
98,10,gout tophus,leukotriene receptor antagonists|equipped,media|measurement error,percentile)||biochemical signs,pleural biopsy,left ventricular (lv),wageningen university & research (wur),with the exception for,idd|on maintenance treatment,within three months prior to the commencement,"≤75,000/ul|hemoglobin",≥ 48,,symptoms|able to read,availability of signed informed consent|adult men,if they had,"refusal to participate,|has a pacemaker or a neurostimulator,|has an insulin pump,|coagulation disorders,|current thrombophlebitis,|current pregnancy,|burning sensation at the treatment area,|current cancer,|insensitivity to warm or to pain,|current infection (tuberculosis, etc.), especially of the surgical site,|current fever,|bladder wound during cesarean,|under guardianship or conservatorship, deprived freedom, or in the custody of correctional authorities,|keloid scar from previous cesarean,|previous tecar therapy,|strong hypertension (systolic > 150 or diastolic > 100)"
99,breastfeeding|men,tumor tissue sections,amino acid aminotransferase,expected hospitalization,and|sitting clinic values,extensive small cell lung cancer,close contact,signed||mild cognitive impairment (mci),with the exception of any of the following:||adequately treated,end of induction therapy,within 6 months before the first dost,5-11 years,more than 2 pre-study,,inappropriate for,ability to understand and the willingness to sign an informed consent.|diagnosis of luts secondary to bph refractory to/contraindicated for medical treatment,a current,"patient who fully completed per protocol a 24-week randomized withdrawal period (for the first 20 randomized patients), or the preparation therapy after the end of enrolment into the randomized withdrawal period in the main study cl04018068.|voluntarily signed and dated patient informed consent form for participation in this study.||the patient's ability and willingness, according to the investigator, to follow the schedule of visits, the study procedures and follow the protocol requirements, including the following:||come to the study site every 2 weeks for the study drug administration by qualified site staff"
100,subjects||age,indolent lymphoma,antibiotic instillations,inadequate biventricular pacing,absolute neutrophil counts,coronary artery bypass graft (cabg) surgery|inability to clearly identify,central cavitating pulmonary lesions,university of ottawa heart institute;|able,with the exclusion of,amenable to research biopsy,for the first time;||the patient's laboratory tests,=< 7 and surgeon,≥2 times,,mucosa.|presence of a urinary artificial sphincter,informed consent signed by the subject|males and,unwilling patients,provision of informed consent.|age
101,13,retinal biopsy,labetalol,psychiatric disorders|history,hepatitis b core antibody positive (hbc stands,pancreatic surgery|patients,prosthetic heart valve,pediatric otolaryngology outpatient clinic,excluded,within the visual axis|neovascularization,at the time of screening||evidence,than 12%||comparator group||previously,transplantation.|at least one,,older|need,"informed consent of the parents or patient.|patient must be, in the investigator opinion, able to comply with all the protocol procedures.|age",female subjects must not donate,willing and able to follow all study requirements|eighteen (18) years of age or older|subject is willing and able to follow all study requirements|subject will undergo a colectomy||
102,males,sclerosing cholangitis,fentanyl|acetaminophen administration,unable to give informed consent|medical diagnosis,ctp,minimum temporal resolution,including||severe eczema|parental,pediatric infectious diseases society/infectious diseases society,except minor,non-obese,30 days before first study drug administration,less than 100 μm,maximum 2 g per day,,practiced sexual,patient whose,women of childbearing potential,capable of giving informed consent|aged 18-70 years|compensated advanced
103,flow,1.failure of,advil®,women.|person under guardianship,anti-gbm antibodies constituting,local palliative xrt,condom plus diaphragm,pediatric cancer|patient,with the normal outcome;|positive,site of disease,within the next 3 months|self-reported,> 3 grams/d,2 consecutive psa rises,,referred to,ability to provide valid informed consent|18-60 years,women of childbearing age,written informed consent for the procedure signed according to regulations in the hospital)|available blood test results - plasma lipid profile|patient agrees to participate in the study
104,greater.|age,impaired skin integrity|gastrostomy,trial drugs,unable to perform basic activities of daily living,estimated glomerular filtration rate (egfr) ≧,awakening phase.||,implanted cardiac pacemakers,pediatric oncology for cancer,not including,screening|active,within six weeks|women,≥3×uln,≥ 1 line of therapy regardless of the timing,,active risk of,be capable of understanding the investigational nature of the study and all pertinent aspects of the study|be capable of signing and providing written consent in accordance with institutional and federal guidelines|be willing and able to comply with scheduled visits,is clinically,compliance with the protocol.
105,new,left ventricular outflow tract.|stroke,l-citrulline malate,commit to performing the required study tasks|can speak/understand english||,bi,upper gi endoscopy,cardiac resynchronization,obvious,diabetes.|patients,"american college of rheumatology criteria,|western",during this study,≤ upper limit of normal,1 or more,,planning to be pregnant,patient's,the subjects are,patient's age 18 and above|patient with cbd stone documented
106,or|age,spastic hemiplegic cp.|their chronological age ranged,epidural steroid,unable to oral take,kps,damage;|disabling,biopsy||,university hospitals of strasbourg between,not the intervention or,deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent,within 2 years prior to the screening visit,≤ 5 × uln；||creatinine ≤ 1.5 × uln,3-month,,eligible for entry in,able to provide informed consent|age,children who,"the patient will be excluded from the study in the event of the presence of at least one of the following criteria:||having undergone ankle, knee"
107,●,growth hormones,monoclonal antibodies.||4.2.17,close proximity,musculoskeletal injuries|bmi,binocular fixation,emergency contact,pediatric renal transplant,aside from the known,ureter,within 30 days of screening.|have a known,≥ 100mmhg,12 months).|patients,,unwillingness to use,able to provide signed informed consent,being a nursing home resident,"patient opposing to participate in the study.|patient subject to legal protection measures (guardianship, curatorship or safeguard of justice)"
108,suspension)|female|age,inadequately controlled heart disease,narcotic drugs,progression of another tumor.|postoperative radiotherapy,equation:||creatinine clearance,anemia).||infant inclusionary criteria:||infants,neurovascular injury|poly trauma,amiodarone)|diabetes,years.|both,acr/eular classification,for the next menstrual cycle,≤ the lower limit of normal (lln),maximum keratometry value,,planned,parents accept participation in study.||,the patients in,the investigator judges that the subject may withdrawn the supportive treatment on the first day; the investigator believes that there is evidence indicating
109,iv|lvef,gilbert's,norplant®,admitted in besançon university hospital|exigible for,pth,total resection of the recurrent tumor|no anticipated physical connection,pain associated,live outside of washington state|bowel-related surgery,not owning,amenable to percutaneous access,during previous 12 months).|willing to travel,less than 3.5meq/,≥ 48 hours||,,niv other,unwillingness of the patient to participate in the register;|diagnosis of ckd made before the screening for the register;|diagnosis of diabetes mellitus (dm) type 1 or type 2 made before the screening for the register;|pregnancy;|long distance running or very strenuous physical activity,females of childbearing potential.|males,children with redo hypospadias
110,french.|person,ligamentous involvement,cheis,radiation therapy||with,new york heart association classification class,cardiopulmonary resuscitation (cpr),hormone implants,pediatric adverse events:||ast,player|volunteer to,very often')|functional impairment reported,within 6 months before enrollment|serious,>3uln|total bilirubin,once a year,,eligible to start,injured|any reason can not complete all the required training sessions,true abstinence,patients who need an
111,collection)||patients,screening.|active hepatitis c virus (,local anesthetic agent allergy,rhogam,samhsa suicidality,etc.)|shift worker|participation,soft contact lenses,washington county,requires icu,low-risk neoplasms,during the period of use of the ingestible thermosensor,> 3 times the upper limit of normal|history of,<7 days)|intestinal stricture,,likely to fail than for an eye,"inability to provide informed consent|inability to comply with the study protocol|subjects who may be unavailable for the duration of the treatment course, likely to be noncompliant, or who are felt to be unsuitable by the investigator for any other","additionally,",the subject has or had a
112,inmate of correctional,dpb1,components of the drugs of the investigational procedure|patient under guardianship,difficulty in hearing test,weight loss.||pregnant,serological testing for hcv at screening,hormonal implants,outpatient clinic for surface ocular diseases.|patients,not have,impedes daily activities.||3,within 30 days prior to surgery|asa iv (,> 160 kg,> 2,,clinical evidence,written informed consent|patient is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits,participants who can understand and follow instructions,unwilling to participate in zoom sessions and have their voice and face recorded for research purposes.|currently tends a vegetable garden (as measured by if they have tended a garden in the past year or are planning to tend a garden (outside of this study) in the coming season)|moving out of the area in the next 5 months|non-english speaking
113,randomization|female,hiv-associated malignancy,halifax,immunophenotyping,weight management.|be involved,higher;|pregnant,aortic valve replacement/repair|combined,emergency surgery;|preoperative,not allowed)|kps,stage ib,within 28 days before to the first dose of study treatment,subjects|aged of 18 and more|agreeing,pirads scores 3-5|prostate,,interfering the compliance with the protocol.|women,informed consent as documented by,"additionally, the effects of niraparib on the developing fetus are unknown.",the patient is <18 years of age;|the patient is suffering from
114,placenta,cardiopulmonary function,high potency,unable to understand and respond to questionnaires,dyspnea nrs rating,venous puncture,direct,adult ibd,higher than,therapeutic devices,at least 2 months after the last use of,5-7 days,at least six,,refusal to,patient refusal|spine deformities|coagulopathies|infection,not proficient norwegian language skills,refusal to consent|alcohol use > 14/21 gm/week cutoff|other causes of chronic liver disease|meld > 12|hepatic and
115,fulfillment,lesional sstr2 expression,cerebellum,feeding,brief psychiatric rating scale,ns,attorney in relation to the tbi|pregnant,adult emergency department,hypertension)|able,intra-ocular inflammation|retinal,at least 4 weeks after the cns-directed therapy,over 60 years,more than 3,,expecting to,able and willing to comply with the treatment/follow-up schedule and requirements.||7,the absence of any of the above criteria will exclude the participants from the study,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|female
116,placement).**true,non-reproductive age,screening,difficulty understanding the clinical trial due to,worst itch nrs of,percutaneous coronary,implanted pulse generator,ambulatory,w/o,non-plaque forms of,within the last 5 years except,more than 25%|patients,once and/or,,able to read,able to understand and willing to provide informed consent and able to comply with the study procedures,may not have,willing and able to give informed consent.|age
117,male,insurance.|parent(s)/legal representative(s,zika natural,unable to safely complete the study,serum creatinine level,alternative cause suspected,implanted metal parts,ambulatory care,not attending,expanded cag repeat,in the past 2 weeks|chronic,< 37.3℃,> 20 mg daily,,setting,inability to comprehend written consent form or provide informed consent|bmi,females of,"signed written informed consent|diagnosis of symptomatic osteochondral or chondral lesion of the talus, deemed by surgeon amenable to arthroscopic treatment with debridement and microfracture|age of 18-65 years|subject is willing and able to comply with all study procedures, including visits"
118,girls,liver transplantation||,anemia;|patients,genetic syndromes,alzheimers,routine laboratory tests,cl prescription,standardized uptake value (suv) mean,negative,advanced,at time of study enrolment);|in the,≥ 480 ms,hysterectomy|nsaid use,,likely to confound study endpoint evaluations like severe,capable of verbal communication with a parent.|children who are in foster care or are currently wards of the state.|primary caregivers under 18 years,the pregnant,"the subject is participating in this study, or is in a period of exclusion determined by a previous study|consent refusal|patient with a polymicrobial blood culture|patient with a second episode of bacteremia|moribund patient"
119,criteria|age,uterine fibroids|azospermia,document||,screening.|life expectancy,overall health status,treatment|pharmacological treatment,services|resides,outpatient physical therapy,no prior,post-herpetic neuralgia,in the past 7 days,below 50%,1-week intervals,,willing to use,parents/guardians,"adolescent whose parents, or the child if possible",unwilling to consent to microvessel ultrasound imaging|younger than 21 years of age
120,1.age,sensitive)|ii always burns easily,monoamine oxidase inhibitor,volume challenges,tds,ventriculo-peritoneal shunt,saphenous vein,outpatient hf clinic,with the exception of the following noninvasive malignancies:||basal,equipment-based,at least 12 weeks.|patient,"25-30 kg/m2,|the number of normal deliveries ≤",≥ 14 days,,diseases|documented,inability or unwillingness to give informed consent;|blood pressure,participants who do not consent|have a,able to provide written informed consent|within 6 weeks of discharge from hospital following admission for bronchiolitis|child aged
121,≥7|have,living nutrition cognitive,anti-vegf agents|known serious,baumannii,car-t cell preparations,corona radiata,aortic valve repair (avr),university hospital of ghent,inhibiting,index diabetic ulcer|wound duration,throughout their treatment in our hospital|patients,< 12,2 ng/ml rise in psa over,,eligible,written informed consent obtained before any study procedure.|literate,pregnant patients;|patients,unwilling to provide a pre and post-exposure urine sample|current cancer diagnosis|tobacco use
122,never,transient venous thrombosis risk,interleukins,mitraclip|current,prostate cancer|recurrent,walk,intracranial atherosclerotic occlusive disease,lactulose,allowed per institutional guidelines)||patients must,"in the neck (cn0),who underwent",within the study catchment,less than 100 ui/ml,at least 6,,willing to start,difficulty to adhere to a twice daily,being a resident,the child who ages
123,robands):||adults,incomplete left hemiblock,smart phones,sexual activity,study|estimated glomerular filtration rate (egfr),secondary localization,vascular access device,pediatric intensive care unit,acute,grossly,within 1 month prior to screening,no least than 5,≥ 2 prior,,menstruating regularly,inability to give informed consent|prior surgery,the nursing student,the subjects voluntarily participated in the study with full informed consent and signed written informed consent form;|aged ≥18 years and ≤75 years when the subject signed the informed consent;|locally advanced
124,except,lcpd,bexarotene,willing to participate in the study,aternal age,x-tole3,psychoactive substances,pediatric allergology unit,except female,high grade gliomas,<28 days prior to administration of prth-101.||a,> 24||,more than 6 weeks,,likely to become pregnant,the exclusion criteria for participation in the study will be as follows: (1) patients,participants who do not consider themselves healthy|have,the subject is a non-pregnant
125,subject:||males,complications|urinary tract infection,bile acid,progression of disease course,prostate cancer working group criteria,standard medical care,contact sports,pediatric physical therapy.|children,do,since the pathology is linked to the x chromosome,at the randomisation visit.|documented,<90/60 or >140/90 mmhg);|low blood oxygen saturation,2 to collect,,perceived,subjects polysensitized to other aeroallergens with clinically relevant symptoms.|subjects,"additionally, participants who have received",capable of signing informed consent.|ecog score 0 or 1
126,cycle|patients,ml]/ minute [min]/1.73 meter square [m2,digoxin,unable to fulfil all inclusion,creatine phosphokinase|blood sugar,bile excretion,intrauterine contraceptives,international pediatric consensus conference|need,lar)|stable,siblings,within 4 weeks prior to vst infusion.|receipt of thymoglobulin,< 3|montreal cognitive assessment,≥ 1 week,,unwillingness to undergo,written informed consent to store samples and perform,participants who cannot take orally,agreed to participate in the study will be included.||
127,treatment|measurable,lack of internet access,sedative-hypnotic drugs;|history,"egg allergy,|at",north zealand hospital.||exclusion criteria||concomitant fracture of the ulna,whole body vibration (wbv),intrauterine pessars,none,preceded,moderate-vigorous intensity exercise,admission|more than 2 hours from hospital admission to randomization|transfusion of more than one,greater than 80 years|pregnant,once monthly or more,,referred,females)|written informed consent to the participation in the study||,pregnant participants will be,provision of written informed consent.|histological or cytological confirmation of
128,patients;|patients,healthy child,interleukin-11)|esas,living in a care facility;|(h,partial thromboplastin time ≤1.5× uln,health insurance|gerd,potentially curative surgery,scheduled,can affect,nearest tenth,within 1 year of,≤ 1.5×uln；alt和ast ≤ 3×uln(alt,more than 30 minutes,,testing for,written informed consent is signed and dated by the participant.|male,children otherwise,"willing and able to give consent/assent;|if under the age of 18, guardian(s) is/are willing and able to give consent;|prior study treatment with eb-101.||"
129,malignancies;|2.male,maintenance from the change phases|not,physiotherapist,anticipated subscapularis tenotomy,best corrected visual acuity of 20/30,isolated flow limiting,artificial tears,in intensive care medicine,no apparent,b+c):||oral,within 24 hours prior to the study vaccination.||male,<4 hours,at least on,,permitted,inability to perform physical activity,female subjects,"the first stage:||subjects meeting one of the following conditions will not be included in the trial:||for dili and chb population, mixed with other"
130,surgery.|patients,acute myelogenous leukemia,xylitol,cigarette smoke,elevated,chemo-radiotherapy|serious medical comorbidities,prosthetic valve,ultrasound||,colorectal tumors.|intolerance,acetabular,during the last 5 years;|patients,≥18.5 kg/m2|aged,years|uc diagnosis,,clinical chorioamnionitis|intake of,inability to submit video recordings of instruction for data collection and,i. written,the investigator's decision that a healthy volunteer is to be excluded in the interests of the volunteer.|any serious adverse event occurring to a healthy volunteer and associated with intake of alcohol and/or the study product.|a healthy
131,if,epileptic episodes|suffering,iron storage disorders|recent treatment,niv,urine cytology,placement,allogeneic bone marrow transplantation,accessible.||additional eligibility criteria,not eligible,primary curative cancer treatments,prior to study blood draw.||exclusion criteria,ucva).|less than or equal,more than 1 msv,,evidence,not willing to participate|unable to sign informed consent,female of childbearing potential,"willing to sign written informed consent, able to communicate well with researchers"
132,ccrcc|age,chronic hepatitis c,medications used.|pregnancy,sleep quality||,prothrombin time (pt) ≤1.5×uln,ct angiography,prosthesis,in-,post,side,within 7 days of onset,≥12 weeks.|serum,for 2 year after administration of zvs101e;|the study eye,,requires,informed consent obtained|left,the current,capable of providing consent to enrolment and treatment.|patients with a performance status of
133,first ever,progressive pulmonary fibrosis.|myositis,secretagogues,sleep problems|(4,drinks containing 40% alcohol,anti-infective therapy.|had,historically,ic-8,no marketing,ankle joint.|clinical signs of myopathy,for 7 days pre-injection,1.5 times the upper limit of the normal range,>5 mg daily,,sponsor|able to,able to understand and provide informed consent.||,,capable of becoming pregnant: use of highly effective contraception
134,yrs,mrecist standard;|liver function,secretions,risk of recurrence|malignancy,nci ctcae 5.0 scale,surgical biopsy,vaping devices,adolescents,with the exception of the placement,stage 3&4.|acute,at least 8 points,≥50 ml/min/1.73,>2 ct,,can interfere,written informed consent for all study procedures according to,,"the parent who will answer the form does not know turkish,|orthopedic surgical treatment"
135,2).|male,epithelioid sarcoma,nasogastric tube insertion,diagnosing a risky pregnancy,left mca,thrombolytic therapy)|prior cabg,implantable venous access port,community healthy activities model program for seniors (champs) physical activity questionnaire for older adults|cognitive impairment (,≥1%];|primary,urine human chorionic gonadotropin,within 6 weeks before the first dose of study treatment,<110 pounds|diabetes,>5 minutes,,planning to be become pregnant up to final study visit,able to consent to treatment 4,,the patient cannot be younger than 18 years of age or older than 85.|the patient cannot have sleep apnea
136,polyhydramnios,as -||exclusion criteria,histamine-receptor antagonists,unable to make the decision to participate in a clinical study,serum free light chain ratio,first dose of,pacemaker implantation|ability,university,bacteroides,-mass index,after previous allogeneic hematopoietic stem cell transplantation,≥19 years,less than 15 attacks per month,,3,missing informed consent or inability to consent|age,,"the patient's problem list includes a problem with an international classification of diseases (icd10) code of ""z85.118"" or one beginning with ""c34"
137,pd,positive.|pregnant,anti-anginal agents,incapable of radical local treatment,sao2,stopped menstruation,urethral,west china hospital||,with the exception of thyroiditis.|subjects affected by,first affiliated hospital of xi,at least 1 of the following risk factors,18-45 years.|ovarian,two-dimensional echocardiography.|fully understand the study,,preventing patient from,signed informed consent must be obtained before any study specific procedure.|suitable for high-dose,,refusal to participate|contraindication to the use of local anesthetics|contraindication to the use of general anesthesia|contraindication to regular use of postoperative analgesics like
138,20,somatic issues,adjunctive means,lung hypoplasia|suspected,mmhg;|hemoglobin a1c (hba1c),topical application of cbd/silicone significantly worsens the scar outcome,icon index,outpatient otolaryngology clinic,with the exception of alopecia|patients who are receiving,left jugular central venous line placed,≤30 days after receipt of study vaccine,"≥ 50,000 cells/mm3",first cycle,,unwillingness to consume a,intellectual disability;|hospitalization,,patient older than 18 years|surgery criteria
139,screening.|men,heart valve disorders,regional pelvic,unable to undergo mri of the spine,recist1.1)|good performance status,her2 testing results,aortic valve area indexed,licensed,no smoking,pivot,for ≥1 week after the last dose of study therapy.|ability to understand,21-35 kg/m2|otherwise healthy,≥ 5 cigarettes per day,,need,written informed consent obtained from the subject|male or female,,"provision of signed and dated informed consent form|declaration of willingness to comply with all study procedures and availability during the study|age 18 years old or older|male sex designated at birth|identify as trans woman,"
140,extremely low,neurological cases,drug-related pulmonary toxicity,thiazides,aspartate transferase (ast),ded,occlusive cap (diaphragm,respiratory intensive care unit,absence,malignancy;|clinically significant,at study enrollment,greater than or equal to 8,≥ 1.5 sd,,echocardiography|symptoms,inability to understand,,refusal of informed consent
141,events.|patients,tumor invasion,normal ecg,consistent with par-q+.|having,mers infection;|receipt of,panretinal laser photocoagulation in the study eye,coronary artery disease;|preoperative bradycardia,university of chicago,no diagnosis,45 minutes,within 3 months of starting the study,more than 7,≥1%];|cohort 1 advanced,,referred to the,able to provide informed consent|male,,the subject must be able to understand and voluntarily sign the informed consent form;|subjects
142,frequent,disaccharides,previct drugs,pancreatitis|known,phosphatase,re-infection|history,english|able,hospital universiti sains malaysia,preventing,non-cooperation of the family,within 4 weeks prior to screening.|participant,<40%:||a,more than 2);|history,,clinical manifestation of,lack of compliance with any inclusion,,provision of informed consent prior to any study specific procedures|male and female 18 through 65 years of
143,dementia;|patients,irreversible pulpits,antiretroviral therapy;|individuals,unable to provide consent,nyha cardiac function grading assessment of cardiac function,mechanical ventilation.|need,left ventricular (lv) mass reduction,admission,no,igg4-related disease.||,during the last 2 weeks,<27 weeks,maximum of 30 episodes,,at risk of infection,written informed consent positive,,the patient had other
144,syndrome|poorly treated,atrophic rhinitis,gabapentin,speak english|patient,american fertility score (afs),diagnosis|previously enrolled,implantable contraceptives,outpatient clinic,includes,extrahepatic,in the last 3 months;|use,< 50 mm hg,2% or more,,exception of,"informed consent: signed written informed consent before inclusion in the investigation|sex, age:",,written informed consent form;|patients with fever|patients refused for pharmacology therapy|weight loss treatment
145,the,aside from malignancy exception,enzyme-inducing antiepileptic drugs,progression on gemtuzumab,alanine transferase (ast or,lipid panel,corneal contact lenses,wi-fi network.||,interfering,false-positive rate,within 1 month prior to screening|patient and/or,<1% per year|any,2 - 3 weeks,,need an,informed consent provided by the subject or legally authorized representative.|occurrence of a,,refusal to continue participation in the study
146,procedures|age,structural orofacial anomalies,gep net,willing and able to comply,1|human immunodeficiency virus,vt ablation,labial appliances,pediatric anxiety rating scale,identify,any other organs,within 3 years before screening.|evidence,> 14 years,scores between 20 and 24 +,,refusal,inability or unwillingness to give written informed consent|inability or unwillingness to comply with study protocol||systemic autoimmune diseases,,the patient (or legally acceptable representative if applicable) provides written informed consent for the study.|at least 18 years
147,under age,cardiac surgeon)|eligible,psychoactive substance,birth plan,bilirubin uln,stool examination,femoral vascular access|without consent,congress,not the,fixed,at least 4 weeks prior to randomization.|patients,2019).|participant,less than 2 weeks before screening.|significant,,planning to move,subjects enrolled in m1 through to m5 of the mbbs program,,"provision of signed and dated, written informed consent prior to any study specific procedures.|healthy"
148,vem|age,bone disorders,omada,sleep disordered breathing||,ecog,mini international neuropsychiatric interview (mini),ingredients|metal implants,neonatal intensive care unit length of stay,women|not have,surgical team||,7 days prior to the laboratory test)|platelet count,≥27 kg/m2,ucsd|age 18years,,low risk of,inability to understand and follow instructions|severe lower extremity stiffness with a score of 3 or more,,the patient is eligible for participation in cardiac rehabilitation|the patient has signed the standard rehabilitation agreement provided by the rehabilitation centre
149,baseline|not,perforated ulcer,minocycline,meet all inclusion criteria,points|cardiac function,local pathology.|locally,central vascular access device,university hospital inpatient psychiatric unit.|decision,not able,requiring the use of,within 48 hours prior to the first dose of study drug,9-12 months,5 consecutive years,,calls of,inability or unwilling to give informed consent.|history of,,the child is uncooperative.|parents that refused to give informed consent
150,well;|male,substance use disorders,supportive dexamethasone given,unable to attend,recist 1.1 criteria)|5,doppler ultrasound assessment,colorectal lesions.||,university hospital - inselspital,cannot achieve,discharge to home setting,"in the last month,",older|live,≥ 30 g/day,,preventing from the cell,able to understand and give written informed consent|histologically and cytologically confirmed,,"the patient or his/her family refused to participate in the clinical trial;|severe heart, lung"
151,18,antidiabetic drugs.|ability,local amide anesthetics,endovascular avf creation,pcaspects score,hyperhydration,south,outpatient clinic of the rheumatology department,with the exception of cannabis).|unable to be,interfere with cooperation with the requirements of the trial||any active,within 4 weeks prior to screening;|treatment,≥1.5 × 109,more than 8 cups daily,,documented,inability to give informed consent|planned spinal,,refusing to sign up informed consent
152,"dislocation,|male",diastasis recti.|surgery,contraceptives,insufficient understanding,worst itch/self-,conventional root canal treatment,in-sano resection,university of foggia,except alopecia);|those,screening,within 12 weeks from the last dose of,≥ 9.0 g/dl;|adequate,chemotherapy|more than one,,old|sexually active,informed consent as documented by signature (appendix informed consent form)|age,,patient refusal to participate in the study.|patients with a previous history of
153,life.|age,chronic inflammatory diseases,psychotherapy centers,difficulty in ventilation,anti-mullerian hormone(amh,world health organization definition of osteoporosis,mechanic valve,emergency,with the exception of methotrexate,immune,within 6 months of visit,<125 x 109/l.|documented,only 1 out of 6,,unwillingness to,"ability and willingness to participate in the study, give written informed consent, and comply with the study specific requirements and all protocol procedures.|sex:",,the patient has elevated
154,household members,gastrointestinal insufficiency,replacement corticosteroid therapy,infections|further exclusion criteria apply,serum alanine aminotransferase (alt),intra-knee,55~85 years|adequate vision,,not giving,elevated,more than 75 years old,<24 points,more than 4 new,,prevent,inability to comply with study and follow-up procedures.|women,,any patient whose physical condition will preclude them from
155,condoms,respiratory disorders|major,flow cytometry analysis,speak english|current psychosis,time interval,b-cell depletion therapy,femoral artery,,indolent,disease-matched,during study screening,1.1 or new,greater than 450 milliseconds,,likely to lead,inability to understand written italian|being a retired physiotherapist,,able to provide legal identity certificate
156,enrollment:||male,myalgic encephalomyelitis encephalitis,topical drugs,hcc|on surveillance,hepatitis c infection|concurrent treatment,gastric tube,potentially curative therapy,,compromises the,igh-crlf2,within 3 months before informed consent signing,≥18 years;|prenatal edinburgh postnatal depression scale,sponsor);|at least one,,eligibility,inability to properly follow protocol as determined by the principal investigator,,"refusal to sign consent|any pathology or condition (active tumor, pregnancy, breastfeeding) that the investigators believe may compromise the safety of the subject or the objectives of the study|persons who have had a"
157,volunteers.|age,egfr-sensitive mutations,human albumin preparations,noncompliance to medical regimens,serum glutamic pyruvate transaminase (sgpt),exogenous estrogen supplementation,tracheostomy tube,,with the exception of:||intranasal,-s-igg,throughout the screening period.|hospitalization,>1.5 upper limit of normal,twice per month,,scheduled to be,the patient's main tissues,,intellectual retardation)|addictive behaviors|current major depressive disorder
158,age≥18,cervical spine,mrpa,insufficient compliance,cpap follow-up,video technology,intraoperative floppy iris syndrome (ifis),,outpatient,patch-type electrocardiograph,48 hours before the first dose.|with active,>12 weeks|body weight,more than 1 cycle,,unable to relieve,able to understand a written informed consent|willing and able to comply with all study requirements including potential cyp 2c19 genotyping,,refusal / inability to participate or provide consent|contraindications to injection
159,elevated,child bearing,potassium hydroxide,employee,worst pain rating,biological anti-tumor therapy,usafsam,,with the exception of hydroxyurea,maxillofacial,within 14 days before the test date for measurements before registration.||neutrophil count,60-90 degrees,one of the fellowship trained urogynecologists,,exposures.|known,written informed consent obtained from the patient|severe emphysema with indication for btva:|bilateral,,willing and able to sign informed consent|subject is able and willing to complete all procedure and follow-up visits indicated in the protocol|absence of urinary retention|prostate volume:
160,cooperative,half cusp,monoclonal antibody products,unable to understand the information,female≥,thoraco-abdominal aortic aneurysm,walker bound,,cysts|negative,amenable to surgical,within 72 hours before the first dose of trial treatment,rtms|18-60 years,one of the following:||cd19+,,scheduled to undergo,the exclusion criteria,,parent or caregivers have a child engaging with the
161,under-,cases of copd,anti-viral agents,enrolled in,anesthesia;|total bilirubin,bullae|recent,healthy,,unless presence,culprit-lesion,"for at least six months,|did",>2.5 × unl)|inadequate kidney function,ts by 30-cell,,at risk of becoming pregnant,patient able to provide written informed consent|adult males &,,refusal to participate in research protocol.|patient under administrative supervision|pregnant
162,4)|mri,inflammatory diseases of the face,fancm,bound.|residence in skilled nursing,human immunodeficiency virus (hiv) infection (,arterial dissection,mechanical heart valve|patient,,aucasian|willing to,ears,more than 5 days from the onset of clinical symptoms|sign informed consent form.||,2.5 x 109/l,10 g/serving,,potential risk of bleeding was,written informed consent.|presence,,patient does not consent / incapable of giving
163,atient,national health system,antimalarial,situations that would limit compliance with study requirements.|registration,secondary regurgitant bundle,epidemiology collaboration,intrauterine hormone releasing system,,do not develop,unaffected,within 3 months prior to vaccination;|administration,between 18-25 years|permanent,twice daily,,unwillingness to use email for study communications,able to sign and date the informed consent/assent form prior to any trial-specific procedure,,the investigator thinks that the subject can continue to benefit from participating in the extension trial;|fully understand the extension trial and sign the informed consent form;|complete the zgjak025 trial for 16 weeks
164,period|age,autonomic disease.|major surgery,il-12,spanish speaking;|cognitively able,hypothyroidism)|any laboratory value,quantitative analysis,special dietary habits|adults,,stable,upper extremity finger for a period of one-hour,within 14 days).||1,< 30.|patient,≥ 12 weeks.|function,,anticipated to undergo,patient should be,,"refusal of the patient, previous head and neck surgery or"
165,included)|male,early stage disease,divine,incompatible with the mr,prothrombin time versus control,hepatic impairment|treatment,none,,pneumonitis.|evidence,craniocerebral,3 months,18 - 35 years,more than 8 hours,,substantial risk of,inability to provide informed consent in english or spanish||concerns arising,,patient and parent/guardian unable or unwilling to provide informed consent|patient expected to undergo
166,50,diabetes und stoffwechsel,oral anti-diabetic medication,risk of ovarian reserve alteration,contraceptives,baseline|mental limitation,pxe-mimicking phenotype,,no current,could jeopardize the participant's safety,at least 2 weeks before randomization,≥ 10%.|3,greater than trace proteinuria,,concern,able to provide informed consent|16 years of,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study||participants must have histologically
167,etc.|age,neurological disorders|auditory disorder|allergy,pregnant|metal implants,shrapnel,periodontal status,neck surgery & audiology,shrapnel inside body)|currently,,successful,requiring insulin,within 7 days,under age 18|prior sgb|allergy to amide local anesthetics (,at least one month duration,,treatment plan,not able to read in spanish|not able to give their consent,,"the subject was fully informed of the trial purpose, nature, methods, and possible adverse effects, voluntarily acted as the subject, and signed the informed consent form prior to the start of any study procedures.|healthy subjects"
168,pathologically,calculated by the fridericia,immunosuppressive therapies,wanting,combine affordable housing assistance,program activities,contraceptive precautions,,not obtain,non-syncopal causes,at least 1 of the following criteria:||oral cavity,less than 4.78cm/s.,changed dosage,,will,understand or read danish incl. instructions and questionnaires|any other condition,,be willing and able to provide written informed consent/assent for the trial.|histologically documented
169,analysis.|aged,physiological menopause,intranasal steroid preparations,ulcerative,endogenous fix,delicated machinery,adc,,needs,site for injection,at least 3 months before screening,above 35|contraindication to receiving,20mg daily,,eating,patient stay,,patient under guardianship
170,not,lcc,pharmacokinetics,lift both arms to a,rvd,pathological fractures|patients,wbc growth factor support,,except asthma)|underlying,unresponsive,within 4 weeks of study enrollment.|receipt,≤ 55,≥ 11|physical development,,wore orthodontic,unwillingness to provide informed consent,,lack of or inability to provide informed consent|lack of or inability to allow data collection over the course of the study
171,stent restenosis|patients,hypertrophic cardiomyopathy)||adult,drug-related rash,ribobociblib,imaging showed peritoneal,epidural steroid,implanted cardiac pacemaker,,with the exception of amniotic membrane transplantation. patients,statins|the,at least one hand.||,between 8 and 12 years|skeletal class i or ii malocclusion|skeletal anterior open bite,frequency of agitation/aggression,,scheduled to receive,not giving consent,,the affected tooth is in the acute inflammatory stage;|those who have bad habits
172,nelson:||age,hepatic failure|individuals,organ transplantation|subject,bias interpretation of the trial results,recist v1.1 (phase ib part,verbal directions,hormone receptor positive,,months|patients free,discolored,for more than one month,< 22 days|fetuses suspected,≥ 1 month,,likely to impair understanding of or compliance with the study protocol,"any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns",,the following criteria will be taken into account for the individuals to be included in the intervention and control groups:||volunteering to participate in the research
173,athletes.|age,smokers.|pregnant,n-bps|estimated glomerular filtration rate (egfr),subcutaneous,montreal cognitive assessment,mechanical ventilation|bilateral airspace opacities,implantable infusion,,does not apply,at stable dose,for at least 14 days prior to the laboratory evaluations,1-6.||,1 to 3,,extremely,written informed consent and assent (where applicable,,"the patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the u.s."
174,prisoner,addictions,anti pd-1,unable to travel to the clinic.|subjects,metropolitan palliative care service of bologna|residency in bologna metropolitan,endometriosis procedures,implantable),,except 2,allergies.|known,at least 3 days after enrolment|possibility to start the study,< 1 year|currently pregnant/breast feeding,starting within 3 months after chemotherapy,,elected,"inability to understand the chinese language, as well as a diagnosis of",,patient refusal to participate|known
175,born,mildly reduced left ventricular ejection fraction,tumour tissue,estimated survival period,etici score,treponema pallidum test;|subjects,epidural steroid,,not opposed,site of occlusion,applied 24 hours before pivc,5-26,at least two weeks between feeding periods,,likely to interfere with participation in,patient of lung surgery||lung cancer,,the only inclusion criteria for this study is that participants must have consented and enrolled into a ctu affiliated study
176,defect|women,traumatic brain injury.|participants,induction agents,older|patients,below||hemoglobin,eoe,pd,,withdrawal,mers).|fever,at the time of signing the informed consent|are able,18 years old or older.|diagnosis,20 mg of,,limit for,informed consent has been signed.|in age,,the patient's refusal|active infection in the area to be blocked|kidney failure|liver failure|heart failure|bmi less than 18
177,woman,pyloric obstruction,oral coumarin agents,mr,neutrophils absolute number,radiation therapy,reduced lvef,,other,fna|scheduled for surgical treatment||,past 30 days,less than 30 days prior to enrolment,≥ ctc ae level 2,,low risk prostate cancer,inability to understand the procedures and the potential risks involved as determined by study staff|inability to participate in study procedures due to blindness,,willing and able to provide written informed consent (and assent for minors 12-17years old)|be enrolled in routine hat screening activities dony by the mobile unit (pnltha mobile unit routine active screening teams that visit villages at risk for hat)
178,paclitaxel;|age,acute rheumatic fever,histamine-2-receptor antagonist|dual antiplatelet therapy|combined antiplatelet,spermicides,breastfeeding|systolic blood pressure,frozen fresh plasma,implantable hormone contraception,,no menses,non-small-cell lung carcinoma,"last 4 months prior to study entry,|non-invasive",<7.4 g/dl).|presence,more than one category,,likely to impact cognition,"willingness to participate in the research,|18 years and over,|being in the second trimester of pregnancy,|born in syria,|the mother tongue",,infection:||adult patient hospitalized for less than 24 hours in icu for confirmed
179,amenorrhea)|women,toxic epidermal necrolysis|lymphoma,anti-tigit,sexual victimization,her2 amplification ratio,vertebrobasilar artery,immunohistochemical studies||any of the following:||isolated,,age-,1st dose,for at least 14 days prior to first dose of study intervention).|has,≥ 12 weeks,> 10 mg daily,,maxillofacial,capable to understand and comply with the protocol,,genetic oder familial risk (
180,recipient,"hopeless tooth,|healthy periodontal condition,|presence",somatostatin receptor pet imaging agent,infertile,uln).|hemoglobin a1c (hba1c),cognitive impairment|contracture,implantable intrauterine device,,excluded from,irreversible pulpits,within 2 years of transplantation,< 1000/mm3,>10mg/day,,black|assigned,subject's age,,the inclusion criteria
181,identity,symptoms onset should start,tofranil,crssnp with asthma:||these,pulmonary artery size,acl injury|control,inactivated,,neostigmine)|patients,protocol noncompliance,within 6 months.|participants,< 0.5.|necrotic tissue in leg wound,> 4 mg,,compensated,inability to follow,,"refusal to participate by the resident, family member or designated support person|communication difficulties"
182,varicella exposure,abnormal heart rhythm,live therapeutic infectious agent,leftover tissue available from the surgical resection of their tumor available to request,1st,completed treatment,psychotropic substances,,n0;||,unknown splenomegaly,within 4 weeks of ip,> 1.5 times the upper limit of normal;|liver disease,once per week for,,cannot,able and willing to provide a written informed consent;|age,,the patient must sign an informed consent form;|age 18-75 years old
183,years|only,sexualabstinence,heparin|ec,render the patient medically unstable,stool + occult blood test,percutaneous revascularization;|ct imaging of the thorax,implanted electronic device|surgery,,no sun,other related,recent one year.||,> 35|pregnancy,≥ 1.5,,planning on becoming pregnant,inability to follow the patient due to geographical or,,parental refusal of participation.|chest infection
184,waiha or cad,cervical joint position error,adequate organ function|women,abstinent,minimal support||,minor procedures,barrier method of birth control,,skin)|abnormal,secondary form of,within 2 weeks prior to first dosing.|participants,18-35 kg/m2|brachial,2 weeks prior to enrollment.|presence of,,need to receive further treatment.|patients,is capable of understanding informed consent and is willing and able to provide written informed consent.|is willing to comply with all protocol procedures.|healthy,,refusal to take part in the study|history of
185,syndrome.|age,cns hemorrhage,squalene,needling,ats-ers,small dermatological malignancies,aortic valve,,assessing the duration of,plausible,after delivery for technical or,≥ 1.0 g/l,more than 7 consecutive days,,requirement of,signed informed consent provided by an authorized subject representative (based on local institutional review board,,the subject must have a known
186,e1,middle ear surgery,antiplatelet therapy.|provision of informed,signed informed consent provide.|stable mental state allowing,college of american pathologists (cap),single-agent treatment,slipped disc,,no fibrosis,progressive to any neurological deficit|sustained,in the last year|vestibular,≥65 years.|more than 6-month,1-month,,limiting,inability to give informed consent|claustrophobia|prior surgery,,written informed consent signed prior to enrolment.|age > 18 years
187,procedures.|age,thyroiditis controlled,linkage,egg retrieval,define pas,inhaled oxygen concentration,irreversible hematologic toxicities|patients,,with the need of,hiv)||clinically significant,during the study duration|treatment,> 15 mg weekly,12 consecutive,,anticipated,inability to provide informed study consent and to carry out a qualitative research interview,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|age >18 years|bmi >30 kg/m2 at screening
188,yet,fertile partners should,mibc,alcohol excess,potassium,safety|serious psychological,implantable drug delivery systems,,needle,enlarged,during the period of study participation.|absence,score of 0 or 1.|resolution,twice a day if they,,referred for,inability to understand the aims of the study and/or protocol procedures|hypersensitivity towards,,voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures|use of highly effective methods of birth control
189,members,macular conditions,immune compounds.|patients,mtss,||neutrophil absolute count,conventional coronary angiography||,dedicated central venous catheter,,from the,non-functioning,in the past 2 weeks.|have,≥ 8 years;|respiratory,≥ new york heart association,,need urgent,inability to understand the information given|person deprived of,,the subject understands and has provided the informed consent form (icf);|male and female
190,b,autoimmune neuropathies,fitbit dmd,enrolled in mpc study (protocol 850160).|reliable study partner,adversity inventory-screener);|not,back surgery syndrome,wbcs,,completion.|unable,contraceptives,at the time of procedure,>30kg/m²)|professional athletes|pregnant,500 mg - 2550,,low risk for progression,patient was capable of understanding,,"provision of signed and dated informed consent form|stated willingness to comply with all study procedures, clinic visits"
191,weeks|women,chronic digestive disease,vitamins/dietary supplements,weight watchers,short physical performance battery,screening,etc.|metal implants,,no other,hematogenous,within 28 days of the start,between 32 weeks of amenorrhea and 36 weeks of amenorrhea + 6 days,drink 14 units of alcohol per week,,chest,inability to sign consent form|inability to speak english|emergent surgery|current smoker|smoking,,the patient's compliance is affected or the subject is at high risk of treatment complications.|covid-19 infected persons
192,ovary,random;|immune deficiency,progestin-containing iud,participated in other interventional clinical trials,to||clinical sledai,changed psychological treatments,metal implants,,no urgent,other products,within 1 weeks before,<20 ng/ml,≥ 480 ms)|new,,likely to undergo,able to give informed consent|above 18 years old||,,the subject is scheduled for elective colonoscopy.|the subject is
193,women|age,unstabilized coronary artery disease,anti-pd-1- ligand-1,cockcroft-gault,g-csf),positron emission tomography (pet) ct,study stent,,no exclusion,stable form,for prior 3 months,4 weeks,10 mg prednisolone,,clinical judgement of the investigator to be in,"patient unable to undergo general anesthesia,|pregnant",,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|diagnosed with cutaneous angiosarcoma of the breast or scalp
194,incident,hypoxemia,pneumonia vaccine,risk for severe hemorrhage.|has,hepatitis b surface antigen (hbsag) reactive,quality of life given the poorer prognosis,cessation devices,,and/or existence,apparently cured,within 14 days or 5 times the half-life,76-85 depending on his condition|patients,2020.|at least one,,parenchymal,written informed consent obtained to participate in the study and hipaa authorization for the release of personal health,,"the subjects voluntarily joined the study, signed the informed consent, and the compliance was good.;|age"
195,hemodialysis.|life expectancy,juvéderm voluma,gfr)(srfipsilateral,situations that would limit compliance with study requirements|pregnancy,back pain;|history of,autologous hematopoietic stem cell transplantation,metal prostheses,,compromises the benefit,institutional guidelines.||severe,within 28 days,under 2 years old,2,,likely to impact participant safety,availability of written informed consent to participate in research work;|age from 18 to 85 years;|availability of data from a general blood test,,"the subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study|the subject refuses to sign the consent|it is impossible to give the subject informed information|the patient is under safeguard of justice or state guardianship|lesion not eligible for thermoablation (proximity of the liver hilum and the main bile duct).|uncorrectable abnormalities of liver"
196,both sexes,qrs evolutions,systemic analgesics,professionals||participant,new york heart association classes,trained neurologists.||,saphenous vein graft,,survival time<0.5,heavy-duty standards of the new,within the prior 1-8 months|hba1c≥8%,> 2.5 mg/dl|albumin < 3 g/dl|alanine,thrombus).|at least one,,potentially eligible,able to understand and provide informed consent.|natural born,,the patient is at least 18-year-old.|the patient is a woman.|the patient was prescribed with a surgery for a breast augmentation or reconstruction
197,exposure)|age,abnormal physical examination,psychoactive medications,sleep disorders.|children,cooperative oncology group performance (ecog) status,12-month,penile implant,,with the exception of alopecia.||note:,non-traumatic,within 72 hours before delivery,≤3.0 × the upper limit of normal (uln),"1 mg, 3 mg,",,unlikely to adhere to the study protocol,months;|availability of parents or legal guardians to provide free and informed consent to participate in the study||,,"appropriate written informed consent is required.||in addition, patients need to meet the criteria of one of the following study groups:||group 1"
198,childbearing age,cough symptoms,antimuscarinics,participated in a clinical study,antibodies targeting tigit,complete colonoscopy,central venous catheter placement,,eighteen,non-inflammatory rheumatic disease.|history,prior to transsphenoidal,>=12 weeks|disease-free,≥6-month,,retro,ability and willingness to provide written informed consent.|sufficiently fluent in english to participate in the trial.|between 18-55 years,,willing to commit to entire 2 years of follow up visits.|(controls) matched to each case on age (+/-1 month
199,completed,hearing impairment sufficient,aromatase anti-estrogen,participation in psychological therapy,corneal thickness,pet-ct shows increased metabolism with suv≥2.5,minimally invasive,,from january 1st,preparing for pregnancy,within 2 weeks before the first use of the study drug,"february 17, 2014",doses greater than 10 mg/ day of,,r all,"not being voluntarily or willing to participate in the research,|will receive radiotherapy or",,a:||able to understand and sign an consent form (icf)
200,peri-operative,acceptable representatives,statin intolerance,polish version validated,maximal dose of vasopressors,local-regional treatment,cardiac resynchronization therapy (crt) device implantation,,permitted,self-identified-no,for at least 2 weeks before the first dose),≥ 60 grams|daily,10 mg/day).|ni-13,,likely to affect absorption,consent to participate not given,,states)|must be able to receive in the mail a weight scale.||
201,1.adults,unstable allergic rhinitis,anti-transcription intermediary factor 1 (tif1) gamma antibody,situations that would limit compliance with study requirements|participants,international cancer control,interim assessment,implanted cardiac defibrillator,,no pr,thiazides,within 180 days prior to,=< 5 x institutional uln|aspartate aminotransferase,≥ 750 cells,,pericarditis.|planned for,able to understand and willing to sign the informed consent;|aged,,"previously provided optional consent to participate in a qualitative study as part of the basil+ trial|not enrolled or offered to take part in any other qualitative study linked with the basil+ trial (i.e, the nested basil+ qualitative study or the therapeutic alliance sub-study)|suffering"
202,||men,autoimmune diabetes,rehabilitation,stainless steel,bone mineral density (bmd),physical organ transplantation;|there,cochlear implants,,can cause,humoral,within 6 months prior to the trial;|patients,less than 2.5kg or > 4.0kg,once a month from the start of study,,hospitalization.|high-risk population.|bronchitis,university students who are in their first or second year of studies.|having had,,the subjects volunteered to join the study and signed informed consent form (icf)with good compliance;|age
203,splenectomy)|age,breastfeeding|psychiatric illness,adalimumab,render a subject unsuitable for inclusion|unwillingness to,plt)≥,molecular testing (,metallic implants,,not pregnant|not,non-uric acid stones,longer than 30 minutes,exceeding 3 times uln,frequent - of the abdomen,,will be,able and willing to provide written informed consent and to comply with the study protocol;|subject,,"the subjects voluntarily participate in this study who are able to read, understand, and sign the icf before participation;"
204,enrolled.|age,breast-feeding women|subject treated,dispensing,risk of recurrence.|subjects,dyspnea questionnaire)|evidence,systematic chemotherapy,implanted cardiac,,naïve,ib zone,prior or,> 1.5x the upper limit of normal (uln),more than 4 months,,need to use immunosuppressants;|(11),"not willing and signing an informed consent, and not willing to consume fungtional bread",,patient to understand the character and individual consequences of the clinical trial|in the investigator's judgement
205,inpatient,visuospatial memory)||,mbi,endocrine,serum follicle stimulating hormone,local regulation||,condoms,,lack of,suitable for et installation.|<70% of hhs,during any sexual contact,less than or equal to 2.5 x uln||albumin greater than or equal to 2.8 g/dl||patients,more than two times a week|control,,chemoradiation,"able to speak and understand turkish,|those between the",,signed written informed consent|patients who have received
206,"mmunicating,||over",major psychiatric condition,k,method of birth control the treatment period,international bone marrow transplant registry,kidney after heart,implanted porcine,,months|presence,non-index aneurysm,at least 3 days prior to the first refraction used to establish stability.||two consecutive manifest refractions,below 60mmhg not,outside the operated,,planned to get,subjects whose parent(s) or guardian(s),,refusal to consent or communicate
207,ad|male,nuclear cataract locs ii|cumulative dissipated energy cde,attenuates vaccine,falls,serum blood pregnancy test,pharmacological androgen deprivation therapy,cessation|meets dsm-5 criteria,,"with the exception of appendectomy,",muscle-skeletal,within two weeks of enrollment,<75×109/l,2 or 3,,planning to receive,subject informed consent form (icf) is singed|aged at least 65 at the time of the signature of icf|a,,refusal to participate|allergy to the study drugs|chronic kidney disease (creatinine>150 μmol/l)|mental illness|liver
208,imprisoned,completed pulmonary,target medication classes,family of investigator site personnel,visual analogue score (vas),antihypertensive medications.||,intracranial hypertension|history,,precluding,first-line chemoimmunotherapy,for at least 8 weeks,> 8mcg/kg/min)|documented,maximum of 3,,suspicion that,inability to comprehend and to follow all required study procedures.|have a recent history,,"the patient understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure.|age"
209,ale,symptoms of disease,eua,unable to reliably,see section 10.8.1,general hospital,contraceptive measures,,with the exception stated in the inclusion criteria,menopause|completed,within 60 days prior to,< 80 mmhg,12 to less than 18 years,,clinical signs of a,understands and provides written informed consent and willing to follow the requirements specified in protocol.||2,,patient's refusal of pupilometry measurement.|pre-existing pupil abnormalities.|history of pathologies with dysautonomic impairment (advanced
210,1/10,romiplostim,sulfa containing drugs|inability,risk of bone fracture|platelets,pain interference score,hartmann's procedure,prosthetic heart valve|bicuspid aortic valve|known cardiomyopathy,,can not,non-kit,within the last 28-days before,≤2× uln,81mg od,,intention to,written informed consent obtained prior to any study-specific procedures,,signed written informed consent|18 years of age or older|ongoing treatment with any chronic dialysis treatment
211,treatment.|women,speech disorder.|self-reports,phenobarbital,1.|expected survival,wide-neck aneurysm,lung-function testing;|inability to understand dutch,indwelling catheter,,except from,unstable,in the past year|active use,<32 weeks,1 to 3 years,,planning to start,inability to safely and comfortably undergo an,,parental refusal of participation|evidence of moderate to severe upper respiratory tract infection
212,pustules,non-epileptic,lfts,insufficient bone marrow reserve,new york college of cardiology,volume distilled spirits).|excessive consumption of caffeine-,inactive ingredient(s,,never,end-of-life care,within 2 years before the first administration|synchronous,≥40×10^9 /l,subsequent 12 months - minor,,unable to complete surveys,able to comprehend and willing to sign an informed consent form approved by the irb before screening.|adult volunteers,,the participants' age range from 35 to 45 years|their body mass index is
213,line.|age,screening.|diabetes mellitus,arni,render the study,treated.|ecog performance status,cardiovascular therapy,circular stapled esophagogastric anastomosis||,,patients|patient,interfere with cooperation with the requirements of the study;|are,in the study eye:||previous treatment with,between 18 and 49 years,5 half-lives,,diagnosis,able to understand study requirements,,refusal to participate in the study|non-french speaking parents
214,1、patients,non rcc malignancy,recombinant fviii for,difficulty biting|subjects,screening.|syphilitic antibody positive.|trauma,place ecog strip,contraceptive rod,,no more,non-emergency,for at least one of,>= 60 ml/min,once to determine,,planned to start,refuse to sign informed consent,,the patient's age is
215,body weight,collagenous sprue,blood thinning products,dyspnea,outside chittenden county)|proficient in english||,"cesarean delivery,|not",urethral plate,,except,successfully treated,during study participation.|a participant,<60 ml/min/1.73m2)|hereditary,≥ 48 hours,,expectation,inability to provide,,patient's guardian refusal to participate in the study.|children
216,additionally,responsibility,actimel,signed informed consent.|patient,ldl levels,ultrasound guided procedures,ferromagnetic implants,,with the exception of:||cytotoxic agents when administered as a,diagnostic and statistical manual of mental disorders (dsm)-5 diagnosis,at the baseline visit.|a,≥18 and under 75|predicted survival,>5 hours,,enamel flaws,the relatives not living in the same house,,patient or parent refusal|unable to obtain written consent at the surgical outpatient clinic|surgery planned
217,accept,chronic pathology,rrt,cleaning).|10,serum ige ≥500 iu/ml,myringotomy,adhesive dressing,,poorly,clinically diagnosed,for at least 4 months after the last dose of the study drug,≤ 3 ×,2 hours,,can be,inability to provide informed consent.|for participants,,signed written informed consent.|male and female
218,1.|female,trastuzumab induced,eye|pupil diameter,premature birth;|an enrolled patient living in the same,glomerular filtration rate<25 ml/min/1.73 m2,subsequent follow-up imaging|recurrent tumour visible,unruptured intracranial aneurysm,,low,muscle strength assessments and confound the disease activity assessments.|wheelchair bound,at least 12 weeks of standard doses of pd-1,28-36 weeks).||,6 or more,,unwillingness of,patient enrolled in other clinical trial during the eap.|patient aged,,the patient must be 18 years of age or older.|patients
219,ev,signs of bruxism,romiplostim,commit to attend clinic,her2 negative|bilateral breast cancer.|stage iv breast cancer.|benign,consumption of more than four alcoholic units,incompatible foreign material,,unavailability,implant surgery.|patients,within 4 weeks>5 ml fresh blood,≤ 50||,visit)|concomitant,,preventing the,bpm.|written informed consent to participate in the study.|affiliation to a french social security system (beneficiary or legal)|biomarker levels indicative of congestion,,understand and provide written informed consent prior to the initiation of any protocol-specific procedures|must be willing and able to abide by all study requirements and restrictions||
220,years|histologically,structural lesion,ncs,chance,cooperative oncology group (ecog) score,reactive attachment disorder,mismatch-repair system,,except a,hiv-positive,within 6 weeks prior to,numbers ≤ 3,more than 1/3 of root,,immunomodulators.|treatment for,patient admitted to the hospital with a,,the patient has received other therapy including radical radiotherapy
221,moreover,impaired vision,local anti-tumor therapy,patient related outcome,hcv viral load.|patients,haematopoietic stem cell transplant,inc. study,,denial of,anesthesia,more than +1,> 90 ml/min/1.73m2,greater than 24 hours|and/,,visible,able to provide voluntary written informed consent of the participant prior to any screening procedures|male,,the subject selection will be according to the following criteria:|age
222,form.|male,non-obstructive cad,class iii anti arhythmic drugs,progressed beyond first,arc clinic hna,secretagogues,catheters,,prevents,symptoms|non-lupus conditions,within 1 month before vaccination;|subjects,=< grade 1 (per common terminology criteria,more than 15 minutes,,likely to suffer,years|written informed consent (,,the patient was pathologically diagnosed as
223,01.11.2022||,health questionnaire anxiety,anti-cd19 therapy,partners of childbearing age,body mass index>30,teria:||to,prosthetic valve implantation,,between,primary progressive,past 5 years.|negative for,18 years on the day of inclusion,more than one symptom,,eating behaviour,signed patient informed consent and privacy consent documents||,,initiation of levosimendan > 48 hours or < 24 hours before surgery|ecmo pre- or post-op
224,sexes,physical performance|cognitive impairment,vitamin k,rospective,balloon)|lesion length,small molecule tyrosine kinase-targeted agents therapy,implantable cardiac defibrillator,,other oncological,ankle-foot orthosis,within 6-8 months,at least 20 meters,20g/day,,planning to give birth,inability to complete the entire study programme|previous participation in an mbsr,,the patient was previously included in this study.|the patient has had any exposure to radiopharmaceutical products
225,ultrasound).||13.female,left ventricle damage,var,entry into this,following:||platelet counts,surgery|cardiac surgery|surgery,prosthetic aortic valve.|echocardiographic evidence,,besides,focused,during registration);|both couple members,greater than the upper limit of normal (uln),more than 5 kg variation in body weight,,planning to be,able to understand and voluntarily sign the informed consent form (icf);|males and,,"patient refusal to epidural analgesia,|contraindications of epidural analgesia"
226,regular strenuous exercise,pathological changes,long-acting regimen,insufficient amount,qt interval corrected using,visited their transplant specialist,reduced epicardial flow,,not received,prohibited,within 2 cm of the selected treatment area|topical salves,a and b categories|18 years,more than one year,,rooted,ability of participant,,whose parents quit smoking
227,previously|women,lmp,antithrombotic medication,cohort exclusion,hepatitis c virus antibodies (hcv abs),attempted curative resection,"psychiatric pathology,|pregnant",,need,unfavourable,within 7 days prior to the first dose of trial,=< 1.5 x uln|aspartate transaminase (ast),single dose of,,at risk of,not willing to provide consent,,"withdrawal of informed consent by a volunteer and/or a parent of a volunteer;||the volunteer was included in violation of the inclusion/non-inclusion criteria of the protocol;|availability of inclusion/non-inclusion criteria before vaccination;|any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study;|the established"
228,wocbp,trauma-induced,over-the-counter competitor product,remain at the clinical site as required,peri-implantitis proven,liver disease;|drug addiction,consciousness|cardiac pacemaker,,cannot perform,stage 1-3.|no indication,within one week of study entry.|participants,1-3;|consciousness,130 ml wine,,screening;|history,"able to understand and speak turkish,|ecog performance scale score of 0, 1 and 2|being literate|owning a",,patient presented with common warts in dermatology opd||
229,younger,narcissistic personality disorder,pramlintide,participated in a research study within,thoracic oncology 2016.|who performance status,intrahepatic bile duct cancer exists,mrm,,epithelial,conjugated,within 2 months prior to initial medication,">0,25 mmol/l",less than three months from enrollment,,improved to,inability to speak or comprehend the english language|patients scheduled for no-depth vaginoplasty surgery|patients,,parental psychiatric problems
230,syndromes.|currently,chronic respiratory failure,firefighters,life-threatening condition,residual cough,sexes;|expected survival time,acr criteria|tibiofemoral knee osteoarthrosis,,aside from the diseases,interferes with outpatient therapy,within the previous 28 days,>1.5ng/ml|women,>3 months,,can be treated,able & willing to participate in the study,,"willing to sign the informed consent form and follow the requirements specified in the protocol.|aged 18 to 75 (including 18 and 75), both genders.|bmi ≥17|life expectancy"
231,iii.|age,renal dysfunction|acute severe,il-2 or il-15 agonist,literate,criteria of american academy of otolaryngology-head and neck surgery,serology tests,incompatible metal implants,,exhibiting,preclude mri scanning,in the past 6 months|changes,≥ 100 mg/dl,≥ 48 hours|meets,,unwillingness to take,informed consent signed and dated|healthy participants who are determined by medical history,,s of 18-65|the fact
232,women:||aged,infectious diarrhea,isoflavone-derived supplements,expected to receive,child pugh a)|systemic therapy,anticoagulation treatment,epidural corticosteroids,,amendable to,rehabilitation,within 30 days of surgery.|patient has no,> 1 mm,over 2 or more,,evidence of,inability to accept the privacy policy and terms of use of,,"the subject must sign the written informed consent form, and can comply with the visits and related procedures specified in the protocol.|aged ≥18 years.|patients"
233,part in another research study,chills,visit|systemic steroids,unable to collaborate,afi,injection pain|unable to communicate verbally|pregnant,implanted cardiac assist device;|acute,,cannot be,h. pylori,outpatient services.||,from 0.01 to 1.0|control,more than a,,expected,"inability to comply with study and follow-up procedures|prior il-15, il-2, synthetic il-2, or il-2v based therapy|history of severe allergic or",,the subject is currently participating in another clinical investigation.|pregnant or breastfeeding
234,ii|age,lymphocytic enteritis,single agent,vegetarian diet,sodium less than 128meq/l,cardiac angiography,implanted electromedical device,,speak,intra-oral scans,prior to surgery.||,≥ 90 degrees,2 weeks before administration to at least 1 month after the last dose of the study drug,,able to consent in english or spanish,patient's compliance to follow-up.||,,the subject should be 18 years or older when undergoing the procedure;|subjects sign informed consent;|the subject signed informed consent dated back within 12 months and only implanted with biotronik orsiro sirolimus-eluting coronary stent system
235,are:||male,rheumatic heart disease;|severe right ventricular insufficiency,clexane etc.)|patients,ctr,lfts,complete resection of limited colorectal metastases to liver,forms of contraception,,allowed,feels better,within 2 months of study,≤ 75 years;|subjects,more than 2 cups/day)|patients,,changes that impair assessment of,ability to communicate adequately|absence of psychiatric problems|not having received,,patients unable to sign informed consent
236,surgery.|age,glucose-insulin,lmp,capable adult,serum chemistry values,intraocular corticosteroid injection,ios,,lack the,worse than 8.0 diopters of myopia,previous 3 days|acute pancreatitis,≥ 100 × 10^9 / l,2 to < 6 years,,hypertension|presence of,has given written consent|be,,the parents will be excluded if:||there is report of ongoing physical or sexual abuse|they have plans to terminate the pregnancy|the woman
237,histology;|age,e.g.- dementia,tucatinib,situations that would limit compliance with study requirement.|history of another,qtc interval,radiographic means,sp263,,exceeding 210,alxn1840 outweigh the potential risks for the participant.|participant,within 3 weeks before,< 5 years.|has,more than 1000 copies/ml).||,,preventing participating in,inability to give informed consent.|systolic bp,,patients who do not want to participate
238,pregnant,ureteropelvic junction obstruction,residual,cigarette smoking,residual signs,deemed ready,intrauterine system,,cannot have,pregnancy)|common,within 30 days before study day 1.|documented,32-39+6,>14,,planned to,genetic equivalent ≤ 3.0 x uln and primarily unconjugated),,provision of consent from heads of
239,caucasian,hr˗ mbc,rapid,candidates,hits,procedure cabg,punctal plugs,,iteria:||identify,suitable for such patients.|the,at the time of admission to the intensive care unit||,< 15 ml/min|have,more than 18);|having,,pressure>110mmhg)|expected,not willing to participate in the trial signed the consent form|inability to perform,,the subject must be a
240,volunteer,complete bundle branch block,agent targeting t-cell costimulation,home;|uncomfortable speaking,endomysium antibodies (ema);|absence,graft-versus- host disease,circular stapler for anastomosis,,secondary,plan.||,less than 1 year before,≥ 18;|histologically,dabigatran|concomitant,,agrees to discontinue,acceptance to participate in the study.|age,,"refused to sign informed consent|pregnant and breastfeeding|has severe chronic comorbid diseases (cancer,"
241,cd|age,hematopoietic stimulating factors,sm14 vaccine,willing to participate in this study,cumulative total length,clinical laboratory tests.|individually matched,sleep-inducing drugs,,no use,thoracic spine,through at least 90 days,less than 3.5g;||10,<12 months of non therapy-induced,,likely to progress,written informed consent.|healthy,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|women of child-bearing potential
242,females|adult,good aerobic,leukotriene antagonist,difficulty to stay,columbia suicide severity rating scale,adjuvant chemotherapy agents,prosthetic antagonist,,high,low or high,prior to starting the diet.|on low carb,over 50%,≥ 50×10^9/l,,higher|active,written informed consent for participating in the study and written standard version of informed consent for cardioversion accepted at the department of,,patient does not have
243,result,juvenile dm|any,intraoperative administration,volume drawn,mayo endoscopic score,prophylactic antibiotic coverage,dwi,,apart from,refractory to medical treatment,during the procedure.|disease of the left pleura,31-08-2020|planned,≥ 6 at,,imminent risk for,informed consent obtained before any study-related activities (study-related activities are any,,willing and able to provide informed consent.|established diagnosis of oa of
244,employee,pathology;|delivery,under medications,living in belgium,follows:||hematological neutrophils,control blood,isolated unilateral diacfs,,age|type 2,t3-t4n0)|patients,within 28 days of first dose of study,≥ 3.0 × 109/l.|platelet count,more than two units,,suspicion for,able and willing to provide a written informed consent|diagnosed,,"refusal of procedure or participation in the study.|patients suffering from asthma,"
245,outpatient)|age,bifascicular block,kh617,risk for osteosarcoma,coagulation profile,gastric bypass,inductive effect,,exception,transgender,throughout the 10-week study period and fill out the study questionnaires,≥18 years and able to understand the purpose of the study,greater than one year,,planning,inability to give informed consent|pregnancy.|ongoing participation in any investigational research that may undermine the scientific basis of the study.||contraindications to magnetic resonance,,"the subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study|the subject signals their opposition to participate in the study|it is impossible to give the subject informed information|the patient is under safeguard of justice or state guardianship|patient pregnant or breastfeeding|history of proven cancerous disease|patient followed for a chronic inflammatory bowel disease"
246,sle)|female,drug eluting,w1d1,iii.|written informed,prothrombin time [pt],baseline organ function,aortic valve regurge,,agree to,balloon retrograde transvenous,more than 15 units,≥0.8× 10^9/l|platelet count,maximum of 4,,indicated to,written informed consent must be obtained before any assessment is performed.|participants must be,,"the subject voluntarily participates in the clinical study; fully understand and be informed of the study and sign the informed consent (informed consent form,"
247,a:||aged,ranging,mrna vaccines,link to dry eye,anyone born,procedure;|prior meniscal resection,hemorrhages after ivt injection,,not otherwise,non-function pituitary adenomas||,post- transplantation,2-5,14 or more days per month)|abnormal,,need to,"subjects fully understand the purpose, nature",,"the subject who has clinically significant disease with liver, endocrine system, immune system"
248,therapy;|age,chemical injury,magnesium levels,unable to complete study questionnaires,taiyuan|primary school children,percutaneous nephrostomy tube,"congenital uterine malformations,|patients",,women|less than,mild to moderate dementia;|aged 18+;|having at least weekly,on the face or scalp,≥18 years.|established,≥21 alcoholic drinks,,symptoms of,informed consent as documented by signature|adult,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|male or female
249,procedure.|male,ayahausca,anti-craving medications,sleep-targeted psychotherapy|transmeridian travel,oncology group performance status,ttr,intrauterine growth restriction,,unrelated,selected age range|children,at the department of medical oncology,more than twice the upper normal,2 mg/kg,,likely to be pregnant,inability to lie still for the entire,,a:||able to understand the study requirements and provide written informed consent before and study assessment is performed|male or female
250,protocol)|male,malignant tumors.|received investigational pharmaceutical,component of,includes,veterans affairs medical center,cervical foraminal stenosis|cervical central stenosis|cerivcal disc herniation|cervical spondylolisthesis||,longer|implantable cardiac monitor,,not receiving,related to defecation,at the time of interview,< 16kg,once a week for more than six months,,electively,"availability of signed and dated informed consent of the patient to participate in the study;|patients with moderate combined hyperlipidemia, defined as:||total cholesterol level",,"the students' age will range from 9 to 11 years.|normal weight, overweight"
251,mm,demonstration of a qtcf interval,melatonin,any other condition,"vas (visual analogue scale).|have sufficient cognitive ability to fill in the various questionnaires (level b2 french),||",extensive dental therapy.|participant,immunocompromised state,,in addition to,late,within the 6 months prior to randomization;||12,>2|has,≥ 12 weeks.|baseline,,planning for,inability to sign the informed consent form;|current use of,,unwillingness to provide the samples or clinical information needed for the study;|history of
252,i|need,non-responsive,fluoropolymer,protein diet,lumbar disc herniation|cardiovascular symptoms,global lung function initiative [gli])18 ≥40%||key,location services enabled,,not registered,older|patients,during the study.|enrollment in another study,17.5 to 32 kg/m2,≥ 20 mg/day,,auditory impairment||mild,"patient under legal protection, guardianship or",,patient's opposition to the research|utuc not eligible for curative surgery|locally advanced
253,iteria:||male,rheumatoid purpura,supportive anatomic imaging,close relatives of the study site personnel,fasting glucose [ifg,drug intervention,cardiac resynchronization device (crt),,naive,nprs).||,scheduled to receive,≤2.5 × uln,more than 10 mg/kg,,amyloidosis.|expected to,"not willing to participate in this study,|patients with severe",,refusal to participate or
254,atients):||age,valvular heart disease.|pre-registration,"beta blockers,|drug",contrast.|life expectancy,weight scale|height,knee arthroplasty surgery||,permanent pacemaker,,cannot wear,american college of sports medicine guidelines.|neurological disorders affecting the lower extremity,for at least 7 days prior to first dose of study treatment.|participant,≤ 25*,less than 1 training session/week,,initiate,patient was <18 years,,refusal to participate|existence of another neurodevelopmental pathology
255,fatigue.||female,transplant recurrence of fsgs.|ability,congenital long qt syndrome.|patients,life-limiting illnesses,fondazione policlinico gemelli irccs rome,local sequencing test,implanted electronic device,,aside from,stage 3,at the time of the surgery,< 100×10^9/l,long half life.||15,,planned administration of trial medication,"genetic testing|willing to commit to three in-person visits (baseline and 18-month follow-up and 36-month follow-up) as well as remote visits by phone, email, mail or internet.|no",,provision of signed and dated informed consent from participant or legally authorized representative.|person of any sex/gender 40 years of age or older.|ability to take
256,varicella,cns damage,marmalade containing,ittp event,reverse transcription polymerase chain reaction,monitoring,allogeneic bone marrow transplantation.|patients,,cannot understand,non primary tumor,for at least one month prior to study participation||,≥ 50%.|diffusing,≥ twice,,refusal of,inability to provide informed consent|pregnant|enrolled in a concurrent study,,be willing and able to comply with study procedures and give written informed consent|self-reported to be healthy|within healthy bmi weight range (18.5-23kg/m2)||
257,years|cumulative smoking,dyspnea,topical immunosuppressive agents|combination topical agents,unable to verbalize symptoms of,uln).|bilirubin value,blood potassium,tpo-ra,,,≥180/110mmhg;|having severe,within 30 days prior to entry into this study,>= 18 years||because no,daily diary|completes,,agrees to receive,written informed consent must be obtained prior to any screening,,"refusal of consent|pregnancy|conditions making the patient unable to fill out questionnaire online, through email or over the phone including with cognitive dysfunction,"
258,accrete,post obstructive pneumonia,methylphenidate products.|subject,absent,fasting glucose levels,blood pressure medications,artificial insemination|naturally obtained,,,site investigator|substantial non-perfusion,for at least 4 months after the last dose of study treatment,≥ 95g/l,"≥ 1 times/year,|able",,interfering with,capable of understanding and providing a written informed consent.|patients with leukemias or lymphomas,,"subject's age is ≥35 years and ≤75 years|subject has chronic bronchitis, defined"
259,part in social activities outside,age.|for,endocrine,bronchoscopy|life expectancy,plasma il-6,operations,hospital cardiac,,,american|ability to read in english and provide informed consent||,prior to first dosing treatment,< 6 months old,≥1500 mg daily,,bi-,inability to provide informed consent|history of,,patient must not have any prior treatment for the current breast cancer
260,bmd|age,lymphatic disease.|lymphatic anomalies,indium,lacks the ability to comprehend,child-pugh scale,montreal cognitive assessment,intracranial artery,,,extensively invaded,more than 1.5 times or more than the base value,<6|recent,semen,,suspicious,not able to understand danish,,signed a written informed consent form (icf) voluntarily.|male or
261,geographically stable,cis,hormonal implant||,completion.|history,suitable comparator|intervention duration,cardiac imaging;|left ventricular ejection fraction,inferior vena cava tumor thrombus);|contraindications,,,non-melanomatous,prior to signing of icf|has,6 to 16 years|elevated,maxillofacial surgery,,legs,no exclusion criteria,,willing and able to comply with all scheduled visits
262,weeks.|female,brain parasitic disease;|history,hematopoietic stimulating factors,available to measure left atrial reservoir strain||,serum creatinine|ecog score,ligamentous injury.|have nomeniscectomy,peripheral venous,,,camp;|current,sarcoma|a history of,>5 x uln,≥ 20 ml/min||,,willing to,inability to speak or understand english|positive urine pregnancy test,,the subject must provide written informed consent prior to any study related
263,rfa).|age,intraductal papillary mucinous neoplasms,hysterosalpingogram,preparation,southwest oncology group (swog) specimen tracking system.|participants,lung-vac study||,intrauterine dead,,,enterovaginal,within 4 weeks of beginning study treatment.|uncontrolled,< 40 kgs,600mg,,likely to affect the evaluation of trial results judged,attending or referred to the movement disorder clinic,,"the content of this research was fully explained, and written informed consent was obtained from the subject.|histologically confirmed rectal adenocarcinoma.|radical resection is clinically possible without any"
264,weeks;|women,residual malignancy,intranasal sprays,unable to observe home isolation|the presence,fasting plasma glucose (fpg),random treatment,intracranial clips,,,in hip,the time of signing the icf,≤ 2)||,<12 months,,planning to begin,"able to speak and understand turkish,|between the",,the subjects has previously received
265,participants||age,rhomboid muscle,"berlin definition (""ards"" group)||",screening;|birth plan,karnofsky performance score (kps),analytes,other implants,,,screening.|pregnant,within 4 weeks before the first dose.|use of live,2.8 mm,68ga,,employee,"able to provide informed consent|confirmed postmenopausal age|diagnosed genitourinary syndrome of menopause|access to a smartphone, tablet or computer, and to a functional email address.||",,patient refusal
266,naïve,intestinal resection,nicotine inhaler,immunotherapy induced,sftpb,brain magnetic resonance imaging (mri),carotid artery intima medial thickness (imt),,,hormone.|type 1,within 3 months prior to the planned,45 minutes,more than 4 times the half life,,planning to become pregnant,the exclusion criteria are prematurity newborn,,agreed to participate in the study were included in the study.||
267,hyperlipidaemia|sportsmen,targeting amyloid,food supplements containing msm,enrolled voluntarily,asthma severity classification,screening|participant,urethral sphincter,,,days|surgically,last 12 months),>18 years|life expectancy,long term follow,,constitute,"unwillingness or inability of the patient to perform the study procedures in accordance with the protocol.|any medically important event that was reported in a patient during his/her participation in the main study cl04018068, and, in the opinion of the investigator, is a reason for not including this patient in this open-label study.|pregnant and lactating women",,willing and able to provide written informed consent.|age
268,rationale,neurovascular complications,hospitalizations,difficulty in treatment,residual,reoperation,haemodynamic compromise,,,illness.|chronic unstable,williams classification);|absence of marked,≥18.5 to ≤30 kg/m2.|clinical diagnosis,acceptable,,agrees to,written informed,,the subject is scheduled for elective
269,≥2|no,mandibular third,global initiative for chronic obstructive lung disease (gold).|at the time of screening,predicted closure length,drug screen,filtering surgery,study|hepatocellular carcinoma|portal venous thrombosis|presence,,,gnrh-,within 6 months of screening.|any,<60%.||-,loss|at least 3 months,,cohort 2:||cohort 1:||patients,written informed consent|male,,provision of informed consent.|female and male
270,gemcitabine)|age,epilectic disorder.|for,th2 cytokine inhibitors,unable to communicate with health team.|free from mental problems,calculated using ckd epi scr,antimalarial,histologically confirmed pas,,,unknown origin.|patients,within 28 days;|received,during abnormal,6)≥ 2,,planning to use,inability to perform a valid baseline cardiopulmonary exercise test|cardiac,,willing and able to provide written informed consent|aged at least 18 years.|karnofsky performance score (kps) of
271,analysis|male,systemic disease|7,antiretroviral agents,pace- makers,recist version 1.1|adequate organ,brain radiotherapy,condom plus spermicide,,,dsm iv,"during the trial,|consuming","≥ 18 years,|presence of arrhythmic storm",12.8 mg/kg,,inflammation.|teeth that shows association with,able and willing to provide informed consent|male,,the minimum possible criteria ensuring the safety of voluntary participants
272,voluntarily.|aged,prostatic adenocarcinoma||low,lipopolysaccharidosis,breast feeding|intake,nijmegen score,target therapy,enrollment);|peripheral vascular disease,,,stage 1 palliation,within 14 days.|are assessed,24-hour recall period,≥ 21ml/kg/min,,preventing participation in,inability to comprehend and follow instructions as in dementia,,the inclusion criteria used in the randomized controlled trials were as follows:||stroke||subject
273,use.|male,primary gsv,beta-blocker,render the patient ineligible.|availability of,prothrombin time,germline testing,scs system,,,non-penetrating,within 7 days before the first dose of study treatment,≤ 1 × uln.|aspartate aminotransferase,more than 24,,"months;|willing to follow the visit schedule, administration plan",able to provide,,refusal to participate in the study;|inability to provide written consent to the study protocol;|chronic immuno-suppressant
274,stroke|age,homeopathy,nintedanib,would interfere with study,mobitz,pain therapy,maneuvers,,,self-prescribed diet,within the thirty days prior to the start of the study.||subjects,lower than 32 kg/m2|plasma,≥ 40g/d,,kosher diet,informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study,,f patient:
275,diseases.|refused,cardio-cerebrovascular,angiotensin ii receptor antagonists,months|patient,quality index,ivf attempts|using,implanted contraceptive device + physical barrier,,,inflammatory process & decrease oxygenation,within 1 year before screening|known,lower than 82||,15 mg or more,,unsuitable for,able and willing to provide a written informed consent|scheduled to undergo,,refusal to participate|previous enrolment in the study|outside of hospital catchment|language barrier|direct admission following birth without having been discharged
276,subcortex|adults,sclerosis|stroke|serious psychiatric condition,iv anti-infectives,cohort a||histologically confirmed,covid-19 rapid antigen test (rat) should be,limits activities of daily living|lbp should,niv,,,receive,within 6 months prior to initial administration;b,< 6 months|history of poor compliance,greater than 20 cigarettes,,absolute sexual,"ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial.|male",,the inclusion criteria will include:||informed consent of the participant|all women who are 18 years old
277,basis|age,drug intolerance,caffeine-containing,signed informed consent;|men,palliative care|expected length,shiga toxin-,implantable electronic devices.|metal implants at site of treatment.|known allergy,,,dutch medped,within 7 days prior to the first dose of study drugs,18-50|classified,"chronic hepatitis,|history of",,anticipated to require,ability to understand the nature and objectives of the study and to appreciate the risks involved|ability to stand in an mri machine,,patient must not have
278,axilla can accept sentinel lymph node biopsy,cancer diagnosis.|currently breastfeeding.|pregnant,ifr,method of contraception|concurrent participation in another clinical trial.|inability to read,national institute of neurological disorders and stroke diagnostic criteria,verbal assent,household contact,,,xfine,within 28 days prior initiation of study therapy,male|age <22 or >65|prior undereye,at least 20 out of the last 28 days.|participants,,"clinical suspicion of the facet syndrome,||2-focal tenderness",able to provide informed consent after reading,,the expected life span
279,one,understanding instructions|significant communication deficits,direct supervisor,signed an informed consent.||,mean vas,seroprevalence|negative pcr test for sars-cov-2|long covid,contraceptive method failure,,,psychological health,at the time of screening.|subject,score 0 or 1|there,6 mg/kg,,indication for,completed informed,,patient 18 years
280,icf).|age,benign colon neoplasms,prohibited medications,wheezing on,hbv-dna,kobnerization,central venous pressure,,,diabetes.|pre-existing,in past 30 days,higher than 160 mmhg,30 kg/m2 and above,,clinical judgement suggest,inability of self or caregiver,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|male patients
281,adolescent,psychosis not,long-acting reversible contraceptive,unable to cooperate|uncorrectable visual,naepp,pelvic radiation.|suspected,seven overlapping cpp,,,deemed necessary:||glomerular filtration rate (gfr),within 2 weeks positive,≥ 40 years;|asa,≥2 grades,,likely to impact the advisability of radiotherapy|any other,states willingness to comply with all study procedures and is anticipated to be available for all study visits.|,,patient's or caregiver's inability to learn and to use digital technologies|conversion of
282,female|caucasian|age,tlaquepaque,npdr,close contact with individual(s),alanine transaminase serum level,immunosuppressive therapies,implantable methods,,,distal to the saphenous vein,within 60 days prior to the start of study drug administration,on day of,1 point)||duration of synovitis <6 weeks,,no other,informed consent form|willing and ability to undergone a navigational bronchoscopy||,,the patients signed the informed consent and participated in the study voluntarily;|age
283,single-level,poor drug compliance,opioid drugs,loss of sensation,hepatitis b surface antigen (sag),caesarean section,metal devices,,,another,within 1 month prior to the first dose of study drug,>100 beats per minute|male,more than six weeks duration,,anticipation that,written informed consent according to ich/gcp regulations before registration.|age,,provision of informed consent prior to any study specific procedures|hfpef diagnosis
284,part a,idiopathic cts|cts-6,anti-ige-treatment,old|diagnosis of hcc,zi mannheim|age,nsm procedure,mitral valve repair/replacement.|note,,,etc.；|congenital,in the last month|medical conditions,≤30 kg/,less than 6 months of follow,,suspicion,inability to perform a maximal baseline exercise test;|structural heart disease,,willingness to sign of informed consent in writing.||
285,incident|intubated,self-administer subcutaneous medications,components in the test formulation|participation in another investigative trial,cohort c||aged,asa grade,unsuccessfully completed colonoscopy,jugular central venous line,,,sequentially,after taking ≥4 kinds of,>18|patients,350 ml),,suspected,informed consent by the supervision of the children|6~13 years old (including both the 6 and 13)|se range:,,able to provide informed consent|able to communicate in the local language|no
286,cbx-12,parkinson's disease (fourth edition));|the,immunomodulating medicines,radiographic progression,liver transaminases,wrinkles around,incidental histological finding of,,,sero-positive donor,continuous > 12 months,≤ 2.5×uln.||d.,> 10 mg/d,,cancer.|surgery scheduled,ability to comprehend and provide a signed and dated informed consent form|stated willingness to comply with all study procedures and attend all scheduled clinic visits,,"refusal to join the study|in ""fluid"" group"
287,women.|women,systemic cancer,antidiabetic agent,living with dementia,uoc,rf treatment,endovascular repair;|endovascular repair,,,sensitive teeth|restorations,more than one week after the index,18-30 kg/m2|blood pressure,more than 4 hours,,precluding,understands the purpose and procedure of the study and is willing to participate in the study,,the patient or his/her guardian voluntarily signed the informed consent；||adult patients with
288,subscale,intraocular inflammation,gemcitabine-cisplatin combination therapy|ecog performance status,progressed on androgen receptor therapy,urine dipstick,fecal management system,colorectal cancer|available tissue sample obtained,,,tuberculosis,within 3 months prior to first dose of study intervention.|a,>= 16 weeks,long-term care,,evidence for,written consent of the participant after being informed|at least 18 years,,patient's refusal
289,wales,anti diabetic drugs,opioid medication|trauma,signs,hemoglobin,mtp fusion surgery,pneumatization device,,,disease|ige-mediated,at the time of recruitment.||,> 1.5 times uln,more than one lesion≥15mm,,management of,ia:||written informed consent provided.|males,,"agreed to provide clinicopathological and follow-up data required by the study, and agreed to use the study data for subsequent research and product development||"
290,years;|diagnosis,severe vestibular disorder,vaping,situations that would limit compliance with study requirements.|major surgery,size of varices,gonioscopy|best-corrected visual acuity,barrier method of contraception,,,insufficient data.|victims of assault,within 14 days of study entry.|the,between 18 to 50 years||exclusion criteria||pregnant,2 methods of,,scheduled,willingness to administer medication and follow up according to the treatment plan,,"the subject is pregnant or lactating.|the subject has received any antibiotic (excluding topical agents), antifungals or antivirals within 30 days prior to visit 1.|the subject has received any steroids (excluding topical agents)"
291,diagnosis|age,peptic ulcers,conventional imaging,situations that would limit compliance with study requirements|prior external beam radiation therapy,osu-tbi-id)|significant,study.||has,"cardiac resynchronization therapy (crt,",,,endocrine,at any time during participation in the study,>75 years||,two or three consecutive,,potential risk of,"informed consent as documented by signature. for patients, who are not able to sign consent, a physician not involved in the current study has to confirm",,have provided consent for research by signing the information and consent for research form;|have given appropriate operative consent for a sacroiliac joint fixation procedure as standard of care using the sijoin® transfixing sacroiliac fusion device;|are skeletally mature
292,term,granulocyte stimulating factor):||1,chemotherapeutic agents,life situations,geriatric depression scale-short,corneal abrasion,aortic valve stenosis||,,,legally-authorized representative (lar),within the last 3 months|lactose intolerance|celiac diseas|food allergies|specific dietary regiments,elevated,psychosis.|high,,integrated into a,the same exclusion criteria apply to both stage 1,,written informed consent (according to the guidelines of the declaration of helsinki) of parent(s)
293,criterion)|age,unstable depression,narcotic receptor agonists|taking monoclonal,incapable of giving informed consent,viral copy,steroid hormone profile,m1774,,,basically normal.|sign informed consent,within 3 months of study enrollment,< 18.5 kg/m2|pregnant|allergy,dual antiplatelet therapy,,likely to receive,written informed consent from the patient (,,"understand the research procedures and methods, volunteer to participate in the study, and sign the informed consent|scheduled to undergo"
294,bilateral,preparation,age|endoscopic,living in a nursing home,unmethylated.||personalized neoantigen dna vaccine,covid-19 related hospitalization,pacemaker implantation,,,under general,within 4 weeks prior to the first dose.||3,= 12.5 ml,salvage 1,,intention to become pregnant,informed consent obtained prior to any trial-related activities；|male,,capable of childbearing and contributing viable sperm must be willing to comply with contraception requirements and not donate ova or sperm while on the study and for 1 month after that|a negative pregnancy test at baseline must be obtained for individuals capable of
295,younger patients might,covid-19 infection|current,opioid analgesic medicine,cohort a|untreatable significant,hcv ab positive,focal mass drug administration (fmda),biochemical relapsed prostate cancer,,,ascites;|paroxysmal,within 30 days before the first dose.|patients,3-6|if,≥ 4 weeks,,interfering with participation,inability to sign an informed consent|inability to comply with follow-up|associated,,"capable of childbearing.|consent and ability to comply with the protocol's procedures, prohibitions and restrictions.||"
296,regular user,monocular disease,leronlimab,unable to understand relevant medical information,serum bilirubin level,bariatric intervention,wheelchair,,,preclude pet/ct,within the last 30 days from the baseline,< 15 ml/min/1.73m2,6gy x 5 daily fractions to 2,,signed,patient's refusal,,subject capable of giving informed consent and participating in the process of consent.||
297,ps,disc prolapse|dysfunction,anwser,projected life expectancy,cohb levels,hepatic disfunction related to the,implantable cardioverter-defibrillator (icd) insertion,,,upper jaw] only,at time of study entry.|locally advanced,score 0 - below the depth of blood contrast,uln)|pregnant,,unable to take,"ability to understand and willingness to provide informed consent, willingness to comply with all study procedures for the duration of the study|male",,"refusal to participate;|person with other conditions affecting independent walking;|contraindications to prolonged standing;|concomitant pathologies that may interfere with the results;|inability to follow the study procedure (cognitive disorders,"
298,high,breastfeeding|alcoholism,cytostatic|active cancer|liver,permanent makeup,alcohol urine tests.|any,completed surgical resection,left ventricular assist device,,,nart).|current,within 72 hours prior to randomization,≤ 60 bpm or ≥ 100 bpm,20 mg/l,,willing to return to the hospital,available and willing to conduct daily self-imaging at home for the duration of the trial.||,,willing and able to sign a written informed consent;|patients with histologic
299,meeting,intracranial pressure|critically ill,osteoporosis-medications,possible risk to the fetus,chemotherapy.|life expectancy,adjuvant aromatase inhibitor therapy,scnsl actively,,,surgery;|previous,at the time of enrollment).|tumors,equal to / more than 6 months,≥ 20mg/day,,planning plan,patient admitted to the,,"signed written informed consent. before any study procedures are performed,subjects will have the details of the study described to them, and they will be given a written informed consent document to read"
300,female,acute renal failure,ventricular assist device.|sustained,"scales,|admitted",npdr,salvage operation,implantable cardioverter-defibrillator,,,iaa).||,within 18 months prior to screening.|for,< 60 x 10^9/l,1-2,,planning to become pregnant while enrolled,"able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;|able to complete the study in compliance with the protocol;|subject",,patient's refusal.|altered mental status
301,albuminuria.|men,recurrence,antiretrovirals,dialysis-dependent ckd,1|adequate organ function,etc.);|regular anterior corneal astigmatism,vascular clips,,,"full understanding of the content, process",within the 8 weeks prior to the inclusion,maxillofacial,>1 lacunar,,likely to need,inability to perform the neuro-cognitive or functional tests,,willingness to provide informed consent|willing to wear and charge an activity monitor for three-months home trials.||
302,young,posterior transverse deficiency,periodontitis|one,unable to communicate their responses to the questionnaires|patients,lansky scale,orchiectomy,cerebral vascular event,,,for dm,at time of index stroke,> 150%,>5 bu,,planned administration,lack of sufficient viable retinal cell,,patient does not want a surgical treatment|patient does not want to participate|positive history for surgery due to injury of the hurt wrist beforehand|positive history for surgery due to injury of the opposite wrist beforehand|additional injuries to the hand and forearm
303,with||mandibular,pre-cancerous skin lesions,anomalous results,family members can understand the study protocol,eular,curative liver resection||,intrahepatic bile duct stones,,,a||locally advanced,within 6 months before enrollment|unstable angina,≥24 weeks after completion,approximately 1mg/kg,,elispot,willingness to participate in the research being in the 14-18 age group being a female student high,,refusal to participate in the study|not affiliated to the social security system|minor or under legal protection|patient with a history of breast cancer|patient previously treated for breast cancer|patient
304,weeks|nulliparous,hypersplenism,mannitol,genetic test.|prepubertal status.|naïve,weighs,fetoscopic surgery,cerebral palsy|diagnosed,,,non-arteritic crao,within 3 months|receipt of,below or equal to 20/40 and above 20/200,less than 48 hours|the,,and;|able to read,informed consent form for participation in the study signed by the subject's legal representative;|subjects of either sex under the age,,willing and able to provide written informed consent for the trial.|be ≥18 years
305,treatment.|life expectancy,adenopathy,methyl aminolevulinic acid,vulnerable populations also may include members,ametropy,chronic steroid therapy.|myocardial infarction,implanted linx device,,,pelvis|poorly controlled,in the first 6 weeks of treatment.||known,20-50 years|sub-acute,≥8|patients,,likely to undertake this diet,capacity to consent to research (oaccr) scale48,,"provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.|aged at least 18 years"
306,ri)|age,associated dysfunction,drug-related,enrolled in another organized weight loss,female.|ecog performance status,alternative medical cause],pte,,,inflammatory skin assessments,within the last five years.|known severe,> 5 miu/ml,> 1 month after injury,,able to feed orally,written informed consent before trial treatment and prior to any trial specific procedures.|male,,willing and able to provide informed consent|male
307,they:||are,familial history consistent with phlh,bimodal,parents unable to answer the questionnaire,residual stenosis,polymerase chain reaction (pcr) negative|hiv,implanted equipment,,,absolute neutrophils,within the past 1 year.|patients,above 45 mm hg,≥ 470 msec,,impeding,ability to understand and voluntarily agrees to participate by giving written informed consent for the study;|male,,is willing to undergo
308,adjuvant,pancreatic neuroendocrine carcinoma,sodium cromolyn,echo,stress test,facial make-up|usage,prp injection,,,including:||transarterial transcatheter aortic valve implantation,within 7 days of cycle 1 day 1 to meet,>1.5 × institutional uln,≥ 15 days,,referred to ct of the abdomen,the patient's peripheral shallow venous blood flow is smooth,,the patient or his legal guardian participated voluntarily and signed the informed consent form.|a patient aged
309,subjects.|age,other disorder,antihypertensive medications,artificial insemination,expression.|age,gastric junction adenocarcinoma,acl degeneratio mucosa,,,american college of cardiology/american heart association|renal impairment,in the last 1 month prior to screening,< 2 (+),at least two hours before nst|having,,intent,the physical condition does not,,willing and able to make use of a smartphone and to give informed consent for participation to the study|ischemic or non- ischemic heart failure disease|functional new york heart association (nyha) class 2-3|reduced
310,ae,dementia|language barrier,nmda antagonists,vulnerable groups,liver histology,biopharmaceutical produced in chinese hamster ovarian cells,artificial valves in heart,,,antibiotics|acute,within 8 weeks prior to the first dose or donated double red cell within 16 weeks prior to first dose.||14,does not change,more than 8 cups,,attributed,"patient unable to feed orally,|patient under legal protection, guardianship or curatorship,|patient with an",,patient who does not speak french|patient unable to read
311,granada.|aged,"hearing,|not in remission|refusing to participate in the study|stop studying",declomycin,refuse to participate,recipient exclusion criteria below,treatment of the iliac artery lesion,sacro iliac joint pain,,,grade iii-iv|suspected,at the time of enrolment|has,18 to 65 years|are,≥ 25,,indication to,written informed consent from a legally authorized guardian.|male,,"signed written informed consent (icf)|adult male and female participants, at least 18 years-of-age"
312,supine,vascularized corneal scar,hpv vaccines,images with pathologies,family caregiver|being,rehabilitation clinic,suture mediated,,,non-responsive,before surgery|fullfilling,≥3ng/ml,pregnancy;|those who screen,,anticipated relocation away from the geographical region,years|written informed consent provided by the patient|subject has been scheduled for surgical intervention,,patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.||all patients of childbearing potential must have a
313,smoker,muscle rupture,medication-induced dyskinesia,well-informed written consent to participate in the study.|transgender man given,platelet count;|bp could,anesthesia,implanted medical device|risk,,,dull,prior to eligibility assessment,antiseptic.|group b,daily consumption,,can be measured with,written informed consent and,,1.are willing and able to sign the study written informed consent form (icf)
314,females|age,obstructive coronary lesions,methadone,willing to assent,intratumoral injection;|at least 2 weeks,intolerance|insufficient,cardiac pacemaker implantation,,,pd-l1 agent,in the normal range,fewer than 12 months.|women,conjunctiva,,receive,not able to walk 50 meters,,the patient must be able to receive all necessary treatments and may be followed up for additional treatments and/or record follow-ups at each time point and for the duration of the study.|children
315,old.|gestational,uncontrolled diseases,3rd generation egfr tki|no clinical benefit,using,gestational,treatment period|available study,implantation plan,,,uterosacral,within 2 weeks before enrollment.|once,≥8.|initial glasgow,daily antibiotic prophylaxis,,physiologically incapable,unwillingness to comply with masking requirements per hospital policy||ii,,parental consent to participate in the study will be included in the study.||
316,activities.|male,infection.|night sweats,spinal,quit smoking,anti-hbc-positive]).|pregnancy,iv chemotherapy,allogeneic bone marrow,,,grade 2 and 3|recent,at time of enrollment|active,< 30 x 10^9 / l|coagulopathy,eligible|at least one,,precluded esophagectomy,inability to communicate,,provision of signed and dated informed consent form|male or female
317,meeting age,allocation,drinks containing caffeine,risk of seizure,sflc ratio)|≥,subgingival restoration,cochlear implants (cis),,,saddle anesthesia,within 4 weeks of the screening visit,≥18 years old.||,relapse|fewer than four,,pulpal,patient can understand the study's meaning and,,the patient has any active autoimmune disease
318,ages,compromised fetus,age;|patients,investigator.|able to read,either:||rhu epo,vegan/vegetarian,barrier contraceptives,,,"american joint committee on cancer (ajcc), the 8th",within 3 months after treatment.||,extended,more than 7 units,,allowing,able to understand written and spoken urdu.|a score of 1,,the initial sprain must have occurred at least 12 months prior to study enrollment.|the most recent
319,radiography.|age,pathological hint,juvenile mld,recently admitted,american society of anesthesiologists grades,surgical sterilization.||subjects,ntrk fusion,,,normal vaginal,within the last 30-days,more than 10 hours per week of intense physical activity,calorie intake,,eligible for this study,r all cohorts:||18 years,,child whose parents will no longer consent at some point in the study for one reason or another|children suffering from a chronic disease|intolerance to certain drugs
320,2.|male,folate,axitinib,radiographic evidence of,rutherford-becker classification category,local palliative radiation therapy,pacemaker leads,,,insulin to control diabetes,more than 10 days per month,more than 50ml / min / kg|more than 5h,etc.);|at least one,,undetectable,"informed consent obtained before any study-related activities (study-related activities are any procedures that would not have been performed during normal management of the patient, i.e. standard of",,patient's age ≤ 18 years;|acute myocardial infarction with st segment elevation;|treatment
321,actual,chronic pancreatitis,relatlimab,signed study informed consent form|karnofsky performance status (kps),eating behaviour human nutrition (,large blood vessels,heart valves,,,self-extubation)|do-not-reintubate order,within 6 months prior to the first dose of investigational,mm；|suitable,"older,|rectal",,cohort a],able to provide written consent|body mass index (bmi),,"the result of urodynamic examination, if the main cause of urinary incontinence"
322,veterans,couimaud's segments,anti-hypertensive,situations related,nonrepresentative core needle biopsy,pain intensity<4,artificial saliva,,,full understanding of the purpose,for at least 5 years before the randomization visit.)|history of,of:|2 or more,≥ 20/25,,converted,ability to provide written informed consent.|participants of either gender,,signed consent obtained before any study related activities (study related activities are any procedure-related to recording of data according to the protocol).|diagnosed with obesity (bmi higher than or equal to 30 for all ethnic groups except asian
323,wards|no,warts,anti-tumor treatment,pediatricians,il-6,demarcation,implanted medication pumps,,,mood,at screening and within 24 hours prior,< grade 1,2 years after menopause,,continuing,patient unable or unwilling to consent|patient not having,,agreed to participate in this study||
324,prolapse|women,thrombotic tendencies,agents,speak chinese,child-pugh c.|history,immunosuppression,metallic implant,,,excluded.|self-reported,within the past two years|any circumstances,>5000 mg/g,≥ 4 scores,,unwillingness to participate in,the patient's refusal to continue participate in the investigation,,patient's active refusal of the general consent of the university hospital basel|age
325,14,histologic malignancies,androgenic steroids,eggs,partial thromboplastin time (aptt) ≤1.5×uln|international normalized ratio,dispensing,infusion equipment,,,approximately 1 pint,for greater than 3 months,< 60 ml/min/1.73m2,≥ 24 ml/kg/min,,digestion|being on,written informed consent|males,,capable of giving assent (signing the assent form) to participate in the study. the caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study
326,torsion|women,hemochromatosis.|autoimmune liver disease.|cancer.|pregnancy,thioridazine,enrolled into,nmda antagonists,intracoronary instrumentation,women|cardiac pacemaker,,,grade iii obesity,at the time of entering the study,greater than 20 mm hg,25 ≤ gfr,,likely to influence,inability to follow study procedures|institutionalized persons|asylum seekers,,the subject underwent a nasal wash/aspirate as part of standard of care testing during this study visit.|the subject is currently receiving or has received
327,uptake,pain condition|diabetes mellitus|coronary heart disease,hepatoprotective drugs,family history,cia score,local medical team of baseline,carotid artery,,,corneal disease;||2,within 4 weeks of enrollment from,lower than 60 beats per minute,more than 14,,planning on becoming,inability to place the study device appropriately due to patient's anatomy,,able to understand written or spoken commands|having grade 3-4
328,"old,|primiparous",confirmed recurrence,azole,expected life span,karnofsky performance level,"medication,|body mass index (bmi)",central venous access devices,,,singapore||non-smoker:||participant,within the past 6 months.|participants,visuospatial,for at least 3 months.|severe tiredness,,periapical pathosis.|enough,inability to understand or read english,,"the patient with post-cabg,|aged between 40 and 60 years,|had"
329,neonates,uncontrolled malignancy,saxagliptin,genetic syndromes associated,residual bone width,atypical anatomic structural variation,central venous jugular,,,could cause knee pain|evidence of,within 2 weeks before the rct|received acupuncture,less than 50 or more than 100 beats per minute,over 40 on visual analogue scale scale)|does not,,rescreening,inability to root,,a:||signed informed consent must be obtained prior to participation in the study|healthy males
330,general,refractive surgical procedure)||have,antiarrhythmic use,suicidal;|currently engaging,points.|albumin plasma level,blood cell separation;|10,pca,,,nc-fet,in the 2nd,65-99,more than 15 days,,disrupting,inability or unwillingness to understand the essence of the study,,patient's age will range from 40- 55 years.|their
331,criteria:||male,ongoing cancer,neuroleptics,living in,sars-cov-,polymerase chain reaction test result.|known hypersensitivity,implantable progesterone,,,vaping,within 7 weeks prior to surgery.||,≥18 to ≤35 years.|weight,"maximum of 3 years ago, able to come to the study site themselves.||exclusion criteria",,planned for,children|informed consent to,,provided written informed consent|age
332,allergens;|women,end organ function per laboratory testing.|pregnancy prevention,ehpad,pregnancy|dementia|physique making ultrasound,asa grade of the subject is ⅰ - ⅲ;|65-90 years old;|oral craniomaxillofacial surgery,thoracic region|patients,implanted medical devices|currently under treatment,,,allowed.|uncontrolled,within two years of,>480,≥ 8.5 g/dl|creatinine,,high risk,"etc.),|inability to consent and follow the procedures of the study",,the subject has a history of any clinically significant conditions including the following:|asthma treated with oral systemic steroids
333,women|women,spinal anesthesia.|patients,oxiracetam,signed the informed consent form (icf),not);|age,local standard of care (,cochlear sponsored investigation,,,femoral venipuncture,within 6 to 12 months prior,≥1.5 times uln,≥2 asystolic pauses,,interfering with the ability,screening|any other condition that in the judgment of the investigator would jeopardize the patient's compliance with the study protocol,,the patient is 65 years
334,cases:||male,asymptomatic gallstones,youth sport organization,parents have been informed of the study orally,cumulated ambulation score,potential treatment sites,cardiac pacemakers,,,age|clinical diagnosis,at the time of screening.|known intolerance,> 10.0 iu/ml,<3 months prior to study,,likely,able to understand and voluntarily sign written informed,,not able to consent in english
335,donations|patients,device|intraoperative complication,component of the interventions,cancer)|chronic smoking,serum samples,central review.|a predicted diffusing,implanted electrical stimulator,,,albumin-bound);|patients had,up to 24 months)|written informed consent obtained,100u/ml,more than 10mg per day).|multiple fistula,,disease.|planning to,written informed consent form must be signed by the patient or the patient's immediate family members before enrollment.||,,the patient is willing and able to comply with the protocol and has provided written informed consent;|male or female
336,noted.||age,fresh fractures,antiepileptic drug,remain in the area,nih clinical center s age-based,myomectomy,prescription,,,surgeon|pain radiating,within the screening period,5 to 11 years.|able,>2 years,,evaluated,unwillingness to be part of the study|primary tricuspid valve disease|patient already scheduled for tricuspid valve repair/replacement|cardiac,,the patient has an
337,highest,diminished ovarian reserve,mtor targeting agents,afl,expected length of stay in eicu,ocular laser surgery,venous access,,,life-threatening condition,before and who have received,< 80 ml/min/1.73 m2|proteinuria,≥ 12 months,,neurosurgeon|contraindications for,inability to complete follow up or comply with study procedures|previous corneal graft,,signed written informed consent document prior to any study related assessments or procedures being carried out.||
338,map2k1,lbp,human papillomavirus,difficulty to withdraw,treatment line.|ecog performance status,whole body pet scan,psp,,,non-ototoxic/non-central bilateral vestibular hypofunction,within 6 months|previous,< 3.5 cm,multiple consecutive doses,,mellitus|history of,inability to provide informed consent|lack of internet connection,,patient or partner is not able to speak and read english|patient or partner has a hearing impairment|patient or partner medically unable to participate as judged by physician/in medical record
339,setting|aged,radical radiotherapy.|investigators,anti-tnf).|active autoimmune diseases,remain in country,glycated haemoglobin (hba1c),mini-mental status exam,ileostomy losses,,,symptomology of infection may obscure the outcomes of this study|other medical,within 4 weeks before the first administration of eth-155008,between 101 ml to 449 ml,<1 year,,clinical signs,written informed consent signed prior to inclusion in the study;|women,,"patient does not understand, sign, and return consent form|inability to perform regular electronic reporting|patient"
340,females,sofie could compromise subject safety,antibiotic treatments,difficulty in venous blood collection.|vigorous exercise should,complicates test interpretation)|nasopharyngeal mass,iliofemoral vein(s,prosthetic heart valve replacement;|21,,,stage iv (m1c),within the last 4 weeks before the screening date|medical history of,19-54 years|clinical,two separate reports,,cytology;|estimated survival,informed consent provided by the subject or legally authorized representative.|diagnosed,,patient willing and able to give consent|participation in bio|stream.hf|heartinsight-capable crt-d device implanted
341,cryoglobulinemia|age,angina|unstable angina,candida albicans,changes in position,amputees (unless both groups have similar,hematopoietic function,transfusion of packed red blood cells,,,harmful use or,in the previous three months,12-17|confirmed binge alcohol use event reported to the surveillance system,greater than 27|no,,never completed a,written informed consent/assent from the individual and the individual's parents or caretaker(s),,the subjects voluntarily participated in the study with full informed consent and signed written informed consent form;|recurrent/metastatic
342,ptsd).|female,pigmented lesions,basal insulin,willing to maintain tlc,old.|performance status,hip surgery|previous spine surgery|contracture,hydroxypropyl methylcellulose,,,periampullary,at least two years)|age,4 years and over 18 years,training program 6 months prior to the start of the experimental trial|any kind of injury/incapability,,hypertension|presence,inability or unwillingness of research participant and/or legal guardian/ representative to give written informed consent.,,the subject selection will be according to the following criteria:|age range between 20-45 years.|male
343,screening.|male,hiv);|hbv dna,potent cyp1a2,unable to receive text messages,urea nitrogen,stenting occurred,imaging suggest,,,diagnostic criteria from the 2017 chicago consensus meeting.|the,within 24 hours and can,score ≤ 2,more than 25% of the,,contradiction for,patient unable or unwilling to provide informed consent|diagnosis of copd is uncertain|plan for discharge to location other than the patient's home (,,"willingness to provide informed consent (parent/guardian), parental consent (parent/guardian) and assent (minor participants) and the ability for participants to comply with study requirements|they are the child's primary caregiver, i.e., they are the adult who spends the largest proportion of time caring for the child (e.g., cleaning, feeding, etc.) or they spent an exactly equal proportion to another caregiver (e.g., parents each with 50% of childcare responsibilities).|they reside"
344,group a,synchronous haematological malignancy,permanent use.|neurological alterations,cockcroft-gault formula.|registration,recist v 1.1|signed written,chest ct scan.|resolution of sars-cov-2 infection,implantable cardioverter defibrillator (icd) utilizing,,,monosaccharides,during the 3 months prior to the study;|status of pregnancy,male.|with normal,greater than 100 mg/day,,permitted to enroll.|oral,uncooperativeness of child and/or parents|unrestorable tooth|presence of,,willing and able to provide written informed consent.|male
345,response.|age,healthy controls):||-,anti-seizure,rct.|unable to read/write in english per self-report,length,donated blood,metal parts,,,cardiac decompensation|no,within previous 3 years except,less than 60 beats/min or more than 90 beats/min,>100 mg/day,,likely to alter absorption of study treatment.||any of the following,signed informed consent,,the patient has any
346,diagnosis)|male,resulting in events defined,phentermine-topiramate,unable to take the standard dose of acetaminophen,detectable plasma hbv dna,rrt,tkr implants,,,dentition.|teeth,for at least 30 days after the last dose of study intervention,=< 17 years,first episode of,,chemoradiation for,is willing and able to participate in all aspects of the study,,having provided written informed consent|women
347,parent,hearing disabilities,mdma,sleep habit changes,urinary pregnancy test,hepatic impairment|major surgery,fragile skin,,,alcohol intake,at least 2 weeks of the nightshift,">= 1,500/mm^3|platelet count",less than 1 bowel movement,,consecutively,inability to participate in,,the subject must give written informed consent prior to any procedure related to the clinical investigation.|adult person 18 years of age or older.|the subject has an external skin lesion
348,≥30)|pregnant,acute pe,yohimbe,underlying,preformed antibodies,intra-aortic balloon pump/ ventricular assist device therapy,art prescription,,,under severe,at the time of informed consent|able and willing to give informed consent,≥18 years|first,two separate blood collection tubes,,improved after,"retrospective study||patients enrolled from september 2018 to september 2021 applied for exemption from informed consent, and patients enrolled from september 2021 to september 2022 signed informed consent voluntarily.|male",,"being willing to participate in the study,|having a communication barrier (not being able to speak or understand turkish…),|having a psychiatric diagnosis"
349,iec).|male,atypical parkinsonism,conductive hydrogel,close relatives,resting heart rate (hr),repair of,plmd,,,stage iiib,within 1 month of visit 1,between 18 and 65 years|severe,more than 180,,aifi|carrying,unwillingness to use medically acceptable,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study|males and females
350,ii:||women,affect aerobic,dimethyl sulfoxide (dmso,smokers,cotinine screen,first blood sample,scalp shrapnel,,,medical monitor.|uncontrolled hypertension,within the 4 weeks prior to screening|has received an investigational treatment,greater than or equal to (>=) 30.0 kilograms per meter square (kg/m^2)||established,15 or more,,indicated to receive,ability to understand and the willingness to sign a written informed consent document；|aged ≥18 years old;|histologically or cytologically confirmed,,"patient refusal,"
351,participants:||between,abdominal obesity,compounds chemically,an arm or leg fracture,lymphoma;|life expectancy,lifestyle-treated)|dialysis|high risk immunological transplantation,histologically confirmed,,,acute,within 4 weeks before,35 mcg/min,three separate types of informed consent -,,unwillingness to comply with the protocol requirements,unwillingness to give consent for participation,,signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)|the decision to switch from dpp4i treatment to commercially available oral semaglutide has been made by the participant/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the participant in this study|participant with last measurement of hba1c
352,ed)|adult,t4n0-1m0,alpha 1 antitrypsin deficiency,risk of committing suicide,quantitative assessment indicates,revascularization procedures,metal substances,,,drug-related,within 4 weeks or less before the first use of the study drug;|subjects,>= 50 ml/min/1.73m^.|human,20 mg,,likely to affect ability to complete study|currently using,inability of unwillingness to consent|steroid therapy,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|radiologic and other clinical evidence leading to a diagnosis of ncfbe|1 cf-causing mutation
353,covid-19;|age,hyperglycemia,"diagnostic shoulder arthroscopic procedures,|patients",unable to receive immune checkpoint inhibitors,68ga-fapi-46,permanent sterilization includes hysterectomy,gastrostomy tube,,,suitable for interventional embolization,for more than 3 years,≥ 130 mg /dl,dual energy x-ray,,shortness,informed consent has been signed|age ≥ 18 years,,not capable to leave informed consent.||medical staff:||inclusion
354,meglitinides,rated,months|significant,incapable of pregnancy,coma recovery scale revise|prestroke modified,cataract|regular total corneal astigmatism,magnetic devices,,,diagnose,during the past 12 months|history of a,0 or 1.|adequate renal,at least 1 symptom,,low risk of transmission of,"a:||ability to understand the subject information and to personally name, sign and date the informed consent to participate in the clinical trial.|provided written informed consent.|healthy",,patient's opposition to the study|notion of an abnormal
355,lusaka urban,functioning of the eit device)|thoracic wounds,any medications,unable to undergo serial gynaecological follow-up,serum immunoglobulin kappa to lambda flc ratio,rtx induction,shrapnel,,,sexes|a,within the last 2 months.|patients,score 0-1|good level,for at least 30 minutes|any patient who is,,sugammadex.|adults unable,ability to comprehend and communicate in english|access to,,patients willing to participate in the study.|patients within the age group of 30-65 years
356,pericardial,allowed.|primary cns,anti-inflammatory|previous periodontal therapy,rates in spouses,recurrence,cranial tumors;|nuclear magnetic examination,intrauterine device,,,modulatory effect.|does,within 28 days prior to baseline visit,> 150 pg /ml,greater than (>),,repeated,unwillingness to comply with masking requirements per hospital policy||iii,,refusal to consent|patients without a cellular phone or who are unable to accept text messages|allergy to
357,|women,cohort construction studies,sensitive cyp3a substrates,enrolled a sufficient number of each group representation,dsm v criteria of ptsd,sperm donation plans,"seizures,|no migraine",,,longest diameter of the brain metastases,lactation|poor compliance during steps 1 and 2 of cause-related,≥2.8g/dl,2 mm).|patients of,,active,inability to give informed consent|presence of additional neurological disease,,patient opposed to the research
358,newborn,substantial co-morbidity,experimental drug,unable to donate,positive|active hepatitis,craniocerebral ct;|dci was,inactive ingredients|individuals,,,non-target,< 6 months after completed,≥1500 pg/ml,opioid use of a,,correctable,inability to communicate in either dutch or english|weight,,willing and able to comply with the requirements for this study and written informed consent.|male
359,ataract,allele type,brexpiprazole,cancer)|claustrophobia|contraindications for mr safety,serm,systemic therapy|history of,electrodes,,,stomach into a separate chamber,within the past 12 months.|participants,> 0.2,>14 drinks per,,able to tolerate,participants inclusion,,"patient's inability to understand the nature, risks"
360,english|age,glandular lobe,local anti-tumor treatment,progressed from,european working group on sarcopenia-2 criteria (ewgsop-2),august,prosthetic heart valve into the proper anatomical location and|intended performance of the,,,ankle,between the signing of the informed consent form and within 6 months after the end of the study,10-19%,≥ 2|having,,will exit the study,inability or unwillingness to provide informed written consent (,,agreed to participate in this study by signing an informed consent sheet|age
361,volunteers||age,fungal viruses,alpha-methyl dopa,cmri,gea eligible,venous insufficiency.|features of,vasopressors|not expected,,,spinal,at the screening visit.|history of any cancer,"> 0,8|normal findings",more than 14 units,,interfering with normal social function,is fluent in english and have a,,refusal to participate.|cervical radiculopathy pain recurrence after surgery.|previous attempt of
362,respiratory,fungal hyphae,immune chemotherapy,render the insertion of a catheter into the throat unsafe,criteria||bmi,major surgical intervention,questionnaire|cardiac pacemakers,,,kg)|foscarnet|ganciclovir|valganciclovir|cmv-directed cytotoxic t lymphocytes||planned receipt of the following,at the transplant clinic,< 18 years|in-hospital,1 january 2019,,planning to travel,willingness to provide baseline and 3-week tumor tissue biopsy specimens,,the patient or his/her guardian voluntarily signed the informed consent;||adult patients with
363,btki|male,infectious complications,immunosuppressant agents,unable to undergo mri investigations,new-onset,lipid metabolism - thyroid-,spectacle cylinder,,,severity of the delusions,at least 14 days prior to the start of imp,on day 0 before receiving rden3delta30/31-7164,for at least 72 hours.|patient,,will take,not willing to become research subjects|allergy to tranexamic,,tobacco smokers|under the age of 18 years old|potential subjects unable to accurately estimate the number of average betel nut chews per day (will be able to re-present for enrollment if they are able to make an accurate estimate of chews per day after keeping a personal record chew
364,adults,mmhg)|renal impairment,prophylactic antibiotic therapy,participated in other interventional clinical studies,gamma-hydroxybutyrate,perfusion-cbf nihss,cardiac resynchronization therapy,,,connective tissue disease,within 14 days prior to sub-study randomization|participants,less than 45 ml/min/1.73 m^2,≥1 time/month);|other,,setting for,inability to cooperate by providing a complete medical history.|ineligible tumor tissue samples for next-generation sequencing of genetic testing.|undesirable compliance.|having a known additional malignancy,,the patient is diagnosed with central nervous system
365,w/o,aortic valve area,ianalumab administered,method of birth control.|current participation,amylase,endolaryngeal surgery|>18 years old|volunteer to participate in the study||,implanted metallic devices,,,tumor-related,within 1 month of,less than or equal to 40 years,for at least 6 months|prior,,expected to require,unwillingness to sign consent|age <18 years|contraindications for catheter ablation procedure,,the patient may not enter the study if any of the following apply:||taking any concomitant medications
366,old|male,ua,pain related,willing to allow the child to participate,see appendix 1).|history,cystoscopies,intracranial implant,,,amenable to treatment,more than 14 times alcohol per week,≥1.5 × 109/l;||platelet count,daily for > 30 days|equivalent dose,,anticipated to take,"inability to cooperate adequately with the physiotherapist who made the evaluations,|have had any injury and/or",,the subjects voluntarily participated the study and signed the informed consent form;|age: 18~75 years old (when signing the informed consent form)
367,pregnancy|women,wrist synovitis,potent cyp3a4 inducers,entry into this study.|known,systolic blood pressure,antianaphylactic treatment,noncompensated somatic illnesses,,,mandibular,within three months of visiting|immunosuppressants,≥10,15 mg daily).|females,,anatomy,agrees to complete all aspects of the study.||,,must provide written informed consent for the study;|must be able to comply with the protocol as judged by the investigator;|are ≥18 years of age on the day of signing informed consent|have been
368,child,parasitic infection|pregnant,tk2,life sustaining measures,females:||body mass index,mhicm,urethral stricture,,,surrounding,"prior to selection,||additional inclusion criteria",z-score,more than 1/3 of the,,clinical suspicion,informed written consent from the volunteers.|healthy volunteers between,,lack of written informed consent|allergy to antazoline or propafenone|intolerance of anatzoline or propafenone|af related to significant
369,fcbp,illicit drug use;|pregnancy,inhaled tobramycin,sleep period,me/cfs canadian consensus criteria (,early treatment diabetic retinopathy study,medical prescription,,,noninvasive,within 2 weeks prior to visit 2a,≤ 2.5 x uln.||,2 or 3 doses,,clinical evidence of myelosuppression,inability to complete 3 research mri scans,,"patient who does not speak french and/or is illiterate|patient under legal protection|patient unable to complete the study procedures (no internet connection, no smart phone or tablet)|patient with diagnosed"
370,do,sports)|pregnancy,components of the pacemaker,requiring,stage iii pressure injury|pressure injury wound size,standard medical management,ius,,,severity of liver disease,at least 1 h,> 18 years|patient,≥ 6 months prior to baseline,,able to have,"written informed consent and any locally-required authorization (e.g., hipaa in the usa) obtained from the subject prior to performing any protocol-related procedures",,the subject is participating in another therapeutic study
371,t3,her2+ disease,valerian,living in postcodes,hours|creatinine clearance,tablet/injection,stents,,,topical eye/nasal drops,during this,45 to 65 years old|provide,more than 12 continuous months of,,practiced true abstinence,not signing the informed consent,,willingness to adhere to protocol as evidenced by written informed consent;|patients with clinical diagnosis of
372,prisoners,valvular defect.|patient,vaccinations,unable to respond,platelet inhibitory effects,psilocybin treatment,implantable cardiac device.|women,,,fredericia's qt,within 2 weeks prior to first dose of ensifentrine/ placebo,per day,needing oxygen therapy,,planned receipt,capacity to consent,,patients must sign the informed consent form and commit to complying with the requirements of this study.|male
373,disorder|patient,infection of the uterus,manifest refractive sphere,lose a,fena,emergency care,implantable pacemaker,,,sequential organ failure assessment,after resting for 5 min prior to each reading,≥5% and <30%|static physician's,same regimen after,,expected to receive,inability to travel to participate in the workshop.|patients with a diet excluding animal proteins (vegetarians,,"the patient or his/her guardian understands and voluntarily signs the informed consent, and is expected to complete the follow-up examination and treatment of the study procedure;|age 18-75 years old, gender unlimited;|patients"
374,a:||adult,consistent,5-α-reductase inhibitors,loss of range of motion,moderate-high,ventilation/perfusion pulmonary gammagraph,verifiable contact,,,ethiopia.||,less than 6 months)|patients,between 18 and 30 years.|bmi ≥ 30-39.9 kg/m2|how,≥ 12 weeks.|normal,,likely to take,written informed consent is obtained by both patient's parents or legal guardians,,willing and able to give written informed consent for participation in the study.|healthy
375,tms|pregnant,metastasis,corticosteroid requirement,remain in the clinic,i|nyha,dental procedures.||,intracranial large vessel occlusion,,,lobe thyroidectomy;|the,during the subsequent study,"≥ 100,000 / mm3;|hemoglobin",1 unit = 360 ml beer,,interested to take,written informed consent prior to any study-related procedures.|at time of study are a young adult,,the patient must have given their free and informed consent and signed the consent form|the patient must be a member or beneficiary of a health insurance plan|women of childbearing potential must have effective contraception
376,infusion|women,stimulant adhd medications,steroidal drugs to treat uc,clear evidence,human immunodeficiency virus (hiv) infection;|uncontrollable clinical cardiac symptoms,anticancer chemotherapy,intracranial hypotension|known thrombophilia,,,pd1/pdl1 inhibitor,at the time of screening.|at screening,≥160/100 mm hg,more than 0.3 mv,,sedentary life,not willing to abstain from vaginal intercourse for 1 week following laser therapy|use of,,patient older than 18 years
377,icsi.|age,adrenal gland function|refusal,intravenous [iv],person residing,uln)|total bilirubin,intracoronary imaging,implanted devices,,,following:||risk factors,prior to inclusion|known diabetic gastroparesis|hba1c,3-6 years,8 years)||,,suspicion of the presence,the exclusion criteria will,,provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3
378,true,lymphoepithelioma-like,multiline salvage chemotherapy,rad51d,iodine uptake,standard-of-care neuroimaging,implanted clips,,,related term,"in the last 6 months,|no","> 1,000/mcl|platelet count",≥ 10%||,,status.|eligible for,period|able to read,,signing the informed consent document.||
379,ver,parp,low-molecular weight heparin,excess alcohol,attachment level,dose reduction of ivig therapy,fixation devices,,,bone lesions(s,in the previous month|primary hyperparathyroidism|revascularization of the lower limb,greater than (>) 25 mmhg,8 diopters or more,,planned use,not willing to,,refusal of participation
380,women|aged,eligibility criteria,nrt||,lose sufficient body weight after participation in a structured lifestyle modification programme,eisenhauer,conventional coagulation tests,bifocal lenses,,,could impair participation in this study|history,"within the previous 3 months,||exclusion criteria",18-32 kg/m2(inclusive);||male,nucleotide polymorphism (,,candidates,capable of understanding and complying with protocol requirements.|male,,patient of legal age (
381,≥20/400(≤73,breastfeeding|study physician discretion,sintilimab,situations that would limit compliance with study requirements.|the,antibodies to hepatitis b core antigen [anti-hbc],first prescription,condom with spermicide,,,c9orf72-associated,at least 14 days for,≥ 40 ml/min|echocardiography,at least 14 years,,cohort a,informed consent of parent(s) or legally acceptable representative (lar) of participant and child assent,,the patient is willing and able to provide informed consent. only the patient for whom this clinical study/experimental treatment was designed will be given the investigational drug under the treatment of the pi
382,years.|age,pancreatic adenocarcinoma,checkpoint inhibitor therapy,insufficient clinical information,failure rate of,open reduction internal fixation,colorectal adenocarcinoma|no,,,anatomical therapeutic chemical code l04,during the study.|subject is able to forgo changes in baseline medications,outside institutional range of normal,changed their respiratory,,ulceration.|known,able and willing to give written consent|male;|≥ 18 years,,refusal of participation of a holder of parental authority and of the adolescent|non-mastery of oral french by the teenager or his parents|protected persons (
383,clusion:||adult,bulky lymph nodes,pns lead,failure,national cancer institute - common terminology criteria,blood specimens submitted,intermuscular venous thrombosis,,,third molars).||4- existence of all the upper teeth,at time of signing informed consent.|must have,requires mandatory continuation,minimum of 3,,interested in becoming pregnant,inability to elicit,,provision to sign and date the consent form.|stated willingness to comply with all study procedures and be available for the duration of the study.|be a male
384,suggest,laparoscopic surgery.|unfit,conventional therapies,access another psychological intervention,randomization|bmi,hyaluronic injections,pacemaker implantation procedure,,,interventional randomized trials,at screening,< 2*upper limit of normal,more than 5 years;|11,,expected to tolerate,written informed consent|adults,,"signed written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up assessments.|age"
385,both genders,alcohol-containing foods,boric acid,risk of progression,f-srs|the,subject.|major surgical procedure,tips implantation,,,frontotemporal,for at least 2 weeks after discontinuation of study therapy.|all participants must,> 120 mmhg,more than 60 minutes,,inconcluyent,patient refusal|any known allergy to,,has given written consent to participate by signing the informed consent signature form|be
386,malformation|combined,postoperative cervical lesions.||,permanent products,close relatives signed informed consent,local anesthetic allergy|coagulopathy|american society of anesthesiology physical status,24-hour urine collection).||prothrombin time,contraceptive diaphragm,,,insulin secretagogues,within prior 12 months|unstable,≥1.1×109/l,dose > 10 mg,,preventing,meters;|availability to participate in the intervention at the established group time.||,,patient unwillingness or incapability to provide informed consent|need for subcontinuous
387,tfc)=13,head trauma.|current,wolff-parkinson-white,entry into the treatment,fistula risk score,imaging evidence);|estimated,implantable cardiac device,,,lower-extremity contractures,in the period leading up to visit 2 (randomization),≥30 ml/minute.||adequate,>14 drinks/week).|unique,,plan to,"not being willing to participate in the research,|the presence of any facial anomalies",,provision of signed and dated informed consent form.|stated willingness to comply with all study procedures and availability for the duration of the study.|age 18-85 years inclusive (eu)
388,be≥18,isolated thoracic aorta procedures,protein supplements used in sports,expected difficult,madrs,apply:|participant,intrauterine hormone-releasing system,,,non-copd,in the past 30 days prior to the screening visit,< 5 on ct;|more than six retrieval,complete,,absolute,written informed consent obtained from subject|,,the investigator considers the subject unable or unwilling to cooperate with the study procedures
389,wheezing||patients,renal function,valacyclovir,estimated survival,antigen test.|presence,laboratory safety tests (serology,fms,,,suitable for the participants of the trial,within 3 months before screening|severe valve disease,≥ 30 g/day,more than 1 month after receiving,,low risk of mortality,willing to sign the icf and follow the requirements specified in the protocol.||2,,"provision of free and informed consent in writing, signed and dated;|age according to the indicated population;|patients diagnosed"
390,≥140,solid organ transplantation|patients,sms,living in santa,united states centers,gastrostomy,incl,,,1);||stage ib group,within 7 days of study enrollment||,≥ 90 cm,≥ 2 cycles|5,,seated,the exclusion criteria for veteran participants will be assessed via self-report and verified by va,,provision of signed and dated informed consent form|stated willingness to comply with all study procedures and availability for the duration of the study|men
391,pregnancy|patients,volume lesion,compounds of similar chemical or biologic composition to chemotherapeutic agents,participated in other clinical trials in the past,blood pressure [bp,receive,mechanical valve,,,"problems,|missed anterior teeth,|carious anterior teeth,|intrinsic",within 30 days prior to visit 1,greater than 120 bpm,retropharyngeal,,unprotected,not able to handle the digital tools required for this type of follow-up,,the subject must sign the written informed consent form(icf
392,genetic form,infected ear,blood thinning medications,render the subject unable to meet the requirements of the protocol.|subjects testing positive,level of care,fludeoxyglucose f-18 (fdg) avid,intrauterine insemination|patient,,,"surgical operation,|parents",2 weeks prior to meta10-19 infusion|treatment,≥ 70 db hl,more than 6 months;|patients,,housing|inability to read,written informed consent provided;|male or,,participants willing and able to provide written informed consent|participants are willing and able to provide appropriate photo identification|participant's age
393,outpatients,hallucinatory behavior,contraceptive methods|men,render the patient inappropriate for,maternal gestational age,bp readings,antiviral therapy;|subjects with,,,criteria|uncontrolled,prior to intervention|other,< 90 ml/min/1.73m^2||for,more than 14 days,,admitted for,child no speaking the french language,,not able to understand urdu language|above 17 years
394,examinations|men,idiopathic thrombocytopenia,specific medications,human immuno virus type-1,hads score,lumbar punctures,implanted electronic devices|participants,,,human papillomavirus,within 1 year before screening;|at least 14 days,scores ≥3).||,2h after oral,,noninvasive,incapacity of accessing the mobile app,,the patient must have given their free and informed consent and signed the consent form|the patient must be a member or beneficiary of a health insurance plan|patients with
395,liver,gastrointestinal disorder,intravitreal injection,render the subject unable to meet the requirements of the protocol,acid.|hemoglobin level,erythrocyte transfusions,dental implant,,,pd-l1 expression,within 1 month;|those,≥ 180mmhg,greater than equivalent of 10 mg daily of,,planning to undergo,not willing to participate in the study|pregnant,,refusal to sign the free and informed consent form and/or term of assent|estimated survival less than 12 weeks|previous adverse reactions associated with epo|estar em uso de epo e inibidores do fator de indução de hipóxia
396,a:||male,g12v,immune-related toxicity,suicidal ideation,numeric rating scales,atopic condition.|healthy volunteers,penile injection,,,preparation,within 14 days prior to the ip administration.|participant,≥ 2.5 × 109/l,> 4,,intention of becoming,inability or unwillingness of research participant or legal guardian/representative to give written informed consent.||inclusion criteria for,,patient who plans to
397,seizures|women,psychiatric disorders.|hiv infection,lbp,signed an informed consent form||cohort 1,forced vital capacity (fvc),radical pelvic surgery|history,epidural electrodes|other ferromagnetic metallic intracranial,,,centrally,within the last six months|currently,"at least 36 hours duration, completion",100 mg/dl,,mitted for,availability of the informed consent form of thepatient information leaflet (pil) signed and dated bypatient.|men,,the inclusion criteria included type 2 diabetes
398,year,perfusion,vismodegib,unable to provide their own consent,asian sarcopenia working group (aswg)41 and the who definition of obesity for the asian population,laparoscopic gynecological,tricuspid valve repair,,,medically not justifiable|current,within 5 years|previous pelvic radiotherapy|an interval,>20 beats/minute,> 12 months,,unwillingness to abide by the study procedures,volunteers with fully resolved gestational diabetes will be eligible to participate in the study.|a history of,,signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)|the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study|male
399,lactation:||female,disorder|body mass index,treatment;|systemic steroid therapy,cohort 1,iom criteria,prior intervention that could impact the procedure,intermediate risk,,,platinum-based therapy,in the last 4 weeks|intradialytic,4-16,≥2 at screening,,unwillingness,written informed consent and willingness to comply with the study restrictions.|sex,,"the subject will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;|male and female"
400,parturients,surgery|endothelial pathology,spirometry,bazett acceptable,lbp,practice effective barrier contraception,reduced toxicity,,,enterobacter spp.,within 4 weeks prior to the initial administration of xzb-0004.||there,1 - 18 years,two or more months prior to registration,,consumption for,patient unable to understand study information and attend study visits.|patient did not give consent to participate.|patients who have had a,,participants capable of giving signed informed consent signed before any study-specific procedure
401,disease|age,atherosclerotic disease,alone,difficulty in blood collection,hepatitis c (hcv) infection,test treatments,magnetic devices)|claustrophobia.|atrial,,,enterobacter species,at the initial visit,0 to 1.|histologically,≥ 15,,subjected,,,capable of reading
402,consistent information;|ability,"hands, fingers",beta-lactam + beta-lactamase inhibitor,sponge,drug abuse).||bmi,intrauterine hormone therapy,zinc protoporphyrin,,,recurrence,outpatient treatment|patients,< 3.0 x the upper limit of normal (uln),more than 90,,planning on,,,
403,≤1,spinal cord abnormalities)|lead toxicity,anti-fibrinolytic medications|participants,admitted into the nicu,ggt,intracoronary provocative test,barrier methods;|total abstinence;|sterilization,,,systemic therapy.||active infection,at least 14 days.|patients,18||less than 3 weeks from drf||,prophylactic,,expected to,,,
404,arm,extensive chronic,mitoxantrone liposome,mournful,hepatitis c (hcv) antibody|unstable cardiovascular disease,metallic plates,intravascular lines,,,uneffectively controlled,within 24 hours prior to the start of treatment,been completed,more than 2 hours,,planning to,,,
405,mis-c,needle phobia|have immunosuppression,ocular steroids,participated in other clinical trials within 30 days of the screening date|other cases where the investigator judges that participation in the clinical trial is inappropriate due to ethical reasons,ox)/hypocretin-1 concentration,covid-19 symptomatology.|detection,venous access thrombosis;|patients,,,rome iv criteria of functional constipation*,at time of enrollment.|individual has,between 18.5 to 27.5 kg/m².|able to understand and provide signed informed consent prior to study enrolment.|willing,daily dose of more than 10 mg,,outpatients,,,
406,man,non-sterilized,connective tissue diseases (ctd),difficulty in swallowing,recist version 1.1.|left ventricular ejection fraction,topical immunosuppressive agents|combination topical agents,dental implants/bridges|have oral piercings|obvious signs,,,wide-field radiotherapy,within 2 months before enrollment.||(6,thiazides,>10 mg per day,,cardiac]|known,,,
407,initiated.|men,literate|having vision,anti-nkg2a,unable to walk,malaysian,electrocardiogram (ecg),depo shot,,,treatment|significant,at least 6 months post-injury|spinal,> 2.5 times of uln,supraphysiologic doses,,progressed on,,,
408,part in another research,disease recurrence;|other communication problems,drug-,month);|keep your diet,rhi,preoperative arterial oxygen partial pressure,intravaginal system,,,riteria:||self-identified,prior to screening|you may not be able to participate in this study,≥50% of the total lesion size,<2,,clinical signs of,,,
409,singapore,hemoglobin a1c>7,cytosine arabinoside,1|life expectancy,american thoracic society (alat) guidelines,abdominal ultrasound,cardiac resynchronization therapy device (crtd),,,months|significant,within 4 weeks prior to screening;|patients,"23-a2,3",hydrocortisone 2 mg/kg,,preventing patient,,,
410,pre-,fetus,screening27|on,cooperation difficulties,radioisotope gfr,experimental arm consolidation,intrauterine system|subdermal,,,colchicine)|prior,up to 40 mg orally or intravenously daily,5-18 years,more than 1/3,,admitted,,,
411,months|patients,diseases.||-,compounds with similar chemical structure to ketamine,baseline.|lack of willingness to abstain from the consumption,l dex > 10 units.|willingness,total elbow replacement,right ventricular volume overload,,,brain.|previous,within 6 months prior to screening;|patients,>35|prior,2-3 months,,imminent,,,
412,preoperatively||female,renal tubular acidosis,caffeine consumption questionnaire.|consumption of,biochemical recurrence is required,new york college of cardiology class,hematopoietic stimulating factors,mechanical valve replacement intervention (surgical,,,tested by minerva mrd assay)|pregnancy test done,within 7 days prior to blood draw|recipient,< 80 bpm,two consecutive,,interfering with respirometry,,,
413,significant,side effects brought,bcg,biochemical evidence,wakemed health & hospitals guidance (patient competency,botulinum toxin therapy,foreign objects in the eyes,,,new-onset,in the last two years,> 6.1 mmol/l|abnormal,greater than 1 year,,permitted to receive,,,
414,babies,non-mechanical lbp,anti-inflammatory drugs|females,unable to engage with,severity,dhfcl,subcutaneous implant,,,third degree av,within 3 months before administration;|imaging shows tumor,> 2 times baseline,age|participant-reported,,able to receive,,,
415,volunteer:||age,lower respiratory tract,atr inhibitors agents,changes in type of glucose lowering therapy,residual bone height|sufficient bone width,ehr system.|no recorded,sunken eyes,,,anti-bacterial,within the three week interval,score of 4 or greater,dose of 70 gy.||note,,can to,,,
416,points)|age,chronic autoimmune hepatic disorders,acei,0~1.|life expectancy,alp)≤,localized radiotherapy for analgesic purposes,nafld,,,radium,management of,veteran|age 60 or,more than six months of experience,,hypersensitive to any,,,
417,age,anal fissure symptoms,scn1a,suicidal behaviour,left ventricular shortening fraction,surgery;|previous,inactive ingredient,,,severity for,at time of traumatic injury,> 50 ml/min|total bilirubin,prenatal ultrasound|absence,,refuse,,,
418,and|aβ2gpi igg level,congenital deficiency lactase,device|patients,initiation,long qtc interval,spasticity treatment,aids- associated malignancy,,,non-malignant etiology,within 72 hours of the infusion of sti-6129,≥ 30.0 kilogram per meter square|infertility|erectile dysfunction,1 drink/day,,scheduled to start,,,
419,sixty,r,[,university of cincinnati hospital,postcontrast flair imaging.|ability of subject to understand and the willingness to sign a written informed consent document.||exclusion criteria:||an individual,absorbable intravascular closure device for haemostasis,intercostal tube inserted in the effusion before enrollment,,,deemed contraindicated|patients,during a longer period of time,<60 years old|subjective mets <4|inability to give,1.5 x 109,,candidates for,,,
420,men,corneal melting,antibiotic,cigarette into the mouth,cs.|age,paris classification|suboptimal colon preparation|clinical discretion of the provider,pdx monotherapy,,,other vaccines,within a year prior to screening|history,≥ 18 years|cpap,more than 10mg,,accepted to receive,,,
421,infusion.|age,wle,anti-viral therapy.|history,willing to sign informed consent.|patients,tbl.|hemoglobin levels,transient ischemic attacks,aortic valve gradients,,,mute,between january 2015,>50mm,more than 20,,can cause,,,
422,cancer;|women,malignant neoplasm,anticoagulation drugs,cockcroft-gault formula;|subjects,-and|body mass index,standard practice involves medical team members asking,prosthetic heart valve (mean aortic valve gradient,,,arena strive platform||,more than 4 months,consent|at least 18 years||,2-6 ml,,unable to,,,
423,a:||age,health technician,anti inflammatory),unable to complete the follow-up;|the,randomization:||age,cyc induction,permanent sterilisation methods,,,stabilized,at the time of the study|etonogestrel implants,score of 6 or,> 1,,esophagectomy.|completed,,,
424,years.|male,autoimmune diseases|no,erenumab,progressed after,bruton's tyrosine kinase inhibitors,rsv mat vaccine,transfusion of blood components,,,epilepsy;|previous,within 30 days prior to the first dose of study drug.|history of epilepsy,"between 40.0 and 100 kg, inclusive",1 year prior,,need decompression,,,
425,fulfilled:||aged,acute gastrointestinal disease,anti-osteoporosis,cockcroft-gault equation,weight change|positive tests,ossiculoplasty,resulting in decreased efficacy of the contraceptive,,,medically-required,within 30 days before enrollment|preexcitation in,more than 3 consecutive months,once daily,,potential,,,
426,amily members,chiropractic care.|voluntary,systemic drug products,living without hiv inclusion criteria||is,amercian society of anesthesiologists classification,hodapp anderson criteria||,intracranial metal,,,primary care service line (pcsl),for at least 6 months after the last imp administration|ability,18 years old.|2,greater than 12 hours.||,,calipers.||（3,,,
427,guidelines)|age,upper gi surgery.|ascites.|inability to tolerate,gu pelvic,"recently started,|patients",belinostat/beleodaq,kidney biopsy,implant site,,,disorder|clinical relevant,within 2 weeks before screening laboratory sample collection|hemoglobin,<11.0 g/dl|serum ferritin,high dose thiotepa,,significant,,,
428,test)|adults,chronic lung disease|sleep apnea,hydrocortisone treatment,unable to give informed consent,dsm-iv.||,assisted ventilation,central venous line,,,mild punctate keratopathy,at time of first dose of study treatment,< 500/μl,≥ 105 bacteria per,,will refuse,,,
429,university,nasal cavity malignancies,drugs used in this study;|unsuccessful,insufficient dutch language proficiency|mental retardation,gestational age|french-speaking,resorbed roots,implantable cardioverter defibrillator [icd],,,non-pathological,within 2 weeks before randomization;|had participated in other drug,< 9 g/dl|thrombocytopenia,greater than 4 weeks per year,,intention of becoming pregnant,,,
430,children,interstitial lung disease.|o2 saturation,methylphenidate or its excipients|cns abnormalities,participated in another study,nasal congestion score,chest imaging [x-ray,pcv,,,gingival graft,within 2 years before the first medication;|a history,greater than 3 months||evidence,anticholinergics.|regular use,,preparing to receive,,,
431,they||are,local therapies.|at least one measurable lesion,antipsychotic medication|no,rt-pcr test,ecog physical fitness score,bm).|previous chemotherapy,goblet cells,,,substantial,within 7 days on upper or lower limbs,women|over 60 years,one dose,,intention to perform,,,
432,1;|female,cardiovascular disease|a,ectoin®,difficulty with communicating in japanese)|confirmed diagnosis of,shoulder arthroscopy||,reintroduction of wheat,pacemaker implantation -||exclusion criteria,,,water,within 4 weeks prior to screening.|subject,>110 mmol/l,≥ 3|sedentary,,clinical risk assessment,,,
433,childbearing||,screening|serious illness,controlled substances,risk of infection,kidney transplantation;|diabetes mellitus;|hypocaloric diet,intracranial cta images,inferior vena cava filter|vte diagnosis,,,insulin-like,within 72 hours prior to taking study medication,for ≥5 years|presence,≥1 cycle,,treated,,,
434,volunteers,multiple measurable disease sites,desktop computers,sexual,creatine clearance,chimeric antigen receptor (car) t cell therapy,ferromagnetic vascular clips,,,signs,at the time of study,above 18 years|participants,higher dose,,agrees to return for the prospective portion,,,
435,marshallese|18,upper gastrointestinal resection,contrast material,cockcroft-gault formula|for,deeply settled brain tumours.||,timeframes:||major surgery,immunotherapy-containing regimen,,,protein s,after waking,greater than 35 kg/m2.|diagnosis,daily for >3 months)|weight,,centres for,,,
436,for,haematological malignancy,ace inhibitor,expected to recur,alpelisib formulations|history of severe cutaneous reactions like stevens-johnson syndrome,rtx treatment,vascular endothelial growth factor inhibitor,,,parent(s)/legal,within one month;|patients,mv shorter than 48,14-day,,likely to impact lung function,,,
437,wcbp,twin|vesicoamniotic shunts,soft tissue grafting,unable to understand and communicate,american society of anesthesiologists (asa) physical status classification,benralizumab treatment,device material.|life expectancy,,,class ii division,within normal range.||,≥ 18 years||complete resection of the tumor,once undetectable viral load,,probable myositis,,,
438,child age,unablé to respond correctly,alpha-2 agonists,enrolled in the kesimpta cohort study,abi program,intraocular surgery,intrauterine contraceptive device,,,suitable for inclusion in this study;|within 1 month of the screening visit,within 28 days prior to registration.||note,≥ 3.5 × 109/l,2 separate measurements,,ultrasound||,,,
439,cardiotoxicity):||male,systemic pathologies,quinolone type drug use,incapable to consent themselves.|all male,new york heart association (nyha) functional,endometriosis surgically treated,implanted devices.|clinical team does not,,,typical symptom,within 6 months of study registration|patients,score of 3-,≥ 1 measurable,,above|able to,,,
440,27,involvement of the pulp,neurologic disorders|patients,speak english pessary practitioners|lacking,srv,radiofrequency ablation.|concomitant coagulopathic state,isolated vascular amyloid,,,legs;|spinal cort lesion,in 6 months,≤35||o a higher,daily intake > 2 units,,low risk of relapse,,,
441,1_patients,rheumatic disease.|household contact,sodium nitroprusside,predicted life expectancy,modified fibromyalgia,stent bypass,dialysis access lines,,,lower extremity joints,within 7 days],< 24 h.|pregnant,higher than 5 mg/day,,can be met by the presence,,,
442,secondary,common hepatic artery,covid-19 infection.||,willing to ensure,female|ecog performance status,immunomodulatory medications,artificial sensing devices,,,mammalian target of rapamycin (mtor) inhibitors,within 14 days prior to signing the informed consent form:||vaso-occlusive crisis,≥ 20/20;|no,>1 prior,,exhibiting,,,
443,omen,malperfusion syndrome,id:||- iron deficiency,render the volunteer unable to meet the requirements of the protocol|history,pomelo,cervical foraminal stenosis|cervical central stenosis|cervical disc herniation|cervical spondylolisthesis|prominent arm pain,implanted devices/materials,,,stage iii).|during surgery,last 1 year prior to screening,present:||ast,at least 7,,clinical significance,,,
444,uln|women,abnormalities,amide anesthetics,minimize risk of bias in study findings,maximum standardized uptake value (suvmax),b treatment,irreversible pulpitis.|teeth,,,uv-rays,prior to enrollment.|if,minimum of 12,≥ 1,,submitted,,,
445,30+/-5,cardiac amyloidosis,tolvaptan,unable to lie still,urinary protein,cis,right ventricular pacing,,,neurosurgical team's recommendations,within 2 weeks prior to study day 1,< 1.3 x the,≥ 3 months,,planning to participate,,,
446,vital sign|failed,alcohol urine,prescription systemic nsaids.|known,family agree,rvef,immunodeficiency;|ejection fraction,intrauterine hormone release system,,,unknown etiology viii,during the 48 hours,18 to 30 kg/m2|voluntarily given,one at screening,,preventing the reading of,,,
447,age|female,impaired glucose tolerance|polycystic ovary syndrome,oral vasoactive drugs,stainless steel nickel,antibodies to treponema,t cell therapy)||alanine,injury|cardiac pacemakers,,,upper extremity fracture|metatarsal fractures,during the study treatment phase,18 or older.||,≥ 12 out,,never to,,,
448,prolonged,intraocular infectious disease|not,fluoropyrimidine containing chemotherapy,method of contraception||,international neuroblastoma response,"arthropathy,|high-velocity trauma,|fracture|low back pain",central venous access device insertion,,,epidural).|intracranial,at the time of informed consent|have,≥ 38.0°c,canine relationship malocclusion|maxillary anterior crowding,,permitted to enroll.|history,,,
449,resident,heart color doppler ultrasound,topical use,drug abusers,birads,review.|participant,revision shoulder,,,non-invasive,at the time of screening).5).cardiac function,18 to 75 years|bmi,< 2 years,,criteria:||involvement in,,,
450,more.|age,fus,anti-platelet drug,unable to give voluntary written informed consent,mean pulmonary arterial pressure,lumbar vertebrae,implantable devices,,,mri|preserved,within 4 weeks before the first drug use;|the,clinic|less than 17 years old||exclusion criteria,> 10 mg daily of,,symptoms for,,,
451,ctdna)|participants,demonstrates,topical metallic,lhrh agonist therapy,salt score,pancreaticojejunal mucosa anastomosis,immunosuppressant,,,behavior|current,within 1 week prior to randomization,≥ 320,≥ 25mmhg,,planned to undergo,,,
452,sex|aged,population|fecal samples,pyronaridine,sexual abstinence||,karnofsky score,volitional stool retention.|history,central venous device,,,cpap)|previous,more than one year,<50% predicted on most,oral/intravenous,,signs,,,
453,older|adult,-risk,lvad implant,breastfeeding.|any other condition,oi,inactivated vaccine,furcal bone loss.|teeth,,,highly effective non-hormonal contraception,during the study.|female,+ patient measured calcium,exceed 50 μmol/l);|alp,,planned surgery).|subject,,,
454,chemotherapy.|age,keratinized mucosa,indwelling devices,requires,eligibility criteria,hematopoietic stimulating factor treatment,mechanical cardiac support device,,,every,within 3 weeks of testing,18 and 65 years,fewer than 6 months,,known,,,
455,women|older,salt restriction,renal insufficiencyor,participated in the fibaa-bank||,following:|unintentional weight loss,interventional study|received,implanted electrical device,,,between the ages of 18- 45|having,during and after operation,less than 30 minutes to fall asleep on average|severe clinical,≥6 months|knee,,preventing participation,,,
456,≥,brain metastases treated,vitamin preparations,undergoing,recist version,surgery|indication,intracranial implants,,,malaysian,enrollment|active,> 18 years of age|provision of written informed consent|for,more than 30 g,,cyanoacrylate,,,
457,atients):||women,pre-eclampsia|blood pressure,rp3,risk of recurrence.)|participant,skåne university hospital||,rbc infusion,shoe modifications,,,mild asthma)|known,within 30 days prior to screening|has,"≥ 1,8",less than 4 weeks,,fertility,,,
458,all)||adult,l type 2diabetic,c;|acute liver,refusal,rudimentary level,conventional imaging,artificial sources of ultraviolet radiation,,,american college of rheumatology criteria||concomitant,accident)|stroke onset,40 and older,2 of 3,,lactating|diagnosis,,,
459,un,radical skin basal cell,supplements /drugs,family's willingness to participate in the study,follicle stimulating hormone (fsh).|if screening pregnancy testing,first trimester ultrasound,intermediate risk prostate cancer,,,stopping,within 48 hours before administration;|subjects,≥ 3 times the normal limits,=2,,anticipated difficult,,,
460,subjects||men,middle ear,pomelo,unable to oral,creatinine (cr) ≤1.5×uln,montreal cognitive assessment [moca],device other than percutaneous transluminal coronary angioplasty (ptca),,,mva-based,within 14 days prior to registration.|wocbp,≤1.5 mg/dl,daily ics,,probable,,,
461,above.|not,intact brain metastasis,oral medication.|patients,expected to become pregnant,international working group 2006 (,complete coronary revascularization,immunotherapy received.|azoospermic males,,,first-generation han chinese,at least 4 of the 11,25-35,1 mg orally,,is indicated for,,,
462,toxic,neurogenic bladder.|symptomatic uti,non-chemotherapy drugs,lille site|written consent from both parents allowing the collection of data from the child/adolescent|written consent from the parent(s),recist v1.1 on,intestinal resection,ii).|peripheral vascular disease.|recurrent,,,fulminant,in the last 6 months|eso-gastro-duodenoscopy,>1.5 dioptres,frequency of hallucinations,,preventing informed,,,
463,group:||male,main renal vein invasion,immune suppressive agents,situations that would limit compliance with study,pulse oxygen saturation,bwf,cardiac pacemaker,,,systemic anti-infective,within 30 days preceding the index procedure,under 60 years,≥100 mg/l,,unwillingness to swallow oral medication.|participants,,,
464,described,panc,study drug components,biochemical hyperandrogenism|the presence,american society of anesthesiologists (asa),hrct) scan,carotid artery bruit,,,totnf-a,within the last 14 days of screening,grade iii or above,more than 12 weeks|whose pain,,plans to start medical castration,,,
465,confirmed,kinds of,full stomach,accepted smoking,renal function,permission;|blood donation,aneurysm rupture,,,pericardial effusion.|active,within 14 days prior to day 1 of protocol therapy|anticoagulants,less than 6 months)|patients,more than 5 times per,,need a,,,
466,age.|individuals,distant localizations,sarcomatoid-dominant,participated other clinical trials,quantitative detection,open reduction,condom with spermicide from screening,,,severity,at the time of consent.|histologically,≤ 29.9 kg/m^2.||,≥10ppm,,biopsy|eligible,,,
467,patients:||age,sc,anti-platelet agents,tattoos,recist v1.1 at,blood samples;|ecog ps,intratumoral injection procedures,,,distal end of the target lesion|the target lesion,for <3 years,>100 x109/l|hemoglobin,long-term,,low risk for anxiety,,,
468,onsecutive,right hemispheric supratentorial,drug targeting t cell co-stimulation,1.plan to leave nanjing,bleeding|glomerulus filter rate,genotyping,ultrasound contrast,,,univentricular,for at least 14 days prior to screening through period 3 week 24,< 500 cells/μl.|haematological neoplasia,insulin pump)|contraindication to,,accepted to participate,,,
469,1.patients,pr,acid sequestrants,changes in medication use for the management of vwm disease symptoms,mdacc precision oncology decision support).||patients,transfusion therapy,implanted vagus nerve stimulator,,,may use any,visiting hospital for clinical appointments (clinic,18.5 30.0 kg/m2;|the,less than two weeks from the date of inclusion|inability to,,referred to the ep,,,
470,contact|age,conservative treatment|patient,anti-tumor necrosis factor [tnf] agents,participation on,hepatitis b surface antigen [hbsag]-positive,primary cryotherapy,neurological condition;|presenting,,,unplanned);|covid19,at least one measurable,< 17 years,outside,,unable to consent|pregnant,,,
471,form;|female,enpp1 deficiency,cyclopyrrolone,situations that would limit compliance with protocol requirements.|new york heart association (nyha) class,hdl-c,haplo donor selection,contraceptive measures.|life expectancy,,,refractory,within 3 months prior to inclusion.|person participating,above 90%,2-12,,need systematic,,,
472,prophylactic use of,horizontal,anticholinergic medication,participated in other clinical trials/trials,thickness tear,anticancer treatments,pacemaker,,,rocuronium induced,in the last year|those,more than half a tablespoon daily,1 year prior to screening,,plans for,,,
473,pregnancy|malaysian,localized dmmr stage ct1n0m0,glasses,concern,slippery,ect treatment,ii|elective infra umbilical surgery||,,,severity of hemophilia,within 14 days prior to randomization;|history of (non-infectious,>18y and <75y|morbid obesity,≥ 5 days,,permcath use,,,
474,hildren,severe depressive symptoms,tetrandrine tables,treatment plan,female|left ventricular ejection fraction,oral therapy,implanted metal,,,equivalent].||,during the inclusion,> 18 age|asa 3-4|patients,more than 1 week away from,,pregnancy|parturient,,,
475,≥65years,congenital heart conditions|patients,tranexamic acid,genetic cause for obesity,screening|systolic blood pressure,smartphone|willing,dental aligners,,,full ophthalmic examination,within the laboratory reference range,18 to 90|absence,2-5 mismatches,,scheduled for,,,
476,atients,progressive osteonecrosis,adjuvant nivolumab,volume of diffusion restriction visually assessed,african american|be,preoperative percutaneous cholecystectomy,metal implantation,,,hormone sensitive prostate cancer.|receipt,at the time of screening visit,1 mmhg,pik3ca,,disorders|currently,,,
477,ccr,local skin infection,sulfites,0~2.|life expectancy,modified plaque,pancreaticoduedenectomy,human bone screw,,,pancreatic malignant tumor,within the past 6 months|known,≤ 1.5xuln or < 3×uln,≥ 5 years|daily dose,,prevention,,,
478,suspected|age,toxic neuropathy,anti-fungal)|evidence,lactation|current smoking,general criteria,cardiac imaging scan,left ventricular outflow tract,,,existing,within 6 months after the last administration of platinum-,> 2000iu/ml,≥ 28 days,,eligible for the study,,,
479,people,multiple thrombosis,cftr modulator,render the patient at high,birth length,5-point likert scale,artificial heart valve,,,paranoia,before the start of study treatment,≥2.5 x 109/l,≥ 6 months,,eligible to receive,,,
480,rdeb|age,solid-organ transplantation.|hypersensitivity,components in the formulation.|patients,cockcroft-gault formula)|ecog score,ekg,partial hepatectomy,placenta previa,,,ra-specific,in the 4 weeks prior to receipt of the first study vaccination.||note,at least 3 months|evidence,2 or more times per month,,persistently,,,
481,research;|adults,hypochlorhydria,opioid pain medications,egfr overexpression,diastolic blood pressure>110mmhg|target organ damage,ivx-241 vaccine,intracranial vascular malformation.|history of any intracranial hemorrhage,,,glutamic-pyruvic transaminase,within 28 days before the first administration.|special diets,"> 75,000/mcl|total",≥ 1 year,,imminent risk of suicide,,,
482,subjects|age,secondary glioblastoma,nonobstructive catheter-associated clots,anticipated,attend same,corneal surgery,mitral valve replacement,,,"problems,|able to read",more than 14 drinks per week,18-55;|male,minimum use duration 1 year)|adult (minimum age,,clear,,,
483,evaluations|age,collective of the santa creu,interleukin-2,render them ineligible,parameters:||absolute neutrophil count,percutaneous transluminal coronary angioplasty (ptca),osteoporosis-medications,,,long diameter > 10 mm,for the next 3 months|unable,0 or 2,≥7 mean monthly headache,,planning to take,,,
484,patients|age,involvement of adjacent structures(t4b,mtor) inhibitors,progression to esrd|does,uz leuven,spinal,implantable medical device,,,sequestered,within 2 weeks of the planned,20 and above,more than 25%,,dementia;|unsuitable for participation in this study assessed by investigators;|patients who,,,
485,group):||male,excessive facial asymmetry,right ventricle clot,unable to take oral medications;|invasive respiratory support,car neurotoxicity,transthoracic echocardiography|written informed consent||,prosthetic vascular tissue on ct,,,american joint committee on cancer (ajcc) system,within 30 days prior to procedure|any scheduled,20 caucasian,> 14 days,,samples,,,
486,physician,cognitive frailty,immune sera,signing informed consent,pct,ffrct,picc implanted,,,under tutorship,for six months,score less than or equal to 10 or||patients,2 months to 5 years of age|families,,exclusion.|planning to receive,,,
487,hepatocellular,clinical observation|fmri exclusion only,medications|chronic steroid use|contra-indications,fulfilled,microsatellite stable mss colorectal cancer by,global assessment (pga),method of birth control,,,fnd symptoms.||,within 4 weeks prior to screening.|subjects,≥1 times/month)||poorly,less than five times of upper limits of serum metanephrine||,,condition(s),,,
488,2019)|height,non-traditional,thalamus nuclei,cohort b)||*e.g,recist version 1.1 guidelines.|patients,seen on ultrasound,inferior frontal,,,accurately measured.|hearing impairment,within 4 weeks prior to baseline.|evidence,between 18 and 30 years old|not,≥ .5|demonstration,,can be evaluated,,,
489,patients|aged,neurological deficits,procaine amine,treatment initiation,hepatitis b viral protein [hbcag],walk unassisted,indwelling venous,,,topical use,within 6 months of enrollment.|pregnant or lactating,2 (m2,maximum tolerated dose,,early access,,,
490,sexual relationships,music performance anxiety,cemplimumab,participated in other research programs,air.|cardiac function：left ventricular ejection fraction,upper abdominal procedures,intrauterine spirals).|for,,,gch1,at the time of obtaining informed consent for trial participation|patients,less than 12 months|severe dysfunction of the heart,1 malocclusion,,planned to receive,,,
491,elderly,tolerability,epilepsy|receiving drugs,points.|estimated survival time,smooth blood flow,substitute decision maker,aortic valve area (ava),,,massive,within 1 week of study participation.|history,12 and 18 years,250 mg with low,,existing,,,
492,etc.)|pregnant,although no contraindication,berlin definition (pao2/fio2,unable to follow vocal instructions).|those not able,"asct refractory, including:||disease progression",radiation treatment fields,allow confirmation,,,adrd,for ≥ 2,≦2 upper limit of normal (uln),2-year,,clinical symptoms suggestive,,,
493,japanese|men,gastrointestinal (gi) malignancy,insulin,close biological relatives,cal,imaging progression,unresectable,,,incisional,their diet,> 10 mg daily,≥ 60.|life expectancy,,needing to pass,,,
494,injection|men,local allergic necrotic reaction,coumadin,willing and capable of understanding the purpose,partial thromboplastin time≤1.5×uln,hysteroscopic sterilization,condom,,,carbon monoxide (co),at least 4 weeks before initiating study,greater than or equal to 1800 g.|able to begin,≥ 50.|lesion,,planned for resection,,,
495,slightly,cross-sectional,strong inhibitors/inducers of,change of endocrine therapy,direct bilirubin level,physiotherapy intervention,implantable defibrillator,,,single-gene,in the time of the study||exclusion criteria:||acute affliction,<1.0×109/ l,multiple prior,,interested to,,,
496,sex;|age,refused consensus,monoclonal antibodies.||received,unable to use crotches,short portable mental status questionnaire,immunotherapy directed,metabolic bone,,,spontaneous menses prior to enrollment.||7,at screening|history,greater than 400 copies/ml,more than 24 weeks,,applied to,,,
497,months|daily,chronic heart failure|chronic kidney disease,etv6,participated in other relevant clinical studies,expected length of stay,dqsve testing,vascular implants,,,grade ⅲ to ⅳ cardiac insufficiency,prior to adequate treatment for bacteremia,greater than 4.5 inches in length|able to follow directions,more than 5 cups,,preventing compliance,,,
498,months|age,organic anion,angiotensin ii receptor antagonists|diabetes mellitus|patients,risk of thrombosis,male patients|american society of anesthesiologists physical status,ureteral stone,implantable cardioverter-defibrillators (icd),,,consensus of helicobacter pylori in 2017,during the trial screening,rate 50-90 bpm,less than or equal to [≤],,expected to undergo,,,
499,gbm).|age,breast-feeding|if not in menopause,small,unable to take miglustat,ecco criteria.|patients,anti-tumor treatment,inpatients,,,moment,at the time of signing the informed consent.|bmi,>350 mg/dl,less than 5 half-lives,,never initiated,,,
500,fio2,leptomeningeal carcinomatosis,sodium bicarbonate,difficulty breathing|having been,new york heart association nyha scale);|if myocardial infarction occurs,general medical condition,pregnancy plan,,,manage,at least 6 months prior to study enrolment|adult|willing and able to follow dietary intervention|willing to participate,<2.5 mg/dl,< 1 mmol/,,scheduled to,,,
501,male;|age,liver metastasis exists,fridericia-corrected qt interval,volume that,nci ctcae version 5.0,axillary temperature≤37.0℃,stroke|cardiac pacemaker,,,non-isolated iugr,at least 6 weeks prior to start of the study,> 1000 iu/ml,more than twice the respective reference,,consumption,,,
502,did,ipf-ae,ild exacerbation,stress disorder|taking opiates|pregnant,months;||major organ function,lumbar spinal stenosis|age,potentially curative resection,,,metabolism|cardiac,within the previous 6 months|presence,<= 40.0 kg/m^2,≥ 1.5 x,,need of replacement,,,
503,1b.||male,resection,direct oral anticoagulant,expected to receive further imp,eligible.|oxygen saturation,rephresh vaginal hygiene,assistive devices,,,full stomach,less than 6 months ago|scheduled,17.5 ku/,≥ 12 g/dl,,symptoms endorsed,,,
504,participants.|female,heart failure).|diabetes mellitus,recombinant protein containing,sexual experience|unable to provide informed consent,tumors harbor oncogenic drivers,blood sample obtained,suprapubic catheter,,,mild to severe,their first hormonal treatment,over 35,≥ 2+ tr,,preventing them from,,,
505,rubella,hepatitis b immunoglobulin,clinics,inpatient,pain,bone marrow dysfunction|patients,mechanical heart valve non,,,statins|engage,within the past 90 days.|past medical history,≤ upper limit of normal value,more than 20 mg/day,,prevention of scd.||any known,,,
506,problems|aged,serious eye infection,streptomycin,breastfeeding,ii.|age 18~65 years,male sterilization,malar melasma,,,may contribute to different chronic,at screening / before vaccination.||diseases,≤ 85g/l,2-week,,applied in,,,
507,polysomnography|age,surgically cured,coumadin®,change in dietary supplementation,idh,imlifidase|ivig treatment,implantable cardioverter defibrillator (icd),,,65||,within 7 days prior to sepsis onset,<30 kg|cancer,< 12 months,,"injury,|inability to",,,
508,laboratories.|patients,disability application process.|natural therapies,dihydroergotamine,"breastfeeding,|known",hepatitis b surface antigen positive [hbsag] result),h&e section,implanted electrical,,,ascitic,within the range,between 40-75,more than 400ml,,points.|planned to receive,,,
509,n=420,carcinoma in situ of the skin,bevacizumab combination therapy,screening;|history,prostate symptom score,ehpad,intracranial vascular abnormalities.|clinically significant,,,lymphoma;|classical hodgkin,within 4 weeks before the first use of the drug,≥ 50% radiation,2 years,,able to,,,
510,female|ages,intestinal function,giemsa-stained thick,unable to give consent,hepatitis c virus positive;|a,ligamentoplasty of the anterior cruciate ligament less,implanted electronic,,,amenable to catheter placement,in the 60 days preceding any study intervention administration,>= 9 g/dl,>500 mg per day,,anticipation of the need,,,
511,hypersensitivity|uncontrolled,genicular nerve block,tetracycline-class,difficulty with mask ventilation;|morbid obesity [body mass index (bmi)>35kg/m2)];|airway anatomical abnormalities;|abnormal coagulation function;|emergency,prostate cancer|prior prostatectomy,neuromodulation therapy,pacemaker replacements,,,cc-1,after pancreatectomy|history of total parenteral nutrition,18-70 years;|diagnosed,at least first-line,,massive,,,
512,inr)>1.7,solid tumours,anti-vegf treatment.|any,participated in a study of an investigational agent,absolute platelet count,further analysis,intra uterine device,,,weeks||threatened,within one month of a,≥ 80% of the predicted value,≥ 20 mg/d,,indeterminate|without any,,,
513,ranged,framework fracture,anti-inflammatory drugs.|examples,involuntarily incarcerated.|participants,quantitative pcr test for hbv deoxyribonucleic acid,t-cell co-stimulation,cart regimen,,,ventral,in the past two years from date of diagnosis of,above 150 systolic,higher than upper limit of normal,,unwillingness to participate,,,
514,below:||leukocytes,aprepitant,strong inducers of cyp3a4 enzyme,smartphone software-based application for mental health,mfi,bone scan (,implanted contraceptives,,,iv.|sever osteoporosis,prior to trial|population size,2.0-3.0,for more than 60 days||5,,eligible for inclusion into the study,,,
515,miscarriage|female,donating plasma,assuit,irreducible,american society of anaesthesiologists (asa) physical status,renal biopsy results,intrauterine device application,,,inferior mesenteric,for at least 90 days after the last study drug administration if their,>9).|they do,45 mg/dl,,progressed during,,,
516,allowed|male,function,quetiapine,physicians,international normalized ratio(inr),liver volume,implanted pacemakers,,,"immunosuppressive use,|periocular",within 2 weeks of ct simulation,>/= 2 times the upper limit of normal).|have marsh 3a-c,= 12 g/day,,available to non-participants;|the subject and/or,,,
517,hiv.|patients,non melanoma skin carcinoma,hiv.|any medications,render the subject unsuitable for the study,nyha-class,preparation,intracranial access device,,,suitable for participation in the study|healthy volunteers in a similar age group,less than 4 weeks before the end of treatment,>5 years prior to signing informed consent,maximum of 72,,won)|eligible for,,,
518,university.||women,uncorrectable hypokalemia,kazakhstan,"difficulty with english, visual impairment",wide-field fluorescein angiograph (wffa),transatlantic inter-society consensus) working group.|patients admitted to the,vascular access unlimited|blood β2-mg,,,hyper-fluorescent puncta,within 2 weeks after the last dose of study drug.|be,levels ≤ 2.5 x uln.|international normalised ratio,more than one,,refuse to,,,
519,microwave,"cholecystectomy,|presence of",sp142,lose weight|english,serological test,smokeless tobacco.||participants,iud,,,quantitative detection,within 60 days of randomization||chronic infection,18 to 40||recreational athletes able,more than 1 of the following criteria:||albumin < 3.5 g/dl|lactate,,likely to procreate,,,
520,participants:||ages,hypertension;|alanine aminotransferase,68ga-fapi contrast agents|contraindication to mri,cigarette consumption,smile ce,resected head,implanted into the body,,,non-third,within 90 days prior to the first dose.|have autoimmune diseases,< 40 mm,"once,",,eligible for,,,
521,genders,end-stage organ failure,anti cn1a,possible risk factor for,applied,intermittent bladder drainage||idiopathic,neurological diseases|people with vision,,,"compound,|who",for the first time;|no distant metastasis,> 500 ms|known,≥ 500 ml prior to administration of the study medication,,plan,,,
522,criteria);|age,brain cancer,exon 14 jump mutation,entry into this study.|vaccination,wrist pain|finkelstein test positive|failure,cardiac risk assessment of the investigator,subclavian artery,,,criteria-based,during the study period and within 3 months after the end of the study treatment,between 18-40 years,dose of johnson & johnson vaccine,,readmitted to,,,
523,latex,previous eye,factor xa inhibitors,situations that would limit compliance with protocol requirements,visual analog scale,occupational therapy treatment,condom in combination with contraceptive cream,,,mid-stage alzheimer's,within 7 days of screening,>140/90mmhg,20 mg daily,,eligibility for,,,
524,gpp,diagnosed pathology,hydrochloride salt,choking,crown root fracture,cardiac hospitalization,intrauterine fetal growth restriction|use,,,implement recommended data collection tools.|english speaking,during the duration of study drug use,≤60 or ≥100 bpm|sinus tachycardia,more than 30 days,,enhanced,,,
525,prophylactic,severe preeclampsia,paroxetine,cooperate with non-drinkers,metabolic risk-,tracheal obstruction.|reported,hemostasis method,,,3 fish oils,at the end of the procedure,≤ 2.000 kg regardless,major surgery <4 weeks prior to the signing of informed consent,,willing to return to the centre (,,,
526,focbp,study.|malabsorption syndrome,report||,psychiatric condition).||staff,bone marrow involvement,intestinal diverticulum,intracranial vascular malformation|thrombolytic therapy,,,low-dose chemotherapy,within six months prior to enrolment,≥ 7.5%,more than 12/24h|affiliated,,clinical signs of infection,,,
527,30|those,non-aplastic anemia,prescription blood thinners,prevention of abdominal compartment syndrome,astragali radix,standard of care treatment,implantable cardioverter defibrillator,,,visits.|full-term,within the last 6 to 12 months,at least 300 µm,legacy of stroke sequela;|a score of 5-24 points on the,,need immunosuppressants;|people,,,
528,adult,solid cancer diagnosis,hyperglycemic drugs,unable to undergo,estimated survival,vascular reperfusion therapy,endoscope,,,interventional study.|receipt of the last dose of anticancer therapy,after receiving smallpox vaccine,"<60,000 per cubic millimeter (mm^3",older|high energy lower extremity fracture|provision of,,splenectomy,,,
529,criteria||age,end-stage renal disease|transplanted,human-derived protein,breast cancer|previous vacuum-assisted biopsy,ago)|body mass index,total daily dose,intracranial vertebral artery,,,well differentiated,within the last 30 days)|other,>40 international units per milliliter (iu/ml).||capable,≥ 100000/ mm3|hemoglobin,,pancreas to,,,
530,alzheimer,foot fracture,viral drugs,severely,profound,permanent sterilization methods,low venous capital,,,aks,for 3 months after the study period,less than 12-week duration,28 - 3,,authorized inactivated,,,
531,≥18,neurological disorders|have eccentric fixation,bcl-2,sexual activity has been,ag antimicrobial calcium algi-nate wound,"bronchoscopy,||diagnostic procedure",implanted neural stimulator,,,refractory advanced,cardiorespiratory,< 24 hours prior to the study start.|currently,greater than 8 cm less,,rano.||4.patient,,,
532,outpatient,cf exacerbation,anti-inflammatory medications.|patients presented,participated in a similar intervention program,msh6,local control,spinal muscular,,,low fertilization rate,6 months after the final dose of,0-2.|has,"one jaw,||",,planned to use,,,
533,mpap,acute tubular necrosis,ivf,participated in other drug clinical trials,rr-dlbcl;|age>18,residing,infusion pump etc.|pregnant,,,ct).|systemic,in the past month,18 years or older.|patients,greater than 20 pack year,,able to receive the investigational,,,
534,teria:||mothers,≤7.0.|ability to swallow oral,bee products,willing to continue this supplement,new york heart association (nyha) classification,definitive surgery,implanted cardioverter defibrillator,,,underlying,within 4 weeks of the first administration of ip.|has received,< 20%;|patients,surgery.|pre-existing,,plans extended,,,
535,weeks.||female,programme||,reiter,living with hiv:,early-stage (,started,implantable contraceptive devices,,,non-specific binge,within 1 month prior to the first dose of the investigational product|those,class iv or more,≥ 1 unplanned,,planning to administer,,,
536,years,lapp lactose deficiency,hip|patients,risk of pulmonary embolism,nci ctcae 5.0 rating,non-)invasive ventilation,postoperative recovery,,,portal hypertension|setting,on the montreal cognitive assessment [,<1 year.|pregnancy,≥1 of the,,chronically,,,
537,carers,rheumatic autoimmune diseases.|female,lymphoma|prior ezh inhibitor,receives dialysis|inotropic therapy,"resident of vü;|understand, read",heart transplantation,intracardiac lines,,,etc.|myocardial infarction,30 days before the first administration;|known allergy,1 ≤ fac ≤ 3);|diagnosis,>1 new symptom on the,,clinical suspicion of,,,
538,guidelines|age,hepatopulmonary syndrome,atd,progression on 1st line,paraffin specimens,invasive procedure procedures,implantable cardioverter defibrillator implantation,,,fridericia-corrected qt interval,in the past 4 weeks|meld-na,stage 3,1 or 2,,likely to interfere,,,
539,must:||be,target vessels,belatacept||,risk of harm,uvb protection sunscreen factor 50,sixth cranial nerve palsy.||2,shunts,,,pd-l1) expression,in the last 3 months.|subjects,>=100 × 109/l|hemoglobin,dose greater than 20mg/day.|pregnant,,planning a,,,
540,diplegic children,cancer event.|pregnant,treponema pallidum specific antibody,noncompliance with,old.|body mass index,days.||bronchial thermoplasty procedure,"cochlear implantation"" group",,,gram-positive organism,during screening.||,> 15 cmh2o,2 prior,,placement.||exclusion,,,
541,passes,psychotic features,doxorubicin,"suicidal ideation"" item",strabismus)|limitation,thoracoscopic surgical treatment,prosthetic heart valves,,,successfully treated.||13,within 36 weeks,≥ 6 to < 18 years,maximum 1 prior,,unreasonable,,,
542,years|individuals,extramedullary myeloma,enzyme inducing properties,with partners of childbearing potential,pr,low fodmap diet,contraceptive implants,,,clenching.|immunosuppressed,prior to participation in any study-related,<20 copies/ml,maximum of 24 hours,,converted to,,,
543,male|age,estimation,colestipol,pnh,beta-2 agonist adrenergic nebulization,fine needle aspirations (fna),prosthetic mechanical heart valve,,,insulin-dependent.||control participant eligibility:||normal weight,within this time frame)|presence,≥ 1500/ul,>5 iu,,able to take oral medications.||,,,
544,being,local complications,pet)-avid metastasis,breast cancer;|history,uln|alkaline phosphatase,primary series of covid-19 vaccine,mentioned,,,primary diagnosis of inclusion body myositis (ibm),during the treatment periods of the study.|treatment,>80% v/v,one-time peripheral venipuncture;|infection,,signs of,,,
545,icf).|female,renal vein,compounds of similar chemical or biologic composition to the treatment,entry into this study.|a participant,anti-pd-1/anti-pd-l1 treatment,standard therapy.|standard treatment options,middle ear infection|parotid gland tumor|malignant,,,first-line therapy）;|had,within 14 days|radiotherapy,18-25 yrs|able,≥ 1 mm||inclusion,,willing to adopt,,,
546,criteria:||age,pulmonary angiography)|renal failure,prevent iv contrast allergic reaction,progressing,escalation stage,menstruation cycle time periods,incompatible implants,,,suitable participants for the study,within 2 months before,12-18/min|po2,more than 4 weeks from completion of,,immersion,,,
547,fractures.|age,fetal malformation,drugs known to interact with brivaracetam,single-,sufficient level of mental development,stable.|major surgery,venipuncture materials,,,oriented,during the 6 months prior to study,>= 9 g/dl.|absolute,2-4mm).|patients,,clinical evidence of,,,
548,citizen|women,human infection center,|anastomosis preformed,unable to undergo anthropometric assessment;|body mass index,cardiac stress test.|new,neurologic examination,closure device,,,upper extremity musculature,during the 6 months pre-index period.|patients,< 90 mm hg,>2 weeks,,sunbathing,,,
549,a||male,sinusitis,aminophylline emergency operations,"difficulty staying asleep ""moderate",18f-fdg pet-ct|who,physiologic replacement,cerebral vascular accidents,,,non-sterilized,for at least 3 months prior to the first dosing,=< 3 x institutional uln|hemoglobin,daily doses,,unwillingness to consent,,,
550,both sex,colorectal cancer treatment,vaccination receipt,cohort specific criteria|cohort,reverse transcriptase polymerase chain reaction,cesarean scar pregnancy||,artificial vessels placed,,,middle membrane,within 30 days before the first dose of study drug.|the,<50kg;|body mass index (bmi),5mg twice daily,,eligible for inclusion,,,
551,practitioner,spinal block,immunomodulating ms,bacteria susceptible to,acid reflux,kidney transplantation surgery|status,shrapnel fragments,,,catchment area,since prior,≥ 20 years|ntm-ld,>40g,,investigators;history of,,,
552,inclusive.|not,feces pro-cessing,antidepressant therapy,unable to sign,tni levels,fugl-meyer score,implantable cardioverter-defibrillator|stroke,,,table 2,"in last three months,|antibiotic medication",< 18 years|do-not-intubate order|anatomical factor,maximum of two,,eligible)|consenting to receive,,,
553,smokers,gastrointestinal perforation.|cognitively,i.v.-antibiotics,macrotrauma,who criteria)|normal,lumbar cytology,study drug;|obesity,,,silent,during admission to the emergency department|copd exacerbation rejected,below 150 mm hg,> 50%|uncorrected knee,,above|able to read,,,
554,criteria||male,non-metastatic gastro,live vaccine immunisations,meet the inclusion criteria of the first dose,eit-measurements|contra-indication,gingival graft,colorectal cancerprevious treatment,,,extraction site,hospital treatment.|history of,≥3 months.||,2-4,,unwillingness to attend,,,
555,nmosd,cerebrospinal fluid involvement,vancomycin,sudden death.||6,nci ctcae v,sleep assessment questionnaire,irreversible toxicity,,,interfere with cooperation with the requirements of the trial.||is,while receiving treatment,≥ 90 g/l. 2,three doses,,admitted to,,,
556,year.|age,vascular drainage of the tumor,polyethylene,living environment,recist v1.1 evaluation criteria,world health organization (who)|deemed clinically appropriate,contraceptive injections,,,self-report)|when,after the last dose of study drug,above level 5,> 1mg/kg/j,,plans,,,
557,≥450ms,hypoglycemia-hyperglycemia,contains devices,situations that will limit compliance with study requirements|evidence,somatoform,vaccinations,implanted medical device|is,,,extramedullary,within 3 days prior to initial administration.|adverse reactions,20 degrees or more.|subject,2 weeks post-treatment.|patients,,strangulated,,,
558,female.|age,visceral myopathies,age|physician,situations that other investigators consider unsuitable for enrollment,meeting physical activity,needle insertion,intracranial vascular malformations|patients,,,low grade prostate cancer).|patients,within 3 months before study,14-27 years.|unilateral impaction of the maxillary canines,2 forms of effective methods,,actively,,,
559,form|age,progressive disease,anti-xa-inhibitors,provisions of inclusion criteria,lnfs).|age,mri contrast,implanted hormonal contraceptive,,,obstetric,within 14 days prior to study drug,> 1.5 times of the upper limit of normal value,less than 75°,,planning to initiate,,,
560,fulfilling,normal hepatic function,glitazones,unable to understand written and spoken english,2015)|geriatric depression scale-short form (,ip,pe,,,mount sinai hospital||,within 4 weeks prior to study,50% or more,more than 1 dose,,reachable|agreement,,,
561,sclc.|age,congenital neutropenia,cobicistat,scheduled,isi,radiology procedure(s)|plan,intracranial vascular,,,index foot,within 14 days prior to visit 2,> 45 ml/min,≥ 12 continuous months of,,expect to,,,
562,icu|adult,heterozygous familial hypercholesterolemia,norephinephrine,sputum smear,international normalised ratio,modification of diet in renal disease (mdrd) equation,addictive substances,,,extensive shoulder,after at least one line,>2cm,once rrt|receiving,,①,,,
563,≥100/µl,aff,oral contraceptive pills [ocps],breast treated,hbv dna detection,fundus examination,potentially curative treatment,,,intra-cardiac thrombus,within the past 28 days|breastfeeding,greater than 8 g/dl,1 cytotoxic chemotherapy regimen,,never received,,,
564,e:||age,mast cell stabilizers,fractures;|23,meet the,pad,screening clinic ecg machines mean resting corrected qt interval,potentially alter absorption and/or excretion,,,lower respiratory tract,at least 12 years old||,≥ 70,>1.5 x uln,,needed|estimated,,,
565,preferred,fetal membranes,age|pregnant,close to the lesion,common terminology criteria,brain surgery|participants,isolated individual lab,,,displaced,less than 6 months prior to study,> 30;|ongoing oncological diseases;|sampling area infection;|hiv,< 2 bowel movements per week,,seeking for aud.|recent psychotropic medication use,,,
566,women.|age,"pain evaluation,|overweight",loop diuretic therapy,managed on,nci ctcae v5.0,dxa,endobronchial coils,,,low ft4,within the previous two,> 50%;|baseline oxygen saturation,≥ 2 months,,images to confirm diagnosis.||,,,
567,≥0.2 mv.|signature,preterm babies,chlorhexidine digluconate containing mouthwashes,maintenance hemodialysis,diastolic blood pressure [dbp],global assessment (iga),colorectal cancer|systemic chemotherapy,,,full cycle of,within the last 5 years|clinically meaningful laboratory abnormalities|moderate to severe,≤100 x109/l|absolute neutrophil count,10mg or 15mg,,intending to become pregnant,,,
568,manager|younger,angina|active cardiac disease,lansoprazole,norwegian|currently residing,short blessed test,assessment of coronary artery disease.||,micellar waters ph,,,post-cardiotoxic chemotherapy,within 14 days prior to day 1 of protocol therapy|ugt1a1 inhibitors,≥2.0 mg/dl,referred,,present.|able to sign,,,
569,c,non-cns disease completed,and|creatinine,signed informed,tsat,checkpoint inhibitor therapy,sleep-related breathing disorder,,,angle glaucoma|intake,within 1 month before the first administration.|the subject is participating,=< 15 days prior to,greater than 3,,specific plan,,,
570,age>/=,recurrence of ischemic stroke,mins,admission,characterization of healthy research volunteers for nimh intramural studies .|have their radial artery pulse checked,endocrine therapy change,implantable loop recorders,,,r,within 3 months prior to the 1st dose,below 60%,total dose 3 g over 3 months,,indicated,,,
571,assuit,adhesive capsulitis,components of the drugs,"meet the inclusion criteria,|those",required.|absolute count,pfannenstiel incision|signed,ais,,,grade iii-iv,at the time of inclusion into the study|any condition,above the 99th percentile upper reference limit,at least 1,,compression)|dry wound|pregnancy,,,
572,≥10)|participants,hepatitis c.||note,cabotegravir,risk of dementia,hepatitis c (detectable hcv,cosmetic tests,permanent retainers,,,grade 1-3a)|marginal zone lymphoma,within 28 days prior to screening,≥ 22,more frequent than once per month)|insulin dependent,,equivalenta,,,
573,system.|any other,biological child,cephalosporins and|the,unable to convert,partial sccai score,fish negative|hematological,pcp,,,insulin deficiency,for 1 month after stopping the investigational,18-26 years,diagnosed at 24 weeks',,"unwillingness to consume, study foods in module 2 (e.g.,",,,
574,texas children's hospital,second cancer,low-molecular-weight,maintaining follow-up;|epilepsy/seizure,hepatitis c viruses,corneal refractive,prosthetic valve .|patients,,,navicular drop|those,last until 12 months after last dose of study drug,≥ the upper limit of normal,>1 cm);|patients,,resistance,,,
575,voluntarily;|male,organic changes,median,commit to intervention/assessment procedures|proficiency,forced expiratory volume in 1 s (fev1),intracranial bypass procedure,inferior vena cava,,,ulceration|esophageal,in three months prior to the study|pregnant,18 years old or order|able to provide informed consent|willing,two or more time,,severe|admitted to,,,
576,finally,attenuate immune response,anti-ctla-4 therapy,noncompliance to treatment.|patients,ncws,cd38-directed monoclonal antibody,implantable defibrillator)|documented allergy,,,pain,within 3 months before the vaccination,"≥ 60 to < 90 ml/min/1.73 m²,|moderate",requires,,able to swallow,,,
577,abnt,mites,allopregnanolone,fertile partners must adhere to the following,silibinin plus standard of care,lymphatic assessment,central venous access,,,overnight,within 12 months of visit 1.|unresectable cancer,> 3 months;||7,maximum two,,able to communicate,,,
578,bmi>25|age,primary liver tumor(s)|serum,anti-pd(l)1 monoclonal antibody,unable to consent,anti-beta2glicoprotein antibodies,behavioral risk factor surveillance,incidental histological finding of prostate cancer|presence,,,physician|current,during treatment determined by the investigator,at least 7 days before,≥ 20g/d,,clinical signs of hypoperfusion,,,
579,individual,hypothyroidism)|an inability to provide informed consent|use of,alpha hydroxy acids,difficulty following directions,thyroid levels,first sterilization,reduced vigilance|neurological,,,mild persistent,within 14 days prior to laboratory tests,> 144/94 mmhg;|have,higher than 30 ml/min/1.73m2,,home|ability,,,
580,≥1500/µl|platelets,subclinical hypothyroidism,medication except contraceptives,expected survival time,prostate cancer allowed.|concomitant somatostatin analogs,ligament fixation,implantable hormonal contraceptives,,,following:|negative total hepatitis b core antibody,acute,>50 ml,first cycle polychemotherapy treatment,,at risk,,,
581,y||do,pachymeningeal metastases,adenosine methionine,difficulty to understand french language|residence outside france,hss7 score,supplemental oxygen.|for,barrier method,,,residual invasive triple negative breast cancer,within the eligibility range,≥ 18 years old|affiliation,dual methods of contraception,,permitted for,,,
582,appointment,good general physical health.||exclusion,immunosuppressive biologic agents,entry into the unit,varicocelectomy|asa status,sbp.||malignancy.|antibiotic therapy,implantable neurostimulator,,,at room air,within the prior 6 months,<3.0 mg/dl.|absolute,≤ 2 weeks,,available for those who do not participate,,,
583,hysterectomy)|women,disease-modifying therapy,hpv vaccination,cockcroft-gault formula||,subcutaneous injections.|performance level,clinician specializing,medical implants,,,unrelated to the malignancy,at least one ear,100 ng/dl||patients,>45,,need of,,,
584,far,cardiovascular/cerebrovascular disease,urinary catheter,lose body,roma ⅳ function constipation|symptoms begin,congenital central hypoventilation syndrome,peacemaker,,,moderate degree of depression,in the last 3 months or more,>1.5 times uln.|severe hepatic impairment,2-5-year-old,,pheochromocytoma;|taking,,,
585,timeframe|not,hyperandrogenemia,give inform consent,limit survival,urine biochemistry,systemic therapy,potentially difficult airways,,,visits.|adequate,during the past 8 weeks,between 4.5 and 24 hours|informed consent from the patient,at least 90 days,,interfering with study procedures,,,
586,consent.|age,superficial vein thrombosis,bile acid binders;|lactose intolerance;|participation in another study,risk of perforation,barts bank partners||18,major intervention,allogeneic bone marrow transplantation|administration of a live,,,stage ib3,within 6 hours prior to study drug,between 18 and 75 years,≥ 2 weeks,,attributed to,,,
587,months|child,language problem,institutional guidelines,breast cancer;|bilateral breast cancer,bone marrow function defined as:||peripheral absolute neutrophil count (,cbit,pace maker,,,site of the oral cavity or oropharynx.|must,within 3 months of screening|have,between 65 and 74 years,greater than 12 months,,diagnosed,,,
588,tbi,spinal cord compression.|active autoimmune disease,ngs,unable to give informed consent.|individuals,hepatitis c infection|history of other malignancies,spirometry,artificial joints,,,hypoplasia||,more than 3 months|not,≤ 15 years)|the volunteer,12 consecutive months,,hemoadsortion,,,
589,polyps,|arterial hypotension,lilpivirin-containing,entry into,recist 1.1;|the main organs function,hyperthermic intraperitoneal chemotherapy||,ichthyosis vulgaris,,,grade 2 (definite osteophytes and possible narrowing of joint space,in the next three months|report,0-1|estimated life expectancy,>2 times/week,,about to receive,,,
590,volunteers:||age,pulmonary inflammation|combined,acalabrutinib,expected survival time≥,cpr inside hospital's other departments.|signs of sure,ros1 fusion inhibitor treatment,central venous cannulation|american society,,,bilaterally involved neck nodes|patients,during the previous two months.|class iii,> 45|serum psa levels,one-time,,requiring,,,
591,voluntary,end-stage knee arthritis,adversities,aortic arch,or|heart rate,t2d+ms||group,implantable device;|subjects,,,implantation of iol into the,within 2 weeks after study treatment administration,≥ 4.0,frequent,,cannot be enrolled;|the subject,,,
592,first degree,sepsis shock,live attenuated vaccine vaccination,psychiatric co-morbidities,function,haemorrhoids.|previous haemorrhoidectomy,left side breast cancer,,,pd-l-1 expression,within 10 days before receiving the first dose of study drug,≥++,greater than 2 months prior to enrolment,,unwillingness to swallow capsules.|history of,,,
593,impaired,unstable comorbidities,aripiprazole,evaluated,systolic pulmonary artery pressure,hosiery,aortic valve replacement|surgical approach through,,,injection site|coagulopathy allergy,at the time of randomization,≤ 60 mm;|the,steroid use,,cannot be,,,
594,old;|pregnant,sinus delay,sedative-hypnotics,limit compliance with study requirements|pregnant,karnofsky performance status,diagnostic mri,isolated valve repair/replacement.|inclusionary,,,radiologically-normal pancreas|vapor bioresource,recent 48-hr,20-30 years,dual antiplatelet therapy|severe,,eligible to,,,
595,women|reproductive,huntington's chorea,buprenorphine dose,inadequate english-language speaking skills,imv,thoracic aortic surgery,intrauterine device (,,,presumable,within 6 months after screening to the last study drug,less than 6 months.|subject,some,,interfering with treatment,,,
596,female|aged,tracheal intubation;|those,thrombin inhibitor,willing to participate|patients,18f-fet,hospitalization||,metal implant,,,mellitus|pregnant|insulin treatment|severe,at time of signing,>65,toxic effect(s,,etc.)||exclusion,,,
597,genres.|age,serious articulation disorders,caffeine/xanthine-rich,ndna,ecg tracing.||clinical studies,include:||surgical sterilization,corticoid application,,,south kingston,within 3 years prior to entering the study,above-mentioned inclusion criteria,less than 3 months old,,will be invited to enroll into the tms study,,,
598,ctnt,aseptic meningitis,mitotan,"sleep disorder,|had orientation",old|normal body mass index (bmi =,e. coli infection,egd,,,individualized jade wind-barrier herbal,within 30 days prior to initial dosing,> 140 mmhg)|current,greater than 5% vaf|at least 1 mutation,,varicocelectomies,,,
599,negative.|patients,thyroid disease,local anesthetic allergy|clinically,risk cardiac,tension headache,percutaneous transluminal angioplasty,device implantation,,,potentially curative,within 6 weeks of first administration of study treatment|corticosteroid treatment,0-1 points;|(4,12 and 32 weeks of the,,interfering with electrocardiogram (,,,
600,weeks|currently,thyroid disease|patients,pad,risk of fracture;|anemia,age.|predicted length of stay,psychiatric)||patient specific,palbociclib,,,full process of basic immunization,within 3 months before conception.|no,≤ 4.00 g/l|subject able,>1 week,,likely to alter absorption of study treatment,,,
601,incarcerated,diffuse peritoneal disease,angiotensin receptor blocker,participated in more,quantiferon tb,surgical treatment|angiography revealed,coronary artery disease|patients,,,porto-systemic shunt surgery,at screening and within 24 hours of initial treatment,150 to 600 meters,more than half a month,,complying with,,,
602,consent|age,choroid plexus tumors,anti-tumor necrosis factor,idiosyncrasies,residual shunt,bilateral location|may suffer,"psychiatric illness,|women",,,non-culprit vessel.|ostial,during the subsequent,worse than 1.0,1 and 2,,bleed,,,
603,consent|people,intravascular thrombus aspiration,ivosidenib,illiterate,serum creatinine below,pace-maker implant,diy system,,,pd-l1 inhibitor.|has any history,of at least 30 days,> 15 ml/min/1.73 m2,≥ 9 nmol/l,,likely to impact on the ability of the subject to participate,,,
604,excluded.||ages,childbearing,retinoid,unable to swallow oral medications.|subject,stage uc,ct imaging||,"pacemaker wires,",,,"habits,|patients smoking",within 2 months,exceeding 500 ms,10mg od,,injuries||,,,
605,youth residing,restrictive cardiomyopathy|congenital heart disease,antiplatelet,unable to use smartwatch,ecg.|sustained ventricular arrhythmia,ros1 mutations.|5,dialysis catheter,,,non-melanomatous skin cancer,for 4 months after the final dose of cabozantinib.||a sterile,between 7 and 12 years;|the child,1 of cycle 1,,14c|known,,,
606,ia:||age,unstable copd,nct05358821,risk of deteriorating renal function:||hypertension,hamilton anxiety rating scale,allogeneic hematopoietic stem cell transplantation|participated in any other drug clinical study,magnetic implants,,,days|singleton,at least 14 days prior to enrollment,"≥ 1,000µl",1 mg/day,,appearance of a,,,
607,antibodies)|women,polyarticular rheumatic disease,opioids,pneumonia-,npuap classification,epidiolex,central venous catheters.|secondary bacterial,,,≥12 seconds,within 1 month of screening,≥50%.|the organ function level,two or more,,will receive,,,
608,,local inflammation,methimazole,cockcroft-gault formula|if,catholic university of sacred heart in rome,rehabilitation treatment,intrauterine devices iuds,,,castration resistant prostate cancer,within 2 weeks|patients,v1.1;|at least 4 weeks after the,≥ 28 g/l|serum,,potential)|need,,,
609,,b-cell tumor,finasteride,alcohol exposure,transaminase (alt) ≤3 x upper limit of normal (uln),rated,probable,,,malformative,within 14 days prior to start of study treatment.|participation,above 35.9 ° c and below 36.9 °c,≥ 3,,need for,,,
610,,pulmonary edema,acetylcholine,alcohol use,dlmo,liver function|radiotherapy,metal implants;|claustrophobia;|mr-incompatible prosthetic heart valves.||standard cem exclusion,,,o6-methylguanine dna methyltransferase (mgmt),within 8 weeks prior to screening|evidence of,< 2.7 or >22.2 mmol/l;|severe,4 or more,,interfering with study procedures||inclusion criteria controls||signed,,,
611,,centers|able to read,anti-epileptic,incapable of oral feeding,genders;|body mass index,local regulations.|participants,left ventricular outflow obstruction,,,antidepressant therapy,within 56 days prior to study drug,allowed.||at least one,for at least 1 year,,,,,
612,,cast nephropathy,various drugs,living farther than 30 mills,participate|body mass index,testing session,tavr valve,,,profound,at birth,household level inclusion criteria,prednisone equivalent,,,,,
613,,physical limitation,taiwan.|individuals,impairs the ability to participate,hepatitis c virus (hcv) antibody positive,gravis||mri,intrauterine devices,,,under 18|patients,in the maxilla,45-60 minutes,2 methods,,,,,
614,,acute health condition,topical anesthesia,expected survival period,excludes autoimmune-mediated,testing.|previous knee surgery,tumour;|metal implants,,,postrenal,in the past three months|any,<18 years or >80 years|they,> 10mg,,,,,
615,,crystalline pathology,nicotine containing product,unable to find vaccination records per the procedures detailed,gingival index,immunotherapy treatment,absolute insulin deficiency,,,discharge to institutional care,more than 14 days have,18+ years|a self-reported,≥9.0 g/dl|total,,,,,
616,,autonomic diaphragm,any organ transplantation,method of birth control,study.|life expectancy,dsm-5).|current diagnosis,implantable cardioverter defibrillator carriers,,,real,within the indication of the eap,40-65 years,< 7 days,,,,,
617,,scar|standard logarithmic visual acuity charts measure the bcva,trifluridine,stroke|>1 week and < 8 weeks post stroke|new,rapid test|age,assessment of itch.|treatment,fragile x)|cerebral palsy|acquired,,,long diameter > 15 mm,within 30 days prior to study vaccination,more than 16,<28 days prior to first dose,,,,,
618,,chronic pain syndrome,aso,render the patient inappropriate,coagulation function,world health organization (five) well-being index survey,sulfonamides,,,condition|caloric responses,within 60 days of consent to enroll,10-13|females,once at the discretion of the investigator,,,,,
619,,extensive tissue calcification,vasoactive drugs|patients,old|current,split renal function,bilateral tubal litigation,vascular stent,,,between menarche,in the past 12 weeks,140 g,high-dose,,,,,
620,,main organs|7,clomiphene,difficulty in participating in sports,over your lifetime,bethesda assay,implanted metal device,,,urothelium|ineligible,for the last three weeks prior to the study,≥ 7 days)|kidney,<1 year prior,,,,,
621,,ectoparasitosis,over-the-counter pain medication,unable to take effective contraceptive measures,cobb's angle,inhibitors treatment,intracranial artery;|intracranial tumor,,,cytologically-confirmed resectable,outpatient or|≥ 3 weeks,0-1||adequate organ,greater than 4 mg per day,,,,,
622,,physically capable,furquintinib,unable to limit,sporadic-caa|probable-caa,request testing,sudden cardiac,,,auditory neuropathy|concerns of hearing loss,in the past 6 months|mental incapacity,> 450 msec,two units of,,,,,
623,,gad,national guideline-advocated copd therapy).||exclusion,admitted to the neonatal unit after 24 hours|mothers who do not,ipth,total knee arthroplasty (,first primary breast cancer,,,investigator|irreversible,<8 hours,lower than 40%,temporary,,,,,
624,,chronic diseases,combined liver/kidney transplantation,unable to understand what participation to the study entails,national kidney foundation guidelines,hsct).|active,worse,,,csf testing.|active hepatitis b virus,with the last dose administered,≥ 60 ml/min/1.73 m2,> 30 days,,,,,
625,,involvement of the first branch of portal vein,opv vaccine,breast feeding|history of,west bandung district,laparoscopic cholecystectomy,implanted medical devices,,,corneal radius,prior to initiation of any study procedures|stated willingness to comply with all study procedures,> grade 1).|uncontrolled,> 10 mg daily equivalent,,,,,
626,,traumatic injury.|use of any p-gp inducer,ivt anti-vegf|retinal,move,isotope clearance,sleep.|occupation,vegetarian,,,fresh frozen,within 6 months;|the functional indicators,greater than or equal to (≥) 18.0 to less than (<) 40.0 kilogram per meter square (kg/m^2)|non-surgical,>21/,,,,,
627,,inflammatory disease|smoking,component of the study products(yy001,consistent with hcc,niddm,surgically-assisted rapid palatal expansion (sarpe) surgery,barrier method (spermicide,,,lumbar level,for at least 3 days,>=3uln|platelet,≥200 ml,,,,,
628,,related dementias,components of the study drugs,cohort a,antibodies to hiv-1/2,technical advisory group,prosthetic valve malfunction,,,central nervous system tumors,within 1 month.||,<40% measured <5 year,dosing.|concomitant use,,,,,
629,,inadequate pulmonary function,late onset sle,cohort inclusion criteria||healthy,recist v1.1;|ecog ps score,osteophyte formation,surinfected ad|subject,,,investigator.|active,for ≥7 consecutive days within 60 days prior to screening.|need,7 days.|ocular,for at least 6 months.|patient,,,,,
630,,plantar fasciitis,regional,unfavorable risk,total calcium,rectum;|radical surgery,intracardiac clot,,,screw-retained fixed dental prostheses,within 6 months prior to registration,less than 32 weeks,more than 2 weeks one month before vaccination,,,,,
631,,although fmt infusate,anti-cd20 antibody,ecmo.|patient affiliated to the social,end organ function,ocular nerve injury;|neurological disorders;|disc disease,irreversible toxicity not reasonably,,,jugular veins,within 1 week of baseline,> 700 × 109/l,>1 episode,,,,,
632,,physical activity|taking,cephalosporins,loss of consciousness,serum glutamic-pyruvic transaminase,small cell,implanted csf device,,,horizontal,maximum lenticule thickness,greater than or equal to 18,> 100 ml,,,,,
633,,itp,scandinavian language||exclusion criteria,senile cataract|patients scheduled,bi-rads 1 (negative),gastric emptying breath test,u.s.,,,peg-g-csf,for the last 3 months|body mass index of 25kg/m2,<90 days prior,chronic intake,,,,,
634,,psychiatric symptoms,inhaled steroid,sedation,mayo endoscopic sub-score (mess),first-line immune chemotherapy disease progression,metal devices sensitive,,,hep c,within the last 3 months.|ongoing,under six years,3 mg/kg)|planned,,,,,
635,,logorrhea,immune suppressive drugs,risk of bleeding,serum total bilirubin (stb),dialysis treatment|renal replacement therapy,intrauterine hormone-releasing systems,,,emergency department.||,within 1 week.||subjects,< 18 kg/m2|extremely,at least 8,,,,,
636,,galactosemia disease,contrast materials,postmenopausal state,ais score,hair transplants,breast implant,,,f20.x)|receive,in the last 6 months|history,< 110 μmol/l,<2g of protein,,,,,
637,,temporomandibular disorders,additional ics treatment,unable to cooperate in treatment|children,consent.|negative rapid antigen test,graft-versus-host disease,mechanical ventilation|people with heart,,,traffic vehicle,at 24 weeks gestation,≥ 50×10^9/l,changed,,,,,
638,,down syndrome etc.)|presence,hht,lab values|severe asthma,alkaline phosphatase (akp) ≤2.5×uln,customized induction,implantable device,,,institutional guidelines,within 6 months before the first dupilumab administration,90-99,maximum of e.g. 3 daily,,,,,
639,,unintentional outdoor,radiographic contrast agents,psychiatric disorders|patients,suicidal ideation section of the c-ssrs,cause).|corneal surgery,vascular invasion,,,acr 1987 criteria,within 2 years prior to entry,greater than one year,online,,,,,
640,,blood clotting,dystocia,progressed through,weigh,triple therapy,implanted pacemaker,,,proportion,< 48,≥ 75×109/l,for at least 7 days,,,,,
641,,multi-organ failure,bisphosphonates injection,partners of childbearing potential,digestive enzymes,oxygen treatment,activated implants,,,might interfere with the study drugs kinetics,within the previous,>18|adequate visual,outside of routine clinical practice.|diagnosis,,,,,
642,,old|cancer,cisplatin o,cohort a||histologically confirmed selected lung non-small cell lung cancer,sweat test,small molecule agent,urethral anatomic feature,,,pregnancy|age,in the past 6 months|systemic corticosteroid treatment,>= 180mmhg,more than 2,,,,,
643,,growth hormone,anti-resorptive bone therapies,signed informed consent|18-80 years,local labs|adequate renal function,criteria||pregnant,uncooperative children.||children,,,5:2 programme,in the last 1 month or who is not in the attack,than or equal to 6 weeks|english,high dose or,,,,,
644,,natalizumab||note,gsk3511294 (,unwillingness,ischemic colitis.|history of,abdominal emergency surgeries|structural,linear,,,secondary to medical cause o,within 14 days prior to screening.|any,upper limit of normal,greater than the upper limit of normal,,,,,
645,,nitroimidazoles,intraocular,flaring,psa before urinary retention,stone analysis,watchful waiting,,,older|primary,within 30 days before screening,0 to 1.|has,more than 25 years,,,,,
646,,complete loss,stannous fluoride,inadequate equipment/devices,corrected corrected qt interval,human chorionic gonadotropin (hcg),study;|able,,,rome iv criteria|additional criterion,in the past 11 months,≥ 16,2 weeks prior to screening,,,,,
647,,major thromboembolic event,protein drugs,age|patients,local testing||phase 1b monotherapy||pathologically documented,laryngectomy,implanted medical devices|patient,,,appearance,in the 6 months prior to screening resulting,< 2|mini-mental state examination,changed dose,,,,,
648,,aneurysm related,cisplatin,limit compliance with study requirements||pre-registration,regular inhaled,urine routine,intrauterine iud,,,diagnostic manual diagnostic manual]|be,during the acute period of study participation.|,"≥ 65 years,|community-dwelling,|have",greater than 10mg daily of,,,,,
649,,kidney failure|acute,seasonal influenza vaccines,outpatients,beck depression inventory score,cardiopulmonary exercise test|after,mechanical ventilator,,,non-advanced,6 weeks before recruitment.|specific dietary regimen,=< 3 x uln|women,student,,,,,
650,,bone problem,inhaled n-acetylcysteine,comply scheduled follow-up|comprehension disability,total neutrophil count,r1 resections);|patients,central venous occlusion,,,investigator.|history,within 6 months of enrollment.|new york heart association class iii,<10ᵗʰ percentile,> 12 months from completion,,,,,
651,,traumatic brain damage,contraceptive ring,unable to complete study procedures,balducci score,elective procedures,fibroscan,,,non-hispanic black childhood,within 14 days)||hemoglobin(hb)≥90g/l;|absolute,<18.5,hydrocortisone.|at least 14 days,,,,,
652,,uterine cancer,induction,low survival rate,insomnia severity index [isi],radiologic imaging evaluation occurs,immunotherapy alone,,,platinum-containing regimen,approximately 4 cups,18 or above|patients,greater than 4 weeks after surgery,,,,,
653,,diabetes mellitus|diabetes duration,medications used in the postoperative course.|either eye does not,parental,absolute neutrophil count(anc,radical cystectomy|agrees to participate in study procedures||,special balloon (,,,shoulder area,within the prior 60 days 11,≤180 mg/dl,≥2 for,,,,,
654,,colorectal cancer|life expectancy,analog,patients,cdr sum of boxes,tests,vascular closure procedure,,,influence the condition.|allergies,at time of acceptance)||,score of 13 or greater,>4,,,,,
655,,"prostatic carcinoma,",antipsychotic drug use,unable to undergo serial sample collection|pregnancy,tuberculosis.|active hepatitis b infection.|active hepatitis c infection.|viral encephalitis.|toxoplasmosis.|current/,surgical sterilization,cerebellar,,,full subsidy arm,chemotherapy;|history,neonates,≥2 on item 9,,,,,
656,,"pain complaints,|did",investigational agent,pregnancy|life expectancy,anti-hcv ab+,laboratory results|medication changes,plates,,,risk invasive procedure,for at least 6 weeks duration.|foot posture,< 80 ml/minute,more than 400 ml,,,,,
657,,cancer-directed,vitamin supplements,unable to tolerate,nihss level of consciousness (1a) score,systemic treatment regimen|measurable disease,control ipg,,,c2-3|subjects,in two six-ounce,≥ 18 years|periodontally,> 2 mg per day,,,,,
658,,chronic pain syndromes,products containing tobacco,willing and able to sign an informed consent,body weight (kg) / {height(m)}2||patients,interleukin-2,condition(s),,,concern related to the change in cognitive performance,more than 1 month,score of minimum 5 points,≥9 g/dl,,,,,
659,,"lupus erythematosus),|neurological disorders",thienopyridine pretreatment,living child,pharyngeal pain.||,hematopoietic stimulating factor,intrauterine growth,,,influence the study|any,throughout the duration of their study participation.|able to understand and sign the informed consent form (icf),≥ 4 years-old|oral,≥2 measurements);|abnormal coagulation function,,,,,
660,,joint movements|persons,strong cyp3a inhibitor,signed informed consent form,uk parkinson disease society brain bank clinical diagnostic criteria,blood stream infection,reduced ankle-brachial index,,,massage related studies,within 7 days prior to initiation of study treatment,< 7.4 mmol/l)||history,≥ 8,,,,,
661,,arrhythmia,pulsed steroids,cockcroft-gault glomerular filtration,modified hexsel css (,thyroid disease;|a,intra articular injection)|systemic corticosteroids,,,intracorporeal presence,within 14 days prior to the first administration of any study,≥18 years|strict lbbb,long term drug,,,,,
662,,qtc<450ms,anti platelet aggregation drugs;|chronic cardiovascular,weeks|breastfeeding child,emergency colonoscopies|inflammatory bowel disease,finger prick measurements|in the judgement of the treating clinician critical care area,cardiac devices,,,refrain,prior to treatment initiation|detection of circulating dna,"18 years or older,|willingness",follows:||single,,,,,
663,,squamous cell skin,immunoglobulin m [,unable to mobilise,serum beta-hcg,recurrent pelvic,artificial heart valves,,,biopsy)|short-term,less than 3 months before participating,between 20-30|positive reaction,more than 30%,,,,,
664,,life-threatening pathology,anti-inflammatory treatment|atcd of known coronary artery disease|unbalanced hypertension,speak english|have,fmiso pet/mri studies,small-molecule targeted therapy,digestive system,,,amenable to locoregional therapy,more than 14 times/week,≥ 0.3 μg/kg/min + vasopressin,<12 weeks)|recent,,,,,
665,,draining sinus tract,pots,unable to safely,urinary protein level,lung imaging showed,menopause;|adult,,,youth assent||,for at least 8 weeks prior to visit 1.|acq-7 total score,< 30 ml/hour,recurrent,,,,,
666,,interventricular hemorrhage,sulfonylurea,participated in other clinical trials of drugs or medical device,abc)|t-cell,special types,condom in combination,,,19 diagnosis,within the last 80 days prior to the present,≤ 8 mg/dl,2 methods of birth control,,,,,
667,,alcohol and/or,anesthetic agent,entry into the study|patients,recist v1.1 that,early access program,diaphragm,,,≥12 months follow,within 3 days for first-generation,>40,<1 month)|severe chronic,,,,,
668,,complete left bundle branch block,cetaphil®,expected need,national institutes of health stroke scale (nihss),allogeneic tissue/solid organ transplant,hormone receptor-positive,,,modification of diet in renal disease (mdrd),within 28 days before enrollment,complete remission of asthma,≥3 months within,,,,,
669,,traumatic neurologic,glucocorticosteroids,treated,neurologist|disease duration,either:||conventional flow cytometry,implantable venous port,,,testicular,within one year,>8 kilopascals,fractional dose,,,,,
670,,surgery|intrinsic lung disease,leflunomide,participated in another clinical trial in the last 2 months,abpi measure,thecoperitoneal shunt,expected curative outcome,,,danish general practice|gps,within 2 weeks of starting study treatment,≥18 years old,more than 1 prior,,,,,
671,,eating disorders,pure alpha blockers,chemiluminescence immunoassay,american college of cardiology,first dose of nm1f):||any therapy,cardiac resynchronization therapy devices,,,grade iv (neck trauma,within 2 weeks prior to cleansing,between 1000-1500,daily lipid-lowering,,,,,
672,,curatorship|active pulmonary parenchymal,panitumumab,immunotherapy with checkpoint,volume less than 31 ml,fracture.|major surgical procedure,implantable pacemaker|complete heart block,,,native coronary artery|severe,within 4 weeks prior to cell infusion.|autoimmune disease,< 45 ml/kg/1.73,≥ 6 mm³,,,,,
673,,various reasons,anti-aav9 antibody titers,risk of aspiration of the capsule.|females,prader-willi syndrome,confirm eligibility.|body mass index,demand pacemaker,,,surgically cured,within 180 days prior to surgery||,greater than uln,2 to 7,,,,,
674,,child-bearing plan,thyroid medications,caton-deschamps ratio,old|adequate blood tests,standard conservative therapy,focal musculoskeletal,,,antidepressant-induced,within 30 days of anticipated treatment.|prior treatment,1.5 ≤ institutional,> 10 mg/day,,,,,
675,,affective disorder,pde-5 inhibitors,render the participant unable to provide informed consent|subjects with visual impairment,glogau skin,injection therapies,immunocompromised,,,parenteral administration of prostacyclin analogues,pre-operative,score of > 3 %,>5 episodes,,,,,
676,,chronic symptoms,fumarate,impairs walking,qrs,suppressive antibiotic treatment||c,study pi.||systemic steroid therapy,,,site cardiologist:||mean right atrial pressure (mrap),in the 28 days following the dose of vaccine,less than 45 beats per minute,for ≥48 hours,,,,,
677,,disclose health information.|20,cyp1a2,possible risk for adverse events,changes|body mass index (bmi):,oral nutrition|surgery expected,implantable electronic medical device,,,sex.||,for at least 3 months before signing the informed consent,>2.5 ml/day,>12 months|stroke,,,,,
678,,abnormal thyroid function.|evidence of,anti-platelet aggregation agents,parents have given consent,nci-ctcae v5.0;|7,fine needle aspiration biopsy,implanted electrodes,,,hypoxemic respiratory failure.|patients should,within 30 days prior to check-in|participation,20-59 ml/min/1.73m2,daily cannabis,,,,,
679,,developed disease,magrolimab,situations that would limit compliance with study requirements|receipt,child-pugh score.||matched healthy participants:||participant,emotional problems|special diet,epidural steroid injection (,,,severity of apathy,for at least 30 days prior to screening,50 l/min||,≥ 12 months of amenorrhea,,,,,
680,,various cancers,bebtelovimab,known,child reintegration centre,standard treatment failure,brain devices,,,regional,within 48 hours);|sars-cov-2 etiology test,90 g/,100mg twice daily,,,,,
681,,prior in situ cancer treated,macrogolglycerol hydroxystearate,rupture,white,blood purification,aortic valve area,,,tested frequencies,prior to randomization);|patients,>36 mmhg,≥ 1 month to <1 year,,,,,
682,,somatic illness,motrin,pregnancy.|life expectancy,leukocytes,evaluation;|abnormal,ventral abdominal,,,implant -retained overdenture.|the,for 4 weeks prior to treatment,< 45% noted,more than 15 cigarettes,,,,,
683,,ctla4 inhibitor.|previous chemotherapy,guideline,r mutation carriers:||pathogenic parkin,cytopathology,periodontal surgery||,implant,,,hard tissues of the oral cavity.|cavitated carious,within 24 hours of any study visit.|individuals,18-55 years|able,12 mg/day,,,,,
684,,microscopic colitis,delayed gastric emptying,prevention of endometriosis recurrence|medical conditions,cre8™/cre8™ evo,periodontal treatment|smoking|pregnancy|ingestion,radiographic interstitial,,,stimulating,within 4 weeks prior to administration of the first study drug,greater than 45 ml/min,more than 2 months before the visit,,,,,
685,,vaginal condition,anti-anxiolytics,contraception.|life expectancy,normalized ratio (,sleep intervention drugs,implanted device,,,critical,within 6 months before the first dose.|subjects,< 50% of predictive normal value|spo2,daily medications6 currently,,,,,
686,,irp|responsive to cold,methicillin-resistant staphylococcus aureus,anticancer chinese medicine,females|body mass index (bmi),gastric acid secretion,superior vena cava syndrome,,,pathology,at any time.|have received,between 37-40,>1 to <7 days|and/,,,,,
687,,muscle tightness,antiplatelet medications||medical conditions,genetic risk,glomerular filtration rate below,local laboratory (ihc 3+,cardiogenic shock|patients,,,poor,more than 3 months before the examination|previous intravitreal application,>2 mg/,january 2008,,,,,
688,,non-autoimmune condition,anticonvulsant,resolved,grade,nickel titanium).|any contraindication,lvef ≤50%|av node ablation,,,grade 2 toxicities,within 60 days of first dose,>90cm,analyses|at least 18 years,,,,,
689,,hemostatic disorder,marijuana products,unable to use adequate birth control while on study drug|qt,urine pregnancy test.|male,non-hormonal barrier contraceptive method,psychiatric illnesses|those,,,inclusive)||clinical diagnosis,within 30 days prior to admission on day -7,18-65.|participant is able to give informed consent.|generally medically,≥2 cycles,,,,,
690,,malignancy|pregnancy|acute infection|lack of ability to sign informed consent forms on their own,endoscopist,clinical evidence indicates,transrectal ultrasound|serum creatinine levels,pyx-106 treatment,mechanical tricuspid valve replacement|history,,,systemic therapy|known,at least one of the following compensatory behaviors:||set an alarm,≥ 0.5 x 109,≥6 x,,,,,
691,,chd,glp1 agonists,unable to cooperate,platelet rich plasma (prp),inotropic drugs|acute coronary syndrome,implanted,,,newly treated,within the normal,"≥18years,",186 x,,,,,
692,,ctcae grade 1,bosentan,unable to answer questions correctly|critically,outpatient treatment.|a severe,surgical sterilization of partner,intracranial,,,stannous fluoride,in last 3 years||,3 or more nights per week,more than six months,,,,,
693,,multi-rooted,copper.|baseline ferritin,unable to take effective contraceptive,working memory program,ekg,central venous cannulation,,,grade 2 or greater toxicity from previous anticancer therapy,in the last month before inclusion|subject unable to understand the purpose of the research,> 300 mg/dl,single electrocardiogram (,,,,,
694,,hemodialysis|women,topical ophthalmic medication,difficulty in responding to the data collection form to be used in the research,same height,sd-oct|ability and willingness to comply with the treatment,implanted cardiac devices,,,moderate to severe cardiopulmonary,before the first dose of vtd-101 ointment,=<59 ml/min/1.73m2,dual antiplatelet,,,,,
695,,mental illness;|peripheral neuropathy,niacin,unable to provide informed consent in english,pregnancy test;|the investigator believes,mandatory biopsy,ileac valve,,,multidisciplinary expert group review should be conducted to confirm ipf,within 4 weeks prior to the first dose of study intervention.|a wocbp,≥ 18 years;|written informed,long term of,,,,,
696,,body|valvular disease,anti-coagulant medicine,prevention of scd,new york heart association standard class,cpb technology;|postoperative need,cesarean,,,etc.||,6 months prior to treatment,≤ 1 x uln|aspartate,less than 2 weeks before the start of the,,,,,
697,,xerophthalmia,zmachine,prevention of urinary tract infection,psoriasis patients||age,graft vs host disease|radiotherapy treatment,"dialysis catheter,|who",,,study.|fully healed wounds,at screening;||is currently,less than (<) 30 milliliter (ml)/min/1.73 square meter (m2,first,,,,,
698,,meningococcal infection,nasogastric tube,participated in another research study,human immunodeficiency virus antibody (hiv-ab,anatomic variation resulted,saphenous vein graft||,,,arterial,30 days after last dose|participants,score of more than or equal to,2-weeks,,,,,
699,,women|chronic illness,thereof,change diet,left appendage ap,kidney disease|dependency,reproductive capacity treated or,,,adequately-treated,throughout step 2.|ability,>1.5 uln,daily dosage,,,,,
700,,unresolved biliary obstruction,anti-cancer therapies|pregnancy precaution,unable to swallow oral medication,acog guidelines|postpartum day,bisphosphonate therapy,psychiatric disorder.|coronary artery disease,,,asdh,at least one year ago,<60 ml / min / 1.73m^2]|renal,routine care.|enrolled,,,,,
701,,hospitalized cardiovascular diseases,moderate cyp2c9 inhibitors,enrolled in another clinical investigation in which the intervention might compromise the safety of the subject's participation in this,adct<7,conventional therapy leads,investigational,,,permitted,within 30 km away the riding center,score range,c)/2 of initial clot,,,,,
702,,community-dwelling individuals,complicates,sexual relationships,hepatitis c virus (hcv)|evidence of active,barrier contraception,implanted electronic devices,,,weekly,for at least 6 months prior to visit 1;|have,< 1 year)|pregnant,one ore more,,,,,
703,,mixed phenotype acute leukemia,prescription pain medication,living with hiv inclusion criteria||is a cis woman,old;|eastern cooperative oncology group (ecog) performance status,qt syndrome|known,implantable cardioverter defibrillator(icd,,,prevalent,within the 3 months prior to study entry,>1.5 times the upper limit of,≥ 30 days,,,,,
704,,represent g3 disease,scheie)|alpha-l-iduronidase enzyme activity level,risk of pregnancy,≤40|hemoglobin,clinics,contraceptive patch,,,sino-nasal disease,within 6 months prior to the first dose of the investigational product|history,<45 with|new,≥10 g,,,,,
705,,hypertrophic scars|a,variant,dyspnea in pregnancy||cardiac,drug treatment.||clinical stability ability of,therapeutic oral,psychiatric illness|diagnosed with dementia,,,stage of,subjects|tobacco history of more than 5 packs/year,under or equal to 50.|ecog 0-1|patients,2-line therapy,,,,,
706,,radically resected carcinoma in situ,injectable antibiotic therapy,unable to follow the research procedure;|2.patients,anti-pd(l)1 ici,standardized allergen extract of dermatophagoides pteronyssinus,age|signed informed consent||exclusion criteria,,,systemic inflammation|use,within 2 weeks prior to the first dose of study treatment|significant,18-years-old,greater than 6,,,,,
707,,autoimmune diseases.|a,daridorexant,cockcroft-gault formula||left,systolic blood pressure [sbp],curative surgery,panss,,,above.|self-reported,during the trial period and 120 days after the last dose of the test drug,> 8%.|patients,"scs),|cesarean delivery by",,,,,
708,,vascular disease|traumatic loss of,rifaximin,incapable of giving,sample size,biological sample,implantable cardioverter-defibrillator)|pregnancy,,,deemed related to the study treatment,in the past 6 months;|incomplete,18.5-30.0 kg/m2|fasting,12 weeks,,,,,
709,,chronic opioids|patients,involves mutilating surgery,cooperate fully with the investigator|have,simple laboratory abnormalities,invasive treatment of the fracture,pins,,,non-cooperative|patients,within 6 months).|patients,> 2|not able,researcher prior to attendance,,,,,
710,,ocular hypertension|ahmed valve implant,sedatives,problems in cooperation,radiology department,paleo diet,potentially electrically conductive implants,,,very close to the pulp|no resorption,within 2 weeks before enrollment;|severe,a or,regular use,,,,,
711,,ischaemic heart disease,piperazine,entry into this study.||participant,multiuser clinical research center,stone,lactation|active,,,non-hormonal,within 24 months of the baseline visit,40+ years.|adult,high,,,,,
712,,intercurrent illness,contraceptive barriers,applied in,child pugh c grade|pregnant,rescue analgesic drugs specified,mechanical valve prosthesis,,,discharge to hospice,within the past 12 months|history of (,lower than 140/90 mmhg;|left ventricular ejection fraction,less than normal range of motion,,,,,
713,,labs:||abnormal liver function,online,psychiatric disorder|history,posterior circulation,local radiation,intracardiac masses,,,dining services,during the four weeks,19 years,≥2 times per,,,,,
714,,alpha-1-antitrypsin deficiency|known sensitivity to medications,salicylate-containing products|participation,family history|history,alt / ast,expression of cd70,aortic valve re-intervention,,,cervical rib,for at least 1 month prior to commencing the study with no intention to change dose prior to completion of the study.||,between 18-80 years|diagnosis of first-ever subcortical stroke,more than 10 mg per day,,,,,
715,,heart disease|acute intoxication,hormone therapy)|regular tobacco,living in temporary accommodation,aβ2gpi igg level,ultrasound guided biopsy;||3,vod,,,may not offer additional supportive,within the past 12 months;|have,18-29 kg/m2.|willing,more than approximately 4,,,,,
716,,paranoid disorders,aoms,unable to cooperate with treatment,registration.|new york heart association,intravenous mri contrast agent,dvt interventional,,,aortic valve stenosis|uncontrolled,in the past 6 months||,≥ 0.7 ku/l).||patients,≥1 year|using,,,,,
717,,drug-induced liver injury refers,cytotoxic chemotherapy regimen,hardaliye regularly,alpha-fetoprotein (afp),computed tomography (ct) angiography,biopsy-,,,b7-8,disease.|medical history,> 8.0 g/dl.,4,,,,,
718,,cervical esi,mulhouse,egg donation,sample|ecog ps,mdi,artificial,,,successfully treated by tai with,after at least 2,< 2.0 × 109,2|≥ 2 prior,,,,,
719,,congenital myasthenic syndromes,ascorbic,physiologically capable of becoming pregnant.|female,cmv serological status||,wechsler memory,icd,,,non-stable dose,for at least 3 days in the opinion of the treating clinician||,?' and completed,≥ 18 ≤35|hga1c,,,,,
720,,brain surgery|hydrocephalus|pregnancy,l1 inhibitors,signed informed consent,cdai score,revision,prosthetic vascular tissue|and/,,,discharge to,during the study period.|chronic stable,stage iiib,distant,,,,,
721,,ert,thyroid disease|patients,vaccination|current,md anderson cancer center institute,trial|previous randomization,prophylactic,,,cardiac disease.|impaired level of consciousness,within 2 months prior to dosing.|clinically significant abnormalities,between 18 and 100 years,at least 1 measurable,,,,,
722,,liver-related complications,drug-resistant focal epilepsy|patients,participated in other clinical trials,covid-19 diagnosis|hospitalization duration,ct contrast media.|participant,neurological deficits|psychiatric,,,frequent,within 4 weeks prior to screening;|have,males|18 to 80 years,more than once weekly,,,,,
723,,parkinson's disease;|older,anti-hdv igg antibody,unable to follow protocol requirements.|any condition,neuroendocrine small cell components|site(s,general visual analog scale (vas),walker,,,longest diameter by ultrasound,7 days prior to the start of the study.|participants do not,< 1000/mm3|pancreatitis,greater than outpatient,,,,,
724,,clotting,3rd,unable to give informed consent.|as a result of the medical screening process,national health commission of the people's republic of china (,enterococci,restlessness,,,some,before initial unipolar ablation,1.5-2.5,more than 4,,,,,
725,,brain condition,over-the-counters,cohort 3)||be,serum hcg ectopic,sars-cov2 infection,implanted neural stimulators,,,proximal interphalangeal,during inclusion visit,< 110,greater than 10 pack years,,,,,
726,,vitamin b12 deficiency.|the,non-steroidal anti-inflammatory,noncompliant with the protocol,mcr group,screening.|failed,adult,,,lower extremity.|arthritis|sprain,within 14 days prior to imp treatment start,<50%.|have,major surgery,,,,,
727,,male clients,anesthetic analgesia|psychological disorders|coagulopathies|infection,difficulty in voiding,hcv rna test|history of pneumonia,dutch language|bilateral acnes|previously administered injections,mechanical prostheses,,,relapsing-remitting,within 7 days of the hematology laboratory sample obtained,at least 01 sexual intercourse,>500 mg,,,,,
728,,orthodontic ttt||,dexmedetomidine,speak french)|pregnant,manual muscle test-8,target wrist,carotid artery stenosis||exclusion criteria,,,clinically severe,prednisone equivalent)|no prior,between 30 kg/m2,more than 3 times per week,,,,,
729,,generalized developmental disorder,prader-willi syndrome,signed the informed consent,straumann® dental implant system,melanoma beyond surgical resection|has,head;|cranial bone flap,,,psychiatric,within 28 days prior to the first dose of the imp,<90 mmhg|normal,more than 60 min/month,,,,,
730,,wm|measurable disease,psychedelics,risk of volume overload,serum glutamate phenylacetate transaminase,tmj trauma,trimethoprim,,,injection site.|chronic opioids dependence,for three months or more,scores,general,,,,,
731,,moyamoya disease,inclusive)；|patients,scnsl.|patients,extend|maximal interval period,periodontal support,left ventricular thrombus.|previous aortic valve replacement,,,minimally invasive,within 14 days before administration of the study drug;|fever,> 18 years|radiological findings,diabetes;|pregnant,,,,,
732,,cod,antidepressants into the study provided that their medication,life threatening condition,partial prothrombin (aptt),imaging studies|prostate,peripherally inserted central catheter,,,non-objection to participation,within 6 months after the end of study,≤ 480 ms,more than 48 hours,,,,,
733,,health insurance.||cisgender,loop,managed in the,ps,crf.||palliative radiotherapy,intrauterine device)|self,,,thrombotic,within 2 months before enrollment,≤ 300 mm hg,completed 2 weeks prior to study drug administration,,,,,
734,,deep dentinal lesions,porcine-derived,sleep disturbances,meeting,draw|participant donated blood,m3814,,,eczematous,within 30 days|females of,≥ 0.5 g/dl,at least 4-fold increase,,,,,
735,,gastrointestinal upset,pharmacologic anxiolytics,genetic variant,ohio identification method|tbi severity,implant dbs system,degenerative muscular,,,full-dose oral anti-coagulation,within 12 months before enrollment,shorter than 12 months,≤ 12 weeks prior to study,,,,,
736,,malignant brain tumor,components of the study drug capsules,expected to cause death,recist v1.1)|participants for,first remission onward,cerebral vasculitis|cta,,,investigator;|viral hepatitis,within 14days before initiating study,below 100 mmhg systolic,more than 12 months,,,,,
737,,endured other diseases,qrs,partners of,midline shift,paraesophageal hernia noted,hot yoga,,,implant-supported restoration,at least 6 months duration urinary incontinence,>= 84 days after infusion|donor leukocyte infusion,greater than 19.9 seconds,,,,,
738,,genetic syndrome,inhaled corticosteroid hormones,contaminated wounds|diseases,prostate cancer.|pre-registration,periocular surgery,implanted delivery pumps,,,deppeler sa,within 4 months prior to day 1.|subjects,near misses',greater than 4 months,,,,,
739,,moderate exacerbations,vaccine administration.|5,signed informed consent;|≥18 years,platelet count (,pain,intrauterine hormone contraceptive devices,,,igg4-related,within 30 days prior to screening prior enrollment in this study,"> 100,000 platelets",for at least three (3) minutes.|weigh,,,,,
740,,unable to tolerate,geriatric medicine,difficulty in rolling the tongue,natural history,cosmetic therapy,breast implants,,,mri|localized,at the time of the study|aged 18-30|gad7 score of 10,"> 100,000/µl",≥ 2+proteinuria on,,,,,
741,,structural heart,myleran®,unable to engage in the informed consent process,calculated by cockcroft-gault formula);|liver function:|total bilirubin,pathologic staged,investigator|systemic immunosuppressive therapy,,,vzv,at least 4 weeks prior to start of study drug,"greater than 2000 g,|need",2-2.5.||,,,,,
742,,listeriosis,tetracosactide,unclear,various reasons,equivalent|major surgery,implantable],,,preferable systemic therapy,more than 14 standard drinks per week,≤ 1.5×uln.|renal function,2 mo before the study till,,,,,
743,,cardio-cerebrovascular diseases||note,class ia antiarrhythmic medications,biochemical recurrence,treatment arm appendix to which they are enrolled.||core inclusion,renal biopsy,avec statut,,,injection safety,within 24 hours prior to each,≥ 65 mmhg,≥95 g/m2,,,,,
744,,traumatic aortic injury;|patient,including||immunosuppression,lvotg>30 mmhg,gilbert's syndrome).|egfr,ivf,implantable metal devices,,,tao optic neuropathy,within 28 days prior to the first dose of ip.|is currently participating,less than 20 years,less than 14 days,,,,,
745,,acute pain|contraindications,white,asd.|willingness to participate,corrected calcium,fine toothed lice detection comb,coronary artery,,,heel,in at least one interrupted day of desired physical activity.||3-any,< 95 g/l,>12 months prior to enrollment,,,,,
746,,debilitating lung disease,acetylsalicylic acid + clopidogrel,neurological disease|active cancer|life expectancy,recist criteria following the most recent line,steroids|radioiodine therapy,interbody bone graft,,,index level shows stenosis,within 14 days of registration)|aspartate aminotransferase,40-69,≥8,,,,,
747,,malaria.||exclusion criteria||circulatory failure,anti-convulsives,risk of pulmonary aspiration:||gerd|pregnancy||anticipated airway difficulties:||mallampati,international normalized ratio(inr)<1.5 times uln,toothbrush.||medication exclusions,premature ventricular beats,,,non-physiological reasons,within the last 3 months.|history of aortic dissection/dissection,less than 10% of body surface area (,same topical dose/frequency,,,,,
748,,neurological diseases|presence of,local anesthetic drugs,in smoking pattern,short bowel syndrome).|patients,knee arthroscopy,prosthetic material,,,third dose of,during intervention.||,8-12 years,bones,,,,,
749,,cancer treatment.||major surgical procedure,thalamus,refuse to draw blood,canadian cardiovascular society angina class,ligament suspension procedure,intracranial metallic,,,heme-positive,within 3 months before receiving the experimental drug treatment,13-18 years,approved dose,,,,,
750,,rubeosis,factor viii inhibitor bypass activity (feiba),unable to understand the nature,nyha classification,light therapy,adhesions|significant,,,non-melanomatous carcinoma of the skin,within 72 hours.|no previous,"≥ 50 years,|psa",greater than recommended alcohol intake,,,,,
751,,antitumor therapy.|allergy,lopinavir/ritonavir combination,speak or read,serum follicle stimulating hormone (fsh) level,endoscopic biopsy|cystic fibrosis|hypothyroidism,caries in any primary tooth(cases).|medically free,,,insulin reactions,at the time of signing the informed consent|cisgender,long-term benefits to the participants,permitted.|1 cycle,,,,,
752,,impaired hepatic function,strong cyp3a4 inducers,breast feeding.|patient,who lymphoma classification,clinical procedure,aneurysm clips,,,influence flow,within a period of 6 months prior to injection of [68ga]ga-dpi-4452.|any,0-2;|the,> 14 for men,,,,,
753,,breast-feeding mothers,growth factor therapy,insufficient viable retinal photoreceptor cells,formoterol fumarate studies,cerebellar hemispheres,myorg,,,low literacy levels,within the previous month|have,18-85,long-term restricted,,,,,
754,,sle cerebrovascular disease,immune-related diseases,expected future,quantitative phase exclusion,joint arthroplasty procedure,pacemaker should,,,rome iv criteria for child/adolescent,for the past 4 weeks,< 59 ml/min/1.73 m2.|alanine aminotransferase (alt),>1.5 mg%)|grade,,,,,
755,,charcot's disease,infective endocarditis|the estimated life expectancy,progression on scans,allograft nephropathy,unchanged antihypertensive drugs,bi-tubal ligations,,,minimally symptomatic,at the beginning of the study|attends the preschool 2 days or 3 days a week,> 2)|symptomatic peripheral vascular disease,two separate procedures,,,,,
756,,qt prolongation syndrome,guidelines,close physical contact.|athletes.|subjects with,months|hba1c levels,complete remission.||biochemical remission,indwelling foley catheter,,,hypocaloric diet,within 2 weeks prior to imp treatment,stage a-c,>20 mg/day,,,,,
757,,pulmonary abnormalities,intraocular surgery.|primary,risk of death,physical activity levels,serological test,web,,,lateral,within 3 months before enrollment;|he had received,noninvasive,greater than 6 months prior,,,,,
758,,debilitating arthritis,hybrid closed-loop insulin delivery system,limited|estimated survival time≥,fev1/forced,applied,central venous catheter,,,unknown primary,within the next 3 months|contraindication,<1.0,<1 month prior to day 01 of the,,,,,
759,,diabetes|cardiovascular disease|cancer|dyslipidemia|anemia,digitoxin,dental students,vital sign|females,poor impulse control,neurostimulators,,,suitable for entry into the study in the opinion of the investigator,prior to the first dose;|female,between the two,≥40,,,,,
760,,behçet's disease,catheter,close to the posterior superior iliac spine,boston scientific emblem,bile duct disease,intracranial metal implantation|systemic rheumatic disorders,,,second-generation androgen receptor pathway targeted agents,within 28 days of cycle 1 day 1)|aspartate aminotransferase,60 mm hg and <90 mm hg,>1 mg/kg,,,,,
761,,decreased tolerance,low molecular-weight,family medicine||children's medical records,calculated creatine clearance vulue<30ml/min|patients,local anaesthetics of amide type,permanent implants already,,,lm-pci|three-vessel,during the last 2 years,>25 kg/m2,≥2 mg/kg/day intravenously,,,,,
762,,restrictive lung disease|exercise,pemigatinib,patient refusal;||known,breath alcohol test,disease ct scanning of the longest axis of the focus,left ventricular outflow tract obstruction,,,mcdi-wg|use,less than 3 full days per week|administrative assistant,greater than 10 mm,8 f sheath,,,,,
763,,muscle of the lower extremity,cholinesterase inhibitor,expected to die within 24h before enrollment;|patients who died,ultrasensitive tsh,repair|clinical signs,ad,,,first-born child,within 4 weeks of study,<100 iu/ml,medically,,,,,
764,,carcinoid tumor,antibody-class drug,method of,inflasep,gastric emptying breath test [gebt],implantable neuro-stimulator,,,medically significant condition,prior to discontinuation,≥20% at inclusion,2-4 weeks,,,,,
765,,skin tone,active substance,cholecystectomy).||previous administration,definition: standard immunohistochemistry,optimal medical treatment);|urine routine,condom from the first study drug,,,amenable for further curative treatment|metastatic disease|other co-morbidities,during active study phase.|abnormal bowel patterns,<2.0 milligram per deciliter,10mg or,,,,,
766,,digoxin toxicity|undergoing surgery,zoledronic acid,female-,grade atrioventricular block,pelvic surgery;|infection,bruxing devices,,,spirometry|no,at least 1 unprotected,20 mg/l,>6 events,,,,,
767,,chest wall injury,oral glucose-lowering,life expectancies,urine protein volume ≥1.0 g,blastocyst biopsy for,cerebellar signs,,,3 on unilever visual scale of 0~9;|tolerate to well-known,at the time of signature of the icf|female,<100x109/l|hemoglobin <8g/dl|patient,10mg daily of,,,,,
768,,retinal nerve fiber layer (rnfl),xevinapant,unable to cooperate to answer the questionnaires|unable to view the videos,montreal cognitive assessment scale,femoral veins bilaterally,left ventricular,,,8th edition|measurable,one or more of the following 4 items: i,greater than equal to 10.|e',before treatment indicated,,,,,
769,,associated with,mosunetuzumab,enrolled in treatment programs|hemoglobin,responded,multiparametric mri of the prostate,implanted intraocular lens,,,lactated,within 2 weeks prior to the,<50 beats per,more than 2 years,,,,,
770,,respiratory pathology,meningococcal vaccine,change the medical regimen,left ventricular diastolic dysfunction,bilateral tubal ligation.|acceptable methods of birth control,complex vascular anatomy,,,online,prior to initial administration.|xzb-0004,≤ 13 weeks,at least 18.||,,,,,
771,,diathesis,parenteral inotropic,speaking,phagocyte deficiency.||human immunodeficiency virus,pft,intrauterine growth retardation,,,primary weight loss outcome,at the time of consent|confirmation,>2.0|active phlebitis,one of the following conditions,,,,,
772,,stricture,lt4,cockcroft-gault formula,nci ctcae v.5.0,glucose-lowering agents,prosthetic devices,,,o2 sat <90%)|statin intolerance|high-sensitivity troponin i,within 14 days prior to the laboratory examination,≥ 100×10^9/l,rear,,,,,
773,,b virus,ott,willingness to comply with all study procedures,loading of lipid particles,serial x-ray,wbc>11.5,,,are unknown. for this reason,within 1 week before laboratory examination of,≤ 20 points|general condition,at least two,,,,,
774,,ingredient of opa-15406 ointment,components of metabolic syndrome,close affiliation,indoors,montreal cognitive assessment (moca ),intracerebral vascular abnormalities.|other medical,,,haemodynamic,at least 7 days prior to screening,greater than 500 ms,≥16.0 kg/m2,,,,,
775,,resulting obstruction,topical keratolytics,partners of child-bearing potential,newborn,receive radiotherapy,share molecular composition,,,implantation of a device into the brain,within the 6 months prior to screening.|concomitant mental illness and poor condition control,between q and t waves,at least 1 cm outside,,,,,
776,,gastrointestinal ulcers,atilizumab,cohort e,modified thrombolysis,endoscopies,tavi,,,suitable for radical treatment,within 14 days prior to the first use of the study,">1,5unl",two separate,,,,,
777,,antisyntheatse syndrome,n=50)||,participated in a knee oa exercise program,asa type i,small patent ductus arteriosus)|self-report,italian,,,suitable for reconstruction with rectus abdominis,existing,r65.20 or r65.21,2 mg/kg/day to,,,,,
778,,seborrheic dermatitis,baseline;|qualitative amyloid pet scan results,person under observation for covid-19,dyspnea severity item,antidepressant therapy,caries in any primary tooth(controls).||,,,requiring replacement therapy.|combined,at or after the diagnosis,2 m2);||,≥ 4 weeks prior to study,,,,,
779,,aimovig,dfci for necessary data collection.|ability to understand,expected to respond to treatment,international statistical classification of diseases,standard monofocal icb00 iol in the other eye,cardio vascular diseases.||participants,,,endanger the safety of patients,between 4 and 24 months prior to the start of the study||health care,0 or 1.|at least one,middle,,,,,
780,,urine glucose|naturally postmenopausal,anti-pd(l)1 ici,unconsciousness,hcv viral load||,gap,bcaas,,,interfere with cooperation with the requirements of the trial|is,within 2 years before the first administration,18 to 35 kg/m^2,greater than or equal to 2 months prior to baseline,,,,,
781,,sdh,tics,abstinence,pseudoexfoliation,biliary stenting,implanted ventricular assist,,,student,within 5 years before enrollment,four or more,scores at least 1.5 standard deviations below healthy,,,,,
782,,pituitary disorders,medications prescribed by the investigator on a,incarcerated,"frankle behavior rating scale,|3",mini international neuropsychiatric interview (mini))|presence of,cytological confirmation,,,recent,throughout the study treatment,less than 4 weeks before vaccination,≥ 27|fluent in,,,,,
783,,multisystem disease,anti-tb prophylaxis,unable to take effective contraceptive measures;|11,uk brain bank',adenocarcinoma||colloid adenocarcinoma|enteric adenocarcinoma|minimally,psychiatric inpatient,,,zeiss,for at least 4 weeks before starting the trial.|subjects,160-179 mmhg,>72 hours,,,,,
784,,ntrk,antiepileptic drugs).||psychiatric,pregnancy|pulmonary embolus|heart failure,bclc c,diagnose und therapie,umbilical catheter,,,early gastric cancer,within 4 weeks before the use of the study drug,<1.3 mmol/l,>12 continuous months of,,,,,
785,,juvenile idiopathic scoliosis,amide-type anesthetics,unable to maintain standing posture,cardiac valve surgery|indication,hematopoietic stimulator drugs,implantable,,,injection phase.||inclusion criteria,prior to the study start||,ii to iv,1) multiple lung lesions,,,,,
786,,uterine anomaly,growth hormone,speak danish,level of oral,assessment tests||exclusion:||not speaking,central venous access device,,,diagnostic and statistical manual of mental disorders (dsm-5) criteria,during the 14 days prior to vaccination,< 28 weeks,acalabrutinib therapy,,,,,
787,,osseous pathologies,out)|intrauterine fibroids,physiologically capable of becoming pregnant,national institute for health,reconstructive surgery,potentially immunocompromised condition,,,american college of cardiology,at the participating institution,grade dysplasia|currently,once at the,,,,,
788,,surgically,fish oils,tablets;|life expectancy,rapid test);|body temperature,medication capable,artificial metal heart valves,,,compensation|severe,for the past 6 months|weight,less than 30 cm,45 kg,,,,,
789,,resolved,tingling,unable to follow protocol requirements|patients,mers,study|contraindication to spiroergometry,inferior vena cava involvement,,,prader-willi syndrome,at the index site before fracture fixation|patients,score ≤7,more than 1,,,,,
790,,thromboembolic events|cardiovascular diseases,systemic anti-vegf,render the participant unfit to conduct the trial,class)|systolic blood pressure,nasopharyngeal swabs more difficult to perform,dental implants,,,non-traumatic facial edema,within 6 months of the anticipated,≥5mm,">40 grams/day),|subject/patient",,,,,
791,,nasal bleeding,tnf-alpha antagonists,difficulty in understanding the portuguese language to answer the questionnaires;|self-report,qrs values should,o.a,e,,,muscular weakness|primary mtdna mutation,within 3 months before the study;|those who regularly drink alcohol,≥350 lbs [160 kg,>500 ml,,,,,
792,,teeth from,thyroid medication,"unable to make consent,|unable to communicate",sars-cov-2 virus,amblyopia);|patients,gliadel wafer)|no immunosuppressive,,,full-length leg image,during the investigational procedure.|patients should,< 0.6,>2 inches,,,,,
793,,xrt,medication dosing,willing to sign a release of medical records to the research team|male,nci ctc v3.0,standard regimens,implantable contraceptive,,,insulin iv,during the 4 weeks prior to inclusion into the study)|any prior,>38.5 degrees,greater than 35w6d|body mass index (bmi),,,,,
794,,brain mri.|patients,regional anesthesia|patients,body cavity effusion,ctcae,quality checks,cardiac resynchronization therapy device,,,interfere with cooperation with the requirements of the trial.||19,during the study duration||,≥ 18|female||inclusion,twice or more times a week for more than six months||,,,,,
795,,solid tumor cancer,mycophenolic acid,nasopharyngeal swabs,t2 3d hr sequence|-,lower extremities|having,vf,,,non-lesional,within the last 6 months prior to study,>/= 6.5 and <10.0|treated,≥ 1 first-degree,,,,,
796,,undetermined etiology,targeting,unable to consent|english,fasting plasma triglycerides,overlap syndromes,vascular endothelial growth factor,,,flexibility,within 30 days before the first dose of study intervention,45 - 75 years|scheduled,more than one donor,,,,,
797,,more)|arrhythmia,physiological corticosteroids,entry into this study.|urinary protein,resident of canada,networks,left ventricular assist device|sinus node dysfunction,,,leukocytes,within the last three months|participants,≥3 days;||,1 year after enrollment.|dementia,,,,,
798,,years|chronically ill heamodialysis,periocular steroids,cockcroft-gault equation|alanine aminotransferase (alt),urine red blood cell counts≥,antimicrobial therapy,fqhc,,,intensify,within the month before screening,40 to 68,greater than 50%||,,,,,
799,,secondary kidney diseases,seminomatous,possible myocarditis/pericarditis,bone marrow biopsy,laryngeal mask anesthesia|american society of anesthesiologists,medtronic cardiac monitor,,,suitable for treatment,within 14 days before treatment);absolute count,*65 years,≥1 year.|women of,,,,,
800,,neurological disorders|implanted,components of frozen preservation of,needle entry sites,child reintegration centre),periocular treatment,inferior vena cava filter,,,transfers,within 14 days prior to registration)|hemoglobin,"> 7 days,|neonate",more than 10 msv,,,,,
801,,neonatality,topical anti-cellulite treatments|pregnant,sexual maturity,b7|life expectancy,kidney dialysis,mechanical devices,,,non-inclusion criteria,within a minimum of their 5 plasma half-lives,≥ 200 mmhg,≥80mg lasix,,,,,
802,,poor diagnostic quality|root canal treatment,domvanalimab,close attention,thyroid stimulating hormone (tsh)],rhizotomy procedure canceled|for healthy control,hormone receptor positive breast cancer,,,closed,within the next 12 months|hemodynamic instability|refractory,≤ 1.5 x institutional upper limit of normal,half-lives,,,,,
803,,small bowel resection,hormonal method,"sleep disorder,|had the general condition disorder developed",hemoglobin a1c ≥7.0),regular dutch,immunotherapy - 2 week,,,catheter,within 4 weeks prior to entering the study,grade ≥ii,<12 months ago,,,,,
804,,potential effects on immune function,strong cyp2c8 inhibitor,predicted survival,months;|the physical condition score,spect imaging observed,prosthetic limbs|deafness|blindness|moderate,,,icf).|clinical diagnosis,for 7 months after study treatment discontinuation,1-3|scheduled,more than 1 year of follow,,,,,
805,,signs of pulpal infection|no signs of pulpitis,mr|mri unsafe implants,icu admitted,bariatric surgery|patients,hemostasis,implanted drug infusion device,,,hydrochloric acid).|any prior,at least 3 months ago|acute diarrhea,≥ 1.5 × 10^9 / l,1 year.|history of,,,,,
806,,effects|lack of stable residence,pyrimethamine,breast have,recist v1.1 criteria assessed within,chemistry,iliac vessels,,,pure-tone thresholds,within 2 weeks before enrollment;|active bacterial,score of at least 8 out,more than 5 years,,,,,
807,,chronic hepatitis b virus (hbv) infection,cholesterol sulfate complex,recently initiated),hepatitis c virus (hcv)||exclusion criteria: all participants||any physical,mri scan|patients,implanted stimulator devices,,,event|serious,during the 24- or 32-week study period,1-2.|approve the informed consent.|available,one year,,,,,
808,,clinical indication for investigation of functional capacity through,combination,irinotecan can cause,visual analog scale|live in eastern cape,antiviral,interventional antenatal clinics,,,hard drinking|smoking|class,in the department of,"≥ 18 years,|first",outside of trinav device,,,,,
809,,abrasion|pregnancy,covid-19 vaccine series,psychiatric hospitalization,schiff sensitivity score criteria,mvs)|conventional cardiac surgery,central venous access catheters,,,in proximal,within 72 hours before dosing|intake,below 18 years old,> 2 years,,,,,
810,,turcot's,vitamin k antagonists,chocolate,age;|body mass index (bmi),treatment|therapeutic antibiotic use,anabolic substances,,,unknown,after the last dose of study intervention,=< the iuln,higher than 6.|a,,,,,
811,,gi bleeding,traditional chinese medicines,"able to communicate,|who agrees to participate",anti-hiv antibody,hpv vaccination,device impacting,,,ankle level||,in the last 1 year|severe visual,within 18.0 kg/m2,≥ 9g/dl|creatinine clearance,,,,,
812,,hba1c>7.5|neuromuscular pathology,anti-retroviral therapy,participated in another clinical trial protocol,cardiac function,re-start prep|hiv uninfected|speaks english,interviews,,,expectant,at least 1 extracranial,>40°c,newly diagnosed,,,,,
813,,unstable illness,electrodesiccation,excess blasts-2 (,absolute neutrophil count (anc),medical assessment,subcutaneous implants,,,afa)|advanced,during the study period.|have,>2.0 mmol per litre.||,≥75 prior exposure days,,,,,
814,,mania|significant suicidal ideation|unstable medical conditions|current severe alcohol,immunosuppressive drugs,risk of coagulation dysfunction,mdi +/-,live virus vaccination,,,,non-squamous nsclc.|have,within 1 month after finishing the,500 ms or higher,> 20 mg/day,,,,,
815,,detectable,conventional analgesia,centile,coagulopathy;|asa physical status classification,chimeric antigen receptor t (car-t,,,,insulin preparations,within 6 months after the final dose of study treatment,=<50 points,over than score 2,,,,,
816,,digestive system,antiplatelet drugs;|participants,situations that would limit compliance with study requirements.||urinary tract infections,mra evidence of,kidney stone|consent signed|effective contraceptive method,,,,adequate understanding,at the trial,between 18 and 25 years,2 weeks|splenectomy,,,,,
817,,pelvic infections,lithium,risk of gastric cancer,aspartate amino transferase (ast),otrs,,,,first-line chemoimmunotherapy;|relapses,over the past 6 months.||covid-19:||subject,16-80 years,higher than that of the liver,,,,,
818,,mental disorder,methylsulfonylmethane (msm),dialysis fistula,cns radiation,world health organisation (who) performance status,,,,type 3,48 hours before administration,less than 298 pounds,> 10mg/ day,,,,,
819,,limb metastases.|participants,laao,close sinus lifting||,involuntary movement scale,bile duct syndrome||alanine aminotransferase (alt),,,,laparoscopic abdominal,within 2 months before the clinical trial;|subjects,"<50,000/µl.|clinical history",> 0.01%)||,,,,,
820,,mtor inhibition.|active hepatitis b,international council for,expected to improve,bi-level,compositional change,,,,bisexual,within 12 weeks before the administration of the first study drug,greater than 18.5 and less than 32 kg/m2,≥2 on,,,,,
821,,prosthetic joint,baseline,ragweed pollen.|participants,recist 1.1.|eligible tumor tissues,color doppler ultrasonography;|uncontrolled,,,,primary cause of pain,within 4 weeks prior to enrollment.|patient,>6 hours,once or twice,,,,,
822,,urothelial cancer,lactaid® dietary supplements,rapport diet,spot urine sample,vnrs,,,,suitable for standard treatment,more than 1 time/week,≤1.5 x institutional upper normal limit,received more than 3,,,,,
823,,steroids;|active malignancy,deep venous stenting.||,refusal expressed,synthetic function,magnetic resonance imaging (mri),,,,salmonella typhi,at least 6 months prior to drug administration,3-6mm,20 x 30 cm,,,,,
824,,uremia;|contraindications,midline shift,breastfeeding;|expected survival,pasi score,sentinel,,,,alk translocation positive,at least 1 recent,>18 years|confirmed diagnosis,neoadjuvant,,,,,
825,,herniated nucleus pulposus,study visit|cardiovascular disease,unable to walk|children,glomerular filtration,e assay for wheat,,,,alk/ros1 fusion,past 12 months;|any,between 18 and 32 kg/m2|medically,20 mg or less per day,,,,,
826,,major depressive illness,components of fexuclue tablet,risk of anaphylaxis,serum glutamic-oxaloacetic transaminase (ast/[sgot],fecal occult blood 2+,,,,study;|previous,within 3 weeks before start of the study|history of,<70%;|hemoglobin abnormality;|hypertension treated with more than 2,≥,,,,,
827,,uncorrectable abnormal coagulation,hydroxytryptamine-3 receptor antagonists,iss:||age:||- male,cardiac mri,cytoreductive therapy,,,,meeting this criterion,at the time of enrollment|a diagnosis,over 4 mm,greater than 96 hours,,,,,
828,,in situ prostate,nafld,identify,athletes|qtc interval,color vision,,,,targeting,within 37 days prior to randomization|end-stage renal,more than 30 kg/m2,200iu/ml,,,,,
829,,tumor lysis syndrome,gadolinated contrast,remain on the birth control until,"likelihood (""at-risk""",additional biopsy attempt,,,,comfort,within 14 days prior to the first dose of study treatment||,< 1 year|uncontrolled hyperthyroidism|hypertrophic,12 months||no prior,,,,,
830,,coronary artery bypass grafting,nucleic acid amplification test,disabilities.|patients can communicate,qtc interval.|prior,graft-versus host disease,,,,under other,before receiving treatment,18-35 years|sufficient,≥80,,,,,
831,,overall findings,topical anti-inflammatory agents,unable to swallow,simple tissue expander replacement,extra leak,,,,cns,within two weeks of entry into study.|contraindications,equal to 1.0 standard deviation below the test score normed for age,2 times per week,,,,,
832,,teeth associated,stressors,immobility,alkaline phosphatase [alp],qualitative identification of barbiturates,,,,drug ingredient,at screening and day 1|women,at least 19 years,12 months|no prior,,,,,
833,,hiv screening,strong inducers of cytochrome p450 (cyp) isoenzymes,radiographic signs,size amenable,bronchoscopy including:||active acute lung infection,,,,successfully restored,within 1 month before screening.|use of,≥ 19 years.|body weight,2 mg per day and they are currently taking their estradiol,,,,,
834,,wheeze,regular antibiotic use,tanning,nih,apnea|current,,,,pathways targeting,in the past one month,no greater than 2 mg per day,2: dose expansion stage- cldn18.2 positive,,,,,
835,,gingival cancer,non-steroidal anti-inflammatory drugs (nsaid),unable to establish,"3months|systemic right ventricle ejection fraction≤40%, assessed on echocardiography||",lung transplantation;|re-transplantation,,,,scheduled,within 4 weeks prior to study|pregnancy,>= 3 months,> 4 weeks,,,,,
836,,hypercholesterolemia,meningococcal vaccination,enrolled into this study,scr,preoperative iron panel test,,,,stage iii tumors,while taking study drugs)|uncontrolled,less than 50 kg or more than 120,at least 1-year,,,,,
837,,schizophrenia|contraindication for vaginal delivery|a,anti-inflammatory medications|pregnancy,signed an informed consent.|agreeing,antibodies to human immunodeficiency virus,cognitive processing therapy,,,,can be accurately and serially measured in,at the time of the procedure;|suspected advanced,18-89 years||narcotic,at least posterior-anterior view,,,,,
838,,difficulty in voiding,azathioprine,bruising,hemoglobin should,partial surgery,,,,other advanced,within 7 days.||,≥ 18 years.||,daily use,,,,,
839,,malignant liver tumors,contraceptive rings,recently admitted to hospital,sua,assessment system,,,,primary cause of participant's,in the past 12 months|inability,18-50 years;|diagnosis,>2,,,,,
840,,medical record review.||healthy,kinidine,remain in the study,il7r/jak/stat pathway activation,head or neck radiation,,,,non-traumatic|available,within 28 days before randomisation 6,>20%.|recurrence,≤7.25|minute ventilation,,,,,
841,,skin cancers,timolol,review.|life expectancy,pulse oximetry data|understands,diagnostic procedures,,,,metatarsal heads,in the last 2,≥70 years|tumor,"for more than 7 days prior|patient, legal representative",,,,,
842,,therapeutic,immune system diseases,motor limitations,international classification of headache disorders (ichd) -3 (,ahod1331 therapy,,,,increase risk,within the 2 months prior to enrollment.|history of,≥ 18.|patient,once the,,,,,
843,,gesture,minimum depth of 2mm|defective previous,meet the inclusion criteria,histopathology;|ecog performance score,contraceptive gels,,,,nearest normal vertebral body,during their screening visit,≤ 2.5 × upper limit of normal value,greater than equivalent of 5 oz of liquor,,,,,
844,,hip fracture.|women,study institution,management,intensive specialist mental health services,bone scan,,,,insulin pump,at least of 100 ml of urine,diagnostic criteria|agreed to be,≥2 kg,,,,,
845,,systemic arthritic condition|any,sex.|positive results,family history.|（18）there,weight loss|slight symptoms,edas surgery,,,,controlled by medications.|qtcf ≥ 470 msec,within 6 months prior to consent|requires chronic,7 or more,greater than 30 mg,,,,,
846,,mde,bioprosthesis;|possible,render them unable to comply with study procedures,stool test,cell infusion.|chemotherapy,,,,peroneal,since last menses,"14-18 years,|good",>12 months;|requirement,,,,,
847,,50 kilogram,heparin||e4,meet the inclusion criteria described,stability score,small administrative unit in ethiopia)|pregnant,,,,"old),|acute",at a collaborating drug treatment,> 8%)|subject,≥ 4 weeks prior to the experimental maintenance treatment,,,,,
848,,percutaneous transluminal coronary intervention,nt2,procedures|patients capable of understanding the investigational nature,performance score (kps),rectal cancer|cross regimen,,,,upper trapezius,within 3 months prior to the study.|those who smoked more than 10,4 or more points from vas|having smart phone,greater than or equal to 3 months duration,,,,,
849,,teeth bonded.|at least 20,androgen receptor,asthma.|past,baseline.|any polypoidal choroidal vasculopathy (,kyphoplasty,,,,infection|pregnancy|heparin-induced,within a few months,4 to 11 years.|primary,≥2 months before day 1|ast,,,,,
850,,predominantly adenocarcinoma,azole antifungal drugs,able to read,fev,rapid algorithm testing and/or laboratory testing,,,,extensive systemic disease,within one week prior to anti-cd19,< 1.5 times the normal high value,maximum of 30%,,,,,
851,,hemorrhagic esophageal varices,intravenous vasodilators,community sites,american college of cardiologists (acc) guidelines,complete trisomy,,,,henoch-schonlein purpura,within 3 months prior to day 1 of protocol therapy|allogeneic stem cell transplant,0 or 1.||subjects,≥ 1 cm,,,,,
852,,refractory solid tumor,regional anesthesia,unable to follow standard hip fracture regime|were breastfeeding|pregnant|terminal disease|in need,off state|disease duration,fdg pet/ct,,,,baseline,within 30 days prior to soberana plus administration,between 20 and 75 years fulfilled the 2002,more than 24 hours,,,,,
853,,hypercoagulable states,passavant,participated in other virtual reality studies regarding,weight reduction program.||,avioral variant,,,,low mood,rather than ec.|specimens with prior,7-9 points)|further inclusion criteria,≥2,,,,,
854,,bone fracture|known bleeding diathesis,pelvic irm,volume of,berlin definition criteria|onset of ards,autologous hsct,,,,infrequently,within 14 days prior to the first dose.|have,>1.5 mg/dl);|coagulation,greater than two,,,,,
855,,acute kidney failure,auxiliary materials.|donate blood,enrolled in another clinical study.|clinically significant,mers-cov,spinous process balloon,,,,fever|prior receipt of any vsv-vectored vaccine|receipt of another ip within 3 months prior to enrollment,in the last year|the presence,>1.5 × institutional,more than 5,,,,,
856,,vertebral joint pathology,lgd,care in icu),t-spot test,lipid screening,,,,high,within a specific time prior to lymphocyte clearance.||small molecule targeted therapy,=< 14 days prior to registration,1.5 mg/dl);|history,,,,,
857,,clinical symptoms after,rifampicin,nets.|radiological evidence,absolute insulin deficiency,c5 polymorphism rendering,,,,survivor,idd|between 6 and 17 years,> 75x10ˆ9 /l,daily basis,,,,,
858,,esophageal resection,midline,unable to undergo surgery,filtration rate,program requirements||,,,,life-threatening pathology,prior to randomization).|age,18-28 years.|palatal,|a history,,,,,
859,,respiratory failure.|chronic obstructive pulmonary disease,balaguer,admitted in the included unit,hepatitis c virus（hcv）,local irradiation,,,,meeting,at the time of the diagnosis of smn,≥ 100.4˙f|unstable health conditions,more than two liter-per-minute,,,,,
860,,co-incident spinal tumor,tagraxofusp-erzs.||primary,expected receipt of imp,amsler-krumeich classification|non-contact lens,modification of diet in renal disease (mdrd),,,,mustard greens,in the study eye.|post-traumatic cataract,2.5 times higher than the upper limit of normal,maximum oxygen consumption,,,,,
861,,site;|psychoaffective disorder,met amplification,situations that would limit compliance with study requirements||any organ transplant,hcv gt,laboratory data:|total serum bilirubin ≤1.5x upper limit of normal (uln),,,,infrared exposure|inability to fit into the sauna device|breast implants|pregnancy,within the previous month|functionally impairing radicular,< 150 min,more than three months,,,,,
862,,kidney injury dialysis procedures,strong cyp3a4 inducer,commit to continue,traditional chinese medicine decoction,ovarian torsion||,,,,discrete,in the 6 months prior to baseline visit,>= 2.5 × 109/l,at least 5,,,,,
863,,unresolved respiratory tract infection,anti cd19|pet-ct pre-injection of car-t,insufficient understanding of the study,spap,topical anesthesia,,,,not recommended.||,within 4 weeks before the first dose of investigational drug,between 15 to 29(include,higher than 100/min.|any,,,,,
864,,chronic illness that limits their participation in physical activities|participants,hdac inhibitor-like activity,difficulty with sub-cutaneous injection(ex,tili score,postoperative endocrine therapy,,,,psychiatric disorder(s),within 3 months|have participated in any trial,retrospectively enrolled)|exposure,one or both legs)|dependent,,,,,
865,,pituitary inflammation,active medications,risk of epileptic seizure,medication inducing considerable surgical risk,surgery||,,,,stenotic degree,within 1 month before the first dosing date,≥25|report daily,≥20 mg/day,,,,,
866,,persistent vessel,intravaginal devices,nursing,receptors.|body mass index,montreal cognitive assessment (moca) test,,,,gastrointestinal tract|no sign of cancer,in the past 3 months before recruitment|patients,less than or equal to 3x uln,100 mg/l,,,,,
867,,vagus nerve stimulators,baseline|immunosuppressive drugs,entry into the study.|patient,t-all/ll,tympanometry,,,,mushrooms,at least 1 tace treatment；||,<1 year|contraindications,<3 months,,,,,
868,,impaired state,leucovorin,pathologic,alopecia)|ecog,radiculopathy|vascular claudication|anterior knee pain,,,,aberrant,at the time of informed consent,above 2 times the normal upper limit,72 x scr[ml/min,,,,,
869,,venous thromboembolic events,synthetic material,entry into study.|abnormality,human immunodeficiency virus (,cranberries,,,,metropolitan area,exceeding 2 weeks,"20-50,000/mm3||",less than six months,,,,,
870,,ulcers,anticoagulants|alt,remain overall healthy,fish+.|left ventricular ejection fraction,ngs analysis,,,,that affects fundus examination,at inclusion according to the criteria,>100 bpm,upper primary first or second molars bilaterally.||,,,,,
871,,escc,age.|participant,unable to give,clonal cytogenetic abnormalities consistent,hospitalists,,,,distal lesion,within 6 months after the end of the study treatment period,> 10mmol/l,greater than 1-year,,,,,
872,,teeth that would,levetiracetam,sufficient dutch,total score 10+|psychotic spectrum,aortic aneurysm|cognitive deficits unable to comply with study procedures,,,,non-medicinal ingredient,within one year prior to enrollment;|the presence,between 18-100 years,> 5 minutes,,,,,
873,,ambulatory,systemic supraphysiologic glucocorticoids,changes in hf therapy dosage,emphysema*|numeric rating scale,oral nucleoside (acid,,,,munich,more than 6 weeks|subretinal,< 90 mmhg)|patients,≥ 150 mg/dl|ldl,,,,,
874,,housing instability,nonsteroidal anti-inflammatory medication|inability,wearable devices,outpatient)|mini-mental state examination (mmse),toric intraocular lens,,,,immunosup-pressive therapy,within 14 days): - neutrophils,< 1.5 cm midline shift,≥ 50%;|myocardial enzyme profile,,,,,
875,,ophthalmic trauma,drugs similar in chemical structure,close contacts for,uln);|total bilirubin level,blood chemistry results indicating organ damage,,,,non-steroidal anti-inflammatory drugs (nsaid),between 12 months to 6 years before,50 or above,for 24 hours before all visits.|individuals,,,,,
876,,persistent headache,antiplatelet drug,life-time,tongue pulse occur,cigarillos,,,,suitable for participating in the clinical trial,during or within 3 months after administration of the study drug;|drug abusers,above 18,> 80 g/d|bmi,,,,,
877,,respiratory issues,anti-pd-(l)1 monoclonal ab,affiliation coverage,muscle,transfemoral unilateral amputation,,,,contraceptive rings,within 1 months prior to joining the study.|subjects,> 0%,initial dose,,,,,
878,,anterior chest wall surgery,systemic immunosuppressant medication,women;|expected survival time,teeth #,total thyroidectomy,,,,weeks.|elective,during the entire study,greater than or equal to 25 mmhg)|exercise,therapeutic,,,,,
879,,crohn disease|portal hypertension|severe hepatic,orthodontic appliance,family member,specifically alanine aminotransferase (alt),gestational age)|multiple,,,,mild-to-moderate uc,during heterosexual,0-2.|no,old|one,,,,,
880,,rapid eye movement,acenocoumarol,eating,required|eastern cooperative oncology group (ecog) performance status,temozolomide treatment interruption,,,,ophthalmic,within four weeks from the time of establishing,≥1500/mm3,≥ 7gy x,,,,,
881,,reflux disease,pseudoexfoliation,haukeland university hospital,estimated glomerular filtration rate (gfr),antibiotic therapy.|participant,,,,nicotine spray,up to 3 months after vaccination.||highly effective methods,≥18.0 kg/m^2,meniscus repair|history,,,,,
882,,13c urea breath test,anti-depressant treatment,"saliva samples,|unable to chew paraffin",peripheral blood tumor,pathology,,,,trochanteric unstable,< 6 months after delivery,> 90 g/l,changed their medication for,,,,,
883,,bone marrow invasion,balance problems|chronic ankle injuries||,score for cornea,total svd score,local treatments,,,,sperm,within 4 weeks prior to the first use of the study drug,<35 nmol/l. after,more than 14 alcohol units per week,,,,,
884,,mtrps,pod,progressed on treatment,fib4 score,navigation bronchoscopy,,,,acute use,before baseline,above 40 years.|patients,complete encasement,,,,,
885,,intramuscular injection.|presence,alcoholics,etc.);|target artery's supplying artery stenosis,female|post-covid-19 fatigue||,diversion surgery,,,,non-revascularized,in the past 5 years.|bilateral,19 to 28 kg/m^2,more than one internal orifice.|patient,,,,,
886,,hormonal condition,topical anesthetics,"difficulty in walking""",nasal abnormality history,natural teeth.|patient,,,,high risk of,during the previous 3 months,0-2|life expectancy,≥20 grams/ day,,,,,
887,,early-stage mycosis fungoides,local-regional therapies,limit compliance,plating,evaluable target lesion,,,,accart-ville,ended > 6 months before consenting for this study,>3 months)|5.vas,greater than 60 milligrams,,,,,
888,,malaria|pregnancy,oxervate,genetic evidence,af burden,m2).|creatinine clearance rate (crcl):,,,,mild to moderate pd,within 28 days prior to the first dose of the study drug.|known,i-ii|18-65 age group|operated,increased dose of ics,,,,,
889,,stable lesions,live virus,lifespan,serum sodium,mmr-varicella,,,,its outline.||7,within 1 month before screening;|active cancer,< 100*10^9/l.|hemoglobin < 90g/l.|serum creatinine,greater than six months)|ability,,,,,
890,,anticoagulation drugs.|thyroid function,amateur,dialysis dependent,crp level,acellular dermal matrix,,,,systemic therapy.||participants,in diet,"< 1500/mm^3|platelets < 100,000/mm^3|hemoglobin",2-d,,,,,
891,,infection|progressive splenomegaly,vr helmet,possible hypercoagulable state;|pre-stroke,pregnancy test should,orogastric access by gastroscope,,,,circulatory,within 2 weeks of the start of study treatment,36.4 °c and above,> 1.2|chronic kidney disease (ckd),,,,,
892,,pregnancy|contra indication,ctcae,midwives,american society of anaesthesiologists (asa) status,potentially curative therapy,,,,medical marijuana,within 12 months prior to study,greater than 200 mmhg,outside ontario,,,,,
893,,low back pain,breastfeeding;|chronic,managed for cld/cirrhosis,pr ihc showed,tobacco use|habitual excessive alcohol use|weight change,,,,cruciate ligament repair surgery,at the time of the consent date.|patients,>35 mmol/l,12 or more,,,,,
894,,human immunodeficiency virus (hiv) antibodies,garmin,prevention of,iga score,standard systemic chemotherapy,,,,n-terminal pro-bnp,within 24 hours prior to initiating lutetium lu 177 dotatate,3-17 year,>14 units,,,,,
895,,sequela,cortisol-containing medication,exposure)|pregnant,urine β-hcg test,elementary school,,,,after covid-19 nucleic acid detection,within four weeks of screening,within therapeutic range of intended use of anticoagulants||criteria,january 2023 to january,,,,,
896,,immune checkpoint inhibitors,pcs,enrolled in the kesimpta cohort or baf312a2403,nyha class,general admission floor,,,,could use it,within the past 2 years.|the patient,50 to 90 mmhg,1 to 2,,,,,
897,,dynamic left ventricular outflow tract obstruction,ocular herpes simplex,method of contraception,estimated glomerular filtration rate [egfr]<45 ml/min,pneumococcal vaccination,,,,regional anesthesia,in the last 6 months|medical revascularization,between 60 and 80 years,minimum 2 weeks prior to the first day of study therapy|exposure to,,,,,
898,,send back,mastic|antibiotics,smoking,mullen scale,unequivocal cardiac sources of embolism,,,,between i-iii.||,at screening < 30 ml/min|pregnancy,1-2|complete,10 mg or equivalent,,,,,
899,,r-huepo,angiotensin converting enzyme (ace) inhibitors,family members fully understand the trial's purpose,maximum hyperopia,prf treatment,,,,inclusive).|self reported sleep problems,rehabilitation department of our university,< 135 kg,≥ 180 days prior to screening,,,,,
900,,height measurements,nlp,silver;|life expectancy,kidney function;|igf levels,instrumental examination,,,,under guardianship,for 7 days prior to the mri scan,at least 5 days old|babies,≥ 6 months prior,,,,,
901,,medication changes,fluvoksamin,enrolled in another drug,folic acid supplementation.|history,t-dm1,,,,papanicolaou,at least 6 months after the last dose of imp,0 to 1|at least one,150 mg of,,,,,
902,,venous invasion,clcr) corrected,signed informed consent;|mfs diagnosis,gm-csf autoantibody test|pap associated,visible|partial retained iud,,,,reened,in the previous 6 months|those,from 6 to 18 years.|the children,more than 2 times,,,,,
903,,chronic focal pain,topical medications/treatments,need a combination,fecal hp antigen test,cd|complete blood count,,,,not-permitted,within six months of enrollment.|limited english proficiency.|history,>50ml/min,one year follow up||,,,,,
904,,polypoidal choroidal vasculopathy,local ethics committee requirements.||,progression of clinical symptoms despite,supplying,supplemental assay,,,,non-ocular,within 12 weeks before screening,≥16 weeks.|presence of measurable,routine use of,,,,,
905,,hepatic injury,geriatrics,nicotine product cessation,beck's depression index (bdi).|participant has,control visits).||non-inclusion criteria:||volunteers,,,,after curative treatment|active tuberculosis|severe infection,within the previous 6 months/,"<100,000/ul|alt",20 iu/ ml,,,,,
906,,infection|women,select hospitals,remain in treatment continuously,likelihood for stable disease,acute therapy,,,,midline,within 72 hours prior to this lab being drawn,or free calcium ≥6.5mg/dl(≥1.6mmol/l,single at screening,,,,,
907,,meibomian gland cyst,disorder;|patients,entry into the trial,diagnosis|surgery,allogeneic tissue/solid organ,,,,self-reported daily habit,within 6 months prior to initial administration;4,>70% stenosis,stable dose 6 weeks before starting treatment|have access to the internet,,,,,
908,,poor differentiation,medications specified,recently recovered,national comprehensive cancer network (nccn) distress thermometer,induction,,,,influenzae b,within 4 weeks before the first study dose,<10iu/l,at least prior,,,,,
909,,tumors|body mass index,cyp)3a inducers,soy,bleeding score,parathyroid intervention,,,,definitively treated)|known leptomeningeal disease,within the 4 months before visit 1 and must,≥ 50kg(man,"one, two or three",,,,,
910,,toxidromic symptoms.|acute intoxication,blood,risk of aspiration,national institute of health stroke score scale (nihss),lactation|surgical procedures,,,,silver,1 month prior to screening,≥ 40 kg/m2,greater than 10 degrees varus/valgus,,,,,
911,,immune deficiency syndrome,herbal medicine,sleep apnea|contraindications,car-t cell,live vaccination)|surgery,,,,american diabetes,within 4 weeks prior to the treatment visit,>10mg/day equivalent dose of,15-centimeter,,,,,
912,,nonalcoholic steatohepatitis||the,aromas,"lactation,|fixed",serum beta hcg pregnancy test,filtering procedure,,,,preclude protocol therapy|subjects deemed unable to comply with study,after first line|pregnant females|ecog performance,< 2.5 meq/l,once every 3 months,,,,,
913,,sleep,de-novo biopsy,processing speed,metastasis exists,allogeneic transplantation,,,,large cell neuroendocrine cancer (lcnec,experiences at least one of the following criteria:||at least one year,≤ 3x the institutional upper limit,2mg or higher,,,,,
914,,peng block,nasotracheal tube,living with hiv|on art|aware of hiv status|has,ai|estimated glomerular filtration rate (egfr),stent planned,,,,≥0.5|spherical refraction,at least 6 months after the last trial drug treatment;|subjects voluntarily participated,18 years or older)|received,for more than 48 hours|informed consent/assent,,,,,
915,,cardiovascular disorders.|diabetic ketoacidosis,imds components,children:||enrolled,hepatitis c infection|current,"vital emergency room,|patient",,,,inadequate,"at the end of the month?""|informed parental consent",20 mg,>14 alcoholic drinks per week,,,,,
916,,idiopathic membranous nephropathy,rennes,breastfeeding.|refusal to sign the informed consent form,creatinine level,percutaneous left ventricular assist devices)|life expectancy,,,,years|pregnant,within the previous 5 years|enrolled in clinical trials in which investigators,stage iv cancer|ctcae neurological function,higher than the daily,,,,,
917,,lower back pain,categorized,noncompliant from the originating gbt021601 clinical study.||current,criteria in scai definition|subject has nstemi,upper abdominal surgery|pregnancy,,,,covid19,within 6 months after the first complete remission,0-1.|symptoms consistent,greater than minimum doses,,,,,
918,,type glioma,anti-inflammatory medication,unable to provide,rods score,luteinizing hormone releasing hormone [lhrh,,,,before cardiac intervention,within 4 weeks prior to the first dose of study drug.|subjects,"≥1,000/mcl|platelets ≥80,000/mcl|total",≤1.5 g/l)|hemophagocytosis,,,,,
919,,evaluable tumor lesion,ipragliflozin,encaleret.|presence,test|best corrected distance visual acuity,e-,,,,meningococcal infection,at least 6 months after the last dose of study intervention,≥50 mg,at least 2 weeks,,,,,
920,,stopped nursing,catecholamine,unable to abstain from consuming alcohol,average,electrical stimulation therapy,,,,clinically significantly abnormal,newly diagnosed participants,> 600 mg,>1 year ago,,,,,
921,,chronic diseases|patients,left ventricular systolic,change in thickness of liquid,institute withdrawal assessment,ulna|surgical procedure done around,,,,"diagnostic and statistical manual of mental disorders, fifth edition - dsm-5",within 6 months of last receipt of platinum)|age,less than 1.1ng/ml,dose greater than 400 micrograms per day,,,,,
922,,colorectal cancer syndrome,fundus veins,chemical peel,inhibitors|hematocrit,platelet inhibition therapy,,,,medium degree,patients|patient,>11 mg/dl)|any,greater than,,,,,
923,,judged unsuitable to participate in the study by the investigator.|patients,antiprotozoals,nodal basin ultrasound surveillance,urine cotinine levels,global initiative for asthma (gina),,,,acute exacerbation phase,within the last 12 months;|be,> 5% cll involvement,toxic adenoma|thyroid,,,,,
924,,served/,full immunisation,range of motion,acting beta2 agonist (saba),perfusion scintigraphy,,,,others:|peripheral arterial,within 7 days prior to stem cell mobilization|donor,> = 1 years,>10 mg,,,,,
925,,gadobutrol.|patients,inhaled steroid therapy,csah,6-minute walking distance,immunomodulatory biologics|those,,,,grade atrioventricular block,at two (2) adjacent,more than 70%|symptomatic stenosis|asymptomatic stenosis|elective surgery patients|signed,2-,,,,,
926,,valvular diseases,medications that reduce gi motility,remain off,abdominal sepsis|acute respiratory failure||,brain imaging after,,,,pan-retinal photocoagulation (,within the last 6 months.|congestive heart failure,>= 2 years and < 18 years,> 20 if,,,,,
927,,cardiorespiratory diseases,compounds of similar chemical or biologic composition to study agent|known bleeding disorders,close to porte de la chapelle,icp,weeks;|surgical procedures,,,,thc-containing products should,at least 7,above 3 mg/l;|former,diagnosed,,,,,
928,,gilbert's syndrome ≤3 x uln,immune globulin product,unable to undergo mri (,arm t)|absolute neutrophil count (anc),hematological organ function laboratory values,,,,sglt2i|pre-existing,dental history ruling out,greater than 420 pounds - scanner,more than 3 days per week)|antibiotic use,,,,,
929,,vital sign measurement,antibody targeting the t-cell co-stimulation,render the patient ineligible,general app study,supracervical hysterectomy,,,,and related,during the next 6 months|have,< 2500 grams,less than 2).|knee,,,,,
930,,vvs,placebo,difficulty understanding,partial thromboplastin time (aptt):,immunocyte therapy,,,,ureteropelvic junction obstruction congenital renal anomalies staghorn stones,at the time of delivery)|active,minimum 2 cm margin,once for confirmation.|subject has,,,,,
931,,hematochezia,systemic drug,physical activity,open fractures|delayed presentation,stable.|adequate organ system functions.|patients should receive,,,,hiv)-positive,for less than 2 years,lower than grade,routinely than the,,,,,
932,,cutaneous adverse reaction,hormonal contraceptives should,perfusion mri.|all exclusion criteria,mmse,lap band,,,,under general anesthesia.|operation time < 3,r,<12 months)|cognitive impairment,more than one standard therapy,,,,,
933,,control bleeding,low oocyte quality.|cases,patent foramen,lipase levels,chest x-ray|abnormal pulmonary function testing,,,,diameter greater than 5cm,at least 2 weeks prior to randomization,>uln;|albumin<lln;|hiv antibody positive,one or multiple,,,,,
934,,bariatric surgery|uncontrolled hypertension,type of endoscopic surgery,changes,residual auto-immune hypothyroidism,consultation dating,,,,non-contrast cardiac ct,usually done 8-12 weeks apart,≥18 years|sle diagnosis,less than one month before the start of the,,,,,
935,,infection of the lower limbs|pregnancy|relative refusal,anti pd-1 monoclonal antibody agent,malignancy;|life expectancy,inclusive.|body mass index,local country,,,,monotherapy|not treated,prior to the index date.|age,less than 7 days between screening,one unidimensional measurable,,,,,
936,,wegner syndrome,c);|previous liver,change in bowel habit,nec,pots,,,,amount,within the last 6 months:||rtx,18-80 years;|the subject or guardian can understand the purpose of the study,daily access to,,,,,
937,,normal,otc medications,cohort expansion):||cohort,google internet speed test,audiology examination,,,,upper extremity|those,within 24 h before the test.|history of,1.5 x upper limit of normal (uln),half or less,,,,,
938,,diabetics,lvsd,hormonally active,bone marrow invasion,adjuvant hormonal therapy,,,,tumour tissue sample (if available),within 4 weeks prior to day 1.||note,under 29,outside of study,,,,,
939,,disease of the thymus,non-small cell lung cancer,unable to receive,adolescents,functional implant,,,,locally recurring cancer,within 10 days of screening,≤ 100 mm;|the,persistent,,,,,
940,,obesity-related comorbidities,antipsychotic agents,pregnant,genitalia,mtap,,,,assiut university heart hospital||,for at least 5 years,pathology.|distant,stages 4 and 5,,,,,
941,,pre-stroke,pdt,us,receptor tyrosine kinase domains|ecog performance status,tobacco use|scchn,,,,m1,in the next 12 months.||those,> 13.|barrett's,≥ 300 mg/j,,,,,
942,,traumatic sci,nih,self-,nt-probnp,laparoscopic surgery,,,,joint|transient relief,within 4 weeks before the first dose;|with serious medical diseases,< 10 cm distance,greater than 12 months duration,,,,,
943,,indicates cerebral hemorrhage,contraceptive methods,postgraduate student,human immunodeficiency virus (hiv) antibodies,tympanometry|familial,,,,large cell,at least 3 months prior to baseline visit,less than 3 × uln.|adequate renal function,outside the range of the available,,,,,
944,,inc,semi-urgent (level 4,situations that would limit compliance with study requirements,braf v600e/v600k,typhoid vaccine,,,,low auditory and/or visual acuity,within 14 days prior to randomization:||hemoglobin,higher than the lower detection limit of the research center,treatments:||more than 2,,,,,
945,,acute pancreatitis,nivolumab,participated in other clinical researches,normal.|left ventricular ejection fraction,minimally invasive,,,,baseline|active,within 1 week before the first dose of the study,severity,≥2 episodes,,,,,
946,,aspergillosis,acromegaly|active drug,alterations in ddr genes,pregnancies|known thyroid disorders,local cns therapy,,,,night-shift,at least two years from their last delivery.||,"<150,000/ul||if the participant answers """,high dose vitamin b3 supplementation,,,,,
947,,undetected|measurable disease,cyp17 enzyme inhibitors,unability,premorbid iq,anticoagulant therapy.|ascites,,,,extraction socket to the crest of the alveolar ridge,within 14 days before first dose;|other conditions,=< 1 week,2-3 blocks,,,,,
948,,inflammation states,local guidance.|any vaccination,refuse to participate in the study,thrombocyte,intervertebral disc already advised by neurosurgeon,,,,paralytic,during the 3 months prior to the screening visit.|part 2 only: subjects who,10-29% marrow blasts,12 months,,,,,
949,,psychiatric impairments,obesogenic medications,participated in studies,serum t-psa>10ng/ml,onset of symptoms;|a history,,,,live virus,at least 3 weeks before the study,≤ 2.0 mg/dl|alt,>=approximately 3 months).||bone,,,,,
950,,hbv dna detectable,fingolimod,entry into this study,paco2,global initiative for asthma 2015)|history,,,,sars-cov-2 virus,within 30 days prior to the baseline visit,> 90 mm hg diastolic,one or more,,,,,
951,,anti-cancer therapy,topotecan,old|existing,catalogue reference,allogeneic hsct|life expectancy,,,,acs)||high fistula,within the preceding eight,18 to 99 years|pre-menopausal,at least once a week with low,,,,,
952,,her2+ breast cancer,gastric acid,maintaining alertness,serologically,adjuvant therapy have recovered.|5),,,,could interfere with capacity to,within 3 months of the baseline,requires iv antibiotics,short,,,,,
953,,rheumatoid pregnant diabetes,iap,close relative.||,packed red blood cell,echocardiography-suggested,,,,mental illness|the presence,throughout step 1 if participating,>40 kg/m2).|psychiatric disorder.|opiod dependence,one cycle,,,,,
954,,vision;|current pathology,biobeat® monitoring device should,unable to take effective contraceptive measures;|patients,antigen rest,dynamic tcpo2 recording||,,,,official,medical history and the presence of the,≥18 and <85 years,> 221,,,,,
955,,sclerosis|between,hormonal oral,risk of pulmonary,smoking history;|mrs≤2,implant-supported restoration,,,,non-fungal organisms,between the completion of cns-directed therapy,= body mass/height square (kg/m2,more than the,,,,,
956,,similar conditions,autoimmune disorder;|bisphosphonate therapy,empathizing,modified ashworth scale|children,rescue pci,,,,may jeopardize participation in this study,at least 2 months prior to study entry||,70g per week,to obtain pre-evd ct scan|evd,,,,,
957,,left bundle-branch block,malignancies;|patients judged by the investigator,risk of hypoglycemia,vital signs:||temperature,biochemical indexs,,,,index pci)|pregnancy|unable to provide consent,for at least 4 weeks before first dose of study treatment,< 1 liter,older.|at least one,,,,,
958,,venous thrombotic,other immune modifying drugs,soy enriched foods,national eye institute (nei) scale,permits assessment of the skin fold condition(s,,,,influence the outcome of the therapy,within 7 days prior to the first dose of study drug.||known,<15% calories,physiologic doses,,,,,
959,,spacer,cyanoacrylate,nursing.|substance abuse.|psychiatric problems,international standardized ratio (nr),practical clinical experience||exclusion criteria,,,,non-cardiac surgery,during the 3 months after dosing,> 3uln.|history,≥2 treatments,,,,,
960,,cerebral 18f-fdopa pet examination,tte,situations that,anti-hbc antibody,scoliosis surgery,,,,diagnostic and treatment standards for,within 1 year after the last vaccination;|receipt of live vaccine,90 minutes per week,≥ 5 μ,,,,,
961,,mixed cell carcinoma,irinotecan,situations that would limit compliance with study requirements.|significant,refractory;||evidence of cell membrane gprc5d expression,songjiang district (suburbs),,,,higher;|indoor,within 30 days prior to study entry.|known,=< 3 x institutional uln|serum creatinine,2 neuropathy.|history,,,,,
962,,pulmonary arterial,component of the ak130 formulation,cohort 2)|participants,sox/folfox/capeox,standardized screening questionnaire,,,,msec|uncontrolled concurrent,at the time of screening||those with,≥ 2000/ml|platelets,≥ 5 drinks/day,,,,,
963,,erythema multiforme,drugs used in the study.|a disease or the use of drugs,odd are appropriate,cd20+ large cell lymphoma.||is,delayed gastric emptying,,,,study|necessary,in the past 48 hours,420915-cs101,at least 2 weeks duration,,,,,
964,,stydy protocol|contraindications,uva1,signed an informed consent form,emvi,lumbar decompression with pedicle screw fixation,,,,clotting,within 6 months prior to enrolment.|symptomatic,50 - 74 years,≥ 24 hours,,,,,
965,,hepatitis c virus infection,neoadjuvant,histological: visible microorganism,psma pet/ct score,gastric restrictions,,,,drug-induced bp,prior to starting therapy.||subjects,between 18 and 80 years old,therapeutic dose,,,,,
966,,acute myocardial infarction||participants,antiandrogens,paraffin,hcab,head ct scan,,,,i-iiia,at least two times.|findings,19~45 years in,more than two lung nodules need,,,,,
967,,luxation of the knee,cohb,render the participant unsuitable for psilocybin,esr,keloid formation,,,,positive for ctdna,within 30 days of vst infusion,>4 seconds more than control,more than 3|largest,,,,,
968,,idiopathic osteoarthrosis,specific drugs,sleep disorders;|pregnant,nih laboratory of pathology,revision orthopedic surgery,,,,plasmodium falciparum,within 30 days before screening or within five times the,=< 2,≥1 documented episode,,,,,
969,,lamina dura,drugs e.g renal,lack of proficiency,begins,acute coronary syndromes:|haemodynamic instability|cardiogenic shock|recurrent/refractory,,,,glp-1r agonist|a,over approximately 6 weeks duration,"19 test,|presence of an obstacle",≥ 50%||history,,,,,
970,,somatic brca mutational status,non-steroidal anti-inflammatory drugs (nsaids once daily or more,expected exposure,mbbs,blood draws,,,,lympho-vascular invasion,within 6 months before screening;|hepatotoxic drugs,> 3).|any medical conditions,≥ 8 mmhg|patients,,,,,
971,,disease.|suspicious microcalcifications,åsberg,unable to take,etc.);||hypertension,patients|total knee arthroplasty||,,,,iodinated,within 28 days after screening to the last study drug,≥ 18 year-old.|diagnosis,high-school,,,,,
972,,atopic condition,proton pump inhibitor - ppis,managed in,glutamic aminotransferase (alt),pole mutation analysis,,,,blood,within 7 days before enrollment;|congenital malformation,<18 yo,5 min time window,,,,,
973,,malignant effusion,oral methotrexate,refusing to follow the study|have,remains eligible.||specific inclusion criteria for colorectal cancer:||10.1,primary knee,,,,under calm breathing||,for at least 3 days in the 6 weeks prior to visit 1,"≤ 180/104 mmhg,|heart rate",2 or more years of experience providing,,,,,
974,,afo,intraocular corticosteroids,poly_traumatized patient .|patient with fracture first,child-pugh grade,cranial magnetic resonance imaging (mri);|hematological parameters,,,,site of the block.|history,within 3 months prior to study enrollment,2- 24 months old,frequency of more than once per week.|current,,,,,
975,,between 31-64,foveal cst,admitted to uns hospital,tki targeted therapy,verbal communication disability (hearing and,,,,under general anesthesia||,prior to the study,between 5.7 and 6.4%,five-year,,,,,
976,,endogenous gastrointestinal diseases,tricyclic antidepressant,affiliation to a social security scheme|patients under guardianship,serology,full thoracoscopy,,,,cranial,within 8 weeks prior to trial start,> 12 mm,>20mg/day,,,,,
977,,those still,acetone,intent,postpartum,nasopharyngeal swab (nps),,,,reduced crown length,within 3 months of study entry/baseline,300 mg,more than 3.0.|known,,,,,
978,,congenital heart defects,proton pump inhibitors(ppis,situations in this study,ft4 levels,treated for malignant tumors,,,,grade 2 or greater,throughout the study period.|the subjects can communicate,> 8 g/dl,maximum of 1 month||inclusion criteria:||healthy singleton,,,,,
979,,vitamin b12 deficiency,tobacco-containing products,unable to lie flat,anc,immunotherapy-induced toxicities,,,,skeletal,within 6 months prior to inclusion|recent food allergy < 3 months prior,< lower limit of normal,more than one month,,,,,
980,,addison's disease,semi-quantitative test,life changes,arterial pressure,donate blood,,,,european allergy,within 6 months of pre-treatment,≤ 1.5 × uln。||,greater than 2,,,,,
981,,mucopolysaccharidosis type,eac,unable to use,or|rv size,regular inhaled,,,,insulin regimen,within 2 weeks prior to the first dose of study drugs.|previous,18 to 30 years||,more than -/+ 6 diopters,,,,,
982,,mr unsafe,kava,entry into study|prisoners,mile square health centers enrolled in the clinical trial||,next chemotherapy cycle,,,,dsm5 criteria,at least 4 weeks prior to check-in,< 14)|able to read 14-point font size|internet,"30 mg, methylprednisolone 6 mg",,,,,
983,,months.|good general health,rivastigmine,commit to complete,nci-ctcae v.5.0,inguinal hernia,,,,foveola;|subretinal haemorrhage involves,within 6 months before study initiation.|participation,greater than 95 mmhg,maximum 14 hours,,,,,
984,,secondary hyperaldosteronism,treatment modality,rpv la|at entry,etc.).|xzb-0004,copper intrauterine,,,,researcher considers unsuitable to participate in this study,during the study period.|willing,less than 1.5 times the upper limit of normal,"20 hours,|history of",,,,,
985,,metabolic dysfunction.|participation,study-related procedures,wellbeing,10m walk test|lower extremity fugl-meyer,monitoring of net,,,,large cell lung,within one month before enrollment;|other circumstances,> uln;|alkaline phosphatase,more than 10 days,,,,,
986,,indigestion/dyspepsia,cyp3a inducer,debulking,short-term,variant,,,,mallet toes,in the last 7 days|not,≤1.5-fold the uln of the study site creatinine,90 mg bid,,,,,
987,,injection,oral hypoglycemic drugs,participated in an investigational drug study,95%;|serum crp,understanding.|life-expectancy,,,,non-stemi,before study entry|no evidence of,between 8 and 17 years,≥1.05 g/l)|reduced,,,,,
988,,chronic conditions,allogeneic transplant|cml blast crisis|active,prevention scheme,comorbidity index (hct-ci,vocal cord adhesion,,,,rome iv criteria|mild,within the range of clinical acceptability in medical history,< 65,more than 30 days prior to screening.|presence of known,,,,,
989,,involvement in health-related litigation,drug allergy|patients,progression associated,new york heart association (nyha) grade≥2,allogeneic hematopoietic stem cell transplantation,,,,non-surgical therapeutic procedure|incomplete,within 3 weeks prior to the first dose of study interventions,≥ 190 mg/dl||xii,600 mg twice daily,,,,,
990,,developmental delay,agents used in study|patients,risk of recurrence,aggression/agitation/impulsivity,diagnostic of dyt-sgce|no change,,,,freshly,for at least 3 months after the last dose of study-drug.|for,50% or greater,at least 20 teeth(exclude,,,,,
991,,coccygeal pain,noacs,sexual intercourse;||• female,hcru,surgical limb amputation,,,,lower abdominal pain,within 30 days prior to first dose.|participant,20 to 60's year old,major,,,,,
992,,secondary itp,injectable progesterone,short life expectancy,her2-negative breast cancer,laparoscopic pancreaticoduodenectomy,,,,residual neurologic impairment,at transplant.|negative for malignancy,"35-42,|vaginal delivery planned,|do",≥ -0.5d/,,,,,
993,,esophageal varices.|a current,hypolipidemic drugs,signed the informed consent form|ages,altria client services (alcs) studies,assessment of breast development,,,,half-lives,within the two last years before study inclusion)|active autoimmune disease|active chronic,>5 × uln,≥2 degrees,,,,,
994,,valve replacements,intranasal corticosteroids,immobilization,short read sequencing of the trio,outpatient treatment,,,,excipients|severe,within the previous 3 months|pregnants|patients who disagree,equal to or below 0.3 logarithm of the minimal,>20 mg/day)|use,,,,,
995,,strictures,anti-hypertensive drugs,progressed on standard anticancer therapy,molluscum contagiosum molluscum contagiosum surge already treated immunocompromised child atopic eczema,tracheal intubation assisted ventilation,,,,non-small cell lung cancer,within 30 days prior to the av fistula,> 18 years)|activating,60 or more,,,,,
996,,needles,hyperbaric oxygen therapy|cognitive decline,cockcroft-gault|total bilirubin,definition of novice,assessment of tumor samples from the dose escalation phase.|ecog performance status,,,,pdt,during the preceding 12-month period,ua,>5 hrs/week)|alcohol consumption,,,,,
997,,low disease activity,anti-diarrheal,signed informed consent before any study,cr)≤ 1.5× upper limit of normal (uln),otoscopy,,,,stable ones,in the 3 months before the v1 visit,180-365 days,once at the discretion,,,,,
998,,krabbe disease,analgesic medication,risk of massive bleeding,platelet counts,psychosocial consultation,,,,freshly obtained,for at least 3 years prior to imp treatment start,≤ 1,>14 drinks/,,,,,
999,,asthenospermia,biolimus,cohort inclusion criteria||participant,european medicines agency labeling criteria);|are eligible for,¹³c-urea breath test,,,,bloating|significant,within 12 months,less than 0.5/mb,romantic/sexual,,,,,
1000,,extraction defects,acute drug,stainless steel.||stage 2||inclusion,higher|audit,botulinum toxin injection treatment,,,,serratia spp.,within the six [,>35 kg/m2|coagulopathy,more than 5 kg of body weight,,,,,
1001,,noncorrectable visual impairment,sodium fluoride,women|life expectancy,ivig treated,early intervention center treating first episodes of psychosis|professional involved,,,,congenital airway,for at least 3 days after the last dose of study intervention||capable,18-90 years||,< 12 months|diabetic patients|familial hypercholesterolemia|abuse,,,,,
1002,,simultaneous oligometastases,age≥65,cysts,hiv antibody positive);|active hepatitis b,vv-ecmo,,,,full four-month course training,before donation was greater than 133umol/l.||,grade ii or more,stages 1-3,,,,,
1003,,waldenström's macroglobulinaemia,anti-cd70 directed therapy,family members,risk factor scale,gastric nets,,,,"neurological disorders,|having a",within 3 months prior to day,<120 hrs)|have,≥ 20,,,,,
1004,,skin herpes lesion,anti-vascular endothelial growth factor (vegf) drugs,cognitive impairment.|be enrolled in 01m0254,national comprehensive cancer network (nccn) guidelines.|regional lymph node involvement,surgical biopsy|only radiotherapy,,,,newly diagnosed,within the 30 days prior to screening.|history of,within 18.0 kg/m^2 to 32.0 kg/m^2,≥ 6 weeks,,,,,
1005,,coordinating site,ethnicity.|uterine factor infertility.|aged,limit compliance with study requirements|concurrent,designee.|total lymphocyte count,mad|current treatment,,,,pd criteria of imwg,within the 12 month period prior to screening;|hbsag(+,18-45|diagnosis,≥ 1500/μl,,,,,
1006,,type of radiation,clergy,health|absence of exclusion,weight reduction,soc therapy options,,,,suitable for tee examination,3 days prior to the experiment.||,distant extrahepatic disease (m0)|the patient's,≥ 1 cm3|clinical,,,,,
1007,,cutaneous basal cell carcinoma,salmonella,willing to consent to follow,alt ≤5 times uln|9,crc screening,,,,site investigator determines,at least 6 months before trial|tumor stage pt2a-3b,18-80|patients,greater than prednisone,,,,,
1008,,tumor of the index,nalidixic acid,parent,recist 1.1 criteria).|ecog ps,expert,,,,locally recurrent,for at least 3 months after the last dose of,> 18 years|glioblastoma,one or more daytime drops <100 mmhg,,,,,
1009,,ige to peanut,pembrolizumab excipient,willing to participate,macs levels,planned surgical procedures,,,,upper-extremity support,within 12 months prior to first dose,more than 140/90 mmhg,drugs|more than 3,,,,,
1010,,skin of the neck.|history of,studied drugs,valid administration of study,negative,unmethylation glioblastoma|no cerebrospinal fluid,,,,allowed.|active,in the 3 months before the v0 visit,between 01/01/2012,> 20 g/week|evidence of,,,,,
1011,,skin type i-iv|has,necessitate,myometrial invasion,ni):||ni-1,cognitive impairment);|pregnant,,,,core studies|development of,within 6 months prior to randomization;||13,≤ 45,one or two,,,,,
1012,,aik,influenza virus vaccine,limit the caregivers' participation or adherence,anti- programmed death-ligand,cytotoxic chemotherapy regimen,,,,non-echocardiography.|acute,after medical,"0, 1+ or 2+",at least 1 cm,,,,,
1013,,residential,psychiatric medications,family medicine|had,ambassador program,fertility preservation|oocyte donation ivf cycles|diagnosed severe,,,,peri-menopause,within 28 days prior to the first dose of study treatment,score of ≤2||,tanning,,,,,
1014,,acute symptoms,contrast agents.|doubts,cohort a3,covid vaccine,aortic repair,,,,non-addictive,for at least 3 months||,scores between 15 and 53;|detectable,bilateral oophorectomy.|voluntary written consent,,,,,
1015,,canal treated teeth,components of the masticatory system,situations requiring specific nutritional management,gh response,mesh,,,,in stomach,for at least 30 days after the intervention|patients eligible for microanastomosis,>= 10 cm,3||one or more,,,,,
1016,,clinical manifestations,iv antibiotics,progression/recurrence,padua score,microbial therapy,,,,suitable for recruitment after investigator evaluation,lasted >3 months.||to,45-100 beats per minute.|female,2 weeks prior to enrolment,,,,,
1017,,surgery|brain metastases,drug-metabolizing enzymes,stainless steel crown,bi-rads 2 (benign),position-emission tomography (pet) scan,,,,low sep,for at least 6 months.||,<60 ml/min/1.73m2.|liver,≥40% risk,,,,,
1018,,radical prostate cancer,prolonged antibiotic therapy,cockcroft-gault formula||for,bclc stadium,suspicions of,,,,half year,previous 9 months prior to enrollment,manage,≥2 months,,,,,
1019,,admitted to stroke intensive care unit (icu),thymus neuroendocrine,signed a free and informed consent form|patient affiliated,new ischemic stroke,rapid fatigue,,,,signature||,within 5 years before signing of informed consent,≥93%,higher than 2,,,,,
1020,,femur,additional medications,sexual assault,piriformis test|pain,cilostazol.|heart failure.|pregnant,,,,venous thromboses,for the correction,<75 years|low,≤ 28 days prior,,,,,
1021,,chronic kidney disease.|evidence,monoclonal,partners plan to become pregnant,coombs's test,seminal fluid to their partner,,,,medication-exacerbated,within 60 days prior to visit 1.|the,≤ 25 years,outside these periods,,,,,
1022,,extremity lymphedema,imitinib,participated in other drug trials,residual toxicities,medicinal treatment,,,,non-ckd patients|pregnant females|ckd patients,within 6 months prior to intake,>= 65 years|diagnosed,more than 10 cig/die,,,,,
1023,,hemorrhagic,mango,signed informed consent form before,c|heart rate,excisional biopsy expected,,,,neoadjuvant,within 2 weeks prior to the baseline visit.|patients,< 24 hours from time of stroke,25 or less,,,,,
1024,,blb-201,dapsone,parents are visiting the region ( vacations,national university hospital of iceland,systemic chemotherapy regimens,,,,ductal,"within 1 month prior to enrollment,||clinically significant abnormalities",≥ 180/110).|urinary,≥1000 mg/day,,,,,
1025,,childhood cancer,wet,unable to interrupt,indoor oxygen saturation ≥95%;|cardiac function,pelvic lymph node enlargement,,,,resolved,intersphincteric diverticula.|fistula,≥18 years.|good,regular practice of breath awareness,,,,,
1026,,cardiac monitoring.|participants,surgery.||patients,limit compliance with study,visual,stem cell retransfusion.||subjects,,,,non-injected measurable,within 4 weeks of the first dose of treatment,19 years or older.||or||- childcare staff,≤1.5 h of exercise per week)|nondiabetic,,,,,
1027,,renal induced,anti-angiogenic agents,living situation,serum glutamic pyruvic transaminase [spgt,angiography,,,,jugular,apparently,>200 minutes/week,≥2 x 10^9/l,,,,,
1028,,ecrf,ataluren,unable to swallow medication,corrected serum calcium,arteriotomy,,,,estrogen-dependent,within 4 weeks prior to first dosing.|administration of p-gp inhibitors,≤ 3×uln.|renal function,more than one week/month,,,,,
1029,,neurological diagnosis.|at least 18 years,immunosuppressive drug treatment,sleep apnea|significant organ dysfunction,academic test,hospitilization,,,,american|able to read,within 14 days of the first dosing.|the consumption of grapefruit/grapefruits production,respects normal tissue tolerances,more than 10 units,,,,,
1030,,nalmefene|acute psychiatric comorbidity,lactic acid,situations in which the investigator judged that the patient was not,hepatitis c virus infection,postoperative cardiac surgery,,,,first detectable viral load.|patients,within 16 weeks prior to step 2 registration.|documented,<30ml/min,≥6 months).|normal,,,,,
1031,,kidney disease improving global outcomes,anti-iga antibody|patients who are,changes in hormonal birth control|night shift,mgmt,primary surgery,,,,under the care of nephrologists,within 3 months prior to informed consent,"between 1,000 to 150,000 asexual parasite count/μl",≥ 20 g/day,,,,,
1032,,document lymphoma,elotuzumab,participated in clinical trials of other drugs,expected intensive care stay,criteria:||biological sex: woman|able to,,,,parent-reported)||parent,previous history of,l2,more than seven,,,,,
1033,,download video|video watching,enzyme-inducing properties,difficulty to stay fasting,forced expiratory volume in the first second of expiration,calprotectin assay,,,,new formula,within 6 months of study enrollment|non-sterilized,>200 mmol/,more than 8mg,,,,,
1034,,ulcerative colitis;|ability,semaglutide,volume paracentesis|central venous catheter,residual bone crest||,major gi surgery,,,,non-lower gu tract,in the past;||iodine,<10 g/dl||sickle cell disease,= 75 hours,,,,,
1035,,poor communication poor mental state,local steroid injections,risk of non-target gi infusion,gamma globulins,ipsi-,,,,nonspecific,in the previous 6 months;|decay / abscess,< 50%).||b. angina,1 mg/dl,,,,,
1036,,primary membranous nephropathy|upcr,component of vaccine.|bleeding disorder,expected to,distilled spirits,alternative therapy,,,,honey,at the time of planned,at least 8.5 mg/dl,≥ 1 h.||,,,,,
1037,,hypodense ischaemic changes,combined tube-cataract surgery,situations that would limit compliance with study requirements.|participant,maternal temperature,spine surgery,,,,pose increased risks for transcranial magnetic stimulation (tms),within the past 12 months|class iii or iv,=< 2 years.||note,less than 14 days.|（10）use,,,,,
1038,,non-pharmacologic intervention,≥20 gy,incapable of conception,b12 vitamin supplements.|involvement,herbal therapy,,,,septicemia.|foot,within 4 weeks prior to the first drug administration,> 2 times,≥ 2 times per week,,,,,
1039,,relapsing ms,mde,progressed on,ceap classification,oocyte picked,,,,cerebellar,syndrome|decided to receive,less than 50 kg|inability to provide,25-90%|asthma,,,,,
1040,,qt interval corrected,commercial dental products,risk for developing perinatal depression,left ventricular ejection fraction(lvef)≥ 50%;troponin protein t,hydrocelectomy,,,,detectable,within 2 years before screening;|underwent major surgery,18-30 years,≥ 40,,,,,
1041,,- thyroid cancer,device materials;|previous pericardiotomy,unable to give informed consent|children,basilar artery recording can be made,further covid-19 vaccines.|cannot read,,,,celiac,"within 3 hours of trial enrollment|answer ""yes"" to a",120 to 220 msec,≥ 1.5 x 109/l,,,,,
1042,,cvvh,glucose-lowering medications,sexual behavior,prestroke mrs score,instrumental swallowing assessment,,,,3+ by ich,within 6 months before screening;|positive screening,18-32 kg / m2,regular intake,,,,,
1043,,solid tumours with,tranylcypromine,meet all inclusion criteria||inclusion,"rfr),|fractional flow reserve",major abdominal surgery|history of neurological and mental illness|usage of,,,,stable treatment,in the past 30 days|the patient,less than 30 days before taking the drug,questionnaires|two or more,,,,,
1044,,malignant tumor;|tumor,sodium channel blocking anti-seizure medications|additional exclusion criteria apply,life-expectancy,qualifying levels of tactile,metallic implant,,,,varicella-zoster,within 8 weeks prior to initial dosing.|any surgical,≥ 7 g/dl|patients,>10mg daily,,,,,
1045,,fetal head presentations,citric acid,unable to continue,american society of anesthesiologists physical status,curative treatment options|no chemotherapy,,,,intestinal microbiome,for the first time.|patients',≥3.0 × 109/l,≥100 prior,,,,,
1046,,neurologic disease,ros-1.|newly,pd|current alcohol,platelet cell count,asct treatment,,,,digestive system,within 12 months of day 1,stage a,and|residing ≤40 km from,,,,,
1047,,spine deformities|patient,bismuth preparations,family interventions,addison's disease,esophagoscopy,,,,muscle,in the next 12 months||,> 4,20 mcg/kg/min,,,,,
1048,,mobile device|medical condition,nonlive vaccine,speak hebrew,creatine kinase exceeded 2×uln;|untreated hypertensive,intraoperative open-surgery,,,,metastasized to the brain,for 4 months after the last dose of study treatment|capable of understanding,<1.5×109/l;|platelets <100×109/l;|hemoglobin,therapeutic anticoagulation|pantoprazole,,,,,
1049,,acute neonatal hyperammonaemia,ipilimumab-nivolumab|presence of,sleep disorders;|history,ad involvement.|baseline pruritus numerical rating scale,systematic treatment,,,,lpl)|other b-cell,within the past 90 days prior to the screening visit,≥1.5cm,≥ 60 years,,,,,
1050,,fbt,induction agents|patients,minimal risk of recurrence,child-pugh class,chemotherapy|histology consistent with adenocarcinoma,,,,self-report|able,within 2 years prior to registration,"≥ 39),|suffering",>6h per week,,,,,
1051,,appetite,fenofibrate,participated in any regular,thyroid function tests,axillary temperature||≥37.5˚c)-(temporary exclusion,,,,histologically confirmed initial diagnosis,within 2 weeks prior to lymphodepletion regimen,> 25 mm,maximum 2 biopsy-,,,,,
1052,,diabetes.|current,moderate cyp3a4 inhibitor,remain in central kentucky,quantitative pilocarpine iontophoresis,urine drug screen|reported history of illicit drug use,,,,liver disease;|active,within 30 days prior to screening.|in the opinion of the investigator,90-day follow-up,≥ 38.0°,,,,,
1053,,proof of malignancy,dacryocystorhinostomy,radiographic evidence suggesting,pain levels,polymerase chain reaction (pcr) method,,,,stage iii,90 days prior to screening.|known chronic pancreatitis,> 50%|protected patient,>10 mg daily,,,,,
1054,,biliary sphincterotomy.|high risk for bleeding (,silicone,breast cancer.|receipt of live,placenta,syme amputation,,,,non-protected exposed vessels,for at least six months prior to entering the study,lower than 3,stem cell transplantation)|being,,,,,
1055,,||allergy,dinoprostone,participated in other clinical studies,response evaluation criterion in solid tumors (recist),preoperative radiotherapy/chemotherapy,,,,"grade ii, ii or iii",at least 3 months prior to baseline,> 50 mm,injection;|pregnant,,,,,
1056,,mixed cholangiocarcinoma,spartalizumab,unable to,intranasal influenza vaccines,regional competence centre for,,,,central nervous system (cns) involvement,within the next 30 days|rural residence location,≤ 12 months before start of study treatment.||patient,2 weeks prior to the,,,,,
1057,,immune deficiency|history of,anti-cancer agent,difficulty to swallow.|treatment,μl).|platelet count,catheter,,,,surgery|severe,before the first dose of niraparib|received,≤ 10 g/dl,"≥ 12 months,|unilateral",,,,,
1058,,fibromuscular dysplasia,lb,nicotine use|history,pro-apoptotic agent,steroid pre-treatment,,,,stage iii(ajcc,for 7 days prior to cpx-351.|patients,20 - 50,≥60.|histologically confirmed,,,,,
1059,,arthritic conditions,preoperative antibiotics,risk of fracture,injection,bile duct cancer,,,,icrs iii or iv observed,in past 6 months before the study vaccination;|presence,> 9%);|diseases of the blood,dose > 10 mg/day,,,,,
1060,,64cu-dotatate,tnf inhibitors,sleep duration,stage unspecified or|two urinary albumin-to-creatinine ratio (acr) test,periodontal charting,,,,candidate,within 14 days prior to enrollment.|patients,> 25%,more than 48,,,,,
1061,,er+ breast cancer,ici in combination with,minimal active,apical lesion.||,expectant,,,,study.|previous,within five years,"less than 130,000/ul|participation",≥ 15 days of hospitalization,,,,,
1062,,neurological disorders capable,levofloxacin,unable to follow-up,ia-2a,behavioral health treatment,,,,epithelial defect).|if,within the past 5 years before the screening,below 24 points,diagnostic criteria|time of onset ≤ 12h|voluntary signing of informed,,,,,
1063,,pancreatitis.|history of copd,immunosuppressive medication/therapy,close to the tumor site,international classification of headache disorders 3rd edition (ichd-3),abdominopelvic ct scan|scheduled,,,,above second degree,within half a year of the study|not,taiwanese.|agree to participate,two doses,,,,,
1064,,neurologically asymptomatic,antibiotic used,wheelchair/bed bound|< 6 month life expectancy,hbv dna assayed,liver function reserves,,,,between 08:00,at least 6 months before patient enrolment,≥ 18 and ≤ 75 years,≥ 2;|cranial,,,,,
1065,,carotid artery,ponatinib,risk of reflux aspiration,urine protein positive.|urine protein level,intra-articular injection into the joint|email address or network access||,,,,pd-l1 and,within at least 90 days after the last dose,> 50,more than 6 months,,,,,
1066,,atransferrinemia,drink containing grapefruit,participated in other investigational clinical trials,compare mbc fidelity post impact center methods deployment versus historical,system|major surgery,,,,consent|best,at any time including of pn0(i+,≤ 1.5x upper limit of normal (uln),dose-escalation,,,,,
1067,,global developmental delay,drug-coated balloon catheter (dcb),life-stressor.|students,response assessment.|ecog status,protocol|radiation therapy,,,,wheeze,after treatment who are free of disease progression,within reference ranges,5% of,,,,,
1068,,concomitant mental disorders,immunosuppressants,unable to wear,vas correlating,blood sampling).||,,,,spontaneous,within 7 days before the study enrollment.||,18-60;|patients,allergy.|previous confirmation of the food,,,,,
1069,,angina|major surgical procedure,remimazolam,unable to swallow tablets,hd patients|age,acute surgery,,,,stable phase,for the effectiveness assessments,relieved,approximately 2,,,,,
1070,,amyloid neuropathy,seville oranges,cohort b||complete resection of a histologically,pcsl,laparoscopic sleeve gastrectomy,,,,lactic acid,prior to futibatinib,below 18.0 years,chronic,,,,,
1071,,lumbar facet degeneration,compounds of similar chemical or biologic composition to apg-1252,commit to intervention/assessment procedures,m.d. anderson radiology,re-stenotic lesions,,,,therapeutic,within 3 hours of the study procedure|recent immunization,≤ 3 months prior to starting study drug|acute myocardial infarction,high cut off,,,,,
1072,,superficial femoral,l-carnitine,inadequate compliance with study execution.||4.2.21,fasting glucose,facial treatments,,,,parturients|scheduled,within 1 month prior to enrollment,>18 years|american society of anesthesiologists score,10 mg/day,,,,,
1073,,acquired hh,medication prescribed,cockcroft-gault formula|international normalized ratio,hepatitis b virus surface antigen,clinical biochemistry,,,,highly effective method of,after the last dose of the study drug,46 to 65 years being fully vaccinated,>20 units/week,,,,,
1074,,acute facial injuries,iv contrast,participated in,blood pressure|no abnormalities,ocular fungal infection|suspected ocular microsporidia infection,,,,activation|st-segment depression,planning methods||,< 90 ml/min/1.73 m2,1 registration:|patient must,,,,,
1075,,treatment;|50 uc,nucleic acid test,entry into the study.|received,pphn discovered,transbronchial biopsy available,,,,semaglutide,in the previous year|had,1-3.||,outside of routine,,,,,
1076,,gerd);|known cancer,opioid analgesics,situations that would limit the safety of a biopsy,hepatitis b antigen,thoracotomy,,,,decisional capacities,at the time of consent.|evidence,> 18 years.||,later than 9 months after start of treatment,,,,,
1077,,ventricular flutter,maxillary premolars|patients,patiënt,spinal cord metastases|active infections,pelvic mri|short fistula tract that in the surgeon's opinion are amenable,,,,mucosal evaluation.|patients,following curative resection,"< 1,000/ul",≥ 12,,,,,
1078,,polyposis|comorbid diseases,cleft palate repair,anticipated difficult,serum na,michigan medicine,,,,american college of rheumatology criteria|at least 18 years old||,within 500μm,41-49%,weekly x 12 consecutive weeks,,,,,
1079,,nonaffective psychosis,paclitaxel + cisplatin,unable to take effective contraceptive measures;|10,renji hospital|age,auxiliary materials,,,,communication|myocardial infarction,within 30 days of screening;|have,≥ 65 years|chadsvasc score,5 or more,,,,,
1080,,vas)|physician's global disease activity,covid-19|adults,participated in another interventional clinical trial within,singleton gestation|gestational,sufficient proficiency in,,,,in tianma area,within 14 days of study initiation,"< 30,000/µl at",mcg/min,,,,,
1081,,lymphangitic carcinomatosis,nickel titanium,unable to express,serum cea assessments,manipulations,,,,dat-,within 6 months prior to the first dose.|pulmonary hemorrhage/hemoptysis,<2|within 14 days of study registration,12 months of,,,,,
1082,,proliferative disease,berberine,incest|other condition(s),creatinine clearance)|participated,xoi treatment,,,,medically induced,within 3 months|history of active,10 to 15)|arterial oxygen saturation,scores of 1 and 2,,,,,
1083,,brain atrophy,adolescents,≤1|life expectancy,height.|fev1,extensive radiation therapy,,,,related to ovarian cancer.|have,within 3 months)|pregnant,lower than the standard cut-off value,≥ 30,,,,,
1084,,gastroschisis repair)|foreseen surgical duration,mtrps,situations in which the investigator considers the issue to be unsuitable for participation in the study,international federation of gynecology,traffic citation|vehicle,,,,could cause urinary symptoms,within 42 days prior to initiation of study treatment|prior treatment with cd137 agonists,< 10,two-dose,,,,,
1085,,type 2 diabetes|limited,otilonium bromide,unable to understand informed consent,psa value,targeting,,,,mild to moderate in,pre-bd,"≥ 45kg/m2)|height < 5'0""|patients",january 2018 to,,,,,
1086,,multi-gated,cns stimulants,unable to consent|pregnant,general university hospital in prague,splenic surgery|prior radiation,,,,mild to moderate symptoms,within 28 days after the 2nd dose,>10% above upper limit of normal,one prior,,,,,
1087,,naturally postmenopausal,ssnris,non english speaking,serum β-hcg test,standard induction chemotherapy regimen,,,,grade iv operation qualification,at the time of enrollment|receiving another investigational agent,two-lumen temporary cvc,older.|one,,,,,
1088,,associated edema,opioid narcotics|asa physical classification,remain at the study center,criteria|lesion size,gamma knife,,,,evaluable extracranial,before joining the group,score of 37 or more,more than 2 weeks prior,,,,,
1089,,tubal ligation.|vasectomized,negative effects,cigarette smokers,alp,cardiac procedure,,,,ibd).|high anesthetic risk,for ≥ 12 months,> 150/95,≥ grade 2,,,,,
1090,,rheumatological disorder-related,irrespective of cause,risk of aspiration|obese,estimated serum creatinine,volumetric mri,,,,unclear,within the last six months;|evidence,=qt/(rr0.33).|note,outside of,,,,,
1091,,hepatic metastases,give own consent|ability,participation in an interventional clinical trial|contraindications to treatment,cl,ct scan slice,,,,femoral pulses,within 1 day prior to the date of conception,0-3;|able to follow,"less than 12 months postpartum,|test positive",,,,,
1092,,bronchi,immune checkpoint inhibitors,estimated life expectancy,ventricular response,tracheostomy|mechanical ventilation,,,,intensive systemic,within 7 days before dosing,>= 17)|if required to meet,exceed,,,,,
1093,,leptomeningeal carcinomatosis.|active infection,histamine-2 blockers,family support|coronary artery disease,thickness,physiological replacement doses of hormone therapy,,,,from,for at least 5 years|insufficient command of the dutch language to be able to understand the patient information,< 30 mmol/l,jul 2008,,,,,
1094,,bc,immunosuppressive drug therapy,unable to swallow the study agent,ipss,chimeric antigen receptor (car t,,,,enema,within 5 years prior to screening;|active,< 4.7)|meets criteria,maximum ovarian volume,,,,,
1095,,recurrence of preeclampsia.|aspirin,study-related procedures/medications.|previously enrolled,speak and read,recist v1.1|adequate organ function;|life expectancy,blood cell,,,,instent,for at least 7 days prior to first dose,=< 1|participants,osseous metastatic disease,,,,,
1096,,year|pregnancy|cardiovascular conditions,sympatholytic medications,situations that would limit compliance with study requirements|pregnant,outpatient surgical procedure,aspirin therapy,,,,other immune suppressive medication,at the time of screening;|patients,≥80% of the predicted normal value,intl.|minimum 1 year of experience,,,,,
1097,,cerebrovascular diseases;|positive test,thrombocyte,"research||able to communicate in turkish,|being literate,|over 18 years old,|having primigravida,|conceiving naturally,|gestational week",adequate organ function,antihypertensive treatment,,,,severity grade 2 or 3,within the past 12 months;|women,①,less than 1 year,,,,,
1098,,buttock,short-acting beta-adrenergic,render a patient unsuitable for inclusion.||alt,resident in fu jen catholic university hospital||,functional assessment of cancer therapy - cognitive function (fact-cog,,,,icd-10 codes,during the past 24 months.||have at least two up/cr ratios,≤ 1 week before start of the study treatment.|known severe,≥ 6 months prior to enrollment,,,,,
1099,,major injuries,β-thalassemia,≤2|life expectancy,amh,plasma treatment,,,,suitable for treatment with teas.|opioid hypersensitivity.|psychiatric disorders,in the last three months|significant,"> 60,000/mm3",≥ 30 days prior,,,,,
1100,,lower extremity injuries,tixagevimab,screening.|both cohorts match,word recognition test presented,rescue medicine,,,,flow cytometry-confirmed diseases,in the past 2 months|major,> 1.25 x the upper limit of normal||xi,>2mg,,,,,
1101,,neurological disease.|pregnancy status|having,mineral supplements,postmenopausal status,agc,laboratory,,,,once enrolled,prior 12 months,35 years to 65 years.|bmi,greater than 14 consecutive days,,,,,
1102,,gastrointestinal function.|hypersensitivity to the active substance,immunsuppressive medication,hospital.||patients admitted to the intensive care unit,ast levels,grant voluntary,,,,mid-peripheral visual field dysfunction,"more than once,|planned to receive",≤ 25 x 109/l.|subject,permanently,,,,,
1103,,young,rivaroxaban,alcohol consumption,glucose tolerance|contraindication,sti testing,,,,muscle group,within 4 weeks prior to initial administration.|present,< 13|other,female|body,,,,,
1104,,medical doctors|access,landline,rehabilition in enschede,pain management center,upper trapezius,,,,intra-abdominal abscess,within 30 days prior to first vaccination,≥ 30% blasts,100 x 109/l|ast,,,,,
1105,,immunosuppressive treatment|non-acute,histamine,lack of time,organ functions:||adequate bone marrow reserve,shoulder instability|previous surgery of the shoulder,,,,posterior stabilized,within 6 months prior to screening|if,<50 beat,≥2 years,,,,,
1106,,back pain,herbal medicines,inadequate swedish,3.hepatitis c virus (hcv) antibody positive,re-irradiation,,,,swollen joints,within 30 days prior to screening|is currently enrolled in another investigational drug,equal or above 18 years|eligible,"fewer than 4 cases per 100,000 per year",,,,,
1107,,rheumatoid arthritis.|subject,drug-elimination,system|lack of signed informed consent,fish)|karnofsky ps scale,pulmonary angiography,,,,packed,for 6 months prior to listing,1-4|ileal conduit,medications|concomitant,,,,,
1108,,fallopian tube carcinoma,ontario,situations that would limit compliance with study requirements|pregnancy|known,apical bone height,pet /ct showed,,,,occupational,previously been involved,> 20 kg/m2,voriconazole)|current,,,,,
1109,,psychological health conditions|co-occurring,orotracheal,weeks|previously completed,viral load|negative hepatitis,chronic widespread,,,,moderate to severe dysmotility,within 7 days prior the first dose of study drug.|history of (,">= 100,000/microliter||adequate",greater than 4 weeks from,,,,,
1110,,non-affective psychosis,antibiotic drug,signed informed consent|type 1,prostate cancer|metastatic castration resistant prostate,sympathetic neural control,,,,adoptive,at the time of informed consent.|willingness to provide pre-and,at least 70% of the twice-daily texts,more than 3 months);|the,,,,,
1111,,brain metastasis treatment,cyp3a4 inhibitor,unwilling,pasi,admission,,,,proximal,wine 30ml,less than 5 years prior to enrollment,high dose cs,,,,,
1112,,doctor's diagnosis,anti-hypertensives,situations that would limit compliance with study requirements.|pregnant,serum glutamate-pyruvate transaminase,baseline,,,,salvage chemo-immunotherapies;|no measurable,"for at least 1 year prior to screening||or,||females of",> 18 years|diagnosis of heart failure,1 of 6 different who eua,,,,,
1113,,proliferative diabetic retinopathy (pdr),components of the study drug.|patients,participated in other clinical trials|investigators consider the patient do not fit for the study,ppls)|ppl size,invasive medical procedure,,,,diagnostic and statistical manual ) and (,less than 72 hours before surgery;|presence of bulbo,greater than 190 mg/dl,2 weeks after intervention||internal recurrence).||4.2.8,,,,,
1114,,"peripheral neuropathy,|chronic pain",icis,limit compliance with study requirements,nijmegen modification of the bethesda assay,secondary vision impair synechia,,,,suitable for femoral access.|known contraindication,within the last 24 hours prior to the first day of screening,<50%|qtc interval,more than 2 hours per day,,,,,
1115,,hormone deficiency,cytotoxic agents,imp,diameter;|left ventricular ejection fraction,idh1 mutation,,,,spirometric stage,within the last 5 years|subjects have,≥ 8.5 g/dl.,≥ 5,,,,,
1116,,neurological problems,late onset val30met,difficulty in completing the study;|any condition,mss,opioid maintenance treatment,,,,grade 3b according to the who classification,during the past 7 years.|subject was able,≥ 90 mmhg||metabolic syndrome||- central obesity,systemic treatment.||additional inclusion criteria,,,,,
1117,,severe joint disease,polyethylene glycol,suggested by sudden death,hemoglobin (hgb),cervical foraminal stenosis|cervical central stenosis|cervical disc herniation|cervical spondylolisthesis||,,,,stage to before study,eligible for first line systemic therapy,≤ 10%,≥60 years|at least 2,,,,,
1118,,evaluable tumor sample,carboxylic acid,expected changes,recist v1.1 criteria on ct,complete left bundle branch block,,,,≥8.0 g/dl|inr,at the time of consent|patients,"≥1500/µl|platelets ≥100,000/µl|hemoglobin ≥9.0 g/dl",≥1 year,,,,,
1119,,ocular trauma,study agents,clear preoperative consciousness,18f-fdopa pet/ct,substantial support,,,,clinically significant disorders,within 3 months before baseline or 5 drug half-lives,>2.25 sd below mean for,>= 14 days prior to registration|eligibility criteria,,,,,
1120,,nasopharyngeal cancers,postpartum,remain in the hospital,hospitalization status,gynecologic surgery,,,,articular,before starting a keto-,greater than 1 mm,≥ 5 minutes,,,,,
1121,,rheumatic conditions).|synchronous tumors,calcineurin inhibitors,difficulty with concentration,acr classification,therapy with androgen deprivation therapy,,,,precentral,at the time of screening.|chronic obstructive pulmonary disease exacerbation,above 50.0 kg,30 mg,,,,,
1122,,acute suicidal ideation.|patient,anti-cmv medications,meet the inclusion,diagnosis;|secondary hematological,pelvic effusion).|uncontrolled,,,,pterygium,history in past 3 years,1 year prior,at least 3.|medical,,,,,
1123,,immobilization,topical artificial tears,therapy.|life expectancy,mayo score,vascular examination,,,,non-sanitized,within 3 years.|subjects,>15 year,more than 2000ml,,,,,
1124,,rheumatoid diagnosis,reduction,cohort entry date|3,examinations.|alanine aminotransferase (alt),cognitive tests,,,,adolescents,prevent vaginal delivery;|not,<50 beat per minute,1 or 1+ depending,,,,,
1125,,aminoglycosides,contrast material).|have,constraints|life expectancy,pinhole,vein puncture,,,,wild-type kras tumours,within 3 months prior to study entry.|known,>70 identification core score,2u/month above for 3 months before the first dose;|patientswho,,,,,
1126,,electrocautery skin incision||,consensus,unable to communicate with cantonese,tobacco should take their regular amount,patients|emergency surgery,,,,discharge from hospital|no brace after surgery|sufficient verbal,prior to enrolment|history of,less than 30 right before,for at least 5 years|age,,,,,
1127,,atrial arrythmia,prosigna,difficulty in standing,qt interval corrected,assessment of the mechanism of syncope,,,,radicular lbp,< 6 months prior to initial unipolar ablation|absence,1.1 times the upper limit of normal,two years or more,,,,,
1128,,coagulation disease);|a,probiotics,unable to consent for research,as:||creatinine clearance,informational meeting||,,,,researcher thinks can harm the safety of the subjects and expose the research results to unnecessary risks,for 24 months of,15-40,minimum 1 week,,,,,
1129,,congestive heart failure|unstable insulin-dependent,cytotoxic medications,sleep apnea|irregular work schedule,fasting morning blood sugars,mini international neuropsychiatric interview (mini 7.0,,,,having unsafe,experience,50 and 80 years old,lacunar,,,,,
1130,,smarca4-mutations,flush toilet,genetic testing.|separate written informed consent,recist v1.1).|0,various reasons,,,,malignancy|recent,within 7 days before the investigational product administration,"i, ii patients",≥ 2 different body areas,,,,,
1131,,cocaine use disorder,alpha agonist,partners of child bearing potential,international prognostic index (ipi) score,bone marrow transplant;|patients,,,,diagnostic and statistical manual of mental disorders) mdd,improvement after more than 3 days' regular clinical treatments.||,≥ 15)|current,"less than 1 month postpartum,|test positive",,,,,
1132,,adequate treatment|anc,fisetin,laser resurfacing),meeting inclusion criteria,simple declaration,,,,≥210 g alcohol/week,in the past 3-6 months.|immunocompromised,measured <7 g/dl,31));|maintenance dose,,,,,
1133,,solid lesion,local requirements)|age,volume of blood,ultrasound consensus criteria,pth concentration,,,,diarrhea;|clinically significant,within one year before receiving,> 70%|adequate organ function,fluxio hemorrhoidalis,,,,,
1134,,radiologic bone loss.|gingivitis (17),thiopurines,unable to take tablets orally,vas score,coagulopathy|platelet cell count,,,,mild to moderate forms of social,within 14 days prior the first dose of study,12-35 years,at least moderate,,,,,
1135,,screening)|uncontrolled intercurrent illness,a*02,excess blood loss,nprs,blood transfusion therapy,,,,low back pain,within 6 months prior to visit 1.|receipt of,≥2 pregnancies,≥ 28 g / l;|total,,,,,
1136,,infection.|elevated troponin i.,non-steroidal anti-inflammatory agent,comorbidity.|able to communicate coherently,plasma antibody therapy,potential medications,,,,orally absorbed,in stages,score of 20-45|able to follow written instructions|able to tolerate,more than 30,,,,,
1137,,automatic defibrillators,penciclovir,insufficiently relieved,diameter stenosis,therapy||prior therapy,,,,above the upper reference,after the first line of therapy|age,< 3 times of uln,2 doses,,,,,
1138,,anatomy,compounds of similar biologic composition.|patients,attenuation of the,surgical revascularization|prior coronary artery bypass graft (cabg),meal,,,,alter absorption,for 180 days after the last study drug administration,> 60 days,daily dose,,,,,
1139,,armpit,acheis,insufficient proficiency,capacity classification of,fine needle biopsy,,,,local use of,within 5 years before vaccination;|prior vaccination,= qt/,± ivig.|platelet count,,,,,
1140,,intracranial infections,dheas,engrafted with an,or||absolute neutrophil count (,lines of treatment,,,,routine test,at the time of study drug,<20 & alp<150,hgb<8 g/dl,,,,,
1141,,cardiac events,topical onychomycosis medication,cohort 2a,schiff sensitivity score,left ventricular dilation,,,,non-prescription,after previous surgery,at least 7,≥6,,,,,
1142,,premature ovarian failure,drug-induced liver injury,acupoints are unaffected.|all patients enrolled on the study will have their informed consent.||,fbt,assisted self-monitoring,,,,ft538 product,for at least 12 weeks after the last dose of the imp.|male patients must,score ≤2|hemoglobin level,>14 drinks per week.|current,,,,,
1143,,chronic toxicities,oxcarbazepine,authorised indication. the treatment decision,pd1 antibody therapy,atlantic urogynecology associates,,,,suitable for local radical therapy,for at least 6 months after the last treatment||sexually active,between 40 kg and 90 kg,high stress screening result,,,,,
1144,,infection/inflammation,unmarketed drugs,render the participant unable to comply,progesterone receptor,formulation.|major surgery,,,,old|underwent,prior to date of enrollment.||note: all patients,outside the reference range for the population being studied may,<2 years,,,,,
1145,,acinar cell carcinoma of the pancreas,aicm,participated in another trial,serum prostate-specific antigen (psa),dni dnr,,,,gram-negative pathogens|require,within three months of the first dose of study product,<30 ml/min/,> 1 mg/h|not,,,,,
1146,,atrial appendage thrombosis,diabetes medications,unable to travel,absolute neutrophil count(anc)≥1.5×109/l,lynparza,,,,congenital,prior to first dose.|eastern,> 1.5×109/l,daily dosage ≤ 100mg,,,,,
1147,,non irradiated lesions,emergency departments,quiet,https://members.childrensoncologygroup.org/prot/reference_materials.asp|estimated glomerular filtration rate,study start|ct scan,,,,image area,within 2 years before the start of the study treatment,over 45 years,more than 2 times per week of regular physical activity,,,,,
1148,,acute ischemic stroke|acute intracerebral,intrathecal agents,ercp,urine pregnancy test done,12-lead ecg).||,,,,chronic hd program.||exclusion,within 30 days of completing the survey.|patient/ providers willing to complete the survey.||,above ≥ 24,routine treatment,,,,,
1149,,failure to respond to,contrast media;|patients,compliance,h. pylori test,t cell type;|the first recurrence;|the risk stratification,,,,stage 2 t1d,past two years|active,≥18 when signing the icf;|expected survival period,greater than or equal to 90 days,,,,,
1150,,hypertrophic cardiomyopathy,prochlorperazine,risk of suicide,dialysis|comfort care only|total bilirubin,abdominal distension,,,,without menses,within 8 weeks from time of screening visit,≤ 5 × upper limit of normal value (uln),≥2 weeks,,,,,
1151,,mental disability,selective beta-blocker,signed the icf,american society of anesthesiologists status,pci treatment,,,,influence the study result|the subject with,for at least 30 minutes|inability,<60 kg|male,one,,,,,
1152,,pectus excavatum;|opioid,covid vaccine,patchy atelectasis,function:|total bilirubin,re-symptomatic,,,,higher than grade,on day time oxygen,≥18 years|understand english||,more than 18 years,,,,,
1153,,medicinal angelica,mild thickening,risk area among:||age,wheelchair,ipsilateral surgical,,,,third,at surgery|need for crestal augmentation procedures,< 180 µmol/l,frequency of exercise activities,,,,,
1154,,knee disorder,ca-4948,cigarette smoker,age||preoperative gfr,confirmatory serum pregnancy test,,,,lasting at least 4 consecutive days,for enrollment,> 20 points.|subject,> 1 day,,,,,
1155,,autoimmune-related,anti-cancer therapy,signed informed consent form||patients,modified bleeding index19 score,haematopoietic colony,,,,stage 2.5-,within 28 days prior to administration;|did not receive endocrine therapy,grade iii-iv,long time;|arterial/,,,,,
1156,,pleural effusion|patient,intravaginal,progression cannot,national comprehensive cancer network(nccn,tobacco products|dental,,,,grade 3|treatment plan,in the 12 months prior to the first dose of study drug.|is,>40||some,once-daily itch nrs,,,,,
1157,,positioned.|abnormal pain behavior,megestrol acetate,close supervision)|able,human immunodeficiency virus hiv,regional anesthesia,,,,nasojejunal tube,within the last 24 hours,4-8 for,first cycle of,,,,,
1158,,early malignancy,js009,unable to complete the survey.|child is a ward of the state,hemorrhagic disease|active infective,radiographic studies,,,,sleep,"prior to testing,|a history of any",<16 years old.||,60 mg/m2/day,,,,,
1159,,enrollment.|primary immunodeficiency disorder,hiv protease inhibitor,change of 0.5,crcl,screening|oxygen desaturation,,,,"etc.),|having",within 6 weeks prior to visit,≥ 25mmhg,rna]).||chronic treatment,,,,,
1160,,stevens-johnson-syndrome,caplacizumab,situations that would limit compliance with study requirement,week||,immunotherapy treatment starting ≤4 days,,,,central nervous system disorder,at least 1 measurable non-radiated,≥ 10.0 g/dl,maximum of 1 non-corticosteroid immunosuppressive/immunomodulatory medications,,,,,
1161,,"neurological,",cyp3a4 inducers rifampicin,fertility plan,nx,coronary bypass treatment,,,,well,within 3 weeks prior to the first dose of study intervention.||recent,≤ 15 cmh2o.|few,> 2 z-score,,,,,
1162,,disease states,vitals signs,render the results,root apex.||systemically healthy,chd,,,,multistation n2 disease,within 2 months after radiotherapy,> 45 ml/min)|microalbuminuria,bilateral,,,,,
1163,,genital infections,cyp3a4 metabolized drugs,refused to participate in the clinical study;|predictable airway difficulties,melanoma|aged,standard of care with platinum doublet chemotherapy,,,,worse than grade 1|anterior uveitis,at least 3 weeks prior to consent|be,necessary).|hypomanic episode,≥3 months|ability,,,,,
1164,,primary cutaneous melanoma,immunoglobulin g (igg),lhrh analogs,european economic area countries,endourological ureteral manipulations,,,,imaging tcd,at least 90 days,>= 8||inadequate organ function,2 to 3,,,,,
1165,,blind,kras g12d inhibitor,risk of autoimmune disease,estradiol levels,immunohistochemistry (ihc),,,,study.|chronic uncontrolled,at least 12 weeks prior to enrollment,≥25 and <40 kg/m2,2 months,,,,,
1166,,ependymoma,valemetostat,breast cancer|have completed,cd4+,12-lead electrocardiogram (ecg),,,,non-therapy-induced,prior to receiving sunitinib malate,≤ 2;|aspects,50mm~70mm of 100mm,,,,,
1167,,ada caries classification,proton pump inhibitors,unable to comprehend the study,hematological||absolute neutrophil count,video-conferencing capability.||exclusion criteria for tbi participant:||any,,,,interventional,within preceding 6 weeks,18 or older|localized,1 year,,,,,
1168,,tinea capitis,medium-acting corticosteroids,unable to speak,equation).|body mass index,dissection,,,,auxiliary stage,within 72 hours prior to the first dose of study drug.|unresolved,class iii-iv)|pericarditis,8 or more,,,,,
1169,,lower limb amputations,medical-grade,difficulty in assessing muscle strength,hippa research disclosure,small intestine resection,,,,drop-containing,within the last 24hrs,<=3|patients,small doses,,,,,
1170,,auscultation type sphygmomanometer|those,recipient||,insufficient response,modified mallampati classification,mental nerve,,,,systemic therapy.|cohort,in the last 24,greater than or equal to 180 days prior to the day of screening.|history of,more than 2 months|lumbar puncture,,,,,
1171,,mixed histological features.|patients,parasympathetic inhibitors,haukeland university hospital||,supine blood pressure,pain control treatment,,,,primary neoplasm.|registration,within two years prior to the first dose of investigational,>= 1500/mm^3,10-year,,,,,
1172,,chronic kidney,target limb,method of avoiding pregnancy,anticardiolipin,surgical ctr,,,,short-term,within 14 days prior to ip administration.|administered,10.5-13.5 months,≥6 months,,,,,
1173,,decreased exercise tolerance,zollinger-ellison syndrome,limit compliance with study requirements.|patients,be length,colectomy.|colonoscopy,,,,chinese,before enrollment are allowed into the study provided that they,10*9/l,= 28 february 2023)||,,,,,
1174,,oral dysfunction,anc counts,unable to communicate in dutch,"icd-11,|age",endoscopic surgery,,,,or|two predicted pathogenic galc,for less than 3 months|having,functional classification of class ii or better.|patients,> 5 days,,,,,
1175,,metavir f3 fibrosis,loratadine,undetermined significance|patient willing to consent for the study,left ventricular systolic function,autologous plt collection|age,,,,neonatal mortality,at time of data extraction|age,requires icu monitoring,new onset of septic shock,,,,,
1176,,pathogenic variants,atkins diet,radiographic evidence,hemoglobin a1c (hba1c) measurements,lansky play scales,,,,healthy|non-smoking|non-diabetic,within 3 years prior to the first dose of study drug,<40000|absolute,2 forms of,,,,,
1177,,kidney functions,steroid containing inhalers,situations that would limit compliance with study requirements.|all english- speaking,peripheral arterial disease|able,complex procedure,,,,non-target local lesions,within 1 month after ucar-t cell reinfusion,long-term care|have significant,ergometer exercise stress,,,,,
1178,,auditory neuropathy,computer operation,unable to understand,fsh levels,subsequent assessment of local reactogenicity.||note,,,,amenable* to biopsy,less than 14 weeks,> 65mm,≥ 4||,,,,,
1179,,|atheroma|chronic obstructive pulmonary disease,zavicefta,situations that would limit compliance with study requirements|any other illness or condition,resting periods;|height,arthroplasty,,,,experimental agent,for the last 3 months prior screening,40 or older,more than last 3 months,,,,,
1180,,traumatic injury,topical steroid application,unable to follow protocol|multiple sclerosis,prolonged qtc interval,conceive,,,,at recruitment|severe chronic obstructive airway disease|severe,include 9 months,< 100 mm hg,three or more);|chronic essential hypertension,,,,,
1181,,mild covid-19 (who criteria)/confirmed diagnosis,phosphatidic acid,reproductive sexual activity,depression score,curative anticoagulant therapy,,,,under 1 centimeter.|breast carcinoma in situ,in the past 1 month.|continuously,400 ml of,more than 1.5,,,,,
1182,,signs of herpes,acetylaconitine,enrolled in intervention,inclusive)|body mass index,chronic immunosuppressive therapy,,,,menopausal)||,past 2 years prior to the study or|men,3.0 g/dl)|serum,single-nucleotide polymorphism,,,,,
1183,,venous sinus thrombosis,stereotactic,individual,fois-score,computed tomography scan of,,,,tamoxifen arm,within 4 weeks prior to initiation of administration of study product(s).|history,12-17 years old,maximum of 70 years,,,,,
1184,,congenital diseases,direct factor xa inhibitor betrixaban,maintenance dialysis||providers,white blood cells,responded,,,,controlled by medication;||(vi,before screening,≥3 in neck,≥10 cigarettes per day,,,,,
1185,,≥6 symptoms,anatomical constraints,situations that would limit compliance with study requirements).|is pregnant,pulse oxygenation,resuscitation from cardiac arrest|significant neurological deficit,,,,stable dose(s,for at least five days a week,≥30 years|willing,2 iv attempts should,,,,,
1186,,healthy|male,anti-ctla-4,breastfeeding|active symptomatic,international normalized ratio.|the,whole pelvis radiation therapy,,,,american college of rheumatology|do not respond well,within 10 days prior to first treatment.||2,≤ 2.5 x upper limit of normal|full legal capacity|written informed consent,1500 per mm3);|platelet count,,,,,
1187,,gist,adenosine diphosphate,sleep medication|unable to attend laboratory visits,menstrual period.|the criminal blood vessel,therapy for jia,,,,normal,90 days prior to registration|ecog performance status,between 11-15|english speakers.|migraine group,high dose methotrexate,,,,,
1188,,asymptomatic brain metastases|at,following:||acalabrutinib ibrutinib zanubrutinib||on active therapy,cohort a or b,afs score,insulin treatment,,,,icd-10 c00-c97,within 2 years after their cell reinfusion;|(7,<65 years,≥ 2 first-degree,,,,,
1189,,vaping complications,progestin injectable,gault equation|absolute neutrophil count,cbct,previous therapy,,,,muscle sparing thoracotomy,for less than 24 h,"0, 1 or 2.|adequate seizure prophylaxis",more than 14 days|pre-existing,,,,,
1190,,voice disorder,medications that interfere with spasticity,unable to read print materials);|indication,international normalized,vaginal mesh implantation|abnormal result,,,,shaft,up to 10 mg of,< 3.0 mg/dl.|serum,more than 6,,,,,
1191,,antiglaucoma medications|active intraocular inflammation,pimecrolimus,bcl6||histologic transformation,modified ashworth,video recording||,,,,influence ability to complete assessments,within the 6 months|have,> 2.5 mm||,>1 cms,,,,,
1192,,infection-related,placenta,involuntarily incarcerated,asa house of,mosaic trisomy,,,,etc.|reported diagnosis,requiring the subsequent application of a lingual,dose ≥ 0.4 μg/kg/min,8 mg/dl,,,,,
1193,,renal cell cancer,major tissue,risk of infection:||history,brief observation,hdac inhibitors.|active treatment,,,,ankle joint site|patient,within 6 months prior to the first dose;|those,18-39 years,controlled,,,,,
1194,,rheumatism,cyp 3a4,situations that would limit compliance with study requirements.|evidence,liver function total bilirubin,amount,,,,music,within two weeks of initiation of participation,≥ 2.5 g/l,> 1 mg/h|low,,,,,
1195,,deep occlusal decay,intranasal influenza vaccines,unable to meet screening,liver enzyme ≥upper normal limit x 2.5)|renal dysfunction,local radiotherapy,,,,non-standard local ablative therapy,at least 3 m,greater than 20s,>14 days after initial covid-19,,,,,
1196,,fertility,injection,render the individual unable to independently provide consent,car t-cell,therapy for breast cancer.|patients,,,,"temporomandibular joint, orthopedic treatment",during the study|donated,≥ 18 years)|(2,maximum 15 days before and 5 days after admission to icu)|maximum administration,,,,,
1197,,valve disorder;|urgent hospitalisation,hormonal treatments,willing and capable of,vas assessments,small bowel surgery|patients,,,,2019-related,for at least 24 hours before the study visits,l1 mab.|note,females,,,,,
1198,,gastrointestinal conditions,normal hepatic,sexual partners of childbearing potential,dsm v criteria,active therapy.|participate in,,,,halal,for four months after receiving the preparative regimen|signed,greater than 1cm,gist)|at least one,,,,,
1199,,large cell carcinomas,furosemide,written informed consent|chronic,response evaluation criteria in solid tumors (recist) version 1.1 (appendix b,positron emission tomography,,,,unmanaged,within the last 3 months|unstable angina,abnormalities,once a week,,,,,
1200,,functional asplenia,angiotensin-converting-enzyme inhibitor,situations that would limit compliance with study requirements|receiving,car-t/hct,test panel,,,,criteria:||ambulatory,within two months prior to registration,more than 2 times the upper limit of normal,20 hours,,,,,
1201,,impaired gastrointestinal function|the,allowed.|proton pump inhibitors,any other condition that may increase the risk associated with study participation,etdrs,oct examination,,,,non-inclusion criteria.|ni-7,within 28 days before the start of study drug,≥ 1.5 ×103/l);|platelets,> 4 hours/night 21/30,,,,,
1202,,major organ functions,strong inhibitor,participated in an investigational study,respiratory exchange ratio,endocrinopathy,,,,telephone|a stable,in the first screening of emergency intensive care,higher than 145 mg/dl.|previous,≥1 month,,,,,
1203,,severe drug allergy,amitriptyline,progression of the illness leading the consulting physician to offer treatment,skåne region.||,ivf treatment,,,,preclude delivery of stimulation,at screening.|patients with active,<7.2,20 mg/day,,,,,
1204,,mild bilateral disease,menin inhibitors,established,urine culture,tooth extraction,,,,incompletely,at the time of initial diagnosis|performance status,> 6%);|hemostasis disorders,year 1-5|current enrollment in anesthesiology,,,,,
1205,,acute exacerbation of copd,vaporized,tq,substance abuse|cancer|blood pressure,central laboratory test||key exclusion,,,,iii|undergoing,within 7 days prior to enrollment)|diffusion,"18-65,|having orientation",more than 1 year|willing,,,,,
1206,,parasitic fungal,ecmo,enrolled in a clinical trial,drinking,bladder catheter,,,,nitrile|pregnant,within the past 3 years||excluding fully cured,=< 7 days prior to registration.|requirement,2 or more times per week,,,,,
1207,,terminally ill,anti-tumor radiotherapy,risk of stroke,test result).|requires treatment,breastfeeding|drug treatment,,,,left ventricular outflow tract.|primary liver disease,within 24 hours after burn,< 50 beat per minute)|cardiac morbidities,"daily,",,,,,
1208,,lower extremity rehabilitation,gilenya®,unable to comprehend the extend,apnea hypopnea index (ahi),voided,,,,monoallelic dominant mutation,within 7 days before the first dose of study drug,> 1 g.|pregnancy,more than 4 months before enrollment,,,,,
1209,,hypertensive encephalopathy|significant vascular disease,oral tacrolimus,unable to understand the dutch language|pregnancy,basic cognitive ability test (bcat),preoperative co-morbidities.|provision,,,,flt3-itd testing has been ordered,absolute value(anc)≥1.5×10^9/l(solid tumors,more than 25%,less than 10%,,,,,
1210,,neurologic function.|subjects,injection glucocorticoids,unable to take oral medications.|clinically active,close corrected visual acuity,mental health intensive case,,,,primary vaccination,while on study.||note,score of 6 or above;|voluntarily participate,≥ 100 × 109/l;|hemoglobin,,,,,
1211,,maxillary retrognathism,related products,progressed following radiation,nkle arm index,general practice||,,,,in-office procedure,on the test site.|skin type falling under the fitzpatrick scale skin types,> 2.5 × upper limit of normal,more than 24h apart,,,,,
1212,,endodontic-periodontal,aromatase inhibitor therapy|individuals,physiologically capable,sgot,enteral tube feeds.|non-english-speaking,,,,urinary bladder,more than 3 days a month,≥ 35 kg/m2|risk,20g/d,,,,,
1213,,gastric cancer||,murine proteins,shortness of breath,fish her2 negative);|at least one measurable or evaluable lesion,abdominal aortic aneurysm,,,,low-grade,at least 4 weeks prior to the start of study,"> 2.0 mg/l),|high",2 separate clinical,,,,,
1214,,meld,electrolytes|patients,cohort 3.||,estimated gloverular filtration rate (egfr),ciliary body,,,,non-hospitalized,"during the research process,|serum",0 to 5 years||,≥ 24 weeks before randomization,,,,,
1215,,immunotherapy,eyelid nevus,signed informed consent form|≥ 1 year of age||disease status||patients,surgery|aged,biotargeted therapy,,,,suprapubic catheters,at the time of screening.|habitually wear soft contact lenses,<500mg,at least some,,,,,
1216,,respiratory tract symptoms,lactobacillus acidophilus,cgs of,absolute plasma cell count,chest ct scan||,,,,non-invasive support|suspected,within the last 12 months|significant,> 90 g/,more than 15,,,,,
1217,,bowel resection;|gastro-intestinal ulcers,salicylate-containing products,situations that would interfere with compliance with study requirements,subscale score,tissue biopsy,,,,accurately assessed at baseline,within six months prior to screening visit,iii-iv)|documented,more than 2 consecutive weeks,,,,,
1218,,type ii av block,anti-inflammatory treatments,living in a nursing home|presence,serum creatinine levels,histopathology|missing,,,,medically treatable,within past 2 years|received another investigational drug,45-65|having,t3-4,,,,,
1219,,acute cv19 infection,mucosal protective agents,progression of disease on,hba1 c,ocular herpes simplex,,,,greater than ten (10) days,within 4 weeks prior to first dose;|patients,18-65|pain level,> 2 weeks,,,,,
1220,,ovarian cyst,agalsidase beta,unable to understand the study,visit;|oswestry disability index,emergency use authorization (eua),,,,needle replacement,within the reference range,>= 18 years,efficient,,,,,
1221,,histological validation,fluphenazine,unable to follow protocol requirements,functional status,transarterial chemoembolization,,,,longest diameter of target lesion,in past six months,over 120 beats per minute.|coronary heart disease,≥ 2+,,,,,
1222,,obstructive apnea hypopnea index (ahi),non-arb/acei,volume of disease to allow implantation of the microdevice|patient,plasma ast,ect,,,,etc.|left,within 1 month of scheduled surgery,<2 x 30 min/week).|age,< 2 weeks,,,,,
1223,,autoimmune mechanism,rare,unable to return,evolution||• exclusion criteria||pacemakers|coagulation disorders|pregnancy|active neoplastic,bone marrow biopsy,,,,greenstick,at the screening visit.|participants treated,≤ 4|permanent occlusion.|existence of,more than 8 cups a day,,,,,
1224,,neurological disease|lateral spinal misalignment,calcium channel blocker medication use|monovision,change in physical activity,maximum variation,other treatment methods,,,,skin testing|renal,within 2mm of the spinal,"≥ 100,000",more than mildly reduced kidney,,,,,
1225,,stent thrombosis,salt-restricted,willing to consent to the child participating,gir score,valvular heart,,,,s judgment at screening.||positive pregnancy test,during the time of participation,≥2+ in intensity,>1 day per week,,,,,
1226,,femur fracture|knowledge of the spanish language|24-hour,intravenous bisphosphonates,expected life,rutherford class,oral antiretroviral therapy (art),,,,oestrogens,since the onset of symptoms.|poorly controlled,0-1;|major organ functions,once per month,,,,,
1227,,utis|severe skeletal malformations,bedside echo|patients,risk of infection transmission,ugt,lobectomy,,,,nf1-related intervention,during this onset period;|presence,>2000 iu/ml,500 ml,,,,,
1228,,her2-negtive,pd medications,dyspnea on exertion;|any condition,hepatitis b core antibodies,study|brain surgery,,,,in the absence of measurable,before first scheduled study drug administration,over 6 years old,dose >10mg/ day,,,,,
1229,,reversible cause,hydroxychloroquine,signed an informed consent||exclusion,peripheral arterial disease|black,vascular surgery,,,,distal metaphyseal radius,at time of enrolment).|severe,≥ 1l.|patients must provide verbal,10mg per day or,,,,,
1230,,upper gastrointestinal perforation,anti-hypertensive medication use|measured,hydroxychloroquine|life expectancy,ecog physical status,pause therapy,,,,highly effective starting,within 48 hours prior to c1d1,5 years or less,≥ 10mg/day,,,,,
1231,,hypertrophic scar,cl,render the person unable to comply,new york heart association (nyha) heart function,etc.)|electroconvulsive therapy (ect),,,,apple,within 4 weeks of the first dose of study,≤ 3× uln;aspartate aminotransferase(ast,at least 1 designated symptom,,,,,
1232,,related diseases,contraindicated drugs,signed an informed consent form to participate in the study.||,systolic blood pressure (osbp),cessation pharmacotherapy,,,,ovulatory,in the last 3 months.|have,greater than 3 times the upper limit of,long term,,,,,
1233,,ipsilateral stenoses,acetonitrile,unable to use highly effective methods,mass index (bmi,herbal remedy,,,,multidisciplinary evaluation by neurosurgeons,"within the last 6 months,|lumbar spinal surgery",above the 90th percentile,≤100 mg/d,,,,,
1234,,acute cardiac insufficiency.|acute exacerbation,asa diuretics,breast surgery||,oc-dc vaccines,bone scan defines,,,,injection,within 4 weeks before apheresis,≤ 2|target mismatch profile,>25%,,,,,
1235,,parkinsons disease,low-dose methotrexate,signing the informed consent through,total prostate volume|psa,complete epidemiology,,,,hip joints,during the period of study participation 2,<18 years|inability to provide,2 months|allergic to >3,,,,,
1236,,endometrial carcinoma,polysorbate,failed,intimate partner,ct-scan,,,,ada prediabetes diagnostic criteria,"during the study,|no additional sedation-analgesic medication",34 weeks,5% increase,,,,,
1237,,acute gastrointestinal illness,cannabis,incapable of pregnancy.|of childbearing potential,intensive care unit (icu),smartphone|conditions,,,,mild to moderate acute covid-19 cases,within three months.|patients,under 6 years old,2 weeks prior to randomization,,,,,
1238,,complete intestinal obstruction,chronic corticosteroid,progressed on imaging,single level,pet-ct scan upon completion of all planned bridging therapy,,,,grade ii-iv,more than 24hr|elective surgical admission,> 18-year,more than 20 seconds|patient refusal,,,,,
1239,,familiarity,anti-diarrhea treatment,gluten challenge,response evaluation criteria in solid tumors (mrecist).||must have lab,pharmacological immunosuppression,,,,t,within following 1 year of the dbt,> 130mg/dl,daily ≥20 g,,,,,
1240,,deep brain stimulators.|current,lamotrigine,conceive of,anti-hcv||of,blood,,,,reflux-related,within 2 weeks prior to the first dose of the study drug.|any corneal,class iii-iv,emergency use,,,,,
1241,,neurodevelopmental behavioral disorders,contrast medium,ctca related,cm.|body mass index,herbal medicine,,,,13c-urea breath test,at the time of screening.|possess the hla dr3-dq2 haplotype.|seropositive for gada,0 year,high presev score|pregnant,,,,,
1242,,mini bal,prokera,risk for tb.|any major surgery,fracture,expert reports,,,,lactation;|diagnosed,in the last year.|living with a smoker,40 to,greater than [,,,,,
1243,,non-targetable lesions,azd1390.|patients,tobacco,anesthesia;|surgery time,routine care,,,,except,within 3 months|fractures,35.5 to 37.7,>100 km from,,,,,
1244,,higher)|diabetes mellitus,jak inhibitors,insufficiently understood disease,residual volume,liver failure;|easy,,,,inspiratory flow limitation|predominantly,more than 6 months.|the,25.0-29.9 kg/m2)|pregnant|following,various,,,,,
1245,,t2 staging,mineral dusts,expected remaining treatment duration,hepatitis b virus deoxyribonucleic acid (dna),chemical sterilization|surgical sterilization of the subject or the subject's partner,,,,non-squamous cells,within 30 days before operation|use special balloons,> 7.5%);|present,first and,,,,,
1246,,neurologic deficit,exemestane)||,withdrew,serum folate concentration,prosthetic socket|soc socket made,,,,parent-rated emotion regulation difficulties,within 48 hours.||,≥88%,greater than 5 days per week|walking aid,,,,,
1247,,antibacterial dentifrice,cobalt chrome,unable to comply,recist 1.1.|progressive disease,anemia treatments,,,,peripheral iv catheter placement,in history;|a history of,≤ 1.2 x normal,≥70,,,,,
1248,,stds pathogen infection,ampreloxetine hydrochloride,unable to receive standard therapy,hcv viral load|participants,simple excision,,,,long-term hormonal therapy,within the 24 months before screening with intravitreal (ivt) injections of an,females ≤470 msec|pr,january 2020)||,,,,,
1249,,acute glomerulonephritis,anti-amyloid-beta vaccines|immunomodulators,signed informed consent form (icf),peripheral arterial disease.||pregnancy||asa class,child enrolled in impaact 2036,,,,strictures,in the previous 3 months before enrollment,more than 24 weeks,10 mg od,,,,,
1250,,erythematosus systemic lupus,vitamin d conatining drugs/supplements,noncompliant to treatment,fridericia's formula,translocations,,,,persisted,within the previous 14 days of the administration,≥ 50 ml/min.|patients,2 g/day,,,,,
1251,,neurological level,anticardiolipin anti-bodies,virus|pregnant,serum bilirubin≤,stent implantation,,,,stage iv (t any,through 120 days after the last dose of study therapy.||,at least 6 months|optimum oral hygiene|maximum,same dose,,,,,
1252,,unresectable metastases of the primary colorectal cancer,type ii skull base,female;|expected survival,ckd,traditional therapy,,,,allowed|physiologic doses,in the next 18 months,>=9 g/dl,2 or greater,,,,,
1253,,acute impairment of functional status,lipoproteins,breast-feeding,rutherford's rating,mini international neuropsychiatric interview plus (mini plus,,,,cytological confirmed,during active participation in this study.|willing,no more than 5,recurrent uti per patient report,,,,,
1254,,regular aerobic exercise,pbm,pregnant|suspected child abuse|families,prostate cancer;|the,standard treatments,,,,recommended)|avoid consumption of grapefruit juice,within 30 days of initiation,18.0 kilogram (kg)/meter (m)^2 through 32.0 kg/m^2,more than five years before the start of experiment,,,,,
1255,,diastolic dysfunction)|hepatic dysfunction,angiotensin receptor blocker (arb),birth weight,enrichment,medical attention|current,,,,suitable for taking anthropometric measurements|the use,at least 1 of the following criteria:||serum/plasma prostate specific antigen (psa) progression defined,<4 more than 4%,30g/day,,,,,
1256,,lymphoma,anti-inflammatory drugs,sedentary,bone specimens.|no abnormalities,wasid,,,,dysfunction;|uncontrolled,<180 days prior to study procedure.|severe renal insufficiency,< 2800 cells /mm2|patients,more than needing more,,,,,
1257,,hip prosthesis,vasopressor,errors in data collection,drinks day,laparoscopic sleeve gastrectomy surgery|signed,,,,3-months following course.||,during the 3 months prior to randomization,> 90 ml/min/1.73 m2,partial,,,,,
1258,,neuroretinal disease.|patients,golimumab,life-threatening illness,calculated by cockcroft-gault formula);|for,stimulatory therapy,,,,esophagus||locally advanced,during study,>= 30kg|planned allogeneic hct,1 month|cabg within 3 months|pci within 1,,,,,
1259,,dermatitis lesions,oral anti-diabetic prescription|active cancer|terminal illness|cognitive impairment|pregnancy|cardiovascular disease|inability,bi bleed,nyha grade,kampala district||health centre exclusion criteria:||1,,,,non-oncological origin.||,in veranópolis,55 - 74,>4 mg loperamide,,,,,
1260,,cerebrovascular stroke.|history,avelumab,risk of falling|bone metastasis,alanine aminotransferase(alt)≤2.5×uln,vasectomy||,,,,conventionally,continue for 1 year after all treatment,score is 6-10,≥ 300 µm,,,,,
1261,,solid tumor disease,peptide receptor radionuclide,incapable to provide informed consents,total mayo score,rectal resection,,,,ocular astigmatism,at the time of index surgery|any,< 3.0 mg/dl,once a month,,,,,
1262,,disorder,gastroscopy,irreversible pulpitis||,sharp,cardiac mri,,,,ischemia|significant,for the year prior to study,between 18 and 70 years,maximum allowed dose of 6 g per day.|participants,,,,,
1263,,psychological factors,adalimumab alemtuzumab atezolizumab belimumab blinatumomab brentuximab certolizumab daratumumab durvalumab eculizumab elotuzumab,difficulty in communication,women|body mass index,oral antidiabetic drugs,,,,guideline-recommended bb,5 months after the last dose of,greater than 3%,2 weeks before the start of the,,,,,
1264,,judged by the investigator to be unsuitable for other factors,components comprised in preparations.|diabetics|chronic kidney disease,ultra,psychotic symptoms|are,health evaluation (apache ii) score,,,,reactivated,during the baseline period.|smoking more than 5 cigarettes a day in the 3 months before screening,0-10,2 forms of birth control,,,,,
1265,,clinician impression of red,gallium dotatate,clinical evidence,moderate physical activity,1 supervisor,,,,rare,within the last 6 months prior to the screening run-in,<3 months)|recent surgery,changed dosage of,,,,,
1266,,medical problems threatening,similar cosmetics,signed informed consent;|body weight,fasting hdl-c,radiographic imaging.|target stone,,,,non-myeloablative,within 4 weeks of the first administration of the ip.|chest x-ray,< 3x normal,long term safety,,,,,
1267,,antiepileptic drugs)||ix,b,unable to read english,nct,clear cell subtypes,,,,on room air||renal function,within 6 months after the end of the clinical trial,<5°/sec per ear for each of,regular use of,,,,,
1268,,palliative measures,sodium chloride per vial,alterations in electroencephalogram,urine cultures|contra-indications,interventional psychiatric treatment,,,,pd medications,at the time of treatment initiation,≥ 30 years,2-2,,,,,
1269,,heart arrhythmias,sf-12,difficulty in chewing,syphilis antibody positive,partial hysterectomy,,,,topical use of external steroids,more than 24 months prior to randomization|presence,>100 millimeter of mercury,more than 3 months,,,,,
1270,,hepatoma,initiate cbt,breast feeding|poor baseline health conditoin|disability to complete lung function test|receiving pirfenidone,urine drug screen for illicit,imaging technology,,,,investigators.|stable dose,candidates.|willing,between 10 and 16 years old,≥ 2 weeks prior to the first administration of study treatment.|previous,,,,,
1271,,colorectal neoplasms|patients,btk inhibitor,sleep walking,hyperthermia|body mass index,needing resection,,,,inserted their pessary,within 3 months before administration,above 5 events per hour associated,long term treatment,,,,,
1272,,exists.||for,anti-arrhythmic therapy,risk of hypokalemia,new onset hypertension,adrenal hormone replacement therapy,,,,non-imdc causes|ctcae v 5,prior to enrolment||group 2,at least three months|no,≤10 mg/kg,,,,,
1273,,ascites,regional anesthesia|internet access,stimulants|unstable diabetes|bupropion,/μl|platelets,fusion mapping biopsy,,,,intra-articular disease,at least 48 hrs,≥50% of predicted normal,metastasis.|at least 1,,,,,
1274,,inflammatory eye diseases,topical antibiotic use,consent;|expected survival,sb diameter ≥2.3 mm)|(3),pathological types,,,,adequate organ function,at least 90 days prior,> 450 ms|exposure,≥1000mg daily,,,,,
1275,,img basketball program.|pregnant,medications used to treat,changes in working environment,blood coagulation function,non-small cell lung cancer,,,,refugees,groups.|during one year from the start of the study(6 months,at least 10% is needed,≥ first-line,,,,,
1276,,pregnancy|participation,klh)).|pregnant,unable to fill in questionnaires,urine drug screen.|used,cardiac medications,,,,suitable for ar antagonist therapy,for 3 months after the last dose of study drug,≥1 year|subject,"for more than 48 hours,||suspected vap",,,,,
1277,,skin infection,chondroitin sulfate tablets,healthy,new york heart association (nyha) functional classification class iv,refractive procedures|preoperative visual acuity,,,,c5-l5,at the time of signing the icf|histologically,>65 years,35 g,,,,,
1278,,inflammatory bowel disorder.|current severe,entecavir [etv,risk of diabetes,serology test of hepatitis b surface antigen [hbsag (+)],treated for frey syndrome,,,,maximum tolerated labeled dose,within 4 weeks before the first use of the study drug;|major organ surgery,≥ 59 ml/min/1.73 m2.|eastern,more than 12 months.||'consider' implies,,,,,
1279,,bppv,systemic administration,difficulty breathing|persistent chest pain,dat ≤1+,gnrha therapy,,,,non-business,mutations.|history of b cell related,≥ 3.5 l/min,at least one-line,,,,,
1280,,adenocarcinoma of the gastric,icotinib,never,new york heart association|myocardial infarction,active electrode contact,,,,chronic,within 6 weeks.|start of intake of,more than 400 ml blood,≥ 7 days continuously||patient exclusion,,,,,
1281,,psychosocial disorders,glp-1 analogues,unable to get mri,testing positive for,contraceptive methods,,,,mild episodes.|person not,for at least 180 days after the last dose of study treatment,< 3.0 mg/dl)||adequate,reliable,,,,,
1282,,retinal problems,cytotoxic chemotherapy|willing,cooperate with nurses,serum ldh level,hip flexion,,,,h. prior,during the test period and within 8 weeks of the last drug administration,≤ 8,>10mg,,,,,
1283,,myocardial ischemia,acid inhibitor,risk for suicide,penetrating visceral peritoneum,cardiac angioplasty,,,,140 millimeters,during the trial period and,above baseline pre-pci,changed their ifn-β,,,,,
1284,,spontaneous pain,inhaler medication,living in same house,nar,available standard therapy,,,,sacroiliac joint surgery;|found,at the same time,<1% of all breast malignancies.|pregnancy,1-12 months prior to study enrollment,,,,,
1285,,psychological problems,systemic prednisolone,contractions,serum lipase,hydrogen breath tests,,,,≤16,within 14 days prior to the randomization visit (day 1,between 20 years,>7 days consecutive treatment,,,,,
1286,,verbal,postmenopause,admitted to icu and received,suicidal ideation|t-score,combination of rekovelle,,,,sanofi,six months after leep|no residual material available,<35%|uncontrolled fungal,2 times the upper limit of normal;|patients,,,,,
1287,,sexually transmitted infection,herbal agents,close (,visits.||exclusion criteria - children:||formal,chronic pain|gastrectomy,,,,hemorrhagic,6 months after treatment,≥ 18 years who,outside the target range.|neck pain associated,,,,,
1288,,extensive metastasis,perfloxacin,eligibility,nyha class iv);|have mental disease,total colectomy,,,,non-compliant.|patients,over 2 weeks prior to and,a,> 12 months after injury,,,,,
1289,,menstrual cycle irregularities,medications that prolong the qtc interval,participated in counseling,urine analysis,procedural materials,,,,surgical treatment.||,at least one aeroallergen.||,> upper limit of the reference value,continuous use of,,,,,
1290,,50 bpm,compounds of similar chemical or biologic composition to study agent,refuse to participate/to give consent|presence,nonchildbearing potential|body weight,verbal report.|receipt of the t2 cytokine inhibitor,,,,full escalation,within 30 days prior to enrollment|major,higher than 120 beats/minute.|injuries,≥20 mg/d,,,,,
1291,,- premenopausal,hematopoietic factors,participated in the intervention clinical research in the past 30 days should pass,suicidal behavior section,spirits.|positive smoke breathalyzer indicative of smoking,,,,mild to moderate pd (hoehn and yahr stage i,within 30 days of removal|participation in another interventional treatment study,≥130 ms,at least one vessel,,,,,
1292,,cerebral neurologic impairment,grapefruit juice,change in therapy,icu)||,pittsburgh sleep quality,,,,points;|right-handed.||,during the period 2009-2010,less than 18 years|lower than 5th grade reading level,less than 2 millimeters,,,,,
1293,,pancreatic cystic tumor;|the,component of the sc0245 tablets,unable to understand the study procedures,hbv-dna positive|severe,intracranial tumours.||applicable to children,,,,systemically free,recent,18-99,<14 days prior to the,,,,,
1294,,ciliary dyskinesia,anticoagulants).|participant,s. aureus,diastolic blood pressure [bp],"tomography,|acute myocardial infarction",,,,first-generation antiandrogens,for at least 4 weeks prior to study enrollment,to sunlight,complete online surveys,,,,,
1295,,brucellosis,tobacco products|vapers,signed informed consent obtained from patient/parent/legal guardian/independent witness,urine drug screen,abdominopelvic imaging,,,,full term,for less than 5 years,18 to 80|participate in this study,one dose of the,,,,,
1296,,opv,antigen),incompatible with life|receiving palliative care|patients,medication history||,item 1.a of the nihss).|patients,,,,b,performed more than 5 years ago,> 2.0mg/dl,more than 1 year,,,,,
1297,,ageusia,fine,volume overload|medical conditions,refusal.|body mass index,brain surgery|general anesthesia,,,,pd-l1 positive,past 5 years,>21 days,≥ 1.5 nmol/l,,,,,
1298,,reading,β2 adrenoceptor agonists,render the insertion of a catheter unsafe)|they,ppd skin test,gastric antiacids,,,,glinides,within allowable criteria,between 15 to 25 years|have smoked,1 h&e stained,,,,,
1299,,hemophilia b,wheelchair,expected to continue,gallium,fresh,,,,infection.|severe,in the previous 5 years except,100-139 mmhg,≥10 mg/day,,,,,
1300,,cerebral hernia,hypopneas,fasted,fasting albumin-corrected blood calcium level,invasive ventilatory support,,,,diagnostic and statistical manual of mental disorders fourth edition criteria for schizophrenia,"after week 20, 24",≥ 50,doses,,,,,
1301,,sexually transmitted disease,amines,disorders of consciusness,urinary cultures|shim score,t-cell transfer therapy,,,,amendment 2),diagnosed within 3 months of enrollment,> 2cm,72 x serum creatinine,,,,,
1302,,alteration of any of the following laboratory tests:||serum,progestin sensitive neoplasia.|history,enrolled in another investigational study,interviews with,sahloul hospital,,,,dmds|confirmed diagnosis,in the past 3 months|other,40 - 100 bpm,maximum of 3 consecutive days,,,,,
1303,,hbv-dna<2000 iu/ml,asthma medications,lhrh agonist,estimated glomerular filtration rate ˂,ig cessation,,,,optic,within 28 days before the first dose of study treatment.|central nervous system,i-iii|children,≥ 3 times/week.||,,,,,
1304,,cas,clopidogrel,noncompliance with medication.||unwillingness or inability to follow the procedures outlined,gds-s,consistent dose regimen,,,,ocular surface|any structural change,at least 6 months prior to surgery|literate,≥ 30 ml/min,≥10mg,,,,,
1305,,immune deficiency,hpv vaccine,infection.|history,"hepatitis b surface antigen (hbsag),",health deterioration,,,,could delay healing,at the time of study|medroxyprogesterone acetate,≥ 2.0*,20 g of alcohol,,,,,
1306,,active myocarditis,over,unable for fmt,sclc,hbv vaccination,,,,peri-operative,in the next 2 years,< 90 on,≤ 2,,,,,
1307,,non-hospitalization,anti-sperm antibody (+),person with covid-19 infection,classification of,tte,,,,below the functional occlusal plane|incisor,within 52 weeks after,≤ 5 times uln,1 to 1.5 years survival,,,,,
1308,,aortic regurgitation neck width,anti-tumour indication,etc.);|has,stress cardiac echography,communication treatment,,,,relapsing ms,on the patient,<100 m,more than,,,,,
1309,,hospitalization)|symptoms,crcl,prevention for cardiovascular disease|hiv,hcv dna,biological products,,,,wide-local excision,in the last 6 months|parkinson's disease|history of,> 1000,≥ 6,,,,,
1310,,facia,leukotriene inhibitors,"""stable"" diabetes mellitus",hasbled score,pedobarographic evaluation|those with flexible pes planus|have more than 10 mm,,,,hinged,within 30 days prior to the first dose of,18-75,<1 month);|bariatric,,,,,
1311,,patients|active hepatitis infection|patients,non-steroidal medications,subsides,hepatitis b surface antibody (hbsab) test,back surgery syndrome pain,,,,disorders|self-reported,within 14 days prior to first dose.|has,below 15,at least 4,,,,,
1312,,end-organ t2dm,antihypertensive medications.|participant,faculty|to,left ventricular ejection [lvef],robotic bronchoscopy,,,,hemodynamically unstable,in the past 2 years prior to the surgery,55 -75 years,≥ 1 line,,,,,
1313,,tte|cardiac,β-adrenergic receptor blockers,sleep apnea|history,angle,vaginal hysterectomy,,,,hyperarousal,in the last 12 months|rbc transfusion,>400 pg/ml,once-a-day,,,,,
1314,,inadequate quality,baseline.|baseline pn-related,unable to read,partial thromboplastin time were,percutaneous paravalvular leak closure,,,,qtc formula,within 6 months prior to baseline.|major surgery,greater than 40.0 kg/m2,greater than 450 msec,,,,,
1315,,bleeding history|cardiogenic shock,recombinant thrombopoietin,unable to swallow pills,stress scale,t-spot test,,,,age|previously treated,within 28 days prior to screening visit,between 18 and 89 years old,< 140/90mmhg by 24,,,,,
1316,,alcohol abuse|recent head traumas,multiple medications,cease smoking,north american symptomatic carotid endarterectomy,supplemental oxygen|known,,,,multiple-session protocol,emergency ≤ 6h,0 or 1;|adequate,8 x uln,,,,,
1317,,laundry,cyclosporine.|participants,unhealthy diet,cooperate|chest drains|pneumothorax,whole-body pet-ct scan,,,,study|adequately,within 120 days prior to first dose of study agent.|any,17 and below|unfortunately,only for subjects,,,,,
1318,,vestibular symptoms,topical ocular corticosteroids,render the participant,ckd-epi creatinine equation refit,venous cannulation,,,,secondary to,at least 48 weeks)|signature,≥40 ml·kg-1·min-1,>= 1 week prior,,,,,
1319,,autonomic involvement|other types,ventilation,risk for undertaking physical activity,physical activity readiness questionnaire (rpar-q,world health organisation,,,,stage 2-,at the time of informed consent no longer fulfills the psychosis criteria,over 180mmhg,≥1 mg/kg,,,,,
1320,,limiting physical disabilities - to the extent that they,|systemic steroid therapy,organs,aalborg university hospital,metallic screws fixation,,,,pd-l1) analysis,within 2 years,less than 37.3 ℃,1 drink / day or more than 2,,,,,
1321,,hepatitis c virus,anticholinergic,situations that would limit compliance with study requirements|unwilling,google play stores|ability to lie supine,critical value);|physical examination,,,,delivery unit|37+ weeks gestation|planned vaginal delivery|planned,in at least one eye,> 500 cells/mm3,≥ consecutive,,,,,
1322,,pathological q waves,cytotoxic chemotherapy.|patients,diagnosis,risk estimation,abdominopelvic ct,,,,postmenopause,before the five week follow up|unsuitable for inclusion,> uln|total bilirubin,twice a week,,,,,
1323,,nervous system disease|asa iv|emergency surgery|patients,suppository,caring,old;|cd19+,surgically,,,,mid face volume deficit,at the time of the study||ii,180 to 545 days,more than 5 days after the occurrence of the first symptom,,,,,
1324,,connection|receiving regular diabetes,uterine,children||,3uln;|left ventricular ejection fraction,chronic care model.|patients,,,,thoracic cage,before operation.|complete auxiliary examination,minimum 2 years follow up.||,"more than """,,,,,
1325,,dme,opioid addiction,life-stressor exposure,response evaluation criteria in solid tumors 1.1,alv.|contraindications mentioned,,,,supplies,72 hours prior to visit 1|have,18 - 80|able,≥5.0 x uln)|has,,,,,
1326,,solid organ transplantation.||5,lacunar,wb-ems,forced expiratory volume in one second (fev1)/fvc < 70%,resolved,,,,buccal mucosa,recently,>= 3 months prior,2 or fewer defecations,,,,,
1327,,self-awareness,transforming growth factor β-1 gene|patients,british columbia recreation,pet/ct|pathologically,exercise regimen significantly,,,,papulopustular rosacea)|age spots/telangiectasia||telangiectasia,7 days prior to and,3-5 years,≥ 28 days prior to screening,,,,,
1328,,electrical injury,dawnone,scoring,addiction care services,resuscitation,,,,function.|third year of,upon admission within the last 3 months.|a,blunted taste responses,more than 4 weeks,,,,,
1329,,ureteral calculi,antiangiogenic agents,lack english language capability,egg protein,preclude surgery,,,,low level laser therapy,within 6 months prior to enrollment,≤ 400 mg/day,at least 3,,,,,
1330,,pullback fails,confirmatory,cohort 1 and 2:||1,serum creatinine (scr) ≤1.5×uln,walk overground,,,,peptic,within 24 hours before visit 2.|have active,≥40 years referred,daily exercise,,,,,
1331,,developmental impairment,someone,progression of disease,mgh cancer,gi,,,,dislocated,during the study period;|gastrointestinal disorders,between 21 and 38 years old,for at least 48 hours,,,,,
1332,,tendons,g719x,bcg.|life expectancy,epinephrine,topography method)||,,,,maximum pain intensity,before or first onset during pregnancy,≥ 5 μg/l||,2 accessible non-adjacent teeth,,,,,
1333,,chronic gastrointestinal (gi) diseases,drugs affecting the psychiatric system|have severe visual,life expectancy,telemedicine consultations,transarterial embolization (tae),,,,high dose busulfan,prior to inclusion,> 80 ml/min/1.73 m2||no proteinuria,30-day safety,,,,,
1334,,vigorous physically activities,ivt,cockcroft-gault formula.|for,diabetic retinopathy|diabetic macular oedema|macular oedema,intraocular lens.|patients,,,,second-generation,at the time of signing the informed consent|antiparkinsonian medications,between 18.5 and 24.9kg/cm2,≥ 60 days and ≤ 4 years,,,,,
1335,,kidney disease kdigo,over-the-counter solutions,contrasts|incompatible implants,estradiol levels consistent with menopause,surgical sterilization of the subject,,,,scores of,in the past 6 months|use,greater than their chronological age||,higher than 45 ml/mn,,,,,
1336,,dependent persons|patient,mrna drugs.|have,life threatening,urinary flow rate,radiotherapy treatment,,,,irresectable,in the shoulder region,>1000 mg/dl,≥2.75mm|target,,,,,
1337,,incorporating,bendamustine,constipation,musculoskeletal)|calcium,suppressive treatment,,,,non-intervention,after 6 months of treatment.||,> 38.5℃ fever,trial,,,,,
1338,,emergency medicine,sarcomas,collections,syphilis test positive;|serious heart disease,surgical shunt,,,,mycobacterium tuberculosis,during the study period.|in the case,sf®,more than 2 times the vessel diameter；5 points,,,,,
1339,,papillary thyroid cancer|patients,analgesic drugs before surgery,breastfeeding.|any other condition that,kaiser permanente northern california (kpnc),sperm donation from initial drug administration until 90 days after the last dose of study drug.|females of childbearing potential,,,,over,within 6 hours before tewl assessments.|willing to not apply any moisturizers,between 60 and 80,greater than or equal to 12 months of amenorrhea,,,,,
1340,,hashimoto syndrome,denovo,radiographic intrabony defect,gaenslen's test,dental x-rays,,,,non-neuroendocrine,at the time of screening visit.|in,≤ 10.5%,1 or higher adverse reactions,,,,,
1341,,parenchymal hemorrhage,target stone,breast cancer.||-,hole population -||exclusion criteria,diagnostic biopsy,,,,aed,within 45 days of randomization|planned medical treatment of all qualifying non-culprit lesions,0-1.|subject,2-3,,,,,
1342,,spinal traumata,dextrometropine,lang,nci-ctcae version,radiation treatment involved,,,,crcl,at least 2 hrs before administration of an h2 blocker.|treatment,stage 0,half-life,,,,,
1343,,arrhythmias - valve disease,io,psychiatric care|protected,households,produce abnormal sunlight responses.|history,,,,dietary requirements.|subjects,within 6 months from study enrolment,≥3|contraindications,dose equivalent to > 10 mg/day,,,,,
1344,,upper gastrointestinal anatomy,serotonin,wean criteria|written informed consent from the patient or his/her legal representative||,attenuation parameter,global initiative for,,,,procedure|pre-existing,within 28 days prior to enrollment;|new york heart association (,"≥ 60,000|hemoglobin",at least 2g/day,,,,,
1345,,chest pain condition,saline,humanized antibodies|known hypersensitivity,glycated hemoglobin of 7%-9.5%.||,treatment modality,,,,vitamin b deficiency|previous medical cannabis,within the first 3 months,45 to 55,alt≤ 2 x uln,,,,,
1346,,radiologic bone loss.||gingivitis,hs,volunteers|bmi,hbv dna becomes,small bowel resection,,,,endocrinopathies,within the past 6 months|the,>18 yrs|diagnosed,≥ 5 mg,,,,,
1347,,sleep score,danazol,adjuvant therapy.|the first lymph node dissection,ecog gr,presacral neurectomy|concurrent surgical procedure,,,,influence ocular health,in the fellow eye than in the study eye 2,greater than 4|patient,>20 consumptions,,,,,
1348,,typhoid vaccine.|seasonal influenza vaccines,psychotropic medications,participates,gross motor function classification system,color duplex sonography,,,,could cause the angiographic,less than 4 weeks before screening|known,1 or 2,more than 8,,,,,
1349,,traditional medicare,xanthine,radiation exposure,50%|hemoglobin,sub)mucosal dissection|distant metastasis,,,,≥1 year,within 3 months|with,≤ the upper limit of normal.|vital signs,greater than 10,,,,,
1350,,irm,thorazine,contradiction to trns,kidney transplantation|ongoing aki,ovulation|blastocyst embryo,,,,without effective contraception,prior to initiation of radiation therapy (standard protocol for,> 0.5 g/l|patients,mri||,,,,,
1351,,pregnancy.|venous thrombotic event,microsoft teams,consistent with pre-vious covid-19 infection explaining,american thoracic society (ags) / european respiratory society (ers) / japanese respiratory society (jrs) / latin american thoracic association,manipulation techniques.|implantable,,,,highly effective contraceptive method,within 1 month of visit.|visit 1 person who consumes vitamins,> 150/90,≥ 10mg,,,,,
1352,,asymptomatic qt interval corrected (qtc),clofazimine,situations that would limit compliance with study requirements.|history,immunohistochemistry,nonspecific,,,,unable to receive,within 6 months prior to study entry|documented,above uln).|estimated,20 mg of citalopram,,,,,
1353,,perineal pain,photosensitizing medication,situations that would limit compliance with study requirements.|4,hepatitis c virus antibodies,tasc working group,,,,under general anesthesia|access,more than 6 months|pre-transplant,above 18 y old undergo,less than 14 days before enrollment,,,,,
1354,,seizures.|patients,drugs used in the study|subject participating in another clinical study|adults under guardianship,cohort a - mac,partial trisomy 21,artificial knee,,,,numeric pain scale,within 5 year prior to screening,> 30 kg/m2,≥2 new,,,,,
1355,,steroids.|diabetes mellitus type,microcrystalline cellulose,difficulty understanding the study,blueshield|anthem bluecross|empire,dienogest treatment,,,,poorly differentiated.|follicular,within 48 hours before the first dose of the study drug.|intake,below 6 years or above 18 years,subsequent cycle of,,,,,
1356,,parkinson s disease,treatments,risk for tuberculosis,creatinine,cassini topography devices)||,,,,mci.|self-reported,during pregnancy|< 6 months,class ii or iii,two times the upper limit of normal,,,,,
1357,,hepatitis c infection.|patients,mercury,cohort a||healthy volunteer|>18,influenza)|bmi,cardiac ultrasound,,,,amenable to sbrt,prior to the procedure,≤1.5 x upper limit of normal (uln),fewer than 3 hours,,,,,
1358,,traumatic malocclusion|pregnant,athletics,consistent clinical symptoms.|informed consent is given by the patient or the legal representative.||,suitable tissue sample,lung consolidation,,,,non-english speaking|unable to swallow,for at least 4 weeks prior to randomization into the,<12 months|severe calcification,more than 270,,,,,
1359,,neurological degenerative disease;|night shift,regional block,enrolled in another clinical trial.|any other factors,kidney function abnormalities|colorectal,stable treatment,,,,central nervous system effects,within the range 18 to 35 kg/m2,12 through 17 years,dose equivalent to > 10 mg,,,,,
1360,,dry eye syndrome,focus,life-sustaining equipment,males.|for gh treatment,barrier laser,,,,uterine,within 24 hours before inclusion|whose consent to participate in this study,≤ 2.|patients,at least 1 month before check-in (day -1,,,,,
1361,,treatment|unstable angina,nicotinamide adenine dinucleotide (nad),participated in related research projects will be excluded from this study,months;||major organ functions,rapid antigen testing (rat),,,,infective,within 12 months of study enrollment|normal,18.0 - 74.9 years,more than 0.4 l per,,,,,
1362,,obstetrics）stage|physical condition,strong cytochrome p-450,change lifestyle (diet and/or exercise,national dpp.||a. dpp inclusion criteria:||1) bmi,allogeneic hematopoietic stem cell transplantation.|drug abuse,,,,sponsor.||adequate organ function:||renal,more than 1 year ago,6-11 years,20mg twice daily,,,,,
1363,,madison,renin,excess alcohol intake|recent cvd event (< 3months)|relevant liver disease,asa score,mgus,,,,oxford scale,in the last six months|not being willing,≥50 kg.||,greater than 150 minutes/week,,,,,
1364,,deep vein,computer||inclusion criteria,phobia,load blood glucose,smokeless tobacco use,,,,aims 1 +2):||patient,within 90 days prior to screening;|intraocular surgery,≤ 30mmol/l,multiple pre-existing,,,,,
1365,,acute optic neuritis,neuroendocrine,seropositivity|concurrent,functional classification,xanthan gum,,,,consents,after failure,18 - 80 years,greater than 5 days per week;|current smokers,,,,,
1366,,thrombophlebitis,nsaid,affect interpretation of the results of the study,cyst,birth-control,,,,know serious,during the entire study treatment period|for subjects,"at least 12 weeks,|an akle brachial index",> 1/week)|chronic,,,,,
1367,,pimples,ifnα for antecedent pv,render the administration of the investigational product hazardous,gastroenteral bleeding;|known hypersensitivity,activities specific balance confidence scores|demonstrate,,,,long-term toxicity,for at least 4 weeks before screening,<10%,subsequent,,,,,
1368,,pfbc,combative,unable to communicate in english,prostate fusion biopsy procedure,infection|immunosuppressant therapy|coagulation disorder|surgery,,,,unknown effects with,at time of signing the informed consent form|histologically,=< 1.5 x the upper limit of the normal range,30 days.|leukotriene antagonists,,,,,
1369,,acute tb|has,ocular medications,situations that are,blood glucose level,6-hour wash-out,,,,site investigator|allery,within the last 6 months.|subjects,greater than 80 mmhg,1.5 x 103 /cc and 1500/μl);||platelets,,,,,
1370,,neurologic disorder|current,slums,entry into this study.|pregnant,insomnia severity index|>2.5 kg additional weight loss,facilities,,,,ivt,"last 24 hours"" in the brief fatigue","≥ 75,000 per mm3",more than one unit,,,,,
1371,,crystal arthropathies,retinoic acid,premature ventricular contractions,meld,mini international neuropsychiatric interview (version 7.0.2)|active suicidal ideation|current,,,,self-care behaviors,"during, and after treatment",> 500 cells/,≥500 μg/l|soluble,,,,,
1372,,non-tuberculous mycobacterial (ntm) lung disease|acute infection,conventional full acrylic-based,the activity of cyp3a in the liver,autoantibody status,cag for,,,,csf))|persistent,at the cleveland clinic o all altruistic living donors,"<30 ml/min),|moderate-to-severe",≥ 4 daily,,,,,
1373,,tympanic,anti-iga,meeting the inclusion criteria,body mass index comprised,photographic,,,,researchers|primary,at the time of enrollment.|participant's,> 14 units,physiologic doses ≤ 0.2 mg/kg/day,,,,,
1374,,sp).|intact rotator cuff,angiotensin converting enzyme 2 (ace-2),dietetic plan,iii|mas score,hypertension)|pregnancy,,,,conditional,for at least 1 year prior to baseline,18-years,https://www.omnicalculator.com/health/blood-volume|long term,,,,,
1375,,gastrointestinal dysfunction,age|participant,remain in the study.||if sexually active,boston scientific genus/gevia|unable to complete follow-up visits|dbs brain targets,"implant site,|periodontally",,,,mild persistent asthma,within one week before operation|severe cardiac dysfunction,between ≥ 15% and ≤ 40%,>30 days,,,,,
1376,,randomization;|fibromuscular dysplasia,illicit drug,participated in other interventional,trial).|body mass index,antimicrobial treatment,,,,clinically cured,within 48 hours prior to taking the study drug,between 18.5 and 24.9 kg/m2.|patients,>10 mg/day,,,,,
1377,,depressive symptoms;|the,noninsulin anti-diabetic injection therapies,signed informed consent form;|male,i̇ntracranial mass surgery|craniotomy|asa,breatfeeding|positive breath test,,,,women|other,during their first-line therapy|all,≤ 2.5 × uln.||follow,≥ 16 h/day,,,,,
1378,,associated cause of liver disease,antiplatelet therapy,impingement,"anti-hypertensives,|treatment",control blood pressure|the,,,,high-dose methotrexate,within 2 weeks of receiving ultrasound delivery|history of,≥3 at 2 or more,≤100 mg/d)|those,,,,,
1379,,partial cystectomy.|prior malignancy,contraceptive foam,enrolled a sufficient number,criteria below:||hepatitis b virus (hbv):,echocardiography showed,,,,epilepsy;|uncontrolled,over past 30 days prior to visit 1,from 18 to 70 years.||,one year|on multiple daily injections (,,,,,
1380,,benign gynecologists,medications containing,volume),braf v600e,lumbar laminectomy,,,,low,at time of screening endoscopy,> 0.5 ng/ml|fiv/,>170/110mmhg)|uncontrolled,,,,,
1381,,skin colonization,immunosuppressive steroids,dyspnea on exertion|stable clinical condition,partial thromboplastin time (ptt)/ activated ptt (aptt),1;|carotid artery ischemic symptoms ≤3 months before,,,,arid1a,during exercise.||,<50% they,3 separate,,,,,
1382,,months|pulmonary hypertension,amino acid substitution,genetic susceptibility,ilae,plasma-lyte® 148 are considered appropriate fluids|blood glucose level,,,,third molars,within 28 days prior to the first dose of zanubrutinib,between 25 and 70 years,ssw)|six or more,,,,,
1383,,communication issues,nicotine products.|drug,working,promis measures|t-score,contrast brain magnetic resonance imaging (mri),,,,minimally invasive nasal trabeculostomy system,within the next 12 months from the run-in visit.|addison's disease.|hepatic insufficiency classified,> or = 150 mmhg,at least 12 weeks duration,,,,,
1384,,ischemic heart disease.||for,component of the dengue vaccine,cooperate with assessments,period).|age,hematopoietic growth factor,,,,foodvalley in the netherlands|interested in combined lifestyle programs,prior to enrolment allowed)|neutrophil,greater than 0.3 grams,maximum of 2,,,,,
1385,,procedures|able to read,monoclonal antibodies],whose partners plan,lv ejection fraction,drug treatment related,,,,li-fraumini syndrome,within 6 weeks of enrollment.|presence of,january 2020-2021.||,|concomitant,,,,,
1386,,acute symptomatic seizures,sphincterotomy|percutaneous liver biopsy|biopsy,need of care,study|american society of anesthesiologists (asa) physical classification,immunomodulatory therapy|prior allogeneic transplantation|hsct graft dsa ≥3000 mfi|current,,,,investigator.|active systemic,palsy.|under 4 years and over 18 years.|participants,≤ 29.9 kilogram,25-35 days length)|in,,,,,
1387,,wolfram syndrome,btk inhibitors,change in glucose control medications,urine m-protein,technical reviews,,,,moderately hypofractionated,lasted 96 consecutive hours or more prior to baseline,> 91%.|left,frequency of delusions,,,,,
1388,,actively breast feeding,implantable)|intrauterine devices|intrauterine hormone-releasing systems|vasectomized partner||barrier,unable to understand or communicate in english|serious mental health problem|unable to give informed consent,neutrophil count (anc),telemetry,,,,adequate organ function||absolute neutrophil (,at least 6 weeks before the start of the study therapy,25-30 kg/,≥ 500 ng/ml,,,,,
1389,,metal,pcv,volume ≥70ml,hcv antibody,treatment for aml: for disease control,,,,"uhmwpe allergy;|is mentally incompetent (if questionable, obtain psychiatric consult);|is a prisoner;|is pregnant",at the time of signing informed consent.|body mass index,grade 0 or 1,8）at least 1,,,,,
1390,,malabsorption disease,great vessels,violence,mva,complete resection of any type of carcinoma in situ,,,,implantation of any drug,within the current episode,at least 5 years;|willingness,≥ 1 prior,,,,,
1391,,thoracic endovascular aortic aneurysm repair,mandarin,cttp,predicted vital forced,coronary artery bypass grafting,,,,mg);|acute,at least 3 months prior to study start||,≥18 years|normal,high dose,,,,,
1392,,major episode,anti-pd1 immunotherapy||,unable to understand the contents of the questionnaire,alt (gpt),radical excision of,,,,term,within 60 days prior to visit 1.|have,>=45.0 kg,daily low dose,,,,,
1393,,several distinct cutaneous sites,vasovagal syncope||,family planning;|patients,serum pregnancy test.|6,nicotine replacement therapy,,,,used,within the last 3 months|patients,=< 3.0 x uln|no,lower than -6.00d|coexisting,,,,,
1394,,cm;|unhealthy habits,lidocaine patch,changes in medication).|naïve,american association for the study,bile duct syndrome||aspartate aminotransferase (ast),,,,diagnostic and statistical manual,greater than 6,>/= 3 weeks of,less than 4 months ago.|sars-cov-2,,,,,
1395,,pathogenic variants of cyp4v2,silicon,signed informed consent obtained,y-chromosomal material,alternative methods,,,,without neck,discontinued at least 2 weeks before first dose date.|recovery from the adverse effects,>1000 ng/ml|white,100 mg/day);|platelet count,,,,,
1396,,floor of mouth,olive leaves/olive oil|use,difficulty to apply exercise program,her2-positive breast cancer,injection into the affected knee joint,,,,neuroendocrine,within 7 days prior the randomization|must voluntarily sign,≤ 14%,>15 min,,,,,
1397,,etc.;|syphilis,immobilization,nonsurgical,ent,local regulatory requirements.||,,,,protocol|hemodynamic instability,at the time of sars hospitalization,>=50,>100 mg daily)|fish oils,,,,,
1398,,malignancy|pregnancy,portal-systemic shunt procedure,change in medical therapy,prostate specific antigen,curative-intent,,,,c.|active,over 3 weeks duration,more than 10 packs/year;|17,2 mg film/tablet done before visit|willingness,,,,,
1399,,cognitive impairment|brain,prp,available curative therapy,diffusion- weighted imaging (dwi),laser therapy|eyes,,,,ecog-ps,"at the time of enrolment,|must",at least 24 weeks.||the patient,= 2 mg daunorubicin,,,,,
1400,,csf||,aminoglycosides,comply with program,lems,sts,,,,hormone therapy|karnofsky performance score (kps),for 8 weeks after last imp dose.|non-smokers,less than or equal to 10.0 percent,≥ 50%|target,,,,,
1401,,site of cancer,stiripentol,risk of preterm birth,rutherford-becker,testing procedures,,,,enrolled):||positive result of hiv antibody,within one month.|those,< 3|english-speaking|with,> 1 year,,,,,
1402,,visceral metastasis;|8,mucosal malignancy|scheduled to undergo treatment for their malignancy,unable to sign informed consent,uln).|body mass index,astct criteria).|no tocilizumab,,,,"alter the absorption, distribution, metabolism",within the 4-week period prior to screening|history of,">= 1,500/mcl|hemoglobin",≥ 4 weeks.|radiation therapy；≥ 4 weeks,,,,,
1403,,chest drains|presence,filgotinib treatment||,signed informed consent form and assent form,recist v1.1 30,tubal ligation/salpingectomy,,,,icd-10 f43.1|pcl-5 score,within 12 months prior to providing informed consent,>500 ms,doses equivalent to > 10 mg,,,,,
1404,,respiratory viral infection,genitourinary,unable to understand the purpose,pma,liver biopsy,,,,≥37 weeks,7 days prior to initial dosing;|cardiovascular diseases,≤ 2.5 x 109/l|neutrophil count,approved or investigational,,,,,
1405,,benign etiology,inflammatory arthritis|a,affiliation to the national,diabetes)|body mass index,complete median sternotomy,,,,interfering with cognitive performance,5 months to <8 months,≤ 70 mm hg,590 mg of,,,,,
1406,,hematopoietic system disease,age|indication for surgical extraction,living in the greater victoria area,t-vec,local regulatory authorities,,,,identify the target volume and may determine uncertainties in cirt dose distribution,baseline,≤ 2.|subjects,at least 1 year of treatment,,,,,
1407,,right bundle branch block,agents used in the study|individuals,unable to perform step training,urine protein>1+ receive 24-hour urine protein quantification,hormonal therapy -,,,,grade iii and iv according to nyha),before oocyte retrieval|recipient,after surgery.||,more than 5 half-lives).||subjects,,,,,
1408,,wegener syndrome,lopinavir,unable to complete the initial assessment,mmhg)|diastolic blood pressure,pharmacological treatment:|anti-inflammatory drugs,,,,10-year,within 7 days of the planned date of ip administration.|for sad,54-60gy,more than one episode of,,,,,
1409,,curatively malignancies,component of the formulation||history,sleep disorders||,blood tsh,pelvic node dissection,,,,salbutamol)|inter-hospital,within 6 months prior to randomization;|subjects,>= 3 uln,≥ 0.3mg/,,,,,
1410,,cytogenetic,hip|participant,entry into this study.|pregnancy,glomerular filtration rate estimation.|participants,treatment|life-expectancy,,,,region|another aetiology of neuropathy|previous allergic reactions,within 7 days prior to check-in.||other exclusions||receipt of blood products,18 - 55 years|body mass index,single dose,,,,,
1411,,orofacial pain,surgery|patients,genetic evidences,old|symptomatic multi-level degenerative cervical spondylosis,homicidal,,,,stable use of,at time of enrollment|singleton gestation - defined,0-1||adequate hematologic,≥2 moderate exacerbations,,,,,
1412,,neurodevelopmental deficiency,sulfasalazine,never smoked,c|child-pugh classification,endosseous diameter,,,,stage iv breast cancer.|performing regular resistance,at least 12 months,score of 600 or more,therapeutic doses of lmwh,,,,,
1413,,astrazeneca staff,ophthalmic medications,risk of harm to the fetus,lmf,psychological state,,,,intra-nasal,prior to completing,≥ 18 years;|suspected,2-5 minutes,,,,,
1414,,candidiasis,d0,clinical involvement;||,urine test completed,produce uptake in organs,,,,once treated,for at least the last 6 months|diagnosis,≥32 weeks)|having an anomaly,≥ 8 cigarettes/day,,,,,
1415,,impaired communication,immunosuppressive medication.|patients,meet the inclusion criteria.||teacher inclusion,hepatitis b core antibody [hbcab],corrective cardiac surgical,,,,primary problem|≥,within 2 weeks prior to enrollment,< 50%)82.|severe hypoxaemia,maximum of 5 years before starting cbct,,,,,
1416,,intestinal ulcerative disease,oral contraceptives containing oestrogens should,refused to participate in the study,liver fibrosis;|no,modification of diet in renal disease (mdrd) study equation,,,,neurological damage|（6）previous,prior to diagnostic,> 23|no,moca);||,,,,,
1417,,posterior communicating,peptide receptor radionuclide therapy,managed by watchful waiting,estimated birth weight,intramuscular vaccination,,,,potentially effective,for ≥ 4 weeks,> 1:1000 by,≥ 3 kg,,,,,
1418,,unusual site thrombosis,mtx,progressed in response,plasma aldosterone,electromyography,,,,chemically related,in the last 6 months before the first assessment,≤2.5 cm,greater than (>)2,,,,,
1419,,heart-valves,protease inhibitors,cockcroft-gault|urine protein/creatinine ratio (upcr),dsm axis i disorders,health center.|not illiterate,,,,stage 4,for three consecutive days)|medically cleared,32-38 weeks,≥ 7.5%|blood creatinine,,,,,
1420,,diabetes type 1,vaccine ingredients,unable to receive the study treatments,syphilis spirochete antibody,lower abdominal surgery,,,,non-hormonal contraceptive,during the last three months before entering the study.||absence of coagulation,≥60y||,2-month,,,,,
1421,,sid,compounds of similar chemical or biological composition to calcipotriene,unable to lie supine,memory complaint scale,imaging study,,,,middle-aged,natural history,< 150 minutes per week,>14 days,,,,,
1422,,enrolment.|congestive heart failure,oxaliplatin,centers|english-speaking,gema,ophthalmological examination,,,,could significantly affect the pharmacokinetic,recent 6 months,score of 19 to 28 pts,mri||at least two,,,,,
1423,,pulp sensibility,laser treatments,histological evidence available|patient,rv ejection fraction,regular consecutive cycles,,,,without,within 2 weeks before giving the first dose of medication|patients,≥1.0 × 109/l,dose equivalent to >10 mg,,,,,
1424,,diabetes)|uncontrolled pain,sidabamine,remain in a stable,stated)|normal blood pressure,undertake emergency operation,,,,authorized,for at least six months,greater than 0.5,≥ 1 intrabony,,,,,
1425,,intense orofacial,non-selective pi3k inhibitors,sleep disturbance,response evaluation criteria in solid tumors (recist) version,glioma|radiologically,,,,contagious,within 2 weeks before randomization.|subject expects to be,between 0 to 2||,>10 mg qd,,,,,
1426,,physical problems|females,several agents,unable to consent for themselves,hemoglobin dropped,bone marrow transplantation/hiv,,,,fracture,in the previous three (3),≥ 9 g/dl||adequate,greater than 5,,,,,
1427,,rhinorrhoea,peg tube,progression of lesions,gh stimulation tests,mpa procedures,,,,sars-cov-2 n-protein,for at least 1 year|at least primary school,greater than 15° will be included in the study.||,second dose,,,,,
1428,,intra-cranial progression,medication that the investigator believes would interfere with the objectives of the study,sexual partners are,larimer county,radical treatment .|in,,,,section 6.5.|pregnant,prior to projected completion of prehab exercise intervention|current pregnancy||exclusion,>= 8.0 x 10^9/l,more than p3cs,,,,,
1429,,icr,hematopoietic,unable to participate,prostate puncture,colonic endoscopic polypectomy,,,,disclosed on health assessment form which mean that participant is not healthy|allergy to lidocaine|allergy,within 30 days as demonstrated,requires icu care (3,2 hours after a 75 g glucose load,,,,,
1430,,"dry eye symptoms (dryness,",age.|baseline ecg,life expectancy from the clinician's point of view|health problem limiting ability,iiic disease.|histology described,fiberoptic laryngoscopy,,,,for current infection)|uncontrolled anxiety disorder,before enrolling at baseline day 1|participant,> 2.5 x,more than one episode,,,,,
1431,,retinal breaks (mrbs),tbsa,iagnosis,fetal heart rate baseline,palliative care|older,,,,generations 2,in the 2 weeks preceding screening,>190 mgdl-1,fewer than 4,,,,,
1432,,phrenoblabia,live vaccines.|current treatment,family visits,failure rate,ventilatory reasons.||,,,,lymphoblastic,since the last,≥ 2600g|informed consent,recurrent lifetime history,,,,,
1433,,i endometrial cancer,radioparticle implantation,cytologic evidence,ecog performance scale,mechanical ventilation|shock occurs|combined,,,,genitourinary,in the last 6 months);|is pregnant,>ii.||patients,more than 2 years duration,,,,,
1434,,oral cancer,adolescents (ipt-a,mrsa,spontaneous tidal volume,general anesthesia periods,,,,kosher,at the start of treatment,>= 18,at least 20 teeth.|non-smokers.||,,,,,
1435,,psychiatric diagnosis|receiving,erlotinib,body-mind therapy,rai refractory thyroid cancer,tumor resection,,,,diagnostic criteria of coronary atherosclerotic heart disease,within the last 6 months before the initiation of the study,1 year after the car t-cell infusion,fdopa,,,,,
1436,,head and neck radiotherapy|patient,bexsero® vaccination,breast feeding|written informed consent||,inferior alveolar nerve,endoscopic examination,,,,iv,last at least 2 months,equal to (4 - [,regular intake of more than an average intake,,,,,
1437,,nsgct,anti-tumor indications)|have,patient,aspartate aminotransferase /alanine aminotransferase,once enrolled,,,,grade 2 and above,within 1 year prior to screening|pregnant,less than 4|being between,≥ 50kg,,,,,
1438,,ankylosing spondylitis|factors,calcium channel blockers,unable to safely substitute,cerebral blood flow (rcbf),etc|patients,,,,observable,for at least 12 consecutive months,measured greater than the 95th percent,≥ type c)|(3,,,,,
1439,,bidimensionally measurable lesion,gep net|concurrent anti-cancer treatment,close relatives of people with epilepsy,thyroxin ft4,gastric resection.|participants,,,,non-union,before enrollment);|hematopoietic function,18.0 kg/m^2 to 32.0 kg/m^2,routine,,,,,
1440,,ticagrelor)|active malignancy,interferon beta,unable to obtain contact to next of kin for informed consent,linear lv mass,mini mental test score,,,,topical,for more than four weeks|no,below the lower limit of the normal range,2-10,,,,,
1441,,poor immune tolerance,antibiotic medication,incapable of following postoperative care instructions|patient,calculated chronic kidney disease epidemiology collaboration (ckd-epi,laparoscopic surgery||patients,,,,periapical radiolucency|furcation,within 14 days prior to initiation of protocol therapy,score ≤ 25,≥ 1.7 mmol/l,,,,,
1442,,thoracic kyphotic deformity,p1np,unable to consent|individuals,icdas score,"mechanical ventilator support,|no",,,,upper limb study|wounds,1 month,≥ 75 × 10l|hemoglobin ≥ 9gdl|serum,opioid use,,,,,
1443,,intraventricular hemorrhage,non-stimulants,child,dyspnea grade,octa,,,,clinical exam.|eastern,at the time of consent.|gog performance status,between (18-23,infection:||consecutive,,,,,
1444,,athletes||participant,mania)|severe visual,impossible to understand instructions.|presence of,fasting test,coherence tomography angiography,,,,irreversible,at least two months before the patient is,less than 80 lbs|use,first episode,,,,,
1445,,reproductive system|already,similar products/formulations|the,address cutaneous,tbil≥85.5,rescue chemotherapy,,,,≤80% corneal diameter.||study procedures:||only,at least 1 month prior to enrollment,score of 120 or less,daily reusable,,,,,
1446,,use disorder,mild tbi,unable to obtain,rheumatology care,fitbit every day,,,,enrollment|requirement,greater than 20,at least 21 years,more than one-third,,,,,
1447,,knowingly under investigation,flourish,render the subject unable to comply with the protocol,gld,dialysis treatment;|pregnant,,,,distal radius fracture||prior distal radius fracture,at the usual education session|access to,≥ 12%,one form must,,,,,
1448,,vascular deficit,lugano,progression on appropriate,hcv rna test results||known positive test,standard methods|primary,,,,dj insertion.||,within 8 hours of treatment sessions,≤ 3× times upper normal limit(uln,≥3 at screening,,,,,
1449,,hiv positivity,lacidophilin,unable to feed,sbrt,biological therapy,,,,pathologically proven,within the range of 19 to 40 kg/m2,between 19 to 35 kg/m2,daily,,,,,
1450,,cardiovascular diseases.|participants,tnf-α inhibitors.|women of childbearing potential,unable to give assent,between neurological level of injury c5,stress ball,,,,sharp,prior to study treatment).||15,18-79 years,at least one,,,,,
1451,,facial pain,radioactive iodine contrast material,difficulty with,arterial blood gases,t cell infusion only,,,,unvaccinated,in the past 3 months|any,> 210/110 mmhg,acceptable.|radiotherapy treatment to more than 30% of the bone marrow within 4 weeks of the first dose of study,,,,,
1452,,chest radiography;|enlarged liver,il-6 inhibitors,ubjects must:||be able,indocyanin green angiography,escc,,,,stage iv features,within 3 years prior to the first dosing of study drug,≥ 10 mmol/l,greater than edss,,,,,
1453,,compliance|pre-menopausal,compounds of similar biological composition to hsv-1,conduction system;|patients,homozygous hemoglobin ss (hbss),active wsl,,,,height|surgically sterile,for the reason,2½ to 5 years,10 mg/d,,,,,
1454,,unmanageable urinary incontinence.|participants,drugs used in this study.|subjects,understand the consent form,ses-cd,reason(s,,,,self-test,up from first bdmard administration.|patients,≥ 6 points.||,at least 1 measurable lesion|at least 42,,,,,
1455,,focal shock,monoclonal antibody/components of the study intervention,unable to give consent.|participation,sexually transmitted infection,ocular procedures,,,,shoulder surgery.|patients,prior to dose 1 of the,18 years or over,1 year between,,,,,
1456,,acute change in condition,argatroban,azathioprine|initiating,refuse it|liver function,graft-vs-host disease|re-do,,,,non-cooperative,at least 8 weeks after the end of treatment,≥ 2 weeks,scores ≤ 8,,,,,
1457,,local skin infections,drugs that could influence sleep patterns,participated in another clinical trial within 30 days or within,present||total bilirubin,bone marrow concentrate (bmac),,,,ultraviolet a radiation,during the treatment period,> 12 months.|histologically confirmed,newly diagnosis,,,,,
1458,,obstructive pulmonary disease,african americans||inclusion criteria,family members||,hba1c level,gynecological laparoscopy,,,,locoregional anesthesia,within 28 days prior to the first dose of ip|has known,20 mm hg,≥2 from previous,,,,,
1459,,non-obstructive coronary artery disease,medications/supplements/therapies,sprututbytesprogrammet in uppsala defined,serum glucose,foam sclerotherapy,,,,index date:||a diagnosis,within three months before the study,scores <50%of,1 year prior to the,,,,,
1460,,dressing)||france,antihypertensive drugs,dosimetry cohort||1,cooperate;|systolic blood pressure,central laboratory.|performance status,,,,mid-penile hypospadias,more than 3 times the normal upper limit|patients,50 years old|provision of informed consent,3 x uln,,,,,
1461,,resting oxygen saturation,diabeloop,unable to understand danish,50 bpm,ambulatory,,,,been,at least 3 months before surgical periodontal treatment (baseline day,< 40%||,minimum 12 weeks,,,,,
1462,,esophageal space,cyp3a inhibitor/inducer,illiteracy|refusal to take part,diagnostic radiologists,surgical valve repair,,,,non-head and neck,preceding month,< 2000 iu/ml,once a day,,,,,
1463,,adjuvant chemotherapy,molecular-targeted therapy agents,progression on,weeks.|adequate blood count,focal segmental,,,,hemodynamic,within 28 days prior to the first administration of the study drug,≤ 2.5 x upper limit of normal||able,routinely,,,,,
1464,,intracranial surgical procedure|any contraindication to tms determined by the tms adult safety screen (,other immune-modifying drugs,sex-specific,natriuretic peptides.|sedentary,computed tomography angiography in coronary artery,,,,high resolution computed tomography (hrct) scan,for 2 stays of 10 consecutive days over the course of 5 weeks.|willing to allow samples,125-450 10 9/l.|comorbidities,≥0.05,,,,,
1465,,visceral metastases,blood components,entry into this study|covid-19,nci ctcae,doppler echocardiography,,,,spo2 sensor,within 14 days before clinical trial;|subjects,18-40).|gestational,< 2 months after injury,,,,,
1466,,primary pulmonary hypertension,sorafenib,volume difference,overall pelvic pain,donate sperm,,,,male hockey,at least 1 year prior to enrollment,greater than 10 iu/l.|early menopause,less than 1 hour,,,,,
1467,,cyanotic cardiac disease,flumadine,life +,alanine aminotransferase/serum glutamic pyruvic transaminase (alt/sgpt,"assisted reproductive techniques,|electing cesarean section.||exclusion criteria",,,,suitable for the couple,before surgery.|patients treated,< 3.5 mmol/l,daily medication|no,,,,,
1468,,ovarian stimulation.|allergy,dynamic full-field optical coherence tomography observation,close to ho chi minh city,reading english|can swallow,knee flexion,,,,low-moderate level,at least 1 month before starting the study,20 pie,>20 hours per week,,,,,
1469,,nonmalignant disease,operation,growing,new york heart diseases (nyha) heart function,heated intra-peritoneal chemotherapy,,,,are judged by the investigators,"preceding month, despite appropriate",<= 20|reduced peak hip,flow,,,,,
1470,,late relapse should,potent p-glycoprotein,expected to respond to atm avi,nci-ctc version,carbohydrate antigen)||having,,,,first-degree relatives,at least 6 weeks before taking study treatment,≥90 mm hg,dose greater than 20 mg per day,,,,,
1471,,hypoglycemia unawareness,hormonal contraceptives,enrolled onto eay191,wisci,fev1 percent predicted value,,,,timed up and go test||,during the study.||**methods of contraception,=< 35 kg/m^2|must,three or more,,,,,
1472,,common contraindications,pmd,not residing,male qtc,radical surgeries,,,,member of staff,within 28 days prior to the 1st dose of chs-006;|nsclc,3-70|diagnosis of r/r,5lb 8oz)|consumes milk,,,,,
1473,,problematic gambling behavior,hygiene-dietary measures|high-resolution manometry (hrm),enrolled on this protocol,iq test,bone marrow invasion,,,,positivity|eastern cooperative oncology group (,after inhalation,greater than 40 g,≥ 8 ppm|smoking,,,,,
1474,,intracranial vasculopathy,discipline,willing to participate||inclusion criteria,herceptin spcs.|overexpression of her2,routine physical examination,,,,efficient,in the last year.|current smokers,less than 8,"1, 13",,,,,
1475,,synchronous,methotrexate.||-,matching the stroke group|absence of,hepatitis-c antibodies or hiv,adolescents,,,,retrieving,within the past 5 years|smokers,"5%, cream",new,,,,,
1476,,aortic stenosis.||caregivers:||inclusion criteria:||to,apixaban,situations that would limit compliance with study requirements.|any,semen parameters.||,revibe connect,,,,preclude resection|step 2,within the past year.|participants,≥ 3 months.|at least one,more than 1.5 times of upper limit of normal,,,,,
1477,,systemic autoimmune diseases.|other,drugs of similar chemical classes.|other concurrent cytotoxic chemotherapy,situations deemed unsuitable by the doctor in charge,lipase,talar tilt test (hubbard and kaminski,,,,3 occurred,last 5 years,less than 20ml/min,≥ 15/week,,,,,
1478,,non-ablationed,immunobiological drugs,sleep disorder|psqi score,count,cytomorphology,,,,ii|no,during the study period.|free of any disease state,> 0.7cm,≥ 45 ml/min,,,,,
1479,,systemic lupus,bupivacaine,auditory,macular photocoagulation)|macular edema,open-label phase,,,,mild tbi,at the onset of the study,between 30 and 85 years old|having,> 5mg/day,,,,,
1480,,ischaemic colitis,panic,speak french|parents of,peripheral arterial disease.|coagulopathy.|uncontrolled,invasive surgery,,,,cmv,less than 30 days,">/= 100,000/ul",≥64 at 4°c (v),,,,,
1481,,astroblastoma/nm-1,malignancies;|patients,life-threatening,pregnancy tests,eicu,,,,4g network etc.)||,during the trial;|received,>200 ng/l,≥ 14 units per week,,,,,
1482,,congenital bilirubinemia,decongestants,physical evidence,blood institute guidelines,e-vapor products,,,,systemic treatment.||11,in the three months preceding,within therapeutic range of intended use of anticoagulants||9.1 hepatitis b positive,more than 30 days.|the participant,,,,,
1483,,severe coagulation disorders,low-carb,dyspnea on exertion,icg dermal backflow|age,mechanical ventilation|chronic kidney disease,,,,5-syndromic,within 14 days prior to asp1002 administration,m2,≥1.25 x the upper limit of normal (uln),,,,,
1484,,gynecological tumors,immune suppressive medicine,wi-fi internet,body mass index ranged,"magnetic resonance imaging,|signed informed consent;|affiliation",,,,implantation of a buried cardioverter-defibrillator (icd),within 28 days of icrs).|patients not eligible to icrs,more than 12 weeks.|karnofsky,1,,,,,
1485,,splenomegaly,regional anesthesia technique,conceive children,screening.|active hepatitis b or,covid-19 booster vaccination,,,,hormone-releasing implants,inadequate,> 30 kg / m2,for more than 48 hours|patients,,,,,
1486,,friend,hematopoietic growth,unable to meet inclusion criteria,males|aged,psychological therapy,,,,suitable for endovascular repair in vascular morphology;|patients,in the past 6 months|individuals,≤ 7 %,= 2 mg epirubicin,,,,,
1487,,fungal cutaneous diseases,serious medical condition;|think,unable to evaluate,alkaline phosphatase (akp),pfts)|positive local allergy panel,,,,non-mri safe metal,within the last 10 days prior to day -1.|history,0-2.|absolute neutrophil count,more than one hour per month,,,,,
1488,,tumor.|pregnant patients.|any condition,epinephrine,person with dementia,new york college of cardiology (nyha),early treatment diabetic retinopathy study (,,,,geriatric rehabilitation,within 2 to 4 weeks;|adult,≥ 3×10^9/l,once or not,,,,,
1489,,spinal cord injury|can,"local anesthetic allergy,|coagulation disorder,|morbid obesity",nursing includes,hepatitis c virus,conventional commode chair,,,,peri-articular,within 4 weeks before first dose of study drug.|received,score 24 and more less|nor agreed to participate,more than 12 weeks,,,,,
1490,,rectal cancer|adenoma,plasmalyte,expected survival,alanine aminotransferase level,botulinic toxin injection,,,,clearly related to nstemi|st-segment depression>1mm/6 leads,for at least 2 months prior to screening.||*,1.1,more than 1 level,,,,,
1491,,s4+,augmentation medication treatments,difficulty in taking the investigational product orally,vo2 peak,t-cell receptor agent,,,,epilepsy.|known,within 6 months from start treatment|on-line,>21 years,more than 2 standard alcoholic drinks per day or more than 10 drinks per week,,,,,
1492,,progressive neuronopathic phenotype,conventional laryngoscopy,6 to less,child-pugh score>7),pelvic radiation,,,,bulbar,in the 6 hours prior to recruitment|sputum viscosity,25 - 65 years.|consents,regular cycle,,,,,
1493,,gustilo-anderson class,rocuronium for,cohort a|progression of disease,blood pressure readings,elective craniotomy,,,,weaned for more than 2 years,prior to radiologic recurrence,≥1.0 g/dl,more than ctc ae,,,,,
1494,,living independently|dementia,1a2-inducing,ambulation,myopia,induction chemotherapy,,,,age;|symptomatic,within the last 5 years|patients,greater than 3.0 × upper limit of normal (uln),1-year,,,,,
1495,,gastric ulceration,dietary supplements,pace their breathing,iief,institute of medical sciences,,,,primary uncorrected,within the year before study entry|diagnosed,>18 years|interested,≥ 100 beats/min,,,,,
1496,,neck peripheral nerve sheath,palbociclib,lung activity,test value,apical repair,,,,influence the cutaneous state.|subjects participating,since more than three months,confirmation,>= approximately 3,,,,,
1497,,breast feeding|background therapy of any oral aads,conventional brackets|3.the treatment,render the participant ineligible for the study,mean baseline hb,β-thalassemia,,,,hypovolaemia|adam's-stokes,at the time of 3-month follow-up|no sexual life 3 days before the examination -||,30-50 kg/m2|individuals,20,,,,,
1498,,junction obstruction,push messages,signed informed consent form|male,best obstetrical estimate,local anesthetics.|revision surgeries.|refusal,,,,human influenza challenge,more than 28 units,18-75||,≥1500 mg/day,,,,,
1499,,/carcinoma,evusheld,indeterminate,recist 1.1 standard,multiparametric mri software guided fusion biopsy of the prostate (,,,,old|non-elite athletes,after prior therapy for mcrpc:||disease progression after treatment,=< 14 days from,more than 2 units,,,,,
1500,,uk brain bank criteria,seville orange- containing products,participated in another asthma-related pharmaceutical study,b-cell nhl,ct assessment,,,,non-medicated,throughout the study|participant is compliant,12-18,100 mg/die per os,,,,,
1501,,g3 net).|uncontrolled blood pressure,creatinine,expected survival time>6,logical memory test,adrenocortical hormone replacement,,,,standard,at time of study entry.|eastern,1.18 years old ≤ age,<3 months of,,,,,
1502,,uncorrectable coagulopathy.|patients,oral analgesics abuse,change in behavior proposed,modified recist 1.1 criteria,loose anagen hair,,,,campylobacter spp.,during the trial;|gfr<80 ml/min;|abnormal results of laboratory examination,less than 1 sd compared,45 ml,,,,,
1503,,intra-spinal canal mass,drugs targeting other t-cell co-stimulatory receptors,artificial tears.|significant eye lid droop blocking the pupil.|persistent blurry vision,response evaluation criteria in solid tumors version 1.1 (recist 1.1) .||,hematopoietic stimulator treatment,,,,suitable for participation in this trial,within 12 weeks before the first administration,<= 10 days from diagnosis,fewer than 3,,,,,
1504,,inflammatory rheumatic disease|patients,migrants,signed informed consent||subjects,cardiac catheterization,blood sugar control,,,,reduced-size,within four weeks before study visit 1|major medical,*does not,once-daily,,,,,
1505,,poor skin condition,luseogliflozin,expected survival duration,cm)|radiological proven recurrence,consumption of any products included,,,,admit to intensive care unit in postoperative period|patients with the end of operation,after onset of symptoms,>5 kg,nivolumab maintenance,,,,,
1506,,pancreatic insulinoma,anti-il5/5r therapy,cessation of menstrual activity,efferon lps neo column,herbal medicines,,,,inhaled,within 12 months after administration;|patients,%<40%,≥ 50 ml/min/1.73 m2,,,,,
1507,,dysesthesia,darunavir,stainless-steel,criteria of hanifin and rajka (see appendix 1).|atopic dermatitis,open pelvic surgery,,,,adequate organ function.||,within 7 days prior to the first dose of,> 45 years-of-age,at least ≥3,,,,,
1508,,criteria):||talks in word,mobility.|patients,retreatment in the,hepatitis c infection|concurrent,carotid artery stenting,,,,known to affect appetite,within the last 2 years|subjects,18-65 years.|chb,≥6 at time of,,,,,
1509,,systemic complications,kanamycin,unable to maintain contact with the healthcare professional.|use,vv ecmo,esr,,,,clinically unstable,at least 12 weeks.|without,longer than 30 seconds,≥1 prior,,,,,
1510,,acute respiratory disease,psychotherapeutic drugs,risk of inhalation,urine mph screen by dipstick,ct angiography.|execution of,,,,highly effective contraceptive measures,disease;|bruxism;|smoking|a history,less than 2cm;|the condition,≥15 monthly migraine,,,,,
1511,,middle cerebral artery [,caffeine-containing sodas,probable,oral temperature,brain imaging done,,,,alopecia)|previous,within 3 months from the first dose to the last use of the study,12 to 21 years,more than 20/day,,,,,
1512,,acute cardiovascular event,surgery.|participant,speak english,eligibility criteria (for step 2,blood chemistry tests,,,,semi,for ≥ 2 months,between 18 and 80,upper and lower clavicular lymph,,,,,
1513,,extracoronary arterial,sternocleidomastoid,situations that limit participation compliance with study procedures,moderate femorotibial osteoarthritis,sleep,,,,ipsilateral neck port.|karnofsky performance score,at time of conception|diagnosis of a condition for,2.5%,before treatment,,,,,
1514,,non-squamous nsclc,silibinin,need a,platelet count<10,deterioration of renal function,,,,successfully received;|2,in the last 2 months|able to participate,> uln).|patient,≥ 30 minutes,,,,,
1515,,prolonged qt syndrome,lover,willing and able to write a written consent form for this,hiv)|clinical signs,bilateral pulmonary artery bands)|presence,,,,center for autism,during the study.|participant,3 to 5 years and 11 months,≥2 chest/abdominal ct,,,,,
1516,,cervical carcinoma in situ,abnormal hematology,unable to give informed consent|histological high-risk features,definition: stroke,passive flexion,,,,suitable for participate the study,within 2 weeks prior to the first dose of investigational product.|medication,less than 3.5 cm,more than 4 cups of caffeinated beverages per day|any,,,,,
1517,,non substance,radioactive agents,remain located in the pittsburgh area,hyperthermia.|weigh,refractive error surgery,,,,schizo-affective disorder,within 3 months prior to screening;|subjects,within therapeutic range of intended use,5 x,,,,,
1518,,sjogrens syndrome,mefloquine,willing to follow up.|medically stable,uln|absolute neutrophil count,qt corrected,,,,non-antibody molecule therapy,within 14 days or live vaccine,718-cih-202,at least 12 months of amenorrhea,,,,,
1519,,chemotherapy contraindications,anti-retroviral therapy agents,neurological symptoms||,estimated blood volume,functional testing.|participant is enrolled in any interventional study.|participant,,,,non-primary,within 14 days prior to the first dose of study drug.||--of note,"9 to 16 years,|are able to read",1 unit of alcohol,,,,,
1520,,left ventricular impairment,anti-cd70,meet the inclusion criteria|did,change of ++,mild uri,,,,large area,within 30 days of inhaled,iv|eligible,greater than 30,,,,,
1521,,esophageal stricture|severe hepatic disease|severe renal disease,bcnu,mri.|tumor in non eloquent brain region,european nmsc-registry,major head and neck,,,,f50.1,in the airway evaluation,less than 24 hours,daily treatment,,,,,
1522,,marevan,glp1r-agonists|intolerance,unable to communicate,weight fluctuation,standard mri contraindication,,,,cardiovascular,in first 5 days of hospitalization)|urine output < 0.5 ml/kg/h,<60ml/min/1.73 m^2,nucleotide/nucleoside,,,,,
1523,,brain contusion,lidocaine containing topical compounds,difficulty with visits|bariatric surgery,others|body mass index,serology,,,,tetras-ps,at time of surgery,≤ 2.5x uln.|serum,at least received,,,,,
1524,,maxillofacial trauma,compartment repairs for prolapse,render the patient unable to understand his/her participation in the study,dkd,oral topical treatment,,,,pericardial friction,within 7 days before trial entry,≤ 30 kg/m2|asa i-iii.|first unilateral surgery,hsct):||autologous hsct,,,,,
1525,,e.g.hepatic impairment,benzodiazepine,conversion,quantitative rt-pcr,camh chart review,,,,molecular features,< 12 months|contact lens wearers|past refractive surgery|severe,>50%,one arm more than the,,,,,
1526,,tablet|frontotemporal dementia,tegafur,unable to use mobile money-based sms,less)|body mass index,computed tomography angiography (cta)- source,,,,successfully crossed,more than 30 days prior to the study,50 to 80 years,"exceed 50 μmol/l),|ap",,,,,
1527,,lens opacity affect the observation of the fundus,mechanical ventilator,unable to complete cognitive function evaluation,suicidal ideation from columbia suicide severity rating scale,therapeutic dose,,,,symptomology,before the first dose of investigational drug,>18 years||,two consecutive times,,,,,
1528,,significant bowel,pi3kδ inhibitor,inpatient services,slr test,iron chelation therapy,,,,histopathologically confirmed,within 28 days prior to cycle 1 day 1:||thrombopoiesis-stimulating agents,≥ 5 × uln,>4 months,,,,,
1529,,mri)|weight loss,esotropia,render the participant unable to meet the requirements of the protocol,vas criterion,ivig transfusion,,,,meta-pm classification,grade>1 within 4 weeks prior to enrollment,> 90 mm hg,20mg for ≥ 14 days before enrollment|non-,,,,,
1530,,ophthalmological disorders,local measurement,living in nursing homes,detectable hiv rna levels,interventional study||control,,,,dietary intake of,within the prior 3 months|known,greater than 1.0g;|clinically significant,recipient,,,,,
1531,,dysmenorrhea,drug-induced pneumonitis,unable to receive oxaliplatin,enrol,vomited,,,,non-high,within the 3 months period prior to baseline;|intraocular use,18 to 60 years)|understands danish||,"> 10,|clinical cut-off on depression subscale",,,,,
1532,,attributed,anti-rejection medication,unable to provide informed consent,general/ocular inclusion criteria||1,eswt,,,,nia-alzheimer's association workgroup||cognitive function allows independent (or minimally assisted,between 4 and 12 weeks before the enrollment|patient,<18|having,2 weeks prior,,,,,
1533,,malignant colorectal tumor;|multiple,bronchodilators,insufficiently treated,pao2/fio2,venous blood collection,,,,unilateral,in the two weeks prior to the screening|history,sensitive mutation;|stage iv;|ecog score 0-2;|prior to receiving the,less than or equal to 0.5mg/kg,,,,,
1534,,organic pathology,erectogenic aids,progression to severe,monocyte clone,ap x-ray,,,,clinician- administered ptsd scale,during the 6 weeks immediately prior to visit 0,> 70 ml/min/1.73 m^2,≥2 mg/kg/day,,,,,
1535,,hepatic abnormalities,fast plate,stopped smoking,n1-3m0 breast cancer,complete cessation,,,,performed,4 days prior to randomization.|the,8-10,less than 14 days before,,,,,
1536,,consent|radiographic disease,mirikizumab,prevention in place,hepatitis c virus (hcv)|is pregnant,mean sitting diastolic blood pressure (dbp),,,,arteriolar,within 1 week prior to the first administration of the study drug.|antitumor therapy,≥ 60 ml/beat,more than two years of endocrine therapy,,,,,
1537,,deep tumor tissue,imdc,points;|expected survival,recist version 1.1 (annex 1),only);|total colectomy,,,,low-carb,within 6 months prior to screening.||prior treatment,>21 and <40,january 2011 to january 2022.||,,,,,
1538,,nv-amd,hdac inhibitors,situations that would limit compliance with study requirements.|patients,1|adequate organ function||,chloroquine treatment,,,,gynecological b-ultrasound,within 4 weeks prior to the first dose of study treatment|current,older than 2,300 mg/day,,,,,
1539,,end of life care,anti hiv treatment;|participants,unable to consent to surgery,cholesterol level,physiological glucocorticoid for adrenal,,,,for curative,prior to the first administration of study intervention,< 14 cm,< 48 hours,,,,,
1540,,chronical medical condition|women,drugs used (nivolumab and ipilimumab,risk of airway obstruction,pao2/fio2 ratio,shoulder|previous surgery of the affected shoulder|previous,,,,low-risk prostate cancer,after allogeneic hematopoietic stem cell transplantation；||basically normal,> 2.5 mg/dl||reproduction:||a,1 january 2022 to 31 december,,,,,
1541,,swallowing disorder|prior gi surgery|intrathecal pump|concurrent,transfusions,change in antitussive therapy,ecog performance scale.||liver function,treat cns disease,,,,world);|current,within the previous 30 days.|requiring,between 40-60 years||patients referred from neuro,≥6 months|stage 2,,,,,
1542,,major factor,stabilizers,willing to follow and able to complete,total wbc,healthy|non-smoking|non-diabetic,,,,highly effective contraception measures,within 48 hours prior to randomization，first diagnosis,more or equal to 23 kg/m2.|in,more than 1 week,,,,,
1543,,cardiovascular disease,nicotine-containing,participated in clinical trials of any other drug,≤3,lymph node biopsy|active,,,,ovary under ultrasound,at least twice,≤1.73 nmol/l,≥ 8 hours,,,,,
1544,,spasmodic crying,h2-receptor antagonists,limit compliance with study requirements|is,islands of belém,tcc,,,,inserted,within the past six months.|neurological condition,25-45 years|bmi,cytology;|at least one,,,,,
1545,,disease of the uterus|malignancy,naglu,genetic mutation,dci,therapeutic anticoagulation,,,,acr / eular,within 3 months before screening|hbsag,less than two,maximum of 32 weeks 6 days,,,,,
1546,,restrictive pulmonary diseases;|can tolerate,vitrectomy,notching,antidiabetic medication|abnormal diabetic foot review,image collection,,,,interfere with cooperation with the requirements of the trial.|has,within 28 days prior to receipt of study vaccine,≥ 2.5 × 109/l.|neutrophil count,> 10 mg,,,,,
1547,,secondary osteoporosis,stimulant,parturient,creatinine ≤1.5×uln;|tbil≤1.5×uln;|alt,ocular metallic foreign body,,,,naso-gastric tube,within 1 month prior to the screening visit,≥ 70%|age ≥ 18,long term before,,,,,
1548,,spinal injury,intravenous immunoglobulin,from offering cooperation,overall proportion,hrct chest suggestive of,,,,ics refills,within 14 days prior to enrollment;|pregnant,18-32 kg/m2,≥ 2 months prior to the study treatment|bmi,,,,,
1549,,ioobö9-sf,local readings,sleep latency,antifungal therapy,produce irritation of the lumbar roots,,,,treatment|current dose of lorazepam,before the screening period are,= 75 x 10^9 per liter,≥cn1；large,,,,,
1550,,parkinson disease|contraindications,imaging modality,risk of hypercalcemia - renal failure|know cardiac valvular disease|allergic to calcium gluconate,general activity scale (peg),neurological surgery,,,,/unresectable,during the study|willing to follow all study procedures,less than 40 miu/ml.||men of reproductive potential,changed medical conditions.||,,,,,
1551,,a3 segment of the anterior cerebral artery (aca)|occlusion of the p2 or p3 branch of the posterior cerebral artery,tazoretin,plan,mlh1,e-cigarette,,,,ngs input formats available,during maximal cardiopulmonary exercise test.|comorbidity,between january 2015,generalised,,,,,
1552,,believes,antibody-drug conjugates,remain for all uon fmhs urec approved,stress [12n],extraction orthodontic treatment,,,,addressed,in the next 18,18-95 years,daily treatment the,,,,,
1553,,large prospective cohort study,phosphodiesterase (pde) inhibitors,parents infected,iad)|expected length of stay of seven,lung function tests,,,,preclude prep initiation,within 3 months prior to the first dose of study drug.||8,≤3.0-fold the upper limit of normal (uln),2 or more times in the 4 weeks prior to the first dose of study,,,,,
1554,,pulmonary involvement,cts,remain on this regimen,ast ≤5×uln);|alkaline phosphatase (akp) ≤2.5×uln|creatinine clearance rate,patients||population,,,,creatinine|negative infectious tests (,in the lower limbs,>250 ml,less than 4 weeks of follow-up|patients,,,,,
1555,,serd,drugs that target immune regulatory points,participated in other clinical trialists,alanine transaminase),mitral valve surgery,,,,non-tuberculosis mycobacteria,during the 28 days prior to vaccination,≥ 6 points,dose greater than 60 mg/day,,,,,
1556,,oncologic disease,components used in the program.|pregnancy,smoke research,hbv,cardiac ct,,,,mild to moderate renal impairment,at the time of consent acquisition,less than 70)|substance dependence,once weekly,,,,,
1557,,acute myocardial infarction occurred,biological agents,products.|pregnant,time below range (tbr),endoscopic,,,,vascular tone,within the prior 30 days||d,≥ 125 g/l,long half-life,,,,,
1558,,childhood sexual abuse,psychotropic agents,participated in another interventional drug trial,carcinoma|total bilirubin,tumour expression,,,,dutch guidelines (ed,within 3 months before screening;|the investigator believes,>1000 pmol/l,≥ 5 half-lives,,,,,
1559,,ductal carcinoma in situ,pediatrician,ejaculation disorders;|suffer from mental disorders,gh,peripheral blood cell apheresis,,,,non-lactating.||participants,within 28 days before yttrium-90 administration;|participated,<5.25 millimoles per liter,at least 2 years,,,,,
1560,,abstain from dry eye/mgd medications,periprosthetic infection|rivaroxaban,furthermore,asco/cap,surgery.|redo surgery,,,,diabetes.|people use insulin,in the next 12 months|currently,< than 1.4 meters/second|ability,scooter|currently,,,,,
1561,,"difficulty swallowing whole capsules,||additional",non-)investigational products,incapable of following postoperative care instructions,study|outpatients|patients,implant loading protocols|uncontrolled,,,,not).|chronic phase of,in the last 4 weeks|patients,> 3x's the upper limit of normal,> 25 mg/week,,,,,
1562,,ventricular tachy-arrhythmias,disinfectant,close relative|70 year or older,optic nerves|absence,laboratory safety testing obtained,,,,post-traumatic arthritis,at least one of the following three impingement tests,≥ 10.0 g/dl|wbc,for 300mg dose,,,,,
1563,,uncontrolled seizure,vesicular monoamine transporter,unable to communicate verbally,modified ashworth scale,hernia operation,,,,non-ischemic)|ulcer duration,within 6 weeks before eecp|recent cardiac catheterization,drop <90 mmhg,online questionnaires).|signed written informed,,,,,
1564,,idiopathic cough,anti-alopecia,living in the united states|18 years,anti egfr monoclonal antibody treatment;previous chemotherapy,elective surgery ranging,,,,unilateral location,in the past 1 month.|laboratory examination of coagulation function should show,> 18|non anastomotic biliary strictures,more than 20 times,,,,,
1565,,cns infiltration,oral contraceptive pill,sleep related,standardized uptake value (suv) max,blood lipid profile,,,,stability.||prior treatment(s)||note,in the last 5 years|expected non-compliance,≥1.5 ×10,3 or more,,,,,
1566,,btx,jak inhibitor,expected in rdeb patients,mass index(bmi)≤27.0kg/m2||,treatment program,,,,non-covalent btk inhibitor,within the past 7 days prior to the ed visit,≥ 48 mmol/mol,replacement dose,,,,,
1567,,pacemaker,intravenous antibiotic,physiologically capable of||becoming pregnant,glomerular filtration rate (egfr),other procedures,,,,full thickness rectal,during the study period,≥ 50|smoking,systemic,,,,,
1568,,gastrointestinal diseases|on coagulant therapy,anti-tb drugs regimen,cigarettes,serum glutamic oxaloacetic,arterial blood,,,,ifr ≤0.89,before the first administration need to stop taking drugs,< 17;|the,secondary or higher,,,,,
1569,,viral hepatitis c,inducing substrates,risk of ckd,child reintegration centre services,cardiac ultrasound examination showed,,,,trans-rosalee study,within 6 months prior to screening.||5,≥ 5%,for at least five,,,,,
1570,,structural cardiac abnormalities,menstruation,any other condition that,volume-viscosity swallowing test,ct chest obtained,,,,counselors:||inclusion criteria,at least 1 of the following at least 30% of the,"three times, provide",maximum 2000 mg/day,,,,,
1571,,lithotripsy||,left ventricular assist device implantation|cardiac amyloidosis|pregnant,cooperate swallow therapy||,fev1/fvc ratio,percutaneous coronary angioplasty,,,,interfere with calcium metabolism,defect.||cohort 2,">= 100,000/mm^3|serum",twice daily or higher,,,,,
1572,,tuberculosis|serious infection,immunomodulating agent,breast cancer|inability to participate in the study,af,placement of,,,,non-squamous cell carcinoma,within 14 days of initiating study drug,20 vps,cap||at least 2,,,,,
1573,,elective heart surgery,drug-related grade,pericardial cavity,pulmonary capillary hemangiomatosis|persistent pulmonary hypertension,osna|molecular analysis,,,,need systematic,during the screening period and baseline period;|subjects,=< 3 x uln|alanine transaminase (alt),greater than one,,,,,
1574,,pneumonia.|acute respiratory failure,short-acting somatostatin analogs,difficulty in swallowing drugs,hepatitis b surface antigen (hbsag) positive,standard echocardiography clips,,,,plasmodium species,within 1 year prior to randomization,< 12 breaths per min;|history,more than 5 days,,,,,
1575,,sprue,similar anticoagulation,mucoid,qigong,west virginia,,,,stage iv renal insufficiency,at time of enrollment.|adequate,> 3 × upper limit of normal (uln),more than 4h to maintain map>65 mmhg,,,,,
1576,,accessible to biopsy,fexuclue tablet,reducing life expectancy,phq-9 score,concussion resulting,,,,narrow-angle glaucoma.|pregnant,past six months,<70% of predicted,five,,,,,
1577,,cardiopulmonary pathology,creatine,informed consent form;|a diagnosis,ccs,invasive intervention,,,,u.s.,for at least 30 days prior to trial||,≤ 93%,≥ 4 months prior to study entry.|prior,,,,,
1578,,orthodontically banded,toxins,unable to abide,immunotherapy +/- platinum,orthognathic surgery,,,,pd-l1,prior to visit 0 (day 1).|known rb1 mutations,≥ 2.5 times the upper limit of normal|bilirubin,more than 10%,,,,,
1579,,carcinomas in situ,permanent medication,unable to intervene,body mass index (bmi= weight/height2),covid vaccine,,,,non-degenerative neurological condition,in the past 9 to 24 months before screening,between 22 and 75 years,<3 x uln)|estimated,,,,,
1580,,anatomic abnormality of the kidney|fecal incontinence,cerebellopontine,child psychiatry,total bilirubin (serum),chest ct scan screening;|neurological,,,,toxic reactions.||.previous autoimmune,for at least 7 days)|≥6 years to ≤22 years,">=2|completion of ""if",1) pre-existing,,,,,
1581,,iraes from immune checkpoint inhibitor antibody therapy|co-morbid,components of the drug|epilepsy|severe renal impairment,etc.).|not,burn;|central respiratory failure;|severe myasthenia,optimal management,,,,specifically a pre-disposition,for at least 30 days after study termination|subject is capable to,=< 3.0 x institutional uln,1 mg doxorubicin,,,,,
1582,,extra hilar lymph nodes,medications for,consistent with covid-19) ≤5 days prior to randomization.|presence,indocyanine allergy.|gastric cancer subtype,optimal control of symptoms|history,,,,squamous,prior to first dose of study therapy.||adequate organ,≤ 40mm,daily intake,,,,,
1583,,hepatic impairment;|presence,nicotine-containing products,cockcroft-gault equation||registration,tests:||systolic blood pressure,implant-supported restoration|presence,,,,chest abdomen,prior to the study.|female,18- to 36-month-old,therapeutic doses,,,,,
1584,,ovarian clear cell,components of the headband,consistent with pnh,mild upper respiratory tract illness,physiological profile assessment (total z-score,,,,infection|active systemic,within 30 days prior to screening,between 35 kg and 90 kg,more than 30% of the,,,,,
1585,,allergic comorbidities,js004,sexual relationships in,days||hyperandrogenism:||clinically,biopsy.|kidney biopsy,,,,stool for h. pylori antigen +,in the last year|patient,≥25 kilograms per meter squared (kg/m²)|presence of,>1/week,,,,,
1586,,chronic obstructive,pancreatic cyst,limit life expectancy,surgery.|body mass index,anti-cancer therapy,,,,suitable for this clinical study,within 28 days or,< 50%)|abdominal,more than 1 month despite,,,,,
1587,,45|skin type,solids,resistance,diastolic blood,rickham catheter,,,,neck,within less than 72 hours before first study intervention,between 20-70,> 20 mg,,,,,
1588,,congenital abnormality,lineage,unable to understand spoken,peripheral blood blasts,combined immunotherapy|written informed consent||,,,,genital fistula,during the whole study period.||,iv-vi patients);|systemic diseases/medications,two consecutive examination dates,,,,,
1589,,unresectable malignant duodenal obstruction,medium-to-high dose ics.|subjects,variations in morphology of teeth|patients,ngml-1;|systolic blood pressure,between end of radiotherapy,,,,3d high-density mapping system,within 60 days before inclusion,50 to 70 years inclusive,≥ 1 of the following,,,,,
1590,,adrenal malignancy,fracture)|systemic illness|subacromial,prevention interventional research study|upper arm circumference,probing depth,apheresis,,,,non-prentiss)|concurrent,within 6 months prior to study drug administration,4-40,pneumothorax,,,,,
1591,,chronic psychiatric disorder,abiraterone acetate,refuse to participate in this,menstrual-related,complete pros,,,,etc;|part c and d:,within the last 15 years,> 50 years old,> 15 g,,,,,
1592,,etc)|enrollment in separate study,hyperforin,insufficient bone support,ecog score,biological equivalence test,,,,peri-implant bone loss,past 12 months,<50% of predicted,≥500mg/day,,,,,
1593,,hbv carriers,azacytidine,tobacco use,uln)|glomerular filtration rate (gfr),minimally invasive therapy,,,,refractory to standard therapy,within the past 1 year);|participants enrolled,score ranges,more than ii degree,,,,,
1594,,pulmonary edema);|asplenia,sbrt,psychiatric inpatient,adult level,transfemoral tavi implantation scheduled,,,,american heart association (aha) definition,in the 13 months following study entry,20-65 years|both,10 mg daily prednisone,,,,,
1595,,non-amenable to soc;|at least,cobicistat-containing products,venous|sign of infection,schirmer test,dbs controller,,,,stage iv disease,within 2 weeks before treatment.||previous anti-tumor,≥1 × 109/l,≥ 12 consecutive months,,,,,
1596,,impaired end organ perfusion,oral steroid inhalation,risk for pregnancy with their partner(s) must agree to use,cooperative oncology group (ecog) physical status score,receive hormone therapy,,,,site)|ineligible,< 6 months prior to enrollment,< 102 cm,at least two years,,,,,
1597,,recurrence (local,manias)|acute suicidal ideation|cognitive impairment|dementia,remain in the study area,basal fsh level,visual,,,,diagnostic criteria for cnsv||the presence,within 14 days prior to initiation of study treatment,>= 40%.||participants,one impacted third,,,,,
1598,,low-grade dysplasia (lgd),symptomregistration autumn,bi-lateral mtp fusion,panel reactive antibodies (pra),elective procedure,,,,guidelines|eastern cooperative oncology group (ecog) performance status,in the knee three months before the study inclusion|patients,under 270 lpm,glucocorticoid use,,,,,
1599,,scoliosis,technician,special diet.|the subject is,sweden,radiation overlapping,,,,study.|pregnancy,within 2 weeks before the first administration;|within 2 weeks before the first administration,higher than or equal to150mg/dl,≥ 1 of,,,,,
1600,,thrombotic lesion e,local anesthetic product|history of wound healing disorders,risk of considerable harm from standard treatment,aspartate transaminase ≤1.5x upper limit of normal (uln),effective antibiotic therapy,,,,malodorous,within 4 weeks before dosing,< 200mmhg,at least screening,,,,,
1601,,ocular health,verrucous,family's,estimated glomerular filtration rate (egfr:,fmt treatment|contra-indication,,,,critically,within 1 year of signing study consent form.|unstable physical disorders,>55 mm|patients,≥ 100 000,,,,,
1602,,acute exacerbation of hepatitis,anti-cancer medication,managed in outpatient,renal impairment|history of receipt of any treatment,encephalopathy|patient,,,,asthma;|various,in the last 12 months before screening.|life expectancy,childbearing,>48hr.|not taking,,,,,
1603,,recurrence occurs 6 months after,tavi,enrolled into a smoking cessation treatment,occurring every 21-38 days,chronic treatment,,,,pericardial effusion|finger oxygen saturation>93%；|neutrophil (,in the last six months|use,> 14.4,more than 30 days|18 years,,,,,
1604,,right heart catheterization,erythromycin,prevention of cardiovascular disease|use,fatigue;|tear secretion test,mesothelin antigen expression percentage,,,,user,within 6 months prior,≥ 18 years|bariatric surgery,female,,,,,
1605,,pregnancy conditions,anticholinergics,enrolled in clinical studies of,quantitative hepatitis c virus (hcv) rna results,general disease:|diabetes,,,,non-autoimmune allergic diseases;|those,at the time of signing the informed,between 18-and 65-years,hepatic encephalopathy)|treatment,,,,,
1606,,rectal cancer surgery,essure,risk for intracranial bleeding|subjects presenting,gestational age|living,skin testing,,,,petechia,less than 90 days prior to,= erythropoietin,at least one pad per 24 hours,,,,,
1607,,judged by the investigator to be ineligible for enrollment.|planned or anticipated major surgical procedure,anti-thymocyte globulin,researchers,estimated hba1c (gmi),mgmt,,,,large vessel occlusions,within the 4 weeks prior to signing the informed consent form.|subject,> 450 milliseconds,at least 2,,,,,
1608,,sudden cardiac arrest,walks,expected life expectancy,total cholesterol,primary vaccination,,,,influence the safety of the subject or the compliance of the test,within 48 hours of admission to,below 1.5 times the upper limit of normal,more than the equivalent dose to tablet prednisolone,,,,,
1609,,bisoprolol dose|uncontrolled diabetes mellitus,antihyperlipidemic agents,participated in another brain stimulation experiment the same day,response evaluation criteria in solid tumors (recist 1.1),dmt therapy,,,,neutral pad placement area,pathways|history,>3ⅹ109/l,voiding diary,,,,,
1610,,17b-estradiol,p2y12 inhibitor,partners plan,arterial partial oxygen pressure,treatment protocol,,,,pnh-mediated,within 28 days prior to sub-study randomization)|platelets,score 0-2;|full organ function:||blood system,once,,,,,
1611,,vitritis,opv,able to swallow a tylenol sized,mate1,communicate|general anesthesia,,,,suitable for intensive chemotherapy:||75 years,assessment||,≥ 90,"exceed 1,5 x uln",,,,,
1612,,her2 ultra-low/null,immunosuppression drugs,incapable of understanding,nasal swabs collected,intrathecal chemotherapy,,,,type ii diabetes mellitus||,at least 12 months prior to inclusion,over level 1 in ctc ae,"--or---|""high"" in total cholesterol",,,,,
1613,,diabetes|uncontrolled hypertension,anti-platelet medication|impossibility,participation in another interventional,serum intact pth concentration,cognitive impairment|mild cognitive impairment,,,,affiliated,within the previous 12 weeks of the,between 35.0 and 37.5°c note: these will be measured after resting for 10 min.|able to understand and communicate,one week prior to the first dose the study drug.|infection,,,,,
1614,,parkinsons disease|stable,qualtrics,,modified radical,lateral ray,,,,acquired,in the 3 months prior to screening;|those who are,less than or equal to an equivalent,1a combination breast cancer||documented,,,,,
1615,,partial brain radiation,theranova,,detectable hepatitis c rna).|known human immunodeficiency virus (hiv),ahus|chronic dialysis,,,,transfusions,within 12 weeks of each other,19.0-26.0 kg/m2,rather than,,,,,
1616,,weight loss,egfr inhibitor,,hepatitis c virus ribonucleic acid,regular endoscopic surveillance|gastric localization of,,,,grade iv,last for more than 3 months|those,≥470 msec,for ≥ 48 hours,,,,,
1617,,skin tumor,urti,,braf,applied medical nutrition therapy,,,,under general anesthesia|patients,within 14 days before the first dose of study intervention|participant,>1.5 times the upper limit of normal,<3 months)|recent trauma,,,,,
1618,,solid organ transplantation.|any other disease,platelet-rich fibrin,,columbian hospital,intraoperative dissection,,,,immunodeficiency.|sars-cov-2,within 28 days.|any use,-arrythmia -linguistic,own,,,,,
1619,,abpa,anti-arrhythmia,,recist 1.1 criteria；chemotherapy,re-identification risk,,,,"single,|not",at screening endoscopy|a diagnosis,≥ 14l/min|known,function|full capability of consent||,,,,,
1620,,ridge|medically compromised,cox-2 inhibitors,,recist criteria,transurethral prostate resection,,,,"upper trapezius, scm",received at least 2 weeks prior to enrolment||,>10%,only applicable,,,,,
1621,,bariatric surgery|previous,pain.|positive icvm findings|if,,air|forced expiratory volume in 1 second (fev1),tobacco users|patients,,,,represent,within 4 weeks prior to study entry,18 year,for 2 minutes,,,,,
1622,,left main,components of injection,,alt)(serum glutamic pyruvic transaminase [sgpt],ecr,,,,mg/24,prior to study participation,at least 55 years,more than 1 episode,,,,,
1623,,auditory,online programs,,uln)|alanine transaminase (alt),ocular anesthesia,,,,non-hemolyzed,at least 3 each,≥ 60 ml/min/1.73 m2.|direct,dose> 10 mg/day,,,,,
1624,,institution,tape,,car t-cell leukapheresis,covid fpg vaccination,,,,non-stimulant adhd,prior to screen/baseline|retinal vein occlusion,13-16,at least,,,,,
1625,,antiphospholipid antibody syndrome,antiarrhythmic drug,,aspartate transaminase (ast),namsos,,,,study;|clinically significant abnormalities,in the exclusion criteria,>6|suicidality,more than 2 prior,,,,,
1626,,chronic skin disease,ionic,,fit,recreational purposes,,,,pd-l1 mab,within the last year.|severe infection,>15 mmhg,three or fewer,,,,,
1627,,chronic corneal epitheliopathy,intervention|moderate,,walking speed,pneumonia|patient,,,,pathological,at least 2 of the following core set measures,>35 kg/m²)|insufficient,more than 10 cigarettes/day,,,,,
1628,,non-invasive means|pregnancy,topical application,,crea-clearance,quality of life (presence of the symptom,,,,urinary sediment|egfr(mdrd),within previous 90 d)||non-sinus rhythm|significant qtc prolongation,>5 cm,≥ iii|history,,,,,
1629,,progressive disease.|the,drugs known to prolong qt/qtc,,recist 1.1|adequate organ function|adequate cardiac function|agreement,asd closure device,,,,laptop,for at least 6 months after the last trial;|those who have no,60 mg/d,at least 1 year.|participants,,,,,
1630,,etc;|acute disease,b drugs,,lansky play,imaging scan,,,,on room,prior to initial administration,=< 3.0 × uln,≥ 12-month,,,,,
1631,,exudative amd,aromatase-inhibitor.|no adjuvant,,lymphocyte count.|pregnancy test results,stress reduction techniques,,,,could interfere with daily activities,within 48 h before the first dose of the study drug.|the results,<20/200)|satisfying,spasticity);|lower,,,,,
1632,,unacceptable toxicity,component of the imaging agent,,ccam/cpam,nonsurgical treatment,,,,fistula||known,within 2 months of the start of the study|any vaccination,≥1.5×109/l;|platelets ≥80×109/l;|hemoglobin ≥9g/dl;|serum,1 mg/dl=88.4,,,,,
1633,,joint mechanics,folinic acid,,endomysium antibodies (ema);|absence of wa,baseline;|macular laser treatment,,,,secondary to medical cause).||a female participant is eligible to participate if she is not pregnant,more than 6 months before screening,>1.5mg/dl.|participant,maximum of 24 weeks,,,,,
1634,,motion sickness|nausea|seizure,inactive components,,smoking.|active h. pylori infection|weight,alternative management,,,,digestive,within 180 days of registration,> 100 mg/dl,at least 1 prior,,,,,
1635,,screening.|adequate liver function,phone,,mra evidence,perfusion index ulnar/ulnar+radial ratio test,,,,insufficiently relieved,at least 3 months|stable,greater than 1.0 g;|within 4 weeks before the start of the study treatment,12 mg/dl,,,,,
1636,,spinal anatomical factors,orlistat,,united kingdom brain bank criteria of bradykinesia,alternative medical cause,,,,"index date|2. enrollment in medicare part a, b",prior to the start of imp administration,> 8%).|current,≤1 mg/d,,,,,
1637,,cns disorders,5-alpha reductase inhibitor,,depression scale,stipulations,,,,acceptable effective contraceptive measure,before administration of la||,baseball,1000mg paracetamol,,,,,
1638,,occupational disease,canada,,weeks.|estimated glomerular filtration rate,p16 immunohistochemistry,,,,any dietary supplements,1 prior to start,< 5% change,more than 10 weeks before entering the,,,,,
1639,,treatment|medical condition,liver disease|all medications,,hbv surface antigen (hbsag) result,first psychotic episode,,,,unerupted,during the previous 10 years|signed consent to study participation||,"physician,|7-25 years",greater than new york heart association,,,,,
1640,,diabetes.||if these events occurred,norvir,,imaging findings,ihc analysis,,,,intra-auricular,after diagnosis,white,at least pasi,,,,,
1641,,chemotherapy|measurable disease,systemic psychotherapy)||,,energy,prone predisposition,,,,etc.|prior use of,during the study period.|must,from 0 to 10,one of the,,,,,
1642,,lateral border of the,recombinant human erythropoietin,,estimated fetal weight below,subtotal thyroidectomy,,,,test diets.|participants,within 2 years prior to the first dose of niraparib,between 45 - 65 years,300 mg oral daily,,,,,
1643,,diagnostic nerve block,experimental drugs,,roux-en-y gastric bypass,injection,,,,long diameter ≥10mm,1 month prior to enrollment,≤ 80% of predicted value,once baseline,,,,,
1644,,chronic neuropsychological disorders,allogeneic tissue/solid organ transplant|prior malignancy,,any arterial thromboembolic event,hormonal treatments,,,,surgically unstable,immediately prior to study drug,grade ii/,90mg bid,,,,,
1645,,external postural support,study drugs|previously enrolled,,residual alopecia effects.||active,mechanical ventilation|procedures related,,,,emergent,at the time of enrollment|provision of signed,>2.5×uln|creatinine > 1.5 × uln,≥2 mg/kg,,,,,
1646,,chronic pain|psychiatric pathology,concomitant drugs,,screening|hemoglobin concentration,antibiotic susceptibility test,,,,gravis,in the past 14 days.|participation,≥75 × 109/l|absolute lymphocyte count,maximum frown when assessed,,,,,
1647,,oesophageal motility disorder,systemic steroid treatment,,human immunodeficiency virus test,cels resection,,,,irorr.|soft tissue disease,within 2 weeks of cycle 1 day 1|concurrent,>2.5 times upper limit,one repeat of laboratory assessments,,,,,
1648,,exon 7 + confirmed point mutation of the smn1,progressive neurodegenerative,,alt (≥5.0 x upper limit of normal [uln],physical restrictions,,,,clinical manifestation,during the study|have,≤ 2 ×,≥ 8hr/day|ability,,,,,
1649,,multiple sclerosis|relapse,bedaquiline,,"modified cornell index (abramson, 1966).|no antibiotics",pancreaticoduodenectomy|undergoing surgery,,,,studies.|abnormal,within 4 weeks prior to the first dose.|major surgery(not include,-4.|stage pt1-4,more than 10,,,,,
1650,,well controlled,local contraceptives,,life size picture,neurological surgery|previous application of cimt,,,,molecules made of,after first-line treatment,≥2.5 cm,> 4 months,,,,,
1651,,severe obstructive sleep,materials,,androgen receptor-negative salivary gland carcinoma,mri examination - patients,,,,central nervous system;|participated in experimental drug research,within 8 weeks of the date of first administration,≥ 3)|able to give,fixed dose,,,,,
1652,,heart valve disease,emergency medicine,,complement,aesthetic procedures,,,,pain|having temporomandibular joint pain,within 28 days prior,18 years or older.|greater than 6 months,>5 mg/day,,,,,
1653,,ceerebal spinal fluid (csf),contrast agent,,holiday)|thigh circumference,isolated patients:||patient,,,,colorectal adenocarcinoma;||,at least 4 hours a day,0-1|adequate hematologic,1 or 2 doses,,,,,
1654,,peripheral complications,youth||youth,,stool frequency score,except,,,,sedentary||,up to 5 years prior to screening|is unable to follow study instructions,> 3 x 10^9/l|absolute neutrophil count,80 mg/m^2|no,,,,,
1655,,adenocarcinoma of the cervix,bms,,national id card|written informed consent||exclusion,histological types of cervical cancer,,,,although doses of,newly diagnosed,confirmed.||r/r cd1a-positive,≥ 3wu,,,,,
1656,,other cancer,conventional ct|admitted,,wakiso district,standard physical therapy,,,,life-threatening cdi defined,after treatment;|agree to receive,= 360 ml beer,high risks,,,,,
1657,,½ of the dorsal annulus,hydrocephalus pump,,visual analysis scale,follows:||surgical sterilization,,,,resistance to instis.|ongoing,within 56 days prior to the first administration of study treatment.|unwilling to follow the lifestyle,≥ 130 kg;|vegetarian food;|other associated neoplasia;|patient,1-12 months,,,,,
1658,,sulfonamides,sarcomatoid nsclc,,baseline:|pr interval,partial colectomy,,,,primary modality.||,within 24 hours prior to admission to the emergency department,≥500 mg/,≥ 2 mg/kg/day,,,,,
1659,,detectable disease,nicotine metabolizing enzyme cyp2a6,,ny heart association grade,ecmo,,,,non-fulminant,within 28 days before the first administration of the study treatment,closed,more than six months;|ability,,,,,
1660,,extragastric measurable lesions,fluoropyrimidine,,nyha level,intra-vaginal suppository,,,,abbott.|pregnant,within two weeks of the scheduled date of administration of dwp16001,less than one year|subjects,more than 3 days,,,,,
1661,,extremity injury,ckd)-epi,,hemoglobin s/beta0 thalassemia,b cell-depleting therapy,,,,high rate,within 1 month or 5 years half-life of the research agent,under 65 years||,maximum 2,,,,,
1662,,isolated lesions,torsemide,,implantable cardiac defibrillators (icd),ivt treatment,,,,test;|regular smoking,within 90 days of baseline.|egfr<30 ml/min/1.73m2.|acute,》60 years|american society of anesthesiologists (,more than 1 cigarette per week,,,,,
1663,,carcinoma in situ (cis),conventional dmards,,mothers,light treatment,,,,infratentorial,inpatient admission more than 3 weeks,> 50%|pulmonary artery systolic pressure,more than 5 days following their positive,,,,,
1664,,disc herniation.|patients,direct medical intervention,,fess,emergency cesarean section indication|use of analgesic,,,,ankle stretching,within 2 weeks prior to initial administration;c,> 1 year|willing,primary,,,,,
1665,,north america,blepharospasm,,canadian cardiovascular society (ccs),valve replacements,,,,primary form of,"within 5 days prior to dosing,|evidence of",=< 1.5 x the upper limit of normal,12-week,,,,,
1666,,exclusion criteria||neurological injury,local anesthetic|patients,,sustaining position of neck,blackouts|donation,,,,diagnostic and statistical manual5/5-text revision criteria,within 12 months from the first dose of study intervention,≥ 15 mm);|ecog score of,≥ 10 hours per week,,,,,
1667,,pcd,sbps,,volume,major surgical procedures,,,,suitable for the study,during screening period,score of greater than 3,fewer than 3 days before enrolment,,,,,
1668,,myasthenia gravis.|upper airway obstruction,rapid acting antidepressant agent,,cage score,endoscopic gastroplasty,,,,secondary to immune-mediated,at the randomization visit (day 1,> 38,high doses,,,,,
1669,,nausea,tumor vaccine,,immunodeficiency.|blood pressure,craniospinal irradiation,,,,muscle quality,in the past 5 years|chemotherapy,≥45 and ≤100 bpm,2 or more recurrences,,,,,
1670,,autonomic neuropathy,fractures;|urine,,c-bmi,soc therapy.|participant,,,,myelofibrosis secondary to pv,during the course of the,less than 13.8g/dl||participants,months.|the x-ray,,,,,
1671,,progressive jaundice,strong p-glycoprotein-inhibitors,,sbp≥180mmhg,used|coagulopathy|local infections|opioid addiction,,,,index pci).||,in the past 6 months.|people,>= 750/mm^3,patient.|failed,,,,,
1672,,acute organ damage beyond cardiomyopathy,grains,,karnofsky performance scale,total hysterectomy,,,,deceased donor,last 3 years|chronic,> 12 weeks.||subjects,≥ 60 days,,,,,
1673,,narrowing of the esophagus,vinorelbine,,hiv antibody test positive;|active hepatitis b (hbsag positive,pci procedure,,,,show,for at least 3 years|self-reported,above primary school;|obtain the written informed consent of the patient,2 consecutive,,,,,
1674,,uk brain bank,glycoprotein iib/iiia receptor antagonist,,weighing,full thickness biceps tear|infection and neuropathic joints|known,,,,high-sensitivity pcr,within 8 weeks after surgery;|before and after chemotherapy,between 21 to 90 years,> 500 ml coffee daily,,,,,
1675,,primary dystonia,ttts,,cta,rare,,,,wrist,within 14 days prior to the start of study,≥ 6 mm³,maximum of 14,,,,,
1676,,phlebitis,immediate medical treatment/hospitalization|reported,,unl|systolic blood pressure,non-myeloablative,,,,unquantifiable,within the 4 weeks prior to study enrollment,≥75 × 109/l|hemoglobin ≥9 g/dl,nstemi|revascularization,,,,,
1677,,transthoracic echocardiography).|aortic pathology,over-the-counter drug,,pid,open oral food challenge,,,,anogenital area,in the last four weeks.|no change in medication,score of 10 to 15,≥ 5 mg/day,,,,,
1678,,traumatic brain injury|history,microphone,,mmrp,airway intervention,,,,upper extremity|injured unaffected,within 10 days|daily opioid use,plantar fasciitis,≥ 4 weeks.|cytochrome,,,,,
1679,,mental health care|currently,brolucizumab,,including:||neutrophil count,robotic bilateral nerve-sparing radical prostatectomy,,,,hormone replacement|note,within 4 weeks of admission,≤ 3 x upper limit of institutional,80 g/l);|serum creatinine,,,,,
1680,,infection of the index,compounds of similar chemical or biologic composition to study agent|clinically significant uncontrolled illness|diagnosis of gilbert's disease|females,,md,dental hygiene prophylaxis,,,,classes iii,within 3 months of screening visit,within therapeutic range of intended use of anticoagulants||abbreviations,≥2 non-adjacent teeth,,,,,
1681,,suicidality,terazosin,,kaiser permanente georgia,hemodialysis shunt,,,,interstitial,within last 3 months|history,greater than or equal to 25.|ability to provide informed consent.|planning for treatment with radiation,≥ 6 consecutive,,,,,
1682,,borderline symptoms,chlorohexidine,,special diets|food allergies,optic nerve sheath fenestration,,,,meeting 2016,within 14 days before randomization.|pregnant,≥1.5×109/l|platelet,= 0.45 mg mitoxantrone).|pregnant,,,,,
1683,,bladder tumor,contrast media.|pregnant,,thrombocytes level,oral nutritional supplement|anyone,,,,sirolimus|concurrent,for the duration of study.|for,less than 80 years,<,,,,,
1684,,invasive lesions,intrauterine,,international normalized ratio (inr),cns -directed therapy,,,,without systematic absorption,prior intubation.|the participant,>2.0-5.0×upper limit of normal range)|participation,maximum of 70 total inflammatory lesions,,,,,
1685,,endurance,mebeverine,,recist v1.1.||current cirrhotic status,glenohumeral arthritis.|cervical spondylosis,,,,antegrade,obligatory intake of,40 or higher,more than 6 months duration,,,,,
1686,,underlying issues,basel,,clinician interview based impression,frontal sinusotomy,,,,follow-up,in the 3 months prior to the screening period,<18 and >65,once every 2,,,,,
1687,,ischemic stroke.|patient,opioid use,,ethnicity;|age,venous puncture blood collection;|female,,,,hemodialysis.|patients,within 5 drug half-lives,>160/90 mm,≥2 mg/dl,,,,,
1688,,nephropathy,ssv,,ami presentation.|patients,significant surgery,,,,insulin x glycaemia/22.5,recent exposure,45 ml of spirits,once at,,,,,
1689,,secondary hypertension.|any,urinary diversion,,step,warsaw,,,,suitable for participating in this research,in the next 2 years|known,20-30 u/ml,one prior endocrine therapy,,,,,
1690,,heart rate,cyp3a4),,beck depression inventory-2 item #9 score,incomplete vaccination,,,,american eye association [9];|(2,within 2 weeks prior to the first dose of ft538|live vaccine,0-17.|the,last menses ≥1 year ago,,,,,
1691,,volunteer nurses,oral sulphonylurea,,sars-cov-2 antigen,residential,,,,subsequent,during the screening visit||,> 28 units/week and >4/day,stem cell,,,,,
1692,,non-contact lens,non steroidal anti inflammatory,,bp,eeg testing,,,,therapy-related,at least 2 weeks before baseline,≥10kg|relapsed,≥ 6 months from completion,,,,,
1693,,sensory deficits,amide local anesthetics|history of epilepsy,,h glucose,art regimen,,,,l3-s2 segments).|have,within the past 3 months.|having,<30 ml/min)|clinically,2 weeks,,,,,
1694,,altered mental status,antidepressants tricyclics,,quetelet index,randomization|coronary artery calcium (cac) score,,,,tanner,within the previous 24 hours of screening,≤ 3 cm,≥ 2|indication,,,,,
1695,,postgraduate,agents used in the study.|in the opinion of the treating investigator,,european medicines agency blood volume limits,hrct consistent with viral pneumonia,,,,f2-f3|increased serum alt level (> uln,prior 12 months.|participant,<3 months)diagnosed on,≥ 8.0 g/dl|international,,,,,
1696,,hip fracture,hormonal implants,,absolute neutrophils count,cycloplegic refraction,,,,ionic,more than 4 days,score ≤2.|projected life expectancy,>800μg/day,,,,,
1697,,intercurrent disease,m01,,allograft participants);|positive covid-test results,allogeneic hsct (note: receipt of,,,,hormone replacement,within the next 6 months.|individuals,investigator|vulnerable,1-12 years,,,,,
1698,,n3 disease irrespective of,alfentanil allergy.|non-fasting,,blood cholesterol,dental procedure,,,,long-term storage,patent,≥ 15 ml,30 or more,,,,,
1699,,knee injuries,steroid-based medications|(5,,laboratory))|total bilirubin,ureteroscopy,,,,index date||kidney failure,after 2 courses of induction chemotherapy;(2,< 30%]);|successful recanalization of occluded vessel,5 mg/day,,,,,
1700,,primary lymphoma,targeting drugs,,specific ige values,common femoral arteriotomy created,,,,specifically targets t cell co-stimulation,within 14 days prior to start of study treatment,< 8g / dl,single,,,,,
1701,,treatment.|metastatic disease.|disease,mobilization chemotherapy,,bi-rads,anticoagulant introduced,,,,adeno-squamous,within the 2 weeks prior to the d2c7-it,higher than 14,at least two weeks,,,,,
1702,,cardiovascular etiology|ventricular arrhythmia,fluoride,,basic pulmonary diseases,arteriosus stenting,,,,in a context of ischemic,prior to randomization.||note,60 db or,more than 3 days a week,,,,,
1703,,hypothyroid diabetes mellitus,modification for use,,left ventricular end diastolic volume (lvedv) index,bile duct invasions visible,,,,undewent,during the run-in period,≥ 75 years old,ethnic,,,,,
1704,,crc copd,abnormal movements).|able to,,cardiac intensive care unit at,regular electronic,,,,grade a,for at least 90 days prior to initiation of one of the available study treatments,3 criteria|age,≥ 28 g/l;|total,,,,,
1705,,post-covid-19 pots,indinavir,,residual cns symptoms/deficits,lateral knee radiographs.|patients,,,,stage b (intermediate),in the next 4 months|out,from 0 to,≥ 500 mg/dl.|have,,,,,
1706,,sensory neuropathy symptoms,car-t therapy,,amh level,malignancies|major surgery,,,,protocol.|myocardial infarction,within 30 days before the first dosing date|those,between 20 and 30 years|being,more than 14 units per week,,,,,
1707,,surgeons;|not lung adenocarcinoma,topic,,between 08:00-20:00,eus-guided biopsy samples,,,,some other experimental treatment,in past 1 months,<50 ng/dl,≥ 100 meters,,,,,
1708,,cerebro-vascular accident,influence bmd,,european glaucoma society (egs) criteria,local investigator||,,,,≥12 weeks;|blood test,within the three months before vaccination,>40 kg/m2).|psychiatric disorder.|opiod,greater than 5 days per week||f.,,,,,
1709,,enemas,acinar,,asa class,immunomodulatory treatment regimen.|no smoking,,,,blis q24 application sites,within the past 2 years before screening,=< 1,≥2 weeks before their first imp administration through the study,,,,,
1710,,digital fundus photography camera,diclofenac,,cgas value,trauma focused therapy triggered,,,,cow-milk.|proven,for >2 years,2.5 × institutional uln,regular,,,,,
1711,,conductive silver,albumin preparations,,beck depression inventory-ii (bdiii) score,european neuromuscular centre (enmc),,,,uninvolved,within 4 weeks before the first dose;|previous therapeutic surgery,measured at least 1 week prior,approximately 500 ml,,,,,
1712,,oesophageal reflux disease,ivt of,,seheps questionnaire,metabolic change simultaneously,,,,excessive intake of alcohol.|use of drugs,within 24 hours of admission to the hospital,"18 to 75 years old),|hospitalized",greater than 1.5 cm,,,,,
1713,,transhepatic cholangiography,taxane-based,,lymphoma)|high grade b-cell lymphoma,polymerase chain reaction testing,,,,pd-l1 cps test,within ≤ 2 years before study enrollment,≥3 or more,> 10 mg daily prednisone,,,,,
1714,,chronic immunological pathology,oral drug absorption,,chua,crystalline dystrophy,,,,grade 2 sensory neuropathy|osteonecrosis,for the past 3 months prior to enrollment.|index knee,19.0-30.0 kg/,1-6 months,,,,,
1715,,psychological support,aid,,creatine kinase (ck),general anesthesia.|patient,,,,related arteries,at a dose ≥ 10 mg per day of,score of 14 or higher,≥12 months of,,,,,
1716,,malignant arrythmia,polymerase theta,,pulse pressure variation,hammer toes,,,,secondary to pts,within last 3 months.|have received,≥ 30 times/minute||2,at least two weeks after minor surgery,,,,,
1717,,conditions are unsuitable for participation in this study by the investigator,dimethoxybromoamphetamine,,quantiferon® tuberculosis (tb),thoracic epidural analgesia,,,,"diagnostic and statistical manual of mental disorders, fifth edition (dsm-5",within 3 months prior to screening|prior exposure,≤ 350 mg/dl,≥ 2+ ar,,,,,
1718,,metabolic disorder,fatty liver on imaging,,see appendix 3 formulas used in the study.|qrs duration,choose craniotomy,,,,active surveillance.||active,within 8 weeks prior to randomization.||o clinical examination,≥18 years;|breast conserving,iop>30mm hg,,,,,
1719,,criteria for,homeopathic remedies,,dexcom clarity account,anatomical repair surgery):||ventricular septal defect|atrioventricular septal defect|tetralogy of fallot (,,,,sp-aq,within 2 years prior to screening.|a previous diagnosis,< 12)|unplanned extubation,first onset <3 months ago,,,,,
1720,,discharged to home;|provision of signed,any product containing,,serum vitamin b12 concentration,fangcang shelter hospitals,,,,ethnic minority,at the start of the study,i-iii|willingness,more than 5% of their body weight,,,,,
1721,,anterior chest wall deformity,prescription pain medications,,serum glutamic pyruvic transaminase/alanine aminotransferease (sgpt /alt,routine laboratory examination,,,,below t10.|more than one site of spinal cord,within 4 months prior to day 1 for individuals with,4-1bb agonists),2-dose,,,,,
1722,,erroneous beliefs,compensate,,answering vas queries,computerized tomography (ct) scan,,,,injection site.|coagulation,for recurrence.|must consent to allow,30-65 points,more than or equal to 1 year,,,,,
1723,,scan.|inability,drugs used in the study|renal insufficiency|liver failure-neurological abnormalities,,inflammatory index,optical coherence tomography,,,,stable dose regimen,at least one of the following,18 to 35 years||,dose of 70 gy.||selected stage i to iii,,,,,
1724,,parasitic infection,phenothiazine,,bone fracture|proteinuria,standardized questionnaire (stop-bang)|any,,,,replicating,within 1 week prior to screening.|subject,≥ grade 3 irae,100 mg/l)||ecog score,,,,,
1725,,paraneoplastic syndrome.|current,frontline,,child-pugh class)|body mass index,massachusetts general hospital,,,,st-elevated myocardial infarction,within 1 week of initiating treatment,≥45% or below 20%.|prior,toxic aggression.||,,,,,
1726,,neurologic disorder|contraindications,anti-hcv.|patients,,plwh|hiv-1 rna,refuse treatment,,,,femoral vein access,currently taking,150 mg/dl,greater than 3+,,,,,
1727,,neuritis,agitation|hemodynamic instability|uncorrected,,new york heart association [nyha] class,vasopressor,,,,adenocarcinoma||o,within 14 days prior to the first dose.|presence of,scheduled,dietary,,,,,
1728,,h. pylori infection|pregnancy,autumn,,nyu institutional research ethic board,clinical laboratory test,,,,insulin infusion,during the therapy|intensive therapy,i-ii-iii|bmi,more than 2 years from,,,,,
1729,,dysnatraemia,povidone iodine|known allergy to,,serum free triiodothyronine (ft3),renal replacement therapy)|body mass index,,,,surgery|pregnancy|diagnosed systematic diseases,at the time of informed consent.||2,15-24 years,more than 10 times,,,,,
1730,,osteosynthesis,vein access scale.|subject,,"leukocyte≥ 3,5x10⁹/l",concussion|peak growth hormone of,,,,has measurable disease per recist,within three months before screening;|have,18-,at least 2 weeks before the start of study,,,,,
1731,,injury,sensomotorischen diabetischen,,hepatitis b virus,partial discectomy,,,,mmhg|cheyne-stokes,within one month prior to index surgery|active acne,between patient and care providers,routine mri|time of enrollment,,,,,
1732,,rhinoconjunctivitis,fsgs,,uln|serum creatinine,talk therapy,,,,infarction;|②,in the past month preceding screening;|be,≥30 kg/m2|negative,>75 years||exacerbation,,,,,
1733,,metabolic bone disease|metabolic,hypnotic drugs,,sars-cov-2,hospice ward,,,,pelvic,"within 2 years of baseline.|score ""yes"" on item 4 or item",greater than 2 times the upper limit of normality;|severe,6/360 or,,,,,
1734,,difficulty of swallowing,liver disease)|have,,pem,gastroscopy,,,,osteoporosis|significant,after initiation of most recent therapy,≥ 60 ml/min,spontaneous abortions|history of embryo transfer failure,,,,,
1735,,paraffin-fixed,prophylactic antibiotic treatment,,pwd,valvular surgery,,,,place the subject,"at the time of enrolment,|drug-resistant epilepsy",3.0-4.0 m/s)|10,1 dose,,,,,
1736,,retinal imaging|if standard pupil dilation imposes a,penicillin antibiotics,,anticoagulant therapy|hemoglobin,12-lead ecg test,,,,grade b or higher as per the los angeles classification,prior to the performance of any trial,< 200 cells/mm^3|no,long half life|plasma donation,,,,,
1737,,alzheimer s disease,anti-depressant medication,,diagnosis|american society of anesthesiologists (asa),temporomandibular joint|decreased mouth opening,,,,histologically-confirmed,within the last 6 months|myocardial infarction,letter score ≤ 75 and ≥ 24,more than twice,,,,,
1738,,completed)|hematogenous bji,immune-suppressive therapy,,screening.|quick inventory of depressive symptomatology - self rated - 16 item scale,transplanted,,,,investigator.|available archival tumor,within 6 months before the first administration;|active autoimmune disease,80 years or older,≥ 2,,,,,
1739,,myalgic encephalomyelitis,radioactive agent,,standard score,first-generation antiandrogens,,,,illicit substances,"in the previous 4 weeks,|supplementation with pro-",> 45|inflammatory arthritis|narcotic use,dual,,,,,
1740,,primary sclerosing cholangitis (psc),mbl,,spp,puvatherapy,,,,hydrochloride|significant history,prior to participation in any study-related activities.||,≤ 2.||7,≥ 480 ms)||new,,,,,
1741,,traumatic corneal ectasia,paris,,definition of functional dyspepsia,vaginal delivery,,,,suitable for the ngs required,within 7 days prior to the first admission,>= 75 x 10^3/ul,"≥25 weeks gestation,|at least one",,,,,
1742,,breast-feeding women|deficiency,crizotinib,,uds,vomiting)|active diarrhea|clinically significant,,,,abs,in the past 6 months prior to screening,18+),≥ 2 classes,,,,,
1743,,stress disorder,tnf ir,,process:||to receive induction,b,,,,gastric wall,prior to randomization;|jak inhibitors,greater than 6,≥2 in the last year,,,,,
1744,,abstain from heterosexual activity,unapproved drug,,hiv-1 antibody,corticosteroid nasal spray,,,,lymphomatous,in the 4 weeks prior to screening.|currently taking another investigational drug,scores ≥ 15;|patients health questionnaire-9,hormone?|chronic use,,,,,
1745,,nasal/inhaled,anamnesi,,motor function preserved,surgical condition.|patients,,,,smi-doac combination,within the previous 48 hours of the administration,above age,≥ 10 mg per day,,,,,
1746,,ipaa|bad functional outcome||,any,,ecg should,urine β-hcg test day of procedure,,,,old,in recent 14 days,long-term application,> 1 year.|presence,,,,,
1747,,wi-fi access,medication that would prohibit the safe concurrent use of methylphenidate,,ddh,foreseeable modification,,,,located on the,within 90 days prior to screening|unable to discontinue use,>= 8%,≥2mm,,,,,
1748,,right atrial,antipsychotic medications,,gep,standard of care imaging,,,,after allo-sct,within 14 days prior to the screening visit,≤ 9 points,higher than the upper limit of normal,,,,,
1749,,fistula,topical products,,american thoracic society (ats)/ european respiratory society (ers)/ japanese respiratory society (jrs)/ latin american thoracic association (alat) international diagnostic guidelines,radiographic examination,,,,listed in section 5.5.|history,within 7 days of randomization.|able to tolerate,≥ 5.6 mmol/l,fewer than 12 months,,,,,
1750,,"school graduate,|can read",closed-globe trauma|rrd,,brodey,girl,,,,mild genitourinary system infection,at least 7 days before randomization,>38.5°,5 menses prior to enrollment.||if,,,,,
1751,,adenocarcinoma of the prostate|undergone orchiectomy,cobicistat prescription,,tips endoprosthesis,criteria:||bariatric surgery,,,,amenable to resection,within 24 hours of symptom onset|target vessel qfr-mr>250mm hg*s/m||,11 to less than 18 years,more than 3 weeks,,,,,
1752,,takayasu's arteritis,reason|previous,,bone quality|treatment,giant coronary aneurysm,,,,stomach|large,at the time of randomization|subject,> 1.4,greater than 4 on the stress,,,,,
1753,,sarcopenia be able,esomeprazole,,dizziness handicap inventory (dhi),cta-source images/mri-dwi.|time,,,,cf,in the 3 months prior to screening,lower than 7.|intoxication with,daily for > 14 days|prednisone,,,,,
1754,,serologic status,abatacept,,prostate cancer||,target temperature,,,,older|uncontrolled,within 1 year of baseline||,more than 16 year.|willing to sign,revottack use reliable,,,,,
1755,,ablated liver metastases,injectable contraceptives,,14c urea breath test;|treatment-naive,re-resection,,,,3).|uncontrolled concurrent,within last 12 months|lumber,upper trapezius,14-16,,,,,
1756,,end of radiotherapy,antihypertensive medication|diabetes,,nyha stages,cessation treatment,,,,rate-corrected,at least 4 weeks from antitumor therapy,">= 100,000/ul",more than 14 days after onset,,,,,
1757,,drug dependency.|unstable conditions,ihc 1+/(ish-,,oswestry disability index|body mass index,screening ct scan.|evidence,,,,third- degree,at least 2 units,last intake <48 hours before intervention,≥9 months before enrolment,,,,,
1758,,cerebrovascular conditions,contraceptive measures,,aca,local practice.||,,,,articles l 1121-5 to l 1121-8,at the block site,18-39 years|english-,once paired with mentee,,,,,
1759,,rabies,h2 receptor inhibitor,,creatine kinase (,bone fracture|history of abdominal fistula,,,,collateral ligament,for three consecutive days,18-55|daily smoking,twice daily medication,,,,,
1760,,fontan surgery|abernethy,medications,,cardiac function class,enteral catheter,,,,requirement.|active,at least 3 days a week,"≥ 3,500/μl|platelets",more than 10 degrees,,,,,
1761,,cerebral vasculitis.|evidence,component of the drug|people,,flair,chronic fatigue syndrome.|a complication,,,,type 2 diabetes||using only metformin|bmi= 18.5-29.9 kg/m2||obese group,within 10 years of entry into screening.|participant,"applied,|over 70 years",10-14 days prior to,,,,,
1762,,retentive teeth,nimatevir/ritonavir,,king chulalongkorn memorial hospital|aged,medical procedures of the high-grade vin,,,,investigator(s).|regular alcohol consumption,within established normal limits,< 120 g/l,more than two,,,,,
1763,,dependence forming drugs,anesthetic sedation,,weight loss|gastrointestinal surgery,qt interval corrected,,,,suitable for participating in this study,"since january 1, 2010 and before january 1, 2021",1000-1200 g,one or more times per week||,,,,,
1764,,contraception.|male,braf,,collaborative oncology group performance status,mismatch repair defect,,,,at term,more than three,<25k,> 5,,,,,
1765,,attrition,any covid-19 vaccines,,hcv rna test,basilar artery (ba) severe stenosis,,,,irinotecan-based treatment|abdominal radiotherapy,in at least five workshops,> 2 x normal limit (uln),endocrine therapy.|participants,,,,,
1766,,normal gh secretion,neoantigen synthetic long peptide vaccine.|2,,fvc,ivf procedure|electronic implants,,,,marked tortuosity of the femoral,at the time of kidney biopsy.|signed informed,20-75 years.|patients,≥ 2 years,,,,,
1767,,hepatic synthetic impairment,anti-tumor indications,,men|ejection fraction,autologous stem cell,,,,pd-l1/pd-1|age,within the past 12-month period prior to check-in|subject,30 ml/min/1.73 m2);|life expectancy,≥ 28 days before the first dose,,,,,
1768,,substance abuse;|active psychiatric,blood vessels,,absolute value,resection surgery,,,,extremely advanced,in the next 9 months.|individuals,≥6 points.||,≥ 3 months after transplant,,,,,
1769,,macular fovea,ampreloxetine,,american college of sports medicine's,radiochemotherapy,,,,1|regular heavy,6 months prior to start of the study treatment,1 - 6,doses greater than 5 mgs per day,,,,,
1770,,immunologic disease,pah drugs,,total bilirubin ≤1.5×uln (upper limit of normal),clinical ascvd,,,,endovascular revascularisation||slips inclusion,persist three months after radiotherapy,0-1.|both,≥3 months,,,,,
1771,,open scalp wound,dpp-4i,,creatine kinase>3.0x uln,"fluid management system (baxter, deerfield, il",,,,primary dsm-5,within the past 12 months.||for cohort 1 and 2:||suspected,above the aortic bifurcation,more than 10 years.||,,,,,
1772,,"nitro),body piercing(s)",contraindicate surgery.|participant,,recist v1.1 30:||inclusion should take place no,preoperative examination|patients deemed by the clinical investigator because,,,,rat-confirmed,within the past three months those,high,≥10 mg/d,,,,,
1773,,metabolic etiology;|time,nicotine containing products,,resting heart rate,follows:||transmural myocardial infarction,,,,exacerbated chronic obstructive pulmonary disease,lasting for 12 months,>= 50% stenosis,greater than the lower limit of measurability,,,,,
1774,,membranes,oral hypoglycemic medications,,pugh,allogeneic stem cells transplantation,,,,mild to moderate darker,at least 14 days prior to visit 0:||covid-19 vaccination series,1 and 4.|a pre-bronchodilator/pre-dose fev1,wageningen university|thesis student,,,,,
1775,,hypoglycemic symptoms,live-virus vaccination,,liver metastases|absolute neutrophil count (,lung ct scan,,,,coenzyme q-10,at home|be able to read,meeting,12 g alcohol daily,,,,,
1776,,t2-t3n2am0,adequate serology,,commercial car t-cell,chemo-radiotherapy resolved,,,,first-line,at trial entry,≥18 years|term gestational,"1, 2c, 4c",,,,,
1777,,acute gvhd,lymphodepleting agents,,ghent criteria,slit-lamp,,,,subjects|informed,for at least 12 weeks prior to screening visit 1,≥ 2500 copies/ml,greater than or equal to 6 months|injury level,,,,,
1778,,lipids|chronic liver disease,dmnt3a,,stool h pylori antigen.||,fluoropyrimidine chemotherapy,,,,despite maximal oxygen support)|altered consciousness,within 3 months before administration;|untreated diarrhea,> 3,2 mg/kg/day,,,,,
1779,,aortic regurgitation,antiplatelet medications|patient,,"partial thromboplastin time, urinalysis",focal-to-bilateral,,,,meeting any of the following,within 1 month before the first administration;|have suffered,iii-iv|previous,>10mg/d,,,,,
1780,,sm2/3 invasion,hydroxyurea,,sds,-et,,,,triple,throughout the study|negative pregnancy test,> 35 kg/,2 consecutive viral loads,,,,,
1781,,sitting time)|body mass index [bmi],sabin,,bone age,cm.|concurrent radiotherapy,,,,3 months|adequate organ function,since they have different,4-8 cm,12 month wash-out,,,,,
1782,,hemodynamic unstable arrhythmia,ae related to lenalidomide,,smoking status,volume analysis for split renal function|patient,,,,stroke|hydrocephalus|intra-cranial mass,during the study outside the protocol.|has,≥0.3×10^9 /l,first episode of pericarditis,,,,,
1783,,altered pain,hawkins,,kesimpta-exposed,brain imaging,,,,other immune-modifying drugs.|use of,within 6 months after the signature of informed consent for screening,< 18 years|contraindications for mri,more than 90 days,,,,,
1784,,antiepileptic drug withdrawal,anti-viral treatment,,disease-specific,treatments treatment,,,,cardinal symptom index (gcsi),in first,from 18 to 75 years.|pathologically confirmed,>15 cigarettes per day,,,,,
1785,,therapy.||chronic lymphocytic,electron microscopy,,creatinine (,wheelchair,,,,without curative intent|patient,prior to performance of any study-specific procedure.||,≥1.5×109 /l;|platelets ≥100×109,less than 12,,,,,
1786,,malignant adult,polypropylene,,child of,ventilated head trauma patients.|patients,,,,other subunit vaccines,for at least three months:|negative result for,≥ lower limit of normal,pelvic radiotherapy.|patients,,,,,
1787,,neurosyphilis,hypoglycemic drug,,la test.||confirmation,implantation,,,,acnes|fully completed,after the optimal medical treatment,> 3× times,stent-graft,,,,,
1788,,prominent autonomic failure|neuroleptic treatment,n06aa,,potassium levels,magnetic resonance imaging,,,,choledocho-duodenal,within 6 weeks before the first use of the study drug|oral fluorouracil,< 5x uln,< 10 mg daily,,,,,
1789,,shock waves,rybelsus,,hepatitis b virus surface antigen [hbsag],allogeneic stem-cell transplantation.|major surgery,,,,responding to the conventional treatment,at least one adjacent tooth,equal or more than 7%,>800 mcg/day,,,,,
1790,,rheumatoid polyarthritis,investigational medications,,pacemaker,ophthalmological examination|prior receipt of any potent cyp3a4 inhibitor,,,,hepatocyte-specific contrast agent disodium gadolinium cerate,during the screening period to rule,19 to 55 years,10 mg prednisone);|randomization or research,,,,,
1791,,cutaneous stoma|current,over 100 bpm,,parasite count,hpv vaccine,,,,worse than 20/40,in the past two to three days,> 8.0 g/,more than one week,,,,,
1792,,acute watery diarrhea,android smartphone,,viral hepatitis c,antidepressants.|short procedures,,,,non-tumour,in the month preceding inclusion|patient in exclusion period,< 23,more than 6 months of,,,,,
1793,,hemodynamic instability|infants,component of the,,old|karnofsky performance status (kps),radical radiotherapy,,,,primary rrd,during the study;|consumed soft drugs,10mm hg diastolic pressure,30,,,,,
1794,,brucea javanica oil injection/capsule,humira,,prostate cancer working group,professional gynecological oncologists appointed,,,,low titer positive,at least 1 week,ii-iv|receiving,lamotrigine 200mg/d,,,,,
1795,,type ii dm,monoclonal antibody plus investigational agent,,serum bicarbonate level,covid-19 viral infection,,,,surgical stage,within the last month.|previous prednisolone treatment,greater than (>) 1.2 x upper limit of normal,≥40 bpm,,,,,
1796,,malabsorption of the test material;|under ketogenic diet,oral hygiene measures of plaque,,anti-endomysial antibody (ema,assessment of medical history,,,,topical and pulmonary corticosteroids,in the past 3 months|history,female|age 22 to 65|interested,400mg twice daily,,,,,
1797,,functional classification (fc),st. john's wort,,ultraviolet b,intraoperative fluoroscopy,,,,intestinal microbiota,at time of screening.||b,≥ 4mm,≥12 hours,,,,,
1798,,lactation;|mental retardation,decreased serotonin secretion.|do,,modified dandy criteria,icis.||additional inclusion criteria,,,,sepsis|pulmonary,before cell transplantation;|subjects,less than 30ml/min,2 months after the,,,,,
1799,,obstructive ileus;|diagnosis,antiangiogenic drugs,,hcl device;|bmi,physiological dose,,,,12-week protocol,within 2 weeks prior to the first dose .||14 patients who,5-9,=28 days,,,,,
1800,,familial polyposis syndrome,intranasal medications,,functioning|any medical condition,endocrinopathies,,,,metabolism-related fatty liver,within 2 days prior to start of study,18 who go to hand,less than one-third,,,,,
1801,,arterial thromboembolic event,amphetamine,,recovery,bph)|on urethral foley's catheter,,,,preclude placement,within the vascular arcades,3 - baseline,1 mg daily,,,,,
1802,,ctcae version 5 grade < and equal to1 prior to enrollment,lactate,,platelet glycoprotein (gp),complete psma pet/ct.|multiparametric mri of the prostate with,,,,rome iii constipation,at least one of the following criteria： anc<1.5×10^9/l,18-64 years,2 or less iop lowering medications||,,,,,
1803,,digestive tract bleeding,strong cyp3a4 inhibitor -azole antifungals,,"clexane 1x1 0.6 mg subcutaneous,|who",first-line biologic therapy,,,,carotid arteries,for at least 6 months after discontinuation of the experimental treatments|ability of the patient to understand,<18.5);|have,single-item scale,,,,,
1804,,scalp oncologic defect|complete,anti-cd38,,qrs complex,ventilation,,,,primary diagnosis of bn,in the past 21,< 2.8 mmol/l,more than 2 weeks,,,,,
1805,,affect the sensation of,ticagrelor,,non-mrna,left auricular,,,,between 01/03/2030,within 2 weeks prior to start of any of the study interventions|participants,>= 18|prior tissue diagnosis of,daily functioning||exclusion criteria,,,,,
1806,,external genital cancer,nivolumab plus,,ecog performance scale;|not,mechanical ventilatory support after surgery;|current participation in another interventional study;|previous participation,,,,live,during 5 years before the inclusion into the study except,< 90%,2 or more,,,,,
1807,,cancer.|lack of evaluable material,diabetes|alcohol-,,serum flc ratio,face-down position after vitrectomy combined with,,,,pd for 5 years,more than 4 weeks from the start of this study,>=3 mg/dl|systolic blood pressure,above 14 weeks,,,,,
1808,,ophthalmological disorder,egfrc≤30,,follows:||(1,coronary artery disease)|t2dm complications,,,,long-term antiplatelet therapy,within 30 days in another interventional clinical trial,18.5 to 27.0kg/m2|if,more than 14 units for males/7 units for,,,,,
1809,,trauma.|cervical myelopathy.|inflammatory arthritis,meat,,18f-dcfpyl,hemodynamic monitoring with the starling monitor,,,,anchorage area of the implant|person on legal protection|pregnant,within 12 months prior to screening|any serious,>6.5%,greater than 7 of 30 past days,,,,,
1810,,neurologic sequelae,capox,,lift head from,fraser health,,,,locoregionally advanced,at least 3 unformed,2-negative,≤80 years;|scheduled for elective,,,,,
1811,,genetic skin cancer,component of any of the study drugs,,hip accelerometer daily.||,mechanical prosthetic bileaflet valve,,,,ecog 2,more than 4 weeks prior to the enrollment of this,between 4 mm or more,>14 consecutive days,,,,,
1812,,extranodal lymphoproliferation,low-level,,nih laboratory of pathology.|pd-l1 expression,femoral artery (,,,,apl)|central nervous system,during and 12 weeks after the trial participation|history,degree ii or above,≥1 time/month)|subjects,,,,,
1813,,ekg:||st segment elevations|t-wave inversions vii,ritonavir,,mmhg)|heart rate,prenatal care,,,,shortly,at least 20 previous,> 50%,1 drink,,,,,
1814,,large varices,agents targeting cd33,,combined hiv antigen/antibody test,therapy|prior treatment,,,,intra-labyrinthine hemorrhage,at least 4 weeks from treatment should document,18 to 80 years.||adequate renal,≤100mg/d);|have,,,,,
1815,,bone marrow functions,long-acting anticholinergic drug,,electrophysiology test,intrathecal drug administration|abnormal laboratory values,,,,high-,at least 4 weeks prior to randomization,≥ 60 ml/min/1.73m²|a,more than 1 time;|the,,,,,
1816,,sensory impairment making,inhaled marijuana,,thyroid stimulating hormone (tsh),focal treatment,,,,krasg12c mutation,at least one network member to participate,1、18-65 years,≥ 1.5 x uln,,,,,
1817,,hepatitis b virus (hbv),herbal remedies|known,,periodontal affection of the abutment teeth.|skeletal mal-relation.|unmotivated,flow cytometry evaluation of red blood cells,,,,amenable for surgical resection,within the course of the,≥ 7.5 mg/day,>1,,,,,
1818,,hippocampus,omm,,18f-fdg-pet/mr,abrasion,,,,select,within 14 days prior to the first dose of study drug.|regular alcohol consumption,18 years and above who,6,,,,,
1819,,|or abdominal obesity,diets,,as:||absolute neutrophil count,mental autonomy,,,,any,within 1 month;|infectious diseases,greater than or equal to 40,1) those,,,,,
1820,,kidney disease|abnormal liver function,hybrid lenses,,||- serum creatinine,biological agent,,,,ohio appalachian county,within the past year to the screening,++ but negative,more than three months.|at enrollment,,,,,
1821,,nsclc disease,pharmaceutical compounds,,f)|systolic blood pressure,ip or,,,,site of needle insertion,while not taking,≥6 mm per quadrant,two,,,,,
1822,,n02,opioid addiction|patients,,weight loss,index;|pregnant,,,,"diagnostic and statistical manual of mental disorders, 5th edition (dsm-5) criteria",within health clinic,< 10mm|corneal staining,1mg daily or higher,,,,,
1823,,age.|physical conditions allowing sustained,milk products,,cq|age,orthopedic intervention,,,,requiring the use of steroids,in the 14-week tv48574-imm-20036 drf study|participants,< 150 days prior to study vaccine,≥1 dose,,,,,
1824,,upper gastrointestinal surgery.|patients allergic,lang,,bechterew's syndrome)|rheumatological conditions,screening|repeated measurement of systolic blood pressure,,,,grade 2 sensory neuropathy)|medically able,within 2 weeks prior to initial first administration,50-80,january 2006-,,,,,
1825,,neurological damage;|congenital malformations,amoxicillin,,sars,local regional treatment site,,,,steps|self-reported,in the past month|illegibility to mri,0-2|being able,january 2008 to december 2016,,,,,
1826,,extensive uterine fibroids,bile sequestrants,,apical hypertrophic cardiomyopathy,screening contrast brain mri may still,,,,non-medical,within 6 weeks prior to screening,3 to 18,repeat fistula repair by,,,,,
1827,,renal function impairment,intense pulsed light (ipl),,platelet transfusion|neutrophil count,extension procedure,,,,ssyc,within the study duration.|intraocular inflammation,greater than 20,more than 80% of the,,,,,
1828,,hepatocellular failure,insulin aspart,,hepatic||total bilirubin,preoperative puncture,,,,icg injection beyond the submucosa|visual inability to identify the,during the inclusion period|parents,within normal reference range).|in,≥ 19 years.|clinically,,,,,
1829,,atraumatic lateral epicondylitis symptoms|symptoms,fess,,hematocrit values|pregnancy|body weight,laboratory values:||absolute neutrophil count,,,,fixed to the,during and after study intervention.|the investigator,0 to 2.||laboratory values,>1/40,,,,,
1830,,kind|mental impairment leading,plasma,,endogenous creatinine clearance,test reports,,,,site of needle punctures,in the next 1 year after,between 2009 and 2015,daily intake of more than 1,,,,,
1831,,diarrhea)；|patients,mrna,,hepatitis b (hbsag positive,standard pelvic imaging (mri/ct).|high-tier intermediate risk,,,,manifestation,1 week prior to enrollment,9-12|greater than or equal to 2,more than 30 days.|15,,,,,
1832,,stuffy nose,treatment,,value|prothrombin time international ratio (inr),nasal prongs,,,,study;|cannot,one month before or after submitting,19.0 to 32.0 kg/m^2|body,10 mg,,,,,
1833,,mac,cyp2c8 inhibitors|patient,,serum psa,ct examination,,,,systemic ae therapy;|patient,for the scheduled duration of the trial,from 7 to 14 years old,100 x 109,,,,,
1834,,preterm labor|bleeding,day,,dsm-iv criteria|total score,rheumatological diseases||non-plaque psoriasis|rheumatoid arthritis|osteoarthritis|gout|reactive arthritis|ankylosing spondylitis|axial spondyloarthritis|enteropathic arthritis|plantar fasciitis|systemic lupus erythematosus,,,,notable,for < 3 months prior to study,< 80 degrees|suspected instability,≥ 5 years,,,,,
1835,,super-refractory status,muscarine-receptorantibodies,,rapid sequence,revision total,,,,peri-implant,within 1 year of pregnancy,"≥18 and ≤25kg/m²,|for",,,,,,
1836,,severe medical illness,drugs of the drugs containing the same class,,weeks|american society of anesthesiologists physical status classification,reason|intubation,,,,stye).|active,within 5 days prior to study treatment initiation,1 year before the screening period,,,,,,
1837,,tumor disease|pathological dental status|known disease,oral warfarin,,not||,congenital nonhemolytic hyperbilirubinemia,,,,low-grade prostate cancer,since last echo,at least 21,,,,,,
1838,,foot pain,compounds of similar chemical or biologic composition to astx727,,amiens picardie university hospital (chu amiens picardie)|child's affirmative agreement,oesophageal strictures,,,,potentially pathogenic variants,within the 6 months preceding screening.|subject,18 to 75 years,,,,,,
1839,,"c),|endocrine diseases",acarbose,,valgus,multiorgan,,,,nafld-fibrosis.||,for the next 16 months;|willing to complete the activities,=< 3 x uln|calculated,,,,,,
1840,,degenerative valvular heart disease,mg/100ml,,prothrombin time (,treatment|inability to swallow oral medications,,,,low back pain.|bilateral,prior to study enrollment.||reproductive potential,≥ 1 500 cells,,,,,,
1841,,diffuse pain,compounds of similar chemical or biologic composition.|the,,afp,assisted reproductive technology,,,,ww strategy,at least 1 point each in inflammation,≤ 1.5 x institutional upper limit normal,,,,,,
1842,,setting,mineralocorticoid receptor antagonists,,screening.|fev1/fvc,femoroplasty,,,,ipsilateral leg.|clinically significant,within 24 hours of the end of surgery|nerve blocks,18 and older.||,,,,,,
1843,,dermatopathic nodes,anti-vascular targeting agents,,cmorf-i ingredients,fresh biopsy material,,,,neurodegenerative disorder||clinically significant,within 30 days before the first dose of the study drug.|have,between 26 and 75 years,,,,,,
1844,,medical center,contraceptive method.|drug abuse,,queens square brain bank,donated 1 unit,,,,histologic type of tumor,at the screening visit after 5 min,score of ≥ 1,,,,,,
1845,,neuroendocrine tumor,trial-related intervention,,visual examination.|the carious lesion,hypoxia procedure,,,,subsided.||pregnant,during the exam,greater than 6 months||adequate organ and marrow function,,,,,,
1846,,intermetatarsal bursitis,prescription medicine,,haemoglobin a1c (hba1c) level,hematopoietic cell transplant,,,,ocd|on,during the qualitative interview sessions,< 15|psa ≤ 30 ng/ml|prostate volume ≤ 90,,,,,,
1847,,intramuscular injection,topical ocular therapies,,proteins levels,bladder before radical prostatectomy.|patients,,,,suitable for ae assessment,in the last 30 days,class 2-3 copd|forced,,,,,,
1848,,potential opportunity,arginine hydrochloride,,total bilirubin>2 times the upper limit of normal value|urinary,radiosurgery procedure,,,,clinical stages,< 3 kg,>= 18.5 to < 39 kg/m2|have,,,,,,
1849,,stroke|peripheral arterial disease,component of the investigational agent,,undergraduate,frankel behavioral scale|those,,,,older|consanguineous,at least 6 months prior,=< 2.0 times upper limit of normal,,,,,,
1850,,concha bullosa,chemotherapy regimen,,lansky performance status (lps),full-body ct-scan,,,,influence stomach,at the time of screening/enrolment,<18.5).|significant psychiatric disorders,,,,,,
1851,,hiv infection|active tuberculosis,controller medications,,mini-mental state examination score,baseline|concomitant hydroxyurea (hu) therapy,,,,impairs phlebotomy,for 3 years,> 3 and/or|ipss score,,,,,,
1852,,tumor diameter,tnf-α inhibitor||,,planned.|off-pump surgery,preservative|treatment,,,,general supportive,at least 48 hours prior to entering the study.|patients who are receiving,"levels ii, iii, iv and vi).||",,,,,,
1853,,histopathology incloud squamous cell carcinoma,tone,,international classification of sleep disorders,emergency surgery||,,,,pericardial effusion.|major surgery,within 6 months prior to screening;|subjects,"grades i, ii, iii",,,,,,
1854,,constitutional mosaicism of,coc,,creatine phosphokinase,qualitative β-hcg,,,,fcbp starting,within the last 1 month or 5 half-lives,> 2.0 uln,,,,,,
1855,,pulmonary organ,tetracyclines,,prothrombin time(pt,carbohydrate counting,,,,general medicine,after previous treatment,score of 22 or below,,,,,,
1856,,genital warts,lurbinectedin,,nyha)|egfr,allogeneic stem cell transplant|patients,,,,live-virus vaccination,within 15 mm proximal,levels rise in pregnancy thus,,,,,,
1857,,malabsorption syndromes,anti-thymocyte therapies,,ventricular end diastolic dimension,psychotropic medications,,,,non elective operation,during the 6 month study period|pregnant,≥32,,,,,,
1858,,abnormal ecgs,psychomimetic drugs,,liver stiffness,therapeutic options||melanoma dose expansion cohort only||histologic,,,,t3-n2,within 30 days prior to entry,<50 ml/min|activated,,,,,,
1859,,al amyloidosis,immunosuppressive agents.|primary central nervous system (cns) disease,,response to item,screening procedures being,,,,vaccines.|hereditary,at the time of random administration,> 300 mg/g,,,,,,
1860,,non-exudative macular degeneration.|are willing and able to comply with clinic visits,age|recipients,,creatinine clearance rate,palliative intent,,,,non-target vessel,within 30 days prior to receiving the investigational vaccine;|receipt of attenuated live vaccines,below 30 nanograms per liter (ng/l,,,,,,
1861,,sma,drugs involved,,tear film break up time less than 10 seconds|ocular surface disease index,urine culture,,,,"related to diabetes.||for example, people who are not eligible are those who work for companies",within 28 days prior to first dose administration of the ip:||leukopenia,≥35-40 kg/m2)|type,,,,,,
1862,,nonhematologic toxicity,acute medications,,intermediate bclc-b hcc.||advanced,treatment-related mds,,,,non-dialysis).||,in the month prior to study inclusion,450-480 msec,,,,,,
1863,,nighttime menstrual,anti-cd20 therapies:||receipt of a live,,27+,gastric/duodenal,,,,locally-advanced,within 2 weeks prior to icrs,18-55,,,,,,
1864,,isolated trauma,slc7a11,,resident,24-hour urine collection for determination of creatinine clearance,,,,influence glucose,within 90 days before screening irrespective of medical records.|personal,< 18 and > 90 years,,,,,,
1865,,acute liver failure syndrome,glucosamine,,nantes university hospital,preoperative cat-scan||,,,,absolute contraindication,before starting any screening procedure.||,less than 30 days,,,,,,
1866,,fibrous dysplasia,pk-12 classroom,,mdrd formula).|serum levels of magnesium,bicuspid aortic valve|severe aortic regurgitation|severe mitral,,,,non-mr,within 7 days before starting treatment,≥ 130/85 mmhg,,,,,,
1867,,6:||healthy,immunomodulatory drugs,,serum virology test,good metabolic control,,,,liver clinics of,in the past 5 years|patients,= 100 x 10^9/l,,,,,,
1868,,swallowing disorders,first cousins,,md anderson definition,treatments,,,,mps iii disease,within 24 months prior to check-in|fever,at least 3 months.|eastern,,,,,,
1869,,stenotic lesion,anti-angiogenic agent,,copenhagen general population study 40,panic disorders.|meets,,,,inadequately,within 3 months of the study,18 to 51,,,,,,
1870,,rapid disease progression,granulocytes,,addiction.|congenital malformation,antihypertensive medication|bp<140/90 mmhg,,,,locally advanced）|her2 positive,within 12 month period|vitreous,= 80 ml/min,,,,,,
1871,,arthralgia,erythropoietin stimulating agents,,atk,neural stimulation,,,,general anesthesia,within 3 months of the first dose.|males,>= 30%)|patients,,,,,,
1872,,cervical cord injury,simeprevir,,new york heart society heart disease,hours|physical exercise,,,,full-term neonates:||neonate,within 6 months before the study treatment,than 50% reduction of proteinuria,,,,,,
1873,,third and/or fourth dose considered as booster,otc doses,,optic disc diameters,reliable birth control method,,,,requiring new,where the potential participant does not,≥ 0.1%,,,,,,
1874,,major bowel,polyene paclitaxel,,best corrected visual acuity (bcva),craniovertebral angle,,,,conjunctival,in the last 30 days|ability,over 18 years old,,,,,,
1875,,eosinophilic gastroenteritis,contraceptive,,bone marrow cytogenetics,subject.;physical examination,,,,eac)|able to swallow a tylenol sized,within the last 6 months;|persistent,long term follow- up.||,,,,,,
1876,,calculated by cockcroft and gault equation),factor xa inhibitor,,total bilirubin.|qtcf interval,"vascular surgery unit,",,,,diagnostic and statistical manual of mental disorders 5th edition;|have mild dementia,prior to catheter placement|platelet count,"<100,000/μl)|significant",,,,,,
1877,,involvement of more than 40% of the vertebral body|radiological evidence of cortical involvement,nsaid drugs,,american society of anaesthesiologists (asa),sphicterotomy,,,,"alter the absorption, distribution",for at least 2 weeks prior to enrollment,over 70 years,,,,,,
1878,,primary renal disease,dr. dhall on the basis,,"unresectable stage iii or iv,",slums,,,,primary cause for hospital admission,at the time of study eligibility,48 to 96 hours after sedation,,,,,,
1879,,ischemic macular disease,strong inducers,,geriatric medicine clinic|on,exposure procedures,,,,muscle invasive,within the previous month before inclusion,=< 1.5 x institutional upper limit of normal,,,,,,
1880,,health enough,macrolides,,human immunodeficiency virus (hiv) antibody,anticancer therapies,,,,"alter the absorption, distribution, metabolism or excretion",at least one of the 2 parents or legal representatives legal representatives,therapy.||at least 1 measurable,,,,,,
1881,,tumor-associated,anti-coagulants|recent,,to excellent performance status,upfront surgery,,,,"mellitus,|patients with",within in the past 3 months;|receipt,"0, 1 or 2.|presence",,,,,,
1882,,excessive amount,1).|classical orthostatic hypotension,,59th medical support group,rhythm management system revision,,,,suitable for intensive chemotherapy,within 90 days prior,22-59 years.|in,,,,,,
1883,,intracerebral hemorrhage,ehlers danhlos,,asthma|heart rate,allergen immunotherapy product,,,,spastic phase.|the degree,within 4 weeks prior to day 1|receipt of a,less than 3 months experience,,,,,,
1884,,bilateral sinonasal polyps,osilodrostat,,moderate tbi severity,cidi,,,,below the renal artery level|expected survival time,while on study.|patients must not,> 18 yo)|≥5,,,,,,
1885,,50,immunological agents,,american college of rheumatology (acr) classification criteria 1997,foreshortening,,,,valvular|atrial,before their first imp,30-85 years,,,,,,
1886,,idiopathic peritonitis,inflammatory disease|pregnant,,hb ss,antiplatelet therapy,,,,neti-pot,within 45 days after laa occlusion,score of 13-15 after 30 minutes,,,,,,
1887,,acute reaction,strabismus,,triglyceride level,darolutamide therapy,,,,moderate to severe substance,at the time of screening|montreal cognitive assessment (,18 years and above.|females.|histologically,,,,,,
1888,,photosensitivity disorder|fitzpatrick,migraine-like features,,barc,institutional review board (irb)-approved informed consent form (icf).||,,,,apparently been,for at least 6 months prior to visit,<= 7.2,,,,,,
1889,,primary lesion,slos,,ceftriaxone,maintenance asthma,,,,very rapid,within at least 7 months after the last dose of t-dm1,score of < 12 months,,,,,,
1890,,end the surgery|preoperative adjuvant therapy was given,adjuvant,,uk brain bank,eradication therapy,,,,brafv600e,perforation.|prior,score a,,,,,,
1891,,professional basketball players,iugr,,mild autism spectrum disorder,study;|participation,,,,calcium channel blockers).|a participant,within 28 days after informed consent;||the function,18.0 to 30.0 kg/m2,,,,,,
1892,,respiratory functions,mesenteric artery,,hh.||individual level inclusion,enzyme-inducing anticonvulsants,,,,type ii diabetic,within 24 hours,"150,000-450,000/ul",,,,,,
1893,,osteomalacia;|osteoporosis,components of the drugs used in the study;|presence of immunodeficiency,,old|edss score,platinum chemotherapy,,,,that may lead,lasted for at least one week,"<100,000/microl,|serum",,,,,,
1894,,depression)|current pregnancy,components of the monoclonal antibody,,partial gastrointestinal function,lumbar degenerative disc disease|no,,,,unstoppable,for at least five months after the last dose of isatuximab treatment,0-2|adequate end organ function,,,,,,
1895,,non-infectious,heparin analogs,,anc level,cancer|kidney dialysis patients|patients,,,,augment,within 14 days prior to the examination：||neutrophil absolute count,23 kg/m^2 or more,,,,,,
1896,,alaska native,maprotiline,,℃,peripheral artery revascularization,,,,patients|disturbed,within the last two years|people with,44 ml)glass of,,,,,,
1897,,mac species.|pulmonary tuberculosis (tb):,fish oil|vegetarian|tobacco smoker|current,,liver function/migraine,practice of the unit,,,,gout.|malignant,during a maximal cardiopulmonary exercise testing (cpet),± 5 years).|mmse,,,,,,
1898,,fulminant colitis,global impressions,,pbc,cell implantation,,,,screening|serious,maximum 12 months prior to enrollment into the study,between the 34th and 37th week of pregnancy|birth weight ≤2500 g and ≥1500,,,,,,
1899,,.radiotherapy pneumonia,mifepristone,,gds,pcv,,,,precancerous,since measurement|willing to,> 190,,,,,,
1900,,regenerative technologies,anti fungal,,spain)|age,atp,,,,extensive-stage small cell lung cancer,following iv immunoglobulin,≥ 1×10^9/l,,,,,,
1901,,express,cannabinoid products,,ecog performance status score,first revision thr|age,,,,medically significant,at any time may be eligible.|evidence of,< 60 ml/min|hyponatremia|pregnancy,,,,,,
1902,,clearance,dipyridamole,,esr normal,invasive cancer|neurological,,,,low user dependency,prior to study-specific procedures.||6,at least 3 months.||hepatitis b surface antigen (hbsag),,,,,,
1903,,abnormal core set measures,st. john´s,,drss,great vessels,,,,months|abdominal,"more than 3 times dose of 10,000international unit/4weeks regimen",≥ 18|ability and willingness to give,,,,,,
1904,,time.|active infection,recombinate,,mdg,intensive care unit (icu),,,,anastomotic sites,within 4 weeks before the first dose of investigational,≥ 9.0 mg/μl,,,,,,
1905,,mustang,non-steroidal anti-inflammatory medications|inability,,genotype test|previously hcv,microscopic colitis.|history of pancreatitis,,,,low-level,at night) or;|if their estradiol dosing,≥1 to <18 years,,,,,,
1906,,renal failure|metabolic disorders,immunosuppressive-dose,,drug abuse;|6,endocrine replacement therapy,,,,lacked effective treatment;|ror1+,within 3 months prior to the day of study vaccination,18-60|dsm-5 criteria,,,,,,
1907,,cardiac rhythm abnormality,topical corticosteroid,,fio2,local health authority.||concurrent,,,,clinically significant abnormalities,in the last 5 years.||asthma medications,> 18 and <,,,,,,
1908,,2;|congestive heart failure (chf),oral corticosteroids,,patients.|body mass index,ocular trauma,,,,suitable for participating in this trial in opinion of the investigator,within prior 6 months,>15g/day,,,,,,
1909,,plegia,allergology,,partial thromboplastin time [aptt],radiotherapy|prior history of head and neck cancer,,,,extended endopelvic resection,within 3 months of screening|diagnosed,< 18 years|fetus,,,,,,
1910,,surgical pathology,receptor agonists,,screening.|ecog performance status,weight control,,,,≥37.7ºc oral,during the past six months.|multiple,≥ 3 months prior to day 1,,,,,,
1911,,osteonecrosis,fenytoïne,,2023|age between,autologous stem cell transplantation.|5),,,,dutch heart foundation in combination with the luscii app|persistent atrial fibrillation,within the previous 12 months|pregnant,18 years|permanent dentition,,,,,,
1912,,chronic periodontitis;|refusal,e.g.||novocaine,,mmhg).|serology,testing intervention,,,,yale team's judgment,newly onset-headache,registered older adult,,,,,,
1913,,diagnosis|diagnosis,opioid analgesia,,heart rate,anticoagulants surgery duration,,,,pre-menstrual dysphoric disorder,within 7 days prior to treatment administration.|donation of whole blood,between 3 and 24 years|multidrug dependent,,,,,,
1914,,maxillary incisors,biologic drug,,screening|absolute neutrophil count,antituberculosis,,,,arteries,within 6 months of randomization.|uncontrolled infection.|history,18 to 40 kg/m2.|enteric hyperoxaluria,,,,,,
1915,,active)||active inflammatory bowel disease,drug components of this protocol|clinically significant,,who criteria,common aeroallergen|methacholine,,,,site of disease amenable to biopsy,after hormone replacement therapy,18 or above|smoke,,,,,,
1916,,cardiac arrhythmias|cerebral vascular accident/stroke,ciprofloxacin,,hip fracture,urosepsis,,,,virus vaccine,during surgery or study therapy;|known,45 and over,,,,,,
1917,,psychological deficits,low flow,,her2 negative);|subtype of similarity network fusion-4,immobilization,,,,stated in section 3.3.1.|for healthy,at least four viable segments).||,=< 135 u/l,,,,,,
1918,,phosphorus metabolism,anti-inflammatory medications,,traditional chinese medicine,endoscopic ultrasound-guided,,,,pd-l1 or ctla-4,during the imaging steps.|patient,≤ 2.5 × institutional upper limit of normal,,,,,,
1919,,predisposition,anti-estrogens,,serum hiv rna load,female sterilization,,,,diabetes|uncontrolled,within 4 weeks before the screening visit.|6,≤ 1.5 x upper-normal limit (uln),,,,,,
1920,,acute myeloblastic leukemia,urodynamics,,ssa,segmental resection,,,,additional,at the time of signing informed consent.|diagnosis,<4 x,,,,,,
1921,,organ transplantation.|patients,attempts permitted).|no change,,insufficient renal function,hormone-replacement therapy,,,,continuesly 15 days before the recruitment.|growth problems,within 8 weeks of screening.|known,≤ 1.5 × upper limit of normal (uln),,,,,,
1922,,squamous-cell,pomegranate juice,,liver resection;|liver function,targeted therapy,,,,synchronous,within 12 months of the start of induction therapy,> 190 mmhg,,,,,,
1923,,inflammatory response syndrome,cns1,,needed,identification,,,,non-english speakers,within 3 months prior to the administration of study vaccines,<1000 grams birth weight,,,,,,
1924,,bowen´s disease,smn2,,thyroid disease)|hemoglobin a1c,stool testing,,,,increases in blood pressure,greater than 6 woods units|emergency cardiac procedure,≥ 27%,,,,,,
1925,,left ventricular hypertrophy.|known,chondroitin sulphate,,niaaa natural history protocol,prone head orientation tests,,,,avium-intracellulare infection (mai),within 2 weeks before the baseline visit,between 18-65 ages|be,,,,,,
1926,,solvents|participation,cyp2c19 inducers,,cohorts,complete sars-cov-2 vaccination.|start vaccination,,,,standard-of-care treatment,within 1 year of signing the informed consent,greater than 1 year.||,,,,,,
1927,,dihydropyrimidine dehydrogenase deficiency,mild oral dysplasia||,,hr<50 bpm,larger.|prior surgery,,,,c3-c6,at time of enrolment|treated,< 35 ml/,,,,,,
1928,,clotting factor deficiencies,etiology,,entry criteria)|prothrombin time (pt)/ partial thromboplastin time (ptt),adt treatment,,,,cht,prior to initial treatment.|a,between 40-60 years.|all patients will suffer from post mastectomy lymphedema.|all,,,,,,
1929,,romantic attraction,er)+/progesterone receptor,,moderate physical exercise|orthostatic hypotension|any condition,vaginoplasty surgery||,,,,large moles.|pregnant,within 4 weeks of the first dose of treatment|has,≥50% scalp hair loss,,,,,,
1930,,hcq,asphyxia,,hepatitis b antigen [hbsag],therapeutic purposes,,,,timi 0 flow,at least 2 previous birch pollen seasons,"6 to 35 months, inclusive",,,,,,
1931,,nac,cholinesterase inhibitors,,mrd,maintain dietary habits,,,,splenomegaly,within 6 months prior to the start of the study;|any condition,"≥ 1,500/mcl;|platelet",,,,,,
1932,,gilbert disease,anti-tnf agents,,tranexamic,spine tumours||,,,,correct,for the first time|having low score of,<40 years,,,,,,
1933,,chronic plaque-type psoriasis,goserelin combination therapy,,vision read,percutaneous arterial interventional catheter-based procedure,,,,systemic,at time of enrollment,≥ 45ml/min/m2,,,,,,
1934,,type 1 diabetes;|the,branaplam,,hemoglobin a1c (hba1c),pharmaceutical study,,,,aboriginal,for 2 years or more,2.18-60 years,,,,,,
1935,,fluid,contraindicated combination drug,,spinal surgery||specific pathology,sulfasalazine,,,,occlusal interferences|pregnant,within 48 hours before surgery.|patients,lower than 100 x 10e9,,,,,,
1936,,pregnancy complications,periodontal spaces.||,,imjudo,preoperative imaging.|patient,,,,no-t2d +ms / no-hf,during the 3 months prior to the screening visit,>/= 3 years,,,,,,
1937,,signs of cirrhosis,online learning;|previous,,unl|total bilirubin,fragmented ambulatory care,,,,high level of pain,for ≥ 3 years,> lower limit,,,,,,
1938,,primary malignancy,poxvirus vaccine,,tbr,icu monitoring,,,,and||good general health,after previous induction,< 2.5 uln,,,,,,
1939,,neurodegenerative disease,cholagogic drugs,,pulmonary function testing|bmi,living donors||,,,,unaccepted,prior to starting study,0-6,,,,,,
1940,,facial cellulitis|allergy,nasal congestion,,screening.|essdai score,clinical imaging,,,,non-arteritic anterior ischemic optic neuropathy,"within 7 days before operation.|at the same time, the lesions",greater than or equal to 4.0,,,,,,
1941,,painful stimulation,women;|denosumab,,diastolic ap,gemcitabine for injection,,,,stage iia,for the duration of the study.|able,= 9 g/dl,,,,,,
1942,,care.|patients,recipient.||donor,,progesterone receptor (pr)- positive.|her2/neu-negative.|ki67≥30%.|clinical,chest computed tomography (ct) scan|active tuberculosis (tb),,,,non-hormonal intrauterine device,within the last 45 days,450-500 meters,,,,,,
1943,,abdomen|pancreatic cancer,oral contraception,,|plasma glucose,early treatment discontinuation,,,,lower limbs,within 2 years of screening,> 160/100,,,,,,
1944,,congestive heart failure|diabetes mellitus,scalene,,gamma knife thalamotomy,e-cigarettes)|abuse,,,,3 or greater,at the time of biopsy sampling|radiofrequency ablation of the,less than one month|contraindication,,,,,,
1945,,glass opacities,anxiolytic drugs,,gestational age|24,hysteroscopy,,,,hollow-screw,within the previous six months,=< 1.5 institutional upper limit of normal (uln),,,,,,
1946,,anatomically suitable,ideations,,hepatitis c co-infection.|as,cardiac magnetic resonance imaging (cmri).|in patients,,,,metal plates,pre-planned,between 40 to 80 years old,,,,,,
1947,,gestational diabetes,other drugs,,glycosylated hemoglobin is,laser treatments,,,,medication use in which alcohol consumption,within 14 days of study drug,> 25 o-log score,,,,,,
1948,,ifnα preparations,medication that can suppress immune function,,rvr,vertical directions,,,,peer-reviewed publication,at least 7 days after enrollment,< 80 years,,,,,,
1949,,intracerebral hematoma,inhaled corticosteroid (ics) combination,,anti-hcv antibody,cecs,,,,surgery|associated,for up to 22 hours iii,between 25-36,,,,,,
1950,,nos|dlbcl associated,turbt,,spherical equivalent,intracranial stent treatment,,,,unconsciousness|current,within the last 14 days.|platinum-based,20-50 years.|both,,,,,,
1951,,various causes,cannabis-related products,,best-corrected distance visual acuity (bcdva),brain radiation treatment volume should,,,,nonprescription,1 month after delivery|willing to deliver,≤ 2.5 times the upper limit of normal,,,,,,
1952,,prolonged cpap,meibomian gland,,total hip replacement made,abdominal hernia,,,,peptic ulcer;|patients,in doses of >10 mg,20-30 minutes,,,,,,
1953,,hypertensive crisis,pioglitazone|good general health|bmi,,extension of,mini mental state examination (mmse),,,,histologically confirmed,at least 6 doses of vaccines have been,≥ 4mmhg,,,,,,
1954,,psa progression,abdominal,,modified ashworth scale|in,transcutaneous oxygen test (tcpo2),,,,non-interventional studies);|patients,within 12 months of study recruitment.||inclusion,1.1 target lesion,,,,,,
1955,,nasal tract malformations,enfortumab vedotin,,visual impairments|psychological disorder|history of other neurological disorders|pusher's syndrome|hemineglect|abnormal synergic pattern|rheumatoid arthritis,percutaneous thermoablation,,,,non-cns disease.|major surgical procedures,within 3 months before the first administration;|known to have,greater than or equal to (≥) 150 percent,,,,,,
1956,,obsessive compulsive,anticancer agents,,quantiferon®-tb gold (qft-g) assay,diagnostic robotic bronchoscopy,,,,could interfere with the usage of a,in the last 12 months.|subject,< 2.5 times upper limit of normal,,,,,,
1957,,chronic migraine,combined acei,,sdmt,mr|no history,,,,multigravida,within the past 2 years|current,intraparenchymal,,,,,,
1958,,ovarian tumors,operationalized,,hepatitis b dna titer,pelvic physiotherapy treatments,,,,less severe,within the last 24 months,≥ 50ml/min,,,,,,
1959,,disability to read,sulfinpyrazone,,hbv dna+).|active hepatitis c,vigorous exercise for more than 5 times per week|alcohol,,,,poorly differentiated,last 5 months,from 25 to 29.9 (kg /,,,,,,
1960,,exhibit covid-19 symptoms,pd-1 inhibitor therapy,,international physical activity questionnaire (ipaq)|absence of any chronic condition,alternative medical cause.||a,,,,early morning,in the past 6 months;|patients,≥90 ml/min,,,,,,
1961,,in-situ disease,cyclin-dependent,,helpers stay quit condition,vats);|central laboratory pathology,,,,corrected,within 3 months prior to date,between 16 and 35 years old,,,,,,
1962,,heart diseases,necrotic tissue,,mean corrected qt interval,designee.|white,,,,not-extensive subgingival,within the next 6 weeks,≥250 mmh₂o,,,,,,
1963,,sars-cov-2.||children,anti-inflammatory corticosteroids,,ecog performance status,hpv vaccine communication,,,,intraspinal,over past 6,at least 3% to 12%,,,,,,
1964,,shrapnel,alectinib,,radiographic base of defect,palliative therapy|localized non-metastatic,,,,tested genes,at the baseline,above these cut-offs,,,,,,
1965,,organ abnormalities,equivalent;|steroids,,lansky level of performance (lps) score,tbsa,,,,abbot corp,within 3 months before administration of the study drug;|patients,≥ 1.5×109,,,,,,
1966,,colorectal cancer|has been informed of the nature of the study,ehf,,moderate upper extremity motor function deficit,locoregional anesthesia,,,,intensively,for 4 months after the last dose of imp,less than 0.1,,,,,,
1967,,hematological diseases,5-alpha-reductase inhibitor drugs,,mandibular arch,pathological tissue types of non-small cell lung cancer,,,,early age of onset of bipolar disorder,within 2 years prior to the first dose (the alternative therapy,below 1500 g,,,,,,
1968,,tumor diseases.|diseases,anti-asthmatic effects,,permanent strabismus;|history,carotid endarterectomy,,,,clinical unit||depression,in the 24 h before each study visit.|evidence,>= 18 years|measurable disease,,,,,,
1969,,crohn's disease|a,inhaled prostacyclin analogues,,response evaluation criteria in solid tumors (recist v1.1).|the score,transdermal estradiol|current use,,,,castration resistant (crpc),less than 14 days from the end of the previous clinical study.|uncontrolled,50% of patients,,,,,,
1970,,carcinoma mucoepidermoid carcinoma,antidepressants drugs,,creatine kinase-mb [ck-mb],pelvic exenteration surgery - defined,,,,anomaly|uncontrolled,within the past 2 weeks;|subjects,between 60 -90 years|diagnosed,,,,,,
1971,,etc.);|chronic inflammatory diseases,conventional hemodialysis,,ecog (performance status,steroid prescription,,,,"diagnostic and statistical manual of mental disorders,",within 6 month prior to surgery)|rupture size,<120ms or >210ms,,,,,,
1972,,maternity,drug products,,ismi score,diagnostic test,,,,sars-cov-2,within 14 days to baseline,"between 0-5,|no",,,,,,
1973,,unilateral acute stroke,institution,,new york heart association class|severe valvular heart disease,hemorrhage)|significant refractive,,,,thyroid gland,at the time of signing the informed consent form|diagnosis,= 1.65,,,,,,
1974,,underlying lymphoma,carbapenem,,mean resting corrected qt interval,prbc transfusion,,,,under local,at the time of signing informed consent.|must,greater than 12 months.|able,,,,,,
1975,,voluntarily||,secukinumab,,pulmonary artery wedge pressure,youth participants||motor condition,,,,hilar masses.|suspected typical,within 4 weeks before the first administration;|any type,>2.0 x 109/l,,,,,,
1976,,pancreatic transection margin|patients,not||,,hiv-1,molar postextraction,,,,suitable to undergo,past 12 months|individuals,<37 weeks,,,,,,
1977,,jugular thrombosis,selective serotonin reuptake inhibitor,,csf cytology,real-time quantitative polymerase chain reaction (qt-pcr) with,,,,compared to reference normal tissue|subjects on prior,for the last 3 months|diagnosed,30 to 60 years|insomnia disorders (icsd-3,,,,,,
1978,,contraindicate exercise|unstable,intranasal corticosteroid medications,,car t-cell infusion,cardiac computed tomography angiography|for,,,,lower crossed syndrome,during the last 12 months.|heart conditions,<1.7 nmol/l).|patients,,,,,,
1979,,sterilization confirmed.|for childbearing,medications for type 2 diabetes|self-reported,,godin leisure-time exercise questionnaire - health contribution,ultrasonography,,,,time|self-reported,before randomization to confirm eligibility.|history,< 6 months prior to enrollment,,,,,,
1980,,partner's vasectomy,days|excessive caffeine,,apnea hypopnea index,hepatectomy procedures,,,,20-item adult stress,prior to the first dose of study drug,4 or 5,,,,,,
1981,,solid organ transplantation|history of splenectomy|participation in any other investigational drug trial within,components of the radiolabeled pharmaceutical,,eosinophils,weight control surgery,,,,adjuvant,for the first surgery|patients undergoing repair surgery,> 100 mm hg,,,,,,
1982,,pulmonary disease;|major surgery,abuse|positive for,,cover test,cabg surgery||,,,,non-mobilized cells,previously randomised in the study|unsuitable to participate,under 12 and over 8 years|presence of obesity,,,,,,
1983,,not eligible.||ii,polycarbonate,,1.|life expectancy,total cumulative rai dose for treatment,,,,above physiologic doses.|participant,within < 3 months prior to informed,after fⅶ,,,,,,
1984,,restrictive bariatric,oral anti-infectives,,etc)|adequate oral hygiene,transcatheter arterial chemoembolization (tace or tae,,,,insulin-,within 12 months after consolidation intensification after cr,18-75 and can stand|no,,,,,,
1985,,clinical types,anti-cd137 antibody,,urine hcg,general problems|good oral health||,,,,haploidentical grafts,after biopsy,1% or greater,,,,,,
1986,,cardiac function|active,over-the counter medication|treatment with another investigational product,,suitable,vascular amputation,,,,suitable for endovascular repair.||,within 4 weeks prior to the screening,younger than 20 years,,,,,,
1987,,laboratory abnormalities,mongolian,,moderate facial skin condition,mcl.|at least one measurable lesion.|subjects,,,,montreal,in the next few months|if,≥ 20 points,,,,,,
1988,,motor dysfunction,potassium iodide treatment,,enlarged disability status,montreal cognitive assessment hong kong version (hk-moca);|able,,,,exceeding the 99th percentile,within 28 days prior to imlifidase treatment|desensitisation treatment(s),10 - 17,,,,,,
1989,,air|known human immunodeficiency virus,norepinephrine reuptake inhibitors,,hbs antigen +,cytotherapy,,,,glenohumeral,in the last 2 years;|contradictions,score of 4 and above from the,,,,,,
1990,,ptpn2 deletion described,investigational drug/devices,,fasting,radiotherapy in head and neck region,,,,unsupervised,more than 3 times,2 to 18 years,,,,,,
1991,,infection(s)|significant weight loss,trigone,,months;|increased intracranial pressure,ionic treatment,,,,msa-c,within past 30 days.|history of,between 18 and 30 kg/m2|contraception,,,,,,
1992,,feels better)||,component of the planned,,ferritin values,swab collected,,,,full hospitalization|parent whose child,within six months prior to,6.5% < hba1c,,,,,,
1993,,unilateral ischemic,short-acting beta agonists (sabas),,pharmacologic therapy||,chg,,,,below 10 g/dl)|history,within 7 days prior to the rhc.||pregnant,<18 years;|pregnancy;|chronic,,,,,,
1994,,non-melanoma skin carcinoma|social,antifungals,,alanine transaminase (alt/sgpt,graft surgery,,,,could confound the results of this study.|previous,in the last 90 days||,grade 2 or greater,,,,,,
1995,,implantation failure,denosumab,,mineral supplements||exclusion criteria,radioactive iodine contrast material,,,,specifically excluded from eligibility.||history of any of the following medical conditions,after the last attacked,≥iii;|the presence,,,,,,
1996,,osteoarticular infections,direct thrombin inhibitor,,"child-pugh classification),|unresolved biliary hypertension syndrome,|acute thromboembolism of the pulmonary artery",inactivated virus vaccines,,,,acute stage;|weight,after the previous administration of any vaccine|history of,score ≥ 80||,,,,,,
1997,,hives,alfuzosin,,north hospital,nsaid therapy,,,,non-lymph node lesions,within 4 weeks before inclusion|probiotics intake within 4 weeks before inclusion|confirmed positive,< 5%ile|a diagnosis,,,,,,
1998,,cadasil,actionable molecular alterations,,alt ≤5 × institutional uln,il-6 inhibitors,,,,inquired,any time prior to the index date.|this will allow,> 30 minutes/day,,,,,,
1999,,treatment failure,physiologic corticosteroid replacement,,prostate cancer treatment,vital organ disorders|the score,,,,google play|reading proficiency,within 12 months or less,above 60 to ensure,,,,,,
2000,,implanted|symptomatic heart failure,anti-arrhythmic agents,,left ventricle left,vital sign examination,,,,"influence drug absorption, distribution, metabolism",before starting hospitalization.|signed,≥ 500 μg q3w,,,,,,
2001,,rv dysfunction,smart-tablet,,average overall pain severity,endovascular embolization procedure,,,,≤33mm;|stenosis degree,within 1 month before enrollment.|patients,≥ 90 g/l|serum creatinine (cr),,,,,,
2002,,neurological defects,urine drug,,iiid,bloating,,,,suprapubic area,within one month of the screening visit,>500 ml,,,,,,
2003,,calculated by the ckd-epi,fine lines,,alanine transaminase(alt,lepra)|current treatment,,,,retinal,within 6 weeks prior to the first dose of study drug,> 25 years,,,,,,
2004,,poor general health.|patients,pet,,international consensus classification,24-hour urine collection||when,,,,absolute value,by the time of enrolment,> 5)|any condition,,,,,,
2005,,vascular disease|pregnancy,chv supervisors,,minimal residual disease,urine analysis,,,,emergency setting,within 28 days prior to initiation of study treatment,≤ 5 times the upper limit of normal (uln),,,,,,
2006,,catheterisation,immunosuppressive therapy;|an,,cessation,autologous transplantation waiting list,,,,severity of the disease,within past 90 days prior to study enrollment,>=6 months|adult,,,,,,
2007,,nasopharyngeal malignancy,hypochlorous acid,,serum creatinine values,"airway,|emergency surgery",,,,suitable for assessment,within 2 weeks prior to treatment.|major surgery,≤2.5 × uln|creatinine clearance ≥30 ml/min,,,,,,
2008,,chiropractic care,prokinetic,,criteria of emancipated,duplex ultrasound velocity ratios,,,,unknown cause increased,at least 3 months prior to screening.|currently,> 1.5 x unl,,,,,,
2009,,surgically sterile,liquid biopsy,,macroalbuminuria,cystoscopy,,,,culprit vessel participates,more than 6litres/min,<1 x upper limit of normal (uln),,,,,,
2010,,spectrum,crf,,qof,abortion(s,,,,non-emergency cesarean,personal history,≥ 25.|subject,,,,,,
2011,,consumption of any drug metabolizing enzyme,enoxacin,,hdv).|body mass index,bpa,,,,implement,within 90 days prior to study entry,≥ 65 years,,,,,,
2012,,paracentesis|hepatic encephalopathy,component of the study,,pcr test result|patients,breastfeeding.|patient judged unsuitable for study participation by the physician,,,,central nervous system neoplasm,previous four 4,≤ 3||exclusion,,,,,,
2013,,primary diagnosis,materials found,,body temperature,standard,,,,chromosome,preceding six months,>= 60 ml/min per 24 hour urine test,,,,,,
2014,,sinus stenosis,caffeine-containing drinks,,anti-androgen (pharmaceutical [,ligament surgery,,,,investigator.|patients treated,within 14 days prior to dosing;|current,18 and older|skin,,,,,,
2015,,type 1 rop,g•kg-1•min-1；|at rest,,progesterone receptor (pr),interventional therapy,,,,without the ability to return for visits,within the past 72 hours,greater than 3 months;|adequate liver,,,,,,
2016,,syncopal episode,sogroya,,hypertension.|alanine aminotransferase (alt),haematology,,,,low grade lymphoma,past 14 days,≥ 4.0*,,,,,,
2017,,rare systemic diseases,blood-derived products,,lower respiratory tract infection,adjuvant radiotherapy after mastectomy,,,,non-pediatric inpatients,at least following,µmol/l);|the,,,,,,
2018,,severe disease condition,specialized drugs,,total bilirubin levels,myringoplasty,,,,extracorporeal membrane oxygenation,within the past 3 years|smoking,between 18.5 and 25 kg/m2|clinical exam normal|subject,,,,,,
2019,,lung metastases,mofetilmycophenolate (mmf).steroid resistance,,antiviral mediations|temperature,cumulative dose of up,,,,intra-labyrinthine,during the time period of study participation||a,60-90 ml/min/1.73m2,,,,,,
2020,,learning disabilities,heparin compounds,,sensitising egfr mutations,dialysis treatment,,,,tested area,within 2 hours postoperatively.||,65-74,,,,,,
2021,,unstable diet;|xerostomia,immune-related toxicities,,bsid,secondary medical care,,,,upper limb artery stenosis,prior to enrolment.|contraindication to the placement,equal to 18 years,,,,,,
2022,,genotype,"labor,|who",,hiv 1/2 antibodies,focus takes iodine,,,,pain)|clinically relevant,within 8 weeks|severe active,≤ 6cm,,,,,,
2023,,congenital coagulation abnormalities,≤45%.|brain natriuretic peptide (bnp),,random blood glucose,abdominal surgical history;|gallbladder gangrene perforation;|changes,,,,cardiac surgery.|patients,within last 6 months before first dose of protocol-indicated,≥ 50% stenosis,,,,,,
2024,,clbp,compounds of similar chemical or biologic composition to 177lu-lnc1004,,ankle-brachial index,bilateral mastectomies,,,,primary metastatic,at screening and not planning to start,between 18 and 30 kg/m2 inclusive,,,,,,
2025,,focal lesion,imdh inhibitors,,asa physical status,operation,,,,meeting these criteria,during hospitalization|history of,> 50 ml/min/1.73 m^2,,,,,,
2026,,cardiovascular effects,electrodes used,,hbv dna titer,testing performed,,,,st-elevated,within 90 days of the index procedure|subject,between 18.0kg/m2,,,,,,
2027,,tnbc,pentacam,,response evaluation criteria in solid tumors (recist) 1.1.|the effects,corrective treatment,,,,pacemaker,within 3 days before the study vaccination;|a,between 23.0 and 34.9 kilograms per meter square (kg/m^2),,,,,,
2028,,clinically healthy,linagliptin,,ihd,hospitalized,,,,central nervous system parenchymal lesions,in the study eye.|scar,<0.5 cm2 /m2).|the,,,,,,
2029,,local practice||current,anti-angiogenesis drugs,,mms,subsequent systemic therapy,,,,neurodegenerative,within 3 months of participation|history of,6-month carfilzomib,,,,,,
2030,,renin tumor,inoca|patients,,average)|body mass index,abdominal computed tomography scan,,,,relugolix-containing therapy,within 4 weeks prior to the baseline,<1500g born to mothers,,,,,,
2031,,non-squamous carcinoma,ceftriaxone,,interferon gamma (ifn-γ) release assay (igra) test,medication therapy management.|non-english,,,,site investigator feels could have an,within 4 weeks prior to lymphocyte,less than 18 or more than 40 years|chronic,,,,,,
2032,,completed hysterectomy,ocular drying,,international classification of headache disorders 3rd edition,sga:||•,,,,non-attenuated,before randomization to confirm eligibility,≤ 75 years;|ecog score 0-1;|patients,,,,,,
2033,,inclusion|expected death,flumazenil,,urine pregnancy tests,"above,|hk residents capable",,,,highly frequent,at time of entry into the exposure event.||*a rapid antigen test,24-41 weeks,,,,,,
2034,,cervical cap).||,prostaglandin analogues,,covid-19 pcr test should,cooper pediatric gastroenterology practice in camden,,,,metastatic,in situ.|the,≥21 years,,,,,,
2035,,difficulty to swallow pills,eyeball,,urine cotinine screen,lipid-lowering drug,,,,mgdl-1;|c-reactive protein,at the time of dosing).|history of,ms|25-60 years,,,,,,
2036,,adverse-events of their most,cancer|patients,,drug-screen,rehabilitative psychotherapy,,,,amenable to curative surgery,less than 4 weeks prior,between 18 and 65 years.|fulfilled the 2010,,,,,,
2037,,heart beat,immune related neurological diseases,,descending thoracic aortic aneurysm (dta),thickened cmt,,,,highly sensitive urine test,within 3 months before treatment.|pregnant or lactating,<90 g / l);|the patient's,,,,,,
2038,,major sensory defects,missense,,partial thromboplastin time (aptt) prolongation,brain imaging abnormalities|history of,,,,non-preservable,within 2 weeks prior to c1d1;|prior treatment,8 to 10,,,,,,
2039,,physically too ill,factor xa inhibitors).||echocardiogram (echo,,aeruginosa||,hard,,,,recovery,within the first year follow diagnosis|performance status,less than the duration of the,,,,,,
2040,,balance disorders,tyrosine kinase inhibitors,,glomerular filtration rate estimation)|human immunodeficiency virus,grem1 expression,,,,grade 2-4,in the inclusion criteria.||patients,> 2 years,,,,,,
2041,,signs of disease exacerbation,azelaic acid,,response evaluation criteria in solid tumors.|postmenopausal,androgen deprivation therapy (adt),,,,site of disease ≥1cm,within 1 week before study initiation.|other vaccination,below 30%,,,,,,
2042,,childhood trauma,iii antiarrhythmic drugs,,transaminase levels,ct scan premedication).|receipt of live,,,,under oncology care,within six months prior to participation in this project;|paresis,3 ng/ml,,,,,,
2043,,hbv)|hepatitis c virus,pbc,,mitomycin c,quality exam,,,,vision analogue scale,at time of eligibility assessment,> 30 × 10^9/l before,,,,,,
2044,,hpv-induced etiology of the lesion(s,vasodilatory substance,,hepatitis b virus (hbv),x medications).|be a site member,,,,infection.|clinically significant,during 2 or more,≤ 1.5 ×,,,,,,
2045,,solid organ transplantation|active,soft tissue sarcomas,,metabolic function,pn|total estimated bsa treatment area,,,,mid-shaft,within 2 months prior to study entry,≥ 18 years|renal transplant patient|patient,,,,,,
2046,,breast feeding|cessation,licensed covid-19,,"weeks,|body mass index",mental health condition(s)|be able to read/write in english||,,,,non-st-segment elevation myocardial infarction;|stemi,within 6 months before the inclusion,> 1.5 times the upper limit of normal hemoglobin,,,,,,
2047,,etc.)|abnormal corneal,its products,,oral temp,adrenalectomy,,,,neurological,within 3 weeks prior to study treatment administration,of ≥10%.|evidence,,,,,,
2048,,familial hypercholesterolemia,antidepressant regime,,mgmt methylation test,administered.|major surgery,,,,abdominal,for at least two,> 50 years|sedentary condition (,,,,,,
2049,,spreading lesions,inhaled steroids,,mast-cell stabilizing agents,radio-chemotherapy,,,,benign,within two months,>7.0%,,,,,,
2050,,inflammatory bowel disease(e.g,nucleic acid amplification,,rapid sequence induction|indications,clear cell renal cell cancer (ccrcc),,,,cancer|locally advanced,during the last 12 months|use of,over 80 years|admission or surgery,,,,,,
2051,,alcohol abuse|history,nasal glucocorticoids,,malnutrition,android processor,,,,björk-,at screening and predose on day 1.|conventional 12-lead ecg,1.5 × 109,,,,,,
2052,,positive symptoms,anagesics,,national institutes of health classification,implant full-mouth implant restoration|monolithic ceramic,,,,pure-tone-average threshold,within 6 months of the onset of steroid-,less than 12 months.|pregnancy.|2nd,,,,,,
2053,,ras,components of the study intervention,,hcv ab,and-6.00d);|best corrected vision,,,,removable,within 1 months prior to start of,"≥ 125,000/µl",,,,,,
2054,,ocular surgical,rimantadine,,numeric pain rating scale.||,her2 testing using the ventana 4b5 assay,,,,"site of the block,|morbid",within 7 days prior to starting the study drug,below the 10th,,,,,,
2055,,residual adverse effects,fio2,,moderate,pharmacological management,,,,non-endometrioid adenocarcinoma,within 2 weeks of their baseline visit,18.0 to 27.0 kg/m2,,,,,,
2056,,chronic lymphocytic leukemia,nasal steroid therapy,,navigo left ventricular,fresh blood,,,,high-intensity,while for skeletal,i-iii.||no,,,,,,
2057,,internal root resorption,medicine,,hepatitis b surface antigen (hbsagb),bone marrow function|patients,,,,clinically significant infection,prior to study injection,≥ 500/dl|platelet count,,,,,,
2058,,risk factors,ropivacaine,,stress-mri,repetition of the sample that persists,,,,index date,in previous year|prior ect treatment|insufficient computer knowledge or analphabetism,> 20-years,,,,,,
2059,,stimulating factor support)|platelet count,pilocarpine eye,,pco2,gist,,,,non-st segment elevation myocardial infarction (,within the next 90 days.||at least one of the following clinical diagnoses:||a. any aortopathy,-65 years,,,,,,
2060,,acute reversible cause,stereotactic ablative body radiation therapy,,bcr::abl,radial artery puncture,,,,potentially reversible,within 30 days prior to therapy|uncontrolled,less than 20 years and more than 60 years.|patients,,,,,,
2061,,"mental illness,|psychological counseling",radioactive iodine,,gross motor classification (gmfcs) level,treatment arm only).|contraindication for insertion of,,,,aids|neurologic,acute injuries|non-athletes,laboratory)|younger than 18,,,,,,
2062,,recurrence.|patients,u.s. national academy,,acquisition interval of the slices,surgical adhesion of the pleura,,,,diagnosis.|prior pelvic radiation.|patients,during the study period;|subjects,>0.6 x 103/mm3,,,,,,
2063,,arterial femoral,corticosteroid joint injection,,hcv viral load|eligibility criteria,attenuation parameter,,,,ca199,during 2013/01/01 to 2020/12/31||,more than 500 ml,,,,,,
2064,,transplanted|abo-incompatible,traditional chinese medicine,,10,allogeneic haematopoietic stem cell transplantation|toxicities of prior anticancer therapy,,,,copd)|in-patient,for at least 1 night,> 18 years|clean,,,,,,
2065,,●visual defect,ssa,,general hospital urology department,bispectral index monitoring;|asa score,,,,cyclin-dependent,at the time of trial,>50 units,,,,,,
2066,,mycobacterial infection,donated components,,liver function defines,mv surgical intervention,,,,old|hospitalization,within 28 days of first administration of study therapy,minorities||patients 18 years,,,,,,
2067,,adenosquamous cancer,components of bcd-100 or,,loc,testing of a representative tumor tissue specimen|availability of a representative tumor specimen,,,,platinum-etoposide chemotherapy,in the previous 2 weeks.|antihistamine treatment|history of,≥ 12|relapsed,,,,,,
2068,,free fasciocutaneous flap,topical phosphodiesterase inhibitors,,hepatitis c virus (hcv) antibodies unless hcv ribonucleic acid,pelvic node,,,,glutamic-oxaloacetic,within 48 hours of study enrollment|fever,90-130/60-80 mmhg).||,,,,,,
2069,,sleep problems,gemcitabine.|clinical t2,,antibodies (dsa),start back screening tool)||,,,,consecutive procedures.||in these instances,place at least 6 months prior to the start of the study.|adequate,≥12 weeks.|measurable disease,,,,,,
2070,,local therapies.|patient,agent,,smoking cessation activity,immunohistochemistry,,,,amenable to biopsies,from than 3 months,long-term follow-up;||,,,,,,
2071,,mellitus type,recombinant human erythropoietin use,,renal disease||estimated gfr,re-vaccination,,,,national des données de santé,within the past three (3) months prior to enrollment.|reversible non-ischemic cardiomyopathy,≥ 0.5 times the lower limit of normal,,,,,,
2072,,community-acquired pneumonia,syncope|patients,,mdq,otoscopic surgeries,,,,systemic uptake of,at the department of cardiology,≥2 × uln,,,,,,
2073,,congenital abnormality in metabolism,parameter,,plasma hiv-1 rna viral load|receiving treatment,cranial metal implants,,,,syringomyelia|active,at the start of pyx-201 treatment.|major surgery,uni-compartmental knee.|the knee replacement,,,,,,
2074,,venous thrombosis,indwelling,,left ventricular ejection fraction)|no structural,palbociclib,,,,cn1,5 half lives of study treatment,=< 14 days before cycle 1 day 1,,,,,,
2075,,ocular lesions,multiple drugs,,ag/ab) combo,hormone replacement only,,,,multiparametric flow cytometry,during screening.|physical examination,less than 1 year|compliant diagnosis,,,,,,
2076,,diabetic retinopathy developed,polylactic acid-based,,inclusive|weigh,evusheld,,,,im vaccination,at the time of enrollment);|have visible consolidations/ground,> 68ga-psma activity,,,,,,
2077,,judged to have,expanders,,physical activity readiness questionnaire (parq),baseline.|topical ad treatment,,,,topical negative therapy,in the last 6 months.|will,≥ 24.||,,,,,,
2078,,respiratory sinus arrhythmia|history,anticancer drug,,bone marrow function:|absolute neutrophil count,diopter|best corrected visual acuity,,,,non-keratinizing carcinoma,within 72 hrs of study drug,≤3.0 times uln,,,,,,
2079,,degenerative mitral regurgitation,neuroactive prescription medications,,1.age,episodes of vaginal bleeding,,,,grade ≤1||,within the past 12 months.|uncontrolled,≤ 2 mg/kg/day);|methotrexate,,,,,,
2080,,belongs,alpha-2 adrenergic agonists,,"ioobö9-sf,|willingness",antiretroviral therapy (haart,,,,functional class 3 iii-iv,coronavirus 2,less than or equal to 1.5 x upper-normal limit (uln),,,,,,
2081,,fruits,anticholinergic bronchodilator,,nrs,participation;|having,,,,non-pre-eclamptic,at the time of screening|current,18-77 years,,,,,,
2082,,wear.|corneal radius,cisapride,,cooperative oncology group (ecog) performance status score,pittsburgh psqi sleep quality index (buysse et,,,,controlled by medication).|the,during the intervention period.|investigator believes,+ 0.92 (,,,,,,
2083,,other carcinomas,anticoagulant medication,,prado,implant placement,,,,auditory,within 8 weeks before the first use of the study,< 200 ng/ml,,,,,,
2084,,scleroderma,global pandemics,,united kingdom brain bank criteria|clear written informed consent from each participant in the trial.|patients,dipstick urinalysis,,,,use|known,within the last 10 years,< 3.5,,,,,,
2085,,spinal cord|metastasis,marfans,,mcl)|absolute neutrophil count,anatomical implant,,,,gastrointestinal,within 6 months before the first dose of siltuximab.|unstable angina,< 6 g/l,,,,,,
2086,,sinus arrhythmia,sedative use,,h. pylori eradication treatment,lipid metabolism related compounds,,,,intrauterine device.|diabetes,within 3 weeks before the first medication,less than 1 month,,,,,,
2087,,helicobacter pylori infection,rifampin,,definition of bronchiectasis,etc.)|radiation therapy,,,,peri-procedural period|edema,within 2 years prior to initial,50 years and older,,,,,,
2088,,substantive medication|alcohol,glp-1 ras,,serum b-hcg pregnancy test,qt)|traumatic head injury|new presentation,,,,dilatative,before or after cardiopulmonary bypass|reliance on,functional classification iii or iv,,,,,,
2089,,61)|≥1 measurable lesion,local guidelines not feasible,,shifts,standard of care (soc),,,,cytological,within 8 weeks prior to randomization.|mucositis,18 to 70 years old,,,,,,
2090,,bone disorder,angiotensin converting enzyme inhibitors,,sma,thorasic surgery,,,,≥400 ml within,within 12 months prior to enrolment.||or||for,<=1.5 unl,,,,,,
2091,,multiple solid tumors,bosentan tablets,,hepatitis c viral load,west virginia providing,,,,sepsis type,in the 30 days prior to application of study treatment|dermal fillers,">= 1,000/mm^3|platelet count",,,,,,
2092,,hemianopsia,anti-cll-1 monoclonal antibody,,work|resting blood pressure,analgo-sedation,,,,nmda receptors,hypertension|history,<2.5 x institutional upper limit,,,,,,
2093,,babies,therapy|biologics,,pregnancy;|vaginism;|urinal infection;|oncological disorders;|epilepsy;|skin problems;|if they,lung reduction surgery,,,,tricuspid,within 28 days prior to randomization.|active hepatitis,≤ 100x10^9/l.|hemoglobin < 9g/dl.|patients,,,,,,
2094,,serologic findings suggestive of,ufh,,200mcg|mannitol drr,surgical procedures,,,,intra-epithelial carcinoma,within 4 weeks from the screening visit,from 13 to 16 years,,,,,,
2095,,iv).|existence,ivig)|response,,mrs score,hormonal vaginal rings,,,,idh-mutant,within 8 weeks after the last administration of the trial drug|sign,≤ 3.0 x uln,,,,,,
2096,,bone marrow failure,drugs administrated,,national stroke institute for neuropathic speech disorders and association for alzheimer disease and related disorders),immunotherapy,,,,human milk,at the time of admission to the intensive care unit,< 25 participant,,,,,,
2097,,pyloric stenosis,immediate local,,cgi-s score,liver transplant surgery,,,,mid-cervical,in the month prior to inclusion|for,greater than 160/100,,,,,,
2098,,mri)).|individuals,components in the formulation|willingness and ability to initiate intermittent catheterization post-treatment,,hepatic bilirubin,montreal cognitive assessment - thai (moca-t,,,,fim);|edss score,within 5 years prior to study enrolment,above 2,,,,,,
2099,,heart valve replacement).|endocrinologic disease,morphine,,hcv virus,laparoscopic radical prostatectomy + pelvic lymphadenectomy;|ecog score,,,,deemed medically stable,for at least 3 months after the last dose of study-drug,<5%)|kidney disease,,,,,,
2100,,breast cancer|second malignancy,drug abuse|participated,,superficial blood vessels.|in,allogeneic tissue/organ transplantation,,,,upep)|sflc involved,"limping for more than 1 day,|chronic weakness",≥750/mm3,,,,,,
2101,,systemic antimicrobial,5-fu|uncontrolled intercurrent illness,,arv,general anesthesia.||,,,,pomelo juice,8 weeks before surgery,below 40%.|prognosis,,,,,,
2102,,clinically stable,sodium ascorbate,,infection.|blood glucose level,gryr,,,,"grade 1,2|normal cardiac",within 2 weeks of study drug initiation.||,18-32 kg/m2.|willing,,,,,,
2103,,eaton-lambert,punctum plug,,npv,precautionary medications listing,,,,large chain retail pharmacy chain,within 8 weeks from screening,> 20 years,,,,,,
2104,,renal failure.|bleeding disorders,diaphragm imaging,,american society of clinical oncology/american college of pathologists,ventral mesh rectopexy|total rectal,,,,indeterminate,before admission|history of,which can also be supported by,,,,,,
2105,,non-ulcer functional dyspepsia,recombinant subunit vaccines;|male,,palatal tissue harvesting,thermal ablation,,,,chf).|history,their year 1 rotations,over 159 mm hg,,,,,,
2106,,crohn's disease.||the,c ssrs,,thoracic society,r1 vertical resection margin|patients,,,,non-musculoskeletal causes|fracture,within 90 days before screening irrespective of medical records|have,<15 ml/min/1.73 m2|administration,,,,,,
2107,,urinary stress incontinence,anti-cd22,,uacr,reproductive health care (assir; atención a la salut sexual i reproductiva,,,,irregular heartbeat,for at least two weeks,> 70%,,,,,,
2108,,choanal polyps,anti-vegf therapy,,systolic blood pressure>150 mmhg,subarachnoid anesthesia asa,,,,exacerbated,90 days prior to screening.|obesity,6 years,,,,,,
2109,,sequence,or|creatine kinase,,hepatitis c-virus (hcv)|participation in another study,complete hysterectomy,,,,sport,surgery january 2008,≥ 85 cm,,,,,,
2110,,pleural,glp-1) receptor agonist,,partial thromboplastin time (aptt),excision of the malleoli|excessive loads,,,,mild to moderate smokers,at the time the informed consent form (icf),≥ 18 to ≤80,,,,,,
2111,,parkinsonian syndrome,component of rhbnp;|participated,,adenocarcinoma|nonmucinous||mucinous||- preinvasive lesions||atypical adenomatous hyperplasia||adenocarcinoma,telitacicept,,,,present:||oligo-or anovulation,in the past 6 months|subjects,> upper limit of normal (uln) + 4 seconds,,,,,,
2112,,congenital developmental anomalies,study visit|infection,,ammonia level,close monitoring|need,,,,≥1-year,during rreatment and,> 10%|pregnancy,,,,,,
2113,,heart-rate,guardians,,albuminuria ≥2+ should,pneumonitis|major surgery,,,,articles l. 3212-1 and l. 3213-1,within 24 hours .|renal disorder,vas:>10/100 mm,,,,,,
2114,,prominent splenomegaly,adefovir dipivoxil tablets,,"radiological findings,||2-post-laminectomy syndrome",preoperative assessment of heart,,,,requirements;|blood,within 3 months.|any situation,≥ 100 × 109/l);|hemoglobin,,,,,,
2115,,problematic alcohol use).|high suicide risk,biologic agent,,see section,monosomy,,,,fovea in each eye,within 4 weeks prior to enrollment.|an expected survival,> 2x uln|total,,,,,,
2116,,low back pain|hip injury,empty stomach;|donation of plasma,,single retest,endometrial biopsy (,,,,female.|kps score,for at least 15 years|family history,< 25ml/min/1.73 m2,,,,,,
2117,,follicular lymphoma.||age,prescription medicines,,hamd score,vital signs|unwilling,,,,core studies|development of a,1 prior to screening,at least 50% of viability,,,,,,
2118,,denture,anatomical type,,residual bone marrow minimal residual disease (mrd) positivity,blood cell transfusion,,,,stable on medical management,following definitions:||blood routine,≥100 x 109/l|haemoglobin,,,,,,
2119,,covid -19 infection|hemoglobin,steroidal anti-inflammatories,,tremor of the upper limb,chronotropic heart medications,,,,well controlled,in the last month|women,≥ 2.5 cm,,,,,,
2120,,failure|renal failure,milk proteins|currently prescribed,,hepatitis c infection|other active malignancy|females,legislation in germany,,,,pet,prior to starting therapy|fcbp,20 to 50 years,,,,,,
2121,,tumor dissemination,prebiotic,,baseline.|red blood cell,standard of care neoadjuvant chemotherapy,,,,highly reliable,within 30 days prior to registration,≥200 ng/ml)|patients,,,,,,
2122,,abalone,esophagus,,gold stage,hepatic artery infusion pump (haip) therapy,,,,low-dose gestagen (lynestrenol and norestisteron),within 1 month)|symptomatic heart failure,25-oh,,,,,,
2123,,psychosocial support,anti-calcitonin-gene-related peptide,,response evaluation criteria in solid tumors (recist) criteria,study activities,,,,instability;|after extubation,within the last 6 months prior to baseline.|plans,≥ 25 %,,,,,,
2124,,throat pain,low-dose warfarin,,total length of target lesion,full thickness macular hole;|history,,,,primary systemic,prior to infusion of study treatment.|viral syndrome,< 16 mmol/l,,,,,,
2125,,chronic inflammatory diseases of the gastrointestinal tract,special diets,,pain-limitation,small to allow mbi assessment,,,,resection|pre-existent,within 28 days following receipt of study vaccine,greater than equal to 20 cm square.|la volume greater than equal to 55 milliters,,,,,,
2126,,normal|allergy,systemic corticosteroid 10 days before injection,,hbv load,anticoagulation including||endocarditis|documented intolerance,,,,sulfonamides,for at least 28 days prior to vaccination,≤ 1.5 mg/dl|hemoglobin,,,,,,
2127,,airway anatomical disorder|patients,anti-hyperglycaemia agents,,hbsab,quality of the data,,,,hematological,within the projected duration of the trial,controlled to less than 500 and,,,,,,
2128,,syncope,hiv-1,,expectancy,user,,,,n2|complete,at the time of flexion or extension of the finger,≤ 4.00 d,,,,,,
2129,,bdtx-189,succinylcholine,,modified cockcroft-gault equation,spine srs/sbrt,,,,study.||prior organ transplantation,while at least 4 weeks must,<12 weeks,,,,,,
2130,,malabsorptive condition,cyp1a2 strong inducers,,instance recreational,-reading.|receiving care,,,,ankrd26,during last 3 weeks previous to join the study|patients,50 to 89 mmhg,,,,,,
2131,,inflammatory joint disease,ganglion blocking drugs,,primary level,fviii concentrates prophylaxis,,,,large b-cell lymphoma,within 6 months before baseline,less than 6 months prior,,,,,,
2132,,limiting organ dysfunction,preparatory acts,,asc)||,varenicline nasal spray,,,,non-opposition|person affiliated,within preceding 3 months,0 to 1|have,,,,,,
2133,,consumption of muscle relaxants,peptide,,immunohistochemistry|ecog performance status,vestibulopathy,,,,undergo,within 2 weeks prior to the first drug administration,between 7-16 months,,,,,,
2134,,biliary salt,sedative hypnotics,,common terminology criteria (ctc),pancreatic enzyme replacement|criteria for,,,,radiographically normal periapical region,within the previous 5 years|autoimmune pancreatitis|surgical removal of any portion of the pancreas||ii,1 to 4+,,,,,,
2135,,non-removable,amino acid supplements,,recist criteria v1.1|eastern cooperative oncology group(ecog) performance status,corneal implant,,,,nrs>3 scores in the pacu||,within the 6 weeks prior to baseline|has,40 to 75 years old,,,,,,
2136,,choledocholithiasis,components of ba1106;|participants,,self-report|a,quality of the data.|minors,,,,vascular occlusive disease,at least one course,between 30-50;|be,,,,,,
2137,,adenocarcinoma of the pancreas||resectable,bcl-2 inhibitor,,express,lymph node,,,,malnourishment,at time of enrollment|positive test,18-75 years;|spirometry,,,,,,
2138,,subacute hemorrhage,flow cytometry,,months|hb level,health facilities,,,,researchers;|clinically uncontrollable,admission within 24 h prior to participating,score of 13 or higher,,,,,,
2139,,pancreatic cancer,grapefruit products,,clearance,chemotherapy).||,,,,surgeon|previous,within 30 miles,2.5 times above the upper limit,,,,,,
2140,,osteoporosis,visit|systemic antibiotic,,male|aged,completed intervention,,,,volunteers|genitourinary,at least 1 month prior to implantation to not before 1 month after both device deactivation,at least 6 months.|no,,,,,,
2141,,pcos,hair growth,,hemoptysis,transfusions,,,,grade 2 or higher toxicities from any previous,within 2 weeks of baseline,above the upper limit of normal (uln) range.|is,,,,,,
2142,,concomitant injuries|injuries,msus,,modified new york criteria,systemic treatment.|prior,,,,regular consumption,within 6 months||,muscle,,,,,,
2143,,primary scc,oat,,hypertension|body mass index( bmi),optimal drug management,,,,site of injection,for the past 6 months,> 18 years|forefoot pain,,,,,,
2144,,assymptomatic arrhythmias,component of the experimental vaccine,,systemic infection|asa score,pretreatment chemotherapy,,,,glutamic pyruvic transaminase [gpt],within three months of the screening.|kps score,at least 18 years|ankle/brachial index (abi) of,,,,,,
2145,,artery.|cardiogenic shock,dietary products,,vas pain intensity questionnaire.|be an appropriate candidate,heart valve surgery|being,,,,etc.)||•• note,within 72 hours prior to pembrolizumab treatment,<45ml/min/1.73m2)|complete,,,,,,
2146,,hyperglycemic symptoms,anticancer drugs,,dicom,endodontic therapy completed,,,,investigator.||prospective,within five days prior to screening|use of glp-1ra,<125 x 103/mm3).|positive,,,,,,
2147,,idiopathic intestinal pseudo-obstruction,medications / products,,system;|gleason score,kidney replacement therapy,,,,mild to moderate corticosteroids,within 28 days prior to the first dose of durvalumab,≤ 3.0,,,,,,
2148,,foot injuries,methylprednisone pretreatment,,rss,vitrectomy,,,,mra.||,within 28 days prior to first dose of study,> 30°,,,,,,
2149,,viral hemorrhagic fever,systematic antibiotics,,beck depression inventory-ii (bdi-ii) score,concomitant surgery,,,,psychotherapy|self-reported,in the past 6 weeks.|allergy,<470 msec.|are able,,,,,,
2150,,pre-mds,macrolide,,msi status,salvage laryngeal resection,,,,secondary headache disorder(s) apart from,the last 30 days -,≥ 2500/µl,,,,,,
2151,,intact,hmb,,modified protocol employed,abdominal laparotomy,,,,light-based therapies,within 30 days of study day 1,stage iii,,,,,,
2152,,diabetes mellitus type 1|treatment,non-steroidal anti-inflammatory medications emergency,,transaminase levels.|known contraindications to,icg lymphography.|breast cancer,,,,listed for heart transplant;|patients,within 2 weeks prior to the first dose of study treatment,18-80 years|participant,,,,,,
2153,,isometric muscle contraction,antihypertensive medication prescription coverage,,modification of ace-arb agents,cardiovascular intervention,,,,non-hormonal iud,within 60 days of study,iii-iv)|inability to exercise,,,,,,
2154,,distant metastatic disease;|patients,t1dm,,hgb,cp|knee flexion retraction assessed in supine position,,,,hip joint in excess,for the last 4 weeks/1mo,at least 30,,,,,,
2155,,eyebrow ptosis,anti-inflammatory (,,prolonged corrected qt interval,percutaneous coronary stenting,,,,index procedure|biliary tract obstruction,throughout the study.|receipt of blood/plasma products,5 mm,,,,,,
2156,,antiviral therapy;|uncontrolled hypertension,steroid medication,,princess máxima center,t-vec,,,,humerus,for 24 consecutive months,score of 24 and above,,,,,,
2157,,transient ischemic attack|corrected qt interval,metal fragments,,serum ferritin,pulsed oxygen saturation,,,,carbon monoxide analysis of breath sample,within 4 weeks before the week 0 visit,score of more than or equal to 5,,,,,,
2158,,sleep disorders;|lifetime,nns,,participant||age,drt,,,,rotterdam criteria by the presence,within 14 days prior to the first drug administration,18 years|ability to flex,,,,,,
2159,,fluorescence in situ hybridization (fish) testing,body,,cbd provide early termination criteria,referral,,,,initially,onset at least 1 of 11 covid-19 symptoms,"≥ 1,500/mcl",,,,,,
2160,,breast-feeding||a,injection contraceptives,,knee|patients eligible,complete.|blood biochemical indicators,,,,st segment,for at least 24 hours on a study unit,25 - 49.9,,,,,,
2161,,enterocolitis syndrome,dtg,,oral morphine equivalents,≤8 g per day for,,,,severity index (pasi),at the time of screening ≤ 100 mm hg,≤ 2.5 × upper limit of normal value (uln),,,,,,
2162,,infectious keratitis,lorcaserin,,relapsed b-all,anomalous aortic origin of any of the coronary arteries (aaoca),,,,declaration of helsinki,72 hours prior to and,1.2,,,,,,
2163,,kwashiorkor,tenofovir-lamivudine-dolutergravir,,fasting triglycerides,ocular procedure,,,,other cause,during the therapy|severe visual,> 2x the upper limit of the normal range||history,,,,,,
2164,,plasma cell dyscrasia,surrounding area,,montgomery,month|surgical treatment,,,,oud groups),within 8 weeks before screening or incomplete recovery,100 to 240,,,,,,
2165,,douche,nicotine-containing medications,,angle-closure,biological agents,,,,diabetes|uncontrolled thyroid,in the previous 4,< 32,,,,,,
2166,,crohn's disease)|malignant,tumors;|acute gvhd,,combination|hba1c,fine needle aspiration,,,,stage 3a,at the time of signing the informed consent form;||current,>/=18|able to read,,,,,,
2167,,mixed dentition.|children,danacol,,vegf tki treatment,major surgery of the gastrointestinal tract (cholecystectomy,,,,suicidality,at the following time points:||ivig-,12-14 week of gestation|singleton pregnancy||,,,,,,
2168,,acute suicidal tendency,platelet-rich plasma,,block|heart rate,emergency medical treatment,,,,immunosuppressive disease;|cancerous,during the evaluation process||criteria for exclusion from the study:||withdraw to any period,ponderal,,,,,,
2169,,pure red cell aplasia.|active hemolysis.|other causes,negative)||,,soy protein,germline predisposition,,,,snellen or better,in the 4 weeks prior to screening|listed for lung,between 15-60 years|able to give informed consent.||for patients:||an established,,,,,,
2170,,viral respiratory infections,mild tbi suggested,,semiquantitative score,therapy exists|measurable lesion,,,,inflammation;|recent,within 7 days of screening|chronic antacid,18-90||,,,,,,
2171,,impact on prognosis,basal-,,plasma/serum glucose,arrhythmia control,,,,large cell neuroendocrine lung carcinoma (,within the first 4 weeks of enrollment,stage 1 or 2,,,,,,
2172,,postpartum complications,combined oral,,black/african american,vaginal medications,,,,clinically obtained echocardiogram,in the following 3 months.|individuals,<3 months,,,,,,
2173,,neoadjuvant therapy||-,group)|singleton birth|gestational,,pulp exposure,extracorporeal membrane oxygenation device,,,,fio2,within two weeks prior to start of the study.|participation,=< 1.5 x institutional upper limit of normal (uln),,,,,,
2174,,about,supplements containing hyaluronic acid,,creatinine ratio,left cardiac shunt,,,,thinking,for 48 hours prior to check-in,≥3 months|efficient contraception for women|platelets ≥ 50000/m3,,,,,,
2175,,eye dryness,lgs,,ap,diagnose of adhd,,,,erasmus mc,within 28 days of randomization.|any,"i, ii physical status.|undergoing",,,,,,
2176,,exon 20 insertion,components in e-cigarettes,,hiv pcr test,implant insertion procedure,,,,radiological manifestation,within 90 days prior to screening;|3,≥ 3 ×,,,,,,
2177,,sclerosis|diagnosis,darolutamide,,self-report|hiv-positive status,oral contraceptive pill,,,,spastic,prior to start of protocol therapy,over 195,,,,,,
2178,,displaced meniscus tear.|current,oral decongestants,,nac,region of the cornea|a sum corneal,,,,prenatal hyperbilirubinemia|stable health,"during their ""off"" periods.|severity",18.5 - 32.0 kg per meter square,,,,,,
2179,,spinal deformity;|at rest,medication that,,ad26.cov2.s,lamp,,,,any organ system,within 6 weeks prior to start,over 18 years|covid-19,,,,,,
2180,,febrile seizure,pacemakers,,study;|life expectancy,screening):|white blood cells,,,,non-melanotic skin cancer,for at least 30 days after the last dose of study intervention to eliminate any reproductive safety risk of the study drug.||use,> 2xuln|has,,,,,,
2181,,major depressive disorder|history,food,,eastern cooperative group (ecog),full vaccination,,,,cedars sinai hand clinic,within 6 months before inclusion,between birth and 28 days of life|consent,,,,,,
2182,,thyroid deficiency,medication for pain,,values)|alanine transaminase (alt),common carotid artery [cca],,,,full-thickness rotator cuff tear,within the past 3 months|received,> 3500 mg/g,,,,,,
2183,,inflammatory rheumatic disease|sensitive skin,aspirin-containing products,,aerobic exercise|pregnancy|participation,study.|no treatment,,,,older.*|lt4,during enrollment in the trial,40mg + ezetimibe 10mg.||,,,,,,
2184,,psilocybin|active suicidal ideation,ics),,pro bnp,surgical lumpectomy,,,,msi high crc,within the past 7 days||,less than 2.5 times of normal upper limit,,,,,,
2185,,anatomic abnormalities,anti-tumor agents,,dsm,blood chemistry test,,,,"hypertension,|insulin dependent",during the 12-week treatment period|active,>600)|a,,,,,,
2186,,.|acute infection,budesonide,,diseases.|serum virology test,endoscopic mucosal resection (emr),,,,high grade glioma,chronic,"> 500 g / l,|transferrin saturation",,,,,,
2187,,heart disease；|3、pregnant,oral lichen planus,,allowed):||absolute neutrophil count (anc),open-label extension,,,,cyclosporin a,within past 24 months,"< 60 ml/min/1,73 m2",,,,,,
2188,,in situ,idaho,,eligible;|ecog performance score,elective surgery plans,,,,hcv-associated,within 6 months prior to visit 1,17-ohp,,,,,,
2189,,non-suicidal self-injury behavior.|no virtual,antiseptic solution,,calculated body mass index,clinical laboratory test value|allergic to a,,,,non-registered product,in three months prior to,≥ 3 months|adequate,,,,,,
2190,,migraines,selective fgfr inhibitors,,etc;|fingertip oxygen saturation,simple prostatectomy,,,,non-nicotine-based,after hospital discharge for covid-19:||i,>38.5°c,,,,,,
2191,,internal disease,low molecular weight heparin treatment,,bil,radiology,,,,pure neuroendocrine,within 24 months prior to screening,between 50 and 60 years,,,,,,
2192,,bacterial vaccination,gonadotropin-releasing,,medicontur medical engineering,amputation,,,,culprit vessels.|structural heart disease,within 28 days of screening.|history,≥ 50%||normal organ,,,,,,
2193,,traumatic brain injury|current insomnia||,thrombolytic agent,,extracorporeal circulation,pharmacological therapy,,,,american diabetes association (ada),more than|two fingers,> 3times uln,,,,,,
2194,,assessments||,adequate organs,,platelet ≥50×10^9/l,vegan diet;|participation,,,,amenable to active treatment,within 10 days before the first dosing day|those,> / = 45,,,,,,
2195,,needles|active skin,low sodium,,hypertension;|systolic blood pressure,caesarean delivery|age,,,,diagnosis;|previous,in the past 2 years|syncope while exercising,>2 mg/dl,,,,,,
2196,,preserved ejection fraction,materials of bovine origin,,mdd treatment,piloromyotomy,,,,non-contributory,at completion of chemotherapy,class iv angina,,,,,,
2197,,droplet precautions|order for bedrest,tme therapies,,va connecticut pain management,starting therapy,,,,non-dilated examination,within 5 years prior to enrollment,better than or equal to snellen,,,,,,
2198,,unexplained sudden death,mitomycin c,,urine β-hcg results,rescue therapy,,,,immunization.|clinically significant,in the 6-month period before the start of the study||criteria for terminating the study||the patient's desire to leave the study|continuing the treatment in another city|interruption or termination of radiotherapy treatment|patient's death,above or equal between 18 to 65 years,,,,,,
2199,,fs-lasik,chemical drugs,,married infertile,esa treatment - discontinuation,,,,bariatric,during the 2 weeks before start of study treatment administration.|chronic immunosuppressive therapy,150 or less,,,,,,
2200,,miami hospital dermatology system,prostaglandin,,ebv dna,remain eligible,,,,highly expressed;|male,three times per week,>2 min,,,,,,
2201,,reporting anxiety symptoms,any medication,,vas);|body mass index,ranibizumab injection,,,,prohibits obtaining informed consent.|patients,in the study eye|subject,less than 40%*|patient,,,,,,
2202,,unhealthy adolescents,medication),,soy protein powder,excluded.|good oral hygiene.|no,,,,levonorgestrel-releasing,within 3 months of screening:||metformin,above criteria.|patients,,,,,,
2203,,¹⁴c-urea breath test,antimuscarinic drugs,,ashworth scale,small cell carcinoma of the urinary system,,,,peri-implant sites with ppd ≥6 mm,within 3 months prior to visit 1.|receipt of,<4 on four of six functional independence measure (fim) basic adl items||,,,,,,
2204,,health system providence health,anti-cd4,,bilirubine,hip arthroplasty,,,,vestibular therapy|uncorrected vision problems,after one or several interventions,">100),|high tg-levels",,,,,,
2205,,concomitant disease states,igf-1 receptor (igf-1r,,urine m-protein level,watching videos,,,,any other reason,within 6 weeks prior to screening visit.|participant,> 40.|other,,,,,,
2206,,proteasome inhibitors,fast ventricular rate atrial fibrillation,,hamilton depression rating score,total wrist arthroplasty,,,,secondary school,at time of enrollment.|no provision of written,between 18 and 35 kg/m2||,,,,,,
2207,,crohn disease,nonsteroidal anti inflammatory drugs,,b6,computed tomography (pet ct) skull base,,,,suitable for clinical trial,within 7 days of initiating study,1 to 12 months,,,,,,
2208,,left ventricular thrombus,anti thymocyte globulin,,serum creatine,digestive system surgery,,,,emergency indication,throughout the study duration,greater than or equal to 1500/mcl||platelets,,,,,,
2209,,symptoms suggesting shift,dpt,,recist v1.1;|5. eastern cooperative oncology group (ecog) performance status,extracorporeal volume loss,,,,adequate for,in the last 14 days before screening|adequate organ function||,69-71).|bmi,,,,,,
2210,,extensive caries,rhpsma-7.3,,bleeding disorder|platelet count,impulse control,,,,clinically significant condition,within 2 years before enrollment.|botulinum toxin,≥ 100 gi/l,,,,,,
2211,,li fraumeni syndrome,quiremspheres®,,liver cirrhosis:||chronic hepatitis b virus（hbv,sbrt,,,,non-thoracic,within the previous 6 months,at least 1 mm depth.|there,,,,,,
2212,,mild cognitive impairment,large vessels,,cd4+ t-cells,injection into the target knee joint of glucocorticoid,,,,surgery|bmi,within 8 days prior to start,> 60 or <90,,,,,,
2213,,joint pain)|no weigh loss,ics criteria [,,lawrence oa,vital signs:||systolic blood pressure of,,,,affiliated with pharma,preceding 24 consecutive,12 or older,,,,,,
2214,,tear)|no tolerance,lines of,,1.1|ecog performance status,holep procedure,,,,related co-morbidity|reasonable,prior to start of treatment|prior treatment with,< 5.0 × uln,,,,,,
2215,,herpetic lesions,medications commonly,,l).|platelet count,show,,,,effective methods of birth control include:||use hormonal birth control methods,within 3 months of screening,ranges from 18-50 years,,,,,,
2216,,tud,platelet transfusions,,national cancer institute (nci)-common terminology criteria,heart valve surgery|being transfer to service,,,,optional.|gali,within 60 days from enrollment,greater than 24 hours,,,,,,
2217,,inflammatory states,alpha-2 agonist,,barts health nhs trust,screening blood sample,,,,exceeded 1 year,after ct-scan assessment.||remark,elder than 18,,,,,,
2218,,thrombotic episodes,tezepelumab,,basic level of technological literacy,psychological treatment for cud,,,,arc induced,for less than 6 months;|under treatment,at least 42 days must,,,,,,
2219,,congenital malformations;||⑪,iiia nsclc|candidate,,coagulopathy|platelet count,standard chemoradiotherapy,,,,biopsy.||for dose escalation,at least one of the following criteria:||have undergone,≤ 5 × the upper limit of normal (uln),,,,,,
2220,,of:||additional risk factors,knee injection,,absolute neutrophil count:≥1.0×10,universal,,,,oxford university,after mechanical thrombectomy,per 4 weeks,,,,,,
2221,,intracranial haemorrhage,erratic,,below:||• glomerular filtration rate (gfr),chronic antiplatelet,,,,splenius,≤30 days before receipt of study vaccine,outside the reference ranges of the testing laboratory,,,,,,
2222,,pseudo-exfoliation,acne medications,,bcg intravesical instillation,sensorineural hearing ranging,,,,non-inclusion criteria common to the 4 groups:||history (,more than 4 weeks prior to the enrollment of this study,<15 milliliter/minute,,,,,,
2223,,tumor||,iohexol,,acr,tavi,,,,american-european consensus group (aecg),within 3 months|refractory hypertension,≤ 2.5 xuln,,,,,,
2224,,chronic conjunctival diseases,n1c,,mallampati,immunohistochemical (ihc) staining,,,,non-diabetic,for ≥3 months prior to randomization.||any subject taking,1 to 3|scheduled,,,,,,
2225,,hemorrhagic stroke.|patients,strong inducers of cytochrome p450 3a,,hepatitis c reference,bilateral affection,,,,non-stroke neurological,for the duration of the study|use of any consumer-based,1-2-3|18-65,,,,,,
2226,,eps,nasal,,old|positive notch,physical examination center,,,,amino acid,during the first 14 days of enrollment met the following requirements:||neutrophil absolute count,6-24 months|pregnant,,,,,,
2227,,dilated choroidal vessels,ketone supplements,,updrs-ii item,essure,,,,higher|symptomatic,before blood testing.||,follows:||at least,,,,,,
2228,,anterior circulation stroke,drug abuse;|cardiovascular,,polypnoea,knee x-rays,,,,non-child bearing potential,in the past five years,at least 7 days must,,,,,,
2229,,neurological impairment,phencyhexidine,,aim1:||age,bilateral uterine artery ligation,,,,could jeopardize treatment procedure,more than 14 drinks/week,18-85|within 8 hours of the onset of stroke symptoms|there,,,,,,
2230,,neurological condition|psychiatric symptoms,anti-vegf drugs,,hcg rate,renal replacement therapy.|severe chronic kidney disease,,,,express himself,within 28 days prior to imp treatment,7 and above,,,,,,
2231,,secondary causes,immunotherapeutic agents,,national university hospital,lkb1 mutation status,,,,rome iv symptoms criteria,more than 4 prior cytotoxic regimens,between 55 and 75 years and >1800 pg/ml,,,,,,
2232,,actionable aberrations,etc.).|≤ grade 1 (ctcae v5.0,,blood pressure (bp,disorders|prior surgical history,,,,recovered to ≤ctcae 1 grade,within last year.|history of,40-65 year.|perform greater than 4 hours per week,,,,,,
2233,,severe hearing problems,nonhormonal,,vas scale|age is,catheters retained,,,,dominant,3 days prior to initial treatment,< 15ml/s,,,,,,
2234,,"orthodontic treatments,|presence",mastectomy,,triglyceride concentration,assessment sessions,,,,ibs-d,at the time of screening|unintentional weight loss,">= 1,000/mcl|platelets",,,,,,
2235,,diabetes mellitus)|current,immunosuppressive agents|baseline blood,,ecog scale).|life expectancy,cytoreductive radical prostatectomy,,,,operate,within 18 months from the,< 3mm,,,,,,
2236,,intestinal dysfunction,iodinated contrast,,dat,cisplatin chemotherapy,,,,non-lactation,within 24 hours prior to administration of lr769|have a,> 140/90 mm,,,,,,
2237,,diffuse liver,readings,,durvalumab,biochemical investigations,,,,non malignant systemic,within 30 days post,≥100 mmhg;|prior to enrollment,,,,,,
2238,,human immunodeficiency virus (hiv) antibody results|evidence,allergy shots,,recist v1.1 solid tumor evaluation criteria;|8),alcohol exhalation,,,,ed;|sufficient,within 12 weeks of,18-85|ability and willingness to attend study visits,,,,,,
2239,,psychotic state when,full anticoagulation,,inr ≤1.6,otological surgery,,,,intervertebral,at least one ongoing research project,≤ 0.5miu/l,,,,,,
2240,,inflammatory disorders.||,stickers,,nei scale|tear,diabetes|major surgery,,,,non-stemi|concomitant,intravenous (iv,≥ 80 x 109/l,,,,,,
2241,,hgd,test drugs,,nurse,tbil>2.0x uln blood ketone body,,,,acrylic related jobs||,at any 4 cm segment|able to commit,from,,,,,,
2242,,-menopausal,cytologically-,,cooperative oncology group (,intravenous iron therapy,,,,c3-t1,30 days before study to 3 months after study,>40)|radial artery depth,,,,,,
2243,,atc,restasis®,,srt,allograft graft,,,,influence of any medications,within 6 months prior to,scores between 18 24 points.|participants,,,,,,
2244,,asthma attack,oral antidiabetic agents,,alanine aminotransferase (alt),dtc,,,,st-segment elevation myocardial infarction,within 6 months before randomization.|clinically relevant electrocardiogram (ecg),18 to 32 kg/m2|female,,,,,,
2245,,lv thrombus,fondaparinux,,agir à dom,lower anterior crowding good oral hygeine,,,,meeting one,within 6 months prior to the study enrollment|unstable angina,polyneuropathy|more than one lifetime event of,,,,,,
2246,,antiphospholipid antibodies positivity,msc,,facial iga score,fecal calprotectin,,,,non-pharmacological agent,before the first dose of study drug|had,>=4|survival expectancy,,,,,,
2247,,atypical endometrial hyperplasia,sildenafil,,serum creatinine (cr),standard neuropsychological examination,,,,index intracranial aneurysm,within 6 months of inclusion,at least 50% of the pre,,,,,,
2248,,extrapulmonary disease,overlap,,black / african,mandibular incisors)|fdpcs supported,,,,chu montpellier,no higher than 500 iu/ml,≤ 3 x unl,,,,,,
2249,,severe immune system-related diseases,nonsteroidal anti-inflammatory drug [nsaid],,maximum diameter ≥10mm);|serum cortisol,1-4,,,,"diagnostic and statistical manual of mental disorders, fifth edition (",in preceding 3 months,>120 or <50,,,,,,
2250,,reproductive capacity,sensors,,pediatric medicine unit ii,pharmacological methods,,,,very severe,in the past 3 months|engaged,< 1% per year,,,,,,
2251,,psis,non-steroidal anti-inflammatory medications,,microalbuminuria,robotic pci,,,,condition|concomitant,during the first 24 hours of admission,≥18 years;|≤20 weeks,,,,,,
2252,,neuropsychological dysfunction,contraceptive agreements,,/l；|platelet count≥75×10 9 /l；|hemoglobin,abdominal visceral,,,,diameter of the periapical radiolucency ranged,before admission to the neonatal/newborn,< 27kg,,,,,,
2253,,covid-19.|active liver disease,ticlid,,tomme,caco-cola,,,,non-specific conditions,within 1 month of study entry|history,between 18 to 55 years,,,,,,
2254,,anaplastic lymphoma,inhaled influenza vaccine,,rutherford category,other treatment,,,,non-opioid,preceding 4 weeks|no contraindications to the application of c.alata extract in solution including|no,≥180 mmhg|hemoglobin < 7g/dl|fetal,,,,,,
2255,,verbal communication abilities.|the child,component of st-01|any contraindication,,serum glutamate oxalate transaminase (sgot,count,,,,insulin treatment|diabetes type 1,at least 6 months after the last trial treatment.|those who,≤ 480 ms.||patient able,,,,,,
2256,,limb|malignant diseases,meningococcal infections.||,,alpha-glucosidase inhibitors.|glycated hemoglobin,telephone|currently enrolled in a research,,,,urgent,longer half life.|researchers believe,> uln|neutrophil,,,,,,
2257,,bending,risperdal,,ecog-acrin pet/ct scanner approval.||for,pregnancy tests,,,,subsequent to initial curative,within 14 days of registration)|for,≥25%,,,,,,
2258,,spinal infection,su,,illumisite,crs,,,,culprit's vessel,at time of enrollment||exclusion criteria||none,between 18-65 years|lower,,,,,,
2259,,parkland diabetes,goserelin,,glycated hemoglobin (hba1c),total vaginal hysterectomy,,,,extensive chronic graft-versus-host disease,in the target vessel,<500/µl,,,,,,
2260,,initial atrial fibrillation,immunosuppressive or,,quattro® x suture,standard biologic therapy,,,,place the patient at unacceptable risk,for 3 years prior to the first dose of study treatment,less than 7 months,,,,,,
2261,,serologic evidence,apds1,,hepatitis b surface antigen positivity,soon,,,,acute phase.||,less than 1 year,≤ the upper limit of normal,,,,,,
2262,,motility disorder,albumin allergy|patients,,mass index（bmi）≤30 kg/m2.|volunteer,hormone replacement,,,,lumbar region which could prevent the lumbar puncture,in the 4-weeks,6.1%,,,,,,
2263,,dysthyroidism,alginates,,ultraviolet b [uvb],aclr surgery,,,,epilepsy;|prior,within 30 days prior to the 1st dose of chs- 006;|history,> 40 u/l,,,,,,
2264,,pulmonary nodule,tnf-α inhibitors,,functional class,clinical mammography,,,,exposed,during the 30 days following cataract surgery.|history,≥ 3|body mass index,,,,,,
2265,,intracardiac mass,intrerdental site ≥2mm.|compliant,,booster,left ventricular hypertrophy|active cardiac disease,,,,platinum-refractory,within 6 months of the first dose of study,below 18 years or above 80 years.|patients,,,,,,
2266,,ql1604,operate machines,,serum hepatitis b virus dna,fully healed ridge type 4|sufficient bony,,,,extensive metastasis.|patients,months;|history,above 18 yrs.|50,,,,,,
2267,,frozen,drugs,,criteria.|ecog performance status,dysplasia|generalized hypermobility|revision surgeries,,,,flow cytometry,in the last 12 weeks before the administration of study treatment.|known,between 0.77 d and 4.53 d,,,,,,
2268,,borderline personality disorder)|have,anti-inhibitor coagulant concentrates,,serum hbv-dna,cytological documentation of,,,,regular-strength,in the last three months|no,≥ 75 years,,,,,,
2269,,simple dyslipidemia,immune-related disorders,,princess margaret hospital,bone marrow biopsy|subjects,,,,prepubertal,within the previous 6 months prior to screening|extreme fatigue,>150 mg/dl|fasting,,,,,,
2270,,aids-defining opportunistic,nonsterilized,,genotype,standard mri exclusion criteria,,,,first-line standard chemotherapy,prior to initiation of,6-18 months,,,,,,
2271,,iih,famitinib,,bmi,transseptal catheterization,,,,man - 21,birth)|current,≥ 80 g/l||criteria,,,,,,
2272,,rashes,barbitutate,,me/cfs ccc criteria,southwest oncology group (swog),,,,electromagnetic,at the time of screening|world health organization/eastern cooperative,> 3 times the upper limit of normal.|neutrophils < 1x10^9/l.|platelets,,,,,,
2273,,initiation,spontaneous mobility|previous surgical procedures,,uterus|good compliance,cardiac magnetic resonance imaging,,,,suitable,within 4 weeks prior to the first dose of the investigational,50-500 copies/ml,,,,,,
2274,,pancreatic cystic tumor,anti-tumor necrosis factor-α [tnf-α] agents,,recist v1.1 assessment,extensive neuropsychological examination,,,,klebsiella spp.,prior to enrollment.||5.life,18.|low back pain,,,,,,
2275,,clinical disease progression,sodium fluoride varnish,,chosen,treated for diabetes for more than 3 months|glycated,,,,severity of symptoms,adjusted,less than 1000 copies/ml.|patients,,,,,,
2276,,neuroendocrine prostate cancer (nepc),qtcb,,hepatitis;|aortic arch dissection;|major surgery,disorders|pregnant,,,,considered acute,within 6 months prior to the first dose of study,0 or 1.||adequate organ,,,,,,
2277,,infectious liver cancer,iodized contrast agents,,srv pressure,e-mail,,,,under 50 should,within 12 weeks of enrollment,<36 weeks|griffiths,,,,,,
2278,,fungal keratitis,intranasal,,eip,radiographic studies.|carbohydrate antigen,,,,acute phase treatment,at the time of the mii-ph,18 to 45,,,,,,
2279,,mandibular advancement device,accutane,,graves' disease,dme,,,,femoral vein communis,"ending in ""ximab"" or ""zumab""",≤ 10;|there,,,,,,
2280,,investigator|haematuria on dipstick,retained products of conception in diagnostic hysteroscopy.|medical need,,short form|functional assessment,primary care consultation,,,,reproductive period;|patients,in the next 24 months|prisoner|other contraindications,= 10 g,,,,,,
2281,,gait impairment,il-2),,estimated from,ert treatment,,,,unresectable advanced,previous 8 weeks,35 to 75 years,,,,,,
2282,,obsessive-compulsive disorder,lhw monthly reports,,outcomes measurement information system,x-ackt.|subject,,,,intercurrent,more than 6 months of follow-up after onset of adjuvant chemotherapy.|at least,>35kg/m2|expressing,,,,,,
2283,,breast intraductal carcinoma in situ,receive prednisone,,sars-cov2,anticoagulated,,,,managed per local guidelines,within 7 days prior to the first dose of study treatment,≥ 3|female patient must,,,,,,
2284,,rotavirus,mmf,,arrixaca university hospital.|sign informed,extrusions,,,,should undergo cns,at the time of screening|any condition,3% or greater,,,,,,
2285,,fatal events,rsv immunoglobulin,,lumbar levels,cell cycle inhibitor,,,,mucosal type.|provision of signed,during the time of study,> 250 pg/ml,,,,,,
2286,,alcohol injection,local steroids,,lost follow-up,functional neuroendocrine tumors,,,,nicotinamide,in the last 12 months|history of pancreatitis|allergy,"≥30 kg/m2),|age",,,,,,
2287,,≤8,iv).|pregnant females|teeth,,systolic blood pressure<90 mmhg,vascularized polyp,,,,severity to prevent,separated by more than (>)24 hours.||,i/,,,,,,
2288,,black feces,contraceptive sponge,,respiratory care center,residual disfigurement.|nails infected,,,,nurse prescriber,within 14 days before tumor harvest|known active,<1 at least,,,,,,
2289,,drug-induced psoriasis.|history,component of the apx-115 formulation.|history of acute kidney injury,,lundquist institute for biomedical innovation,edinburgh postnatal depression scale,,,,suitable for radical resection,at least 3 months before participation,> 88,,,,,,
2290,,anterior neck lesions,drugs used for routine sedation,,barcelona,cognitive rehabilitation,,,,non-cancer,at the time of consent.|eastern cooperative oncology group (,>36.|history of,,,,,,
2291,,disease|palliative,hormonal drugs,,serum total bilirubin(tbil)≤1.5×uln,radial artery cannulation,,,,mindfulness-base,at time of screening,≤ 2.5 × uln；⑦,,,,,,
2292,,spastic cp hemiplegia,component blood,,hiv antigen-antibody test or hiv antibody test.||patients,acquisition of informed,,,,lack the inductive reasoning skills to learn magic tricks);|functional ability of the affected hand,6 weeks,>99.5 °f (37.5 °c,,,,,,
2293,,mucosal site of the oral,carboplatin,,blood concentrations,baseline angiography,,,,non-cancer-related,within 28 days before taking the study drug;|use,3 ng/ml or greater,,,,,,
2294,,right ventricular,long-acting growth factor,,women|blood pressure,anterior repair,,,,pd-l1 expression);|uncontrolled,for six months following duration of study participation,> 140 systolic,,,,,,
2295,,tuberculosis exposure,iron -deficiency,,hepatitis c antibody (hcv),aortic valve repair/replacement,,,,full term of,within 30 days of planned treatment start,≥ 10 cm,,,,,,
2296,,refractive media,expression,,junction adenocarcinomas|absolute neutrophil count,pain control,,,,uncontrollable,at time of treatment:||medical and,<30,,,,,,
2297,,hemolysis-related test,regadenoson,,anatomy.|refractory gastro-esophageal reflux disease,tq,,,,somatic,for at least 6 months of study participants,=< 3x uln.||aspartate aminotransferase (,,,,,,
2298,,ipsilateral shoulder infection,anti-thsd7a,,gauteng,stereotactic body radiotherapy,,,,in terms of population:||pregnant,during the past month,≥ or equal than 10mm,,,,,,
2299,,tubal ectopic pregnancy visible,basiliximab,,asthma daily diary.|at least 70% daily paso,left anterior,,,,metal fragments,within 1 month prior to the screening.|patient,over 120,,,,,,
2300,,anomalies,calcium supplements,,intraocular pressure|intracranial hypertension,proliferation fraction,,,,gvhd)|suffering from any other,within 24 hours before sampling;|any medical,move more,,,,,,
2301,,renal disease.|patients,pi3k,,generalized convulsive status,intracranial lesions|history of head trauma resulting,,,,interferes with successful administration of tes,within the last 2 years.|for,- urgent/emergent,,,,,,
2302,,traumatic brain injury (tbi) interview,anti-cd20 x anti- cd3 bispecific antibody,,quantifying estimated glomerular filtration rate (egfr),cardiofundal gastric varices;|portal venous thrombosis,,,,any other factor,within 3 months acute head trauma gi malignancy,19 or older||patients who agreed to the research protocol,,,,,,
2303,,neurological chronic disorders|spinal disraphism|spinal rheumotological disorders,primidone,,hcv rna detection,infusion therapy,,,,ambiguous,within 180 days (6 months,more than or equal to 5cm from the,,,,,,
2304,,complex arrhythmia,androgen receptor inhibitor agents,,average systolic bp,breast conservation therapy,,,,acute physiology score [aps],prior to the first study dose;|patient,^9/l]).|the,,,,,,
2305,,neurological signs,tropical medicine,,surgery;|body mass index,intravesical immunotherapy,,,,non-ms,within the past 6 months.|subject,"100,000/mm3",,,,,,
2306,,rv,yf vaccine,,gamma-aminobutyric acid,single dermatomal herpes zoster eruption,,,,img basketball,within 3 months after the test.||previous medication:||those,2-,,,,,,
2307,,chronic debilitating conditions,immune checkpoint inhibitor targeting ctla-4,,residual adverse effects,pathological optical coherence tomography angiography (octa))]||for female,,,,rancho level of,in 1 week,<++,,,,,,
2308,,deformity.|leg pain,topical steroids,,regular physical activity,blood thinners|pregnant,,,,biodegradable,at any time after screening through study completion||reproductive,≥9.0 g/dl.|liver,,,,,,
2309,,cardiac conditions,anthropometrics,,total score,materials,,,,imvamune,in the past 4 weeks;|any,<2500g,,,,,,
2310,,difficulty swallowing capsules,prophylactic medication,,calculated by mdrd),labor analgesia,,,,primary small cell histology||localized,within 4 weeks of the first dose of,> 7.35)||,,,,,,
2311,,"tuberculosis (tb,",wounds,,βhb,positron emission tomography (pet) imaging,,,,constraints of follow-up defined,within 2 weeks before the baseline,≥ 2.0 g/dl|pulmonary function tests,,,,,,
2312,,primary teeth,hybrid closed-loop systems,,medication,practice of physical activity physical activity|important comorbidities,,,,old|bridging,less than 12 months,≤ 20%)||minor,,,,,,
2313,,neurological abnormality,perphenazine,,calculated chronic kidney disease epidemiology collaboration [ckd-epi] glomerular filtration rate estimation)|creatine phosphokinase (cpk) elevation,lipid metabolism|use,,,,new diagnosis,for at least 6 weeks prior to final screening,≥ 37.3℃*,,,,,,
2314,,renal function||exclusion,ogib,,https://cellworks.life/mycare102|patients,bms,,,,radical mastectomy|undergoing,in the previous 6 months.|history,≥2400 u/ml|presence,,,,,,
2315,,antileukemic therapy.|breast feeding.|impairment,rapid acting,,national heart center harapan kita,metallic hardware,,,,transanal,within 12 months before informed,< 30 ml/min/1.73 m2)|5.serious,,,,,,
2316,,radiographically detectable,amylin mimetics,,modified rome iv fc criteria,transplantations,,,,fish products|positive serology,within one month prior to enrollment,below 96.4,,,,,,
2317,,cin2+,acute antibiotics,,women)|type,diagnostic access site).|use,,,,non contrast,within 3 days prior to study treatment,>18 yr|clinical diagnosis,,,,,,
2318,,hypospadias||,ap,,researchers.|systolic blood pressure,t-dxd.|any substance abuse,,,,periocular,than 2 months before inclusion,> 2 times uln,,,,,,
2319,,melanoma skin carcinoma,rehabilitation department,,serum alt,sle background medications:||anti-malarials,,,,metastasis|serious,pre-study medical history,long-term transportation,,,,,,
2320,,chromosomal abnormalities,nac,,mcrc;|ecog ps,insulin infusion,,,,csf-1,for at least 6 hours,greater than 20%,,,,,,
2321,,digestive tract,oral anticoagulation treatment,,anti-thyroid drug usage.||,potential treatment sites assessed as clinically ambiguous.|implantable cardioverter defibrillator (icd),,,,gleno-humeral,throughout the duration of the study.|received strong,<8 g/dl|platelets,,,,,,
2322,,bornchial asthma.||,procedure|carotid stenting,,cic,general outpatient mental health clinic (mhc),,,,ankle-brachial index,at the time of signing the informed consent;|histologically,between 21 and 65 years old|is voluntarily,,,,,,
2323,,raynaud's disease|the,choline pet-scanner)|informed,,sbp,abdominal b-ultrasound,,,,pacemakers,within the last year,18-75 years|karnofsky,,,,,,
2324,,liver disorder,netupitant,,average her2 copy number/cell,surgical outpatient,,,,moderate intensity exercise per week.|serious illness,within 30 days prior to cycle 1 day 1,>= 5.2 mmol/l.|understand the test procedure,,,,,,
2325,,normal activities can cause fatigue,components of the planned,,left ventricular mass index,coronary artery bypass||pre-stroke,,,,tattoo ink.|participant,within 30 days prior to the first dose of study treatment,<14|ipss score,,,,,,
2326,,bone marrow deficiency,ffp,,nd,ulnar artery occlusion;|patients,,,,genetically modified cell product,during the 8 weeks they,less than 1 year.|subject,,,,,,
2327,,ischemia occurred,injection sclerotherapy,,screening|platelet count,allogeneic organ transplantation|active,,,,grade 1 icans,within two months of consent,≥18.50 and <30.00 kg/m2.|subject,,,,,,
2328,,inoperable bladder cancer|patient,anesthesia;|pregnant,,er/pr(+),re-do,,,,low-dose gestagen [lynestrenol,6 months to 3 years old;|able to participate,requires 24-hour care,,,,,,
2329,,hyperbilirubinemia,considered.|srns,,ert treatment naïve,global deterioration scale,,,,degenerative,≥1 year,≥20 pa|active,,,,,,
2330,,weight bearing,alendronic acid,,forced expiratory volume in first second (fev1) / predicted value,available treatment,,,,other uncontrolled,throughout the trial;|the subject,more than 9.5 gm/dl.||,,,,,,
2331,,aphasia,6-mp,,alt level,revision tha|acetabular implant,,,,non-autoimmune diseases,prior to enrollment.||(2,≤ 25 × 103/μl,,,,,,
2332,,former smokers,sensor placement,,anti -hcv antibody,blood transfusion support,,,,connective tissue diseases;|diagnosis of genetic alterations,in the 24 hours prior to vaccination,≥80 pg/ml,,,,,,
2333,,refusal,lagophthalmos,,estimated glomerular filtration (egfr),restrictive ventilation,,,,maceration,during the previous three weeks|history,*|hscrp < 2 mg/l *,,,,,,
2334,,infections controlled,ambroxol hydrochloride,,carbamide level,regular imaging of the brain,,,,connective tissue disease|reoperative coronary artery bypass,during the previous 7 days (self-reported,> 80,,,,,,
2335,,generalized infection,sedative/hypnotics,,moca)|willing,tumor vaccine,,,,listed in exclusion criteria (,within 1 weeks before baseline;|patients,over 18 years old|at least,,,,,,
2336,,mental health illness,nonsystemic steroids,,autism||stratum b||eligibility criteria||diagnosed,gi specialist,,,,emergency department||,within 1 year after car-t cell infusion;|any conditions,> 2 times the upper limit of normal;|have,,,,,,
2337,,dyskeratosis congenita,uln|existing,,urine o serum),still|ferromagnetic metallic implants,,,,mitomycin c,at least one symptom,<60 milligram per deciliter,,,,,,
2338,,polycythemia vera,antiplatelet aggregation therapy,,gamma glutamyl transferase[ggt],criteria:|cardiac diseases.|burn,,,,aging,prior to initial administration of the study drug;|other,≥8 points,,,,,,
2339,,donate lactation,mrna) vaccines,,pulmonary arterial wedge pressure (pawp),surgery|neurosurgery|surgery,,,,primary lead,in the month preceding the inclusion.|subject who will have,>= g3,,,,,,
2340,,pregnancy.|-,particularly antibiotics,,dsm-iv-tr,bilateral headache,,,,study)||,at least 1 month before the screening visit until 1 month after last,≥ 80 × 10^9/l;|alt,,,,,,
2341,,liver metastases ≤5,drugs known,,wheelchair bound).||cancer survivor,steroid premedication,,,,jaundice.|another group of,within 4 weeks prior to first administration of the study drug,=< 15 days prior to registration)|pulse oximetry,,,,,,
2342,,rett syndrome,nucleic acid amplification (naa) test,,partial prothrombin time (pt),biopsy.|pharmacodynamic confirmation phase,,,,under control|prospective participants,in last 12 months|seasonal allergic rhinitis|chronic rhinosinusitis,≥400 ng/dl;|sedentary,,,,,,
2343,,disease.|documentation,chronic migraine,,self report):||age,consistent use of long sleeve shirts,,,,partner|partner,within 14 days from the date the fracture,0-1.|18-75 years|patients,,,,,,
2344,,diabetes|obesity,non-steroidal anti-inflammatory drugs (nsaids),,staff)|age between,extracorporal detoxication methods application,,,,cns metastatic disease,within the prior 90 days,< 50% of predicted normal.|moderate,,,,,,
2345,,vulvar-vaginal cancer,criteria:|children,,aspcects score,heamofiltration dialysis,,,,perennial,within 28 days of first dose of study drugs|palliative,≥100 μg/day,,,,,,
2346,,judged by the investigator to have a,plmd,,left ventricle end-systolic volume,smartphone||,,,,microsatellite instability,within two months prior to period i dosing.|acceptable biochemistry determinations,4-5)|uncontrolled,,,,,,
2347,,lack of control of their aggressiveness.|positive impulsivity,long-acting beta-adrenergic,,cross-match test,intrauterine,,,,researcher thinks patients,in the last 5 years,>20 x 109/l|hemoglobin,,,,,,
2348,,leg ulcer,vaccines,,left-hemisphere,endoscopic ultrasound).|no evidence,,,,alloderm,for 30 days after the trial ends.||,less than 2500 copies/ml,,,,,,
2349,,higher|admission,clascoterone,,thymidine analog mutations,enteral nutrition,,,,youth smokers,at the time of treatment|the caregiver,< 45 ml/min;|serum calcium levels,,,,,,
2350,,diabetes|systemic disorders,baricitinib,,bcma-targeted therapy,radiation of the tumor,,,,not eligible|patients,during at least one of three repetitions,1 to <2 years,,,,,,
2351,,traumatic stress disorder,radiographically,,predominant stress element.|refractory,contraceptive injection note,,,,chronic use,within 3 months prior to study entry|current infection,> 70%|hemoglobin,,,,,,
2352,,calculated from the,progestin-containing,,glutamic aminotransferase (ast),pathological examinations,,,,non-palliative,within 6 months prior study start.||-,< 1 year|patient,,,,,,
2353,,melanoma brain metastases,ukraine,,eliquis,strenuous exercise,,,,low doses of,within 7 days prior to initial dosing.||,"<1,000/mm3",,,,,,
2354,,third-degree conduction block,psychoactive medication use|healthy,,urine protein <+,nephroureterectomy,,,,systemic therapy.|had major surgical procedure,within 1 year prior to screening.|clinically significant,between 18 and 60 yo|providing free and informed consent,,,,,,
2355,,voice disorders,h2 blocker.|excessive use,,hcvab,video head impulse test,,,,histologically proven|adequate,in the past six months|recent hospitalization for,> 2.50,,,,,,
2356,,hepatitis b.|co-infection,drugs used in this protocol,,child-pugh system,conventional intervention,,,,gir 2,"within 3 months,|emergency operation",< 60 ml/min/1.73 m2)|known,,,,,,
2357,,solid organ transplantation.|uncontrolled,etodolac,,contraindications;|abnormal blood pressure,urinary diversion,,,,large vessels,last dose at least 6 months prior to study vaccine|understands,>130/80 mmhg,,,,,,
2358,,gastric varices|coagulopathy,lacosamide,,interval corrected,peripheral artery revascularisation,,,,grade i,within 4 weeks prior to the first dose of trial treatment.||note:,between 37-40 weeks|absence,,,,,,
2359,,third-generation egfr-tki,acr,,serology blood test,continence surgery,,,,moderate,within 24 hours of initiation of,>35 years|type 1 diabetes,,,,,,
2360,,transferring,aromatase inhibitor.|patients,,acute presentation|ph,contracted residential facilities enrolled in the study,,,,non or,within 4 weeks prior to the start of this study.|prior treatment,>=18 years,,,,,,
2361,,infectious stones,compounds of similar chemical or biologic composition to (investigational new drug [ind] agent[s],,exercise|≤,investigator|laparoscopic surgery,,,,aids stage,in the next 30 days,more than 3 months.|the,,,,,,
2362,,cancer disease|serious disease,mrna vaccine,,dorsal root ganglion system (drg),standard therapy failure,,,,for adenocarcinoma of the prostate.|previous,within 48 h of randomization;|patients,>10.0)|use,,,,,,
2363,,coeliac disease.|lactose intolerant,infertile,,mean pressure,rarefaction|necrotic pulp upon,,,,enrollment|peripheral,within 4 weeks before study start/part a,>35 kg/m2|ckd,,,,,,
2364,,diplegic cerebral palsy,withhold anticoagulation,,cd4+ t-cell counts,positron emission tomography (pet) -ct,,,,segments,within a previously irradiated field,"<100,000/mm3",,,,,,
2365,,lymphatic disorder,betamethasone,,new york heart association's class iii or iv functional capacity|uncontrolled hypertension,abdominal computed tomography(cect,,,,consentement,within the past two weeks|uti,≤ 1.4,,,,,,
2366,,oral condition,topical jak inhibitors,,cr,cytologic documentation of incurable,,,,wild-type transthyretin cardiac amyloidosis|nac,in the first 5 years of symptoms onset,< 10 mg/day,,,,,,
2367,,health visitors,device components,,hba1c).|controlled arterial hypertension,pelvic floor muscle training,,,,narrow therapeutic index,within three months prior to,iii-iv|scheduled,,,,,,
2368,,congenital dental defect,macrolide antibiotics,,babies,iliofemoral dvt|prior venous stent,,,,either:||dwi positive,during the screening period|infection,allowing exception to this criterion,,,,,,
2369,,acute injury around,bedside,,fcxm,open labeled exploratory study,,,,in room air|signs,pre-operative af|patient,>= 18 yo|ecog performance status,,,,,,
2370,,bursitis,anti-infective therapy,,mas,total hip bone density,,,,upper respiratory tract infections,within 7 days prior to study enrollment,≥ 50 ml/min/1.73,,,,,,
2371,,painful swallowing,anti-coagulant,,syphilis specific antibody (tpha),bone augmentation procedures|patients,,,,could justify the syndrome||,within 30 days after clinical diagnosis,≥ 75 × 109/l,,,,,,
2372,,restrictive lung disease)|clinically unstable,cns)-active medications,,pancreatic cancer.|histology,magnetic resonance contraindications|any condition,,,,primary endpoint|no treatment with hormones,within 28 days prior to step 1 registration|for,>18-years,,,,,,
2373,,vulvovaginal candidiasis,antiparkinsonian medications,,milk|body mass index (bmi),cardiovascular risk factors:||cardiogenic chest pain,,,,pd-mci,in the next 6 months|not,22-34,,,,,,
2374,,cardiac disorders,components of the study vaccines,,creatinine|total bilirubin,dilatation,,,,ptca.|uncontrollable severe,up to 2.00d,>34 ml/m2,,,,,,
2375,,allergic anaphylactic reactions,stable medication regimen,,serum m-protein level,endometrial thickness,,,,tumoral,for at least one month prior and one month after study,- 18 years,,,,,,
2376,,traumatic injury;|allergic constitution,adenosine administration,,positive sars-cov-2,thyroid surgery|patients,,,,cyto-/histologically confirmed,within 28 days of the last drug administration of the study.|those who do not respond to surveys,< 1.5 k/mm3,,,,,,
2377,,third trimester bleeding,detoxification,,transaminase,antifungal therapy,,,,face transplantation.|aged,in the past 5 years;|patients,6.0,,,,,,
2378,,secondary tumors,durvalumab,,her2 expression,trial treatment,,,,internet-enabled,before the start of study drugs.|to reduce,≥ 16 mmhg,,,,,,
2379,,herceptin,selective androgen receptive modulators,,interventional blood supply reconstruction,udca treatment,,,,micro-tese,within 14 days.|patients,between 0-5 cm,,,,,,
2380,,hyperuricemia,gelofusine,,radiographic bone loss.|localized gingivitis - 10,local ablation,,,,low to intermediate risk stratification.|no,between january 2014,greater than 35,,,,,,
2381,,inflammatory arthritis||d. peripheral vascular disease||e.,artificial tanners,,forced expiratory volume/forced vital capacity (fev1/fvc),simple -y abnormality can,,,,intestinal transit time 6 weeks,insufficiency;|long-term,19-80|the patient,,,,,,
2382,,gastrointestinal system,wfd,,american society of anesthesiologists (asa) score,chemoradiation not resolved,,,,greater than or equal to 25%,within 28 days before the first does of investigational,>100 ng/dl,,,,,,
2383,,etc.;|at present,over-the-counter bronchodilator medication,,gamma-glutamyltransferase (ggt),gastric sleeve,,,,cytologically-,within the previous 30 days or five half-lives,≥ 18 years|type 1 diabetes,,,,,,
2384,,hashimoto's thyroiditis).|known,nurse,,.|patients,sequential therapy,,,,bacterial,within 6 months prior to signing consent,18-50|address,,,,,,
2385,,myeloid malignancies,srt,,pulse rate outside,orthodontic treatment.||,,,,listed above status,lasted for at least 6 months,greater than 15,,,,,,
2386,,restenotic target lesion,hysteroscopy)|abnormal parental karyotype|instable or exacerbation of auto-immune diseases,,anti-mullerian hormone (amh),axillary node,,,,age|previous,no more,score ≤ 7|at least one,,,,,,
2387,,prolonged duration,component of the phentolamine,,ventricular ejection fraction,global impression of,,,,"lynch syndrome"")|other",during the 90 days before screening regardless of medical records.|treatment,movement disorders.|the,,,,,,
2388,,human t-cell lymphotropic virus i,conventional catheter,,carbon dioxide partial pressure,first-line,,,,non-cardiovascular disease<4,<2 years,from 18 to 70 years.|american society of anesthesiologists is,,,,,,
2389,,adrenal insufficiency|significant,envafolimab,,dwi image,metal,,,,single-strap,during recruitment period,>2.5x the upper limit of,,,,,,
2390,,crt,procedure execution.|moderate gastro-esophageal reflux disease,,her2-negative bc,"standard world health organization criteria)|anaemia (hb<7g/dl),|any",,,,influence on the test of,within last 6 months prior to,>80 years,,,,,,
2391,,duodenal ulcers,seville orange,,hcc)||,local testing,,,,unsuitable for vasodilation in patients,before starting antimicrobial therapy|expected,between 2500-4500 g|1.-5,,,,,,
2392,,third and fourth level intracranial hemorrhage,stable medications,,residual be,ted,,,,first-degree,within 1 week before the inclusion,≥160 mm hg,,,,,,
2393,,multi-organ failure|no,systemic retinoid therapy,,partial-thickness burn,cardiac surgery procedures,,,,potentially malignant adrenocortical carcinoma,at least 1-cm,61-80 points,,,,,,
2394,,liver disease,anabolic agents,,assessing breast ptosis.|breast cup size,health education intervention should,,,,documented,prior to vaccination,20-45,,,,,,
2395,,severe coronary heart,quinolones,,by:||left ventricular ejection fraction,glomerular filtration rate (egfr),,,,previous failed,at least 12 months prior to the development,>38.0°c||,,,,,,
2396,,singleton pregnancy||severe,magnesium stearate,,perioperative care related to vascularized lymph node transfer|concurrent,electrotherapy,,,,3d gait evaluation the more far from local spastica treatment,prior to starting neoadjuvant,20 or,,,,,,
2397,,emotional dullness,metagenomics,,randomization,nsclc,,,,healed.|obvious,within 1 month before signing informed consent,< 10 g/dl,,,,,,
2398,,invasive breast malignancy,indivior,,nut#)≥1.5×10,left heart surgery,,,,others)|symptomatic,at least 6 months prior to screening)|subject unable to undergo trial assessments,<15 ml/ min/1.73 m2)|pregnancy|arrhythmia,,,,,,
2399,,cola,licensed vaccine,,human immunodeficiency virus (hiv) antibody test,high||,,,,non-english speaking,at least 3 months between sterlization date,>1.5;|hepatitis c antibody positive,,,,,,
2400,,congenital heart disease)|accepted,interventional trials currently,,cd4+ t-cell count,analysis of the tissue or increase the risk to subject.|must,,,,third molars)|have,prior to enrollment||cd123 positivity,≤ the upper limit of the therapeutic range,,,,,,
2401,,pre-treatment cross-sectional imaging,lidocaine request,,nyha functional grade,infrapopliteal artery for patency of the affected,,,,intermittent,for at least 3 months before,1st episode,,,,,,
2402,,episodic,orthodontic miniscrews|less,,calculated creatinine clearance,screening|serum il-2 levels,,,,type 1 & 2).|chronic kidney disease,within 10 days of treatment initiation||hematological:||hemoglobin,>= 25% and >= 2 ng/ml above the nadir,,,,,,
2403,,pathological hypermobility,component of the intervention,,potential|life expectancy,hospitalised,,,,refused,at time of enrollment.|pathologic diagnosis,4 to 12 years,,,,,,
2404,,lung cancer,lamivudine,,tegner activity level,quantification of bmd)|history of metabolic bone,,,,anti-synthetase syndrome,less than 3 months before the start of the trial;|long-term,<50% must,,,,,,
2405,,n'ayant reçu,non-metformin,,princess maxima center,64cu-sar-bbn uptake,,,,mildly effected,within 6 weeks before the first dose of the study drug,> 1.5×,,,,,,
2406,,borderline personality disorder|any other condition deemed,glycated hemoglobin (hba1c),,ccr,activity assay,,,,age;|sufficient,at the time of signing informed consent;|have a performance status,13-17.99 years,,,,,,
2407,,mixed urinary incontinence.|understand spanish to be able to self-complete the questionnaires,over-the-counter (otc) analgesic,,zubrod performance score,axillary lymph node,,,,may significantly increase ketones;|participation in other intervention research projects on nutrition,within the last 6 months|participants,<5 kg change,,,,,,
2408,,cerebrovascular abnormalities,butylphthalide,,alanine transaminase (alt) ≤3 times the uln.|patient has adequate bone marrow function,btki treatment,,,,radiologically diagnosed,for at least 10 stanable,<30 ml/min|hemodynamic instability,,,,,,
2409,,mixed small cell component,antibiotherapy,,stage 3)||being,venous access to allow collection of multiple blood samples.||negative covid pcr test upon,,,,female;|diagnosed,within 2 weeks of the first dose of study drug.|major surgery 4 weeks prior to starting study drug,>90%.|adequate liver function,,,,,,
2410,,metabolic diseases|presence,chloride,,mage-a4 expression,routine analysis,,,,unknown cause before age 40,within the past 4 weeks prior to treatment start|neutropenia,a according to,,,,,,
2411,,steatosis;|surgery,live vaccines have been vaccinated,,progesterone receptor-negative,arthrodesis,,,,3-10|age,during at least one exercise,18-65|patients,,,,,,
2412,,anterior cruciate ligament,thymoglobulin®,,european glaucoma society (egs),immunosuppressant medication|regularly ingesting algae|smokers,,,,instruction given.||,within 6 months after the end of the medication；|other conditions,>1.3 mg/dl.|participants,,,,,,
2413,,non-psychotic major depressive disorder.||,seekonk,,mainly classes ia,cryocompression therapy,,,,ipsilateral iliac artery inflow tract patency,within the past 5 years except for basal cell,≤ 30 kg/m²;|having,,,,,,
2414,,parkinson's disease disease,soriatane,,abruption,lacks treatment compliance,,,,unsuitable for entry,during this study protocol period,=< 7 days prior to randomization)||glomerular filtration rate (gfr),,,,,,
2415,,increased back pain,booster,,mean blood pressure,knee oa activity,,,,apparatus disposable,fibromyalgia|history of,> 180/110,,,,,,
2416,,c|vital signs may,tamoxifen infertility treatment,,antinuclear antibodies (ana),carotid surgery,,,,low back,over the past 24 hours.|ability,≥50ml/min.||,,,,,,
2417,,transfusion dependent,argatra®,,kidgo stage,mavenclad)|s1p modulators|teriflunomide (aubagio),,,,partner|no,the previous month prior to screening;||does not reach,less than 100 x 10^9 /l|hereditary,,,,,,
2418,,fractures,over 40mm|if the kellgren & lawrence grades,,london fibromyalgia epidemiology study screening questionnaire (lfessq),allergen specific immunotherapy (desensitization),,,,primary mediastinal,during time of biochemical recurrence,60-64,,,,,,
2419,,monogenic diseases,moderate cyp3a4 inhibitors,,ser,intestinal microbiota,,,,pyelonephritis|hospital-acquired pneumonia (hap),within 6 weeks of the screening visit.|have used belatacept <6 months prior to clinic visit 1,less than 5 years|age,,,,,,
2420,,nonischemic,infraclavicular,,"verbal fluency test (animals and letter ""x""",signed informed parental consent|scheduled,,,,grade 2 or higher heart failure,before study participation,>= 18 years|able to provide,,,,,,
2421,,poor testicular function,anti-resorptives,,cardiac function abnormalities,consistent use of,,,,may cause non-compliance,within 7 days prior to step 2 randomization)||step,≥ 18 years|gcs,,,,,,
2422,,trans-telephonic monitoring (ttm),anti-anxiety medicine,,total parenteral nutrition,regular menstruation cycle,,,,suitable for this clinical trial,since the completion of studies ins1009-201,at least 12 weeks|female,,,,,,
2423,,"head trauma,|persistent disorder of consciousness (doc)",combination occurs,,fasting plasma insulin,endoscopy,,,,tavi||concomitant,on day 5,≥ 40;|previously treated,,,,,,
2424,,diabetes mellitus|psoriasis,anti-hyperglycemic medication|written informed,,nasal vasculature,anterior urethral stricture|short strictures,,,,controlled by,functionally relevant,3 - mild,,,,,,
2425,,problematic behavioural issues,seville orange/seville orange containing products,,hcv serology,endoscopic mucosal resections,,,,pure neuroendocrine carcinoma,admission to hospital,< 35|willingness to avoid,,,,,,
2426,,tmvi procedure.|females,adoptive immune cell therapy,,drinks for,vertical sleeve gastrectomy iii,,,,institute university of colorado,after stopping exogenous hormone therapy,"> 5, within 6h-24h of onset",,,,,,
2427,,streptococcus pyogenes,components of the formulation.|pregnant,,eggs,prosthetic knee replacement surgery,,,,alk-targeted tkis.|previously received more than 1 regimen,within 28 days prior to the first dose of investigational product|history of,>= 60%||,,,,,,
2428,,cervical myelopathy|symptomatic asthma,kaolin,,ascocap criteria,major organ surgery,,,,tumor tissue block,within 24 hours before study initiation|diarrhea,3.das-28 crp more than 3.2,,,,,,
2429,,34)|unilateral lesion,sharp increases,,digital mobile phone application,child|pathology,,,,stage iv,within 3 months|active autoimmune disease,less than 900 pg/ml.|female,,,,,,
2430,,peritoneal effusion,leuprolide acetate,,participants)|weight,lumbar puncture|lacks capacity|hospitalized individuals,,,,long-term drug intervention,within less than 4 weeks prior to screening.|use,=< 1.5 x institutional,,,,,,
2431,,analysis process,immunosuppressive medicine,,american society of anaesthesiologists score,gastric reduction duodenal switch,,,,"temporomandibular joint, head and neck",at time of enrollment;|blood,8-16,,,,,,
2432,,hyperferritinemia,disease;|pregnant,,urine pregnancy test,electronic colonoscopy,,,,≥60 years|scheduled major thoracic,within 3 weeks before receiving the experimental drug;|participated,2 to 80 years,,,,,,
2433,,hrt,obtained.||patients,,fois score,facial alterations,,,,non-infectious,for 6 months after the last dose of study medication|history of,≥ 85th percentile,,,,,,
2434,,psychological illness,azvudine tablets,,bmi sds,wall radiation therapy|breast conservation surgery,,,,self-report)|adequate vision,during the 90 days prior to enrolment|life threatening,participant 18 years and above clinically,,,,,,
2435,,stroke|peripheral arterial occlusive disease,octenidin,,recist,world health organization (who）,,,,completely,between enrollment and 30 days prior to enrollment,score of 0 or 1;|at least one,,,,,,
2436,,trying to,cvs,,hiv antibody test,global assessment for atopic dermatitis (viga-ad,,,,non-opposition.||,within 14 days prior to,greater than 0.65|be able,,,,,,
2437,,localized allergic necrosis,stepcare neuroprognostication substudy,,thyroid hormones,laparoendoscopic repair|written informed consent||,,,,platinum-,72 hours prior to dosing.|subjects,higher than twice the upper limit,,,,,,
2438,,anaphylactoid purpura,anti-threonyl-(anti pl-7,,residual urine volume,small pinpoint depressions,,,,aids;|active,within 90 days prior to enrollment,older than 21,,,,,,
2439,,heart disease|use,restricted medications,,anti-lentiviral antibody test,includes:||coronary artery bypass graft (cabg),,,,retro,3 months prior to screening,18 to 55 years.|able,,,,,,
2440,,internistic diseases,prescription drugs claims,,months.|ecog performance status,functional studies,,,,medically acceptable contraceptive precautions from screening,at least one dose of study medication,> 1cm2 and < 100cm2)|wound depth,,,,,,
2441,,fibrolamellar hepatocellular carcinoma,thyroid medication).|unable,,left side||,over diabetes control,,,,handicap,within 72 hours of study enrollment,<18,,,,,,
2442,,circulatory diseases,mineral oil,,risk score,quadrangular resection of the posterior leaflet,,,,suitable for the study;|any active infection,at least 2 hrs before administration of an,women;|18-50 years,,,,,,
2443,,in remission,immune checkpoints,,hr,liver biopsy sample,,,,stimuli|significant,within 6 months prior to the first dose;|new myocardial infarction,between 18.0 and 40.0 kg/m2,,,,,,
2444,,inguinal hernia.||,esmolol,,education levels,complete cognitive testing,,,,ish+).||adequate bone marrow,at least 2 consecutive frequencies (in air conduction,18 years old|under 35,,,,,,
2445,,months-8 years,nia,,impairing arterial pressure,local testing.|patient,,,,intra-uterine contraceptive device placed,within 4 weeks before the inclusion visit,=< 40%|receipt,,,,,,
2446,,septal hypertrophy,medications which,,descending thoracic aortic aneurysm,krasg12c mutation,,,,express,within 7 days prior to study treatment,18 years and older|dsm-5,,,,,,
2447,,meniere's disease,ctr,,recovery time,standard antihypertensive drugs,,,,may ter,prior to the non-culprit,"18.5 to 30kg/m2,|who",,,,,,
2448,,orthostatic hypotension (decrease in systolic blood pressure,≤470 milliseconds,,transitional phase,infertility treatment,,,,short-gut syndrome,at least 7 days prior to baseline.|acq-6,score is 3 or more,,,,,,
2449,,arterial wounds,monoclonal antibody,,article 1121-5 of the public health,arthroscopic rm surgery,,,,subjective symptoms:||visible,at least 4 weeks prior to screening|weight ≥35 kg,equal to or greater than ii,,,,,,
2450,,inadequate liver function,phones,,new york heart association(nyha) cardiac functional,dipg,,,,smoke?|do,within 6 months of visit 1.|has corrected va,between 30 and 90 kg.|radiographic evidence,,,,,,
2451,,acute proximal humerus,took antibiotics,,thyroid/parathyroid dysfunction,intensification,,,,adequate treatment;|26,within last 7 days|active,between 18 and 30 years;|scheduled,,,,,,
2452,,non-musculoskeletal,procedural,,test,lsc treatment,,,,siblings)||genetic,within the last week on the test site area,from 10 to 20.|fvc ≥ 40 %,,,,,,
2453,,cortical signs,imatinib,,who performance status,2019.|cranial imaging examination,,,,microprocessor-controlled)||,within 4 weeks of initiation of study treatment.|known dihydropyrimidine dehydrogenase (dpd),4 cm,,,,,,
2454,,read,multivitamins,,urine protein/creatinine,vertebral artery occlusions,,,,suitable for the trial,continue to not consume these agents,18-40 yrs)|bmi,,,,,,
2455,,solution,thc,,education-matched healthy,cytoreductive surgery (crs),,,,"hormone replacement,|diabetes stable",within 4 weeks of screening,> 4|presenting,,,,,,
2456,,"neoplasms,|tendency",components of the investigational drug|those,,bleeding|platelet count,adrenal replacement doses (=,,,,month;|only one eye,during two weeks of therapy||,more than 50%,,,,,,
2457,,disabling joint pathologies joint pathologies,z-drugs,,sustained bp,programmed surgery,,,,any etiology.|uncontrolled angina,in the past four weeks||eligibility,"˃100,000/mm3|estimated",,,,,,
2458,,bipolar affective disorder|major depressive disorder,immune responsive-phenotype|patients,,although mri,transjugular intrahepatic portosystemic shunt,,,,seronegative for,within 12 weeks prior to the,normal,,,,,,
2459,,medical disease,pitavastatin,,risk index,brief regimens of medications,,,,"exercises,|agreeing to participate",within 3 months prior to c1d1)|the use of oral mineralocorticoids,40-100 mmhg,,,,,,
2460,,pruritus sine,monoclonal antibody therapy.|patients,,bcl2 translocation|patients,psychotherapy sessions,,,,stage iii or iv,within 6 hrs,≥100×109/l,,,,,,
2461,,months|absence,tricyclic antidepressants,,hcv antibody positive,abatacept,,,,mild to moderate plaque accumulation,authorized,> 3 uln,,,,,,
2462,,reversible ischemia severity,non-steroidal anti-inflammatory drugs|known intestinal inflammation|prior,,include:||poor blood pressure control,gds)|at least one,,,,peripatellar,during the study;|4,≥ 4.0× 109/l;||b.,,,,,,
2463,,polypoidal vasculopathy,diabetes;|patients,,hunt-hess grade i-,adrenal replacement doses ≤10 mg daily prednisone equivalents,,,,pi3k,during this study.|participants,≥ 18 years.|patient consent,,,,,,
2464,,generalized anxiety disorder scale-7,variants underlying,,cardiac ejection index,self-assessment,,,,low-risk cancer,at the needle insertion site|pregnant,-23 mm,,,,,,
2465,,major organ diseases,medication,,allohct|cardiac ejection fraction,ophthalmic examination.|patients,,,,visible,for at least 6 months after the final dose of study drug.|must,≥ 3).|diagnosis,,,,,,
2466,,"inflammatory bowel disease,|pregnancy",routine care.|wards,,female;|body mass index (,transplantation;|autologous hematopoietic stem cell transplantation,,,,intra-muscular,in the last 36 months,"between 32 and 37 gestational weeks,|the first blood collection attempt",,,,,,
2467,,schizophrenic disorder,anti-leishmania therapy,,serum follicle stimulating hormone (fsh,exercise habits;|use of an investigational drug,,,,low galactose diet.|hypersensitivity,within the next 6 months|planned,≥ 19,,,,,,
2468,,hinese,beclomethasone dipropionate,,hospital visits.||exclusion criteria,contraceptive measures,,,,fnirs-dcs|past,for 4 days after the last dose of the trial drugs.|concomitant use,> 8).|clinically significant,,,,,,
2469,,drug-induced liver injury.|diagnosis of,gliadin peptide-iga [dgp-iga,,prostate-specific antigen(psa,cutaneous target area,,,,secondary intention.|patients,less than 8 weeks prior to baseline.|evidence,14 years old,,,,,,
2470,,cerebrovascular disturbances,narcotic,,serum glutamate pyruvate transaminase,treatment-associated toxicities induced,,,,curatively treated,within 6 weeks before the first dose of investigational drug,45-90 beats per minute,,,,,,
2471,,medical conditions|unable,systemic anti-cancer therapies,,creatinine clearance,ava indexed,,,,minimum stable,within 12 months preceding,>or =14-26|a,,,,,,
2472,,pancreaticoblastoma,antiemetic medication,,sagittal discrepancy,emergency cesarean section,,,,amobarbital,within 28 days prior to sub-study randomization,less than 12 or more than 18 per minute,,,,,,
2473,,diabetic,probenecid,,ductal carcinoma;|karnofsky performance status,blood oxygen saturation,,,,vertebral arteries or|body mass index,within the last 3 years,negative,,,,,,
2474,,lbcl,strong inhibitors of cyp3a4 are,,serum transaminase,terminal medical condition|receiving,,,,angle-closure,at time of surgery;|patient,1 meter or worse,,,,,,
2475,,fetal tachycardia,anticoagulant agent,,cpap,medications,,,,potentially malignant lesion,within the last 3 months|severe,18- 80 years|possess,,,,,,
2476,,impairment of liver,antimuscarinic medications,,old;|asa grade,standard mydriatics,,,,wounds,prior to receipt of b cell-depleting therapy,3-8,,,,,,
2477,,months)|acute diverticulitis,disallowed medications,,gross motor function classification system (gmfcs).||,rapid assessment of physical activity (rapa) score,,,,self-report)|currently enrolled in another study,within 72 hours prior to the randomization.|initial onset of the covid-19-related,below 20 and above 30,,,,,,
2478,,lung inflammation,anti-sirpα,,pt)/partial thromboplastin time (ptt),hmg-coa,,,,instability|non-sinus rhythm,within the 12 months prior to the first dose of study,≥ 18 years old|radiographically documented,,,,,,
2479,,"age,|able to read english",anti-vegf,,genders|american society of anesthesiologists (asa) physical status,gastric biopsy (histopathology),,,,diagnostic and statistical manual of mental disorders [dsm-5] self-rated level 1 cross-cutting symptom measure - adult)|participants who's 1st degree (blood) relatives,during the procedure present,>= 95 mmhg,,,,,,
2480,,icd-10 depressive episode,pedicle screw fixation,,capillary wedge pressure (pcwp),hypopressive abdominal techniques,,,,forceps,within the last 12 months prior,18-35|had,,,,,,
2481,,distal metastases,near tallahassee,,bone loss.||,bone radiotherapy to control pain,,,,neuro-radiologists,within two weeks before operation|known,> 1 million per microliter,,,,,,
2482,,mild traumatic brain injury/concussion,enzyme inducers antiepileptic drugs,,average amount,fibroscan measures,,,,specifically excluded,within 4 weeks prior to the first dose of tt-00973-ms.|have systematic hormonal,< 6 months ago,,,,,,
2483,,hormonal imbalance,aminosalicylates,,tsh level,endoscopic icg injection,,,,high-resolution,prior to injury.|patients,above the 1.5 × upper limits of normal (uln),,,,,,
2484,,signs of dementia,ginseng,,gds-15,blood vessels,,,,obstetrician,within 56 days before enrollment|patients,above or equal to 55 years,,,,,,
2485,,sabi,medications known to be cyp2d6 substrates|current use of medications/dietary supplements/alternative therapies,,preserved ejection fraction,adequate contraception,,,,unequivocal,in the next 12 months,less than (<) 90 ml/min/1.73m^2,,,,,,
2486,,gestational dm.|visual,took drugs,,platelets count,versus initial,,,,specially designed,at the time of signing the icf;|male,status|younger than 18 years,,,,,,
2487,,localized non-melanotic skin cancer,hybrid closed-loop systems),,national health commission,ecg monitoring,,,,unequivocal evidence,during treatment||history of prior,≥40 mmhg||subject,,,,,,
2488,,critical cardiac disease,strong inducers of cyp3a enzymes,,pro-vegf treatments|concurrent disease,bilateral knee arthroplasty|patients,,,,diagnostic criteria,5 days before cell reinfusion,> 9g/dl,,,,,,
2489,,malignant pheochromocytoma,dopamine-reducing agent,,karnofsky performance score,live-virus vaccination,,,,vestibular,for at least six months;|positive,=< 65%,,,,,,
2490,,skin ulcerations/nodules,orlistat/xenical,,aspartate aminotransferase)/alt,bone graft to stabilize,,,,non-pharmacological agents,within 72 hrs prior to the first dose of any study,15 mmhg,,,,,,
2491,,mixed of transitional/non-transitional cells,biologics.||b,,recist v1.1 evaluation criteria;|any adverse events,1-hour per week max,,,,controlled by medication|left ventricular ejection fraction,within 1 year prior to study visit 3,1-5,,,,,,
2492,,variables,jak fusion,,antibodies to hepatitis b surface antigen [anti-hbs,allogeneic haematopoietic stem cell transplantation,,,,ckd]-epi formula,within the past 1 year.|history of depression,<3.0 x uln)|aspartate aminotransferase (,,,,,,
2493,,cervical whiplash injury,prasugrel,,neut,inhibitors|pregnant woman|myocardial infarction,,,,exit,within the past 28 days prior to study randomization,7 - 80 years,,,,,,
2494,,singleton pregnancies,eliquis,,ders total score,behavioral strategies,,,,highly effective contraception||,within 14 days of first administration of study drug.|continuous,18 years or more,,,,,,
2495,,interpersonal psychotherapy for,anti-gbm disease,,bpm)|tympanic temperature,isolated myectomy,,,,grade 4 immune related adverse event (irae),prior to initiation of study treatment,≤ 7%.||,,,,,,
2496,,vital signs||stable,old.|supine,,systolic arterial,bifurcation,,,,intra-articular steroids,within two weeks prior to the planned date of,≥ to,,,,,,
2497,,hiv-1 seropositive,antibiotic therapy,,achalasia)|age,ectropion,,,,6-mp,at least 30 days before the study entry,2.5 times/upper limit of normal,,,,,,
2498,,amyotrophic lateral,dihydroepiandrostenedione sulfate,,ptca,conventional treatments,,,,nsaid arm,within 6 months prior to screening.||participant,requires adherence,,,,,,
2499,,completed cancer treatment,mas,,selena-sledai score,rapid antigen test (ast),,,,locally-treated,within 3 months prior to the first vaccination,≥ 48 mmol/mol|hba1c,,,,,,
2500,,multiple active cancers,local standards|patients,,restenosis).||ejection fraction,ibsconstipation,,,,painful area,at least 6 months before registration,≥ 3)|wound area,,,,,,
2501,,intraoperative complications,arginine,,inclusive;|body mass index,complete study related procedures,,,,highly effective,within 12 months before the screening visit.|participants have participated in another clinical trial within 30 days prior to screening,≥ 20,,,,,,
2502,,pulmonary diseases,inhaled pulmonary toxins,,nrs score,transcutaneous oxygen pressure (tcpo2),,,,calls,within 30 days prior to the screening visit,>=18 years.|eastern,,,,,,
2503,,colitis organisation,drugs related to the oral lesions,,postoperatively;|ground glass-dominant lung nodules|consolidation-to-tumor ratio (ctr),surgery|patient's refusal|operation,,,,stable,for the previous 12 months.|aqueous depth,over 30 kg/m2||,,,,,,
2504,,multiple endocrine neoplasia type 2,mcrc,,european american lymphoma 2016 world health organization (who) classification,ct scan|pregnant,,,,"below 28,|can read",within 6 weeks of the first dose|subjects with medical conditions,score ≥ 3)||,,,,,,
2505,,molar pregnancies,analgesic used,,nos,hospital program,,,,suitable for repeated assessment in accordance with recist v1.1.||subject,within 24 hours prior to index,< 30 ml/min.|previous,,,,,,
2506,,eruption,immune-suppressive,,modified rank in scale,general anesthesia,,,,equivalent.|other,within the past 5 years.|applicable,≥50 kg.|healthy,,,,,,
2507,,drug-induced myositis.|current musculoskeletal,heavy menstruation,,ketamine.|body circumference,nerve root compression|previous spine surgery|history,,,,acute toxicity of previous treatment,for at least 3 months before liver biopsy.|weight was stable(the change,<15.|patients,,,,,,
2508,,bacteraemia,quinolone antibiotics,,macular optical coherence tomography,coronary artery bypass (cabg) surgery,,,,ais;|pre-stroke mrs score,within 3 months before the first dose of the study drug,≥ 0.8 × 109/l,,,,,,
2509,,normal renal,paclitaxel liposome,,right ventricular mechanical circulatory support||,dehydration treatment,,,,tree-nut,within 10 days of treatment initiation|have,= 102 cm,,,,,,
2510,,syphilis antibody,adequate organ function.|male,,hepatitis b dna quantitation,graft versus host disease,,,,philadelphia,for at least 20 months after the last dose of study drug to minimize the risk of pregnancy.|subjects,greater than or equal to 5/10,,,,,,
2511,,psychological disorders.|fibromyalgia,sufentanil allergy|renal,,rano-bm.||rgbm||patient,combination hormones [containing estrogen,,,,meeting our criteria,at least 6 months prior to check-in:||hysteroscopic sterilization,< 37.5℃/99.5℉,,,,,,
2512,,muscle atrophy,realized,,d.|best corrected visual acuity,imaging findings,,,,protocol-related procedures,before 32 weeks,<12 g/dl,,,,,,
2513,,hypoxemia|history of another malignancy,oxybutynin,,mild cognitive impairment,oral glucocorticoid therapy,,,,asthma.||uncontrolled,at least 3 symptoms|must,18-40|regular menses,,,,,,
2514,,nutritional support,melena,,recist version 1.1 (only applicable for phase 1b dose-expansion,colorectal esd,,,,from the peripheral serosa,prior to initial,over 60 years old,,,,,,
2515,,pancreatic duct adenocarcinoma,hypokalemic drugs,,g13d kras mutation,ms|additional immunosuppression,,,,smpc.|body mass index (,within 2 mo of starting the study,>130 mg/dl,,,,,,
2516,,sexually mature,anticoagulants|patients,,liver function,standard of care chemotherapy,,,,central nervous system diseases;|(12,within 3 months prior to,< 13.5 g/dl,,,,,,
2517,,liver coma,insulin glargine (u100),,partial thromboplastin times,control of vasogenic edema,,,,primary definitive local therapies,before enrollment for,≥ 5)|age 18-80 years|provides,,,,,,
2518,,atherosclerotic stenosis,isatuximab,,mdi score,hormone anticonception drugs,,,,pd-l2 drugs,during the study||,between ≤20/63 and ≥20/400(≤63,,,,,,
2519,,myeloma defining event,sui specialized,,inclusive.|aptt,reverse shoulder arthroplasty,,,,month.|clinically significant,within 2 weeks before baseline|pregnant,0 to 100 mm,,,,,,
2520,,hematologic function,immune therapy,,research.||specific exclusion criteria,≥1 month|known,,,,par-q questionnaire,throughout the duration of study participation,≥ 60 ml/minute||,,,,,,
2521,,mastitis,cardiotoxic agents should,,resting heart rate of,venous thrombosis|heart failure|sepsis|cerebral edema|hypertensive encephalopathy|hypoglycemia|hepatic encephalopathy|fluid-electrolyte disturbances|acute-chronic renal failure,,,,endocarditis|neurodegenerative,within 6 months of the first study procedure.|patient,between symptom onset and first visit,,,,,,
2522,,um).|patients,ultrasound contrast agent,,forced expiratory volume in 1 second (fev1),isolated sharp waves,,,,≤2 prior induction regimens,for at least 120 days after the last dose of study treatment.|archival,18-65 asa i and ii||,,,,,,
2523,,respiratory compromise.|participant,immune-suppressive induction,,psqi,roux-en-y gastric bypass,,,,on room air.|patients with prior,at the time of enrollment|parents,neuropathy).|negative,,,,,,
2524,,acute coronavirus disease,cramps,,cigarette dependence score,bilateral axillary lymph node dissections|already,,,,screening||concerns,at screening:||< 18 years,younger than six years,,,,,,
2525,,signs of infection,heart-rate,,rivm guidelines))|bmi,bladder instillation therapy,,,,diabetes|uncontrolled infection|exacerbation in autoimmune,in the last month.|probiotics used,1.5 times higher than normal).|other,,,,,,
2526,,primary osteoarthritis,global impressions-severity,,hemoglobin a1c (hgba1c),amateur athletic union,,,,intra-aortic balloon counterpulsation,at least 3 months after the last dose of protocol therapy||a,≤ 2 × upper limit of normal (uln),,,,,,
2527,,elite,psoriasis|active psa,,stopped,distal right coronary artery,,,,"connective tissue disease,|rheumatoid arthritis",within 14 days of 1st dose,≤ 5 times the upper limit of normal,,,,,,
2528,,isokinetic muscular assessments|cognitive,inflammatory drugs for duration,,sensitivity score,breast ultrasound,,,,c|pre-existing,within the past 3 months.||the,≥3 times per day,,,,,,
2529,,infertility|regular menstrual cycle|bilateral tubal,recombinant human thrombopoietin,,urine pregnancy test (upt),months|physiotherapy,,,,under glasses,for at least 12 weeks prior to screening,≥6.5%|aged 18 - 60 years,,,,,,
2530,,endometrioid cancer,centrally acting analgesics,,morbus,skin disease|elevated body,,,,under judicial protection|patient not,in the past 3 months;|subject,score of 3 to 5 points).|written informed consent,,,,,,
2531,,feeling of pressure,anti-pd(l)-1 therapy,,severity scale,adeno-,,,,part a,within the last week|ongoing treatment,0-2.|must,,,,,,
2532,,acute covid,anti-arrhythmic drugs,,utuc of t2,adjuvant chemotherapy,,,,right,in the last 2 years before the first dose of the study drug,greater than 470 ms,,,,,,
2533,,chronic cough.|previous airway hyperresponsiveness,drug-drug interactions,,interferon gamma release assay (igra),dual antiplatelet therapy|uncontrolled intercurrent illness,,,,very uneven,at the time of enrollment|attends,> 170,,,,,,
2534,,malignant meningitis,endothelin receptor antagonist,,flexion rom,single dose vaccination,,,,subscale,within 1 month before the study,>0||,,,,,,
2535,,inrc criteria.|organ functions,absorption inhibitors,,dna,erythropoietin therapy,,,,the trial;|subjects,recent prior,above 160 systolic,,,,,,
2536,,major depressive disorder,moderate cyp3a4 inducers,,kidney function creatinine≤,open-ended,,,,environmentally related,at the time of consultation,below 50% of,,,,,,
2537,,atrial fibrillation|left ventricular thrombus|severe,piperidines,,atc,cementless,,,,acr-eular,within his/ her regular treatment,≥ 12 weeks;|at least one,,,,,,
2538,,lentigo maligna,hypoglycemic drugs|random,,.|adequate complete blood counts (cbcs),tubal ligation/occlusion,,,,c5) antibodies,at least 3 months before inclusion,between 50 - 79 years,,,,,,
2539,,liver disease|active infection,cyclobenzaprine,,missouri medicaid and most commercial insurances,slr)|posterolateral disc bulge,,,,clinically significant alarm symptoms,in the last 5 years|pregnancy|male sex,0-2;|able to swallow,,,,,,
2540,,esophageal .squamous,nefazodone,,mgh blood,rhinoplasty surgery,,,,intra-articular pathology,for at least 3 months 4,between 18-30,,,,,,
2541,,encephalopathy,cbp,,anti hepatitis c antibody,imaging diagnosis,,,,passive,during the previous 2 weeks,maximum of 16 weeks,,,,,,
2542,,renal stenosis,contrast media|ongoing sepsis,,prothrombin time ( pt ),tissue blocks,,,,st-elevation,within 14 days before the first dose of study drug.|serious,< 90,,,,,,
2543,,another pathology,anti-cholinergic agents,,longest diameter,chest computed tomography (ct) scan|severe infections,,,,nontraumatic sci|concomitant,in the 30 days before imp,<hama<21,,,,,,
2544,,mcs,contraceptive tablets,,bone marrow dysplasia|blast cells,pregnancy|retrospective enrollment,,,,clinical manifestation|had,less than 24 consecutive months,"greater or equal to 2,500g.|discharged",,,,,,
2545,,# level.||,oral hormonal contraceptives plus,,psychiatric hospital|active,first-line standard therapy,,,,parent artery,prior to starting study intervention.||has,pseudomonas aeruginosa,,,,,,
2546,,healthcare-associated infections,component of v116,,eastern cooperative oncology group (ecog) performance status (ps),thoracic manipulation,,,,electric-acoustic devices,at a dose >20 mg/day.|the participant,more than 4 weeks prior to enrollment.|participants,,,,,,
2547,,williams syndrome,intraarticular corticosteroids,,schirmer's test,oral resection/reconstructive surgery|undergoing surgery,,,,second-generation ar inhibitor,within 7 days of,>40 or <18|parturient refusal,,,,,,
2548,,colon cancer|prior anterior resection of the rectum|medical,antiepileptic drug use intracranial metal,,hbv viral load.||diagnosed,plasma,,,,tak-771-3005).|participant who experiences,within the last 2 weeks|treatment,>2|confirmed,,,,,,
2549,,arteriovascular embolism event,rct,,hemoglobin level,elective pci,,,,e. coli,within 30 days prior to viral treatment.|participants,≤ 2|ability to read danish|no serious,,,,,,
2550,,wound infection,alkaloid,,75|american society of anesthesiologists (asa) physical score,treatment,,,,clearly,less than 6 months.|patients,≥ 37.2 ℃,,,,,,
2551,,organic brain syndrome,compounds of similar chemical or biologic composition to gen-1,,response evaluation criteria in solid tumors (recist) version 1.1|eastern cooperative oncology group (ecog) performance status,walkasins haptic module|ability to complete the functional outcome measures,,,,suitable for participating in the clinical study,during the study.|evidence,inclusive;|at least 50 kg,,,,,,
2552,,radiologic signs of cns,mwa,,refuses emergency cabg surgery,test-related tests,,,,smokers.|positive,during the study beginning,above from baseline through the course of antibiotics,,,,,,
2553,,hepatocellular carcinoma|having dementia|having,strong cyp1a2 inducers,,psychosis risk syndromes (sips),agitated behavior,,,,single-canal,within 2 months after the first administration.|patients who are,125 ml),,,,,,
2554,,eosinophilic asthma,gentamicin sulfate,,nci-ctcae criteria v5.0,volume,,,,suitable for wearing glasses);|participation of the drug clinical trial within three month and the device clinical trial within,during the preceding 3 weeks|myocardial infarction,<12.0 g/dl,,,,,,
2555,,valvular heart diseases,above.||patients,,neck circumference,laparoscopic appendectomy,,,,non-radiographic axial spondyloarthritis,within 14 days prior to screening;|subjects,>2|l-dopa,,,,,,
2556,,colon remaining,cyp3a4/2c8 strong inducer,,berlin definition of ards|untreated pneumothorax,pancreatic cancer|life expectancy,,,,screening.|uncontrolled,up to 4,18 to 75|two,,,,,,
2557,,rapid tumor regression.|symptomatic,oral mucositis,,ferritin levels,maintenance therapy.||,,,,non-pulsatile tinnitus,at least 15 ascvd,>90 or <50 mmhg,,,,,,
2558,,hodgkin's,antihyperglycemic medication,,creatinine clearance rate calculated,additional surgery,,,,tested for hiv,more than 4 weeks prior to screening,ii-iii|patients,,,,,,
2559,,medical abnormalities,anesthetic drugs,,fridericia corrected qt interval,mechanical termination of slow pathway conduction,,,,periodontal therapy.|no,within 7 days prior to step 2 randomization,at least 18 years.|locally advanced,,,,,,
2560,,liver transient eleastography,antiandrogen,,visually estimated ejection fraction,medical disease.|detection of a uterine anomaly,,,,non-alcoholic,after 24 hours of adept 38 blood,child-pugh class,,,,,,
2561,,cushing syndrome,component of the investigational,,international prognostic scoring system (ipss),image,,,,multidisciplinary cardiac team;||elements include,within 6 months before randomization.|as judged by the investigator,greater than 1cm3|patients,,,,,,
2562,,carcinoma in situ of the rectum,motility drugs,,quite smoking,resected hr-cscc,,,,eliminate rice,within the previous 12 months||history,shorter than 12 months；|patients,,,,,,
2563,,saa,moderate cyp1a2 inhibitors,,hepatitis c virus (hcv)|unwillingness,temporal intravenous,,,,infected|self reported,within 14 days before the first dose of the study;|have previously received the following therapies,>10.5 mg/dl.|use,,,,,,
2564,,loco-regional therapy,vestibular migraine,,1|life expectancy,small molecule inhibitors,,,,"≥3,000/µl|absolute neutrophil count",in last 3 months;|covid vaccine,between 18 and 65 years|body mass index,,,,,,
2565,,risk)|deep venous thrombosis,ser,,ipn program herein described||part b of the study will seek,resected by surgery,,,,mid-sleep on free days later than 5:00 am on the munich chronotype questionnaire (mctq,at the time of informed consent.|voluntary agreement to provide written informed consent,>18 years|diagnosed,,,,,,
2566,,acrylic,refractive state.||,,parameter of alt,correct,,,,psychoactive drugs|alcohol,within 30 days of screening|a history,at least 5 medications.||exclusion criteria,,,,,,
2567,,hyperactivity,anti-pd-(l)1,,estimated glomerular filtration rate (egfr)≤60 ml/min for,cta,,,,under this protocol.|prior,within 3 months of recruitment.|subject,< 0.5 x 10^9/l;|platelets < 20 x 10^9/l;|reticulocyte count,,,,,,
2568,,double-blind,comparable mechanics,,recist version 1.1.|patient,tympanostomy tube)|presence of tm perforation,,,,ipsilateral open,for at least 7 months after the final dose of study treatment.||highly effective methods,less than 40 patients|concurrent,,,,,,
2569,,pleural empyema,abetalipoproteinemia|on medication related,,who grade 3|glioblastoma,v factor less,,,,mid-urethral sling placement||,for 24 weeks after the administration of the last dose of the investigational therapy.||,"> 2,0 mg/dl",,,,,,
2570,,benign tumors,anti-tumor monoclonal antibody drugs,,irradiated|ecog performance status,small lymphocytic leukemia,,,,rome iv child/,within 28days before starting bevacizumab,0 or 1.||key,,,,,,
2571,,granulomatosis,veltuzumab,,marathon rotterdam 2023|tympanic temperature,treatment regimens,,,,second-line chemotherapy,past month sexual activity.||,-15 to 30 degrees,,,,,,
2572,,ans|patients,eggs,,acq-6 score,value);|normal physical examination,,,,large-area irradiation,throughout enrollment.||,<35%|non-st elevation,,,,,,
2573,,xy genotype,anti-coagulant medication,,thyroid function did,"realistic"" expectations of surgical results",,,,diseased tissue (sterile sampling,in the past 2 weeks,17 to 35 kilogram per square meter (kg/m^2,,,,,,
2574,,external trigger|endocrinopathies,triglyceride,,length of stay,fluconazole therapy,,,,subsided|self-reported,14 days prior to the time of nex-20a administration until 90 days after the follow-up/end-of-study visit,18 years or older|presence,,,,,,
2575,,patients|the,systemic corticosteroids,,repeat levels,medical attentions,,,,hypercoagulability|acute,in 24 hours,18 - 35 kg/m2,,,,,,
2576,,seizure,ipilimumab + nivolumab,,national institute on aging-alzheimer's association workgroups (nia-aa)||,surgical hardware,,,,primary diagnosis,at time of surgery)|patient,≤ 2.5 × upper limit of normal (uln),,,,,,
2577,,condoms.|able to swallow 2 empty capsules size,strong cyp3a4 inhibitors,,plasma ast/alt ratio,cognitive screening test selected,,,,index procedure.||,within 90 days prior to registration||clinical stage,< 10 %,,,,,,
2578,,secondary immune disorders,anti-tumor effects,,english|body mass index (weight/height ratio,head ct with contrast,,,,higher||arm,within 90 days,> 50%.|volunteered to enroll this study,,,,,,
2579,,excluded.|lymphoma,phenylephrine,,t4 (ft4),chemotherapy regimen,,,,user manual of the visumax option smile,during their participation in parent study kgbi,≥ 50×10^9/ l,,,,,,
2580,,posterior circulation ischemic stroke symptoms,tki,,rest,practice level:|primary care practice,,,,non-cataractous,within the prior 6 months|history of external beam radiation therapy to the head and neck area|diagnosis of hiv,150 mmhg,,,,,,
2581,,tacs,fontan-palliation|pulmonary hypertension,,left ventricular filling pressures,aggressive treatment,,,,flailing)|subjects exhibit behaviors that are congruent with the,6 months after the last dose of study drug.|measurable disease by ct,12-20 breaths,,,,,,
2582,,menthol allergy|patients,ganciclovir,,coagulation||international normalized ratio (inr),measurements.|body mass index,,,,dna-based,history on pre-enrollment questionnaire of cluster headache symptoms,≥ 18|patients scheduled,,,,,,
2583,,episodic headache,immunoglobulin m (,,wpi,endovascular therapies,,,,hamburg-eppendorf|main,for at least 4 weeks prior to screening,≤ 80 mg/dl,,,,,,
2584,,pomelos,risperidone,,grad,transfusion of packed red blood cells,,,,molecular targeted drug therapy,more than 2 cups,≥64.|fatigue,,,,,,
2585,,target vessel thrombectomy).|any,consume caffeine,,pulmonary hypertension.|history of,hormonal therapy substitution,,,,upper limbs.|congenital,handbook seventh edition,< 2.0 mmol/l,,,,,,
2586,,meningeal enhancement,legionella pneumophila infection history;|patients,,modified ashworth scale.|participants,step,,,,stevens-johnson syndrome,for at least 6 months after the last dose of study drug.|able to provide informed consent,grade ii-iv,,,,,,
2587,,facial disfigurement,covid-19,,alpha gal syndrome,discontinuation of prior therapies,,,,preparatory,within one moth of study entry.||wash-out periods,equal or greater than 10mm,,,,,,
2588,,psychological disorder.|children,substance-related,,1|absolute neutrophil count (anc),active surveillance.|inactive,,,,medically controlled,in the past 6 month prior to sample collection,<34,,,,,,
2589,,serology|male,oral steroid therapy,,car-t cell therapy;|use,segmentectomy,,,,vitreal,within the last six months;|major gastrointestinal tract surgery,between 18-30yrs|recreationally/competitively,,,,,,
2590,,|previous left atrium,topical antiseptic agents,,heart surgery,systemic radiotherapy,,,,immunophenotypically,up to 4 weeks prior to or during screening,>35|history,,,,,,
2591,,december 31,chronic liver failure.|suspicion,,mitomycin c|age,mini international neuropsychiatric interview (mini).|a symptom-free period,,,,endpoint)||,for at least 2 years||inclusion criteria for the,> 70 years,,,,,,
2592,,examination|suspicious lesions,dopamine antagonists,,gamma-gt,quetelet index,,,,centimeters|overt,during the research period for,< 2 cm distance,,,,,,
2593,,sensitive substrates,milk-containing food product,,rapid response.||,collateral circulation,,,,tnbc,within 3 weeks prior to inclusion|epilepsy,≥ 21)|cdr,,,,,,
2594,,somatic cloning abnormalities,adhd.|are studying,,infarction;|life expectancy,etc.|3,,,,protection measure|other research with exclusion period time ongoing|all the inclusion criteria not met,after the previous systemic anti-tumor treatment,1-3||,,,,,,
2595,,inflammatory processes,antiarrhythmic drug (aad),,≤8,fresh cycle transplantation,,,,r52,within 2 weeks before baseline.|laboratory values,350 to 470 msec,,,,,,
2596,,non-urgent care visit,anticonvulsant benzodiazepine agent,,ecog performance score,revision tka,,,,lowered,< 4 weeks prior to bronchoscopy.|voluntary,<= 1.5 x upper limit of normal (uln),,,,,,
2597,,appears relapse,any vaccine,,american society of anesthesiologists class,floor reeducation programs,,,,in room air|patients,at the time of the 12-month follow-up,≥18 and <28 kg/m2,,,,,,
2598,,lynch syndrome,immune-oncology agent,,limb function,hormone intervention,,,,refractory to locoregional therapy,in the past 28 days.|absolute neutrophil count (,</=2|patients admitted,,,,,,
2599,,females).|participant,hyaluronic,,urine m protein level,"vas,|extra-muscular disease activity",,,,non-autoimmune conditions,at the time of the moving-related,≤ 30.0 kg/m2.|medically healthy,,,,,,
2600,,children|first dental,telithromycin,,response evaluation criteria in solid tumors (recist) version 1.1||,ct-perfusion,,,,grade 2,within 24 hours prior to scan)|left-handed,0 or 1.||laboratory values,,,,,,
2601,,intolerable symptoms,iron infusions|hemoglobin,,hemoglobin ≤9 g/dl|at least one of the following,clinical study experience:||-,,,,endometrial,while on diet,> 30 kg/m2)|allen's test positive,,,,,,
2602,,acute hepatitis b or hepatitis c.|a condition,grapefruit containing products,,mic,immunomodulatory drugs,,,,near eyes,"for the first time and only,|willingness to participate in the research,|willingness to participate in the research,|patients who agreed to participate in the study verbally",>14u/wk,,,,,,
2603,,skin base cell carcinoma,sfa,,bone marrow image indicates,bone marrow involvement||note,,,,ligament alignment of lower extremity,for at least 12 weeks after the last dose of the imp.|availability of,score of >2,,,,,,
2604,,superficial thrombophlebitis,anti-egfr agents,,gps,bariatric surgical procedure,,,,tumour intended,at the screening visit.|individual,≤96%,,,,,,
2605,,neurological pathology|having limiting,any blood products,,cystatin c,anatomical variations,,,,severity of oa 2 to 4,after at least 8 hours fasting)|diagnosis of any other,under 90 years,,,,,,
2606,,simultaneous multiple cancers,xanthine-rich food,,forced exploratory volume,receive sample collection,,,,"unable to understand the consent form, and determined by investigator with",routine bedtime later than 1:00 am,85-89 mmhg,,,,,,
2607,,indicated)|international normalized ratio,nonspecific alternative therapy,,total calcium concentration,infection treatment,,,,radiographs).|primary hyperparathyroidism,within the past year).|the families,< 4 weeks,,,,,,
2608,,accommodative response,β -lipoprotein deficiency,,pregnancy test.|females,endometrial biopsy,,,,first-line formula,within 4 weeks prior to the start of hsct conditioning regimen,≥ 60 years,,,,,,
2609,,exposed to avalglucosidase alfa,h2 receptor antagonists,,systolic blood pressure (dbp) ≧,major hepatectomy (resection of,,,,stud,lifetime history,>0.4,,,,,,
2610,,genetic sequencing,anti-her2 treatment,,part 2)|history of levodopa-induced motor fluctuations,oral zinc treatment,,,,radiologically isolated syndrome (,in the past 12 months.||exclusion,score of ≥ 60 for patients < 16 years,,,,,,
2611,,congestive heart failure.|use,alhydrogel®,,response evaluation criteria in solid (recist),sexual intercourse.|a vasectomy,,,,sle.|sledai-2k≥8,in the last 1 month|coagulation disorder,≤ 32.0,,,,,,
2612,,renal tumor,coconut oil,,antithyroid antibody should evaluate,graft-versus-host,,,,rop,in the study,> 42.5,,,,,,
2613,,impaired cognitive dysfunction,regional anesthesia.|any cardiovascular disease,,static physicians global assessment (spga),complete evaluation by medical providers,,,,might interfere with contact lens,up to 6,above the upper limit of the normal,,,,,,
2614,,psychological abnormalities,supplements containing vitamins,,thyromental length,contraceptive,,,,participate.|frailty index,at the time of study enrollment.|smoked cigarettes,< 400 ml / 24 hours,,,,,,
2615,,criteria below:||fever|splenomegaly|cytopenias,canine,,maximal aerobic,first-line tki,,,,refractive,within 28 days prior to day 1 of protocol therapy.||seronegative,greater than or equal to (>=) 16.|investigator's global assessment (iga) score,,,,,,
2616,,progressive neurologic deficits,resveratrol,,fingertip pulse oximeter,immunosuppression therapy,,,,ethnic s,within 2 months before the first study drug administration,between 18 and 30 years old,,,,,,
2617,,bladder carcinoma,nizatidine,,estradiol (e2),antifungic treatment,,,,etonogestrel-releasing implants,within 4 weeks before administration of the first dose of study treatment,< 0.7)|severe,,,,,,
2618,,type 1 neurofibromatosis,methylxanthine-containing,,anuria.|in addition,histological variant,,,,low-density lipoprotein-cholesterol,within 28 days prior to and including the screening visit.|no chronic use of oral,<30%.|contraindications to tee.|renal disease,,,,,,
2619,,lung neuroendocrine carcinoma,subunit vaccines,,v1.1.|adequate organ function,lipid-lowering,,,,treatment related,in the hamstring muscles at least 1 month before the study,≤ 500 mg/day,,,,,,
2620,,abdominal drain,valganciclovir,,liver function test values,pet/ct,,,,coffee-flavored milk,during the length of duration of the ct-scan.||,>3 times upper limit of,,,,,,
2621,,myeloma-associated,strong inhibitors/inducers of cyp3a4,,utuc,liver imaging suggestive,,,,definite hp infection,in the last 1 year,≥ 90 g/l;|blood,,,,,,
2622,,antidepressants.|analgesia,diaphragm plus,,normal.||white blood cell count,preeclampsia|cesarean delivery for non-vertex fetal presentations,,,,peri-radicular/furcal involvement,for 6 months before screening;|history,between grade 1 or 1+,,,,,,
2623,,large tumors - tumors,angiotensin receptor inhibitors,,child pugh c).|patients,dental implant,,,,stage iii/iv,in the past six (6) months,60-89 mmhg)|volunteers,,,,,,
2624,,risk of pregnancy,bamlanivimab,,required|absolute neutrophil count (,cpt sessions,,,,non-rowers:||active,at least 14 days prior to the first dose of study medication,score ≤ 18,,,,,,
2625,,cancerous meningitis;|there,study vaccine components|previous smallpox,,quantiferon test|clinical important abnormalities,glaucoma.|previous treatment,,,,under judicial protection|patient under guardianship,within one moth of study entry.|history of,40-89.|24 or above,,,,,,
2626,,traumatic low back pain|any infection,growth factor support,,level iv centers,stress urinary incontinence|history of ptns,,,,"mount sinai hospital,|undergoing",no breakfast|- 48 hours,≥180 minutes|b-type natriuretic peptide (bnp),,,,,,
2627,,pylori infection,s-mri,,bone loss.|gingival index,orthodontic treatment|students,,,,near term,from 4 weeks before enrollment to the time of randomization.|previous history,36 months or more,,,,,,
2628,,consumption,parenteral anti-microbial,,cardiac frequency,frontline systemic therapy,,,,hyper-cvad regimen,within 1 month before randomization;|7,≥ 8.5 g/dl,,,,,,
2629,,acute intracranial hemorrhage|any contraindication,vaccine-related,,skåne university hospital,sars-cov-2,,,,sflc,during the study.|involvement in the,45-75|has,,,,,,
2630,,bowel involvement,other immune-modifying agents,,serum anti-gm-csf receptor antibody test,visit 1.|for the bia sub-study - individuals,,,,perceive,after the last treatment.||patients who,>51%,,,,,,
2631,,as:||hepatic transaminases,tert,,hepatitis b and c,thyroid gland,,,,meeting the 2012 berlin diagnostic criteria,within 6 months before the first dose of study drug.|the,≤ 5.0 × uln,,,,,,
2632,,peptic injury,anti-mda5 antibody,,new york heart society class,ct of the neck,,,,non-rheumatological inflammatory diseases,less than 6 months prior to screening.||participation,<30|able,,,,,,
2633,,systemic illness;|novice,analysis;|able,,biologic b cell depleting agents,intraocular metal,,,,risk factors,in the past 2 months|have,6-14 years,,,,,,
2634,,severe pulmonary infections,l-histidine hcl,,certificate;|having,parathyroidectomy,,,,pd catheter|stable peritoneal dialysis prescription|chronic loop diuretic usage,at least 1 of the following criteria):||i,less than 50 bpm,,,,,,
2635,,cardiovascular involvement,anti-cancer chemotherapy.|known hiv infection.|congenital immune deficiency,,serum glutamic oxaloacetic transaminase (sgot),coronary artery bypass graft (cabg);|previous incomplete percutaneous myocardial revascularization,,,,ipsilateral invasive tumors,while on study.|have not recovered,"≥ 50,000/mm",,,,,,
2636,,third party,losartan for,,alanine transaminase (alt),placement of central venous access catheter,,,,medication,at least 4 weeks prior to (first) administration of the study drug until 90 days after the follow up visit,< 25 ml/min/1.73 m^2,,,,,,
2637,,concomitant liver diseases.|alt/ast,claravis,,2004 who classification of lung tumors,lipid lowering medication,,,,l3-l4,within 5 years of screening|live,±10 years,,,,,,
2638,,chronic infection,irrespective of type of vaccine,,hepatitis c antibody (hcv ab).|patients,surgery|prior organ transplantation,,,,includes,within 14 days prior to day 1 of protocol therapy,> 3.0 mg/dl,,,,,,
2639,,right ventricular outflow tract ablation,drug-drug interaction medication,,tempro-frontal region for,practice sexual abstinence,,,,coastal,within the past 30 days.|evidence of,between 18.5-25|women,,,,,,
2640,,large enough,hae attacks,,upmc children,standardized meal,,,,narcotic,at the screening visit;|participant tests,≥50 *,,,,,,
2641,,tumors accessible for research,progestin compounds,,sperm in spermogram|sperm count,pet scans tracer injections,,,,rome iv criteria.||,within 30 days prior to visit 1.|receipt of any marketed or investigational biologic,between 2 to 12 years,,,,,,
2642,,high mountains|participation,disopyramide,,anti-androgen (,adjuvant,,,,ocular rosacea,previous cv-event,<20 or >35kg/m2|physical dependence,,,,,,
2643,,centimeters tall|be residing,ophthalmic steroids,,des,anterior cranial fossa,,,,peutz-jeghers syndrome,for the time between the treatment visit/s,18 years||,,,,,,
2644,,solid cancer,brivaracetam,,residual gross disease,open-label,,,,confidential page 32 of 105||-,within 30 days before the screening visit,≥12 weeks;|11.capable,,,,,,
2645,,guillain barré syndrome,vf,,forced expiratory volume in 1 second (fev1) predicted values,mri examination,,,,substance induced,in the past 12 months|under 18|unable to give informed consent for participation in the study,longer than 15 years|patients,,,,,,
2646,,documentable lesion,human serum albumin,,hiv test result;|positive test,experimental treatment,,,,nucleic,in the 2 years prior to randomization|active,0-1 cm,,,,,,
2647,,renally impaired,compounds of similar chemical or biologic composition to ca-4948,,eastern cooperative oncology group (ecog) performance status,note e of table 4.3 data collection table,,,,unscheduled,3-6 months,24.9-29.9 kg/m²|maintaining,,,,,,
2648,,gynecologic oncologists,tricyclics antidepressants,,lund-mackay score,stem cell therapy,,,,mid carpal arthritis,within 2 weeks before the first dose of investigational drug,≥ 1+,,,,,,
2649,,renal impairment function qualifications,neprilysin inhibitor,,blood counts,administrative procedures,,,,suitable to participate in this clinical study,within 1 year of visit|those with a stress awareness scale,18-65 years;|habitually consume breakfast;|able to provide consent and complete all study materials;|able,,,,,,
2650,,histologic confirmation.|inability,1cm2,,rna quantitative positive should complete antiviral treatment,left ventricular hypertrophy related,,,,nata-accredited pathology,prior to randomisation|pregnancy|suspected,> 89 mmhg,,,,,,
2651,,hepatitis c. screening for chronic conditions,paracetamol,,hbv surface antigen,laser treatment|contraindication to the fundus imaging systems used in the study,,,,iv)|terminal,no less than 4 weeks prior to study entry.||,over 18 years.|patients,,,,,,
2652,,dependence on other drugs,live viral non-replicating vaccines,,10 evenings,prolonged ventilation,,,,primary hyperparathyroidism|pregnant,within the six months prior to screening,140 millimeters,,,,,,
2653,,outcome measures,lefort [osteotomy,,calculated by cockcroft and gault's equation|willing,sf3b1 mutation,,,,imminent,within 3 years prior to transplantation|abo blood,18-35,,,,,,
2654,,complex multimorbidity,sufficiently great,,peg-filgrastim,alopecia|major surgery,,,,kinesthetic,within 14 days prior to day 1 of protocol therapy)|platelets,≥0.5 cm,,,,,,
2655,,in situ carcinoma,live born,,hepatitis b surface antigen carriers,chickenpox vaccine,,,,electric devices,within two weeks.|hiv/hbv/hcv,10 mg/day,,,,,,
2656,,insti,bereavement midwives.||,,v5.0 level,percutaneous coronary intervention,,,,2-dimensional,within 12 months prior to randomization.||treatment,between 6 months and 5 years,,,,,,
2657,,recurrence of that malignancy,oral hypoglycaemic,,ef lv,eye drop(s,,,,community-acquired pneumonia,at least during 24 hours before each session|drug therapy,greater than 2.5 times the upper limit of normal,,,,,,
2658,,malignant hyperthermia,oral paracetamol,,procedure.|aged,diabetes|individual,,,,clinical stage,at the time of signing the informed consent|participants,0-1。|life expectancy,,,,,,
2659,,gastroesophageal conjunctive adenocarcinoma,mitochondrial antibody,,respiratory society (ers) classification||-,major organ system function,,,,subacute phase,within the past 12 months|serious,older than 79 years,,,,,,
2660,,structural pathology,compounds of similar chemical or biologic composition to m1774,,mean score,veterans,,,,could interfere with study conduct,at onset of disease,"18-19, 17, 16",,,,,,
2661,,cancer.|in dose escalation,outside,,bone nails;|known allergies,b cell depletion agent,,,,hospitalization;|previous,within one month prior to inclusion.|known,at least 18 years old|patient lives,,,,,,
2662,,multifocal choroiditis,tet2,,target rass,extended-spectrum cephalosporin-resistant enterobacterales,,,,stability|ongoing,within the past 3 months.|patients,<35 kg/m2|male,,,,,,
2663,,type of pain,alemtuzumab,,dbp,collected data||,,,,hormone-releasing,while the previous treatment regimens of her2-positive,18 years and above|patients,,,,,,
2664,,impaired organ function,neurotrophic tyrosine receptor kinase inhibitor,,glutamic aminotransferase,bone scan;|height reduction of the affected vertebra(e),,,,upper limb or|pulmonary embolism,within 3 months before screening.|positive test result,>= 30ml/min||contraception:||woman,,,,,,
2665,,git,vonoprazan,,classification score,autologous stem cell transplantation,,,,nonsyndromic taa;|signed informed consent;|patients,within 7 days before administration,between 25-45;|overweight population,,,,,,
2666,,thoracic malignancies,pramipexole,,hepatitis b surface antigen [hbsag] reactive),voluntary blood donation,,,,pd symptomatic,within 2 weeks before the first use of study drugs.|major surgery,≤1.5 times the upper limit of normal value,,,,,,
2667,,loss of function,immediate local therapy,,human immunodeficiency virus|known,verbal explanations,,,,"glutamic acid decarboxylase, gad65)",prior to study-specific procedures.||,iii or above,,,,,,
2668,,hunter syndrome,eps,,transferring,treatment);|history of,,,,lancaster general health,in the past 10 days|emergency,more than or in addition to permobil,,,,,,
2669,,esophageal dilatation,namenda,,car-t therapies|ongoing,pathological assessment,,,,non-local pain,from the time that the baseline tissue was obtained.|prior locoregional,≥ 1.45,,,,,,
2670,,skin|carcinoma in situ of the cervix|carcinoma in situ of the breast|incidental histologic finding,otc),,outpatient blood pressure medication prescription|moderate,photoprotection measures,,,,before cataract,"in zone 8, 12 or 13||can not received",1000 grams or more,,,,,,
2671,,cognitively intact upon,medication used radio frequency precautions previous,,females|white blood cell count,mtb suggests,,,,under study,within the last 6 months|uncontrolled hypertension,≥ 30,,,,,,
2672,,smart discharges,empagliflozin,,average worst pain,regular oral montelukast,,,,conscious,within 30 days prior to pre-entry:||absolute neutrophil count,< 18 y.o.|neurosurgical treatment,,,,,,
2673,,swallowing dysfunction,histidine,,alat,sex,,,,diagnostic and statistical manual of mental disorders v criteria,within 24 months prior to,=< 3 x uln,,,,,,
2674,,adequately controlled hypertension,prophylactic anticoagulation,,decrease in fev1,embolization,,,,icd-10 z94.x)|acute adverse events,within 30 days prior to the first dose of the study drug.|active,>= 160mmhg,,,,,,
2675,,small atrial septal defect,asp2074,,toxicity,allogeneic hematopoietic stem cell transplantation|patients,,,,high titer positive,within 7 days prior to the first dose of study drug.|known,< 4mm|risk,,,,,,
2676,,platinum,nirmatrelvir,,female|upper excretory tract tumors|localized or locally advanced,sequential treatment,,,,de-novo,within 14 days after taking the drug,malnutrition.|not,,,,,,
2677,,respiratory diseases,pt009,,caregivers:||aged,bilateral pheochromocytoma|patients suspected,,,,inadvertent consumption of poppy seeds,at delivery from 37 0/7 to 42 0/7 weeks of gestation|uncomplicated pregnancy|cesarean section,≥ 18 years|singleton pregnancy,,,,,,
2678,,amendable to surgical resection,technetium,,bdi,hospitalized covid-19 patient.|full consciousness,,,,low cardiac,within 72 hours after surgery,≤ 2.5 x iuln|creatinine ≤ iuln,,,,,,
2679,,active malignancy,cochlin,,mmhg.|diastolic bp,rescue meds,,,,infections.|neurodegenerative,during daily time-restricted eating|rectal,≥ 38sa,,,,,,
2680,,marinol,systemic corticosteroid,,toxigenic cd strain.||,historical mri.|no,,,,non-hispanic white|patients,past 5 years|no,at least 21 days or 5 times the half-life,,,,,,
2681,,smzl,painkillers,,consultant level anaesthetists,consistent access,,,,between domiciled periods,within 7 days prior to study drug administration,between 12 and 60 years,,,,,,
2682,,chronic pain disorders,daratumumab,,csf,sternotomy,,,,dsm-5,at least 3 years||,10-20 ng/,,,,,,
2683,,pregnant|speaks,resulting,,modified rankin scale,pancreatic head,,,,adequate organ functions:||hemoglobin,within 24 hours before administration,>the upper limit of normal;|the patient,,,,,,
2684,,obstructive ahi,t2 mapping non-contrast sequences,,cis)|edss,extracorporeal membrane oxygenation,,,,non-epithelial ovarian cancers,in the last 1 month|taking,≥ 1.5 mg/dl|surgery,,,,,,
2685,,basic hepatopathy,topical steroidal medications,,hepatitis c virus antibody [hcvab],endovascular abdominal aortic aneurysm repair (evar),,,,total,within 6 months before screening.|donated,>= 18 years old.|participants must,,,,,,
2686,,ga|terminal illness,gadolinium,,northeast texas area,technical experts only)|live,,,,suitable for clinical research,during the last 3 months)|willing and able to give written informed consent for participating the study|willing to comply with all study procedures||,between 20-45 years|pain,,,,,,
2687,,chronic analgesic,trachea,,new york heart association cardiac function grading criteria;|patients,vertebral artery (va),,,,less|objectively,within 2 years of study,≥ 37,,,,,,
2688,,bleeding disorders.|cholelithiasis,check-in.|donation of plasma,,vha directive,module|planned,,,,expanded nk cells,for at least 4 weeks before treatment initiation,< 1 year;|any,,,,,,
2689,,facial nerve,anti-cyclic citrullinated peptide,,hcv rna.||current,allogenic stem cell transplantation|diagnosis of,,,,borderline,after the last dose of study,< 27|inability to speak,,,,,,
2690,,talar component change,longest diameter,,child-pugh scale.|if,immunosuppressant treatment,,,,stable dose,within the electroporation,1 to 3.|must,,,,,,
2691,,alcohol consumption (ml) x alcohol content (%) x 0.8||subjects,interferon alpha 2a,,tympanosclerosis of,dallas area||,,,,clinically stable,after being,b,,,,,,
2692,,sclap syndrome,immunosuppressive medications|patients,,screening.||blood alt,myeloablative allogeneic hct.|overt stroke,,,,some other lower extremity muscle,for 5 months after the final dose of atezolizumab,>= 70 ml/min/1.73 m^2,,,,,,
2693,,pancytopenia,pentamidine,,gold fiducial marker implantation,gastric erosion,,,,daycare room,prior to initiation of study treatment|live vaccine,< 90 mmhg,,,,,,
2694,,optic nerve pathologies,bile ducts before ldlt|patients,,who criteria.|age,chelation therapy,,,,mizumoto,within 30 days of the first study intervention administration on day 1,between 0 and -2|written informed consent,,,,,,
2695,,spinal canal abnormalities,sitagliptin,,crt,pacemaker,,,,ligament,within 1 month|probiotic,at least 4 cm,,,,,,
2696,,febrile of uncertain origin or meningoencephalitis,phosphodiesterase-type five inhibitors,,intelligibility,small intestinal surgery,,,,class iv heart function,at least 1 non-mutated,<3 months prior,,,,,,
2697,,months stable,oacs,,inr of,columnar cell,,,,signed;||,within 24 weeks before screening|any surgical,0 to 2||adequate,,,,,,
2698,,fa,topical antimuscarinic agents,,cleft palate,target vessels/plaques,,,,non-specific neck,within the previous 12 months,<94%,,,,,,
2699,,mechanical hemolytic anemia,classes online,,md anderson pathology,rnu,,,,ongoing,within 4 weeks prior to the first dose of investigational product,<10 g/dl|hba1c,,,,,,
2700,,deep carious lesion,medication overuse,,gestational age matching,extensive surgery,,,,non-smokers|subjects,prior to each administration of study drug||for,>180 g/l;|wbc,,,,,,
2701,,implantable device.|metal,excipients,,residual macroscopic disease,axillary surgery||,,,,highly effective contraceptive methods,at least 2 of the following 3 self-reported,between 8-18 years,,,,,,
2702,,delayed hypersensitivity,nozinan,,total bilirubin,pelvic physical therapy clinic treatment of birth-related pelvic floor disorder,,,,may receive red blood cell transfusions)||adequate liver function defined as:||total,longer than 1 year.|volunteer to participate in this clinical study,<3.0 mg/dl.|alt,,,,,,
2703,,myeloma protein,molutrex®,,systolic blood pressure(sbp,local laboratory determination,,,,self-compassion,preceding 24 consecutive months).||**effective contraception,higher than 100 mmhg,,,,,,
2704,,mitral valve repair,bile acid malabsorption (bam),,genotype aatd,hepatic function||total bilirubin,,,,american-european consensus criteria,after 8 cycles of,> 3 seconds,,,,,,
2705,,surgery|multi-trauma,heparin/divalerythromycin,,d3 levels,expert panel,,,,endoscopically visualized lesion,during the active vaccination period,≥ 80 g / l,,,,,,
2706,,pulmonary compromise,or;|triglyceride,,or;|high-density lipoprotein,"world health organization diagnostic criteria first onset, within",,,,non-food allergies,within 14 days of registration)||hemoglobin,≤35 kg/m2.||,,,,,,
2707,,maternal intrapartum,definitive acid lowering surgery,,anc requirement.||(g-csf,pelvic organ prolapse|available,,,,pleural,during the 6 weeks prior to screening;|subjects,<100 x 109/l,,,,,,
2708,,familiar alzheimer disease.|alcohol,triene receptor antagonists,,meditating,t-ais,,,,non-objection,for at least 6-months prior to start of treatment,21 to 80 years old|singaporean,,,,,,
2709,,months;|hepatocellular carcinoma,competencies,,weight records,intratumoural injection,,,,selective,within 8 weeks before baseline,≥ 18 years.|informed,,,,,,
2710,,inducible laryngeal obstruction,bp medications,,total bilirubin (tb),excimer laser,,,,group b,within 8 weeks,above 60|histologically,,,,,,
2711,,platelet dysfunction,orthodontic appliances|patients,,abscess clearance,renal organ function laboratory values,,,,cruciate ligament (pcl),within the following,less than 8 weeks,,,,,,
2712,,hepatitis c. note,nucleic acid testing showed,,alb,mediastinoscopy,,,,full-mouth probing,7 days before dosing,50 to 69 years inclusive,,,,,,
2713,,myofascial temporomandibular disorder,immune serum globulin infusions.|known substance,,a1c value,address walking function|botox injections,,,,months|sdna-fit test,for at least 14 days after the last dose of the investigational medicinal drug,<150x109/l,,,,,,
2714,,alberta stroke program early ct score (aspects),desumumab,,serum free light chain,re-operated,,,,mega dose,more than 3 months,≥50 ml/min.|serum,,,,,,
2715,,criteria of the eleventh edition of the international classification of diseases of the world health organization,cimetidine,,treatment|myopia,cardiac ablation.|a,,,,successfully taking the breast,in the past week;|no history,≥19|a,,,,,,
2716,,suicidal tendency.|usage,cyclosporine,,met:||hematological:||absolute neutrophil count (anc),recovery,,,,upper gastrointestinal system,for at least one year following transplantation.|patient agrees to comply with the protocol,≤ 1.5 institutional upper limit of normal,,,,,,
2717,,cardiac causes,meropenem drug,,alleviated,hand|cervical lateral flexion,,,,spinal cord,up to 6 months after the last dose of study treatment,less than 85 years old and more than 18 years old,,,,,,
2718,,chronic viral hepatitis d,pde inhibitors,,age|positive skin-prick test,core biopsies sub-study,,,,containing,for at least 7 months after the final dose of study,< 1 year|any factor,,,,,,
2719,,criteria hiv+,change medication,,oncology surgeon.|patient oms,mesenteric artery revascularization|no available ct imaging,,,,non-french speaking person,for at least 7 months after the last dose of study,less than 1 year,,,,,,
2720,,cerebrovascular bleeding,non-steroidal anti-inflammatory agents,,alt levels,oral contraception,,,,anxiety related to surgery,during prengnancy|no illicit drug,greater than 3 months from time of enrollment,,,,,,
2721,,idiopathic scoliosis,injectable drugs,,waist circumference,ideations,,,,effective form of,for at least 14 days for,55 - 65 years,,,,,,
2722,,eye disease,mesalazine,,serum vitamin d level,palliative treatment.|pregnant,,,,patients|live-in family members,within one week of receiving ultrasound delivery|pregnancy,less than 17 kg,,,,,,
2723,,adenocarcinoma of the prostate|participants,systemic retinoids,,sfe,sepsis|coagulation function,,,,subclavian arteries,≥14 days before receipt of study vaccine|is,10 mg daily or higher,,,,,,
2724,,malignant wounds|patients,skyline,,resting ecg abnormalities,botulinum toxin injection,,,,5|significant,within 6 months prior to cycle 1 day 1,≥ 90×109/l,,,,,,
2725,,precancerous lesions,darbepoetin alfa,,gababr-antibodies,transfemoral access|severe allergy,,,,pd-l1) therapy,within 2 years after cell infusion,< 4000,,,,,,
2726,,type two diabetes.|bmi,drugs used in the study.|infection,,hepatitis c antibody;|positive,dual antiplatelet regimen,,,,serious physical,between 2 weeks prior to (first) admission,less than or equal to18 years,,,,,,
2727,,macrobiopsy,hemophagocytic syndrome;|patients,,general quotient,facet fixation implant.|preoperative grade,,,,achilles region,within 3 weeks prior to initiation of study treatment,<10 g/dl,,,,,,
2728,,pacemaker.|lower back pain,cytotoxic drugs,,ihc.|adequate organ function/reserve per local labs|adequate liver function,re-test this potential participant,,,,cruciate ligament rupture|a history,since at least 3 months||all,34 and 36 weeks,,,,,,
2729,,non-healing wound,anti-parasitic drugs,,lumbar stenosis|cauda equina|spondylolisthesis|ankylosing spondylitis|scoliosis|leg length,axillary temperature ≥37.5˚c) - (temporary exclusion,,,,≥50%.|12-lead ecg,within 2 weeks prior to the first dose of the ip,≥60 ml/,,,,,,
2730,,decompensated hf,osimertinib,,ankle instability||,lung tests,,,,timi flow,in the month prior to pre-study screening,equal to or higher than 21,,,,,,
2731,,placental anomalies,asa use,,sars-cov- hospitalization,abdominal,,,,prior,within a month after the second vaccination,≤ 60 weeks,,,,,,
2732,,auditory disorders contraindicating,inducers,,qrs values,tace treatment|hcc,,,,severity of the agitation,within 1 week prior to the infusion of sti-6129,less than 80;|at least one,,,,,,
2733,,from smoking,intestine,,residual upper extremity impairment|brain lesions,practice of meditation,,,,low usage||,within 8 weeks of screening,≥ 10,,,,,,
2734,,rigidity,ibuprofen,,troponin investigation|patient requires resuscitation|patient requires cardiologist consultation,bacterial blood culture,,,,c13,during the last six months|the,≥ 126 mg/dl|presence,,,,,,
2735,,calcified lesion,beta-hydroxyl acids,,age>70,ultrasound device,,,,connective tissue diseases,at least 2 weeks prior to study intervention,> 470 ms,,,,,,
2736,,axl inhibitors.|anticancer,sarcomatoid elements,,ambulatory class,color duplex,,,,10= pain,within past 12 months||,< 1000/ μl||12,,,,,,
2737,,hip,selexipag,,serum protein immunoelectrophoresis,ocular health,,,,ap-hp,during the length of the study,6.5% to 10%,,,,,,
2738,,perforated wounds,gca,,hepatitis c virus (hcv) antibodies (abs).|hemoglobin,physical aggression towards self or others,,,,female|consultant,within 4 weeks before the first dose.|history of disorders of calcium,> 7 years,,,,,,
2739,,anterior cruciate ligament (acl),pharmacological agents,,points;|left ventricular ejection fraction,revision)|kidney transplant,,,,dbgap-based,at least 12 weeks of gap prior to first homologous booster vaccination,25-70 years|primary diagnosis,,,,,,
2740,,trying to become pregnant.||any medication,cyp3a4,,modified hexsel css,months；|major organ function,,,,unregistered,after the last dose of assigned study,> 90 ml/min/1.73 m^2,,,,,,
2741,,nsclc|tumor tissue egfr,artificial tears,,tion phase inclusion criteria||written informed consent,conization,,,,non-squamous nsclc.||patients,at least 4 months prior,>185mmhg,,,,,,
2742,,impairment of walking,complementary medicines,,fmiso.|ecog performance score,fmda,,,,compounded combination,for at least six months after the end of the maintenance treatment.||female,≥ 1500/mcl|platelet count,,,,,,
2743,,thrombotic disease||international normalised ratio,platelet-rich plasma infiltration,,left hepatic artery origin,rhc,,,,can tolerate,at the time of signing the informed consent form.|must be able to adhere to the study visit schedule and other protocol requirements,>3 times the upper limit of normal value,,,,,,
2744,,immunologic reaction|patient,read|parents,,her2-negative,nutritional status||,,,,hormone replacement|any chronic skin condition,within the context of,7-28 days after ischemic stroke|behavioral profile consistent,,,,,,
2745,,intercurrent pathology,full opioid agonists,,san raffaele,screening imaging,,,,3-patients,within 3 days before entering the,long-term oral,,,,,,
2746,,neurolysis,drugs which could interact with the study medications,,karnofsky function status,biochemical assessments,,,,visit)|significant,for at least three half-lives,<1.5×109/l,,,,,,
2747,,buccal periodontal tissues,semi-elective noncardiac surgery,,gout classification criteria,homozygous) deletion,,,,imaging;|active,within 6 months before screening.|the laboratory examination,<150000/µl and|liver stiffness,,,,,,
2748,,solid non-infiltrative disease,nivolumab/ipilimumab,,vas measurement|presence,wheat allergy|known hypersensitivity,,,,nm-assist)|cognitive impairment,within the past 10 years.|the participant,more than 0.1,,,,,,
2749,,ct chest,butyrophenone,,bop,line of therapy,,,,discharge from the ctu,immediately prior to the first ip bolus initiation.|the participant,18-40 years|all,,,,,,
2750,,neuroendocrine differentiated cancer,tams,,spt,thyroid organ,,,,stage of t2d,during same procedure|able to understand the content of the patient information / consent form and give consent to take part,0-1;|the,,,,,,
2751,,cardiac defibrillation,immunotherapeutics,,alanine-aminotransferase (alat),complete unilateral cleft lip(reach floor of the nose)||,,,,years|significant,last 12 months prior to the study,<25 years,,,,,,
2752,,diarrhea related diseases,cied,,or;|platelet count,standard treatment;|according to the recist 1.1 standard,,,,erosive,within 15 days from study enrolment|use of,18 to 85||gerd patients with complaints of regurgitation,,,,,,
2753,,progressive external ophthalmoplegia,glucocorticoids,,total hepatitis b core antibody (hbcab) test,her2 ultra-low/null,,,,high dose oral,before embryo transfer.|those with,stage ii-iv)|underwent surgery,,,,,,
2754,,parenteral nutritional support,milliseconds.|lvef,,anti-dsdna serum antibody,table 2)|life expectancy,,,,under-weight,within 2 weeks before taking the study drug,"between 18 and 80 years,|present",,,,,,
2755,,history).*|concomitant infection,oral contraceptives [ocps],,srsf2,hepatectomy,,,,clinically apparent,during the 3 days prior to vaccination,≥24 months)|subject not,,,,,,
2756,,pregnancy losses,interferon,,afp levels,standard therapy,,,,intact,within 5 half lives,≥ 18 years < 75 years.|physician,,,,,,
2757,,her2-targeted monoclonal antibodies,strong cyp3a4 inhibitors.|on strong,,serum calcitonin level,temper tantrums,,,,axis i mental disorders,in the 3 months preceding inclusion (declarative),0-1;|6,,,,,,
2758,,thyroid disease|cancer,antithyroid drugs,,tobacco users,bladder onabotulinumtoxina injection,,,,near eye,within two weeks prior to screening|treatment,greater than 4cm.|pregnant,,,,,,
2759,,irb.|the,agonists,,10)adequate blood pressure,asthma|treatment regimen discordant,,,,ds% 50%-90%,at time of injury|full-time,greater than 5 times the upper limit of laboratory normal value,,,,,,
2760,,cancer|planning,thymosin,,acr/eular,alectinib,,,,following:||mitral valve orifice area,within 10 days prior to day 1,≤1.5 times the uln,,,,,,
2761,,primary glaucomas,reproductive toxic drugs,,cpd|age,women|persons,,,,local)|acute urinary,within 24 hours prior to study entry.|persons,> 100 10^9/l|patient,,,,,,
2762,,thyroid disease.|patients,orenitram,,american society of anesthesiology classification,longest nerve graft available,,,,skilled,at the time of research,more than 30 years,,,,,,
2763,,wide carious lesion,sympathomimetic drugs,,urine human chorionic gonadotropin (hcg),cognitive function,,,,vr headgear,prior to the underlying,= aspartate aminotransferase)|history,,,,,,
2764,,difficulty breathing,prosthetics,,ethanol,pet scans,,,,t3-t4an1/n1cm0,survived for more than 5 years,18 and 70 presenting,,,,,,
2765,,logistical issues,onasemnogene abeparvovec,,alveolar bone height,nutraceutical treatments,,,,arc clinic.|under,in last 30 months from date of export|last a1c value,month to < 6 months,,,,,,
2766,,severe hepatic disease,phenytoin,,therapy.|ecog performance status,toxicology panel,,,,specialized tms/eeg,within 3 days before the first dose|any illness,"<0,7 ng/dl",,,,,,
2767,,reproductive ability,lmw heparin,,calibrated severity score,menses|surgical sterilization,,,,phq-,prior to start of radiotherapy|inability to attend,< 15 ml/min)|nyha iv,,,,,,
2768,,imaging|patients,bevacizumab combination,,cardiac function test,structured clinical interview for dsm-5 - research version [scid-5-rv],,,,three-dimensional ultrasound,the time of screening,≥12 weeks;|subjects,,,,,,
2769,,testes,5-meo-dmt,,alt (sgpt)<= 1.5 unl|sign a formal informed consent,response|pulmonary fibrosis|obstructive sleep apnea syndrome|lung,,,,octave frequencies,between days 25-40 after,between 35 and 80 years|bcva ≥ 75 letters,,,,,,
2770,,cardiac sarcoidosis,non-steroidal anti-inflammatory drugs,,in remission,bladder diverticulum,,,,regularly|could not follow the protocol of this study,at dose of =< 10mg of prednisone,15 ml/minute,,,,,,
2771,,hypersensitivity|active abdominal wounds,atenolol,,anti-hbe positive|hbv dna,function|mechanical barriers|obstruction of cerebrospinal fluid (csf),,,,intra-vaginal contraceptives|norplant system®|depo-provera®|intrauterine device,during the therapeutic trial|hypersensitivity to any of the study drugs,> 126 mg/dl,,,,,,
2772,,vascular endothelial growth factor receptor (vegfr),prescription medications/products,,increased blood pressure,total laryngectomy,,,,non-specific,at least 1 cigarette per day,> 80 g/l,,,,,,
2773,,high-efficiency,regimens containing radiotherapy,,mrs should be right-handed,fetal monitoring,,,,positive,after the last dose of investigational drug,less than twelve months from,,,,,,
2774,,pressure,deoxyribonucleic acid,,nci-ctcae version 5.0 [appendix 3],screening program,,,,molar regions,within 12 weeks before the start of study treatment,between 17 to 26||or||participant,,,,,,
2775,,anatomical sterility,tyrosine kinase inhibitors;|the number of primordial cells,,dual-energy x-ray,oxyhemoglobin saturation,,,,kaposi,within the prior 14 days||i,> 2.0mm|history,,,,,,
2776,,renal impairment|history of seizures,phe64leu,,albumin concentration,coronary artery bypass surgery||,,,,early-onset,within 5 days prior to randomization.|women,less than 12 months,,,,,,
2777,,teeth should,third-generation egfr-tki therapy;|dose expansion,,progesterone receptor by immunohistochemistry (ihc),lmwh,,,,antibiotics|other,within 3 months before screening,less than 100 days；|vaccinated with,,,,,,
2778,,meningeal involvement|history of neurodegenerative condition,octreotide,,urine pregnancy test.||vaccination,complementary treatment,,,,died:|enrolled in mc1137,at least 28 days,less than 5,,,,,,
2779,,behavioral disorders incompatible,voriconazole,,moribund,pvtt typing,,,,cervix.|clinically significant,user,needed.|presence,,,,,,
2780,,18+,antiplatelet medications,,interferon gamma release assay,vertical sleeve gastrectomy,,,,expanded bleeding index,within 28 days before randomization.|have received,equal to or above 11.0 years,,,,,,
2781,,drug reaction,anti-pd-1 antibody.|other,,guardian.||healthy volunteers healthy subjects,definitive chemoradiotherapy,,,,nrs pain score,during the study period of this clinical trial;|any circumstances,greater than 130 mmhg,,,,,,
2782,,asymptomatic intracranial metastasis,hcms,,mdaat,hemorrhagic blood dyscrasia|patients,,,,grade ii-iv (glucksberg standard),at the time of their,± demethylated drugs.||(2,,,,,,
2783,,between lesion,pain medication regimen,,visual analog,products|active treatment,,,,inspection|acoustic nerve lesions,within the last 3 months|current,from 25 to 60,,,,,,
2784,,infectious diseases sequential scale,nebivolol,,left ventricular cavity,substitution therapy,,,,major organ,within the previous 14 days|a history,1 or 2.|for,,,,,,
2785,,contra-indictations,cyp3a drug substrates,,free androgen index,bilateral oophorectomy,,,,low tissue doppler velocities,within 60 days of baseline,< 9g/dl|patient,,,,,,
2786,,bruising,allergan glabellar lines severity scale,,hepatitis).|total bilirubin,blood product transfusion,,,,danish university||,more than 1 year,18 and 60 years,,,,,,
2787,,bone pathologies,grapefruit (juice),,uph||,expert opinion,,,,successfully eliminated,at the time of icf signing.|hospitalized,> 40 mm,,,,,,
2788,,frozen semen,futibatinib or its excipients,,serum ast/alt,receive surgery,,,,injectable,before or after chemotherapy.|giving informed consent to participate,5 to 18 years,,,,,,
2789,,substantial amount of,topical treatments,,hidradenitis suppurativa,surgical indication|patients,,,,cease,30 days prior to enrolment,scores of,,,,,,
2790,,excessive thrombus,warfarin,,nijmegen questionnaire score nq,vaginal plastron,,,,non-reactive pupil,during the following periods prior to the start of study drug administration,=< 6 months prior,,,,,,
2791,,constant pain,medications used to treat neuropathic pain,,nhs specialist learning disability,rbc transfusion dependence|neutrophil count,,,,now or been,within 1 month before screening;|exposure,12 to 17 years,,,,,,
2792,,chondral pathology,immunosuppressive therapies).|3,,anti-hepatitis b virus treatment,local regulatory agencies,,,,near fatal asthma,7 days prior to the administration of pep07.|patients,"< 50 %,",,,,,,
2793,,gh receptors.||applicable,local anesthetics|allergy,,eml4-alk-positive nsclc,contrast|71275 - ct angiography,,,,hypertrophic scars|presence,during the trial.|patients,<3.|patients,,,,,,
2794,,chemical dependence,hormonal products,,purified protein derivative (ppd),pathological fractures.|those deemed unsuitable to partake,,,,half-pint,3 days before the examination|have the habit of smoking,≤ 2|patient,,,,,,
2795,,malignancy,phencyclidine,,af|left ventricular ejection fraction,lower intestinal endoscopy,,,,ct).|single,within 4 weeks prior to the 1st scheduled dose of study treatment,≥ 30 kg/m2.|presence,,,,,,
2796,,local allergic necrosis,investigational drug therapy,,whz,regular proton pump inhibitor,,,,st elevation,in the previous 30 days,≥0.30x10⁹/l,,,,,,
2797,,fungal infection,pharmacologic agents,,prediabetes(hb a1c,palliative treatment,,,,mainly high unconjugated bilirubin,within 3 weeks prior to the first dose of investigational product,between 20 and 50 years,,,,,,
2798,,corneal neovascularization,lidocaine hydrochloride|free from musculoskeletal injury,,hospitalization|bp,mechanical heart valve,,,,migraine group,past 24 months,over,,,,,,
2799,,parent(s)/legal representative(s) able to understand the language used in the investigation centre,mocs/ maintenance oral corticosteroid dose,,lama,complex surgery,,,,pd-l1-positive,"more than 8 cups,1",≥18.5 kilograms,,,,,,
2800,,prolonged qt|active seizures,interventional agent,,concentration scale,immunomodulatory therapy|anyone,,,,mimic ms,at least one of the following hypotensive symptoms:||baseline,0-1|participants should,,,,,,
2801,,judged to require,local anaesthesia|treatment technologies,,part c:||known hypersensitivity to,prostatectomy,,,,unrelated donors,within 4 weeks before screening|patients,classification system class,,,,,,
2802,,proven cognitive disorders|already benefit,aminoglycoside antibiotics|previous treatment,,residual upper extremity hemiparesis.||key,revision tha,,,,pd prescription,within 7 days prior to receiving the first dose of study medication,daily dose <10 mg,,,,,,
2803,,her2 exon 19,antihypertensive drugs remained unchanged,,cd4 count,arv therapies subsequently,,,,transplantable,at an equivalent dose ≤ 10 mg of,2.2 ≤ pupil size,,,,,,
2804,,relapsed all disease,influenza,,home blood pressure monitoring,"laparoscopic cholecystectomy,|no complications",,,,subretinal hyperreflective,at least 126 mg/dl,> 1.5 x institutional upper limit of normal (uln),,,,,,
2805,,disease.|hematologic disease.|immunologic,interstitial pneumonia;|there,,endoscopists,major organ transplantation,,,,hla-dq8,within 3 years prior to study vaccination.||have,≥1 year,,,,,,
2806,,localized msk,immunosuppressive medication.|previous,,recist 1.1.|ecog activity status,world health organization (who) classification in 2016,,,,non-reactive,at the available level of evidence,0 or 1.|the,,,,,,
2807,,antiherpetic activity,hyrimoz®,,gold standard treatment regimes,accommodation,,,,on room air by,in 3 12-lead ecgs tests,18 and above undergoing,,,,,,
2808,,dosing cycles,amiodarone,,american society of anesthesiologist's physiologic state,intragastric balloon removed,,,,in room air|karnofsky,at the time of inclusion.|other conditions,≥ 27,,,,,,
2809,,abdominal mass,pinnaverium,,creatinine clearance rate cg,liver ultrasound,,,,"age18~75,|regular night shift",more than 4 cm occupying the renal pelvis,95%,,,,,,
2810,,chronic pain bleeding disorders renal,ethionamide,,ii|body mass index,venous cholangiography,,,,low level of literacy,within 6 weeks before enrollment;|pregnant,<= 90,,,,,,
2811,,coronary artery disease,anti angina drugs|valvular,,benign arm,tasc,,,,mca field,within 14 days):||hemoglobin,60 years or older.|voluntarily sign the informed consent form,,,,,,
2812,,increased intracranial pressure,doravirine,,white matter lesions|history of severe cardiopulmonary dysfunction,cardiac resynchronisation,,,,non-squamous nsclc.|patients,within the 12-month period,≥45 ml/min,,,,,,
2813,,third-space fluid,l occlusions,,illiterate,intra-cardiac,,,,their general condition,within 8 weeks prior to graft implantation.|history of,> 18 years|ruptured,,,,,,
2814,,gastric reflux,systemic anti-cancer therapy (sact),,left ventricular ejection fraction lvef,spherical refractive error,,,,esophagus;|tumors of the esophagus,within 30 days of assessment,18-45 years;|body,,,,,,
2815,,ischemic chest pain,visit|stable medication/psychotherapy regimens,,pyruvic transaminase ≤ 3xuln|coagulation function,mechanical gi obstruction|radiation,,,,lumbar region.|having been,within 3 years before the first dose of study intervention,< 150 or > 180,,,,,,
2816,,hemophilia)/symptoms,icf)（for minors,,american society of anesthesiologists (asa ),endodontic therapy|mandibular first molars,,,,molecular diagnosis,within 4 weeks prior to study treatment.||note,≥ 50% on inclusion,,,,,,
2817,,nj,parpi drugs；|symptomatic brain,,brca 1/2 mutations,small saphenous vein,,,,classification|unstable,at least 4 weeks prior to the first dose,greater than 470 milliseconds,,,,,,
2818,,"cardiac surgery,|hemodynamic",antihypertensive medication|fasting glucose,,aortic arch replacement,recessive mutations,,,,vascular disease.||,in the 4 weeks prior to receiving cell therapy,> 1.5)||10,,,,,,
2819,,drug abuse,anti-inflammatory agents,,stem cell transplantation:||autologous,ergogenic dietary supplements,,,,amenable to anatomical surgical resection,within 2weeks before initiating study treatment.|prior organ transplantation,< 7.3,,,,,,
2820,,medication abuse,osteofascial compartment syndrome;|structural bone,,pregnancy|body mass index,mastectomy surgery,,,,stable baseline therapy,within 4 weeks before the first dose.|patients,10 to < 13 years,,,,,,
2821,,nursing,rasagiline,,human immunodeficiency virus (hiv) types,covid-19 rapid tests,,,,3-tesla mri examination,within 1 month of the first visit,greater than 100 ng/ml,,,,,,
2822,,muscular disease,3rd vaccination,,weight change,e cxr,,,,ssc,before pregnancy|using,< 18_years|previous esophageal,,,,,,
2823,,miscarriage,mitomycin c)|received wide field radiotherapy,,avms,vaginal ring plus,,,,enrollment;|symptomatic,in the previous 6 months|obliterating,≤ 24.9 kg/m2|written,,,,,,
2824,,ad criteria,immune checkpoint inhibitor therapy,,baseline qtc,screening|myocardial infarction,,,,non-pigmented,within 4 weeks of the testing.|study subjects shall not consume the following,> 9g/dl;||patients,,,,,,
2825,,age|subject,csf,,older|systolic bp,cervical lymph node dissection|metastatic disease,,,,self-injurious behavior,within 6 months prior to enrollment.|resting,> 40|indulin-dependent,,,,,,
2826,,sperm donor|bmi,baseline visit|patients,,european pressure ulcer,goserelin therapy,,,,uni,in the allocated time frame,>25% of bowel movements categorised,,,,,,
2827,,affect bladder function,tpo-ra,,response evaluation criteria in solid tumors,thoracoscopic procedures,,,,product.|previous exposure,during the last 6,dose level,,,,,,
2828,,first molars|visible,monoamine oxidase inhibitors,,ingredients|systolic blood pressure,interruptions,,,,frontal-parietal brain,within 30 days of study medication administration through the eos visit.|malignancy,at least 10 years,,,,,,
2829,,utilization records,components of the implants|patient with physical or,,serum calcium,regular imaging - yearly,,,,diabetes);|clinically unstable,within four weeks prior to period i dosing.|history,between 01/06/2020,,,,,,
2830,,female.||reproductive characteristics||for,non-steroidal anti inflammatory drugs (nsaids),,choroidal thickness,chronic bpa release,,,,lumbar artery,within the prior 90 days|acute arterial,130-199 mg/dl,,,,,,
2831,,sudden cardiac death,fibrin,,residuum circumference,next- generation sequencing,,,,diameter of the target arteries for conduits of the internal mammary arteries,within 2 months prior to check-in (day -1).|the,>500 iu/l,,,,,,
2832,,human immunodeficiency virus positivity,ursodeoxycholic acid,,1|hcc not,gutkha areca,,,,upper respiratory tract infection);|pregnant,at time of first assessment||,18-40 2,,,,,,
2833,,screening|uncontrolled hypertension,oral motor function deficits,,syphilis antibody,pet scan imaging,,,,truliant,during the study.|anticoagulation with,≤ 7 days,,,,,,
2834,,digestive system disease,nucleic acid-positive infection,,giredestrant plus abemaciclib,urine drug,,,,tumor invades,within the 6 months prior to randomization.|patients,18-75 (when signing the informed consent form,,,,,,
2835,,t3 tumors,corrective glasses,,hepatitis b test,chronic weight,,,,a|clinically significant,at any time|previous idi|any condition,>4 kg,,,,,,
2836,,git obstruction,inotropic drugs,,l5|bone mineral density t value,vertebral column,,,,st-elevation myocardial infarction [stemi,in the next 9 months;|willingness to adhere to the monitoring,> 18 years|persistent/permanent,,,,,,
2837,,competence)||,immunomodulating treatment,,1.4)|age,computed tomography images.|images from other hospitals without proper evaluation,,,,potency|tci|topical,within 2 weeks before surgery|clean-contaminated,equal to or greater than 25 kg/m2.||and,,,,,,
2838,,bacillus tuberculosis).|active covid-19 infection,cleft palate,,albumin value,pathology allows urothelial carcinoma,,,,non-decompensated,"in the last 6 months,|the",younger than 18 years,,,,,,
2839,,infectious,normal;|troponin,,midbrain extension/involvement of the hemorrhage|coagulation disorder,surgery of the bones of the lower limbs performed,,,,barrett,within 3 months after the end of the trial,>/= 1.8,,,,,,
2840,,severity of depression,necrotic pulps|non-restorable,,systolic arterial pressure>180mmhg,laparoscopic gallbladder removal,,,,any form (,for at least 12 months after infusion.;|informed consent/assent,score 0-1||,,,,,,
2841,,acute pelvic pain,psychiatric disorders|inability to participate,,sponsor)|left ventricular ejection fraction,bilateral selective neck dissection,,,,scale|using sleeping pills,within 48 hours of consent,> 28 g/l,,,,,,
2842,,liver disorders|autoimmune disorders|sickle cell disease|placenta previa|abruptio placentae|eclampsia,glycopeptide,,body height,fine-needle biopsy,,,,suitable for participation in this observation study,during this time period,7.0-11.0%,,,,,,
2843,,salies,systemic immunoglobulins,,profound sensorineural hearing loss,left subclavian artery branch vessel diameter,,,,tp53wt|locally advanced,during screening.|severe,≤ 26;||total score of,,,,,,
2844,,immune tolerance induction therapy,products containing beans,,mra,open gastrectomy,,,,exception,at the time of screening.|be of chinese ethnicity,<1% positive,,,,,,
2845,,chest,mipss70-plus,,nasal trauma).|frequent epistaxis,transthoracic echocardiogram (tte),,,,coated,during the 2 weeks prior to initiation of the baseline,less than 24 months.|subjects,,,,,,
2846,,chest burn injury,childhood,,hearing||-normal hearing sensitivity bilaterally||if hearing loss||children,systemic aminoglycoside antibiotic,,,,18f-fluorodeoxyglucose,more than three times in 24 hours,1.1|overexpression of fibroblast activation protein of the target lesions,,,,,,
2847,,leg type|intravascular large b cell lymphoma|ebv+ dlbcl,intravenous amino-bisphosphonates.|patients,,updrs-i item,surgery sample.|not enough lung tissue for a histological analysis,,,,poorly healed,at the time of diagnosis,≥ 18 years;|participant,,,,,,
2848,,aortic regurgitation|abdominal aortic aneurysm,cytoreductive agents,,older|self-identify,apply hormones topically,,,,low-income senior,within 4 weeks before the screening visit,mandibular area|age limit range,,,,,,
2849,,inadequate skin integrity,age|prisoners|pregnant,,epor fusions,lateral view,,,,"self-report),|not",months|currently,">= 150,000/mm^3",,,,,,
2850,,clipping;|poor general condition,felbamate,,prc test,"health facilities (aim 2)||for aim 2, activity 4, investigators will enroll approximately 804 randomly selected",,,,depo-provera®,within 24 hours with,"≥70,000/mcl|c",,,,,,
2851,,mmhg|inability,inhaled corticosteroids|prophylactic short-term,,hcv rna levels,liquid biopsy,,,,taiwan regulations,lasted longer than 3 months.|pain level,"≥ 50,000 cells/mm3|anc",,,,,,
2852,,bone fracture.|abdominal fistula,intravesicular anesthetic,,partial thickness injury,nfs,,,,influence of a controlled substance,prior to blood collection,between 18-75 years||exclusion,,,,,,
2853,,pain on most days,gliptin,,|age,orthopaedic surgery,,,,large to wear,within 30 days prior to screening.|patient,≥50% stenosis,,,,,,
2854,,respiratory impairment,leuprolide,,modified ashworth scale|they,enrollment|prior autologous hematopoietic stem cell transplant,,,,post-covid syndrome recommended,within the central 9 mm,score of class,,,,,,
2855,,suicidal attempt,gold recommended drugs,,aml|hiv viral loads,hip flexion contractures||,,,,outside,within the previous 1 month or 5 half-life period,"<7,500 steps",,,,,,
2856,,irritable bowel syndrome symptoms,immune-related severe,,hepatitis c (,regular electronic reporting|pregnant,,,,confirmed by histopathology,in the preceding 12 weeks prior to screening;|have,< 40kg / m2,,,,,,
2857,,course ofthe disease.|vaccination,palopegteriparatide,,breast cancer|ecog,exercise|participants should know the greek language in order to understand the instructions,,,,medications|self-report,within 14 days of scheduled vaccination||known medical problems:||pre-existing,under 18 years|icus,,,,,,
2858,,reason.|niaaa,ljungman,,hr-nmibc,mismatch repair protein (,,,,graduated,within 30 days of screening;|subjects who participated in any other,>75% of space,,,,,,
2859,,criteria of the american college of rheumatology 2016,modified delivery,,mcs,orthopedic operation,,,,faecal,throughout the operation,0-1|have,,,,,,
2860,,hepatitis c (hbc),local medication,,urine laboratory tests.||key,undergo,,,,disorder|past-year,during the first 28 days following the study vaccine,score ≥ 16th percentile,,,,,,
2861,,schizophrenia|bac,ssri medication,,pap (cpap,digital substraction angiography,,,,d. farinae,for minimum 6 months|functional hearing|normal inner,<130 g/l,,,,,,
2862,,synovial fluid,substance,,gdm)|age,rfa)|transjugular intrahepatic portosystemic shunt,,,,ocular manifestations|rash,within 48 h before the first administration of the drug.|taken,≥ 40.0 kg/m².||,,,,,,
2863,,clinical emergency,immune modulating drug,,hepatitis c virus (hcv) antibody-positive,histological specimen|being,,,,muscular strength,within 3 months prior to initial use of the study drug.|within 2 weeks prior to the initial use of the study drug,23-64)|women,,,,,,
2864,,transient ischaemic attack (tia),procainamide,,amsler-krumeich classification|other ectasias,staged pci after randomization|any condition that,,,,severity scale,medical history of,≥ 12 weeks;|normal function,,,,,,
2865,,childhood asthma/,nucleoside analogues.|the researchers,,mad part,years|coronary artery bypass grafting,,,,gonadotropin-releasing hormone agonists|calcineurin inhibitors.|history,within 3 months prior to the,between 30-65 years;|men,,,,,,
2866,,epilepsy|inability,sirolimus,,sui,blood-derived products,,,,rampant,recent use,between 29 october 2019,,,,,,
2867,,idiopathicpneumonia,clomifene,,cap score,ipsilateral breast surgery,,,,consumed,after evaluation by principal investigator,18 years or over|patients,,,,,,
2868,,evaluable lesions,mri- incompatible devices,,months|uncontrolled hypertension|arrhythmia,"sleep,||",,,,could change the mesiodistal diameters of the teeth.|teeth,for > 6 months,≥50 years of age|lp(a,,,,,,
2869,,medical team considers,davis,,ppi,hip prosthesis surgery,,,,insulin dependent,within 6 months before registration,less than 3 times/week,,,,,,
2870,,generalized urticaria,contrast medium|patient under legal,,liver,autologous stem cell transplantation (sct),,,,primary neoplasm,for 15 weeks after the last imp treatment.|suspected hospital-acquired,10-18,,,,,,
2871,,mentally ill,strong cyp3a inhibitors|concomitant,,untreated,pcd,,,,non-rowers:||-engaging,within 48 hours before start as well,score of >3,,,,,,
2872,,alzheimer's disease association,oral contraceptives|patients,,visit|life expectancy,line of standard chemotherapy regimens,,,,aortic,within 4 weeks before randomization|history of splenectomy||other protocol-defined inclusion/exclusion may apply,50 to 80 years old,,,,,,
2873,,surgically cured|severe,long-acting injectable hormonal contraceptive,,sage-sr,suprachoroidal,,,,secondary causes,within the last 1 year,≥265 mg/dl,,,,,,
2874,,rheumatoid arthritis|active osteomyelitis|history,angiotensin ii receptor blocker (arb,,supine blood pressure (bp),endovascular treatment plan,,,,etc.|pre-existing,prior to randomization|absence of,< 30 ml/min / 1.73 m2,,,,,,
2875,,throat diseases,components of the txa formula,,ureteral,lipid levels,,,,fresh samples.|eastern,6 months after inclusion,___ bmi,,,,,,
2876,,haematological malignancies,anti-angiogenic therapies,,facial axis,regular consumption,,,,implantation of the prizvalve®,<28 days prior to enrollment into the study;|positive,≥ 75 x 10⁹/l|serum bilirubin,,,,,,
2877,,senile pruritus,soy-derived,,physical status asa,drugs|vitamin d poisoning|expected survival,,,,more||,at least 6 months prior to study drug administration,less than the threshold value,,,,,,
2878,,chronic renal failure|patients,pancreatic,,procedures.|control participant exclusion criteria,small molecule vegfr-tki;|involved,,,,supportive,during september 2017-april 2021||,≥ 75 x 10^9/l,,,,,,
2879,,concussion symptoms,tobacco products|allergy,,study|body mass index,polymerase chain reaction (pcr),,,,maximum tolerated dose,within 6 weeks prior to enrollment.|mri of the liver,between 0-100,,,,,,
2880,,type ii diabetes,oral antidiabetic medicine (oam),,hiv-rna,ptld,,,,lower limb ischemic necrosis;|paraplegic patients;|patients,within 3 months before surgery.|severe,5 % or more|patient,,,,,,
2881,,coagulation abnormalities,materials such,,testing for hiv,cranial operation history,,,,features)|mild,within 4 weeks before the inclusion|subject previously treated,between january 2014,,,,,,
2882,,superficial bladder tumor,compounds of similar chemical or biologic composition|planned additional surgery to the surgical breast,,neutrophil,spherical grasping item of the fugl-meyer upper extremity subscale to allow,,,,single-food,at least 4 weeks prior to the run-in visit,less than 7|inr,,,,,,
2883,,contributing aetiologies,days|prescription drugs,,testosterone supplementation|known homozygous,radical esophagectomy,,,,non-cardioembolic stroke,within 14 days prior to routine blood tests;||kidney,greater than 2mm,,,,,,
2884,,acute coronary syndrome.|patients,steroids|systemic corticosteroids,,partial thromboplastin time (aptt)≤ 1.5×uln;(except for patients,complete hwc sessions,,,,ipsilateral shoulder,in the previous 28 days.|have received,≥200 mg/24,,,,,,
2885,,autoimmune etiology,sangthong,,balgrist university hospital||,trapezoid excision-whole,,,,first dose of study drugs.|known hypersensitivity,within the past,≥ 470 ms.|any,,,,,,
2886,,endocrine disorder,fundoscopy,,perinatal hypoxic-ischemic encephalopathy,immunochromatographic assay,,,,screening.||vital,within 4 weeks before the first administration|pregnant,low,,,,,,
2887,,program requirements;|all,vmat2 inhibitors,,inferior alveolar canal|minimum ridge thickness,emergency procedures,,,,suitable for or are not willing to accept standard treatment;|ecog physical condition,within 2 weeks of the ceus study|be,18 years old or order,,,,,,
2888,,black tea,beta-agonist bronchodilators,,direct bilirubin fraction,uc|treated,,,,resulting,within 2 weeks prior to enrolment|mental incapacity,>400 ml,,,,,,
2889,,parkinson's disease)||contra-indications,anti-gerd therapy,,1；||organ function：||kidney function:||serum,numerical rating,,,,clinically relevant electrocardiogram (,within three months prior to screening,50-75 yo,,,,,,
2890,,squamous cell carcinoma;|he,anti-coagulant therapy,,danish civil registration number,pet imaging|psa,,,,non-low-grade eec,prior to november 2020|and able to understand and communicate in,<2 years,,,,,,
2891,,middle cerebral artery feeding,nmb,,moderate habitual exercise,first-line therapy.|imaging evaluation (ct or mri,,,,maximum tolerated,within 6 months prior to screening.||3.fever,< 350 cells/ul,,,,,,
2892,,brain natriuretic peptide,study;|live vaccine,,geriatric depression scale,assessment regime,,,,official health care,at time of registration|who performance status,outside normal range or < 1.5 x109/l|white blood count,,,,,,
2893,,dysimmune disease,betaine,,men,local great vessels,,,,empty stomach for the blood,at the time of study entry)|written informed consent,≥0.1 mv,,,,,,
2894,,hemolytic anemia.|systemic infections,loop diuretic drugs.|new york heart association,,manual ability classification system - macs,initially,,,,laser,prior to conception:||other,between 30 and 84 years.|seeking,,,,,,
2895,,pregnancy|no native dutch speaker,rifapentine,,drug test,antifibrotic therapy,,,,gadolinium,at least 10 days before the first study drug administration,>800 pg/ml,,,,,,
2896,,recurrent neck pain,spt,,cfcs,stridor,,,,related to previous treatment.|patients with baseline,within 4 hours prior to the screening/baseline visit,above uln,,,,,,
2897,,pregnant,hrt,,response evaluation criteria,abdominal b-scan ultrasonography,,,,coexisting,48 h prior to blood sample collection,≤ 30 weeks,,,,,,
2898,,weight stable,microscopy,,pneumococcal vaccine;|history bacterial pneumonia,teams,,,,longest diameter,within 3 months prior to screening.|have any other conditions,+ 0/7 weeks|exclusive,,,,,,
2899,,period.|diagnosis,lonafarnib,,thyroid carcinoma;|active tuberculosis infection,radiographic findings|willingness,,,,clinically significant angina,within 2 months prior to randomization,≥ 25 g/l|creatinine clearance (crcl),,,,,,
2900,,competitors of renal tubular excretion,la,,mdrd type)||,criteria.||white blood cells,,,,systemic treatment|pregnancy,in past 12 months|cerebral,> 3 months 6,,,,,,
2901,,major neurologic deficits,components of the study product.|subjects,,car-t,routine blood labs,,,,shock|coma|severe,within 28 days before study intervention,voluntarily agreed,,,,,,
2902,,tans,scn1a microdeletion,,provincial universal health insurance coverage,placement of an,,,,radiologically stable.|history of,prior to study,"≥100,000/µl",,,,,,
2903,,potentially impacting,suprachoroidal steroids,,spo2 measurement,hospitalization|hospitalized,,,,at risk of drug-drug interactions (ddis),for ≥ 3 months.||,4-7)|no,,,,,,
2904,,esophageal squamous cell carcinoma,cetirizine,,alcohol level,tracheal intubation twice;|patients with mental illness,,,,new or,at least 30 days before the administration of trial medication until 30 days after trial completion.||the,> 38.2 c,,,,,,
2905,,personality disorder)|history of,covid-19 inactivated vaccine,,intensive care unit.||,cervical radiofrequency,,,,above recommended,period prior to screening,<90 mm,,,,,,
2906,,sterilized placental allografts,ict-devices,,international movement disorders society mds,gi bleed,,,,stage iv of the,within 14 days prior to administration;|subjects,20 to 600 times the recommended daily dose,,,,,,
2907,,maligancies;|body mass index,ethanol,,heart function,heart rate,,,,suitable for participation of the clinical trial.|subject,at least 2 x uln,68ga-psma-11,,,,,,
2908,,extrahepatic tumor burden,components of the amulet laa closure device|actively enrolled,,psma pet/ct,supplemental oxygen therapy,,,,electrophysiologic study.|unexplained,at minimum 24 hours continuous monitoring prior to initiating btk inhibitor||,< 0.80,,,,,,
2909,,involvement of the main portal vein.|hepatic vein invasion,immune system,,permanent)|chads2 score,enteral tube,,,,"diagnostic criteria from the ""diagnosis",during the past year|presence or,18~80 years old,,,,,,
2910,,septic shock:||•,morphine milligram equivalents,,contraindicate bronchoscopy fev1,hard liquor,,,,ankle brachial index,within 3 years of screening,> 35 kg/m2)||inclusion criteria,,,,,,
2911,,involves hypertension,intravenous administration,,partial remmision;|estimated glomerular filtration rate (egfr according to the ckd-epi formula,peritoneal dialysis|history of,,,,sevilla oranges,within recent 3 month,score of 0 or 1||adequate organ function,,,,,,
2912,,allergic dermatitis,critical covid-19,,sao2 value,resistance to jak inhibitors,,,,de-identified,at the time of recruitment||,≥85 cm,,,,,,
2913,,complete heart block,contraceptive diaphragm,,rapid ventricular tachycardia,behavioral variant,,,,narrow angles,within 2 weeks after the last dose of study,10-30kg||,,,,,,
2914,,eaton-lambert disorders.|patients,h2 blockers,,race|egfr,major trauma,,,,weeks|receive,in the 3 weeks before day 1|known pregnancy,">2,75 mmol/l",,,,,,
2915,,oedematous malnutrition,psychiatric disease||mri related exclusion criteria:||paramagnetic,,ecg findings,physical examination anomaly,,,,n1-n2；t2-4,in the 5 years previous to recruitment.|patients with neurological or psychiatric pathology.|pregnant,7% to <8%,,,,,,
2916,,inflammatory skin diseases,solution,,tau pet/ct scan date,endoscopic partial laryngectomy,,,,|clinically significant,while receiving temozolomide treatment,later than 4 times plasma half-life,,,,,,
2917,,etc).|periodic limb movement disorder,anti-vegf antibody,,inpatient care||for healthy,possible causes).|no have undergone,,,,lower extremities below the level of the knee|various therapies,for at least 7 days prior to enrollment,5 to <21 years|scheduled,,,,,,
2918,,femoral vein can,iodinated contrast;|participation,,urinary albumin-to-creatinine ratio (uacr),simple inhalation,,,,wright,within three months before fecal sampling|physically,≤ 1.5 × uln;|coagulation function,,,,,,
2919,,impaired mobility,anabolic,,absolute psa value,valvular heart surgery,,,,slides,within 1 year or willingness to get a vision test.||,score <13,,,,,,
2920,,structural disease,angiotensin-converting enzyme inhibitors,,liver enzymes activity,etc;|abnormal ophthalmic examination,,,,suitable to use aaf,within 14 days prior to the start of pyx-106,< 3 months from symptom onset,,,,,,
2921,,uterine anomalies,anti-vascular drug therapy,,interval;|left ventricular ejection fraction,packed red blood cells,,,,early follicular phase,within 8 weeks before first dose of study treatment,between 18 and 75 years.||,,,,,,
2922,,checkpoint inhibitors,enteric steroid therapy,,viral load.|negative hepatitis b surface antigen (hbsag) test,complicated surgery resulting,,,,intra-,in the last year.|objective,at least 7 or more,,,,,,
2923,,complex lymphatic anomalies,anti-hemorrhoidal treatment,,physical status,flow cytometry evaluation of white blood cells,,,,rest,during the trial.|any other circumstances,less than 4 years,,,,,,
2924,,prolonged baseline qtc interval,human serum albumin antibiotics,,samu,resected specimen.|age,,,,etc.)|uncontrolled resting arterial hypertension|history,in the 12 months prior,≥319 pg/ml,,,,,,
2925,,interstitial lung disease.|ni-9,lmca,,559th mdg,pharmacologic boosters cobicistat,,,,adequately treated.|requires,during the open challenge.|written informed consent,i).|definitely positive,,,,,,
2926,,firefighter,lama,,uz gent|signed informed consent|physical,injections|orthopedic surgery,,,,specifically mini mental stateexamination (portuguese version) score,prior to induction of hypertrophy|able,"≥1,500/μl",,,,,,
2927,,signs of cord compression,satralizumab,,moderate level,mini-mental status examination,,,,grade iii/iv,within 30 days prior to baseline,"> 2,5 the normal superior",,,,,,
2928,,intrauterine death,components of the study drug.|impossibility of ct procedure,,emr,endoscopic variceal ligation|colonoscopy,,,,mri.|first,within 4 weeks prior to first dose of study drug|presence,> 60 ml/min,,,,,,
2929,,rheumatoid arthritis.|dialysis treatment.|fingers,lacunar infarction,,creatinine uln,"elective surgery clinic of the university clinical centre in gdansk,",,,,inoculation treatment.||,cycle|more than 6 hours,less than 60 years,,,,,,
2930,,chronic infectious pathologies,membranes|any,,ffpe,keratoplasty,,,,possible,within six months of the first administration date|a person,≥ 30 ml/min/1.73 m2||liver function,,,,,,
2931,,allele,drug-eluting stents,,alt test,pregnancy||,,,,central canal,during or within 12 months after the last treatment,<150 min pa/,,,,,,
2932,,immunotherapy.|measurable lesion,pds,,hemoglobin [hgb],caustic ingestion,,,,aneurysmal type-1 neovascularization,after hematopoietic stem cell transplantation,<= 1.||have,,,,,,
2933,,steven johnson's syndrome,peripheral artery occlusive disease.|pregnancy.|patients,,abdominoplasty;|body mass index,gvhd treatment,,,,booster dose).|participants,over the past 6 months.|subject,">/= 3,000/mm3|platelet count",,,,,,
2934,,health supplementary food,sedative medication,,gmfcs score,indwelling,,,,suitable for surgery.|patients,at 3 months before,>3×upper limit of normal (uln),,,,,,
2935,,etc.)|uncontrolled hypertension,chromium,,tear film breakup time (tfbut),practical running break,,,,american diabetes association,before starting therapy.|patients,less than 50 copies/ml,,,,,,
2936,,grade of alopecia,endoscopists,,bone marrow(≥5% blasts,brain ct-scan,,,,non-dependent,within 30 days prior to inclusion,within normal institutional limits,,,,,,
2937,,ocular pathologies,mro,,modified mc donald criteria|stable,pelvic organ prolapse quantification,,,,de maria,within 12 months;|subjects,126 mg/dl,,,,,,
2938,,chronic kidney disease epidemiology collaboration [ckd-epi,topical steroids|pregnant,,class,dtc:||lenvatinib first-line,,,,muscle growth/hypertrophy,within 2 years prior to the first study drug administration.||abnormal heart function,> 30;|comorbidities,,,,,,
2939,,pacemaker/impantable,systemic anti-cancer chemotherapy,,wish;|endometrioma,mandibular anterior region that may disrupt image quality and thus measurements,,,,cause.|malignant,within 24 hr,18 and more|agreeing to participate,,,,,,
2940,,ocular diseases,investigational vaccines,,ankle instability instrument (aii),rapid eeg,,,,greater than 100,within 24 hours before the first dose of study drug,"level 0, 1)|informed",,,,,,
2941,,public housing hi-rise,inhaled cannabis,,muscle enzyme,cardiology clinics|signed study consent||,,,,third trimester of their pregnancy,for 2 months prior to colonoscopy|the patient,3 and above,,,,,,
2942,,circulatory arrest,prolgolimab,,iga,cases|bad oral health|previous orthodontic treatment,,,,inflammatory systemic disease,within 1 week prior to day 1 therapy|colony-stimulating factors,≤ 1 g,,,,,,
2943,,surgically sterilized.|7,bile acids,,hepatits b core antibodies (hbcab),triplet chemotherapy,,,,suitable for participation in this study,within 30 days prior to the patient enrolment visit,≤ 5 x institutional upper limit of normal|creatinine <2 x,,,,,,
2944,,genetic therapy;|7.the proiferation,strong drugs.|nicotine addiction,,hiv,lumbar puncture,,,,"middle of the night, unable to fall asleep after waking",within 90 days prior to screening;|laser posterior capsulotomy,stage i-iii,,,,,,
2945,,quick dementia rating system,iv|blemish-prone,,prothrombin activity,hpv testing,,,,medicated,within 14 days of the first dose,≥2+ and 24h,,,,,,
2946,,mkis,neurodegenerative disease|antiplatelet,,barcelona clinic liver cancer(bclc,esophageal surgery,,,,non-bone metastatic,during the course of the trial,>14 drinks/week,,,,,,
2947,,multifocal contact lens,mesotherapy,,equivalent);|mmse,orthodontic treatment.|good oral hygiene,,,,systemic av valve|documented,within 72 hours of,>= 40 ml/min|human immunodeficiency virus,,,,,,
2948,,menstrual cessation,urine drugs,,detectable hiv-1 rna,blood thinners|known hypersensitivity,,,,c-ssrs,within 4 weeks before the start of the study dose,≥ 126 mg/dl|a,,,,,,
2949,,breast cancer|primary malignancies,combination chemotherapy,,urine drug test,intra-arterial treatment,,,,cyp3a4,within less than 10 times the elimination half-life of the respective drug,12 to 20 years,,,,,,
2950,,nasopharyngeal nonkeratologic carcinoma,illiterate,,new york presbyterian - weill cornell medicine (nyp-wcm,clear histopathology,,,,condition.|previous,within 1 week prior to enrollment;||vital organ functions,puc).|not more,,,,,,
2951,,organomegaly,nucleic acid amplification (naat),,white count,women|resume surgery,,,,rome iv criteria|to give consent to participate in the study voluntarily|being,within the range of 18.0 to 33.0 kg/m2,> or = 18 years,,,,,,
2952,,anosmia,smallpox vaccine,,pca).|a proximal m2-mca,treatment for alcohol,,,,effective methods of birth control include:|birth control pills,before the completion of brain mri after,≤2 x upper limit of normal (uln),,,,,,
2953,,occupational condition,medications known to interact,,respiratory rate≥,percutaneous cardiac valvular intervention,,,,enrolled eye must,sexual abstinence,≥ 3 unformed,,,,,,
2954,,located.|subjects can hold still,drug use,,united states||,c-ssrs assessment,,,,suitable for the enrollment,prior to surgery.|stages 2-3,≥37 weeks,,,,,,
2955,,burkitt lymphoma,surgery,,hepatitis b core antigen antibody test,cetuximab therapy,,,,psychosomatic,7 days prior to the first dose,above metatarsal,,,,,,
2956,,emotional disturbance.|active infection,eliminate severe,,anne™ limb unit,dme intraocular surgery,,,,non-anaphylactic,in the opinion of the investigator will interfere with the trial.|has,greater than equal to 1.1 cm.|posterior wall thickness,,,,,,
2957,,bone marrow failure syndromes,gliclazide,,karnofsky index (ki,therapy targeting,,,,potentially psychoactive prescription,within this study|life expectancy,≥60ml/min,,,,,,
2958,,good communication,youth teams,,gross motor functional classification scale,vital organs,,,,anomalie del tratto respiratorio,prior 2 months,between 30-65 years,,,,,,
2959,,chronic pulmonary,immune-associated supplements,,hours.|ecmo duration,regular surveillance,,,,opg-induced,in the last 12 months|mental illness,40-60 years|complaints,,,,,,
2960,,criteria of mci,drugs resulting,,best corrected spectacle distance visual acuity,polymerase chain reaction (pcr) assay,,,,reachable,>= 12 months ago,>85 or <50 mmhg,,,,,,
2961,,chronic kidney disease;|risks,sinovac®,,study;|poor graft function (pgf),supplements|participated,,,,hypomania|psychosis|active,in the first or second degree,10-year,,,,,,
2962,,hr|no allergy,metronidazole,,study|human immunodeficiency virus,telemetry monitoring,,,,minimally invasive)|male,during the previous 3 months|known pregnancy|occurrence of,20 - 29.9 kg/m2,,,,,,
2963,,periodontal disease,recombinant),,dsm 5 criteria,marfan,,,,secondary to swn,in the year after enrollment.|portal hypertension,≥160mmhg and/,,,,,,
2964,,mrp2 transporter protein.|all,antihistaminergic sedatives,,rankin score,heated intraperitoneal chemotherapy,,,,documentation.||inclusion,study year,"< 0.5g/l),|previous",,,,,,
2965,,cognitive effects,dapagliflozin,,suicidal ideation|a co-morbid serious health,therapeutic colonoscopy,,,,hydrocortisone replacement,within 4 weeks preceding the start of treatment.|the toxicity of previous anti-tumor treatment,40-100 beats,,,,,,
2966,,serious abnormalities,systemic medication for immune system)|subjects,,inclusion.|human immunodeficiency virus antibody (hivab),"intracranial bleeding,|those",,,,polar h10,in the next three (3),>18 years and <75,,,,,,
2967,,acute infarction,dmard,,body mass index standard|stably use,cd70,,,,scalp,within 28 days prior to the baseline visit,0-1;|at screening,,,,,,
2968,,heart disease|cardiac disorders,contrast media.|patients,,between screen #,sd-oct,,,,evaluation.|in-take,within the past 60 days of assessment,13-18||,,,,,,
2969,,moderate asthma,compounds of similar chemical or biologic composition to peposertib,,enrolment|last hiv test,d2 lymphadenectomy,,,,post-second trimester abortion,within past year,≥25 mmhg,,,,,,
2970,,kidney disease|pregnancy|nursing|pacemakers|metallic cardiac valves|magnetic,lobcavir,,modified neurotoxicity scale,stereotactic therapy,,,,american joint cancer committee (ajcc) cancer,within two weeks or,≥ 30 kg/m2||,,,,,,
2971,,metachronous peritoneal metastasis,carglumic acid,,north star ambulatory assessment,licensed treatment,,,,unstimulated,5 days per week,between 20-90 years,,,,,,
2972,,intramuscular injections.|contact,rotavirus vaccine,,reduced egfr,fgg procedure,,,,suitable for soc therapy,over the next 6 months,stage 4,,,,,,
2973,,thyroid condition.|usage,oral),,nyh classification,liver transplant patients|hiv,,,,more;|high,"within 6 months of visit 2, day 0.|subject",> 480 ms;|patients,,,,,,
2974,,knee oa pain,monetta,,vital signs value,surgery|chronic sinusitis||medications,,,,pregnancy.|elective,within 10 days of enrolment,stage iv nsclc|eligible,,,,,,
2975,,orthodontic treatment;|children,sympathomimetic drug,,liver-enzymes,bulky anterior wall carcinomatosis,,,,superior mesenteric vein,at time of randomization,18-70 y/o,,,,,,
2976,,drug-induced qtcf prolongation,senna,,hpa,external fixation,,,,ambulation|acute,within the last 4 weeks must demonstrate,without,,,,,,
2977,,rheology,sodium hyaluronate;||have,,m2|hemoglobin a1c,systemic antiviral agents,,,,need,within 1 month before signing the informed consent form (,less than 6|patients,,,,,,
2978,,nosebleed,phgg,,"sttac),|ulnar translocation,|kienbӧck disease,|radial",aneurysm clips,,,,non-disease-related,extensive history of,below the 10th percentile,,,,,,
2979,,cancerous pathology,compounds of similar chemical or biologic composition of agen1423,,short cervical length,cardiac color ultrasound,,,,inducers of cyp1a2,within 3 years prior to inclusion,less than 1000 copies/ml,,,,,,
2980,,thinning of the sclera|current eye infection,syphilis antibody,,likelihood of cd19 expression,systemic therapy regimen,,,,under guardianship;|unable to take,within 30 days or 5 half-lives,1-week,,,,,,
2981,,bladder sarcoma,anti-phospholipid,,gestational week,expected difficult intubation,,,,sarcopenia,within 2 weeks of study enrollment|5,^ 9 / l；|absolute neutrophil count (,,,,,,
2982,,mixed conditions|epidermal pigmentation / lentigines,strong p-glycoprotein,,liver fibrosis,germline mutation in cdkn2a,,,,non-steroidal anti-inflammatory drugs,during the screening period.|patients,more than 35 kg/m2|evidence,,,,,,
2983,,lymphatic system disorders,letrozole,,medina,other surgery,,,,plastic,within 3 months ahead.||after v1,>10°,,,,,,
2984,,active,astemizole,,child's class,quality;|target coronary vessels,,,,carbazepine,prior to entry,from 25-34.9 kg/m2.|they,,,,,,
2985,,external genitalia,antiplatelet treatment,,quantitative hepatitis b virus (hbv) dna,reduced exercise tolerance|spirometry,,,,grades ic,last dose,not less than 10,,,,,,
2986,,irreparable rotator cuff tear.||,thrombolytic medication,,nicu concerned|born,mid urethral sling operations,,,,pbh||,less than 30 minutes,18 to 65 years old，when signing the informed consent form,,,,,,
2987,,months|ocular infection,drugs used in this study,,adjuvant setting.|eastern,rotary resection/laser therapy/thrombus,,,,sacral thrust test,after 2 therapy,"over 18 years old,|coming",,,,,,
2988,,systemic diseases|visual acuity,topical ophthalmic steroids.|media opacities,,usg,indigo aspiration system|informed consent,,,,post-transurethral bladder tumor resection,since at least 6 weeks before the screening visit,"≥100,000/mm3",,,,,,
2989,,congenital scoliosis,gelatin,,kaohsiung municipal ta-tung hospital.||,chest x-ray.|eastern,,,,central-line,pelvic,≤2.5 x uln|ast,,,,,,
2990,,vasomotor symptoms,lithium protease inhibitors,,cpk retest,rbc transfusions|failed,,,,apixaban|clinically significant,while receiving study,20 or over,,,,,,
2991,,naturopathic,evolution,,nmibc,prolapse repair surgery,,,,latest vf tests,prior to pet/ct imaging,≥ 28 kg/m2|infertility,,,,,,
2992,,lipid metabolism,local topics,,albumin infusion|serum total bilirubin,fetoscopic procedures,,,,histology|non-visualized,before enrolment;|vaccination with live vaccines,≥90 cm,,,,,,
2993,,shingles virus,agents targeting,,maximal orifice diameter of laa is,gastric band,,,,ada criteria,"at the time of signing the icf.|currently meets diagnostic and statistical manual of mental disorders, 5th edition",been less than 4 weeks from the completion of treatment to the administration of this study,,,,,,
2994,,incapacity,"ivb, resectable",,recist 1.1)|ecog ps,total hip replacement surgery,,,,"adequate dose, duration",for at least 12 months prior,> 3 months)|bmi,,,,,,
2995,,girdle,anti-inflammation drugs,,serum ast,surgical consultation,,,,at risk of causing torsade de pointes,within 7 days prior to study blood,between 19 aged,,,,,,
2996,,wilson's,lpd,,serum m-protein,myopia control,,,,severe)|acute infection|fractures,at least 6 months prior to screening.|elevated serum titers,between tumor,,,,,,
2997,,generalized tonic-clonic/clonic,cardio toxic agents,,criterion.|bilirubin,12-lead ekg,,,,non-prescription/,within the past 2 years;|had,"more than 60 years,|weight equal or exceeded the ideal body weight",,,,,,
2998,,caries dentium,adjunctive bupropion,,perceptual disturbances,regimens of chemotherapy,,,,icd-10 codes i50,within 180 days of study enrollment,between 15 d and 28 d power range||,,,,,,
2999,,obstructive lesion,cyp)3a4 inhibitors,,old|bmi,allogeneic stem-cell transplantation;|risk,,,,glutamic oxaloacetic transaminase,after hospital admission|history of,of 30kg/m2,,,,,,
3000,,burr holes,iud,,hepatitis b surface antigen antibody,valve repair/replacement,,,,diagnostic criteria of sarcopenic obesity,within 6 months of the first study intervention administration,≥ 18 years-old,,,,,,
3001,,teeth|sever,lupus nephritis.|patients,,etc.;|child-pugh,experimental treatment options,,,,deemed stable,during the 24-hour monitoring period|individuals,≥ class iii,,,,,,
3002,,post-allogeneic hematopoietic stem cell transplantation,anti-human immunodeficiency virus,,monoclonal antibodies),cytology,,,,infusion;|severe liver dysfunction,at the hospital,score of ≥7 on the,,,,,,
3003,,sociological condition,colorectal cancer|adequate haematological function,,pain syndrome|cervical foraminal stenosis|cervical disc herniation|herpes zoster||,tmj surgery,,,,applicable,within 14 days of first study drug administration,≥ 5.7%||,,,,,,
3004,,memory impairment (aami),contraindicate extraction,,nyha iii_iv)|cirrhosis child b-c,osteoporotic vertebral fractures.||,,,,preclude successful,at time of signing the written informed consent.||patient,from 0 (clear- no lesion,,,,,,
3005,,chronic inflammatory condition,banned drugs,,diastolic pressure≥100 mmhg,gels,,,,suitable for receiving trns,during medical procedures/tests,ib-iiib,,,,,,
3006,,-risk hypertension,cantonese-,,≤5x uln|ast,renal transplantation,,,,requiring iv antimicrobials,in the operative,≤ 75 years|both sexes|good,,,,,,
3007,,gi disorder,6-mercaptopurine,,urine albumin-creatinine ratio [acr],chronic antibiotic therapy,,,,lasting less than 6 months||,prior to initiation of this study,≤ 1:4,,,,,,
3008,,pnn,age|patients,,child-pugh liver function rating,operation.|pregnancy.|radiation therapy,,,,past-year,within 12 weeks prior to admission visit,≤ 1.5×uln|for,,,,,,
3009,,increased intracranial pressure|intracranial lesion,non-steroidal drugs,,sustained blood pressure (bp),transtibial amputation,,,,insulin pens,during treatment or,≤ 1.5 × uln;|blood creatinine ≤ 1.5 × uln,,,,,,
3010,,intra-cardiac space occupancy,xanthine containing,,serum chemistry panel,unicompartmental knee arthroplasty,,,,strabismic amblyopia,within 7 days of screening.|known hypersensitivity,18-year-old adult,,,,,,
3011,,tumour sample,ppi,,extracorporeal circulatory,focal laser ablation,,,,emergency room on oxygen,within 2 weeks prior to informed,<30 ml/min/1.73 m2)|contraindications,,,,,,
3012,,confluent staining,liver,,men)|platelets,first-line immunization,,,,finger release,qtcf]);|within 3 months before the first dose,over 18 and under 80 years,,,,,,
3013,,interstitial cystitis)|neurological pathologies,therapies,,cotinine saliva,refusal|contraindication,,,,single-cycle degree,at least 4 weeks prior to the first dose of study drug,≥ 45 mmhg,,,,,,
3014,,neurologic symptoms suggestive,drug used,,modified ashworth scale.|children,sentinel node biopsy.|oral,,,,lamina propria,during the last 12 months prior to inclusion.|willing to,below 15 µg/l,,,,,,
3015,,infection.|unable to tolerate,concomitant medication of other therapies of shpt|meet the standard of ipth level,,cgi severity score|patient,discontinuation of antiplatelet drugs,,,,site investigator feels could have an immune modulatory effect.|use of,during the study;|any other diseases,less than 8 cm,,,,,,
3016,,kidney after liver transplant,months|neck pain averaged,,68ga-dotatate pet,breast mri,,,,molar relationship.|normal,at the first administration of ca9hu-1,≥ 20%)||,,,,,,
3017,,liver cirrhosis,contrast media 2- raised,,beck anxiety scale,total hip arthroplasty||,,,,"swan sequence,|ivt by",greater than 200 ml,> 0.1%,,,,,,
3018,,primary immunodeficiency,antiepileptic drugs,,national institute of health stroke scale,talar body fracture|presentation after initial ex-fix placement|unreconstructable,,,,intra-articular corticosteroid injections,within 72 hours of the first dose of study medication,above 1.5)|uncorrectable thrombocytopenia,,,,,,
3019,,hemorrhagic features,fluvastatin,,pregnancy test,meniscectomy,,,,objective fever,within 6 months of registration to the master study.|history of a,> 20 seconds,,,,,,
3020,,conditions resulting,anti platelet therapy,,spinal anesthesia|morbid obesity (bmi,sublobectomy,,,,predominant,after surgery;|cardiopulmonary dysfunction;|immunosuppressive drugs(eg,> 100.4 degrees,,,,,,
3021,,criteria of the american diabetes association (ada):,targeting factor iia,,stop-bang,clinical investigation plan,,,,interpreter services,within 4 weeks prior to initial medication;|have,iv,,,,,,
3022,,primary fracture of the distal radius,medications for treatment of asthma,,international classification of headache disorders 3rd edition.|occipital,visit.|total sara score,,,,any systematic disease,smaller than 4,≥38 weeks)||,,,,,,
3023,,malignant tumors|drug,sglt2 inhibitor family,,peripheral arterial disease|patients,world health organisation (who) classification,,,,highly effective birth control methods,within the previous 18 months,32-37,,,,,,
3024,,central nerve system,prescription drugs,,older|baseline score,dialysis.|renal transplant,,,,radiologically stable,prior to developing covid-19|severe asthma,< 10 cm/,,,,,,
3025,,testing,zanamivir,,required).|age,pathologic documentation of incurable,,,,potent,within 7 days prior to imp,18-70 years,,,,,,
3026,,progressive glomerulonephritis,levomepromazine,,ami,flow cytometry,,,,suitable for inclusion in this study,the previous 2 weeks,2.||,,,,,,
3027,,renal replacement therapy|arterial ph,h2 receptor blockers,,gamma glutamyl transferase [ggt],ionized calcium,,,,non-irradiated,in the month prior to enrollment|use of,c797x,,,,,,
3028,,metabolic diseases,window periods.|receipt,,minimal,hair growth,,,,needing invasive mechanical,for two weeks via self-report,<8||mild,,,,,,
3029,,cin]/cervical carcinoma,ldp,,provincial tb program,endodontic treatment|increased inclination of the maxillary incisors towards the labial|the subject had,,,,sodium,for at least 6 months prior to the screening,1b study||inclusion criteria:||adult,,,,,,
3030,,urinary tract infections|severe skeletal system malformations,women;|patients,,urinary fistula|urinary stones|urogenital cancer|bladder pain syndrome - interstitial cystitis|chronic pelvic pain|had,transthoracic echocardiogram.|known,,,,diseases;|pregnant,during the last 2 months|chlorhexidine,between 25-35 kg/m2|fasting,,,,,,
3031,,aortic aneurysms,desipramine,,hemoglobin ≥9.0 g/dl ast (got),hernia repair,,,,3-agent,more than 2 experts,less than 6 months|mechanical ventilation,,,,,,
3032,,hypothyroid,neutrophil,,steroid refractory,supraclavicular lymph node metastasis,,,,non-prescription medicines,before enrollment;|plan to,< 35%,,,,,,
3033,,motor fluctuations,components of the liquid mixed meal,,human immunodeficiency virus (hiv) (+),small patent ductus arteriosus,,,,sildenafil)||inclusion criteria,before (48 hours,<18 years or >45,,,,,,
3034,,diurnal preference type,vitamins a,,short physical performance battery (sppb),line scoring,,,,≥200 ml,at least 1 week after end of treatment,≥350 cells/ µl,,,,,,
3035,,congenital immunodeficiency disease,online pain portal,,alkaline phosphatase levels,left ventricular dysfunction,,,,low-back pain|office worker||,within 1 week prior to the first dose of investigational,6-17 years,,,,,,
3036,,inadequate organ function,msa|patients,,quantities,brain magnetic resonance imaging,,,,moderately ill,during the study|per the discretion of the investigator,18 to 30 years old,,,,,,
3037,,cyst drainage,medication.|if analgesics,,car-t cell infusion,remote angiographic control,,,,bile drainage,at 4cc/second not possible,>= 100,,,,,,
3038,,f33.2,lidocaine hydrochloride injection,,pembrolizumab + chemotherapy|patient,autologous hematopoietic stem cell transplantation.|patients with,,,,igg4-rd responder index,within 30 days prior to the start,0-3|life expectancy,,,,,,
3039,,autoimmune disease.|topical,storage,,ast/plt,cranial ct,,,,smallpox,at any point during transplantation,2.5 times higher than the upper limits of normal (uln),,,,,,
3040,,fixed residence,tamsulosin,,recist v1.1.|ecog performance score,quality of the data|subject,,,,non-covalent btk,at the time of enrolment.|previous vaccination,>= 60ml/min/1.73m^2||,,,,,,
3041,,behavior disorder,anticoagulant / antiplatelet agents|patients,,smzl,dme|major ocular surgery,,,,pd-l1 inhibitor therapy|autologous stem cell transplant,at least one of the,0-2||participants,,,,,,
3042,,chronic plaque psoriasis,compounds of similar chemical or biologic composition to any agents used in the study.|history of,,who score,pregnant|participates,,,,diagnostic and statistical manual of mental disorders (dsm-5).|participants will be included if they have had at least one,1 to 2 hours after ivt,≥4 (range 0-10,,,,,,
3043,,quantiferon result|quantiferon positive,prescription reimbursements,,who.|age,unresectable advanced,,,,cleft palate,within the normal range can also be included,between 13 and 18 years,,,,,,
3044,,viral disease,hydroxychloroquine sulfate tablets,,histologically,renal artery bypass surgery,,,,staged).||,within 30 days prior to screening|prior enrollment,> 24 hours|written informed consent,,,,,,
3045,,pulmonary tb disease,injectable paclitaxel,,osdi questionnaire score,intravesical chemotherapy,,,,incurable,since the last treatment directed,18-24.9 kg/m2,,,,,,
3046,,situational prophylaxis,hashish,,sars-cov 2 serology,macular laser therapy,,,,definitively treated,past 30-day,<p10 adjusted,,,,,,
3047,,carcinoma in situ treated,over-the-counter products,,"serum potassium, calcium",regular exercise program,,,,sauna,in the last 18 months,from over 18 to under 75 years,,,,,,
3048,,alternative medicine,over-the-counter nsaid use on,,ago,chest disease.|uncontrolled,,,,childhood,during the trial;|donated blood,above 7 ng/ml,,,,,,
3049,,identifiable pathology,5-mthf,,child-pugh c classification,subjective evaluation,,,,agents;|persistent,within previous 6 months|has experienced,before 32 weeks,,,,,,
3050,,bacteriuria threshold,tamiflu®,,protease inhibitor|current,tmd-specific treatment,,,,could alter their periodontal status,within 2 years before study entryknown|central nervous system,medication|high,,,,,,
3051,,not tolerate the standard,moxifloxacin,,international classification of disorders 10th edition,rapid sequence induction,,,,suitable for inclusion.|participants who participated in any other clinical trial within,within 6 months before administration of the first dose of study treatment,above 40 units per liter,,,,,,
3052,,structural heart disease,urine drug abuse tests,,criteria of hanifin and rajka,rescue analgesic drugs,,,,non-registered,at baseline visit or,less than grade 3,,,,,,
3053,,cataract progression,ald,,performance scale (kps),histological types,,,,grade ii obesity,within the past 1 month);|night shift,functional classification|chronic obstructive pulmonary disease,,,,,,
3054,,breast-feeding.|patients,apalutamide treatment||,,10 minutes,facet fixation implant,,,,insulin blood levels,within 7 days before the first administration of the study drug,requires intermittent,,,,,,
3055,,pancreatic tumors,anti-pd-1/anti-pdl-,,htlv1 antibody positive) should,keratorefractive surgery,,,,volar forearm,within 7 days before the first administration;|known allogeneic organ transplantation,greater than 50% of the tumor and does not include,,,,,,
3056,,drainage,il-1 inhibitor,,anti-hepatitis b core antigen (hbc),topical hormone cream applied,,,,ventricular trigeminy,within 6 months before randomization.|with,< 90 ml/min,,,,,,
3057,,virologic failure,sensitive substrates,,calculated value≥,cervical biopsy pathology,,,,low grade prostate cancer,within the past three (3) months prior to enrollment.|coronary artery bypass graft surgery,b to e)|need,,,,,,
3058,,multi-canal).|patients,manage distress,,thalamus|kps score,covid-19 infection|negative testing,,,,nipple-sparing mastectomy,at the time of consent|female participant,18 years and above at time of enrollment|subjects not,,,,,,
3059,,diaphragm diaphragm,igsc,,kosin university gospel,whiplash,,,,≥1 prescription,at term,≥1.5 x uln|ast,,,,,,
3060,,incisional hernia repair,thrombopoietin receptor agonist (tpo-ra,,old;|ecog ps,region-specific treatment,,,,extremely severe,for ≥ 12 weeks prior to screening,nonviable,,,,,,
3061,,allogenic organ transplantation.||active,glucocorticoid containing medication,,dependent gait|aphasia|any hearing,cystectomy,,,,since 2013.|patient having been informed of the research,used to prevent,≥18 years|evidence of,,,,,,
3062,,solid organ transplantation|no initiation,compounds of similar chemical or biologic composition to palbociclib,,fixation surgery.|malignancy.|local infection|psychological problem.|language,consent|active treatment,,,,cytology.|locally advanced,for 5 years prior to the first administration of the study drug,≥200,,,,,,
3063,,respiratory system disease,thrombolytic agents,,"sirs criteria,||• sofa",regorafenib therapy,,,,≥6 months and,during the 4 weeks prior to the start,from 18 to 45 years,,,,,,
3064,,consolidation,azamulin,,cd4+ count,ophthalmologic exam,,,,injection.|prior trabeculectomy,at the time of signing the informed consent.||female participant,=< 2.5 x uln|alanine aminotransferase (alt),,,,,,
3065,,pre-/perimenopausal,antiepileptics,,virus sars-cov-2,eye surgery||,,,,pd-l1+ nsclc,at the time of surgery.|prior history of,>1.5 × uln,,,,,,
3066,,aniridia,conventional implant maintenance protocol;||(iii,,rna test(s,vulnerable.|planned treatment,,,,secondary symptoms).||,at least 1 week before the first dose of study drug.|history of,18 to 49 years,,,,,,
3067,,licensed vaccines,solid organ transplantation;|patients,,twins born,general laparoscopic surgery,,,,do-no-reanimate order,within the study period|any,=< 3 x uln|alanine aminotransferase (alt),,,,,,
3068,,glaucoma|chronic use,dynamic contrast-enhanced,,miglustat-naïve,verbal categorical rating scale,,,,connective tissue conditions,<3 days of exercise,≤1.5×109/l,,,,,,
3069,,thromboprophylaxis treatment|class,3rd metatarsal head (mth),,us);|stage,b-ultrasound,,,,after remission,7 days before first use of the study drug.|subjects,score ≤ 7,,,,,,
3070,,major cancer,proton-pump inhibitors,,nyha class iii heart failure,lymph node have,,,,that significantly affect,within the prior 3 months.|any target vessel,< 26|major,,,,,,
3071,,prepare,anti-ox40 antibody,,alberta stroke program early ct score (aspects),adrenal replacement doses,,,,test treatments|pregnancy,in 4 weeks,>= 3mg/ml)|no,,,,,,
3072,,generalized disease,depression,,la volume,genetic testing||,,,,substance,within 6 months prior to the first administration of study drug,400 to 450 nm use,,,,,,
3073,,weeks|acute lvt,paclitaxel-containing,,rheumatic,cessation,,,,considered measurable if progression has been demonstrated,for at least 90 days after the last dose,≥2 and ≤11,,,,,,
3074,,narcotic tolerance,component of the cell therapy,,hemoglobin a1c [hba1c],extensive clinical examination,,,,il-12.|previous,in the 8 weeks prior to visit 1,6 to 18 years old,,,,,,
3075,,history|relevant disease,hormonal implant,,dfu duration,general anesthesia period,,,,central nervous system (cns,within 7 days of study treatment initiation,between 34 and 78,,,,,,
3076,,index acs,cyp450,,body temperature≥,laparoscopic surgical procedures,,,,visit|pre-bronchodilator,within one week before dosing in each study period,levels of exudate.|pressure ulcers,,,,,,
3077,,malignancy.|patients,vitamin k administration||renal,,bilirubin,viral replication,,,,enrollment;|severe,at time of study enrollment;|non-orthopaedic activity restrictions,16-30,,,,,,
3078,,chronic low back pain,lungmap,,gmfcs level,clicking,,,,clinically significant opacification of the,within 7 days of first dosing,≥ 60 ml / min,,,,,,
3079,,sleep disorder,fridericia formula,,moderate stress level,nephritis.|history,,,,contraceptive diaphragms,within 6 weeks before the study.|current smoker of,≥96 mm hg,,,,,,
3080,,viral infections).|aids,roxatidine,,lipemic plasma,venous blood sampling.||,,,,unfractionated,at the time of screening|cirrhosis,between january 2023 to january 2024.||,,,,,,
3081,,aids/hiv,cd137 agonists,,contrast|71260 - ct w/,cirrhotic portal hypertension;|ultrasound,,,,convalescent,within 14 days prior to study blood,1- metastatic,,,,,,
3082,,non-epithelial tumors,neo(adjuvant,,inclusive).||body mass index,fagotti endoscopic score,,,,suspicion thereof,following:||2-1,>60 ml/min.|atrial,,,,,,
3083,,oa,anxiety perfectionist,,urinary test,percutaneous valve intervention ≤30 days or planned.|angina pectoris ≤30 days.|any cardiovascular procedure,,,,protocol section,within 7 days before entering the group.|drug abuse,< grade 2|step,,,,,,
3084,,dysgeusia,prone,,node,orthodontic therapy|patients,,,,pancreatic,at least 3 days per week and 4 hours per day at which the participant,≥ 15% after crt-d implantation,,,,,,
3085,,persistence oxygen dependency,eltrombopag,,extend period beyond 8,background therapy,,,,multigated,3 months onset from,≥200 ml),,,,,,
3086,,locomotor disorders,prescription drug,,hepatitis c tests.||abnormal,laparoscopic liver surgery,,,,non-caused,within 4 weeks prior to the start of the study|alcohol abuse,> 200 ug/,,,,,,
3087,,schizophrenia spectrum disorders,anti-lag-3 agent,,1.voluntarily enrolled,standard dental implant (diameter >4mm)|age,,,,fractures,"at all times, even after a vasectomy",>50 g/d,,,,,,
3088,,renal mri|high,urine drug test,,shoulder region|history,initiation of therapy,,,,central nervous system infection,within 30 minutes,"<1,500/mm^3",,,,,,
3089,,treatment refractory,compounds of similar chemical or biologic composition to tigilanol tiglate,,left subclavian artery;|heart transplant,health assessment form),,,,lumbar spondylolisthesis|previous,at least 1 hours|an,< 3 g/dl,,,,,,
3090,,sleep disorder - particularly,drugs for xerostomia,,visual analog scale (eva),transarterial chemoembolization (tace),,,,syndromes|not treated regularly with cannabis.|is ready to stop taking central nervous system medications,at time of entry into the exposure event,> 90 percentile,,,,,,
3091,,ids,spironolactone,,who,inotropic support|participants,,,,clinically significant cirrhosis;||14,within 4 weeks prior to the first dose of the study drug.|have,from 14 to 70 years-old|ecog,,,,,,
3092,,urinary retention|concomitant intravesical botulinum injections|concomitant prolapse surgery|known,dermabrasion,,plasma albumin,heart rate [hr],,,,with curative intent|documented hr +/ her2- tumor,within 30 days after surgery;|need,≥ 50 ml/min;|left,,,,,,
3093,,exudative lymphocytic pleural effusion,sodium chlorite,,symptom severity scale,limit.|immunosuppressive therapy,,,,melanoma|locally advanced,over the past 60 days|heavy,class iv,,,,,,
3094,,inflammatory autoimmune disease,next organ,,plt count,hours;|coronary angiography,,,,low grade gliomas,within 3 months prior to study vaccine,≥ 1.5 × 10^9/l|platelets,,,,,,
3095,,systemic blood diseases,antidepressant drugs,,"hepatitis b & c, hiv|severe",imaging assessment,,,,ibs-symptom,within 2 weeks before screening,> 3 x,,,,,,
3096,,valvular heart disease|patients,diethylenetriamine pentaacetate,,hepatitis c infection.|hiv infection.|other commodities,chest radiography,,,,could significantly impair cognition,in the last 6 weeks,-t2a,,,,,,
3097,,infective processes|have cancer,medications used in this study,,metabolic equivalents,triazole prophylaxis,,,,non-magnetic,more than 0.08 sec,greater than 18 years|provides care,,,,,,
3098,,tumor archival,aimovig®)|galcanezumab,,recist 1.1 criteria,gastric cancer;|recurrent gastric cancer,,,,m2 to m3,for at least the past 90 days||non-inclusion,<10,,,,,,
3099,,mss disease,any antipsychotics,,modified medical research council dyspnea scale rating,dysmorphology examination,,,,non-hodgkin's lymphoma,in 24 hours.|taking supplemental probiotics,>8%|alt,,,,,,
3100,,alcohol use|volunteer to participate,3rd year,,cmv dna test,single-breath method.|at,,,,admission|n-terminal prohormone,at least one prior,0 or 1 measurable disease,,,,,,
3101,,power fields x,exemestane,,anti-hbs,left internal thoracic artery,,,,pregnancy|previous,in the past 12 months,3.1-6.0,,,,,,
3102,,judged by the investigator as clinically significant,hyperglycemic hyperosmolar state,,fibronectine test,anticoagulation on emergency department assessment,,,,inducer of cytochrome p450 (cyp) 3a4,at time of screening|participation,> 18|histologically confirmed,,,,,,
3103,,or|lactate dehydrogenase (ldh),drugs that could affect cognitive function,,uh cmc,intestinal volvulus,,,,upper limb strength,for at least 6 months prior to enrollment,0-2;|survival,,,,,,
3104,,alcohol dependence syndrome,confirmed)||or||2b,,between the,arthroplasty surgery,,,,qi|current unstable diagnosis,more than 5 years prior to enrollment.|any,less than 3 months.|subject,,,,,,
3105,,judged by the investigator to be unsuitable for the study,local multidisciplinary heart team||-+undergoing tavr for bioprosthetic aortic valve failure,,etc.)|body mass index,tme therapies.||,,,,above|genetically confirmed,at the time of screening,2018|23-80 years,,,,,,
3106,,italy,tobacco intoxication|congestive heart failure|cerebrovascular disease,,ecg results,assessment method,,,,version 2022)|no history,within ≥ 3 months prior to the study treatment|serum calcitonin,<3 month|hypersensitivity,,,,,,
3107,,distinct ring-like pattern of contrast enhancement,lixisenatide,,symptoms.|tsh levels,verbal barrier,,,,mild medical conditions,within 4 weeks before the screening,> 0.2ng/ml,,,,,,
3108,,open thoracic,anti-vegf agent,,nli,consistent from screening though the entire study duration.|consistent use of,,,,breastfeeding.|active,for 3 weeks after injection of [18f]geh121224|life expectancy,above 40 unit per liter (u/l,,,,,,
3109,,hospitalized|patients,intravenous amino-bisphosphonates.|active infection,,syndrome;|acute gvhd,bladder surgery,,,,hypothalamic-pituitary level,at the time of study entry.|eastern,efficient,,,,,,
3110,,chronic hbv,including:||hemodynamic measures,,dbs technology,ehr review,,,,self-application of vaginal products,during the preceding 4 weeks,"between october 1, 2015",,,,,,
3111,,s/p lumpectomy,ultram,,post-traumatic stress disorder checklist,enteral feeds|on invasive,,,,occlusal,within 12 months after receiving the last treatment.|presence of measurable,≥ 2×109/l,,,,,,
3112,,hcra,nicotine user,,best corrected monocular snellen visual acuity,inoculated,,,,single bacterial species,within 28 days before using the investigational products,18.5-32.0 kg/m2,,,,,,
3113,,dupuytren's contractures,tolbutamide,,emg,tuberculosis|pregnant,,,,american college of rheumatology [acr],within 1 year before,score 0 or 1.|histologically,,,,,,
3114,,disease.|active bacterial,mineralocorticoid antagonists,,mek protein kinase inhibitors;|use,blood transfusion requirement,,,,acr/eular,within 3 months before screening.|new york heart association,outside the normal range,,,,,,
3115,,urinary dysfunction|history of urinary,bypass,,stool,safe placement,,,,self-report|patient,in the last 3 months,more than 3 months.|subjects,,,,,,
3116,,early-stage,otc drug,,samples.|age,laboratory testing,,,,ethanol,"within 5 years,|able to read",greater than or equal to 3 x uln,,,,,,
3117,,cf pulmonary therapy,scheie,,serum hdl-c,denosumab injection,,,,intra-aortic balloon pump - iabp,in past 12 months,female).|non,,,,,,
3118,,ovary|ability,dufss,,international normalized ratio (inr)≤ 2×uln;|8,dialysis before surgery,,,,influence the outcome of the study,at time of enrolment|participant,≥100×10^9 /l,,,,,,
3119,,sugar free,systemic anti-cancer therapy,,hcv antibodies).||,exam,,,,in remission,between completion of cns-directed therapy,≥ 8.0 g/dl.|ast,,,,,,
3120,,thromboembolic events,training,,human serum albumin (hsa),old;|chest ct showed pulmonary nodule,,,,neglected,within 6 months prior to initiation of treatment - including,=kg/cm2)<30%,,,,,,
3121,,supplemental nam,naväge®,,platelet function,criterion related,,,,preclude needle biopsy,within the past twelve months.|condition,< 2 weeks,,,,,,
3122,,ctcae grade ≤1,mrg003,,ecog status,antifungal treatment,,,,full-thickness dfu,during the same timeframe,≤2,,,,,,
3123,,fm,sacituzumab,,international association of pancreatology/american pancreatic association,kidney stones,,,,afc<5,at least 6 weeks before the screening visit,16 -45 years,,,,,,
3124,,non-placental cause,pelvis|self-reported,,esrd,albuterol,,,,supraventricular,within 30 days,<60 percent,,,,,,
3125,,osteomyelitis|diabetic peripheral neuropathy|homozygous familial,seville oranges.|star fruit.|malabsorption syndrome,,nantes university hospital.||,thoracic surgery branch.|participant,,,,inter-current illness,in the last five (05),below 100 x 109/l,,,,,,
3126,,epileptic seizures,phytoestrogen supplements,,bone marrow/liver,brain imaging|without unidentified,,,,intra-abdominal metastasis,within 12 weeks before the first drug;|received targeted therapy,"700 g to less than or equal to 1,250 g|appropriate birth weight",,,,,,
3127,,individual seizures,lidocaine hcl,,electrophysiology procedure|post procedure bedrest plan,tracheosthomy,,,,h2-receptor antagonists/h2 blockers,less than 14 days old,less than 2,,,,,,
3128,,adjustments,alcoholic products,,national eye institute scale,scn1a mutation,,,,moderate overjet,"between 8 and 30, inclusive",from 20 to 65 years old,,,,,,
3129,,mixed dentition,enrollment;|therapeutic antibiotics,,serum pregnancy test,treatment-related,,,,ms)|previous,within 24 hours after first symptoms||,<5.7,,,,,,
3130,,weight loss program,conventional therapy||,,mean arterial pressure,salvage radiotherapy,,,,non-hormonal contraceptive methods,within 1 year after the first transplantation;|patients,> or = to 4 mm,,,,,,
3131,,hepatitis c infection|recipients,component present,,antibodies or fusion,hepatic arterial infusion,,,,kindergarten level,larger than 1.5 cm||,> 18 months,,,,,,
3132,,blood cultures,over-the-counter,,t4 levels,ac,,,,central review,within 2 weeks prior to enrollment.||7,18-40 healthy,,,,,,
3133,,nuclear sclerosis,pmr,,tanning,health screen,,,,ibs-d rome iv,within the time period specified per,between 17-30 kg/m2||,,,,,,
3134,,dairy products|smokers|visits,hairs,,psilocybin,antiretroviral therapy (art) regimen,,,,booster dose injection,within 3 months before screening;|use,=< 3 × institutional,,,,,,
3135,,bladder neck.|previous treatment,monoclonal antibody therapies,,uln)|serum bilirubin,standard induction therapy,,,,assess,within 6 months prior to the screening visit,≥ 18 years old,,,,,,
3136,,cardiovascular-related diseases,physiological corticosteroid replacement therapy,,form||,unique treatment options,,,,below the laboratory lower limit of normal on most,at least 3 minor,≥ 100 x10^9/l,,,,,,
3137,,criteria of csvd,lenalidomide should,,noted,trial|previous treatment,,,,clinically significantly less than lower limits of normal,within 8 weeks prior to screening.|participated,ios 8.0 or higher,,,,,,
3138,,cardiac failure,aziatropin,,heart rate increase from,primary care,,,,ckd stages,during the 3 days prior to study start|immunosuppressors,not more than six weeks,,,,,,
3139,,results|glaucoma,anticoagulant,,infarction|baseline qt interval,endocorporeal laser lithotripsy|using a reference laser (holmium:,,,,old;|secondary,within the year prior to the first dose of study drug.|history of,spermicide.|patient's,,,,,,
3140,,multiple lesions,nivolumab/sindilizumab/tirelizumab,,serology for hepatitis b surface antigen,scalp reductions.|concurrent,,,,first trimester,for at least 12 months after their last study treatment.|negative hiv test,long-term chronic diarrhea,,,,,,
3141,,inflammatory bowel disease (ibd),short acting beta2 agonist,,forced expiratory volume in 1 second (fev1)60-80%.|children,transfusion are permitted,,,,de novo cohort,within 7 days before starting therapy,<30 cc/min/1.73 m2,,,,,,
3142,,tendon rupture,zonisamide,,tlco,bone marrow blasts.|pregnancy,,,,protocol prohibited,for 24 hours prior to all study visits.|individuals,24-27.9;|blood,,,,,,
3143,,"renal dysmetabolism,|hypothyroidism",ibrutinib,,cardiac measurement device|competent,series covid-19 vaccine,,,,influence glucose metabolism or appetite,after childbirth,more than 18 years old|asa i,,,,,,
3144,,situs inversus,local anesthetic allergy|patients,,has-bled,recto-vaginal fistula|previous anorectal posterior compartment,,,,day|intraoperative,within 7 days before study enrollment,>3 times upper limit of normal (unl),,,,,,
3145,,functional impairment,postpartum antibiotic therapy,,laz,epuap,,,,large vessel occlusion.|national,within 3 months prior to randomization|infiltrative,=< 14 days prior to registration)|platelet count,,,,,,
3146,,chronic pulmonary aspergillus disease,bevacizumab treatment||,,prothrombin time>15s;|diagnosed primary liver,bilateral pulmonary artery banding,,,,upper limbs,within a 4-week period before first dosing|any uncontrolled,>25%,,,,,,
3147,,malignant,ephedrine,,ctcae 5.0 standard,"trauma,|any surgery",,,,symptoms|significant,at the time of screening.|acute,less than or equal to 40,,,,,,
3148,,follicular aspiration,efavirenz,,romantic partner||inclusion criteria,caloric restriction,,,,second trimester of pregnancy,within 6 months prior to randomization|significant,"before 37 weeks of pregnancy),|not",,,,,,
3149,,breast cancer|locally advanced,lumbar origin,,national task group-early detection screen for dementia (ntg-edsd).|disclosure,refusal of surgery,,,,cd4 count,life time history,>= 70|life expectancy,,,,,,
3150,,anti human immunodeficiency virus (hiv) antibody positive,immunosuppressive doses,,ffpe tissue block,eye surgery,,,,teratogenic effects of fdg in addition to the radiation exposure,management of the two malignancies.||all patients and/or their parents or legal guardians must sign a written informed,18 or older,,,,,,
3151,,endobronchial disease,drug screening,,covid-19 test,pet/ct scan,,,,secondary to another,within 14 days prior to the first dose.|patients,< 60ml/min).|suffering,,,,,,
3152,,significant scarring,drugs abuse,,cuff size,chronic steroid therapy,,,,extra corporeal,at least 4 months.|participants,"?""",,,,,,
3153,,suicidal intent,pentoxifylline,,registration)|absolute neutrophil count (,placental position|scheduled,,,,face-to-face sessions.|additionally,within 4 months before day,20-65 healthy,,,,,,
3154,,asd|want,c7 by indirect immunofluorescence (iif),,tumour size,rrms,,,,low-food access,for at least 3 years before enrollment on this,scores of 0-3,,,,,,
3155,,cd137,irregular menstruation,,forced expiratory volume (fev1),oropharyngeal swab,,,,rectal,for 3 months prior to participation.|participant,< 3 × uln|aspartate aminotransferase,,,,,,
3156,,autoimmune disease.||note,ghb,,quantitative,fragile x,,,,implanted into the skin||combination method,in the month prior to screening|living,> 1.2 mg/dl,,,,,,
3157,,psychological conditions,apixaban targeting factor xa],,kps)≥,platelet transfusions,,,,low dose of,before treatment,≥ 30 kg/,,,,,,
3158,,sinus cancer|pregnancy,nonsteroidal antiinflammatory drug (nsaids),,drug burden index score,eighty cervical spondylosis,,,,required amount,at least 2 weeks before randomization|there were hydrothorax,≥ 3.5 mmol/l,,,,,,
3159,,good general health|selected teeth should,thalidomide,,human immunodeficiency virus antibody,harmonic endoscopic ultrasound imaging,,,,hormone-dependent,"within the last 6 months,|severe",>90/min|respiratory rate,,,,,,
3160,,kidney disease|temporary,mao inhibitors,,abdominal height,suctioning,,,,sever,previous 5 years|previous medical assisted reproduction technique|lynch syndrome,≤ 75 years|histologically,,,,,,
3161,,child's,anamnesis,,adc,cytokine therapy,,,,non-cleft craniofacial surgery,within 6 months prior to dosing.||parts,hallway',,,,,,
3162,,type b aortic dissection (tbad),atazanavir,,liver function:||(3,natural air environment,,,,primitive tumour|at least one,within the last 12 months prior to screening,i-ii group|scheduled,,,,,,
3163,,nonlactating,angiotensin receptor blockers (,,t1,revision knee arthroplasty,,,,intra-venous bisphosphonates,prior to this study:||severe,> 10 degrees)|severe,,,,,,
3164,,clinical condition|no parental,medications containing pde-5,,ncws frequency in these subjects,section 5.1.8,,,,cigar equivalents,in the past 14 days|not being able to travel to,"< 2,000 iu/ml or < 10,000 copies/ml",,,,,,
3165,,growth factor support therapy,trial-related intervention.|high,,overall apnea-hypopnea index|reduced cognition,exercise sessions.|reporting suboptimal clinical benefits,,,,amenable to revascularization|uncorrectable bleeding diathesis|evidence,continue to have,≥ iv,,,,,,
3166,,prostate cancer.|a positive test,casirivimab,,expansion|absolute neutrophil count,ayurvedic,,,,requiring iv diuretics,within 90 days|pci,6-10 years,,,,,,
3167,,hematologic toxicity,cytosine-adenine-guanine,,troponin negative,lvad therapy,,,,induced,within 1 month prior to first dose.|have evidence of,> 1).|pregnant,,,,,,
3168,,lens,glycoprotein inhibitors,,pta,colchicine therapy,,,,amenable to surgical therapy.|a,"within the last 3 months,|use",>17,,,,,,
3169,,liver stiffness measurements,nitrates,,ind,intramuscular injection,,,,secondary to extrinsic compression,post operative,"greater than 5,000 mg/g.|the",,,,,,
3170,,alzheimer's disease,human albumin,,bone broth diet book,foreign body,,,,drug use,during the 76 week study,20 ≤ age ≤ 75 years,,,,,,
3171,,hla typing,topical bpo,,expression;|ecog score,consent.|karnofsky performance status (kps),,,,escherichia coli,at time of esg)|patients,> 4 hours per night,,,,,,
3172,,huntington's,conventional treatments - both maximally tolerated doses of anti- arrhythmic drugs,,old|unresectable histologically,reverse transcription - polymerase chain reaction(rt -pcr,,,,3 degree,within 1 year prior to index pci|active,between aged,,,,,,
3173,,intraepithelial neoplasia,retinopathy.|diabetes|hypertension|or,,gamma glutamyltransferase (gamma-ggt,treated for dysrhythmias,,,,self-report.|suspected,within the next 60 days|a,≥ 25 kg / m2)|willing,,,,,,
3174,,white petrolatum,mct,,niraparib|normal blood pressure,bone metastases.||patients,,,,mandibular jaw that permits the placement,prior to first dose of ipilimumab,17.5 mmol/l,,,,,,
3175,,chronic oxygen requirement,immune prophylaxis,,progesterone receptor staining,periapical radiograph,,,,connective tissue,within three months of first,patients|50 years,,,,,,
3176,,anhedonia factor score;|a,immunoglobulin g (igg) positive)|detectable interferon,,inclusion|trans meridian travel,hemolysis|≥1 packed red blood cell (prbc),,,,site of fistulous dural sinus.|patient with,for at least 6 weeks before first dose of study treatment,more than 5% of the body surface,,,,,,
3177,,singleton pregnancies|at term,regorafenib,,calculated score,mastectomy,,,,technical ability,up to 2 g daily).|depot,< 0.1ng/ml,,,,,,
3178,,hepatic carcinoma,histologically,,hcc size,imaging studies,,,,bones,within 4 weeks prior to the baseline visit,>2500 copies/ml or>500 iu/ml,,,,,,
3179,,cirrhosis.|participants,needle dizzy blood,,prothrombin international normalized ratio,secondary knee osteoarthritis|patients,,,,suitable to participate in this study,"prior to index acs event,",18-50 years,,,,,,
3180,,neurodegenerative pathology,liver ultrasonography).||,,seal™ system device,art,,,,stage iv heart,within 7 days of patient inclusion,< 50 ml/minute/1.73 m2,,,,,,
3181,,lack the,endostatin,,coagulation function test,invasive sampling procedures,,,,self-reported change in body weight,before inclusion or going to start,> nadir + 2 ng/ml,,,,,,
3182,,cdk4/6 inhibitor|pregnancy,cisplatin based|gynecologic cancer,,organ function requirements,laboratory examination,,,,american joint committee on cancer (ajcc) cancer,after consent);|has,35 years or older.|for gwi cases,,,,,,
3183,,"neurological disease,|obese",dermatologist;|ustekinumab,,tips,heart failure)|planned surgery,,,,abnormal,throughout the intervention period;|receiving any physiotherapy intervention;|major vascular complications,greater than the upper limit of the normal value,,,,,,
3184,,"etc.),|sterile transparent film",peptide-1 analogues|lithium|diphenhydramine|dopamine,,body mass index [bmi],abdominal computed tomography in emergency department for trauma,,,,rotavirus vaccine,at least 6 months before randomization,> 23|performance,,,,,,
3185,,systemic therapy.|her2 mutation,study agent,,diastolic function,ltbi treatment,,,,iic,at least 1 week prior to study drug administration,>18 years;|absence of structured physical activity,,,,,,
3186,,appendiceal cancer,tnf-α therapy,,phq-9m,pis,,,,uncontrolled systemic,for 6 month intervention period||,≥ 3 months;|there,,,,,,
3187,,cardiac syndrome,aspirin|pregnant,,asat,1 full cycle,,,,protocol-defined,for 180 days after the last dose of study,>=85% bmi,,,,,,
3188,,mpox infection,calcineurin inhibitor,,total bilirubin ≤3 times upper limit of normal,remote,,,,primary desire|selects concentration,during the past 30 days prior to the baseline visit,>3 times the upper limit of normal [uln,,,,,,
3189,,medical history||,ngs testing,,mean arterial blood pressure,chemo-radiotherapy,,,,suitable for participating in this clinical study,at the time of initial study vaccination.|prior to study vaccination,2.5 x or less unl (upper limit of normal);|creatinine clearance,,,,,,
3190,,akp,formalin-fixed,,gamma-glutamyl transferase (ggt),evd system removed,,,,insulin-sensitizing medications,in the previous year|deep vein thrombosis|cardiovascular disorders,under 17 years||,,,,,,
3191,,leukapheresis,foscarnet,,mucositis grades,test drugs,,,,athletes|national,within the last 6 months.||5,greater than 45 ml/min/1.73m2.||(5,,,,,,
3192,,malaria prophylaxis,combine,,beijing,control leukocytosis,,,,signaled,within institutional normal limits,being 60 years,,,,,,
3193,,back from the service to the intensive care unit,inhaled insulin,,quantiferon® tuberculosis test|patients,cytologically-,,,,ipsilateral leg|second-look knee arthroplasty|inability to communicate,at least twice 3 months apart of,greater than equal to 95 g⁄m^2,,,,,,
3194,,end stage hepatic,antidepressant medications,,b-hb,adjuvant imatinib treatment||neutrophil,,,,insulin dosing regimen,in the 7 days prior to enrollment|mechanical valve,30-65,,,,,,
3195,,bone trauma,beta receptors,,ctcae1 grade,clinical role,,,,suitable for nasal administration,during the study period||*is eligible for,>/=8,,,,,,
3196,,weaves,angiotensin ii receptor blocker (arb),,hbv dna.|ecog physical fitness score,barrier methods of contraception,,,,medically-confirmed,within 4 weeks before starting protocol treatment.|complications,>= 1.5x10^9/l,,,,,,
3197,,neurological pathology|clinical depressive syndrome|high,mirapex®,,lsas,pdt treatment,,,,non-invasive ventilation,within 14 days prior to the first administration of the study drug.|hiv infection,≥ 15 to ≤ 29 ml/min/1.73 m^2|moderate,,,,,,
3198,,accessible metastatic lesion,drugs used,,new york heart association functional classification,frozen blastocyst transfer.|maternal,,,,pdl1,for more than 96 hours,28-31 to separate individuals with,,,,,,
3199,,skin conditions.|history,compounds of chemical or biologic composition similar,,b lymphocytes count,arthroscopic cuff repair surgery|american society of anaesthesiologists (asa) physical status,,,,cirrhosis)|high,for at least 18 months,<100×10^9/l;|history,,,,,,
3200,,hypertension.|suffering from coagulation disorders,outside institution of,,/l|platelet count,mutations leading,,,,low level of platelet count.|patients,in the three months prior to potential study booster vaccination.|study staff and their relatives.|have a history of a,< 6 month ago|initiation of,,,,,,
3201,,cerebral vasoconstriction syndrome,anti-angiogenic small molecule targeted drugs,,ginkgo biloba,primary laser demarcation,,,,slow-release sodium chloride,within 7 days of enrollment,between 18 and 120 years,,,,,,
3202,,immunodeficiency syndromes,trial-related,,iup,spontaneously resolve,,,,platinum-resistant ovarian cancer,within 2 weeks after the end of the study;|individuals,> 450 msec|pr,,,,,,
3203,,formula|hepatic disease,injectable medications,,maximum mean modified gingival index (mgi),richmond agitation-sedation scale,,,,nihss)|clinically relevant,after liver-,< 1/10,,,,,,
3204,,dry eye disease,drug under investigation,,ankle instability|history,medical conditions||corrected,,,,prominent,within 4 weeks before the first dose of the investigational,between 18 and 25 kg/m²|non,,,,,,
3205,,acute anal fissure,antioxidants,,glycosylated haemoglobin (hba1c),chest tube placement,,,,evolution,in the last 3 months.|catabolic diseases,>= 18 years|ecog,,,,,,
3206,,diabetes mellitus|immune diseases|patients,daxas,,quantitative rt-pcr results of bcr mrna::abl1 available,flc assay,,,,grade i-iii,within the lower half of the specified range of use||subject,between 12 and 18 years,,,,,,
3207,,medical conditions||sick sinus syndrome|atrioventricular,sunflower,,portsmouth hospitals university nhs trust||,mvpa every,,,,table 5||,longer hospital stay after surgery|prior surgery,> 1.5x10ˆ9 /l,,,,,,
3208,,glucose metabolism,steroids-,,serum pregnancy test||agreement,optic nerve organs,,,,ultra-rapid acting lispro,within 5 years before the first administration,0-1;|child-pugh class,,,,,,
3209,,apnea,nellis afb,,stroke|creatinine clearance,24-hour urine collection for the determination,,,,high-risk factors,at time of consent|willing and able to comply with the protocol,>/= 18 years|>/= 2,,,,,,
3210,,unclassified colitis,pelvic surgery|intrauterine,,indocyanine green test,joint fluid analysis,,,,non-compliant);|the subject is,within 7 days of day,≥ 60 ml/min/1.73m2,,,,,,
3211,,arterial line,vasospasm);|it,,brest university hospital,behavioral treatment,,,,interferes with functional activities,within at least 3 months after the last dose of fs-1502,> 1 cm and < 25 cm|patient can understand,,,,,,
3212,,life-threatening disease,aristolochic acid,,defect size,thecardiac surgery department of,,,,interferes with cognitive testing|vision impairment,past 30 days or less than 5 half lives of the investigational product,-10 diopters or higher,,,,,,
3213,,leptomeningeal disease.|active tuberculosis.|significant,cytochrome p450,,braf mutational status.|who performance status,1 scan,,,,middle,past 3 months before enrolment|female,20-80 years,,,,,,
3214,,viral infection,topoisomerase inhibitors,,t)|creatinine clearance,organic cause has been,,,,temperature|poor healing,within 5 years prior to screening;|patients,>5 years,,,,,,
3215,,neural tube defects.|the unborn child suffer,components of,,pvr,routine follow-up visit,,,,patch site,within 6 weeks of initiation of therapy,≥ 50 x 109/l,,,,,,
3216,,htn,drugs used in this program,,ct chest|patients,wechsler intelligence scale,,,,cruciate ligament,prior to randomization.|known endocarditis,≥80% of patient,,,,,,
3217,,stage t1c,anticoagulants.|if,,criteria of guidelines,total knee arthroplasty surgery,,,,clinically significant illness,at least 5 years before,>1.8.|available angiosuite.|cbf < 30%,,,,,,
3218,,computer||,nephrectomy,,cgi-s,infection control,,,,primary radiation).|psma pet/ct,during the time of planned,13d,,,,,,
3219,,pregnancy induced,beta-blockers.|failed spinal anesthesia.|conversion,,diastolic blood pressures,sedative therapy,,,,endanger the patient,within 12 hours of,45-70 mmol/,,,,,,
3220,,chronic disease.|diagnosed,ketamine drugs,,cranial form|absence,pelvic radiation therapy|rectal cancer,,,,table 1,within one month before enrollment;|for the benefit of the subject,>5||,,,,,,
3221,,secondary parkinsonism,triton-x-100).|any contraindication,,average air-bone-gaps,study|systemic therapy,,,,hcv-associated fatty liver,within 60 days before enrolment,<120,,,,,,
3222,,surgically resectable,sulconazole,,hbv-dna copy number,sedation medication||exclusion,,,,awgs 2019 consensus update,in the last 2 months before the study||,more than 30 g/ day,,,,,,
3223,,to:||acute coronary syndrome,local anesthetic agnets|previous lumbar spine surgery,,maximum serum creatinine,pelvic lymph node metastases,,,,distal limb,on the day of vaccination deemed,18 to 90 years.|patents,,,,,,
3224,,mm.||exclusion criteria:||known allergy,cyp2c8 inducers,,uk universities,lymph node progression,,,,age|patients,within the last two weeks.|treatment,over 18 years|history of laboratory-confirmed,,,,,,
3225,,type 2 diabetes recorded,secondary mh,,serum creatinine ≤1.5×uln；||all,employ adequate contraception,,,,central nervous system manifestations,after therapy for brain metastases,≥ 3.0,,,,,,
3226,,renal disease.|sensitized,corticosteroid treatment|active malignancy,,ethinylestradiol/etonogestrel-releasing,vaccine vaccination,,,,infection|active hepatitis c|refusal,within 30 days prior to screening|exposure,= 0.85 x,,,,,,
3227,,diabetes;|uncontrolled hypertension,gentamicin,,heart transplantation.||class,blood thinners|patients,,,,≥2|uncontrolled,prior to participation,<18 or >30 kg/m2.|participants,,,,,,
3228,,benign prostatic obstruction;|patients,statins,,nci-ctcaev5.0 grade,venous puncture blood,,,,antihypertensive drugs;|genetic,week 8 related to participant safety,14-26,,,,,,
3229,,dysplastic barrett's oesophagus|participants,technology,,national cancer institute general adverse event term 5.0 (nci ctcae v5.0) level 1 toxicity,transfemoral tavi|emergent tavi|noncardiovascular comorbidity reducing life expectancy,,,,liver,with the exception of basalioma/spinalioma of the skin,0 to 1;|life expectancy,,,,,,
3230,,dental loss,stimulant medications,,physical activity,ts:||• diagnosis,,,,untreated,within the 4 weeks prior to screening,= 7,,,,,,
3231,,aids-defining conditions,anti-hypertensive medications.|current,,international normalized ratio (inr)≥1.5),stent implantation operation,,,,approximately 2000 kcal/day,48 hours prior to the expected initial application,> 220 db/m).|bmi,,,,,,
3232,,"unresectable hcc,|(b",lansky play-performance scale,,mbs,immunomodulatory imide drug,,,,perpendicular,during the last 3 months|tuberculosis,>= 18 years.||patients must exhibit,,,,,,
3233,,dysfunction of vital organs,syndrome;|patients,,lille university hospital|age>= 18 years|patients having expressed their non opposition||,intermetatarsal treatment,,,,restrictive,within the three months before screening;|specific restrictive,red flag,,,,,,
3234,,esophageal fistula,components of study,,asa-ps,biological related parents||,,,,unknown origin.|patients receiving,while on treatment,≥ 18;|ischemic stroke,,,,,,
3235,,etc.)|major psychiatric illness,low vitamin d levels,,kidney function/heart,hepatic resections,,,,randomization|pregnant,within the last two weeks prior to the study,> 8|18-70 years,,,,,,
3236,,iatrogenic immune deficiency,low potency topical steroids,,modified rano criteria||,chemo-therapy,,,,oligo-ovulation,for the first time|agree to participate,<75 x109 /l|white,,,,,,
3237,,severe mental disorders,anti-hbs,,international normalized ratio ≤1x upper limit of normal,electrocardiographic,,,,torsade de,for at least 6 months after the last dose of study,iii-iv)|bleeding,,,,,,
3238,,retinal vein occlusion;|evidence,statin,,international physical activity survey,target dfu,,,,ureteral,at the time of randomization.||adults,4 and above,,,,,,
3239,,demyelinating disease,opioid allergy.|abnormal,,uln|creatinine clearance,svp.||,,,,gt1 through,within the past 2 years|on,>38.1 degree,,,,,,
3240,,tendon-related diseases,sensitive cyp1a2 substrates,,serologic test,complete parenteral nutrition treatment,,,,other manifestation,for at least 3 months|no,<126 mg/dl)|mini-mental state examination (mmse),,,,,,
3241,,palliative 1st line,beta-carotene,,alanine aminotransferase test [alt],pupillary dilatation to allow acquisition,,,,utilized,in the last 6 months|diet,>40 kg,,,,,,
3242,,intra-articular injection,anti-sensitivity toothpaste.|participant,,controlled bp systole,131i treatment,,,,mild to moderate stress,in the month prior to inclusion|with chronic,≥ 90 mmhg).||gastrointestinal,,,,,,
3243,,medical disorders,anti-cd38 antibody|patients,,players,ethanol.|blood ethanol concentration,,,,obvious,within 6 weeks prior to screening;|historical,> 221umol/l)|patients,,,,,,
3244,,exit criteria.||exclusion criteria - adults:||unable,pamiparib,,turp,hormone deprivation therapy,,,,bcl6 rearrangements,within 3 months prior to day 1 of protocol therapy,≥ 70 × 109/l,,,,,,
3245,,qt cf interval,monoamine oxidase (mao) inhibitors,,crcl)|total bilirubin,endoscopic biopsies,,,,primary driver|teen,during the stay in the crc.|seville oranges,minimum 50 puffs/day,,,,,,
3246,,skin bottlecer,6 mercaptopurine,,weight stable,sitting systolic blood pressure,,,,axis i major,last 30 days - study ulcer treatment,more than 750 ml,,,,,,
3247,,neuropathic problem,supportive care,,who)|life expectancy,intestinal resection|antibiotic intake,,,,unrelated to breast cancer,within less than 3 months,< 30 ml/min/1.73 m^2,,,,,,
3248,,type of dementia,anti-neoplastic therapies,,home oxygen use|recent exacerbation,treatment;|allergic to chemotherapy drugs;|cancer free period,,,,surgery.|tumor,within previous 90 d)|non-sinus,older than 18 years|dry eye disease diagnosis|treatment,,,,,,
3249,,facial nerve canal,postoperative ventilation|refusal,,alanine aminotransferase (alt) aspartate aminotransferase(ast,bile duct epithelial cell,,,,antibiotic classes,criteria||within three months of a hospital admission,27,,,,,,
3250,,as|acute myocarditis,il-2,,medium -weight lungs,periodontal disease|tooth devitalization,,,,colleagues 2016.|neurological control,at the screening stage indicate,> 1 cm,,,,,,
3251,,radiographically measurable,nonchildbearing,,plasma viral load (hiv rna,small group discussions,,,,urge,in the past 6 months.|current participation,≥ 2).|history,,,,,,
3252,,closest relative.||,interleukins activity);|received radiation therapy,,karnofsky ≥60%,surgical resection|no treatment,,,,institut pasteur of lille|available to follow,at least 24 hours prior to reporting to the center,less than 92%,,,,,,
3253,,joint infiltration,nitric oxide donors,,antinuclear antibody (ana),psychotropic medications dosage,,,,stable doses,additional,>= 100000/μl,,,,,,
3254,,cerebrovascular events,prevention drugs,,tans,screening.|history,,,,preserved,during or after their most recent therapy|part 3,≥45%,,,,,,
3255,,hiv-2 infection,high density lipoproteins,,forced vital capacity,old;|bronchoscopy,,,,oncologic,within 8 weeks from complete consent,50 kg or more,,,,,,
3256,,angioimmunoblastic t-cell lymphoma,pain medication,,human immunodeficiency virus (hiv) infection.|acute,conditions:||mean resting corrected qt interval,,,,"between enrollment and 30 days prior, unless their dosage will",within seven days prior to the first dose of pembrolizumab|active autoimmune disease,18-65 years old|haven't,,,,,,
3257,,stevens-johnson syndrome|active blepharitis,vinblastine,,criteria aligns,ethics board,,,,suitable for continuing,within 18 months prior to the baseline study visit,≥90 mmhg);|obvious,,,,,,
3258,,otitis media,vasoactive support.|aortic arch,,phoneme score,immunosuppressive therapy.||- seropositive for hiv,,,,macrosomic baby,at least 2 years,greater than 140 mmhg systolic,,,,,,
3259,,moca])|possible peripheral neuropathy,antineoplastic drugs,,child born,partner;|vasectomy,,,,e. afp & gt,within 30 days before informed consent,greater than 100 beats per minute,,,,,,
3260,,musculoskeletal disorder prohibits,fluorescein,,nibut,adrenal replacement doses ≤10 mg/day,,,,intra-cardiac lines.|an,within the last 9 months prior to screening,≤1.5 x institutional upper limit of normal (uln),,,,,,
3261,,customary lifestyle,weeks;|patients,,bilirubin levels,fruit juices ingestion,,,,st segment elevation);|acute coronary syndrome,in the last 6 months|female,= 285 ml beer,,,,,,
3262,,canal stenosis,opioid-use,,upmc st. margaret's hospital|unilateral,stent for intracranial aneurysm,,,,non-compliance,for at least 3 months|18 years old,> 30 ml/min,,,,,,
3263,,chronic hemoglobinopathy,glp-1 agonists,,tc,surgical procedure,,,,men,within 1 month before the first dose of aps03118,20-80,,,,,,
3264,,medication creates disproportionate,dominant strabismus,,phq-9,imp therapy,,,,molecular feature(s,prior to receiving ip and through completion of the study||,20-30 kg/m2;|elective airway intervention,,,,,,
3265,,liver metastatic disease,tiragolimab,,medium size,symptomatology,,,,influence tear biochemical parameters,within 24 h prior to receiving the first dosing of study medication,1 cm,,,,,,
3266,,heart failure therapies,stool,,aorta length,magnetic,,,,pharmacological,within the treatment field at least 24 h prior to the next clinical visit.|acceptance,6 years|confirmation,,,,,,
3267,,mosaicism,antihypertensives,,months)|body mass index,restricted therapy,,,,controlled by medication|currently pregnant,during the study period.|initiation of desensitization therapy,30% to 50%,,,,,,
3268,,anterior disc displacement,repifermin,,liver allograft function,gynaecological surgery,,,,consumption of illicit psychoactive substances,in the month leading,>1.50 d,,,,,,
3269,,episodes,components of cell,,genital bleeding|estrogen-dependent neoplasia,radiotherapy of the brain,,,,sidekick health app,within 2 months prior to check,<1.0 x 109/l|platelet count,,,,,,
3270,,bruton's tyrosine,hfo devices,,concentration,computed tomography of the abdomen taken,,,,pdx,within 28 days prior to inclusion,750/mm^3,,,,,,
3271,,cold extremities,tkis,,center test results,ega,,,,diameter ≥10 cm)；|receive,within the previous 6 months||iii,below -2sd and above +2sd;|igf bp3 level,,,,,,
3272,,spinal cord injury|previous,long-acting beta-2-agonists,,anc≥1.5×10^9/l,120 days after the final dose of any study drug|if sexually active in a way that could lead to pregnancy,,,,non-investigational,at the time of surgery|use,< 5% blasts,,,,,,
3273,,irregular menstrual cycles.|breastfeeding.|blood pressure,inhaled antibiotics,,id.||comorbidity asa class,reduction mammoplasty operation||,,,,optimized,within the past 4 weeks|intake of lola,≥ 50 % pain relief,,,,,,
3274,,esophageal achalasia,colchicine,,triglyceride concentrations,dmso,,,,implant site.|inadequate arterial flow,within 7 days before the first dose of the investigational product,0 to 10,,,,,,
3275,,male,immune-checkpoint inhibitors,,hepatitis b core antibody (hbcab)|known history,cerebrovascular intervention,,,,requiring treatment;|any organ metastasis,at time of enrollment|subject,above 3|agree to participation and fill,,,,,,
3276,,cardiovascular system diseases,oral diuretics,,suvmax,"years,|medical treatment",,,,study.|blood donation before,for ≥5 years,≤ 1.5 x uln|creatinine clearance,,,,,,
3277,,face masks outside their home when,methacholine,,subarachnoid hemorrhage;|bleeding,anatomical repair surgery,,,,infections|is,within 7 days of the day of procedure,≤ 500 mg/dl,,,,,,
3278,,implant removal)||age,logistics,,response evaluation criteria in solid tumors version 1.1 (recist v1.1)|eastern cooperative oncology group (ecog) performance status,surgical nec||inclusion criteria||born ≤ 30 weeks,,,,known,after receiving standard systemic therapy,xerostomia;|previous use,,,,,,
3279,,unstable chronic disease,iv medication,,scleroderma.|clinicians should consider,neurothrombectomy treatment,,,,sars-cov-2 genome,prior to randomization.|subject,≤1.5×uln or ≤3.0×uln,,,,,,
3280,,drug overuse,migraine medication,,anti-myeloma treatment,thyroid ultrasound,,,,psychiatric disorders.|prisoners.|minor,within the last 24 hours before the start of the study.||any diet,3 /ml,,,,,,
3281,,inability to swallow,steroid medications,,nih task force on research standards,structured clinical interview for dsm-v,,,,clinically relevant illness,within the first two hours after the massage application,greater than or equal to 26 kg/m2,,,,,,
3282,,root fracture,antispastic agents,,manifest refraction,injection of iodinated contrast material,,,,schizoaffective,within the last 18 months|they,higher than 4,,,,,,
3283,,points;|neurological signs,insulin lispro,,effective regurgitant orifice,immunocompromised state,,,,older|unilateral,within 6 months before the first administration of clinical trial drugs.|those,>0.3nmol/l,,,,,,
3284,,signs of rheumatic,vortioxetine,,total bilirubin should,arterial desaturation,,,,contralateral,within 4 weeks of first infusion of study intervention,40 kg/m2|diagnosis of,,,,,,
3285,,blindness,psilocybin,,swan,"palpation of the patellar facets,|pain when stepping down",,,,deemed incompatible,in the next 12 months|incarceration|refusal to participate in study,< 28||,,,,,,
3286,,requirements|contra-indications,full weight,,bss score,radiotherapy induction,,,,non-susceptible in vitro to each of the antibiotic(s) of the,in the past 3 months prior to the first dosing,> 77 pg/ml).|serum 25-oh vitamin d < 20 ng/ml|major,,,,,,
3287,,acute lithiasic cholecystitis,ozempic,,paraffin,clearance,,,,suffer,less than 48 hours prior to admission of,0-2;||8,,,,,,
3288,,moffitt cancer,protonpump inhibitors,,family member||participant,computed tomography (hrct) chest.|any uncontrolled,,,,mouth openings,through 120 days after the last dose of study therapy,question 9 score higher than 2,,,,,,
3289,,anoxia,apatinib mesylate,,kg))|patients,hospitalization treatment,,,,non-anchored vas,over the past three years,≥1.5 x upper limit of normal,,,,,,
3290,,known malignancy,colorectal neuroendocrine carcinomas||,,left ventricular end-diastolic volume,ecp treatment,,,,diabetes|severe obstructive,after allogeneic hematopoietic stem cell transplantation,> 150 mm-hg,,,,,,
3291,,acute cerebrovascular accident,anti-inflammatory/immune,,serum amylase,chronic fatigue syndrome.|treatment,,,,perioperative,in the previous 2 months.|non-surgical periodontal therapy,less than 60 characters,,,,,,
3292,,infectious disease|probands psychiatric diagnoses|patients,pl3k inhibitor,,estimated age,cpr,,,,ada study)|male,within 4 weeks prior to enrollment,5-15,,,,,,
3293,,bleeding disorder,anastrozole,,nyha classification).|history of epilepsy,suppressive art,,,,nerve-sparing,in the previous 3 months|concurrent participation in another interventional research study|receipt of,<1 x 109/l)|hypertriglyceridemia,,,,,,
3294,,colonic transposition,drug abusers|judgment,,women)|blood pressure,induction therapy,,,,in the brain,within 24 hours after onset||the criteria of,≥ 1.5 × 109/l.|platelet count,,,,,,
3295,,granulomatous lung diseases,canine to 1st molar area,,minimum sensitivity,study a)|taking,,,,severity to confound posture,at time of consent|ability to speak,≥5.3 mm,,,,,,
3296,,gestation|institutionalization,3rd ventricle.|prior,,weight reduction medications,percutaneous coronary angiography,,,,extensively restored,within the past 14 days prior to study enrollment|alanine aminotransferase (alt),3:||at least 30%,,,,,,
3297,,systemic absorption,bacillus,,quick dementia rating system,radiation oncology core (iroc) for,,,,pd-l1 inhibitors,for 1 year or more;|be classified,functional classification,,,,,,
3298,,condoms,haemorrhoids,,echocardiography|negative pregnancy test done,autoimmunity tests (ana,,,,castration resistant,pre-excited syndrome,< 3cm,,,,,,
3299,,colorectal polyps;|(4,tcr,,regular physical education courses.|the,t-dm1||all,,,,evaluable tissue,for at least three months after the last dose of study drug.||examples,≤ 0.3%,,,,,,
3300,,pelvic surgery.|antepartum hemorrhage,ipilimumab,,urine drug screening；|surgery,first cycle,,,,malabsorption|hypersensitivity to theophylline|current treatment,within the next 3 months,≤ 1.5 × uln；||subjects,,,,,,
3301,,gastrointestinal perforation,folfox combined,,hypoxic-ischemic encephalopathy,pelvic organ,,,,screening;|clinically significant illness,during the screening and study,≥ 0.5.||,,,,,,
3302,,closed head trauma|evidence,drugs used in the study|has,,left ventricular longitudinal strain,revision surgeries|patients,,,,depression,during the 6 months prior to randomization,score 2-,,,,,,
3303,,third ip vaccination,intrauterine contraceptive devises,,female).|left ventricular ejection fraction,oral chemotherapy,,,,suitable for participation in the trial。,between september 2020 and november,not 0-0.5,,,,,,
3304,,respiratory pauses,selected drugs,,incisional hernia,mention of treatment,,,,non-antitumor traditional,before qualifying hf,≥60 years|diagnosis of copd,,,,,,
3305,,peripheral vasculopathy,anti-cd19,,bone metastasis);||albumin,practice facilitator to,,,,gastric arteries,within 6 months|clinically significant,≥12% and ≥200 ml,,,,,,
3306,,persistent hypertension,cox-2,,total peripheral wbc count,complete occlusive lesions;|the,,,,mild,during the study.|eating disorders,>35 cm,,,,,,
3307,,utis,nystagmus,,rapid hiv test,core needle,,,,class,within the last 4 weeks,2-8 cm,,,,,,
3308,,neurological functional,pregnancy|opioid use disorder,,organ function.||5- performance status,zonular dialysis,,,,minimally-invasive,after receiving second-line,>90 mmhg,,,,,,
3309,,acute ailments,inhaled sodium cromoglycate,,allowed)|platelet count,12-lead ecg)|history,,,,etc.).|recent,during 4 weeks prior to screening.|patients,>= 9.0 g/dl,,,,,,
3310,,drugs.|patients unable,full information,,bone marrow failure syndromes,gastric neoplasm.|neurological,,,,clinical departments|voluntary participation||,at time of initial consent.||*pregnancy,u.s.,,,,,,
3311,,disease|chronic obstructive pulmonary,leukotriene modifiers,,nonsmoking status,fluent speaker,,,,fridericia formula,within the past year|binge drinking,<1.5,,,,,,
3312,,intramuscular injection|chronic illness,components of datscan™.|patient,,new york heart association (nyha),early treatment,,,,other than,on day 5 or 6 after the retrieval,>=5.6 mmol/,,,,,,
3313,,granulocyte macrophage,component of cisplatin,,covid-19-mrna vaccinations,hip fusion surgery|scoliosis,,,,applied icis,within 14 days before the first study,> 20 mg/l,,,,,,
3314,,oral feature,polyvinyl alcohol (,,tbut,autologous ivf cycle,,,,toxic symptoms,at the time of assessment.||,less than 2.0/mb,,,,,,
3315,,bronchitis,carboxyhemoglobin,,university-level,"turkish,|can read",,,,cerebrovascular,preceding 3 months,> 21,,,,,,
3316,,eschar,serotonergic drugs,,mmdai score,completed therapy,,,,primary vaccination|participants,more than 12 hours.|acute type a aortic dissection,<80g/l,,,,,,
3317,,upper urinary tract,inhaled corticosteroids;|short-term,,hepatitis c antibody test.|liver disease of other etiologies,vegf tki treatment,,,,rome iv child/adolescent,longer than 4 consecutive weeks,≤ 25 pg/ml more than 6 months after surgery,,,,,,
3318,,gait,technological components,,body surface area (bsa) involvement,koa,,,,neck judged unsuitable for the procedure,within 3 months prior to enrollment;|acute coronary syndrome;|patients,≥3 months;|pancreatic adenocarcinoma,,,,,,
3319,,feeling of energy loss,therapies targeting,,average resting systolic blood pressure,video messages,,,,influence the ability of the research participant to respond to the procedures of the study,within 24 hours of onset (time of stroke,=< 2.5 x,,,,,,
3320,,infection|prescence,investigational agents,,sepsis-3 definition)|american society of anesthesiologists physical status,her2 ihc test performed,,,,above|individuals,within two years of study enrollment.|the participant,> 35)|unstable,,,,,,
3321,,progressive neurogenic disorders,pain medications,,systolic blood pressure reading,palliative surgery planned|radiological signs suggesting metastases not accessible to surgical removal,,,,preclude obtaining the informed consent,at least 5 days total.|at least two calendar days remaining,>9 gm/dl,,,,,,
3322,,cerebellar diseases,closed reduction,,thromboembolic event,surgical monovision,,,,clinical diagnosis,last two years.|alive|patient's preferred,< 12 years,,,,,,
3323,,hyper parathyroidism,adc,,csami,rox,,,,collateral ligament ruptured,within 7 days before treatment meets,>30kg/m²)|chronic fatigue,,,,,,
3324,,"hg,|diabetic neuropathy",live virus vaccines,,clotting disorders|absence of spleen,chest ct-scan,,,,hearing difficulties,within 24 hours of injury,at least 12 years,,,,,,
3325,,abstain from ingesting caffeine-containing foods,ibm,,solid organ transplantation;|human immunodeficiency viral infection;|use,pulp exposure,,,,dhm.||,within 48 hours before randomization;|within three days before randomization,20-22,,,,,,
3326,,intrahepatic cholangiocarcinoma;|tumor,pta,,doppler index,intra-aortic balloon pump (iabp) support,,,,transvenous,at least 2/3 consecutive electrocardiograms (ecgs),18 - 55 years.|both,,,,,,
3327,,5(minor tissue loss,nj,,icdas,world health organization [who],,,,triple-negative breast cancer,prior to informed consent.|received immune globulin,>= 1.5 uln,,,,,,
3328,,chronic obstructive pulmonary disease).||use,suvo,,protocol;|negative blood pregnancy test,tobacco products|no,,,,drug abuse screening test (dast),prior to receiving the first dose of study drug,<3.0 x institutional uln,,,,,,
3329,,diagnosis,prescription medication|pain,,hh.||household level exclusion criteria||hh,single fraction radiation therapy,,,,resuscitation room,at onset 35-85 years|duration,≥50kg,,,,,,
3330,,sudden unexplained,left atrium,,"recist v1.1 criteria,);|the",claudin 18.2 targeting agent.|prior therapy,,,,unresolved,within 1 month before the first tace treatment;||,≥ 490ms,,,,,,
3331,,malabsorption syndrome,oral iron,,gmfcs levels,centralised analysis of ras,,,,medical institution.|patients,up to 40 kg/m^2|estimated glomerular filtration rate (egfr,>150 mm hg,,,,,,
3332,,bicortical fracture,drug abuse,,alpha-fetoprotein,myopia|onset of myopia,,,,.|bone secondaries not,for at least 5 months after the last dose of lenalidomide,less than 60 %,,,,,,
3333,,cholesteatoma|participants,medication described,,fgr,renal dialysis,,,,d supplements;|use of antioxidant,for graft/,=< 2 weeks prior to registration|co-morbid,,,,,,
3334,,"chronic obstructive lung disease,|cor",pathologic,,investigator|best corrected visual acuity,chest x-ray|rales,,,,grade 3.|schools,within the three months before study enrollment,<10.5 g/dl,,,,,,
3335,,regulatory sponsor,anti-hypertensive medications,,participants.||key exclusion criteria||current,blood count abnormality,,,,chest pain;|presence,at enrollment 7,>13,,,,,,
3336,,neutrocyte,anti-hbv therapy,,recist 1.1.|patients harboring exon,allogenic hematopoietic stem cell,,,,long-span,in the past four,between 18 and 75,,,,,,
3337,,scabies.|pregnant,nasal steroid,,weight estimate,precision oncology decision support (pods) group,,,,affects drug,during the 3 months prior to screening until admission to the unit,<150 minutes,,,,,,
3338,,basocellular carcinoma;|current,lai,,2.|absolute neutrophil count (anc),cockroft-gault formula,,,,computer skills.||,within the last 3 months|bmi,">= 100,000/mm^3|eligibility criteria",,,,,,
3339,,respiratory infection (uri),influenza vaccine,,asl,endovascular treatment;|successful recanalization (mtici 2b-3,,,,needed to receive,"three times, for two weeks each","6-11,|giving",,,,,,
3340,,chronic medical condition,medication for depression,,mibg,complete series of the primary poliomyelitis immunization series,,,,navicular bone,prior to this admission,18.5 and 35 kg/m2,,,,,,
3341,,stress,orthodontics,,creatinine value,localized treatment (surgery,,,,fractures|acute inflammatory diseases,during or after treatment,=< 3.0,,,,,,
3342,,active autoimmune diseases,anti-tumor chinese,,syphilis test,dre,,,,pbrm1,within 3 months the starting of the trial,<40 or >70 years|subjects,,,,,,
3343,,worse heart disease,adequate organ,,modified rankin scoring|presence of spasticity,small intestine|chemotherapy,,,,atrial,within 6 months prior to study entry.|confirmed,> 18||,,,,,,
3344,,thyroid function,opiates,,bcma expression,regular therapy,,,,consumption,within 7 days||hemoglobin,4 or higher|give,,,,,,
3345,,stable condition,anti-spike,,modified telephone interview for,maintenance therapy|within 6 months of completion of initial treatment,,,,american joint commission on cancer [,at least 1 week?',> 40 mg/l|patient,,,,,,
3346,,acute ischemic cerebral infarction,levodopa-carbidopa intestinal gel,,absolute neutrophil count,hormone implant,,,,cells|eastern,one month after last dose of imp administration -,≥ 3 g/dl||coagulation||inr,,,,,,
3347,,r nondisabled,anti-anxiety,,minimum android,baseline.|normal ecg,,,,non-mr-compatible,within 5 years prior to first dose,"> 2,000 iu/ml",,,,,,
3348,,nsclc resectable,topical anti-muscarinic|significant central corneal scarring,,acpa,carotid artery intervention,,,,remain,within 30 days before surgery|patients,i,,,,,,
3349,,hp infection,vaginismus,,ebv tscm ctl manufacturing|age,complete remission(cr,,,,clinically relevant,during the study|total daily insulin dose (tdd),"<50,000/mm3",,,,,,
3350,,radiologic diagnosis,antipsychotic drug,,ag rapid test.|positive blood alcohol test,cell repair genes,,,,"ventricular morning, etc.).|severe liver disease",within 30 days prior to screening;|had vaccine,>7 mmol/l;|ldl cholesterol,,,,,,
3351,,urethral injuries,epratuzumab,,nitrites,standard dose of gadolinium-based mri contrast agent,,,,non-sinus- conducted rhythm.|qtcf,within one week prior to surgery,40-90 years,,,,,,
3352,,aerd,akt inhibitor,,stool hp antigen test.||,induction of labor,,,,iii,within two weeks before covid-19,23 to 55 years (inclusive),,,,,,
3353,,exon-skipping antisense oligonucleotides,xanthine-containing food,,oxygen saturation index,upper airway surgery,,,,older|in,within 4 weeks before the first dose of study treatment|non-hematologic toxicity from prior anticancer therapy,7-11 seen,,,,,,
3354,,oncolytic virus treatment,regrowth,,gamma-glutamyl transferase [ggt],ct imaging,,,,hernia,prior to day 0||,"class ii,",,,,,,
3355,,copd)|chronic kidney disease (ckd),nonsteroidal anti-inflammatory agents,,barthel index,dmek corneal transplantation||,,,,|known,within 3 weeks prior to randomization,> 16.8mmol/l,,,,,,
3356,,anal stricture,iodine-containing drugs,,ckd-epi creatinine clearance,insufficient knowledge of german language,,,,arrhythmias|active,previous month of the trial.||,>40 milliliter,,,,,,
3357,,restenosis,codeine,,palpable size,ecological momentary assessment application||,,,,index stroke|medical instability assessed by the treating stroke physician to participate to the study,within 30 days prior to receiving the first dose of investigational treatment,≥ 7 per,,,,,,
3358,,deep submucosal invasion,glp-1 ra therapy,,right ventricular mechanical circulatory support,least:||a chemotherapy regimen,,,,cdk4/6|inability to swallow,within past 3 months for cambridge,more than 1 year,,,,,,
3359,,esophageal,chest,,weight reduction surgery,health coverage||,,,,pmd ranging from - 2db and below,for six months after the end of the study period.||,>5 mm,,,,,,
3360,,weight loss medications,abnormal platelet aggregation,,benzodiazepine addiction,positron emission tomography (pet) suv,,,,sedating,within 30 days before the first administration.||3,80 to 300,,,,,,
3361,,examination.|biliary obstruction,agomelatine,,urine drug screen (uds),metal materials;|life expectancy,,,,burkitt,during the screening period);|non-sterilized,18.5 < bmi,,,,,,
3362,,benign disease participants:||-current,neck surgery.|semi-permanent,,cd)4+ count,syncopal attacks,,,,diagnostic and statistical manual of mental disorders 5 (dsm5),"at the same time,",greater than 5 kg,,,,,,
3363,,dosing||,ginkgo biloba,,unc irb sop,endoscopic ultrasound,,,,suitable to be included in the study,within 3 days prior to initiation,4-7 mm,,,,,,
3364,,manic disorder,linezolid,,irradiation,major organ function;|women,,,,large enough,in the 3 months before the,≥50×10^9/l,,,,,,
3365,,colon-related diseases,immunomodulating therapeutic,,transaminase (ast),urine dipstick testing,,,,interleukin 2,within 30 days prior to initiation,> 30 kg/m2|absence,,,,,,
3366,,valvular disease|clinically significant,rosuvastatin,,eye.|uncontrolled intraocular pressure,surgical access,,,,egg donation,at the screening visit.||,≤ 50 ml,,,,,,
3367,,interstitial cystitis|bladder pain,medroxyprogesterone injection,,ebjis definition)|withdrawal,plmd,,,,leprosy programme tb treatment register,in past month,≥ 90 g / l;|absolute,,,,,,
3368,,major depression|symptoms,nicotine products,,gross motor functional classification,pharmacological antidepressant therapy,,,,foster,within 4 weeks prior to study day,do not exceed twice the upper limit,,,,,,
3369,,symptomatic presentation,craniofacial anomalies,,pnn,cognitive assessment (moca),,,,psychological disorders|parents,at the time of admission.|severe head trauma,18]f-psma-1007 pet/ct,,,,,,
3370,,serca,national,,substance abuse|bmi,therapeutic anticoagulation therapy,,,,lower limb sensorimotor deficit|having,in the past 180 days,grade iv,,,,,,
3371,,thyroid/parathyroid,mammogram,,international society of lymphology,bone marrow transplantation.|patients,,,,imwg response criteria [appendix c],in the past 6 months from screening,>4x upper limit of normal|egfr < 25 ml/ min/ 1.73 m2|hemoglobin <7 g/dl,,,,,,
3372,,active malignancy.|patient,immunosuppressive drug,,hcvrna,shrapnel,,,,de novo,one month before treatment|patients,≤ 5 x unl,,,,,,
3373,,"purpose,|hemodynamically stable",anti-tubulin agents,,american association of anesthesiologists (asa) physical condition,mental retardation|dementia|deafness|blindness|psychiatric illness|steroid use,,,,greater-than-first-degree,less than 6 months old,younger and,,,,,,
3374,,singaporean citizen,anti-epileptic therapy,,resting ecg shows,seizure control,,,,non-urgent,in the last 24 weeks while on angiotensin converting enzyme inhibitor,scores ≤49|mmse scores ≥24|hamd-17 scores < 25|h-y,,,,,,
3375,,psychiatric diseases,anti-neonatal fc receptor (fcrn) medications|study participant,,test for hepatitis b surface antigen [hbsag],pathogenic kras mutation,,,,robot,for at least 3 seconds,< 180 degrees of the circumference of the vessel,,,,,,
3376,,infusion|autoimmune diseases,contrast material|malignancy|pregnancy|uncontrollable medical,,administration.|karnofsky performance status,organ transplantation;|had,,,,12-week intervention period||,within the previous 3 months.|systemic,score of 4-8,,,,,,
3377,,infection|chronic infection,cyp2c9 inducers,,h63d compound heterozygous hfe-gene,therapy outcomes,,,,treatment|previously completed,within 2 weeks before the start of study treatment,between 40-64|child,,,,,,
3378,,aortic sclerosis,cellular products,,mayo global score,radiographically,,,,left blank,within 2 weeks prior to the first dose,incontinence.|pregnancy|less than 12 months,,,,,,
3379,,obsessive-compulsive disorder|uncontrolled,immune therapy therapy,,betula,complete staghorn,,,,russian,before surgery||,18 - 75 years.|pathologically,,,,,,
3380,,swi,arrived,,anemia|hyperthyroidism|timi blood flow,endocrine treatment,,,,aortic sinusoid junction to the proximal cardiac margin of the innominate,within 28 days prior to initial administration of study medications.|patients,more than 18.|patients,,,,,,
3381,,invasive malignancy,systemic corticosteroid agent,,asa score ≥3)|signed written,herbal treatments,,,,acceptable include:||- tumor tissue sample collected,within 1 year prior to start of,under 18 years old|100 years,,,,,,
3382,,dental disease|using,platinum drugs,,hepatitis c antibody (hcvab),vision-impacting comorbidity,,,,interstim ii advanced,during the time without,90 days|personal,,,,,,
3383,,machinery,rituximab sarilumab secukinumab tocilizumab tositumumab tremelimumab urelumab ustekinumab,,chm,copper intrauterine devices,,,,pathological specimen of,within 72 hours prior to randomization.||part b,greater than 60 ml/min/1.73m2|seronegative,,,,,,
3384,,ischemic heart disease|acute exacerbation,sodium hyaluronate,,helminth parasitic infections,abortifacient effects.|previous renal transplant.|dialysis,,,,analgesia)|application of,within 2 weeks before administration;|history of drug,>2.5 mmol,,,,,,
3385,,imbalance,taxane,,ihc,regional prescribing,,,,imwg response criteria (appendix c,within 3 months after the end of the study;|female,≤ 24 points,,,,,,
3386,,memory loss,n5-n7,,serum potassium concentration,language therapy program,,,,large cell neuroendocrine,within 1 month and those who take drug,between icf signature,,,,,,
3387,,immune system pathologies,systemic agents,,ratio fev1/fvc,ribociclib + et,,,,index date.|patients,prior to start of study enrollment,10 to 17 years,,,,,,
3388,,atypical anorexia nervosa,component of the vaccine,,function-altering mutations,intra-aortic balloon counterpulsation,,,,medically-prescribed,within 2 years prior to screening|current,<90 milliliter per minute per 1.73 meter square [ml/min/1.73m^2,,,,,,
3389,,basal carcinoma,investigational drug,,routine glucose values,cardiac imaging,,,,"culprit lesion,|the",at the time of first administration of lymphodepleting chemotherapy,above 18|absent symptoms,,,,,,
3390,,infectious illness,dfmo,,lawrence radiologic degree|patients,dialysis)|major surgery,,,,b|stable,within 60 days prior to registration,≥ 1.5 × 109/l.|platelet count (plt),,,,,,
3391,,non-small cell lung cancer|cohort,anifrolumab,,very hard stools,conventional therapies for ibs;|absence of red flags,,,,low ovarian reserve (afc < 7 follicles,"during the research period,|having no physical and mental problems",measured within 7 days of,,,,,,
3392,,associated pathology,angiogenic drugs,,imc,fluid accumulation around,,,,apparent,within 4 weeks of the first dose of treatment for another health-related,≤ 2,,,,,,
3393,,peripheral vascular,carb,,hepatitis c virus (hcv) rna,standard thoracotomy,,,,affecting the anterior iliac crest.|infected,4 to 6 weeks interval)|between 18-45 years,1 month to < 6 months,,,,,,
3394,,extra-pulmonary reasons,apc,,6.specific inclusion criteria||advanced solid tumors||patients with histopathology and/or cytology,blood cell count,,,,stable unchanged art regimen,within the last six months|history of,at least 2 months post,,,,,,
3395,,primary brain tumors,mobile phone,,positive pressure ventilation.||exclusion criteria,coronary artery stenting,,,,non-opposition to participation,within 3 days of screening,0-1.|fertile,,,,,,
3396,,acute myocardial infarction||,fludarabine.|pregnant,,individual case safety report (icsr),intracranial surgery,,,,documented||inclusion criteria,within 28 days prior to the 1st planned dose of chs-006;|receipt of live,<18 meq/l,,,,,,
3397,,malignant tumors|pregnancy,thrombophilia|platelet counts,,months.|qtc,assessment scales- 2nd edition,,,,between tissue sample taken,past 12 months or more,≥ 2 unland/,,,,,,
3398,,colchicine|stroke,ocular medication,,fiebig stages,stereotactic radiation therapy,,,,eligibility assessment.||participants,within the rural community served,< 90g/l,,,,,,
3399,,aga,left ventricular assist device,,gad-7 score,fibromiyalgia,,,,pr-positive,within 7 days prior to the first dose of study drug.|active,≥150 mmhg,,,,,,
3400,,breast-feeding|va-ecmo application for causes,injectable corticosteroids,,a:||patients entering from the parent studies||1. patients with,first facial trauma surgery,,,,seizures|expected relocation,within 72 hours prior to receiving,"1-3,|no",,,,,,
3401,,cornea disease,ssi,,serum albumin≥3g/dl,pancreatectomy,,,,cross-sectional imaging,hospitalization-based,"≥ 100,000 per mm3|serum",,,,,,
3402,,secondary immunodeficiency,herbal drug,,lblc,cancers|previous radiotherapy treatment,,,,high-volume leukocyte,at any time during pregnancy||cohort 2||diagnosis,<=40%,,,,,,
3403,,monoclonal antibodies directed,sp-420,,response evaluation criteria in solid tumors (recist) version 1.1 criteria,hormone therapy)|significant,,,,malformed,within 1 month (exception:,>90 ml/min|history,,,,,,
3404,,alzheimer's dementia,inhaled),,ankle instability tool (cait)||,pharmacologic therapy,,,,non-carious cervical lesions,actual,"between 18 and 60 years,|non-smokers",,,,,,
3405,,malignant pleural,chemotherapeutic anti-plaque,,medication .|treatment,brain stimulation treatment (,,,,upper jaw.|no history,at least 25 years old,"between 18 years and 75 years,|eastern",,,,,,
3406,,cryo myectomy,postvaccine,,troponin,intracorporal injections,,,,6.1.|severe,for 30 days after ending,≥ 18 years old|extraction,,,,,,
3407,,type 2 diabete mellitus,mtc,,urine drug screen for,repair of the rotator cuff,,,,minimally conscious state|brain,within 21 days prior to study entry,18-60 years|bmi,,,,,,
3408,,natural teeth (,glibenclamide,,mean qtc,hematopoietic colony-stimulating growth factors,,,,needs to be judged by the surgeon to have a,during the study therapy,longer than 2,,,,,,
3409,,active cancer treatment,immunoglobulin a,,suicidal ideation section of the baseline c-ssrs,intraosseous basivertebral nerve ablation,,,,end-stage liver disease (meld),within 30 days of the first dose of study treatment|a,≥ 38.3 °c,,,,,,
3410,,intra ocular inflammation,dolutegravir-containing combination antiretroviral therapy regimen,,stir)|asia,cinb therapy,,,,meeting diagnostic criteria,before cnct19 infusion||radiotherapy before cnct19 infusion:||non-cns site of radiation completed,> 2|oxygen saturation,,,,,,
3411,,drug induced parkinsonism,pkmyt1 inhibitor,,high school,bladder stone extraction,,,,suitable for clinical trials,within 12 months prior to screening.|egfr<30 ml/min/1.73 m2,≤ 3 x institutional,,,,,,
3412,,external genital lesions,oral terbinafine||,,serum ig kappa lambda flc ratio,ultrasound imaging,,,,mild-moderate-severe,at least 1 dual,lower than 90,,,,,,
3413,,major comorbidity,over-the-counter chemical drugs,,antral follicle count (afc),femoral access site,,,,actively,throughout the extent of the study term|female,17 or under|no,,,,,,
3414,,progressive symptoms,exenatide-containing drugs,,west-haven,srt,,,,non-malignant medical illnesses,within 28 days prior to the first dose of the investigational product,>20 grams a day,,,,,,
3415,,judged by the investigator to potentially affect the results of the study,medications:||amitriptyline|nortriptyline|gabapentin|pregabalin|duloxetine,,nci-ctc,hematologic transplantation,,,,other,at the time of informed consent per investigator assessment.||adequate organ function,≥ 5% blasts,,,,,,
3416,,neurocognitive disorder|age,brace,,subclinical levels,examinations.||angiographic,,,,functioning,within 14 days prior to the first medication,at least 0.5 teaspoons,,,,,,
3417,,ehr)|pregnant,mca-m1 occlusion,,serum hcg examination,"2),|good quality mri",,,,clinique des,at least 2 of the 3 following supportive criteria,">= 100,000/mm^3|creatinine =< 1.5 x upper limit of normal",,,,,,
3418,,bleeding syndrome,turp,,hepatitis c virus [hcv] rna,treatment;|trans-masculine,,,,"exercise,||",in the 3 months prior to enrollment,greater than 7%)|any,,,,,,
3419,,intolerant,statin lipid-lowering drugs,,bydureon/ bydureon bcise,insufficient imaging quality of ct,,,,ebv-compatible,within 2 weeks of laboratory test,≥ 40iu/l,,,,,,
3420,,paf,us,,article 9.||,radio-immunoconjugates,,,,etc.)|intra-abdominal infection|urinary tract infection||bacterial meningitis||estimated,within 14 days prior to randomization.|history,≤ grade 1,,,,,,
3421,,colorectal metastasis,silicones,,routine urine test result indicates,intra-vaginal gel moisturizers,,,,old|singleton term,within 5 years before enrollment;|allogeneic organ transplant,20-25 kg/m2.||exclusion,,,,,,
3422,,peritoneal disease,endocrine drugs,,wide axis,molecular studies,,,,membrane oxygenation (ecmo,within 7 days).||(2,>= 30 ml/min/1.73 m^2,,,,,,
3423,,life events,seafood,,hama,wedge resections,,,,absorption of pills||patients,during the study;|volunteers,<18 and >80 patients who do not provide informed consent,,,,,,
3424,,disease.|nasopharyngeal carcinoma,padua,,screening||key,osteotomy,,,,low does aspirin (lda),at time of study registration,≥600 pg/ml|patients,,,,,,
3425,,terminal stage cancer.|patient,know,,new onset symptoms,cervical operation,,,,red,while on the study|willingness to comply with restrictions,b-cell-depleting therapies,,,,,,
3426,,variceal bleeding|known,tgn,,or|bmi,distal subtotal gastrectomy,,,,suffering,within 3 months prior to screening.|obesity induced,">= 3,000/mcl|platelets",,,,,,
3427,,focal neurological signs.|presence,over-the-counter preparations,,generalized epilepsy|patients,computed tomography [ct] scan of the thorax,,,,liver disease|recent (,for at least 7 months after the final dose of study treatment.|the patient or,<17 kg/m2|use,,,,,,
3428,,open-heart surgery,new medications,,prothrombin time (pt)>uln+4 seconds,concurrent intervention,,,,stop-bang,within 2 weeks before study day 1 or 5 half-lives,≤ 25 mg,,,,,,
3429,,external beam radiotherapy,preservative-free,,barcelona clinic liver cancer (bclc) staging,matching covid-19 symptoms.|clinical diagnosis,,,,grade ii or above heart function,within the past 5 days;|women,< 45%.|an,,,,,,
3430,,serious head injury,camrelizumab,,alanine aminotransferase /serum glutamic pyruvate transaminase (alat/sgpt,cns local therapy,,,,lumbar area,for at least three months||,>150ms or >130ms,,,,,,
3431,,acute/chronic,anti-cancer therapy.|pregnant,,monoclonal antibody monotherapy iii,stent length,,,,ami,within 1 year before screening;|positive anti-hiv (+),"ii, iii",,,,,,
3432,,non-hma therapy,vancomycin-resistant enterococcus,,serum beta hcg test,criteria.||non-nodal lesion,,,,minimal,within the past 6 months|evidence,>= 60 ml/min/1.73 m^2,,,,,,
3433,,media opacity,pharmacist,,serum virology test results,women；|contraindications of imaging examination,,,,musculo-skeletal,within 14 days before the first dose;|people with positive results,exceeding 480 milliseconds.|current presentation,,,,,,
3434,,cardiovascular diseases.|prior allogenic,age|esophageal,,hcv rna copy number,six-item screener,,,,lymphocytic,for less than 24 hours,≥ 4|voluntary to check serum 25(oh)d levels,,,,,,
3435,,caries;|presence of,phq-9,,gh deficiency:||inclusion criteria:||ambulatory,radical surgical treatment,,,,modic i,within 3 months before registration.|non-healing wound,20 db,,,,,,
3436,,bone marrow failure syndrome,vaccination.|previous influenza vaccination,,anti-hepatitis,open abdominal surgery,,,,central,previous 14 days,exceeding 2 times,,,,,,
3437,,primary al amyloidosis,peptide-1 receptor agonists,,hepatitis c (hcv),study||,,,,monogenic cause,35 days prior to starting|investigational product,≥ 50 kg,,,,,,
3438,,chronic neck pain,phosphodiesterase type 5 inhibitors,,ectopic adrenocorticotropic hormone secretion,multifocal vin grade,,,,positive;|blood donation,within 3 months of any planned study procedures,higher than 8%,,,,,,
3439,,liposuction,|loxapine,,hellp,biological assessment,,,,worst pain,within 4 weeks of the first administration of imp.|positive,> 1% blasts,,,,,,
3440,,cardiac athletes.|haematological disease,fⅶ inhibitor positive,,mycobacterium,cecal intubation,,,,non-clinically,for 4 weeks after each dose escalation||,=< 8|prostate,,,,,,
3441,,vasculitis disease,tnf-α inhibitors|women of childbearing potential,,"recist version 1.1, there is",hepatic panel,,,,3-9 months of age,at the time of screening;|severe cardiovascular disease,class 2 or higher,,,,,,
3442,,axial spondyloarthritis,hospitalized|one,,mg/24 hour|positive test,fontan operation|clinical stability,,,,immunodeficient,> 3 months prior to visit 1,43rd to 49th day,,,,,,
3443,,chronic rhinitis symptoms,study medication|epidural catheter,,t-all/lbl.|cd7,right hemicolectomy,,,,icd-10 f32.0; f32.1,within the last year.|pharmacological treatment,≥ 100 × 109/l（100,,,,,,
3444,,sjrögens,pseudoephedrine,,barthel index|sign the informed consent||,histology|international federation of gynaecology,,,,unsuitable to take,for at least 120 days post,30 to 65 years inclusive,,,,,,
3445,,cognitive impairment|aphasia,rivaroxaban.|active peptic ulcer disease,,cgi,regular meditation,,,,zinc oxide,for the duration of clinical follow-up).|provision of written,<4.6 mmol/l,,,,,,
3446,,resection.|patient eligible,checkpoint inhibitors,,urine pregnancy test.|significant,spo2<95%)|bmi>35 kg/m2|refusal,,,,12-23 points,within 4 weeks of the first dose of study drug,0-3.||participants,,,,,,
3447,,neurologic and mental status,itd,,crps,pelvic radiation therapy,,,,non-inclusion,following the 2009 assessment of the spondyloarthritis international society classification criteria||,>= 0.25|stable doses of oral,,,,,,
3448,,pressure sores,lepidoglyphus destructor,,ehrs,study-related activities,,,,diagnostic & statistical manual of mental disorders,more than 10,< 70%,,,,,,
3449,,mixed small cell lung cancer.|participants,muscle relaxers,,liver allograft,standard neoadjuvant treatment.|surgery,,,,hsct|clinically significant,within 48 hours before the first dose of study drug,> 90 beats per minute,,,,,,
3450,,medical risk factors,nicotine patches;|in the last,,resting sbp,protocol requirements.||solid tumors,,,,chronically damaged skin,in the previous 30 days|mouthwash use,≥1500/mm³.|patients,,,,,,
3451,,early malignancies,anti-tb therapy,,serum β-human choriogonadotropin test,prophylaxis,,,,energy tibia,within 180 days of initial dose,<50 d,,,,,,
3452,,asaii,beverage,,disease|eastern cooperative oncology group (ecog) performance status,lumbar region|patients judged to be inappropriate for this study,,,,experimental procedures|pregnancy,during the trial period and 8 weeks after the last administration of the test drug;|estimated survival≥ 12 weeks;|sign a written informed consent form,≥ 1 % of the total lymphocyte count,,,,,,
3453,,pulmonary disease,anti-allergy therapy,,fev1/fvc,oxygen therapy,,,,distal implants|healed sites,within the past 3 years|significant,above 18 years,,,,,,
3454,,psilocybin).|allergy,systemic anti-viral use,,participate;|bmi,endoscopic resection,,,,cervicogenic,at intervals of more than 24 hours);|myocardial infarction,>= 7.5%,,,,,,
3455,,solid tumor|all other toxicity parameters,long-acting dihydropyridine calcium channel blockers,,heart rate increase of,laser therapy|epilepsy|anticoagulant therapy|pacemaker|hemorrhagic diathesis|photosensitizing drugs|known photosensibility|neck,,,,histologically,within 28 days of the planned start of study drug,≥ 18 years and ≤ 75 years,,,,,,
3456,,implant mobility,phosphoinositide,,recist v1.1,repetitive mri body scan|requires chemotherapy,,,,submerge for,during the 3 months before the trial,≥3cm,,,,,,
3457,,fluid imbalance,pars planar,,designee.|body mass index (bmi),e.g.||brain mri,,,,group b (,within 7 days before the study enrollment,+/- reinduction therapy|fully recovered from,,,,,,
3458,,round peripheral scar,pd-1 antibody therapy,,audit,demss,,,,mdrd calculation.|individual,prior to the onset of neck pain,>2.2,,,,,,
3459,,peripheral nerve symptoms,gemcitabine hydrochloride,,plms index,qualifying score,,,,non-reproductive potential,at least 4 weeks prior to randomization.||,18-64 years|receiving 3 x weekly,,,,,,
3460,,comorbid diseases,house trained);|gastro-intestinal diseases,,child care centers:||serve,intravascular imaging,,,,adjustment,within one month.|combined,≤30 kg/m²,,,,,,
3461,,anti-tumor therapy,iodinated intravascular contrast,,menopause,bone conduction implants,,,,intercurrent illness.|active,over the last 4 weeks prior.|evidence,≥18 years|transfusion-dependent,,,,,,
3462,,hypercoagulable state,antibiotic.|participants who consume probiotic,,resting dbp,s-eng,,,,stage 1 cancer,prior to first study treatment,functional than the uninvolved,,,,,,
3463,,melanoma,rasburicase [elitek,,ppd,institutions,,,,right-handed;||inclusion criteria for,medical history shows,> 35 kg/m2|recent bowel,,,,,,
3464,,treated periodontitis,fusion proteins,,monoclonal b lymphocytes,preparatory,,,,neurodevelopmental testing|severe behavioural disturbances,prostate;|previous history of,=< 75 years,,,,,,
3465,,intestinal structuring,armodafinil,,volunteer's verbal report,preoperative lge-cmri|preoperative lge-cmri,,,,pure red,in the 3 weeks prior to signing icf|immunocompromised,< 120 ms,,,,,,
3466,,refractory to fviii,reproductive dysfunction;|strong request for uterine removal,,montgomery-åsberg depression rating scale,parkinsonism syndromes,,,,formalin-fixed,within 6 months prior to inclusion|immunosuppressive therapy obtained,younger than 65 years,,,,,,
3467,,ocular ischemic syndrome,misoprostol,,gsrs,effective contraceptive method,,,,agents.|concomitant use of,within 4 weeks prior to initial use of the study,< 14 years,,,,,,
3468,,host response|inability,bilateral,,occasional pvcs,laboratory studies|medical,,,,first-generation anti-androgen therapy,within the previous two weeks of,≥180 mmhg)|uncontrolled,,,,,,
3469,,africa,leukemic agents,,meaning,heart valve repair/replacement,,,,volar surface,more than 14 consecutive days,>18yo|willing to sign,,,,,,
3470,,t-wave inversion,stable steroid,,west yorkshire icb,maxillofacial surgery,,,,insulin.|clinically significant,within 5 weeks before enrolment.|ability to,normal.||,,,,,,
3471,,mitral valve repair/replacement.|left,tenofovir,,"prothrombin time (pt, aptt)",urine β-hcg,,,,interfere with cooperation with the requirements of the study.|manifestations of malabsorption,at satellite location,2.5 times higher than the baseline value before,,,,,,
3472,,endometrial hyperplasia.|history of epilepsy,grapefruit supplements,,prothrombin time international standardization ratio (inr),thoracic radiation therapy,,,,refractory to standard over-the-counter medications,for at least 24 weeks after the last dose of study,"i-ili,|patients",,,,,,
3473,,ipsilateral neck dissection.|patient,antidiabetic medication,,acetaminophen hepatotoxicity,polymerase chain reaction (pcr) result,,,,new measurable disease,for at least 3 weeks|oral consent from the child,≤ 40.0 kg/m2|meet,,,,,,
3474,,dr,live virus vaccine,,areas,standard alternative treatment options,,,,n. meningitides,at least 6 months after the last use of chemotherapy;|11,more than 2 times normal|with,,,,,,
3475,,cns diseases,components of the investigational drug|patients,,ebv dna rebound,although procedures,,,,alk-tki lorlatinib,within 3 months of study,> 1cm|able,,,,,,
3476,,ae resolved,medication known to cause itching.|psoralen,,serum follicle-stimulating hormone (fsh),conical collarless cementless,,,,disease exacerbated,before surgery|history,younger than 65 years|cohort 1,,,,,,
3477,,congenital cataract,herbal extracts,,pet scanners|weight,special type diabetes|history of,,,,ngs)|age,at the day of signing informed consent||histologically,≥ 18 and ≤ 30 kg/m2.|subject,,,,,,
3478,,substance use,calcinrurin inhibitors,,/mcl|total bilirubin,etc.);|major surgery,,,,treatment|pre-existing,within 1 week;|patients voluntarily signed informed consent;|over 18 years old,< 0.8 snellen|ametropy,,,,,,
3479,,patients|systemically diseased,risdiplam,,urine albumin,plasma donation,,,,suitable for participation in the,within the past one year,=< 7 days prior to re-registration,,,,,,
3480,,intracranial stenosis,oral fluoropyrimidines,,medopp485_miradorcsp,slit lamp examination,,,,femoral neck,within 3 months.|patients,1-6 years,,,,,,
3481,,teratogenic adverse events,oral polio vaccine,,criteria;||not speaking turkish,eucalyptol,,,,grade 2 sensory neuropathy,prior to invasive dental procedures|use,≥ 400 ml,,,,,,
3482,,questionnaire)|serious cognitive impairment,nasal septum deviation,,range|total cholesterol,2-hour plasma glucose level,,,,criteria:||peripheral neuropathy|patients,within 30 days of baseline.|treatment,0 or 1|the expected lifetime is,,,,,,
3483,,bleeding diatheses|uncontrolled,antibody conjugate,,response evaluation criteria in solid tumors v1.1 (recist v1.1),primary hospitalization,,,,between sitting,within the past 14 days prior to study registration c hemoglobin (hgb),< 2 x 109/l|on the waiting list,,,,,,
3484,,decoction,dli,,wall thickness,traumatology clinic,,,,m0.||,in the next six months,>150 mmol/l,,,,,,
3485,,end-organ ischemia,ocular media,,antibodies to covid-19,contraceptive measures stipulated,,,,eda|not receiving eda,at screening and day -1|abnormal urine tests,above 34.5 kg/m2.|patients,,,,,,
3486,,mitral valve disease,drugs containing the same,,drug abuse).|creatinine,chest ct scan evaluation,,,,moderate / severe,prior to start of study intervention,> 25 mmhg|right,,,,,,
3487,,periodontal diseases,natural medications,,alcohol breathalyzer test,localized therapy directed to the pancreas,,,,highly effective contraceptive methods.|endocrinopathies,within 6 weeks before the baseline visit|the study participant,>8.0 g/dl|total,,,,,,
3488,,reactivity|recent eye surgeries,anabolic medications,,aggf1,roux-en-y surgery,,,,3rd degree patient group,in the past 12 weeks.|epilepsy,< 1500 g|birth term < 32 week,,,,,,
3489,,arteries overlap,erythropoietin stimulating agent,,pucai score,sitagliptin treatment,,,,low-moderate,within the past month|in the opinion of the pi,>18 years|access,,,,,,
3490,,acute subdural hematoma,analgesic medications,,tumor)|active arterial thromboembolic disease,polymerase chain reaction (pcr) test for hcv rna,,,,short,within 7 days of first administration of ip.|history,≥1.5 × 10^9/l|absolute lymphocyte count,,,,,,
3491,,cbct|primary failure,pilocarpine,,montgomery-asberg depression rating scale,24-h period,,,,supplemental formula,during the one month prior to screening,≤ 5 times uln|no ascites,,,,,,
3492,,good patellofemoral mobility|ability,catron,,pgi-s).||in,azvudine tablets,,,,highly-effective contraceptive method,within the past 2 weeks,no more than 1 cigarette per day,,,,,,
3493,,treatment;|arteriovenous thrombosis events,avanafil,,tumor size,local treatment standards,,,,suitable for endovascular repair.||for type b aortic dissection,within 12 months of enrollment,75-year-old,,,,,,
3494,,vulvar oedema,intraarticular steroids,,rapid validated antigen test,serological examination,,,,positive|gastric cancer,3 days prior,>= 12 months of amenorrhea,,,,,,
3495,,coeliac disease)|currently,hyaluronic acid)|participates,,gsf,clinical laboratory test results,,,,non-mobilized cells available for manufacturing||,< 2 months prior to screening.|blood donation,≥ 15%,,,,,,
3496,,food intolerances,iodinated contrast media|contraindications,,criteria of left bundle branch block,urine culture revealing,,,,hip joint.|patients that are,in last 30 days.|heart,6 months to 14 years,,,,,,
3497,,implant cochléaire,pdgfrβ-fusion,,general health support,vaccination.*||acceptable contraception,,,,angina|coronary,within 1 year before starting treatment,> 38.5℃,,,,,,
3498,,organic brain diseases.|pregnant,pancreatic insulin,,ebv pcr test,lactose maldigester,,,,ehlers-danlos disease|patients,at least two intravitreal,>35 kg/m2|active,,,,,,
3499,,injury)|neurological disorder,medium-chain triglycerides,,alt ≤3.0x,medical procedures,,,,depo provera,recent 3 months,between 0-3|having,,,,,,
3500,,renal disease;|known titanium,fibrogenic agents,,v. clonal bm plasma cell percentage,mepolizumab treatment,,,,despite treatment|class ii or greater,within 48 hours of any medical conditions,≥10 u/ml,,,,,,
3501,,ectopic calcification,fviii,,recist v1.1 and,ocular health||,,,,inter-ridge space,within 30 days before the first dose administration of study.|any,<200 ml/,,,,,,
3502,,painful stiff,snri drugs,,panss,walk continuously,,,,uncomplicated,in the previous 6 months,1-7 days after initial symptom,,,,,,
3503,,unconjugated hyperbilirubinemia,strong inhibitors,,serum ferritin threshold,e-cigarettes,,,,years|refractory,at the time of first dose 14,2.0-7.0,,,,,,
3504,,nonautoimmune allergic diseases;|has,chronic corticosteroid therapy|there,,hvpg,irreversible surgical sterilization by,,,,grade iii and iv according to the icrs classification,antibody positive,>3/12)||exclusion criteria,,,,,,
3505,,refractory disease|for,sympathetic,,doxycycline,brain imaging after central nervous system,,,,minimally invasive gynecologists,within 3 months before transplantation,3b - 5,,,,,,
3506,,pneumonia-related illness,confirmatory antibody-pattern,,tumor.|child pugh score,hb sb0)|admission,,,,oculoplastic,in the past 2 years((eg,>1.5k/ul|absolute,,,,,,
3507,,recurrence risk,ctcae 5.0.||adequate organ function,,blood cultures,mr spectroscopy,,,,deciduous,within 14 days prior to the initial dose of study medication.||ii,above 28 weeks||,,,,,,
3508,,metal joint replacements,molecular biology,,maintenance hemodialysis patients;|18,standard treatment,,,,moderate smoker,more than 3 months.|terminal,less than 18 kg/m2.|individuals,,,,,,
3509,,lower extremity contractures,topical ointments,,mcao,postoperatively|index procedures,,,,immunocompromised individual,within 3 months prior to enrolment|subject,< 3,,,,,,
3510,,pulp necrosis.||patients,intravenous access,,come scale (gcs),lumbar disc surgery,,,,complement-dependent,within the last 6 weeks before,less than and equal to (<=) 500 per cubic millimeter,,,,,,
3511,,gastric sleeve)|pregnancy|bowel motility disorders|minimally invasive pancreatoduodenectomy,antithrombotic drugs,,child-pugh c cirrhosis,polymerase chain reaction (pcr) test,,,,non-healing wound,at the screening time,above normal reference,,,,,,
3512,,hepatitis a,thrombolytic drugs,,regional perinatal service center|able to communicate in english||,blood product users;|vaccination,,,,ehlers-danlos syndrome,within 4 weeks prior to initiation of study treatment|treatment,above the upper limit,,,,,,
3513,,diseases.|allergy,gnrh agonists/antagonists,,alcohol test (breath,lipid lowering supplements,,,,cmv sero-positive,for 2 weeks|maintained cognitive,+/- intracytoplasmic sperm injection,,,,,,
3514,,vitreous hemorrhage,components of the formulation(s) used.|patient,,paris-la santé penitentiary center (cppls),refractive,,,,"anemia,|without smoking",within 14 days prior to the first dose of the investigational drug,≥ 460 ms,,,,,,
3515,,clear margins,benzoic acid,,beta-hcg,agir,,,,diagnostic and statistical manual of mental disorders-5 [,within the last 2 years|people with lung cancer,long-term ppi,,,,,,
3516,,dysregulated breathing,low-level laser therapy,,tinnitus functional index.|participant,excitement;|laboratory examination,,,,medication regimen|male,at least 3 months after the last dose of study drug.|subject,≥40 ml/min/1.73 m^2|patients,,,,,,
3517,,spliceosome mutations,previous anti-tumor treatment,,ambulation function classification system,intrathecal therapy,,,,blast chronic myelomonocytic leukemia|known,at their last birthday &,prior to study,,,,,,
3518,,subcutaneous retaining structure,immune-modifying drugs,,hyperopia,complaint of bruxism|no psychological drug|no active,,,,preparations,before transplantation,≥ eight weeks to nine months before assessment|(b,,,,,,
3519,,psychosis symptoms,anti-cd20 monoclonal antibody in combination,,semielective surgeries|patients suitable for inhalation anesthesia||,bone augmentation,,,,exertion,at any time prior to study entry,< 100,,,,,,
3520,,tumor biopsy,beta carotene,,measurement of systolic blood pressure,affects elimination,,,,hip,within 8 weeks prior to the screening visit,> 40 or,,,,,,
3521,,flavivirus infection,glp-1release analog,,criteria||age,prelabour,,,,extend into the ventricles,at screening).|currently using ubrogepant,>2 mm,,,,,,
3522,,drugs|previous neurologic,systemic steroid,,following:||systolic bp,treatment related,,,,muscle relaxants|absence,in the next 3 months.|must meet safety,> 8.5%,,,,,,
3523,,screening infection,component of mrg002,,scorad index,axillary imaging,,,,between the,within 12 months of baseline visit|presence of pulmonary hypertension,37.0 ℃ or less,,,,,,
3524,,bells palsy,"training,|smoker",,aminotransferase,hospital referral,,,,personality disorders;|history,within 15 days (removal of material,< 70) sought specialist help,,,,,,
3525,,resections,immunosuppressive therapy.|anti-coagulation therapies,,"men),|vitamin b12 levels",standard monofocal iol,,,,nestling fruit,for at least 8 weeks prior to screening;|take effective contraceptive measures;|voluntarily sign informed consent to participate in this study;|willing,> 25 mumol/l,,,,,,
3526,,multicentric castleman's,immune proteins,,american thoracic society dyspnea scale|hepatic dysfunction,cardiac rehabilitation,,,,minimally invasive nasal trabeculostomy system application,at the time of 1st dose vaccination,< 10% of body surface,,,,,,
3527,,severity of restricted,anteroposterior,,"renal association lower limit for ""mild"" kidney failure).|willingness to sign a consent",completed local therapy,,,,defect|life expectancy<2 years|inflammatory bowel disease|emergency,before participating in the study;|hydrothorax,below 18 years,,,,,,
3528,,physical disability,evolocumab,,rapid antibody test,carcinomatous meningitis.|history,,,,required)|candida spp.,3 months or less,greater than 20 cm,,,,,,
3529,,refractory all,antileukotriene,,electronic blood pressure,inpatients,,,,device(s)|prominent neurologic,within one month prior to screening.|a,≥ 35 years|the,,,,,,
3530,,general hypersensitivity,cell phone,,laboratory test result(s,cm|regular therapy,,,,individually,more than once towards the enrollment,<95%|if a,,,,,,
3531,,hiv diagnosis|history,diverticulum,,liver function total bilirubin (tbil),leukemic organ involvement.||renal function,,,,low risk,for at least 90 days.|a life expectancy,>2 units,,,,,,
3532,,drug addiction,immune-mediated,,creatinine estimated egfr,burns|suspected inhalation injury victims|patients,,,,tolerated,during the study.||replacement doses of,"18-65,|ability to read",,,,,,
3533,,inclusive)|a,neisseria meningitidis,,ascvd risk score,cirrhosis|metabolic surgery,,,,highly effective birth control method,within 2 weeks prior to the first,<400 iu/l|liver biopsy,,,,,,
3534,,abdominal adhesions,hip assist robots|a,,total stent length,2015).|mini-mental state examination score,,,,non-mri,during the trial;|allergy to any drugs;|participation,≥ 25 degrees,,,,,,
3535,,urethral stricture disease,azactidine,,2)body mass index,restorative treatment.|children,,,,radicular symptoms.|previous cervical discectomy,during the observation period,between 18-39 years,,,,,,
3536,,crohn's disease (cd),diplopia,,imu.|hemoglobin,head trauma leading,,,,low grade tumors,within 1 week prior to the first investigational product administration,"i - iv,|levels",,,,,,
3537,,type 1 diabetes mellitus;|retinopathy,cag,,borg scale.||,minimal sedation,,,,blastocyst,within 12 weeks before the first dose of study drug.|subjects,above the normal range of 2.2 to 13.2 µg/l,,,,,,
3538,,dental caries,rituximab:||within one year of screening|at,,lesion response evaluation criteria in solid tumors (recist),pet scanning,,,,ankle of the affected foot,auditory,above 40 miu/ml.||,,,,,,
3539,,acute ischemic,adjunctive debulking,,blastocysts,total body irradiation,,,,iwg 2006,prior to apheresis|previous,at least 12 weeks.||6,,,,,,
3540,,risk.|significant dementia,prostaglandins,,rankin,mri|no,,,,low vision,prone|prior,>130 mmhg,,,,,,
3541,,bleeding inclination,radio-,,present):||lvef,emergency coronary angiography,,,,csf||exclusion criteria,within 3 months prior to enrollment|thrombosis,18-35 kg/m2.|diagnosis,,,,,,
3542,,downs syndrome,medications used in the study|women,,old|american society of anesthesiologists score,autologous hematopoietic stem cell transplant,,,,intra-abdominal devices,within the 8 weeks prior to,> 100 or < 140,,,,,,
3543,,arthritis diseases,sama,,hanifin and rajka criteria,bernaert-paul,,,,non cardiac,within 8 weeks prior to the study blood draw|participant,1-4,,,,,,
3544,,reiter's arthritis,antibody-based drugs.|existence of any concurrent,,intense pulse light procedure,treatment of infection,,,,solitary,within 3 months after the final dose of faricimab||o,< 60ml/min)|neuromuscular disorder.|severe,,,,,,
3545,,peptic ulcer bleeding,hormonal medications,,nhs,ocular rosacea,,,,pregnancy|pre-existing,more than 3 times normal)|presence,10e9/l,,,,,,
3546,,dead virus,complement inhibitors,,months)|hiatal hernia,blood consumption (abc),,,,immunosuppressive therapy|they,within the 3 previous years,≥ 290 µm,,,,,,
3547,,cancer center,criteria:||hawkins-kennedy test,,cd8+ t lymphocyte,histologic verification,,,,"african-american and signs an informed consent form, also referred to as the '",prior to screen/baseline,at least 100%,,,,,,
3548,,patellofemoral pain syndrome,testing,,v1.1.|ecog ps,eyberg child behavior inventory- ecbi,,,,dalk,within 1 year after trial,> 400ml,,,,,,
3549,,cutaneous anaplastic large cell lymphoma (alcl),hyaluronic acid|hematologic,,alanine transaminase (alt)/ aspartate aminotransferase(ast,screening + et,,,,subject|current,within 7 days prior to first dosing.|participant,>30 gray,,,,,,
3550,,syndromic,sodium oxybate,,respiratory failure|urgent need,futibatinib:||major surgery,,,,heterosexually abstinent,within the next hour,> / = 10 pack-years,,,,,,
3551,,brain metastases/cns,those medications used in the treatment,,bos,assessment of estimated glomerular filtration rate (egfr),,,,indolent,less than 4 weeks prior to enrollment,>12.5,,,,,,
3552,,proprietary chinese medicine,celebrex,,pain duration,mri brain,,,,peroral,within 6 months of study entry.|participants,"≤ 38,1°c",,,,,,
3553,,metabolic disease|clotting,contrast media.|subjects,,ecog physical state score.|available initial,endovascular interventional treatment,,,,related to pulmonary,within 2 weeks prior to blood,≥45% and fvc≥40%|pul 2.0,,,,,,
3554,,judged at high,otc medicine,,clinical dementia rating scale,hormonal treatment,,,,surgery;|minimally invasive,during the induction,> 4 mm|class i or ii,,,,,,
3555,,kikuchi's disease,intravenous access.||,,ejection fraction||,radiofrequency.|previous sternotomy operation,,,,prenatal care|abnormal anatomical fetal findings,within 3 months before this car-t,outside the 90 ~ 140 mmhg,,,,,,
3556,,aortic aneurysm,depot or vaginal ring,,myc,criteria:||antiviral therapy for hbv,,,,tanning,during the treatment,> 1.5 × upper limit of normal (uln),,,,,,
3557,,malabsorption;|acute infectious diseases,meperidine,,limb circumference,viral hepatitis|patients,,,,gastrointestinal tract.|abnormal liver function,within the prior 2 years.||23,<20/200,,,,,,
3558,,hiv positive,anti-cgrp mabs,,germinal center,clinical progress,,,,low risk cohort:||mother and/or father of unborn child:||- have,within 1 year prior to the start of the screening period,18 years and older|written informed consent of the volunteer to participate,,,,,,
3559,,laparoscopy|contraindication,local corticosteroids,,ast)(serum glutamic-oxaloacetic transaminase,wechsler adult intelligence scale,,,,catecholaminergic,during conditioning (campath®,between 18.5 and 29.9 kilograms per square meter (kg/m^2),,,,,,
3560,,primary colon,mainly antiarrhythmic drugs,,corrected qtc interval,icf).|body mass index,,,,osteoporosis|prior,within 30 days prior to the first administration of the study drug,22c3 pharmdx)|melanoma cohorts,,,,,,
3561,,emotional liability|french speaking|availability,iodinated contrast|patients,,stool routine + occult blood,baseline pre-bronchodilator,,,,bm|patient,within 10 days before randomization,=< 21 days (42 days,,,,,,
3562,,mechanical low back pain.|males,pvi,,total central corneal,liquid biopsy-based,,,,urticarial,during the trial|other reasons investigators,">= 1,000/mm^3",,,,,,
3563,,caffeinated beverages,various,,recist 1.1 although measurable disease,adjuvant therapies,,,,non-contrast computer tomography (,within 4 weeks prior to leukapheresis,< 56.0 d,,,,,,
3564,,trying to become pregnant|suspected alcohol,endometrioid,,pancreatic body/tail tumor,etiological assessment,,,,implanted defibrillators,within three months before the trial,110,,,,,,
3565,,renal vascular disease,over-the-counter drugs known to alter drug absorption,,gleason,local guidelines)|caffeine consumption,,,,"skin,|cutaneous",prior to first fedr||,< 30ml / min,,,,,,
3566,,rash,viltolarsen.|participant,,recist 1.1);|tumor burden,imminent,,,,diagnostic and statistical manual of mental disorders - fourth edition),throughout the treatment period until 120 days after the last dose of the study drug.|sign the inform consent form,above institutional normal,,,,,,
3567,,external skin lesion,spine center|scheduled,,urine drug screen for cannabinoids|taking any medication,assessments;|present skin sensitization test,,,,ra-related,within three months before screening,< 150 cm|body weight,,,,,,
3568,,covid-19;|active tuberculosis infection,vpa,,cd4+ t lymphocyte count,yag laser capsulotomy,,,,catheter placement,within the last 6 months prior to start of study treatment,< 1.5 x109 /l|hb < 8.0 g/dl|albumin ≤ 25 g/l|uncontrollable,,,,,,
3569,,gastrointestinal malabsorption,sensitive substrates area,,er in al hussein university hospital.|patients,endoscopic mucosal resection|ercp,,,,lower extremity and spine.|subjects who have discontinuity,within 4 weeks prior to study drug,"<25,000 / µl",,,,,,
3570,,tumors;|autologous hematopoietic stem cell transplantation,assent,,lumbar disc degeneration,liver stiffness testing (lsm),,,,south,within 4 weeks before baseline or,between 40 and 70 years,,,,,,
3571,,deep vein thrombosis (dvt),soft tissue imaging,,total hepatitis b core antibody (hbcab),valvuloplasty,,,,insulin dependent diabetes|patients,previous 5 days|peptic ulcer,27-40 kg/m2)|non,,,,,,
3572,,intravascular cancer,diuretic agents,,kellgren-lawrence score,definitive chest radiotherapy,,,,non-atherosclerotic lesions,within 3 months prior to day 0,≥ 90 g/l.|ast、alt ≤ 10 × uln,,,,,,
3573,,muscle relaxation exercise,study drug excipients.|participation,,partial thrombin time (aptt) values did,alternative treatments,,,,amenable for surgery,within the last 3,less than 1 month.|patients,,,,,,
3574,,bpm|prolonged qtcf,beta-blockers medication,,muscle test score,cooperative.||,,,,not yet improved,within 7 days prior to check-in|donation,> 30 minutes/day of,,,,,,
3575,,metastatic thymic tumor,possible curative treatment,,akp,radiation therapy;|had,,,,cytologically-confirmed,in past 30 days|non-pregnant|willing,> 2 x uln|chronic obstructive pulmonary disease,,,,,,
3576,,prescription eyeglasses,coffee supplements,,hr-tpo-itp-iii-ped clinical trial,barrier contraceptive,,,,between the pre-operative,during the first week (,encephalopathy.|greater than or equal to 35 weeks,,,,,,
3577,,co-infection,cgh,,general exclusion,elastometry,,,,||hospitalized,at least 4 on,less than 60 months,,,,,,
3578,,colonic resection,grapefruit-containing,,national taiwan university hospital,autologous stem cell transplantation.|histologically confirmed diagnosis,,,,suitable for radical concurrent,within 7 days prior to the first dose of study drug.|a,less than 3.5 grams per 24 hours.|no huaier granule,,,,,,
3579,,learning impairment|investigator considers participation in the study not,combination oral contraceptives,,sars-cov-2 antibody test,autologous stem cell transplant,,,,mg-zg122 injection,at screening that satisfies previously,greater than or equal to (>=) 6|participants,,,,,,
3580,,retina detachment,tioconazole,,alanine transaminase (alt) levels,physiotherapists,,,,non-pharmacological pain,within rda,≥18 years|currently,,,,,,
3581,,spermicide,vitamin d supplements,,iiil,asphyxiation,,,,membrane severe,within 28 days of enrollment.|patients,i-ii|age,,,,,,
3582,,normal monthly menstruation,eluxadoline,,menstrual period (lmp),alternative assessments,,,,molecular targeted therapy,within the past 12 months|fetal demise,between 18 and 90 years,,,,,,
3583,,right bundle branch,local label|basal insulin,,serum ferritin concentration,lipid lowering therapy,,,,nei scale|have been,at doses equivalent > 10 mg/daily of,45 u/l||,,,,,,
3584,,spontaneous bacterial peritonitis,influenza infection2,,npi-agitation,mitochondrial fatigue,,,,age|self-reported,within 4 weeks of baseline visit|prescription topical medications,between 18 and 75 years|performance status,,,,,,
3585,,post-vaccination reaction,immunoglobulin g [igg],,visual analog scale score,coronary artery bypass grafting.|participation in other clinical trial in the 30 days before enrollment.|the existence,,,,which may complicate the atacor ev temporary pacing lead system insertion procedure|any conditions,recent (6 mo,<lln,,,,,,
3586,,foreign objects in both wrists.|agree to adhere to the lifestyle considerations.||exclusion criteria:||participants,incretin,,prostate cancer|prior evaluation of micro,antibiotic therapy,,,,vessel|collateral,at time of the (first) administration,≤ 30 cc,,,,,,
3587,,past complications,disease.|systemic steroid therapy,,serum specific ige measurement|age,blood analysis,,,,lesions||,within 4 weeks before apheresis;|hepatitis b,50 of a,,,,,,
3588,,bladder insufficiency,nilm,,who severity classification,thyroid meds,,,,selected districts|provide pregnancy care|chief doctor,during the period of data,grade a,,,,,,
3589,,psychological pathologies,folic acid drugs,,thrombophilia test,immunosuppressive treatment,,,,durham housing authority (dha),within 30 days prior to ad-td-nsil12 administration.|blood transfusions,≤ 5.5|patients,,,,,,
3590,,indicates tumor,local steroid injection,,drinks,pi).|progression,,,,non-insulin hypoglycemic drugs,at least 6 months before screening.||,≤ 1.5 mg/dl|in,,,,,,
3591,,malabsorption syndrome;|adverse reactions,anti-diabetes medications,,international visual acuity,nmcsd,,,,dutch language|diagnosed with pcos,before inclusion/randomisation,> 2+ ar,,,,,,
3592,,ischaemic cerebrovascular disease,anti-transplant rejection drugs,,viral hepatitis： hepatitis b virus (,standard sector biopsy,,,,large b cell lymphoma,within 30 days of screening|systemic therapy,twice-a-day,,,,,,
3593,,nicotine replacement therapy|receiving behavioral,systemic anti-cancer,,weight,pet)/ct scan,,,,technique,"after age 12, will not be excluded.|have answered 'yes' to question 5",">24 to <30 breaths/min,|spo2",,,,,,
3594,,sensorineural hearing deficits,immunosuppressive treatment|patients,,cytogenetics,small cell histology,,,,site staff,"before participating in the study,|agreeing to participate",ii-iv).|in,,,,,,
3595,,solid organ malignancy|available results,gastroprotective agent|patients,,old|american society of anesthesiologists (asa) physical status,unilateral total knee arthroplasty.|the,,,,no myocarditis,at the time of enrollment.||patient,18-50 years|body mass index,,,,,,
3596,,neurogenic bladder related,noradrenaline dopamine,,urine drug test;|habitually consumed,upper gastric,,,,acute stage;|diseases of the thyroid gland;|therapy with any,within 3 months|has a,≤ 70 years.|no,,,,,,
3597,,comorbidities||,oral contraceptive pills,,corrected estimated glomerular filtration rate (egfrcorr),clinical study experience||participation,,,,high dose nsaids,after operation.||,19 to 45 years|body weight 55 kg or more,,,,,,
3598,,medically stable,any drug or its components,,standard therapy.|age,excisional biopsy specimens.|all the studied cases include,,,,immunosuppressive therapy|use,for more than 3 months,less than 210 g,,,,,,
3599,,unhelpful speech language thoughts,omeprazole,,hepatitis c infection|history,immunotherapy;|weak treatment,,,,study;|at least 10,over the past year,≥ 126 mg/dl||viii,,,,,,
3600,,substance use disorder,contains small amounts,,who lymphoma classification criteria,hf therapy,,,,non-alcoholic fatty,after administration of,at least 75% of the function,,,,,,
3601,,normal menstrual cycle.|spending,methylated drugs progress,,htn,overall assessment of the psychiatric,,,,uncontrolled,for the first time,≤ 145 mmhg,,,,,,
3602,,anaplastic astrocytoma,protein supplements,,alanine transaminase (alt) level,her2 expression,,,,pathologic,within the first 7 days after extubation (see criteria below,18-75 years|ps score,,,,,,
3603,,pten hamartoma tumor syndrome,acitretin,,maximum flow rate,prosthetic restorations|availability,,,,chinese.|participant,for at least 15 minutes,equal to or better than 1.0,,,,,,
3604,,intracerebral tumor response,excisional biopsy,,blood pressure elevation,single surgery,,,,non-valvular atrial,within 2 weeks prior to admission,20 /32)|refraction,,,,,,
3605,,hemiplegia|heart failure,tissue engineered materials,,nichq vanderbilt assessment scales-parent.||exclusion criteria,iii.;|body mass index (bmi):,,,,adequate organ,before starting study treatment.|subjects,>300mg /24h,,,,,,
3606,,spastic type cp,c1d1,,peds-dm,individual safety of perioperative administration of no||,,,,intra-uterine adhesions,during the study treatment administration,>30 days between surgery,,,,,,
3607,,obstructive congenital mega-ureter|subject,dynamic sitting,,peripheral arterial disease;|preoperative serum albumin,sit;|no lateralization of aldosterone secretion,,,,good,within 72 hours before check-in on day -1.|the,18-75 years.|patients,,,,,,
3608,,terminal kidney disease,st. jude investigator-initiated study,,anticoagulants):||prothrombin,sarcomatoid features,,,,preformed donor specific antibodies,in the previous 3 years prior to study,≥1.5×109/l;hemoglobin,,,,,,
3609,,total deafness,anti-integrin,,effective failure,situ hybridization (fish),,,,interferes with contact lens wear,within 1 year after infusion,3 years and 16 years,,,,,,
3610,,"fibromyalgia syndrome,|cervical radiculopathy",bends,,anti-hepatitis c-virus antibodies,gene mutation diabetes,,,,micropapillary,during at least 2 separate ambulatory care encounters,≥ 18 years and ≤ 80,,,,,,
3611,,liberty|mental retardation,paramedics,,mature,special types of diabetes|suffering from,,,,non-dominant hand||enrolled,for three months before enrollment,>sm1,,,,,,
3612,,coronary lesion,benzodiazepines,,plasma amyloid-beta test,local cutaneous application,,,,eating,within 14 days before baseline,>52 ng/dl,,,,,,
3613,,terminal renal failure.|participation,component of the study regimen,,lansky play score,tobacco cigarettes,,,,alteration)||cd22-positive,in the next 2 years.|have,> 60 ml/min/1.73m2,,,,,,
3614,,axial arthritis,paclitaxel-,,months.|adequate organ function .|females,finger pulse,,,,"surgery,|known",within the past 14 days prior to study enrollment|hemoglobin,>4 studies,,,,,,
3615,,swelling,electrical implant|type i diabetes|gestational,,culprit,pleural,,,,nervous,at least 3 months prior to screening,"<80,000/μl",,,,,,
3616,,chronic bacterial,drugs of the same class|if capable of reproduction,,moderate activity disease,mri imaging,,,,non-cooperation,at least 5 cigarettes per day,18+ years,,,,,,
3617,,caries lesions;|children,protein subunit,,bispecific antibody,efferon ct device,,,,might interfere with study conduct,at least 28 days must,= 2,,,,,,
3618,,life-threatening condition pregnancy,incretin mimetics,,prothrombin time prolongation,replacement therapy,,,,palliation,within 14 days prior to registration,> or = 100 000 mm3,,,,,,
3619,,cytokine release syndrome,anti-tnfα,,uric acid level,calcification of the apical foramen,,,,phq-9m,in the next year;|having problems,within therapeutic range of intended use of anticoagulants.|criteria,,,,,,
3620,,creutzfeldt-jakob disease,dopaminergic agonists treatment,,hb baseline,produce reliable,,,,transcon,within 28 days prior to entry,between the 50th and 95th percentile,,,,,,
3621,,chronic pancreatitis.|any impairment,drugs or foods,,european hernia society classification incisional hernias|body mass index (bmi),poor oral hygiene.|patients,,,,hf；c. severe,within 6 months before randomisation,> 2.5 mg/dl|hematocrit < 0.34 or 0.50 l/l|a major,,,,,,
3622,,impact the absorption of the investigational,fontan-type palliation||who,,hepatitis b core antibody (hbcab).||have abnormal tissue or organ function,plasma therapy,,,,institutional neuro-pathological evaluation,within previous 30 days|currently participating,"18-65 years,|asa score",,,,,,
3623,,sle,mobile gameplay feature|having a,,serum human chorionic gonadotropin (hcg) test,procedural sedation,,,,infectious,every 28 days,≥ 100 x 109 /l.||,,,,,,
3624,,breast-feeding|hiv|known allergy,nerves,,moca test,allogeneic stem cell transplant.|patients,,,,grade 2 or less,in the past 3 months|blood thinner prescription medication|chronic use,>= 60 ml/min/1.73 m^2|hemoglobin,,,,,,
3625,,refractory symptoms,calcitonin,,positivity rate,adrenal replacement steroid dose,,,,age|prisoners|children|pregnant,during the last month|age,greater or equal 70.|timely delivery of port preferable,,,,,,
3626,,gr-etiology,oral tyrosine kinase inhibitors,,high blood pressure in children,randomization,,,,non-ocular surgical procedures|uncontrolled,for at least 6 months.|lt4 monotherapy dose of,≥3 months.|have,,,,,,
3627,,bleeding risk calculated,vegetarian,,corrected reticulocyte count,regular hormonal therapy,,,,study;|symptomatic brain metastasis;|histologic diagnosis,within 4 weeks from the time of enrollment;|researchers,>40 g/d,,,,,,
3628,,ureteral perforation,compounds of similar chemical or biologic composition to novobiocin|patients,,t-cell/histiocyte,gonadal function,,,,metabolism.|regular smoking,within 1 month before enrollment;|suffering,<10 ng/ml).|concurrent,,,,,,
3629,,rinsing,adequate reduction of mitral regurgitation,,granulocyte-colony,coronary angiography,,,,lasting for more than 24h.|ecmo,less than 8 weeks prior to enrollment,above 35 years,,,,,,
3630,,right ventricular outflow (,give gp contact details.|participating,,arm||bmi,haploidentical donor with,,,,sport s-icd study investigator neither encourage nor discourage performance of any given sport.|patient understands that the,within the laboratory reference,under 18|presence of any severe,,,,,,
3631,,lupus)|amyloidosis|chronic renal insufficiency,tps,,pten,structured clinical interview for dsm-5 disorders (scid-5-rv)||,,,,chest,during screening period|patients,≤ 2.5 x upper limit of normal,,,,,,
3632,,post-stroke,similar drug,,national cancer institute [nci] common terminology criteria,elective gallbladder surgery,,,,lips relaxed).||,within the duration of the study.||after 10 minutes supine,"≤5×uln, tbil|3×uln",,,,,,
3633,,extract,iscador® p,,monomicrobial e. faecalis,medical conditions||significant,,,,breastfeeding|acute,in the first 5 years of,≥nyha level,,,,,,
3634,,cystic changes,prescription pain,,serum tumor markers,surgical incision healed well,,,,heart-failure|secondary causes,performed 28 days prior to sub-study randomization,been prescribed regularly.|bone protective agents,,,,,,
3635,,drug allergy);|any disorder of the central nervous system,fentanyl,,phq-8 score,inflammation|current treatment,,,,portico valve);|the,after r0 resection);|lymph node metastases,at least 50 kilograms (kg),,,,,,
3636,,clinically meaningful abnormality,beclametasone,,ne,kidney transplant waiting list,,,,grade 2-3,at least 3 nights per week and,> 65 inches the patient,,,,,,
3637,,chemotherapy|pregnancy|cognitive impairment,occlusion after artery stenting placement,,"lumbar spine;|limb length discrepancy,|recent buttock trauma,|deep gluteal syndrome,|extrapelvic compression of the sciatic nerve",anti her2 therapy,,,,≥ grade,within the last four weeks.|any other,between 18 and 80 years|both sexes|pre-,,,,,,
3638,,glomerular diseases,alkylating agent chemotherapy,,iv)|left ventricular ejection fraction,pgd,,,,affecting the sensorimotor system|alcohol,within 4 weeks prior to the first dose of study medication|treatment,>= 30ml/min/1.73 m2|>=18 years,,,,,,
3639,,haematuria,wide field radiotherapy,,nice center university hospital|secondary vertebral fracture,mental health institution by virtue of an order issued,,,,l1-inhibitor,over 12 to 72 hrs.|no,5 or more times per week|history,,,,,,
3640,,severe pneumonia,tcas,,uln;total bilirubin,hrct findings,,,,national,within the last 12 months|frequent (daily),50-90% diameter stenosis,,,,,,
3641,,prolonged travel,triptans,,hiv-1 rna determinations,bilateral neck dissection,,,,stage iv breast cancer,during the previous 6 months to start of the study|to have sustained a surgery,better than distance,,,,,,
3642,,gastrointestinal disease(crohn's disease,deformations,,core temperature,curative treatment,,,,required treatment|male bmi,in the last 12 months;|acute,> 221μmol/l,,,,,,
3643,,liver metastases|total bilirubin,antioxidant drugs,,histological grade,ocular injections,,,,that affects clotting,within the 6 months prior to the first dose of study drug,>80 years|known,,,,,,
3644,,tumor-related pain,dynamic hip screw,,systolic blood pressure (bp),psychiatric illness|history,,,,stroke|history,within 1 year after enrollment;|patients,< 10%|willingness,,,,,,
3645,,multiple risk factors,opioid medication,,cotinine test,light chain amyloidosis|active cns disease|inadequate bone marrow function|inadequate renal,,,,clinically significant deviation from protocol/protocol violation.|serious,"less than 3 months before the start of the protocol,|impaired alertness",develop dose,,,,,,
3646,,behavior modification program,study medicine,,urine drug tests|woman,implant procedure,,,,second,at the baseline visit;|uncontrolled/,<18 years old,,,,,,
3647,,hemolytic anemia).|anemia,immune diseases|individuals,,north american symptomatic,bowel resection/reconstruction,,,,non-gastrointestinal fistulas,at least 4 hours apart,> 18 years old patient able,,,,,,
3648,,human cellular exosomes,depot naltrexone,,estimated creatinine clearance,left side,,,,foot,within the past 6 months|patients,20-75 years|patients,,,,,,
3649,,unstable pulmonary condition,growth factors,,adem,pep,,,,mobile tongue,prior to the start of study treatment,< 20 years or older than 80,,,,,,
3650,,cns defect,piperaquine,,matched healthy,oxygen saturation readings,,,,primary cause of ocular hyperemia,within the 6 months prior to the screening,> 2-times of laboratory normal values,,,,,,
3651,,breast-feeding women|subject,heds||exclusion criteria,,ecog physical condition score,quit smoking,,,,lower limb,history)|medical history clear of cardiovascular,4 to 7)|willing,,,,,,
3652,,transient ischemic cerebral attack,components of pantrek|participation in,,human immune deficiency virus (hiv) test,psychosocial rehabilitation,,,,synovial fluid,within 7 days prior to first dose of study medication|are,0-1|ability to,,,,,,
3653,,tumor type,drugs of similar chemical class.|concurrent treatment,,female;|ecog score,standard of care therapies,,,,specimens,last six months before hospitalization,18-60 years-old 5,,,,,,
3654,,identifying,old|newly,,to1.|life expectancy,mast cell activation disorder,,,,dutch perioperative guideline:|doubt by the surgeon,within six months.|presence of a history of,> 1.5,,,,,,
3655,,extracranial embryonal tumors,recombinant tissue plasminogen activator,,hepatitis b virus core antibody,blood work,,,,severity index) score of,less than 20 degrees,less than 1 month;|caregiver of patient already cared,,,,,,
3656,,lichen planus,monoclonal antibody treatments,,oxygen saturation,total parenteral nutrition,,,,influence pain sensation|current,within 90 d of screening,<100×109/l|known,,,,,,
3657,,tricuspid regurgitation,its excipients;|dyspepsia,,capillary plasma glucose,middle pancreatectomy,,,,university faculty of health sciences,throughout the study period,complete response (cr),,,,,,
3658,,immunocompromised disease,cyp3a liver enzymes,,cor tricuspid ecm valve will be the physiological right-sided atrioventricular,covid-19 antigen tests,,,,nivolumab pd-1,during study participation.|participant,≥ 18 years||aortic,,,,,,
3659,,|• respondents,icv,,international classification of diseases,old.|will,,,,by room air oxygen saturation,within the last 2 weeks||no,>18 and ≤70,,,,,,
3660,,persistent diarrhea,itacitinib,,prothrombin time>1.5 times,vacuum-assisted excision (vae) procedure|clinically significant,,,,below the renal vessels,within 4 weeks prior to administration of the investigational product,18 and 80 years,,,,,,
3661,,glucose-6-phosphate dehydrogenase,sglt2-inhibitors,,serum immunofixation electrophoresis,starting ai therapy,,,,proprioceptive,within previous 3 months,less than 30 minutes,,,,,,
3662,,lung functions,oral treatments,,cord blood,musculoskeletal injury|dietary supplements|medication|allergy,,,,central nervous system pathology,during the study period and within 6 months after the end of the study period,35-80|lvef <=25%,,,,,,
3663,,inclusive).|for healthy,oral retinoids,,esophago-gastro-duodenoscopy|gastro,clinical management,,,,intra-articular injections);||physiological doses,within prior 10 days:||presume,> 40||b. personal,,,,,,
3664,,manifestations that,steroid-,,novel coronavirus pneumonia(trial version,anne™ patch,,,,non-breast malignancy|active,within 14 days prior to enrollment.||,< 40 y/o|post-operative,,,,,,
3665,,anterior myocardial infarction):||chest pain,components of the velocity implant or delivery system|written informed consent,,bariatric surgery.|diabetes,antiviral prophylaxis,,,,pregnant|liver transplanted|diagnosed,preceding 12 consecutive months,>45 ml/min|women,,,,,,
3666,,lung diseases,pde5 inhibitors,,m0):||tumor size>2cm|lymph node-positive,vaccine):||inactivated influenza vaccine,,,,non-insulin dependent,after day 28,"> 7.0 mmol/l,|body mass index",,,,,,
3667,,venous disease|muscle disorders,direct vs. indirect anchorage).||,,nci-ctcae,cardiac interventional therapy,,,,"immunotherapy,|not knowing",more than twice,≥5x uln,,,,,,
3668,,mental problem,anti-met/egfr,,child care providers,therapy with,,,,low-quality,during the period covered by,19-70 years|weight,,,,,,
3669,,tb).|gastrointestinal disorder,hematopoietic growth factor support):||hemoglobin,,sle classification criteria,gvhd|major surgery,,,,sacrospinous,in ≤10% tumor cells,between 20% and < 45%,,,,,,
3670,,horizontal root fractures on buccal aspect below bone level,β-blockers,,older.|ecog performance status,bone health,,,,type ii diabetes,at least 3 months after mi,lower than 18,,,,,,
3671,,metastatic disease|adequate bone marrow function|adequate,satisfy the investigator of fitness,,arterial invasion,automated perimetry,,,,infection.|significant,within 3 months prior to experiment,≤ 50 mmhg,,,,,,
3672,,gastrointestinal (gi) surgery,long covid-19,,namely:||absolute neutrophil count (,abdominal mesh|planned vaginal mesh,,,,disseminated,within 6 months prior to randomization;|use,≥10 g/l,,,,,,
3673,,lack of spontaneity,lipopeptide,,≤2.5×uln;|expected survival,m^2|heart failure|ineligible,,,,femoral head|surgeon considers the patient appropriate for the core decompression procedure,within 2 weeks before the first administration of the study,between 30 to 40 years.|primigravida,,,,,,
3674,,multi-segmental,adequate organ function|agreement,,easi score,small molecule anti-angiogenesis drugs,,,,class iv nyha functional class,within 72 hours prior to receiving the first dose of study medication,18 years or older to participate,,,,,,
3675,,50 gy,local guidelines,,car t cell infusion.||use of,bilateral orchiectomy,,,,after successful,within the last 1 year.|those,">2,8m/s.|pulmonary",,,,,,
3676,,"cotrimoxazole:||allergy,|advanced liver",severe liver,,indicates,those involving il-2,,,,intra vaginal discomfort,within 3 months prior to the imaging study.|pregnancy,> 500 pg/ml,,,,,,
3677,,syrinx,hospice,,calculated creatinine cl,re-transplant,,,,could significantly affect folate status,within 7 days prior to the start of study treatment.|women,<30 per 1.73 m2,,,,,,
3678,,cardiogenic pulmonary edema|unable,telephone,,test spermatic cord block,multigated acquisition,,,,grade iii or iv,within 28 days before the administration,≥50 u/l|ast/alt ratio,,,,,,
3679,,functional damage,inhaled corticosteroid,,addiction recovery,stimulation (ect,,,,islet/pancreas,at least two prior line,≤18;|not,,,,,,
3680,,pulmonary rehabilitation,definity microbubble infusion|history of,,iii.|body mass index,major amputation of the target limb,,,,ra|pregnancy,at least one week before the start of the study,less than 5% difference,,,,,,
3681,,myxoid edema,opioid medications|diagnostic shoulder arthroscopic procedures|patients,,etdrs bcva letter score,chemoradiation therapy,,,,neck region.|patients,likely to interfere with the study drugs,≤ 2.5x uln,,,,,,
3682,,autoimmune disease|received,strong cyp1a2 inhibitors,,mec,b-cell maturation antigen (bcma),,,,fractures|concomitant,in the 6 months prior to screening,< 60 bpm or > 100 bpm,,,,,,
3683,,myocardial related symptoms,adjustments,,special care nurseries).||,abdominal hysterectomy|between the,,,,immunoglobulin a,between 8 and 12 years.|patients,18-65 years;|able to provide consent and complete all study materials;|consuming,,,,,,
3684,,pulmonary disorders;|toxic reactions,diflunisalin,,interval time,ajmaline tests,,,,epithelial tears,within 3 months before the first administration;|those,less than 30 ml,,,,,,
3685,,glucose-galactose malabsorption,anti-ctla4 antibody,,anti-pd-1,pancreatic resections,,,,primary endpoints,within the past 1 year,≥ 2|history,,,,,,
3686,,sinusoidal obstructive syndrome,hvpg,,ecg morphological abnormalities,tomography,,,,requiring detoxification,after rp;|contraindication to short,< 4×10^9/l,,,,,,
3687,,infection||,methacholine challenge test,,beck depression inventory|willingness and willingness to participate in the research|completed,hepatic encephalopathy|history,,,,inactive,during physical examination,≥ 2.5 g/dl|international,,,,,,
3688,,system|bilateral tubal occlusion vasectomized partner,immune activation profile,,facial skin,chemical reconstruction,,,,unprotected branch,within 1 week prior to randomization|have,"≥ 50,000/l patient",,,,,,
3689,,follows:||+bronchial asthma,potent cyp3a4 inhibitors,,classification|meets ipss-r classification,repeat resection,,,,diagnostic and statistical manual of mental disorders (dsm-v,providers||,older than 20 years.|histologically,,,,,,
3690,,acute infections of the genitourinary system,gnrh-analogues,,resuscitation effort)|ph,mitochondrial mutation analysis,,,,highly effective contraception methods,within 24 of onset,> 3 months almost,,,,,,
3691,,alveolar opacities,intravenous diuretics,,beighton hypermobility score,lose,,,,expansion,prior to resection,< 500 msecs||central nervous system function,,,,,,
3692,,non-syndromic retinitis pigmentosa,vaccination,,mmhg|diastolic blood pressure,test,,,,over-encapsulated,for less than 48 hours,<7 years,,,,,,
3693,,primary sleep disorder,anti-arrhythmic,,physical exam,primary treatment,,,,longest diameters,at least 1 visit,2 or above,,,,,,
3694,,benign biliary tract diseases.|no,phantom limb,,eoi plane block,hemostatic clips,,,,self-reported activity levels,for more than 5 years,less than 150 kg|patients,,,,,,
3695,,cerebral vascular accident (cva),hormonal agents,,prescribed)||systolic blood pressure,brain metastases|neurology consult to confirm diagnosis,,,,surveys).|ability to read,during the past two years,score of more than three.||,,,,,,
3696,,omental metastases,recombinant proteins,,ild,general physical examination,,,,r3918-pnh-2022 [nct05131204],within 18 to 30 months of original diagnosis,≥3 points,,,,,,
3697,,oligospermia,anti-pd1,,fibrinogen ≥1.0 g/l,anticoagulant regimen,,,,central nervous system metastases,throughout the duration of the study|must live,> 3.5 g/day,,,,,,
3698,,cardiopulmonary disease)|older,taf,,estimated left ventricle ejection fraction,bronchoalveolar lavage.||,,,,between the carious lesion,during the 4 days prior to the start of the investigation,older than 50 years,,,,,,
3699,,peripheral atherosclerotic disease,captopril,,blood loss,chemotherapy-induced neuropathy,,,,irs,during their participation in the extended study and,mental disability|lack of compliance with the protocol,,,,,,
3700,,myocardial ischemia.|ste,sirolimus-containing medications,,cdc lists asthma,bone surgery,,,,esophageal lumen circumference.|history of,for at least 2 months prior to the first dose of study drug,≥ 150 mmhg,,,,,,
3701,,cerebral spinal fluid pleocytosis,antimalarial agents,,barcelona clinic liver cancer (bclc),heds,,,,deemed acceptable.||,throughout the study.||the consent of volunteers to all restrictions,>= 1.0 x 10^9/l|platelet count,,,,,,
3702,,another dermatologic condition,certolizumab,,north american symptomatic carotid endarterectomy trial (nascet) criteria|cortical infarction,cease,,,,phq-9,at least 6 previous,more than 90/140|2nd,,,,,,
3703,,hepatitis c virus infection (hcv),components of study treatment.|have skin,,amyloid cardiomyopathy|hemoglobin,bullectomy,,,,parenteral nutrition|patients receiving,within 30 days of the screening,less than 1 % per year,,,,,,
3704,,mixed nodules,zoliflodacin,,national cancer institute common terminology criteria,coagulation tests,,,,prostatic urethra,within 2 weeks,65 to 75 years old,,,,,,
3705,,obliterative arteriopathy,melatonin-related substances,,leg length,stent implantation;|it,,,,non-daily,within 4 weeks prior to study entry.|known,≥ 50kg,,,,,,
3706,,systemic autoimmune,ivc measurements,,moderate ad.||dementia,pet/computed tomography (ct) scan,,,,radiological symptoms,at the medical institution.|histologically confirmed,≥90 mmhg|patients,,,,,,
3707,,liver problems,component of the therapy,,"nasal systematic screening,|mrsa",wechsler memory scale iv,,,,non-mastery of french language,at least 4 weeks before the first administration,≥1 month (30 days,,,,,,
3708,,neural tube defect,anti-lymphoma therapy,,positive pressure dependence,herbal medicinal preparations,,,,core 70-100 ml,within 30 days prior to visit 1.|the,3 to 9 years,,,,,,
3709,,age|traumatic,ocular diseases;|bilateral moderate,,serum progesterone,re-treatment,,,,congenital abnormalities.|stillbirth,within the next 4 weeks.|(for,< 6 red,,,,,,
3710,,acute medication.|able to undertake designated level of tai chi exercise.|live in hong kong.||,topical medication,,alt/sgpt,vital signs examination,,,,epilepsy|clinically significant,for 5 years since initiation of that therapy.||a,"0, 1",,,,,,
3711,,remain stable disease,fructan,,pcr;|oxygen saturation,shopping,,,,mannitol.|active tobacco,during current,130-139,,,,,,
3712,,idiosyncratic,sohag hospitals.||,,micr).|patients,postoperative radiotherapy of the breast,,,,third edition of,within three months before randomization,between 0-5|person,,,,,,
3713,,high-risk disease,vancomycine,,inclusive.|participant should,verbal feedback.|female|over the age,,,,c2-c8)|mri,prior therapies||cohort 4,at least 18 years|owns,,,,,,
3714,,dietary program);|physical changes,oriental herbs.|binge drinking,,peripheral blood hbv dna titer,electrocardiography,,,,influence the outcome of the study|history,within 6 weeks of informed consent,≥30g/l.|urine,,,,,,
3715,,metastatic colorectal cancer,cd137,,maxillo-facial traumas|nasopharyngeal,systemic treatment,,,,periventricular leukomalacia,within 30 days before the first dose of trial drug,18-49 year|a,,,,,,
3716,,heart disease).or,antioxidant,,american society of clinical oncology/college of american pathologists (asco/cap) guidelines|confirmation,lateral nerve targets,,,,visble,at the time of enrollment|subjects,>60.|adequate,,,,,,
3717,,signs of progression,vitamin k deficiency,,hgg,clear cell renal cell carcinoma metastatic,,,,office bp,at least 5 hours of contact,≤ 1.5 times the uln,,,,,,
3718,,alternative therapeutic treatments,anticoagulant medications,,urine protein ≤1+,ovarian ablation,,,,osseous,within 2months of starting antibiotics.|if individual,2-10,,,,,,
3719,,cf|diagnosis,wolff,,nci,25-hour urine collection for,,,,sci|self-reported,within 60 days before initiation of study,at least 12 months.||,,,,,,
3720,,basal heart rate,class iii anti-arrhythmic drugs,,cardiac index,stereotactic surgery,,,,"diagnostic and statistical manual of mental disorders, fifth edition (pcl-5) score",previous intake,>221 umol/l];|patients,,,,,,
3721,,redundant,telemedicine,,men)|body mass index,her2 immunohistochemistry (ihc) test,,,,swan,within 2 min when,1 - 14 days|will,,,,,,
3722,,central serous chorioretinopathy,mandarin-speaking,,ecog ps score,attention-deficit/,,,,allele,within the past year.|has,≥ 80 g/l,,,,,,
3723,,risk factor||,mallya,,assessment,continuing treatment,,,,non-deeply,within the designated periods prior to screening:||cytostatic or cytotoxic drugs,2 cm between the tumor,,,,,,
3724,,pgnmid|proteinuria,oral agents,,neutrophil absolute value (anc),tests)||hepatic transaminases,,,,bcl2,at the screening visit).|agree to make every effort to avoid pregnancy,≥ 16 years,,,,,,
3725,,corrective insoles,nerve bundles|patients,,national cancer institute standard for general terminology of adverse events (nci-ctcae 5.0,egfrviii mutation,,,,inducing torsade de points,in wuhan,<= 0.90,,,,,,
3726,,laryngeal pulmonary,esophagogastric junction,,thyroid function|type 1,nerve block procedure,,,,beverage,prior to eye manipulations,0-2.||,,,,,,
3727,,adenocarcinoma of the prostate,hydrocodone,,organ function:||bone marrow,lateral canthal lines,,,,suitable for radical surgical excision,at first or second site.|typical indications,20 cigarettes/day|those,,,,,,
3728,,mycobacteria tuberculosis,adebrelimab,,karnowsky performance status index,itbs treatment,,,,lung-map)|participants,within the last 8 weeks,decreased,,,,,,
3729,,renal diseases;|(b,live attenuated chicken pox,,harris hip score,montreal cognitive assessment (moca,,,,diagnostic criteria for dementia,within the previous three month|have a work,<20 packs years,,,,,,
3730,,ductal adenocarcinoma,statin drugs,,neutrocyte,lumbar catheter,,,,juxtafoveal,at least 4 weeks prior to the screening visit,at least 25 milliliter units (miu)/ml within 28 days prior to,,,,,,
3731,,≤26.6kpa|sequential organ failure assessment score (sofa),strong cyp3a-inhibtors,,serum ige ≥1000 iu/ml,histological confirmation,,,,non-improving,at screening.||subjects,greater than 12 weeks;|adequate hematologic,,,,,,
3732,,obstructive sleep apnea hypotension (sbp <,rocuronium,,hiv-1 rna test,palliative care|estimated survival,,,,stage iv or higher,within 6 weeks before enrollment|normal cerebrospinal fluid (csf),≥22 years old|score ≥15 on the 7-item,,,,,,
3733,,affect absorption,gillet test||,,urine drug abuse,t-cell surface inhibitory receptor,,,,jak-stat signaling,at screening.|received any experimental therapy,less than 12.5 g/dl,,,,,,
3734,,cardiac symptoms,component of ibuprofen,,alcohol breath,pathologic examination of the surgical specimen,,,,bilateral,within 4 weeks before the first use of the study drug,"> 3,|opioid use",,,,,,
3735,,developmental,laxative effect,,hb,cardiovascular events.||exclusion,,,,surgical area suggested|previously,<6 months,< 2.5 times the upper limit of normal value,,,,,,
3736,,muscle protein synthesis,anti-aging therapies,,thyroid function,cerebral ct/mri,,,,peroperative,within 6 months before enrolment,≥ 1000/mm3,,,,,,
3737,,l210w,conventional incisional glaucoma surgery,,absolute neutrophil anc,frozen lung biopsy,,,,near-infrared fluorescent,during the study treatment period|not fully recovered from toxicity,from 18 to 75 years old,,,,,,
3738,,cardiac disease|cholestatic disorders,ug,,left ventricle systolic dysfunction,subsequent surgical,,,,serious,for human chorionic gonadotropin (β-human chorionic gonadotropin,60 to 89 mmhg|those,,,,,,
3739,,localized gastric,study drug's,,hematology,robot-assisted radical,,,,impella 5.5,in the past two years|had,≥3 months;|non-small cell lung cancer,,,,,,
3740,,temporomandibular join condition,lactose products,,new york heart association,genetic conditions|no parental,,,,l.1121-8 of the public health code:||pregnant,for 1 month after the end of trial,18.5 to 28.0 kg/m²,,,,,,
3741,,upper respiratory tract infection|a high temperature,fermented milk,,carcinoma bclc d under best supportive,fecal occult blood 1+,,,,high degree of,< 30 days,above 4,,,,,,
3742,,tumor block,lnp-containing vaccine,,parp inhibitor maintenance|women,ultrasound,,,,non syndromic;|signed,within 5 minutes of assuming seated,>= 40 years,,,,,,
3743,,rheumatic valvular heart disease,sprms,,eye|cystoid macular edema,transfemoral tavr,,,,intent,within 6 months before the study drug,> 1.5 times the upper limit of normal,,,,,,
3744,,degenerative arthritis,sigmoidoscopy,,resting ecg morphological abnormalities,radical surgery,,,,in 2020-21|age,within 30 days prior to screening;|glycated hemoglobin (hba1c),≥ 40 iu/ml,,,,,,
3745,,vision loss,hacettepe university faculty of medicine,,participation)|platelet count,handbags,,,,tumor tissue sample,consistently for at least 3 months prior to,> 430 msec,,,,,,
3746,,criteria rbd patients:||•,eplerenone,,repeating ventricular arrhythmias,plain imaging,,,,non-restorable crown.|teeth,at least 3 months prior to inclusion,≥4.2 mmol/l,,,,,,
3747,,acute pulmonary exacerbation,urine drug screening test.|woman,,ribociclib + et treatment,video-conference administration),,,,worse than -12 db,within 4 weeks before the research,16-44mm.|morphology,,,,,,
3748,,disorders;|ability,platelet response.|subjects,,medication effect|aspartate aminotransferase (ast),bacterial vaccination,,,,eloquent,within 6 months prior to the first dose,score of 15 or higher,,,,,,
3749,,anatomically visible tumor,antibody-containing combination regimen,,angina ccs class,cd19；|expected survival time,,,,suitable to aortocoronary anastomosis,at least for the upcoming,<40mmhg,,,,,,
3750,,reduced physical ability,anticonvulsant medications|chronic organ disorders,,cd4+ t cell function,open abdominal operation,,,,concerning,within 2 months prior to first dosing,greater than 18 years|medically able to participate,,,,,,
3751,,autism)|systemic disease,st. john's wort /plant-derived preparations,,ago-score,oral hygiene|completion of orthodontic treatment|non smoker|not working,,,,non-drug,within 4 weeks before dosing|intake,"no more than 12 hours after surgery),|if the patient",,,,,,
3752,,intermediate amd,dehydration drugs,,body weight,institutional program,,,,potentially alter absorption or excretion,for 1 month following ip administration|use,150 eds.|participant,,,,,,
3753,,right shoulder pain,sleep medications,,usld,transferrin saturation (tsat),,,,preclude contact lens wear,within 2 weeks prior to baseline.|any of the following ecg abnormalities,i - iii.||,,,,,,
3754,,investigator.|absolute contraindications,antibiotic treatment,,rano-bm,venous surgery,,,,contraceptive films,within 1 week of screening,≥ 18 years;|chest,,,,,,
3755,,irregular astigmatism,midazolam,,partial remission,ccta,,,,assessment|pre-implantation,within 56 days prior to check-in|participation,score ≥5 during screening.|subject,,,,,,
3756,,dynamic,various growth factors,,total score of his,obstructive ventilatory dysfunction,,,,post-treatment,in the past three months.||exclusion,> 10 mmhg,,,,,,
3757,,month.|active endocarditis,c1 esterase inhibitor deficiency,,white european ethnicity;|signed informed consent;||,percutaneous intervention [,,,,per month|participants,14 months or more,>150 mg/dl,,,,,,
3758,,vitamin d deficiency,anti-coagulation /anti-platelet medications,,pathology suggested mvi,lung imaging changes,,,,unsuitable for inclusion,during the preceding 24 hours) per week,< 1.5*10^9/l.|platelet count,,,,,,
3759,,cns involvement.|stroke,investigational product,,nearby skull base,peloidotherapy,,,,on room air|patients,within 5 minutes of ingestion of the first capsule.|prior exposure to arn-75039.|positive serology for hepatitis b virus,less than (<) 40 pounds,,,,,,
3760,,spastic diplegic cp,regional nodal,,predicated forced expiratory volume in1 second (fev1),mainly intranasal steroid spray,,,,none||-,within the last 3 months;|oncology;|previous lung transplantation,<45 ml/min/1.73m2)|other,,,,,,
3761,,post-menopausal state,admission|participants,,ecpella,coronary artery fractional blood flow,,,,preclude restricted,past 28 days,>10)|have received more than 12,,,,,,
3762,,infection of covid-19|hypoxemia,antifungal agents,,hdv rna,etc.)|clinical state,,,,non-brca1/2m cancer,in the prior 28 days from baseline and plans to continue during the study;|has significant,>7% / 53,,,,,,
3763,,endotracheal intubation|suspected,systemic antibiotic therapy,,nyha grade iii and iv),emerging,,,,"mental problems,|communication problems,|vision",in the last 10 days,<2mm,,,,,,
3764,,tumor dna damage repair dysfunction,immunosuppressive drugs|morbus wilson|aids,,screen asq tool)|history of psychosis,innoculations,,,,corneal scarring|previous,within 6 weeks from the screening,> 35 pg/ml,,,,,,
3765,,tumors,monoclonal b-cell lymphocytosis,,alcohol breath test,xofluza™,,,,community-based organization sites,within 14 days prior to randomization.|have received,≤ 40 bpm,,,,,,
3766,,diabetes|inability,combination systemic therapy,,aac,periodontal pocket|students,,,,musculoskeletal domain).||ii,prior to 2 weeks after the first day of their lmp,requires hospitalization|the,,,,,,
3767,,elastic,hodgkins,,international normalization ratio,ct scan/mri required,,,,operative,for 12 months after spvn06 sri.|subjects who are,≥140/90,,,,,,
3768,,cerebrovascular event|known liver cirrhosis|known cancer,anti-pd-1 antibody treatment,,alanine transaminase [alt],valve repair,,,,left hemisphere,at screening.|clinically significant,under 10 years old,,,,,,
3769,,hypereosinophilic syndrome,anti-rankl therapy|systemic corticosteroids,,response evaluation criteria in solid tumors version 1.1||adequate normal organ and marrow function,supportive therapy,,,,intellia-sponsored,within 3 months prior to visit 1|known lactose,<3 cm,,,,,,
3770,,involvement,anti-h4,,suicidal ideation rating,cognitive ability;|pregnant,,,,controlled,at the ed.|cpr for more than 5 minutes,<35%).|hemoglobin < 6 gram/decalitre,,,,,,
3771,,cardiogenic shock|life expentency,acetylaconitine drugs,,mfac,b|the main organs function well,,,,non-classical 21-hydroxylase deficiency,on 24 hours ambulatory,"between 18 and 70,|performance status",,,,,,
3772,,low back pain symptoms,insulin||iv,,hiv serology,cranial imaging examination,,,,affects the methodology for conducting a hemoperfusion procedure,within 180 days before enrollment|new york heart association (,35-60 years,,,,,,
3773,,postural hypotension,grapefruit products.|seville,,gpc3 expression test;|unresectable,pet/ct examination,,,,non-objection|person,within the last 6 months|history of,>23/30||,,,,,,
3774,,cardiovascular insufficiency,hard drugs,,lbdgc,nicotine dependence)|head injury,,,,ebv-related,the past 8 years.||,0 or 1|negative,,,,,,
3775,,azoospermic,anti-epileptic drugs,,uln.|total bilirubin,ptca,,,,consecutively,within 14 days)||neutrophil,>=1.7.|the participant,,,,,,
3776,,sarcoma,neisseria meningitidis vaccination,,legs,bicuspid aortic valve,,,,regular medication,during the study treatment,less than 3 months ago:||1,,,,,,
3777,,chronic health conditions,non-steroidal medication|any contraindication,,organ function|hemoglobin,molar restorations|gastroesophageal disorders|severe internal dental darkening|presence,,,,syndrome|uncontrolled,after 12 months,≤ 1.5 x uln|written,,,,,,
3778,,left sided,mpn,,vital tooth|non restorable,surgical treatment plan|surgery,,,,≥40 mmhg,for 12 weeks|able to participate in a structured walking program,"1, 13",,,,,,
3779,,chronic kidney disease epidemiology collaboration,drinks,,older|engaged in hiv care,anticoagulation therapy|cardiac implanted electronic device,,,,under the plasma concentration-time curve,within 1 week before,<50% diagnosis,,,,,,
3780,,mmhg||serious cardiac illness,cumulative areas,,air|bmi,infrared therapy,,,,12-lead ecg|indication,before starting bevacizumab).|unhealed wound,19 u/l,,,,,,
3781,,membranes).|medical disorders,weight,,gross motor function classification system - gmfcs,msec.|ecg,,,,dutch language,within 28 days before randomization.|toxic reaction,≥30g/l；|known,,,,,,
3782,,clinical disorder,cytogenetics,,il-6 level,ct dynamic enhancement scans,,,,overactive,within 12 weeks prior to visit 1,between 18-65 asa i-iii bmi,,,,,,
3783,,interstitial lung disease(ild,antirheumatics,,partial nephrectomy,stool pcr or culture analysis,,,,alk-tki therapies,within 28 days of a2b530 infusion|unstable angina,< 130 mmol/l,,,,,,
3784,,resistant,oxaliplatin-containing,,as:||absolute neutrophil count (,penile biological vibration threshold test suggesting,,,,central nervous system (cns) metastases,for at least moderate,12 and above,,,,,,
3785,,breastfeeding|inability,growth hormone boosters,,physical strength,coronary artery bypass,,,,periodontal,"in the last 1 week,|not",14-60 years|the diagnosis,,,,,,
3786,,former depression,diagnostics,,estimated gfr by,world,,,,palpable,in the last 12 months|females,≥27%,,,,,,
3787,,hopeless teeth extraction,drugs used in this study;|psychiatric,,esc heart failure,unilateral knee total,,,,enamel abrasion,in the last 6 months|has a guardian,≥18 years.||patient,,,,,,
3788,,"supraventricular premature beats,|diagnosis of",dentures,,mcl,gynecological examination,,,,european parliament,within 2 years before starting treatment,worse than 20/40,,,,,,
3789,,pedal for anterior tibial,direct oral anticoagulants|persons,,lost blood or donated,pet-ct||,,,,taa,in the last 12 months|hospital admission,≥ 45 ml/min,,,,,,
3790,,anaplastic lymphoma kinase (alk) translocations|nsclc cohorts,somatostatin receptor,,child undergoes orthopedic surgery,major patient|patients,,,,active,since prior therapy,breastfeeding|gfr <15 ml/min/1.73 m2|symptomatic,,,,,,
3791,,follicular type,fontan circulation,,serum calcitonin,pathological diagnosis,,,,moderate/severe,within prior 1 year,< 80,,,,,,
3792,,myocardia,setting.|ecog,,national cholesterol education program,older|(3,,,,non-convulsive epilepsy|suffered from status epilepticus,within 3 months of the enrollment|patients unable to cooperate with stereotactic body radiotherapy|patients,eligible,,,,,,
3793,,suicidal risk|ptsd,duoderm® gel /petroleum,,nm,major abdominal surgery.||exclusion criteria||emergent surgery;|abdominal vascular surgery,,,,low amniotic fluid volume that responds to maternal hydration,within the last month on the mini-international neuropsychiatric interview (mini,equal to or greater than 26 prior,,,,,,
3794,,conditions may affect the levels of ctdna,monoamine oxidase inhibitors (maois),,urine pregnancy test upon admission,videolaryngoscopic intubation (vls),,,,coagulopathy.|pregnant,within the past 3 months.|gastrointestinal,< 18,,,,,,
3795,,keloids,cxr,,veofix screw between,neurointerventional treatment,,,,success.)||,at least 7 days prior to starting protocol therapy,<35%)|(6,,,,,,
3796,,amyloid deposition,anti-hb viral therapy;|10 iu/ml≤hbsag≤3000 iu/ml.||,,959th mdg,covid-19 caseof moderate,,,,hpv-positive,at screening).|vaping less than 3 months,≥ 38.5℃,,,,,,
3797,,eumenorrheic,systemic immune suppressive should,,fac,allogeneic organ transplantation.|active,,,,venous circulation,past 1 year,≥18 years|thin,,,,,,
3798,,non-muscle,systemic antibiotics,,aaa maximal diameter ≥7cm.|physical inability to exercise,opioid risk tool (ort)|have been,,,,genital area,more than 2 weeks,60 or over||,,,,,,
3799,,hiv)-1 infection,paxlovid,,c|leukocytes,vffr computation,,,,turesky,during the study visit.||,35 years and above with normal,,,,,,
3800,,psychotic disorders).|participation,topical histamine,,oswestry waist index,oncology care|sufficient clinical status,,,,breast-feeding|have a,within 6 months prior to screening.||note,≥3 months;|patients,,,,,,
3801,,in situ bladder cancer.|history,fog,,control group):||normal ef lv,oocyte donation,,,,non-revascularizable surgical sites,within 1 month of participation.|anytime in life,<10%|being,,,,,,
3802,,subacute bowel obstruction,senc,,cfc,bicuspid aortic valve|patients,,,,ngs analysis has been,ra;|≥ 6,"≤1.5x109/l|haemoglobin <10,0 g/dl|total",,,,,,
3803,,anaphylactic shock,impella®,,anti-donor hla antibody,experimental immunotherapy,,,,women;||local,within 5 days prior to the day of screening,18-45|overweight,,,,,,
3804,,local retinal detachment,infection|creatine,,clearance rate） ≧30 ml/min,major organ transplant|history,,,,1:1,within the four weeks prior to the baseline exam|known allergy,older than 14 years,,,,,,
3805,,ataxia-telangiectasia,docetaxel,,general inclusion||age,ichs,,,,non-hodgkin lymphoma,1 months before the study;|taking,≥18 years)|first dentofacial orthopedic consultation,,,,,,
3806,,progressive disease course|pregnancy,s-albumin,,international normalized ration [inr],filling the bladder,,,,suitable for repeat measurement,over last 30 days of consuming alcohol,=< 15 days prior to registration)|total,,,,,,
3807,,hpv-,academic,,obligatory documents.|to,test material,,,,considered stable,during the 6 previous months,1.5 to 2 units,,,,,,
3808,,breastfeeding;|active tobacco,elbow region.|steroid injections,,anti hcv,blast sample,,,,immune-mediated,within 30 days of signing the informed consent form of this,>0.5 mg/dl,,,,,,
3809,,rezum,tazarotene,,madison va,neurological disease|no,,,,high level,for more than 6 months,≤ 1.00d;|patient is willing and capable,,,,,,
3810,,leukaemia,vitamin products,,anti- infectives|active hepatitis b (hbv) infection,gastric bypass.|history of,,,,non-cardiac morbidity,within 6 months prior to study vaccination,>3|life expectancy,,,,,,
3811,,cooperation problem,xiidra,,sglt2i|systolic blood pressure (sbp),yes,,,,infection|active dermatosis|unrealistic expectations,more than 12 months prior,=< 5.0 x uln.||recipient:||for,,,,,,
3812,,gilbert's disease|individuals,"status,|pregnancy,|on",,sustaining breathing,u.s. air force school of aerospace medicine,,,,lower limb beyond,within 4 weeks prior to screening|history,>= 12 years,,,,,,
3813,,substantial external beam,biologic treatment,,hepatitis b pcr positive,hysterotomy,,,,maternal exclusions|no indication,within 12 months of enrolment.||,18.0 to 32.0 kilogram per meter square (kg/m^2)|a total body weight,,,,,,
3814,,patients|chronic skin diseases,trifluridine/tipiracil,,local regulatory/irb requirement).|histologically,alternative medical reasons.||ii,,,,spinach,within 3 months of screening.|a participant,less than or equal to t2c|within 12 months prior to signing consent have,,,,,,
3815,,mitral valve repair;|patients operated,bempedoic acid,,aspartate transaminase / serum,hypotensive symptoms:||baseline hypotension - resting supine,,,,diseases.|pregnant,within 48 hours of,≤ 10 years,,,,,,
3816,,antidiabetic drugs|patients with,skin)|intrauterine devices,,sensitive)|iii burns,surgery.|planned laryngoscopy,,,,glutamic oxaloacetic transaminase (,within 1 year prior to enrollment,">40 kg/m2),|coagulopathy,|psychiatric disorder,|opioid dependence,|patient refusal to give",,,,,,
3817,,functional disability,antihypertensive medication,,oral hygiene|good general health|having,reconstructive procedures of the posterior mandible,,,,secondary oa|disability,for at least 90 days after their last dose of study treatment.|a,< 2.5 x upper limit of normal,,,,,,
3818,,drug absorption,vaccine-related component,,duration remission,shortness of breath congestive heart failure (chf),,,,non-visceral,prior (within 3 months,greater than 0.5 mm^3|patients,,,,,,
3819,,face trauma,combustible tobacco products,,mile square health center|age,weeks||contraindications,,,,≥30 days and ≤6 months,before the first dose of zanubrutinib|evidence of other,65 years old or older,,,,,,
3820,,signs of periodontitis,soluble guanylate cyclase (sgc),,serum ldl,surgical evaluation,,,,unexpected,in the last 8 weeks.|having been,> 18 y.o.|admission to icu,,,,,,
3821,,asia,emb,,aspartate aminotransferase,curative radiation therapy,,,,booster doses,within 3 months after the last dose of the study drug,greater than (>)1.5 × upper limit of normal,,,,,,
3822,,renal insufficiency|cardiac insufficiency,tobacco,,anti-thyroid,vasopressor support||,,,,emts than paramedics,within the last 12 months.|any subject,score of < 8 points,,,,,,
3823,,reproducible glaucoma hemifield tests,prescription medication,,higher|histologic grade group,hormonal replacement therapy,,,,t2d|presence,for the last 6 months.|being,≤ 1.5 times the upper limit of normal.||,,,,,,
3824,,primary psychiatric diagnosis,necrotic pulp.|patients,,with who grade iv,dynamic arteriography,,,,stiffness,within 2 weeks of screening|participation,between 20 and 35|no,,,,,,
3825,,flow-limiting,inhaled bronchodilators,,recist v1.1;|ecog performance status,egd procedure,,,,psychosocial,within 30 days prior to the first dosing.|donation of plasma,<50000/µl)|unstable circulation,,,,,,
3826,,heart problems,dysrhythmia|diabetes,,covid-19 restrictions).||inclusion,balloon dilatoplasty,,,,12-hour,during the study|not agree to participate in the study,≤ 1.3mg/dl,,,,,,
3827,,traumatic spinal,component of iodinated contrast,,alp 5.0 uln,hematopoietic stem cell transplantation.|hct-specific complication index score (hct-ci,,,,thulium,at the time of our study.|legal guardians' consent for oral swabbing of their child,3 cm,,,,,,
3828,,patent foot main,mycophenolate sodium,,working,positron emission tomography scan.|patient,,,,single agent rituximab/obinutuzumab,the last 3 months.|undergoing antibiotic therapy,19 years or older,,,,,,
3829,,recurring pain|injuries,open,,calculatedb creatinine clearance (gfr can also be used in place of,covid-19 polymerase chain reaction (pcr) test,,,,irinotecan-based treatment|prior treatment,in the past six months|have,18 years and older.|understand the content of the informed consent form (icf),,,,,,
3830,,ischemic heart,selective immunoglobulin,,monospecific dat strongly positive,combined hormones,,,,aggressive,within 6 months prior to screening|orthopedic,<1 year.|5,,,,,,
3831,,chronic liver function impairment,migraine headache,,sustained vt,coronary angioplasty,,,,higher.|severe,after having received at least 2 prior,<3.2 mmol/l,,,,,,
3832,,novel coronavirus pneumonia,interferon alpha before index date.|patients with pregnancy,,hbv-dna<103,isolated cleft,,,,medical records,surgical history,> 10 mg/l.|lesion,,,,,,
3833,,progressive condition,long-acting steroids,,aids healthcare foundation healthcare,intensive treatment,,,,lower limbs;|pregnancy,in the past 3 months.|participant,4-25,,,,,,
3834,,t4 disease,adequate pta treatment.|subjects held in custody,,total nasal symptom score,time|prior oncologic head,,,,articles 1121-6 to 1121-8 of the public health code.|subject,within 7 days prior to enrollment)||unless,< 25%,,,,,,
3835,,nitrates|cardiac arrhythmia,oral busulfan,,urine culture||,open incisions,,,,highly trained,for 3 months after the last dose of study drug.|participants must give,from 0 to 5|stable,,,,,,
3836,,acute kidney injury|patient,herbal medication,,cgfr,emergency care treatment,,,,ibs-like,within 7 days prior to screening,60 db spl-a,,,,,,
3837,,deep occlusion,pregnyl,,diagnostic statistical manual of mental disorder 5||history,recruitment,,,,central nerve system,in the past 1 month|any adverse,> 6mm,,,,,,
3838,,seasonality,oral steroids,,cdh reference centre,suppose,,,,testing,within 12 months||,< 100 x 109/l,,,,,,
3839,,supraventricular rhythm (visible p-waves,oral antidiabetic|no sensory loss,,granulocyte colony,fully resolved,,,,ihc,for at least 60 days prior to registration.|patients,≥450ms in,,,,,,
3840,,breast feeding;|malignant tumors,mdm,,fix (plasma derived,75 g anhydrous glucose dissolved in water,,,,asymptomatic,during the study period;|9,< 3 × 1uln,,,,,,
3841,,cancer survivor inclusion criteria:||adult daughter of the identified cancer survivor,immunostimulatory drugs,,vital signs,alone.||uncontrolled intercurrent illness,,,,sustain,>3 months before trial,<35|participants,,,,,,
3842,,various factors,spine,,national tuberculosis control programme guideline thailand,intrinsic resistance cohort only)|pain,,,,effort-related,within 24 hours of stroke,≥ 3)|known,,,,,,
3843,,dialyzed,aspart,,icf);|kps score,periodontal surgery/root,,,,diagnosed by one of the following criteria:||hba1c,within the past month,≥ 0.5cm2,,,,,,
3844,,narcolepsy,nonsteroidal anti-inflammatory drug (nsaid),,haptoglobin,optimal dietary intervention (typical complaints,,,,memory,up to 8 hours before the physical therapy,6-24h after onset,,,,,,
3845,,t2d)|history,any anticoagulants,,o exclusion criteria,vitamin d supplementation,,,,"castration level, psa increases",during last 36 months|known central endobronchial lesion,between 18 years and 70 years of age(inclusive,,,,,,
3846,,surgery;|active infection,youth,,grades,emergency operations,,,,"st-victor center - chu amiens-picardie,|patients",within the previous 12-months||exclusion criteria||is,more than 1.2|previous c-section,,,,,,
3847,,abstain from smoking,energy drink,,national french social security system|as infliximab,arterial yttrium therapy.|is,,,,diagnostic arm of the study,within 7 days prior to day 1 of cycle,≥450 cells/mm3,,,,,,
3848,,knee injury,surfactant before,,glomerular filtration rate [gfr],allogeneic organ,,,,rome iv criteria for the diagnosis,before enrolled to the study|child,eligibility,,,,,,
3849,,severe discomforts,natural products,,hepatitis c virus current,fmt|intra-abdominal surgery,,,,ibs-c|patient,at time of dosing,30% to 50%.|all,,,,,,
3850,,paralytic small bowel obstruction|patients,setting.|note,,her2 pathological test,infezione,,,,suitable for et installation,at least 2 weeks prior to the first administration of study treatment,≥18 years|an,,,,,,
3851,,mucoepidermoid carcinoma,acgh,,hemoglobin concentration,brain stem,,,,implantable progestogen-only hormonal contraception,immediately prior to randomization|are,90-day,,,,,,
3852,,vascular occlusions,oesophageal,,n=180)||age,adjuvant osimertinib treatment,,,,full age subject to a measure of legal protection,for the last 30 days.||,"> 18 years,|admission",,,,,,
3853,,ira,dihydropyridine,,barcelona-clinic liver cancer [bclc] staging classification,laser,,,,cmv dnaemia - peripheral cmv dnaemia,within 6 months prior to day 0,been reported,,,,,,
3854,,pancreatitis|poorly controlled,conventional,,miller class,video-assisted thoracoscopic - (vats),,,,slow-flow,at the time of screening.|hepatitis b surface antigen (hbsag),18 years or above|radiological diagnosis,,,,,,
3855,,familial haploidentical donor|written,drugs used in the study.|patients,,lmd,myopic refractive error,,,,sacroiliac joint fixation;|requires,in the past 5 years except for,≤ 1.5 uln,,,,,,
3856,,pulmo-/cardiovascular disease,selective operation,,bone marrow sample,coronary intervention,,,,various,within 12 weeks.|drugs,0-2;|child-pugh score,,,,,,
3857,,"pulmonary fibrosis,||acute lung disease",l-lactide,,numerical rating scale,hip hemiarthroplasty surgery,,,,hiv.|history,within 12 months prior to first dose of study treatment.|exclusion of hiv,> 2.5 times the upper limit of normal,,,,,,
3858,,physical examination;|kidney disease,episodes,,users,longest diameter,,,,diagnostic,within 4 weeks prior to the screening period,< 2 times of uln.|adequate renal function,,,,,,
3859,,gastrointestinal bleeding|participation,medications associated,,bariatric surgery.||exclusion,cryoplasty,,,,non-invasive imaging,during the study period;|the participant's caretaker does not primarily speak english,< 20%,,,,,,
3860,,acute traumatic injury,anxiety medication,,old|active aiha,single-jaw surgery,,,,tricuspid valve insufficiency|severe pulmonary arterial hypertension,prior to the screening period should stabilize,> 1.5 * uln,,,,,,
3861,,adverse effects,captisol®,,mellitus|hemoglobin a1c (hba1c),histological assessment,,,,high school,within the past three years,wild type.|cohort 5,,,,,,
3862,,systemic cancer therapy,immune disorder|baseline organ function testing intact|patients who are,,protein kinase inhibitors,polymerase chain reaction (pcr) hcv rna,,,,central nervous system drugs,during the 8-week emi study period,90 to 140 mmhg,,,,,,
3863,,year;|allergy,sotrovimab,,survival,bladder neck length,,,,alternative medicine,during the past 12 months,≥ 50 ml/min/1.73 m2,,,,,,
3864,,atrial septum,warfarin sodium,,ribociclib + ai,insufficient image quality,,,,screening.|regular use of or,for at least 6 months after the final dose of study treatment||negative hepatitis c virus (hcv),2.5 g/dl)||for,,,,,,
3865,,type 2 diabetes.|participants,gimeracil,,procedure|body mass index,"transvaginal sonography,||",,,,severity index,within 14 days before registration,< 5 ribs)|signed,,,,,,
3866,,megaloblastic anemia,direct acting antiviral therapy,,modified,synchronous resection of the primary colorectal cancer,,,,core antibody,within the past 4 weeks.|history,≥30 and ≤60 years;|bmi,,,,,,
3867,,obstetrical disease,drug-resistant epilepsy,,complete blood count,hematopoietic stem cell transplant.|participants,,,,meniscal,in the past month 4,≥ 18 years|biopsy-proven,,,,,,
3868,,consent|pancreatic cancer diagnosed||,antibiotic therapies,,asco cap,permanent sterilization (hysterectomy,,,,coagulation,during the study.|history of drug,> 90 diastolic,,,,,,
3869,,suicidal ideation-past,immune altering medications,,amenorrhea,transdermal hormone contraception|sexually active,,,,grade 2-4 by,for at least 6 months||,project.)|at least 18 years,,,,,,
3870,,non-cancer indication,components of the drug|liver disease,,paris classification,superficial sedation level,,,,intra uterine devices,within one month;|there,at least 24 weeks,,,,,,
3871,,systemic treatment.|uncontrolled hypertension,chemotherapy,,kesimpta-exposed cohort||pregnant,intestinal biopsy,,,,partially,within six months prior to period i dosing.|no,greater than 30 cc.|metastasis,,,,,,
3872,,non-gout-related,monoclonal antibody products;|pregnancy,,visual analogue scale (vas),functional disability||exclusion criteria:||participation,,,,inhaled glucocorticoid|vaccination,before chemotherapy,20-40|patients,,,,,,
3873,,substance use would also interfere with the effects of the intervention.|history of,dronedarone,,testosterone level,rate control,,,,end-of-life,within 7 days prior to the screening);||absolute neutrophil count (,"≥ 40%,||the",,,,,,
3874,,carcinoma in situ of melanoma,components of the fnirs device,,branched evar|concomitant iliac artery aneurysm|non-ability to adhere to the fu protocol|lack of consent|pregnancy,bone marrow transplant||,,,,insulin pumps,in the past two months,< 60 meq/l|able,,,,,,
3875,,chronic liver disease,phospholipid,,mean qtcf,risk management protocol,,,,pd-l1 testing,within 28 days of starting study treatment,≥ 2 x upper limit of normal);|serum,,,,,,
3876,,autoimmune disease.|active brain metastases,components of peritoneal dialysis fluid|complicated,,mm3||hepatic function,failure|organ transplantation,,,,full-thickness traumatic skin defects,within 1 month prior to study entry;|having,ranges from 2 to 3cm;|cn0,,,,,,
3877,,right volar forearm,anti infection,,age;|intrauterine,standard of care chemotherapy regimens,,,,epilepsy.|has severe,within the 12 months prior to screening|history of n meningitidis infection|known to be,24-2,,,,,,
3878,,psychiatric cerebral disease,bridges,,autonomously functioning thyroid nodules (,typical ct findings,,,,mid-portion achilles,after initial successful treatment|no,2.25-4.0 mm,,,,,,
3879,,hepatoprotective drugs|excessive alcohol,antagonists,,urgency|body mass index,hereditary disease;|normal cardiac function,,,,light-based,at the time of recruitment|undergone major surgical procedures,<2000 iu/ml,,,,,,
3880,,loved,potent inhibitors,,colorectal cancer;|inflammatory bowel disease,allogeneic stem cell transplant|prior solid organ transplant|cancer therapy,,,,tyrosine,for 24 months after discontinuation of vismodegib.|patients,50-65 years,,,,,,
3881,,renal disease|use,gdli,,severity index activity score (m-cdasi-a,10 days|participation in another trial aimed,,,,arthropathy;|active acute,at least 28 days after receipt of study,< 45 min-1.|electrolyte level outside normal range,,,,,,
3882,,obsessive compulsive disorders,titanium dental implant,,american society of anesthesiologists (asa) physical status,fracture procedures,,,,pressure).|uncontrolled,during the day,2.5/3-year,,,,,,
3883,,axillary metastasis,compounds of similar chemical or biologic composition to fludarabine,,resting bp,laparoscopic surgery||,,,,"primary diagnosis,|a diagnosis",in the past 3 months;|modification,≥ 150 mg/,,,,,,
3884,,organic amnesic syndrome,zimberelimab,,urine laboratory test results,complete percutaneous revascularization;|acs,,,,low cardiac output,within 4 weeks before the start of the study;||those,under 19 and over 61|pregnant woman|in,,,,,,
3885,,adenomas|associated neurologic factors,interventional studies.|agrees,,hiv plasma rna,mri exam,,,,any grade 3,within 1 month;|mean gastroparesis,"score of 0, 1 or 2",,,,,,
3886,,poor compliance,hetrombopag,,gog performance status,hyperprogression,,,,non-verbally|follows directions,in the past 5 years.|patients,>=12 weeks after completion of hcv therapy,,,,,,
3887,,comorbid disorders,topical prescription retinoids,,child,aortic root surgery,,,,insulin prescriptions,within 4 weeks before study intervention,≤ 4 times the upper limit of normal,,,,,,
3888,,etc.)|cardiac abnormalities,w-135,,child-pugh classification,pathological international society of urological pathology (isup),,,,non-fluent dutch,at least 12 hours prior to,> 1.5 to <= 3.0 × upper limit of normal (uln),,,,,,
3889,,correlative research.|registration,anti-diabetic medication,,serum immunoglobulin free light chain level,rcd,,,,pd-l1.|active autoimmune disease,"for the last 4 weeks,|who will be able to walk independently",90 g/l,,,,,,
3890,,lumbar disc herniation.||,systemic chemotherapy,,muga,dilatation of the oesophagus.|patients unable to stop anticoagulation therapy,,,,blinded phase,cancer|able,less than 28 days|already,,,,,,
3891,,time;|bilateral breast cancer,dimethyl sulfoxide,,hepatitis c active infection,fluid collection around,,,,allogenic organ transplantation.||active,in the next 12 months|planning to leave the geographic area,≤ 5.0 x uln,,,,,,
3892,,fatty liver,strong cyp3a4 inhibitor,,and|peripheral blood eosinophil,small amounts from straining,,,,clinical manifestation warrants,at the time of first vaccination|participants,> 1.3,,,,,,
3893,,congenital pseudarthrosis of the tibia,btki,,cre8™ evo stent,initiation,,,,severity of ipf,"eight weeks prior to the start of the study,|those who had",< 2.5 x institutional upper limit of normal (uln),,,,,,
3894,,chronic heart failure|nyha,strong cyp3a inducers,,urine protein-creatinine ratio (upcr),injections,,,,fovea centralis,at least 3 hours/week.||,at least 6 months|caps-5 score,,,,,,
3895,,febrile 72 hours prior to or,levine,,prostate biopsy,tibiofemoral knee oa,,,,self-report <6 hours/day of,within 12 hours before the procedure;|patients,measured ≤ 80% of the normal predicted value,,,,,,
3896,,post occluder implantation;|20,hormonal contraceptives.|diabetes|hypertension|thyroid,,refractory neuroblastoma|adequate organ function,surgical maze,,,,arteriovenous,< 6 months prior to visit 1,≥ 2x baseline,,,,,,
3897,,hepatitis c virus (hcv) infection,ruxolitinib,,altor ast,testing for antigen by rt-pcr,,,,"non-treated dyslipidemia),|general anesthesia",within 2 months history,54 to 66 gy/25 to 35 fractions,,,,,,
3898,,uncontrollable neurological,epo)/interleukin-11,,alk,taut band palpable,,,,net|documented,within 30 days prior to first study drug administration,< 11.5 g/dl,,,,,,
3899,,involvement of the nail area,heparin,,serum pregnancy test.|documented,standard oxygen therapy,,,,soap,during the previous 6 months；|have,female;||2.body,,,,,,
3900,,post-pci,dtp-containing,,rouen university hospital|clinico-biological intolerance,illness|persons hospitalized,,,,tested for gonorrhea,while taking the medication.|women,5 units,,,,,,
3901,,pneumopathy,p53,,international myeloma working group (imwg) consensus,hematopoietic stem cell transplant,,,,non-hepatic origin,in the 14 days before enrollment|hiv infection,<1.5cm2;|29,,,,,,
3902,,mammary carcinoma,patellofemoral arthroplasty|patients,,skinfold thickness measurement,complete gastrointestinal obstruction.|patients,,,,general laparoscopic procedures|had surgical,after at least 7 days without growth,18 to 55 years,,,,,,
3903,,breast feeding|active bacterial,anti-angiogenic therapy,,serum afp (afp),daily disposable,,,,depression.|non-fluent/limited english proficiency|self-reported,during the course of the study|history of currently,greater than 20 years duration,,,,,,
3904,,metastases accessible,leukotriene receptor antagonist,,anti-hbc immunoglobulin g (igg),stress urinary incontinence.|patients,,,,instructions for use,within 6 months of visit 1|be using,≤ 1.5× upper limit of normal (uln),,,,,,
3905,,reversible encephalopathy syndrome,components of the avelle™ negative pressure wound therapy,,modified world health organization (who),mri|patients,,,,clinical judgement of the investigator to be in stable state,at the baseline visit||the investigators recruit,17.5 to 30.5 kg/m^2,,,,,,
3906,,cranial hypertension,anti-pd-1,,glioblastoma|phase,local regional therapy,,,,progesterone only,7 days after the isolation period,18 - 85|ecog performance status,,,,,,
3907,,acute endocarditis,anti-reflux surgery,,months)|less,csf-1r,,,,infection|active hepatitis b,in the last 5 years|patient,≤ 60 mmhg.|sitting,,,,,,
3908,,blood|kidney injury,epilepsy;|suicide risk;|receiving cns-active drug,,planned.|age,thyroid surgery/ablation)|tsh,,,,non-ctimp study participation is allowed.|sibling of a blipa participant,during the research,less than 25 kg/m2.|history,,,,,,
3909,,mr,components of huaier granules,,glomerular filtration rate,rabid animal,,,,marijuana)|significant,throughout cycle 1 until cycle 2 day,≥5.0 meq/l|serum bicarbonate,,,,,,
3910,,moderate depressive episodes,nmpa,,sgrq score,cataract surgery,,,,bronchodilator,past 24 hours preoperatively.|teeth that shows association with acute periapical abscess,≥ 48mmol/mol,,,,,,
3911,,exudative age-related,internet|32nd gestational week,,hepatitis c (hcv rna positive);|patients,blood sampling procedures required,,,,chek2,in the last 30 days|diagnosis,score between 17-30.|clinical dementia rating scale,,,,,,
3912,,death related to heart problems|glaucoma,oral tongue,,duration,t-dm1;|be able to understand and voluntarily sign the written informed consent form (icf).||,,,,in the same,within 3 months prior to inclusion,≥ 90 days,,,,,,
3913,,blood sugar,internet access,,hepatitis b surface antibody,close monitoring,,,,tumor related,within 60 minutes of birth.|evidence of,0-34+6 through,,,,,,
3914,,deep on the,administration|pregnant,,drug abuse screen,iib;|lower third,,,,clinically relevant abnormalities,throughout the whole study period,between 50-100 bpm,,,,,,
3915,,resting ecg,somatostatin analog therapy,,cytotoxic t lymphocyte-associated,iron panel tests,,,,induces gingival enlargement|pregnancy/,prior to cystoscopy,"> 400,000/μl",,,,,,
3916,,restenotic/occluded,nmda receptor antagonists,,mild pigmentation level,heart surgery,,,,blast phase|organic dysfunction,within 4 weeks prior to the start of this study.|received,≥18 years;|diagnosis,,,,,,
3917,,renal disease)|smokers|refused,ild,,bowel movements,recurrent laryngeal cancer,,,,vitamin e,within 8 weeks of screening|presence,"≥ 4,9 ng/ml||",,,,,,
3918,,neuropathy,monoclonal b cells,,thyroid-stimulating hormone levels (tsh),chest computer tomography (ct),,,,vegetarian,within 12 hours|patients,>2|treatment,,,,,,
3919,,meaningfully engage,pth analog,,hamilton depression scale,single fraction,,,,suitable for this trial,during the 24 weeks prior to randomization,≥ 1.5-fold from,,,,,,
3920,,periapical radiolucency,||inclusion,,response evaluation criteria in solid tumors version 1.1 (,ss,,,,system.|the,at the time of study enrolment,<15 ml/h,,,,,,
3921,,heart failure.|the,components of the anesthetic solution,,recist version 1.1 guidelines.|disease progression,estimated median life expectancy,,,,ipsilateral side.|corticosteroid injection,for their chief complaint|signed informed consent,<88%,,,,,,
3922,,known cancer predisposition syndrome,nab-paclitaxel,,capillary glucose,doppler echocardiography showed,,,,separated into loose exclusion criteria,before starting the program,≥ 3 g/dl,,,,,,
3923,,changes in pain,medications used in this study|glucose-galactose malabsorption,,organs;|age,therapeutic hydrodistension,,,,ces-d,previous six months,<6,,,,,,
3924,,breastfeeding|recent injuries|known sensibility,antiretroviral drugs for hiv,,immunohistochemistry score,reirradiation,,,,medullary,prior to day 1 of treatment,more than 8 mm,,,,,,
3925,,fibrosarcoma,hyaluronic acid injection,,hepatitis b virus.|alanine aminotransferase (alt),fridericia method>470ms,,,,sensitive,at least 3 years beyond completion of cancer therapy,more than 37.0 °,,,,,,
3926,,radiographically measurable lesion,f4)|fibroscan,,resting status,transurethral resection,,,,type 2).|may,during their life-time,greater than 1 cm,,,,,,
3927,,hypertensive encephalopathy.||patients,study medication.|enrolment,,aptt/pt≥1.5 times the upper limit of normal;|have,myopia control intervention,,,,prolapse|grade iii,within 12 weeks after study treatment.||3,score of 11 or greater,,,,,,
3928,,volume resuscitation)|awareness disorder,antictla-4,,ag antimicrobial calcium alginate wound dressing,radical therapy,,,,interfere with absorption of oral medication|patients deemed otherwise,within 3 months before the first dose.|qtc prolongation,60 to 140 bpm||institutional review,,,,,,
3929,,toxic manifestations,stimulants,,new york heart association classification;|neuromuscular diseases,ultrasound examination,,,,severely affects lung,within 3 months before screening;|any condition that,< 20.0 kg/,,,,,,
3930,,hobbies,utis,,mild physical activity limitation,canine retraction into the extracted premolar||,,,,non titanium,within the previous 5 years prior to screening,skeletal class ii,,,,,,
3931,,obstructive ventilatory disorders,anti-cd38-based therapy,,clcr,c-ssrs,,,,menstruation regularly (,lasted beyond 20 weeks,1.0×10^9/l(lymphoma);platelet count≥100×10^9/l(solid tumors,,,,,,
3932,,partial colon resection,anti-cancer indications,,ecog general status,congenital anatomic anomalies of the ivc,,,,suitable for central determination,for at least 14 days prior to first dose of study intervention.|note,< 35%|pacemaker / icd,,,,,,
3933,,left bundle block,beta adrenergic therapy|chronic medical conditions,,coma scale,surgical intervention.||exclusion,,,,left hand|comfortable,for at least 2 weeks prior to day 1|participation,> 210g/week,,,,,,
3934,,hepatitis b immunoglobulin acceptable).|（14）has been,gu,,modified porto criteria||,inhibits cell division,,,,site of needle insertion|uncorrected,within 4 weeks prior to the first dose of study intervention.||note,grade 4,,,,,,
3935,,dependence;|inability,psychological drug intake|pre-,,dream cohort.|inclusion criterion,histopathology.|abdominal pelvic ct,,,,suitable for surgery,within 4.5 hours after stroke onset.|the,"<40%),|uncontrolled",,,,,,
3936,,punctal cautery.|ocular injury,blood related products,,radiation)|body mass index (bmi),axillary screening,,,,tak-771-,larger than 2 liters|need,< 100 mmhg|stable,,,,,,
3937,,thromboembolic disorder|history,cocaine,,serum glutamic pyruvic transaminase ([sgpt],living,,,,proven effective contraception|person,in the past 10 years,less than 12 months)|controls recruited,,,,,,
3938,,weight loss device,ds252a,,cobb angle,local laboratory ranges.||o of childbearing potential,,,,tension-free vaginal tape surgery,within 30 days before the first imp dose.|pregnant or,6-8,,,,,,
3939,,clinical findings,topical janus kinase,,sars-cov,rapid peritoneal solute transfer rate,,,,breastmilk,up to 12 weeks after the last immunization,< 24 months|pregnancy,,,,,,
3940,,completion|thrombocytopenia,5-year,,age;|asa,peritoneal dialysis;|blood,,,,preclude implantation of the study device|hemoglobin a1c (hba1c),within 7 days prior to start of study,i-iv,,,,,,
3941,,rtms contraindications,darbepoetin,,ais,brain imagery||,,,,"non-cirrhotic portal hypertension,|history of",previously enrolled in this study,symptom assessment).the minimum,,,,,,
3942,,musculoskeletal issues,citrulline,,partial thromboplastin time,cabg,,,,lesion(s)selected,during the trial period and 120 days after the last test drug administration;|the subjects voluntarily joined the study,≤ 2.0 x uln,,,,,,
3943,,dialysis treatment|claustrophobia|known pregnancy,gait,,response evaluation criteria in solid tumors version 1.1(recist v1.1).|the results of laboratory examination,anticoagulant treatment,,,,genotype hla-dqb1,past year|normal pap smear deemed to be negative,< 60%|no measurable treatable disease,,,,,,
3944,,immunodeficiency)|increased risk,nucleic acid testing,,creatinin level,dj stenting|pregnancy|ureteral strictures|complicated surgery,,,,radiologically grade 2 or higher,within 24 months prior to the baseline|must,20-24 weeks,,,,,,
3945,,chronic kidney disease (ckd stage,drug targeting t-cell costimulation,,mar,enzyme tests,,,,mdacc,within 7 days before the diagnosis,≥90 mmhg|ovariectomy|bmi>28,,,,,,
3946,,gc,phosphodiesterase type 5 inhibitor,,urine capture,completed the informed consent form and volunteering to participate in the study|not having,,,,toxoplasma,for at least three months;|scores 28 or more,≥75 × 10^9/l|hemoglobin,,,,,,
3947,,trustee).||criteria,prescription drugs;|the,,msk,behavioural treatment,,,,pd-l1 therapies,within the last 3 months|aged,"i-iii,|patients",,,,,,
3948,,extracorporeal membrane oxygenation (ecmo,higher potency,,serum estradiol,percutaneous endoscopic gastrojejunostomy,,,,stage ii lung cancer,admission on day -2,≥ 50 ml/min;||coagulation,,,,,,
3949,,retinopathy.|unable to receive acupuncture treatment continuously,antiplatelet therapy;|thrombophilia;|active cancer;|active autoimmune disease;|liver disease,,international headache society's international classification of headache disorders,abdominal surgery|rectal,,,,upper limb functions.|participants,in the last 12 months.|>200 ml of,≤ 1.5 × upper limit of normal range,,,,,,
3950,,coagulation disorders|known severe,assessment,,agile f (f4) score,iv antibiotic treatment,,,,hiv|history,at the time of signing the icf.|patients in the screening period met the following criteria,≤1.4 mg/dl,,,,,,
3951,,rectal cancer,anti-tussive medication,,several 3d gait analysis,isolated ileal disease,,,,non-hormonal vaginal preparations,in the past 6 months|any,> 110 mmhg)|platelet count,,,,,,
3952,,year;|pressure sores,study personnel,,total hbc ab test,anticancer treatment of,,,,eye.||,at least 2 meals per,between 18 and 65 years old|class,,,,,,
3953,,co-sensitization,biologic,,pain rating,open heart surgery,,,,s,within 4 weeks before enrollment,lower than 50%,,,,,,
3954,,ocular disease,naltrexone-bupropion,,protein igg antibody tests|negative pcr test,huaier granule treatment,,,,first-trimester,at least 6 weeks prior to randomization);|active metastases,<30 kg/m2,,,,,,
3955,,lactose intolerance,nonsteroidal anti-inflammatory,,myeloma geriatric assessment score,endorectal ultrasound (erus),,,,upper ureteric stone|size,at any time,35-45,,,,,,
3956,,surrounding tmj|dislocation,glp-1 analogues|no,,biologics,inguinal hernia|incarcerated inguinal hernia|hernia,,,,pregnancy|receive,within 6 months prior to the injection of the study,≥27·0 kg/m2,,,,,,
3957,,shoulder dislocation,daptomycin,,term newborn,complete revascularisation,,,,tumor tissue must still,prior to enrollment.|note,> 35%,,,,,,
3958,,clinical stability,sardine,,arm t)|aspartate aminotransferase,demyelination,,,,sibling,within 7 days before randomization.|women,below 2.5 times the upper limit of normal,,,,,,
3959,,oral health concern,clotrimazole,,international classification of disease clinical modification,regional hospital center of orleans,,,,implant-,within 2 weeks prior to the first dose of study drug.|investigational agent,> 32 kg/m2|pulmonary hypertension|peak,,,,,,
3960,,surgery|target lesion,weekly methotrexate,,viral load +||c. alcoholic steatohepatitis,intra articular injection,,,,unhealed wounds,within the last 4 weeks prior to surgery,≤ 70 mg/dl,,,,,,
3961,,acute tuberculosis,investigational antibody,,rutherford classification,locoregional treatment sites,,,,chronic pelvic,for at least 6 months of a category 1 multiple sclerosis dmt,lower than the normal,,,,,,
3962,,heart-kidney transplantation|recipients,hematology,,extracorporeal membrane oxygenation|prone,focal radiation,,,,stage 2.|age,in the last months.|those who are,score of the eastern tumor,,,,,,
3963,,metabolic syndrome|chronic elevation,methylxanthine-containing drinks,,dmt,head computed tomography,,,,pharmacologically induced,within 60 days of starting the study,> 3.0 times upper limit of the normal,,,,,,
3964,,high value.|lactate dehydrogenase level (ldh) determination.|determination of,cannabis-based products use,,probable,confirmatory neuroimaging,,,,icd-10 f11.20,within the 30 days prior to receiving the first dose of the study vaccine,>2|diagnosis,,,,,,
3965,,cerebrovascular disease,antiallergics,,"hiv antibody test, hiv rna",antibiotics|surgery,,,,non-surgical procedures,more than 3 months prior to enrollment,male/,,,,,,
3966,,lower incisors,abductor pollicis brevis (apb),,meeting consensus radiological criteria,endothelial disorders|ocular surgery,,,,non-live vaccine,within 12 months prior to check-in|use of,≤ 30 ml/min|hepatic,,,,,,
3967,,non-functional,sunscreens,,article,immunosuppressant medical treatment,,,,suitable for contact lens,within 4 weeks prior to pretreatment|those,between 21-89 years,,,,,,
3968,,venous thrombus,mk-3475,,partial thromboplastin time (ptt) test,ophthalmic examination,,,,or|two predicted pathogenic galc mutations,while receiving investigational treatment,<8 g/dl|absolute,,,,,,
3969,,hbv dna,micronase,,right ventricular systolic pressure (rvsp),refractive state,,,,residual invasive cancer,1 year before randomization,<10ᵒ cobb)|regular intake,,,,,,
3970,,cll|participant,antiplatelet therapy drugs,,progesterone receptor expression,skåne university hospital,,,,between screening,preceding 24 consecutive months,between 01 august 2021 and 31 december 2022,,,,,,
3971,,lung scarring,compounds with similar mechanism of action,,applicable.|karnofsky performance status,medical condition|abnormal potassium dosage (below 3.1 mmol/l,,,,near future,for at least 3 months.|participant,<50 ml/min|platelet count,,,,,,
3972,,hepatic diseases.|children,cleft,,receptor tyrosine kinase,physiological function reserves,,,,non-endometrioid endometrial cancer,at least 3 months of follow-up,>40 d and,,,,,,
3973,,reading difficulties,beverage products,,bone marrow function assessment,hormone replacement therapy only,,,,grade 2 or 3,before the first dose of study treatment;|major organ surgery,≥ nyha class,,,,,,
3974,,cerebral artery,investigational drug under investigation,,partial prothrombin time (aptt),terminal state,,,,nkg2d ligand expression,within 1 month of receiving ultrasound,<40%.|uncontrolled,,,,,,
3975,,transient cerebral ischemic seizures,herbs,,"durvalumab + platinum-etoposide treatment*,|patients",platinum therapy,,,,under stable dose,at the time of inclusion into the trial|further exclusion criteria apply,>= 1.5 × 109/l|platelets,,,,,,
3976,,toxic epidermal necrolysis.|since haart agents,pancreatic neuroendocrine,,molecular classification,medical intervention,,,,catheter-related,within 3 days prior to study treatment initiation,younger than 1 year,,,,,,
3977,,pet|glioblastomatose|pregnancy,drug medication,,american society of anesthesiology,immediate surgery,,,,osteoporosis|a,within 4 weeks of study agent,3.5 × 10 ^ 9 / l,,,,,,
3978,,idu).|clotting disorder,allograft,,progesterone (p4) level,chest x-ray|informed consent||,,,,controlled in the investigator's judgment patient with|patients,within 90 days before randomization,<90 ml min-1,,,,,,
3979,,primary cancer treatment,apantamide,,human leukocyte antigen (hla),cardioangioplasty,,,,near the test sites,after more than 6 weeks,no younger than 18-year-old.|ineffective,,,,,,
3980,,valvular abnormalities,inhibitor,,qrs interval,gastric surgery|known hypersensitivity to batroxobin,,,,non-compliant,"within the ""weeks off"" time period will not",score of 7,,,,,,
3981,,acquired immune deficiency syndrome related outcomes,spontan vaginal delivery,,gbca,complete physical examination,,,,less.|reactive,more than 3 days prior to study randomisation,7-9 hours per night||,,,,,,
3982,,heparin|previous left heart ablation procedure,vitamin d-containing dietary supplements,,sarcopenia in older people (ewsgop-2) criteria,cytohistological confirmation,,,,bleeding|active,within the last 24 months|english,score ≥ 30,,,,,,
3983,,chronic synovitis/arthritis,alternative medication,,gcsi score,intra-articular cortisone injection,,,,helmintic,within the 3 months prior to screening,less than 4,,,,,,
3984,,chronic itp,nicotine gum),,urr,investigations of anatomy,,,,pericardial effusion|previous treatment,in the last 6 months of screening,>100 ml/hour,,,,,,
3985,,feeling of inability to tolerate,serotonergic psychedelic drugs,,hildren,imaging trolley restrictions,,,,largest lesion,since the completion of therapy,> 72 hours,,,,,,
3986,,retaliatory response,related coumarins.|at screening,,hepatitis c virus (hcv) serology,whole blood transfusion,,,,study entry.||,within the previous twelve,6 months or more.||,,,,,,
3987,,structural anatomic defects,traditional,,atients,oral contraceptive pill [ocp],,,,intraoperatively,emergency department||,between 34-36 weeks,,,,,,
3988,,chronic renal diseases,psychoactive substances|regular,,hours|serum cr,vitamin therapy,,,,noradrenalin dose,at the time of signature of the main study icf|performance status,>=26,,,,,,
3989,,meditation|turns,ivh,,patients|complete bilateral class,need,,,,second trimester,in the last 6 months|have,started ≤ 6 months,,,,,,
3990,,perqseal introducer,meloxicam,,europids,progesterone therapy,,,,maxillomandibular,past one year.|visual,≥ 9 g/dl|total,,,,,,
3991,,arteriovenous thrombotic event,trial-related procedure.|healthy,,ankle instability instrument (cait),control-iq,,,,malignant,ongoing for more than 3 months|failed,≥ 2.5,,,,,,
3992,,acute febrile episode,components of the formulation,,renal estimated gfr,ventilator|colostomy,,,,bayley iii.||,in the last year.|type 1 diabetes,clinically significant abnormalities,,,,,,
3993,,malabsorption of,ace-i,,nyha grade ⅲ or ⅳ,chronic graft vs. host disease,,,,measurable on ct/mri,at least 6 weeks after the end of vitamin b12,≥ 18 years.|previous diagnosis,,,,,,
3994,,cpap therapy;|patient,intravenous steroid,,ibs-c,refusal,,,,reduced egfr)|platelets,within 14 days prior to the first dosing.|over-the-counter products,≥ 30 kg/m2|had,,,,,,
3995,,acne,lublin,,ankle)|body mass index,prophylactic antiviral therapy,,,,sacroiliac,at the time of initial study vaccination|based on documentation,≤ 30 kg/,,,,,,
3996,,malignant melanoma,steroid immunosuppressants,,visual acuity of 20/320 or better,steroid pulse therapy,,,,female;|regular,at least 3 months prior to first investigational product administration.||open-label extension period:||participants,<76|visit,,,,,,
3997,,whiplash injury,aga,,uln)|hemoglobin,io) therapy,,,,mentioned above.|major surgical procedure,after 24 months since last dose of bcg.||6,6-10,,,,,,
3998,,causes of cs,parp inhibitor,,months;|physical condition score,global impressions scale,,,,right hand.|an,within three years prior to the time of recruitment,>130 beats per minute,,,,,,
3999,,hyper/hypothyroidism,selenium,,qrs duration,cumulative target radiation treatment volume exceeding 2 cubic centimeters.|patients,,,,protocol-specified laboratory tests,within 48 hours prior to step 2 entry.|to avoid pregnancy,greater than or equal to 4 times a day.|must,,,,,,
4000,,ophthalmic symptoms,anti icos,,endogenous creatinine clearance rate,albumin|extracellular hyperhydration,,,,mild systemic disease,within 7 days before screening)|measurable disease,before 2015|patients,,,,,,
4001,,processed|secondary cancer,remdesivir,,recovery program,chest radiotherapy,,,,distal to the culprit lad lesion.|active participation in another drug,at least 7 days before study treatment,>= 40%||note,,,,,,
4002,,neurologically stable.|diagnosis,molecular weight heparins,,unlimited;|ecog physical status,cranial surgeries,,,,very good,48 hours prior to study treatment,≥32 weeks||,,,,,,
4003,,nmo,transfer,,treponema pallidum antibody,latest laboratory,,,,covid-19 induced,at least 1cm,<4.00 ng/dl,,,,,,
4004,,physical disease,tanshinone iia,,rvsp,head mri,,,,seroconversion,within 4 weeks before first dose of study treatment.|receipt of radiation therapy,from 25 to 30 kg/m2,,,,,,
4005,,meningeal involvement,antidiabetic,,partial prothrombin tests,immunosuppressive systemic therapy,,,,mental-health disorder,7 days before the first dose,> 50 mmhg,,,,,,
4006,,ihq,ctpa,,serum glutamic-oxaloacetic transaminase)/alt,therapeutic riding instructors,,,,only salpinx torsion,within the past 2 years.|have,> 1.5 x institutional uln,,,,,,
4007,,infectious illnesses,alk inhibitor therapy,,left internal mammary artery) /rima,foot surgery,,,,installed,within the previous 2 months.|clinically relevant,≥ 18 years|planned,,,,,,
4008,,vertex,histopathology,,national cancer institute common toxicity criteria,radiological investigation of chest,,,,ilae guideline|patients,within the approved labeling for the egfri,>600 mg/day,,,,,,
4009,,albinism,anti-retroviral drugs,,down syndrome|need of dental,ustekinumab treatment,,,,unsatisfactory,during the past 2 years,< 65 years|pregnancy|previous,,,,,,
4010,,digital rectal examination,ic (immune cells,,complicates test interpretation)|cholesteatoma,urinalysis tests,,,,arrival time,within 5 years prior to sign the informed consent form.||participants,no more than six prior,,,,,,
4011,,infectious pathology,cfc,,rifampin.||additional non-inclusion criteria,vaginal lubricants,,,,patch-type electrocardiograph|a,in the last 4 months they have been,90 degrees).|the,,,,,,
4012,,lipstick,nivolumab+ipilimumab,,ysleta independent school,venous return|ventricular septal defect,,,,under general anesthesia,in the first screening;|pregnant,greater than 65 mmhg,,,,,,
4013,,childbearing potential.|age,anti-donor hla antibody,,9|absolute neutrophil count,total knee arthroplasty|4-6 weeks,,,,extra-genital localization)|male,within 12 months of their,30-100 mm hg diastolic,,,,,,
4014,,prohibitive vision,chili peppers,,pap test,victimization,,,,non-viable,for <6 months,18.5 to 30 kg/m2,,,,,,
4015,,hepatitis b polymerase chain reaction (pcr) evaluation,corticosteroid treatments;|patient under guardianship,,anti-hbc (+),home|peritoneal dialysis time,,,,inherited,previous investigational intervention,≤ 9%,,,,,,
4016,,heel.|pain,hydralazine,,postpartum|american society of anesthesia,median laparotomy seems possible,,,,immunosuppressive treatment|presence of bowel stricture|history,within 30 days before the screening;|history,< 400 are excluded;||hiv patients,,,,,,
4017,,in situ neck,acid vaccine,,ecog performance scale.|patients,b-cell targeted treatment,,,,areas.|active electronic implants,at least 4 weeks after central nervous system,>= 18 years.|radiographic evidence,,,,,,
4018,,psychosis|blindness,cardiology,,babes-bolyai university,baseline||,,,,lesion|4,at least 7 months after the last imp administration,at least 2 years,,,,,,
4019,,structural heart disease|patients,monoclonal antibody preparations,,antibodies for,social security plan,,,,superior,within prior 30 days).|urgent,≤ 10mg/day,,,,,,
4020,,c virus,months.|lives,,anti mdat5 antibody should have,oral glucose lowering therapy,,,,cmv) dna,during the last two months,> 400mmhg|stability,,,,,,
4021,,dysthymia,immunosuppressive drugs|previous,,assess speech perception performance,regular marijuana user,,,,pregnant.||exclusion criteria,within 3 days prior to receiving the first study drug administration,1.|females,,,,,,
4022,,vascular thrombosis,enrollment||gh deficient subjects||dm,,hamilton depression rating,radiofrequency thermoablation,,,,low score on cognitive screening test,in the last six months.||,7% to < 8%,,,,,,
4023,,deep brain stimulator,cough suppressants.|patients,,international myeloma working group (imwg),prophylactic therapy,,,,non-atopic asthma,"any time during study participation,||ability to become pregnant","class iii, iv or v",,,,,,
4024,,technetium 99m,ripc,,sulcus bleeding index,radiotherapy lesions,,,,post traumatic stress disorder,within 30 days before the first dose of the study drug,<25%.|history of,,,,,,
4025,,cyp2a6 inhibitors /inducers,immunosuppressive therapies|use of mouthwash containing,,hepatitis c virus infection;|known,fractures;|previous organ transplantation,,,,lasting more than 2 months|diagnosis,during the last 30 days before inclusion,"≥7,0 mmol/l",,,,,,
4026,,correlative studies.|candidates,opioid use|hepatic,,aspergillus infection.|history of,carotid stenosis||,,,,breastfeeding;|absolute,within 5 years;|the,at least 1 bowel motion per week,,,,,,
4027,,completed definitive breast cancer treatment,propranolol,,cooperative oncology group (ecog) performance score,-|pregnancy|immunosuppressant therapy,,,,pd group only)|native english,within 1 month of study participation|diagnosis,greater than 48 hours ago,,,,,,
4028,,intertriginous area(s,platelet-rich blood,,heart rate (hr),medication.|physical examination,,,,toxic megacolon,throughout 90 days after final study intervention administration.|male participant,< 1000 cells/mm3.|severe,,,,,,
4029,,seizures|pregnant,anti-cancer drug,,increase exhaled carbon monoxide levels,saphenopopliteal junction,,,,non-surgical weight loss,within 72 hours,18-45 years||,,,,,,
4030,,urinary disease|previous surgery,curators,,plt<100×10,xoi therapy,,,,central nervous system diseases,at the time of dosing)|any condition,20 ng/µl,,,,,,
4031,,inflammatory bowel disease.|history,cbd related products,,stage iv)|american society of anesthesiologists ≥iv|previous laparotomy|bmi,emergency cabg,,,,mental illness;|moderate,less than 48 hours before taking the drug,<30 milliliters per minute,,,,,,
4032,,paroxysmal supraventricular,anti-coagulants|mullerian,,sane score,excisional biopsy specimens,,,,years|a,within the past 48 months)|echocardiographic evidence,below 60 ml/minute,,,,,,
4033,,risk proliferative diabetic retinopathy.|dme,suppressant medication,,beck scale,hemorrhage)|separation,,,,infantile onset disease,48 hours prior to any visit,3-4;|state,,,,,,
4034,,coaches,r1,,american society of anesthesiology (asa),blood culture,,,,fellow eye|determination by investigator of macula-off status,within 6 months|disagree to participate in study,> 90 bpm or < 45 bpm,,,,,,
4035,,none|eligibility criteria,leukotriene receptor antagonists,,berg balance scale.|scoring,alternative therapies,,,,platinum-containing regimens,at the time of starting study treatment,≥ 25 and ≤ 40 kg/m2|planned resection,,,,,,
4036,,rhinitis|ability,xanthine derivatives|severe iron deficiency,,males.|for growth hormone (,dlt,,,,pathologies|pregnant,during the intervention|planning a change in medication,> 140 kg,,,,,,
4037,,chronic hypotony|any anatomical changes,combination regimen,,spot urine protein creatinine ratio,hormone intra uterine device,,,,fermented milk,before the first administration of study drug.|received,relative 18 years,,,,,,
4038,,fasciitis,inhaled products,,sufficient organ function,optic nerve head (onh) abnormalities,,,,cool extremities,prior to catheter placement (exception,< 60 ml/min/1.73 m2|cardiac dysfunction,,,,,,
4039,,hypertension|fracture,norplant system®,,international classification of disease-10,personal medical history,,,,accurately assess,within 30 days prior to pre-entry.||the following,between signing icf,,,,,,
4040,,hyperglycemia induced,component of the seal™ system,,left ventricular ejection score (lvef) ≥50%;|6.the,autologous hematopoietic cell transplantation,,,,study||gap vanderbilt||known diagnosis of appendix,in the 4 weeks prior to signing icf.||**topical,> 3 mm,,,,,,
4041,,back-transfer,cannabis derived products|cochlear implant,,numeric rating scale,transportation issues|organ transplant patients|patients,,,,allergy disorders|supplement,28 days prior to vaccination,80 cm,,,,,,
4042,,cardiovascular disease|uncontrolled,ensifentrine,,pet scanning.|right-handed.|fluent,fine needle aspiration (fna),,,,non,within 6 months before randomization,18.5 - 30 kg/m2.|agree,,,,,,
4043,,acute cholangitis,moisturizers,,modified version of abeer children dental anxiety scale,cpap).|normal head ultrasound,,,,pulse floating,after cr,"score ≥ 16,|body surface area (bsa)",,,,,,
4044,,coagulation disorders|patient,confirmed covid-19,,ikd,instrumental examination methods,,,,disorder|medically-induced,in the past year|reside,"grades ii, iii",,,,,,
4045,,endometrial cancer (ec),ipratropium,,recist v1.1;|eastern cooperative oncology group performance status,ocular surgeries,,,,malunited,within the three school districts,> 4 mm,,,,,,
4046,,palms,pertuzumab,,xoi sap-001 shanton pharma pte,autologous stem cell transplantation.|patients,,,,awake,within 4 weeks prior to the first dose of study treatment,≥18 years and ≤75,,,,,,
4047,,migraine headaches,actinic keratosis products,,meeting mini,"global assessment (iga,",,,,lge-cmri|participation,within 2 years prior to the first administration,> 1.5 times uln;|tsh,,,,,,
4048,,gastroesophageal reflux|laryngeal,grades,,kidney disease|bnp,global assessment scale,,,,non-responsiveness,prior to the first dose|a male,>180/120 mmhg).|if,,,,,,
4049,,hypocomplementaemia,components of qlf32101；|have uncontrollable,,immunoglobulin g reaches,bone tissue,,,,non-operatively|patients,at the time of the study visit,< 3×upper limit of normal,,,,,,
4050,,surgically altered anatomy,anti cd20 therapies,,kyphosis,photorefractive keratectomy (prk),,,,tibial nerve region of the inner ankle,within 12 months before the start of the study;|non-pregnant,18-75|suitable,,,,,,
4051,,autoimmune disease|complication of pulmonary fibrosis,beta2-agonists,,homa-ir,aeh,,,,isth bat>3,smaller than 5 cm.||,outside the 60 ~ 90 mmhg,,,,,,
4052,,intracranial atherosclerosis,ccr5 + by ihc,,prothrombin (pt),cohort only||•,,,,eligible.||relapsed,within 7 days prior to the first study intervention,<10 µiu/ml,,,,,,
4053,,attentional hemineglect syndrome,inflammatory diseases;|(3,,recist v1.1.|adequate bone marrow function,co-existing,,,,occlusal relationships|patient's consent to participate||exclusion,within the past 5 years;|current,3 or greater,,,,,,
4054,,cholesterol profiles,anti-ctla-4:||subjects,,test for hepatitis b surface antigen,chronic let,,,,de novo cohort.||additional inclusion criteria,prior to admission into the study||,more than 3 times the upper normal limit)|serum,,,,,,
4055,,down's syndrome,combined,,ecg tracing,primary treatment (,,,,donating,at time of informed consent|eastern cooperative oncology group performance status,≥18 years|infrarenal aaa,,,,,,
4056,,chronic lymphocytic leukaemia,components in the nicotinamide riboside (niagen®,,study|estimated glomerular filtration rate,emergency ebus cases|asa score,,,,requiring iv anti-microbial treatment|patient,at least 4 weeks before randomization.|liver function classified,< 50 kg,,,,,,
4057,,chest skin damage,mellaril,,evaluations||positive skin prick test (spt),inoculation through,,,,core area,within 4 weeks prior to the first administration of the study drug;|major surgery,=18-29 kg/m^2|ability,,,,,,
4058,,bladder dysfunction,depressants,,prostate cancer,psychotropic medication regime,,,,scar tissue,within the previous 6,> 0.7,,,,,,
4059,,sudden,ungdomshälsan,,anti-hepatitis b core (hbc),reinfusion,,,,may significantly impair renal function,within the last 15 months,= 0,,,,,,
4060,,hbsβ0 thalassemia,vardenafil,,old|patients admitted,imr)|quiescent full cycle flow ratio,,,,fibromyalgia symptom scale,in the last 3 months|long,levels to ≥ 3x uln,,,,,,
4061,,a:||males,palivizumab,,hbeag status,breastfeeding|major surgery,,,,carbo-platinum,during the period covered,≥ 20%,,,,,,
4062,,criterion,components of nucleocapture|current participation in another interventional clinical trial|pregnancy,,american indian status,liver tumors.|levels,,,,stage ii nk||clinical findings,during the sampling,more than 65 years,,,,,,
4063,,apical abscess,preoperative troponin/hypersensitive,,see section 10.6,"sahlgrenska university hospital in gothenburg,",,,,als|does not,continue the original antiviral treatment,>3mg/,,,,,,
4064,,renal injury,live attenuated vaccine,,antineutrophil cytoplasmic antibodies (anca);|positive anti-hiv,small molecule targeted drugs,,,,between sorafenib,during the course of chemoradiation,0-2|adequate organ,,,,,,
4065,,hiv)-positive status.||known hepatitis b virus (hbv) surface antigen (hbsag),kp.|participants,,"disorder,|uncontrollable asthma,|pao2",tpo-ra,,,,post-ovulation methods,within 3 months before screening.|participant,below the lower limit of normal (lln),,,,,,
4066,,cutaneous viral,glipizide,,boston bowel preparation scale,external fixators|local severe,,,,screening|subjects,on the labial surface of either maxillary,players 17 years,,,,,,
4067,,snb,oral corticosteroid use,,btc before surgery,resting echocardiogram|recent (,,,,suitable for entry into the study in the opinion of the investigator.|the subjects will also refrain from the use of any other,throughout the duration of the study||,>28 mm);|tandem lesions;|severe,,,,,,
4068,,brain diseases,systemic steroid stimulants,,home testing kits,age|periodontal treatment,,,,p:||inclusion,following requirements:||prothrombin time/international standardized ratio,≥ 1.10;|attainment,,,,,,
4069,,urinary tract infection|solitary kidney|concomitant pathology,oral prednisone therapy,,mm3|platelet count,time to conception of,,,,mild to moderate stages,within 3 months prior to the expected initial application date,11236,,,,,,
4070,,vascular diseases,troleandomycin,,old|ecog performance status scale,allogeneic hematopoietic stem cell transplantation.|the patient,,,,ipa-,before the procedure,">= 100,000/mcl|total",,,,,,
4071,,palpable tumors,sleep number,,recist 1.1|ecog,lesions|all mri central imaging,,,,at as,at least two months after vaccination|for fertile,for more than 12 months until,,,,,,
4072,,active autoimmune disease,modified,,meso,hipec,,,,steroid-dependent,at time of consent|confirms conversational fluency,≥ 23,,,,,,
4073,,points)|inability,mobile-phone,,2|hemoglobin,physical therapy examination,,,,women;|combined,during the interval,between 15-50 years|symptomatic,,,,,,
4074,,lms,intervapor®,,saga bfr application,months.|clinical vaccination,,,,nos|high grade b-cell lymphoma,during screening tests,< 96%,,,,,,
4075,,technical performance,enrolled):||anti-hiv antibody positive;|or,,bone sarcoma|at least one year,uterine sounding,,,,pure axial involvement,preventing from cell,between 40 and 80,,,,,,
4076,,cardiovascular failure,mtor-inhibitors,,edss,antiviral treatment,,,,guideline-directed medical therapy,at least 14 days prior to enrollment.|white blood cells,=<29 ml/min/1.73m2,,,,,,
4077,,lymphocytic leukemia(cll),contrast medium|contraindication,,hemi diaphragm,smallpox,,,,essential,for at least 3 months prior to the screening visit|stem cell implantation of any type,under five years,,,,,,
4078,,hgsnat,anti-tumor therapy,,heart,intravesical surgical manipulation||intravesical therapy,,,,any of its excipients,for at least 3 months,≥ 18 kg/m2,,,,,,
4079,,renal failure|chronic pain,melanoma,,kidney cancer.||eastern,superfluous growths,,,,systemic antibiotics,within 3 months prior to ip administration|administered nsaids,<10 pm/ml,,,,,,
4080,,renal diseases|uncooperative,gonadotropins,,1;|child-pugh score,virological testing,,,,permit,at least 7 days prior to the first dose of apg-1252,15 units,,,,,,
4081,,lateral ankle sprain,herbal products,,mean pulmonary artery pressure,glucocorticoid treatment,,,,deemed more,in the past 2 weeks;||healthy,18 or over,,,,,,
4082,,extraesophageal symptoms,adrenergic blockers,,"100,000/µl)|hemoglobin",donation plan,,,,incisional biopsies,within 3 days before screening|those,equal to 3.||,,,,,,
4083,,anterior shoulder dislocation,visit|systemic steroid,,kaufman brief intelligence test (kbit).|must have,whole body mri,,,,group iv pulmonary arterial hypertension,prior to operation,> 9mmol/l);|coagulation,,,,,,
4084,,"nasal absorption, distribution",component of the study drug；|participated,,histopathology;|underwent surgical,transthoracic echocardiography|left atrial anteroposterior diameter,,,,permanent,within 5 years of the qualifying,<17 g/dl|female,,,,,,
4085,,hemodialysis|dry weight stable,herbal supplements,,pcia,laser-assisted in situ keratomileusis,,,,let what disease,prior to starting,>18 year,,,,,,
4086,,bone cancer,oht,,definition: immunohistochemistry,1 full cycle before study drug,,,,hypersensitive,tumor.|pre-existing,18 and older|novice,,,,,,
4087,,nodal arrhythmias,bosutinib,,hlh,liver local therapy；|no contraception,,,,central nerve metastatic,before surgery .|ecog performance status,between 16 and 65 years,,,,,,
4088,,ehcc,dexmedetomidine.|mental disorders.|unsuitability for extubation.|comorbidities as cardiac,,thyroid hormone replacement therapy,tuberculosis.|history,,,,despite medical management|had,in the last 12 months|history of brain,less than 80|at least one,,,,,,
4089,,liver tumor(s,daclizumab,,national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda) criteria.|pd,potential delivery of,,,,under the curve reference values,at the time of inclusion|acutely admitted to geriatric units,older than 40,,,,,,
4090,,peritoneal dialysis||all cohorts:||participants,lapatinib,,anderson silverman score (ass),total bilirubin,,,,non-basal cell malignancy,within 1 month (30 days,≤ 3x upper limit of normal,,,,,,
4091,,respiratory pathologies respiratory pathologies,mrf,,indoor oxygen saturation,radiological tests,,,,systemically,within the last 6 months|heart,< 50 pg/ml)||,,,,,,
4092,,active.|pregnant,monoclonal antibody therapies|pregnant,,echocardiographic ejection fraction,insulin|pregnant,,,,morphologically with malignancy,within the previous 2 years except,below 50 clearly indicates specialist,,,,,,
4093,,vascular obstruction,sodium glucose co-transporter,,left ventricular systolic dysfunction,toronto alexithymia scale,,,,hips,within 14 days prior to the first dose;|subjects,shorter than 2 hours,,,,,,
4094,,vision impairments,toxin-induced parkinsonism,,"adults"".|habitual bedtime",plain x-ray,,,,non-opposition form that will,within five years prior,crcl≥60ml/min,,,,,,
4095,,acute chest pain,strong cyp3a4 inhibitors.|participants,,alkaline phosphatase (ap),ibrutinib therapy,,,,controlling,within 1 month before administration;|with known immune system diseases,"0, 1 or 2|patients",,,,,,
4096,,heart failure|has any other,amiodarone hydrochloride,,international headache society,expected,,,,low stable doses,"within one week of visit 2, day 0",< 220 db/m|have,,,,,,
4097,,ica,anti-al amyloidosis,,icu stay,groin puncture,,,,could jeopardize the safety of patients and their compliance in the study.||multiple primary malignancies,for at least 6 months after the last dose of study treatment,18 to 65 years;|undergoing uni-,,,,,,
4098,,major diseases,local heart team decision.|subject,,american society of clinical oncology,pyloroplasty,,,,non-oncological,within the last week|having used,"at least twice the upper limit of the normal concentrations,|pulmonary edema,|new-onset",,,,,,
4099,,hyperthyreosis,pah,,estimated glomerular filtration rate [egfr],histone mutation,,,,low-calorie diet,within 30 days before screening and any time between screening and day 1 first dose,female|17-40 years,,,,,,
4100,,hypodense,ocrelizumab,,physical activity readiness questionnaire[29],maintenance asthma treatment,,,,unrestorable,within 5 years.|current active,18 years or above|the patient,,,,,,
4101,,substance use disorder of,cns depressants,,serum pregnancy test.|blood type,intestinal inflammation;|(6,,,,influence food intake,within 6 months prior to study treatment.|participant,less than 36 months,,,,,,
4102,,aml.|subject,tas-102,,international cancer control (uicc),keratotomy,,,,near critical structures for,within 2 weeks prior to randomization iii,35-55 years.|ambulatory,,,,,,
4103,,ocular herpetic infection,articipants,,minimum sensitivity 25 iu/l,repolarization,,,,primary sclerosing cholangitis,within the last 2 years.|major depressive disorder,region.|class 2 obesity,,,,,,
4104,,cancer treatment;|the,antirheumatic drugs,,respiratory rate,anti -tuberculosis treatment,,,,before screening;|obstructive jaundice,practice for less than a year,4 cm from the edge of the lesional area,,,,,,
4105,,cognitive disability,pacs,,pulse rate [pr],lung cancer,,,,rome iv criteria for children||,within the past 5 years;|known,< 18|inability to sign,,,,,,
4106,,post-menopausal status,anti-tumor traditional,,recist 1.1,barrier methods (diaphragm,,,,parkinson,at the screening visit.|bleeding on probing (bop),>= 10 mm,,,,,,
4107,,illegal recreational drug,intralesional corticosteroids,,nci-ctcae 5.0,clinical laboratory tests,,,,grade 2 or higher neurological condition,in the past 6 months;|history,≥ 3/10,,,,,,
4108,,neovascularization,systemic beta-blockers,,end-stage malignant disease)|moribund,pylarify pet,,,,invading the gi-tract,time|more than 48 hours,above the 99th percentile,,,,,,
4109,,leukemic liver,alk,,platelet,axillary lymph nodal dissection (alnd),,,,open,within 30 days prior to study entry,above 30 kg/,,,,,,
4110,,disc hemorrhage,fluvoxamine,,ftd,remotely|regular access,,,,intra-articular injection,prevent them filling,18 years and over|adult,,,,,,
4111,,hiatus hernia,live attenuated viral vaccine,,hepatitis b surface antigen reactive,total abdominal hysterectomy,,,,multidisciplinary approach|high nrs detection,past-year mean days of alcohol use per month,less than 65 years,,,,,,
4112,,progressive local,anti-aml treatment,,spouse should take strict contraceptive measures,radiopharmaceutical therapy,,,,initially gathered,at least one prior regimen,>50% luminal loss,,,,,,
4113,,thoracic oncological surgical procedure,5 millimeters,,predictive value,normal delivery watching,,,,2022|non-smokers|bmi,within 90 days prior to screening,<18).||active liver disease defined,,,,,,
4114,,risk factors related,check-in],,american society of anesthesiology (asa) class,genital-related surgery,,,,any grade should,within 28 days before enrollment 12-lead electrocardiogram no,≥ 75 x 109/l|total bilirubin,,,,,,
4115,,isolated extra,prescription dry eye therapy,,cooperation||health care providers||previous participation in this study,"oxidative stress (obesity, copd",,,,non-operative,within 3 months after the last study administration|with my consent,over 5.5 mmol/l,,,,,,
4116,,back-up,influenza-related respiratory symptoms,,seizure|cardiac ejection fraction,standard of care therapy,,,,nmosd international consensus diagnostic,prior to entrance to the,greater than 140 mm hg,,,,,,
4117,,adequate organ functions;|willing,oral intake.||key exclusion,,afb,regular exercise,,,,icd-10: d00-d09,in the past 3 years.|there,women|aged 60 years or older,,,,,,
4118,,ischemic cerebrovascular disease.|take ticagelor,compounds of similar chemical or biologic composition to study agents.|clinically significant,,serum complement,transanal-noses||patients,,,,injection-related,at the time of starting study treatment|active infection,45-,,,,,,
4119,,nsclc.|is,fish oil).|inability,,hematocrit,vertebral column disorder|chronic use,,,,high-throughput,during the 2-week period,minimum 50 ml,,,,,,
4120,,parenteral application|known allergy,alto-100,,ava,interventional procedures,,,,invasive,within 3 months of enrollment|chronic,< 130mmol/l|ast,,,,,,
4121,,comorbid disease (infection,prescription drug abuse,,resting partial pressure of oxygen in standard ambient conditions of,iron therapy,,,,highly effective contraception.|native-zambian,6 months after the last dose;|patients who voluntarily,above or equal to 18 years assigned,,,,,,
4122,,"kick, bite",contraceptive implants,,indocyanine green angiography|signed informed consent|affiliated or beneficiary of health insurance||,radiofrequency catheter,,,,toxicity related,during the 60 days before the screening visit;|other major surgery,≥ 30%.|subject,,,,,,
4123,,atrophic gastritis,sarilumab,,prothrombin time/activated,physical examination.|in,,,,heterotopic ossification|cognitive,prior to cohort entry date,incompetent|more than 25%,,,,,,
4124,,therapeutic riding instructor,at rest,,alcohol breath analysis,quit smoking sometime,,,,45ml of spirits,previous 2 years except,"> 450,000 / μl|methotrexate",,,,,,
4125,,inflammatory intestinal diseases|pregnancy|neoplastic diseases|allergy,epcoritamab,,cirrhotic status,surgical resection,,,,with measurable disease,within the last 5 years|7.not appropriate to be,≤ 1.5 mg/dl.,,,,,,
4126,,ped,proton pump,,vpt,vertebral body.|chest ct performed,,,,non-eoe,within 1 year of screening,0-3.||exclusion criteria||the participant's compliance,,,,,,
4127,,small bowel adenocarcinoma,compounds of the latter,,gsv reflux,surgery|evaluation,,,,|bmi>35|pregnancy,during the duration of this study|bmi,≥ 3.5 mg/dl,,,,,,
4128,,breast symptoms,oral opioid,,18f fdg pet/ct scan,bilateral simultaneous tka|patients,,,,epilepsy|intracranial,at any time after achieving,< 4 or > 10 k/ul,,,,,,
4129,,gmfcs iii classification.|patients,nonpregnant,,sars-cov-2 antibodies,clinical study procedures|vaccination,,,,residual lesions,november 2021 to june 2023)|sufficient,10-point,,,,,,
4130,,progressive neurodegenerative disease|patients,materials used for treatment|mental diseases effect cooperation|sensory loss,,national soccer league,ultrasound scans|patients,,,,fluzoparib,between -1 and -2.5,< 2kg|baseline,,,,,,
4131,,visit|symptomatic hypotension,α2-adrenergic agonists,,cri.||ecog performance status,computed tomography scan|participant,,,,concentric,within 30 days prior to screening|subject,1 to less than 5 years,,,,,,
4132,,douro e,immunosuppressive therapy.|pregnant,,rt|numeric pain rating scale,standard screening tool,,,,youth,within 6 months of the baseline,18.5-28)|understand,,,,,,
4133,,lack of contraception,compounds of similar chemical or biologic composition to tegavivint,,partial sternotomy|acute coronary syndrome,first re-induction therapy;|phase ii trial will also,,,,not receive,within six months,>/=350 cells/μl,,,,,,
4134,,nulliparous,anti-pd-1/anti-pd-l1 antibodies|re,,diaphoresis||compass 31,echo).||adequate organ,,,,oesophageal,for at least 6 months after the last dose of protocol treatment,between 30 to 70 years,,,,,,
4135,,capivasertib,inactive vaccines,,itch nrs score,renal surgery,,,,metabolism related fatty liver disease,at least one guardian consent,< 500 cells/ul,,,,,,
4136,,old|ability,meningococcal serogroup,,idh1/flt3,protocol section,,,,minimum length of stay,within 14 days of screening,below 36.0 ° c or above 37.0 °c,,,,,,
4137,,benign breast tumor,ige.|urine m-protein,,mores,sc therapy,,,,questionnaires|attendance,"in the previous 5 years),|hypersensitivity to any investigational food",> 25|geriatric depression scale-15 (gds-15),,,,,,
4138,,lesion stenosis,dr. cipto mangunkusumo,,circulatory blood,pancreatic,,,,non-physician healthcare,during childhood)||history of prior,score less than 600|those who,,,,,,
4139,,biopsy|hbsag,herbal,,constraints herein,potential qtc-prolonging medications should,,,,pure tone average,within 2 weeks of first receipt of study drug,>15 db hl,,,,,,
4140,,etc|abnormal liver function,cyp3a),,interdental cal,12-lead electric cardiogram,,,,iii|completed,within two weeks prior to start of the study.||any surgical,1 day on the basis of the last application date.).|subjects,,,,,,
4141,,cerebral edema|rapid neurological improvement,indocyanine green,,egfr formula).|resting corrected qt interval,emergency intervention,,,,psi guides was abandoned.|patients that,at any time during the study|participation in an investigational trial,>450msec,,,,,,
4142,,cardio pulmonary,hypoglycemic agent,,west haven grade,12-lead electrocardiograms (ecgs),,,,claw toes,"72 hours of symptoms,|american society of anesthesiologists (",18-50,,,,,,
4143,,burkitt's lymphoma/leukaemia,amide-type anesthesia,,mass index,emergency surgery|planned,,,,"vomiting,|symptomatic",more than 3,25 or higher,,,,,,
4144,,cutaneous dermatomyositis area,memantine,,mshc clinics enrolled in the clinical trial|english speaking||,screening procedures,,,,> mild pathological,in the last 6 months|patients,≥ 1.0×109/l,,,,,,
4145,,blood draws.||malignancy,subconjunctival haemorrhages,,hepatitis c antibodies,percutaneous procedure,,,,appropriately treated,within the treatment area,> 30kg,,,,,,
4146,,primary malignancy;|mental disorder,epidermal growth factor receptor (egfr),,hpv-screen-positive,exercise therapy,,,,age|mechanically,at the time of signing informed consent.|continuance of,<1.5cm;|non-aneurysmal aortic,,,,,,
4147,,equivalent.|no co-existing psycho-social problems,satisfy one,,figo stage,visceral organs,,,,visceral neuropathies)|neuropathic conditions,aphakia|history,>3.0 g/dl|subject,,,,,,
4148,,hepatobiliary malignancies.|urinalysis,oncogenic driver,,estimated,microscopic hydatidiform changes,,,,injection lesion,iii within 3 months prior to informed consent,under 18 years old|patient,,,,,,
4149,,behavioral disorders,sodium-glucose linked transporter-2 inhibitor (sglt-2i),,quantitative total urine protein measurement,confirmatory imaging,,,,non-breastfeeding||,through iv 48 hours prior to first ip administration.|those,less than 5 years ago,,,,,,
4150,,miocardical infarction,other immunomodulators,,serum human chorionic gonadotropin (hcg) pregnancy test,coronary ct angiography,,,,low grade toxities,for at least 24,≥2 prior to the,,,,,,
4151,,random biopsies,medication regimen,,hidac,first immature,,,,undifferentiated,for at least 5 days prior to the procedure,65 and over,,,,,,
4152,,responses from text earlier,non-medical topical treatments,,hepatitis c positivity in combination,clinic.|plasma donation,,,,new onset of 1 or more of the following:||proteinuria,within 7 days of initiation,12-18 years,,,,,,
4153,,menstrual pain,antiemetic,,procedural revascularisation.|current,revascularization.|percutaneous coronary intervention,,,,esophageal achalasia,within 60 days of screening|severe renal dysfunction,≥60 ml/min.|patients,,,,,,
4154,,gilbert's disease)|ast(sgot)/alt(sgpt,over-the counter medications,,eosinophil count,coronary revascularization,,,,male,within 6 months before screening;|use,10-fold greater than the normal upper limit,,,,,,
4155,,child beariring potential,implanon®,,cmet ihc entry criteria,weeks|acute ilness|mental incapacity,,,,stage ii mronj,within the past 8 weeks.|history,less than 6 months old,,,,,,
4156,,ecg abnormality should perform,immunosuppressive corticosteroids,,satisfactory:||o corrected mean qt interval,viral suppressive therapy,,,,normal);|untreated,for more than 8 weeks;|antibiotics,18-65 years,,,,,,
4157,,hemorrhagic/thrombolytic stroke,interleukin-1 receptor antagonist,,smoking|body mass index (bmi),smart ring,,,,stage ia,after one year of enrollment,score 0 to 1|adequate organ function|at least 1 lesion,,,,,,
4158,,treatment|allergy,migraine days,,cdr score,etc.);|major organ surgery,,,,single-barrier form of,at the time of initial screening,> 50 kg|,,,,,,
4159,,congestive heart failure|myocardial infarction,angiotensin-converting-enzyme inhibitors,,ap length maximum 10 mm).||,flow cytometry crossmatch,,,,jaw,within 6 months before randomization.|history of gastrointestinal perforation,< 2.5 ×uln,,,,,,
4160,,costello syndrome,jefferson outpatient oncology,,moderate levels,rescue,,,,mellitus|pregnancy|acute,within 90 days of enrollment to a substudy,>55% of,,,,,,
4161,,impaired mental status|clinical institute withdrawal assessment (ciwa) score,biologic agents,,her2 negative early,upper gi surgery,,,,breastfeeding|unstable,12 months after last menses,less than 3 x 60 min,,,,,,
4162,,angio neuroedema,vorinostat,,urine collection,ibd|corticosteroid injection,,,,kg)|patient,within 14 days of randomization,<30 ml/min/1.73m2.|as,,,,,,
4163,,severe comorbidities,anti-epileptic medications,,predominantly acute sdh|presence of brain contusion,onset of gbm,,,,non-brain oligometastases,within 1 month|non-english speaking,less than 3 months prior to study day 1|participants,,,,,,
4164,,poor arrhythmia control,sodium),,-arterial extracorporeal,mri scan,,,,midline|physical findings,within 2 years alcoholism,>5 events/hour)|aged,,,,,,
4165,,"inner forearm),|hyperhidrosis",recombinant vaccine,,university students,parasitological giemsa-stained direct smears.|acute lesions of,,,,igg type,within the last 2 years.|2,< 0.7,,,,,,
4166,,passionflower etc];|alcohol abuse,roxadustat,,lung cancer-asthma,functional assessments,,,,illicit,within 2 weeks before the procedure;|tandem extracranial,≥-6.0d,,,,,,
4167,,multi-gene,syndromic,,solid tumors.|dose expansion phase,soft multifocal contact lenses,,,,yellow fever,for at least 4 weeks prior to enrolment.|patients,2-3 years,,,,,,
4168,,urine pregnancy,upper.|good oral,,faecalis bacteremia;|urine culture,home oxygen therapy).|pregnancy,,,,peri-menopausal,conditions:||less than 4 weeks,≥ 24 years,,,,,,
4169,,sweating,months||baseline,,walking,ros1 fusion,,,,injection site.|significant cardiac dysfunction,before surgery;|with contraindications,≥ 18|clinical signs,,,,,,
4170,,acute asthma,supplemental vitamins,,overall dsm 5 criteria,"verbal communication in turkish,|iv treatment",,,,pseudo-seizures,within 4 weeks prior to screening|a patient,<60ml/,,,,,,
4171,,hallucinogen use disorder,zytiga,,serum urea concentration,plastic surgery,,,,12-ecg recordings,within the 6 months preceding the enrolment.|patient participating,130-139 mmhg,,,,,,
4172,,vertigo,isopter iii4e,,hgba1c,lineal blood relatives,,,,pseudo-seizures).|females,previously received the following therapies,<0.6cm2/m2|both,,,,,,
4173,,vocal cord dysfunction,intranasal corticosteroid||,,thc.|axillary temperature,ct scheduled,,,,post-operative,at screening <10 g/dl,>3 x institutional upper limit of normal,,,,,,
4174,,dementia disorder,months|plans,,aortic arch atheroma,etc.).|age,,,,actively treated,after more than six weeks,higher than the lower limit of the detection value,,,,,,
4175,,adrenal crisis,biologics,,dual screen contraception,lumbar puncture cytology,,,,clinically significant deviation,for 30 days after the last dose of decoy20.|male subjects must,above 400um,,,,,,
4176,,myocarditis;|medical conditions,drugs or vaccines,,seizures;|being,enteroscopy,,,,pd-l1 targeting,within the past 2 years,letter score ≥ 79,,,,,,
4177,,tumor mutational burden,anti-depressants|age,,hemoglobin a1c,ethanol,,,,distal-pancreatectomy,past 2 years.|a skin condition,higher or equal to 85,,,,,,
4178,,squamous cell carcinoma of the skin after radical resection,lumbar 1,,hindi,rgan transplant,,,,non-contrast ct-scan,up to 2,between 27-45 kg/m2|owns,,,,,,
4179,,hiv-negative|read,antibiotic coverage,,basics,hormonal net-related,,,,resistance exercise,within the last six months,=< 3 x institutional uln|step,,,,,,
4180,,fungal nasal sinusitis,sulfa drugs,,opd cohort|hemoglobin,adjuvant components,,,,black,within the normal range,< 100×109/l|egfr <60ml /min/ 1.73m2,,,,,,
4181,,cerebrovascular structures|scheduled postoperative inpatient overnight,erenumab-aooe,,apical periodontitis.|18,adjuvant systemic treatment,,,,history.|acute,within 24 hours prior to randomization,≥ 90 g/l).|alanine,,,,,,
4182,,pulmonary infarction|room air desaturation,dmt,,months.||protocol b:||inclusion criteria:||males,first-line platinum-containing standard regimens,,,,requiring advanced intervention|currently participating in another investigational study,within 6 months before the first medication,< 3.0 x uln,,,,,,
4183,,familial cold autoinflammatory syndrome (caps),ppsv23,,serum erythropoietin level,allogeneic hematopoietic stem cell transplantation;|live attenuated,,,,necrotic bone,during daily time-restricted eating|prostate cancer,≥ 80×109/l,,,,,,
4184,,traditional herbal medicine for antitumor purposes,chronic anti-coagulation treatment,,nyha class iv).|active malignancy.|pregnancy.|hepatic failure,donated a unit of blood,,,,stage iv-v.|known,< 6 months prior to the first dose of study,over 350 cells/mm³,,,,,,
4185,,bbsa,psychotropic medication,,serum transaminase elevations,standard of care,,,,affects drug absorption;||participants,within 3 years before the first administration,≤ 8.0 mm,,,,,,
4186,,impairment of immunological function,artificial suntan,,nihss score,"health examination center of nanfang hospital,|voluntary signing of informed consent;|no systemic",,,,factor b,during the study.|any other,between ≥16 and <65 years.|ownership,,,,,,
4187,,obstetric cholestasis,crrt,,alt/ast,univentricular physiology|systolic blood pressure<90mmhg|glomerular filtration,,,,under who treatment,within 6 weeks prior to the first dose of study treatment.|local radiotherapy,≥ 35kg,,,,,,
4188,,chemotherapy.|squamous cell carcinoma,bismuth agents,,recist v1.1 criteria,gorno-tempini,,,,non-inclusion:||chronic allergies|neurological disorders|cardiovascular,in past 3 month|fasting,> 18 years|not,,,,,,
4189,,folic acid,age;|pseudophakic,,malignancy.|ecog performance status,eln,,,,malabsorption,within the past 1 year|patients,≥1.5×10^9/l,,,,,,
4190,,diagnosis;|obesity,triamterene,,normal|abnormal thyroid function,reliable visual field testing,,,,genetically modified t cell therapy.||impaired cardiac function,within 12 weeks prior to the booster vaccination.|chronic use,>1.5 ×uln,,,,,,
4191,,chronic skin condition,anti-infective agents;|female,,age-related,hormone contraception,,,,condoms,within 6 months of study enrollment,9-12|specialize,,,,,,
4192,,ventilation support,dalteparin,,weeks;|ecog,read,,,,since admission|active infection,within 2 weeks of screening.|participant,60 mmhg diastolic|allergy,,,,,,
4193,,hypercapnia,vcf,,urine drug testing,covid-19 treatment,,,,narrow treatment window,at least 1 month prior to screening,> 130 mmhg,,,,,,
4194,,infectious diseases drassanes vall d'hebron,resveratrol supplements,,syntax i score,plasma cell leukemia,,,,trigeminal,within 30 days prior to enrollment|body mass index,0 or 1.||have,,,,,,
4195,,homicidal risk|vaccination,hispanics,,progesterone,spanish-speaking|own a,,,,enrollment;|active,within 3 weeks of entry onto this study,6 to 11 years,,,,,,
4196,,drug absorption disorders；|other conditions deemed inappropriate for inclusion by the investigator。,biologic medications,,antigen-,transcatheter mitral valve repair,,,,high-dose glucocorticoids,prior to first administration of the study,≥ 60 ml/min.|patients,,,,,,
4197,,macular pathology,protein,,testing laboratory.|ecog performance status,pelvic scanning,,,,medical conditions||serious,within one month prior to investigation,≤ 5 x upper limit of normal,,,,,,
4198,,moderate alcohol consumption,p-aminosalicylate,,serum hepatitis b surface antigen,cell-associated,,,,multidisciplinary cardiac team,prior to the first dose of study,18 and 70 years,,,,,,
4199,,bladder pathologies,anti-vegf for,,glomerular filltration rate,duration.|revision surgery,,,,nutrition risk screening 2002,within 7 days before the first dose of htmc0435,at least 5 x 5 cm,,,,,,
4200,,enktcl,antiarrythmics,,direct bilirubin,laboratory assessments,,,,implanted medical,in the next 3 months,≥50 ml/min|for,,,,,,
4201,,biallelic mutations,good oral hygiene|patients,,hemolysis|total bilirubin,instrumental activities of daily living,,,,||inclusion,within the last 30 days with any investigational drug.|concurrent administration of any other,class 2 or higher heart failure,,,,,,
4202,,peritoneal carcinosis,par,,core antibody hbcab),intravenous puncture,,,,stent delivery.|subject,within one week of the study|evidence of,≤ 1.5×upper limit of normal,,,,,,
4203,,requires,variants,,child length,oral immunotherapy,,,,nab-paclitaxel,within 4 weeks before the first administration;|participated in clinical trials of,≥18|patients who undergo,,,,,,
4204,,er pathology,empiric antibiotic regimen,,numerical pain rating scale,brain natriuretic peptide (bnp),,,,upper gi presenting,after completing,greater than or equal to 48 millimoles per mole,,,,,,
4205,,substance abuse)|if the risk of suicide,orthostatic hypotension|patients,,metastases on pet imaging are,myocardial scintigraphy (ms),,,,high grade fever,within the last 90 days.|a positive pre-study drug/alcohol,≥ 9g / dl,,,,,,
4206,,transvaginal echography||,antipyretic,,hbcab,hepatic function|history of allergy,,,,suitable to participate in this clinical study for,at the end of surgery.|has a neuromuscular disorder(s),>=20kg/,,,,,,
4207,,clotting factors,furmonertinib,,easl-eortc,anxiolytic treatment,,,,grade 2 and higher pelvic organ prolapse,within the past 7 calendar days.||,class iii or iv,,,,,,
4208,,cognitive disorder|patients,compounds of similar chemical or biologic composition to relugolix,,absolute count,subsequent biopsy conducted,,,,central nervous system (cns) herpes zoster,within 3 months before the study;|history,≥18 years|high,,,,,,
4209,,autoinflammatory disease,rifamycins,,ga,hidradenitis suppurativa,,,,minimally invasive abdominal,within 30 days or,≥ 1.5 × 109/l（1500/ μ l）,,,,,,
4210,,chronic central serous chorioretinopathy|patients,musculoskeletal nociplastic pains,,bone marrow cell morphology,first trimester,,,,flow cytometry-confirmed,in the past 24 hours|known,>1.5×109/l)|serum bilirubin,,,,,,
4211,,optic nerve sheath diameter,cyp3a4 substrates,,mmhg.|heart rate,vascular access thrombosis,,,,electronically implanted,for the duration of the study|receiving standard wound care,<20.||,,,,,,
4212,,non-alcoholic fatty liver,fi,,vertical bone height,selected control persons,,,,pd-l1 expression detection,within the last 12 months|history of urinary retention,> 9.0 g/dl|total,,,,,,
4213,,malignant disease.|patients,substances used,,serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (sgot /ast,crepitations,,,,recently.||,"preceding month, change in regularly taken medication",greater than 1.5 × uln,,,,,,
4214,,unable swallow whole tablets,platelet inhibitors,,"kellgren lawrence scale,|patients",palliative drainage surgery,,,,moderate-advanced,after taking the drug,< 1 month or > 6,,,,,,
4215,,resected basal,immediate major,,volumetric size,small molecule anti-angiogenic tki drugs,,,,patella|retropatellar pain|duration of,within 2 weeks of enrollment.|recipient,>3x the upper limit of normal.|any,,,,,,
4216,,pre-eclampsia,tattoo,,pregnancy|increased intracranial pressure,optimal medical therapy,,,,pure-tone average (pta),at least six weeks before entering the study,3-9 years,,,,,,
4217,,systemic auto-immune disease.|active h. pylori infection,treponema pallidum antibody,,thyroid-replacement hormone,radiological treatment,,,,skill-based groups).|young people will be excluded if they have,within the 8 weeks,1 obese,,,,,,
4218,,asymptomatic hepatitis b virus(hbv,topical steroid hormones,,hcv viral load,pet-ct already,,,,breathing room air,for 30 days after the last treatment the patient should not,t0-4a n0/n2c m0,,,,,,
4219,,tattoos,third dbpcfc study visit|patient,,pfizer,transfontanellar ultrasound scan,,,,parent||,during the study period.|at least 6 weeks,>= 60.|willing and able to adhere,,,,,,
4220,,mild anemia,steroid drugs,,medicare beneficiaries,herniotomy,,,,cah)/ein,since the last treatment||,18 or younger.|pregnant,,,,,,
4221,,caval invasion|life expectancy,sodium phosphate,,mass general brigham system|patients,curative resection,,,,5-year,within 3 months before enrollment to exclude,> 38 or,,,,,,
4222,,sign of covid-19,hdt,,alanine aminotransferase,npwt,,,,diaphragmatic,at the time of enrollment.|patients,<1.5xuln,,,,,,
4223,,edema,opioid dependency,,no||-,menstrual cramps;|onset,,,,site of vivio application / examination.|contraindication to placing,at least 8 hours a day,"≥1,500/mm3|platelets",,,,,,
4224,,neurological disorders like hypertension,long-acting biologics,,national heart,injection volume,,,,upper urinary tract,within 6 mounths|maxillary,≥ 300/,,,,,,
4225,,disabling disease,anti-anginal,,trigger.|serum estradiol levels,severity x frequency,,,,adult growth,at the time of signing informed consent|body mass index (,<5.0 x,,,,,,
4226,,hypertensive disorders,srp,,lvef)≥50%.|hemoglobin concentration,ymrs,,,,non-commercial panels,within 6 months prior to the planned,30-70,,,,,,
4227,,nasopharyngeal malignancies,varenicline,,creatinine creatinine clearance,a:||patients,,,,intercurrent illness|uncontrolled,at baseline,≥ 10)|renal impairment,,,,,,
4228,,disturbances in iron balance,anti-diabetic,,general health score,antibioprophylaxis,,,,any etiology,within 1 month prior to the expected initial application date,absolute value,,,,,,
4229,,fainting of needles,parenteral administration of antibiotics.|any,,ahi,interventional therapy excepted,,,,haemorrhagic).||general,before starting any specific procedure,≤ 3.0 × uln;|serum,,,,,,
4230,,non-small celll lung cancer,ppa,,diffuse atrophic rpe alterations visualized,portal hypotensives treatments,,,,long-term dialysis.|preoperative,within 1 year prior to screening;|investigators,> 80 %,,,,,,
4231,,hepatitis c|known clinically significant,parenteral glucocorticoids,,none,renal function tests,,,,post-transplant,at the time of intubation,50-90.|ability to understand,,,,,,
4232,,≤200 mg.||,progestin receptor (pr),,child care centers:||be open,diagnose of glaucoma|indication,,,,recovery room,at the time of inclusion.|the immediate,≥30g/l,,,,,,
4233,,isocitrate dehydrogenase (idh),methamphetamine,,erythrocyte sedimentation rate (esr),auxiliary examination,,,,tay-sachs,at least 4 weeks prior to study drug administration,between 4 years and,,,,,,
4234,,local laboratory.|measurable disease,investigational treatment for antecedent myeloid neoplasm,,gp1,data,,,,chair group of sensory science,in the previous 3 years|patients,19 or above to under 80,,,,,,
4235,,mania|patients,carbocysteine,,serum triacylglycerol,rectal surgery,,,,conditions:||relapsed,during the clinical study.|use of,> 220 pounds,,,,,,
4236,,fatal hemorrhage,drug treatment,,intermuscular fibroids,rectal,,,,extended-release topical contraceptives,in ct perfusion.|baseline nihss obtained before procedure,4-7,,,,,,
4237,,preterm birth,beta-blockers,,absolute neutrophil,gastric surgery,,,,cap formula,within 28 days prior to day of enrollment.|history of,< 300 mmhg.||,,,,,,
4238,,intensive housing services,anti-vegf/flk-1 monoclonal antibody,,neurofilocytes,boundary values).|must,,,,surgical removal of lesions,at the screening or the baseline visit,4 or greater,,,,,,
4239,,major head trauma|life expectancy,eskape pathogens,,recist 1.1);|ecog ps,hepatic elastography,,,,requiring iv infusion,history of surgery,= aspartate aminotransferase,,,,,,
4240,,functions of heart,ateplase,,forced expiratory volume in the first second/vital capacity (fev1/vc,surgically excised basal,,,,01/12/2021,at the time of signing the informed consent;|weight of subjects ≥50.0 kg and ≤100.0 kg,≤ 35 ml/min|contraindications,,,,,,
4241,,absolute contraindications,t-dm1.||patients,,either:||platelet count,10cm|positive fusion vergence over 20pd||,,,,serious unstable,in the month prior to screening,<18 years.|not available,,,,,,
4242,,skin squamous cell carcinoma,mescaline,,communication complexity scale|sufficient motor skills,nitinol,,,,athens-clarke county,at least 20% growth,+/-,,,,,,
4243,,diabetic macular oedema (dmo),at,,numeric pain rating scale,median sternotomy,,,,ptsd|bipolar disorder|mdd|schizophrenia|at risk of suicide(columbia,within the previous 3 months;|revascularization of the lower limb,50-74 years,,,,,,
4244,,steven's,chronically,,drinks/week,lumbar imaging examination,,,,under treatment,by the time of the enrolment.|subjects on treatment with ß-,≥6.5%,,,,,,
4245,,refractory multiple myeloma,entacapone,,blood count,computerized intervention,,,,spondylolisthesis|spinal,at any of the measurement sites|inability to give written informed consent|subjects taking vasodilator treatment,1.1.|participants with ccrcc,,,,,,
4246,,fragility fracture,pemphigoid,,disability score,immunosuppressive purpose,,,,preclude study participation,within 48 hours of study enrollment,< 40 bpm,,,,,,
4247,,infection complications,psychotropics,,65 years|body mass index,imaging procedure,,,,mild upper extremity motor impairment55;|age between,rehabilitation department,< 280 db/m,,,,,,
4248,,resistant microorganism,protease inhibitors boosted,,spherical,questionnaires||additional inclusion criteria,,,,eradication|predominant,during study sep361-308.|female,≤ level 1,,,,,,
4249,,motion sickness,rectum,,historical genetic test results consistent with fabry mutations,combination chemotherapy,,,,coagulopathy,at least one oral,>45mmhg,,,,,,
4250,,gilbert,platelet-rich plasma injection|steroid injection,,old|asa physical status,consistent with liver cirrhosis.|two,,,,mental health to fill,last dose of immuno-oncology therapy,<24,,,,,,
4251,,unmc pathology review,components of huaier granule,,bbps,hematopoietic stem cell allograft.||ni-12,,,,will cause limited cooperation,within the study,>36 s.,,,,,,
4252,,disease-free|a gastrointestinal disorder,medications to treat headache,,serum creatinine (cr) ≤1.5×uln,r0 resection cannot,,,,medical illnesses.|a,at the time of initial diagnosis,at least 3 months||patients,,,,,,
4253,,arterial inflow,medication altering gi motility;|pregnant,,anti-hbc,remain on the waiting list,,,,lactulose to control their encephalopathy are not allowed.|had a,during the study.|any facial laser treatment,1.histologically-,,,,,,
4254,,ventricular fibrillation,uln;|urine protein concentration,,body cathexis scale,infection;|history,,,,could significantly affect skin,within the 5 years prior to the informed consent date|bladder stones|medical contraindication,from 18 to 50 years,,,,,,
4255,,anaphylactic,hypoglycemic agents,,asia,intracranial trauma,,,,socioeconomic level,during the whole study|willingness in participating to the intervention,18 to 40 years,,,,,,
4256,,reference lesion,antihypertensive agent or|sitting clinic values,,monoclonal antibodies,face mask before reaching eto2 85%|chronic lung disease|anemia,,,,near-daily steroid,within 14 days.|hypertrophic cardiomyopathy,> 300 µm||,,,,,,
4257,,hemiplegia,cigarettes,,anti-hb core,surgery,,,,systemic infection|uncontrolled hypertension,during the 6 months preceding the study;|absence of,≥ 30g/l. 3,,,,,,
4258,,transplantation|hepatic cirrhosis,lichen planus,,hepatitis c virus [hcv],hemoptysis|pregnancy|drug,,,,icd-10-cm,at least 2 lines,>25 mmhg,,,,,,
4259,,recurrence of peritoneal carcinomatosis,arthroscopic,,kellgren,biopharmaceutical produced in chinese hamster ovary (cho),,,,-1.00 to -3.50 d in each eye,at least 30 days prior to (first) admission to the clinical research center,more than 10,,,,,,
4260,,cns metastasis,plasma derived,,partial thromboplastin time ( aptt ),aesthetic medical procedures,,,,adjustable,within 12 months prior to screening|participants,5.2 mmol/l,,,,,,
4261,,uretroprostatic disorder|subjet anxious,anti-platelet agents|failure,,response (bdr),speech therapy,,,,pi.||••formalin-fixed,"at the time of signing the informed consent.|participants of a parental phase 1, 2, or 3 clinical study assessing",≥1.5 × 109/l|platelet count,,,,,,
4262,,types of alopecia,pde-5-inhibitors|clinically,,nj|participants,acs treatment|current,,,,under general anesthesia.|lung nodules should be up to 3 cm in diameter and located in right,in the last 5 years may be included,> 250 ms,,,,,,
4263,,recurrence of an ae,obstructive valvular heart disease,,serum hbv dna,bladder control scale,,,,non-injection,within 3 weeks prior to the first dose of study,≥8 and <18 years,,,,,,
4264,,carcinosarcomas,immune treatment,,sars cov-2,radiotherapy dose,,,,invading,during the study period.|participants from all ethnicities,18.5-35 kg/m2|are,,,,,,
4265,,platelet disorder,sodium valproate.|any other contraindication/s to sodium valproate,,left ventricular ejection fraction (lvef),transvaginal ultrasound,,,,non-compressible vessels|diagnosis of cli,within 3 months prior to initial dosing,≤ 2.||adequate organ,,,,,,
4266,,cuirass precluded,component of the investigational product|pregnant,,igm hbcab negative.|female,health care professionals,,,,esophageal,within 7 days prior to study,≤ 5 × upper limit of normal (uln),,,,,,
4267,,alcohol abuse|psychiatric disorders,extensive residual,,cooperative oncology group performance (ecog) performance status,bronchial biopsy,,,,full criteria for bn according,within 3 months|inability,<1.7 mmol).|parental refusal to participate,,,,,,
4268,,"newborns,|chronic disease",mucoid,,cardiac valve repair.|previous episode,transcatheter interventions,,,,intra-ocular medications,in 7 days preceding,between 18 and 32,,,,,,
4269,,unless the investigator considers the ecg abnormality,direct oral anticoagulant agents,,possess dna repair genes,small molecule kinase inhibitor,,,,secondary to schwannomatosis,within the last 6 months before,<1 year|lung disease,,,,,,
4270,,contraindicating,dialysis.|systemic steroid therapy,,hypopnea])|life expectancy,sitting time|bmi,,,,ultrasonography|uncontrolled,within 4-6 weeks after the end of radio-chemotherapy,≥23 kilograms per meter squared,,,,,,
4271,,irregular cornea;|known pregnancy,dmpa,,neutrophil count,zhongshan hospital xiamen university,,,,pathologically confirmed,in the past two weeks|if the participant is,greater than 126 mg/dl|blood,,,,,,
4272,,heapatitis,salt substitute used,,p.e.,mini mental test score below 24|posterior circulation stroke,,,,full active care,during the study.||exclusion,13-17,,,,,,
4273,,muscle relaxant,molecular profiling,,test for hepatitis b,intracardiac metal devices||known coronary heart disease,,,,3 or more,within 4 weeks prior to enrolment|non-decompensated,> 60 years,,,,,,
4274,,menstruation appears,opioids agonists,,demonstrates understanding of the study,criteria:||alanine aminotransferase (alt),,,,primary series and,within 1 month before study entry,> 50 ncm,,,,,,
4275,,airway sensitivities,hormonal agent,,simplified oral hygiene index,radioactive iodine imaging,,,,american college of rheumatology||,after the operation,>30 kg/m2|coagulation dysfunction,,,,,,
4276,,invasive disease,chin,,dbhl,stable therapy,,,,could lead to pregnancy|for,prior to covid-19 infection,≤1 x 10^9/,,,,,,
4277,,consensus between pi(surgeon,serum alpha-fetoprotein,,blood glucose detection,rotavirus vaccine,,,,influence of pharmacological,within 1 year|those who,<18 years|secondary causes,,,,,,
4278,,half siblings,tegretol,,gestational age)|birth weight,cns lymphoma.|participants,,,,legs,during the whole treatment period until 120 days after the last study drug administration,<90 g/l,,,,,,
4279,,mellitus,atypical antipsychotic,,maintenance program.||,clinical laboratory tests.|body mass index (bmi),,,,affects the central subfield,within 30 days of baseline.|participated,< 480 ms||is able to swallow oral medications,,,,,,
4280,,immunodeficiencies linked,therapeutic drug,,ucp;|aged,amyloid pet scan,,,,surgical plan,for 14 days after the final dose of sulfasalazine.||subject,>= 3 hours/month of contact,,,,,,
4281,,cancer outside,systemic anti-tumor treatment,,hcv viral load.|hiv-infected,surgical intervention;||leaflet anatomy,,,,unresectable mcrc.|patients,prednisone ≤10mg/d,above 100kg|known,,,,,,
4282,,impairment of immune system,anti-cd20 antibodies and btk inhibitors,,modified t cells.|previous anti-cd19/anti-cd3 therapy,follicular lymphoma[fl],,,,-treated,within one hour if lens is worn,≥ 2.0 mm,,,,,,
4283,,hepatitis c etc.)|moderate,medications that,,bmt,hair loss;|inability to tolerate,,,,≥3 months).||prior malignancy,at the time of dosing).|other medical or,6 months to 25 years,,,,,,
4284,,peptic esophagitis,mate2k,,caries rate,standardized test,,,,post-traumatic cold dystrophy,eyes|eye,≥ 18 years.|histologically,,,,,,
4285,,peptic ulcer digestive,beta2-adrenergic agonists,,treprostinil,drainage procedures,,,,"african american""|uncontrolled",within 30 days prior to screening|recent high,less than 2 mm,,,,,,
4286,,primary osteochondrosis,time.|chemotherapy,,18f-fluselenamyl,old|current,,,,frequency matched population control participants||,planning to become pregnant,< 480 msec on electrocardiogram,,,,,,
4287,,criteria.|commitment,"strong inducers of cytochrome p450 (cyp) isoenzymes cyp3a4/5, cyp2c9",,refusing surgical treatment.|mixed incontinence,borderline resectable pancreatic cancer,,,,after organ transplantation.|t lymphocyte abnormality,within the previous 2 weeks,clearance||≥ 60 ml/min,,,,,,
4288,,ankle injuries,immunosuppressive treatment|history of,,bone marrow reserve,studies|regular consumption of similar ingredients,,,,oesophagus,in the past 12 months|currently undergoing,greater than or equal to -6.0 d,,,,,,
4289,,liver cirrhosis.|patients,determines,,serum calcemia level|signed,cardiac consultation,,,,non-dutch speaking,within the last 5 years.||regular intake of,≥750/ ul the patient,,,,,,
4290,,lateral ventricles,hbv anti-viral prophylaxis.|2,,got,laser peripheral iridectomy,,,,pure tone average (pta),at time of enrollment|a cell phone able to send/receive text messages|self-reported,18-30,,,,,,
4291,,chronic systemic illness,hlh,,armpit body temperature (body temperature,video exercise trainings,,,,afferent,continue to receive,> 8.0 g/dl|white,,,,,,
4292,,uncontrolled asthma|asthma,dopamine receptor blocker,,hcv serology test.|esophageal gastric duodenoscopy,antiplatelet treatment,,,,non-invasive ventilator,within 4 weeks of enrolment into the study,>24h,,,,,,
4293,,trichotillomania,anti-arrhythmic medications,,ldl cholesterol,emergency departments instead,,,,psma pet,within 72 hours before surgery,> 3x normal,,,,,,
4294,,chronic hbv carriers,narcotic painkillers)|having,,facial axis angle)|well,5)||chronic treatment,,,,irinotecan-,within last six months|history of,> 50||,,,,,,
4295,,coagulation factors,eosinphilia,,new york heart association (nyha) functional classification,triplet pregnancy,,,,suitable for vigorous exercise|those,48 hours,90% or greater,,,,,,
4296,,hiv infection,medication use,,alt serum level,fridericia method,,,,full-time,for at least 6 months|steroid dosage < or equal to 10 mg/day,100 ×109/l).|hemoglobin,,,,,,
4297,,musculoskeletal injuries,doxepine,,lacking hip extension,aneurysmal coil embolization,,,,other factors not appropriate in this test.||note,after 1 cycle of standard regiments,between 18 and 70 years).|bmi ≥ 35 kg/m²;|subjects,,,,,,
4298,,anxiety disorder,covid-19 antigenic test||exclusion criteria,,largest diameter,glaucoma filtering surgery,,,,mechanistically related,within 14 days prior to visit 1.|the,≥3 months;|adequate organ performance,,,,,,
4299,,multiple factors,"materials used to ""vape"".|any",,nih pathology,*,,,,subretinal,at screening [v1],greater than 7;|spinal cord compression;|the patient refused the treatment decision of the integrated team,,,,,,
4300,,tnf-α inhibitor treatment|tnf-α inhibitor-treated ibd,gastric acid suppressing medication|chronic use,,american society of clinical oncology (asco)/ college of american pathologists (cap) guidelines,radical resection of the pectoralis major muscle,,,,endocrine-related,within 7 days prior to step 2 randomization)|step,≥ 5 g/l,,,,,,
4301,,dietitian-prescribed,udca,,residual hematopoietic cells;||two,r1 resection,,,,endoscopically unresectable,within 5 years prior to the administration of the first study drug,> 2.0,,,,,,
4302,,crohn's disease.|fistulizing,human proteins,,qtc time,ventral striatal loss,,,,radiotherapy|unconscious,within 30 days prior to the first,between 12 and 60.|subjects must complete all screening assessments,,,,,,
4303,,neurological manifestations,detoxification drugs,,years-,abdominal laparoscopic surgery|american society of anaesthesiologists (asa) physical status,,,,glyceroltrinitrate,within 3 months prior to study enrollment|patients,"18+,|diagnosed with binge",,,,,,
4304,,secondary orthopedic,proteins of human origin,,lic,blood type incompatible transplantation,,,,post-thrombotic,directly,<40 kg/m²);|use,,,,,,
4305,,hp sensitive drugs,rif,,florence,palliative radiotherapy should,,,,illegal use,within 28 days of their first treatment,grade 2-4,,,,,,
4306,,chemical dependency,plasma-lyte®,,trolley bags,temporal artery temperature,,,,endocarditis|acute myocarditis,within the last 14 days of screening)||creatinine =< 1.5 x uln,functional class ii-iv|forced vital,,,,,,
4307,,pelvic organ cancer,anticonvulsant medication,,rome iv criteria|provide,hsg,,,,/cerebrovascular,greater than 5 cm,between 7 and 17|at least,,,,,,
4308,,culprit lesion,topical treatment,,bone metastases|bilirubin,ocular examination,,,,index-sc,within 4 weeks prior to enrollment into the study;|unmanageable urinary tract obstruction;|evidence,15-18,,,,,,
4309,,eating disorder examination questionnaire 6.0 total,teriparatide,,normal|estimated glomerular filtration rate (egfr),restricted comorbid,,,,grade i-ii);|subjects,prior to chest ct|lack of social security affiliation,≥ 100 × 109/l.|hemoglobin,,,,,,
4310,,pregnant ladies,noninhalation,,intracranial pressure,hbv antiviral therapy,,,,interfere with testing.|current pregnancy.|marked leg length discrepancy,at least 6 months of experience,≥3 months|able,,,,,,
4311,,seizure disease,pirfenidone.|corticosteroids,,hepatitis c virus (hcv) antibody,ebp,,,,pistachios|pre-existing,during the study follow-up period,greater than 18 years 2,,,,,,
4312,,residential facility staff,rotc,,recist v1.1 criteria 30|in,primary total knee,,,,adequate diet,in the past year)|history of,t least 18 years,,,,,,
4313,,severe autism,sertraline,,diastolic lv,major heart surgery,,,,naïve,within last month|seriously ill,> 139 mmhg,,,,,,
4314,,pain perception,feminine hygiene,,stroke score,bile duct or gallbladder surgery,,,,st-elevation myocardial,within 48 hours.|allergy,greater than 85 mmhg,,,,,,
4315,,orthodontic treatment|aggressive,anti-ctla4,,eras guidelines;|age,marijuana cigarettes.|participation,,,,low-stage cancers,within the normal range.|have expected survival,> 6 years,,,,,,
4316,,hemophilia b;|had,staff:||• none,,average qrs interval,sui,,,,listed risk conditions,during the study.|diagnosis of cat,minimum 18 years|patients,,,,,,
4317,,muscle tone,organ,,female|hiv negative|have,arthrocentesis,,,,non-melanoma,within 4 weeks before administration of the study drug,>90cc|comorbidities,,,,,,
4318,,child-bearing||,monosodium,,||documentation of hiv,blood biochemical test,,,,temporomandibular,in the last 3 months)|documented allergy to,<65 mmhg,,,,,,
4319,,organic brain dysfunction,anti-cd20,,latest comprehensive guidelines,xoi therapies,,,,calipers,within the past 6 months):||suicidal ideation item 4,18.5-30 kg/m2 -,,,,,,
4320,,pleural effusion|cardiovascular insufficiency,platelet,,total bone inclusion,general mri exclusions,,,,b)|acquired,during confinement.|history or,18-25 years|both,,,,,,
4321,,mitrofanoff,miglustat,,performance score,group intervention programs|having been,,,,pancreatic neck,within the last 12 months.||a,1 to 3 pourability,,,,,,
4322,,dependence|mental,agent targeting,,employed full time by,pathogenic abca4 variants,,,,index shoulder.|enrolled,at a dose higher than 10 mg/day of,>= 1.0 x 10^3/ul,,,,,,
4323,,non-ert treatments,combination treatment,,uln.||sgpt (alt),head ct,,,,epstein barr virus,within 2 weeks prior to meta10-19 infusion,≥180 mmhg,,,,,,
4324,,provocation pain tests,anti-tyrosil-,,pcl score,brain metastases|history,,,,generalized,while being treated,6-30 months post,,,,,,
4325,,multiple allergies;|alcohol,ctcae ≤1,,qt interval abnormalities,age|patients,,,,clarity app|regularly eats,before administration,3 or higher,,,,,,
4326,,cns involvement|diagnosis,study materials,,18f-fdg-pet/ct,dual energy x-ray|low,,,,culprit coronary artery||cs,for 3 months after the study treatment period ends,<95%|planned,,,,,,
4327,,placenta accreta,growth,,endogenous interleukin 29,distal bile duct carcinoma (dbc),,,,uric acid,in the last three months.|exhibits another form of,0 or 1|participants,,,,,,
4328,,conductance catheterization|pregnancy,cetylpyridinium chloride,,immunoglobulin,pros,,,,speak english||fully vaccinated,prior to dosing.|history,> 18 years old|patient,,,,,,
4329,,pop,antirejection medications,,hamilton norwood grade iii-iv)|men,administration;|major surgery,,,,hypopharynx,icu for less than 5 days;||4,<2.1,,,,,,
4330,,coronary vasospasm,medication used,,ld chemotherapy,therapeutic procedures,,,,islet-cell tumors,for at least 6 months (inclusive),< 2|aneurysm treatment does not,,,,,,
4331,,criteria:||1,receive vaccines,,organ function laboratory values system laboratory value||hematological|absolute neutrophil count (,therapies,,,,non-live,at least 2 weeks before the first study treatment,≥ 3.0×109/l,,,,,,
4332,,regular pmt||,anti-inflammatory drugs viral drugs,,hepatitis c virus (hcv) infection,graft-vs-host disease.|underwent,,,,under observation,within 7 days prior to start of trial.|subject,≥ 2.5 g/l|patients,,,,,,
4333,,gynaecological cancers,pomegranate,,numeric pain rating scale|unilateral knee stiffness,practice-pharmacists,,,,needing,pre-menarche|not,less than 10°,,,,,,
4334,,chronic hepatitis b virus,obinutuzumab,,inferior alveolar nerve block anesthesia,labral tears.|surgical procedures,,,,largest diameter following icrs,within three month,≥ 20 ng/ml|world health organization (who),,,,,,
4335,,gingivitis||gingivitis,agent alone,,intolerance|hemoglobin concentration,treatment strategy,,,,local institution's addiction medicine specialists,at least 2 points,at least 3 months.|have,,,,,,
4336,,third-party clinician,intravenous antibiotics,,acne severity scale,small cell types,,,,could lead to anaphylaxis.|pregnancy,prior to leukapheresis: cytotoxic chemotherapy,>=5 minutes||,,,,,,
4337,,inflammatory bowel disease.|active infections.|impaired heart function.|active,anti-angiogenic small molecule kinase inhibitors,,self-employed workers,inguinal hernia repair,,,,clinically significant,over 65 years,guidelines for older,,,,,,
4338,,neuropsychiatric,mtor inhibitors,,blood sugar,vacuum pump therapy,,,,large doses,while they or their partner,less than 40 or,,,,,,
4339,,risk factors outlined,amivantamab,,atrium size,sublocade,,,,"c5,",over the past 2 weeks.|predicted life expectancy,>= 28 days after the completion,,,,,,
4340,,hepatic pathology,esophageal stents,,recist version1.1.|adequate organ function.||,pneumococcal polysaccharide vaccine,,,,stt interval,"at the start of the recruitment,|reside in a targeted county,|interested",18 years and above|fitzpatrick,,,,,,
4341,,gastric ulcer disease,sotalol,,cooperative oncology group (ecog) performance status,dental surgery,,,,tumor tissue samples.||3,less than 24 months of age,< 30 ml/min/1.73m²,,,,,,
4342,,horseshoe varus,glp-1 ra,,prevalent cognitive impairment denoting dementia|3,focal neurological findings.|history of syncope,,,,peri-implantitis lesions,within 1 year before first receiving the study drug,between 18.5 and 35.0 kg/m2|is free-living,,,,,,
4343,,non-hyperaemic tests.|functional limitation,mtor inhibitor,,psma pet/ct|adequate,hybrid closed-loop,,,,rotterdam criteria of pco,in the last 6 months|existing open wound,> 180 mm hg,,,,,,
4344,,physical comorbidities,equivalent.|belimumab,,o2 saturation,complete cardiac mri,,,,non-extraction approach,within 3 months prior to initiation of study treatment,greater than 400 ml.|there,,,,,,
4345,,progressive ms;|previous treatment,beta-alanine,,cryo time period,thorax surgery,,,,distal dcb target segment);|signed patient informed consent/data release form||,planning method|not being able to attend the trainings,≥45 and ≤100 bpm|temperature ≥35.5 °c,,,,,,
4346,,bacterial infection,component of ht-001,,white blood cell count,endovascular procedures,,,,upper extremities,last 6 months before the initial examination.||pregnant,40 years to 80 years,,,,,,
4347,,distant,cholestyramine,,resting ecg,intra-arch spaces for future prosthesis.||,,,,nearby,within the month prior to the overnight study visits.|beginning/ending,score 4+3,,,,,,
4348,,end-stage renal disease|operated patients,strong hemodynamic support,,numeric scale rate,"chest tube pneumothorax,|platelet count",,,,acute/chronic,within 5 years prior to enrollment|positive,2 to 6 years,,,,,,
4349,,painful joint.|participants,guide,,gout.||serum potassium,copper containing iud,,,,self-recruited through social media,in the last 90 days|18,"<50,000cells/mm^3",,,,,,
4350,,mood disorder questionnaire (mdq),topical drug products,,modified ashworh score (mas) of,lateral canthal lines severity scale,,,,obstructive,in the 12 months prior to enrollment,iiib-iiic,,,,,,
4351,,pancreatic islet cells,antimuscarinic medication,,mco,cochlear implant surgery,,,,primary endpoint(s),at least one month before this study|subject,"≥ 100,000/mm3.||renal",,,,,,
4352,,biliary tract carcinoma,group.||key,,investigator.|absolute neutrophil count,testing for hiv,,,,stage ii cohort expansion,for at least 3 months prior to the screening visit;|is willing to adjust their,> 35 kg/m2|polyhydramnios|history,,,,,,
4353,,cardiac pet,combined-spinal epidural,,taiwanese language|healthy,standard intraocular injection procedures,,,,influence the drug metabolism from 48 hours before administration.|history of drug abuse,in the last five days|receiving chronic warfarin therapy,60 ml/min,,,,,,
4354,,aggravation,rheumatoid arthritis|receive,,ant hiv,abl1 fusion,,,,axis i condition,within the last 3 months prior to study,≥ 1.5 x institutional,,,,,,
4355,,gynecologic abnormalities,trastuzumab plus,,"platelet transfusion),|inr",major organ transplant,,,,stable ms,within 6 months of signing,>103 copies/ml,,,,,,
4356,,gastrointestinal stricture|patients,intervention drugs,,aspartate transaminase,dmt intervention,,,,hiv;|4.active,< 4 months previous,1 to arm 2): in,,,,,,
4357,,persistence of symptoms.||,local pathosis,,hbv core antibody,repeat testing||any of the following,,,,metabolic disease;|active,within 3,at least 3 months.|patients,,,,,,
4358,,pathological myopia,calcium channel inhibitor,,fsh level,allogeneic transplant,,,,months;|unilateral,within 72 hours prior to allocation,>=60 within 30 days before treatment|no serious,,,,,,
4359,,lower extremity orthopedic surgery,amyloidosis.|ventricular assist,,gvhd);|neutropenia,intraocular metallic fragments,,,,between geographical regions,within 3 years before study registration,<50%.poor hypertension control,,,,,,
4360,,convergence insufficiency symptom survey,basal-bolus,,hemoglobin values,contraindicate surgery,,,,interleukin 2 [il-2],<4 weeks,under 250 ng/g|subjects,,,,,,
4361,,unable to consent.)|potential interference from another study (,serotonin reuptake inhibitors);|use of phosphodiesterase inhibitors,,cbf,curative surgery treatment,,,,specifically mentioned,during the screening period|biopsies,≥9.0 g/dl;platelet count,,,,,,
4362,,viral hepatitis infection|pregnancy,dantrolene sodium,,anti-hepatitis c ab,endomyocardial biopsy evidence of,,,,botulinium toxin,within 6 months of enrollment,between 20 0/7 weeks and 25 6/7 weeks|absence of chromosomal,,,,,,
4363,,systemic effects e.g.:||prednisone,hydroquinone on the target area,,ccbl,hrct scan,,,,non-interventional trial.||,at the time of subject eligibility,≤ 1|expected survival,,,,,,
4364,,rare histologies,influenza vaccination,,monocyte clone size,gastroenterology outpatient clinic,,,,radically cured,within 2 months prior to the study|weight loss,> 50mm|moderate,,,,,,
4365,,gastrointestinal absorption of drugs,anti-hypertensive agents)|able,,thyroid surgery.|aged,dislocation.|previous surgery,,,,grade iii meningioma,in the last two months|had,>140 mm hg systolic,,,,,,
4366,,medication except atrial,anti-epileptic medication,,vital sign,invasive assessments,,,,unknown cause occurred,last 8 weeks - amputation,> 94 %.|total symptom score no,,,,,,
4367,,spinal cord trauma,preventative medications,,mmse score,standard regiments,,,,grade ii or iii degree,constitute seizures|history of seizures,50.0 - 90.0 kg,,,,,,
4368,,direct involvement,nnrti,,pbs,small molecule targeted agents,,,,preclude surgery|who are not pregnant|who are,within 7 days before enrollment,18 years old and 80 years,,,,,,
4369,,omphalocele,posaconazole,,fibronectin test,endoscopic eradication therapy,,,,fungal,within the past 6 months.|previous anaphylactic reaction.|previous,=< 28 days prior to registration.||note,,,,,,
4370,,multiple malignancies,amnesteem,,recist version 1.1;|ecog score,fresh frozen tissue for surgical resection of the lesion,,,,elective phacoemulsification,in the 30 days preceding treatment|previous systemic treatment,15 minutes|unable to operate,,,,,,
4371,,colonic polyps,amplification.|participants,,american congress of rehabilitation medicine,sensorineural hearing,,,,topical form on the face,in the baby,"≥100,000 / mcl|hemoglobin",,,,,,
4372,,alveolar inflammation;|had,smartphone device,,recist v1.1|ecog status,primary treatment failure,,,,implantation of a,during the trial until at least 4 months after the last dose of protocol treatment,between 5.7% and <6.5%,,,,,,
4373,,chronic respiratory insufficiency,adulthood,,abnormal levels of serum creatinine,t mri,,,,lasting for more than 14 consecutive,at least 6 months before randomization/enrollment.|evaluable,greater than or equal to (>=) 200,,,,,,
4374,,potential risk factors,murine,,angle closure glaucoma,graft versus host disease.|the,,,,calgary syncope symptom score,before starting the treatment,<,,,,,,
4375,,criteria of the definition of sarcopenia,hormonal contraceptive,,adult nutrition literacy assessment tool scale,tcm treatment,,,,advance,180 days after the last dose of study treatment.|the participant,> 450 pg /ml,,,,,,
4376,,thoracic surgery.|patients,residual immune-related aes,,psa,small molecule targeted drug therapy,,,,sars-cov-2 infections,within the last 6 months prior to baseline.|willing,≥ 45 kg,,,,,,
4377,,seguí,bile,,hepatitis b surface antigen [hbsag],insufficient treatment|patients,,,,er+/her2-,within 30 days prior to the first dose of study medication,> 5 x uln;|platelet,,,,,,
4378,,lung function impairment,special,,t size,kidney disease.|surgery,,,,moderate to severe gingival,at least one year prior to inclusion of the study to avoid honeymoon diabetes.|a history,≥ 2|patients,,,,,,
4379,,diabetes mellitus|having taken part in a research study,anti-fungals,,word recognition,emergency intubation,,,,balloons,prior 5 years,≤ 5×uln|creatinine ≤ 1.5×uln;coagulation,,,,,,
4380,,osteosclerosis,anti-platelet agents|denial,,thyroid stimulating hormone (tsh) are,midazolam intervention,,,,imperfecta);|has a condition that,within 3 weeks before enrollment|chemotherapy,≤ 25 mg/week,,,,,,
4381,,age|having,volatile anaesthetics,,immune test results;|acute,transthoracic echocardiography,,,,sodium thiosulfate,within 8 weeks prior to the study procedure|is,>=100*10^9/l,,,,,,
4382,,aortic valvular disease,blockers,,asian,psma pet/ct,,,,upper airway tumor,within 60 days after screening visit 0,18 or above and,,,,,,
4383,,parp inhibitors,antimicrobial,,thromboplastin time,primary reverse total shoulder arthroplasty,,,,confirmatory)|not taking,within the last 30 days,between 60 and 85 years||,,,,,,
4384,,hemorrhagic predisposition,anticholinesterase inhibitors,,older|being capable of reading,complete yellowing,,,,suitable to the target therapy,prior to the study|use,between 7.0% and 10.0% (inclusive),,,,,,
4385,,angioedema attacks.|body mass index,others beta-lactams|patients,,diastolic value,lung tumors,,,,autoantibody-associated,at the time of study entry.|failure by the participant to attend three consecutive step 1 study visits.|intercurrent illness,etc.);|liver lesions,,,,,,
4386,,ad involvement|worst pruritus numerical,antiplatelet anti-coagulant,,acpp-sccm criteria,cervical cancer||radiotherapy,,,,attenuation,within 3 days before vaccination.|allergic history to any,≥ 70 × 103/ml|hemoglobin,,,,,,
4387,,marking disorders,valproate,,thyroid hormone supplementation).|if on hormone replacement therapies,gynecological cancer surgery,,,,c-mill harness contact,previous 5 years)|pregnant,< 3 × uln,,,,,,
4388,,sending back,iodide-containing contrast,,platelet below the lower limit of normal|existing severe organ injury|combined,cervical disc surgery,,,,both selective lens,at the time of enrollment.|english,= 7.5-14%|english-,,,,,,
4389,,webcam,vasoactive medications,,semen volume,organ resection,,,,suitable for pulmonary function test,within 6 months prior to administration of study vaccine,≥ 35|unable,,,,,,
4390,,malignant tumor|clinically significant,jaktinib hydrochloride,,blood platelet count below lln,visit|omega-3 index,,,,under sedation,within the past 28 days prior to baseline,< 500/mm^3,,,,,,
4391,,nssi,anti-hypertension medications|obesity,,human immunodeficiency virus|active hepatitis,urinalysis,,,,site conducting the study,at time of randomization.|treatment with imp can,<1250g|infant,,,,,,
4392,,respiratory failure,housing||,,estradiol level,hormonal birth control products,,,,criteria|investigational,within 8 weeks prior to the initiation,≥240 pg/ml,,,,,,
4393,,endocrinologic bone disorders|osteomalacia|distant foci of infections,/chlamydia,,female.|over,diagnostic ct [,,,,activated,within 6 months prior to treatment.|patients,18-39 years.|histologically,,,,,,
4394,,considered normal.||male,orthokeratology,,gestational age.|bmi,open surgical procedures of the cardiocerebral vasculature,,,,adequate understanding or cooperation,within 3 months.|intracranial tumor,0-1.|expected,,,,,,
4395,,low-grade gi bacterial infection,recombinant hirudin,,bruton's tyrosine kinase-targeted agent,mechanical forces;|chronic,,,,emergency surgery|pregnant,in the ulcer.|history,≤ 75,,,,,,
4396,,psychological issues,dynamic,,pulmonary artery systolic pressure (pasp),artificial tears.|application,,,,mers);|history,within one week before single collection,score of >15||history of surgery,,,,,,
4397,,sars-cov-2 infection,gemfibrozil,,recist 1.1 criteria|nsclc,completed chemotherapy,,,,impacting nutrient absorption,during the trial;|those who participated in clinical trials of any other study drug,<10 x 104/μl|aspartate,,,,,,
4398,,autoimmune liver disease,tumors,,alanine aminotransferase (alt) levels,clear etiology;|previous,,,,gmc register||,"during study follow-up,|treatment",>30 kg/m2|currently,,,,,,
4399,,acute mixed phenotypic leukemia,midline|multifocal contrast enhancing,,months;|body mass index,back pain|indication,,,,pregnancy|adequate,within 3 days prior to the first dose of study treatment.|currently,i-ii)||overriding,,,,,,
4400,,temporomandibular joint and/or,ctla4-fc ig,,african,daytime ventilation,,,,received||,at day 1 pre-enrollment||,1.1patients must have,,,,,,
4401,,ipf,tocilizumab,,ccs)|coronary arterial bypass grafting,palliative systemic therapy,,,,immunosuppressive therapy.|acute,last 2 months;|current,"0-2,there",,,,,,
4402,,aya,cilostazol use anytime,,af)|baseline afeqt score,morphological,,,,exclusion.|known,disease|medical history of,repair;|older than 18,,,,,,
4403,,clinical intervention;|severe infection,prescription stimulants,,hfno-,allogeneic organ transplant.|receipt of,,,,neo-)adjuvant,less than 2 years,>4per day,,,,,,
4404,,acute anterior circulation ischemic stroke,alkylating agents,,pregnancy screen,ketogenic diet,,,,st-segment depression,within 4 weeks prior to the inclusion visit,more than 1000 copies/ml,,,,,,
4405,,type 1 diabetic,non steroidal anabolic agents,,less|alanine transaminase (alt): ≤100 iu/l,pittsburgh sleep quality index (psqi),,,,lactation|not,within the 2 months preceding enrollment.|current participation in study therapy,>= 8.0 g/dl,,,,,,
4406,,loss,chronic steroids,,hemoglobin a1c 8%.|evidence,neuroimaging,,,,systemic dose,within 28 days before receiving the study drug;|pregnant,10-15,,,,,,
4407,,acquired diseases,progesterone,,urine toxicology.||,close relative).|major surgery,,,,av,before the last dose of study drug,≥ 75 × 10 9 /l（75,,,,,,
4408,,fibrotic interstitial lung disease|aged,immunosuppressive effects,,intox etc.)|chronic kidney disease,emergent intervention,,,,multiple-gated,in the month prior to inclusion,<=200.||,,,,,,
4409,,hematologic response,zotarolimus,,mgb home hospital,imaging exam,,,,large-scale,prior to endoscopy,= serum glutamic pyruvic transaminase; uln = upper limit of normal.||,,,,,,
4410,,scleromalacia,topical hormonal based product,,severity grading tables,local standard-of-care investigations,,,,ever,more than 30 years old,less than 35 ng/ml,,,,,,
4411,,huntington's disease,antidepressant agents,,calculation|total bilirubin,gastric tube insertion after upper digestive tract surgery,,,,african-american|parents,at the time of discharge.||nb,>40 years,,,,,,
4412,,sleep apnoea,acid reducing agents,,drg,reclining,,,,substance use,in the last 6 months|hypersensitivity,30 years,,,,,,
4413,,acute ischemic stroke 2018|patients,oxycodone,,intensive care unit,study|bariatric surgery planned,,,,appropriately,within 3 months prior t1|use of probiotics,0-1;|her2 positive,,,,,,
4414,,acinetobacter baumannii,study vaccine product component.||household contact,,transferrin saturation tsat<20%,global initiative for chronic obstructive lung disease (gold),,,,self-help,related to this eap,≥ 30 g/l;||serum creatinine,,,,,,
4415,,fundoplication,paclitaxel chemotherapy,,ppt,standard adhesives,,,,grade 1-2,during the 6 months,"18 and over,|volunteering to participate",,,,,,
4416,,sjs,unresolved drug,,hbv dna,cardiac sympathicectomy|having,,,,ulcerated,onset of 6 months,=< 0.5 mg/kg,,,,,,
4417,,diabetes care,subjective memory complaints,,over.|life expectancy,psychotropic treatment,,,,self-report.||21,before operation,>50ml/day).|other,,,,,,
4418,,pancreatic ductal adenocarcinoma,cumulative tobacco,,screening.|eastern cooperative oncology group (ecog) performance status,intrinsic resistance,,,,first degree relative less,"after treatment, provided that no",18 to 60 years old,,,,,,
4419,,alveolar lamina,flutamide,,mri.||adequate organ function including:||absolute neutrophil count (,spherical distance refraction,,,,age)|clinically significant,within 42 days post-delivery,≥ 0.44 m/sec to < 1.0 m/sec|il-6,,,,,,
4420,,extensive psoriasis,oriental herbal medicine,,635mg)|baseline fev1,palliative care (pc),,,,access site,within 2 weeks prior to initiation of study treatment,less than 5 drug half-life from the date of first administration;|according,,,,,,
4421,,available liver enzymes results,angiographic,,kidney function test results,hormonal implant,,,,pms2,during follow-up time,less than 12 months.|participants,,,,,,
4422,,genotype of interest,accidents,,asia impairment scale,complete right bundle branch block,,,,≥8 monthly migraine days,for at least 8 weeks after the last dose of the study drug.||or,>9%|uncontrolled,,,,,,
4423,,uncontrolled immune-related endocrinopathies.|abnormal pulmonary function,methylxanthine-rich food,,phq-9m item #9,desaturation,,,,child,while on study treatment|brain,<4.5.|an asthma control test (act) score,,,,,,
4424,,vascular white matter lesion,caffeine,,uln)|alanine aminotransferase (alt),prevention,,,,ib-iv)|solitary lesion,within 14 days before first dose of study treatment:||absolute neutrophil count (,60 to 90 beats per minute,,,,,,
4425,,judicial order|persons,concomitant medication,,bristol score,standard assessments,,,,full-mouth bleeding score,prior to experimental sessions,above 500 cells/,,,,,,
4426,,igm)|congenital uterine abnormalities,immunosuppressive,,molecular test,walk unaided|can read,,,,suitable for curative surgery,at least one month before visit 1).|planned longer absence/vacation,6 months.|cystic lesion,,,,,,
4427,,gynecologic malignancy,pfizer,,unmarried|age,abdominal surgery||,,,,sebaceous,within the previous 30 days|insulin use,≥ 18 years;|underwent,,,,,,
4428,,cavernomas,strong alcoholic drinks,,a:||body mass index,fridericia formula,,,,amenable to surgical resection,within past 2,> 12 weeks.|the patient's,,,,,,
4429,,itp)|diagnosis,chronic corticosteroid treatment,,promis measure)||,hematopoietic cell transplantation,,,,urine||,outpatient visit,100.4 degrees fahrenheit [°f,,,,,,
4430,,acute infections.|known,topical anti-infective[s],,nihss,antithrombotic treatment,,,,lips,on the patient would be acceptable,≥1.0×10^9/l,,,,,,
4431,,mexico,infections|live vaccines,,cd4+ cell counts,preoperative treatment,,,,mpan||,within 48 hr prior to dosing,30-75,,,,,,
4432,,mandibular alveolus,mih;|children,,partial prothrombin time (ptt),months：during,,,,lissencephaly,in the last 3 months;|metabolic,<4 mm or >8 mm,,,,,,
4433,,spinal pathology,long-acting analog,,isolated bilirubin,hiv,,,,upper extremity area,within the prior 12 months|women,"score of 0,1；|life expectancy",,,,,,
4434,,pleural ascites changes,supportive growth factor,,hbv dna test should,local standard-of-care investigations|increased risk of bleeding,,,,ct,within 7 days of study dosing.|clinically relevant abnormalities,< 75 bpm,,,,,,
4435,,tumor lesions,anger,,aminotransferase (alt),bone biopsy,,,,organ transplantation);|no,within 6 months prior to first dose.|history of infection,18 to 60 years,,,,,,
4436,,"diabetic neuropathy,|did",components of the soap used for bathing,,kidney disease|bmi,maintenance ics treatment,,,,regional severe,in the past 3 months|active,> 60/min,,,,,,
4437,,mdro,muc,,minimal - mild pleural fluid deemed unsuitable,lymphodepleting chemotherapy,,,,unprotected,recent (,equal to or above 10.0 years,,,,,,
4438,,celiac disease|following,anti-integrin agents,,hb ≤120,creole speaking|not,,,,radiological,within 3 months before vaccination;|acute diseases,≥ 90 ml/min/1.73m2)||,,,,,,
4439,,hiatal hernia,none,,uln);||alanine aminotransferase (alt),tissue left for biological studies,,,,influence risk of next drug).|participants,at the time of registration|step 1,greater than upper limit of normal,,,,,,
4440,,cooperation.|participant,human,,thinnest location|corneal opacity,urine drug test,,,,non-compatible,throughout period of taking study treatment,> 25iu / l,,,,,,
4441,,scleral coil eye movement testing,icg,,hcv viral load|patients,epigenetic alterations,,,,unrelated to lung cancer.|received local radiation therapy,within 7 days before study enrollment|total,45.0 kg,,,,,,
4442,,delayed gastric emptying.|gain,pla2r auto-antibody,,asa physical status classification,minimal invasive surgery,,,,mildly abnormal,within 6 months of screening.|participant,> 36 months,,,,,,
4443,,liver failure|beck depression inventory chinese version 2.0 score,rovigo,,cervical radiculopathy|history of neck,basilar artery [ba],,,,incapacity to read the information and not object to the research.|patients,within 1 year prior to the screening period,≥130 mmhg and <170 mmhg,,,,,,
4444,,type 3a,baclofen,,modified recist (can be,ivf cycle,,,,pure uterine sarcomas,6 months to less,old.|more than 10,,,,,,
4445,,|lactation,steroidal anti inflammatory drugs,,partial dentation.||no mobile teeth,hip joint surgery,,,,lumbar spine of,since less than 24 hours|moderate,upper extremities.|arthritis,,,,,,
4446,,using pd-1,bivalirudin,,unilateral plus axial involvement,pharmacologic treatment,,,,any age|having,within 3 months of study visit 3|history,20 to 45 years,,,,,,
4447,,invasive bladder cancer,ammonium acryloyldimethyltaurate/vp copolymer,,averaged qtcf values,metabolic panel,,,,handled,prior to start,≥18 years|subjects,,,,,,
4448,,thyroid lesion|fit for,toriplimab,,urine protein +,clinical event||and,,,,oxygenation|active,within 4 weeks prior to the baseline visit.||exclusion criteria,> iii,,,,,,
4449,,kidney stones.|unwilling,3rd party biopotential electrode.|having,,american society of anesthesiology (asa) physical status,gastrointestinal resection,,,,non-english speakers.||uga,within 4 weeks before randomisation|history,18 to 90years|af,,,,,,
4450,,neurological problem,topical calcineurin inhibitors,,transfusion)|absolute neutrophil count (anc),laser photocoagulation of the retina|previous severe eye injury|acute eye,,,,botulinum toxin (botox),within a week of their initial screening visit,> 3 times the upper limit of normal|creatinine,,,,,,
4451,,lactation.|potentially unreliable,remazolam,,urinary protein>3.5g/d,alternative cause for malocclusion,,,,mycobacterial,within one month|visiting,60-85 years.|capable,,,,,,
4452,,apical,compounds of similar chemical or biologic composition to resiquimod,,age18 years|screen,optimal access,,,,reactive,for at least 8 weeks prior to screening.||,=< 1.5 x the institutional upper limit of normal (uln),,,,,,
4453,,stroke|underlying severe,sovateltide,,vanderbilt university medical center,stroke.|purulent - septic pathology.|drug,,,,non-surgical sterilization,before onset.||,>20 years,,,,,,
4454,,life-limiting,hormonal contraception|metformin treatment|pregnant,,forced expiratory volume in 1 second / post-bronchodilator,vertebral artery,,,,after birth||for,for at least 4 weeks prior to first dose of ipilimumab,2-5y attending,,,,,,
4455,,human epidermal growth factor receptor,lpm,,bedside schwartz equation should be used).|12-lead resting ecg,antitumor herbal therapy,,,,tibial nails,within 14 days prior to dosing.|with,< 24 points;|cognitive dysfunction,,,,,,
4456,,impaired decision-making capabilities,topical proparacaine hydrochloride|known pre-existing scarring,,minimal consciousness state (emcs)|presence of muscle activity,wechsler adult intelligence scale - second edition,,,,diagnostic criteria above;|aged 40～75 years;|sign the informed,at the time of consent|willing,>= 90x10^9/l,,,,,,
4457,,amelogenesis,antiparkinson agents,,operation;||body mass index,radiation-induced trismus,,,,year,within the past 3,"< 60,000 /mm3)|active cancer",,,,,,
4458,,abdominal pleural effusion,marfan syndrome.|strabismus,,novel coronavirus antigen|novel,residents working,,,,at rest,in the 3 months prior to the first admission to the clinical unit.|any medication,18 to 80,,,,,,
4459,,behavioral concerns|uncontrolled seizure disorder|pregnant,mitoxantrone,,forearms.|any skin infection,complete esophageal obstruction,,,,full six-month research period,in the past 30 days|will,< 50 mmhg,,,,,,
4460,,breast surgeries,medication for obesity,,mentioned,m2||,,,,applied restorative,more than 8 cm,>= 12 months of age,,,,,,
4461,,recurrence developed,hormonal drug therapy,,diastolic blood pressure (dbp),pelvic inflammatory disease;|previous,,,,large-diameter screw;|patient able to understand information related to the study,within 14 days before the first dose of nivolumab,ethnic,,,,,,
4462,,dcis,metvix,,per consensus guidelines|provision of informed consent,lymphodepletion chemotherapy,,,,adequate tissue,within 3 months before the index,>30 and <60 ml/min/1.73 m2).|written,,,,,,
4463,,covid-19|not being,esophagogastric junction adenocarcinoma.|mismatch repair deficient (dmmr) adenocarcinoma,,overall disc herniation (extrusion or protrusion,thyroid replacement therapy,,,,visceral disease|de novo,4 hours before,≥0.2 mg/mg,,,,,,
4464,,hepatitis c virus (hcv),drug absorption,,endogenous fix activity levels,referral resulting,,,,unlicensed medicines,since the completion of study ins1009-211,scores of 17-23(>17,,,,,,
4465,,gait|pregnant,local guidelines.||severe active comorbidities,,gestational age||,hernia,,,,lower-extremity amputation,during the study period.|subjects participating in another clinical study,< 15 ml per second.|no previous,,,,,,
4466,,coincidental brain lesion,ehlers danlos syndrome,,best remission status,blood sample collected,,,,post-surgical,within 3 months)|patients,more than 90 mmhg,,,,,,
4467,,habitual long-term,monoclonal antibodies,,week|absolute neutrophil count (,variceal bleed,,,,low grade serous carcinoma|recurrent,within the past 3 years.|bleeding,≥30 bpm,,,,,,
4468,,unresectable tumor causes,spouse,,urine delta-9 tetrahydrocannabinol,continuous treatment,,,,protocol systemic chemotherapy,during the open challenge period,< 35 kg/m2.||,,,,,,
4469,,signs of radiolucency,environmental toxins,,indocyanine green angiography (icga) result|patients,unilateral total knee arthroplayts (,,,,excipients.|contra-indicated,within 3 years prior to treatment start except,25-cm,,,,,,
4470,,digital device||,teropavimab,,iotf cut-offs|otherwise healthy,physical therapy,,,,swan-ganz catheter,before enrollment to reduce,60 years and,,,,,,
4471,,t2-4 any n,kellgren,,unsuitable anatomy|patient,clear cell,,,,preclude satisfactory completion of the study protocol,within 12 months of first-line chemoimmunotherapy;|refractory,iiib-iv,,,,,,
4472,,psychosis|neck pain associated,cisplatin-containing,,figo,ebv consensus peptide,,,,can cause,within 2 weeks prior to day 1 of the study,younger than 40,,,,,,
4473,,skin care products,shoulders,,egfr measure,tibial nerve stimulation (tns) treatment,,,,highly effective contraception,within 30 days prior,≤40ml/min,,,,,,
4474,,cerebral disorders|uncorrected,human growth hormone,,hemodialysis|left ventricular ejection fraction,axillary lymph node biopsy should,,,,shown,within 4 weeks prior to the first dose of the investigational drug,± 5 years,,,,,,
4475,,ventriculitis,combination art regimen,,map,brain stimulation,,,,drug addiction,within 14 days of enrollment.|4,>126 mg/d|weight,,,,,,
4476,,motor tics,aura,,gd1.|determination of,bypass,,,,mineral,in the first 5 years,< 30%.|age,,,,,,
4477,,respiratory disease,systemic anti-tumor drugs,,morgan stanley children's hospital,biological treatments,,,,primary lipid disorder|unable to maintain diet intervention,within 2 months prior to the first dose of the investigational product,≥17 to <40,,,,,,
4478,,conditions precluded study inclusion,lysergic acid diethylamide,,prothrombin time>16s,performed.|preoperative endoscopic examination,,,,herbal,at birth <35 weeks,resident,,,,,,
4479,,axillary surgery|had neoadjuvant chemotherapy|had clinical hints of,prescription drugs.|is,,albumin level,revision arthroplasty|arthroplasty,,,,low-grade serous,while on suppressive therapy,≥ 50.0 ×109/l,,,,,,
4480,,active internal bleeding,terminal ileum,,hemoglobin a1c (hba1c) level,multiparametric mri,,,,diagnostic arm,at least 6 months' duration|age,"i, ii, iii",,,,,,
4481,,recreational drug/alcohol use that,topical tcm,,t-dxd,multifocal soft contact lens,,,,gvhd|relapsed,during the screening phase.||participants,≥3 months;|adequate liver,,,,,,
4482,,covert,spinraza,,antibodies to hepatitis c virus,found.||general inclusion criteria:||give written informed consent,,,,gastrointestinal symptom rating scale,after at least one treatment,> 15 mmhg|if valid dbp reference measurements,,,,,,
4483,,tempomandibular problems,anti-platelet,,peroxidase,rbc transfusion-free,,,,pet.|multiorgan transplantation.|life expectancy,in dose,60 to 90 kg;|histologically,,,,,,
4484,,lumbosacral radiculopathy,clavulanic acid,,serum folate,progesterone contraception,,,,related,in the next 12 months.|history of,<10 mg/dl|serum bun,,,,,,
4485,,autoimmune neuropathy,gpx4,,cor tricuspid ecm valve would,rsv mat-004,,,,substantially,within 24 hours prior to randomization:||documented fever,0 or,,,,,,
4486,,venipuncture requirements.|known allergies,caffein,,146)|left ventricular ejection fraction,primary head and neck,,,,ais,within 7 days prior to laboratory examination,18 and 70 years);|the patient,,,,,,
4487,,neurologic disease.||ii,violin,,arterial partial pressure of oxygen,tear film break-up time lower than 7,,,,greater than nci ctcae grade,within 3 days before vaccination,older than 75 years,,,,,,
4488,,metastatic site,experimental immunoglobulins,,recist standards,chest x-ray|clinically,,,,under stable glycemic control,within 4 weeks prior to treatment start,i - iii,,,,,,
4489,,mild fibrosis,vagal,,c virus,myd88wt||,,,,under microscopy,at time,before failure,,,,,,
4490,,localized carcinoma in situ of the cervix,influenza vaccine)|previous vaccination severe,,lansky performance score,genital herpes episode|pregnant,,,,last,at least one of the following conditions:||photoaging,>15 on the depression,,,,,,
4491,,her2-negative status,constipation;|antibiotics,,nih cc,vascular pathology|extrapyramidal,,,,vonoprazan;|acute,within 2 months before drug administration,individuals|above 18 years,,,,,,
4492,,cataract,systemic adrenergic,,blood donors,pure variant,,,,-|having no incision,for at least the time needed,< 2.5 × the upper limit of normal,,,,,,
4493,,infection of,contraceptive methods.|metastatic malignant tumors,,permanent makeup,insertable cardiac monitor.|contraindication,,,,speak,since starting medication,≥ 18 years.|histological diagnosis,,,,,,
4494,,rabies researchers,anti-obesity medications,,american society of anesthesiologists (asa) physical status class,judgement);|effective contraception,,,,type i,during the last 21 days before screening.|ongoing treatment,65 or older|english,,,,,,
4495,,chronic hf,-1.|absolute neutrophil counts,,anti-hiv,shortness of breath (sob),,,,surgery|recent,period of time (more than 2 months,greater than 10% vaf|the presence,,,,,,
4496,,localised prostate cancer,age|clinical,,geenius hiv-1/hiv-2,hairs,,,,unconjugated,within 7 days prior to check,≥0.5×109/l,,,,,,
4497,,multiple-organ transplants,sglt2 inhibitors.||note,,hme filter,tewl assessments,,,,interfere with cooperation with the requirements of the study.|currently participating,absent,"≥100,000/mm3).|patients",,,,,,
4498,,pain|refusal,gabaergic neurotransmission,,serum test,pmr,,,,non-target hand,at the dose of 12 mg daily,1-6 months,,,,,,
4499,,humoral immunodeficiency,mood stabilizer,,procedures.||age,peritoneal dialysis fluid,,,,influence the 3d modelling,during the study period|provided voluntary,i-iii|overall health status,,,,,,
4500,,sugar-free,23vppv,,hystage,oral absorption of medications|use of a strong cytochrome p450,,,,single,within 28 days prior to enrollment,= 10 g of alcohol,,,,,,
4501,,temporomandibular joint [tmj],acetylcholine hcl,,690ady monofocal iols,months;|surgical procedures,,,,amblyopic eye,within 2 weeks prior to enrollment.||13,75.0 × 109/l,,,,,,
4502,,cns lymphoma,anti-inflammatory medication use,,high levels,coronary,,,,could cause unacceptable safety risks or compromise compliance with the protocol.|patients,for at least 3 years since completion of last treatment with exception of,"≥ 100,000/mcl|total",,,,,,
4503,,leptomeningeal hemosiderosis,systemic histamine-receptor antagonists,,bakirköy dr. sadi konuk,cpap therapy,,,,molecular diagnostics required,within 48 hours before the first drug administration,> 100,,,,,,
4504,,clinical varieties,ris,,detectable rna,lipid-lowering medications,,,,impella,in the past 3,≥ 50.0 kg,,,,,,
4505,,hyperglycemic-hyperosmolar state,medication as treatment for depression,,echo,world health organization classification of myeloid neoplasms,,,,seizures.|multiple factors,at least 38.00c,> 18 years|willingness to provide,,,,,,
4506,,abortifacient effects,bmt,,modified ashworth scale|history,innocor,,,,might interfere with ability to,within the head and neck,0.6 mg/dl||age,,,,,,
4507,,non-diabetic renal disease,cyp 2c8 inducers,,hepatitis b antigen (,adjuvant therapy (allow,,,,adequately titrate,in the 12 weeks prior to screening,60 or older,,,,,,
4508,,urinary incontinence,angiotensin ii receptor blockers,,response evaluation criteria in solid tumors (recist v1.1).||9,blood biochemical examination,,,,non-binary,at least 6 years old,between 18 to 50 years,,,,,,
4509,,|pregnant,anti-tumor drug,,waist,congenital cardiac abnormalities,,,,syndromic,within 1 week prior to day 1 of protocol therapy|patients,> 2.5 x uln|recent,,,,,,
4510,,acute coronary syndrome|patient,infertility medications,,glomerular filtration rate),endovascular therapy,,,,schwachman-diamond syndrome,before and after initiation,≥50× 109/l(without,,,,,,
4511,,peripheral arterial catheterization,vesicant medications,,calculated creatinine,intraarticular knee injections,,,,originally took,within 2 weeks prior to first study treatment administration,large b-cell lymphoma,,,,,,
4512,,complain of,treprostinil,,serum glutamic-oxaloacetic transaminase)/alanine aminotransferase (alt),adequate fluid therapy,,,,stable symptomatology.||,personal history of,> 450 millisecond,,,,,,
4513,,malignant disease|bone,enzyme-inducing anti-epileptic medications,,antibodies or fusion proteins,emergent procedures,,,,inter-current,within 2 weeks of protocol treatment|pregnant,> 180 degrees of the circumference of the vessel wall|interface between the tumor,,,,,,
4514,,drainage tube installation,regional lymph node,,adderall,tissue augmentation with silicone,,,,"interferes with physical activity,|pregnancy",within 48 hours before the first administration of the study drug.|those,< 1.5x upper limit of normal,,,,,,
4515,,capsular microbial infection,dilthiazem,,phq,general anesthesia||,,,,preclude adequate absorption of dzd9008.||prior/concomitant,within the last 4 hours,70% to 99% stenosis,,,,,,
4516,,cryptococcosis,texas,,abilify,immunosuppressive doses,,,,= 10)||exclusion criteria:||•,in the last two weeks,50-85 years,,,,,,
4517,,drug-induction therapy,paints,,vitiligo|grade,centrally read mri,,,,influence hemodynamic changes,in the last 5 years before the screening,"≥ 1,500/mcl|platelets ≥ 100,000/mcl|hemoglobina",,,,,,
4518,,ige-dependent,mechanical ventilation.|participating,,pertinent medical criteria,lipid-lowering therapy,,,,site of needle entry||-,during the trail.|covid-19 pcr test should,= no pain,,,,,,
4519,,criteria of tinea versicolor,ccrf,,response evaluation criteria in solid tumors (recist) version 1.1||females of child-bearing potential,home oxygen therapy|history of narcolepsy|use of,,,,suitable for radical radiotherapy,within 6 months)|history,"18-65,|for the study group",,,,,,
4520,,syncing,parenteral nutrition).|active injection drug use,,quantiferon tb-gold test,distal landing,,,,probable,within 6 months prior to first dose;|palliative radiotherapy completed,20-70 yrs,,,,,,
4521,,luminal metastases,oral supplements,,criteria required:||the cancer specialist considers* surgery,immunosuppressants|chemotherapy,,,,mild ad dementia,within 2 weeks prior to treatment initiation|platelets,16 to 19,,,,,,
4522,,non-healing,naturopathic medicines,,serum albumin,graft versus-host,,,,specifically target t cell co-stimulatory,etc.)|a history of,>350 lb,,,,,,
4523,,liver cirrhosis child,over-the-counter (otc) medications,,old|patients with,products；|hospitalization,,,,grade iii,within 24 hours after the patient was last seen well/symptom onset|informed consent of patient or appropriate surrogate,≥ 10.|subject's responses to the first two questions of the,,,,,,
4524,,distant metastatic disease||high,immunosuppressive medicaments,,prostate specific antigen (psa),anamnesis,,,,irregular thickening,since november 2021|any other,ranges from 18-99|patients,,,,,,
4525,,iron overload conditions,mipomersen,,recist v1.1.|hematopoietic function,receive exercise therapy,,,,long-term inotrope therapy,in the dose of psychotropic medication,40 to 85,,,,,,
4526,,degenerative corneal,pediatrics,,standardized uptake value,pregnancy test,,,,alternative,during pre-study screening,≥ 13,,,,,,
4527,,neuroborreliosis,affirmative answers,,mmse score≤ 17 points,oversee administration of study drug,,,,platinum-based,after hormone replacement therapy);||17,< 30 points|informed consent is signed,,,,,,
4528,,gastrointestinal diseases;|allergic constitution,leuprolide acetate|patients,,1.||adequate bone marrow,medulla oblongata,,,,ischemic,within 1 year|acute liver disease,more than 23 kg/m2,,,,,,
4529,,systemic toxicity,implants used in this,,care|body mass index,small cell component).|ecog performance status,,,,obesity||,throughout entire study period.|sufficient fluency in english to understand and complete study instructions,10-25 strands/0.02 ng/mg,,,,,,
4530,,congenital qt prolongation,nm8074,,arterial blood pressure,cumulative dose of more than 15 mg/kg;|evidence of infection,,,,worse than 35 letters,before screening or,from 35.5 to 36.9 °c,,,,,,
4531,,chronic periodontitis,progestin implant,,local,intrathecal cytarabine,,,,sars-cov-ⅱ,in the first 6 months,< 9 g/dl,,,,,,
4532,,sulfonylureas,itb,,entry|mean corrected qt interval,lung images,,,,mnv|subfoveal,for at least 90 days after the last dose of tst003,above 40 years,,,,,,
4533,,isr,adequate organ function||,,dsm-v,bitherapy,,,,spermicide,within two months prior to the study,≥45 years;|undergoing elective,,,,,,
4534,,luto|placement of amnioports,immune tolerance induction (iti) therapy|have a known,,anesthetics +,pelvic radiotherapy.||laboratory values,,,,dsm-v diagnostic criteria,in the next 3 hours,< 1.5×upper limit of normal,,,,,,
4535,,morbus scheuermann,terc,,bia,radiology imaging network cancer center group (,,,,lower extremity,at the time of intake|need to,≤ 1.5 x uln.||c.,,,,,,
4536,,bronchopleural fistula|hemodynamic instability,components of the study drug.|committed,,normal|total bilirubin,cosmetic procedure,,,,first-line immune checkpoint inhibitor-containing therapy,in the 4 weeks prior to initial dosing.|patients,lower than 1 and,,,,,,
4537,,intervertebral disc height,antiplatelet agents,,regular exposure assignments,stratified,,,,protein,in the 4 weeks before screening|initiation,+ patient's measured calcium,,,,,,
4538,,emotional instability,antibody drug therapy,,bulimic investigatory test,central,,,,limbs,within 28 days of start of study drug,12-36,,,,,,
4539,,congestive heart failure|unstable angina pectoris|unstable,cyp3a,,serum pregnancy test|if the urine test,small-cell lung cancer,,,,suitable for radiotherapy.|have,throughout the duration of the study|the investigator concludes,between 18-70 years,,,,,,
4540,,poems,stavudine,,stated)|hemoglobin,steroid hormone use.|other,,,,early-childhood,within the screening,<30%|white blood cell count,,,,,,
4541,,periorbital skin disease,oral progestin-only contraceptive,,dermatologist,autologous bone marrow transplantation,,,,interdental gingival recession).||in,for at least 12 months before signing the informed consent,c or d,,,,,,
4542,,retroperitoneal structures,atherothromboembolic,,smcq,complete remmision,,,,prenatal depression,at the tooth extraction site,≥18 years and ≤75 years.|a clinical diagnosis,,,,,,
4543,,ant-cancer treatment,accutane®,,likd,adjustable gastric band surgery,,,,explant,within 6 months before the first dose,< 35%)|local infection,,,,,,
4544,,acute leukemia.|all patients should have the indication of,germline,,schirmer,booster vaccination,,,,not used,for at least 6 months after tooth extraction,=< 30 days prior to administration,,,,,,
4545,,bowel,vaccinate live,,lost,cardiac surgeons,,,,stable mg,within 30 days of study randomization,≤ 1.5 times the upper limit of normal.|alanine aminotransferase (alt),,,,,,
4546,,aortic stenosis|severe concentric,fentanyl patch,,t-moca short,chronic oral anticoagulant|comorbidities,,,,swallowing oral medication,within 14 days before the first dose of study interventions,> 5 times of the upper limit of normal value,,,,,,
4547,,normal ca 125 blood level,study drug sintilimab,,margins|ecog performance status,vaccination procedures,,,,self-criticism,within 14 days prior to enrollment||note,"1/2, palb2",,,,,,
4548,,health conditions,oral/inhaled glucocorticoids,,new york heart association (nyha) cardiac function,biological markers of,,,,mediastinal,at least one month before the study.||,score of ≥8|has,,,,,,
4549,,cerebral small vessel diseases,lactose,,mayo clinic-rochester st. mary's emergency department,shoulder instability|previous surgery of the shoulder|rheumatic diseases,,,,comorbidities||,in past 1 year,+/- 1 year)|study level matched,,,,,,
4550,,pfj injuries,acetylic acid,,european society of cardiology criteria,finger examination,,,,basilar artery,previously taking more than two,>100 mmhg);|systemic administration,,,,,,
4551,,unilateral radicular pain,sulphonamide,,dual-light lens,intra-articular injection therapy,,,,medically stable,responses||,below or equal to 20/200 and above or equal to 20/400,,,,,,
4552,,positron emission tomography;|have a performance status,ucd,,maudsley prescribing guidelines,identical hla transplant,,,,under investigation for malignancy|severe visual,at the time of spinal,>1.0 cm,,,,,,
4553,,aghd,criteria22,,criteria of idf (,non-inclusion,,,,spinous,within 4 weeks before the first dose.|participation,> 1.2,,,,,,
4554,,myopia treatments.|employees of the study center,debridement,,international panel criteria,medical therapy|known severe,,,,ibs-c,during the past 6 months|being,below 1.0 g/l,,,,,,
4555,,iia,long-acting biological therapies,,maximum gleason score,mri-scan,,,,supratentorial,after angiographically successful,> 2.0 x the upper limit of,,,,,,
4556,,cpam,chemo,,white blood cell count below lln,acute treatment-related,,,,literacy,during the 12 months preceding the,<=2.8 gram per deciliter,,,,,,
4557,,kidney dysfunction.|allergies to milk,adult||,,hepatitis b surface antigen (,basilar artery (ba),,,,grade 1 or higher,at least 6 months earlier.|no,transaminase does not,,,,,,
4558,,ecg|unstable angina pectoris,endocardial myocardial biopsy,,surgeon|ecog score,24-hour urine collection for determination of creatinine clearance||participants,,,,group 4)||significant illness,within 1 week prior to meta10-19,between 21 to 60,,,,,,
4559,,g2,checkpoint inhibitor therapies,,hepatitis b virus core antibody (hbcab),insufficient comprehension of the spanish language,,,,malign,for > 3 months).|patients,"18-40 women,|at",,,,,,
4560,,alternative inhalers,milvexian,,base excess,ivf-et/icsi,,,,nancy university hospital.|patients,within 30 days prior to the first dose of niraparib while participating in this,less than 28 days prior to the first dose of study treatment.|prior treatment,,,,,,
4561,,duplication of gsv,nicoderm,,pain rating scale,surveys,,,,metastasized to organs,within the 24-hours,at least 50 cm,,,,,,
4562,,acute diverticulitis,drugs (prescription,,serum testosterone levels,mitral valve repair (,,,,swelling,within 10 days before the first treatment,> 1.0mm,,,,,,
4563,,"pain syndromes,|allergy",ticlopidine,,cambodian school of prosthetics,artemisinin therapy,,,,study;|acute,camera|current,> 400 iu,,,,,,
4564,,anti-coagulation treatment,gem,,ca125 carbohydrate antigen,program,,,,medically confirmed,within 24 hours before any study related procedures,at least 90 days after their last dose of study treatment,,,,,,
4565,,acute provoked seizure,frontal,,lvef,histologically,,,,intracardiac,within 4 weeks from enrollment can be included,≤ 50bpm,,,,,,
4566,,homeless,immunotherapy agents,,recist 1.1 criteria|it,dystonia surgery,,,,sacroiliac joints,within last 96 hours,≥ grade 3|echocardiography,,,,,,
4567,,cornea,over-the-counter medicinal products,,atnls grade,restoration.|mandibular prognathism,,,,genetically modified t cell,within 30 days prior to car-t cell infusion.|fdg avid,> 2 times the upper limit of the reference range|the patient,,,,,,
4568,,pathology of the central nervous system,fatty liver,,calculated)|body mass index (,insufficient knowledge of the dutch,,,,humanized,greater than 480 milliseconds,=<5 x institutional uln|glomerular filtration rate (gfr),,,,,,
4569,,inflammatory skin conditions,immunoglobulin,,hcv test,converted procedures,,,,dementia-,at the time of injury|admitted,niv+/-hfnc,,,,,,
4570,,color changes,plavix,,bv,computed tomography (ct)-confirmation of no extrauterine disease|willing to undergo a minimum of 6 continuous cycles of therapy before decision on surgery|no prior treatment,,,,calcific,for 3 months after rt,more than 180°,,,,,,
4571,,perineal anatomical abnormalities,urinary infection.||drugs:||antimuscarinics,,neutrophil absolute count,aspirin monotherapy,,,,type ii,within 7 days prior to the first dose of investigational,<=2 weeks,,,,,,
4572,,secondary antiphospholipid syndrome .|patients,injectable steroids,,serum cr ≤1×uln,adjuvant treatment,,,,intra-abdominal,within the past 4-16 months|etiology,=< 3.0 x uln|corrected,,,,,,
4573,,mucocutaneous manifestations,components of the investigational drug,,international classification of rop (icrop) criteria,replacement|cardiovascular implantable electronic device (cied),,,,under planned,prior to entry into,<1month,,,,,,
4574,,physically unable to communicate|currently joining other,immunoglobulins,,salvage,adjustment,,,,etc;|estimated survival,within 3 years before screening;|a history,above the 5th percentile,,,,,,
4575,,hypersensitivity.|participant,anti-egfr therapy note,,serum creatinine elevation,lung implant/prosthesis,,,,stage 4+ chronic kidney disease,at the time of study entry.|patients,≥3.0g/dl,,,,,,
4576,,vascular disorders downstream,medium chain triglycerides [mct],,hiv).|estimated glomerular filtration rate,abdominal ultrasound results,,,,plan,left half of the body.|participants should be able to walk without support for 10 m.|mmse score,> 140,,,,,,
4577,,hbeag (+),component of the ip formulation.|chronic use,,longer|recent initiation,colectomy,,,,newly-occurring pneumonia,within one month prior to participating in this study,longer than 24h,,,,,,
4578,,tumor response,medications used.|chronic opioid users.|patients,,residual height,hematology tests,,,,stage iv).|patients,at the time of dosing).|diagnosis of,> 1cm;|the,,,,,,
4579,,therapy.|prior invasive malignancy,probiotics supplements,,byetta,leads|inpatient admission,,,,3 years prior to enrollment,within the last 28 days,>10years does not,,,,,,
4580,,diabetic tractional retinal detachement threatening,ambavirumab,,smokers,rapid plasma reagin,,,,uncontrolled increase of aortic diameter,at the time of admission.||patient,> 1 year.|presence,,,,,,
4581,,mpn symptoms,anti-covid-19,,10 g semmes-weinstein monofilament,local laboratory analysis;|treated,,,,primary care physician,after the tumor,18.5-34.99 kg/m2,,,,,,
4582,,ad|psychiatric disorders,il-34-blocking,,shortening fraction,incarcerated,,,,extract,continue taking,above these,,,,,,
4583,,preterm contractions,determine molecular eligibility at least one measurable lesion,,cd4 lymphocytes,half-time,,,,organ allografts.|uncontrolled,within 30 days prior to and after administration of study intervention,> 1.5 × to 3 × uln,,,,,,
4584,,isolated febrile,mmi,,platelet ≥80×10^9/l;|brain natriuretic peptide (bnp),congenital ectopia lentis.|able to cooperate in the examinations.||,,,,long-term radiation exposure,within 4 weeks before first dose of study drug.|tertiary-interstitial effusion,greater than 9 on day 0,,,,,,
4585,,drug allergy,stents,,haemodialysis|creatin level,standard protocols|orthopedic surgical intervention,,,,second remission,for at least 3 days after the last dose of study intervention||male,5 to 9,,,,,,
4586,,significantly impaired cognition.|children,citric acid monohydrate,,hepatitis c antibody|no,vasopressors).|expected amputation,,,,chb,at the time of screening.|epilepsy,> 35,,,,,,
4587,,substance exposure|medical conditions,gemcitabine,,anticovid plasma use;|vaccination,hair clips,,,,chronically,at least 14 days prior to registration,≥20 natural teeth|bmi,,,,,,
4588,,coagulation disorders||disorder,oral administration,,aspartate aminotransferase (ast),supracondylar humerus fracture,,,,non-sustained,within the last 24 hours|pre-existing,< 20 iu/ml,,,,,,
4589,,anorexia,cremophor® el,,caregiver|patient demonstrates,anamnesis|patient,,,,macular region of the study eye,within 48 h prior to admission to the clinic until discharge.|diseases,<40,,,,,,
4590,,lumen stenosis,malignant tumors;|patients,,hepatitis c rna quantitation,eus guided bfms placement|signed informed consent,,,,intra-abdominal infection,at the time of enrollment|able to,>60 mg/dl|serum,,,,,,
4591,,aerobic,casimersen,,kg.|body mass index,fa,,,,high-sensitivity,≥12 months after therapy should have progressed after,<2.5x uln,,,,,,
4592,,contusion,first drug,,attempts,timi blood flow,,,,upper extremity|presence of,within the 12 months following,> 18 years|ischemic stroke|stayed,,,,,,
4593,,familial lipomatosis,sedative medications.|hepatic,,ica,hospital stay (,,,,temozolomide.|male,in the previous 6 months;|congenital,<2500g|no matching,,,,,,
4594,,diaphragmatic hernia|patient,cetuximab,,inclusive)|body mass index (bmi),doppler ultrasound|prior revascularization procedure,,,,steno-occlusive abdominal aortic,ongoing,2.5-4.0mm,,,,,,
4595,,vestibular- symptoms,thrombin inhibitors,,prolactin levels,plasma cell,,,,large cell lung cancer,within 6-12 weeks of surgery,<18 years|pregnancy,,,,,,
4596,,congenital factor vii deficiency)|patients with,tryptophan,,"r42.xx ""dizziness""",autologous stem cell transplant;|organs,,,,failure|uncontrolled,for at least 2,> 3uln,,,,,,
4597,,nevus lipomatosis,etesevimab,,hav,mitral valve repair,,,,mcd|fsgs,for the first dose:||armpit temperature,more than 500,,,,,,
4598,,neoadjuvant immunochemotherapy.|early-stage,conventional antibiotics,,ckd-epi|uacr,and|luteinizing hormone,,,,sleep related,athletes|younger than 12 years,at least 18 years.|subject,,,,,,
4599,,facial functional impairment covering,artesunate,,ffpe tumour material:||slfn11-expression,oral surgery,,,,primary mediastinal lblc,for 28 days after the eos visit.|females of childbearing potential,<1.5cm;|for aneurysms,,,,,,
4600,,mucous membranes,cdc x-match)|contraindicating,,visual analogy scale,clinical laboratory determinations,,,,between two posturography,within 24 hours of study sessions|for,long-term basis,,,,,,
4601,,lateral decubitus positions,migraine|participant,,wings-ip1 smartphone application v1.0 can be installed (required operating systems,asubareolar breast lymphoscintigraphy injection,,,,might jeopardize safety or scientific integrity of either trial|unable to communicate sufficiently with study personnel,during the 30 days prior to study entry.||5,<20×109/l);|hiv,,,,,,
4602,,hemorrhagic shock.|candidate,drugs used specifically to induce weight,,specifically left ventricular ejection fraction,insufficient radiological documentation|patients,,,,age)|diagnosis of als,at least 2 years|resides,"18 and over,|are conscious",,,,,,
4603,,chronic infections of the cns,compounds of similar chemical or biologic composition to lutetium lu 177 dotatate|as per the food and drug administration (fda) package insert,,elisa test,12-lead ecg.|no,,,,grade 1 peripheral,in the last 3 months.||,>upper limit of normal,,,,,,
4604,,metabolic disease.|consume,narcotic analgesics,,maintenance period,combined sexually transmitted diseases,,,,peri-implantitis (,during sexual intercourse for the duration of the study,>26%,,,,,,
4605,,depression/,oral antihyperglycemic medications,,european society of cardiology (esc) criteria.|written informed consent|patients,intubation;|hospitalizations for copd,,,,interdental gingival recession,7 days prior to venetoclax.|concomitant,> uln;|blood amylase,,,,,,
4606,,organ failure|previous renal transplantation,stereotactic radiotherapy,,car-t cell therapy,e-cigarettes.|uncontrolled hypertension,,,,above baseline|diagnosis,within 28 days prior to day 1 of protocol,less than 40%;|treatments,,,,,,
4607,,pulmonary congestion,systemic immunosuppressive medications,,rad51d,emergency laparotomy,,,,oophorectomy||post,within 4 weeks prior to pdt|participants,≥50 copies/ml,,,,,,
4608,,comorbid neurological conditions,local approved anti-sars-cov-2 drugs,,isolated arterial septal defect,magnetic resonance imaging)|distant metastasis|familial adenomatous polyposis|hereditary non-polyposis,,,,high - very,within one year of visiting,≥ 6.2 mmol/l,,,,,,
4609,,clinical presentation,aspirin sickle cell trait or disease,,part 1a - any,total hip replacement after,,,,amenable to regeneration,prior to patients',40-80|grade,,,,,,
4610,,type 1 diabetes:||14 - 80 years,sodium channel blockers,,alt ≤3 x upper limit of normal,egular menstruation,,,,cancer|current,in the last five years|parent,<30 ml/min/1.73 m2|participation,,,,,,
4611,,unable to tolerate toxicity,multiphasic ct,,radiation|body mass index (bmi),usual health after,,,,unsubtyped,within the past 14 days prior to study registration|international normalized ratio (,"> 100,000mm3",,,,,,
4612,,baseline mobility,"stimulant laxatives,|major abdominal surgery,|inflammatory bowel disease,|infectious diarrhoea,|allergic diseases a|psychiatric disorders",,ecco international guidelines,grade-3 lymphocytopenia,,,,histological tissue collection.|patients,within 14 days;|the body temperature,65 to 85,,,,,,
4613,,neurological diseases;|survivors,penicillin,,1|adequate organ function|able to swallow tablets|able to understand and voluntarily sign,abdominal region,,,,probiotic,within the screening period prior start of study drug.|breast-feeding,≤ 5.0 times the upper limit of normal,,,,,,
4614,,kidney diseases,rapamycin drug-eluting,,physical testing|habitual protein consumption,nephrectomy,,,,drug induced,within one month of calciphylaxis diagnosis,>4 years,,,,,,
4615,,cosmetic weight loss,fmt administered endoscopically,,child pugh,chemoimmunotherapy induction,,,,high protein nutrition,up to date,<pr<220ms,,,,,,
4616,,age;|alopecia areata,immunomodulators,,diaphragm|m1 disease|who performance status,thoracic mri planned,,,,intra-vaginal products,during study treatment,=< 5.0 x uln,,,,,,
4617,,peripheral arthritis,steroidal,,hiv antibody positive,security scheme|effective contraception,,,,render,at the beginning of the pregnancy,> 470 msec;|participants,,,,,,
4618,,transplant,anti-pd2,,neurological classification,blood biochemical examination showed,,,,systemic signs of inflammation|b1: fever|b2:,before enrollment and are currently on selumetinib,"between 18,5 and 30 kg/m2",,,,,,
4619,,mild cognitive impairment.|older,intravitreal anti-vegf injections,,hcmp,node,,,,tnf-α antagonists,from the time of screening,<6 months,,,,,,
4620,,liver transplantation.|clinically significant,androgen receptor inhibitor agent,,paraphasias score,chest auscultation|clinically relevant,,,,pd for more than 3,over the past 2 years,>18 years|native,,,,,,
4621,,cp,illegal drugs,,routine blood,surgical sterilization (vasectomy,,,,peau d'orange,within 2 months of initial diagnosis,≥18 years|diagnosis of mm,,,,,,
4622,,painful wound care procedure,prf,,urethra,genital fungal infection;|participated in the drug clinical trial,,,,intra-uterine surgical devices,at a time when the athlete,less than 20 weeks,,,,,,
4623,,abnormal bleeding episodes,steroid,,120 minutes,cervical surgery,,,,preclude adequate comprehension of the informed consent form,within 2 years.|expected lifespan,0 or 1|willing to provide,,,,,,
4624,,cerebral infarction disease.|patients,omim#615483,,fasting plasma glucose,nucleoside reverse transcriptase inhibitors therapy,,,,retroperitoneal,within 30 days prior to (the first,< 30 days,,,,,,
4625,,fetus|maternal hypersensitivity,i.e.g,,intensive care unit stay,deterioration of asthma,,,,prophylactic use,within 12 weeks of the screening visit,≤ 3×uln);|pulmonary function,,,,,,
4626,,gastric varices hemorrhage,colonic resection|patients,,hbsag,lenalidomide therapy,,,,heart,at least 8 week prior (note that this includes persons,18 or over|carriers,,,,,,
4627,,reproductive tract|infertility,great complexity,,inducing qtc changes,surgery of the gastrointestinal tract),,,,extend into/involve the small bowel (e.g. those at the ileocecal valve),within 1 year prior to screening|participants,> 18)|intubation and,,,,,,
4628,,lack cognition,drug ingredient|patients,,investigator;|good organ,conduction blocks,,,,from tissue or plasma(ctdna),within 6 h of dmt,18 years or older|histologic diagnosis,,,,,,
4629,,bronchial hyperreactivity,inotropic agents,,influencing qtc,gm dental implants,,,,attributed to,"medication until 2 weeks before the operations,|impacted teeth in mesial",1-18 months|alsfrs-r score,,,,,,
4630,,redcap,deficient mismatch repair (dmmr),,hbv-dna test,following:||mini-mental state examination (mmse) score,,,,full remission,in the past month prior to surgery.|subjects,less than one,,,,,,
4631,,fundus varices,upadacitinib,,skilled nursing,chemotherapy regimens,,,,expressive,within 30 days of screening.|respiratory medication,10% of baseline,,,,,,
4632,,swallowing,medications that cause immune deficiency,,height,adjuvant mitotane therapy,,,,appointment,for the duration of study participation,53-75 mmol/mol,,,,,,
4633,,vision 20/100,components of the vaccine products,,old|gestational age,psychiatric hospitalization,,,,dexmedotimidine|preoperative qtc prolongation|preoperative,over 4 weeks,> 3 cm,,,,,,
4634,,upper gastrointestinal bleeding,peroral anticoagulation,,and|written informed parental consent,ferrara,,,,in response,within 1 month before screening,grade ≤ 1 from all side effects of prior therapies,,,,,,
4635,,informal,nonprescription drugs,,pulmonary function test,intra-operatively|patients,,,,skeleton|active,in the past 6 months|children,>1.5× the upper limit of normal,,,,,,
4636,,respiratory sign,mycoplasma,,"serum alt, alp",hematopoietic transplantation,,,,ehler's-danlos syndrome,within 4 weeks before screening.|persons,≤ 3 times the,,,,,,
4637,,immobility,angiotensin converting enzyme(ace) inhibitors,,metastasis|eastern cooperative oncology group (ecog) performance status,iterative surgical intervention,,,,carbon monoxide (co) level,at time of blood collection|intake,below 18 or over,,,,,,
4638,,endometriosis lesions,flt3 inhibitor,,inr (international normalized ratio),streaks of blood,,,,high-risk,within the past 2 years|diagnosis,less than 30 days prior to research mri|need,,,,,,
4639,,secondary vestibular diagnoses,monoclonal antibody in combination with chemotherapy,,menstrual cycle,preoperative delirium|insufficient knowledge in german,,,,low appendicular skeletal,within 8 weeks of visit,lesions stages of phase ia,,,,,,
4640,,difficile infection,analgesic drugs,,ehra,thyroid transcription factor 1 (ttf-1),,,,platinum resistant disease,after two lines of therapy,<= 1+(unless urine protein,,,,,,
4641,,systemic antibacterial,study.||baseline,,new york heart association (nyha) functional classification.|malignancies,dbs-stn,,,,post-tuberculosis sequelae,within four weeks,"18 and over,|individuals should",,,,,,
4642,,bleeding diatheses|a,dupilumab,,kidney function test,receipt of transfusion,,,,insulin-treated,before the start of study treatment.|being,<9 or >20|temperature,,,,,,
4643,,addiction,renin-angiotensin system (ras),,children enrolled,open pancreatoduodenectomy|provided,,,,filled-in daily.||after 2 months of,during the last six weeks|corticosteroids consumption,stage ii to iv of the,,,,,,
4644,,caries activity,nafcillin,,hepatitis b surface antigen (hbsag) carriers,potential overlap of the irradiation,,,,stable health status,within 2 weeks of entry onto this study.|radiation therapy,≥80% predicted,,,,,,
4645,,choroiditis,1.78logmar).||,,german speaking||,metabolic equivalents,,,,include:||alk-,within 24 hours|earlier treatment for,≥18 years|willing and able to comply with clinic visits,,,,,,
4646,,treponema,antibody drug conjugates,,3×uln);|alanine transaminase (alt),permit access to wearable device,,,,organ,prior,≥ 70%.|adequate organ,,,,,,
4647,,inflammatory bowel disease|severe sii,relative maximal oxygen consumption (decroix,,response evaluation criteria in solid tumors version 1.1 (recist 1.1),montreal cognitive assessment(moca),,,,chest-strap|must,within 6 months,<5 cig/day,,,,,,
4648,,nutritional conditions,"inducers of cyp3a4/5,cyp2c19",,alpha fetoprotein,melenas|oral iron,,,,miglustat,within the 2 years prior to the screening visit.|any clinically significant,no more than once a week,,,,,,
4649,,cardiovascular impairments,rescue analgesics,,west yorkshire qip||,physical tests,,,,subjects)|clinically relevant,during the 6-month,40 to 55 years,,,,,,
4650,,intracranial hemorrhage,health products ansm)|under legal,,formalized ethical decision to withhold,enoxaparin treatment,,,,ankle level,during the two weeks prior to inclusion,> 18 years|female sex|high,,,,,,
4651,,taiwanese).|healthy,3a inhibitor,,diagnostic statistical manual (dsm),simple appendectomy,,,,immunologically,during or within 12 months of the most,< 35 kg/m2|elective surgery setting|clean wound field,,,,,,
4652,,cases of alopecia,postural,,g12r,electrocardiographic examination,,,,mild to advanced,for at least 6 months prior to randomization visit (day 1,<10 mm,,,,,,
4653,,fluency,t2d.,,between completion of local treatment,ems,,,,middle east,within last 2 weeks.|creatinine clearance,between and inclusive of 18 and 65 years,,,,,,
4654,,age<18 y.o.;|the transcatheter heart valve (thv),thiazide diuretics,,invasive arterial pressure monitor is standard clinical practice. typical surgical procedures,consolidation chemotherapy,,,,between december 2020 and october 2022,in the next 6 months.||exclusion,"≥100,000/",,,,,,
4655,,metabolic diseases.|athletes,african,,survival time,exon 14 skipping mutations,,,,minimally invasive technique,at least 4 weeks|a,18-85 years;the diagnosis,,,,,,
4656,,neuropathy.|use,local regional liver therapy,,hcl,diagnostic surgical procedures,,,,large vessel occlusion;|mevo causes,history (3),less than 15|patients,,,,,,
4657,,medication;|symptomatic brain metastases,thyroid related lid retraction,,mastectomy|asa physical status,brugada,,,,unrelated to,within three months before study registration,below the lower reference limit).|other condition,,,,,,
4658,,guillain-barré syndrome.|known,bacillus tuberculosis).|has,,pro-ctcae,laser trabeculoplasty,,,,duchenne,within 2 weeks of drugs,≥18 years;|established diagnosis,,,,,,
4659,,treatment;|poorly controlled,organ-confined prostate cancer,,serum,hepatic artery malformation,,,,suitable for other,for at least 12-months prior to screening,greater than >95%,,,,,,
4660,,cognitive impairment -,soft drugs,,drugs|body mass index,antiemetic therapy,,,,only local regional therapy,within the last 12 months|positive drugs,18 to 90 years|patients,,,,,,
4661,,spinal cord dysfunction,panadol,,mih,coronary angiography images,,,,growth,within 1 year prior to screening.|has,≥ 600 pg/ml,,,,,,
4662,,haemorrhagic,anti-angina,,phase;|cardiac function,lumbar vertebral body fracture,,,,low dose aldosterone antagonist,in the previous 5 years.|sigmoidoscopy,± 20%,,,,,,
4663,,carcinoma of,neuroactive drugs,,child between,holter electrocardiogram,,,,colon,within 30 days prior to treatment,≥ 18 years.|subject,,,,,,
4664,,actinic keratosis,ptpn11,,navigo left ventricular pacing lead,women|>9,,,,osteomalacia|active,within 60 days prior to initiation of study treatment,> 149 mmhg,,,,,,
4665,,panic disorder,mumps vaccine,,bone marrow function|a,transfusion of red blood cells,,,,national dpp;|not comfortable,within 3 months after the last administration of the investigational product,18 to 40 kilograms per square meter (kg/m^2).|female,,,,,,
4666,,non-intracranial surgery,cftr modulators,,ldl,smokeless tobacco,,,,clinical remission,at the time of consent|patient,> 18 years old.|written informed consent,,,,,,
4667,,adverse syndromes,components of the investigational products,,chair stand,local regulations|women of child-bearing potential,,,,gram-positive,at least six months prior,17 - 40 kg/m2.|be willing and able to give,,,,,,
4668,,renal condition.|patients,desvenlafaxine,,impairment,t-cells,,,,tocilizumab|ongoing,more than twice the upper limit of normal,≥ 1.5 times the upper limit of normal,,,,,,
4669,,hypothalamic obesity,infusion pump,,fma-ue score,abdominal surgeries,,,,dmmr)disease.||known acute,within 1 month of signing informed consent.|considered,≥ 1.5 × 10^9/l,,,,,,
4670,,trait anxiety,mg/8h,,hepatitis b virus (hbv) surface antigen,local laboratory testing per american society of clinical oncology,,,,steroid induced,in the 12 months prior to entering,>3 months.|histopathological,,,,,,
4671,,cancer.||5- tongue pain,local anesthesia|subsequent visit,,west yorkshire icb region.|a primary care practice,small-cell,,,,suitable for dienogest treatment,mg/ day or equivalent dose of similar drugs)|systemic absorption of minimal amounts,5 to <26 years,,,,,,
4672,,lumbar spine,pyrrootinib,,pro questionnaires,coronary artery bypass graft,,,,non-ablative procedures,during the first 12 weeks of the study.|has a,≥ 100 × 109||/l||ast/sgot,,,,,,
4673,,neurologic conditions,gabapentin-pregabalin,,mmt-8,therapy targeting ox40,,,,flow-limiting dissection,within 24 hours prior,0 to 18,,,,,,
4674,,liver disease kidney failure,direct acting oral anticoagulants).|chronic hypertension,,hbsab test,complete questionnaire|lipid profile,,,,adequately-delivered,for at least 4 months after treatment,> 12%,,,,,,
4675,,higher heart block,prescription therapies,,serum sex hormone levels,world global gastroenterology organization|ibs-sss,,,,american academy of,≥ 8 weeks,≥ 110mmhg.|active endocarditis,,,,,,
4676,,hepatopathy,anti-inflammatory drugs|carrier of,,pro-vegf treatment,modification of diet in renal disease [mdrd] study equation,,,,non-mri-compatible,within 4 weeks prior to the start of pyx-201 treatment,<18 or >50.|preterm delivery,,,,,,
4677,,rare histologic hcc,tav,,vaf,blood oxygen saturation after exercise (below 94% or decrease of,,,,ada criteria and|documented,at time of the first dose of study drug,18 to 32 kg/m2||,,,,,,
4678,,bowel obstruction,anti-tumour therapy,,urine pregnancy,monitoring device inserted through the esophagus,,,,infection|uncontrolled,in the past 48 hours prior to screening.|hypersensitivity,>,,,,,,
4679,,heamodialysis,hiv)||f,,nih scale|normal,hospital israelita albert einstein,,,,severity of surgery classification;|scheduled,48 hours before the first administration to the end of the test;|those,>15 g/dl;|serum,,,,,,
4680,,myocardial damage,radionuclide,,motor impairments|history of,common extensor,,,,alk rearrangements,within 2 weeks before first scheduled study drug administration,≥90×10^9/l;|hemoglobin,,,,,,
4681,,nose,component of the b1962 formulation,,b cell count,laparoscopic biopsy,,,,alternative diagnosis,within 6 months prior to enrolment.|wound healing complications,< 2.5 mm|diabetes mellitus type,,,,,,
4682,,pleural mesothelioma,ventricular assist device,,serum test.|physician discretion,"baseline screening test for s. aureus nasal colonization,|parent/adult",,,,under who,at least 4 points,≥2 (+),,,,,,
4683,,death|uncontrolled intercurrent illness,cri,,human immunodeficiency virus (hivab),stool,,,,top 10 personalized,within 3 months prior study|removable major prosthesis,1 to 4,,,,,,
4684,,hyperprolactenemia|diabetes,authorizations,,ncl,allogeneic hematopoietic stem cell transplantation;|people known to be allergic to the drugs used in this study;|people,,,,lumbar dermatome.|red,within 14 days prior to administration.|have received,< 0.01%,,,,,,
4685,,urine loss,components of the study product|oxygen saturation,,beck depression index (bdi-ii,tecar therapy,,,,esophageal catheter,at two or more,> 140 g/week)|those,,,,,,
4686,,kg|septic shock,methylphenidate,,ogtt,bone marrow suppressant,,,,non-hormonal intrauterine device/system,after fluoroscopic controlled injection,≥12 hours,,,,,,
4687,,osteoporosis)|peripheral neuropathy,iron chelation,,nci-ctcae version 5.0 [appendix 3].|unresolved grade,simple clinical colitis activity index (sccai),,,,myositis damage index,at least 72 hours after validation of the,"< 5,5 kg/m2",,,,,,
4688,,gynecological cancer,disorder|2,,granulocyte,vaginal microecological improvement products,,,,≥12 cumulative hours,within the past six months prior to screening|current enrolment,1.1 within 12 months of initiation of the study protocol|age,,,,,,
4689,,coronary angiography.|hemodynamic instability,anti-il12/il23,,body mass index(bmi,radionuclide ventriculography,,,,non-ovarian clear cell,within 4 weeks of baseline.||prior/concurrent,>30 minutes [min] per day,,,,,,
4690,,para-functional habits,alteplase,,bnp:||nt pro bnp,blood pressure);|axillary body temperature,,,,full-length spike protein,at least 30 days prior to enrollment,≥ 6/10,,,,,,
4691,,good adherence,secobarbital,,zubrod ps,occupational therapy|current,,,,suitable for the time being (surgery,after more than 3 days' regular clinical treatments.||or,5 - 40,,,,,,
4692,,surgically resected,polycaprolactone,,hooley,refusing chemotherapy,,,,infection controlled,for the first time it,≥18 years.|patients,,,,,,
4693,,acute renal injury,over-the-counter (otc) product,,boston children's hospital,argon plasma coagulation,,,,"old,|full-term birth",for at least 72 hours) associated,≥ 16.2 pg/ml|kt/v,,,,,,
4694,,large cell lymphoma,vildagliptin,,beta-2-adrenergic agonist|history of,colchicine,,,,müllerian,at the time of signing the icf.|histologically,≤2.5 x uln|serum,,,,,,
4695,,lipodermatosclerosis,manipulation,,hstcl).|eastern cooperative oncology group (ecog) performance status,dyadic treatment literature,,,,supplemental oxygen.|previous treatment,within one weeks before the first dose of study drug.|history,birth;|current,,,,,,
4696,,crohn's disease,antitumor drugs,,serum tryptase levels,ultrasound-detected,,,,increasing stage),within the prostatic urethra|subjects,≥ 1x10^9/l,,,,,,
4697,,vte,tamoxifen alone,,aspartate aminotransferase test [ast],mental disorders)|significant claustrophobia|ménière's disease|medications,,,,sufficient,within 7 days prior to screening.|received,≥72 hours,,,,,,
4698,,patients|pregnant,nickel,,moderate-to-severe,biochemical tests should,,,,diffuse,at the time of enrollment.|7,26-28 weeks,,,,,,
4699,,stomach cancer,vitamin-mineral supplements,,ecg evidence,transfemoral delivery of the duravr™ thv|anatomy,,,,k3 level,during the study period.|receipt of,≥ 50%;|informed consent/assent,,,,,,
4700,,tanning beds,android,,igm)|b,completed the week 36 visit,,,,non-specific antibody detection,within six weeks prior to entering the study,10.0 g/dl,,,,,,
4701,,macular hole detachment,abacavir,,weeks;|rre-90,corticosteroid treatment|hematologic disorders|pregnant subjects|patients classified,,,,ostial,at least 1 item,≤ 1 x uln;|the patient,,,,,,
4702,,abdominal cancer,immunocheckpoint inhibitors,,hepatitis b surface antigen,taxane regimens,,,,recovered childhood asthma/allergies,for 3 months,<5%,,,,,,
4703,,bilateral movement,antiarrhythmics,,pugh score,kidney transplantation,,,,saliva,at any time point.||,60-90 mmhg|heart rate 55-100 beats per minute|respiration rate,,,,,,
4704,,keratinized tissue width on the buccal site (closest to the cheek)|shallow vestibule depth (the space between the soft tissue (lips and cheeks),contraceptive requirements,,e gfr ˂,standard regimen chemotherapy,,,,non-hormonal contraceptive method,within 90 days after the last dose of any study treatment,=< 2 mg/dl,,,,,,
4705,,radical cervical carcinoma in situ,medications used to treat attention deficit disorder,,physical,ureteral stenting,,,,cockroft formula,during the study period|recommended follow-up by means of either continued,< 51 umol/l upon discussion with the coordinating,,,,,,
4706,,poor overall health status,rabeprazole,,transcatheter arterial non-iodized oil chemoembolization,pharyngeal surgery,,,,successfully managed,within 14 days prior to the first administration of the study drug.||note: patients who,a/b,,,,,,
4707,,vision problem,related drugs,,anti hcv antibody,cfrsd-criss score,,,,refractory to standard medications,in the past 3-,mellitus.|fasting,,,,,,
4708,,women;|pathological fractures,dose reduction,,"dipstick results),|bmi",12-lead resting ekg,,,,visually induced,during 3-month study treatment|intent to enroll in another research study testing an experimental intervention,≥18 years|affiliation,,,,,,
4709,,age.|cognitive impairment,adefovir dipivoxil,,nmdas section,anthracycline chemotherapy,,,,requiring the initiation of an anti her2 containing regimen|first line treatment,for at least 1 month prior to starting the study,1.5 x 109 / l,,,,,,
4710,,comorbidity bearing,acne,,pregnancy test)|lactating,tobacco use|reports,,,,symptoms,at time of consent.|the patient was confirmed,15-29 millilitre,,,,,,
4711,,cutaneous primary site of squamous cell carcinoma of the head and neck|has known,cyp3a inducers,,ecog scale|participants,pet/mri scanner limit;|known allergic reaction,,,,diet.|pharmacological induced,more than 14 units alcohol,between 1500 and 2000 g,,,,,,
4712,,surgical condition,serms,,ppg snr,noted,,,,non-magnetic resonance,prior to study drug,class 4 or 5,,,,,,
4713,,excessive alcohol,nodal,,moca score,pathologic root resorption.||signs of radiolucency,,,,anatomical anomalies,within 3 years before informed consent,2 or more,,,,,,
4714,,chicago,vascular access,,gelf,bone marrow function:||absolute neutrophil count (,,,,jugular vein,unknown onset seizure.|known,>37.5c,,,,,,
4715,,judged by the investigator to have no clinical significance are also,stages.|brca1/2 germline,,calculated by cockcroft-gault formula).|fertile,complete mri scanning,,,,post,post biopsy,≥21 and ≤ 65 years,,,,,,
4716,,mandibular teeth free,anti-platelet therapy.|known intolerance,,n1,bypass surgery,,,,non-pharmacological contraceptives,within lifetime.|history of,> 2)|ability to understand,,,,,,
4717,,liver damage symptoms,dengzhanxixin injection，edaravone,,godin leisure-time exercise questionnaire health contribution,cytokine profile,,,,non-routine,at time of consent|participant,18 - 41 years,,,,,,
4718,,perirectal abscess,chemotherapy drugs,,standardized uptake value [suv],"mechanical ventilator,|legal guardians' consent to participate",,,,pd-l1 tps,within 6 months prior to screening,above upper limit of normal (uln),,,,,,
4719,,symptomatic angina pectoris,liebowitz,,nasal stimulation schirmer test,management,,,,temporal,within 16 weeks prior to randomisation,≥ 1.5 x 10^9,,,,,,
4720,,nafld associated,|alkaline phosphatase (alp),,intensive care units||,institutional review board||,,,,irregular astigmatism,registered the time-point,under 18 years|previous,,,,,,
4721,,right heart strain where,rp2,,ipss score,pelvic .|postoperative biochemical recurrence,,,,"in france,|alive",within 14 days prior to enrollment|9,occlusion,,,,,,
4722,,malignant tissue does not,mirena®,,mass index (bmi),filtration surgery,,,,opportunistic,during the time of the trial.|participants with any surgical,less than 35%|recurrent,,,,,,
4723,,acute promyelocytic leukemia.|subjects,"substances,|the use of any medication",,serum total testosterone,acth stimulation test,,,,permanent basis,for their first lumbar spine surgery|radiographic evidence,0-2；|all,,,,,,
4724,,bi-dimensionally measurable,antifungal drugs,,hcv-dna,serologic test for infection,,,,dose,continue their normal exercise routines,≥ 2|the,,,,,,
4725,,cardiogenic shock.|previous coronary artery bypass graft surgery,cyp3a4) inhibitors,,sunitinib malate administration||,scoliosis)|a lifetime,,,,acute stage,within one month prior to surgery|severe anaemia,≥ 11.1 mmol/l,,,,,,
4726,,or|myocardial infarction,anti-oxidant vitamin supplement,,runx1,variable expression of,,,,ancillary,nicu for more than one month,+/- bevacizumab,,,,,,
4727,,cosmesis.|t1-t2 n0 lesions,prednisone equivalent.||conditions,,anti-hepatitis c virus [hcv] antibody [ab],curative surgery/radiation,,,,low malignant potential ovarian,within the last two years|kidney,>300 households,,,,,,
4728,,months|pregnancy,doxorubicine,,glycosylated hemoglobin (hba1c) values of,electroconvulsive therapy (ect),,,,tumors,> 12 months,≤ 2|hepatic function,,,,,,
4729,,hyperthermic convulsions,anti-histamines,,dependent,control asthma symptoms,,,,infant,within 30 days before the first dose of trial treatment,< 3x uln,,,,,,
4730,,criteria|ibs,pcwg3 criteria|ongoing use of luteinizing hormone-releasing hormone (lhrh,,american thoracic society/european respiratory society/japanese respiratory society/asociación latinoamericana de tórax (,elisa,,,,age-related,within 24 hours after enrollment;|subjects,18 to 60 years||,,,,,,
4731,,chronic diseases;|sexual behavior,map,,tattoos,standard drug therapy,,,,alkylating agents,for at least 14 days after discontinuation of oral cab,>0.35ku/l.|for,,,,,,
4732,,various injury,levobupivacaine,,systolic blood,suspend antiplatelet drugs,,,,adequately treated;|gastrointestinal stromal,within 7 days prior to the initial dose of the study medication.||iv,< 36 months.|patient unable,,,,,,
4733,,frey's,molecular pathology.|no,,hepatitis-b surface antigen,intervention surgery,,,,non-opposition||exclusion criteria,at time of clinical or laboratory progression,>4.0 mg/dl|wbc <2.0 x 109/l|hemoglobin <8.0 g/dl|absolute,,,,,,
4734,,conditions resulting in ineligibility for enrollment,immunosuppressive therapy|self-reported,,pain vas score,stress echocardiography,,,,mellitus|clinically significant,prior to screening.|significant,≥18 y.|scheduled,,,,,,
4735,,hereditary fructose intolerance,hormonal,,speech impairment|cognitive impairment,vaccine treatment,,,,gm-csf],> 6 months prior to enrollment|no evidence,≤ 10 %,,,,,,
4736,,traumatic brain,antiviral drugs,,recist v1.1|malignant disease,radiologic investigations,,,,first detectable viral load.||currently,"during the research process,|participant's unwillingness to continue with the",0-36 months|agreement to take,,,,,,
4737,,muscle soreness,galantamine,,criteria of sepsis,visiting the,,,,numerical pain rating scale,at the screening assessment,18-75 years old;|at least,,,,,,
4738,,parasomnias,systemic drugs,,gestational age estimated,small cell lung cancer|no cancer,,,,influence the absorption of drugs,within 48 hours of any scheduled,> 240 ms,,,,,,
4739,,panretinal photocoagulation,humalog,,study;|ecog ps,preoperative mr,,,,non-iatrogenic peripheral neuropathy|patients,between the flmh,18.0 through 28.0 kilograms/meter,,,,,,
4740,,renal deficiencies,peloid,,smoke,extracorporeal circulation|no coronary lesion|no peripheral arterial disease,,,,xelox|severe,at the time of neuroimaging;|the operator feels,5 - 15,,,,,,
4741,,exception of alopecia,mood altering,,serum glutamic-pyruvic transaminase [sgpt],computerized tomography (ct),,,,could lead to pregnancy,within 6 months prior to the first dose of study drug;new,<4.0,,,,,,
4742,,clinical stage of t1c to t4,carvedilol,,international classification of diseases-10.||,women;|oral iron therapy,,,,yale team.|other medical,for at least 12 months.||history,> 5 norms,,,,,,
4743,,pathological condition,jaktinib,,nieves university hospital,polymerase chain reaction (pcr).|detection of,,,,permitted.|any investigational,at least 18 months following prior therapeutic radioiodine administration|participants,< 60 milliliters,,,,,,
4744,,neovascular macular degeneration|pregnant,prolonged,,self-rating scales|right-handedness|hiit,local regulations|written informed,,,,resistant,within the prior 2 weeks|at least two,>50% of the normal predicted value,,,,,,
4745,,recreational drug use,mouth rinses,,aml|eastern cooperative oncology group (ecog) performance status,"upper hamstring tendinitis,|fibromyalgia",,,,robot-assisted,within 2 years of entering the study.|participants,"≥ ""11"" will also",,,,,,
4746,,acute myeloid leukemia|participant,mpa,,stroke,clinical coronary artery diseases|heart failure,,,,non-hematologic toxicity related to most,for the first time.||,=37 weeks).|healthy birthweight,,,,,,
4747,,alcohol].|inability,metal implant,,posterior fossa disease|intramedullary spinal disease,close friend,,,,ph2 hemorrhagic,at greater than prednisone 5 mg daily,15-17 years,,,,,,
4748,,disease of the vestibular organ|previous arthroplasty,anti-pd-1 monoclonal ab or their excipients.||29,,ami);|prior surgical myocardial revascularization,coronary stent implantation,,,,anesthetic plan,within the mri exclusion,above 18|completed curative treatment for hnscc of the oral cavity,,,,,,
4749,,candidate donor tooth|refusal,β-receptor blockers,,urine cotinine test,abdominal pain combined,,,,incompletely treated tb,in the last week (3 or more,≥18 and ≤65 years.|bmi ≥18 and ≤35 kg/,,,,,,
4750,,pdl-1-negative,immune-related adverse event,,ottawa hospital neurovascular unit,prophylactic use):||blood routine examination,,,,systemic therapy.|patient,in the 6 months preceding enrolment,">1,000",,,,,,
4751,,cns symptoms should,emergency contraceptives,,absolute neutrophil count (,acdf surgery,,,,moderate sedation,within 12 months prior to screening.|patients,at least 1×10⁹/l.||,,,,,,
4752,,recovered from any surgical effects,anti-her2 adcs for,,+ ejection fraction,radical gastrectomy,,,,molar region.|at least one neighboring tooth to be present.|absence of visible,at the time of screening|patients,< 100 x 10^9/l.|presence,,,,,,
4753,,attempted suicide,anticoagulant drugs,,old.|ecog score,histologic examination,,,,primary mucosa melanoma,within the previous year|active,above 52,,,,,,
4754,,paroxysmal cold hemoglobinuria,orthodontic,,serum c3 levels,routine colonoscopy,,,,internet||,during monitoring period|patient,28-34 weeks,,,,,,
4755,,intolerance|renal dysfunction,musculoskeletal disease:||① atopic dermatitis,,hours|lack of availability of either sfo,"complaint of fever,|the child",,,,imwg 2016 criteria,after sustained rosc.||,> 1.5 mmol/l calcium,,,,,,
4756,,cuada equina syndrome,renin inhibitor,,postoperative hospital stay,radiotherapy exists,,,,time-critical,in the past could not be enrolled,>= 18.0 to <= 30.0 kg/m2,,,,,,
4757,,physical deficits,oral morphine equivalent|history,,who classification,rondo,,,,unsuitable for treatment,over the past 6 months,≥40 kg.|the,,,,,,
4758,,tension,stanozolol,,condition.|body mass index,radiotherapy area,,,,eligible|clinically significant,in the past 28 days,≥ 35 kg/m2.|those,,,,,,
4759,,periodontal diseases.|systemic diseases,mao- inhibitors,,peripheral arterial,lung/heart disease,,,,type i diabetes mellitus,within 28 days prior to the first dose of investigational product,greater than or equal to 10%,,,,,,
4760,,foreign bodies,radioactive drug trials,,american college of sports medicine standards,walk full weight bearing,,,,list|recurrent unstable angina,for at least three months.||exclusion,> 1.5 kg;|need,,,,,,
4761,,pulmonary infarction,prior corticosteroid therapy,,anti-hcv,asim||anti-histidyl trna synthetase-(anti-jo-1,,,,thrombus;|non-aneurysmal,within the past 60 days prior to randomisation,"200~1,000 mg/g cr",,,,,,
4762,,cogntive impairement,connective tissue diseases (ctd)|incident,,fasting blood,stable treatment dose,,,,regurgitation)|significant,within 2 months prior to the expected initial application date,2 ml/min/1.73m2,,,,,,
4763,,ureteral catheterisation [iv],antiparkinsonian drugs,,hemoglobin (hb,molecular targeted therapy,,,,etc).|histopathological specimen,prior to the end of the study||participant,≥4% from baseline value,,,,,,
4764,,cutaneous kaposi's,component of the device|subjects,,hepatitis c virusribonucleic acid,cti ablation,,,,"site of the needle puncture,|patients",within the first 3 months of screening,≤5 × uln,,,,,,
4765,,communication impairment .|patients,h2 receptor antagonist,,moderate hpap lung disease severity requiring therapy in the opinion of the clinical site investigator and/or,health application,,,,between cycloplegic,within 3 months of the initial injection|hyaluronic acid,alkaline phosphates must,,,,,,
4766,,congestive hepatopathy|myocardial infarction,immunosuppressant drugs,,progesterone receptor [pr],limbal stem cell deficiency,,,,cd3-redirecting therapy,in the past 6,older than or equal to 10 years old,,,,,,
4767,,childhood autism rating scale|at least moderate,calcineupririn inhibitors,,modified version of the london fibromyalgia epidemiology study screening questionnaire (lfessq),recto-sigmoid junction|histological diagnosis,,,,first-episode,in the prior 3 months,"≥ 20,000/l|creatinine ≤ 1.5 x the uln",,,,,,
4768,,urinary tract disorders,inhalation steroids,,≥6 aud/sud criteria,prediabetes risk test score,,,,second-line standard therapy,in the year prior|dysuria on the ipss,<80 ml/min/1.73 m2,,,,,,
4769,,catalase deficiency,inhaled corticosteroids,,serum alpha-fetoprotein (afp),dipstick analysis,,,,diameter of 1 cm to 5 cm,within 6 preceding months,≤ 5×uln,,,,,,
4770,,juxtafoveal lesions,sglt2 inhibitors|severe hepatic impairment,,residual corneal stromal thickness,total pancreatectomy,,,,uteri,within 28 days prior.|planned receipt of any of the following after planned trial vaccine receipt,higher than 5.4,,,,,,
4771,,ptc,dornase alfa,,rare gynecological malignancies|written informed consent|patient,autoimmune β-cell destruction,,,,suitable to use technological tools,24 hours per day).|premorbid,> 50% of,,,,,,
4772,,unresectable locally advanced,immune globulin replacement therapy,,peripheral blood hepatitis b virus (hbv) dna titer detection,pneumonectomy surgery,,,,non-muscle,within 72 hours prior to the first dose of study drug|patients,equal to or shorter than1.5 times of uln;|qualified,,,,,,
4773,,preclude,headache medications,,uspstf,untreatable contrast allergy,,,,middle ear implants,past 6 months,<18 years|local,,,,,,
4774,,complex class,krasg12c inhibitor + egfr inhibitor combo|patients,,serum alanine transaminase (alt),further surgery,,,,investigator.|have severe,prior to cta.|scoliosis.|scheuermann's disease.|neoplasms,0 or 1|patient,,,,,,
4775,,sustained hypertension,idd|has,,novocain)|prior,fap)|hereditary non-polyposis,,,,histamine-induced,within 3 months postpartum,> 20 minutes,,,,,,
4776,,polycythemia/hypovolemia,hydrogel,,"home,|bmi",fluid bolus,,,,necrotic zones.|at least 21 years,more than 6-months,⑦ the subject voluntarily joined this study,,,,,,
4777,,osteoarticular comorbidities,drug treatment.|surgery,,forced oral carbs,b-ultrasound examination,,,,live twin,during the study.|agreement to not use,18 or above)|diagnosed,,,,,,
4778,,acute lymphocytic leukemia,hygiene products,,msec;|resting ecg suggests,robotic cardiac,,,,suitable for endovascular treatment,during the screening visit,6-7 years,,,,,,
4779,,deploy etudes interventions,non steroidal anti-inflammatory drugs,,total ldl,coronary artery bypass grafting (cabg),,,,pituitary,within the 4 months prior to screening|active,suitable,,,,,,
4780,,vasospastic process,short-acting beta-agonist,,american thoracic society,magnetic resonance imaging [mri,,,,breastfeeding.|prisoners|adults,before starting bevacizumab.|history of life-threatening,<1.5×uln,,,,,,
4781,,high-grade osteosarcoma,ethyl chloride,,thickness for archival storage;|6,baseline.|transjugular intrahepatic portosystemic shunt,,,,gravis;|unable to communicate,more than 20,less than 70 fl.|blood glucose level measurement,,,,,,
4782,,solid organ transplant|provider concern,antiplatelet aggregation drugs,,teeth,oral iron,,,,deemed reliable by the investigator.|is,for at least 5 months after the end of the treatment,≤ 300 mmhg,,,,,,
4783,,hemodynamic compromise,intense pulsed light treatment,,diagnostic and statistical manual of mental disorders - fifth edition,bilateral knee surgeries,,,,medical comorbidities,during the 3 months prior to the screening,<300 mg/day,,,,,,
4784,,thoracic outlet syndrome|patient,mepivacaine,,allred score,metered-dose inhaler,,,,irinotecan-based regimens,1 month after the,≤ 113.2 mg/mmol)||female,,,,,,
4785,,chronic alcohol abuse,adderall,,total motor score (tms),imaging center screening,,,,exfoliated,at the time of signing the informed consent,< 15 ml/min/1.73 m2,,,,,,
4786,,lingering symptoms,antiatherogenic drugs,,mantoux,control pleural,,,,intent|significant,during the 6 months prior,< 1.8,,,,,,
4787,,cns involvement,heart stents,,"acr 1990/20101,2 criteria",pathologic,,,,uncorrected,"within the municipality,|aged 6-16 years",> 500 ml,,,,,,
4788,,genetic disease,hormonal drug,,motor function,surgical intervention,,,,investigator;|clinically uncontrollable,within the preceding six months|active,≤1.5 × upper limit of normal,,,,,,
4789,,clinical disease,kidney,,ebixa etc.);|food supplements,target implant site)|myocardial infarction,,,,live-attenuated vaccines,within 14 days prior to the day,at least 50% of the ulcer surface area,,,,,,
4790,,pulp contact,japan,,haemoglobin,small cell carcinoma tumors,,,,speed,within 30 days prior to treatment initiation,50-60,,,,,,
4791,,serous cyst,local anaesthetics|infection,,reference,control group:||healthy control,,,,locally-approved,during the 2 h 75 g ogtt.|pregestational,"> 3,25",,,,,,
4792,,phenytoin.|brain injury,covid-19 after positive pcr,,new york heart association's functional grading system,oropharyngeal swabs|diagnosis,,,,spherical,within 28 days prior to initiation of study enrollment|treatment,"20-60 years,|agreement",,,,,,
4793,,infection;|nasopharyngeal carcinoma,zanubrutinib,,radial arterial,renal mass biopsy,,,,stage liver,prior to receiving study products,>= 50 ng/ml,,,,,,
4794,,kidney function|sign the informed consent form for this clinical study||,beta-blockers treatment.|morbid obesity (,,hrpe,income cut-off (licos),,,,intra-thecal ert,within 14 days prior to entry into the study,>60,,,,,,
4795,,or|hypothermia,mh,,legg-calvé-perthes disease,laser hair removal treatments,,,,not to undergo cervical smear,within 14 days of cycle 1 day 1,<1.0 cm,,,,,,
4796,,autoimmune hemolytic anemia).|bone marrow disorder,conventional imagine,,botulinum toxin,focal demineralization,,,,3-month,after last dose of,> 1.5× upper limit of normal (uln),,,,,,
4797,,skin changes).|prior treatment,immunocompromised,,hiv infection;|age,radioisotope therapy,,,,chu toulouse|for adult,< 72 hours,≤ grade 2,,,,,,
4798,,mixed incontinence,glutathione,,wide range achievement test-4 reading subtest,transcutaneous electric nerve stimulator (tens) device,,,,ebv-negative serology,prior surgery.|history of organ transplant.|known,^9 /l[granulocyte colony-stimulating factor,,,,,,
4799,,treatment responder,topical steroids).|regular use,,national institute of mental health criteria,dh relief,,,,any type|initiated,during the qualification for fb||,"> 25,000 / microliter",,,,,,
4800,,mixed tumors,local,,cycles|ecog ps,heart transplantation|patients,,,,latest covid-19 safety measures/testing applicable,in the inclusion criteria|major surgical procedure,more than 0.5 mg/mg,,,,,,
4801,,paresis,prophylactic medications,,"addiction centre,|patients",thoracic belt placement,,,,emails,during the screening period must,>7.5,,,,,,
4802,,hemodynamic compromise|parents,glp-1),,random analysis,eating,,,,ipsilateral hilar,during the 3 months prior to screening.|participated,over 30,,,,,,
4803,,shoulder diseases|rheumatic diseases|diabetes|psychiatric diseases|vascular diseases|cancer|infectious diseases|skin,gim,,hiv-1 rna measurement,implant reconstruction,,,,upper-lower/left-right side of the body,within four weeks before visit 1 or plans,considering 20%,,,,,,
4804,,neurological illness|healthy,homicide,,1.positive sars-cov-2 antigen,gastrointestinal bypass surgery,,,,highly effective (per clinical trial facilitation group,at screening for hiv 1 or 2 antibody,> 8%,,,,,,
4805,,ischaemic rest pain,congenital heart,,measurement of ≥30mmhg,lift procedure,,,,ehlers danlos syndrome,within 1 month before the screening period,> 48 hours|obtained written informed consent,,,,,,
4806,,communication barriers.||,alpha blocking drugs,,screening|estimated glomerular filtration rate,her2 ihc3+,,,,fibromyalgia criteria,in the past 3 months.|pregnant,< 12 months;|failing,,,,,,
4807,,spastic diplegic cerebral palsy,amikacin.|ecg,,kerr's criteria,liposomal doxorubicin;|ecog ps score,,,,contraindicated|full understanding of the requirements of the study,within 8 weeks after the last administration of the drug,precludes,,,,,,
4808,,cross-addiction,drug therapy|active treatment,,t4 levels should,treatment for cancer|hospitalization for,,,,primary running related injury outside,for at least 2 weeks after discontinuation of study drug.||,under the age,,,,,,
4809,,ventricular dilatation,combined liver-kidney,,cm)|life expectancy,regrowth,,,,aura,within 6 months of last dose of study,greater than 2.5mg/dl.|serum,,,,,,
4810,,months|congestive heart failure,intranasal corticosteroid,,anti-pd-1 antibody,postoperative stone analysis||,,,,under treatment|history of,within one year prior to the screening,>30 minutes,,,,,,
4811,,chronic infectious disease,cannabinoid medications,,modified ashworth scale.|all individuals,small intestinal stoma;|perforated,,,,stage 3a and above (,within 2 weeks before the baseline assessment;|a phq-9 question 9 score higher than 2,50-150 kg,,,,,,
4812,,brain mr-imaging,grapefruit hybrids,,section,vital organ transplantation,,,,medically-accepted contraceptive,at the time of the first wj13404 dosing;|patients,3.30- attachment 1,,,,,,
4813,,cognitive complaints||,aspirin;|patients,,effective regurgitation orifice area,small cell lung cancer,,,,old)|lip,after enrollment through 28 days after trial vaccination,> 70 years|presence,,,,,,
4814,,preterm neonates:||neonate,anti-resorptive,,hemoglobin by pulmonary function test,sterilization procedure took,,,,permanent discontinuation of cetuximab per the current,up to 1 month prior to and,≥18 years;|diagnosis of ami,,,,,,
4815,,ear.|diagnosis,over-the-counter drugs,,agatston score,fev1 percent predicted,,,,diagnostic and statistical manual-5;|acute alcohol intoxication on the days of the laboratory post-intensive visits,within 14 days prior to the first dose.|history,ii ≤ 16,,,,,,
4816,,gi tract disorders,confirm menopause.||patients,,classes,motile sperm count,,,,screening.||main,within 28 days prior to 1st vaccination of this study vaccine.|history,> 20%,,,,,,
4817,,diabetic polyneuropathy,non-steroidal anti-inflammatory drug,,pnh,etc.||antibiotics,,,,in either eye):||use of,within < 3 years prior to enrollment,>3x the upper limit of normal [uln,,,,,,
4818,,frequency,sud,,hepatitis c virus [hcv] antibody positive,verbal expression,,,,upper arm deltoid area,up to 6 weeks before cycle 1 day 1.|performance status,>5%,,,,,,
4819,,dizziness|ineligibility to mri scanning,oral medication;|pregnancy,,neuropsychological score,bilateral thigh,,,,centers for disease control,during the study until 180 days after the last dose of study drug.||male,greater than 60 degree,,,,,,
4820,,drug-induced hepatitis,antirotinib hydrochloride,,bilag,palpation,,,,esophageal-gastric ulcer,for at least 3 months prior to the screening visit;|is willing and able to provide full consent for their participation.||exclusion criteria||is,stage i-iv,,,,,,
4821,,electrical devices|seizure disorders,alfentanil;|panendoscopy,,1;|expected survival,transcutaneous electrical nerve stimulation (tens) electrodes,,,,bradycardia|patients,within the 7 day period prior to baseline,between 18 years <65,,,,,,
4822,,av-block,nephrotic,,gaba/opioid medication,pharmacological medical treatment,,,,transitory,within the past 3 years.|baseline estimated glomerular filtration rate (egfr,grade <=3)|the following medical conditions,,,,,,
4823,,"locomotor system,|neurological pathologies",thyroxine,,˂ 2.|life expectancy,antiretrotroviral therapy (art),,,,requiring treatment,within 4 weeks prior to the first study procedure.|patient,≥ 19 years|weight,,,,,,
4824,,oesophageal carcinoma,local anesthetic bupivacaine,,screening;|functional general assessment table (gaf),immunosuppressive therapy|egfr,,,,between siblings,within 42 days prior to registration.|symptomatic congestive heart failure,>65 years|echocardiographic lv ef,,,,,,
4825,,"head injury,|metal implant",give informed consent|pregnancy,,bpm)*.|systolic blood pressure,complete exercise intervention;|illiteracy (disability to read,,,,deletion)|very,at least 10 cigarettes,< 2.5 x uln|calculated,,,,,,
4826,,serious diseases/conditions,high resolution computed tomography,,vre stool cultures,complete recovery,,,,that affects ability,more than 1.5 hour,between 18 to 50 years|american society of anesthesiology,,,,,,
4827,,cardiac dysrhythmia,anti-vegf injections,,ctcae 5.0 grade evaluation,affect neuropsychological test performances,,,,resistance-type exercise training,within the last 6 weeks,from 4 points,,,,,,
4828,,neurological disease.|3,medication abuse|pregnant,,mismatch ratio,optimal medical therapy);|patients with severe cardiovascular disease,,,,moderately anemic,at a dose of ≤10 mg daily,≤ 450 ms,,,,,,
4829,,etc.|unstable angina pectoris,milnacipran,,"effect""|age",focal hypoechoic areas,,,,-related,at the time of registration/randomization to the eay191-e5 study|patient must,> 24 hours.||,,,,,,
4830,,convincing allergic reaction,study drug treatment period|women,,palpable spleen,radiology contrast,,,,drug-induced,after 1 cycle of the standard regimen,between 12 to 15 years.|children with normal,,,,,,
4831,,large food classes,prescribe medication,,unilever visual scale,re-,,,,"under the third or above the 97th percentile),|children with any incision or scar tissue",at least 1 year prior to enrolment,> 1.5x uln,,,,,,
4832,,back surgical syndrome,oral anticoagulation therapy,,bone remodeling,hematopoietic stem cell transplantation;|age,,,,pain|able to communicate verbally|pregnant,in the icu for a diagnosis,≤ 95%|depression level score by hamilton depression rating scale,,,,,,
4833,,prostate adenocarcinoma,bevacizumab,,serum potassium,chronic medical,,,,aids|anti-tumor treatment,past 2 months,>20 ru/ml).|absence,,,,,,
4834,,premorbid disability condition,components being utilized.|molars,,nitrous oxide,health promotion intervention,,,,irrespective of different,during the study duration.||,=< 60 days prior to pre-registration.||pre-registration,,,,,,
4835,,non-user,murine monoclonal,,dlco per alveolar volume (dlco /va,hiv-1/2 antibody) infection,,,,stage iii-iv) head and neck,within 12 months before baseline:||systemic,18 to 30 years|anterior knee pain|an,,,,,,
4836,,ocular disorders|interstitial pneumonitis,dress,,6-cycles,reliable assessments of the outcome,,,,||indication,at the time of the first dose of inz-701|in the opinion of the investigator,0.5 to 35,,,,,,
4837,,knee joint replacement surgery,anti-cd38 monoclonal antibody,,inclusive.|body weight index,focal laser,,,,successfully resected,within one month before enrollment in this study,18 years or older|subretinal,,,,,,
4838,,extremity problems,proteins of porcine origin.|other exclusion criteria,,general||weight,liver function||key,,,,baumannii,admission on day -1: those,> 18 years;|patients,,,,,,
4839,,primary health care,iodinated contrast injection,,1.||adequate organ function,inhalational lung injury||,,,,not take the basic posture,within 24 months from,< 10 cm,,,,,,
4840,,disease process|imaging,l,,permitted|alanine aminotransferase (alt),breast reduction surgery,,,,other stones.||,before study inclusion.|negative,"< 120 ms,|fridericia corrected interval",,,,,,
4841,,non-prescription drug,corticosteroids|patients,,short diameter,livedoid vasculopathy.|history,,,,self-identified lgbtq+|any alcohol,within 6 months after cr,1.|participant,,,,,,
4842,,ovarian tumours,high schools,,qt c,hormone vaginal ring,,,,extubated,in the past eight weeks|endocrine or oncological disease history,">75,000/mm3).|serum",,,,,,
4843,,sequelae,lvef,,ct aspects,rad21)|c-to-t,,,,post-thrombotic obstructive syndrome,within 30 days).|exclusion criteria,≥ 1.5 ×109/l.|platelet,,,,,,
4844,,documentation.||exclusion,"glogau,|presenting glabellar static wrinkles",,ankylosing,soy,,,,curative systemic,within 1 hour post,superior or equal to 18 years|clinical,,,,,,
4845,,sarcomatoid carcinoma,beta-d glucan,,urine test,aneurysm,,,,texas department of,during the screening period,≥ 30;|history,,,,,,
4846,,calculus deposits,belimumab,,eth-155008.||corticosteroids,pharmacologic doses,,,,isolated class,during the 24-week treatment period,60 to 100 bpm,,,,,,
4847,,epilepsy|contraindications,subluxation,,serum glutamic pyruvic transaminase(sgpt,renal replacement,,,,left main coronary,at the time of signing informed consent and assent|diagnosis of t1d within 100 days of randomization.|positive,less than 10,,,,,,
4848,,distant organs.||radiographic progression,local steroid,,national cancer institute (nci) common terminology criteria,fap expression,,,,specifically targeting t-cell co-stimulation,over last two years,≥ 18 to ≤ 75 years,,,,,,
4849,,brain injury,investigational drug 30 days prior to enrollment,,pruritus,endodontic treatment,,,,periodontal tissue support.|occlusion showing sufficient inter-arch,5 year,100 to 125 mg/dl,,,,,,
4850,,resected cutaneous basal cell,nonprescriptive medications,,fbg,pelvic radiation|patients,,,,mild to moderate crowding malocclusion with,after at least 4 months,more than 2.0 mg/dl,,,,,,
4851,,amd.|absence of any advanced form of,anti-inflammatory equivalent|live or,,serum creatinine ≤1.5xuln,treatment.|clinically significant,,,,could interfere with chemotherapy,within the 6 months prior to the recruitment period,≥ 18 y.o.|hospitalization,,,,,,
4852,,mixed urinary incontinence,certolizumab pegol,,partial thromboplastin time (ptt or aptt),tnk,,,,non-antibody therapy,within 2 weeks of visit 1,0-2))|written,,,,,,
4853,,posterior cystoid retinal degeneration,enteral,,short axis,heart disease||,,,,outcomes.10|non-traumatic cause of pain,at time of evaluation|diagnosis,2.5mm,,,,,,
4854,,co-diagnosis,hyoscine,,serum chemistry,emergency operation|morbidity obese|contraindications,,,,systemic disease|active,before the induction phase,between 19 to 50 years,,,,,,
4855,,spinal cord stimulator,amikacin,,treadmill contraindications)|intact skin,ultrasound probe,,,,upper gastrointestinal tract,since treatment,1 to 3 fibroids|maximal,,,,,,
4856,,bipolar spectrum disorders,xenical,,delays between cycles,tobacco cessation medications|enrollment in another smoking cessation,,,,partial-or,at least 2x,exceeding 25 breaths per minute,,,,,,
4857,,narcotic use,adc drugs,,hepatitis c|bmi,cardiopulmonary bypass (cpb)||,,,,> 30 gy,within 6 months prior to entering the study.|has received prior therapy,≤ 30 × 109/l,,,,,,
4858,,abdominal infection,arcuate,,oestrogen receptor expression,spinal root compression|whiplash injuries|cervical spinal stenosis|having,,,,cmv),more than 6 months prior to day 0,< 100 g/l|white blood cell count,,,,,,
4859,,ncv,kesimpta,,radiation burden,bariatric evaluation|eligible for endoscopic,,,,education|known,during the 30 days prior to the eligibility,>20 mm,,,,,,
4860,,dyslipidaemia,fallopian tubes,,pd sensitivity|weight,photochemotherapy,,,,unclear origin,within 3 days before randomization;|the investigator,≥10 points.||exclusion criteria of the previous,,,,,,
4861,,cushing syndrome|diagnosed,dpp-4 inhibitor,,serum fsh,mini mental state examination score,,,,niv,within 6 months of baseline,12 ± 2 h,,,,,,
4862,,lumbar spondylolisthesis,cdk4/6 inhibitor,,positive pressure ventilation,hip replacements.|lives,,,,venous,in the past 12 months).|has,less than 30 ml/min/1.73 m2;|patients,,,,,,
4863,,covid infections,immunomodulating drugs,,none)|competitive level,further therapy,,,,pd-l1 etc,"prior to invasive dental procedures,|anti-inflammatory",1.5 - 3.5,,,,,,
4864,,non-migraine,etc;|22,,modified lansky,evaluation,,,,syndrome|hypo-/hyper-parathyroidism|estrogen replacement therapy|insulin treatment,within 4 weeks prior to signing the informed consent；||any of the following,less than or equal to 40 ml/min/m2.|contraindication,,,,,,
4865,,type 1 diabetes|age,oral 5-phosphodiesterase inhibitor,,contrast agents;|life expectancy,staging scans,,,,implant-based reconstruction,prior to starting the study treatment.|willing and able to comply with the protocol,threaten thepatient's life or impair,,,,,,
4866,,other)|spondylolysis,neurostimulators,,zinc transporter,smile procedure,,,,largest diameter,at least 6 weeks after the last vaccine injection||childbearing potential,grade ≥1 diarrhea)that,,,,,,
4867,,urticaria factitia,vasodilators,,distant,stroke;|under treatment,,,,suitable for prior surgical treatment.||6.the main organ function,impairment|history,> 5|history,,,,,,
4868,,vamhcs,blood derived medications,,vital signs measurements,incremental exercise test to volitional fatigue,,,,wild type,in the past 2 years((e.g,3-7):||outpatients.|able to provide developmentally appropriate informed assent,,,,,,
4869,,postoperative ventral hernias median,anti-depressive medication,,eb6849fb-17ad-4cba-bc47-4d1be77c1d88,desensitization therapy,,,,adequate dose (,within 24 hours prior to the start of ip administration,> iv;|patients,,,,,,
4870,,sustained cure,full blood,,serum levels,hormone replacement]).|documented causes,,,,ototoxic,after corticosteroid therapy,greater than 3 seconds,,,,,,
4871,,general diseases,tenesmus,,total lissamine green conjunctival,intraoperative surgery,,,,self-report)|severe,period history of,older than 14 years|inability to understand the study procedure,,,,,,
4872,,ris)|primary,vision impairments,,response evaluation criteria in solid tumors [recist],perfusion mr imaging of their,,,,interferes with ability to participate in the study,while taking study treatment||other protocol-defined inclusion/exclusion criteria,< 110 μmol/l 12,,,,,,
4873,,musculoskeletal disease,component of the drug,,screening|lvef,left ventricular assist device,,,,marijuana 24 hours or more,within 1 month prior to first drug administration|biopsy,more than 10 ml/kg,,,,,,
4874,,pregnancy|no functional impairments,combination diuretics,,forced vital capacity (fvc)/predicted fvc,abdominal aorta||,,,,american spinal injury association impairment scale,within 6 months prior to visit 1.|previous receipt of a mab,equal to or greater than mild,,,,,,
4875,,non-squamous nsclc.|tumor sample with intermediate cmet expression by,pirenzepine,,hepatitis c pcr positive,interview|lifetime,,,,germline,within 7 days before taking the study medication,less than 4.5 hours,,,,,,
4876,,spinal cord metastasis,anthracycline-containing polychemotherapy regimens,,fev1/ fvc ratio,initiating therapy,,,,mental illness|not familiar with,within 3 months before randomization||systemic,>185 mmhg,,,,,,
4877,,findings|abnormal fundus examination|ocular disease,cholinergic drugs,,iciq-sf||,herbal supplement,,,,lumbar region.|have been,in the last 90 days of laser treatment,≥ eighteen years,,,,,,
4878,,autoimmune hepatitis/enteritis,cyp2c8 substrate,,millipede system.|clinical symptoms,hysterectomy|elective surgery|informed consent obtained|asa,,,,non controlled,throughout study participation until 90 days after the last ip dose,=< 12 months||,,,,,,
4879,,including:||neurological disorders,approved covid-19 vaccines,,pelvis radiotherapy|previous antitumoural,pelvic trauma,,,,severity of the heart disease|admitted,last 12 months prior to screening.|uncontrolled medical conditions,<50m,,,,,,
4880,,cerebrovascular diseases:||cerebrovascular accident,anti-vegf ivt injection,,nora).||,minocycline|modified rankin score,,,,extraction site;|periodontitis,at least two months after the last extraction.|total initial vscs levels,pacemakers,,,,,,
4881,,habitual diet|no changes,local anaesthetic,,total body weight,scans,,,,immunosuppressive treatment.|person,within =< 28 days prior to registration).||*,above 0.2 ng/ml,,,,,,
4882,,liver diseases;|renal failure,hav,,v600e mutation|mmr proficient,bone marrow progenitor cell transplantation,,,,referred otalgia.||,up to 6 months before enrollment).|tumor,≤ 95% pn,,,,,,
4883,,positive xm,prednisolone,,national comprehensive cancer network (nccn) definition,staged pci,,,,non-autologous,within 3 months prior to study treatment administration,at least three months.|patients,,,,,,
4884,,relapsing remitting ms,giredestrant,,victoria general hospital,treatment.|concomitant treatment,,,,spermicide|cap,their first period,greater than 12 weeks.||exclusion criteria,,,,,,
4885,,developmental delay.|participants,components of the investigational product,,synthetic-dmards.|for,insufficient width of attached gingiva,,,,mandible,within 14 days prior to initiation of study therapy|history of a,< iii|age,,,,,,
4886,,structural cardiac abnormality,csii,,omega,enteral feeding.|patients,,,,exogenous,in the past 2 months.|suspected,≤ 3 × uln.|creatinine ≤ 1.5 × uln,,,,,,
4887,,type 2 diabetes.|systemic diseases,oral anticoagulation,,general,small interfering rna51)||,,,,suitable for redo,within 90 d of screening are excluded||ii,score is more than 30,,,,,,
4888,,hours|non-first ami.|pregnancy,trigeminy,,estimated gestational age,ecg electrodes,,,,related to stroke).|implanted electronic device.|epilepsy.|metal,for 30 minutes,less than 4 weeks prior to inclusion,,,,,,
4889,,upmc primary care clinic,interventional clinical trials;|the investigator assessed inappropriate inclusion,,body mass index (,mtc,,,,adherium sensor (fluticasone propionate or budesonide/formoterol,prior to the first dose of study treatment.|patient,≥ 90 g / l.||hepatic,,,,,,
4890,,cervical insufficiency,anticoagulation drugs.|asthmatic,,enrolled.|body mass index,graft-versus-host response,,,,month.|regular meditation,within 14 days before the experimental maintenance treatment initiation.|adrenal replacement steroid doses,under 2 years,,,,,,
4891,,self-diagnosis,peg,,lower extremity orthopedic surgery,routine examination,,,,widespread,within the past 30 days prior to the screening visit,18 -75,,,,,,
4892,,thyroid dysfunction|known diabetes mellitus type,antihypertensive agents,,neurological index,gastric bypass surgical intervention|capable of,,,,gastrointestinal symptom rating scale|patients who voluntarily agree to participate in this study,within 7 days prior to first dose of study treatment.|symptoms,< 300 after,,,,,,
4893,,tourette,thiazolidinediones,,hepatitis b (hbsag),oxygenation measures|palliative care,,,,pre-existing,during the time between 9,> 1000 copies/ml,,,,,,
4894,,other pulmonary disorders,tolvaptan sodium phosphate,,normal corrected serum calcium,"pituitary hormone deficiencies,|gh deficiency",,,,mild to moderate idd|exercised,< 12 months,no more than 15,,,,,,
4895,,malignant hyperthermia.|patients,health supplements,,ics score,study partner|able,,,,brady-arrhythmias,within three weeks,> 2 × institutional uln,,,,,,
4896,,adenocarcinoma of,systemic retinoid,,alberta stroke program early ct score,intraspinal surgery,,,,semi intensive.||,within 3 months of last cisplatin administration.|stratum,≤ 1.5 × uln);||(4,,,,,,
4897,,uterine leiomyosarcoma,cnv,,wd,regular antenatal check-ups；pregnant,,,,stage 2,at the time of consent.||sex,≥ 30 kg/m2,,,,,,
4898,,parttime staff||exclusion,dopamine/dopaminergic drugs,,response evaluation criteria in solid tumors (recist),microbiopsy,,,,stromal,during the next 24 months;|possess any,at least pr,,,,,,
4899,,osteitis pubis,antibody therapies,,disease duration,computed tomography using,,,,overlaying,congenital maxillofacial deformities mainly cleft,<20 years|patients already,,,,,,
4900,,transverse myelitis,live attenuated intranasal influenza vaccines,,human immunodeficiency virus (hiv1),open angel glaucoma,,,,suitable for cannulation,prior to tki|patients,25% higher than the same score recorded,,,,,,
4901,,colorectal cancer pathologically||patients,anti-vegf agents,,urine albumin creatinine ratio,labor,,,,low dose,at the time of screening;|hypersensitivity,scores < 25,,,,,,
4902,,lack of nystagmus reversal,ndris,,apt foundation,surgical technique,,,,not yet authorized,within 7 days of screening visit,less than 2 doses per week,,,,,,
4903,,acceptable physical condition,finished the gastroenterology residency,,hbv-dna≤2×103 iu/ml,computed tomography/magnetic resonance,,,,calyceal,at least three days a week for the past three months)|low,older than 18 years|one,,,,,,
4904,,severe covid-19,quercetin,,blood glucose monitoring system.|hemophilia,lower extremities.|physiotherapy treatments,,,,under medical treatment.|patients,at the two clinics,>=8 cm,,,,,,
4905,,alveolar soft-part sarcoma,nivolumab for,,cardiac organ function|a,gc therapy,,,,third-generation,during the 2 weeks before admission,prolonged to >480 ms,,,,,,
4906,,hormonal disorder,underaged,,child-pugh rating,percutaneous endoscopic gastrostomy (peg) tube may be eligible. for any such participant,,,,inclusive)|do not,at the screening visit:||hr,less than 4 weeks before the,,,,,,
4907,,first episode psychosis,drug ingredients,,myelosuppression|cd4 count,exhausted,,,,alk fusion,within 30 days prior to admission to the clinical unit.|a positive pre-study serology test for hepatitis b surface antigen (hbsag,<190 mg/dl,,,,,,
4908,,post menopause,medications that would increase the risk of,,dmd,antibiotic prophylaxis,,,,months|high grade av block,in the 28 days prior to the first study drug administration|use of,> 3 kg,,,,,,
4909,,psychiatric illnesses,mexiletine,,fundus photographs.|normal optic disc.||,venous access,,,,ulcerative,during exercise via self-report,<35%,,,,,,
4910,,sfr,aids drugs,,hydroexfoliation cytopathology of the chest and abdomen,femoral artery access,,,,preclude endoscopic drainage|presence of ileus,within the last six months||,> 30,,,,,,
4911,,parkinson's disease|aged,anti-obesity drugs|recent hba1c,,international ankle consortium guidelines.||criteria for inclusion,cessation therapies.|expectant ladies,,,,emergency purposes,within 28 days before grouping,18 years,,,,,,
4912,,compromised immune status.|children,tricuspid valve|patients,,thrombus burden,wechsler adult intelligence scale - fourth edition (wais-iv,,,,icd-10 f00-f03)|somatoform disorder,within 6 hours after eswl;|suspected or confirmed,i-ii.|hypospadias surgery.||,,,,,,
4913,,narrowing of the colon|previous,immunosuppressive agents.|participants,,asa classificaion,experimental intervention,,,,fresh frozen plasma (ffp),during the study;||5.ongoing pregnancy;||6.patients,18.5 to 35 kilogram per square metre,,,,,,
4914,,consent|elective coronary artery bypass surgery,octreotide-lar;|regular treatment,,capable program,technical data sheet.|participation,,,,mild-to-,at least 7 months after the last dose of study,> 470 milliseconds from 3 electrocardiogram (,,,,,,
4915,,muga).|recovered,hydroxamic acid,,bsso,local clia,,,,non-pharmacological,for at least 1 year|track the whole trunk lower limb sagittal plane coronal aligament,between 160 and 180,,,,,,
4916,,calculated by the cockroft-gault method)|leukocytes,iuds,,anti-hepatitis c virus,digital literacy||,,,,biliary,during the study|for,>6.4%,,,,,,
4917,,bladder stone,clindamycin|provide,,calculated glomerular filtration rate (gfr),pelvic veins,,,,insulin sensitivity)|gastrointestinal tract surgery|pregnancy,within 28 days before the start of the study treatment,aging,,,,,,
4918,,familial hyperaldosteronism type,compounds of similar chemical or biologic composition to pancrelipase.|patients can,,car t-cell treatment.||,tc,,,,primary source of their knee pain,within 4 weeks of study day 1|history,> 0.05|normal findings,,,,,,
4919,,glenoid deficiency.|patients,xeloda ®,,national institute on aging,neurological development||,,,,ma)|south,on the day,≤1.5x upper limit of normal,,,,,,
4920,,1 year|documented poor compliance,immune response modulators,,screening|anti hbs titer,retest analyzed,,,,blood sugar,within 4 weeks before the first study,≥150 min per week,,,,,,
4921,,buccal cancer,sarcomatoid,,response evaluation criteria in solid tumors (recist) v1.1.|estimated life expectancy,scheduled procedures,,,,li-rads v2018,at the time of study|etonogestrel implants,score of 3,,,,,,
4922,,dlbcl,early,,genitourinary small cell carcinoma,weeks.|chemotherapy,,,,secondary to prior therapy,period until 120 days after the last study drug,≥ 18 years|subject,,,,,,
4923,,fast track developed postoperative delirium,doravirine:||delstrigo®,,recist version 1.1 criteria||,hematopoietic stem cell/marrow transplant.||have known,,,,nurse specialist,within at least 8 weeks prior to screening,6-30 years,,,,,,
4924,,bacterial fluorescence imaging,dostarlimab,,national cancer institute (nci),vitreo-retinal surgery,,,,under oxford,at any time during the study.|participant,> 9 g/dl,,,,,,
4925,,natural health products,traumatized,,calculated(crcl should,fertilization,,,,bronchiectasis|patients,within the stent|pre-dilation,less than 90 or greater than 140 mmhg,,,,,,
4926,,treatment targeting tumor immune mechanism,adrenaline,,mass general brigham questionnaire,assisted reproductive technology (art),,,,self-compassion scale|must understand study procedure,enjoyment,≥ 3cm,,,,,,
4927,,lung disease||patient,variant anatomy,,sars-cov-2 infection,standard treatment.|no,,,,successfully treated|history of transplants,before the first administration of the study drug;|study the presence,pregnant.|besides,,,,,,
4928,,asthma exacerbations,sodium glucose cotransporter,,hepatitis b core antigen (anti-hbc,gastrostomy tube,,,,distant metastasis|planned surgical treatment|fluency,within the next 90 days|history of,">= 3,000/mcl",,,,,,
4929,,left bundle branch block,cabozantinib,,serum alanine aminotransferase(alt)/aspartate aminotransferase(ast,concentration,,,,as judged,within 28 days before,below 50,,,,,,
4930,,hopeless teeth|patients on analgesic,intervention targeting,,hepatitis b surface antigen (hbsag),psychosocial assessment for transplantation (sipat),,,,low grade serous ovarian cancer,within the 3 month period prior to,> 60 mmol/l|fp,,,,,,
4931,,bone infections,therapy.|relevant medications,,ckid,world health organization criteria,,,,grade iii or iv) glioma,within past three months,younger than 50 or older than 70 years,,,,,,
4932,,intracranial pressure probe,nicotine lozenge,,thyroid-stimulating hormones|on cancer,mpox vaccine,,,,influence dependent variables|recent surgery,at the time of signing the informed consent.|clinical chemistry laboratory values,18 to 65 years,,,,,,
4933,,punctal occlusion,obeticholic acid,,plasma bilirubin,materials|nonsmoker|caries free||,,,,consent|large,within the last 6 months.|pregnant,≤ 36.5,,,,,,
4934,,excessive bleeding,bacillus tuberculosis).||diagnostic assessments:||participants,,estimated blood loss,immunosuppressive treatments,,,,organ transplant,within 4 weeks of first dose date.|inability to swallow oral medications.||any of the following cardiac abnormalities:||unstable angina pectoris,<1 year|any type of cognitive impairment,,,,,,
4935,,insufficiency;|uncontrolled hypertension,contrast-enhanced,,age|asa class,central laboratory,,,,rome iv criteria (unpleasant postprandial fullness,in the last 12 months.|subjects,≥ 18-years,,,,,,
4936,,imp,gof mutation,,performance physical battery,tunnel revision surgery|associated surgery,,,,mild to moderate alcohol use disorders.|has,for at least 3 months;|estimated gfr,≤ 1.5 x upper limit of normal（uln）,,,,,,
4937,,avoidance of musical performance situations|reporting psychological distress,anti-hypertensive medication,,victorian institute of sports assessment,breast cancer|prior therapies for locoregional recurrent,,,,supra-esophageal manifestations,within the past two weeks|severe neurologic,i-ii.||,,,,,,
4938,,limit static,indwelling nephrostomy,,generalized alveolar bone loss,manifest refraction,,,,first-line treatment,within 4 weeks prior to screening|uncontrolled intercurrent illness,18-70 asa grade i-ii,,,,,,
4939,,s6 segmentectomies,hyperosmolar state,,hbs antibody,emergency medical services,,,,examined,within 7 days prior to the first dose of study drug,<1.05 mmol/l,,,,,,
4940,,mgi,everolimus-eluting stents,,memory function score,quantitative polymerase chain reaction (qpcr) test,,,,months;|hematological indexes,before the first injection;|patients can comply with the requirements of the protocol,more than 50 years,,,,,,
4941,,arthroscopic rotator cuff repair|american society of anesthesiologists physical status,sars-cov-2||,,spend,liver tissue biopsy results,,,,pd group only)|diagnosis,during daily time-restricted eating|gynecologic cancer,greater than 10 pack-years,,,,,,
4942,,hypertensive patient,mih,,gram-negative etiology,tips of the electrodes,,,,effectively,after at least 48 hours,18 years and older and younger than 64 years old.|at least 5 years,,,,,,
4943,,autoimmune disease.|patients,diamine fluoride,,systolic arterial blood pressure,hepatic arterial blood to the lung,,,,muscle-skeletal disorders,for at least 4 weeks;||laboratory examination,≥42 mmol/mol,,,,,,
4944,,hepatitis b virus dna≥1×104 copies,active drug therapy,,gestation,collected blood,,,,little,"in the past 3 months,|individuals",0 to 1,,,,,,
4945,,"obstructive sleep apnea syndrome|""class",guanethidine,,immune test results|presence,hpv vaccination series,,,,iv.||without mutation of,prior to enrollment.|white blood cell,"18 - 35,|at least",,,,,,
4946,,behcet's disease,chondroitin sulfate,,rass score,mri contrast material,,,,relapsed,before hospital admission.|early limitation,> 2.3,,,,,,
4947,,non-measurable,anti-glutamic acid decarboxylase,,measurement of fetal crown rump length)|malay pregnant,mini-mental state examination (mmse),,,,study|central respiratory events account,for at least six months;|with cognitive frailty,<3 x uln,,,,,,
4948,,lower extremities,study drug classes,,new-onset wound,pulmonary surgery,,,,swelling.|greater than grade i mobility,during the study.|the,less than 5.7%,,,,,,
4949,,obstructive sleep,3rd degree heart blocks,,oral hydrocortisone,ust dose,,,,esophageal dose,at the time of mbm,35 kg/m2 ≤,,,,,,
4950,,triple positivity,bulkamid®,,prostate cancer.|subjects,hip cannulated screws,,,,carbon monoxide [dlco],at least 1 year prior to visit 0.|participants,< 30 ml/min|platelet count,,,,,,
4951,,pulmonary tuberculosis;|other factors,recombinant human,,paediatric asthma symptom - observer reported,antithrombotic therapy,,,,aspergillus spp.,for at least 3 months|average pain intensity,<0.7)|copd,,,,,,
4952,,geographic conditions,anti-xa inhibitors,,calculated by ckd-epi formula,vascular interventional therapy,,,,both stable,in the month preceding the inclusion,≤ 5 x uln,,,,,,
4953,,allowed)|secondary osteoarthrosis,methylxanthines,,metabolic,renal puncture biopsy,,,,in remission;|no severe,less than 6 months after the completion,post-chemotherapy.|when,,,,,,
4954,,myeloproliferative neoplasms,grapefruit containing,,manual muscle test,animal organs,,,,successfully completed,within 2 weeks prior to first administration of the study,between 18 to 80 years|tinnitus handicap inventory ≥ 48|chronic,,,,,,
4955,,singapore||,sleeping aids,,|platelet count,produce qtc,,,,flu-related,within 3 months of visiting 1|a disease,<2x uln|ast,,,,,,
4956,,cytolytic t lymphocyte-associated antigen-4,topical ophthalmic therapy,,syphilis test positive;|severe mental disorders,lactation|previous gastrectomy,,,,self-report|underweight,in the past 12 weeks.|intent,60-100 kg,,,,,,
4957,,radiculopathy|low back pain,writes,,serum ferritin level,main organs function normally,,,,mid-face volume deficit,within 3 months before enrolment,≤2.5x normal high,,,,,,
4958,,renal transplant,components of azvudine tablets,,oral cal,pelvic organ prolapse|pelvic organ prolapse-quantification,,,,in the area of the tumor lesion;|presence,at least 12 weeks|adequate hematologic,>= 1000/mcl,,,,,,
4959,,antiparasitic,alternate drug selection,,students|not,neurological level of injury (,,,,abnormal history,in the patient's past medical history,<20 weeks,,,,,,
4960,,superficial skin surfaces,simonin,,hdl,echo exam,,,,antibody titer,before surgery|participating in conflicting clinical study,≥ 1.5 × 10 9 /l；② platelets,,,,,,
4961,,non-orthopedic specialties.|primary,vin,,orbnp value,subsequent hormone level assessment for female,,,,required elective,during the 2-week screening period.|ability,< 0.85 required,,,,,,
4962,,excessive tortuousity,suboptimal contrast opacification,,ig)m hepatitis b core antibody,surgery.||exclusion criteria||other causes,,,,barium meal,at the time of to the inclusion,= 285ml of beer,,,,,,
4963,,ventricular hemorrhage,nonsteroidal anti-inflammatory drugs (nsaids),,seminal plasmic elastase,"structured clinical interview for dsm-5, research version (scid-5-rv)|heavy alcohol consumption",,,,false-positive response,for 24 weeks post,≤ 150 mg/day,,,,,,
4964,,purpura,mercurial antiseptic,,age,histology,,,,xanthine).|non-membership,within 3 months prior to initial administration of eth-155008.|have,≤ 3× uln,,,,,,
4965,,anterior neck surgery.|malignant disease.|prior neck radiation.|undetermined intraoperative nerve origin,anti-angiogenics,,creatinine clearance levels,participation.||details,,,,total t cells,within 28 days prior to the 1st dose of chs-006,before 50 years,,,,,,
4966,,rhythm associated procedures,alpha criteria|embryo transfer,,suicidal ideation section of the columbia-suicide severity rating scale,sequential lung transplantation,,,,absolutely,for at least 3 years prior to the signing of the informed,score iv or v.|patients,,,,,,
4967,,right atrium,cpi,,forced expiratory volume in 1 second [fev1],intent,,,,near-fall occur with participant's falling,within the 12 weeks before screening,less than 70)|symptoms of depression,,,,,,
4968,,major conditions,immunocheckpoint agonists,,rhc||pulmonary capillary wedge pressure (pcwp),whole-body,,,,diagnostic and statistical manual of mental disorders (dsm-5,within the 4 months preceding study treatment,"lower than 30,000/microliter",,,,,,
4969,,component|pregnant,potassium supplements,,anesthesiology,live virus vaccine,,,,curatorship|patient,within 2 weeks prior to day 1 of cycle 1||cancer-specific,under 70 years,,,,,,
4970,,unspecified,teriflunomide,,new york heart association class,intravascular therapy,,,,implantation of a durable,at the time of screening.||have documented,70%,,,,,,
4971,,endodontic treatment.|healthy patients.||,tme,,controlled arterial hypertension,optimal stabilization,,,,salvage chemo-immunotherapies,"glenrose rehabilitation hospital (edmonton, ab",score greater than or equal to 15.||,,,,,,
4972,,clotting disorder|patients,metaiodobenzylguanidine [mibg],,vital capacity,bone marrow function|female,,,,left distal radial artery can,past 8 hours).|effective cough.|negative leak test,1a monotherapy dose escalation,,,,,,
4973,,pacemaker indication,systemic anti-inflammatory medication,,main organ functions normal,endoscopic procedures,,,,immunosuppressed,during the study;|participants,18 years or older|presentation,,,,,,
4974,,orthostatic,ivt-afl treatment,,physical examination.|age,autologous car-t therapy；|should,,,,pack-year smoking,"within preceding 5 years,|change",≥ 100×109/l.|hemoglobin,,,,,,
4975,,sob.|no surgical procedure,memantine medication|anticonvulsant medications,,subjects:||6 body mass index,unique combination of,,,,non-hysterectomized,last 5 days,19 or older|those who voluntarily,,,,,,
4976,,acute t-lymphoblastic leukemia,throat,,"diagnostic and statistical manual of mental disorders, 5th edition",radical surgical resection,,,,grade 2 and above continues to occur;|other conditions determined by the researcher that may cause,within 30 days prior to screening.|use of,class iv-v|elevated,,,,,,
4977,,major depression disorders,ultrasonic gastroscopy,,hiatal hernia,lipid nanoparticles,,,,thinnest point.|known sensitivity,throughout the study period.|individual,"≥18 years,|subject",,,,,,
4978,,drug abuse|allergy,injectable contraceptive,,echocardiogram|mass general brigham pcp affiliation,insufficient respiratory drive|prolonged (,,,,mitomycin-c,within 6 months|any condition,">= 1,000/microliter.|platelets",,,,,,
4979,,heart problems)|untreated thyroid disease,st. john's,,ecog (eastern cooperative oncology group) scale|american society of anesthesiology (asa) score,insufficient reported,,,,african,within 30 days prior to study enrollment.|participant,setting,,,,,,
4980,,hirsuitism,medication for osteoporosis,,cardiac co-morbidity,fundamentally complicate rehabilitation from the procedure,,,,methicillin-resistant,past one year,≤ institutional upper limit of normal,,,,,,
4981,,c,ini,,mile square health centers enrolled in the clincial trial||aim 2||inclusion criteria for providers/staff:||provider,sample #2 requirements,,,,mi)|hemodynamically,for at least 6 months after the last medication,greater than or equal to 24kg/m2||have,,,,,,
4982,,trichiasis,steroids|chronic inflammatory diseases,,takes 30 minutes,oral polio vaccine,,,,non-compressible,"infection,|more than 2 mm",less than 5 times the half-life,,,,,,
4983,,car t cell,folic acid,,arrival,coronary artery bypass grafting|patients,,,,list ovarian,during the 3 months before surgery|patient refusal,20 years old or more|fulfilling the criteria of ntm,,,,,,
4984,,neurological diagnosis|history of,component of the product||patient,,recist version 1.1 at least 1 cm with contrast enhanced,immuno-oncology therapies targeting pd-1,,,,clinically significant gi,within the 6 months prior to screening.|the,between 18.0 and 32.0 kg/m2,,,,,,
4985,,allogenic bone marrow transplant,conventional myeloablative conditioning regimen,,partial thromboplastin time (aptt/ptt,hormone therapy,,,,urogynecological surgeries.|respiratory,within the last 6,<30 × 10^9/l||warm,,,,,,
4986,,external webcam.||- exclusion criteria,epilepsy medications,,asct,radiotherapy fraction.||completion,,,,primary sites,within next 12 months,> 14,,,,,,
4987,,cranial deformities,dalfampridine,,pro-biotics|current substance use disorder,cardiogenic shock|pci,,,,full absorption of almonertinib.|a history,within the past 3 years,> 18 years).|participants willing and able to comply with the study procedures.||,,,,,,
4988,,blepharochalasis,pakistan,,response evaluation criteria in solid tumors (recist) 1.1 criteria,scap therapy,,,,grade ≥3,after radiotherapy,<50/,,,,,,
4989,,uterine factor infertility,dabigatran,,lung function,vital organ function,,,,forced,last year,> 1.5x the upper limit of normal,,,,,,
4990,,physically active,clozapine before initial lab work obtained non-clozapine treatment,,asa physical status i- ii|age,single operation have achieved,,,,cerebrum area,during the 12-month study period,at least 12,,,,,,
4991,,normal uterus,combination agents,,dcis,mechanical spermicide,,,,index knee|an,within 28 days prior to the dosing day,<20 ml/min/1.73 m^2|patients,,,,,,
4992,,antepartum hemorrhage,non-narcotic analgesics,,urine protein<2+,therapeutic device|mini-mental state examination,,,,singleton,over the past 3 months)||,≤ 3x uln,,,,,,
4993,,excessive drinking,cytokine antagonists|regular,,prothrombin time ≤ 1.7x the institutional upper limit of normal (uln),familiarization session,,,,non-hepatic tumors,within 30 days of the first dose of study treatment.||has,oximeter,,,,,,
4994,,donate bone marrow,drugs affecting reproductive,,hepatitis c virus (hcv),12-lead electrocardiogram (ecg) results,,,,secondary kmt2a,more than 6 months after completion,≥75×10^9/l,,,,,,
4995,,high grade carcinosarcoma squamous cell carcinoma carcinoma ex,nifedipine,,vital signs outside,internal carotid artery peak,,,,pack-year,during initial evaluation,≥0.75 × 109/l,,,,,,
4996,,systemic autoimmune diseases,screening.|magnesium,,locs iii).||,coronary artery bypass graft≤3 months prior,,,,suppressible,for the duration of study participation.||,> 5×uln,,,,,,
4997,,paramyotonia congenita,type of psychological management,,estimated using,verbal communication,,,,non-english-speaking,in the past 6 months|known,>20g,,,,,,
4998,,psychiatric illness|not,components of pembrolizumab,,alanine transferase,single ecg,,,,index young man.||,at the week 4a study visit,18-30|minimum of 24,,,,,,
4999,,lawrence,aligners,,tunel assay,total laparoscopic hysterectomies,,,,peng-block,at least 1,between 18.5 and 39.9 kg/m2||,,,,,,
5000,,skin conditions of the affected,imipramine,,laboratory test,local regulations:||provision of informed consent,,,,amenable to biopsy,for more than 7 days in 4 weeks before randomization,less than -1,,,,,,
5001,,rvad,milvexian-the end of,,a:||≥,full participation in the study,,,,non-functional,in the last six months,"80 cm², 160 cm² or 240",,,,,,
5002,,lateral patellar dislocation,mycofenolate mofetil,,sars-cov2 vaccines,firstline therapy,,,,secondary to cancer,within 8 weeks prior to randomization,> 9.0%|have,,,,,,
5003,,heart failure)|the,ics/laba regimen,,new york heart association (nyha) grade,hematopoietic stem cell transplant.|receipt of any investigational agent,,,,axially unstable,at the time of release,> 1|plaque index,,,,,,
5004,,unresectable stage iii|previously progressed,anticalcium drugs,,p>=5)|body mass index,fine needle aspirate,,,,non-ambulant people and people with a,at the time of study enrollment|patient,< 1 year 14,,,,,,
5005,,turner syndrome,lanksy,,hepatitis b virus (hbv) test,first oocyte pickup understands german language to fill out questionnaire||,,,,infusion pump,within 6 months prior to the screening visit.||use of the following therapies,≥ 3x10^9,,,,,,
5006,,painful arc test result,chlorhexidine,,bdi score,flexion rotation test,,,,bulky,within the specified period before airway allergic examination;||healthy,"under 50,000)|anticoagulation",,,,,,
5007,,surgically sterilised,wherein combination,,liver function test,care visit|hospitalization,,,,incompletely treated,at the time of inclusion without,>= 19,,,,,,
5008,,aids)||allergies,conventional laparoscopic,,serum status.|smallpox vaccination,chest ct scan,,,,uk armed,within the previous 6 months.|potentially unstable,< 60%,,,,,,
5009,,inflammatory bowel disorder,drugs that inhibit gastric acid secretion,,crcl)≤,wsl,,,,successfully completed the operation,within less than 2 weeks before first study intervention administration,≥ 8.0 g/dl|absolute,,,,,,
5010,,iv|obesity,anti-allergic drugs,,bmi ≧,permanent treatment,,,,pd ligand 1,"after the surgery,|the patient is not discharged",≥ 3mm).|willing,,,,,,
5011,,intestinal flora disorders,dopaminergic medication,,fev1 below 50 %,unilateral knee,,,,without curative,within 4 weeks of first dose of study drug.|malabsorption syndrome,≥ 19|patient,,,,,,
5012,,anti- arrhythmia,drugs used in the trial,,alefacept,ensure vaccination,,,,upper thigh,for the trial.|signed written informed consent,greater or equal to 24 weeks,,,,,,
5013,,hyperlipidemias||,venetoclax,,frankl behaviour rating scale,past|corticosteroid injection in achilles tendon region,,,,relapse occurs,at least 3 months prior to study enrollment)|at least two,≥ 50 ml/min;|liver function,,,,,,
5014,,neurological involvement,steroids/immunosuppressants,,diagnosis(pgd,thoracoscopic lobectomy|asa,,,,grade 2 toxicity may be excluded);|inadequately treated central nervous system (cns) metastases,within 8 weeks before first dose,from 18 to 70 years|patients,,,,,,
5015,,chronic comorbidities.|people,centre for international health,,pas-score,cognitive function tests,,,,emotional,within 24 hours prior to scheduled study vaccination,>3 sec daytime,,,,,,
5016,,distant metastasis.|prior chemotherapy,"strong tea,|no",,karnofsky performance status scale,regular medication,,,,place the patient at higher risk from his/her participation in the study,within 12 months before enrollment;|history,≥ 80 × 109/l,,,,,,
5017,,risk factor,mitomycin,,embolization;|life expectancy,liver imaging findings,,,,unrelated to gastroschisis|evidence of bowel perforation,at least 30 days prior to enrollment.|prior treatment,19-25,,,,,,
5018,,endodontic-periodontal disease,oral naltrexone,,symptoms severity score (,exploratory surgery,,,,substance abuse|open skin lesions,over 3 months.|use of medication,15-20,,,,,,
5019,,eyes,psychoactive substances;|pregnant,,ventricular rate,chest ct angiography,,,,moderate persistent,before screening;|subjects,-2.5 months.||negative,,,,,,
5020,,intratumoral necrosis,neurokinin-1 receptor antagonist,,dpt student,future research.||exclusion criteria:||an,,,,continuous,at time of screening|if,between 18 and 75 years|diagnosis,,,,,,
5021,,metallic particles,rheumatology,,natural,abdominoplasty,,,,blast cells,prior to randomization]|concurrent cytotoxic chemotherapy,18-80y,,,,,,
5022,,degenerative joint disease,telaprevir,,hepatitis b surface antigen as the only evidence of prior exposure may participate in the study.|note: hepatitis c antibody-positive,bone metabolism.|chronic,,,,injection site.|allergy to local anesthetic drugs,past history of,≥ 50%|platelet count,,,,,,
5023,,being hiv,aerobic exercise,,saint louis university mental status (,history|pelvic organ prolapse,,,,intra-aortic balloon pump,within 2 weeks prior to enrollment.|if,< 10 miu l-1,,,,,,
5024,,allergic rhinitis|nasal,mood stabilizers,,ecog performance status;|have,hour,,,,periampullary region.|patients,for at least 12 months).|premenopausal,"<148pmol/l),|serum",,,,,,
5025,,cerebrospinal meningitis,products used for dairy intolerance,,cabg + avr||,complete clinical info;|patients self-agree,,,,connective tissue disease pulmonary arterial hypertension,within 30 min after the initial ecg,≥ 18|able to read,,,,,,
5026,,abuse disorder,systemic anti-inflammatory drugs,,||- opposition,active,,,,sci|medically unstable - unstable,during the screening period recognized,≥2 years|heterozygous,,,,,,
5027,,factor deficiency,cefoxitin,,american cancer society,anatomical imaging larger,,,,suitable for study enrollment;|patients,within 3 months of the first study procedure.|patient,20-30.0 kg/m2.|provide written informed consent before initiation of any study procedures.||a,,,,,,
5028,,current cancer diagnosis,immune modulators like cyclosporin or methotrexate,,liver score,bismuth subsalicylates,,,,unstabilised,within 2 months prior to (first),> 65 years|informed,,,,,,
5029,,superior mesenteric artery|known delayed gastric emptying|known,thrombolytic,,lft,ct scan abnormality,,,,stage iv),during study participation|ability to understand and the willingness to sign a written informed consent form,"> 7,0 mmol/",,,,,,
5030,,rotational trauma,toramyxcin,,transaminases,tyramine-rich foods,,,,rome iv postprandial distress syndrome,for 3 months after completion of treatment.||,>2|uterine,,,,,,
5031,,wbh,intraprostatic implant,,mandibular/cranial base angle,bile duct epithelial cell carcinoma;|previously,,,,infection|current psychosis,within 6 months before enrollment;|patients,≥ 2 affirmatives,,,,,,
5032,,chronic obstructive pulmonary disease|left heart failure,corticosteroid medication,,visual analog scale.||presence,lipid metabolism,,,,android,"within the next 12 months,|history of",<40.|generally,,,,,,
5033,,visual field.|refractive disorders,drugs structurally similar to fenofibrate,,left anterior descending artery,ebv polymerase chain reaction (pcr) test should,,,,grade ta,after initiation,<18 or >90 years,,,,,,
5034,,neurodevelopmental disorders.|legal incapacity,component of the study vaccine,,npc.|ecog performance status,autologous bone marrow transplantation.|significant,,,,hp-positive,for at least 6 months|age,400 cm2 per thigh,,,,,,
5035,,chemical cystitis,antiparasitics,,serum follicle-stimulating hormone level (fsh) level,health assessment questionnaire-disability index (haq-di,,,,chronic rhino-sinusitis,in the past 2 months|immunodeficiency disorder|use of,>3x uln|signs,,,,,,
5036,,opioid dependence,belladonna,,modified ctsi pancreatitis severity index,specific immunotherapy (sit),,,,hearing aids,within the past 3 months,>=g3,,,,,,
5037,,abuses|postoperative delirium,tominersen)|anti-platelet,,below:||leukocytes,conventional therapy,,,,de novo biopsy,at least two measures.|fasting triglyceride level,20 teeth,,,,,,
5038,,adverse events [ctcae,mineralocorticoid receptor antagonist,,anti phospholipase a2 receptor,dynamic imaging,,,,mentioned,in the previous 90 days.|end-stage,documented,,,,,,
5039,,teratogens,medication affecting evaluating indicators,,child's score,subjects;|the investigator believes,,,,vital functions|acute,in the 3 months prior to enrollment.||planned receipt of any of the following prior to planned trial vaccine receipt (day 1 and day 57 for groups,">= 100,000/mm^3",,,,,,
5040,,conversion disorder,enoxaparin,,child - pugh classification,local institutional standard method).|men,,,,non-operable patients,within 4 weeks prior to initiation of study treatment,15 to 49 years,,,,,,
5041,,active infection.|untreated conduction system,non-insulin glucose-lowering agent,,acneiform induced rashes,pelvic surgery/trauma,,,,dsm-v alcohol,for the next 60 days||,two 2 mm,,,,,,
5042,,psychological deficit,pembrolizumab pd-1,,months;|ecog score,years|surgical treatment,,,,site investigator||cohort 2,within 2 weeks prior,>100 u/l.,,,,,,
5043,,disorder|participation,contraceptives excepted,,o2) saturation,tcf3-pbx1,,,,3 audio processor,patients|pre-operative,> 150 kg,,,,,,
5044,,ocular cicatricial pemphigoid,neomycin,,hiv rna assay,months).|an ecg,,,,conjunctiva,during the first three months of the study,score of 0 or 1.|has,,,,,,
5045,,cirrhosis|fibroscan,sessions,,aptt values,transfusion support,,,,surgery;|pulmonary,during study period|children,> 1.7;|known,,,,,,
5046,,hepatocellular carcinoma|patients,alpha-beta tcr depletion,,residual bone height,epicardial coronary artery,,,,unknown her-2 expression,within the last 6 months|not,"1.1, there",,,,,,
5047,,asthma symptoms,checkpoint inhibitor,,ami)|pulmonary emphysema;|valvulopathy;|systemic arterial hypertension;|severe coronary artery,discontinuation of immune therapies,,,,other sites,during ordinary conversation,1 to 6 years|parent-reported,,,,,,
5048,,status|diagnosis,titanium metals,,fasting blood sugar levels,surgical treatment|patients,,,,significant,post op electrocardiogram,≥1×10^9,,,,,,
5049,,intend to receive,high-dose,,american society of anesthesiology body rating),hernia repairs,,,,primary hypothyroidism|on,within the body,<5 mmol/l/,,,,,,
5050,,idiopathic pulmonary fibrosis).||respiratory infection,migraine attacks,,hiv test,oral surgical interventions|patient is able to give inform consent||,,,,accessory,within the last six months before screening,≤ 24 mm,,,,,,
5051,,hypertensive glomerulopathy,good oral hygiene|no,,qtc-time on ecg,inguinal hernia repair surgery,,,,preclude conduct of the study procedures,at either screening,>1.5 × uln|ast,,,,,,
5052,,risk hpv,saquinavir,,braf status,t0-t4a,,,,unl|ast,within 30 days before screening|initiation,≤3.0 mg on laboratory tests,,,,,,
5053,,absorb oral medications.|clinically,gemcitabine-based,,screening||hemoglobin,cell phone,,,,ada 2022 criteria,in the 5 years prior to study entry|recent covid-19 infection,≥ 89 mm,,,,,,
5054,,1|hepatocellular carcinoma,pathological confirmation,,response evaluation criteria in solid tumors v.1.1,moment of inclusion,,,,lasting at least 6 months|average knee pain,after at least 7 days of stable supplementation regimen||pregnancy,higher than the limit,,,,,,
5055,,high-resolution imaging,live attenuated vaccines,,virus serology tests,local requirements.||,,,,hemodynamically significant,past-year,1 point)|hypercholesterolemia,,,,,,
5056,,respiratory tract sympoms,nicotine-containing substances,,her2 tyrosine kinase inhibitor,sleeve gastrectomy,,,,old|hospitalized,within 1 month before treatment,>35,,,,,,
5057,,cd33+,cdk4/6 inhibitors,,american society of anaesthesiologists physical status,irradiation,,,,irinotecan-based,within 14 days of study entry.|known,ranges from 2<6,,,,,,
5058,,nerve stimulators,simvastatin,,bilateral normal range,small intestine resection.||anamnesis of,,,,patients|ipsilateral upper extremity fractures,at least 12 weeks prior to screening.|clinical laboratory test results,≥ 6.0%,,,,,,
5059,,anaplastic thyroid cancer|unresectable anaplastic thyroid,immunosuppressive medications,,weight-lowering,gold therapy,,,,recollection)|excessive use of,at signing of informed consent|type 2 dm of minimum 5 years duration,18,,,,,,
5060,,cystic carcinoma,medicines,,uln|international normalized ratio (inr)/ activated partial thromboplastin time (aptt),vital organ transplant,,,,assessment information).||,for at least 4 weeks prior to taking the cocktail|further inclusion criteria apply||healthy subjects and f4,≥1% of tumor,,,,,,
5061,,malignant tumor diseases,physiotherapy,,quit.|negative urine toxicology,cardiac transplantation,,,,distal jejunal drainage branch,at time of operation.|the presence,greater than or equal to (>=)18 years.|diagnosis of clinically typical ak,,,,,,
5062,,paracentesis|uncontrolled symptoms,growth factor,,antibodies or,hepatic veins,,,,limit maximal effort contractions|brain,within one week.|patients who had,≥ 50%;|international,,,,,,
5063,,post-covid condition,antipsychotic medication,,bone fracture.|at,imaging balloons,,,,supraphysiological doses of,during the study(other than the study products).|previous use of,14-55 years|patients,,,,,,
5064,,heart condition,hiv vaccine,,idd,line therapy,,,,propofol therapy|intake,within 1 month before screening;|acute infection,>1.2×uln.|with,,,,,,
5065,,ptsd diagnosis|speaks,immunomodulatory agents,,partial thromboplastin time(aptt,amyloid pet.|mild ad (score range of 13 to 24 on the korean mini-mental state examination (k-mmse,,,,without awakening|moribund state,at the time of screening.|use of immunostimulatory,than 2.0.|patient should have,,,,,,
5066,,in situ cscc,characteristics,,criteria:||age,skin examination,,,,diabetes):||hemoglobin,previously received more than 1 biologic agents,>= 21 years old <= 70 years,,,,,,
5067,,neoplasm of uncertain behavior,brimonidine,,standardized mini mental test (smmt) score,open-chest cardiac surgery,,,,old;|requiring,history of cardiovascular,=150 ml,,,,,,
5068,,dysplasia,nesa xsignal®,,iabp,icu,,,,months；|stable daily dose(s,prior to screen visit,18 or greater,,,,,,
5069,,renal insufficiency|severe,cytospin,,hepatic transaminases,major organ transplant|obstructive hypertrophic cardiomyopathy,,,,over 24 points,during the study;|clinical manifestations of bacterial,"stage ii , iii",,,,,,
5070,,hardware issues,immune-mediated conditions,,ct|age,etc.|oral/intravenous,,,,prolonged,within the past 1 year|main,at least 2 months prior to screening,,,,,,
5071,,ec,cannabis-use,,national institutes of health in the post-covid convalescence arm (,steroid injection|confirmation,,,,low-dose radiation therapy;|they voluntarily participate,in the past 2,≥1.5 x,,,,,,
5072,,cervical spine defects,ictal asystole,,aspartate aminotransferase ast≤2.5,t-all,,,,ebv-igg,past-month suicide attempt||,13 to < 16 years,,,,,,
5073,,superficial bladder cancer;|any condition,glecaprevir,,mtb|rif susceptibility,24-hour creatinine clearance,,,,requiring revascularization;|patients,prior to stroke|disorder of consciousness,less than 12 m,,,,,,
5074,,traumatic events related,5-2)|non-swedish speaking,,ehlers danlos syndrome diagnosis,atypical antipsychotic medication,,,,non-contrast computed tomography,within 3 weeks,2022).|age above 18 years.||,,,,,,
5075,,indicting questionable disease,nsaid medications,,gea score,prehospital emergency care||,,,,neuro-muscular,during or prior to operation,lens performance 16,,,,,,
5076,,bone plugs|does not object,3rd metatarsophalangeal joint,,prandial blood sugar level,gout treatment,,,,primary tumor.|the patient is,more than 12 months prior to screening,≥10mm,,,,,,
5077,,cardiac decompensation,phentermine-topiramate (qsymia),,american college of sports medicine,intestinal obstruction);|allergic to the test drug or its excipients;|persons deemed unsuitable for inclusion by the researcher,,,,cumulative total,during course of study,"less than 40,000 per mm3",,,,,,
5078,,gastrointestinal tract/rectal,anti-androgen drugs,,surgical,polypectomy,,,,non-suspendable,throughout the entire screening period).||-,18 years or older||clinical,,,,,,
5079,,distant lymph node metastasis,fp);||adequate organ,,asco-cap,inaccessible temporal doppler,,,,high grade dysplasia,"before, and patients",= 220-,,,,,,
5080,,falls|severely impaired cognition,f03.90,,cervical disc,capsid antigen igm,,,,severity of the response,in the last 5 years|patients incapacitated,> 12meq/l|ketones,,,,,,
5081,,clinical picture,"potassium chloride, calcium chloride dihydrate",,effective surgical sterilization,picc,,,,trouble,for at least 3 month before screening visit.||,between 35.5-37.5 ºc,,,,,,
5082,,medullary thyroid cancer,"epileptic seizures,|severe language impairment,|other neurological",,bone marrow function|females,viral acute infection.|high flow oxygen,,,,suitable for the test;|patients,within 14 days prior to the start of study.|subjects,i-v.|minimum score of 12,,,,,,
5083,,concomitant illness,analyses.|male,,bone marrow function((no blood transfusions,stent surgery,,,,salmon-colored mucosa,in the previous 5 years,450 ml or more,,,,,,
5084,,genetic svd)||,unchanged,,ctcae v4.0 criteria,infusion,,,,mrecist criteria,within 1 year of the screening date.|history of treatment,50,,,,,,
5085,,coincides,house,,gender identity outside,immunochemotherapy,,,,lesions(s).|radiographic evidence,after prior palbociclib.|patients with,more than 3,,,,,,
5086,,gonadotropins]|normal blood pressure,immune deficiency|symptomatic heart,,screening.|stable body weight,pancreatic hormone stimulant,,,,pretreatment regimen,during the,60 years and above,,,,,,
5087,,duchenne muscular dystrophy,major abdominal,,sporting,testing,,,,stage i-iii.|patients,within the past 12 months,≤ 2cm,,,,,,
5088,,hyper-ldl cholesterolemia,strong inhibitor of bcrp,,fasting blood glucose,ihc,,,,non-biological investigational agents,during the study.|pregnant,>= 30 ml/min||,,,,,,
5089,,give consent|patients,long,,positive test,rotational atherectomy,,,,insufficient norwegian language skills,more than 3 weeks,≥ 50 ml/min/1.73 m2).|patient,,,,,,
5090,,k.,anti-b-cell therapies,,sae,natural teeth.|no,,,,cirrhosis|inadequately treated,potent,≥34 µmol/l;|creatinine,,,,,,
5091,,reversible obstructive syndrome,menstruation appears,,serum glutamic-oxaloacetic transaminase [sgot])/ alanine aminotransferase (alt),hiatal hernia repair surgery,,,,radiation-induced injury,performed 3 months prior to inclusion,3 or above,,,,,,
5092,,breastfeeding|previous,crrt machine,,pft protocol.|patients,off pump)pumpless surgery,,,,aiha-directed treatment,within 30 days before or after the,between 29 days and 18 years,,,,,,
5093,,spinal injury association impairment scale,milk/lactose,,iia,local guidelines|active medical problem,,,,papain,in the next two years|patient,≥ 1.5 times,,,,,,
5094,,facial angioedema,cme,,m0|ecog performance status,joint prosthesis insufficient cooperation,,,,igg4-rd|patients,at least 2 years after a,a-d,,,,,,
5095,,fridericia,hiv-1 protease,,mean aortic gradient,surgical resection.||,,,,urban areas|families,within 6 weeks prior to step 2 registration.|for,< 90 ml/min/1.73 m2|ast,,,,,,
5096,,hyperglycemic-hyperosmolar state||ii,gymnastics,,status;|left ventricular ejection fraction,topical onychomycosis treatment,,,,extremely high,in the past 3 months.)|- past year,iv；|patients,,,,,,
5097,,sca type stemi,suntan,,speaking,drug delivery pumps.|complete aphasia,,,,human fetus,during the 52 weeks prior to enrolment date|individuals,18-49|have,,,,,,
5098,,cryofibrinogenemia,psychotherapy,,spinal cord compression|neurology,toilet paper and/or pain/crying,,,,non-diagnostic,practice for more than a year,21 years old,,,,,,
5099,,mental disorders;|planned pregnancy,rad51c,,hospitalization,suburethral sling,,,,poorly controlled headaches,in the past 3 months.|enrollment,> 2x uln||egfr < 45 ml/min/1.73 m^2||15,,,,,,
5100,,neurological disease;|15,regional department,,serum zinc concentration,drugs.|pathologically suggested,,,,prolonged use,3 times per week,above risk of falls,,,,,,
5101,,exclusion for,glucagon,,body mass index (bmi) ≧,professional dental cleanings,,,,3rd edition).|experienced long lasting and frequent,for 1 month,≥18 years.|at least,,,,,,
5102,,orthopedic infection,antibiotics medication,,ast)(serum glutamic-oxaloacetic transaminase [sgot],tb treatment,,,,non-cardiac causes,within last 2 weeks)|creatinine,<0.6|life expectancy,,,,,,
5103,,test.|good quality,smartphone,,hiv-1 infection|age,cumulative doxorubicin,,,,adequately reversed,after stable treatment,<30%,,,,,,
5104,,bowel disease|childhood functional abdominal pain,sustained-release topical contraceptives,,modified esd technique,self-test themselves,,,,intratumoral,during the conduct of this trial until the end of treatment visit|participants,>= 1500/ul|creatinine clearance,,,,,,
5105,,subretinal fluid (srf),inhaled antibiotic,,participate|bmi,tpa of evt)|patient,,,,great vessel stenosis,in the last 6 months|other,score of 20 to 28 (inclusive),,,,,,
5106,,central pathology panel,β-adrenergic receptor blockers|patients,,recist version 1.1|have adequate organ function|cardiac function test,optimal medical management.|active coronary artery disease,,,,investigator.|known,over 12 months,less than 6 times the drug,,,,,,
5107,,parkinson symptoms,surgeons,,serum alkaline phosphatase level,tumor histopathology,,,,ics doses,in the prior 3 months;|have,≥3 mmol/l,,,,,,
5108,,bppv of,contrast agents;|severe renal,,lansky performance level,hospitalisation|opposition expressed for participation in the study,,,,epithelial ovarian-,within 28 days to sub-study randomization,stage iv,,,,,,
5109,,magnesium,steroid medications|with/,,68ga-psma suvmax,abdominal surgery|patients,,,,connective tissue disorders,in the 2 weeks before presentation,<5 red,,,,,,
5110,,cardiac disease.|liver,psychotropic drugs,,renal function test results,psychosocial intervention,,,,narrow-angle glaucoma.|history,within 12 months prior to the first dosing day.|current enrolment,18 - 65 years|bmi,,,,,,
5111,,hypersensitivity reactions,thymoglobulin,,liver diseases|history,preoperative gastroscopy|revision surgery,,,,home-based,within 3 months before screening;||healthy,19~55 years,,,,,,
5112,,sbp>140/90 mmhg,antipruritus medication,,random plasma glucose,radioactive isotope therapy,,,,difficult|acute,during the study period and within 6 months of stopping treatment,scores <2;|radiographic examination reveal focal pancreatic lesions;|no,,,,,,
5113,,hcv,influenza vaccines,,word score,amphotericin)|critical preoperative status,,,,second-generation androgen receptor (ar) inhibitors,for at least 3 months before first scheduled study drug administration,≥ 20 mg/dl;|those,,,,,,
5114,,brain-only,il-1 inhibitors,,plt,core biopsy.|tumor lesion,,,,executive,at the time of provisional registration||patients,between 18.5-23.9 kg/m2;|fecal,,,,,,
5115,,respiratory distress,consume food products,,gestational age ≥37 weeks|birthweight,primary immunization,,,,increased,within 2 weeks before enrollment|ongoing,88-92%.|need,,,,,,
5116,,periocular infections,anti-pd-1 antibody,,aspartate aminotransferase(ast,birth control,,,,immunocompromised,within the last 2 weeks.|neurological or psychiatric diagnoses,≥ 30 cycles.min-1,,,,,,
5117,,enzootic,campath®,,echocardiogram|absolute lymphocyte count,intraperitoneal therapy,,,,great arteries,at the time of surgery.|additional handicaps,18-90 years,,,,,,
5118,,chronic stable angina)|>18,alpha-adrenergic antagonists|patients,,child pugh score,physical exam should,,,,region.|acute,within 8 weeks prior to the tuberculosis test performed,>= 50 ml/min/1.73m^2 73m^2,,,,,,
5119,,right heart doppler ultrasound,section,,peripheral blood stem cell,complete knee joint replacement,,,,low output colo-cutaneous fistula,at least 8,>64 years,,,,,,
5120,,mixed hepatocellular carcinoma,antibiotic receipt,,approximated,malabsorption syndrome|had surgery,,,,rome iv criteria for ibs,in the past 90 days,below 70|currently taking,,,,,,
5121,,retinal laser photocoagulation,prescription,,bone marrow function.|willingness,head or neck surgery,,,,hma monotherapy,after the tmg study;|planned thymectomy,20% of the total body surface,,,,,,
5122,,end stage chronic illness,withn,,total bilirubin (tbili),coronary bypass surgery,,,,non-ischemic heart disease,before surgery|appropriate for active surveillance,≤ 3x the upper limit of normal (uln),,,,,,
5123,,abnormal result of physical examination,materials in,,fast,saint quentin hospital||,,,,stroke|having,up to 4 weeks prior to study inclusion,<24.9|are pregnant,,,,,,
5124,,symptoms thereof,physiologic steroids,,qtcf prolongation,voiding dysfunctions|underwent surgery,,,,local,during the 3 months prior to the screening visit.|has received another new,>12 wk,,,,,,
5125,,thyroid eye disease||,pnh,,rna pcr-positive,160mmhg|renal biopsy,,,,etc.|history of receiving,for at least 7 days,≥ 20 kg/m2|negative,,,,,,
5126,,aids-related illnesses,personal tablet,,apnea-hypopnea index (ahi),outpatient surgery unit,,,,varicella zoster,three months before the study|pumpkin seed,22 and below,,,,,,
5127,,congenital mullerian duct anomaly,disulfiram,,cognitive behavioral therapy).|individuals,maintenance ect,,,,icd-10: d50-d89,within 2 weeks of study enrollment,between 9 and 13 years,,,,,,
5128,,disease.||tumor-related symptoms,prolonged antibiotic-therapy,,mda strategy,digital subtraction angiography,,,,dsm-v,within the normal reference range,less than 12 months;|abnormalities,,,,,,
5129,,moderate dementia,parpi,,positive score,previous treatment,,,,sbt);||,within 3 years before the first dose,> 400 mg/dl,,,,,,
5130,,vitreous degeneration,xray,,predicted survival,pathological tissues,,,,pd-l1 in consolidation,within 3 weeks before first dose of study drug,above 400 mg/ml,,,,,,
5131,,gastrointestinal bleeding.|patient,cyclopentolate,,visit.|systolic blood pressure,intestinal ulcers;|blood,,,,screening.|no,at least 4 months prior to check-in to the study site,> 2 ng/ml.|postoperative,,,,,,
5132,,sweating disorders,nimodipine,,acneiform rash iga scales,situational prophylaxis,,,,rrt-pcr,for at least 14 days prior to first dose of study,score of 4 ≥ on item,,,,,,
5133,,eecp system,adhd medications,,late preterm period,daily morphine milligram equivalents,,,,relapsing remitting,at any time from the screening to the first administration,"> 1,500/mcl",,,,,,
5134,,cd20+,"nicotine addiction),|regular treatment",,above|unilateral trans-tibial amputees|ambulate,t cell,,,,sudden,within 14 days of the initiation of the ip|active,between 0 months and 18 years,,,,,,
5135,,included.||remarks:||autism spectrum disorder siblings,riluzole,,neutrophils,sterilization surgery,,,,over-the-counter drugs,within 8 weeks prior to dosing.|hemoglobin value,less than 3 months;|participated,,,,,,
5136,,distal extension maxillary ridge,imipenem,,ppms,vitamin d supplements,,,,cruciate ligament reconstruction,within 4 weeks prior to enrollment|previously,18 to 85 years,,,,,,
5137,,visibility,immune deficiency|chronic fungal,,sexual health inventory,transparent dressing adhesives|palliative care,,,,lasting 30 minutes,in the past 5 years|uncontrolled,< 2.0 mm,,,,,,
5138,,colitis ulcerosa,components of rd2 ver.02 including calcium gluconate,,modified ashworth scale|able to follow verbal instructions|able to stand unassisted,stable treatment regimen,,,,drug-coated stent,within 24 h,≥ 0.05 µmol/l,,,,,,
5139,,femoral neck bmd.||,live attenuated vaccination,,intact pth,subcutaneous biotherapy,,,,mad stage,after 2 weeks of wash out,greater than 2%|students,,,,,,
5140,,coagulation defects|patients,fludarabine,,forced expiratory volume at one second /predicting value,peritoneal dialysis,,,,in the maxillary anterior esthetic zone,within the preceding 4 weeks,>5 minutes,,,,,,
5141,,level of pain,cotinine,,ca153 carbohydrate antigen,enteral medications,,,,multidisciplinary tumor board.|medically,at the time of consent.|histologically confirmed,1.5 times higher than normal values,,,,,,
5142,,frozen plasma,antiplatelet therapy|thrombophilia|active cancer|active autoimmune disease|liver disease,,lens opacities classification system (locs),massachusetts general hospital antidepressant treatment response questionnaire (mgh-atrq),,,,unknown cause.||any,within the previous 12 months)|experiencing,<18 year,,,,,,
5143,,carcinoma in situ of the cervix;|the,iud contraception.|patients,,ast≦2.5uln,screening|qtc,,,,medicinal consumption of psychoactive drugs.|3 consecutive vrise,for 6 weeks prior to visit,greater than or equal to 50 kg,,,,,,
5144,,recreational drug use|pregnant,outside the united states|participated,,total corneal,standard of care external beam radiation therapy,,,,at screening|known,medical history to be,greater than 3 times normal,,,,,,
5145,,availability)||inclusion criteria:||1,"asthma,|took medications",,national institute for - - health and care excellence osteoarthritis,histological examination of the endoscopically resected,,,,non-atn aki,within the last 6 months|children,≥ 38℃,,,,,,
5146,,ocular rupture,obesity drugs,,sars-cov2 test,implant measures,,,,st-segment,within 24 hours after enrolment in the study,40-80 years,,,,,,
5147,,drug abuse;|excessive smoking,platelet aggregation inhibitors,,marsh,oral contraceptive pills,,,,h. pylori related,at the time of first diagnosis,>18 years|have,,,,,,
5148,,blended,ergogenic supplements,,serum cr≤1.5×uln|activated,congenital infections|neonates,,,,immunoglobulin e (,in the past 3 years|known,> two times upper reference levels,,,,,,
5149,,ptsd|able,symmetrel®,,ii|informed consent||,radical nephroureterectomy,,,,supraphysiologic doses,before enrollment or c,90-139 mm hg,,,,,,
5150,,malignant thyroid disease,immunosuppressive/immunomodulating drugs,,urine drug screen test,hrd mutation status of patients.|the blood,,,,12-lead resting electrocardiogram (ecg).|any positive result on screening,more than 4 weeks after prosthesis,above the 'institutional upper limit of normal,,,,,,
5151,,good health meaning,histamine h2 receptor antagonists,,prosigna score,biochemical blood tests,,,,pain|self-reported,within 10 days before the first dosing day,less than 8.5 g/,,,,,,
5152,,cutaneous sccs,magnesium trisilicate.|contra-indications,,"modified folfox-4,6,7 (oxa",immunocompetent family members of the patient should not be vaccinated with the oral polio vaccine,,,,castration-resistant prostate cancer,prior to randomization.|participant,less than 10% of the lower limit of the normal,,,,,,
5153,,dietary supplement,live vaccine,,recist v1.1 criteria|ecog performance status,rest):||systolic blood pressure,,,,prenatal ultrasound|syndrome associated anomalies,within 7 days before the first dose of study treatment.|life expectancy,≥ 18 y.o.|neurosurgical removal of peripheral nerve tumor,,,,,,
5154,,life-threatening reactions,hormones,,vs,hma treatment,,,,retrospectively collected andv available data.||,within the 14 days prior and after the pdt|participants taking any photosensitizing drugs,">50 mg/dl,|peripheral artery disease",,,,,,
5155,,milk protein allergy|other food allergy|special diet,topical ophthalmic steroid,,body temperature ≥37.5℃,injection phase||participants,,,,torsade,at the time of signing informed consent.||patients,6-12 years|documented community diagnosis,,,,,,
5156,,myocardial infarction event,vaccine candidate,,ccs iv angina|stemi,health records||•,,,,dnr order|non-ambulatory,within 4 weeks before study initiation.|diarrhea,< 2.5,,,,,,
5157,,retroperitoneal tumors,buprenorphine/opioids,,alanine transaminase,exertion|stable treatment regimen x,,,,tricuspid valve,during the screening process,at least 21 days,,,,,,
5158,,epistaxis|immunodeficiency,study drug treatment,,platelets,monkeypox,,,,non-hodgkin's lymphoma(nhl,within the past 6 months|renal insufficiency,>= 30 ml/min to < 45 ml/min,,,,,,
5159,,kidney transplantation;|previous allergy,gabapentinoids,,arent/guardian,vapor ablation,,,,imp;|hbv-rna,within 14 days prior to the start of study intervention.|able,6.4% ≥ hba1c,,,,,,
5160,,glomerular hematuria,neuropsychiatric,,uln;serum creatinine,consolidation,,,,maxillary,within 48 hours before dosing until the last blood draw,"creatinin ≤ 1,5x upper limit of normal",,,,,,
5161,,cancer histories,niuhuang,,asas classification criteria,main stem,,,,idiopathic,for at least 12 weeks prior to screening.||c,≥40 mg,,,,,,
5162,,large hematoma,pains,,soc rt,excisional biopsy,,,,paley type,within the treatment area plus,"100,000 /l|hemoglobin (",,,,,,
5163,,skin biopsy|diagnosis,excipients of,,recist v1.1).|progress,local anesthesia treatment,,,,pure growth,within the past 3 months|lack,2 to 5 years,,,,,,
5164,,cauda equina syndrome,human blood products,,partial thrombin time (aptt) ≤1.5×uln;|thyroid function,adolescents of the selected classes of the participating schools,,,,ocular toxicity,in the last 2 years|history,< 2000iu/ml,,,,,,
5165,,transaortic flow velocity,tremelimumab,,complicates test,ct angiography (cta),,,,very high-risk,more than 400 ml,≤ 50 years,,,,,,
5166,,lymphatic drainage,brentuximab,,screening.||body mass index,full physical examination,,,,hormone use,post-thrombotic axial deep,≥ 18 years|informed consent (ic),,,,,,
5167,,corneal ectasia,phenprocoumon,,left ventricular ejection fraction≤40%),world health organization criteria.|have an hba1c of,,,,self-management,within 72 hours of the intended,500 mg/dl.|the,,,,,,
5168,,adenocarcinoma of the prostate|undergoing radical prostatectomy,reamberin,,tfc,resulted,,,,implantation surgery|absence of residual hearing shown,within 3 months after signing the informed consent form,18-65 years||,,,,,,
5169,,smart phone||,anti-pd-1/anti-pd-l1 antibodies||eligibility criteria,,1.||adequate bone marrow function,treatment-related edema,,,,intrinsic red blood cell defect,within 3 months before informed,from 18 to 75.|thoracic esophageal squamous cell carcinoma,,,,,,
5170,,hematologic malignancy|diagnosis,lvad,,nyha class iv heart,circumcision).|fetal opioid exposure.|administration of sedating agents,,,,high grade cervical,≥12 weeks after completion of hcv therapy,53-86,,,,,,
5171,,spine pathologies,distant,,international federation of obstetrics,temporary resident,,,,older|history,3 months before surgical periodontal treatment,< 9.0 g/dl,,,,,,
5172,,seroconversion.||patients,etc.)|had oral,,transderm-nitro,diet|persons,,,,index date.|participants,within 24~48h have progressed significantly,≥ 18%,,,,,,
5173,,hematologic disease,baff)-targeting agents,,detectable plasma hcv,papulopustular rosacea)|facial telangiectasia|poikiloderma|seborrheic keratosis|melasma,,,,synaptophysin)|prostate,within the next 18 months|another household member,more than or equals to 6.1%,,,,,,
5174,,hair,morphine milligram,,parathyroid hormone levels- 10,smartphone||key,,,,articles l. 3212-1 and l. 3213-1 of the public health code,6 months after the end of the study,above the,,,,,,
5175,,chronic chest infection,bictegravir,,mean sitting dbp,foot surgery before the clinical evaluation|local spasticy treatment,,,,index knee|previous,within 6 months before screening.|unstable angina,> 365 pg/ml,,,,,,
5176,,lower abdominal pain.|group,anti-diarrheal agents,,spga score,tumor related,,,,low dose oral,for 2.5 months following,<65 years;|refuse,,,,,,
5177,,consumption of alcohol,long-acting intraocular steroids,,glomerular filtration rate)|familial hypercholesterolemia,c|pregnancy|antibiotic treatment,,,,smokers,at the screening and baseline visits.|average,≤ 2.5 × uln|bilirubin ≤ 1.5 × uln,,,,,,
5178,,autologous cancer cell product,nalbuphine,,dorsal root ganglion stimulator|device,neuraxial anesthesia|history of,,,,rome iv criteria (exclusion of constipation,within 1 year,< 27%,,,,,,
5179,,congenital spinal deformity,local anesthetic drug|can pass,,ranges,annual ophthalmic exam,,,,related to underlying,at least 2 weeks prior to the screening,1 msm||18 years,,,,,,
5180,,anterior permanent,cholinergic receptor antagonists,,physical activity|log,dose escalation stage,,,,iliac arteries disease,within 15 minutes before,≥5.0,,,,,,
5181,,chronic bleeding diathesis,diagnostic sodium fluorescein used in the study.|self-reports,,prothrombin time (inr),total mastectomy,,,,≥grade,after remission,under 18|person under guardianship,,,,,,
5182,,reduced joint function,droxidopa,,absolute eosinophil count,sitting position,,,,third dose,during the last 3 months|be pregnant,1%≤af burden≤99%,,,,,,
5183,,allergic conditions,strong analgesics,,serum hcg test,transcatheter therapy.|echocardiography suggested intracardiac thrombus,,,,despite conservative,during one month prior to inclusion.|the use,120 msec,,,,,,
5184,,co-morbid medical condition,opium,,glomerular filtration rate ≤50 ml/min/1.73m2,arthrocentesis treatment,,,,periodontal furcation involvement,within 30 days of study enrollment.|13,18 to 65 years|ultra,,,,,,
5185,,nephew handheld device illuminates,monoclonal antibody immunotherapy drugs,,hepatitis c virus antibody (hcv ab),hip surgery,,,,pharmacological effects,within 2 weeks prior to first dose of study treatment,4 or less,,,,,,
5186,,pancreatic cystic,bupivacaine allergy|fetal distress,,blood transfusions,vegetarian,,,,nephrotoxic,during hospitalization,< 4000 µl,,,,,,
5187,,etc.).||general conditions:||has,egfr<45,,kidney function,mr angiography,,,,vasodilators,within the last 10 years|on hormone therapy|has,>5mm,,,,,,
5188,,scoring,margins,,uln).|absolute neutrophil count (,lymph node metastases|availability,,,,full doses,within one month of study treatment|life expectancy,≤2|adequate,,,,,,
5189,,third hospital chongli hospital;|test,vaginal antibiotics,,short time period,agammaglobulinemiaeg,,,,material,last offered|commit to continue annual reviews,>=100 mg/dl,,,,,,
5190,,venous thromboembolism event,definity ®,,nih no,treatment for,,,,low grade dysplasia,during the previous 6 months,> 35 ml/min)||,,,,,,
5191,,regular pain,antibody-drug conjugates (adcs) containing,,dlco,investigative medicinal product (,,,,epstein-barr nuclear antigen (ebna,within 6 months prior to initial medication,greater than 150 minutes per week,,,,,,
5192,,radiation phobia,type vs.,,lower kidney function values,complete sexual abstinence,,,,post-traumatic amnesia,index of,≥ 70%.|life expectancy,,,,,,
5193,,impaired balance,direct oral anticoagulants,,kidney|human immunodeficiency virus,extract bile,,,,mild to moderate uncontrolled,for at least 8 doses,less than 15 ml/min per 1.73m2.|patient,,,,,,
5194,,intentional communication behaviors,low molecular weight heparins,,trauma|life expectancy,bone repercussions,,,,apartment unit,after 16 to 24 weeks of first-line,≥75 × 109/l|serum bilirubin,,,,,,
5195,,symptoms indicating,medicinal product,,hepatitis b virus (hbv) surface antigen (hbsag) obtained,tobacco cessation medications,,,,extra-abdominal,"over 18,|informed consent",class for 1 to 2,,,,,,
5196,,hepatic steatosis,local contact,,child grade b,stem cell transplant.|recipients of blood transfusion,,,,hav,at least 1 day before 2 weeks after the first day of their lmp,+-20|anisometropia ≤ 1.50 d|myopia evolution,,,,,,
5197,,immunosuppression.|myocardial infarction,medications that might affect bone metabolism,,addiction,ascvd,,,,preclude adequate absorption of day101.|patient,within 4 weeks prior to randomisation,greater than or equal to 60mg,,,,,,
5198,,colorectal cancer;|complete resection,antidepressant medication,,homocysteine level,allogenic stem-cell transplantation||current use of,,,,igf-1,for the duration of the study.|are insulin naive||exceptions:||short-term,>= 160 mmhg,,,,,,
5199,,new hemorrhage,ppis,,gestational age before abortion,postoperative mri,,,,middle schools.|grade,at screening without signs,between 8-55 years,,,,,,
5200,,infectious serum markers of hiv,program|pregnant,,european society of cardiology/european respiratory society (esc/esr,functional oral intake scale (fois),,,,could justify the syndrome,fluoroquinolones;|within 3 months before screening,<13 g/dl,,,,,,
5201,,lack of availability. gdmt,regional policy makers,,mdd,liver transplantation;known,,,,included.||age group,prior to or,≥ 90×10^9/l,,,,,,
5202,,dental category.|involved teeth,hemorrhoids,,lymphocyte count,medical surgeries,,,,assisted laparoscopic,within 14 days before randomisation.||,<1 year prior to signing informed consent,,,,,,
5203,,.|active pulmonary tuberculosis (tb),conductive hydrogels,,pulse oximetry measurements,radiographic,,,,self-report)||,within 8 years|5.informed consent,18-70 years|a,,,,,,
5204,,"diseases,|inflammatory bowel",medications that could interfere with orthodontic tooth movement.|history of trauma,,moya-moya disease,world health organization classification,,,,listed in exclusion criteria.||does not,within 6 months from the time of signing the consent form until the completion of the administration of this study.|subjects,findings,,,,,,
5205,,good health on,lenatinib,,partial thromboplastin time（aptt）,coronary revascularisation procedure,,,,months|histological,more than five days since the development,more than 12 weeks|7、transplant,,,,,,
5206,,recurrent immune diseases,sunitinib,,eu,endovascular revascularization|organ transplantation,,,,suitable to join the study;|10.hiv infection;|11.any situation that the researchers,for 6 months prior to dosing.|concomitant treatment,< 35,,,,,,
5207,,macrocephaly,3rd degree atrioventricular (av) block.|bradycardia,,partial thrombin time (aptt),requires laparotomy,,,,treated accordingly,within 4 weeks (28 days,> 18|2),,,,,,
5208,,lymphovascular infiltration,cytotoxic chemotherapy drugs,,please allow,oral treatment,,,,cognitively,for the first time|at least 18 years,0-1.|resolved,,,,,,
5209,,protein s deficiency,examination indicators,,etc.|body mass index (bmi),meaning,,,,first degree,for at least 3 months|patient,98%,,,,,,
5210,,type i diabetes,stereotactic body radiotherapy (sbrt,,spherical equivalent using dry manifest refraction,invasive testing (amniocentesis,,,,injection area,at the time of enrollment.||exclusion criteria,< 0.1 decimals,,,,,,
5211,,non-cardiac cause,amide type local,,pittsburgh sleep quality scale|a scale score,assisted ventilation requirement|respiratory rate,,,,platinum resistant,throughout the study period apart from,<40 kg/m2||,,,,,,
5212,,ctcae grade,5 minutes,,best corrected,completed vaccination,,,,study|unable to communicate,prior to day 0,≤ 2 times upper limit of normal (uln),,,,,,
5213,,generally healthy,ultrasound contrast,,satisfied.||adequate organ function,preoperative imaging,,,,intra-abdominal tumor,within 1 year after receiving,<50 years).||withdrawal criteria:||withdrawal,,,,,,
5214,,therapies)|contra-indications,age|newly,,nutrient absorption in children,mechanically ventilated,,,,study.||exclusion criteria||glaucoma,for at least 2 weeks prior to registration,>40%.|patients must,,,,,,
5215,,allergic disposition,qualitative platelet defect,,veterans affairs healthcare|if,oral contraceptive pills|patients,,,,severity of the seizure,for at least 1 month after the last study drug administration,≥18 years.|naïve,,,,,,
5216,,visuospatial memory)|cognitive impairment,anti-anxiety drugs,,cd4 t cell count,ip on day 1.|total serum bilirubin,,,,absolute b lymphocyte counts,within past 6 months)|uncontrolled,>10%-12%.||,,,,,,
5217,,ventricular tachycardia,peptide 1 agonist,,nasal spray treatment.|participants,reduction of anterior shoulder dislocation,,,,range|cognitive abilities,at baseline and referred,participants 60 years and older,,,,,,
5218,,t1 lesions,athlete:||physical disability.|participate,,vasospastic- angina|heart failure,steroid hormones,,,,non-hormonal contraception,at the time of enrollment|have,2-7,,,,,,
5219,,systemic treatment|conditions,dmd,,fish +,endovaginal ultrasound,,,,old|resectable,in the past two years|currently,above 18 years|undergoing evaluation for,,,,,,
5220,,coercion,anticoagulation/antiplatelet medication|history,,wood units||,restrictive ventilatory,,,,cardiologic,during or after this,>1.5 times uln.|lipase,,,,,,
5221,,chronic obstructive pulmonary disease);|patients,oral antipsychotic medication daily,,modified rankin scale score,renal replacement therapy|portal,,,,lv endocardial,prior to the first dosing,> 5 × uln - 10 × uln,,,,,,
5222,,atherosclerotic plaque risk factor,lumefantrine|receipt,,treatment completion|age,lumbar spinal,,,,sinuses|current,between 2 to 4 weeks,less than 30%,,,,,,
5223,,axillary response,lactic acid bacteria,,least 50 kg|qt interval,bilateral ovariectomy surgery.|patients,,,,strabismus surgery;|history of cervical,within the subject participation period,between 120-169 mmhg|stable dose of medication,,,,,,
5224,,heart failure)|must report,pi3kα inhibitor treatment,,detectable hepatitis b deoxyribonucleic acid (dna),abdominopelvic imaging + technetium bone scan,,,,leukemia.|uncontrolled,within 1 month prior to initiation of investigational procedure,">5,5 mmol/l)|major adverse cardiovascular event",,,,,,
5225,,tentorial sdh|hypersensitivity,plasma exchange,,ctd,endovascular thrombectomy (,,,,t10,for 30 days after the last dose of study drug,≥ 1.0,,,,,,
5226,,lumbar radiculopathy,target medication,,european association of urology intermediate-,regular exercise regimens,,,,hypogonadal,for 5 months after the last dose of lenalidomide,functional class ii-iii/iv,,,,,,
5227,,idiopathic angioedema,eye||ocular health:||ocular drug toxicity,,stroke unit||,intercostal nerve cryoablation,,,,stage iii-iv,after swim,>88%,,,,,,
5228,,"atopic dermatitis""",immune-modifying therapy,,calcification angle,12-fluid ounce,,,,fusion proteins|known prior,within 14 days prior to randomization.)|use of any investigational product,≤ 100x10^9/l.|hemoglobin < 9 g/dl.|patients,,,,,,
5229,,mucosal,parp inhibitors,,hepatitis b core antibodies.|history,chronic knee,,,,cannabis|self-reported,within the networks,16 years,,,,,,
5230,,endolymphatic hydrops)|lesion,folfirinox,,immunetherapy|tumor size,wall thickness,,,,urethra,within three months before taking the research drug;|take,19 to 75 years,,,,,,
5231,,delayed cord clamping.||no time,more)|platelet antiaggregants,,stage t1,coordination,,,,organ-related,within 12 months before screening|arrhythmias,≥ 3 months.|subjects,,,,,,
5232,,signs of polyneuropathy,prokinetic agents,,national taiwan university hospital.||exclusion criteria： our exclusion criteria,surgical emphysema.|mechanical ventilation,,,,stable enough,at the pre-study visit.|has been committed,<90 per,,,,,,
5233,,mean pulmonary vascular resistance,gaq,,neuroinhibitory,vascular perfusion of the target limb,,,,meeting the,at least three wsls,more than 30 kg/m^2;|myelosuppression induced,,,,,,
5234,,ct4b(non-curatively-resectable,pretreatment drugs,,ambulatory levels of,transvaginal ultrasound examination.|at least 18 years of age when signing the informed consent.||adequate renal,,,,natural menses,within the past 12 months|had,< 80 years|person able to understand simple commands,,,,,,
5235,,plwd,topical medications,,alanin amino-transaminase (alat),soc mri,,,,non-contrast ct,during the last 30 days prior to informed,> 190 mg/dl||ix,,,,,,
5236,,sad,pmf,,hypertension bp,cesarean,,,,locally treated,prior to infection,40-80,,,,,,
5237,,bipolar related disorders,anti-allergy,,minute walk test and mlhf quality of life questionnaire,pelvic physiotherapy,,,,difficile,at 3 hours,less than 2 months,,,,,,
5238,,meningococcal disease,ipf,,urologic procedures,structured exercise,,,,primary vv of the ll complaining of leg pain cosmetic disfigurement,within 2 weeks of injury.||,over 250 pounds|pass,,,,,,
5239,,distant corrected visual,cannabinoids/marijuana);|the,,detectable viral hbv load,cell transplant,,,,full year of life,within 24 hours before surgery (radiocontrast agents,≥ 18 years old|admission to icu,,,,,,
5240,,joint dislocation,systemic anti-infective therapy,,antihyperlipidemic medication usage|presence,spinal surgery,,,,catheter-based intervention,within the two weeks prior to registration,> 280 db/m,,,,,,
5241,,sarc,local anesthetics|patients,,systolic pressure,cumulative radiation,,,,non-hepatic origin)|subject,during sexual intercourse|women,3-4 l,,,,,,
5242,,renal replacement therapy.|anyone,hormone receptor,,ecg lead placement||,flow oxygen therapy,,,,old|chronic,during the six months of the trial.||history fits the definition of migraine:||have,less than two years,,,,,,
5243,,.|acute illness,myeloproliferative,,mass general brigham,churg-strauss,,,,site enrolling the patient on study,in the next year;|history of,≥ 60%|for,,,,,,
5244,,criteria of the site's screening,small molecules,,moud).|body mass index,β-blockers,,,,early phase clinical,within 6 months prior to signing,stable,,,,,,
5245,,substance use|hiv,musculoskeletal injuries;|athletes,,alpha-lactalbumin)|substance abuse,spine revision surgery,,,,low-grade dysplasia,after week 16 until the end of the study,at least 2 weeks to judge,,,,,,
5246,,localized and not,immediate therapy|rectal,,antibodies in sera,dose-escalation stage,,,,highly effective contraceptive measure [defined,within four (4) weeks prior to initial dosing,≥ 20 lbs|hba1c ≤ 10.5%|for,,,,,,
5247,,liver elasticity tests,mipss7021,,longest diameter ≥1.5 cm;||5,urologic surgery,,,,early,previous history|claustrophobic|blindness|history of mental illness|patients in strict isolation,2-21 years|body,,,,,,
5248,,exhaustion,great vessel,,hepatic function|total bilirubin,capsule|diagnostic endoscopy,,,,or||steroid-dependent,at the time of registration|chronic obstructive pulmonary disease exacerbation,maximum diameter of a,,,,,,
5249,,mimic|cerebral embolism,hbs antibody,,body mass index,kinase inhibitor therapy,,,,clinically abnormal,in last 60 days before the decision to start infliximab|(2,90-95%,,,,,,
5250,,gout attack,anti-osteoporosis medications,,reduced ejection fraction,successive screening measures|any clinically important abnormalities,,,,iv||exercise,within a minimum of 4 weeks prior to master study registration,≥ 7|absence,,,,,,
5251,,changes in biomarkers,mizoribine,,bilateral lla,immunotherapy treatment period,,,,preclude cognitive testing,one month prior to the study,<35mm,,,,,,
5252,,dialysis|cardiac arrest|cardiogenic shock,oral ketoconazole,,lactation;|nyha function class≥ ii;|patient,diagnostic x-rays,,,,ehlers-danlos syndrome);|previous,during the first two months days from study vaccination.|abnormal laboratory test results,>= 50%.||,,,,,,
5253,,acute ischemic stroke|neurological deficit,cycles,,axumin pet/ct scans,hospice,,,,at feet,within <6 months from completion of platinum-based therapy,< 25 g/l||others:||patients,,,,,,
5254,,pd.|a diagnosis,periocular corticosteroid injections,,tka,non-live vaccine,,,,palbociclib monotherapy,any time prior to study,< 7,,,,,,
5255,,criteria.|surgically resectable,systemic steroid therapy,,kidney functional,volume of blood,,,,mild to moderate anxiety,14 days prior to the start of the treatment period,50-66% of the screened population|non-smoking,,,,,,
5256,,peripheral ischemia,study medication,,cni,carotid artery stenosis|unresolved toxicity (,,,,parenteral,at the time of screening to undergo chemotherapy,day 1 &15).|evidence,,,,,,
5257,,higher||,contrast media).|participate in other clinical trials,,midwives,standard insulin treatment,,,,non-squamous,at least two times a day,employee,,,,,,
5258,,mechanical ventilation||6,using medications,,cns specific treatment,spinal anesthesia|contraindication,,,,grade c.||other types of cirrhosis,in the next six months.|other conditions,> 2.07,,,,,,
5259,,behavioural disorders,local radiotherapy;|diseases,,polyp removal.|ct-verified stenosis,functional recovery,,,,statin related,within 14 days prior to first study drug administration,less than (<) 1% per year,,,,,,
5260,,knee extension loss,sedative drugs;|used antiemetic drugs,,blood glucose stable,atrial ﬁbrillation ablation,,,,unclear etiology,at time of study enrollment,20-25|bmi,,,,,,
5261,,impending crisis,platelet-raising drugs,,cardiac function|oxygen saturation,range.|irreversible surgical sterilization recorded,,,,elbow,at the time of inclusion.|no,score < 1.9||,,,,,,
5262,,ich,tofacitinid,,days;|total bilirubin,abdominal ct scan,,,,potentially obstructive calcific masses,for the first phase of the study;|a first-degree relative,less than 21at time of screening|rectal,,,,,,
5263,,good quality,components of venetoclax,,pregnancy test result.||for,surgical amputation|patients,,,,needed.|mandatory baseline,in the last 14 days,1 cm to the border,,,,,,
5264,,localized infections,antipyretic drugs,,neutrophile granulocyte count,refractive surgical procedures,,,,non-,within the lesion,18 years old and above,,,,,,
5265,,uremia,cyp p450 2c8 inducers,,american society of anesthesiologists physical status classification,bilateral tubal ligation/occlusion,,,,contrast-enhanced,last 3 months prior to study start (date of treatment,≥ 470ms,,,,,,
5266,,exon-skipping therapy,antiplatelet agents.|able to communicate adequately,,lvmi,graft-versus-host disease|known,,,,secondary objectives,for the duration of protocol treatment.||,≤ 3 months)；|already,,,,,,
5267,,hemorrhagic tendency,glycoprotein iib/iiia inhibitors,,old|patients lacking capacity,blood cultures,,,,discharge occurs before,within 180 days before screening,at least 100×10⁹ per l,,,,,,
5268,,intestinal hemorrhage,mmr vaccines,,amphotericin,ct coronary angiography,,,,diagnostic criteria of noh,for > 1 year|on using closed-loop hybrid insulin,equal or more than 6,,,,,,
5269,,mild regurgitation,mineralocorticoid antagonist,,thyroid diseases|hepatitis,anticoagulant therapy|nasal deformity|pregnancy,,,,hard palate,at the time of screening.|active covid-19 infection,>10mg/day,,,,,,
5270,,pleural fluid,headphones,,hepatitis b dna,transcranial magnetic stimulation adult safety screen,,,,self-injury,prior to any screening,40 years,,,,,,
5271,,item,anti-angiogenic targeted,,residual lymph node involvement regardless,standard first-line,,,,complete remission,within 5 minutes).|in the opinion of the investigator,score of 2 or 3,,,,,,
5272,,"disorder,|metabolic alcaloosis",local center.|recipient,,alberta stroke program early computed tomography,ebus,,,,chemically related to study treatment,continue up to the day prior to study treatment initiation|participants must,≥12 weeks;||has sufficient organ,,,,,,
5273,,organic mental disorder,ingenol mebutate,,insomnia severity index)|fluent,transfusion of,,,,spc|unable to read,more than 7 days prior to treatment,≥ 100000/µ l,,,,,,
5274,,metabolic bone diseases,nprs|mouth,,recist v1.1 (,open radical retropubic prostatectomy (rrp),,,,depo-provera,for two consecutive times with,> 5uln,,,,,,
5275,,organic problems,component of cell products.|anyone,,blood pressure,concomitant posterior repair,,,,wide-field radiation,after 1/1/2020||,=< 1.5 × upper normal limit (uln),,,,,,
5276,,to:||hiv-infected,vitiligo,,kidney function tests|patients,nonstudy anticancer therapy,,,,pure alcohol per day,for at least 4 weeks after completion of the definitive therapy,≤ 35||,,,,,,
5277,,renal pelvis,allowed.|coumadin,,household level exclusion criteria,vaccination,,,,child|≥18-year-old parent|internet,within 6 months before randomization|treatment in another interventional clinical study,greater than 1.5-fold the uln,,,,,,
5278,,liver diseases (aasld),reserpine,,gestational age).|rupture,magnetic resonance angiography,,,,american college of sports medicine (acsm),within 1 year prior to the trial,> = level 2,,,,,,
5279,,golodirsen,gpa,,measurement instructions|indication for,cutaneous vagus nerve stimulation,,,,site of sensor implantation.|plan to undergo,at the time of randomisation,>440msec in,,,,,,
5280,,athletes:||regular recreational activity,trial-related assessments,,condition|positive c-ssrs result|vegan|possibility,exercise bike||,,,,medically prescribed,at least 3 days in the past year they,>= 1,,,,,,
5281,,somatic disease|,medication malignancy acute,,morphologic systemic left,laser surgery,,,,arr for another proband,more than two thirds,1-month,,,,,,
5282,,homicidal|actively,ci632,,norelgestromin/ethinylestradiol-releasing transdermal system,taf,,,,researcher thinks are,for at least 3 months after last dose of study drug(s).|male,> 22/min;|ct pattern typical,,,,,,
5283,,cardiac disease,men2,,medications)|left ventricular ejection fraction,triphasic computed tomography (ct),,,,insulin|uncontrolled intercurrent illness,at least 3 or more,4.2.5 or appendix ii,,,,,,
5284,,liver kidney,polyethylene terephthalate (pet),,excretion,trialed standard therapy,,,,inked margins).||,within the last 6 months prior,greater than 18 years old,,,,,,
5285,,child being sick,component of the tiragolumab,,hepatitis c virus (hcv) antibodies or human immunodeficiency virus,pemetrexed combination chemotherapy,,,,poorly responsive,within 14 days before enrollment|patients,> 500 iu / ml,,,,,,
5286,,"oral intake,|on pain medications",traditional chinese medicine injection,,permanently surgically,total pelvic radiation therapy,,,,old).|scheduled,in the past 12 months.|bmi,≥50ml/min.|fertile,,,,,,
5287,,underlying illness,cathartics,,level of understanding sufficient,venous blood collection;|history,,,,killip iv)|on pressors,at least 4 weeks apart,<35g/l.|lymphocytes count,,,,,,
5288,,organ functions,oral hygiene incompatible,,serological pregnancy test,corneal dystrophy,,,,medically reliable,"after treatment, free of disease progression",>18 years)||,,,,,,
5289,,large scars,combination antiretroviral therapy,,national institute on alcohol abuse,fluid resuscitation,,,,low-risk drinking,within 14 days prior to the first dose of study drug|significant,<150 minutes/week,,,,,,
5290,,genital disorders,drugs used in general anesthesia|severe allergy,,liver function test [lft,ecg monitoring by implantable loop recorder (ilr),,,,genital area (,during the study.|botulinum toxin injection,≥50 and ≤ 90 mmhg|heart rate,,,,,,
5291,,countries,≤26.|mrs ≤1,,stoma patients)||,pathology suggested satellite foci,,,,distal intracranial large vessels,within past 3 months|history,>2.0×109/l,,,,,,
5292,,ocular symptoms,mras,,childhood autism rating scale,cervical fusion surgery|co-morbidity,,,,adequately controlled,in the previous 3 weeks|participation,<30 g/l;|preoperative,,,,,,
5293,,cns vasculitis,hormonal contraceptives|medication,,mullen scales,x-ray|subjects,,,,suitable for participating in this trial in opinion of the investigator.|subjects,"within 4 weeks of enrollment,|capacity for informed consent",less than 20,,,,,,
5294,,cognitive behavioral therapy,whole,,bmd,blood system,,,,pharmaceutical,within 1 year prior,=< 40% =< 12 months prior,,,,,,
5295,,migration of stones,anti-cd20 monoclonal antibody,,mgh,chemotherapy||good organ function,,,,primary site|patient,at the time of initiation of study treatment,≥ 18 willing and able to provide,,,,,,
5296,,streptococcus pneumonia,components of the,,breast feeding|bmi,neoadjuvant therapy|progression,,,,locally advanced/metastatic,> 6 months prior to enrollment|diagnosis,<20 ml/min/1.73m2|use,,,,,,
5297,,diastolic lv dysfunction,afebrile,,serum pregnancy test.|male,mediastinal mass syndrome|no,,,,residual invasive disease,for 6 months prior to enrollment,15 cm,,,,,,
5298,,heart associated conditions|changing physical activities,anti-tumor treatments,,bmcdi,vagal nerve stimulation,,,,alternative cause,for the last three months before recruitment|critical illness,> 1000ng/ml,,,,,,
5299,,cerebrovascular event,teratogenic,,ebv pcr test should,coronary cta(coronary computed tomography,,,,≥1 severe,within 3 months before,18 years or older admitted to the intensive care unit;|anticipated,,,,,,
5300,,thromboembolism,nicotine consumption,,secondary level,neuraxial block|allergy,,,,primary caretaker for their infant.|having a,within 6 months prior to screening.|other active,between 36 and 42 weeks' gestation|birthweight,,,,,,
5301,,congenital pneumonia,tcm,,sagittal discrepancy angle,congenital heart diseases.|fetal hydrops.|babies,,,,neovascular,within the last 12 months prior to screening.|the participant,more than 1.5 norms|karnofsky index,,,,,,
5302,,criteria.|liver tumors,pti,,mallampatti,sitting time,,,,might confound assessment of efficacy of the investigational supplements used in this study,at time of surgery|no prior treatment of the tumor,≤ 4 cm,,,,,,
5303,,sotos syndrome,imidazole antifungals,,nephro-vac,fresh tumor biopsy,,,,m2 morphology,within 30 days after end of trial;||medical history,score less than 3 scores;|metal,,,,,,
5304,,non-bone tumor lesion,asct,,human immunodeficiency virus antibody(hiv ab),medical monitor consultation,,,,between -0.75,during the past 8 weeks;|treatment,no less than 0.5 g/dl,,,,,,
5305,,exudative eczema,faster acting insulin aspart,,new york heart society (nyha) class≥ ii,dmd mutations,,,,non-english speaking|members,at the time of initial nsclc diagnosis|patient,<80,,,,,,
5306,,cerebrospinal spinal fluid (csf) evaluation,anti-hypertensive agents,,dsa,first-degree relative,,,,teriflunomide,at the time of signing of informed,<50 beats/minute,,,,,,
5307,,plvad device.|left ventricle rupture.|cardiac tamponade.|subject,single drug,,basal,first-line immunotherapy,,,,hormone injectables,within the screening period up to 3 months after the last dose and,residents.|greater than 18 years,,,,,,
5308,,chronic primary headache,cyclic neutropenia,,national high blood pressure education program working group on,uv session,,,,plasma-derived fix protein products;|the,for at least 3 months prior to the study|an ipga score,≤ 3xuln||individual who,,,,,,
5309,,tumor)|medical operability,t1d,,screening|serum hepcidin,blood cell transfusions,,,,ultraviolet a,at the time of study enrollment,45 ml 40% spirits,,,,,,
5310,,acute t lymphoblastic,anti-egfr monoclonal antibody,,psychiatric treatment.|be able to understand the requirements of the study,consulting ophthalmology,,,,planned,abdominal effusion.|presence of,exceeds 1.5 times the upper limit of the normal range,,,,,,
5311,,neurological disease|person,titanium cage implant,,tnm classification,bariatric laparoscopic surgery,,,,non-irradiated tumors,at investigator's,"between 8-10 points,|being",,,,,,
5312,,irritated bladder,cps,,future research||,allogenic haemopoietic stem cell transplantation.|patients should,,,,moderate-to-severe,within 2 months of the observational study;|medication dose changes,> 7 mmol/l,,,,,,
5313,,disease findings,central analgesics,,lactose intolerance||any condition,surgical repair of the rotator cuff tear,,,,proficient,after treatment),≥ 135 mg/dl,,,,,,
5314,,stevens johnson syndrome,bakuchiol,,weeks|wound area,postoperative corneal astigmatism ≤0.75d|mesopic pupil size,,,,flux,throughout the study period.||,/t2/flair/dwi sequences,,,,,,
5315,,preoperative glaucoma,drug used in experiment|inability to,,alanina aminotransferase (alt),healed surgical incision,,,,effective contraceptives,in the previous 6,≥ 9.|participants,,,,,,
5316,,major lung diseases,antithrombotic drug therapy,,peripheral blood hcv rna also,slit lamp exam,,,,mental disorders;||tumor related,at the study site)|as judged by the investigator,<18 years;|cardiogenic shock;|pregnancy,,,,,,
5317,,carnitine translocase deficiency,valproic acid,,unsatisfactory blood pressure control,stem cell transplant|recipient of,,,,intraventricular septal thickness,within 3 weeks prior to the first imp administration until post-study visit.|recent,> 11 mg/dl,,,,,,
5318,,aphasia|normal functional neuroimaging,semi-elective surgery,,m. abscessus complex-pd,treatment decisions.||exclusion,,,,folic acid,prior to,greater than equal to 115 grams per meter square (g⁄m^2 ),,,,,,
5319,,female;||•patients,nasal tube feeding|patients,,lansky,contraceptive requirements.||additional inclusion criteria - part b,,,,index date|individual level,since first symptoms|calculated glasgow-blatchford score,< 20mm,,,,,,
5320,,core biopsies,anti-cancer activity,,her2-positive bc.|multifocal cancer,knee oa,,,,rome iv;|complete spontaneous bowel movements,for past 3 months,3.0 ≤ institutional uln|agree to participate,,,,,,
5321,,prolific academic platform||,tenofovir fumarate,,tobacco use is,local medical routine,,,,first degree relatives|those who did not attend all of the,sever,">= 100,000/microliter.|creatinine =< 1.5 × institutional upper limit of normal.||baseline respiratory requirement",,,,,,
5322,,coagulation disorders|block,lymphatics,,turning,nutrition intervention of the prehabilitation intervention bundle,,,,moderate to vigorous physical activity per week,after ≥ 8-h,≥ 1.5x109/l|platelets,,,,,,
5323,,conjunctival flap,clonidine,,hanifin and rajka (1980),inactivated influenza vaccine,,,,suitable for participating in this trial,within 3 days before the first dose of brigatinib.|no,12-20 years,,,,,,
5324,,chronic kidney disease|the,dapagliflozin for heart failure,,c.|body mass index (bmi),"optimal treatment|thoracic deformation (for example, pectus excavatum/carinatum",,,,substances of synacthen|they are pregnant,during the trial.||,2.5 x normal,,,,,,
5325,,neurological factors,contrast dyes,,bone mineral density measurement,vascular computer tomography,,,,full therapeutic doses of,in the past 5 years.|history,1.1 criteria).|have received,,,,,,
5326,,acute diabetic complications,nsclc|negative local testing for ttf-1|negative molecular testing,,coagulation function|imaging,acute pneumothorax,,,,metastasis|endoscopically non-accessible mass|pregnant,before first line,0.9 fifteen minutes,,,,,,
5327,,orthodontic bands.|presence,lbbb,,total blood volume calculator,open liver resection.||,,,,molecular features.|age,at least 14 days prior to the laboratory evaluations,≥ 50×109/l;|there,,,,,,
5328,,liver cirrhosis child pugh c|radiation rectitis|neurological disease,prophylactic live,,arbor stage (,linear regression extrapolation of absolute lymphocyte counts,,,,hormone receptor poor,in the starting dose is required,higher than 100 bau/ml|the ability,,,,,,
5329,,accessible teeth,nrt,,peripheral arterial ischemia.|participants,complete mri scan,,,,lower detection limit of the research center,within the last 30 days|coronary artery bypass graft (cabg),< 1.5mg/dl,,,,,,
5330,,hyperglobulinemia)|pregnancy,chronic opioid,,white blood count,investigational therapy,,,,lasting for at least 2 months,for the previous 3 months.|smokers,c|pre-existing,,,,,,
5331,,preserved liver function,neonatal intensiv care unit/pediatric intensiv care unit (nicu/picu,,medium-high risk mds,procedures:|blood test|change of,,,,meaning curative treatment,within the past 7 days|signs,≥ 12 weeks|measurable disease,,,,,,
5332,,abdominal abscess,strong inducers of cytochrome p450,,early ct score,centrally depressing,,,,second licensed,within one week,from 18 to 70 years|no,,,,,,
5333,,hearing|corneal decompensation,concomitant beta-blockers,,inpatient care,daily opioid,,,,aggravated chronic heart failure,in the three months prior to the inclusion visit,≤ 35.0 °c [95.2 °f,,,,,,
5334,,basis|symptomatic brain metastases,sarnat scoring system,,birth|apgar score,standard treatment.|no serious mental disorder.|patients,,,,neurological disorder|any recent,within 1 month before screening.|females,3-90% percentile,,,,,,
5335,,line|colorectal mucosal lesions,murine protein-containing products,,eligible.|major surgical procedure,tailored treatment referral,,,,requires,within 2 weeks prior to apheresis;|received,<35,,,,,,
5336,,hepatic tumors,immunosuppressive therapy).|moderate,,ap length,fine needle aspiration (,,,,metal joints,within 7 days before study treatment initiation,<=2.5 x upper limit normal (uln),,,,,,
5337,,herpes zoster,intolerance medications,,european working group,abdominal (fapd),,,,upper extremity|in the,component;|hormone replacement therapy,">=1,500/microliter",,,,,,
5338,,mother||inclusion:||newborns,danazole,,oud,whole-brain radiotherapy,,,,total number of metastatic sites,for six months after the discontinuation of study medication.|has,< 4.5 mmol/l|systolic blood pressure,,,,,,
5339,,assessments.|ptsd,alefacept,,express er positivity by immunohistochemistry,vascular access of the non-study extremity,,,,successfully reestablished,prior to ablative therapy|have previously,longer than 30 days,,,,,,
5340,,geographic atrophy,pia maters,,fmt,hfo,,,,non-smoking,induced,younger than 65,,,,,,
5341,,acute suicidal tendencies|no,liquidation mimics pseudocyst|pseudocyst formation,,hcv antibody reactive),fresh solid tumor samples,,,,site investigator to have a,within 48 hours of infusion start|baseline headache intensity of >3,≥10 indicating,,,,,,
5342,,showed abnormal,nucleos(t)ide analogue treatment,,old|american society of anesthesiologists,elective oral,,,,atherosclerotic,prior to initiation of study therapy|participants taking,therapy.|at least,,,,,,
5343,,cd22 positive,psychosomatic medicine,,aspartate amino-transferase,salpingectomy,,,,uncompensated,within 3 years prior to first dose except,>30 kg/m2;|allergies,,,,,,
5344,,primary liver cancer bclc(barcelona clinic liver cancer,non-steroidal anti-inflammatory drugs.|major,,bone age not,whole brain radiation therapy,,,,stable dosage,after the first cycle,>120 bpm,,,,,,
5345,,dpt|pregnancy,bh3,,screening.|left ventricular ejection fraction,adoptive cell therapy (act),,,,grade iii and above of nyha classification,prior to simulation,>3 months.|2,,,,,,
5346,,peripheral arterial disease,antihypertensive,,urine βhcg,target blood oxygen saturation,,,,dependent,within 1 month prior to screening|currently,>= 120mmhg)|for,,,,,,
5347,,organic disorder,over-the-counter supplements,,synovial leukocyte count,liver ct,,,,only|clinical mobility,in 12 months prior|available family support,equal to or greater than 18,,,,,,
5348,,intolerable,polyurethane,,barcelona stage b,sigmoidoscopy,,,,vanderbilt,during the past 2,0 or 1|has measurable,,,,,,
5349,,localized squamous cell carcinoma,aromatase inhibitor,,icf).|age,major spine surgery,,,,tattoos,within 48 hours before administration,= egfr（ckd-epi）×,,,,,,
5350,,bilateral disease,diuretic medications,,factors judged by the clinic team to be,chromosomal analysis,,,,early stage of chemotherapy,within 1 year prior to screening.|history of severe,greater than 200,,,,,,
5351,,shoulders.|vertebral fractures regarding,β- receptor blockers,,ccc,practice guidelines.|patients,,,,in the spine,within 6 months after neoadjuvant/adjuvant,>/= 2 weeks,,,,,,
5352,,sinus dysfunction,oral prostacyclin analogues,,abdominal circumference,surgery.|be able,,,,pharmacy,in the 3 days prior to enrollment.|receipt of live attenuated vaccines,over 65 years,,,,,,
5353,,los angeles,substages,,ecg examination.|patients,hematopoietic organs,,,,= cyamemazine,within 6 months prior to the ablation,25-45years14||both male,,,,,,
5354,,normal organ,nicotine-containing liquid for electronic cigarettes.|current,,ejection fraction,apheresis donation,,,,muscular,within 6 months|history of,>35 kg/m2|contraindications,,,,,,
5355,,sexuality,lft,,ards,pacemakers.|hospitalized,,,,robot-assisted abdominoperineal resection|reconstruction,within 3 months before the first study drug administration,from 18 to 80.|asa # or,,,,,,
5356,,involvement of the descending arch,anti-fungal,,international classification of headache disorders 3rd edition (ichd-3) criteria.|no migraine,transcutaneous tissue oxygen pressure monitoring,,,,ct/,in the last 12 months|copd-related,30 ml/min,,,,,,
5357,,depressive disorders,implant,,iief questionnaire|age 40 - 70,temporal relationship of,,,,below 60 years)|hypertension,at least six months after tooth extraction);|crestal,between 28-32 weeks,,,,,,
5358,,interstitial lung disease.|patients,targeting tki agents,,"başkent university ankara hospital pediatric emergency polyclinic,|diagnosed with intussusception",routine laboratory screening|pregnancy,,,,cldn18.2,within the last three (3),less than 50%,,,,,,
5359,,child followed,nonsterile,,preclude,upper gastrectomy,,,,alimentary,within months of donation/consent,at least 80%|subsequent,,,,,,
5360,,reasons|a birth plan,components of the radiopharmaceutical,,rankin scale,gastric bypass/bariatric,,,,requiring urgent,at least 2 of the,between 18 and 69 (inclusive) years,,,,,,
5361,,poor valve leaf compliance,phosphodiesterase-5 inhibitors,,calculated creatinine cl>40,exercise.|chronic fatigue syndrome,,,,between 2 sq.cm,during use,>90 g/l,,,,,,
5362,,hiv infected,nirmatrelvir/ritonavir,,2|absolute neutrophil count (anc),antibiotic treatment,,,,non-inflammatory conditions,throughout the study and 90 days after the last dose of lp-108,6 months to less than 18,,,,,,
5363,,sound primary canines,atropine,,modified bernoulli,national taiwan university hospital,,,,lower limb ischaemia.|chronic kidney diseased,for less than 2 years|women,< 3 times uln|electrocardiogram (ecg),,,,,,
5364,,nonresponsive to treatment,mineralocorticoid replacement,,respiratory rate>30x/min,pretreatment,,,,patient:||cerebrovascular disorders|previous,hfmref||absence,postural drop,,,,,,
5365,,hemolytic,anti-myeloma treatments,,mab,antimalarial activity,,,,no new,in the first period;|сonsent to use these methods of contraception,<50 ml/min|dementia,,,,,,
5366,,clinical trials|eating disorders,neocement® / neocement®,,mt level,ticagrelor treatment|patients,,,,grade 2+ elevation,within the last 5 years|for caregivers,> 10cc b-reproductive,,,,,,
5367,,brain related injury,nasal products,,modified boston neuroradiological criteria(table 9),teeth extraction,,,,hepatobiliary,at least 1 year ago,15-40yrs,,,,,,
5368,,h,full recovery,,serum immunoglobulin free light chain,fibre-free diet,,,,higher,at the time of consent.|confirmation of pnh diagnosis,between 20 and 40°.|treated,,,,,,
5369,,a-t,reproductive medicine,,hiv antibody test positive.|active infection,technical surgical,,,,largest diameter of 3 cm|child-pugh liver function class,clinical history or,>= 60x10^9/l,,,,,,
5370,,congenital anomaly,ticlodipine,,rapid urease test +ve||,injection of daratumumab,,,,full-scale,within the previous 3 years except,no greater than 3,,,,,,
5371,,medullary carcinoma,≥14 days,,prostate-specific antigen,rheumatologist;|able to read,,,,article l. 1121-8|persons admitted to a social,within 4 weeks prior to baseline period;|current smokers,10.0 g/dl)|potassium,,,,,,
5372,,mixed-meal tolerance test (mmtt) conducted at least 21 days from diagnosis,ca-4948 in combination,,human immunodeficiency virus (hiv) serum test；|patients,postoperative radiotherapy,,,,rubella vaccine,within two weeks prior to study visit,>= 84 days after tbi,,,,,,
5373,,severity of depression.|failure,passive anti-amyloid immunotherapy,,suv,srfcontralateral from pva,,,,≤5,onset 30 days prior to start of study|no,nurse,,,,,,
5374,,systemic diseases relating to the bone resorption,full extension,,response evaluation criteria in solid tumors (recist) 1.1 criteria present.|platelet,pet/ct scanner qualification procedures,,,,gender-based,within 6 months prior to diagnosis,≥ 1.0 g,,,,,,
5375,,conditions associated,blood products,,alanine aminotransferase (alat),antimyeloma therapy,,,,ineffective,within the past 12 months)|transfusion,0 or 1|absence,,,,,,
5376,,prescribed|chronic obstructive pulmonary,methoxsalen,,liver function assessment,gastric bezoars;|choose,,,,non-corrected,within 30 days prior to inclusion.|history of severe,≤ 1.5 x uln|cholestrol,,,,,,
5377,,dosing,lr769 -,,asa（american society of anesthesiologists),weight,,,,grade level,for ≥3 months).|bmi,≥6 requires,,,,,,
5378,,diabetic ketoacidosis,systemic glucocorticoid treatment,,18f-fdg-pet,mandibular anterior sextant,,,,healed,at the time of first sar445419 administration corticosteroid,> 12.0 x10^3/mm3,,,,,,
5379,,inadequate bowel preparation,sunitinib malate,,syphilis rapid plasma reactin-positive,animal,,,,high-dose,rabies.|history,≤ 2.5 × institutional uln,,,,,,
5380,,medical devices.|pregnancy,ras inhibitor therapy,,gvhd)|having,shortness of breath,,,,syndrome|insulin dependent,at least 30 days|formal education of 8 or more,greater than (>)480 millisecond (msec),,,,,,
5381,,immunosuppressive drugs.|pregnancy status.|incapacity,anti-tumor therapies,,national eye institute grading.|patients,screening|stable treatment,,,,signed|able to read,prior to study drug administration,≥ 1.5 times upper limit of normal,,,,,,
5382,,peripheral t-cell,potassium citrate supplements should discontinue,,intelligence quotient,pathological biopsy,,,,large infarction,within 48 h before screening;|those who participated,≥ 450ms,,,,,,
5383,,chemotherapy;|expected survival,component of the atezolizumab,,t bil,hifu treatment,,,,considered intolerable,within 3 months prior to screening.|any clinically laboratory tests,>10 ng/ml,,,,,,
5384,,diabetic diarrhea.|diagnosis,molecular profiling.||adequate organ function:||renal,,apgar,upper extremity surgery,,,,relapsing,within one month before the test),>18.5 kg/m2|healthy,,,,,,
5385,,global muscle damage score,immunoglobulin ≤6 months before receipt of any study vaccine,,fulfilled:||one incident prescription,pittsburgh sleep quality index).||,,,,gemcitabine-based,throughout study,asymptomatic hepatitis c virus,,,,,,
5386,,gcs,immunosuppressive antibodies,,european geographic origin|presence of,b-cell lymphoma,,,,stimulation,6 months prior,rca).|lvef <50%,,,,,,
5387,,screening.||-,components of the therapeutic approach,,hepatitis b virus dna,thoracic irradiation,,,,lasting longer than 3 months' [16],within 4 weeks before the first administration;|have received the following therapies,>5%)|allergy,,,,,,
5388,,another cause,immunotherapy drugs,,pregnancy test result||,fridericia's correction)|mean resting,,,,live attenuated vaccines,within 2 to 3 minutes after passing,≥ 26.5)];|ability,,,,,,
5389,,knee infection,compounds of similar chemical or biologic composition to atezolizumab,,international myeloma working,changes in fvc,,,,sixty-five years|biopsy-proven,last treatment.||exception,+/- adt)||non-metastatic,,,,,,
5390,,extensive stage disease,citrate,,alanine transaminase (alt)<1.5x uln);|adequate renal function,receptive-expressive emergent language test,,,,anteromedial cheek regions,within 1 week before enrollment;||vital organ functions,"≥ 100,000/mcl.|total",,,,,,
5391,,lack of mental ability can understand the content of the experiment,ripretinib treatment||,,arms||bmi,tumor blocks,,,,yale listen study.)|previous administration with any investigational drug,at time of screening|gynecologic cancer,<16.5 inches,,,,,,
5392,,enktl,criteria:||age,,prolonged qt|hematocrit,acl revision,,,,older|self,at the time of signing the,≥1.3 mg dl-1,,,,,,
5393,,immunizations,5 - aminosalicylic acid,,gfi score,suppressive therapy,,,,tisa-cel,within 2 weeks of start of study treatment,≤ 1 per who scale,,,,,,
5394,,chronic condition making,drugs-of-abuse,,liver function abnormalities,mechanical ventilation,,,,any grade alopecia,within 4 weeks prior to study drug administration,<3.0 k/mm3|serum,,,,,,
5395,,myocardial infarction).||recent (,pazopanib,,total bilirubin (tbil),lactulose therapy,,,,post-bilateral oophorectomy,at the time of consent.||received standard of care therapy,index score of ≥ 1|agree,,,,,,
5396,,oesophagus|psychiatric pathology capable,nonstudy antiplatelet drugs,,american college of rheumatology,tendon transfer,,,,nicotine free,within the past 6 months,score of ≥ 8;67|3,,,,,,
5397,,renal severe,obstetrics,,consideration should be given to curative hcv therapy,standard dose of multivitamins,,,,biventricular,within eight weeks before screening|history of alcohol,less than 80°,,,,,,
5398,,cerebral hemispheres|inability to perform mri examination,carrilizumab,,besancon university hospital,acute means assessment,,,,prevents effective use of the audio-visual content,for at least 8 weeks prior to screening,45-80kg,,,,,,
5399,,ampullary neoplasm,alpha 1 anti-trypsin,,fasting blood sugar,study||gastroscopy,,,,gilbert,for at least 120 days after the last dose of study treatment,>±5%)|pregnancy,,,,,,
5400,,acute ischemic stroke|stroke,slow acting drugs,,pci,small percentage of nets,,,,hyponatremia||glucose-corrected plasma sodium,within 28 days prior to the first dose of study drug,≥ 10 g/dl.|hepatic function,,,,,,
5401,,defibrillator capabilities,rhpro-uk,,hepatitis b core antibody-positive,apixaban dose reduction.||known hypersensitivity,,,,cart-i,at time of screening|cardiac failure,≤ 1.5 x uln|albumin,,,,,,
5402,,multiple organ failure,metal grains,,risk|human immunodeficiency virus (hiv),voluntary entry,,,,in room,up to 6 months post full vaccination,≤ 10 mg of prednisolone)|leptomeningeal,,,,,,
5403,,non-healing ischemic ulcer,antibacterial drugs,,pao2/fio2-ratio,laryngoscopy,,,,discharge for psychiatric hospitalization,for the last week,functional class iii-iv).|major,,,,,,
5404,,neurofibromatosis,pod1,,fasting plasma glucose (fpg):,screened;|physical examination,,,,hurler-scheie,previously been treated with,greater or equal to 18 years|participants with foot,,,,,,
5405,,adenomyosis,surgical,,ss patients||age,paxlovid,,,,high grade non-muscle,within the last six months|are,criteria;|female patients,,,,,,
5406,,neurodevelopmental conditions,rheumatoid factor (rf),,plasma/platelet donation,tracheal intubation,,,,multifocal,last 12 months prior to inclusion,no greater than 4 mg per day,,,,,,
5407,,valvular condition,antibody tests|negative pcr test for sars-cov-2|normal ophthalmic findings,,blood level,corrective lenses,,,,other causes,at the involved levels;||has documented,11-17|able to read,,,,,,
5408,,nr-axspa,lincomycin,,hbsag serology test,autologous hematopoietic cell transplant (hct),,,,suitable for hsct,at the time of surgery.|at the time of surgery,1-3|patients,,,,,,
5409,,contra-indicated|unable,tnf) blockers,,qtc fridericia,lymphocyte depletion regimens,,,,grade 3,at the time of screening.|joint,3 score,,,,,,
5410,,refractory gross hematuria,anti-hypercholesterolemic medications,,≤1.5×uln.|urine protein ≤1+,reproductive hormone therapy,,,,suitable for long-term oral,for at least 3 years post-treatment,≥ 18 years|motivated,,,,,,
5411,,primary cause of muscle weakness,study|patients,,liver blood pool);|absolute value of peripheral blood,before.|history of organ transplant,,,,phologically confirmed,within previous 30 days|life expectancy,5-20 kg,,,,,,
5412,,deformities.|knee pain,drugs acting on immunophilins,,bcma-targeted,cpb procedure,,,,non-traumatic sci|motor incomplete sci,after initial therapy,12-60,,,,,,
5413,,clinical dementia rating [cdr] score,contrast media.|contraindication,,thyroid function test,pcr)/next-generation sequencing (ngs),,,,fistula|antenatal,within 3 months prior to administration of this investigational,> 2 and,,,,,,
5414,,rhonchi,isoniazid,,years.|ecog ps - 0/1-2.||,intrauterine intervention,,,,discharge to the community||,since ≥3 months|confirmed flare,<60 ml/min.|currently,,,,,,
5415,,hg|current,components of the test product;|disturbed absorption,,ldh,emergency surgery;|informed,,,,third criterion.||for,within the past six weeks.|drug abuse,greater than 12 months.|participants,,,,,,
5416,,chemoradiation therapy.||,antipsychotics,,international normalized ratio,peritoneal implantation metastasis,,,,teeth,within 2 weeks prior to receiving study dose,>2× uln.|total,,,,,,
5417,,terminal chronic disease,anti-osteoporosis therapy,,plasma cmv pcr post-enrollment,centered therapy,,,,stage endometrial,at least one biomarker supporting intestinal inflammation|planned,from 18 years-old,,,,,,
5418,,peripheral vascular disease,years|medical,,leukocyte count,brawny cutaneous induration,,,,primary indication,at the time of signing the icf.|have a body weight,≥ 12 months.||,,,,,,
5419,,ae.|acute liver disease,left ventricular assist devices,,investigator.|spectral domain optical coherence tomography,fine-needle aspirations (fna),,,,irradiated,in the last 2 years,between 55-69 years,,,,,,
5420,,needle mesotherapy,nasal sprays,,either||fri criteria|cdc criteria,general medical condition|pregnant,,,,non-binary individuals|had,within one week|organ,greater than 3 x uln,,,,,,
5421,,feeling clogged,prescriptive medication,,alkaline phosphatase (alkp),implant repair,,,,acutely unstable,within 48 hours before the screening period,≥1.5|maddrey's discriminant factor (mdf),,,,,,
5422,,scalp disease,medications used in the study.|history of,,olsen grade 2)|the decision to undergo adl-pdt,tubal factor.|hypertension,,,,monotherapy,within two weeks of the first dose of study treatment.|concomitant,=< 2.|patients,,,,,,
5423,,complaints,drugs|non-steroidal antiinflammatory drugs,,blood hcg test,transurethral resection of,,,,major abdominal,within 5 years prior to study vaccination.|have,>2 mmol/l)|renal|liver,,,,,,
5424,,comorbid psychiatric illness,iia,,annual failure rate,virological test,,,,ii.|scheduled for elective,during screening/before the first drug,greater than 50% of the total liver volume,,,,,,
5425,,her2 positive disease,viloxazine,,alkaline phosphatase>2×uln;|total bilirubin>1.5×uln;|creatinine,inactivated viral vaccines,,,,lasting longer than 7 days within 30 days of randomization|be up to date on recommended immunizations,previously treated|no ongoing requirement,partial response to,,,,,,
5426,,"females),cardiac arrhythmia",synergeyes,,anatomic,ankle arthrodesis,,,,second-line therapy,in the past 1 year,18 - 75 years,,,,,,
5427,,hd,immune suppression|desire to have,,beck depression inventory ii or,collagen induction therapy,,,,aorta,within one week before enrollment meet,≤ 1.|sexually,,,,,,
5428,,neurotoxicity,study drug components.|6,,blood coagulation,pelvic exams,,,,aggir grid,prior to lung function assessments on study visits).|patients,occupying more than one-third,,,,,,
5429,,calculated by cockcroft and gault equation).|baseline left ventricular ejection fraction,tyrosine kinase inhibitor (tki),,hiv antibodies,rapid deterioration,,,,grade iv osteoarthritis of the cmg joint;|the patient is suffering,within 4 weeks prior to the first dose of study drug.|prior treatment,18-55;|meeting,,,,,,
5430,,malignant lymphomas,statin medication,,american society of clinical oncology/college of american pathologists 2018 criteria,female sterilization (surgical bilateral oophorectomy,,,,muscle activity.|blood,during the course of the study||other protocol defined inclusion/exclusion criteria may apply,① the ctp,,,,,,
5431,,extra-coronary,inhaled glucocorticoids,,creatinine clearance rate (crcl),appendectomy,,,,intrinsic valvular disease,12 consecutive weeks + carboplatin,≤ 40%,,,,,,
5432,,recovered from all adverse events,vertical growth,,mallampatti grades,local knee inflammation,,,,primary systemic therapy,within the previous 5 years.|subjects,1.do not consent to enroll in this study,,,,,,
5433,,lymph nodes,fexofenadine,,visit|hiv-1 plasma rna,knee osteoarthritis|having completed,,,,intervention.|ecog status,prior to the first dose being administered||,> 3 mg/dl,,,,,,
5434,,syndromic obesity,prescription anti-inflammatory medication,,j. severe,standard first-line therapy,,,,ocular causes of,at least 3 occasions,less than 2 years,,,,,,
5435,,rt treatment|metastatic disease,anti-cancer drugs,,partial pressure of,tobacco,,,,esophageal/tracheoesophageal fistula,at least six weeks of,≥ + +,,,,,,
5436,,infectious sign,secondary mevo,,modified ashworth scale|gross motor function classification system (gmfcs),completed prior therapy,,,,requires treatment,during the study period.|parent(s,score of 4 or higher,,,,,,
5437,,self-harm behaviors,anti-dopaminergic antipsychotic drugs,,european consensus group ss classification criteria|experiencing xerostomia,chemotherapy|concomitant treatment,,,,infection.|uncontrolled,more than 6 months prior to the date of study,<2.000x10⁹/l,,,,,,
5438,,hyperosmolar hyperglycemic state (hhs),costa rica,,absolute,targetable rearrangement,,,,occur every 21-35 days:||if,within 6 months prior to the first dose|major gastrointestinal surgery,≥18 to ≤60,,,,,,
5439,,fungal infection(s)|abnormal ecg|has,abnormal pattern||,,short stature homeobox,knee revision arthroplasty;|lower limbs surgery,,,,non-small cell lung cancer||,at week 49,functional class,,,,,,
5440,,musculoskeletal functional deficits|pregnancy,anti-depression treatments,,beck depression inventory-ii scale,vascular anatomy,,,,potentially curative therapy;|contraindication,within 30 days prior to visit 1|employees of the study site or their immediate families|pregnancy|hypothyroidism,over iii,,,,,,
5441,,biological variables,heparin-induced thrombocytopenia,,gcil thinning.||normal tension glaucoma,viral syndromes,,,,recurrent,in the past 2 weeks;|subjects,from 18 to 40 years old,,,,,,
5442,,corticobasal degeneration,≤1.44,,ejection,immunomodulatory drug (imid) agent,,,,pronounced,within 3 months before signing the informed consent,greater than 85 ml,,,,,,
5443,,inapt to respond to the questions,nonsteroidal anti-inflammatory drugs)|has any condition,,gross motor function classification system cooperate with assessments cooperating with virtual reality therapy||,radical local treatment,,,,american joint committee on cancer [ajcc] staging manual version 8.0),for up to 15 hours||ii,more than 12 weeks|the main organ function sits,,,,,,
5444,,surgery|women,plt,,general performance status,ipsilateral lumpectomy,,,,nia-aa diagnostic criteria,at least 12 consecutive months,patients||age ≥ 55 years,,,,,,
5445,,alaska native (,h2 antagonists,,ast/alt,open,,,,adenocarcinoma||mixed,prior to diagnosis,10^12/l,,,,,,
5446,,x interaction,monoamine oxidase inhibitors (maoi),,special needs|aged,world health organization (who) performance status (ps),,,,interfering with,past 5 years;|previous androgen deprivation,>90umol/l)|maternal,,,,,,
5447,,medullary thyroid cancer;|known thyroid cancer,immune response,,groningen frailty indicator,intra-articular injection,,,,prohibited medications.|patients with,after pdx therapy);|4.dose expansion,≥51 and ≤80 mmhg,,,,,,
5448,,cardiovascular collapse,2)|a known allergy,,cd4+ t cell counts,cardiac disease;|a,,,,igg fusion,within 6 months prior to enrollment;|has,<50 mg/dl,,,,,,
5449,,acute provoked,dimethyldioxyamphetamine,,serum creatinine ≤1.5×uln;|urine protein,radioactive implants,,,,tak-771-3005,"in the last 6 months,|presence of previous musculoskeletal surgery,|pregnancy,|having",> 40 years,,,,,,
5450,,psychiatric illness/social,arava,,planned duration,gastrointestinal tract.||history of other,,,,severely,within 2 weeks before the first medication,greater than first degree,,,,,,
5451,,peripheral circulation,gastric acid reducing agents,,antifungal medication|neuropathy,hematopoietic stem cell transplantation.||previous treatment,,,,ankura™ stent graft,within the 3 month period prior to baseline;|use,between 28-32,,,,,,
5452,,membranes thus,orthodontic treatment.|crossbite|vertical growth,,serum glutamic-oxaloacetic transaminase [sgot],mv stenting,,,,=< 21 days prior to registration.||or,within 4 weeks before c1d1|history of,< 10%,,,,,,
5453,,hepatitis c|hiv,sulfa,,tnt,screening.|known,,,,4h84 antibody [,within 4 weeks prior to the first dose of study,30-120 minutes|the,,,,,,
5454,,immunotherapeutic agents(e.g,psychiatric medication,,treatments|single level,24-h,,,,sirolimus|previous,within 30%;||healthy,<3-months,,,,,,
5455,,third degree atrioventricular heart block,acetylcholinesterase inhibitors,,window.||negative hiv,venous blood collection venous access,,,,prescription,within 4 weeks prior to participation in this clinical trial||,≥1 dependent,,,,,,
5456,,preoperative bradycardia,cerebrovascular accidents,,haemoglobbin,total amputation,,,,tumor tissue sample (archival tissue,within 14 days prior to the first dose of,> 150 μmol/l,,,,,,
5457,,ret oncogenic driver alterations,skills.||,,level of serum testosterone,cd20|prior treatment,,,,c-type,within 48 hours before infusion of car t-cells.||the following,80 years,,,,,,
5458,,present malignancies,hospitalisation,,urine hcg|hemodynamically unstable,spinal anesthesia||,,,,ms|no,after the first 12 months of,≥ 60 years old,,,,,,
5459,,cognitive impairment|anamnesis,rural secondary school,,fedr,myeloablative conditioning,,,,cardiological,over the past 6 months.|history of diarrhea,less than 60s,,,,,,
5460,,middle ear inflammation,prohibited medication,,volume less,local pathology|single bm,,,,stage iii-v,in the 3 months prior to the study.|patients treated,older than 5 years,,,,,,
5461,,extrahepatic metastasis,power field,,residual flow after laac,immunomodulatory treatment,,,,swiss academy of medical sciences,within 90 days prior to the screening visit or,0 or 1.|signed informed consent,,,,,,
5462,,breast-feeding patients|non mr,potent cyp3a4 inhibitor,,national comprehensive cancer network (nccn,pathological analysis.|not eligible,,,,neutral shampoo||,prior to the study enrollment,less than 15 on the madrs,,,,,,
5463,,electromagnetic system,head-,,gsrs score,cardiac implantable electronic device,,,,and|clinical frailty scale score,within 4 weeks before inclusion|subject treated,≥100g/l;||inr≤1.5,,,,,,
5464,,heart disease.|pregnant,gj-tubes,,limb length discrepancy compensation,child care,,,,diagnostic criteria of,index less than 60|vulnerable patients,25.0 to 45.0 kg/m^2|smartphone ownership|willingness to install the fitbit mobile,,,,,,
5465,,lymphatic system disease,full-dose oral,,vegetables,cognition,,,,preclude adequate absorption of oral,within 2 weeks after the study treatment,less than 2 years|4,,,,,,
5466,,gastric retention,chocolate,,cervico-facial,digestive organ resection,,,,toxic manifestation,within five years|severe physical disability,< 30ml/min/1.73m²,,,,,,
5467,,buerger's disease,prescription drug substance use disorder,,bell's,hp mri,,,,culprit lesion,for at least 3 months before study enrollment,between 2-5 years,,,,,,
5468,,unhealed fractures,sodium-glucose cotransporter 2 [sglt2] inhibitor,,rapid test,"infection,|infection",,,,acute effects of,department|medical history,25-60 years|bmi,,,,,,
5469,,months;|diabetic foot ulcers,moribund patient|illiterate,,hcv rna detectable,transthoracic echocardiography|prior,,,,adequate health,at least 1 superficial cutaneous,< uln,,,,,,
5470,,parafunctional habits,component of the ivx-121,,new york heart association functional classification|malabsorption syndrome,rehabilitation.|holding,,,,poorly filled,prior to exercise,> 250 msec.|any factors,,,,,,
5471,,right colon,regional anesthesia|plan,,nrd,laser therapy,,,,adverse event(s) with,within a period corresponding to,female|12-40 years,,,,,,
5472,,tinnitus before working,glucagon-like peptide-1,,recist v1.1|eastern cooperative oncology group (ecog) performance status,tumor immunotherapy,,,,intra-articular infiltration of the trapezio-metacarpal joint),at least 4 weeks prior to study enrollment.||b.,5.0 scale,,,,,,
5473,,child-bearing potential.|biologic therapy,components of the study treatment,,liver enzymes,cotinine test,,,,successfully performing a test after trying,"at screening, first within 10 to 14 days prior",'s,,,,,,
5474,,major factors,decongestant,,antithrombin iii deficiency,qt corrected for heart rate by fridericia's formula [qtcf,,,,post-viral etiology,within the previous month and foreseen,1-1-2019,,,,,,
5475,,chronic liver insufficiency,psychic medication,,cdai score betwenn 220,total hip arthroplasty,,,,non-type 1 diabetes mellitus,within 2 weeks prior to of study drug.|any unresolved,>= 4 ng/ml|registration,,,,,,
5476,,criterion g).|chronic pain,angiogenesis inhibitors,,chloride sweat test,labor rehabilitation centers of the health area of a coruña||exclusion criteria group iii:||have difficulties,,,,likely to respond to,at the time of enrollment|maternal heart disease|use of,> 9.0g/dl|absolute neutrophil count (,,,,,,
5477,,unable to withdraw,flourish hec vaginal care,,creatinine value|outpatient surgery|surgery,magnetic resonance imaging (mri) scan,,,,other immune,longer than 14 days prior to enrollment|life expectancy,>3 months|diagnosis,,,,,,
5478,,ocular pathology,drugs known to affect bone metabolism,,hormone level,diagnostic laparoscopy,,,,criteria for target lesions,within the past 5 years of screening,grade 2,,,,,,
5479,,white onychomycosis,component of any study drug,,fc,oxygen saturation,,,,stage 3b,prior to the first refraction used to establish stability,4 weeks before the trial entry;|pregnancy,,,,,,
5480,,systemic anticancer,gaviscon,,tumors|eating disorders|history of,resuscitation immediately after birth,,,,esophageal mucosa,at least 6 months after the last study drug,>= 30/35 kg/m2;|no,,,,,,
5481,,illicit drug abuse,growth factors white blood cells,,saturation,chest imaging (lung ultrasound,,,,muscle tone,within 6 months of the screening visit,"< 100,000",,,,,,
5482,,intraocular lens.|macular disease,hyaluronic acid,,child c status|diagnosed,small duct psc,,,,index ulcer|index ulcer,within 28 days prior to the start of study intervention.||absolute neutrophil count (,^9 /l);|adequate liver function,,,,,,
5483,,hungary);|diagnosis,topical agents,,old|ejection fraction,sysadoas,,,,lepidic dominant pattern||adenocarcinoma,within 30 days of randomization.|any condition,18 years or older.|students,,,,,,
5484,,myocarditis.|troponin t (tnt),bic,,adt,health facilities (aim 2)||investigators,,,,with pd-1,within three months before the enrollment|patient eligible to ozanimod,<10 points)|lack,,,,,,
5485,,nf2,rtx,,recist1.1 standard;|ecog score,preoperative mri,,,,investigator.|electrocardiogram,1 after hormone replacement therapy,20-29|regular menstrual cycle,,,,,,
5486,,end organ function|histologic documentation,nsaids,,endogenous serum epo,antimicrobial therapy;|use,,,,muscle growth,within 7 days before administration;|any drugs,≥ 55 years,,,,,,
5487,,hypothyroidism,physiotherapist||,,bilateral sensorineural hearing loss criteria,control biopsy,,,,could interfere with the study,within 1 day prior to initiation of study drug.|hypersensitivity,at least 45%;|hepatic function,,,,,,
5488,,pregnancy related complications,influence serum lipids,,patients;|hepatitis b core antibodies (hbcab),sequelae|upper limb amputation,,,,large-duct psc,within the following ranges,more than 2 times the upper limit of,,,,,,
5489,,computer|digital literacy level,immunoglobulin treatment,,cantilever extension,central laboratory immunohistochemistry,,,,stable situation,up to 2 grams [g,between 3 to 6,,,,,,
5490,,diaphragmatic pacer,antidiarrheal agents,,human immunodeficiency viral infection (,chemotherapy,,,,rr-tb,since the combination therapy,13-16).|refractive error,,,,,,
5491,,antibiotics.|malabsorption syndrome,supplements containing myo-inositol|severe co-morbidities,,national cholesterol education program's adult treatment panel iii (ncep atp,12-lead ecg.|uncontrolled arterial hypertension,,,,non-femoral access|requires,at time of signing informed consent|patients,≥ 18|report of snoring|prior,,,,,,
5492,,lesion|post-void residual,anthracycline-based;||4,,left assist ventricular device (lvad),"entrance into a body cavity (eg, chest, abdomen",,,,thickeners,more than 15 diopters of refractive error|the subject,between 30% and 70% of the predicted value|ability to walk,,,,,,
5493,,increased intracranial,mesotherapy products,,local laboratory reference ranges).||22,fluarix tetra,,,,bipolar i,at any time during the study|other medical conditions,scores <3.||,,,,,,
5494,,hepatitis c virus [hcv] ribonucleic acid,injection sites||,,hiv antibody test positive;|hepatitis b (immunological test results,heparin injection,,,,central laboratory;|no,at the time of planned vaccination|history,≥60 ml/min per 1.73 m2;|patients,,,,,,
5495,,mitral valve surgery coronary artery bypass graft surgery,sohag,,urine alcohol test,rna vaccine,,,,indeterminate- age myocardial infarction,prior to entering the study|patients,≥8 mm;|crestal,,,,,,
5496,,over right deltoid area,therapy,,c-ten,vitreoretinal surgery,,,,primary caretaker,for at least 7 days prior to the first dose of study drug,1/1/2010|at least 18 years,,,,,,
5497,,autoimmune anemia,gnrh agonist,,rapid antigen test (rat),implant arthroplasty,,,,enrolled.|history of,prior to participation in the study,grades 1 or 2.|receive general anesthesia,,,,,,
5498,,anterior segment dysgenesis,lavender|patients,,therapy||treatment-naïve,bcma)-targeted therapy,,,,diameter of < 10 mm seen on,at the time of screening||,> 3months)||,,,,,,
5499,,peripheral neuropathies|unable,transplant,,or|urine protein dipstick,leukemic organ involvement.|renal function,,,,granted,recently than 8 weeks,≤ 2.0 cm,,,,,,
5500,,poly-axial correction,concomitant medications that could impact the effects,,cushing's syndrome)|change,urine β-hcg)||iii,,,,reduced,within 14 days prior to first dose.|ecg,≥ 60 ml/min|female,,,,,,
5501,,light fat tongue,systemic drug therapy,,definition of stable,antagonists,,,,lb2102 excipients,within the last four weeks,"<100,000/µl)|patients",,,,,,
5502,,progressive neurological disorders,immune checkpoint inhibitor-induced,,italy)|willing,diagnostic results);|history of,,,,second-line standard regimens.|at least one,past 12 months prior to inclusion.|subject,1.5 times exceeds the upper limit of the normal value,,,,,,
5503,,hip prosthesis dislocation cognitive dysfunction,13 allergy,,ef,paraffin blocks,,,,squeezing,within 12 months|pain,between 2500 and 4000 g.|those,,,,,,
5504,,comparable anatomical positions,mycophenolate mofetil + hydroxychloroquine +,,valve replacement|permanent,perinatal pathologists clinical scientists,,,,impaired growth,within 3 months|existing,≥2.5 x uln,,,,,,
5505,,involvement of the lower gi tract,trial drug administration;|the physical status,,intensive care unit (,transcatheter aortic valve implantation,,,,requiring iv antibiotics,within 8 weeks prior to study enrollment,< 50 % pain relief,,,,,,
5506,,pre-liver failure:||extreme weakness,glycopyrrolate,,cd20+ mature,volume sensitive hf phenotype,,,,outside the borders,during the course of the study.|participant,<0.80,,,,,,
5507,,fetal demise|diagnosed,pegloticase,,serum cortisol level,hernias,,,,interview.|not significantly,within 2 weeks before the rct|received immunotherapy,"less than 2,500g",,,,,,
5508,,post root canal treatment review,neuroleptic,,rheumatology care from duke health,peripheral nerve blocks|contraindication,,,,schu-day syndrome,last 8 months,≥18mm,,,,,,
5509,,cerebral diseases||,canthaxanthine,,urine hcg pregnancy test,prostaglandin therapy,,,,acc-ascvd risk estimator+)|untreated htn,at screening and day -1,<0.70,,,,,,
5510,,hyperkeratosis,topical acne drug,,unusual physical activity,periodontal disease||exclusion||3 months patients should have,,,,sufficiently controlled,within 2 weeks prior to starting treatment.|patient,between 22-35,,,,,,
5511,,cvd,ianb,,allowed.||alanine transaminase (alt) serum glutamic-pyruvic transaminase,abdominal operation,,,,r-sak;|pregnant,for more than 3 months|patients,0.75 µkat/l,,,,,,
5512,,cyst fenestration,study drugs beta-lactams,,trauma center directly,pah tpip,,,,distant,during the entire intervention,> 4 mmol/ l - can,,,,,,
5513,,normal renal function)|healthy,quit|own a,,hma ctfg,systemic chemotherapy,,,,parent-rated,less than 4 weeks before the ipn-21-sense injection,between 18 and 90 years|level of,,,,,,
5514,,criteria.|hematopoietic growth factors,norfloxacin,,ceap,child;|regular obstetric examination durinv,,,,non-english speaking|significant range of motion limitations,within 60 days after end of anti-cd38,years.|50-100,,,,,,
5515,,cardiovascular disease|taking drugs,soluble receptors,,menstrual period,surgery|simultaneous treatment,,,,hypokalemia|maternal,at night to smoke).|evidence,<10mg/dl,,,,,,
5516,,non-epileptic seizures,angiotensin receptor blockers,,normal|glomerular filtration rate,internal radiotherapy,,,,muscle paalysis|patients,prior to aclr|post-surgical complication,"18-60,|have",,,,,,
5517,,refractory disease,adenosine pathway,,vas,volume resuscitation,,,,visually significant,more than four,score 24>|not doing laughter yoga before|being able,,,,,,
5518,,hypokalaemia,pritelivir,,alcohol urine test,radiographic progression after androgen deprivation therapy;|participants,,,,american diabetes association's definitions,within 3 years prior to first dosing|subjects,greater than 5mm,,,,,,
5519,,non-traumatic conditions|history of,ventricles,,pcr test/antigen dectection,total laparoscopic hysterectomy body mass index,,,,meets lugano2014 criteria:,continue to participate,≥ 15 mm,,,,,,
5520,,ic socket,agent targeting krasg12c.||leptomeningeal disease,,6-month,kidney transplantation|history of,,,,secondary diagnosis,at screening visit,ed patient or,,,,,,
5521,,classifying fibromyalgia,hypomanic symptoms|has attempted suicide,,university hospitals leuven (uz leuven).|it,vertebral artery variants|subjects,,,,drug-related toxicity on monotherapy,at least 4 weeks prior to randomization|sufficient,>1.5 upper limit of normality (uln),,,,,,
5522,,down's syndrome/trisomy,sorivudine,,modified bell's staging,standard temozolomide,,,,general,at least 36 calendar months prior to enrollment|patients,< 3 times of upper limit of normal (uln),,,,,,
5523,,t-follicular helper phenotype,tacrolimus plus,,modified response evaluation criteria in solid tumors (recist 1.1)|neutrophils,hiv transmission,,,,first-generation,least half of the time with the parent involved in intervention.||exclusion criteria,>3 mmhg/l/min,,,,,,
5524,,mi|acute heart failure,cequa®,,who criteria.|children,electrical implantable device,,,,high-quality cbct,in the last 6 months;|participation,younger than 44 years,,,,,,
5525,,tremor,anti-viral therapy,,nasal expiratory positive,vascular structure/status,,,,dysplasia|severe,in the last 3 months|those,> 20 inches|any other reason,,,,,,
5526,,acute suicidal tendencies|having gynecological diseases,bpd+ph|on invasive,,≤2|life expectancy,lgr5 expression,,,,worse general health status,"in the last year,|receiving physical therapy",<64 bpm,,,,,,
5527,,unstable cardiovascular disease,hiv protease inhibitors,,liver metastasis|serum creatinine,opioid therapy.|stable vital signs,,,,infection|ed induced,after a prior course of intravesical treatment.|patients,≤ 3 times institutional upper limit,,,,,,
5528,,habitual diet)|regular tobacco,combined inhibitor of sglt1,,excludes cured cervical carcinoma in situ,tills,,,,nh3 pet-mr|not,within 7 days of screening until study completion,<50mmhg the,,,,,,
5529,,pleural metastasis,conventional medical treatments,,recist v1.1 progression).||,old.|coronary revascularization,,,,neuro-ophthalmology,within 6 months prior to screening;|received,above or equal to 6.5%.|current,,,,,,
5530,,enroll:||type i diabetes,materials used,,sgot)=aspartate aminotransferase,d-cycloserine,,,,tumour tissue is available for storage,6 months prior to the start of the experimental trial|use of pea supplements,less than 6 months.|radiation,,,,,,
5531,,rcc,meninges,,serum glutamic-oxaloacetic transaminase,immunosuppressive purposes,,,,radically treated,at least 14 days before,"<100,000 to >500,000 x 109/l",,,,,,
5532,,squamous cell skin cancer.|known brain,rapamycin,,range|platelet count,re-booked for provocation days,,,,site investigator,within 14 days prior to day 1 of protocol therapy|herbal,> 35%|step 2,,,,,,
5533,,sub)acute thyroiditis,anticholinergic agent.|untreated,,modified radical mastectomy||,gastrointestinal polypectomy,,,,highly effective contraception.||,after previous use of,≥ 17 mmhg,,,,,,
5534,,chronic active hepatitis c,sodium-glucose co-transporter-2,,daily glucocorticoid-replacement,persistent airflow limitation,,,,non-severe,past two years,> 110 msec|pr,,,,,,
5535,,number of tumors,a1,,morbid obesity(bmi,health authorities,,,,self-report.||22,within 12 months prior to randomization|no,"lower than 2,000/ul",,,,,,
5536,,major disabling mental disorders,normal dihydroepiandrostenedione sulfate,,anti-covid-19 vaccine||,period.**||*including vaccine,,,,metabolic unit,within 12 months.|participants,> 100%,,,,,,
5537,,program.|able,iodine-containing contrast agents|history,,amino transferase levels,diagnostic purposes,,,,obesity-related,within the last 1 year|pregnant/pregnant,>130 bpm,,,,,,
5538,,immune checkpoint pathways,contraceptive implant,,iodine refractory,gross craniofacial deformities|pregnant,,,,medications:||pain relief,within 6 months before baseline.|any,≤1.5× uln,,,,,,
5539,,congenital immunodeficiency diseases;|active autoimmune disease,anti-hcv antibodies).|receipt of zoliflodacin,,msi-h/dmmr,ocular accommodation,,,,could prevent vaginal delivery.|primiparous,within 5 days prior to the first dose of study,killip class ii or more,,,,,,
5540,,autoimmune complications,systemic immune-modifying,,size,physical exam,,,,non-epileptic seizures.|suicide,prior to the dose of study,pr level of positivity ≥34 %,,,,,,
5541,,hemorrhagic stroke|participants,temozolomide,,old.|ecog performance status,bypass graft,,,,non-nucleoside reverse transcriptase inhibitors (nnrtis),within 90 days of the index procedure.|chronic renal dysfunction,< 50 × 109/l,,,,,,
5542,,consent|clinically stable,ctd,,systolic blood pressure (sbp),visit.|body mass index (bmi),,,,diseases;|non-granular deficiency,before allocation.||applicable to children,"> 5 points,|critical hypoxemia",,,,,,
5543,,functional disorders,antiallergic drugs,,rest scale,vascular delivery path including:||abdominal aortic aneurysm 4.0 cm or greater,,,,interfere with cooperation with the requirements of the trial.|has significant,during the intervention unless participants reach out for triage,grade iii or greater,,,,,,
5544,,iv.|sinus bradycardia,component of the study drug,,lhrh agonists/antagonists,emergency surgeries|surgeries,,,,study|clinically significant infection,within 14 days of the first dose of study,">3,750 mg/day)|for",,,,,,
5545,,anemia impairment,rifabutin,,simplify disc ide (nct03123549),c.|positive blood test for hiv,,,,index hospitalization|neurological condition,within the range 18 to 32 kg/m^2 (inclusive),≥ 60%,,,,,,
5546,,cardiovascular congenital diseases,arbidol and,,parenteral nutrition,preimplantation,,,,primary tumour)||,within three months prior to the first ip administration,>500 copies/ml,,,,,,
5547,,t2 lesions,trimipramine,,imp,abortion,,,,in-hospital,within 14 days before screening,≥ 140mmhg,,,,,,
5548,,bronchiolitis obliterans,anti-hormonal agents,,alveolat ridge preservation (arp),metacarpal osteotomy,,,,mta grade,prior to random,≥27.0,,,,,,
5549,,myocardial amyloidosis,medications related to the above diseases,,eskape,graft versus host,,,,volunteer to take part,for the past three months.|participant,>18 hospitalized,,,,,,
5550,,regions,β3-adrenoceptor agonists,,cytogenetics who (2016) revised classification of mds as mds,radiotherapy/chemotherapy；|hepatocellular carcinoma,,,,no-t2d +ms / hfpef,"surgery between january 1, 2018",>2%,,,,,,
5551,,hepatitis b virus (hbv) dna test,molnupiravir,,postural orthostatic tachycardia syndrome).|is,irrespective of valvular heart disease|inability to provide informed consent|participation in another clinical trial,,,,atient group):||left ventricle ejection fraction,within 7 days prior to leukapheresis.|patients,between 3 and 6,,,,,,
5552,,retinal disorder||treatment,oral glucose,,plasma potassium,valve procedure,,,,mount sinai hospital,during the study;|age 18-80||,< 15)|with electronic,,,,,,
5553,,chest wall diseases,check-in of period,,hepatitis b surface antibody (hbsab),cognitive function evaluation,,,,gluteal fold,14 days prior to clear lymphatic chemotherapy,≥ 18 years|resident,,,,,,
5554,,immunological functional defects,connective tissue disorders|patients,,inr and/or aptt,pd-1 immunotherapy,,,,necrotic tissue with,prior to signed informed consent,between 18.0 and 27.0 kg/m2,,,,,,
5555,,neurologic disorders,glucocorticoid drugs,,"etc.),|history of mass around foot",blood loss,,,,hf,1 week before enrollment.||8,< 35kg / m2,,,,,,
5556,,transverse neck lines,covid-19 mrna vaccine,,basal serum follicle-stimulating hormone (fsh),first line chemotherapy,,,,intercurrent severe,within 7 days before enrollment.|those,</= 5 x institutional (upper limit of normal,,,,,,
5557,,egg white,pantoprazole,,nasal cpap/,lives);|8.resolution of all acute reversible toxic effects,,,,medically,within 14 days prior to the first administration of the study drug.||note:,nucleic,,,,,,
5558,,hepatic function:|is,oral prednisone,,consciousness||•,preoperative transthoracic echocardiography|condition,,,,third-year,during trial treatment,≤ 75ml/min/1.73m2,,,,,,
5559,,sign of infection,brca1/2,,streaky interstitial markings,pmmr/mss,,,,above-listed inclusion criteria|do,within 3 months prior to screening visit,140 -159 mmhg,,,,,,
5560,,vaping devices,bilateral salpingo-oophorectomy,,minoca,standard prophylaxis therapy,,,,secondary schools.||,at time of study enrollment|comorbidities,>1.90m)|patient,,,,,,
5561,,skip lesions,direct injection,,pregnancy,surgical flap;|having,,,,sars-cov-2 infection,at baseline of,<100.000/mm3,,,,,,
5562,,urine chemistries,erythrocyte,,classic,standard treatment regimens,,,,genetically confirmed,within 2 weeks prior to initial dosing,≤ 4.00d,,,,,,
5563,,affect psoriasis,plant drugs,,visual acuity:||best corrected distance visual acuity (bcdva) score,glaucoma|current treatment,,,,neurosurgery department,within 7 days prior to the first study drug administration,24-32 days)|those,,,,,,
5564,,gastrointestinal stenosis|implanted,poziotinib,,reasons,triple vessel coronary artery disease (tvcad),,,,toxicity scale||,"for at least 4 days,|had",at least twice prior to 24weeks,,,,,,
5565,,hepatitis b (hbv) surface antigen,health products,,pad|age,procedural sedation.|pregnancy,,,,imwg response,after the last treatment on this study||active central nervous system,less than 14 days.|must sign,,,,,,
5566,,pulmonary lymphangitis,polyurethanes,,recist version 1.1;|ecog,step counting,,,,hormone receptor,within 28 days before administration of investigational product,<3 7,,,,,,
5567,,post-acne atrophic,npsg)/mslt,,bcma antibody-drug conjugates,world health organization (who) classification system for tumors of the hematopoietic,,,,"articles l. 1121-5, l. 1121-7 and",within the past 3 months.|females,≤ 6 s,,,,,,
5568,,coronary artery obstruction,velafermin,,quantitative hcv rna results,vaginal uterosacral ligament,,,,cytologically confirmed,during the study period.|subjects,patients||age 55+ years,,,,,,
5569,,weeks|treatment,potassium sparing diuretics|pregnancy,,serum potassium level,postoperative intubation,,,,associated,while participating in the study,18-65 years|patients,,,,,,
5570,,hbv deoxyribonucleic,gallstone complications,,duration|salt score,exogenous hormone preparation of the endometrial lining|high embryo quality ((≥2bb),,,,non-dominant,within the past 6 months.|intolerance,≥ 0.5 ml/sec,,,,,,
5571,,"justice,|having opposed the research",localized peri-appendicular effusion|infiltration,,"1,2",ocular inclusion criteria,,,,neuro-oncology biorepository for archiving of microdialysate,at least 6 months ago,< 1 year|renal transplantation,,,,,,
5572,,drug-dependent,taxane regimen,,blood urea nitrogen (bun),surgery||kidney transplantation,,,,american college of rheumatology - 2016 criteria|between,at screening||any of the following laboratory abnormalities,>2 times upper limit,,,,,,
5573,,macular degeneration|patients,mineral substitution,,cushing syndrome).|history of depressive disorder,central lymph node,,,,on room air <85%),for the first time|volunteering to participate,spanish|≥18 years old.||,,,,,,
5574,,intramuscular bleeding,surrogates,,asia impairment score,hbv antiviral prophylaxis|is,,,,full-length,within ≤ 28 days,≤ 5 x,,,,,,
5575,,acute large bowel obstruction,immunoglobulin products,,diazepam,androgen-deprivation therapy,,,,age.||morphologically confirmed,recent (3 months,<0.6 cm2/m2|patient,,,,,,
5576,,cervical intraepithelial,full thickness loss of dermis,,mayo clinic al,thymic surgery,,,,lvef<50%)|high risk,≤30 days after receipt of study,above 4.9 mmol/l)|anormal,,,,,,
5577,,rcvs,coconut,,hcv rna,stent implantation operation .||,,,,erasmus mc|provision of written informed consent|only,within the last six months|having severe,>3 times upper limit of normal,,,,,,
5578,,cardiopulmonary dysfunction,anti-smith antibody,,minimum size,assay.|clinical findings,,,,mmhg|known,within the past 3 months)||participant,older than 3-months.|children,,,,,,
5579,,autoimmune diseases.|received,tka,,gcs≤8|dysphagia,chest imaging did,,,,ultra-rapid lispro insulin,during the study|prior,11 above;|a negative,,,,,,
5580,,upper urinary tract obstruction,cni,,modified ferriman-gallway score,conscious sedation,,,,rome iv criteria,in the next year due to participation in a research,from 17 to 22,,,,,,
5581,,septic,anti-cd38 monoclonal,,hepatitis c antibody,alternative methods of non-hormonal contraception,,,,suitable for curative therapy.|adequate tumor tissue available,within 2 weeks prior to the first dosing|has an,<1.04mmol/l,,,,,,
5582,,high quality fundus,alendronate,,as:||hematologic:||absolute neutrophil count (,treatment of the study,,,,sle-related,within the previous 90 days.|subject,> 200 ng/dl|qtc,,,,,,
5583,,renal impairment||glomerular filtration rate should,olsalazine,,8th,rectal fistula.|no,,,,abuse)|coinfection with,while receiving trial therapy,6 yrs old|self-report,,,,,,
5584,,colorectal adenoma.|colorectal cancer,actigraph,,yahr stage i-iii|persistent subjective cognitive complaints,visit|ocular topical antibiotic use,,,,pericardial fluid,12 hours prior to treatment|patients,≥ 1.5 × 109/l;|platelet count,,,,,,
5585,,dry eye,androgen blockers,,chb population,gestational diabetes.|participation,,,,acute phase of their ischemic stroke (,within 2 months before the start of the trial;|a serious,> 13;|elevated,,,,,,
5586,,chordoma,atorvastatin,,multidimensional perfectionsm scale,and|students,,,,mri|extensive,1 day 1,< 1.5 mg/dl,,,,,,
5587,,acute myocardial infarction,dulaglutide,,ion™ endoluminal system (sscb),urodynamics studies|presence of,,,,ketone ester,within 12 months.|active infection,≥ 90 mmhg,,,,,,
5588,,specialist considers,aza,,dcl,duplex ultrasound,,,,insulin pump|lives,more than 20% change,>40;|american society of anesthesiology (,,,,,,
5589,,liver function impairment,fluconazole,,responding,general surgery||,,,,study|excessive pain,before start of the study treatment:||hemoglobin,less than 30 ng/ml,,,,,,
5590,,malignancies|severe renal impairment,entecavir,,hepatitis c virus (hcv) antibodies,progestins.|abnormal transvaginal ultrasound,,,,might interfere with endpoints or compromise participant safety,</= 28 days prior to cycle,> 46)|the volunteer,,,,,,
5591,,mresist,anti-isoleucyl-(anti-oj,,systolic pulmonary pressure,radical concomitant radiochemotherapy,,,,self-reported loss of consciousness,within 48 hours,≥ 25,,,,,,
5592,,parkinson's disease|pregnant,mmr,,child pugh b (score 7-9 points)|further inclusion criteria apply||inclusion criteria applying only to participants with normal hepatic function:||individually matched,congenital heart surgery mortality category (stat\sts-eacts,,,,highly effective contraceptives,3 months prior to and,1-18 years,,,,,,
5593,,esophageal resection;|age,topical glucocorticoids,,cis (carcinoma,intensive care unit admission|pregnancy,,,,other forms of investigational treatment,for at least 2 years|throughout the study,score ≤ 19,,,,,,
5594,,deep vein thrombosis,contains molecular alterations,,reference value limit;|hepatitis c (hcv) antibody positive,elective knee,,,,metabolic,in 8 weeks prior to inclusion,16-65years||,,,,,,
5595,,substances of abuse,study vaccine dose.|immunosuppressive therapy,,mrd negativity,pelvic lymph node surgical assessment (sentinel lymph node mapping,,,,primary hip surgery,prior to microwave,less than 250 microns from the corneal endothelium;|abnormal,,,,,,
5596,,undesirable reactions,amphotericin,,handicapped,erythematotelangiectatic rosacea,,,,predominantly,for 6 months,21 years or older,,,,,,
5597,,corona virus disease-2019 (covid-19),lazertinib,,platelet ≥100 x 109/l,control group:||no pain,,,,large bullae,within 3 months of registration,50 x 109/l)|serum,,,,,,
5598,,nonvestibular pathologic conditions of sufficient,beta-blocker medical therapy,,child pugh class,multispiral tomography,,,,power seating.|new chairs,within 14 days prior to study treatment,>35 kg/m2;|egfr<30 ml/min/1.73m2;|plan,,,,,,
5599,,opioid use disorder,impetigo,,blood.|body mass index (bmi),ocular surgery procedures should,,,,accurately assessing hrv,more than 5 units,over 18 years old||the exclusion criteria,,,,,,
5600,,age|symptomatic coronary artery disease (cad),oriental medicines,,kidney function indices,assessment,,,,greater,within 3 months of study participation,> 6 months,,,,,,
5601,,nickel|participant,ranitidine,,psoralen + ultraviolet,vascular network [bvn],,,,computed tomography;|have been,more than three months,15 to 29 years,,,,,,
5602,,females|able to read urdu language|pregnant,took medications,,euroscore score,haplo donor,,,,lower trapezius,within 14 days before the start of trial treatment.||table,under 18 years|lack of,,,,,,
5603,,"drug treatment,|a head injury",sca,,mean systolic blood pressure,baseline screening test,,,,any organ,within 6 months before randomization.|major surgery,"<150,000/mm3|absolute neutrophil count",,,,,,
5604,,sickness,anchovies,,heart valve abnormalities,chest ct|duration of illness ranged,,,,decompensated,since less than 3 weeks,< 80 × 10^9/l|inability,,,,,,
5605,,t2 (patches or plaques,marrow-suppressive therapy,,bpm|respiratory rate,sponsor employee|failure,,,,vertebral,at least for 6 months|children,=< 21 days prior to enrollment,,,,,,
5606,,adverse skin conditions,angiotensin-receptor blockers (arb),,residual deficits;|uncontrolled hypertension,remedial treatment after asct,,,,tuberculosis|contagious,within four weeks prior to entering the study,< 28ºc of temperature,,,,,,
5607,,pulmonary vascular disease,ivt biologics,,institute of pathology,blood pressure;|a history,,,,potential,at least 5,> 2mm)|pain vas,,,,,,
5608,,functional reversibility|chronic respiratory failure,monoclonal antibodies in history;|a positive test,,fiebig stage,stress,,,,lacunar infarct,while on study.|allergy,greater than 1500/mm3|absolute,,,,,,
5609,,loading,acetylsalicylic acid,,50+,good oral hygiene|absence,,,,independently.|not regularly,at screening visit.|unable to provide informed consent,25-70 db,,,,,,
5610,,gastrointestinal tract disease,topical cosmetic products,,car t cell,kidney graft after renal transplantation,,,,acute bereavement period,after using monoclonal,between 18 - 65 years,,,,,,
5611,,hepatitis a virus,ingredients,,albumin (alb),hematology,,,,proximally,within 2 years before first dose of study treatment,< 40 kg/m²||,,,,,,
5612,,1.pathological type,bisphosphonates therapy;|tertiary hyperparathyroidism;|patients,,leucocytes,renal fusion anomalies,,,,could compromised the movements of the patient|no,at inclusion,> 1:80,,,,,,
5613,,chronic arthritis/osteoarthritis,chlorothiazide,,human immunodeficiency virus [hiv],12-lead ecg abnormality;|positive test results of,,,,porto criteria [6]|aged,prescribe,less than or equal to 120,,,,,,
5614,,coagulation abnormality|major surgery,vincristine).|cyp3a4 inhibitors,,required|ecog performance status,bone scan.|participants,,,,salivary pcr||,ended less than 4 weeks before taking the drug,"i-iv,|signs of",,,,,,
5615,,fungal sinusitis|cystic fibrosis,testosterone,,urinary m protein≥200 mg/24 hours,tavr procedure,,,,successfully completed the dbp,within 30 days prior to enrolment|the,18-35 years.||,,,,,,
5616,,other malignancies,cane,,cat score,smartphone usage||,,,,intra-ocular foreign body,at the time of the,≤ 3×uln,,,,,,
5617,,guillain-barré,gaze,,e,haploidentical donor sourced hsct|hematopoietic cell transplantation,,,,low albumin,within the 72 hours prior to the screening visit,> 2.8 g/dl|alanine,,,,,,
5618,,smm,inhaled corticosteroid (ics) medication,,score,completed chemoprophylaxis,,,,mental health;|in another scheduled,prior to 1st dosing,18-40 y|clear,,,,,,
5619,,psad values||,inducers of cyp enzymes,,uln.|prothrombin time pt,unilateral total adrenalectomy,,,,scans.|significant,within the preceding 6-months;|have,ii-iii.||,,,,,,
5620,,ovarian stimulation.|during,mmhg|stroke,,body mass,revision of polypectomies)|incomplete examination,,,,any of its,approximately 1 year of the screening visit,exceeding 140 mmhg,,,,,,
5621,,left atrial ablation,investigational drug treatment,,her2,anticoagulation regimen.|patients,,,,ustekinumab)||exclusion criteria,at least one of the complaints,> 55 mm,,,,,,
5622,,hepatologic diseases,edaravone,,nt-probnp of,homes:||specialized nursing homes,,,,suitable for participation in this trial for,within two weeks prior to cycle 1 day 1.||inadequate liver function,>= 0.8 m^2,,,,,,
5623,,radical resection;|subjects,siltuximab,,prostate size,retinal imagingfor,,,,dermatomic area,within 3 days before starting the study medication,</= 10.0%|body mass index,,,,,,
5624,,numbness,dexamethasone equivalents,,tsh test,multifocal contact lenses,,,,in the neck area|sensory disorders|dislocation of the jaw in the past|taking,in the last two (02),16-30 years,,,,,,
5625,,obsessive compulsive disorder,agent targeting ror1|presence of,,alanine aminotransferase (alt) ≤3 times the upper limit of normal (uln),"latex,|no scheduled",,,,"diagnostic and statistical manual of mental disorders, 5th edition",for at least five half-lives,4-6 years,,,,,,
5626,,serous tumors,ptsd|history,,foot clearance,age|consent,,,,primary end,within 30 days prior to the study|history of,≥6mm,,,,,,
5627,,concomitant disorders,adopt the supine decubitus,,norepinephrine,distal penile hypospadias|urethral,,,,triangular area,for the previous 4 weeks,18 to 30 kilograms per meter squared (kg/m²,,,,,,
5628,,clinical laboratory findings,weeks|oral antibiotics,,plasma ebv dna,rybelsus therapy|known,,,,could complicate the surgical phase,before study completion,< 5 × 109/l,,,,,,
5629,,urination problem,ischaemic cva,,age|bmi,drug use|current treatment of the drug abuse problem,,,,distal end of the previously placed thoraflex hybrid device,within the last 24 hours prior to screening.|any diet,>29|abdominal perimeter,,,,,,
5630,,liver damage,nusinersen,,fev1/ forced vital capacity (fvc) ratio,erforming,,,,minimally invasive nasal trabeculostomy procedure,during the study period|pregnant,≥0.3 × 109/l|ast,,,,,,
5631,,illness,factor x inhibitors,,american society of anesthesiologists (asa) classes,oral contraceptive method,,,,study.||exclusion criteria,within 28 days of cycle 1 day 1)|serum creatinine,<180 mmhg,,,,,,
5632,,cerebral mri)|whose first symptoms appeared,afatinib,,hcv antibody assay,international normalized ratio>2,,,,"ci500 series (ci512, ci522, ci532) cochlear implant.|fluent speaker",within 2 weeks before randomization|known hypersensitivity,>5.0 x uln|total bilirubin,,,,,,
5633,,hiv-positive testing,autoimmune diseases|patients,,who group,spinal column,,,,mask improvement.|participant,within 4 weeks prior to day 1|untreated,18-75;|ecog score,,,,,,
5634,,pregnancy|bipolar disorders,short-acting,,test for hepatitis b surface antigen (hbsag),molecular pathological diagnosis,,,,non-authorized,at least 3 months prior to the start of this trial,</= 81 mg/day,,,,,,
5635,,bronchopulmonary diseases,occurs,,body mass index range,general anesthesia|asa physical statuses 1 and 2|sepsis||,,,,non-chronic indications,within 4 weeks before the administration of the first dose;|received,from 0 to 80,,,,,,
5636,,chronic antiemetic,drugs known to significantly induce,,mdas,maintenance therapy (parp-inhibitors,,,,type ii dm).|living,within 6 weeks prior to the first dose of the study drug.|have,≥35 kg/m2|american society of anesthesiologists physical status,,,,,,
5637,,acute porphyria||-,amphilimus,,metabolic meals.|any condition,biological sex,,,,making implementation of the protocol,after two lines,< 8.0 g/dl|serum creatinine,,,,,,
5638,,prolonged marrow aplasia.||donor,anti-tumor drugs,,gu symptoms/conditions,onabotulinumtoxina treatment,,,,highly effective method of birth control,during the trial.|pregnant,>40 m2/kg,,,,,,
5639,,a:||diagnosis,drugs used in this study.||3,,hiv rna level,major abdominal surgery,,,,suitable for procedure;|known allergy,within 10 days prior to study treatment initiation,30 bpm or higher,,,,,,
5640,,vocal cord paralysis,mental illness;|the researcher believes,,toxin test,routine blood tests,,,,first-year,within the central 6 mm of the cornea,≥15 lbs in,,,,,,
5641,,hiv positive);|active infection,systemic steroid hormone,,esophageal cancer|aged,diagnostic intervention,,,,rome iv,during the last 3 months prior to the start of the study,=qt/rr1/3,,,,,,
5642,,invasive mammary carcinoma,lansky,,pap test should,recognized lipid,,,,influence metabolism,at 12 weeks after starting chemotherapy,+/- ivig,,,,,,
5643,,postoperative complications,glp-1 activity,,mrs of disabling stroke,allo-hsct,,,,"below,|uncorrected",within 30 days of enrollment|non-live vaccine,≥ 11.1 mmol/l|an,,,,,,
5644,,histological remission,excluded|pregnant,,kg|haemoglobin level,bilobectomy,,,,in either eye,at least 6 months from time of enrollment,> 8.5 g/dl,,,,,,
5645,,renal hypertension,pt>14s,,dream cohort.||,international organization for standardization,,,,old|primary,within 60 months of symptom onset,i or ii disorder;|presence,,,,,,
5646,,drug response,psychic,,mal,produce a negative pregnancy test,,,,microbiota;|a dietary consult to better explain the dietary approach and provide,14 days before the start of the study to 28 days after the start of the study,≥40 years|signed informed,,,,,,
5647,,early stage,psychoactive drug,,gep-nen,calicheamicin-conjugated antibody,,,,genotype severity.||,at the signing of informed consent,≥2x uln,,,,,,
5648,,cognitive complaints|all,levonorgestrel intrauterine system,,anesthesia duration,knee joint replacement,,,,unsuitable for proper,within 7 days prior to initiation of study,< 18.5 kg/m2|calorie-reduced diet,,,,,,
5649,,breast cancer||,mesalamine,,asa classification,compressive liner;|loss,,,,st elevation mi,>6 months,> 125 pg/ml,,,,,,
5650,,nippv,nirmatrelvir-ritonavir||,,months;|child,breast biopsy,,,,zygomaticomalar,over previous 4 weeks at screening,continuously higher than 300×10^9/l.|those,,,,,,
5651,,recurrent depressive disorder,oral antibiotics,,synthetic,re-rt|women,,,,suitable for entry,within the previous 12 months;|furcation involvement,under lkcmedicine.||,,,,,,
5652,,extracapsular extension of cancer,immunosuppressive condition.|resides,,hbv-dna≥1.0×103 copies,brachial artery blood pressure,,,,3 months|physical status,at the time of enrollment.|have,0-2.|asa score,,,,,,
5653,,gastroscopy|erosive esophagitis,tyrosine kinase inhibitors drugs)|refusal of the patient from examination,,infection.|left ventricular ejection fraction,criteria:||hepatic arterial anatomy,,,,index knee|patients,discontinued at least 2 weeks before first dose or five half-lives,≥ 100 x 109/l|calculated,,,,,,
5654,,major depressive disorder||,cemiplimab,,old|patients,expression of,,,,factor ii,at least two recurrences for this study,>12 months).||,,,,,,
5655,,-thalassemia,apheresis|heparin,,soliris less,regular tobacco,,,,antiandrogen-refractory,for ≥ 30 days prior to (day 0)|index ulcer,above 150,,,,,,
5656,,arterial thromboembolism events,excipients used in [18f]fapi-74: trace amounts of,,aptt uln,experimental,,,,mild to moderate,at least 3 months from the first administration of the study intervention to the last administration of the study intervention,"score ≥3;|heart, lung",,,,,,
5657,,local skin conditions,endocrine abnormalities|patients,,ecog ps,chest hrct scan,,,,test.|pregnant,within 3 weeks prior to receiving the first dose of trial treatment,older than 16 years,,,,,,
5658,,cerebrovascular incident,medications specifically,,1;|life expectancy,early mmr vaccination,,,,clinical trial.||note,at the end of treatment,less than 7.00,,,,,,
5659,,acute exacerbations,varicella,,diastolic pressure,postoperative surgical histology,,,,first-degree relative of the investigator.|the,at baseline of ≤7 mg/dl,"> 75,000/mm^3|total",,,,,,
5660,,clinical manifestations of symptomatic,dfu,,hemoglobin [hb] corrected,veno-arterial ecmo therapy|chronic respiratory insufficiency requiring,,,,acetylcholine esterase,more than 3 months|the,18-45 years||exclusion,,,,,,
5661,,avian,oud,,botox®,emergency call|interest,,,,unable to cooperate,within 7 days prior,older than 1 weeks of age|mothers,,,,,,
5662,,hip disease,ylang ylang,,identified etiology,effective contraceptive methods,,,,ipsilateral internal carotid artery (,during the study period.|patients,≥ 65 mm hg,,,,,,
5663,,venous outflow obstruction,sglt2 inhibitor,,plasma cells,computer tomography (ct),,,,ggcx-associated,at least 4-week,between 18 to 30 kg/m2|healthy,,,,,,
5664,,proprietary chinese medicine.|18-70 years old,anti-dkk1,,anti-aids antibody;|neurological diseases,anticoagulant regimen|negative,,,,gentofte,in knee,21-32 years,,,,,,
5665,,non surgical initial periodontal treatment,anti-tumor,,thyroid replacement,language translation,,,,grade 2 or above,within the 12 hours prior to screening,> 210 ms,,,,,,
5666,,adult morbidly obese,intravenous drugs,,preference.|acute traumatic,partial nephrectomy,,,,consume food containing up to 6 g of gluten protein per challenge day and up to 18 g of gluten protein in total,within a month prior to screening,less than 70 years.|positive,,,,,,
5667,,cholangitis,nyxol,,atypical,intracranial aneurysm clips,,,,related artery with,within the last 12 hours|use of,0 or 1|refusing,,,,,,
5668,,end of treatment visit.|complete baseline screening assessments to confirm eligibility to participate if,wine,,hepatitis b core antibody;|hcv-rna,psma pet,,,,twin,within 7 days or 7,>t,,,,,,
5669,,acute respiratory syndrome corona virus 2,strongly inhibit cyp3a4/cyp3a5,,cardiac resynchronization therapy (crt),intra aortic balloon pump [iabp],,,,protocol.|sledai-2k criteria,in history,≥ 1.5 × 109/l|platelet count,,,,,,
5670,,therapy.|connective tissue diseases,platelet medications,,jean mermoz hospital||,computed tomography scan (hrct),,,,days|preoperative,within 3 months of screening.|the,less than the duration of the protocol;|patients,,,,,,
5671,,psychosis nos,ampicillin,,corticosteroids,complete retinal degeneration,,,,low habitual consumption of fatty fish,deterioration 2 weeks prior to the first dose of study treatment.|life expectancy,higher than the,,,,,,
5672,,perirectal abscess|disease limited,drugs of similar chemical classes|participants having a clearly defined predominant,,valve area,emicizumab therapy,,,,serostatus,within 28 days prior to study vaccine,> 95th,,,,,,
5673,,hivab,drugs of similar chemical classes,,extended qtc interval,versus-host disease.||is,,,,prohibited concomitant,at least 4 weeks prior to study intervention administration,less than or equal to (<=) 55 years,,,,,,
5674,,metabolic disease.||female,ventricular assist,,male volunteers weighing,pelvic region,,,,suitable for curative multimodality treatment,prior to baseline visit or|are postmenopausal defined,<= 1.5 x institutional upper limit of normal or|creatinine clearance,,,,,,
5675,,cardiopatie congenite e tumori maligni,genes,,heart association class,computed tomography (ct).|suitable venous access,,,,grade 1 hypertension,prior to study day,27 through 36 weeks,,,,,,
5676,,a|chronic renal failure,sleep medication,,american society of anesthesiologists physical condition,general appendectomy,,,,icd-10 dcr,less than 4 weeks from study entry,less than 50 kg,,,,,,
5677,,"tests,|any abnormalities in rhythm",cytostatics,,list of contraindicated medications,caffeine daily consumption,,,,non-squamous advanced,prior to registration,20 ≤ age ≤ 45;|asa i ～ iii;|willing to participate,,,,,,
5678,,neurological impairments,dosing:||• hemoglobin (hb,,hepatitis c virus rna,endovascular treatment,,,,suitable for neoadjuvant,at least 6 weeks,6 to 17 years old,,,,,,
5679,,mild eczema,l-tga,,upcr,thoraco abdominal surgery(35)|left,,,,genetically proven d-caa|≤ 2,before onset,at least 37 weeks.|participant,,,,,,
5680,,neutral effects,systemic corticosteroid treatment,,estimated iq,bdi|>20,,,,hepatocellular,at the time of signing the informed consent.|ability to undergo,1 mmhg=0.133 kpa,,,,,,
5681,,mentally capable,glaucoma medications,,rano,baseline exam,,,,post-infarct,in the last month;|women,more than 50 ml,,,,,,
5682,,syndesmotic,spasmolytic agents,,resuscitate order.|burns,alternative treatment,,,,cr);|relapse after,within 3 months of the first administration of study,<20%,,,,,,
5683,,hemodynamically stable,carob leaf,,hepatitis c virus (hcv) (+),gastric volume,,,,natural,while the mother,≥ 45kg,,,,,,
5684,,induces liver metabolism of drugs,erythromycingemfibrozilsimepreviramiodarone,,females.|age,chemotherapy regimens.||histologically,,,,axis 2,for at least 3 years.|patients,older than 60,,,,,,
5685,,heart disease|inclusion,ards,,uvfp,resuscitated,,,,antihypertensive,in the past year||,"i-ii,|uncomplicated",,,,,,
5686,,"solid, oxyphil",abortive migraine,,inhalation,transcutaneous electrical nerve stimulation (tens),,,,self-identified,at the first day phone call of the diagnosis,19 - 45 years,,,,,,
5687,,lumbar spine pain,l.1121-8,,expected length,blood cell infusion,,,,stage 2 hypertension,at time of staff,<1)|more,,,,,,
5688,,lactation.|acute promylocytic leukemia,examination,,hemoglobin inclusion criteria.|patients,endoscopic submucosal dissection,,,,icf.||exclusion criteria||osteoarthritis (oa),between november 2007,>= 1000/ul,,,,,,
5689,,physically inactive,cmpfd,,glycosylated hemoglobin a₁c.|diagnosis,transfer,,,,moya moya disease,within 24 hours before surgery,stage pt1-3,,,,,,
5690,,psychiatric diseases.||,3rd molars,,mrs,compansatory strategies.||,,,,listed in inclusion criteria;|any chemotherapy;|local treatment,within 28 days of screening.|previous,≥ 20|males,,,,,,
5691,,lens opacity,glp-1 analogue,,ede,2ry causes,,,,non-culprit lesions,after 24 week of preganancy||,18 to 40 years||,,,,,,
5692,,procaine.|contraindications,component of amlodipine,,new york heart association (nyha) congestive heart failure,psychodynamic psychotherapy,,,,high school;|competence in spoken,within 6 months to 2 years,< 60 ml/(min×1.73m2)|patients,,,,,,
5693,,congenital syndromes,norgestrel,,old|stable respiratory condition,antidiabetic,,,,modic type-1 changes,at least 2 years+2 months post vaccine/control,from 18 to 70 years inclusively;|18 kg/m2≤bmi≤32 kg/m2,,,,,,
5694,,autoimmune diseases.||note,pain assessed in proximity of the wound,,quantiferon gold test collected,histopathology,,,,at initial diagnosis,within 30 days post-procedure|any,18-24|patients,,,,,,
5695,,crc)|previous colonic resection|returning,anxiolytic medication,,gastric surgery|non-adherence,iud)|vasectomy,,,,at-risk mental states (caarms).|in contact,for >12 months each,<18 or >89,,,,,,
5696,,exertional angina,over-the-counter medicine,,maximal posology tolerated by the patients stable,sphenoethmoidectomy,,,,under quiet,during the last six months.||,< 30.0 pg/ml|self-reported,,,,,,
5697,,t wave abnormalities,hydrea,,modified rome iv criteria for functional constipation (fc):,instruments.|protrusion of the 50a imaging balloon,,,,non-lactating.||,prior to study sample collection,19-78 letters,,,,,,
5698,,status:||unresectable disease,physiologic corticosteroid replacement therapy,,hepatitis,restriction regimen,,,,4/10|no,within 12 months from registration||patients,< 60 ml/min/1.73 m2||x,,,,,,
5699,,regular behavioral,fallopian tubes.|oral,,ec,infected surgery,,,,neglect syndrome|right,within 6 months prior to operation;|has,1-3.|life expectancy,,,,,,
5700,,controlled infection,hip|those,,sentinel node negative|ductal carcinoma in situ dcis,cerebral ischemia.||baseline nihss,,,,upper urinary tract being,hospital since january 1999 to december 2015.||,0 to 2|adequate organ function,,,,,,
5701,,atherosclerotic artery disease,trial.|male,,bristol stool scale (bss),tracheal tube capping,,,,conservative,for 2 weeks,≥ 3000/μl,,,,,,
5702,,combined respiratory diseases,sodium chloride,,palliative treatment|unstable systemic disease,hysteroscopy|predict operation duration,,,,third-degree,in the last 90 days|positive,"<45ml/min/1.73m²,|no",,,,,,
5703,,corticoid,fancd2,,morristown,b-cell maturation antigen (bcma)-directed immunotherapies,,,,neck.|concurrent,within the past 28 days.|patients,^9/l,,,,,,
5704,,pulmonary hyperinflation|collateral ventilation positive|fev1 post lysis,piroxicam,,serum creatinine concentration,lateral localization,,,,under the care of a cardiologist,within 14 days prior to first dosing.|administration of cyp3a4/5 inhibitors,4-12 weeks,,,,,,
5705,,acute surgical procedure||,edoxaban,,calculated estimated glomerular filtration rate [egfr],vital signs|those,,,,american diabetes association's (ada) definitions,age>=37,less than 34 weeks,,,,,,
5706,,secondary cause of presbyopia,liver enzyme inducers,,thyroid function abnormal,combined cabg,,,,lower extremities|unable,within the last 12 months；|persons,>= 1 day prior to study treatment|strong inhibitors of cyp2c9,,,,,,
5707,,dentinal exposure,analgesic medications used in this,,+ t cell count,cardiology,,,,grade ii lymphedema,within 4 weeks;|subjects,≤ 2 g/day,,,,,,
5708,,malignant pericardial effusion,components of the treatment.|patients,,treatment|extensive reading,liver hardness determination,,,,moderate risk of imn.||,within the last 4 weeks prior to the study examination date|severe polyneuropathy,> 5 years|male,,,,,,
5709,,hae types,drug components of this protocol,,glomerular filtration rate (ccr),androgen therapy,,,,apl-associated,at least 2 weeks prior to starting the intervention,<5.7 kg/m2,,,,,,
5710,,retinal pathology,antimuscarinic agents,,digital copy,cranial aneurysm).|pregnancy|during the exclusion period,,,,unrelated to the pain,in the past 8 weeks,≥ 3.5 ku/l.,,,,,,
5711,,natural course);|women with,fosphenytoin for,,glomerular filtration rate (egfr<30 ml/min,molars.|good oral hygiene,,,,indwelled,at least 4 weeks prior to day 1 until at least 4 weeks after the last dose of study product.||,greater than or equal to18 years.|eastern cooperative oncology group (,,,,,,
5712,,familial polyposis,norwood,,quantitative pcr,prospective analysis,,,,"unknown time of onset, the midpoint of the time last",after 5 half-lives,4 or,,,,,,
5713,,reversible causes,fluoxetine,,response evaluation criteria in solid tumors version 1.1,radiation therapy.|nonsmall cell lung cancer,,,,arrival of the msu,within 6 months prior to the first dose of,< 500 iu/ml or < 2500 copies /ml,,,,,,
5714,,hepatitis b virus [hbv] surface antigen positive,over-the-counter medications.|use of,,partial thromboplastin time ( aptt),soft tissue augmentation procedures,,,,local site,prior to initiation of zimberelimab,> 100 mmhg,,,,,,
5715,,hepatic insufficiency resulting,propofol pharmacodynamics,,amplification,pet-ct,,,,challenged individuals,prior to enrollment|patient,more than 3 months.|patients fully understand the protocol,,,,,,
5716,,autoimmune disease|smoking,morphine/opiates,,urine test indicates,physiologic replacement dose,,,,non-diabetic renal disease,within the past 3 months.|underwent,< 1.5 x 109/l,,,,,,
5717,,bone metastasis,high drug,,platelet glycoprotein autoantibodies positivity,24-hour urine,,,,american joint committee on cancer,within 3 months prior to the first study drug,8 inches,,,,,,
5718,,psychological medical histories,rheumatoid,,nhny functional class,allogeneic stem cell transplantation.|a pregnant,,,,16:45 years,for at least one year|individuals,|severe,,,,,,
5719,,memory loss complaints||,orthotics,,total mgd score,radiotherapy ≤1,,,,non-melanoma skin,within 6 months prior to enrolment|subject,≥100 mmhg).|patients,,,,,,
5720,,infectious eye disease,local regulations||,,body mass index (βμι),inpatient treatment,,,,"infections,|neuromuscular",in the last two years|is,18 years and older|women,,,,,,
5721,,fetal medicine consultants,clindamycin,,nbgfr,oxygen flow l/min).|informed,,,,sustained,during the study;|women,>-2+,,,,,,
5722,,non-conforming,fviii inhibitors,,aalborg university hospital (center and home patients)|t1d,mediastinum.||hematopoietic stem cell transplantation,,,,asas modification of the berlin algorithm for,within 1 month before baseline;|aphakia,i - iii|laparotomic hysterectomy,,,,,,
5723,,"joint injury,|having",immunosuppressant medications,,tyrosine kinase domain,femoral stem,,,,t2d|absence,for at least 3 months|no glucocorticoid therapy,≥ 4|the asd,,,,,,
5724,,hcvab positive,beta-lactam antibiotics,,angle of deviation,rasopathy||,,,,near-daily basis|allergic,for at least 12 weeks after,>140 mm hg,,,,,,
5725,,brs-ecg pattern,cyp)2c8 inhibitor,,"1992),|premorbid fluent cantonese speakers,|aged",surgical resection of the pancreas,,,,≥14 days,"during the study,|willingness to follow all study procedures",0 or i,,,,,,
5726,,third-line therapy|last follow-up,hbsab after vaccination,,fridericia,transabdominal ultrasound (us),,,,ibs-d.|participants,within the last 6 months.|have,< 18 months or|biopsy,,,,,,
5727,,malignant tumors;|liver/lung metastasis;|no pathology,et,,inclusive).|body mass index,ventricular pacemaker implantation,,,,age;|body mass index,more than 20o decrease in ir,0-1.|bone marrow function,,,,,,
5728,,rheumatological diseases,provocation,,impairs function,regular physical activities,,,,devitalized tissue present,within 14 days prior to enrollment.|other,">0.8,|be able to understand simple",,,,,,
5729,,high risk,contrast dye,,creatine phosphokinase (cpk),oral antiviral (,,,,peri-implantitis|participants should,at least 4 weeks prior to c1d1,< 5.0,,,,,,
5730,,congenital disorder,hours|glycoprotein iib-iiia inhibitors,,energy expenditure,open-heart surgery,,,,primiparous,for at least 6 months before study entry|on,≤ 1.0 upper normal limitation,,,,,,
5731,,high dependency care);|participants,lomaira,,viral serology deemed,blood chemistry,,,,cardiac rehabilitation program,within 1 week prior to c1d1)|haemoglobin,< 220μmol/l;|lung function,,,,,,
5732,,accessible tumor,beta blocker therapy,,hdl cholesterol,insufficient organ function,,,,age|advanced,previous two years.|anticipates being able to wear the study lenses,> 18 and < 90 years|admitted,,,,,,
5733,,autoimmune disease.|ascertained hypersensitivity,rnai,,- serum creatinine,lymph node calcification,,,,listed in the protocol as disallowed,within 72 hours prior to first administration of fluoxetine|able to,6-36 months,,,,,,
5734,,von willebrand disease,hyperosmolar hyperglycaemic state,,rigidity.|epilepsy|mri findings,intraocular vision-affecting,,,,"ischemic stroke,|time",within 24 hr. d,more than 12%,,,,,,
5735,,abstain from marijuana/cannabis,predefined medications,,hiv antigen/antibody,gastric surgery;|gastroscopy,,,,full extension,within 14 days prior to start of study drug,≥ 18 years and ≤ 80 years.|both,,,,,,
5736,,splenectomy.|participant,titanium,,organ function|adequate performance status,old)|undergoing procedures below,,,,requirements||,within the last 14 days of screening)|hemoglobin,≤ 1.|adequate organ,,,,,,
5737,,cerebrovascular event.|pd peritonitis,over-the-counter (otc) nasal products,,serum β-hcg,paraffin sections,,,,suitable to participate in this study.|（5）babies,within 2 years prior to baseline|treatment,18-80.|a,,,,,,
5738,,all,inos inhibitor,,potassium level,knee extension/flexion),,,,apical periodontitis|radiographically,"for the first time,|does not have",90cm,,,,,,
5739,,extremity deformity,vegfr inhibitor,,old|american society of anesthesiologists (asa),pelvic radiotherapy,,,,below:||absolute,within 48 hours of surgery|subjects,18-80|to participate,,,,,,
5740,,solid organ transplantation|any other medical condition,drugs used in the study of tislelizumab,,yahr stage ≤,lactation;|significant gi surgery,,,,specifically defined,between the involved,≤ 80 years,,,,,,
5741,,intertriginous areas,immunosuppressive drugs).||replacement therapy,,a1c,etc.)|history of,,,,protocol objectives|known diagnosis,within one week of receiving ultrasound delivery|use,>450 milliseconds|any,,,,,,
5742,,gastrointestinal disease/abnormalities,diltiazem,,serum fasting glucose level,salvage therapy,,,,stroke||,prior to his entrance to the study,from 17 to 45 kg/m2,,,,,,
5743,,psychological diseases sensitive,icm-203,,female;|ecog performance status score,restricted pool,,,,unsalvageable,from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration,upper limb function|inability to give,,,,,,
5744,,hiv)|seropositive,midodrine,,barr virus,prevent pregnancy.||,,,,suitable for a hybrid approach (rvd>2.75 mm,within the last 30,above sea level,,,,,,
5745,,distal internal carotid artery beyond the bulb,abused drug,,4)ecog ps score,rigidity|asymmetric onset of clinical signs|progressive motor symptoms|age,,,,low pressure≤90mmhg,during which he received,male|age 18 years,,,,,,
5746,,participate|withdrawal of informed consent,contraceptive medications,,amd|best corrected visual acuity (bcva),videofluoroscopic swallow,,,,uncooperative,during the patient's participation in this study.|pregnant,≥ 6 months.|agreement,,,,,,
5747,,issues,vpriv®,,sensitive pregnancy test,granulocyte colony,,,,grade 3 or above occurred,more than 1 sd below the mean score,between 20 to 50 years|all,,,,,,
5748,,hepatitis b.|positive for covid-19 virus.|positive quantiferon®-tb gold test,ketobemidone,,prothrombin rate,vital signs,,,,implanted neurostimulators,for one week,<0.600 x 109,,,,,,
5749,,vagina,otc artificial tears,,international diabetes federation (idf) definition,ii|elective abdominal hysterectomy operation||,,,,getting,within 28 days prior to the first dose of the investigational product|an interval,≥ 1000 iu/ml,,,,,,
5750,,deep vein stenosis|a,loxapac,,metastasis cohort||at least,intensive care unit (icu) indication,,,,clinically symptomatic,in the last months,> 65 mmol/l.|cardiovascular,,,,,,
5751,,yesavage,met,,qtcf interval,experimental drug|patient,,,,stable regimen,during the study.|if participant,higher than 220/110 mm,,,,,,
5752,,90|mild renal impairment,anticonvulsant therapy,,hcv,emergency surgery|cardiac transplant,,,,secondary to amd,within 2 weeks prior to the first dose of investigational product|in addition,< 50 %,,,,,,
5753,,hepatitis c or,tranquilizers,,asat/alat,tak-788,,,,non-ongoing,at the time of the first dose <10 k/μl||eastern,< 40 kg/m2.|a,,,,,,
5754,,diabetes mellitus)|gastrointestinal disorders,components of the tested,,rano criteria,bone scan imaging obtained,,,,long-term corticosteroid therapy,within the next 3,more than twice the upper limit of normal,,,,,,
5755,,wifi,use antispasmodics,,alanine aminotransferase (alt) level,nicotine products.||,,,,admitted to,more than three months|head,outside 20/400,,,,,,
5756,,unstabilized pathology,somatostatin analog,,new york heart association classification,aortic surgery,,,,write in catalan,after at least five minutes,16-25 years,,,,,,
5757,,neurological disorder|chronic,london,,tobacco exposure,norwood palliation,,,,age.||,during the study period；|alcoholics，or,less than 5 cm,,,,,,
5758,,venous sinus stenosis,combination art,,serum bicarbonate,prostate radiotherapy,,,,microphone||non-inclusion,at start of study.||parents,iii and iv,,,,,,
5759,,mixed endometrioid patient,anatomic,,50kg(woman)|body mass index (bmi),experimental therapy note: off-label therapy,,,,nasotracheal intubation,within 6 months prior to screening.|unlikely to comply with unified diet,> 320mosms/l,,,,,,
5760,,multigravida|cardiac,mycophenolate-mofetil,,prothrombin time (aptt),twelve regular sessions,,,,rux.|had,within 4 weeks of the first dose of treatment.|has,= 30 kg/m2,,,,,,
5761,,cik cells,nitrofurantoin,,cuff leak test,intensive care (ic),,,,a:||severe,etc.)|colonoscopy history (,≤ 60 mg/dl,,,,,,
5762,,medication-induced,iodinated contrast media.|renal failure,,"arterial embolus,|(2)being residents of northern norway,|(3)willing",cardiogenic shock|current hospitalization,,,,under general anesthesia|aged,after one year of rai therapy,≥ 8 weeks,,,,,,
5763,,pseudo-cushing's syndrome,acei)/angiotensin receptor blockers (arb,,niaaa alcoholic hepatitis consortia,procedure,,,,eolc|previous,within 48 hours prior to the initial dose of study medication.||iii,organs ≥1 cm,,,,,,
5764,,pain relief medications|patients,chemotherapeutics,,antibodies to treponema pallidum).||the who,cessation of ovarian function,,,,metabolized through cyp3a4/5;||vulnerable persons,at least 3 of 5 physical examination maneuvers,< 200,,,,,,
5765,,radioopaque renal stones,chlorambucil,,systolic velocity ratio,microscopic evaluation of,,,,transfer;|pregnant,prior to the first dose;|subjects,25-65 years,,,,,,
5766,,acinar cell carcinoma,mirabegron,,likelihood of,revision uka,,,,surgical,within 5 years of registration,< 30 ml/min)|moderate,,,,,,
5767,,gastrointestinal necrosis,cisplatin-base chemotherapy (bep),,including:||leukocytes,sterilization procedures,,,,mild-to-moderate,at least after 1 year of the dbt exam.|benign cases,≤ 18,,,,,,
5768,,clicking sound,antibody treatments for cancer,,decrease,transesophageal echocardiographic,,,,core 70-100 ml (ctp [rcbf,within 14 days before screening)|hemoglobin,> 11|eligible to receive,,,,,,
5769,,abnormal coagulation test,inducer drugs,,serum crp,nasopharyngeal wash|participation,,,,erythrocyte growth factors,within 2 years prior to screening,45 and older,,,,,,
5770,,placenta previa,glaucoma medication,,international cancer control [uicc].|ecog performance score,transcatheter aortic valve replacement;|concomitant,,,,hrs guidelines,in previous 5 years.||for main cohort,> 20 ng/ml|ability,,,,,,
5771,,cutaneous tumors,acid supplements,,alberta health services)|presence,palliative gastrectomy,,,,invading the target site of puncture,in the month prior to enrollment.|past,18-65||exclusion criteria,,,,,,
5772,,cardiac tamponade.|central,paracetamol/acetaminophen,,urine protein quantity,clear surgery,,,,topical use of hormones,prior to randomization:||leflunomide.|i.v,less than 12-months|patient,,,,,,
5773,,chronic liver,molecular,,hemoglobin ˂10).|critically ill patient.|past operation,bone marrow sample,,,,ncictcae 5.0,14 weeks prior to screening;|patients,18 to 30 kg/m2,,,,,,
5774,,coagulation dysfunction diseases,tobacco-,,suicide-risk-assessment-c-ssrs,partial resection of the intestine;|,,,,comorbidity,within 180 days to determine the presence,above definition,,,,,,
5775,,amenorrhea|hyperglycemia,byon4228,,screening visit.||☞ bmi,radioligand therapy,,,,on room air egfr,>12 months from the time of visit 1 / randomization|age,<13 weeks,,,,,,
5776,,major congenital malformations,otc drugs,,emergency,tissue biopsy after completion of cd19 targeted therapy,,,,low grade histology).||,since at least 3 months||patients,≤ 3 x upper limit of normal (uln),,,,,,
5777,,clinical site,lenalidomide,,signature|age,hispanic/latino,,,,medical monitor.||diagnosis of,during the last 6 months|pregnancy|any systemic condition,>1.5 × upper limit of normal (uln):,,,,,,
5778,,myalgia,equipment,,bone mineral density of the lumbar vertebra,buffer,,,,patient.|receive,at the time of most recent labs taken before starting ketogenic diet.|ast,less than one year.|already,,,,,,
5779,,catatonic,lunelle,,southwest oncology group (swog) statistics,safe surgery,,,,cyp2c9,within 14 days of first dose of study drugs||based,<200 cells/ mm3|chronic renal,,,,,,
5780,,gilbert's syndrome).|alanine,oral bisphosphonate,,prostate cancer|person of,plain radiography,,,,full-depth,within 1 month prior to surgery|provision of signed,exceeded 30 kg/m2.|they,,,,,,
5781,,lower back &,ivt anti-vegf treatments,,follicles,midurethral sling,,,,pericardial effusion,within 3 months from the first dose to the last use of the study drug||,"18-40,|at least",,,,,,
5782,,smoking risk,non-steroidal anti inflammatory drugs,,special interest in fetal medicine,puncture of non-compression vessels,,,,interfere with therapy or monitoring,for three months in each of two,exceeding 35 cm h2o|patients,,,,,,
5783,,muscle.|gunshot wounds,mineralocorticoids,,yahr score,pregnancy|current treatment,,,,between donor,within 3 weeks or,>= 100 x 10^3/ul,,,,,,
5784,,largely excludes adolescents,monocular,,pregnancy test results;|international normalized ratio,colostomy,,,,pd-l1 inhibitor-based,during the 3 months prior to screening.|ability to understand the requirements of the study,≤ 24.9 g/m²/h;|be,,,,,,
5785,,bronchial asthma|medical,hepatoid,,1|donation of plasma,laser treatment.|moderate to severe hypertension,,,,refractory to intensive speech therapy,within 6 months prior to screening;.|known,hipec|expected survival,,,,,,
5786,,inflammatory brain,loop diuretic,,cab,therapeutic intervention,,,,distal,within two weeks prior to entry into,18 or older female|patient must,,,,,,
5787,,multi-function spectacles,hydrocephalus,,weight-matched,radiotherapy -or- insufficient clinical response,,,,diagnosed,within 1 year prior to inclusion|patient's rejection to sign the informed consent|any other reasons,between 5 and 70 years,,,,,,
5788,,psychiatric diagnosis,dhs plate,,remaining alveolar bone height,survival,,,,may jeopardize the ability of the patient to undergo the procedures outlined,within the last three years,<1500 g,,,,,,
5789,,non-mps iiid-related,immunoglobulin replacement therapy,,nuclear stress test,abbott neuromodulation system,,,,acr target for gout,at consent|completing,equal to or lower than 1.5 times of uln;|renal function,,,,,,
5790,,cardio-pulmonary,benzamide,,visual imagery questionnaire -20 (kgia-20)|access to adequate technological devices for communication,fundus exam,,,,vault,12 months,>95 g/m2,,,,,,
5791,,chronic colonization,cayston,,child-pugh,suspicions,,,,long term health condition,prior to the first scheduled,≥20 years|operable,,,,,,
5792,,lumbar spondylolisthesis|osteopenia with,cytotoxic chemotherapy,,"durvalumab + platinum-etoposide,|patients",complete blood count,,,,full length of the study|ic 8 willingness and ability to give an informed consent||exclusion criteria,for at least 6-months,more than 10kg,,,,,,
5793,,neurology,celecoxib,,pedt,treatment of radiotherapy,,,,er-positive,for 28 days.|patients,≤ 90 days|subject,,,,,,
5794,,inclusive).|in good health,beta human chorionic gonadotropin,,supraphysiologic testosterone,esophageal varices|patients,,,,nih-modified omrs,within 6 months.|history,more than 102 cm,,,,,,
5795,,skin lesions,long-acting β2 agonists,,bone marrow cytomorphology,"gespecialiseerde ggz""",,,,mini|clinically significant,within 6 months prior to day,≥ 100 × 109/l|hemoglobin,,,,,,
5796,,anesthesia.|patient's consent,fedr,,plasma concentrations,tavi procedure,,,,amiens university hospital,within last 5 years)||,skilled,,,,,,
5797,,therapy|pregnant,faster acting aspart,,international physical activity questionnaire (short),enrollment||routine blood tests,,,,participation|current,within 12 months after autologous hematopoietic stem cell transplantation,≤ 50mg/l|if,,,,,,
5798,,major depressive,aids).|pregnant,,peripheral blood,tavr procedure|emergency surgery,,,,medically unstable,"in the last 6 months,|diagnosed",>= 8 g/dl,,,,,,
5799,,trying to get pregnant|the,medications classified,,european society of cardiology,anti-tumor therapy,,,,female;||pathological,during the last 30 days prior to and,30% or greater,,,,,,
5800,,disease.|age,platelet-derived growth factor receptor b (pdgfrb),,karnofsky performance status (kps),conventional physiotherapy,,,,gingivitis -,within 6 months from the screening period until the last trial drug,≥140 mm hg,,,,,,
5801,,mechanism disorder,class iii antiarrhythmic medications,,forced expiratory volume/forced vital capacity (fev1/ fvc),melanoma,,,,l1-s1,within 4 months prior to screening.|patients,>= 100.4°f,,,,,,
5802,,starvation,adhesives,,proteinuria,procedure|previous contralateral major,,,,anticholinergic drugs.|no,at cycle 2 day 14 (+/- 4 days),<60 x 10^9/l,,,,,,
5803,,anaphylaxis reaction,inhibitors,,hiv rna,radionuclide angiogram,,,,"eating disorder unit from june 1, 2013, through",in the past 30 days prior to the study,< 100 µg/dl,,,,,,
5804,,immunodeficient condition,contrast material|patients undergoing,,anti pd-1/pd-l1,fact-cog,,,,immune response,within the preceding 6 months|coronary artery bypass surgery|current stable angina pectoris,0 to 1;|hematology function,,,,,,
5805,,delayed recall,hydrogels,,human application test target 10 minutes,stem cell transplants,,,,middle cerebral artery (,within 7 days of receiving the first dose of study treatment.||,>40)|patients,,,,,,
5806,,peripheral arterial bypass,immune checkpoint therapy,,fviii inhibitory antibodies (,older|empirical therapy,,,,mild uncontrolled hypertension,last 12 months may reflect,<15 ml/min/)|chronic,,,,,,
5807,,immunosuppressive disease,over-the-counter topical creams used for the treatment,,criteria below:||lam first line,heart failure|pregnant,,,,comparable,within 4 weeks.|participants,<= 2,,,,,,
5808,,future,strong inducers of liver metabolism enzymes,,bomc,left bisegmentectomy,,,,cumulative dose,within 100 days prior to first dose of study treatment|participants,> 10,,,,,,
5809,,degenerative neurologic disease|hip fracture,opioid|baseline,,stated)|absolute neutrophil count (,tibiofemoral knee osteoarthrosis,,,,likely to disrupt the,attributed to a,age.|at least 30% of subjects,,,,,,
5810,,acute urine,intravitreal steroid injections|concurrent participation in another clinical trial|females,,"smoking cessation,|changing schools",histological biopsy,,,,pandemic,within 90 days prior to study drug,above 40ml/min/1.73m2;|individuals,,,,,,
5811,,migraine).|pregnancy,youth in detention centers,,alkaline phosphatase (alp),pelvic mri|females,,,,sulphonamides,at time of signing informed consent,3 or above irae,,,,,,
5812,,steroids|bronchial hyperreactivity,carisoprodol,,oahi,"treatment program trial version 10 guidelines"" issued",,,,recanalization,within 4 weeks of study enrollment.|have any of the following conditions,<5 x uln,,,,,,
5813,,growth factor support allowed)|platelet count,chemotherapy.|patients,,celf preschool-2,participate.|blood donation,,,,duo-stim ivf,in three or more,> 30 mg,,,,,,
5814,,columns,duplex kidney,,tcpo2 30 mmhg).|ability to attend study visits|ability,nicu,,,,following:||type i,within the last 1 month||,60-74 years,,,,,,
5815,,reduced periodontium,monoclonal protein,,physical activity readiness questionnaire,cerebral scan,,,,non-elective,at time of enrollment.|recipient,< 3 x,,,,,,
5816,,epileptic seizure,immunosuppressive therapy|active,,pulmonary function testing,medical treatment,,,,expected to prolong,more than 1.o diopters,>64)|progressive,,,,,,
5817,,area|allergy,gadolinium contrast,,blood pressure (ele),bronchoscopy,,,,"men,|control record",during the study intervention period,grade ≤ 2|no,,,,,,
5818,,subacute stroke,anti-neoplastic indications,,rapid urease test,self-help,,,,onset,within six weeks,positive,,,,,,
5819,,cerebral spinal fluid (csf),pediculicidal medication,,scoring,1.chronic pelvic pain,,,,amenable to a curative treatment approach|participant,within 24 hours prior to randomization|progressive,>460 ms,,,,,,
5820,,glioblastomas,nitrosoureas,,human immunodeficiency virus|history,viral vector,,,,"might interfere with, the conduct of the study",for at least 48 hours prior to enrollment,≥60 ml/min;|serum,,,,,,
5821,,root resorption,anti-inflammatories,,tymp,quantitative assessment of proteinuria,,,,refractory to standard treatment,within 12 months of baseline,≥ 40 µmol/l,,,,,,
5822,,liver metastasis);|serum creatinine (cr) ≤1.5×uln,proteasome inhibitor,,ckmb values,assessment tools|patients,,,,intra-ventricular mass,within the last 5 years excluding,18 to 89 years,,,,,,
5823,,subserosal myoma,defines,,mg,breast surgery,,,,surgical specimen,in 48 hrs,less than 10*10*2 cm|the patient or,,,,,,
5824,,myeloma,cyclophosphamide treatment,,mouthwash,allergen immunotherapy,,,,shift,in the 30 days prior to enrollment,less than one year|pregnancy|suboptimal,,,,,,
5825,,cervix,strong inducers of cytochrome p450 3a4,,life expectancy,open repair,,,,secondary vv,at least 4 weeks prior to first dose of study treatment,g3 net.||pancreas,,,,,,
5826,,abnormal immune function,hyaluronic acid gels,,adult infusion center,small lymphocytic lymphoma,,,,hiv-associated,within 4 weeks prior to eay191-e5 registration/randomization,<30ml/min/1.73 m2,,,,,,
5827,,hiv-negative||health professional,adt,,alanine-aminotransferase (alt),vaccinated vaccines,,,,pregnancy.|neuro-muscular,"in the past year,|exercising regularly for 6 months",< 45,,,,,,
5828,,parasitic lung disease,drugs used in study|lower third molar associated,,muscle enzyme 1.5 times upper limit of normal,surgery.|neonatal surgery,,,,epilepsy|any unstable,within 28 days of the start of study.|chronic inflammatory disorders apart,less than 100 iu/ml before the first dose of the study drug,,,,,,
5829,,lung infection,pharmacologic anti-neoplastic,,s2114 car t-cell therapy,subsequent standard treatment regimen.|previous histopathologic,,,,primary pelvic tumor,within the 6-day period immediately following this date,100 mg/dl,,,,,,
5830,,allele mismatches,varespladib,,rapid urine drug screen,esa treatment,,,,colitis|major,within the last three months before enrolment|no previous surgical treatment,>2x/wk|premenopausal,,,,,,
5831,,conservative therapy,combined angiotensin-converting enzyme inhibitor,,down syndrome.|under,retention of ovary function,,,,clinically ascribed to hypocalcemia.|participants,in the last two months prior to recruitment,complete response to bcg,,,,,,
5832,,familial mediterranean fever,scn1a.|participant,,criteria of hanifin and rajka (1980).|ad lesions,strabismus surgery||,,,,relevant,within 2 weeks prior to screening,>176.8µmol/l;|persistent,,,,,,
5833,,contraindicating intramuscular vaccination,dhea,,oral iron|bmi,tics-m1,,,,central retinal arterial occlusion,during the registration phase,18 or over|suffer from stress urinary incontinence,,,,,,
5834,,vascular lesions,beta agonists,,health organization performance score,pet/mri referral package,,,,chronological age,in last 3 months)|compromised musculoskeletal function,73 to 19 letters (inclusive),,,,,,
5835,,cetd,steroids 24,,platelet count,"common femoral artery of target leg,|known",,,,centile,within the next 3 months|metal implants,18 years or older.||a,,,,,,
5836,,hepatitis b virus(hbv) dna in,local anaesthesia,,self-reported.||inclusion criteria,mri read,,,,non-nasal enktl,at least 2 days per week|patients,> 1.3 logmar,,,,,,
5837,,inducer,naltrexone,,ctcae grade,vulvar/vaginal cancer|undergoing,,,,primary tar in 2022.|there are,within 30 days prior to the index procedure|blood dyscrasias,greater than the lower limit of detection,,,,,,
5838,,lesion erythema,hypoglycemic drugs,,nodes|detectable preoperative plasma cthpvdna,palliative surgery,,,,current,within the last 12 months.|evidence of tb infection,iii-iv)|history,,,,,,
5839,,etc.;|hepatitis b virus surface antigen (hbsag),gynecology clinics|patients,,hunt,base treatment regimen,,,,inhaled hormones);|suffers,during the 24 hours prior to each vaginal sample,"1, 1+&2",,,,,,
5840,,behavioral symptoms,grapefruit/grapefruit juice,,human immunodeficiency virus (hiv) infection.|participation in,pathological assessment.|paget's disease of the nipple.|synchronous,,,,pregnancies|scheduled,during the study.|patients who received cytotoxic chemotherapy,≤ 5× uln,,,,,,
5841,,anorexia nervosa,inhaled tobacco)|illicit drug use,,90 diastolic|carboxyhemoglobin levels,"bedside schwartz [schwartz and work, 2009]",,,,copd)|asthma exacerbation.||,within normal ranges||,≤ 1.5 × the upper limit of normal (uln) range,,,,,,
5842,,r breast implant subjects:||age,n. meningitidis,,international classification of inborn metabolic disorders [icimd])12,palliative stereotactic radiation therapy,,,,thoracoscopic,after taking the last dose of the study drug.|hereditary,≥ 20 years,,,,,,
5843,,hip or forearm,steroids & benzodiazapines,,ers,brain imaging after cns-directed therapy,,,,citrobacter spp.,at least 4 weeks prior to initial administration,less than 25 kg/m2|are younger than 22 years,,,,,,
5844,,lactation;|allergy,myocardial revascularization,,hepatitis b,prostate biopsy,,,,group 2,for at least 3 days after surgery|patients,"< 100,000 µl-1|exempt from",,,,,,
5845,,functional etiology,lithium.|adequate visual,,hepatitis c (hcv rna,ct,,,,upon excavation of caries.|rapid exposure,for at least two weeks prior to study enrollment|sinonasal surgery,>60 ml/min/1.73 m^2|hba1c,,,,,,
5846,,stiffness & tenderness,icd-10],,nci ctcae 5.0,valve intervention,,,,upper respiratory infection).||positive for any of the following,within 6 months|any,8-14,,,,,,
5847,,mitral valve leaflet changes,cyclophosphamide,,test for hepatitis b virus (hbv),january 2020)|chest radiographs from patients with,,,,malignancies;|at least 1,<6 months since completion,≥ 18 years;||patients,,,,,,
5848,,chronic hemolytic anemia)|minimum level of pulmonary reserve,fc fusion proteins,,hr reaching,vision problems|no uterine contraction,,,,therapy,prior the first dose of study drug,≥ 60,,,,,,
5849,,breast cancer|undiagnosed abnormal,bile acid metabolism,,weeks|ferritin,electrical stimulation,,,,diseases treated,at screen/baseline|any,"1, and 2||",,,,,,
5850,,medication use can be accurately documented).||in the opinion of the site pi,brackets,,cooperative oncology group (ecog)/who performance status,chiropractic management,,,,inducible,within 14 days prior to initiation of study treatment.|ability to understand,from the first day of screening until the follow-up visit;|volunteers,,,,,,
5851,,either:||elevation,amino bisphosphonates,,estimated on,laparotomy,,,,suitable for local therapy,within the 12 months preceding the enrolment.|for,"< 1,5 g/l",,,,,,
5852,,heart failure|after,topical anaesthesia,,national standards).||age:||- male,justification for its avoidance,,,,low-dose aspirin;|age,at least one of:||apgar score of,less than 20×109/l;|patients did not respond to glucocorticoid therapy,,,,,,
5853,,pre-cancerous lesions,gsm,,training load,clinical slt assessments,,,,nonmalignant,within four weeks before enrolment in this study.|known,≥ 100 g/l|serum,,,,,,
5854,,esophageal lesion,soluble guanylate cyclase stimulators,,uz gent)|patients,chronic oxygen therapy,,,,specifically,"in the last 6 months,|patients",18 to 70,,,,,,
5855,,acute renal insufficiency,dressing,,hamilton depression scale||,cephalometric,,,,major,in the 2 days before study treatment start|participant,18 to 65 years.|patient,,,,,,
5856,,sinus tract,steroid implants,,respiratory function,d-j ureteric stent placement,,,,oxford university student,in the first 6 months of randomization|according to the investigator,"stage 3,4),|receiving",,,,,,
5857,,sans,components of bcd-217,,systolic velocity,sedative/hypnotic drugs,,,,mandibular anterior region,within three months prior to the start of the current study,less than 1.5mm,,,,,,
5858,,difficulty concentrating,anti-coagulation,,rocuronium|body mass index,complaint of memory loss|scoring,,,,females)|double-barrier,at the time of enrollment;|osteoarthritis of the index knee graded,≥ 80g/l,,,,,,
5859,,melanoma).|significant bowel disease,hydrogenated castor,,pbc-specific antinuclear,12-lead electrocardiogram (ecg).||,,,,uninterruptible,within 3 days before receiving the first study drug administration,18 years or older,,,,,,
5860,,hepatitis positive,compounds of similar chemical or biologic composition to the study agents|prior,,thyroid-stimulating hormone (tsh),obesity treatment,,,,full-diastolic blood,within 3 weeks prior to treatment.|patients,0-1.|individuals,,,,,,
5861,,dysfunction of another major organ system,prolonged corticosteroid therapy.|patients,,blood urea,xm) test,,,,non-common,the previous 12 weeks||,<2 year|active,,,,,,
5862,,proximal stenosis,mealtime insulin,,pain rehabilitation center,fabry,,,,new origin,for 1 month after.||,0-100-mm,,,,,,
5863,,cancer mortality risk||patients,clofibrate,,btc,admitted for induction of labor,,,,non-psychiatric medicines,in the last year,≥10 mg,,,,,,
5864,,chronic lung disease|triggering,selective inhibitor of the dll3 pathway.|participant,,blood dna methylation,actionable egfr mutation,,,,latent,within 6 months before the start of the study|an expanded disability status scale,"functional class ii, iii",,,,,,
5865,,penile-vaginal intercourse,direct thrombin,,reduction rate ≤20%,coronary artery bypass grafts,,,,seropositivity for hiv,within 6 months from completion,>= 0.01%,,,,,,
5866,,semi-quantitative assessment of the degree of aortic regurgitation,diuretics,,pad test,progression on,,,,passive smoker,during the study period|the,> 5.2 meq/l,,,,,,
5867,,sleep quality index,msi,,hepatitis b seropositivity,therapeutic arm):||participants,,,,mater misericordiae university hospital|current diagnosis,"at least 8-12 hours before blood sampling,|who",≤1.5 x upper limit of normal,,,,,,
5868,,mycosis,fibroscan,,minute apgar score,open treatment,,,,annex 4);|severe infections,within the previous 1 year,0-2|able to provide,,,,,,
5869,,hypersensitive reactions,cerebrolysin,,composite score,neurological disease|having,,,,postural orthostatic tachycardia syndrome,within 3 months prior to enrollment);|m1a/b,lower to 40mg/dl,,,,,,
5870,,hbsag+,parenteral antibiotics,,ankle disability index-sport survey score,creatine phosphokinase [cpk],,,,neuroleptic,since injection.||previously,score 0 or,,,,,,
5871,,living abroad)|comorbid disease,age|ipf,,split thickness skin,cam morphology,,,,first-degree relatives.||exclusion criteria,within 3 months prior to inclusion|diabetes|severe chronic disease,18 years or older|non-icu professional staff,,,,,,
5872,,associated sepsis,aromatase inhibitor|psychiatric illness,,pulsatility index,testing of tumor pd,,,,endovascular embolization.||,within 3 months)|pulmonary,≥ 18 years and ≤ 65 years,,,,,,
5873,,genetic abnormalities,disability|antiepileptic medication,,tunnel syndrome|weakness,blood cell count>3.5×109/l,,,,suitable for long-term,within 14 days prior to randomization;|has received,outside the reference range,,,,,,
5874,,clients,breztri,,greater.|ecog performance status,mental health treatment,,,,planned same day,in the past 1 year prior to screening.|use of,≥2.5×uln (≥5×uln in case of subjects,,,,,,
5875,,non-anterior non-infectious uveitis,phosphodiesterase type 5 inhibitors;|use,,low calcium level,trail making test,,,,lower extremity peripheral artery|lower extremity amputation,prior to enrollment.||if potential study,ii-iv|lvef,,,,,,
5876,,inducible urticaria,echocardiographic,,antithrombin iii level,admitted,,,,largest diameter ≤5,at time of baseline despite acei,above the uln.|positive test results,,,,,,
5877,,period;||uncontrolled diseases,otc pain medications,,new york heart association class (nyha) functional classification system|patients,alcohol pharmacotherapy,,,,"diagnostic and statistical manual of mental disorders (5th edition)'s criteria (dsm, american psychiatric association, 2013).||",pelvic disease.|individuals,not more than 100 kg,,,,,,
5878,,skin substitutes,porphyrin drugs used in photodynamic treatment,,estimated gfr,pcr assay,,,,unplanned,in the next 2 years|uncontrolled intercurrent illness,≥ 24 weeks,,,,,,
5879,,solid tumor malignancies,dc-cik,,macs,emergency procedure||,,,,contraindications|structural heart disease|corrected qt,in the past 3 months|household member already participating in study,<90 ml/,,,,,,
5880,,above.|no vision,soft drinks,,alcohol breath screen,esophageal biopsy,,,,amenable to fresh tumor biopsy,within the last 2 months;|patients,"<75,000 /μl",,,,,,
5881,,left atrial catheter ablation,dopamine agonist,,sad,breast radiotherapy,,,,cc-122-nhl-001,within 14 days of the first study drug administration,<88 ml/min,,,,,,
5882,,ige mediated reactions,selective slowing,,hemoglobin concentration should,local regulations,,,,old.|pregnancy.|severe,within 7 days prior to the first dose of protocol anti-fungal prophylaxis,≥ 30 ml/min.|liver function,,,,,,
5883,,residual symptoms.|healthy,anthracyclines|left,,recist1.1 standard;|ecog score 0~2.||,covid prevention program.||exclusion criteria: 1),,,,cabg|isolated,within 3 months prior to the study;|subjects,less than 40 umol/l,,,,,,
5884,,neurological conditions;|have severe hearing,components of the linaprazan glurate formulation,,neuropsychiatric disorders|it,wood's lamp fluorescence|no treatment for versicolor in,,,,genital bleeding.|undiagnosed vaginal discharge,within 48 hours of a suspected,less than 30 milliliters per minute per 1.73 square meter,,,,,,
5885,,disease qualifies,pta<40%;|no,,child health law;12)exposure,endoscopic biopsy,,,,in therapy,within the previous four weeks,score ≤3|the clinical,,,,,,
5886,,digestive tract obstruction,immunomodulators|transplantation|cancer|autoimmunity|rzv after covid-19 vaccination|covid-19 pcr+ before covid-19 vaccination|other types of covid-19 vaccines,,analgesic,lateral neck dissection,,,,loading dose,at any time excludes the,greater than or equal to 8 g/dl,,,,,,
5887,,anosognosia,anti-vegfs,,left ventricular ejection,cell blood count,,,,internal tissue,in the last 30 days and|any chronic medical diagnoses/conditions,under 18 years,,,,,,
5888,,hypercapnic respiratory failure,anti-cytokine therapy,,mean qtc interval,fidelio-dkd,,,,mesorectal fascia,within 4 weeks before screening.|with six months before screening,> two times of normal levels,,,,,,
5889,,october 1st,anti resorptive drugs;|oncologic,,sish +,anuria|icu readmission,,,,long-covid,within one month prior to initial screening,"recipients,|participant",,,,,,
5890,,brain stimulators,midline shift.|known arterial condition,,s.cr,stem cell transplant||patients,,,,systemic antibacterial,last for 1 year||,>6months,,,,,,
5891,,unexplained syncope|recent,medications to treat,,oswestry disability index score,assessor,,,,other investigational,at the time of the study|persons,< 450 msec,,,,,,
5892,,completed menopause,ptsd medication changes,,international classification of sleep disorders (icsd-3) criteria|at,tumor biopsy,,,,proximal humerus,within one month;|not willing,more than 20,,,,,,
5893,,cardiopulmonary disease,antiplatelet therapy|thrombophilia|contraindication to endovascular revascularization,,fasting plasma,combined chemotherapy drugs.|pregnancy,,,,block|pre-existing,for at least 6 months after the last administration of study treatment|men,≥40 ml/min per the cockcroft,,,,,,
5894,,psychological disease,accompanied,,brachial index,ebv vaccine,,,,diabetes|english-speaking|baseline,5 half-life periods before screening,greater than 8mm,,,,,,
5895,,cerebrovascular lesion,milk,,"north american symptomatic carotid endarterectomy trial (nascet) criteria ([d - n]/d x 100, where n",arthroscopic classification|patient,,,,nonseminomatous,during the 12 weeks prior to screening,6-10 weeks,,,,,,
5896,,human immunodeficiency virus,fontan operation,,hepatitis b surface antigen or hbv(hepatitisbvirus) dna,fungal culture,,,,copd:||clinically relevant,at least 3 nights per week and last for at least 3,≥40%,,,,,,
5897,,d|esophageal strictures,monoclonal antibody therapy,,60%)|absolute neutrophil count (,resections,,,,full ﬂexion,in the first 2 years after menopause|experiencing vasomotor symptoms||,18 - 40|healthy|recreationally,,,,,,
5898,,defects,defecate,,residual hemodynamically significant,transfusion of any blood,,,,central nervous system (cns),within 1 week to control symptoms of,> 18 years old and > 85 years,,,,,,
5899,,human beings,lupron,,microdeletion disorders.|bone marrow transplant,tei,,,,ventricular septum,within 4 weeks before enrolment,18 years)|eligible,,,,,,
5900,,spontaneously breathing,minoca,,total bilirubin ≤1.5x upper limit of normal (uln),24-hour urine collection for determination of creatinine clearance:||creatinine cl,,,,greater).||,in the past 1 year;|subjects who take nintedanib,>100 mm hg,,,,,,
5901,,genetic defects,oral dicloxacillin,,hbsag (+),intramuscular injections,,,,large screen,at least one month prior to surgery|alcohol,<25,,,,,,
5902,,cyanosis,warfar,,body-mass index,laboratory testing performed,,,,self-administered questionnaire,at least 4 weeks before examination,16 or 17 years,,,,,,
5903,,impaired cognition|children,ehoa,,visual-ice ablation,obstructive coronary artery,,,,site pi.||note 2:,previous 2 months.|no plan,0-3.99 u/ml,,,,,,
5904,,gait pathology,immunosuppressive treatment|transplantation,,2.|life expectancy,immunosuppressive therapy.|pregnant,,,,grade 3 or above neurotoxic reactions,prior 24 months well health status,18-60 years;|normal,,,,,,
5905,,recreational cannabis,liver contrast,,asxl1,retropubic mid-urethral sling surgery,,,,infection|active acute,in the past 6 months|history,<= 1,,,,,,
5906,,left main coronary disease,issues surrounding contraceptive requirements,,multiplex nucleic acid amplification test,ct scan of chest,,,,incompatible smartphone,within 7 days prior to screening;|(6,18 and older||subjects,,,,,,
5907,,neurofibromatosis type ii|preexisting profound hearing loss,radiographic contrast dye,,serum free light chain (flc):,intravesical treatment,,,,discharge through,within 3 months of the screening,<10 mmol/l,,,,,,
5908,,inability to read questions,local anesthetics inability,,calculated validated health survey,postoperative echocardiography,,,,low-grade cervical intraepithelial neoplasia,pre-emptive|for,≥ grade 3 result,,,,,,
5909,,arteriovenous fistula,methyltestosterone,,numeric rating scale-11,small molecules.||,,,,total hip replacements,within the previous 5 years.|for mtc,21-99 years|diagnosis of,,,,,,
5910,,pi.|pregnancy,tacrolimus,,hepatitis c height,molar in the row with no neighbour tooth,,,,suitable for participating in this,during the last 18 months prior,≤ 1.5×uln.|adequate renal function,,,,,,
5911,,congenital syphilis,heal,,uk working party criteria,iv iron therapy,,,,unhealed fractures.|other conditions,in last 24 hours before surgery|major intraoperative hemodynamic,<18 and >65 years;||severe,,,,,,
5912,,interstitial thermal therapy (litt),latex,,glomerular filtration rate egfr,standard systemic therapy.||additional criteria,,,,standard-of-care medications,within 48 h prior to dosing,> 125 mg/dl|fasting,,,,,,
5913,,intracranial hemorrhage;|coagulation disorders,components of similar chemical or biologic composition to either cemiplimab,,etc.)|drug,pth-treatment experience.|serum,,,,unsuitable for inclusion in this study,within 14 days prior to sub-study randomization,≤ 2-month apalutamide,,,,,,
5914,,histiocytosis,oral steroid therapy|precapillary pulmonary hypertension|bmi,,urine protein (upro),multidisciplinary discussion,,,,american college of rheumatology of,for at least 10 years prior to the disease or||nlst inclusion,"<3 mm,|absence",,,,,,
5915,,aids-related illness,diazepam,,hearing,lipid-reducing drugs,,,,enough tissue,before enrollment and in trials administration,>1.00 d,,,,,,
5916,,hypoglycaemia,nitroimidazole,,rna dependent,frozen section-based).|pre-enrollment patients lps,,,,requiring administration,within last six months;|pancreatic injury,≤ 30 ml/min/1.73 m2,,,,,,
5917,,globes,germline tissue,,quantitative test,anatomical regions,,,,microbiota related conditions,at least 2 of the following csm abnormalities,between 2-17 years old|hemoglobin <12g/dl|solid tumors,,,,,,
5918,,pericarditis typical chest pain,platelet-elevating drugs,,biological,surgery|preventive ileostomy|patients,,,,clostridioides difficile,within 7 days before the first dose of investigational drug,≥ 1,,,,,,
5919,,bone mass,romisvir,,quigley hein plaque index (tpi) score,ii|children,,,,pd-l1 inhibitor treatment,within 30 days prior to enrolment of the current,upper limit of normal)|serum total bilirubin,,,,,,
5920,,acutely psychotic,anti-obesity drugs,,dsm criteria|autism/schizophrenia|clinically significant,penile-vaginal,,,,"near the stimulated area,|pacemaker,|vestibular disorders",diet.||before starting the elimination diet,"< 1,500 /μl|lymphocytes < 800",,,,,,
5921,,hematogenous infection,duvalizumab,,pro-bnp,total gastrectomy,,,,robot-assisted surgery|patients,tanning,i-ii||adequate,,,,,,
5922,,fascicular block,antibody;|patients,,partial-thickness / second degree burn wound,decoy20.|adequate organ function,,,,tumor tissue sample may also be enrolled,during the study|agree to follow,> 120 μmol/l,,,,,,
5923,,iodine|chronic kidney disease,topical retinoid use,,left ventricular ejection fraction,tia])|current treatment,,,,maintenance-dose of atd,within the next year|concomitant use of or unwillingness to avoid,<3.0 × institutional uln,,,,,,
5924,,chest pain,medications listed in appendix i,,response evaluation criteria in solid tumors (recist) v1.1,verapamil hydrochloride);|patients,,,,procedure related,within 28 days prior to and after|previous receipt,≤ 2 x,,,,,,
5925,,benign prostate hypertrophy,hookah,,pain relief,hla-haploidentical nk-cell donor available||,,,,h. pylori treatment,at least 8 weeks prior,1/2 mutated|cohort 3,,,,,,
5926,,digital photographs,nonstudy muscle biopsies,,national comprehensive cancer network of the united states,lymph node involvement,,,,sinoatrial heart block|history,at the time of,= 1)|vaccination,,,,,,
5927,,bcc)/squamous cell carcinoma,antidiabetic drugs,,pacs-cfs,cerebrovascular division,,,,low-potency topical corticosteroids.|no occurrence,in the past two months|patients,procedures.|greater than or equal to 18 years,,,,,,
5928,,non--infectious,purpura,,sustained hr increase,psychological illness|current treatment,,,,medical technicians,within 4 weeks prior to initial administration.|no,≤ 18 years|unable to give informed consent|unable,,,,,,
5929,,lchf,immune related adverse events (iraes),,fish,bilateral symmetrical distribution or|t2w hyperintense/t1w hypointense lesions,,,,index knee|comorbidities||operative:||date of surgery|type of,at least 2.5ml or,>26,,,,,,
5930,,liver involvement).|2nd malignancy,agents used in study||patients,,bone conduction|patients,asd cut-offs|capacity to follow the study procedures,,,,registered,after 6 months after the first complete remission,"less than 1 month before,",,,,,,
5931,,washes,stimulant medication,,transfused)|white blood cell count,cranial ct confirmed,,,,prescribed,within the previous 12 months demonstrating,≤ 5.0 x uln.|patient,,,,,,
5932,,showed,dbs,,anc count,primary pci,,,,"related to the health of the fetus,|pregnant",within the past five years;|the investigator believes,between 24,,,,,,
5933,,cystic ovary syndrome,polymyxin,,"fondazione policlinico universitario a. gemelli irccs,|written informed consent.||",cosmetic procedures,,,,intra-ocular,at least twice per year,>= 18 years old|within 4 weeks of study entry,,,,,,
5934,,non-response,cyp2c9 substrates,,laschman's drawer test,graft disfunction 2 weeks prior,,,,stage 1-2-4-5||being illiterate|not,within the 28 days prior to screening.||participant,< 18years,,,,,,
5935,,non-viral-hcc,asthma medication,,transaminase (alt),rbc,,,,liver area,< 2 weeks before randomization,< 3xuln,,,,,,
5936,,side effects of cancer,tre,,mallampati classification,pathogenic scn1a mutation,,,,serious covid-19|pregnancy.|bedridden|insufficient,for the last 3 months|the,≥ 3cm||,,,,,,
5937,,pre-)eclampsia,contraceptive requirements)||,,oral egfr-tki therapy,t cell inhibitor.|patients,,,,esthetic zone,during therapy||creatinine =< 2.0 x upper limit of normal (uln),younger than 18 or older than 35 years,,,,,,
5938,,signs of disease activity suggested,urethral diverticulum,,platelet transfusion,local radical therapy pointers,,,,simplified,within 2 years prior to start of study treatment,etc.)||exclusion,,,,,,
5939,,vaginal canal,arteriole,,hematocrit (hct),complete clinical,,,,haemorrhagic,within 72 hours before the first dose of dostarlimab,18 to 70 years|they,,,,,,
5940,,intracranial surgery|a,gray matter,,nyha,vagotomy,,,,influence of alcohol|had,within 2 months of baseline,> 1.25 x the upper limit of normal||viii,,,,,,
5941,,benign neutropenia,investigational products,,"investigator,|body mass index (bmi)",local transplant team,,,,first-line chemotherapy,within 1 week before enrollment,< -2.5;|serum 25-hydroxyvitamin d (25-ohd,,,,,,
5942,,deep dermal scarring,omalizumab,,surgery;|functional mitral regurgitation,implantation surgery||,,,,prolific,for 1 week following the study treatment.||psychiatric illness/social,< 65 mmhg)|contraindication to treatment,,,,,,
5943,,leigh syndrome,tobacco|active malignancy,,mean pulse rate,infection.|major surgical procedures,,,,site-specific,for ≥3 months before screening,participant|able to participate,,,,,,
5944,,renal impairment,oral immunosuppressants,,bilirubin level,consistent exercise training)|weight stable,,,,flanders|eligible,within the past 10 years.|have,≥ 18 years|participants,,,,,,
5945,,contagious skin disease,non-study stents,,≥75 minutes/week,it.|expectation of survival beyond 1 week,,,,medium term,within 30 days before trial entry,>4 weeks prior to screening|if,,,,,,
5946,,fibromyalgia,anxiolytics,,hrd,surgery|endoscopic resectable gastric cancer,,,,plasmodium vivax index,in 24 hours prior to enrolment|gp-diagnosis,from 6 to 8 years.|height,,,,,,
5947,,evaluation|post-hysterectomy,metoclopramide,,hamd,brain radiation therapy,,,,suitable for a treatment by,within last 12 months from date of export||exclusion criteria,³ 26|in case,,,,,,
5948,,pharmacological conditions,antibiotic ceftriaxone,,short diameter of lymph node lesions,confirmatory biopsy,,,,podocyte genes,at the time of consent,less than 4 weeks,,,,,,
5949,,treated carcinoma in situ,examinations,,modified systemic lupus erythematosus disease activity index-2000 (msledai-2k,signed informed consent.||exclusion,,,,stage 1,within 14 days),deficiency|hyperoxaluria|hyperuricemia|haemochromatosis|sickle cell anemia|serum creatinine,,,,,,
5950,,epigastric pain,anti-il-17 antibody,,median numeric rating scale-11,gastrointestinal malabsorption,,,,could cause weight loss,at least 2 of the following,≥21 years|outpatient,,,,,,
5951,,carcinoma in situ of the breast.|known,local anesthetic,,igd level,pelvic mri,,,,non-traumatic reason,during the period of trial,≥ 15 ml/min/1.73 m*2,,,,,,
5952,,multi-focal disease,guidelines recommended hf drugs,,mrsa,clinical laboratory exam,,,,stage iii b/iii c,within 7 days prior the first dose of study,<60×109/l.|cerebral stroke occurred,,,,,,
5953,,soft tissue sarcoma,ozanimod,,total hip.|body mass index,first-line anti-her2 therapy,,,,low dose cytarabine-based,low dose combined oral contraceptive,<15 ml/min/1.73 m2,,,,,,
5954,,sperm loss,chronic systemic steroid therapy,,subsequent hiv plasma rna,exemption,,,,lumbar spine,"at time 0,",50 years old,,,,,,
5955,,sight problems,dialysis||end-stage renal disease (esrd),,ckd3,psychotropic medication,,,,centre for disease control,prior to enrollment:||hematology,≥90 ml/min per 1.73 m2,,,,,,
5956,,imperfecta,metamizole,,urinary drug screen,thyroid surgery,,,,remission,for at least 60 days prior and willing,between 35-42,,,,,,
5957,,excludes biliary obstruction,ocular topical medication,,synovial neutrophil percentage,screening.||hepatic transaminases,,,,highly permeable,within 24 months|known allergy,>18 years||inclusion criteria healthy,,,,,,
5958,,burning,components of the study,,pregnancy test results,"auditory problems,|no",,,,european union,more than twice the upper normal limit|bilirubin,1.6 - 2.3 mg/dl,,,,,,
5959,,heart failure|rheumatoid arthritis,illicit drugs,,antibodies to hepatitis c,peritoneal dialysis|participant's,,,,ibs-m,within 96 hours before the first administration of the drug|according to the 12 common symptom assessment forms,≥ 15 kg.||sex,,,,,,
5960,,carotid artery stenosis,dexmedetomidine|nitrous oxide,,liver enzyme values,digital mammography,,,,compensated,within 2 weeks before or after the investigational medicinal product,<15ml/min/1.73m2,,,,,,
5961,,heart failure)|prior heart transplantation,d supplements,,1q21 amplification/t(4;14)/t(14;16)/t(14;20)/17p deletion/tp53 mutation,vertebral artery disease|end stage renal disease,,,,apache ii score,prior to and,>= 1 line,,,,,,
5962,,villous adenoma)|tnf-α inhibitor-naive ibd group: ibd patients,stsg donor site wounds,,blood cells:||absolute neutrophil count,pet/ct scanner.|participant,,,,not,"in the last month before enrolment,|cognitive decline",0 - 100 mm,,,,,,
5963,,severe coaptation defect,dexcom g6,,eular/acr classification criteria.|renal biopsy showed lupus,remaining,,,,angio-ct study performed,at least 3 months from completion of blood or marrow transplant,≥ 18 years|ic 2,,,,,,
5964,,acute nephritis,over-the-counter (otc) products,,menstrual function,barrier birth control measures,,,,corneal disease.|uncooperate,at the time of surgery|patients,< 6 seconds above control,,,,,,
5965,,normal menstrual history|had,iron chelator,,remimazolam infusion|history of hypersensitivity,chest compressions,,,,maxilla-mandibular,at the insertion site|change of central venous line,21-45 years,,,,,,
5966,,give rise to cognitive sequelae|people,anti-platelet medications,,portacaval shunt|major surgery,cardiac ablation,,,,moderate to severe intellectual disability,during the study period and within 6 months after the end of the study period.||,200 g/l,,,,,,
5967,,closest relative's informed consent,transmasculine,,physical activity readiness,lymph node dissection,,,,mitotic,up to four alcoholic drinks,< 50 copies/ml|stable,,,,,,
5968,,abstain from all activities that could result in pregnancy,supportive periodontal treatment||,,odi,conventional coagulation,,,,vasoactive,within two months prior to period i,> 30 mg/l,,,,,,
5969,,ductal carcinoma in situ of the breast,hereditary,,msa-p (,genetic testing obtained,,,,central nervous,after induction therapy,< 8 g/dl,,,,,,
5970,,brain metastasis.|male,corticosteroid prescribed prophylactically,,white blood cells count,endotracheal tube,,,,"antidepressant treatment,|not",during the day shift||exclusion criteria for care providers,between 60 and 85 years.|diagnosed,,,,,,
5971,,syphilis serum reaction|patients,gbc,,human immunodeficiency virus (hiv).|participation in another clinical study,months|sufficient organ functions|negative pregnancy test results of,,,,locally required authorization,during the intervention period.|have a high,>14g/day,,,,,,
5972,,biological cancer therapy,live born infants,,ess,major organ transplant|active pneumonitis,,,,low-active,3 months prior to vaccination,≥ 1.5 × 10 9 /l,,,,,,
5973,,sickle cell anaemia,tobacco products,,race term.|absolute neutrophil count,positive.|those vaccinated,,,,secondary)|history of deep vein thrombosis|pacemaker|artificial joints,at least 2 consecutive scans,350 ml of beer or about 83 ml of red,,,,,,
5974,,t2,narcotic substance use,,pao2,lung transplantation,,,,echocardiography|chronic severe,at least 4 weeks prior c1d1.|ni-8,>120 mmhg,,,,,,
5975,,recurrent.|ability,norepinephrine,,ast(sgot)/alt(sgpt,additional procedures,,,,aligners|general joint,within the last 3 months)|able,"greater than or equal to 100,000",,,,,,
5976,,"criteria of the world health organization,|hemoglobin a1c (hba1c)",cns2 status,,screening.|history of,empiric antibiotic regimen,,,,diagnostic and statistical manual of mental disorders (dsm) -5 checklist,within 3 months of baseline,female's vagina,,,,,,
5977,,immune function defects,subunit recombinant vaccine,,university traumatic brain injury identification method (osu tbi-id,ct scans/mri obtained,,,,rehabilitation programme,within 3 months of screening.|clinically,> 2000 ml,,,,,,
5978,,migraine diagnosis.||,fluoropyrimidine-based chemotherapy,,gfr,baseline situation of the patient that does not allow the examination,,,,non-brain sites,at the time of device placement|subject agrees to comply with all follow-up,<20 ml/min,,,,,,
5979,,fs-1502.|active infection,bullet fragments,,qt interval,hysterectomized,,,,could influence the state of the subjects or the results of the study.|that the mri,more than 12 hours from the time of,≤ upper limit of normal (uln),,,,,,
5980,,multiple trauma,medications.|active suicidal ideation.|risk,,nih clinical center||exclusion criteria:||an individual,computed tomographic pulmonary angiography (ctpa) imaging,,,,large restorations,during the first month after any intraocular surgery,≥100×109/l；|biochemical tests,,,,,,
5981,,breast free flap reconstruction,combined drugs,,specified test|disease progression,chronic pji,,,,15 minutes apart,within the shoulder girdle,outside,,,,,,
5982,,chronic apical abscess,combined oral contraceptive pills,,hanifin & rajka atopic dermatitis,single antiplatelet therapy,,,,criteria:|histologically-,"within 24 hours, the participant",nutrition|less than 12-months,,,,,,
5983,,upper airway tumors,plastics,,serum specific ige;|able to express the intensity of their pain using,cetuximab targeted therapy,,,,joints,at least 6 months after the last use of the test drug;|volunteer to join the study,0 - 1|agreement,,,,,,
5984,,ever been enrolled in a,topical ocular medication,,modified allred score).||clinical stages,major surgical operations,,,,lines of therapy,in previous 30 days|living,+/- androgen deprivation therapy or|locally advanced,,,,,,
5985,,persistence fatigue assessed via facit,contrast allergy,,velocity,extracorporeal blood purification,,,,injection site.|known allergy to any of the,overdenture|more than 2,> 80g/d.|patients,,,,,,
5986,,systematic malignant diseases,povidone,,hemoglobin (hg),technology treatment,,,,female|advanced,within the bowel mucosa|patients,>8°,,,,,,
5987,,gastrointestinal stromal tumor,janssen covid-19 vaccine,,iotn,robotic surgery,,,,financial,within 6 months before first dose of protocol indicated,< 50 ml/min/1.73m2,,,,,,
5988,,musculoskeletal medical history.|regardless,medium chain triglyceride-containing,,ecog physical strength,dexa,,,,mellitus|self-reported,at least one cycle of induction chemotherapy||research participants,less than 4 mm,,,,,,
5989,,hemorrhoidal disease,mood stabilizer treatment,,multiplex pcr,series vaccination,,,,locally progressive,at least 1 year prior to informed consent,>1%,,,,,,
5990,,headache,gnrh,,focus groups with healthcare professionals|unable,hormonal contraception,,,,enrolled|clinically unstable,for at least 24 weeks after their last dose of study treatment.|male,"50 to 110 kg, inclusive",,,,,,
5991,,intracranial infection,pravastatin,,platelet ≥100×10^9/l,treponema pallidum antibody,,,,volunteer refuses,within 1 week;|subjects,≥ 2 days|consent from patient||,,,,,,
5992,,collagenopathy,strong inhibitor of the p-gp drug efflux pump,,glycosylated hemoglobin≥7%,prolapse repair utilizing,,,,neonatal pediatrics,in the past 24 hours every day,>100,,,,,,
5993,,recreational drugs,dressing components,,short axis than size criteria,emergency sternotomy,,,,procedures|pregnant,in the 4 weeks prior to the study,<13,,,,,,
5994,,chronic respiratory failure|had respiratory distress syndrome,setting.|patients,,serology for hiv,color ultrasound,,,,could change properties,within 14 days of the study entry,≥10 mg/dl,,,,,,
5995,,lower-limb endovascular,egg,,mdrd egfr,other surgery of the gastrointestinal tract,,,,attenuated,at the time of enrollment:||fever,>90,,,,,,
5996,,spinal deformity,anti-serotoninergic 5ht3,,medication score,donated whole blood,,,,non-hematologic toxicity may,within the past 2 years except,0 to 2.|must,,,,,,
5997,,untreated gastrointestinal disorders,nccr,,peripheral arterial disease,corticosteroid).|previous treatment,,,,ici-induced hepatitis,in previous 6 months.|urethral,>= 1500/ul|total bilirubin,,,,,,
5998,,unfavorable candidacy,older|anti-hd-positive,,hip pathology|leg length,cytokine release syndrome,,,,diseases|devitalized,within 24 hours prior to day 1,between 2 and 17 years,,,,,,
5999,,vision problems,masimo,,urine human chorionic gonadotropin (hcg) test,multispiral computed tomography,,,,walkasins|self-reported,for at least 12 weeks after the last dose of study intervention|female,130 mmhg,,,,,,
6000,,normal|severe hepatic impairment,anti-ccr8 antibody,,prothrombin time-international normalised ratio,cancer|adjuvant chemotherapy,,,,stage ib ⅱa,performed three months,> 103 copies/ml,,,,,,
6001,,symptom-free interval.|functional disability,elian,,good clinical practice,limb leads,,,,other live vaccines,within the 6 months prior to screening,≥20 mm hg,,,,,,
6002,,aids|patients,nerve blocking agents,,bilirubin levels should,gastric stimulation device surgically implanted,,,,excluded.|no prior,within 30 days before study drug administration or 90 days for a biologic study.|clinically significant,>95,,,,,,
6003,,liver function|adequate renal,eyes,,recist v1.1:||in,breastfeeding|workers,,,,months|participated,during the study period.||participants deemed unsuitable for participation in this study,18 and older|fluent,,,,,,
6004,,non-melanoma skin carcinoma,synthetic,,arm,focal epilepsy.|estimated,,,,non-mci group,within three months before inclusion|uncontrolled,38°c,,,,,,
6005,,dysmorphic features,fix agents,,plasma amylase,type1 dm.|arabic speaker.|smart phone,,,,permanently,in all pre-menopausal,"≥ 1,500/l",,,,,,
6006,,right upper quadrant pain,b7,,significantly increased intracranial pressure,meal plan,,,,invading important,within the past 6 months prior to screening.||irregular use,≤ 10cm;|patients,,,,,,
6007,,3.1.7 above.|prior cancer directed therapy,loop diuretic treatment,,urine pregnancy tests);|measure,supine position,,,,adeno-squamous cell carcinoma,more than 12 weeks before randomization,i/ii/iii||,,,,,,
6008,,smoking habit.|presence,monophasic,,gold,it|prisoner|participation,,,,fc-bearing proteins,within 2 weeks of visit 2|willing,50-89 mmhg,,,,,,
6009,,uncontrollable disease,drugs prescribed for indications,,nyha functional class,stem cell preparation,,,,months|histologically confirmed,within the scope of web-based intervention,between 2.5 and 15 cm2|failure,,,,,,
6010,,urgency urinary,covid-19 related acute respiratory syndrome,,bruton's tyrosine kinase (btk),cancer therapy,,,,participation unsafe,during the study therapy;|known,months.|cerebral,,,,,,
6011,,parenchymal lesions,aggression,,serum pregnancy test.|for,postoperative quality of life,,,,grade 1 tc99-pyp scans,at least 4 weeks,> 4m/,,,,,,
6012,,product.|heterozygous familial hypercholesterolemia,old|patients,,piper fatigue scale|a score,invasive procedures,,,,azole fungicides,at least one treatment,<2 months prior to administration of prth-101.||subject,,,,,,
6013,,"pulmonary embolism,|intracranial hemorrhage",chronic immunosuppressants,,fix level,prenatal ultrasound screening|delivery,,,,elective,in the previous 12 months before screening,at least 10mm,,,,,,
6014,,mental health conditions,normal;|oral anticoagulants,,t score,pap test,,,,ihc 1+,> 3 months ago,refusing to participate|families,,,,,,
6015,,bilateral ovaries,topical anti-androgen,,registration - exclusion,restrictive eating,,,,clostridium difficile 16s rdna,in past 2 years,≥grade 3).|prior,,,,,,
6016,,s. pneumoniae.|coagulation,wbh,,anti-vegf targeted therapy,pelvic radiotherapy.||subjects,,,,hep b,within 7 days before enrollment;|subjects must give informed consent to the study before the study,≥ 37.3℃,,,,,,
6017,,pancreatic tumor.||,potassium-competitive acid blocker,,recist v1.1),24-hour urine creatinine clearance,,,,very unwell,during the trial;|allergy,at least 40 years,,,,,,
6018,,compound glycyrrhizin,bisphosphonate drugs,,mass general brigham|any,ventriculostomy,,,,antibiotic-multiresistant,within six (6) months of completion,13 to 14 years|who,,,,,,
6019,,rca,experimental drug treatment,,hepatitis b surface antibody positive,chronic fatigue,,,,sagittal plane,within 8 weeks prior to beginning trial treatment,35 - 70 years old|bmi,,,,,,
6020,,idiopathic thrombocytopenic purpura,sodium chloride for injection usp,,transplantation;|positive ebv serology,plan,,,,≥70 years|if surgery,within 28 days prior to vaccination;|subjects,25-65 years.|a body mass index,,,,,,
6021,,msm,gastrin receptor antagonists,,vas scale,flags,,,,formaldehyde,in year,score of 50 or more,,,,,,
6022,,significant diseases,equivalent.|hormonal contraceptive,,university,intravenous diuretic therapy,,,,suitable for participating in the study,within 8 weeks before enrollment in the study;|ibs drugs,<9%|able to,,,,,,
6023,,excimer laser.|desire,cyp 3a4 inhibitors,,tbut test,investigator.|have,,,,>160'|advanced liver,throughout the study|is of childbearing potential,a-b||,,,,,,
6024,,gi symptoms,systemic antibiotic,,test for hepatitis b active infection (hbsag),drug treatment,,,,ardt,prior to first treatment after tcr|started anti-mm treatment after tcr mm eligibility|eastern,> 7||,,,,,,
6025,,chronic central serous,contrast media|the,,retention score,sd-oct|total lesion size,,,,older;|national,within 12 hours prior to the screening/ baseline,≥ 2.0 × 109/l,,,,,,
6026,,vigorous exercise);|healthy,orthodontic appliances,,black/african american;|english speaking,natural head position|unsuitable radiographs,,,,stage ivc)|previous treatment,within 30 days before enrollment；|known coagulation dysfunction,<20|current,,,,,,
6027,,intracranial abnormality,fuquinitinib,,saturation levels,heart rate (hr),,,,basal,in the past year|hba1c reading,<95 millimeters,,,,,,
6028,,host factor,exatecan,,1|plaque index,interventional pulmonology procedures with radial probe endobronchial ultrasound,,,,"low grade dysplasia,|confirmation of",more than 6.0 diopters,0-1|hemoglobin (hgb),,,,,,
6029,,aneurismal disease,iodine,,neutrophil count (,massive effusion.|central lung squamous carcinoma,,,,estrogen-receptor positive,within 30 days prior to screening;|systemic administration,< 12.4 kpa.||,,,,,,
6030,,prevention system,contrast medium allergy,,response evaluation criteria in solid tumors [recist] assessment)||,contradictions,,,,mental diseases;|no,after 24 hours from its diagnosis|map<65 mmhg,> 99.5°f/37.5°,,,,,,
6031,,uk,recombinant hidua|body mass index,,gregory's classification,steroid hormone medications.|medications,,,,coiling,at time of inclusion.|subject prone,iii to iv|unable to provide,,,,,,
6032,,length of hospital stay,regimen,,local exclusion criteria,therapy|previous receipt of supplemental oxygen therapy,,,,retropharyngeal lymphatic drainage area (vii),in the next 6 months.|two or more amenorrheic months,≥55 years.|sign the informed consent,,,,,,
6033,,spastic hemiplegic,pstt,,hiv-1 rna measurements,transcendental meditation,,,,study.|nicotine dependence,within 2 weeks prior to check-in|plasma donation,personal free consent,,,,,,
6034,,tb infection,thyroid replacement,,estimated glomerular filtration rate,cvc,,,,american college of rheumatology-,at the same time.|portal vein tumor thrombus invaded the superior mesenteric vein.|patients,'s willingness to participate,,,,,,
6035,,serious diseases,immunosuppressive agent)|patient,,neonatologist judges intensive care,her2 amplification,,,,inflow artery free from the significant,nervous,greater than or equal to 50% radiation of pelvis|patients,,,,,,
6036,,vestibular disorder,adenoviral vaccines,,prostate-specific antigen (psa),revascularisation procedure,,,,formalin fixed,at screening or day -1 for substances of abuse,15 and above (≥15 years old,,,,,,
6037,,acute vaginitis,anti-pd-1 immunotherapy combined chemotherapy,,hepatitis c.|known existence of gilbert syndrome|use of medicinal plants/dietary supplements,headphones|autism spectrum disorder|claustrophobia|confusion|medical,,,,measurable,in prior 3 months.|platelet count,less than 5 half-lives,,,,,,
6038,,sleep-related breath disorder|history,fluoroquinolones,,modified cockcroft-gault formula)|aspartate aminotransferase (ast),chronic pancreatitis|mechanical ventilation,,,,patient|allergy,within 4 weeks prior to enrollment;|patients,>100 beats/minute,,,,,,
6039,,psychotic symptoms.|no,mesenteric blood flow mainly supplied,,test for hepatitis b-,chronically,,,,non-infected,within an exclusion period,18-75;|open,,,,,,
6040,,cardiac disease|neuromuscular,corticosteroids,,difference,embryo-lethality,,,,c1-inh,within 60 days following,0-1.|expected lifetime≥ 3,,,,,,
6041,,decreased sensation,months|bilateral cleft,,ast ≤3x uln*|ef >35%,spinal mri|life expectancy,,,,non-radical resections,1 month before yttrium-90 administration;|pregnant and lactating,50.0 kg.|female,,,,,,
6042,,lobular inflammation,soft tissue fillers,,bell score,major surgical operation,,,,myopathy;|clinically significant,within 1 week before the trial,between 21 and 35,,,,,,
6043,,medications.|current tobacco smokers,methoxyflurane,,muscle length,b cell directed engineered cell,,,,m2 segment,at the time of joining the group,≥ 200 mg/j)||patient,,,,,,
6044,,poor surgical candidate,portal vein thrombosis|hepatocellular carcinoma,,cdai,surgically implanted electronic device,,,,suitable for the period after end of trial,eight weeks prior to enrollment|signed informed consent,>300 mg/g|since,,,,,,
6045,,ovarian cancer reaching ned,non-prescription drugs,,"gestational age,|where",anterior circulation occlusions,,,,tobacco).||,within 7 days before the first dose,high-impact,,,,,,
6046,,discharge from the hospital,medications/dietary supplements/alternative therapies,,individual values,distrophic recessive epidermolysis,,,,anti-tumor drugs,14 days before plasma collection|participants,between 4 and 100,,,,,,
6047,,effect vision,aromatase inhibitor therapy,,aspects,biopsy-,,,,le-fort,within 3 months of the target hand procedure,< 12 months,,,,,,
6048,,tuberculosis 7,chlorhexidine containing mouthwashes,,vas grade,hrct,,,,hallux,within the past 48 hours,>30 days and <52,,,,,,
6049,,cognitive difficulties,phq-9 questionnaire,,anticoagulants|total bilirubin,daily pharmacological treatment,,,,non-breastfeeding,within 14 days prior to randomization.|pregnant,≥1+ considered,,,,,,
6050,,autoimmune disease.|serious,oral anticoagulation use,,serum tgs,active anticancer therapy,,,,moderately uncontrolled,at any time previously|participants,< 4 000/mm3||,,,,,,
6051,,child's assent,alpelisib,,gcs,bilateral salpingectomy,,,,acute period,for at least 28 days prior to first dose of study drug.|any of the following,≥ 1000/μl|platelets,,,,,,
6052,,periodontal disease|active caries|pregnant,alternative medicine products,,antimicrobial before blood sample collection,pathological examination.|patients,,,,hypercoagulation,include:||total abstinence,2 years,,,,,,
6053,,impact on,interventional radiology,,recist 1.1 after first-line,regenerative periodontal therapy,,,,"diagnostic and statistical manual of mental disorders, 5th edition (dsm 5) alcohol",within 12 months of day 1 of this study,>3000 cells/μl,,,,,,
6054,,gonarthrosis,immunomodulating therapy,,buss-perry aggression questionnaire,knee replacement surgery,,,,systemic health|history,approximately three months of treatment sessions||,b-type natriuretic peptide (bnp),,,,,,
6055,,cerebrospinal fluid);|white blood cell count,acyclovir,,weight managent supplements|blood transfusion,consent|unilateral corneal opacity,,,,locally excised,within 30 days prior to signing informed consent|subject unwilling,less than 80,,,,,,
6056,,breast feeding.|known hypersensitivity,oat3 inhibitors,,mtb|molecular test,special precautions,,,,could interfere with judgment of the efficacy of the investigational product,within 14 days of enrollment)|hemoglobin,<1.2 times the uln.||patients,,,,,,
6057,,age|multimodal interventions|lack of,hydroquinone,,who clinical,imfinzi combination therapy,,,,low-dose dobutamine stress echocardiogram,within 72 hours prior to vaccination,>1×10e3 copies/ml,,,,,,
6058,,onset|diagnosis of aphasia,pcsk9 inhibitor,,screening.|in good general health,psychotropic drugs)|previous,,,,radiologically on stressing,during dose escalation,< 8.5%,,,,,,
6059,,slc,medium cut-off membranes,,venous reconstruction|interface,assessment of the vaccination,,,,age.|referred,during the 12 months before the screening visit|active malignancy,≥70 years,,,,,,
6060,,rom,strong cyp3a4,,fmbs,cigarettes,,,,non-pharmacological interventions,within the planned,≤ 2.5 x uln,,,,,,
6061,,pulmonary rehabilitation.|unable,s768i,,overall survival rate,nonpharmacological therapy,,,,site pis.|unresectable,last six months,>92%,,,,,,
6062,,ra criteria,sodium-glucose cotransporter-2 [sglt2i],,autoimmune antibody,mrcc|major surgical procedure,,,,investigators.|any severe,within the last 30 days|part,>= 24||,,,,,,
6063,,grade;|chronic obstructive pulmonary disease,tops,,mca,refusing randomization,,,,"ostium of the right coronary artery,|patient",at least 6 months of diagnosis,between 50~80 years old,,,,,,
6064,,viral hepatitis type b,long-acting somatostatin analogs,,residual biopsy,histological variants.|patients,,,,highly effective contraceptions,within the last 12 weeks before,< 1 y)|engagement,,,,,,
6065,,oncologic disease|no bone fractures,iodinated contrast medium.|patient,,basic value,pharmaceutical therapies.|patients,,,,polar,within 30 days of visit 2,≤ 5×uln.4).blood,,,,,,
6066,,metabolic syndromes,interventional radiologist,,diastolic bp>100,treated by laparotomy,,,,site of measured disease by,within 6 months prior to study start.|planned surgical intervention,>2.0×10^9 /l,,,,,,
6067,,chronic kidney disease (ckd,fusidic acid,,syphilis antigen,separated,,,,inoculation site,< 4 weeks prior to first dose of lymphodepleting,≥ 0.3,,,,,,
6068,,poliomyelitis,pelvis restraints,,indocyanine green (icg),transesophageal ultrasound doppler evaluation of,,,,maximum tolerated): sulfonylureas,throughout the course of the study,less than or equal to 1,,,,,,
6069,,need drainage,nicotine replacement,,aspartate aminotransferase [ast],bone resorption apparent,,,,finger muscles,prior to day -1.|family history,≥ 18.5|university student,,,,,,
6070,,liver metastases|renal function,medications for memory and cognition,,genuine stress urinary incontinence.|mixed urinary incontinence,bone marrow transplant.|non-leukocyte,,,,native arteries,for at least 1 year|those,30 to 60|motivated to change their lifestyle||smoking cessation,,,,,,
6071,,acute viral hepatitis,treatment regimen,,ambulatory care).|hf,coronary artery,,,,naps|any,during the 2 weeks prior to the first administration of imp,> 7%,,,,,,
6072,,upper neck extension,anti-her-2 medication,,international normalized ratio (,none covid-19 pneumonia.|patients,,,,varicella,prior to starting study treatment.||prior radiotherapy,>40% to <=90% of the predicted normal,,,,,,
6073,,progressions,components of the nuc-3373 drug product formulation (super refined polysorbate,,international performance level|current participation,24-hour urine collection for determination of creatinine cl,,,,angle take-off.|presence of,during the 6 months prior to screening.|subject,less than two weeks before the start of the,,,,,,
6074,,meningococcal meningitis,anti-pdl1 immunotherapy|prior chemotherapy,,subsequent blood pressure readings,x-rays,,,,participation.||exclusion criteria||is,prior to trial enrolment,<110 mm,,,,,,
6075,,constitution,immunosuppressive drugs).||--- note,,disease severity|unequivocal cortical sensory deficit,pelvic irradiation,,,,intracranial ica,within 2 weeks before screening.||● partb:||all subjects||breastfeeding,greater than equal to 3.8 centimeter,,,,,,
6076,,active cancer therapy,βl|non-complicated urinary tract infection,,sars-cov-2 vaccination,foley catheter placement,,,,ipsilateral shoulder surgery,randomization;|history,less than 45kg,,,,,,
6077,,rf,qol,,fasting insulin level,psychosocial treatment,,,,geographically stable,within 1 month before the first injection,6-12hours/,,,,,,
6078,,non-life-threatening,5.|children,,viral load test,gastrointestinal endoscopy,,,,haplo donor must,prior to treatment start).|intake,from 350 to 450 ms,,,,,,
6079,,|refusal,oral contraceptive steroids,,managed care organization (mco),local law).||,,,,adequate oct||key exclusion criteria||macular edema,at the time of intake|severe,3.5 × 10^9/l,,,,,,
6080,,abnormal immunofixation,moderate ad diagnosis|adequate,,modified natural cycles|poor ovarian response,insufficient control of the dutch language to read,,,,art;|planned start,at least 2 measurements,< 18 years old|poor acoustic window|atrial fibrillation|recent,,,,,,
6081,,uterine bleeding occurred,l-dopa-based drug intake parameters,,bone height,optimal medical management,,,,materially,within 4 weeks prior to the first dose of study drug.||3,>=1.0 cm in diameter,,,,,,
6082,,physical diseases,sedentary,,modified bruce exercise tolerance test duration,centre irccs policlinico san donato;|signed informed consent;||,,,,cardiac,within the 2 months preceding screening,0.3 mg/dl,,,,,,
6083,,clinical keratoconus,neuroprotective medications,,nidcd crp,ileostomy,,,,clinical,at least 4 weeks prior to study entry,= partial thromboplastin time,,,,,,
6084,,renal transplantation||,restoration,,anti,chin,,,,central nervous system disorders,for two years,"< 4000g,0-3 years",,,,,,
6085,,protective measures,blood-related products,,physical function,first-line platinum-based chemotherapy,,,,mp,within 2 weeks of visiting|a,score of >3.5,,,,,,
6086,,autoimmune disorders,anaesthesia,,serum protein electrophoresis,laparoscopic surgery lca vascular absence was found,,,,mesio-distally).|the,within 3 months|diagnosed,45-60 years.|presence,,,,,,
6087,,breast cancer|premenopausal,drug trial,,gestational age|infants,frankl behavior scale.|no,,,,densiron-68 tamponade.|age=,during the study|dilation of esophagus required|insufficient dutch,≥20 ng/ml;|patients,,,,,,
6088,,donor age,vitamin,,liver metastasis;||• serum albumin,t-cell receptor,,,,low failure rate,within one year prior to the screening|individuals,< 18 2,,,,,,
6089,,or|cancer,central stimulants,,cpap therapy.||,effective contraception,,,,greater than ctcae level,in the last 3 months including medical or,≥ 45 kg/m2|neoadjuvant,,,,,,
6090,,non-melanoma skin cancer.|patients,hormonal therapies,,inpatient rehabilitation facility post-stroke|signed informed consent,patient|chronic hemodialysis|uraemic calciphylaxis,,,,dual chamber (dr) system in combination,during the study.||6,> 177,,,,,,
6091,,complex congenital heart disease.|pulmonary hemorrhage.|cardiopulmonary arrest,vaccine components,,insomnia severity index (isi) score,basic oxygen saturation,,,,medical history.|if,within 10 days after the final dose of giredestrant (gdc-9545),< 24 hours)|asymptomatic up to the moment,,,,,,
6092,,band ligation,centrally acting antihypertensive|etiology,,al raghy hospital,peau d'orange,,,,meningeal,within 6 months of the start of screening,18 years and older.|physician-,,,,,,
6093,,foot surgery|no pain,pbmc,,palliative care clinicians,enrollment.||myelosuppressive chemotherapy,,,,pharmacological causes,during the study period;|allergic to any,below 20|anatomy of the adrenal vein,,,,,,
6094,,radiographic metastases,amplification,,neurotoxicity,medication adjustment,,,,nf1 del,before the first dose of the study drug,9-26 years,,,,,,
6095,,portal vein,herbal/vitamin supplements,,atlanta classification of op (2012),lewy-body dementia,,,,platinum-contained doublet regimens chemotherapy,within the next 12 months,18 to 30 kg/m2||those,,,,,,
6096,,duodenal,ics,,platelet count<100,congenital heart surgery,,,,t0 scan,at least one offspring after spontaneous pregnancy||,>=8|are willing,,,,,,
6097,,liver kidney microsome antibody,topical chemotherapy,,cylinder,organ transplant recipients|patients,,,,pittsburgh scale,within 7 days before taking the study drug,≤ 1 uln,,,,,,
6098,,for:||cervical carcinoma,etravirine,,nasal high-flow oxygen therapy,full mouth plaque index,,,,consent|enrollment,last 2 years.|present,130-159 mmhg,,,,,,
6099,,simple extramedullary recurrence;|pregnant,anti-resorptive bone agents,,mdt,said regimen,,,,likelihood,before performing any procedure,< 20 ng/ml|able to provide informed,,,,,,
6100,,mainly cough,blacks,,nasal ventilatory function,rivermead post-concussion questionnaire (rpq).||,,,,emergency room visit,during the course of the intervention.|participants must,≥25 kg/m2,,,,,,
6101,,cardiometabolic risk,wheat,,pregnancy test (βhcg),2-stenting technique,,,,adp-ribose] polymerase,within 28 days before first administration of study drug,18 years or older|histologically,,,,,,
6102,,fibrolamellar cell carcinoma;|extrahepatic,fridericia,,fpg,smile surgery,,,,intra-cranial neurosurgery,within 30 days before the date of informed consent.|including participation in this study,">= 1000,000/mcl.|total",,,,,,
6103,,liver metastasis,age|inadequate,,norwood-hamilton grade,vertical descending supranuclear gaze,,,,erectile,at the time of enrollment|females,above,,,,,,
6104,,"psychiatric diagnosis,|not",genders.|abdominal surgery.|asa,,sflc level,computed tomography (ct) of the pelvic|planned surgical resection||,,,,highly-effective contraceptive method(s),since at least 4 weeks prior,> 18 years||,,,,,,
6105,,virus carriers,sca type stemi,,rai stage,completed vaccinations,,,,≥ctcae grade 3,after trauma & lt,-10.5 mg/dl,,,,,,
6106,,those allergic,component of the study drug.|have,,partial thromboplastin time (aptt) should,exposition,,,,smarca4,the two years,≥ 2x,,,,,,
6107,,profound hearing,immediate intervention.|has,,plasma lactate levels,complete decongestive therapy (cdt),,,,used|emergency surgeries|patient's refusal to accept the procedure|hearing,within 3 months before screening;|subjects with decreases,≥1 of the,,,,,,
6108,,metabolic interventions,local anesthetic;|smoking habit,,aspartate-amino-transferase (ast),pulmonary rehabilitation,,,,suitable for therapy,within six months prior to screening.|history of positive,≥100 × 109/l,,,,,,
6109,,mental illness;|autoimmune disease,glp-1) receptor agonists,,volunteers age,inactivated vaccines,,,,machine,within the past 3 months|having,= 0.21 + 0.03 x,,,,,,
6110,,osteoporotic fracture,nonprescription medications,,gout classification,midline laparotomy procedure|patient,,,,alk positive nsclc,more than five days of therapy,inr≤1.5,,,,,,
6111,,abnormal ecg,persantin,,cto,ultrasound guided biopsy|standard contraindications for biopsy,,,,non-measurable disease,at the time of enrollment|weight,≥70;|patients received,,,,,,
6112,,subretinal fluid,local anesthetic administration|systematic use of analgesic agents preoperatively|chronic pain syndromes preoperatively|neurological,,vaccine,reconstructive knee,,,,hypothyroidism|clinically significant,in the previous 30 days before the index date,b-cell lymphomas,,,,,,
6113,,asthma-copd overlap,nucleic acid amplification test (naat),,normal].|body mass index (bmi),dermatological treatment,,,,wearing glasses,within 7 days prior to enrollment,younger than 15 or older than 19yrs|non-english speaking|lives,,,,,,
6114,,breast-feeding patients|patients considered to be ineligible for the study by the investigator,strong drugs.|positive test results for alcohol,,african american,verbal numerical rating scale,,,,localised,in the past 12 months;|subjects tolerant to bronchofiberscope;|subjects fully informed of the purpose,1.5 times the upper limit of normal (uln),,,,,,
6115,,ischemic diseases,local anesthetic solutions,,prostate cancer.|participants,thyroid hormone replacement therapy,,,,"interferes with the educational process,|transferring to another school,|the participant's right to withdraw",within 2 months before initiating,< 1% failure,,,,,,
6116,,volume overload,cox2 inhibitors,,clermont-ferrand university hospital,ip excipient|participant,,,,non-hyperkeratotic,for the duration of the study and 180 days after the final dose of study treatment.||,between 12 and 50 years oae,,,,,,
6117,,chronic infectious diseases,sibutramine,,partial elbow extension,absorption of oral agents|patients,,,,highly effective methods,before cesarean,≥3 mm above normal.|clinical activity score (cas),,,,,,
6118,,chronic glucocorticoid use)|severe pre-existing neuropathy|tka for,3rd trimester,,13c/14c breath test,liver transplant recipient|major surgery,,,,perinatal women|heavy smoker.||,within the last 3 months.|uncontrolled,>37w)|primary elective,,,,,,
6119,,hepatitis infection.|female,unlicensed vaccine,,abusers;|human immunodeficiency virus,cognitive therapy,,,,vaccine;|there,within 12 weeks before enrollment,≥ 30 g/l 9,,,,,,
6120,,adequate immune function,ns:||•,,her2 negative);|subtype of similarity network fusion-3 (snf-3),lumbar disc herniation surgery|hospitalized,,,,pain:||mild-moderate,prior to starting the protocol)|current use,age|greater than 5 years,,,,,,
6121,,muscle conditions,n03,,hamd-21,clinical reviews,,,,high-dose glucocorticoids|psychiatric,within 1 month prior to visit 1,"18 to 80 years inclusive,|females participating",,,,,,
6122,,moderate covid-19,delstrigo®,,left ventricular wall,blood biochemistry,,,,biochemically,within six months before enrollment.|patients,≥ 1.5 × upper limit of normal (uln),,,,,,
6123,,pectus carinatum,physiotherapy regimen,,hemi-diaphragm,gastric sonography,,,,non-hla identical,in the last 5 years.|history of any significant,greater than twice the upper limit of normal,,,,,,
6124,,hiv positive.|active hepatitis c,illegal drug/substance abuse,,systolic blood pressure<90mmhg,preoperative diagnostic hysteroscopy||,,,,surgery)|diagnosed,during the study period；|other,> 1)|contraindications to,,,,,,
6125,,psychiatric abnormality,anisometropic,,smoking test,tace,,,,interventions;|chronic kidney disease,within the range 18.5 to 35.0 kilograms per square meter (kg/m^2,greater than or equal to 36,,,,,,
6126,,nodal marginal zone lymphoma,skin assessment,,bilateral lung transplant,arthroscopy,,,,amenable to radical surgery,within 14 days of the initial dose of study medication.|consent,19 to 70 years,,,,,,
6127,,alcohol withdrawal delirium,nas components,,metastases,head imaging examination,,,,110 lb).||,within the last 3 years possibly,less than 1cm,,,,,,
6128,,corneal epithelial,tissue expander-,,nancy university hospital,complete neuropsychological scales,,,,dsm iv tr®,within the past 6 months.|neuropathy,above the upper limit of normal||xi,,,,,,
6129,,etc|major vascular disease,antiarrhythmic drugs,,liver metastases);cr,topical treatment,,,,sore throat,within 1 month prior to the screening visit.|current urinary tract infection,less than 2500 g,,,,,,
6130,,renal impairment|positive test,adrenergic agonists,,emn,early intervention,,,,related to the diagnosis,in the time of diagnosed|primary cancer,≤2.5×upper limit of normal (uln),,,,,,
6131,,rmlo,drugs involved;|pregnancy,,urine creatinine clearance,episiotomy,,,,highly effective forms,during the study course.|communication partners,<15 ml/min.|ami,,,,,,
6132,,febrile|body temperature,antiplatelet therapy.|patients,,response assessment recommendations,cross sectional imaging,,,,unanimous,14 days after taking the drug,<50 × 10^9 /l,,,,,,
6133,,sclerosis.|inflammatory bowel disease,caffeine-containing foods,,rtnss score,professional medical attention,,,,adequate,at time of sars-cov-2,0-1 points,,,,,,
6134,,gave,antipsychotic drugs,,paresis|home,12-lead ecg measurements,,,,rheumatoid,between 8 and 13;|level of cognitive function (,≦3 uln,,,,,,
6135,,age<18 years|a,20,,international classification of headache disorders,injury|truncal nerve damage|presence of psychiatric pathology|communication,,,,american college of sports medicine pre-exercise screening tool,at the time of screening.|participant,≥12 years,,,,,,
6136,,unstable hypothyroidism,anti-epileptic treatment(s,,age|informed,cgh array,,,,partial shoulder flexion or abduction,within 6 months prior to screening|angioplasty,>10|severe,,,,,,
6137,,allergic diathesis,albumin-bound type,,m)]2;|fasting plasma glucose,computed tomography [ct] scan,,,,grade 2 (ulcer of the skin,at the point of enrolment,≤ six months prior to screening visit,,,,,,
6138,,moisture,anticholinergic agents,,abi,allogenic stem-cell transplantation.|major surgery ≤28 days prior,,,,metabolized through cyp3a4/5|is currently,within 6 months of screening,≥ 200 cm/sec,,,,,,
6139,,reference image,injectable|intrauterine device,,takotsubo stress cardiomyopathy,brace treatment,,,,non-radiation field,5 times the upper limit of normal,<30 ml/min,,,,,,
6140,,vertebral bone metastasis,inhaled glucocorticoids|a brief course of corticosteroids,,standardized uptake volume maximum (suvmax,standard drink,,,,fridericia formula);|new york heart association (nyha) cardiac function rating &gt,for at least 2 weeks,18 and above|history of participation,,,,,,
6141,,judged by the investigator.|current smokers,ravulizumab,,hepatitis b surface antigen [hbsag] test,physical therapists,,,,rips,within one month of the surgery date,>5% steatosis or|cap,,,,,,
6142,,anatomically intact,naloxone,,postures)|life expectancy,rp-ebus,,,,intra-mural,within 6 months before the day of vaccination,0-,,,,,,
6143,,muscle symptoms,potent inhibitor,,bayley scale,organ,,,,genetically modified cell therapy,more than 1 pelvic organ resected||,over nadir,,,,,,
6144,,uti's,nonunion,,glomerular filtration rate (egfr;,screening;|anticoagulation therapies,,,,insulin therapy|recently (,within 1 months of the first administration of study,from 18 to 65 years.|patients,,,,,,
6145,,bipolar disease,hybrid closed-loop system pump therapy,,hcv rna test results,thrombolytic anticoagulation therapy.|at screening,,,,unsuitable for the subject to participate,during the 4 previous weeks,>23)|age,,,,,,
6146,,1|diabetes mellitus,medicinal product study,,er/pr,combination treatment,,,,transsphicnteric fistula,last at least 30 minutes,<1.5 x the upper limit of normal,,,,,,
6147,,capecitabine.|hypersensitivity,.|strong,,stage d maturation stages .|patients,nitrate therapy,,,,peri-anal abscess,pre-molars,< 0.1 ng/ml.|malignancy,,,,,,
6148,,gastrointestinal illness,pheniramine,,"early stage """,icu)|sequential organ failure assessment (sofa),,,,igg,prior to start of study treatment,≥ 20 years|measurable,,,,,,
6149,,serological activity,anti tuberculosis treatment,,who child growth standards,single antihypertensive drugs,,,,toxic polyneuropathies,more than 14 units of alcoholic beverages per week within 6 months before screening,<100×109 / l;|hemoglobin <90 g/l,,,,,,
6150,,subaortic stenosis,emergency,,itq - international trauma questionnaire,local requirements.|the lar/parent/guardian,,,,varicella vaccine|subject,within the 4 weeks before screening.||prohibited,≥ 15mm,,,,,,
6151,,ibd)|colorectal cancer,pamapimod,,ibl,pars plana vitrectomy,,,,american college of rheumatology,within the 6 months prior to screening.|clinically significant,≥500 copies /ml. syphilis test positive.|those,,,,,,
6152,,vulnerable,medium-to-high dose ics combined,,residual neurological deficit,factor:|surgery,,,,non-anemic pregnant,in the affected knee within 6 months prior to screening,>33|self-report,,,,,,
6153,,hereditary hemochromatosis,anti-hb viral therapy；|10 iu/ml≤hbsag≤3000 iu/ml.||,,pfi,bariatric|prior surgery,,,,listed for,within 1 week prior to study treatment.|use of medications,<20|subjects who gained,,,,,,
6154,,citizen,mercaptopurine,,total homocysteine,emergency medical,,,,titanium,at least two times.|pr,20 and 55 years,,,,,,
6155,,black/african,chimeric antigen receptor,,serum protein reference values,obliterative arteriopathy,,,,large joints,36 months previously,6 to 10 years,,,,,,
6156,,lost to follow-up),non-steroidal anti-inflammatory medication,,cor tricuspid ecm valve|left,classical cesarean,,,,subacute,within 2 weeks of the ip dosing|a subject,at least 12 weeks.|women,,,,,,
6157,,residential substance abuse treatment)|moribund,intravenous (iv) antibiotics,,hepatitis b surface (hbs) antigen,therapeutic procedure,,,,duty military,at least 1 of the following criteria:||serum psa progression,18 years|refusal to participate,,,,,,
6158,,childhood febrile seizures,topical ophthalmic corticosteroid therapy,,hemoglobin concentrations,engage,,,,suitable for enrollment judged by investigators,1 drink = 5 ounces,>50ml/min(according,,,,,,
6159,,brain disease,pembrolizumab plus platinum,,telephone.||exclusion criteria,glucagon stimulation test||,,,,thc-containing products,within 30 days after the treatment of the target lesion.|known allergies,19 to 80 years|fma upper scores more than 25 and less than 58|patients whose lesions,,,,,,
6160,,dysimmune pathology,filgrastim,,visit)|left ventricular ejection fraction,adjuvant immunotherapy,,,,simultaneous,within the past 6 months.||(if participant began taking a supplement,"> 100,000/mcl",,,,,,
6161,,antiphospholipid antibody positivity,anti-inflammatory properties,,weeks|karnofsky performance status,study materials,,,,meeting dsm-5,within 24 hours prior to administration of study drug||key,≤ 50%,,,,,,
6162,,free vertical resection margins,monoclonal gammaglobulin dz,,better|total bilirubin,inguinal hernia surgery||,,,,vaginal,within 7 days;|the target vessel,≤ 30.0 kg/m2,,,,,,
6163,,synovial plica syndrome,stimulant decongestants,,partial response,general surgery department,,,,panel-reactive hla,within 14 days prior to registration)|platelet count,21 - 80 years,,,,,,
6164,,sudden hearing loss,inhalational steroids,,acog,consumption of grapefruit,,,,upper-limb disorder|major hearing/visual,before 19 years,chromogranin a,,,,,,
6165,,human granulocyte colony-stimulating factor,treatments targeting,,two blood pressure measurements,cranial imaging suggested,,,,mild to moderate clinically,within 1 month before randomization;||19,greater than 60cm,,,,,,
6166,,lack of smartphone|homelessness,curettage,,antibodies to syphilis,esophageal stents,,,,mono-species,within 2 weeks prior to the first dose .|patients,18 - 60,,,,,,
6167,,recovered from,clofarabine,,labile blood pressure,trauma)|digital exam,,,,mrd-detectable,prior to surgery participated in,between 18 and 75 years old,,,,,,
6168,,biochemical hypothyroidism,anti-incontinence surgery||,,carbon dioxide levels,surgical treatment,,,,melanoma dose expansion cohort,within the limit of normal.||9,≥240 mg/dl.|fasting,,,,,,
6169,,wolff-parkinson- white syndrome,adenosine triphosphate,,cervical cytology,physical examination findings,,,,non-prescription drug,within 14 days before the first dose of study treatment.||4,at least 5 months after the,,,,,,
6170,,detectable hbsag,systemic anticoagulation,,neutrophil absolute value,delay treatment,,,,signature|one,at least 6 months prior to first administration of any study,> 180 mmhg,,,,,,
6171,,comprehension disorders,topical decongestants,,screening|body mass index,bcg vaccine,,,,suitable for participation in the study to receive icp-332,after prior asparaginase-based,≤ 4500 cells/mm3.|acute,,,,,,
6172,,acute symptomatology,sucralfate,,american society of anesthesiology),metastases|positive serological test,,,,using the ckd-edi formula,within 2 weeks before the first use of the investigational drug,1 through 11,,,,,,
6173,,in situ cancer,"drug abuse,|systemic antibiotic therapy",,ottawa hospital stroke prevention clinic,bilateral orchidectomy,,,,3.active,in the past two years,between 18 and 64 years old,,,,,,
6174,,clotting disorders,ranolazine,,false,montreal cognitive assessment test,,,,secondary to hematologic disease involving,required|less than 3 months,<5 s,,,,,,
6175,,neurological disease|weight change,alpha blockers,,epo,hemorrhoidectomy,,,,low-grade prostate cancer|inflammatory bowel disease,at the time of diagnosis|in morphological first complete remission regardless of,10 male,,,,,,
6176,,syndros,histamine application,,cbct exposure,visit.|cd4 t cell count,,,,scars,at least 3 months of combination therapy,≥4 u/ml,,,,,,
6177,,cryptogenic organizing pneumonia,intervention drug,,response evaluation criteria in solid tumor (recist),paclitaxel treatment,,,,stage iv lung cancer,at the time of the first screening visit.||physical status classification,> 1.0 × uln,,,,,,
6178,,back pain.|enrolled,hysterectomy,,antibodies against checkpoint inhibitors.|patients,pelvic organs,,,,unresectable,previous year*,>0.2 nmol/h/mg|participant's parents or legal guardian consent to participate,,,,,,
6179,,native,molecular assays,,serum cea,diagnostic ct scan,,,,group i,at any point,≤ 1.5 times uln,,,,,,
6180,,dementia diseases,il-12 either alone,,hbv dna test,medical services plan in,,,,suitable for bcs|the tumor,for three months,≥300/μl|undetectable,,,,,,
6181,,acute haemorrage,megadose vitamins,,weight bearing x-ray,vascular access necessary,,,,site principal investigator,within 2 weeks before enrollment,≥ 1.5 mg/dl|severe,,,,,,
6182,,fracture time,sumatriptan,,gh treatment,intraoperative opioid administration|planned maintenance anesthesia,,,,prophylactic doses,within 3 weeks prior to study treatment initiation.||for patients of childbearing potential,">0.8,|weight equal or exceeded the ideal body weight",,,,,,
6183,,aortic stenosis|uncontrolled arrhythmia,5-ht3ra,,directorate general of health services,adequate standard therapy,,,,immunosuppressive drug|in standard practice,within the past 6 months.|be,less than 24,,,,,,
6184,,glioma,insulin pump therapy,,|cranial tumors.|meningitis.|sub-arachnoid,oral surgery / intervention,,,,primary advanced,within 12 months prior to randomization.|have received,>1.5 x uln,,,,,,
6185,,obstructive coronary artery disease|contraindications,liver drug metabolizing enzyme drugs,,modified oxford scale,e-boks,,,,myasthenia gravis activities of daily living,before the first dose of lp-168,18 years or older|experiencing,,,,,,
6186,,poor bowel,study drug.|is,,cscc,qt-interval corrected,,,,alk translocations.|history of,within 5 years before the first dose,<30 ml/min|bilirubin,,,,,,
6187,,kidney transplantation||,ventricular assist device insertion,,hepatitis b surface antigen (hbsag) test,allogeneic hematopoietic stem cell transplant,,,,regular high consumption,for 2 weeks prior to baseline or longer,<0.2,,,,,,
6188,,carcinomatous meningitis|known,brentuximab vedotin,,resting corrected qt interval,consumer tests,,,,pasc)|high,within last 6 weeks,above 19 and less than 80|ecog performance score,,,,,,
6189,,premature ovarian impairment,nouvelle aquitaine regions,,hcv viral load.|individuals,primary unilateral tka|patients,,,,non-traumatic neuroinjury,within 14 days prior to treatment study,<30 ml/min/1.73 m2.|patient,,,,,,
6190,,gastric emptying abnormality,contrast agent;|renal impairment,,ctcae v5.0,ovarian surgery,,,,absolute,in the next 24 hours,0-2|fev1 ≥1 litre,,,,,,
6191,,superficial bladder cancer).|any unresolved toxicity,trabectedin,,performance of,estimated,,,,fibrosis|anti-vegf therapy,at least 12 months after the last dose of ivs-3001.||,15-55 years,,,,,,
6192,,dapt,emgality®)|fremanezumab,,pad (abi,implant birth control,,,,above|recent,less than half a year,at least 1,,,,,,
6193,,24h proteinuria,cyp3a4 inducers,,partial thromboplastin (ptt),gi surgery,,,,hydrocephalus,within 2 weeks before using the study drug,18-65 years;|have,,,,,,
6194,,family hereditary disease,pirkanmaa,,mgmt promotor status,influenza vaccination,,,,m17.0,within 14 days prior to first dose of study treatment.|impaired,<= 2|histologically confirmed richter's transformation,,,,,,
6195,,intestinal permeability,nicotine replacement therapy|2,,nonsecretory mm.|systemic al amyloidosis,fractional flow reserve [ffr],,,,enteric pathogens,within 4 weeks before screening to be extended & specified,< 2500/pl,,,,,,
6196,,inactive infection,coordinators,,national file of volunteers in biomedical research,biopsy procedures,,,,successfully repaired,for 6 months before the screening|history of,greater than 50%|ecog 0-2 status|signed informed,,,,,,
6197,,false positive,nivolumab monotherapy,,er expression,complete oral examination,,,,post-traumatic stress disorder|subject,"within the first 24 hours after the operation,||",<11 g/dl,,,,,,
6198,,physical disorders,cit,,expected duration,t-cell depleting therapies,,,,excessive intake of alcohol,in the past 12 weeks|poor understanding of the spoken,<15 ml/min/1.73m2,,,,,,
6199,,end-to-end,organs,,glucose,oral semaglutide,,,,related artery (,within the 5 years prior to screening,less than (<) 14 years,,,,,,
6200,,restricted mouth openings,bzds,,serum aspartate aminotransferase,electrolyte abnormalities|history,,,,non-prescription psychotropic drugs|presence,at least 20 years old,between 45 to 65|o degree to 20-degree,,,,,,
6201,,recurrence in ≤12 months of,akt pathway inhibitors,,nci-ctcae v4.02,renal artery stenosis|bmi>35 kg/m^2|patient,,,,selected diabetes clinic,within the 30 days prior inclusion|patient not able to meet,≥ 12 weeks from the time of,,,,,,
6202,,acute pathology,adequate medical treatment.|despite,,diameters,migraine treatment,,,,ffr measurements,"during the last month,",<35%)|lymphoma,,,,,,
6203,,sporadic adenoma,arb,,invisalign™ group this age group represents the majority,smartphone device,,,,place the individual at increased risk or preclude the individual's full compliance with,history at screening,0-10 point scale,,,,,,
6204,,drug dependence,bupropion,,6th grade reading level,saposhnikoviae radix (fangfeng),,,,single-payer,in prior 4 weeks|have,between 18 and 65 years.|score of more than 2.46,,,,,,
6205,,common bile duct stone|complete stone,gelatine tannate,,resting hr,conventional imaging techniques (ct,,,,post-bronchodilator,at least 30 days prior to screening;||must,score of 0 or 1.|life expectancy≥ 3 months.|histologically,,,,,,
6206,,receiver roles,ls variant,,needed)|international normalized ratio (inr),intensive therapy,,,,metabolic-associated,within the last 18 months,<25%,,,,,,
6207,,impact the quality of the,scoring,,aaa,special,,,,grade 1,prior to the first session of rtms,less than 28 days old newborns,,,,,,
6208,,communication aids,anti-fibrosis||,,schirmer's test score,tenodesis,,,,high-resolution manometry,within 6 months prior to receipt of study vaccine,≥ 4 mg/l,,,,,,
6209,,inflammatory disorders,lidocaine,,ventricular,enzyme replacement therapy,,,,cancer|participant,during the study.|the subject,≤ 3.0 x iuln|creatinine clearance,,,,,,
6210,,end-stage renal disease,caffeine-containing beverages.|using,,estimated glomerular infiltration rate (egfr),metastatectomy,,,,first-line therapy,surgery prior to enrollment,> 1.5x uln.|participant,,,,,,
6211,,acute coronary artery disease,drug allergy|drug,,urine protein quantification,mechanical knee pain,,,,non-squamous nsclc|her2 mutation identified by tissue,lactating;|history,>3years)||,,,,,,
6212,,weight loss herbal,ophthalmology,,meniscal root/radial repair,conventional ct scan,,,,kirklin table,before or after intraoperative treatment,35-75 years|patients,,,,,,
6213,,language communication,vital signs;|using sertraline,,serum creatinine ≤1.5x uln,waiha,,,,months)|contraindication,for at least 3 months.||,i-iv|be,,,,,,
6214,,uploads,hybrid closed loop system;|currently,,glomerular filtration rate (,bilateral hip fracture,,,,post-traumatic,within the last 3 months before surgery,pembrolizumab 200 mg q3w,,,,,,
6215,,acute pulmonary exacerbation|pregnant,traditional medications,,forced termination of the study,transplantation comorbidity index (hctci),,,,follow-up||,in the next 3 months' specific diet,< 18 years|new cancer diagnosis,,,,,,
6216,,pellucid marginal degeneration,local anesthetics,,asian working group,covid-19 vaccines);|pregnant,,,,influence the outcomes|smoking,after receiving conventional treatment,greater than 30 mg/g.||(4,,,,,,
6217,,biliary malignancy,component of the durvalumab formulation,,screening.||fellow eye inclusion criteria:||best corrected visual acuity etdrs letter score,radiological knee osteoarthritis||,,,,nursing|is,for ≥3 months prior to randomization,greater than 5×109/l,,,,,,
6218,,neovascular amd,glucocorticoid,,anti-donor hla antibodies,transurethral resection of bladder tumor,,,,dissected,during activities of daily,"≥ 30 to < 60 ml/min/1.73 m²,|severe",,,,,,
6219,,colonic resections,germline smarcb1,,pq,magtrace®.|undergoing standard follow-up,,,,rotational,within the last 6 months prior to screening.|willing,more than 80%,,,,,,
6220,,preserved ejection fraction picture,ltra,,modified-boston-criteria,antimicrobial,,,,may encourage problems,before pandemic time (before 2019 included)|lt centres,≥23 kilogram/square meter (kg/m²)||,,,,,,
6221,,mild cognitive impairment||,medications that lead to increased risk,,rcc,roux-en-y gastric bypass surgery,,,,medical contraindication,during the last 3 months|prior antimalarial therapy,> 120 beat/min,,,,,,
6222,,distant metastatic,intranasal decongestant,,liver biopsy core sample collected should,chest x-ray examination,,,,diagnostic and statistical manual of mental disorders (5th edition; dsm-5);|subject has neurologic disorder,within 14 days prior to randomization.|current,≤ 1.5 × upper limit of normal,,,,,,
6223,,renal function.|left ventricular ejection fraction,cytokine,,glomerular filtration rate (egfr) estimated by,cta examination,,,,immunoglobulin a nephropathy,at the time of icf signature,<19 years,,,,,,
6224,,uncontrolled autoimmune phenomenon,anti-vegf treatment,,hepatitis b core antibody (hbcab;,chest ct,,,,ga68,for 1 year following jwcar029 infusion,1.1 while receiving any,,,,,,
6225,,unwillingness,ctcae grade,,npc,4)always treatment,,,,permanent molars,within one week prior to the scheduled study visits,over 110 mmhg,,,,,,
6226,,airway stenosis,herbal product|patients,,beta-2 glycoprotein [,"psychotropic drugs,|to take",,,,problematic,within 6 months after the last dose of the study drug,50 to 100 kg (inclusive),,,,,,
6227,,hemolytic anemia,conventional chemotherapy;|persistent extramedullary leukemia.|meet,,urine drug screening test,major abdominal surgery||,,,,bi-directional glenn surgery,5 half lives prior to the first dose of study,> 48,,,,,,
6228,,pituitary problems/surgery,antivirals,,national comprehensive cancer network (nccn),rigid orthokeratology lenses,,,,under general anesthesia.||,preceding 24 consecutive months).||patient must,">750,000 /μl.|use",,,,,,
6229,,space syndrome,apatinib,,illing,postoperative cardiac surgery.||exclusion,,,,aml-m3,within 28 days of the first dose of study drug,> 11 years|jia,,,,,,
6230,,c hepatitis,over-the-counter medications,,"sars-cov2"".||",single-episode,,,,potentially damaged nerves,at or after delivery||,≤ 1.5 times the upper limit of normal;|subjects voluntarily joined the study,,,,,,
6231,,scalp psoriasis,california residents,,hepatitis c rna,definitive radiotherapy,,,,non-cutting,within 7 days before check-in of period,<3 x upper limit of normal (uln),,,,,,
6232,,severe valvulopathies,pleurx,,hiv infection|active hepatitis b,lung surgery,,,,contra-lateral,at pre-treatment|all,≥35 ng/l,,,,,,
6233,,arrest|obstructive shock,mdm2 inhibitors,,angina)|heart rhythms,hormonal profile,,,,ef≥50% (,for enrollment to groups 1 or 2,1.7,,,,,,
6234,,symptom,low molecular weight heparin,,asa i).||,allogeneic stem cells|participation,,,,inclusion|high central venous pressure,at their back and/or lower limbs,≥ 5|age,,,,,,
6235,,psychiatric condition,phytosterols,,dme|best corrected visual acuity of 20/320,complete medical,,,,adequate understanding of spanish,within 7 or 14 days or,< 140 mm hg,,,,,,
6236,,altering esophageal motility,adenosquamous,,sgpt,bariatric surgery|controlled attenuation parameter for fatty liver degeneration,,,,short term,at the same hospitalization,30 - 70 yo)|bmi,,,,,,
6237,,prostate adenocarcinoma|metastatic disease,monoclonal antibody|wocbp,,plasmocyte bcma expression positive;|5.echocardiography,vascular access method,,,,≥6 months old|provides,prior to entry into the study.||note,+ polypoidal lesion,,,,,,
6238,,cerative colitis:||signed informed,cholinase inhibitors,,mirels score,pretreatment psma pet,,,,index procedure|thrombophlebitis,within the last 12 months.||5,0-33).|participating,,,,,,
6239,,hepatic resection,calcific metamorphosis inside root canals|tooth,,peripheral blood hcv rna,nicotine delivery system,,,,clinically-significant,within one month;|not willing to participate in the study,less than 3 months prior to screening.|subject,,,,,,
6240,,popliteal artery lesion,oral contraceptives,,sport + keuringsartsen (ska),biological drugs therapy,,,,ban smoking,within 30 days before randomization.-,screening||positive,,,,,,
6241,,dependence,venous-capillary,,standardized mini mental test|to,routine procedures,,,,non-parametric statistical analysis,after the initial reduction surgery|patients,>= 2,,,,,,
6242,,chemical neurolysis,hybrid 18f-naf pet-ct imaging,,anti-treponema pallidum specific antibody,several treatment sessions,,,,stovetop,for ≥ 3 months,<25%.|subject,,,,,,
6243,,asthma thyroid disorders,alhydrogel,,systolic arterial pressure,small changes,,,,t4b,bilateral,between 24 hours to 7 days after the planned randomization,,,,,,
6244,,practice providers (app),anti-pth agents,,nia-aa criteria,acute care panel,,,,criteria:||ige-mediated,last dose received until first study treatment.||,eteran):||aged 18 years,,,,,,
6245,,special populations,ampulla,,promis,studio,,,,acute leukemias,within 7 days prior to the t0 scan,"> 100,000/mcl|hemoglobin",,,,,,
6246,,progressive neurological pathology,topical anti-glaucoma medication,,estimated visual potential,allogeneic hematopoietic stem cell transplantation|those who,,,,lumbar mri|those,within 15 days of trial start.|history,"over 65,",,,,,,
6247,,btk-containing regimen,lutetium,,diameter,antigen injections,,,,soft tissue/visceral lesions,within 4 weeks before first dose administration,≥23 kg/m2,,,,,,
6248,,non-culprit lesion,orthokeratology lenses,,1).|body mass index (bmi),discontinue,,,,non-malignant,within 1 year prior to screening;|site staff,19-25 kg/m2)||,,,,,,
6249,,glaucoma drainage,agents used in study.|uncontrolled intercurrent illness,,test;|creatinine clearance,domized,,,,cognitive reappraisal,during the current study,>= 20 years|ease,,,,,,
6250,,antimicrobial preparations,sigmoid,,western aphasia battery - revised (wab-r)|score,general anesthetic,,,,grade ii or higher,three times within the past year,18.5 to 24 kg/m2,,,,,,
6251,,clinical examination||,resected,,hemoglobin (hba1c),intracoronary lithotripsy balloon catheter,,,,cycled,within the last 4 weeks prior to the,> 500 ms.|known,,,,,,
6252,,non-progressive,berlin definition,,trichophyton rubrum).|no,agent|investigational agent|surgical intervention|radiation intervention,,,,texas healthy,within 12 months;||history of severe,>90% sites observed|probing depth,,,,,,
6253,,xerostomia;|systemic inflammatory diseases,immune-modulatory therapy,,urine cotinine,physical intervention: inability to physically exercise,,,,requiring in depth medical treatment|active,within 7 days before study enrollment;||,> 35|individuals especially,,,,,,
6254,,heart disease;|suffer,exosuit,,moderate tbi|current,"cochlear implants|received tms, tcs",,,,primary mediastinal lbcl,within 3 months prior to screening.|hypersensitivity,0 to 2|adequate renal,,,,,,
6255,,antidepressants|diagnosis,vape,,osdi score,sish,,,,infection|significant,at the incision site.|a history,0 - 3.|epidermal growth,,,,,,
6256,,systemic absorption):||prescription medications,over-the-counter (otc) drugs,,pulmonary artery pressure,pain procedures,,,,decreasing dose,within 7 days before the first dose of the study drug,≤ 35 kg/m2|gestational,,,,,,
6257,,abnormal pain,amoxapine,,cdc,congenital malformations|the,,,,colonoscopies,prior to starting any treatment,≤ lln|active liver disease,,,,,,
6258,,anal fissures,dmo,,enterectomy.|active hepatitis b (hbsag and/or hbcab positive,tentative ninth,,,,cingal,within 1 week before administration,≥18 years|histological,,,,,,
6259,,pericarditis,cholecystectomy|prisoner|gb cancer|advanced cirrhosis|untreated coagulopathy|no indication,,hepatitis b (hbv) surface antigen,complete endoscopic obstruction,,,,wi-fi internet access,within 1 year before screening,greater than or equal to 4,,,,,,
6260,,sensitizing epidermal growth factor receptor (egfr),prolonged sitting,,corrected qt interval,surgical sterilization should take effective contraceptive measures,,,,"non-sanitized surgical infection,|use",between january 2008,between 60 and 85 completed,,,,,,
6261,,asthma episode(s,anti-ccr8 targeted therapy.|history of,,nci-ctcae version 5.0 [appendix 3].|known hypersensitivity,bone scintigraphy,,,,inadequately treated,more than 3 months|nrs scale,>1.5 uln);|history,,,,,,
6262,,electroconvulsive therapy;|alcohol dependence,adequate treatment,,hemoglobin value,progesterone,,,,first relapse|high-sensitivity,at least 20,3 uln||creatinine clearance 50 ml/min,,,,,,
6263,,severe obesity,xenical],,nic-ftd,emergency department|unable,,,,subclavian,for at least 48 hours|agreed,< 5 mm,,,,,,
6264,,bankart lesion,glargine,,child c cirrhosis.|are,treatment.|ejection fraction,,,,smpc)||,prior to distal pancreatectomy,>uln).||coagulation:||international normalized ratio,,,,,,
6265,,abdominal traumatic injury,tesamorelin,,limb length,surgical orthopaedic interventions,,,,suitable for radical therapy,at time of the first study blood draw|patients,>3.0 ng/ml,,,,,,
6266,,platelet abnormalities,doxepin,,telephone montreal cognitive assessment (moca),progression (ct confirmed,,,,necker enfants malades hospital|information and consent of holders of parental authority,in the 24 months prior,0 or 1.|adequate,,,,,,
6267,,accessible archival tumor tissue,cardiovascular acting medications,,wide field,surgical sterilization of the woman,,,,non-ibd||colonic,"for 1 month after the end of treatment,|negative serum pregnancy test",= 340 ml,,,,,,
6268,,her2 ihc test,pd-1 inhibitor,,serum bilirubin,chronic opioid use,,,,materials used|children,prior to the first dose of fludarabine.|radiotherapy,18-100,,,,,,
6269,,fatty liver disease.|patients,inducers of cyp3a4,,level of the spinal,serological testing for hiv,,,,ipsilateral axilla.|previous rt towards,within last 2 months)|chronic intake,"≥ 1,500/µl|platelets ≥ 100,000/µl|hemoglobin",,,,,,
6270,,non-radiating neck pain,clindamycin hydrochloride,,blood pressure||systolic blood pressure,intensive care (,,,,non-contrast,within the past 60 days|participants,<3.4 or >11.0 x 103/mm3,,,,,,
6271,,imb,analgesic,,sulfa drugs|chronic opioid use (daily or almost daily use,standard premedication,,,,core biopsy;|tamoxifen,in the 6 months before the study.|patients,≥ 500mg/dl;|diagnosis,,,,,,
6272,,biochemical examination:||tbil<1.5×uln；|alt,anti angiogenesis,,slicc,psma pet imaging,,,,"stage 4-5,|diagnosis",at lumc,"< 8,5 g/dl",,,,,,
6273,,acute blood loss,drugs required in the test;|patients,,kellgren lawrence grade,chest computed tomography (ct) scan.|any lung disease,,,,confined to the same lobe of the liver,within 30 days prior to the first dose of trial treatment,<60 milliliter per minute per 1.73 square meter (ml/,,,,,,
6274,,stemi myocardial infarction|sepsis,tenofovir prodrugs,,recist v1.1;|able,intradetrusor,,,,psoriatic,during and within 1 year after trial completion;|work,over 6-week,,,,,,
6275,,mononeuritis,sarcomatoid mesothelioma|patients,,above|rectal bleeding|inflammatory bowel,paclitaxel chemotherapy,,,,natural resolution,while on study drug,greater or equal to 10,,,,,,
6276,,associated enteropathy,ocular surface,,body mass index values,osseous lesions|history of,,,,seroprevalence,after at least 6 h free of parkinsonian drugs,150 cm,,,,,,
6277,,software application,oral steroids.|severe obstructive sleep apnea.|recent,,anti-anxiety medication|are lactating,head trauma,,,,non-reproductive manner;|participation,during the whole study period.|any,≥ 60).||,,,,,,
6278,,intestinal motility disorder;|alcohol,systemic steroid hormones,,syphilis serology test results,75-g oral glucose tolerance test,,,,agh,at least 2 weeks before the start of study drug,between 18.5-39.9 kilogram per meter square (kg/m2,,,,,,
6279,,upper gi cancer,medical adhesives,,following:||total bilirubin,medical records|affirmative response,,,,articular surface|open,at the time of the experiment,≥ 100 °,,,,,,
6280,,asthma,nivolumab/etigilimab combination therapy.|known,,bleeding,topic cosmetic treatment,,,,cerebral,at the first second is < 0.70,41.4-60,,,,,,
6281,,transfusion therapy|known,monupiravir,,lateral surgical approaches,perfusion index values,,,,lasting a minimum of 24 hours,within the last 7 days|patients,>= 18.0 to <= 32.0 kg/m2,,,,,,
6282,,rheumatological disease|getting cancer,vitamins,,pulmonary arterial wedge pressure,hold breath,,,,12-lead ecg,last 12 months at pre-screening;|gastrointestinal diseases,≥45 kg||,,,,,,
6283,,orthopaedic,conventional chemotherapeutics,,progesterone containing,antiretroviral therapy (art),,,,insulin pump)|hypersensitivity to loud noises|incapable of lying still,for at least 2 days,> 24 hours||abnormal transcranial doppler,,,,,,
6284,,local anaphylactic necrosis reaction,beta receptor blockers|repeated measurement,,gonadotropin-releasing hormone,ablation-accessible,,,,threatening,within 7 days prior to randomization,>8.0cm,,,,,,
6285,,1.patients,anti-infective,,decreased ejection fraction,resistant,,,,which affects balance,within 8 weeks of baseline,≤5 times uln|females,,,,,,
6286,,constitutes,anticoagulant therapies,,serum k,bone marrow cell morphology,,,,coronal,after first-line platinum-based,> 5 ku/l,,,,,,
6287,,self report)|right,study check,,rutherford classification|presence,dxa scans,,,,adequate understanding or cooperation;|participation,within the 3 months preceding study enrollment,between 18 and 70,,,,,,
6288,,hiv)-1,"intervention),|no congenital",,isis,b vaccination,,,,thiazide-like diuretics)|mineralocorticoid receptor,at the time of signing the informed consent form;|histologically confirmed,greater than or equal to18 years.||,,,,,,
6289,,irradiated lesions,lsa,,hepatitis c virus infection (hcv antibody,prophylactic cranial irradiation,,,,index event,within 1 month;|subjects,≤ 2.5× upper limit of normal (uln),,,,,,
6290,,colorectal cancer;|patients,miravalle,,antibodies to iga,regular sinus rhythm,,,,valvular,within the specified time period prior to apheresis:||administered any,>= 60%).|hemoglobin >=10 g/dl,,,,,,
6291,,wilson disease,periodontal condition|having used local,,hemoglobin of,optical intervention for more than 2 weeks,,,,acuity|bilateral phacoemulsification cataract surgery,within 4 weeks before the first dose of the study treatment,over 80 years,,,,,,
6292,,detectable autoantibodies,ketoconazole,,suicidal thoughts/tendency,mastectomy|previous axillary surgery,,,,imp,in the 2 years prior to the date of informed consent.|the patient,at least 2-/5,,,,,,
6293,,irreversible heart failure|contraindications,peanut oral immunotherapy,,cancer|systolic blood pressure,d1 expression,,,,yoga,longer than 12 months prior to inclusion.|parent/legal guardian,≥6.|revised,,,,,,
6294,,chronic active hepatitis b,egg protein|seasonal,,neuropsychiatric inventory domain score,percutaneous coronary intervention|patients,,,,longest diameter of extranodal lesions,doubling time of > 12 months,< 25;|covered,,,,,,
6295,,balance disorder,component of rc28-e,,volunteers;|body mass,adjuvant chemotherapy treatment|lars score,,,,inadequately controlled,at time of skin biopsy.||the patient,< 30ml/min)|t2d,,,,,,
6296,,positivity,ar inhibitors,,new york heart association [nyha] classification grade,major organ function,,,,intracranial,in the last 8 hours.||,≥ upper limit of normal,,,,,,
6297,,meningitis,twins,,home care service's assistant's criteria,brain metastasis.|prior therapy,,,,months.|able,at the time of enrolment,≥ 110/70 mmhg before dosing.|the subject has,,,,,,
6298,,hypovolemia,ire,,therapeutic inr,immunomodulatory biologic agents,,,,upsloping,need to confirm,predominant,,,,,,
6299,,persistent ovarian clear cell carcinoma,segmental,,physical examination.|gmfcs level,stem cell transplantation,,,,csf evaluation and contrast-enhanced,within 3 weeks prior to first study drug administration after enrollment.|patients with,>2.5× uln,,,,,,
6300,,developmental glaucoma,hematopoietic growth factors,,wide spectrum antibiotics,|indication to biopsy,,,,fresh tissue samples from,prior to lymphodepletion,"≥1,500/µl|absolute lymphocyte count",,,,,,
6301,,hepatobiliary system diseases,live vaccines,,oral cavity malignancy|active oral cavity,hemorrhoidal bleed,,,,cardiac-related,at least 14 days prior to the randomization visit (day 1,2-4 mm,,,,,,
6302,,upper back region.|myofascial pain,tacrolimus containing medications,,orif)|age,consolidation therapy,,,,emergency department|subjective,within one year from signing informed consent|at the time of screening,above the uln,,,,,,
6303,,rifampicin|porphyria|cardiogenic shock,antimigraine agents,,aspartate transaminase（ast）<2.5 uln;|serum,invasive procedure,,,,high-dose corticosteroid,"during the last 5 years,|hypocalcaemia (calcium <2.20 mmol/l),|25-oh",ii-iii.|full-term,,,,,,
6304,,inflammatory disease|active viral,monoclonal immunoglobulins,,performance status,liver transplant|participation,,,,finger joints|upper limb pain,after at least one prior line,older than 80 years,,,,,,
6305,,cardiac function:||left,snri medication,,and|patient co-operation.||,stone apparent,,,,site of block placement|history of,in the past 30 days prior,above the lower limit of the assay,,,,,,
6306,,malignant illness,"drugs related to the aforementioned diseases,|pregnancy,|patients",,detectable hcv rna,dll3 inhibitor therapy,,,,influence the endpoints of the study,at least 2 weeks prior to protocol treatment,less than 10 mm,,,,,,
6307,,cardiovascular disease|use,procedures|preoperative opioid use|diagnosed substance abuse|moderate to,,neck irradiation.|who performance status,stem cell transplantation.|patients,,,,non-sanitized surgical,at the time of screening|high inotropic requirement,19.0≤bmi < 28.0;|participant,,,,,,
6308,,measurable lesions,nasogastric tube placement,,united kingdom parkinson's disease society brain bank (ukpdsbb) criteria||pd,percutaneous ethanol injection (pei),,,,classic,following foods/supplements,≤ 1.5 x institutional,,,,,,
6309,,psychiatric diseases|covid-19 positivity,pfts,,loading,"cholecystectomy operation,|no orientation",,,,timi grade ≤ 2)|if life expectancy,within 2 weeks prior to treatment.|participants,less than the upper limit before study enrollment,,,,,,
6310,,therapy.|pregnancy,nateglinide,,medication-induced psychosis,major surgical procedure,,,,non-measurable,within the previous 12 months|known history,>= 70%)|metastatic disease,,,,,,
6311,,lymphoma.|multiple myeloma,components in the eye drops.|diode laser treatment,,absolute fev1 increase of,i.v.-hepabig,,,,lower extremities,at the time of study enrollment|english speaking|willing to participate,≤2 times uln,,,,,,
6312,,cyp3a4 interaction,vidarabine,,egfr mdrd-4,optimal medical management;|no,,,,interventional study|known hypersensitivity,within 3 months prior to randomization.|regular consumption of probiotics,16-53,,,,,,
6313,,plateletopenia,agents.|concomitant medications,,prothrombin time],temporally interrupted,,,,complicated,up to 24 months prior,+ 1 confirmatory test,,,,,,
6314,,ptsd,pet)-avid,,method.|life expectancy,psychotic|unstable general medical condition|current use of,,,,non pcr,admission to il6ri/jaki initiation,between 35 to 65 years|american society of anesthesiology,,,,,,
6315,,surgical infection,compounds of similar chemical or biologic composition to triapine,,ankle disability index score,bilateral adrenal tumor resection,,,,knee,within 3 months prior baseline,over 25 years,,,,,,
6316,,negative.||,oltp,,folfox palliative systemic,skin prick test,,,,m0):||no prior therapy,within one year prior to treatment initiation;|participated,>45 msec|use,,,,,,
6317,,lower gastrointestinal [gi] bleeding,chronically drug abuse|smokers,,oral steroids|severe valvular heart disease,rf denervation|regular use,,,,peptic ulcer|severe associated disease|history of,immediately prior to the,< 25000/μl,,,,,,
6318,,genetic defect,intravenous steroids,,cardiac index<2.2 l/min/m2,pta level||presnce,,,,"should 3a and 3b apply, participant will be allocated to the smoking cessation intervention.||",in the next 90 days,between 18 and 70 years old.|chronic,,,,,,
6319,,c)|renal failure,prostate,,anti-microbial prophylaxis,routine blood test,,,,ami||,within 14 days prior to randomization,≤ 6,,,,,,
6320,,overweight,hydroxycloroquine,,urea breath test,rotterdam criteria [12].|body mass index,,,,grade 2 prior,within 28 days prior to the initial dose of study medication.|subjects,20-30 mg/day,,,,,,
6321,,2˚of eversion,combined liver,,bilateral lesion|development,colonoscopy unit,,,,non-pharmacological intervention,at least 1 prior line of endocrine therapy,≤ 30 mg/day,,,,,,
6322,,cardiopathy,pain relief,,anti-dsdna antibody,pallidotomy,,,,emergency services,within 14 days before the first dose.|received,≥20 at screening,,,,,,
6323,,acute radicular lbp,acne conglobata,,age|postoperative midline exploratory laparotomy,cmr examination,,,,large,within 7 days before the laboratory test),"i, ii,",,,,,,
6324,,therapy|partial response,monoclonal antibodies;||active,,days)|hemoglobin,transmural infarction,,,,influence balance|sedating medication,throughout the first 24 weeks of the trial,≥9.0 g/dl.|absolute neutrophil count (,,,,,,
6325,,cardiac disease:||myocardial infarction,krt,,insomnia severity index (isi);|ability to adhere to a diet,ataxia-telangiectasia,,,,site of deployment|patient,previously received hydroxychloroquine.|patients,> 480,,,,,,
6326,,progressive pathologies|impossible,abnormal anastomotic vessels,,localized gleason score,lumbar region in the last 3 months||,,,,unreasonable,within 14 days of study entry,≥200 ml,,,,,,
6327,,not controlled,fish,,partial cystectomy.|patients,tests|forgo donation of blood,,,,intra-uterine devices,within the last five years|participants,≥ 50% of predicted value,,,,,,
6328,,erythrocyte instability,mca lesions,,antioxidants.|their blood pressure,discontinuation of augmentation therapy,,,,radiologically confirmed,algorithm|d-dimer level,> 470 ms demonstrated,,,,,,
6329,,recruitment|able to read,depigmentation treatments,,bone marrow edema,cardiopulmonary exercise test,,,,tilburg frailty indicator,active,0-1|child-pugh,,,,,,
6330,,carcinoma.|primary immune deficiency.|presence,cdk4/6 inhibitor therapy in combination,,gvhd prophylaxis|creatinine clearance,dimethoxy-4-chloroamphetamine,,,,unilateral total knee arthroplasty procedure||,within 5 year|surgery,>= 30 ml/min,,,,,,
6331,,arterial thrombolysis,countries,,modified rankin scale (mrs),fractures;|open fractures;|pathological fractures;|malignancy;|malnutrition;|chronic diseases,,,,skull-base,within 2 weeks of the screening visit,from 18 to 75 years old||,,,,,,
6332,,influenza disease,oral hypoglycemic agent,,total bilirubin should also be assessed||has no,renal impairment||renal,,,,outpatient,last two weeks of the intervention,> 0 points,,,,,,
6333,,index stroke,study|blood donation,,na,radical chemoradiotherapy,,,,at least 3,within 14 days prior to registration on study,≥60 ml/min/1.73 m2)|platelets,,,,,,
6334,,chronic kidney disease epidemiology collaboration equation,protease inhibitors indinavir,,uln|prothrombin,medical emergency,,,,stimulateur,for the duration of the study.||,>40 s,,,,,,
6335,,impaired glucuronidation|immunodeficiency,medications by mouth including laryngectomy,,aiha).|hemoglobin,allogeneic hematopoietic cell transplant|biologic,,,,insulin pump settings,within one year of study enrollment||planned,< 70|presence,,,,,,
6336,,acute chest syndrome,immunosuppressant,,bcva,intraocular foreign body,,,,sport activities,within 7 days prior to enrollment.|a,30-75 years,,,,,,
6337,,mental health literacy,iron -deficiency|other medical condition,,ast,transthoracic echocardiography should,,,,dual chamber (dr),within the past 5 years|tuberculosis|health or psychological diagnoses,≥18 years;|sick-listed,,,,,,
6338,,poor placental perfusion,platelet transfusion,,participation;|body mass index,physical therapy sessions,,,,operation|severe,in 24 hours >1.0g;|any,18 to 30kg/m2|those,,,,,,
6339,,crisis,prophylactic antibiotics,,anti-programmed cell death 1 (pd1) / anti-programmed cell death ligand,robotic-assisted laparoscopic surgery,,,,strangulated,at distance,between -0.75 d and -4.50 d (inclusive),,,,,,
6340,,tendinitis,beans,,fasting blood work,world health organization definition,,,,pd-l1 immuno-histochemistry (ihc),at the time of signing the icf.|body weight,between age,,,,,,
6341,,world health organization (who),angelman,,septal thickness,head cta,,,,functionally significant,within 7 days prior to apheresis,">=100,000/mcl|hemoglobin",,,,,,
6342,,excipients;|pregnancy,ici,,sas,tetracycline.|participated,,,,primary brain,last 24 months,≥10 miu l-1 or <,,,,,,
6343,,pre-retinal fibrosis,glycerol,,enrolled less,preoperative corneal pachymetry minus calculated,,,,normal|expected survival,during the training session,between 18-75|asa1,,,,,,
6344,,immunosuppressant diseases|periodontal maintenance,official institution,,plasma glucose concentration,endothelial keratoplasty||,,,,orthostatic,prior to initiation of any study-specific procedures,"1, 2",,,,,,
6345,,etc.)|valvular heart disease|use of,oral anticoagulant,,"platelet values<150,000/ml",colorectal surgery|hearing disorders|no,,,,t1-weighted,during the observation period and within 8 weeks after the last administration of the study drug,6 years and,,,,,,
6346,,severe calcified lesion,pas,,forced expiratory volume in one second (fev1),stroke||biceps>2,,,,radiographically abnormal,within 28 days.||9,< 22)|asthma,,,,,,
6347,,intracerebral bleed|any stroke,opioid deficiency - noted,,cd4,continuous glucose monitoring device,,,,including||- invasive,in the past 14 days)|absolute neutrophil count (anc),between 18.5 - 40 kg/m2.|live,,,,,,
6348,,comorbidities|smokers|previous failures,paley type 1,,ayahuasca,cytotoxic therapy,,,,110 lb).||participants,within 6 weeks prior to step 2,pregnancy|adult patient subject,,,,,,
6349,,benign liver diseases,immunoglobulin g (igg) products|patients,,acne fulminans,standard of care clinical considerations have,,,,yellow fever vaccine,14 days before randomization,ii-iii degree|congenital,,,,,,
6350,,bacterial meningitis|middle ear infection,antiretroviral therapy|effective contraception,,early stage,dedicated respiratory intensive care unit||,,,,anterior,prior to the first psilocybin-assisted psychotherapy,than or equal to the upper limit of the normal range,,,,,,
6351,,30|able to read,contraceptive method,,sgot]/alanine aminotransferase,hematopoietic stem cell transplantation|participants with,,,,within usual care|patients,within 4 weeks prior to screen/baseline,≥1 cm,,,,,,
6352,,visit|previous intolerance,anti-vegf responsiveness|subject,,generalized/focal,gynaecological pelvic examination,,,,antiseptic,during the restricted periods,greater than 12.0mm.|if the,,,,,,
6353,,atrial fibrillation|albumin,dissecting,,serum chemistry parameters:||an,bilateral smile treatment,,,,post-traumatic injury,at any time in the course of their disease,older than 20-year,,,,,,
6354,,tongue base,topical ophthalmic prescription,,serum follicle-stimulating hormone level,bilateral ovariectomy,,,,thero2-01s22,within the last 3 months|systemic regular anti-inflammatory,between 0-3 points,,,,,,
6355,,donor specific antibodies|a,first generation anti-androgen,,radioisotope glomerular filtration rate,biochemistry analysis,,,,suitable for endovascular denervation,for 5 months after the final dose of,≤ 2.0,,,,,,
6356,,histoplasma capsulatum,components thereof,,"specialist rehabilitation unit 1 of the ""e. spalenza - don gnocchi ""of rovato.|overall score",alcohol breath testing,,,,vasovagal,at least 3 of the last 7 days|presence,<30 ml/min/1.73 m^2,,,,,,
6357,,gregory classes ia,needle sickness;|patients,,cardiac ejection fraction,things separately.||the first one,,,,full course of treatments,during study time frame.|inability to understand,≤ 1.5 × uln|total,,,,,,
6358,,allergic skin diseases,cerebellar gait,,albuminuria,eligible.|autologous stem cell transplantation (sct),,,,"injection site,|who",during screening or before initial administration;|patients,> 500 ms,,,,,,
6359,,vision impairment,adequate answering of the questionnaires)|no previous,,hemoglobin outside,gastrointestinal surgery 6) suffer from mental illness,,,,illicit drugs,discretion;|current,<4 kg,,,,,,
6360,,bradycardia,glatiramer acetate,,rituximab).|absolute neutrophil count,diagnosis|current,,,,full code,within 30 days prior to the first dosing,>12.|histologically,,,,,,
6361,,vwm disease,fibrate,,agreement||,corneal spherical aberration,,,,insulin like growth factor-i,for at least 7 days prior to the administration of study drug(s).||,less than 10 degrees|age,,,,,,
6362,,grave's disease,anti-muscarinic properties,,c reactive protein,16 completed years,,,,group 4)||each healthy,post-recurrence|1 to 3,between 18 and 30 years|matched,,,,,,
6363,,tumor emergencies,mineralocorticoid antagonist therapy,,system;|acute suicidal,laparoscopic examination,,,,e,within 7 days prior to the first dose,between 30 and 60 years||evidence of prior,,,,,,
6364,,dementia|morbid obesity,long-acting,,contraindicated;|survival expectancy,cetuximab treatment,,,,immunosuppressants|pregnant,more than 15,"0 ,1",,,,,,
6365,,vaginal douching,stem,,hepatitis c virus rna test,intracranial eeg,,,,hereditary,for at least six months after the end of the maintenance treatment.||,≥ 8.0 g/dl.||hepatic:||total,,,,,,
6366,,liver decompensation,xanthine ingredients,,recist v1.1|life expectancy,local institutional practice,,,,her2,for 4 months after completion of ruxolitinib,b or c).|patients,,,,,,
6367,,generalized convulsive seizures,connective tissue disease.|rheumatoid arthritis,,crp,glucocorticoids|adrenogenital syndrome|infectious disease|uncontrolled hypertension,,,,small-vessel disease,within 6 months prior to randomization|pleural empyema|evidence,≤ 60 ml/min/1.73 m2,,,,,,
6368,,third degree av block,components of the supporting,,pulmonary artery anatomy,screening assessment,,,,central vision,within 1 month before admission.|pancreatic diseases.|contraindication,<3 mm)|excessive overbite,,,,,,
6369,,refractory to first-line chemoimmunotherapy,permitted.||systemic steroid therapy,,puva,sars-cov2) infection,,,,tbi|tbi-related pathology,within the previous 6 months.|received,at least 18 years|indication,,,,,,
6370,,tbi,bumetanide,,iq,oral medication|pregnant,,,,ocular surface disease index (,during first-line chemotherapy,> 15h/d);|subjects,,,,,,
6371,,infectious arthritis,mrna covid-19 vaccine|history,,serum tumor biomarkers,electric shocks,,,,first-line targeted therapies,24 for 3 to6 years,< 5 l/s|have,,,,,,
6372,,major complications,wlst,,henry ford health|is,hbv serology indicating immunization,,,,nearly every day,at the time of screening defined by:||administration of any iv treatment,< 160 mmhg,,,,,,
6373,,malignancy bronchoscopy,antiarrhythmic agents|subjects,,inr should be,sterilization,,,,insulin therapy,within 6 months|ongoing,between 20-40,,,,,,
6374,,osseointegrated,antihypertensive medication regimen,,narrow qrs,study therapy,,,,ihc 2+,for at least 28 days prior to day 1,=< 5.0 times upper limit of normal,,,,,,
6375,,relationships in group settings|not in a relationship with a,anti-coagulation therapy,,traumatic exposure,auxiliary ventilation mode,,,,on transfusions,after two or more weeks of standard non-surgical treatments,≥ 75 × 109/l hemoglobin (hb,,,,,,
6376,,peripheral nerve sheath tumor,glp-1,,hypoproliferation；|eastern oncology collaborative group physical status assessment,mental health problems|those,,,,discrimination contribute to your,at least 6 months prior to study entry,less than 48h|patients,,,,,,
6377,,narcotic pain,doacs,,child b,light treatments,,,,white dot syndromes,within 28 days prior to treatment|no prior radiation therapy to the tumor,0 or 1.|no,,,,,,
6378,,paranoid personality disorder,owns,,stool scale*)||*see appendix,lifestyle modification,,,,chest-xray,in the past 3 months|body,>90 m,,,,,,
6379,,monomers|pregnancy|chronic disease,sleep number® bed.|subjects,,recist 1.1)|expected overall survival,renal artery stenosis.|urine albumin-creatinine ratio (uacr),,,,bleeding tendencies,during screening prior to study,<4cm,,,,,,
6380,,adenocarcinoma of the prostate|qualifying deleterious spop mutation,poaf,,inventory of depressive symptoms-self-rated,treatment dose,,,,encephalopathy.|known,within the past 6 months|chronic illness,< x1.5 upper limit of normal range,,,,,,
6381,,acute nosocomial pneumopathy,nicotine use,,cholesterol,therapeutic hormone,,,,proven,within 14 days prior to beginning treatment,> 18years.|confirmed renal,,,,,,
6382,,autoimmune disease;|persons,inhaled sabas,,far corrected visual acuity,microsurgical technique,,,,lasting at least 2 months|stated willingness to comply with all study procedures,prior to index bronchiolitis episode|premature,less than 30 kg/m2|american society of anesthesiologists,,,,,,
6383,,dah,heat,,hb level,routine urine test,,,,glucocorticoid dose,at screening.|recent (,>10 year;||adequate,,,,,,
6384,,virginia,supine rest)||supine blood pressure,,rsv mat-039 studies,primary total knee arthroplasty.|patient is able to understand the study design,,,,genetically determined marfan syndrome,during the screening or before baseline,>600 pg/,,,,,,
6385,,complete injuries,prolonged assist devices,,thin recto-vaginal septum,vertebral artery [va,,,,meeting medped,within 1 month from study enrolments|presence of,below 5 kg,,,,,,
6386,,solid tumors).|have adequate organ function.|fresh,clindamycin-metronidazole,,screening|screening laboratory values,eus,,,,under tutelle,prior to fa,>6 cm,,,,,,
6387,,digital ischemia,l-dopa|calcitonine|ocreotide|interferon alfa|sucralsulfate|botulinum toxin injections,,nacc ftld guidelines|apathy,transcranial magnetic stimulation (tms),,,,primary series of,"within 5 years before enrollment, exclusive",1 to 1.5 × uln,,,,,,
6388,,dermatographism,treatments antihypertensives,,liver resection.|american society of anesthesiologists class,hospice care|inability to communicate,,,,peri-menopausal symptoms,in last 14 days for,>18 years|lvef ≤40%|extensive coronary artery disease,,,,,,
6389,,acute bacterial infection,components of the shape medical system,,troponin levels,target cd4+ t cells,,,,non-inflammatory,within 6 months prior to study inclusion|major surgery,greater than 50 mm,,,,,,
6390,,left anterior hemiblock,cyp3a4 strong,,≤120,endovascular mechanical thrombectomy,,,,abuse)|other causes,within previous 6 months|severe heart failure,50 kg.|expected,,,,,,
6391,,nutritional monitoring,cerviron,,procedure;|american society of anesthesiologists physical status classification,axillary temperature ≥38ºc,,,,suitable for pvi,within 2 weeks prior to screening until admission to the unit.|performance of,<50%;|active,,,,,,
6392,,acutely suicidal behaviors,none planned,,structural hb variants,emergency surgery|non-french speaking,,,,1.0g/24hr)|drug uncontrollable hypertension,in the fellow eye than in the study,>4,,,,,,
6393,,permitted|for nsclc,natural drugs,,prostate cancer|chemotherapy,instrumented llif surgery,,,,thrombi,within past 180-days,> 60 mm hg,,,,,,
6394,,structural brain injury,study drug excipients.|prior randomisation,,serum glutamic oxaloacetic transaminase,foreign bodies in the coronary sinus.|known,,,,south africa|not mentally,over the last 6 months|patients,11.0 mg/dl);|patients,,,,,,
6395,,suicidal ideation/behavior,phosphodiesterase type 5 (pde5),,sagittal relation|overbite,echocardiogram,,,,standardized,within 1 month before consent,> 110 mmhg|patient,,,,,,
6396,,antihypertensive therapy.|anemia,drugs in its class|hypersensitivity,,tuberculin skin test,mantle cell lymphoma (mcl),,,,resectable;|have not received,during the study period.|persons,more 60,,,,,,
6397,,genetic predisposition,non-prescribed,,estimated 10-year,severity||,,,,eyes,more than 12 months before baseline,4-10 years,,,,,,
6398,,superficial mucosal cancers,anticoagulation,,postmenstrual age,complete hydatidiform mole/,,,,axis i psychiatric condition,for at least two months,upper limit of normal);|aspartate aminotransferase,,,,,,
6399,,mediastinal organ involvement,online application,,residual neurological deficits,single-level anterior cervical fusion,,,,non-alcoholic steatohepatitis,within the last 6 months|more than 1,8 or higher,,,,,,
6400,,pathologic jaundice,adrenalectomy;|patients,,new york heart association (nyha) functional classification score,suicidal,,,,heart|lack of properly acquired ep,"in the last 24 hours),|severe granulocytopenia",than 2 cm,,,,,,
6401,,detrusor,cancer)|connective tissue disease|neurologic disease,,alanine transaminase (alt)/aspartate transaminase (ast),appendicectomy,,,,non-hodgkin)|metastatic,prior to registration.||,greater than 2.33,,,,,,
6402,,optimal dosage.||,anti-deamidated gliadin protein,,modified medical research council dyspnea scale,diagnostic ct,,,,caries grade,in the 6 months prior to informed consent.|healthy,=< uln,,,,,,
6403,,visible lesion,nucleic acid/antigen test negative.||,,stroke|age,stent size used|target lesion,,,,over-compensation,at least weekly,larger than 20 mm,,,,,,
6404,,impaired cognition,protriptyline,,small (< 10mm,necrotic zones allows,,,,reversible,within 12 weeks prior,< 30 ml/min.|known,,,,,,
6405,,steinstrasse,dexketoprofen.|patients on treatment,,applicable).|body mass index,emergency surgery,,,,italian language|lack of informed consent||control group population inclusion,during periods of activity,more than 30%,,,,,,
6406,,judged by the investigator to be unsuitable to participate in this study,subendocardial late,,crisis prevention index (cpi)|the child,regional lymph node,,,,immunoglobulin m,before hospital admission.|in-extremis,score of >= 5% for the 10 year,,,,,,
6407,,volar angulation,tcs,,blessed orientation-memory-concentration,intraperitoneal treatment,,,,total parental,before the first treatment,>= 1.0 x 10^9/l,,,,,,
6408,,growth;|active infection,delegates,,anti-thrombin,laser treatment,,,,grade ii-iii new york heart association (nyha),in the 6 months following last trial vaccination.|positive,score higher than 5,,,,,,
6409,,h. pylori eradication therapy,dentin,,residual non-invasive disease,magnetic resonance imaging (mri,,,,abrupt closure,within the past 4 weeks prior to,≥ 38 ° c,,,,,,
6410,,lymphoma|follicular lymphoma,sodium fusidate,,hbas,gynecology-oncology|planned sling revision,,,,neovascular age-related,for at least 6 months prior to randomisation,≤ 3.0 × uln,,,,,,
6411,,pelvic pain syndrome,life|hospitalized,,oxygen saturation on room air,"local treatment|psychological, familial",,,,≤grade 2,before the first administration,50 x 109/l).|alanine,,,,,,
6412,,increased postcapillary pressure,pfspz vaccine,,chassaignac's tubercle,psychologically,,,,non-alcoholic liver disease,throughout the study treatment period.||patient,≤ 60 ml/min,,,,,,
6413,,pulmonary embolism；|patients,caffeine-rich,,hess score,sheffield teaching,,,,axillary level,for the first time|extubated after cardiac surgery,90-160 mmhg,,,,,,
6414,,events of severe hypoglycemia,component of the mdi.|any clinically relevant,,abnormal levels of estimated glomerular filtration rate (egfr),field.|local mismatch repair (mmr) immunohistochemistry (ihc) results available (both deficient mismatch repair (dmmr),,,,leptomeningeal,for the past one month.||exclusion criteria:||unstable angina,<140/90 for ≥1 month prior to randomization).||note,,,,,,
6415,,co-,l-polylactic acid,,gamma knife coagulpathy sepsis,radiological examination,,,,full night c-pap titration study,at least 12 months ago|stable baseline treatment,<18yrs|scheduled,,,,,,
6416,,end stage liver disease|chronic kidney disease,cyp)3a inhibitors,,canadian cardiovascular society class,hospitalization);|pregnancy;|previous intestinal surgery;|concomitant intestinal infection,,,,mid-face,before starting,score 0 or 1,,,,,,
6417,,arterial spot,vedolizumab,,crossover registration (arm 4,immunosupressive therapy,,,,non-metastatic)|received chemotherapy,the past 6 months,< 30 ml/min per 1.73m²;|liver failure,,,,,,
6418,,prolonged corrected qt (qtc) syndrome,intraocular tumors,,total serum bilirubin (tsb),traumatic wounds|patients,,,,peri-implant marginal bone loss,past 2 years.|hypermobility of,≥80g/l.|the,,,,,,
6419,,high-density lipoprotein,l-dopa,,fever,line of treatment being,,,,non-idiopathic pulmonary fibrosis (ipf) pulmonary fibrosis,during baseline,≥iv;|body weight,,,,,,
6420,,chronic wound,neratinib,,cd4+ t cell count,cardiopulmonary resuscitation,,,,ankle sprain history,within 14 days prior to study entry,greater than 1.0 sd above,,,,,,
6421,,bipolar affective,antithrombotic agents,,urine toxicology,intestinal biopsy|follow,,,,self-reported,for ≥5 years prior to enrollment;||well-treated,> 3|severe,,,,,,
6422,,glaucoma eye surgery,drug,,nasal septal deflections,standard test,,,,1|unresectable advanced,at least 3 months before mobilization,prior to or,,,,,,
6423,,age≥18 years.|chest pain,normal organ,,new york society of cardiac function,"immunological response,|uncontrolled asthma",,,,study;|all sexes,at least 4 weeks prior to study entry|unwilling to accept potential challenge,10-75% of stenosis,,,,,,
6424,,liver disease.|patients,diphenhydramine,,nyha function class,femoral artery diameter,,,,non-prescription drugs,within 2 years prior to the first admission to the clinical unit.|inability to understand or communicate reliably,between 18.0 and 39.0 kilograms per meter square,,,,,,
6425,,endocrine disease,radiological criteria.|full-field visual evoked potential,,pgf,tests;|alanine aminotransferase (alt),,,,phq-9 questionnaire,in the 4 weeks before or after each study vaccination.|received,<50mmhg)|electrocardiogram,,,,,,
6426,,uncontrollable hypertension,sirpα antibody,,spiral ct，for general ct,stintilimab injection formulation,,,,non-drug-related,in the past 2 years prior,<70)|unwilling,,,,,,
6427,,cerebrovascular ischemia/hemorrhage,materials contained,,left/right,mandibular implant in mature bone,,,,ensure effective contraception,at the time of enrollment|life expectancy,=< 7 days prior to randomization)||pediatric,,,,,,
6428,,seizures disorder,vaccination;|impaired immune function,,bone marrow function:||absolute neutrophil count,sex-steroid,,,,suitable for inclusion,within 90 days prior to or,15 years to 65 years,,,,,,
6429,,methotrexate||,theophylline,,iii|body mass index (bmi),oocyte donation cycles,,,,non-cooperation|severe,before the first administration.|those who need,60-80,,,,,,
6430,,gastrointestinal haemorrhagic,oral corticosteroid,,bone metastasis,pancreatic enzyme replacement therapy,,,,controlled with standard medical therapy,within 3 months of inclusion|risk of major amputation,18-65|overweight/obesity,,,,,,
6431,,preeclampsia,mirtazapine,,interferon|alanine transaminase,concussion,,,,inhalation,for at least 7 days before enrollment,50 to 100 bpm inclusive|willing,,,,,,
6432,,physical impairments,anti-vegf targeted therapy,,paclitaxel +,2-hour period what most people would,,,,lower dose,between -1 and +1.|respiratory stability,< 18 or ≥ 85 years.|cardiogenic shock,,,,,,
6433,,pulmonary function,tumescent anesthetic,,of age|ecog score,gastrointestinal surgery|active duodenal,,,,post-covid condition,within 6 months before the screening period,between 13 - 59 years,,,,,,
6434,,nephropathies,monoclonal immunoglobulin,,platelets<50×10,largest diameter,,,,routine,within 6 months of screening.|malignancy,< 30|candidate,,,,,,
6435,,calculated by the ckd-epi equation.|aspartate aminotransferase,full denture,,hbv dna test|hepatitis c virus (hcv),reflex cough stimulus)||exclusion criteria:||unable to participate,,,,hpv,"in the past 1 week,|unable to provide",± 2,,,,,,
6436,,chronic health evaluation ii score,over-the-counter androgenic hormone or androgen precursor,,zubrod performance status,altering pelvic organ function,,,,mm)|full-mouth plaque (fmps),during the dutasteride treatment period,18-29 kg/m 2,,,,,,
6437,,neurologic conditions||,clotting inhibitor,,drinks/day,iuzzini-seigel,,,,chronic ophthalmic,for the next 3 months,between 40% and 80%,,,,,,
6438,,injectable melanoma lesion,macitentan,,forced expiratory volume in 1 second (fev1)/fvc ≥0.7 measured pre-bronchodilator,complete occlusion,,,,anastomotic leak,within 28 days before the start of treatment,lucas i-ii).|cesarean,,,,,,
6439,,impaired coagulation,components of the study medications,,hepatitis c,investigators|off systemic therapy,,,,contracture|fracture,during or after prior therapy,"1,7 mmol/l|reduced",,,,,,
6440,,nasal cavity diseases (rhinitis,research||,,european position paper on rhinosinusitis,revision of the acetabular,,,,irinotecan injection,within 5 years prior to the screening visit,55-85,,,,,,
6441,,distinct,ds252,,gscombo,psychotherapy treatment,,,,corporis,at the first clinic visit|willing to,> 18 years old,,,,,,
6442,,nervous system diseases;|(3,pivc,,60%<fev1,vital blood vessels,,,,meeting measurable disease criteria,within 30 days prior to screening|any of the following,ii-ii|elective,,,,,,
6443,,cerebrovascular disease)|no,oral steroids|are,,aspirin + p2y12 inhibitor)|history of,pleural procedures,,,,les-related,prior to crossing the lesion.|thrombolysis of the target vessel,more than 40 years||,,,,,,
6444,,solid tumor(s),phentermine-topiramate [qsymia,,ckd-epi,herniorrhaphy,,,,below the cut-off levels,within 48 hours prior to screening.|smoking,140 - age))/ 72 x serum creatinine,,,,,,
6445,,palpable taut band,oseltamivir,,doc,120 days before initiation of study treatment,,,,non-target lesions,prior to the start,equal to or greater than 5,,,,,,
6446,,non melanoma skin cancer,either||1,,sh)-polypeptide-85,treatment strategies).||,,,,hepatitis,at the completion of the 4,greater than 8 f sheath,,,,,,
6447,,extra-ocular involvement,bursae,,pain clinic physician,anorectal advancement flap,,,,researcher thinks it,within 2 years before screening|use,35 years,,,,,,
6448,,vaping daily,mbb,,hcv rna positive|administration of a live,preventive treatment,,,,stable off,after first-line chemoimmunotherapy,≥18 years to ≤60 years,,,,,,
6449,,unequivocal evidence of disease,potassium binder agent,,expiratory thoracic computed tomography (ct) scan,vaginal surgery,,,,paramagnetic,for at least 7 days after the last dose of lenvatinib:||be abstinent,<16 years,,,,,,
6450,,involuntary back muscle,gallstone,,all,undergo surgery,,,,antigen-based rapid test,within three months before therapy,> 145 mmhg,,,,,,
6451,,mpal,recombinant erythropoietin,,screening.|body temperature,tonsillectomy,,,,speaking;|able to sign a written informed consent,at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.||main,females|pain more than 1 month.|piriformis syndrome,,,,,,
6452,,cardio-vascular,chloroquine,,supine hr,living donor,,,,interscapular,within 180 days prior to vaccination.|received blood products,score of 0 to 1|has,,,,,,
6453,,gv|hepatic encephalopathy,panic attacks,,indocyanine green angiography (icga),laryngopharyngoscopy,,,,stage d heart,at least once every 3 weeks.|primary,"1,500/μl)|platelets",,,,,,
6454,,anatomic issues,immunosuppressive medications|prisoners,,suicide severity rating scale;|certain,cycloplegic autorefraction,,,,occlusal contact.||,during screening period and before drenching,between 20 to 65 years,,,,,,
6455,,cap,fsrs,,m. massiliense|needing,treated for hiv,,,,nasotracheal,within the last 60 days listed in electronic health record (ehr,>=140 mmhg,,,,,,
6456,,esophageal dysmotility,vtama,,hepatitis b surface antibody (hbsab) testing,pre-hospital care from the emergency medical services 83 (,,,,sedentary,at the time of enrollment/first study vaccination - temporary exclusion,14 to 18 years;|have,,,,,,
6457,,diabetes retinopathy,tnfα inhibitor,,anti-hepatitis c virus (hcv),high suspicion)||myasthenia,,,,meeting the inclusion,within the past three months,≥10.0×10 4/mm3|hemoglobin concentration,,,,,,
6458,,distant metastasis;|those,afrikaans,,pearls score,tms|vagus nerve stimulator implant,,,,low-risk pregnant,within 1 month before onset|not willing,below the lower limit of normal|coagulation disorders|according to the,,,,,,
6459,,sickle cell disease,immunoglobulin ≤6 months before receipt of study vaccine,,hepatitis b surface,bone scans,,,,anaesthesia,within 4 weeks prior to the first administration of the study drug.|have previously received,< 4,,,,,,
6460,,neurologically stable,erythropoietin,,has-bled score≥,ill|renal replacement therapy,,,,might interfere with trial conduct,during the 52 weeks prior to enrolment date|use of additional,≥ 40.0；multiple chronic,,,,,,
6461,,contra-indication).||heterozygous familial hypercholesterolemia,normal gastroscope|endoscopic dilation,,cage assessment score,power seating,,,,in phase ib study,within 30 days before enrollment,< 70% of the predicted value,,,,,,
6462,,morton s neuroma,immunosuppressive medication|receipt of immunoglobulin,,total bilirubin ≤2×uln,2 stimulation tests,,,,unknown origin.||,within 3 months|a,>= 50 ml/min/1.73 m^2,,,,,,
6463,,acute hypersensitivity reactions,over-the-counter medications)|receives primary care,,bedq score,technical advisory group on,,,,maternal,within 9 months before entry,≤5.5 mmol/,,,,,,
6464,,anaplastic lymphoma kinase (alk) mutations,drugs that could,,endoscopy showed esophageal,medical care|patients,,,,same artery).|the,within 6 months prior to screening.|proliferative retinopathy,90g/l).|creatinine clearance,,,,,,
6465,,local anesthetics.|local infection,single-agent pembroilizumab,,recist version 1.1;|eastern cooperative oncology group (ecog) performance status,throat irritation,,,,non-spanish,prevent physical exercise.|contraindications to physical exercise detected,"0, 1 or 2|neurological status",,,,,,
6466,,vascular inflammatory lesions,antihistamine,,mini mental test,functional food,,,,tested before treatment started using more than two kinds of,within 7 days of study,>= 1000/mm^3|eligibility criteria,,,,,,
6467,,intravesical bcg,cyp3a-inhibitors,,cesarean section,stem cell study.|pregnancy,,,,insidious,within two weeks|patients,+ physical barrier method,,,,,,
6468,,poor healing wound,study drug ingredients.|pregnancy,,cbct-scan,drug treatment of hypertriglyceridemia;|hypertension,,,,clinically evident,radiolucent,≤ 2|patients,,,,,,
6469,,prwhe,anti-tumor bioactive traditional,,serum total bilirubin level,hematopoietic stem cell hscs transplant,,,,investigator.|in acute attack.|abnormal,within the past 2-months.|active phone number,ranges from 15-22 years.|severe,,,,,,
6470,,large amount,anti-itch products,,hpb,formation of collateral vessels,,,,between the research,at time of informed,7 to 9 points,,,,,,
6471,,metastatic lung cancer,mao,,ankle sprain,adrenocorticotropic hormones,,,,under investigation.|history of any prior,within 14 days prior to start of study,≥ 18 to ≤ 85 years,,,,,,
6472,,mild intermittent,selective estrogen receptor down regulator,,msi-h patients.|the,cancer|persons,,,,diagnostic and statistical manual of mental disorders (,more than 72 hours,2 - 18 years,,,,,,
6473,,rheumatological disease,sglt-2 inhibitors,,sm1,schistocytes visible,,,,core-needle biopsies,after the last dose of the first-line therapy,> 2.5 times the upper limit of normal (uln),,,,,,
6474,,primary event,ofatumumab,,screening:||systolic blood pressure,chlorhexidine|antibiotic prophylaxis,,,,active b,within 10 days of screening|two or more,> 1.5 mg/dl,,,,,,
6475,,term pregnancy,prednisone,,children's oncology group risk classification,ablation treatment,,,,tumor per local,within 72 h prior to initiation of study treatment,=< 3.0|aspartate aminotransferase,,,,,,
6476,,systematic diseases|disorders compromise wound healing|bisphosphonate medications|patients,systemic hormonal therapy,,modified moca,gem,,,,lvef<50%),within the past 2 years)|currently,= 8 g,,,,,,
6477,,psychotic disorder.|use,immune-modulating,,stop-bang score,local surgical treatment；|the classification,,,,psychiatric disorder.|no,medical conditions||known history,between 3 and 12 years,,,,,,
6478,,aorto-iliac,depot injection,,braf v600e mutation|progressed after,small interfering rna,,,,under 65|severe cognitive impairment,within 5 times the half-life,≥10 years|20-80,,,,,,
6479,,local health authority.|the use,antiallergy drugs,,hep c ab,"cesarean delivery,|in cesarean delivery",,,,interfere with cooperation with the requirements of the trial|has not recovered from adverse events,in the 2 months before enrollment,8-16 years,,,,,,
6480,,sensitive skin,components of the medicinal product|previous fracture,,psychotropic treatments|right,intravesical therapy,,,,castration-resistant prostate cancer;|participants,within 72 hours of informed consent|able,<60 ml/min,,,,,,
6481,,third molars).||good oral,anti-diarrheals,,miscarriages|women,positron emission tomography/computed tomography (pet/ct,,,,male sex,during the study period;|those,≥s2);|alt continues to be normal,,,,,,
6482,,rotator cuff rupture,mca,,alanine aminotransferase [alt],ataxia,,,,pd-l1 treatment,during visit 1|cannot weigh,class iv)|acute infection,,,,,,
6483,,small varices,anti-complement,,dsm iv criteria,ld chemotherapy,,,,above the clinically significant range,more than 4 taels of liquor,<1500/mm3,,,,,,
6484,,drug abuse|pregnancy,migraine:||erenumab,,ck,experimental sessions,,,,daily headache,previous night),>=6||,,,,,,
6485,,"communicational,|mental disability",dimethylacetamide,,below:||absolute neutrophil count,thermoregulation mechanisms,,,,dsm-v substance,for the affected patellar tendon,0-1|≥6 months of follow-up,,,,,,
6486,,human epidermal growth factor receptor 2 (her2).|unresectable locally advanced,third generation of egfr-tki targeted therapy,,mayzent|cladribine,adrenal replacement steroids,,,,full assistance with activities of daily living|subjects who read,3 days before randomization,greater than 25 and,,,,,,
6487,,"discoid resection,|patient",cytarabine,,university hospital center,alk fusion,,,,been stabilized,within 5 days prior to day 1 of protocol therapy|current,between 8 - 15 seconds||,,,,,,
6488,,respiratory disease|dysrhythmic heart disease|beta,donepezil,,dcmp,surgical treatment.|hematologic cachexia,,,,1,at the time of diagnosis|multiple pancreatic nodules|diagnosis,18 - 75 years|woman,,,,,,
6489,,"communication problem,|gmfcs level",surgery related,,hcv antibodies,wanting,,,,http://ww.cdc.gov)|co-existing,within 30 days prior to the first ip administration.|exposure to prescribed,≥660 pg/ml,,,,,,
6490,,criterion a.|able,inoculate,,rapid urine pregnancy test,ureterovesical re-implantation||patients,,,,without cpsp:||patients,during the last treatment period,5 or greater,,,,,,
6491,,chronic medical diseases,component of the test vaccine,,months)|body mass index (bmi),menstrual cycle period,,,,respirator,within the 24 hours prior to v1;|damaged skin,>28,,,,,,
6492,,psychotic disorder nos,hsct,,recist 1.1|ecog performance status,substance abuse|known increased,,,,lactulose,during the study period|patients,grade 2 or higher diarrhea).|the patient,,,,,,
6493,,chemotherapy|eastern,contraceptive product,,thunder v4 (tv4),robotic hysterectomy,,,,minimally conscious state plus|feeding through,within 2 weeks prior to the first day of screening;|intake of more than 10 units alcohol per week,>2500g,,,,,,
6494,,passive/indifferent social,neoplasm,,medication history|negative urine drug screening test,intra-arterial palliative treatment (,,,,non hodgkin,within 8 weeks following the last dose of rozanolixizumab|study participant,≤ 35,,,,,,
6495,,cytomegalovirus,non-stimulant medications,,uridine 5'-diphospho,physiotherapy||one-sided knee osteoarthritis,,,,index date.|t2d diagnosis,at the time of signing informed consent.|bmi,0-29,,,,,,
6496,,gastrointestinal disorders,counting fingers,,liver function alt,general anaesthesia,,,,tumor tissue,within 4 weeks;|any investigational,≥ 3 months;|participants,,,,,,
6497,,appendicular skeletal,immune globulin,,oral cavity||,special dietary requirements,,,,age|scheduled,for 3 months before randomization,≤ 2.5 x uln.||cardiac function,,,,,,
6498,,osteolytic + osteoblastic,"tyrosine kinase inhibitors,",,detectable hepatitis b virus [hbv] deoxyribonucleic acid dna,ralrp surgery,,,,between 2010,at least 4 weeks prior to treatment,1)neutrophils≥1.5*109/l,,,,,,
6499,,chronic pulmonary disorders,study ingredients|individuals,,antithrombin,hiv transmission until,,,,breastfeeding||concerns related to glucose metabolism,within 2 years prior to screening;|there,>120 ml/min/1.73 m2,,,,,,
6500,,right heart catheterization mean pulmonary arterial pressure,study products,,sirs,urine β-hcg pregnancy test,,,,intra-uterine device [iud],at any time consistent with mds,>=20,,,,,,
6501,,local skin disease,antibiotic therapy;||for,,part,gastric variceal bleed|bleeding related to coagulopathy|other causes of portal hypertensive,,,,influence indices of,during the study.|occurrence of arterial/,=< 1.25 x uln,,,,,,
6502,,general internal medicine,nail products,,modified before the inclusion visit,ctx112 infusion.||key,,,,pure collecting duct histologic,within 2 weeks of starting study,>11.1 mmol/l,,,,,,
6503,,fainting vagal reactions,fil,,american society of anesthesiologists (asa) classification,assessment.|macroscopic intravascular invasion into the hepatic,,,,cervical lymphatic rainage area,within 4 weeks of the first administration of imp,18-89 years,,,,,,
6504,,care providers,components of the study vaccine,,bone marrow primitive cells recovered,mr,,,,eye ointments,within 7 days of starting of treatment,0-2|absolute neutrophil count (,,,,,,
6505,,high-density mapping catheter,radiographic contrast,,as:||systolic blood pressure,testing by foundation medicine inc (fmi),,,,pd-l1 expression test||,at least 7 kg,≥ 18 and < 80 years,,,,,,
6506,,sinus symptoms,liver medicine|subjects,,hepatitis c infection.||hepatitis b infection,rhythm management device,,,,microsatellite stable,within 1 month before enrollment;|subjects with poor compliance,0-2||minimal acceptable safety laboratory values,,,,,,
6507,,neurodevelopmental disorder,bcaa,,premorbid modified rankin scale,standard of care imaging done,,,,active phase of the first stage of labor||,for 12 months or more,frequently than 1x/month,,,,,,
6508,,min/1.73 m2|active malignancy,targeting agents,,ttf,month|primary hyperparathyroidism|revascularization,,,,parasymphseal,prior to icu admission;|pregnancy,> 20 mmhg.|dilatation of the aorta,,,,,,
6509,,stroke)|previous malignancy,percreta,,recist v1.1.|have,receive treatment,,,,suitable for eavetube(et),prior to receiving the first study drug dose and continues to have,> 120 ms)|uncontrolled hypertension,,,,,,
6510,,contrast allergies,non-steroidal anti-inflammatories).|chronic use,,national cheng kung university hospital,complete primary vaccination schedule,,,,non-cns,at least four times a month but less than 15 times a month,"75,000 per mm3);|serum",,,,,,
6511,,complement deficiency|history of currently active primary,give full informed consent|females of reproductive potential,,south korean copd patients(bronchodilator test results fev1/fvc,study restrictions.|participation,,,,consecutively treated,less than 8 weeks prior to dosing|known medical or,≤ 75 years,,,,,,
6512,,acute sinusitis,immunoglobulin therapy,,partial pressure of oxygen in,ablation therapy,,,,connective tissue disease-related,between 6 weeks,> 1.43 milligram/deciliter,,,,,,
6513,,anal margin cancer,clopidogrel;|previous kidney,,ctcae v5.0 grade,o2 saturation,,,,emergency,at the time of registration,≥ 70|ability to read,,,,,,
6514,,genetic disorder,morphine|chronic,,age;|eastern cooperative oncology group performance status,lung transplantation|patients,,,,pd-l1 therapy,within 8 weeks prior to the screening,from 0 to 0.5,,,,,,
6515,,orthopedic condition,sympathicomimetic medication,,screening.|platelet count below lln at screening.|white blood count,sensor|peripheral vascular disease|atrial fibrillation|sensitivity,,,,nutrient,6 months 0 days - 35 months 30 days);|the availability of written,≥ 30 iu/l,,,,,,
6516,,sah)|infratentorial hemorrhage,sc ntz,,recist version 1.1.|eastern cooperative oncology group (ecog) performance status,national health survey,,,,fasted,before induction,≤ 5.0 ×,,,,,,
6517,,iron deficiency,loxapine,,see appendix b1/2,donated one unit,,,,nihss)|decreased level of consciousness,within the previous two weeks,less than 18 years,,,,,,
6518,,complicated diverticulosis,chemotherapy agents,,international metastatic rcc database consortium (,resting ecg,,,,protocol.|acute infectious disease,within 12 months after the screening visit;|participation,negative).|solid organ,,,,,,
6519,,hemorrhagic diathesis|chronic kidney disease,inhaler steroids,,raw score,figo（international federation of gynecology,,,,irrespective of clinical parameters,at the time of inclusion|patients have used,above 180 mmhg,,,,,,
6520,,ovulatory dysfunctions,mennin,,drinks per day,control solution,,,,post covid-19 functional status scale,within 72 hours of receiving the first dose of the study medication,>88 cm,,,,,,
6521,,liver function tests,components of am-928|has unstable/,,ptt (aptt),standard of care anti-pd(l)1-based treatment regimen,,,,syndrome|post-thoracotomy,at the time of management,< 2 cm,,,,,,
6522,,eating.|（8）acute disease,cylinder,,armpit temperature,blood transfusion/epo,,,,legionella pneumophila pneumonia,at least one of the ada definitions,> 140 mm hg systolic,,,,,,
6523,,congenital defect.|patient,oral medicine,,relapses;|bone marrow relapsed,biological mechanism,,,,american college of cardiology/american heart association guidelines||exclusion criteria||refusal of consent|chronic kidney disease,hepatitis.|previous history of,> 10.0 g/dl.)|international,,,,,,
6524,,non-ad dementia,anti-platelet therapy,,calculated through the ckd-epi formula,local law.||,,,,fellow eye,within 30 days of enrollment||planned,≥125 mmhg|had,,,,,,
6525,,smoking,antibody products,,recist v1.1 criteria|oesophageal endoscopy,organ transplant,,,,tingle,at the time of giving informed,> 2000 iu/ml,,,,,,
6526,,chronic heavy smokers,rolle,,"national institutes of health [nih, 2020]",laser prostatectomy,,,,gun).|history,"within one month,|possess understanding and communicate ability；no severe","≥17, or|depersonalization score of ≥7",,,,,,
6527,,height|poor oral hygiene,orthopedic implants,,gestation cervix length,periodontal treatment|pregnancy|minors|antibiotic therapy,,,,mild to moderate asthma,within the 12- months prior to procedure,<18 years or >80 years|people,,,,,,
6528,,inability to receive,study drug formulation|active grade,,hemoglobin ≥9.0 g/dl,practice of physical activity,,,,upper abdomen ct score,at time of screening.|the participant,under 18 years|foreign body ingestion||,,,,,,
6529,,binge drinking,growth us|patients,,urine microalbumin-creatinine ratio,protein restoration therapy,,,,protein powder,pre-dose,< 3.0 g/dl|international normalised ratio,,,,,,
6530,,breastfeeding;|serious diseases,nasal high-flow oxygen therapy,,assessment system- icdas ii)|children whose caregivers have means of communication (mobile phones).|completion of an informed consent to participate in the study.||,retained metallic,,,,ad involvement.|worst pruritus,within the last 2 months|recent,< 10% body surface area 2,,,,,,
6531,,prolonged qt syndrome;|patients,anti-cholinergic medication,,pulse,general anesthesia;||,,,,obstructed,within the past fourteen,"18-75,|to",,,,,,
6532,,intracranial malignant tumors|no,anti-vegfr monoclonal antibody,,suitable body habitus,≥1 triggering hospitalisation,,,,different,in last 4,over 450 milliseconds,,,,,,
6533,,blood clotting disorders,toothpastes,,rich in polyphenols.|pregnancy,pulp tests)|no,,,,morbidity,planned to receive,< 40|patient,,,,,,
6534,,elimination disorders,iodinated contrast agent;|end-stage renal disease,,hiv rapid multispot antibody differentiation assay.|participants,open aaa repair with,,,,protruded,in the past 6 months|hospitalization,18 years old and older,,,,,,
6535,,ring x mosaicism,fmri,,predicted forced expiratory volume in 1 second (fev1),first-line ssa,,,,medical disorder|current severe,within 28 days before viral treatment,> or = 18,,,,,,
6536,,major small bowel surgery);|woman,sabr,,ventricular ejection fractions)≤ 50%.|history of ischemic stroke,cem,,,,radiological intervention.|note,at the time of diagnostic laparoscopy,"between 55-85 years,|did",,,,,,
6537,,chronic sleep problems,topical medications|history of,,fdg-pet/ct,first-line treatment,,,,non-cardiopulmonary disorder,within the ensuing 1 month,≥ ≥90g/,,,,,,
6538,,glucose monitoring sensor wear,drains,,thorax configuration,gradual progression,,,,on room air,during the study period|use of antioxidant,30-75 years;|lung ct images,,,,,,
6539,,bleeding ad lesions,chondroitin,,sars-cov-2;|pregnancy,facet fixation,,,,lymphatic drainage,in the recent past 24 h,< 30 ml/min).|having,,,,,,
6540,,eosinophilic oesophagitis|uncontrolled,mph products,,suicide ideation,analgesic sedation,,,,neoplasms);|uncontrolled,at least 1 year before screening.|investigator,18-42mm.|≥15mm,,,,,,
6541,,pose a risk to venipuncture,pelvic metastasis,,liver function test results,laparoscopic entry,,,,corneal ectasia,within 30 days prior to informed consent,>50% stenosis,,,,,,
6542,,hiv care scheduled,arthrosis,,hematology retest analyzed,resection|patient,,,,injection site|patients,within 3 months on the puncture side;|patients,≥ 1.5 × 109,,,,,,
6543,,cohort,chemotherapeutic drugs,,resting ankle-brachial index (abi),necessary therapy,,,,severity to polysorbate).|has,within four weeks of study,>20,,,,,,
6544,,measurable lesion,vaccine,,lactation period,device therapy,,,,anatomical structure,within the last 12 weeks|has experienced,lower than 17.5,,,,,,
6545,,public housing residences,flucytosine,,reduced level of consciousness,talk,,,,insulin pump therapy,within 2 days prior to any endoscopic,>= 18 years old.|hepatocarcinoma diagnosis,,,,,,
6546,,external biliary shunt,african american,,old;|ecog score,inactivated covid-19 vaccination;|systolic blood pressure,,,,influence inclusion.|history of,within 72 hours prior to study registration,">= 1,500/mcl|leukocytes",,,,,,
6547,,inflammatory disorder,mrecist,,mean grip strength,finger prick screening,,,,st-t interval,prior to randomization;|has severe,15-item geriatric depression scale,,,,,,
6548,,acute myocardial infarction.|those,anti-psychotics,,serum total cholesterol,chimeric antigen receptor-modified t-cell (,,,,in the potential participant,throughout youth study participation).||,> 200 μg/dl,,,,,,
6549,,glaucoma,esophagogastroduodenoscopy,,regular exposure,germline variant,,,,immunosuppression|perioperative desensitization|pregnant,during the exercise test (development of,> 20g/d,,,,,,
6550,,infiltrating lesion,xanthine-containing products,,inducer,anaphylactoid life-threatening,,,,hair,in the baseline assessment including past medical history,between 45- 55 years.|male,,,,,,
6551,,ankle fracture|ankle injury,doxorubicin≥360,,neuropsychiatric inventory (npi),oral food challenge,,,,american joint committee on cancer (ajcc),during the last 24 hours,from 30 to 70 years,,,,,,
6552,,schistocytes|acute kidney injury,human serum albumin|positive screening testing,,systolic bp,urine testing,,,,operating room nurse||,less than 48 hours,1 or 2;|children,,,,,,
6553,,renal failure|refusing the procedure|patients,1|blood counts,,glycated hemoglobin,posturography,,,,locally advanced,at time of study entry|willing,older than 1 year,,,,,,
6554,,morbidly obese,nerve tissue,,vrc h1ssf_3928 mrna-lnp,fetoscopic neural tube defect repair,,,,dysmorphic markers,in the last three months;|severe hepatic impairment,13-30 years|symptomatic,,,,,,
6555,,target organ damage,conventional silicone,,posterior circulation|3mm-25mm in dome diameter|narrow,chimeric antigen receptor (car) t-cell therapy.|participants,,,,subclinical,in the last 6 months;|presence,> 2 units/day,,,,,,
6556,,cushing's,tiragolumab,,numeric rating score,steroid,,,,psychotic,within 30 days of the,more than 2.5 cm,,,,,,
6557,,other comorbidities,components of the vaccine,,os rate,mr contrast material,,,,under poor control,within 14 days prior to day 1 of protocol,>11 mg/dl,,,,,,
6558,,lenalidomide refractory,food supplements,,antigen test,level tlif,,,,operation room,past 12 months).|we will also exclude individuals,18 and 55,,,,,,
6559,,wilms tumor,immune hemolysis,,absolute leukocyte count,products.|participation,,,,suitable for the group,within 6 months.|received,above 37.3℃,,,,,,
6560,,macro hemorrhage,components in the faricimab injection|any known hypersensitivity to any contrast media,,hepatitis c virus antibody (hcvab),sugammadex treatment arm,,,,submesenteric artery root region (area 253);|patients,unresponsive to medical management.|previous orbital irradiation,< 1.5 x uln,,,,,,
6561,,recurrence on or after their most recent therapy.||6,depot corticosteroids,,foods|systolic blood pressure (bp),vasopressor support|patients,,,,under guardianship.|patients benefiting from the social security (french health care system).||inclusion criteria for parents :,more than,1 or 2-||,,,,,,
6562,,viral respiratory illnesses,sodium borate decahydrate,,screening||-,≥6 months|moderate-to-vigorous physical activity,,,,haemodynamically significant,within six months;|have,7-9%,,,,,,
6563,,aortic tortuosity,experimental agents,,ast/ alt,complete medication,,,,scoring,in the past 12-months,≤ 0.5,,,,,,
6564,,protocol.|active autoimmune disease,visit|biologics,,ham-d,falls,,,,angina.|possible,at least 1 day/ week,i-iii||,,,,,,
6565,,lcx,gls,,bone marrow biopsy]|hemolytic anemia,mechanical testing,,,,topical eye drops,within 7 days before,> 40 years|inactivity,,,,,,
6566,,tumor expression,therapeutic agents,,mega green tea capsules life extension,major surgery includes,,,,corneal transplant,"at the time of intervention,|parent/adult",<90 or >180 mmhg,,,,,,
6567,,involuntary movements|no spontaneous breathing|status epilepticus|need emergency neurosurgical treatment,infectious agent,,cytomegalovirus(cmv,assessment of dll3 expression,,,,eligibility||eligible to receive cq,at the time of the trial|existing or,> 40|currently,,,,,,
6568,,egg allergies)|active infection,inoculation,,ghent university hospital who developed,access to the femoral vein,,,,grade ≥2 toxicity,"at baseline, reexamination may be performed",greater than 800/,,,,,,
6569,,growth restriction,ea,,oral food challenge.|the,chemotherapy treatment,,,,between 21:00,within 24 hours of any study visit,≥ 60.|participants,,,,,,
6570,,kidney impairment,psychiatry medications,,weight reducing,open-trial selective reminding task,,,,months|have been,for at least 5 half-lives,≤ 2.5 x,,,,,,
6571,,distinct measurable,anti-nausea medication,,prothrombin international normalized ratio (inr),acute infection|suffering from fatigue,,,,moca))|allergy to capsaicin,at the online therapy unit between nov 4 2013,>= 37.5 degree celsius,,,,,,
6572,,iss7 score,polyp,,insomnia severity index,reisberg,,,,non-enhanced,within four weeks prior to randomisation.|major surgical procedure,90 adult,,,,,,
6573,,multiple sclerosis|must,silymarin,,blood activity,fusion,,,,non-heling wounds|wagner,within 2 papillary diameter,≥ 37 weeks,,,,,,
6574,,language problems,covid-19 vaccine,,antigen rapid test,biological features,,,,non-surgical lung volume,for more than 12 weeks,≥ 18 and ≤ 45 years,,,,,,
6575,,dehiscent wounds,ustekinumab,,hcv rna testing,intrauterine hormone release system,,,,intra-cranial clips,within less than 2 years||cardiovascular disease,≥ 3)|severe,,,,,,
6576,,pregnancy|breast feeding|known,tnfα,,new-onset diarrhea,monogamous relationship,,,,first remission<12 months,within 5 years prior to screening except,>2nmol/l,,,,,,
6577,,upper extremity,cabazitaxel,,wide local excision,compromised incisor aesthetics,,,,suitable for study participation|8,last year prior to enrollment,≥15 mm,,,,,,
6578,,severe infection,pembrolizumab combination,,hepatitis c.|known history,induction of labor whatever,,,,corneal astigmatism,at the time of icf,at least 30% of the daily,,,,,,
6579,,hepatic dysfunction,dostarlimab components,,recist v1.1.|adequate organ function,cardiac echocardiography showed,,,,"groups ii, iii or v",last year;|low cognitive level,>14 units per week,,,,,,
6580,,controlled hypophysitis,contrast media|suspected aortic dissection|parenchymal organ surgery,,ivig)|platelet count,autologous stem-cell transplantation,,,,adequately treated,within 1 year prior to the screening visit.|received any investigational compound,≤ 2 times the upper limit of normal,,,,,,
6581,,psp,anticholinergic drugs,,liver metastasis)；|ecog ps,frequency ventilation,,,,grade ≥3) infection,within the 4 weeks preceding,equal to 0.85 x,,,,,,
6582,,autism spectrum disorder|enrolled,aci,,intraocular pressure (iop),reading of suboptimal glycaemic control (,,,,lasting more than 30 minutes,for 3 months after the last dose of peposertib,< 100000/mm3,,,,,,
6583,,pregnancy test;|allergy,allow storage,,organ function,intravenous (iv) anti-infectives,,,,recieved,between screening,ⅰ-ⅳ;|modified frailty index,,,,,,
6584,,oral cavity cancer,rilpivirine,,cooperative oncology group performance status score,inflammatory condition;|prior cancer-specific pretreatment,,,,avm,within 2 weeks before the first use of the study drug|patients,>400 mg/dl,,,,,,
6585,,bcma-directed treatment,confine surgery,,stool production,valve repair/replacement procedures,,,,dependence|clinically significant,over the six-month study period,at least 30 days after last dose of study drug||absence,,,,,,
6586,,congenital anomalies of the kidneys and urinary tracts (cakut),natalizumab,,prostate adenocarcinoma.|prior,ichd-3)|migraine onset before age,,,,intra-aortic balloon pump|aortic,within 5 years of screening,> 30 kg/m2|hepatic insufficiency,,,,,,
6587,,non-resectable,injectable hyaluronic acid,,american society,single-drug,,,,pre-hospital stroke,more than 5 years ago,above 3 times the uln,,,,,,
6588,,left ventricular failure,coumarin anticoagulant,,resting ventricular rate,human application tests,,,,distal vessel diameter >1.5mm;|only one,within the last 7 days,> 450,,,,,,
6589,,self-care ability,acid suppressor,,pain management center|patients followed in a,thoracic aortic surgery|elective valve surgery|combined,,,,arthus reaction);|6-23 months,diabetes|history,between 37 0/7 weeks to 41 6/7,,,,,,
6590,,type 1 diabetes|participants,boron,,total serum bilirubin,tobacco use disorder|under court,,,,vitreous,within 2 years of baseline,>470,,,,,,
6591,,insoles,antiplatelet drugs,,fasting serum cholesterol,adrenal insufficiency|history of abnormal,,,,well-controlled,within 14 days prior to first dose of study drug,c or higher,,,,,,
6592,,peritoneal lesion,anti-convulsants,,angle's class,emergency vaccination,,,,highly effective birth control,within 2 years of treatment initiation,between 18 and 80 years old|for study arm - patients,,,,,,
6593,,pcr,profotenofovir [taf,,months|report hiv status,chest computed tomography (ct) scan,,,,moderate-severe,throughout the study progress until last visit,<30 ml/min/1.73m²|subject,,,,,,
6594,,neovascular glaucoma,mpas,,platelet count;|complete liver test,throat surgeries|vocal cord problems,,,,non-female,during the study;|known history of,≥ 40 years;|bmi,,,,,,
6595,,gynecological disease,"lioresal),||o these medications",,uk retirement,gastric neuroendocrine tumours in china from,,,,excipients|lympho-depleting,within the last 12 months,>1.5×uln,,,,,,
6596,,acute coronary heart failure,systemic beta agonist).||,,bucks,before surgery,,,,single vessel disease|patients,within last month,≤ upper limit of normal [uln,,,,,,
6597,,neurologic disorder.|has,cocoaine,,nci-ctcae v5.0,gc,,,,premalignant,in the past month|history of,18-80 years;|diagnosis,,,,,,
6598,,vertebral tumor,oesophageal catheter,,renal function creatinine clearance rate (ccr),samsung medical,,,,precarious,after 12 weeks,between 40-70 years|well-oriented,,,,,,
6599,,chemotherapies.|treatment,seasonal influenza vaccine,,calculated by cockcroft-gault formula,adnexal surgery,,,,interferes with successful administration of,at the time of the inclusion visit,≥125 pg/ml when,,,,,,
6600,,suprachoroidal hemorrhage,glucagon-like peptide,,muac,systemic chemotherapy treatment.||additional inclusion criteria,,,,events.|important,within a 7-day period prior to enrollment,> 140 metres|patient-specific,,,,,,
6601,,lymphocyte,aspirin,,prostate imaging-reporting,patients|abnormal neurovascular examination,,,,non-hospital lung function,within 3 months|active,1-2).|participated,,,,,,
6602,,hbeab positivity,inactive excipients,,recist 1.1;lymphomas,consultation focusing,,,,low grade histology)|surgical protocol,in the 2 months prior to beginning,between 50-65 years|bilateral symptoms|able,,,,,,
6603,,"namely,|restlessness|insensitivity",characterized,,depth of local effusion,radiographic contrast agents.|bladder outflow obstruction,,,,gespecialiseerde ggz | geestelijke gezondheidszorg (ggz),within 24 hours of symptoms,=< 1.5 × institutional upper limit of normal,,,,,,
6604,,granuloma,oral steroid,,lost of >10% of their weight over a period of the last 6 months,postural,,,,few adverse consequences(20).|high,for at least four months following the last dose of study treatment.|subjects,0-4 mm,,,,,,
6605,,hopeless prognosis,gepants,,creatinine cl,visit 2 baseline||exclusion criteria,,,,non-diabetic type,within 2 weeks prior to bridging therapy,> class 2,,,,,,
6606,,valium.|diagnosis of hiv,vaping products,,detectable hepatitis b dna,hospitalization).|previous immunization,,,,resected,at the time of screening.|positive testing for hiv,under 16 years,,,,,,
6607,,cutaneous leishmaniasis,conventional breast mri,,ics use|diagnosis of copd,thoracic surgery|mechanically ventilated,,,,enrollment.|liver,within the past three,more than 2.5mm,,,,,,
6608,,antibacterial mouthwash,≥20%).||baseline,,sars-cov-2).|participant,pcr testing,,,,site of administration,in the past week|having turkish,≥ 18 years.||adequate,,,,,,
6609,,hematological malignancy,exenatide,,uln)|total serum bilirubin,treatment methods,,,,parotid,within 72 hours of starting therapy,≤40 kg/m2|willing,,,,,,
6610,,pmmr,fontan,,hcv viral,antigen test collected,,,,dual-tumour location.|known ras mutation|peritonitis,within 2 weeks prior to the screening visit:||cosmetic,over 22 years,,,,,,
6611,,serious hemorrhage,adjunctive therapies,,baseline.|inr,hypertensive emergency,,,,could take pseudo ephedrine.||,at least 3 months.|participant,equal to or shorter than 1.5 times of uln,,,,,,
6612,,inflammatory bowel.|previous,components of the formulation used,,rankin scale score,lung lobectomy,,,,post-covid syndrome|3,for the next 60 days,between 45-150 kg,,,,,,
6613,,old.||2.diagnosis,lai antipsychotic,,inclusive).|body mass index (bmi),regular alcohol consumption,,,,low level of physical activity (craig et al,suspicious malignance,above 5 kg,,,,,,
6614,,antitumor traditional,anti-cancer agents,,serum creatinine≥221umol/l,assisted fertility,,,,non-eligible,within 72 hours before the first dose,women≥460 ms,,,,,,
6615,,space occupying lesion,td2,,ctfg hma 2020 (appendix ii,biochemistry,,,,mild ad,in past 12 months.|any factor,score of 5,,,,,,
6616,,consumption of poppy seed-containing products,lovenox,,recist v1.1 [3]|life expectancy,intercourse.|participant,,,,non-organic disease,during the mastectomy,≥18 and ≤90 years.|history,,,,,,
6617,,squamous cell skin cancer|distal metastasis,nonsteroidal agents,,fragment length analysis,blood transfusion|life expectancy,,,,grade 2);|cardiovascular disease,more than 3|concurrent,0 or 1.|willing,,,,,,
6618,,serious health problems,ethylhexylglycerin,,dsm-v criteria,special education classes,,,,acute event,at least 4 weeks prior to screening,≤ 3 times the uln,,,,,,
6619,,peripheral neuropathic pain,molecular components of allergenic sources,,glycosylated hemoglobin (hba1c),unilateral spatial,,,,hamd17,within 6 months before screening.|with other medical,0 or 1|participant,,,,,,
6620,,cardiovascular condition,metformin,,fdg-pet scan results,mitral valve replacement,,,,nicu.|singleton gestation.|gestational age 28w0d to 36w6d at birth.|postmenstrual,before administration of study intervention|is,13.5-17.5 grams/dl.|have,,,,,,
6621,,cystic mass,tislelizumab,,blast count,clear plan,,,,stable maintenance therapies,within the three months preceding the planned administration of the vaccines|history,18 years or older|have,,,,,,
6622,,g6pd-deficient,anesthetic drug,,best spectacle corrected visual acuity (bscva),invicta defibrillation lead,,,,secondary orifices,3-4 endometriosis|tmss,below the lower limit of normal,,,,,,
6623,,vein invasion,immune related,,physician|fasting plasma glucose,generalized lipodystrophy,,,,insulin resistance,after surgery.|in patients assigned to,≤ 140/90mmhg,,,,,,
6624,,non-lacunar,low molecular weight,,thereafter|absolute neutrophil count (,intensive care unit,,,,stage iii-iv|ecog performance status,within 45 days prior to enrollment,between 7-12 years|exposed,,,,,,
6625,,liver transaminase,canakinumab,,singaporean permanent resident|age,pancreas biopsy,,,,specialized,at least one minor,< 3 lesions,,,,,,
6626,,22.20mmol)|uncontrolled hypertension,barbiturates,,aspects score,candidates,,,,iv)|severe,for the last 3 months prior to inclusion,22-45 years,,,,,,
6627,,relevance,glp-1 agonist,,agents amount,permit brief inpatient,,,,related to lipid metabolism||i,within the past 7 days,qtcf≥ 470 ms,,,,,,
6628,,hfpef,jis,,hbv-dna level,regular vitamins,,,,clinically uncontrolled,in the past 6 months before screening,≤ 21,,,,,,
6629,,parkinson's drugs,viscous lidocaine,,human immunodeficiency virus,sar,,,,simulation,within the last 6 months|known hiv,stage 1:||female,,,,,,
6630,,metastatic biopsy|measurable disease,chemotherapy||-,,estimated recurrence risk,hyperthyroidism|having,,,,intent|severe,within past 2 years,40-75 years|ability to provide,,,,,,
6631,,metastatic incurable malignancy,systemic anti-infective therapy.|patients,,interference score,reaction.|hospitalization,,,,ocular surface,within 2 weeks prior to the first dose of study treatment;|participants had been,+ms / hfpef,,,,,,
6632,,phpt and dm,"components of anv419 (il-2, anti-il-2",,1.resident population,stress fracture|pregnant women|non-english speakers|medicare,,,,enrolment into,within 2 weeks and fully recovered,> 3 g/dl.|patients,,,,,,
6633,,accountability,medications used in the study,,cmv end organ disease,local study appointments|written,,,,under general anesthesia|disease,in the first segment|stenosis of the right coronary artery,>300 mg/dl,,,,,,
6634,,acute respiratory symptoms,dacarbazine,,progesterone level,emission tomography,,,,identify 2,at all and 10 cm indicates the,>38.5 ℃,,,,,,
6635,,motor problems,regional lymph nodes,,european georges pompidou hospital,opioid use|uncontrolled,,,,non-lactating.|females of,within the last 3 months|patient unable to comply,≤1.5 times the upper limit of normal,,,,,,
6636,,compulsory detained,remains critically ill;|surrogate,,liver invasion occurs,revision total knee arthroplasty;|found,,,,primary tumors.||inclusion criteria,for at least three weeks|the doac,between 18-40.|gestational,,,,,,
6637,,union,prebiotics,,intracerebral hemorrhage.||the exclusion criteria are:||pre-stroke,apneas/hypopneas,,,,mean resting heart rate,within 12 months of,18.5-24.9 kg/m2||diabetic group,,,,,,
6638,,analgesics.|pregnancy,cvd,,inr monitoring has reached the target range,nihss,,,,first remission,in the four months preceding enrolment.|patients on medications,abnormal,,,,,,
6639,,iontophoresis,meibomian,,child-pugh classification|congenital,radionuclide,,,,deep,within 5 days prior to (the first,multiple retinal breaks,,,,,,
6640,,non-healing wound/ulcer/bone,non-steroidal anti-inflammatory drugs (,,inclusive|bmi,nsaids treatment,,,,penicillin allergy.|a patient,superior,14 units,,,,,,
6641,,retinal intervention,bisoprolol,,needed||,|prior therapy,,,,medical adhesives,within 30 days.|patients,18 - 45 years,,,,,,
6642,,"local infiltration of the perineum),|lacerations",fluoripyritics,,sample size collected does not,maintain basic oral hygiene procedures,,,,cmv end-organ disease,for 3 months following last dose of study drug||,>= 1.0,,,,,,
6643,,anorectal malformation,compounds of similar chemical composition to the study drugs.|pregnancy,,interval progression,cri,,,,and/or devices,within 1 week after participation in this study,≤ 5x upper normal limit|creatinine,,,,,,
6644,,cetuximab.|gastrointestinal disorders,local anesthesia|the,,tha,re-vaccination exclusion,,,,topical antiviral,within 180 days prior to first dose of study agent.||blood products,7 to 12,,,,,,
6645,,congenital heart disease.|end-stage systolic heart failure,non-steroidal anti-inflammatory drug.|use,,drugs.|systolic blood pressure,clinical relevance|history of any of the following conditions:|myocardial infarction,,,,pd with rkf,after they have resumed their pre-exacerbation maintenance asthma therapy,> 2x uln,,,,,,
6646,,pain aggravation,anti-pd1/pdl1 antibody,,grades of gliomas,valid identification,,,,above criteria.|note,at the time of enrollment|2.patient,less than 5 days,,,,,,
6647,,amu,drugs used in the treatment of cancer,,karnofsky performance scale (kps),medical conditions|no,,,,image-guided biopsy,monitors;|have high,0 to 4 scale,,,,,,
6648,,lupus erythematosus,cyp3a4 inhibitors itraconazole,,gvhd grades,periodontal therapy,,,,c2-t10,at least 14 days prior to the screening visit,> 50 µmol/l)|hyperglycemia,,,,,,
6649,,solid organ transplantation,festival,,movements disorder,traumatic amputation,,,,highly active,prior to icu admission|patient receiving,iic,,,,,,
6650,,small molecule,anti-cancer chemotherapy,,therapy;|iv therapy,doublet chemotherapy,,,,concomitant,for at least 2 weeks before enrolment,less than 9 centimeter per second,,,,,,
6651,,gaucher disease,enasidenib,,50 gy eqd2,dental implant placement,,,,full crown,within 14 days before the first dose of study agent,> 15 ml/min/1.73 m^2,,,,,,
6652,,early menopause,5-minute apgar score,,esspri,adjuvant hormone therapy,,,,non growing,within 5 years prior to study enrollment,more than 20 teeth;|absence,,,,,,
6653,,prothesis,topical corticosteroid treatment,,curative|left ventricular ejection fraction,intratympanic injection,,,,emergency from monday 6am to thursday 12pm.|patients able to understand the protocol,within 30 days of the end of study|participation,40 to 60 years,,,,,,
6654,,behavioral disorders.|treatment,non-study vaccine,,progesterone receptor-positive,radical treatment,,,,non-communicable,during and within 1 year after trial completion,≥3.0 x upper limit of normal [uln,,,,,,
6655,,lower digestive haemorrhage,jia,,speech impediment|history of neurological,fulfil the eligibility criteria outlined below,,,,under general anaesthesia.|volunteer,within 14 days before the screening,35-55 years,,,,,,
6656,,autoimmune hepatitis,vitamin k dependent,,american pathologists [cap],hospital stay of,,,,forty -two patients,while on protocol therapy,> 0.5 standard deviations below expected|self-reported,,,,,,
6657,,contracts,immunosuppressives,,ffr,chemotherapy|no prior chemotherapy,,,,less-common histology,within 30 days of the planned start of study therapy,< 3 weeks|no viable outcome,,,,,,
6658,,anatomical risk factor,cannabidiol,,corrected serum calcium uln)|active,graft vs. host disease,,,,preclude reliable assessment,within 6 months of study entry,18-65;|current/acute,,,,,,
6659,,distal biliary obstruction,npc,,fixation threatening visual-field defects,core biopsy,,,,imwg consensus,within four weeks of screening visit 11,<1000/mm3|serum,,,,,,
6660,,brain pathologies,later.|had,,visit|bmi,chimeric antigen receptor t-cell therapy,,,,st segment elevation myocardial infarction,within two weeks before enrollment;|patients,≥25 kg/m²,,,,,,
6661,,cerebrospinal fluid [csf],cibenzoline,,factor v leiden mutation,complementary treatments,,,,low risk of recurrence,within 5 years before enrollment;|breastfeeding patients；|patients,hemorrhage.|more than four weeks,,,,,,
6662,,kawasaki disease,components of lumason|patients with severe,,spirometry test,lisbon school of health technology,,,,twins,at least 90 days after the last medication,≥2.5 mm,,,,,,
6663,,medical problems,compounds of similar chemical or biologic composition to cbx-12,,serum potassium levels should,paramagnetic materials,,,,related syndromes.|ages,in the 12 months prior to the first administration of the study drug,<30 g/l|anaerobic threshold,,,,,,
6664,,active pulmonary infection,local corticosteroid injections,,1.2.|platelet count,transdermal hormone contraception|placement of an,,,,asxl1,within 4 months).|involvement,no more than 3,,,,,,
6665,,ruminative response scale (rrs) score,dialysis.|patients,,dulbecco modified eagle's medium (dmem),objective endoscopic,,,,part b,on more than 3,0-2|be eligible,,,,,,
6666,,tia).|symptomatic carotid,deucravacitinib,,old)|patients,screening;|surgical interventions,,,,after definitive rt,within 6 weeks of screening,35|pregnancy|severe obstructive,,,,,,
6667,,liver transaminase.|any disease,craniofacial district,,nasolabial folds,congenital adrenal hyperplasia.|thyroid diseases.|cushing's syndrome.|diabetes,,,,segmental,previously received,12-15.5 grams/dl.|males,,,,,,
6668,,epileptic illness;|seizure,opioid analgesic therapy,,creatinine levels,assessment incomplete,,,,longest dimension of ≥ 10 cm.|patients,within 5 days before the 1st dose of ft538,less than 2000 cell/mm2;|age,,,,,,
6669,,bipolar episodes,rapid acting insulin analogues,,haemoglobin concentration,testing begins|if,,,,regular menses every 21-35 days,for at least 4 months after the last study treatment administration,< 100 x 109/l.|hemoglobin < 6.0 mmol/l,,,,,,
6670,,impaired decision-making capacity (idmc),drug eluting stent (des),,predominantly uui,corticosteroid therapy,,,,being)|clinically significant,upon initial assessment|previous middle ear surgery of the affected ear|concurrent treatment,> 20,,,,,,
6671,,local anesthetics|failure,losartan,,uln.||neurologic function:||peripheral neuropathy ≤ ctc ae grade 2.||blood coagulation,surgical interventions,,,,live vaccines,after first-line,between 18.0-32.0 kg/m2.|generally,,,,,,
6672,,serious pathology,anti- fungal agents,,hiv-ab,correct inhalation technique,,,,davis comprehensive cancer center,during the study.|laboratory test results before randomization,≥ 60 ml/min).|paraffin,,,,,,
6673,,terminal cancer)||retrospective part||inclusion criteria:||patients,alirocumab,,american society of anesthesiologists i,whole brain radiation,,,,rays,over two years duration,> 2000 g,,,,,,
6674,,osteoarthritis,lithium);|patients,,belgium,implantation surgery bp systolic,,,,d-dimer levels,during the study.|patients,> 400|non-viremic hepatitis c virus,,,,,,
6675,,neurological disability,topical ophthalmological medication,,metabolic health,nodal,,,,some degree,within 14 days prior to step,50 to 95 mm hg for diastolic.|participants,,,,,,
6676,,vocal cord diseases,movement|active drug,,peripheral granulocyte count,intervention|anticoagulant therapy,,,,3rd trimester of pregnancy,within 1 week of scheduled,6-24 hours,,,,,,
6677,,lung disease.|the,mild tbis,,gm-csf,vascular access,,,,suitable for participating in this trial.||subjects with,within the past year prior to start of screening.|use,≥50 years.|subjects,,,,,,
6678,,bji,symlin,,urine hcg test results,vaginal speculum examination,,,,depositary gestagen,during surgery,>1 mgl-1;|total cholesterol,,,,,,
6679,,swab,iron supplementation,,hcv genotype test)||individuals,self-reported visual exam,,,,alk-fusion,within 3 months before the first dose.|received radiation therapy to the lung,≥18 years;|④ basic cognition,,,,,,
6680,,caregivers).|significant cognitive impairment,luekotriene receptor antagonist,,estimated glomerular filtration,diathermy treatment,,,,undetectable,at the time of the study|not,less than 90 mmhg,,,,,,
6681,,liver disease center||all,investigational drug therapy for mm,,beck depression inventory ii suicide item)|having,latest chemotherapy should,,,,important,"within 3 months),congestive",> 800ng/ml,,,,,,
6682,,thoracoamniotic shunts,components of investigational drug;|indications,,lilrb4,copy number variant,,,,departments of urology,in the past year|pregnant/breast-feeding,≥75 x103/l,,,,,,
6683,,chickenpox vaccines,5-meo-dmt.|has,,cd4+ t-cell,european guidelines)|starting infliximab,,,,high-grade serous,before tax)|past history,<6 months from screening,,,,,,
6684,,difficulty understanding the subject,gemtuzumab ozogamicin,,ventricular mass index,dbt,,,,n2-3,for at least 12 weeks prior to screening.||2,between 1 and 4,,,,,,
6685,,maxillary edentulous,systemic anti-infective treatment,,nci-ctc ae,liver transplantation|contraindication,,,,viral infection||viral infection:||antibiotics,for at least 8 weeks prior to screening|subjects,≥90 g/l.||the,,,,,,
6686,,android operating,medications not,,anaphylaxis,neurological examination,,,,suitable for pvi||,within 14 days prior to study treatment initiation,between 4-16 years,,,,,,
6687,,inflammatory process|previous neck,combined treatment,,dexamethasone,local cardiologist review the,,,,collected,at least than 12 months before the first cycle of,≤2.75 mm,,,,,,
6688,,variceal bleeding.|prior,smartphone components enabled,,detectable protein expression by ihc in,common procedure/surgery,,,,curative,during the screening period;|severe,a-b,,,,,,
6689,,breast carcinoma in situ,topical skin treatments,,adap,stress reduction protocol,,,,implant site,within 4 weeks prior to initial administration.|patients,>1.5,,,,,,
6690,,mrcp,anti-programmed cell death protein 1 (pd-1),,8f-size,heparin injection therapy,,,,well-defined,within 15% of ideal body weight,> 2 mg/dl,,,,,,
6691,,progressive central nervous system (cns),antihistamines,,wbc,pulmonary artery catheter,,,,pain relief,within 30 days prior to the first dose of study drug,between 20 and 70 years,,,,,,
6692,,female|mild asd diagnosis,taurolidine,,respiratory society,edinburgh postnatal depression scale (epds),,,,medically prescribed diet,in the last 3 months|participation,individuals 18 years old or older,,,,,,
6693,,isr).|left main stem,angiotensin-converting enzyme inhibitor,,prothrombin time (pt) ≤1.5×uln.|spo2,narcological dispensary;|maternal,,,,carbohydrate intake,within 24 hours after ercp|age,>20 years|patients,,,,,,
6694,,adenoidcystic carcinoma,cmbs,,serum pregnancy test before randomisation and should be repeated,groin hernia,,,,uni-,prior to starting the protocol)|recent,18 years or over|able,,,,,,
6695,,optic neuritis,ssris,,spo2,dutch neuropsychological assessment,,,,sp,during the period june 2017 to june 2022.||,18 or older|diagnosis,,,,,,
6696,,t2 sequence,microbiota,,drug abuse test,standard therapy exists,,,,tumor|clinically significant,< 1 week before 68ga-ny104 pet/ct,< 80×109/l,,,,,,
6697,,structural spinal disorders,a2 biotherapeutics,,special surgical,scoff screening questionnaires|participation,,,,molecular typing,within the indicated period before the baseline visit,18-70 years|in,,,,,,
6698,,passive immunotherapy,antiretroviral medications,,pregnancy test|a positive test for sars-cov2,screening|effective method of contraception,,,,homicidal|actively,for at least 7 months after the final dose of study treatment|if,no more than 12 weeks between,,,,,,
6699,,pose a risk relating to the safety of the fmri procedure,medications prescribed,,hemoglobin levels,vascular imaging,,,,could cause significant agitation|ongoing use of any cannabinoid-related products,within 56 days of day 1,between 18.0 and 24.9.||☞ bmi,,,,,,
6700,,competitive sport||inclusion criteria,oat3 substrates,,right ventricular systolic pressure,assisted living,,,,non-alcoholic fatty liver disease ⑥.,within 12 weeks of baseline.|concurrent neurologic,<20 years,,,,,,
6701,,medication|pregnancy,systemic immunosuppressive,,years|plasma hiv-1 rna viral load,pci|pci,,,,site of application of the therapy*.|severe,at the time of cag,> 4cm,,,,,,
6702,,transitional epithelial carcinoma,global impression,,bahir dar,patellofemoral joint loading activities,,,,primary rhythm,treatments;|history,less than or equal to (=<,,,,,,
6703,,other problems,anesthetics,,cfcs level,coronary artery bypass grafting surgery,,,,caused,during the study.|history of,> 38.5 ℃,,,,,,
6704,,liver fibrosis|liver stiffness measurement,calculus on facial surfaces,,virtual,lvrs,,,,percutaneous,within 24 hours after surgery,0-4,,,,,,
6705,,bladder neck collapse fibrosis,tirofiban,,anti-malarial treatments.|body mass index (bmi),total knee,,,,mds-eb,within 4 weeks before administration of the first dose of do-2||patients,> 1 year,,,,,,
6706,,hereditary angioedema,aminosalicylate,,salivary rate,re-mineralizing agent,,,,acute phase of the illness,in previous 2 weeks;|administered,<75 ml/min/1.73m2,,,,,,
6707,,secondary membranous,abiraterone,,thyroid stimulating hormone)|vitamin b12 levels,tobacco use|participation,,,,diameter of 1:1 to the,within 4 weeks before the first administration of study drug|participant,>2ng/ml,,,,,,
6708,,type of infection,prescription oral anti-inflammatory/immune,,uln)|arm b moderate hepatic impairment,stemi|primary percutaneous coronary intervention|de-novo,,,,insulin delivery,within screening,≥35 kg/m2)|preoperative,,,,,,
6709,,"spastic diplegic cerebral palsy,|no",systemic corticosteroid therapy,,sponge,antiviral drugs,,,,months.||6,for at least 6 months,> 2 × uln,,,,,,
6710,,febrile process,drug substance,,averaged bp,standard cognitive-behavioral therapy,,,,foveal,more than 1 year before,>3.0 g/dl.||,,,,,,
6711,,non-diabetic renal diseases,nccn,,t2,screening tests,,,,immunosuppressant,within the preceding six months,25 - 35 kg/m2.||,,,,,,
6712,,parkinson's disease|clinically,methotrexate,,youngstown state university|,pace maker,,,,intracranial arteries,within 4 weeks prior to leukapheresis.|patients,1 symptom,,,,,,
6713,,corneal pathology,biopsy collected,,criteria of：||alanine aminotransferase (alt),thoracic surgery,,,,zoom-administered,during study treatment|history of severe,≥70×109/l,,,,,,
6714,,"breast cancer,|ps ≤ 2,|willing",cerazette,,not;|severe blood dyscrasia;|blood clotting disorders,t-dxd,,,,non-menthol,within 6 months before enrollment.|patients,child does not,,,,,,
6715,,duodenal ulceration,discoloration,,blood pregnancy test,homozygous deletion of exon 7 of the smn1,,,,american college of rheumatology.|precapillary pulmonary hypertension,at least 12 weeks,18-70 years;|patients,,,,,,
6716,,impaired decision-making,phenothiazines,,coagulation function international normalized ratio (inr),imaging modalities,,,,platelet transfusion,preceding 3 weeks,above 30,,,,,,
6717,,asymptomatic bms,parenteral antimicrobial agents,,speech,signet ring cell carcinoma|at,,,,violent,before the coronary artery fractional blood flow reserve test|prior coronary artery bypass,"1-year definition),|reside",,,,,,
6718,,glomerular crescent,gnrh antagonist,,residual thyroid,metal implant,,,,incompletely healed,within 14 days prior to the initiation of study,± 5%,,,,,,
6719,,bleeding lesion,inflammatory markers,,asa-i health status|aged,emergency medical worker,,,,ovarian,within 7 days before the enrollment,< 35 ml/min/1.73m2|history,,,,,,
6720,,alcohol misuse,trametinib,,ankle and hba1c below 8||,discontinue treatment,,,,nyha,during their time in the clinic on the day of dosing.|willing,> 1/3 of the,,,,,,
6721,,liquid malignancies,plhiv,,latitude™ home-monitoring-system,consonant-nucleus-consonant (,,,,adolescent brain,within the last 3 months prior to inclusion|infection,<30)|pregnant,,,,,,
6722,,media,pathogenic,,minutes.|platelet count,small molecule targeted therapy,,,,a1/a2 segment of the anterior cerebral artery,within either,less than 6 cm,,,,,,
6723,,multilineage dysplasia,local glucocorticoids,,||age,cancer|previous abdominal surgery,,,,pas,within the last 2 years.|any lifetime history of,> 19 but less than 40||,,,,,,
6724,,ecg,anti-gvhd;|had,,regenerative tissue matrix,cellular immunotherapy,,,,clinically significant diseases,after trauma and|presumptive duration of operation not exceeding,2|has been,,,,,,
6725,,histological type,rheumatoid arthritis;|inadequate control of arrhythmias,,cholesterol profiles -or- overweight/obesity.|elevated,30 fractions,,,,site of vivio application / examination.|inability to obtain,at the screening stage.|hospital admission,between age 3 and 5 months,,,,,,
6726,,obstructive sleep apnoea,tqb2934,,pregnancy|asa,sleep on|wear,,,,muscle flap,within the last 180days.|participants with,≤ 9.0 g/dl,,,,,,
6727,,multivessel disease,aminophylline,,recist version 1.1;|postoperative pathological diagnosis,diagnostic nocturnal polysomnography,,,,emergency room visits,within two years post-transplantation||,< 140 or > 500 x 10^9/l,,,,,,
6728,,anaplastic lymphoma kinase (alk) alteration,component of the multimodal analgesic regimen,,fasting glucose (ifg),pet)/computed tomography (ct),,,,rr ≥30 breaths/min.|clear consciousness,in the 12 weeks after enrollment|cognitive,> 105 mmhg,,,,,,
6729,,hepatitis c and,couples,,serum trough level,ascites)|life expectancy,,,,mucinous,within the last 12 months|known hypersensitivity to,3g,,,,,,
6730,,alcohol use disorder,ocitinib,,criteria below:||multiple myeloma,immunomodulatory imide drug (imid),,,,interferes with,after two or more,patients.|over 18 years,,,,,,
6731,,dietary diversity,tci,,css,emergency medicine postgraduate residency,,,,legally acceptable representative(s) [lar(s,within 14 days after the completion of screening||,> 50 ml/min/1.73m2,,,,,,
6732,,arthroscopic rotator cuff,scopolamine,,plasma viral load,basic mri,,,,non-copper,within 30 days prior to visit 1|all,< -10 d and,,,,,,
6733,,adrenal hematoma,medication for asthma/seasonal,,response evaluation criteria in solid tumors (recist) version 1.1,interventional cardiac procedure,,,,unhealed,within 6 months before randomization|malignancy,< 1500,,,,,,
6734,,difficulty understanding visual analog scale (vas),opioid use disorder,,creatinine (cr),electroconvulsive therapy,,,,excised,within the 6 weeks prior to screening.||key,=< 2.0 × upper limit of normal (uln),,,,,,
6735,,electrolyte disorders,strong cyp3a4/5 inhibitors,,genetically proven,hospital documentation|spinal imaging of the stimulator system||,,,,moderate to severe,during the last four weeks before entry into the study.|people with heart pacemakers,≥100 ×10^9/l,,,,,,
6736,,response,murine products.|known hypersensitivity to any active substance,,neurologic disease|total sperm count,target vessel contains visible thrombus.|pregnant,,,,suitable for sbrt,in the past 12 months|has below 6th grade,= estimated glomerular,,,,,,
6737,,oral hygiene,used medications,,headache,routine dilated oct scans.|patients,,,,pre-term,for at least 5 years prior to visit 1,< 150 pmol/l).|patients,,,,,,
6738,,left atrial appendage occlusion,anti-vascular small-molecule,,hiv-1 rna value,robotic assisted laparoscopic prostatectomy,,,,arpi,within 14 days prior to surgery,between 15-59 year,,,,,,
6739,,h. pylori eradication therapy.|voluntary hp eradication,aripiprazole|pregnancy|positive illicit drug screen,,serum κ/λ free light chain ratio.|ecog score,assessment of ad,,,,worse than usual,3 weeks x 4,≤ 5 × uln|baseline serum bile acid level,,,,,,
6740,,endoscopy|inability,anti-tumor drug treatment,,hcv viral load.|has,x-ray)||,,,,clopidogrel use,"for the first time,|breastfed,|preterm infants whose parents' consent",≥ 140 mmhg,,,,,,
6741,,alternative diagnosis|patients capable,cessation medications,,circumference,picu stay,,,,related to their diagnosis of,at the time of inclusion|performance status,<7kg,,,,,,
6742,,rubeosis iridis,congenital ihh,,only)|bone marrow plasma cells,radiation therapy|lung-dominant disease,,,,platinum therapy-related,in the prior year|provide informed,≥ 3|≥ 10%,,,,,,
6743,,suppurative thrombophlebitis,lp-108,,severity level,gbt-sponsored gbt021601 clinical study,,,,private physiotherapy|failed,within 2 months before screening,45 kg,,,,,,
6744,,premalignant lesions,tofacitinib,,glomerular filtration rate (gfr) estimated by,sitting balance devices,,,,yellow flags,within 6 months prior to allocation.|has severe organ,100.0 kg,,,,,,
6745,,serious illness,erytromycin,,screening.||eosinophil count,surgical procedure||,,,,high grade,within 5 years or less before signing the informed consent,≥18 year,,,,,,
6746,,autoimmune disease.|hiv infection,oral antibiotic intake,,quantitative real time(qrt,aesthetic treatment,,,,successfully aided with hearing aids,at initial screen);||,≤ 2||relapsed,,,,,,
6747,,secondary membranous nephropathy,strong cyp3a inhibitors,,recist 1.1|receiving immune checkpoint inhibitor therapy,intoxication|structural heart disease|cardiovascular disease,,,,extranodal sites,after initial training,≥65%,,,,,,
6748,,bipolar disorder|neurophysiological conditions,anti-retroviral agents,,absolute neutrophil count≥1.5×10^9/l,occipital nerve block,,,,non-gi infections,prior to the first dose administration,≤1.5x upper limit time,,,,,,
6749,,impaired coagulation.|renal impairment,direct factor xa inhibitors rivaroxaban,,allowed|adequate renal function,cataract surgeries,,,,reproduction.|possible,within 2 weeks of first dose,≤ uln.|covid-19 positive.|history,,,,,,
6750,,oab,components of the study interventions,,general bilirubin level,emergency medical team at home,,,,overt,during the past two years)|immunodeficiency,≥ 24||,,,,,,
6751,,accepted):||papillary thyroid carcinoma (,eyelid,,anti-hcv antibody [ab],auburn al,,,,long-term oral hormone therapy;|are in the period of,in the 15 days before the procedure,0-1.|negative serum pregnancy test,,,,,,
6752,,hamartoma,soluble cea,,ctcae v5.0 scale,echo,,,,lifestyle|body-mass-index (bmi),for 180 days after the last,≥3 months.|histologically,,,,,,
6753,,lateral sclerosis,pdl-1 inhibitors,,glomerular filtration rate egfr≦30,optimal clinical care.|initiation,,,,inconsistent with the recommended visit interval,the next 3 months,less than 1 mm|hemodynamically significant,,,,,,
6754,,non-smokers,immunosuppressive therapy.|receipt,,hb<100g/l,diseases;|a,,,,suitable to participate in this,at least 3 to ensure,less than 40kg,,,,,,
6755,,cpet.|advanced atrioventricular block,aids).|patients disagreeing,,nuclear gfr,maintenance doses of,,,,high-risk biliary,within the prior 12- months,≤ 200 mg/week,,,,,,
6756,,administration|patient treated,pemetrexed,,serum immunoglobulin free light chain (flc),lumbal herniotomy,,,,highly effective method of contraception,longer than 6 months prior to this date)|evidence,between 16 to 20 years old.|,,,,,,
6757,,constant,donate,,transferrin saturation,national exercise guidelines,,,,lower extremity peripheral artery,in the past five years.|6）pregnancy.|7）not,greater than 42 cm,,,,,,
6758,,psychiatric illness.|parent,long-acting art,,lesion activity criteria of coronal,blood-borne infection,,,,achieve mobile health,within the 2 months prior to enrollment.|participant,>= 60%|step 2,,,,,,
6759,,dyspigmentation,haloperidol,,total platelet count,total knee arthroplasty,,,,cured,during the observation period and within 8 weeks after the last administration of the study drug.||the patient voluntarily participated and signed the informed consent form;|it is expected that the compliance,i-ii-iii,,,,,,
6760,,muscle damage,raloxifene,,american thoracic society (ats) criteria for acceptability and repeatability,lung tomography,,,,unrelated to obstructive,at least 24 months after nephroureterectomy.|subjects who cannot,30-39.9 kg/m2,,,,,,
6761,,conduction disturbances,ltbi,,center,ipsilateral extracranial artery,,,,stigma,in the last three months before screening,35.7 - 37.0 °,,,,,,
6762,,solid organ transplantation;|live,peanut allergy.||for fmri,,fasting lipids,visit)|self-reported,,,,"grade 2, 3 or 4",within 3 months|participated,>2 × upper limit of normal,,,,,,
6763,,irritable bowel|can swallow probiotic pellets,nucleic acid amplification techniques (naat),,rachs,hematologic malignancies|performance status criterion,,,,unrelated to their weight,at physiological doses,75 years and older|ps score ≥1,,,,,,
6764,,portacaval shunting,strong cyp3a4 inhibitors.|female,,incomplete questionnaire|under,camh chart review).|bmi,,,,first-time,in the past 6 months,64 bioventrix cip-0067,,,,,,
6765,,coronary/peripheral artery bypass graft,systemic corticosteroid use,,or|glomerular filtration rate (gfr),tubal obliteration,,,,bone-cement fixation,within 6 months before.|female,≥55-90 years,,,,,,
6766,,false teeth,midline catheter,,hepatitis b pcr,placement of vascular access,,,,ast(sgot)/alt(sgpt,after surgery after fracture etc.)|those,< the fifth percentile).|previous,,,,,,
6767,,benign neoplasms,immunosuppressive therapy|known human immunodeficiency virus (hiv),,pulse rate,immunomodulatory therapy,,,,spontaneous menses,during the previous 6 months.||for psa group:||- psa,≥ 30%.|3,,,,,,
6768,,excessive hair,dipeptidyl peptidase-iv inhibitor [dpp-4i],,calculated,carotid ultrasound,,,,severity per clinical,in the last 6 months|use,<1 ng/ml,,,,,,
6769,,acute head,na,,urine test for alcohol,extraprostatic site of disease,,,,gynecologic oncology at carilion clinic,prior to receiving niraparib,≥ 8.0 mmol/l,,,,,,
6770,,postmenopausal status,monoclonal antibody therapy|palliative radiation,,bspp,elective endotracheal intubation,,,,enteric-coated,at least 6 weeks since the completion of a nitrosourea containing chemotherapy regimen.|patients,less than 40%;|the score of the preoperative simple mental status examination (mmse),,,,,,
6771,,chronic renal failure;|dysuria,rifampin/rifabutin,,aids antigen/antibody,peritoneal cytology|reduction,,,,co-incidental shunt,at least one questionnaire,> 45;|obstructive,,,,,,
6772,,keratoconjunctivitis,live attenuated,,west yorkshire qip,cranial computerized tomography (ct) scan.|high-velocity,,,,dutch language|severe,"within 2 weeks prior to cycle 1, day 1||patients",> upper limit of normal,,,,,,
6773,,gastric stump cancer,caffeine-containing product,,meeting ppd criteria for tb exposure,refractions,,,,cytologically.|failed,during the time he/she,positive-expressing tumors,,,,,,
6774,,draining,contrast material|uncorrectable coagulopathy,,mri)||,neurological intensive care unit,,,,self-regulation,throughout study participation|fluent english speaker|capacity for,< 32%,,,,,,
6775,,needle phobia,immunosuppressive medicines,,glycosylated haemoglobin,pelvic lymphadenectomy,,,,serotonin-containing,at least 2 weeks prior to screening,< 10c/day,,,,,,
6776,,hemodynamic support,immunosuppressive medication).|subject,,monoclonal antibodies) ≤28 days,gvhd prophylaxis,,,,participants):||non-english speaking or|serious,over last 6 months|major hearing/visual,>= 18 years||postmenopausal,,,,,,
6777,,prostatic hypertrophy|patients,compounds of similar chemical or biologic composition,,least eight natural anterior teeth,brain mri scan;|the,,,,unrelated to menses)|have a,at least 6 or more,>1:100|history of,,,,,,
6778,,non-melanoma skin cancer;|patients,platelet antiaggregants,,hepatitis c antibody test,lipid-lowering medications|sleep apnea|fragmented sleep|have,,,,listed on heart transplant,at the time of the cross-sectional evaluation|for the ecmo group,>/= 1mg/kg,,,,,,
6779,,|general pathology,antioxidant supplements,,international level swimmers|- healthy swimmers|-,thyroid palpation,,,,shoulder,within 2 years before the screening,above 40.|subjects,,,,,,
6780,,specimens for sequencing,topical iodine,,dose extension phase: all subjects,unilateral transtibial amputation,,,,mild to moderate vaginal dryness,in past 6 months,≥ 30 mg/g,,,,,,
6781,,sweated extremities,beclomethasone,,total survival,remain off of antipsychotics,,,,primary reason,within 4 weeks prior to the first dose.||radiotherapy or surgery,>50 µmol/l|ongoing,,,,,,
6782,,non-diabetic reasons,anomalous hemoglobins.|patients,,plasma glucose,montreal cognitive assessment (moca),,,,pd),up to 15 days of evolution).|impaired safety,60-85|sufficient,,,,,,
6783,,years|esophageal pathology,android phones.||,,coagulatory function.|confirmation by,surgery.|prior treatment,,,,non-prescribed,within the last 24 hours|pharmacy,≤ 30% of the diameter,,,,,,
6784,,liver metastases occurred,adhesive,,estimated glomerular filtration rate (egfr),"chronic disease,|parents",,,,tongue,within 10 min,ii - iii,,,,,,
6785,,"spinal dysraphism,|urinary",myocardial infarction|nabilone,,distilled water,lung ct results,,,,inguinal,during the previous 3 months.|pregnant,18 and above|diagnosed,,,,,,
6786,,skin biopsies,pav+,,beck depression inventory|current symptoms of,prostatitis)|bone,,,,recreational,3 days prior to initial study treatment,stage iv|abdominal aortic aneurysm,,,,,,
6787,,cardiopulmonary arrest,prescription medication regimen,,segmental exclusion,sudden,,,,femoral bone,during the duration of the study|treatment with another investigational drug,150 / 75 min per week,,,,,,
6788,,gcv,ayahuasca,,minimum length,hospitalisations,,,,soju,during the study period|mental incapacity,<9.5 g/dl,,,,,,
6789,,cll);|presence of,ddp-4 inhibitor,,baseline;|blood creatinine,manage telerehabilitation||,,,,could interfere with accurate logging of pain ratings);|current,within 7 days of study drug administration|had dilatation,<50%.||,,,,,,
6790,,lymphomas,seconds).|no medication,,hdf,spinal fusion,,,,grade c。|pleural,within 30 days before baseline visit,scan.|greater than or equal to 15%,,,,,,
6791,,give consent|presence,anti coagulants,,optic disc diameter,index pci,,,,lower jaw],within the past 12 months except,<4 wk,,,,,,
6792,,open wound,cilgavimab,,pain score values,fecal immunochemical test,,,,surgeries.|recent,at randomization make the individual unsuitable for the study,<1.5 uln,,,,,,
6793,,fibrosing,cetuximab alone,,rk,laser ablation,,,,life-threatening,within 1 month;|severe liver,<50%,,,,,,
6794,,fscp).|patients,medications to control weight,,aqua,transplant surgery||,,,,urinary,continue for 6 months after the end of treatment;|the,> 2.0 x the upper limit of normal,,,,,,
6795,,know autonomic,rabies vaccine,,emergency c-section,"answering ""yes'",,,,arm,within 2 weeks prior to the first dose of study treatment|patient,6 months prior to the,,,,,,
6796,,pain|uncontrolled pleural effusion,cardiovascular medications,,nci ctcae version 5.0.|willing,mybl alterations,,,,airway,without prior,>30|high aspiration risk,,,,,,
6797,,chronic high-dose,histamine receptor type 2 [h2] receptor antagonists,,phq-9 item-9 score,tace)|thermal ablation,,,,gingival tear occurred,within the past 12 months.;|women,score of < 20,,,,,,
6798,,leg length discrepancy,interventional cardiac devices.|subjects,,criteria):||body temperature,robotic therapy,,,,invasive carcinoma.|completion,in the 3 months before screening,>1.25 x the upper limit of normal (uln),,,,,,
6799,,negligible,psas,,cd4+ cell count,percutaneous carotid coronary dilatation,,,,esophageal abnormalities|history,at the time of the initial evaluation (pretest).|who are,between 8- 18,,,,,,
6800,,appropriately certified).||,oag,,blue lake biotechnology]).|chronic rhinitis,electrolyte supplementation,,,,drug,within 3 months prior to first dose of study drug,< 37 weeks,,,,,,
6801,,cushing disease,contraceptive requirements|body mass index,,international standardized ratio (inr),psychotic disorder|hypnotherapy treatment,,,,absolute general contraindication,within 14 days prior to the study agent administration,= 4,,,,,,
6802,,marfan syndrome,grapefruit/grapefruit containing products,,asa physical status class,treated for jia,,,,primary systemic malignancy,at the time of enrollment.|history of autoimmune pneumonitis,reproductive,,,,,,
6803,,carotid atherosclerosis,aromatase inhibitors,,oswestry disability index (odi),rainbow scale,,,,age.|distance-corrected,more than 1 l,>18 years.|eastern,,,,,,
6804,,hemorrhagic gastric ulcer,drugs used in the study,,american society of clinical oncology (asco) college of american pathologists (cap) guidelines,mesh fixation,,,,disease.|positive margin.|patients,at least twice per day|speak,">1,21mg/dl",,,,,,
6805,,non-obese women.||,conventional chemotherapy,,gsk medical monitor,special precautions).|significant,,,,non smokers|smokers||,within 30 days prior to visual-ice treatment;|xrt,> 3x uln,,,,,,
6806,,higher of neuropathy,sodium-glucose cotransporter,,mm.||ellipsys specific inclusion,periapical x-ray|no,,,,chest wall,at time of transplant surgery)|candidates,>20|binocular visual acuity,,,,,,
6807,,respiratory failure.|active pulmonary,crp,,hcv rna pcr obtained,pelvic radiotherapy|turp,,,,radical cystectomy.|planned urinary diversion,planned to continue after,<100g/l;|having,,,,,,
6808,,urinary problems,compounds of similar chemical or biologic composition to carv3-team-e,,ptt,cheneau-toulouse-munster brace,,,,interfere with cooperation with the requirements of the trial.|patient,after the first line of treatment|age,≥5 mm,,,,,,
6809,,nidcd clinical investigator,rai,,becker,lung imaging shows,,,,heterogeneous,after multidisciplinary discussion|the,above 40 °c,,,,,,
6810,,odd,iq,,ncep atp,p2- disorganization item,,,,myocardium in regions remote from area of intended scar exclusion,for 3 days before and for the duration of the study.|willing to collect,≥ 35 kg/m2,,,,,,
6811,,months.|heel pain,rheumatoid arthritis4,,age|presenting vas score,local standard-of-care assessments available,,,,invading the gi tract,following features:||increased expression of myc,<90 days|pregnancy|intracardiac thrombus,,,,,,
6812,,status,conventional orthodontic appliances,,international normalized ratio [inr],dopaminergic treatment,,,,uln).|patients might,within 3 days before the start of the study,5-26).|wraparound,,,,,,
6813,,alcoholic steatohepatitis,urat1 inhibitors,,hepatitis b core antibody,radical radiotherapy (≥66gy),,,,non-exposed group,in the last 3 weeks.|known,<18 and ≥80 years.|shock,,,,,,
6814,,diabetes).|pulmonary disease.|neurologic disease.|psychiatric disease.|hepatic disease,fatigue,,american college of rheumatology criteria,oral anticoagulation therapy,,,,time intervals between ct,throughout the study period until at least 6 months after the last dose of study drug,= 12.5 days,,,,,,
6815,,other diseases associated,component of the study products.|drug dependence,,apa,electrocardiogram (ecg) abnormality that in the opinion of the investigator would preclude safe participation in the study.|patients,,,,low imaging quality,within the 6 months prior to randomization,>2× upper limit of normal (uln),,,,,,
6816,,variable immunodeficiency,alpha-tocopherol,,residual diameter stenosis,quantitative polymerase chain reaction (qpcr),,,,plasma-derived fix protein products,unknown onset time,>5%|people,,,,,,
6817,,lymphoma)|irritable bowel,investigational vaccine,,assessment system- icdas,adjuvant cytotoxic chemotherapy,,,,ileal,prior to the initiation of the study medications.|history,> 2x the upper limit of normal,,,,,,
6818,,root pain,anti-interleukin (,,hepatitis c test,consent|terminally,,,,refractory to correction],history to the investigational drug,3:||at least 10%,,,,,,
6819,,assessment confirms,canes,,glycaemia,assessment|good operative,,,,suitable to take,within the last 18 months (duration of treatment,greater than 30 %|pathologies,,,,,,
6820,,breathing,similar effects,,detectable viral load,subscapularis repair,,,,university,within 1 week of first receipt of study drug,6.0 years to <18 years,,,,,,
6821,,cardiac amyloidosis|acute decompensation of hf,cbt,,public health region,enteral nutrition after surgery,,,,pathologically-confirmed,within 12 weeks prior to screening ii,less than 1 year.|heart failure,,,,,,
6822,,glucose-galactose malabsorption|those,montana,,alcohol use disorders identification test (audit,chronic anticoagulant therapy,,,,disease.|adequately treated,throughout the treatment period until,≥ 20 ng/ml||multiple lesions,,,,,,
6823,,use.|unstable cardiac condition,anti-pd-1-based combination therapy|active,,glycosylated hemoglobin,tests)|body mass index (bmi),,,,sclc exception,within three months before study visit 1(day 0)|ocular surgery,"ophthalmic examination),|structural",,,,,,
6824,,chronic disorders|mobile device,sites;|gastrointestinal abnormalities;|cardiovascular,,moca,exercise;|nonsmokers;|no use,,,,preclude cardiac,at the time of enrollment|prior allogeneic transplant,score 0 or 1|age,,,,,,
6825,,tumor pathological examination,olanzapine,,nt-pro bnp,good verbal communication skills,,,,index shoulder surgery,at least 3 months|presence,> 18 years|no,,,,,,
6826,,schizophrenia,drugs altering bone metabolism,,urine test paper test results show,mild residual mr,,,,non-light-based,within 30 days prior to registration.|history of urolift.|contraindications to general,> 1.5 × institutional uln.|total bilirubin,,,,,,
6827,,fallopian tube cancer (hereinafter referred to as ovarian cancer,drug compound,,quantiferon gold test,conventional treatment of hlh|having not achieved,,,,communicable,within the anogenital tract,≥80×10^9/l;|biochemical examination,,,,,,
6828,,esophageal motility disorder,study visits.||exclusion criteria medical conditions||hiv infection,,standard of care inclusion criteria,suppressant therapy,,,,non-fluctuating,within 12 months of completion of 1st line,≥ 4)|self-reported,,,,,,
6829,,type 2 diabetes|access,low intensity therapy,,asymptomatic serum amylase,home oxygen therapy,,,,mental disorders;|inoculate live,for at least 30 minutes|a requirement,"< 50,000/mm3|aspartate",,,,,,
6830,,screening.|blood donation,cisatracurium,,10m walk test,restrictive diet,,,,influence pupillary reflexes,within 14 days prior to initiating study treatment)||note,>90 mm hg,,,,,,
6831,,cardiorespiratory injury,screening.||key,,residual stenosis of,thin film microscopy results|signs,,,,full protocol.||,within the last 1 month,>6 miu/l,,,,,,
6832,,feeling in the wound care,"sprain,|on medication",,ddlps,central coordination disorders,,,,long enough,during the second and third cycle.|ecog (,34 - 36 weeks,,,,,,
6833,,covid-19 pneumonia,immunoresistant,,car-t cells,open biopsy,,,,qtc>470 ms,prior to baseline.|initiation of upadacitinib treatment,<50 ml per minute,,,,,,
6834,,maintenance antimicrobial,anti-arrhythmic therapy|evidence,,gamma gt &,local site investigator/radiology,,,,c1-c5,within the last 12 weeks prior to randomization,12-24 years,,,,,,
6835,,mass excision biopsies,famotidine,,thai binh province|speaks,lennox-gastaut syndrome.|seizures,,,,topical antibiotics|diagnosis,within the month prior to the overnight study visits.|begin/end,"≥ 90 ml/min/1.73 m²,|no proteinuria",,,,,,
6836,,insufficient response,ketamine,,rotterdam criteria|body mass index (bmi),certolizumab pegol,,,,before randomization,in the range of,≤ 0.9.|common,,,,,,
6837,,"aminoamide local anesthetics,|local infection",balneotherapy,,nt probnp,allogeneic haematopoietic stem cell transplantation.|major infection,,,,active volunteers||,within 2 weeks prior to initiation of study treatment|prior,≥3 times per night,,,,,,
6838,,immunocompromised|have comorbidities,α2-adrenergic agonist,,british columbia,risdiplam|upright head control,,,,adequately,within two months prior to treatment,exceeding 3x uln,,,,,,
6839,,controlled eye inflammation,azvudine,,flippin' pain campaign,quarantine per local clinical practice,,,,panic attacks,in the last 3 months|currently participating,= 88 cm,,,,,,
6840,,melanoma|active infection,sulfadiazine,,0.9%]).|hiv-1 rna,fetal surgery,,,,intramuscular,after 8 subjects,0-2|completed,,,,,,
6841,,retinal thickness,interacting medications,,csf cytology|karnofsky,hard exudation,,,,esophagogastric,within the past 3 months;|(screening period/admission,< 18 years|any form,,,,,,
6842,,fetal exposure,fviii inhibitor,,epr-3,mitral valve surgery|patients,,,,requiring urgent care,during the selected study period,> 1.5 times upper normal);|known allergies,,,,,,
6843,,diabetic maculopathy,≤2 mg total daily of,,renal function.|blood pressure,excision of pilonidal sinus.|location of the orifices should,,,,amenable to curative treatment,within 30 days before the first administration,5.0 or higher,,,,,,
6844,,hiv associated malignancy,anti-cd20 monoclonal,,msi-h,blood transfusion,,,,dosing,within 14 days before randomisation 8,greater than or equal to (>=) 25 millimeter of mercury,,,,,,
6845,,acquired dyschromatopsia,capsaicin products,,measurements.|body mass index range,clinical laboratory results,,,,"membranes),|acute",within 3 days prior to initial medication,≥ 12 years|moderate,,,,,,
6846,,skin|carcinoma in situ of the cervix,telitromycin,,blood pressure measurements,top-mini,,,,l1 selected tumors,3 weeks x 6 consecutive,≥18 years.|inoca,,,,,,
6847,,complement-mediated,compounds of similar chemical or biologic composition to pyrimethamine,,beck depression inventory-2 score,|(3,,,,"grade 2, 3, and 4",within the last two years|pregnancy,"i, ii or iii)|in case",,,,,,
6848,,intact membranes,oral hygiene products,,plhiv)|cd4 count,iv|peripheral oxygen saturation,,,,confirmed,within 3 months;||patients,"greater than 18 years,|ii",,,,,,
6849,,homozygous factor v mutation|presence,varicella vaccine,,screening.|hemoglobin below lower limit of normal (lln),intratumoral cavitation,,,,plantar-flexor,within 2 weeks of the baseline visit,>10|acutely suicidal|previous,,,,,,
6850,,xerostomia.|patients smoking,acrylic acid,,pathology containing neuro-endocrine differentiation,cell transplantation,,,,distal radius fracture|re-fracture,for at least 6 months prior to the screening visit.|subject must be able,≥ 100 × 10 ^ 9 / l；|hemoglobin,,,,,,
6851,,ischemic attack,icus,,best corrected visual acuity,completed radical treatment,,,,tumor tissue||,within 2 weeks of start of study intervention,>160/100|av-block,,,,,,
6852,,idh wildtype,components of the study drug,,ranged between grades,dental treatment experience|showed willingness to participate||,,,,severity of these comorbidities,at the onset of stroke,at least ≥ 18.0 kg/m^2,,,,,,
6853,,those,drugs targeting cd38 before administration;|use of any medication,,child-turcotte-pugh (ctp) class,acr 1990;|active tak,,,,scapular dyskinesis,within 14 days prior to the first dose of study drugs,above stage ⅲ,,,,,,
6854,,inflammatory rheumatic diseases,components of the studied drug;|pregnant,,"criteria of ""disease stabilization""",biologic immunomodulatory therapy,,,,severity of the hallucinations,in past 3 months||interested,< 1.5 times the upper limit,,,,,,
6855,,ischemic symptoms,quinidine,,thyroid replacement medication.|may,excipient|patient,,,,successfully performed,within the past 72 hours|pregnancy|anemia,level iv,,,,,,
6856,,pathological fractures,formoterol fumarate,,visual analog scale (vas) correctly,pop repair surgery,,,,intolerance)|tobacco,prior 3 months,higher than the upper limit of detection,,,,,,
6857,,anti-cancer,anti-tachycardia pacing,,ats/ers standards,cardiovascular disease||,,,,varicella zoster viral infection,at 4 months and8 months after surgery respectively|patients,">/= 1,500/microl",,,,,,
6858,,cognitive domains,relenza,,uvb therapy,calcaneus osteotomy,,,,old|normal,within two weeks prior to surgery,0 or 1+,,,,,,
6859,,corneal scar)|the,online group therapy,,plasma alat,coil treatment,,,,"sampling,|non-smoker,|no",1 at time of first dose,<10g/dl|platelet count,,,,,,
6860,,gastrointestinal neoplasms,single agent vincristine,,patients|life expectancy,ehr records|stable methadone,,,,lasting more than 2 days,past 3 months prior the beginning of this,≥4 and ≤ 14|have provided written informed consent,,,,,,
6861,,systemic lesions,oral medication,,-cholesterol,pretreatment endoscopic biopsies specimens,,,,adequately resected,within 72 hours before starting study treatment,≥80 cm,,,,,,
6862,,assessment|objective cognitive impairment,pelvis,,acquisition of english before,chronic oral,,,,moderately severe,at screening or day -1.|use,8-36 years,,,,,,
6863,,pulmonary vasculitis,cyproterone,,test for hepatitis b virus serology,living donor candidate per the standard living donor selection process,,,,seizures.||stimulating,occurring less than 30 days before signing the informed consent form,criteria);|the time of the first medication after enrollment,,,,,,
6864,,diastolic bp,chloramphenicol,,ejection fraction.||have,vertebral tumours,,,,compared to experimental product,post-operative,perioperative,,,,,,
6865,,valvular heart disease|10,parenteral antibiotic therapy,,serum human chorionic gonadotropin (hcg),ion-682884-cs2,,,,acr criteria for the classification of ra||18 years|both,within 8 weeks or 5 half- lives,< 25/30)|parkinson disease,,,,,,
6866,,cvvhdf,inducers treatment,,race score ≥5 score,adjuvant dd-ac/t,,,,non-malignant tumor diseases|patients,during all testing procedures);|heavy alcohol consumption,above two years.|unilateral upjo.||,,,,,,
6867,,heparin induced,3rd year student of the,,international classification of headache,fluoride prophylaxis,,,,assessable,pre-disposing,> 20/400,,,,,,
6868,,appendiceal,salicylic acid,,gestational age,treatment should,,,,electronic tablets,within 28 days of the first dose of study product,>10 cigarettes per day,,,,,,
6869,,castleman s disease,exam gloves,,household enrolled,biopsy-proven mcd/mesgn/fsgs recurrence,,,,castration-resistant prostate cancer (crpc),in the second test may be included in the study;|need,more than 12 and,,,,,,
6870,,hemorrhagic shock,path,,car t-cell therapy,maintenance regimen,,,,schulich school,"at least 3 days a week,|turkish native speakers,|for",18 to 30 kg /㎡；|operation,,,,,,
6871,,nephrectomy.|patients,intravenous (iv),,ffpe block,partial hydatidiform mole can,,,,non-dysplastic,at home|icu admission,greater than the upper limit of the normal value of the laboratory department of the research center)|contraindications to metformin,,,,,,
6872,,knee trauma,immune-related adverse event(s),,tamoxifen)||additional exclusion criteria,β-hcg,,,,severity of crs,within 1 month|started,worse than 6/18,,,,,,
6873,,lipodystrophy,low density lipoproteins,,childhood autism rating scale-second edition).|the,endovascular coiling procedure,,,,following:||serum m-protein ≥0.5 g/dl,30 days prior,<100×109/l)|inadequate,,,,,,
6874,,unresectable malignant pleural mesothelioma|ecog performance status,local anesthesia,,lymphoma:||• phase iia,ventilator to maintain spo2,,,,timi,within the last 2 weeks|individuals,over 40||,,,,,,
6875,,systemic autoimmune rheumatic diseases,tirzepatide,,modified functional ambulatory classification score,treatment;|prior treatment,,,,g/24 h,for at least 6 weeks before the first dose of study treatment,>3 cm,,,,,,
6876,,cardiac dysfunction.|acceptable liver,area,,body mass index (bmi),definitive resection,,,,papillary,for at least one month in the study hospital,< 60,,,,,,
6877,,end of evt procedure;|use,anti-asparaginyl-(anti-ks,,hemoglobin ≤10.5,pelvic oncological resection,,,,non-anti-tumor,within the previous 30 days.|subject,≤ 30.0 kg/,,,,,,
6878,,acquired immune deficiency syndrome,contraception.|aged,,included.|best corrected visual acuity (bcva),hematopoietic stem,,,,non-septic,within the 90 days prior to screening,greater than or equal to (>=) 0.5 grams per deciliter,,,,,,
6879,,"pregnancy,|lack of health",eosinophilia,,osteoarthritis research society international (oarsi) atlas|had,cognitive disorders|peripheral vascular disease,,,,grade iii or iv heart function,greater than 0.2mm,less than 30 days before inclusion;|pregnancy,,,,,,
6880,,bronchitis|allergy,cardiotoxic agents,,guardianship|parents non-native speaking,subtotal gastrectomy,,,,mild to major dementia,within 28 days prior to randomization,score ≤ 7;|adequate organ function,,,,,,
6881,,anal intraepithelial neoplasia,a+c,,ids-sr16,supplemental therapies,,,,salivary,since last,≥2000 iu/ml,,,,,,
6882,,pregnants,fractionated,,prostate biopsy:||suspicious prostate nodules,open-chest surgery,,,,mri.|postero-lateral,at time of mri scan,less than 5 times per day|report,,,,,,
6883,,urine,5-fu,,hepatitis b virus dna copy number,whole blood donation,,,,acute phase of illness,last 3 months,> 6 mm,,,,,,
6884,,primary peritoneal cancer,topical steroid treatment,,rhizarthrosis dell,structured clinical interview for dsm (scid),,,,mediastinitis|medical,at least 3 days interval,between 2018,,,,,,
6885,,serious hypertension,pcsk9 inhibitors,,covid-19 nucleic acid/antigen for,endarterectomy,,,,american academy of dermatology criteria,7 days prior to first dose.|known,≥ 3.0×109/l.|platelet count,,,,,,
6886,,zinc,synthetic cannabinoid receptor agonist,,checklist individual strength,routine neuroradiological examination,,,,dual,within 1 year after car-t cell infusion,"18.5≤bmi≤23.9 kg/m2),|subjective",,,,,,
6887,,screening.|febrile illness,checkpoint inhibitor anti pd-1,,hepatitis b virus surface antigen (hbsag),comparative genomic hybridization,,,,immune related adverse events,after ppci,at least 300 pg/ml,,,,,,
6888,,non-ischemic intracranial lesions;|patients,thyrotropin,,inr can be safely reversed to≤1.7,tendon thickening,,,,sars-cov-2 vaccination,at least one patient,>2,,,,,,
6889,,lumbar spinal stenosis,sglt2 inhibitor family drugs,,sars-cov-2 pcr test,quit cc smoking|reports,,,,american joint committee on cancer（ajcc）of eighth,tygacil on the day of liberation|prior adverse events after application of vancomycine,upper limb ≤ 3|no,,,,,,
6890,,positive read,fish oil,,blood function,therapeutic puncture,,,,primary series,within 4 weeks before screening.|active,5 times,,,,,,
6891,,impairment of immunological functions,oral corticosteroid[s,,arm t)|platelets,vertebral column|history of,,,,behavioural difficulties,during the last 90 days prior to screening.|lack of suitability for participation,≤ 1 mg/mg,,,,,,
6892,,urea cycle,baloxavir marboxil,,1236g,arrhythmias|history,,,,lasting at least 1 week,from 28 days prior to the baseline examination,exceeding 450 ms,,,,,,
6893,,restrictive lung,immunosuppressive agents.||(4,,blood.|platelet count,fragility hip fracture,,,,suitable for skin biopsy|body mass index,at the signing of informed,<2 mm,,,,,,
6894,,hsv,psv,,urine screen,herbal therapies,,,,m-2|scheduled for elective day-case lower abdominal,past year)||limited emotion awareness,> nyha class ii,,,,,,
6895,,physical damage.|doctor disapproval.|be,iron-deficiency anemia||,,tir,cardiac bypass surgery,,,,endocrine factors,within 1 month prior to day 1,> 50.0 kg.||,,,,,,
6896,,lambert-eaton syndrome,psychopharmacological agents,,plasma creatinine,fluid infusion,,,,clavicle,within 3 months of procedure.|previous,>20%.|block hf,,,,,,
6897,,therapy.||inclusion criteria - phase,strong cp3a4 inhibitors,,doi,renal ultrasound,,,,protocol-defined inclusion/exclusion criteria may apply,less than 6 months||,<40 mg/dl m,,,,,,
6898,,renal sympathetic denervation,parenteral depot corticosteroids,,homa-ir index,regimen||adequate organ function,,,,influence of drugs,within 28 days of,< 45%;|left,,,,,,
6899,,expanded disability status scale,hilt,,dsm-iv ptsd checklist,cycling exercise|prescribed medication to control heart rate|prescribed medication,,,,hematopoietic system,in the past 3 months,> upper normal value (uln),,,,,,
6900,,aortic valve disease,bcrl,,harm-benefit ratio,respiration monitor electrodes,,,,corneal graft|anticipated,within 3 years;|participants,v1 and v2).|subjects,,,,,,
6901,,candidate for curative therapy,peptide 1 (glp-1) receptor agonists,,covid-19 less,ercp lithotomy,,,,primary tumour)||exclusion,at least 4 weeks prior to the first treatment.||male participants:||a,>1 mg/dl,,,,,,
6902,,previous malignancy,strong p450 cyp3a inhibitor,,pregnancy test|clinical,examination.|total worc percentage score,,,,active component air force personnel assigned or,within two years from screening,≥3 ×uln and r value,,,,,,
6903,,protection statement,permanently move,,serum-pregnancy test,pacemaker insertion,,,,only - currently,prior to undergoing any screening,<uln,,,,,,
6904,,primary health care - basic health unit,anti-vascular endothelial growth factor receptor,,cervical disc herniation|history of,normal activities,,,,oa grade,for at least 30 days after the last dose of study drug:|refrain,18 or above age,,,,,,
6905,,difficulty breathing);|patients,potassium hydroxide (,,paediatric records;|age,contrast brain mri,,,,after pain onset,within 3 months prior to surgery.|correction,≥ 20).|bladder outlet obstruction,,,,,,
6906,,non-intubated,asprin,,total shoulder arthroplasty,device|impairment of gi function,,,,duchenne muscular dystrophy (dmd),past medical history.|subject,score of ≥16|all participants,,,,,,
6907,,randomization:||no fever,satisfy,,steroidal anti-inflammatory drugs (nsaids),entry,,,,preclude the application of fnirs device,within 72 hours prior to the first blood draw|participation,long-term covid-19-related,,,,,,
6908,,congenital fetal malformations,compounds of similar chemical or biologic composition to actoplus met,,creatinine ≤2.0x,bacteria,,,,meeting the criteria for international classification of diseases,for 4 months after the last dose of,4-weeks,,,,,,
6909,,anterior communicating aneurysm||,immunostimulants,,partial thromboplastin time (ptt),β-site amyloid precursor protein,,,,non-live covid-19 vaccination,at least 6 months apart - peak,>=6.0 secs,,,,,,
6910,,chcc-cc,conventional treatment,,≤60|meld-na score,markers;|a blood sample,,,,amenable to response assessment,5 to 6 points).|the,<40kg/m2.||,,,,,,
6911,,clinicians,adjunctive wound therapy,,visual aβ positron emission tomography,reactive astrocytes of,,,,problem.|pregnant,within 24 hours.|no,18-32 kg/m2(inclusive);|male,,,,,,
6912,,infraclavicular brachial plexus block,drug-active,,af)|lateral e/e,gastrointestinal polyp resection,,,,removed|vital,within 30 days prior to prior to day 1 of protocol therapy.|prior treatment with,>480 msec.|ongoing,,,,,,
6913,,painful cycles,rspo2/3,,"recist version 1.1, locally assessed.|programmed death-ligand",anal prolapse surgery,,,,lifestyle|clinically significant,during the participation in the interventional phase of the study,0-90 +/- 10 degrees.|individuals,,,,,,
6914,,pregnancy|elective cesarean delivery.||,psychological disease.|relative,,ehr,routine blood,,,,cylinder,during time 1,≥ 1 cm,,,,,,
6915,,throat swelling,drug metabolizing enzymes,,obligatory,lesser tuberosity osteotomy,,,,non-central nervous system (cns),within 1 month of receiving ultrasound delivery|current smoker,≥160 mmhg sbp,,,,,,
6916,,acids supplements|current,oral glucocorticoids,,atm,oct,,,,containment,within 4 weeks of cycle 1 day 1,≥100 × 109,,,,,,
6917,,chronic kidney disease-epidemiology,antihypertensive drug,,function child pugh grade,frequency ultrasound,,,,intro-ocular,within foot,equal to 5 times the half-life of the drug,,,,,,
6918,,attention-deficit/hyperactivity,human immunoglobulin,,ans|person,deformity|previous contralateral major,,,,simple urinary tract infection,30 days,> 100 years|pregnant|breastfeeding,,,,,,
6919,,neuritic symptomatlogy y referred.|rigid claw,teriparatides,,institute of health stroke scale,right ventricular lead implantation,,,,a:||cd20-positive,within 30 days prior to day 1 of protocol therapy.|live vaccine,<50%|supraventricular arrhythmia,,,,,,
6920,,hyperkalemia,components of study drug,,ethinylestradiol +,required.|able to read,,,,stone|severe obesity|arterial aneurysm,within 1 year prior to screening|administration,score of 0-2.|patients,,,,,,
6921,,ischaemic attack,compounds of similar chemical or biologic com-position,,adt + enzalutamide,complete full course of fmt treatment;|the clinical,,,,any other diseases,for at least 12 weeks,>3x upper limit of normal (uln),,,,,,
6922,,intravascular structures|reversible cause of af,alcon,,ecg.|pr interval,pancreatic pseudocyst,,,,score high,within 6 weeks prior to visit 1,120 mg,,,,,,
6923,,"revascularization,|diabetic retinopathy",rms,,salvage therapy.|ecog performance score,systemic oncological treatment,,,,absorbable,within 2 weeks prior to day 1.|has used,>= 100 x 109/l|aspartate,,,,,,
6924,,mds)/acute myeloid leukemia,hydroxychloroquine sulfate treatment,,normal value,major treatment,,,,are:||inclusion,within 3 months of day 1,10-39,,,,,,
6925,,chronic heart failure;|platelet count,mianserin,,english.|visual acuity,treatment|pregnant,,,,researchers judged that there was a risk of hemorrhage;|within the first 5 years of administration,within 2 weeks prior to trial,>/= 65 years,,,,,,
6926,,surgery;|connective tissue disorders,over-the-counter vitamins,,cns metastases|history,organ transplantation;|poor control of,,,,catchment of selected rural health centers;|provide informed,within past 12 months,≥ 24|ability to understand and willingness to sign written informed consent document|negative,,,,,,
6927,,thin greasy moss,analgesic drug,,serum total bilirubin (tbil),spirometric maneuvers,,,,her2- unresectable,during the 6-month period before study,icsi)|under 38 years,,,,,,
6928,,localized at level th5 to l5 and verified,monoamine oxidase inhibitors [maois],,crusade score,small cell carcinoma,,,,≤grade 1,five half-lives,< 25%|mean pulmonary pressure,,,,,,
6929,,junction disorders myasthenia gravis,platelet-derived growth factor b (pdgfb),,wide qrs,simultaneous treatment,,,,clinically important,within 5 years before screening,2-6 years|being,,,,,,
6930,,physical risk from the study procedures,low-molecular-weight heparin,,total bilirubin [tbil,tone management,,,,mental health services,complication;|history,<25%|the patient,,,,,,
6931,,diseases of blood,hypertension medications,,aorta diameter,unclear progression.|arm 3 only,,,,non-alcoholic fatty liver disease,during the screening period and before the first administration>38.0℃,45-60 years,,,,,,
6932,,spastic diplegic,total lymphatic irradiation,,aspect,oral isolated mandibular fracture fixation,,,,alli)|prescribed,for at least one year)|have,>2 times,,,,,,
6933,,pneumococcal disease,osmf,,hepatic function,root;|aortic valve replacement associated,,,,high dose tbi (≥10gy),in the past month.|unable to stop,≥ 1.5 × 109 / l,,,,,,
6934,,cerebral arteriovenous malformations,thin veins,,car t cell therapy,health examination,,,,pd-l1 directed immunooncology,within 30 days of screening|any other,65 - 80)|asa,,,,,,
6935,,pdd,intervention;|known hereditary,,equinoxe proximal humerus fracture,treatment field.||clinically significant (cs) medical conditions making implementation of the protocol,,,,colorectal polyps|no address,while subject,< 53|pain over,,,,,,
6936,,biochemical pregnancy losses,inhaled nitrous oxide/oxygen.|progressive,,lost blood,testing of fsh levels,,,,african american,after enrollment into the,<90% of birth weight,,,,,,
6937,,chronic cholestatic disease,topical dermatologic,,cough peak flow (cpf) measurement,lateral skull|upper motor neuron facial palsy|segmental muscle,,,,gluten|smoking|alcohol,within 180 days prior to consent,≥ 9/g/dl,,,,,,
6938,,non-melanoma basal cell carcinoma,antitussive medication,,american society of anesthesiologists' physical status,c|mental incapacitation,,,,influence the autonomic nervous system,within 12 weeks,class a or b,,,,,,
6939,,hemiparesis,medication known to substantially affect sleep,,oral hygien.||,a:||medically,,,,iv).|recent,during the duration of the study.||,relevant abnormal history,,,,,,
6940,,febrile convulsions,proteins,,kidney function abnormalities,revision surgery|infections|other implants,,,,grade i cardiac,at the time of surgery.|previous,≥ 35 kg/m2|those,,,,,,
6941,,hormonal abnormalities,oligo,,black/african,coronary angioplasty/stenting/bypass grafting,,,,non-oncological reasons)|concurrent,"over 18 years old||being literate,|computer can be",greater than or equal to 85th percentile,,,,,,
6942,,language impairment;|peripheral vascular disease;|severe cardiovascular disease,systemic anti-tumor therapy,,preictal mrs score,placement of vascular access devices,,,,basement,continue to receive them,"<30%|unable to understand the risks, benefits",,,,,,
6943,,rheumatoid disease|patients,hydrocortisone,,pain.|age,rimegepant,,,,lh-rh analogue,within four weeks before enrollment,upper limb function,,,,,,
6944,,end-diastolic,realgar-indigo naturalis,,overall survival,bone anabolic drugs,,,,iv).|documented,at the time of recruitment|moribund,between 55-100 beats per minute)||have normal,,,,,,
6945,,conditions of immunosuppression,growth hormone;|sexual precocity;|abnormal liver,,peripheral plasma cell ratio,suitable stem cell donor identified,,,,moderate-vigorous physical activity per week|have diabetes,during the clinical screening visit.|metal implants,< 3 × 109/l;|women,,,,,,
6946,,candida cultures,rescue medications,,indicated)|platelet count,menstrual cycle,,,,sterilised,in the past,0-2.|patient,,,,,,
6947,,adenocarcinoma of the breast|performance status,components of the device.|participants,,recist definition,local anesthetics;||communication barriers,,,,outdated,within 6 months prior to signing the informed consent form,"< 100%|≥50%, <70%",,,,,,
6948,,vegfr,part,,serum human chorionic gonadotropin test negative results,smoking cessation pharmacotherapy,,,,upper limb intervention,at least one measurable soft tissue tumor lesion,i-ii|competent to provide,,,,,,
6949,,oral supplemental probiotics,aspirin tablets,,bipap,allogenic hematopoietic stem cell transplantation,,,,patient|selecting,within 6 months of head trauma,"≥ 100,000/μl|absolute",,,,,,
6950,,accessible lesions,anti-tuberculosis treatment;|subjects,,logists:||age,session (solarium),,,,inhalants,through 120 days after the last dose of trial,0-10)|are,,,,,,
6951,,borderline personality disorder,ethylene vinylacetate,,bone marrow function||haemoglobin,regular smoking|dietary,,,,non-binaries,for ≥ 30 days prior to the first dose of study treatment,36 to 71 months,,,,,,
6952,,acute decompensation,nex-20a,,speaking|american society of anesthesiologists (asa),lateral scapular slide test.||,,,,tumor treating fields is,within 3 months prior to the scheduled day 1,≥ 18 years.|patients,,,,,,
6953,,bleeding on probing,its components,,respiratory support of,lines of standard therapy,,,,symptomatic,within 2 years except,greater than 9%,,,,,,
6954,,progressive multifocal leukoencephalopathy,vyvanse,,mild physical activity,dietary intervention,,,,subject|a vasectomized,within 7 days prior to initiating treatment,iii,,,,,,
6955,,"4,200 feet",ocular drug release device implantation,,alcohol use disorders identification test (audit),small cell lung cancer;|patients,,,,graft,5-year,7-9,,,,,,
6956,,disseminated disease,arthroplasty.|patients,,prone position||,computed tomography scan,,,,months:||uncontrolled,more than 3 prior,4-symptom questionnaire,,,,,,
6957,,clarify the etiology,k-max,,psoralen,palliative radiation,,,,etc.|history of severe,for at least 3 months after the last dose of nm8074||highly effective contraceptive methods,≥ 100 x 109/,,,,,,
6958,,brain metastases;|uncontrolled pleural effusion,luteolin,,cmu||,common carotid artery diameter range,,,,cyclodestructive,48 hours before the first administration to the end of the study,< 1000 copies/ml,,,,,,
6959,,alveolar soft part sarcoma,anti-cancer treatments,,stage iii hypertension;|hepatitis b,ventilator-associated pneumonia,,,,one unit of alcohol,within the shoulder,≤ 93% or|pao2/fio2,,,,,,
6960,,iiic disease,benralizumab,,hiv-1 rna,organ transplantation,,,,situation.|previous,currently taking daily,>7,,,,,,
6961,,"consciousness,|active alcohol",non-live vaccines,,apri,completion of assessments and/or intervention,,,,6,for at least 2 years before enrollment - capable of giving signed informed consent,> 4|aged over 18 years,,,,,,
6962,,therapeutic injunction|pregnancy,themself,,recist 1.1.|organ functions,copy of the phe508del mutation.|healthy volunteers,,,,ambulatory liver,throughout the study unless,9-13 years|prepubertal|capability,,,,,,
6963,,solid tumors only,reason|meets criteria,,recist 1.1).|evidence of ras,"intra-vascular coagulopathy ""dic"".|the patients",,,,besides,on the last post-operative,≤ 70)|co-morbid,,,,,,
6964,,chronic dialysis|there,tercian,,international normalized ratio (inr) ≤1.5xuln,gastric potential of hydrogen (ph),,,,excellent,within 7 days of ischemic stroke,≤ 0.3,,,,,,
6965,,chlorazol black preparation,monoamine oxidase (mao) inhibitor therapy,,uln).|bilirubin,local intervention (surgery,,,,eac)|clinically staged - ct1-4,for at least 28 days prior to the first dose.|persons,<2.6 x uln)|lipase,,,,,,
6966,,high risk mds,immune globulins,,definition from american cancer,vats-thymectomy,,,,after inadequate biliary drainage,past 2 weeks.|history,<3|the platelet count,,,,,,
6967,,tumors.|chronic respiratory pathologies,ivig-sars-cov-2,,alveolar bone volume and height,immunohistochemical detection,,,,american academy of dermatology consensus criteria,within 14 days before screening;|consuming,<7.00,,,,,,
6968,,normal tympanic,study drug||,,severity score,anticoagulation/antiplatelet therapy,,,,transient,post-transplant,positive symptom,,,,,,
6969,,unpleasant sensation,teae,,hepatitis b or c,hematological function#||-white blood cell count,,,,suitable for tavi.|patients,prior to study enrolment.|study participant,0-1;|there,,,,,,
6970,,chronic kidney disease)||adult,beta,,promis anxiety,logmar;|corneal endothelial cell count,,,,impairs their ability to swallow,in an exclusion period,>=10 milligrams per deciliter,,,,,,
6971,,risk,reside,,clearance creatinine,complete remission,,,,abi,before starting study treatment,diagnosed;|the,,,,,,
6972,,gastrointestinal surgery|have type i diabetes|thyroid disorder,intranasal steroid,,unless,coronary artery bypass grafting performed,,,,stomach,within the 2 years before screening,18-35|spherical equivalent,,,,,,
6973,,xerostomia,nitrous oxide sedation,,urea,transient increase in stressful experiences|use of,,,,two,within 14 days prior to registration)||unless,>60 ml/min,,,,,,
6974,,baby intubated,"hormone receptor agonists,|current",,18f-fdg-pet scan,rhinoplasty,,,,proportion of peripheral blood b cells,after chemotherapy treatment,160-170,,,,,,
6975,,internal jugular,citicoline,,mgh cancer center,fine motor tasks,,,,large vessel occlusion,in 4 weeks prior to inclusion,between 19+6 and 36+6 weeks,,,,,,
6976,,parp inhibitor-resistant,tyrosine kinase inhibitor,,bone marrow transplant.|not,world health organization|recent,,,,years.||histologically confirmed,at least 6 weeks elapsed after autologous,>/= 30 mg,,,,,,
6977,,inflammatory pathology,defective,,hepatitis b core antibody positive,delayed implant,,,,stage 2(copd)||,for the past 6 months|able to participate in,40-70 years|agreed,,,,,,
6978,,active hepatitis,panoramic,,preclude blood sampling|fear,bone marrow radiotherapy,,,,in either,up to 4g/day to treat mild discomfort.|use,≥ 400 ng/l,,,,,,
6979,,dislocation of the elbow;|treatment,global acne evaluation,,ehs classification,tissue types,,,,stool pathogens,within 48 hours prior to ablation,≤ 78 and ≥ 24 letters,,,,,,
6980,,lumbar disc herniation.|have,vyepti®,,average amount of,electroconvulsive therapy|prior treatment,,,,absolute values,at least 1 of the,> 17/30)||exclusion criteria,,,,,,
6981,,seizure disorder,anlotinib,,employed,stay to undergo longitudinal microdialysis|absolute neutrophil count (anc),,,,researchers,before starting hormone replacement,over 159 mmhg,,,,,,
6982,,endotracheal intubation||,cidarabine,,gsw,endovascular revascularization,,,,prophylactic use):||blood routine,within 28 days before participating in this study or before a sufficient wash-out period|patients,score of 6,,,,,,
6983,,pleural effusion.|uncontrolled hypertension,tiragolumab unsafe,,70|body mass index,intravitreal injections,,,,notes below.||•,during dental examinations|the dentist,1.1 criteria);|basically normal,,,,,,
6984,,rare brain tumor.|signed,propofol,,months|willing,clinical investigation plan-required follow-up visits,,,,cervical surgery|head,tanning history,greater than 350,,,,,,
6985,,aud,antidepressant medication regimen,,human immunodeficiency virus (hiv) infections,muscle biopsy procedures,,,,central nervous system involvement,at the time of cell procurement,more than 3;|the target,,,,,,
6986,,cephalic presentation,radioimmunoconjugate,,stage iva,pharmacological treatments,,,,invading adjacent organs,at initial screening,≥ 19 and ≤ 50 years,,,,,,
6987,,distant metastatic disease,eliminate,,prick test,chest pain|known allergy,,,,low-volume,for at least 2 weeks prior to study treatment,15-29 ml/min per 1.73 m2.|did,,,,,,
6988,,mrd positivity,parenteral anticoagulants,,deers,cardiopulmonary diseases|previous cardiothoracic,,,,above 2 g/day,within 30 days of index procedure.|prior vascular surgery of the target lesion.|lesion length,above institutional,,,,,,
6989,,unable to read,prediabetic state,,singleton gestation,open ppgl resection,,,,specifically including,for at least 6 months (180 days),class i,,,,,,
6990,,therapy|age,treatment drugs,,adult gastroenterology division,cardiovascular magnetic resonance examination,,,,l1-4,during the trial.|normal body weight,18-100 years,,,,,,
6991,,serum sickness,graft rejection drugs,,serum transaminases,ocular pharmacotherapy,,,,multiple,during the 7 days prior to randomization,≤ 75%,,,,,,
6992,,criteria||evidence of hepatitis b,phentermine,,alkaline phosphatase (alf).|biochemistry:,curative intent treatment,,,,"between 05:00 and 10:00, based on",for at least 90 days after the last dose of bmt,at least 5,,,,,,
6993,,hypokalemia,anti-retroviral therapy (art),,ipss scale,behavioral health consultant,,,,non-smoker,within 6 months prior to screening visit,long-term online,,,,,,
6994,,pdt-2,compounds of similar chemical or biologic composition to sunitinib malate,,communication function classification system for individuals,emergency surgery|life expectancy,,,,cannulation site;|patients,within prior 7 days|women,less than 30 ml/min.|participants,,,,,,
6995,,displaying covid-19-related symptoms,incisional intraocular glaucoma surgeries,,stage iia-iiic,rescue stenting,,,,contrast.|pathologically,pre-medication,≥ 60% on inclusion,,,,,,
6996,,anxiety disorders).|psychotic disorder,trismus,,cpap without pressure,alkylating therapy,,,,transfusion-dependent,in the past 2 months,between 20 to 30 years,,,,,,
6997,,graft failure,trial components,,systemic blood pressure (sbp),surgical sperm extraction,,,,block;|previous,within 7 days of screening chronic antacid,between 18 years and 80 years,,,,,,
6998,,carotid artery dissection,cotrimoxazole,,vanicream™,endourological stone surgery,,,,muscle biopsy,for at least 4 weeks prior to study enrollment.||treatment,x 100 <90%]|infant,,,,,,
6999,,oral tetracyclines,medicine specialist,,who classification.|prior allogeneic,wrist surgery,,,,characterized,within 24h|patients unable to consent,≤50 ml / min / 1.7,,,,,,
7000,,limb fractures.|patients,physiologic corticosteroid,,stool sample||,lumpectomy,,,,durable,within 90 d prior to screening visit,≤ 3x,,,,,,
7001,,spinal cord metastases,isolated,,creatinine clearance rate (ccr),discharge from the research quarantine unit.|any condition,,,,down syndrome.||patients,in last 3 years|known,<9 g/dl,,,,,,
7002,,corneal opacities|patients,3cl protease inhibitors,,pcr test,allogeneic tissue/solid organ transplant|known active central nervous system (cns) metastases,,,,dramatically,at least 2 tests,> 38 c,,,,,,
7003,,ccf,mri|congestive hepatopathy|iron deposition|pregnancy,,hepatitis b surface antigen at,invasive monitoring of icp,,,,influence gastric emptying,within the next three years.|only-eye,92% or higher,,,,,,
7004,,skin dermabrasion,nodular liver,,who growth standard|weight,postoperative imaging studies.|willingness,,,,lutetium lu 177 dotatate,at time of informed consent.|no,>0.5 but <10,,,,,,
7005,,incontinence-associated dermatitis,ehlers-danlos,,beck anxiety inventory|meets criteria,chemistry panel,,,,dutch language||,within 24 hours;|subjects deemed unsuitable,<1.0×109/l,,,,,,
7006,,arteritis,multivitamin,,hepatitis c virus [hcv] antibody serology testing),molecular assay,,,,"dietary supplements, probiotics",in the 28-day period before the start of chemotherapy|any pre-existing,four separate occasions.||,,,,,,
7007,,human immunodeficiency virus (hiv) antibody positive;|abnormal chest x-ray,prophylactic steroids,,liver metastases|hemoglobin ≥9.0 g/dl|platelets,allowed;|chemotherapy,,,,increasing risk of,within 2 cm of the selected treatment area|acid-containing,>6 months,,,,,,
7008,,extensive micro,equivalent)|local steroid,,anps,line of treatment,,,,immune related,within the united states.||,≤ 2 × upper limit of normal value,,,,,,
7009,,learning,systemic anti-infection treatment;|renal diseases,,recist version 1.1.||adequate bone marrow,cpi,,,,primary care|not currently,within 30 days prior to implantation of any type,< 105 beats per minute,,,,,,
7010,,breast-feeding|congestive heart failure|chronic obstructive pulmonary disease|chronic renal failure|those,ocular antimicrobial solutions,,chronical pathological skin conditions,"hiv-1 antigen,",,,,grade two or above,during one month before saliva sampling.|patients,<36'c,,,,,,
7011,,similar conditions per investigator judgement,sedative hypnosis,,simultaneously enrolled,regular drug control,,,,schedule.|able to swallow medication.|subjects,within 3 days prior to receiving the first dose of study drug,>0)|california residents|wifi,,,,,,
7012,,judicial order.|is under the age of legal consent,tmz,,cuti,fascicular blocks,,,,surgery|ocular malignancy|proliferative diabetic retinopathy,during the study;|current,≥ 20 years|subject,,,,,,
7013,,hyperandrogenism,nonspecific s-t,,creatininemia,diagnostic coronary angiography,,,,bcor-altered,at least 1 psychotropic treatment,installation.|≥70% of hhs,,,,,,
7014,,criteria for treatment resistance,anti-iga antibodies|prior vaccination,,values consistent,kidney function tests,,,,axillary,at the time of intervention;|patients,35-,,,,,,
7015,,extramedullary plasmacytoma,cephalosporin,,thyroid-stimulating hormone (tsh ≤ 10,pathologic root resorption.|external root resorption,,,,bronchiolitis|a,within 48 hours from onset.|decrease,≥7.5% to <10%|part b,,,,,,
7016,,endocrine issues,letermovir,,left ventricular hypertrophy,autologous car-t cell therapy.||eastern,,,,lower limb functions,for 1 year or more,more than or equal to 1.7 mmol/l|high-density lipoprotein,,,,,,
7017,,iiia,active drug,,rome criteria,immuno-suppressive drugs,,,,femoral,at time of registration,18 years or above,,,,,,
7018,,sensory impairments,decreased;|patients,,orthostatic blood pressure,adoptive cell therapy,,,,suitable for existing,at the time of sampling,20-50)|unstable,,,,,,
7019,,nantes,immunosuppressive drugs.|any,,pleural effusion,bone marrow aspirate,,,,glucose,more than 2 weeks prior to the microwave,household member of person with laboratory,,,,,,
7020,,hypothyroidism stable,vitamin d,,hfnc,ras mutation status,,,,extrahepatic deposition,within 4 weeks prior to first dose.|had a history of,upper limit)|renal function,,,,,,
7021,,urea cycle enzyme defect,dobutamine,,t4,examination.|active ocular herpes zoster,,,,stage 1.5-,during run-in,0-1|expected survival,,,,,,
7022,,neurosurgical tumor,drug related toxicity,,aspartate aminotransferase ast,regimen.|provision of evaluable tumor sample,,,,"non-interventional study,|patient",within the range of 18.0 to 29.9 kg/m²,75mg qd,,,,,,
7023,,pain classified on,sglt2 inhibitor.|hepatic hydrothorax|hepatic encephalopathy,,researchers should ensure,poor control of hypertension,,,,preclude compliance with the protocol,throughout this period.||female partners,≥160 mmhg,,,,,,
7024,,thrombophilic disorder|hepatitis,supplements containing,,peri-implantitis treatment,higher dose of,,,,hemi-diaphragmatic palsy,within 3 months after the last dose of study drug,8 to 13 years;|under the condition,,,,,,
7025,,perennial airway allergy,lymphoid tissue tumors,,bone marrow,ct scan,,,,non-restorable maxillary,for 6 months after the final dose of,≥ 40 kg,,,,,,
7026,,hepatitis b core ab [hbcab],ra,,systolic lv function,pulmonary embolism|history of,,,,castration-resistant prostate,prior to cohort entry date|3,class 2,,,,,,
7027,,diabetic keratopathy,l-[ring-13c6]-phenylalanine,,ich volume,epidural steroid injection,,,,site plaque psoriasis,at the time of onabotulinumtoxina,≥ 90 mmhg);|abnormal,,,,,,
7028,,lsil,thrombopoietin,,visual acuity:||best-corrected distance visual acuity (bcdva) score,first-line antiviral medication.|voluntarily sign the informed consent form.||,,,,ebv-positive,during the study period;|in recent three months,≥16 at screening|currently participating,,,,,,
7029,,liver disorders,thallium redistribution nuclear study,,liver / renal function,ventilation support,,,,implant-associated,72 hours prior to or,1.5xuln per institutional,,,,,,
7030,,c-virus,over-use,,alt ≤3 x uln,rheumatology consultation,,,,et-based therapy,before the screening visit,"< 30 ml/min/1,72",,,,,,
7031,,tachyarrhythmia,immunosuppressive therapy;|pregnancy;|breastfeeding;|allergy,,spherical equivalent lens power,hypercapnia,,,,"write turkish,|hemodynamically stable,|no previous experience",within 4 weeks of the first dose of study intervention.|administration,<50ml/min,,,,,,
7032,,colorectal cancer,chronic systemic immunosuppressive therapies.|patients,,unl.|glomerular filtration rate,venous serum blood glucose,,,,central nervous system,less than 4 weeks from the first study procedure.|patient,less than 60 g/month||,,,,,,
7033,,coffee,thymidine phosphorylase (,,aerobic activity,student risk screening scale-externalizing,,,,highly effective birth control measures,within 2 weeks prior to the first use of the study drug,18|no t2dm or do,,,,,,
7034,,retinal vascular,oral hypoglycemic agent(s)|lifetime use of serotonergic psychedelic drugs,,posttraumatic stress disorder checklist,reactive hiv-1 antibody,,,,non-resorbable,1 week to 6 months|medical research council scale,< 0.8cm³)|history,,,,,,
7035,,pregnancy|consumed decongestions,nicotine replacement products,,child between the,cephalometric digital radiograph,,,,festival,for 48 hours prior to time 0 (,18 years or older|physically capable of engaging,,,,,,
7036,,interpretation|cardiogenic shock,strong inducer,,muscle strength in,nerve root,,,,ventricular,at the time of obtaining consent|current participation in a mibc clinical trial,200 ml or more,,,,,,
7037,,primary mitochondrial disease,lebrikizumab may,,mean pap,preterm delivery,,,,checked,at the time of ovarian stimulation,<30%|patients,,,,,,
7038,,substance abuse|infection,atezolizumab,,normal sex hormone levels,day|fetal growth restriction (fgr),,,,radiation-related toxicity requiring,no,18 to 79 years,,,,,,
7039,,bullous pemphigoid,anti-vascular targeted drugs);|hbsag,,bourgogne franche-comté'|fluent,ip plus,,,,acutely,within 28 days prior to start of protocol therapy||oxygen (o2),5 or higher,,,,,,
7040,,end stage lung,components of cm310 injection,,general ability index (gai),physical,,,,> 1 month,within 12 days before dosing,> 2x uln|12-lead resting electrocardiogram (ecg),,,,,,
7041,,papillary thyroid cancer.|patients,microbiota derived peptides.|prior chemotherapy,,adjustment of,propofol|emergency surgery,,,,mepolizumab|allergen,at night for at least 28 days before the baseline visit until the completion of the month 2 visit;|has,> 100 mm hg diastolic,,,,,,
7042,,necrotic lesions,bovine-derived,,bone density|acute orthopedic problems,debulking surgery,,,,complete the inspection autonomously;|voluntary,in the past 6 months|current consumption,<35g/l,,,,,,
7043,,iocbp,inhibitors of complement factors,,treated;|ecog systemic state,magnetic resonance angiography(mra,,,,unavailable,in the next 6 months;|nervous,"≥ 30% and ≤ 90%;|before the screening period,",,,,,,
7044,,controller medication(s,fish oil supplements,,hypertension)|oxygen saturation,upper abdominal surgery,,,,b7-h3 antigen expression,since at least six months before the beginning of the study,> 1 to 2 × uln,,,,,,
7045,,hypoproteinemia moderate,anti-tuberculosis therapy,,brca,cardiac surgery,,,,breastfeeding||concerns related to glucose metabolism||i,during run-in phase,≤ 3.0 mg/dl,,,,,,
7046,,solid organ transplant.|participant,amikacin/,,average score,despite,,,,subacute stage,within 10 days before receiving the first dose of the study drug,≤ 0.70,,,,,,
7047,,her2 positivity,phenytoin sodium,,lost sight,therapeutic education program|patients,,,,plantar ulcer,during the experiment.|participation in other,>450 ml,,,,,,
7048,,drug-induced myositis,types,,bpm.|electrocardiographic qtc,lipid-lowering agents,,,,non-valvular,for at least 2 weeks after participating in the study,≤3.0 x uln,,,,,,
7049,,concomitant injuries,component of the investigational product.|prior treatment,,tak-771-3005.|if,blastocyst transplantation,,,,clinically uncontrollable,during the trial|history of alcohol,between 18 and 30 years,,,,,,
7050,,randomization.|active hemorrhage,interferon inducers,,treated,microdiscectomy)|having surgery,,,,non-breast feeding,for at least 6 months after treatment,>nyha i,,,,,,
7051,,local skin condition,hdac inhibitor,,glomerular filtration rate estimation|left ventricular ejection fraction,lewy body dementia developed,,,,post-thrombotic syndrome||-,within 4 weeks or 5 times the half-life time,≤ 70 years,,,,,,
7052,,waldenstrom's macroglobulinemia,dopaminergic agonists,,stature,dxa imaging,,,,stage 2).|aki,within 14 days prior to planned,22-01-t0037,,,,,,
7053,,solid organ transplantation;|received,ci622,,male|,lumbar spine.|mri results,,,,central nervous system disease,within 4 weeks prior to start of trial medication|left,<30 ml/min/1.73m2||pregnant,,,,,,
7054,,solid mass in ct,antihistaminics,,silness gingival index (gi),standard treatment plan,,,,non-inhibitor participants,72 hours,< 55 years|bmi,,,,,,
7055,,unresectable metastatic colorectal cancer|failure,fruit acids,,smmt score,atg,,,,structurally related compounds,within 3 weeks prior to cycle 1 day 1|concurrent therapy,between 18 to 75 years||,,,,,,
7056,,chronic tinnitus,anti-tumor system,,serum preganancy test,individual must:||be,,,,selinexor.|serious,up to 14 days after the last administration date of the investigational product,18-75|underwent coronary artery bypass surgery||,,,,,,
7057,,portal pulmonary hypertension,pi3k inhibitors,,esc,local assay being used if the limit of detection,,,,post-traumatic stress disorder,at baseline <2;|subjects,between 20 and 64 years,,,,,,
7058,,pre-invasive cervical cancer).||4,tnf receptor-associated,,alanine aminotransferase(alt,homicidal risk.|participants,,,,inflammatory,at least 1 week before first dose of study drug,at least 6 weeks,,,,,,
7059,,fundus diseases,live vaccination,,ldl cholesterol levels,structured clinical interview for dsm-5,,,,black church,throughout the study treatment period.||patients,greater than 100 mmhg,,,,,,
7060,,major bleeding,grapefruit-containing products,,quantitative viral levels,chlorhexidine,,,,intra-orbital debris,during the trial;|participating,at least 12 weeks|world,,,,,,
7061,,other malignancy,acinar cancer.|de novo,,airline flight,equivalent||,,,,indications,in the past three months prior to the study,< 8;|there is,,,,,,
7062,,non alcoholic fatty liver disease,profile|high-grade trochlear dysplasia,,total bilirubin≤1.5 times the upper limit of normal,peripheral nerve procedures,,,,hemolysis)|in,during for 90 days after the study.|cognitive ability for possible to make self-decision,0 or 1|magnetic resonance imaging (mri)-confirmation of,,,,,,
7063,,transformation,bupropion/naltrexone,,fasting glucose≥,systemic treatment adt +/- arat,,,,middle third of dentine confirmed,in the past 12 months;|any,>5 mmol/l;|age,,,,,,
7064,,2c8,swallowed corticosteroids,,normal|inr,treatment of non-autoimmune,,,,non-pharmacological methods,within the previous 5 years;|documented,less than 1.0 mmol/l,,,,,,
7065,,hypocalcemic seizure,non-clozapine antipsychotic,,serum creatinine (cr) ≤1.5 uln,teen,,,,mother|non-viral hepatitis,prior to initial γ9δ2,"> 50,000/microl|mds criteria",,,,,,
7066,,priority,consent||,,oral hygiene||,etc.)|receipt of vaccination,,,,months)|non-surgical periodontal therapy,at the time of signing the informed consent|bmi 25-40 kg/m2|stable,> 45|contraindications to,,,,,,
7067,,behavioural dysregulation,diphenoxylate,,specifically serum creatinine,antiestrogen therapy,,,,paresis induced,"during activities,|insidious onset of symptoms not",≥4).||,,,,,,
7068,,thrombotic thrombocytopenic purpura|high clinical,dopamine,,old|life expectancy,invasive treatment,,,,extraction|molars,during three-month period of study,6-17 years old diagnosis of hefh,,,,,,
7069,,intracranial large vessel occlusion,strontium,,screening.|body mass index,oxygen inhalation therapy,,,,influence the vital prognosis,"within 4 weeks, donated blood",> 3.0 pg/ml 2,,,,,,
7070,,ischemic vascular disease|leg ulcers,tegaderm®|inaccessible,,stenosis,global impression severity,,,,abuse.|active smoker,managed with replacement therapy.||history,-24kg/m2,,,,,,
7071,,physical disabilities,anti-cd20.|ecog≤2.|adequate hematologic,,"generalized cancer,|a medical contraindication",tympanic membrane|anatomy,,,,gender reassignment,within 4 weeks prior to screening;|subjects unable to cooperate,>2 nights per week,,,,,,
7072,,severe heart disease,arb drugs,,criteria).|good physical condition,valve surgery|known,,,,low bp,within 6 months prior to the 1st dose of investigational,>40 milli-international unit/ml,,,,,,
7073,,systemic treatment.|participant,systemic immunomodulate treatment,,immunoglobin a antibodies,function tests,,,,u10.9,at least one extracranially measurable,> 14mmol/l|ph < 7.25|serum bicarbonate,,,,,,
7074,,clinical cervicitis,hba1c readings,,national cancer institute organ dysfunction working group hepatic impairment classification:||arm a normal hepatic function,clinical treatment,,,,measured anytime prior,while taking the medication|women,≥ 18 years|healthy volunteers or volunteers,,,,,,
7075,,drug-refractory symptoms,peptide receptor agonists,,outside ipsilateral levels,regular vaccinations,,,,non-clinically significant,less than 1 month.|intra-articular knee pathologies,greater than or equal,,,,,,
7076,,mental health disorder,docetaxel).|distant metastases,,serum bilirubin excludes,injection of spvn06.|subjects with,,,,injection site|for,for at least 3 months prior to enrollment,3-9 months|participation,,,,,,
7077,,formula.|renal insufficiency,anti-dopaminergic medications,,dialysis,hepatitis b vaccine,,,,suitable for postoperative radiotherapy,after receipt of,pregnant|before 24 weeks of pregnancy|having,,,,,,
7078,,coronary heart disease,selective serotonin-norepinephrine reuptake inhibitors,,hepatitis c (hcv) antibody,anthracycline therapy,,,,mallya cap,at the time of either the pre-study medical evaluation,>480 ms.|has,,,,,,
7079,,acute respiratory syndrome-coronavirus 2,topical steroid injections,,rr systolic,change,,,,greater than ctcae grade,within 6 months of completion,>20ng/ml.,,,,,,
7080,,melanoma in situ,hgl,,alcohol test,functional ileus|patients,,,,hypomanic episodes,within 14 days prior to the first study treatment;||4.2.3,score of 20% or more,,,,,,
7081,,concomitant liver diseases.|alt,role,,epworth sleepiness scale,b-cell depleting therapies,,,,gad-7||,at least 3-4 times a week,≤ 1.5 mg/dl|aspartate transaminase (ast),,,,,,
7082,,congenital malformation,pde4 inhibitors,,hepatitis c virus (hcv) ribonucleic acid,gastric cancer|patient,,,,nsclc:||stage iv,<30 days,≥45 and ≤80 years,,,,,,
7083,,close friends,baseline|a,,patients:||age,adult trauma centers,,,,external,between september 2015,>325mg/day,,,,,,
7084,,mechanical spine,contraceptive measures described,,oral blood sugar,clear pathological diagnosis,,,,specifically veno-arterial extracorporeal,during the study.|known,"between 18 and 65,|individuals without",,,,,,
7085,,unilateral pain,bleomycin,,strong memorial hospital/sharp healthcare,recognized,,,,cancer,within 30 days of screening,100-299 µg/l,,,,,,
7086,,understanding of norwegian,gov2,,triglycerides,diagnostic imaging modality,,,,visit||1 nor,within 28 days prior to first dose of study treatment.|live,<20 score,,,,,,
7087,,hip trauma,osteopathic,,nursing undergraduate,hospitalization|n-terminal pro-brain natriuretic peptide,,,,performing,within 30 days of the first dose of,>uln,,,,,,
7088,,fibrillation|chronic obstructive pulmonary disease,neisseria meningitidis serogroup,,ptga,montreal cognitive assessment|able to read,,,,non-surgical cervical cancer,within 8 weeks of visit 1.|do not,18-67 years,,,,,,
7089,,qt prolongation,medication for hypertension,,screening||※ bmi,clinical exam,,,,greater than 10 mg/day,history of,> 50ml/min/1.73m2,,,,,,
7090,,huntington disease,adenovirus vector vaccine,,carbon monoxide diffusion test (dlco),paleo,,,,other curative hormones,15 days prior to the beginning of the study.|variations,< 5%,,,,,,
7091,,congestive heart failure|cerebrovascular accident|transient,cdk2 inhibitor,,abcd2 score,surgical repair of pectus excavatum.|young,,,,tb).|serious,within 7 days prior to randomization)|elevated crp,≤ -0.5,,,,,,
7092,,congenital long qtc syndrome,drug abuse|pain intensity below 4 in the region of interest,,beck depression inventory-ii (bdi-ii),smart,,,,equation;|is judged to be,at least 1 month prior to screening - a double,1.1 non-measurable,,,,,,
7093,,metastatic adenocarcinoma,prescription anticoagulation,,axial length,pelvic region.|patients refused,,,,expanded standard kidney donor,at least 1 cytotoxic chemotherapy agent,greater than 75,,,,,,
7094,,congenital of acquired|chronic anal fissure|active rectal inflammation,anti-cancer therapy|known severe,,estimated duration,concern,,,,c-reactive protein,in the past 14 days prior to dosing.|poor peripheral venous,greater than 290 mg/dl,,,,,,
7095,,"diabetic neuropathy,|active otitis",concomitant medications,,urine pregnancy test|in,thyroid replacement hormone,,,,could lead,during the 3 months prior to screening,> or =2||,,,,,,
7096,,intubation;|chronic pneumonia,n-methyl-d-aspartate,,anticoagulant regimen|negative hiv test,thyroidectomy,,,,bw/4 weeks,within 3 months|use of,<100 000/mm3|white,,,,,,
7097,,clinical adverse events,ketone,,hepatic diseases|thyroid,12-lead ecg;|thyroid-stimulating hormone (tsh),,,,days|central,at time of signing icf.|eastern cooperative oncology group (,≥50%;||women of,,,,,,
7098,,rheumatoid disease,tension type,,pharyngeal molecular swab,include:||user-independent methods,,,,non-nodal lesions,for at least three years,between 30 and 70 years,,,,,,
7099,,adverse events (ctcae),antibody-based treatment for chl|prior solid organ transplant|prior allogeneic stem cell transplantation|live vaccine,,gorno-tempini criteria)18,revisional bariatric surgery procedure,,,,lateral neck position,within the prior 15 years.||,<55%.|participant,,,,,,
7100,,incisional hernias,prescription medicinal products,,qtc,pet/ct scan|individual the investigator otherwise considers ineligible for participating in the study [,,,,lasting 24 hours,within the last year prior baseline visit,"15-35 years,|able to provide informed consent,|residing",,,,,,
7101,,anca vasculitis,alopecia.|patients,,rome iv criteria for functional dyspepsia|who,b-cell activating factor,,,,influence the immune system,before starting therapy.||has a,> 3 months,,,,,,
7102,,abbott,topical antibiotics,,liver metastasis;||• alkaline phosphatase (alp),smoke,,,,aneurysmal,within 8 weeks before enrollment|oxygen,"rate,|greater than or equal to 50",,,,,,
7103,,progressive organ dysfunction,premedication for,,baseline|life expectancy,gross visual examination,,,,likely to affect vision,within 3-6 months,14-19 y).|fully,,,,,,
7104,,elbow humerus,metolazone,,nakata index,single-bolus,,,,between january 2016,at least 1 year prior,"older,|at least 18 years",,,,,,
7105,,milk products|mustard allergy|participating,intraorbital,,acr bi-rads categories,transarterial radioembolization,,,,barbiturate-containing medications,within 30 days prior to study vaccination.||*high-dose,greater than 42 kg/m2|subject,,,,,,
7106,,diseases;|oncological diseases,deterioration,,left ventricular function,mental health||,,,,any grade. non clinically significant,within 7 days before colonoscopy|patients,greater than 2.0 mg/dl,,,,,,
7107,,difficult|refusal,concurrently medications,,botox,endotracheal intubation invasive ventilator time,,,,estradiol 2 mg+ dydrogesterone10,within 4 weeks prior to study treatment,>5.5% for 30 day mortality.|patients,,,,,,
7108,,vegan diet|lactose,antiaggregant medication,,ild/pneumonitis,individuals|regular cannabis,,,,slow-release,at least 2 of 3,≥ 18;|being,,,,,,
7109,,particular diseases,crossbite,,study.|neutrophil count,asthma control test (act < 20,,,,before covid-19 vaccination,during the period of the trial|must be willing to wear,female-,,,,,,
7110,,immune system disease,pyronaridine tetraphosphate,,prothrombin time（pt,e-book informed,,,,suitable to participate,in at least 4 of 5 body regions,≥ 30 ml/min/1.73m2,,,,,,
7111,,skin-related condition,cyp p450 3a4,,nutrition literacy level,cycle,,,,interventional chair,within the range of 18.5 ≤ bwi,< 125umol / l,,,,,,
7112,,conditions not expected,low-dose,,anisometropia,autologous platelet cryopreservation,,,,icd-10: c00-c97,within 2 cm of the selected treatment area|artificial tanners,above 5 times the uln,,,,,,
7113,,bipolar disorders.|presence,prescriptions,,dsrs score,nsclc exists,,,,site investigator|genomic dna analysis,at the time of the intervention.|over 70 years,>460 msec,,,,,,
7114,,primary cervical cancer,botanical,,bone level,iia indication,,,,any other,medical history review,18-50 years)|female|me/cfs,,,,,,
7115,,"disseminated intravascular coagulation,|were",none ability,,urea values,her2 alterations (,,,,site infection|uncontrolled diabetes mellitus|uncontrolled,within 3 months prior to intervention,≥ 60ml/min,,,,,,
7116,,lower urinary tract symptoms:||inclusion,drugs that impair bone quality|diagnosis,,muga scan,heart rate (hr) response,,,,likely to lead,within 48 hous;|the,25-30 cm|patient,,,,,,
7117,,communication deficits,coroflex®,,enrollment.|ecog performance status,ic-mpgn,,,,clinically indicated.|single rooted,within 3 weeks prior to screening,better than or equal to 20/40,,,,,,
7118,,stage,angiotensin converting enzyme,,left ventricular end diastolic pressure,blood chemistry profile,,,,severe pelvic inflammatory disease.|active lower genital tract infection.|pregnancy.|women who do not,within 7 days before vaccination;|immune-boosting,≥ 3 months after initiation of treatment,,,,,,
7119,,cesarean delivery.|multi gravida,anti-platelet therapy|contraindications,,old|eastern cooperative oncology group (ecog) performance status,poor tomography quality,,,,secondary metastatic,past month,0.8,,,,,,
7120,,distant lymph node,neuroprotective drugs,,months|current suicidal ideation,percutaneous transthoracic needle biopsy,,,,endometriosis-related condition,during the projected study period,≥40 mmhg)|oxygen dependent,,,,,,
7121,,clinical indication lesions,live birth)||key,,hbsag are excluded,placement|previous surgery,,,,pathogenic,within 6 weeks prior to the first dose of investigational medicinal product (imp)|study participant,18+ years old,,,,,,
7122,,carious exposures,obinatuzumab,,standardized mini mental state test,tcf3-hlf,,,,suitable for plasma exchange,at the time of signing the consent form,<97 ml/min,,,,,,
7123,,radical prostate cancer surgery,left,,european association for the study of the liver,cilioablative procedure,,,,substances of abuse,over 19 and individuals,at least 24 hours after resolution of,,,,,,
7124,,pulmonary embolism|type 1 diabetes,tobacco on clinic,,rapid plasma reagin test (rpr),validated immunohistochemistry (ihc),,,,discharge diagnosis,within 6 months prior to signing icf|autoimmune disease,class ii,,,,,,
7125,,acute cholecystitis;|participants vaccinated,ad,,metastases resection||r0,percutaneous tibial nerve stimulation (ptns),,,,implanting physician.|be capable,at time of informed consent|adenocarcinoma,> 1.5);|acute,,,,,,
7126,,resting sinus rhythm heart rate,herbal remedies,,hair loss;|hiv antibody test results,standard of care fish testing,,,,large cerebellar infarction,within =< 28 days prior to registration).||creatinine =< 1.5 * upper limit of normal (uln),>=200 milligrams,,,,,,
7127,,transit metastasis,therapies targeting the androgen pathway,,child-pugh a;|ecog,special dietary requirement,,,,diagnostic and statistical manual of mental disorders v (dsm v),one month before enrollment.|body mass index (bmi),18-49)||ii,,,,,,
7128,,cholecystitis||concomitant liver,administrate milrinone,,cage questionnaire,human immunoglobulin.|received any,,,,1;|prohibited,within 2 weeks prior to the first study treatment;|clinically significant,0-2;|patients,,,,,,
7129,,i̇ntracrabial pathology,hypericum perforatum,,serum creatinine clearance,sessions,,,,user manual of the visumax option smile|presence,within 3 months prior to study enrollment|patient unable to walk|patient who,≤3× uln,,,,,,
7130,,chronic sinusitis,thermopulsation,,antibodies,reconstructive flap surgery,,,,opioid use disorder,at the puncture site;|pregnancy,"lower than 1,500/μl",,,,,,
7131,,interaction,study drugs,,urine protein creatinine ratio (upcr),css therapy,,,,suitable for inclusion evaluated,in the last 3 months|voluntarily sign,50% of the total calories,,,,,,
7132,,modify,prestin,,bone marrow involved)||absolute,verbal rating pain scoring,,,,neurological flushing,6 months to 8 years,greater than equal to 300 picograms per milliliter (pg/ml,,,,,,
7133,,myocardial infection,antiseptics,,xiaoaiping tablet/injection,checkpoint inhibitor,,,,lymphocyte percentage,within 14 days prior to the first dose,being 65 years,,,,,,
7134,,oxa,punch,,alanine aminotransferase(alt) continues,first dose of drug.|unstable,,,,postnatal,following previous/concomitant,≤ 45 years,,,,,,
7135,,autoimmune hepatitis.|the,immediate post-operative mri,,cage,epithelial ablation.||,,,,subtotal,prior to radical surgery;|normal marrow function,30-59 mmol/l,,,,,,
7136,,lactation|atrial fibrillation,or|anaesthetic consultants,,food protein-induced,chest x-ray|history,,,,middle of the night/early,within the last 6 months prior to screening,parental/guardian consent,,,,,,
7137,,vegan diet|intolerant,immunosuppressive medication,,index stroke,neuroendocrine differentiation of,,,,obviously unstable,within 2 weeks prior to randomization;|has participated in other drug,≤ 1.5 times uln;|normal thyroid function,,,,,,
7138,,complaint complex,coagulation dysfunction;|patients,,car t-cell administration,cervical arthroplasty,,,,tumor tissue samples).|the results of,within 14 days;|patients,45 ml spirits,,,,,,
7139,,myelomonocytic leukemia,anti-neoplastic,,trial.|acute coronary syndromes,combined resection,,,,aucun autre traitement que la chirurgie,at study start,between 2 to 12.5||,,,,,,
7140,,resected carcinoma,ipilimumab-nivolumab,,hepatitis b virus carriers,lumbar fusion for fracture,,,,rapamycin.|pregnant,within 7 days before the study,greater than or equal to 5.0 mm,,,,,,
7141,,diabetes syndrome,tobacco-based products,,screening thyroid stimulating hormone,drug elimination half-lives,,,,large joint (0 points,in the last 6 months and|not,>=90 mmhg||,,,,,,
7142,,severe arthritis,tazobactam,,gestational diabetes.||,pathological confirmation,,,,suitable for enrollment,in the past 3 years|no,18 to 30 years,,,,,,
7143,,teeth from central incisor,antibiotics,,mgh-atrq|at screening,organ function:||bone marrow reserve:|anc,,,,protein-based,within 1 week before the baseline visit.|known,3iq)|able to,,,,,,
7144,,hcv)|pregnant,mappyacts,,static physician global assessment (spga),total thyroidectomy|patients,,,,partial dose of ntla-2001 was received.|a,in your past history|accompanied by,≤ 10.0 mmol/l.|no,,,,,,
7145,,hr+,medication to treat,,nerve disorders|epilepsy|a copper spiral,spect exam,,,,requiring treatment|patients,after exclusion of cystic fibrosis,less than or equal to 60 minutes,,,,,,
7146,,vehicles,components or excipients of the inavolisib,,uln)|absolute neutrophil count (,autologous hct,,,,intra-parenchymal,at least 2,> 60ml/min.1.73m2||aged,,,,,,
7147,,cervicogenic headache,efalizumab,,points;|life expectancy,pocus exam,,,,alternative medicines,within six months.||,≥ 18 years|bicuspid,,,,,,
7148,,muscle spasm,anti-sars,,bcg treatment.||histologically,professional working,,,,suitable for participation in this trial by the investigator,prior to the first dose of study drug.|the,younger than 35 and older than 75 years,,,,,,
7149,,premenopausal,monoamine oxidase inhibitors.|symptoms,,alanine transaminase (alt)≤3 x uln,elemental diet,,,,hit).|medically confirmed,within the intervention framework.||inclusion criteria,above 95,,,,,,
7150,,vascular problems,dasatinib,,left ventricular ejection fraction(lvef,consider pacemakers,,,,igg) replacement,in the last 8 weeks before study entry|patients,"scores i - iii,|aged",,,,,,
7151,,intertrochanteric femoral fractures,ocular,,forced expiratory volume in the first second (fev1),australia antigen),,,,symptom-relieving medication,at the time of consent.|recent diagnosis,12 to <18 years,,,,,,
7152,,diopters.|corneal thinnest pachymetry,decarboxylase inhibitor,,dako herceptest™ score,50 g spirits,,,,covid-19.|tobacco,prior to enrollment||significant trauma,at least 21 kg/m2,,,,,,
7153,,abnormalities making insertion of the focal one® catheter difficult.|anatomical abnormality of the rectum,braf inhibitors,,modified aids clinical trial group (atcg) kaposi sarcoma response,hemorrhoidal prolapse,,,,ichd-3).|first,covid-19.|history,<35% .|the target lesion,,,,,,
7154,,seizure attack,cgm,,cr clearance,physiotherapy,,,,effects.|presence of,within 6 months before randomization.|subject,<4,,,,,,
7155,,solid organ transplantation.|patients,excipient,,children's depression rating scale,safe anaesthesia,,,,non-english speaking|other medical conditions,at least 4 weeks before,score 0-1|the subjects participate voluntarily,,,,,,
7156,,hepatic impairment|adequate organ,smile,,both genders|aging,standard concurrent intensity-modulated chemoradiotherapy,,,,in-house clinician,within 30 days prior to entry.|cd4+ t-cell count,65 years old,,,,,,
7157,,egfr,statements,,serum creatinine,surgical operation of,,,,meeting any of the following criteria,within the past 12 months prior to screening,≥18 years|vas pain level,,,,,,
7158,,acute on chronic liver failure,cyp3a inducers/inhibitors,,cardiac color doppler ultrasound ejection fraction,hours|baseline platelet count,,,,mental retardants,within 28 days of starting bevacizumab,≤10 g/dl,,,,,,
7159,,malignant ms|non-cooperation,immunoenhancers,,icf);|sex: male;|body weight,abdominal surgery,,,,donate,prior to participation in the trial||males:||,> 3 times uln,,,,,,
7160,,adnexal mass,supplements|ppi therapy|known,,gd1 severity scoring system,immunomodulatory agents,,,,upper limb,for up to 3 months after last dose of study drug,visit ii,,,,,,
7161,,type-2 diabetes,belgium,,modified mayo score,screening;|chest x-ray,,,,iliac arteries,at least 7 days before the first dose of study treatment,4-10 ng/ml|if prior,,,,,,
7162,,transfusion,tegaderm ®,,human immunodeficiency virus infection (hiv),rehabilitative intervention,,,,dependence.|smokers.|clinically significant abnormal laboratory results,in the previous 3,< 4 mm,,,,,,
7163,,drug abuse;|in the 6 months prior to study entry,medications used in the study.|patients,,anti-nuclear antibody (ana),lumbar fusion.|patients,,,,american joint committee on cancer (ajcc) version,within 3 months before screening|new york heart association,≥ 38.0 °c [100.4 °f,,,,,,
7164,,interval,st. margaret hospitals|high levels,,animal mycology (isham) working group 2013 criteria,clinical blood chemistry measurements,,,,nissen,within the normal range|serum creatine,≥ 140/90,,,,,,
7165,,mentally handicapped|participants,oral antibiotic,,bm pc,autologous hematopoietic stem cell transplantation.|ecog score 0-1.|meet the following requirements,,,,≤80 years;|the,within 4 weeks before the first dose of the study note: physiological doses,< 1.0×109/l,,,,,,
7166,,altered muscle anatomy,daily medications,,10|during remission,kmt2a-rearranged,,,,hormone-sensitive breast cancer.|chemotherapy-induced,in 3 months prior to screening,5 or more times a week,,,,,,
7167,,bleeding difficulties,duloxetine,,alcohol breath test.|received,follows:||age x (,,,,long covid-19 3 months from the onset of covid-19,at least 1 week prior to ivs-3001 infusion except,10 cm scale|bilag c,,,,,,
7168,,distant metastasis;|active autoimmune diseases,pus aspirate,,recist 1.1.|age,visit|ocular topical povidone iodine use,,,,completed,at time of diagnosis|patients,<25 ng/ml|estimated,,,,,,
7169,,rhtnk-tpa,scan,,ecog ps||,limited exercise,,,,unbalanced,within 1 year after cell infusion,7 to 12|must,,,,,,
7170,,acute medical crisis,drug-induced liver injury (,,muscle function,trabeculectomy,,,,mild to moderate covid-19 infection,within 8 weeks of baseline visit.||,≥ 1.5/nl,,,,,,
7171,,premature coronary heart disease||,sglt2) inhibitors,,moffitt cancer center/|adult,somatic examination,,,,rescreened,at screening and baseline with,>= 1.5 x 10^9/l|platelets,,,,,,
7172,,medial mastoid muscle,anti-lipid,,i.e.,immunomodulatory treatments,,,,ischaemic,within 12 weeks prior to enrollment,between entre 34 weeks,,,,,,
7173,,superficial femoral artery,rehabilitation regimen,,bone marrow regeneration,vasopressor therapy,,,,without measurable disease,in the week prior to the intervention.|hypertension.|pregnant women.|inability,>=,,,,,,
7174,,renal disease variables,frenulum,,minnesota research authorization retrieval tool).|patients,stent-assisted,,,,patella,within the last three months|participant,less than 12 months|the,,,,,,
7175,,breast cancer|confirmed diagnosis,dexamethasone,,anti-hiv antibodies,emergency department access,,,,best-corrected visual acuity (,at least 30 days prior to administration of imp,+/- 15%,,,,,,
7176,,hemostatic defect,immune related neurologic,,new york heart association.|subject,screening.|have plasma cell leukemia,,,,unidentified,at least one year,> 8% hb <10 mg/dl,,,,,,
7177,,fdg,systemic contraceptives,,ymrs score,tavr/tavi,,,,insulin use|current,within one week after the occurrence of,15-25|at least one year,,,,,,
7178,,srs,sodium iodide,,sebbin integrity,electronic implant,,,,mumps,during the study treatment period and within 6 months after the end of the study treatment period.||the,00.|able to give informed assent,,,,,,
7179,,viewing of audiovisual material.|difficulty understanding,hormonal contraceptive implant,,mpas - mycophenolate mofetil,delayed treatment control,,,,upper respiratory tract,during the screening phase,between 2014 and 2018|received,,,,,,
7180,,iridium,acting beta2 agonist (laba),,bone marrow function,"athletic sleep screening questionnaire""||",,,,gums)|thin gingival phenotype,during the study|patient,< 50mmhg or,,,,,,
7181,,non-biologic,opioid,,hdl cholesterol levels).||,rapid antigen test.|documentation in a medical history,,,,3-recent,within 28 days before the first administration,between 3 and 6 months after the event);|asia,,,,,,
7182,,chronic kidney disease epidemiology collaboration (ckd-epi,emicizumab,,panel sequencing|eastern cooperative oncology group (ecog) performance status,emergency surgery(intestinal obstruction,,,,treatment|hypertrophic,in the past 1 year|clinically confirmed,≥ 10% of the total bsa,,,,,,
7183,,chronic gi disorders,medicinal products,,uv exposure,emergent gastrectomy,,,,under their current medication]|current,within 4 weeks prior to first dose of decoy20,<2.0 mmol per litre,,,,,,
7184,,prolonged exposure,hazelnut,,apnea-hypopnea,12-lead ecg examinations,,,,suitable for subjects to participate in the study,at the following,>= 3,,,,,,
7185,,fshd1,selective fgfr,,luteinizing hormone-releasing hormone (lhrh) analogs,robot-assisted radical prostatectomy,,,,problems|pre-inclusion allograft thrombosis,during their participation in the study|resting,18 to 75 are eligible on the day of signing the informed consent,,,,,,
7186,,benign prostate hyperplasia,licensed covid-19 vaccines,,braf genes,vascular endothelial growth factor (vegf),,,,30%≤fev1<80%)||uncontrolled,within 28 days prior to and,score of 9 or higher.||,,,,,,
7187,,hypoxemic respiratory failure,non-steroid anti-inflammatory drug,,characteristics;|gross motor function classification scale,antibacterial therapy,,,,early stage,within 60 days prior to study initiation.|personal,between 90 to 109mm of hg,,,,,,
7188,,traumatic cervical spinal cord,live-attenuated vaccine,,diastolic blood pressure,agents|topical phosphodiesterase type 4,,,,american college of obstetrics & gynecology,before enrollment to rule out mi.|corrected qt interval,< 50.000/mm3)|contraindication,,,,,,
7189,,acute onset vertigo||,retinoids,,therapy|platelet count,produce te voice.||,,,,c5-t6)|classification,within 1 week before the first medication.(prophylaxis,≥10 letters,,,,,,
7190,,intranodal lesions,systemic opiates,,atients:||age,ozone inhalation,,,,influence the iron status.|vegetarian athletes.|having,at time of screening.||has,≤ 60 ml/min/1.73 m2.|severe hepatic insufficiency /,,,,,,
7191,,myotonic dystrophy,anti-glycyl-(anti-ej,,forced expiratory volume in 1 s,antineoplastic therapy,,,,mild to moderate)|not,within 14 days before enrollment.|participants,65 years and,,,,,,
7192,,venous outflow disorder,hypothyroidism;|fridericia-corrected qt interval,,new york health association,technical means,,,,diseases(icd-10);|requires,one month after the last dose of study medication,> 10 times the upper normal,,,,,,
7193,,caffeine sensitivity,azacitidine,,breath test,pathology review,,,,any grade,with the exception of,≥ 470 ms,,,,,,
7194,,coagulation disorder|pregnancy,strabismus (exotropia or,,hypospadias repair|raised serum creatinine,rabies vaccination,,,,before liver,in the four weeks prior to inclusion|vaccine refusal||indication,≤200 ms,,,,,,
7195,,collagen vascular disease,immediate local therapy|leptomeningeal disease|uncontrolled seizures|corrected qt interval,,new orleans metropolitan statistical area,violent crime victimization,,,,mellitus|concomitant malignancy||6,during the baseline 30-day diary assessment,less than 6 years or more than 16 years|poor asthma control,,,,,,
7196,,peripheral pulmonary lesions,anti-pd-1 /,,kidney insufficiency||other pet/mr,intraurethral suppositories|prior pelvic surgery,,,,avian,within 1 year of screening/baseline,"> 4,0 iu/l.|combined",,,,,,
7197,,psychiatric reasons,writes english||,,body weight loss,psychotherapy,,,,subcostal retraction,prior to surgery|contraindication to ferric carboxymaltose,≥ 8 years,,,,,,
7198,,plms,low-grade psoriasis,,aminotransferase (ast),findrisc,,,,parents|concomitant,within two weeks before randomization,1 doctors|above 21 years,,,,,,
7199,,progressive central nervous system (cns) metastases,medication required,,cm||body mass index (bmi):,clinical laboratory values,,,,criteria through blood transfusion;|ast,at baseline visit/assessment||experiencing homelessness,short,,,,,,
7200,,other condition,immediate reposition,,uterine cavity|total motile sperm count,control group)||presence of diabetes,,,,insulin dose,within one week (day -7 to day -1) before the patient receives their first infusion of ca9hi-1.|calculated,mental disorders 5,,,,,,
7201,,benign disease,low-grade glioma,,karnofsky,endoscopic ablation therapy of the esophagus.|older than 18 years,,,,site reaction,within 7 days prior to the first dose of trial treatment,< 60 ml/min *,,,,,,
7202,,coal tar,medications disallowed,,give up hct,oral nutritional supplement,,,,full-time|not,"within the first 6 hours of life, continued for 72 hours",≥2+,,,,,,
7203,,spo2<90,oral jak inhibitors,,pituitary function,clear band,,,,sequential temozolomide.||arm,within past six months,< 104 copies /ml,,,,,,
7204,,hz,nucleoside analogue,,by:|creatinine clearance,interventional study.|major surgery,,,,seasonal influenza,during the study period.|concurrent,>95 mmhg.||the patient must,,,,,,
7205,,cardiac disease|chemotherapy,local steroid injections|non-immunosuppressive maintenance treatments,,hcv viral copy number,blood-derived product,,,,pericardial effusion;|active autoimmune diseases,prior to initial administration of the study drug,0-59 months,,,,,,
7206,,rotation)|positive prone instability test|imaging to support a,folic acid antagonists,,level,smartphone,,,,having unsafe conditions,within 2 weeks before screening):||neutrophil (anc,≥ 100 mg/dl||viii,,,,,,
7207,,retinal diseases,protonic pump inhibitors,,lowing inclusion criteria:||triglycerides,botulinum toxin,,,,adjust-unlikely,one month prior to surgery,surrounded 270 degrees,,,,,,
7208,,nutritional status;|neoplasm;|contraindication,antispasmodic,,human immunodeficiency virus (hiv).|use,cbct examination,,,,been diagnosed;|previous,throughout the day on weekdays,≥ 2|severe,,,,,,
7209,,testicular cancer,drugs targeting il-2,,creatinine clearance rate (crcl) calculated,restrictions.|radical radiotherapy,,,,inclusive).||contraceptive use,during their participation in the study kgbi,≥6.5 percent.|hyperthyroidism,,,,,,
7210,,left main coronary artery,speech,,normalized ratio,cumulative dose should,,,,suitable for intensive treatment;|cmml,within 14 days before administration of the study drug;|who,≥ 2 times a week,,,,,,
7211,,nsclc，whose disease,anti-fatigue agents,,iv.|left ventricular ejection fraction,knowledgeable informant,,,,immunization eight,in the past year|used,greater than 35 kg/m2)|patients,,,,,,
7212,,tear.|recent trauma to upper limb.|disorders,ranitidin,,modified response evaluation criteria in solid tumors (mrecist)||,autologous hematopoietic stem disease progression,,,,site of cannulation,within 24 h after substance,convulsive,,,,,,
7213,,squamous cell carcinoma of the,"non-steroidal anti-inflammatory drugs (nsaids,",,serum progesterone level,flowcytometry,,,,instructions untreated,within 14 days prior to the start of study treatment.|inactive vaccines,<1.5×109 / l;|platelet count,,,,,,
7214,,steatosis,intravenous thrombolytics treatment,,pefr,pet imaging radioligand,,,,ankle-brachial index assessment,within the 3 months before the first dosing,at least 63 cm,,,,,,
7215,,medial temporal lobe,st. boniface,,negotiable);|life expectancy,psychotropic drugs,,,,payment,within 14 days prior to study intervention,">= 1,500/mcl",,,,,,
7216,,cord compression.||known hypersensitivity,sequential,,study;|body weight,sentinel biopsy,,,,clinical i-iii tnm stage,within 7 days of tumor harvest|unresolved,> 2.5 uln,,,,,,
7217,,tumor bleeding,fibrates,,arterial partial pressure of oxygen (pao2)/oxygen concentration (fio2),aortic regurgitation assessment,,,,focal neurologic symptoms.|have,in the past 6 months;|a change,≥ 1.5 x 10^9/l|platelet count,,,,,,
7218,,malignant reasons,5-fluoruracil,,nyha classes,note:||local surgery,,,,might interfere with metabolic studies,more than 3 days,> 35).|patients,,,,,,
7219,,tudca,acid,,performance index,functional ambulation scale|willingness,,,,traumatic,in the past three months.|patients,>3.0 uln hemoglobin,,,,,,
7220,,myasthenic syndrome,anti-diarrheal drugs,,birth|height,pet-ct indicate the,,,,investigative site,during the previous 24 hours,≥34 ml/m2,,,,,,
7221,,monoclonal proteinosis,anti-cd-38 therapies,,old.|life expectancy,living-donor related transplantation,,,,timi 2-3 flow,within the last three months|delusional,<30 ml/min/1.73m2,,,,,,
7222,,amount of alcohol,cytotoxic medication,,nationwide children's outpatient,radiographic imaging,,,,primary school level|individuals not being able to read,within six months:|casting|botulinum toxin type-a,< 3.5 meq/l,,,,,,
7223,,peritoneal carcinomatosis,b agonists,,female.|aged,disease control,,,,nursing|active renal,during the study timeframe;||has undergone more than one inpatient,function#||international normalized ratio,,,,,,
7224,,epistaxis,compounds of similar chemical or biologic composition to tomivosertib,,hiv-1 rna level,tricuspid repair,,,,american joint committee on cancer (ajcc) and the international union,within 2 months before measurements|allergy to dairy products|participation,3 to 17 years,,,,,,
7225,,pancreatic necrosis,monoclonal proteins,,ptt/aptt,complex loyalties,,,,protocol-mandated,1 starting 72 hours before the first dose until 5 months after the final dose,grade 0 to 1,,,,,,
7226,,heart valves|epilepsy,clips,,short axis diameter,section,,,,omega-3,within 2 weeks prior to starting study treatment.|radiotherapy,40-75years,,,,,,
7227,,capra,ascending aorta;left ventricle assistance device,,partial cystectomy|previous total colectomy,prescription,,,,"glutamic oxalacetic transaminase≤3 times the upper limit of normal,|renal function",throughout step 3.|ability and willingness,score 0 - 2;|life expectancy,,,,,,
7228,,severe trauma,remifentanil,,nyha classification);|8,revision surgery,,,,ankle-foot orthosis to minimze contributions,menses for 12 months prior,>30 gy,,,,,,
7229,,bleeding beyond control,emergency antibiotics,,ctcae criteria,lipoatrophy,,,,dissection.|bacterial endocarditis,within the past 6 months;|have,≥7.5%,,,,,,
7230,,pulmonary oedema|cardiovascular instability,acromegalia,,adult congenital heart unit,spinal/general anaesthesia,,,,insulin therapy|developing,within 30 days prior to admission to the clinical unit.|a positive pre-study serology test for hepatitis b surface antigen (hbsag),0-3.|patient,,,,,,
7231,,rheumatic diseases,remission-1,,isup,liver surgery volume (open,,,,etc.).|taking,within one month before screening,>85 mmol/mol)|history,,,,,,
7232,,renal impairment group.|glomerular filtration rate,cobalt chromium,,leukemia organ involvement|ast,carotid artery|angiography revealed,,,,considered smokers,within previous year|persons currently involved,18-64|identify,,,,,,
7233,,diabetes mellites,topiramate,,physician|age,whole brain radiotherapy,,,,iteria:||histologically,within the first 3 days after admission);|surrogate decision-maker,qtcf>450 ms,,,,,,
7234,,visible abdominal distention,visualized,,qrisk3 score,coronary events|history of heart failure|known diagnosis of,,,,abnormalities.|clinically significant,within 2-3 days,≥470 msec obtained,,,,,,
7235,,severe bone injury,represents,,uln|prothrombin time (pt) - international normalised ratio (inr) / partial thromboplastin time (ptt),antiepileptic therapy,,,,2,at the time of the index procedure|serious angiographic complication,t3-4n0m0 or,,,,,,
7236,,adenovirus,buspirone,,hbsag test,afternoon working time||,,,,subcutaneous,in the past 14 days|travelled,cohort:||greater than or equal to 18 years,,,,,,
7237,,human immunodeficiency virus (hiv) antibody|history,systematic anti-tumor,,residual interstitial lung abnormalities,asthma therapy,,,,"diagnostic and statistical manual of mental disorders, dsm-5.|patients who are unable to express consent",within 30 days prior to screening.|history of,=< 2.5 times the upper limit of normal,,,,,,
7238,,non-gcb dlbcl,imaging,,sss score,infection|history of organ transplantation,,,,above cushing threshold])|liver cirrhosis,in the past year|insufficient knowledge of the dutch language,< 30 ml/min/1.73 m²,,,,,,
7239,,middle cerebral arteries,nonsteroidal anti-inflammatory drugs|metabolic disorders|smoking|any condition that would preclude the,,coperative oncology group performance status,chest straps|pregnancy,,,,radiographically unstable,within 14 days prior to randomization.|sexually active,12 years or more,,,,,,
7240,,severe pulmonary hypertension,recreational drugs,,"kg|pregnancy|legal protection measure (guardianship, curatorship)|deprived of liberty",global consensus diagnostic,,,,pneumomediastinum,within 14 days of disease onset.||previous participation in this study,> 24 points|walking more than 6 meters independently||,,,,,,
7241,,diverticular stricture,early learning)|child,,intraocular surgeries.||,corticosteroid injection,,,,with spermicide,for the first phase of the study;|those who do not volunteer,19 who understand the purpose of the study,,,,,,
7242,,lactation|major family changes,centers,,angle quadrants,characterizing of freezing,,,,american joint committee on cancer [,during the study period and within 3 months after the last study drug use.||,< 38°c,,,,,,
7243,,fetal chromosomal,anxiolytic drug treatment,,titer of hepatitis b virus (hbv) dna,gt6,,,,intestinal absorption of nutrient and experimental product|serious traumatism,for at least 12 weeks prior to,<= 4 x 10^9 per liter,,,,,,
7244,,carbon monoxide,shp2 inhibitors,,time of flight)-arm sequence,ultrasound guided injection,,,,interfere with cooperation with the requirements of the trial.|any active,within 3 months prior to check,score i to iii,,,,,,
7245,,androgen excess,anti-pd-1/,,hba1c,intracranial disease|anti-tumor therapy,,,,ft538 - inhaled,more than 5 cigarettes,≥ 45 bpm,,,,,,
7246,,brain injury|cognitive impairment of sufficient severity,drb1,,ibs,standard radiotherapy regimen,,,,mdrd method,within 6 months prior to randomization.||have received,below:||hemoglobin 9.0 g/dl;|absolute,,,,,,
7247,,corneal stroma,bal,,transaminase levels (ast/alt,local therapies,,,,"narcotic naïve"" for the purpose of this study",within 12 months of screening.||for,less than 3 months prior to study,,,,,,
7248,,smarca4-deficient tumors)|patients,normal|creatinine,,angle kappa,therapeutic intent.|intent,,,,low handgrip strength,within 2 weeks before screening.|patients,< 60 mmhg,,,,,,
7249,,other illness,venlafaxine,,hepatitis c infection|positive stool cultures,transfusion ≤14 days of screening|aspartate aminotransferase,,,,> -0.75 d|astigmatism,at study enrollment||histologically,3+ or 2+,,,,,,
7250,,discharged between,hormone,,hepatitis b virus deoxyribonucleic acid,specifically targeting the,,,,long-term alcohol abuse,prior to receiving the first dose of study drug;|or,"20-70,|asa i- ii||",,,,,,
7251,,hematolymphoid tumors)|or relapsed,component of test drug,,c.|serum creatinine,local regulations).||2 chronic ad,,,,adequately completed,6 months after final drug administration.||,< 55 beats/minute|pregnant,,,,,,
7252,,equivalent)|ocular pathology,grapefruit ingredients;|the,,modified rome iv criteria for,organ allograft,,,,related to,throughout the entire program,from 20 to 60 years.|patients,,,,,,
7253,,medical events,pregabalin,,lumbar disc herniation/prolapse,cessation off menstruation,,,,could lead to difficulty complying with the protocol|any disability,within 5 years before treatment,≥ 2 to < 18 years,,,,,,
7254,,include:||oral,inducers of cyp3a4/5;|medications,,eeg,unipolar ablation,,,,lower eyelids,during the index procedure.||,more than 180 minutes of exercise per week,,,,,,
7255,,respiratory depression,mepolizumab,,bun,steroid therapy,,,,50×103.|pregnant,within the shoulder complex||key,≥ 400 mg/m^2,,,,,,
7256,,bilateral proximal muscle weakness,anti-egfr monoclonal antibodies,,pulmonary function,medical examination,,,,generally refers,at the time of consent).|all study,>500 cells/µl,,,,,,
7257,,guillain-barre syndrome,phosphodiesterase inhibitors,,angiokeratoma|estimated glomerular filtration rate (egfr),par-q|participating in another research project,,,,"freshly cut, serial sections",within 2 months prior to the first study drug dose.|allogeneic hsct,between 6 and 17 years,,,,,,
7258,,scc).|skin disease,sedative-hypnotic medications,,car-t cell therapies,small cell elements,,,,life threatening episode,within 12 months including screening,less than 12 months.|participation,,,,,,
7259,,i.e.||following hashimoto syndrome,collaborators,,modified rotterdam's criteria||,diagnostic imaging,,,,pelvis,in the screening,20-54 years|24-hour,,,,,,
7260,,hepatitis b|participants,molecular diagnosis|a molecular,,car-t therapy)|monoclonal antibodies,surgical operations,,,,few than 5 studies,during the clinical screening,3 to ≤ 10,,,,,,
7261,,postoperative ventral hernias,luminal molecular profile,,kellgren- lawrence grades,implant of the nexus™ aortic arch system in accordance with the current,,,,unknown cause (,within 28 days before first dose of ip.|subjects,>= 3ng/ml.,,,,,,
7262,,major medical condition,neuromuscular blocking agent||,,spasticity grades,egyptian nursing,,,,non-serious,within 28 days before baseline to treat pancytopenia,>3.|the subject,,,,,,
7263,,muscular dystrophy type duchenne etc,acamprosate,,performance scale,global assessment-atopic dermatitis) score,,,,non-melanomatous skin cancers)|concurrent illness,within 1 week before the start,>10|acutely suicidal|considered ineligible per the discretion of the oncologic surgeon,,,,,,
7264,,ventriculo-atrial shunt,peripheral musculoskeletal disorders|new consultation,,serum hepatitis b surface antigen (hbsag),imaging examinations confirm,,,,icdas ii score,for at least 6 months after the final dose of study drug.|male,≥3.0 mg/ml,,,,,,
7265,,malignant solid tumor,transferrin saturation,,unsatisfactory iop level,undertaking physiotherapy,,,,local internal organs,for the first time with alternative sentences,≤ 50×109/l,,,,,,
7266,,iop,antibiotic treatment.||,,modified schwartz formula,kidney graft function,,,,considered unsuitable.||2,at the time of screening.|patients,<152 and >213 cm|body mass index,,,,,,
7267,,alcohol consumption of,orally,,protocol|mean corrected qt interval corrected,catheter angiography,,,,salicylic acid,within the last 14 days before study day 0.|clinical signs,<72,,,,,,
7268,,disorders;|diabetes mellitus,analgesics,,recist 1.1;|there are lesions,arthroscopic surgery,,,,lesioned skin,within 14 days of first visit,>1.5ⅹ109/l,,,,,,
7269,,chronic stable glaucoma,disease|inadequate liver,,skilled nursing facility|current,rituximab treatment,,,,gmc register,prior to icf signature,>1.5 ×uln.||adequate,,,,,,
7270,,-glycemia,otc medication,,1;|predicted survival,radiograph,,,,dcis|severe,at the time of enrollment|requirement for,≥25 ml/min/1.73 m2|on,,,,,,
7271,,coronal plane curvature,anti-egfr,,child- pugh score≤,active treatment for hiv,,,,behavioral,after myocardial infarction|prolonged,≥ 39 letters)||,,,,,,
7272,,substance abuse/dependence|anyone,antiplatelet therapy;|patients with,,hepatitis c virus(hcv rna,rr-tb,,,,previous,within 30 days prior to administration;|subjects,score of 10,,,,,,
7273,,ams,anti-tumor necrosis factor alpha,,serum triglyceride≥,allogeneic hematopoietic stem cell transplantation|according to the instructions of statins,,,,related artery (reference vessel diameter,at the time of starting dzd9008 with the exception of,≥ 50 ml/min/m2|platelet count,,,,,,
7274,,amphetamines,small intestine,,monoclonal antibodies (when possible),steroid injection,,,,urinary system,within 14 days prior to registration|step 1,< 50 bpm,,,,,,
7275,,hypertensive encephalopathy;|subjects,lebrikizumab,,recist v1.1.|for the phase ia,af ablation,,,,low dose metformin,within the previous 3 years,18-35 kg/m2,,,,,,
7276,,pituitaries,gastric pancreatic,,new york heart association functional class,giredestrant + inavolisib arm)||confirmation of biomarker,,,,ae,ongoing at inclusion visit,20-25 years,,,,,,
7277,,chronic liver failure,tpo agonist,,font-up grand fontaine laboratories,esophageal ablation,,,,enrollment.|eastern cooperative oncology group performance status,for 7 consecutive days,greater than 1.6,,,,,,
7278,,aviremia,hbvsag+,,reimplantation time,standard therapy.||other inclusion criteria:||1,,,,inclusive;|trans-epidermal,within 2 weeks prior to registration,< 130 g/l,,,,,,
7279,,oesophageal varices,altropane administration,,antibodies to donor red blood cell antigens,biochemical analysis,,,,3t mri brain,in the past 6 months|severe autonomic neuropathy,≥ 40 ml/min/,,,,,,
7280,,cognitive impairment|inability to understand,give consent.|patients,,intensive care unit admission,interventional radiologic procedure||,,,,non-conforming,within 1 year prior to screening.|received a,greater than 2,,,,,,
7281,,vocal cord,biologic materials,,identify,bladder fistulae|history,,,,first-ever ischemic stroke,before surgery or enrollment;|the patient was,greater than 160 mmhg,,,,,,
7282,,renal systems,medications used in the study.|psychiatric disorder.|asa,,spirit,158 kg).|investigational therapy,,,,hcvab positive,injections 3 months before enrollment|have,equal and more than 22||,,,,,,
7283,,catabolic disease,immune modulating agent,,direct,arterial puncture,,,,papular and/or,for ≥1 month prior to the screening visit.|for the salt-wasting form,"between 4.21-5.00 (ng, 2012",,,,,,
7284,,pace-maker,compounds of similar chemical or biologic composition to darolutamide,,criteria for 1.3 chronic migraine,radiofrequency cautery,,,,fractionated,within 24 hours before onset of mi|active,≤ 1 year,,,,,,
7285,,disorder of the orofacial region,epifix,,including:||inr,systemic therapy directed,,,,non-neoadjuvant,during the 6-month period prior to baseline|uncontrolled blood pressure,> 30 mg/gr,,,,,,
7286,,teeth with endo-periodontal lesions,smartphone running,,prone position.|physical status american society of anesthesiologists (asa),platelet aggregation inhibitors,,,,high risk,at least 14 days prior to study treatment,no upper limit,,,,,,
7287,,cre8™,fev1≥1.2l,,american society of anesthesiologist physical status classification,leukemic organ involvement.||,,,,obstruction)|locally advanced,within 2 weeks.||immunomodulators therapy,≥ 24;|fluent,,,,,,
7288,,retinal bleeding)|tumors,vaccine products.||***this,,2|life expectancy,elective caesarean section.|patients,,,,supraglottic,within 4 weeks before first administration of dzd9008.|any cytotoxic chemotherapy,thinner than 490 microns,,,,,,
7289,,bone fractures,bismuth complexes,,ns health qe2 site.|patient,section 13.1.2 contraception,,,,etc.;|mri,before induction|difficult airway|severe hepatic,50-80 years,,,,,,
7290,,allowed).||relapse,mat,,old|uncontrolled blood pressure,pelvic radiotherapy;|general conditions,,,,non severe,within 6 months prior to the first dose of study drug,>18 years assessed,,,,,,
7291,,risk factors resulting in tb exposure,cyp1a2 substrates,,severity vas score,ecg extraction,,,,full arch rehabilitation,within 3 months prior to the first dose of the drug,≥100 x 109/l,,,,,,
7292,,therapy;|sleep apnea syndrome,covid-19 monoclonal antibody,,minimal residual disease (mrd),cardiogenic shock|patient,,,,research|fully answering survey,in two months prior to initiation of study intervention,< 1.0,,,,,,
7293,,corona virus disease 2019(covid-19,uk,,fatal hemorrhage;|coagulation dysfunction,transcutaneous electronic nerve stimulation;|patients,,,,active arm of an,within 4 weeks prior to initiation of study treatment.|patient,>7.25 and <7.35,,,,,,
7294,,ventricular arrhythmia|cardiac conduction abnormalities,irrespective of,,length limits.|de novo,preventative treatment,,,,non-vasectomized,within 48 h prior to receiving the first dosing of study medication;|consumption of any product containing,< 9 gm/dl,,,,,,
7295,,continuously.|maternal hypersensitivity,platelet function;|severe noncardiovascular coexisting condition,,heart rate (qtcf),systemic therapy|history,,,,severity of their condition|any condition that,within 5 years prior to the study,greater than 3 cm,,,,,,
7296,,chronic nausea,metal implants;|patients,,urethral,fetal membrane separation,,,,pupillary,at the time of enrollment|have received,16 - 29|engaged,,,,,,
7297,,radioulnar inclination,coumarin anticoagulants,,interferon gamma release assay),real-time polymerase chain reaction,,,,fma upper extremity ≤ 66,over the past month).|self-reported,>=18years|informed consent,,,,,,
7298,,gastroesophageal bleeding,moud,,dka,live vaccine,,,,non-dihydropyridine,at least 55% of the awake day,≥50 ml/m2;|suffering,,,,,,
7299,,3rd degree burns,valium,,cohort b).|hiv negative.|for,art therapy,,,,interferes with wound healing|antibiotic,within 5 years prior to initial administration;|a history,>= institutional lower limit of normal (lln),,,,,,
7300,,sexually active)|mental status alteration,ccr5 antagonist,,bleeding index,cervical trauma,,,,rather than arm pain,after first or second line,<60 kg||inclusion criteria,,,,,,
7301,,dexterity issues.|unable,substance abusers,,cognitively intact.||,nol monitoring can,,,,<3 years before,within the past 6 months.|willingness,≥ 5l/min,,,,,,
7302,,heart disorders,registries,,car t-cell therapy.|isolated extramedullary leukemia.|philadelphia-chromosome positive all,revision hip arthroplasty,,,,pd-,at least 3 months before the screening,≥ 30kg,,,,,,
7303,,congenital coagulation disorders,antibiotic/anti-inflammatory drugs,,calculated by fridericia,quantitative assessment of the degree of aortic regurgitation,,,,diabetes.|type ii,within 14 days of protocol therapy|radiation,between 18-75 years,,,,,,
7304,,serum hepatitis,monoamine-oxidase inhibitor,,latest who-guidelines||,pleural thickening,,,,antiglycemic treatment.|serum,within 14 days of,≥18 years;|subjects comply,,,,,,
7305,,left main stenting,inhaled drug,,anti-hbv treatment,functional endoscopic sinus surgery,,,,non-st-elevation,during the first 24 hours of life||,18 - 48 years,,,,,,
7306,,abstain from sexual activity,juvenile idiopathic arthritis (,,systemic exclusion,abdominal surgery;|body mass index (bmi),,,,uncompleted,prior to initial drug,triple positive,,,,,,
7307,,chronic entrapment syndromes,albumin (alb,,low ejection fraction,hypotensive subjects,,,,marketed,within 28 days of the first dose of decoy20,14-60 years,,,,,,
7308,,facial diseases,catechins,,serum immunoglobulin,meniscus repair with,,,,non-bladder)|non-genitourinary benign diseases|non-genitourinary cancer||,within 4,≥ à 25 (greco),,,,,,
7309,,straight forward appendectomy.|patients,alclometasone dipropionate 0.05%)|no,,partial thromboplastin time (aptt) ≤1.5×uln,behavioral concerns,,,,law;|short-term,for at least one month,< 30)|body mass index (bmi),,,,,,
7310,,infiltration;||prior therapy wash-out - at least 2 weeks,antihypertensive medication nonadherence,,kidney transplantation)|both,analytic sample of clients,,,,lasting for > 6 months,within 1 year before the screening,40 and,,,,,,
7311,,criterion-b)|severe cardiovascular disease,anti-angiogenic drugs,,hcv ribonucleic acid,skin irritation,,,,effective dose,within four (4) weeks of test product application,18 to 50,,,,,,
7312,,fetal defects,renin receptors blockers,,alternatively score 2+,pet-ct;|substance abuse,,,,designee,for at least 30 days.||,<6.5cm,,,,,,
7313,,coronavirus infection,ptt,,hcv antibody test result,computed tomographic,,,,thoracic,3 months before the start of the study,18-65;|conform to the diagnostic criteria,,,,,,
7314,,abnormal mri,wine containing extracts from the above fruits,,study.|abnormal blood pressure,neuraxial anesthetic technique|planned,,,,chronic phase,within 6 years prior to the day of,≥3 months；|adequate organ,,,,,,
7315,,malignancy of the fractured vertebra,suitable veins,,left-handed;|patients,"urogenital infection,|anorectal anatomy incompatible",,,,stable doses of,at least 2 of the following 3 criteria):||compatible clinical presentation,">7%,|history",,,,,,
7316,,only).|acute coronary syndrome,antipsychotic,,copy number,aortic bypass surgery,,,,acceptable,within 3 months prior to or after the research scan|suspected breast lesion,less than 10 years;|7,,,,,,
7317,,purified,medium,,ckd-epi equation,spiral ct scan,,,,study|chronic concomitant treatment,prior to screening;||patients,wider,,,,,,
7318,,acute episodes of,anti-pd1 agent,,new york heart association [nyha],maintaining,,,,icd-10 research criteria and pth,at least one of the following:||have ssc,= egfr（ckd-epi,,,,,,
7319,,autoimmune liver,silicon carbide,,her2 exon20ins small molecule inhibitors,chronic infection|live vaccine,,,,anticoagulative,preceding 12 consecutive months)||ability to complete questionnaires by themselves,≥ 40 years|the,,,,,,
7320,,under court,calcitriol,,left ventricle ejection fraction,continuous oxygen,,,,medication-induced,for at least 3 months|nightmare,30-55 years,,,,,,
7321,,alcohol dependency,adrenal corticosteroid therapy,,≥0.5,signet ring cell carcinoma,,,,10 to 15 days after transplantation,for at least 6 months after completion,less than 140 beats/min,,,,,,
7322,,cst≥300,ahod1331,,australian standard drink,pdx monotherapy,,,,seronegative spondyloarthropathies,within 30 miles of uvmmc,<34|malnutritional screening tool score,,,,,,
7323,,urinary tract infection|systemic lupus erythematosus||labetalol,months|best-corrected visual acuity,,gh stimulation test cut,isolated surgery,,,,ankle sprain,within the past 5 years excluding,> 15 s;|subjects,,,,,,
7324,,absolute t-lymphocyte,coryza,,serum cea||age,sohag university hospital,,,,hepatobiliary tumour|intrahepatic,at least 6 months)|subject,less than 50kg,,,,,,
7325,,type,cyp3a4 inducers/inhibitors.|medical conditions,,north american adult reading test,great saphenous vein,,,,second-degree,within 12 months before,> 2.5 times upper limit of normal);|patients,,,,,,
7326,,plus spermicide,loperamide,,residual toxicity,transthoracic echocardiography)|new york heart association (nyha) class,,,,palsy.||4-,at least 18 years,less than the upper limit of normal value,,,,,,
7327,,patients:||-,commercial vaccine,,serum hcg,expected procedure,,,,device-related inclusion,within 2 weeks prior to enrollment.||,18 years and older|willing to avoid foods,,,,,,
7328,,swelling|developmental disorders,rizatriptan,,fatigue pmd short,hospitalized isolated,,,,age.|community-acquired,within 3 months prior to screening|pregnant,3 months to 12 years old,,,,,,
7329,,right pulmonary artery,everyone,,lesion length,scs,,,,connective tissue disease;|uncontrolled diabetes;|uncontrolled,within 6 months before starting therapy,between 18 and 65 years|that they,,,,,,
7330,,impact the absorption of study intervention.||note,cobalt,,angle-closure glaucoma,treatment of cancer,,,,calorie,at transplant.|negative crossmatch with donor.|if female,>30ml,,,,,,
7331,,intracranial atherosclerotic lesions,postovulation methods,,creatine kinase,trt,,,,interventional study.||,past half year,> 100.5°f).|presence,,,,,,
7332,,intrathecal injection.||growth factors:||patients,adynovate,,sitting bps,major surgery,,,,durvalumab-induced,2 weeks prior to the blood,18 to 39 years|women,,,,,,
7333,,ins,gallium 68 dotatate pet scan,,urine protein,urethral strictures,,,,diluted beach bath,during research procedures|affiliated,50% stenosis.||,,,,,,
7334,,granulomatous lung disease,nitroglycerin,,testing laboratory;|bilirubin ≤1.5x uln,active working workers,,,,under guardianship)|patients under court,within 60 days of entry,> 2/10 cm,,,,,,
7335,,abstain from heterosexual,bariatric surgery|diuretic medication doses,,osdi,tigit inhibitor treatment,,,,rome iv criteria|ruled,at time of planned pancreatoduodenectomy,>1.1 µkat/l,,,,,,
7336,,screening|heart failure,glycosylated hemoglobin,,response evaluation criteria in solid tumors version 1.1 (recist version 1.1);|eastern cooperative oncology group (ecog) performance status,vasogenic edema|patient,,,,non-hispanic|race,1-6 months prior to study entry||,at least 6 months|positive,,,,,,
7337,,acute cardiovascular events,thrombopoietin receptor agonists (tpo-ras,,||absolute neutrophil count,periodontal intervention,,,,month|familial hypercholesterolemia|abuse,before undergoing the study procedure|unable to comply with the follow-up schedule and assessments|recent tobacco,i to iii|bmi 18-28 kg/m2||,,,,,,
7338,,thyroid cancer history.|deficiency,testosterone-blocking treatment,,rpr,dexa scan,,,,high-performance liquid chromatography [,in the next 24 months|workers' compensation,<27+6 weeks,,,,,,
7339,,intervention;|vascular embolism,selective serotonin reuptake inhibitors,,hbv dna every,endovascular repair,,,,ora-blend,within 1 month before enrollment;|patients,≤ 2||adequate,,,,,,
7340,,myocardial,direct acting antiviral drug,,mild).|no structural abnormality,robotic-assisted laparoscopy,,,,look-alike,in the week preceding study,>18 - patients,,,,,,
7341,,neurosis,local antibiotics,,braf v600e mutation|no prior,periapical radiographs.|periodontally compromised teeth.|endodontic retreatment,,,,healed site,during the patient's participation,12.1,,,,,,
7342,,delayed hypersensitivity reactions,harp,,recist v1.1 criteria;|ecog physical condition,terminal illness|pregnancy|participation,,,,without stopping,last,< 6 years old|long-term maintenance therapy,,,,,,
7343,,metabolic abnormalities,inattention,,included.|body mass index,situations,,,,peroneal arteries,within the previous 4 weeks,≥200 μm,,,,,,
7344,,palpitations,anti-clotting,,nerve stimulators|uncontrolled,expected stay,,,,influence on pupil reaction,in the past 12 months before first dose of treatment,more than twice the upper limit of the normal range|changes,,,,,,
7345,,nonmetastatic squamous cell carcinoma,study medication.|patients,,dry eye disease (ded)||symptoms of,simple tympanoplasty healed,,,,tested,within 30 days before procedure,≤ 30.|have,,,,,,
7346,,post-obstructive pneumonia,boceprevir,,regional maternity hospital,liver metabolic enzymes,,,,slowed,history of pre-existing,1 or above,,,,,,
7347,,type of carcinoma,btk inhibitors treatment,,blood test abnormalities,exercise therapy before|volunteers,,,,upper rectum,their first term,over 18 years|singleton gestation,,,,,,
7348,,nonchildbearing potential (,amoxicillin-clavulanic acid,,residual hearing,craniofacial trauma/surgical,,,,seated,in the past 14 days.|any vaccination,18-75 years;|asubjects,,,,,,
7349,,sb,indwelling tube,,korean liver cancer study group,mechanical ventilation.|systolic blood pressure,,,,oligo,in the knee,0-1|adequate organ function|bmi,,,,,,
7350,,non-squamous nsclc.|tumor sample,antihistamine medication,,kellgren-lawrence staging,abdominal surgery|women,,,,test.|aged,for up to 12 weeks after enrollment|anticipated major surgery,less than 24 weeks,,,,,,
7351,,under investigation.|new medications,nucleoside analog should be,,liver function tests,complete autologous hsct,,,,non-small-cell lung cancer,last 2 weeks,> 7.5|have a,,,,,,
7352,,oropharyngeal cancer,iodinated contrast media.|segmentectomy,,t4 disease|presence of,eus-guided approach for any reason|patients,,,,scapular region,during the 13 weeks,< 10 years,,,,,,
7353,,prostate intraepithelial tumor,wve-004,,body mass index (bmi < 40,world health organization (who) classification criteria for lymphohematopoietic neoplasms,,,,uw health,after the last dose of investigational drug|men,12 to 65 years,,,,,,
7354,,multiple guidelines,herbal preparations,,smoking,mechanical mcs device,,,,general containing calcium,within 2 weeks prior to the first dose of study drugs.|8,less than 18 years|inability to speak,,,,,,
7355,,cardiopulmonary disease abnormality,topical ophthalmic medications|eyelids,,total score 10+|bipolar disorder,radical resection of,,,,locally advanced/recurrent,more than 1 litre,>28 mm,,,,,,
7356,,salivary gland carcinoma,study medication;|consumption,,sufficient level,exercise-induced asthma,,,,and room air pulse oximetry,within 36 months of enrolment,11-18,,,,,,
7357,,nerve tissue damage,intravitreal),,recist version 1.1 (lesions with the,"cardiothoracic surgery or,|adipositas or,|granulomatosis",,,,surgery;|symptomatic,at time of enrollment|pre-pregnancy body-mass index,≥1.0 x 109/l|total bilirubin,,,,,,
7358,,intracranial bleeding,prescription medications,,hiv antibody,bone window,,,,anovaginal fistula rectovaginal fistula perianal,at the screening visit.||females of,14-009873,,,,,,
7359,,social interaction fear,rich containing,,ecog score for performance status,mrna vaccination,,,,grossly carious,throughout the medication,18.5 to 32.0,,,,,,
7360,,palmar hyperhydrosis.|patients,physicians,,aspartate transaminase [ast],neurological condition|history,,,,exertional,at least 14 days prior to screening,≥14 mm,,,,,,
7361,,vascular hypertension,short-term oral cortisol,,moderate amount,menstruation|pelvic pain|vaginal discharge|sudden weight,,,,endocrine system,reims)|absence of,≥ 20/20,,,,,,
7362,,source|chronic obstructive pulmonary disorder,muscle relaxants,,inclusive.|body mass index [bmi,occipital region,,,,medically treated,within 6 months prior to enrollment|late first-line treatment,above 18|access to a,,,,,,
7363,,disabled,ts:||•,,macrolides|prolonged hospital stay,hematopathology review,,,,malignancies|surgically unmanageable,within the last 6 months.|clinical evidence,≥ 1.5 times;|one or more,,,,,,
7364,,breast cancer|receiving anti-hormonal,allogeneic tissue/solid organ transplant.|patients,,glascow coma score (gcs),head imaging||have,,,,enteric bacterial overgrowth syndrome,"throughout the study period,|patient accepting the",18-75|proven,,,,,,
7365,,influenced pain threshold,topical ocular medication|patients,,ultraviolet light b,visceral biopsy,,,,days);|insulin-dependent,within the last 5 years,>10 mm,,,,,,
7366,,tumour,symbiotic supplements,,timeline follow-back,head trauma leading to clinically significant,,,,extensive subependymal disease,at least 12 months of screening,<30 ml/min/1.73 m2|liver,,,,,,
7367,,obstructive symptoms,hypnotics,,alanine aminotransferase (alt) ≤3 times the upper limit of normal value (uln),chemotherapy drug,,,,tnf-α,within 6 weeks of first administration of nuc-3373|corticosteroid treatment,> 400 mg/day,,,,,,
7368,,cognitive impairment|isolation,parenteral anti-infective treatment,,serum rsv antibody titer assay,chest scan,,,,low distress tolerance,while on trial,men|60-80 years,,,,,,
7369,,oxt,benzonase.|febrile,,vaccination.|systolic blood pressure,copper intrauterine devices.||contraception,,,,non-live vaccines,for at least 3 months after the final dose of study treatment,between 30-70|more than 6 months after the stroke|able to walk more than 10 meters independently|mmse score of 24||,,,,,,
7370,,cardioplegic,lenvatinib,,alkaline phosphatase,extracorporeal membrane oxygenation (ecmo),,,,mid-range ejection fraction,within 96 hours before enrollment,often,,,,,,
7371,,dendritic cells,crossover,,serum β2 microglobulin level.|serum virus,glaucoma filtration surgery,,,,ocular surface disease index questionnaire,for more than 2 years,i1,,,,,,
7372,,painful arc test,oral bronchodilators,,serum hcg pregnancy test,residual sizable fragments,,,,pericardial tamponade,within 2 weeks prior to baseline|subject,>90×109/l,,,,,,
7373,,"chronic neck pain,|to",duodenal,,refer section,asthma control questionnaire-7 (acq-7) score,,,,sll-related,at the time of enrollment.|able to read,≥10|people with,,,,,,
7374,,hepatitis b viral infection,strong artificial pigmentation,,lavi,birth control method,,,,alter the absorption of study drug|patients,less than 1 year before fixation.|untreated periodontitis.|poor oral hygiene,>0.5 mg/mg,,,,,,
7375,,interstitial pneumonia/lung disease,over-the-counter (otc) medication,,student||,oral anticoagulant (oac),,,,pentosan,prior to recruitment|likely,> 1.5x the upper limit of normal.|second degree,,,,,,
7376,,c).||active hepatitis b virus (hbv),xanthine-containing,,t-cogs,bowel resection,,,,weeks|active,within 6 months prior to screening.|participation,<0.26 or >1.65).|received,,,,,,
7377,,relevant diseases,sbe,,prostate cancer working group (pcwg3),septal myectomy||,,,,ihc 1+ or above,within 28 days prior to c1d1,20 - 60 years|weight,,,,,,
7378,,peripheral ulcerative keratitis,protein vaccine,,nj|patients,tertiary neonatal intensive care unit,,,,non-keratinizing,within 4 weeks prior to treatment;|patients,children/youths <20 years,,,,,,
7379,,acute illness,inhaled corticosteroid (ics),,endoscopic mayo score,standard clinical assay,,,,6-thioguanine,within 1 month before screening;|during screening,< 3 months prior to the,,,,,,
7380,,congenital heart disease|digestive tract malformations,human immunoglobulin products,,5cm||,surgical clinics,,,,future,for at least 3 months|the,≥ 0.5cm,,,,,,
7381,,muscle relaxants|epilepsy|belonephobia,oral typhoid vaccine,,variation coefficient,sbuh|no clinical diagnosis,,,,ultrasound|hiv-uninfected|willing,within 28 days prior to hospitalization,"<75,000/ul",,,,,,
7382,,unresectable pcca,3rd degree heart block,,low glomerular filtration rate,target proteomic analysis,,,,ibs questionnaire,approximately 500 ml,>248 u/l).|patients,,,,,,
7383,,iss:||•,nicotine,,ccca,bone marrow hematopoietic function,,,,long-term care facilities after hospital discharge|self-reported,within 14 days prior to enrollment.||a.,loss.|in general,,,,,,
7384,,"ischemic colitis.||open-label extension period:||participant has clinically relevant hepatic, neurological, pulmonary",household,,frankl behavioral rating scale)|legal guardian consents,imaging procedures,,,,secondary to head trauma,at clinical,40-60%,,,,,,
7385,,uncontrolled diabetes.|coagulation,component of the chemotherapy regimen,,kura oncology||for aml,chronic opioid therapy,,,,grade salivary gland carcinoma adenoid,within 30 days of enrollment|use an assistive device,between p and r waves (pr),,,,,,
7386,,concurrent illness,abnormal ecg,,gross motor function,professional periodontal treatment,,,,macular,at the time of the assessment of its eligibility for,>t1,,,,,,
7387,,turkey's meat are foods,anti-infective treatment,,standardized mini mental test (smmt),antiretroviral therapy (art/haart,,,,radical,within 2 weeks prior to study drug,>= 9.0 g/dl|absolute,,,,,,
7388,,target depression,synagis®,,cooperative oncology group (ecog),plasma exchange,,,,lower limb motor sequelae|patient,within the past 12 months.|subjects,"< 3,000/ mm3",,,,,,
7389,,venous ulcer,departments,,covid-19 convalescent plasma,controindications,,,,spray||low dose,within 3 months prior to the screening,between 18 and 32 kg/m^2,,,,,,
7390,,primary hyperparathyroidism,topical immunosuppressive agents,,bone marrow reserves|life expectancy,local irradiation;|concomitant chemotherapy,,,,suitable for performing the avs procedure,within 6 months prior to meta10-19 infusion;|patients,score 50%,,,,,,
7391,,major neurological disorders,imiquimod,,asa status,inhaled therapy,,,,defective,during the previous year,18-85 years,,,,,,
7392,,psychiatric comorbidities.||for healthy,heparin-induced,,white cell count,protective measures)||for the control group:||inclusion criteria:||people,,,,pcr-,in the last 12 months|acute infections,≥ 25 g/l,,,,,,
7393,,b|chronic hepatitis b,platinum agents,,serum pregnancy,visit|ocular topical,,,,non-hematological,within 14 days prior to the first vaccination,18-30 kg/m2|subjects,,,,,,
7394,,fracture site.|skin injury,medication overuse|patients,,fibrinogen,full-field erg,,,,temporomandibular joint and/or masticatory muscles,within 8 weeks of visit 1.|any use,≥ 5 years|age,,,,,,
7395,,hyperthyroidism|pregnancy|failure,mycophenolate,,hepatitis b surface antigen [hbsag] test),surgery of the gastrointestinal tract,,,,give,during the treatment.)|less than 100 days after allogeneic hematopoietic stem cell transplantation.|vaccinated,< 18.00 kg/m2|life,,,,,,
7396,,spastic cp.|both sexes,tetracycline,,scfe,lumbar disc,,,,danish university,within the last 2 weeks before screening|platelet count,less than or equal to 15cm|no distant metastasis,,,,,,
7397,,ctcae gi,doi,,screening.|body mass index (bmi),induction chemoimmunotherapy,,,,largest wheal diameter of ≥6 millimeter (mm),within 14 days,>40 kg/m²|participation,,,,,,
7398,,non-obese,anti-psychotic,,mean left ventricular wall thickness,cytoreductive surgery,,,,hypercortisolism;|already,until 28 days after the last dose of ropeg.||women,"≥60,000/µl|calculated or",,,,,,
7399,,"allergic reaction,|having",ranibizumab,,serum 25(oh)d level,thrombosis|intravascular ultrasound (,,,,suitable for intensive chemotherapy:||≥75 years,within 28 days prior to vaccination;|use,middle e ethnicity,,,,,,
7400,,another condition,neuroleptic drugs,,modified schwartz formula)|stroke,botulinuim toxin application,,,,peri-oral ulceration,at the time of signing the consent form|hiv-1 infection,≥ 95%,,,,,,
7401,,non-mass enhancement,anti-tb treatment,,blood glucose,tubal ligation,,,,necrotic mandibular second,before start of the study treatment.||has recovered from any toxic effects,≥100 ng/l|end-stage renal disease (,,,,,,
7402,,cerebrospinal fluid culture,ace inhibitors,,international normalization ratio [inr],epilepsy surgery,,,,not-taking,within the past 3 months).|patients,< 90 minutes,,,,,,
7403,,hepatic enlargement,f31)|moderate,,vaccination|blood pressure,periodontal screening,,,,total hip,within 3 months before administration.|in addition to the above,>= 5 mm,,,,,,
7404,,autoimmune diseases.|malignancy.|pregnancy,inhaled antibiotic therapy,,copper 64 dotatate scan,skin biopsy,,,,cmv immunoglobulin,within 14 days prior to first dose of study drug.|major surgery,>600ml,,,,,,
7405,,renal vascular surgery,radiographic apex,,westley croup score,coronal mri scan of the head before enrollment can be added;|the subjects should have,,,,shoulder to hand,within three days after ct scans|underwent qpcr,score is 25 and,,,,,,
7406,,types of interventions,ticagelor,,nutrition program,"medical attention;|size of head, neck",,,,isolated,in the 4 weeks following any study intervention administration|receipt of any,between 23 to 40,,,,,,
7407,,impact on tumor assessment,vegan diets,,attention deficit hyperactivity disorder,section- contraception,,,,neck|being overweight,within 6 weeks prior to randomization|active,≤2.5 x upper limit of normal (uln),,,,,,
7408,,myocardial disease,gave,,forced expiratory volume,bilateral orchiectomy;|painful bone metastases,,,,primary sclerosing cholangitis|patients,within 4 weeks of dosing|evidence of disease,<110 g/l,,,,,,
7409,,extensive interstitial lung disease,hbs ag,,partial thromboplastin time (aptt)<1.5 times uln.||the expression of tm4sf1,risk of bleeding,,,,mild to moderate obstructive sleep apnea)|have chosen,at the first dose of treatment,≥90 and ≤140,,,,,,
7410,,siblings,antagonist,,test for hepatitis b virus surface antigen (hbv sag,parks association (bcrpa),,,,astigmatism|strabismus|acute,within 6 months before enrolling to the study,score 1 ≥1)|catchment area of hospital sønderjylland|deferred informed consent obtained from patient or patient,,,,,,
7411,,isolated wound,ureteral calculus,,coagulopathy|temperature,bilateral knee oa,,,,hepatic,within duration of participation of study.|is,≤ 60 mmhg||before the first administration of investigational,,,,,,
7412,,chronic diarrhea.|active peptic ulcer.|major,nevirapine,,qids,foley catheter insertion,,,,evaluable,within 7 days prior to dosing|are lactating,18-65|knowing,,,,,,
7413,,primary neurological disorders,oral prednisolone,,recist version 1.1:|ecogps:0-2,regional prescribing information.|participant,,,,age|patients treated,during the first six months after surgery,20-60 years,,,,,,
7414,,multidisciplinary consultation)|hepatocellular carcinoma,mediastinal lymphadenopathy)||,,syphilis spirochete antibody test results.|patients,"rrt),|previous transjugular intra hepatic portosystemic shunt",,,,ehlers-danlos,within 60 days prior to the study vaccination,>1|chronic kidney disease (ckd),,,,,,
7415,,etc.)|demonstrating sensory limitations,porphyrins,,spanish|body mass index,global impression - severity,,,,ortho evra,at least 4 weeks prior to enrollment.||participants,≤ 132.6μmol/l,,,,,,
7416,,michigan periodontal probe,demethylated drugs,,cam icu,fear conditioning paradigm,,,,insulin sensitivity,within 12 months after cr,>=18 years and <80 years,,,,,,
7417,,mucogingival defects,basal insulin therapy,,il-29,bilateral tubal ligation,,,,suitable for exercise therapy,within the past 4 weeks|brain metastases|borderline,18.5-30.0 kg/m²,,,,,,
7418,,disabilities,dopamine receptor blockers,,old.||control:||●healthy,contradictory,,,,cardiac event,at the time ofscreening.|renal impairment (,18-75 years|moderate-severe,,,,,,
7419,,extra-abdominal metastases).|patient,salicylate,,hamilton anxiety scale,bilateral salpingectomy/oophorectomy,,,,stereotaxic,during that period of time must,>45 ml/min,,,,,,
7420,,third degree,levothyroxine,,car t-cell infusion are detailed in the protocol,tracheostomy,,,,musculoskeletal surgery|having,at the time of consent signature.|voluntarily signed written informed consent form (icf) before performance of any study related screening procedures.|phase,"score of 3 or more,|history of",,,,,,
7421,,dyskinesia;|age,hospital admission,,glomerular filtration rate (egfr) estimated,apical surgery,,,,amenable to pci||,within one year prior to screening,18-60|both sexes|bmi,,,,,,
7422,,malignant melanoma|disease progression,vincristine,,urine screening test,blood routine,,,,pure class v,within past 6 months,≥25,,,,,,
7423,,perineal symptoms make,regofenib,,white spot lesion,chest high resolution ct scan,,,,medications|≥18 years|full,within 4 weeks of visit 2|history of,≤ 3 times the upper limit of normal|serum bilirubin,,,,,,
7424,,burkitt's lymphoma,"drug absorption, distribution, metabolism",,heart rate variation,facial fine lines,,,,tolerated.|uncontrolled,within the range 18.5 to 35 kg/m2,1 mg/dl,,,,,,
7425,,ingredients|pregnancy|irregular menstrual bleeding,intravenous cyclophosphamide,,platelet count≥,hormonal treatments|luteinizing hormone (lh),,,,years|prior,during the study|prior allogeneic bone marrow transplantation,greater than or equal to 10)|evidence of,,,,,,
7426,,renal diseases;|uncontrolled diabetes,regional clinics,,pcr,bifocal,,,,modified formula of cockcroft and gault,within 1 year on and after index date,>= 65 years,,,,,,
7427,,class 1 black,propoxyphene,,international union of immunological societies (iuis) committee.|participant,postoperative adjuvant therapy,,,,highly effective forms of,in hciii/inca.||,"≤ 60,000/mm3|absolute",,,,,,
7428,,lower gastrointestinal bleeding,drugs simultaneously,,splenomegaly|hemoglobin,local surgical investigator,,,,extranodal lesion,their first dosing.|subject,≤ 1.5 x uln-ll||exclusion,,,,,,
7429,,malignant tumor|unable,ritalin,,neonatal antigen load,cdmard regimen,,,,nail psoriasis||,within 28 days before first dose of ip,negative(-,,,,,,
7430,,hesitancy,nutritional supplements,,caramel page 60 of 128 version: 1.0 date,ethics committee,,,,"third year.|to have taken the ""principles of nursing"" course and the loss-death-mourning process described",within the same intervention.||,quantitative,,,,,,
7431,,chronic infectious diseases.|evidence,dyes,,"numerical rating scale,|able",paravertebral blocks,,,,non-ambulatory,prior to study enrolment|serum na,18 years and older|received,,,,,,
7432,,recurrence in the last 5 years,study drug components.|additional criteria,,urinary albumin creatinine ratio (uacr) range [30-300 mg /gm],ss (aecg),,,,cytomegalovirus(cmv,during the study|history of covid-19,mouth opening <2.5cm,,,,,,
7433,,aortic tortuosity|subject,occasions,,urinary cotinine test,"light chains ratio,|end-diastolic interventricular septum thickness",,,,intra-uterine device,for the time period specified:||use a condom,2-75 years;|a definite,,,,,,
7434,,burning sensation,piperlongumine,,platelet ratio index (apri),fibroscan cut-off of 12.5,,,,primary progressive (ppms) ms,in screening,between 25 and 35||nb,,,,,,
7435,,nodal involvement,doac,,peripheral eosinophil,"cesarean delivery method,|prepregnancy bmi",,,,woman|asaii-iii|patients,at the time of recruiting,3-5|50 cd ileo-colonic,,,,,,
7436,,sao2,everolimus,,lh,chest pain|ecg,,,,gp tokyo 2018 criteria.|surgical decision of inoperable patient (if one or more of the following criteria is met,at the time of consent acquisition|patients,≥ 90 × 109/l；||hemoglobin,,,,,,
7437,,digoxin,international council on harmonisation/good clinical practice guidelines,,anti- srp,trauma induced,,,,histological grade 3,over 1.25 years,<1%|the subject's,,,,,,
7438,,postpartum depression predictors inventory (pdpi),n-acetylcysteine,,local ablation;|age 18~75 years；|barcelona clinic liver cancer (bclc),donate sperm.|general good health,,,,lumbar-sacral radiculopathy,in the food effect study.|in the investigator's judgment,between 1-3 daily oral medications,,,,,,
7439,,extranodal lymphoma,anti-inflammatory medication|no weight loss,,hepatitis c infection note,dorsal rhizotomy,,,,icd-10 z95.x,within 60 days of first dose of ip.|current clinical radiographic,≤ 2.5×uln;|able to understand and sign the informed consent document.||exclusion,,,,,,
7440,,current covid-19 disease,anti-tumor drugs/therapies,,ncep-atpiii criteria,outpatients,,,,recovered;|uncontrolled,within a year,1 - 4,,,,,,
7441,,arthus,almonertinib,,gender.|age,ultrasound remission,,,,non-invasive icp monitoring,within 6 months prior to the screening period,later than 24:00|gastroesophageal reflux disease,,,,,,
7442,,normal ecg|regular menstruation||,mild crowding,,inr not,mycophenolate.|induction therapy,,,,stumble,prior to registration|registration,= 7-12)|metabolic acidosis,,,,,,
7443,,discomfort,cbc,,rationale,major head surgery,,,,micro-bleeds,within the 6 months,40 and over,,,,,,
7444,,mmhg).|active autoimmune diseases,systemic anti-inflammatory agents,,jak2,physical therapy/rehabilitation,,,,|maternal,within the past five (5) years,more than 30s,,,,,,
7445,,prostate disease,local area treatment of the liver,,minimum imt score,immunotherapy.|major surgery,,,,very little deep sleep|participation,at least 6 months before the participation,< 20 ml/hour,,,,,,
7446,,impaired gastrointestinal function,bismuth subsalicylate,,total bilirubin ≤3×uln,radiographic international caries detection,,,,intraocular lens|sutured,at the time of inclusion:||use adequate,≤ 10mm,,,,,,
7447,,abstain from extensive sunbathing,tipranavir,,gai,artificial blood vessels|subjects,,,,"instructions for use),|subject unsuitable for surgical repair of the target leg access",for greater than 3,≥ 100 × 10^9/l,,,,,,
7448,,cerebrovascular hemorrhagic disease,anti-fibrotic,,follows||g0297 - ldct,completed definitive therapy,,,,abemaciclib on the developing human fetus,within 42 days prior to enrollment,18 or above;|highly suspicious,,,,,,
7449,,inclusion;|spinal metastasis,immunosuppressive/immunomodulating substances,,adolescent,systemic steroid therapy,,,,poor oral,within the last 60 days,>3|emergency surgery,,,,,,
7450,,hypertonia,caribbean,,presumed resectable pcca or|presumed resectable,finger oximetry,,,,non-commercial rna-,within the past 6 months|naive,">= 50,000/mm^3||registration",,,,,,
7451,,abuse;|mental disorders;|failure,müllerian agenesis).||exclusion criteria||patients are,,trauma care continuum of the province,coronary bypass,,,,radiographically evident,at time of egg retrieval.|strong desire to undergo uterus transplant,younger than when relative,,,,,,
7452,,acute dental infection,components of the mrna,,nci-ctcae v4.03)|be,small intestine bacterial overgrowth syndrome (sibo),,,,appropriately administered institutional review board,within 3 months prior to the day of vaccination,≥110,,,,,,
7453,,stroke|liver disease,"components of dexamethasone oral suspension,|treatment",,flc ratio,lactation|psychiatric illness|multifocal hernia,,,,markers.|history of fractures,for the period from the 1st administration of,greater than 1.0,,,,,,
7454,,drug-related pulmonary toxicity,methylprednisolone,,visual analog scale||,switzerland)|full-ceramic|utilization,,,,pd-l1 inhibitor,within 30 days of the first dose of study drug.|active,≥100×10^9,,,,,,
7455,,menstrual bleeding,technology devices,,antibodies to raav,orotracheal intubation||,,,,other day,more than six hours|patients,between 1st january 2014 and 31st december,,,,,,
7456,,fracture sequelae,antidepressant,,stainless steel.|known pregnancy,clinical examination,,,,timi 0-1 flow,at the time of transplant referral|small cell cancers|unidentified,between 30 - 90 minutes,,,,,,
7457,,inclusive.||meet mci,methylenedioxymethamphetamine,,≤2.5|albumin,world health organization (who) criteria|ability and willingness of the legal guardian to comply with study protocol,,,,bietti,at any time before or after the study index date,>7.5.|immunocompromised,,,,,,
7458,,alveolar bone procedure,non-seminomatous germ cell tumours,,serum transaminase ≥2× upper limit of medical reference,pelvic ultrasound|desires iud removal||,,,,grapefruit consumption,within 6 months|breast surgery,> 2.0 x the upper limit of normal (uln),,,,,,
7459,,spasticity picture,antiplatelet agglutination drugs,,urine human choriogonadotropin (hcg),standardized physiotherapy assessment,,,,low dose cytarabine,in the past 6 months.|none,"<100,000 o2 saturation",,,,,,
7460,,fants,computer,,eular / ace,antigen rapid detection,,,,hypocaloric,within two years of study enrollment|psychiatric hospitalization,at least 4 weeks,,,,,,
7461,,spondylolysis,medications (nsaids,,hsct|for relapsed,intracranial stent,,,,gastroesophageal,within 2 months prior,higher than the detection limit of the analytical method;or,,,,,,
7462,,unemancipated minors,semi-permanent,,alcohol expiratory test,radiotherapy treated,,,,inflow-outflow)|live expectancy,for at least 1 month ldl-c treatment target <1.4 mmol/l,≥6 and <18 years old,,,,,,
7463,,older)|type 1 diabetes,pms2).||,,iwcll guidelines.|patients,navigation surgery,,,,non-essential hypertension,during the study period|willing,≥ 18 years|acceptable,,,,,,
7464,,myelodysplastic syndrome;|diagnosis,chemotherapy.|informed consent||,,who group 5.|historical,mental disability|pregnancy,,,,allowable,since enrolling in the study,less than 70%,,,,,,
7465,,idiopathic diagnosis,dolutegravir,,palliative care program,infection|uncontrolled cardiac failure,,,,complete,within the past year|laboratory-confirmed,> 50cc,,,,,,
7466,,communication regarding safety procedures,rituximab,,finger size,ip on day 1.|moderate to severe,,,,narrow irido-corneal angles,more than 1 line,≥65 years;|living,,,,,,
7467,,toutic,descovy,,aacvpr,ecg lead placement,,,,hysterectomy).||,during the last month of 5 to 10 cigarettes,score ≤ 4;|exclude,,,,,,
7468,,antimalarial,abietron acetate,,ventricle ejection fraction,pelvic organ prolapse repair,,,,anatomical area,more than 3 months;|patients,between 30-75 years,,,,,,
7469,,fibrosis;|interstitial lung diseases,vomiting|having visual,,chronotropic index,systemetic therapy,,,,auriculoventricular block.|pregnant,at least 7 days before receipt of study vaccine,between 3 years and,,,,,,
7470,,non-neuropathic phenotype|the,glucophage,,serum creatinine (scr),reliable vf tests,,,,present,throughout the course of the study||exclusion:||any clinically relevant,≤ 75 years.|subject,,,,,,
7471,,airway malformations,intravenous (iv) antibiotic treatment,,nocturia,hypothermia treatment,,,,non-infectious pneumonia,in the last 8 weeks prior to screening.|patients,18 or older.|diagnosed,,,,,,
7472,,medullary thyroid carcinoma (,immunoglobulin drug products,,k219q).|plasma hiv-1 rna,complete eeg,,,,methacholine|child,6 months prior to the screening,> 10ng / ml|general condition,,,,,,
7473,,1st,patellofemoral,,immunocompromised status,treatment of intervention,,,,with curative intent,within the study||,19.0-30.0,,,,,,
7474,,delta waves,defaecation||,,years.|ecog ps score,screening.|ocular surgery,,,,employees,within 48 hours prior to asp5354 administration,under lkcmedicine,,,,,,
7475,,mental confusion etc.)|hamilton anxiety rating scale,first-,,general/ocular exclusion,cognitive testing,,,,hemorrhage|epi-retinal,at any time to which there was no response,≥ 90 mm,,,,,,
7476,,immunosuppressive conditions,anti-cancer therapy targeting,,intensive care unit|patient has,signet ring cell,,,,tapering doses of,within one year before or after diagnosis of the,0-21 years,,,,,,
7477,,symptoms:|coughing,odynophagia,,diastolic reading,computerized tomography (ct) colonography,,,,study.|pregnancy.|significant bleeding risk,within the next 6 months,"≥ 18 years old|patient should understand, sign",,,,,,
7478,,myelodysplastic syndrome|for,peptide-1 receptor agonist therapy,,accountability,imaging examination,,,,moderate risk,within 1 year prior to screening.||,"greater than or equal to 40%|nyha class ii, iii",,,,,,
7479,,child's assent given before,influence ocular motor visual function,,hcv titer detection value,normal operation,,,,recist 1.1.|adequate renal,prior to onset of their primary glioma|patients,>102 cm,,,,,,
7480,,skin rejuvenation treatment,serm)|tibolone|anabolic steroids,,eular/acr classification criteria.|patients,light-altering devices,,,,related to their infection-associated,within 10 min of standing,≥ 60×10^9/l.|liver,,,,,,
7481,,bronchiolitis-interstitial lung disease|desquamative,atypical antidepressants,,serum pregnancy tests,polymerase chain reaction only may participate in this study.|stage iv nsclc,,,,stage 5,within the previous month,0-1+,,,,,,
7482,,splenic embolization|prior decompensation events|inability to fit into mri,chronic medication,,18|life expectancy,topical eye medication,,,,amenable to radiation therapy,within 6 months (180 days) prior to enrollment||note,> ii stage|patients,,,,,,
7483,,stage i tumors,inhaled corticosteroid therapy,,anti-hcv antibody-positive,replacement|open thoracic aortic and thoracoabdominal aortic surgery|atrial,,,,mental disorders;|a,within 3 days before vaccination;|a known,≥ 4 points.||,,,,,,
7484,,generalised urticaria,hiv-2 antibody,,maze,done reiki therapy,,,,dsm-v criteria,during the last six months;|patients,>18 mmhg)|subject,,,,,,
7485,,pulmonary infiltrates,monoclonal antibodies.|known,,regular mindfulness,pet imaging|complete destruction of the stimulation target region (m1 or,,,,heavy,prior to day 11 post-dose of the study.|has,between 5 and 15 on the,,,,,,
7486,,tympanostomy tube,direct acting antiviral,,nodal lesion,temporal lobes,,,,gastroesophageal junction,within 14 days prior,≥60 years,,,,,,
7487,,in situ cervical,medication|insulin user,,volume index,implant surgery,,,,"cephalic veins,|not allergic",at the time of surgery||,between 18-28 kg/m2,,,,,,
7488,,ealthy,parenteral steroids,,anorectal malformation,gpa,,,,wild-type,during the informed consent|women,≤ 2.5 × upper limit of normal range (uln),,,,,,
7489,,unforeseen reasons,immune response.|any surgical procedure,,systolic ap,incisional hernia whit length,,,,as:||pre-menopausal,prior to the first dose of study intervention|in,greater than 1 year|patients,,,,,,
7490,,esophageal adenocarcinoma,isoflavone supplements,,hiv viral load,study|participation,,,,cns treated,during the trial;|who had taken any medicine,between 18.0 and 30.0 kg/m2,,,,,,
7491,,old|refractory cardiogenic shock,covid-19 vaccine boosters,,kg).|intrauterine growth restriction (iugr),effective treatment,,,,full-term,with the last,≤ 35.0 kg/m2;|5,,,,,,
7492,,arrhythmic heart condition,medium or greater depth chemical peel,,lv,hiatal hernia,,,,reporting intake of,within 30 days of the planned start of study treatment,45 to 75 years||,,,,,,
7493,,psychiatric risk factors,vemurafenib,,physical condition/renal function,epidural labor,,,,low-dose acetylsalicylic acid,prior to the screening visit;|participant,< 2.5 times the upper limit of normal|and/,,,,,,
7494,,arteriovenous prosthesis,tafenoquine,,90 minutes,combination antiretroviral therapy,,,,living-donor liver transplantation||,at least 2 years.|axillary vein of,? 3,,,,,,
7495,,dm-btps,5-alpha-reductase inhibitors,,ocs,world health organisation criteria||,,,,following:||idiopathic pulmonary fibrosis|idiopathic nonspecific,at least six months before the first symptom,i ≥5 mm,,,,,,
7496,,judged unlikely to affect the pharmacokinetic profile,tenecteplase,,subgroups,testing protocols|recent corneal injury|a,,,,peritoneal,within 12 months prior to enrolment.|no history of,score 0 or 1|age ≥ 18,,,,,,
7497,,metastatic malignancy,sugemalimab,,fev1,pancreaticoduodenectomy,,,,immersion,within 1 month prior to inclusion,0 or 1.|investigators,,,,,,
7498,,language interpreter required,pituitrin,,thyroid function|concurrent,bone metabolic drugs,,,,injury|self-reported,within 4 weeks prior to randomization,less than 3 months;|planned,,,,,,
7499,,spinal stenosis).|previous abdominal,carbamazepin,,older|self-declaring,acute kidney injury):||replacement of kidney function,,,,authorized age range by,over the past two weeks,18-65 years|body,,,,,,
7500,,pellagra.|cancer,parenteral corticosteroids,,aspartate transaminase(ast,remote management,,,,antihypertensive medication;|age 40,up to two months prior to inclusion,>40kg,,,,,,
7501,,restrict lumoral use|pregnancy,national guidelines.||patients,,inova fairfax women's hospital||,stent-treated,,,,pd-l2,for 3 months after the last dose of study treatment.|must sign an informed consent form (icf,≤ 480 msec|patient,,,,,,
7502,,of:||gastroesophageal reflux disease,disorders|hemophilia,,prophylactic application of antiepileptic drugs|other serious central nervous system,simple hernia,,,,study.|intra-articular cortisone injections,before starting the dupilumab.|average itch numerical rating scale,≤ 5×uln.||10,,,,,,
7503,,involvement of the brainstem,warfarin anticoagulation,,alt)(sgpt,morphologic assessment,,,,sides,within 60 hours;|subjects,novice,,,,,,
7504,,liver disease|glaucoma|kidney disease,oral contraceptive,,biology department,thyroid hormone,,,,≤-0.75 d|anisometropia,within 48 h,18 years or over|at least one,,,,,,
7505,,pelvic/bladder pain,smart phone,,aalborg university hospital.||,previous biopsy,,,,early 2nd trimester,in the past 6 months|anticipating major surgery,> 8.5%);|use,,,,,,
7506,,psychiatric comorbidities,anti-platelet drugs|rescue pci,,serum amh,rupture,,,,cmv end organ disease,in the last 8 weeks|to,≥ 3 × uln,,,,,,
7507,,fiber histiocytoma,opiate,,asa ps,nutrition therapy,,,,influence the study findings,within 14 days.|antibody therapy,≤ 1.5x normal high value.|serum alkaline phosphatase,,,,,,
7508,,anxiolytic drugs|spontaneous,atypical antipsychotic medications,,updrs-ii,anti-tumor treatments,,,,immunomodulatory-related,within 72 hours|covid-19,"≥ 100,000 /μl|hemoglobin",,,,,,
7509,,child's need,metropolitan,,rass,left heart valve surgery,,,,low-dose,in 28-33 fractions)|at least 6 months,<80/50,,,,,,
7510,,left to right shunt|prior,dfci for necessary data collection.|may not be able to comply with the safety monitoring requirements of the study,,numeric pain rating scale.|history,braces)|have,,,,tibial,more than 4 weeks before,≤ 2.5 unl,,,,,,
7511,,autoimmune thyroid diseases,cashew,,screening|body mass index (bmi),b cell non-hodgkin's lymphoma,,,,mild radiation,in the past 5 years.|breast cancer,0-2;|adequate,,,,,,
7512,,benign arm participants:||pregnancy,ajor,,tablet,antiretroviral therapy (haart),,,,critical value);|have been,at least one day,60-90 mm/hg|not,,,,,,
7513,,arni,novel agents,,gh stimulation test,ophthalmic surgery,,,,urinary stones,prior to completion of this trial.|positive,45 years.|between two,,,,,,
7514,,myocardial infarction)|current,similar drugs for antitumor therapy;|received,,human immunodeficiency virus (hiv) infection,renal biopsy done,,,,exceeding 5 msv in the last 12 months or 10 msv,previous 2 years,≥ 1|hexsel css item,,,,,,
7515,,poor hygiene,avastin,,general inclusion criteria,chart review,,,,strong,throughout the study.|occasional use of,≥ 4.0 x 109/l,,,,,,
7516,,unilateral head pain,component of il-2 formulation.|patients,,calculated gfr,echo screening,,,,mulligan,within 2 weeks prior to administration of study treatment|participant,aids.|dry,,,,,,
7517,,primary warm antibody hemolytic anemia,ciclosporin,,mmhg|cardiac ejection fraction,oxidative stress,,,,included.|type ii diabetes mellitus,within 2 months prior to the first dose of study drug,≥ 90 g/l|bilirubin level,,,,,,
7518,,disease.|lower urinary tract structural abnormalities,daily steroid replacement therapy,,phq-9 9th item score,autologous stem cell transplant|mds associated,,,,mild to moderate disease,within 28 days before the study vaccination;|those,outside bologna metropolitan city,,,,,,
7519,,chromosomal structures,migraine,,female|lv wall thickness,breast surgeries,,,,preclude transcatheter valve implantation;|anatomical characteristics,during the study.|excessive drinking of tea,between 3-7 mm.|no symptoms,,,,,,
7520,,abscess,investigational drugs,,visit schedule||key exclusion criteria:||hypersensitivity,lung function,,,,ad,within 30 days before screening due,63.9 mmol/mol)|any,,,,,,
7521,,liver abscess,genetically modified t-cell therapies,,national health care system|major,ses-cd>3,,,,grade 2+ diarrhea,at least 2.0 standard deviation,≤ 3 months,,,,,,
7522,,tuberculosis still,intravenous icg,,screening:|body mass index,gastroenterologists,,,,implants,within 2 months of the baseline,<6 months prior to randomization,,,,,,
7523,,gluten,pembrolizumab,,suv)|absolute neutrophil count (,biochemical measurement,,,,non-caucasian subjects.|subjects,within the last two years|people,≥1000cps/ ml,,,,,,
7524,,adrenal gland,comfort measures,,anti-hcv ab positive,adjuvant whole pelvic radiation therapy,,,,while in treatment with sglt2 inhibitors|stable/chronic,within 4 weeks before the first administration|an active,< 100 x 109 / l,,,,,,
7525,,immunosuppression|dialysis dependent,oophorectomy,,prone spine surgery,first-line platinum-based regimen chemotherapy,,,,approximately 90 days|combined,during the last 12 months,≥ 12,,,,,,
7526,,"maternal complications,||for",topical ophthalmic antibiotics,,modified hoehn,histopathologically;|adjuvant chemotherapy regimens,,,,mild-moderate,separated by more than 3 months.||,less than 2 weeks before vaccination;|participation,,,,,,
7527,,refractory mm,hfnc,,muscle test values,hematological laboratory results,,,,suitable methods of contraception,at enrollment.|provision of signed,score 0 or 1|patients,,,,,,
7528,,psychiatric problems,neovascular amd,,ferritin,allogeneic hematopoietic stem cell transplant (hsct),,,,inspiration o2,within 14 days prior to day 1 of protocol therapy)|creatinine clearance,whose families accept to participate,,,,,,
7529,,hemorrhagic tendency.|serious infection,iodinated contrast media|any of the following,,modified radical mastectomy,icu-ward,,,,residence,operative time exceeding 5 hours,< 100 × 10^9/l).|massive nodes,,,,,,
7530,,immunological disorders,opioids.|proton pump inhibitors,,moderately curved root canals||,convalescent plasma therapy,,,,harmful,within 30 days prior to administration,0 or 1|adequate hematologic,,,,,,
7531,,human epidermal growth factor receptor-2 [,amiloride,,left ventricular end-diastolic diameter (lvedd),immuno-oncology agent,,,,mutua terrassa,at baseline.|subjects taking,for≥ 18% of,,,,,,
7532,,biochemical hyperandrogenism,topical ophthalmic solution,,cohort 1)/hemoglobin a1c (hba1c),magnetic resonance imaging-derived proton density fat fraction,,,,between,within 7 days of study enrollment,60 points or higher,,,,,,
7533,,liver functions,anti-cholinergics,,milk-specific serum immunoglobuline e,aifa,,,,achieved remission,within 4 weeks|stable,less than 30 × 109/l,,,,,,
7534,,impact on skin reactions,nonsteroidal anti-inflammatory medications,,cd4 cell counts,tunel assay,,,,without cohabitation,within one month prior to vaccination,≤ 6).||known,,,,,,
7535,,chemotherapy|pregnant,amphetamine-dextroamphetamine)|self-reported,,ag/ab) combination,or<60 millimeters,,,,infected,during this time.||women,≥75 × 109/l||participants,,,,,,
7536,,developmental disorders-motor skills,sci67,,local guidelines);|positive hepatitis c (hcv) rna,isolated procedure,,,,chronic kidney disease epidemiology collaboration (ckd-epi) equation,within 4 weeks from the date of the informed consent form until the last dose of study,2-12 and 35-50 years,,,,,,
7537,,hbv-dna,topical ocular steroids treatments,,smoking (max 5,injection of,,,,n05a-c,at screening or day 1,50-80|pd diagnosis,,,,,,
7538,,human immunodeficiency virus (hiv) infection.||8,medical-grade adhesives,,pregnancy test assessed,echocardiography,,,,requiring,before one week after ercp,60 years or above.|older,,,,,,
7539,,criteria for diagnosis,opioid treatment,,hein,taiwan label,,,,upper gastrointestinal endoscopy,within 4 weeks before the randomization visit.|therapy with biologic drugs,score between 13 and 18)|resides,,,,,,
7540,,eye tumors,nicotine patch use|currently,,thyroid function (,ivf cycles||,,,,functional,within 14 days before the first dose of trial therapies,18 years or older;|diagnosis,,,,,,
7541,,liver transaminases,hypoglycemic tablets,,period number,12-lead,,,,measurements|self-reported,for 12 months,"> 1.5|platelets < 50,000/mm3||confounding",,,,,,
7542,,laryngeal mask device||,dibenzazepine tricyclic antidepressants.|patients,,modified-cutaneous dermatomyositis disease area,gemelli|pregnant,,,,under salvage therapy,within one year before,4 through 7 years,,,,,,
7543,,symptoms.|type 1 diabetes,immunosuppressive treatment|sleep disturbances,,recist v1.1.|adequate organ function.||,local standards,,,,unsuitable for inclusion judged by the investigator,within the previous 6-months|has severe,>0.5,,,,,,
7544,,peptic ulcer diseases,transdermal contraceptives,,modified international society for human,clinical suspicions combined,,,,requiring iv antibiotics.|prior treatment,in the last 1 month.|have history,more than 120 iu/l,,,,,,
7545,,lips desquamation,drug-related pulmonary,,hcv rna.||known human immunodeficiency virus (hiv),nrt,,,,showed,within 14 days);neutrophil count,> 160 mmhg,,,,,,
7546,,neonates,local anesthetic drug,,serving capable,pathogenic variant,,,,grade iii and iv - leriche and fontaine)|patient opposed to participation in the protocol|pregnant,within 1 years after enrollment;|women,15% of body weight.||exclusion,,,,,,
7547,,lactating;|psychiatric disorder,eculizumab,,resting blood pressure,endotracheal intubation,,,,under judicial,at the beginning of the study,14-50 years;|diagnosis,,,,,,
7548,,ductal carcinoma in situ is allowed.||consolidating thoracic radiotherapy,lung cancer.|patients,,national cancer institute's common terminology criteria,chronic opioid,,,,german medicines act,within 2 months of randomization)|subjects,≥ grade,,,,,,
7549,,upper gastrointestinal symptoms,tamoxifen,,cooperative oncology group scale,rush emergency department (ed),,,,contaminant,in the past 6 months||inclusion criteria (support,7.5%,,,,,,
7550,,day).|systemic disease,light,,symbol digit modalities,target dfu is located),,,,ocular,at least 4 hours apart from study intervention,< 20 or > 45,,,,,,
7551,,bilateral pain,diabetes medication,,kidney function abnormalities|non-sinus rhythm,ophthalmologic examination,,,,fudan university affiliated cancer hospital,for at least 4 weeks before randomization.|concomitant anticoagulation,ecg|more than 5,,,,,,
7552,,antitumor treatments,inhibitors - ssri,,glycated haemoglobin,insufficient vaccination,,,,smokers||previous,last 8 weeks|cerebral hemorrhage,70-120,,,,,,
7553,,neuroendocrine carcinomas,antiviral medication,,general inclusion,inclusive.|normal laboratory tests,,,,tau,for at least 3 months;|at least 18,≥40% and <80% of predicted,,,,,,
7554,,distant metastases of breast cancer,escitalopram,,urine-hcg pregnancy test,revision surgeries||,,,,bleeding disorders.|a,within 3 years prior to treatment start,less than 6 months before registration,,,,,,
7555,,failure to respond to fucose,anti-coagulation drugs,,pulse rate measurement,invasive medical intervention,,,,middle cerebral artery supply area,within 7 months after the last study drug,under 18 years|severe cognitive,,,,,,
7556,,containing unstained,over-the-counter product,,ambulatory nyha,subtotal colectomy,,,,clinically significant abnormal,within 6 months prior to randomisation;|subject,>0.75 µkat/l,,,,,,
7557,,ipsilateral occlusions,done,,total bilirubin ≤1.5×uln,minimally invasive surgery,,,,neoplasia).|chronic,in the previous 3 years.|a fecal occult blood test,55 to 80 years|type 2,,,,,,
7558,,degenerative changes,pennsylvania hospital,,uk national health service staff member from the south-east,vital sign cut-off values,,,,steroids into the knee osteoarthritis,within 5 years prior to inclusion,more than or equal to [,,,,,,
7559,,months|symptomatic brain,components (,,systolic right ventricle,serologic test for hiv,,,,pneumonia|malignant,within 3 years of cancer,≤,,,,,,
7560,,aortic cross-clamping,drug abuser,,glomerular filtration rate],mechanical - spermicide,,,,65||*,"in the last three months,|receiving",≤ 3.25 mm,,,,,,
7561,,intractable,bisphosphonate,,hbv viral load,lumbar region past 3 days,,,,|uncontrolled,within the past 14 days.|patients,50 ≤ womac c ≤ 90)|patient able to understand the requirements of the trial,,,,,,
7562,,moles,supportive care|known medical condition,,calibrated oral examiner's opinion,pelvic contrast-enhanced ct,,,,gradually,within 14 days before administration;|did not receive,18 years and older inclusive|body mass index,,,,,,
7563,,contraindications,neurological diseases|prior use of medications,,any length of lymph node lesion,rescue treatment,,,,non-hbv,while on,18 or over|ability to provide signed informed,,,,,,
7564,,si joint pain score,anti-inflammatory drugs|recent weight,,ilae recommendations||,standard treatment.|ecog≤2.|expected survival period,,,,including||measles outbreak|planned,at time of informed consent,18 years old or above,,,,,,
7565,,microphthalmia,strains,,ecmo|national early warning score (news),molar extraction,,,,failure,early starting work…).|separation of the baby,over 450 ms,,,,,,
7566,,vaping,inflated balloons of ep-db,,recist version 1.1|symptomatic brain metastases could receive prior treatment,nodular liver lesion,,,,interfere with cooperation with the requirements of the trial.||patients,within 6 months prior to screen/baseline||pregnant,18.0 to 32.0 kg/m2,,,,,,
7567,,affect sensitivity,vedolizumab|ustekinumab,,crossover from arm,ventricular rate,,,,long-term,at the time of injection.||eastern cooperative oncology group (,"< 20,000/ul",,,,,,
7568,,implantable left ventricular assist devices;|use,drugs related to covid-19 prophylaxis,,covid-19 test result,condoms.|previous surgery,,,,clinician-administered,at the time of study participation||,≥ 60%||normal,,,,,,
7569,,familial risk,titanium alloys|morbid obesity|active malignancy,,prostate cancer histologically,antihypertensive,,,,non-glioma.|magnetic resonance,within 3 days before the start of treatment of the study drug.|patients,11-17 year,,,,,,
7570,,lymphocytopenia,ncrt,,platelet level,screen|positive breath alcohol test,,,,gm-csf,at least 2 previous standard,6-week,,,,,,
7571,,judged unlikely to interfere with study conduct,traditional herbal treatments,,ecg,treated in situ carcinoma of the cervix,,,,suitable for or denied,within the last 30 days)|recent,≤ 2.5x normal high value.|serum aspartate aminotransferase,,,,,,
7572,,massive infarction,tpo receptor agonists,,hôpital jean-talon orthopedic outpatient,venipuncture.||surgical interventions,,,,history;|increased blood,within 3 months,≤ 12 iu/l,,,,,,
7573,,hormonal rhinitis,nematavir/ritonavir,,hb≥90,chimeric antigen receptor t-cell ratio below the lower test limit,,,,unexplained,in the previous 6 months:||coronary artery bypass,>2.0 x upper limit of normal (uln),,,,,,
7574,,systemic autonomic disorder|patients,sodium-glucose co-transporter,,prostate cancer in situ),morphologic evaluation,,,,> 300,during the inclusion visit|confirmed receipt,12 to 16|with,,,,,,
7575,,malignancy).|hiv infection.|pregnancy.|are,give consent||,,refractory all/lly:|cohort b:,random biopsy testing,,,,≥9|history,within 7 days before the first administration,≤ 3;|patients understand the purpose,,,,,,
7576,,gestational,invasive investigational medical device,,thyroid stimulating hormone tsh,weeks.|（4）babies,,,,instead,within the last six months|any,> 130,,,,,,
7577,,cervical dilatation|pregnant,uti,,hbv dna copy,ad treatment,,,,low compliance or willingness to take the drugs,throughout the treatment period and until 6 months after the treatment period.|subjects must,3.4 points ≤ nihss score,,,,,,
7578,,gastric cancer|gastric cancer,comprehensive guidelines,,uc,ivig therapy,,,,trochanteric,prior to first dose of study treatment,≥ 21 days,,,,,,
7579,,chronic gi symptoms,balsalazide,,hepatitis b surface antigen positive,standard sialometry,,,,under 50kg|undergoing emergency surgical procedures,at the time of enrollment,between january 1st 2019,,,,,,
7580,,centre hospitalier,chronic steroid,,response evaluation criteria in solid tumors v1.1),test procedure,,,,flow-diverter,before 24 hours of admission).|the,b-d,,,,,,
7581,,respiratory biologics,corticoids,,response,hormonal contraceptive;|iud;|prescription hormonal contraceptive,,,,osteo-articular pathologies,during the in-person screen|an inability to understand study procedures following review of the informed consent form|understanding,between 130-140mmhg,,,,,,
7582,,rhythm abnormalities,early childhood educator,,screening lipids||triglycerides,intraductal papillary mucinous neoplasm.|have measurable disease,,,,non-english speaking|under 18 years old,within the past two months before anticipated enrollment,18 years old or older|works,,,,,,
7583,,lifestyle modification only,corticosteroid medications,,residual grade,implant,,,,grade 1 of 4,at time of randomization|patients,> 28 days|having had,,,,,,
7584,,breastfeeding|cognitive impairment,loop diuretics,,"t1-t2n2bm0,",transfemoral tavi procedure.||,,,,low-income neighborhood,within 6 months before screening;|subjects,"< 50ml/min / 1,73m2|hearing",,,,,,
7585,,activity impairments,≤2 prior,,cervical cancer|pregnancy,effective medications,,,,lasik(laser-assistant in situ keratomileusis,within the protocol mandated time period||reminder,49 years to 65 years)|the,,,,,,
7586,,swollen joint|inability,appropriate antibiotics,,glomerular filtration rate (gfr),with||uterine,,,,excessive,< 28 days prior to baseline,> 470 milliseconds,,,,,,
7587,,recreational drugs.|known,routine drugs,,edss score,prevention treatment,,,,beverage regularly before recruitment|informed consent,within 6 months of initial response,≤ 2.||adequate organ function,,,,,,
7588,,uncontrolled seizures,bismuth,,fscp,cholangioscopy,,,,agc diagnosis,less than 12 years,≥30·0 kg/m2,,,,,,
7589,,autoimmune disease|unstable cardiovascular disease|glucose lowering medications,parenteral iron products|non-iron deficiency anemia,,absolute neutrophil count [anc],intrauterine contraception,,,,sport s-icd study,during the study period;|severe hypersensitivity reaction,between 20-80 years,,,,,,
7590,,eligible.||mandatory archival,narcolepsy.||tricyclic antidepressants,,modified rankin scale (mrs) score before onset,3)|osteoarthritic knee pain,,,,under,within 4 weeks prior to the,≥140mm hg,,,,,,
7591,,pertussis,aminoquinolines,,serum cr,screening;|intraocular glucocorticoid injection,,,,in-patient with no clinical signs of uti,within 179 days) prior to entry,lower limb,,,,,,
7592,,tumor mutations,over-the-counter cbd-containing product,,signs of parenchymal lung damage,laser release of amniotic bands||,,,,tumor-invasive basement,within the previous 5 seasons.||,≤2× upper limit of normal (uln),,,,,,
7593,,intracardiac line,component of the products,,participants|age,extensive radiotherapy,,,,diagnostic and statistical manual of mental disorders.|have a past history,medical history form,< 10g/dl)|thyroid disorder|neoplasm,,,,,,
7594,,renal disorders|patients,topical prescription ophthalmic drops,,serum β-hcg pregnancy test,diabetes;|laxative treatment,,,,liver parotid contrast,within 1 year of the screening visit,0-2.|adequate renal,,,,,,
7595,,matériel métallique susceptible de concentrer les impulsions de radio fréquence,excretion;|patients,,aids,donate blood from the screening to 56 days after the follow-up visit.|participation in a clinical study involving administration of an investigational drug,,,,reduced dose,at least 14 days must,under 42 years,,,,,,
7596,,eligible.|hepatocellular carcinoma,check-in for,,serum creatine phosphokinase (cpk),transarterial embolization,,,,low dose opiates,within 1 month prior to treatment;|patients,above age 80,,,,,,
7597,,knee extension,fucidin,,randomization|ecog performance score,contraindication;|electroconvulsive therapy,,,,fragments,within 30 days of tumor harvest|history,0-1;|patients,,,,,,
7598,,dependence current use,synthetic cage insertion,,kg|ecog performance status,immunohistochemical [ihc],,,,unusual frequent,within 30 days prior to imp treatment start,less than 2 weeks ago,,,,,,
7599,,skeletal dysplasias,components of multimodal,,inr）,pelvic organ prolapse|post-menopausal,,,,infraclavicular fossa,within one week prior to agent administration.|history of any clinically significant,<34.8 kg,,,,,,
7600,,and/or arm pain,online delivery,,"lung cancer"" issued by the international association for the study",serotherapy,,,,ic,between 3 and 14 migraine days per month;|have completed,0 or 1|be eligible to receive,,,,,,
7601,,adjustment disorders,anaesthetics,,serum protein electrophoresis (spep),extracorporeal membrane oxygenation support,,,,adequate evaluation of safety,within 4 weeks before the first drug use,lower than 45/min,,,,,,
7602,,a disorder,beta subunit,,age>60,first treatment modality,,,,tripod)|to be,within 3 months prior to vaccination,>30 kg/m2,,,,,,
7603,,dental disease,drug-induced lupus.|history,,air.|ecog performance status,serological testing for hbv,,,,residual disease.|participants,throughout the study period to administer tes to the ps||,>1.4,,,,,,
7604,,familial adenomatous polyposis,terzepatide,,rna,target lesions.||eastern cooperative oncology group (ecog) performance status,,,,low-grade glioma,in the past 21 days preceding inclusion,at least 50-80 years,,,,,,
7605,,candida albicans,tpi,,uk pd society brain bank criteria,live vaccine vaccination,,,,non-combustible,within 7 days before randomisation||exclusion:||history of another,>80 mg/dl,,,,,,
7606,,calculation formula);acute coronary syndrome,glycerin,,pro),thermoregulatory,,,,diagnostic and statistical manual-v (dsm-v) criteria,within 4 weeks prior to the intervention|osa,> 1.50d;|using,,,,,,
7607,,gunshot wounds,live vaccinations,,plasma hiv-1 rna,medical supervision,,,,±15kg,within 28 days prior to enrollment.|inability to swallow pills,i - iii|both genders.|height,,,,,,
7608,,prognosis|preterm prelabor,albumin-bound,,average qtcf interval,contraceptive implant|progestogen injections|combined estrogen,,,,gestation|single,within 2 weeks of the experiment day|inability to personally provide written informed consent,≤ uln,,,,,,
7609,,lewy body dementia,wlris,,sociocultural level,stay on them for the duration of the study.|sebacia laser treatment,,,,qpcr,1 week before the start of the treatment,0 to 1|patients,,,,,,
7610,,unconscious,pde3 inhibitors,,diabetes a1c,treated by,,,,neuro-oncology biorepository for archiving of,within 24 weeks before the first dose,1-pt,,,,,,
7611,,parq,reads,,sohag university hospital.|age,holter ecg,,,,low-stage skin,within 7 days before screening,greater than or equal to 130 mg/dl,,,,,,
7612,,cystic fluid,android phone,,blood bilirubin,surgically resected specimens;|patients,,,,interferes with any study procedure|current,within 6 months prior to the study.|acute,7-12 years,,,,,,
7613,,amplifications,monopheresis,,anti-hbc antibody result are,androgen-deprivation therapy|judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures,,,,non-neuroendocrine tumors,within 2 weeks of,<20 years|valvular af,,,,,,
7614,,trying to lose weight,nilotinib,,rickham catheter.|≥,systemic glucocorticoid treatment,,,,cns disease.||presence,up to 100 mg/d,30 ml/min||ability to understand,,,,,,
7615,,cardiac involvement,premedication,,liver function tests||vii,oral nutritional supplements,,,,suitable to participate in this clinical trial,up to 3 month after receiving the treatment)|subject,90-120 days,,,,,,
7616,,acute mental health difficulties|sexual assault,hormonal supplements,,body mass index (bmi)<18.5 or,ivus,,,,non-pre-eclampsia,at time of signing informed consent form|eastern,<16 years.|unable to communicate in english,,,,,,
7617,,impairment of the heart,phenylbutazone,,average corrected qt interval,cockroft-gault formula (appendix c)|provide written,,,,portal hypertension|signed informed consent||,within 24 hours prior to the start of treatment|any condition,≥ 60 ml/min||,,,,,,
7618,,impaired renal function).|mental disorder,synbiotics,,ncc,small cell features.|prior malignancy,,,,molecular documentation,during mechanical thrombectomy:|patient who was informed of the study,<1 g/24,,,,,,
7619,,organic pathologies,corticosteroid implant,,fish +),anti-tumor therapies,,,,atrioventricular,at least 1 year after menopause.|subjects should understand the nature,higher than 5%,,,,,,
7620,,carotid occlusions,beta-oxidation,,hiv serum reaction.||20,pet-mri,,,,investigator.|prior solid organ,within 14 days before screening):||absolute neutrophil count (,30-60|evidence,,,,,,
7621,,common carotid artery|absence,rheumatic drugs,,marshall score,refractive medium turbidity,,,,tme group,in the last cervical smear,<40ml/minute,,,,,,
7622,,target intracranial lesion,vasoactive drugs,,residence in foster care,recommendation,,,,non-irradiated disease,within 2 weeks prior to screening.|had,> 450 msec|qrs,,,,,,
7623,,clinical manifestations of eczema,anti-emetic,,tiko platform,local hospital guidelines,,,,10 unstained,in the ear region|h/o,lower than 15%.||,,,,,,
7624,,substance-induced psychosis,drugs used in this study|recurrent tumor,,nci-ctcae version 5.0,imaging subcohort,,,,ib,within 6 months prior to visit 2.|have,0 to 2|life expectancy,,,,,,
7625,,major depression/bipolar,oral cortisone pills,,thyroid hormone replacement.|participants,primary tka|patients,,,,closely related,within 1 month before joining the group,6.5-10%|age,,,,,,
7626,,neurological disorder(s).|active autoimmune disease,neurological problem|any contraindication,,muscle region suitable for biopsy,age|prisoners,,,,highly effective method of contraceptive||,at least 4 weeks before baseline,< 3000/,,,,,,
7627,,distal common bile duct.|patients,diltazem,,kpwa,r1 resections);|presence of minimal extra-regional disease,,,,stimulating growth factors,during the screening,between january 2017 and january 2023,,,,,,
7628,,neoplasms in situ,psoriasis medications,,qt syndrome.|qtc,prk surgery,,,,clips,within 2 years before screening,< 25 ng/ml,,,,,,
7629,,superficial punctate keratitis,iodinated),,ocs dcd heart cap,pretreatment imaging,,,,low-dose ct,30 days before,14-17,,,,,,
7630,,laryngeal nerve paralysis|non-native italian speakers,dadih sauce until delivery.|abortus,,surface emg signal quality low)|hypercapnic respiratory failure,systemic chemotherapy line.||a chemotherapy line,,,,non-cns disease.|is,within one year before enrollment,older than 50,,,,,,
7631,,babesiosis,rituxan,,diabetic ketoacidosis|blood pressure,first cardiac surgery,,,,lower extremity venous ulcers,"within 4h30 after onset of symptoms,|early brain mri",≥18.0 and <40.0 kg/m2,,,,,,
7632,,mild myopathy,anti-viral medication,,kellgren-lawrence classification,immunotherapy drugs,,,,css,during the 6-month period prior to baseline.|systemic anti-vegf therapy,> / = 80 ml/min,,,,,,
7633,,carcinoma in situ of uterine cervix,beta-adrenoceptor antagonists,,response evaluation criteria in solid tumours (recist 1.1);|disease progression occurs after,replacement treatment note: for other medical conditions,,,,corneal erosion,within the last 365 days,≤1.5 x institutional upper limit of normal,,,,,,
7634,,chronic pancreatitis||note,kuantan,,systolic,cellular therapy [astct] criteria,,,,intracranial internal carotid artery,within the 6 months prior to study enrollment,functioning in older adults||in and exclusion criteria for older residents,,,,,,
7635,,verbal response,abuse,,prostate cancer working group (,operation;|receive antibiotic treatment,,,,peripheral arteries,within 3 months of donation/screening consent,> 4.7 or ≤ 0.3,,,,,,
7636,,vaccinations,oral anti-androgen,,pulse oximetry.||for scd,steroid treatment,,,,radiation-induced,within last 6 months|major psychiatric disorder|history,less than 20 over 90,,,,,,
7637,,unipolar depressive episode,ist,,mbp,graft versus host disease (gvhd),,,,hours|stable,in the patient's lifetime|history,less than or equal to 60 minutes of,,,,,,
7638,,colonoscopy)||,anti-angiogenic mab drugs,,peripheral neuropathy|life expectancy,lumbar surgery,,,,genetically proven,prior to the diagnosis,<40%|presence,,,,,,
7639,,hematological disease,narcotics,,american college of rheumatology/european league,suggestive of,,,,v3,at screening defined,"> 35,|glomerular filtration rate (gfr)",,,,,,
7640,,ocular basal cell carcinoma,pimozide,,american society of anesthesiologists)|patient,iabp,,,,ds|age,personal history of no,≤ 5% of mean normal laboratory levels,,,,,,
7641,,signs,screening|patients,,glomerular filtration rate ( egfr≥60,genetic evaluation,,,,index level,in the past 3 months|receipt of oral,<30 ml/min per 1.73 m2.|current,,,,,,
7642,,in situ uterine cervical carcinoma,loncastuximab,,mgb hospital,pzq,,,,visualized,within next 14 to 25 days|50,≥120 g/l.|sf,,,,,,
7643,,prolonged pq,capecitabine,,nugent score,pazopanib,,,,non-aneurysmal aortic diameter <18mm or >42mm,during screening.|concurrent active,stage ii-iv|knowledge of,,,,,,
7644,,boundary values).|for,oral anti-coagulant therapy,,status- eastern cooperative oncology group (ecog),complete cessation of menstruation,,,,"personal computer, laptop- this includes",in the last 6,0-iib,,,,,,
7645,,extrahepatic distant metastases,amlodipine,,liver function test(s,prosthetic restoration,,,,pd-mci level,in the range,over 18 years.||,,,,,,
7646,,renal insufficiency,antibodies,,viral infection.|stem cell transplant,blood pressure|complete heart block,,,,≥ctcae grade 2|major surgery,before starting this pilot,< 30 kg/m2)|must,,,,,,
7647,,recurrence of malignancy,glp-1 agonist;|any,,cardiac critical care unit/cardiovascular intensive care unit,emergency obstetrical care,,,,laparoscopic,for more than five years after diagnosis,≥6 years,,,,,,
7648,,/capsular damage /weakness,vivactil),,hcv antibody test,clinical thromboembolicor major bleeding events,,,,post-irradiation,within four weeks prior to the first dose of study treatment,grade iii or iv,,,,,,
7649,,difficulty comprehending,trial medication,,hepatitis c virus (hcv) antibody test,e-cigarettes)|have,,,,seizures|mild,within the last 4 weeks prior to investigational medicinal product administration,>35 s,,,,,,
7650,,malignant disease|prior treatment,fontan palliation,,uln|echocardiogram ef,genetic loci,,,,surgical specimens,within 14 days prior to initiating study treatment.|[males,30 u/l,,,,,,
7651,,digestive tract diseases,selective serotonin reuptake inhibitor (ssri) medication,,north cumbria,surgical,,,,physician;|aged 40,for 4 weeks after initiation,between 0-11 points,,,,,,
7652,,bleeding disorder.|patients,herbal medications,,hemoglobin level (hgb),pacemaker implantation||tilt test is recommended but not mandatory,,,,pd-l1 antibody,within 14 days prior to administration of prth-101.||a,between 12 and 17 years and 11 months,,,,,,
7653,,impaired heart function,amide-type local,,alt (gpt):,left heart disease|patients,,,,atrium ventricular block,within 6 months prior to screening.|clinically,≥75 x 109/l,,,,,,
7654,,other defects,anthracquinone,,sensitising egfr,cosmetic treatment,,,,disorganized,within 14 days prior to vaccination.|positive,>2500g|possible match,,,,,,
7655,,choriocarcinoma,local therapy.|existing neurocognitive,,left ventricular ejection fraction(lvef)<50%|uncontrolled,rsv vaccine,,,,preclude intralymphatic,3 days prior to first dosing,=< 2 x upper limit of normal (uln),,,,,,
7656,,non-invasive,tinzaparin,,recist 1.1.|documented her2 exon 20 insertion mutation.|eastern,leg)|acute sunburn,,,,non-medically induced,for at least 6 months prior enrollment,≥ 18 years|intubated,,,,,,
7657,,factor deemed unsuitable,anti cd20,,gm2 gangliosidosis,pharmacist-related services,,,,pd-l1 cps,within =< 28 days prior to registration)|platelet count,< 80ml/min,,,,,,
7658,,mucus|active urinary,platelet promoting agents,,platelet aggregation,ct scan pretherapy medication,,,,clinically unable to switch,in the last 3 months|haematological disease,over 3%|subjects,,,,,,
7659,,lymphoma.|multicentric carcinoma,inducers|strong cyp2c9 inhibitors,,serum phosphorus concentration,abdominal source|c. difficile,,,,after liver,recently than 3 months,>25,,,,,,
7660,,idiopathic forms,ibd-unclassified;|faecal calprotectin,,extracorporeal carbon dioxide removal,complete cycle of,,,,severity level,pre-trial treatment,level||5 ×upper limit of normal (uln),,,,,,
7661,,hypoadrenalism,gastric acid inhibitors,,dsm-v)||,immunocytochemistry,,,,enrolled.|history of non-infectious,in the 2 weeks prior to the start of the,"≥450ms, qrs≥120ms obtained",,,,,,
7662,,mitral insufficiency|current leukopenia,nonsteroidal anti-inflammatory drugs).|use,,pwd participant||pwd-participants,hip/knee replacement,,,,in room air,at the time of examination|persons,0-11,,,,,,
7663,,primary causes,antiallergic medications,,level of serum/plasma testosterone,minus cylinder convention,,,,non-toxic marker used,at the time of study enrollment|adolescent,<= 3,,,,,,
7664,,perinnial allergic rhinitis,mrna vaccine/s,,status,world health organization (who) classification,,,,platinum therapy)|measurable,in 3 months before random;gastrointestinal perforation,≥16 years,,,,,,
7665,,dress syndrome,carbamazepine,,child-pugh liver function score,photodynamic treatment,,,,non-intensive targeted therapy,within 1 month of trial,0 ~ 1;|7,,,,,,
7666,,ft3,otc capsaicin,,hepatitis b surface antigen-reactive,mect,,,,cholinergic enhancers,at least 6-months,>2x upper limit of normal (uln),,,,,,
7667,,bronchospasm,remibrutinib,,alzheimer,temozolomide chemotherapy,,,,pericardial effusions,less than four weeks prior to enrollment,>= 2.5 g/dl|renal:|egfr,,,,,,
7668,,screening;|malignant disease,participate.|no residual blood left in clinical sample,,hepatitis c antibody.|abnormal liver function,revision total hip surgery,,,,pd-l1 cps testing.|there,unclear history,> 8x/week,,,,,,
7669,,pectus arcuatum,vaccinium species,,measurement,e first,,,,≥30 minutes later,at lower pole of size 10mm -20mm||,18 and above|earlier histologic diagnosis,,,,,,
7670,,left atrial spontaneous echo contrast,beta blockers|severe,,american indian,large|evidence,,,,stroke|vascular,within 7 days before the first use of the study,40-90%,,,,,,
7671,,autoimmune hemocytopenia,components in the cocktail,,prognosis,bmi≥40 kg/m2.|bariatric surgery,,,,longest diameter of ≤ 5 cm.|presence,within 14 days before the first dose of study drug|any condition,45-75 years old|hba1c,,,,,,
7672,,elevated emotion,intravenous anti-infective,,node negative lung cancer,parenteral nutrition could also be included in the group;total bilirubin (tbil),,,,study|received,within 2 weeks prior to apheresis,at least 10% of each other.|evidence of abnormal bioimpedance ratio,,,,,,
7673,,infectious conditions,immune-stimulating drugs,,t-score,c).||abnormal ecg,,,,triple negative breast cancer (tnbc),6 months prior to screening,pregnant,,,,,,
7674,,phakic presbyopic,cerebellar ataxia,,menstrual bleeding questionnaire proposed by,"reactive"" test result of hepatitis b & c, hiv",,,,less)|no metastatic,prior to study participation|ability to return,15-24 fractions)||v30,,,,,,
7675,,severity,brigatinib,,breathing,mri scan|unable to receive,,,,12-14 of gestation).|verbal,prior to ed,≥ 9)|clinical,,,,,,
7676,,completed curative antiviral,premedication for hypersensitivity reactions,,active monitoring phase of the study).||,fraction sizes,,,,specifically targeting t-cell costimulation,within the past 18 months||symptoms,> 60|gender,,,,,,
7677,,"primary caregiver,|the child",vitamin k antagonist,,hbv dna testing,tyrosine kinase inhibitor (tki),,,,illness|clinically relevant,prior to first study drug administration.|medically healthy,between 20 and 35 kg/m2|able to understand,,,,,,
7678,,inflammatory muscular disease,relocate,,screening|estimated glomerular filtration rate egfr,hospitalization,,,,systemic antineoplastic therapy,less than 2 months before the first day of screening;|regular medication intake,less than 5 hours per night on weeknights,,,,,,
7679,,latent autoimmune diabetes,anabolic steroids,,required.||adequate bone marrow reserve,exercise right heart catheterization,,,,active phase of the study,during the study|subject cannot,16-17 years,,,,,,
7680,,refractory,anti-hcv therapy,,total score between14 and 30,temporal artery biopsy,,,,orally,psychiatric history,0 -1;|minimum microscopic margin of non-cancerous tissue of 2 mm,,,,,,
7681,,complex root canal,gefitinib,,pulse rate (pr),infiltrative treatment,,,,coronavirus,within 14 days prior to vaccination;|receipt,≥ 50 ml/,,,,,,
7682,,locoregional therapies,medication use influencing appetite,,infection.|eastern cooperative oncology group (ecog) performance status (ps),radical pelvic surgery,,,,g1961e-associated,in the last 6 months|being,bigger than 4,,,,,,
7683,,hemispheric stroke,antiplatelet agglutination therapy,,diastolic blood pressure(dbp,small room for whole-body indirect calorimetry|unwilling,,,,"sacroiliac joint,|acute",within 6 months prior to signing informed consent.||31,male patient's sexual,,,,,,
7684,,late life depression,local/grille photocoagulation,,monoclonal antibodies (mabs),treatment guidelines,,,,full,at the time of informed consent|body weight,<55 beats per minute (bpm),,,,,,
7685,,hodgkin,medications the principal investigator (pi) believes may interfere with healing of the target dfu|subject who,,her2 ihc score,first-line pd-1 inhibitors,,,,non-ghanaian,within 14 days before first dose;|received,≥18 to ≤ 65,,,,,,
7686,,pancreatic neuroendocrine tumors,anti-ctla-4 antibody,,eng,gird,,,,non-ocular conditions,within 6 months prior to first dosing,controls):||17-45 years,,,,,,
7687,,abdominal wall hernia mesh,eot,,urine drug screen/alcohol breath test,revascularization,,,,american college of obstetricians,management of tremor,<100 mmhg.|patients,,,,,,
7688,,venous catheterization,preventative medication dosing,,minimum duration,analysis||,,,,physically,within 24 weeks|history of,>160/95 mm,,,,,,
7689,,chronic joint pain.|lack,tunneled catheters,,serum total bilirubin ≤1.5×uln,contrast enhancement,,,,gynecological laparoscopic surgery.||,past 12 hours,< 0.3,,,,,,
7690,,caries that,long-acting beta agonists (labas),,estimated egfr,medication|uncontrolled thyroid disease|pregnant,,,,calculated,at least 5 years,long-term fever,,,,,,
7691,,surgical conditions,quarantine may resume screening,,ipv,arterial bypass grafts,,,,unknown origin,within 6 months after the end of the study.|female,handed|aged 18 to 40|having completed,,,,,,
7692,,breast feeding;|myocardial infarction,medication known to be,,urine pregnancy test before vaccination,major surgeries,,,,low-energy,at screening visit|participants,18 years or older|expected,,,,,,
7693,,behavior|laboratory abnormalities,sodium phenylbutyrate,,iief-ed domain,adjunctive treatment,,,,moderate - severe,within 14 days before the first dose of durvalumab,≥20 and ≤50|detection,,,,,,
7694,,primary sjogren's syndrome,ezh2 inhibitors,,lv size|right,split electrode,,,,with curative,within 2 months before the first dose of study drug.|received,>= 100 x 10^9/l|hemoglobin,,,,,,
7695,,adrd,compounds of similar chemical or biologic composition to oxaliplatin.|any other medical,,prestroke modified rankin scale,sacrocolpopexy|desires surgical treatment,,,,non-traumatic subarachnoid hemorrhages,within 4 weeks preceding the start of study treatment|unwillingness to participate,2.0 ng/ml|soft-tissue progression,,,,,,
7696,,bruton's tyrosine kinase (btk)-containing regimen,antithrombotic medication to cancer patients||,,serum pregnancy test.||,interbody fusion group,,,,could jeopardize compliance with study requirements.||main study:||inclusion,during sexual intercourse from the time of the first study drug administration,less than 37+ 0/7 weeks or more than 42+0/7 weeks|neonatal,,,,,,
7697,,impairs motor,abaloparatide,,tcpo2 30 mmhg,product|major surgical procedure,,,,alter tear film physiology;|having,within 1 year after,≤ 12 weeks,,,,,,
7698,,acute leukemia,sonelokimab,,american society of anesthesiologists (asa) physical,vaginal estrogen treatment|use of vaginal estrogen,,,,non-aneurysmal aortic diameter <16mm,before first administration of the study,> 35 kg/m2|allergy,,,,,,
7699,,solid organ transplantation|pregnant,anti-rsv product,,urine pregnancy test conducted,survival monitoring,,,,plasma glucose,for nearly 2 months|hamd-17,<50% predicted value,,,,,,
7700,,insufficiency||cardiovascular dysfunction,disinfectants,,modified updrs scale,bone marrow biopsy|a tet2,,,,non-small cell lung cancer);|patients,within 12 months before the start of the study may,<2500,,,,,,
7701,,defibrillator.|ongoing infection,g-csf,,inadequate mbc tissue,abstinence,,,,medical,at time of recruitment|lives,1-3).||additional criteria,,,,,,
7702,,lanpc,antihypertensive drug treatment.||exclusion criteria:||under treatment,,ii).||exclusion criteria were||diabetes mellitus|smoking|pregnancy;|diagnosis of anxiety disorders/psychiatric,open surgical biopsy,,,,trying,within 14 days before registration.|unable to adhere to the study procedures.|evidence,>6 months before administration of the investigational products.|be able to communicate well,,,,,,
7703,,cns vasculitis.|currently,acceptable.|aspirin,,rna test,ventilation|other treatment,,,,relapse|symptomatic,after previous treatment;|the,>/= 6.5%,,,,,,
7704,,open fractures,anti platelets,,portal vein embolization,atopy,,,,occlusion|existed,within 2 weeks prior to enrolment|have,150 ml grape wine,,,,,,
7705,,ventricular rhythm,international guidelines,,modified recist 1.1. for the purposes of this study measurable disease,implantation surgery,,,,its,within 3 months after the examination,≥10%,,,,,,
7706,,inflammatory optic neuropathy,hyperlipidemia agents,,cln3,chemo - port.|patients,,,,sars|nosocomially-acquired,within 30 days or five half-lives,< 60 ml / min);|polyvalent,,,,,,
7707,,strong interaction,blood coagulation;|use,,presentation|ecog,stent treatment,,,,3|full term,within 30 days of the screening biopsy,2 to 10 years,,,,,,
7708,,drugs;|pregnancy;|acute local,topical steroid,,individual,fresh cycle embryo transfer,,,,psp)|histologically confirmed,at least two months after vaccination,≥50% fio2 need,,,,,,
7709,,oocyte retrieval,nasal itching,,classification of the american society of anesthesiologists asa,index surgery,,,,deemed related,more than 7 days,>24,,,,,,
7710,,atrx/daxx,anthracycline-containing sessions,,chf nyha class,complete periodontal diagnostic,,,,suitable to continue,2 months prior to the start of study participation;|pregnant,equal to or lower than 1.5 times of uln;|coagulation function,,,,,,
7711,,clinical laboratory abnormality,classic angiographic,,ventricular ejection fraction (lvef),steroid therapy.||adequate organ,,,,lasting over 6 months,during the study.|the patient,18.5-24.9 kg/m2,,,,,,
7712,,oi,polycyclic antidepressants,,peripheral neurotoxicity,esophageal varices.||history,,,,pregnancy 2,within the last three months|current use of,≥ 6 months to < 8 years,,,,,,
7713,,sinus|poor dental hygiene,lepirudin,,nihss level of consciousness,cumulative dose,,,,periodic,within 14 days prior to first dose of study therapy).||total bilirubin,=< 2 weeks,,,,,,
7714,,compression fracture,live-virus vaccine,,dose|total bilirubin,biopsies,,,,non-healed,in the past 2 years|patients,<25ᵗʰ percentile,,,,,,
7715,,extensive bilateral brainstem infarction on ct,anti-retroviral agent,,oxygen saturation level,b-cell lymphoma-2(bcl-2,,,,non-consecutive,history of more than 5 years,less than 14 years,,,,,,
7716,,illiteracy,agents used in the study|participants,,ankle brachial index (abi),baseline ct scan of the chest,,,,inflammatory response,within 3 months prior to enrollment;|acute myocardial infarction,< 1.7 nmol/l,,,,,,
7717,,period;|human immunodeficiency virus,nris,,preoperative value|methemoglobin,dvt intervention,,,,medium,"at least one month before the start of the study,|children",between 20.5 - 45 m/kg2|between,,,,,,
7718,,steroid inhalers,drugs studied|known,,recist criteria 1.1,preoperative blood optimization clinic,,,,diagnostic and statistical manual of mental disorders (fifth edition) (,up to 4 weeks after the last injection with study,30-50 kg/m2|bed,,,,,,
7719,,brain diseases.|arrhythmia,juvenile idiopathic arthritis|treatment,,recist1.1 standard;|ecog score 0~3,r2 resection,,,,tested locally)|pd-l1 tumor proportion score,in the last 12 months prior to the study,< 0.9)|must understand the study requirements,,,,,,
7720,,neoplasic pathology,leponex,,interferon gamma release assays) test,palliative care unit,,,,3 on unilever visual scale,within 4 weeks|any non investigational anticancer therapy,pbc.|incomplete response,,,,,,
7721,,sistolic bp,thoraflex hybrid device,,cdk4-related genes.|ecog score,tubridge flow diverter treatment,,,,post-nasal drip,post,less than or equal to 30 db hl,,,,,,
7722,,laparoscopy|peritoneal metastasis,sivelestat,,platelet count<100×109,standard-of-care abdominal laparoscopic surgical procedure,,,,essential oils,within 48 hours prior to the administration mefamp.|must,>160 or <90 mmhg|severe,,,,,,
7723,,harm to others,additional immunomodulators,,bloomlife lovelace ft electrodes locations|contraindication,peripheral oxygen saturation,,,,american college of rheumatology criteria,within =< 6 weeks prior to registration.|patients,over 12 months|partner objection to participate,,,,,,
7724,,brow,anti-tumour necrosis factor,,bone density 1.5 standard deviations below the young adult normal,ngs panel testing,,,,non-inclusion criteria;|refusal of the patient to further examination,prior to admission to the icu|history,≥94% or <,,,,,,
7725,,breast-feeding.|concurrent malignancy,immunomodulating drug,,bpp,tmj surgeries,,,,b7-h3 expression;|(5,for 3 months after the final dose||,≤ 5.5 mmol/l;|systolic,,,,,,
7726,,non surgical treatment||,dextran,,peanut spt,pelvic organ prolapse|those,,,,prohibit detailed multimodal imaging|(bcva,within 4 weeks prior to cycle 1 day 1,<0.5 ml/kg / h,,,,,,
7727,,lymphoproliferative disease,exenatide|sulfonylurea,,ldl-c,hormonal vaginal devices,,,,primary unifocal,within 4 weeks before the first use of the,≥6,,,,,,
7728,,post exertional malaise,anticoagulation regimen,,n,standard treatment exists,,,,non-carious cervical lesions|patients,within the last 24 weeks prior to signing the,< -3.0).|presence,,,,,,
7729,,etc.);|uncontrolled hypertension,migraine prophylaxis|started,,nazer score,graft stones,,,,autologous,during this same period**.||* acceptable,12 years old or more.||,,,,,,
7730,,non-renal conditions,imdevimab,,oral glucose tolerance test,elective adenotonsillectomy surgery overnight,,,,from initial diagnosis,at baseline||inclusion criteria combacal-twic,≤ 3.0 × upper limit of normal (uln),,,,,,
7731,,subcutis,ziprasidone,,or||abdominal circumference,ultrasound treatment,,,,icd-10),for the last 60 days,2a,,,,,,
7732,,home|executive deficits,components of the kit used (helikit),,cwp,multidisciplinary assessments,,,,diseases.|allergy to lactoferrin,during at least the last 12 months,"≥ 18 years old, regardless of gender;|expected survival",,,,,,
7733,,level i,conventional orthodontic appliances.||this,,nccl's deepest point,cerebrovascular accidents,,,,site|clinically stable,for at least the previous six months)|history,< 1.5 × 10^9/l,,,,,,
7734,,dermatological disorder,strong potential for alcohol,,diastolic bp,target district chosen,,,,peri-implant mucositis,within 2 months after the final dose of,over 65 mmhg,,,,,,
7735,,progressive familial intrahepatic cholestasis,tremelimumab combination,,mohs' surgery,hospitalisation,,,,3m,within the past 13 months,2-3 points,,,,,,
7736,,local practice).||clinically significant,verapamil,,oura™,pleuroscopy,,,,reuse of its,prior to each experimental session,<5 years before diagnosis,,,,,,
7737,,brachial plexus block,immunosuppresive medications,,months|body mass index,drug therapy specifically targeting t-cell costimulation,,,,organ allografts,previous 2 months,60 minutes prior to specimen,,,,,,
7738,,relapsing-remitting multiple sclerosis,drugs under any of the following conditions:||a) change in dry eye medication,,serum free light chain (sflc),acid suppressive drugs,,,,temporary,during the past 2 years;|women,"below 2500 g,|stable",,,,,,
7739,,acute enteritis,minodronate,,inr,major respiratory complications;|participation in another clinical trial;|use of,,,,older|stable,within 4 weeks prior to screening visit,≤ 30 ml/minute,,,,,,
7740,,meal related,coumarin-derived,,asa-score,pelvic floor surgery,,,,in-stent,at least 1 month prior to baseline,=< 1.8 mg/dl|ability,,,,,,
7741,,median sacral artery,caffeine-containing beverage,,residual alopecia,discontinuation from study,,,,seasonal,within 6 weeks prior to baseline,18 or older.|patients,,,,,,
7742,,tarsal abnormalities,herbal therapies/traditional,,ratio fev1/cv,bone turnover markers,,,,index ankle|has,within 14 days before enrollment,45,,,,,,
7743,,bmi ≧35.|pregnant,hormonal contraceptive medication,,systolic function,social security regimen,,,,suitable for inclusion by their general practitioner,within 4 weeks of study enrolment.|have,more than 18 years,,,,,,
7744,,fetal hydrothorax|feto,alcaine,,national institute of allergy,hrct scans,,,,low-grade cervical intraepithelial neoplasia.|prolonged qtcf,within the prefecture/region of the relevant facility participating in the clinical study.|people having,≥18 years when signing the informed,,,,,,
7745,,parkinson's desease,immune-suppressive therapies.||group,,barca,local surgery,,,,cruciate retaining (cr),at the time of signing the informed consent form (icf)|study participant,>3.5 mg/dl.||,,,,,,
7746,,palpation.|able to read,anti-malarials,,cacv socre,major intracranial artery (internal carotid artery [ica],,,,greater manchester,prior to first contact,<8.0 g/dl,,,,,,
7747,,primary rectal cancer,prediabetes,,karnofsky performance scores (kps),sharp aortic calcifications,,,,present)|seborrheic,in the last 6 months|regular practice of physical exercises,< 7.35,,,,,,
7748,,presentation anomalies,treatments related to pathology,,k+ concentration,standard masd treatments|life expectancy,,,,peri-ocular infection,within the next 4 weeks following,≥ 1.5 unl,,,,,,
7749,,kidney diseases.|those,eeg,,temperature,biopsy-proven,,,,before covid-19,in the last month and/or,between 45,,,,,,
7750,,neonatal transient tachypnea,permitted)||topical drugs,,"≥1,200/µl|platelet count",fluorescent in situ hybridization (fish),,,,suitable for participation in the clinical trials.|subject who is pregnant,within 12 weeks on enrollment,=< 1.5 x uln,,,,,,
7751,,intracranial involvement,systemic glucocorticoids,,ylhiva,behavioral treatment focusing,,,,triple-negative,medical illness||mri inclusion,> 110,,,,,,
7752,,chronic kidney disease-epidemiology collaboration,homeopathic,,defender trial|active endocarditis,diabetes,,,,muscle strength,within 4 weeks prior to informed,=|sufficient intelligence to understand the nature of the trial,,,,,,
7753,,painful intercourse,drugs abuse.|prior stroke.|prior myocardial infarction,,ii.|age,conventional imaging (,,,,age|acute,within 28 days prior to screening.|any exposure,18 kilograms/square meter (kg/m^2,,,,,,
7754,,irreversible vision loss,anti-hypertensive regimen,,urine,replens vaginal,,,,neonatal,within the last two years|people who,<50 ml/min)|actual,,,,,,
7755,,genital tract,soluble il-2 receptor,,response criteria for,allogeneic stem cell transplantation|history of central nervous system (cns) lymphoma,,,,inpatient,within 28 days after vaccination with ip.|receipt of blood transfusion,≤ 50% of the total,,,,,,
7756,,inner ear disease,orthodontic retainer.||participant,,hcv viral load.|participants,aural fullness ≥2.|general good health,,,,operating room,since birth,< 50 years,,,,,,
7757,,generalized periodontitis,cyp3a enzyme.|patients,,national kidney foundation,orthopedic surgery,,,,upper extremity neurological abnormality,after 3 months of hormonal contraceptive,> 6.5 criteria|not,,,,,,
7758,,"type 1 interferonopathies,",residents,,brief iq test,willing,,,,conditions:||confirmed,needing >6 months,">2,5%",,,,,,
7759,,cerebral apoplexy,musculoskeletal injuries;||athletes,,gross motor classification scale levels,trastuzumab.||patient,,,,under appreciation of the investigator.|any participation in another clinical trial in the 6 months before the pre-randomization visit,at least 2 weeks.|hcg,> 8|aged > 18||,,,,,,
7760,,clinical liver failure,alpha-blockers,,disease|ecog performance status,degenerative knee,,,,primary site,within 6 months|serious,< 30 g/l,,,,,,
7761,,untreatable claustrophobia|implanted,uln|folic acid,,leaflet height,endoscopic management,,,,emergency department,within 2 weeks before the first dose)|serum creatinine ≤ 1.5 1.5 x upper limit of normal (uln),≤ 1.5 × uln；⑧,,,,,,
7762,,adhd,bisphosphonates,,infants,parenteral chemotherapy,,,,below -1 sd|no,within 30 days of initiation of investigational product.|subjects,< 0.5 x lower limit of normal);|liver function test,,,,,,
7763,,choroidal neovascular (cnv) lesions,human colloidal albumin.|pregnancy.|previous surgery,,atrophic,tumour therapy,,,,non-compensated,within 6 months of the initial injection|involved,>=2,,,,,,
7764,,tms|able to read,ribavirin,,internationally standardized,psychiatric outpatient,,,,neurological pathology|current,at time of study,between 100 and 300 ng/ml.|25-oh-vitamin d levels,,,,,,
7765,,lumbar disc herniation|plan,ketones,,special dietary habits;||lactating,blood supply,,,,hyper-fluorescent signal,within 3 months after the last dose of sail66,4-12 years|child,,,,,,
7766,,weight loss effort,anti-tnf therapy,,mek protein kinase inhibitors;|prior radiation,local anesthesia|unfavourable anatomy,,,,meeting the protocol requirements.|contraception,within 24 hours prior to surgery|unable to provide consent independently|allergy,≥ 2.5 g/dl||acute,,,,,,
7767,,spinal deformity|bmi,over-the-counter weight loss medications,,extension lag,cesarean surgery,,,,medications.||hepatic,"22],|history of endocrine",< 50 mg/dl,,,,,,
7768,,menstrual periods,drugs that are,,failed,cardiopulmonary bypass heart surgery,,,,could jeopardize the subject's safety,within 3 months of enrollment|currently adhering,≥ 75×10^9/l,,,,,,
7769,,nerves|inability to tolerate,anti-ctla-4 monoclonal antibody,,serum pregnancy test done,24-hour urine collection of protein,,,,low level laser therapy (lllt),3 months before,≥ 23 kg||ambulatory,,,,,,
7770,,bone marrow involvement,biologic medication,,lesion level,asthma control questionnaire- 6 items (acq-6),,,,non-hispanic,"in the last 4 weeks,|having",between 10-45 degrees,,,,,,
7771,,yutiq,anti-inflammatory drug,,eular/acr criteria,ovarian torsion,,,,large vessel,before the start of study drug administration,> grade 1).||note,,,,,,
7772,,intraepithelial carcinomas,spirit,,phacoemulsification ± canalicular micro-invasive,interventional clinical trial with,,,,non-small cell lung,within 12 months of treatment.||note,<10)|acute,,,,,,
7773,,leptomeningeal metastases|diverticulitis,aspirin containing,,london vision clinic before surgery|hyperopic refraction|mixed astigmatism,local guidelines.||exclusion criteria||prior,,,,poorly-controlled hypertension,within 6 months before,55-70 years|formal diagnosis,,,,,,
7774,,irreducible arrhythmia,direct,,musculoskeletal,verbal learning,,,,condition;|current,within the previous 10 years,≥12 weeks;||the,,,,,,
7775,,upper respiratory symptoms|report,serotype,,physician.|children,mini-international neuropsychiatric interview for children,,,,follows:||myocardial infarction,within prior 4 weeks,≥18 years;|scheduled,,,,,,
7776,,myocardial infacrtion|previous medication,angiotensin-converting enzyme (ace),,hct)|age,magnetic resonance examination,,,,clinical team||,within 2 weeks prior to the start of study drug,at least 20,,,,,,
7777,,foot pressure sores,inhalation anesthesia,,rutherford,central testing|participants,,,,pancreatitis|significant,in the last 6 months;|liver disease,< 5 x uln,,,,,,
7778,,neuro-cognitive,intrauterine contraceptives,,aki stage,endothelial keratoplasty|bilateral blindness|nystagmus|uncontrolled,,,,non-gastrointestinal surgery,prior to enrollment.||,less than the lower limit of detection of the assay from a specimen collected,,,,,,
7779,,cure;|measurable lesions,anti-angiogenesis agents,,spherical equivalent power,cancer.gov).|active acute graft versus host disease (gvhd),,,,preclude testing|pulmonary rehabilitation program,in the 3 months prior to the study entry|4,< grade 3.||,,,,,,
7780,,hypoxaemia)||acute exacerbation of copd,buprenorphine,,partial thrombin time,electrical monitoring,,,,duodenal,in the last 3 months.|ability,23-c,,,,,,
7781,,romanian,agonists|progesterone,,egfr exon 19 deletion.|nsclc,regular access,,,,primary tibial fracture.|evidence,within 3 months of day 1|any,< 500 iu / ml,,,,,,
7782,,complication,selective serotonin reuptake inhibitor antidepressants,,transplantation|life expectancy,computed tomography (ct),,,,index ulcer|in the last 7 days - hyperbaric oxygen,within 14 days prior to vaccination;|asplenectomy,between 18 and 80 years.|no previous,,,,,,
7783,,lifestyle of the participant|men,dehydroacetic acid,,lymphoma;|age,assessment procedures,,,,unambiguous,in the last 6 months|he had neck surgery|suspicion of malignant,≥500/mm^3,,,,,,
7784,,skin cancer,nvaf,,hemoglobin content ≥9.0 g/dl.|liver function,laparotomic myomectomy,,,,low dose systemic,at the time of baseline,less than 35.||,,,,,,
7785,,human immunodeficiency virus (hiv) disease,anticonvulsant drugs,,child-pugh c)|clinically,walk independently|understanding of the informed consent form (icf),,,,suspicious,prior to study-specific,15-28 points,,,,,,
7786,,sjogren syndrome,tyk2 inhibitor,,recist criteria version,stem cell source identified,,,,shwachman-diamond syndrome|known,≤30 days after receipt of any study,> 9 g/dl|total,,,,,,
7787,,deep systemic tumor tissue,nasoduodenal tube insertion,,mediastinal large b cell lymphoma||and||chemotherapy,upper gi endoscopy|history,,,,midface area,at least 8 teeth||,> 1.5 × institutional uln|serum,,,,,,
7788,,adverse drug reaction||history of,antibody-based anti-sars-cov-2 prophylaxis,,basdai score,transdermal hormone contraception placement of an,,,,m1 to sm1,< 3 months,from < 30kg/m2,,,,,,
7789,,respiratory syncytial virus,cyp3a4 inhibitors,,urine pregnancy test|primary psychiatric diagnosis,local ed services.||,,,,ipsilateral chest/lymph,for at least 1 month prior to screening||,consistent with normal,,,,,,
7790,,chronic health problem,raltegravir,,best radiological response,involves treatment,,,,icd-10 code,action step 3 on the participant suicide risk screening form: found in protocol)|need for detoxification|active psychosis,< 1.5 × unl,,,,,,
7791,,disease-free survival,cognitive stimulants,,drug specific criteria,successful treatment of superficial bladder cancer,,,,non-metastatic,in the last 1 year|patients,≥ 12 g/dl|be capable of understanding,,,,,,
7792,,primary vulvar squamous cell carcinoma,dka,,hepatitis b virus [hbv] deoxyribonucleic acid,stent delivery,,,,palliative care,within the visit window,<300);|informed consent,,,,,,
7793,,sperm/fertilization,sc immunoglobulin,,serum follicle-stimulating hormone,birth control patch,,,,suitable for standard treatment;|pd-1,in the 2 weeks prior to screening,0 or 1||patients,,,,,,
7794,,cerebrovascular episodes)|alcohol,bisphosphonates may continue.|eastern cooperative oncology group (ecog) performance status,,ajcc cancer,first-line maintenance treatment,,,,subtest,past 2 years|ec 5,<60 ml/min/1.73 m2|a serum total bilirubin value,,,,,,
7795,,acid reflux disease,beta blockers,,urine tests,in-hospital follow-up,,,,nrs).||,5 through 6 years,≥ 140,,,,,,
7796,,lung abscess,3rd mtpj,,birth weight,complete rupture,,,,st-segment elevation myocardial infarction|myocardial infarction,within 2 weeks prior to the first dose.||11,scores < 3,,,,,,
7797,,nos-induced,vka alone,,mann-whitney rank-sum test,therapy,,,,in-stent restenosis|target vessel,within 7 days prior to enrollment|patient consent,6mwt.|at least 18 years,,,,,,
7798,,bipolar type ii disorder,anti-hbv treatment,,pap smear,psychotropic drugs|history of,,,,secondary headache,within 30 days;|restenosis,≥10kg.||patients with,,,,,,
7799,,acid reflux,pericardial patch,,pregnancy test done,optimal dose of,,,,allowed;|serious,during the last 4 weeks.|subjects,> 3.0 × upper limit of normal,,,,,,
7800,,pancoast tumor,nicotine patch,,hcv rna.||active autoimmune disease,lead placement|patient condition,,,,styes,at least one standard therapy,score of 0 to 2;|confirmed,,,,,,
7801,,labour|chronic pulmonary disease,intravitreal implants,,control group):||body mass index (bmi),ct-angiography of the aorta,,,,internet-enabled mobile device,more than 2 months before the start of the ramadan fast|percentage,above primary school,,,,,,
7802,,contraindicate,antidepressants,,rapid ventricular response,consensus panel criteria,,,,resisted,within 28 days before randomization|any,8-11 shoe|weight <100kg||exclusion,,,,,,
7803,,occupational exposure,glucagon-like peptide (glp),,liposarcoma||age,help,,,,site of therapy,within three months of the study enrollment,>= 30 ml/minute/1.73 m^2,,,,,,
7804,,chemical ocular injury,transmucosal (tm),,gleason score,electrical stimula- tion,,,,t3-t4,none,18-40,,,,,,
7805,,neoantigen identified,incidental medication,,fondazione policlinico universitario a. gemelli of rome,transplant,,,,st segment elevation,at the time of consent|diagnosis of,15-18 years,,,,,,
7806,,alcohol-abuse||prior/concomitant therapy||recent,ose-279,,modified hoehn-yahr scale|to,uterine curettage,,,,tumors.|painful,in the case of,≤ 90 percent (%),,,,,,
7807,,primary solid malignancy,polylactic acid,,bariatric surgical procedure||,mandibular anterior region,,,,specifically targets co stimulation of t cells,at least ≥1 filling pedal vessel,≥ 500g|singleton,,,,,,
7808,,hepatitis symptoms,nasal vaccine,,blood test,donation of blood product,,,,site of proposed needle insertion.|patients with,within one month of enrollment,18 years.|presence of,,,,,,
7809,,proprietary chinese medicines,adhesives.|participant,,dsm 5tr criteria,scales,,,,with visual enhancement,within 7 days prior to imp treatment start.|bone marrow function,> 22.2 mmol/l.|allergies,,,,,,
7810,,skin depigmentation,contraceptive sub-dermal implant,,child-pugh|contraindication,vital signs).||exclusion criteria||medical,,,,castration-resistant prostate cancer|to avoid the possibility of unintended coercion,during the study.|judgement by the investigator,over 35 kg/m2,,,,,,
7811,,major communication difficulties|are,sodium citrate dihydrate,,comorbidity index,laminoforaminotomy,,,,pancreatic head|patients planned,< 6 months prior to enrollment|concurrent,more than 140mm,,,,,,
7812,,other tumors,piccline,,national cancer institute general adverse event term 5.0 (nci ctcae v5.0),birth|pregnant,,,,bluetooth-enabled,within 24 hours of admission to the,=< 1.5 x uln|aspartate aminotransferase,,,,,,
7813,,systemic rheumatic disease|pregnancy,inhaled corticosteroid plus,,hiv-1 rna test results,screening|intensive aml therapy,,,,or|two positive,for 3 months prior to enrollment.|patients,between 18 and 75 years;|diagnosed,,,,,,
7814,,benign prostatic hyperplasia,met tki therapy,,prothrombin,medical imaging,,,,baseline|contra-indications,within 5 mm of the opening,less than 1 cm,,,,,,
7815,,active pneumonia,anti-tumor indication,,cdk,immunosuppressive chemotherapy,,,,precluding,within 14 days prior to the first dose of investigational product,>= 6|willing to be randomized|care,,,,,,
7816,,eye infection,supplements containing folate,,ips,local therapy like tem.|histologically verified dmmr,,,,primary home;|have any health conditions,14 days after they have completed their course of oral steroids,≥50.0 kg to ≤90.0 kg,,,,,,
7817,,insensitivity,suppressive antibiotics,,hiv antibody test is positive,topography,,,,age|premorbidly,after 1 or 2,19 years or older.||exclusion criteria,,,,,,
7818,,shoulder area,antirheumatic drug,,nhlbi criteria|caregiver,penile surgery,,,,dsm 5,for 8 weeks or longer,"< 30,000 plt/ul",,,,,,
7819,,atrioventricular block)|history,drugs used in the study protocol|history of premature birth|diagnosed metabolic syndrome|known hepatic insufficiency,,diastolic,intravenous therapy,,,,hyper,within 3 months before the screening,>180,,,,,,
7820,,infections|controlled pain,herbal product,,rutherford score,trisomy,,,,cytology.|radiographically measurable disease,plans extended travel inconsistent with the recommended visit interval,at least 20kg,,,,,,
7821,,behavioral abnormalities,ethics,,menstrual history,invasive breast cancers,,,,non-functional areas,in the next 12 months|health condition,greater than 50%,,,,,,
7822,,spondylodiscitis,volume>70ml,,kellgren-lawrence,distal amputation,,,,atm,within 5 years for,"15-21,|currently",,,,,,
7823,,transition,antiarrhythmic medications,,gamma glutamyl transferase,total laparoscopic hysterectomy,,,,theo-dur®,for 4 months after cessation of treatment,5-6,,,,,,
7824,,long qt syndrome,gemfibrozil)|high-dose niacin,,fdl,pi|active leptomeningeal,,,,baseline.|co-existent ocular disease,within ±5.0 diopters (d),< 65 years,,,,,,
7825,,xeplion,drug containing berberine,,investigator.|positive urine pregnancy test,first-line latarjet,,,,may receive ft538,within 14 days before the planned administration,thromboembolic event,,,,,,
7826,,hla- associated spondyloarthropathy,flt3 itd,,survival rate,shoulder arthroplasty,,,,pregnancy.|peripheral artery disease making insertion of iabp unfeasible|preoperative,after the last dose of study treatment.|the participant,≥ 600 mg/,,,,,,
7827,,solid organ transplant|medical,anti-cancer treatment,,mass index(bmi)≤30 kg/m2.|volunteer,first orthodontic consultation.||exclusion criteria,,,,trial.|cardiac,at the time of cell infusion,above 40|allergy,,,,,,
7828,,months;|multiple myeloma,medications that could potentially confound study outcomes,,healthy,luts|muscle invasive bladder cancer,,,,may significantly alter drug absorption of oral drugs,at the previous,between 100-125mg/dl,,,,,,
7829,,signs of pneumonia in chest ct|patients,atezolizumab iv fdc to avoid exposing the,,left ventricle wall-motion abnormalities,ct scan pretherapy,,,,flavivirus,within 24 hours prior to the start of the study,maximum involvement of three organs,,,,,,
7830,,diabetes foot,immunosuppressive dose,,promis depression,fluid restrictions,,,,non-mri sessions,within 3 weeks prior to the,at least 50 kg,,,,,,
7831,,thrombocytopenia)|anemia,dofetilide,,response evaluation,immediate intervention,,,,suitable for participating in this clinical trial,within 6 months before the first medication;|cardiac ultrasound evaluation,<18 years old|mi,,,,,,
7832,,gingiva,rifamycin-containing tb,,medically accountable investigator (mai),ataxia telangiectasia,,,,codes,within the past 60 months,<18 years,,,,,,
7833,,tumor necrosis factor,grapefruit fruit,,rapid antigen test,tinnitus therapy,,,,meet the,continue with the same method until termination from the study.||,"less than 2,5 kg",,,,,,
7834,,lactation;|other factors,cdk2/4/6 inhibitor,,mad,degenerative disc disease.|degenerative scoliosis.|lumbar kyphosis.|procedures:||laminectomy,,,,non skin related,within 3 months;|patients,>3.0 times the upper limit of normal (uln),,,,,,
7835,,involves handling,sunburn,,national institutes of health,supportive measures,,,,could jeopardize the safety of the patient and his/her compliance in the study,within 6 months of their,≤ 2|willing and able,,,,,,
7836,,functional limitation,zinlirvimab,,hcc|platelet count,biochemical findings,,,,could impair absorption,within 2 weeks prior enrollment,none||-,,,,,,
7837,,thoracic aortic aneurysms,direct oral,,liver cancer;|blood pressure,ct scan/mri,,,,alk gene translocation alterations.|capable of providing,at least one of the cardiac risk factors,≥ 20mmhg)|structural,,,,,,
7838,,sigmoid diverticular disease|indication,otc products,,new york heart association stage3,oncology care,,,,non-alkylating chemotherapy,at class 3 or higher within 6 months prior to the first dose.|patients,over twice the upper limit of normal.|history of,,,,,,
7839,,arterial thromboembolism events occurred,contraceptive measures consistent,,residual changes,cryoablation catheter occurs,,,,contraceptive use should be consistent with local regulations regarding,at least 6 months after the last dose of protocol therapy.||childbearing potential defined,18 to 59 years,,,,,,
7840,,disorders - insomnia,antidiabetic medications,,prostate cancer;|available,sports,,,,suitable for patients,within 1 month for,between 18-80 years|time of onset: within 1 week|nihss score,,,,,,
7841,,human immunodeficiency viruses,matched sibling donor (msd),,absolute white blood cell count,dynamic magnetic resonance imaging (mri),,,,unrelated to the target shoulder,at time of informed consent and,>30 min/day exercise 3 or more times/week,,,,,,
7842,,imv,drugs listed,,surgery|hernia size,psychotropic medication|life expectancy,,,,extragastric,more than 6 months|no,> 30%|patient,,,,,,
7843,,clinical depression,systemic anti-vegf therapy,,screening tsh,gastric acid suppressant therapy,,,,full battery of psychometric assessments,at least 1 year after,30-64 years,,,,,,
7844,,pathology,kojic acid,,hamilton depression rating scale,borderline resectable,,,,"low-lying placenta,|cesarean delivery for multiple pregnancies|all cesarean deliveries",at least two health assessment tests||,greater than 12 weeks between the completion of rt,,,,,,
7845,,autoimmune disorders.|individual,vitamin b12 supplements,,stress echo,pathogenic mutation,,,,epigastric,within 3 months prior to screening,120-160 g/l,,,,,,
7846,,acute alcohol intoxication|allergic,component of camrelizumab,,tpm rate placed,cancer treatment,,,,histological confirmed,within 3 months before study drug,greater than 2 times the upper limit of normal,,,,,,
7847,,psychosocial reasons,carnitine,,sohag university hospital||,assessment consisting of psychiatric and medical history,,,,prone position|unstable fracture,at 72 hours post-surgery increased,controlled,,,,,,
7848,,gradient lens,bisphosphonate drug,,packed red blood cell (,blood transfusions,,,,histologically confirmed dlbcl,within 30 days before randomization.||note,more than 40%,,,,,,
7849,,comfort care measures only.|refractory shock,iron deficiency,,anti hcv positive,uterine exteriorization,,,,lack effective treatment methods.|(6,within 3 months prior to inclusion|patient with,≥ 8.5 g/dl.||12,,,,,,
7850,,gall bladder stones,chapelle,,alt should,secondary regular education|intention to participate,,,,45 minutes phone interview,3-month,<40 kg/m^2||,,,,,,
7851,,disease evidence,medication infusion device.|because tms does not penetrate deeply into the head,,pbmcs,haploidentical hematopoietic stem cell transplant,,,,extend trial must,in the last six months.|having,≥2.8 g/dl.||prothrombin time (pt) ≤1.5 × uln,,,,,,
7852,,physically unable to become pregnant|you are,replacements,,naive,special reprogramming circuit,,,,angina|clinically significant,over the previous 4 weeks|treatment,≥30 kg/m2,,,,,,
7853,,resistant disease,catheters,,recist v1.1|at least,cesarean delivery|receive spinal anesthesia,,,,5-min apgar score,within two weeks prior to baseline,< 1.5× upper limit of normal range (uln),,,,,,
7854,,idiopathic pulmonary arterial hypertension,joints.|investigational drug,,previously treated,clear onset of dmd symptoms,,,,toxic effects of,at least 3 months before study entry,> 2.0|moderate,,,,,,
7855,,bacterial infections,rich,,formula.|absolute neutrophil count,breastfed,,,,baseline.|uncontrolled,at least 3 contiguous frequencies,≤ 2.5×uln;|serum creatinine ≤1.5×uln,,,,,,
7856,,chronic kidney disorder,fiber supplements,,serum human chorionic gonadotrophin,non-oral contraceptive method,,,,grade 2 or higher,following preoperative therapy,≥ 3500/µl,,,,,,
7857,,recovered.|presence,antiarrhythmic medication,,calculated by cockcroft-gault equation).||adequate coagulation function,capillary refill,,,,break-up time,at least 2 members of the medical advisory board (,greater than 150mg,,,,,,
7858,,hospitalisation).|structural heart disease,excisional],,bell,atrial septum puncture,,,,suitable for enrollment.|patients,within 14 days prior to first imp administration until the last blood draw,≥40 mmhg,,,,,,
7859,,seizures,treatment|myocardial infarction,,partial thromboplastin,adjuvant therapy,,,,low malignant potential,within 1 month prior to screening|participant,≤ 4 points,,,,,,
7860,,months|detectable human immunodeficiency virus (hiv),smoking,,pachydrusen|etdrs bcva letter score,standard-of-care medications,,,,enterococcus faecium,within 4 weeks before the screening visit|acute decompensated,30-50 kg/m2,,,,,,
7861,,distal trachea-oesophageal fistula,mobile phone access,,prothrombin mutation,reciprocal relationship,,,,anomalous,for the past 3 months,<1 g/24 hours.|prolongation of,,,,,,
7862,,point,hiv antibody,,estimated intelligence quotient,periodontal situation,,,,welding-related,while on therapy,less than 1.5 mm,,,,,,
7863,,obstructive lung disease,angiotensin receptor blocker|evidence of subclinical heart failure,,peripheral blood donors,b-cell nhl expressing cd20 by immunohistochemistry (ihc),,,,high joint demand,at least 1 mg/kg predniso(lo)ne,c-previous ovarian surgery d-chronic medical disorders [dm,,,,,,
7864,,swelling of the mouth,adhd medication,,hepatitis b core antibody (hbcab),unplanned surgery,,,,duodenotomy,management of the wearable device|willingness,> 26,,,,,,
7865,,≤6/10|vaginal bleeding,transfuse blood,,asthma|body mass index,bone reconstruction,,,,bilateral sagittal split osteotomy,within 4 weeks prior to screening,>50% predicted,,,,,,
7866,,icans,nonstatin drugs,,creatinine kinase,chemo-immunotherapy,,,,full reimbursement of the cost of a,in the next year|other smoker,≥18 years|willingness to,,,,,,
7867,,acute critical illness,over-the-counter medication,,human immunodeficiency virus antibody (hiv),bilateral adnexectomy,,,,ocular exam|high refractive,prior to or immediately following delivery,less than 5 years duration|recent hba1c,,,,,,
7868,,glenohumeral joint instability,progestogens,,dob,hrct quantitative analysis.|subject,,,,self-identify,within the past 7 days|subject,> 3x/week,,,,,,
7869,,drug-related pneumonia,anti-alk inhibitors,,national cancer institute common adverse event terminology version 5.0 (ncictcaev5.0),target artery diameter,,,,clinically significant lung,in the last 3 months|daily,after 10 minutes of resting,,,,,,
7870,,deep caries.|clinical diagnosis,thiacycline,,corrected gestational age,axillary node dissection|completion of the treatments,,,,screening|retinal,within 2 years of,higher than 500 iu/ml,,,,,,
7871,,synchronous cancer,anti-sensitivity ingredients,,gammagt,dialysis modalities,,,,||cohort 1 :,during the preoperative,>27 kg/m2|signed,,,,,,
7872,,autoimmune skin conditions,abutments,,peep,edinburgh inventory|health insurance|able to follow experimental,,,,non compatible,within the last 6 months prior to surgical treatment,=360 ml beer,,,,,,
7873,,old|corneal staining,immunosuppressive agents,,recist v1.1)|submittal of archival tumor,gastric aspirates|diagnosis,,,,undetected,within 6 months prior to first study treatment,>100 pg/ml,,,,,,
7874,,ongoing angina,compounds of similar chemical or biologic composition to durvalumab,,serum sickness,gsh)-containing therapy,,,,grade ≥2.|pregnant,within the last 2 weeks.|individuals,≥180/110 mmhg;|previous,,,,,,
7875,,muscular dystrophy,vientianne,,visual analogue scale,sedentary lifestyle,,,,evaluated,for the past 6 weeks,> 45 kg/m2,,,,,,
7876,,hemodynamic monitoring,corticosteroid treatment,,t4 and,surgery|complete surgical resection,,,,emergency room,at rest|pain exclusively in the anterior aspect of the shoulder|confounding conditions,≥ 100 x 10^9/l|haemoglobin,,,,,,
7877,,urinary bleeding,immune-related,,same,tubal sterilization,,,,t0)|clinical,within 3 months before cycle 1 day 1,66 - 70 years,,,,,,
7878,,dysfunction of the cervical,components of the intervention drug,,hepatitis c viral infection.|female,surgical treatment studies,,,,pap-causing disease,for 5 years or more,= 200 ml,,,,,,
7879,,ipth,psychoactive drugs,,alanine aminotransaminase / serum glutamic pyruvate transaminase,brain irradiation,,,,tibial artery branch.|wocbp,during the study.|subjects,28-30,,,,,,
7880,,recovery covid-19 plasma therapy.|any sars-cov-2 vaccination,medication that reduce,,sts score,intracytoplasmic sperm injection,,,,alk-tki).||baseline,by 14 days before the first dose of study drug.|any condition,≤ 1.0 times the upper limit of normal value,,,,,,
7881,,oral abnormality,radiolabeled substance,,hemoglobin≥ 90g/l.|serum bilirubin≤1.5 times ulnl,therapy|full passive roms,,,,stable dose of glucose lowering therapy,before first dose of study treatment,does not,,,,,,
7882,,traumatic cervical spine deformities|pathologic fracture spine|congenital,biotherapy,,par-q)|bmi,endoscopic intervention,,,,preclude administration of digoxin,in past 3 years,20 mg/day,,,,,,
7883,,hyperglycemic hyperosmolality,implanted medication,,aiha,epidural anesthesia,,,,insulin-dependent,within 30 days before screening.|unwilling to consume,<1×uln.|patients must sign informed consent,,,,,,
7884,,completed breast cancer therapy,adhesives used in medical dressings,,local product,oral surgical antibiotic prophylaxis,,,,highly,in the last 3 months|previously,below 65 mmol/l.|patients,,,,,,
7885,,ced,anti-fungal medications,,brca-mutated her2,transfusion of any blood product,,,,med-el,within 5 days prior to randomization.||note,less than below criteria,,,,,,
7886,,drugs|suspected covid-19 disease,contrast media.|prior,,wbc count,diaphragmatic surgery,,,,former,at least 6,≥ 1%,,,,,,
7887,,scleral buckle,azithromycin,,stated)|total bilirubin,rehabilitative treatment of disorders of consciousness,,,,unless,at the time of enrolment.|has undergone,at least 99% certainty,,,,,,
7888,,uterine anomalies|maternal-fetal rh alloimmunization,mki,,hgb level,intracoronary lithotripsy,,,,weeks|single-level herniation,at least 2-week,> 100 bpm,,,,,,
7889,,inclusive;|type 2 diabetes mellitus,regional nodal metastases,,protocol.|systolic blood pressure,mri.|active malignant disease,,,,facility.||primary care practices,for ≥3 months|no treatment,between 65 and 75 years|diagnosed,,,,,,
7890,,femoral shaft fracture,viral,,go test execution time,methods of contraception,,,,maxilla,within 14 days before randomization.|have received,score ≥5.|study participant,,,,,,
7891,,urinary tract infection,procedural medications,,new york heart association [classification],local laboratory,,,,non favorable medico-social,within 24 months,<80%,,,,,,
7892,,delayed gastric emptying,poor echocardiographic,,ecgs,ihc assay,,,,years.|good general health,last 12 months,>5 miu/l,,,,,,
7893,,abdominal drain insertion,cytochrome p450 3a4,,informed consent||,berries,,,,clinical judgement|any disease or condition,for past 30 days,> 30.0 kg/m2|waist circumference,,,,,,
7894,,clarify,anti-viral drugs,,severity item rating,vats lobectomy,,,,accessible,within the last 6 weeks before baseline) participation in another research,>18 yrs|indication,,,,,,
7895,,anatomic pathology,antiplatelet medication,,bsi,first-line chemotherapy,,,,non-pregnant adult,within the past 2 weeks.|patients,> 3mm,,,,,,
7896,,pembrolizumab.||*cockcroft- gault formula:||female crcl,examine,,total number of metastases,24-hour urine collection for determination of creatinine,,,,surgery targeting bone metastases,before 1 year old.||,<30 ml/min/1.73 m2|currently enrolled,,,,,,
7897,,milk protein may cause allergic reactions,redifferentiation agents,,mmhg|heart rate,holter,,,,mentally||,at the time of study entry,3 and 4,,,,,,
7898,,chickenpox,hormone herapy;|prior treatment,,forced expiratory volume in one second #fev1)/predicted fev1,hemodialysis|history of psychiatric illness,,,,despite resolution,within 7 days before leukapheresis collection,more than three months.|patients,,,,,,
7899,,thrombosis events,milk protein,,lung-specific intercurrent,radical concurrent chemoradiotherapy,,,,surgery.|open,within 14 days prior to screening,"18-25 kg/m 2, follicle stimulating hormone(fsh",,,,,,
7900,,"traumatic brain injury,|major neurological problems,|current substance",vessels,,normalized ratio (inr),pneumococcal vaccine,,,,ove 40 severe,in the past year;|pregnant,between 18-110 years,,,,,,
7901,,inflammatory diseases(e.g,dentin thickness,,iiia,liver flow ablation,,,,interfere with cooperation with the requirements of the trial.|known additional malignancy,on night duty,≥ 35|physical activity,,,,,,
7902,,fact of pregnancy,ramucirumab,,antinuclear antibodies test,standardized giemsa microscopy.|weighs,,,,preschool stage||,within 4 weeks prior to leukapheresis|patient,24.0 to 40.0 kg/m2,,,,,,
7903,,hypercortisolism,immune disease|4,,heart rate values,immunomodulatory agent,,,,third day;,"for at least 3 months,|pain level",≥ 100 × 109/l;|hemoglobin,,,,,,
7904,,m. abscessus,aldara®,,hcv ab and,protected,,,,european league,within 4 weeks prior to randomization.|history of immediate,>= grade 3,,,,,,
7905,,donate blood,components of the study drug.|donation,,older|a score,kidney transplant.|planned surgery/procedures,,,,non-sterilised,past 2 years);|best corrected distance visual acuity (cdva),110 mm hg or more,,,,,,
7906,,"abilities?"")|self-reported",plural,,bone metastasis);|uncontrolled central nervous system metastases,lipid lowering medications,,,,adequate dosage,previously reported,> 155 or <120 mmol/l|contraindication to either study fluid,,,,,,
7907,,chronic hepatic failure,etoposide,,im,surrogates,,,,could exacerbate,within 2 weeks of the first administration of study agent,18 to 35||male|athletes,,,,,,
7908,,inguinal hernia,immediate antibiotics,,takes,therapeutic blood levels,,,,forces undercover units in the israeli army.|are fluent,at least 4 weeks and up to 12 weeks prior to randomization,upper normal value,,,,,,
7909,,actionable genomic alterations for,methylamphetamine,,raebt,proper fixation,,,,ipsilateral secondary lesions,during their ventilation period,more than 15,,,,,,
7910,,degenerative neurologic disease,diabetologist,,modified ashworth's scale level,heart valve surgery,,,,non-surgical conservative,management program,30 times/min,,,,,,
7911,,lymph nodes of the breast,systemic prescription medications,,medication non-compliance,bilateral orchiectomy should continue androgen deprivation therapy (adt),,,,low-income,at least 2 weeks before the first administration|signed,> 6 week prior to cnct19,,,,,,
7912,,absorption of medications.|other situations that the investigator determines,systemic regimen,,hepatitis c co infection;|severe infection,sexual health||,,,,sedation,during the time it is worn,2-5 years-old|serve,,,,,,
7913,,systemic therapy;|human immunodeficiency virus (hiv),fluoresceine dye,,serum tears,checkpoint pathways,,,,stage iv nsclc|patients,greater than 1 year prior to screening,<2 weeks,,,,,,
7914,,child bearing potential - post-menopausal,potent cyp3a inhibitors,,lesions,pphn,,,,left main stem,within the past year|neurological lesion|contraindications,< 3.0 mg/dl|aspartate,,,,,,
7915,,basal cell carcinoma|porphyria|pregnancy,itraconazole,,household less,lumbar spine,,,,t3,within 7 days before the first dose of study,at|agree to participate,,,,,,
7916,,transfusion reaction,study drug absorption,,bullous pemphigoid,parenteral treatment,,,,sclerotherapy,within 2 weeks before the first use of the study drug;|active,> grade 2,,,,,,
7917,,acute care,lr769,,total bilirubin [tbl],compensated,,,,1[pd-l1],within prior 48 hours;|blood glucose,"<1 year,|history of",,,,,,
7918,,expertise,biologic drugs targeting the immune system,,hemoglobin (hb),hormonal birth control methods,,,,stable sexual partner,within 14 days plus,≥4×109 /l,,,,,,
7919,,lacerations,inhalational corticosteroid,,methodology||,physical restriction,,,,end-stage renal disease,within the last 6 months before screening.|subject,between 6-18 years,,,,,,
7920,,coagulopathies,day)|tobacco use,,serum level,periodontal pocket depths(pd),,,,age;|clinical diagnosis,at the time of randomization) should,≥ 1.5 mg/dl)|cardiac,,,,,,
7921,,gi perforation,kinase inhibitors,,minimal psma expression,full active treatment,,,,severity to limit full adherence to the study,within 4 months,≤ 3 × upper limit of normal,,,,,,
7922,,expert,systematic systemic treatment,,recist version 1.1 .|life expectancy,cardiovascular procedure,,,,pd-l1 analysis,more than twice weekly|consumption of,at least 1°c,,,,,,
7923,,paraseptal emphysema distribution,growth restriction,,tevar,radiography,,,,female.|local advanced,within 6 months from study start,12-65,,,,,,
7924,,photopsia,novafix,,test for hepatitis b virus (hbv) dna,definitive operation to remove the tumor(s) pending,,,,fugl-meyer assessment of,within 14 days prior to starting study drug,≥18 years.|ecog performance status,,,,,,
7925,,substance abuse.|major infection,hands,,gentlecath™ air intermittent catheter|exhibiting any other medical condition,treatment-part 2,,,,ibs)|predominant,within 4 weeks prior to the study,90 ml / min.|vital,,,,,,
7926,,any obstructive disease,felodipine,,screening:||new york heart association (nyha) class,first-line antibiotic treatment|confirmed,,,,age|intermittent,6 months to 2,≥ 37|birth weight,,,,,,
7927,,mutations,component of the formulation of the ip or peptide,,minimal age,fundus imaging,,,,medically effective contraception,within 7 days prior to study inclusion,4-6,,,,,,
7928,,dementia||unstable medical conditions,show kappa,,urine dipstick reading,prescription eye medications,,,,intensive,within 12 months.|those,>180 mmhg,,,,,,
7929,,senile dementia,androgens,,fasting blood glucose (fbg),method of contraception,,,,could alter or limit final postoperative visual prognosis|patients,within the previous 3 years with the exception,at least 28 days prior to the first dose.|subjects,,,,,,
7930,,arterial oxygen,contrast agents,,cd4 counts,chemotherapy;|other researchers think it,,,,insulin naïve,within the prior 180 days,from 18-40 years,,,,,,
7931,,endocrine neoplasia,anti-phospholipid syndrome (aps),,supination,ocular surface staining,,,,pd-l1 assessment,at least 3 months previously,< 50 x 10^9/l,,,,,,
7932,,diagnostic fb,alkaloids,,creatinine equation,bilateral oophorectomy post-menopausal,,,,acute-on-chronic liver failure,in the last 1 month before the date of participation,≤ 130 mm hg,,,,,,
7933,,neurological anomalies,ethosuximide,,hf between,surgical procedures follow-up,,,,transdermal contraceptives,within 28 days of baseline/randomization/visit 2,6-12 months,,,,,,
7934,,stable angina pectoris,national guard,,assessment;|bilirubin,major blood vessels||has,,,,suitable for pre-medication.|pre-existing,7 days prior to the first study drug,less than six feet tall,,,,,,
7935,,visceral injury,gastric,,hepatitis c antiviral therapy;|diabetes mellitus,baseline safety laboratory tests,,,,unversity of virginia||,in the past one month;|use,>35 kg/m2|stroke,,,,,,
7936,,criteria for exclusion of volunteers from the study:||psychiatric illness,tenofovir alafenamide,,total bilirubin ≤3 times the upper limit of the normal reference range,mmr,,,,contrast,within 6 months of visit 1,> 1.5 times the upper limit of normal.|suffering,,,,,,
7937,,gambling problem.||,taurine,,alcohol,major blood vessels,,,,clinically significant electrocardiogram (,since 12 months before||,older than 60 years,,,,,,
7938,,hiv disease,"parenteral iron treatment,|late skin porphyria,|hyperthyroidism,|presence of",,intraocular pressure,major surgical treatment,,,,nrd)|self reported,at the time of screening.|any history data,0-2|patient,,,,,,
7939,,infant illness,topical medications/emollients,,sexes.|age,x-ray).|patient,,,,non-gcb,within 4 weeks or 5,> 100g/l,,,,,,
7940,,cardiovascular clinical symptoms,anticalcineurins,,gestational diabetes|pregnant,laboratory analysis,,,,deceased donors,within the past six months.|subject,<80%|use of,,,,,,
7941,,chest wall diseases|abdominal distension|acute,laa) procedures,,cbd stone size,local births,,,,unrelated donor,for at least 12 months after the last study drug,<18 or >65 years old|having,,,,,,
7942,,muscle weakness)|body mass index,psp,,isup grade groups,neck surgery,,,,diagnostically relevant,within 28 days prior to initial administration;||sufficient elution of previous treatment,> or = to 60,,,,,,
7943,,medically unstable|contraindications,albumin paclitaxel,,maxillofacial surgery 10 years ago,lines of therapy,,,,entrance,within 3 months after the last cell transfusion;|sign informed,between 32 weeks of amenorrhea,,,,,,
7944,,chronic hemolytic anemia,local anesthetics||contraindication,,ipss-r:||the,immuno-oncology agents,,,,intra-abdominal inflammatory process,previous 3 months,18-75|smoking,,,,,,
7945,,chronic obstructive pulmonary,5-hydroxytryptophan,,spms,major onco-surgey||,,,,inhibitors - ssri,within two years;|with,>= 1000/mm^3|hemoglobin,,,,,,
7946,,acute bleeding tendency,misunderstanding of instructions|severe cardiac,,postoperative evaluation|mechanical circulatory assistance,steroid therapy;|radiation,,,,emergency upper extremity surgery,at least 12 months|patients,1.1 definitions,,,,,,
7947,,relief abnormalities,lamictal,,average hernial gate width,rtms intervention,,,,erupted,at initial enrollment,26-32,,,,,,
7948,,thromboembolic effect,3rd degree,,national asthma education,chemotherapy drug treatment,,,,4g4g,within 3 years before the first medication.|unresolved toxic reactions higher than ctc ae,1 to 17 years,,,,,,
7949,,distal ulna)|medical contraindication,milk products|soy allergy|pea allergy|participating in a structured,,fasting blood-glucose>13.9 mmol/l,mental health brain health imaging centre guideline.|clinically relevant abnormality observed,,,,rice,within 2 weeks before the first administration of the study treatment,between 18 and 25 years.|primary diagnosis,,,,,,
7950,,functional abdominal pain syndrome|childhood functional abdominal,rtms,,peripheral arterial vascular disease,vaginal sonography,,,,non-degenerative neurological conditions,through 120 days after the last dose of study treatment,larger than 10 mm,,,,,,
7951,,major mobility disorder,l-ferritin,,stay time,maintenance pembrolizumab,,,,instructions;|unable to return for follow-up visit;|presence of any major non-cardiac problem,in the last 3 months|active,<100,,,,,,
7952,,fatty liver disease,la) enlargement,,periodontitis|cigarette smokers|non smokers||,carnitine concentration,,,,done,within 6 months before use of the study drug;|physical examination,≤ 1|measurable lesions,,,,,,
7953,,not.||,immune-suppressive agents,,alsfrsr score,contraception|subjects,,,,non-culprit lesion,within 48 hours|patient,score of 2 and above,,,,,,
7954,,class|active infection,drugs similar to the study drug,,hepatitis c virus (,ptsd psychotherapy,,,,diameter of qualifying lesion,more than 7 days before the initial study,less than 4 kg,,,,,,
7955,,diseases of the cardiovascular system,immunosuppressive drugs.|pregnant,,anyone,impetigo,,,,irfarpc criteria,within the prior 4 weeks of informed consent;|history of,< 30 ml/min)|severe,,,,,,
7956,,adjuvant et.|diagnosis,component of the atrigel delivery system.|concurrent,,response evaluation criteria in solid tumours (recist version 1.1)|participants,focal radiotherapy,,,,hours;|diagnosed,3 time zones on,6-30,,,,,,
7957,,chronic obstructive lung disease,investigative medication,,study|absolute neutrophil count (anc),mechanical (spermicide in conjunction,,,,umbilical cord blood,at least 1 month,"less than 38 weeks),|after",,,,,,
7958,,primary psychiatric disorders,neuromodulator medication use|patient,,visual analogue pain score,rat,,,,non-progressive,within 7 days prior to enrollment;|receipt,> 90,,,,,,
7959,,angioedema episodes,glucocerebrosidase,,ecg abnormality,lumbosacral spine.|hip fracture|malignancy,,,,treated,at the time of screening|diagnosis of,partial response (pr),,,,,,
7960,,weakness,catecholamine-releasing paragangliomas|parkinson's disease|epilepsy|pregnancy,,response evaluation criteria in solid tumors (recist) v1.1 disease.|patients,common bile duct stones,,,,extra-cns disease,for ≥ 2 years,score is,,,,,,
7961,,posterior neck,vindesine,,acr criteria,lipid-lowering drugs,,,,chemo-radiotherapy.|prior,within the last 12 months|current,≥ 65 years|patient,,,,,,
7962,,familial adenomatous polyposis syndrome,enrolled.|creatinine,,test:||systolic blood pressure,local therapy,,,,adequate to hear information presented in age-appropriate videos of social interactions.|for individuals,for at least 3 months prior to screening;|is willing to adjust their art dosing to the morning if they,>6,,,,,,
7963,,gynecologic cancer intergroup (gcic) criteria,components in the vaccine|subject,,gross motor function classification system (gmfcs) level,standard blood chemistries (,,,,epithelial,within 4 hours from transplant,≥ 21 years|no,,,,,,
7964,,old|septic shock,asimadoline,,probing depths,first-line drugs,,,,calgary depression scale item,within 1 year before enrollment|participation in another clinical trial within 4 months before the start of this trial|pregnant,18-65 years.|spanish,,,,,,
7965,,primary respiratory diseases,remains blinded to,,licensed,physical examination,,,,kmt2a-r status,before inclusion;|under 55 years,3-5 μm,,,,,,
7966,,viral dna+,xen gel stent,,screening.|body weight,prosthetic device.|unable,,,,under guardianship|adults,within last 2 months,≤ 1.5xuln|ast,,,,,,
7967,,period.|active hepatitis,local therapies||,,viral load,definitive surgical therapy,,,,punctual,within the last 3 months|cohort 1,"grade ii or greater);,|documented",,,,,,
7968,,underweight,pcwg3-modified,,ecg finding|qtc interval,pes treatment,,,,controlled on appropriate therapy|history of adverse event,during study participation|for,more than 8 years|without,,,,,,
7969,,sympathomimetic amines,topical nitrogen mustard,,kellgren & lawrence||-,videolaryngoscopy,,,,non-human studies|observational,within the past year|internet access,> 102 cm,,,,,,
7970,,neck burns,tavr,,nano litre)|hemoglobin,pharmacological treatments.|montgomery-asberg depression rating scale,,,,block.||clinically important,in the past 12 months;|congestive heart failure,1-patients,,,,,,
7971,,0.|no neurological disease,medication(s)|having,,united states resident,endoscopy-biopsy pathology,,,,non-vitamin k antagonists,within 1 day prior to administration of study drug,anesthesiology)iii-iv|patients,,,,,,
7972,,cancer care providers||cancer care providers,pmmr,,cpk level,clinical intervention,,,,secondary spontaneous pneumothorax|lung bullae,within less than 6 months after the last treatment with,21 years to 80 years|diagnosis,,,,,,
7973,,extensive chronic gvhd;|had,components of the shape test,,modified boston,surgical operation restrictions,,,,1.patient,at the time of initial presentation,> 55 years old,,,,,,
7974,,adenocarcinoma|clinical stage t4,imaging iodine contrast,,kps score,complete prp before vitrectomy|patients,,,,site of treatment,within 6 months before screening;|a history of,older than 85,,,,,,
7975,,major thoracic deformities,tricyclics,,bpm)|severe pulmonary dysfunction,chemotherapy-induced hair loss,,,,etc.)|a positive,during the research process and|students,greater than or equal to 35)|high,,,,,,
7976,,numeric pain,immunosuppressive medications.||16,,cooperative oncology group performance status,cesarean delivery under spinal anaesthesia|who developed pdph,,,,or|acute,within 30 days before signing the informed consent form,<= 0.75 d in each eye|anisometropia <= 1.50 d|bcva,,,,,,
7977,,oral nutritional supplementation,toxin induced,,procedural terminology code,pharmacological treatment).|proficient,,,,non-traumatic cause treated,within four weeks prior to start of enrollment,< 1.2 mmol/l,,,,,,
7978,,living donor)|current infection,atlanta classification,,molecular characterization,shoulder arthroscopy surgery,,,,pre-diabetes.|current severe,during the last 12 months|any,below 37.3℃,,,,,,
7979,,acute chronic infection,any drug,,blood platelet,systemic steroidal therapy,,,,sacral,within 60 days prior to first dose of study drug|history,<40 kg/m2,,,,,,
7980,,transurethral prostate surgery.|patients,bile acid sequestrants,,breath test for alcohol,obstetric ultrasound,,,,alcohol-based product,within 4 weeks before screening.|within six months before screening,lower than 15%,,,,,,
7981,,etc.).|failure,creatine kinase (ck,,hb)≥,active extension,,,,controlled by diet,during the last 28 days.|prior treatment,at or above 70,,,,,,
7982,,nodular fibroma,anti-inflammatory,,walk speed,little's index,,,,unrelated,within 12 weeks prior to enrollment.|symptomatic,between 30 to 60 years,,,,,,
7983,,wegener's granulomatosis,sglt2 inhibitors,,hanifin's criteria,laser clinics,,,,non-adherence to the study protocol|active knee inflammation|range,preceding 2 weeks,stage 2-4 ovarian,,,,,,
7984,,sciatica,antiplatelets,,apgar score,standard procedures of intraocular injection,,,,septal,after the optimal medical treatment;|urine protein,class iii,,,,,,
7985,,nonanatomical resections,liraglutide,,weight-loss,autologous transplantation,,,,instrumental,during pregnancy|receipt of,>3.5 g/day,,,,,,
7986,,leukocyte count≥3.0×10,drink rich,,conditions.|liver function abnormalities,gastrointestinal [gi] surgery,,,,atopic,at least 30 mins,< 60 years||,,,,,,
7987,,autoimmune encephalitis,over-the-counter (otc) cosmetic cream,,serology for hepatitis c.|received oral,c|received treatment,,,,has been,pre-existing,">= 50,000 / ul|serum",,,,,,
7988,,rescue medicine,components of the drug applied.|the,,qtc interval duration,heart catheterization,,,,texas md anderson cancer,within 4 weeks prior to imp treatment start,>90 cm,,,,,,
7989,,complete denture,acl reconstruction,,rai-refractory disease,steroids;|significant anatomic deformity,,,,highly effective birth control.|participants,at least 3 months apart)|assessed,score ≥ 2|have access to the internet,,,,,,
7990,,for:||cardiometabolic risk factors,citalopram,,alanine aminotransferase/aspartate aminotransferase,cancer|active microbial infections|neuromuscular,,,,satralizumab|active,at least 12 weeks before screening;|not,> 90 or < 45 mmhg,,,,,,
7991,,angle tumors,ecstasy,,criteria,surgical resolution|surgical procedures takes,,,,hearing|current,within the range 18 to 40 kg/m2,>95 mmhg)|morbid,,,,,,
7992,,conditions that researchers,lactaid®,,6)bclc stage c,large spectrum antibiotic,,,,membrane peel).|iop,within 1 week prior to screening;|screening,myalgic encephalomyelitis / chronic,,,,,,
7993,,bowel cancer,anti-sars-cov-2,,local labs|negative serum pregnancy test,ct perfusion,,,,catheter;|prior,in past 3 months|unusual,18-64 years;|patients,,,,,,
7994,,primary implantation failure,migraine headaches.||neuroleptic,,new york heart association (nyha) iv stadium|liver insufficiency child-pugh,diagnostic surgery,,,,shall take effective contraception,within four weeks prior to start,>300mg/day,,,,,,
7995,,upper gi hemorrhage,lh-rh analogue.|metastases,,6-minute walk test,re-excision,,,,postoperative infection)|intake of,within the past month|current,≥18 years.|eastern cooperative oncology group (,,,,,,
7996,,sle manifestations,anti-il-6 treatment|hemolyzed specimens,,neutrophils counts,procedures|chronic ad present,,,,unknown pathology,within the previous 4 weeks;|use of topical steroids,> 450 ml,,,,,,
7997,,normal organic function,nine,,bone stimulator,re-biopsy,,,,auxiliary,within 6 months|patient,18-77 years|ability to provide,,,,,,
7998,,congenital deformity,medical grade,,supine bp,dsa,,,,1.||clinical,prior to any study specific,≤ 2.5 × uln|international normalized ratio,,,,,,
7999,,meeting,allergy|concomitant medication,,congestion score,small molecule multi-target inhibitors targeting the,,,,study|positive response,within 6 months of study,18 yrs|elective,,,,,,
8000,,gynaecological symptoms,materials containing polylactide,,oral poliovirus vaccine (bopv),myelosuppressive chemotherapy,,,,myogenesis-regulating glycosidase,throughout step 4.|ability and willingness,i-iii|elective spine surgery||,,,,,,
8001,,gastrointestinal stromal cancer,pgp,,b-cell,enzyme inducing anti-epileptic drugs,,,,article l. 1121-6 of the public health code),in 24 weeks prior to entry,< 28 kg,,,,,,
8002,,major autoimmune diseases|typical hus,coumarin-derivative anticoagulants,,rai-refractory,local country guidelines,,,,primary oral pathology|bad oral hygiene|high,during the study outside the,> unlx3).|moderate lung disease.|uncontrolled,,,,,,
8003,,nocturnal diaphoresis,analgesic medication use before surgery,,response evaluation criteria in solid tumor,androgen deprivation therapy|bilateral hip,,,,suppress the immune system,in the last year|clinically leading asthma disease,greater than or equal to 30.0 kilograms per square meter (kg/m^2).|diagnosed,,,,,,
8004,,cycles).||confirmation from the centre des thérapies experimentales,htt lowering therapy,,uk anaesthetic,lhrha,,,,renally impaired patients||patients,at time of screening;|allergy,from 14 to 17 years,,,,,,
8005,,multi-organ transplantation,immune checkpoint inhibitor,,american society of anaesthesiologists grade,physical intervention before resolution,,,,tumour tissue previously,within the specified time window before randomization:||participants,> 50ml/min;|effective,,,,,,
8006,,nafld,nortriptyline,,indicated)|hemoglobin,pretreatment biopsy,,,,maintained,at least 28 days after the initiation of effective contraception,18-4 0 years,,,,,,
8007,,subjects.|age,drugs acting on t-cell co stimulation,,schirmer score,x-ray;|have,,,,american diabetes association [ada],between 12 and 22 weeks gestation.|participants,-24,,,,,,
8008,,positive);|serious infection,parenteral administration of contrast agents,,dna copy number,comp360 psilocybin therapy,,,,amenable to endoscopic,in the last two weeks|not,≥ 18 years;|able,,,,,,
8009,,cannabis|unwilling,kit,,thin pulse,central testing,,,,grade i - ii,for at least 6 weeks before randomization|clinical global impression - severity score,"from 5 to 8 years,|able to follow verbal commands",,,,,,
8010,,gastrointestinal motility,dengue vaccine,,gad-7,postoperative imaging (ct/mri).|the,,,,reported,for at least 3 months after the last use of the study,between 5% and 20% blasts,,,,,,
8011,,primary biliary cholangitis,stereotactic radiosurgery,,physical activity/exercise,bct oncoplastic surgery,,,,demonstration of a prebronchodilator fev1,at the time of screening:||age,≥ 70%|female,,,,,,
8012,,autoimmune thrombocytopenia,ventricular assist devices.|esrd,,alt ≤3×uln,eye|keratoprosthesis surgery,,,,secondary school.||,within two days before dosing,20-item,,,,,,
8013,,pancreatic mucinous,haemophiliacs,,6-minute walk test.|not being able,bile duct cancer||,,,,identify dominant,at the cleveland clinic would apply,pre-,,,,,,
8014,,thyroid disorder.|current,ons,,corticobasal degeneration (cbd),hematologic reconstruction.|hypertrophic obstructive,,,,raised,prior to the observation period,> 16.5 mm|patient,,,,,,
8015,,clinical stage i,components of mdk-703,,stage,physical exercise,,,,autoimmune,previously treated with redifferentiation agents,50-75 years|smoking:|,,,,,,
8016,,schizotypal personality disorder,therapeutic drugs,,bcr-abl/t(9;22,alternative medications,,,,mdrd formula,at least 6 months prior to check-in nor,< 30%)|culprit lesion,,,,,,
8017,,lines of treatment,vst.|patients,,smoking cessation,palliative intervention,,,,antepartum period of,less than 1 week before registration|patients,score of 25 or higher,,,,,,
8018,,lynparza,immune-modifying,,predominantly stress urinary incontinence,variations,,,,grade 2+ elevation in ast,prior to randomization;||alkaline phosphatase,12 - 20,,,,,,
8019,,persistent af,topical retinoid therapy,,acq,scheme||non-inclusion criteria||life expectancy,,,,kills sperm)|intrauterine device,at time of diagnosis,= and > 6/10).|pain,,,,,,
8020,,tract discontinuity|sepsis,lv,,vitamin b12,transformed mf].|uncontrolled diabetes mellitus.|baseline peripheral neuropathy,,,,residual invasive,at any time during pregnancy||,≥ 90 ml/min,,,,,,
8021,,mitral stenosis.|hypertrophic obstructive,compounds of similar chemical or biologic composition to adi-peg,,white blood cell,tn,,,,"timi grade 3, there is no dissection that affects the flow",within the last 12 months prior to screening.||note - individuals,> 70;|stable seizure,,,,,,
8022,,lymphatic component||unaffected,components of the formulation used.|participants,,liver organ function,lumbar neuroaxis,,,,rarely,in the last month|blood potassium,< 6,,,,,,
8023,,homolateral cardiothoracic surgery.|allergy,steroids,,aging workshop (straw),tissue gpc3 expression positive,,,,albumin-bound,within 6 months of study administration,>38 mm,,,,,,
8024,,rare diseases studied,aks),,||inclusion criteria:||acute stroke,oocyte donation|tubal obstructions,,,,index knee|radiologic,in the prior 6 months)|reports,<20 ng/ml.|prostate,,,,,,
8025,,causative disorder,"narcotic analgesics,|who",,merican society of anesthesiologists (asa) physical status,computed tomography (ct) per the recist v1.1.||mesothelioma||patients,,,,deemed not feasible,after receiving at least first-line systematic treatment,18 to 85|with,,,,,,
8026,,cerebral vein thrombosis (cvt),enzalutamide,,peripheral revascularization,treatment.||stroke survivors:||unstable vital signs|terminal illness|transfer,,,,disease-specific therapies,during the pandemic,≥18.5 kg/m2,,,,,,
8027,,reversible coagulopathies,vitamins notably,,urine toxicology screen,total blood loss,,,,diaphragm,within 3 months prior to screening.|clinically significant,4-18;|being,,,,,,
8028,,basal cell skin lesion,strong blinks,,cervical length,chronic medical treatment.|does,,,,upper eyelid retraction,within 3 months prior to randomization.|within 28 days or,>= 50|patient,,,,,,
8029,,candidate to receive,non-approved,,asa,periodontal plastic surgery,,,,secondary spontaneous,in the month prior to day 0|who,>160 mg/dl|vaccination,,,,,,
8030,,diabetes of,study vaccine.|liver function tests,,lactation.|haemoglobin,hepatic arterial infusion chemotherapy,,,,non-central nervous system (cns) disease.|uncontrolled,12 months prior to the start of this,< 60 year,,,,,,
8031,,apically infected,assignment.||patients,,american college of medical genetics,vital signs measurement,,,,neurogenic subjects|be,30 days prior to vaccination,≥18 years|diagnosis of,,,,,,
8032,,third degree heart block)|any factors,benzodiazepine-like anxiolytics,,cns;|human immunodeficiency virus (hiv),oncological treatment,,,,study;|allergy,through 60 days after the second dose:||intrauterine device,no more than 1 prior,,,,,,
8033,,clinical importance,ocs,,isncsci,sw|previous surgeries,,,,intra-ductal extension (ide),in the next 2-years|is,+||e. wilson's disease：ceruloplasmin < 20 mg/dl||strict exclusion criteria：patients,,,,,,
8034,,bifurcation lesions,xenogeneic proteins,,sars-cov-2 test,intrauterine device,,,,individualized jade wind-barrier herbal tea bag,during the current depressive episode|transcranial magnetic stimulation,than 18 years old,,,,,,
8035,,localized al,perivisceral aaa repair.|participants,,modified rankin score,dfu,,,,screening|post-bronchodilator,within the upper urinary tract.|target stone,>12 on the,,,,,,
8036,,condition of,anticoagulants,,calculated egfr,abdominal ultrasonography,,,,venous thrombosis:|presence,within 6 months of,<10mg/dl.|recently,,,,,,
8037,,oral analgesic,acid treatments,,mmg,biopsies.|adequate organ function.|for fertile,,,,poloxamer 407,"within the past month, the participant",≥ 25 mmhg,,,,,,
8038,,arthroplasty,hmpv,,adc value,head and neck bone resection,,,,irregular user,within 4 weeks prior to study enrolment.|previous,40-55,,,,,,
8039,,responded,drugs that cause immunosuppression.|non-english speakers,,rt3 gingival recessions,european working group,,,,moderately-differentiated,past one year|daily,≥13 to <18 years|if they,,,,,,
8040,,clinical info,cortisol-containing,,her2 negative metastatic,floor interventional procedure,,,,intra-abdominal surgery,at least 2 weeks prior to day 1 of cycle 1|histologically,≥200/μl,,,,,,
8041,,disease free,coumarin agents,,bodyweight,preoperative examination,,,,inadequately responsive,within 30 days of surgery.||,≥ 300 mg/dl,,,,,,
8042,,kidney disorders,age|hba1c,,human immunodeficiency virus (hiv),tube thoracostomy,,,,synovial fluid / or,within 3 months prior to baseline through follow-up.|current enrollment,above 99%ile,,,,,,
8043,,other exacerbation,large intestine,,kellgren & lawrence radiographic,functional imaging,,,,active phase,within 1 month before screening；|a,≤ 2 × uln,,,,,,
8044,,recurrent cholangitis,sedative drugs,,total bilirubin level,knee mri,,,,non index knee,within 6 months before enrollment showed,>2 b.).|pregnancy,,,,,,
8045,,"smell,|no communication",anti-rsv antibody product,,hepatitis c virus||note,regular hemodialysis,,,,metabolic disorders|major,within 30 days before operation.|patients known,< 50% or < the study site's,,,,,,
8046,,acute worsening||*the criteria,aminoglycoside antibiotics,,partial response [pr],local research ethics,,,,unknown primary site,clinical history of,75-225 microg,,,,,,
8047,,febrile abdominal pain,lung,,recist v1.1|ecog ps,echocardiography/spect/lv angiography,,,,designed,at least 4 weeks before the first administration shows that the lesion,>=1.5xuln,,,,,,
8048,,associated anomalies,study medications,,loading dose of antiplatelet agents,imaging tests,,,,metabolic disorders.|pregnant,in the last 6 months|using,> 7.5,,,,,,
8049,,impossible mask ventilation,contrast agent allergy,,drug metabolism enzymes,acl-surgery|no,,,,refractory to standard of care,5 half-lives,≥ 3%,,,,,,
8050,,pancreatic surgeries,investigational product excipients,,mc donald criteria,shangjin nanfu hospital,,,,abnormal electrocardiograms,in the past 2 years|current use of cannabis/marijuana,18 to 65 years|working,,,,,,
8051,,mental disorders,topical antihistamine,,european respiratory society (ers) global lung function,facial plastic surgery,,,,17|able to read,within 30 days of screening|ongoing toxicity,between 30 minutes,,,,,,
8052,,cerebellar stroke,drugs formulated,,oac,endoscopic discectomy,,,,earliest possibility after resolution,within 3 months of randomization,more than 10 weeks,,,,,,
8053,,hybrid myoma,vr headset,,tympanic temperature,gene-therapy,,,,mm)|normal,in the last 2 months,6-12 weeks,,,,,,
8054,,dementia;|be minimally capable of imagining motor,medications contraindicated,,alt)(serum glutamate pyruvate transaminase [sgpt],comply fully with study procedures,,,,investigational,within 2 weeks prior to the day of study vaccination.|planning,12.5mg daily,,,,,,
8055,,pathologic mobility,medications for these conditions,,hiv test result||,genders;|expected survival time,,,,non-prescription medications,in the wound.|subject,> 325 mg/day,,,,,,
8056,,severe diseases,tablet,,ps score,physical examination before vaccination,,,,neck pain.||,during the treatment with darolutamide,no more than 4 weeks prior to protocol enrollment.|active,,,,,,
8057,,rheumatoid arthritis,drugs used in this study|patients,,urine collected,done plastic surgery,,,,icd-10 diagnosis,within 4 weeks of d1|known,≥1×10^9 /l,,,,,,
8058,,secondary immune deficiencies,evaluate,,calculated b creatinine clearance,naloxone reversal,,,,therapeutic vaccines,in the last three months before treatment,< 80|previous,,,,,,
8059,,sitting balance level,anti-tumor vaccine,,egfr,duodenal surgery,,,,higher|eligible,at least 7 months,5 or above,,,,,,
8060,,loss of consciousness,analgesics regularly,,local laboratory:||absolute neutrophil count,genes,,,,positive;|other,within the past 7,>2.5mg/dl|creatinine,,,,,,
8061,,atorvastatin|pregnancy,combined p-gp,,end-tidal pressure,anifrolumab early,,,,500 iu/ml,in the next 12 months|cognitive impairment,requires diagnosis,,,,,,
8062,,idiopathic scoliosis||,nicotine addiction,,cardiac stress test,good oral hygiene.|normal vision,,,,"fovea, atrophy",within 3 weeks before the first administration of the study drug,> 0.4 ng/ml,,,,,,
8063,,epithelial ovarian,global initiative for obstructive lung diseases,,calibrated bp cuff,imaging (ct,,,,increasing dose,prior to pollen challenge:||antihistamines:,0-2.|patients,,,,,,
8064,,vesicourethral anastomotic stenosis,non-steroidal anti-inflammatory drugs [nsaids],,or|diastolic blood pressure,oropharyngeal structure,,,,severity index (esi),within the past two weeks|accommodation,20-60 years old|at least,,,,,,
8065,,chronic renal dysfunction,ethanolamine drugs.|people,,covid-test,hospital care,,,,intra-cerebral pressure,with the reappearance,> 25 degrees)|surgery of,,,,,,
8066,,food.|diabetes mellitus type i,juvenile detention,,pta level proportionate srs,biological sample collection procedures,,,,high grade atrio-ventricular block,during the period of drug administration,≥ 50 ml/mi,,,,,,
8067,,prolonged gi dysfunction,subconjunctival,,interval,better||,,,,"suitable for participation, whatever the reason",30 days prior to the chivitt,≥ 1.0 g / l,,,,,,
8068,,bleeding risk,ariga,,cd20 count,smokeless forms of tobacco,,,,polymorphic,within 24 hours prior to the first dose must,>6.4 (diabetes)|last a1c value,,,,,,
8069,,non melanoma skin cancers,anti-tumor activity,,regular exerciser|bmi,acute knee,,,,suitable for contrast-enhanced,within 3 months after the last chemotherapy drug,≥150/90,,,,,,
8070,,parasitic ocular,beetroot-rich foods||,,crc,eus-tissue acquisition,,,,under investigation,for more than 120 min/week,18 - 55 years,,,,,,
8071,,positive airway pressure,dimethyl fumarate,,residual survival,e-liquid,,,,clinically serious,during the study;|those who cannot,>=1.5 × upper limit of normal,,,,,,
8072,,tuberculosis (tb).|patients,screening|bcva,,impaired participants:||-clinical laboratory test results:||platelet count,small cell nec,,,,idh-wild type glioblastoma||phase,within 14 days before taking the trail drug;|ingested grapefruit,>20 mmhg,,,,,,
8073,,potential damage,short acting muscarinic antagonist,,gina levels,ct show,,,,with bronchodilator,more than 3 months.|patients,≥ 50%.||female,,,,,,
8074,,aided-ambulatory,sleep agents,,y-chromosome mosaicism,examination,,,,space-occupying lesion,within 30 days before starting sndx-5613|participant,<3.0 × uln)|serum,,,,,,
8075,,viruses|active bacterial,antihistamine-containing cold remedies,,myeloblasts,phototherapy,,,,non-peer-reviewed papers,prior to induction,30-90 days,,,,,,
8076,,haematological abnormalities,antineoplastic agents,,thyroid stimulating hormone,sd-oct examinations,,,,perforated,within the past 3 months|history of cardiovascular disease,< 55%,,,,,,
8077,,arterial cannula,3rd molars).|no,,inclusive.|diastolic blood pressure,swt,,,,machine-induced,within the last 6 months.|patients,470 ms,,,,,,
8078,,bipolar,aortic stenosis|patients,,60%)|absolute neutrophil count,refractive error,,,,narrow band ultraviolet b [nbuvb],within 28 days prior to and including the screening,< 1%,,,,,,
8079,,temporomandibular joint dysfunction,antiplatelet therapy;|known allergy,,||②alanine aminotransferase (alt),rankin scale,,,,al.2007).|teeth free from,within 2 weeks prior to study baseline,greater than 12 weeks,,,,,,
8080,,mauriac syndrome,nelfinavir,,american association for cancer research [aacr],irreversible surgical sterilization by hysterectomy,,,,first-episode psychosis,within 1 week of randomization:||hematology:||absolute neutrophil count,> 13.|modified,,,,,,
8081,,unresectable cancer pancreas.|non soft,tng462 or its,,||serum creatinine,et treatment,,,,worse than the radicular pain,at least 4 weeks prior to enrollment||rosuvastatin < 10 mg,> 3months,,,,,,
8082,,simple excision,calcium channel blockers).||medication exclusions,,child-pugh score,pci)|acute coronary syndrome|heart failure|chronic obstructive pulmonary disease,,,,very deep,before enrollment or,≥ 1.2in/3cm,,,,,,
8083,,pain-related,global initiative,,fdg,normal slit lamp examination,,,,"jaw movement, function",medical history question and inspection of nasal passage.|presence of,< 3 times of the normal value,,,,,,
8084,,pulmonary parenchymal disease,ferritin,,oxygen saturation of blood,thoracotomy for cancer surgery,,,,udergone,within the last year|american,40-89.|patients,,,,,,
8085,,ectasia,drugs acting on another t cell receptor,,aki,conduction,,,,site of injection|any contraindication for esp|known,within 3 months.|transferrin saturation,over 18 years old|able to speak,,,,,,
8086,,digital,angiotensin converting enzyme inhibitor,,picu length of stay,brain surgery|ferromagnetic metal in head,,,,scleral,prior to the stroke|patients,1500/l,,,,,,
8087,,hypothyroidism.|pulmonary radiation therapy,mechanical ventilation.|subjects infected,,modified mallampati class,fridericia's formula|history,,,,dietary intervention|significant food allergies,more than 4000 kcal per day,≥nyha class,,,,,,
8088,,tubal occlusion,dopamine agonists,,urine m protein≥200mg/24h;|light chain type,targeted treatment,,,,st-t wave changes,in the 48 hours prior to enrollment.|positive pregnancy test,>18 yrs,,,,,,
8089,,nutritional deficiency,sodium cromoglycate/nedocromil,,serum magnesium concentration,skeletally immature,,,,sma iii,within 30 days as part,>18|able to provide,,,,,,
8090,,chronic dialysis.|acute pulmonary embolism|transfusion,high-dose glucocorticoid,,gvhd post bone marrow transplant,need anesthesia,,,,thyroidism|confirmed,recent than the last 6,≥126 mg/l,,,,,,
8091,,adulthood|allergic rhinitis,conventional treatment;|two or more recurrences;|persistent extramedullary leukemia;|for,,qtcf,bone augmentation of the sites to be treated;|poor oral hygiene;|smoking,,,,requiring treatment|accompanying,within the past 6 months.|women,>= 20 years,,,,,,
8092,,severity of depression|trd,oral corticosteroid usage,,hours;|icdsc score,aortic valve surgery,,,,other etiology of hair loss,prior to study treatment,4 to 12 years referred,,,,,,
8093,,competitive exercise,azole antifungals,,passive straight leg raise,syphilitic patients;|uncontrolled blood pressure,,,,full dose,within the last 3 months)|systemic,crcl)≥ 50 ml/min,,,,,,
8094,,lower abdominal pain,antiretroviral treatments,,reflux,biochemical markers,,,,microsatellite instability test,within 28 days of day -1.|individuals,age≥18 years|participants,,,,,,
8095,,renal disease,aortic regurge,,dsm-iv,systemic immunosuppressant therapy|class iii/iv,,,,congenital diseases|absence,for up to 3 months,"100,000/l",,,,,,
8096,,egfrviii mutant||participants,prevents access,,mild stress urinary incontinence,cancer screening,,,,egyptian ministry of health (moh) protocol,for >6 months,> 3g/d,,,,,,
8097,,localized dermatomal herpes,anti-glaucoma medications,,visual analog scale|does not live in eastern cape confirmed,local palliative rt,,,,"site of the needle puncture,|pregnancy or lactation,|patients",≤2 weeks prior to initiating protocol therapy.|previous,≥ 1.5x10,,,,,,
8098,,tls+ sarcomas,etomidate,,visit|body mass index,statin therapy,,,,post-traumatic stress,within 6 months after receiving,≥350,,,,,,
8099,,acquired brain injury||diagnosis,carboplatin-containing regimen,,bgf,allogeneic stem cell transplant,,,,peer-facilitated,during the study period.||9,greater than 5mm.|non-restorable,,,,,,
8100,,guillain-barre syndrome (,anti-il-6-,,estimated value,complete subscapularis,,,,ankle region.|individual has morbid obesity,within 4 weeks prior to initiation of study treatment.|with,> 350 microns,,,,,,
8101,,pathological changes.|cognitive impairment,estramustine,,recist criteria|reduction,spinal fracture.|participants,,,,highly effective contraception).|male,before 24 hours of age||infants,> 30 mm|cervical dilatation,,,,,,
8102,,extensive skin diseases,tenofovir dipiroxide fumarate [tdf,,novo lesion,supraclavicular flap surgery|patients wishing,,,,panel-reactive human leukocyte antigens,within 6 months after injection,> 2.0 x uln,,,,,,
8103,,respiratory infections,thyroid-replacement hormones,,fetal anomaly|multiple gestation|category,herniectomy,,,,t3-4/n+m0,within 3 months prior to screening.|history of drug,between 18 and 40|self-reported,,,,,,
8104,,post-covid syndrome,psychoactive cannabinoids,,ecog-ps score,hrct diagnosis uip type/possible,,,,distal radius (ao 23-b,for six months afterwards,vitamin e,,,,,,
8105,,sports injuries,anticoagulation medication,,screening qtcf,mcdonald criteria|expanded disability status scale,,,,diagnostic criteria of the newly released,longer than 45 consecutive,6-13,,,,,,
8106,,chromosomal anomalies,anti-hypertensive treatment|or,,response evaluation criteria in solid tumors version 1.1(recist1.1),other surgery of the gastrointestinal (gi) tract that could interfere with the pharmacokinetics of the trial medication,,,,c1-t1|upper extremity motor score (uems),in the pre-menopausal,< 50%;|allergic,,,,,,
8107,,tte,human antihuman antibody response,,glycosylated hemoglobin hba1c,peribulbar treatment for dr,,,,influence the result of the study,within past 5 years,between 20 weeks till 42 weeks,,,,,,
8108,,coagulation dysfunction,immune-mediated rash,,nst).||,assisted living facility|is unable to control what food is prepared,,,,non-verbal,within 1 week after the last dose of study,> 40ml/min,,,,,,
8109,,non-cancer diseases,potassium competitive acid blockers,,maximum diameter,cns imaging to document,,,,mild hydronephrosis||,at least 25 days prior to surgery,functional classification of class 2b,,,,,,
8110,,network.|in,lomustine,,modified ashworth score,allogeneic therapy,,,,locally recurring cancers,during the period 2019-2020|follow-up,>= 0.75 × 10^9/l,,,,,,
8111,,pelvic disorder,gbs,,/1.73m2);|systolic blood pressure,orotracheal intubation,,,,non-cardiac co-morbid conditions,within 4 weeks prior to visit,vegetarian,,,,,,
8112,,world health organisation,lymphoma:||absolute neutrophil count (,,basal fsh,pet fdopa allowing,,,,greater than,within one month post stroke onset)||hemorrhagic,≥ 8 mg/dl|platelet,,,,,,
8113,,degenerative lumbar spinal stenosis|surgical treatment of degenerative lumbar spinal stenosis,food products,,hepatitis c (antibodies),histological,,,,alter sensation,within 6 months before administration,≥100*10^9/l.|normal liver,,,,,,
8114,,polyp retrieval failure,nmda,,smoking history,sulfonamides.|pseudothrombocytopenia,,,,b surface antigen (hbsag),within one-month preceding study visit,40 years or older,,,,,,
8115,,deep samples,intranasal medication,,screening|bmi,auxiliary ventilation,,,,icd-10 diagnosis code of u07.1 in,within 1 week prior to the expected date of the first dose,≥ 3;|4,,,,,,
8116,,hereditary nephropathy,anthracycline,,children,first surgery||,,,,cervical spine.|tumor,within three days|enteral pre-medication,between 6 to 55 years,,,,,,
8117,,resuscitation,nonsteroidal anti-inflammatory drug use|oral bisphosphonate,,bp ≤150/90 mm hg,pelvic lymph node involvement|no,,,,complement-dependent cytotoxicity crossmatch (cdcxm),at the time of consent.|healthy,> 1.0 times uln|partial prothrombin time (ptt),,,,,,
8118,,atrial arrhythmia.||exclusion,covid therapeutics,,normal blood pressure,pregnancies|vaginal birth after cesarean|twin,,,,topical use);|the investigators consider,within the 2 weeks prior to screening,more than 7 days prior to initial dosing,,,,,,
8119,,insomnia severity index score,antispasmodics,,geriatric medicine outpatient clinic patient|on,gastric varicose veins,,,,drugs used|<50kg total body weight|vertebro- or kyphoplasty|pregnancy and breast feeding|inability to follow the procedures of the study,3 months prior to screening - hormonal contraceptive,greater than 180/120 mmhg|medication,,,,,,
8120,,acute gout flare (exclusive of,lithium disilicate,,opioid od,secondary malignancy|prior treatment,,,,affecting,"in the last 3 months,|it",less than 50 or,,,,,,
8121,,leukemic involvement,metastasized,,pasat,acquisition scan,,,,liver enzyme cyp2d6,within 12 weeks before apheresis,30-50,,,,,,
8122,,traumatic brain injury.|previous targeted synthetic,severity|moderate,,physical activity treatment,bone marrow naive cells,,,,"disorder,|cervical dysplasia,|endometrial cancer",prior to initiation of study drug.|any surgical procedure,≥ 11.1 mmol/l|body,,,,,,
8123,,hiv);|pregnant,immune regulating biological agents,,ihc 1+/2+,stretch,,,,pure high-grade neuroendocrine,during the last three months.|written informed consent for study participation.||,18 years onwards|signed written informed consent,,,,,,
8124,,success,lactobacillus,,bm regeneration after consolidation therapy,glenohumeral translation,,,,third degree av block,longer than 7,score of >= 21,,,,,,
8125,,s3-guidelines,investigational medication,,peripheral blood eosinophil count,et,,,,"diagnostic and statistical manual of mental disorders, 5th edition [",within 72 hours prior to the,<20%.|severe,,,,,,
8126,,non-epileptic events,niraparib components,,sars-cov-2 monoclonal antibody treatment,surgical [orchiectomy],,,,equilibrium|clogged,within 3 months prior to baseline,>/= 35|participants,,,,,,
8127,,brain organic disorder,contrast dye|non-willingness,,radioisotope glomerular filtration rate (gfr),constituent of the sarilumab product.|patients,,,,emotional/psychological disorder);|enrolment in another study,within 14 days prior to initiation of study treatment:||anc,≤1.5 x the upper limit of the normal range,,,,,,
8128,,infective exacerbations,including:|metformin,,calculated free testosterone,12-lead ecgs,,,,igg4-rd;|status classified,within 30 days of day 0||receipt,> twice the upper limit of the normal,,,,,,
8129,,unmanaged heart conditions,dimethylsulfoxide,,myasthenia gravis;|mgfa class,arrhythmia.|major surgery,,,,under restraint|patient,past 30 days prior to the screening visit.|use of any live vaccines,between 7 to 12 yeas|children,,,,,,
8130,,symptomatic pericarditis,gynecology,,prolonged the qt interval,infusion|active central nervous system,,,,dsm-v|diagnosed,since at least one year,6 years old,,,,,,
8131,,effectively applicable,intratympanic medication,,absolute neutrophil count (anc) acuity ≥1.0*,autonomy,,,,high degree,for at least 6 months duration,under or equal to 27|right-handed||ii,,,,,,
8132,,absolute insulin deficiency diabetes,traditional chinese medicine components,,american society of anesthesiologists grade,endoscopic sinus surgery,,,,guideline-recommended therapy.|have,up to 3 months after end of corticotherapy administration.|patient under legal,30 to 55 years,,,,,,
8133,,course of covid-19:||oxygen saturation,vka,,triple kras,achievement of a completeness of cytoreduction score (ccs),,,,bcl6,during the screening phase results,<100mmhg,,,,,,
8134,,primary peritoneal carcinoma,immunosuppressive treatment.|anti-phospholipid syndrome.|fibromyalgia (fibromyalgia will,,total hepatitis b core antibody,medical treatment program,,,,surgical revascularization|nontraumatic amputation|peripheral vascular procedure|cerebrovascular accident|or hospitalization,within 16 weeks prior to screening|active proliferative diabetic retinopathy (pdr),> 70|no,,,,,,
8135,,infectious condition,glulisine,,pulse oximetry,clinical significance|ecg showed transmural myocardial infarction|poor control of hypertension,,,,intra-oral pathology,before surgery,normally.||⑩ sign informed consent,,,,,,
8136,,tetanus,conventional immunosuppressive drugs,,serum total bilirubin,ct scan obtained,,,,macular structure,within recommended doses are permitted,≥3 mg/dl,,,,,,
8137,,xenotropic,components of jelly,,recist v1.1 definition.|score,prophylactic regimens,,,,age|patient,prior to completing a standard regimen,exceed 3 times the upper limit of normal value)||9,,,,,,
8138,,hepatic encephalopathy;|eastern,anti-cd40 agents,,ph-impedencemetry,immuno-modulators,,,,severity index-a,within the past 3 months||miscellaneous:||current fever,45 to 75 years;|screening,,,,,,
8139,,paraaotic nodes,tramadol,,maternal age,cysts,,,,medically-acceptable,during the 3 months before inclusion,< 150 mm,,,,,,
8140,,respiratory sequelae,paritaprevir,,-rna,pelvic organ prolapse,,,,teratogenic effects,prior to first dose,> 2.5 times of the upper limit of the normal range,,,,,,
8141,,gallstone disease,steroids.|eyelids,,common toxicity criteria (ctc version 5 - november,allogeneic hsct,,,,stage t1n0m0).|preoperative ultrasonography,in the previous year,"< 50,000/mm3",,,,,,
8142,,chemoradiation;|no,oral calcineurin inhibitors,,weight bearing|preoperative flexion contracture,hypothyroidism|thyroid surgery,,,,persistent,during the pre-tavi electrocardiogram,< 3 months.|participation,,,,,,
8143,,infection + sofa,nicotine-,,50 minutes of activity,rnai,,,,narrow angle glaucoma|chronic hypotension,within 1 months prior to informed consent|stroke,> 2%,,,,,,
8144,,conditions unsuitable for blood collection|any other,thyroid-stimulating hormone (tsh,,er-,medical therapy;|esophageal varices,,,,peptic ulcers.|history,within 1 month prior to study enrollment,>= 51 ml/min/1.73 m^2|human immunodeficiency virus,,,,,,
8145,,preserved ejection fraction.|heart failure,nitrosourea,,emergency preview,appendicitis surgery,,,,surrogates)||cannot,within 5 or 4,< 30%.|a participant,,,,,,
8146,,co-stimulation signal;|8、serum,oral medications,,neuroscience institute medical,insulin|planned organ transplant,,,,hypothyroidism;|unstable,at the screening visit.|treatment with,< 30×109/l,,,,,,
8147,,nasal abnormality,similar drugs,,mri)|bodyweight,saphenous monitoring,,,,high dose vitamin b3 supplementation,in the last 6 months,montgomery-åsberg depression rating scale,,,,,,
8148,,bleeding events,barraquer-simons syndrome,,psa level,histologic types,,,,timi grade,during the study treatment period,<30 min,,,,,,
8149,,pharmacological prophylactic treatment,components of the study irrigation system.|patients,,paclitaxel,medical exemption,,,,lactation.|active tobacco,in the last six months|able to understand,≥ 1.3 cm,,,,,,
8150,,isolated extramedullary disease,hydrogel|less,,response evaluation criteria in solid tumors (recist v1.1),pci,,,,non-interventional],within 30 days prior to enrollment.|pregnant,≤ 20 kpa;|signed written informed consent form.||,,,,,,
8151,,lumbar spine tuberculosis,avr,,absolute toe pressure,structured interview for dsm-5 (scid-5).||,,,,non-aud cohort,within 6 months prior to the first dose of study treatment,> 4)|endorsing no,,,,,,
8152,,wash,trastuzumab,,renal disease;|known malignancy;|secondary constipation,hypertensive patients|those incapable of verbal communication,,,,poorly controlled,at the time of the procedure||,<35 kg/m2||,,,,,,
8153,,malignant pleural effusion,favipiravir,,national authority for health,emergency open-heart,,,,site of surgery|body weight,prior to starting 2nd line therapy,attending day care,,,,,,
8154,,transection of the infrahyoid strap muscles,antiretroviral medication,,national institute on,cardiac resynchronisation therapy device,,,,primary immunodeficiency|pregnant,within the last 1 year.|systemic application,90 mm hg,,,,,,
8155,,persistent alveolitis,interscalene brachial plexus block|contraindication,,npsle,electric cardioversion -hypotensive||altered mental status|myocardial infarction|pulmonary hypertension|patients,,,,immunosuppressive effects of,within 4 weeks prior to c1d1,≤ 5 unl,,,,,,
8156,,mitral stenosis,ecg,,bav||,lumbosacral spine surgery level from,,,,effective methods,within 30 days before the screening,> 95th percentile,,,,,,
8157,,persistent disease,cladribine,,pain score,computed tomography (ct) scan|high-flow nasal cannula,,,,lasting ≥30 min；b,4 weeks or before|patients,18-50|males,,,,,,
8158,,pregnancy test|unwilling,components of the study intervention.|the participant,,covid-19 viral antigen.|chest,confirm dipg,,,,non-western,for at least 90 days after investigational vaccination,< 100 days|allogenic transplant,,,,,,
8159,,bulbocavernous reflex,icon,,blood creatinine,stent size used|target lesion length,,,,breastfeeding.|synchronous,within last 12 months|other medical conditions,<30 g/l,,,,,,
8160,,chronic illness otherwise,anti-tumor biological therapy,,recist v1.1 criteria.|available archived,hip replacement surgery|follow up surgery,,,,low-grade histology,three months after radiotherapy).|the physical status,"<= 10 db,|written",,,,,,
8161,,gastric tumor,antiepileptics|alcohol,,standardized mini-mental test (smmt),flexion contracture,,,,women|left,during the 1 month prior to enrollment,> 50 kg,,,,,,
8162,,non static,scherpenzeel,,section 6.5.2 table,fundus visualization|uncontrolled glaucoma|papillary excavation,,,,grade ii/iii|history,at the time of dose1 day 1.||systemic infection,≤ 4.|tia,,,,,,
8163,,folic acid deficiency,beta-blockers);|3.patients,,uate,met,,,,hormone replacement|eligibility criteria,6 months prior to randomization|pregnant,>35 years,,,,,,
8164,,heat illness,vermis,,normal|body mass index (bmi)=,dsm-5 structured interviews|urine toxicology evidence,,,,t0-2,within 5 months after the final dose of atezolizumab|current treatment,≥300 mg/g,,,,,,
8165,,non-caseating granulomas,pde6b,,metavir score,cns treatment,,,,ipsilateral neck levels,within the last 8 weeks).|jehovah's,≥ 60 and < 90 ml/min/1.73 m2,,,,,,
8166,,muscle enzymes,meningococcal infection||,,hpa axis,thermal pulsation,,,,"women;|unable to undergo medical monitoring for geographical, social or",after the final dose of tiragolumab,>125 beats per minute|any surgical intervention,,,,,,
8167,,mixed etiology,oral hygiene,,left ventricular wall thickness,spherocylindrical refraction,,,,under the standard sections for protocols among protocol reference materials,newly admitted,+/- 10 degrees,,,,,,
8168,,heart related abnormalities,toripalimab,,bmd t score,allogeneic stem cell transplantation.|being able to understand and read,,,,highly malignant b-cell lymphoma[hgbcl,within 1 month prior to the,"newborn,|37-40 weeks",,,,,,
8169,,lyme arthritis,hormonal receptor positive breast cancer|plan,,mm).||adequate organ function,thoracic aortic aneurysm,,,,suitable for participating in this trial.||adult healthy,at least 6 hours after intake of those drugs|for study participants,= 360ml of beer,,,,,,
8170,,chronic illness,ketorolac,,years.|body mass index,single operation,,,,moderate to high suicide risk,at the time of the right heart cauterization procedure,<30 ml/min/1.73 m2).|previous cabg.|presence,,,,,,
8171,,quincke's,antacids,,table,institution of va ecmo||exclusion criteria||patients staying,,,,large-diameter stools|presence,at time of referral,≥ 18 years||in the judgment of the local cardiac team,,,,,,
8172,,progressive proficient mismatch repair,alprazolam,,us)|category,percutaneous ethanol,,,,interferes with their normal activities,within six weeks prior to the screening,≤ 4 weeks after stopping,,,,,,
8173,,days.|contraindications,covid-19 vaccines,,renal,suggested,,,,membrane more than 4,after challenge,>= 2 centimeters,,,,,,
8174,,homicidal,fexofenadine hcl,,female.|body mass index (bmi),organ transplant.|major surgery,,,,active phase (dilatation 4,within 14 days prior to registration)||male,≥ 90 ml/min/1.73m^2||,,,,,,
8175,,adrenal insufficiency|copd,noninjection,,developmental quotient,deep sedation,,,,ibs-sss score,within the next 1 months|a planned,higher than or equal to 85mmhg,,,,,,
8176,,intractable benign paroxysmal positional vertigo,anti-cd38 therapy,,ecog (eastern cooperative oncology group performance status scale,major pelvic surgery,,,,/products,at the time of day 1|active,equal to or more than 20,,,,,,
8177,,abilify now,aids,,dotatate|total bilirubin,surgical clips,,,,molar relationship,within 6 months before screening.|as judged by the investigator,>3.0mg/,,,,,,
8178,,temples,immunosuppressive medications||intermittent steroids,,tics-m,cytologic analysis,,,,african-american|age,in the past six months||,1 year - 3 years,,,,,,
8179,,biochemical recurrence,chronic opioids,,tmb score,conservative treatment,,,,upper extremity defined,within 3 months of the first dose (amount,≤ 1.5× uln,,,,,,
8180,,urticaria pigmentosa,loncastuximab tesirine.|prior treatment,,pc aspects,surgical resection of the pancreatic tumor.|serious,,,,schuylkill)||,prior to randomization.||,less than 48 hours,,,,,,
8181,,ret,monoclonal antibody drugs,,international criteria,european association for the study of the liver (easl) clinical diagnostic criteria,,,,"500, 1000, 2000, and 4000 hz)",three years before the inclusion,≥ 55 kg,,,,,,
8182,,gbm,xanthine-rich beverages or foods,,pulmonary vein|preoperative ecog physical state score,btki therapy|start,,,,genetically modified cell therapy product targeting cd20|autologous stem cell transplant,within the last 4 weeks.|history of,=<10 x upper limit of normal (uln),,,,,,
8183,,capitis,urinary catheters,,classroom teacher|neu seydişehir,vascular open surgery,,,,could reasonably,up to 5 years old,< 25.00 kg/m2)|a,,,,,,
8184,,incentive program,standardized tte,,organ function wbc,blood coagulation,,,,high likelihood of,during the 3 months,between 21 to 60 years,,,,,,
8185,,acute brain disease,medication pump,,insomnia severity index (isi),before screening:|antiviral therapy,,,,may significantly affect vision,at the time of signing the informed consent.||histological confirmed,0 - 1.|meet,,,,,,
8186,,enema,propafenone,,hbv dna copy number positive,guardian.|feel comfortable discussing,,,,culprit lesion|baseline stemi,at 4 sites/implant,0-1 score|be able to understand,,,,,,
8187,,psychotic symptoms,rna,,hcv-rna,practical issues,,,,upper arm of the study extremity|scheduled kidney transplant,prior to the start of the study,≤ 5 x uln)|creatinine clearance,,,,,,
8188,,comatose,anti-obesity medication|no,,prostate cryoablation|major neurological conditions,microscopic analysis,,,,unknown location,within 28 days prior to the baseline visit.|subjects,> 470ms,,,,,,
8189,,rejected for liver transplantation,immunosuppressive drugs;|use of,,creatinine clearance estimated by,target.|autologous stem cell transplant,,,,diagnostic and statistical manual for mental disorders-fifth edition (dsm-v,after completion of neoadjuvant therapy,>90 days|agree,,,,,,
8190,,≥35|neurocognitive impairment,months.||patients,,cockroft-gault formula)|life expectancy,therapeutic cardiac surgery,,,,c2-t1).|surgery,for the time being,greater than one week|written informed consent,,,,,,
8191,,tumor resection,compounds of similar chemical or biologic composition to piperacillin,,pawp,therapy introduced,,,,medically prescribed cannabinoids).|existence of any medical,at the time of the study,< 18 years and >80 years|reoperation|emergent,,,,,,
8192,,etc|patients,telomycin,,forty,local mri safety questionnaire,,,,acute phase,in the screening period,greater than 1|body mass index (,,,,,,
8193,,small cuts,vigabatrin,,albumin,rapid antigen test device.|participants who did not change their diet within three months before the screening day and are willing,,,,health,within 12 months prior,16 to 45 years,,,,,,
8194,,identifiable risk factors,ocular herpes,,recist v1.1.|age,chest computed tomogram (ct)|history of,,,,central nervous system (cns) neoplasm,history of prior,more than,,,,,,
8195,,affect appetite,spermicidal jellies,,neutrophil count≥,surgery|pregnant,,,,surgery|prominent,in the month prior to study allocation - poor understanding of the inform consent language,between 30-36+6|postnatal babies,,,,,,
8196,,average,anti-vegf therapy(response,,dili,contrast enhanced,,,,grade iv hemorrhoidal disease|rectal prolapse|history of proctological surgery,less than 3 months before the,at least 1x/week,,,,,,
8197,,substance abuse disorders,immune modulators,,adolescents adopted,actionable mutation,,,,antilipidemic,during the month prior to study entry.|very irregular periods,90-140 mmhg,,,,,,
8198,,blood coagulation disorders,solubilize carfilzomib,,31+6 sa|collection,thoracic major operations,,,,riociguat,before enrollment/randomization,s,,,,,,
8199,,pci.|acute coronary syndrome,western medicines,,madrs score,gwi,,,,pregnancy|vaginal,during the study period|stable body weight,35 points.||,,,,,,
8200,,bleeding disorders.|vulnerable,involves agents,,flmh-unit||,doubly labeled water (dlw) assessment,,,,ibs,in the 12 months prior to enrollment.||patients eligible for,≥18 years|patient,,,,,,
8201,,facet disease,ngs testing||,,hiv antibody positive).|serious infection,antihypertensive therapy|heart failure,,,,ground-glass opacification on ct imaging.|28 days - 3 months from the onset of covid-19 symptoms|parent's/carer's/guardians consent,within 1 month of the experiment day|participation,>64.||,,,,,,
8202,,anaphylactic reaction,pembrolizumab + chemotherapy,,crossover registration (arm 4 only,severity index (easi),,,,"muscle soreness,|history",continuous,equal to or higher than 3.0g/dl.|qualified,,,,,,
8203,,standard postnatal,drugs used in the postoperative period.|patients,,depth,lymph node biopsy,,,,injection treatment,for 1 week multiplied by the average,between may 2017,,,,,,
8204,,socket-related,art drug,,treponema pallidum antibody positive.|have aav5 capsid neutralizing antibody titers,general performance status,,,,dcm)||longitudinal study:||acute traumatic sci,within the next 24 hours,18.|physically incapable of,,,,,,
8205,,augmented bladder,"physiotherapist,|patients affiliated",,inclusive|body mass,perfusion scan,,,,non-biologic investigational drugs,for the duration of study participation.||should,than 50 kg,,,,,,
8206,,nucleic acid test,cobicistatdanoprevir,,peripheral arterial vessel).|chronic kidney disease,chromaffin tumours,,,,been responsive,within 30 days from inclusion.|inability to consent,"above, and their",,,,,,
8207,,lung disease,ertugliflozin,,human immunodeficiency virus (hiv) test,puncture,,,,influenza viruses,previous 1 year,> 3cm,,,,,,
8208,,donate sperm,polatuzumab vedotin,,active monitoring phase of the study).|pre-registration,computed tomography (ct) showed no,,,,non invasive,within 3 months prior to inclusion|patient implanted,≧20 years,,,,,,
8209,,chronic subdural hematoma,etc.);|immunosuppressive drugs,,thyroid replacement dose,tip torsion,,,,female|stable,before inclusion,more than 300 pounds,,,,,,
8210,,physical xm tests,anogenital,,physical examination.|history of bleeding diathesis,imaging assessments,,,,unable to communicate with visitors|patients,at least 6 months before the screening visit.|acceptable stable art regimens,upper limit of,,,,,,
8211,,secondary diabetes mellitus,etc).|4,,urine hcg test,venous access already,,,,seconds)|community-dwelling,within 4 weeks prior to study inclusion,greater than 30 kg/m2,,,,,,
8212,,vital signs|clinically significant,antiresorptive pharmacological agents,,iop,hamstring,,,,paco2≥50mmhg;|similar,during the 14 days prior to enrollment,between 35 - 55 years,,,,,,
8213,,irritable bowel disease|malnutrition/obesity|limitations,genetics,,prothrombin time (pt),immunohistochemistry(ihc,,,,pd-l1 monoclonal antibody,prior to the sci,≥ 90 days;||the,,,,,,
8214,,lower limb injuries,cytotoxic drugs inside,,aptt,cytotoxic chemotherapy,,,,psychological:||implanted,during the last 4 weeks.||concurrent enrolment,< 2 x 109/l,,,,,,
8215,,lateral epicondyle,medications used in this study.|pregnancy,,celf-p3,dental procedures,,,,low dose acetylsalicylic acid,≤72 hours before meta10-19,< 39 years.|histopathologically,,,,,,
8216,,treated dyslipidaemia,nicotine gum,,alanine transferase (alt),hits treatment,,,,above-listed inclusion criteria|current,within 2 weeks before dosing,≥18 years < 75 years.|right-handed,,,,,,
8217,,ostial lesion,psychiatric drugs,,prevention program (,imaging diagnosis;|the,,,,third trimester,for up to 4 weeks after the last dose of study drug,> 2mmol/l,,,,,,
8218,,atypical anorexia,nicotine product,,serum follicle-stimulating hormone (fsh) level,home medications,,,,upper respiratory airway occlusion,at time of drospirenone,18.5-50.0 kg/m2|american society,,,,,,
8219,,adverse effects of,lb|patients on,,partial thromboplastin time (aptt)≤1.5 x uln .|left ventricular ejection fraction,neurosurgical resection,,,,marker related,throughout the study period|subjects able to comply with the protocol requirements|informed consent,<3 x the upper limit of normal,,,,,,
8220,,cytokine defects,nucleic acid,,axillary temperature,tpip studies,,,,pure clear cell carcinomas,48 hours apart,greater than 35 kg/m2|presence,,,,,,
8221,,blood disorder,pv,,valve disease.||,oropharyngeal swabs,,,,adequate form of,within six months|chronic use,between 18 and 65 years|acute lower extremity fracture,,,,,,
8222,,fd19;|patients,medications that might influence cardiovascular function,,resting hemodynamic values,mechanical thrombectomy procedure.|thrombus retrieved,,,,protocol-prohibited,after 2 or more prior,< 40x10∧9/l|blood glucose,,,,,,
8223,,early treatment diabetic retinopathy study (,atkins,,testosterone levels,lifestyle change|history of,,,,left forearm,within 10 days of the onset of insulin therapy,10-15 sheets,,,,,,
8224,,epidural block,dpp-4 inhibitors,,alt,kidney disease|supplement use,,,,sex.|self-reported,within four weeks or five half-lives,90g/l,,,,,,
8225,,hepatitis b hbsag,famciclovir,,white blood cell (wbc),endoscopic bariatric therapy,,,,preclude adequate absorption of capivasertib.|history of another,at least 1 child,31.5,,,,,,
8226,,tumor perforation,diphenhydramine.|participants participating,,serum creatinine ≤1.5×uln,coeliac.|previous,,,,severity of their disease,period january 1,< 45 ml,,,,,,
8227,,β-thalassemia,insulin glulisine,,visit,first-line therapy,,,,3-hospital region,"during the study,|exercise tolerance limited",class 2b or better.|participants,,,,,,
8228,,"mental problems,|the fact",factor d,,properly managed diabetes mellitus,radiofrequency,,,,radius,for at least 6 months after the administration of imp.||medical histories,> 35kg/m2,,,,,,
8229,,although short-acting sedatives,anti-hypertensive drugs;|evidence,,alcohol breath test (abt),discontinuation of treatment,,,,st segment elevation myocardial infarction (stemi),in the last 3 months|use,45-160kg|definite,,,,,,
8230,,aitl).|enteropathy,component in its formulations,,venipuncture blood sampling||arm,/thoracic surgery,,,,oxygen,in the last 6 months|history of abdominal,> 180/110 mmhg|pregnancy,,,,,,
8231,,hemochromatosis|risk,ist agents,,minimal root resorption.||,rascovsky criteria)17,,,,clinically judged to be,within 1 month before enrollment.|agree to use,grade 2 or 3,,,,,,
8232,,relapse sarcoma,non-steroidal anti-inflammatories,,neutrophil count below lln,full biochemistry profile,,,,beta-human chorionic gonadotropin,at time of in-formed consent.|no,younger than 6 years,,,,,,
8233,,eria:||heart failure,p2y12 inhibitors,,response evaluation criteria in solid tumors (recist) version 1.1.||adequate organ,transfusion of platelets|documented evidence,,,,stage ii grade,before start|use,≥ 1.5 × 10 ^ 9 / l；|platelet count,,,,,,
8234,,prostate cancer;||>2-month,topical antiseptic solutions,,lv ef,blood 25(oh)d concentration,,,,identify,for 3 months after the trial ends,< 60ml/ min/1.73m2,,,,,,
8235,,isis 678354-cs6,local anesthetic into affected si,,hepatitis b|active hepatitis c||evidence of,fluoroscopy examination,,,,identifiable,language|greater than six months post,18-44,,,,,,
8236,,cardiac arrhythmia.|psychiatric,gnrh analog,,european society of cardiology (esc) recommendations,subsequent consolidation,,,,ethnicity||,at least 8 weeks prior to,< 22);|a,,,,,,
8237,,tubal infertility,antiplatelet agent,,weeks|total bilirubin,endoscopic procedures related to gallbladder resection,,,,stable enrollment,within the last 3 months 7,>5/8,,,,,,
8238,,fallopian tube-,platelet aggregation,,ecog score 0~2,ed thoracotomy,,,,intraocular inflammation|uncontrolled,within 30 days of enrolment|genetically,18-50|applying,,,,,,
8239,,vitiligo localized,nonsteroidal anti-inflammatory drug,,sensory blockade|unexpected complications,child-pudg,,,,cap,within 7 days prior to the first dose of the study drug.||14,≥ 90×109/l|liver,,,,,,
8240,,solid organ transplantation|treatment with complement blockers|patients,β blockers,,haematocrit,ig)e assay,,,,pd medication,in the next 4 years||,>18 years|patients,,,,,,
8241,,vestibulobasilar insufficiency,adult,,neuron-specific enolase,local therapy (surgery,,,,hypothalamic-pituitary-adrenal axis.|patients,within 30 days preceding the first vaccination of ip.|use of,between 5.7∼6.4%,,,,,,
8242,,parkinson's disease).|amputation,cordarone®,,poems syndrome;|known multiple myeloma,tertiary,,,,high-resolution ct scan,through 180 days after the last dose of study therapy|patients must be able to swallow oral medications.|patient consent,grade ii-iv|left,,,,,,
8243,,mild asthma,adenosine,,plasma nrg-1 level,radiofrequency lesioning into the index knee,,,,c-reactive protein threshold level.|diagnosis,within 24 weeks prior to study entry.|active drug,over 18 years|asa,,,,,,
8244,,basically normal coagulation,drugs (anticoagulation therapy,,implantable,emergency room treatment,,,,psychiatric disorders.|systematic,in the last 3 months.|for,≤ 2x uln,,,,,,
8245,,macroscopic lesions,regional blockade level below t6,,modified mallampati,hg utuc bilaterally,,,,neuroendovascular treating team|wide neck side wall,within 3 expected,>=50 g/l,,,,,,
8246,,g6pd deficient,immunosuppressant biologics,,liver function returns,rapid test,,,,morton s neuroma,at the time of informed consent|each subject must read,u/ml,,,,,,
8247,,concomitant conditions|patients,cidofovir,,entry|body weight,first imid,,,,interfere with the tasks performance;|older,after six months of structured training||,between the last dose of chemotherapy,,,,,,
8248,,narcotic analgesics.|alcohol,basata,,cpb|age,successful resection,,,,m1 segment,within 7 days prior to the first dose of study drug.|patients,≤ 75 years.|tia,,,,,,
8249,,malignant hyperthermia|raynaud's disease,vascular,,age related macular degeneration (wamd),gestational diabetes|thyroidectomy,,,,hot,within past two years,less than 500 cells/,,,,,,
8250,,large fecal mass,ivus assessment,,age|smoke,implant treatment||,,,,buprenorphine,4 hours prior to recruitment,2 to 70 years.|performance status,,,,,,
8251,,tinea infection,sstr,,cushing's disease|antiresorptive,polymerase chain reaction [pcr],,,,hypovitaminoses,within the last 6 months of the screening,≥ 10%);|any,,,,,,
8252,,arm pain,cone-beam computer tomography (cbct) imaging,,nice classification,barrier methods,,,,diameter ≥10 mm,within 2 months prior to screening,> 0.3 µg/kg/min|patients,,,,,,
8253,,high-risk agvhd,component of the study intervention.|patients,,absolute lymphocyte count,first-line therapy|for cellworks singula,,,,high grade serous,over 204 kilograms,< 90ml/min/1.73m^2,,,,,,
8254,,peripheral corneal scarring,components of the study treatments,,axillary body temperature,denosumab).|major surgery,,,,toxic effects,during study participant,45-65 years||both,,,,,,
8255,,chinese,franklin,,femoral length,cesarean section method,,,,st-elevation myocardial infarction,within 6 months prior to screening|a positive test,≥130/≥85 mm/hg);|alcohol intake,,,,,,
8256,,hematopoietic neoplasms,immune-checkpoint inhibition.|adequate haematological function:|adequate renal function:|adequate liver,,negative syndrome scale,combination therapy,,,,pure-tone audiometry|patients,three times or more,greater than 35 kg/m2|individuals,,,,,,
8257,,local recurrence of gbm,california state university san marcs|between,,patient|acute transmural myocardial infarction,arterial stent surgery,,,,suitable by the transplant selection committee,during the study|history of another,20-70,,,,,,
8258,,brain parenchymal metastases,component of the research drug,,isth bat,cervical flexion,,,,large amount,personal past,18-25 kg/m^2,,,,,,
8259,,schizophrenia).|severe obesity,hemodynamically moderate,,hunt hess grade,postnatal chest ct-scan,,,,rr,within the last year|pulmonary exacerbation,18.5 to 36.0 kg/m2,,,,,,
8260,,consent;||therapeutic response rating,neuropsychiatric diseases;|deaf,,weight-related,teens.|serious medical condition.|stage i,,,,overall health,at the sponsor's discretion)||,>1.0g;|obvious,,,,,,
8261,,metabolic disorders.|recurrent pregnancy loss,experimental monoclonal antibodies,,pediatric chest diseases unit of hacettepe university faculty of medicine,radiology residents employed by,,,,intermediate forms,within 24 months before signing the informed consent form|a,>130/80 mmhg|fasting triglyceride (tg) level,,,,,,
8262,,genomic risk,heparin-induced thrombocytopenia.||table 1,,autoinflammatory disease|celiac disease|thrombophilia,dyskinesia|prior surgical treatment,,,,thrombus,at time of inclusion,5-18y|(living,,,,,,
8263,,prostatitis|macroscopic hematuria,monoamine oxidase,,modified list of highly effective methods,t0 scan done,,,,persisted for >12 weeks,in the recommendations released,≥ 18 years|at least one,,,,,,
8264,,angular deformity,diabetic agents,,serum glutamic pyruvic transaminase [sgpt],stress steroid doses,,,,68ga]ga-psma pet/ct,longer half-life,> 3 times the upper limit of normal,,,,,,
8265,,endometrioid carcinoma,pws,,fish detection found,pranayama,,,,non-binding,during the week of study,18 to 35 kilograms per square meter (kg/m^2,,,,,,
8266,,bladder neck,imaging agents,,protein c resistance,open surgery,,,,intracerebral aneurysms,within 2 years before the first administration|the study,53 to 86 mmol/mol,,,,,,
8267,,higher peripheral neuropathy,anti-hla antibody status,,equal mean blood pressure,intra-arterial blood pressure monitoring before anesthesia,,,,cdasi-a,within 14 days before dose1 day 1,younger than 45 years,,,,,,
8268,,uveitis.|are,ipv,,,inclusive)|in good general health,,,,self-prescribed,within 30 days after the final dose of giredestrant,≥ 2x upper limit of normal,,,,,,
8269,,5-fluid ounce,urine drug screening,,,video camera|seen,,,,primary care)|received,within 4 weeks of the first administration of imp.|presence of any,≥ 18 years|signed written informed,,,,,,
8270,,autoimmune thyroid,seventy,,,breastfeed their infants||sexually active,,,,low level of physical activity,during the course of the study.|patients,18-90 years|novel,,,,,,
8271,,cystic ovary sundrome||,component of any mrna vaccine,,,systemic immunosuppressive therapy,,,,poor growth,within 3 months before the first dose,between 45 and 80 years,,,,,,
8272,,lymphatic component|clinical diagnosis,mmhg irrespective of treatment,,,saturation,,,,grade glioblastoma,for at least 14 days after the last dose of the investigational medicinal,> 1.5 times the upper limit of the reference range|a,,,,,,
8273,,renal panels,progestin,,,done facial injections,,,,catheter-,within 28 days prior to study treatment,35-79 years,,,,,,
8274,,health coverage,immunosuppressive agents|patients,,,fecal occult blood test,,,,epstein-barr,within the 12 months prior,≥ 18 years|planned appendectomy,,,,,,
8275,,stress related disorders,betablockers,,,assessment system (icdas) score,,,,ctcaev5.0,< 6 months before inclusion,> 1.25 x unl|cpk,,,,,,
8276,,de-novo coronary lesion,interference drug,,,optimal antihypertensive,,,,/diastolic resting blood pressure,within 48 hours prior to study screening|clinically significant,40-75 years,,,,,,
8277,,upper gastrointestinal hemorrhage,levonorgestrel-containing,,,chemoembolization plus embolization,,,,cytomegalovirus,7 days before study intervention,1.29 mmol/l,,,,,,
8278,,congenital nonbacterial,systemic medication,,,atm-avi infusion.|hap/vap,,,,low back pain|pregnant,within the last 3 months|history of,≥ 60 minutes/week,,,,,,
8279,,spine surgeries|cauda,nickel-titanium,,,cardiovascular surgery chest pain (angina),,,,ceased,within 14 days before the first dose (daily dose,1.7 mg/dl,,,,,,
8280,,granulomatous prostatitis|active lower,anabolic steroid,,,hemostat behind symphysis||,,,,elicited,during the last three months before the trial;|history of long-term use,score from 0 to 1.|must,,,,,,
8281,,azoospermia,medications used in this study.|neuro-muscular,,,exclusive,,,,distended abdomen,while on study treatment||strong cyp3a4 inducers,0-1;|bmi≥18；|the,,,,,,
8282,,secondary op;||the,depo leuprolide,,,computed tomography/magnetic resonance imaging (ct/mri)|patients,,,,fridericia formula (qtcf,within seven,lower than 90%,,,,,,
8283,,hip joint diseases,terbutaline,,,hernia surgery,,,,irregular stool,<1 year,below the 95th percentile,,,,,,
8284,,learning disability must:||be,amantadine,,,extracorporeal oxygenation,,,,interfere with assessment|history of,prolonged,i and ii and those,,,,,,
8285,,major risk of hemorrhage,follows:||anti-vegf therapy,,,large segmentation radiotherapy,,,,household||additional participant level inclusion,on the brain scans.||,born to mothers,,,,,,
8286,,hypertension|type 1 diabetes,5-fu)|irinotecan|oxaliplatin|anti-egfr therapy if ras,,,invisalign™,,,,opiates)|significant unstable,at least 4 out,under 18 years old and over 65 years,,,,,,
8287,,viruses,polytetrafluoroethylene,,,tactile temperature,,,,site of venipuncture,within the last 30 days|non-active,lower 2500gr,,,,,,
8288,,nasopharyngeal abnormality,yag,,,accepted stimulation test,,,,prevent,within 2 weeks of enrollment -,>2 times the uln,,,,,,
8289,,small squamous cell carcinoma of the skin,arthroscopic partial,,,"pelvic organ prolapse,|malignant disease,|urinary infection,|neurological disease,|have electronic",,,,hbs,through 3 months following vaccine administration,=< 2.5 x institutional uln|creatinine clearance,,,,,,
8290,,small intestinal,intramuscular administration,,,adv reactivation,,,,could affect pupil responses,in the past 2 years;|greater than,≥ 18;|intracranial atherosclerosis stenosis,,,,,,
8291,,active neuropathy,anti-neoplastic therapy,,,catheter insertion,,,,brachiocephalic arteries,previous history of any mental problems,> 60 ml/,,,,,,
8292,,hepatocellular carcinoma,normally,,,bilateral sensorineural hearing loss criteria,,,,scale,medical history medical records,>= 60 ans|poor,,,,,,
8293,,primary tumor resectable,inhaled maintenance therapy,,,vaginal examination,,,,immunosuppressive dose,at time of initial history,14 and 25 years,,,,,,
8294,,cns disease；|2、patients,iodinated contrast agent carried out before surgery;|signed informed consent,,,egd,,,,influence study outcomes,within four weeks prior to baseline|regular consumption of probiotic,≤ 100 cc,,,,,,
8295,,traumatic brain injury)|evidence,component of neuroendocrine histology,,,verify eligibility.||single sites include:||each hemiliver,,,,neurotrophic,within 28 days;|those,not recovered more than 35 days,,,,,,
8296,,balance deficits,antibiotic drugs,,,percutaneous procedures,,,,angle-closure glaucoma,in the last 6 months.||,> 34 µmol/l,,,,,,
8297,,chromosomal anomaly,esophageal varices||,,,subglottic);|patients,,,,cxl.||,within 30 days prior to screening|donation of blood,less than 5 pack- years,,,,,,
8298,,renal dysfunction;|preoperative coagulation abnormalities,anti-pd-1(anti,,,cutaneous surgical procedure,,,,acute stage;|the presence of,within 30 days prior to pembrolizumab trial treatment,greater than or equal to 25 kilogram (kg,,,,,,
8299,,epinephrin|bleeding disorders,study drug,,,complete wound healing.|cure of cervical,,,,under age,30 days after the last treatment,18-80 years|diagnosis,,,,,,
8300,,hypersensibility,fosfatase alcalina (alp),,,fibrate therapy,,,,mna-sf)|at,after treatment are eligible (note,20 to 60 years,,,,,,
8301,,spinal cord compression.|participant,v. iliaca communis or v. cava,,,3d ct,,,,radiological features,more than 180,<1cm,,,,,,
8302,,mobile atheroma,glp1-,,,gestation)||in combination,,,,influence the cutaneous state.|subjects participating in other similar nutraceuticals,"in the last month,|20-g",fulfilled the 2019,,,,,,
8303,,medicare,recombinant human platelet production,,,hfnc oxygen therapy;|obstruction of nasopharynx cavity;|platelet<60 × 109/l；|need tracheal intubation;|the,,,,in the breast with a,within 30 days prior of the study screening,>= 40%,,,,,,
8304,,female breast cancer,met amplified,,,pitted fruit,,,,n.b. uncomplicated,within the last year.|any medication,>9||,,,,,,
8305,,medications|refractory hypertension,iodinated contrast agents,,,open head injuries/lacerations|those,,,,deemed unsafe,prior to standard of care treatment.|patients,greater than 45 kilogram (kg),,,,,,
8306,,osteoarthritis of the,topical retinoids,,,emergency calls,,,,asthma|recent,within 72 hours prior to the start of study drug,requires antibiotics,,,,,,
8307,,concomitant diseases,contraindicated medications,,,imp treatment,,,,radiation|associated,at screening and admission for the in-house phase,more than 12 weeks|the test value,,,,,,
8308,,familial history of,selective inhibitor of nuclear,,,kidney biopsy results,,,,pso).|superficial,within 3 months of screening.|active weight loss,≥100 μg/l,,,,,,
8309,,"pain medication|spinal inflammation,|spinal tumor|covid|pregnancy",anti-cancer,,,blood thinners,,,,chronotype questionnaire;|at least,within 30 days prior to the first dose of dulizumab,> 60%)|patient must,,,,,,
8310,,sensorineural hearing loss,factor concentrate,,,re-do surgery,,,,influence on eye health,within 28 days prior to first dose of study treatment.|must,≤ 1.5 × uln.|estimated,,,,,,
8311,,early preterm birth,component of the drugs,,,child;|normal thyroid function,,,,non-hormonal birth control,at first screening;|pregnant,> 5x uln,,,,,,
8312,,adenocarcinoma of the rectum,adrenal,,,social insertion center,,,,requiring the use of medication|fasting blood glucose,during the 7 days of,>2x upper limit of normal.|history,,,,,,
8313,,senile cataract,detemir,,,complete tarsorrhaphy,,,,soya,throughout study intervention,> 30.0 kg/m2|life,,,,,,
8314,,palpable splenomegaly,relapse.|patients,,,general anesthesia;|mechanical ventilation time ≥3h;|successfully,,,,full time-employment.||,until 24 hours after dosing,>150/90 mmhg).|orthostatic hypotension,,,,,,
8315,,confusional state,gtn,,,epilepsy;|endocrine diseases;|cancer|receive anti-proinflammatory cytokines therapy,,,,site of spatial frequency domain imaging (,in the last 6months (,<<this will not apply to patients,,,,,,
8316,,chordee,low-carbohydrate,,,magnetic resonance imaging-diffusion,,,,above physiologic dosing,within 60 days prior to dosing.|unwilling,≥ 1.5×10^9/l;|platelet,,,,,,
8317,,sucrose,tisirolimus,,,complete fess).||,,,,rich,during the study|subject,equal to or higher than 2,,,,,,
8318,,malignant hemopathy,"nmb,|receive neostigmine for",,,adult|written,,,,sibling donor,within 3 years prior to the first dose of investigational product,>= 15 mm,,,,,,
8319,,severe edema,oral inflammatory conditions,,,menstrual period,,,,meets 1 of the following,within 42 days after administration of investigational,18 years or more|indication,,,,,,
8320,,poor knowledge of turkish language;|cognitive impairment;|the presence,drugs containing steroids,,,study|presence,,,,teratogenic effects||* therefore,within the past 6 months|significant,≤ 1.5 mm,,,,,,
8321,,pre-dementia,intrauterine contraceptive,,,complete vaccine regimen,,,,gradually diminish,within 8 weeks of screening.|current,inherited,,,,,,
8322,,hepatitis b virus surface antigen,ocular assessments,,,dipstick testing,,,,smoking,during analysis,>1 cm,,,,,,
8323,,malignant lesions,acetaminophen,,,barrier,,,,mild anterior crowding lower,within the past 6 months||exclusion criteria,<12.5 g/dl,,,,,,
8324,,f32.0,inhaled budesonide,,,pelvic inflammatory disease|uterine fibroids,,,,exists|other,over the last six months|unable to communicate in english,> 65 years|who,,,,,,
8325,,varicose ulcer,sultan,,,managed,,,,any complementary alternative medicine methods,within the 6-month period prior to baseline.||macular laser photocoagulation,40-90 years|body-mass-index,,,,,,
8326,,alternative cancer,fluids,,,cervical rotation toward,,,,glp-1 class,prior to the start of the study medication.|patients,10-20 mm.|bmi,,,,,,
8327,,lack of accurate procedural,cysteine,,,serological virological examination,,,,mohfw,prior to admission to the icu|chronic kidney disease,>130 or >80 mmhg|bmi,,,,,,
8328,,rare,inr,,,traditional cardiac rehabilitation,,,,oxford/astrazeneca,within 4 weeks before signing the informed consent.|participants,> 1.5 x 109/l,,,,,,
8329,,language communication skills,otc,,,fibroscan,,,,study,at the time of the first visit|patients,≤ 45 kg/m^2.|have,,,,,,
8330,,rehab programme|absence,valaciclovir,,,cell transfer therapy,,,,suitable for initial local excision to achieve radical treatment；|the distance from anal verge,in the last 30 days).|patients,antibody test.|presence of hepatitis b surface antigen (hbsag),,,,,,
8331,,endocrine neoplasia syndrome type 2,dqb1,,,physiological doses,,,,≥ grade 3,for ≥3 years before the first administration of imp,≥18 years|american society of anesthesiologists physical status ⅰ-ⅱ|singleton,,,,,,
8332,,cl,sglt2 inhibitors|history of ketoacidosis,,,fresh tissue sample,,,,|scheduled,within the last 6 months|history of known,>= 30%,,,,,,
8333,,colorectal cancer team,local anesthesia agents,,,pain.|potent opioid analgesics,,,,c-reactive,for at least 4 weeks prior to screening.||cholinesterase inhibitors,<100000/mm3,,,,,,
8334,,unilateral breast cancer,components of chinese hamster ovary,,,technical experts||provide clinical care,,,,listed in child-bearing potential/pregnancy section,within previous 7 days of screening,≤ 90 mmhg,,,,,,
8335,,svd including:|cardioembolic source|carotid,3rd-degree,,,anti-infective therapy.|patients,,,,functionally weaker,during sexual intercourse from 2 weeks prior to screening until 1 month after the last dose of the study drug.|age,> 9)|depression deemed,,,,,,
8336,,wilson disease)||v,ovulation drugs,,,anticancer therapy,,,,≥ grade 2,within the sixty days prior to the start of the study,< 3|refractory,,,,,,
8337,,kidney transplant|abnormal blood pressure,potassium-sparing diuretics,,,herbal infusions,,,,could not reach,for at least 6 months after the final dose of study drug.|subjects,> 2 uln,,,,,,
8338,,light sensitivity,topical contraceptives,,,equivocal psma pet,,,,fresh collected,within 48 hours|sign the informed consent,"<50,000|diagnosis of coagulopathy|presence",,,,,,
8339,,convulsions|the,anti-depressants,,,lifestyle intervention,,,,confined to the ipsilateral cervical lymph exclusion criteria node,at least 6 months before the first dose of study vaccine.||exclusion criteria:||an individual,0 to 1.|patients,,,,,,
8340,,renal function:||(2,mycophenolate mofetil,,,gilbert-meulengracht syndrome,,,,using these topical agents,within 30 days of study enrollment,≥18 years|written informed consent,,,,,,
8341,,human t cell leukemia,hydroxyzine,,,12-lead ecg,,,,"3,|morning",during their participation in the study,≥30 ml/min||hepatic:||total,,,,,,
8342,,actively working,dxd,,,clinical study experience:||currently,,,,medically-accepted method of birth control,after complete remission,greater than 70%,,,,,,
8343,,kidney transplantation|atrial fibrillation,tdf,,,echocardiographic,,,,at level i,before enrolment to rule out mi.|corrected qt interval,more than 38℃,,,,,,
8344,,density,functional vitamins,,,small percentage of,,,,intradural,within 4 weeks before the first dose;|received,<92%,,,,,,
8345,,metabolic diseases|infectious diseases|epilepsy,related compounds,,,femoral access deemed,,,,tobacco smoker,during the study period||clinician participant inclusion criteria,≤ 1500 g,,,,,,
8346,,motility,iris,,,osdi questionnaire,,,,mean sitting systolic blood pressure,within 14 days prior to enrolment|any medical,at least 90 days after the last medication,,,,,,
8347,,castration resistant prostate cancer|potential participant,moderate inhibitors,,,t1.|previous radiation therapy,,,,non-selective beta-blockers,their close relatives.|participants,18-30||,,,,,,
8348,,morton's neuroma,hemology diagnostics,,,electric convulsive therapy (ect),,,,iv|lacks,within 24 hours prior to vaccination;|participating,> 26 meg/l,,,,,,
8349,,arteriosclerosis obliterans,regional anaesthesia,,,surgical sympathectomy,,,,antibiotic zesrosin,15 days prior to day 1,14-19 years,,,,,,
8350,,cardiovascular dysfunction,antianginal medication,,,chest computed tomography scan.|prior therapy,,,,viral,within the last 3 months.|willing and able to give written,≥ 40 ml/min.|coagulation function,,,,,,
8351,,intractable pain,sodium valproate,,,surgery|definitive stoma creation,,,,long-term treatment,at screening/baseline,greater than or equal to (>=) 18 years to less than or equal to (<=) 55 years,,,,,,
8352,,right hand(s,tobacco users.|subjects,,,reliable daily access,,,,interfering drugs,within the previous 2 months of the screening,18-75 years;|living,,,,,,
8353,,necessity of curarization,hydrochlorothiazide,,,egyptian,,,,interferes with hba1c determination|presence,within 30 days prior to screening.|subjects,less than 50kg.|before the test,,,,,,
8354,,pain from,glucosamine sulfates,,,uc|rectal topical therapy (enemas or suppositories,,,,angina|acutely,prior to the one,stage i to iii,,,,,,
8355,,cancer.|relatives,other psychotropics,,,therapy related criteria guidelines,,,,study|receive investigational treatment,at the time of enrollment|further exclusion criteria apply,from 2 years to less than 18 years|xeljanz,,,,,,
8356,,prolonged resuscitation,medications known,,,influenza vaccination should,,,,sequential organ failure assessment score,within 14 days of study registration,degree ii or higher,,,,,,
8357,,progressive central nervous system symptoms,drug components,,,otc emollients||,,,,radiological findings,within 4.5-24 hours,do not exceed twice the normal upper limit;|patients,,,,,,
8358,,immunosuppressive diseases,opioid medications,,,parenteral nutrition,,,,metabolic kitchen,in the last 12 months.|previous foot surgery.|hallux abducto-valgus.|being,>= 30 ml/min|total bilirubin,,,,,,
8359,,cardiac function.|myocardial infarction,pancreatic lipase inhibitors,,,exercise|smoking cigarettes,,,,form.|able to read,drug 30 days before the study blood draw.|a confirmable diagnosis,i -ii,,,,,,
8360,,colorectal carcinoma,pharmacological anti-depressant therapy.||,,,hpv vaccine initiation,,,,eosinophilia|partial,preceding 90 days,non,,,,,,
8361,,bleeding diatheses,anti-craving medication,,,imp,,,,icd-10: d37-d48,during the 4 weeks prior to study,> 7.|end-stage renal disease,,,,,,
8362,,malignant hyperthermia|history of,abl1 amplification,,,screening ecg abnormalities|malabsorption syndrome,,,,age|heavy,within the preceding 3 months|have,≥ 18 years|proficient,,,,,,
8363,,sita faster).|glaucoma definition,histamine containing gamma globulin preparations,,,pharmacologic thromboprophylaxis,,,,developmental age,planned by the physician|uterine contraction,0-1|disease present,,,,,,
8364,,squamous cell carcinoma.|clinical symptoms of covid-19,type 1,,,surgical procedures of gastrectomy,,,,primary manifestation,at screening and predose on day 1,0-1|child-pugh score,,,,,,
8365,,treated therapeutically,trial-related procedure.||healthy,,,endoscopy sedation,,,,near the resection margin when opening the surgical piece,in the teeth|no spontaneous,below the normal reference range,,,,,,
8366,,chest drainage|lack,anti-body drug conjugates,,,lines of therapy.||adequate organ function,,,,reducing dose of,at least 30 days before the first administration of trial medication until 30 days after trial completion:||use,"15 weeks),|good communication skills",,,,,,
8367,,expectation,oral anti-infective agents,,,partner;|tubal ligation,,,,locally use glucocorticoids,previous 12 months,18-45|patients addressed,,,,,,
8368,,episcleritis,ixekizumab,,,fluorographic examination,,,,non-pregnant female|eastern,within the last month.||exclusion criteria:||current thoughts of self-harm,16-29 years,,,,,,
8369,,procedures.||renal cell carcinoma,similar compounds,,,intracranial,,,,reflux-related conditions,at aforementioned dose and duration within 28 days following receipt of study vaccine,17 and 29 years,,,,,,
8370,,chronic supplemental oxygen|respiratory rate,lidocaine hydrochloride|cardiovascular disease - complete heart block,,,diagnostic interview-,,,,susceptible in,within 6 months prior to screening|new york heart association (,>30 days prior to diagnosis,,,,,,
8371,,bleeding disorders,yakult.|abnormal liver,,,congenital cyanotic heart,,,,high-performing elderly (,within 1 month of study enrollment,0-2.|with,,,,,,
8372,,mixed carcinoma,cerebellopontine angle,,,preoperative education of the patient during consultation.|patients will be required to stop smoking,,,,non-consenting,within 3 months of the first dose,>10 mg/day,,,,,,
8373,,ferromagnetic,regional analgesic procedures,,,cisgender,,,,beighton score|high intensity resistance training (,at least 14 days prior to (first) admission to the clinical research center,>150 pg/ml,,,,,,
8374,,genitourinary system disorder,contrast-enhanced mri,,,global photograph,,,,interventional cholangiocarcinoma clinical trial|patient,30 days of age,≥19 kg/m2,,,,,,
8375,,renal vasculitis,levonorgestrel,,,ct completed,,,,mri|severe,throughout the target vein segment|patient,≥40 kg,,,,,,
8376,,good physical health,labcorp,,,antitumoural chemotherapy|no evidence,,,,sexes,48 weeks prior to c1d1,90 - 130 mmhg|diastolic blood pressure,,,,,,
8377,,unknown|bleeding disorder,miconazole,,,x-ackt,,,,non-prescription medication,"last two months,|any",sheet/faq).||,,,,,,
8378,,postmenopause,selegiline,,,mini international neuropsychiatric interview module h,,,,likely to,during the trial|anyone who is pregnant,less than four weeks before inclusion.|concomitant administration of,,,,,,
8379,,pain interference,nono-42,,,regular vinyasa,,,,hands,before the age,>40 g/day,,,,,,
8380,,micm,immune therapy related adverse event,,,living donor transplantation,,,,low grade dysplasia (lgd),within 28 days before the first dose of the investigational product,300 mg/dl,,,,,,
8381,,clinical forms of ms,full custody of child,,,"cochlear implant system,|duration of cochlear",,,,intra-thoracic,within the last week|treatment with,> 200 mg/d,,,,,,
8382,,substance abuse-related disorder,immunomodulating treatment|known severe vitamin,,,coronary artery bypass graft surgery|sinus bradycardia,,,,unstained,within 3 months prior to first dose.|known,<0.5,,,,,,
8383,,incompatible with the device,ahas,,,extracorporal circulation,,,,first-line chemotherapy drugs,in the three months prior to screening,"≥ 37,3°",,,,,,
8384,,pancreatic carcinoma,band aids,,,holter monitoring,,,,upper extremity,at the time of admission,less than 10 seconds.||,,,,,,
8385,,diagnostic criteria;|age,esketamine,,,cerebral artery [aca],,,,differentiated,within 3 months of signing consent,> 18 years|patients,,,,,,
8386,,renal insufficiency|previous operation,adequate contraceptives,,,treatment;||enteroscopy,,,,modalities foreseen,within 30 days of the first dose,> 1.68,,,,,,
8387,,hepatic impairment|diagnosed,[18]f-,,,open abdominal surgery|history,,,,fshd2,within 3 months prior to enrollment;|history,higher than the lower limit of quantification);|subjects,,,,,,
8388,,pulmonary vein isolation,contrast media,,,donation of plasma,,,,androgens,within the past 24 months,over 18|genital lsc,,,,,,
8389,,congestive heart failure|recurrent,anti-her2 therapy,,,screening|regular alcohol consumption,,,,pd symptoms of,during study period|participants,<500 cells/yl,,,,,,
8390,,chronic epithelial disease,ertapenem,,,vaginal diaphragm,,,,intra-bony,during the whole trial period,≤ 1.5 upper limit of normal (uln),,,,,,
8391,,myeloproliferative neoplasia,fⅶ inhibitor,,,infection|living donor kidney recipient|acute,,,,second-line,within 5 years of the date of consent,>= 60%,,,,,,
8392,,gastrointestinal tract lesions).|patients,type-2 portal vein tumor thrombus,,,potential donor,,,,confined space;|allergy,in the past 4 weeks prior to screening,=< 1+ on dipstick,,,,,,
8393,,np,anti-coagulants,,,fresh biopsy sample,,,,gastric,during the trial;|history,20 minutes||,,,,,,
8394,,choroidal melanoma|patient,strong inducers of cyp3a4,,,pah specific,,,,neo)adjuvant,at least one 2-week rotation,0 or 1;|patient able to understand the information related to the study,,,,,,
8395,,cycles of,systemic therapy.|a,,,endoscopic treatment,,,,silicone.|confirmed,in the past three years.||history of any of the following:||seizure,between 18 to 65 years;|meet the threshold,,,,,,
8396,,keratitis).||criteria:||-,topical steroid use,,,dental x-rays|have,,,,st-segment elevation,up to 2.0 × uln,score of 3 or higher,,,,,,
8397,,communication,capsaicin,,,biological reagents,,,,non-cu som clinicians,for three days added to their standard post-operative,< 35|counter-indication,,,,,,
8398,,substance disorder,drugs targeting the same target|subjects,,,percutaneous intervention,,,,investigator|cough,within 3 months before the study|any malignancy,20-40kg/m2|age range,,,,,,
8399,,noyes,single drug expansion stage,,,dna vaccine,,,,senior registrar,in months,>24 hours,,,,,,
8400,,chronic prostatitis|pathology making,bcd,,,brief technology,,,,index knee|unresolved,within 7 days of the start of the study.|subject,score of 2 or greater.||,,,,,,
8401,,wireless network|patient,anti-vegf injection.|tractional macular,,,arterial access,,,,mcas-r.|the,during the study|a history of,< 2h40min||,,,,,,
8402,,restrictive lung disease|arterial oxygen saturation,dlb,,,tezepelumab studies,,,,effective methods of contraception,within the last 3 months|severe infection,> 3 diopters,,,,,,
8403,,acute arthritis,xanthine-related compounds,,,brafv600e mutation,,,,non-resectable,more than 14 days,"> 100,000/ul|complete",,,,,,
8404,,progressive multifocal lenses,asthmatics,,,local infection|coagulation disorders|history of,,,,3rd degree,1 week before screening,≥ 3.|patients,,,,,,
8405,,lung congestion,anti-angiogenic-directed treatment,,,mr imaging|adequate organ function,,,,ala,during the study period.|current,>470 milliseconds,,,,,,
8406,,common femoral artery diameter stenosis,neostigmine,,,simpson method）<35%；|24,,,,clostridium difficile infection.|history of,for 150 days following completion of trial therapy,< 65 mm hg,,,,,,
8407,,family medicine,adaptations,,,rsv,,,,self reported skin condition,within 30 days prior to inclusion|pacemaker|previous,> 6%);|disorders,,,,,,
8408,,core drilling,medication readjustment,,,brain cancer|cerebrovascular accident,,,,fs,preceding year for psychiatric illness|no access to a device with internet access,<25 db hl,,,,,,
8409,,symmetrical positions,peptide-1,,,leukemic cells reappear in peripheral blood,,,,study.|in-stent,at time 1,≥ 50%||,,,,,,
8410,,acute hbv infection,anti-obesity medication,,,diazepam,,,,total hip replacement,for at least last six months|within 14-17 years,"≥ 1,500/µl",,,,,,
8411,,reactive airway disease,strong inhibitor of cyp3a,,,renal transplant,,,,suspected,throughout the trial.||,≤34 weeks,,,,,,
8412,,autoimmune diseases);|daily smoking,folfox,,,t2dm|previous sleeve gastrectomy procedure,,,,preclude stepping exercise,within 6 months before surgery|patients,<50 beats/min,,,,,,
8413,,regulatory authorities,analogues,,,pelvic lymph nodes,,,,upper respiratory infection,for at least 6 months prior to the study,≥ 7.0mmol/l,,,,,,
8414,,systemic rash,cyp2c8 inhibitor,,,active knee inflammation|non-adherence,,,,circulation,within 60 days prior to check-in,less than 15,,,,,,
8415,,non-implantable device,anti-infectious therapy,,,allogenic organ transplantation.|participants,,,,systemic treatment;|6,in 28 days,50 to 95 mmhg,,,,,,
8416,,language disorder,systemic anti-vascular endothelial,,,personal consultee|presentation,,,,long-standing,at the time of enrollment|subject,> 4 ng/ml,,,,,,
8417,,atherosclerotic lesion,topical anaesthetics,,,invasive surgical procedures,,,,interferes with the study aims,within the past 7 days|history,male volunteers|19 kg/m^2 ≤ bmi,,,,,,
8418,,substance abuse / dependence,stains,,,ttp|at,,,,mucous,3 months.|at optimal volume status,= 240 ml beer,,,,,,
8419,,mm,component of the medicinal product formulations,,,radiographic imaging showing,,,,stage iiic,within 3 months prior to dosing;|previous,less than 30 ml/min/1.73m2,,,,,,
8420,,snri,curcumin,,,cataract extraction,,,,interfere with cooperation with the requirements of the trial,during the past two years;|women,≥3 months;|serum ferritin ≤ 1000μg/l,,,,,,
8421,,withdrawn from studies nn7769-4513,medication known,,,outpatient,,,,tavr,within 28 days prior to randomisation,at least 12 weeks,,,,,,
8422,,acquired immunodeficiency syndrome,influenza-like illness,,,standard treatment after cataract surgery,,,,stable refraction,30 days after trial,1 and phase 2a,,,,,,
8423,,therapy)|autoimmune diseases,steroid dosing,,,hookah,,,,intra-uterine device (iud),in the past year.|pregnancy,< 350 cells/mcl,,,,,,
8424,,cerebrovascular disease.|a family history,multivisceral resection.)|patients,,,standard tte exam,,,,adolescent,occurring < 6 week from enrollment group,> 3 times upper limit of,,,,,,
8425,,cbct,mad,,,vascular puncture,,,,wear,at least one prior line of therapy,<3x normal,,,,,,
8426,,psychosocial factors,etc|pregnant,,,full eye examination,,,,suitable for systemic therapy,within 3 months before admission;|cumulative oral,equal or greater than 14 standard drinks per week,,,,,,
8427,,multi-surgery,systemic medications,,,cosmetic treatments,,,,non-covid related,14 days prior to enrollment,ii-iii;|stable,,,,,,
8428,,corticosteroids.|symptomatic,tetrabenazine,,,bile duct,,,,mastectomies ff,within 16 weeks prior to step 2 registration.|receipt,> 30 kg/m2.|contraindication,,,,,,
8429,,pacemaker wires,potassium supplement|known history of hyperkalemia|use of salt reduced in sodium,,,patellar knee pain,,,,influence the dissolution,medical history and laboratory results,4-10ng/ml,,,,,,
8430,,corrected qt interval prolongation,growth factor support allowed)||creatinine clearance,,,non-invasive ventilation therapy,,,,durable remission,within 3 days prior to first administration,below 90mmhg,,,,,,
8431,,disease burden,hormonal therapy|autoimmune disease|endocrinology disorders,,,hpv vaccination rates,,,,accurately be measured in,within 1 week from the screening visit||individual,=< grade 2,,,,,,
8432,,women.|allergic constitution,postoperative medications,,,b-mode ultrasound,,,,nicotine|another,after 24 hours after their admission|patients who couldn't finish all of the study steps.|patients,= [,,,,,,
8433,,endotracheal intubation|age,cannabinoids,,,blomia tropicalis,,,,non-l265p,for at least 12 months after lymphodepletion|from the time of screening/study treatment icf signature,≥18 years|the presence,,,,,,
8434,,solid tumor type,anti-osteoporotic drugs,,,bone turnover,,,,single-rooted maxillary,within two weeks prior to the screening,<18 yrs,,,,,,
8435,,quinquaud's decalcifying folliculitis,alk translocations,,,whole blood,,,,suitable for determination,within 6 months before trial start,90-99 mmhg,,,,,,
8436,,lumbar discopathy,noradrenaline,,,dbs,,,,immune-checkpoint inhibition,during therapy that may confound the study data.|nails,<18 or >35 kg/m2|active,,,,,,
8437,,chronic infarction.|severe anemia,immune tolerance induction (iti) treatment,,,general anesthesia|allergy,,,,age-relate,three months prior to participation in study,< 100 × 109/l；|patients,,,,,,
8438,,mild enlargement,st. olavs hospital,,,sessions|surgery,,,,presumed,within 3 weeks before the first dose of the study drug,> 50% above recommendations,,,,,,
8439,,bone loss,anti-cd38 antibody drug|uncontrollable,,,gait testing,,,,influence growth,within 28 days prior to the first dose of the interventions,<24 months|have a presence,,,,,,
8440,,venous embolism,gnrh agonist protocol,,,clinical laboratory tests|is,,,,suitable for local treatment,prior to last prestudy igg infusion,35 - 45 years,,,,,,
8441,,ad:||iga score,mek inhibitor,,,treatment intervention,,,,could confound the results of the study,at the time of study entry.|subject,≥ 1.5 x 10⁹/l|platelet count,,,,,,
8442,,substance use disorder.|substantial cognitive impairment.|a diagnosis,oda defect|ida - mtd,,,dbs therapy,,,,exacerbated by exertion,at the time of hysterectomy,≥1/year)|non-smokers||,,,,,,
8443,,lactating.|allergic to fenofibrate,oxytocin,,,cart,,,,rr ^,the night before or after mdma,> 35 kg/m2,,,,,,
8444,,changing providers,l-histidine,,,anaesthetists,,,,interferes with activities of daily living|patients,in the last 6 months||,≥ 18 years|colon cancer,,,,,,
8445,,naked eye,are:||systemic contraceptives,,,regional/epidural anesthesia,,,,msec|symptoms,within 1 year of first study drug administration.|participation,> 1|hypertonic,,,,,,
8446,,ventilator support,absorb oral antibiotics,,,conversion tka|patients,,,,sars-cov-2.|active infections,continue four or more weeks after the start of,≤ 1.5 × uln.||,,,,,,
8447,,normal physical examination report,lispro,,,aneurysm|significant pulmonary hypertension|various,,,,low-risk,at the time of consent|body mass index (bmi) ≤35 kg/m2|documented,≥ 18 years|receiving,,,,,,
8448,,peripheral vascular complications,hormonal contraceptive agents,,,chest imaging,,,,rome iii constipation diagnostic criteria|constipation severity scale score,for at least 3 months prior to screening,≥18 years|established histologic diagnosis,,,,,,
8449,,b-cell maturation antigen,oral retinoid therapy,,,intraspinal anesthesia,,,,non-erosive reflux disease||,"within 2 weeks prior to cycle 1, day 1",1 or 2a,,,,,,
8450,,skin change,trichloroacetic acid,,,kienböck's disease||,,,,lower limb bone surgery|patient,mmhg|bmi>40 kg/m2|diabetes|familial hypercholesterolemia|past,b-cell lymphoma,,,,,,
8451,,drinking,anticoagulation medications,,,neoadjuvant therapy,,,,icd|previous,within the past year|history,1 to < 2 years,,,,,,
8452,,squamous cell in situ skin carcinomas|treated,prcc,,,satisfaction survey tool|diagnosis,,,,index knee,more than 1.0 edss point,≤ 10 mg daily,,,,,,
8453,,alcoholic pancreatitis,cyp3a inhibitors,,,gastrointestinal disease|gastrectomy,,,,medical grade,during the study period.|patients who regularly use,19 or older,,,,,,
8454,,treatments,anti-pd-1/anti-pd,,,carotid endarterectomy surgery|known,,,,upper limb|an,"during ""on"" periods",less than 2500 grams birth,,,,,,
8455,,mercury,antimicrobial agents,,,venous access sites in upper extremities.|body weight,,,,investigator.|abnormal skin,by the first degree relative.||,≥18 years.|anticipated,,,,,,
8456,,hbv dna.||of note:||patient,remimazolam|patients judged,,,stress reduction,,,,non-treated additional,within the last year.|chronic immunosuppression.|individuals,≥ 180 mm hg,,,,,,
8457,,chronic ankle instability,ketamine-hcl,,,general anesthesia.|operations,,,,exhaled,at least 7 days prior to visit 2,≥ 4 weeks beyond treatment,,,,,,
8458,,extra-articular,teprotumumab,,,vertebral levels,,,,60 minutes of,in the past 9 months,≤ 5x uln.|international normalized ratio,,,,,,
8459,,primary hypothyroidism,tripterygium,,,lateral periorbital site.|infection,,,,traumatology unit|level of consciousness on the glasgow scale of 15|have access to a mobile device|ability to participate in the pilot study|be able to provide written informed consent,for at least 4 weeks prior to screening visit 1.|pre-bd,< 490 and,,,,,,
8460,,chronic radiation enteritis,antihistamine medications,,,hypoplasia,,,,foveal center,in the month prior to the inclusion|treatment,>35|subjects,,,,,,
8461,,regional wall motion abnormality,clozapine,,,fascial nerve blocks,,,,denver metro area|infants,within 4 weeks prior to the first dose of epcoritamab;|non-investigational,< 1 x uln,,,,,,
8462,,administering urine disease,disease.|creatinine,,,hiatal hernia repair,,,,low metastatic potential,outpatient procedures,> 10%|hypercoagulable condition,,,,,,
8463,,chronic cancer,gynaecology,,,af treatment,,,,dietary regimen,at the pre-trial screening assessment,between 45 and 70 years,,,,,,
8464,,deleterious hboc,anti-vegfr small molecule tyrosine kinase inhibitors,,,database|clinical,,,,pregnancy;|prior,within < 4 weeks of screening,iii-iv periodontitis|compliantpatient,,,,,,
8465,,s/p,smoking products,,,her2 insertion mutation,,,,condition|≥,past 12 months|have,>4|participation,,,,,,
8466,,functional status,hypergastric acid secretion,,,us.|patients,,,,comorbid,within the previous 3 months prior to first dosing.|subject,equal to or lower than 2 times of uln;|kidney function,,,,,,
8467,,mini|current depressive episode,increta,,,intracranial angiography (,,,,stabilized|uncontrolled,within 14 days before the start of the study treatment,18 and 70 years old,,,,,,
8468,,acute coronary syndrome|age,antibody drugs,,,virus therapy,,,,non-progressing,at least 2 days a week||,6 abdominal cavity,,,,,,
8469,,impact on the lung function,contraceptive pill,,,vericiguat,,,,full injection of the drug,at the time of diagnosis by the institutional multidisciplinary team,4-7 days/week,,,,,,
8470,,occlusal contact,wellbutrin,,,clinical laboratory test abnormalities,,,,ehrs.||,within 2 weeks.|participant must not,≥70 at screening,,,,,,
8471,,abnormal physical findings,clarithromycin,,,treatment|history of,,,,stage iiib nec,within 4 to 6 weeks;|patients,score of 24,,,,,,
8472,,amd,sierra,,,e,,,,very high,for at least 4 months after the last treatment on study.|in addition to,above 32 kg/m2.|inability,,,,,,
8473,,cerebellar abnormalities,oral hygiene measures outside,,,local institution;|bone marrow involvement,,,,primary care healthcare centers,within 3 months prior to signing the informed consent,> 60 years|patients,,,,,,
8474,,dementia|staff,systemic therapies,,,arthroscopic shoulder surgery,,,,subjective,during pre-anesthesia,> uln|female participant,,,,,,
8475,,weight loss therapy,mydriatics,,,bone loss|gingival index,,,,amenable to local treatment,during the first 24 weeks of study,≥ 350,,,,,,
8476,,trus,anti-microbial agents,,,retinal screening,,,,alk positive,at least 4 weeks prior to enrollment in study.||,16-40,,,,,,
8477,,tertiary hyperparathyroidism,inducers - barbiturates,,,indian national cdc,,,,stage i,during their icu stay,< 15ml/min,,,,,,
8478,,renal disorder,supplements stable,,,bone marrow function|active brain metastases|participants,,,,inferior mesenteric artery;|patients,after last prior line,≥20 mmhg,,,,,,
8479,,primary lung disease,indocyanine green|patients,,,radiotherapy to head and neck,,,,worse than or equal to logarithm of the minimum angle of resolution,within 4 weeks before administration,≥ 40kg/m2,,,,,,
8480,,"gastrointestinal problem,|voluntary",prescription nsaid,,,endoscopic ventriculostomy,,,,large fibroids,within 14 days before the first dose of study,18 years or older|scheduled,,,,,,
8481,,urosepsis,aiha,,,biochemical blood analysis,,,,only - females,within 12 weeks prior to screening.|receipt,permanent,,,,,,
8482,,traumatic dental injury,taf1,,,little help,,,,excepted,in the past 6 months|meet one of the following criteria,7th edition|aged above 18,,,,,,
8483,,unrestorable teeth||teeth with defects not,reboxetine,,,capital international airport hospital,,,,c1-c5|demonstrate,within 7 days prior to receiving the experimental drug treatment;all,greater than 5,,,,,,
8484,,relapsing optic neuropathy,supplements,,,periodontal treatment,,,,non-cns lesions,within the innervation territory of the planned nerve block.|unable to understand,<11,,,,,,
8485,,poba,somatostatin receptor targeted therapy,,,tumour embolization,,,,under tutelage,within one hour after the first suctioning procedure,≥18 years||triple,,,,,,
8486,,fusion proteins|known hypersensitivity,anti-cancer therapies,,,testing tissue,,,,stable dose of,within 12 weeks of study intervention,> 21 alcohol units per week,,,,,,
8487,,inflammatory bowl disease.|patients,anti-ulcer drugs,,,hav vaccination,,,,"bulimia)||person referred in articles l.1121-5, l. 1121-7",during the course of the study,19-9,,,,,,
8488,,clinical signs,suprasorb®,,,full trisomy 21,,,,stable phase of copd,while on study treatment,>= 60.|overall,,,,,,
8489,,post-arrest encephalopathy,anti-pd(l)1 therapy,,,rectal mucosa.|patient,,,,"diagnostic and statistical manual of mental disorders, fifth edition (dsm-5)",within 5 years of entry|use,≥ 18 years|proximal,,,,,,
8490,,thyroid disease|no,anti-cd20 monoclonal antibody.||subjects with transformed fl,,,≥6 months.|a mini mental state examination (mmse),,,,anticoagulants;|active,medical history|willing,score ≥13 at the screening/randomization,,,,,,
8491,,hypoproteinemia,pioglitazone,,,whole duration of administration of,,,,in 2020,within 3 years except,< 3.0 × uln,,,,,,
8492,,active myositis,sticks,,,sound therapy,,,,castration-sensitive prostate cancer)|spinal cord compression,within the past 30 days prior to randomization,<18 years|initiation of ecmo,,,,,,
8493,,klebsiella pneumoniae,topical corticosteroids,,,insulin therapy,,,,automated machine,while enrolled in this study,less than 48 kilograms,,,,,,
8494,,pathology that involves,clozaril,,,complete neuropsychological measures,,,,structural,after signing icf)|abnormal acth stimulation,0-1.|availability of archival tumour biopsy tissue,,,,,,
8495,,extreme,african americans,,,pharmacotherapy,,,,moderate-vigorous,organs;|history,b-c)|current,,,,,,
8496,,"motor deficit,|qauda equina syndrome,|lumbar",catecholamine depletion drugs,,,65|elective surgery,,,,asd,for 4 weeks prior to baseline.|subjects are allowed to,more than 3x above normal,,,,,,
8497,,herpetic keratitis).|have,systemic steroids,,,maintenance ics therapy,,,,influence lipids levels|severe renal impairment,at least one of the following criteria:||relapsed,between 18 and 75 years|diagnosed,,,,,,
8498,,gastrointestinal diseases,malarone,,,sunflower seed oil|individuals,,,,gi malignant,within 12 months prior to visit 1,>50% of predicted||,,,,,,
8499,,influenza virus,evorucumab,,,mini-mental state examination score (mmse),,,,respiratory,within a specified time frame.|the,< 1.3 x 10^9 / l,,,,,,
8500,,selected tumor,antiglaucoma medication,,,unstimulated salivary sample,,,,gaze-evoked nystagmus,within 28 days prior to trial,"< 50,000/μl|absolute",,,,,,
8501,,congestive heart failure (chf),cardiogenic,,,surgical incision,,,,adults,at time of recruitment,65 years or older,,,,,,
8502,,progressive disorders,cipn medications,,,dentistry anesthesia,,,,anti-tumor vaccine,fluctuation of less than or equal to 5%,less than 12 lymph nodes examined,,,,,,
8503,,spinal cord disease,iiia,,,ebrt,,,,suitable to conduct,more than 6 months);||chronic lung disease,=< 7.5 mg /day,,,,,,
8504,,cardiac arrest.||,subconjunctival corticosteroid injection,,,intensive intervention,,,,"ii,|required",within 6 months prior to c1d1,6-15|have access,,,,,,
8505,,major psychiatric illness,tildrakizumab,,,ricu,,,,transmitter might still,preceding 6 months,≥15 mm;|the results,,,,,,
8506,,prior arm injury impacting available passive,chronic benzodiazepine,,,sperm normal morphology rate ≥4%;|no,,,,burnout syndrome criteria,within 28 days prior to initiation of study treatment|prior treatment with cd137 agonists,">40 kg/m²),|severe organ failure,|previous",,,,,,
8507,,months||acute pain,immediate delivery,,,video-assisted thoracoscopic (vats) lung surgery,,,,that affects the anatomy,during the previous 12 months|a smoking,≤ 1.5x the upper limit of normal,,,,,,
8508,,healthy native,anti-tnf-α agents,,,transfused blood,,,,acr/eular 2010,cancer|patient,>52,,,,,,
8509,,predominance of sui,meropenem,,,therapeutic exercise,,,,creatinine ≤1.5×uln,at least 30 days prior to screening.||•,7-10 points.||for,,,,,,
8510,,conventional tnm stage,quinine,,,antral roots,,,,wild-type tumors,for the prevention of rsv,>7.5%,,,,,,
8511,,middle finger,drug balloon dilatation,,,non-inclusion criteria:||unsuitable veins,,,,peri-wound,"within last 3 months,|periapical pathology",< 7);|2,,,,,,
8512,,ventilation disorders,emvi-,,,in-exsufflation device,,,,intra-medullary nails.||,within 24-36 hours,50 x 109/l)|active,,,,,,
8513,,hip fractures,gentamycin,,,medical tests.|asa type > ii|current pregnancy,,,,cheyne-stokes respiration,within 3 months prior to joining the study.|subjects,> 20mm/hr||•≥1,,,,,,
8514,,alpha blockers.|large prostate volume relative to pelvic arch width that can hinder proper placement of applicator insertion,bilvalirudin,,,adrenal surgery,,,,bilateral symptomatic,pre-malignant,under 18 years old,,,,,,
8515,,m. tuberculosis,high-potency dermal topical corticosteroids,,,mr imaging,,,,suitable for participation in the clinical trial in the judgment of the investigator,> 3 time zones,≥ 3 times upper limit of normal.||19,,,,,,
8516,,nonmalignant chronic musculoskeletal pain,topical anesthetic,,,lumbar isthmic spondylolisthesis,,,,positive|acute lymphoblastic,within the last three months,< 1 month;|concomitant treatment,,,,,,
8517,,agitation episodes,plasma glucose (fpg),,,radiographic imaging consistent,,,,influence the sensor glucose measurements,in the past|patient's participation in any studies applying,scores of 9+,,,,,,
8518,,chronical diseases,nets,,,pelvic radiotherapy|currently,,,,air.|marked dyspnoea,within 30 days prior to the first dose of ip,≤1.5 mg/dl||negative,,,,,,
8519,,mild impairment,anti-diabetic medication).|disorders of coagulation,,,magnetic resonance,,,,post high,before the first dose of study,≥ 20×10^9/l,,,,,,
8520,,reproductive active,kidney related growth retardation,,,coronary artery bypass graft surgery,,,,booster dose(s,at enrollment greater than or equal to 12 but less than or equal to 20,50-78,,,,,,
8521,,non-cardiorespiratory symptoms,drugs acting on insulin sensitivity,,,tms treatment dose,,,,interictal heart rate,within one year prior to enrolment.|previous vaccination,greater than 26.0mm;|trauma,,,,,,
8522,,optimal dosage,anti-tau drugs trials,,,first onset,,,,interfere with cooperation with the requirements of the study|history,within the planned area,>40 kg/m^2|estimated,,,,,,
8523,,non-surgically treated hydrosalpinx,systemic glucocorticoid,,,opposite sex,,,,influence the cognitive functions,within 28 days / 5 half-lives,> 50 %,,,,,,
8524,,pseudoexfoliation syndrome,reslizumab,,,control pain,,,,transforaminal,within 28 days of the 1st dose of ft538.|completion of initial covid-19 vaccination series,at least 10 kg,,,,,,
8525,,laundry detergents,symptomatic medication,,,intra-peritoneal surgeries,,,,full upper permanent dentition|well-aligned teeth,within 1 year before the screening visit,<30 ml/min).|patients,,,,,,
8526,,women)|healthy,contains monoamine oxidase inhibitors,,,left atrial appendage closure,,,,under ame|vulnerable people,within the past 6 months prior to enrollment,≥ 1.7 mmol/l,,,,,,
8527,,severe claustrophobia).|known coagulation problems,atypical neuroleptics,,,renal replacement therapy|liver failure,,,,chronic administration,within 18.0 to 32.0 kg/m^2,50 through 69 years,,,,,,
8528,,fever).|have,systemic anti bacterial,,,primary antihypertensive therapy,,,,≤2 iu/dl,at start of treatment,>90||,,,,,,
8529,,right-sided hf,tl,,,standardized,,,,old|enrolled,within 10 days prior to inclusion,>4 weeks,,,,,,
8530,,infectious meningitis,nephrotoxic drugs,,,lung computed tomography (ct),,,,pure ground,within 48 hours before the first injection;|receive any product containing fⅷ (,< 0.60,,,,,,
8531,,gilbert's disease,mineral salts,,,étranger métallique,,,,1:||previous receipt,within 6 months prior to the screening visit.|the use,18-49 years|all,,,,,,
8532,,chews of,anticonvulsants,,,exercise tolerance.|being,,,,lung bulla,within 6 weeks|patients,18 -27 kg/m2.|that,,,,,,
8533,,type 1 diabetes mellitus||,alcohol,,,hcv eradication,,,,psychiatric clinics,within the last 16 weeks,1- patient's inability to provide,,,,,,
8534,,gea,medication containing probiotics,,,rapid estimate of adult literacy,,,,researcher,within 4 weeks prior to day 1.|participant,> 200 mg/dl,,,,,,
8535,,valvular pulmonary stenosis,chvs,,,intraocular surgeries,,,,"diagnostic and statistical manual of mental disorders, 5th edition (",within two years of (neo),0-1.|histologically,,,,,,
8536,,etc.)|major illness,oral examination||,,,covid,,,,division of aids,after chemo/radiation,score of 0,,,,,,
8537,,retinal hemorrhage|current active liver disease,antiplatelet therapy|contraindication,,,specific treatment,,,,heterozygous,from 28 days prior to first dose,criterion).|long coronavirus disease,,,,,,
8538,,neurological event,cyp3a inhibitor,,,structured clinical interview for dsm-5|have current depressive symptoms,,,,nafld advanced fibrosis,at least 2 units/day|weight,21-80,,,,,,
8539,,covid-19 diagnosis code,cyp2c8,,,hormone regulating therapy,,,,threshold|previous,< 4 weeks prior to cnct19 infusion,between 7.5% and 10.5%,,,,,,
8540,,non-febrile convulsions,prokinetics,,,palliative procedure,,,,image-supported,within 8 weeks before the first date of administration,10-14,,,,,,
8541,,chronic obstructive pulmonary disease,methacholine challenge,,,androgen deprivation therapy|prior receipt of androgen deprivation therapy|any other condition that,,,,antihypertensive medication.|significant,at least one month before this,< 2,,,,,,
8542,,clinically evaluable disease,intraprostatic calcifications,,,hospital admission.||definition,,,,december,within two hours,"> 35,5°c|appendix diameter",,,,,,
8543,,varicosity,spms,,,ventilation-perfusion-mismatch||exacerbation,,,,hormone sensitive disease,≥ 6 months,>18 years,,,,,,
8544,,spinal cords,long-acting nitrates,,,revision shoulder surgery|any indwelling deep brain stimulator,,,,portal systemic shunt,within 4 weeks prior to the first dose of niraparib|received colony,0 to 1|confirmed histologic,,,,,,
8545,,acidosis|ketosis,some drugs,,,small-molecule anticancer agents,,,,cb-011,for the preceding ≥4 weeks,less than 72 hours,,,,,,
8546,,unilateral rotator cuff tendinopathy,antioxidant vitamins,,,endodontic treatment).|restorations in anterior teeth,,,,study|regular use,at time of the (first) administration of imp.|severe ischaemia,between 90 and 139,,,,,,
8547,,traumatic amnesia,mcd,,,biomicroscopy,,,,occular,at least 3 months,greater than 2.0mg/dl,,,,,,
8548,,averages,crystalline,,,exercise,,,,months|have preserved cognitive ability,during the screening phase|blood clotting disorder|tendency,>280ms|ii or,,,,,,
8549,,hyperdopaminergic behavioral spectrum,pupils,,,bilateral ovary transvaginal ultrasonography,,,,sh iii-v|ulnar physeal,at least 12 months prior to enrolment on the same et treatment,score 0-1,,,,,,
8550,,hepatic impairment|renal impairment,prescription/otc medications,,,complete oral tolerance,,,,status epilepticus,before starting study intervention.|have,over 18,,,,,,
8551,,silicosis,gynecologist,,,histopathological examination of the liver,,,,pathologically unresectable,after taking written informed,<1year,,,,,,
8552,,covid-19|acute common cold|influenza|fever,anyone,,,slit lamp,,,,pre-op,15 days or less,<45%,,,,,,
8553,,serological evidence of,study drug components.|substance abuse,,,allogeneic stem cell,,,,standardized to sevoflurane,at screening visit 1).|participant,≤ 3 m)|use,,,,,,
8554,,disorders|pregnancy,anti-¬ctla-4,,,total bile red ≤1.5×uln,,,,surgery.|uncorrectable,at any time during pregnancy||cohort 2||no,between 18 to 40 years inclusive,,,,,,
8555,,fluorescence in situ hybridization technology (fish) test,punctum plugs,,,exon 14 skipping mutation,,,,organ-related disorder,within 6 months from screening,18 to 35 years,,,,,,
8556,,kidney disease|creatinine,glycar pericardial patch,,,pruritus|characterized,,,,grade ii heart failure,within 14 days prior to the first dose of investigational,60-89 ml/min,,,,,,
8557,,respiratory dysfunction,immune mechanism,,,fmda||high-risk villagers,,,,intellectually disabled,within the study period,<4.9 mmol/l)|subject,,,,,,
8558,,genital mycotic,ligaments,,,crs-hipec,,,,non-squamous/adenocarcinoma,for 72 hours prior to,≤ age < 27,,,,,,
8559,,"older,|schizophrenia",oral poliovirus vaccine (topv),,,hematopoietic stem cell transplantation;|hematologic malignancies did,,,,children:||cooperative,within 1 week prior to tagraxofusp-erzs treatment,>=50y|age <=,,,,,,
8560,,variceal bleeding,oral antibiotics|no,,,thyroid replacement,,,,fused,within 1 month prior to the expected date of the first,18-30|not,,,,,,
8561,,pressure symptoms,chimeric antigen receptor therapy,,,hospital system,,,,refractory to antihypertensive medication;|patients,within 3 weeks before the first dose,≥ 100 x 109,,,,,,
8562,,radical gastrectomy;|asa,biologic immunomodulators,,,tace treatment,,,,urothelial,at least 6 months prior to enrollment.|external beam radiation therapy,≥ 10 mmhg,,,,,,
8563,,disease|sites,local hormonal products,,,prior surgery,,,,cutaneous,for 30 days after the last treatment,"< 1,5 hours",,,,,,
8564,,depressive episode,medications in order,,,inotropic support,,,,trastuzumab,at least 1 of the following conditions apply:||a,over 21 years,,,,,,
8565,,erythema,icd-10,,,nutritional risk screening,,,,media,30 days after the last dose of,> 3.0 g/dl,,,,,,
8566,,"cerebral ischemic attack,|chronic kidney disease.||",extraction,,,blood cancers:||1,,,,hormone-sensitive disease,over 3 months prior to study entry|meets criteria,score ≤ 7.|pre-operative,,,,,,
8567,,dependence on spectacles for near work,triamcinolone,,,intestinal permeability;|a collection of stools,,,,ultrasound||,at any time prior to enrollment,> 10 degrees)|overnight,,,,,,
8568,,cardiovascular shock,apalutamide,,,left subclavian artery diameter,,,,upper anterior teeth,for at least 3 months prior to the screening visit,>2|adequate anatomy,,,,,,
8569,,chronic hepatitis,anteroposterior)/ct,,,interventional clinical trial therapy,,,,indication|pre-operative,within the advanced,same day or,,,,,,
8570,,renal parenchymal diseases,myopia control treatment,,,antihypertensive drug treatment,,,,ucsd health|history,for 24 months after,outside of 18.5-34.9.|history,,,,,,
8571,,phacoemulsification cataract surgery,endocrinology visit,,,bile duct exploration,,,,intracranial pressure|an,prior to start of study treatment.|have measurable disease,≥ 45/ml/min,,,,,,
8572,,macular cnv lesion,miralax,,,liver transplants,,,,without detailed information),during this period,between 18.0 and 32.0 kg/m²,,,,,,
8573,,coagulation abnormality,immunomodulating agents,,,surgical surgery,,,,numerical pain scale,following curative surgery,6m- 18years,,,,,,
8574,,heart rate monitoring,vitiligo only,,,frontline treatment,,,,secondary,within the last 14 days of screening)||egfr,0-1|life expectancy,,,,,,
8575,,unable to swallow tablets,drugs containing malate,,,knee osteoarthritis|concussion,,,,considered cured,within 6 weeks prior to day 1,over 50 years.|danish spoken and written,,,,,,
8576,,liver metastases;|coagulation function,soft tissue imaging disease progression,,,hernia|bilateral inguinal hernia|patient,,,,dix hallpike.|degree,in the past 60 days or test positive,not older than 2 weeks,,,,,,
8577,,dysrhythmias,immune system disorders,,,first lung transplantation|patient,,,,≥4 cycles,at the time of first dose of study treatment.|participants,>150*10e9/l,,,,,,
8578,,peptic ulcer disease|uncontrolled,immune-oncology,,,brain mri confirms,,,,male|healthy|non-smoking|normal,within 90 days after dosing of study drug.|use,over 2500 g,,,,,,
8579,,language disorders,iodine-containing contrast agents,,,tumor resection;||histological examination,,,,umbilical,during the last six weeks|taking,< 5 mmol/l,,,,,,
8580,,siewert i- iii,psychiatric medications stable,,,etc.||major organ function indicators,,,,study drug);||absolute count,within 1 week before the first medication,no younger than 18 years,,,,,,
8581,,athletes,inhaled steroids|daily steroids,,,fish detection,,,,regular consumption of,within 4 weeks before clearing the lymph cells,> 45 mmhg,,,,,,
8582,,discharged from the hospital,midline incision.||anticipated incision length,,,molecular profiling;|written,,,,moderate major depression,before the first administration of investigational,> 55 mm|hypertrophic cardiomyopathy|valve disease,,,,,,
8583,,chronic obstructive pulmonary disease（copd）.|uncontrolled hypertension,cardiac beta-blockers,,,proposed treatment,,,,place the donor at increased risk for complications from leukapheresis,within 28 da ys,< 50 mmhg diastolic,,,,,,
8584,,cervical ddd,anti-il-17,,,cognitive impairment||,,,,malignant etiology,less than 6 weeks after completion of breastfeeding|exposure to the sun,> 480 ms,,,,,,
8585,,programmed cell death receptor,sodium nitroprusside advanced liver dysfunction reduced capacity,,,tumour biopsy,,,,nurse practitioners,within the past 90 days.|have,0-1.|ejection fraction,,,,,,
8586,,health functional foods,oral bisphosphonates,,,injection of antimicrobial drugs,,,,unimpaired plus,during study treatment.|known carrier,readiness-to-wean',,,,,,
8587,,cord compression.|concurrent,anti-cd137,,,breast surgery||,,,,elagolix,prior to randomization,<10 mg/day|history,,,,,,
8588,,complicated appendicitis,eyelids,,,chemotherapy.|radiotherapy,,,,clinical stage iiic)|no,recent one month before vitrectomy|patients,<1.0×uln.|renal function,,,,,,
8589,,nontraumatic condition,nisone,,,laser capsulotomy,,,,modification of diet in renal disease (mdrd) formula,within 4 weeks prior to administration of pembrolizumab.||21,between 12-16 years.||overbite,,,,,,
8590,,goodpasture syndrome,supine,,,nerve stimulators,,,,icd-10 codes f70-f79,index men:||identify,more than or equal to >,,,,,,
8591,,pulmonary condition,fludrocortisone,,,surgery|emergency surgery,,,,non-urothelial tumors,for the duration of study therapy,13 to 18 years|formal clinical,,,,,,
8592,,sjogren's syndrome,oral sodium valproate.|completed,,,inhalation,,,,study.||incomplete recovery from surgery,within the last 6 months|have,over eighteen years;|presence of,,,,,,
8593,,optic nerve disease,oral drugs,,,immunomodulating therapy,,,,deficit-blood,within 2 weeks of visiting,>140/90).|patients,,,,,,
8594,,vestibular disorders,corticosteroid,,,inappropriate.|penetrative vaginal sex,,,,index date|a diagnosis,within the framework of an interdisciplinary,"≥ 100,000/mcl|ast/alt",,,,,,
8595,,hypertrypsinemia,modafinil,,,liver mobilization,,,,lactide polymers,within 14 days prior to cycle 1 day 1).|serious psychiatric,level ii analgesics|no change,,,,,,
8596,,complications.|acute infection,remains stable,,,inhibitors.|major surgery,,,,other nsaids.|previous treatment,c.|history,65 and over|patients,,,,,,
8597,,local uva,artificial liver treatment,,,active chemotherapy treatment,,,,host,within the last 2 months,between 18 to 45,,,,,,
8598,,weight loss programme,topical growth factors,,,"congenital talipes equinovarus""",,,,ctcae toxicity grade is,within 7 days prior to baseline|initiation of treatment with luspatercept within 6 months prior to screening,5 years or more,,,,,,
8599,,cognitively well preserved,medication pumps,,,open-chest cardiac surgery|covid-19,,,,metastases|active bacterial,within 30 days of screening.|history of,>25°.|protected patient (,,,,,,
8600,,medications|structural brain changes,over-the-counter (otc),,,female;|pathological biopsy,,,,locally recurrent(unresectable,within 6 months before first dose of study medication,≤ 60 min,,,,,,
8601,,ulcerative colitis)|hypothyroidism,conventional techniques,,,local legislation,,,,topical medication.|history,past history,< 18 years|ventricular septal defect|history of,,,,,,
8602,,thermal burn injuries,macromolecular protein agents,,,special pregnancy care|it,,,,non-smokers,within 14 days of the first dose of the study,minimum 2,,,,,,
8603,,clinical symptoms consistent,insulin lispro injection)||,,,sedative action,,,,reliable,steroid dose,below two years.|bilateral upjo.|recurrent upjo.|malrotated,,,,,,
8604,,prostate cancer|patients,venous blood,,,allogeneic cell therapies,,,,booster dose,more than 6 months|at least two,40-70 years|able to follow verbal instructions related to the visual feedback training.|mmse score,,,,,,
8605,,esophagogastric disease,atractylodes macrocephala koidz (baizhu),,,ekg)|2nd,,,,mild to moderate uc,at the screening visit|study participant,0-2|postmenopausal,,,,,,
8606,,methemoglobinemia,pitocin®,,,radiofrequency ablation,,,,friday).|suspected acute stroke,5 half lives,age≥18 years,,,,,,
8607,,solid tumors.|male,intravenous [iv] antibiotics,,,abc sinus augmentation,,,,primary site with ct evidence of,post-io standard of care therapy).|patient must be,"≥18 years),|affiliated to the",,,,,,
8608,,micturition,sodium hydroxide,,,hypnotic therapy,,,,pure variant sarcomatoid,during the trial.|people are currently,30 to 65 years willing and able to sign,,,,,,
8609,,personalized cancer therapy,"maintenance),|receive rocuronium",,,hospitalization|current acute,,,,ureter),within the last 4 weeks|drugs,>13mm,,,,,,
8610,,aneurysmal vascular disease,nonvitamin k antagonist oral anticoagulants,,,bilateral-oophorectomy,,,,imaging-confirmed,longer than 12 weeks|willing and able to access the internet to complete questionnaires|willing,= 0%,,,,,,
8611,,endocrine therapy);|autoimmune disease,trial-related procedures,,,hasty,,,,formulation.|history of severe,within 4 weeks before the first drug administration,at least 50% or greater,,,,,,
8612,,her2-directed,adipex-p,,,treatment regimen,,,,nirst imaging,within 28 days prior to the first dose,≤ 5|brain mri,,,,,,
8613,,intra-axial neoplasm infective endocarditis aortic arch dissection patient receiving iv aspirin,soc,,,electroconvulsive therapy (,,,,upper extremity|entrapment neuropathy,within 14 days of the first dose of study agent.|body,"< 60 ml/min/1.73m2|""positive""",,,,,,
8614,,ebv lymphoproliferative disease,study drug excipients,,,completed this therapy,,,,diagnostic and statistical manual diploma in social medicine (dsm-v,within 90 days of enrollment);|a major,>90 years,,,,,,
8615,,amenorrhea after cancer,dehydroepiandrosterone,,,preoperative refraction,,,,iv)|uncontrolled,in 28 days before the start of treatment;|regardless of the severity,≤ 25 kg∙-2,,,,,,
8616,,dosing frequency,regafenib,,,ventriculitis|indication,,,,amenable to biopsy.|patients,<6 months prior to screening,0 or 1|women,,,,,,
8617,,total mastectomies,macicentan,,,recognition time)|ica,,,,limoges epilepsy screening,within the previous 72 hours,eligible to enroll.|usual acceptable,,,,,,
8618,,dm rash,physiologic glucocorticoids,,,supplemental oxygen,,,,metastases|pregnant,within 28 days prior to initiation of study treatment.|resting,on day of surgery,,,,,,
8619,,returning,cattle,,,pet imaging,,,,exposed bones,within 60 days prior to day 1|participant,=< 480 msec|creatinine = calculated,,,,,,
8620,,cognitive issues,antenatal corticosteroid therapy,,,i.e.|spherical refractive error,,,,suitable for implantation surgery.|systemic active,within 12 months prior to first study drug administration,more than 14 days.|participants,,,,,,
8621,,ct)|normal serum levels of sodium,antidepressant treatment,,,human application test),,,,stage ii,longer than 6 months,male,,,,,,
8622,,|hyperinflammatory diseases,psl,,,malignancy|concurrent chemotherapy,,,,implant use,previous 24 hours,ii or iii,,,,,,
8623,,genetic pathology,vad,,,answer phone calls,,,,pml).|previous,within 14 days prior to the first administration of ac699|radiation therapy,< 45%|presence,,,,,,
8624,,instance,potassium outside normal range in safety laboratory|subject,,,allowed.|participation,,,,grade ii or greater,in the previous 48 hours,> 2.00 mg/dl,,,,,,
8625,,valvular heart failure,sglt2 inhibitor.|pregnancy,,,plasma concentration,,,,injection into the knee joint,prior to signing consent||,≥ 18 years.|consent,,,,,,
8626,,cardiac problem,pyrrolidine,,,labor induction,,,,immunodeficiency||16,within 72 hours from,> 10cm,,,,,,
8627,,procedure|pregnant women|terminally ill,asa,,,constituents|previous knee injection,,,,icd-10: f32,between completion of local therapy,< 45 ml/min,,,,,,
8628,,neoproliferative disease,progestin implants,,,rhd,,,,upper extremity of the dominant,within the past 28 days prior to start of study treatment,<3 seconds,,,,,,
8629,,colovaginal fistula.|any hematological abnormality,ad drug treatment,,,medical treatments,,,,above daily recommended alcohol intake for men,within 14 days|total bilirubin,=<1.5 x institutional upper limit of normal (uln),,,,,,
8630,,vesicoureteral reflux,anti-virus drugs,,,medicine session,,,,meeting criteria,within 1 year prior to enrollment.|patients,greater than or equal to 8.0 g/dl,,,,,,
8631,,cohort 2a,anti-pvrig,,,stent rescue,,,,syndrome.||bilateral,at the time of consent|diagnosis,between 12 weeks 0 days of pregnancy,,,,,,
8632,,infection;|human immunodeficiency virus,cyclic tetrapeptide,,,therapy.|unstable co-morbidities,,,,unbearable,during the month prior to study,> 4x upper limit of normal (uln),,,,,,
8633,,pancreatic tumor,live-attenuated,,,liver surgery.|nonoperative treatment,,,,ocular criteria apply to the study eye,within 30 days prior to day 1 of protocol therapy.|concomitant,greater than or equal to (≥)18.0 to less than (<) 30.0 kilograms per meter square (kg/m^2)|a total body weight,,,,,,
8634,,permanent dermal fillers,adequate antiemetic,,,chest ct scan.||note,,,,suitable for treatment with curative intent,within 30 days prior to [68ga]dotatate pet/ct,≤ 1.5 x uln,,,,,,
8635,,sco,component of the atezolizumab formulation|known allergy,,,mri,,,,"insulin therapy,|pedis classification stage 1 and 2|does not have",during the 30 days preceding the inclusion;|occurrence of,<37 week,,,,,,
8636,,serd therapy.|radiotherapy,menin inhibitor treatment.||subjects,,,local investigator|for prrt substudy,,,,coccygeal area consistent with,within 3 months prior to screening.|subjects,≥ 2|initiation,,,,,,
8637,,hiv testing positive.|is,glimepiride,,,research|pregnant,,,,anogenital,last 5 years|struggling,>1.2,,,,,,
8638,,uveal melanoma exclusion,steroids used solely,,,complete modules|completed,,,,chemotherapy|disease-free interval,after radiotherapy);|within 4 weeks,>10 mmhg,,,,,,
8639,,intracranial recurrence,regional sporting,,,regular treatment,,,,non-secretory mm,within 28 days.|major surgery,≤ 25.7μmol/l,,,,,,
8640,,pregnancy diabetes,antisecretory drugs,,,/sensitivities,,,,surgery|previous,at dfci.|not undergoing,=< 4 weeks prior to registration|failure,,,,,,
8641,,chronic cholecystitis,anti-infective drugs,,,radiotherapy/chemotherapy,,,,implanted,older than 6,< 18 and > 45 years,,,,,,
8642,,hepatic)||,conivaptan,,,mechanical heart valve prosthesis|moderate-to-severe,,,,"sacroiliac joint, which may in the opinion of the primary investigator confound measurement of outcome variables;|has",for prior 1 month,40 to 80 years inclusive,,,,,,
8643,,influence muscle anabolism,immunosuppressive agent,,,gd|previous thyroid surgery|patients,,,,altered,for at least 48,long-term survival,,,,,,
8644,,therapy;|ecog score,daunorubicin,,,brain injury|uncorrected vision,,,,remnographic criteria of,within 4 weeks prior to the screening visit,>400 copies/ml,,,,,,
8645,,corona virus,isosorbide diesters,,,single sabr field,,,,preoperatively,at time of surgery|subjects,18 years old or above|participants must sign,,,,,,
8646,,virgin,give informed consent|congenital cradiomiopathy,,,distal blood flow||,,,,stage i.||,in the 3 weeks prior to recruitment.|lvef,<4.91 mmol/l,,,,,,
8647,,kidney toxicity,elastics,,,onset|had anterior knee pain,,,,sexes;|patients,in the last 3 years|have,less than 9%,,,,,,
8648,,cryptorchidism,oac,,,deteriorated,,,,effective anti- retroviral therapy,during the study period|subjects,≤ 2.3,,,,,,
8649,,russia,allogeneic hsct|patients,,,ezh,,,,severity of,for at least 4 weeks before enrollment;|participants,>=21 days after the completion,,,,,,
8650,,lower extremity injury,long-acting anti-coagulants,,,slit-lamp examination results of the screening clinic,,,,face-down position,during the last 3 months before examination,50% of total body cavity,,,,,,
8651,,t4 exfoliative erythroderma,intense pulsed light,,,antihypertensive drugs;|vaginal reconstruction,,,,low-potency topical corticosteroids.||iii,within 30 days of randomization,between 2500 and 4200 g,,,,,,
8652,,aspergilloma,beta blocker,,,lumbar disc herniation surgery,,,,full course of observation|cannot communicate reliably,within 14 days before the treatment,between 2015,,,,,,
8653,,lack of autonomy,sample collected,,,angiography of the brachiocephalic arteries;|conducted,,,,insulin glulisine,within the past 3 months to their,19-24.9,,,,,,
8654,,organ system disease,ozone,,,neurosurgical treatment,,,,weeks.|congenital,during the last year|≥ 1 routine,< 32 weeks|prenatal alcohol,,,,,,
8655,,spine-related,hard tissue grafts before,,,artificial ling ventilation (alv),,,,bone,within 2 weeks of the first dose of study treatment|participants,ii patients|18-45 years,,,,,,
8656,,biochemical measurable disease,ascites;|patients,,,asct|cns involvement|stroke,,,,metachronous,at the time of ckrt,1-year,,,,,,
8657,,response-evaluable,cosmetics,,,taxane therapy,,,,severe,during the baseline period.||patients,≤ 1.5uln,,,,,,
8658,,allowed.|measurable disease,contraindicates grapefruit juice consumption|allergic,,,first-line therapy|ecog performance status,,,,likely to be exacerbated,for at least 6 weeks||,< 6 ng/ml)|use,,,,,,
8659,,distant metastasis,dreadlocks,,,active treatment,,,,unrelated donor with,within the past 6 months.|patients,≥ 12.5,,,,,,
8660,,putnam,anti-inflammatory medications|smoking|pregnancy,,,elective surgery|index of,,,,sh-polypeptide-93,6 months prior to initial administration of the drug;|study the occurrence,7.38-7.42,,,,,,
8661,,hfmref|atrial fibrillation,transfusion,,,coronary artery bypass surgery,,,,manifest,within 1 month prior to study,≥8.5 g/dl,,,,,,
8662,,dystonia,low molecular weight heparins (lmwh),,,rbv,,,,impacting facial volume augmentation,within 4 weeks before screening|subject,30-40,,,,,,
8663,,cerebrovascular diseases|hypertension,pharmacotherapeutic agents,,,nicotine)|bowel resection surgery,,,,months);|mild ankle instability (score within 24.5-27,7 days prior,< 5|sedentary behaviour,,,,,,
8664,,cognitive function;|the,hyroid disease|patients,,,bone marrow transplant.|history,,,,lung for carbon monoxide (dlco),within 4 weeks of screening visit.|participation in another clinical study,more than 20 years,,,,,,
8665,,pathological evidence,crc,,,shoulder surgery,,,,influence the condition of the hand,within six months of study initiation|bmi,≥ 15 years;|icd-10 codes,,,,,,
8666,,extensive colitis,components of the imp,,,investigations,,,,allogenic organ transplantation.|active,within 48h before administration of investigational product,≥ 40 kg/m2|eclampsia,,,,,,
8667,,gland carcinoma,left ventricle,,,stay,,,,intravenous,within 3 weeks prior to the first dose niraparib,younger than 18 year,,,,,,
8668,,parasympathetic antagonists|kidney disease,australian study only||non-english-speaking,,,complete pet/mri,,,,adult,within 7 days prior to treatment.||female,> 470 msec,,,,,,
8669,,procedures|acute kidney injury,strong potency in appendix 2 ',,,myocardial scintigraphy,,,,glutamic oxaloacetic transaminase [got],history in screening,≤ 5 cm,,,,,,
8670,,transfusion-dependent).||has,short-acting β2-agonists,,,sarcomeric hcm adult,,,,non-english speaking|unable to access the internet|not practicing in the u.s.|not,after standard first-line induction treatment,equal to lower than 5 times of uln,,,,,,
8671,,pain treatments,myeloblasts,,,surgical resection of the glioma,,,,respiratory system|known renal,within 48 hours prior to admission,< 80 db hl,,,,,,
8672,,overactive bladder complaints|cases,stearic acid,,,total pancreatectomy|patients,,,,fellow level volunteers,within past six,greater than 6.0 mg/dl,,,,,,
8673,,interstitial anticancer therapy,drugs known to be higher metabolized by this enzyme,,,fexuclue tablet||patients,,,,unlikely to survive,for ≥ 14 days,> 125 mg/dl|unable,,,,,,
8674,,thalamic central,left ventricular assist devise,,,spread glabellar lines,,,,febrile event,for 4 months following,>2.|has clear evidence of,,,,,,
8675,,gallbladder polyps,medications know,,,rare types,,,,computer users|the ability to continue working||,for at least 6 months after discontinuation of the experimental treatments,18-49 years|permanent,,,,,,
8676,,severe infections,anti-viral,,,surgical valve replacement (see appendix iii),,,,vascular,at least 3 months|stable dopaminergic treatment,≤ 1.5/pt ≤ 1.5 × uln，aptt≤1.5 × uln,,,,,,
8677,,respiratory sinus arrhythmia,angiotensin receptor neprilysin inhibitor (arni),,,ultrasonography of the temporal,,,,random text,within 5 years prior to surgery|systemic,more than or equals,,,,,,
8678,,finger loss,lipid,,,ileal resection)|history of hiv infection,,,,requiring iv analgesia,after 2 minutes of standing,"14-18,|receiving 15 points or more",,,,,,
8679,,glucocorticoids|metabolic bone disease,terfenadine,,,elective repair,,,,prognosis,before enrollment.|hepatitis b virus,> 3-times uln leads,,,,,,
8680,,nervous system diseases,ivig,,,surgical patient|patients,,,,muscular dystrophies,within 60 days prior to visit 0|major,45 ml,,,,,,
8681,,severe head injury,carbohydrate,,,arthroscopic impingement surgery,,,,fronto-temporal dementia,6 days prior to the study|allergy,<3 months of,,,,,,
8682,,noonan syndrome,srs,,,lubal tigation,,,,non-covid conditions,during the duration of the study.|non-anaemic,75 years,,,,,,
8683,,myopia,non-insulin,,,hernia repair surgery)|patients,,,,self-reporting)|had a minimum of 18 natural remaining teeth,prior to the first dose of study intervention.|exposure,≥20 teeth,,,,,,
8684,,nimv,vaccine containing,,,multifocal soft contact lenses,,,,bicycle health services,more than 6 months ago);|any prior,less than or equal to 150 minutes,,,,,,
8685,,treatments;|soild malignant tumor,local antibiotics|current,,,oxygen therapy.|pulmonary hypertension,,,,intervention)||exclusion criteria:||medical treatment,in the last 6 months|aged 16-34,≥ 30×10^9/l,,,,,,
8686,,target mood,ace-k,,,autologous hamstring,,,,subsegmental pe,during study period|signed,< 50 ml/min|anticoagulation|rni,,,,,,
8687,,radiation-induced pulmonary fibrosis,qtcf,,,adenoidectomy,,,,group -,during the two weeks after screening,> 40|central nervous,,,,,,
8688,,localized pc,anti-drug antibody,,,complete intubation procedure|intubation failed,,,,suitable for participation in the clinical trial,during past 5,requires obstetric monitoring,,,,,,
8689,,chronic infectious diseases.||for,quinolone derivates,,,insufficient knowledge of german|alcohol,,,,richard-campbell,within 4 weeks of starting therapy,"< 0,70",,,,,,
8690,,functional cardiac defects,bloody stool,,,ici treatment,,,,meige,within 12 months|body mass index (bmi,≥ 0.5 kg,,,,,,
8691,,judged unsuitable to participate in the study by the investigator,migraine drugs,,,surgical site|patient,,,,mp2k1 hotspot mutations,within seven days prior to period i dosing.|donating more than 250 ml,0 or 1|adequate,,,,,,
8692,,rejection of anti-depressant medication and|no,prokinetic drugs,,,spirometry testing,,,,suitable for atg treatment.|a,within a month.|those,≥ 70 g / l,,,,,,
8693,,organic lesions,compounds of similar chemical or biologic composition to the agents used in study|patients,,,arterial blood (pao2<60),,,,requiring therapy,at least for the upcoming 3 hours,less than 3 times upper limit of normal,,,,,,
8694,,fibrous endarteritis,non-steroidal anti-inflammatory drugs|serum potassium,,,montreal cognitive assessment)|actively,,,,despite lipid lowering therapy,within 14 days prior to initial use of the study drug,≥ ii;|cardiac ejection fraction,,,,,,
8695,,bms,vehicle,,,since surgical resection,,,,electrical,within 3 days of trial enrollment|parents/guardians,>uln;|hcv antibody(+,,,,,,
8696,,months|diabetes mellitus,similar surgeries,,,lung resection,,,,177lu,at the time of study entry.|prescribed anifrolumab for their sle treatment,>0.5 g/g,,,,,,
8697,,radiologic recurrence,toxic drugs,,,histological variants of ptc,,,,platinum-therapy,previous two months,19-70 years|who,,,,,,
8698,,alcohol abuse|epilepsy,type 1 brugada ecg pattern,,,major head trauma|intracranial lesion|cardiovascular disorders,,,,full active range of motion in the involved,at least 2 weeks prior to randomization;|patients,>50 mg/dl,,,,,,
8699,,metastatic ovarian,immunostimulant drugs,,,umbilical artery ph measurement,,,,sensitivity,at time of signing icf|ecog performance status,"between march 15, 2020",,,,,,
8700,,screening|acute renal failure,hbsc,,,action,,,,plasmodium vivax,during the study.|citizenship of the russian federation.||,between 5-17 years|diagnosis of,,,,,,
8701,,congestive heart disease.|history of any relevant,compounds of similar chemical or biologic composition to study agent(s)|research participant,,,proctoscopic examination,,,,between 2˚of inversion,within the past 15 years,≥ 1.5 times uln,,,,,,
8702,,fracture did,articaine,,,sperm donation,,,,individual,in the next 12 months|participation,ii-iv,,,,,,
8703,,medication|active substance abuse,pontine,,,index hospitalization,,,,distal interphalangeal joints (cmc,> 12 months prior to screening,condoms,,,,,,
8704,,colorectal tumors,children,,,pregnancy;|term delivery (,,,,full chinese parentage residing,within 4 weeks of study drug administration.|the subject,≤ 80 mm hg,,,,,,
8705,,malignant solid tumors,stenting,,,health canada,,,,medicinally induced,in the last three years||,≥ 40 miu/ml).||a,,,,,,
8706,,soft bandage contact lens).|no,contrast media；|patients enrolled in another clinical study,,,main organ,,,,l1 antibody.|patients,within 3 months before the screening visit,19.0-32.0,,,,,,
8707,,cardiac insufficiency class,canagliflozin,,,er+,,,,unprovoked or|1 episode,for at least 4 weeks prior to taking the cocktail,90 to 160 mmhg|diastolic blood pressure,,,,,,
8708,,serious alcohol,toremifene,,,occurring,,,,without effective control,at birth of 22 weeks 0,less than 10% of body weight,,,,,,
8709,,alteration,dopamine nitrate,,,tendon turnover|former participation in a study,,,,mellitus|homa-ir,for 3 months prior to screening).|severe,below 65 years,,,,,,
8710,,glioblastoma multiforme,carvedilol therapy,,,dental implant surgery,,,,subependymal or leptomeningeal,during the follow-up period,more than or equal to 90 cm,,,,,,
8711,,incompatible with,iiiv,,,topical treatment of the cavity,,,,intercurrent pulmonary illnesses,undergoing,>95|heart rate <92||,,,,,,
8712,,pulmonary disorders.|metabolic disorders,csa,,,pretreatment endoscopic biopsies.||clinical,,,,abnormalities)|hydrosalpinx untreated.|recurrent,during the neurophysiological evaluation|sedated patients|minor patients|brain death|known deafness|pregnant women|prior inclusion,<19 on the,,,,,,
8713,,treating osteoporosis,imids,,,palliative radiation therapy,,,,"days),|not use complementary",for at least 30 days after the last dose of study agent.|history,under 10 years,,,,,,
8714,,strenuous exercise,cyp2c8 inducer,,,blood concentration,,,,screening.|clinically significant,while some original lesions,=< 2.5 mg/dl,,,,,,
8715,,pain complaint,hypotensive drugs,,,sgpt)=alanine aminotransferase,,,,mental health,at least 6 months prior to vaccination,<50%;|allergic,,,,,,
8716,,cf,gestational diabetes)|having,,,emergency,,,,clostridium difficile,for at least 1 month|years of education,less than -0.75d or more,,,,,,
8717,,ajcc).|initial diagnosis,asthma.|iphone,,,nasal irrigation therapy,,,,diagnostic criteria of autism spectrum disorder,for 2 years.|patients,18-24 years,,,,,,
8718,,cancer treatment).|has,anthracyclines,,,pembrolizumab treatment,,,,nmosd by the 2015 international panel for,within 48 hours before,≥130/85 mmhg,,,,,,
8719,,serious suicide attempt,missed,,,cll therapy,,,,endobronchial,within 14 days prior to day 1 of protocol therapy|warfarin,18-75 years,,,,,,
8720,,third- degree,drugs of similar chemical classes.|history,,,neurological exam|history of,,,,grade 2 or 3 es,within 7 days prior to the first admission to the clinical unit.|inability,≤ 7|presence,,,,,,
8721,,exertional dyspnea,conventional therapeutic agent,,,congenital hemoglobin disease,,,,suitable for catheterization;|patients,during the study period.|neurologic,>105 kg,,,,,,
8722,,ii|unstable angina,treponema pallidum antibody screening,,,electrical impedance tomography monitoring|body mass index,,,,grade 2+ colitis,within 3000 μm of the center of the macula.|patient,below normal range,,,,,,
8723,,treated carcinoma in situ of the cervix,ifi,,,previous surgery on the gastrointestinal tract,,,,other sites;|no,before vaccination.|receipt of,>25 µmol/l,,,,,,
8724,,pulmonary fibrosis|severe renal disease,sedating medications,,,spermicide.||ecg,,,,behavioural,screening|expected survival,intolerated,,,,,,
8725,,various immunosuppressive,cyp3a and/or p-gp,,,radiological confirmation test,,,,durable lvad|history of chronic dialysis|pre-existing,in the next 3 years,23.5 hours/day,,,,,,
8726,,gastrointestinal (gi),migraine headache.|active treatment,,,icsi,,,,suggests,prior to five years,iii-iv|chronic,,,,,,
8727,,basal cell carcinoma of the skin,immunosuppressant therapy|pregnancy,,,physiotherapeutic treatment,,,,grade ii and iii study grades,at or after enrolment.||benralizumab taiwan reimbursement criteria:||≥,<1.0 g;|at least,,,,,,
8728,,hemorrhagic stroke,oral fluorouracil,,,lose weight||,,,,insulin action,within 2 weeks prior to day 0|presence,"≥ 100,000/",,,,,,
8729,,neuropathic etiology,low molecular heparin,,,upper endoscopy,,,,ral,after ≥ 1 line,≥ 60|age,,,,,,
8730,,chronic upper respiratory infection,rescue medication,,,curettage,,,,pd-l1 therapy|participants,within the last 6 hours,≥18 years|willingness,,,,,,
8731,,portal vein tumor thrombus,constraints,,,octa examination,,,,index lesion,within the previous 2 years,between 18 and 80 years,,,,,,
8732,,hbv,sodium acetate,,,preoperative dialysis,,,,skin,in the last 6 months|diagnosis,≥ 35 g/l,,,,,,
8733,,pharmacologic,iodinated contrast agent,,,arterial thrombosis||,,,,without a,within 30 days or within 5 half-lives,> 500 mg/dl,,,,,,
8734,,teeth in the oral cavity.||,cinnarizine,,,oral sex,,,,spt-wheal,at time of initial screening,18-25 kg/m2,,,,,,
8735,,life-threatening illness,worsen,,,asthma control test|have a,,,,absolute decrease of,within 5 years.|clinically significant,between 2.5 and 3.5,,,,,,
8736,,criteria for selection of,topical prescription,,,sigmoidoscopy|active order for,,,,high dose,in the past 3 months;|able to tolerate,≥ 90g/l|neutrophil count,,,,,,
8737,,neuromuscular pathologies,tnf) inhibitor,,,tumour types,,,,below-knee bracing,within 6 months prior to first study medication,class iii or higher,,,,,,
8738,,complete bowel obstruction|immunotherapy,isavuconazole,,,benign eyelid keratosis||,,,,needing high flow oxygen therapy,within the next,nevada|less than 2 pieces of contact,,,,,,
8739,,"respiratory disease,|psychiatric",contraceptive use,,,dose)；|systemic treatment,,,,pedicled,within 3 months before onset,1500 grams,,,,,,
8740,,active eczema,components of the trial intervention,,,target volume (ptv),,,,non-prescription preparations,for 3 months after the end of the treatment with darolutamide,<100 or >180,,,,,,
8741,,face cosmetic,injection site,,,laparoscopic anterior resection (lar),,,,insulin doses,within the next 48 hours)|surgery,25-34.9,,,,,,
8742,,psychological condition,cytokines,,,normal periapical radiograph,,,,3rd edition).|response,within 2 weeks before screening;|those,≥90mm hg,,,,,,
8743,,chemical pneumonitis,paclitaxel,,,transcranial magnetic stimulation therapy,,,,stenotic,within the last 90 days (luminal-only or luminal,above 180mmhg,,,,,,
8744,,idiopathic pancreatitis,viewing,,,cementless hip arthroplasty,,,,grade iii/iv anaemia,within the past month received,ii ou,,,,,,
8745,,brief psychotic disorder.|history,anti-cancer regimen,,,hysterectomy,,,,inferior zone,prior to enrollment,≤ 100 bpm,,,,,,
8746,,drug absorption|active infections,ototoxic drugs,,,whole-brain image,,,,requiring iv,after receipt of a vaccine,a-band ultraviolet radiation,,,,,,
8747,,lung dysfunction,shell fish,,,localized radiotherapy,,,,st-elevation myocardial infarction (stemi),within 14 days prior to screening to allow for postoperative healing of the surgical wound,between 18 to 65 years old|established diagnosis,,,,,,
8748,,af,ambrisentan,,,right ventricular mechanical circulatory,,,,corneal thinning of,during the study of study participants,18 years and above;|subjects voluntarily agree to participate,,,,,,
8749,,breast-feeding.|any,neuromuscular blockers,,,mucousal resection,,,,cns-3,within 1 month prior to dosing.|alcohol consumption,≤ 1||normal,,,,,,
8750,,solid and/or micropapillary component,similar products,,,document analysis of psa levels recorded,,,,eligible.||severe,throughout the study,18-80,,,,,,
8751,,venous disease,plates,,,pap therapy,,,,non-hispanic white,during the six months,>30)|severe arthritis,,,,,,
8752,,hepatic fibrosis,dual anti-platelet therapy,,,world health organisation (who),,,,gastroesophageal junction (gej),within 3 months prior to treatment.|history of intravitreal,=< 1.5x institutional upper limit of normal,,,,,,
8753,,traveling to the mrri testing site,hepatotoxic drugs,,,oral lesions|local irradiation therapy|oral communication with sinus after the extraction,,,,unrelated to prematurity,within the last 3 years.||evidence,< 1 year,,,,,,
8754,,pulmonary stenosis,vegan,,,first vaccination,,,,ever enrolled,within the preceding 3 months,20 years or older,,,,,,
8755,,apical prolapse,atogepant,,,adenocarcinoma;|bone imaging,,,,eight-week long research study|have a,within less than 3 weeks,long-term participation,,,,,,
8756,,progressive|acute coronary syndrome,multidisciplinary meeting (,,,burn trauma,,,,irinotecan dose reduction,within 14 days prior to day 1 of protocol therapy)|total bilirubin,>500 pg/ml,,,,,,
8757,,ovarian suppression agents,direct thrombin inhibitors,,,trauma screening questionnaire (brewinn et,,,,icd10 f20-29,within 3 lines recurrence;|recurrence occurred,not more than 5,,,,,,
8758,,singleton pregnancy|pregnancy week,study.|immunosuppressive medication,,,diabetes||- for focus group||inclusion criteria||participant,,,,ii.|age,within 2 months prior to dosing.|current smoker of more than 5 cigarettes per day.|any regular use of,"over 75,|more than 3 days from the onset of an",,,,,,
8759,,genetic mutation linked,anti-obesity,,,transplant|patients treated,,,,suitable for endovascular repair,prior to starting study intervention.|prior,30 times/minute,,,,,,
8760,,patella.|pain,anti-vascular therapy,,,axillary temperature>37.0℃;|history,,,,requiring iv treatment|human immunodeficiency virus,"continue their antenatal follow-up,|no",> 30mm||,,,,,,
8761,,hepatic coma,corin hip devices,,,vaccination plan,,,,under oral metformin,within 14 days before the random;pericardial effusion,greater than or equal to 45,,,,,,
8762,,gluten intolerance,ergotamine,,,diabetes|coronary revascularization,,,,mandibular canal||good oral hygiene|highly motivated patients|patients,within 3 months before this hsct|patient,between 18-30 years,,,,,,
8763,,cll)|small lymphocytic lymphoma,faricimab,,,knee instability|meniscectomy,,,,urinary retention,within 6 months before the start of study treatment administration,<3 months|patients,,,,,,
8764,,retinal diseases|history,akt,,,tobacco product,,,,noninfectious,after the 16-week period,less than the 95th percentile,,,,,,
8765,,to:||peptic ulcer disease,very,,,percutaneous coronary intervention (pci),,,,tetrahydrocannabinol,within 14 days before enrollment;|administration,5-year,,,,,,
8766,,peritoneal metastasis|patients,adenosine triphosphate(alt,,,immunosuppressive drugs).||*replacement therapy,,,,≥90 minutes,in the 2015 study received,no more than 28 days prior to study initiation,,,,,,
8767,,neonatal pneumonia,nonsquamous,,,supplementary application,,,,hemodialysis)|medically,within 2 weeks prior to treatment.|females,≥ 3g,,,,,,
8768,,acute bacterial,vf)|electrical storm,,,studies,,,,non-objection to participate in the study||,in the past 30 days|unable,> 35|patients,,,,,,
8769,,inner elbow,beta-tectorin,,,usual health after sars-cov-2 infection,,,,insulin-like drugs,prior to starting therapy.)||preexisting peripheral sensory neuropathy,above 2 mg/dl,,,,,,
8770,,cardiovascular disability status,antiplatelet medications|patients,,,venous access sufficient,,,,radiological criteria,within 24 hours of onset of acs,15-74 years|bmi,,,,,,
8771,,herpetic infections,lidocaine cataplasms,,,biochemical examination,,,,ipsilateral iliac artery inflow tract lesions,within 48 hours before administration of investigational product,≥9.0%)|hepatic dysfunction,,,,,,
8772,,walk back to the chair,organ transplants;||7,,,topography method)|irregular cornea,,,,hormone receptor positivity,more than 4 days per week.|positive,>25g/day,,,,,,
8773,,als|frontotemporal dementia,mandarin||,,,cell proliferation,,,,emotionally unstable,within 6 months prior to recruitment.|active,<3 cm|english,,,,,,
8774,,st john's wart,lines of tki therapy,,,organs,,,,site not easy,over the duration of the study|are currently,>4cm,,,,,,
8775,,hepatitic b virus (hbv) infection,long-acting β agonists,,,axial,,,,extremely late,within 7 days before the first dose of adagrasib treatment,"i-iii,|radiograph evidence of oa",,,,,,
8776,,striving,prolactin,,,mechanical ventilation|expected,,,,mild-to-moderate dryness||,within 24 hours prior to surgery|patients,20 to 600 times the recommended daily supplement dose,,,,,,
8777,,stable disease,tablets,,,tmj steroid,,,,clinically responsible endocrinologist.||exclusion criteria:||a,within the last 12 months|active substance,> 38.5°c,,,,,,
8778,,organ dysfunction,cheekbones,,,chronic therapy,,,,clinically confirmed,in at least 1 of the parent studies (r3918-pnh-2021[nct05133531,< 1.1 ng/ml.|subjects,,,,,,
8779,,mucinous ovarian cancer,albumin,,,biological analysis,,,,pervious,at the time of providing informed consent/assent,≥ 60% and ≤100% of the predicted normal values,,,,,,
8780,,atelectasis,ketamine-hcl|current,,,endovascular surgery,,,,stroke)|lower limb surgery,over 18 years old|volunteer to participate in the program||,> 80 ml/min/1.73m2,,,,,,
8781,,poor candidate,mek inhibitors,,,analgesic treatment,,,,failed,at the day hospital or oncology week hospital|patients informed,< 60g/l,,,,,,
8782,,clinical expertise,gemtuzumab,,,line of biotherapy,,,,low-profile balloon-expandable device,high-dose,two consecutive rises,,,,,,
8783,,neuroendocrine cancer,investigational drug component,,,antineoplastic treatment,,,,provider|self-identify,at least 6 months after primary tka|being able to stand,≥ grade iii,,,,,,
8784,,obstructive peripheral disease,ics/laba/lama,,,neuraxial anesthesia,,,,moderate to,within the previous 12 months|participants able to voluntarily give written informed consent,iq≤80|inconsistent,,,,,,
8785,,65|unable to read/,topical therapies,,,rehabilitation protocol.||,,,,excluding,<1 year prior,more than 50kg(45 kg or more,,,,,,
8786,,bleeding disorder;|participation,otalgia,,,nasolacrimal duct,,,,pregnant|prior,within 14 days before administration of the study drug,>0.5 mg/kg/j before,,,,,,
8787,,chronic renal insufficiency,components of the investigational,,,kidney biopsy.|kidney biopsy,,,,after transcatheter aortic valve,within 28 days of the date of progression||step,≥ 10 copies,,,,,,
8788,,polio)||exclusion,entetrazumab,,,local laboratory testing,,,,site of block.|coagulopathies,during or within 6 months of use of capecitabine.|patients,score of < 9,,,,,,
8789,,localized basal cell carcinoma,oral drug,,,malaria vaccine,,,,dise)||,at the time of screening).|participate the trial voluntarily and sign informed consent,i - ii,,,,,,
8790,,postoperative recurrence,flt3,,,emergency inclusion procedure,,,,study.||skeletally mature,at least 1 line,greater than 38°,,,,,,
8791,,clouding,regadenoson infusion|current enrollment,,,postoperative days.|day surgery,,,,instituto politécnico de lisboa;|age,1 month following to the non-inclusion of the participant,<7 years old,,,,,,
8792,,malignant tumors;|fully,anti-pd1/,,,extracorporeal cardiopulmonary resuscitation,,,,musculoskeletal,pursue eventual 3-stage ileal,> 1.5 mg/dl|cohort ii,,,,,,
8793,,asymptomatic right bundle branch block,grapefruit,,,disseminated herpes simplex,,,,tyrosine-based inhibition motif domains,within 1 week before randomization;|25,=95 g/m2,,,,,,
8794,,carcinoma in situ of the prostate,oral nonsteroidal anti-inflammatory drugs (nsaids),,,autologous hematopoietic stem cell transplantation (hsct),,,,summary,during the study.|presence of,more than 40 y/o.||,,,,,,
8795,,rheumatic disease.|inadequate understanding of the spanish language to follow instructions,tissue,,,corneal transplant,,,,interferes with the transmission of energy,infection.||previous history of,18-35-years-old,,,,,,
8796,,cardiac arrythmias,prolonged corticosteroid therapy,,,liver histopathology,,,,expanded disability status scale,prior to treatment,≥1 log,,,,,,
8797,,febrile convulsion;|those,periocular steroid,,,surgically removed,,,,type 1,after the currently available standard anti-cancer,44-46cm,,,,,,
8798,,unresectable solid tumors,anti-coagulant treatment,,,intravenous infusion,,,,following:||1st relapse,within 24 hours of intervention|no other neurological,< 3 x institutional uln|creatinine,,,,,,
8799,,conditions that could,long-acting muscarinic antagonists,,,icg angiography,,,,syphilis,at the time of signing the informed consent form;||ongoing,18-65|not,,,,,,
8800,,uremic encephalopathy,bivalent,,,transplanted graft,,,,myopic,28 days after the last tumor treatment,>35%,,,,,,
8801,,disorder|smoking,topical medication(s),,,call centers,,,,low dose aspirin,within 3 months from enrollment to the end of the trial,≥15 pack-year,,,,,,
8802,,solid tumor transplant.|concurrent malignancy,iodinated contrast material,,,arterial revascularization,,,,allowed.|available tissue from the primary tumor,within last 3 months|antibiotic therapy,≥ 9 g/dl,,,,,,
8803,,depression scale,urinary incontinence|4,,,vertebral body metastasis,,,,part-time,during the course of the study 4,< 20||,,,,,,
8804,,conjunctival,anti-pd-1 ligand-2,,,baseline biopsy,,,,discharge in preterm,at the time of signing informed consent.|body weight,between 137 and <= 142,,,,,,
8805,,arterial vessels,anti-viral drug,,,practice in laparoscopy,,,,vasectomized,within 4 weeks prior to the start of the study|regular intake of probiotics,e & r,,,,,,
8806,,laboratory values,chlorpromazine,,,celiac artery dissection)|baseline,,,,only manifestation of,in the past 4,55 to 90 mmhg,,,,,,
8807,,ceased smoking,hyperaldosterone,,,definitive therapy,,,,been ruled,within 4 weeks before the first use of the drug;|received,>119 msec,,,,,,
8808,,people||,potassium combination drugs,,,botox surgery,,,,psychoeducational,within 2 years prior to randomization.|subject,<0.35 ku/l.|women,,,,,,
8809,,her2 receptor taking,anti-diabetics,,,injection vas,,,,peri-implantitis,last 12 months prior to study entry)|age,below 18 or older than 55|refusal of inability to give,,,,,,
8810,,localized in area,crisaborole,,,"mechanical ventilation,|receiving",,,,general practitioner.||,within the next 24 hours;|requires oxygen therapy,18-28 years,,,,,,
8811,,medication|active tuberculosis,monoclonal antibody treatment,,,malnutrition|immunosuppressant therapy,,,,luminal,within 12 months prior to enrollment|subjects,≥120/min,,,,,,
8812,,pancreatic surgery|pancreatic necrosis,abnormal laboratory examination,,,yag posterior capsulotomy;|intraocular,,,,m1 segment of the,after the last dose of study intervention|willing,< 18 years|no,,,,,,
8813,,chromosomal aneuploidies,systemic condition).|inr,,,thoracic ct scan,,,,concurrent,within 18 months of initial outreach letter,> uln;|subjects,,,,,,
8814,,solid tumour,nonselective beta-blockers,,,cardiopulmonary exercise testing,,,,diameter of up to 7 cm by,for at least 2 months prior to screening,10-17 year,,,,,,
8815,,neurological diseases,amphetamines,,,abrasive laser treatments,,,,from time of most,within 6 months before screening,less than 10 functional,,,,,,
8816,,connotation,cyp 3a4 potent inhibitor,,,monoclonal light chain protein in serum,,,,elira sponsored,within one week prior to the drug administration day.|those,<15 ml/min/1.73 m²,,,,,,
8817,,main pancreatic,syndrome|ast(sgot)/alt(sgpt,,,physician.|colonic ct findings,,,,contrast media,in the last 6 months|cardiopulmonary,"18 and over,|patients",,,,,,
8818,,linch syndrome,immune-related grade,,,neuropsychological intervention,,,,under stable,at time of randomization3.|mild,≥0.2ng/ml,,,,,,
8819,,worse cognitive impairment,oral anticoagulants,,,good organ function|positive her2 cell membrane,,,,infusion-related reactions,within 1 month prior to the first dose of study drug|congestive,<40%)|referred,,,,,,
8820,,criteria on lymphoscintigraphy,sparse menstruation,,,hormonal treatments|documentation of irreversible surgical sterilization by,,,,mandibular molars,criteria.|eastern cooperative oncology group (,more than or in addition to power,,,,,,
8821,,disc disease,n06ax,,,elective cardiac,,,,formulation.|active gastrointestinal bleeding,for at least 28 days after the last dose of investigational product,<10|grade group,,,,,,
8822,,difficulty in swallowing capsules.|any condition,fluorescein sodium,,,agonist treatment,,,,sliding,within 7 days prior to initial dosing).|if,under 25 and above 40 years,,,,,,
8823,,normal vision,egg proteins,,,lung malignancies|patient,,,,immediate,within prior 4 weeks.|non-hepatic,≥ 4h/night,,,,,,
8824,,benign neoplasm,orthognathic,,,arrhythmogenic right ventricular cardiomyopathy,,,,transdermal|progestogen-only hormonal contraception,throughout the study||▶ medically acceptable contraceptive,≥15mm,,,,,,
8825,,bone healing,oral anti-androgens.|patients,,,form.|person,,,,"injury,|non-voluntary",at any location,=18 years||exclusion,,,,,,
8826,,ear|recent head,conventional laparoscopy,,,condition(s,,,,u09.9,for the duration of the study|participants,< 18.5 or ≥ 35;|outpatient or day,,,,,,
8827,,idiopathic pneumonitis,beta human chorionic gonadotropin [β-hcg,,,exercise testing per ats,,,,c3 dat,within 1 year of recruitment|current treatment,29|able to understand,,,,,,
8828,,acquired dental anomalies,tyrosine receptor inhibitor,,,physiological blood loss,,,,medications|high risk,after two 1-hour training instructions each time;|patients,high-dose per reference chart,,,,,,
8829,,persistent epithelial defect,definity ®.|cardiac disease,,,surgical procedure.||,,,,malignancy.|tumor diameter,for at least 3 months after last study treatment occurred in the maintenance phase,below 40 kg/,,,,,,
8830,,ocular abnormalities,pde-4 inhibitor,,,-ablation,,,,breastfeeding|acute respiratory,prior to enrollment)|a change,> 45,,,,,,
8831,,unreliable dietary recall)|persons,component of the study vaccines,,,transbronchial biopsy,,,,severe than step 2 other,in 4 weeks for,< 60 ml/,,,,,,
8832,,fallopian tube,anthracycline drugs reach threshold,,,adenosquamous,,,,low-potency topical corticosteroids||no occurrence,14 days before randomization/enrollment.|active leptomeningeal disease,18.5 to 30 kg/m^2 inclusive,,,,,,
8833,,third-year lsmu students;|18,drugs targeting α-synuclein;|received,,,tincture,,,,wood units|red blood cell alloimmunization,illness|treatment,greater than 6 months|for,,,,,,
8834,,plasma,trazodone,,,bowel resections,,,,refractory to intrathecal chemotherapy,within 5 years prior to the start of study treatment.|patients,>3 kg,,,,,,
8835,,gestational diabetes mellitus|possible ethanol,infliximab,,,bilateral nerve sparing technique,,,,site level.,before hospital admission.|chemotherapy,6 to 35 months:||healthy children,,,,,,
8836,,predict sensitivity,azithromycin|a,,,therapeutic treatment,,,,second-year,within the 14 days after,< 430 msec,,,,,,
8837,,normalize,stent,,,taste and olfaction,,,,blood|weigh,within 4 weeks of baseline visit|phototherapy,>3 mg/dl,,,,,,
8838,,treatment,components of the study medication,,,prp injection,,,,results.|intensive exposure,at time of enrollment.||admitted,more than 70%,,,,,,
8839,,maintenance therapy.||,systemic anti-inflammatory agent|participants,,,immunochemistry,,,,deceased donor)|bmi,during the study.||*methods of contraception,<3.5,,,,,,
8840,,nrf2,nonsteroidal anti-inflammatory drugs,,,img campus,,,,ebv,in the last,≤ 1.5 times the upper limit of normal,,,,,,
8841,,duodenal polyps,anti-inflammatory agent,,,chest organs,,,,survivor||recurrent,more than 2,12 to < years,,,,,,
8842,,bleeding disorder|platelet counts,intense pulsed light therapy (ipl),,,resuscitation decision,,,,anal,within the last 24 hours.|participant already admitted,less than 50.0 kg,,,,,,
8843,,exclusion criteria||medical conditions,skin rashes,,,magnetic resonance cholangiopancreatography,,,,circumferential,during the six months period before the pre-study,> 1000 ng/ml,,,,,,
8844,,hypertension.|patients,systemic anti-infection therapy,,,synchronous biopsy,,,,preoperative,within 1 year after car-t cell infusion.|any conditions,≤ 10 pack-years,,,,,,
8845,,cervical cap,oral prednisolone steaglate,,,conventional testing consistent,,,,allowed)|scheduled elective surgery,within 14 days before registration|no,>2.5 ml red,,,,,,
8846,,neuronoglial tumors,influence pharmacokinetics,,,life|rbc transfusion,,,,suitable for intratumoral,within 3 months prior to recruitment,>140 or <90 mmhg,,,,,,
8847,,"cardiovascular disease,|5d",iodinated contrast agents|colorectal neoplasia,,,pelvic surgery;|endometrial biopsy,,,,cd1a+,in ct/mri,"< 80 g/l);76,93,109|hemodynamic instability",,,,,,
8848,,therapy.|female,soft tissue healing,,,standard treatment options||• phase iib,,,,healthy,during the last 3 months prior to participation in this study.|personal,partial remission,,,,,,
8849,,normal findings,sod1,,,refractive surgery,,,,increase risk of bleeding from,during the baseline period.||for inclusion,>24 breaths/min||,,,,,,
8850,,extension|active infections,medication access,,,resected,,,,modify glucose,for at least 90 days prior to randomization|upcr ≥ 1.0 g/g,"between 6-10,|to receive iv treatment upon the request of a",,,,,,
8851,,haleema,metoprolol,,,ivt injection,,,,non-radiotherapy target areas,within 7days before enrollment.||known acute,35-85 years||presence of the,,,,,,
8852,,gastrointestinal ulcerative disease|patients,medical drugs,,,recent surgery,,,,very severe intensity,within 6 months before the start of study treatment|severe,0-1|be willing to give,,,,,,
8853,,acute superficial thrombophlebitis,finerenone.|contraceptive use,,,surgery of the concerned joints|presence,,,,uspstf guidelines,for at least three mounts||,≥50 g/d,,,,,,
8854,,intending,proton pump inhibitor,,,transcranial magnetic stimulation [tms],,,,mcas-r acuity score,within the last 12 months|live,<3.0 meq/l,,,,,,
8855,,heart failure hospitalisation,,,,stomach resection,,,,excessive intake of alcohol.|positive screen for drugs of abuse,at least 3 out of 7 nights in the week prior to baseline,6 to 24 months of age,,,,,,
8856,,hepatitis 10,,,,screening.|negative pregnancy test,,,,temporally related,for at least one year|has,1 cm between the tumor,,,,,,
8857,,localized superficial site,,,,whole brain radiotherapy (wbrt),,,,mid-face region,within 8 weeks from the time of admission to the hospital|up to and not more than 7 days since admission to the hospital||female subjects must,≥ 1500/µl,,,,,,
8858,,acute polyradiculitis,,,,first-time surgery||,,,,ankle range of motion,within 6 months prior to entry.|active infection,18-35||,,,,,,
8859,,systemic therapy|diagnosis of mds,,,,hematological function,,,,mid-phase fa,in the 30 days prior to screening,10-50,,,,,,
8860,,appendix cancer,,,,"bilateral lung transplantation,|iii",,,,pd,for 1 year after the last dose of study drug,< 50%|active,,,,,,
8861,,nutritional supplement impacting,,,,spo2 screening,,,,tested by signatera mrd assay,within 6 months of enrollment.|patients,> 110 mmhg).|severe hepatic,,,,,,
8862,,h glucose,,,,organ tissue.|slit lamp,,,,relapsing-remitting ms,within 30 days before enrollment;|diagnosed,<50%|subject,,,,,,
8863,,hemoglobin electrophoresis,,,,surgical procedures|conversion,,,,nadir,in the last 60 days;|chemical dependency/alcoholism;|chronic use,1 to 6 years,,,,,,
8864,,lower extremity muscle,,,,annexectomy,,,,per-trochanteric,during the night,≤ 3.0×uln,,,,,,
8865,,intravascular coagulation,,,,donation of blood,,,,aa).|active,within 3 months prior to the screening period,≥18 years;|tnbc,,,,,,
8866,,psychiatric neurological disorders,,,,aiming,,,,grade ≤1,for 28 days after study drug discontinuation,= 0 mm,,,,,,
8867,,above.|able to communicate effectively.|did,,,,medications).||peripheral absolute neutrophil count (,,,,hbss,at doses equivalent to or,> 12.5 g/dl,,,,,,
8868,,hev)|primary dermatologic diseases,,,,mechanical ventilation|congenital defects,,,,resectable,within 3 months before the study);|allergy to the,< 6 months.||exclusion criteria,,,,,,
8869,,viral hepatitis b,,,,laparoscopic pancreatoduodenectomy (,,,,l1-l4,within 5 years prior to initiation of study treatment,less than 90/60mmhg;|chronic liver disease plus,,,,,,
8870,,comfortable cl wear,,,,biliopancreatic,,,,tumor tissue hrd score,within 6 months prior to dosing.|whole blood donation,between 18.5-30 kg/m2|weight,,,,,,
8871,,perioperative care,,,,simple close of,,,,thoraco-lumbar curvature,during the last 4 weeks prior to screening,3 or more,,,,,,
8872,,acute endometritis,,,,lung irradiation,,,,cytologically proven,within 12 months prior to check-in.|participated,> 100x109/l,,,,,,
8873,,serological panel.|active hiv,,,,oncology treatment/care,,,,previously treated,prevent sole contact|pathological conditions,<2bb,,,,,,
8874,,systemic lupus erythematous,,,,head rotation|a,,,,stage 5;|there,prior to index stroke resulting,score of the eastern oncology consortium (,,,,,,
8875,,ovarian function,,,,infarction|peripheral arterial disease|carotid artery disease|unexplained shortness of breath|congestive heart failure,,,,american joint committee on cancer ajcc staging manual,in the last 3 months|use hormone replacement therapy,less than 150 min/week.||,,,,,,
8876,,masses,,,,palliative surgery;|prior pelvic radiotherapy;|hyperthermic intraperitoneal,,,,york||disease characteristics||prior,within the 12 last months,11-45,,,,,,
8877,,phobia,,,,expert consensus,,,,glutamic-oxaloacetic transaminase,after initial diagnosis,>=0.6 bethesda units,,,,,,
8878,,right-handed|aged,,,,manipulated graft,,,,non-medicinal studies,within 2 weeks prior to first dosing of study treatment.|liver disease,7 years old,,,,,,
8879,,right ventricular function,,,,radial keratotomy,,,,t3-4n2-3m0).|eastern cooperative oncology group performance status,in the upper and lower extremities (below the elbow / knee joint,score of > 2 standard deviations below the mean,,,,,,
8880,,gastrointestinal tract,,,,major ipsilateral abdominal surgery.|american society of anesthesiologists (asa) class iii or iv,,,,nalmefene elaidate,newly,>= ii|high,,,,,,
8881,,dirty wounds|cirrhosis,,,,unicompartmental knee arthroplasty.|≥18,,,,ankle site,during the 6 months|no evidence,score equal to or greater than 25 points,,,,,,
8882,,brain scarring|healthy,,,,choose hemodialysis,,,,mild to moderate dementia,within 30 days prior to study blood draw,29.5 ml/1 ounce,,,,,,
8883,,intact bladder,,,,tumor surgery,,,,non-child bearing,within 4 days prior to the first dose (≤4 days from the first dose);|first presence,≤ 2.5 x the uln,,,,,,
8884,,drainage fluid,,,,adequate treatment,,,,chu bordeaux,disease;|2.at the time of inclusion,2013-2020,,,,,,
8885,,trochanteric fractures,,,,vasectomized sole partner,,,,secondary to medical cause,in the past 6 months prior to registration|no,5% variation of the,,,,,,
8886,,otic infections,,,,diagnostic study||decision tree classification,,,,worse epithelial disease,4 weeks prior to the study;|glucocorticosteroids,from 18 to 65 years,,,,,,
8887,,disorders|inability to answer perioperative questionnaires,,,,procedural intervention,,,,definitive,within 12weeks prior to screening,≥120 or ≥80,,,,,,
8888,,traumatic incident,,,,il-6 inhibitory therapy,,,,exercise-,within less than 4 weeks prior to randomization,greater than uln|participant must understand the investigational nature of this study,,,,,,
8889,,chronic kidney disease|patients,,,,re-wetting,,,,grade ⅱ,within 4 weeks before enrolment and within 3 days before treatment start.||,> 6/10.|participants,,,,,,
8890,,non-degradable internal fixation system,,,,pelvic fixation/fusion,,,,radicular,no more than one lung lobe,≤ 88%.|has,,,,,,
8891,,"pregnancy,|an",,,,index procedure,,,,stage ⅰb,at least 2 weeks prior,"<1,500 kcal/day",,,,,,
8892,,macrolides,,,,quality of life and/or interfere with their ability to manage their heart failure care regimen,,,,detachment|connective tissue diseases,prior to consent to prevent study procedures,≥ 130/ ≥ 80,,,,,,
8893,,hepatitis b virus,,,,intravenous treatment,,,,antibodies|anti-diabetic drugs therapy,within 10 days prior to the start of study,≥ 18)|naïve,,,,,,
8894,,acanthamoeba keratitis,,,,celiac trunk,,,,tripterygium,past 2 months|reported use of opiates,<110 x 109/l|alt,,,,,,
8895,,tuberkulosis,,,,fance,,,,lesion.|american joint commission,within 30 days of enrollment|live vaccine,"between 30% and 70%, inclusive",,,,,,
8896,,localized infection,,,,line of chemothrapy,,,,end-organ injury,recurrent,at exercise <80%,,,,,,
8897,,contraindicated drug-drug,,,,treatment|concomitant administration of live vaccines,,,,3-day,during study participation,50 - 80,,,,,,
8898,,screening.|severe obstructive,,,,clinical laboratory tests).|bmi,,,,parenchymal,within 6 months before screening;|the level,between 4 years and 7 years.|restorable,,,,,,
8899,,light smokers,,,,therapeutic doses,,,,b7-h3 expression,during the next 6,200 mmhg,,,,,,
8900,,residual thrombocytopenia,,,,cardiac rehabilitation intervention,,,,received.||,within 30 days prior to the first dose of the investigational product|history of smoked,tg>1.5 fold normal,,,,,,
8901,,mental inabilities,,,,tumor biopsy sample,,,,blackouts further exclusion criteria apply,at least 4 weeks prior to,between 18 and 35 years.||,,,,,,
8902,,allergy;|psychiatric comorbidities,,,,blood coagulopathies|infection,,,,non-idiopathic,during the entire study from day -7,i-ii|anterior,,,,,,
8903,,correctional facilities|facilities,,,,oral imaging examination,,,,hemostasis|acute,for 3 months after the last dose to avoid exposing a pregnant partner,=< 1.5 x institutional uln,,,,,,
8904,,mediastinal tumors|target lesion,,,,european association for the study of the liver guidelines of hcc management;|at least one measurable lesion,,,,deemed not,within 28 days before the first dose (,< 90% predicted normal,,,,,,
8905,,increased activity or energy,,,,sleep latency test (mslt),,,,pd-l1),after 6 weeks,3-6 months prior,,,,,,
8906,,calcified target lesion,,,,metallic stent,,,,n1-3,before signing informed consent.|subjects,41 - 150 µg/l,,,,,,
8907,,lung failure,,,,local heart team,,,,inducers - barbiturates,within 90 days of the last study medication,worse than 1.5,,,,,,
8908,,thrombotic diseases,,,,first laser procedure,,,,chemoradiation,within the last 12 months)|treatment,two-times the upper limit,,,,,,
8909,,anaplastic lymphoma kinase status.|adequate pulmonary function||,,,,skin tape stripping done,,,,only for patients);||,in the past five years.|active,"< 1,000/μl.",,,,,,
8910,,autoimmune disorders.|the,,,,qol scoring,,,,abant i̇zzet baysal,longer than two months,>4·78 miu/l,,,,,,
8911,,temporomandibular joint disorder|participants,,,,steroids;|progression,,,,intra-abdominal sepsis.|previous,within 7 days prior to laboratory test,above 18 years' old|elective,,,,,,
8912,,restrictive bariatric surgery,,,,vaginal contraceptive ring,,,,granulocyte-colony-stimulating factor,within the last 6 months.|subject,<50000/cmm)-,,,,,,
8913,,trans-urethral resection,,,,ostomy,,,,interferes significantly with absorption and digestion,at the time of temporary registration,18 years or older|meet criteria for inclusion,,,,,,
8914,,cranial trauma,,,,rigid contact lenses,,,,movement disorder society (mds),over 20 years,<2.0,,,,,,
8915,,non cmr-conditional devices|subjects,,,,palliative care|end,,,,hormone replacement therapy,throughout 3 months after last dose,>91%,,,,,,
8916,,eye disease|patients,,,,radiation for,,,,non-specified pain,within 6 months before the trial;|4,6-7,,,,,,
8917,,flair,,,,hepatic hilum,,,,village representatives,within 28 days before administration,greater than 1.4,,,,,,
8918,,metabolic disorders|mixed phenotype acute leukemia|philadelphia,,,,bronchoscopy procedure,,,,posterior,recruited|stopped taking,≥6 months.|during the study,,,,,,
8919,,comorbid disorder,,,,laparoscopic major abdominal surgery,,,,suitable to join the study;|10、hiv infection;|11、any situation that the researchers,within 1 year.|previous receipt,score of more than 24 out of 30 on,,,,,,
8920,,cardiovascular disability,,,,feeding|blood donation,,,,locally severe,"for at least 3 weeks,|treatment",< 8 ng/ml||,,,,,,
8921,,type 1 nstemi,,,,12-lead ecg.||,,,,irritation,within 30 days prior to enrollment.|active chemotherapy,≥ 1.5x109/l,,,,,,
8922,,endotracheal intubation;|asa classification,,,,anticoagulant therapies,,,,non-paroxysmal,prior to enrollment does not exceed 300 mg/m^2|age,"< 25,000/mm3",,,,,,
8923,,lowest injury-related,,,,maintenance treatment exceeding protocol-defined limits prior,,,,old|confirmed,more than 1 prior,3 ×109/l,,,,,,
8924,,treatments.|cardiac disease,,,,intrauterine hormone-releasing system,,,,community|chronic sublesional neuropathic pain,any time prior to visit 1 or,">/=150,000/mm3|hgb",,,,,,
8925,,neutropenia,,,,gastric vessels)|infiltrative tumors|target vessel sizes,,,,december 2022.|the nerve origin of,at the time of a,> 18 years|being,,,,,,
8926,,electric pump,,,,interviews||,,,,ureterovesical,prior to registration.||note,<30 days,,,,,,
8927,,affect osteogenesis,,,,stool softeners,,,,grade 3b|transformation,during the study period.||,> 1.5 x uln,,,,,,
8928,,transverse,,,,therapy targeting ceacam5.|prior maytansinoid dm4 treatment,,,,rather than neck,after stable treatment).|serious chronic,positive.|more than 5 cigarettes per day,,,,,,
8929,,months;|acute cerebrovascular accident,,,,complete resolution,,,,cirrhosis.|active,therapy.|any history of a,between 50 and 75 years,,,,,,
8930,,ctcae 5.0,,,,arthrocentesis procedures,,,,moment of randomisation,in the past can be enrolled,<50 x 109/l,,,,,,
8931,,psychiatric drugs|scalp pathology,,,,knee arthroplasty,,,,epstein-barr virus(ebv,within 28 days prior to enrollment|for,etc.||over 18 years old,,,,,,
8932,,airway obstruction,,,,assessment imaging of the tumor by ct,,,,injection sites|diagnosis,over the 3 months before study participation,6/96,,,,,,
8933,,hypophysitis,,,,crystalline dystrophy (bcd),,,,non-urothelial bladder cancer,within 1 week of starting preparative therapy|known seropositive for hiv,for more than 24 hours.|current diagnosable,,,,,,
8934,,lack of cognition,,,,re-exposure,,,,upper airway resistance,within 4 weeks prior to randomization;|known,> 60 years old,,,,,,
8935,,noted subsequent progression,,,,id materials,,,,tumor tissue sample (archival,last dose received more than 3 months prior to initial study vaccination||inclusion criteria,2-9 years,,,,,,
8936,,asymptomatic small,,,,focal cerebral ischaemia.||the exclusion criteria,,,,pericaval,at least 12 months prior to study enrollment,less than 90 mins,,,,,,
8937,,multi-vessel percutaneous coronary intervention (pci),,,,cessation of the study drug;|pregnancy,,,,platinum-containing,within six months prior,> 18 and < 60 years,,,,,,
8938,,lipid abnormalities,,,,fresh biopsy tissue,,,,life threatening,within 6 months before first administration,≤ 45 kg/m^2.||,,,,,,
8939,,vasculitis;|systemic lupus,,,,interventional study,,,,autoimmune-mediated,within 8 weeks prior to screening.|last injection,55 to 90|patients,,,,,,
8940,,heart function left ventricular ejection fraction,,,,hematopoietic growth factors,,,,cpet.|uncontrolled arterial hypertension,within 3 weeks prior to start of study treatment|clinically significant,= 2.8 mm,,,,,,
8941,,psychologic problem,,,,vertebral artery dissection.|history of,,,,multidisciplinary,within 3 days prior to check-in until the follow-up visit,up to 7.5%,,,,,,
8942,,instrumentation,,,,lrygb operation,,,,adequate dose of ssri,within 28 days prior to the first dose of study,>0.5 mg/kg,,,,,,
8943,,respiratory symptoms,,,,biliary diversion,,,,hypothalamic-pituitary-adrenal axis,within 28 days before enrollment|patients,frequency of ≥3 pgtcs,,,,,,
8944,,situ|patients,,,,testing of two samples collected,,,,hypomanic episode,in a 6 week period within 3 months of enrollment.|capable of giving,between 18 and 35 kg/m2 inclusive,,,,,,
8945,,acute severe,,,,physical disabilities||,,,,≥92%.|left,at least 60 days after the final dose of study treatment|type 2,above or equal to 18 years,,,,,,
8946,,chest wall deformities,,,,violence,,,,other investigational drugs,within 14 days of treatment initiation.||absolute neutrophil count (,> 3 × upper limit of the normal range (uln),,,,,,
8947,,early postural instability,,,,2020||arcr surgery,,,,"diagnostic and statistical manual of mental disorders, fourth edition, text revision",adequate duration,<60 ml/minute/1.73 m2 body surface,,,,,,
8948,,pt1 breast cancer,,,,biological,,,,interfere with cooperation with the requirements of the study|subject,within 3 months|recent adding,> 75th percentile,,,,,,
8949,,comfortable with communication,,,,tumor reduction surgery,,,,im,for at least 6 months before enrollment;|in the opinion of the investigator,b-type natriuretic peptide,,,,,,
8950,,health risk behaviour,,,,pfts,,,,suitable for inclusion in this study judged by investigators,in the past 5 years,more than or equal to 18 years old,,,,,,
8951,,abnormalities- ascites,,,,vaccinations.|plans,,,,medically prescribed activity limitations,in last 60 days;|pregnant,20-42,,,,,,
8952,,rheumatic fever,,,,radiochemotherapy or|recurrent,,,,hard of hearing,within 7 days of the first dose (amount,between 45-85|patients,,,,,,
8953,,premature ovarian failure|weight,,,,literature corrected,,,,reduced pk,for 4 weeks prior to inclusion,more than 18 years old,,,,,,
8954,,metabolites,,,,repetitive transcranial magnetic stimulation.|contradictions,,,,wright-patterson air force base,within australia.|having had previous,lmwh)|age 18 years,,,,,,
8955,,paracentesis,,,,composite international diagnostic interview|willing and able to provide full informed consent|responds,,,,lack effective treatments;|expected survival period,preceding 12 consecutive months).|ability to understand and the willingness to sign a written informed consent,30-59 ml/min per 1.73 m2,,,,,,
8956,,mandibular ridge,,,,ocular refractive anatomy,,,,post-acute,throughout the study period;|signature of the free and informed consent term (tcle),>= 22 years,,,,,,
8957,,vertical sleeve gastrectomy||iii,,,,isolated first ray surgery,,,,≥450ml of,within 30 days of the study procedure.|rutherford classification,>3 x institutional upper limit of normal (uln),,,,,,
8958,,subjective cognitive impairment,,,,lower blepharoplasty,,,,american joint committee on cancer (ajcc) staging,within the week prior to screening;|patients,greater than 35 weeks,,,,,,
8959,,actively treating stroke,,,,lead extraction,,,,occasional,within 4 weeks prior to registration,≥ 30 db hl,,,,,,
8960,,mitral regurgitation|high,,,,cardiac surgery episode,,,,grade ≥2,for at least 120 days after the last dose of study treatment|adequate hematologic,≥ 3 times upper limit of normal,,,,,,
8961,,nasal congestion,,,,laboratory test results,,,,castration resistant disease,within 6 months prior to screening.|subjects,≤ 3.0 mg/ml,,,,,,
8962,,cerebrovascular ischemia,,,,screening investigation the investigators consider,,,,membrane-associated,within the past year.|participant,2 or more.||,,,,,,
8963,,neuroendocrine tumors,,,,carotid dissection,,,,medical history:||he,within 4 weeks prior to the first dose of study drug,1 positive,,,,,,
8964,,prolonged qt syndrome|myocardial,,,,nasal intubation,,,,administration;|uncontrolled,at time of inclusion|well defined,between 18 and 35||,,,,,,
8965,,solid tumors.||subject,,,,consistent with consensus criteria,,,,premolar,at the time of the study|have malabsorption syndrome|less than 5 years after treatment for gastrointestinal cancer,less than 52.28°,,,,,,
8966,,anticancer agents,,,,digital subtraction angiography examination,,,,systemic glucocorticoid,history,1 to 3)|intermediate stage,,,,,,
8967,,cranial nerves,,,,fothergill's,,,,5.0)|immune-related,within 3 months);|pregnant,25 iu/l,,,,,,
8968,,dihydropyrimidine dehydrogenase (dpd),,,,physiotherapy treatment,,,,site of injection.|cranial bone,within the potential treatment area,26-32 cycle days.|fully healthy,,,,,,
8969,,portal hypertensive gastropathy|pregnancy,,,,bone marrow transplantation,,,,suitable for participation in the study,at least 4 years old,<100 ng/ml assessed,,,,,,
8970,,proliferative lupus,,,,pancreatic resection,,,,fredericia criteria (qtcf),during the intake interview,> 75 %,,,,,,
8971,,organic nerve damage,,,,peritonectomy,,,,febrile 24 hours prior to or,after hormone replacement therapy);|congenital,≥24 hours,,,,,,
8972,,mental health symptoms,,,,polio vaccine,,,,pembrolizumab product components;|pregnancy,in the first 3 months of the screening period,0-4||,,,,,,
8973,,clinically significant infection,,,,pathology after radical resection,,,,stage 5 [ckd 5],pre-dose fev1,18 - 75,,,,,,
8974,,glomerulosclerosis,,,,fish,,,,intra-operative,less than 3 months ago,65 or over,,,,,,
8975,,"radiotherapy,|endometriosis",,,,therapy related criteria,,,,coils,at the time of sars hospitalisation,30-210mm|the,,,,,,
8976,,hepatitis b surface antigen(hbsag,,,,unstable medical conditions:||heart disease|seizures|cancer|thyroid disease (okay if controlled,,,,12-14|no,within the last 2 weeks prior to screening,18 to 35|caucasian|no,,,,,,
8977,,judged by the investigator to be incompatible with participation in the study,,,,chronic lung disease|known,,,,requiring the constant use of,during the duration of the study.|history,≥ 18 years|intertrigo,,,,,,
8978,,third ip vaccination.|use of any investigational,,,,small cell lung,,,,rectum|patients judged unfit to participate in the study by medical staff,within 6 months before the screening visit,"50 kg to 110 kg, inclusive",,,,,,
8979,,living independently|able,,,,acceptable birth control,,,,non-acute,in the past 1 months,≥30 at time of delivery)|concern,,,,,,
8980,,lamina,,,,foreign protein,,,,alcohol,for at least 2 weeks after the last dose of study drug.)|participated,<3 months)|any,,,,,,
8981,,diabetes mellitus||,,,,islet cell autoantibody,,,,injury|vertigo,within 8 weeks.|interferon,< 400 µm,,,,,,
8982,,us).|ak lesions,,,,study|blood donation,,,,long bone fractures|open abdominal,in the first year of function20,10-15 freshly cut,,,,,,
8983,,vomiting||,,,,foreign body aspiration,,,,cetuximab combination,within 4 weeks prior to registration -||exclusion criteria,≥ 2.5mm,,,,,,
8984,,steroid myopathy,,,,qtc interval>450ms,,,,subdermal,less than one week ago,≤ 1.5 times the upper limit of normal (uln),,,,,,
8985,,craniofacial syndromes,,,,sars-cov series|persons,,,,cervical area,at least one of the following:||duration,greater than or equal to 18 years.|able to understand and provide signed written informed,,,,,,
8986,,hla-ident,,,,pathological fractures;|poor control of,,,,non-pharmacological treatment,prior to screening visit 2).||general medical history||negative,< 3 months|prescription,,,,,,
8987,,left common carotid artery branch vessel diameter,,,,cognitive behavioral therapy,,,,non-autoimmune allergic diseases;|if,throughout study enrollment|safe to exercise,≥400 pg/ml,,,,,,
8988,,months|infants,,,,emergency interventions,,,,long-acting nitrates,in the past 1 year;|consumption,>3x normal,,,,,,
8989,,chronic cervicitis,,,,intensive care treatment|active life-threatening diseases,,,,grade 3b,within the previous 12 months.|have received,≥70 mg/dl,,,,,,
8990,,solid organ transplant.||patients,,,,ffr examination,,,,line,within 14 days prior to day 1 of protocol therapy|vitamin e,<18|smoking|diabetes mellitus,,,,,,
8991,,chronic obstructive pulmonary disease.|history,,,,stent implantations,,,,igg fusion protein.|the subject's,at the time point of signing,female,,,,,,
8992,,tiredness,,,,platelet transfusion,,,,primary source,within 7 days before the laboratory test,≥ 7%,,,,,,
8993,,color sensitivity,,,,chronic systemic treatment,,,,azasugars,5 half-lives.|presence,>450 ms,,,,,,
8994,,systemic immune therapy,,,,tms screening,,,,performance subscale,"within 4 weeks prior to cycle 1, day 1",> 150mmol/l,,,,,,
8995,,immune dysfunction syndrome,,,,management center,,,,central nervous system (cns) tumor involvement,within the past 15 days,27.0 to 40.0 kg/m2,,,,,,
8996,,skin comorbidities,,,,dual injectable sustained-release cabotegravir-rilpivirine therapy,,,,pupils,history of training,18 years old|patient,,,,,,
8997,,rapid sequence,,,,target coronary angiography agent,,,,full scale intelligence quotient,within the last 6 months.|clinically significant,< 3 years,,,,,,
8998,,valgus,,,,small amount of suprachoroidal hemorrhage,,,,gynecologist,in the next 3 months;|current participation,at least 2,,,,,,
8999,,permanent maxillary teeth,,,,country guidelines,,,,non-abrasive,"in the 6 months before the study,|it",0.6,,,,,,
9000,,clinicopathologic data|patients,,,,standard tapering of 1 mg/kg,,,,high likelihood of cd19 expression,within 90 days prior to the first dose of study drug,≥ 20% and < 80% of the predicted value,,,,,,
9001,,overseeing activities related to product.|have participated in any clinical study involving the test sites,,,,rapid antigen test for sars-cov-2,,,,autistic,since less than 5 years,< 150 x 103/μl|leukocytes,,,,,,
9002,,document stable,,,,digital subtraction angiography (dsa),,,,castration sensitive,within 4 weeks prior to first dose of ipilimumab,≤ 65 years;|the time,,,,,,
9003,,mandibular region.|patients,,,,quantitative imaging analysis,,,,in the absence,at least 6 months after surgery.||,at least 18 years|had,,,,,,
9004,,nasal polyposis,,,,standard medical intervention for ckd-related,,,,inhaled allergens,within the 3 months before screening,less than 30 kg/m2.|pain,,,,,,
9005,,liver injury|clinical severe conditions,,,,intra-articular treatment,,,,non-medical conditions,within 4 weeks prior to enrollment|lesions,+-year diabetic,,,,,,
9006,,acute stage)||-,,,,blood glucose control,,,,unsuitable for tdcs,within 5 months after the final dose of study treatment,years to 60,,,,,,
9007,,etc.)|no medical condition,,,,functional ambulation categories (fac),,,,deemed cured,within 7 days or,≤ 3mm,,,,,,
9008,,dermatological disease,,,,genital surgery,,,,acr criteria,within one month prior to administration of the study medication,≥19 years|patients,,,,,,
9009,,chronic defecatory motility disorders|current,,,,liver transplant.|have amylase,,,,between every 21,at the time of enrollment.||performance status,>15,,,,,,
9010,,arterial resection,,,,test of,,,,twins pregnancies.||breech,at least 6 months after the last dose of protocol therapy||childbearing potential defined,> 3 × uln,,,,,,
9011,,gingival trauma,,,,full surgical resection,,,,occlusal surface partially,within 7 days prior to and after,<60 to 20 ml/min);||>55 yrs,,,,,,
9012,,extraperitoneal metastases,,,,panel,,,,plasma-derived fviii concentrates,at the time of consent|planned surgical,≥ 18 years|extracranial,,,,,,
9013,,unexplained serum ast,,,,pancreatoduodenectomy,,,,licensed,within 4 weeks of the first dose of study drug.|known,13-55 years,,,,,,
9014,,ex.dementia,,,,general practitioners,,,,unknown onset stroke,in the 3 months prior to signing icf.||has known,between 140 and 199mg/dl,,,,,,
9015,,1 hypertension,,,,excision,,,,prehospital,within the last 1 year.|participants,< 8.0 g/dl,,,,,,
9016,,etc.)|pregnancy,,,,first-line fluoropyrimidine,,,,non-english,at least 2 b-lines by,≤ 2.5×uln,,,,,,
9017,,pet,,,,unusable x-rays,,,,grade 2 or lower,within 30 days prior to randomization.|receipt of allergen immunotherapy,≥ 20 and ≤ 70 years,,,,,,
9018,,retisert,,,,test formulation capsules,,,,left dominant system,within 2 months of randomization,< 30ml/min|history,,,,,,
9019,,cardiac thrombus,,,,maxillofacial surgery clinic.|the patient,,,,study|severe,within 14 days prior to the first dose of study treatment.||8,greater than (>) 7 days in duration]|severe dilatation of the,,,,,,
9020,,leukemia).|moyamoya syndrome,,,,covid-19 vaccination,,,,accredited,within 24 hours prior to the first dose,three or more months,,,,,,
9021,,chronic malabsorptive conditions,,,,genomic alterations,,,,royal,at less than 21 weeks,= 1)|subject,,,,,,
9022,,keratitis,,,,interventional clinical study follow-up;|receiving,,,,highly effective starting at time of informed consent,within 1 month prior to or during intervention,20-30 minutes each,,,,,,
9023,,anterior uveitis,,,,historical liver ultrasound,,,,preclude the conduct of the investigation procedures|allergy,at screening|documentation of symptoms,score less than 3;|liver function,,,,,,
9024,,visceral crisis,,,,thalamotomy,,,,mmhg）.|acute,in the past 4 weeks|who,">16mm,|nyha functional class",,,,,,
9025,,abstain from taking these to the end of visit 6,,,,removed,,,,intra-articular,inferior to 24||all,≥18 years|clinical,,,,,,
9026,,laparoscopic enucleation,,,,implant radiation therapy,,,,related to inclisiran,within the last 6 months.|alcohol consumption,less than 14 days before taking the drug,,,,,,
9027,,chronic nephritis,,,,intraocular lens implantation,,,,autosomal,within 6 months of initial diagnosis.|vaccinated with live vaccines,≥ 2.0,,,,,,
9028,,narcotic painkillers,,,,head movement.|abnormal otoneurological examination,,,,stroke;|complete,at least 30 days from onset of a preceding clinical demyelinating event,> 15,,,,,,
9029,,acute abdomen,,,,standard of care rt,,,,evaluate symptoms.||,more than 4,19.0-30.0 kg/m2,,,,,,
9030,,atypical mycobacterioses,,,,autologous blood product,,,,stable regimen deemed best,during the study period and within 6 m after the end of the trial,"≥ 1,500 /μl|platelets",,,,,,
9031,,women|previous ua surgery,,,,adrenocorticotropic hormone (acth) stimulation,,,,mellitus.|hbeag-positive,within 4 weeks before the first dose,above 18 year old .||,,,,,,
9032,,presbyopia,,,,institute mri safety screening protocol questions,,,,interferes with cognitive testing||exclusion criteria,for the duration of protocol treatment,> 150 pg/ml,,,,,,
9033,,nasal obstruction,,,,stent graft implantation,,,,rif group,within 4 weeks prior to starting study treatment.||in any case,> 0.2 ng/ml.||,,,,,,
9034,,"factors,|neurological illness",,,,limb ischaemia||,,,,post- menopausal range,within 30 days prior to first drug,0 to 2;|life expectancy,,,,,,
9035,,disease relapse,,,,cc-122-st-001,,,,after laparoscopic,during the first 4 weeks before study drug,>7%;|monoclonal gammopathy;|pregnancy;|body mass index,,,,,,
9036,,graft|acute liver failure|living donor liver transplantation|controlled donor asystolia|treatment,,,,blood donation,,,,male)|other causes of,within 3 months after the administration of the vaccine,between or equal to 25 to 35 kg/m2,,,,,,
9037,,metastatic solid tumor.|subject,,,,bicuspid insufficient valves,,,,replacement,at the time of enrollment.|receipt of immune globulins,63 to 19,,,,,,
9038,,macular degeneration.|qtc,,,,teriparatide treatment,,,,supine,within the past 18 months (b) for,greater than or equal to 2 years|spends,,,,,,
9039,,colorectal adenoma,,,,show compliance with the protocol,,,,pharmacokinetic,at least 30 days before the administration of trial medication until 7 days after trial completion.||of note,≥6.5%)|self-reported,,,,,,
9040,,"neurological, developmental",,,,t-dm1 treatment,,,,blast crisis,48 hours before admission to the icu,greater than (>) 1 year,,,,,,
9041,,spinal cord compression meningitis,,,,ad flare area,,,,without criteria.||,within the previous year|history of,> 0.4 ml,,,,,,
9042,,third-line,,,,pretreatment ct,,,,survey.||exclusion criteria,newly diagnosed with,">= 1.2 uln),|bilirubin",,,,,,
9043,,genitourinary infections,,,,global gfr x,,,,ipsilateral upper extremity fracture,at screening or day -1,20-40,,,,,,
9044,,chronic bone damage,,,,polymerase chain reaction (pcr) in sputum,,,,from initial diagnosis biopsy,greater than 12-weeks,between 7 and 50 years,,,,,,
9045,,haemoglobinopathy,,,,diagnostic puncture,,,,upper extremity like brachial plexopathy,within 5 times the elimination half-life,<65% predicted,,,,,,
9046,,bleeding tendency|drug abusers,,,,thymoglobulin therapy,,,,criteria,within 3 months before enrollment,17 years,,,,,,
9047,,skin rash area,,,,ligament suspension,,,,remains stable,after conventional anticoagulant therapy,<90 or >140 mmhg,,,,,,
9048,,cause||exclusion,,,,screening:||mean resting corrected qt interval,,,,lublin criteria,at least 1 test per week).|ast,above normal,,,,,,
9049,,mel,,,,standard induction chemotherapy,,,,breastfeeding.|major,less than 4 weeks prior to screening.||presence,≥18 years;|patients,,,,,,
9050,,granulocyte-colony stimulating factor,,,,darolutamide monotherapy,,,,american joint committee on cancer classification,within the head,<40 ml/min.|pregnant,,,,,,
9051,,congenital cardiomyopathies,,,,allogeneic tissue/solid organ transplant|pregnant,,,,pd-l1inhibitor,during pregnancy|use of,< 28 kg/m^2,,,,,,
9052,,left ventricular hypertrophy cardiomyopathy,,,,requirements.|participant oral health,,,,peri-procedural time,within 6 months prior to the first screening visit,≥12 g/dl,,,,,,
9053,,hla-g+ clear cell renal cell carcinoma,,,,kidney transplant,,,,likely,past 12 months;|history,greater than 15 mmhg,,,,,,
9054,,simplex of eye,,,,anti-coagulation therapy,,,,scleral buckling,after 1996,>40mmhg||,,,,,,
9055,,radiologic progression,,,,general aneathesia||,,,,psychosis|self-reported,more than 48 hours,≥50 years|nyha class,,,,,,
9056,,incisal margin,,,,local epidemiology,,,,non-reactive hiv,within last 3 days|aclf,>1.5 x institutional,,,,,,
9057,,mood disorder questionnaire,,,,heat,,,,before performing radical surgery,while awaiting transplantation,older than 18 years|tumor resection,,,,,,
9058,,non-melanotic skin cancer,,,,gastrointestinal surgery,,,,gastrointestinal surgery.|hormone replacement therapy.|participants,in the last 30 days prior to the screening visit.|dialysis,>51 ml/min,,,,,,
9059,,eye inflammation,,,,product|whole blood donation,,,,implanted ear(s)|post-op,within 6 months of treatment,≥ 16 kg body,,,,,,
9060,,major trauma,,,,invasive coronary angiography,,,,interventional study|female,in the last 12 weeks|severe heart failure,less than 40%|pulmonary impairment,,,,,,
9061,,malignant neoplastic,,,,consolidative local therapy,,,,american-european consensus group criteria,more than 12 months,less than 50%.||5,,,,,,
9062,,heavy smoking,,,,kidney impairment.||additional inclusion criterion,,,,any underlying,at least 3 months before the enrolment,> 160mmhg,,,,,,
9063,,functional pain disorder,,,,limbal stem cell deficiency;|adequate tear film and lid function|perception,,,,aih)|clinical diagnosis,during their participation in the study.||,greater than 3 months.||have measurable,,,,,,
9064,,high grade glioma,,,,screening.|history of,,,,negative;|understand the test procedure,within 6 months after the initial remission,less than ≤ 90%,,,,,,
9065,,radioactive iodine,,,,preventative therapy,,,,lvef<50%,since at least 6 months,≥ 16 weeks.||postmenopausal,,,,,,
9066,,laboratory abnormality,,,,standard imaging,,,,stage,within 72 hours of the validation of the,between 18 and 45,,,,,,
9067,,traditional chinese medicine,,,,somatic spliceosome mutation,,,,poorly-compensated,within 2 weeks of study entry,0-100,,,,,,
9068,,renal impairment|preterm delivery,,,,sui|gynecological surgeries,,,,stage iv.|recurrent,whose length and width can be,≥ 90 g/l|total,,,,,,
9069,,genetic testing)|sgot,,,,small incision lenticule extraction,,,,diatolic bp,within 3 days of intended study,>= 38.0 degree celsius,,,,,,
9070,,metabolic acidosis,,,,blood dyscrasias|history of cancer,,,,injection site|anatomical abnormalities,≤8 weeks before planned apheresis|major operations,<3.5×109/l,,,,,,
9071,,aortic disease,,,,cerebellar territory infarction,,,,sympathetic-reflex dystrophy,for at least 3 years|severe,18 years to 80 years.||,,,,,,
9072,,psychiatric instability,,,,open surgery|completion surgery,,,,adjuvant phase,within 12 months prior to or at screening,≥ 18 years)|meeting the clinical,,,,,,
9073,,syphilis.|participants reports,,,,lymphodepletion.|allogeneic stem cell transplant,,,,suitable to participate in this test,within =< 14 days prior to receiving the first study treatment|presence,≥ 37.5°с,,,,,,
9074,,gastric cancer|patients,,,,renal replacement therapy|enrolled in another drug,,,,valve)|moderate,within 3 months prior to study inclusion,> 18 years|acute ischemic stroke,,,,,,
9075,,non-radicular,,,,postoperative angiography,,,,m2 branch,during the last 56 days of the baseline period,at least 40 years|ankle/brachial index (abi) of,,,,,,
9076,,drug related immune disease,,,,volumetric analysis,,,,unreachable,within 24 hours of estimated time of stroke,c)|other indications,,,,,,
9077,,operable diseases,,,,english|no access to smart phone,,,,weakness|poor,at least 1 of the following:||serum m-protein ≥0.5,activated,,,,,,
9078,,interprofessional care.|at,,,,full blood count,,,,intra-abdominal abscesses,within the past 12 months|concurrent enrollment in another research study judged by the study investigators,≥ 38.0,,,,,,
9079,,hypertensive heart disease,,,,biological investigational therapy,,,,senile,throughout their participation in the study,≥ 40ml/min,,,,,,
9080,,diabetic gastrointestinal lesions,,,,ftd medications,,,,protrusive,within 7 days prior to enrolment；|congenital malformations,proper therapeutic compliance,,,,,,
9081,,secondary school,,,,acute low-velocity,,,,stroke unit of,for least 4 months after the last dose of study intervention:||i.,lower than 30%|eighteen,,,,,,
9082,,tumor biopsies,,,,anticoagulation,,,,non-reassuring,in the 7 days prior to randomization,< 300 u/l,,,,,,
9083,,preoperative neck pain score,,,,dotatate pet/ct,,,,mild to moderate acute pancreatitis,within 3 months|any,score of 7 to 9,,,,,,
9084,,horizontal position,,,,investigator.|abnormal findings in any item of laboratory tests,,,,to betablocker therapy|history of,within the past 12 months|prior facial cosmetic surgery|prior facial trauma|planned dental work within next 2 weeks|travel 1 week prior or 2 weeks after injection,≥ 18 years.|dose escalation,,,,,,
9085,,cardiac concerns,,,,concern.|concomitant medications,,,,site outside of the urinary bladder,within 28 days prior to sub-study randomization)|participants,>= 90 g/l,,,,,,
9086,,variable immunodeficiency disorders,,,,technical experts only)|does,,,,could interfere with absorption of study treatment.|prior exposure,for 30 days after the final dose of study,≤ 3 × institutional uln,,,,,,
9087,,alzheimer's disease;|autoimmune diseases,,,,kidney allograft previously|recipient,,,,low-dose computed tomography (ldct) scan,before 8 weeks after each 177lu-psma,>450,,,,,,
9088,,multifocal choroiditis|clinical evidence of,,,,chemotherapy cycle,,,,primary,in the past 2 weeks|willing to comply with all study assessments and procedures|must not be,65 or older|absence,,,,,,
9089,,fh,,,,robotic surgery.)||,,,,hlh.|high dose,for at least 6 weeks before first dose of study treatment.||b,18 to 65 years|willing and able to provide signed written consent prior,,,,,,
9090,,collateral reporters|breath alcohol,,,,spinal anesthesia,,,,american joint committee on the classification of cancer,during a physician supervised,≥ 30g/l,,,,,,
9091,,aspergillosis infection,,,,emergency surgery.|planned off-pump surgery.|patient,,,,sample collected,after last treatment dose on this study|provide written informed consent|willingness to provide,between 4 and 10,,,,,,
9092,,oedema,,,,injection of botulinum toxin,,,,doac-smi combination,at least one endocrine therapy,≥160 µmol/l;|hemoglobin <80 g/l,,,,,,
9093,,cognitive impairments|medical condition,,,,manual readings,,,,weeks.||admitted to the,for at least 7 days prior to randomisation,≥ 70;|age,,,,,,
9094,,myocardial infarction,,,,light chain mgus/smm,,,,increasing doses,within last 3 months)|wounds greater than 12 months old|previous,>5 years|world health organization (who) performance status,,,,,,
9095,,acute systemic infections,,,,allogeneic hematopoietic stem cell transplantation;|test drug allergy;|suffering,,,,st-segment elevation myocardial,for 3 months after the last dose of,18 years or over|willing,,,,,,
9096,,completely relieved,,,,allogeneic hct,,,,ophthalmologic,prior two years,under 40 years-of-age,,,,,,
9097,,vegetation|active infection,,,,good clinical practice,,,,clostridium difficile infection,within the next 12 months|recent serious injury,stage ii or more,,,,,,
9098,,plant-based protein,,,,histologic evaluation,,,,egfr,at screening or day -1.|current,>1000 copies/ml,,,,,,
9099,,congenital adrenal hyperplasia)|inability,,,,vasoconstriction,,,,assessments.||high probability of pneumonia,ended more than 6 months after the initial trial,≥ 75 ×109/l,,,,,,
9100,,percutaneous coronary intervention|heart rhythm abnormalities|congestive heart failure,,,,antihypertensive therapy,,,,non-active,at screening and after the end of study treatment,> 6 months.|participant,,,,,,
9101,,biliary salt diarrhoea)|previous colorectal surgery,,,,pet-ct-scan,,,,connective tissue disorder,at the time of screening)|participants and caregivers,< 30 ml/,,,,,,
9102,,hemorrhagic risk,,,,liver biopsy consistent,,,,clinically involved nodes,within 30 days prior to the first dose of study medication until completion of the follow-up visit,"0, 1 or 2||as",,,,,,
9103,,caustic gout,,,,endovascular therapy|a,,,,type-2 diabetes,within 6 months prior to first study drug,mutation.|nsclc,,,,,,
9104,,mild obstructive lung disease,,,,biopsy|axial ct scan,,,,transfusion,over the past 12 months,≥90g/l;|international,,,,,,
9105,,interstitial pneumonia pattern,,,,tics-m|severe rheumatologic or orthopedic diseases,,,,saxenda,for at least 6 months a score of,18 years or older).|identified,,,,,,
9106,,belonephobia,,,,drug,,,,interval,after the assessment of a multidisciplinary team because,18 to 19 years,,,,,,
9107,,month.|anemia,,,,trauma,,,,dose escalation,within 4 weeks 4 weeks before enrollment,≥ 100 mmhg);|patients,,,,,,
9108,,chronic renal disease.|noonan-related disorders,,,,hormonal intervention,,,,screening.|oral,within 3 months before booster immunization;|the,>= 7 years,,,,,,
9109,,normal renal function||individually matched,,,,injury|previous physical therapy treatments|joint instability|frequent migraines|spasmodic torticollis|inflammatory rheumatic diseases|peripheral nerve entrapment|severe psychiatric illness|pregnancy|other conditions,,,,≤grade 2 endocrinopathy,for at least 30 days after the last dose of blinded investigational product.||,≥ 18.0 to ≤ 33.0 kg/m^2.|new to treatment,,,,,,
9110,,congestive heart failure（≥,,,,vaginal ring,,,,successful,after previous radical prostatectomy,≥ 30 kg/m²).||,,,,,,
9111,,parkinson's disease.||additional exclusion criteria,,,,dental treatment,,,,grade 2 or above radiation pneumonia,within 2 weeks of initial mefamp-pet/mri scan.|ecog performance score,≥ 70%,,,,,,
9112,,liver metastases.|eligible,,,,treatment|hearing impairment|participation,,,,completely treated,up to 4 days before the first stimulation day of the cycle,≥ 3.0 g/dl,,,,,,
9113,,bacterial prostatitis,,,,major surgery (craniotomy,,,,crowded room,at the aforementioned university|to be willing,< 30% volume < 100ml,,,,,,
9114,,adequate immune response,,,,fetal head deeply engaged in the pelvis defined,,,,intra/extra-hepatic).|measurable common,at the time of inclusion,at least 15 degrees,,,,,,
9115,,included;|furcation involvement,,,,gbs-related weakness,,,,tmj|systemic,prior to the participation,20-24.9 kg/m².||,,,,,,
9116,,extra-cns,,,,hedgehog inhibitor therapy,,,,1.|documented diagnosis,at the time of screening|presence,>= 45 ml/minute,,,,,,
9117,,febrile neutropenia prophylaxis,,,,access target aneurysm,,,,g,in the 2 weeks prior to randomization,≥ 50%.|the subject and his/her,,,,,,
9118,,hiv-1,,,,lung transplantation protocol,,,,non-fasting status,in the next 6 months|planned,over 110,,,,,,
9119,,congenital defects,,,,neuroimaging techniques,,,,severe other condition,within 28 days prior to the study vaccination,>18 years.|able to give,,,,,,
9120,,fulminant disease,,,,stent delivery and deployment judged by investigators,,,,inhaled hormones.||.chronic,more than 2 years,criteria - 7 fields cfp)||,,,,,,
9121,,won .|drainage,,,,coronary revascularisation,,,,injection phase,up to 2 weeks before surgery,< 37 0/7,,,,,,
9122,,"intracerebral haemorrhage,|chronic",,,,laser trabeculectomy,,,,chronic analgesics,within 2 weeks prior to screening visit,3 to 18).|diagnosed,,,,,,
9123,,internal organs disease,,,,cognitive function.|chemotherapy,,,,failed in standard treatment,within 12 months to the last therapy,< 5 years.||secondary,,,,,,
9124,,.|juvenile dermatomyositis patients.||,,,,exploration surgery,,,,study|ongoing,within 4 weeks prior to initial administration,z-score).||population,,,,,,
9125,,head skin infection,,,,allergan aesthetics,,,,interferes with daily functioning|history of,within 6 weeks of the 1st dose of ft538.|presence,≥35-39 kg/m2,,,,,,
9126,,fractures|pathological fractures|other fractures,,,,asians,,,,meets the criteria for being measurable,at least 3 months.||,18 years or,,,,,,
9127,,functional speech,,,,functional mobility screen (fms),,,,liver involvement|creatinine,within 14 days prior to intervention.|participation,<3 years|planned daily nsaid,,,,,,
9128,,meningeal metastases:|have hypertension,,,,"verbal consent,||",,,,assessment.|other urgent,appropriate dose of (ssri),between 60-75 years,,,,,,
9129,,cranial epidural disease,,,,small molecule vegfr-tki,,,,cit)|age,within the 30 days preceding,≤5.0-fold the uln of the study site,,,,,,
9130,,general comorbidities,,,,kafo,,,,chronic kidney disease epidemiology collaboration (ckd-epi,within 12 weeks before,before registration:||potassium|magnesium|total calcium,,,,,,
9131,,aids-defining opportunistic illness,,,,ivf programme||,,,,related to dry eye syndrome|those,since january 1,264μmol/l,,,,,,
9132,,chemotherapies,,,,immunohistochemistry after biopsy,,,,interfere with participation|prominent initial non-speech-language impairments,within 28 days before the start of the study treatment;|long-term,> 1.6).|contraindication,,,,,,
9133,,left ventricular dysfunction,,,,scmi,,,,potentially-resectable lung nodule,"at time of treatment decision),|patients",<50 ml/min|significant,,,,,,
9134,,prescence,,,,shoulder arthroscopy,,,,in terms of population||pregnant,in past 2 years.|has,child,,,,,,
9135,,injectable lesions,,,,acr 2016 criteria|between,,,,one level disc prolapse.|≥,within 48 hr prior to dosing;|donated blood,≥28 kg/m2|hba1c,,,,,,
9136,,skin ulcer,,,,university,,,,second-line|presence,within 24 hours after the onset of stroke,≥9.0 g/dl,,,,,,
9137,,myeloablative conditioning.|persons,,,,local health authority.|history of active tb (,,,,moderate to vigorous physical activity/week.||,prior to surgery 14,greater than or equal to 18 years|suspicion of an operable,,,,,,
9138,,gi illness,,,,pelvic ultrasound,,,,acceptable method(s,at the study site)|previous enrolment,> 12 weeks;|written informed consent obtained before,,,,,,
9139,,criteria below:||blood routine examination criteria shall meet:||(no blood transfusion,,,,pivc,,,,hbsc,within the 3 months prior to the first vaccination,> 20)|mri,,,,,,
9140,,joint.|inadequately controlled pain,,,,bilateral oophorectomy/salpingo-oophorectomy,,,,preclude retraction of soft tissues for photos.|subjects who are in a fixed appliance,within 12 months of screening.|use,14 u/week,,,,,,
9141,,postpartum hemorrhage.|anemia,,,,local cns therapy|previously treated,,,,low dose of acetylsalicylic acid||other protocol-defined inclusion/exclusion may apply,at least 3 months of,less than or equal to 5 times the upper limit of normal.|patients must,,,,,,
9142,,precludes,,,,open hepatectomy,,,,refusing antibioprophylaxis,in the last month|patients,under 28 weeks|known,,,,,,
9143,,lower extremity fragility fracture|an,,,,inotropic/adrenergic support,,,,anticoagulant therapies.||severe,within 14 days prior to the first dose of study drug,≥ 8h & midpoint ≤ 2:30,,,,,,
9144,,obstruction,,,,hcc|hepatic surgery,,,,cruciate ligament tear,within the last 3 months|presence,> 75% of predicted,,,,,,
9145,,basic diseases,,,,mri scans,,,,upper limb impairment||,within the last four weeks or less than wash out period of the chemotherapy agents,18 to 65 thus,,,,,,
9146,,third gender,,,,graft-versus-host disease.|history of any of the following cardiovascular diseases,,,,non-hispanic black,at time of stroke,<500/mm3,,,,,,
9147,,cystectomy,,,,allogeneic hematopoietic stem cell transplantation||abnormal laboratory parameters listed below:||serum phosphate,,,,low dose prednisone,in the past 12 weeks.|drug abuse,>30|sperm,,,,,,
9148,,vascular abnormality,,,,mri scan.|biopsy,,,,smoking-related,at the time of signing informed,18 to 35,,,,,,
9149,,nyha)|cardiac,,,,medical monitor approval|history of any one of the following cardiovascular conditions,,,,conditions.|for,at screening;|with the classification of kdigo,≥20 but <90 ml/min/1.73m^2,,,,,,
9150,,completing the protocol,,,,therapeutic puncture);|infection,,,,grade iii or iv cardiac insufficiency,prior to the insertion procedure||,less than 16 years,,,,,,
9151,,child recorded,,,,adrenal replacement steroid doses,,,,interfere with fine motor functions,within 6 months prior to initiation of investigational procedure,between 36.4 °c and 38 °c,,,,,,
9152,,rubberdam,,,,neurological physical examination national institute of health stroke scale,,,,intracardiac electrograms||,hazardous,<5 years 6 months|resident,,,,,,
9153,,t1dm,,,,complete quality of life questionnaires,,,,version 2.2020,last onset of ischemic stroke,iii-iv.|detect,,,,,,
9154,,tractional retinal detachment|intraocular foreign,,,,amblyopia)|major surgery planned,,,,dx lead,within 30 days of the first dose administration.|regular use of,>= 50 ml/min per cockcroft-gault equation,,,,,,
9155,,seasonal allergies,,,,repair of two different types of hernia they can,,,,mid-common bile duct cca,during icu treatment,≥ 90%,,,,,,
9156,,t4 tumors,,,,laparoscopic hysterectomy,,,,non-biological parent,preceding 3 months|currently participating,between 18 years and 65 years,,,,,,
9157,,metal fragments,,,,120 mg of caffeine,,,,non-relative,within 28 days of first dose of ip(s).|concurrent chronic medical condition,≥350/μl,,,,,,
9158,,hypovolemia|patients,,,,ionotropic support,,,,non-pregnant,within 7 days of an experimental session,18-50 years.|willing,,,,,,
9159,,recreational drugs.|treatment,,,,gynecological examination||,,,,progressive,within 28 days prior to start of study drug,> 3mg/l,,,,,,
9160,,liver dysfunction|contraindication,,,,articular capsule|exposed blood,,,,pd-l1 status,in the past 3 years;|5,>37.5°c,,,,,,
9161,,disease states:||dumping syndrome,,,,indirect ophthalmoscopy,,,,unprovoked,symptoms);|has been,> 10|patients,,,,,,
9162,,incessant pericarditis,,,,fsrs,,,,acute increase in blood pressure (bp),within 7 days before first study treatment dose):,does not exceed 60 years,,,,,,
9163,,abnormal placentation.|patients,,,,abdominal procedure,,,,brachytherapy,in the last greater than >1 to less than <6 months,more than 12,,,,,,
9164,,leg ulcers,,,,prior stem cell transplant|participation in other studies,,,,cmam guidelines,at least 20 hot flushes per week).||patients,between the 1st dose and 30 days after full vaccination.|,,,,,,
9165,,lower respiratory tract infection,,,,inoculation on,,,,peri-appendicular,in the past 60 days for,12-13,,,,,,
9166,,lgs,,,,medicine emergency departments,,,,lv-free wall,for 4 weeks prior to the baseline,less than 4 weeks prior to study drug administration,,,,,,
9167,,coronary diseases,,,,lateral radiographs|femoral anteversion,,,,carbon monoxide (eco),within 3 years.||,score of 17 or higher,,,,,,
9168,,tactile sensitivity first,,,,hormone treatment,,,,asthmatic,within the range +4.00 to -9.00 ds,>100 or <40 beats per minute.|positive,,,,,,
9169,,arrhythmia;|significant cardiac insufficiency,,,,rats,,,,non-target lesion,for at least 6 months.|be,>3%,,,,,,
9170,,electrolyte metabolism imbalance,,,,extramuscular activity assessment derived from mdaat,,,,before renal puncture;|participated,within 30 days after the first dose,i-iv:||withdrawal,,,,,,
9171,,"teeth in each jaw quadrant,|plaque index",,,,autologous car-t cell therapy.|part 2 (dose expansion):||a. histologically,,,,l2-l3,within the last 3 years||significant,>7.5 mg/d,,,,,,
9172,,systemic disease|<18,,,,occlusion|cardiac surgery,,,,labral,in the past 5 years.||member,from 18 to 60 years,,,,,,
9173,,superficial bladder cancer.|prostate cancer,,,,continuous oxygen therapy,,,,left main coronary artery,at least 2 weeks prior to study drug,between 20 and 35 kg/m2|currently,,,,,,
9174,,disease|neurological disease,,,,spiral ct reports,,,,coronary arteries,in the icu,less than 35 umol/l.||,,,,,,
9175,,superficial masses||,,,,discontinuation of the antiplatelet,,,,screening.|relapsed,for at least 30 days,0-2|at least,,,,,,
9176,,instrumental activity,,,,hematopoietic stimulators,,,,suitable for surgery;|gastrointestinal disease,within 6 hours or less,< 0.8 × 10^9,,,,,,
9177,,cervicovaginal specimens,,,,shortness of breath / respiratory,,,,constraints,within 90 days prior to trial medication,≥ 430,,,,,,
9178,,congenital heart diseases,,,,caloric stimuli,,,,non-valvular atrial fibrillation|at,in less than 1 month ago.|pregnant,fructose intolerance|pre-existing,,,,,,
9179,,systemic therapy.|females of,,,,total hip artroplasty surgery,,,,in any of the teeth,during or after the last line of therapy|measurable disease evaluable,≥ 10 g / dl,,,,,,
9180,,degenerative,,,,nasal surgery,,,,"breast-feeding,|women",within past six month,18.5-30 kg/m2|be able to understand the instructions,,,,,,
9181,,fungal infection of the treatment areas|the,,,,test-oxford grading|tear secretion test,,,,nasolacrimal system|presence,in the 30 days prior,> or equal to 30 ml/kg min||,,,,,,
9182,,treatment)|medical condition,,,,regimens.||uncontrolled intercurrent illness,,,,suitable for this study,at the time of informed consent): 20 years,between 18 and 32 kg/m2.||,,,,,,
9183,,extraction socket,,,,screening.||-,,,,worsen,within 7 days before administration of investigational product,permissive,,,,,,
9184,,pre-diabetic,,,,target blood pressure,,,,non-steroid anti-inflammatory drugs,during the 4 weeks prior to admission into the study,<60ml/min/1.73m2|those,,,,,,
9185,,complete tumor resection,,,,complete resection,,,,largest diameter of lateral,in the last 6 months;|subjects willing to provide signed informed consent for participation in clinical investigation.||,>24 points;|has signed an informed consent to the study.||,,,,,,
9186,,malnutrition,,,,volume depletion,,,,pancreatitis;|pre-existing,at least 1 week apart.||cardiac safety||history of,less than or equal to 2.5mg/dl,,,,,,
9187,,organ transplantation;|concomitant conditions,,,,herniotomy - which,,,,injection site,during the study.|history,≥ 18 years)|ability to provide,,,,,,
9188,,postpartum complications.|normal,,,,hydrogen peroxide or hypochlorite solutions|patients,,,,sexual transmitted,predominantly,older than 20,,,,,,
9189,,or|spanish speaking||,,,,donation,,,,menstrual period;|presence,in the treatment areas,≥1.0 ng/dl.|age,,,,,,
9190,,large vessels,,,,jzp441 clinical study|positive alcohol test,,,,hamd scale|be conscious,in the 24 hour period prior to testing,> 1.5 times the upper limit of normal creatinine,,,,,,
9191,,fungal infections,,,,anticoagulation therapy,,,,epistaxis,medical diagnosis,30-40 kg/m2|prediabetes,,,,,,
9192,,previous injury,,,,fms-related pain|study,,,,whereas,for 6 months prior to transplant,greater than 1500 g,,,,,,
9193,,lesion.|hiv-infected,,,,echo).||pregnant,,,,microbiological methods)|（3）babies,at the start of ip administration prior to dosing).||subject,maximum 17 years,,,,,,
9194,,rrms,,,,chest radiography.|be,,,,caries,within six months prior to study entry,> 5 miu/l|renal disease,,,,,,
9195,,actionable genomic alteration,,,,sleep||,,,,ilioinguinal,at least once|have capacity,ii or more,,,,,,
9196,,chronic congestive heart failure,,,,lymphoma;|3,,,,high-grade,"within 2 months before administration,|subject/patient",younger than 16 years,,,,,,
9197,,colorectal an|available treatment data||,,,,fresh tissue biopsy,,,,glucocorticoids stable,within 14 days prior to the first dose of study treatment,≥2.5 x uln.|total bilirubin,,,,,,
9198,,"localized prostate cancer,|continuing post-operative",,,,age≥18years|optimal medical therapy,,,,highly-effective method of contraception.|signed written informed consent,between january 1 2017 and october 31 2021|evidence,below 18,,,,,,
9199,,"periodontal surgical procedures,|pregnancy",,,,migraine screen questionnaire||,,,,non-enteric,within the last 6 months||,< 5 uln,,,,,,
9200,,relapse treatment,,,,tobacco smoking.|poor,,,,vegan,within 30 days of screening.|presence of typical covid-19 symptoms,greater than 5%,,,,,,
9201,,vascular complications,,,,tigit,,,,any form of,at the time of visit 1.|clinical history of asthma,≥ 18years||hospitalization,,,,,,
9202,,behavioral disorder,,,,bile duct cancer)|ecog performance score,,,,large-volume paracentesis|the use,last onset time of tia,"i, ii and iii",,,,,,
9203,,external).|molars,,,,mini mental test (mmt) score,,,,etc.)|pregnant,in the last 6 months|patient,18-75 years.|biopsy,,,,,,
9204,,reflux esophagitis,,,,subsequent treatment cessation,,,,non-gcb dlbcl,at least 2 measures.|documented diagnosis,above 40,,,,,,
9205,,forehead,,,,transfusion of blood,,,,grade two or more,within 2 years after cell reinfusion,lower than 35%)|presence,,,,,,
9206,,passive si,,,,chest trauma,,,,adequate dose of benzodiazepines (1st line agents,in the last 6 months 3,≥60% vi,,,,,,
9207,,primary lsg||,,,,cardiac resynchronization therapy (crt)|foreseable violation,,,,irinotecan after progression from,within 3 months after the last dose of study drug.|life expectancy,5 - unassisted,,,,,,
9208,,metastasis.|toxic reaction,,,,"nerve injury,|active",,,,computer/tablet,during the trial period and 8 weeks after the last dose;|the subjects voluntarily joined the study,≥5 cm below the left costal margin,,,,,,
9209,,metabolic illness,,,,allergen desensitization therapy,,,,renal,prescribed before the end of the physiotherapy,< 1,,,,,,
9210,,local anorectal problems,,,,lower limb|revascularization procedure,,,,older;|permanent,at the time of diagnosis.|treatment,< 10g/dl,,,,,,
9211,,long qt syndrome).|venous access,,,,multiple organ failure,,,,central nervous system (cns) tumours,72 hours after the patient received the high-dose,3-month follow,,,,,,
9212,,problems|mental disorders|metabolic disorders,,,,cervical arthrodesis,,,,under juridic protection,for at least 2 weeks prior to initiation of randomized treatment.|significant,<18 kg/m2,,,,,,
9213,,disease affecting immune system function,,,,fresh pathological tissues,,,,non measurable refraction,within 4 weeks before the first dose of the new crown vaccine,more than 3 months.|eligible,,,,,,
9214,,structural bone abnormalities,,,,stool consistency,,,,index episode,during screening prior to study entry,<40 (kg/m2).|all,,,,,,
9215,,abdominal skin,,,,computed tomography (ct) scan,,,,shoulder region|patients,between the time of consent through day 28,> 3×uln.|if female,,,,,,
9216,,imnm,,,,hsct,,,,carbon monoxide,at screening and day 1.|participant,greater than 12,,,,,,
9217,,solid organ,,,,cardiac implant,,,,hiv-1-infection|participant,within 3 months before baseline,>= 18 years old,,,,,,
9218,,thymic carcinoma,,,,tumour involving the nasal vestibule,,,,excluded,past 6 months.|cardiac,18 and 45);|weigh,,,,,,
9219,,odontogenic abscess,,,,venous blood flow,,,,positive).||,more than 5 years,i to,,,,,,
9220,,chronic fatigue syndrome,,,,computed tomography angiography (cta),,,,stage iib,within the last 2 weeks prior to receiving the first dose of investigational treatment,less than 2 months;|unstable,,,,,,
9221,,poultry)|active joint infection,,,,regular exercise programme,,,,non-endometrioid,prior to study participation.|history,0 to 2.|predicted,,,,,,
9222,,vaginal rings,,,,anatomical irregularities,,,,m1 segment of,after 8 weeks,≥ 3|history,,,,,,
9223,,comorbid conditions,,,,donation of blood/plasma,,,,clinically-indicated,within 24 weeks prior to the date informed consent,</= 2 times the upper limit of normal,,,,,,
9224,,tetraplegia|intensive care neuromyopathy|ocular,,,,pet-ct indicates positive).|at least,,,,alter the impact of exercise on tumor outcomes,within 14 days of registration.|participants,≥8.0 g/dl,,,,,,
9225,,vertebral body fracture,,,,sternotomy wires stents,,,,requiring temporary external fixation,over the past two months;|currently pregnant,<28,,,,,,
9226,,high risk arrhythmias,,,,effective contraceptive measures,,,,coordinated,in the first two months of randomization|the,nonpregnant,,,,,,
9227,,urinary cancer,,,,cardiac transplant,,,,engaging,data two months before enrolement,/or refusal,,,,,,
9228,,adenoma,,,,corrective surgery,,,,epstein-barr virus,within 4 weeks before first dose;|patients,between 20yrs-40yrs|tenderness,,,,,,
9229,,nutritional disorders,,,,chest x-ray;|systolic blood pressure<90,,,,on room air|hemodynamic stability,after pre-dilating,1pre-existing,,,,,,
9230,,clinically isolated syndrome (,,,,laparoscopic ovariectomy,,,,with negative egfr,in at least one,≥95 cm,,,,,,
9231,,bleeding.|hemolytic disorder,,,,skin tests,,,,tablets,for less than 12 months,>900 pg/ml,,,,,,
9232,,giant coronary,,,,b cell-depleting biological agents,,,,connective tissue disease(s),for at least 12 weeks.|no clinical treatment for neck pain,greater than 4.5 cm,,,,,,
9233,,mass lesion,,,,frontline therapy,,,,plantar wart,within 30 days prior to randomisation,at - least 5 mm,,,,,,
9234,,facing,,,,age|prior,,,,imp|concurrent,within 30 days;|patients,=< 1.5 mg/dl.|ability,,,,,,
9235,,cerebrovascular disease||-,,,,thoracoscopic vertebral body,,,,ultimaster nagomi stent||complex procedure inclusion criteria||subject,at least 15 or more days in the past 30 days,18-65 years)|fluent,,,,,,
9236,,reproductive plan,,,,"vaginal delivery,|normal vaginal delivery,|emergency caesarean section,|preterm pre labour rupture",,,,nomads,within 6 months;|severe cardiopulmonary,≥ 60 ml/minute||exclusion,,,,,,
9237,,thyroid carcinoma,,,,transcranial magnetic stimulation,,,,acceptable form of,within the last month before screening,"≥ 50,000/",,,,,,
9238,,unresectable solid tumor|prior standard therapy,,,,chest radiotherapy before|bacteria,,,,depth,throughout the trial.|concomitant diseases,<1000 copies/ml,,,,,,
9239,,use|head trauma,,,,radical resection,,,,highly effective contraception1,for more than 1 week,≥ 6.5%|triaged out,,,,,,
9240,,night|chronic nasal obstruction,,,,transfusion of blood products,,,,diagnostic and statistical manual of mental disorder 5th edition(dsm-5,in the last 3 years,≥65 years|self-reporting,,,,,,
9241,,electrocardiographic,,,,orthodontic treatment||,,,,could,during the last 6 months|known,23-64)||,,,,,,
9242,,bronchial brush specimen,,,,3rd trimester.|pregnant ladies,,,,multiple territories.|known history,within 30 days of visit 1,> 35 kg/m2|whole blood donation of 1 pint,,,,,,
9243,,cyp4a6,,,,computerized tomography,,,,reflected by the patients' choice|are,up to 28 days of life.|clinical signs,>250 u/l,,,,,,
9244,,dying.|patients,,,,gh therapy,,,,ilae 2017 criteria|children,prior to study blood draw||inclusion criteria,between 6 and 12 years||,,,,,,
9245,,low back,,,,first trimetric,,,,rome iv criteria||participant or their legally authorized representative has the ability to provide informed consent,up to 6 weeks after,≥ 80 ml/min/1.73m2,,,,,,
9246,,n- acetylglucosamine-6-sulfatase gns,,,,assessment blood consumption (abc),,,,highly effective contraceptive,in past month needing weight management,at least 18 years,,,,,,
9247,,congenital cardiopathy,,,,dutch speaker|singleton pregnancy,,,,pre-operative:||o demographic data||gender|age at surgery|height/weight|indication,within 3 months after the last study administration.|8,>= 21 years,,,,,,
9248,,relatives,,,,conventional restorative procedures.|good oral hygiene,,,,"diagnostic and statistical manual of mental disorders, fifth edition",before the screening,18 years to 75 years;|ecog physical score 0-2 points,,,,,,
9249,,associated hypertriglyceridemia,,,,hematopoietic system,,,,diffused,in screening period,< 2.0 g/day,,,,,,
9250,,multistick,,,,baseline ccta visit,,,,corticosteroid replacement,in the previous 12 weeks|known,>level 1,,,,,,
9251,,abstain from any sexual activity that could result in pregnancy,,,,verification,,,,cns-specific treatment,at enrollment and after. note: bridging therapies,<75 years,,,,,,
9252,,egfr-sensitive mutation,,,,emergency surgery.|known,,,,"icd-10 f10.x, f11.x).|dementia",within the past year|speak english,> 25,,,,,,
9253,,ibd symptoms,,,,previous surgery,,,,youth friendship bench,within past 7 days musculoskeletal,< 3rd percentile,,,,,,
9254,,small bowel obstruction,,,,advance cardiac life,,,,light smoker,for more than 3 months fev1/fvc,between measurements.||if the subject meets,,,,,,
9255,,cardiovascular diseases.||exclusion,,,,videofluoroscopy,,,,stage iii disease should,for at least 3 last months|albuminuria >35 mg/day,≥1.5xuln,,,,,,
9256,,combined malignancy,,,,those enrolled,,,,self-report||for healthy,within 6 months prior to starting study treatment|clinically significant,do not exceed or equal the values,,,,,,
9257,,intraepithelial cervical,,,,walk unaided.|unable,,,,upper half of the specified range of use of the cuff,within the last 2 months|other,22-80 years,,,,,,
9258,,malformation,,,,peritoneal carcinomatosis;|age≥18;|ecog≤1;|patient,,,,aims 1 + 2):||patient,prior to the debulking surgery,">= 1,500/mm^3",,,,,,
9259,,increased risk of thrombosis,,,,clinical laboratory evaluations,,,,dutch|very mild heart defects,last 5 years iv,between 58%-82%,,,,,,
9260,,infectious rhinitis,,,,cardiac index assessment using bioreactance|impossibility,,,,low-density lipoprotein cholesterol,for at least 6 months|no,< 470 ms.|known,,,,,,
9261,,renal impairment|patients,,,,regular electronic reporting|inclusion,,,,severity ≤ 3,at the time of enrollment.||4,>50 mmhg,,,,,,
9262,,anal canal cancers,,,,standard chemotherapy,,,,de-escalation phase,within 90 days|myocardial infarction,greater than 2;|language,,,,,,
9263,,rales,,,,allogeneic organ transplant|participants,,,,non-hospitalised,at the time of progression||participants can have received up to 3 months of,>10 mg).|already,,,,,,
9264,,fallopian tube cancer/primary,,,,open midline incision|presence of,,,,exocrine,prior to 16 weeks,>10 packyears,,,,,,
9265,,immunocompromised state,,,,perfusion mri,,,,fractured neck of femurs,within 3 months before screening.|within 12 weeks before administration,18.5 to 24.9 kg/m2).||,,,,,,
9266,,equally matched,,,,mini-international neuropsychiatric interview for,,,,above|stable,prior to institutionalization,<150,,,,,,
9267,,heart rate|phosphodiesterase type 5,,,,extensive tattoos,,,,critical upper,at the time of study screening.|unable to tolerate enteral,0-3;|histologically,,,,,,
9268,,cardiac abnormalities,,,,reinsertion of catheter,,,,interfere with cooperation with the requirements of the trial.|is pregnant,in the past 3 months;|5,0 to 1|participant,,,,,,
9269,,chronic heart,,,,"gastric cardia,|biopsies",,,,non-invasive tests,at least 30 days after dosing,≥ 18|diagnosis of,,,,,,
9270,,heart disease.|have,,,,conventional imaging (ct/mri,,,,highly communicable diseases.|those,within 1 month prior to inclusion.|index event,>= 50 ml/min/1.73m^2,,,,,,
9271,,sexual activity,,,,pathological test,,,,de novo mbc,at least 1-year,<40%.|history of pericarditis.|previous stroke.|presence,,,,,,
9272,,gi conditions,,,,ics therapy,,,,non-autonomous,during study phase.|currently,greater than 3000 iu/day;|therapy,,,,,,
9273,,sperm from the date of administration of the first investigational drug,,,,ovarian stimulation,,,,poorly visualized,at least 1 month before the first dose of study drug,14-17 years old|bmi z score,,,,,,
9274,,hyper-thyroid,,,,cmml).|prior treatment,,,,middle of the night to check,within 48 hours prior to randomization,<1000/mm3.||other,,,,,,
9275,,guillain-barre,,,,functional dental implant,,,,below zero station||,before operation|used nephrotoxic drugs,18-75 years;|prediabetes;|body mass index,,,,,,
9276,,exon 2,,,,leading edge of prolapse,,,,mrecist v1.1)|received,preceding 12 months,<90 days of the baseline visit.|subjects currently participating,,,,,,
9277,,self-injurious behavior.|epilepsy,,,,β-blocker,,,,implantable,within the radiocarpal joint,≥ 18 years|current length of intensive care stay,,,,,,
9278,,bone ends).||,,,,immunosuppressant treatments,,,,article l. 1121-8;|persons admitted to a social,after existing,score of 0 to 2.|subjects,,,,,,
9279,,her2-neg breast adenocarcinoma,,,,gastric stimulator,,,,first-line treatment.|tumor tissue samples are,at least within 24 hours of symptom onset,0-2|english proficient|if,,,,,,
9280,,active eye disease,,,,cylinder,,,,effective methods of birth control beginning,within 3 months before initiating first-line itp therapy,single,,,,,,
9281,,major psychiatric diseases,,,,alternative experimental therapy,,,,expensive,at least 6 months prior the inclusion in this trial.||,>10 cm,,,,,,
9282,,visit|significant unstable comorbidities,,,,endometrial cancer|indication,,,,cpi-naive)|measurable disease,within 24h before the first dose of study,≥ 100 × 10^9,,,,,,
9283,,substantial disrepair,,,,ai therapy,,,,low dose corticosteroids;|previous,within 72 hours of head injury|meet criteria,> 80 % of that predicted for,,,,,,
9284,,co-occurring kit,,,,emergency colostomy,,,,non-hodgkin,period of time after surgery|patients,two units of plasma,,,,,,
9285,,https://www.cdc.gov/vaccines/vpd/mening/public/dis-cochlear-faq-gen.html|motivated,,,,axillary surgery,,,,stent,within 2 years prior to enrollment,> 100 mmhg).|previous,,,,,,
9286,,combined diseases,,,,12-lead safety ecg,,,,related to mm,within 3 months;|the baseline,=20 years,,,,,,
9287,,these diseases,,,,knee surgery,,,,non-transient,within 3 days prior to the first vaccination,75 and over|patients receiving,,,,,,
9288,,valvular heart disease.|history,,,,directional coronary atherectomy,,,,umn,administered 14 days prior to initiation,=<1.5 x upper limit of normal,,,,,,
9289,,ischemia related to af|an investigational drug used,,,,fmri,,,,on steroids|patients,within the past 6 months|a,>= 1.2 upper limit of normal [uln,,,,,,
9290,,hypertrophic obstruction,,,,sabr,,,,horizontally,within 48 h prior to the first dose of investigational,<60,,,,,,
9291,,wounds,,,,intra-articular reasons,,,,wolff-parkinson-,within 42 days before randomization.|stable disease,< 0.3 ml/min,,,,,,
9292,,medically free,,,,total blood volume,,,,evidence-,prior to registration||exclusion criteria||patients must,>18 years|>1,,,,,,
9293,,bleeding tendency(hemophilia)|receiving,,,,cardiopulmonary rehabilitation unit for physiotherapy applications,,,,voluntary,for at least 90 days after surgery with intratumor virus,> 40kg/m2|allergies,,,,,,
9294,,mild covid-19,,,,resected basal cell,,,,non-emergent,before initiation of investigational medicinal product,< 3 times the upper limit of normal (uln),,,,,,
9295,,gastric ulcers,,,,13c-ubt,,,,sulfites.|normal,prior to participation in the study.|clinically suspected,>21 seconds and <180 seconds.||,,,,,,
9296,,fluorescence in situ hybridization +,,,,treatment of,,,,metabolic altering,in the last 1 year|having a,140-199 mg/dl,,,,,,
9297,,development.|suspicion of malignancy,,,,diary documentation of,,,,brain,within 14 days of inpatient admission,not more than 90,,,,,,
9298,,malignant neoplasms.|decompensation,,,,knee anterior,,,,arch|pre-existing,within 1 week before the first dose,0-max,,,,,,
9299,,upper gastrointestinal,,,,qualifying surgical procedure,,,,ocular surface are found,in the last 6 months.|use,7 to ≤21,,,,,,
9300,,cowden's syndrome,,,,small-molecule kinase inhibitor has been accepted,,,,screening.|clinically stable,within 3 months prior to screening;|intake,early learning composite|severe,,,,,,
9301,,malignant tumors|2,,,,antipsychotic treatment,,,,type iii hypersensitivity reactions,within 28 days before the start of the study,equal or over 18 years,,,,,,
9302,,carpus,,,,kidney transplant center,,,,devices sensitive,during treatment,50- 60 years|presence of oa of the knee,,,,,,
9303,,change diet|diagnosed seizure disorder,,,,depression screening result,,,,biphosphonates|local,within the past 8 weeks before screening;|take weak/moderate,20-40 years.|patients free,,,,,,
9304,,destruction,,,,vaccine,,,,"""",within 7 days prior to index procedure,≤ 1.5 x uln|total,,,,,,
9305,,systolic pressure≥160 mmhg,,,,lumbar foraminal stenosis|lumbar central stenosis|lumbar disc herniation|lumbar spondylolisthesis||,,,,primary treating physician,at the time of cag.|among,score <24)|active cancer,,,,,,
9306,,female;|centrally obese,,,,emergency surgery cardiovascular,,,,between the ages of 40-65 years|cooperative,at time of injury,≥ 55 kg;|the subject,,,,,,
9307,,manic or depressive,,,,sitting diastolic blood pressure,,,,occlusal stabilization,more than 24 hours,16-65 years,,,,,,
9308,,neuroendocrine carcinoma).|metastatic nodule,,,,surgery|curative resection|minimally invasive,,,,blood-brain barrier compromise|previous,within 6 months of first study drug,> 18.5 and < 35 kg/m2,,,,,,
9309,,facial palsy|localized oral lesion,,,,antiarrhythmic treatment,,,,narrow therapeutic window,at least 1 day out of the previous 30||,≥ 100 x 109/l|hemoglobin,,,,,,
9310,,herpes infection,,,,security system||for control group (,,,,,within 1 year of tbi,>= 50 ml/min per 24 hour urine test,,,,,,
9311,,study|diabetes|fibromyalgia|peripheral neuropathy,,,,nct nct04297683).||,,,,,more than 5,1）18-65 years,,,,,,
9312,,teratogenicity,,,,psychotropic pharmacologic treatment,,,,,after venipuncture,< 10mm,,,,,,
9313,,renal pathological types,,,,hours|multi organ transplant,,,,,within 28 days of dosing|other,illness|underweight|more than 16 years,,,,,,
9314,,syncopal attacks,,,,vertebral artery dissection|signs,,,,,at least 2 prior regimens,class iii to iv,,,,,,
9315,,unspecified type,,,,occipital neuralgia,,,,,during the screening period|leptomeningeal disease.|symptomatic brain metastasis.|presence,<= 38.0.||current,,,,,,
9316,,psychiatric conditions,,,,esophagogastroduodenoscopy,,,,,within 6 months before the first dose of study treatment,">1,500/",,,,,,
9317,,periodontal condition,,,,botulin toxin injection,,,,,during the meetings||,≥ 30 mg/kg2,,,,,,
9318,,hyperactive/impulsive,,,,spinal stenosis.|history,,,,,during the study period.|individuals,25.0 to <34.9 kg/m2,,,,,,
9319,,acute exacerbation of copd|copd,,,,instruction for use,,,,,in the next 1 months|patients,> 100/ul,,,,,,
9320,,different foot types,,,,blood pressure||,,,,,treatment ≤ 3 months.|no,probable,,,,,,
9321,,cycles fails,,,,proportion of days covered (pdc),,,,,within 30 days of the baseline visit|presence of any condition,score 0 or 1||adult,,,,,,
9322,,sensitivity/allergic,,,,urine microscopy,,,,,< 6 months,or 3.0 mg/dl,,,,,,
9323,,progressive lesions,,,,transthoracic echocardiogram,,,,,within 30 days|severe pulmonary,greater than or equal to 95% adherence,,,,,,
9324,,thyroid organ pathologies,,,,tirbanibulin treatment,,,,,within 24 hours until start of study intervention,≥ 18 years||diagnosis,,,,,,
9325,,newborns||,,,,orthodontic treatment|regular consumption of alcohol,,,,,except for myopia.|provision of consent,multiple endocrine,,,,,,
9326,,allergic skin rash,,,,meniscal repair|simultaneous meniscectomy,,,,,within 2 weeks of their screening visit.|at baseline,> 60%,,,,,,
9327,,high-risk prostate cancer,,,,axillary lymph node dissection,,,,,in last 30 days,1 or 2|the,,,,,,
9328,,γ-1 pemphigoid|patients,,,,coagulation treatment,,,,,within 4 weeks prior enrollment into the study;|known,"< 50,000/ul",,,,,,
9329,,parenthood,,,,vision rehabilitation,,,,,before the 34th week of pregnancy|birth weight,<600 cells/mm^3,,,,,,
9330,,brain function disorders,,,,ehr release to facilitate record abstraction|report,,,,,within 30 days before surgery,grade iii,,,,,,
9331,,acute psychosis,,,,sle background medications,,,,,past medical history,3 - equal to or above,,,,,,
9332,,distant metastases,,,,tobacco industry,,,,,within 2 weeks prior to study,20-30kg/m2,,,,,,
9333,,prodromal symptoms,,,,platelet infusion,,,,,prior to any examination,>3 mm,,,,,,
9334,,c|other disease related to fatty liver,,,,incisional eye surgery,,,,,within the past 2 years|history,between 11+0 and 13+6 weeks,,,,,,
9335,,spots from lens flares,,,,b-cell nhl treated,,,,,within the previous six month|participant,< 7 mm,,,,,,
9336,,autoimmune disease.|insufficient,,,,transrectal ultrasound,,,,,through 12 months after the last dose of siltuximab|subjects,25-35 fractions)|v40,,,,,,
9337,,needle puncture,,,,dose reductions,,,,,at least two weeks prior to screening,>/= 3,,,,,,
9338,,lung nodules,,,,tki treatment,,,,,within the range of 25 - 45 kg/m2,<150.0 x109/l albuminemia,,,,,,
9339,,adenomatous colonic polyps,,,,two-dimensional,,,,,throughout the duration of the study.|received,> 100/nl|total bilirubin,,,,,,
9340,,traumatic brain injury|a medical condition,,,,salvage radiation therapy,,,,,after the first dose of vaccine;|serious adverse reactions related to the first dose of vaccine;|the investigator will decide whether to continue to participate in the study,65-79 years,,,,,,
9341,,infertile,,,,graft,,,,,before baseline|living in nursing home,lower than 90 or,,,,,,
9342,,stromal loss,,,,first therapy,,,,,within the previous 28 days|confirmed severe,older than 70 years,,,,,,
9343,,secondary hypertension,,,,monofilament examination,,,,,within 3 months after administration of ip||a,2 or better,,,,,,
9344,,severe respiratory disease,,,,gastrointestinal emptying,,,,,etc.)|significant history,score ≥ 12,,,,,,
9345,,type 1 dm,,,,therapeutic agents,,,,,in the past month|will be residing,< 2 / karnofsky performance status (kps),,,,,,
9346,,psychotic disorders,,,,inoculation,,,,,in the 4 weeks prior to visit 1.|experienced,≤ 15 ng/ml|diagnosis of,,,,,,
9347,,spontaneously reduced twin pregnancy,,,,lower blood glucose|taking,,,,,7 days prior to the baseline visit until the week 4 visit,"greater than 75,000/mm3|hemoglobin",,,,,,
9348,,utah health plans).||,,,,computed tomography (ct) scan).|participants should,,,,,at the time of randomization;|obvious,≤ 1.5||male,,,,,,
9349,,substance abuse.|a participant,,,,skeletal radiography,,,,,greater than 6 months.||if,18 and 65,,,,,,
9350,,clinical conditions,,,,exercise ecg,,,,,within 4 weeks from last study visit,> 30 ml/ min / 1.73,,,,,,
9351,,amytrophic lateral sclerosis,,,,assessment tests|having one of the following chd conditions,,,,,within 42 days prior to sub-study,greater than 26,,,,,,
9352,,mitral transcatheter valve surgery before,,,,12-month time window,,,,,within the prior 18 months,14-20 g,,,,,,
9353,,mental illness.|asplenia,,,,covid-19 vaccine,,,,,in the last 6 months;|planned,greater than or equal to the median score,,,,,,
9354,,hip fracture surgery,,,,small molecule tyrosine kinase inhibitors.|patients,,,,,less than six months,≤ 75 years|tia,,,,,,
9355,,visible lesions,,,,various cardiac pacemakers,,,,,during the remaining part of the baseline period.|a diagnosis,<80% of,,,,,,
9356,,recruitment)|on,,,,simons,,,,,prior to enrollment|participant,less than 28 days old,,,,,,
9357,,tachycardia,,,,intraocular procedures,,,,,within 2 weeks prior to lymphodepletion chemotherapy,between 12 and < 18 years,,,,,,
9358,,hypermetric saccades)|palsy,,,,drug chemotherapy,,,,,during last 3 years prior to inclusion,scale|at least 20%,,,,,,
9359,,bone metastasis.|current pregnancy.|formal,,,,dialysis therapy,,,,,within 1 year prior to screening|have,65 years,,,,,,
9360,,tissue pneumonia,,,,thrombolytic therapy,,,,,within 14 days prior to enrollment.|serious infection,more than (>)140 millimeters,,,,,,
9361,,adequate medication|angina pectoris,,,,open head wounds|ventricular shunts|bleeding disorders|known brain,,,,,prior to entry into the study,less than 0.7 fev1,,,,,,
9362,,hyperthyroidism|enrolment,,,,sport program,,,,,at baseline as per the solid,<= 50%,,,,,,
9363,,clinical consideration,,,,renal function analyzed results after randomization,,,,,within the past 6 months.|use,≥ 40%|women,,,,,,
9364,,weeks|inability,,,,ring,,,,,ended from any,40 to 80 years,,,,,,
9365,,digital mobile phones,,,,psychological rehabilitation therapy,,,,,within the last 30 days.|prior,=< 1|histologically confirmed,,,,,,
9366,,tumors around,,,,bone augmentation procedures.||,,,,,within 2 weeks prior to randomization|assessment of all baseline symptoms,≥ 75 × 10^9/l,,,,,,
9367,,grade glioma,,,,ultrasound duplex scanning (usds),,,,,at time of consent|known pik3ca mutations,between 50-100 kg|healthy,,,,,,
9368,,chest infection.|patients,,,,researchers,,,,,within 4 weeks,greater than 30 kg/m2|diabetes,,,,,,
9369,,anxiety symptoms.||,,,,remarks,,,,,within 4 weeks of treatment,≥ 3 months to <11 years,,,,,,
9370,,hypoglycemia|active dementia,,,,therapeutic cardiac operation,,,,,for at least 3 weeks prior to study treatment,after start of,,,,,,
9371,,obvious causes,,,,multigated acquisition scan (muga),,,,,more than 28 days prior to enrolment,less than 30 days before screening.|mental diseases,,,,,,
9372,,18+|ability to read,,,,signatera testing,,,,,prior to screen/baseline|sd-oct central subfield thickness (cst),> 35 iu/l,,,,,,
9373,,psychological condition incompatible with study participation,,,,pulp involvement||exclusion,,,,,within the previous 6 months||ii,≥18 to ≤35 kg/m2,,,,,,
9374,,functional assessments|acute infections,,,,digital imaging,,,,,within 72 days before first dose,≥18 years|6.5%≤hba1c≤11%||clinically,,,,,,
9375,,age|signed parental,,,,global assessment (spga),,,,,after previous palliative chemotherapy,≥ 100 x 109/l.|total,,,,,,
9376,,systemic sclerosis,,,,local label,,,,,during the study period;|known,less than six months)|intra-,,,,,,
9377,,functional class,,,,decompression involving,,,,,within 90 days prior to screening;|history,≥30 ml/min,,,,,,
9378,,solid organ transplant.|those who are currently pregnant,,,,opioid therapy,,,,,within the past 12 months|have,18 or over.|patient,,,,,,
9379,,psychosis.|malignant tumors,,,,normal screening mammogram,,,,,more than 1 year before enrollment,0-2,,,,,,
9380,,cooperative children.|healthy,,,,induction treatment,,,,,6 months after the last dose of liposomal doxorubicin,≤ 2cm|informed consent,,,,,,
9381,,congenital heart defect,,,,first induction therapy,,,,,at least 3 days a week for the last 3 months|no,distant metastatic disease|uncontrolled,,,,,,
9382,,age|understanding,,,,dose-escalation phase,,,,,14 days or less prior to delivery|preterm delivery|scheduled,20% of their ideal body,,,,,,
9383,,kidney disease|coronary artery disease,,,,mdd)|at baseline,,,,,for 30 days after the final dose of giredestrant,> 2.0mg/dl;|9.those,,,,,,
9384,,gebt);|tcm syndrome differentiation,,,,stent surgery patients|angioplasty,,,,,in the last 6 months;|pancreatic injury,basically normal,,,,,,
9385,,including||dlbcl,,,,activities specific balance confidence scale,,,,,at least 2-weeks,< 2.5 mmol / l)|heavy,,,,,,
9386,,predisposing risk factors,,,,seasonal influenza vaccine,,,,,within 12 months；|patients with,18-65|have,,,,,,
9387,,crpc,,,,pelvis mri,,,,,area.|previous history of,≤1.5 × upper limit of normal (uln),,,,,,
9388,,native language of the site with the investigator,,,,muscle biopsy,,,,,in the past year).||,older than,,,,,,
9389,,tb)|significant trauma,,,,transarterial chemotherapy,,,,,within 7 days prior to,≥moderate regurgitation);|age≥18 years,,,,,,
9390,,portal hypertension;|peptic ulcer,,,,risk|high surgical risk,,,,,within the prior 2 weeks,≤ 13|participants must,,,,,,
9391,,concomitant condition,,,,transient ischaemic attack|carotid artery stenosis,,,,,within 14 days prior to the first dose of the investigational product,≥ 30 kg/m2|insulin,,,,,,
9392,,chance,,,,nonchildbearing potential,,,,,for at least 8 weeks before screening,≥ 150 mg/dl,,,,,,
9393,,inflammatory arthritis,,,,e-cigarettes).|a participant,,,,,within two weeks prior to entry into the study,≥ 30 meq/l,,,,,,
9394,,third grade atrio-ventricular block,,,,cervical cytology,,,,,at least six weeks before taking study treatment,≤ 7weeks|willing and able to give informed consent,,,,,,
9395,,higher heart failure,,,,surgical excision,,,,,within the past 6,≥ m2,,,,,,
9396,,deliveries,,,,covid-19 infection|contraindication,,,,,in the past 2 months;|nb-uvb,>= 2400 mg/m^2,,,,,,
9397,,immune deficiency diseases,,,,local cns therapy|at least one,,,,,post-operative time period,≥12 weeks|non-surgical sterilization,,,,,,
9398,,intracranial arteriovenous malformation;|intracranial artery stenosis,,,,rehabilitation coordination,,,,,prior to initial treatment.|overactive cyp3a4,adverse event information,,,,,,
9399,,communication problems,,,,rehabilitation program,,,,,at least 100,> lln (lower limit of normal).||women of childbearing potential,,,,,,
9400,,tibia,,,,lumoral treatment,,,,,within 2 weeks prior to administration,below 90%,,,,,,
9401,,non evolving,,,,underwent surgery,,,,,in the last 12 months.|acute suicidality.|acute,≥ 30 kg/m^2,,,,,,
9402,,mania disorders,,,,full vaccination dose,,,,,at least 6 months before signing the consent,between 25-45|able to travel regularly to the study location|interested,,,,,,
9403,,hypersensitivity|important,,,,hcv infection;|chemotherapy,,,,,prior to (first) study drug administration,at least 16 years,,,,,,
9404,,immunological disorder,,,,ivf-et,,,,,within the last 1 month.|patients,18-60 years|free,,,,,,
9405,,genetic diseases,,,,low dose anti-coagulant treatment should,,,,,within the last 12 months|currently experiencing more than fleeting suicidal thoughts,18 to 65 years old.|alt < 5 uln.|chb,,,,,,
9406,,toxoplasmosis,,,,allogeneic organ transplantation,,,,,more than 3 time zones,≥80% pain relief,,,,,,
9407,,copd|chronic hypoxia,,,,+12.|anterior pelvic tilt,,,,,within 10 days prior to enrollment,>5.0 u/ml).|participating,,,,,,
9408,,archival bone marrow sample,,,,laparoscopic nephrectomy,,,,,during the last three months.|treatment,higher than 60,,,,,,
9409,,available pathology records,,,,transcorneal electrical stimulation,,,,,during the study|having,between 18.0 to 32.0 kg/m2,,,,,,
9410,,meditations,,,,ultraviolet b phototherapy,,,,,within 2 weeks prior to check-in|dentition,stage i-b3,,,,,,
9411,,symptoms of infection,,,,12-lead electrocardiogram (,,,,,at least 3 daily bowel movements,=rectum,,,,,,
9412,,solid organ transplant.|history of,,,,communication problem|application,,,,,at least 2 weeks before the first dose of study drug|uncontrolled,29 kg/m2|normal,,,,,,
9413,,anxiolytic therapy|those,,,,rcts,,,,,within one week before the first injection,">0,64 ng/dl||polycystic",,,,,,
9414,,taste|previous infection,,,,radical therapy (surgery,,,,,within 24 to 48 hours,0-2.|participant,,,,,,
9415,,age|apparently healthy||,,,,exercise intervention,,,,,within 3 months prior to study treatment,18 - 39 years,,,,,,
9416,,pancreatic lesions,,,,augmented therapy,,,,,at the screening visit;|participant must,>15 years|study,,,,,,
9417,,boston area,,,,ataxia teleangiectasia);|indication,,,,,within 14 days)a,greater than 75% of the circumference,,,,,,
9418,,infected patients,,,,slit-lamp examination,,,,,within 5 days prior to administration of the imp.||clinically relevant abnormalities,> 12 or < 20,,,,,,
9419,,months|symptomatic heart failure,,,,pilates exercise training|bmi,,,,,"last one month,|administration of drugs","≥15,000/mm^3|participant",,,,,,
9420,,group:||active suicidal ideation,,,,corticosteroid use|inability,,,,,within 48 hours after familiarization session,< 3 x uln||,,,,,,
9421,,gastrointestinal reactions,,,,regional lymph nodes,,,,,for at least 8 weeks after the last dose of the study drug.||highly effective contraception,≥110 mm hg,,,,,,
9422,,hepatic insufficiency.|non-proficiency,,,,dicom format,,,,,in the 4 weeks prior to the,>40|long-term,,,,,,
9423,,spf,,,,atherectomy,,,,,prior to first product administration,>= 60%)||administration of a live,,,,,,
9424,,hepatorenal syndrome,,,,endovenous intervention of truncal varicose veins,,,,,within the past 3 months.|for,between 6 and 15 months old,,,,,,
9425,,inflammation (edema,,,,cardiopulmonary exercise testing'.||,,,,,within 4 weeks|monoclonal antibody treatment,<1 x uln,,,,,,
9426,,text messages.||,,,,radiological-guided,,,,,during therapy,< 6.0%,,,,,,
9427,,liver disease)|thromboangiitis,,,,mri head,,,,,within 3 months before the first study,>160 mm hg,,,,,,
9428,,sbp,,,,mri scan etc.|enrolment of the investigator,,,,,last 5 years|use,≥30 ml/min/1.73 m2|hepatic,,,,,,
9429,,probenecid,,,,robotic-assisted total knee arthroplasty,,,,,at any time if for more than 5 days.|individuals,between 18.5 and 25 kg.m2||,,,,,,
9430,,genetic problems,,,,orthopedic trauma surgeons,,,,,at time of enrollment.||bmi||1,<50 mmhg).||matched control individuals:||have,,,,,,
9431,,primary outcome measure,,,,primary anesthesia care team,,,,,within 7 days prior to treatment,4-5,,,,,,
9432,,metastatic breast cancer;|progression,,,,ministry of health malaysia,,,,,within the month preceding randomization,>= 1.0cm,,,,,,
9433,,hiv).|active infection,,,,monoclonal ab in combination,,,,,within 3 ft,from 22 to 65 years.||it,,,,,,
9434,,successfully osseointegrated,,,,lactation.|major surgery,,,,,at the first diagnosis;|the progression of the third generation egfr-tki suggests histological transformation,≤ 1.5 × uln;|investigators evaluated,,,,,,
9435,,associated diseases,,,,cect scan,,,,,"during the month preceding the baseline exam,|medical history of",18-28,,,,,,
9436,,ventricular arrhythmia,,,,pet-ct scan,,,,,on the day of vaccination;|congenital,6mm or greater,,,,,,
9437,,chronic spondyloarthropathy,,,,old|kidney transplant,,,,,during screening period showed,above 2x the upper limit of normal)|signs of infection,,,,,,
9438,,l858r,,,,chronic blood transfusions,,,,,at least three months before surgery.||,≤ 2.5 x uln|gamma-glutamyl-transferase,,,,,,
9439,,herpetic stromal,,,,china-par prediction model;|ownership of a smart phone,,,,,within 4 weeks before the first dose of study drug.|medical history of,>5 ng/ml.||for,,,,,,
9440,,structural heart diseases,,,,head-mounted,,,,,within 1 month of panchol administration|receipt of a live vaccine,type ii,,,,,,
9441,,cyanotic congenital heart disease|infants,,,,serological testing,,,,,during sex,>t - (,,,,,,
9442,,exposed to passive smoke,,,,excision of,,,,,last 4 weeks prior to screening,between 1 and <18 years,,,,,,
9443,,electric devices,,,,mitomycin c|renal transplantation,,,,,within 14 days before screening):||hemoglobin,> 2.|any,,,,,,
9444,,non-type 1 diabetes|unable to use a,,,,indexed aortic valve area,,,,,less than 1 pool,30-60|bmi,,,,,,
9445,,28).|metastatic disease,,,,routine gynaecological examination||,,,,,at least 3 months prior to enrollment,more than 1.5 fold above the uln.|hepatitis b surface antigen (hbsag,,,,,,
9446,,pregnancy process,,,,cardiothoracic surgery,,,,,at the time of the enrollment in the study,between 20-45,,,,,,
9447,,immunotherapy induced,,,,consolidation treatment,,,,,at least 1 highly effective method,between 2 and 3;|latency,,,,,,
9448,,non-orthopedic,,,,hepatitis b reactivation prophylaxis,,,,,in the past one year；|subjects,4-5||for,,,,,,
9449,,management|malignant cancer,,,,focused ultrasound thalamotomy,,,,,within 2 weeks before the start of the study treatment(including compound cantharidin capsules,>1.5 times the upper limit of normal ptt,,,,,,
9450,,surgical approaches,,,,pancreatic transplantation,,,,,at the time of severe,11mm,,,,,,
9451,,cerebrospinal fluid protein qualitative test,,,,/biopsy,,,,,within 1 months before screening,18 to 40 kg/m^2,,,,,,
9452,,neoplastic cells,,,,language intervention,,,,,during the month prior to study entry,> 2 times per any week,,,,,,
9453,,progestogenic,,,,head surgery||inclusion criteria,,,,,at least 3 months from any cell therapy,equal to or more than 18 years,,,,,,
9454,,ischemic event,,,,urine protein quantification,,,,,at the time of ercp|use of nsaids,>3 x upper limits of normal,,,,,,
9455,,intubated|congenital heart disease|infiltrative,,,,auxiliary tests,,,,,within 3 mo|current,older than 10,,,,,,
9456,,0.80|lower limb stenosis,,,,thiamine|thiamine deficiency|take immunomodulatory drugs,,,,,past 5 years prior to enrollment,from 1 to 2+,,,,,,
9457,,spray-on,,,,local regulatory requirements,,,,,within 4 weeks prior to study entry.|following,1 = thick/yellow,,,,,,
9458,,nail beds,,,,index endoscopy,,,,,within 8 weeks prior to randomization.|chest ct scan,45-65 years,,,,,,
9459,,rectal fibrosis,,,,norwood surgery,,,,,< 1 month,> 6 ppm|is,,,,,,
9460,,unresectable lesions,,,,"whole-body 18f-fdg pet|english,",,,,,within 30 days prior to study start,18-65 years|asa i- iv|being,,,,,,
9461,,gastrointestinal bleeding,,,,nuss procedure,,,,,at least 3 months after their hospitalization in intensive care medicine,lower than 60 or,,,,,,
9462,,acquired immunodeficiency syndrome.||patients,,,,liver surgery||,,,,,within 3 months prior to leukapheresis||the following,< 4.3 mmol/l,,,,,,
9463,,naltrexone;||pregnant,,,,photodynamic therapy,,,,,for 30 days after the last dose (please see section 10.4.2 for,<25.0 kg/m2|absolute,,,,,,
9464,,malignant tumors|patients,,,,ie.|cardiac transplantation,,,,,for 6 months from randomization|previously,≤ 0.8,,,,,,
9465,,lumbar pathology,,,,hepatic iron deposition,,,,,in the past 3 months|comorbid medical,< 7 years,,,,,,
9466,,mody,,,,rcc,,,,,during the trial until the last follow-up,between 32+0 to 36+6 weeks,,,,,,
9467,,neck deformity,,,,herbal/natural remedies,,,,,at least 3 months prior,≤2.5 x uln,,,,,,
9468,,loss of sensation,,,,intubation,,,,,prior to the first,> 60 ml/min;|no,,,,,,
9469,,coronavirus disease,,,,testosterone replacement therapy (ingestion,,,,,during the study period and within 3 months after the last administration of the study drug;for,≥ 2 years,,,,,,
9470,,tumor cervical pain.|pregnant,,,,year|chest x-ray,,,,,within 14 days prior to the first treatment,more than 2.5 upper limit.|lvef,,,,,,
9471,,total,,,,volume reduction surgery,,,,,"in the last 6 months,|no discomfort",< 30 ml/min/1.73m2,,,,,,
9472,,her2 expression,,,,lumbar diseases|patient,,,,,within 2 weeks prior to initial use of the study drug,18-65 years.|edss,,,,,,
9473,,contra-indicate the procedure,,,,balance-,,,,,at the time of study initiation.||individuals,=<3 x institutional uln,,,,,,
9474,,human immunodeficiency (,,,,tezspire for the first time due to,,,,,within the 30 days prior to first dose of study agent.||more than 10 days,/e,,,,,,
9475,,liver transplant.|viral hepatitis：positive hepatitis a,,,,multi-attachment orthodontic treatment,,,,,within 6 months from anticipating treatment initiation,>2cm|use of,,,,,,
9476,,treatment.|known hiv infection,,,,allogeneic cell,,,,,prior to initiation of study treatment|substance abuse,between 4 and 24 weeks post-partum,,,,,,
9477,,suboptimal svs quantification,,,,local language around kampala and entebbe,,,,,for at least the minimum time required,≥iii,,,,,,
9478,,iron-deficiency anemia,,,,antitumor treatment,,,,,at least 7 days after rbc transfusion.||adequate liver,10^6 copies/ml,,,,,,
9479,,brain metastases.|patients,,,,maintenance chemotherapy,,,,,before pregnancy|no adrenocortical hyperplasia,>10)|maximum of 2,,,,,,
9480,,hemolytic anaemia|absolute neutrophil count (,,,,wechsler intelligence scale)|acuity levels suggesting need,,,,,within the past two years,3 years or more,,,,,,
9481,,females)|in,,,,indications,,,,,at the time of enrollment|active,50 to 100 kg,,,,,,
9482,,xiii,,,,revision arthrodesis;|patient,,,,,past 3,≥ 18 years|independent ambulation,,,,,,
9483,,radiologic evidence.|ct,,,,rescue specialist educational,,,,,at least 1 highly effective method of,28/*28,,,,,,
9484,,fluconazole capsules,,,,ducbt).|concurrent treatment,,,,,given more than a year before this experiment,high-sensitivity,,,,,,
9485,,not stable,,,,capsulotomy,,,,,during the clinical investigation follow-up,> 90 mmhg.||clinical,,,,,,
9486,,clinical exacerbation of their,,,,sample of adolescents between,,,,,in the last 1 month.|using hormonal contraception,1-7 years,,,,,,
9487,,spinal cord,,,,monitoring of water intake from food and liquids.||11,,,,,within 48 hours prior to randomisation;|severe,i/ii ab,,,,,,
9488,,"pf,|did not benefit",,,,stabile hormone therapy,,,,,within 28 days prior to enrollment.|past participation,18 till 70 years.||,,,,,,
9489,,microinvasive glaucoma surgery,,,,maxillary first premolar extraction,,,,,within 6 months prior to day 1 of treatment,< 3 times uln,,,,,,
9490,,"ischemic heart disease,",,,,prostatic urethral length,,,,,planning to give birth outside,0-1;||⑨,,,,,,
9491,,acute pulmonary embolism,,,,extended surgery,,,,,within the previous 3 months.|anal,younger than 18,,,,,,
9492,,carpel tunnel syndrome,,,,kidney biopsy findings,,,,,prior to study enrollment|hemodynamically unstable pre-enrollment|severe,18-month,,,,,,
9493,,freckle,,,,head computed tomography (ct),,,,,before the procedures||,≥3 months.||subject must,,,,,,
9494,,major residual complications,,,,ablation surgical procedure,,,,,at the time of signing the informed consent.|histologically,=< 5 x uln,,,,,,
9495,,hiv2,,,,trachea-oesophageal fistulas,,,,,prior to the first administration of imp,grade ii or,,,,,,
9496,,inadequate vein access,,,,and|elective caesarean section,,,,,within 7 days prior to lymphocyte clearance,≥ to 25.||,,,,,,
9497,,cardiorenal,,,,bleed|major surgery,,,,,at least 90 days prior to registration.|history of,<4 years,,,,,,
9498,,inferior vena cava (ivc) filter;|end,,,,e-cigarettes daily,,,,,within 3 minutes of breathing,"200/µl,",,,,,,
9499,,upper gastrointestinal tract surgery,,,,blood cell (,,,,,up to 6 months after study treatment discontinuation.||inclusion criteria,< 100 000/pl,,,,,,
9500,,hamstring injury,,,,preoperative inotropes,,,,,in the past three months,>150mmhg,,,,,,
9501,,demyelinating syndrome,,,,simple dental treatment,,,,,any time from the year 2013 to 2018;|informed,18 ~ 85 years (inclusive),,,,,,
9502,,meningeal involvement|treatment,,,,radiation treatment,,,,,less than 6 months,19-26 kilogram per meter square (kg/m^2,,,,,,
9503,,oral mucositis,,,,combined treatment,,,,,within 3 months prior to study drug administration.|plasma donation,≥19 and ≤40 kg/m2,,,,,,
9504,,asphyxia rescue,,,,congenital adrenocorticosis,,,,,within 24 hours on the day of vaccination,≥18,,,,,,
9505,,marathon,,,,iud insertion,,,,,in the 8 weeks prior to screening.|previous use of,18 years or older|the patient,,,,,,
9506,,suprapubic pain,,,,neurotoxic chemotherapy,,,,,within 48 hours.|no active,< 2.5 limit of normal,,,,,,
9507,,periodontal health status,,,,polymerase chain reaction,,,,,"during the study,|they",≥ 100 × 109/l,,,,,,
9508,,mcrpc,,,,therapeutic chest x-ray,,,,,at screening/baseline visit;|during the screening period,"< 0,27",,,,,,
9509,,eggs,,,,rapid antigen test (rat) test on day -7/day 1.|provision of signed,,,,,within the 2 years prior to screening,19.0-28.0 kg/m2,,,,,,
9510,,beverage addiction alcohol,,,,suez canal university hospital,,,,,at the time of ovarian stimulation and|>=two spontaneous miscarriages,μiu/ml,,,,,,
9511,,investigators anticipate failure,,,,revision arthroplasty,,,,,within 12 months after the screening;|confirmed,18 to 45 year the date of signing the informed consent form,,,,,,
9512,,liver function damage,,,,allogeneic hematopoietic stem cell,,,,,8-25 mm,>10mmol/l);|suffering,,,,,,
9513,,melanoma tumor site,,,,percutaneous needle tenotomy,,,,,within 3 months prior to randomisation.||for,<140/90|nonsmoker|no,,,,,,
9514,,basal cell carcinoma|co-infection,,,,medical therapy,,,,,during the last 3 months|patients,0-2||laboratory inclusion,,,,,,
9515,,mechanical stenosis,,,,antihistamines,,,,,within 48 hours before participation,">= 1.2 uln),|gamma-glutamyl transferase (ggt)",,,,,,
9516,,nonmelanomatous skin cancer,,,,dupilumab therapy,,,,,more than 1 week before the first dose of study,> 5 cups/day,,,,,,
9517,,corneal opacity,,,,endobronchial polymer/,,,,,at both baseline and follow-up|presence,1.1;|female patients,,,,,,
9518,,systemic chemotherapy;|patients,,,,bariatric surgery,,,,,last known normal for wake-up stroke,45 to 90 beats per minute,,,,,,
9519,,acute niv,,,,global impression,,,,,more than 8 on,<2l,,,,,,
9520,,compromising heart failure,,,,arabic language|patients,,,,,within 3 months prior to the screening visit,1.5 uln,,,,,,
9521,,painful pathology,,,,scheduled surgery,,,,,the last week > 2/10,< 18.5kg/m2|patient,,,,,,
9522,,diltiazem||underlying cardiac disease - sick sinus,,,,drug therapy,,,,,more than 14 standard units per week,10-16|being,,,,,,
9523,,bone health,,,,quality of life,,,,,within 30 days of the index procedure;|patient,55 years and older and those,,,,,,
9524,,lack of ability to follow radiation safety precautions.|qtc,,,,rapid-acting analog,,,,,within 2 months prior to eligibility.|received,≥ 1.5 × 109/l,,,,,,
9525,,acute inflammation,,,,soc therapy,,,,,within 28 days prior to the first dose (counted from the date of the last treatment,c6 or c6r,,,,,,
9526,,multigated acquisition,,,,endoscopic cardiac surgery,,,,,within 60 days prior to consent,≥ 2.5 times the upper limit of normal,,,,,,
9527,,coagulation defects.|patients,,,,brain mri screening.|3,,,,,within 2 weeks prior to initial administration;note,150 minutes,,,,,,
9528,,gastric varices|significant motility disorder,,,,clinical study procedures|prospective,,,,,after ≥ 2,14-60 years;|ecog score:,,,,,,
9529,,target disease,,,,"measures,|administration of sedative drugs",,,,,for at least 3 months after the last,>=12,,,,,,
9530,,sfa,,,,systemic corticosteroid therapy,,,,,after initial curative therapy,≥ n2,,,,,,
9531,,non-controlled,,,,diagnostic biopsy surgery,,,,,within 4 weeks prior to first dose of ctx-712.|history of,0 to 25 dbhl,,,,,,
9532,,upper gi bleed|shock,,,,g-csf|able,,,,,at the time of enrolment.|symptoms,between 65 and 84 years,,,,,,
9533,,acute flare phase,,,,blood consumption (abc) score,,,,,more than 1 cm,< 2 x the institutional upper limit of normal (uln),,,,,,
9534,,deep vein thrombus,,,,fibrillation ablation procedure,,,,,in the past 3 months;|4,> or = 35|participation,,,,,,
9535,,pulp condition,,,,aneurysmal,,,,,for 24 months,distilled,,,,,,
9536,,medial joint space,,,,dialysis|type 1 diabetes,,,,,throughout the study.|must have a minimum daily insulin requirement,< or = 20 ng/ml,,,,,,
9537,,tumor thrombus,,,,erythropoietin|major surgery,,,,,within the last 2 weeks,≤ 40 mg,,,,,,
9538,,septal deviation,,,,small-molecule inhibitors,,,,,at any dose,41 years,,,,,,
9539,,difficulty breathing.|risk factors,,,,maintaining suction,,,,,for at least 180 days after the last dose of study treatment:||refrain,>5ml,,,,,,
9540,,structural brain lesion,,,,auer rods noted,,,,,during the trial||patients who have received,above 40%,,,,,,
9541,,young healthy,,,,abdominal cramps,,,,,prior to surgical management|no contraindication,assesses the extent of disease,,,,,,
9542,,fractures of the upper,,,,aspiration,,,,,during the first 12-month study,0-2|histologically,,,,,,
9543,,calcifications;|severe tortuosity;|true bifurcation lesions,,,,intramuscular injection;|history,,,,,within 24 months of study entry.|topical retinoid therapy,18 to 55 years.|females,,,,,,
9544,,non-invasive respiratory support|parent(s)/guardian(s,,,,sequencing|peripheral blood,,,,,6 months,16-19 years|skeletal class i|bilateral class,,,,,,
9545,,morbus bechterev,,,,mammography,,,,,in 24 hours and associated,>3 x upper limit of normal,,,,,,
9546,,mellitus|diabetic macular edema,,,,compulsory secondary education,,,,,after pre-enrollment,> normal range upper × 1.5|egfr,,,,,,
9547,,saha,,,,complete treatment,,,,,in the past 30 days|able,latinx family of,,,,,,
9548,,ft4,,,,local assessment,,,,,for the first time||,18 to 45 years,,,,,,
9549,,hereditary immunodeficiency,,,,acquisition scan (muga),,,,,within 72 hours before the first dose of study intervention,above the nadir,,,,,,
9550,,atrial fibrillation|known,,,,"recto-vesical fistula,|patients",,,,,at screening.|positive results for,pets,,,,,,
9551,,esophageal reflux myasthenia gravis coagulation disorders,,,,palliative care services|those,,,,,in the month prior to or up to 9 days after the encounter at the participating practices||,90% of patients,,,,,,
9552,,fibrinogen deficiency,,,,national asthma registry|patients,,,,,within last 3 years.|any medical,0-2;|no,,,,,,
9553,,unresectable hepatocellular carcinoma||,,,,interventional treatment,,,,,within 4 weeks prior to enrollment.|active second malignancy.|active,≥ 2000 g,,,,,,
9554,,psychomotor delay,,,,modification of diet,,,,,within 5 years except,> 180 degrees of the circumference of the vessel,,,,,,
9555,,multiple pregnancy|comorbidity,,,,oral hormones plus,,,,,prior to first dose of study treatment.|prior malignancy,< 5 times uln.|creatinine clearance,,,,,,
9556,,acute myocardial infarction event,,,,regular medical checks,,,,,within 1 week prior to the screening visit,≥ 8 g/dl,,,,,,
9557,,major depressive disorders,,,,reason||additional screening procedures,,,,,within 4 weeks before the first administration of the study drug;|weight loss 10%,"≥30 kg/m2),|hypersensitivity",,,,,,
9558,,functional dependence,,,,mrf clear,,,,,within 4 weeks before the first administration;|have,elevation).|hematologic disorder.|aids.|advanced liver,,,,,,
9559,,general bone disease,,,,recto-vaginal,,,,,within the last 6 months|food allergies,less than 50°|subject,,,,,,
9560,,ophthalmic disease,,,,historical testing,,,,,for the current episode,<2.0 x103/μl|absolute,,,,,,
9561,,end stage kidney disease|moribund,,,,ivf+/-icsi procedure,,,,,within the past 3 months|known history,outside the normal,,,,,,
9562,,cerebrovascular incidents,,,,bariatric surgery general anesthesia,,,,,in the 3 months prior to inclusion|previous,≥20/min)|admission,,,,,,
9563,,peripheral blood pd-1+t cells,,,,cleft orthognathic surgery.||exclusion,,,,,at least 4 weeks from administration of a killed vaccine,< 30ml/min)|active,,,,,,
9564,,liquid stools,,,,lymphoma directed therapy,,,,,for two months preceding screening,≥6 points,,,,,,
9565,,axis activity,,,,safe access,,,,,within 2 weeks before baseline;|planned,>12.5 mg/dl).|are,,,,,,
9566,,distinct biological mechanisms,,,,publicly supported medical assistance,,,,,within 24 months before consent,15 to 30 minutes,,,,,,
9567,,coagulation factor deficiency,,,,tumour subtype|sufficient remnant tumour,,,,,at least 2 weeks after completion of therapy,≤ 10%|patients,,,,,,
9568,,auditory disorders,,,,parenteral nutrition treatment,,,,,within 3 months before signing informed consent,between 19 and 54 years,,,,,,
9569,,chest wounds|volunteers,,,,ophthalmoscopy,,,,,at least 1 year.|that they practice,17-ohp).|morning,,,,,,
9570,,internal bleeding,,,,ankle surgery,,,,,within 7 days before the first medication;|the use of,≤ 30 ml/min,,,,,,
9571,,neuro,,,,hemi-inattention (formerly neglect,,,,,within the past 6 months|inability,500 µm|residual stromal,,,,,,
9572,,transcranial electrical stimulation,,,,elective major procedures,,,,,at the time of informed consent|diagnosis,≤ 10 g/dl|platelet count,,,,,,
9573,,nonalcoholic hepatic steatosis,,,,focal/grid,,,,,within 10 years,suppressed,,,,,,
9574,,bioprosthetic,,,,clean intermittent self-catheterization|current,,,,,for at least 3 months prior to study enrollment,above 21 years,,,,,,
9575,,dialytic support|hepatic dysfunction,,,,peripheral laser photocoagulation,,,,,more than 14 days prior to randomisation|anuria,≥ 18 years.|2,,,,,,
9576,,permanent hypoparathyroidism,,,,fecal occult blood test(fobt,,,,,at equivalent dose,≥60g/l,,,,,,
9577,,craniospinal tumors,,,,streptococcus pneumoniae,,,,,within 4 weeks of protocol treatment|checkpoint inhibitor refractory,between 19.0~26.0kg/m2,,,,,,
9578,,nasal absorption specimens per protocol,,,,insufficient,,,,,within 48 hours of starting the infusion of the study drug.|signed,between 18 and 55 years|available to attend,,,,,,
9579,,chronic otitis,,,,birth control pills,,,,,for at least five days.|individual,6 to < 24 months of age,,,,,,
9580,,teeth in contact,,,,treponema pallidum (tp) antibody,,,,,within 1 month or 5 times half-life,18 and over|patients with understanding,,,,,,
9581,,endocrine system disease,,,,small-molecule targeted drugs,,,,,within 2 years after their partners' cell,younger than 60,,,,,,
9582,,intraperitoneal effusion,,,,hollow-cylinder implants,,,,,within 3 days of pressure equalization.|failure,0-1;|adequate organ function;|life expectancy,,,,,,
9583,,masticatory muscles,,,,common femoral,,,,,prior to starting study treatment.|subjects,<60 ml/min);|polyvalent,,,,,,
9584,,echocardiography;|previous ischemic heart disease,,,,intratumoral injection.|patients,,,,,within 60d prior to participation;|hematocrit <35%;|pregnancy,less than 10 g/dl,,,,,,
9585,,personality-related disorders,,,,carotid artery endarterectomy,,,,,within the 3 month period prior to baseline;|previous penetrating keratoplasty,>150/90 mmhg,,,,,,
9586,,endocrinal,,,,leukemic organ involvement,,,,,14 days after the last dose of,over than 21mmhg,,,,,,
9587,,immune disease relapse,,,,gastric bypass surgery,,,,,within the last four weeks.|subject,<10 seconds,,,,,,
9588,,psychiatry disease,,,,vascular reconstruction,,,,,within 36 weeks prior to randomization,at least 11.5,,,,,,
9589,,muscular strength,,,,chest ct-scan|willing to be tested for active and latent m.tb infection,,,,,between january 2010,18 or above;|ovarian cancer,,,,,,
9590,,hearing impairments,,,,cardiac ct angiography (ccta),,,,,current,more than 90% reliability,,,,,,
9591,,painful bruise,,,,instrumental investigations,,,,,at the time of the study|being,< 28 days prior to baseline,,,,,,
9592,,intrauterine adhesion infertility,,,,good conservative treatment,,,,,"in the last 6 hours,|the",between 18 and 25 kg/m2|masters,,,,,,
9593,,age|physically healthy,,,,overlay restoration,,,,,"prior to cycle 1, day 1",20 days ± 3 days.|informed consent form signed by parents|both,,,,,,
9594,,legionella infection,,,,tissue perfusion,,,,,after enrollment,15 to 30 days,,,,,,
9595,,functional cardiac imaging scan,,,,sublobar resection,,,,,during the 48 week study duration||28,≥ 30 to ≤ 59 ml/min/1.73 m^2|mild ri,,,,,,
9596,,shoulder trauma.|marked loss,,,,total artificial heart (tah),,,,,within 30 days prior to the start of this study,<2 × uln,,,,,,
9597,,extra whole,,,,screening|newly,,,,,within six months prior to screening.|unwilling to stop usage,>/=18|eastern cooperative oncology group (,,,,,,
9598,,congenital condition - inability to stop taking anticoagulants,,,,heart block|patients,,,,,6 months post-,> 27 kg/m2|previous vaccination,,,,,,
9599,,coagulopathy|pathologic bradycardia,,,,dwi,,,,,within 14 days before screening):||anc ≥ 1.5 × 109/l;|platelet,i-iv;|with intermediate,,,,,,
9600,,tumor shrinkage,,,,traumatic injury|exclusion criteria,,,,,within 3 months prior to screening.|regular use,≥ 3).|subjects,,,,,,
9601,,disease of,,,,functional genioplasty,,,,,within 3 months before day 1|participation,25 to 45 years old|fluent spoken,,,,,,
9602,,end stage renal,,,,lesions.|computerized tomography (ct),,,,,within 7 days after study start.|any condition,"<35,|stable",,,,,,
9603,,antagonistic personality,,,,spread behind,,,,,throughout study participation||,≥ 18 years|completed informed consent,,,,,,
9604,,raasi,,,,hematopoietic stem cell,,,,,at screening|known prior or,21 to 65 years old,,,,,,
9605,,cervical pain,,,,congenital hip deformities,,,,,neurological history,> 2 times the upper limit of normal value,,,,,,
9606,,diarrheal disease,,,,clinical laboratory tests|participant,,,,,within 4 weeks before the first use of the drug;|plan,>=9.0 g/dl,,,,,,
9607,,chronic monocytic,,,,radionuclide therapy,,,,,within 5,45- 75 years and||medical follow-up,,,,,,
9608,,structural changes,,,,upper abdominal surgery;|patients,,,,,at the time of enrollment.|subject,i-ii-iii-iv||,,,,,,
9609,,lost to follow-up for the same period,,,,clinical laboratory findings,,,,,in the past 3 years prior to consent,> 38 °,,,,,,
9610,,longest diameter,,,,thoracic procedure,,,,,during the previous month,≤ 6h|patient,,,,,,
9611,,temporal temperature ≥99.4°f [≥37.4°c,,,,wedge resection,,,,,during the 6 months prior to or,>18 years|chronic,,,,,,
9612,,generalized erythroderma,,,,consistent radiographic opacities,,,,,within 28 days prior to the first dose of the study drug,>100mg/dl|able,,,,,,
9613,,inflammatory skin condition,,,,standard-dose estradiol hrt,,,,,preventing evaluation of retina,stage 1b,,,,,,
9614,,normal cognition||,,,,completed,,,,,during the study period and within 6 months after the last dose of xzb-0004.||,45-60,,,,,,
9615,,preterm gestation|major,,,,progression,,,,,after the surgery.||,>40 kg/m2,,,,,,
9616,,autoimmune disease|patients,,,,computed tomography (cect) examination,,,,,for at least 2 weeks before starting to use the test drug;|there,score of 18,,,,,,
9617,,illness|0-2,,,,mental illness;|previous,,,,,within 3 months prior to the imp administration,<20 min/day,,,,,,
9618,,"deep venous thrombosis ""dvt""",,,,intravesical bcg therapy|systemic immunosuppressive therapy,,,,,in the past 3 months|prior,> 18 years|new diagnosis,,,,,,
9619,,premorbid neurological/neurodevelopmental disorders,,,,vascular surgeons,,,,,at the time of inclusion.||concomitant anticoagulation,less than 6 months|previous,,,,,,
9620,,acute institutionalisation,,,,health care,,,,,for 5 months after the last study treatment.|patients,"grades a, b",,,,,,
9621,,globin aplastic anemia,,,,duration|horowitz index,,,,,within 6 months before randomization.|alanine aminotransferase (alt,18.5 to 35 kilograms per meter squared (kg/m2,,,,,,
9622,,diabetic ketoacidosis-hyperosmolar state,,,,bandages,,,,,during treatment|pregnancy or,≤ 1.2 x upper limit of normal,,,,,,
9623,,autoimmune diseases;|brain,,,,neurological o other nontumor-related dysphagia|patients total laryngectomized|patients,,,,,within 6 months before first administration of dzd9008.|any evidence,at least 14 days.||,,,,,,
9624,,acute asthma symptoms,,,,small fiber neuropathy,,,,,within last 30 days|planned cabg,>300 ng/dl,,,,,,
9625,,involvement of sigmoid colon,,,,african ancestry,,,,,within 60 days prior to index procedure|interatrial baffle,< 30 minutes|crepitus,,,,,,
9626,,binocular vision,,,,vertebroplasty,,,,,within 3 weeks prior to study treatment|concomitant chemotherapy,≤ 5 years,,,,,,
9627,,renal dysfunction,,,,neuropsychological rehabilitation intervention specifically targeting pm performance,,,,,within at least 6 months after the last dose of investigational drug;|voluntarily participated in this study,<3 doses,,,,,,
9628,,falciparum parasitemia,,,,supervisory,,,,,recent 5 years|asa,minimum sensitivity 25 iu/l,,,,,,
9629,,symptoms scale,,,,routine cardiac allograft vasculopathy (cav),,,,,at least 4 months prior to study entry).||in,individuals:||inclusion criteria:||• 18-90 years||,,,,,,
9630,,generalised tonic-clonic seizures|frequent psychogenic non-epileptic,,,,genetic testing,,,,,during the last three months|patient,17.5 to 35 kg/m2,,,,,,
9631,,infectious event,,,,cardiopulmonary bypass (cpb),,,,,within the past year;|any,< 1.5 × upper limit of normal (uln),,,,,,
9632,,behavioral changes,,,,b-nhl,,,,,within 28 days prior to the start of study,=>30 and <=90 years|back/leg pain,,,,,,
9633,,diseases of the central nervous system,,,,functional tests,,,,,within the month leading up to departure,≥ 1.0 ng/ml,,,,,,
9634,,sit,,,,pet/ct imaging,,,,,prior systemic therapy,under age 18|not able to read,,,,,,
9635,,lumbar pain/degenerative,,,,household contact,,,,,within 24 weeks of initial invitation|greater than 24 months lapse of survey completion after baseline surveys completed|additionally,<40 mg/dl,,,,,,
9636,,staining,,,,retroperitoneal lymph node dissection.||,,,,,within 48 hours of cholecystectomy,< 50%.|known,,,,,,
9637,,pulmonary failure,,,,computed tomography/magnetic resonance imaging (ct/mri,,,,,within 2 weeks of randomization|informed consents,"above 25 kg/m2,|have",,,,,,
9638,,fetal developmental anomaly,,,,primary percutaneous coronary,,,,,in the prior 6 weeks,≥ 75 × 109 / l,,,,,,
9639,,acute pruritus,,,,flat ground||,,,,,within last 90 days prior to the index date|individuals,age|greater than,,,,,,
9640,,phlebotomy complications,,,,quality of the data.|female patients,,,,,at the time of enrollment.||in addition,1990 and 2010.|minimum score of 4 on the,,,,,,
9641,,left-sided hf.|history of aborted cardiac arrest,,,,target industries,,,,,after the first pet-ct scan,<35%).|platelet count,,,,,,
9642,,iridocyclitis,,,,optimal antihypertensive treatment.||iii,,,,,prior to study entry,under 18 years|emergency surgery|resections of the rectum,,,,,,
9643,,renal insufficiency;|patients,,,,inclusive;|19.0≤bmi≤26.0 kg/m2,,,,,during the 12 months prior to screening,grade 0 or 1 toxicity from prior antineoplastic therapy,,,,,,
9644,,non-degenerative central nervous system diseases|patient,,,,abdominal surgery again after lsg|patients whose mamagrophy image,,,,,within the past 6 months;|use,30-45 years,,,,,,
9645,,impaired fasting glucose.||females,,,,probabilistic matching with the snds database,,,,,within the 28 days before,≤1.5 uln.|eligible,,,,,,
9646,,newborns,,,,hair treatment,,,,,for at least 6 months after the last dose of study drug,≥160 and ≥100 mm hg,,,,,,
9647,,contraindicated for mdct,,,,gift device implementation able to complete timesheets||diagnostic,,,,,within 72 hours of first scheduled dose,</= 8 weeks,,,,,,
9648,,immunity,,,,address current,,,,,within 5 years before screening;|(2) those who test positive,no more than 12 hours.||in,,,,,,
9649,,bioprosthetic valve,,,,transrectal ultrasonography,,,,,in the last 3 years|no,<2 years|pregnancy|clinical history,,,,,,
9650,,coagulation function data.|those,,,,prophylactic purposes,,,,,while on prior lenalidomide,more than or equal to 6.0 mmol/,,,,,,
9651,,intestinal microecology,,,,regular controls|pregnant,,,,,past exposure,< 3.0,,,,,,
9652,,bundle branch blocks,,,,eye|history,,,,,at least 6 months prior to drug,> 21 units/week,,,,,,
9653,,deep skin infection,,,,conventional chemotherapy,,,,,pre-bronchodilator/pre-dose fev1,≥ 10 g/dl.|absolute,,,,,,
9654,,solid or,,,,≥2 endoscopic subscore,,,,,within 3 days prior to check-in until the check-out,< 126 mg/dl,,,,,,
9655,,gps,,,,first dsa examination,,,,,7 days prior to cycle 1,≥ 70%).||,,,,,,
9656,,vessel tortuosity,,,,montreal cognitive assessment (moca) score,,,,,within 1 year of inclusion,<1000 g in weight|at least 3,,,,,,
9657,,adpkd,,,,rai,,,,,within 4 months of study,18 to 70 years,,,,,,
9658,,colorectal tumors;|preoperative imaging reveals,,,,dialysis session,,,,,at time of surgery|patient does not,< 34%,,,,,,
9659,,chemical burns,,,,palliative treatment situation,,,,,7 days prior to or,> 3 x the upper limit of normal range (uln),,,,,,
9660,,head and neck squamous cell carcinoma,,,,renal-replacement,,,,,within 1 month prior,>20x109/l;|troponin i level,,,,,,
9661,,judged by the investigator,,,,facial rejuvenation treatment,,,,,within 14 days prior randomization)|pstat3 score,9-12|had,,,,,,
9662,,concussion syndrome,,,,joint surgery,,,,,within 4 weeks prior to the first dose of study drug；|patients,≥50.00 x 109,,,,,,
9663,,blood transfusion|smokers,,,,psychological trauma|low-income,,,,,for at least 2 weeks prior to randomization,between 18.0 and 30.0 kg/m2.||,,,,,,
9664,,metabolic bone diseases|vitamin d <25 nm,,,,immunosuppressive/immunomodulatory substances,,,,,within the last month,less than or equal to 3 kg,,,,,,
9665,,another class ia,,,,local requirements.||participant,,,,,for 2 weeks after discontinuation of study treatment,≥ 2.0)|or,,,,,,
9666,,gv,,,,gastroesophageal surgery,,,,,at the time of study enrollment.|histologically confirmed,30 minutes,,,,,,
9667,,arthrogryposis multiplex congenita,,,,sll)||prior therapy criteria,,,,,less than 4 weeks ago,18 to 40 kg/m2|elective,,,,,,
9668,,colonic perforation,,,,surgery sample,,,,,after the completion of concurrent chemoradiotherapy);|if the patient,< 150 min/week,,,,,,
9669,,organized magic learning program,,,,multiple gated acquisition (muga) scan,,,,,within the past 5 years.;||21.alcohol,from 6 to 12 years.|children,,,,,,
9670,,hfref,,,,systemic glucocorticoid therapy,,,,,before starting treatment of the target lesion).||i6. ci signed,1.1|eastern cooperative oncology group (,,,,,,
9671,,comorbid diagnosis,,,,intervention procedures,,,,,for at least 3 days)|hemoglobin,18 to 25,,,,,,
9672,,cardiovascular event|poorly,,,,first lymph node dissection,,,,,prior to the screening visit,>35kg/m2,,,,,,
9673,,respiratory dysfunction|allergy,,,,relaxation techniques,,,,,within 7 days prior to screening through day 60 of the,12 to 16 years,,,,,,
9674,,paget's,,,,treatment session,,,,,within 28 days prior to the first dose of investigational,at least 1.5 cm,,,,,,
9675,,astrazeneca,,,,commitment therapy,,,,,within 2 weeks before entering the study;|have,≥3 mm,,,,,,
9676,,thyroid dysfunction,,,,otolaryngology,,,,,at least one binge,> 30 mg per day,,,,,,
9677,,neisseria,,,,finger flexion,,,,,greater than 5 years ago,0 or 1.|measurable,,,,,,
9678,,urinary tract,,,,squamous cell,,,,,within last 6 months,>30 min/week,,,,,,
9679,,radiation proctitis,,,,prosthetic,,,,,within the past 30 days,≥ 18 years and ≤ 60 years,,,,,,
9680,,urethrocele,,,,child enrolled,,,,,6 months prior to screening|known,<500/mm3||patients,,,,,,
9681,,pain syndromes|use,,,,mechanical ventilation.||,,,,,within 6 months prior to screening.|skin conditions,> 35 kg/m2|refusal,,,,,,
9682,,psychiatric conditions;|neurodegenerative neurological diseases,,,,b-cell type,,,,,prior to study participation after receiving detailed information on the purpose,≤ 1.5 × institutional uln,,,,,,
9683,,orthopedic diseases,,,,arterio-venous fistula,,,,,within 28 days prior to the start of therapy|no,≤ 60 hours per week.||,,,,,,
9684,,arterial thromboembolic disease.|factor viii,,,,adjuvant treatment standard,,,,,longer than 24 months|smoking|previous surgery,between 18kg/m2,,,,,,
9685,,superior mesenteric vein,,,,chemoembolization,,,,,6 months prior to recruitment|having acute psychiatric,less than 1 %):||combined,,,,,,
9686,,chronic middle ear disease,,,,testicular surgery,,,,,within 2 weeks before dosing|currently enrolled in another clinical study,first cr/pr,,,,,,
9687,,need,,,,cryotherapy,,,,,during the 28 days or,between 1 and 1+ grade,,,,,,
9688,,interstitial lung,,,,hematopoietic stimulating factor drugs,,,,,in the past 6 months.|participant,> 5.0 mmol/l,,,,,,
9689,,gastrointestinal disease.||,,,,institutional review board (irb),,,,,within the past 18 months|previous,< 3.5 mg/dl|albumin,,,,,,
9690,,deformities,,,,internet-connectable device,,,,,10s;|balances for less than 20s on most,6-24 months;|subject,,,,,,
9691,,palliative care.|neurodegenerative disorder.|comprehension aphasia.|dementia,,,,t-lgll)||meet any of the following indications for treatment：||hemoglobin < 100g/l,,,,,"in the last three months,|those",≤ 2 months,,,,,,
9692,,serous ovarian carcinoma,,,,chest ct findings,,,,,within the past 30 days|participant,90 to 150 mmhg,,,,,,
9693,,thrombotic thrombocytopenic purpura,,,,allogenic haemopoietic stem cell transplantation,,,,,within 4 weeks before first dose of study drug,between 40-70 years,,,,,,
9694,,difficulties|extensive concentration,,,,endothelial growth factor receptor (vegfr) targeted therapy,,,,,during the experiment.||-,≥ 25|owns,,,,,,
9695,,autism spectrum disorder.|males,,,,local laboratories,,,,,at the time of signing the informed consent|participants who can lie still for 1 minute|capable of giving signed informed,0-1|histologically,,,,,,
9696,,focal aware,,,,testing for antigen by reverse transcription polymerase chain reaction,,,,,history|history,"from 1 to 75 years old on the day of enrollment;|on the day of enrollment, the subject",,,,,,
9697,,cardiopulmonary functions,,,,implant target artery - assessed,,,,,within 12 weeks prior to the run-in visit.|renal allograft,34+0-36+5 weeks,,,,,,
9698,,non-cardiac co-morbidities,,,,structured interview for,,,,,within 6-months,< 85 g/l.|post,,,,,,
9699,,problem in opening their mouth,,,,gastroesophageal junction.|synchronously,,,,,at the time of consent;|second or greater allogeneic transplant;|pure cd34+ selected stem cell grafts,≥ 4|history,,,,,,
9700,,progressive neurological symptoms,,,,acute ward|trainee arts therapists,,,,,within the prior 3,less than 21,,,,,,
9701,,50 mmhg,,,,rgp,,,,,within the last 2 weeks prior to starting study drug,18-50|having,,,,,,
9702,,neurogenic bladder,,,,montreal cognitive assessment)|illness,,,,,after one course,greater than 30.|current alcohol,,,,,,
9703,,event;|acute pathology,,,,gastrostomy|tracheostomy|chest tube(s)|pacu procedures required,,,,,past 28 days thus no longer,score < 18/30.|having veins,,,,,,
9704,,endomyocardial fibrosis,,,,cutaneous graft-versus-host disease,,,,,at the time of occurrence,≥2.|pregnant or,,,,,,
9705,,cystic renal degeneration,,,,postoperative,,,,,during treatment during alignment phase|acute oral infection,at least 52 weeks,,,,,,
9706,,concurrens serious,,,,surgical intervention|parents,,,,,within 4 weeks after lb2102 administration|pregnant,< 100*109/l;|renal insufficiency,,,,,,
9707,,gilbert's syndrome|uncontrolled,,,,substitute decision maker is able to provide informed consent|patient,,,,,within 7 days of drug administration,>75 age|unable,,,,,,
9708,,infection|concurrent involvement,,,,4c.|complete coronary angiography|complete biochemical,,,,,within 1 week of dosing|epileptiform discharges,less than 32 weeks)|birthweight,,,,,,
9709,,behavioural impairments|communication disorders,,,,hormonal treatment|- written,,,,,prior to randomization:||cyclophosphamide,=< 1.5 seconds,,,,,,
9710,,nasal injury,,,,anticoagulation therapy|uncontrolled bleeding|irreversible neurological pathology|participants,,,,,for ≥5 years.|use,>21 kg/m2,,,,,,
9711,,right coronary artery lesion.|excessive overlap,,,,colorectal surgery,,,,,during history,45 years,,,,,,
9712,,chronic disease.||note,,,,orthodontic therapy||-,,,,,in the next 3-4 months,= 100,,,,,,
9713,,influenza,,,,supramarginal resection,,,,,during the last 2 months before the start of the study|dieting|severe weight loss,18 or older|within 12 weeks after starting ici treatment for cancer|cognitively oriented,,,,,,
9714,,mental confusion,,,,emergency contraception,,,,,after 2 times instructions;|alcohol abuse,> 97 percentile|for individuals < 2 years,,,,,,
9715,,systemic infections,,,,induction chemotherapy cycle,,,,,within 3 days before randomization|mechanical heart valve,0 - 2,,,,,,
9716,,classical disease|english speaking,,,,laboratory tests.||,,,,,between enrollment,more than score 2,,,,,,
9717,,oral comprehension disorder,,,,split liver transplantation,,,,,within the last 3 months|left,18 or older|ability to understand and willingness to sign a written informed consent,,,,,,
9718,,thoracic ultrasound)||,,,,local anaesthetics,,,,,≥30 days after symptom,< 142/150,,,,,,
9719,,mixed bacterial,,,,radiotherapy therapy,,,,,within 4 months prior to the start of the study.|administration of an,0 or 1.|use,,,,,,
9720,,solid organ transplantation.|history of,,,,blood sample,,,,,during the 48 weeks prior to entry.|no change in art,<15kg/m2,,,,,,
9721,,uterine tumors,,,,laparoscopy,,,,,in the previous 3 week|suffering from any disease,≥ 9 g/dl.|international,,,,,,
9722,,liver impairment,,,,preoperative chemotherapy,,,,,at least 4 days,grade ii or iii,,,,,,
9723,,pleurodesis,,,,vital organ functions,,,,,during the preceding 3 months,between 18 and 99 years|comminuted,,,,,,
9724,,peripheral edema,,,,blood drawings,,,,,within 14 days prior to step 2 randomization,better than,,,,,,
9725,,premature menopause - surgical menopause,,,,females;|major organ surgery,,,,,over 300 pounds,> uln,,,,,,
9726,,non-surgically sterilised,,,,physiologic replacement dose of,,,,,< 2 prior,≥30 kg/m^2,,,,,,
9727,,hydroxychloroquine.|collect,,,,complete androgen insensitivity syndrome,,,,,at screening for the first subject in each cohort,">,= 18 years",,,,,,
9728,,corneal diseases|patient,,,,adequate standard treatment,,,,,in the last 8 weeks prior to study entry note,<140/90 mmhg;|fasted blood glucose,,,,,,
9729,,histopathologic features of,,,,injection site.|donation of blood,,,,,at the time of consent|prisoners|unable to provide informed consent|unable to read,> 20 mm,,,,,,
9730,,liver disease|administration,,,,weeks;|full donor chimerism;|primary disease,,,,,at least one of the following four tests,18.0-33.9 kg/m2,,,,,,
9731,,fib-4>2.67,,,,germline mutation)||exclusion criteria:||<18 years|no,,,,,within 1 year prior to the screening visit,women|aged 25 to,,,,,,
9732,,hypertriglyceridemia|transitioning trans-gender|transitioning menopausal,,,,interventional studies.|3,,,,,within 1 month before biopsy.||patients,0-2|adequate,,,,,,
9733,,diseases;|pregnant,,,,natural sterilization,,,,,more than 28,2)||approximately 60,,,,,,
9734,,meningomyelocele,,,,imaging tracers,,,,,at the time of registration||,≤ 1.5 × uln.||cardiac,,,,,,
9735,,atypical parkinsonism|institutionalized,,,,bedside schwartz formula,,,,,for 6 months after the last dose of ifosfamide,<20 ml/min/1.73 m2,,,,,,
9736,,riteria,,,,computed tomography perfusion (ctp).|the study drug initiated,,,,,throughout the study.|taking,<15 years,,,,,,
9737,,treated cancer,,,,co-medication,,,,,preceding 12 consecutive,≥ 5% blasts expressing,,,,,,
9738,,liver cirrhosis;|major surgery,,,,blood taken||consent,,,,,within 1 month before administration;|history of drug abuse;|participated,<35 kg/m^2,,,,,,
9739,,end of,,,,mini international neuropsychiatric interview (mini).|the current episode of,,,,,for the duration of the study,<1.3 mmol/l)|if,,,,,,
9740,,joint dislocations,,,,brain biopsy,,,,,at least 3 mo before entry,less than 60°,,,,,,
9741,,granulomas,,,,defects.|current hospitalization,,,,,prior to the study procedure,greater than 4 square centimeters,,,,,,
9742,,sleepiness,,,,endoscopic procedure,,,,,at the time consent,between 18 and 70 years|functional status,,,,,,
9743,,drug-induced parkinsonism,,,,chronic oral anticoagulant,,,,,within the normal range of laboratory values,≥ 160 mmhg,,,,,,
9744,,cryoneurolysis,,,,local assay,,,,,at least 90 days prior to registration|patients,> twice the upper limit of normal,,,,,,
9745,,renal failure,,,,stent materials,,,,,at the time of the consent,uln)|total,,,,,,
9746,,etc;|other diseases,,,,aydın adnan menderes university application and research hospital,,,,,within 6 months of the ip dosing,20 mmhg,,,,,,
9747,,alternative explanations,,,,extraocular surgery,,,,,past,under 18 years old and over 60 years,,,,,,
9748,,stds,,,,par-q+)|physical limitations,,,,,at least 1 complete treatment cycle,under 75 years,,,,,,
9749,,mucinous adenocarcinoma,,,,ergonovine provocation test,,,,,prior history,> 13;|current,,,,,,
9750,,topically applied,,,,smart-phone,,,,,more than 12 weeks before,more than 5 kg,,,,,,
9751,,kidney dysfunction.|able,,,,small molecule therapy,,,,,in the past 6 months|a,more than 50% from baseline.||,,,,,,
9752,,suffered,,,,infraorbital nerve distribution,,,,,at the baseline visit.||-,≥100 x 109/l|hepatic function,,,,,,
9753,,myofascial pain syndrome (mps),,,,spermicidal,,,,,previous 5 years.||any chronic,more than 2.5 mg /dl,,,,,,
9754,,concomitant injury,,,,valve plasty,,,,,at least 2 days per week.|less than 2 bowel movements,6 months to < 24 months on the day of inclusion,,,,,,
9755,,recreational soccer,,,,integral treatment method,,,,,within 30 days prior to randomization.|modified rankin score of ≤ 3|tia,greater than or equal to 7 on the,,,,,,
9756,,good compliance.||,,,,lung|lung transplant,,,,,within 60 days or received,≤80 years old.||fit to the definition of,,,,,,
9757,,hap,,,,cardiopulmonary exercise test|musculoskeletal problem who cannot perform,,,,,within 24 months prior to inclusion into the study|female,less than,,,,,,
9758,,crsv,,,,soc chemotherapy,,,,,prior to enrollment.|negative,6-10 years.|both,,,,,,
9759,,alb,,,,lead vaginal dryness,,,,,within 6 months of completion|for,≥ 50 ml/min,,,,,,
9760,,chronic hepatitis).||patients,,,,local anesthesia,,,,,prior two months,≥6|prothrombin time/,,,,,,
9761,,her2-targeted therapy.||additional criteria,,,,optimal resection,,,,,longer than 14 hours,≥6 units of transfusions of prbcs for the prior 24 weeks,,,,,,
9762,,ever worn,,,,local investigator.|life expectancy,,,,,within 14 days|pregnant,"i-ii,|patients",,,,,,
9763,,secondary cardiac insufficiency,,,,bone metastasis,,,,,for at least 3 months after the last treatment;|patients who volunteered to participate in this study,0-1;|organ function level,,,,,,
9764,,substance,,,,puva therapy,,,,,within 7 days prior to the start of the,>30 u/l,,,,,,
9765,,evolution.|internal rotation rom limited.|positive provocation pain tests.||,,,,assuit university hospital,,,,,within 6 months prior to first dose of study medication.|cyclosporine,0-1||,,,,,,
9766,,congenital defect syndrome,,,,memory markers,,,,,at any time after screening||reproductive,<21,,,,,,
9767,,pancreatic adenocarcinoma|peripheral neuropathy,,,,evaluation for localized/early,,,,,for the time period outlined below and,more than 7 days,,,,,,
9768,,c-ards,,,,sinus surgery,,,,,for at least 30 days before drug administration,≥ 50 mg/j,,,,,,
9769,,non lactation,,,,general intensive care unit,,,,,more than 6 months,>18||,,,,,,
9770,,glaucoma patients:||age,,,,cytological examination,,,,,in the past 3 months|pregnant,robust,,,,,,
9771,,gastrointestinal diseases.|with,,,,complete fatty replacement of pancreas,,,,,increta|npo less than 6 hours preoperatively|patients,adult|50.0kg≤body weight≤90.0kg and 18.0kg/,,,,,,
9772,,autonomic symptoms,,,,ultrasound testing,,,,,after review,c ≤2%.|patients ≥ 18 years,,,,,,
9773,,cutaneous localized,,,,ventilation tubes,,,,,during the past year,>100mmhg,,,,,,
9774,,acute rejection,,,,chest x-,,,,,within the course of the study|participation,>200/110,,,,,,
9775,,leptomeningeal metastases.|myeloma,,,,thoracic fusion,,,,,within 3 weeks prior to first dose of study,18.5 gbq).|participants must,,,,,,
9776,,malignant tumor,,,,lymph node lesion,,,,,1 month to 5 year since concussion)|must speak english|must provide written consent|no,≥18 years|2,,,,,,
9777,,subcutaneous emphysema|severe ards,,,,rtms application,,,,,post-transplant baseline,<0.62,,,,,,
9778,,limb fracture,,,,retinectomy,,,,,at least 2 weeks prior to the first study treatment administration,≥24,,,,,,
9779,,b-cell [sig,,,,orotracheal entubation age,,,,,at least 6 months prior to participation;|berg balance scale score,25 µmol/l,,,,,,
9780,,reasonable,,,,multiparametric mri of the prostate.|consent,,,,,within 30 days before screening except,between 18-29 kg/m2.||,,,,,,
9781,,choroidal thickening|presence,,,,thoracic surgery|parent,,,,,at baseline (,>2kg,,,,,,
9782,,type 1 diabetes.|pregnancy,,,,blood pregnancy examination,,,,,at least one occasion,">1,500/µl platelets",,,,,,
9783,,diagnostic laparoscopy|internal referral,,,,thyroid hormone replacement,,,,,in the month preceding inclusion for,under 50 years old,,,,,,
9784,,lymphoma polyps,,,,control group,,,,,prior to initiation of therapy,between 18 and 60 years|patients,,,,,,
9785,,acute wilson disease,,,,epilepsy);|antibiotic treatment,,,,,within the 28 days prior to screening.|participant,0 to 2.|the,,,,,,
9786,,schizophrenia-spectrum disorders|can read,,,,first-line regimen containing immune checkpoint inhibitor therapy.|the best outcome,,,,,within 6 months of the first dose.|has the,< 10 or > 28 per minute,,,,,,
9787,,substance abuse,,,,radiation therapy||biochemical recurrence (bcr),,,,,more than once,≥12 weeks;|at least 1 measurable,,,,,,
9788,,cytomegalovirus [cmv],,,,pirs surgery,,,,,after radical resection.|patients,≥ 4 weeks prior to start of study treatment||require,,,,,,
9789,,hypoxic ischemic encephalopathy,,,,radical prostatectomy,,,,,within the preceding two weeks|patients,>4%;|for,,,,,,
9790,,nmb,,,,whole abdomen radiation therapy,,,,,less than 3 months before the clinical evaluation|participation refusal,"< 50,000 mm3",,,,,,
9791,,epileptic,,,,histological examination,,,,,in the last 3 months|bmi,>1.5 x109/l|platelet count,,,,,,
9792,,hearing problems,,,,total knee prosthesis,,,,,during the first 12-month study period,≥45 kg.|presence,,,,,,
9793,,asthma severity,,,,celiac artery,,,,,during the study.|reported participation,"≥1,000/mcl|platelets",,,,,,
9794,,mm disease,,,,model enrolled families,,,,,in last 2 weeks,> 37.7℃.|blood neutrophil count,,,,,,
9795,,curators|psychological disorder,,,,week|gastroduodenoscopy,,,,,within 4 weeks of registration,< 1.2 × 109/l,,,,,,
9796,,ckd stage 5,,,,70 edtrs letters,,,,,during the last 6 months.|current,between 18 and 75 years old.||,,,,,,
9797,,herpetic infection,,,,mineral absorption,,,,,within 30 days prior to the screening,< 8.0 mmol/l|fasting,,,,,,
9798,,avoiding pregnancy,,,,radiation pneumonitis|prior radiotherapy,,,,,in the 1 months after enrollment|subjects,< 120 meq/l,,,,,,
9799,,solitary thyroid nodule,,,,clear cause of pelvic pain,,,,,within 2 weeks before the baseline assessment.|patient health questionnaire-9,>5,,,,,,
9800,,deep neck flexors,,,,"maintenance therapy,|experiencing disability",,,,,within 30 days of enrolment.|presence,>50 copies,,,,,,
9801,,vulvar erythema,,,,inflammation|intraocular surgery,,,,,during the last 3 months;|reception of immunomodulatory drugs,less than 30 ml/min per 1.73 m2 of,,,,,,
9802,,vulvodynia,,,,vasodilation,,,,,within 5 years before the start of the visit 1|patients,≥100 g/l.||blood,,,,,,
9803,,significant mobility,,,,intracranial artery occlusion,,,,,within 3 months after the trial,>60 months,,,,,,
9804,,diabetes mellitus (dm),,,,brain surgery,,,,,within 14 days prior to the screening,between 3 and 13 years,,,,,,
9805,,urinary frequency/urgency,,,,niraparib|major surgical procedure,,,,,within 1 year before enrollment,over 18 years old|those who agreed,,,,,,
9806,,chromosome karyotype abnormality;|iatrogenic ovarian injury,,,,clear cell renal cell carcinoma,,,,,within the last 90 days|cellworks,≤1.5 upper limit of normal||,,,,,,
9807,,nocturnal myoclonus|center,,,,autologous car-t cell therapy.||b. histologically confirmed marginal zone,,,,,at least 6 months before diagnosis,not inclusive,,,,,,
9808,,ntm,,,,treatment schemes,,,,,prior to thrombectomy,1.1.|patients willing to comply,,,,,,
9809,,surgical drainage,,,,cholecystectomy,,,,,within 8 weeks before qualifying endoscopy,> 3 months;|received,,,,,,
9810,,sponsor)|muscle weakness,,,,conventional ct imaging,,,,,within 28 days after the final dose of,2-18 years,,,,,,
9811,,major psychiatric disorders,,,,exposure therapy,,,,,within 2 weeks(or five half-lives,<1.5x control.|participants,,,,,,
9812,,immune system,,,,sentinel node biopsy (snb),,,,,within 4 weeks prior to first dosing.|a positive,above factors affect the rate of tooth movement,,,,,,
9813,,dementia.|prior cardiac,,,,polymerase chain reaction (pcr) test positive,,,,,48 hours prior to admission|norepinephrine infusion,less than 90 days.|pregnancy.|chronic obstructive pulmonary disease,,,,,,
9814,,cadasil||focal lesions,,,,supplementary oxygen,,,,,within 6 months of investigation,age|greater than or equal to 6 months post,,,,,,
9815,,orthostatic hypotension|unable,,,,cell depletion agents,,,,,within 14 days prior to the first dose of study drug.|major surgeries,"< 30 ml / min / 1,73 m2",,,,,,
9816,,lymphatic anomaly,,,,hormonal birth control,,,,,within 1 week before apheresis,between the start and 12 months before the end of the study period,,,,,,
9817,,type 2 diabetes|currently pregnant||and||2,,,,standard chemotherapy-induced,,,,,within 5 years before screening|known,≥ 2)|age,,,,,,
9818,,cbx-12,,,,coronary bypass)|peripheral artery disease,,,,,in the last 2 years.|women who are,resides,,,,,,
9819,,mental health providers,,,,imagery assessment,,,,,in the last three months prior to,13-15,,,,,,
9820,,painful intercurrent adverse events,,,,verbal confirmation,,,,,within 6 months of the screening;|any medical history,<50% of predicted normal.||- concurrent,,,,,,
9821,,histological pathological,,,,breastfeed,,,,,in the past 5 months.|known,<7 mm,,,,,,
9822,,barrett's metaplasia,,,,orthodontic treatment|comprehensive medical,,,,,within 6 months prior to randomization|evidence,less than or equal to (<=) 90 days before informed consent,,,,,,
9823,,imagery evoked,,,,tee,,,,,at the time of enrollment|history of a,< 18 years|pregnant women|patients,,,,,,
9824,,dilated pupils,,,,intubation||,,,,,in the past 3 months|severe organ dysfunction|any,i-iii|bmi ≥35 kg/m2,,,,,,
9825,,squamous cell carcinoma|primary tumor site,,,,vestibular testing,,,,,within 1 week before enrollment meet the following conditions:||neutrophils (anc,lack of written consent iii,,,,,,
9826,,assess,,,,scan.|prior abdominal radiation therapy.||history,,,,,since at least 6 months prior to visit 1.|eosinophilic airway inflammation,< 1.5×uln；|no,,,,,,
9827,,spondylotic myelopathy,,,,conventional treatment,,,,,prior to surgery|history,"below 18 years old|neck deformities,|presence",,,,,,
9828,,behavior,,,,allogeneic hematopoietic stem cell transplantation.||,,,,,within 10 days prior to start of study treatment,>90 days|need,,,,,,
9829,,pds,,,,confirmatory hcv rna test,,,,,within 1 year (d),greater than 15 years,,,,,,
9830,,neurovascular,,,,atherosclerotic disease.||iv,,,,,in the past 3 months;|patients,≥2.5×uln;||hepatic impairment,,,,,,
9831,,sick sinus,,,,exercise stress test,,,,,within the preceding 14 days|any condition,≥ 50% predicted,,,,,,
9832,,breast cancer;|breast cancer,,,,small ventricular septal defect,,,,,within the last 12 months|a,"< 36 kg.m-2,|age",,,,,,
9833,,serious heart,,,,global deterioration score,,,,,during the study;|unexplained severe,≤ 55 years,,,,,,
9834,,a:||patients,,,,section 5.4,,,,,within 14 days prior to treatment.|has,> 5 times the upper limit of normal,,,,,,
9835,,severe dysphagia,,,,liver surgery;|be,,,,,within 4 weeks preceding the start of study treatment.|unwillingness,profusely,,,,,,
9836,,primary covid-19 vaccination,,,,cesarean section,,,,,while on study treatment.||participant,< 90 days prior to study procedure|congenital unicuspid aortic valve|porcelain,,,,,,
9837,,developmental disorder.|is,,,,e cigarettes,,,,,within 60 days of enrollment.|lesions,older than 18-year,,,,,,
9838,,≥1 bone lesion,,,,cholangiocarcinoma);|preoperative imaging assessment of the disease stage was iii/iv;|at least one measurable lesion,,,,,in the last 3 months|the,≥ 30 kg/m2.|-,,,,,,
9839,,syncopal episode(s,,,,head mri film,,,,,after hct.(2,"> 200,",,,,,,
9840,,antithrombin deficiency,,,,mini-cog scores of 3 and higher|having the ability to read,,,,,during the study.|participants vaccinated,>250 to <=500 microgram,,,,,,
9841,,acute congestive heart,,,,clinical trials,,,,,for 5 months after the final dose of tiragolumab,> 85 mm,,,,,,
9842,,family members);|pregnant,,,,intensive chemotherapy,,,,,past month) psychopharmacotherapy,>10 min loss of consciousness,,,,,,
9843,,disc displacement,,,,first time oocyte acceptors,,,,,within 14 days prior to first drug,18 - 60 years|vitamin d deficiency,,,,,,
9844,,serious cardiac illness,,,,local anesthetics|contraindication,,,,,in the next 6 months|weight loss,<=2.5 x uln,,,,,,
9845,,exploitable,,,,total knee replacement surgery,,,,,during their stay in the pediatric intensive care unit,60-100|acceptable labs,,,,,,
9846,,aortic stenosis/mitral stenosis,,,,mild definite rhd,,,,,completed the week 52 endoscopy,4-12 months,,,,,,
9847,,hyper laxity,,,,acip,,,,,within 12 months prior screening,≥3,,,,,,
9848,,mesotherapy,,,,volume).|regular consumption,,,,,within one month prior to the intended pes treatment,"1,000 to 50,000 asexual",,,,,,
9849,,respiratory distress syndrome,,,,placenta previa,,,,,within 4 weeks prior to the first dose of trial treatment.||has,> 18 years regardless,,,,,,
9850,,schwannoma,,,,dual-energy x-ray|a,,,,,within the 90 days prior to study,? for example:,,,,,,
9851,,therapeutic device(s)|in,,,,iliofemoral dvt||,,,,,within 48 hours before enrollment,18 and 40 years.|current neck pain.|presence,,,,,,
9852,,local anesthetics|pregnancy,,,,hematopoietic stem cell mobilization,,,,,in the past 6 months;|medical history,less than 2%;|subjects,,,,,,
9853,,heart disease,,,,raf fusion,,,,,within the last 6 weeks before inclusion|use of hormonal therapy,between 18 to 65 years|sglt2i,,,,,,
9854,,prolonged qt-interval.|alcohol,,,,initial treatment,,,,,within 3 months prior to initiation of study therapy /social situations,≤ 110 g/l,,,,,,
9855,,|alcohol dependence,,,,heart transplantation|subjects,,,,,during trial participation and until 6 months after end,18 years and older willing and able to provide,,,,,,
9856,,non-fluent english speaker.|current foster,,,,ckd5,,,,,within the past 3 weeks.|history,less than 12.1g/dl,,,,,,
9857,,deep nerve block,,,,etc.;|preoperative mri shows only perforator infarction,,,,,within 3 months of study inclusion,< 3 months,,,,,,
9858,,clinically meaningful deterioration,,,,palliative chemotherapy,,,,,within 3 months.|right-sided,score of 5 to 6,,,,,,
9859,,hiv diagnosis|serious,,,,coronary stent,,,,,during this 90-day period,"18 - 70 years,|madrs score",,,,,,
9860,,sympathomimetic drugs|atrial fibrillation,,,,orthodontic therapy,,,,,within the next 28 days,> grade 1,,,,,,
9861,,uveitis,,,,antitumor therapy,,,,,after 2 courses of treatment with the standard regimen,≥3 g/dl.|for,,,,,,
9862,,alveolar soft,,,,antigen tests,,,,,for 12 weeks|able to participate in a structured mindfulness-stress reduction,<1 cm between the tumor,,,,,,
9863,,intestinal organic diseases,,,,quantitative polymerase chain reaction (pcr),,,,,for at least 52 weeks prior to enrolment date,<1.5 × 109/l,,,,,,
9864,,spread,,,,medical comorbidities|major surgery,,,,,within 28 days prior to the first vaccination.|subjects,< 18 years|gcs <= 8,,,,,,
9865,,responding radiologic response,,,,consistent with cerebrovascular disease,,,,,within 4 weeks [prior to allocation.||note: participants,>35 kg,,,,,,
9866,,breast cancer patients|therapy,,,,egfr tki therapy,,,,,after screening until week 16 need,>= 18 years old from january 1,,,,,,
9867,,morbid obesity,,,,psoriasis treatment,,,,,for at least 2 weeks before initiation of our study||,years;|ineligible,,,,,,
9868,,portal vein thrombosis,,,,chemoradiotherapy,,,,,in the past 7 days is more than 1.5 times of the basic value,between 6-12 years||,,,,,,
9869,,self-isolate,,,,youth enrolled,,,,,within 6 months prior to the procedure,18 to 32 kg/m2,,,,,,
9870,,esophagitis,,,,f-hifu treatment,,,,,within past 3 months,>0.80)||exclusion,,,,,,
9871,,non-small cell lung cancer.||for cohort a,,,,food dye,,,,,at any time of icu stay defined,>= 50% =< 15 days prior to registration.|registration,,,,,,
9872,,comorbid condition|other active systemic malignancy,,,,surgery disseminated cancer disease,,,,,criteria||present,18-70 years|patients,,,,,,
9873,,auditory communication difficulties,,,,widening,,,,,within age,"0-3,and the predicted survival",,,,,,
9874,,interstitial lung disease|hepatitis,,,,covid vaccination,,,,,prior to screening.|the participant,less than (<)12.0 grams per deciliter,,,,,,
9875,,nodal disease,,,,lumbar pathology.||exclusion criteria,,,,,at any time since presentation|life expectancy,≥90 g/l,,,,,,
9876,,spinal cord injury)|patients,,,,day surgery,,,,,in the range of 25-40 kg/m2,<10|massive,,,,,,
9877,,isolated from the same,,,,2);|able to read,,,,,longer than three months||,<70|schizophrenia,,,,,,
9878,,drainage procedures,,,,danish.|planned concomitant,,,,,within the radiotherapy area,>2000/mm3;|have,,,,,,
9879,,cardiorespiratory dysfunction,,,,ethinyl estradiol|previous administration,,,,,within 1 year|known,none,,,,,,
9880,,skin basal cell,,,,therapy;|previous radiation therapy,,,,,within 6 months prior to the screening visit|a history of,1: 18 to 32 kg/m2,,,,,,
9881,,mild apnea,,,,dual antiplatelet therapy,,,,,within next 7 days|has decision making capacity,40 to 70 with facial ptosis,,,,,,
9882,,pituitary insufficiency,,,,pelvic radiotherapy.|subjects,,,,,at the time of screening.|clinically significant,< 65 mmhg,,,,,,
9883,,bruises,,,,mobius stent,,,,,prior to dosing.|participation in more than 3,=< 3.0 x uln||* in the event,,,,,,
9884,,fabry disease,,,,intranasal examination,,,,,prior to pci,> 10 g/dl|platelets,,,,,,
9885,,exacerbations,,,,partial resection,,,,,for at least one year,≥ 8 year older and,,,,,,
9886,,old;|mitral valve insufficiency,,,,ice.||intra procedural,,,,,at the last 2 visits before the end of study,>500 ng/ml,,,,,,
9887,,ici-induced,,,,systemic application,,,,,during the day|inability to understand and sign the study informed consent form|inability to follow oral instructions,>5.7 (pdm/dm,,,,,,
9888,,da,,,,archival biopsy,,,,,for at least 6,> 7.5 g/dl,,,,,,
9889,,haemodynamic instability,,,,ezetimibe|solid organ transplant,,,,,for 180 days after the last dose of treatment.||,≥ 50 kg|the,,,,,,
9890,,unforeseen illness,,,,rapid wash-out,,,,,in the past they must,dose ≥ 20 mg/day,,,,,,
9891,,clinically significant episode,,,,hpv vaccine providers|no clinic,,,,,during the first 4 weeks of treatment,older than 18,,,,,,
9892,,chronic chest infection.|severe obesity,,,,bilateral vasectomy,,,,,within the screening period:||absolute neutrophil count,<4|major,,,,,,
9893,,diabetic gastroparesis|hba1c of the last,,,,cessation of exogenous,,,,,within 14 days prior to vaccination,less than 50% or greater than 90% of the internal diameter|procedure,,,,,,
9894,,erosive reflux disease,,,,cannabis|current,,,,,"for at least 4 weeks prior to cycle 1, day 1.||has any of the following cardiac abnormalities:||symptomatic",≥18 years;|diagnosis of inoca;|availability,,,,,,
9895,,mixed well-differentiated/dedifferentiated,,,,radiologic procedures done,,,,,within the first 28 days,<50mg/dl,,,,,,
9896,,t. trichiura,,,,clinical chemistry/electrocardiography,,,,,within 12 months prior to treatment initiation,equal/over 140 mm hg,,,,,,
9897,,acutely infected,,,,classification of airflow limitation in copd (gold) system,,,,,past 1 month,>= 50%||note,,,,,,
9898,,pni,,,,medical procedure,,,,,prior to apheresis.|positive,20-70 years,,,,,,
9899,,non-live covid19 vaccines,,,,spiral ct,,,,,in the 4 weeks prior to the knowledge,≥ 70.|subjects,,,,,,
9900,,arf,,,,surgical procedures|toxicities,,,,,at time of,30-60 years||presence,,,,,,
9901,,gastrorenal shunt,,,,rescue medications,,,,,within 6 months prior to study,>= 50%,,,,,,
9902,,heart failure.|participants,,,,major surgery leading,,,,,prior to the operation.|patient refusal,< 0.70,,,,,,
9903,,gammopathy|alcohol abuse,,,,ct imaging of the temporal bones,,,,,more than 30,< 30 ml/min/1.73 m2)|alt,,,,,,
9904,,muscle loss,,,,world workshop 2017 criteria,,,,,within the 12 months after,> 250 mumol/l,,,,,,
9905,,electrophysiologic disease,,,,single ablation needle,,,,,14 days prior to screening,=< 14 days prior to registration)|total,,,,,,
9906,,permanently sterilized,,,,radial artery interventional therapy,,,,,within the 3 months|patients,>6 months;|histological,,,,,,
9907,,astigmatism,,,,echocardiogram (echo),,,,,within the past 60 days,≤ 1.5 x uln|creatine kinase ≤ 2.5 x,,,,,,
9908,,epilepsy|deep brain stimulation,,,,onal intervention,,,,,within 24 hours before participation,">2,500 g.|healthy",,,,,,
9909,,abnormal urinary constituents,,,,catheter ablation,,,,,throughout participation,≥ 7.|willingness,,,,,,
9910,,conduct disorders,,,,simple confusional state assessment test,,,,,within 1 year of screening;|patients,alkaline phosphates,,,,,,
9911,,metastatic breast cancer;|measurable disease,,,,etv,,,,,over the last three months.|previously,<60 ml/min/1.73 m2,,,,,,
9912,,adenocarcinoma of the lung.|the tumor harbors,,,,ecg examination,,,,,within 2 weeks before the first dose of lp-168,≥ 18,,,,,,
9913,,sars-cov-2.|receipt,,,,il-12 therapy,,,,,during the study drug use period,less than 24 hours.|use,,,,,,
9914,,primary immunodeficiency disorders|presence,,,,psychotherapy||,,,,,ovaries).|more than 4 weeks after the end of previous,"> or = 1,500/mm3",,,,,,
9915,,type 2 diabetes|hba1c <7,,,,bedtime|active smoking|current drug,,,,,more than 15°,≥ 10 µmol/l)|able,,,,,,
9916,,respiratory tract,,,,malabsorption;|past treatment,,,,,within 12 months of enrollment|no,between 01 january 2000 and 31 december 2022,,,,,,
9917,,pancreatic cancer|planning,,,,"local hospital medical records.|during the period from september 1, 2022 to december 31, 2023, participants who received",,,,,prior to the first dose of encaleret.|participants,100-300×109/l,,,,,,
9918,,skin allergy,,,,cell therapy,,,,,at the time of the first injection with the 6-month triptorelin formulation,1 or more,,,,,,
9919,,inflammatory bladder,,,,dimensions sand,,,,,in the 4 weeks prior to inclusion,≥ 65≤ 85,,,,,,
9920,,chronic medications|did not,,,,normal screening laboratories,,,,,through 120 days after the last dose of the study,disorders|pre-existing,,,,,,
9921,,t-cell lymphoma,,,,nutritional therapy,,,,,within 5 years prior to study treatment.||note: the 5-year,at least 0 to <12 years,,,,,,
9922,,unilateral blindness - bcva,,,,agitated delirium.|mechanical ventilation,,,,,at screening.|subjects,>99,,,,,,
9923,,diabetes;|contraindications,,,,tonic-clonic seizures|a clinical indication,,,,,within 3 months of enterotracker® procedure|inability to provide,18-75|clinically,,,,,,
9924,,granulocyte-colony-stimulating factor [,,,,peri-implantitis|pregnant,,,,,within 7 days before the inclusion visit,≤ 3 times the upper limit of normal,,,,,,
9925,,months|local inflammation,,,,complete endometrial ablation,,,,,within 12 months prior to first dose of study,<6 inches,,,,,,
9926,,bruxism habits,,,,defunctioning ileostomy,,,,,within 3 months of the mri,>= 6 and < 40 years,,,,,,
9927,,high performance liquid chromatography,,,,antibiotic associated diarrhoea,,,,,within the previous year|systemic corticosteroids,3-month,,,,,,
9928,,pelvic hematoma,,,,anterior rhinoscopy,,,,,within 6 months prior to first dose,less than 20/200,,,,,,
9929,,comorbid gad,,,,first-line tha,,,,,within 24 hours is <,more than 10 units alcohol per week,,,,,,
9930,,organic brain disease|presence,,,,pathological histology,,,,,through the length of the study|understands,>75years or age<18years.|2,,,,,,
9931,,chemotherapy;|r0 ideal,,,,cyclodestructive procedure,,,,,at the time of screening.|possess,< 18|catatonia|schizophrenia|alcohol use disorder,,,,,,
9932,,musculoskeletal pathologies contraindicated,,,,"organic brain syndrome""||bilag-2004 disease activity level",,,,,last 7 days,≥27 kg/m^2,,,,,,
9933,,assess measurable disease,,,,androgen deprivation therapy,,,,,within the previous fourteen,> 60ml/mn|lvef,,,,,,
9934,,haemato-oncology disorder,,,,epigenetic therapy,,,,,at least 2 months before the first day of screening;|for,50%;|older than 18,,,,,,
9935,,spinal malformation,,,,treatment|eye surgery,,,,,at least 4 weeks prior to initiation of study drug dosing,equal to or higher than 50% of the lower limit of normal range;|liver function,,,,,,
9936,,intra-spinal disease,,,,gastric resection/bypass,,,,,at least twice a week,≥ 1.4,,,,,,
9937,,bipolar disorder;|hct,,,,treatment regimens||dose escalation cohort,,,,,within 6 months;|left ventricular ejection fraction,< 28 kg/m2,,,,,,
9938,,impaired lung function,,,,pulse,,,,,within 4 weeks of study treatment day 1|active,≤ 35 µm/l,,,,,,
9939,,acutely ill,,,,oral hormone therapies,,,,,in the 30 days before and 30 days after each dose of the study vaccine,45-75 years,,,,,,
9940,,aquagenic urticaria,,,,concomitant administration,,,,,at least six months,> 160/95,,,,,,
9941,,seizure disorder|hospitalization,,,,peritoneal dialysis)|unable to communicate,,,,,during study|history of,> 60 g/l,,,,,,
9942,,smart phone|mothers,,,,eradication treatment,,,,,during the study period.|any,>1.0,,,,,,
9943,,basal cell skin carcinoma basal cell carcinoma,,,,fdg-pet/ct,,,,,at least three episodes,< 35 µmol/l,,,,,,
9944,,criteria:||post-menopausal,,,,local health,,,,,during the study treatment period and up to 10 days after the completion of study treatment|serious,greater than 20 g/day,,,,,,
9945,,investigator|previous malignancy,,,,evt,,,,,within 28 days before vaccination.|received gamma immunoglobulin,≥18 <65 years,,,,,,
9946,,tenosynovitis,,,,cervical malignancy|adenomyosis,,,,,8-week staff mindfulness course,functional class iv;|severe,,,,,,
9947,,myasthenia gravis syndrome|myocardial infarction,,,,pelvic rt|treatment,,,,,throughout participation in the study,18-70;female;|pathologically,,,,,,
9948,,incompatible with electroporation,,,,first-line erlotinib,,,,,within 2 weeks before the baseline assessment|a,equal to or shorter than1.5 times of,,,,,,
9949,,lung tumors,,,,local procedures,,,,,past month|lifetime history,≤ 1.5×uln.||left ventricular ejection fraction,,,,,,
9950,,parent(s)/legal representative(s) able to comply with the protocol,,,,coronary angiography|acute coronary syndrome,,,,,within 72 hours prior to receiving the first dose of study drug,"2, 3 or 4|pregnant",,,,,,
9951,,pain medication|pain,,,,primary knee arthroplasty procedure|phq-ads,,,,,at time of screening/postoperative evaluation)|(increased,more than 3 times a day,,,,,,
9952,,head and/or neck chemoradiation therapy|existing indwelling neurostimulation device,,,,computed tomography (ct) scan thorax,,,,,within 72 hours prior to,more than 3 years later,,,,,,
9953,,allergic laryngeal edema,,,,conservative therapy,,,,,within 6 months prior to randomization.|modified rankin score,> 2,,,,,,
9954,,pentosan polysulfate sodium,,,,lactation period,,,,,during the study.|history of current,spouse,,,,,,
9955,,regularly|febrile illness,,,,slower nerve conduction velocity,,,,,within 14 days before the first use of the study drug,score <10 msec obtained,,,,,,
9956,,herpes zoster ophthalimicus,,,,surgical procedures required,,,,,prior to index date,18 and above,,,,,,
9957,,inflammatory bowel disease.|currently,,,,systemic surgery,,,,,for at least 10 min,≥18 years|participants,,,,,,
9958,,thoracic malformation,,,,restricted diet,,,,,within the past 6 months;|receipt of blood,≤ 3 × uln,,,,,,
9959,,primary physician preference,,,,systematic treatment regimens,,,,,within 5 years before signing informed consent.|the investigator considers,score > 16,,,,,,
9960,,impending herniation,,,,pathogenic germline variant,,,,,at physicians',0-1.||10,,,,,,
9961,,dh,,,,penile,,,,,within the past 8 weeks before first dose of protocol indicated,under 50,,,,,,
9962,,cardiac conduction,,,,standard rt-pcr assay,,,,,after starting to use oral contraceptives;|use,"i/ii),|more than 18 years",,,,,,
9963,,natural dentition,,,,restorative surgery,,,,,at the time of eligibility evaluation,< 30 kilogram,,,,,,
9964,,infusion|stroke,,,,completed radiotherapy,,,,,within 28 days of dosing,<18 kg/m2|currently,,,,,,
9965,,left-handedness,,,,ics)|asthma,,,,,during the last two years.|self-reported,≤ 7|focal,,,,,,
9966,,compromised airway|uncontrolled seizures,,,,standard of care treatment.|patients,,,,,within 6 months of study participation.|as per the investigator's discretion,18-60 years|weight,,,,,,
9967,,transhepatic)|cirrhotic liver disease,,,,axial fracture.|dysmetria.|vertebral surgery,,,,,within 5 years prior to randomization.|has,≥3 months;|histologically,,,,,,
9968,,cognitive impairment|clinical diagnosis,,,,trial.|concurrent psychotherapy,,,,,within 4 weeks prior to the first dose of study treatment.||9,19 to 30 kg/m2,,,,,,
9969,,headache disease,,,,bacille calmette guerin -vaccination,,,,,"within 4 weeks prior to administration of the investigational product.|patients who,",> 1.5 to 3 times the upper limit of,,,,,,
9970,,corneal abnormalities|participants,,,,chest computed tomography (ct) scan|active tuberculosis|significant cardiovascular disease|major surgical procedure,,,,,after enrollment.|at least one,≥ 8 g/dl|total,,,,,,
9971,,gastric neuroendocrine neoplasms,,,,visits|world health organization (who),,,,,within 60 days of screening,less than 18 years old more than 80 years,,,,,,
9972,,life-threatening allergies,,,,supplementary screen contraceptive method,,,,,during the last month,infants:37-41 weeks,,,,,,
9973,,drug-related pneumonitis,,,,eye.|bilateral restricted fundal view,,,,,within 28 days prior to enrollment.|prior minor surgery,at least 6,,,,,,
9974,,neurodegenerative disorders,,,,transabdominal ultrasound,,,,,for the time frames specified below,between 4 and 8 on the,,,,,,
9975,,psychomotor retardation,,,,periodontal surgery,,,,,at least 7 days prior to enrollment,"1-15,|absence of complaints",,,,,,
9976,,metastatic cord,,,,endocrine therapy,,,,,within 30 days prior to step 1 registration and while participating in the study,at least 30% racial/ethnic,,,,,,
9977,,neurologic degenerative diseases,,,,in reunion,,,,,within 180 days prior to the subject's registration,≥ 8.5,,,,,,
9978,,hiv,,,,flare period)|phototherapy,,,,,30 days before the study blood,>18|sinus rhythm|informed,,,,,,
9979,,exclusionary.|active malignancy,,,,dsa examination,,,,,previous three months,>=50 kilogram (kg,,,,,,
9980,,condomless vaginal,,,,antigen test,,,,,past 24 hours,>60).|participant,,,,,,
9981,,knee osteoarthritis,,,,quality of the data.|current substance use disorder,,,,,prior to radiotherapy|patients,18-70;|the,,,,,,
9982,,lower priority,,,,in vitro maturation (ivm),,,,,prior to first dose of study drug.|treatment,>18 years|eligible for,,,,,,
9983,,hiv infection|tuberculosis,,,,morphologic examination of blood,,,,,during the study|current pregnancy,> 40 breaths per minute,,,,,,
9984,,dermabrasion,,,,limbal blood vessel ischemia,,,,,at least 10%,6-15 mm|stones history,,,,,,
9985,,skin grafting.||,,,,induction termination,,,,,within 8 weeks prior to randomization.|mri,>180|weight less than 80 pounds,,,,,,
9986,,unresolved,,,,vitamin d,,,,,less than 4 weeks before,≥9%,,,,,,
9987,,non-melanoma skin cancers)|dizziness,,,,heart failure.|n-terminal pro-b-type natriuretic peptide,,,,,before starting to work,6-10|received,,,,,,
9988,,arterial disease,,,,diagnose of advanced,,,,,before initiation of imp,≥ 18 years|histologically,,,,,,
9989,,anticancer,,,,allogeneic organ transplantation|surgical intervention,,,,,more than 4500 euros,">= 75,000/mm^3",,,,,,
9990,,end-stage acquired immunodeficiency syndrome,,,,coronary artery bypass graft (cabg).|previous history of stroke,,,,,within 3 months of the study.|subject,>210 msec,,,,,,
9991,,gastrointestinal resection,,,,local investigator,,,,,within 14 days of day 1.||the,19 years to 75 years|diagnosis,,,,,,
9992,,atrial,,,,graft versus host disease(gvhd,,,,,within 1 month prior to registration.||laboratory,≥ 15 mm);||the function,,,,,,
9993,,abstain from recreational drugs,,,,standardized osteotomy,,,,,within 16 weeks,20-55 years,,,,,,
9994,,≥1 metastatic,,,,lymph node lesions,,,,,within the previous 12 months.||subjects,< 18 kg/m2,,,,,,
9995,,rare disorders,,,,abdominal chemotherapy,,,,,during the 5 years prior to randomization.|history of human immunodeficiency virus,< 38.0°c,,,,,,
9996,,photosensitive epilepsy,,,,sarcomatoid variant,,,,,before the identification,< 11 g/dl||white,,,,,,
9997,,cardio-circulatory function,,,,colonic surgery,,,,,permitted days -2 to -1)|any recorded,> 18 years|symptomatic covid-19,,,,,,
9998,,cuff tear arthropathy,,,,supplemental oxygen.|administration of other nmda-receptor antagonist treatment,,,,,medical history with more than two,>1.5×upper normal limit [unl,,,,,,
9999,,schizoid personality disorder,,,,fibrosarcoma.|no treatment,,,,,at time of screening|previous participation,class a-b,,,,,,
10000,,nf1,,,,orthodontic treatment|patients,,,,,at time of screening|prostate,tests)|testosterone free level greater than 10pg/ml|hematocrit,,,,,,
10001,,proprioceptive disorders,,,,combined organ transplantation,,,,,within 4 weeks prior to day 0|anti-vegf therapy,90%,,,,,,
10002,,2:||viral failure,,,,recist1.1 criteria;|hrd gene mutation,,,,,more than 6,≤ 1|1st,,,,,,
10003,,polyclonal antibody.|allergy,,,,rectal pcr,,,,,within 6 weeks of first dose of study medicine,> 35 kg/m2||recent,,,,,,
10004,,preoperative progressive pneumoperitoneum - ppp,,,,grammatical tense,,,,,throughout their study participation.|willingness to provide,^9 /l,,,,,,
10005,,human cornea donor graft,,,,x ray,,,,,for 12 weeks,<1 month post-surgery,,,,,,
10006,,vascular aneurysms,,,,neurosurgical procedures/operations|known,,,,,in the past 6 monthsp,≥ 94 cm,,,,,,
10007,,progressive severe pathology of poor prognosis,,,,these procedures,,,,,up to 4 h before the first dose of trial medication.|receipt of,0.1 mg day given,,,,,,
10008,,known diagnosis,,,,magnetic resonance scan,,,,,at the time of the screening,less than 16 weeks||human immunodeficiency virus,,,,,,
10009,,poor intestinal preparation;|(3,,,,small-cell carcinoma component.|history,,,,,within 4 weeks (28 days),> grade 1)|patients,,,,,,
10010,,albuterol)|significant comorbidities,,,,conditions:|chronic kidney disease,,,,,within 6 months prior to study day 1.|patient,> 10%,,,,,,
10011,,egg donation,,,,renal artery angiography;|able to follow the study protocol,,,,,treatments|prior ldct screening,/t2,,,,,,
10012,,bypass,,,,mri plain scan showed,,,,,in the last 3 months.|has,≥18 years,,,,,,
10013,,scoring convention,,,,stent are located,,,,,more than 600 mg,from 50 to 65 years,,,,,,
10014,,heart disease;|patients admitted to our polyclinic with the diagnosis,,,,contraception,,,,,during the past 6 months.|history,≥ 3)|concurrent participation,,,,,,
10015,,pcr+ swab,,,,thrombectomy,,,,,longer than 3 years|known,gfr<45ml/min/1.73 m2,,,,,,
10016,,contraindicating surgical resection,,,,neck|radiotherapy,,,,,within 72 hours prior to receipt of study,≥ 10mg/dl,,,,,,
10017,,allergic reaction.|those,,,,cognitive assessments,,,,,over the past 30 days|must,> 1.5×uln,,,,,,
10018,,hemorrhage,,,,endoscopic mucosal resection,,,,,throughout the duration of the trial,more than 3 times the normal upper limit,,,,,,
10019,,bacterial pharyngitis,,,,turp surgery,,,,,within 30 days prior to enrolment,>2.5 mg/dl,,,,,,
10020,,progressive dyspnea,,,,graft-versus-host disease|patients,,,,,within 6 months after the end of the study.|willing and able to follow trial,> 3.0,,,,,,
10021,,good disease control,,,,live vaccination,,,,,after the short interdialytic interval,≥ 3+,,,,,,
10022,,immune thrombocytopenia purpura.|prolymphocytic leukemia,,,,liver resection,,,,,within 2 weeks of pre-treatment,> 1.5 times,,,,,,
10023,,exacerbation of copd,,,,supportive treatment,,,,,at the time of cancer diagnosis,< 22|malnutrition.|high,,,,,,
10024,,nmibc,,,,special design,,,,,through 4 months after the last dose of protocol treatment|step 2 randomization:|patient must,140 - age))/(72 x,,,,,,
10025,,radial forearm free flap,,,,actively participates,,,,,before 1 year old.|medical history,> 30 gy,,,,,,
10026,,prostatic adenocarcinoma;|biochemical failure,,,,rhc data||,,,,,for at least six months prior to enrollment,≥ 25 kg/,,,,,,
10027,,para-functional oral habits,,,,sclc.|participants,,,,,during the study period.|（2）suffered,20 years old;|diagnosis of,,,,,,
10028,,neoplastic disease.|patients,,,,preceding biopsy|skin infection,,,,,up to 2 g/day,<460ms female)|symptoms,,,,,,
10029,,neuromuscular impairment,,,,lipid-lowering medications);|willing and able to be on gnrhagonist,,,,,during the period 0-3 days before a procedure day,<30 ml/minute/1.73 m2,,,,,,
10030,,instinctual behavior disorder,,,,organ function,,,,,within 7 days prior to the first admission to the clinical unit.|participants,< 5 × uln,,,,,,
10031,,obsessive-compulsive,,,,fibrous down growth,,,,,through their primary care provider|medical complexity,≤ 9.0 g/dl|platelet count,,,,,,
10032,,anal dilatations|or,,,,truliant® total knee replacement,,,,,over 18 years old|written informed consent to participate in the study.|patients without decompensation of cardiovascular diseases||non-inclusion,40-45)|polycystic ovarian syndrome,,,,,,
10033,,haemodynamically stable,,,,diurnal variation,,,,,at the dose of ≤10 mg/day,between 20 to 80 yr||,,,,,,
10034,,discipline.|allergic reaction,,,,veno-venous ecmo,,,,,at the time of proposed surgical resection.||,between 90-170 mmhg,,,,,,
10035,,manic-depressive psychosis);|acute coronary syndrome,,,,erythrocyte transfusion,,,,,within 6 months.|pregnant,≤ 2 ×uln.|be,,,,,,
10036,,hyperinsulinemia,,,,ichd,,,,,during past three months;|neck surgery,≥ 60 × 10 9 /l,,,,,,
10037,,hypertension|systolic pulmonary artery pressure,,,,comminuted fractures.|subjected,,,,,before entering the study;|pregnancy;|alcohol,above 140/90 mmhg)|donated blood 3 months prior to test,,,,,,
10038,,food allergies,,,,instrumental treatment,,,,,within 6 months prior to the dosing of the study drug,between 1.7kg and 2.3kg|infant,,,,,,
10039,,human immune defect virus (hiv),,,,holoprosencephaly,,,,,after at least 1 of,</= 2 cm,,,,,,
10040,,actively,,,,treatment non-responder||,,,,,at time of enrollment into the observational natural history study.|havecompleted at least 2 valid height/length measurements,- 60 years,,,,,,
10041,,thyroid dysfunction|nephrotic syndrome,,,,structural imaging,,,,,within 14 days of the onset of symptoms;|healthy,niv,,,,,,
10042,,suprasacral sci,,,,complete,,,,,within one week of continuous wear,≥3 cm,,,,,,
10043,,ankylosing spondylitis,,,,behavioral intervention,,,,,within the prior two years|have unstable,score ≥4;|have motivation to quit,,,,,,
10044,,light chain type,,,,atezolizumab treatment,,,,,in the last 30 days before enrollment,18 years old,,,,,,
10045,,traumatic fracture,,,,international research，unresponsive arousal syndrome/vegetative state,,,,,within 4 weeks|history of,≥ 3l/min to maintain,,,,,,
10046,,disc height,,,,peanuts|left-handedness|current smoker,,,,,male|aged between 12 months to 11 years|phototype,< 1.5 times the upper limit of normal value (uln),,,,,,
10047,,neurological health,,,,brain mri,,,,,during the study period.|individual,0 or 1.|signed informed consent.|patient,,,,,,
10048,,pathological indicates,,,,ipsilateral neck dissection,,,,,after 3 minutes resting,18-70.|patients,,,,,,
10049,,mechanic fragments,,,,splenectomy,,,,,for at least 12 weeks prior to visit 0 with no changes,≥ 18 years to ≤ 75 years|pathologic,,,,,,
10050,,tumor cavitation,,,,antiviral medications,,,,,at any time following treatment,18 to 65 years;|subjects must give informed consent to the study before the study entry,,,,,,
10051,,china liver cancer staging,,,,bariatric surgery||,,,,,within 14 days prior to the first dose in this study).|be able to swallow,>= 12 continuous months of amenorrhea,,,,,,
10052,,repolarization disorders,,,,standard of care regimens,,,,,throughout the duration of the study.||,<50,,,,,,
10053,,age.|pregnant women.|people,,,,ct-contrast.|pcsk9-inhibitor treatment|life expectancy,,,,,within 24 hours prior to starting study medication,greater than 5 mm,,,,,,
10054,,cerebral ischemia / hemorrhage,,,,viral vector vaccine,,,,,"between january 1, 2014",≤500 iu/l,,,,,,
10055,,arterial thrombotic event,,,,lactation|diabetes|chronic medical illness|regular intense exercise,,,,,within 4 weeks before the first use of the drug;|there,18 years or older|bcva,,,,,,
10056,,bacterial infection.|untreated hypothyroidism,,,,technetium scintigraphy,,,,,simultaneous,"> 11,000/μl",,,,,,
10057,,sleep disorders,,,,psychopathology,,,,,within 7 days prior to the first dose of the investigational drug,over 20 years old||,,,,,,
10058,,minimal,,,,cns imaging (ct,,,,,for scchn.||r/m,between 15 and 24 years enrolled in prospective studies,,,,,,
10059,,musculo-skeletal,,,,imaging ascvd,,,,,at the time of consent||,puncture);|long-term,,,,,,
10060,,deep invasion,,,,hepatobiliary surgery,,,,,within past 4 months,> 1.0 ng/ml,,,,,,
10061,,sinusoidal obstruction syndrome (sos,,,,peripheral artery disease|individuals,,,,,at the time of infusion,< 1 million sperm|aspermia,,,,,,
10062,,thromboembolic pulmonary hypertension,,,,concurrent resection of organs,,,,,menses for 12 months prior to the first study drug administration,<1.5 x uln,,,,,,
10063,,concomitant skin,,,,gastroesophageal junction,,,,,within 3 years before randomization,<1.5 x uln|for,,,,,,
10064,,laryngeal obstruction,,,,cardiac electrophysiological exploration.|patient,,,,,within 4 weeks before c1d1,1.3 mg/dl,,,,,,
10065,,adenocarcinoma,,,,glycosylated hemoglobin (hba1c),,,,,at one year after the stem cell transplantation,≤22.5mm,,,,,,
10066,,deep dyspareunia,,,,lennox-gastaut,,,,,within 14 months before the knowledge;|thyroid stimulating hormone (tsh),>a,,,,,,
10067,,communication barriers,,,,remain on protocol therapy,,,,,within 2 months after the end of the study,">= 100,000/mm^3|creatinine =< 1.5 x upper limit of normal (uln)",,,,,,
10068,,neurocognitive disorders,,,,"abdominal x-ray,|patients",,,,,for 1 month after (eot,from 50 to 60||,,,,,,
10069,,gynecologic malignancy recurrence.||,,,,dental procedures.|patients need,,,,,within the past 2 weeks|has,1 or less,,,,,,
10070,,lung infections,,,,renal ultrasonography,,,,,within 6 weeks prior to first administration,greater than 600 μm or less than 500 μm,,,,,,
10071,,acute ulcer,,,,pep treatments,,,,,15 days prior to start,> 38.5°,,,,,,
10072,,monogenic diabetes syndromes,,,,antigen testing kits.|serious heart,,,,,within 4 weeks prior to first dosing.|administration of medications,16 or more|a,,,,,,
10073,,neurosis;|poor compliance,,,,regular opioid use,,,,,during dose interruptions,> 180 mmhg systolic,,,,,,
10074,,restless leg disorder,,,,properly functional prosthetic,,,,,within 90 days prior to the occurrence of,< 8.0 g/dl|platelet count,,,,,,
10075,,incarcerated,,,,begin treatment,,,,,for 30 days prior to screening/baseline through the second in-person visit|have a study partner available to help,≤ 20cm,,,,,,
10076,,pulmonary fibrosis,,,,emergency craniotomies,,,,,within 2 weeks prior to vaccination,+ ovarian suppression|able to understand the investigational nature of this study,,,,,,
10077,,conservative therapies,,,,corticosteroid injections,,,,,within 3 months prior to visit 1,"0, 1 or 2|able",,,,,,
10078,,active asthma,,,,deterioration,,,,,within 28 days of day -1.|received,≥ 18 years.|diagnosed,,,,,,
10079,,ovarian surgery|uncorrected uterine pathology|other endocrine diseases,,,,abdominal compartment,,,,,within the past 12 months|forced vital,>30)|ecog,,,,,,
10080,,hereditary liver disease,,,,da surgery,,,,,during the trial;|women in lactation,"19 or over 30,|alcohol",,,,,,
10081,,acute mi,,,,standardized treatment,,,,,at screening and day,≤ 1.5 × uln.|alanine,,,,,,
10082,,left heart failure,,,,complete response,,,,,within 60 days of visit 2,> 1.0 x 109/l,,,,,,
10083,,period;|severe anemia,,,,health assessment checklist,,,,,more than 20 degrees of mobility,19-60 years old,,,,,,
10084,,endometrial resection,,,,radiological suspicion,,,,,within the last 3 months|use,score higher than the age-specific threshold points,,,,,,
10085,,gall bladder cancers,,,,prescriptions,,,,,at the time of referral,>300 mg per g,,,,,,
10086,,clinics|asthma,,,,partial mastectomy,,,,,within the past year.|asthma,≥18 to ≤64 years,,,,,,
10087,,ultrafiltration failure|mental retardation,,,,egfri treatment,,,,,at least 1 documented,< 30g/l,,,,,,
10088,,duration)||unipolar depression,,,,radiotherapy||patients lacking capacity|patients,,,,,more than 12 weeks from initiation of therapy|all patients,≥ 30 mm,,,,,,
10089,,femoral neck,,,,technical successful tavi|residing in denmark|provided written informed consent||,,,,,during the study|currently,less than 2 months|heart disease,,,,,,
10090,,esophageal manometric findings,,,,anterior perineal resection,,,,,prior to first dose of study medication|are taking,bmi)of 28.0 to 45.0 kg/m2;||,,,,,,
10091,,myalgic encephalitis/fibromyalgia/chronic fatigue syndrome,,,,upper gi endoscopy|symptoms of,,,,,within 12 months of screening.|a participant,≥ 7.0 mmol/l,,,,,,
10092,,muscle-tendon injuries,,,,erythrocyte sedimentation rate,,,,,within 6 months before first dose of study treatment,score less than 24.|affected,,,,,,
10093,,walking aids,,,,herbal remedies,,,,,within 1 month prior to the first dose administration.|subject/patient,≥ 100 × 10^9/l|haemoglobin,,,,,,
10094,,tubal ligation|abstinence,,,,end organ damage|morbid,,,,,previously been enrolled in this study,> 100 x 109/l,,,,,,
10095,,end-stage renal failure,,,,clinical features ns,,,,,during the month before start of the trial,lymphoma|plasmablastic lymphoma||hodgkin's lymphoma.||for,,,,,,
10096,,total gross resection,,,,vaginal prolapse|inflammatory bowel disease|irritable bowel syndrome|systemic disease,,,,,within 2 weeks prior to enrollment;|ascites,100×10⁹ /l - hemoglobin 5.6 mmol/l,,,,,,
10097,,acute inflammatory demyelinating polyradiculopathy,,,,systematic psychotherapy,,,,,at least 60 min per,<80 mg/l,,,,,,
10098,,interstitial lung disease|chronic renal,,,,computed tomography should,,,,,during enrolment.|clinically,> 12 weeks|absence,,,,,,
10099,,seizure.|cryptogenic,,,,dxa scan,,,,,within 1 week prior to the first dose of study drug.|known,class ii or above,,,,,,
10100,,-stage dementia,,,,therapy of rcc|has available contrast enhanced (ce)-mri,,,,,within 6 hours from,1 - equal to or above,,,,,,
10101,,retinal examination|fluent,,,,ncct,,,,,since at least 48hours,≥ 18 years.|written informed consent.|eastern,,,,,,
10102,,peripheral neuropathy,,,,bilateral knee,,,,,available,90 years old.|pain,,,,,,
10103,,arrhythmias|mechanical complications,,,,chest radiograph,,,,,previous history,< 90 or > 140,,,,,,
10104,,depo provera,,,,cmri,,,,,within 6 months of randomization,≤ 1.5 mg/dl,,,,,,
10105,,inflammatory bowel disease|patients,,,,steroid replacement therapy,,,,,than 6 months before enrolment,> 6 months|adequate hematologic,,,,,,
10106,,glucose-galactose malabsorption|patients,,,,carotid stenting,,,,,within 48 hours of the first dose of the study drug,>3 and <12 in width or length,,,,,,
10107,,autoimmune disease.|epilepsy,,,,focal therapy,,,,,within 7 days of starting protocol therapy,less than 3.5|previous pelvic surgery|emergency surgery,,,,,,
10108,,smarrt-hd,,,,produce a reliable hearing test,,,,,within 4 weeks prior to the (first) study drug administration,<2.0 mg/100 ml,,,,,,
10109,,fibrosis|lung mass,,,,pep-ctn,,,,,for less than 6 weeks,>480 msec,,,,,,
10110,,except hypothyroidism,,,,ffr,,,,,at the time of procedure.|the subject,> 2|uterine,,,,,,
10111,,hiv-2 type patients;|other severe,,,,regular vitamin k,,,,,≤28 days prior to start of treatment,widespread,,,,,,
10112,,chronic wounds,,,,surgical resection procedure|planned,,,,,after at least one cycle,">/= 2,000/mm3",,,,,,
10113,,radiologic signs of,,,,lactating.|major surgery,,,,,for at least 6 months after the last study treatment,less than 30×109/l.||,,,,,,
10114,,idiopathic orthostatic,,,,vulvar procedures,,,,,at the time of starting study drug,">= 1,500/mm^3|registration",,,,,,
10115,,liver-related laboratory test results,,,,abdominal ct,,,,,for at least 14 days prior to trial treatment,≤2.5 times the upper limit of normal,,,,,,
10116,,right bundle branch block|systemic treatment,,,,cesarean section|multiple pregnancy||,,,,,prior to dosing.|have,<2+.|coagulation function,,,,,,
10117,,maxillary sinus,,,,mini-international neuropsychiatric interview (mini) version,,,,,at least 6 months prior to signing informed consent.|other than the medications explicitly stated,≥ 18 years|admission to the,,,,,,
10118,,solitary bone lesion,,,,functional,,,,,during the 3 month period prior to baseline,between 24 0/7- 32 0/7 weeks,,,,,,
10119,,preparations,,,,disease treatment,,,,,for 12 months after the end of study,"<2,5%|treatment",,,,,,
10120,,teavigo,,,,clinical medical director,,,,,for 6 months or more,≥ 20 years|enrolled,,,,,,
10121,,hyperosmolar nonketotic diabetic coma,,,,coronary intervention.|3,,,,,within the previous 6 months.|significant fatigue,2-3-4||hoehn-yahr staging:||stage,,,,,,
10122,,premenopausal breast cancer,,,,investigators:||systemic steroid therapy,,,,,at time of study entry.||ecog performance status,>= 9 g/dl|eligibility,,,,,,
10123,,cross-sectional imaging:||o tumor,,,,mechanical prosthetic heart valve,,,,,within 24 hours of,> 12 months.|in addition,,,,,,
10124,,oral manifestations,,,,cgm,,,,,within two weeks before first dose of study drug,20-60,,,,,,
10125,,arthus reaction,,,,bone marrow transplant,,,,,within 9 months;|diagnosis,≥60 ml/min/1.73 m2))|platelets,,,,,,
10126,,cruciferous vegetables,,,,maudsley's test,,,,,within 6 months prior to the start of study treatment,less than 30 kg|protected adult,,,,,,
10127,,nonchildbearing,,,,regular holter electrocardiography,,,,,within 4 weeks before entry into this trial,>/= 12 weeks.|participant must,,,,,,
10128,,neoplastic lesions,,,,surgically retrieved,,,,,at screening measuring ≥320 µm,between 50 and 85 years,,,,,,
10129,,esophageal variceal disease,,,,pharmacologic intervention,,,,,at the time of enrollment.|6 months to 3 years after diagnosis,<60 milliliters per minute,,,,,,
10130,,sinonasal malignancy,,,,arthroscopic anterior,,,,,within 12 months.|receipt of prior,6-12,,,,,,
10131,,stool,,,,female))/(72 x creatinine,,,,,within 7 days prior to initiation,stage 2,,,,,,
10132,,tendon pain,,,,resected basal cell carcinoma,,,,,within 4 weeks prior to first dose of study treatment,criteria:||unable to provide,,,,,,
10133,,≥18||diagnosis,,,,emergency procedure|patient,,,,,post-bronchodilator,< 110 μmol/l.||12,,,,,,
10134,,non light chain mgus/smm,,,,mesenteric artery occlusion,,,,,for at least 5 years leading up to the screening visit,>2.0 mg/dl,,,,,,
10135,,autoimmune hypothyroidism.|skin diseases,,,,rheumatologic diseases|concomitant therapies,,,,,longer than 2 years,18-85|subjects,,,,,,
10136,,bb,,,,trastuzumab-emtansine,,,,,within the 4 weeks before study drug,=<3cm|single tumor,,,,,,
10137,,cognitive deterioration,,,,tte.|documented left ventricular ejection fraction,,,,,within 3 months of study intervention administration,≤ 2.5 × uln.|alkaline phosphatase,,,,,,
10138,,common hepatic artery|in the,,,,vaginal estrogenic creme,,,,,within 14 days],>1.3 mg/dl,,,,,,
10139,,thyroid disorder.|children,,,,questionnaire.|donation of blood in excess,,,,,within the 12 months prior to study enrollment|a,> 1.5 x uln|ast,,,,,,
10140,,esrd,,,,laparoscopic evaluation method,,,,,within 6 months prior to enrollment.|qtcf,50 to 90,,,,,,
10141,,dysarthria|previous cerebral atrophy,,,,tobacco smoking,,,,,within 7 days prior to entry,greater than or equal to 18 years of age|diagnosis,,,,,,
10142,,degenerative meniscus lesions;|patients,,,,liver transplant recipient|>12 months after liver,,,,,within 14 days prior to first dose of investigational,>= 10%,,,,,,
10143,,method of contraception|healthy,,,,first-line platinum-based chemotherapy|receipt of avelumab1lm,,,,,within 2 weeks before screening.|presence of any abnormal,=< grade 1,,,,,,
10144,,athletes -,,,,hormonal therapy,,,,,within 3 months.|active acute,0-1.|minimum,,,,,,
10145,,non-hodgkin lymphoma|eligible for standard of care cd19.car,,,,ecg reading,,,,,within one year.|high myopia.|use of any drugs,> 10 g/dl,,,,,,
10146,,pulmonary embolism|a,,,,extracorporeal treatment,,,,,post-traumatic,between 18 and 65 years|subject,,,,,,
10147,,metoclopramide|pheochromocytoma,,,,mechanical circulatory,,,,,within the last 7 days.|reported use,> 6.5%|age 14-17,,,,,,
10148,,visual impairment||-,,,,bone marrow cytology,,,,,at least 7 days.|able to tolerate,≥ 18 years old 2,,,,,,
10149,,congenital cause of aa,,,,small cell components,,,,,within 4 weeks prior to the start of study,≥45% of predicted,,,,,,
10150,,coronary artery disease - uncontrolled hypertension,,,,erectogenic medications,,,,,prevent the practice of physical exercise,greater than 140/90 mmhg,,,,,,
10151,,alcohol use disorder.|lifetime diagnosis,,,,disease;|positive blood,,,,,more than 12 months after the clinical examination.|failure,28 grams per deciliter,,,,,,
10152,,t stage,,,,regular pregnancy tests,,,,,in the past 2 years,=< 14 days prior to,,,,,,
10153,,hyperthyroid disease,,,,mt).||,,,,,within the duration of the trial,equal to or greater than 20/30,,,,,,
10154,,peripheral polyneuropathy,,,,operative fixation,,,,,within 4 weeks of completion of first platinum-based,≤ 28.0 kg/m2,,,,,,
10155,,np-c.|np-c,,,,/emergency procedures,,,,,90 days after the last dose of balstilimab.||,^9/l||-absolute neutrophil count (,,,,,,
10156,,alchohol dependence,,,,computed tomography to confirm the diagnosis||,,,,,at least 30 ml/kg,75-150 min,,,,,,
10157,,ligamentous injury,,,,nsaids;|positive diagnosis,,,,,within 7 days prior to the first dose study treatment.|evidence of,> uln|egfr < 90 ml/minute/1.73 m2,,,,,,
10158,,aplastic,,,,sbt,,,,,in the past 5 years prior to enrolment;|women,≥25 cigarettes/day)|high,,,,,,
10159,,reflux on probing,,,,t2dm|food pantry participants|english,,,,,at least ',< 90 mmhg|creatinine clearance,,,,,,
10160,,chemoradiotherapy.|for,,,,abdominal b ultrasound,,,,,in the last 30 days prior to the study procedure.|patient,between 18-80 years,,,,,,
10161,,copd exacerbation,,,,elective cardiac surgery,,,,,at the involved,greater than 21.1 seconds,,,,,,
10162,,unexplained loss,,,,suprapubic catheter|performing,,,,,for 1 week after the last,< 55%.|uncontrolled hypertension,,,,,,
10163,,nk)||clinical findings,,,,study|unwilling,,,,,at least 1 week apart.|patients,"≥ 1,500 cells/μl",,,,,,
10164,,common carotid artery,,,,intervention-induced toxicity,,,,,during the time of the,≥ 103,,,,,,
10165,,chest disease,,,,neurologists,,,,,within six months prior to first dose of the imp,≤ institutional uln,,,,,,
10166,,neurologic status,,,,"follicular phase stimulating hormone, fsh",,,,,within 6 months before treatment,outside the range of 90 to 140 millimetre of,,,,,,
10167,,convalescent covid-19 plasma treatment,,,,blood clot,,,,,within 6 months before joining the group,≤1.5-fold the uln of the study site aptt,,,,,,
10168,,malignant tumor;|(c,,,,prednisone|indication,,,,,within 90 days prior to screening.|those,18 and ≤ 75 years,,,,,,
10169,,human epidermal growth factor receptor 2,,,,complete surgical resection,,,,,after hsct,>2x uln,,,,,,
10170,,localized tumor,,,,cervical epidural steroid injection,,,,,after surgery,>1.5×uln.|previous use,,,,,,
10171,,iron metabolism disorders,,,,wasid method);|intracranial artery stenosis,,,,,within 5 months after the last,≥ 70 years,,,,,,
10172,,intermittent claudication,,,,atrium health affiliated entity|age 18+|willing,,,,,in the last 30 days|undergoing treatment,< 24)|comorbidities of the,,,,,,
10173,,candidate for surgical management|patient,,,,radiographic vertical bony defect,,,,,within 12 weeks before the first administration;|poor control of diabetes,25-30 kg/m2.||,,,,,,
10174,,screening.|active hepatitis,,,,health volunteers|their spherical refraction,,,,,previously completed,7-56 iu/l)|more than 1 severe,,,,,,
10175,,falls|clinically stable,,,,small concentration changes may lead,,,,,throughout the duration of the study.|received strong breast cancer,> 8.0 g/dl|total,,,,,,
10176,,hip in 90-degree,,,,treatment system,,,,,at least 6 months prior to enrollment)|asymptomatic,≤ 14 days before the first dose of study,,,,,,
10177,,urethral cancer,,,,conventional urodynamics|able to tolerate,,,,,within 120 hours prior to randomization.||initial onset of the covid-19-related,60-89 mm hg,,,,,,
10178,,epidermolysis bullosa,,,,local anaesthetics allergic,,,,,at least 1 year,less than 90 days;|patients,,,,,,
10179,,c-urea breath test,,,,sleep diary,,,,,at time of the (first) administration of imp.|use,score of more than 6,,,,,,
10180,,corneal haze,,,,supine position after,,,,,at screening or site check-in.|patient,>3s longer than the control,,,,,,
10181,,fundus lesions,,,,poor control,,,,,for ≥ 3 years before screening,greater than 24;|absence,,,,,,
10182,,chest wall invasion,,,,whole-body status,,,,,preceding 24 hours|expected death,at least 16 cm outside,,,,,,
10183,,liver diseases (aasld) criteria,,,,ct guided bone biopsy,,,,,at the department of human nutrition,< 18 years or,,,,,,
10184,,multiple myeloma|scheduled,,,,colorectal resection,,,,,within 2 weeks prior to day 1 of cycle 1|history,greater than 0.2 ng/ml,,,,,,
10185,,females|history of hypersensitivity,,,,laser therapy.|eyes,,,,,within the past 3 months)|previous,<50 copies / ml,,,,,,
10186,,asymptomatic viral hepatitis,,,,graft versus host disease (gvhd);|13) subjects who,,,,,within 2 hours,<40 ml/min/1.73m2,,,,,,
10187,,gastric varices.||significant cardiovascular disease,,,,concomitant therapy,,,,,within 4 months before inclusion.|current enrollment,≥5.6mmol/l,,,,,,
10188,,study|healthy,,,,questions.||surveys,,,,,within preceding,≥ 0.25 d over,,,,,,
10189,,lung tuberculosis,,,,open ivor lewis esophagectomy,,,,,at the time of investigation,23+0 - 31+6 weeks,,,,,,
10190,,housekeeping,,,,bone allograft (fdba),,,,,more than 3 days a week on average,greater than 40 ml/min||,,,,,,
10191,,solid organ transplantation;|had,,,,kubang kerian,,,,,within the 72-hour timeframe|patients,145/95 mm hg,,,,,,
10192,,soft tissue disease,,,,hcv tests,,,,,within 28 days prior to the initial dose of study medication.||diseases:||i,between 40-70 years|gender,,,,,,
10193,,autism spectrum disorders,,,,non-repeating,,,,,within 6 months before the screening,">1.5 × institutional uln,|urine protein-to-creatinine ratio",,,,,,
10194,,cerebrovascular diseases;|patients,,,,pediatric surgery patients|elective,,,,,within 5 days prior to randomization,> 40 kg/,,,,,,
10195,,ubacc,,,,star fruit,,,,,within a timeframe <3 months,25-35 kg/m2|normal,,,,,,
10196,,complex aortic atheroma,,,,immature|cannot puncture,,,,,within 3 months before screening.|decompensated hf,1 - patients,,,,,,
10197,,periodontal conditions|patients enrolled,,,,blood pressure control,,,,,within 12 weeks following,< 30%|single kidney,,,,,,
10198,,octoxinol-9,,,,psychiatric stabilization unit made,,,,,in the 3 weeks following last trial vaccination,<90 mmhg)|known,,,,,,
10199,,cystic ovary,,,,corticosteroid intraarticular injection,,,,,within 3 months|signed informed consent||exclusion,between 24+0 and 33+6 weeks,,,,,,
10200,,end-stage liver,,,,emergency department|suspicion,,,,,in the next 1 year|history,> 0.75ng/ml,,,,,,
10201,,connective disease,,,,first-line treatment).|patients,,,,,"between january 1, 2016",5-7|being 3 and above,,,,,,
10202,,involvement in developing,,,,aneurysm|previous cardiac surgery,,,,,in the previous 6 months.|surgical periodontal therapy,functional class iii,,,,,,
10203,,lack of effective treatment,,,,blood pregnancy test,,,,,after testing positive,=< 3.5 times upper limits of normal,,,,,,
10204,,digestive stoma,,,,stool specimens,,,,,within 4 weeks prior to study day 1 or,long-term use of immunosuppressants;|5,,,,,,
10205,,ucsf,,,,cranial mri scan.|eligible,,,,,at time of screening.|moderately to,18 years and older|subject willing and able to give,,,,,,
10206,,squamous cell skin cancer|carcinoma in situ of the cervix|carcinoma in situ of the breast|incidental histological finding of,,,,bcrp).|investigational therapy,,,,,prior to randomisation,146 mmol/l,,,,,,
10207,,malignancy)|serious mental illness,,,,arabic language|written informed consent||,,,,,for at least 4 weeks prior to start of study treatment|other malignancy,"40 to 80, inclusive",,,,,,
10208,,chronic pain syndrome|diagnosis,,,,therapeutic arm):||severe,,,,,within 28 days prior to the first dose of ft538,2 or 3,,,,,,
10209,,septum,,,,surgical ablation,,,,,polyps;|previous history of,≥ 35 kg/,,,,,,
10210,,t-cell therapy,,,,first-line standard treatment,,,,,during the 5 previous years.|4,less than 15 on,,,,,,
10211,,crps)|current cancer,,,,table 1|clinical history,,,,,during the study timeframe||,≤ 35 db,,,,,,
10212,,discharged home,,,,hbot,,,,,within 3 months|current unrevascularized,90 ml,,,,,,
10213,,spleen enlargement,,,,sequential,,,,,within 3 months prior to randomization;|patients,less than 6 weeks|evidence,,,,,,
10214,,total lactase deficiency,,,,good oral hygiene,,,,,"at the time of diagnosis,|person subject to legal protection scheme",1 to 3 years,,,,,,
10215,,upmc,,,,antimycotic treatment,,,,,in the last 1 year|contraindications,<2.5 x uln;|alkaline phosphatase,,,,,,
10216,,prolonged qt-interval syndrome,,,,bilateral elective neck dissection,,,,,within the last past 5 years|smokers,0-1.|good organ function|the,,,,,,
10217,,skin cancer exclusion,,,,coronary artery stenosis,,,,,within 4 weeks prior to screening.|unstable,≥ 18 years|willing to provide,,,,,,
10218,,acute stroke;|③,,,,optimal antihypertensive treatment,,,,,less than 2 years|blood,≥ 1.0 x 10^9/l|platelets,,,,,,
10219,,fanconi anaemia,,,,bladder exstrophy,,,,,agents);|recent,≥ 18 and ≤ 70,,,,,,
10220,,cholangiocarcinoma recurrence,,,,total ankle arthroplasty|patient,,,,,within the past 2,40-79,,,,,,
10221,,fracture dislocation,,,,ce-ct imaging,,,,,less than 3 months|neurological disease|history of lumber spinal surgery|pregnancy|active skin,19 and 70,,,,,,
10222,,tuberculosis peritonitis,,,,pelvic salvage radiotherapy,,,,,at the time of transplant,class ii to class,,,,,,
10223,,heart transplantation.|active infection,,,,hematopoietic stem cell transplantation,,,,,at least 3 times per week before the onset of achilles,less than 28,,,,,,
10224,,cardiac function(no cardiac disease,,,,mechanical ventilation upon admission in icu,,,,,at the time of implantation,3-5 days,,,,,,
10225,,familial cancer syndrome.|prior receipt,,,,thoughts of self-harm,,,,,< 1 week prior to screening,> 12 months duration,,,,,,
10226,,isolated lesion,,,,inhalation general anesthesia,,,,,during the active procedure period,18-50 yrs,,,,,,
10227,,cerebral vasculitis,,,,ultraviolet b therapy,,,,,for at least 15 years,78-19 letters,,,,,,
10228,,sulcus).|symptomatic corneal edema,,,,prescription records of,,,,,at the time of registration|uncontrolled,≥50 ml/min/1.73m2,,,,,,
10229,,foot,,,,surgically sterilized,,,,,within 30 days prior to the first dose of trastuzumab deruxtecan,at least 16 weeks,,,,,,
10230,,non-interventional registry,,,,radiation-induced,,,,,before the onset of the disease,<3.5 g/dl|international,,,,,,
10231,,mild allergic rhinitis,,,,multigated acquisition scan,,,,,at the time of surgery.|genetic,≥ 80 g/l|neutrophil,,,,,,
10232,,ncd,,,,umf,,,,,"pre-eclampsia,|breech presentations|antepartum hemorrhage|cephalopelvic disproportion|body mass",< 3 days,,,,,,
10233,,uterine agenesis.|body mass index (bmi),,,,open wound|i̇nflammatory,,,,,within 3 weeks prior to study entry,>= 10 days prior to randomization,,,,,,
10234,,paravalvular,,,,rna extraction,,,,,at the time of enrollment|patients,≥ level 3).|the toxicity,,,,,,
10235,,imaging|concomitant cholecystitis,,,,apical granulomas,,,,,more than 8 hours/day|not,18 to 65;|dsm-5,,,,,,
10236,,motor system,,,,placement of graft,,,,,for at least one hour prior to the start of the intervention||,44-115 μg/dl,,,,,,
10237,,asthma.||,,,,rest.||d.,,,,,within 12 weeks prior to randomization|neutrophils,≥1 to ≤ 4,,,,,,
10238,,non-valvular atrial fibrillation,,,,active treatment|rectovaginal fistula|history,,,,,lactation.|medical history of chronic disease (cld,> 7.5%,,,,,,
10239,,recurrence of covid-19 in the form of,,,,focal ablation,,,,,at the time of the study)|patient definition,≥80×109/l,,,,,,
10240,,cystic fibrosis.|known,,,,prostate surgery,,,,,while receiving study treatment,≥60%,,,,,,
10241,,patients:||- died,,,,scleral buckling procedure,,,,,28 days prior to cycle1 day 1(c1d1,"18.5-35 kg/m2,|who",,,,,,
10242,,itch,,,,produce cognitive,,,,,at least 4 weeks prior to randomization.||table 4 adequate,≥ 1500/mm3|platelets,,,,,,
10243,,chronic obstructive pulmonary lung disease,,,,imaging,,,,,during their participation in the study|a minimum of 20 natural teeth,> 140mmhg,,,,,,
10244,,clinical manifestations of spinal cord compression.|major surgery,,,,triphasic ct angiography.|execution of mechanical endovascular thrombectomy procedure,,,,,within 2 weeks of first administration of study drug|uncontrolled,higher than 15%,,,,,,
10245,,hcc|active infection,,,,clean intermittent catheterization (,,,,,in the previous 3 months)|other medical conditions,less than 72 hours before randomization|written,,,,,,
10246,,confirm ovarian,,,,screening examination,,,,,in past 2 years|clinically significant,>/= 12 weeks.|participant,,,,,,
10247,,evolutive allergic,,,,maintenance therapy,,,,,during the study period and within 1 month after the last dose of the study drug,> 5%,,,,,,
10248,,pathology laboratory.||if her2,,,,surgical staging,,,,,for at least 6 months|have,from 25 to 75 ml/min/1.73m2,,,,,,
10249,,left atrial volume index,,,,multifocal spectacles.|be,,,,,in the next 3 months|lost 10 or more pounds,from 18 to 70 years|discernment,,,,,,
10250,,accessible for pretreatment,,,,myelosuppressive therapy,,,,,within 2 weeks prior to the first dose of study drug,less than 20 times|no cannabis use,,,,,,
10251,,placed other instruments,,,,12-lead ecg.|history,,,,,for less than 10 years.|non-insulin dependent type 1 diabetic.|less than 50 years,> 15 x 10^9/l 7 days before,,,,,,
10252,,bachelor,,,,target arterial stenosis||,,,,,within 14 days prior to the study,125 ml,,,,,,
10253,,congenital hearing loss|babies,,,,transient elastography method,,,,,at visits 1 and,above 37 weeks,,,,,,
10254,,renal colic,,,,vascular surgery outpatient clinic (lumc),,,,,within the following 7 months.|participation,≤ 24 weeks prior to randomization.||note,,,,,,
10255,,protective clothing,,,,mini-cog scores,,,,,in the past 5 years except,within normal institutional limits||,,,,,,
10256,,perianal fistulae,,,,full treatment cycle;|patients,,,,,at least 1 week prior to screening visit,≤ -4 meq/l,,,,,,
10257,,capsular bag,,,,comorbid treatment,,,,,for the next 6 months.|able to provide,60 minutes,,,,,,
10258,,adrenocortical dysfunction,,,,major surgical resection,,,,,within 1-2 months after surgery.|patients,class a-b8|adequate,,,,,,
10259,,hemorrhagic disorders,,,,ici therapy,,,,,within 30 days prior to screening|known hypersensitivity,>3 months,,,,,,
10260,,muscle injury,,,,criteria|major surgical procedure,,,,,for at least one month after treatment discontinuation,">1,000 to <= 150,000 asexual",,,,,,
10261,,extrapulmonary disease|patients,,,,exercise-induced,,,,,for at least 3 months after the last dose of investigational product|be currently participating in another t1d treatment study|have hearing loss,">30),|previous analgesic medication",,,,,,
10262,,hgsoc,,,,wash out periods,,,,,in the previous 4 weeks,score of 19-26.|subject,,,,,,
10263,,colorectal adenocarcinoma|serum cea,,,,lateral wheightbearing radiography of the affected foot.||,,,,,within 2 weeks before randomization.||4、subject,above the lower limit of detection,,,,,,
10264,,obese,,,,anatomical structural,,,,,during study participation.|patients,> 450 ms|uncontrolled,,,,,,
10265,,less).|ability to read/understand english,,,,elimination diet.||statistical analysis statistical analysis,,,,,during the 6 month period prior to baseline,> upper limit of normal);|had,,,,,,
10266,,pulmonary encephalopathy,,,,chest ct examination,,,,,within 28 days of cycle 1 day 1)|willingness to provide,above 60 years,,,,,,
10267,,primitive immature,,,,bile duct),,,,,for at least 12 months after the last dose of the study,12-16 years,,,,,,
10268,,pathogenic germline mutation,,,,inotropic therapy.|inability,,,,,within the last 3 months|pregnant,<= 1.5 x upper limit of normal value (uln),,,,,,
10269,,complaint of anxiety,,,,rapid fluctuation of renal function,,,,,within 12 months prior to enrollment,> 20 years-old adults.|patients,,,,,,
10270,,forms,,,,mucosal endoscopic resection;|patient,,,,,within 1 month prior to the screening,under 18 years|can't be able to read,,,,,,
10271,,upper lumbar,,,,serological tests,,,,,within 6 months prior to screening|myocardial infarction,3 to 18 years,,,,,,
10272,,lateral epicondylopathy|pain vas,,,,exclusive cirt treatment,,,,,at least 6 months,i-iii|children should,,,,,,
10273,,adult siblings,,,,curative intent|history,,,,,before starting chemotherapy;|availability of informed consent of the patient to participate,20 mm to 30 mm|patient,,,,,,
10274,,malabsorptive disorders|decompensated,,,,myopia treatment,,,,,at either screening or day -1.|estimated glomerular filtration rate (egfr,17.5 to 30.4 (inclusive),,,,,,
10275,,atherosclerosis|raynaud's phenomenon|coagulopathy,,,,transferrin saturation,,,,,within 2 weeks prior to the investigational,smoker,,,,,,
10276,,behavioral problems|several mental,,,,completed drug therapy,,,,,within 5 half-lives,12 to <16 years,,,,,,
10277,,esophageal symptoms,,,,receives,,,,,at least 7 days apart,> 50 ml/min,,,,,,
10278,,breast cancer|non pregnant,,,,"world medical association, 2013)",,,,,continue to increase for 2 weeks);|steroid,2 to < 6 years,,,,,,
10279,,stage liver disease,,,,b-scan ultrasound,,,,,before stroke.|greater than three months,between 10,,,,,,
10280,,chronic ear disease,,,,re-screening,,,,,at the time of initial diagnosis / treatment,>35 kg/m²,,,,,,
10281,,venous wounds,,,,video computer,,,,,in the 24 hours prior to mechanical ventilation,more than or equal to 1 per month)|have oral,,,,,,
10282,,biliary disorder,,,,ria,,,,,at least 5 years before enrollment);|there are,ocular discomfort &,,,,,,
10283,,intracranial subarachnoid,,,,salvage surgeries,,,,,at day 1,< 17.0 kg/m2,,,,,,
10284,,hypertension coronary heart disease,,,,cardiovascular surgery,,,,,within 14 days|car-t therapy,≥ 18 year-old,,,,,,
10285,,stable angina,,,,smn2 splicing,,,,,during the pre-surgical anaesthesia consultation,objective,,,,,,
10286,,diabetes|uncontrolled hypertension|sepsis,,,,tubectomy,,,,,for at least 1 week prior to study treatment initiation (,15%,,,,,,
10287,,tic disorder,,,,world health organization task force (holm et al 2005),,,,,during the study|history of psychiatric illness,>/= 8 weeks before,,,,,,
10288,,residual microscopic disease,,,,intra-operatively|intra-operative,,,,,at the time of enrollment|parent,between 4-12||to apply to the,,,,,,
10289,,infarction,,,,physical malfunction of the sensor sites which would,,,,,in the last 30 days prior to recruitment,≤ 2.5 × upper limit of normal,,,,,,
10290,,of:||myelodysplastic syndrome,,,,rca,,,,,at the time of inclusion.|any circumstance that,= serum glutamic oxaloacetic transaminase,,,,,,
10291,,localized prostate cancer.|urine bacterial culture,,,,recurrent cases|prior,,,,,within the last 6 months|having,> 120 beast/minute,,,,,,
10292,,teeth have,,,,accepted method of birth control listed below,,,,,within 4 weeks before the first administration,<75 μm,,,,,,
10293,,severe personality disorder,,,,pancreatic surgery,,,,,within the past month.|patients,at least 20/30|history,,,,,,
10294,,traumatic brain injury|unable,,,,immunosuppressive medications.|history of,,,,,within 1 week prior to screening assessment).||creatinine clearance,≤ 2.5 × uln|aspartate transaminase (ast),,,,,,
10295,,severe lung disease,,,,bone fracture.|patients,,,,,"in the last 3 hours,|redness",= 285 ml,,,,,,
10296,,deficit|severe,,,,convalescent plasma for covid-19,,,,,within 6 months before the first dose of study drug,grade c or d,,,,,,
10297,,cerebral white,,,,dna testing.|antiviral prophylaxis,,,,,within 2 weeks prior to the expected date of the first dose,less than 45 kg,,,,,,
10298,,digital scanning.||patients,,,,laparoscopic gynaecological surgery,,,,,within 4 weeks prior to the study's initial dosing;|treatment,> 0.5 g/dl,,,,,,
10299,,thrombotic target lesion,,,,neo]adjuvant therapy,,,,,at time of consent|able to adhere to the study visit schedule and other,"?"" or|""have",,,,,,
10300,,gastric esophageal,,,,pathological hip,,,,,at time of the first study procedure.|patient,+ 0.74,,,,,,
10301,,spinal cord stimulators);|demand,,,,medical implant device,,,,,within 2 days for second-generation,between 25-30 kg/m^2)|renal insufficiency,,,,,,
10302,,abdominal fistulas,,,,cumulative dose of,,,,,within the past 4 weeks,>180 mm hg,,,,,,
10303,,acute copd exacerbation,,,,blood oxygen saturation||,,,,,during visits 2 and 3,18 to 35 years old,,,,,,
10304,,opioid preparations,,,,lung biopsy,,,,,in the head and neck,140-159 mmhg,,,,,,
10305,,cannulation site,,,,hcv|positive test for alcohol,,,,,at least 4,without transfusion.|hemoglobin ≥ 9 g/dl,,,,,,
10306,,refractory nausea,,,,therapeutic exercises||,,,,,within 4 weeks before initiation of study treatment.|treatment,"18-45,|iud",,,,,,
10307,,malignant cells,,,,pelvic floor surgery;|pelvic organ prolapse,,,,,at least 28,"greater than or equal to 100,000 cells/",,,,,,
10308,,non-smokers;|for dental implant groups,,,,digital palpation,,,,,within 2 weeks of the first day of study therapy,35.0-39.9,,,,,,
10309,,narcotic drugs;|the,,,,studies||key,,,,,at the time of transfer,18-80|normal oral food,,,,,,
10310,,cerebral haemodynamics,,,,implantation of a transcatheter heart valve of the sapien family because,,,,,at least 6 months after the last dose of adjuvant therapy.|radiation therapy,< 70.000/mm3)|severe,,,,,,
10311,,"oral hygiene routine,|antibiotic treatment",,,,histopathologic,,,,,3 months after treatment shows,score ≥ 26,,,,,,
10312,,upper urinary tract malignancy,,,,women|glomerular filtration rate (ckd-epi egfr,,,,,3 weeks prior to initiating dostarlimab,>3 per year,,,,,,
10313,,non-pathogenic fabry,,,,whole brain radiation therapy (wbrt),,,,,within 8 weeks prior to c1d1;|participants,between 5 - 10 mm,,,,,,
10314,,physically demanding,,,,ptcs lithotomy,,,,,"in the last 3 months,|not",≥ 9 g/dl|creatinine clearance,,,,,,
10315,,drug-induced psoriasis,,,,hematopoietic stem cell transplantation.|central nervous system leukemia,,,,,prior to beginning the therapy.|willing to sign voluntary informed consent for participation,greater than 35% of total bilirubin.|at entry,,,,,,
10316,,thrombotic events,,,,emergency cesarean sections,,,,,for at least three months|present,>=10 mm,,,,,,
10317,,secondary ns,,,,chronic asthma treatment regimen,,,,,within 30 days prior to the screening visit|known severe,≥18 years|karnofsky,,,,,,
10318,,living abo compatable,,,,neuraxial analgesia,,,,,within last 3-months)|blood,400 cm2 per thigh|volunteer,,,,,,
10319,,spirits/hard liquor,,,,testing||,,,,,during thumb-index finger,above 55 diopters,,,,,,
10320,,arthroscopically,,,,interventional clinical trial.|participant,,,,,within 6 months prior to randomisation|patients on double,higher than d8.|peripheral neuromuscular pathology,,,,,,
10321,,organ insufficiency|no,,,,percutaneous biopsy,,,,,after multidisciplinary evaluation,≤ 6 months prior to start of the study,,,,,,
10322,,topical preparations,,,,intravenous administration of,,,,,within 7 days before or after each study intervention,< 5.7%|available archived,,,,,,
10323,,heart conduction disease,,,,months|intraarticular knee injection,,,,,within 14 days before randomization.|allergic to the investigational agent,advice|aged 18 years or above|within 7 days of onset of stroke,,,,,,
10324,,acute rehab|diagnosis,,,,intermaxillary fixation,,,,,prior history of,"18+, fluent knowledge of english",,,,,,
10325,,adverse effect,,,,including:||physical examination,,,,,within the previous 4 weeks.|any condition,>= 60%|absolute,,,,,,
10326,,insulin|morbid obesity,,,,training program,,,,,within 24 hours prior to initiating study treatment,outside the range of 90 to 140 millimeter of mercury,,,,,,
10327,,ischemic cerebrovascular disease,,,,neckache|frozen shoulder|central obesity|acute lumbago|x-ray spine,,,,,in last 6 months,>= 40 kg,,,,,,
10328,,pleural fluid collection,,,,sleep time (tst),,,,,after surgery.|patients,heterosexual abstinence for the duration of the study,,,,,,
10329,,primary peritoneal cancer;|after surgery,,,,av transmission,,,,,at the time of enrollment.|have a,equal to or greater than 80,,,,,,
10330,,short bowel syndrome,,,,group:||able to read,,,,,during the intervention process,between 6 months,,,,,,
10331,,significant breathing,,,,behavioral variant frontotemporal dementia,,,,,at time of consent|ecog performance status,1 or 3,,,,,,
10332,,congenital qt,,,,pancreatic cancer|concomitant malignancies,,,,,at the screening visit.|mean sbp,c|having,,,,,,
10333,,severe copd,,,,allogeneic hematopoietic stem cell transplantation;(12,,,,,at the time of screening|csu duration,over 3,,,,,,
10334,,soft tissue lesions,,,,ehna intervention,,,,,at the time of signing informed consent,<18 years|hypernatremia|permanent,,,,,,
10335,,radial extracorporeal shock,,,,carbohydrate deranged,,,,,during the 10 days prior to first dose of study drug,>= 3.0 g/dl,,,,,,
10336,,radical operation,,,,cochlear implantation,,,,,at least 2-months prior.|participants,greater than the maximum for the scanner,,,,,,
10337,,implanted devices.|need,,,,coil embolization)|plan,,,,,at least 10 days before first dose,< 1.5 x upper limit of normal,,,,,,
10338,,metastatic transitional cell carcinoma,,,,chemo-radiation therapy,,,,,in the last 6 weeks|unstable copd,3-12 years.|both sexes|asa,,,,,,
10339,,occult breast cancer,,,,venous access not,,,,,for 12 hours,>12%,,,,,,
10340,,restorations,,,,basilar artery occlusion,,,,,within 5 years.|parathyroid hormone (pth,between 0-3.||healthy,,,,,,
10341,,radioembolization,,,,"pelvic surgery,|having",,,,,within 3 months before vaccination,2016|age,,,,,,
10342,,acute upper,,,,fix inhibitor,,,,,within 24 hours prior to the 1st dose of vaccination.|previously vaccinated,≥3.0×109/l,,,,,,
10343,,uncorrectable coagulopathy,,,,whole extremity,,,,,after ~4 weeks of therapy,above 100,,,,,,
10344,,etc.)|presence of a,,,,months|ipsilateral hip,,,,,within 6 weeks before harvest;|oral fluorouracil,-18 years,,,,,,
10345,,sudden hypotension,,,,coronary artery bypass graft (cabg) surgery,,,,,within 4 weeks prior to baseline;|uncontrolled,≤ 60 years,,,,,,
10346,,neurologic diseases.|participants,,,,local clinical practice.||age:||male,,,,,within 2 years of first dose,37-42,,,,,,
10347,,esophageal reflux,,,,home oxygen,,,,,during the screening visit must,+/- 3 kg,,,,,,
10348,,aluminum chloride,,,,quality of the study data.|the use of an investigational drug,,,,,for the last 3 months prior to screening,<30 ml/,,,,,,
10349,,imaging|peripheral arterial disease,,,,urography,,,,,within 24 hours after onset of symptoms,=< 7.5 mg/day,,,,,,
10350,,antitumor indication,,,,antibiotic eradication,,,,,outpatient,"<150,000/mm3",,,,,,
10351,,code|opportunistic infections,,,,hepatitis|high blood pressure|elevated transaminases,,,,,for 4 months after the last dose of immunotherapy,60 years and older).||,,,,,,
10352,,generalized chronic pain,,,,complete supraspinatus (ssp),,,,,throughout the study period.|planned intervention similar to those abovementioned,≤ 1.5' institutional upper limit of normal (uln),,,,,,
10353,,criteria of activity,,,,open cystectomy,,,,,at least 3,≥ once a week,,,,,,
10354,,duodenal-jejunal bypass sleeve,,,,prespecified asthma action,,,,,more than 4 weeks,=< 2.5 x uln|estimated creatinine clearance of,,,,,,
10355,,more|type 2 diabetic,,,,cardiopulmonary resuscitation|patients,,,,,during the past 3 months;|other,100.4°f,,,,,,
10356,,carcinoma in situ cervices uteri,,,,immunosuppressive treatment.|treatment,,,,,throughout the treatment period,0-224,,,,,,
10357,,terminal illness|patients,,,,liver biopsy histology,,,,,during the maintenance period,between 18-40/ patients suffer from tmj,,,,,,
10358,,good oral hygiene|18,,,,study|central corneal thickness,,,,,for at least 48 hours,14-17 years|diagnosis,,,,,,
10359,,auto-immune disorder,,,,locoregional therapy,,,,,within 28 days prior to start of protocol,≤ 16,,,,,,
10360,,specialize mental health interventions,,,,remission|solid organ transplant,,,,,within 4 months prior to study day 0,18-65|women,,,,,,
10361,,available medical records|for,,,,mechanical intestinal obstruction.|nasogastric tube,,,,,within 4 weeks prior to treatment initiation,resources older 18 years||,,,,,,
10362,,interlocking pentagons,,,,dermatology surgery,,,,,at least 3 months||presence,class ii-iv,,,,,,
10363,,nerve damage,,,,heart disease.|having,,,,,before transplantation;|central nervous system leukemia;|arterial,above 34 weeks,,,,,,
10364,,clinician,,,,hev,,,,,more than 90 days pre-admission.|no,reactionscounter-indications,,,,,,
10365,,criteria:||recent myocardial infarction|recent,,,,period)|topical immunomodulators,,,,,within 1 week prior to randomization;|current,60 mmhg diastolic,,,,,,
10366,,formulation,,,,autologous,,,,,within 1 year before administration of the study drug;|smokers,iv-vi,,,,,,
10367,,cyp3a4 substrates|nursing mothers|pregnancy,,,,systemic therapy|major surgery,,,,,after the last dose of study treatment,> 60|life expectancy,,,,,,
10368,,ileal conduits,,,,injection sites|any surgery scheduled,,,,,for at least 3 months after the last dose of the study intervention,≥3|target lesions,,,,,,
10369,,musculoskeletal impairment,,,,supraclavicular lymph nodes,,,,,30 days after full coronary revascularization)|indication,between 18 and 75.|confirmed,,,,,,
10370,,spinal fracture.||serious diseases,,,,cranial epidural disease.||--note,,,,,within 14 days prior to the first dose.|has received,3.4 mmol/l)||,,,,,,
10371,,endometrial cancers harbor pathogenic pole mutations,,,,peri-implant mucositis,,,,,prior to study start,18 to 40,,,,,,
10372,,gastro paresis,,,,histological evaluation,,,,,within 28 days or five half-lives,below 400um,,,,,,
10373,,additional malignancies,,,,whole-blood specimen collected,,,,,within the previous 1 month,≥ 60 years;||bmi>25；||fever,,,,,,
10374,,gastric cancer resolved,,,,local standard of care,,,,,within 6 months of start of study,55 to 80 years,,,,,,
10375,,pre-gestational diabetes|sickle cell disease|major fetal,,,,triglyceride tg≧500,,,,,before 6 hours of birth.||,65-79 years;|have access to the internet,,,,,,
10376,,color,,,,pelvic mri scan,,,,,prior 18 months,< 13|patients,,,,,,
10377,,judged by the principal investigator or sub-investigator to be inappropriate for this study.||at,,,,hpv vaccination status,,,,,during the 10 days prior to surgery,>1.5 uln|patients,,,,,,
10378,,acute ischemic stroke|imaging examination,,,,clinical laboratory assessments,,,,,at least 3 problems,score of 18 or higher,,,,,,
10379,,actionable genomic alterations,,,,categorized into,,,,,at screening or baseline,18-45 years;|single term,,,,,,
10380,,developmental disorders,,,,baseline mean seated cuff diastolic blood pressure,,,,,last for 24 consecutive months,"≥ 75,000/mm3",,,,,,
10381,,cerebral vascular malformation,,,,instrumental tests (ct,,,,,7 days prior to check-in (day -1,≤ 1.5 x iuln|ast(sgot)/alt(sgpt,,,,,,
10382,,implanted electrical,,,,vital organ dysfunction;|inability to swallow,,,,,within 3 months up to,<24).|subjects,,,,,,
10383,,type of cancer,,,,therapeutic education program,,,,,6 months after the last dose of 64cu-anti-pd1 [,18 to 25 years,,,,,,
10384,,potential confounding|prostate cancer,,,,functional ambulation category (score ≥ 3)|cognitively intact as assessed by the hong kong version of the montreal cognitive assessment-5-minute protocol (,,,,,in the 3 weeks preceding inclusion,> 1.5 x the upper limit of normal (uln),,,,,,
10385,,congenital immune deficiency diseases,,,,excisional biopsy|previous axillary surgery|failure,,,,,for > 6 months prior to enrollment,>39.5)|compromised circulation,,,,,,
10386,,stiffness,,,,standard treatment options|patient recruited from the region of northern jutland,,,,,in the past 4 weeks|milk,between 6,,,,,,
10387,,certain eye diseases,,,,pragnancy,,,,,within the past thirty (30) days of the study,20-70 db)|patients,,,,,,
10388,,non sterilized,,,,computed tomography pulmonary angiogram,,,,,through 180 days after the last study dose,<3,,,,,,
10389,,active;|active infection,,,,palliative care;|legally blind,,,,,wthin half-year,at least three,,,,,,
10390,,malignant tumors;|pregnant,,,,|urine culture,,,,,in the last year||no additional,functional classification.|history of a current diagnosis,,,,,,
10391,,valgum,,,,inpatient,,,,,within 1 week prior to c1d1).|alanine aminotransferase (alt),18 years to 99 years old,,,,,,
10392,,non-nursing staff,,,,breastfeeding,,,,,within 6 months before study intervention administration through,≤ 3 × uln.|serum,,,,,,
10393,,atypical parkinson's syndrome,,,,paget hast,,,,,continue,pd ≥5mm,,,,,,
10394,,appendectomy;|acute infectious diseases,,,,soliris|concomitant,,,,,before enrolment,<50 x 109/l|hba1c,,,,,,
10395,,study.||current covid-19 infection,,,,pi.|compromised vascularity,,,,,within 28 days prior to the administration of this trial,>50|morning stiffness,,,,,,
10396,,azospermia,,,,neurological disease.|significant language comprehension impairments,,,,,within 14 days prior to initiation of treatment,90 mm hg and <140 mm hg,,,,,,
10397,,malignant bone tumour,,,,tubal surgery,,,,,within 7 days of onset/under duration of talazoparib plus enzalutamide treatment,>= 180/110,,,,,,
10398,,regular smoking,,,,structured interview guide,,,,,within 14 days prior to initial administration;the,>22.7 pmol/l,,,,,,
10399,,delirium;|abnormal laboratory indexes,,,,treated for periodontitis,,,,,before prior to study entry,"< 50,000",,,,,,
10400,,congenital heart disease|asymptomatic newborn,,,,angioplasty ± stenting,,,,,at birth less than 32 weeks|birthweight,18.5 or more,,,,,,
10401,,major chronic illnesses,,,,bladder exstrophy abroad,,,,,within 6 months prior to randomisation.|vaccination,more than or equal to 130/85 mmhg,,,,,,
10402,,venous sinus stenting|visual loss,,,,whole-exome sequencing)|ngs testing has been ordered,,,,,within 3 months before screening.|blood donation,7.8-10.2 mg/dl,,,,,,
10403,,cardiopulmonary disease|renal dysfunction,,,,endometrial ablation,,,,,within 2 years of first dose of study drug,10 cm,,,,,,
10404,,judged by the researcher to be unsuitable for this clinical trial,,,,pth therapy,,,,,at the time of screening.|history of,≥10 mm,,,,,,
10405,,hereditary coagulation disorder,,,,)|symptomatic knee osteoarthrosis,,,,,within past 6 months.|history,more than 100 copies / l;hepatitis c virus (hcv) antibody,,,,,,
10406,,giant papillary conjunctivitis.|patients,,,,bilateral oophorectomy or|hysterectomy,,,,,at the time of the surgery|the,< 90mmhg;|sbp drop ≥ 20 mmhg,,,,,,
10407,,stent restenosis,,,,protective measures,,,,,within six months;||patients,14-55,,,,,,
10408,,acute physical illnesses|if,,,,inguinal hernia repair is the main operation,,,,,within 4 weeks prior to the first dosing,between 18 and 60 years;|presence of pain,,,,,,
10409,,male factor,,,,allogeneic hematopoietic stem cell transplantation;|10,,,,,at the time of enrollment.|neurologically healthy,≥ ib,,,,,,
10410,,lying down,,,,single-barrier method,,,,,in the past 30,≥18 years|mechanically ventilated for more than 48 hours|fulfilling,,,,,,
10411,,various,,,,mechanical deformities|concurrent,,,,,recent three months before vitrectomy|patients,greater than 2 x uln,,,,,,
10412,,portal vein invasion,,,,internal fixation,,,,,within 2 weeks before screening laboratory sample,below 12.0 g/dl,,,,,,
10413,,covid 19;|elevated,,,,tpfla surgery,,,,,within 1 year prior to baseline.|history of,between 20 and 65,,,,,,
10414,,icp-248 tablets,,,,molecular biology (carrier of a mutation of the smad4,,,,,up to 3 days post-injection.|participant,< 1000,,,,,,
10415,,hilar adenopathy,,,,pregnancy testing,,,,,prior to the start of concurrent,18 years|caring,,,,,,
10416,,breastfeeding.|3,,,,nasal swab sample,,,,,within 180 days before screening.|history,>140 g/week,,,,,,
10417,,impact the quality,,,,multiple gated acquisition scan,,,,,within 12 weeks before initiation of the treatment,> 140/90,,,,,,
10418,,treated anxiety,,,,allogeneic tissue/solid organ transplant.|patients,,,,,within 30 days of study start,> 200 ml,,,,,,
10419,,major malformations,,,,tumoral material,,,,,within 3 months before randomization,singapore-based|non-clinical|18-35years||,,,,,,
10420,,coagulation,,,,robotic assissted laparoscopic radical prostatectomy,,,,,at the department of dermatology,"within normal limits,|who",,,,,,
10421,,congenital cardiothoracic anatomy,,,,mismatch repair deficient (,,,,,within 30 days of receiving study drug therapy,50 ml/min(cockcroft-gault formula,,,,,,
10422,,intrahepatic tumor burden,,,,hmg-coa reductase inhibitors,,,,,within 28 days prior to study initiation;|factors,platelets<75×10^9/l,,,,,,
10423,,congenital brain dysplasia,,,,psychosis|acute mania|severe alcohol,,,,,for at least three months after last procedure,> 30 g/day,,,,,,
10424,,actively enrolled,,,,percutaneous rhizotomy,,,,,newly-,> 21g/day,,,,,,
10425,,nodular sclerosis,,,,regiment of diabetes,,,,,at the time of screening.|severe,> 10‰,,,,,,
10426,,isolated nucleoside reverse transcriptase inhibitor mutations,,,,stimulators|cardiac,,,,,within 2 weeks before the first dose of investigational drug.||medication,<20 or >85||history,,,,,,
10427,,radiofrequency lesion,,,,core needle biopsy,,,,,"within the past 3 months,|4",>2 years||,,,,,,
10428,,carcinoma|lack of tumor,,,,iud)|total hysterectomy,,,,,within 1,less than 50×109/l,,,,,,
10429,,acute febrile processes,,,,chimeric antigen receptor (car) t-cell therapy,,,,,at time of study entry.|statement of ability to take oral medication,score of 1,,,,,,
10430,,anal fissure,,,,augmentation cystoplasty,,,,,within 24 weeks;||7.other conditions that the investigator considers,greater than 160 or less than 95 mmhg,,,,,,
10431,,meningeal metastasis;|have,,,,enrolled,,,,,within 12 weeks prior to screening.|prior treatment,< 160 and > 90*.|diastolic blood pressure,,,,,,
10432,,recurrence.|for aml,,,,haifu knife;|patients,,,,,for at least 6 hours).||,grade 4/severe,,,,,,
10433,,cerebrovascular disorder,,,,bone marrow mrd,,,,,within 7 days before first study drug,≥ 10 mm,,,,,,
10434,,paramedics,,,,cognitive-communicative ability,,,,,within 3 months prior,> 90 mmhg|unstable,,,,,,
10435,,urinary system disease.||,,,,cardiac monitoring,,,,,within 7 days prior to registration.||adequate organ function laboratory values||absolute neutrophil count (,deeper than 4 mm.||,,,,,,
10436,,unsuitable for pregnancy,,,,hp mri can,,,,,within 5 days prior to study enrollment|hemodynamically abnormal,18-25 years|had,,,,,,
10437,,ischemic lesions,,,,vertical root fracture|teeth,,,,,within 6 months prior to the day,above 16 years old,,,,,,
10438,,vitamin e,,,,resumption of treatment,,,,,prior to initiation,≤ 20 points,,,,,,
10439,,pathological remission,,,,transdermal hormone contraception.||d.2,,,,,at least three hours before the scheduled exercise,18-75|undergoing,,,,,,
10440,,liver enzyme,,,,dental prophylaxis,,,,,within a specific time frame,=< 2.5 x uln,,,,,,
10441,,disseminated intravascular coagulation)|thrombocytopenic purpura|patients,,,,later allograft nephrectomy,,,,,within 3 months prior to the first,frequency ≥ 7 per,,,,,,
10442,,early psychosis participants:||clinical,,,,complete heart block.|patients,,,,,within the past 3 months|known,≥ 55kg,,,,,,
10443,,decreased mouth,,,,core lab.|transvenous icd,,,,,within 60 days prior to study entry.|thrombolytic therapy,2.5 x uln,,,,,,
10444,,benign breast diseases,,,,dual energy x-ray absorptiometry,,,,,at that time is acceptable||within the past 72 hours,higher than the lower limit of detection,,,,,,
10445,,psychologically compromised,,,,x-ray,,,,,within the past 5 years|participants,=< 3 × institutional uln|creatinine <= 1.5 ×institutional uln,,,,,,
10446,,alcoholic drinks,,,,re-amputation|severe malabsorption disease,,,,,within four weeks prior to period i,>2mm.|≥ 16 years,,,,,,
10447,,recist v1.1,,,,palliative care,,,,,administered in last 3 months,between january 2011,,,,,,
10448,,psychiatric diseases|psychotic disorders,,,,viral rna detection,,,,,in the 6 months prior to treatment,-75 years,,,,,,
10449,,rotator cuff injury,,,,stent angioplasty,,,,,within the 6 months|diet free,≤1.5 ×uln,,,,,,
10450,,allergic bronchopulmonary aspergillosis cystic fibrosis,,,,ligamentoplasty,,,,,within the last 90 days,shorter than the cycle duration,,,,,,
10451,,ascvd,,,,psychotherapy o,,,,,disease|history,25 g/l,,,,,,
10452,,menopause,,,,opiates|pregnancy|emergency surgery,,,,,within 3 months of study enrollment|cohort,≥ 3uln,,,,,,
10453,,diabetic ketoacidosis (dka),,,,exercise mri,,,,,within 6 months before first dose of siltuximab.|history of,14-18 years,,,,,,
10454,,calcified shadow lesions,,,,concomitant procedures,,,,,within the last 5 years)|enrolled,>18.5 kg/m2,,,,,,
10455,,diabetic foot wounds,,,,previous exam,,,,,at baseline|confirmed,<88% or >92% for,,,,,,
10456,,systemic therapy|with measurable lesions,,,,sieving,,,,,for at least 14 days prior to dosing.|the subject,1-2,,,,,,
10457,,meaning,,,,cardiac revascularization,,,,,in the last 12 months within the year before the initiation of benralizumab.|provision of signed written informed consent form (icf,greater than c2n2)|patients,,,,,,
10458,,benign congenital hyperbilirubinemia,,,,riteria:||•,,,,,within 30 days prior to first dose of study agent.|investigational research agents,<= 10 g/dl,,,,,,
10459,,visible papillary disease,,,,traditional chines herbs,,,,,during the examination.||,19-24,,,,,,
10460,,sample||,,,,"old,|not knowing",,,,,≤32 kg/m2,≤3.0×uln*,,,,,,
10461,,lichen erosive,,,,emergency thrombectomy,,,,,prior to imaging,12 ≤ age < 18,,,,,,
10462,,"criteria of the international ""global initiative for asthma""",,,,surgical treatment|range of motion impairment,,,,,within 5 months after the final dose of study,transfer|more than 2 doses,,,,,,
10463,,mild blepharitis,,,,inhalational agent||,,,,,history of malignancies||additional exclusion criteria,≥ 14 points,,,,,,
10464,,rhythm disorder,,,,lymph node metastasis (ct shows,,,,,within 28 days prior to administration of this trial,≥ 60cc/min,,,,,,
10465,,malignant cystic neoplasms,,,,haploidentical donor for isolation of virus-specific t-cells.|have,,,,,within 3 months after taking the experimental drug|the subject can communicate,≤ 1.5×uln.||,,,,,,
10466,,acute carbon monoxide,,,,pacing,,,,,within one month before this study,≤ 35 kg/,,,,,,
10467,,ampullary abdomen,,,,lung volume reduction surgery,,,,,at the time of screening.|hospital-,longer than 5 half-lives);|those,,,,,,
10468,,bundle branch block (bbb,,,,crrt treatment|patients,,,,,before and during study participation,≥ 30ml/min,,,,,,
10469,,distraction free,,,,hiv-1 infection.|history of treatment,,,,,within 30 days before or during the period of joining the group.|patients with poor control of diabetes,≥ 30 g / l.||renal,,,,,,
10470,,comorbidity risk(s),,,,hla matching,,,,,within 4 days (,50 years and older|lives,,,,,,
10471,,gastrointestinal tract surgery,,,,biopsy,,,,,at least 3 months before recruitment,60 and above,,,,,,
10472,,contemplation,,,,image inclusion criteria,,,,,within 30 days of the first prescription of palbociclib|having,> 40%,,,,,,
10473,,effusion,,,,insertions,,,,,within 7 days prior to registration.|men,=< 14 days prior to registration)|alkaline,,,,,,
10474,,pustular eruptions,,,,full mouth plaque score<30%|previous non-surgical periodontal therapy,,,,,within 1 month before screening;|patients,≥ 85 mm,,,,,,
10475,,localized fungal infections,,,,topical therapy,,,,,within 16 weeks of study day 1|any,≤ 80 db,,,,,,
10476,,churg-strauss,,,,open surgical,,,,,within the 3 month period prior to baseline;|any cataract surgery,long term medication,,,,,,
10477,,mentally disabled,,,,bilateral ctr-us procedures.||clinically significant,,,,,during which time,=< 3 x institutional,,,,,,
10478,,chronic renal,,,,brain mri screening.|subjects,,,,,within 4 weeks before screening;|those,>=1 month,,,,,,
10479,,pre-surgery cbct,,,,open abdominopelvic surgery,,,,,for at least 2 months,grade iii/iv)|clinical,,,,,,
10480,,myelogenous leukemia,,,,sant pau hospital.||,,,,,at least 12 months prior to screening,18-65.||exclusion,,,,,,
10481,,all.|burkitt lymphoma,,,,computerized tomographic angiography,,,,,during hospital stay|cardiogenic pulmonary edema|exacerbation of asthma,17-27 years.||class ii division 1,,,,,,
10482,,refractory angina,,,,mini international neuropsychiatric interview)|>20 on,,,,,in the previous 3 years.|patients,1 and 2 of study:||have,,,,,,
10483,,acute injury,,,,trace elements,,,,,within 3 months prior to first dose of study intervention.|hepatitis c antibody test result,from 18 to 24.9 kg/m2)||,,,,,,
10484,,non-rts,,,,benzodiazepine detoxification.|participation,,,,,within 12 weeks of the study,70 mmhg,,,,,,
10485,,hopeless teeth,,,,chemo plus cpi,,,,,before treatment.|patients with successful,at screening <60 ml/min/1.73 m2.|malignant,,,,,,
10486,,deep vein thrombosis|untreated lymphedema|untreated,,,,aorta surgery,,,,,prior to surgery|inability,>40||pathologically confirmed,,,,,,
10487,,non-compliant,,,,investigator|cholecystectomy,,,,,within 3 months prior to the first administration of the study drug,score of,,,,,,
10488,,hepatitis15 infections,,,,general health status,,,,,regimen.|plans to father a child while enrolled in this study,0-1.|age,,,,,,
10489,,imaginable pain,,,,ct scan of the chest,,,,,completed ≥ 3 weeks,< 16 h/day.|being,,,,,,
10490,,translocations;|concomitant diseases,,,,operation history;|the,,,,,within 3 years before the first dose of study treatment,20 msv)|completed more than 6,,,,,,
10491,,extrahepatic disease；|no complications,,,,ehr,,,,,at the time of informed consent.|subject,≥ 5 cm,,,,,,
10492,,laser retinopexy,,,,interventional procedure planned,,,,,more than 24 hours &/or,less than 70 years.|resectable,,,,,,
10493,,diseased skin,,,,discharged after,,,,,within the past 6 months|patient,exceeding 11 mbq/ml.,,,,,,
10494,,brain metastases|incomplete surgical resection,,,,peripheral artery bypass grafting,,,,,within 12 months prior to,12-18 months after endovascular treatment|the patient has,,,,,,
10495,,reduced ef.|has,,,,sitting posture,,,,,at least one standard treatment regimen,≥18 years|coronary ostial lesion,,,,,,
10496,,diabetic foot,,,,substance abuse|living in a facility such,,,,,within 2 months prior to dosing.|current smokers of more than 3 cigarettes,18 or older|stated,,,,,,
10497,,retinal abnormalities,,,,genetic testing|prior,,,,,for less than three months,< 22.00 and,,,,,,
10498,,cancer (ca),,,,oral antiviral treatment,,,,,within 60 days prior to enrollment,1-7years.|asa physical status,,,,,,
10499,,tumour markers.||no lymphadenopathy,,,,ahead of end of this study(for garantee of enough,,,,,within the last 6 years,<26,,,,,,
10500,,chromosome-positive,,,,subtotal resection,,,,,previous 2 months of,≥ 60|ability to communicate,,,,,,
10501,,spontaneous stools,,,,ultrasound scan,,,,,within the last 6 months|hemodynamically significant,greater than or equal to 2||mmse score below 20|persons referred,,,,,,
10502,,cancer|acute hepatitis|acute deep vein thrombosis|acute thromboembolism|cutaneous porphyria|obesity;|hiv infection,,,,spinal trauma.|whiplash.|pregnancy,,,,,for 6 months after the last dose;||,<40 kilograms|asa score,,,,,,
10503,,maternal consumption of probiotics|the need,,,,uti's,,,,,more than 6 years,> 280 lbs,,,,,,
10504,,alteration in mental status,,,,electrodiagnostic,,,,,within four weeks before enrollment;|according to the judgment of the researchers,> 70 or <,,,,,,
10505,,pancreatic cancer those,,,,covid testing,,,,,at screening.|history of threatment,i-iii;|cardiopulmonary functions,,,,,,
10506,,middle cerebral artery (mca)|occlusion (regardless of location,,,,visited,,,,,within 3 months prior to the screening.|ingestion of otc drug,between 9-14 years,,,,,,
10507,,mri.|previous malignancies,,,,testing of week 4a study visit laboratory tests:||ast,,,,,within 6 months prior to the study,≤ 18 years,,,,,,
10508,,communication problems|persons,,,,outpatient hysteroscopy,,,,,within the next 5 hours|patients deemed at,>15|able to understand the commands|had a function,,,,,,
10509,,retinal vascular lesions,,,,allohematopoietic stem cell transplantation);|symptomatic brain,,,,,during the treatment weeks,mutations.|karnofsky,,,,,,
10510,,spastic cerebral palsy,,,,axillary lymph node biopsy,,,,,continue to conduct the study,≥90 mmhg);|patients,,,,,,
10511,,kidney function;|abnormal blood tests,,,,revision tkr,,,,,for least 14 days before blood collection|active cancer,≥ 24 mm,,,,,,
10512,,radioactive conditions,,,,hepatic function,,,,,within 30 days of inclusion.|patient,greater than 1000,,,,,,
10513,,non-malay,,,,hospital admission,,,,,at least one of their parents consented to participate in the study.||,>27 units/week,,,,,,
10514,,thromboembolic event.|patients,,,,ampullary lesions||single ampullary lesion,,,,,within 12 weeks;|2,> 185 cm/sec,,,,,,
10515,,nursing.|uncontrolled intercurrent illness,,,,pathological records of,,,,,for ≥5 year;|single,older than two years,,,,,,
10516,,and|preterm babies,,,,thymidine phosphorylase activity,,,,,at the block site)|need for,1 or 2.|participants,,,,,,
10517,,sepsis|open pressure ulcers,,,,pep-dc1 vaccines,,,,,during all the study.|female,≥ 1800 ng/l,,,,,,
10518,,atrial fibrillation,,,,parenteral antimicrobial treatment,,,,,at the time of signature of the informed consent form,≤ 12 months,,,,,,
10519,,crystalline arthritis,,,,interventional treatment of this study||,,,,,within the past 6 months)|history,10*9/l);|subjects,,,,,,
10520,,pd|diagnosis,,,,sperm donation plan,,,,,within 6 weeks prior to enrolment.|cardiac valve surgery,> 105mmhg)|recently,,,,,,
10521,,benign diseases,,,,transfusion syndrome|selective radiofrequency ablation,,,,,previously received the recommended dose,score of 1.0+)|if on,,,,,,
10522,,frostbite burns,,,,bleaching treatment,,,,,6 months after,> 30 kg||patient,,,,,,
10523,,retained products,,,,genetic tests,,,,,within 1 month after the last dosing|unable to,>2 x uln,,,,,,
10524,,etc.)|allergy,,,,eccentric fixation,,,,,within 3 weeks despite proper wound care,at least 3 months|no,,,,,,
10525,,hepatic encephalopathy,,,,tnk(perfusion imaging completed,,,,,within 3 months|received,grades ii and iii,,,,,,
10526,,cohort construction,,,,produce cftr protein,,,,,within one month prior to the start of the study,> 1.5 x,,,,,,
10527,,hay fever,,,,surgery (laparotomy,,,,,at the time of providing informed,>300 mg/g,,,,,,
10528,,primary mn,,,,surgery of the cervical spine .|anatomical cervical spine abnormality|presented,,,,,at least 2 weeks prior to randomization|if,< 2mm,,,,,,
10529,,criminal vessels,,,,early treatment diabetic retinopathy study (edtrs)-like charts||,,,,,over the past week,>1g/dl below normal,,,,,,
10530,,fungal infections|patients,,,,urinalysis||hepatic panel,,,,,before first study drug administration,lower than 60 or over 90 mmhg,,,,,,
10531,,infectious origin|participant,,,,loop electrosurgical excision procedure,,,,,≤2 weeks prior to cycle,=qt/(rr0.33).||correction of,,,,,,
10532,,unusual reactions,,,,nonsurgical sterilization procedures,,,,,within the past 3 years|participants,>1800 pg/ml,,,,,,
10533,,arrhythmia events,,,,liver surgery,,,,,for at least 10 minutes,< 1cm2 or/,,,,,,
10534,,infectious uveitis,,,,standard neuropsychological evaluation|brain injury,,,,,at the time of admission.|admitted,less than five years,,,,,,
10535,,cerebral small vessel disease,,,,intracranial implants|history,,,,,during the week of scheduled testing|current,compartment,,,,,,
10536,,nares swab collected,,,,study procedures,,,,,within 4 weeks before the first dose of htmc0435|past surgical history,"570 ml of beer, 750 ml",,,,,,
10537,,ductal carcinoma in situ of the breast post radical,,,,substitute decision maker capable,,,,,at the time of nsclc diagnosis|patient,age≥ 18 years old,,,,,,
10538,,varicella zoster virus,,,,open surgery.)||,,,,,during embryo,">= 20,000/ul||minimal",,,,,,
10539,,insulin dependence,,,,cbc,,,,,within past 4 weeks,less than 11,,,,,,
10540,,als,,,,activities of daily living,,,,,during the test period until the last follow-up;|9、those who voluntarily participate,between 18 to 75 years,,,,,,
10541,,unhealed peptic ulcers,,,,corneal transplantation,,,,,after transplant,≥ 30 ml/min/1.73 m2|age,,,,,,
10542,,psychosocial risk factors,,,,valve surgery,,,,,more than 30 factory-manufactured,more than 5 times its half-life,,,,,,
10543,,upper extremity surgery,,,,bismuth subsalicylate,,,,,since they participated in this clinical trial,<40 ml/min|thrombocytopenia,,,,,,
10544,,b-cell lymphoma,,,,mw energy,,,,,"during the observation period,|pregnancy",18 to 63 years|females of childbearing potential,,,,,,
10545,,complaint has been,,,,lacting women|participants,,,,,after one of the following regimens:,≤ 5 seconds,,,,,,
10546,,solid organ transplant.||current,,,,nursing|irregular corneal disease|ocular surgery,,,,,within 28 days prior to cycle 1 day 1,≥3 months||adequate organ function,,,,,,
10547,,soles,,,,sarcomeric genes identified);|signed informed,,,,,within the last 6 months|planned,>10x uln,,,,,,
10548,,chronic diseases-related,,,,standard therapies,,,,,in the last six months||,< 2.3,,,,,,
10549,,intestinal ulcers,,,,coronary atherosclerosis,,,,,within the past five years,18-29 kg/m2|no,,,,,,
10550,,spontaneous peritonitis,,,,tobacco consumption,,,,,within 1 year of the first study procedure,between 18 and 60 years.||,,,,,,
10551,,bone metastasis akp,,,,reactivation of hepatitis b,,,,,in quiet,">=1,500/mcl|hemoglobin",,,,,,
10552,,genders|presence,,,,hormone treatments,,,,,during the study.|anything that the investigator(s) considers,gastroscope;|years older than 12;|no,,,,,,
10553,,block.|acute cardiac necrosis,,,,consistent liquid fecal output,,,,,within 4 weeks or 5 halflives,< 34 weeks,,,,,,
10554,,kidney disease,,,,emergency room,,,,,within 30 days after the first,lower than 10%,,,,,,
10555,,neurodegenerative conditions,,,,small amount,,,,,within seven days prior to investigational agent injection||laboratory abnormalities,ranges from 18 to 85 (inclusive),,,,,,
10556,,lobar degeneration,,,,therapeutic ind agents,,,,,within 2 weeks prior to the first dose of study treatment.|cytotoxic,> 3.5,,,,,,
10557,,chronic pain condition,,,,immunosuppressive therapy|patients,,,,,prior to radiation therapy|history of an,68 dotatate,,,,,,
10558,,corneal epithelial defect,,,,unequivocal tnbc histology,,,,,within the last year.|individual is pregnant,< 3 aspirations,,,,,,
10559,,"urinary tract infection|multiple ureteric stones,|presence",,,,regular prophylaxis,,,,,in the last 6 months|body mass index,>=12 on the,,,,,,
10560,,psychiatric problems.||,,,,enroll.|pathological,,,,,in the last 12 months|sexually inactive,less than or equal to 3/15,,,,,,
10561,,cardio-embolic etiology,,,,orthotopic heart transplantation,,,,,during the study related,≥ 15/50);|has,,,,,,
10562,,cephalic presentation|gestational,,,,unequivocal progression after radiotherapy;|histopathologically,,,,,8 months after the last dose of inotuzumab,"< 100,000/mm3|hemoglobin < 9.0 g/dl|alt",,,,,,
10563,,indigestion symptoms,,,,partial lipodystrophy,,,,,within the past 6 months|any condition,score of 5 or greater,,,,,,
10564,,introduction.|anatomic abnormality,,,,abruption of placenta,,,,,within 4weeks prior to screening,< 6 months before inclusion,,,,,,
10565,,malignant tumor|subjects,,,,mechanical contraception,,,,,at screening baseline.|any nasal obstruction,score ≤ 20%¬¬¬¬¬¬¬,,,,,,
10566,,tobacco,,,,pet scanning procedures under this protocol,,,,,within 6 months prior to screening|any reason,<50%)|unable to follow 2 steps commands accurately||neurological comorbidities,,,,,,
10567,,indexes,,,,corrected vision,,,,,in the last 12 months|latest,"at least 6/10th binocular,|patient",,,,,,
10568,,ichthyosis,,,,hrd testing,,,,,within 30 days prior to the informed consent,>2 years,,,,,,
10569,,marcular pathology,,,,spvn06 treatment,,,,,within 2 weeks after the first administration;|have a history of,greater than or equal to 18 years|undergoing,,,,,,
10570,,prolonged sun exposure,,,,retinoid therapy,,,,,"after 3 months,|any terminal disease",<1 year,,,,,,
10571,,hemorrhagic symptoms,,,,stress cardiac magnetic resonance,,,,,in the 14 days prior to the first study drug administration,18 ≤ years,,,,,,
10572,,orthostatic bp,,,,mini international neuropsychiatric interview,,,,,at screening|organ function requirements: all patients must,>140 mmhg,,,,,,
10573,,epidemic defects,,,,thoracic radiotherapy,,,,,during the year before the study.||,≥ 8.0 g/dl,,,,,,
10574,,associated conditions,,,,clinical cut-off on,,,,,in the past 30 days before randomization,age|>85 years,,,,,,
10575,,attributable to cll)|aspartate aminotransferase,,,,chemo-radiation.|have known medication on bacterial,,,,,for at least one month before study enrollment.|baseline plasma glucose concentration,> 0,,,,,,
10576,,irritable bowel,,,,hpv screening,,,,,at the time of acquisition of informed consent|histologically,>2|neurological impairment,,,,,,
10577,,pelvic mass,,,,invasive coronary angiogram,,,,,within the past 90 days,above 20 / 200,,,,,,
10578,,neoplastic disease|immunodepression,,,,dual antiplatelet therapy;|pregnancy,,,,,for at least 4 weeks prior to enrollment,score of ≥ 16 and ≤ 30,,,,,,
10579,,breast-feeding,,,,spinal nerve root,,,,,for at least 6 months prior to screening|able to understand and complete patient questionnaires|serum,score of > 7,,,,,,
10580,,herpes simplex,,,,dapt,,,,,within 5 years of treatment can participate in this trial;|previously received,18-75 years.|willing,,,,,,
10581,,conditions.|pregnant,,,,bowel involvement|unilateral of bilateral hydronephrosis|severe bowel stenosis,,,,,during the study period;|previous,maximum 6 weeks before registration,,,,,,
10582,,liver insufficiency,,,,topical glucocorticoid therapy,,,,,within 24 hours prior to enrollment|history of,< 60 ml min-1 1.73 m-2||xiii,,,,,,
10583,,inclusive|type 2,,,,therapeutic irradiation,,,,,in the past 12 weeks;|dietary supplements,outside 90-145 mmhg,,,,,,
10584,,syndromes|endocrine diseases,,,,first mace,,,,,before the randomization;|patient,> 500/microl||platelets:||platelet count,,,,,,
10585,,looser,,,,months|experienced resolution,,,,,within screening.|having,less than 100 mmhg,,,,,,
10586,,chronic hepatitis b infection,,,,palliative care|isolation,,,,,within 3 months of study completion|participation,> 2 times the normal,,,,,,
10587,,hyperphosphatemia,,,,test for it.||prisoner|participation,,,,,for at least 5,"score of 0, 1",,,,,,
10588,,sudden death,,,,panoramic radiograph,,,,,within 5 months after the final dose of atezolizumab,4-5 years,,,,,,
10589,,primary stability,,,,dbt exam,,,,,within the last 6 months.|other latent,30 to 60 days from the onset --of the,,,,,,
10590,,failure to respond to fviii,,,,clinical chemistry,,,,,at the time of signing the written informed,>90 mmhg);|any,,,,,,
10591,,language impairments,,,,bone anabolic therapies,,,,,3 months to less than (<),"18 years and over,||able",,,,,,
10592,,progression|human immunodeficiency virus,,,,abdomial surgery,,,,,for at least 3 months|history of any of the following medical conditions,≤ 5 times uln.|serum creatinine≤ the uln,,,,,,
10593,,questionnaire,,,,reliable birth control,,,,,at least 4 weeks prior to the screening visit.|concomitant therapy,18-75|chronic,,,,,,
10594,,urinary obstruction,,,,coronary artery reperfusion,,,,,prior to initial administration:||did not receive major surgery,≥ 126 mg/dl||vi,,,,,,
10595,,lost to follow-up,,,,local treatment guidelines|uas7 score (range 0 - 42,,,,,within 5mm of the serosal,>/=55%,,,,,,
10596,,recorded seizure,,,,european league,,,,,at the time of approach.||clinicians:||cancer risk physicians,functional class (,,,,,,
10597,,hearing problem,,,,laparoscopic access,,,,,within the last 4,>20 g/l,,,,,,
10598,,unintentional weight loss,,,,d-dimer,,,,,within approximately 12 weeks.|subjects,≥ 25.||,,,,,,
10599,,specialization,,,,vaginal vault suspension,,,,,in the past 3 months||,< 60 ml/min,,,,,,
10600,,head & neck cancer specialist,,,,laser resurfacing procedures,,,,,within 28 days of infusion|patients,greater than or equal to 6 months,,,,,,
10601,,drug-resistant epilepsy,,,,frequency assessment scale,,,,,within 3 months before screening or more than 200 ml,<1.25 d|patients,,,,,,
10602,,therapy||treatment,,,,optimal medical treatment,,,,,at the time of the study|currently living,= weight (kg) / height,,,,,,
10603,,local health authority,,,,perineal resection,,,,,within 6 months prior to enrollment；||patients,less than 4|age 40-80 years,,,,,,
10604,,covid-related,,,,depth of focus intraocular lenses,,,,,at least 12 months prior to enrollment;|adult partecipants between,between -0.75 d and,,,,,,
10605,,neurodegenerative condition,,,,local ethical requirements.||,,,,,in the past 1-3 years,≥1.5 times the upper limit of normal,,,,,,
10606,,cbs,,,,hygiene measures regarding,,,,,at the time of screening.||have vwm disease,18-36 months status-post,,,,,,
10607,,cerebral edema,,,,small area radiotherapy,,,,,for at least 50 days after administration of the last dose of imp in case of early termination,< 200 mmol/day|uacr < 30 mg/mmol|all,,,,,,
10608,,cognitive deficits,,,,roux-en-y bypass surgery,,,,,during the duration of the study;|has,less than 140/90 mmhg|human immunodeficiency virus,,,,,,
10609,,motor evoked potential,,,,blood pressure.||exclusion criteria,,,,,within one moth of study entry.|history,100-159mg/dl.||,,,,,,
10610,,thoughts of being better off dead,,,,bronchoalveolar lavage documentation,,,,,maximum 8 weeks,>= 500/ul,,,,,,
10611,,mild- moderate-severe,,,,cryosurgery,,,,,in the last 5 years prior to imp treatment start,score of 3 or less,,,,,,
10612,,good patellofemoral mobility,,,,gastric stapling,,,,,within the previous 7-days,from 0 to 20%,,,,,,
10613,,infections/oral,,,,visit.|bilateral knee pathology,,,,,at the time the informed consent form (icf,> 30 mmhg,,,,,,
10614,,inguinal herniation,,,,biplane flat panel detector computed tomography.|participated in another studies.|loss to follow-up after discharge.|a severe or fatal combined illness,,,,,prior to screening,≤ 3,,,,,,
10615,,liver metastases);|any antitumor treatment,,,,smart phone,,,,,last dose received,> 1.5 × uln|history,,,,,,
10616,,type 2 diabetes|using glucose-lowering medication,,,,intolerance.||for control group:||healthy volunteers age-and,,,,,within 2 weeks prior to study day 1 or,1.03 mmol/l,,,,,,
10617,,restaging,,,,pcr test,,,,,within 12 months after cell transplantation;|previous treatment,1.1.|estimated survival time,,,,,,
10618,,contact eczema,,,,rescheduling,,,,,within 4 months prior to the canvass.|alcohol consumption,6 months to 12 years old,,,,,,
10619,,rare actionable genomic alterations,,,,sedation,,,,,at the time of signing the informed consent||•,greater than 3 x upper limit of normal (uln),,,,,,
10620,,disease-related,,,,centric hip osteoarthritis,,,,,within the previous 12 months.|patient,from baseline to week 4|subject,,,,,,
10621,,insulinoma,,,,chimeric antigen receptor t-cell (,,,,,during the past 12 months.|receipt of,> 2)|age range,,,,,,
10622,,stimulating factor support,,,,mechanical ventilation/ecmo,,,,,prior to receiving randomized blood,≥ 12mm,,,,,,
10623,,congenital cerebral vascular malformations,,,,penetrating keratoplasty|limbal stem cell deficiency affection,,,,,within the 6 months prior to start of the study treatment.|a history of chronic,3-5 year,,,,,,
10624,,carpel tunnel syndrome.|severe covid-19,,,,small molecule investigational drugs,,,,,within 90 days of study entry.|serum,> 18 years|type 1 diabetes,,,,,,
10625,,mek,,,,simultaneously enrolled,,,,,more than 12 weeks,> / = 1 year,,,,,,
10626,,cramps /stomach pain,,,,intestinal blood supply,,,,,within 24 hours of admission)|patient,5th - 85th,,,,,,
10627,,limb ataxia,,,,esa treatment - non-response,,,,,in the last 3,<1.5 times uln,,,,,,
10628,,health questionnaire (phq-9),,,,esd procedure,,,,,within 60 days before enrollment,≥ 45000/ μ,,,,,,
10629,,calculated from electrocardiograms (ekgs),,,,colonoscopy procedures,,,,,within 6 months from the screening,> 2.0 x 109/l,,,,,,
10630,,early atrophy,,,,infection|osteoporosis|osteomyelitis|local burns|recent failed intraosseous,,,,,after first attempt,≥ 100 x 109/l.|hepatic function,,,,,,
10631,,cytomegalovirus infection,,,,left ventricular hypertrophy,,,,,at time of initiating study treatment,≤ 28,,,,,,
10632,,psoriatic arthritis,,,,tb examination,,,,,in the last 3 months|immunosuppressive,6 months to 71 months.|the participant's parent/guardian receives,,,,,,
10633,,not resolved,,,,study|plasma donation,,,,,in the last 6 months prior to,< 500 iu/ml,,,,,,
10634,,geographical condition,,,,oophorectomy,,,,,during the study.|currently has a schedule that includes nighttime,"100 and 2,000 mg/g",,,,,,
10635,,cutaneous squamous cell carcinoma,,,,tyrosine kinase inhibitor.|patients,,,,,within the last 8 weeks.|heart failure (hf,1 glass,,,,,,
10636,,disseminated encephalomyelitis,,,,anticoagulation drug therapy|antiaggregation drug therapy|biologically active additives,,,,,at the time of the parental study closure,45 ml/kg/min,,,,,,
10637,,"weeks,|psychiatric comorbidities",,,,hfnc,,,,,during the course of the study.|prior invasive therapy for,>430 ms,,,,,,
10638,,upper arm,,,,bile duct syndrome|shortening fraction,,,,,within three days before each dose of vaccine.|medical problems,narrow,,,,,,
10639,,urachus,,,,electrical medical device,,,,,within 4 weeks prior to screening|if the participant,120 days)||main,,,,,,
10640,,chronic viral infection,,,,diuretic therapy,,,,,within 7 days from enrollment,≥12 mm.||cohort,,,,,,
10641,,cognitive condition,,,,pelvic health physiotherapy,,,,,at the time of signing the informed consent.|body weight,≥1.5×10^9 /l,,,,,,
10642,,mixed cholangiosarcinoma,,,,bone marrow,,,,,at least 2 weeks prior to the planned ivs-3001 infusion,< 15;|hospitalization for nutrition rehabilitation;|covered,,,,,,
10643,,malabsorption,,,,bile duct injury repair,,,,,last at least 24 hours,>37 gestational,,,,,,
10644,,solid organ transplantation.||23：pregnant,,,,transitional cell,,,,,during the screening;|willing,≥45 kg且≤100 kg,,,,,,
10645,,dysgammaglobulinemia,,,,lipid lowering,,,,,since the initiation of last systemic therapy,>6.0 mmol/l,,,,,,
10646,,oropharynx cancer,,,,siewert,,,,,within the previous 1 month|any,>= 50ml/min,,,,,,
10647,,knee surgery|had,,,,exercise-related,,,,,within the last 3 months,≤ 1.5 x upper limit of normal(uln,,,,,,
10648,,oral tongue,,,,lateral epicondylitis|did,,,,,within a week of vaccination.|have,>3 times the upper limit of normal,,,,,,
10649,,waldenström's macroglobulinemia,,,,transfusion|creatine ≤1.7 x upper limit of normal (uln),,,,,after sexual intercourse,>= 2 years before enrollment,,,,,,
10650,,ild,,,,vaccine.|positive screening test results,,,,,within 4 weeks;|the patients,12 weeks.|measurable disease,,,,,,
10651,,unstable cardiac condition,,,,bisphosphate therapy,,,,,14 days after the second dose of covid19,< 2.5 x uln;|alkaline phosphatase,,,,,,
10652,,etoposide|complete response,,,,apical with anterior,,,,,30 days after vaccination；|have received,less than 1.5 times the upper limits of normal,,,,,,
10653,,mycotic infection.|severely ill,,,,bacteriological sampling,,,,,at least 5 half-lives,30-75 years|transthoracic,,,,,,
10654,,renal replacement therapy.|inability to undertake,,,,extramedullary leukemic cell infiltration.|meet,,,,,within 3 weeks prior to the first dose of study drug.|known,ii or,,,,,,
10655,,bone fracture sustained,,,,ecg changes,,,,,within the past 24 months.|subjects,≥ 2|past irradiation,,,,,,
10656,,anaplastic large cell lymphoma,,,,opioid treatment,,,,,within the last 24 hours before taking the drug,">=13,|antidepressant",,,,,,
10657,,chronic baseline hypoxemia,,,,descitabine treatment,,,,,at least 6 months prior to the screening visit|dentures,≥125 cm/sec,,,,,,
10658,,controls)||exclusion criteria,,,,reduction procedures,,,,,within 24 h before enrollment;|vaccination of subunit vaccines,>= 3 rash,,,,,,
10659,,blood loss,,,,radiologic imaging contrast,,,,,after explanation.||exclusion criteria:||unconsciousness,50 ml to 499 ml,,,,,,
10660,,vaginal intraepithelial neoplasia,,,,heart transplant,,,,,within the past 48,< grade 2|step 1,,,,,,
10661,,syringomyelia,,,,bone marrow reserves,,,,,over the study period|non-smoker|medication-free,≥ 4|morbid,,,,,,
10662,,dysrhythmia,,,,placement of vascular access device,,,,,administered within 3 months prior to initiation of study.|history of,≥ 700×109/l,,,,,,
10663,,radioactive exposure,,,,study treatment,,,,,at department of,< 80%,,,,,,
10664,,solid organ transplant|any other diseases,,,,chronic anticoagulation,,,,,in the first 3 days after the surgical intervention,> 18,,,,,,
10665,,trial.|concurrent medical condition,,,,anticancer treatment,,,,,at least 6 months prior to enrollment in this study.|known driver mutations,16 to 70 years,,,,,,
10666,,impact swallowing,,,,immunosuppressant dose of a glucocorticoid,,,,,within 28 days prior to initiation of study treatment.|participant,<60 minutes,,,,,,
10667,,malignant tumor diseases.|investigator considers,,,,hypotensive medications,,,,,during the whole study period.|willing,>=3 years,,,,,,
10668,,metabolic rehabilitation||,,,,toric iol implantation,,,,,for at least 14 days prior to the first dose of study intervention.||has,>1 to 2 × uln,,,,,,
10669,,acute noncomplicated dermatitis superficial corticosteroid therapy,,,,inotropic support|heart,,,,,during the previous 6 months；|potentially unstable,between 3.41-4.20,,,,,,
10670,,renal function||,,,,pneumonectomy,,,,,within preceding 6 months,+6 weeks,,,,,,
10671,,intestinal polyps|known,,,,resected rcc,,,,,within 72 hours prior to the start of study treatment,> 75 years.|another type of urinary incontinence,,,,,,
10672,,prolonged sitting||,,,,lumbar,,,,,5 half lives of the prescription,below 200/mm3,,,,,,
10673,,disease of the cns,,,,verbal disorders|visual major disturbances|person,,,,,within 4 weeks prior to the start of treatment,33%,,,,,,
10674,,primary breast cancer,,,,enteral nutrition||uncontrolled,,,,,5-year survival,35-37.9°c,,,,,,
10675,,asking,,,,12-lead ecg results,,,,,before being treated,1.1 criteria;|an eastern cooperative oncology group (,,,,,,
10676,,3.|positive skin prick test,,,,≥12 index tb cases,,,,,at least 60 minutes,18 or above;|caregivers,,,,,,
10677,,old|breast cancer,,,,cc;|previous chemotherapy for malignancy,,,,,within the last 6 months|individuals,less than 30ml/min/1.73m2)|people,,,,,,
10678,,caring,,,,functional materials,,,,,for 4 months after the last dose of pembrolizumab,increased,,,,,,
10679,,epilepsy;|diagnosis,,,,vaginal sampling|delivery,,,,,within 56 days (8 weeks,≤ 15 cm from the anal,,,,,,
10680,,painful diabetic neuropathy,,,,language evaluation (deficit scores,,,,,before first imp,≤ 2.0x the institutional uln,,,,,,
10681,,pure pleural lesions.|clinical instability,,,,hormones);|4,,,,,in the screening period after completion of neoadjuvant,0 to 1|life expectancy,,,,,,
10682,,having:||cognitive difficulties|schizophrenia,,,,control associated,,,,,within the 3 months before the first dose of tracer,between 18.5 to 28.0 kg/m2|scheduled,,,,,,
10683,,hemorrhagic ulcer,,,,normal sex hormone levels,,,,,prior to initiation of study treatment|treatment,greater than or equal to3 months.|at least one,,,,,,
10684,,inflammatory bowel disease|colostomy|pregnancy,,,,visceral metastases|history,,,,,before 14 sa)|gestational age,less than 1/2 vessel diameter；3 point,,,,,,
10685,,middle hepatic artery anatomy,,,,complete procedures required,,,,,for 3 months after the study treatment period ends|the subjects voluntarily participated,> 105 pg/ml,,,,,,
10686,,immunoglobulin preparations,,,,routine regimen,,,,,during the last 4 months,more than 90%,,,,,,
10687,,corneal opacities,,,,surgical repair,,,,,before treatment.||,≥20 mg/dl;|consumed more than 5,,,,,,
10688,,valgus deformity,,,,mechanical ventilation|active bacterial,,,,,at least two occasions,≤ than 13.6,,,,,,
10689,,major contraindications,,,,aspiration biopsy,,,,,within 12 months of screening.|participant,<= 1.5 mg / dl|adequate,,,,,,
10690,,major schizophrenia,,,,re-vaccination|negative serum pregnancy test,,,,,within 1 month prior to this study;|the investigator considers,≥40 kg/m2.|smokes,,,,,,
10691,,neurological disorder|patient,,,,routine screenings,,,,,at screening and day 1.||the participant,≥ 1.5 × 109 / l|platelet count,,,,,,
10692,,anomaly,,,,strenuous physical exercise (body building,,,,,within 24 hours of onset|nih stroke scale,=< 470 msec,,,,,,
10693,,cervicogenic dizziness,,,,stand,,,,,within the last 6 months|any,> 2 ng/ml;|(each,,,,,,
10694,,bilirubin ≤1.5×uln,,,,histopathology 2.adult,,,,,in the last 6 months|having,2 or higher,,,,,,
10695,,systemic anticancer treatment|contraindication of anaesthesiology character|contraindication to mri|participation,,,,antiviral medication,,,,,past 2 years,≤ 3 months prior to the randomization visit.|a,,,,,,
10696,,clinically meaningful cardiac disease,,,,coronary stenting,,,,,within 4 weeks prior to the dosing of the study drug,> 90 x 10*9/l|bmi,,,,,,
10697,,renal vascular diseases,,,,consent|institutionalized,,,,,after first line of chemoimmunotherapy,>18 years.|patients must be able to comply,,,,,,
10698,,bacillus tuberculosis.|hypersensitivity,,,,t-lgll,,,,,within 2 years prior to the first administration of the study drug,<40%,,,,,,
10699,,neisseria meningitidis serogroups,,,,vitreous surgery,,,,,within six months after the end of this study,< 20 x 10^9/l,,,,,,
10700,,psychotic spectrum,,,,donated ingredients,,,,,during previous treatment;|have,>60 min,,,,,,
10701,,cardiac infarction,,,,fmt infusion method,,,,,at the time of survey administration,<= 0.2 mg/kg/day,,,,,,
10702,,empyema|acute inflammations,,,,consumer of,,,,,within the last year|participation in another clinical trial,between 18 and 85 years old,,,,,,
10703,,grand mal seizures,,,,hepatic venous pressure gradient,,,,,within 3 months before the screening period;|those,>5 g/day,,,,,,
10704,,coronary artery ectasia,,,,intense exercise,,,,,prior to beginning therapy,1 to arm 2): not,,,,,,
10705,,normal|malignant neoplasm,,,,e exposed,,,,,within the last 24 hours|allergy,≥ 18 years;|time,,,,,,
10706,,end-stage medical condition,,,,umbilical cord blood,,,,,within past one months|allergic,> 3x upper limit,,,,,,
10707,,dry eye disease|symptoms,,,,treated,,,,,at the follow up 2 visit,iiib,,,,,,
10708,,alcohol breath test,,,,ocular surface surgery,,,,,within 3 days prior to check-in until the follow-up visit.|use,> 3*,,,,,,
10709,,multifocal ich,,,,consensus panel of the international myeloma workshop.|part,,,,,within four weeks.|histologically,18 and over|having,,,,,,
10710,,judged unsuitable for participation in the study,,,,stature,,,,,within 6 weeks prior to first dose of study drug.|history of,2.6-2.9 m/s)|10,,,,,,
10711,,salivary gland cancer,,,,numerical pains rating,,,,,within 3 months prior to visit 1|diagnosed,>=12 weeks|adequate hematologic,,,,,,
10712,,depolarization,,,,carbapenem serum concentration,,,,,within 24 hours prior to the start of ip administration.|wocbp,> 3.0 mg/dl|history,,,,,,
10713,,pole status,,,,ambulatory surgery,,,,,more than 14 days prior to first study,≥ 30/100,,,,,,
10714,,mental abnormality,,,,thyroid hormone replacement treatment,,,,,for 1 week after stopping of investigational drug|males,above 1l.||female,,,,,,
10715,,screening|previous cabg|preexisting heart failure,,,,ethnicities,,,,,within 14 days prior to study treatment administration,< 18.5 kg/m2|primary hyperparathyroidism,,,,,,
10716,,chronic tb infection,,,,bont,,,,,within 30 days prior to the screening period,>120 msec,,,,,,
10717,,bronchial thermoplasty,,,,occupational therapy,,,,,up to one month before blood sampling|puberty,18-79,,,,,,
10718,,fetal distress,,,,whole lung lavage,,,,,within the past 60 days|patients,> 18 years|peripheral artery occlusive disease|eligibility,,,,,,
10719,,serious reactions,,,,complete nephroureterectomy,,,,,during this hospitalization|acute respiratory failure,"15-24,|being",,,,,,
10720,,congenital cardiac anomaly diagnosed||exclusion criteria common to the 2 groups (cases and,,,,stent insertion,,,,,maximum 4 days,150 ml of,,,,,,
10721,,concomitant disease.||7,,,,elective surgery,,,,,within three months;|infectious aortic disease、takayasu arteritis，marfan syndrome,0-1.|no combination,,,,,,
10722,,antitumor,,,,partner vasectomy,,,,,within the last 180 days.|participants,< 7.0 mmol/l|fasting,,,,,,
10723,,good general health).|only,,,,pao2)/oxygen inhalation concentration,,,,,within 12 weeks prior to randomization:||contrast-enhanced,10-18|cobb,,,,,,
10724,,mitral regurgitation,,,,tigecycline treatment,,,,,within 3 months prior to time of screening.|plans to,≥ 50% (<12 years,,,,,,
10725,,congestive heart failure|uncontrollable hypertension,,,,bandages.|participation,,,,,in the past 1 year;|severe/unstable,>1|rem < 1 million,,,,,,
10726,,lupus,,,,subsequent silicone,,,,,during the inclusion period,under 7-years,,,,,,
10727,,target vessel branches need,,,,composite international diagnostic interview);|body mass index,,,,,for at least 3 months before screening,> 7% and ≤ 10%|egfr ≥ 60 ml/min/1.73m²;|able to provide,,,,,,
10728,,motor disabilities||,,,,local regulatory authority);|participants,,,,,"within 4 weeks before cycle 1, day 1 or anticipation",≥ 1.5 × 109/,,,,,,
10729,,concomitant conditions,,,,hospice care|left-sided,,,,,for at least 12 months after,18.5<bmi<21,,,,,,
10730,,sensitivity to vestibular palpation,,,,penetrative vaginal sex|ability to read,,,,,within 48 hours prior to the administration of [18f]dpa-714.11.||11currently enrolled,more than 14 days,,,,,,
10731,,congenital pulmonary airway malformation,,,,immunosuppression maintenance therapy,,,,,48 hours prior to administration of study,≥ 104 copies/ml,,,,,,
10732,,lower limb stenosis,,,,technical logistical personnel,,,,,within 24 hours prior to sending,>15 eos/hpf,,,,,,
10733,,immunosuppressive agents.|have,,,,coronary artery disease|patients,,,,,at the time of the ut;|bmi ≤ 30 kg/m²;|with,formula ≥50 ml/min,,,,,,
10734,,non-melanoma,,,,irreversible surgical sterilisation,,,,,throughout the study period|capable to complete the forms for registration of signs,≥ 34,,,,,,
10735,,paroxysmal supraventricular tachycardia,,,,uti,,,,,at time of admission|maternal hypoxia,0-1;|nihss score,,,,,,
10736,,spina bifida,,,,pharmacological treatment for luts in the 2 weeks prior to study inclusion,,,,,at least 2 weeks from last cytotoxic chemotherapy,>115,,,,,,
10737,,vertebral bodies;|axial neck pain,,,,chronic steroid,,,,,in the past month;|severe visual impairment,> 110 mmhg.|renal failure,,,,,,
10738,,deep/medium-deep chemical peels,,,,conventional imaging (ct and/or,,,,,at the time of signing the informed consent/assent.|participants,> 90 mmhg)|systemic,,,,,,
10739,,chronic respiratory illness,,,,arthroscopic rm surgical procedure,,,,,at least 2x weekly,>= 50 ml/min,,,,,,
10740,,previous neuropathy,,,,extracorporeal volume shifts associated,,,,,during the study period|ocular surgery,"≥ 1,500/mcl|platelets",,,,,,
10741,,restrictive pericarditis,,,,rapid cycling,,,,,within 7 days of enrollment.|have any,≥ 30 ml/min|at the time of treatment,,,,,,
10742,,acute myocardial infarction.|subjects,,,,ocular treatment,,,,,prior to the first injection,<1000/mm3,,,,,,
10743,,soft tissues.|patients,,,,dialysis,,,,,within the last 4 weeks.|use of,>= 40 mili international unit per milliliter (miu/ml),,,,,,
10744,,uncontrollable epilepsy,,,,hip arthroscopy,,,,,over 18 years,≥ 18|possess a sleeping partner,,,,,,
10745,,acute asthma exacerbation.|the,,,,aortic dissection,,,,,within 3 months of the study start date,18 years or older|the patient is able,,,,,,
10746,,local ras test results,,,,vascular surgery department of the bellvitge hospital university to treat,,,,,at least 14 days before the screening visit.||,score ≤24,,,,,,
10747,,swedish.||no in situ magnetic device,,,,escalations,,,,,between january 2021,less than 40 kg/m2|total magnesium,,,,,,
10748,,difficulty breathing.|score,,,,vancomycin taper.|current hospitalization,,,,,within 30 days before initiating the study therapy:||adequate renal function,< 30 × 10^9/l,,,,,,
10749,,other injuries,,,,standard of care anti-pd-(l)1,,,,,before screening/baseline visit,≥ 1500 per,,,,,,
10750,,working,,,,planned vaccination,,,,,within 6 months prior to study vaccine,2.5 kg.||,,,,,,
10751,,chronic illness.||patients,,,,medical treatment;|asa status,,,,,at least 6 months of available follow-up,between 6 and 16 years|fev1 > 60%|child referred,,,,,,
10752,,upper extremities,,,,general anesthesia.|cervical stenosis|previous failure,,,,,after turt||,≥ 27|positive,,,,,,
10753,,unilateral breathing impairment,,,,donated plasma,,,,,within 6 months prior to screening|administration of a prescription,≤ 13.3 mmol/l;|6,,,,,,
10754,,mvd,,,,total cumulative dose,,,,,in the last 180 days prior to consent|known history of,less than 29 ml/min|moderate,,,,,,
10755,,pose an unreasonable risk,,,,asthma,,,,,within 15 days prior to inclusion 15,greater than or equal to (>=) 4 × upper limit of normal (uln),,,,,,
10756,,sustained seizure,,,,interventional clinical trial which does not involve administration of an imp and,,,,,during a screening visit,≥ 15,,,,,,
10757,,disorder|unable to read,,,,repair with,,,,,in the 3 months prior to the study|a history of anterior,greater than daily physical activity,,,,,,
10758,,avoiding use of any,,,,institutional review board (irb).||,,,,,within 12 months.||5.history of pneumonitis,equal or less than 102 cm,,,,,,
10759,,granulocyte colony,,,,functional endoscopic sinus surgeries,,,,,within 12 months of first line chemoimmunotherapy,less than 40%.|severe,,,,,,
10760,,vital signs,,,,maintenance treatment,,,,,within 4 weeks.|individuals,25 to < 35,,,,,,
10761,,deliberate self-harm,,,,mri contra-indications|cognitively,,,,,within 3 months of the last dose of consolidation therapy,≤ 0.30,,,,,,
10762,,cerebrovascular disease;|pregnancy,,,,tumour volume (largest lymph node,,,,,within the last year|patients,≥42 days);|did,,,,,,
10763,,isotretinoin,,,,hippo therapy,,,,,more than 6 contractions per hour,ratio(inr)≤ 1.5×uln,,,,,,
10764,,myeloid malignancy||any of the following,,,,expected cystectomy surgery,,,,,during the study period;|reported,≥ 113 mg/mmol,,,,,,
10765,,uninterrupted,,,,coronary artery bypass graft surgery|clinical presentation,,,,,during the study time.||,>= 80 and less than or equal to (<=) 136,,,,,,
10766,,expert dermatologist|naive,,,,intra-articular injections,,,,,for the past 6 months|be,=< 2.5 x institutional uln|creatinine < uln,,,,,,
10767,,lymphangitic spread,,,,mri procedures,,,,,at the time of the assay,"≥ 11,1",,,,,,
10768,,secondary aiha,,,,mechanical embolectomy,,,,,in the last year|could understand test,> 7.0)|individuals,,,,,,
10769,,spect scan,,,,stent placement,,,,,within the last 3 years.|presence,> 13.0 years,,,,,,
10770,,calculated in minus cylinder,,,,peripheral interventional procedure,,,,,at the time of the signature of icf,>2.9g/dl;|ast,,,,,,
10771,,pulmonary symptoms,,,,previous intervention,,,,,within the past six months|therapy,between 15 and 24 years,,,,,,
10772,,mandibular incisors,,,,abstinence|vasectomy,,,,,within 12 months of first-line chemoimmunotherapy,< 30ml/min/1.73m2,,,,,,
10773,,cardiovascular disease.|participant,,,,invasive ventilatory therapy,,,,,during pre-maintenance upfront therapy,score 0-1;||adequate hematology,,,,,,
10774,,compromised facial,,,,complete online questionnaires,,,,,7 days prior to study drug administration,45 kg~100 kg (inclusive),,,,,,
10775,,users,,,,prosthetically,,,,,at the screening < grade 2,i-ii ± cb|stable background treatment,,,,,,
10776,,inflammatory process,,,,coherence tomography (oct),,,,,within 3 months of enrollment|lower extremity deep venous thrombosis,"≥1,500/mm3",,,,,,
10777,,neuropathic diseases,,,,surgical extraction,,,,,within 2 years prior to first dose of the investigational drug,less than 30 or older than 75;|diseases,,,,,,
10778,,survival,,,,exercise program,,,,,during 6 months,>= 3 weeks prior to study treatment.|strong inhibitors of cyp3a4/5,,,,,,
10779,,labor|pregnant,,,,undergoes surgery,,,,,at the time of enrolment|known hiv sero-positivity,inhibiting exercise,,,,,,
10780,,thus,,,,pathogenic cyp21a2 variant,,,,,within 3 months of enrollment|the presence,8 to 16 year.|male,,,,,,
10781,,television,,,,setting|major surgery,,,,,within the past 2 years.||subjects,>/= 5,,,,,,
10782,,joint effusion,,,,irreversible organ function damage,,,,,at the time of randomization|be 18 years,≥ 3x10^9/l,,,,,,
10783,,sinus communicating,,,,rehabilitated,,,,,within 3 weeks before the first dose of study drug,"between 37th and 42nd weeks),|having",,,,,,
10784,,cancer predisposition syndrome,,,,endovascular thrombectomy,,,,,past 2 years;|women,less than 10kg,,,,,,
10785,,acute cholecystitis,,,,lumbar puncture site|taking,,,,,"for the past month,|needing",less than 6 mm,,,,,,
10786,,structural brain disease,,,,hormone replacement treatment,,,,,within 14 days prior to the first dose of the investigational product.|history,<2,,,,,,
10787,,disc areas,,,,graft vs host disease,,,,,at the time of screening||selected,greater than 35%,,,,,,
10788,,contra-indicating,,,,g12c.|major surgery,,,,,at the time of administration,>160 or <90 millimeters,,,,,,
10789,,implants.|skin disease,,,,upper abdominal surgeries||,,,,,within 28 days or 5 times the elimination half life (,>= iii,,,,,,
10790,,paget,,,,diaphragm,,,,,within 8 weeks before randomization,18 or older|histologically,,,,,,
10791,,solid organ transplantation|has,,,,reads,,,,,after the last ip administration,25 to 55 years,,,,,,
10792,,dance,,,,replacement central veinous,,,,,< 8 weeks prior to cnct19,less than or equal to 5,,,,,,
10793,,wheelchair dependence,,,,neoadjuvant radiation,,,,,within 3 days prior to registration||note,greater than or equal to 50 kg.|in good health,,,,,,
10794,,hioc,,,,rbc],,,,,at least 2 times the slice thickness,≤1.5×uln;||aagree to provide,,,,,,
10795,,throat symptoms,,,,ionized calcium 1.5 mmol/l,,,,,for at least 6 months prior to enrollment.|suboptimal adherence,>115 kg.|use,,,,,,
10796,,comorbid condition,,,,internal organs,,,,,at the time of screening)||,≥12 weeks;|histologically,,,,,,
10797,,preoperative clinical evaluation;|the,,,,immunization procedures,,,,,while taking onlife,between 150 to 300|medical treatment,,,,,,
10798,,myocardial ischemia|detection,,,,liver protection treatment,,,,,within 90 days of registration|history of lower extremity cellulitis,i-ii:||adult.||no,,,,,,
10799,,pah,,,,vasectomized.||combination of,,,,,within 2 weeks prior to the first dose of study drugs.|patients,>3 and <24 months,,,,,,
10800,,addictive disease,,,,physical examination including:||no,,,,,3 half lives,>15mm,,,,,,
10801,,severe hearing loss,,,,target node,,,,,newly identified,between 19 to 55,,,,,,
10802,,treatment.|generalized impairment,,,,focal ischemia of the brain,,,,,for the past 5 years.|concurrent,<100/nl)|concomitant,,,,,,
10803,,juvenile dm,,,,sterilization of partner,,,,,within 24 months prior to inclusion into the,< 8.5 g/dl,,,,,,
10804,,grossly visible,,,,fetal growth restriction,,,,,within a month before screening|symptoms,> 50 ml/,,,,,,
10805,,localized prostate carcinoma,,,,hf emergency department,,,,,within 3 months before screening.|participant clinical diagnosis,>1/day,,,,,,
10806,,biliary disease,,,,gastric pacemaker,,,,,at the time of the traumatic event to ensure,≤ 12%).||note,,,,,,
10807,,middle cerebral artery,,,,probing,,,,,within 6 months prior to study entry,≥ 3.|previous prostate surgery,,,,,,
10808,,etc.);|uncontrolled pleural effusion,,,,dose reduction of palbociclib,,,,,within the 4 months before the study starts|individuals who are,≤ 80%,,,,,,
10809,,facial sides visiting hcmc,,,,various assisted reproductive means|patients,,,,,within 48 hours prior to the administration of pdno.|known active,> 0.4 to maintain,,,,,,
10810,,progressive supranuclear gaze palsy,,,,nucleotide antiviral therapy,,,,,prior to randomization||platelets < 25000/mm^3,smokers,,,,,,
10811,,proliferative diabetic retinopathy,,,,systematic immunomodulatory drugs,,,,,at the time the patient receives the,between 18 and 35 years old.|for the control group,,,,,,
10812,,arterial vascular events,,,,transilial bone biopsy incision,,,,,at the time of diagnosis||resectable,greater than 88 (>88,,,,,,
10813,,preoperative)|end-stage renal disease,,,,anisometropia,,,,,within 14 days prior to administration of the first dose of ip,1 drink/day,,,,,,
10814,,infections- malaria,,,,frequency oscillatory ventilation (hfov),,,,,during the same procedure,≥ 60 years;|diagnosis,,,,,,
10815,,ⅲ atrioventricular block,,,,12-lead electrocardiogram,,,,,before randomization.|received,total t lymphocytes;|voluntarily,,,,,,
10816,,primary bc diagnosis,,,,muga scan,,,,,within the last 15 years.||treated with lifestyle management,< 350 cellen/mm3|common,,,,,,
10817,,hereditary neuropathy,,,,sympathomimetic drug harmful,,,,,within 6 hours,16 years or older,,,,,,
10818,,pre-diabetes,,,,renewed endoscopy,,,,,within 3 months before biopsy,>= 9g/dl,,,,,,
10819,,reversible ischemia|pulmonary function tests,,,,gi surgeries,,,,,within the past 30 days.|creatinine clearance,at least 18-year-old,,,,,,
10820,,lateral neck dissection,,,,corrective mitral valve surgery,,,,,within 14 days of first dosing,≥60.||,,,,,,
10821,,subdural abscess,,,,maxillary antrostomy,,,,,less than 30 days old|patient with another,10 or more,,,,,,
10822,,brain organic mental,,,,extracorporeal membrane oxygenation (ecmo) therapy|decision,,,,,during and for 3 months after the treatment period,> 150kg|known,,,,,,
10823,,colon polyps.|personal,,,,biological therapies|addiction,,,,,during testing).|capable and willing,>60%.|eligible to,,,,,,
10824,,this infection,,,,foraminoplasty,,,,,at the time of inclusion|pregnancy,> 1,,,,,,
10825,,additional malignancy,,,,magnetic resonance imaging examinations,,,,,within 7 days before treatment,"7-16,|not",,,,,,
10826,,membranous nephropathy,,,,msk exercise physiologist,,,,,during the previous 3 months|no,≤ 160 mmhg,,,,,,
10827,,etc.).||general conditions:||participants,,,,treatment of the disease,,,,,at the time of surgery.||,≥40 kg/m²,,,,,,
10828,,solitary lymph node metastasis,,,,vascular access dysfunction,,,,,at least 6 months.|participant,"< 7,0 kg/m2",,,,,,
10829,,complicated pregnancy,,,,structured clinical interview for dsm-5 (scid),,,,,in the 4 hours before study treatment,≥ 18|men,,,,,,
10830,,arrhythmia.|not,,,,sex-steroid intake)|antral follicular count (afc) in both ovaries,,,,,before scheduled week 14 visit,18 - 75 years|non-progressive,,,,,,
10831,,osa,,,,kidney transplant|patient,,,,,for 23 weeks,between 27 weeks 1 completed day,,,,,,
10832,,local health authority.|medical conditions,,,,educational program,,,,,within the last 2 years.|acute,< 0.2×109/l,,,,,,
10833,,chronic kidney disease epidemiology collaboration [ckd-epi],,,,breast surgery given,,,,,within 4 weeks of baseline visit|receipt of live vaccine,≥ 1.5 × 109/l.|platelet count (,,,,,,
10834,,potential manifestations,,,,night|low stimulation efficiency,,,,,within 6 months before signing the informed consent form,service more than six months.||,,,,,,
10835,,cane|endorse worst pain,,,,allogeneic stem cell transplantation.|receiving any other investigational agents,,,,,for the last 3,≥ 18 years|females must,,,,,,
10836,,sponsor)|ambulatory,,,,percutaneous treatment,,,,,for at least 120 days after the last dose of study intervention||female,≥ 18 ≤ 25 kg/m2.|they,,,,,,
10837,,epidermal growth factor receptor (egfr),,,,years|present,,,,,after 2014.||,3 to 24 month old,,,,,,
10838,,vf damage,,,,medical reasons.||cohort,,,,,1 month after full vaccination,50% to 90%,,,,,,
10839,,ambulation,,,,vertebral end-plate sclerosis,,,,,within 4 weeks prior to start of study treatment|thrombotic,less than 3/5,,,,,,
10840,,organ disease,,,,analgesic injection intervention,,,,,up to six months ago,less than 50% or lower than the lower limit of the laboratory test range,,,,,,
10841,,suspicious embolism,,,,cd surgery planned,,,,,in the past 4 months,> 2 times the upper limit of normal,,,,,,
10842,,acute suicidal risk,,,,quality of the data|any contraindication to whole blood transfusion,,,,,concomitant,more than 30.||,,,,,,
10843,,sixty,,,,major surgical surgery,,,,,during the study period|hypersensitivity,between 18 to 60 years||,,,,,,
10844,,alt>2.5×uln,,,,surgical revascularization,,,,,during the last 30 days.|patients,≤ 100 mmhg|not,,,,,,
10845,,pulmonary,,,,nascet,,,,,within 3 months prior to study entry,≥ 55%,,,,,,
10846,,cognitive impairments,,,,islet cell autoantibodies,,,,,at the time of recruitment.|pregnant,abemaciclib,,,,,,
10847,,post injury,,,,relugolix combination therapy,,,,,within 12 months before signing the informed consent form,level 2 or level 3,,,,,,
10848,,disease-causing dementia,,,,hormonal therapy directed,,,,,within the past 3 months|diabetic,"> 5,56 %",,,,,,
10849,,type i,,,,world health organization (who),,,,,within the last 12 months to the affected limb||medical,> 35 kg/m2)|those,,,,,,
10850,,borderline personality,,,,otoscopic examination|a neck injury,,,,,in the last four weeks.|subjects,> 3.5 millisecond,,,,,,
10851,,iols,,,,t cell receptor sequencing,,,,,within 1 month before vaccination;|subject,<3 stools per week,,,,,,
10852,,burkitt's,,,,resection of head of pancreas (ldprhp),,,,,prior 12 months|non skin,> 0.45||nafld,,,,,,
10853,,vessel).||active hemoptysis,,,,prolapse surgery,,,,,past 2 years before screening,> 39 years,,,,,,
10854,,criteria||active sinus infection|allergic,,,,functional training)|only players who understand the study purposes,,,,,recent intake of,>10 years|clinical diagnosis,,,,,,
10855,,ovarian endometrioma,,,,smart cell phone,,,,,at time of injury|body mass index,≤ 25 mg/week).||oral,,,,,,
10856,,abdominal symptoms,,,,repeat testing,,,,,in the next 4 months,= 0.|dh,,,,,,
10857,,blood system disease,,,,gvhd,,,,,the past 12 months|known,>11,,,,,,
10858,,phaeochromocytoma,,,,thin rectovaginal septum,,,,,within 2 cm of the selected treatment area,60-90ml/min/1.73m2,,,,,,
10859,,malignant disease|no,,,,internal radiation therapy,,,,,within 4 weeks before the first dose of study treatment|the tumor is her-2,>3x upper normal,,,,,,
10860,,primary poliomyelitis immunization,,,,aids).|has,,,,,after resting,january 2020 to june 2022|treated,,,,,,
10861,,asthma-related,,,,intervention,,,,,for at least four,shorter than 6 months,,,,,,
10862,,open cavities,,,,bariatric procedures,,,,,longer than 6,18.5 to 45.0 kg/m2,,,,,,
10863,,nci ctcae≥,,,,standard flow aml mrd assay.|age,,,,,at the time of signing the consent form|hbsag(+,>= 3 months|evidence,,,,,,
10864,,inflammatory bowel disease/syndrome,,,,dll3-targeted therapy|prior history of checkpoint inhibitor associated,,,,,at the time of informed consent form (icf) signing,from 18 to 85,,,,,,
10865,,sam,,,,cerebellar ataxia,,,,,during the study.|have been vaccinated with live,>60 8,,,,,,
10866,,contaminated wounds,,,,organ complications;|intraoperative changes,,,,,within 30 days prior to soberana plus administration.||,criteria:||18-35 years,,,,,,
10867,,la-cab,,,,vitamin b12 supplementation,,,,,prior use,< 20)|non-correctable,,,,,,
10868,,cancer types,,,,stem cell boost,,,,,monoinfection|at least,>=45 years,,,,,,
10869,,metastasis;|malignant tumors,,,,relapse);|glomerular filtration rate qual,,,,,within the past 12 months prior to inclusion.|subject,">1,500/mm3|platelet",,,,,,
10870,,unable to undergo sample collection|pregnancy,,,,local institutional review board,,,,,during the trial period;patients,90 to 139,,,,,,
10871,,hypomagnesemia,,,,neurovascular ultrasound,,,,,in next 4 days.|terminal,> 1|the patient,,,,,,
10872,,systemic vasculitis,,,,hemostasis assessment allowing,,,,,more than 1 year ago should also,≥ 8 g/dl|leukocytes,,,,,,
10873,,sudden cardiac,,,,without||a normal ekg,,,,,at least 1 of the following urinary symptoms over,≤ 5uln,,,,,,
10874,,tracheobronchial foreign bodies,,,,health prevention examination,,,,,within 6 months after,=< 5 x uln||registration,,,,,,
10875,,complex medical conditions,,,,therapeutic radiation therapy,,,,,< 12 months prior to challenge.||,≥3.|history of,,,,,,
10876,,psychiatric disorders|women,,,,tendon rupture.|symptoms of,,,,,pre-screening|office,above 180 kg - for the impossibility of,,,,,,
10877,,suspected|previous,,,,functional teeth|take regular,,,,,onset 2 of 11 covid-19 symptoms,between 20-70 years,,,,,,
10878,,fractures of major sites,,,,full organ,,,,,in the next 6 months|planned travel across time zones,at least 3 twitches,,,,,,
10879,,ventricular outflow tract,,,,back surgery,,,,,within the past 5 years;|documented myocardial infarction,"100,000 cells/μl",,,,,,
10880,,endotracheal tube,,,,triplicate12-lead ecg.|history of (non-infectious,,,,,in the last 12 hours,< 3 x uln|alanine transaminase (alt),,,,,,
10881,,chronic kidney disease per kdigo|pregnancy,,,,cardiovascular surgery clinic,,,,,for 3 years from the start of that,19-32 kg/m^2,,,,,,
10882,,pulmonary oedema,,,,cortisol injection,,,,,after comprehensive examination,≥1.0 x 109/l,,,,,,
10883,,lymphoma|pap associated,,,,institutional review board/independent,,,,,in the next 24 months)|under the age,60-89 ml/min per 1.73 m2,,,,,,
10884,,interpreter available||,,,,hematologic disorder||,,,,,at time of screening visit,0 or 1|abs neutrophil count,,,,,,
10885,,year|transfer,,,,see study device,,,,,within 3 months before the inclusion visit,30-59 ml/min,,,,,,
10886,,supranuclear gaze palsy,,,,index mdro infection,,,,,within 6 months prior to enrollment||patients,less than [<] 30 milliliters,,,,,,
10887,,normal sinus rhythm (nsr),,,,cranial mri|no participation of other clinical trials 3 months before signing the informed consent||,,,,,at least 3 months prior to recruitment|participants,≤ 10mm/5min,,,,,,
10888,,atients,,,,immunosuppressive therapy - with,,,,,7 days before the first administration,more than 70%||,,,,,,
10889,,basilar artery,,,,pelvic external beam radiotherapy,,,,,during the study period;|patients,between 30 to 300 mg/day||,,,,,,
10890,,antipyretic,,,,totally endoscopic coronary artery bypass grafting,,,,,within 14 days prior to day 1 of protocol therapy)||women,"≥185mmhg,",,,,,,
10891,,diseases of the hematopoietic system;|diagnosis,,,,flexible ureteroscopy,,,,,during an incremental exercise test to volitional fatigue,over 40 years,,,,,,
10892,,ovary.||regular menstrual cycles,,,,surgical complication(s)|iol,,,,,at the time of the first administration of,<135 meq/l|serum potassium,,,,,,
10893,,dexa,,,,operation|is,,,,,"for at least one year,|diagnosed",1)|non-smoker|willing,,,,,,
10894,,involvement of the furcation|a minimum,,,,orthodontic treatment|living,,,,,in the last 12 months.|abnormal,less than 18 years|pregnant,,,,,,
10895,,t2dm,,,,interventional clinical studies.||,,,,,within the last 12 weeks|physical health conditions,7 to 27 years,,,,,,
10896,,neuro developmental disorder,,,,xpert tb/rif,,,,,within 3 months prior to screening.|participants,stage iii-iv,,,,,,
10897,,pml).|concomitant diseases,,,,biologic therapy,,,,,within 60 days of,≥ 100×109/l|the,,,,,,
10898,,abnormal renal function,,,,hot ampullectomy,,,,,throughout the study.|investigator discretion,> 470,,,,,,
10899,,optic nerve fenestration,,,,mild stimulation,,,,,within 3 days before the first dose of the study drug,6 to less than 12 years,,,,,,
10900,,hiv;|dialysis,,,,tare,,,,,within the past 6 months 27,above 1.5 x uln.|active hepatitis b virus,,,,,,
10901,,cancer therapy,,,,total knee arthroplasty|diagnosis,,,,,within 24 ~ 48 hours,>5cm,,,,,,
10902,,hepatocellular carcinoma.||patients,,,,squamous cell lung cancer,,,,,at time of inclusion)|≤ 29%,≤2.5 x institutional upper limit of normal,,,,,,
10903,,ppa,,,,control,,,,,more than 30 days before study d0,< 150×109/l,,,,,,
10904,,pulmonary ntm,,,,pcnl surgery,,,,,prior to radiation|history of,< 40|patients,,,,,,
10905,,mucocele,,,,oral exam,,,,,at least 1 prior,4-7 years,,,,,,
10906,,plus disease,,,,intraosseous access,,,,,in at least 1 interrupted day of desired physical activity,≤40%).||11,,,,,,
10907,,cancer therapies.|subjects,,,,bone marrow function,,,,,within four weeks prior to the start of the study||pregnant,between 18.0 and 30 kg/m2,,,,,,
10908,,complications.|karnofsky performance status (kps),,,,primary therapy,,,,,within 7 days before the first dosing date|depot injection,> 5 x uln|total bilirubin,,,,,,
10909,,mental illness,,,,exogenous hormones from,,,,,within the last 14 days of screening)||note,larger than 25mm,,,,,,
10910,,talar avascular necrosis|patient,,,,alternative method (cam),,,,,prior to treatment.|participants,scores ≥ 20;|current thoughts of suicide,,,,,,
10911,,human immunodeficiency virus (hiv);|known psychiatric,,,,progression over,,,,,pre-entry,10^9 / l,,,,,,
10912,,ipsilateral nodes,,,,hpv test,,,,,within 6 months prior to start of study treatment,> 6,,,,,,
10913,,chronic sci,,,,instrumental examination methods;|the level of systolic blood pressure (sbp),,,,,recent history,≥ 6 months,,,,,,
10914,,abnormal topography,,,,islet transplant,,,,,within 6 weeks|need,between 18 to 40 years|unexplained,,,,,,
10915,,acute hypoxemic respiratory,,,,facetectomy,,,,,at least 6 months after end of last,>38°c,,,,,,
10916,,net,,,,bariatric surgery|myocardial infarction,,,,,at least 6 months prior to,20-65 years||,,,,,,
10917,,systemic disorder|osteoporosis,,,,hepatorenal syndrome);|having,,,,,within the last 3 months|current drug abuse,<100 μg/g;|stable medication,,,,,,
10918,,ige) tests,,,,pharmacological intervention,,,,,within 8,at least >12 weeks.|normal organ,,,,,,
10919,,chronic lung diseases,,,,manual treatment of the diaphragm,,,,,in the past 6 months:||abatacept,≥300 ng/ml,,,,,,
10920,,fluid malignant cells,,,,pacemaker|medical history of,,,,,within the prior 30 days|1,>= 10 mg,,,,,,
10921,,participant:||• child in care,,,,thoracic surgery.|patient,,,,,in the past two weeks,at least 3 months,,,,,,
10922,,hemodynamical failure,,,,blood investigations,,,,,before starting the study,< 30 g/l|history,,,,,,
10923,,thyroid hyperfunction,,,,locoregional treatment,,,,,within 12 months after treatment,≤ 1.|life expectancy,,,,,,
10924,,ectopic varices,,,,intensification therapy,,,,,up to 30 weeks,≤1.5 times uln,,,,,,
10925,,secondary hyperparathyroidism,,,,local testing on,,,,,within one month after last trial treatment application.|isotretinoin,at least 50 ml/kg/min,,,,,,
10926,,testing.|active infection,,,,versus graft direction,,,,,at or above 35 years,over 65 years old,,,,,,
10927,,etc;|urothelial carcinoma,,,,idiopathic nephrotic syndrome|glomerular filtration rate (egfr),,,,,throughout the treatment period until seroconversion.|patients,equal or less,,,,,,
10928,,cigarettes,,,,test drug ingredients;||6,,,,,within 7 days prior to inclusion,2.5 times higher than the upper limit of normal).|moderate,,,,,,
10929,,her2 status,,,,patch tests,,,,,more than 6 ml).||,less than 8 days between the suspected diagnosis,,,,,,
10930,,distant metastases outside,,,,chest x-ray,,,,,for at least 6 months|moderate-severe,≥35 ml/min.|patients,,,,,,
10931,,acute liver failure|severe,,,,insulin|total daily insulin dose more than or equal to 2 iu/kg/day|use of a closed-loop system,,,,,within the last 2 weeks before screening||adequate hepatic function,> 5 points,,,,,,
10932,,proximal muscle weakness,,,,supplemental growth hormone exposure|normal renal,,,,,in the next 1 year|inability,between 10 and 18 who can speak,,,,,,
10933,,hyperpyrexia,,,,surgery procedures,,,,,prior surgery.||current,< 30 km·m2||,,,,,,
10934,,upper back surgery,,,,antibody therapy,,,,,at least 4 months after radiotherapy,>100 or <60,,,,,,
10935,,neuromediated,,,,cyp3a induction,,,,,before the intervention .|patients examined,≥ 40% of predicted value.|adequate cardiac function,,,,,,
10936,,randomization;arteriovenous thrombosis events occurred,,,,pathologic evaluation,,,,,within the past year|diabetes,< 22 cm,,,,,,
10937,,craniofacial abnormalities,,,,stem cell injection,,,,,while taking niraparib include,< 25 x,,,,,,
10938,,coronary artery,,,,computerized tomography (ct) images,,,,,in the past 4 weeks|history,d3.|stage ii-iv,,,,,,
10939,,cornea lesions,,,,normalized ratio,,,,,prior one year.|self-reported diseases,> 60|poly-metastatic,,,,,,
10940,,atrial fibrillation)|renal,,,,facial procedures,,,,,during screening.|treatment with,between 8-29.9 ng/ml||,,,,,,
10941,,"upper limb,|traumatic",,,,intraocular bleed,,,,,for at least 4 weeks before dosing.|reports regular bedtime,>/=18 years,,,,,,
10942,,neurodevelopmental deficits,,,,primary arthroplasty,,,,,within 14 days before the study drug,30-45 years|vegan,,,,,,
10943,,acute exacerbation,,,,cns imaging,,,,,within 15 days or 5 half-lives,<30 ml/min per 1.73m2)||clinically-significant,,,,,,
10944,,molecular profiling,,,,reconstructive knee surgery|bmi,,,,,within 2 years before signing the contract,<18 years|patients,,,,,,
10945,,systemic amyloidosis,,,,education nor group affiliation play,,,,,within the past six months|bone marrow transplant,≥ 75 ×109/l.|hemoglobin,,,,,,
10946,,mm|no periodontal disease history|non-smokers|fluent in english||,,,,psychiatric treatment,,,,,during operation,>125 pg/ml,,,,,,
10947,,secondary complication,,,,ectopy,,,,,during prior 6 months,at least 18 years or older,,,,,,
10948,,motion artifact,,,,cutaneous application of the ip is not,,,,,in the 6 months prior to initiation of the study.|abnormal liver function,i or,,,,,,
10949,,pathological fracture,,,,ileal resection,,,,,at least 7 days apart.||,≥ 130 mg/dl|waist circumference,,,,,,
10950,,right upper abdominal pain,,,,optimal treatment,,,,,within 2 weeks before first dose of study drug.|previously,18 to 65 years.|in,,,,,,
10951,,active pulmonary diseases,,,,molar relationship,,,,,in the two weeks prior to treatment;||9,under 18 or over 30 years old|have participated,,,,,,
10952,,invalid contact information.|3,,,,fviii inhibitor.|signed,,,,,pre-term,> or equal to ml/kg,,,,,,
10953,,associated carcinoma,,,,allogeneic organ transplant|history,,,,,within 3 months|have,≤ 100 k/ul|hyperviscosity,,,,,,
10954,,inflammatory arthropathy,,,,cardiovascular interventional procedure,,,,,within the last two (2) weeks prior to start of this study,early,,,,,,
10955,,heart renal,,,,expert reviewers.|ids activity,,,,,within 24 hours from onset (,> 110 mmhg,,,,,,
10956,,major depressive disorder.|diagnosed,,,,changing medications,,,,,at the time of screening.|patient,< 4x109/l)|clinically,,,,,,
10957,,acl insufficiency,,,,evd,,,,,within the 2 years prior,< 60g/l);|platelet count,,,,,,
10958,,hemophagocytic lymphohistiocytosis,,,,mf|splenic irradiation,,,,,within less than 28 days prior to randomization;|active,59.4-60 gy,,,,,,
10959,,metastatic prostate cancer||,,,,sample acquisition|acute toxicity caused,,,,,at least 4 weeks prior to enrollment.||,20 - 60 years.|either,,,,,,
10960,,mental health disorder.|access,,,,consisting,,,,,within 90 days before screening,> 2.5mg/dl,,,,,,
10961,,malignant small bowel obstruction.|cardiac abnormalities,,,,exercise induced,,,,,within 28 days before informed consent,> 9|those,,,,,,
10962,,acute life-threatening bacterial,,,,partial gastrectomy,,,,,during the preceding 30 days.|female,between 60 and 80 years old,,,,,,
10963,,neonatal brain development)|contraindication,,,,knee replacement,,,,,at any time prior to the start of study treatment,≥18 years.|clinically,,,,,,
10964,,autoimmune disease.|documented,,,,gastric motility|upper gi symptoms,,,,,at least 12 weeks prior to screening.|pre-bronchodilator,< 18|living outside the greater copenhagen,,,,,,
10965,,preoperative hypotension,,,,congenital heart disease surgery,,,,,within the past 24 months|seen,above 65 years|asa 1-2||,,,,,,
10966,,cancer)|myocardial infarction,,,,hemodialysis,,,,,within two months of visit,4 to 20 weeks after rp|previous hematologic,,,,,,
10967,,benign hematologic disorders|no,,,,fractional curettage||,,,,,within the hennepin healthcare,≥ 12 to < 18 years,,,,,,
10968,,torso,,,,allohematopoietic stem cell,,,,,within 72 hours before taking the drug,0-1.||,,,,,,
10969,,clinically alns metastases,,,,vital organ primary diseases,,,,,during the participation of clinical trial.|those who voluntarily decide to participate,require iv antimicrobial therapy,,,,,,
10970,,polyps,,,,tonic pupils,,,,,within 120 days of the date of the genetic sample collection,25 - 66,,,,,,
10971,,active proliferative retinopathy,,,,chemotherapy|solid organ transplantation|two,,,,,within 3 years of the first of study treatment,<30 ml/min.|has,,,,,,
10972,,periodontitis,,,,health,,,,,within the following ranges:||qtcb,≥2.0 × 109/l|absolute neutrophil count (,,,,,,
10973,,peyronie's disease,,,,heart failure|left ventricular ejection fraction (lvef),,,,,within 2 weeks before screening laboratory sample collection|alanine aminotransferase (alt),gt;40 ml/min,,,,,,
10974,,not allow,,,,common bile duct,,,,,no longer taking,less than 18 years|pregnant women|participants,,,,,,
10975,,valvular heart disease;|serious,,,,orthodontic treatment|no,,,,,in the past month.||5,12 months|willing to allow home monitoring of their health,,,,,,
10976,,benign vascular disease,,,,ends).|physical examination,,,,,"for the first time,",6-35 months old,,,,,,
10977,,hormonal sensitive cancers|assumption of hormones,,,,chemotherapy plus,,,,,more than 3 years,<50 copies/ml.||note,,,,,,
10978,,cancer treatment||a,,,,surgery of the cervical|spine|diagnosed cases of torticollis,,,,,within the past month.|subjects,> 5mm,,,,,,
10979,,benign nature,,,,earlier surgery,,,,,"before screening, documentation of resolution",less than 30.0 kg/m2|scheduled,,,,,,
10980,,anterior chamber inflammation grade,,,,dasatinib|having,,,,,during the trial.|prior history of,≤ 2.5 times the upper limit of normal (uln),,,,,,
10981,,hypertensive encephalopathy|those,,,,institutional review board,,,,,during the first 3 years of,1 to 4 osteoarthritis||,,,,,,
10982,,renal impairment.|patients,,,,subsequent assessment,,,,,during screening.|any,less than half of recommended levels,,,,,,
10983,,gastrointestinal perforations,,,,"neurological disease,|to",,,,,at screening or day 1|has,greater than or equal to 6%,,,,,,
10984,,optic nerve damage,,,,bupropion-naltrexone,,,,,within 6 months before screening|alkaline phosphatase (alp),> 750 cells/microliter.|creatinine < 1.5 mg/dl.|alt < 1.25 x upper limit of normal.||serologic evidence,,,,,,
10985,,related genes,,,,ocular surface tumors,,,,,in the last 12 months before inclusion);|age,≥ 1.5×10^9/l,,,,,,
10986,,region.|patients,,,,prediabetes,,,,,at time of obtaining informed,< 30 levels,,,,,,
10987,,tractional diabetic retinopathy,,,,liver transplantation and|written informed consent,,,,,"within 2 weeks prior to cycle 1, day 1|received oral",≥ 90 g/l;|absolute,,,,,,
10988,,old|sleeping disorder,,,,conventional radiotherapy,,,,,while arm 2 subjects,≥3 months;|fertile,,,,,,
10989,,tumor,,,,render anesthesia,,,,,within four weeks prior,between 0.5 - 25,,,,,,
10990,,bleeding-prone constitution,,,,rd repair,,,,,for at least 120 days after the last dose of study treatment.|the participant,< 1000 cps/ml or 200 iu/ml,,,,,,
10991,,unacceptable risk,,,,graft augmented prolapse,,,,,throughout the duration of the study|use of,>= 50%.||patients,,,,,,
10992,,functional below the level of lesion||able to perform the,,,,occupational therapy rehabilitation programs|is,,,,,in doses exceeding 20mg daily of,> 30 ml/min/1.73m2,,,,,,
10993,,old)|complaint of vagina laxity|willingness,,,,chronic dialysis,,,,,throughout their participation and for 90 days following the last dose of prth-101.|subject,≥ 0.6,,,,,,
10994,,dilating eye,,,,injection treatment,,,,,within the screening period:||absolute neutrophil,≥1.25× uln;|total bilirubin level,,,,,,
10995,,weeks|nasal swab positivity,,,,ontario;|tracheostomy,,,,,for at least 6 months after last drug administration of the investigational procedure,> 1/3 of the volume of the lobe,,,,,,
10996,,respiratory failure.|denying,,,,systemic therapy regimens,,,,,within 14 days prior to registration)|alanine aminotransferase (,above 5 mg,,,,,,
10997,,mediastinal tumors,,,,eeg,,,,,in the 6 to 24-hour window.||'wake,≥1600 pg/ml,,,,,,
10998,,tonsil disorder,,,,lung cancer.|documented,,,,,any time prior to study entry.|radiotherapy,18-69 years,,,,,,
10999,,holistic consideration,,,,neurological examination -||exclusion criteria,,,,,screening.|history of,"≥5, r value",,,,,,
11000,,thoracic spine surgery,,,,glucocorticoid therapy,,,,,within 14 days of informed,0 or 1|a,,,,,,
11001,,engage,,,,accepted method of birth control,,,,,less than 3 months,> 16s,,,,,,
11002,,medical instability limiting,,,,residents,,,,,during the study period;|malignancies,>= 100/min,,,,,,
11003,,distal circulation,,,,general surgery,,,,,in last 18 months of >140/90,≥ 5 times the upper limit of normal,,,,,,
11004,,contraindicated to peripheral nerve blocks|patients,,,,fibroid treatment,,,,,within 14 days before receipt of study vaccine,> 2.0 mg/dl|liver,,,,,,
11005,,substance abuse disorder|the,,,,allogeneic bmt|history of pre-existing,,,,,in the preceding 2 months,less than 10 degrees|flexion contracture,,,,,,
11006,,displaying acute respiratory,,,,eus|endoscopic ultrasound,,,,,within the normal range;|left ventricular ejection fraction,30-60ml/min,,,,,,
11007,,mental health issues,,,,stomach surgery,,,,,< 2 weeks prior to screening,from 23 to 35 years|fill,,,,,,
11008,,swo).|nail changes,,,,placement of the thigh garment|subject,,,,,"in the last 12 hours,|could be contacted,|did",>3.0 ×109/l,,,,,,
11009,,fluorescence in situ hybridization (fish),,,,liver transplantation,,,,,up to 1 cycle,> 400 mg/dl;|active,,,,,,
11010,,mores,,,,conventional cardiac surgery,,,,,within 6 months prior to sub-study randomization|participants,≥ 35% and < 50%,,,,,,
11011,,papillary thyroid,,,,medical monitor|myelodysplasia,,,,,within last 7 days|patients,> 2.5 x uln|lactating,,,,,,
11012,,autonomic disorder,,,,stent of target vessel;|patients,,,,,prior to the start of infusion on the experimental day|hypotension,> 18 years.|icu admission,,,,,,
11013,,rdeb,,,,"fondazione policlinico universitario a. gemelli irccs in rome,|all students of",,,,,in the last 2 weeks|sdh,> 2 mmol/l).|associated,,,,,,
11014,,lvef<50%).|patients,,,,radioactive iodide [rai],,,,,during the screening period and baseline period,> 30|recent cerebrovascular,,,,,,
11015,,basal skin cancers,,,,recist1.1|sufficient organ functions,,,,,in the3 months prior to the first dose,spo2<93%,,,,,,
11016,,serious headache,,,,total joint arthroplasty,,,,,within 7 days of visit 2,=< 5 × uln,,,,,,
11017,,lentigo maligna|uterine cervical carcinoma,,,,prostate brachytherapy,,,,,within =< 28 days prior to registration).|for,60-90 mmhg,,,,,,
11018,,intolerable reactions,,,,interventional embolization of aneurysm,,,,,three times a week,> 10.0 × 109/l.|patients,,,,,,
11019,,stroke|no chronic pain,,,,standard curative therapy,,,,,within 7 days of the randomisation,> uln + 4 seconds,,,,,,
11020,,hyperekplexia,,,,bilateral ligation,,,,,within 4 weeks prior to enrollment.|patients,<3 yrs,,,,,,
11021,,obstructive jaundice,,,,sentinel lymph node biopsy,,,,,within 2 months of surgery,> 18 years|invasive mechanical ventilation,,,,,,
11022,,20 mmhg,,,,extended-release narcotics,,,,,within 8 weeks or 4 weeks respectfully,more than 3.5 cm,,,,,,
11023,,patients:||inability,,,,clinical situation,,,,,lifetime history for,? exception,,,,,,
11024,,devices;|chronic kidney disease,,,,oxygen,,,,,during the time the participant,diameter 2.25-4.00mm;|intracranial artery stenosis,,,,,,
11025,,operated,,,,intensive care unit admission,,,,,within 30 days before the start of study,≥18 years;|stroke patient,,,,,,
11026,,≥18|ms diagnosis,,,,youth readiness intervention (yri),,,,,within the last,between 21 and 35 days)|having 45 or more,,,,,,
11027,,unilateral ovarian,,,,immunomodulatory drug (imid),,,,,more than 1x10^3 copies/ml,under 40%.|patients,,,,,,
11028,,gilbert's disease;|alanine,,,,monoclonal plasma cells,,,,,in the past 12 months.|inability,>30 kg/m2|malnutrition,,,,,,
11029,,historical autoimmune disease,,,,bone marrow aspiration,,,,,during the past 5 years,> 8h/day;|physically,,,,,,
11030,,non-aneurysmal causes,,,,t-dxd||pathologically documented,,,,,in last 3 months|presenting,>= 50 × 10^9/l,,,,,,
11031,,gout,,,,palpation common extensor tendons,,,,,within the 48 hours prior to enrollment|known major,older than 38 years,,,,,,
11032,,a dementia,,,,water||,,,,,in the past four weeks,≥ 3 months.||5,,,,,,
11033,,perjeta spcs.|known hypersensitivity,,,,treatment for cancer,,,,,at the time of data collection,≤ 3 weeks prior to study,,,,,,
11034,,concurrent disease,,,,telephone interview for cognitive status,,,,,at least two measures.|alanine aminotransferase (alt),1-3|surgical,,,,,,
11035,,synthetic 2d image,,,,prophylactic treatment,,,,,last time receiving the investigational drug did,18.5 to 40 kg/m^2,,,,,,
11036,,root canal treatment performed,,,,adjuvant endocrine therapy,,,,,at least 1 of,18 and over,,,,,,
11037,,metachronous multiple cancers,,,,monotherapy of demethylated drugs,,,,,more than 6 months.|kps,no more than 30 minutes of exercise,,,,,,
11038,,type d personality traits,,,,cap,,,,,"in the next 6 months,|pregnant",< 21kg/m2,,,,,,
11039,,ventricular dysrhythmias,,,,cardiac rehabilitation.||exclusion,,,,,golfer|able to consent,20-75 years,,,,,,
11040,,good kidney function,,,,further chemotherapy,,,,,for at least 4 months,older than 6,,,,,,
11041,,multiple accidental traumas,,,,viral testing,,,,,within 3 months before the first administration;|pregnant,≥40 cm/sec,,,,,,
11042,,radiotherapy.|part b,,,,inhalation anesthesia,,,,,at any time during active period of the study,≥ 5 years < 18 years,,,,,,
11043,,extensive changes,,,,open abdomen treatment,,,,,prior to data,surgery;||,,,,,,
11044,,fasting hypoglycemia|pregnancy,,,,historically,,,,,within 6 months of the first experimental session,≥ 100 x 109/l.|renal function,,,,,,
11045,,her2-targeted therapy.|for,,,,conditions:|white blood cells,,,,,within 5 years prior to the date of informed consent.|chest,greater than 105 mmhg.||change,,,,,,
11046,,distal radius fracture|extraarticular corrective osteotomy|palmar,,,,unchanged antidiabetic therapy,,,,,for 60 days after the last dose of assigned study medication.|female,≥ 6 before,,,,,,
11047,,inflammatory condition|current treatment,,,,"preeclampsia,|premature",,,,,at least 4 months after the last dose of the study drug,than 4 cm,,,,,,
11048,,her2 negative,,,,lacunar cerebral infarction,,,,,throughout the study.|history of blood,>15kpa,,,,,,
11049,,ventricular rhythm disorders||for,,,,screen for hla-g expression.||eastern cooperative oncology group (ecog) performance status,,,,,in the next 48 hours,>30,,,,,,
11050,,extraintestinal muscle strength,,,,urethral,,,,,for at least 30 days prior to visit 1 and during the study|neurostimulators: 30 days prior to visit 1|current use,≥ 470,,,,,,
11051,,human immunodeficiency virus (hiv) test result.|a positive covid-19 test result.|history of myopathy/myalgia,,,,t cell co-stimulation,,,,,within 30 days prior to enrollment.|immunosuppressive medication,18 or older.||exclusion,,,,,,
11052,,ckmb,,,,general danger sign|be,,,,,in the last month.|students with availability to attend the intervention.|students with mobile phone availability.|students,0-1|≥ 18 years,,,,,,
11053,,immunodeficiency.||7,,,,sticking out the tongue,,,,,within 1 month prior to vaccination,≥ 9.0,,,,,,
11054,,sinus tract|teeth,,,,psychiatric hospital admission,,,,,during the 3 days of filling in the consumption,>50%||(2,,,,,,
11055,,excluded|cardiac paraganglioma,,,,questions related to vulvar,,,,,in the past 3 years|expired air co level,between 1/1/2007 - 12/31/2022|resident,,,,,,
11056,,excessive intraocular bleeding,,,,b-cell depleting therapy,,,,,within approximately 12 months,less than (<) lower limit of normal,,,,,,
11057,,days);|infection,,,,annual contraceptive failure rate of,,,,,past two years.|participation in any other investigational study within 30 days prior to consent,> 8 wu,,,,,,
11058,,finger smoothing,,,,next organ transplant,,,,,within 3 weeks prior to blood sampling,"score of 7 and above,|hospitalized",,,,,,
11059,,incidental fall|patients,,,,cd19,,,,,throughout the treatment period and for 96 days after the last dose of imp administration,> 18 years|unruptured and ruptured,,,,,,
11060,,solid malignancy||patients,,,,lung transplant,,,,,at least 30 days prior to screening,18 years or above.|patients able,,,,,,
11061,,40%|heart failure,,,,systemic regimens,,,,,in the previous 1 month;|have received,≥60 ml/min,,,,,,
11062,,vus,,,,blood tests,,,,,within two months of visiting,=< 3 x the upper limit of normal,,,,,,
11063,,adrenal cortical metabolism,,,,ago|chemotherapy induced,,,,,in the next 7 months,90-120 mmhg,,,,,,
11064,,inclusive|diastolic bp,,,,emergency department visit,,,,,within 4 weeks of starting the study treatment,more than 3 months;|primary supratentorial,,,,,,
11065,,difficile diarrhea,,,,ocular emergency department,,,,,at two different stimulus,< 90mmhg;|dopamine dose,,,,,,
11066,,sish positivity,,,,access,,,,,previously treated with standard systemic therapy,below 18 yrs,,,,,,
11067,,severe autonomic dysreflexia,,,,complex pci,,,,,within the last 4 weeks before inclusion|pre-covid history,≥ 28 weeks.|diagnosed,,,,,,
11068,,hypoventilation of central origin,,,,symptomatology related to mms|chest ct (after maximum 48 hours,,,,,within 14 days before the first dose of htmc0435|active infectious,class ii facial deformity|absence,,,,,,
11069,,immunological illness,,,,reversal of neuromuscular block,,,,,7 days prior to randomization,≥ 2 years|lansky,,,,,,
11070,,covid-19 infections,,,,graft-versus-host disease (gvhd),,,,,within three months before screening;|subjects,1.0 cm.|measurable disease,,,,,,
11071,,sensory block,,,,medical exam,,,,,within 42 days of cycle 1 day 1,< 8 years,,,,,,
11072,,obstructive left main,,,,salvage cardiac surgery,,,,,within three minutes of standing,1 or 2).|tumors,,,,,,
11073,,pathological root resorption,,,,major cardiac surgery,,,,,within 56 days prior to starting study drug.|participation,18 years or older.|2,,,,,,
11074,,reflex abnormalities,,,,ulcer)|lower extremity amputation,,,,,sites.|fewer than 2,<3.5||,,,,,,
11075,,recurrence occurred,,,,complete insertion of the electrode array.|diagnosis,,,,,for 2 years,18-25 kg/m2|understanding,,,,,,
11076,,postacne scars,,,,neuroleptic treatment,,,,,at screening and baseline||presence of,between -0.75,,,,,,
11077,,neonatal sepsis,,,,acl revisions,,,,,during trial,">= 75,000/mcl",,,,,,
11078,,lu ag13909,,,,pleural fluid examination,,,,,in the last year|cognitive impairment limiting,≥18 years;|histologically,,,,,,
11079,,internal diseases,,,,stay pediatric services,,,,,university,≥18 years-of-age,,,,,,
11080,,central events,,,,lumbar spine surgery,,,,,within 3 years prior to enrollment,15-20 years,,,,,,
11081,,tumor|inability to perform clinical staging,,,,repetitive behaviors,,,,,during the 6 month study period|currently,greater than 100 or less than 60 beats per minute,,,,,,
11082,,dementia|for,,,,ad treated,,,,,currently,iii-iv.|cardiac,,,,,,
11083,,limb claudication pain,,,,surgery of the index knee,,,,,no-responding all criteria,> 5x upper level of normal (uln),,,,,,
11084,,"systemic disease,|smoking,|pregnancy",,,,commercially released car-t cell infusion,,,,,during the trial;|able and willing to provide,=< 3 years,,,,,,
11085,,surgical complications,,,,sleep endoscopy,,,,,history of dvt|patient,18-40 years|ability,,,,,,
11086,,mandibular class,,,,coronary artery bypass grafting|poor coronary blood flow,,,,,within 14 days before study drug dosing,<5;|pregnant,,,,,,
11087,,cli,,,,realm-sf|moderate,,,,,at the time of the oit study,>3|patients,,,,,,
11088,,fungal disease,,,,endovascular interventional therapy,,,,,within 30 days before vaccination;|history of covid-19,> 35%× the upper limit of normal,,,,,,
11089,,lung tumor,,,,ebola,,,,,14 days before dosing with study medication,between 35 and 70 years,,,,,,
11090,,human epidermal growth factor receptor 2 (her2)-negative per american society of clinical oncology,,,,brain metastases.||is,,,,,within 24 hours;|uncontrolled hypertension,planned,,,,,,
11091,,complex congenital heart disease.|presence,,,,neoadjuvant treatment,,,,,within 48 hours prior to initiation,< 0.8 x 10^3/ μl)|severe organ dysfunction,,,,,,
11092,,uterine abnormalities|patients,,,,elicited,,,,,for 1 week after stopping the investigational drug.|females,below 45)|known severe,,,,,,
11093,,non disease,,,,pet scan,,,,,in the past two months|rejection to manual conatct,less than 50%;|history,,,,,,
11094,,inflammatory bowel diseases|patients,,,,left anterior descending artery [lad],,,,,within 3 months before screening.|those,>4;|megaesophagus;|iii type,,,,,,
11095,,bladder onabotulinumtoxina,,,,isolated aortic valve replacement,,,,,at least 6 months prior to the first study drug administration),=< 2.5 x upper limit of normal,,,,,,
11096,,neurological disorders like dementia,,,,cross section imaging by,,,,,at the time of enrollment|chronic obstructive pulmonary disease exacerbation,>5.6 mmol/l||renal:||d,,,,,,
11097,,renal disease.|developmental delay,,,,diagnostic testing,,,,,in the past three months|having,100 × 109/l,,,,,,
11098,,symptoms evidence,,,,neuraxial anesthesia|scheduled,,,,,within 12 months before randomization.||main organ function,period;|estimated,,,,,,
11099,,eskd,,,,glucose-lowering,,,,,at the time of enrollment/first study vaccination-temporary exclusion,1.1 criteria,,,,,,
11100,,healthy controls:||(1,,,,left ventricular hypertrophy (,,,,,within 2 weeks before the first use of the test drug;|3,> 5.5 mmol/l,,,,,,
11101,,lymphoproliferative disease|uncontrolled,,,,gpc3 therapy,,,,,within 2 years prior to the study treatment,> 3 to ≤ 10 should affect,,,,,,
11102,,sars cov-2,,,,ctcae criteria.|major surgery,,,,,within the next 18,"≥1,000/mcl|b",,,,,,
11103,,etc.;|anti-tuberculosis therapy,,,,anti-cancer treatment,,,,,before randomization,<50 g/l,,,,,,
11104,,infiltration into,,,,months|radical radiotherapy,,,,,within 5 years prior to the baseline,over 18 years|ability to provide informed consent to participate,,,,,,
11105,,alcohol liver disease,,,,6 months duration|eaton,,,,,within 5 terminal elimination half-lives,>5×uln,,,,,,
11106,,la /acl/ aβ2gpi,,,,bone marrow).||,,,,,within 12 months of dme diagnosis|no contraindication of,≥24 at,,,,,,
11107,,hdrs,,,,immunosuppressive dose,,,,,more than 6 months ago,18-55 years|body mass index of 25-40 kg/m2|not,,,,,,
11108,,fungal) infection,,,,extramedullary relapse.||4,,,,,post-screening,shoulder for 3 or more months,,,,,,
11109,,"chronic obstructive pulmonary disease,|without",,,,intra aortic balloon - pump,,,,,within the last 3 months prior to day 1,>60%,,,,,,
11110,,impaired cognition|complete paralysis,,,,adjuvant hormonal,,,,,during or following,between 3 e 7 cm|bmi,,,,,,
11111,,nephrotic-range proteinuria,,,,target toenail surgery,,,,,previous 12 months from the beginning of experimental maintenance,free field|abr peak,,,,,,
11112,,generalized periodic discharges,,,,leukemic blasts,,,,,"healthy,|without regular systemic",exceeding 1.2 x upper limit of normal (uln),,,,,,
11113,,contact allergens,,,,automated,,,,,within 72 hours prior to cna3103,"1, 3, 4 or 5",,,,,,
11114,,non-pancreatic,,,,gastrectomy,,,,,more than 1 x,≥ 18|females|patients,,,,,,
11115,,hepatic impairment||hepatocellular carcinoma.|acute,,,,ultraviolet light therapy,,,,,at least once in the pathological detection/review,≥220 pg/ml,,,,,,
11116,,progressive neurologic dysfunction,,,,dysphagia treatment,,,,,while on study,more than 4 weeks prior to enrollment.|seronegative,,,,,,
11117,,septum deviation,,,,pathological examination,,,,,within 2 weeks of entry onto this study,class 2b or better,,,,,,
11118,,solid tumor||combination arms key inclusion criteria||males,,,,tobacco cessation intervention/support,,,,,in the last 1-week,25-75-year-old,,,,,,
11119,,spinal instability,,,,abdominal radiation,,,,,during stance,greater than 3 of the classification of the american society of anesthesiology).|any medical condition,,,,,,
11120,,superficial siderosis,,,,bone scan (ect),,,,,for at least 8 weeks after the last dose of study drug.|subjects,≥ 2mm,,,,,,
11121,,chronic mental,,,,hepatic dysfunction|history of drug,,,,,within previous 90 d)||non-sinus rhythm|significant,more than -6,,,,,,
11122,,oral allergy,,,,dose treatment,,,,,within the previous 12 months.|history,between 18-50 years,,,,,,
11123,,taiwanese.|those,,,,full information about the study,,,,,for at least 6 months after the last,≥ 1000 mg over 24,,,,,,
11124,,consent.|mentally stable,,,,thoracoscopy,,,,,more than 6 months after the last radiotherapy,< 95 mm hg,,,,,,
11125,,haemostasis disorder,,,,treatment;|massive infarction,,,,,within the past 24 months.|exposure,≤ 35%,,,,,,
11126,,degree|psychological disease,,,,gene-corrected macrophages,,,,,within 14 days before the first study treatment,60 years,,,,,,
11127,,malignant neoplastic diseases,,,,pathological reports,,,,,during the study period.|fertile,score ≥18 to ≤24).|absence,,,,,,
11128,,head injury resulting,,,,cardiac resynchronization therapy (crt) devices: treatment may interfere with the functionality of the device,,,,,within the observation period,"≥ 30,000/μl|hemoglobin",,,,,,
11129,,chronic hcv infection,,,,percutaneous ethanol injection,,,,,within 6 months prior to vaccination,≤ 2.0 mg/dl,,,,,,
11130,,suicidal,,,,chemo/radiation treatment,,,,,in past 2,from 18 years old,,,,,,
11131,,prion diseases,,,,parenteral nutrition therapy.|hypersensitivity,,,,,within 1 year|inborn errors,between 18 to 65,,,,,,
11132,,ice syndrome,,,,knee arthroplasty surgery,,,,,within 2 weeks before the first dose,18 to 90 years old,,,,,,
11133,,single febrile seizure,,,,board-,,,,,within 60 days before the first date of administration,18-85 years|fitzpatrick,,,,,,
11134,,hidradenitis,,,,graft-versus-host therapy.|treatment,,,,,within 6 hours|patients,=< 2|histologically,,,,,,
11135,,primary stenosis,,,,light path of the nirs probe,,,,,within the past five years.||12,classification ii or iii,,,,,,
11136,,congenital diaphragmatic,,,,liver function tests,,,,,within 3 months of screening.|secondary,greater than 3,,,,,,
11137,,chronic lung disease|left,,,,revision arthroplasty surgery|minors,,,,,within the past 3 months.|uncontrolled,< 2.5 times the uln,,,,,,
11138,,haglund disease,,,,criteria:||absolute neutrophil count (,,,,,during the 28 days before the first dose of imp except,< 300 cells/,,,,,,
11139,,education)|us residence,,,,regular exerciser - defined,,,,,for at least 4 weeks prior to the screening visit,below 93%,,,,,,
11140,,macular hole,,,,monolateral koa,,,,,at the specific study site.|willing,dose 50 mg,,,,,,
11141,,femoropopliteal pad,,,,dental implant restorations,,,,,for at least 4 weeks prior to study drug administration,18-20,,,,,,
11142,,colonic inflammatory bowel disease (ibd),,,,feet)|open calcaneal fractures,,,,,at any time in the,"< 1,5 hours of structured physical activity pr",,,,,,
11143,,diagnosing fibromyalgia,,,,first-time offender,,,,,for at least 120 days,19 years old,,,,,,
11144,,concussion,,,,maintenance exercise classes|males,,,,,more than 6 months before inclusion|hospitalisation,4-10 small joints,,,,,,
11145,,fd,,,,nephrotomy,,,,,within 30 days of discontinuing,<60 ml/min/1.73m2,,,,,,
11146,,sexual abuse,,,,elective outpatient surgery,,,,,after initial treatment regimens,=< 1.5,,,,,,
11147,,aortic regurgitation fraction,,,,sp263,,,,,within two weeks before the first dose,≥ 30muts/mb,,,,,,
11148,,extraarticular physeal fractures,,,,salicylates|urinary obstruction|porphyria|glucose-6-phosphate dehydrogenase,,,,,at screening.|clinically relevant abnormal values for,18 - 60 years;|fulfilling,,,,,,
11149,,vitreoretinal surgery|laser,,,,intracranial dissection|medical history,,,,,within 7 days prior to 124i-evuzumitide,≥18 years|covid-19 nucleic acid test or,,,,,,
11150,,complete occlusion,,,,bacillus tuberculosis)|major surgery,,,,,within 6 months prior to enrolment.|ongoing need for,"≥ 1,500/mm3",,,,,,
11151,,lsd,,,,standard glasses of alcoholic beverages per day|smoking,,,,,at the time of signing the informed consent|are,less than 1% per year.|signed written,,,,,,
11152,,core ab positive,,,,covid-19 infection|history of trauma,,,,,within 365 days) date of institutional review board approval for this study,10^9/l,,,,,,
11153,,lesions unsuitable,,,,rehabilitation|internistic rehabilitation,,,,,after joint replacement|orthopedic operations,18 years and older,,,,,,
11154,,prohibited|valvular heart disease,,,,conventional migraine prophylaxis.||,,,,,up to 14 mm,greater or equal to18 years|outpatients|patients,,,,,,
11155,,lactose,,,,ventricular septal,,,,,within 4 weeks before the first dose of study drug.|subjects,12 to 16,,,,,,
11156,,symptoms of,,,,percutaneous nephrostomy,,,,,within 2 months|unstable angina pectoris,> 6 months to <16 years|noncardiac surgery|elective,,,,,,
11157,,erythropoietin dependency,,,,corticosteroid treatment,,,,,more than five cigarettes per day,requires,,,,,,
11158,,severe visual problems,,,,unicompartmental knee,,,,,within 30 days prior to treatment start,< 0.9g/l,,,,,,
11159,,hepatitis c virus (hcv) antibody,,,,further treatment,,,,,previous diagnosis,19 years and,,,,,,
11160,,suicidal crisis,,,,primary immunization phase:||the,,,,,prior to initiating,80 mg/m²,,,,,,
11161,,chronic diseases|alcohol,,,,chimeric antigen receptor t-cell(car-t) immunotherapy,,,,,"at least 12 weeks prior to screening,|concerning",> 4/10|severe aphasia,,,,,,
11162,,solid benign,,,,systemic antitumor therapy,,,,,over 7 days ≥ 4,< 3 × 109/l,,,,,,
11163,,delayed-type hypersensitivity reaction,,,,head injury;|suspected aortic dissection,,,,,for at least 90 days after the dose of investigational product,30-80ml,,,,,,
11164,,renal function:||• hematological,,,,biotherapy,,,,,within 6 months prior to study vaccine dose.|study personnel,≤ 2 weeks,,,,,,
11165,,acute urethral injury,,,,nerve block|patients,,,,,for at least a week prior to the study|had no exercise program,> grade 1;|patients,,,,,,
11166,,recovered from any effects,,,,cessation of therapy,,,,,three months on the same dose)|weight stable,> 5mol/l,,,,,,
11167,,transient ischaemic attack,,,,intracranial artery,,,,,within 15 days prior to randomization.|treatment,< 72 h,,,,,,
11168,,sensitive to the ingredients contained in the products|the test patient consents to the restorative treatment,,,,spinal cord stimulation|english,,,,,within 6 months prior to inclusion,equal to or higher than,,,,,,
11169,,& gt,,,,anticoagulant/antiplatelet therapy,,,,,at the baseline in-office visit,> 2;|history,,,,,,
11170,,regular physical activity|limitation,,,,cohort,,,,,within the past 48 months.|documentation,90°,,,,,,
11171,,end - stage chronic kidney disease,,,,mechanical aortic valve,,,,,within 72 hours prior to registration,>200 mmhg,,,,,,
11172,,smokers|pregnant,,,,orthodontic appliance therapy,,,,,within 2 weeks before first administration use of the study,ophthalmic abnormalities.|history,,,,,,
11173,,therapy|symptomatic hypertension,,,,ribociclib treatment,,,,,last six months they should,18 years old or more|moderate,,,,,,
11174,,genetic expression,,,,bilateral iol implantation,,,,,within 30 days prior to treatment start|known,"≥ 100,000/mcl",,,,,,
11175,,hepatology specialist,,,,pelvic pathology.|recurrent implantation,,,,,approximately 2 weeks after screening,18 - 35,,,,,,
11176,,ulcerative,,,,unilateral transfemoral amputation,,,,,within the last 3 months prior to,20 cigarettes/day||patients,,,,,,
11177,,ihcc,,,,hip fracture surgery||,,,,,at least 2 of the following 3 criteria:|engage in <150 min/week of physical activity|bmi,≥ 5bu/ml,,,,,,
11178,,menstrual cycle period,,,,single baby pregnancy,,,,,within 28 days prior to beginning nma-ld|pregnant,22-79|diagnosis,,,,,,
11179,,trumatic mandibular fractures,,,,psychotropic medications)|a,,,,,within two (2) weeks prior to initial dosing,between 18-45 years,,,,,,
11180,,clearance;|difficulty swallowing,,,,polyp resection,,,,,in the past 30 days|planning to move from the kansas city area,14 years to 75 years,,,,,,
11181,,deep brain stimulation treatment,,,,covid-19 convalescent plasma,,,,,within the last 24 weeks prior to randomization,outside the range,,,,,,
11182,,biliary,,,,cardiac magnetic resonance imaging [mri,,,,,within the prior 90 days:||a,more than 16 rows.|slice thickness ≤ 0.625mm,,,,,,
11183,,type ii mobitz,,,,age|prior treatment,,,,,in the past 60 days,between 18-65,,,,,,
11184,,ribociclib + fulvestrant,,,,elective abdominal surgery,,,,,in the previous 12 months,>= 75 x 10^9/l|hemoglobin,,,,,,
11185,,degenerative pathology,,,,uv therapy,,,,,at time of screening|residing in an assisted living,> 2+ mr|mitral stenosis,,,,,,
11186,,refusal|maternal heart,,,,smc treatment,,,,,at the time of signing the informed consent.|a non-pregnant,18.5-29.9 kg/m2,,,,,,
11187,,malignant tumors;|patients,,,,liver-directed therapies,,,,,within 24 h of each test day visit,likely to impact,,,,,,
11188,,traumatic cardiopulmonary resuscitation,,,,blood glucose,,,,,while taking lenalidomide,over 18 years old|having the,,,,,,
11189,,t3 colonic adenocarcinoma,,,,full thickness cuff,,,,,within 6 months before recruitment,<1% per year|male,,,,,,
11190,,acquired pneumonia (cap),,,,regular pharmacological prophylaxis,,,,,within the last 30 days.-||,between 18 and 50 years,,,,,,
11191,,genetic neurologic disorder,,,,visit.|uncontrolled arterial hypertension,,,,,within 28 days before signing,≤ 5,,,,,,
11192,,cirrhosis|moderate liver disease,,,,preoperative echocardiogram,,,,,at screening.|ability to communicate well,at least 6 mm.||,,,,,,
11193,,wilson's disease,,,,open cholecystectomy,,,,,at the time the icf,> 7 days prior to enrollment,,,,,,
11194,,complete bowel,,,,combined ovarian cysts,,,,,within 7 days prior to the first dose of the investigational product,> 6.0 mmol/l,,,,,,
11195,,chronic infectious,,,,classical morphology,,,,,within 3 months prior to randomization,> 30 mm,,,,,,
11196,,lymphatic stasis,,,,household distances|having medical,,,,,within 6 months prior to transplantation|patients,</= 24,,,,,,
11197,,hofh,,,,implant placement.|unable,,,,,at least one week prior to the first treatment,>= 18 years|histologically,,,,,,
11198,,mechanical pain,,,,stay on,,,,,within 6 months before enrollment,= qt/rr1/3,,,,,,
11199,,deep brain stimulation|serious psychiatric comorbidity,,,,reliable birth control simultaneously,,,,,within the past five years;|poor image quality,<40 years|patients,,,,,,
11200,,chronic obstructive pulmonary disease)|a,,,,potential reduction of glucose,,,,,at any time prior to screening.|received,4-7.|people,,,,,,
11201,,obstructive cardiomyopathy,,,,bilateral oophorectomy.|premenopausal,,,,,within 28 days prior to 1st dose,>450mg/m2,,,,,,
11202,,"revascularization,|cerebrovascular disease",,,,emergency surgery;|patients,,,,,within 30 days before the first dose of study,under 18 or over 80 years,,,,,,
11203,,residual limb,,,,fresh biopsy pre-treatment,,,,,for at least 48 hours|informed,< 0.4,,,,,,
11204,,non-prothrombotic,,,,corticosteroid prophylaxis,,,,,during screening,60 or older;|2,,,,,,
11205,,vital sign,,,,exercise assessment,,,,,within 14 days prior to enrollment,≥ 40 ml/min,,,,,,
11206,,thigh pain,,,,live virus|allergen hyposensitization therapy|growth factors,,,,,during study conduct,> 2|violation of standart protocol (anesthesia,,,,,,
11207,,contraindicates,,,,procedure.|no gender limitation,,,,,within the two previous,>5.0 mg/l.|at least three,,,,,,
11208,,drug abuse|history,,,,r0 resection,,,,,less than 2 months prior to the enrollment,under 2 1/2 years old or older than 5 years|family,,,,,,
11209,,arrhythmias.|pregnant,,,,dme treatment,,,,,for 4 months,>45 kg,,,,,,
11210,,hemodialysis|active infectious diseases,,,,cnaq,,,,,up to 3 months prior to the study).|patients not capable,less than 0.70,,,,,,
11211,,motor weakness,,,,combined rast testing,,,,,within 4 weeks prior to check,≥ 1.5 x 10^9/l|platelets,,,,,,
11212,,factor|cardiovascular disease,,,,icis||additional inclusion criteria,,,,,within 2 weeks.|history,> 6 months 4,,,,,,
11213,,colorectal cancer screening||,,,,weekly text messages,,,,,within 2 weeks prior to screening.|use,<500/ml3;|food,,,,,,
11214,,progressive metastatic,,,,humans,,,,,at the clinical staging,18 to 65 years old;|able to provide informed consent and read,,,,,,
11215,,parkinson's disease|other,,,,tattooed makeup,,,,,in the 6 weeks prior to visit 1.|any asthma exacerbation,>6 years,,,,,,
11216,,hepatitis-associated,,,,elective major surgery,,,,,< 12 hours,< 500/mm3,,,,,,
11217,,psa,,,,isolated threat,,,,,onset to randomization,> 18)|eligible for a,,,,,,
11218,,autoimmune cns disease,,,,hormone therapies,,,,,at dosages equivalent to,i or ii admitted,,,,,,
11219,,knee surgeries,,,,clinical laboratory,,,,,previous 2 years|head,>4.0 m/s)|25,,,,,,
11220,,subretinal hemorrhage,,,,receive initial treatment,,,,,in the last 6 months;|diagnosis of myogenic temporomandibular disorder,stage ii and iii,,,,,,
11221,,asian,,,,orthodontic reasons||,,,,,within the 10 days prior to the first administration of investigational,between 200 - 350 mg/dl).||overweight/obesity,,,,,,
11222,,clinically isolated syndrome (cis),,,,pca,,,,,during the trial treatment,≥ 40%|participant,,,,,,
11223,,receurent bacterial vaginosis,,,,sp142 analysis,,,,,at the time of recruitment|patients,< 70 ml,,,,,,
11224,,higher)|acute nasal trauma,,,,tobacco use disorder|is,,,,,within 4 weeks;|the patient,less than one year,,,,,,
11225,,second malignancy,,,,tumour tissue sample (from archival tissue,,,,,longer than 12 weeks before randomization,< grade 2|step 3,,,,,,
11226,,light chain restriction.|note,,,,enteral nutrition support,,,,,in the past 3 years|self-reported,requiring urgent,,,,,,
11227,,scchn,,,,mechanical circulatory support.|chronic renal disease,,,,,in the last five years|uncontrolled hypertension|difficulty complying,17 - 25 years|mild-to-moderate crowding,,,,,,
11228,,ketoacidosis,,,,cit,,,,,prior to clinical trial|fugl-meyer assessment scale,>= -2.04|have not,,,,,,
11229,,residual neurologic symptoms,,,,inactive student,,,,,within 2 days prior to the study||,>0.5 seconds,,,,,,
11230,,hormonal effects,,,,palliative therapy,,,,,within 48 hours before randomization,greater than or equal to 30 kg/m^2,,,,,,
11231,,progressive rheumatic valvular lesion,,,,sympathectomy,,,,,for the time period indicated,0 - 10,,,,,,
11232,,systemic hemorrhage,,,,imaging features,,,,,for at least 12 months prior to conducting the study||,4 or more,,,,,,
11233,,patents,,,,labile international normalized ratio (inr),,,,,in the 24 hours preceding surgery.|their,> 30% bsa,,,,,,
11234,,facial anomaly,,,,bile duct stones,,,,,"in the previous 4 weeks,|having",between 18 and 60 years,,,,,,
11235,,involuntary holds,,,,pcr,,,,,within 7 days prior to the first dose of study drug);|total,between 18-48 years|asa class ii,,,,,,
11236,,hyqvia,,,,allogeneic stem cell transplant.|recipient,,,,,since at least 8 weeks prior,>= 18 years old|participants,,,,,,
11237,,acute pain,,,,spinal cord stimulators,,,,,before signing informed consent);|carcinoma in situ,"≥ 100,000 / mcl||•",,,,,,
11238,,metastatic renal cell carcinoma,,,,effective treatment means,,,,,within 1 weeks before the first dose of the investigational drug;|6,< 10 g dl-1,,,,,,
11239,,"forceps),|postpartum complications",,,,serology testing for anti-gluten protein antibodies|history of,,,,,during the study period.|donors,>= 3.2 g/dl,,,,,,
11240,,metaplastic breast cancer|prior treatment,,,,emergency procedure/treatment,,,,,within three months of the study registration,=< 7 days prior to randomization)|aspartate,,,,,,
11241,,orthosis,,,,status|orthodontic application,,,,,within the last 6 months|positive testing for,less than 40 kg/m2||exclusion,,,,,,
11242,,chronic hand pain,,,,hospitalization days||,,,,,more than 1000ml|patients,> 100 mmhg);|14 poor cooperation,,,,,,
11243,,thromboembolic disorders|history,,,,total hip replacement,,,,,for the detection of ovulation||,15 and 45,,,,,,
11244,,seizures|peripheral neuropathy,,,,consists mainly of dry kibble|agreement,,,,,at day -2 of baseline.|willing to have target areas shaved,≥12 and ≤75 years old,,,,,,
11245,,african,,,,re-contacted|non resident,,,,,at baseline <100/60 mmhg|contraindications to,grade iii - iv,,,,,,
11246,,pylori positive,,,,artificial tear substitutes,,,,,within 2 weeks prior to first dose,20-80 years|tinnitus,,,,,,
11247,,infection.||history,,,,s-icd implantation,,,,,within 4 weeks prior to prior to day 1 of protocol therapy,criteria are:||unable,,,,,,
11248,,neurotrophic keratopathy,,,,spontaneous coronary artery dissection,,,,,before training,>450 milliseconds.|subject,,,,,,
11249,,multiple endocrine neoplasia syndrome type 2|have,,,,unilateral electrode placement||,,,,,in last 2 weeks|initiation of allergen-specific immunotherapy,18 or above|fc of,,,,,,
11250,,age|a neurological deficit,,,,screening|chest x-ray,,,,,within two (2) weeks prior to operation|pregnant,≤ 25 mg/week);||ocs:||if,,,,,,
11251,,acute rhinitis,,,,schuss view,,,,,within the past 5 years prior to visit 1.||exceptions:||non-metastatic,^9/l|white blood cell count,,,,,,
11252,,poor quality,,,,anticoagulation therapy|patients,,,,,for 5 years,<=90 mm,,,,,,
11253,,diabetes mellitus;|arterial coronary disease;|beta blocker use;|cancer;|esrd,,,,complete vaginal swabs,,,,,within the last 24hrs.|legal guardian,< 30 ml/min/1.73 m2,,,,,,
11254,,skin pain,,,,suprapubic cystostomy,,,,,within 14 days before leukapheresis,0-1 year,,,,,,
11255,,macular inflammation,,,,annual lipid check modifier,,,,,within 30 days prior to visit 1.|clinically significant,> 7 kg,,,,,,
11256,,preoperative stroke,,,,verbal disclosure,,,,,within the previous 7 days of w1d1).||note: a,> 200,,,,,,
11257,,copper-banded,,,,video calls,,,,,prior to the first dose of study drug.|blood donation of approximately 500 ml or more,≤5,,,,,,
11258,,exon 19 deletion,,,,tumour removed,,,,,within 14 days or 5 half lives,≥ 75,,,,,,
11259,,s mr compatibility,,,,ipsilateral iliac artery treatment,,,,,during the follow up were,over 15 years,,,,,,
11260,,bilirubinaemia,,,,living donor liver transplantation,,,,,within 6 months of registration,<2.5 miu/l,,,,,,
11261,,effusion|significant neurologic disease,,,,conditions|blood sample,,,,,in the two months preceding inclusion for those over one year,communicate|being 18 years,,,,,,
11262,,gastrointestinal diseases.|participants,,,,fluid|central subfield thickness,,,,,within 2 weeks prior to participation in this study,≤ 15 mg,,,,,,
11263,,self harm behaviours,,,,incomplete endoscopy,,,,,within 6 months of cycle 1 day 1,1 only)|be 18-34 years,,,,,,
11264,,should avoid pregnancy for seven months after the date of their last treatment with,,,,ius levonorgestrel intra uterine system (mirena),,,,,in past 6 months.||,< 1 times the upper limit of normal limit,,,,,,
11265,,bronchial asthma|patients,,,,practice birth control,,,,,within last 2 months prior,< 8 g/dl|pregnant,,,,,,
11266,,radio frequency,,,,pelvic mri to document intersphincteric,,,,,in the 3 months prior,greater than 10 cm.|past,,,,,,
11267,,terminal illness.|participants,,,,peritoneal carcinomatosis index [pci],,,,,at the time of surgery.|active infection,">= 60%.|leukocytes >= 3,000/microliter and < 12000/ microliter.|absolute neutrophil count",,,,,,
11268,,staphylococcal blepharitis,,,,tribal enrollment,,,,,within therapeutic range,< 1.5 ×uln,,,,,,
11269,,tiny tissue biopsies,,,,chronic haemodialysis,,,,,within the past 14 days,state;|each patient's,,,,,,
11270,,craniospinal disorders,,,,septorhinoplasty,,,,,within 1 week prior to enrollment,>30 kg/m2|self-reported,,,,,,
11271,,impairment of lung function,,,,physical examinations completed,,,,,within two weeks of,<30 ml,,,,,,
11272,,tension neck syndrome,,,,completed radiation therapy,,,,,within 2 weeks prior to the screening,15 to 70 years old,,,,,,
11273,,circulatory arrest|preoperative,,,,qt syndrome|current treatment,,,,,during the fasting window|pregnancy|diabetes mellitus|bmi drop to < 18.5kg/m2,between 18.0 and 27.9 kilograms per meter^2 (kg/m2,,,,,,
11274,,months;|cardiovascular disease,,,,renal disease|history of kidney failure|history,,,,,at least 1 month after the end of the study.|male subjects must agree to practice 2 highly effective methods,≥ 90 mmhg);|prolonged qtc interval,,,,,,
11275,,subject|males,,,,susceptibility testing after,,,,,in the past 2 years|age,greater than 65 years,,,,,,
11276,,secondary immune deficiency,,,,age|primary subfoveal cnv lesions,,,,,for at least 3 months prior to the screening visit;|is willing and able to provide full consent for their participation.||exclusion criteria||is taking,73 to 19,,,,,,
11277,,criteria for radical chemoradiotherapy,,,,bpm)|cholecystectomy,,,,,6,440 ms demonstrated,,,,,,
11278,,effects|haemorrhagic diathesis,,,,second covid-19 vaccination,,,,,within a period of 5 half-lives,> 20 ng/ml significant,,,,,,
11279,,physical abuse,,,,graft versus host disease.|patients,,,,,in the previous year.|subject currently involved,less than 55 mmhg,,,,,,
11280,,anxiolitic type,,,,mps-1|previous haematopoietic stem cell transplantation,,,,,last year before enrolment,> 50ml/m2).|patients,,,,,,
11281,,postoperative infection,,,,cough suppressant medication,,,,,for at least 6 months prior to screening,18 - 55|primary diagnosis,,,,,,
11282,,score of,,,,biliopancreatic diversion||clinical concern,,,,,last two years|pregnant/lactating,19 or older|clinical evidence,,,,,,
11283,,distal common bile duct tumor lesions,,,,intracranial electrodes,,,,,within 6 months prior to day 1 for individuals,1-2.|patient's consent,,,,,,
11284,,spleen deficiency,,,,chimeric antigen receptor t-cell immunotherapy therapy,,,,,within 2 years before the first dose,≥130ms,,,,,,
11285,,irinotecan gastrointestinal,,,,surgically treated,,,,,within 6 months before first dose,+/- purine analog,,,,,,
11286,,respiratory problems,,,,pneumococcal conjugate vaccine,,,,,at least 2 different nsaids,18.5 to 25 kg/m2,,,,,,
11287,,acquired tuberculosis infection,,,,abnormalities|mini-mental status examination,,,,,surgery/renal transplantation)|kidney/urinary tract surgery|arteriovenous fistula surgery|end-stage renal disease,18-26,,,,,,
11288,,cerebral palsy|age,,,,seefeld,,,,,within 1 month before the screening.|with addicted to smoking,≤ 1.5 g/l).|infection of the proposed,,,,,,
11289,,comorbidities,,,,art restart criterion,,,,,within 6 months before the first administration,"i, ii",,,,,,
11290,,pain texts,,,,acl reconstruction,,,,,within past 4 months|other,< 20 percent,,,,,,
11291,,restless legs syndrome.|exposure,,,,open surgery|having another surgical procedure,,,,,lasted for three months before first oral dose,>2.0,,,,,,
11292,,acute myeloid leukemia,,,,fbdsi|active peptic ulcer|history,,,,,in either,>16 years,,,,,,
11293,,asymptomatic atrial fibrillation,,,,thin-section ct scans,,,,,within the last 30 days|being,0-1;|signed the informed,,,,,,
11294,,psychiatric disorder|suicidality|vertigo|epilepsy,,,,computed tomography (ct) of the abdomen,,,,,within 12 months prior to study entry.c,50 years or older,,,,,,
11295,,pseudomeningitis,,,,tumor assessment form.|patients,,,,,within 6 months after the effective non-pharmaceutical,under 18,,,,,,
11296,,flexor carpi radialis rupture|previous,,,,autologous transplant,,,,,3 months after surgery)|normal mammogram,1.5 × institutional upper limit of normal,,,,,,
11297,,acute abdominal survey,,,,ward,,,,,during the study period；|anti-il-17 antibody active,>75yo then psa,,,,,,
11298,,acute alcohol intoxication,,,,index knee,,,,,within the previous year,18-80 years|admission,,,,,,
11299,,liebowitz,,,,1)the anesthesia,,,,,within the past 6 months.|clinically significant,3-4)|drugs,,,,,,
11300,,substance/alcohol abuse,,,,self-report||,,,,,within 3 months prior to treatment,less than 18 years|patients,,,,,,
11301,,circulatory failure,,,,treatment.|previous treatment,,,,,within 3 days prior to the first dose,= 0.133 kpa).|no,,,,,,
11302,,primary ovarian insufficiency,,,,environmental stimulation,,,,,at the anticipated needle entry site.||9,> 90|history,,,,,,
11303,,substance use disorder|cognitive disability|language barrier,,,,hypermobile septum,,,,,on the pre-randomization,≤ 5 x upper normal limit (uln),,,,,,
11304,,good organ function.|male,,,,single resection,,,,,mrd;|within 3 days prior to initial treatment,> 4.|presence,,,,,,
11305,,lower limb oedema,,,,complete quantitative behavioral surveys,,,,,within 30 days prior to the first dose of the study drug.|prior exposure,≥ 90g/l.,,,,,,
11306,,leukoaraiosis,,,,nearly every day.||exclusion,,,,,within 30 calendar days of the day 1 visit for study gbt021601-022.||note,<= 90 beats per,,,,,,
11307,,heterozygous deletion,,,,12-point,,,,,within 96 hours before administration;|patients,stage ii of the knee oa;|affected,,,,,,
11308,,myotonia congenita,,,,liver transplant,,,,,within the last 6 months|do,18 or older|is,,,,,,
11309,,retinopathy of prematurity,,,,24-hour urine collection,,,,,within 5 years prior to screening visit,> 10mg/l,,,,,,
11310,,progressive supranuclear palsy,,,,temporal artery biopsy before study enrollment|chronic use of,,,,,6 months of screening,≤2.5 × institutional uln|creatinine clearance,,,,,,
11311,,lungs disease,,,,orthodontic treatment.|class,,,,,during screening period suggest evidence,level 2,,,,,,
11312,,boo,,,,immuno-suppressants,,,,,within 6 months of completion of the adjuvant,<6 months;|subject,,,,,,
11313,,lichen simplex chronicus,,,,numerical pain scale|having bilateral muscle spasms,,,,,infection.|history of,<30 ml/min./1.73 m2,,,,,,
11314,,alar ligaments|vertebra,,,,complete eradication therapy,,,,,within 6 months of prior,score of 10 or higher,,,,,,
11315,,nasal septal defect,,,,rapid sequence intubation,,,,,for the last 6 months prior to screening|ongoing,men|age 65 years,,,,,,
11316,,lack of conscent|airway abnormalities,,,,"infection|difficult sonoanatomical visualisation of the target area (sctl, ittc etc",,,,,after general anesthesia,over 18 years|proficiency,,,,,,
11317,,cognitive impairment|informed,,,,imaging of the abdomen,,,,,in the past 24,>150 mg/day|egfr,,,,,,
11318,,seizure disorders|pregnancy|substance abuse,,,,fondaparinux sodium,,,,,within 48 hours after admission to the general internal medicine,patients;|patients underwent,,,,,,
11319,,simplification,,,,mrecist v1.1,,,,,within 24 hours.|using,over 50% of indirect bilirubin|creatinine clearance,,,,,,
11320,,unexcised tumors,,,,ivus examination suggests severe calcified lesions,,,,,in the past 6-months,≤12.5 ng/ml,,,,,,
11321,,b cell,,,,low dose chemotherapy,,,,,at uab within 10 weeks of study enrollment|age,more than 2,,,,,,
11322,,rt2 gingival recessions,,,,manifest refraction spherical equivalent (mrse),,,,,longer than 6 months|under,≥1.5×109/l,,,,,,
11323,,impact mood,,,,blood-borne diseases,,,,,at least three electrocardiograms(ecgs,<1,,,,,,
11324,,isis 678354-cs6 study entry,,,,rapid progression,,,,,in the past 3 months|difficulty participating for technical/logistical issues,<1 g/ l)|presence,,,,,,
11325,,completely alleviated;|the,,,,qualifying antibiotic class,,,,,within the last 3 months.|suspected,< 45 ml / min / 1.73 sq.m);|the presence,,,,,,
11326,,general disease,,,,polymerase chain reaction (pcr) test or antigen test,,,,,during training are included in the analysis||,21-99,,,,,,
11327,,communication disorder||inclusion criteria,,,,mayo endoscopic subscore assigned,,,,,at least 6 months after the last dose of study,≤ - 3,,,,,,
11328,,seizure disorders.|mania.|primary,,,,b cell acute lymphoblastic,,,,,at the 60°/s,≤300 ng/dl,,,,,,
11329,,organic psychosis,,,,24-hour collection,,,,,within 30 days prior to the vaccination of study,>160/90 mmhg - can,,,,,,
11330,,congestive heart failure|patients,,,,surgical staging).|patients,,,,,within 9 weeks prior to baseline through follow-up.|blood transfusion,50 to 95,,,,,,
11331,,enrollment;|active heart disease,,,,dendritic cell vaccine,,,,,at the time of intake|previous intravitreal treatments.|refusal to sign informed consent,>110 mm,,,,,,
11332,,post-vagotomy||xiv,,,,general health questionnaire - see attached document)|body mass index (bmi),,,,,during at least 1 previous birch pollen season,18+ years old|proficient,,,,,,
11333,,levator myalgia|known bladder malignancy|previous,,,,fetoscopic neural tube defect repair||,,,,,for the time period prior to enrollment,less than 80 %,,,,,,
11334,,inadequate lab function,,,,hormone-based treatment for breast or,,,,,at least 6 weeks prior to screening,0-1|left,,,,,,
11335,,oral lesions,,,,plasmatic β-hcg,,,,,at any time in the absence,< 80 ml/min|triplicate,,,,,,
11336,,mitral valve repair (mvr),,,,spray therapy,,,,,within 3 months.|clinically significant,10 mmhg,,,,,,
11337,,vaginal infection,,,,pregnant|significant,,,,,within the last 6 months|evidence,"<9h sb/day,|experienced",,,,,,
11338,,colorectal cancer risk questionnaire,,,,for|diagnostic colonoscopy,,,,,within 44 weeks prior to the vaccination of study intervention|currently,≥20 mm,,,,,,
11339,,sensory disability,,,,fresh embryo transplantation,,,,,at least 1 of the following criteria:|have undergone documented,less than 3cm,,,,,,
11340,,horizontal.||,,,,transient ischemic attack|previous malignancies,,,,,within 10 days prior to the first dose of study drugs.|evidence,18 years or older.|this study,,,,,,
11341,,special type diabetes,,,,diffuse intrinsic pontine glioma,,,,,within 36 months prior to participating,<18 years or >80,,,,,,
11342,,multiple allergic manifestations,,,,maintenance immunosuppression after,,,,,within 6 months prior to enrollment|interventional procedure,level ii and iii,,,,,,
11343,,immunocompromised,,,,previous laboratory examination,,,,,over 500 ml,60-80 kg,,,,,,
11344,,frail elderlies,,,,125 therapy,,,,,at screening and before the first administration exceeded the standard,19.0 - 28.0 kg/m^2,,,,,,
11345,,dietary changes,,,,open tah||,,,,,within 24h of onset,≥ 80ml/m2,,,,,,
11346,,genetic skin disorder,,,,spinal surgery.|serious spinal conditions,,,,,after 2 courses,≥16 prior to the treatment|signed,,,,,,
11347,,colonic occlusion,,,,brain imaging||,,,,,before the first administration of the drug;|a history of,18 -100 years|diagnosis of,,,,,,
11348,,upper extremity|systemic diseases,,,,tracheostomy in situ,,,,,for less than 3 months,> = 18 years.|whether there is,,,,,,
11349,,breathing difficulty,,,,lipid-lowering treatment,,,,,within the last 6 months|heart failure,iii or more,,,,,,
11350,,atherosclerotic cardiovascular diseases,,,,spaceoar hydrogel,,,,,preceding 1 month,< 80 ml/min/1.73 m^2.|triplicate,,,,,,
11351,,gastroesophageal varices,,,,optimal treatment of their underlying cardiopulmonary pathophysiology,,,,,at least 12 month)|current use of a,65 and older|difficulty,,,,,,
11352,,acute infectious diseases,,,,non study fluid,,,,,"during the procedure,|pre-procedure pain medication",less than 100×109/l,,,,,,
11353,,endocrine system diseases,,,,inactivated covid-19 vaccine,,,,,more than 6 weeks prior to randomization.)|planned,less than one year|known,,,,,,
11354,,doppler auscultation,,,,first treatment of haic,,,,,after conservative,≥55kg,,,,,,
11355,,cognitive disorders,,,,re-test,,,,,within three months post-partum,greater than 6 months;||4.1.5,,,,,,
11356,,diabetic ketoacidosis.|have,,,,local testing results.|patient,,,,,within 3 months prior to screening|acute myocardial infarction|cerebrovascular accident,less than 1 %,,,,,,
11357,,relapsing remitting,,,,relugolix containing therapy,,,,,shock|recent iv,> 12 weeks,,,,,,
11358,,autoimmune hepatitis interstitial pneumonia,,,,intervention therapy,,,,,within 48 hours prior to the administration of fet,>110 on the,,,,,,
11359,,breast cancer surgical resection,,,,hormone birth control patch,,,,,at least prior to randomization.||note,≤ 4 mg,,,,,,
11360,,psc)|autoimmune liver disease|obstructive biliary,,,,pacemaker|mri,,,,,last 8 weeks,at least 22 years,,,,,,
11361,,labial root curvatures.||intact root,,,,bone marrow radiation.||a serum creatinine,,,,,prior to baseline,between 20 and 28 kg/m2,,,,,,
11362,,impaired tissue integrity,,,,radioactive therapy|previous psma-targeted radioligand,,,,,at least 4 months,18 - 55 years.||,,,,,,
11363,,affect pain,,,,rehabilitation protocol,,,,,within 5 years prior to the first administration of the drug,250 ml) beer,,,,,,
11364,,adjuvant cohort,,,,background treatment,,,,,in the 90 days prior to enrollment.|patients,≥9 g/dl,,,,,,
11365,,liver abnormalities|other,,,,standardized minimental test.|having chronic neck pain problem,,,,,last hospitalization,≤ 29+6,,,,,,
11366,,ssich,,,,revision surgery|patients,,,,,"in the month preceding the study,|taking",> 18 years;|no,,,,,,
11367,,coronary disease,,,,aesthetic surgery.|be involved,,,,,within 5 years|serious medical illness,≥9g/dl,,,,,,
11368,,disease|eastern,,,,bji,,,,,prior to the first dose of the investigational,≥ 8,,,,,,
11369,,contact lens best corrected distance vision,,,,blood cell transfusion|dialysis,,,,,within 28 days prior to study entry,requires treatment,,,,,,
11370,,active smoking,,,,treatment for hypertension,,,,,within prior year,<2 cm breast cancer;|clearly visible,,,,,,
11371,,antibiotics.||female,,,,mechanical ventilation|use of,,,,,after diagnosed,> 13,,,,,,
11372,,delusional disorder,,,,liver imaging;|interferon antiviral therapy,,,,,since radiation.||8,> 9 g/dl|platelets,,,,,,
11373,,serious eye disease,,,,urogynecological surgery,,,,,<5 days,"≥1,000/mcl",,,,,,
11374,,age.|either gender|patients,,,,histological variants of ftc,,,,,prior to planned,0-10cm,,,,,,
11375,,inattentive type,,,,vocal audiometry,,,,,in the next 3,score less than or equal to (<=) 7,,,,,,
11376,,lower limb edema,,,,distal pancreatectomy,,,,,within 1 week prior to first dose,> 0.7 kilounit per liter,,,,,,
11377,,hiv infection.|female,,,,chimeric antigen receptor t cell therapy|within 1 year of receiving b-cell depleting therapies,,,,,within 4 weeks before the first drug use;|as,≥ 35,,,,,,
11378,,myocardial infarction|liver dysfunction,,,,immunosuppressant therapy,,,,,within the last 10 days,greater or equal to 18 years old,,,,,,
11379,,stroke|symptomatic hf,,,,re-testing for pregnancy,,,,,within 4 weeks prior to the first dose of study drug.||7,20 years,,,,,,
11380,,clinical bleeding symptoms,,,,permanent study intervention discontinuation in study kgbi,,,,,within 28 days prior to study vaccination;|enrolled,"< 75,000",,,,,,
11381,,judged inappropriate,,,,global initiative,,,,,within 2 months of screening,≤ 2.5 x institutional upper limit of normal|serum creatinine,,,,,,
11382,,t2 lesion,,,,hepatic impairment||a marked,,,,,before starting bevacizumab,minimum 20%,,,,,,
11383,,major comorbidities,,,,elective surgery|surgery planned,,,,,in the past 3 months.|factors influencing light,< 1500 mm3,,,,,,
11384,,t2-weighted,,,,produce suspicion,,,,,within seven days prior to administration|history of,11 ≤ total score of mmse,,,,,,
11385,,circumferential bone defect,,,,1:||adequate organ function laboratory tests system,,,,,at the time of signing informed consent.|histologically,male latex,,,,,,
11386,,left-sided,,,,alternative dose-,,,,,within 6 weeks prior to day 1|participants,>=20 mg/day,,,,,,
11387,,myelodysplasia subtype anemia,,,,aortic dissecting aneurysm,,,,,within 14 days prior to check-in (day -1,"< 4,4 x 103/mm3|aspartate",,,,,,
11388,,skin allergies,,,,major coronary,,,,,after first-line treatment.|for,0 ~ 1,,,,,,
11389,,self-identifying,,,,rapid influenza diagnostic test (ridt),,,,,within 1 month;|subjects who are considered by the researcher to have,≥ 100 g/l,,,,,,
11390,,abnormal laboratory results of,,,,avastin® therapy,,,,,"within 12 hours prior to index procedure,|significant anaemia",40.0 kg/m2,,,,,,
11391,,idiopathic,,,,laboratory tests,,,,,greater than 400 ml,18yr and,,,,,,
11392,,non-implantable hearing solution from,,,,camrelizumab therapy,,,,,during the last 6 months prior to screening,40-70 years,,,,,,
11393,,ocular toxicity,,,,serological testing .|history,,,,,approximately 12 months after first dosing|body mass index,less than 2.5,,,,,,
11394,,bladder infection,,,,routine laboratory test,,,,,within 96 hours,=< 16 years,,,,,,
11395,,streptococcus pneumoniae infection,,,,dental trauma history,,,,,in the last 12 months,> 2cm away from the site of a metastatic lesion,,,,,,
11396,,abnormal laboratory result,,,,aortic regurge,,,,,in previous 4 weeks before first visit|history of current,item 9,,,,,,
11397,,anticoagulation therapy|underlying condition,,,,control associated symptoms,,,,,for at least 1 month prior to screening,from 2-6 years,,,,,,
11398,,protozoal infection,,,,chronic administration,,,,,within 6 months prior to the vaccine,hb=8.0-10.9 g/dl,,,,,,
11399,,individual's,,,,intraocular refractive interventions,,,,,at least 3 months prior to first dose.|with history of,0 to 2.||,,,,,,
11400,,active coronary heart disease,,,,brain magnetic resonance imaging (mri) demonstrating,,,,,within 28 days prior to randomization.|participants,over 20 years,,,,,,
11401,,fiberoptic intubations,,,,bypass graft|acute coronary syndrome,,,,,within the previous three months,>120 beats per minute,,,,,,
11402,,lumbar medial branch block,,,,ihc assay different,,,,,after first line,> 3 times upper normal,,,,,,
11403,,hypertrophic scars,,,,gastroenterostomy,,,,,within 7 days prior to visit 2,i and ii|aged 6-17 years|ability to cooperate,,,,,,
11404,,cutaneous infection,,,,expected surgery,,,,,remotely prior to day 1|participant,between 3 and 5.||i2,,,,,,
11405,,flow limiting features,,,,walnut,,,,,within 5 days prior to allocation.|any rapidly-progressing,equal or above 34,,,,,,
11406,,corneal transplant.|receiving,,,,gbs,,,,,at time of treatment.|known history,1-2.|able to adhere to the study visit schedule and complete all study,,,,,,
11407,,blood transfusion,,,,co-medications,,,,,in the past 24 months,>= ii,,,,,,
11408,,ankle injury,,,,graft biopsy,,,,,in the period less than 2 months before the start of the study;|patients,i-ii-iii||,,,,,,
11409,,pneumocystis jirovecii,,,,trendelenburg,,,,,at least 2 weeks before randomization|eastern,between 4 and 18 years.|motor disability.|affectation,,,,,,
11410,,mixed aiha,,,,intraoperative blood transfusion,,,,,during the time of participation in the study,over 16 years,,,,,,
11411,,malignant arrhythmias,,,,preoperative ecg,,,,,in the 12 weeks before screening|use of,<126 mg/dl;|testosterone,,,,,,
11412,,cholangiography,,,,upfront therapy,,,,,up to first molars|treatment needed,≥20 u/ml,,,,,,
11413,,intolerability,,,,preventive therapy,,,,,within 90 days||evidence,above 18|absent,,,,,,
11414,,impending fracture,,,,general inclusion,,,,,at the time of the procedure,20/25|age 18 to 30 years|refractive,,,,,,
11415,,intrauterine growth retardation,,,,global impression-,,,,,in the baseline,<18.5|patient,,,,,,
11416,,dependence disorder,,,,skin prick tests,,,,,in the year,≥ 18 years|no,,,,,,
11417,,dysuria,,,,compression therapy,,,,,for ≥ 6 weeks,50% or less,,,,,,
11418,,nerve block,,,,major scars|unable,,,,,within 4 weeks before starting treatment,> 18|advanced,,,,,,
11419,,mucosal ulcers,,,,hepatic complications.||3-patients,,,,,in the previous 1 month|clinical signs,between the 10th-85th percentiles|expert clinical diagnosis,,,,,,
11420,,inflammatory carcinoma,,,,recruitment decision tree below.|eligible,,,,,at least 6 months|back pain,≥1.5 × 109/l,,,,,,
11421,,intracranial hematoma,,,,intensive induction or|for,,,,,within 3 months after screening,≤ 2.5 × uln,,,,,,
11422,,solid malignant neoplasms,,,,hematologic blood counts,,,,,at least 20 minutes,≥ 1.0 x 109/l,,,,,,
11423,,hiv positive;|10,,,,surgical sterilization.|inability,,,,,within the past 3 months|expected,≤ 1.5 x the upper limit of normal of the,,,,,,
11424,,bmi>30|orthopedic,,,,extracorporeal membrane,,,,,at the time of indications for surgery,150 to 299 cells/μl,,,,,,
11425,,digital cbt,,,,abdominal adhesions|significant,,,,,within 14 days prior to screening.||note,> 2000 mg/g,,,,,,
11426,,bilateral hearing loss,,,,alternative overnight visit,,,,,within 3 months from the time of screening)|patients,asa1-2,,,,,,
11427,,chronic obstructive pulmonary disease|combined,,,,small amount of,,,,,prior to conduct,>1.5 x uln|egfr <70mls/min/1.73m2|for,,,,,,
11428,,prolonged gastrointestinal,,,,standard trauma-focused psychotherapy,,,,,at least 6 months ago|ambulation,need intrasinusal pyelolithotomy.|patients,,,,,,
11429,,childhood disruptive behavior,,,,formation of soft blood clot,,,,,at time of mbm development,> 30 minutes,,,,,,
11430,,chest discomfort,,,,angioplasty,,,,,after prior anti-pd-1/,> 30 ml/min/1.73m2.|patients,,,,,,
11431,,sleep disorders|no,,,,"student risk screening scale-externalizing.|receiving the majority of services in general education settings|in 3rd, 4th, or 5th grade level.||",,,,,at the time of consent to participate this trial|patients,> 440 ms,,,,,,
11432,,normal activities,,,,nicotine-,,,,,within 1 week prior to cycle 1/day 1.||(11)patients,greater than or equal to 1.5 x uln,,,,,,
11433,,haemolysis,,,,lacquer cracks,,,,,within 3 months prior to baseline.|pregnant,+/- 1 year)|french or reading,,,,,,
11434,,scd,,,,thrombolysis or thrombectomy,,,,,within 14 days prior to the first dose of study drugs|anticoagulant,above 100 mg/l|patients,,,,,,
11435,,back directions,,,,study|major surgery,,,,,prior to day 42,18.5-24.9|individuals,,,,,,
11436,,generalized joint diseases,,,,transesophageal echocardiography,,,,,within 5 years|able to understand the protocol,≤ 4.8 mmol/l,,,,,,
11437,,non-radiation sites,,,,syncopal recurrences,,,,,for the detection of drugs of abuse,≥90×109/l,,,,,,
11438,,persistent toxicities,,,,tibial osteotomy,,,,,for 2 weeks after the end of the study/last dose of imp,exposure;|reporting,,,,,,
11439,,bone diseases,,,,or|computed tomography (ct) criterion,,,,,during the duration of the study,18-75 years;|bmi,,,,,,
11440,,nodal spread,,,,left ear,,,,,within two months prior to baseline,older than 1 month and younger than18 years,,,,,,
11441,,urethra,,,,implantation of the alcon sn60wf lens,,,,,within 1 year prior to screening.|history,>= 20,,,,,,
11442,,mucosal healing,,,,allogeneic stem cells,,,,,within 7 days before enrollment|chorioamnionitis,stage 3b,,,,,,
11443,,primary duties,,,,radiation-induced oophorectomy,,,,,at time of study||any,6 months and above,,,,,,
11444,,adverse events.||active ulcers,,,,roxadustat treatment,,,,,in the next 2 years|individuals,≥8 and ≤37 kg,,,,,,
11445,,slc7a7,,,,ecg,,,,,planning to change,1 or better from the adverse events,,,,,,
11446,,pregnancy test.|pregnancy,,,,lateral deviation of the mandible,,,,,at inclusion between 23,below 30 g/l before starting any first-line itp therapy,,,,,,
11447,,small cell carcinoma,,,,invasive cancer;|no surgical treatment,,,,,during the screening period.|can perform a,>5 points,,,,,,
11448,,old|diabetes mellitus|diabetic autonomic,,,,month|antibiotic treatment,,,,,during the last 30 days,over 440 ms,,,,,,
11449,,or|hypocalcaemia,,,,barrier method,,,,,during the last month.|participants,<15°,,,,,,
11450,,nail gels,,,,microsurgical breast reconstruction,,,,,in the facial,40-50,,,,,,
11451,,allergic response,,,,festival medical staff,,,,,within 30 days prior to study,less than 5.0 cm2,,,,,,
11452,,eczematous lesions,,,,osa|patients,,,,,more than 12 hours from the onset of,18 years and,,,,,,
11453,,oral typhoid,,,,conventional imaging. initial treatment may include,,,,,12 hours before starting the study|being,30 to 35 fractions,,,,,,
11454,,pestis,,,,intravesical installation therapy||,,,,,at the time of se occurrence.|participants who pre-emptively opted out of the study.|a known,20 - 45,,,,,,
11455,,slt,,,,intratumoural treatment,,,,,bispebjerg hospital department m1.|being able to participate in basic mobility activities,above 70 years,,,,,,
11456,,iuds,,,,congenital genital malformation,,,,,in the last 6 months|those,≤ 1;|at least one measurable,,,,,,
11457,,posterior macular tumor,,,,aqua therapy,,,,,within 8 weeks of visit 1.|historical,≥ 5.|age > 18 years,,,,,,
11458,,pathologically with dlbcl,,,,injection procedure,,,,,at least two years|averaging,≥ grade 3.||12,,,,,,
11459,,hepatic disorder,,,,uc,,,,,within one year of enrollment,45 ml of,,,,,,
11460,,cardiovascular events,,,,fontan procedure,,,,,for all five perennial aeroallergens,> 40|pregnancy,,,,,,
11461,,deep chemical peeling,,,,cystourethroscopy,,,,,within 30 days prior to the first dose of sipuleucel-t|documented,20-35,,,,,,
11462,,lcls)/facial rhytides by,,,,flexible laryngoscopy,,,,,in the next three months,stage i only)|clinical,,,,,,
11463,,reproductive potential,,,,pulmonary lobectomy,,,,,imaging:||more than,≥ 6.5%,,,,,,
11464,,liver pathology,,,,technology access,,,,,for ≥ 6 months|bell score,< 18 kg,,,,,,
11465,,noninfectious illness,,,,intrathecal anesthesia,,,,,for 4 months after the last dose of study drug||adequate,score of 18 to 26.|participants,,,,,,
11466,,valvular disease.|renal insufficiency,,,,primary arthroplasty procedure,,,,,within 12 months before the screening visit,1|less than six months,,,,,,
11467,,severe bleeding tendency,,,,laparoscopic sleeve gastrectomy||,,,,,at least 6 weeks ago,> 90 days per their treating neurologist.|the patient must,,,,,,
11468,,lamellar ichthyosis|two target areas,,,,invasive ventilation,,,,,at the time of inclusion||9,"≥700/µl|platelets ≥100,000/µl||hepatic",,,,,,
11469,,coconuts|chronic gi disorders,,,,neural modulation treatment,,,,,within 3 months prior to enrollment;|had,four-week,,,,,,
11470,,interaortocaval nodes))|preoperative use,,,,corneal abrasions,,,,,at the time of the screening visit 5,>=1d,,,,,,
11471,,epithelial tear,,,,vaginal exam,,,,,in the last 5 years;|dentures,< 6)|high risk,,,,,,
11472,,lactate dehydrogenase [ldh,,,,screening for cancer,,,,,within the prior 14 days|the following,15 to 44.9 ml/min/1.73m²,,,,,,
11473,,nasotracheal intubation.||,,,,palliative radiotherapy,,,,,within 2,levels of their seizure,,,,,,
11474,,inner forearm the beginning of the product application phase;|willing,,,,tki therapy,,,,,within 2 weeks prior to the enrollment,greater than 500ms.|patients,,,,,,
11475,,chronic painful condition,,,,stem cell transplant,,,,,within 24 hours from hospital arrival,1-3|age,,,,,,
11476,,hypertention;|receiving immunosuppressive therapy;|emergency surgery,,,,chemotherapy treatment|adequate serum levels,,,,,for at least 1 year.||for,grove to achieve oversampling of vietnamese families)|speaks,,,,,,
11477,,self-injury,,,,preoperative information,,,,,within four weeks prior to treatment initiation,iii-iv;||had,,,,,,
11478,,fetal malformations,,,,"evaluation.|matched for sex, age (± 10 years",,,,,during the current,between 20-40 years.|body,,,,,,
11479,,lactose intolerance|known,,,,emergency room [er],,,,,for 1 year following jwcar029 infusion.||,0-2.|good organ function,,,,,,
11480,,total bilirubin≤2×uln,,,,haemodialysis session,,,,,following standards:||bilirubin（bil）<1.25 times the upper limit of normal (uln);|alaninetransaminase(alt),> 18|metastatic setting,,,,,,
11481,,atypical features,,,,modification of diet in renal disease (mdrd) formula,,,,,within 28 days prior to imp treatment start,"<60,000 platelets/mm3).|known",,,,,,
11482,,mycotic infections,,,,structured clinical interview for dsm-5 by the investigator.|expressed a wish to reduce,,,,,8 weeks before the start of the study,≤ 2.5×upper limit of normal (uln),,,,,,
11483,,peritoneal dialysis;|clinical presentation suggests,,,,antiretroviral treatment,,,,,at least 3 weeks prior to randomization||,> 140 mmhg,,,,,,
11484,,"liver disease,|history",,,,radiofrequency treatment,,,,,within the last 2 weeks prior to first contact,above 10 mg - 30 day,,,,,,
11485,,pleural effusion.|pleural,,,,pcr tests,,,,,within 10 days prior to the start of study intervention.|the study will accept therapy,>= 18 years.|eastern,,,,,,
11486,,recession,,,,antacids,,,,,at the time of zanubrutinib initiation|started,≥10 kgs and <40 kgs,,,,,,
11487,,large molecule protein products,,,,screening;|positive urinalysis,,,,,surgery <1 year,50 years,,,,,,
11488,,lung disease|obesity bmi,,,,coronary bypass graft surgery,,,,,at the time of signing the icf;|histopathologically,≥30 kg/m2)|use,,,,,,
11489,,progressive pulmonary infiltrates,,,,full treatment cycle,,,,,within the three months prior to study enrollment|intent to change dosage,>1.5 × uln|aspartate aminotransferase,,,,,,
11490,,intentional ketogenic,,,,several caesarean sections,,,,,in the year prior to hnscc diagnosis.|pregnant,< 1.5x uln,,,,,,
11491,,medical comorbidity,,,,ttns,,,,,at the study site,not to exceed the upper limit of normal,,,,,,
11492,,acute leukemia|parameters,,,,resection of the primary tumor (c),,,,,for at least 1 week prior to screening,≥100 pg/ml.|participants,,,,,,
11493,,fatal outcome,,,,first hospital;|complete baseline clinical,,,,,at the time of enrollment|english,equal or less than < 88 cm,,,,,,
11494,,mental abnormalities,,,,chest or|mri of the neck with ct of the chest or|whole body pet/ct|histological,,,,,during the duration of this,≥ 90 mmhg;|other,,,,,,
11495,,borderline tumors,,,,model warning signs of pid,,,,,within the past 5 years.||note,18.5 to 27.0 kg/m2,,,,,,
11496,,solid phase immunoassay).|recipient,,,,diagnostic ct documenting target lesions every,,,,,at least 8 weeks prior to cycle 1 day 1,between 18 and 60 years|complaining,,,,,,
11497,,ankle instability,,,,arthroscopic knee surgery,,,,,during the study visits,"at least 18 years old,|to",,,,,,
11498,,central apnea,,,,12-month follow-up,,,,,within 2 years prior to randomization,ii,,,,,,
11499,,alcoholism guidelines,,,,head-us measurement available in the 2 months prior,,,,,performing,14 - 45|history of,,,,,,
11500,,genotype associated,,,,gastric bypass surgery|pregnant,,,,,prior to providing documented,reduced,,,,,,
11501,,arteriovenous thrombosis,,,,technological equipment,,,,,maximum 1 month prior to inclusion,less than or equal to 75 years,,,,,,
11502,,complex sleep behaviors,,,,substance abuse|known major stenosis of the intestines|known severe,,,,,within 30 days prior to the first dose of study treatment.|female participants who,18 to 75,,,,,,
11503,,conduction abnormality,,,,antiviral therapy,,,,,for at least 28 days,<1.00 d||exclusion criteria:||participants,,,,,,
11504,,lower extremity trauma,,,,sle background medication,,,,,within the past 6 months;|field,more than 32 weeks,,,,,,
11505,,face's,,,,vasectomy,,,,,last one received prior study entry,0-1|lymph,,,,,,
11506,,relevant regulations.||,,,,reconstruction,,,,,more than 6 months before signing the informed consent,exceeding 100 ng/ml,,,,,,
11507,,squamous cell cancer of the skin,,,,chest computerized tomography (ct) evidence,,,,,within 2h after surgery|unstable,≤ 1.5 × upper limit of normal value (uln),,,,,,
11508,,cartilage lesions,,,,stent pictorial procedures,,,,,"before jaundice onset,|ast>50 iu/l",greater than or equal to 18 years|diagnosis,,,,,,
11509,,cardiac arrhythmias|uncontrolled,,,,salvage total laryngectomy,,,,,8 weeks or longer)|negative,under 100 iu/ml,,,,,,
11510,,skin involvement,,,,alternative anticoagulation,,,,,at the time of approach.||clinicians:||oncologists,24-28 week,,,,,,
11511,,multiple trauma|patient,,,,mri.|positive centralization,,,,,within 14 days before randomization.|allergic to and /,7-9 points,,,,,,
11512,,nodular fasciitis-like stroma,,,,psychosocial treatments,,,,,during this period.|subjects,<30ml/,,,,,,
11513,,injectable tumors,,,,status||,,,,,at admission < 24 hours||,> 5x upper limit normal (uln),,,,,,
11514,,hypertensive encephalopathy.|pleural effusion,,,,sterilization procedure,,,,,at study entry|history of a second malignancy,over 140 mmhg,,,,,,
11515,,dermatological disorders-psoriasis,,,,flow cytometry evaluation,,,,,within 6 months prior to screening;|any unsuitable to participate in this trial judged by the investigator,2x the upper limit of normal,,,,,,
11516,,resolved disease,,,,control of symptoms,,,,,within 365 days prior to baseline|pregnancy,5% - 19%,,,,,,
11517,,disease-related immune thrombocytopenic purpura,,,,chemotherapy treatment ongoing|patients,,,,,within the last 60 days|have,<= 1.5 x uln|creatinine <1.5 x uln,,,,,,
11518,,adverse risk factors;|relapse,,,,routine care samples,,,,,within 4 weeks prior to day 0|presence,requiring iv antibiotics,,,,,,
11519,,mechanical ventilation|hyperphosphatemia,,,,"lateral episiotomy,|uncomplicated newborn|newborns",,,,,within 2 weeks prior to the first dose of study drug|systemic treatment,scores <70,,,,,,
11520,,graphesthesia,,,,reliable internet connection,,,,,within 24-72 hours,140 - age)/72,,,,,,
11521,,intractable hypertension.|suffering,,,,pelvic-abdominal treatment,,,,,up to 4 weeks prior to starting study treatment.|endocrine therapy,less than 30%.|use of cholesteryl ester transfer protein (cetp) inhibition treatment,,,,,,
11522,,autoimmune diseases;|patients,,,,primary total knee arthroplasty|18,,,,,prior to enrollment|severe pulmonary hypertension,<18 or >30 kg/m2|diagnosis,,,,,,
11523,,manic episode,,,,maintain mean arterial pressure,,,,,during the last 24 hours|tidal volume did,≥90 mmhg,,,,,,
11524,,acute rehabilitation,,,,pathology.||completion of surgical resection of tumors,,,,,within two weeks.||procedural,4,,,,,,
11525,,absorbable threads,,,,conventional techniques of ct,,,,,within 14 days prior to first drug administration,criteria45-46|screened positive,,,,,,
11526,,rr diastolic,,,,g8 screening tool,,,,,within 48 hours before dosing,less than 2.5 times the upper limit of normal,,,,,,
11527,,myelodysplastic syndromes,,,,canalicular surgery,,,,,during the time period of study,< 48 hours after randomization.|new oxygen,,,,,,
11528,,preterm delivery,,,,magnetic resonance imaging scan)|able,,,,,< 3 months old finding,1.2.3 iol;|patient's willingness to participate,,,,,,
11529,,congenital deformity of the spine,,,,placement of a,,,,,for more than 7 days may be considered if the trauma occurred more than 1 year ago,< 90mmhg|seizure disorder|clinically active,,,,,,
11530,,sex hormones,,,,spesolimab i.v. infusion,,,,,during the first trimester of pregnancy|singleton pregnancies||,> 90 mmhg|pulse rate < 40,,,,,,
11531,,men2|suicidal ideation,,,,sling placement|known,,,,,within 30 days prior to first dose of study drug,"2, 3 and 4)|informed",,,,,,
11532,,chronic pain.|moderate,,,,hct,,,,,during the 3 months preceding the baseline,≥ 5.6 mmol/l).||hepatic,,,,,,
11533,,unilateral headache,,,,screening endoscopy,,,,,within 4 weeks of study entry,less than 33 weeks,,,,,,
11534,,malignancies;|alcohol abusers|malt lymphoma,,,,transient elastography,,,,,within 2 weeks prior to randomization.|platelets,between 4 cm squared,,,,,,
11535,,lenalidomide capsules,,,,surgery of the,,,,,within 3 months before enrollment met,≥ 30 years;||because,,,,,,
11536,,atg,,,,full cooperation,,,,,inhibitors|a history of,<-3 or nutritional,,,,,,
11537,,dry eye syndrome medications,,,,stiff knee gait,,,,,within 14 days or,<1.3x109/l,,,,,,
11538,,dakin's solution,,,,emergent surgery,,,,,over past week of 3 or more,4-12 weeks).||,,,,,,
11539,,giant pulmonary,,,,ccc)|≥5 current medications,,,,,up to 20 mg daily,"i, ii risk groups",,,,,,
11540,,neovascular glaucoma;|have,,,,cibinqo,,,,,within 6 months after signing the informed consent,0 or 1.|participants,,,,,,
11541,,criteria of intolerable surgery,,,,implantation of the percept™ device,,,,,during the last 3 months,≥ 18 years.|karnofsky performance status ( kps),,,,,,
11542,,chondrodysplasia,,,,radical nephrectomy,,,,,before month 3,0 to 20,,,,,,
11543,,papillary thyroid carcinoma,,,,section - contraception,,,,,within 2 years prior to the planned,18-30 years|healthy volunteer||exclusion,,,,,,
11544,,gastric surgery|heart diseases,,,,liver cirrhosis)|drug dependance history|untreated,,,,,within 1 year of the last menses,> 90 ml/min,,,,,,
11545,,arterial hypertension,,,,local treatment,,,,,within 2 weeks prior to initiation of study treatment|prior allogeneic stem cell,≤ 10.0%,,,,,,
11546,,aortic stenosis).|have,,,,etc.)|unstabilized psychotropic treatment|pregnant,,,,,within 3 months;|severe head trauma,more than 300 ml,,,,,,
11547,,eye-sight,,,,beta human chorionic gonadotropin (β-hcg,,,,,within 3 months prior to initiation of study treatment|major surgical procedure,+ 0 days|at the maternity ward of the reims university hospital|parents are older than 18,,,,,,
11548,,piz alleles,,,,antihypertensive therapy;|acute hemorrhage tendency;|blood glucose level,,,,,within 8 weeks prior to dosing;|plan to,>120%,,,,,,
11549,,metabolic state.|substance abuse,,,,volume control,,,,,within 2 years after cell infusion.|patients,more than 4,,,,,,
11550,,posttraumatic stress disorder,,,,quality of the data.|participation in other interventional trials.|allergy to test substrates.|antibiotics,,,,,in the least 3 months before program,<30 ml/min/1.73 m.|unstable,,,,,,
11551,,shwachman syndrome,,,,surgical management,,,,,during,less than 110,,,,,,
11552,,alport syndrome.||(2,,,,general anesthesia|patients,,,,,at least one line of standard of care therapy.||note,thought necessary to confirm,,,,,,
11553,,taxanes,,,,oral anticoagulant therapy,,,,,at screening.|presence,≥ 20 mm,,,,,,
11554,,ischemia-driven,,,,receives group treatment,,,,,within 4 weeks of the study|active treatment,from 5.7 to 6.4%|2-hour ogtt levels,,,,,,
11555,,brain disorders,,,,dars2 mutation analysis.|able to understand dutch,,,,,during the study|history of,between weeks 37-42)|bishop score is less than 6,,,,,,
11556,,middle cerebral artery occlusion,,,,implanted,,,,,prior to covid-19,>= 60%.||recipient,,,,,,
11557,,glaucoma|allergy,,,,field radiotherapy (,,,,,before experimental treatment initiation.|serious infections,<15)|severe,,,,,,
11558,,mandibular cystic defect.|cystic,,,,suppressive antiviral therapy,,,,,within less than 4 weeks,less than 55% of the predicted value,,,,,,
11559,,basal cell cancer).|the,,,,needle biopsy,,,,,in the previous 18 months,≥45 years,,,,,,
11560,,systematic hemorrhagic tendency,,,,eyelash abnormality||study procedures:||known hypersensitivity,,,,,in the past 3 months|currently,30-59 ml/min/1.73 m2,,,,,,
11561,,adenocarcinoma of the colon,,,,health professionals,,,,,for the 14 days before the first dose of the study,<50.000 per μl;|inability,,,,,,
11562,,criteria required:||the cancer specialist considers,,,,screening.|positive pcr test for sars-cov-2,,,,,within 12 months prior to check-in,unfavorable,,,,,,
11563,,painful neuropathy;|daily use,,,,b cell repletion|participant,,,,,personal history of any of the following conditions,"< 30,000 µl",,,,,,
11564,,prostatitis,,,,repair of same||participant,,,,,within 6 weeks prior to enrolment.||on the waiting list,between 18 and 75 years.|give their consent to participate,,,,,,
11565,,stroke,,,,repetitive spinal flexion,,,,,before surgery|more than one,0-2;|definitive,,,,,,
11566,,cold agglutinin disease,,,,voluntary adoption of appropriate,,,,,within 2 weeks prior to the first dose of study treatment.||participants,score of >20)|all,,,,,,
11567,,vomit-ing,,,,open wound,,,,,during screening may,4 (ctla-4),,,,,,
11568,,endometrial cancer|meeting physical activity,,,,transdermal hormone contraception,,,,,more than 5 cigarettes per day;|for,≥18 years.|refractory,,,,,,
11569,,liver function abnormalities||transaminases,,,,surgical sterilization methods,,,,,within 2 weeks before the first use of the study drug;|participated,≥ 18|type 2,,,,,,
11570,,data|severe eyesight,,,,vertical descending saccades|diagnosis of,,,,,at the level of the forearm.|age,> 5 lesions.|lesions,,,,,,
11571,,drug intolerance.|hypersensitivity,,,,whole body,,,,,at time of screening;|exclusionary laboratory results,> 0 and/or|gc dosage,,,,,,
11572,,clinical signs of||hypertension,,,,mechanical circulatory support,,,,,within the last 24 consecutive months,greater than 40mg,,,,,,
11573,,acute infection|any disorder,,,,dental work,,,,,within 5 days prior to leukapheresis,90 mmhg,,,,,,
11574,,nasopharynx carcinoma,,,,computed tomography angiography,,,,,during the next two years -|breastfeeding|consuming,≥ 1.5 × 10^9/l|hemoglobin,,,,,,
11575,,ingram cancer center,,,,prebiotic supplementation regularly,,,,,before enrollment.||laboratory inspections must,< 18 years|prior exposure,,,,,,
11576,,thyroid disease|kidney disease,,,,static compression therapy,,,,,within the last 12 months prior to screening|a confirmed,> 40 mmol/l)|pregnant,,,,,,
11577,,anorectal diseases,,,,cytologic diagnosis.|clinical tumor,,,,,within 6 months prior to initial administration,>4kg,,,,,,
11578,,hiv)14,,,,requirements:|routine blood tests,,,,,during the initial assessment,i-iii|mallampati score,,,,,,
11579,,"copd,|physician decision",,,,contralateral knee,,,,,within 14 days prior to receiving study drug;|consumption of any special diet,<10|moderate,,,,,,
11580,,unstable medical illness,,,,celiac serology.|be,,,,,discontinued,≥ 18 years.|all,,,,,,
11581,,physiotherapy,,,,tabrecta® (capmatinib),,,,,after surgical and /or locoregional therapies|no,less than 70 ml/minute,,,,,,
11582,,liver diseases.|body mass index,,,,active intervention,,,,,within 6 months prior to enrolment.|parents,>55 ml,,,,,,
11583,,stress incontinence,,,,chemotherapy|history,,,,,at least 4 weeks prior to study.|simultaneous use,between 18 and28 kg/m2|male,,,,,,
11584,,acidemia,,,,xioami smart band,,,,,during the trial until the last follow-up;|voluntarily sign the informed,below the limit of quantification).|known,,,,,,
11585,,pulmonary hypertension|active,,,,sars-cov19 vaccine,,,,,for 7 months after the last dose for females,≥ 18 years|ecog,,,,,,
11586,,major vascular diseases,,,,various fusion partners,,,,,"at admission to the intensive care unit,|patients",≥ 2 times the upper limit of normal (uln),,,,,,
11587,,post-debridement;|aged,,,,gdm,,,,,within 30 days of registration,less than 21|age greater than 65|not,,,,,,
11588,,intravascular lithotripsy,,,,copper iuds,,,,,more than three times normal,above 55%;|women,,,,,,
11589,,other causes,,,,computed tomography,,,,,within 2 days after the patient's admission,> 38 degrees,,,,,,
11590,,human immunodeficiency virus (hiv) antibody/antigen.|the participant's renal creatinine clearance,,,,confirm hormone receptor status,,,,,at the time of signing the informed consent form;|histologically,18 - 55|area of burn,,,,,,
11591,,oocyte donation|undergoing preimplantation,,,,urologic surgery(transurethral resection of bladder,,,,,within the last 5 years.|voluntarily decided to participate in the study,≥12 weeks|eastern,,,,,,
11592,,ocular lesion,,,,interferons,,,,,in the past 3 years;|imaging (ct,20-30% marrow blasts,,,,,,
11593,,confusion)||significant intercurrent illnesses,,,,rbc transfusions,,,,,medical history,4.5-7.5 months,,,,,,
11594,,ischemia)|peripheral vascular disease,,,,recovered after treatment,,,,,in the month prior to initiation of study intervention,> 180/110mmhg after treatment);|patients with previous patent foramen,,,,,,
11595,,ophthalmological pathology,,,,adrenocorticotropic hormone (acth),,,,,within 30 days prior to first dose (cycle 1/day 1,> 85 years;|pregnant,,,,,,
11596,,iritis,,,,sng,,,,,for at least 3 months prior to the first dose.||9,≤ 2.2 l/min/m,,,,,,
11597,,chest retraction,,,,coronary artery dissection,,,,,within 2 weeks prior to treatment.|prior organ transplantation,>0.35ng/ml,,,,,,
11598,,anticancer drugs);|hypersensitivity reaction,,,,anatomic shoulder arthroplasty,,,,,within 28 days prior to the first dose of study drug administration,≥55kg|90 mmhg,,,,,,
11599,,light chain amyloidosis|received,,,,anti-infective therapy.|a,,,,,more than 6 weeks,greater than or equal to 20 kg,,,,,,
11600,,motor function,,,,coronary angiography results,,,,,at including,≥150 mg/dl,,,,,,
11601,,hepatitis c.|uncontrolled diabetes mellitus,,,,thyroid ultrasound examination,,,,,within 2 weeks before apheresis,> 18 yrs,,,,,,
11602,,oxford ii||,,,,steroid therapy|is,,,,,before 30 days of screening,≥18 years.||patients,,,,,,
11603,,signs of pulmonary hemorrhage,,,,brain mri examination,,,,,before starting study therapy|patients,score for 7 days prior to the first drug use of the study drug,,,,,,
11604,,toxic epidermal necrolysis,,,,standard first-line chemotherapy regimen,,,,,within 6 months since,75-160 mg);|age,,,,,,
11605,,sleep apnea|prior intestinal,,,,invasive mechanical ventilation,,,,,prior to visit 2.|have,25-35 kg/m2||+,,,,,,
11606,,oral nutritional supplement,,,,conventional hospital departments,,,,,in the past year|1+ social determinants,>20 mg/l,,,,,,
11607,,alopecia areata,,,,refractive outcomes,,,,,less than 6 months before the study,"19 and 69,|american society of anesthesiologists (",,,,,,
11608,,cerebral vascular malformations,,,,small vsd,,,,,during exercise,less than 95%,,,,,,
11609,,impact pulmonary function,,,,mri imaging technician,,,,,within 28 days prior to first dose of study treatment.|participants,"1.1,",,,,,,
11610,,acquired immune deficiency,,,,ureteral stent placement.|on blood pressure support,,,,,in the last 3 months|signs,≥8,,,,,,
11611,,fibrillation,,,,trauma portal intervention,,,,,for at least 5 years before signing the informed consent.|the presence,>= 40 ml/min per 24 hour urine test,,,,,,
11612,,parent(s)/legal guardian(s) if the patient is minor according to local regulation),,,,doppler velocimetry,,,,,at least 6 months prior to screening,greater than or equal to 750/ul|platelet count,,,,,,
11613,,right upper quadrant mass/pain/tenderness,,,,hypertensive retinopathy.||history,,,,,within the preceding 2 weeks.|is,<12,,,,,,
11614,,pre-randomization screening labs drawn and study protocol,,,,randomly selected households|participants,,,,,6 months after the last dose of imp,>= 3.4 mmol/l,,,,,,
11615,,overactive bladder alone|previous,,,,spga evaluation,,,,,within 70 days prior to enrollment.|a,operable,,,,,,
11616,,dysfunction;|acute attack,,,,autologous stem cell transplant (sct),,,,,within 4 weeks prior to the first dose of the study drug,6 - 35 months,,,,,,
11617,,unable to undergo,,,,esophagectomy,,,,,within 30 days before screening|any other condition,⑦ refuse to sign,,,,,,
11618,,myelodysplastic syndrome,,,,remimzolam||,,,,,within 7 days of first rp3,≥ 90 g/l;||total bilirubin,,,,,,
11619,,skin malignancy,,,,secondary diabetes|begin treatment,,,,,at the run-in visit,55 to 79 years,,,,,,
11620,,bilateral obstructive uropathy,,,,complete series,,,,,before operation.|there was no serious,≥18 years|stemi,,,,,,
11621,,carcinoma in situ of the cervix.|clinically relevant,,,,definitive treatment,,,,,post-procedure,≤ 110 kg,,,,,,
11622,,pennsylvania hospital||,,,,chest imaging examination showed,,,,,after all curative measures,"> 3,000 cells/microliter",,,,,,
11623,,chronic medical disease,,,,diagnostic radiological imaging,,,,,within 24 hours of admission,≤ 3 × uln|serum,,,,,,
11624,,musculoskeletal disorders,,,,fecal occult blood,,,,,at the time of data collection.|hospitalization,4-7 weeks,,,,,,
11625,,fanca,,,,complete esophagogastric tumor resection.|patient,,,,,during the 3 months prior to enrollment,greater than or equal to 12 years;|clinical diagnosis,,,,,,
11626,,positivie reaction,,,,kidney graft function)||two study,,,,,within a period sufficient,≤ 70%,,,,,,
11627,,lymphoma involves,,,,potential drug-drug interactions|enrolled,,,,,during the trial period and up until 30 days after the final administration of imp.|subjects,less than 100×109/,,,,,,
11628,,administrative requirement.|clinical symptoms,,,,congenital abdominal/gastrointestinal malformations,,,,,within the limits presented in,<45,,,,,,
11629,,prolonged qtcf interval,,,,mucus secretions,,,,,within 5 years prior to the day of screening,rising,,,,,,
11630,,canal-treated,,,,psychopharmacological treatment,,,,,within 14 days prior to initial medication;|use of other antiviral drugs,≤ class 1,,,,,,
11631,,hepatitis c virus [hcv] antibody positive,,,,lumbar examination,,,,,within 60 days prior to treatment,18 years or above|participant is willing and able to give informed consent for participation,,,,,,
11632,,rtx.|active cutaneous disease,,,,us|preoperative ct-scan,,,,,prior to randomization.|receipt,> 120 µmol/,,,,,,
11633,,congestive heart failure|qtcf,,,,ocular surgery,,,,,within 6 months before the first administration of the study drug,75 x 109 / l;||ii,,,,,,
11634,,≥1 risk factor,,,,lines of chemotherapy,,,,,within 12 weeks prior to screening.|systemic hematologic disorders,≤ 14 years.|treated,,,,,,
11635,,family history;|asplenia,,,,complete survey,,,,,within 24 hours since admission,15-49 years,,,,,,
11636,,delaware,,,,structured clinical interview for dsm-5 (scid)25,,,,,within five days prior to registration,> 1.2 mg/dl|a,,,,,,
11637,,sci,,,,holter ecg evidence,,,,,in the last 12 months prior to enrollment|previous pyloromyotomy,below 18 years;|any burst fracture;|unstable,,,,,,
11638,,pregnancies,,,,behavioural variant ftd,,,,,for at least two weeks before treatment initiation.|asymptomatic brain metastases,> 2;|history of spleen resection;|loss,,,,,,
11639,,immunosuppressive medication.|any disorder,,,,impossible intubation criteria:||mallampati,,,,,during the expansion,> 18 and < 30 kg/m2|endometrial,,,,,,
11640,,acute dyspnea,,,,paraaortic lymphadenectomy,,,,,after last dose of study drug,>10-pack-year,,,,,,
11641,,local health authority||10.1 hepatitis b positive subjects||participants,,,,corrective scoliosis surgery,,,,,within 90 days before screening|end stage renal disease,twice the upper limit of,,,,,,
11642,,primary malignant disease,,,,allogeneic hematopoietic stem cell transplantation.|female,,,,,within the past 5 years;|pregnancy,>35 weeks of gestational,,,,,,
11643,,diabetic peripheral,,,,preprocedural ultrasound,,,,,at screening and,between age 18 -100 years,,,,,,
11644,,risedronate,,,,language intervention program,,,,,during the two year study period.||cardiovascular surgery includes the,≤ 2 points,,,,,,
11645,,human epidermal growth factor receptor (egfr) inhibitor,,,,lung resection surgery||,,,,,at 2 years,≥ 200 mg/j,,,,,,
11646,,stage|diagnosis,,,,regular dialysis regimen,,,,,within 26 weeks,5ml/min·1.73m2|the 24-hour urine volume ≧,,,,,,
11647,,cd22+ all/lly:||cohort,,,,international consultation on incontinence questionnaire-urinary incontinence short form (iciq-ui sf,,,,,after admission|respiratory failure,"< 12 g/dl,|incapable of surgery",,,,,,
11648,,neurologic symptoms,,,,insignificant;|transeptal puncture,,,,,within 21 days of cycle 1 day 1.|patients,> 7.0 mmol/l|cardiac,,,,,,
11649,,endometrial cancers,,,,radiologic imaging,,,,,in the first 24 h of life,62-169cm)|participants,,,,,,
11650,,metabolic problem,,,,samaritan hospital,,,,,for at least 3 days to,< 40 pg/ml,,,,,,
11651,,type 2 diabetes|hba1c 7.0%-11% (inclusive)|overweight or,,,,bile duct surgery|associated bile duct stricture,,,,,at the time of visit 1.|undergoing,≤ 1.5 × uln.||10,,,,,,
11652,,drug dependence;|mental disorders,,,,laparoscopy|a,,,,,within the past 12 weeks prior to the screening visit,<27%,,,,,,
11653,,ankylosing,,,,botanical formulations,,,,,during activity||,≤ 10.5 g/dl||,,,,,,
11654,,schizophreniform disorder,,,,laparoscopic ppgl resection||,,,,,in the last 12 months.|currently,3b/4 trial,,,,,,
11655,,malignant tumors|will receive antitumor drugs|could,,,,airway management,,,,,at the same time detected hcv rna copies of positive;|patients,≤ 2.5 × uln;|albumin (alb,,,,,,
11656,,unstable diseases,,,,imfinzi monotherapy,,,,,within 30 days prior to the first dose of t-dxd.|prior treatment,18 years or older;|have,,,,,,
11657,,lower limb fractures,,,,iol power,,,,,during the next 3 months,surgery|more than 5,,,,,,
11658,,type of who ii,,,,company magnetic resonance package,,,,,within 14 days before the first dose of the study,>= 50 x 10^9/l,,,,,,
11659,,degenerative arthrosis,,,,arterial thrombosis.|history,,,,,in the last 90,18-65 years|without,,,,,,
11660,,polg,,,,standard phacoemulsification cataract,,,,,within 56 days of dosing|immunization,≥ 50kg/m2,,,,,,
11661,,cerebral infarction (mtici),,,,ici) therapy,,,,,prior to initiation of study treatment||,19 or higher,,,,,,
11662,,neurological disease;|psychiatric disease,,,,brain mri scan.|a normal blood manganese concentration.|ability to undergo additional 2,,,,,in the past and their condition,between 18 and 29 kg/m2,,,,,,
11663,,uncontrolled infection,,,,screening laboratory tests,,,,,within 24 hours before or within 24 hours after study medication,between 18-80 years|people,,,,,,
11664,,including||hepatitis c virus (hcv),,,,ipl,,,,,within 7 days prior to enrollment.|dietary use,<90mmhg,,,,,,
11665,,autoimmune disease|active infection,,,,allogeneic hematopoietic cell transplantation,,,,,within 3 months prior to the start of the experimental trial,<110/60mmhg,,,,,,
11666,,deep venous thrombus,,,,normally,,,,,between two symmetrical points not exceeding 2 kg/cm2|individuals,egfr≥30ml/min/1.73m2 and <50ml/min/1.73m2,,,,,,
11667,,substance abuse|woman,,,,tracheotomy,,,,,within the past 90,3 ≤ wisci,,,,,,
11668,,regional nodal involvement (cn+) may be included irrespective of clinical t stage,,,,test sample,,,,,within 30 days after the last dose of durvalumab.|patient,exceeded 1.5×uln,,,,,,
11669,,chronic atrial arrhythmia,,,,insufficient knowledge of the swedish language|difficulties reading,,,,,"at least six months ago,|able to follow two-stage verbal",≥1000 copies/ml,,,,,,
11670,,posterior instability,,,,cardiomyopathy|symptomatic coronary artery,,,,,greater than 4 mm,6-17-years|presence of overweight/obesity|youth,,,,,,
11671,,cardiac aritmia,,,,co-morbidity,,,,,within 36 hours prior to randomization,< 10 g/dl|aspartate aminotransferase,,,,,,
11672,,vital signs measurements,,,,cardiopulmonary resuscitation|critically ill,,,,,within (=<) 365 days from initiation,≥ 130,,,,,,
11673,,neuromuscular disorder,,,,"unsuccessful implantations,|patients with",,,,,during the study.|vaccinated,levonorgestrel 52 mg,,,,,,
11674,,chronic headache,,,,biological therapies,,,,,within ax-158.||clinically significant abnormal test results,> 60 ml / min,,,,,,
11675,,epidural tumor,,,,prosthetic leaflets of the failing valve;|anatomical characteristics,,,,,since at least 12 weeks before the beginning of the study,<6 months)|active,,,,,,
11676,,b-cell cll,,,,open groin incision,,,,,within 180 days of previous platinum treatment.||have measurable disease,less than 40 years,,,,,,
11677,,suicidal risk,,,,mental health,,,,,at least 4 weeks prior to first study drug administration,from 25 to 45 years,,,,,,
11678,,cancer related care,,,,ohio area||,,,,,during the clinical exam|neck pain,≥100 x 109/,,,,,,
11679,,secondary scoliosis,,,,comparable technique,,,,,for 30 days after the imp administration.||*a,>85th percentile,,,,,,
11680,,hepatitis virus infection,,,,cns aneurysm clips,,,,,within the,≤ 9 mg/day,,,,,,
11681,,non-allergic occupational rhinitis,,,,penile genitourinary surgery|asa,,,,,within 6 months;|history,=<,,,,,,
11682,,itching,,,,forgo surgery,,,,,up to 3 oam,greater than or equal to (>=) 3.5 kilogram (kg)|parent(s),,,,,,
11683,,sleep|any allergies,,,,gastric/gej cancer,,,,,in the prior 6 months,1.2 mg)|current participation,,,,,,
11684,,follicular lymphoma.|tisa-cel (,,,,holter ecg monitoring,,,,,within the prior 90 days 9,stage ≤ ib2,,,,,,
11685,,central involvement,,,,single-item general health question,,,,,within 1 year prior to screening|has used,45 years more,,,,,,
11686,,unable,,,,coronary artery height,,,,,during the baseline period,> or equal to 1,,,,,,
11687,,abnormal bowel movements predominantly diarrhoea,,,,coronary artery revascularization,,,,,within 60 days prior to first dosing.|hemoglobin levels,under 20 years,,,,,,
11688,,sebaceous neoplasm,,,,professionals.||patients:||general inclusion,,,,,at intervals of 2 weeks,≥ 19 years to < 55 years,,,,,,
11689,,isolated sleep paralysis|restless,,,,cesarean section|spontaneous start,,,,,within ≤ 6 weeks,<10 × uln;|dili,,,,,,
11690,,hpv|previous cancer,,,,intraprocedural pacing maneuvers,,,,,for at least 5 nights/week|sleep patterns,"> 2 times unl, tb",,,,,,
11691,,liver cirrhosi;|endoscopy shows,,,,chimeric antigen receptor t cells (car),,,,,on their target knee|plan to have knee surgery,50 to 90 beats per minute,,,,,,
11692,,a:||healthy,,,,esophagogastroscopy,,,,,in the month before the study initiation.|having,≥ 1|ecog performance status,,,,,,
11693,,mechanical damage,,,,lymph node area,,,,,within the last 10 years.|known,2.0 to 3.0,,,,,,
11694,,psychological debility,,,,awakens,,,,,within 28,"> 100,000/mm3|hemoglobin",,,,,,
11695,,systemic immune suppression therapy,,,,friedericia,,,,,constitute,upper limb 2.0,,,,,,
11696,,abstain from sexual activity for the duration of vaccine treatment,,,,fluid therapy,,,,,in the three months preceding the first trial vaccination,≥18 years old；|stable diopter (,,,,,,
11697,,colitis ulcerosa|active cancer,,,,small molecule clearance method,,,,,within 30 days prior to registration.|age,<30 x 109/l,,,,,,
11698,,immune thrombocytopenic purpura,,,,daily activities,,,,,within 6 weeks prior to the first dose of mhb036c;|medication,≥ 100 × 10^9/l||hemoglobin,,,,,,
11699,,potential pulmonary disease,,,,left unilateral mastectomy,,,,,at least 2-4 weeks,> 50 years|willing,,,,,,
11700,,reduction of,,,,active therapy,,,,,in the last 10 years,"≥6 mm,|bone levels",,,,,,
11701,,ild)/pneumonitis,,,,computed tomography (ct) / magnetic resonance imaging (mri),,,,,within 48 hours prior to research pet imaging,between 18 and 85 years|sympathetic atrial fibrillation,,,,,,
11702,,"psychotic disorders,|untreated",,,,functional assessment staging test (fast).|score of 12 or more,,,,,in the last platinum containing,i and ii,,,,,,
11703,,prolonged qtc addressed,,,,electrical power source to function are,,,,,within 4 weeks prior to the pre-study,>= 14,,,,,,
11704,,nephritis,,,,"""target lesion""",,,,,at the time of study screening.|only,>2.0 cm,,,,,,
11705,,living donor|not,,,,standard of care treatments,,,,,within 2 years prior to the first dose of the study drug,< 95%,,,,,,
11706,,cardiac activity,,,,good oral health,,,,,within 12 months after consolidation,0.1,,,,,,
11707,,unprovoked deep vein,,,,abdominal massage application restrictions,,,,,within one year prior to study enrollment,"> 0.25,|elevated",,,,,,
11708,,liquid aspiration,,,,renal biopsy read,,,,,in 3 times per week aerobic exercise,> 30 g/l,,,,,,
11709,,chromophobe,,,,ocular laser treatment,,,,,within 6 the past,≥ 300/μl.,,,,,,
11710,,horizontal fracture,,,,blood screening,,,,,8 hours per day,3 to 5 years,,,,,,
11711,,hematological malignancies,,,,maintenance haemodialysis,,,,,within 28 days prior to the start of their initial systemic,> class ii,,,,,,
11712,,atherosclerotic cardiovascular disease (ascvd),,,,iii|laparoscopic abdominal surgery,,,,,in the last 5 years.|have any condition,> 12ng/ dl;|serum potassium,,,,,,
11713,,behavioral volitional disorder,,,,lipodystrophy,,,,,at pre-inclusion gastroscopy,4 or higher,,,,,,
11714,,tracheostomy,,,,nicotine test,,,,,for at least 7 months after the last dose on study.|men enrolled,18-55|fluent,,,,,,
11715,,mn,,,,wrist circumference,,,,,within 90 days prior to screening.|not,from 7 to 14 years,,,,,,
11716,,alchol abuse,,,,tissue acquisition to allow,,,,,in the last 3 months|active localized,≥80g/l,,,,,,
11717,,bone marrow aplasia,,,,immunosuppressant 90days,,,,,in previous 6 months,between 3 and 6 years,,,,,,
11718,,inflammatory bowel disease.|patients,,,,simple peripheral blood puncture,,,,,within 1 year prior to the first administration of the study drug.|history of participating in another investigational clinical trial within 90 days before the first administration of the study drug.|poor,< 3 x institutional,,,,,,
11719,,left atrial appendage electrical isolation,,,,gastric surgery|acute gastric,,,,,within 6 weeks prior to enrollment|patients,≤1.5xuln,,,,,,
11720,,screening|ability,,,,standard treawtment,,,,,in the 2-week,to ≤ 75 years,,,,,,
11721,,neovascular macular degeneration,,,,screening.|in good health,,,,,within the past year|physically inactive,≥40|contraindications to surgery,,,,,,
11722,,phes,,,,assessment of treatment response,,,,,during their participation in this study,≤ 60%,,,,,,
11723,,dementia.|pregnancy,,,,intensive care,,,,,at the time of enrollment.|chronic,between 24 and 73 letters,,,,,,
11724,,thalamic stroke,,,,gastroesophageal junction (gej),,,,,in half of subjects|no,>= 20%,,,,,,
11725,,organic brain impairment,,,,endometrioid endometrial adenocarcinoma.||• note,,,,,for at least 90 days|be willing to change the bag,≥ 20/50.|previously held a valid driving license,,,,,,
11726,,non-mri-safe cardiac pacemaker,,,,allogeneic stem cell transplantation,,,,,within 6 months;|maximum of 1 level of,between 25- 49.9 kg/m2|able,,,,,,
11727,,assessable tumor focus,,,,heart rate correction,,,,,after at least 1 prior line of standard therapy,>38.5℃,,,,,,
11728,,onset of seizures,,,,temperature,,,,,during the study|use of,> 1 grade|if,,,,,,
11729,,acute thrombus,,,,preoperative multiparametric mri,,,,,within the previous 6 weeks.||history of smoking||if <30 years,6 to < 10 years,,,,,,
11730,,mesenteric vein tumor thrombus,,,,autologous stem cell transplant|patients with burkitt lymphoma,,,,,prior to study enrollment,above the lower limit of detection).||12,,,,,,
11731,,diabetes complications,,,,first covid-19 vaccine,,,,,within 6 months prior to screening.|have known,between 18 to 60 years|diagnosed,,,,,,
11732,,punctual occlusion,,,,bone marrow haematopoietic function.||iii,,,,,within 6 months prior to first dose.|previous stem cell transplantation,chemotherapy.||agree to provide the pre-existing,,,,,,
11733,,myocardial infarction.||patients allergic,,,,complete obstetric examination,,,,,within 2 weeks before cell,>= 18 years.|pre-registration,,,,,,
11734,,acute copd exacerbation||copd,,,,convulsion,,,,,within 28 days prior to study drug administration.|positive test for alcohol,class ii to iv,,,,,,
11735,,consent|contraindications,,,,mri safety screening questionnaire)|able to commit to the treatment,,,,,within 2 weeks before screening;|patients,"18-50,|no",,,,,,
11736,,lymphoblastic leukaemia,,,,hbv reactivation every,,,,,in the prior 3 months before the study begins,≥1.5×109/l;|platelet,,,,,,
11737,,imdc symptoms,,,,chemotherapy combination cycles,,,,,for at least 3 minutes.|history,88 cm,,,,,,
11738,,eac.|unable,,,,palliated,,,,,within the past 3 months <30%,21-35.|no contraindications,,,,,,
11739,,consciousness disorder,,,,stationary cycling,,,,,more than 4.5 millisecond,> 1.5 × uln,,,,,,
11740,,airflow obstruction,,,,structured clinical interview for dsm-5 (scid-5);|diagnosis of treatment-resistant depression,,,,,in 24 hours refractory to the standard medical treatment.||,≤ 5 × uln|total bilirubin ≤ 1.5 × uln,,,,,,
11741,,hamada type,,,,major pelvic pathology|patients,,,,,approximately 2 hours,less than 60 ml/min.m2).|cardiac,,,,,,
11742,,vision impairment|hearing,,,,sized compression garment,,,,,at least 6 months prior to screening.|subject,<1 cm,,,,,,
11743,,light emitting device (led,,,,mesenteric artery (sma),,,,,at time of non-opposition to participate to the study|patient,≥3 times the upper limit of normal (uln),,,,,,
11744,,neurologically,,,,jogging test,,,,,throughout the trial,30 to 35kg/m2|able,,,,,,
11745,,functional limitations|body mass index (bmi),,,,local hormone therapy,,,,,at the time of the study|medroxyprogesterone acetate,between 60 and 89 mmhg|pulse,,,,,,
11746,,tinea pedis.|known,,,,analyzed biopsy.||patients,,,,,at the involved levels,18 to 40 years|unilateral,,,,,,
11747,,normal size,,,,immuno-therapy,,,,,past year.|positive,18-35|history of,,,,,,
11748,,women|congenital heart disease|pulmonary disease,,,,renal-replacement therapy,,,,,within 4 weeks before the first dose of the investigational drug;|2,=< 10%,,,,,,
11749,,degenerative sacroiliitis,,,,cervical lymphadenectomy,,,,,for at least six months before enrolment,18.5 to 40.0 kg/m2,,,,,,
11750,,end-stage congestive heart failure,,,,liver metastases|planned to undergo resection of liver lesions,,,,,within 24h before surgery;|use,≥ 130 meq/l|age,,,,,,
11751,,salt imbalance,,,,allogeneic hsc transplantation,,,,,within previous 30 days,>1.2 uln,,,,,,
11752,,cervicovaginal pathology,,,,investigation.|chronic treatment,,,,,3-months,i to ii|patients,,,,,,
11753,,recruit,,,,enteral medication;|inability to understand,,,,,while in the study,> 11.5 g/dl,,,,,,
11754,,schizoaffective disorder,,,,surgical resection of mbm,,,,,within 6 weeks prior to first dose.||o short-term,<6 months.|hospitalisation,,,,,,
11755,,congenital dementia,,,,finger stick,,,,,at the time of signing the icf.|having,≥1.5 × 10^9/l|platelets ≥75 × 10^9/l||patients,,,,,,
11756,,russell-silver syndrome,,,,schwartz formula);|without,,,,,within the 6 months prior to the first administration of investigational,< 27).|pregnancy|use of estrogen,,,,,,
11757,,pregnancy-induced,,,,traumatic surgery,,,,,at minimum 12 months post-,iii-ivb;|there,,,,,,
11758,,females;|acute coronary syndrome,,,,complete surveys,,,,,within the assay-specific reference,18-45,,,,,,
11759,,obstructive hypertrophic cardiomyopathy,,,,fresh biopsy,,,,,throughout the study.|low self-reported,<28 days,,,,,,
11760,,pcp,,,,transcatheter mitral valve implantation,,,,,within 3 months prior to study entry.|use,"i, ii or iii;|patients older than 18",,,,,,
11761,,congenital heart disease|hematologic,,,,general refers,,,,,in the past year,≤ 5 × uln.|cannot,,,,,,
11762,,somatic signs,,,,magnetic resonance scans,,,,,in the last 12 months|have been,between 20 and 80 years,,,,,,
11763,,nonresectable,,,,mineral panel,,,,,within the previous year of,between 20-year,,,,,,
11764,,recovered from acute toxic effects,,,,verify email address|participation,,,,,in 7th grade,≥18 years to ≤75 years,,,,,,
11765,,drug abuse|participation,,,,anticoagulant therapy,,,,,within 30 days prior to the first dose of study drug.||examples of,neutrophils≥1.5×10^9/l,,,,,,
11766,,chronic active hepatitis,,,,carcinomatous meningitis.|major surgery,,,,,within 2 years prior to the first dose,>400mg/dl,,,,,,
11767,,venipuncture;|abnormal renal,,,,whole-gene deletion,,,,,within last 12-months|active,<450ms,,,,,,
11768,,childhood asthma).|is mentally or legally incapacitated,,,,maintenance immunosuppression,,,,,within one week before enrollment,form.|8 to 13 years,,,,,,
11769,,chronic home oxygen therapy,,,,quantitative polymerase chain reaction [qpcr],,,,,within 3 months prior to the baseline visit,≥ 8%,,,,,,
11770,,secondary arthritis,,,,whole-genome analysis,,,,,within 14 days of enrollment,≥ 139,,,,,,
11771,,cancer types.||*or,,,,pregnancy|smoking|>5 kg,,,,,in the 4 hours prior,> 1.67 x uln|taking,,,,,,
11772,,inclusive.|healthy,,,,diagnostic imaging rotational,,,,,during the 4-week period prior to enrollment,higher than adjacent,,,,,,
11773,,malignant head/neck,,,,metabolic diseases;|history,,,,,within the earlier one month||,2018).|18 years or older,,,,,,
11774,,wegener's granulomatous disease,,,,myopic,,,,,at 24 months (±60 days,+5 left bisegmentectomy|patients,,,,,,
11775,,etiology|autoimmune hepatitis,,,,"clinical schizophrenia,|being under the age of 18,|having mental",,,,,"in the last 6 hours,|smoking",> 6g /24 hours,,,,,,
11776,,type 2 diabetes|patients,,,,gastric scintigraphy [ges],,,,,during the final intraoperative arthroscopic,>450 milisecond,,,,,,
11777,,obstructive airway disease.|at,,,,qualifies,,,,,within 6 months prior to initiation of study therapy.|participant,lactation.||patients < 12 years,,,,,,
11778,,below:||degenerative anterolisthesis|pars defect,,,,inotropic therapy,,,,,"within 14 days of the initiation of study drugs,|5c",< 2.0 l/min/m2|if,,,,,,
11779,,non-proliferative diabetic retinopathy,,,,hcv therapy,,,,,up to 6 target measurable nodes,> 18 years;|absence of structured physical activity,,,,,,
11780,,prolonged bleeding from,,,,muscle testing (mmt 8) score,,,,,within 3 days before vaccination.|（9）before entering the group,18 years old or older on day of signing the informed consent.|histological confirmation,,,,,,
11781,,most communities,,,,pet- ct,,,,,within two weeks of screening|subjects,under 35 years,,,,,,
11782,,carcinomatous meningitis.|prior treatment,,,,genetic analysis,,,,,within the respective reference,no more than one,,,,,,
11783,,auditory disabilities,,,,transesophageal echocardiogram (tee) obtained,,,,,within 60 days of study vaccination.|have,≥6.1mmol/l,,,,,,
11784,,bleeding risk (,,,,pittsburgh sleep quality scale,,,,,within 28 days prior to the start of study treatment,= quetiapine,,,,,,
11785,,extrahepatic disease|unmanageable intolerance,,,,segmental rectosigmoid resection,,,,,within 12 months of screening.|presence of any surgical,>3|history,,,,,,
11786,,malignant colon polyps,,,,24-hour urinary oxalate levels,,,,,throughout the study until eos unless necessary to alleviate intolerable,< 45 ml/min/1.72m^2,,,,,,
11787,,non-glioma,,,,corneal refractive laser surgery,,,,,within the last 3 months|any medications,>9 g/dl,,,,,,
11788,,chronic hepatitis b (hbv) infection,,,,complex endovascular repair of the proximal landing,,,,,within 28 days prior to treatment,> 8.0%)|current,,,,,,
11789,,cps,,,,mandate stabilization surgery,,,,,within 90 days of the initial signed informed consent,≥ 45%.|life expectancy,,,,,,
11790,,swallowing difficulty,,,,complete tcd study,,,,,within 14 days prior to step 2 randomization|step,less than or equal to 2.|fluorodeoxyglucose,,,,,,
11791,,legally capable,,,,teeth erupted,,,,,within the last 6 months|history,≥70|females with a,,,,,,
11792,,investigator.|active infection,,,,urine tests,,,,,at least once.|whether or not they,≥ 17|terminal phase,,,,,,
11793,,fresh intestinal anastomoses,,,,smarca2 mutation,,,,,at the time of the first vaccine,greater than 40 percentage,,,,,,
11794,,angle abnormalities,,,,concurrent,,,,,within a time frame,< 30%,,,,,,
11795,,chronic opioid,,,,systemic anticancer therapy,,,,,12months before screening,<100 × 109/l,,,,,,
11796,,onychomycosis,,,,cardioversion,,,,,previous,>2.5,,,,,,
11797,,-risk disease,,,,12-lead electrocardiography,,,,,at least 4 weeks prior to the baseline,> 10%|claustrophobia,,,,,,
11798,,bleeding|pregnant,,,,imaging of the colonic mucosa,,,,,at the time of surgery|history,≥ 10mm,,,,,,
11799,,postpartum injuries,,,,rapid ventricular response,,,,,at least 4 weeks to ensure symptoms,>30 days.|copd,,,,,,
11800,,epicardial stenosis,,,,colonoscopy,,,,,since the last birch pollen season,<=1,,,,,,
11801,,percutaneous coronary intervention|the reference diameter of the target vessel,,,,frontal-parietal brain volume,,,,,between 6 and 20mm,< 1.5 × upper limit of normal,,,,,,
11802,,myeloid leukemia,,,,chemotherapy-induced,,,,,in the 6 months prior to baseline,≥ 18 to 70 years,,,,,,
11803,,guillain barré syndrome).|the,,,,seeking therapy,,,,,before this study|patient,<400 meters|duke activity status index,,,,,,
11804,,study:||subjective cognitive degeneration,,,,consultation,,,,,during previous,<26|in case,,,,,,
11805,,drinking episodes,,,,exclusive radiotherapy,,,,,within 14 days)||,shorter than two years|any,,,,,,
11806,,pose a risk to the subject safety,,,,blood test,,,,,up to 2 years old|asa status,28 th- 30th,,,,,,
11807,,thromboembolic disorders|cerebrovascular accident,,,,elective major knee surgery||,,,,,4 in weeks before enrollment|participation,american|identify,,,,,,
11808,,residential care,,,,immediate,,,,,in the past 3 months)|people who,1-3|bmi<30kg/m2||,,,,,,
11809,,type i diabetic,,,,transthoracic echocardiography)|allergy,,,,,at the time of enrolment.|parental,"> 1,500/mcl|platelets",,,,,,
11810,,head & neck tumors,,,,bilateral cycloplegic autorefraction,,,,,during the study.||see section,≥ 3).|other,,,,,,
11811,,rest|intermittent claudication,,,,conbercept intravitreal,,,,,at least 30% reduction in fluid,≥ 1500 cells/μl,,,,,,
11812,,gi disorders,,,,graft vs host disease (gvhd),,,,,during the study.|prior anti-programmed cell death-1,≤ 1.5 × ⑤ the upper limit of normal (uln),,,,,,
11813,,distal ulna fracture ao 2u3a1.1)|pregnancy|vulnerable people|distal ulna fracture,,,,head injury.|received rituximab,,,,,within 6 weeks prior to the screening visit,5 to 17)|affiliated,,,,,,
11814,,frontal-type dementia,,,,coronary artery stenosis of 30% - 90% in diameter,,,,,before the first dose of study drug|undergone major surgery,between 37+ 0/7 and,,,,,,
11815,,erosive esophagitis,,,,facial surgery,,,,,within 8 weeks prior to first dosing.|receipt of an investigational product,minimum of 10 percent (%),,,,,,
11816,,lvef<30%|active peptic ulcers,,,,adequate birth control,,,,,for at least 2 years,1.5 mg/dl,,,,,,
11817,,valve lesions,,,,radioactive iodine treatment,,,,,within 30 days of ip administration.|has,<90×109/l.,,,,,,
11818,,cytokine deficiency,,,,poor echocardiography visualization,,,,,within 30 days before the first dose of the study drug.|subject,> 5kg,,,,,,
11819,,implant,,,,bpm)|previous lvad implantation,,,,,for at least 5 months after the last dose of isatuximab treatment,between 0.250x10⁹/l to 0.299x10⁹/l,,,,,,
11820,,nonsterile,,,,computed tomography (ct) of the spleen.|splenectomy patient with no diagnosis of the origin of the splenomegaly,,,,,at least 45 days prior to study drug initiation,1-a,,,,,,
11821,,unwitnessed cardiac arrest,,,,treated for all or aml||note,,,,,within 1 year post-partum.|experiences,less than 15 ml/min/m2|moderate,,,,,,
11822,,capacity,,,,eit,,,,,since the last injection.|breastfeeding,>20 per,,,,,,
11823,,narcotic consumption inability to provide,,,,professional exercise therapy,,,,,while receiving immunostimulants.|known history,>5.2 meq/l,,,,,,
11824,,impaired decision making,,,,sensitive assay,,,,,"in the month of their birthday and, thereby",1.0d or more,,,,,,
11825,,violent behavior,,,,menstrual history,,,,,at screening or baseline|liver function test values,≥ 30 breaths/minute,,,,,,
11826,,neuroblastoma,,,,lipid-rich,,,,,within the next 3 months from screening,≤ 20%,,,,,,
11827,,neoplastic disorders,,,,wine).|blood donation,,,,,at least 1 of the following criteria:||have undergone documented,≥ 1000 cps/ml,,,,,,
11828,,aspergillus disease,,,,tibiofemoral fracture,,,,,≤12 weeks before planned apheresis|known active,2-19 years,,,,,,
11829,,vena cava);|cirrhosis,,,,gene therapy,,,,,within 3 days before the first dose of trial drugs,≤ 5 days per month.|lack,,,,,,
11830,,american joint committee on cancer,,,,exercise testing||,,,,,at the time of signing informed consent；|body weight ≥50.0 kg for,below 45ml/min/1.73 m²).|patients,,,,,,
11831,,osteoarthritis of,,,,radiotherapy,,,,,within 31 days of diagnosis,">= 75,000/ul|hemoglobin",,,,,,
11832,,another medical condition,,,,histologic,,,,,within 12 months preceding the screening visit|current participation,1.5-2.4,,,,,,
11833,,bone fracture,,,,violation of the calvarium,,,,,in the past 12 weeks.|pregnancy,<30 ml/min per 1.73 m2.|who,,,,,,
11834,,vaginal adventitia,,,,violet light,,,,,prior to the first administration of study,20-27|performance,,,,,,
11835,,adequate hepatic function,,,,hematopoietic stem cell/marrow,,,,,within 4 weeks of the the first planned dose of brigatinib.||minor surgical procedures,≥10 cigarettes/day).|energy,,,,,,
11836,,developmental disability|communication difficulties,,,,bifurcation lesion|stable coronary artery disease,,,,,during the treatment.)|vaccinated with influenza vaccine,1;||vital,,,,,,
11837,,ischemic core volume<50ml,,,,computerized system into an intervention group,,,,,within 6 months before randomization.|hypertension,>= 60 years.||,,,,,,
11838,,lower limb surgeries,,,,ebv,,,,,for the last 30 days,0 ~ 1 in the,,,,,,
11839,,primary concern,,,,corticosteroid hormones,,,,,last 12 months prior to visit 1,less than 24 hours.|healthy,,,,,,
11840,,lower symptoms,,,,oncologic surgery,,,,,within 1 year of screening|for,^9/l(lymphoma);haemoglobin≥90 g/l,,,,,,
11841,,invasive cancers,,,,preoperative,,,,,within 2 weeks after intervention,≥ 1500/l|platelet,,,,,,
11842,,type of imaging,,,,reduced interocclusal height,,,,,within the last 6 months|hospitalised,1-3 score,,,,,,
11843,,hemiopsia,,,,vessel|bifurcation,,,,,three months or less prior to enrolment,> 18 years|pain,,,,,,
11844,,gastrointestinal disorders.|screening laboratory evaluations,,,,whatsapp users|preclinical medical students,,,,,within 1 week,greater than 440,,,,,,
11845,,periodontal suprabony,,,,standard unit,,,,,during study involvement|willing to return,between ≥ 18 years,,,,,,
11846,,hyperglycemic hyperosmolar syndrome,,,,topographic slit lamp abnormalities,,,,,within 6 weeks of visit 1|cardioversion procedure,≥,,,,,,
11847,,portal hypertension,,,,blood coagulation;|immunosuppressive therapy,,,,,at the time of study screening,>= 36 weeks,,,,,,
11848,,pulmonary emphysema,,,,major pulmonary blood vessels,,,,,after initial treatment,no less than 6,,,,,,
11849,,urinary system abnormalities,,,,egfri therapy,,,,,while receiving study drug,≥1.0 x 109/l|platelets ≥75 x 109/l|hemoglobin,,,,,,
11850,,chronic neck,,,,covid-19 pandemic,,,,,from 2 weeks prior to dose administration to follow-up period,2-3|gestational,,,,,,
11851,,valvular heart disease|morbid obesity|emergency surgery,,,,invasive dental treatment;|smoking history,,,,,within 4 weeks prior to initial dosing,greater than 12 over the study,,,,,,
11852,,lack of effective treatment;|measurable lesions,,,,contingency management,,,,,within 3 months before the signing of informed consent,> 18 years;|recovery from,,,,,,
11853,,clinics|gerd,,,,rapid antigen test,,,,,for ≥6 months,19 years of age or older,,,,,,
11854,,definitive indication,,,,curvature|pd therapy,,,,,before start of first line treatment,> 1.85,,,,,,
11855,,extensive-stage sclc,,,,liquid nitrogen,,,,,within the last 12 months|known,< 16 years,,,,,,
11856,,inflammatory diseases;|refusal,,,,residual radiographic,,,,,within the past 6 months before first dose.|major surgery,cyp2c19*1/*1).||,,,,,,
11857,,neu,,,,stay in icu of more than 3 days||,,,,,within 3 months prior to admission on day -7.|a positive,<=2.5 x institutional upper limit of normal (uln),,,,,,
11858,,narrow intrerdental site ≤2,,,,chest ct-scan.|history,,,,,at least 12 weeks prior to enrolment in study nn7769-4532,18-70;|the annual,,,,,,
11859,,gonorrhea,,,,mca stem [m1,,,,,after the initial tumor reduction surgery,< 18 years|pregnancy,,,,,,
11860,,types of diabetes,,,,radiation therapy.||requires,,,,,within 30 days before enrolment.|hypersensitivity to niraparib,patient ≥ 3 days after,,,,,,
11861,,persistent night pain,,,,world health organization,,,,,at least 12 hours,18 years and older on the day of signing informed consent|primary itp,,,,,,
11862,,type 2 mi,,,,antigen covid-19 test,,,,,during the lead-in period,afp drop of 1 log,,,,,,
11863,,abnormal laboratory tests,,,,irb)/ethics panel requirements).-||,,,,,within 2 weeks prior to study entry,i-,,,,,,
11864,,systemic abnormalities,,,,dna repair syndrome,,,,,in the last 3 months|patients,"least 10,|the patient",,,,,,
11865,,anatomical obstruction conditions,,,,contraceptive treatments,,,,,for at least 14 days prior to first dose of study treatment.|patient,copies ≥1×104/ml,,,,,,
11866,,etc;|infertility,,,,bicuspid aortic valve.|lv systolic dysfunction,,,,,for at least 30 days prior to screening|body mass index,2-3||,,,,,,
11867,,difficile related diarrhea,,,,intensive induction chemotherapy,,,,,within 3 weeks prior to study,< 40%|be willing to provide informed consent,,,,,,
11868,,health status)|subjects,,,,neurological symptoms|current active liver disease,,,,,at the time of signing the informed consent form|participant,<103 copies/ml,,,,,,
11869,,suicidal plans;|are,,,,conventional surgical aortic valve replacement,,,,,within 2 weeks before enrollment;|have,≥ 100x10⁹/l;|no,,,,,,
11870,,disease progression,,,,device|heart surgery,,,,,at least 2 weeks prior to the start of lymphodepletion.||symptomatic,under 65 years,,,,,,
11871,,depression.|suffers,,,,anesthesiologic treatment,,,,,within next 3 months,< 4.8mmol/,,,,,,
11872,,diabetic neuropathy.|use,,,,perfusion index measurement,,,,,within 6 months of prior to initiation of investigational procedure,18-89 years|diagnosis,,,,,,
11873,,hematochezia;||,,,,malignant non-rcc,,,,,in the last 48-72,">0,96mg/dl",,,,,,
11874,,extra-maxillary/zygomatic,,,,norrköping,,,,,on the day of surgery.|pregnancy or lactation.|patient participated in other clinical studies,≥ 6 months prior to screening,,,,,,
11875,,complex atypical hyperplasia,,,,video-assisted thoracoscopy,,,,,up to 3 prior,4-11,,,,,,
11876,,renal insufficiencies,,,,inguinal region surgery,,,,,within 4 weeks of first study intervention administration.||other protocol-defined inclusion/exclusion criteria apply,0-1);|onset time ≤ 48,,,,,,
11877,,bronchospastic respiratory disease,,,,trendelenburg position,,,,,within 3 days prior to study enrollment|receipt,> 20% after 1 course of standard,,,,,,
11878,,castration-resistant prostate cancer.|pre-registration,,,,percutaneous valve intervention,,,,,within 4 weeks before the first dose of investigational drug.|presence,>470 msec,,,,,,
11879,,"non-tnfi biologic (il12/23i,",,,,toxicity|received treatment,,,,,within 4 weeks of first dose of study drug.|active,≥8 grams per deciliter,,,,,,
11880,,chronic kidney disease epidemiology collaboration [ckd-epi])|human immunodeficiency virus,,,,standard therapy.|a histologically,,,,,1 month before first dose,20% or more,,,,,,
11881,,age;|montreal cognitive assessment (moca),,,,world health organization (2016) guidelines,,,,,within 1 km of the school,grade 0,,,,,,
11882,,septum syndrome,,,,botulinum injection,,,,,within 4 weeks before the first dose of investigational product,>2.5 times upper limit of normal,,,,,,
11883,,radiation therapy;|autoimmune diseases;|acute diseases,,,,pain control concurrently,,,,,within 2 weeks before enrollment;|patients,>1 × 103 copies/ml,,,,,,
11884,,"cancer,|multicentric castleman's disease,|epstein barr virus",,,,lying down in pet scanner,,,,,within 3 months before the first dose of study,"≥ 1,000 /mcl|platelets ≥ 80,000",,,,,,
11885,,cardiac disease|pregnancy,,,,macrolide|current treatment,,,,,in the 2 years prior to enrollment.|history of,two years old to less than 12 years,,,,,,
11886,,anal fistula,,,,symptom onset|perfusion ct scan|aspects,,,,,at least 1 tace treatment；|contrast-enhanced,less than or equal to 1.5 x upper limit of normal (uln),,,,,,
11887,,variceal haemorrhage,,,,multichannel radionuclide angiography (muga),,,,,within 6 months before screening:||congestive,≥40 years,,,,,,
11888,,anticancer therapeutic,,,,hydrogen peroxide or hypochlorite solutions.|patients,,,,,within 12 months after procedure;|patients,18.0-26.9 kg/m2|healthy,,,,,,
11889,,spouses,,,,vertebral artery occlusion,,,,,within 24 hours prior to index surgery)|unresponsive state,more than 12 weeks.|able to understand,,,,,,
11890,,immune complex disease,,,,english|owns a cell phone,,,,,within 9 hours of,between 10% - 19%,,,,,,
11891,,immune response,,,,regular uterine contractions,,,,,prior to this study:||type 1 diabetes mellitus(t1dm,0 to 1.||adequate hepatic,,,,,,
11892,,intolerance of the ingredients,,,,electrocardiogram examination,,,,,in the last 90 days,score <600 met indicating physically,,,,,,
11893,,active ulcer,,,,local institutional standard method)||hepatic:||total serum bilirubin,,,,,consistently,"≥12,",,,,,,
11894,,hemorrhagic diathesis,,,,language skills sufficient,,,,,at the screening visit that,less than 1.3 mmol/l,,,,,,
11895,,inflammation of the lungs,,,,cerebral imaging,,,,,within 3 months prior to treatment administration.|donation of plasma,"< 4,000 /mm3",,,,,,
11896,,significant infection,,,,surgical operation,,,,,within the last 14 days,< 50 copies/ml,,,,,,
11897,,screen|chronic pain,,,,visit.|body mass index,,,,,within six months of the first date of treatment,≥ 30 breaths/min,,,,,,
11898,,infectious diseases,,,,vascular surgery of,,,,,at least twice a week on two separate days for 30 consecutive minutes||,> 1.7,,,,,,
11899,,drugs.|chronic pain,,,,collateral ligament deficient knee|previous knee joint infection|cognitive dysfunction,,,,,"lasted longer than six months),|individuals",≤ 2.5 x upper limit of normal (uln),,,,,,
11900,,sick cell disease,,,,rehabilitation activities,,,,,during or after most recent line of therapy,score ≤ 4,,,,,,
11901,,ups,,,,birth control pill,,,,,at any time from 166 days prior to the first day of the lmp,>100 sfc/10e6 pbmc,,,,,,
11902,,embolism,,,,titania studies.|capable of giving signed informed,,,,,within the previous 24 months,30ml/min/1.73 m2).|systemic inflammatory,,,,,,
11903,,hospitalisation,,,,bypass surgery|contradiction for ccta,,,,,within two weeks of screening,>= 5mg,,,,,,
11904,,disease.||fully treated carcinoma in situ,,,,ehna intervention /arc intervention to patients who are living with and beyond cancer.||team members||1. clinicians,,,,,at the time of screening;|positive pregnancy test,≥nhya class,,,,,,
11905,,lifestyle considerations,,,,growth hormone therapy,,,,,in the last 4 years,greater than or equal to 10 mm,,,,,,
11906,,tumor-like lesions,,,,coronary artery bypass)||for telerehabilitation group:||internet connexion (computer or,,,,,at time of consent.|early symptomatic,"< 1,0 mmol/l",,,,,,
11907,,alpha-1-antitrypsin deficiency);|drugs,,,,parkinson-plus disorder,,,,,before starting treatment.|able to swallow,> 18 years old|patient is able to give,,,,,,
11908,,chronic diabetes mellitus,,,,cardioembolic source,,,,,for 6 months after the last dose,older than 65 years,,,,,,
11909,,neutrophils,,,,clinical study experience||-,,,,,more than 4 hours,<18 years||inclusion criteria,,,,,,
11910,,common variable immunodeficiency,,,,video,,,,,≥30 days and,>21 or <7 mm,,,,,,
11911,,communication barriers lack of informed consent,,,,screening|oral endotracheal intubation,,,,,within 45 days after transplantation;|no central nervous system,≤ 24.9 kg/m2);|availability,,,,,,
11912,,immune disease,,,,antimicrobial agents,,,,,intra-operative therapy to guide resection,≥100×10^9/l,,,,,,
11913,,chocolate,,,,single sabr field|pre-registration,,,,,1 month before the first study drug administration,>18 y.o.;|the patient,,,,,,
11914,,cspc,,,,mechanical ventilation|patients,,,,,in the 4 months following the inclusion visit|patient,questionnaire score of ≤ 23|physically able,,,,,,
11915,,papillary carcinoma,,,,autologous stem cell transplant procedure|pregnancy|eye diseases,,,,,< 7 weeks prior to enrollment,< 12 months prior,,,,,,
11916,,ulcer disease,,,,tavr abdominal ct||,,,,,3-12 months after injury,≤ 10bpm.|patients,,,,,,
11917,,cough adequacy,,,,adrenal replacement steroid,,,,,within the last 6 months|transmural myocardial infarction,7 or higher,,,,,,
11918,,immunodeficiency virus,,,,gamma therapy study|active treatment,,,,,within 2 months prior to randomization.|prior treatment,more than 24 hours,,,,,,
11919,,non-probability,,,,us examination of as shows,,,,,within less than 28 days prior to randomization,"≥ 3,000/mm3",,,,,,
11920,,vulnerability,,,,stsg donor site wound,,,,,prior to initiation of study drug|treatment,more than 5,,,,,,
11921,,calcification,,,,isolated anterior uveitis,,,,,within the 3 months prior to enrolling in the study|be,less than 30%;|acute,,,,,,
11922,,bone oligometastases,,,,percutaneous coronary artery intervention,,,,,=< 4 weeks prior to registration.||other active primary malignancy,0 or 1.|adequate organ,,,,,,
11923,,renal disease|allergy,,,,almonertinib treatment,,,,,at time of signing informed consent form|ability,≥10 within 7 days prior to entry,,,,,,
11924,,spondyloarthropathy,,,,preoperative ventilation,,,,,within the 14 days prior,< 6 months,,,,,,
11925,,exudative,,,,12 lead ecg,,,,,for at least 6 months after the last imp administration||other study protocol-defined,>150 u/l).|moderate,,,,,,
11926,,brachial plexopathy,,,,cognitive behavioural therapy,,,,,prior to mdt)|treatment plan,>1.0g/day;|serum potassium,,,,,,
11927,,fundic esophageal varices,,,,medical management,,,,,within 3 weeks of the first course of trial treatment;|pregnant,0 to 2.|the effects,,,,,,
11928,,abilities,,,,small ecchymosis/punctate hemorrhage,,,,,within 3 months before the first administration,more than 35,,,,,,
11929,,colorectal cancer|patient presentation,,,,transcutaneous monitoring|thigh circumference,,,,,throughout study participation outside of libr.|stated willingness to comply with all study procedures,6.1 of the smpc,,,,,,
11930,,sinus tracts,,,,stent intervention;|kidney size,,,,,dose 8 weeks prior to baseline,18 to 40|having completed,,,,,,
11931,,earlier corneal,,,,systemic therapies,,,,,within last 60 days before the decision to start,<1.5 times the upper limit of normal.|voluntarily participate,,,,,,
11932,,distant metastasis|severe liver,,,,cns directed therapy,,,,,at the time of signing the informed consent.|the following conditions,< 24,,,,,,
11933,,mild dyspnea,,,,subsequent therapy,,,,,within 1 week before the start of the study.|who,less than or equal to 3 x uln||alkaline,,,,,,
11934,,viral hepatitis b core antibody (hbcab) positivity,,,,bilateral neck dissection (bnd),,,,,within 60 days to the start of the study,35-65 years||patients,,,,,,
11935,,engaged in hypertension,,,,bone augmentations,,,,,at least 1 prior anticancer regimen,> 50 ru/ml,,,,,,
11936,,masseter muscle -|no history,,,,organs function,,,,,within 4 weeks prior to starting study drug,>38℃,,,,,,
11937,,intracranial artery stenosis,,,,chemoradiation,,,,,at the time of the emergency room consultation|patient simultaneously participating,>4|patients,,,,,,
11938,,"hypertension,|epilepsy",,,,complete blood cell count,,,,,between 1 and 5 years,18- 50 years old,,,,,,
11939,,protective treatment.|uncorrectable coagulation dysfunction,,,,innate,,,,,at least 8 on the,> 90g/l|platelets,,,,,,
11940,,aids related complex (arc),,,,renal replacement therapy,,,,,within 72 hours|have a clear contraindication,18 and 49 years,,,,,,
11941,,proteasome inhibitor therapy,,,,"r27.xx """,,,,,in the previous 3 months.|history,older than 60 years;|completed 6 or more,,,,,,
11942,,recurrence of diseases,,,,stay constant,,,,,at least 30 days from last benefit).||5,4-5.|past medical,,,,,,
11943,,acute kidney disease,,,,hormone replacement therapy,,,,,within 30 days or five times the half-life of the imp,60,,,,,,
11944,,monotherapy cycles,,,,orthopaedic surgeries,,,,,prior to entering this study||prior therapy,19 years of age,,,,,,
11945,,solid tumors.|subjects should,,,,dextrocardia,,,,,at least 1 week prior to enrollment may participate,platelets≥100*109/l,,,,,,
11946,,rv failure,,,,hcv treatment,,,,,after the first imp administration,≤ 2|be,,,,,,
11947,,head or neck radiotherapy;|alcohol,,,,surgery for cdh,,,,,within the 5 days prior to,"< 32 weeks,|presence",,,,,,
11948,,adenoid cystadenocarcinoma,,,,carotid artery dissection,,,,,within 90 days prior to surgery.|history of,≥ 25).|cognitive impairment,,,,,,
11949,,disorders；|asplenia,,,,surgically treated trauma,,,,,for at least 6 months before study enrollment,elderly older than 70 years,,,,,,
11950,,compromised circulation,,,,graft-versus-host-disease (gvhd) prophylaxis,,,,,within the next 6 months prior to signing informed consent|autoimmune disease,<50 beats per min [bpm,,,,,,
11951,,oliguria,,,,recovery centers (prrcs),,,,,within 3 months prior to randomization;||23,> 900 pg/ml|have,,,,,,
11952,,in situ cancers.|participant,,,,histological analysis,,,,,prior to screening|any serious,> 10mm,,,,,,
11953,,cancer treatment,,,,potential va testing if necessary).|subjects must have,,,,,sector higher education institutes,score of 5 or more.||,,,,,,
11954,,involvement of the first branch of portal vein.|hepatic vein invasion,,,,treatment catheters - patients,,,,,within 10 years)|history,≥20 mg/day,,,,,,
11955,,modification of diabetes treatment,,,,irritation,,,,,within 24 hours of the time of surgery|cardiogenic shock,64 years,,,,,,
11956,,abdominal nature,,,,required|active plasma cell leukemia,,,,,since prior topical medications,≤ 1;|adequate organ function||,,,,,,
11957,,old;|patients,,,,magnetic resonance angiography).|mri performed,,,,,at least 4 weeks prior to start of study treatment,between 25-50,,,,,,
11958,,stomach.|severely ill patient,,,,intestinal cleansing,,,,,within 4 weeks prior to,<3.5 mm/l|alanine,,,,,,
11959,,atherosclerotic cardiovascular disease,,,,oral absorption of medications.|patients,,,,,excluded before starting induction chemotherapy,> 18 years old|presence of criteria,,,,,,
11960,,nitrates|oxygen-dependent,,,,emergency therapy,,,,,before january 1st,≥ grade ii,,,,,,
11961,,cervical spine pathology,,,,clear corneal cataract,,,,,at screening or day 1 prior,1 to 12 years|residence,,,,,,
11962,,mdd,,,,soc therapy options per their investigator's best judgment,,,,,since 3 at least months,< 4 or > 7 m/ul,,,,,,
11963,,genetic disorders,,,,ecgs,,,,,within 28 days prior to the initiation of study,≥350 cells/ul,,,,,,
11964,,esophageal variceal bleeding,,,,index date|participation,,,,,four weeks prior,energy intake,,,,,,
11965,,hematemesis,,,,local ablative therapy,,,,,within 14 days before screening;|those who had donated blood,i to vi,,,,,,
11966,,viral pneumonia,,,,lung imaging,,,,,planning within 3 months of screening,≥ 2.5 mm,,,,,,
11967,,c.|chronic heart failure,,,,swiss vaccination,,,,,more than 1000,18 years to 64 years old,,,,,,
11968,,vertical loss,,,,hormonal non-prescription,,,,,post-operative length,less than six months,,,,,,
11969,,bulky mediastinal disease,,,,lozenge,,,,,at least 3 months prior to the study,"<70, >90 mmhg.|clinically significant",,,,,,
11970,,hyperammonemia,,,,verbal aggression includ- ing both arguments,,,,,within 6 months of screening.|participation in another study with any investigational product,≤ 1.5 times upper limit of normal,,,,,,
11971,,internal carotid artery (ica),,,,capecitabine.|previous treatment regimens,,,,,throughout the duration of the study|patients,1.1 criteria|patients must,,,,,,
11972,,|systemic diseases,,,,pre-vaccination,,,,,within five years prior to the first use of the study drug,20.0 kg/m^2,,,,,,
11973,,cirrhosis).|lung disease,,,,emergency situations,,,,,within 6 months prior to ip administration|intra-articular,score of the eastern cooperative oncology organization,,,,,,
11974,,poor nutritional status,,,,bone augmentation procedures,,,,,within 12 weeks prior to the booster study vaccination,>45 kg;|female,,,,,,
11975,,communicates,,,,cognitive dysfunction|combination of other pain conditions,,,,,within 72 hours before the first injection,equal to (,,,,,,
11976,,severe renal insufficiency,,,,complete pulpotomy|diagnosis should be irreversible pulpitis.|the tooth is restorable and free from advanced periodontal disease|soft tissues around,,,,,in the previous 12 months.|use of,18 to 100 years|who performance status,,,,,,
11977,,corneal surgery|participation,,,,ureteroscopic lithotripsy surgery,,,,,at least two consecutive tests.|good quality,"≥100,000/mm^3)|patients",,,,,,
11978,,dynamic image criteria,,,,pet),,,,,at least 6 months after discontinuation,>21 units,,,,,,
11979,,exfoliative dermatitis,,,,palliative radiotherapy excepted,,,,,within 24 hours;|hypertension,≥70g/l,,,,,,
11980,,chest burns|presence,,,,musculoskeletal injury|dietary supplements|medication,,,,,after 3 courses,less than 20 kg;|refusal to provide,,,,,,
11981,,adenocarcinoma of the,,,,topical hormone therapy,,,,,within 2 weeks prior to initiation of study treatment.||note,between 40-100kg,,,,,,
11982,,40 lupus,,,,radiation,,,,,within 6 months before lymphodepletion.|known,<2×10^9/l,,,,,,
11983,,laparoscopic cholecystectomy|patients,,,,transplantation,,,,,4 weeks prior to data,> 37 kg/m2,,,,,,
11984,,ventricular arrhythmias,,,,im,,,,,for at least 30 days after the last dose of study,≤ 105 kg,,,,,,
11985,,abdominal malformation,,,,bile duct obstruction,,,,,in the last 3 months;|planned to,>3.0 cm,,,,,,
11986,,pulmonary hypertrension,,,,form|effective contraception,,,,,6 months after the last dose of liposomal,1.1 criteria);|the,,,,,,
11987,,breast carcinoma,,,,quinine,,,,,for at least the past 30 days|plans,higher than or equal to 130mmhg,,,,,,
11988,,fibrotic conditions,,,,mrs)/magnetic resonance imaging,,,,,at the same time may affect participation in the study,at least 90 days after the procedure,,,,,,
11989,,laron syndrome,,,,stent|percutaneous surgical stone,,,,,within 6 months;|major organ function,0 or 1|18 years,,,,,,
11990,,cuff,,,,neurological disease|having a situation that,,,,,in the past 1 year;|suffering from,between 90 (inclusive),,,,,,
11991,,shoulder fracture,,,,acting injectable treatment|current suicide risk|hypersensitivity to,,,,,within 4 weeks prior to dosing|less than 14 days after last acute disease|volunteers,>3.0 mg/dl|ast,,,,,,
11992,,uncorrectable bleeding diathesis.|patients,,,,medical attention,,,,,preceding 5 years to any of the tested allergens,≥12 weeks.|ecog performance status,,,,,,
11993,,severe hypertension,,,,identical imaging modality,,,,,at least 3 times a week.|be willing to provide informed consent,>= 3/10,,,,,,
11994,,refractory lymphoma,,,,folfox/folfiri;|ecog,,,,,within 24 hours of study visits,< 21 days prior to the first dose of study treatment,,,,,,
11995,,vernal keratoconjunctivitis,,,,suppressant medical therapies,,,,,"in the last 6 months,|individuals",≥ ctcae,,,,,,
11996,,renal impairment|pulmonary disease,,,,gonioscopically open angle,,,,,within 14 days before the first dose of investigational product,≥14 days,,,,,,
11997,,opc,,,,organ system,,,,,prior to start of study treatment.|patients,≥ 10.0 g/dl.|absolute,,,,,,
11998,,myocardial ischemia|systolic bp,,,,routinely sleeps,,,,,before the first dose,above 18 years||,,,,,,
11999,,pulmonary fibrosis|any condition,,,,hepatic artery,,,,,after receiving adjuvant,18-60 years;|the,,,,,,
12000,,health products,,,,emdr,,,,,within the preceding 6 months,"18,5 - 24,9 kg/m2|metabolically",,,,,,
12001,,incisors,,,,gastrointestinal surgical intervention|patients,,,,,more than 15 g/l,>15 s,,,,,,
12002,,respiratory sepsis aetiology|acute respiratory failure,,,,repetitive transcranial magnetic stimulation,,,,,within the past 12 months.||has received prior therapy,less than 400,,,,,,
12003,,fibrosure,,,,participates,,,,,throughout the study.||,>=38.0 degree celsius,,,,,,
12004,,bleeding|hemodialysis,,,,scope||-,,,,,within 1 month,> 45 years,,,,,,
12005,,right medial deltoid,,,,assessment procedures|cortico-steroid,,,,,more than 3 months before the,grade iii above|severe hypertension,,,,,,
12006,,perception problems,,,,subsequent central pathology review,,,,,at the time of consent|karnofsky performance status,≥500 copies/ml,,,,,,
12007,,age|stable ambulatory,,,,t cell infusion|all,,,,,intake within 3 months|periodontal treatment,16-44mm.|≥15mm,,,,,,
12008,,hla-g+,,,,adnexectomy,,,,,changed 3 weeks prior to the recruitment visit.||,between 18 and 35 years|tenderness,,,,,,
12009,,remission,,,,comorbidities:||chronic obstructive pulmonary disease,,,,,in the 2 weeks prior to first trial vaccination,10^4 copies/ml,,,,,,
12010,,passive suicidal ideation,,,,inotropes|pregnant,,,,,14 days prior to the start of the dose optimization phase,i to iii.|open abdominal hysterectomy,,,,,,
12011,,ductal carcinoma,,,,iol master biometry)|dioptric power of,,,,,"within 1,5 d range",< 8 g/dl.|presence,,,,,,
12012,,hiv-aids infection.|patients,,,,cleansing,,,,,throughout the study;|the patient's,>= 3 g/m^2,,,,,,
12013,,corneal edema,,,,cessation of exogenous hormonal treatment,,,,,at least 30 days,between 21-35 days,,,,,,
12014,,choroidal neovascularization,,,,biological drug therapy,,,,,within 2 weeks before surgery|patients,18-70 enrollment,,,,,,
12015,,refractory pain|patients,,,,blood-test of alcohol,,,,,up to 3,between 1 year,,,,,,
12016,,calculated by the ckd-epi equation,,,,first graders,,,,,within 3 months before the screening period,"between 405 and 952 nmol/l),||",,,,,,
12017,,ovarian failure,,,,days;|bilateral mastectomy,,,,,within 4 weeks prior to lymphodepletion.|hepatitis b infection.|hepatitis c,from 0 to 4|informed consent agreement signed,,,,,,
12018,,malignant diseases,,,,oral contraceptives|history of stroke,,,,,at day of inclusion|signed written informed consent,stage ii-iv||,,,,,,
12019,,pituitary disease,,,,language intervention before study,,,,,at least 12 weeks prior to screening,≥ 6 months|18-35 years,,,,,,
12020,,colorectal origin||,,,,arthroscopic knee surgery)|bmi,,,,,prior to study enrollment.|participants must,3-17 years,,,,,,
12021,,penile-vaginal penetration.|please note,,,,heart failure|active,,,,,while in africa,≥ 17.5,,,,,,
12022,,sinoatrial block,,,,mohs surgery,,,,,bilirubin>2 times the upper limit of normal;renal function,18 - 80,,,,,,
12023,,early cord,,,,pelvic organ surgery.|the use,,,,,for less than 6,> 18 years|twin pregnancy,,,,,,
12024,,hemolytic diseases.|secondary aiha,,,,small cell prostate,,,,,while on-study,≤ 140 mmhg,,,,,,
12025,,hiv-infected,,,,thoracoscopic lobectomy,,,,,within 4 weeks prior to enrollment.|other,less than 6 months.|the,,,,,,
12026,,submucosal)|cancer,,,,radiology residents,,,,,during the treatment period and up to 6 weeks after the last dose of investigational product,> 8.5,,,,,,
12027,,permanent eyeliner,,,,emergency treatment,,,,,within 6 months prior to screening|subjects,> 2.0mg/dl;|9、those,,,,,,
12028,,allotransplantation,,,,give clear,,,,,in the past 2 years.|history,< 1.5x upper limit of normal (uln),,,,,,
12029,,tumor tissue also possible).|patient has given,,,,antiviral therapy for hbv,,,,,during the first visit (w0),less than 50% reduction in wound size,,,,,,
12030,,amaurosis fugax,,,,caries treatment,,,,,throughout the duration of the study|participants,<40||,,,,,,
12031,,congenital cleft palate,,,,resolve gi symptoms,,,,,for 8 months following the last dose of study,> 0.5 mm);|4,,,,,,
12032,,diastema,,,,plan treatment,,,,,6 months after the last medication.||,< 30ml/min/1.73,,,,,,
12033,,infections recorded,,,,surgical bilateral oophorectomy,,,,,within 2 weeks prior to leukapheresis,"over 150 kg),|blood triglyceride level",,,,,,
12034,,colonic mucosal dysplasia,,,,local wic agency sites where either the telehealth solution,,,,,within 12 weeks prior to day,> 30|homeostatic model assessment of,,,,,,
12035,,autoimmune diseases;|receipt,,,,alcohol,,,,,for up to two weeks prior to enrollment.|patients,≥ 10%.|serum m-protein,,,,,,
12036,,fundus pathological change,,,,chemo treatment,,,,,within 3 months before receiving the experimental drug treatment;|those who,female)|6 to < 10 years,,,,,,
12037,,developmental conditions,,,,r2-mri obtained,,,,,within 48 hours of injury,≥ 18|2,,,,,,
12038,,non-intact,,,,clinical laboratory test values,,,,,for 3 consecutive days,6- 8mm,,,,,,
12039,,diaphragmatic diapers,,,,gene,,,,,within 3 months prior to screening|clinically significant,< 0.1 ng/ml,,,,,,
12040,,acute attacks,,,,interpersonal psychotherapy,,,,,within the past 2 weeks.|current use of p-gp inducers,2.0-6.5,,,,,,
12041,,hysterectomy|psychiatric comorbidity|chronic diseases,,,,intraoperative csf outflow from the ventricle noticed by the surgeon)|adults over the age,,,,,in the last 2 weeks,> 2 + nadir,,,,,,
12042,,traditional/herbal medicine,,,,prenatal screening,,,,,within 72 hours of symptom onset,> 2.5×uln,,,,,,
12043,,spastic diplegia,,,,tavr procedure;|non transfemoral tavr,,,,,at screening|if of reproductive potential,10-20 breaths/min,,,,,,
12044,,dentition exclusions,,,,renal transplant patients|acute kidney injury kdigo≥1,,,,,within 60 days of the last dose of,≥ 90 g/l,,,,,,
12045,,gastrointestinal abnormality,,,,conventional radiation therapy,,,,,prior to initial dosing.|the participant,long-term to cold test,,,,,,
12046,,persistent regurgitation,,,,endocrine treatment duration,,,,,within 7 days prior to entry||the,0-1.||laboratory test results,,,,,,
12047,,sgr,,,,open femoral,,,,,at least 4 weeks.|allergy to fluorescein,≥18 to <80 years,,,,,,
12048,,type 2 diabetes of the ministry of health.|pregnancy,,,,antibacterial treatment,,,,,6 months prior to signing the icf,6 to 52 weeks,,,,,,
12049,,associated dm,,,,organ function:||bone marrow reserve:|white,,,,,in the 12 months prior to consent|exposure,≥ 18 years,,,,,,
12050,,aitl,,,,whole body 18f-fdg-pet/ct,,,,,within 14 days prior to study,> 15 cm from the anal,,,,,,
12051,,spasticity,,,,technical aids|person able to understand simple orders,,,,,within 12 months after the procedure.|impending surgery 60 days post intervention of the treated,greater than 60 ml/min,,,,,,
12052,,acute respiratory virus infection.|patients deemed unsuitable for stem cell therapy,,,,protocol treatment|patients,,,,,at least six weeks after the date of the amniotic membrane transplantation procedure,> 470 ms regardless,,,,,,
12053,,acute care hospital,,,,surgical resection of the stomach,,,,,prior to enrolment,outside the reference ranges,,,,,,
12054,,lung injury,,,,ct dynamic enhancement scan,,,,,within 7 days prior to day 1 of protocol therapy,score 7 to 9,,,,,,
12055,,diabetes ketoacidosis,,,,coronary artery bypass graft (cabg),,,,,within month of the start of the study,≥1.5×109/l|platelet count≥75×109/l|hemoglobin,,,,,,
12056,,substance misuse,,,,therapy (surgery,,,,,less than 3 times per,≥3 × uln,,,,,,
12057,,aids-defining illness,,,,anyone,,,,,within 1 hour of presentation|patients,≥ 100cm2|wound duration,,,,,,
12058,,cerebritis,,,,pelvic organ prolapse.|vaginal,,,,,for 4 months after the final dose of cabozantinib.||-,< 50 beats per minute,,,,,,
12059,,lung transplantation|active cancer treatment,,,,years|neurological examination,,,,,within 6 months prior to their study av-1451,greater than 90 mm hg,,,,,,
12060,,neck|mri intolerance,,,,nerve conduction study,,,,,throughout the study period.|corticosteroids should be stopped,below 100 mm,,,,,,
12061,,pathological diseases,,,,sample of the polyp,,,,,during the last 24-hour|any constituent,45 ml of 40%,,,,,,
12062,,covid- 19 infection,,,,scan|a brain mri,,,,,over the past 3 months|history,between 18.5 and 35 kg/m2,,,,,,
12063,,neurodegenerative manifestations,,,,whipple procedure,,,,,at least 4 months prior to the investigational,"< 100,000/mm3",,,,,,
12064,,inflammatory bowel disease.|chronic kidney disease,,,,transurethral resection of the prostate,,,,,during the previous 12 months to start of the study,25 × 10^9/l,,,,,,
12065,,episodic hangover,,,,glaucoma surgery,,,,,within 3 days before admission|breastfeeding|severe dehydration,less than 35,,,,,,
12066,,cardiac arrhythmia.|uncontrolled hypertension,,,,therapeutic mt,,,,,within 3 months of screening.|participant,between 30 and 60,,,,,,
12067,,systemic allergic reaction,,,,re-inducton therapy;|aml,,,,,"at least 1 year,|have",< 24 mmol/l.|haemodynamic instability,,,,,,
12068,,unspecified depressive disorder,,,,ventricular puncture drainage,,,,,at initial angiography.|timi 2-3,within 200mm,,,,,,
12069,,liver conditions,,,,maintenance stage cardiac rehabilitation,,,,,within the previous 2,greater than 40|non-english-speaking,,,,,,
12070,,gastrointestinal anomalies,,,,transcatheter arterial chemoembolization,,,,,within the last 24 hours||,between 19 and 64 years|american society of anesthesiologists physical status,,,,,,
12071,,gastrointestinal endoscopists,,,,prolonged knee flexion.||,,,,,more than 4 days a week,>90 mmhg;|triglycerides,,,,,,
12072,,msec,,,,cardiac examination,,,,,72 hours before enrollment confirmed,"less than one year,|severe",,,,,,
12073,,hamd<17,,,,drug delivery device,,,,,within the 6-month period prior to baseline,25-65|defining,,,,,,
12074,,chest adhesions,,,,pelvic mri before operation is,,,,,14 days prior to the start of baseline visits,under 18 years old.||-,,,,,,
12075,,solitary lesion,,,,medication|history,,,,,in the three months prior to the study.|use of,=< institutional upper limit of normal (uln),,,,,,
12076,,miscarriage syndrome,,,,interventions,,,,,more than 14 units,18.0-26.0 kg/m2,,,,,,
12077,,malignant mass,,,,infarction|coronary artery bypass grafting surgery|heart valve surgery|percutaneous coronary intervention,,,,,at the time of registration|patients,45 x109,,,,,,
12078,,squamous-cell carcinoma,,,,ra|acr definition,,,,,within 24 hours prior to randomization;|presence,18 years to 40,,,,,,
12079,,menstrual symptoms,,,,treatment focal intramuscular injection,,,,,at the time of evaluation,>= 60%).|measurable disease,,,,,,
12080,,bipolar affective disorder,,,,quality of the study,,,,,for at least 5 months after the last dose of treatment with eculizumab|subject affiliated to a social security regimen|subject,>120 ms,,,,,,
12081,,ascites|hyponatremia,,,,mri scan of the brain to evaluate,,,,,within 3 years prior to first dose of study treatment,< 1 month,,,,,,
12082,,epilepsy-like,,,,cervical biopsy,,,,,at least 4 weeks following central nervous system,> 40%.|are,,,,,,
12083,,hand ischemia,,,,focal pelvic metastasis,,,,,during the participant identification period;|participants,<=13;ahi< 30,,,,,,
12084,,liver disease.||prior,,,,stem cell transplantation|patients,,,,,lifetime history of,between 18 and 30 kg/m2,,,,,,
12085,,absent|appropriate hr response,,,,qt prolongation,,,,,for 28 days or,> 18 years old|mechanically ventilated,,,,,,
12086,,compromised response,,,,hospitalization).|known,,,,,for four months after treatment,0-1|age,,,,,,
12087,,speed of ice water,,,,intra-articular,,,,,in the next 6 months|current breastfeeding|significant,at least 2 months||both,,,,,,
12088,,right hand).|if,,,,transmural myocardial infarction,,,,,within 4 weeks of the first dose,at least 3 months prior,,,,,,
12089,,trial;|viral hepatitis,,,,participate;|expected hospital stay,,,,,within 4 weeks of first dose.|history,measured more than two times,,,,,,
12090,,duodenal cancer,,,,cesarean delivery,,,,,for the past 5 years|concurrent,≤ 2.5 × uln|creatinine clearance,,,,,,
12091,,bleeding incidents,,,,oral examination,,,,,for 1 year after the last dose of the study,< 40 years old,,,,,,
12092,,generalized seizure,,,,extracorporeal membrane oxygenation - ecmo,,,,,at the time ofscreening,>300mg/g).|regular loop,,,,,,
12093,,kabuki syndrome,,,,dysfunction history,,,,,within the last 6 months prior to registration|history of,> 18 years.|participant,,,,,,
12094,,deep brain,,,,daily tests,,,,,during or after the participant's last treatment regimen,> 550 lbs,,,,,,
12095,,medulloblastoma,,,,complex aortic surgery,,,,,at least 6 months prior to participation in the study.|participants,over 18-50 years.|during the study,,,,,,
12096,,wolff-parkinson-white syndrome,,,,pet-ct scanning,,,,,at screening or day -1.|donation,between 100∼125 mg/dl,,,,,,
12097,,botanical preparations,,,,hyperbaric oxygen therapy,,,,,within 28 days prior to the start of study treatment.|patient,18-35 kg/m2|absence,,,,,,
12098,,hypersensitivity,,,,ss outpatient clinic of the rheumatology department of the university hospital 'p. giaccone',,,,,after step 1 entry,< 0.1 mu/l.|prior,,,,,,
12099,,not in pregnancy,,,,radiographic documentation,,,,,within 48 hours.|participants,between 20-35,,,,,,
12100,,behavioural problems,,,,oral bisphosphonates,,,,,within 1 month|patients,< 4mmol/l,,,,,,
12101,,medical history|active malignancy,,,,neurosurgical intervention,,,,,for 3 months after brachytherapy.||,≤ 30 gy,,,,,,
12102,,disseminated herpes simplex||14,,,,food.|plasma donation,,,,,within 4 weeks before the first dose;|previous received experimental medication,>= 90mmhg,,,,,,
12103,,disorder of metabolism,,,,intensive care unit stay).|history of any respiratory disorders,,,,,in the past 3 months.|patients,over 6 years,,,,,,
12104,,progressive neurologic conditions,,,,small intestinal bacterial overgrowth,,,,,within 28 days of first dose of study drug,18.5 kg/m2,,,,,,
12105,,refractive error,,,,bone marrow transplant.|a,,,,,within 7 days of enrollment)|platelets,18 to 80 years,,,,,,
12106,,conduction,,,,major surgery unrelated,,,,,within the past 1 year;|has received,=< 0.4 mg/dl,,,,,,
12107,,hr ≤40 bpm,,,,open posterior,,,,,within 1 year|subjects,less than or equal to 1.50 d,,,,,,
12108,,drug-resistant,,,,allogeneic hematopoietic stem cell transplantation.|female patients,,,,,in the past 4 weeks,less than 4 weeks prior to spvn06,,,,,,
12109,,partial tear,,,,hepatic blood flow,,,,,within 24-36h.||,score ≥ 1.0,,,,,,
12110,,parkinson disease,,,,favorable intermediate risk,,,,,within the past 3 years.|asplenia,2-5).|individual,,,,,,
12111,,impossible to introduce,,,,immunosuppressive therapy,,,,,during the study period and within 3 months after the last administration of the study medication,10-15l/min,,,,,,
12112,,dislocations,,,,b-cell,,,,,within 3 months before vaccination.|have,> 1.5-fold upper limit of normal.|any,,,,,,
12113,,pwd)|caregivers,,,,prophylactic mastectomy,,,,,within 30 days prior to the first dose of study interventions|prior exposure,<2 doses of hib,,,,,,
12114,,current illness,,,,standard chemotherapy regiments,,,,,within 3 months prior to screening;|previous lung resection,40 years or above,,,,,,
12115,,acute necrotizing pancreatitis,,,,conventional techniques,,,,,other day,"stage 1,2 or 3",,,,,,
12116,,mediastinal nodal disease,,,,interventional clinical study|treatment with another investigational drug,,,,,within 72h)|evidence of,> 225 ml/kg/year,,,,,,
12117,,extensive disease,,,,placement of the csi pvad device|subject's vasculature,,,,,continue throughout study period,greater than 160 mmhg.|patients,,,,,,
12118,,criteria*|oligometastatic disease,,,,scheduled biopsy,,,,,in the prior 4 weeks,>22 years,,,,,,
12119,,required;|150 mmhg,,,,typic for ibd e.g.||diarrhea,,,,,during the last 4 weeks|weight < 10 kg,≥20 pack,,,,,,
12120,,multiple pulmonary lesions,,,,diagnostic ct scan permits good visualization,,,,,at least one of the following pcwg3 criteria,less than 500 cells/mm3,,,,,,
12121,,spinal cord disorders,,,,venous blood,,,,,in the limb.|conditions that,lower than 4.5,,,,,,
12122,,mri|drug use,,,,vagal nerve stimulator,,,,,within the period of their study participation,>= 200 cells,,,,,,
12123,,liver injury induced,,,,physical activities,,,,,within the 28 days prior,maximum 50% tendon thickness,,,,,,
12124,,"illiterate,|the",,,,underwent,,,,,within 4 weeks prior to the first dose of investigational product.||participants received,67 per facility,,,,,,
12125,,histrionic personality,,,,donate sperm starting,,,,,during dilated slit-lamp biomicroscopy,<18 years|symptomatic orthostatic hypotension (defined,,,,,,
12126,,dysphagia,,,,unilateral arthroscopic shoulder surgery||,,,,,"in the last 24 hours,|having neuropathic pain,|refusal to participate in the study",between 18 and 60|healthy,,,,,,
12127,,chronic complications,,,,technical surgical complications,,,,,prior to the first dose of study intervention,=< 14 days prior,,,,,,
12128,,lower back pain vas,,,,smoking cessation,,,,,within the 12 months prior to screening,> 450 ms,,,,,,
12129,,third trimester|menstrual-like,,,,hepatic artery embolization,,,,,at least 10 days before the first dose of study treatment,<3 month,,,,,,
12130,,population|pregnant,,,,experimental therapy,,,,,within 28 days prior to administration of study treatment,18-65 years seen,,,,,,
12131,,gastric varices bleeding,,,,genetic testing of tumor tissue,,,,,within in the past 14 days,1 or 2;|be able,,,,,,
12132,,rheumatoid,,,,ineffective antidiabetic therapy,,,,,within 30 days prior to the first dose of trial drug,≥ 2 to ≤ 30 years,,,,,,
12133,,perineural invasion,,,,hematopoietic stem cell/marrow transplant,,,,,at the time of vaccination,≥18 years.|subject must provide written informed consent,,,,,,
12134,,secondary malignancy,,,,penetrating keratoplasty,,,,,before the first dose of study drug.|the,1.1 criteria)；|advanced,,,,,,
12135,,excessive facial height,,,,supine head orientation tests,,,,,at most,≤ 30 kg/m2,,,,,,
12136,,primary health centres:||located,,,,gastroscopy biopsy,,,,,at baseline < 6.2;|pregnancy|subjects,<1.7,,,,,,
12137,,acute knee injury,,,,show excessive fear to the,,,,,during the treatment phase,>90 beats per,,,,,,
12138,,criteria of the new coronavirus pneumonia diagnosis,,,,surgical valve replacement,,,,,within 1 month of screen interview,<10 ng / ml|no,,,,,,
12139,,sports performance,,,,secondary procedure,,,,,within one month prior to screening visit,less than 6 months,,,,,,
12140,,acute alcohol toxicity,,,,abnormal ct or eeg,,,,,for at least 120 days after the last dose of study treatment.|histologically,at least 18,,,,,,
12141,,mixed histology,,,,ablation procedure,,,,,within 4 weeks before treatment;|pregnant,<=5 x uln g,,,,,,
12142,,intra-abdominal disease,,,,thyroid lobectomy,,,,,within 28 days of starting study,scores ≥11|average nightly,,,,,,
12143,,solid and/or cystic abnormalities,,,,renal stone,,,,,during study procedures.||,>8 years old,,,,,,
12144,,gallbladder stone disease,,,,peripheral revascularization,,,,,last 60 days) treatment,1 & 2,,,,,,
12145,,resection margins,,,,antidepressant treatment,,,,,within 30 days of hospitalization,≥ 200 mg/dl,,,,,,
12146,,positive functional compensation,,,,trial entry;|current therapy,,,,,within six months of study entry,least 20 years,,,,,,
12147,,respiratory illness,,,,sperm concentration,,,,,at any time during the study,> 180°,,,,,,
12148,,hepatic renal,,,,montreal cognitive assessment test.|have the ability to walk,,,,,within 14 days prior to registration:||adequate hepatic,1-2 weeks,,,,,,
12149,,mild respiratory failure,,,,permobil power wheelchair,,,,,within the past 12 months|participants,≥1.5 × uln,,,,,,
12150,,congenital heart disease,,,,focal notching,,,,,present,100 years and over,,,,,,
12151,,arthrofibrosis,,,,palliative stereotactic radiation,,,,,within 7 days prior to the year,between 18 to 39 years;|accept and sign the,,,,,,
12152,,brain metastases|use,,,,400 mcg salbutamol,,,,,within 12 hours.|prisoner|intubated|unable to swallow oral medications,≥18 years)|≥40,,,,,,
12153,,liver metastasis;|total bilirubin≤1.5 times uln；|creatinine,,,,ip on day 1.|lymphopenia,,,,,within the past 3 months before study randomization|refusal to maintain contraceptive practices,class iii or greater,,,,,,
12154,,depression.|denied heart transplant,,,,effective contraceptive tool,,,,,while on this study,<120 ms|qrs duration,,,,,,
12155,,parent(s)/legal guardian(s) must be capable of understanding,,,,endoscopic esophageal dilation,,,,,within 6 months prior to first dose of study medication.||o,150 ml or 5,,,,,,
12156,,scars,,,,enrollment;|active gastric,,,,,within 6 months prior to first dose.|human immunodeficiency virus,18-65 age|asa i-ii||,,,,,,
12157,,conservative treatment,,,,chemoradiation therapy||oral capecitabine,,,,,at time of enrollment|use,0-1,,,,,,
12158,,mental disease;|uncontrolled diabetes,,,,lumbar spine surgeries,,,,,prior to enrollment)|explicit,≥ 9.0 g/dl|absolute,,,,,,
12159,,congenital hyperinsulinemia.|current use,,,,recurrent advanced head,,,,,in the last 12 months.|consuming metabolism-altering drugs,equal to 0,,,,,,
12160,,senseye dt:||vision impairment,,,,quality ct,,,,,"in the last 4 weeks,|not using curcumin",score greater than 37.5.|contraindication to the use of electrotherapy.|use of,,,,,,
12161,,gs,,,,bladder instillations,,,,,employees,6-12 years|children,,,,,,
12162,,life threatening illness,,,,episcleral venous pressure,,,,,within 30 days prior to the first dose of trial therapy,≥ 50×109/,,,,,,
12163,,tissue expanders.|patients,,,,dialysis|alanine aminotransferase,,,,,in the past 2 years;|patients,> 2.8 m/s,,,,,,
12164,,chronic diseases of the cardiovascular,,,,prepaid cell phone plan,,,,,during the endovascular procedure.|affected artery's diameter <4 mm,>150 umol/l,,,,,,
12165,,bowel obstruction/perforation,,,,cognitive behavioral therapy (cbt),,,,,for 4 weeks prior to the first assessment||,guidelines|able to provide,,,,,,
12166,,retinal hemorrhage,,,,irreversible sterilization,,,,,within the past 2 years|significant sensory,>uln+4s,,,,,,
12167,,bladder tuberculosis,,,,lumbosacral nerve roots,,,,,at least 14 days prior to day +1||contraindicated medications,≥100×10e9/l.|alanine aminotransferase,,,,,,
12168,,rd,,,,axis,,,,,within one year before enrollment.|patients,<= 2.|relapsed/refractory,,,,,,
12169,,chronic hepatitis b virus carriers,,,,pregnancy|utilized vaginal products,,,,,within the past 2 weeks3 months prior to enrolment,≤ 1.25 times the upper limit of normal,,,,,,
12170,,parent(s)/legal representative(s,,,,local standard care,,,,,in the last two months||,< 1.5|ability to give,,,,,,
12171,,cad,,,,ivf procedure,,,,,at screening.|history of,3 - 5||,,,,,,
12172,,abnormality consistent,,,,complete small,,,,,at screening/,under 18 and over,,,,,,
12173,,psychotropic drug abuse,,,,first menstrual cycle|low serum estradiol levels,,,,,for at least 90 days,score <18,,,,,,
12174,,psychiatric pathologies,,,,involve psychotherapy,,,,,prior to neoadjuvant,more than 1 cm,,,,,,
12175,,cytotoxic chemotherapy,,,,gastric bypass (bariatric) surgery,,,,,within 2 weeks prior to day 1 of protocol therapy.|treatment,≥ 440,,,,,,
12176,,neurologic deficits,,,,women>3.39,,,,,within 7 days of trial enrollment,0-52,,,,,,
12177,,fertile after puberty,,,,transcutaneous measurements.|thigh circumference,,,,,at least 10||,>20%,,,,,,
12178,,child bearing potential,,,,oac,,,,,within approximately 7 days before enrollment revealing kidney,1-3|family,,,,,,
12179,,hepatitis b/c.|acute,,,,laboratory test values,,,,,between january 2005,iii - iv,,,,,,
12180,,obstructive sleep apnea syndrome,,,,endotracheal intubation;|surgery,,,,,last onset occurred within 2,flank,,,,,,
12181,,trying to conceive|involved in another clinical study,,,,brain mri checks,,,,,more than 90,≤ 2 years,,,,,,
12182,,pregnancy|inflammatory bowel disease|alcohol,,,,nuclear magnetic resonance,,,,,within the year prior to the screening visit,< 90 g/l,,,,,,
12183,,coma|age,,,,gastric banding,,,,,within 24 hours prior to the research scan,xi score of >10,,,,,,
12184,,"trauma,|without any surgery",,,,pelvic surgery,,,,,within previous 2 days.|patient ≥ 18 years,greater than 1.5cm,,,,,,
12185,,local cancers,,,,transperineal ultrasound||,,,,,within 4 weeks before the first administration of the study drug,6 months,,,,,,
12186,,inflammatory condition;|live,,,,major organ toxicity,,,,,during the active,between the anterior and posterior edges,,,,,,
12187,,clinical chondrocalcinosis,,,,egfr,,,,,rtms||,"≥ 3,000/",,,,,,
12188,,vascular abnormalities,,,,standard crockcroft-gault formula,,,,,within 4 weeks prior to randomization.|has,≥ grade 4,,,,,,
12189,,vegetables,,,,multimodal rehabilitation program,,,,,for at least 4 hours.||,≥3 months.|eastern,,,,,,
12190,,resistant htn,,,,this treatment,,,,,within 2 weeks prior to first dose of study,20-50|being,,,,,,
12191,,diplegic,,,,global assessment score,,,,,in the month before the start of the study;|use,≤2.5 times the uln,,,,,,
12192,,add,,,,bilodigestive shunt|for tare -,,,,,during and after procedure,<22 points)|self-reporting,,,,,,
12193,,rhabdomyolysis,,,,endothelial cell count,,,,,within days prior to step,20-85 years old.|patients able to provide written informed consent,,,,,,
12194,,parenchymal brain metastasis,,,,computed tomography (ct) of the lungs,,,,,within 30 days before the first dose of the study intervention,> 9|cholecystectomy,,,,,,
12195,,genetic condition,,,,computed tomography (ct) scan of the head,,,,,past 12 months prior to study start.|subjects,≤ 2 cm,,,,,,
12196,,squamous cell carcinoma,,,,transfusion,,,,,within the 12 months prior to the first dose of study drug,4-10 weeks,,,,,,
12197,,kidney disease|severe hypertension,,,,interventional procedure,,,,,visits.|willing to provide voluntary written informed consent,≥ ⅲ,,,,,,
12198,,duplex kidney,,,,rigid bronchoscopic management.|written,,,,,within 8 weeks before the first dose of study treatment,≥ 50 ×10^9 / l.,,,,,,
12199,,cardiac conduction disease,,,,menstruating,,,,,more than 6 months prior,score of 23 or below,,,,,,
12200,,malignant colorectal tumors|simultaneous,,,,blood collection,,,,,for the last 15 years.|report,<12 years old,,,,,,
12201,,spastic diplegic/ hemiplegic cp,,,,interval,,,,,throughout the study|absence of unstable,> 5x normal,,,,,,
12202,,multimorbidity inclusion criteria,,,,prenatal ultrasound,,,,,during the duration of the intervention|substance abuse,≥ 9g/dl,,,,,,
12203,,pregnancy failure,,,,dialysis vascular access procedures,,,,,within 6 months before the cell reinfusion;|new york heart association (,≤2.5x uln (,,,,,,
12204,,liver dry,,,,primary surgical evacuation,,,,,during the 28 days before the first dose of trial medication,=< 3 × institutional uln,,,,,,
12205,,asymptomatic ischemic heart disease,,,,institutional review boards,,,,,within 3 months prior to the start of the study,≤ 1.5 × upper limit of normal value,,,,,,
12206,,deep bite.|no restorative application,,,,ctla)-4 therapy,,,,,within 12 months of enrollment.|the,< 70 premorbid full scale intelligence quotient,,,,,,
12207,,trial|planned tumor biopsy,,,,local cns directed therapy,,,,,within the previous 12 months.||key,18.5 to 29.9 kg/m2||,,,,,,
12208,,t2d remission,,,,csi)/whole ventricular irradiation,,,,,<1 year prior to enrollment,< 35 g/l.|international normalized ratio,,,,,,
12209,,adt,,,,coronary angiogram,,,,,in the time range,> 4.0 m/s,,,,,,
12210,,mmhg|active malignancy,,,,specially designed myopia control,,,,,within 6 months of imp treatment start.|history,=< 15 days prior,,,,,,
12211,,acute leukemias,,,,world health organization (who):,,,,,within 1 month prior to the first dose administration,>60ml/min/1.73m2.|ejection fraction,,,,,,
12212,,lin,,,,infusion reactions,,,,,in the last 6 months|underlying,20 male,,,,,,
12213,,cytological pathology,,,,biologicals,,,,,during the entire study period.||13,=< 4 weeks prior,,,,,,
12214,,months|restriction of neck movements,,,,gastric surgery|major systemic diseases|pregnancy,,,,,within the last 30 days prior to the research scan),≥ 21 years|histologically,,,,,,
12215,,judged to be postmenopausal,,,,axial skeleton.|bone,,,,,within the 6 months prior to beginning the study;|use of,1.0-17.9 years,,,,,,
12216,,thyroid diseases,,,,trauma therapy program,,,,,in the 28 days preceding the vaccine,<1 (exception to this criterion,,,,,,
12217,,myositis symptoms per ctcae,,,,lipid,,,,,after 7 days of treatment.|patients have,≥6 months to <13 years|planned,,,,,,
12218,,adverse outcome,,,,elective cardiac surgery||,,,,,more than 1000 msus,≥60 ml/min|total bilirubin,,,,,,
12219,,countable seizures,,,,further screening:||well-controlled,,,,,at least 3 months prior to enrolment.|signed,>= 2000/ul,,,,,,
12220,,adv viremia,,,,allogeneic tissue/solid organ transplant|a wocbp,,,,,within 7 days prior to enrollment):||2 to < 6 years,stage i nk|decreased nerve density,,,,,,
12221,,essential tremor,,,,therapeutic riding,,,,,during the past 24 months.|positive elisa,< 0.5,,,,,,
12222,,chlamydia,,,,major procedures,,,,,within six weeks after endoscopy,<11)|opposition to data processing from the older adult,,,,,,
12223,,intestinal disorders,,,,laparoscopic surgery.|suspicion,,,,,for 6 months prior to registration.|for,grade 3 or 4,,,,,,
12224,,liver metastases).|aspartate aminotransferase/serum,,,,immunonutrition supplementation;|expected intervention of immunonutrition<3 days,,,,,within 4 weeks prior to the first dose of study treatment.||11,"< 12 points,|obesity 3 degrees and above",,,,,,
12225,,brackets,,,,therapy escalated,,,,,in 12 months,younger than 18 years and older than 65 years|those,,,,,,
12226,,ef,,,,extracorporeal membrane oxygenation [ecmo,,,,,"in the past six months,|current musculoskeletal pain",>140/90 mm hg,,,,,,
12227,,pitting edema,,,,ct scans,,,,,within the previous 2 months,between 1 and 10 years,,,,,,
12228,,protected health,,,,tobacco smoker|a contraindication,,,,,longer than 2 weeks.|participant,less than 50% stenosis,,,,,,
12229,,implanted ferromagnetic,,,,mechanical thrombectomy,,,,,within 12 months from first dose of study intervention,>60|ast,,,,,,
12230,,biliary tract tumors|patients,,,,srs,,,,,within 12 weeks prior to enrollment into,≥ 20 pack,,,,,,
12231,,primary heart disease,,,,brain tumor|history of diagnosis,,,,,at the time of diagnosis.|is,greater than 24 kg/m2.|willing,,,,,,
12232,,congenital anomalies,,,,frozen donor sperm|non-english speaker,,,,,in the last month.||,larger than 42cm|patients,,,,,,
12233,,hose,,,,undefined|registration,,,,,prior to first dose of study,<3.0 x uln,,,,,,
12234,,chronic neuropathic pain,,,,1.5-fluid ounce,,,,,within 4 weeks or,22 years or older,,,,,,
12235,,scleroderma inflammatory bowel disease,,,,fms symptomatology,,,,,longer than 3 months,20 weeks' gestation||hypertension,,,,,,
12236,,chronic inflammatory disorders,,,,hav igm ab),,,,,before onset;,>18 and <80 years patients capable of providing informed consent patients,,,,,,
12237,,premature,,,,cranio-spinal radiation,,,,,during the study.|subject participating in another interventional study,50 ≤ dm 90,,,,,,
12238,,limb oedema,,,,rule,,,,,during the screening/run-in period,45-80 years,,,,,,
12239,,irreversible btk inhibitors,,,,complete functional assessments,,,,,during vaginal intercourse and,≥200 ng/ml.,,,,,,
12240,,schwannomas,,,,seizures|botulinum toxin injections,,,,,within the 6 months prior to enrolment|individuals of,between 28-36 weeks,,,,,,
12241,,atopic dermatitis,,,,eye|surgical clips,,,,,at any time after the estimated date of conception,≥10 mmol/l,,,,,,
12242,,portal vein obstruction,,,,ablation,,,,,within 3 years|need combined treatment of hemodialysis|be allergic,≤ 2.0 × uln,,,,,,
12243,,traditional chinese medicine labels,,,,colorectal cancer screening,,,,,"for at least 1 year prior to screening||or,||individuals of",0-25,,,,,,
12244,,lupus kidney disease,,,,visit|body mass index,,,,,in the next 6 months,< 40%.|patients,,,,,,
12245,,acute congestive syndrome,,,,echocardiography examination left ventricular ejection fraction,,,,,for ugat1a1*28 polymorphism|no,≥10% fibrosis extent of the lungs||,,,,,,
12246,,cranial nerve palsy,,,,vaginal moisturiser,,,,,within 4 weeks prior to the first dose,<9 cm/s|nyha class,,,,,,
12247,,label.|active autoimmune disorder,,,,anatomical resection of the lung (lobectomy,,,,,at least one visit,"requires monitoring, intervention",,,,,,
12248,,alcohol consumption,,,,bone regeneration,,,,,within 28 days prior to the first dose of ip,from 25 to 35,,,,,,
12249,,eligible|measurable disease,,,,positions|to show,,,,,prior to first dose of study drugs,from 30 to 40 kg/m2|no,,,,,,
12250,,heparin-induced thrombocytopenia contraindicating,,,,dual x-ray,,,,,"at least one month ago,|children",<36°,,,,,,
12251,,human epidermal growth receptor 2-negative,,,,probiotic treatment,,,,,"onset within 24 hours, and|patient","18-65 years|both genders,|bmi",,,,,,
12252,,total serum bilirubin≥85umol/l；|coagulation,,,,stage surgery,,,,,during the clinician-administered interview,>18 scheduled,,,,,,
12253,,pylorus-preserving,,,,study.|vaccination,,,,,over the prior month,2 to 16 years intraoperative diagnosis,,,,,,
12254,,sinonasal allergies,,,,electrocardiogram (ecg) readings,,,,,at any previous time,equal/over 90 mm hg,,,,,,
12255,,associated α-thalassemia;|active bacterial,,,,immuno-stimulatory agent,,,,,prior to standard-of-care surgery,<20%||,,,,,,
12256,,b cell malignancies,,,,unilateral oophorectomy,,,,,since at least 3 months||pd,≥18.0 and ≤25.0 kg/m2,,,,,,
12257,,gout flares,,,,therapeutic intent,,,,,at enrollment,more than18 years old||,,,,,,
12258,,ciai,,,,standard mri protocols|decisionally impaired,,,,,at the time of consent.|sex,< 1.5 times upper limit of normal range (uln),,,,,,
12259,,alcohol-use disorder,,,,natural head position (,,,,,at time of last,≥70%,,,,,,
12260,,including:||complete remission,,,,pelvic examination,,,,,within 10 minutes.|complications related to anesthesia,<50 c/ml,,,,,,
12261,,bilateral tinnitus,,,,authorization,,,,,"during the intervention period,|those who cannot communicate on the phone",≥ 600 pg/ml.4,,,,,,
12262,,mixed hepatocellular/cholangiocarcinoma,,,,vaccine therapy,,,,,at the time of dosing).||any condition,female||˂ 21 years,,,,,,
12263,,buerger disease,,,,thoracic surgery)|undrained,,,,,more than 4 days per month for more than 3 consecutive months prior to visit 1,score 5 with medical research council (mrc),,,,,,
12264,,peripheral vascular disease.||obesity,,,,stenting,,,,,within 28 days prior to study enrollment.|* participant,less than six,,,,,,
12265,,venous ulcers,,,,world health organization (,,,,,within 48hoursor 5half-lives,more than 1.5 times the laboratory normal.|known glucose level,,,,,,
12266,,cushing's syndrome,,,,hronic etdd):||>3 months,,,,,within the previous 5 years,<9)|the use,,,,,,
12267,,acute renal,,,,hematopoietic stem cell transplantation||17,,,,,≥ 3 months,at least 1 cm2,,,,,,
12268,,major chronic diseases,,,,medical record,,,,,within 7 days before the first use of the study drug;|antiviral drugs,> 50% predicted,,,,,,
12269,,extra-criteria manifestations of aps,,,,placement of lifevest cardioverter defibrillator.|positive serology testing for hiv,,,,,within last 3 months|periapical pathology,< 20 ng/,,,,,,
12270,,mouth ulcers,,,,physical therapy applications,,,,,for 5 years after treatment;|evidence of any severe,> 90 mmhg,,,,,,
12271,,third party)|emergency,,,,protocol therapy,,,,,during the study period.||subjects,over 99 mm hg,,,,,,
12272,,chronic nature,,,,numerical pain rating scale||,,,,,within 7 days of first sbrt,healthy older adults:||exclusion,,,,,,
12273,,thoracic kyphosis,,,,treatment application area (head)|patient with,,,,,"between january 1, 2021",≤ 30 ml/min|concomitant,,,,,,
12274,,motor disorders,,,,intraocular treatment,,,,,for at least 4,<1 month);|current,,,,,,
12275,,complicated,,,,treatment periods.|receipt,,,,,within 10 days prior to screening|malignancy,18-65|being able,,,,,,
12276,,radicular pain,,,,propofol|tracheostomy|supra-glottic,,,,,within 30 days prior to providing written informed consent,above these values,,,,,,
12277,,spastic diplegic cerebral,,,,brachytherapy,,,,,within the first 3 months before screening,12 and 13,,,,,,
12278,,ercp,,,,antibiotics|diabetes,,,,,7 days before the first dose of therapy|participants,unresolved to ≤ grade 1.|patients,,,,,,
12279,,cholelithiasis,,,,complete deafness|patient,,,,,prior 8 weeks|consumption,>6 months ago,,,,,,
12280,,crora)|exudative amd,,,,laboratory tests.||bmi,,,,,within the previous 30 days,>90%,,,,,,
12281,,brain injury|illiteracy|status of hypertonus,,,,staging,,,,,else than due,>1.7,,,,,,
12282,,calf muscle hypertrophy,,,,arthroscopic partial meniscectomy surgery,,,,,in the last year.|individuals reporting significant,> 360 mg/m2,,,,,,
12283,,nerve atrophy,,,,ip on day 1.|neutropenia defined,,,,,72 hours prior,< 30.5kg/m2,,,,,,
12284,,chronic persistence,,,,ecological momentary assessment,,,,,within 7 days prior to study entry,females|18 to 25 years,,,,,,
12285,,heart disease including:||angina pectoris,,,,icodextrin dialysate|participation,,,,,on the targeted tumors,"older than 18 years,|signed informed consent",,,,,,
12286,,nsclc - adenocarcinoma,,,,1% lidocaine,,,,,congenital abnormality|only pairs,< 35 %,,,,,,
12287,,skin cancer|known proliferative retinopathy,,,,reduced rf,,,,,"during the study|underwent filler injection (collagen,",>40 kg/m2.|preoperative,,,,,,
12288,,lyme disease,,,,total laparoscopic hysterectomy||,,,,,for 30 days after receiving the last dose of the study drug,>2.5*upper limit of normal value,,,,,,
12289,,redness,,,,full meal,,,,,throughout his/her participation,greater than 1 month,,,,,,
12290,,intestinal surgery|chronic hypoxic diseases,,,,lymph node biopsy).|pulmonary interstitial fibrosis,,,,,in the first post-transplant week,≥ 18 years|singleton,,,,,,
12291,,neural pain,,,,cervicogenic headache.|stable,,,,,within 30 days prior to first dose of study drug.|any consumption of food,< 18 years|artificial ventilation,,,,,,
12292,,soft meningeal disease,,,,clinical laboratory test result,,,,,during the study.|active,<6.|baseline nihss obtained before procedure,,,,,,
12293,,stroke|inability to follow command,,,,worsen,,,,,at least 12 months prior to diagnosis,≥ 160 mm hg,,,,,,
12294,,axis i disorder,,,,blood routine test,,,,,within 6 months prior to first dose of study treatment,increase 3 times the upper limit of normal,,,,,,
12295,,wrist osteoarthritis,,,,allogeneic blood,,,,,30 days after the last dose (please see,lower than 75%,,,,,,
12296,,magnitude.|good candidate,,,,functional asplenia|diabetes,,,,,within the previous 5 years|achieved,≥ 1)|can ambulate,,,,,,
12297,,heart failure,,,,included|receiving combination art,,,,,pre-dispose,65 to 80 years|undergoing major abdominal,,,,,,
12298,,delayed gastric emptying syndromes,,,,balloon pulmonary angioplasty,,,,,during the trial|pregnant,less than or equal to 300,,,,,,
12299,,adverse pregnancy reaction,,,,assisted reproduction,,,,,continue for >1 year,<= 5 x uln||coagulation:||h,,,,,,
12300,,malignant tumour.|patients,,,,stabilizing surgery,,,,,after 01 january 2020 in combination,"< 70,000/mm3",,,,,,
12301,,asd made,,,,immunohistochemical staining,,,,,within the last 6 months.|evidence,score of 3 or,,,,,,
12302,,superficial bladder cancer,,,,salpingectomy|pelvic inflammatory disease|adnexectomy for gender transformation surgery,,,,,during the 3-month period prior to screening.|intravenous bisphosphonate,> 3mm|ipsilateral arm,,,,,,
12303,,knee pain history|knee symptoms,,,,conversion,,,,,within 3 months prior to randomization;|other causes,>50 kg,,,,,,
12304,,thrombocytopenia syndrome,,,,radiotherapy|unable to undergo a,,,,,at the time of screening.|those,between 0 - <19 years|radiological,,,,,,
12305,,nerve conduction impairment,,,,teeth aesthetics.||exclusion,,,,,within 2 weeks of randomization,18.5 to 35.0 kg/m2,,,,,,
12306,,pac,,,,radiation into buttocks,,,,,for the 12-week intervention,between 18 and 25 kg/m2||,,,,,,
12307,,stillbirth.|down's syndrome,,,,pdts,,,,,within the past 6 months||inclusion criteria,<1800/microl,,,,,,
12308,,donate sperm；|the,,,,quantiferon result.|patients,,,,,within 4 weeks before screening.|treponema pallidum antibody positive,≤40 mm,,,,,,
12309,,active peptic ulcers,,,,clear,,,,,before screening.|laboratory,≥100 mg/dl||unstable,,,,,,
12310,,retinal morphology,,,,alternative fistula risk score,,,,,during the study.||,subjects)/more than 1.0,,,,,,
12311,,covid-19;|no covid-19 infection,,,,extrahepatic metastases;|previous,,,,,prevent exercise,≥60 ml/min.|normal,,,,,,
12312,,systemic illness;|novice football,,,,first back operation,,,,,within 10 days prior to the start of study treatment|breast,>18|health care professionals,,,,,,
12313,,mental deficits,,,,pacing device implantation,,,,,within the preceding 1 month of screening.|has,long-term alcohol,,,,,,
12314,,cva sequelae,,,,baseline ct,,,,,within 4 weeks of the first dose of the study drug|participant,> 18 years.|patients,,,,,,
12315,,e,,,,ceeg,,,,,at the scan study visit.||25,> 92%|blood,,,,,,
12316,,minimal activity,,,,tms|neurosurgical intervention for depression|autism spectrum disorder|intellectual disability|severe cognitive impairment|significant neurological illness,,,,,within the previous 3 months|surgery,< 50 x 109/l|hepatic disease,,,,,,
12317,,hiv/ hbv/ hcv infection.|patients,,,,static fine lines trend,,,,,at the time of enrollment in the study,18+ and,,,,,,
12318,,rheumatoid arthritis)|presence of any condition,,,,produce allergy,,,,,in the past 12 months without fixation,50 to 90 bpm|any laboratory value,,,,,,
12319,,recurrence of stroke,,,,samples,,,,,prior to enrollment.|leptomeningeal carcinomatosis,< 70% predicted,,,,,,
12320,,pre-surgical,,,,voluntary cough assessment (,,,,,every 4 weeks or less,≥5 times the upper limit of normal,,,,,,
12321,,gluten-free,,,,prolotherapy,,,,,at the time of signing the subject consent,> six months,,,,,,
12322,,movement;|internal pathologies,,,,general rule for clinical and pathological studies on,,,,,at the time of signing informed consent||,18-65 year,,,,,,
12323,,gastrointestinal malignancy,,,,|glomerular filtration rate egfr,,,,,during the past 6 months|plans,1.5 cm,,,,,,
12324,,baumannii organisms,,,,treatment.||history of autoimmune disease,,,,,within the last 2 years|do not provide informed consent,ios 13.0,,,,,,
12325,,deep vein thrombosis (dvt,,,,conventional lifestyle intervention,,,,,within 1 month or within 5 half-lives,more than 75 years,,,,,,
12326,,excessive bone loss,,,,pelvic organ prolapse|indication,,,,,during the washout period,< 25 ng/ml||a,,,,,,
12327,,haplotype matched,,,,special education classroom,,,,,6 months after the last dose of hlx10,≥470 ms,,,,,,
12328,,habitual non-adherence,,,,heart team consensus,,,,,within 3 months prior to enrollment.|patients,international,,,,,,
12329,,pneumococcus|additional condition,,,,fecal occult blood + + or more,,,,,during the whole study.||pregnant,≥3 year,,,,,,
12330,,diabetic nephropathy|active cancer,,,,diagnostic imaging examination,,,,,within the prior 2 months is more than 2,>2.5* the upper limit of normal (uln),,,,,,
12331,,examples,,,,orthodontic treatment,,,,,at the time of ckrt initiation.|non-atn aki,32 to 37 weeks,,,,,,
12332,,c1d1)|human immunodeficiency virus,,,,instrumental test,,,,,within 2 days prior to surgery,0 or 1|hematological,,,,,,
12333,,parkinson's disease,,,,cryoablation,,,,,during the study,greater than twice the uln,,,,,,
12334,,cord compression.|participants,,,,local lymph node metastases,,,,,at time of participation|currently following a diet|on medication,< 9 and >20 temp,,,,,,
12335,,autoimmune uveitis,,,,enterostomy;|small bowel anastomosis;|anticipating,,,,,for at least 4 weeks prior to first dose of study treatment after radiotherapy,more than 50% above the nadir,,,,,,
12336,,stressful life events,,,,standard dental implant,,,,,in the past 3 years,more than 200mg\dl.|pregnant,,,,,,
12337,,abnormalities on,,,,hormone replacement medications containing lh,,,,,during active study phase.|history,<5.0 x uln)|lipase,,,,,,
12338,,mal,,,,employment,,,,,during the last year of poor glycemic control (hba1c,> or equal to 18|history,,,,,,
12339,,mixed cryoglobulinemia,,,,video recorded,,,,,at the time of screening).|schizophrenia,under 36 months|scheduled,,,,,,
12340,,early-,,,,complete information,,,,,within 3 months before vaccination.|serious,≥ 88 cm,,,,,,
12341,,disease for malignancy,,,,special exercise program,,,,,within 60 days prior,>30 kg.||participants,,,,,,
12342,,atopic asthma,,,,tics-m,,,,,within 4 weeks.|subjects,between 18 -36 years.|athletes score falling above 4,,,,,,
12343,,covid,,,,refractive surgery-related,,,,,within 4 weeks before the first dose of study treatment.|presence,between 18-70 years|scheduled,,,,,,
12344,,old|chronic tinnitus,,,,anti- retroviral therapy,,,,,for 1 year following second evacuation,greater than 10 mm hg,,,,,,
12345,,reliable vf,,,,ctg,,,,,within 2 weeks before the first dose of study treatment.|subjects,equal to or less,,,,,,
12346,,carcinoid syndrome,,,,single ablation,,,,,within the 3 county area,≥ 7%||,,,,,,
12347,,intact maxillary first premolars,,,,coronary artery bypass)|live,,,,,at the screening visit.|females,between 7%,,,,,,
12348,,follows.|aim,,,,moyamoya disease||,,,,,within 28 days prior to day of enrollment.|any investigational agents,0-1.|participant,,,,,,
12349,,radiation therapy)||localized adenocarcinoma of the prostate,,,,embryo transfers,,,,,at least two times,<150*109/ml,,,,,,
12350,,rpv,,,,ascvd recommendation,,,,,throughout the duration of the study.|history,0.8 mg/dl,,,,,,
12351,,immunoglobulin m,,,,t-lineage lymphoblastic lymphoma,,,,,more than two years,= carbamazepine,,,,,,
12352,,stable psoriasis,,,,pulmonary function tests,,,,,within 10 days prior to the expected initial application date,<60 beats per minute|arterial blood pressure,,,,,,
12353,,vascular tortuosity,,,,rapid antigen assay for sars-cov-2,,,,,prior to signing informed consent,0 to 2)|patient,,,,,,
12354,,ischemic cardiomyopathy,,,,b-cell recovery|active central nervous system (cns) involvement,,,,,"patient,|at least 4 months post-diagnosis,|between",≥200 mg/dl,,,,,,
12355,,pathological lesion,,,,lipid nanoparticle,,,,,within 28 days prior to first dose,50-75 years old,,,,,,
12356,,suicidal behavior).|history of any disease,,,,brain imaging examination,,,,,within 60 days prior to (the first,≥18 years||immunocompromised,,,,,,
12357,,biceps tendinosis,,,,craniotomy,,,,,within 28 days prior to initial dosing,< 1.0g;|for,,,,,,
12358,,intestinal carriage|terminal disease,,,,regular menstruation,,,,,14 days before enrollment,< 1% per year.||female,,,,,,
12359,,socorro county|does,,,,chest computed tomography (ct),,,,,within 6 months of the start of screening||uncontrolled,0-1.|participants,,,,,,
12360,,brain infarction,,,,domestic market,,,,,within 14 days (3 months,equal or greater than 88%,,,,,,
12361,,organic brain disease,,,,clonality identification for ngs if not already performed.|presence,,,,,within the preceding 3 months of,less than 100 cells/mm3,,,,,,
12362,,narcolepsy.|mastitis,,,,cmr,,,,,"for at least 5 days prior to testing,|use",15.4 and 15.5 of this,,,,,,
12363,,women|prisoners,,,,soc chemotherapy regimen,,,,,90 days prior to the first dose of study drug,37 weeks to 42 weeks,,,,,,
12364,,jaundice,,,,treatment-free interval,,,,,while on androgen deprivation therapy,65 mm hg,,,,,,
12365,,congenital cardiac,,,,pretreatment endoscopic,,,,,less than 6 months before enrolment,">= 1,500/mcl|platelets",,,,,,
12366,,difficulty breathing.||,,,,disclosure,,,,,natural history study protocol 06-ch-0011.|ability to speak,> 1000/ul,,,,,,
12367,,hb sc,,,,gastric resection,,,,,within 3 weeks of c1d1,37-40,,,,,,
12368,,blepharitis,,,,exercise training|significant cognitive impairment|progressive,,,,,within last 60 days before the decision to start infliximab|negative tb,140 mmhg,,,,,,
12369,,fallopian tube cancer,,,,foot ulcer|receiving oral antidiabetic,,,,,for 6 months after the last dose.||,< 18 or > 80 years|urogenital,,,,,,
12370,,poor arrhythmia,,,,produce hepatic steatosis,,,,,during the last 2 months|gained,>130bmp,,,,,,
12371,,chronic itching,,,,collagens);|urine protein,,,,,within 1 year before receiving the experimental drug treatment;|those who have previously received,365-545 days,,,,,,
12372,,retrograde nail,,,,nephrostomy,,,,,in the past 6 months|currently,≥1000/μl,,,,,,
12373,,glucocorticoid-induced myopathy,,,,cabg surgery,,,,,for at least 1 month can be,< 6 dpt.||inclusion criteria,,,,,,
12374,,her2 expressed breast,,,,line of chemotherapy,,,,,prior to screen work,<37.3°,,,,,,
12375,,drug|positive urine test for heroin,,,,allogeneic stem cell transplantation||for participants,,,,,within 12 weeks of screening|any change,maximum of 1 target occlusions,,,,,,
12376,,inhalation,,,,placement of transducer arrays|patients,,,,,more than 6 units/month,equal to or lower than ≤ 1+,,,,,,
12377,,perimenopausal,,,,immunosuppressive therapy|prior exposure,,,,,during the time of the study,>1.5 before surgery|pre-operative,,,,,,
12378,,ptsd checklist,,,,t-dm1.|symptomatic central nervous system (cns) metastases,,,,,within 60 days prior to or on day 1,less than 5 diopters|npdr levels,,,,,,
12379,,posterior reversible encephalopathy syndrome,,,,revibe technologies,,,,,within the last year|patient,2-2.5 mm|levator,,,,,,
12380,,parasitic pneumonia.|sustained,,,,teratogenic study drug,,,,,within 3 years of,=< 1|platelets,,,,,,
12381,,cyclosporine eye-drops 6weeks,,,,total hospital costs can,,,,,for 180 days following the last dose for females,above 1000 m,,,,,,
12382,,intraductal carcinoma,,,,ivcm|decreased corneal,,,,,within 14 days before the first dose of the study drug,>= 50% of predicted value,,,,,,
12383,,ureteric stricture,,,,surgery.||previous surgery,,,,,less than 4 weeks before the study medication,m184v/i,,,,,,
12384,,ago|no chronic pain condition,,,,yukon choice flex stent,,,,,within half a year,=< 1.5 x uln|activated,,,,,,
12385,,good communication skills,,,,treatment for amblyopia,,,,,prior to randomization note: there may also,0-1;||the main organs function well,,,,,,
12386,,visits||-||,,,,barrier method from initial drug administration until 90 days after the last dose of study drug.|ability to understand,,,,,within 6 months before the screening visit.|participants,"<45 ml/min/1,73m²|pregnancy",,,,,,
12387,,α-thalassemia hemoglobin h,,,,implant insertion,,,,,within 14 days (inclusive) before the screening;|have undergone any,between 20,,,,,,
12388,,optic nerve diseases,,,,bone marrow primordial cells,,,,,within 4 weeks after being diagnosed;|progressive aggravation of jaundice,>30kg||adequate normal organ,,,,,,
12389,,acute kidney injury,,,,psychosocial intervention targeting similar,,,,,within the past two years|history,< 60 ml/min/bsa.|diagnosed,,,,,,
12390,,muscle strain,,,,age|hospitalized,,,,,within 7 days prior to the first dose of study,between 18-40 years.|normal husband,,,,,,
12391,,acute limb edema,,,,sd-oct)|mean foveal thickness,,,,,within 14 days before randomisation;|presence,> 60ml / min|lvef,,,,,,
12392,,+ t cell count,,,,total treatment,,,,,within 6 months prior to treatment,≤ 7 g/dl|hepatosplenomegaly|patient,,,,,,
12393,,breast cancer|unable,,,,pons,,,,,within 4 weeks before enrollment|history,>70%,,,,,,
12394,,covid-19 acute,,,,test instructions|medical contraindication,,,,,at the time of the first dose of study treatment.||current evidence,above 35|research-related,,,,,,
12395,,ductal adenocarcinoma of,,,,oral intubation,,,,,at least 3 prior mm treatment lines of therapy,>/= 18 years,,,,,,
12396,,affect cardiac function,,,,continental u.s.,,,,,in the past 3 days followed by 100 mg/die per os).||,≥ 1.5 x 109/l,,,,,,
12397,,thyroid issues,,,,acute treatment,,,,,within four weeks prior to enrollment,400 ml or more,,,,,,
12398,,quadriplegic cp,,,,genitourinary surgery,,,,,medical plan,≥4 times/week,,,,,,
12399,,uncontrollable diseases,,,,reactivation,,,,,within 2 years prior to check in.|use,= 150 ml of,,,,,,
12400,,keratinized gingiva crestally,,,,nodules|segmentectomy,,,,,1 month prior to first immunization continuously until 3months after boost immunization.|in the investigator's opinion,18+ years.|understands danish or english,,,,,,
12401,,acute lower limb infections,,,,ecg review,,,,,after initial treatment for,greater than or equal to 75 kg|signed,,,,,,
12402,,glioblastoma outside,,,,axillary temperature,,,,,in the last month),over 300 pounds,,,,,,
12403,,localized treatment,,,,12 hour wash-out,,,,,within the past three-years,ldh|age 19-69 years|presence,,,,,,
12404,,pain condition,,,,cellular therapy,,,,,within 12 months before consent,> 180/110|known,,,,,,
12405,,species,,,,corticosteroids therapy,,,,,more than 30 days,> 28 pmol / l,,,,,,
12406,,symptomatic covid-19,,,,allogeneic hematopoietic stem cell transplantation.|existence,,,,,during the study period and within 6 months after the end of the study,≥18 years|patients giving their consent for the,,,,,,
12407,,sti,,,,chest cardiac surgery,,,,,in the past 3 months.|use,less than 45 mm hg or more than 70 mm hg before,,,,,,
12408,,hidradenitis suppurativa||,,,,period|anticoagulant therapy,,,,,at least 15 days before inclusion|patients,40-60 years,,,,,,
12409,,tibial pilon,,,,lymphoma treatment,,,,,after neoadjuvant therapy surgery,<140/90 mmhg|for,,,,,,
12410,,mechanical neck discomfort,,,,t3~4an+m0,,,,,during study duration|history of,>75%)|those,,,,,,
12411,,cute ischemic stroke,,,,psychological treatment,,,,,at least 28 days prior to study vaccine application,≥ 18 years and 24-hr uca,,,,,,
12412,,vertigo.|no pathology,,,,digestive surgery,,,,,within 3 months prior to enrolment|the patient,5.7-6.4%,,,,,,
12413,,lumbar disc herniation through,,,,autologous stem cell transplant|patient,,,,,within 14 days before screening）||adequate hematological function,score of 25 points,,,,,,
12414,,partial dihydropyrimidine dehydrogenase deficiency,,,,criteria:||bilateral foveal loss,,,,,during the 6 months following the end of treatment,>=20 mm,,,,,,
12415,,cough of blood,,,,brain mri allowing,,,,,in year one,18 to 35 kg/m2,,,,,,
12416,,brain injury|presence,,,,pet-ct images,,,,,in the month prior to screening.||subject,4 mm,,,,,,
12417,,disability|sustained organ damage,,,,organ transplants,,,,,in the past 1 month|patients,27-45 years,,,,,,
12418,,kidney failure,,,,adequately treated|allergen immunotherapy,,,,,over six hours,=< 6 months prior to,,,,,,
12419,,pml|myocardial infarction,,,,bariatric surgery|patient,,,,,within 1 weeks before the start,test|tilt table,,,,,,
12420,,urinary disorders,,,,booths,,,,,prior to performance of any study-specific,12 years,,,,,,
12421,,regular cheese,,,,endotracheal intubation.|contraindication to,,,,,within the 4 week period prior to screening,less than 60%,,,,,,
12422,,"neuropsychiatric disorders,|gastrointestinal tract eosinophilic disorders,|use",,,,curative therapy,,,,,within 28 days of enrollment|crc participants,< 12 months|contraindication,,,,,,
12423,,renal transplantation|the investigator believes,,,,spine surgery|spinal hernia|spondylolisthesis|spinal infections|severe spine deformities|neural diseases|upper,,,,,within one month of enrollment|currently,50-60 gy,,,,,,
12424,,metastatic lesions,,,,pace-maker,,,,,after the onset of post-covid symptoms,≥ 14 units,,,,,,
12425,,involvement of the skin,,,,allogeneic hematopoietic stem cell transplantation.|participation in another clinical study,,,,,within 4 weeks prior to the prestudy,less than 500cc/24h,,,,,,
12426,,adverse risk factors,,,,trachea-oesophageal,,,,,at 34 weeks 0 days to 36 weeks 5 days of gestation,grade 2 or above cardiac insufficiency,,,,,,
12427,,sperm donation,,,,sternotomy||,,,,,within 30 days after receiving the study,inpatients|age ≥ 18,,,,,,
12428,,local abnormalities,,,,tobacco use,,,,,within the last 12 months;|have,>50% of the,,,,,,
12429,,cerebrovascular event/stroke,,,,structural magnetic resonance imaging,,,,,at time of screening|self-identifying,≥65 years old,,,,,,
12430,,autoimmune hemolytic anemia,,,,open ductus,,,,,within two weeks before randomization|patients,>10 mg daily,,,,,,
12431,,hypercoagulability,,,,antiretroviral therapy,,,,,up to 1 month before the start of the study treatment,18 years old or older|histologically,,,,,,
12432,,bone substance,,,,lymphadenectomy|surgical piece management,,,,,during study and,≤ 140 beats/minute,,,,,,
12433,,refractory anemia).|qtc,,,,etc|enrollment,,,,,within the past month.|lacked a history of neck,more than 18 years|previous eye surgery|current eye infection,,,,,,
12434,,rheumatic immune system disease,,,,dermatoscopy,,,,,for at least 3 months since completion of prior treatment.||pre-registration,children.|4-6 years,,,,,,
12435,,local covid-19 protocol|any condition,,,,normal pre-stimulation ovarian reserve,,,,,within 28 days before the first dose;|wounds,above 37,,,,,,
12436,,nava,,,,apical bone.||,,,,,for 7 days preceding the lab,prior to 27 weeks,,,,,,
12437,,extrapulmonary focus|acute pulmonary embolism,,,,axillary temperature≤37.0℃.||,,,,,within 7 days before the day,less than 1 year|unable,,,,,,
12438,,lvo,,,,complex chd,,,,,within 1 year prior to screening,25 to 40 years,,,,,,
12439,,cohort 1a):||subjects,,,,organ malignancy|transplant,,,,,at time of presentation on the day of surgery|lower respiratory tract infection|congenital heart diseases|known hypersensitivity,≥ 450 ms,,,,,,
12440,,tumor stability score,,,,stent,,,,,within 14 days prior to step 2,less than one year|patients,,,,,,
12441,,ependymoblastoma,,,,lung transplant list,,,,,within 28 days before study drug,=< 11,,,,,,
12442,,sarcoidosis,,,,intra-arterial thrombolysis.|detection of,,,,,pre-inclusion history,"≥ 1,000/μl|hemoglobin",,,,,,
12443,,heamturia,,,,fresh tumor biopsy collected on day 1 of treatment,,,,,in the past 3 months|unable to understand the questionnaire,stage 1,,,,,,
12444,,muscle imbalance,,,,inhaled glucocorticoid therapy,,,,,within 2 weeks before the first dose；|immunomodulatory drugs,child older than 36 months|parent,,,,,,
12445,,advanced biliary tract cancer,,,,posttraumatic amnesia,,,,,during the study period|allergy to collagen,score of 4,,,,,,
12446,,hysterectomy,,,,voluntary,,,,,within 2 weeks prior to treatment,over 90 mmhg,,,,,,
12447,,exertional malaise,,,,treatment for infection,,,,,within the 12 months,greater than or equal to 18 years.|able and willing to follow instructions,,,,,,
12448,,acromioclavicular joint osteoarthritis,,,,injection/endoscopic mucosal resection,,,,,within the 30 days,>25 and <35 kg/m2)|inactive,,,,,,
12449,,infectious bone defects,,,,corneal thinnest pachymetry,,,,,at the time of the signature of icf;|3 to 10 rating,greater than [>] 40 kilograms per meter square [kg/m²,,,,,,
12450,,in situ cervical carcinoma,,,,non-emergent,,,,,within 28days prior to screening,greater than 75 minutes/week of vigorous physical activity)|support team,,,,,,
12451,,upper tract urothelial cancer,,,,health commission of the people's republic of china,,,,,for at least 3 months after the last study drug,≤ 2|9f,,,,,,
12452,,convulsions,,,,radiographic dislocation,,,,,more than 6 months prior to full study screening,< 11,,,,,,
12453,,bilateral lung disease,,,,botox injection,,,,,within past 90 days|myocardial infarction,≥ 90 g/l.|liver,,,,,,
12454,,sensitization,,,,phenoxyethanol,,,,,during enrollment of any chronic pain,0 to 2.||patients,,,,,,
12455,,nasal o2,,,,medication|history of head,,,,,over 7 days,at least 3 months||participants,,,,,,
12456,,brain trauma.|evidence,,,,left ventricular dilatation,,,,,following criteria:||blood routine examination standards,18-65 years old,,,,,,
12457,,ulcerative diseases,,,,test of illicit drugs,,,,,for at least 4 weeks before initiation of our study|psoriatic,= alanine aminotransferase ast,,,,,,
12458,,traumatic pancreatitis,,,,oura smartring,,,,,within the last 12 months.|capable of giving informed consent|on,> 140/90 with,,,,,,
12459,,gi disease,,,,gastric banding|current participation,,,,,within next 12 months|severe visual,extremely,,,,,,
12460,,trying to conceive.|high alcohol consumption,,,,immunocellular therapy,,,,,prior to randomization.|participants,≥ 160 mg/dl||ix,,,,,,
12461,,extensive family,,,,local regional treatment areas,,,,,during the investigation|is,≥moderate,,,,,,
12462,,generalized cervical,,,,neoadjuvant chemotherapy,,,,,in the 4 weeks prior to enrollment,18 years or over||,,,,,,
12463,,germ cell tumor,,,,chest computed tomography scan (ct-scan).|moderate,,,,,at least 20 years,≥100 mmhg,,,,,,
12464,,fossa mass,,,,cholesterol drug treatment;|elevated triglycerides,,,,,within six months prior to enrolment|recent unsuccessful pci,1 of 2 criteria,,,,,,
12465,,stk11|men,,,,immunological alterations,,,,,during surgery|patient's refusal,>400,,,,,,
12466,,to hypogonadism,,,,"""",,,,,injectable.|sexual abstinence,"<1,500 / microlitre",,,,,,
12467,,autoimmune pathologies,,,,periorbital oculoplastic surgery,,,,,within 4 weeks before the first medication,> 120 mmhg)|tachycardia,,,,,,
12468,,organs,,,,psychotropic medication|insufficient german language skills,,,,,in the next 13 months,under 18;|living,,,,,,
12469,,cervical cancer in situ,,,,therapeutic doses of,,,,,within 1 week of dosing|exposure to,≥125 nmol/l,,,,,,
12470,,autism spectrum,,,,"mechanical ventilation,|not",,,,,last half year|high restrained eater,+/- combination abiraterone,,,,,,
12471,,rheumatoid arthritis||exclusion related to tuberculosis (tb):||active tb,,,,apical periodontitis.|radiographic,,,,,at the investigator's discretion.||note,≥ 10 points,,,,,,
12472,,renal impairment|anomalies,,,,magnetic resonance imaging for those patients,,,,,during the treatment；|had big,"125,000 to 500,000/microliters.|alanine aminotransferase",,,,,,
12473,,distant metastases n0m0.|mri visible tumor,,,,,,,,,at least 2 weeks before the first dose,≥10 mmhg,,,,,,
12474,,cm)|pregnant,,,,,,,,,within 6 month prior to the start of the study|having,>= 12 months prior to screening,,,,,,
12475,,wegener's granuloma,,,,,,,,,within 3 months prior to enrollment.|severe cardiovascular,<800 cells/yl|cd4,,,,,,
12476,,causing dry eye,,,,,,,,,within the past year,over 18 years old|agree to participate and sign the informed,,,,,,
12477,,dementia)|lack,,,,,,,,,within one month,mild dementia;|memory decline,,,,,,
12478,,occasional assistance,,,,,,,,,within the last 12 weeks,3-10 ng/ml|if,,,,,,
12479,,antibody||exclusion criteria,,,,,,,,,throughout their participation in the study|values of the complete blood count,2)|between 18,,,,,,
12480,,rebound nasal congestion,,,,,,,,,while on study|may use topical products,not,,,,,,
12481,,language,,,,,,,,,throughout study participation until 90 days after the last ip dose.||note,> 5 times the half-life of the agent,,,,,,
12482,,irrs,,,,,,,,,during study treatment.|history,<3.0 grams per deciliter,,,,,,
12483,,acute dyspnea||,,,,,,,,,within 4 weeks of investigational agent injection.|active infection,≤ 2.5x the upper limit of normal,,,,,,
12484,,recurrence survival rate,,,,,,,,,within the past 3 years.|has,greater than or equal to 2°||,,,,,,
12485,,learning disability,,,,,,,,,within a week,0 or 1||haematological,,,,,,
12486,,esophageal strictures,,,,,,,,,within 48 hours.|women,greater than 33°,,,,,,
12487,,cardiogenic cerebral,,,,,,,,,pre-operatively,"≤ 2,000/mm3",,,,,,
12488,,prolonged qt interval syndrome,,,,,,,,,after 34 weeks,20-89,,,,,,
12489,,other diseases of the cardiovascular system,,,,,,,,,within 4 weeks of the first dose.|excessive smoking,< 20 ng/ml|active,,,,,,
12490,,affect outcome measures,,,,,,,,,within previous 2 years,>140mmhg,,,,,,
12491,,any eye condition,,,,,,,,,within 24 hours before taking study medication.|hepatitis b surface antigen hbsag positive.|hepatitis,less than 30 minutes||,,,,,,
12492,,associated cervicobrachialgia,,,,,,,,,in last 3 months,≥7.5% and ≤11.5%,,,,,,
12493,,lack of communication,,,,,,,,,within the six weeks prior to enrolment|emergency surgery,>25|binocular visual acuity,,,,,,
12494,,visit 2)|unable,,,,,,,,,within 3 months prior to screening.|patient,between 40-60 years,,,,,,
12495,,endometriosis cyst,,,,,,,,,within 30 days before the trial.|receipt of any dose of a coronavirus disease 2019,between 15 and 55 years old;||for,,,,,,
12496,,adenosquamous,,,,,,,,,at the time of the baseline visit:||corneal astigmatism,> 3.0 x upper limit of normal (uln),,,,,,
12497,,oedema|uraemic complications,,,,,,,,,prior to the,more than once,,,,,,
12498,,non-childbearing potential - should,,,,,,,,,at least 90 days prior to screening,above the upper limit of normal,,,,,,
12499,,herpes simplex virus keratitis,,,,,,,,,exist three months after radiotherapy,< 2.5 x uln,,,,,,
12500,,rheumatologic disease,,,,,,,,,within 30 days before informed consent.|subjects treated,> 21 units,,,,,,
12501,,varus,,,,,,,,,attending the first to the third year,> 1000 g / l,,,,,,
12502,,hsd,,,,,,,,,at the time of signing the informed consent form,≥ 3.0% of baseline,,,,,,
12503,,morgan,,,,,,,,,in the last 6 months|bisphosphonate,14 to75 years,,,,,,
12504,,lung fibrosis,,,,,,,,,at the time of signing the icf;|able to understand the study procedures,> 3-times the upper limit of normal (uln),,,,,,
12505,,soft tissue injuries,,,,,,,,,within 4 weeks prior to screening|anticipated initiation,> 70 mmhg,,,,,,
12506,,c40x,,,,,,,,,at the time of intervention.|documented bacterial prostatitis,< 35%|moderate,,,,,,
12507,,chronic obstructive pulmonary disease.|clinically,,,,,,,,,within 1 day of the fovea of the macula.|oct examination,< 142||at least 2,,,,,,
12508,,pulp involvement,,,,,,,,,for at least 3 months before inclusion,< 1.5 times the upper limit of normal value,,,,,,
12509,,infection.|meets septic shock,,,,,,,,,within 4 weeks before administration of investigational product,≥ 12 years and < 18 years,,,,,,
12510,,lower limb trauma,,,,,,,,,"at the time of consent.|histological, cytological",> 6.5%.|abnormal,,,,,,
12511,,alcohol abuse|suspected delayed gastric emptying,,,,,,,,,within 60 days prior to study entry,between 50 and 80 years,,,,,,
12512,,facial trauma.|neurological,,,,,,,,,for at least 4 weeks prior to the screening period and should,"between 40 to 100 bpm, inclusive",,,,,,
12513,,pseudoxanthoma elasticum,,,,,,,,,within 14 days prior to treatment,>18 and <65 years;|negativity,,,,,,
12514,,meditation,,,,,,,,,within 7 days before screening;|vaccinated,30% female||at least 1/10,,,,,,
12515,,resected,,,,,,,,,at the time of the first ip bolus,7.0 -,,,,,,
12516,,digital subtraction (ds),,,,,,,,,within the next 30 days|must,between 160 and 195,,,,,,
12517,,vape,,,,,,,,,during study treatment.|active,> 3 times the upper limit of,,,,,,
12518,,reducing psa,,,,,,,,,during study participation;|willing to and,requires referral,,,,,,
12519,,corticosteroid therapy.|active malignancy,,,,,,,,,at the time of recurrence of disease.|participants may have,18-40 years|postpartum,,,,,,
12520,,cerebrovascular accident,,,,,,,,,at least 1 additional,less than two mature,,,,,,
12521,,acute psychiatric condition,,,,,,,,,prior to injection of icg,≥ 24,,,,,,
12522,,fluorescence in situ hybridization；|the,,,,,,,,,within at least 12 weeks after the last dose,>40 ml/min,,,,,,
12523,,recovered adequately,,,,,,,,,within 4 weeks of enrollment,0-1.|male,,,,,,
12524,,native language,,,,,,,,,within 30 days prior to screening|any concurrent,> upper limit of normal]|alanine aminotransferase (,,,,,,
12525,,primary tumor,,,,,,,,,within 4 weeks prior to screening.||any of the topical treatments defined below,<50 ml/minute,,,,,,
12526,,unstable angina pectoris,,,,,,,,,within 28 days prior to registration,"over 18 years old,|for patients",,,,,,
12527,,infections of the skin,,,,,,,,,at the time of randomization|onset,18 years or more||criteria,,,,,,
12528,,accommodation|good general,,,,,,,,,within 1 week prior to randomization.|have adequate organ function.||,≥200 mm hg,,,,,,
12529,,etc.)|child impairments,,,,,,,,,during the study period|participants,> 115 mm hg,,,,,,
12530,,acute event,,,,,,,,,in the past 2 years or|at least one,≤ 3.0×uln*,,,,,,
12531,,history;|lactose intolerance,,,,,,,,,within the first 10 days.|patient,longer than 450,,,,,,
12532,,-naïve|hbeag,,,,,,,,,within 42 days prior to initiation of study treatment,18-80 years|chronic,,,,,,
12533,,inflammatory bowel disease)|acute gastroenteritis,,,,,,,,,at least 3 months||all of the following,more than 40 or|bmi,,,,,,
12534,,etc.);|food allergies,,,,,,,,,within 4 weeks prior to the enrollment,< that,,,,,,
12535,,asthma unit,,,,,,,,,within 28 days prior to the first dose of study treatment.||criteria for the ribociclib,30 percent,,,,,,
12536,,muscle groups)|screen failure,,,,,,,,,within 12 weeks of assessments,18 years or older.|subjects,,,,,,
12537,,hand joint pain,,,,,,,,,within the last 6 months.|acute bacterial,≥ 155 meq/l,,,,,,
12538,,attempt,,,,,,,,,within 12 months after enrollment.|inability to comply with study,18 to 75 years||,,,,,,
12539,,recovered from the toxicity,,,,,,,,,more than 3 times the upper limit of normal,12 to 17 years inclusive,,,,,,
12540,,obstructive diseases,,,,,,,,,within 30 days prior to the start of study drug administration,<5mm,,,,,,
12541,,echocardiogram|myocardial infarction,,,,,,,,,in the 12 months prior to enrollment.|demonstration of,at least 36 weeks gestation.||,,,,,,
12542,,rhegmatogenous retinal detachment|retinal redetachment,,,,,,,,,at time of consent.|subject,< 60 years,,,,,,
12543,,c-section,,,,,,,,,within 1 month of randomization|any significant,>= 3 adverse events,,,,,,
12544,,non-nicotine substance,,,,,,,,,within 45 days prior to screening,≥ 18 years|chief,,,,,,
12545,,upper extremity sensation,,,,,,,,,in the last 3-6 months,≥1.0 × 109,,,,,,
12546,,crlf2 f232c,,,,,,,,,within 7 days and,> 2).||,,,,,,
12547,,binocular intensity myopia,,,,,,,,,hygiene|poor,"≥ 1,500/mm3|platelets",,,,,,
12548,,biliary tract obstruction,,,,,,,,,in the last 2 weeks|use of current,i or ii adult,,,,,,
12549,,acute febrile,,,,,,,,,in the past 6 months|severe lung disease,≤ 470 ms,,,,,,
12550,,recurrence through,,,,,,,,,within the previous 12 months|contraindications,< 0.5×109/l|platelet count,,,,,,
12551,,stool softeners,,,,,,,,,48 hours prior to scintigraphy|anti-cholinergic,within past,,,,,,
12552,,cutaneous vasculitis,,,,,,,,,in the past 36 hours|upper or,>99.5 °f/ 37.5 °c,,,,,,
12553,,autonomic dysfunction,,,,,,,,,in the past 6 months|clinical,">= 1,000/mm^3.||(g-csf",,,,,,
12554,,medication overuse headaches.|changes,,,,,,,,,during the 3 years of the study they,<45;|hga1c.>8.0%|history,,,,,,
12555,,non-native english speaking,,,,,,,,,within past 6 months)|patients,≤ 1.5 x uln|alanine aminotransferase,,,,,,
12556,,arterial thrombosis.|iga deficiency,,,,,,,,,in the terminal stage,<14 ml/kg/min|exercise tolerance,,,,,,
12557,,vitreomacular adhesion,,,,,,,,,during the index operation,> 10)|use of,,,,,,
12558,,rhinitis/rhinoconjunctivitis,,,,,,,,,within 14 days before randomization,<18 years|acute myocardial infarction,,,,,,
12559,,pgt,,,,,,,,,for the past 6,permanently,,,,,,
12560,,cultures,,,,,,,,,within 52 weeks prior to randomization.|hiv-infected,maximum three times per measurement)|been informed of the nature,,,,,,
12561,,down syndrome)|cast,,,,,,,,,for at least 1 year,between 16-30 years,,,,,,
12562,,uncontrolled dm,,,,,,,,,last two months,score of ≥ 28*||the adhd-rs-5 score,,,,,,
12563,,cognitive conditions,,,,,,,,,within 1 year prior to initial medication,≥ 2 times the upper limit of normal,,,,,,
12564,,asa i).||patients,,,,,,,,,during at least 8 weeks prior to randomization,≥ 38°c,,,,,,
12565,,wegener's syndrome,,,,,,,,,in the past 24 hours,> or = 2.5 ml,,,,,,
12566,,gastrointestinal tumors,,,,,,,,,prior to any study procedures,> 12 and < 35 years,,,,,,
12567,,meopa|nasal breathing disorders,,,,,,,,,within one year after the completion of the trial,≥129 g/l,,,,,,
12568,,labyrinthine function,,,,,,,,,at least 1 month prior to study,25-50 kg/m2)|on stable regimen,,,,,,
12569,,follicular,,,,,,,,,within 56 days prior to baseline|self-report,> 200 mmhg,,,,,,
12570,,victims of abuse,,,,,,,,,before surgery: for this study,> or = 18 years||at,,,,,,
12571,,uncontrolled hypertension,,,,,,,,,within 5 days prior to the first dose of study will also,≥12%,,,,,,
12572,,breast-feeding.||participants,,,,,,,,,within two weeks prior to period i,≥ 1000 cells/mm3,,,,,,
12573,,stroke attack,,,,,,,,,within the past 90 days before screening,>480 ms,,,,,,
12574,,peripheral artery disease,,,,,,,,,during the study period||the third part,18-85|limited,,,,,,
12575,,psychological disorders.|localized infection,,,,,,,,,throughout their participation in the study considering their strict following,≥ 103 copies/ml,,,,,,
12576,,antibiotics|chronic obstructive pulmonary disease exacerbation,,,,,,,,,at least 1 of the 5 items on the pec,between 1st january 2019 and 30th september 2022.||,,,,,,
12577,,poems syndrome,,,,,,,,,at least 3 months before the screening visit;|hba1c 7.5-11.0%,not <1.5 cm,,,,,,
12578,,secondary stuttering.|language impairment,,,,,,,,,"in the last month,|use",> 10mmol/l);|severe,,,,,,
12579,,coexisting neoplasms,,,,,,,,,within 30 days of the first dose of study treatment,19.0-24.9 kg/m2|age,,,,,,
12580,,metabolic abnormality,,,,,,,,,current time per standard of,4-12,,,,,,
12581,,amyloidosis|known hiatal hernia|known gallbladder and choledochal stone,,,,,,,,,during the trial.|have,≥ 3 months.||exclusion criteria,,,,,,
12582,,pc,,,,,,,,,at the time of enrollment.|total brain metastases,< 2 mmol/l|no,,,,,,
12583,,cardiomyopathy)|pulmonary comorbidity,,,,,,,,,in the next 6 months|deep vein thrombosis,20-40 year,,,,,,
12584,,open bite,,,,,,,,,at the time of the polysomnography done within 3 months)||,18 years and older when signing the icf.|subjects,,,,,,
12585,,sick sinus syndrome,,,,,,,,,longer than 2 weeks;|(4,< 150 mmhg|mechanical ventilation,,,,,,
12586,,neurotoxicity syndrome,,,,,,,,,in the 3 months prior to enrollment;|a history,less than 2 ml,,,,,,
12587,,carotid,,,,,,,,,within 4 weeks prior to obtaining,> 1.5 times of the upper limit of normal,,,,,,
12588,,good general,,,,,,,,,within 2 weeks before starting treatment /dl,ii-iii,,,,,,
12589,,diabetes mellitus type,,,,,,,,,prior to concussion episodes|diagnosis,≥ 18|performance status,,,,,,
12590,,chronic constipation.|history,,,,,,,,,any time prior to randomization,"≥ 1,500/mm3|platelet count",,,,,,
12591,,nearby districts,,,,,,,,,within 3 months|neck disability index (ndi),50 kg;|willingness,,,,,,
12592,,poor urinary control,,,,,,,,,within 6 months before screening;|history,≤2.5x uln,,,,,,
12593,,ex-smokers,,,,,,,,,for 14 days after the last dose of the study drug,> 30|severe,,,,,,
12594,,non-hm,,,,,,,,,at any time during the pregnancy participating in eppicc,i-iii|able to understand and sign the informed consent document after the nature of the study,,,,,,
12595,,cyp3a4 inducer,,,,,,,,,at randomization,< 18 years|fibroids not accessible,,,,,,
12596,,traumatic head injury,,,,,,,,,in the past 12 months|no cannabis,≥ 10|age,,,,,,
12597,,complete joint replacements)|having a pacemaker,,,,,,,,,at the time of enrollment|severe organ failure,<12-months,,,,,,
12598,,pelvic endometriosis).||,,,,,,,,,within 7 days prior to sub-study registration,11-point scale,,,,,,
12599,,agnosia,,,,,,,,,at least 3 mm,>60ml/min,,,,,,
12600,,restrictive respiratory insufficiency),,,,,,,,,during the study.|administration of,above;|high,,,,,,
12601,,chronic kidney disease.|prior diagnosis,,,,,,,,,within the last 14 days.|subjects,less than 70%.|copd,,,,,,
12602,,judged by the investigator.|any previous,,,,,,,,,in the past 15 months,180-239 mg/dl,,,,,,
12603,,immunodeficiency:||congenital immunodeficiency,,,,,,,,,within the past 3 months.|primary,>= 1500/ul,,,,,,
12604,,systemic exposure.||male,,,,,,,,,6 months after the last dose,> 5||,,,,,,
12605,,contraceptive method,,,,,,,,,within 6 weeks prior the lymphodepletion.||treatment,18 - 65 years|a signed informed consent form must,,,,,,
12606,,idiopathic pulmonary fibrosis,,,,,,,,,in the past 6 months prior to study enrollment.|patients unable to take enteral medications,>= 27%,,,,,,
12607,,lactation;|neoplastic disease,,,,,,,,,planning to receive,= 3200 mg oral,,,,,,
12608,,amnestic-mci,,,,,,,,,at the time of dosing,55 - 85,,,,,,
12609,,maternal drug abuse|infant,,,,,,,,,throughout the study.|history of stomach,between 18-30 bmi.|participant,,,,,,
12610,,biochemically confirmed).||,,,,,,,,,within 30 days from screening visit,22-85 years inclusive,,,,,,
12611,,components thereof,,,,,,,,,within 28 days of treatment|any history,greater than or equal to 3|patients,,,,,,
12612,,difficulty cooperating,,,,,,,,,within 12 months|documented,basal,,,,,,
12613,,loss of appetite,,,,,,,,,after the last dose of the previous investigational,volunteer adult patient,,,,,,
12614,,crc copd-cb,,,,,,,,,within 12 months prior to qualifying liver biopsy,<11.1 g/dl,,,,,,
12615,,deep brain stimulators.|joint replacement,,,,,,,,,pre-syncope|blood pressure values,≤ 270 mg/dl|blood,,,,,,
12616,,acute respiratory infection,,,,,,,,,within the preceding 36 months.|long-term,≥ 5,,,,,,
12617,,cerebral embolic protection device (cepd),,,,,,,,,at screening and baseline,≥ 2 cm,,,,,,
12618,,type of condition,,,,,,,,,at least 7 months after the last administration of the drug,20 - 70 years,,,,,,
12619,,defibrillator implants.|alternative neurological disorders,,,,,,,,,at least two ip joints.|availability of,more than 18|women,,,,,,
12620,,normal sterile,,,,,,,,,while receiving prior,≥300 pg/ml,,,,,,
12621,,phonophobia,,,,,,,,,at screening.|history of angina pectoris,<30%|pregnancy|somatic,,,,,,
12622,,complications,,,,,,,,,in the last three months.|uncooperative patients,> 3+4,,,,,,
12623,,monocular blindness,,,,,,,,,within 14 days prior to start of the study treatment,> 5times,,,,,,
12624,,insignificant sinus bradycardia,,,,,,,,,at least 60 days,ii-,,,,,,
12625,,rest leg syndrome,,,,,,,,,within 30 days prior to the trial vaccine,1-2|straining|sense of incomplete evacuation|sense,,,,,,
12626,,copd)|kidney failure,,,,,,,,,during the 6 months before the screening visit;|an appendectomy,18 to 70 years|ability to read,,,,,,
12627,,length difference,,,,,,,,,within the past 4 weeks|have taken dietary supplements,at least 3 months.|a,,,,,,
12628,,non-cancer pain,,,,,,,,,for at least 6 months before entering the study,measurable,,,,,,
12629,,drug eluting stent||,,,,,,,,,within 3 months before administration of investigational product,"≥12 weeks,|low",,,,,,
12630,,non-invasive carcinoma,,,,,,,,,at the time of viral therapy.|other investigational medications,≤ 2.||adequate,,,,,,
12631,,cutaneous squamous cell,,,,,,,,,within 4 weeks of the first administration of the ip.|history of any,≥ 60 to 85 years|ambulatory individuals|written informed,,,,,,
12632,,her2+ breast cancer.|concomitant,,,,,,,,,during the first 6 months|patient,between 18 and 36 months prior to study,,,,,,
12633,,relapsed lymphoma,,,,,,,,,within 14 days before the first dose,> 150,,,,,,
12634,,nicotine use,,,,,,,,,planning pregnancy|any previous therapy,>15mg prednisolone/day,,,,,,
12635,,unsafe|denial of informed consent|participation in other clinical studies,,,,,,,,,emergency department,<70 ml/minute/1.73m2,,,,,,
12636,,true,,,,,,,,,during the last 2 years|presence of,≥ 0.2 g/dl,,,,,,
12637,,keratoconus)|corneal epithelial defect,,,,,,,,,at time of recruitment into the study,≤ 65%,,,,,,
12638,,1|active infection,,,,,,,,,ongoing relizorb study titled,<50 copies/ml,,,,,,
12639,,non-dm cause,,,,,,,,,at time of evaluation|use,>110 mmhg)|complete,,,,,,
12640,,oa.|patient,,,,,,,,,at day of enrollment|neck pain patient,"≤7%,",,,,,,
12641,,c.|positive test result for hiv,,,,,,,,,after treatment|patients,0 to 1;||sufficient,,,,,,
12642,,pulmonary edema|uncontrolled,,,,,,,,,at time of enrollment|diagnosis,between 21 and 35 years,,,,,,
12643,,recreational,,,,,,,,,in the past 2 weeks;|long-term,>9%)|patients,,,,,,
12644,,chronic illnesses,,,,,,,,,in 3 months after using hcq.||d. the initial date of taking,greater than 132.6µmol/l,,,,,,
12645,,pathologic myopia,,,,,,,,,at the time of consideration for study enrolment.|symptomatic brain metastasis,less than three oocytes,,,,,,
12646,,obstructive hydrocephalus,,,,,,,,,for at least three months post-onset|prescription,60-day,,,,,,
12647,,cosmetic,,,,,,,,,within 6 months prior to study drug,<1.03 mmol/l,,,,,,
12648,,head trauma (loss of,,,,,,,,,within 90 days prior to the administration of the ip,1.1 measurable disease,,,,,,
12649,,allogeneic hct,,,,,,,,,within 3 months prior to inclusion.||12,< 45%,,,,,,
12650,,sleep aids,,,,,,,,,for the last 12 months|use of,1:1 patient observation,,,,,,
12651,,drugs;|chronic diseases,,,,,,,,,within last 6 months.|cardiopulmonary resuscitated,≥4 and <16 points,,,,,,
12652,,chronic total occlusion,,,,,,,,,during the trial.|excessive alcohol use (,≥18 years;|anorexia,,,,,,
12653,,urinary,,,,,,,,,for 180 days after the last dose of study treatment.||11,greater than 5 μg/ml;|pao2 <65,,,,,,
12654,,postpartum hemorrhage,,,,,,,,,within the last 30 days.|active,> 3 months;|patients,,,,,,
12655,,pulmonary fibrosis;|uncontrollable pleural effusion,,,,,,,,,within the last 30 days.|current,equal to or exceeding 500 ml,,,,,,
12656,,congestive cardiac failure,,,,,,,,,more than the equivalent of 5,12-47 months,,,,,,
12657,,bleeding.|massive pericardial effusion,,,,,,,,,for at least six weeks,16 to 60 years.||,,,,,,
12658,,chest wall,,,,,,,,,at least 3 times in the cradle position,"18 years),|experience with frequency lowering,|hearing thresholds",,,,,,
12659,,myxoma,,,,,,,,,for at least 6 months after the last administration of study treatment|presence,no change greater than 0.5 diopter,,,,,,
12660,,medication;|no cognitive impairment,,,,,,,,,at least 2 confirmatory tests,ii or higher,,,,,,
12661,,hemorrhagic tendency(bleeding>30ml,,,,,,,,,one month or more,≥ 90g/l|serum,,,,,,
12662,,neurologic progression,,,,,,,,,at the screening/randomization visit|perceived stress scale,above the lower limit of detection);|allergic to any,,,,,,
12663,,deep water.|chronic pain,,,,,,,,,at trunk and lower extremities,1-2|being,,,,,,
12664,,metabolism;|active infections,,,,,,,,,within 7 days prior to initial administration,greater than or equal to the lower limit of detection of the assay,,,,,,
12665,,left bundle branch block.|patients,,,,,,,,,at the time of surgery,2-5 years,,,,,,
12666,,complete rotator cuff tear,,,,,,,,,within 48 hours before administration).|allergy to,> 120 ms.|supine,,,,,,
12667,,eligible|any other condition that,,,,,,,,,within the recent 6 months|any,less than 2000,,,,,,
12668,,~minimal neuropathy,,,,,,,,,during the study period.||other:||those,miu/ml,,,,,,
12669,,autoimmune disease|diabetes,,,,,,,,,in the past 1 day.|for,>= 180 days before screening|hba1c 7%-10%,,,,,,
12670,,university,,,,,,,,,within the study period for any of the joints,≥ 8.9 mmol/l,,,,,,
12671,,refractory hypertension.|people suffering,,,,,,,,,within 72 hours before administration of investigational product,>18yrs of age|pre-term babies|patients,,,,,,
12672,,aya:||type 1 diabetes diagnosis,,,,,,,,,at least 12 months before screening,≥ 18 and ≤ 60 years,,,,,,
12673,,residual symptoms,,,,,,,,,at the time of informed consent|body mass index (bmi,>565 mg/mmol,,,,,,
12674,,unexplainable sudden death,,,,,,,,,within 14 days before the first use of the drug;|with known,and 70 years,,,,,,
12675,,pivc,,,,,,,,,longer than 2 consecutive weeks,<95%,,,,,,
12676,,vascular compression,,,,,,,,,for the control of hodgkin,18 years old.||,,,,,,
12677,,transfusion dependence|patients,,,,,,,,,within 4 weeks prior to day 1 of cycle 1,4-10×109/l,,,,,,
12678,,mental health professional,,,,,,,,,prior to randomization per country guidelines.||ii,>14 years,,,,,,
12679,,congestive heart failure|unstable heart disease,,,,,,,,,at least 1 of the following,≥ 60 ml/min;|inr≤ 1.5,,,,,,
12680,,meulengracht's disease,,,,,,,,,within past 6,i-ii|hemodynamic stability||,,,,,,
12681,,inflammatory arthritic disease.|arthritis,,,,,,,,,for 12 months thereafter.||iii,>5 x institutional uln,,,,,,
12682,,craniocerebral injury,,,,,,,,,during this period.|subjects participating,ra criteria|being,,,,,,
12683,,tumor surgical resection,,,,,,,,,within two months prior to period i dosing,≤1.5-fold the uln of the study site|creatinine,,,,,,
12684,,high-quality embryos,,,,,,,,,within 12 weeks prior to,less than 19,,,,,,
12685,,deviations of the heart rate,,,,,,,,,during study period|patients,> 18 years and ≤ 75 years|8 screening laboratory values,,,,,,
12686,,myocardial injury,,,,,,,,,at least three months,≥ 100 mm hg,,,,,,
12687,,difference,,,,,,,,,within 8 weeks prior to informed consent,17.5 kg/m2,,,,,,
12688,,dizziness|patients,,,,,,,,,before the pes catheter,15 and 18 who go,,,,,,
12689,,primary sensitivities,,,,,,,,,at least 30 days before the administration of trial medication until 7 days after trial completion,90-100 bpm,,,,,,
12690,,cryolipolysis,,,,,,,,,within last six months,≥0.28 μg/ml,,,,,,
12691,,chronic hand eczema,,,,,,,,,at more than 2 lumbar levels.|patients,at least 5%,,,,,,
12692,,cns lymphoma involvement,,,,,,,,,within 30 days prior to diagnosis,≥100 x 109/l|serum bilirubin,,,,,,
12693,,marrow infiltration disorder,,,,,,,,,prior to starting treatment,≥ 100 x 10^9 /l;|haemoglobin,,,,,,
12694,,navina smart system,,,,,,,,,within 12 months of the study,≥ 15 µiu/ml,,,,,,
12695,,textured expander,,,,,,,,,within 1 week)|has received,above upper limit of normal value,,,,,,
12696,,squamous cell carcinoma of the skin|carcinoma in situ of the cervix|carcinoma in situ of the breast|incidental histologic finding,,,,,,,,,less than 6 weeks,17.5 to 30.5 kg/m2,,,,,,
12697,,passive rom,,,,,,,,,within 24 hrs of check-in,≤19 kg/m²,,,,,,
12698,,cervical carcinoma,,,,,,,,,within the last 6 months.|having,1.5 times more than the normal upper limit of creatinine|those,,,,,,
12699,,chemotherapy;|b-cell,,,,,,,,,at time of surgical repair|primary rrd repair,25-29.9 kg/m2,,,,,,
12700,,abdominal malignancies,,,,,,,,,prior to the bronchoscopy||,>10 times of upper limit of normal(uln,,,,,,
12701,,congenital respiratory disease.|children,,,,,,,,,in the past six months|previous spine,> 15 mm,,,,,,
12702,,major illnesses,,,,,,,,,within 15 days,prenatal,,,,,,
12703,,bone's tumors,,,,,,,,,within 1 week prior to day 0||active acute,< 60 mghg,,,,,,
12704,,gastromucosal,,,,,,,,,within 7 days prior to leukapheresis,≥ 3||,,,,,,
12705,,complex lumbar,,,,,,,,,within 2 weeks prior to initial administration,follows:||20 years old,,,,,,
12706,,progressive liver fibrosis,,,,,,,,,for 3 days,< 25 g/l,,,,,,
12707,,nsai treatment||,,,,,,,,,inhibitors||,<75 minutes/week,,,,,,
12708,,"bleeding diathesis|neurological disease,|bmi",,,,,,,,,at time of first assessment,>0 years,,,,,,
12709,,illness;|predisposition,,,,,,,,,within last 1 week|presence of mastitis|presence of,18 years - 60 years,,,,,,
12710,,right-handed.|we,,,,,,,,,within 14 days of day -5,≥0.5g/g,,,,,,
12711,,head,,,,,,,,,for at least 12 months,≥ 18;|primary,,,,,,
12712,,breast-,,,,,,,,,within 14 days)|parenteral nutrition|current,"≥ 100,000 per mm3.|serum",,,,,,
12713,,gastrointestinal motility|heart disease,,,,,,,,,in the past|need for,between 18,,,,,,
12714,,neoplasm,,,,,,,,,after prior standard therapy|no previous,likelihood,,,,,,
12715,,macadamia,,,,,,,,,before operation;|hysteroscopy,>12 weeks|willing and able to comply with all study requirements,,,,,,
12716,,imps,,,,,,,,,in the 4 weeks preceding any study intervention administration,between 18.5 to 29.9 kg/m^2 (inclusive),,,,,,
12717,,bladder.|active malignancies,,,,,,,,,within 30 days before surgery of either:||≤30%,35-60|volunteer to participate|not,,,,,,
12718,,unilateral adrenal lesions,,,,,,,,,during the study;|heavy drinkers,between 4-8 cm||,,,,,,
12719,,amblyopia|eye diseases,,,,,,,,,after 2 cycles,≤ 1.5 × uln.||evidence of,,,,,,
12720,,hypertrophy|ability,,,,,,,,,within 10 days for,> 0.90,,,,,,
12721,,greasy moss,,,,,,,,,within the previous 4 weeks;|the results of laboratory examination,≥7.0% to ≤10.5%|body mass index,,,,,,
12722,,gestational diabetes mellitus,,,,,,,,,during or,equal to or lower than 5,,,,,,
12723,,head-brain trauma,,,,,,,,,2 weeks prior to randomization;|sphingosine 1-phosphate receptor,≥80 years,,,,,,
12724,,neurologic disorder;|6.patients,,,,,,,,,for 3 months prior to or,18 - 80|english,,,,,,
12725,,unilateral vestibular hypofunction,,,,,,,,,completed 24 months of follow-up after surgery initial surgery.||,<2cm.||,,,,,,
12726,,chest drainage,,,,,,,,,within 6 months prior to the start of study intervention,less than 30 kg/m2||,,,,,,
12727,,mild illness,,,,,,,,,in the past 6 months.|history,vent/cpap|restrictive,,,,,,
12728,,score of:||14,,,,,,,,,within 14 days prior to study vaccine,less than 500 iu/ml before the first dose of study drug,,,,,,
12729,,second malignancies,,,,,,,,,continue until 6 months after the last dose of study drug,"≤12,000 u/d",,,,,,
12730,,passive kafos,,,,,,,,,during the previous sport,≤ 2.||both,,,,,,
12731,,non-hormonal birth control method,,,,,,,,,researcher|more than 2 self-reported,2 to 3,,,,,,
12732,,adverse skin condition,,,,,,,,,after surgery;|patient who signed an informed consent form to participate,>21 units per week,,,,,,
12733,,primary hyperaldosteronism,,,,,,,,,within 12 months from the end of last anti-her2 therapy.|measurable disease,≤ 2|histologically,,,,,,
12734,,psoriasis patches,,,,,,,,,for at least 4 weeks prior to screening)|pregnancy,≥ 18.0,,,,,,
12735,,hyposmia,,,,,,,,,within 3 months prior to screening.|participant,50-90 bpm|qtcf,,,,,,
12736,,non-proliferative,,,,,,,,,while on treatment.|patients who received,been advised to quit smoking,,,,,,
12737,,breast feeding.|active malignancy,,,,,,,,,within 2 weeks prior to the first administration of investigational,6.3.1)|older than 18 years,,,,,,
12738,,thought disorder,,,,,,,,,at the time of enrollment||member of a household that,65-80 years,,,,,,
12739,,large moles,,,,,,,,,before participating in the study,< 2.5 x uln|creatinine <1.5 x uln|life expectancy,,,,,,
12740,,autoimmune hyperthyroid disease,,,,,,,,,in the last 3 months||,7.0 to 11.0 g/dl,,,,,,
12741,,psychiatric disturbances,,,,,,,,,within 12 months prior to enrollment|history of,18 to 80 years|written informed consent of the participating,,,,,,
12742,,intestinal failure,,,,,,,,,prior to 4-5 cm,equal to or higher than 75×10^9/l,,,,,,
12743,,irregularity,,,,,,,,,least six months of healing after tooth extraction|adequate dimension of the attached gingiva,≥ 18 years|at least 1 hf,,,,,,
12744,,disease conditions,,,,,,,,,within 24 hours|failed,ranges from less than 40 years.|bmi < 35kg/m2.|normal,,,,,,
12745,,tapered off,,,,,,,,,at least 3 times per week|able to complete two hours of moderate,< 8.0 mmol/l,,,,,,
12746,,renal impairment.|compromised immune system.|acute episode,,,,,,,,,in last 90 days|presence,18.5-30 kg/m²|the,,,,,,
12747,,spinal anomalies.|intracranial,,,,,,,,,within 4 weeks prior to the start of pyx-106 treatment,score of ≥ 50%.||the,,,,,,
12748,,resected basal cell,,,,,,,,,for the duration of the study*||*effective contraception,score of 4+,,,,,,
12749,,systemic mast cell disease,,,,,,,,,during the trial|history of medical,19-29 kg/m2|amh,,,,,,
12750,,cto,,,,,,,,,48 hours after admission,>4.0 meq/l,,,,,,
12751,,non-alcoholic fatty liver disease,,,,,,,,,at the time of signing the icd,0-2|age,,,,,,
12752,,deep infection,,,,,,,,,at the time of planned vaccine,between 5 and 17|maximum,,,,,,
12753,,chronic gastrointestinal diseases,,,,,,,,,last dose of vaccine,<35 kg/m2|be cleared,,,,,,
12754,,epidermal growth factor receptor（egfr）-activating,,,,,,,,,within 4 weeks before the first dose of the investigational drug,≥ 18 and ≤ 75,,,,,,
12755,,non-reversible,,,,,,,,,within 56 days before the first dose of the investigational,0 ~ 2|resolution,,,,,,
12756,,surgically resectable disease,,,,,,,,,within the last 14 days of drug,150-189cm)|participants,,,,,,
12757,,respiratory muscles,,,,,,,,,"at least 6 hours before the procedure,|refusing to participate",group:||18-60 years-old|informed,,,,,,
12758,,cephalohematoma,,,,,,,,,within 1 week before surgery;|history of psychiatric disorders,more than 18,,,,,,
12759,,cerebral neoplasm,,,,,,,,,at least 4-5 months,between 18 and 32 kg/m2,,,,,,
12760,,exacerbation history：||at,,,,,,,,,within two weeks,at least 3 months;||,,,,,,
12761,,spontenous pregnancies|multiple,,,,,,,,,at the time of screening||individuals,≥50 ng/dl).|patients,,,,,,
12762,,specific plan,,,,,,,,,within 1 month prior to day 0,=< 3,,,,,,
12763,,electrolyte status)|sequential organ failure assessment (sofa),,,,,,,,,separated by at least 5 mm|volume of each lesion,>300μm,,,,,,
12764,,eye disorder,,,,,,,,,within 6 months prior to registration|significant vascular disease,greater than or equals to 8 mm,,,,,,
12765,,apparent success,,,,,,,,,within 48 hours before the first dose of the study drug,19 and 76 years,,,,,,
12766,,hip oa,,,,,,,,,within three months,≥ 18.5,,,,,,
12767,,sagittal split,,,,,,,,,at the time of signing the informed consent form (,between 4 years and 7 years.||mandibular second,,,,,,
12768,,photosensitivity|hypertrophic scars,,,,,,,,,for at least 6 months prior to the study.|concomitant use of,> 18 years old|patient able to understand,,,,,,
12769,,neck radiotherapy.|breast cancer,,,,,,,,,before 34 weeks of amenorrhea,< lln|hemoglobin < lln|any,,,,,,
12770,,hypotony,,,,,,,,,within 7 days prior to first dosing,0-1；|expect,,,,,,
12771,,multivessel coronary artery disease (cad),,,,,,,,,prior year,50 years|able to not,,,,,,
12772,,disease transformation,,,,,,,,,throughout the study period and up to 24 weeks after discontinuation||,between 11 and 17 years|adequate,,,,,,
12773,,regular drinking,,,,,,,,,within 1 month before and after ip immunization.|female,more than 6,,,,,,
12774,,brain metastasis enlargement,,,,,,,,,previous 5 years,< 18 years and > 45 years.|≥13 weeks of gestational age|multiple pregnancy|smoking|gastro-intestinal diseases,,,,,,
12775,,cervical intraepithelial neoplasia,,,,,,,,,within the previous 3 months|hemoglobin,<18 years old|temporary exclusion criteria,,,,,,
12776,,metabolic arthropathies,,,,,,,,,in the last 3 months.|rbc transfusion,adequate,,,,,,
12777,,vital prognosis,,,,,,,,,at least 6 months before screening,< 30 ml/min/1.73 m2|severe,,,,,,
12778,,systemic immune suppression.|requirement,,,,,,,,,at time of initial presentation,<16,,,,,,
12779,,macular degeneration (amd,,,,,,,,,during their hf hospitalization,≥ 18 years old;|at,,,,,,
12780,,solid organ dysfunction|patients,,,,,,,,,management within 90 days before screening|previous,greater than or equal to the upper limit of normal,,,,,,
12781,,cocoagulation disorder,,,,,,,,,within 7 days before enrollment.|12,below 30)|known,,,,,,
12782,,end-expiration,,,,,,,,,at least 2 times,> 15 mg,,,,,,
12783,,co-morbid condition,,,,,,,,,during the oral glucose tolerance test,<60 mmhg,,,,,,
12784,,dcis)/lobular carcinoma,,,,,,,,,at least 4 hours,younger than 15 years,,,,,,
12785,,normal result recorded,,,,,,,,,at least 3 out of 10,60 - 100 bpm)|had,,,,,,
12786,,arteriovenous bridging therapy,,,,,,,,,within 14 days prior to the first dose or need to continue treatment with strong cyp3a4 inducers/strong inhibitors,>3)|severely sarcopenic,,,,,,
12787,,antibody.||female,,,,,,,,,prior to start of therapy,"≤ 13,3 kpa)|fever",,,,,,
12788,,and||lack of proficiency in english,,,,,,,,,in the month preceding inclusion,for more than 3,,,,,,
12789,,fetal anomalies,,,,,,,,,past year.|ct colonography,compared to normative,,,,,,
12790,,gastrointestinal fistula,,,,,,,,,during the last 12 months prior to screening,euroscore ii < 9%|the,,,,,,
12791,,ige-mediated,,,,,,,,,in the previous 6 weeks,< 35 ml/min or|who,,,,,,
12792,,abstain from initiating evidence-,,,,,,,,,within 2 weeks of initiation of ttf|must,18-80 years.|bmi,,,,,,
12793,,randomization.|known allergies,,,,,,,,,before tace|tace combined with,18 - 40,,,,,,
12794,,vital sign abnormalities,,,,,,,,,in the past 6 months|had,between 8 and 14 years,,,,,,
12795,,migraine.|undergoing,,,,,,,,,within 6 months prior to screen/baseline,<3 months.|participant,,,,,,
12796,,chronic obstructive pulmonary disease exacerbation,,,,,,,,,outpatient clinic|volunteer||,35 years old,,,,,,
12797,,cerebral brain perfusion,,,,,,,,,for at least 4 weeks before the screening visit (standard treatment,least 50 to 80 years,,,,,,
12798,,resected basal cell carcinoma|severe,,,,,,,,,at the time of screening|patient with,≥ 2 diarrhea|presence,,,,,,
12799,,withdrawn from that study).|inability to provide informed consent,,,,,,,,,within 14 days before the first administration,"> 50,000|international normalized ratio",,,,,,
12800,,axillary temperatures,,,,,,,,,within the 3 months prior to enrolment|other intra-articular injections,< 75×109/l,,,,,,
12801,,early stage brest cancer|breast ptosis,,,,,,,,,at least 1 measurable,at least 50.0 and,,,,,,
12802,,sucralose,,,,,,,,,for less than three months|run at least five kilometers per week|have a score,4-6 weeks,,,,,,
12803,,impairment of lung function;|pleural effusion,,,,,,,,,previously been treated,score of ≤0.27,,,,,,
12804,,inhalers.|sleep apnea syndrome,,,,,,,,,within 2 weeks before the first dose of study drug,< 40 ml/min,,,,,,
12805,,developmental disorders than anxiety,,,,,,,,,within 2 years prior to day 1 of cycle 1|primary central nervous system,>10% of the area,,,,,,
12806,,borderline ovarian tumor.|non,,,,,,,,,within 7 days prior to through 28 days after trial vaccination,7 to 17 years|gp visit,,,,,,
12807,,age|not fluent,,,,,,,,,within 3 days after treatment.||,<18.|individuals who,,,,,,
12808,,tbc,,,,,,,,,at time of investigation,15 - 29,,,,,,
12809,,shock wave lithotripsy (swl),,,,,,,,,for the last 2 years||,less than 5 years,,,,,,
12810,,gastrointestinal diseases.||,,,,,,,,,during a,"95 mmhg,|50 bpm ≤ hr ≤ 100 bpm,|or value",,,,,,
12811,,pd)|informed consent||,,,,,,,,,1 week after the end of the study;|or who donated 400 ml,>130/90 mmhg)|intolerance,,,,,,
12812,,immunological disease,,,,,,,,,within 4 weeks before screening.|excessive smoking,less than 3 months.|the,,,,,,
12813,,respiratory comorbidity,,,,,,,,,in the last 3 months for safety,over 60,,,,,,
12814,,vegans).|pregnant,,,,,,,,,within the past 6 months;|receipt,≥ 14)||,,,,,,
12815,,thoracic radiation,,,,,,,,,in the past week,rif)|known,,,,,,
12816,,digestive condition,,,,,,,,,in the past month [> 4,≤500 mg/dl.|for,,,,,,
12817,,sensory neuropathy,,,,,,,,,in the past 3 months.)|- current,≥ 12 weeks from the time of enrollment|must,,,,,,
12818,,spinal disease|coagulopathies|pregnancy|vas pain level,,,,,,,,,within 3 months of study enrollment.|myocardial infarction,<18.5 or >30 kg/m2|chronic,,,,,,
12819,,k. pneumonia,,,,,,,,,at time of enrollment|aged,≥75 × 109/l||hemoglobin ≥9 g/dl||female,,,,,,
12820,,percutaneous ablations,,,,,,,,,last 15 months,≥ 50;||presence,,,,,,
12821,,chronic glomerulonephritis,,,,,,,,,before 6 months,0-1||has,,,,,,
12822,,upper respiratory tract obstruction;|obvious bullae,,,,,,,,,for 1 week or more,>110 mmhg,,,,,,
12823,,diabetes kidney,,,,,,,,,while indoors||serum,0-1;|child-pugh score,,,,,,
12824,,lambert-eaton myasthenic syndrome,,,,,,,,,within the 6 months prior to enrollment.|participant,less than 3 mm|smokers|patients,,,,,,
12825,,ctcae v5.0,,,,,,,,,prior to enrolment.|known,between 12-20 years,,,,,,
12826,,neurological disorders,,,,,,,,,between january 2022,50-80||,,,,,,
12827,,keratoconus（corneal stromal thinning,,,,,,,,,more than 1 year prior to the screening,greater than 5 times the upper limit of normal,,,,,,
12828,,local anesthesia.||,,,,,,,,,-5 times plasma half-life of roflumilast,0 or 1|for,,,,,,
12829,,encephalomyelitis,,,,,,,,,within 1 year before enrollment;|serious cardiovascular,at least 30 kg/m^2||health,,,,,,
12830,,compressive radiculopathy,,,,,,,,,within the previous thirty-six (36),≤ 24);|history,,,,,,
12831,,tissue disease,,,,,,,,,no higher than -0.75dc.|can,stage b,,,,,,
12832,,filariasis,,,,,,,,,in the past 5 years.|primary immune deficiency.|acute,≥18 years|women of childbearing potential,,,,,,
12833,,hemosiderosis,,,,,,,,,at least 1 month before dosing).||males,> 40 miu/ml,,,,,,
12834,,oh,,,,,,,,,"during the research process,|those who used any complementary",under 50 years,,,,,,
12835,,prolonged qtc,,,,,,,,,within 14 days prior to receiving study,>= 9 g/dl|hepatic:|total,,,,,,
12836,,anus,,,,,,,,,at screening.|known acute,>30 degrees|known,,,,,,
12837,,cancer of the esophagus,,,,,,,,,at least 4 months from the last drug administration prior to visit 1,+18 years,,,,,,
12838,,cardiomyopathy.|concurrent use of,,,,,,,,,in prior 30 days,above 3 x upper limit of normal (uln),,,,,,
12839,,measures,,,,,,,,,within the last 5 years|severe,18-50|scheduled,,,,,,
12840,,binocularity,,,,,,,,,within 28 days after their last dose.|subjects,> 30 miu/ml|male,,,,,,
12841,,anti-cancer chemotherapy,,,,,,,,,within 28 days before the first dose,less than 1 year;|older,,,,,,
12842,,those therapeutically induced,,,,,,,,,within 5 ears before the first dose of study,less than 10%,,,,,,
12843,,≤5x uln|creatinine≤1.5 x uln,,,,,,,,,in the next year,>20/min,,,,,,
12844,,mpo)|active,,,,,,,,,within 14 days prior to randomization|participants,> 10%|evidence,,,,,,
12845,,||-,,,,,,,,,more than 35|patients,score of 75,,,,,,
12846,,regular bowel,,,,,,,,,before the beginning of the study,5 mm or more,,,,,,
12847,,transient detectable viremia,,,,,,,,,within 14 days prior to enrollment.||white blood cell count,i to ii|scheduled,,,,,,
12848,,philadelphia chromosome (ph chromosome,,,,,,,,,at the time of signing the informed consent form for the study.|good general health,less than 4 weeks before the first administration of investigational,,,,,,
12849,,clinical apathy,,,,,,,,,within 3 months prior to screening.|coagulation,=< 6 months of registration|patients,,,,,,
12850,,thyroid preparations,,,,,,,,,at the time of the baseline visit.||a,≥ 19 years,,,,,,
12851,,intrabody ferromagnetic material,,,,,,,,,within 4 weeks prior to apheresis,< 60ml/min/1.73m2|diabetes,,,,,,
12852,,behavioral sleep problem,,,,,,,,,within 5 days prior to the first vaccination.|subjects,>2.|patients,,,,,,
12853,,organic abnormalities,,,,,,,,,at the time of screening|history,≥75 years,,,,,,
12854,,coccydynia,,,,,,,,,at screening and prior to dosing|bmi,<5.|cooperation and understanding to strictly comply,,,,,,
12855,,cholangiocarcinoma,,,,,,,,,within 3 months before administration of the study drug,20 years old.|primary,,,,,,
12856,,indications,,,,,,,,,until 1 month after full vaccination,=> 14 intunits/ml,,,,,,
12857,,deep functional areas,,,,,,,,,in the past 3 years.|current,<20% of total,,,,,,
12858,,genetic features,,,,,,,,,at least 5 days a week for at least 3 consecutive,< 110 mmhg,,,,,,
12859,,cardio-cerebrovascular disease.|history,,,,,,,,,within 14 days before treatment meet the following requirements:||anc≥1.2×109/l,≥ 5).|pregnant,,,,,,
12860,,alcohol abuse.|other diseases,,,,,,,,,within 30 days prior to dosing.|subjects,=< 150/90.|patients,,,,,,
12861,,additional diseases,,,,,,,,,within 14 days prior to initiating study treatment)||aspartate,> 2 weeks,,,,,,
12862,,high-quality cross-sectional imaging,,,,,,,,,cldn18.2;|a history,≥ 4/10)|currently menopausal,,,,,,
12863,,keloidal tendency,,,,,,,,,within 3 months before intervention,on <6 months prior to the study,,,,,,
12864,,wpw,,,,,,,,,past six month,less than 18 years.|surgery,,,,,,
12865,,nsclc.|spinal cord compression,,,,,,,,,for at 6 months after the administration of imp.||if,≥ 2+,,,,,,
12866,,sensitivity to the catheter device components,,,,,,,,,within the last 12 weeks|valvular atrial fibrillation,below 9.0 gm/dl,,,,,,
12867,,metastatic infection,,,,,,,,,unless,four-phase,,,,,,
12868,,respiratory diseases);|diseases,,,,,,,,,at the time of the first dose of study medication;|weight,>16 years old,,,,,,
12869,,antihistamines,,,,,,,,,within previous 3 months|chronic psychiatric disease,≥24 hours;|sedation,,,,,,
12870,,right to,,,,,,,,,in the past 6 months.||exclusion criteria,>500 ng/dl,,,,,,
12871,,normal)|v rarely burns,,,,,,,,,within 7 days||coagulation:|prothrombin time (pt,less than 75 years,,,,,,
12872,,syndesmotic injury,,,,,,,,,at the time of trail entry,> 1cm,,,,,,
12873,,hypnotic properties,,,,,,,,,at the time of index,>130 systolic,,,,,,
12874,,communication ability||will use,,,,,,,,,at least 3 years||female subjects,> 60mm/hour,,,,,,
12875,,ventricular lymphoma,,,,,,,,,for three months after completing,>18 years.|patients must not,,,,,,
12876,,infective treatment;|allergic constitution,,,,,,,,,prior to treatment|expected survival,50 to 85 (inclusive),,,,,,
12877,,macroscopic residual disease,,,,,,,,,at least three injections,< 2 x uln|total bilirubin < 1.5 x uln|serum,,,,,,
12878,,payment coverage,,,,,,,,,prior 48 hours;|platelets <100 000/mm3,less than or equal to 8 weekly,,,,,,
12879,,congenital cervical anomalies,,,,,,,,,in the 28 days prior to the first study drug administration,32 -- 35 mmol/l.||,,,,,,
12880,,hyperlactatemia,,,,,,,,,auscultatory silence|clinical suspicion of another pathology that could explain the respiratory failure,90-100mmhg|female,,,,,,
12881,,strongly discourage,,,,,,,,,within 28 days before the first dose of study treatment,<1% expression of estrogen receptor,,,,,,
12882,,females|healthy,,,,,,,,,at the time of progression on osimertinib,6 to 14 years;|under the condition,,,,,,
12883,,doubtful,,,,,,,,,at least 6 months of follow-up.||,< 10mg/day,,,,,,
12884,,p. aeruginosa,,,,,,,,,within the range of 18.0 to 35.0 kg/m2,>/=,,,,,,
12885,,poor general health,,,,,,,,,within 14 days before first dose,from 8 to 40 years,,,,,,
12886,,sinus,,,,,,,,,during the trial.|blood donation,≥3 in combination,,,,,,
12887,,acute alcoholic hepatitis,,,,,,,,,four months of first-line induction treatment,ranges from 60-75 years,,,,,,
12888,,bladder outlet obstruction,,,,,,,,,within past 5 years;|chronic steroid use,≤ 24 hours,,,,,,
12889,,spermia,,,,,,,,,at least 2 minutes|able,below 9 while not,,,,,,
12890,,immunostimulant,,,,,,,,,within the last 30 days.|subject,< 40 ml/min/m2|history,,,,,,
12891,,others.|enrollment,,,,,,,,,in the last 5 years|immunoglobulins,>2xuln,,,,,,
12892,,itbs,,,,,,,,,at time of screening.||,< 60 ml/min/1.73 m2|positive,,,,,,
12893,,ans dysfunction,,,,,,,,,within 7 days prior to imp treatment start,score 2 - equal to or above,,,,,,
12894,,consent.|thoracic surgical,,,,,,,,,in initiation,>100 bpm.||pregnancy/lactation||pregnant,,,,,,
12895,,back ache,,,,,,,,,within 3 months before the first day,greater than equal to 200 pg/ml,,,,,,
12896,,major depressive disorder)|18,,,,,,,,,more than 5 cigarettes per day within 3 months before administration of investigational product,≤ 1.5;|prothrombin time (pt) and,,,,,,
12897,,progressive mental,,,,,,,,,"in two different times, should only",≥ 30 ml/min/1.73 m2,,,,,,
12898,,autistic features.|significant visual,,,,,,,,,in the last 5 years for alcohol,">97.2 micromol/l,|liver transaminases",,,,,,
12899,,disease|cognitive impairment,,,,,,,,,within 30 days prior to randomization,> 0.3 μg/kg/min,,,,,,
12900,,organ failure|documented,,,,,,,,,within 4 weeks prior to treatment on study with the exception,female.|more than or equal to 2 gallbladder polyps,,,,,,
12901,,fully resectable,,,,,,,,,within the last year);|experiences alarm features,less than 3 mm.|tumor,,,,,,
12902,,recreational drug use|understands,,,,,,,,,during the index primary pci,below or equal to 20 degrees,,,,,,
12903,,evaluable lesion;|the main organs function,,,,,,,,,within the 2-week period prior to first dose,"≥18,",,,,,,
12904,,300 milliliters,,,,,,,,,within 7 days prior to the start of this study,0-1|age 18 years,,,,,,
12905,,anesthetic care||,,,,,,,,,after all relevant standard of care cancer therapies,18-60 years,,,,,,
12906,,defibrillator|psychiatric disorder,,,,,,,,,within the previous thirty (30),≤ 24.9 kg/m2|able,,,,,,
12907,,refuses to receive surgical treatment,,,,,,,,,within 6 months before signing the informed consent,< 750 cells/l,,,,,,
12908,,cutaneous inflammatory,,,,,,,,,within the prior two months,<9g/dl|serum total bilirubin,,,,,,
12909,,signs of cardiac,,,,,,,,,last known,long term,,,,,,
12910,,couples,,,,,,,,,for ≥3 months prior to screening|subjects,≥ 18 years.|cytologically,,,,,,
12911,,bone metastasis located,,,,,,,,,at the time of treatment,1.5×109/l,,,,,,
12912,,mentally handicapped.|patients,,,,,,,,,"prior to vaccination,|having a",less than 12 months||minimum dosage,,,,,,
12913,,brain tumor resection,,,,,,,,,within 12 months after bcg,> 160 mm hg,,,,,,
12914,,affect the sensation,,,,,,,,,during their participation in the study until one month after their last study vaccine,1 - 4cm,,,,,,
12915,,cns disorder,,,,,,,,,within recent 3 years,≤ 5 x uln|eligible for,,,,,,
12916,,alteration of the nose,,,,,,,,,within 28 days before receiving the study drug,5 to < 6 years,,,,,,
12917,,abstain from strenuous physical activities,,,,,,,,,within 1 year after receiving study treatment.|stroke,>=48 hours,,,,,,
12918,,developmental stutter,,,,,,,,,after initiation of,"between 18 and 75 years.||a minimum of 18 teeth, wisdom teeth",,,,,,
12919,,transient ischemic attack|premorbid motor disability,,,,,,,,,prior to the first dose of study treatment,older than 2 years,,,,,,
12920,,uterine agenesis,,,,,,,,,within 2 weeks prior to meta10-19 infusion；|treatment,l1)|segmental reflexes,,,,,,
12921,,allergic history.|bmi,,,,,,,,,in the past two months|evidence-based,therapies|able to provide,,,,,,
12922,,multiple anastomoses,,,,,,,,,over 65 years old|being,0-1|all,,,,,,
12923,,periodontal disease.|patients,,,,,,,,,for ≥3 months prior to randomization.||be on a,4-10 u/ml,,,,,,
12924,,extrahepatic metastasis;|malignant abdominal,,,,,,,,,at the time of informed consent.|signed written informed consent.|braf v600e mutant advanced,≤ 2.5 times the upper limit of normal|alp ≤ 2.5 times the upper limit of normal|serum creatinine,,,,,,
12925,,leukemic organ involvement,,,,,,,,,at the time of the study|norelgestromin,> 1.5 uln,,,,,,
12926,,ischemia demonstrated,,,,,,,,,expansion stages after evaluation by cardiology and discussion,≥3 months;|at least one,,,,,,
12927,,decreased response,,,,,,,,,in the one week before or after each study vaccination.|received,7 prior to enrollment,,,,,,
12928,,trauma|patients,,,,,,,,,within 4 weeks week prior study|periodontal treatment,> three months.|localized disease,,,,,,
12929,,high surgical risk,,,,,,,,,within the 3 months prior to the first dose of study drug.|consumed more than 14 units,<0.26 or >,,,,,,
12930,,thyroid disorders,,,,,,,,,at least two,from screening to 3 months after trial completion,,,,,,
12931,,kidney disease)|alcohol,,,,,,,,,within 3 months before first study vaccination,requires urgent,,,,,,
12932,,cervical spine disease,,,,,,,,,within 3 months after the study.|lactating mothers,+/- 10 years,,,,,,
12933,,chronic hepatitis c virus (hcv),,,,,,,,,14 days before dosing until after the follow-up visit,≥ 2000 iu/ml,,,,,,
12934,,ckd-epi creatinine,,,,,,,,,within 3 months prior to randomization;|arterial/venous thrombosis,at least 30% of subjects,,,,,,
12935,,polyangiitis,,,,,,,,,within 14 days prior to the first administration of the study,15 - september 30,,,,,,
12936,,menopausal,,,,,,,,,in the 6 months prior to study vaccine,≥ 18 & < 90|ldl-c,,,,,,
12937,,hyperparathyroidism|multiple pregnancy|polyhydramnios|premature,,,,,,,,,before screening;|apheresis,6 to 8 weeks,,,,,,
12938,,mental impairments,,,,,,,,,within the last month.|history of known,>30 ml/min/1.73 m^2 calculated,,,,,,
12939,,na,,,,,,,,,in the 3 months prior.|a,greater than 3 times the upper limit of normal (uln),,,,,,
12940,,cutaneous metastasis,,,,,,,,,within 6 weeks before,≥110 mmhg,,,,,,
12941,,genetic disorders|myasthenia gravis,,,,,,,,,more than 100,>3cm,,,,,,
12942,,limb loss,,,,,,,,,"within 3 months before administration,|major surgery",≥ 500 ng/ml.,,,,,,
12943,,communication barrier;|severe liver dysfunction,,,,,,,,,within 2 years prior to starting study drug,27-35 days,,,,,,
12944,,judged as unable to fully comply with study therapy,,,,,,,,,within the 12 weeks prior to the screening,≥470 ms.||current,,,,,,
12945,,paroxysmal nocturnal hemoglobinuria,,,,,,,,,at the time of starting study,<70 years,,,,,,
12946,,health care,,,,,,,,,up to 6 months|have internet,> 180mmhg,,,,,,
12947,,clotting factor v leiden disease,,,,,,,,,in the last 1 year)|history of,≤ 1 x uln|aspartate aminotransferase,,,,,,
12948,,herniated discs,,,,,,,,,throughout the intervention period;|receiving any physiotherapy intervention,images,,,,,,
12949,,hypovolemia|orthostatic hypotension|hyponatremia,,,,,,,,,within 4 weeks prior to treatment;|patients with,i - ii|body mass index,,,,,,
12950,,dizziness,,,,,,,,,"within the previous 5 years,|dietary restrictions",≥ 45 ml/min;|serum,,,,,,
12951,,skin lesion,,,,,,,,,throughout study treatment.|participants,greater than 30 kg/m2|history of diabetes|history of,,,,,,
12952,,cardiopulmonary bypass (cpb),,,,,,,,,prior to the first dose|history of alcohol,< 500 iu/ml obtained,,,,,,
12953,,b-nhl,,,,,,,,,within 14 days prior to check,< 15|chest tube,,,,,,
12954,,upper respiratory tract,,,,,,,,,in the 4 weeks prior to study,≥ 18 years|patients,,,,,,
12955,,organ transplant.|active infection,,,,,,,,,at the screening visit.||acceptable medical history,> 96%;|total,,,,,,
12956,,hdv,,,,,,,,,during or after surgery,equal or less than 600hu.|patients,,,,,,
12957,,intracranial hemorrhagic,,,,,,,,,colectomy|history,above 140 mg/dl,,,,,,
12958,,solid organ transplantation.||14,,,,,,,,,more than 1 log value,score-based,,,,,,
12959,,allergic,,,,,,,,,within 24 weeks prior to screening,18 to 45 years|patients,,,,,,
12960,,hyponatremia,,,,,,,,,at least one of the following criteria,≥ 60ml/min.|for those,,,,,,
12961,,acute kidney injury (aki) patients,,,,,,,,,after undergoing coronary angiography,> 25 mmol/l)|liver,,,,,,
12962,,communication over videoconference,,,,,,,,,within 1-2 weeks;|hrct,1 or below,,,,,,
12963,,right heart catheterization*||elevated left atrial pressure,,,,,,,,,for more than 2 weeks,> 1.5x upper limit normal|fasting glucose,,,,,,
12964,,ranging from 25 to 50 years old.|localized periodontitis,,,,,,,,,within the last month.|subjects with any,< 50 x 109/l|known,,,,,,
12965,,albuminuria,,,,,,,,,within 30 days of ssrs/fsrs,=< 2 x institutional uln,,,,,,
12966,,serious physical disease,,,,,,,,,throughout the duration of the study|vision,18 years ≤ age ≤ 75 years；|performance,,,,,,
12967,,read urdu language||,,,,,,,,,at least one oral medication per day,">= 75,000/mcl|total",,,,,,
12968,,daytime impairment,,,,,,,,,within 7 days prior to the first dose.||,≥1x10-4,,,,,,
12969,,human t-cell leukemia virus,,,,,,,,,within 6 months before inclusion|for,≥50 ml/min,,,,,,
12970,,non-ischemic cardiomyopathy,,,,,,,,,within 12 months.|patients,>50kg/m².|3,,,,,,
12971,,exercise testing|anemia,,,,,,,,,prior pregnancy;|objectively,less than 18 years.|immunosuppression,,,,,,
12972,,restrictive respiratory dysfunction,,,,,,,,,within past 90 days|nyha functional classification iv,20 g,,,,,,
12973,,experience tinnitus,,,,,,,,,before the first administration of study drug,≤ 1.0 d,,,,,,
12974,,chronic cutaneous lupus,,,,,,,,,in the past 1 month;|presence,greater than or equal to 30kg/m2,,,,,,
12975,,retinal dystrophy,,,,,,,,,at least 6 hours,anc)≥1.5×10^9/l|white blood cell count,,,,,,
12976,,pancreatic insufficiency,,,,,,,,,within the range of 18~28kg/m2,0-1;|adequate,,,,,,
12977,,satisfactory response,,,,,,,,,for at least 14 days prior to the first dose of the study intervention.;|patients,under general anesthesia.||,,,,,,
12978,,spinal cord pathologies,,,,,,,,,within normal institutional limits.|clinically normal,≥30 g/l;|hemoglobin,,,,,,
12979,,aplastic anemia,,,,,,,,,less than 4 months,≥ 45 ml/min/1.73 m2,,,,,,
12980,,disseminated intravascular coagulation.|patient,,,,,,,,,7 days before cell collection,"1, 2]|measurable disease",,,,,,
12981,,eisenmenger syndrome,,,,,,,,,within previous 12 months of alcohol,≥ 18 years|depression,,,,,,
12982,,drug-induced urticaria|any,,,,,,,,,within the 14 days prior to day 1,> 50% stenosis,,,,,,
12983,,non-cardiac tissue,,,,,,,,,prior to starting therapy)|an active autoimmune disease,>50% of the portal vein,,,,,,
12984,,rhg-csf,,,,,,,,,in the last 3 months|written consent to participate in the study regardless of the allocation group|eligibility for,<100×109/l,,,,,,
12985,,consent.|epitentorial glioblastoma,,,,,,,,,before midday|access to internet,<18 and >90 years.|akinesia,,,,,,
12986,,psh,,,,,,,,,within the year prior to screening,> 6||have,,,,,,
12987,,teeth that,,,,,,,,,within 4 weeks prior to start of trial treatment phase,at least 1 year,,,,,,
12988,,responses from,,,,,,,,,in the past 3 months|treatment,6-7|including,,,,,,
12989,,primary surgical procedure,,,,,,,,,within 28 days prior to first dose;|long-term,>5 g/,,,,,,
12990,,traumatic glaucoma,,,,,,,,,within 2 weeks.|hematological system,no more than 2 lines.||note,,,,,,
12991,,chemotherapy|usage,,,,,,,,,within 6 months prior to screening|uncontrolled hypertension,3.4 mm,,,,,,
12992,,kidney-diseases,,,,,,,,,within 14 days of study enrollment,greater than or equal to (>=) 18 years,,,,,,
12993,,iridotomy,,,,,,,,,within 4 weeks prior to c1d1|known,between 3-60 months.|patients,,,,,,
12994,,joint disease,,,,,,,,,at the time of screening:||active hepatitis b virus,≤1.5 x uln*|alt,,,,,,
12995,,cases of,,,,,,,,,in the last 3 months|being,≥ 60.0ml/min,,,,,,
12996,,prostate cancer|scheduled,,,,,,,,,within ≥ 30 days prior to randomization|using,>=65 years|primary,,,,,,
12997,,intoxication.|respiratory impairment,,,,,,,,,throughout the duration of the study.|use of 5-ht4 receptor agonists,< 6.5%||for all female,,,,,,
12998,,major hallucinations,,,,,,,,,in two dedicated days (,"≥ 70 years,|patient",,,,,,
12999,,pseudohypoparathyroidism.|currently enrolled in an investigational drug,,,,,,,,,post-operative period,age≥ 18 years,,,,,,
13000,,prolonged analgesic,,,,,,,,,within 28 days of study drug,between 20.0 and 29.9 kilograms per meter square (kg/m^2),,,,,,
13001,,endocrine disorders,,,,,,,,,within the past 24 months|currently,> 30)|systemic disorders,,,,,,
13002,,cardiovascular|musculoskeletal disease,,,,,,,,,stay|able to give informed consent,>10 g/dl,,,,,,
13003,,drug-drug,,,,,,,,,within 12 weeks of the start of study treatment|prior treatment,1 to arm 2): patients,,,,,,
13004,,judged by the investigator to be inappropriate for enrollment,,,,,,,,,at least six months prior to signing the informed consent form have been,fc,,,,,,
13005,,acute depression,,,,,,,,,for 6 months prior to inclusion|evidence of,> 38°c for more than two weeks,,,,,,
13006,,archival tissue should,,,,,,,,,within the last 6 months|are,≥45kg,,,,,,
13007,,inadequate sinus bradycardia,,,,,,,,,last two years,21-65 y/o|receiving pap smear,,,,,,
13008,,hiv|brain metastases,,,,,,,,,within past 2 years):|any of the,symptoms ≤ 4,,,,,,
13009,,chronic gastrointestinal diseases|inability to chew,,,,,,,,,within 6 months prior to first administration,18-34 years,,,,,,
13010,,active:||autoimmune disease,,,,,,,,,within the past 30 days prior to screening;||takes,fasting|1-18 years,,,,,,
13011,,weeks.|acute exacerbation,,,,,,,,,during the study.|have,> 5 ml,,,,,,
13012,,features,,,,,,,,,for at least 4 weeks immediately before the randomization visit (day 1,> 75 years.|an,,,,,,
13013,,vascular lesion,,,,,,,,,more than three months prior to study enrollment,from 32 weeks,,,,,,
13014,,lupus nephritis,,,,,,,,,at least 2 weeks later,> 2 times per week|medical conditions,,,,,,
13015,,pregnancy.|participants,,,,,,,,,within 2 weeks of receiving ultrasound delivery|use,< 50%,,,,,,
13016,,anterior teeth,,,,,,,,,in past 12-months,greater than 72 hours,,,,,,
13017,,neurological (epilepsy,,,,,,,,,during 6 months before the trial;|vaccination of the pregnant,2022,,,,,,
13018,,coronary angiogenesis,,,,,,,,,"during menstruation,|not having",40 - 90,,,,,,
13019,,non-serious,,,,,,,,,continue to maintain treatment,less than two years after menopause);|received,,,,,,
13020,,mixed tumor,,,,,,,,,in the past 3 months|continuous,≥30 mmhg,,,,,,
13021,,recurrent sinusitis,,,,,,,,,up to 75 mg/,between 20 and 45 years,,,,,,
13022,,ruptured aaa|fenestrated,,,,,,,,,for 48 hours prior to enrollment,36-45,,,,,,
13023,,ureteral stone|urinary diversion|active infection|untreated cancer,,,,,,,,,on three or 4,< 18 years,,,,,,
13024,,intracranial tension,,,,,,,,,within the past 3 months||blood,between 24-40,,,,,,
13025,,central adiposity,,,,,,,,,in the past 30 days|any,4|ineligible,,,,,,
13026,,pulmonary disease-,,,,,,,,,at least 2 weeks apart,score of 36 or,,,,,,
13027,,impairment of gastrointestinal (gi) function,,,,,,,,,within 3 months prior to randomization|current smoking,≥ 100 x 109/l|haemoglobin,,,,,,
13028,,runny nose,,,,,,,,,within 6 months before the first study drug,<15 ml/min|requiring,,,,,,
13029,,bilateral tubal occlusion hysterectomy,,,,,,,,,within 4 weeks before the first administration.|subjects,between 18 to 40 years,,,,,,
13030,,chronic skin conditions,,,,,,,,,before starting heparin treatment,greater than 550lbs,,,,,,
13031,,childhood.|prior exposure,,,,,,,,,in the last year prior to either screening or day -1.|has,> 1500/mm3,,,,,,
13032,,pathologic fractures,,,,,,,,,for 30 days after the last dose of,18 years or older.|patient,,,,,,
13033,,type-2 dm,,,,,,,,,in the last 24 hours,15-19yrs|english speaking|lives,,,,,,
13034,,uterine inversion,,,,,,,,,for at least 3 months before enrollment||,b-type,,,,,,
13035,,clusion criteria:||healthy adult,,,,,,,,,at any time prior to or,18-40|regular menstrual cycle|patients,,,,,,
13036,,intestinal continuity,,,,,,,,,in the last 4,>= 1.2 uln,,,,,,
13037,,|acute infections,,,,,,,,,within 2 weeks prior to randomization,grade ii or higher,,,,,,
13038,,incorporating height,,,,,,,,,one month after sars-cov-2,> 37 weeks,,,,,,
13039,,restless legs syndrome rls,,,,,,,,,at the time of inclusion|provides consent to participate||exclusion criteria for,> 3x upper limit of normal,,,,,,
13040,,substance abuse condition,,,,,,,,,within the last week||,> 18 years|provided written informed-consent||,,,,,,
13041,,chronic neurological disorders,,,,,,,,,for the duration of this study (180 days).|agree to avoid blood and,≥ 18 years and <85 years,,,,,,
13042,,autonomic thyroid adenomas,,,,,,,,,for ≥3 days within 1 week prior to enrollment,≤ 28 kg/m^2.|the,,,,,,
13043,,primary invasive carcinoma of the breast,,,,,,,,,within the last 10 days nephrotoxic medications,≥18 and ≤ 65 years,,,,,,
13044,,alzheimer's disease.|patients,,,,,,,,,during the physical examination,<500 stimulations,,,,,,
13045,,metastatic.|measurable disease,,,,,,,,,within 60 days of screen.|participant,less than 7%.|able,,,,,,
13046,,arrythmia,,,,,,,,,within the past 3 years|prior,rate of ≤ 60 ml/min,,,,,,
13047,,interstitial cystitis.|individual,,,,,,,,,during the test,≥18 years old and < 70 years old,,,,,,
13048,,cytology;|previous molecular pathology,,,,,,,,,within the 12 months prior to visit 1,≥ 10 mmhg|resting,,,,,,
13049,,chronic phase,,,,,,,,,within 2 weeks before the first dose;|have received,< 60 ml/min/1.73 m^2,,,,,,
13050,,tee,,,,,,,,,within the previous 12 months.||active infection,within range 18.0 - 35.0|assigned american society of anesthesiologists,,,,,,
13051,,intracavitary,,,,,,,,,disorder.|less than 6 months,9-10 points,,,,,,
13052,,months||for,,,,,,,,,within the previous 2 weeks;||type 2 diabetes,≤300 mg/dl,,,,,,
13053,,left atrial,,,,,,,,,within the prior 24 months,stage 5 ckd,,,,,,
13054,,primary sclerosing cholangitis (psc):,,,,,,,,,within 12 weeks prior to randomization,<30).|new york heart association class iii or iv,,,,,,
13055,,foster care.|does,,,,,,,,,within the past 3 months|weight loss,0-1|eligibility for,,,,,,
13056,,renal allograft,,,,,,,,,more than 5 cigarettes per day,from 1 to 10 years,,,,,,
13057,,"excessive hairiness, edema",,,,,,,,,within last 3 years|online access|english literate||,20-45|both,,,,,,
13058,,unstable plaque,,,,,,,,,during the last 12 months.|patients must carry,≥ 2mg/dl)|pregnancy/,,,,,,
13059,,periodontal disease|dental cracks,,,,,,,,,within 12 months prior to study entry|history of,1 to 5,,,,,,
13060,,chronic underlying disease,,,,,,,,,at least 7 days prior due to,≤ 470 msec,,,,,,
13061,,eastern oncology consortium physical state score,,,,,,,,,before initial administration,≥18 years|presenting to the,,,,,,
13062,,hemorrhoidal bleeding,,,,,,,,,3 months prior,18 - 40 kg/m2 inclusive|full comprehension,,,,,,
13063,,pharmacy coverage,,,,,,,,,before the ra-224 implantation,≥50%.|sign the informed consent form;|good compliance,,,,,,
13064,,bariatric surgery.|serious,,,,,,,,,within 4 weeks prior to first dose,< 2.5x uln,,,,,,
13065,,fk506,,,,,,,,,for 12 hours prior to all study visits.|individuals,minimum 40 years,,,,,,
13066,,drug-induced pneumonia,,,,,,,,,within the past 3 years|has,6-40,,,,,,
13067,,trustees of subjects of,,,,,,,,,up to 4 g/day,between 2 year and <18 years,,,,,,
13068,,abstain from taking these to the end of the treatment phase,,,,,,,,,during cystoscopy,18-75|being exposed,,,,,,
13069,,lower limb involvement,,,,,,,,,prior to c1d1,≥35; 2,,,,,,
13070,,acute pulmonary,,,,,,,,,within three months of visit 1,exceeded 3 times of the upper limit of normal value,,,,,,
13071,,diabetic hypertonic state,,,,,,,,,within 3 months before screening.|the researchers did,18-65 years.|patients,,,,,,
13072,,rate pain,,,,,,,,,"within last 6 months,|uncontrolled",50% ≤ fev1,,,,,,
13073,,allowed.|prophylactic,,,,,,,,,within 48 hours prior,≥90,,,,,,
13074,,bladder epithelial tumor,,,,,,,,,throughout the study||,< 100 mmhg,,,,,,
13075,,pulmonary arteries,,,,,,,,,within 2 months before inclusion.|positive result,>25 kg/m2||,,,,,,
13076,,tested,,,,,,,,,within 30 days of study entrance.|patients,>12.5 kpa|a fibrosure,,,,,,
13077,,prevention center (csapa),,,,,,,,,within 1 week before the screening,class 1 & 2)|availability,,,,,,
13078,,esophageal squamous cell carcinoma|disease,,,,,,,,,in the past 12 months|symptomatic patient,0-1||one or more,,,,,,
13079,,harmonisation,,,,,,,,,within the last 12 months|any intraocular,≤ 2.5 × uln；||11,,,,,,
13080,,traumatic dementia,,,,,,,,,throughout the study.|subject,0-2 score;|9.voluntarily participate,,,,,,
13081,,retinal drusen,,,,,,,,,at baseline screening,> 100 kg,,,,,,
13082,,right colon cancer,,,,,,,,,at least 3 months of diet,"≤ 1,5 time the normal",,,,,,
13083,,ascites infection,,,,,,,,,at least 2 weeks before the first administration of study intervention,85th or greater,,,,,,
13084,,familial hyperchylomicronemia||ii,,,,,,,,,at least 3 days,6-month,,,,,,
13085,,progression.||invasive malignant disease,,,,,,,,,in the previous month to allow safe completion of the cardiopulmonary exercise test (cpet),≥ 8h & midpoint ≤2:30,,,,,,
13086,,the encephalitis,,,,,,,,,at least two separate increase in psa,≥ 110 beats per minute,,,,,,
13087,,allohct from,,,,,,,,,within the past six months|radiation therapy,60-89 ml/min/1.73 m2)|chronic renal impairment,,,,,,
13088,,delusions,,,,,,,,,at least one day/week,"18 or older,|do not",,,,,,
13089,,renal functional compensation,,,,,,,,,for at least 6 months|not,score ≦2;|chief,,,,,,
13090,,performed.|new york heart association (nyha) class,,,,,,,,,during the intervention period of the study,3 to 9 years:||healthy,,,,,,
13091,,intercurrent illnesses,,,,,,,,,during the observational,18 to 22 years.|able to provide,,,,,,
13092,,months.|cardiovascular diseases,,,,,,,,,while receiving protocol treatment,2-5|stable treatment,,,,,,
13093,,systolic heart failure,,,,,,,,,following prior systemic therapies,>= 40 mm,,,,,,
13094,,temporomandibular disorder,,,,,,,,,in the last 3 years).||,> 3000/mm3|absolute neutrophil count (,,,,,,
13095,,procedures|neurologically stable,,,,,,,,,for at least 3 months prior to entry into the study,from 30 to 75 years old.|right-handedness,,,,,,
13096,,ability to swallow medications,,,,,,,,,in the last 6 weeks|participants,at least 6 months,,,,,,
13097,,penicillin|acute illness,,,,,,,,,within 6 months of screening.|participation in a clinical study testing anti-obesity medications,0 or 1|willingness,,,,,,
13098,,stenosis of the gastrojejunostomy,,,,,,,,,at the time of the enrollment.|able to understand,cerebral,,,,,,
13099,,stent insertion|ascites,,,,,,,,,for 14 weeks,≤ 2.5 x institutional upper limit of normal,,,,,,
13100,,degenerative myopia,,,,,,,,,more than 14 days before registration,≤ 75 kg,,,,,,
13101,,txa,,,,,,,,,within the last 3 months|received,fio2)≤ 300 mmhg,,,,,,
13102,,musculoskeletal diseases,,,,,,,,,> 6 months prior to signing consent.|patients,> 40 kg/m2,,,,,,
13103,,prostate cancer disease,,,,,,,,,within 60 days before screening|planned coronary,>= 1 day prior to study treatment.|patients who cannot,,,,,,
13104,,sinusoidal obstruction syndrome,,,,,,,,,within six months prior to administration of trial vaccine.|history,ocular melanoma;|mucosal melanoma;|distant metastases;|impossibility of radical resection of the tumor,,,,,,
13105,,contrast agents;|aneurysms neck,,,,,,,,,continue until 3 months following receipt of vaccine|as applicable undergo,≥ grade b,,,,,,
13106,,ligamentous injuries|previous meniscectomy,,,,,,,,,within two years of treatment,≥ 60 ml/min/1.73 m^2,,,,,,
13107,,tomography|functional evidence,,,,,,,,,within 2 years prior to the first dose of study treatment,long-term follow,,,,,,
13108,,breast cancer.|patients,,,,,,,,,more than 3 months.|amyloid accumulation in brain,0 or 1.|patient,,,,,,
13109,,posterior circulation stroke,,,,,,,,,within 3 months.|decompensation,30-80×109/l.||,,,,,,
13110,,reproductive system infection,,,,,,,,,within 3 months of the last dose,> 70%.|participant must demonstrate,,,,,,
13111,,prediabetic state,,,,,,,,,within the past 12 months prior to the first dose of study drug|had,= 300 mmhg||,,,,,,
13112,,untreated obstructive sleep apnea,,,,,,,,,emergency use authorization,<100×10⁹/l;hemoglobin <90 g/l;alanine aminotransferase,,,,,,
13113,,extremities,,,,,,,,,within the next 48 hours,ii-iv)|kccq-oss score,,,,,,
13114,,clinical factor,,,,,,,,,within the past 5 years|uncontrolled,≥ 150 mm hg,,,,,,
13115,,covid-19.||moderate severity infection,,,,,,,,,after implantation of the,>4x10^9 /l,,,,,,
13116,,surgical menopause,,,,,,,,,within 3 months prior to screening.|planned surgery,"scores 3+4, 4+3",,,,,,
13117,,visible corneal scar,,,,,,,,,at least 12 months no menses,1-2|ages,,,,,,
13118,,localized squamous cell carcinoma of the skin,,,,,,,,,after at least 2 prior,>25 score,,,,,,
13119,,malignant tumors.|received,,,,,,,,,prior to ivt|currently,19-25 years|physically,,,,,,
13120,,trauma.||significant cardiac disease,,,,,,,,,over the past three months,0 to 1||,,,,,,
13121,,age|female,,,,,,,,,within the range of 18.5 to 29.9 kg/m2,between 19 and 55 years,,,,,,
13122,,inflammatory sacroiliitis,,,,,,,,,more than 5 times every two,>94%,,,,,,
13123,,isolated,,,,,,,,,within 4 weeks before the first dose of study drug,≥10)|able to provide signed informed consent||in order,,,,,,
13124,,chronic stroke,,,,,,,,,in the 60 days following any study intervention administration|previous vaccination,≥ 1.5 × uln,,,,,,
13125,,influenced gingival bleeding.|a participant,,,,,,,,,past 3 months,> 18 and < 75 years,,,,,,
13126,,pain controlled,,,,,,,,,within 4 weeks before first dose of study treatment,frequency more than or equal to 5 times in,,,,,,
13127,,jugular venous pressure,,,,,,,,,"within the previous 2 years,|any",40-years,,,,,,
13128,,surgically with curative,,,,,,,,,prior to the first cell sample,≥ 480 milliseconds,,,,,,
13129,,symphysis pubic joint,,,,,,,,,at least 6 months before,labour|iatrogenic preterm labour,,,,,,
13130,,diffuse erythema,,,,,,,,,at least 25% of face,shorter than one,,,,,,
13131,,cognitive comorbidities,,,,,,,,,at least 3 months||,≤ 3 × upper limit of normal (uln,,,,,,
13132,,extrahepatic disorders,,,,,,,,,between august 2019,41-60 points,,,,,,
13133,,disseminated intravascular coagulation;|active hemorrhage;|uncontrollable infection,,,,,,,,,for at least 3 months|ability,less than 6 months prior to screening).|participation,,,,,,
13134,,parkinson disease dementia,,,,,,,,,<30 days prior to study procedure|history,korean male adult,,,,,,
13135,,coagulation disorders;|patients,,,,,,,,,within the past 14 days from the screening,> 1.5 x 10^9/l|platelets ≥100 x 109/l|international normalized ratio,,,,,,
13136,,cholangitis)|chronic liver infection,,,,,,,,,during the 90 days prior to study drug dosing.||estimated,≤ 65 years,,,,,,
13137,,neurologic defaults|carotid stent,,,,,,,,,after 3 months post-eradication,≥ 6,,,,,,
13138,,upper part,,,,,,,,,"in the last month prior to study entry,|shaving/depilation of the arms in the last 14 days before inclusion,|mental incapacity",at least 4,,,,,,
13139,,glaucoma patients.|media opacity,,,,,,,,,at least 6 months prior to visit 1,5-6 points,,,,,,
13140,,metabolic diseases.|history,,,,,,,,,within 14 days prior to the first dose of study drugs.|have,20 sas)|40-70 years,,,,,,
13141,,external beam radiation therapy,,,,,,,,,within 3 days prior to vaccination.|,≥ 40 mmhg,,,,,,
13142,,impact metabolism,,,,,,,,,within 3 months prior to the study.|participation,score ii,,,,,,
13143,,1- lupus nephritis,,,,,,,,,within 28 days prior to randomisation|history of,≤ 20,,,,,,
13144,,smoking|subjects,,,,,,,,,within the prior month to meet this requirement,< 50%);|patients,,,,,,
13145,,pregnancy|no smoking,,,,,,,,,within one week of day 1 cycle 1).|individuals,>35 kg/m2,,,,,,
13146,,breast-feeding|patients,,,,,,,,,during the course of the study.|has sickle cell disease,more than 18 years.||,,,,,,
13147,,contagious disease,,,,,,,,,within the last 14 days|those,>= 100 x 10^9 / l 5,,,,,,
13148,,abnormalities of medical,,,,,,,,,throughout the trial period;|be able to communicate well,≥18.5 and <30.0 kg/m2.|healthy,,,,,,
13149,,criteria of the oncological departments,,,,,,,,,within 14 days before the first dose of study drug,24 points,,,,,,
13150,,obtained||the,,,,,,,,,within 4 weeks before the first dose of study treatment,at least 3 months.|toxicities,,,,,,
13151,,associated cardiac pathologies,,,,,,,,,within 3 months prior to screening|known,less than 3,,,,,,
13152,,sepsis)|severe organ dysfunction,,,,,,,,,through 7 days after the last dose of lenvatinib,less than eighteen years.|for sexually,,,,,,
13153,,spine surgery;|cobb's,,,,,,,,,at mri visit,<126 mg/dl|systolic,,,,,,
13154,,immunochromatographic assay.|no symptoms,,,,,,,,,at least one of the following:||obesity,37-41 weeks,,,,,,
13155,,preoperative antitumor,,,,,,,,,within 4 weeks prior to first dose.||patients,nicotine patches,,,,,,
13156,,branch,,,,,,,,,within following 1 year of the dbt exam.||[for,≥16 years.|a physician diagnosis,,,,,,
13157,,substance abuse.|the,,,,,,,,,after the last ip administration.|women,< 100 g/l,,,,,,
13158,,comorbid multiple sclerosis,,,,,,,,,within 8 weeks after radical prostatectomy (rp),less than 70.000;|internationa normalized ratio,,,,,,
13159,,gluten challenge group:||diagnosis,,,,,,,,,between 4 and 24 months prior to the start of the study||parents:||- parent,pregnancy,,,,,,
13160,,unilateral parkinsonism,,,,,,,,,within 1 year after cell transfusion;|received,<80 years,,,,,,
13161,,cns comorbidity,,,,,,,,,prior ici therapy||failure to recover,< 19 kg/m2.|unintentional,,,,,,
13162,,acute cancer treatment,,,,,,,,,at intended stimulation,less than 2 weeks,,,,,,
13163,,acceptable.|chronic kidney disease,,,,,,,,,within the rage of,18 or older|inactive,,,,,,
13164,,pathologically diagnosed,,,,,,,,,within 4 weeks before the start of study treatment,≥ 60 ml/,,,,,,
13165,,spinal cord dysplasia,,,,,,,,,within 8 weeks of screening.|donation of whole blood,≥75 × 109/l,,,,,,
13166,,nodulokystic acne,,,,,,,,,for 30 days after completion of study,0-3|request,,,,,,
13167,,third molars).||,,,,,,,,,within 2 weeks prior to first dosing,20 to 55 years,,,,,,
13168,,hiv1/2 antibody,,,,,,,,,on the last biopsy available.|age,>1/3,,,,,,
13169,,caries lesions|never,,,,,,,,,for at least three months,18 to 50 years old,,,,,,
13170,,unstable conditions,,,,,,,,,at least 4 weeks prior to infusion;||presence of,seronegative,,,,,,
13171,,non-hiv-associated,,,,,,,,,within 1 week prior to surgery,greater than 440 milliseconds,,,,,,
13172,,t2),,,,,,,,,12 months after leep|a valid,between 500-2000 grams,,,,,,
13173,,lactating|prior malignancy,,,,,,,,,during the period 0 to 30 days,between c3 to c7|is,,,,,,
13174,,mental issues,,,,,,,,,within 6 months prior to treatment initiation,≥ 7.5%.|serious,,,,,,
13175,,axillary clearance,,,,,,,,,within 8 weeks of enrollment,female|18-65 years|residency,,,,,,
13176,,hepatitis c ribonucleic acid,,,,,,,,,for 180 days,>0.2 ng/ml,,,,,,
13177,,vagus nerve stimulation devices,,,,,,,,,within 7days prior to study drug administration.|drugs,≥10 mm2,,,,,,
13178,,chronic respiratory diseases|overdenture,,,,,,,,,heart;|treatment,1 unit=360 ml of beer,,,,,,
13179,,hepatic cholestasis diabetes mellitus,,,,,,,,,during study duration that would,more than 21.||,,,,,,
13180,,hypopituitarism,,,,,,,,,within the previous 3 months before the study start.|use,maximum 6 years after the age,,,,,,
13181,,adhd|current problems,,,,,,,,,in the past 2 years.|sexually,>50 ml/min,,,,,,
13182,,below:||peripheral neuropathy,,,,,,,,,over 500 ml within 3 months prior to screening;|subject,">150,000 x 10^9/l",,,,,,
13183,,myositis,,,,,,,,,in the past 6 months.|use,≥ 18 and ≤ 80 years.|one,,,,,,
13184,,family problems,,,,,,,,,prior to pregnancy.|pregnant,< 2.5 times the upper limit,,,,,,
13185,,canadian diabetes,,,,,,,,,during enrollment represents,greater than or equal to 60,,,,,,
13186,,progressive ms,,,,,,,,,in the past 5 years|history,< 10 microbleeds,,,,,,
13187,,tumor tissue by flow cytometry,,,,,,,,,at any time during the 12 months prior to screening,<=1.5 × uln,,,,,,
13188,,spontaneous hemorrhages,,,,,,,,,during 3 months prior to screening.|use of investigational agent,< 7 kg/m2,,,,,,
13189,,medications.|heart failure,,,,,,,,,within 24 months of the initiation of the study.|currently enrolled,1-2|preoperative hgb,,,,,,
13190,,gastroesophageal junction,,,,,,,,,during previous 4 weeks or,at least 1 designated symptom ≥2,,,,,,
13191,,stereoscopic vision,,,,,,,,,within 14 days prior to the start of study drug administration,≥ 120 ms,,,,,,
13192,,compartment syndrome,,,,,,,,,longer than 4.2 millisecond,from 18 years|signed,,,,,,
13193,,myasthenia gravis|not,,,,,,,,,within 14 days prior to and after,> 23||exclusion,,,,,,
13194,,participation.|external root resorption,,,,,,,,,within 6 months before signing the informed consent.|prior autoimmune disease,> 3 x normal,,,,,,
13195,,interstitial lung disease|new,,,,,,,,,within 3 months or more than 100 ml,> uln|aspartate aminotransferase,,,,,,
13196,,swelling);|bacterial infection,,,,,,,,,within 3 months prior to randomization.|participating in another interventional clinical study,3:||1,,,,,,
13197,,transient ischemic stroke,,,,,,,,,within 30 days prior to entering the study.|the tumor,≥9.0g/dl,,,,,,
13198,,pheochromocytoma,,,,,,,,,within 14 days of the baseline visit,< 1.5|activated,,,,,,
13199,,preparations|pregnant,,,,,,,,,after prior radical radiotherapy,>/= 7.0 mmol/l,,,,,,
13200,,bleeding complications,,,,,,,,,at least 2 weeks,≤ 2.5 × uln;|alanine aminotransferase (,,,,,,
13201,,civilians,,,,,,,,,throughout study duration.||,>300 μm,,,,,,
13202,,plexiform neurofibroma,,,,,,,,,throughout the period of,< 18 kg/m2;|any,,,,,,
13203,,hepatitis b.|patients,,,,,,,,,within 3.0 d||,>100 mg/dl,,,,,,
13204,,ewing sarcoma,,,,,,,,,within 12 months prior to the first dose.|known history,≥ 175,,,,,,
13205,,aortic cross-clamp,,,,,,,,,within 7 days of leukapheresis,≥4 criteria,,,,,,
13206,,cardiopulmonary failure,,,,,,,,,≤20 mg/day,at least 3,,,,,,
13207,,infectious)|infectious exacerbation of lung disease,,,,,,,,,after definitive therapy,<= 93%,,,,,,
13208,,urothelial carcinoma,,,,,,,,,before 4 weeks before enrollment,more than or equal to 1500 cells/mm3,,,,,,
13209,,adrenal hyperplasia,,,,,,,,,after 5 years of the end of treatment|living,22-27 kg/m2,,,,,,
13210,,placeholder lesions,,,,,,,,,before enrollment (,20-40°,,,,,,
13211,,rejection,,,,,,,,,for at least 3,> 1.5 g/l,,,,,,
13212,,acute heart attack,,,,,,,,,during sexual intercourse with,45-65|sedentary,,,,,,
13213,,alcohol breath tests,,,,,,,,,during the trial|there has been,18-64|currently,,,,,,
13214,,under judicial protection|pregnant,,,,,,,,,at least 30%,< 15 ml/minute/1.73 m2,,,,,,
13215,,gynecological cancers,,,,,,,,,within 2 weeks prior to registration||a,more than 4 weeks,,,,,,
13216,,hepatitis b virus [hbv] infection,,,,,,,,,during the past 6 months,greater or equal to 28 days (females),,,,,,
13217,,heart failure;|normal,,,,,,,,,within 2 weeks prior to initial,≥ 65 years;|asa,,,,,,
13218,,drusen,,,,,,,,,within the last two weeks;|engaged,between 25 and 35 kg/m²|subject,,,,,,
13219,,old|unable to read,,,,,,,,,in the past 6-weeks.|participants,<18 and >55 years|individuals,,,,,,
13220,,eyelid malpositions,,,,,,,,,within 12 weeks before baseline,below 50 mg/dl.|those,,,,,,
13221,,thyroid papillary carcinoma,,,,,,,,,between the 2 week historical period,>40 or >35,,,,,,
13222,,pose a safety concern.|history of stroke,,,,,,,,,within 24 hours before surgery|patient presenting,0 days and up,,,,,,
13223,,dedicated ambulatories,,,,,,,,,throughout the trial;|according to the investigator 's judgment,6-7 mm)|absence,,,,,,
13224,,bipolar ii|clinical indications,,,,,,,,,at our centre for evaluation of candidacy,> 9)|display sufficient cognitive capacity to provide informed consent,,,,,,
13225,,valvular stenosis,,,,,,,,,within 48 hours after vaccination,between 5 and 11 on the,,,,,,
13226,,ocular,,,,,,,,,within 5 years prior to consent,between maternal dates,,,,,,
13227,,pulmonary hypersensitivity pneumonitis,,,,,,,,,within 3 years prior registration,2-3,,,,,,
13228,,-spermia,,,,,,,,,within the first minutes,<22 weeks,,,,,,
13229,,lateral growth tumors,,,,,,,,,within the past 12 months.|cohort 3,1.5-3.0mm|high,,,,,,
13230,,resected squamous cell carcinoma,,,,,,,,,history to the agents,<160 mmhg,,,,,,
13231,,pathological staging,,,,,,,,,at least once,65 years old or over,,,,,,
13232,,diagnostic modalities,,,,,,,,,in time,≤ 200mg/l,,,,,,
13233,,endodontic disease,,,,,,,,,within 1 week prior to the first dose of study treatment.|participation,<60 ml/min/1.72 m2,,,,,,
13234,,skin conditions|skull defect,,,,,,,,,at least 1 week in duration in the year prior to enrollment,0-1.|women,,,,,,
13235,,failure,,,,,,,,,prior to start of first-line,>125,,,,,,
13236,,microvascular decompression|age,,,,,,,,,before 01/12/2022,5 to 7,,,,,,
13237,,urinary tract infection.|severe immune deficiency,,,,,,,,,during the year prior to the,60-70 gy,,,,,,
13238,,segmentectomies,,,,,,,,,within 48 h before and,≥12 weeks,,,,,,
13239,,hematochromatosis,,,,,,,,,within the previous 6 months.|ongoing need for,stage ii or iii,,,,,,
13240,,severe depressive,,,,,,,,,for 6 weeks prior to enrollment,8-14 years|diagnosis,,,,,,
13241,,mri;|osteoarthritis of the index knee grades,,,,,,,,,within the range of,> 16 years.|consent,,,,,,
13242,,metabolic health,,,,,,,,,at signing of informed,younger than 68 years|diagnosis,,,,,,
13243,,hf consistent,,,,,,,,,within 28 days prior to enrollment;|has,> 20ml/min,,,,,,
13244,,cavitated lesion,,,,,,,,,emergency operations|re-operation|elective,more than 4 week.||,,,,,,
13245,,psychoses,,,,,,,,,prior to screening.|subjects,18 or older|oral cavity disease,,,,,,
13246,,clarity,,,,,,,,,within the previous 30 days.|stroke,5.5 - 9.0,,,,,,
13247,,nulliparous pregnancies,,,,,,,,,at least 6-months prior to study enrollment.|lack of,> 18.|patients must,,,,,,
13248,,type 2 diabetes|diagnostic criteria,,,,,,,,,within 3 months before screening.|history of,less than 18 years.|unable,,,,,,
13249,,secondary glaucoma,,,,,,,,,for at least 180 days prior to the day of screening|haemoglobin a1c (hba1c),≤ 3.||,,,,,,
13250,,feeling of swelling,,,,,,,,,within the prior year,<30 minutes,,,,,,
13251,,chronic psychosis,,,,,,,,,within the following ranges:|body temperature,> 35 mmol / l,,,,,,
13252,,biopsy;|(2,,,,,,,,,within 3 months of enrollment,> 2mg/dl,,,,,,
13253,,lumbar degenerative diseases|patient,,,,,,,,,prevent the practice of physical exercise.|not attending psychological therapies,≤ 1.5 x uln.|international normalized ratio,,,,,,
13254,,replacements.|symptomatic disc herniation,,,,,,,,,the previous 2 weeks and minimum life expectancy,greater than uln|have measurable disease,,,,,,
13255,,heart failure)|non-sinus rhythm|concomitant,,,,,,,,,within 24 hours of intervention,above 18 years old,,,,,,
13256,,digestive segment,,,,,,,,,within some of the genital vitiligo areas.|at least 1,than 4,,,,,,
13257,,-reading.|cares,,,,,,,,,for at least 12 months|willing,"below 50,000",,,,,,
13258,,degenerative neurological disease,,,,,,,,,within 4 weeks before qualifying endoscopy,> 16 years,,,,,,
13259,,anal stenosis,,,,,,,,,persistent,18-75|definitely,,,,,,
13260,,snhl|inability to read,,,,,,,,,within past 3 months.|history,c,,,,,,
13261,,t2n0,,,,,,,,,within 3 months before the study,12)|race: 50% african american,,,,,,
13262,,age.|biopsy,,,,,,,,,during the trial to be enrolled;|subjects are participating in other clinical studies,>450 ms.|clinically significant,,,,,,
13263,,ctcae toxicity grade,,,,,,,,,at the time of enrollment||willing to provide written informed,≥ 2.0×109/l,,,,,,
13264,,bruton's tyrosine kinase inhibitor (,,,,,,,,,for two hours following product application,twice a day,,,,,,
13265,,imsct,,,,,,,,,within 7 days prior to c1d1.|sexually active,50+,,,,,,
13266,,malignant tumours,,,,,,,,,at the time of enrollment.||,45 to 59;|phase of reproductive,,,,,,
13267,,facet joint stenosis|previously kyhoscoliotic,,,,,,,,,within 12 months of randomization,35-80 years,,,,,,
13268,,renal artery,,,,,,,,,at least 3 months ago,less than or equal to 450 msec,,,,,,
13269,,clinical pathology,,,,,,,,,within 14 days before the first dose;|patients,65 to 90 years old||,,,,,,
13270,,elect,,,,,,,,,within 24 hours prior to study treatment,within 18.0 kg/m^2 to 33.0 kg/m^2,,,,,,
13271,,malignant hypertension,,,,,,,,,for at least 4 weeks prior to the first study,≤ 42.3mg/fev1 %f all,,,,,,
13272,,acute pulmonary insufficiency,,,,,,,,,in the last 2 years|deterioration,between 50 and 60 years old,,,,,,
13273,,disease|asymptomatic prostate cancer,,,,,,,,,within 14 days of first dose of b1962|uncontrolled,18 to 65 years|bmi,,,,,,
13274,,psychiatrically healthy|between the,,,,,,,,,within 30 days prior to screening/enrollment|any condition,≥ 9 points,,,,,,
13275,,cerebrovascular disease|patients,,,,,,,,,within 7 days of cycle 1 day 1,score,,,,,,
13276,,speaker|baseline pain rating,,,,,,,,,within 7 days before leukapheresis,≥ 30 times /min|at rest,,,,,,
13277,,itrathecal anathesia,,,,,,,,,at the time of the signature of informed consent form,≥ 23|reduced,,,,,,
13278,,ctcae adverse events,,,,,,,,,at the study hospital,stage-b or c,,,,,,
13279,,good oral hygiene,,,,,,,,,within 6 months before screening;|alcohol,18-40.|nullipara,,,,,,
13280,,sperm-producing,,,,,,,,,prior to collection,≥ 1500/mm3|hemoglobin,,,,,,
13281,,abstain from sexual,,,,,,,,,one or more,≥18 and ≤80 years,,,,,,
13282,,dynamic small bowel obstruction,,,,,,,,,at least 3 full days per week,<5.0°;|medium/high,,,,,,
13283,,spastic diplegic cerebral palsy|age,,,,,,,,,at the time of surgery|subjects,18.0 kg/m2 or more,,,,,,
13284,,sleep-related breathing disorders,,,,,,,,,within the previous five years|previous,≥50% stenosis of the internal carotid,,,,,,
13285,,conjunctival nevus,,,,,,,,,prior to randomization|treatment with,< 45 ml/min/(1.73,,,,,,
13286,,primary malignancies,,,,,,,,,within 4 weeks prior to the first dose of this study,> 3000/mm^3|platelet count,,,,,,
13287,,old;|acute ischemic stroke,,,,,,,,,before the trial|patients,>5|experimental,,,,,,
13288,,idiopathic bell's palsy,,,,,,,,,at the time of recruitment,>50 ml/min/1.73 m2,,,,,,
13289,,liver tumor,,,,,,,,,within 60 days after the last dose;|patients,18 - 65|first-time transplant|abo,,,,,,
13290,,tumor lifting|refusal,,,,,,,,,within 30 days prior to first dose of trial,< 13,,,,,,
13291,,asymptomatic prostate cancer,,,,,,,,,for 3 months after brachytherapy.|patients must agree to use,<50.00 x 109,,,,,,
13292,,uncontrollable diabetes mellitus|patients,,,,,,,,,prior to index surgery.||prospective,60-89,,,,,,
13293,,acute dental conditions,,,,,,,,,for at least 1 month)|patient,more than (>) 84 days following initiation (cycle 1 day 1,,,,,,
13294,,lumbar stenosis,,,,,,,,,at the day of inclusion|able to understand,<60ml/min/1.73m2,,,,,,
13295,,immune compromised,,,,,,,,,in the 2 years preceding the study,0-3.|white blood cell count,,,,,,
13296,,nutritional fragility,,,,,,,,,following the last dose of study drug,<0.26 or >1.65,,,,,,
13297,,criteria for ivf,,,,,,,,,in 1 year,>2 months,,,,,,
13298,,psoriasis.|history of disease stimulated,,,,,,,,,during the study period|unable to ambulate,> 5 units/day,,,,,,
13299,,ffpe tumor block,,,,,,,,,in the past 2 years.|diagnosis,≤ 3 × institutional,,,,,,
13300,,hay,,,,,,,,,within the past 3 months.|patient,diagnostic laparoscopy.||the,,,,,,
13301,,g93.3,,,,,,,,,within 48 hours before the first administration of the study drug.||vaccines,proven,,,,,,
13302,,peptic ulceration,,,,,,,,,within 12 months prior to the first administration of study vaccine,0 to 2.||brain,,,,,,
13303,,palpable mass,,,,,,,,,at the time of entry into the trial,>20ml/kg,,,,,,
13304,,extrahepatic cholangiocarcinoma,,,,,,,,,more than once a week,between 0 and 1,,,,,,
13305,,left atrial volume index (,,,,,,,,,within the past 90 days|patients,≤ 2 mg/dl|asat/,,,,,,
13306,,preoperative anxiety,,,,,,,,,in the last two weeks in the area,≥ 3.5,,,,,,
13307,,general conditions,,,,,,,,,within the past 5 years.|participants,requires dietary supplementation,,,,,,
13308,,dihs,,,,,,,,,within the last 6 months prior to,later than 48 h,,,,,,
13309,,progressive pulmonary autoimmune,,,,,,,,,within 14 days of enrollment.|history of,<100 ng/ml,,,,,,
13310,,etc.;|asplenia,,,,,,,,,prior to any review,less than and/or equal to 5,,,,,,
13311,,respiratory failure hypertension,,,,,,,,,within two years)||,≥ 12 weeks.|recurrent breast cancer,,,,,,
13312,,developmental performance questionnaire,,,,,,,,,at no more than 4 mg,≤2.5 × institutional uln,,,,,,
13313,,metastatic disease|written,,,,,,,,,in the last 3 years.||antibiotic intake 6 months before • the screening,long-term rehabilitation,,,,,,
13314,,hashimoto's thyroiditis,,,,,,,,,at birth||for,3 irae,,,,,,
13315,,pulmonary hypertension|patients,,,,,,,,,within 2 weeks after study treatment administration note:,males).|immuno-compromised,,,,,,
13316,,systemic immune checkpoint,,,,,,,,,previous 30 days before first imp administration until the last blood draw,50 kg,,,,,,
13317,,complex anal fistula,,,,,,,,,within 23 hours of study,< 60 db hl,,,,,,
13318,,lower limb pain,,,,,,,,,within six (6) months prior to the ablation procedure|acute mi,< 30 ml/minute,,,,,,
13319,,withhold facial cosmetic treatments,,,,,,,,,within 3 years prior,≤26 kg/m2|three,,,,,,
13320,,record food||,,,,,,,,,for 3 months after final study drug administration,2.5 x unl,,,,,,
13321,,subarachnoid hemorrhage;|coagulation disorders,,,,,,,,,after treatment,between 25-85 decibel hearing level (db hl,,,,,,
13322,,exacerbation episode,,,,,,,,,do not,higher than 2 times of the normal upper limit,,,,,,
13323,,systemic illnesses,,,,,,,,,within 30 days before the first dose,≥5 to ≤17 years,,,,,,
13324,,cardiopulmonary diseases,,,,,,,,,within 6 months prior to randomization,≥ 0.3 mg/dl,,,,,,
13325,,finger distal phalanx,,,,,,,,,during the course of the intervention that are attributable to the pregnancy,<18|not admitted,,,,,,
13326,,cardiovascular disease.|chronic hepatitis b,,,,,,,,,14 days before first study,score 0-2,,,,,,
13327,,slope,,,,,,,,,within 1 year after cell transfusion,> 50 g/l,,,,,,
13328,,abnormal impedance,,,,,,,,,less than 5 years prior to the time of study eligibility,>70 years old|donor lungs,,,,,,
13329,,breast tumor.||,,,,,,,,,within 2 weeks prior to,"between 18 and 80 years,|patient",,,,,,
13330,,neurologic pathologies,,,,,,,,,prior to the first dose,<100 g/l.|platelet count,,,,,,
13331,,additional neurologic condition,,,,,,,,,at the time of consent|able and,21 and above,,,,,,
13332,,chronic hepatitis b infection|absence,,,,,,,,,continue for at least 3 months,6-23 months,,,,,,
13333,,neurologic events,,,,,,,,,during past month,greater than or equal to 9%,,,,,,
13334,,male factor infertility,,,,,,,,,at least last 6 months.|pateint,≥ 18 years|signed,,,,,,
13335,,systemic diseases.|participated,,,,,,,,,within 7 days prior to the first dose of study treatment.|use,≤ 10 cm,,,,,,
13336,,hdf,,,,,,,,,within last 3,18-30|free,,,,,,
13337,,end-stage renal diseases,,,,,,,,,within 14 days for rituximab.|radiotherapy,above 18 years.|currently not,,,,,,
13338,,involves,,,,,,,,,during the taking of measurements,>100 mm,,,,,,
13339,,cause of pleural effusion||.patients,,,,,,,,,past 5 years;|history,≥12 weeks;|at least one,,,,,,
13340,,pulmonary obstructive chronic disease,,,,,,,,,while taking into consideration,>100 beats/min);|low,,,,,,
13341,,renal disease|hypertensive,,,,,,,,,at the time of consent|weight,>200 mg/dl,,,,,,
13342,,thromboembolic complications,,,,,,,,,within next 12 months)|renal failure,≥36 months,,,,,,
13343,,polydipsia,,,,,,,,,pre-transplant,> 9 g/dl.|patients,,,,,,
13344,,auditory canal,,,,,,,,,"within the previous 12 months,|antibiotic intake",90 days.||female,,,,,,
13345,,permanent dentition,,,,,,,,,in the last 4 years|≥ 6 weeks,≤ 1+,,,,,,
13346,,iop recorded,,,,,,,,,within three months.||,> +1.00 diopters|ccts,,,,,,
13347,,inflammatory response,,,,,,,,,at the baseline assessment.|patients,0-30 +/- 10 degrees ankle plantarflexion,,,,,,
13348,,gastrointestinal origin should,,,,,,,,,in the 6 months before screening,more than 28 weeks,,,,,,
13349,,ocular inflammation,,,,,,,,,within 4 weeks from the screening,>10);139|orthopedic problems prohibiting tc,,,,,,
13350,,head and neck radiotherapy,,,,,,,,,during the last 3 months of school,20 cm squared,,,,,,
13351,,memory disorder,,,,,,,,,at time of enrollment|has at least one friend/family/household member participating in the study,5.7% to 6.4%|agreement to adhere,,,,,,
13352,,membranous glomerulonephritis,,,,,,,,,within 90 days of registration,"> 1,500/mm3|platelets",,,,,,
13353,,prevent polyps,,,,,,,,,only)|history,>=2 centimeter,,,,,,
13354,,membranous,,,,,,,,,at least 6 months posttreatment completion|patient,>2.0mg/dl,,,,,,
13355,,intestinal strictures|chronic,,,,,,,,,during screening prior to study entry|obvious non-cardiac cause,=< 3 x uln|creatinine clearance of,,,,,,
13356,,nonmelanoma skin,,,,,,,,,within the last 30 days.|do,>6.0%.|any,,,,,,
13357,,arteriosclerosis,,,,,,,,,during the study period|lung cancers,tms)||more than 3 depressive episodes,,,,,,
13358,,asthma;|aortic aneurysm,,,,,,,,,after screening by pediatric orthopedic surgeon,≥ 5mm,,,,,,
13359,,head and/or neck radiotherapy.|use of,,,,,,,,,during the last 2 years before baseline||,>19,,,,,,
13360,,health literacy,,,,,,,,,for greater than 6 months prior to screening,0-1|patient,,,,,,
13361,,tppv,,,,,,,,,within 28 days prior to registration.|participants,> 2.7 mmol/l,,,,,,
13362,,thromboembolic event.|participants,,,,,,,,,at least 6 months post-study treatment,decrease to <90 mmhg,,,,,,
13363,,macroglobulinemia,,,,,,,,,"at least three months ago,|able to follow two-stage verbal commands",18-65 years|both,,,,,,
13364,,end their life,,,,,,,,,in the past 3 months|exercising,"< 200 000/μl,|urine protein/creatinine ratio",,,,,,
13365,,epidural hemorrhage,,,,,,,,,at least 12 months prior to the,at least 2 days per week,,,,,,
13366,,compliance.||exclusion criteria||uncontrolled hypertension,,,,,,,,,within the past 12 months prior to screening|use of electroconvulsive therapy,70 - 100 ml when,,,,,,
13367,,unsuccessfully trying to conceive,,,,,,,,,at least 14 days before the initial administration of the trial therapy,18-90|self-identified,,,,,,
13368,,refractory cachexia;|bleeding,,,,,,,,,throughout the study treatment period,20-24 years,,,,,,
13369,,radio-iodine ablation,,,,,,,,,within the last 5 years;|severe,23-dec-202210abnormalities,,,,,,
13370,,autoimmune vasculitis,,,,,,,,,pre-terminal diseases,> 1.0cm|the patient,,,,,,
13371,,insular,,,,,,,,,prior to the first dose of study medication|participants,≥10 pack years|pregnancy|absolute,,,,,,
13372,,radical prostate cancer surgery|poor physical condition,,,,,,,,,"within last 6 months),|clinically significant",< 5,,,,,,
13373,,clear virus,,,,,,,,,prior to the study drug,>155/95]|breathing,,,,,,
13374,,pneumocystis pneumonia,,,,,,,,,at least 1 year after menopause,> 325 µm,,,,,,
13375,,drug abuse|chronic diseases,,,,,,,,,at the time of signing the icf.|ecog（eastern cooperative oncology group） performance status,2.8 mmol/l,,,,,,
13376,,british columbia,,,,,,,,,in the past month|the patient,4 or above,,,,,,
13377,,hyperlipidaemia,,,,,,,,,within 5 years before the screening visit,? 2,,,,,,
13378,,bradbury-eggleston syndrome,,,,,,,,,during the trial|diet without maintaining daily habits,"21 years, able to provide",,,,,,
13379,,chronic plaque-type,,,,,,,,,within 6 months prior to the first study dose,<5 years|platelet count,,,,,,
13380,,"45,x karyotype",,,,,,,,,for at least four weeks,within normal institutional limits;|ast(sgot,,,,,,
13381,,non-infectious uveitis,,,,,,,,,within 2 weeks before the study drug administration,< 6 months prior,,,,,,
13382,,age|diagnosis,,,,,,,,,"1 month to 14 years,|no more than 12 hours from the moment",<8 g/l,,,,,,
13383,,ischaemia,,,,,,,,,within one week prior to screening/baseline;|self-reported,< 5 years|subject,,,,,,
13384,,pain problem,,,,,,,,,during the 183 day baseline period prior to and including hospital,50-90 years,,,,,,
13385,,intracranial arteriosclerosis,,,,,,,,,occurring < 6 weeks from enrollment group,≤ 5×uln.||(3,,,,,,
13386,,intense physical,,,,,,,,,in the year prior to participation in the,between 15 and 40 years,,,,,,
13387,,herbal preparations,,,,,,,,,within the past 5 days|insufficient mental,> 30 ml/min.|women,,,,,,
13388,,preventive effects,,,,,,,,,timeline for cell therapy|has a diagnosis,< 350,,,,,,
13389,,eligible heart failure therapies,,,,,,,,,within 6 months of treatment initiation,>35kg/m2|patients,,,,,,
13390,,mild heart defects,,,,,,,,,within 5 years (,"1,500/mm3",,,,,,
13391,,impossible to perform,,,,,,,,,within 1 months before randomization.|subject,grade c,,,,,,
13392,,hypocalcaemia,,,,,,,,,within 4 weeks of the first dose of treatment.|patients,||- not able to read,,,,,,
13393,,peripheral hypoperfusion,,,,,,,,,beginning at least 4 weeks before study initiation,class iv heart,,,,,,
13394,,months|mini-mental state examination≥25|biceps ≤2,,,,,,,,,in the past one week,readiness,,,,,,
13395,,non-small cell lung,,,,,,,,,at the time of e-cpr use|patients,between 45 to 90(include,,,,,,
13396,,health care services,,,,,,,,,within 1 month before the screening;|administration of inhibitors,3.0 mg/dl,,,,,,
13397,,non child bearing potential.||,,,,,,,,,at the screening visit,+ high dose cyclophosphamide)|patients,,,,,,
13398,,scorable facial,,,,,,,,,within four weeks prior to inclusion,<5.6 mmol/l,,,,,,
13399,,surgery|systemic condition,,,,,,,,,over 8 weeks,<30 years,,,,,,
13400,,extracranial lesions,,,,,,,,,within the last 14 days to,> 12|inadequate response,,,,,,
13401,,thalassemia,,,,,,,,,at the time of the screening visit,<8||mild dementia:||participants living,,,,,,
13402,,venous reflux,,,,,,,,,in the last 6 months.|women,drop ≥ 20 mmhg,,,,,,
13403,,leukemic cells,,,,,,,,,more than 45,≥40kg/m2,,,,,,
13404,,fibroid,,,,,,,,,within 14 days prior to randomization.|receipt of live attenuated vaccines,10 mm hg,,,,,,
13405,,urticaria|active skin conditions,,,,,,,,,within 24 hours prior to start of imp,between 19 and 75 years|subjects,,,,,,
13406,,traumas,,,,,,,,,within 2 months prior to dosing;|has participated,second dose,,,,,,
13407,,intraabdominal abscess,,,,,,,,,for the first time in their life (,>28 days)|history,,,,,,
13408,,complex /severe isolated injury|rehabilitation goals,,,,,,,,,within 1 year prior to screening.|hiv positive,≥ 18 years old years,,,,,,
13409,,monovalent booster,,,,,,,,,< 1 month prior to screening,greater than 450 ms,,,,,,
13410,,kidney diseases.|use,,,,,,,,,within the last 2 years.|underwent ineligible procedures,18-80|non-smokers,,,,,,
13411,,therapeutic apheresis|metastatic disease,,,,,,,,,at the time of surgery.||exclusion criteria||patients,15-30 months,,,,,,
13412,,amino acid(s,,,,,,,,,within 10 days before inclusion|patients,≥38.0 ˚c),,,,,,
13413,,lymphocytosis,,,,,,,,,during the first year of treatment,≥10 years|age,,,,,,
13414,,criteria of the most current version of the diagnostic and statistical manual of mental disorders (dsm),,,,,,,,,in the last 2 years before randomization,>= 70|ability to read,,,,,,
13415,,pulmonary arterial hypertension,,,,,,,,,within 2 weeks of screening,18-54|female|pre-menopausal|can,,,,,,
13416,,ascites fluid,,,,,,,,,within 6 months before the first dose of the study drug,<60 ml/min/1.73m2;|age ≥70 years.|written informed consent||,,,,,,
13417,,clinical practice|other malignancy,,,,,,,,,within 28 days of study entry,<29.9kg/,,,,,,
13418,,hypertrophic cardiomyopathy)|chronic obstructive pulmonary disease,,,,,,,,,within 2 months prior to the first study drug dose,last intake <48 hours,,,,,,
13419,,radical cystectomy,,,,,,,,,for at least 28 days before baseline|able,≥ 17;|never,,,,,,
13420,,completed curative treatment,,,,,,,,,prior to transplant).||,> 75 years,,,,,,
13421,,heart rate in sinus rhythm,,,,,,,,,within the last 2 weeks before study start.|acute myocardial infarction,1.0 ng/ml.|soft-tissue progression,,,,,,
13422,,mecom syndrome,,,,,,,,,within 1 month prior to the expected date of the first dose,between 40-60 years.|unilateral,,,,,,
13423,,sperm dna fragmentation,,,,,,,,,more than 25||,which does not have the potential to interfere with safety,,,,,,
13424,,merkel cell carcinoma,,,,,,,,,within one year of screening,≤ 2.5 times uln,,,,,,
13425,,nonmetastatic breast,,,,,,,,,at the time of initial study,>= 18 years||patients,,,,,,
13426,,retinal function,,,,,,,,,within 12 months after autologous stem cell,minimum 4 weeks,,,,,,
13427,,postoperative pain,,,,,,,,,within 2weeks prior to investigational drug administration;|patients,>470 milliseconds|history,,,,,,
13428,,drugs or chemicals,,,,,,,,,for at least 14 days prior to first dose of study treatment|active,greater than 30 mm,,,,,,
13429,,months|narcotic use,,,,,,,,,after radiotherapy for a localized lung cancer,between ≥6 to <12 years,,,,,,
13430,,fetal harm,,,,,,,,,at screening of,> 480 milliseconds,,,,,,
13431,,plasma creatinine,,,,,,,,,within 3 months;|history,< 16 years|incomplete,,,,,,
13432,,stroke；|sleep disorders,,,,,,,,,within 28 days of cycle 1 day,under 40 years|insufficient,,,,,,
13433,,restless leg syndrome,,,,,,,,,within 60 days after step 1 registration|step 1,< 60 ml/min/ 1.73 m2,,,,,,
13434,,schizophrenia spectrum disorder,,,,,,,,,for at least 3 months prior to,18 years or older.|ability to complete surveys,,,,,,
13435,,ocular involvement,,,,,,,,,at the time of enrollment|2.generally in good health,<60 beats/minute)|resting,,,,,,
13436,,total shoulder arthroplasty,,,,,,,,,within 30 days or more than 499 ml,over 18 years|moderate-to-severe,,,,,,
13437,,chronic systemic infections,,,,,,,,,at least 3 months after initial ist,19.0 and 24.9 kg/m2.|long-term residence,,,,,,
13438,,intractable bronchial asthma,,,,,,,,,within past 48 hrs.|experiencing,older than 71 years,,,,,,
13439,,vulvar cancer,,,,,,,,,within the preceding 3 months.|women,> 30%,,,,,,
13440,,kütahya||newborns,,,,,,,,,within 3 years before first study vaccination,women|21-45 years,,,,,,
13441,,respiratory syndrome,,,,,,,,,within 14 days before trial product administration.|clinical evidence,0-2|must,,,,,,
13442,,anterior segment,,,,,,,,,during the 4 weeks preceding day 1 of cycle 1 and,between (18-31) kg/m2|they,,,,,,
13443,,acute physical disease,,,,,,,,,within 3 months before signing the icf;|positive,≥ 3.0x10 ^9,,,,,,
13444,,including:||renal cell carcinoma,,,,,,,,,within the last 6 months|no,≥ 28 g/l,,,,,,
13445,,bone cysts|complete,,,,,,,,,for at least 6 months after completion of adjuvant treatment,≥ 2 points,,,,,,
13446,,ischemia).||,,,,,,,,,previous three months before study vaccine,>15% since start,,,,,,
13447,,muscular dystrophy;|any condition,,,,,,,,,in the previous month prior,≥18 to ≤80 years,,,,,,
13448,,metals)|6.active vaginal infection,,,,,,,,,prior to study treatment administration,≥ 1000 prior to catheter,,,,,,
13449,,cancer risk syndromes.||inclusion,,,,,,,,,prior to admission to the trial.||,18-55 years|motivated,,,,,,
13450,,prednisolone|acute bacterial infection,,,,,,,,,in the last 12 months|dysphagia,≤ age ≤ 65 years,,,,,,
13451,,psychotherapy;|allergy,,,,,,,,,in the last 1 month.|have,above 200mml/dl,,,,,,
13452,,bradycardia|concomitant,,,,,,,,,at least 8 years,> 30 ml/min/1.73 m2||baseline audiology,,,,,,
13453,,auditory problems,,,,,,,,,at least 1 episode,>750 cells/mm3.|hemoglobin,,,,,,
13454,,detectable sections.|blood,,,,,,,,,within 12 months.||patients,between 18 and 75 years.|clinical diagnosis,,,,,,
13455,,double-barrier method of birth control,,,,,,,,,within 4 weeks prior to enrollment|ec 4 more than one prior,18.5 to 29.9 kg/m2,,,,,,
13456,,"systemic disease,|gingivitis",,,,,,,,,within the last 2 months|history of,≤ 5x uln|g,,,,,,
13457,,sperm donation plan,,,,,,,,,within 3 months of recruitment,> 50 years,,,,,,
13458,,anaplastic oligodendroglioma,,,,,,,,,≤14 days before receipt of study vaccine,≥ 18.5.|sexually,,,,,,
13459,,aronia berries,,,,,,,,,at the french paraneoplastic neurological syndrome reference center,less than or equal to (<=) 40%,,,,,,
13460,,her2 in situ hybridization assay (fish,,,,,,,,,prevent,score more than 4|clinical presentation,,,,,,
13461,,intrauterine infection,,,,,,,,,within the last week,>=10 percent,,,,,,
13462,,steroids.|patients,,,,,,,,,during last 3 months|other,+ t cell count,,,,,,
13463,,acute wound,,,,,,,,,randomization|history,between 18.0 and 30.0 kg/m2|free from,,,,,,
13464,,avascular necrosis,,,,,,,,,within the last year;|thyroid stimulating hormone (tsh),greater than 32 inches,,,,,,
13465,,pad from the afs,,,,,,,,,within the 4 weeks prior to the baseline visit,≥ 90%).|severe infection,,,,,,
13466,,unresectable nsclc,,,,,,,,,within 4 weeks prior to randomisation)|platelet count,≤ 80 % of predicted value,,,,,,
13467,,early onset strokes,,,,,,,,,within 2 years prior to signing informed,< 500 /μl (0.5 × 10^9/l);|hemoglobin < 7 g/dl;|white,,,,,,
13468,,time from injury,,,,,,,,,within 4 weeks prior to the initial administration of the study,between 18 and 85 years,,,,,,
13469,,hypertension;|absence,,,,,,,,,within the specified time windows.|willingness,≥18 and ≤80,,,,,,
13470,,fⅷ/fⅸ inhibitors,,,,,,,,,within 4 weeks before starting the study,6-35 months,,,,,,
13471,,baseline;|covid-19 infection,,,,,,,,,within 2 weeks prior to treatment initiation,from 18 to 70,,,,,,
13472,,child:||not,,,,,,,,,within the 3 months prior to baseline,18 to 60 years|t2dm||,,,,,,
13473,,suicidal behavior|female,,,,,,,,,within 28 days before the first dose of study drug,grade ii-iv)|stroke,,,,,,
13474,,choroidal neovascularization|cataract,,,,,,,,,within 180 days prior to the screening,≥ 60 mg/dl,,,,,,
13475,,main duct involvement,,,,,,,,,7 days prior to registration,>18 years.|total knee arthroplasty,,,,,,
13476,,tinnitus,,,,,,,,,during the 8 weeks before the first administration of imp,≤ 1.5 x upper limit normal (uln),,,,,,
13477,,sarcoma of the nasopharynx.||2,,,,,,,,,within the prior 90 days 10,below 24,,,,,,
13478,,neuro-,,,,,,,,,for less than 5 years prior to screening,< 20 ng/ml|gleason score,,,,,,
13479,,control group)|for,,,,,,,,,at least 6 months before the start of the study therapy,between 11 and 17 years|italian speaking|patients',,,,,,
13480,,microscopic margins,,,,,,,,,prior to beginning specific protocol,>= 7 days after the last dose of agent.|antibodies,,,,,,
13481,,neoplasia|pregnant,,,,,,,,,at the time of screening.|haemoglobin,3 months to 15 years||presents for care,,,,,,
13482,,skating,,,,,,,,,within 4 weeks prior to screening.|pregnant,≥ 0.5,,,,,,
13483,,former smoker,,,,,,,,,within 7 days prior to enrolment,1.1 criteria|estimated life expectancy,,,,,,
13484,,metachronous tumors|communication disability,,,,,,,,,within 14 days or five,14 to 40 years||,,,,,,
13485,,joint infection,,,,,,,,,for at least,≥ 18|patients,,,,,,
13486,,eczema dermatitis,,,,,,,,,in the last six months|volunteering,< 0.8 snellen|pregnancy,,,,,,
13487,,or|radiographic findings,,,,,,,,,at time of knee injury,≤ 1.5 × uln；||after the completion,,,,,,
13488,,infection|diagnosis,,,,,,,,,prior to the initial dose,responses to warm,,,,,,
13489,,febrile infections,,,,,,,,,within 28 days prior to sub-study randomization|participants,<3.0 kg,,,,,,
13490,,cutaneous basal cell carcinoma.|failure,,,,,,,,,prior to the signing of informed consent;|have,≥ 50%.||sign the written informed,,,,,,
13491,,unless,,,,,,,,,within the specified time frame.|the time from the last use of,≥ 75 db nhl||2,,,,,,
13492,,retinal vein occlusion,,,,,,,,,during the operation,≥1.5 ×109/l,,,,,,
13493,,thrombotic tendency,,,,,,,,,in the past 5 years;|for subjects,≥ 92%,,,,,,
13494,,respiratory disease exacerbations,,,,,,,,,during the clinical screening visit,levels ≤ 2.5 × uln,,,,,,
13495,,withdrawal effects,,,,,,,,,in the last 3 months.|patients,nitrogen>17.9 mmol/l,,,,,,
13496,,operational performance|acute surgical performance|synchronous malignant disease|multivisceral,,,,,,,,,within 30 days of baseline,> 3 x upper limit of normal,,,,,,
13497,,clinical response,,,,,,,,,in first line after 21/jan./2021,≥ 85 mm hg,,,,,,
13498,,covid 19 vaccination certificate,,,,,,,,,within =< 1 year,<8.5 gram per deciliter,,,,,,
13499,,extra-nodal peripheral t cell lymphoma,,,,,,,,,at the time of recruitment|participants,≥ 9.0g/dl,,,,,,
13500,,special communication needs.|subjects,,,,,,,,,at the implantation segment|pre-existing,at least 10 mm hg,,,,,,
13501,,conditions of the arms,,,,,,,,,for at least 6 months|an unanesthetized schirmer's test score (,>1;|contraindication to intravenous,,,,,,
13502,,uveitis|monocular,,,,,,,,,within 3 weeks prior to check-,≤ 30%,,,,,,
13503,,gilbert's syndrome|ldl,,,,,,,,,within 3 months of inclusion|iloprost expected,6 consecutive,,,,,,
13504,,iugg,,,,,,,,,in the past 6 months before the first treatment;|pregnant,1-3 days/week,,,,,,
13505,,x-linked hypophosphatemia,,,,,,,,,<6 months prior to the baseline,25.0 to 40 kg/m2|average self-reported,,,,,,
13506,,active viral,,,,,,,,,"within the past 30 days,|history",less than 55 or,,,,,,
13507,,2021)||astrocytoma,,,,,,,,,within 56 days,> 41 u/l||c.,,,,,,
13508,,parp-inhibitors,,,,,,,,,within 14 days prior to vaccination;|receipt of blood,greater than 75 years,,,,,,
13509,,upper gastrointestinal ulcer/bleeding,,,,,,,,,within the previous 14days,<60/min,,,,,,
13510,,reproductive physician)|number of available embryos(day 3)≥4|informed,,,,,,,,,within 3 months before screening.|bone marrow,> 65 years,,,,,,
13511,,av-block)|serious,,,,,,,,,in the 3 months preceding the enrollment,within therapeutic range of intended use of,,,,,,
13512,,retinal holes.|any,,,,,,,,,within the limit of normal.|patients should,above the level of the horizontal line,,,,,,
13513,,brainstem syndrome,,,,,,,,,up to 18 years|patients,> 2 times upper limit of normal,,,,,,
13514,,polysubstance abuse,,,,,,,,,within 4 weeks before first dose of study,under 1 year|orthopedic,,,,,,
13515,,liver abscesses,,,,,,,,,within 5 years prior to randomization,> 30 kg/m2)|pregnant,,,,,,
13516,,serious illnesses,,,,,,,,,ended prior to enrollment)|results,≤ 1.5;||,,,,,,
13517,,drug toxicity,,,,,,,,,in the 14 days prior to pdt,greater than 40,,,,,,
13518,,non-stable,,,,,,,,,postoperatively,than 75%,,,,,,
13519,,chronic neurologic conditions,,,,,,,,,within 30 days of screening.|history of organ transplant,125-139,,,,,,
13520,,mitral valve insufficiency,,,,,,,,,1 month prior to the screening period.|the patient,> 5 x uln,,,,,,
13521,,abrasions,,,,,,,,,after at least 1 line,37-41,,,,,,
13522,,hsv-1 infection,,,,,,,,,within last five years,score <9 on admission,,,,,,
13523,,hypermobility,,,,,,,,,within 6 weeks before enrollment;|previous participation,≥30 ml/min/1.73 m2,,,,,,
13524,,tyrosine kinase inhibitor.|patients,,,,,,,,,within 2 weeks before the first dose of study drug.||active,< 6 points,,,,,,
13525,,primary immunodeficiency.|known,,,,,,,,,at the time of screening|diagnosed,18 to 80 with provisional diagnose of mi||,,,,,,
13526,,thrombolysis,,,,,,,,,ileostomy|more than three doses,≥ 18 years|csai,,,,,,
13527,,parkinson's syndrome|subcutaneous,,,,,,,,,within the first 2 years after the operation,≥ 3.0 g/dl|egfr,,,,,,
13528,,persistent cancer pain,,,,,,,,,within 28 days prior to start of study medication|other,between 18-35 years|bmi,,,,,,
13529,,vocal cord palsy,,,,,,,,,in the past 6 months:||mean corrected qt interval,≥ 2.0 x uln**|albumin ≥ 2.8 g/dl|ast/alt,,,,,,
13530,,light brown,,,,,,,,,within 14 days of anc assessment,< 18 years)/only,,,,,,
13531,,nasolacrimal drainage abnormalities,,,,,,,,,form|neurological history,score of 8 or higher,,,,,,
13532,,recovered from any surgical effects.|participant,,,,,,,,,within 6 months before the estimated enrollment date,less than or equal to 75 years|willingness,,,,,,
13533,,hla-dq2.5,,,,,,,,,within the past 3 months|presence,i or ii,,,,,,
13534,,oral mucosal lesions,,,,,,,,,at time of screening.|has,18.0 to 32.0 kilogram per meter square (kg/m^2)|a total body weight of more than (>),,,,,,
13535,,conservative care,,,,,,,,,within 24 hours pre-dose,> 5.6)||,,,,,,
13536,,male vasectomy,,,,,,,,,within 30 days prior to enrollment,between 2 1/2 to 5 years of age||inclusion criteria,,,,,,
13537,,intracranial segment,,,,,,,,,within 1 year prior to screening.|subjects,at least 12 weeks||participants,,,,,,
13538,,colorectal cancer|patient,,,,,,,,,within 12 months after the study;|history,less than 3|qualifying stroke event,,,,,,
13539,,brain injury.||exclusion criteria,,,,,,,,,within the last 1 week.|people,5/10 pain level,,,,,,
13540,,drug-related pulmonary,,,,,,,,,during active study phase,9-17 years,,,,,,
13541,,nasopharyngeal cancer,,,,,,,,,in the past 2 years.|abdominal fistula,≥90 × 109/l,,,,,,
13542,,lumbar,,,,,,,,,within 6 months prior to randomization.||,stage ii nk|decreased,,,,,,
13543,,blind-loop,,,,,,,,,within 6 months before the selected treatment,1,,,,,,
13544,,retention urinary tract,,,,,,,,,within 72 hours||,over 180/100 mmhg,,,,,,
13545,,pyruvate kinase deficiency,,,,,,,,,for at least 2 months before recruitment to the study|daily free sugar intake ≥5% of the daily energy intake||,= clozapine,,,,,,
13546,,temporary disease,,,,,,,,,within two weeks prior to period i dosing.|use,> 2 norms,,,,,,
13547,,intercurrent infection,,,,,,,,,during the treatment.|patients,>= 18 years|willingness to provide,,,,,,
13548,,pulmonary surgery|α1 antitrypsin deficiency|autoimmune diseases|patients,,,,,,,,,in the past 12 months|have cognitive,mimi.|timi 2-3,,,,,,
13549,,neurologic condition,,,,,,,,,within the previous 4 weeks prior to enrollment,> 1 year.|patient,,,,,,
13550,,infections contra-indicated,,,,,,,,,at least 20 cigarettes per week,≤ 40 years,,,,,,
13551,,brca,,,,,,,,,for at least two years,never,,,,,,
13552,,pe,,,,,,,,,during the trial period;|used live,exceeding 159 mm,,,,,,
13553,,intraretinal fluid,,,,,,,,,within 30 days of enrolment,100-126 mg/dl)|who,,,,,,
13554,,seizure disorder.|current,,,,,,,,,within 6,<60 days abstinence,,,,,,
13555,,cancer patient|able to start a,,,,,,,,,in the department of anesthesiology,18 - 50,,,,,,
13556,,diagnostic tumor,,,,,,,,,within a week of scheduled,≥3 months.|at least one,,,,,,
13557,,hip pain,,,,,,,,,within 6 months before the first administration of clinical trial,31-84 months,,,,,,
13558,,sick,,,,,,,,,taste disturbance,less than 17.5kg/m2,,,,,,
13559,,old|diagnosis,,,,,,,,,within 12 months.|mentally competent,grade ≤ 1.|no,,,,,,
13560,,rectovaginal fistula,,,,,,,,,30 days prior to screening,=<12,,,,,,
13561,,bph,,,,,,,,,within past 5 years;|renal,above 38.2 degrees celsius,,,,,,
13562,,lipolysis,,,,,,,,,within 14 days prior to receiving the trial drug,18-75 years old,,,,,,
13563,,visible textural lesions,,,,,,,,,in the past 1 month;|those,> 18 years|parent,,,,,,
13564,,indicative of psychosis,,,,,,,,,at the time of consent to participate this,≤ 2 mg/kg/day).|methotrexate,,,,,,
13565,,android operating system,,,,,,,,,within the past 4,>400 ml|age,,,,,,
13566,,idiopathic sudden death,,,,,,,,,within 14 days of starting azeliragon,<0.55 µu/ml,,,,,,
13567,,chronic renal insufficiency (,,,,,,,,,during the 7 days before the first dose of radioligand (pet subjects,≥ iii,,,,,,
13568,,risk features,,,,,,,,,more than 1 year before the screening,=,,,,,,
13569,,smooth muscle sarcoma);|no,,,,,,,,,within 4 weeks before inclusion|active,60%,,,,,,
13570,,neuroendocrine differentiation,,,,,,,,,within the last 4 weeks|spinal,i to iv,,,,,,
13571,,brief psychotic disorder,,,,,,,,,within 56 days prior to the first dosing.|any reason,? must,,,,,,
13572,,type c,,,,,,,,,within 2 weeks of laboratory test used to determine,between 25 and 30 kg/m2.||exclusion,,,,,,
13573,,online qca,,,,,,,,,within 2weeks prior to investigational,< 65 mmhg)|patient,,,,,,
13574,,pacemakers.|atrial fibrillation,,,,,,,,,recent 12 months indicating,≥145 mm hg,,,,,,
13575,,pain on function,,,,,,,,,age>40 years|presence,greater than 300,,,,,,
13576,,urinary malformation,,,,,,,,,within 12 months before the first dose,between 60-75 years|bmi,,,,,,
13577,,death syndrome,,,,,,,,,after receiving at least one line,12-24 months,,,,,,
13578,,psychological diseases;|pregnancy,,,,,,,,,for at least 14 days prior to enrollment.|recently,≥3 x uln,,,,,,
13579,,urinary sample collection|other concerns,,,,,,,,,within 2 weeks prior to meta10-19 infusion|patients who participated in other clinical trials within 30 days prior to enrollment|patients,20,,,,,,
13580,,myeloid leukaemia,,,,,,,,,in the target area.|skin abnormalities,< 28 weeks|singleton and multiple,,,,,,
13581,,non-schwannomatosis cause,,,,,,,,,>5 days per month.|current,<90,,,,,,
13582,,transient ischemic attack [tia,,,,,,,,,within the study area,< 18 years|history,,,,,,
13583,,dialysis,,,,,,,,,more than 3 times higher than the upper limit of normal,"1 or 2),|for",,,,,,
13584,,recurrence liver metastasis,,,,,,,,,"throughout the study.|smoking,|having a lifestyle deemed incompatible",< 8|there,,,,,,
13585,,extensive abdominal adhesions|patients,,,,,,,,,during the taste test,"< 100,000/μl",,,,,,
13586,,hepatic metastasis;||adequate renal function,,,,,,,,,in the next 52 weeks;|absolute,less than 80% of predicted value||,,,,,,
13587,,platelet inhibitory properties,,,,,,,,,following initial curative treatment,<90 ml/min/1.73m2,,,,,,
13588,,cognitive impairment|vertebral,,,,,,,,,during the trial,between less than 25 and greater than 35 kg/m2.|subjects,,,,,,
13589,,organic mental dysfunction|participate,,,,,,,,,within the 3 months before,between 40 and,,,,,,
13590,,hodgkin lymphoma,,,,,,,,,history within 3 months before administration,> 480 msec||long qt syndrome,,,,,,
13591,,isolated mitral valve repair,,,,,,,,,in the last 24 months,≤ 1.5 x upper normal limit (uln),,,,,,
13592,,inflammatory spondyloarthropathy,,,,,,,,,concurrently,<10.0 g/dl,,,,,,
13593,,non-injury,,,,,,,,,for 2 minutes|psychological disabilities,5-25% blasts,,,,,,
13594,,intranodular lesion,,,,,,,,,in the last three months,>126 mg/dl.|history,,,,,,
13595,,cardiac conduction abnormalities,,,,,,,,,after definitive therapy with,≤ 57,,,,,,
13596,,primary immunodeficiency;|for hepatitis b (hbv),,,,,,,,,in the past 12 months||father,17-28 kg/m2||male,,,,,,
13597,,covid-i9.|regular intake,,,,,,,,,at the time of enrollment.||index ulcer characteristics:||ulcer,1 or 2|patients,,,,,,
13598,,chronic gastritis,,,,,,,,,within 14 days prior to day 1|able to comply with treatment,> 3 units/day,,,,,,
13599,,primary anxiety disorder,,,,,,,,,for >14 days,at least 5 half-lives,,,,,,
13600,,hepatitis d virus|patients,,,,,,,,,within the 8 weeks prior to the screening,3x the upper limit of normal [uln,,,,,,
13601,,hypotensive episode,,,,,,,,,at least 1 of the following conditions apply:||not,>80 ng/l,,,,,,
13602,,extensive bleeding,,,,,,,,,within 180 days prior to screening,acute drop of the gfr,,,,,,
13603,,liner,,,,,,,,,in the first line,+ hours/week of care,,,,,,
13604,,functional impact;|known contraindication,,,,,,,,,within 180 days of screening,≥12 weeks;||6,,,,,,
13605,,hypotension,,,,,,,,,within the past 2 years prior,≥1.5,,,,,,
13606,,vestibular diseases,,,,,,,,,within 7 days prior to step 2,0-2|eligibility criteria,,,,,,
13607,,child-bearing,,,,,,,,,within 15 months to 60 months.|thyroid hormones within normal range,≥18 years old|provide,,,,,,
13608,,"successful,|health follow-ups",,,,,,,,,at least one of the legal,≤ 0.50 d,,,,,,
13609,,non-fasting glucose level,,,,,,,,,for at least 7 days prior to baseline,≥50%,,,,,,
13610,,complex coronary lesions,,,,,,,,,within 6 months prior to screening.|poorly controlled,≥ 1|dryness ≥ 1 1||subject,,,,,,
13611,,ffpe tumor,,,,,,,,,at pre-specified,<0.4 miu/l,,,,,,
13612,,cancer specialist considers,,,,,,,,,at least five days a week.|written informed consent,=< 1.5 institutional upper limit of normal,,,,,,
13613,,fetal growth restriction,,,,,,,,,through 120 days after the last dose of pembrolizumab,≥ 30|obese,,,,,,
13614,,type 1 diabetes|use,,,,,,,,,at the time of office visit,from 0 to 3|fluent,,,,,,
13615,,complete coverage,,,,,,,,,in the last 6 months prior,equal or less than 7.1,,,,,,
13616,,adrenalitis,,,,,,,,,6 months to < 1 year,< 1.5 × uln,,,,,,
13617,,"cerebrovascular disease,|uncontrolled asthma",,,,,,,,,prior to surgery|incurable,>15 episodes per hour,,,,,,
13618,,subcutaneous tumors,,,,,,,,,within 12 weeks of screening|any history of vitrectomy,least 18 years,,,,,,
13619,,infarct-related artery,,,,,,,,,within 30 days prior to screening.|as a result of screening,≤ 5 × uln)|creatinine clearance,,,,,,
13620,,her2-low breast cancer,,,,,,,,,for at least 4 weeks before enrollment,0-18 years||,,,,,,
13621,,brain metastases|uncontrolled pleural effusion,,,,,,,,,prior to biopsy,19.0 30.0 kg/m2,,,,,,
13622,,joint contracture,,,,,,,,,within 2 weeks of receiving,≥3 cigarettes/day,,,,,,
13623,,stable copd,,,,,,,,,within 5 years from,2022-2023,,,,,,
13624,,acute deep vein thrombosis|acute soft tissue infection|peripheral artery disease,,,,,,,,,withing the past 2 years,1.it,,,,,,
13625,,kidney function.|unstable cardiac disease.|pregnancy,,,,,,,,,during the last six months prior to enrollment,≥ 2)|evidence,,,,,,
13626,,"drug absorption,distribution",,,,,,,,,in the previous 12 months.|have,singleton pregnancy|patients,,,,,,
13627,,shoulder infection,,,,,,,,,any time prior to enrollment,at least 15 months after the end of antibiotics||,,,,,,
13628,,malignant tumors.|the,,,,,,,,,within 30 days prior to entry into,more than 3 sites,,,,,,
13629,,inflammation of,,,,,,,,,in the past 30 days|pregnancy|enrolled,more than 1×10^6/ml);|erectile dysfunction,,,,,,
13630,,cancer treatment.|bladder stones (inclusion,,,,,,,,,during the study product use.|willing to use,ii-iv).|left,,,,,,
13631,,coke,,,,,,,,,doubling time over six months|psa value,0-is,,,,,,
13632,,preoperative sick sinus syndrome,,,,,,,,,after 14 days of treatment per institutional sop,≤ 100,,,,,,
13633,,b-cell malignancies,,,,,,,,,during the study.|toxicities of prior therapies,> uln;|total bilirubin level ≥1.5 × uln,,,,,,
13634,,bilobular liver metastases,,,,,,,,,at least 6 months prior to screening|individuals,under 18 years old|the patient's refusal|difficult airway story before|congenital,,,,,,
13635,,ectopic,,,,,,,,,< 4 months before randomization.|anticipated need,else than in the breast.||the patient,,,,,,
13636,,interstitial lung disease).||,,,,,,,,,after 4,+ / her2-,,,,,,
13637,,cerebral palsy||•,,,,,,,,,within 3 months prior to the experiment day|recent hospital admission,≤ 6 h,,,,,,
13638,,communication impairment,,,,,,,,,in the first 6 months of the,"at least 1,500 pg/ml",,,,,,
13639,,eb virus,,,,,,,,,within the preceding 90 days.||12,>=4/11,,,,,,
13640,,month|diabetic foot ulcers,,,,,,,,,at the time of signing the informed consent.|male,>=1,,,,,,
13641,,placental site trophoblastic tumor,,,,,,,,,within 4 weeks before screening history,18 years or older.|histologically confirmed,,,,,,
13642,,molecular pathology (amp) criteria1,,,,,,,,,for 180 days after the last dose of treatment.||20,≥18 years|patient has signed,,,,,,
13643,,nervous system damage,,,,,,,,,previously,>30kg||,,,,,,
13644,,mixed urothelial,,,,,,,,,within the last 90 days prior to inclusion|karnofsky index,>550msec,,,,,,
13645,,emotional problem,,,,,,,,,within 180 days before enrollment||patients,0-17;|asa class,,,,,,
13646,,clinical osteoporosis,,,,,,,,,within previous 6 months.|participants,between 7 and 8.5%||,,,,,,
13647,,blood glucose monitoring,,,,,,,,,during the time of the study.|sexually,"<20,000 /µl",,,,,,
13648,,being,,,,,,,,,for at least 3 years.|atopic,≤ 3|life expectancy,,,,,,
13649,,cerebral circulation,,,,,,,,,continue to,>= 7,,,,,,
13650,,glaucoma|abnormal ocular motility,,,,,,,,,at the time of electronic consent,between 0 to 3 years,,,,,,
13651,,interventricular septal thickness,,,,,,,,,don't think clinical trials are appropriate,between 0.2 (inclusive) and 0.6,,,,,,
13652,,caries risk,,,,,,,,,within 3 weeks prior to enrollment|oligohydramnios,> 120bpm)|atrial fibrillation,,,,,,
13653,,gvhd,,,,,,,,,at least 12 weeks after completion of antiviral therapy).|seropositive,≥8.5 g/dl|bilirubin,,,,,,
13654,,axial spondyloarthropathy,,,,,,,,,within 6 weeks before enrollment,greater than three months.|patients,,,,,,
13655,,chronic low back pain)|dementia,,,,,,,,,within 4 weeks of the first dose date.|major surgery,more than 40 kg/m2;|patients,,,,,,
13656,,infiltrative cardiomyopathy,,,,,,,,,within 2 weeks prior to signing informed,≥ 30 g/l,,,,,,
13657,,extrapulmonary tuberculosis,,,,,,,,,in the last month or 500 ml,>=60 ml/min/1.73 m^2,,,,,,
13658,,breast feeding|disease progression,,,,,,,,,at least 12 weeks||adequate,≥ 31 g/dl,,,,,,
13659,,cystic neoplasm,,,,,,,,,for 3 months prior to baseline.||,≤ 1.5 × uln.|a patient,,,,,,
13660,,gum bleeding,,,,,,,,,during initial testing,≥80%|male,,,,,,
13661,,squamous cell carcinoma in situ of the skin,,,,,,,,,during the trial period;|people,<100 µg/g,,,,,,
13662,,myelofibrosis,,,,,,,,,less than 6 months ago,0.90 or less,,,,,,
13663,,back,,,,,,,,,within the last year|reports experiencing,<400 mg/dl,,,,,,
13664,,crohn's disease|familial adenomatous polyposis,,,,,,,,,more than 3 and,greater than equal to 1.1 cm.|left ventricular (lv),,,,,,
13665,,legius syndrome.||applicable,,,,,,,,,over the 3 months prior to date of first dose of study drug.||chemotherapy,≤ 90,,,,,,
13666,,motor neurone disease,,,,,,,,,within 7 days prior to the first dose);|be able to provide,the range,,,,,,
13667,,life-threatening organ dysfunction present.|acceptable vascular access for ckrt,,,,,,,,,within one month of the first session of rtms||,less than 5 or,,,,,,
13668,,reading|allergy,,,,,,,,,at least 15 days of pain,>18.5kg/m2,,,,,,
13669,,polycystic ovarian,,,,,,,,,within 3 months prior to study vaccination;|suspected,0 or 1||adequate,,,,,,
13670,,psychiatric problem,,,,,,,,,within 3 months from enrollment,< 150°,,,,,,
13671,,congestive heart failure.|postural hypotension,,,,,,,,,at any time during study|anti-lymphoma therapy,4 - 18 years,,,,,,
13672,,muscle function,,,,,,,,,in the past 5 years to the university of chicago,<9 g/dl|platelet count,,,,,,
13673,,rapid disease,,,,,,,,,within 3 months before taking the study drug,< 18 years|la thrombus,,,,,,
13674,,"m2,|unstable thyroid dysfunction",,,,,,,,,within 12 months of study recruitment)|renal replacement therapy|systemic treatment,15 and over,,,,,,
13675,,developmental stuttering,,,,,,,,,for at least 1 month,older than 46 years,,,,,,
13676,,metabolic conditions,,,,,,,,,8 weeks earlier before administration,≤ 5 x uln|women,,,,,,
13677,,altered cognitive status,,,,,,,,,during the study.|treatment,18.5-40,,,,,,
13678,,spontaneous coronary dissection,,,,,,,,,within the previous three months;|hematological abnormality,copd|aged 40 years,,,,,,
13679,,co-existent second malignancy,,,,,,,,,within 5 minutes.|with a crown,young than 14 years|patients,,,,,,
13680,,bleeding disorder|pregnancy,,,,,,,,,for more than 120 minutes/week,lower than 100 mmhg,,,,,,
13681,,inflammatory intestinal disease,,,,,,,,,within 24 hours preceding cesarean delivery|insulin dependent,29 for upper 15yo childs|participation opposition.|need,,,,,,
13682,,committed,,,,,,,,,up to 6 months post-partum|untreated,200-239mg/dl,,,,,,
13683,,hm,,,,,,,,,less than 4 weeks prior to baseline,18-30 kg/m2.|the,,,,,,
13684,,injury of the contralateral,,,,,,,,,in the next 15 days|have,>= 5 years,,,,,,
13685,,dihydropyrimidine dehydrogenase,,,,,,,,,in the last year.|fixed deformities,>150 mmhg,,,,,,
13686,,chronic azithromycin,,,,,,,,,at time of picu admission,"≥1,500/mm^3",,,,,,
13687,,mental health agency|access,,,,,,,,,within the past 6 months.|previous receipt of any blood products,≥ 100.0 x109/l,,,,,,
13688,,teeth in,,,,,,,,,for six months before the trial;|treatment with glucocorticosteroids,equal to [,,,,,,
13689,,lower urinary tract symptoms||,,,,,,,,,within 7 days preceding the lab assessment,19 and above for,,,,,,
13690,,organic brain disorder,,,,,,,,,at least one year prior to enrollment|having no to low substance,long-term residents,,,,,,
13691,,deep femoral artery|contraindication,,,,,,,,,within last six months|history of new,greater than equal to 5.0 cm.|la area,,,,,,
13692,,face wounds,,,,,,,,,within 5 months after the final dose of tiragolumab,≤c3 / ≤m5,,,,,,
13693,,poorly controlled,,,,,,,,,for at least 30 days|have,>2.5× upper limit of normal.|any patient judged by the investigator to be ineligible,,,,,,
13694,,pulmonary inflammation,,,,,,,,,within 48 hours before surgery|patients,>3%|indication of,,,,,,
13695,,drug misuse,,,,,,,,,within 30 days prior to imp administration,at least 50 words,,,,,,
13696,,mononeuritis multiplex,,,,,,,,,at the time of enrollment.|at the time of enrollment family must live,< 1.5 times of the normal value,,,,,,
13697,,physical reasons,,,,,,,,,in 6 weeks,greater than 100.5 degrees fahrenheit (f),,,,,,
13698,,severe obstruction syndrome,,,,,,,,,within 48 hours prior to the randomization,≤ 1.5 times the upper limit of normal [uln,,,,,,
13699,,old|pre-diabetes,,,,,,,,,prior to completion of any study-related,≥ 80 cm,,,,,,
13700,,health problems,,,,,,,,,within 28 days before enrollment|patients judged to,≥ 90 g/l.|platelets,,,,,,
13701,,autoimmune disease|positive test,,,,,,,,,at the time of data entry;|a possibility to check,< 15mmhg;|male,,,,,,
13702,,injury.|hypo-/hyperglycemia.|metabolic acidosis.|ketosis,,,,,,,,,msec|active,≥19 early,,,,,,
13703,,er positivity,,,,,,,,,during the intervention,outside 50-90 mmhg,,,,,,
13704,,cl regularly,,,,,,,,,within 2 weeks before first dose.|received,< 12 months.||e3,,,,,,
13705,,.|healthy,,,,,,,,,within 4 weeks prior to the first dose of study drug;|patients,> 10 mg,,,,,,
13706,,phacoemulsification cataract extraction,,,,,,,,,for two months after vaccination;|the girls,>2×uln.|creatinine clearance,,,,,,
13707,,decreased appetite,,,,,,,,,during the past 3 months,≥ 2 diarrhea,,,,,,
13708,,super-eruption,,,,,,,,,for more than 12,> 2.5 ml,,,,,,
13709,,suicidal ideation;|the child,,,,,,,,,within 30 days of enrollment.|known history,between 18 and 55 years|edss,,,,,,
13710,,zone).|previous corneal cross-linking,,,,,,,,,during routine,≥ 10mm|resection,,,,,,
13711,,ectopy,,,,,,,,,at least 3 years,3 months and older,,,,,,
13712,,situs,,,,,,,,,planning vaginal,> 5 times per month,,,,,,
13713,,involvement in psychological treatment program,,,,,,,,,at the time of screening to demonstrate the possibility of,18-70 years|for preclinical cohort,,,,,,
13714,,biliary abnormalities,,,,,,,,,within 3 calendar days after randomization.||weekly paclitaxel x,> 48 mmol/mol,,,,,,
13715,,facial clefts,,,,,,,,,after last dose of osanetant,over 18 years,,,,,,
13716,,coagulation factor deficiency|coagulation disorders,,,,,,,,,within 14 days prior to first administration of study drug,>140/90 mmhg,,,,,,
13717,,head cold,,,,,,,,,within the prior 5 years,<18 years;|unable,,,,,,
13718,,local inflammation|cyst|mucosal disease,,,,,,,,,at the time of inclusion.|mild tbi,stage 0-iii,,,,,,
13719,,transarterial loco-regional therapy,,,,,,,,,within 8 weeks of baseline.|use,30 ml/min/1.73m2,,,,,,
13720,,hypotonia,,,,,,,,,in the study eye|condition,2 - 14 hours,,,,,,
13721,,benign pathology,,,,,,,,,in the past 6 months.|the,does not limit the participant's,,,,,,
13722,,power field(hp,,,,,,,,,within 2 months prior to study,< 1.5' uln,,,,,,
13723,,metal injuries,,,,,,,,,during treatment;|known history,"60 to 80 years""|patient",,,,,,
13724,,myelodysplastic syndrome(mds,,,,,,,,,at least two of the following criteria,<500 or >4000 ng/ml*|current,,,,,,
13725,,isolated ventricular septal defect,,,,,,,,,at the time of enrollment/consent.|subject,functional classification of class 2b or better|patients,,,,,,
13726,,refractory marginal ulcers,,,,,,,,,within 90 days before the first dose of study,stage ii-iv.|must,,,,,,
13727,,ibs,,,,,,,,,within the past six months,52 inches or,,,,,,
13728,,macular traction syndrome,,,,,,,,,at least 30 days|must,"> 3,|severe mental",,,,,,
13729,,tilting-disc,,,,,,,,,1 year,from time of original diagnosis,,,,,,
13730,,severe sensory disorders,,,,,,,,,during the 2 weeks prior to baseline,20 years or older hospitalized,,,,,,
13731,,pregnancy|allergy,,,,,,,,,for at least 12 months|women,≥0.2 ng/ml,,,,,,
13732,,gilbert's syndrome|aspartate aminotransferase,,,,,,,,,within 2 cm of the treatment area,younger than 6 and over 10 years,,,,,,
13733,,irreversible pulpitis,,,,,,,,,within the range of 19.0 to 26.0 kg/m2,≥ 20 kg,,,,,,
13734,,arteriovenous thrombotic events,,,,,,,,,within one year of baseline,≥ 2.0|all,,,,,,
13735,,lensometry,,,,,,,,,administration|any prior receipt of,> 19 years,,,,,,
13736,,hancock,,,,,,,,,4-8,> or =,,,,,,
13737,,jacobina,,,,,,,,,at the screening visit.|ad,≥ 30 ml/min.|activated,,,,,,
13738,,atrial myxoma,,,,,,,,,before starting to use the trial drug;||the,"less than 2.5 times the upper limits of normal).|the patient must willingly provide written, informed consent after being informed of the procedure",,,,,,
13739,,residents,,,,,,,,,for the last 6 months|voluntarily participated,>= 19 years|biopsy confirmed,,,,,,
13740,,disease.|participant,,,,,,,,,within 3 half-lives,between 18 and 70 years old,,,,,,
13741,,c);|congestive heart failure,,,,,,,,,within 3 months indicating,"<10 g/dl|platelets <100,000/μl|inr",,,,,,
13742,,recurrence where inclusion,,,,,,,,,at least 90 days after the last dose of imatinib.||patients,less than 19 years,,,,,,
13743,,acute dental symptom,,,,,,,,,at least 1 month before visit 1.).|taking supplements,≤ 1.5 x uln.|willingness,,,,,,
13744,,attendings,,,,,,,,,within 30 days prior to enrollment;|patients,>/= 18|physician-,,,,,,
13745,,hnscc,,,,,,,,,"after treatment, provided that no exogenous",less than 10% of the lower limit of normal,,,,,,
13746,,mucosal malignant melanoma,,,,,,,,,within 30 days of the index cardiac surgical,≥ 20/100,,,,,,
13747,,pharyngitis responds,,,,,,,,,within 30 days prior to first dose,younger than 5years of,,,,,,
13748,,mitral valve stenosis,,,,,,,,,during the 30 days prior to study entry.||tumors of the central nervous system,≥ 6 weeks antibody-based,,,,,,
13749,,therapeutic antibodies,,,,,,,,,in the past 2 years|regular alcohol consumption,at least 10/10th in binocular.|ability to give consent,,,,,,
13750,,"breast disease|diabetic patients,|medication",,,,,,,,,within the scope,<40 µg/l,,,,,,
13751,,perianal pain,,,,,,,,,for the first time in the 2022-2023,18-65|a,,,,,,
13752,,bacterial endocarditis,,,,,,,,,previous year,≥ 18 years|presence,,,,,,
13753,,identify,,,,,,,,,at the same time；|samples,between 2.9,,,,,,
13754,,solid tumors(dose-escalation phase,,,,,,,,,within 28 days of the first dose of study therapy.|prior,greater than or equal to 10^3 cfu/field;|hospitalized,,,,,,
13755,,aids-defining opportunistic disease,,,,,,,,,prior to immunotherapy,no more than 12 months|patients,,,,,,
13756,,etc.);|3,,,,,,,,,within 12 weeks prior to screening.|participant,between 19 and 45 years,,,,,,
13757,,meningioma,,,,,,,,,within 6 months of screening.|patient,>800ml,,,,,,
13758,,neurodegenerative diseases,,,,,,,,,within 4 weeks of administration of the first dose of treatment.|history of,>2 mg/dl|hemoglobin,,,,,,
13759,,visit|substance,,,,,,,,,within the last five years,18-75;|colonoscopy biopsy,,,,,,
13760,,multiple lumbar punctures,,,,,,,,,within 6 months prior to study treatment,≥ 305 µm,,,,,,
13761,,dementia|traumatic brain injury,,,,,,,,,in the previous 3 months.|anti-inflammatory chronic treatment,≤ 1 g of,,,,,,
13762,,gluconeogenesis,,,,,,,,,one month prior to surgery)|those,>=25||,,,,,,
13763,,skin color,,,,,,,,,for 3 months post procedure,460 ms,,,,,,
13764,,previous covid-19 infection,,,,,,,,,within the last 90 days prior to dosing|history of latent,>3|brachytherapy,,,,,,
13765,,cognitive disorders|has autonomic dysreflexia,,,,,,,,,within the range of intended use,=< 14 days prior to registration)|activated,,,,,,
13766,,ulcer diseases,,,,,,,,,within 4 weeks.|chemotherapy,measure ≥46 cm,,,,,,
13767,,local infections of the skin,,,,,,,,,within the last 2 years from screening.|known medical history,fewer than 15% of the cases,,,,,,
13768,,deficits|left-handedness,,,,,,,,,comorbid,25-70|attended the clinic,,,,,,
13769,,angioedema,,,,,,,,,within three months prior to start of study hdct.|patients,≤ 0.50 mm,,,,,,
13770,,exceptions)|spinal cord compression,,,,,,,,,7 days prior to any,from six to12 years old||,,,,,,
13771,,peritoneal metastases,,,,,,,,,within 28 days prior to sub-study,above 10%,,,,,,
13772,,facial deformity,,,,,,,,,within 3 years,≤ 5 times the upper limit of normal value renal function,,,,,,
13773,,"etc),|neurodegenerative conditions",,,,,,,,,up to 100mg per day)|patients,less than 2 years|ckd 4-5,,,,,,
13774,,dehydroacetic acid,,,,,,,,,in the last 4 months,145 or less||,,,,,,
13775,,regions ocular symptoms,,,,,,,,,within 48 hours prior to the procedure|ec,"≥ 3,000/mcl|absolute",,,,,,
13776,,mci,,,,,,,,,at time of investigation;|hospitalized,iii to iv,,,,,,
13777,,short contact dithranol,,,,,,,,,within 6 months prior to administration of this investigational vaccine,> 1.5 times the upper limit of the normal range,,,,,,
13778,,familial adenomatous,,,,,,,,,during their anticipated months of study participation,less than 12 mm,,,,,,
13779,,parkinson's disease.||,,,,,,,,,within 6 months before the first administration;|qtcf ≥ 480 milliseconds,> 40 iu/l,,,,,,
13780,,scan.|cerebral ischemic stroke,,,,,,,,,within the past six months|cytostatic therapy,between 18.0 and 35.0 kg/m2,,,,,,
13781,,anti-angina medication.|pre-registration,,,,,,,,,at the department of,> 440 msec.|received,,,,,,
13782,,molecularly consistent,,,,,,,,,within 6 months of signing icf.|non-hematological,">= 100,000/mcl||international",,,,,,
13783,,acute hypoxemic respiratory failure,,,,,,,,,at screening before randomization,"< 50,000/μl|infection",,,,,,
13784,,thrombus,,,,,,,,,within 365 days,< the institutional lower limit of normal (lln),,,,,,
13785,,mycosis fungoides,,,,,,,,,in the past 12 months|participants,< 1.5 x upper limits of normal,,,,,,
13786,,"angina,|developed hemodynamic complication",,,,,,,,,at time of hospital discharge||,<38.5°c,,,,,,
13787,,gtps,,,,,,,,,within 28 days prior to,≥90 mmhg)|8,,,,,,
13788,,paroxysmal af should,,,,,,,,,while on study||,60-90 beats/min,,,,,,
13789,,bronchoscopies,,,,,,,,,within 6 months prior to the enrollment,< 6 mm).|missing,,,,,,
13790,,gynecologic malignant disease,,,,,,,,,within the timeframe,< 85% recorded,,,,,,
13791,,anhedonia,,,,,,,,,within the family,>110 mmhg|those,,,,,,
13792,,e those,,,,,,,,,for at least 12 hours,110.5 mg/g).||currently,,,,,,
13793,,occupational therapy|have,,,,,,,,,within 2 weeks before screening and throughout study participation.|participant,us)|stage 4,,,,,,
13794,,neuralgi neurologic disorders,,,,,,,,,6 months after discontinuing the study medication,18 to 59 years.|in,,,,,,
13795,,multiple gestations|chronic pain,,,,,,,,,within the first two weeks of randomization,> 1.5 times uln or < lower limit of normal,,,,,,
13796,,luteal insufficiency,,,,,,,,,during their latest pregnancy.||,greater than 6 months.|normal serum creatinine level,,,,,,
13797,,low back pain|pregnant,,,,,,,,,during the study period and within 6 months after the study;|patients,≥50 ng/ml and <200 ng/ml,,,,,,
13798,,relapsed disease,,,,,,,,,within 12 weeks prior to screening.|history of severe,< 12 months|complex,,,,,,
13799,,peripheral nerve injury,,,,,,,,,for at least 7 days before joining the study,">1,9 ng/dl",,,,,,
13800,,synthetic condom,,,,,,,,,after chemoradiotherapy,65,,,,,,
13801,,alcohol use disorder|women,,,,,,,,,at least 6 months after the last dose.|subjects voluntarily participate,between 19 and 34.9 kg/m2;|the,,,,,,
13802,,vascular anomaly,,,,,,,,,within 6 months after the end of the study|serious psychological,18- 30 kg/m2|asa,,,,,,
13803,,dose|functional net,,,,,,,,,within 4 weeks of baseline,<150cm|current use,,,,,,
13804,,dyslipidemia,,,,,,,,,within 4 weeks of dosing|females,from 7-12 years,,,,,,
13805,,esophageal stricture,,,,,,,,,in the past.|patients who received,more than 3 months;|before,,,,,,
13806,,malignant hyperthermia etc.)|pregnancy|morbid obesity,,,,,,,,,at time of enrollment|pregnancy,>= 12,,,,,,
13807,,habitually worn,,,,,,,,,in the past medical history,> 1.7 before,,,,,,
13808,,significant comorbidities,,,,,,,,,within 7 months;||*female,> 10/hr)|enlarged,,,,,,
13809,,gastrointestinal-related abdominal surgery,,,,,,,,,within 6 months before the start of study treatment,narcotics.||,,,,,,
13810,,sunburn,,,,,,,,,within previous 6 months|diagnosis,> 40%|subject must,,,,,,
13811,,pubic area,,,,,,,,,within 4 hours of rosc||,3-kinase,,,,,,
13812,,day|renal failure,,,,,,,,,during the study period to prevent,≤1.5 times the uln|alanine aminotransferase (alt),,,,,,
13813,,malignant tumor|female,,,,,,,,,at the time of surgery.|patients,above 30 may still,,,,,,
13814,,caries lesions,,,,,,,,,within 4 weeks prior to use of the investigational drug.|stage iia,> 90%,,,,,,
13815,,irritable bowel syndrome,,,,,,,,,≥1 month,-c screen score|has,,,,,,
13816,,uncontrolled epilepsy,,,,,,,,,within the last 6 months|coronary artery disease|chronic heart failure,between 50-65,,,,,,
13817,,postpartum bleeding,,,,,,,,,at least 6 months from diagnosis,between 18 to 45 years,,,,,,
13818,,hockey,,,,,,,,,within the prior 30 days||use of the following medications:||any prior treatment,> 10mg/day,,,,,,
13819,,isolated del,,,,,,,,,within 1 week prior to c1d1)|platelet count,requires urgent intervention,,,,,,
13820,,eating disorders adult,,,,,,,,,within 14 days prior to randomization|mixed,"24-28 weeks of gestation,|ogtt",,,,,,
13821,,impaired height,,,,,,,,,at the time of signing the informed consent.|weight,<=30 ml/min/1.73),,,,,,
13822,,ne||,,,,,,,,,until 3 months after the last dose of study vaccine;|participant,"≥18, ≤75 years old",,,,,,
13823,,eye|eye diseases,,,,,,,,,for the first time|asa,≥60 at least 4 hours per week,,,,,,
13824,,heart failure (chf),,,,,,,,,prior to the first dose of study drugs,greater than 100 ml,,,,,,
13825,,embryonal tumor,,,,,,,,,within 4 weeks prior to receiving cell therapy;|10,≥3 months|willing to,,,,,,
13826,,thrombocytosis,,,,,,,,,before the baseline visit||participation,≥ 9 g/dl|serum,,,,,,
13827,,hepatic failure,,,,,,,,,within 10 days of treatment initiation.||female,≥90cm,,,,,,
13828,,severe peptic ulcer,,,,,,,,,throughout induction/labor course,1 month to < 6 years,,,,,,
13829,,common examples,,,,,,,,,within 7,over 110 kg,,,,,,
13830,,primary peritoneal carcinoma|inoperable,,,,,,,,,within the treatment period (,19 receiving 30 gy,,,,,,
13831,,3|anaplastic oligodendroglioma,,,,,,,,,"within 5 years prior to cycle 1, day 1",≤ 2.5 x institutional upper limit of normal (uln),,,,,,
13832,,urinary retention related,,,,,,,,,respiratory,5+ years,,,,,,
13833,,bleeding diathesis,,,,,,,,,in the past 30 days|a,1 or 2||,,,,,,
13834,,neurocutaneous disorders,,,,,,,,,mri)prior to,> 270°,,,,,,
13835,,swelling episodes,,,,,,,,,within 28 days of study entry.|female,≥3.5 mmol/l,,,,,,
13836,,occlusion conditions,,,,,,,,,within 7 days),objective ≤ 140/90,,,,,,
13837,,pd.|progressive disease,,,,,,,,,previously received up to one line of,≤ 4 mm,,,,,,
13838,,recurrence-free survival,,,,,,,,,within the past 6 months.|a cardiac,>grade 1,,,,,,
13839,,internal medicine,,,,,,,,,for past 6 months,< -3sd)|chronic underlying,,,,,,
13840,,local skin infection|hypersensitivity,,,,,,,,,within the last three months).|previous,< 15 ml/min/1.73m*2,,,,,,
13841,,neurophatic pain,,,,,,,,,during medical interview/anamnesis,>18|a diagnosis,,,,,,
13842,,impaired safety of swallow,,,,,,,,,15 days prior start,less than 6 points;|radiation therapy,,,,,,
13843,,t staging,,,,,,,,,in the 48 hours prior to administration,≥ 18 years;|pathohistologically,,,,,,
13844,,injuries,,,,,,,,,for 150 days after the last dose.|male,>1.0g;|other conditions,,,,,,
13845,,pyelonephritis,,,,,,,,,at least 20 hours per week of clinical,less than 1 or more than 7 years,,,,,,
13846,,metastases;|impossibility,,,,,,,,,within one month before the test,≤ 4,,,,,,
13847,,chronic liver diseases|recent,,,,,,,,,within 72 hours before receipt of any study,>7 mg/dl.||individual level exclusion,,,,,,
13848,,midline hernia,,,,,,,,,within 4 weeks prior to the first dose of study treatment.|known hypersensitivity to,over 18 years|to have trigger finger,,,,,,
13849,,malaria species,,,,,,,,,within 14 days b. hepatic function,foster care,,,,,,
13850,,matutes immunophenotype score,,,,,,,,,at the time of intended treatment,three times more than the normal upper limit of the embodiment|those,,,,,,
13851,,good quality oct,,,,,,,,,at the next visit.|any acute cardiopulmonary condition,<65 years;|residents,,,,,,
13852,,neurologic event resulting,,,,,,,,,within past 6 months|patients,< 500 cells/μl.||,,,,,,
13853,,cerebrovascular diseases;|(2,,,,,,,,,"before enrollment,",1-3|hip,,,,,,
13854,,criteria from vaccination,,,,,,,,,during one of the last two diabetes,> 38.0 °c,,,,,,
13855,,san francisco) classification,,,,,,,,,within 5 days post-sci,less than 7.5%;|the patient's,,,,,,
13856,,breast-feeding|positive igra,,,,,,,,,within 5 years prior to entry,prior to the first study drug administration on day 1,,,,,,
13857,,phenotype||,,,,,,,,,14 days prior,>= 20 kg,,,,,,
13858,,galactose intolerance,,,,,,,,,during feeding,35 -41 weeks to complete the,,,,,,
13859,,herpes virus,,,,,,,,,within 30 days prior to the first administration of study vaccine,=< 2.5 x uln|creatinine clearance of,,,,,,
13860,,standard chemotherapy;|no remission,,,,,,,,,ended more than 6 months before the first cycle of induction chemotherapy.|patients,<40 kg.|current,,,,,,
13861,,paediatric renal tumour|a,,,,,,,,,within 30 days of vaccination,<140/90 (note,,,,,,
13862,,psychiatric disorders|chronic diseases,,,,,,,,,after previous,18-75 (inclusive),,,,,,
13863,,gilbert's disease.||any condition,,,,,,,,,past 3 months prior to screening,i - iii|bmi,,,,,,
13864,,distant metastasis|patients,,,,,,,,,within 3 months prior to testing|any history of lower extremity fracture,"less than 2 years,|contraindication",,,,,,
13865,,signs of non-hypotonic hyponatremia||,,,,,,,,,after at least 4,> 5 × 10^9/l b lymphocytes,,,,,,
13866,,chronic venous insufficiency,,,,,,,,,within one effective illumination area,greater than 2.00 diopters,,,,,,
13867,,serous,,,,,,,,,within 2 weeks before randomization,20 to 70 years.||,,,,,,
13868,,disorder of vigilance compromising,,,,,,,,,during the last 5 days before screening.|any type,≥ 1);|confirmed,,,,,,
13869,,syphilis.|obesity,,,,,,,,,within the 6 month period prior to baseline;|history,< 36 weeks,,,,,,
13870,,primary bone tumors,,,,,,,,,within 12 weeks prior to initial administration.|autologous hematopoietic stem cell transplantation,class ii to class iv,,,,,,
13871,,epilepsy|epileptogenic medications|chronic,,,,,,,,,during the last 3 months|any,≥ 1 mm,,,,,,
13872,,androgens,,,,,,,,,within the past year prior to enrollment|currently enrolled,>3d,,,,,,
13873,,clinically t1c-t4,,,,,,,,,recurrent history,≥ 1.5 gi/l,,,,,,
13874,,focal lesions,,,,,,,,,within 30 days prior to consent,≥ 1.0 × 109/l,,,,,,
13875,,score)>60.||,,,,,,,,,at the time of signing the informed consent)|person informed about study organization,> 100 mm,,,,,,
13876,,malignant blood disease,,,,,,,,,more than 8 units,>159 mmhg,,,,,,
13877,,acute peptic ulcer,,,,,,,,,3 months after the last dose of the study drug.||darolutamide,18 to 80 years old,,,,,,
13878,,under investigation for hiv-associated,,,,,,,,,within 24 hours prior to study treatment initiation.||patients,≥45.0 kg,,,,,,
13879,,adverse events version 5.0,,,,,,,,,within 6 months|serious blood system,≥37 weeks and <42,,,,,,
13880,,poor-quality of ttu image,,,,,,,,,within 28 days prior to enrolement,>= 9 g/dl|serum,,,,,,
13881,,primary substance use disorder,,,,,,,,,for 6 months prior to registration|for,between 20 to 90 years,,,,,,
13882,,sperm donation from check-in (day -1),,,,,,,,,at least 1 months after the last dose of protocol therapy||childbearing potential defined,< 10mm/5 minutes,,,,,,
13883,,itp treatments,,,,,,,,,during study duration.|subject,> 9 g/dl;|absolute,,,,,,
13884,,brain injury|patient,,,,,,,,,before pregnancy.|urogenital infections.|history of,less than or equal to,,,,,,
13885,,respiratory symptoms limit,,,,,,,,,over the past 6 weeks,≥ 2 reactions,,,,,,
13886,,upper extremity impairment,,,,,,,,,within 100 days prior to first epcoritamab administration|primary central nervous system,lasting 4-72 hours,,,,,,
13887,,old|tachypnea,,,,,,,,,within the past 60 days|target,between 19 and 50 years,,,,,,
13888,,resultant,,,,,,,,,at least for four weeks,>12 and <18 years,,,,,,
13889,,diabetic kidney disease;|small vessels,,,,,,,,,appropriate for,≥ 40mmhg,,,,,,
13890,,mesio-distal,,,,,,,,,prior to enrollment；|the presence,>= 14 days after the last dose of a,,,,,,
13891,,acute diseases,,,,,,,,,within 3 months prior to enrollment;|those,≥ 50%.|patients able to comply,,,,,,
13892,,retinal findings,,,,,,,,,at least 12 months post cessation,75-100 mg daily,,,,,,
13893,,psychic functions,,,,,,,,,during the first cycle of treatment;|patients,19 years or,,,,,,
13894,,febrile childhood,,,,,,,,,for at least 30 days after the last dose of study intervention.||a wocbp,between 0-14 years,,,,,,
13895,,cardiac failure|<18,,,,,,,,,within 30 days prior to the first administration of investigational,>140mmhg or <90 mmhg,,,,,,
13896,,early-stage prostate cancer,,,,,,,,,in the last one month|orthopedic,18 to 55,,,,,,
13897,,cis or|ta/t1,,,,,,,,,within 48 hours before taking drugs,"≥ 1,000/mm3",,,,,,
13898,,bipolar type i disorder,,,,,,,,,at least 4 weeks before the colonoscopy.||,> 90 days,,,,,,
13899,,alcohol abuse||control,,,,,,,,,during the study.|received a vaccine,< 4||non,,,,,,
13900,,transfusion protocol||traumatic injury,,,,,,,,,at either screening or day -1.|has,reterms;||between 32-37,,,,,,
13901,,acute eye conjunctivitis,,,,,,,,,within 14 days of study administration,>40 miu/ml,,,,,,
13902,,large carious lesions,,,,,,,,,within one year of diagnosis,≥ 0.50 g/dl,,,,,,
13903,,interruption,,,,,,,,,while on arm 4 (observation),above 18|female patients|with,,,,,,
13904,,carcinoma in situ cervices,,,,,,,,,at least 4 weeks before study treatment administration,18.5 to 35 kilogram per square meter (kg/m2,,,,,,
13905,,esophageal cancer;|radical resection of tumor,,,,,,,,,within 3 weeks prior to the first dose of study drug.|hypersensitivity,≥ 50.0kg,,,,,,
13906,,hematopoietic diseases,,,,,,,,,following standards:||blood routine examination,greater than 2 cm,,,,,,
13907,,achilles tendinopathy,,,,,,,,,in the 3 months before conception||exclusion,between 1 months and 17 years|children,,,,,,
13908,,female|regular smokers|disturbed glucose,,,,,,,,,up to 2nd degree,>4-times upper limit of normal,,,,,,
13909,,"valvular disease,|anemia",,,,,,,,,after standing up,≤ 25 points,,,,,,
13910,,malignancy|phq-ads,,,,,,,,,within the last 5 years at md anderson|able to speak and read,undetectable,,,,,,
13911,,zaleplon,,,,,,,,,for at least 1 year;|screening,> 60)|a life expectancy,,,,,,
13912,,parkinson's disease|diagnosis,,,,,,,,,"within the last 4 weeks prior to hospitalization,|the likelihood",≥18 years;|18.5 < bmi,,,,,,
13913,,compensation claim,,,,,,,,,within the last 4 weeks.|use,≤ 1.5;||prothrombin time (pt) and,,,,,,
13914,,modalities,,,,,,,,,in the previous 30 days|patients,less than 25 ml/min per 1.73 m2.|medical history,,,,,,
13915,,cutaneous toxicity,,,,,,,,,within 4 weeks of the first dose of study drug|medications,0 or 1|histological,,,,,,
13916,,criteria international classification,,,,,,,,,for at least 30 days.|patients,more than 2 lines;|the guardian of the subject can understand the purpose of the trial,,,,,,
13917,,brain malformations,,,,,,,,,within 3 weeks of baseline assessments,>450 millisecond,,,,,,
13918,,colon cancer,,,,,,,,,within four weeks of visit 2,more than 20.000/cmm|patients,,,,,,
13919,,acute intermittent hepatic porphyria;|diagnosis,,,,,,,,,within 28 days before the completion of randomized treatment,=< 5 years,,,,,,
13920,,plgs,,,,,,,,,within 3 weeks before the start of the study,> 5 minutes);|conditions,,,,,,
13921,,lower extremity pain,,,,,,,,,at the screening visit (v1),≤ 3 × uln;|total,,,,,,
13922,,sucrase-isomaltase,,,,,,,,,during the pre-test,<90 millimeters,,,,,,
13923,,cns involvement.|presence,,,,,,,,,before first dose of study treatment.|receipt,40-65|being male|having signed the informed consent,,,,,,
13924,,iver cirrhosis,,,,,,,,,within 72 hours prior to this lab being drawn (,< 35% predicted,,,,,,
13925,,adrenocortical carcinoma,,,,,,,,,at the target grafting site,between ears <= 10 db for 1khz-6khz,,,,,,
13926,,degenerative disease,,,,,,,,,at time of study entry.|willingness,greater than 480ms,,,,,,
13927,,neurofibromatosis type 1 (nf-1,,,,,,,,,less than 3 years,>120 μmol/l)|liver enzyme abnormalities,,,,,,
13928,,comorbid psychiatric disorders,,,,,,,,,at time of inclusion|weight,less than 18 years.|refused to participate.|unconscious.|spontaneous,,,,,,
13929,,classical hodgkin lymphoma,,,,,,,,,before the first administration:||neutrophil count (,250 - 1000 hz,,,,,,
13930,,coagulation defects|chronic obstructive pulmonary disease exacerbation,,,,,,,,,at the time of screening.|acute on,> 100 mmhg|any major,,,,,,
13931,,cerebrovascular diseases;|severe heart,,,,,,,,,during the preceding 24 hours)|history of,50.0 to 90.0 kg (inclusive),,,,,,
13932,,bipolar disorder (bpd),,,,,,,,,within the last 3 months.|history,≥ 80 g,,,,,,
13933,,breast-feeding|participation,,,,,,,,,for < 1 month prior to screening,400 μm.||,,,,,,
13934,,heart failure|myocardial infarction,,,,,,,,,while on this agent.||symptomatic,5-point,,,,,,
13935,,stable;|active tuberculosis,,,,,,,,,"during the protocol,|botulinum toxin injection",>40/min,,,,,,
13936,,nitinol|refractory hypertension,,,,,,,,,within 10 hours of,between 18.5 and 30 kg/m2||,,,,,,
13937,,peripheral muscle weakness,,,,,,,,,in the past 12 months||exclusion criteria||known,"greater or equal to 15,000 pmol/l",,,,,,
13938,,rheumatological pathology|psychiatric pathologies,,,,,,,,,after admission,60 or higher.||,,,,,,
13939,,acute pulmonary embolism|acute,,,,,,,,,during the last three months,≥90 ml/min egfr.|the,,,,,,
13940,,vulvar dryness,,,,,,,,,within 3 months of visit 1,> 10 ng/ml|subject,,,,,,
13941,,pulmonary interstitial disease,,,,,,,,,within the previous 12 months|performs,=< institutional upper limit of normal,,,,,,
13942,,types of malignancy,,,,,,,,,within 28 days|evidence,<1.5 mg/dl,,,,,,
13943,,therapy|active bleeding needing blood transfusions,,,,,,,,,within 14 days prior to or after study vaccine.|bleeding disorder,< 2 years|allergy,,,,,,
13944,,transfusion-free period,,,,,,,,,within 10mm of the target lesion.|angiography confirmed the presence,>=18 and less than (<) 30 kilogram per square meter (kg/m^2,,,,,,
13945,,physical condition|in,,,,,,,,,in the first three months of the trial,i-ii status|patients,,,,,,
13946,,emergency conditions,,,,,,,,,in the 12 months prior to enrollment|prior,< 3 months before enrolment,,,,,,
13947,,bleeding|patients,,,,,,,,,pre-existing stent(s,≥ 9%,,,,,,
13948,,nodal lesion,,,,,,,,,at least 6 months prior to screening).|barrier methods of contraception,at least 0.5 teaspoon,,,,,,
13949,,deafness,,,,,,,,,within 3 years before the first study procedure,≥65 years|diagnosis of,,,,,,
13950,,vaginal discharge pain / bleeding,,,,,,,,,for 2 months to prior,above or equal to 126 milligrams per deciliter,,,,,,
13951,,disorders|spondylolisthesis|inflammatory neck pain|history,,,,,,,,,in the past>6 months,≥ 30% after,,,,,,
13952,,54 gy,,,,,,,,,in the past 12 months.|have,≥140 and <180,,,,,,
13953,,invasive infections,,,,,,,,,before enrollment,<92% in ambient,,,,,,
13954,,ctc ae,,,,,,,,,last dose received more than 28 days prior to initial study vaccination.||inclusion,score 8 or higher,,,,,,
13955,,stone disease,,,,,,,,,between the two fmri sessions||,> 3|7,,,,,,
13956,,results.|active infection,,,,,,,,,for 150 days after the last dose,more than 2 times of upper limit of normal,,,,,,
13957,,retinal detachment||,,,,,,,,,within 6 months prior to registration||step 1,more than two times the laboratory,,,,,,
13958,,normal renal function||age-matched,,,,,,,,,during the study period.|if,under 10,,,,,,
13959,,respiratory diseases;|any,,,,,,,,,at least 2 days per month over the last 12 months.||,between 18 and 35 y inclusive|bmi,,,,,,
13960,,cataracts;|refractive errors,,,,,,,,,within the next 9 months of study period|multiple sclerosis,i-iii.|documentation,,,,,,
13961,,tobacco dependence,,,,,,,,,at least 2 meals into the smartphone app on ≥5 days||,< 65 years discharged home from ulhg,,,,,,
13962,,visceral spread,,,,,,,,,at least 8 weeks' duration and should have,<24 months af duration,,,,,,
13963,,secondary fibromyalgia,,,,,,,,,5 days or longer,≥ 18 years|h,,,,,,
13964,,extrapulmonary reasons|massive aspiration|sepsis,,,,,,,,,within 2 weeks prior to study enrollment).||organ function requirements||adequate,≥ 2x uln|bilirubin,,,,,,
13965,,dental implants|unable,,,,,,,,,within 7 days of study treatment.||postmenopausal,≥ 1000 per mm3);|c,,,,,,
13966,,suplatast tosilate from 7 days prior to the baseline visit until the week 4 visit.|subjects,,,,,,,,,prior to specimen collection,110-159 mg/dl,,,,,,
13967,,deep vein thrombosis;||5.maintain,,,,,,,,,in the last 14 days prior to randomization.||exclusion criteria||life-threatening,≥ 18 to ≤ 75 years.|eastern,,,,,,
13968,,hypertensive deep perforator arteriolopathy,,,,,,,,,within 1 year before the test;|those,above 159/99 mmhg,,,,,,
13969,,mixed histologies)|preoperative figo stage,,,,,,,,,≤10 mg/day,=< 28 days of registration,,,,,,
13970,,cohort a3,,,,,,,,,in the last three months|children,> 1.5 and ≤ 2 x uln,,,,,,
13971,,adoptive immunotherapy,,,,,,,,,within 5 years from the end of treatment,≥48 hours|on contact precautions,,,,,,
13972,,involvement of the celiac artery,,,,,,,,,during the intervention period,≥ 18 years;|written,,,,,,
13973,,structural heart disease|possible,,,,,,,,,in the past 30 days,outside of normal range,,,,,,
13974,,mui,,,,,,,,,after surgery.|no prior,< 400 mg/m2,,,,,,
13975,,doubles,,,,,,,,,within 8 weeks before screening,>12 months from completion of therapy,,,,,,
13976,,clinical stage iv)|approved,,,,,,,,,prior to the first study drug administration,≥ 9 g/dl||hepatic:||total,,,,,,
13977,,universities,,,,,,,,,over last two years deemed by the investigator,≥60 years old,,,,,,
13978,,dermatological disorders,,,,,,,,,before cycle 1 day 1.|current,<8 g/dl,,,,,,
13979,,hemodynamic failure,,,,,,,,,within last month.|cognitive,≥40 ml/,,,,,,
13980,,kidney disease|reported abnormal,,,,,,,,,at least 8 weeks prior to randomization|presence,≥2.8 g/dl|aspartate,,,,,,
13981,,deep brain stimulation,,,,,,,,,since onset of sci,<9 g/dl);|creatinine>1.5×uln,,,,,,
13982,,osteolytic lesions,,,,,,,,,at the time of usfna|unable to give informed consent for,≥75 minutes/week,,,,,,
13983,,jejunal wall when,,,,,,,,,higher|at least 3 months post-amputation,> 180/110 mm hg|coagulopathy,,,,,,
13984,,suicidal/homicidal ideation,,,,,,,,,lasting 2 weeks or longer,superior to 90 mm,,,,,,
13985,,tos,,,,,,,,,within 30 days;|peptic ulcer,0.2 or more.||,,,,,,
13986,,irregular vaginal bleeding,,,,,,,,,before 34 weeks,≥ 18 years.|patient,,,,,,
13987,,thyroid surgery;|the,,,,,,,,,before participating in the,140 mmhg.|moderate,,,,,,
13988,,cardiac shunt,,,,,,,,,"last month prior to inclusion,|diagnosed",≥ 160mmhg,,,,,,
13989,,karyotype abnormality,,,,,,,,,in the previous 2 weeks.|patients,<40mmhg)|known malignancy|patient,,,,,,
13990,,treatment complications,,,,,,,,,72 hours before,between 25 and 45 years|patients,,,,,,
13991,,amputations,,,,,,,,,≥90 days prior to or planned,objective ii only:||admission to icu,,,,,,
13992,,asymptomatic brain metastasis,,,,,,,,,within 14 days prior to registration.||platelet count,"<100,000",,,,,,
13993,,complement deficiency,,,,,,,,,in the past month|shift work,< 6 weeks)|specific,,,,,,
13994,,useless tissue available|information consent,,,,,,,,,at time of onset of parkinsonism|active treatment,> 12 weeks.|hemoglobin,,,,,,
13995,,anticoagulants.|the,,,,,,,,,in the last 5 years (arm a)|patients,4.5-9.0 hours,,,,,,
13996,,cirrhosis.|active autoimmune disease,,,,,,,,,lasted for more than 6,10 years,,,,,,
13997,,pulmonary fibrosis.|pregnant,,,,,,,,,familiarisation / baseline screening,<=1.5 x institutional upper limit of normal,,,,,,
13998,,recurrence after,,,,,,,,,in next 6 months.|-,readiness-to,,,,,,
13999,,extensive interstitial,,,,,,,,,after two attempts,between 4 and 10 years,,,,,,
14000,,lack of prostate,,,,,,,,,within 30 days prior to the first dose of pep07,0 to 1.|female,,,,,,
14001,,optic neuromyelitis,,,,,,,,,within the next month;|aggravated allergic history,at least 2g per deciliter,,,,,,
14002,,dietary patterns,,,,,,,,,within 7 days of day 1,less than 3mm)|no,,,,,,
14003,,cardiogenic shock|moribund,,,,,,,,,less than 2 months before the start of the ramadan fast|patient,stage ii to iii,,,,,,
14004,,scarring,,,,,,,,,booster dose,≥75 years|advanced ckd,,,,,,
14005,,glp-1 ra.|any condition,,,,,,,,,hospital < 48 hours|patient,30 to 80 years,,,,,,
14006,,priapism,,,,,,,,,during the week of study|not,older|less than 40 years|healthy,,,,,,
14007,,sciascia,,,,,,,,,within 24 hours prior to the procedure|generalized skin,grade of 0 or 1.|adequate hematologic,,,,,,
14008,,confused,,,,,,,,,during the period of the study.||patient,between 18 and 28 kg/m2|be able to understand the contents,,,,,,
14009,,uncorrectable inr>1.5,,,,,,,,,within the past 6 months|practice,being 18 years,,,,,,
14010,,secondary sjogren's syndrome).|have,,,,,,,,,within 30 days of randomization|use of any,over 18 years old and less than 65 years,,,,,,
14011,,eligible disease,,,,,,,,,within the past 2 years|history of overt clinical stroke,less than 30 kg/m2.||,,,,,,
14012,,leukocytosis)|confirmed covid-19 infection,,,,,,,,,within 5 years prior to starting study treatment,"<3,5 mmol/l",,,,,,
14013,,renal disease|discharge from hospital,,,,,,,,,"within the first 1 week of the postpartum period,|having",<200 l/min iv,,,,,,
14014,,intrahepatic strictures,,,,,,,,,within 6 weeks prior to enrollment,ranges from 18 to 75 (inclusive),,,,,,
14015,,abstain from drinking,,,,,,,,,within 3 years prior to study blood draw|current autoimmune disease,above 18 years|signed consent,,,,,,
14016,,malignant thymoma,,,,,,,,,after stem cell transplantation,since then.|presence of,,,,,,
14017,,genetic muscle disease,,,,,,,,,during the period of clinical trial,10-60|a,,,,,,
14018,,mepl,,,,,,,,,within 1 week prior to screening,> 7.0%,,,,,,
14019,,left atrial ablation).|able,,,,,,,,,within 12 months of screening.|recent,shanghai children's,,,,,,
14020,,solid organ transplantation.|previously,,,,,,,,,within 14 days prior to study intervention administration,> 2;|age,,,,,,
14021,,impaired hemostasis,,,,,,,,,6 months after myocardial infarction,"stage ii, iii and iv of",,,,,,
14022,,"genetic diseases,|cystic fibrosis,|chronic pulmonary diseases,|gastrointestinal",,,,,,,,,during study participation.|planning,grade ii or higher heart failure,,,,,,
14023,,vka,,,,,,,,,at time of randomization|gait speed,<45 ml/min per 1.73m2)|severe nervous,,,,,,
14024,,atherosclerotic vascular disease,,,,,,,,,at screening must,>18 and <65,,,,,,
14025,,abscesses,,,,,,,,,within 14 days prior to apheresis,1-3 times /week,,,,,,
14026,,carious lesion,,,,,,,,,within 42 days,≥15% and ≤40%|subject,,,,,,
14027,,medication impairing immune response,,,,,,,,,prior to first dose|active,equal or greater than 7,,,,,,
14028,,mitochondrial myopathy,,,,,,,,,within 4 weeks before randomization,greater than 4,,,,,,
14029,,mixed plasmodium infections,,,,,,,,,72 hours before hospitalization,> 20%.|neuropathic,,,,,,
14030,,progressive neurological deficit,,,,,,,,,at least 4 weeks prior to start of study intervention,<25ml per minute per 1.73m2 body surface area,,,,,,
14031,,communicating,,,,,,,,,within the past 2 months,>120,,,,,,
14032,,clinical manifestations of yin deficiency,,,,,,,,,prior to the first study vaccine dose,>100 mg/dl||either,,,,,,
14033,,deep periodontal,,,,,,,,,during the trial period,more than 3 years,,,,,,
14034,,aud.|engage,,,,,,,,,within 7 days of first dose,> 500 iu/ml,,,,,,
14035,,participate|diabetes mellitus,,,,,,,,,during the test period.||people,55 years or older,,,,,,
14036,,vastus lateralis,,,,,,,,,within 12 months prior to screening,≥450 msec for,,,,,,
14037,,risk disease,,,,,,,,,throughout this period,>200mg/dl,,,,,,
14038,,granulocyte macrophage-colony,,,,,,,,,within 28 days prior to administration,>= 28 days|cellular therapy,,,,,,
14039,,day)|excessive drinking,,,,,,,,,after the first cycle of,20 to 60 years inclusive.|localised,,,,,,
14040,,concomitant medication(s).|participation,,,,,,,,,within 14 days prior to the first drug use in this,<50 bpm|qtc bazett,,,,,,
14041,,type have,,,,,,,,,within 28 days before the first dose of study treatment.||note,between 18.5 and 35 kg/m2.|physically able,,,,,,
14042,,cebpa genes,,,,,,,,,in the last 6 months|gerd evolving,exceed the upper limit of normal,,,,,,
14043,,psychiatric distress,,,,,,,,,performed at screening,≥ 3.0 mm,,,,,,
14044,,liver enzyme level (alt and/or ast,,,,,,,,,within 30 days of visit 1;|have,<200 cells/,,,,,,
14045,,diseases.|renal diseases.|blood,,,,,,,,,within 1.5 standard deviation,=< 7 days prior to registration,,,,,,
14046,,metastatic central nervous system,,,,,,,,,for 3 months duratoin.||,22 or older,,,,,,
14047,,androgenic alopecia|aga classification,,,,,,,,,prior to screen/baseline||ocular exclusion criteria for study,greater than (>) 40%,,,,,,
14048,,heart rhythm abnormalities,,,,,,,,,within 14 days prior to first study drug administration|other protocol defined inclusion/exclusion criteria,true,,,,,,
14049,,metastatic nsclc.|evidence of,,,,,,,,,at least 2 blocks)|willing and able to provide pictures of food receipts to study team,higher than 25 pg/ml.|hypoparathyroid,,,,,,
14050,,metabolic neuropathies,,,,,,,,,at any time in the past,<50 nmol/l.|the subject,,,,,,
14051,,organic gastrointestinal disorder,,,,,,,,,within 14 days prior to the first admission,< 32 weeks,,,,,,
14052,,hematologic disorder,,,,,,,,,within 6 months prior to enrollment|history of,0-2;|9,,,,,,
14053,,mild aortic stenosis,,,,,,,,,study|more than 2 weeks absence,12 years or older,,,,,,
14054,,gynecological problems.|psychological disorders,,,,,,,,,prior to study|sign of,less than 4 weeks before the first day of,,,,,,
14055,,autoimmune mediated hypothyroidism treated,,,,,,,,,immediately next,> 3|8,,,,,,
14056,,psychiatric disease|patients,,,,,,,,,at least 4 wks before the observation period and continued,<30 ml/min/1.73m2).|increased,,,,,,
14057,,chemotherapy);|clinical recurrence,,,,,,,,,within the prior 3 months;|both partners endorse being,<50% of the day]||,,,,,,
14058,,higher|pregnant,,,,,,,,,within 3 years before the first dose of study drug,less than 3 months,,,,,,
14059,,anomalies|placenta previa,,,,,,,,,within 30 days prior to planned day,10x lower than what is found,,,,,,
14060,,substances|heart failure,,,,,,,,,patients.|first time affected.|no visual,>160,,,,,,
14061,,primary ciliary dyskinesia|dependence,,,,,,,,,within 2 weeks time period|trochanteric starting point,equal to or better than 20/200 snellen's acuity.||established,,,,,,
14062,,chronic gi disease,,,,,,,,,within the previous 6 months|ic 5,2-18y||,,,,,,
14063,,hepato-biliary,,,,,,,,,within the last 12 months|use of medical,between 40 and 65 years,,,,,,
14064,,defects of the buccal bone,,,,,,,,,"pain,|being addicted to alcohol",=< 2 x uln,,,,,,
14065,,their disorder,,,,,,,,,within 6 months before enrollment.|neck tattoos,<= 65%,,,,,,
14066,,general physical condition,,,,,,,,,within 6 months|uncontrolled,≤ 1cm lower calyceal,,,,,,
14067,,centrimag™,,,,,,,,,during the 3-week,< 10 g/dl|self-reported,,,,,,
14068,,asplenia,,,,,,,,,outpatient iv,20 antral follicles counting,,,,,,
14069,,past abuse,,,,,,,,,within 2 months prior to screening|heavy,≤ 70|life-threatening,,,,,,
14070,,adenocarcinoma；|clinical stage,,,,,,,,,within sixteen weeks,≥ 40 years,,,,,,
14071,,malignant neoplasms,,,,,,,,,within the past 12 months.|known,s/β-thalassemia,,,,,,
14072,,ischemic types,,,,,,,,,outpatient basis,<25 ml/min/1.73m2,,,,,,
14073,,left circumflex artery [lcx,,,,,,,,,within the past 6 months of the (first) study drug,between 18-65 years||diagnosed,,,,,,
14074,,liver disease|hematologic malignancy,,,,,,,,,within 7 days before randomization.|patients with central nervous system,≥20 years);|definitive,,,,,,
14075,,disorders;|mri scans,,,,,,,,,at least 4 hours.||,between >= 5 and < 17 years,,,,,,
14076,,obstetric indication,,,,,,,,,within 3 months from randomization,≥1.5x109/l,,,,,,
14077,,systemic anticancer treatment,,,,,,,,,in the last 30 days;|fulminant,0 to 1.||life expectancy,,,,,,
14078,,gastrointestinal symptoms,,,,,,,,,within 12 months after lymphodepletion.||history of second,lower than 12 months,,,,,,
14079,,hepatitis b virus(hbv) infection,,,,,,,,,during exercise training,19-55 years,,,,,,
14080,,bilateral loss,,,,,,,,,at the time of intervention,greater than 3 times the upper limit of normal.|has,,,,,,
14081,,biopsy)|gastrointestinal bleeding,,,,,,,,,within 4 weeks before baseline,greater than or equal to 30 days prior to enrollment||diagnosed,,,,,,
14082,,abnormal imaging suggesting colorectal cancer,,,,,,,,,within 6 months of the last,≥ 1.5 × the upper limit of normal,,,,,,
14083,,disorders|premature ovarian,,,,,,,,,during the study period|seizure disorder|photosensitivity|hearing,normative z-score,,,,,,
14084,,cns disease;|2.patients,,,,,,,,,at the time of the wats,> 10 mg / day,,,,,,
14085,,transient ischemic attack|any cardiac,,,,,,,,,at the time of initial study vaccination.|based,20-65 years,,,,,,
14086,,"dependence,|medical diseases|psychiatric comorbidities,|pregnancy",,,,,,,,,within the 30 days before the screening,january 2020 to december,,,,,,
14087,,orthopnea,,,,,,,,,within 2 weeks prior to the first dose of fludarabine.|severe renal impairment,≥3%,,,,,,
14088,,infectious ocular,,,,,,,,,in the past 3 months|receipt of intranasal,≤ 3.0 × upper limit of normal,,,,,,
14089,,axial neck,,,,,,,,,after one cycle of prior therapy,depressed,,,,,,
14090,,hepatitis c drugs,,,,,,,,,intravenous,more than 1x10^3 copies/ml,,,,,,
14091,,ocular hypertension,,,,,,,,,for more than 6 weeks,≥5mg/ day or equivalent dose of another,,,,,,
14092,,drugs.|chronic severe hypertension,,,,,,,,,in 4 weeks|those who have a,≥ 20 mm；|left,,,,,,
14093,,hepatitis b core antibody [hbc ab,,,,,,,,,during the participation of clinical trial.|individuals,above grade 1 related,,,,,,
14094,,glaucoma|central retinal artery occlusion,,,,,,,,,last 1 year,>= 8.0%||21,,,,,,
14095,,programme,,,,,,,,,within 3 days before receiving the first study drug,under 18 years old or they have no,,,,,,
14096,,brain edema,,,,,,,,,within 3 months of,18 or above.|parents,,,,,,
14097,,type 2 diabetes|part b,,,,,,,,,prior to initiation of study,"<4,000/μl/",,,,,,
14098,,autoimmune thyroid disease,,,,,,,,,within the range 18 to 40 kilogram per square meter [kg/m^2],"18-65,|2nd",,,,,,
14099,,asthma:||1 hospitalized,,,,,,,,,within 2 weeks before,>23 mmhg,,,,,,
14100,,inflammatory causes,,,,,,,,,etc.)|more than,below 30 kg/m2.|patients,,,,,,
14101,,reviewed by the investigator.||,,,,,,,,,within 1 year;|systemic hemodynamic,≥1% tumor,,,,,,
14102,,risk of suicide,,,,,,,,,at least after 1 year of the,less than 14,,,,,,
14103,,abstain from sexual intercourse,,,,,,,,,at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention,< 6 months;|episode,,,,,,
14104,,cutaneous warts presented,,,,,,,,,within 24 hours after surgery|cardiac surgery,greater than or equal to 30%,,,,,,
14105,,alzheimer,,,,,,,,,within ifu of,≥ 2);|history,,,,,,
14106,,signs of,,,,,,,,,in the next 12 weeks|cardiopulmonary stress test results,<18 years;|diagnosis,,,,,,
14107,,squamous cell carcinoma of the skin in situ)；|any one of hbv surface antigen,,,,,,,,,between 12-32 weeks,1.18-75 years,,,,,,
14108,,asms,,,,,,,,,within 3 days prior to study inclusion|history of,53-86 millimoles,,,,,,
14109,,cardiac devices|person,,,,,,,,,prior to the first administration of investigational product,≥2 x uln,,,,,,
14110,,tumors|melanoma,,,,,,,,,at the time of study initiation,17 years or younger,,,,,,
14111,,dehydration,,,,,,,,,for at least 4 weeks before the first dose of study treatment,50-93 kg,,,,,,
14112,,medicine abuse,,,,,,,,,three years before the inclusion|patients,< 90|less than 5th grade reading level|left handed|non-native,,,,,,
14113,,intracranial bleeding of,,,,,,,,,6 months prior to enrollment,"grade iii/iv,|acute",,,,,,
14114,,familial inherited cancer syndrome,,,,,,,,,within 60 days prior to study,≥7,,,,,,
14115,,irregular heartbeats,,,,,,,,,within 8 weeks prior to graft,0 or 1|archival,,,,,,
14116,,consumption of cannabis,,,,,,,,,at the time of signing informed consent|body mass index,≥300 mg/day,,,,,,
14117,,infection-induced,,,,,,,,,at any time prior to admission.|severe burns,≥ 18 and ≤ 50 years|body mass index (bmi),,,,,,
14118,,retinal vein occlusion|treated,,,,,,,,,prior to starting therapy,>84/168 g/week,,,,,,
14119,,cold,,,,,,,,,within 30 days prior to the first dose of investigational,>35|pregnancy,,,,,,
14120,,permitted.||does not,,,,,,,,,during least 2,> = 50%||,,,,,,
14121,,drug dependence.|have mental disorders,,,,,,,,,within 4 weeks prior to randomization.|any,≤ 1.5 × uln；||j,,,,,,
14122,,sot||for,,,,,,,,,within 6 months of screening.|any laboratory values,≥ 90g/l,,,,,,
14123,,surgery|cerebral ischemic event,,,,,,,,,more than 8,between 18-77 years,,,,,,
14124,,removable orthodontic braces/bands,,,,,,,,,past six months.||children's medical records,<44 mmol mol-1||,,,,,,
14125,,feeling of weakness,,,,,,,,,more than 3 minutes,above ioobö9-sf|not,,,,,,
14126,,parasitic infections;|diagnosis,,,,,,,,,within the last 2,<=2.00d|bcva >=0.8|anisometropia <=1.50d|confirmed to no use,,,,,,
14127,,hyperparathyroidism,,,,,,,,,within 30 days prior to stem cell collection,older than 19 years,,,,,,
14128,,hiv-infection,,,,,,,,,before pregnancy||,≤9%,,,,,,
14129,,non-small cell lung cancer.||eastern,,,,,,,,,within 4 weeks of dosing.|positive test for,between 8 and 25 years,,,,,,
14130,,transjugular portosystemic shunt,,,,,,,,,within 28 days;|history of abdominal fistula,1- 7 at registration,,,,,,
14131,,cr relapse,,,,,,,,,for at least 3 months (90 days,greater than 34 milliliter per meter square (ml/m^2).|la,,,,,,
14132,,ct imaging|patient,,,,,,,,,more than 3 years ago,< 30ml/min,,,,,,
14133,,convulsive syndrome,,,,,,,,,post 8 rounds of intralesional steroids,> 140 or < 90 mmhg,,,,,,
14134,,refractory glaucoma,,,,,,,,,four weeks before,36-42,,,,,,
14135,,chemotherapy.|hepatic,,,,,,,,,in the last year.||,therapy).|at least 18 years,,,,,,
14136,,tetrahydro-cannabinoids.||negative (qualitative) pregnancy,,,,,,,,,before enrolling on study)|if,= weight,,,,,,
14137,,nasopharynx related diseases,,,,,,,,,within 6 months prior to enrollment|difficulty with,grade ii b (,,,,,,
14138,,cardiac structural,,,,,,,,,within 1 week prior to nivolumab,± 12 months,,,,,,
14139,,maissoneuve type injury,,,,,,,,,at enrollment),<30 ml/min/1.73 m2,,,,,,
14140,,feeling hungry).|group,,,,,,,,,throughout the study.|any participant,≥ ii.||,,,,,,
14141,,advanced periodontitis,,,,,,,,,within 14 days prior to the administration of the investigational drug,>1.5 × institutional uln|h,,,,,,
14142,,impaired,,,,,,,,,within the first 5 years of the,>40%,,,,,,
14143,,brain damage,,,,,,,,,within 1 month prior to screening|esrd confirmed,≥ 12 years,,,,,,
14144,,anxiety sign the informed consent form.||healthy control inclusion,,,,,,,,,at the inclusion visit specific criteria,<100 mm hg,,,,,,
14145,,c|hiv-positivity|uncontrolled bacterial,,,,,,,,,within 10 minutes,< 220 μmol/l;|lung function,,,,,,
14146,,respiratory insufficiency|pregnancy|neoplasm,,,,,,,,,within 3 months prior to patient inclusion|acute,≥ 40 mm,,,,,,
14147,,cm|multifocal tumors,,,,,,,,,within 6 months prior to screening.|have,8-15 years,,,,,,
14148,,brain pressure|head,,,,,,,,,within <30 days prior to screening.|parents or legally acceptable representative (lar),at least 2l,,,,,,
14149,,facial skin diseases,,,,,,,,,at least 4 hours after and/or 12 hours before study intervention).||other exclusions||daily,<150.000 g/l,,,,,,
14150,,french;|total blindness,,,,,,,,,at time of all,+ 1.41,,,,,,
14151,,resting heart rate>100 bpm,,,,,,,,,throughout study duration|ability of subject,≥ 1.5 times the upper limit of normal (uln),,,,,,
14152,,ocular infection|evidence,,,,,,,,,within 3 weeks prior to initiating protocol therapy,≥ 2.5 mg/dl,,,,,,
14153,,adrenal,,,,,,,,,within 5 years|any other,20-50 degrees,,,,,,
14154,,atherosclerosis,,,,,,,,,in room prior to enrollment|anticipated patient stay,≤ 2 × uln.|hemoglobin,,,,,,
14155,,instable angina,,,,,,,,,for at least one,>15 cigarettes/day,,,,,,
14156,,acute suicidal thoughts,,,,,,,,,6 hours of therapy,from 18 to 70 years old,,,,,,
14157,,complex primary cases.|patients,,,,,,,,,at the time of signing the informed consent form.|histologically,≤ 4|history,,,,,,
14158,,cerebrospinal fluid pressure,,,,,,,,,within two weeks prior to treatment;|patients,≥ 18.|history,,,,,,
14159,,focal pain,,,,,,,,,within 2 years of the first dose of study,> 40 inches,,,,,,
14160,,muscle dystrophy,,,,,,,,,prior to study day 1,normalized reference values).|weight,,,,,,
14161,,address cancer inequalities.||paired clinicians||clinicians,,,,,,,,,within 6mo of screening,between 18 and 32 kilograms/meter,,,,,,
14162,,oral inflammatory conditions,,,,,,,,,within 14 days of registration)|platelets,≤80 years,,,,,,
14163,,urgently|patient relatives,,,,,,,,,medication history of,<80% of baseline,,,,,,
14164,,detection of raise,,,,,,,,,within 48 hours prior to the randomization，and,>150 mm²,,,,,,
14165,,ms,,,,,,,,,within 3 days prior to randomization.||active inflammatory bowel disease,2 times greater the the normal]|active,,,,,,
14166,,primary musculoskeletal pain,,,,,,,,,6 months after the end of the study period effective contraceptive measures,>288 db/m,,,,,,
14167,,distant metastasis.|participants,,,,,,,,,in the previous 6 weeks|continuous,≥ 7.8 mmol/l,,,,,,
14168,,basal cell carcinomas,,,,,,,,,at night,34.5 kg/m2,,,,,,
14169,,translocation-associated,,,,,,,,,at least 24-months prior,< 4 months,,,,,,
14170,,hepatitis e,,,,,,,,,during the last 12 hours,>400mg/dl|use,,,,,,
14171,,palliative care.|neurodegenerative,,,,,,,,,during the study.|willingness to avoid pregnancy,18 and 70 years);|cd19+ b-nh,,,,,,
14172,,residual alopecia,,,,,,,,,for 3 months after the last dose of bendamustine,0-1;|expected survival,,,,,,
14173,,substance use disorder.|may have,,,,,,,,,in last 6 months.|subjects,<-15 degrees,,,,,,
14174,,xuln||for,,,,,,,,,within 2 years requires,b-cell lymphoblastic leukaemia,,,,,,
14175,,noticeable acne scarring,,,,,,,,,at least 2 weeks before,>60 mmol/l,,,,,,
14176,,clinical hyperthyroidism,,,,,,,,,within the normal range|or further for this study,< 50% of predicted normal,,,,,,
14177,,deep dentin caries lesion,,,,,,,,,for the prior three months|are not willing/interested,less than 1 year|researcher believes,,,,,,
14178,,chronic immune,,,,,,,,,within 7 days of drug administration.|history of intake of,<7.0 mmol/l,,,,,,
14179,,end-organ function,,,,,,,,,within 364 days prior to baseline,before enrolment and|agree to the birth control methods,,,,,,
14180,,co-morbidities,,,,,,,,,within 9 months,≥1 and <16 years,,,,,,
14181,,photosensitivity,,,,,,,,,during the 3 months before commencement of the screening period.|presence of,of ≥10%|evidence,,,,,,
14182,,acute gastrointestinal infection,,,,,,,,,within 1 year.|patients,below upper limit of normal,,,,,,
14183,,epithelial bladder tumors,,,,,,,,,at the initiation of treatment.|patients,greater or equal to 90% predicted,,,,,,
14184,,enforcement officer,,,,,,,,,"in the last three months,|volunteer individuals||",≥1.5xe9 /l|hemoglobin ≥9 g/dl|platelets,,,,,,
14185,,chronic gastrointestinal disease,,,,,,,,,in the past 30 days|own a smartphone,> 2years,,,,,,
14186,,distant metastases seen on,,,,,,,,,criteria.|bi-dimensionally measurable,more than 6 months;|subject,,,,,,
14187,,breastfeeding.|chronic pain,,,,,,,,,for at least 4 weeks before screening|eastern cooperative oncology group (,over 200mmhg,,,,,,
14188,,temperature,,,,,,,,,within 2 weeks before administration,below 0.9,,,,,,
14189,,convulsion,,,,,,,,,in past 3 months,≤ 1.0 × uln,,,,,,
14190,,hypertensive gastropathy;|upper gastro-intestinal bleeding,,,,,,,,,in the last 3 months|the child,are||≤ 50% of the normal predicted values.||oxygen,,,,,,
14191,,vulvar intraepithelial neoplasia,,,,,,,,,at the time of data collection|autism spectrum disorder,20-weeks,,,,,,
14192,,circulatory disease,,,,,,,,,within 2 weeks prior to the first dose.|presence,13-17 years|receiving treatment,,,,,,
14193,,growth patterns,,,,,,,,,prior to catheter,=< 3 x uln|estimated,,,,,,
14194,,breast cancer|stable phase,,,,,,,,,for 4 weeks,≤6 years or,,,,,,
14195,,non-malignant cause,,,,,,,,,in the past month that,18-55 y|individuals can give,,,,,,
14196,,noninfectious,,,,,,,,,for at least 3 years,disease.|more than 5 days of non-migrainous,,,,,,
14197,,cerebral vascular accident,,,,,,,,,prior to participation in the,confirmed,,,,,,
14198,,collection|regular smoking,,,,,,,,,in the last 6 months.|diagnosed,≥ 18 years|be,,,,,,
14199,,chronic pain derived,,,,,,,,,within 5 years prior to the first dose of the study drug,<50 ml/min,,,,,,
14200,,skin squamous carcinoma,,,,,,,,,solely for the purpose,greater or equal to 9 months to less than 18 years,,,,,,
14201,,safely accessible tumor for til harvest,,,,,,,,,within the past 6 months|current major depressive disorder,>= 70 ml/min/1.73 m^2 or|a glomerular filtration rate (gfr),,,,,,
14202,,pleocytosis,,,,,,,,,improvement,20.0 - 34.9 kg/m2.|covid-19,,,,,,
14203,,esophageal temperature,,,,,,,,,prior to first dose of study treatment.|patients,between 18.5 and 30,,,,,,
14204,,nervous system tumors,,,,,,,,,within 90 days after the final dose of tiragolumab,younger than 18 years old,,,,,,
14205,,porphyria,,,,,,,,,within 24 hours of icu admission,more than 3 bowel movements per day,,,,,,
14206,,cd4^+ t lymphocyte,,,,,,,,,within 2 weeks prior to stemi,>= 30 days after treatment with surgery,,,,,,
14207,,schwannomatosis,,,,,,,,,at least 30 days prior to enrollment.|known,younger of 18 years,,,,,,
14208,,base,,,,,,,,,in the last 3 months prior,=< 5.0x the uln,,,,,,
14209,,peptic ulcer,,,,,,,,,within the previous three years||severe,≥50 × 109/l,,,,,,
14210,,tested swab,,,,,,,,,within 2 years before enrollment,first relapse,,,,,,
14211,,prolonged signs,,,,,,,,,in the lower extremities.|individual,<60 years,,,,,,
14212,,benign condition,,,,,,,,,stroke)|medical history of,below normal 2.0 or more,,,,,,
14213,,rods,,,,,,,,,within 14 days or campath,"between 18,5 kg/m2",,,,,,
14214,,immune checkpoint molecule therapy,,,,,,,,,within 14 days of day,>=18 to less than (<) 30 kilogram per square meter (kg/m^2,,,,,,
14215,,non-treated,,,,,,,,,within 30 days prior to treatment administration.|participation,< 1 year)|preoperative urinary incontinence,,,,,,
14216,,dependency,,,,,,,,,while on the via regimen;|(6,approximately 285 ml,,,,,,
14217,,skin reactions,,,,,,,,,after at least two prior therapeutic regimens,from 90 to 139 mmhg,,,,,,
14218,,medications|medical contraindications,,,,,,,,,within 1 days prior to ip administration|subject,> 7500,,,,,,
14219,,transient ischemic neurological attack (tia),,,,,,,,,at least 1 year old);|optimal hf medical therapy.||exclusion,= 3,,,,,,
14220,,primary cancer|patients,,,,,,,,,within 2 weeks prior to admission to the unit.|performance of strenuous physical exercise (body building,< 15 ml/min/1.73,,,,,,
14221,,lung malignancy,,,,,,,,,within 5 years before the first administration;|known endoscopic signs,between 24-35,,,,,,
14222,,photographs,,,,,,,,,in the past 6 months|current treatment,greater than 60,,,,,,
14223,,inclusive);|the,,,,,,,,,within a 4 weeks.|those,above 110 or below 40 beats per minute,,,,,,
14224,,systemic anticancer therapy,,,,,,,,,at time of study entry.|participants,< 20%.|sufficient,,,,,,
14225,,cardioversion,,,,,,,,,within 12 months prior to randomization|history,same class,,,,,,
14226,,umbilical hernia,,,,,,,,,before hospitalization;|the patient,10 cmh2o or lower,,,,,,
14227,,"multiple sclerosis,|expanded disability status scale",,,,,,,,,for the next 30 days,>=10 mg,,,,,,
14228,,contrast media,,,,,,,,,within 14 days of visit,≤ 50 ng/dl,,,,,,
14229,,retinal vessels,,,,,,,,,within 6 weeks prior to initial administration,≥19.|signed written informed consent,,,,,,
14230,,long qt syndrome.|positive serology test,,,,,,,,,for the past month||,"1-2-3,|who",,,,,,
14231,,treatment;|symptomatic congestive heart failure,,,,,,,,,in the previous 2 weeks,≤1.5-fold,,,,,,
14232,,arteriopathy,,,,,,,,,within the last 12 months associated,≥126 mg/dl,,,,,,
14233,,"cryo-sauna,|recreational",,,,,,,,,within 4 weeks prior to the first dose of,between 47 and 55 years,,,,,,
14234,,neck pain,,,,,,,,,within past 12 months|currently,50 msv.|liver function,,,,,,
14235,,primary malignancies developed,,,,,,,,,in the last month.|radiation therapy,"5-30%,|no",,,,,,
14236,,postoperative inflammation,,,,,,,,,leading ≥1 training session/week|caregivers,≥50 ml/min/1.73 m2,,,,,,
14237,,hiv-positivity,,,,,,,,,within previous 14 days,≥50×109/l,,,,,,
14238,,arteriovenous thrombotic disease,,,,,,,,,within 6 months prior to start imp,> 8cm,,,,,,
14239,,diastolic,,,,,,,,,within 14 days before enrolment,≥ 100 000/μl.|bilirubin,,,,,,
14240,,comorbid psychiatric conditions,,,,,,,,,in 30 days|those,more than 10 times,,,,,,
14241,,breast infection,,,,,,,,,during the years 2018-2020,> 30 ml/min/1.73m^2,,,,,,
14242,,# ctcae,,,,,,,,,for at least one month prior to dosing.|the subject,6 to 15 years,,,,,,
14243,,heart transplantation.|patients,,,,,,,,,within 4 weeks prior to enrollment.|prior allogeneic bone marrow transplantation,"2,5-18 years",,,,,,
14244,,dermatologic disease,,,,,,,,,in previous 12 months|ability to provide,≥ 1.8 mg/dl.|patients,,,,,,
14245,,contraception||,,,,,,,,,in the lower extremities|recent spinal,greater than 72$|had fewer than 49,,,,,,
14246,,neurotrophic keratitis,,,,,,,,,within 4 weeks prior to entering the study|prior treatment,"c, d or",,,,,,
14247,,systemic disease|patient,,,,,,,,,within 5 years prior to first administration,< 50%|uncontrolled,,,,,,
14248,,emotional distress,,,,,,,,,> 1 year,18.5 to 32.0 kg/m2||key,,,,,,
14249,,chronic hepatitis b (hbv),,,,,,,,,14 days prior to visit 1.|the,less than 1 year.|moderate-severe,,,,,,
14250,,consultation.|smoking,,,,,,,,,one week before dosing.|the subject,≥450ms for male,,,,,,
14251,,equina syndrome|cancer|pain,,,,,,,,,prior to transplantation,20-50 years2|cohb < 3 %|methb < 2 %|cthb,,,,,,
14252,,massive bleeding,,,,,,,,,systems|weigh at least 35 kg,<60)|healthy,,,,,,
14253,,healthy,,,,,,,,,within 60 days of signing consent,≥ 12mmhg|cardiac output monitoring,,,,,,
14254,,heart rhythm disorder;|pulmonary pathology,,,,,,,,,within 72 hours of admission,"> 3,000/",,,,,,
14255,,progressive multifocal leukoencephalopathy.|patient,,,,,,,,,during the screening period examination.|history of,< 23)|any,,,,,,
14256,,secondary aml,,,,,,,,,within the last 5 years|known,0-2;|pathologically,,,,,,
14257,,above||,,,,,,,,,within 28 days before the first medication,i-iii.||,,,,,,
14258,,psychotropic substance abuse,,,,,,,,,in the past 6 months|botulinum toxin injection,"< 60 ml/min/1.73m2,|statin",,,,,,
14259,,chronic intestinal diseases,,,,,,,,,"within the 12 weeks prior to screening|have any physical,",< 35 mm,,,,,,
14260,,indocyanide green,,,,,,,,,within 12 months before screening,"< 1,000 cells/mm3",,,,,,
14261,,macular telangiectasia,,,,,,,,,at least 2 months,<2cm)|known,,,,,,
14262,,standard platinum,,,,,,,,,at the time of consent.|clinical diagnosis,18-75)||2,,,,,,
14263,,chronic thromboembolism)|fibrinolytic disorders,,,,,,,,,within 4 weeks before the first dose;|pregnancy,"≥ 1),|4",,,,,,
14264,,hiv.|active bacterial infection,,,,,,,,,at least 14 days before the first administration of the investigational treatment,equal or less than 40%|age between 18-80 years||inclusion criteria,,,,,,
14265,,compromised wound,,,,,,,,,within previous 3 months.|they,female||right-handed|≥ 18,,,,,,
14266,,stable euthyroid status,,,,,,,,,at the time of room,≥ 2,,,,,,
14267,,fainting blood,,,,,,,,,prior to cell infusion;|14,> 450ms,,,,,,
14268,,sinus extract,,,,,,,,,within four weeks prior to treatment,score of 7 to 10,,,,,,
14269,,previopus endoscopic,,,,,,,,,within 2 months prior to,"below 35%,|emergency surgery",,,,,,
14270,,icd)|secondary,,,,,,,,,within 12 months prior to signing the icf.|positive drug screen,greater than 0.5 cm||pain clinic,,,,,,
14271,,naive,,,,,,,,,within 6 months prior to the screening,under 18|not fluent in english|blind,,,,,,
14272,,shoulder joint).|diagnosis of autoimmune disorder.|initiation,,,,,,,,,within 4 weeks prior to the first dose.||4,>= 7 days for short,,,,,,
14273,,general internal medicine|caresource,,,,,,,,,within last 2 weeks.||b,< 90 x 109,,,,,,
14274,,ced type i,,,,,,,,,in dose escalation period,<120 ms;|reliable,,,,,,
14275,,hepato-pulmonary syndrome,,,,,,,,,within 30 days|(herbal,< 40 mg/dl,,,,,,
14276,,inflammatory bowel,,,,,,,,,during the first year,+ 6|laceration,,,,,,
14277,,ischemic strokes,,,,,,,,,<3 months before trial enrollment,> 3 g/l,,,,,,
14278,,good compliance;|patients,,,,,,,,,within the 14 days or 5 half- lives,280 db/m,,,,,,
14279,,folic acid nutritional supplementation|methotrexate,,,,,,,,,after radiation|eligibility criteria,=< 3 x upper limit of normal,,,,,,
14280,,extra-regional,,,,,,,,,at any time of the study,2.0).|100-300 hhs,,,,,,
14281,,recovered from radiotherapy toxicities,,,,,,,,,at 4 years) after the baseline ct,< 18 or ≥100,,,,,,
14282,,etc.)|current substance,,,,,,,,,at the screening visit.|hospitalization,greater than 140 mmhg,,,,,,
14283,,severe hearing deficits,,,,,,,,,in the past 12 months|history,higher than the upper limit of normal,,,,,,
14284,,arrival to the hospital,,,,,,,,,within the last 3 years|individuals,more than 19 years,,,,,,
14285,,obstructive pulmonary disease|concurrent,,,,,,,,,within one week after admission,between 17.5 to 42|participants,,,,,,
14286,,aortic valve disease|ability,,,,,,,,,within 4 weeks prior to the first dose of ak130,fewer than 12 months,,,,,,
14287,,transient adverse effects,,,,,,,,,within 14 days before the first dose of investigational drug,greater than 10%,,,,,,
14288,,chronic renal failure,,,,,,,,,at least 1 major,> 18 years|performance index,,,,,,
14289,,glioblastoma treatment-related,,,,,,,,,within the past two years.|they,more than 120 beats per minutes,,,,,,
14290,,tep,,,,,,,,,within 3 months of study entry,< 45 beats per minute,,,,,,
14291,,intubated,,,,,,,,,at least 15 years prior to study enrollment,< 8)|age 18-65 years,,,,,,
14292,,rheumatic disease,,,,,,,,,within 3 months before apheresis,meets,,,,,,
14293,,ctth).|diagnosis of crps,,,,,,,,,during the study.||vaccination with live vaccine,< 3 cm,,,,,,
14294,,human immunodeficiency virus-acquired immunodeficiency syndrome,,,,,,,,,at least 3 months prior to recruitment|the presence,<15 million/ml,,,,,,
14295,,annular disruption,,,,,,,,,during the last 30 days|clinical suspicion,18 years-50 years,,,,,,
14296,,orthodontic treatment.|craniofacial abnormalities,,,,,,,,,at the time of study subject's randomisation.|subject's consent to use reliable,2.5 times than usual situation)|vulnerable population,,,,,,
14297,,bronchial carcinoma.|intolerant,,,,,,,,,in the prior 90 days|cancer,≥90g/l;|serum,,,,,,
14298,,tuberculosis infection,,,,,,,,,for up to 130 days after last dose of study drug,<140 pmol/l).|if the,,,,,,
14299,,cecum,,,,,,,,,3-6 weeks later,≥ 100 bpm|use of,,,,,,
14300,,acute sore throat,,,,,,,,,in the past 12 months.|treatment,12 to 18|agreeing to participate to the study||,,,,,,
14301,,"old,|acute pancreatitis",,,,,,,,,6 months or more,10-21 years,,,,,,
14302,,pelvic inflammatory disease,,,,,,,,,within 7 days prior registration,lower than 3.9 mmol/l;|patients,,,,,,
14303,,severe mental illness)|physical inability to provide,,,,,,,,,within 28 days prior to initiation of study,≤1.5-fold the uln of the study site||women,,,,,,
14304,,randomization;|valvular heart disease,,,,,,,,,within the specified time window,less than or equal to (≤) 9.0 gram per deciliter,,,,,,
14305,,left bronchial segments b2,,,,,,,,,prior to 3 months of age.|has,18 and older;|being,,,,,,
14306,,heavy alcohol,,,,,,,,,in the past 1 month,>100 mls,,,,,,
14307,,renal replacement therapy,,,,,,,,,at least 4 weeks after the last dose of letermovir.||note,≥ 354µm)|mechanical,,,,,,
14308,,coronary artery internal lumen,,,,,,,,,during each of the first and second 4-week periods,ranges from 18 to85 (inclusive),,,,,,
14309,,esophageal disease,,,,,,,,,after one cycle neoadjuvant,within normal limits,,,,,,
14310,,aiha,,,,,,,,,within 2 years of entry,≥800 pg/ml,,,,,,
14311,,matching variables,,,,,,,,,during the screening visit.|negative pregnancy test,≥18 years.||,,,,,,
14312,,myasthenia gravis|those,,,,,,,,,prior to planned diagnostic,less than 10% of body surface area (bsa),,,,,,
14313,,light induced,,,,,,,,,within 4 weeks prior to the first dose of the study drug.|patients,above the 5% limit,,,,,,
14314,,allergy.|pregnant,,,,,,,,,in the past 12 months|for tgw,18 years of age|speak,,,,,,
14315,,attack,,,,,,,,,during the duration of the trial,between 30 0/7 and 33 6/7,,,,,,
14316,,agitation,,,,,,,,,more than 14 continuous days before randomization,scores > 175 points;|the,,,,,,
14317,,affect drug absorption,,,,,,,,,at least 1 year after anthracycline,between 19 and 26 kg/m2,,,,,,
14318,,acromegaly,,,,,,,,,within 30 days|no,≥ 45%;|subject,,,,,,
14319,,heart failure|pulmonary hypertention|acute pulmonary embolism|septic shock,,,,,,,,,within 1 month from the date of the strain elastography,< 2||exclusion criteria,,,,,,
14320,,acute liver failure.|allergic,,,,,,,,,at the time of inclusion into the study|atrial fibrillation,< 1% to prevent,,,,,,
14321,,latent infection,,,,,,,,,for 30 days after the last dose of the study,grade ⅲ or,,,,,,
14322,,hepatic||insufficiency,,,,,,,,,before thrombectomy|unable to complete the study,iii and above patients|patients,,,,,,
14323,,"facial muscle paralysis,|preterm",,,,,,,,,at the time of signing the informed consent.|evidence of biomarker,>=18 years|untreated,,,,,,
14324,,feasibility,,,,,,,,,up to 6 months from,1+ or ihc 2+,,,,,,
14325,,hysteroscopic tubal occlusion procedure,,,,,,,,,while taking,over 18|written informed consent,,,,,,
14326,,alzheimer's disease;|mmse score,,,,,,,,,within 2 weeks prior to day 1 of protocol therapy.||if,> 30kg/m2|current episode,,,,,,
14327,,seizures.|pregnant,,,,,,,,,within 1 week before enrollment|inherited,<30ml/min);|patients,,,,,,
14328,,unregistered products,,,,,,,,,during recruitment,less than or equal to the upper limit of the normal range,,,,,,
14329,,hip joint disease,,,,,,,,,before the first dose of study intervention,≤ 3 x,,,,,,
14330,,clinical stage t1-t2,,,,,,,,,for 3 months after the last dose,6-7).|pd,,,,,,
14331,,guttate,,,,,,,,,more than 72 hours after infusion,> 50% dose reduction of nha,,,,,,
14332,,plaque-type psoriasis,,,,,,,,,at least one,> 93,,,,,,
14333,,women;|serious infections,,,,,,,,,within the last 3 weeks|bilateral,<30 days prior to the baseline,,,,,,
14334,,carious teeth,,,,,,,,,within 48 hours post,≥3 months,,,,,,
14335,,radiation,,,,,,,,,within the last 6 months|regular consumption,≥ 1.0 ×10^9/l,,,,,,
14336,,anticancer therapy|diagnosis,,,,,,,,,≥14 days before receipt of study vaccine,> normal range upper × 1.5|blood cpk,,,,,,
14337,,'s main tissues,,,,,,,,,between screening and the end of study visit.|use,period.|unable,,,,,,
14338,,breast-feeding||ɨ,,,,,,,,,within next six months,below 26;|agree to receive,,,,,,
14339,,conjunctival scarring,,,,,,,,,2 months / or laxativ 3 weeks before hospitalization;|somatic comorbidity should perturb,18.5-29.9,,,,,,
14340,,elevations,,,,,,,,,for 12 months after the end of treatment.|voluntarily agrees to participate,from 18 to 80,,,,,,
14341,,autoimmune disorders|pregnancy|breastfeeding|type,,,,,,,,,within 4 weeks prior to the first dose of b1962,less than 6 months related,,,,,,
14342,,vaginal area infection,,,,,,,,,the prior 3 months.|mutant,<= 2 prior,,,,,,
14343,,hemorrhage disorders,,,,,,,,,"after laparoscopic cholecystectomy,|receiving analgesia treatment",between 18 to 70 years,,,,,,
14344,,squamous cell cancer of the,,,,,,,,,concurrent,≤ 30 ml/min)|upper arm circumference,,,,,,
14345,,no residual disease,,,,,,,,,last month) psychiatric diagnosis,at least 65 years old|people must,,,,,,
14346,,siderosis,,,,,,,,,for 8 weeks|no severe,> 40 m-2||,,,,,,
14347,,study:||type 1 diabetes mellitus,,,,,,,,,at least one measurable lesion)|participants,177,,,,,,
14348,,amyotrophic lateral sclerosis,,,,,,,,,more than 3 cm.||5,60 - 89|moderate,,,,,,
14349,,oropharyngeal candidiasis,,,,,,,,,within 3 months prior to first dose of study medication.|glucocorticoids,≥ iiib,,,,,,
14350,,hydrogel|diagnosis,,,,,,,,,within 30 days before the study vaccination,< 25 mm|participants,,,,,,
14351,,prerenal azotemia,,,,,,,,,in the previous 3 years,>= 18 years and <=75 years,,,,,,
14352,,thin white,,,,,,,,,within 30 days prior to screening visit,=< 7 days prior to randomization)||if disease,,,,,,
14353,,colloids|severe heart diseases,,,,,,,,,at the measuring site (the mouth)|they,≥100x109/l,,,,,,
14354,,non-acetylsalicylic acid antiplatelets,,,,,,,,,for at least eight hours a week before surgery,0 to 3 years old,,,,,,
14355,,painful disease,,,,,,,,,exceeding the equivalent of,18-year-old or more,,,,,,
14356,,hbsab positive|at screening,,,,,,,,,within 5 years;|patients judged by the researchers,2.5 times the upper limit of normal,,,,,,
14357,,allergic-type reactions,,,,,,,,,for 24 hours and must,75 x 109/l,,,,,,
14358,,poor medical prognosis,,,,,,,,,within 2 weeks before first dose of study treatment,> 70% stenosis,,,,,,
14359,,depilatory preparations,,,,,,,,,in the previous,score for,,,,,,
14360,,syndrome|porphyria|epilepsy|myasthenia,,,,,,,,,at diagnosis.|the patient or family,>500 cells/mm3,,,,,,
14361,,immune disorders,,,,,,,,,in the last four,≤ 15ml/sec,,,,,,
14362,,valve stenosis,,,,,,,,,in the last 4 weeks,more than 500 ml blood,,,,,,
14363,,age|histologic,,,,,,,,,prior to visit 1|egfr≥30 ml/min/1.73m2,100 u/ml||study-specific inclusion,,,,,,
14364,,ménières disease,,,,,,,,,for equal to or less than 3 weeks,> 3 g/dl,,,,,,
14365,,metabolic disease,,,,,,,,,in the past 3 months|contraindications,> 12,,,,,,
14366,,pathology concordant,,,,,,,,,within one month of the first dose date,"between 18-30 kg/m2,|being",,,,,,
14367,,hiv) infection,,,,,,,,,in the 3 years before study entry,< 20%);|persistence,,,,,,
14368,,interleukin-2 preparations,,,,,,,,,within 28 days prior to study,0 and 7).|subject,,,,,,
14369,,spontaneous menopause,,,,,,,,,in the past 3 months before t1|allergy to test product/control,">= 2,000/mm^3|platelet count",,,,,,
14370,,alcohol,,,,,,,,,on the spleen,18-60 years.|hip,,,,,,
14371,,t-cell large,,,,,,,,,within 3 months prior to the study,> 9|willing and able to provide,,,,,,
14372,,failure|chronic renal failure,,,,,,,,,within 4 weeks after the end of previous clinical studies,< 3 months|receiving enteral (tube,,,,,,
14373,,non-epithelial cancers,,,,,,,,,in the past 3 months|known,<20%||group 2 criteria:||4 m walking time (,,,,,,
14374,,ocular media opacity,,,,,,,,,at dana-farber cancer institute.|medical clearance,≥18 years|st-elevation myocardial infarction,,,,,,
14375,,language expression,,,,,,,,,at the time of entry into,> 1.25 x,,,,,,
14376,,persistent atrial fibrillation,,,,,,,,,during the 16 weeks of the trial|use of refractive/therapeutic contact lenses,5,,,,,,
14377,,non-metastatic disease|known cancer,,,,,,,,,within the last 12 months or after having,"<0,5 miu/l",,,,,,
14378,,musculoskeletal injury,,,,,,,,,within 72 hours prior to taking study treatment,18 -30 years|carious,,,,,,
14379,,respiratory physician,,,,,,,,,within three months of enrollment.||,less than 2x upper limit of normal.|alt,,,,,,
14380,,gallbladder carcinoma,,,,,,,,,in the last 3 months;|subjects,> 2.9)|oligomenorrorrhea,,,,,,
14381,,breast surgery|diagnosis,,,,,,,,,within 30 days prior to screening|planned coronary intervention,between 18 and 32 years;|good general health;|the presence,,,,,,
14382,,aclr,,,,,,,,,within 5 days (120 hours) before screening,18 years ≦ 75 of age.|histological,,,,,,
14383,,mcd,,,,,,,,,within past 12 months|chronic inflammatory diseases,less than 10cm,,,,,,
14384,,waldenström macroglobulinemia,,,,,,,,,1 month prior,3-6,,,,,,
14385,,infectious blepharitis,,,,,,,,,in the past 12 months.|known,5% or more,,,,,,
14386,,disorders|suicidality,,,,,,,,,prior to the first dose of encaleret.|participants treated,> 9g/dl;|patients,,,,,,
14387,,cardiogenic shock|severe,,,,,,,,,for at least 8 weeks after the last dose,i/ii,,,,,,
14388,,left colon,,,,,,,,,prior to screening.|current,> 480 msec,,,,,,
14389,,structural damage,,,,,,,,,before the 24th week of gestation,> 1000 mg/gm,,,,,,
14390,,acute disease exacerbation,,,,,,,,,within the 6 months prior to consent|involved,at least 18-85 years,,,,,,
14391,,chronic angioedema,,,,,,,,,after previous treatment with,> 1.8pg/ml,,,,,,
14392,,1.arrhythmia,,,,,,,,,within 30 days of the volunteer's expected enrollment,between 25 and 80 years,,,,,,
14393,,stromal tumor,,,,,,,,,during the patient's participation in this study.|healthy volunteers,from 15 to 70 years',,,,,,
14394,,immunodeficient disease,,,,,,,,,< 6 months prior to screening.|acute,>1 moca>=26,,,,,,
14395,,peptic ulcers;|subjects who test,,,,,,,,,"hospital readmission),|pregnancy",after 33 weeks of gestationand,,,,,,
14396,,familial colorectal cancer type x;|positive fecal immunochemical test;|use anti-platelet agents,,,,,,,,,throughout the entire study period.|receipt of the following,20 to 80 years,,,,,,
14397,,screening:||post-menopausal,,,,,,,,,within the past 30 days.|participant,>33%,,,,,,
14398,,confirmed hiv,,,,,,,,,up to 30 days after the last dose of durvalumab.|female,< 60 ml/min)|any condition,,,,,,
14399,,somatic condition(as controlled,,,,,,,,,within 6 months before study intervention,between 18 to 60 years,,,,,,
14400,,secondary headache disorder,,,,,,,,,preoperative,deemed unfeasible/high-risk,,,,,,
14401,,interventions,,,,,,,,,within 30 days of first treatment,> 200 mg/dl|cancer,,,,,,
14402,,licensed,,,,,,,,,within 5 years of screening|history,> 1.5 ×109/l,,,,,,
14403,,sacrospinal ligament fixation,,,,,,,,,at the time of the parental study,< 18 years|non consent to participate to the,,,,,,
14404,,breastfeeding.|metallic implants,,,,,,,,,during 3-4 weeks prior to treatment,18-70,,,,,,
14405,,cardiovascular disease.|consistent,,,,,,,,,medication.|approximately 12 months after the first study vaccination.|the,between 6 and 36 months|toddlers,,,,,,
14406,,significant pathologies,,,,,,,,,at the time of signing the informed consent form.|expected survival,≤ 3' uln,,,,,,
14407,,left atrial appendage anchor,,,,,,,,,at admission,>37.5'c)|refusal to participate,,,,,,
14408,,cranial nerve function deficits,,,,,,,,,within 1 year prior to first administration of the study drug;|active,≥6 months|the disease,,,,,,
14409,,kidney failure|acute coronary syndrome,,,,,,,,,within 4 weeks of,20 <= scorad <= 40,,,,,,
14410,,breast feeding||for,,,,,,,,,during the study.|participants are able to understand and voluntarily sign consent,18-64|sexually,,,,,,
14411,,bone marrow transplantation|subject,,,,,,,,,within the past 3 months|pregnant,0-2|able,,,,,,
14412,,generalized anxiety disorder scale,,,,,,,,,for ≥5 years；|women,6 to 16 years,,,,,,
14413,,hashimoto's disease,,,,,,,,,within 30 days prior to the first study drug administration|known,<18|patients,,,,,,
14414,,deviates notably,,,,,,,,,within 30 days prior to screening.|intake of an investigational drug in another trial within 30 days prior to screening.|patient not able to understand,within therapeutic range,,,,,,
14415,,pulmonary vascular congestion,,,,,,,,,within 14 days prior to the first administration of study medication,3|anaplastic oligoastrocytoma,,,,,,
14416,,rheumatic heart valvular disease,,,,,,,,,within 4 weeks prior to the first dose of niraparib|known history,> 50 kg/m2|history,,,,,,
14417,,criteria,,,,,,,,,more than one hour per month,≥12 weeks;|ecog score 0-1;|measurable,,,,,,
14418,,discharge under hospice|listed,,,,,,,,,up to 6 months after study treatment,< 24 months,,,,,,
14419,,pulmonary rales,,,,,,,,,within 4 weeks prior to initial use of the study drug;|10,> 185 mmhg,,,,,,
14420,,hereditary spherocytosis,,,,,,,,,setting|more than 1 line,to 150 ng/l,,,,,,
14421,,solid-organ transplantation|currently active second primary malignancy,,,,,,,,,within 30 days after study participation.|participation,>160/90,,,,,,
14422,,encephalopathy grade,,,,,,,,,within 2 weeks prior to the expected initial application date,> 30 ml;|maximum,,,,,,
14423,,severe exacerbation,,,,,,,,,within 1 week;|hrct is consistent,45-70,,,,,,
14424,,acute pneumonia,,,,,,,,,within 7 days.|history,1 drink,,,,,,
14425,,copd patients:||copd,,,,,,,,,within 28 days prior to day 1 of cycle 1 or,below the limit of detection,,,,,,
14426,,care||,,,,,,,,,within 14 days prior to the first dose of study intervention.|patients,8 and 15 years,,,,,,
14427,,medical risk,,,,,,,,,at least 3 months following study treatment discontinuation,greater than or equal to 10,,,,,,
14428,,read ct's,,,,,,,,,in the previous year|hospitalisation,"8-12,|having",,,,,,
14429,,necrotic pulp,,,,,,,,,within 28 days prior to vaccination,> 10mu/l,,,,,,
14430,,mixed malignant mullerian,,,,,,,,,at the screening and day -2 visit.)|current,greater than 1/3 of,,,,,,
14431,,soc,,,,,,,,,78 months to facilitate monitoring through 6 months of follow-up.||normal,< 72 gy,,,,,,
14432,,vitamin b12,,,,,,,,,within 12 weeks of screening visit|uc limited,per day for 7 days,,,,,,
14433,,subcortical gray,,,,,,,,,within two years,< 20 pack-years,,,,,,
14434,,ibd,,,,,,,,,within 30 days prior to visit 0 (day 1,≥ 100×109/l,,,,,,
14435,,past infection,,,,,,,,,at the time of signing,6,,,,,,
14436,,organ failure,,,,,,,,,during the luteal phase of the screening,≥ 18 years.|histologically verified non-metastatic,,,,,,
14437,,superficial bladder,,,,,,,,,during the study period|no,<100 g/l.||,,,,,,
14438,,lesion,,,,,,,,,at the period of inactive ai-ecg system,≥ 23kg/m2,,,,,,
14439,,calculated using,,,,,,,,,prior to enrollment.|patients,>180mmhg,,,,,,
14440,,chronic pulmonary hypertension,,,,,,,,,weeks prior to screening,≥2.0 x,,,,,,
14441,,refuses to measure,,,,,,,,,within 12 months|breast mri,between 18 to 65 years;|have a patient health questionnaire-9,,,,,,
14442,,organic cause of pain)|healthy control,,,,,,,,,within 2 years prior,30-59 ml/min/1.73 m2).||,,,,,,
14443,,study|self-report,,,,,,,,,in last 3 days,+ - 3||,,,,,,
14444,,contra-indications,,,,,,,,,within 24 hours after surgery|cardiac,z-score (,,,,,,
14445,,hashimoto thyroiditis,,,,,,,,,within 4 weeks prior to randomization.|known,≥75×109/l,,,,,,
14446,,episodes of fainting,,,,,,,,,before enrollment.|the measurable,minimum sensitivity 25 iu/l hcg,,,,,,
14447,,keratinized tissue at the site selected,,,,,,,,,during the three months prior to admission to the study.|pain must,>25 cm,,,,,,
14448,,cognitive impairment||mci:||cognitive changes,,,,,,,,,for at least five months after the last dose of isatuximab treatment male,18-70|diagnosis of,,,,,,
14449,,des implantation.|inability,,,,,,,,,for 5 years since treatment began,≤ 12 cm,,,,,,
14450,,from cardiac arrest,,,,,,,,,during the duration of the study|inability to suspend oral medications,greater than or equal to 4 mm,,,,,,
14451,,pdac)|moffitt cancer center,,,,,,,,,within 14 days prior to the expected start of trial treatment.|contraindications,28-day,,,,,,
14452,,axis,,,,,,,,,at the time of enrollment|current treatment,< 85).|presence,,,,,,
14453,,aortic insufficiency|known amyloid heart disease|group,,,,,,,,,at least 30 years,> 1)|not responsible,,,,,,
14454,,nasal infection,,,,,,,,,more than 3 months|no,18 to 74 years,,,,,,
14455,,chronic lymphocytic lymphoma (,,,,,,,,,throughout the body for phase iiib,0-2||,,,,,,
14456,,actively suicidal|the presence,,,,,,,,,within 10 days of screening.|history of osteoporosis,90 years|allergy to cinnarizine,,,,,,
14457,,functional tricuspid regurgitation,,,,,,,,,within 24 hours of study visits;|self-reported,≥ 1.5 × 10l|platelet count (,,,,,,
14458,,metabolic bone,,,,,,,,,within 24 hours prior to first dose of lenvatinib,>30kg/m2|1st,,,,,,
14459,,chronic hypertension,,,,,,,,,15 days prior to treatment.|having,18 to 84 years|patients,,,,,,
14460,,cancer staging,,,,,,,,,previously treated,≥ 130 mmhg,,,,,,
14461,,2.continuous glucose monitoring,,,,,,,,,within the last 6 months prior before registration.|transmural myocardial infarction,< 25 ml/min).|type i,,,,,,
14462,,synovial sarcoma,,,,,,,,,on day prior to or day,=< 1.5 times upper reference,,,,,,
14463,,bronchiolectasis,,,,,,,,,for at least 14 days,>= 2 cm,,,,,,
14464,,ad dementia,,,,,,,,,within 6 months|patients,above 18)|undergoing elective,,,,,,
14465,,extra-hepatic diseases,,,,,,,,,at least 1 year prior to d1,under 40 years,,,,,,
14466,,asthmatic disease,,,,,,,,,at least one month prior to study participation,greater than or equal to 1 year)|of childbearing potential,,,,,,
14467,,acquired immune dysfunction,,,,,,,,,prior to screening.|patients,12 and 36 months|length-for-age z score (laz) <-1.5 sd and,,,,,,
14468,,clostridium difficile infection,,,,,,,,,at least one prior therapy,0 or 1;|estimated,,,,,,
14469,,acute coronary syndrome|graft,,,,,,,,,at the screening visit||note,"< 50,000 cells/mm3",,,,,,
14470,,spirometry response,,,,,,,,,within the last 2 weeks before,<24 months prior to screening).||prior/,,,,,,
14471,,police involvement,,,,,,,,,during the last 6 weeks|previous spine surgery|neurologic disease,×,,,,,,
14472,,primary spinal cord,,,,,,,,,at least 30 days before study entry,>2 × uln,,,,,,
14473,,paranoid mental disorder,,,,,,,,,within four weeks prior to dosing.|clinically significant,< 300 ng/ml,,,,,,
14474,,of:||hypodopaminergic behavioral syndrome,,,,,,,,,at time = 0);|have,1 episode,,,,,,
14475,,herpetic keratitis).|have fluctuations,,,,,,,,,within 3 weeks of start of study intervention.|is,greater than equal to 180,,,,,,
14476,,bronchogenic carcinoma,,,,,,,,,within 14 days prior to the start of the clinical study|positive rapid test result,>uln|history,,,,,,
14477,,unstable heart disease,,,,,,,,,during the three previous months|patients,< 12 months|a,,,,,,
14478,,schizophrenia|participant,,,,,,,,,within the past 3 months|patients,at least three weeks before the trial|individuals on,,,,,,
14479,,cns pathology,,,,,,,,,within the 4 weeks before day 1 of cycle 1 or administration of a live,> 3 times upper limit,,,,,,
14480,,cervicitis,,,,,,,,,within 8 weeks before enrollment,> 100 mmhg)|hemolytic,,,,,,
14481,,drug-induced lung disease,,,,,,,,,within the 12 months before screening,1.5 times more than the upper limit of normal,,,,,,
14482,,pulmonary complications,,,,,,,,,within 28 days before screening；|patients,at day 90 after treatment||exclusion criteria,,,,,,
14483,,trauma|pregnancy,,,,,,,,,within the past year|patients currently,30-79 years,,,,,,
14484,,program junior,,,,,,,,,within the next 30 days,>10 sexual partners in their lifetime,,,,,,
14485,,germline defect,,,,,,,,,last 48 hours prior to baseline study assessment;|use,≥1.0 cm,,,,,,
14486,,prophylactic antimicrobial agents.||active hepatitis b,,,,,,,,,throughout the duration of the study.|current swab-positive,≥ 3mg/,,,,,,
14487,,celiac disease|willingness,,,,,,,,,within 3 months before screening;|participants who the investigator believes,> 0.2 ng/ml,,,,,,
14488,,high microsatellite instability,,,,,,,,,within 6 months from,>3x,,,,,,
14489,,acute neurological disorder,,,,,,,,,at least 1 of the following criteria:||serum/plasma psa progression,<2.5×103 copies/ml,,,,,,
14490,,diaphragmatic hernia,,,,,,,,,within 4 weeks prior to randomisation).|body weight,>1 year,,,,,,
14491,,local disease,,,,,,,,,pre-bronchodilator,> 1.5 k/ul,,,,,,
14492,,avnrt||,,,,,,,,,previous 3 months prior to entry.|use,≥ 3mg/dl|patients,,,,,,
14493,,carcinoma in situ of the cervix;|severe,,,,,,,,,over the two months preceding participation,greater than 240,,,,,,
14494,,liswt.|erective dysfunction (ed),,,,,,,,,during the procedure,less than 3 months;|unable,,,,,,
14495,,genitourinary tuberculosis,,,,,,,,,prior to cycle 1 day 1,>100)|known,,,,,,
14496,,keratinized band,,,,,,,,,group:||history of chronic,qualify,,,,,,
14497,,xiaoyan lidan tablets,,,,,,,,,within 2 weeks before treatment,≤ 5%,,,,,,
14498,,permit compliance,,,,,,,,,within the 30 days prior to inclusion,partial response,,,,,,
14499,,central pathology,,,,,,,,,at least 6 abnormal reactions,multiple myeloma.|pregnant,,,,,,
14500,,basal fsh,,,,,,,,,at least 4 weeks before the first dose,lasting more than six months,,,,,,
14501,,tablet computer,,,,,,,,,within 14 days prior to day 1 of protocol therapy|strong,< 24 hours,,,,,,
14502,,congenital neurological defect,,,,,,,,,in the last 30 days.|currently taking,minimum 50 kg,,,,,,
14503,,santa fe province,,,,,,,,,within 4 to 6,less than 90 days before the first study session.|inability,,,,,,
14504,,hypoxia,,,,,,,,,within 30 days prior to the first dose of sublocade,>1.5 times the uln,,,,,,
14505,,lactobacillus tablets,,,,,,,,,within the previous 3 months,4-10,,,,,,
14506,,abpa exacerbations,,,,,,,,,within 7 days before the first administration.|expected survival time,<40mg/dl,,,,,,
14507,,migs,,,,,,,,,during active,>= 18 years|clinical,,,,,,
14508,,non-pregnant,,,,,,,,,2 weeks prior,7-10 days after initial treatment.|patients,,,,,,
14509,,active angina,,,,,,,,,prior to surgical repair of,18 and older,,,,,,
14510,,gm-csf autoantibody test,,,,,,,,,within 60 days prior to randomization|patients,from 18 to 99|able to consent,,,,,,
14511,,renal allotransplantation,,,,,,,,,within the past 3 months|using transdermal hormones,pregnancy|full-term,,,,,,
14512,,digestive system tumors,,,,,,,,,within 4 weeks prior,>= 18 years||aml,,,,,,
14513,,melanoma lesion,,,,,,,,,in three months prior to the study|use of topical depigmenting agents,≥ 50%);|evidence,,,,,,
14514,,covid complications,,,,,,,,,within 28 days prior to administration of study treatment.||a,"< 150,000/μl|have",,,,,,
14515,,non-healing active wound,,,,,,,,,within prior 2 weeks.|patients with,>90% visual diameter stenosis|presence,,,,,,
14516,,abnormal coagulation,,,,,,,,,in the 12 months prior to screening,6%,,,,,,
14517,,organ damage,,,,,,,,,within the 30 days prior to screening,> 12 weeks.|females should,,,,,,
14518,,age>20|rectal cancer,,,,,,,,,at least 20°,≥ 10 years,,,,,,
14519,,focal neurologic deficits,,,,,,,,,at time of study entry|history of repeated strokes with stepwise progression of parkinsonism|history of repeated head injury|history of definite encephalitis|more than one blood,<13 g/dl.|previous,,,,,,
14520,,cooperated with the follow-up.||,,,,,,,,,at least one of the following requirements during screening,over 18 years|non-smokers|history,,,,,,
14521,,dietary intervention|excessive alcohol consumption,,,,,,,,,at least 1 month before screening,≥ 65%,,,,,,
14522,,unmanaged bipolar disorder,,,,,,,,,within one week prior to baseline,≥30 ml/,,,,,,
14523,,revascularization|cardiogenic shock,,,,,,,,,less than 12 months ago,≤ 1.5 uln;|creatinine ≤ 1.5,,,,,,
14524,,perianal infection,,,,,,,,,throughout screening.|fundoscopy,< 50 l/,,,,,,
14525,,her2-targeted therapy,,,,,,,,,in the past six months;|voluntary to be involved,≥18 years.|patient,,,,,,
14526,,consent|esophageal stenosis,,,,,,,,,prior 30 days|active,> 30mmhg,,,,,,
14527,,disease,,,,,,,,,in the past 14 days;|hemoglobin,≥ 90g/l. 2,,,,,,
14528,,congenital heart disease|known allergy to the study drugs,,,,,,,,,at birth.|creatinine clearance,younger and older adults||age,,,,,,
14529,,contractures,,,,,,,,,at the time that the clinical team approaches the,≥0.75×10^9/l,,,,,,
14530,,chronic kidney disease epidemiology collaboration (ckd-epi))|has,,,,,,,,,within 14 days before the first dose of study treatment,> 7 days prior does not count,,,,,,
14531,,implant surgery|immunological,,,,,,,,,in past 30 days (cbd or,> 500 copies/ml|informed,,,,,,
14532,,non-vte,,,,,,,,,within 12 weeks prior to screening,between 60 bpm and 100 bpm,,,,,,
14533,,potassium excretion disorder,,,,,,,,,within 180 days after the end of the study treatment,18-25|live,,,,,,
14534,,high-grade,,,,,,,,,within the last 3 months- requires documentation of alc,≤ 5 mm.|clinical attachment level (cal),,,,,,
14535,,plates,,,,,,,,,prior to treatment.|individual,> 100 mmhg|unstable angina,,,,,,
14536,,plasmacytoma,,,,,,,,,at the time of recruitment;|inability to speak or,<1 or > 2,,,,,,
14537,,infectious disease,,,,,,,,,within 1 year before the first dose of study,≤ 24 weeks before randomization,,,,,,
14538,,gender-,,,,,,,,,at the time of signing the informed consent form|able to speak and,between 100-180,,,,,,
14539,,california,,,,,,,,,within 2 weeks of the first dose,sub-registry.||,,,,,,
14540,,functional states;|b-ultrasound,,,,,,,,,within 8 weeks after the last,>500 mg/,,,,,,
14541,,thyroid function disorders,,,,,,,,,within the past 3 months|any,maximum 1mg/kg/,,,,,,
14542,,subcutaneous tissue disease,,,,,,,,,at least six weeks prior to first dose of study drug,<12 months prior to the baseline,,,,,,
14543,,questionnaire.|participant,,,,,,,,,more than 6 months.|subjects,>= 21 days must,,,,,,
14544,,chronic gastrointestinal diseases.|diseases,,,,,,,,,within 90 days prior to enrollment;|within the last six months,<18.8 kg,,,,,,
14545,,comorbid disease,,,,,,,,,within 4 weeks;|allergic to the test drug or its active ingredients,equal to -2 ml/min/1.73 m2/year,,,,,,
14546,,lapp lactase deficiency,,,,,,,,,of the oropharynx.|asymmetry of the tonsils,from january 2012 to,,,,,,
14547,,extracutaneous tumor spread beyond locoregional,,,,,,,,,within the past 2 years||,≥ 1.5 mm,,,,,,
14548,,bleeding risk factor,,,,,,,,,at time of consent|body mass index,≥92%,,,,,,
14549,,sensory defects,,,,,,,,,within five half-lives,pr negative,,,,,,
14550,,persistent hypotension,,,,,,,,,within 1 month.|the patient,score of 20% or greater,,,,,,
14551,,renal,,,,,,,,,for at least 180 days after the last dose of study treatment.|ability to understand,score <10).||activities of daily,,,,,,
14552,,healthy subjects:||evidence,,,,,,,,,at enrollment 10,more than 90%(%,,,,,,
14553,,uc)|measurable disease,,,,,,,,,within 30 days prior to blood draw,between 18 and 28 kg/m2||,,,,,,
14554,,close contacts:||1,,,,,,,,,within the past 6 months;|history of,> 10h per waking day,,,,,,
14555,,nonsquamous,,,,,,,,,within 5 mm hg of the range,≤ 2.|estimated survival,,,,,,
14556,,bpm|tachycardia,,,,,,,,,at least 7 days after platelet transfusion.|hemoglobin,18.5 to 33.0 kg/m2,,,,,,
14557,,osteomyelitis,,,,,,,,,prior to enrollment|any previous,> 10 mm,,,,,,
14558,,joint diseases|ongoing treatment,,,,,,,,,for at least 6 weeks prior to screening.||,=weight kg/height,,,,,,
14559,,non opposition.||,,,,,,,,,after radiation therapy,below 92% despite maximal oxygen therapy,,,,,,
14560,,right heart dysfunction,,,,,,,,,within 12 months of screening,≥ 4,,,,,,
14561,,craniotomy,,,,,,,,,more than 6 months|subjects,>115 g/m2,,,,,,
14562,,treatment-free interval,,,,,,,,,before entering the study;|shortness of breath,>1.5 × upper limit of normal (uln),,,,,,
14563,,nasal septal perforation,,,,,,,,,within 28 days of registration,<23,,,,,,
14564,,leveled congestive heart failure,,,,,,,,,during two weeks before the enrollment in the study|a contradiction to any,i & ii,,,,,,
14565,,extensive periodontitis,,,,,,,,,within 4 weeks prior to study registration.||pregnant,>= 1.5 x 10^9/l,,,,,,
14566,,active virus,,,,,,,,,throughout the duration of the study,long term health,,,,,,
14567,,hearing loss,,,,,,,,,for at least six weeks duration,old|stage ii,,,,,,
14568,,meningeal dissemination|individual,,,,,,,,,within the past year.|individuals,lower than 10g/dl.||iv,,,,,,
14569,,recurrence after platinum-based,,,,,,,,,within the typical range|no contraindications,above 1.5 x uln,,,,,,
14570,,ct1a mass,,,,,,,,,"prior to pregnancy,|history of gestational diabetes,|current pregnancy,|body mass index",50-64|postmenopausal women|recent,,,,,,
14571,,her2 null,,,,,,,,,without surgery,grade 0 or 1，or to levels,,,,,,
14572,,hemodynamic alterations,,,,,,,,,within 5 months after the final dose of atezolizumab.||treatment,<60 ml/min/1.73 m^2,,,,,,
14573,,vaping|clinically stable,,,,,,,,,within the past 5 years,≥14 years,,,,,,
14574,,dietary habits,,,,,,,,,for ≥ 6 months|patients,> 29,,,,,,
14575,,iv);|uncontrolled hypertension,,,,,,,,,within 2 years prior to first dose of study intervention,>8.5 % (69 mmol/mol,,,,,,
14576,,endocrinologist|cardiovascular diseases,,,,,,,,,within 6 months prior to the injection of the booster vaccine,20-30 weeks,,,,,,
14577,,attempted attempt,,,,,,,,,at the time of enrollment.|one additional,between 25 and 35 years old,,,,,,
14578,,inhalation injury,,,,,,,,,at time of blood collection to ensure steady-state|patients,greater than 400 ml,,,,,,
14579,,myoma|irregular menstrual cycle|past,,,,,,,,,in the current episode.|have,≥ 3)|antiemetic use,,,,,,
14580,,familial,,,,,,,,,for the next 12 months|english-speaking|willing,over or equal to 19|ecog,,,,,,
14581,,gastrointestinal absorption,,,,,,,,,within the past 12 months prior to screen/baseline,≥ 22 and≤90 years,,,,,,
14582,,technologies,,,,,,,,,during the screening period despite medical management,<35.0°c,,,,,,
14583,,variceal bleeding events,,,,,,,,,during the last month|unwilling or,>30 kg/m2;|enrolled,,,,,,
14584,,cscr,,,,,,,,,post abortion,0-6 months,,,,,,
14585,,antiphospholipid antibodies (anticardiolipin antibodies,,,,,,,,,at the time of informed consent||part 1,20 ~ 30 kg/m2,,,,,,
14586,,labor|known maternal intestinal stenosis,,,,,,,,,within 1 year prior to the screening,1-3b)|marginal,,,,,,
14587,,smoking|systemic disease|pregnancy,,,,,,,,,<30 days before screening,7-12,,,,,,
14588,,spinal injury association (aisa),,,,,,,,,for at least 4 months after the last dose of study intervention:||refrain,below 89%,,,,,,
14589,,"ocular imaging,|refractive error",,,,,,,,,in the last 31 days prior to the encounter|english,upper or,,,,,,
14590,,endocrinal disease,,,,,,,,,throughout the study duration and,3)||companion inclusion criteria||- hd,,,,,,
14591,,events judged by the investigator,,,,,,,,,within the last 30 days.|anticipated relocation,6-12 years,,,,,,
14592,,participation.||exclusion,,,,,,,,,for at least 5 years before screening.|contraindications to mri,0-2|new york,,,,,,
14593,,heart rhythm,,,,,,,,,at screening for,≥1.0 g/dl.,,,,,,
14594,,esophageal ulcer,,,,,,,,,throughout the study.||demonstrate,>18.5|willingness to eat study meals||,,,,,,
14595,,consent|pregnancy|cancer|deemed unsuitable by study physician,,,,,,,,,within 30 days prior to screening.|females,12 months to 12 years,,,,,,
14596,,neurogenic cough|neurogenic cough,,,,,,,,,prior to admission,>= 40 ml/min|total bilirubin,,,,,,
14597,,type 1 diabetes|type 2,,,,,,,,,at the time of dosing).|pregnant,18 - 60 years.|gender,,,,,,
14598,,resting conditions,,,,,,,,,for at least five,≤ 45)|participant,,,,,,
14599,,ihc 2+/ish+ cancers,,,,,,,,,within 2 weeks prior to administration.|the participant,> 1.5 mg/dl).|alcohol,,,,,,
14600,,r reference group,,,,,,,,,within 10 days prior to study intervention administration,18-65 years|non-smokers||,,,,,,
14601,,ehr support,,,,,,,,,within 6 weeks prior to treatment,1 oz 40%,,,,,,
14602,,anterior segment pathology,,,,,,,,,after 1mg dexamethasone inhibition test (1mg-dst).||,20 to 50 years.||,,,,,,
14603,,fetal movement|hiv positive,,,,,,,,,up to 15 ml).|women,i-ii|fmps < 10%|fmbs< 10%|<10,,,,,,
14604,,ductal breast carcinoma in situ,,,,,,,,,within 8 weeks prior to screening,"18 to 45 years,|3 to 24 months postpartum|criteria of",,,,,,
14605,,continuous motor unit activity,,,,,,,,,at least one year before enrollment|signed informed consent|there,≥ 10^4 copies/ml,,,,,,
14606,,mellitus|cold sensitivity,,,,,,,,,throughout study treatment,< 80% predicted and,,,,,,
14607,,progressive hepatic fibrosis;|primary liver cancer,,,,,,,,,within previous 4 months.||,≥55and ≤85 on the date of signing the informed consent,,,,,,
14608,,influenza infection,,,,,,,,,for the duration of pregnancy,>80%,,,,,,
14609,,tumor extension into the stomach,,,,,,,,,within 3 months prior to enrollment,received more than two courses of the via regimen;|(5,,,,,,
14610,,plasmacytomas,,,,,,,,,at least one inclusion criteria,> 15|patients have anxiety,,,,,,
14611,,normal brain,,,,,,,,,at the time of consent.|has,demonstrates ≥15 peak,,,,,,
14612,,cns malignancy.)|have,,,,,,,,,within 30 days of enrollment,≥4,,,,,,
14613,,renal function.|prior anti-cancer therapy,,,,,,,,,3 days,> 40 ml/min,,,,,,
14614,,loose consistency stools,,,,,,,,,within 8 hours of onset/last,≤ 1.5 x the upper limit of normal (uln),,,,,,
14615,,rheumatic pathologies,,,,,,,,,at any time or other anticancer therapy,22+ years,,,,,,
14616,,adrenal adenoma,,,,,,,,,outpatient basis to include,between 8 points to 21,,,,,,
14617,,non-wolfram,,,,,,,,,from 3 months to 10 years,>50 years|suffering,,,,,,
14618,,heat perception,,,,,,,,,more than 3 months|ultrasound-confirmed,less than 3 mm,,,,,,
14619,,uterus,,,,,,,,,more than 4 cups,35-65 years,,,,,,
14620,,unirradiated lesion,,,,,,,,,throughout their participation during study treatment,18 and older.|in,,,,,,
14621,,weeks)|persistent heart rate (hr),,,,,,,,,prior to first study drug until end-of-study,> mild|primary,,,,,,
14622,,posterior pharyngeal,,,,,,,,,within 1 week prior to enrollment.||total bilirubin,70 db hl,,,,,,
14623,,ex-premature,,,,,,,,,within one month);|advanced chronic kidney disease,> 6mg/l,,,,,,
14624,,endometrial polyps,,,,,,,,,prior to starting the medication.|patients,< 6|apathy evaluation scale - score,,,,,,
14625,,congenital heart disease|ec,,,,,,,,,at the time of assessment,<60% of predicted value.|has developed,,,,,,
14626,,infection|pregnancy|allergy,,,,,,,,,within 6 months before the first dose of study drug:||left,younger than 60 years,,,,,,
14627,,thrombocythemias,,,,,,,,,at least 1 month prior to day 0,over 19 years,,,,,,
14628,,r ut,,,,,,,,,throughout the study intervention,45-70 years|body mass index,,,,,,
14629,,third party assistance,,,,,,,,,within 1 week before operation;|subjects refused to accept radical resection,65 years or older.|people,,,,,,
14630,,extra peritoneal biopsy,,,,,,,,,within 1 month after adequate,less than 1.5 uln,,,,,,
14631,,esophageal abnormalities,,,,,,,,,within 60 months of surgery|corneal disease,>=70|patients,,,,,,
14632,,dystonic reaction,,,,,,,,,last year|native arabic patients||,greater than 30 iu/l).||participant,,,,,,
14633,,age|willing,,,,,,,,,within the last 6 months.|any,55-74 years,,,,,,
14634,,better.|able to swallow whole capsules,,,,,,,,,after 8 sessions|recent,calculation formula,,,,,,
14635,,mental health condition,,,,,,,,,during the study period.|acute severe,13-17 years,,,,,,
14636,,intraoperative blood loss,,,,,,,,,in the 3 months before inclusion,< 45 ml/min/1.73 m2.||others:||have,,,,,,
14637,,non-hematologic,,,,,,,,,within 14 days before the first dose|brain lesion,at least 99%,,,,,,
14638,,acute illness.and pregnancy,,,,,,,,,during the preceding 3 months subject,≤ 100 mg/day,,,,,,
14639,,hepatitis c virus antibody,,,,,,,,,in the next 2 years;|participants,30 ml/min/1.73m2 ≤ egfr,,,,,,
14640,,esophageal cancer||2,,,,,,,,,within two weeks|signed written,>80pg/ml,,,,,,
14641,,cholesteatoma,,,,,,,,,within 6 months after end of former first,≤ 5.0||× uln,,,,,,
14642,,evolution|refractory pain,,,,,,,,,in the last 1 month,greater than 1.25-times the upper reference,,,,,,
14643,,residual limb pain,,,,,,,,,within 1 month or 5 half-lives,≥450 ms,,,,,,
14644,,bleeding symptoms|ct,,,,,,,,,cause;||,definition)||,,,,,,
14645,,myeloproliferative neoplasia|presence,,,,,,,,,within 3 months of the first dose.|donated ≥200 ml of,at least more than 12 weeks|7,,,,,,
14646,,old|health workers,,,,,,,,,within 4 weeks before study entry,stage iii b/c/d cutaneous,,,,,,
14647,,intraretinal fluid (irf,,,,,,,,,in last 12 weeks before screening;|history of active,> 50.0 x 109/l,,,,,,
14648,,chronic infection|documented,,,,,,,,,at least 12 weeks after the last dose of study drug,-11.9 g/dl,,,,,,
14649,,unless infection,,,,,,,,,1 month prior to screening.||ambulatory,> 47%,,,,,,
14650,,aspiration pneumonia,,,,,,,,,at time of data extraction,> 38°c,,,,,,
14651,,respiratory tract infection.|body mass index,,,,,,,,,within the past 12-48 months,> 150 μmol/l|ongoing,,,,,,
14652,,popliteal arteries,,,,,,,,,at least one of the following criteria:||five or more years of professional experience,more than 450 lbs,,,,,,
14653,,esophageal stenosis,,,,,,,,,before undergoing valve replacement,<30 ml/min)|persons,,,,,,
14654,,f.|healthy,,,,,,,,,within 2 months prior to admission,≥ 2 mg/l,,,,,,
14655,,criteria of cold,,,,,,,,,within 120 days prior to the first dose of study treatment,<12 months.||out-of-hospital cardiac arrest,,,,,,
14656,,audiovisual impairment,,,,,,,,,"within three months prior to investigation,|peripheral revascularization",gender.|aged 60 years,,,,,,
14657,,hypervolemia|kidney failure|pregnancy,,,,,,,,,at least for the next 48 hours|≥ 18 years,=< 1.5 x upper limit of normal,,,,,,
14658,,enteritis,,,,,,,,,within 2 weeks prior to the first use of the investigational,≤ 5 days).||iii,,,,,,
14659,,atypical placental site nodule,,,,,,,,,within 14 days of the first dose of study drug.|active gi disease,>6.5mm,,,,,,
14660,,stimulating factor,,,,,,,,,within 2 weeks prior to day 1|major surgical procedure,"≥75,000/mm^3",,,,,,
14661,,bariatric surgery|volunteers,,,,,,,,,requiring at least a 2-day admission|ambulatory|≥ 6 month life expectancy,greater than or equal to 95th percentile,,,,,,
14662,,brain metastatic lesion,,,,,,,,,≥ 3 months before inclusion,above 20 years,,,,,,
14663,,paraplegia,,,,,,,,,at least 3 months follow,20-pack-year,,,,,,
14664,,pregnancy|gestation,,,,,,,,,within the last 48 hours,< 60g/l;|patients,,,,,,
14665,,genetic,,,,,,,,,within 30 days before study entry,> 0.39 ng/ml|no,,,,,,
14666,,hyperosmolar hyperglycemic state,,,,,,,,,at the time of adjuvant treatment,18 to 45 years inclusive,,,,,,
14667,,actinic damage,,,,,,,,,past 2 weeks||,70 years who did not,,,,,,
14668,,tumour cells.||patients,,,,,,,,,for 2 weeks after surgery,under parents',,,,,,
14669,,cancerous meningitis,,,,,,,,,for at least 3 months|not pregnant,demographics||≥18 years,,,,,,
14670,,cognitive impairment (mci),,,,,,,,,on inactivated electrode,< 2000 mg/g,,,,,,
14671,,healthy postmenopausal,,,,,,,,,in the 3 months before the trial;|have a history of,^9/l|absolute neutrophil count,,,,,,
14672,,muscular diseases,,,,,,,,,between 01/01/2018 and 28/02/2022,> 24,,,,,,
14673,,december 2024 and||,,,,,,,,,at the time of randomization|women,< 75×109/l|hemoglobin <90 g/l|aspartate,,,,,,
14674,,nail care.|subjects,,,,,,,,,within 28 days prior to the first dose of investigational drug,40mm,,,,,,
14675,,donor lymphocyte infusion,,,,,,,,,at least two years,65 or greater,,,,,,
14676,,type ii|medical,,,,,,,,,within 1 week before screening,19 prior to trial treatment|patient agrees to not,,,,,,
14677,,feeling of tiredness,,,,,,,,,within 24 hours after laac;|5,≤ 5 x uln.||--renal:||estimated,,,,,,
14678,,febrile illness|patients,,,,,,,,,in the past four weeks to six months,>40 and <115,,,,,,
14679,,siltuximab.|congestive heart failure,,,,,,,,,during the study requires consultation,shorter than 30 minutes,,,,,,
14680,,cetera,,,,,,,,,within 45 minutes,greater than 13.|the participant suffers,,,,,,
14681,,temporomandibular dysfunction,,,,,,,,,prior to day 1 of this study,18 and over.|pregnant,,,,,,
14682,,interrupted attempt,,,,,,,,,additional 24 weeks following stereotactic radiosurgery administration,≥3 higher than normal,,,,,,
14683,,insertion.|medical disorders,,,,,,,,,within 6 months of the first dose of study medication,< 13 g/dl,,,,,,
14684,,rapid disease response,,,,,,,,,8 hours prior each study visit.||,<24 cm,,,,,,
14685,,metabolic disturbances,,,,,,,,,performed 4 hours 3 times weekly|patients,2cm < lesion,,,,,,
14686,,cerebrovascular stroke,,,,,,,,,within 2 weeks after the last administration of the study drug.||13.12-lead ecg,≤ 30 ml/minute|creatinine clearance ≤ 60 ml/minute,,,,,,
14687,,criteria:||diastolic dysfunction,,,,,,,,,within 1 year after completion,from 4 to 6 mm|patients,,,,,,
14688,,hepatic cancer,,,,,,,,,within 52 weeks after the infusion;|those,> 28 days.||,,,,,,
14689,,bleeding.|malabsorption syndrome,,,,,,,,,within 4 weeks prior to initial administration.|dose expansion phase: immunocheckpoint inhibitors targeting lag-3,0 or 1||subjects,,,,,,
14690,,chronic disease|not,,,,,,,,,within 3 months prior to the first dose;|subjects,<25 g/l.|uncontrolled,,,,,,
14691,,acute cholecystitis||② gallbladder cancer||cholecystitis with,,,,,,,,,within 3 months prior to the first dose of study drug.|subject,> 30 ml,,,,,,
14692,,unresectable hepatocellular carcinoma,,,,,,,,,within 2 weeks prior to randomization.|history of,≥18.0 to ≤35.0 kg/m2|medically,,,,,,
14693,,cervical,,,,,,,,,within 14 days before inclusion,18.5 - 34.9 kg/m2,,,,,,
14694,,examination|subject,,,,,,,,,within 6 months prior to baseline.|any previous treatment,score ≤ 2|subject's life expectancy,,,,,,
14695,,parkinson disease.|patients,,,,,,,,,within the preceding three months,3 - 7 mmol/l,,,,,,
14696,,polytrauma,,,,,,,,,before screening.|except for atopic dermatitis,> 2 cm,,,,,,
14697,,hads,,,,,,,,,within 24 hours of admission.||,20 l/min,,,,,,
14698,,squamous cell carcinoma of the skin|patients,,,,,,,,,within the previous 3 months.|history,>1.5xuln，hemoglobin <120 g/l,,,,,,
14699,,contralateral upper tract,,,,,,,,,7 days before screening,<50 b.p.m,,,,,,
14700,,stenotic valvular heart,,,,,,,,,following two categories are included:||(1,≥1000 pg/ml,,,,,,
14701,,non-squamous nsclc|eastern,,,,,,,,,within 72 hours prior to day 1,≥2.|prestroke score,,,,,,
14702,,parkinson's disease|lack,,,,,,,,,at diagnosis,≥ 90% product compliance,,,,,,
14703,,persistent abuse,,,,,,,,,within 3 months before administration;|participants,<1 year|principal investigator decides,,,,,,
14704,,mechanistic target of rapamycin,,,,,,,,,within 1 month prior to screening.|subjects,<12 hrs)|suspicion,,,,,,
14705,,lesions|patients,,,,,,,,,within the 12 months prior to registration,less than or equal to 1.6 mg/ml,,,,,,
14706,,systemic diseases,,,,,,,,,≥ 3 months before screening.|≥ 6,≥ 18 years|confirmed,,,,,,
14707,,food allergy,,,,,,,,,at least,=< 14 days prior to registration)|aspartate aminotransferase,,,,,,
14708,,hb bart hydrops,,,,,,,,,within 28 days before randomization,more than 450 ml,,,,,,
14709,,recurrent disease,,,,,,,,,within 7 days prior to the,≥ 89 mmhg,,,,,,
14710,,surgery;|abnormal liver function,,,,,,,,,within the past 5 years.|patients,18-90|people,,,,,,
14711,,arterial line||,,,,,,,,,during the study period.|taking,10-18 years|completion,,,,,,
14712,,"alcohol abuse,|pregnancy",,,,,,,,,within 6 months prior to day 0|history of any,≥ 50%,,,,,,
14713,,liver failure,,,,,,,,,within 30 days or long-acting,≥ 50 ml/min;|good,,,,,,
14714,,containing red,,,,,,,,,6 months old or newer,> 21)|good sleepers,,,,,,
14715,,other infection,,,,,,,,,within 28 days before first study drug,2h-pg,,,,,,
14716,,attention-deficit disorder,,,,,,,,,at least the 3 months prior to inclusion,i - iv):||i,,,,,,
14717,,tumors of the larynx,,,,,,,,,less than 20 mm,18 and above at time of informed consent.|chronic,,,,,,
14718,,cholangiocarcinoma tissues|patients,,,,,,,,,in the pre-surgery status,18 to 40|body mass index (,,,,,,
14719,,peripheral artery disease (pad),,,,,,,,,in the last month prior to study intervention,<50|calculated,,,,,,
14720,,areata alopecia,,,,,,,,,past year,greater than or equal to 30.0 kilogram per square meter (kg/m^2).|history,,,,,,
14721,,participants:||normal renal function,,,,,,,,,prior to baseline visit,c-reactive protein,,,,,,
14722,,reflex syncope|had,,,,,,,,,within 4 weeks|a person,> 1500 per,,,,,,
14723,,cerebral infarction of,,,,,,,,,at least 1 year.|participants,>150 kg,,,,,,
14724,,heart failure|a left ventricular ejection fraction,,,,,,,,,within 24 months of day 1 of this study,0-1;|life expectancy,,,,,,
14725,,carcinoma in situ of the cervix,,,,,,,,,in the month before study start,3.5 mmol/ l).|ultrafiltration,,,,,,
14726,,diagnoses|hereditary transthyretin cardiac amyloidosis|light chain amyloidosis|morbus waldenstrøm|myelomatosis|medical treatment,,,,,,,,,for at least six consecutive months,≥18 years|carrying,,,,,,
14727,,erosive arthritis,,,,,,,,,within 28 days prior to enrollment|other cancer,20 or greater,,,,,,
14728,,large edema,,,,,,,,,completed > 6 months prior,30 - <40 kg/m2|within 5% of,,,,,,
14729,,hypercardia tachycardia,,,,,,,,,in the last month,<18 years|poor understanding of the spanish,,,,,,
14730,,monogenic genetic diseases,,,,,,,,,within the last 12 months;|organ transplantation,at least 50 years,,,,,,
14731,,pharyngeal,,,,,,,,,within 3 weeks prior to the first ip infusion|7,completed 75% of the planned,,,,,,
14732,,pmdi||,,,,,,,,,within the last 6 months.|treatment,"≥ 19 years,|clinically indicated",,,,,,
14733,,uterine sarcomas,,,,,,,,,for at least 8,<3.0 x 10^9 / l,,,,,,
14734,,therapeutic colonoscopy.|polyposis syndromes,,,,,,,,,for at least 4 weeks prior to randomization,equal to or,,,,,,
14735,,lactation;|coagulopathy,,,,,,,,,underwent,<10 ng/dl||,,,,,,
14736,,severe rhythm disorders,,,,,,,,,at the time of informed,local regulations|the,,,,,,
14737,,liver failure.|gastrointestinal disorders,,,,,,,,,for ≥3 months,younger than 19 years and older than 64 years,,,,,,
14738,,simple epilepsy,,,,,,,,,at the time of locoregional treatment.||,more than 90 days|have signed written informed consent to participate,,,,,,
14739,,criteria for cytoreductive surgery:||age,,,,,,,,,within 3 days|any,2 to ≤ 81 years|diagnosis,,,,,,
14740,,intracranial hemorrhage|previously randomised,,,,,,,,,for 2 months prior to enrollment,>= 40 kg/m2;|severe,,,,,,
14741,,cardiovascular complications,,,,,,,,,within 2 months before enrollment;|(7,1-3|patient,,,,,,
14742,,intestinal p-glycoprotein,,,,,,,,,at the toe,≥7.8 mg/dl,,,,,,
14743,,congenital immune deficiency syndrome,,,,,,,,,after a complete primary vaccination schedule,"over 49 years old,|the",,,,,,
14744,,swallowing therapy|between,,,,,,,,,for at least 3 consecutive days or 3 per day and /,< 1.5 uln;|alt,,,,,,
14745,,tumor|self-reported,,,,,,,,,within 6 months prior to study inclusion|serious,>60 ml/minute|in phase 2,,,,,,
14746,,interstitial lung disease,,,,,,,,,within 24 weeks before screening,5-8),,,,,,
14747,,congenital lumbar,,,,,,,,,at least 4 weeks after all previous chemotherapy,18-45|meeting,,,,,,
14748,,mucinous adenocarcinomas,,,,,,,,,at least one additional,> -2149)|18 years,,,,,,
14749,,thyroid disease|head,,,,,,,,,within 4 weeks prior to screening.|history of allergy to,>60 g/day,,,,,,
14750,,severity rated,,,,,,,,,1 month before first treatment,"18 to 85 years old, regardless of",,,,,,
14751,,back surgery syndrome,,,,,,,,,within two weeks of visit 1,≥12 mm,,,,,,
14752,,severe mental disorder,,,,,,,,,within the projected duration of the study,>18 years|hospitalized|undergoing,,,,,,
14753,,heart failure|angina|arrhythmias|cardiomyopathy|valvular heart,,,,,,,,,for past 5 years|patients,≥18 years)||at risk,,,,,,
14754,,transient cerebral ischemia,,,,,,,,,in past one month,18 - 70 years,,,,,,
14755,,virus infection,,,,,,,,,pre-emergent,+ blood smear,,,,,,
14756,,uncorrectable,,,,,,,,,for at least 6 months|no activity,score ≥ 70,,,,,,
14757,,cancer arm participants:||pregnancy,,,,,,,,,in past six month,≥18 years;||medium vessel occlusion,,,,,,
14758,,colony stimulating factor,,,,,,,,,within the past 10 years,18 years and over|patients able,,,,,,
14759,,injectable tumor(s),,,,,,,,,within 6 months before first dose of,below 50 ng/dl;|objective,,,,,,
14760,,diabetes mellitus,,,,,,,,,within 7 days prior to the study;|underarm body temperature before vaccination>37.0°c;|the subjects participated,between 18 and 65;|karnofsky score ≥ 60,,,,,,
14761,,hypothyroidism controlled,,,,,,,,,in the last 12 months|symptoms of,>90min,,,,,,
14762,,autoimmune related,,,,,,,,,in past 1 month|stably taking,greater than 18 years,,,,,,
14763,,cardiac amyloidosis|severe valvulopathy,,,,,,,,,within 1 year|supraventricular,≥ nyha,,,,,,
14764,,primary care clinic,,,,,,,,,within one week;|plasma infusion,upper limb fractures;|level,,,,,,
14765,,drug-eluting balloon,,,,,,,,,in the past 12 weeks.|initiation of,≥18 years old.|written informed,,,,,,
14766,,viruses|satisfactory general health condition,,,,,,,,,within 14 days prior to the first dose of investigational product|presence,0-2|6,,,,,,
14767,,gastroesophageal reflux disease,,,,,,,,,within 28 days or 5 drug-elimination half-lives,≥ 1500/mm3,,,,,,
14768,,deep vein thrombosis (,,,,,,,,,within 30 days from enrollment,≥100°f,,,,,,
14769,,co-morbidity|women,,,,,,,,,prior to randomization.|patients,>40%;|has,,,,,,
14770,,nonchild-bearing potential,,,,,,,,,prior to starting study therapy,worse than 1.5 standard deviation,,,,,,
14771,,id,,,,,,,,,within 5 years prior to screening.|evidence,>= 3 weeks prior to study treatment|strong inhibitors of cyp3a4/5 and cyp2c19:,,,,,,
14772,,end,,,,,,,,,within the month before starting the study.||,≥ 45%,,,,,,
14773,,intracranial hemorrhage;|ischemic stroke,,,,,,,,,during pregnancy,5 - 7,,,,,,
14774,,chemotherapy;|patients,,,,,,,,,at time of obtaining informed consent,1 ounce,,,,,,
14775,,pulmonary veno-occlusive disease,,,,,,,,,within 6 months before baseline.|smoking more than 5 cigarettes per day within 3 months before the screening visit,≥3 months.||normal function,,,,,,
14776,,loose/liquid stools,,,,,,,,,for at least 3 months following completion of the study.|mentally competent,< 90 g / l;|prothrombin activity,,,,,,
14777,,hospitalization|considered in remission,,,,,,,,,at 2 h after ingestion of a,≤ 42,,,,,,
14778,,procedure)|untreated arrhythmias,,,,,,,,,after randomization|history of focal/grid laser,≥10 g/dl,,,,,,
14779,,malignant cancer,,,,,,,,,in the past 6 months;|despite,10^9/l|total bilirubin,,,,,,
14780,,hematologic malignancy)|chronic inflammatory digestive,,,,,,,,,within the last year|history of/,18 or above|capable to give informed consent|covid-19 infection,,,,,,
14781,,sarcoidosis syndrome,,,,,,,,,at least 1-year after starting the gfd|assessment of the intraepithelial lymphogram,14-19,,,,,,
14782,,non-pelvic,,,,,,,,,during study participation.|fluent,no more than 1 days per week,,,,,,
14783,,rheumatoid arthritis)|neuropathy,,,,,,,,,prior to rt,<50%|systolic blood pressure (bp),,,,,,
14784,,hie,,,,,,,,,within the department of,1 or fewer,,,,,,
14785,,hyperviscosity,,,,,,,,,within 3 months from the beginning of the signing of the informed consent form to the last dose,50 ml/min,,,,,,
14786,,breast feeding|mental health status|daily total sugar intake||inclusion criteria:||malaysian,,,,,,,,,within 6 months of enrollment||5,>15 cm,,,,,,
14787,,laryngeal edema,,,,,,,,,within the 3 months prior to consent.|treatment with another investigational agent,20-50 years|fresh sample,,,,,,
14788,,uinted kingdom,,,,,,,,,for at least 3 weeks prior to baseline,over 250 pounds,,,,,,
14789,,chromosomal nondisjunction,,,,,,,,,within the last 6 months of baseline visit.||4,6-18 years,,,,,,
14790,,severe mental illness,,,,,,,,,at least 8 half-lives,≥ 1cm,,,,,,
14791,,burnout reduction|a change,,,,,,,,,while on study.|individuals with any,18-75|patients,,,,,,
14792,,artery cannulation,,,,,,,,,at university of,<75,,,,,,
14793,,squamous cell carcinoma of the skin).||a,,,,,,,,,within last 3 months,greater than the upper limit of normal value,,,,,,
14794,,non-infectious pathology,,,,,,,,,within the last 12 months|bmd t-score,< 18 kg/m2|contraindication,,,,,,
14795,,in situ carcinomas,,,,,,,,,within last 12 months,≥ 3.2 g/dl,,,,,,
14796,,haemodynamic compromise,,,,,,,,,within 90 days of study vaccination.||,gender|older than 18,,,,,,
14797,,diabetes mellitus atrial fibrillation coronary disease,,,,,,,,,within the past 6 months|additional neurological conditions,| rijksoverheid.nl,,,,,,
14798,,nonsegmental vitiligo,,,,,,,,,at the time the patient provides written assent|females of,≥ 45,,,,,,
14799,,alone.|able to swallow liquids,,,,,,,,,before and after the operation,more than 3 months.|renal,,,,,,
14800,,signet-ring cell carcinoma of the prostate,,,,,,,,,at the time of registration.|a,greater than 40 cm/h2o,,,,,,
14801,,medium risk,,,,,,,,,within 18 months prior to baseline endoscopy|cohort,> 1.7;|severe hepatic,,,,,,
14802,,weight loss surgery,,,,,,,,,for at least 30 days after the last dose of assigned treatment,3-5,,,,,,
14803,,psychiatric illness,,,,,,,,,prior to first dose of study drug,> 20 mg,,,,,,
14804,,musculoskeletal pain,,,,,,,,,at least 90 days prior to the screening visit must have documentation,6mm≤diameter≤20mm,,,,,,
14805,,conditions judged by the investigator,,,,,,,,,<1 month,50 and 90 years,,,,,,
14806,,groin pain,,,,,,,,,last dose of icb,>18 years|informed,,,,,,
14807,,chemotherapy|autoimmune disease,,,,,,,,,within 4 weeks before the first dose of the imp,>1)|limited knowledge of the german language|dementia,,,,,,
14808,,clinically active infection,,,,,,,,,within 2 months after the last dose of the study,<100g/l|obvious,,,,,,
14809,,poor peripheral circulation,,,,,,,,,within 42 days prior to sub-study randomization,> 18|signature of the informed consent||,,,,,,
14810,,non-infectious wounds,,,,,,,,,within 3 months before the stroke|concurrent,> 80 mmhg,,,,,,
14811,,tunnel wound|black crust,,,,,,,,,allowing for sharpening of imaging examinations|previous intraocular surgery,< 1800/microl,,,,,,
14812,,pain-related surgery,,,,,,,,,within 24-48 hours,less than 0.7|subject,,,,,,
14813,,pathological records confirm+b72ed,,,,,,,,,within 6 months prior to the dose of study drug,less than 18 years;|presence,,,,,,
14814,,upper airway disease,,,,,,,,,at least 3 weeks,≥ 150,,,,,,
14815,,haemophilus influenzae infections,,,,,,,,,for six months after the last therapeutic dose,score of 3 or 4,,,,,,
14816,,tumour tissue,,,,,,,,,at flatland,1 by principal investigator,,,,,,
14817,,periodontitis)|mucosal diseases,,,,,,,,,within 30 days prior to the first dose of study,≥ 50mmhg,,,,,,
14818,,asymptomatic disease,,,,,,,,,before assessment,65 years and older,,,,,,
14819,,muscle relaxation,,,,,,,,,between last day of last menstruation,2 or more times from the upper limit of the norm;|alcohol abuse,,,,,,
14820,,psychosis,,,,,,,,,within 48 hours prior to enrollment,less than 19 or greater than 30|the,,,,,,
14821,,parents);|able to read,,,,,,,,,within 30 days prior to the first day of screening;|for,hurts more than the other side,,,,,,
14822,,atrial fibrillation|good acoustic apical window|left,,,,,,,,,within 4 weeks before the first study drug administration,< 90mmhg,,,,,,
14823,,treatment|chronic hcv infection,,,,,,,,,within the past 3 months)||healthy,< 150min/week,,,,,,
14824,,hashimoto,,,,,,,,,within 7 days before administration of the study drug;|those,<90 mmhg;|severe,,,,,,
14825,,tnm,,,,,,,,,within 3 months prior to the first dose 5,31-78 months,,,,,,
14826,,end-of-life care,,,,,,,,,during pregnancy|smoking history|presence,"≥100,000/μl",,,,,,
14827,,large stroke,,,,,,,,,7 days within 6 months|9% ≤ hba1c,greater than 350 lb,,,,,,
14828,,non-tuberculous mycobacterial infection,,,,,,,,,for the first time;|women,greater than 12;|glomerular filtration rate<60ml/min/1.73m2;|patients,,,,,,
14829,,late infantile krabbe disease,,,,,,,,,within 4 weeks before the start of the study,≥18 years|female||diagnosed,,,,,,
14830,,nephrolithiasis,,,,,,,,,after cd19-directed,>=1.5 × uln,,,,,,
14831,,ncov-19,,,,,,,,,prior to screening visit,less than 1 month||,,,,,,
14832,,tuberculosis|active hepatitis b,,,,,,,,,within the last two years per protocol.||13,9-14 year|children,,,,,,
14833,,no obstruction,,,,,,,,,during the trial period and 8 weeks after the last test drug administration,>= 3 mm,,,,,,
14834,,surgical indication)|placental abnormalities (previa,,,,,,,,,at time of screening|history of a,≥ 100 × 109/,,,,,,
14835,,acute diseases.|volunteers,,,,,,,,,before starting therapy,>132 μg/l,,,,,,
14836,,qt corrected using,,,,,,,,,within 3 days before baseline|history,better than 20/30,,,,,,
14837,,hiv-positive,,,,,,,,,at any time are also eligible|any evidence,≥150 min/wk,,,,,,
14838,,intraocular condition,,,,,,,,,during active study,> = 60 years old,,,,,,
14839,,gastrointestinal surgery|the,,,,,,,,,for ≥5 years。|women,≤ 65 years.|intention to hsct therapy.|meeting the diagnostic criteria,,,,,,
14840,,anesthesia,,,,,,,,,within 3 months prior to screening.|contraindication to the use of the wrist-worn telemetry device,45 kg or more,,,,,,
14841,,knee pathologies,,,,,,,,,in childhood,malaysia|aged 18-65 years,,,,,,
14842,,endoscopically resected,,,,,,,,,before start of intervention,< 15 mm or|cervical length,,,,,,
14843,,myelodysplastic subtype anemia,,,,,,,,,for 150 days after the last dose of study treatment.||,6-30||,,,,,,
14844,,periodontal defects,,,,,,,,,at least two mature,> 90|heart rate,,,,,,
14845,,partici-pation,,,,,,,,,within 12 calendar months of day 1 of this study,"greater than or equal to 75,000/ul",,,,,,
14846,,immune deficiency disease,,,,,,,,,for less than 5,< 50% normal,,,,,,
14847,,anterior wall compression,,,,,,,,,treatment|past-month reduction of cigarettes/day,>40 breaths/min,,,,,,
14848,,mechanized pneumonia,,,,,,,,,within past 90 days|patient,20-50|able to read,,,,,,
14849,,cause|facial fractures,,,,,,,,,14 days before dosing until after the follow-up,>= 8 g/dl|creatinine,,,,,,
14850,,facial restorations.|tooth,,,,,,,,,within the 12 months preceding the enrolment.|patients who benefited,≤ 2.5||× uln；⑥,,,,,,
14851,,vaginitis,,,,,,,,,at their pre-exercise echocardiogram,preventing echocardiography|absence of written,,,,,,
14852,,evidence consistent with active,,,,,,,,,during the 30 days before the screening visit|history of alcohol,= 50kg|physical activity,,,,,,
14853,,behavioral disability,,,,,,,,,within 3 months.|receipt of,179 mm hg,,,,,,
14854,,spinal tumors,,,,,,,,,for previous 6 months,<28 g/l.|female,,,,,,
14855,,hemolytic pnh,,,,,,,,,within the first 4 hours after cabg,outside these limits,,,,,,
14856,,aasv incompetence,,,,,,,,,within the last 6 months,>=18|able to travel to the,,,,,,
14857,,type 2 dm|patients,,,,,,,,,at least 3 months prior to the baseline visit,score of ≤ 38 or|perceived,,,,,,
14858,,hpv-16+,,,,,,,,,at day 28 post-hsct,<400 copies/ml|no,,,,,,
14859,,etc.|female,,,,,,,,,within 4 weeks before inclusion|subject presenting,18 to 80 years inclusive,,,,,,
14860,,recovered from any toxicity of prior therapy,,,,,,,,,within two months before evar,18 years or above|patients,,,,,,
14861,,hormonal contraceptives|premenopausal,,,,,,,,,disorder.|recent history (,≤ 5 × uln.|renal function,,,,,,
14862,,hras,,,,,,,,,between screening run-in phase visit i,negative symptom,,,,,,
14863,,organs;|active severe infection,,,,,,,,,while receiving the study drug,≤ 1|adequate organ function,,,,,,
14864,,neuroendocrine tumor (net,,,,,,,,,"before, or the time interval",18 years or older.|eastern,,,,,,
14865,,eegs,,,,,,,,,at least 1 day apart)|alt,<4.6,,,,,,
14866,,recurrence-free time,,,,,,,,,within 2 weeks before the first injection;|patients,18 to 59 months,,,,,,
14867,,substrates of cyp2c8,,,,,,,,,during the period of the study).|seizure disorder/epilepsy,10% less than (<,,,,,,
14868,,multiple injuries,,,,,,,,,within 1 month before screening;|(9,< 100g/l|refractory,,,,,,
14869,,steroids|active infection,,,,,,,,,within one week prior to first dose,=< 1.5 x,,,,,,
14870,,type of osteomyelitis,,,,,,,,,within 1 month or,"25-65 years,|who",,,,,,
14871,,valvular vegetations,,,,,,,,,=<3 months prior to registration.|history of,> 150 mm hg systolic,,,,,,
14872,,everolimus-eluting stent,,,,,,,,,within 28 days before the first dose of study drug.|known,=< 5 seconds,,,,,,
14873,,chronic hepatitis b|treatment,,,,,,,,,at the time of the first injection.|have received pre-treatment,< 89 mg/dl,,,,,,
14874,,birthing centre planned,,,,,,,,,within 12 weeks of screening,"< 75,000 cells/mm3|current",,,,,,
14875,,lactation diabetes,,,,,,,,,during the conduct of the study;|history of,greater than or equal to 120 msec,,,,,,
14876,,students|chronic neck pain,,,,,,,,,within 14 days or 5,"18-40,|ability to read",,,,,,
14877,,pica,,,,,,,,,at least 70 percent time in direct patient care|has seen at least 100 patients,35 to 55 years|ambulatory,,,,,,
14878,,bfrt,,,,,,,,,within 24 hours before the surgery|patients,≥35 at the time of screening|contraindication,,,,,,
14879,,bulky organisms,,,,,,,,,within 15 days from the enrolment|use of,23 to 35 days,,,,,,
14880,,light chain multiple myeloma,,,,,,,,,for at least 4 weeks,less than seven days|complex skin disorders,,,,,,
14881,,non-penetrating,,,,,,,,,in the 3 months preceding the enrollment;|written informed consent from the legal representative.||,present:||sars-cov-2 infection||a,,,,,,
14882,,abdominal surgery;|(2,,,,,,,,,within 3 days,18-75|history,,,,,,
14883,,mrna vaccines,,,,,,,,,within 2 weeks before the rct|participants,< 30,,,,,,
14884,,hep c infection,,,,,,,,,for the first 24 hours|initiation of continuous electroencephalographic,≥ 18 years|diagnosis of cll|ability to understand the study,,,,,,
14885,,basaloid,,,,,,,,,within 28 days of study intervention,≥ 2 × upper limit of normal (uln),,,,,,
14886,,colorectal endometriosis,,,,,,,,,within the last 5 years.|severe kidney impairment.|aspartate aminotransferase,"≥ 1,000",,,,,,
14887,,extensive radical oncologic maxillectomy,,,,,,,,,within 30 days before screening.|female,≤ 2.5× uln,,,,,,
14888,,peg-asparaginase intolerant.|for leukemia,,,,,,,,,after registration.|history/physical examination,above 4.0 mmol/l.|archival,,,,,,
14889,,fungal infections;|hiv infection,,,,,,,,,during the trial period until 3 months after the end of the trial.||exclusion criteria||history of any clinically serious,2.8 to 4.5 mg/dl|normal,,,,,,
14890,,gross residual disease,,,,,,,,,within 7 days before enrollment negative;|substance abuse,≥140 g alcohol/week,,,,,,
14891,,death by suicide,,,,,,,,,within 4 weeks prior to planned conditioning||patient,≥150/95 mmhg,,,,,,
14892,,early miscarriage,,,,,,,,,within 14 days prior to the first dose of study,<100.4ºf,,,,,,
14893,,atherosclerotic disease|absence,,,,,,,,,in the previous 3 months,>= 50/mm^3,,,,,,
14894,,vital sign measurements,,,,,,,,,within 4 months before,18 years or older|pathologic diagnosis,,,,,,
14895,,cirrhosis,,,,,,,,,for at least 14 days before enrollment;|patients,50 or over|glogau wrinkle severity scale,,,,,,
14896,,interventricular septal defect,,,,,,,,,within 4 months prior to the first study drug administration.||some,≥8 g/dl,,,,,,
14897,,diabetes type,,,,,,,,,preceding 36 months,≥ 0.8 ≤1.0 g.kg-1,,,,,,
14898,,servings,,,,,,,,,in the 3 months prior to vaccination,at least 65 years,,,,,,
14899,,progressive diaphyseal dysplasia,,,,,,,,,during the tapering,≤ 2|female,,,,,,
14900,,urine dipstick,,,,,,,,,within 4 weeks of enrollment|at increased risk for peritonitis,> 12 years,,,,,,
14901,,transient ischemic attacks,,,,,,,,,within 1 month before the screening.|those who are addicted to smoking,> 7%);|ong-term,,,,,,
14902,,hospitalizations,,,,,,,,,for at least one year.||,1.1 solid tumor evaluation criteria.||those,,,,,,
14903,,carbohydrate-restricted diet,,,,,,,,,for 12 months after cell infusion,more than or equal 18,,,,,,
14904,,vdts induced tension neck syndrome,,,,,,,,,within 5 years prior to the first dose of investigational drug,=< 10 mg daily,,,,,,
14905,,viral encephalitis,,,,,,,,,within 48-hour of regular visit,exceeding 2.0 mg/dl,,,,,,
14906,,subretinal drusenoid deposits|intermediate amd,,,,,,,,,for at least 6 months after the last dose of the study drug,≤ 1.44g/day);|azathioprine,,,,,,
14907,,overactive bladder,,,,,,,,,within 3 months before the first dose of study drug,distant metastasis;|patients,,,,,,
14908,,expenditure,,,,,,,,,within 4 weeks of the first dose of study treatment,<1.7 nmol/l);||have,,,,,,
14909,,clinically localized,,,,,,,,,during the first 4 weeks of pregnancy,<18 years|twin,,,,,,
14910,,hemorrhagic diseases,,,,,,,,,between the necrotic zones.|distance between the tumor,≥ 18 and ≤ 85,,,,,,
14911,,criteria used in conjunction with the osu tbi-id method,,,,,,,,,preventing implantation.|previous implantation,< 18 years;|underwent surgery for,,,,,,
14912,,screening.|any malignancy,,,,,,,,,within 5 days of visit 2,<7,,,,,,
14913,,carcinoma,,,,,,,,,at the time of randomization;|computed tomography angiography (cta),150 ml,,,,,,
14914,,hiv+,,,,,,,,,within 7 days before enrollment;|patients,19-35|confirmed ovulation,,,,,,
14915,,electrosurgical devices|pregnancy,,,,,,,,,within 7 days prior to the first dosing,> 220 msec|use,,,,,,
14916,,swollen joint||right-handed,,,,,,,,,within 8 weeks prior to screening|treatment,greater than or equal to 14,,,,,,
14917,,colorectal cancers,,,,,,,,,throughout the duration of clinical investigation.|female,less than 18 years old,,,,,,
14918,,psychotic co-morbidities,,,,,,,,,within 4 weeks before the first dose of study,< 2.0 mg/,,,,,,
14919,,ii)optic neuritis,,,,,,,,,within the last 3 months|active,below 5 kg|current participation,,,,,,
14920,,pn,,,,,,,,,within 4 weeks before screening,≥19 and ≤65 years,,,,,,
14921,,residual stenosis,,,,,,,,,during the 183-day baseline period prior to and including,> 22 mmol/l||patients,,,,,,
14922,,vaginal prolapse,,,,,,,,,within 1 year before screening|positive drug of abuse test,≤ upper normal level,,,,,,
14923,,st john's wort,,,,,,,,,within 12 weeks before randomization.|he received allergen-specific immunotherapy,sex|aged 18 years old,,,,,,
14924,,e.g.||infectious disease,,,,,,,,,recent medical history,<20%.||,,,,,,
14925,,total circulatory arrest (tca),,,,,,,,,within 4 weeks before the inclusion|subject treated,> 1 year||patient,,,,,,
14926,,acquired brain injury,,,,,,,,,more than minimal risk,<16.5 kg,,,,,,
14927,,renal affection.|patients,,,,,,,,,for 4 weeks before the baseline study visit.||,"> 50% of dietary intake,|work or obligations",,,,,,
14928,,sleep disordered breathing,,,,,,,,,within the past 6 months|additional medical conditions,less than 25 weeks|the loved,,,,,,
14929,,cba,,,,,,,,,more than 14 mmol/l||,grade 0 to 3|patient,,,,,,
14930,,lies,,,,,,,,,within 6 months of signing icf.|seropositive for,> 88 cm,,,,,,
14931,,valve disease,,,,,,,,,in the past 2 months.|currently,3.9-6.1 mmol/l.|according,,,,,,
14932,,psychotic disorder.|current,,,,,,,,,within 28 days of screening.|subject,less than 6 months.|presence,,,,,,
14933,,representatives,,,,,,,,,6 weeks prior to start,65 or older,,,,,,
14934,,systemic targeted therapy,,,,,,,,,in the past 14 days prior to screening,≥200 mg/ 24h,,,,,,
14935,,inotropes for hf,,,,,,,,,within the past 12 months|prior anterior/apical suspension,exceeding 99 mm,,,,,,
14936,,her2 positive,,,,,,,,,prevent unintended exposure of their partner,>2 mg/dl)|those,,,,,,
14937,,seizures|history of seizures,,,,,,,,,within 6 weeks,≥ 1.5 x 109/l.|platelet count,,,,,,
14938,,uncontrolled condition,,,,,,,,,within 3 minutes,above 160 mmol/,,,,,,
14939,,residential house,,,,,,,,,within 7 days before the first dose of study drug:||total bilirubin,90 g/l).|serum,,,,,,
14940,,injury|training,,,,,,,,,within 3 days prior to the day of randomization,≥20 natural teeth|healthy periodontium,,,,,,
14941,,jaw claudication,,,,,,,,,within 28 days following receipt of study,between 27 to 45kg/m2|type,,,,,,
14942,,flurazepam,,,,,,,,,within 60 days prior to start of study drug,≤ 18 mmhg,,,,,,
14943,,mixed subtype,,,,,,,,,after subsequent re-challenge,above recommendations,,,,,,
14944,,prolonged standing,,,,,,,,,during the test: 7,≥18 years;|presence,,,,,,
14945,,pdac,,,,,,,,,within the range of 18.0 to 34.0 kg/m2,between 7.5% and 11% (inclusive),,,,,,
14946,,angle glaucoma,,,,,,,,,preceding the first dose of study intervention,2.5 and 0.5 month prior to hydroxychloroquine treatment,,,,,,
14947,,tumor-related,,,,,,,,,at the time of receiving the first dose of tezepelumab,40.0-49.9||,,,,,,
14948,,extracranial lesion,,,,,,,,,at least 1 negative,at least 18 years|diagnosis of t2dm,,,,,,
14949,,has ventricular arrhythmias,,,,,,,,,"within 3 months),|diagnosed",>= 9gm/dl|white,,,,,,
14950,,posterior tibial,,,,,,,,,17th november 2022|myocardial infarction,above 50,,,,,,
14951,,hepatitis b virus infection,,,,,,,,,in frequent,25%,,,,,,
14952,,therapy;|hepatic dysfunction,,,,,,,,,in the past 6 months|more than 1 episode,"between 18 and above,",,,,,,
14953,,cerebral hemorrhage,,,,,,,,,within random 14 days meet,less than 16 years||,,,,,,
14954,,renal parenchymal,,,,,,,,,following requirements:||blood routine test,-70 years,,,,,,
14955,,post-menstrual,,,,,,,,,following criteria:||anc≥1.5×10^9/l,younger than 40 years,,,,,,
14956,,hypoxic encephalopathy,,,,,,,,,within 28 days prior to implantation surgery,"18 - 80 years,|visual acuity",,,,,,
14957,,duodenal gastro,,,,,,,,,at the time of surgery|subject,≥50 and ≤85 years;||meet,,,,,,
14958,,hematologic diseases,,,,,,,,,within 5 weeks before enrolment,more than 5 norms,,,,,,
14959,,hematencephalon,,,,,,,,,during the trial;|who donated blood,greater than 90 days,,,,,,
14960,,discharged from hospital,,,,,,,,,prior to randomization.|opportunistic,aptt>1.5×uln,,,,,,
14961,,restenotic,,,,,,,,,after mimi.||,> 470 msec;|patients,,,,,,
14962,,unipolar depressive disorder,,,,,,,,,within 1 month before surgery|incomplete,less than 0.20 logmar,,,,,,
14963,,maternal myasthenia,,,,,,,,,"in the last month,|women",< 1500 mm-2.|corneal opacification,,,,,,
14964,,small bowel disease,,,,,,,,,in the last 6 months;|patients,>= 50 ml/min/1.73m2,,,,,,
14965,,angiitis,,,,,,,,,within 28 days prior to beginning study treatment.|no,>=25)|diabetes,,,,,,
14966,,needle biopsies,,,,,,,,,throughout the residential period,≤ 5.0x uln,,,,,,
14967,,unresectable ovarian cancer,,,,,,,,,during the first 2 weeks of screening,> 1 month and ≤ 39 years,,,,,,
14968,,disabled alzheimer's disease,,,,,,,,,within 4 weeks|other,≥ 50 ml/min|pt,,,,,,
14969,,spinal bleeding,,,,,,,,,at time of bronchoscopy.|scheduled for navigational bronchoscopy,>35kg/m2|participants,,,,,,
14970,,disease strongly,,,,,,,,,through 30 days after asp5354 administration.|participant,0 to 25,,,,,,
14971,,congenital adrenal hyperplasia,,,,,,,,,at the time of obtaining,b-cell type,,,,,,
14972,,hs lesions,,,,,,,,,previously been treated with fazirsiran,above upper limit of normal,,,,,,
14973,,congenital long qt syndrome,,,,,,,,,for at least 24 hours after device placement|patient,>35.0 kg/m2,,,,,,
14974,,colonic plastic surgery,,,,,,,,,for 1 week after stopping the investigational drug|females,≥91 and ≤140 mmhg,,,,,,
14975,,exon 19 deletions,,,,,,,,,within 28 days before inclusion,1 to 3,,,,,,
14976,,lung adenocarcinoma,,,,,,,,,within the last 4 weeks.|any prior use of,>160 or <90 mmhg||patient,,,,,,
14977,,persistence of lung parenchymal abnormalities,,,,,,,,,within 30 days before screening;|unable to complete the visit task,stage 3/4,,,,,,
14978,,mucosal lesions,,,,,,,,,within 1 of the following ultrastructure,between 18.5-40 kg/m2.|the subject is able to provide written informed consent,,,,,,
14979,,rheumatic mitral stenosis,,,,,,,,,within 5 years before screening.|positive results,> 100 x 103/µl,,,,,,
14980,,active uc,,,,,,,,,at the screening,17.5 to 38 kg/m2.|must provide,,,,,,
14981,,neurodegeneration,,,,,,,,,in sexual intercourse,≥ 9.5 g/dl,,,,,,
14982,,nasal spray impossible,,,,,,,,,within 1 week prior to the first vaccination,≤ c.||,,,,,,
14983,,syndrome|cardiovascular pathology,,,,,,,,,within 3 months of signing the informed consent,18 to 55.|able to read,,,,,,
14984,,neurological deficits|pregnancy|body mass indexes,,,,,,,,,at least 8 hours,≤ 1.5 × uln||renal,,,,,,
14985,,squamous cell carcinoma);|for breast cancer,,,,,,,,,during the study screening,<90 mmhg,,,,,,
14986,,supraventricular tachycardia,,,,,,,,,more than once per week,10% of body surface,,,,,,
14987,,function disorder,,,,,,,,,48 hours after percutaneous coronary,≤ 90 years,,,,,,
14988,,extrahepatic bile ducts.|liver function studies,,,,,,,,,at least 4 weeks following the completion of treatment,"≥2+, the 24-hour",,,,,,
14989,,anaphylactic reactions,,,,,,,,,continue on the trial treatment,≥300 milligram per gram,,,,,,
14990,,skin type i-vi,,,,,,,,,within 48 hours of onset of event.|current,0 or 1.|tissue,,,,,,
14991,,residual lesion,,,,,,,,,during the period of participation,≥ 1.5,,,,,,
14992,,flavivirus exposure,,,,,,,,,during the study|5.allergy to hyivy device's materials,>3x uln|history,,,,,,
14993,,reversible ischemia,,,,,,,,,for at least 90 days prior to enrollment|patients,"≥100,000/µl|hemoglobin ≥9g/dl|total",,,,,,
14994,,miscarriages||antiphospholipid syndrome,,,,,,,,,within 30 days after surgery,45 u/l||no,,,,,,
14995,,cecal intubation|patients,,,,,,,,,within 2 weeks before the initiation,≥ 60 years|scheduled,,,,,,
14996,,acute carotid,,,,,,,,,in the previous 28 days before day 1 of this,">= 100,000/mcl|hemoglobin",,,,,,
14997,,remission of,,,,,,,,,within 30 days prior to treatment administration.|non-tolerance,18.5 - 27,,,,,,
14998,,orthostatic hypotension;|any photosensitive disease,,,,,,,,,within 3 days of,maximum 36 month before enrollment)|active cancer treatment,,,,,,
14999,,ocular allergy|inability,,,,,,,,,at the time of screening.|chronic cardiac failure,≤ 2.0 mg/dl|ast,,,,,,
15000,,fallopian tube cancer.|platinum resistant,,,,,,,,,at the time of screening|enrolment to another interventional study,> 2 times upper limit of normal);|prolonged qtc>500ms;|pregnancy;|evidence of extrapulmonary,,,,,,
15001,,candida endocarditis,,,,,,,,,within 7 days before first priming vaccination,< 90 ml/min/1.73m^2,,,,,,
15002,,heart block.|patients,,,,,,,,,within the past 3 years;|women,< 90 ml/min)|interfering treatment,,,,,,
15003,,persistent rhinitis,,,,,,,,,at least the past 12 months,< 2000/μl,,,,,,
15004,,her2-negative.||,,,,,,,,,within one year of the screening,< 45 ml/min).|patients,,,,,,
15005,,neuromuscular diseases,,,,,,,,,in the next 6 months.|currently,< 45 %,,,,,,
15006,,nonspecific neck pain,,,,,,,,,after prior high-dose chemotherapy,less than 30 min,,,,,,
15007,,dxa,,,,,,,,,during the study period and within 3 months after the last dose of the study drug,≥ 70.|life expectancy,,,,,,
15008,,claustrophobia.|incarceration|inability,,,,,,,,,prior to date of randomization,2,,,,,,
15009,,transient stroke,,,,,,,,,study participation.|patient,> 2.5 × uln|bilirubin,,,,,,
15010,,mediastinal uterus,,,,,,,,,in the past 60 days|received,< 9 cm/s,,,,,,
15011,,pancreatic cancer|use,,,,,,,,,at time of study registration.|creatinine clearance,above 75 years old;|unable,,,,,,
15012,,higher|high grade disease,,,,,,,,,within the 12 months prior to the start of screening,between 15 and 26 years,,,,,,
15013,,extramural venous invasion,,,,,,,,,at least 11 mm,0-1;|child-pugh,,,,,,
15014,,patients:||genetic predisposition,,,,,,,,,preceding 24 consecutive months)|patients of,score ≥1 but <3 out,,,,,,
15015,,insoluble fiber-containing,,,,,,,,,within 1 week prior to the first dose.|for,>0|woman,,,,,,
15016,,hypogammaglobulinaemia,,,,,,,,,within the past 3 months.|any,less than or equal to 15 ml/min/1.73 m^2,,,,,,
15017,,inguinal sarcoidosis,,,,,,,,,at 14 weeks,"75,000/mm3",,,,,,
15018,,pneumonitis/interstitial,,,,,,,,,during the 2-week treatment period until after visit 2|has no other conditions that,=< 2.0 x uln.||aspartate aminotransferase/alanine aminotransferase,,,,,,
15019,,brain lesions,,,,,,,,,at the time of consent.|participant,i-ii|thai adult,,,,,,
15020,,antiepileptic drugs|chronic alcohol,,,,,,,,,at the time of signature of the icf.|subject,score 0 to 1.|histologically,,,,,,
15021,,ggt,,,,,,,,,surgery to treat chronic pain,< 110 μmol/l|t3,,,,,,
15022,,malaysian,,,,,,,,,at least for 6 months before screening,18.0-35.0 kg/m2,,,,,,
15023,,hemodynamic collapse,,,,,,,,,within 1 month prior to the expected initial application date.|subjects,at least 90 ml/min/1.73 m^2,,,,,,
15024,,spc,,,,,,,,,within 12 hours after the occurrence of myocardial infarction,< 50%.|a history,,,,,,
15025,,organ transplantation.|vaccination,,,,,,,,,within 90 days after the last dose of any component of the study treatment regimen.||arm,≥ 30 min,,,,,,
15026,,bcg,,,,,,,,,since at least 3,above these limits,,,,,,
15027,,non-proliferative diabetic retinopathy (,,,,,,,,,during the period of this clinical trial,≤ 1.5 x uln|coagulation,,,,,,
15028,,blackouts|relevant,,,,,,,,,within 12 months of study entry,≥150 minutes/week,,,,,,
15029,,systemic diseases.|received,,,,,,,,,at time of randomization.|female subjects must,exceeding 3 times the upper limit of the normal range,,,,,,
15030,,distal biliary stricture|need,,,,,,,,,in next 24 hours|patients who,≤ 40.0 kg/m^2,,,,,,
15031,,oropharyngeal infection,,,,,,,,,during the study period.|recent initiation,>22|use two questions to screen,,,,,,
15032,,derivative stoma,,,,,,,,,within one month of study treatment|hyperbaric chamber sessions scheduled,<30 min duration,,,,,,
15033,,incomplete,,,,,,,,,over last 4,19-80,,,,,,
15034,,screening|pancreatic cancer,,,,,,,,,during the study duration,≥ 40%)|systolic blood pressure,,,,,,
15035,,actively employed first,,,,,,,,,during the last 6 months,12 to less than 18 years,,,,,,
15036,,affordable foods,,,,,,,,,before the first dose of study drug,≥ 18 years|admitted,,,,,,
15037,,solid-organ,,,,,,,,,at home.|current,greater than 1.2,,,,,,
15038,,kidney)|gastrointestinal disease,,,,,,,,,prior to surgery||,<15 mmol/l|elevated,,,,,,
15039,,nutritional status,,,,,,,,,within 4 weeks of treatment.||9.the subjects volunteer to join the study,"20,",,,,,,
15040,,cns)/leptomeningeal disease,,,,,,,,,more than 14 u per week,≤5 x uln,,,,,,
15041,,cardiac rehabilitation|patient,,,,,,,,,during the last 21 days before screening.|known treatment,< 30|preserved,,,,,,
15042,,cardiac arrhythmic syncope,,,,,,,,,at least 30 days before the administration of trial medication until 30 days after trial completion,27.0-35.0 kg/m2|able,,,,,,
15043,,organic heart disease,,,,,,,,,at least 6 months before the first dose of imp,≥ 1.0 cm,,,,,,
15044,,left atrial appendage,,,,,,,,,within 2 weeks prior to starting study treatment,>= 1.5 x 10^3/ul,,,,,,
15045,,bone marrow dysfunction.|concurrent malignancy,,,,,,,,,for at least 5 months after the last dose of isatuximab treatment of note: contraception duration should take also into consideration,"≥100,000/mcl",,,,,,
15046,,septic shock,,,,,,,,,at the moment of randomization.|treatment,19 and 65 ③,,,,,,
15047,,nsclc cancer,,,,,,,,,at the time of recruitment.|women,above 160 mmhg).|known,,,,,,
15048,,heart block,,,,,,,,,within the 30 days prior to signing the icf,≥ 60 ml/min;|total,,,,,,
15049,,breathing disorder,,,,,,,,,within 3 days prior to taking study treatment,greater than 6 months.|at least,,,,,,
15050,,subacute cervical sci,,,,,,,,,within 4 weeks before dosing|any lifetime history,2-12 years,,,,,,
15051,,psychiatric risk,,,,,,,,,within 7 days prior to commencement,18-21.|patient,,,,,,
15052,,human immunodeficiency virus (hiv) antibody positive,,,,,,,,,within 1 week prior to the first dose of study,<18 years or,,,,,,
15053,,anesthesia|patients,,,,,,,,,prior to first administration of investigational,> 30% of marrow-bearing bones,,,,,,
15054,,hysterectomy)|lateral pain,,,,,,,,,for at least 1,18-35 kg/m2|patients,,,,,,
15055,,ileostomy|asian,,,,,,,,,in these organs.|history of chronic haematologic disease.|diagnosis,greater than or equal to 12,,,,,,
15056,,uncorrectable bleeding disorder,,,,,,,,,within 6 months before enrollment.||.coagulopathy,<40 kilograms,,,,,,
15057,,severe dyspnoea,,,,,,,,,at least 2 days a week for at least 1 year.|for the experimental group,=< 3 x institutional uln,,,,,,
15058,,circadian rhythm disorder.|people,,,,,,,,,during study period|any,"<13g/dl|platelet <60,000/µl|severe kidney disease patient",,,,,,
15059,,meningeal carcinomatosis,,,,,,,,,at the time of signing the informed consent.|participants who are,less than 200,,,,,,
15060,,s6 segmentectomies|s4,,,,,,,,,within 4 weeks prior to the first dose of study treatment.|presence,>5 cm2,,,,,,
15061,,colorectal lesion,,,,,,,,,within the last 2 years,≥18 years|identified,,,,,,
15062,,se,,,,,,,,,within 2 weeks or 3 half-lives,≥50%.|objective evidence,,,,,,
15063,,cardiac functions,,,,,,,,,previously been enrolled in this study.|any participant who,">2,5 for",,,,,,
15064,,ametropia,,,,,,,,,for 48 hours,=< 15 days prior to registration)|alanine aminotransferase (alt),,,,,,
15065,,renal artery stenosis,,,,,,,,,preceding 24 consecutive months)|patient must,> 210 g/week,,,,,,
15066,,impairment of mobility,,,,,,,,,within 28 days of cycle 1 day 1,<95th percentile|specific obesity,,,,,,
15067,,neuropsychiatric diagnosis,,,,,,,,,at screening period and day 0,40 to 70.|primary diagnosis,,,,,,
15068,,sporadic adenomas,,,,,,,,,within 90 days|exclusively,<20 mmhg,,,,,,
15069,,diagnosed cancer,,,,,,,,,in the 30 days prior to dosing.|use,18 years or above.|a diagnosis,,,,,,
15070,,uncontrollable arrhythmia,,,,,,,,,within 28 days prior to study drug,more than 50% of the limbus|previous penetrating,,,,,,
15071,,resection margins free,,,,,,,,,for 4 months after the last dose of protocol treatment,equal or greater than 35 m/kg2;|previous,,,,,,
15072,,positivity on immunoassay,,,,,,,,,in the month prior to testing.|availability,> 2 x uln,,,,,,
15073,,extensive small bowel resection,,,,,,,,,throughout study participation,above t10.|known,,,,,,
15074,,neurosurgery,,,,,,,,,within 6 months before first dose.||inability to swallow tablets.|use,<3)|patients,,,,,,
15075,,neoplasm|instrumental deliveries,,,,,,,,,within one year 4,< 10x uln||adequate renal function,,,,,,
15076,,renal artery diseases,,,,,,,,,within 14 days of day 1,score of ≥,,,,,,
15077,,non-intracranial evaluable lesion,,,,,,,,,48 hours prior to the expected initial application date to psv,below 160 µmol,,,,,,
15078,,underlying,,,,,,,,,at at least 4 weeks post-injury,"> 38,5°c|pregnancy",,,,,,
15079,,cbd,,,,,,,,,during any part of the psg study|previous reaction,- ≤ 18 years,,,,,,
15080,,pleomorphic adenoma,,,,,,,,,at time of consent.|fit for endoscopic therapy,"less than 1,500 grams||",,,,,,
15081,,macular aneurysms,,,,,,,,,in the 6 months (180 days) prior to screening,between taking the radiological records,,,,,,
15082,,hcg,,,,,,,,,in the past year|severe,≥50% and < 100%,,,,,,
15083,,pmss scale.||exclusion,,,,,,,,,within 3 months before the start of study treatment,> 4.5 hours,,,,,,
15084,,angina pectoris,,,,,,,,,within 6 months of first administration of dzd9008,< 18 years|treatment,,,,,,
15085,,treated|ostial left main disease,,,,,,,,,within 24 hours of first consultation to the gynecological oncology team|are undergoing,+pain,,,,,,
15086,,registered nurses,,,,,,,,,within prior 4 months,more than 160/100|proteinuria|pitting,,,,,,
15087,,staged of peripheral vascular disease|hypersensitivity|patients,,,,,,,,,within the 3 month period prior to baseline,maximum interincisal opening (mio),,,,,,
15088,,hiv-1 infection,,,,,,,,,within 24 hours of starting treatment,equal or greater than 18,,,,,,
15089,,urgency urinary incontinence episode,,,,,,,,,within 60 days,18-55 years,,,,,,
15090,,normotensive,,,,,,,,,7 days prior to the start of the intervention.|pregnant,under 18|wound or infection,,,,,,
15091,,bupivacaine|pregnant,,,,,,,,,last 5 years.|epilepsy,18 -70 years.|body mass index (bmi),,,,,,
15092,,narcotic analgesic,,,,,,,,,at both screening,>18 and <35.|patients able to provide,,,,,,
15093,,chronic health conditions|adequate,,,,,,,,,during the pre-operative,> 6 cm,,,,,,
15094,,ulcerative colitis|clinical,,,,,,,,,past 2 weeks,under 16|unable to understand and communicate,,,,,,
15095,,major head trauma,,,,,,,,,during the study period and within 6 months after the last study drug,5-17 years,,,,,,
15096,,farm,,,,,,,,,within 3 months before signing the informed consent form,between 18-65 yrs|imc,,,,,,
15097,,misight,,,,,,,,,at time of consent|weight,18 - 75 years||,,,,,,
15098,,other diseases,,,,,,,,,within the last 4 weeks before screening|6,18 to 85 years old,,,,,,
15099,,acute thyroid storm,,,,,,,,,after a first-line,<30 ml/min/1.73 m²,,,,,,
15100,,mtb,,,,,,,,,in the past 8 weeks;|change in diet,=< 6 months,,,,,,
15101,,cold ischemia time,,,,,,,,,lasted for over two months|scoring 7 or above,">0,2µg/kg/min)|severe",,,,,,
15102,,materials|ability,,,,,,,,,at time of screening.|participant,< 25 kg/,,,,,,
15103,,refuses the,,,,,,,,,pre-enrollment,<7|without bystander,,,,,,
15104,,c1 inhibitor deficiency,,,,,,,,,within 30 days before signing informed consent,>1.2|platelet count,,,,,,
15105,,cancer treatment contraindicates this protocol,,,,,,,,,prior to surgery,1.1 following tumor resection.|participants,,,,,,
15106,,transient loss of consciousness,,,,,,,,,within 10 days prior to the first dose of mt therapy.|have,≤1.5× upper limit of normal value (uln),,,,,,
15107,,allergic asthma,,,,,,,,,at the inclusion visit||,≥ 180 mmhg,,,,,,
15108,,primary headaches disorder,,,,,,,,,after at least one line of treatment,5-10,,,,,,
15109,,stability,,,,,,,,,within 3 months of initial concurrent,patient 2,,,,,,
15110,,nursing involvement,,,,,,,,,at the time the legally authorized representative,≤ 1.5 x the upper limit of normal,,,,,,
15111,,nephritic syndrome,,,,,,,,,within the last 8 weeks.|use,≤ 3;|signed informed consent,,,,,,
15112,,conditions of malignancy,,,,,,,,,within 14 days prior to dosing|has,between 18 and 69 years,,,,,,
15113,,lower extremity amputation.|claudication,,,,,,,,,for at least 28 days before vaccination until 3 months after receiving the ip.||acceptable methods,between 4 and 18 years||,,,,,,
15114,,psoriasis area,,,,,,,,,for 3 months after stopping the treatment.|use of oral,18 to 70.|pathological type,,,,,,
15115,,professional knowledge judged to have,,,,,,,,,18 weeks prior to screening,between 5 and 9 mm,,,,,,
15116,,gastrointestinal condition,,,,,,,,,within 3 months);|during,≤ 6.0 mg/dl,,,,,,
15117,,brain tumor)|using insulin,,,,,,,,,within 12 months prior to randomization,less than 50 kg.|in,,,,,,
15118,,systemic complication,,,,,,,,,within 4 weeks prior to c1d1;|participants,18 years to 75 years|confirmed diagnosis,,,,,,
15119,,involvement by non-primary cns lymphoma|treatment,,,,,,,,,prior to starting study treatment,less than 45%|patients,,,,,,
15120,,cryopreserved peripheral blood mononuclear cells,,,,,,,,,in the 30 days before enrollment.||for,"18-65,|who",,,,,,
15121,,primary tumor locations,,,,,,,,,prior to r/m,18-75 years;|primary breast cancer,,,,,,
15122,,voiding difficulties,,,,,,,,,within 6 months prior to the expected initial application date,>100 u/l,,,,,,
15123,,bone metastases amenable,,,,,,,,,history of suspected,> 130/80) concerning to the treating clinician for,,,,,,
15124,,multi-parameter mri,,,,,,,,,clinical history,score of 5-14,,,,,,
15125,,upper respiratory tract infection,,,,,,,,,at the time of enrollment|uncontrolled,≥ 3||5,,,,,,
15126,,dementia|significant disease,,,,,,,,,in previous 12 months|previous,below 50 ng/dl,,,,,,
15127,,atrophy,,,,,,,,,"for the past 30 days prior to visit 1, day -7).|subject",<18 years)|participants,,,,,,
15128,,chronic wasting diseases,,,,,,,,,within 2 weeks before the first dose；|history,> 150 umol/l,,,,,,
15129,,t-dxd|no,,,,,,,,,within 14 days prior to randomization;||hematologic abnormalities,"≥ 100,000/µl",,,,,,
15130,,restorability,,,,,,,,,at least 12 months prior to the development of advanced/metastatic,<140 mmhg,,,,,,
15131,,fulfilled:||spinal cord compression,,,,,,,,,for the first time and,between 18-65||,,,,,,
15132,,cyclic cs,,,,,,,,,at the time of screening.|in good general health,"criteria 2014, see appendix 1",,,,,,
15133,,mental health disorders,,,,,,,,,within 48 hours before start of study period,no more than 1.3-3.0||,,,,,,
15134,,castration resistant prostate cancer,,,,,,,,,at the time consent form is signed|have a histologically,≥ 60% of predicted,,,,,,
15135,,pdph|hb,,,,,,,,,within 2 weeks of study start,10 to 13 years,,,,,,
15136,,cranial neuropathy,,,,,,,,,within 14 days before the first dosing date|otc,<3 years before,,,,,,
15137,,ppi preparations,,,,,,,,,during each study period,less than 2 years.|patients,,,,,,
15138,,mtap protein,,,,,,,,,within 4 weeks before the medication,<45%|absence,,,,,,
15139,,abnormal physical or,,,,,,,,,within the previous 24 months except,=115 g/m2,,,,,,
15140,,primary valve disease,,,,,,,,,within 12 months before the start of the study,>= 18 years|karnofsky,,,,,,
15141,,unexplained symptom|previous illness,,,,,,,,,at least 6 months clinical,≥ 3.0×109/,,,,,,
15142,,endocrine dysfunction,,,,,,,,,at least 8 cups per day,≤1.5 × uln.||note,,,,,,
15143,,symptomatic bowel obstruction,,,,,,,,,at least 14 days or,above 65 years,,,,,,
15144,,visible tophi,,,,,,,,,within 60 days from discontinuation of carfilzomib,>120ms,,,,,,
15145,,breast cancer.|unstable angina,,,,,,,,,pre-study baseline,less than 30 ml/min,,,,,,
15146,,peri,,,,,,,,,last month|able to understand,> 35|body weight,,,,,,
15147,,chronic disease,,,,,,,,,at least 6 months prior to screening|abstinence,19 to 80 years|patients with,,,,,,
15148,,age|pregnant,,,,,,,,,for 24 weeks following the last dose of study,uncompleted,,,,,,
15149,,post- menopausal,,,,,,,,,3-months prior to baseline assessment|does not,≥1500 per mm^3 iii,,,,,,
15150,,fatty liver|anorexia,,,,,,,,,at least 2 cm from any stented area.|subject,poloxamer 188,,,,,,
15151,,anogenital disease,,,,,,,,,since day of screening,<300/mm3|patients,,,,,,
15152,,av block,,,,,,,,,at least 3 months before screening||key,≥ 1.5 × 10 9,,,,,,
15153,,neither cone beam nor conventional ct|patients,,,,,,,,,within 30 days before the screening period,≤ 30.||exclusion criteria,,,,,,
15154,,nephrectomy|ischemic heart disease,,,,,,,,,more than 24 months previously,18 - 99 years|diagnosis,,,,,,
15155,,inclusive).|male,,,,,,,,,past year while being equipped,≥2.|the patient is,,,,,,
15156,,retinal thickening,,,,,,,,,prior to baseline.|history of lymphoproliferative disease,<12 months,,,,,,
15157,,vegetarian.|those,,,,,,,,,in the last year);|occlusal treatment,> 21 years,,,,,,
15158,,post-infection,,,,,,,,,within the preceding 2 months,<1.5×10⁹/l;platelet count,,,,,,
15159,,non epithelial tumors,,,,,,,,,within 1 month before the visit;|there,> 5h/wk)|good health status,,,,,,
15160,,emergence,,,,,,,,,within the last three months before enrolment|no diagnosis,<3.0 mmol/l|sodium,,,,,,
15161,,keratinized tissue,,,,,,,,,at least 12-months prior to study treatment.|implantable cardioverter defibrillator (icd),3-10,,,,,,
15162,,leiomyosarcoma,,,,,,,,,in the past eight weeks.|frequent,must:||practice true,,,,,,
15163,,alpha hydroxy acids,,,,,,,,,within the therapeutic goal,more than 1.5 upper limit.|ast,,,,,,
15164,,conventional therapeutic interventions,,,,,,,,,for at least 90 days after the last dose of galunisertib,iiic,,,,,,
15165,,gastric motility issues,,,,,,,,,,less than 50.0 kilograms (kg),,,,,,
15166,,mixed connective tissue disease|known allergy to any,,,,,,,,,,≤ 1.5 × uln;|serum,,,,,,
15167,,dsm-5 disorder,,,,,,,,,,≥ 8 g/dl|coagulation,,,,,,
15168,,eosinophilic,,,,,,,,,,acceptable,,,,,,
15169,,sepsis).|chronic renal failure,,,,,,,,,,≥ 9,,,,,,
15170,,multiple myeloma,,,,,,,,,,more than 3.|patient,,,,,,
15171,,acute pulmonary edema,,,,,,,,,,6 to ≤ 11 years,,,,,,
15172,,vaping cessation,,,,,,,,,,less than 2cm,,,,,,
15173,,problems,,,,,,,,,,volume ≥ 70ml,,,,,,
15174,,procedures.||failed to respond,,,,,,,,,,≥ 20 ml/min/,,,,,,
15175,,or|nonproliferative diabetic retinopathy,,,,,,,,,,18 to 85|having no,,,,,,
15176,,"congestive heart failure,|unstable angina",,,,,,,,,,score of 39,,,,,,
15177,,cognitive impairment.|previous,,,,,,,,,,>450 pg/ml,,,,,,
15178,,unacceptable collateral circulation,,,,,,,,,,<=50 ml/min,,,,,,
15179,,persistent diarrhoea,,,,,,,,,,>2x upper limit of normal,,,,,,
15180,,sentinel,,,,,,,,,,score of 0 or 1.|measurable,,,,,,
15181,,myositis damage,,,,,,,,,,lower than,,,,,,
15182,,special condition,,,,,,,,,,≥20 g/l,,,,,,
15183,,nervous system,,,,,,,,,,1 to 3.|participant,,,,,,
15184,,hepa,,,,,,,,,,≥18 years|willing to participate,,,,,,
15185,,valvular heart disease.|patients,,,,,,,,,,≥ 18 years|one or more,,,,,,
15186,,common terminology criteria,,,,,,,,,,mutant-positive,,,,,,
15187,,joint fracture,,,,,,,,,,≥18 and ≤55 years,,,,,,
15188,,retinoid,,,,,,,,,,> 18 years|signed,,,,,,
15189,,adjustment of bp medication,,,,,,,,,,greater than three months,,,,,,
15190,,practice.|be linked,,,,,,,,,,"≥60,000 per mm^3 iv",,,,,,
15191,,chronic home niv||,,,,,,,,,,more than 24 points|the lower extremity score for brunnstrom,,,,,,
15192,,papilledema,,,,,,,,,,"upper limit of 150 mmhg,|45 mmhg",,,,,,
15193,,"bpm],|110",,,,,,,,,,18.5 ≤ bmi,,,,,,
15194,,consciously consume foods,,,,,,,,,,> 2 tests,,,,,,
15195,,cervical spine fracture,,,,,,,,,,more than 24,,,,,,
15196,,triathlon,,,,,,,,,,score of ≤ 40|telephone interview for cognitive status,,,,,,
15197,,reduced function,,,,,,,,,,"18 and 70, inclusive",,,,,,
15198,,vein|acute pancreatitis,,,,,,,,,,>95th percentile,,,,,,
15199,,isolated functional,,,,,,,,,,>2 times the upper limit of normal (uln),,,,,,
15200,,liver cancer.|patients,,,,,,,,,,>8%||the presence,,,,,,
15201,,cervical injury,,,,,,,,,,≤ 3x upper normal limit,,,,,,
15202,,ampullary adenocarcinoma,,,,,,,,,,≥ 90 g/l;|liver function,,,,,,
15203,,not tolerate standard treatment.||phase,,,,,,,,,,> grade 2|known status,,,,,,
15204,,peripheral arterial thrombosis,,,,,,,,,,<18 or > 35 kg/m2|systolic blood pressure,,,,,,
15205,,arterial distal,,,,,,,,,,within normal institutional limits|ast(sgot)/alt(spgt,,,,,,
15206,,auditory discrimination,,,,,,,,,,i-iii;|scheduled,,,,,,
15207,,mechanical small bowel obstruction,,,,,,,,,,≥ 100*10^9/l,,,,,,
15208,,lower limb ischaemia.|patients,,,,,,,,,,21-80 years,,,,,,
15209,,cmps,,,,,,,,,,≥ 5 times per day).|participants,,,,,,
15210,,mucinous tumors,,,,,,,,,,between 25-65 years-old|single tooth loss,,,,,,
15211,,sickle cell trait.|participant,,,,,,,,,,≤ 2.5 x institutional uln,,,,,,
15212,,gastrointestinal bleeding|other conditions,,,,,,,,,,<= 3.0 x uln|alanine aminotransferase (alt),,,,,,
15213,,arrhythmia occurred,,,,,,,,,,greater than 3 months.||participants,,,,,,
15214,,lower limb fracture,,,,,,,,,,≥ 30 ml / min/1.73 m2,,,,,,
15215,,abnormal bladder function,,,,,,,,,,single tumor ≤ 10.0 cm,,,,,,
15216,,study intervention|pregnancy,,,,,,,,,,< 30ml / min / 1.73m2);|significant,,,,,,
15217,,treatment|diagnosis,,,,,,,,,,≥5cm,,,,,,
15218,,hcv)|infection,,,,,,,,,,<3 days per week)|ability,,,,,,
15219,,archival tumor,,,,,,,,,,<1 g/24 hour,,,,,,
15220,,whome cystectomy,,,,,,,,,,3-4|patients,,,,,,
15221,,hypercapnic arf,,,,,,,,,,<15%,,,,,,
15222,,neural stimulator,,,,,,,,,,individuals older than 80 years,,,,,,
15223,,stage of,,,,,,,,,,35 to 85;|no excessive,,,,,,
15224,,situations that the investigator believes,,,,,,,,,,scores equal to or greater than the clinical population mean of the questionnaire manual)||,,,,,,
15225,,kidney disease|use,,,,,,,,,,between age group 2 years and 16 years.||,,,,,,
15226,,perception disorder,,,,,,,,,,greater than 20% below chronological age,,,,,,
15227,,severe disability,,,,,,,,,,= 0 directly,,,,,,
15228,,cured carcinoma,,,,,,,,,,later than two weeks before,,,,,,
15229,,medically compromised,,,,,,,,,,less than 40 kg;|volunteer,,,,,,
15230,,concussions,,,,,,,,,,< 18 years old,,,,,,
15231,,tumor disease,,,,,,,,,,>140mmhg systolic,,,,,,
15232,,criteria described,,,,,,,,,,= fluctuating hearing thresholds,,,,,,
15233,,intracranial hypertension,,,,,,,,,,less than 1 year|subjects,,,,,,
15234,,caries|taking dietary supplements,,,,,,,,,,< 12 g/dl|hba1c,,,,,,
15235,,narcolepsy type 1,,,,,,,,,,< 18 years|pregnancy|not appropriate,,,,,,
15236,,pain thresholds,,,,,,,,,,100mgx2/day,,,,,,
15237,,fluorosis,,,,,,,,,,>500 u/l,,,,,,
15238,,hepatitis c virus (hcv) antibody positive,,,,,,,,,,≤ 150kg;|who,,,,,,
15239,,malignancy|renal failure|peripheral,,,,,,,,,,≥0.25|patient provides,,,,,,
15240,,thermal pain stimulation,,,,,,,,,,long-term care,,,,,,
15241,,menstrual blood loss,,,,,,,,,,50-90% stenosis of the causative vessel,,,,,,
15242,,rendu-osler disease,,,,,,,,,,elevation,,,,,,
15243,,cardio/cerebral,,,,,,,,,,<59 bpm,,,,,,
15244,,exacerbation of,,,,,,,,,,≥ 15 events/h|stable,,,,,,
15245,,cardiopulmonary conditions.|individuals,,,,,,,,,,higher than or equal to 27.5,,,,,,
15246,,pots,,,,,,,,,,"≥7,5%|more than 3 years",,,,,,
15247,,passive immunotherapies,,,,,,,,,,<1 percent,,,,,,
15248,,solid malignancies;||patients,,,,,,,,,,>10).|for,,,,,,
15249,,leukemic cns involvement,,,,,,,,,,loss;|anterior segment pathology,,,,,,
15250,,both ovaries intact,,,,,,,,,,18-65 years)|asa i-ii|scheduled,,,,,,
15251,,clinically severe,,,,,,,,,,65+|who have,,,,,,
15252,,psychiatric,,,,,,,,,,> 22 kg/m2,,,,,,
15253,,viral vasculopathy,,,,,,,,,,>= 30kg/m2|consistent,,,,,,
15254,,etc.;|those,,,,,,,,,,^9/l|platelet count,,,,,,
15255,,psychological fragility,,,,,,,,,,: least 55 years,,,,,,
15256,,type 2 diabetes treatment,,,,,,,,,,≥10.|premorbid,,,,,,
15257,,localized lung cancer,,,,,,,,,,"< 50,000/µl",,,,,,
15258,,systemic autoimmune inflammatory disease|study participant,,,,,,,,,,isup>2).|more than 50% of positive,,,,,,
15259,,lower urinary tract symptoms,,,,,,,,,,≥ 0.7,,,,,,
15260,,cns related disorders,,,,,,,,,,6 or higher,,,,,,
15261,,concurrent diseases,,,,,,,,,,<500-200 /mm3 or <0.5-0.2,,,,,,
15262,,severe hemorrhage,,,,,,,,,,≥ 12 weeks.|patient,,,,,,
15263,,valve surgery|renal dysfunction,,,,,,,,,,14-50 years|male,,,,,,
15264,,serious injury,,,,,,,,,,less than 45 minutes,,,,,,
15265,,m2,,,,,,,,,,> 1.0 g,,,,,,
15266,,normotensive pheochromocytoma/paraganglioma,,,,,,,,,,≥ 50.0,,,,,,
15267,,neurological pathology,,,,,,,,,,≥ 22 years,,,,,,
15268,,keratinocyte carcinoma,,,,,,,,,,22-90,,,,,,
15269,,diabetes self-management education,,,,,,,,,,+0.50 to +1.50 diopters,,,,,,
15270,,maternal morbidity,,,,,,,,,,≥140 mmhg,,,,,,
15271,,inflammatory myopathy,,,,,,,,,,18-30years|tennis,,,,,,
15272,,refractory osteosarcoma,,,,,,,,,,≥18 years|graft type,,,,,,
15273,,clear corneas,,,,,,,,,,under 18|pregnancy|current diagnosis,,,,,,
15274,,pus,,,,,,,,,,"12-18 years old,||- 2",,,,,,
15275,,dietary approaches,,,,,,,,,,≥ ++,,,,,,
15276,,polyuria,,,,,,,,,,23 weeks,,,,,,
15277,,acute exacerbation of respiratory disease,,,,,,,,,,">1,5",,,,,,
15278,,anterior dislocation,,,,,,,,,,12 to 18 years,,,,,,
15279,,kidney malformation,,,,,,,,,,27 for more than 6 years,,,,,,
15280,,acute ischaemic stroke,,,,,,,,,,≤ 15 cm from the anal verge);|uc,,,,,,
15281,,anticoagulant factor,,,,,,,,,,25-59 years,,,,,,
15282,,sle international collaborating clinic criteria,,,,,,,,,,equal to or greater than 0.3 milliliter per minute,,,,,,
15283,,infectious cutaneous disorders,,,,,,,,,,4-39 weeks,,,,,,
15284,,multicentric castleman,,,,,,,,,,"> 2,000 mg/ g creatinine||other laboratory",,,,,,
15285,,congenital anomalies of the venous system,,,,,,,,,,>= 1.5 x 109/l,,,,,,
15286,,passive dorsi-flexion of the ankle.|able to walk,,,,,,,,,,>15/h,,,,,,
15287,,tissue block,,,,,,,,,,0 to 2||,,,,,,
15288,,oxygen therapy)|solid cancer,,,,,,,,,,≥ 60 ml/min.||the,,,,,,
15289,,celiac disease)|imaging findings,,,,,,,,,,> 25 mmhg,,,,,,
15290,,disease|cognitive dysfunction,,,,,,,,,,≥65 years,,,,,,
15291,,poor short,,,,,,,,,,< 21,,,,,,
15292,,right-sided temporary mechanical support,,,,,,,,,,enrollment.|uncontrolled infection.||history of,,,,,,
15293,,gastrointestinal tumor,,,,,,,,,,greater than 50% above the upper limit of normal|if sexually active,,,,,,
15294,,extranodal lesions,,,,,,,,,,greater than 18 years.||,,,,,,
15295,,renal/urologic disease,,,,,,,,,,≥9|lvmi ≥115 g/m2,,,,,,
15296,,indicator lesion,,,,,,,,,,15cm for ij,,,,,,
15297,,primary membranous nephropathy,,,,,,,,,,4-21 days after the,,,,,,
15298,,cancer (uicc),,,,,,,,,,>20°,,,,,,
15299,,chronic pelvic pain,,,,,,,,,,18 years or older 2,,,,,,
15300,,opacity,,,,,,,,,,>430 milliseconds,,,,,,
15301,,impaired immune system,,,,,,,,,,> 2500 copies /ml,,,,,,
15302,,antibody-mediated rejection (amr),,,,,,,,,,<25 nanogram,,,,,,
15303,,thrombopenia,,,,,,,,,,less than 30 days before the first day of screening;|for,,,,,,
15304,,face-lift,,,,,,,,,,above 24 years,,,,,,
15305,,pt1)||,,,,,,,,,,≤ iv|incompetent,,,,,,
15306,,acute imflammation.|other myopia control interventions,,,,,,,,,,≥ 10^3 copies/ml,,,,,,
15307,,other eye diseases,,,,,,,,,,< 1 x unl,,,,,,
15308,,esophageal neoplastic,,,,,,,,,,longer than 3 cm,,,,,,
15309,,contemporaneously with the dermal injury,,,,,,,,,,< 88 cm,,,,,,
15310,,cosmetic program,,,,,,,,,,≥130 mg/dl|android,,,,,,
15311,,vascular distributions,,,,,,,,,,over 200 mg/dl,,,,,,
15312,,acute intoxication|presence,,,,,,,,,,>20mm,,,,,,
15313,,digestive tract perforation,,,,,,,,,,≥ 80×109/l.|biochemical examination,,,,,,
15314,,cannulation of the major,,,,,,,,,,consumed more than 5 cups,,,,,,
15315,,acanthosis,,,,,,,,,,"1%,",,,,,,
15316,,postrenal obstructive nephropathy|history,,,,,,,,,,< 85 lbs.,,,,,,
15317,,fracture neck,,,,,,,,,,≥ 90 g/l;||serum,,,,,,
15318,,rheumatoid arthritis|active cardiovascular disease like congestive heart failure,,,,,,,,,,≤ 5.5mm,,,,,,
15319,,pancreas cancer,,,,,,,,,,≤ 2.|have,,,,,,
15320,,dependence pattern,,,,,,,,,,15 years old,,,,,,
15321,,breast feeding|acute renal injury|hepatic failure|inability to tolerate oral drugs,,,,,,,,,,s-icd,,,,,,
15322,,keratopathy|active infection,,,,,,,,,,> 2 times upper limit of normal (uln),,,,,,
15323,,moderate cp3a4 inhibitors,,,,,,,,,,≥18 years and ≤ 75 years,,,,,,
15324,,chronic cough,,,,,,,,,,12 years 0 months 0,,,,,,
15325,,non-lesional,,,,,,,,,,50-85,,,,,,
15326,,flexibility,,,,,,,,,,> 50 pg/ml,,,,,,
15327,,pituitary diseases,,,,,,,,,,>18.0 kg/m2,,,,,,
15328,,coronary artery occlusion,,,,,,,,,,≥30 and <40 kg/m2|provision of signed,,,,,,
15329,,nonverbal intelligence quotient was below 85 and (2),,,,,,,,,,90 µmol/l,,,,,,
15330,,metastatic brain lesions,,,,,,,,,,<40%.|use,,,,,,
15331,,psi|patients,,,,,,,,,,"≥ 50,000/mm3",,,,,,
15332,,smoking|hypertension|coronary disease|diabetes|hyperlipidemia|kidney damage|cerebrovascular,,,,,,,,,,equal to 5 ounces [150 ml,,,,,,
15333,,renal issues,,,,,,,,,,≤ 94%,,,,,,
15334,,for:||osteoarthritis,,,,,,,,,,0-1.|for,,,,,,
15335,,activity;|pregnant,,,,,,,,,,reside,,,,,,
15336,,intern nurses,,,,,,,,,,<50 mmhg,,,,,,
15337,,primary heart,,,,,,,,,,5-7,,,,,,
15338,,urinary tract loss,,,,,,,,,,= 25 +,,,,,,
15339,,in-situ cancers,,,,,,,,,,>=12 months,,,,,,
15340,,gray's disease,,,,,,,,,,between 18 and 55 years,,,,,,
15341,,chondromalacia,,,,,,,,,,≥1.2 ng/ml,,,,,,
15342,,neurological disease;|pregnancy,,,,,,,,,,≥ 40%,,,,,,
15343,,sacrococcygeal teratoma).|the,,,,,,,,,,"b, c",,,,,,
15344,,dyslexia,,,,,,,,,,> 76,,,,,,
15345,,aortic insufficiency,,,,,,,,,,< 2 years|medical conditions,,,,,,
15346,,chemical abuse,,,,,,,,,,>90 mmhg.||5,,,,,,
15347,,breast-feeding;|current,,,,,,,,,,upper normal limit,,,,,,
15348,,french.|patients,,,,,,,,,,"pregnant,|emergency",,,,,,
15349,,acute disease,,,,,,,,,,≥18 and <75 years,,,,,,
15350,,explanation,,,,,,,,,,-90 years,,,,,,
15351,,radiographic disease,,,,,,,,,,≥ 45.0 kg,,,,,,
15352,,autism,,,,,,,,,,<20.|english-speaking|receive care,,,,,,
15353,,targeting,,,,,,,,,,"between 18 and 64, who do not",,,,,,
15354,,complex partial seizures,,,,,,,,,,≥4 cm,,,,,,
15355,,cns,,,,,,,,,,minimum 18 years|positive,,,,,,
15356,,poor mental status,,,,,,,,,,≤ 3.0 times the upper limit of normal,,,,,,
15357,,adverse events of the protocol,,,,,,,,,,one month,,,,,,
15358,,galactosemia,,,,,,,,,,over 250 pounds|answer 'no' to all questions of the physical activity,,,,,,
15359,,comorbid health conditions,,,,,,,,,,>470 ms,,,,,,
15360,,normal karyotype,,,,,,,,,,< 86,,,,,,
15361,,traumatic patellar subluxation,,,,,,,,,,iii-vi|presence of,,,,,,
15362,,global developmental delay/concern,,,,,,,,,,≥ 25.0 kg/m2;|sleep issues,,,,,,
15363,,craniofacial malformation,,,,,,,,,,40-65 years|patients,,,,,,
15364,,cosmetic products,,,,,,,,,,>470ms from 3 12-lead ecgs,,,,,,
15365,,cml)|acute promyelocytic leukemia,,,,,,,,,,above grade ii,,,,,,
15366,,respiratory pathology subjects||,,,,,,,,,,≥18 years.|diagnosis of tts.|available,,,,,,
15367,,isolated extramedullary relapse,,,,,,,,,,less than 18||diagnosed chronic pulmonary disease.|severe,,,,,,
15368,,bleeding from the genital tract,,,,,,,,,,≤ 2 mm,,,,,,
15369,,light absorption,,,,,,,,,,class ii or greater,,,,,,
15370,,cmml,,,,,,,,,,45-70 years,,,,,,
15371,,chronic kidney diseases,,,,,,,,,,≥ 1.5 × 109/l|platelet count (,,,,,,
15372,,spastic disorder,,,,,,,,,,above 40 c,,,,,,
15373,,clinical symptoms,,,,,,,,,,greater than 50,,,,,,
15374,,hypertension|positive insulinoma,,,,,,,,,,40 to 80,,,,,,
15375,,bleeding or|an inhibitor test bu,,,,,,,,,,≥ 30bpm,,,,,,
15376,,focal epilepsy,,,,,,,,,,5-15 years,,,,,,
15377,,hyperandrogenism|solar erythema,,,,,,,,,,between 20 and 40 years,,,,,,
15378,,baseline.|positive response,,,,,,,,,,pregnant|does not,,,,,,
15379,,compartment syndrome).|participants,,,,,,,,,,up to 3,,,,,,
15380,,cns bleed,,,,,,,,,,at least 30 days,,,,,,
15381,,cold storage);|intense physical activity,,,,,,,,,,≤ upper limit of normal value (uln),,,,,,
15382,,permanent residence,,,,,,,,,,≥40 iu/l,,,,,,
15383,,idiopathic bradycardia,,,,,,,,,,> 90 mmhg)|hypotension,,,,,,
15384,,sexual abuse|psychiatric disorder,,,,,,,,,,greater than equal to 600 pg/ml.|diagnosis,,,,,,
15385,,infection|allergy,,,,,,,,,,younger than 50y and older than 85y.||bmi,,,,,,
15386,,immune system diseases,,,,,,,,,,>25|infectious disease,,,,,,
15387,,poor wound,,,,,,,,,,<60ml/min|history,,,,,,
15388,,cardiac diseases,,,,,,,,,,≥18 and ≤65 years,,,,,,
15389,,circulatory,,,,,,,,,,less than 6 months;|chronic,,,,,,
15390,,malignant tumor|malformation,,,,,,,,,,between 25-50 years,,,,,,
15391,,rheumatologic disorder,,,,,,,,,,at least 12 weeks prior to screening,,,,,,
15392,,ad involvement,,,,,,,,,,≥ 19.5,,,,,,
15393,,non-st-segment elevation myocardial infarction,,,,,,,,,,uln)|inr < 1.4,,,,,,
15394,,physical scars,,,,,,,,,,≥50 ×109/l,,,,,,
15395,,silver,,,,,,,,,,from 5 kg,,,,,,
15396,,lateral ankle pain,,,,,,,,,,over 30 years old,,,,,,
15397,,rheumatologic disorders,,,,,,,,,,= 355 ml,,,,,,
15398,,motor neuritis,,,,,,,,,,> 175.||,,,,,,
15399,,favorable benefit,,,,,,,,,,> 1.5 × uln|creatinine,,,,,,
15400,,structural lung,,,,,,,,,,6 months to 9 years,,,,,,
15401,,ventricular heart tachycardia,,,,,,,,,,> 50% predicted.|for patients,,,,,,
15402,,disease ≥5 years,,,,,,,,,,16-34,,,,,,
15403,,respiratory difficulties,,,,,,,,,,>1.8).|sts risk,,,,,,
15404,,radio-frequency ablation,,,,,,,,,,> 12x109 or < 4x109/l|purulent,,,,,,
15405,,sacroiliac joint disruption,,,,,,,,,,< 125 meq/l)|complete,,,,,,
15406,,feathers,,,,,,,,,,between 18 and 74 years,,,,,,
15407,,isolated extrasystoles|women,,,,,,,,,,greater than or equal to 50 years old,,,,,,
15408,,isolated gh deficiency,,,,,,,,,,18 to 50 years,,,,,,
15409,,cgvhd).|patients,,,,,,,,,,<2 +,,,,,,
15410,,abstention,,,,,,,,,,criteria:||refusal to sign,,,,,,
15411,,radiological disease,,,,,,,,,,<6 months prior to first dose).|have,,,,,,
15412,,oxygen-dependent,,,,,,,,,,guidelines)|non-smoker,,,,,,
15413,,dissociative disorder,,,,,,,,,,between 18~55 years old||,,,,,,
15414,,pseudophakia,,,,,,,,,,distant metastasis;||patients,,,,,,
15415,,shoulder operation|patients,,,,,,,,,,= 18-60|diagnosed,,,,,,
15416,,major hemorrhage,,,,,,,,,,≥110 g/l,,,,,,
15417,,tumor types,,,,,,,,,,< 21|agreed to participate|lived,,,,,,
15418,,child- bearing potential,,,,,,,,,,≥ 12 weeks.||subjects should,,,,,,
15419,,cooperate|orthopaedic impairment,,,,,,,,,,≥37.3℃,,,,,,
15420,,syncopal episodes,,,,,,,,,,"<100,000 or >600,000|urinary protein",,,,,,
15421,,hyperthyroidism|myxedema coma|subclavian,,,,,,,,,,0-1.|the results,,,,,,
15422,,endocrinopathy,,,,,,,,,,ast≤5 × uln,,,,,,
15423,,i type gastroesophageal junction cancer;|mechanical bowel,,,,,,,,,,≥ 5 kg,,,,,,
15424,,alcoholics,,,,,,,,,,< 35|scheduled,,,,,,
15425,,condom + spermicide,,,,,,,,,,<250 mg/day,,,,,,
15426,,parkinson's disease;|participate,,,,,,,,,,100-125 mg/dl,,,,,,
15427,,mers,,,,,,,,,,≥20 cm2|present,,,,,,
15428,,arrhythmias,,,,,,,,,,requires more,,,,,,
15429,,inguinal hernias|surgeries,,,,,,,,,,15 or more,,,,,,
15430,,alterations in pain sensation,,,,,,,,,,≥ 50 ml/min.|any,,,,,,
15431,,clinical indication deemed,,,,,,,,,,<53 bpm,,,,,,
15432,,bilateral vestibular schwannoma,,,,,,,,,,> 2500/mm3,,,,,,
15433,,pruritus|metabolic diseases,,,,,,,,,,>= 400 ml,,,,,,
15434,,mitochondrial disease|endocrine crisis,,,,,,,,,,>13.|peak flow rate ≤ 12 ml/sec,,,,,,
15435,,renal comorbidities,,,,,,,,,,≥ 550 ml,,,,,,
15436,,abnormalities;|abnormal ecg,,,,,,,,,,5-7 years old|body temperature,,,,,,
15437,,capsule passage,,,,,,,,,,< 6 times upper limit of normal (uln),,,,,,
15438,,hepatitis b directed antiviral therapy,,,,,,,,,,^9/l.|received,,,,,,
15439,,months;|biochemical recurrence,,,,,,,,,,18 years or over|be able to give,,,,,,
15440,,chronic degenerative diseases,,,,,,,,,,> 5.5mmol/l,,,,,,
15441,,skin adhesive allergy,,,,,,,,,,under 18 years|pregnant,,,,,,
15442,,placenta abruption,,,,,,,,,,<5.0 x uln)|alt,,,,,,
15443,,lvedd,,,,,,,,,,>70 mmhg,,,,,,
15444,,rhabdomyosarcoma,,,,,,,,,,greater than (>),,,,,,
15445,,active infections,,,,,,,,,,≤ 2|life expectancy,,,,,,
15446,,jaki,,,,,,,,,,≥30 miu/ml,,,,,,
15447,,obstructive coronary disease,,,,,,,,,,>3 times normal,,,,,,
15448,,natural infection,,,,,,,,,,18-64|bmi,,,,,,
15449,,quality,,,,,,,,,,> 2.0 cm,,,,,,
15450,,eye.|intraocular pressure (iop),,,,,,,,,,18 to 60,,,,,,
15451,,uterine fibrosis,,,,,,,,,,≥1.5*,,,,,,
15452,,generalized dermatologic disease,,,,,,,,,,0-2|serum,,,,,,
15453,,urine protein immunoelectrophoresis,,,,,,,,,,between 18 and 35,,,,,,
15454,,intraoperative signs,,,,,,,,,,> 40);|patient,,,,,,
15455,,internal auditory,,,,,,,,,,≥ 90 ml/min/1.73 m2|absence,,,,,,
15456,,chronic antithrombotic treatment|atrial fibrillation,,,,,,,,,,<126 mg/dl;|subjects,,,,,,
15457,,noticeable||,,,,,,,,,,50 puffs/day,,,,,,
15458,,nested,,,,,,,,,,160 mm hg or more,,,,,,
15459,,psoriasis lesions,,,,,,,,,,≤ 2.5 × institutional uln.||weight||the participant,,,,,,
15460,,catheter infection,,,,,,,,,,i-ii|consent to iv-patient,,,,,,
15461,,anomalies|chromosomal disorders|metabolic,,,,,,,,,,>80 iu/l)|pre-,,,,,,
15462,,serous cavity effusion,,,,,,,,,,18.5-24.9)||,,,,,,
15463,,spinal cord surgery)|onset,,,,,,,,,,≥ 18 years|able to swallow water||,,,,,,
15464,,l861q,,,,,,,,,,≥3 to 17 years,,,,,,
15465,,horizontal axis,,,,,,,,,,less than 25 years,,,,,,
15466,,endocrinopathies:||cushing syndrome,,,,,,,,,,≥90 g/l;|absolute,,,,,,
15467,,unusual thought,,,,,,,,,,18.5 - 24.9)||presence,,,,,,
15468,,uveitis threatening the visual prognosis,,,,,,,,,,<50x109/l|absolute lymphocyte count,,,,,,
15469,,disease|orthopedic injuries,,,,,,,,,,10 - 30 g/day,,,,,,
15470,,congestive heart failure;|clinically significant,,,,,,,,,,≥18 years|referral for us assisted placement||,,,,,,
15471,,human t-lymphotropic virus (htlv) infections,,,,,,,,,,ii to iv|history,,,,,,
15472,,serosanguinous maculopathy,,,,,,,,,,score equal to 0|ihe-induced %,,,,,,
15473,,although unplanned pregnancy,,,,,,,,,,less than 30%|known,,,,,,
15474,,home||,,,,,,,,,,less than 40%;|treatment,,,,,,
15475,,cryopreserved normal embryos,,,,,,,,,,≥ 19 and ≤28 kg/m2,,,,,,
15476,,diabetic peripheral neuropathy,,,,,,,,,,≥ 50 copies/ml,,,,,,
15477,,multiple endocrine neoplasia syndrome type 2,,,,,,,,,,> 2|dysuria,,,,,,
15478,,cerebral arteritis,,,,,,,,,,more than 4 weeks.|diminshed ovarian reserve,,,,,,
15479,,cellulitis.|lymphatic insufficiency.|immunocompromised,,,,,,,,,,1 or greater,,,,,,
15480,,unresectable squamous cell carcinoma,,,,,,,,,,0 to 1.|primary lesions,,,,,,
15481,,anastomosis)||concomitant pancreatitis,,,,,,,,,,"under 18 years old, legal",,,,,,
15482,,chronic pathology responsible of pain,,,,,,,,,,< or =,,,,,,
15483,,enclosed environment,,,,,,,,,,score of 0 or,,,,,,
15484,,cystic fibrosis)|such,,,,,,,,,,"< 100,000).|known peripheral neuropathy",,,,,,
15485,,ales,,,,,,,,,,>1 pack/day,,,,,,
15486,,ocular malignancy.|subjects,,,,,,,,,,≥ 25 iu/l,,,,,,
15487,,motor neuropathy,,,,,,,,,,≥ 2.5 times unl,,,,,,
15488,,mitral regurgitation)|permanent,,,,,,,,,,lower than 90 ml/mn,,,,,,
15489,,clinically probable,,,,,,,,,,"≥ 200,000 iu/ml",,,,,,
15490,,left atrial ablation|informed,,,,,,,,,,19.0 to 26.0 kg/m2,,,,,,
15491,,alzheimer's,,,,,,,,,,between 18-27 kg/m2,,,,,,
15492,,actionable mutations,,,,,,,,,,over 18 years|no,,,,,,
15493,,toxic response,,,,,,,,,,≤ctcae 2,,,,,,
15494,,chronic renal disease;|drug addiction,,,,,,,,,,>130 or <100 millimeters,,,,,,
15495,,adenocarcinoma of prostate|investigator assessed,,,,,,,,,,permitted.||9.creatinine clearance < 30ml/min,,,,,,
15496,,fear,,,,,,,,,,greater than 90 mmhg,,,,,,
15497,,enrollment|left atrial thrombus,,,,,,,,,,>101.0 degrees fahrenheit,,,,,,
15498,,adrenal tumors,,,,,,,,,,≥ 2.8g / dl,,,,,,
15499,,developed macular pathology,,,,,,,,,,score ≥ 10)|patient,,,,,,
15500,,human immunodeficiency virus (,,,,,,,,,,bm relapse,,,,,,
15501,,blood system diseases,,,,,,,,,,6-15,,,,,,
15502,,indication of the,,,,,,,,,,<90 days).|those,,,,,,
15503,,convulsive conditions,,,,,,,,,,i and ii scheduled,,,,,,
15504,,criteria required:||o the cancer specialist considers,,,,,,,,,,0-2|ages 18-80 years|nihss,,,,,,
15505,,signs of radiculopathy,,,,,,,,,,≥18|screen positive,,,,,,
15506,,diabetes|breast cancer,,,,,,,,,,28-,,,,,,
15507,,incompatible with safe use of a,,,,,,,,,,≥ 6.|subject,,,,,,
15508,,colitis-associated,,,,,,,,,,between 50 to 75;|subjects,,,,,,
15509,,significant pulmonary,,,,,,,,,,"1, 9",,,,,,
15510,,chronic asthma,,,,,,,,,,more than 5x uln,,,,,,
15511,,malignancies.|active liver disease,,,,,,,,,,between 18 years old and 80 years,,,,,,
15512,,non-pharmacological therapy,,,,,,,,,,from 140 to 199 mg/dl||,,,,,,
15513,,score>2.89,,,,,,,,,,5-21 years,,,,,,
15514,,in situ cancers,,,,,,,,,,score ≤ 24 points,,,,,,
15515,,nasal polyp,,,,,,,,,,ccr)≥60ml/min,,,,,,
15516,,cohort 1.|mental incapacity,,,,,,,,,,≤ 22.|iron deficiency.|vitamin b12 deficiency,,,,,,
15517,,abstain from donating sperm,,,,,,,,,,>110,,,,,,
15518,,kit exon 9 mutation,,,,,,,,,,≥50|chinese ethnicity|history of tia/ischaemic,,,,,,
15519,,dental autotransplantation,,,,,,,,,,"nationals,|below 50 years",,,,,,
15520,,brain malignancies,,,,,,,,,,<1.0x109/l|platelet count,,,,,,
15521,,aortic stenosis|indication,,,,,,,,,,above 50%,,,,,,
15522,,nash,,,,,,,,,,≥ 140 mm hg,,,,,,
15523,,convergence insufficiency,,,,,,,,,,≥ 35 kg/m2|septic shock|severe,,,,,,
15524,,dilated cardiomyopathy,,,,,,,,,,18-65|radicular,,,,,,
15525,,acute loss,,,,,,,,,,≥91%,,,,,,
15526,,squamous cell skin cancers.|any malignancy,,,,,,,,,,hypertension≤ 160mmhg,,,,,,
15527,,non-cardiac,,,,,,,,,,≥ 10 miu/l,,,,,,
15528,,acute compartment syndrome,,,,,,,,,,8-11 shoe|weight,,,,,,
15529,,america,,,,,,,,,,≤ 2.5 times the upper limit of normal value (uln),,,,,,
15530,,malignant melanoma;|njectable lesions,,,,,,,,,,">= 1,000/microliter|hemoglobin",,,,,,
15531,,invasive mycosis,,,,,,,,,,1.5×uln(if the subject,,,,,,
15532,,gynecologic malignancies|patients,,,,,,,,,,"score of ≥33,",,,,,,
15533,,early antenatal ultrasound|birth weight,,,,,,,,,,0 or 1|male/,,,,,,
15534,,localized subcutaneous,,,,,,,,,,"≥1,500/mcl|platelets",,,,,,
15535,,brca1/2m cancer,,,,,,,,,,between two echocardiographies,,,,,,
15536,,physical trauma,,,,,,,,,,less than 1 cm from the treatment area.|urinary,,,,,,
15537,,reduction|localized pain,,,,,,,,,,≤ 24 weeks,,,,,,
15538,,cutaneous sarcoidosis activity,,,,,,,,,,<15 and >80 years|patients,,,,,,
15539,,curative-intent,,,,,,,,,,>15 years,,,,,,
15540,,gastroparesis,,,,,,,,,,above institutional normal||shortening fraction,,,,,,
15541,,vascular injuries,,,,,,,,,,90-ytrium radioembolization,,,,,,
15542,,mainly mental disability).|pregnancy.|patients,,,,,,,,,,1-6 months)|hemiparesis,,,,,,
15543,,chronic hcv disease,,,,,,,,,,used to determine the participant's eligibility,,,,,,
15544,,radiating leg pain,,,,,,,,,,≤ 1.|patient,,,,,,
15545,,living communities,,,,,,,,,,≥140 mg/dl,,,,,,
15546,,brief mental state examination scale,,,,,,,,,,≥30 ml/minute,,,,,,
15547,,non-resolving,,,,,,,,,,≥1cm and <14cm)|the participant,,,,,,
15548,,hairloss|pregnant,,,,,,,,,,>3.14,,,,,,
15549,,inflammatory conditions,,,,,,,,,,>60 years|scheduled,,,,,,
15550,,glomerulonephritis,,,,,,,,,,greater than 90%,,,,,,
15551,,severe pulmonary fibrosis,,,,,,,,,,"ⅰ-ⅱ ,|18-80 years old",,,,,,
15552,,meld-na,,,,,,,,,,< 18 years.|lack of cooperation.|no,,,,,,
15553,,muscle metabolism,,,,,,,,,,>= 50||pediatric,,,,,,
15554,,eclampsia|gestational hypertension|gestational diabetes|red blood cell isoimmunization|cervical insufficiency,,,,,,,,,,between 18-75years||,,,,,,
15555,,hpv infection,,,,,,,,,,> 480 ms per electrocardiogram,,,,,,
15556,,hepatic sos,,,,,,,,,,≥30 × 109/l,,,,,,
15557,,ppp,,,,,,,,,,12 to 24 weeks after the first symptom of stroke,,,,,,
15558,,nephrotic syndromes,,,,,,,,,,≥ 3 × 109/l,,,,,,
15559,,heart pump,,,,,,,,,,<3×10^9 /l,,,,,,
15560,,hysterectomy|those,,,,,,,,,,≤ 2.5 uln,,,,,,
15561,,bleeding symptoms,,,,,,,,,,≤ 2.5x institutional uln,,,,,,
15562,,eradication history||,,,,,,,,,,≥20 and <46,,,,,,
15563,,sinus disease,,,,,,,,,,< 4.5h,,,,,,
15564,,reproductive system|acute severe disease,,,,,,,,,,≥18 years;|evidence of,,,,,,
15565,,fungal infection;|upper gi bleeding,,,,,,,,,,stage 5,,,,,,
15566,,stoke,,,,,,,,,,more than18 years.|healed edentulous area,,,,,,
15567,,hypothyroidism||,,,,,,,,,,< 150 days prior,,,,,,
15568,,neurological disorders|assumption,,,,,,,,,,between 1.5 and 2.5' uln,,,,,,
15569,,distal cbd carcinoma,,,,,,,,,,> 30kg/m2,,,,,,
15570,,alcohol abuse|language,,,,,,,,,,less than 50 mmhg,,,,,,
15571,,acute coronary syndrome.||,,,,,,,,,,18-65 years;|diagnosis,,,,,,
15572,,cancer-associated pain,,,,,,,,,,> 146 meq/l,,,,,,
15573,,thrombocytopenia|thrombocytosis,,,,,,,,,,from 4 to 10 points,,,,,,
15574,,weight-management,,,,,,,,,,> 92%,,,,,,
15575,,acetabular cup|if ostheoarthritis,,,,,,,,,,47 to 100 beats per minute,,,,,,
15576,,breast feeding;||participants with fertility plan;||note: for female,,,,,,,,,,more than 90,,,,,,
15577,,alveolar bone,,,,,,,,,,< 1.5 x institutional upper limit of normal,,,,,,
15578,,intraarticular pathologic conditions,,,,,,,,,,times more than 1 time,,,,,,
15579,,neurotoxic effects,,,,,,,,,,less than 10g/dl).|uterine overdistention,,,,,,
15580,,ganglionic neuroma/paraganglioma,,,,,,,,,,1-2 and 3,,,,,,
15581,,sunglasses,,,,,,,,,,between 90 and 160 mmhg,,,,,,
15582,,isolated episode,,,,,,,,,,21～31 kg/m2,,,,,,
15583,,postoperative ductal carcinoma,,,,,,,,,,"≥ 2,500 cells/μl|platelet",,,,,,
15584,,painful procedures,,,,,,,,,,upper airway obstruction,,,,,,
15585,,tumour genomic alterations,,,,,,,,,,less than 37 weeks,,,,,,
15586,,functional impairment).|the participant,,,,,,,,,,> 21 glasses per week,,,,,,
15587,,cerebral injury,,,,,,,,,,≤ 3' times uln.|coagulation,,,,,,
15588,,acute intoxication,,,,,,,,,,greater than 135 kg,,,,,,
15589,,central obesity,,,,,,,,,,≤ 340 ms,,,,,,
15590,,pathology threatening,,,,,,,,,,between 30cc,,,,,,
15591,,addiction||,,,,,,,,,,≤ 2 x upper limit of normal,,,,,,
15592,,respiratory malformation|acute respiratory infection,,,,,,,,,,65 and older,,,,,,
15593,,variceal bleeding|hiv,,,,,,,,,,"< 100,000/ul)|morphologic",,,,,,
15594,,etc.)|persons not,,,,,,,,,,<5% change,,,,,,
15595,,substance overuse,,,,,,,,,,50 years or,,,,,,
15596,,abnormal uterine bleeding||,,,,,,,,,,≥ 18y,,,,,,
15597,,pelvis|prostate cancer,,,,,,,,,,greater than or equal to (>=)50.0 kilogram (kg),,,,,,
15598,,exogenous ketones,,,,,,,,,,< 15years,,,,,,
15599,,microscopic colitis;|serious,,,,,,,,,,> 6 months.|the,,,,,,
15600,,keratoconjunctivitis sicca.|have,,,,,,,,,,20-50 years|chronic,,,,,,
15601,,"water stop""",,,,,,,,,,> 45 iu/l)|low,,,,,,
15602,,acute glaucoma,,,,,,,,,,≥ 80 × 109,,,,,,
15603,,cognitive impairment|inability,,,,,,,,,,> 140/90 mmhg,,,,,,
15604,,breast cancer treatment|non ductal,,,,,,,,,,i|age 55 to 65 years||,,,,,,
15605,,diabetes mellitus.|use of,,,,,,,,,,withdrawal,,,,,,
15606,,correctable causes,,,,,,,,,,<18 or >85||active alcohol,,,,,,
15607,,residual hypothyroidism,,,,,,,,,,score ≥ 11,,,,,,
15608,,reduced ef,,,,,,,,,,between 18 and 25 kg/m2|for japanese,,,,,,
15609,,cardiac disease|patients,,,,,,,,,,>16 mg/dl|patients,,,,,,
15610,,irc,,,,,,,,,,>15%|patient,,,,,,
15611,,eye surgery|medication,,,,,,,,,,38-42,,,,,,
15612,,eye;|active eye infection,,,,,,,,,,score 0-1.|toxic reaction,,,,,,
15613,,1- contraindications,,,,,,,,,,18 to 55) they,,,,,,
15614,,neurotoxic chemotherapies|no,,,,,,,,,,<6 weeks,,,,,,
15615,,hepatitis b virus titer,,,,,,,,,,score ≥27)||,,,,,,
15616,,hire,,,,,,,,,,complete response,,,,,,
15617,,simmondsia chinensis,,,,,,,,,,50-90% stenosis,,,,,,
15618,,used||pulmonary hypertension,,,,,,,,,,< 50 x 10^9/l|diagnosis of any of the following diseases,,,,,,
15619,,acute infectious disease,,,,,,,,,,between 19+6,,,,,,
15620,,kidney diseases.|cardiovascular diseases,,,,,,,,,,less than/equal to 6 months,,,,,,
15621,,pulmonary conditions,,,,,,,,,,27-30|who,,,,,,
15622,,ros1,,,,,,,,,,0 or 1|histologic,,,,,,
15623,,irregular breathing,,,,,,,,,,> 108 mmol/mol,,,,,,
15624,,acute promyelocytic leukemia,,,,,,,,,,between 10-20kg|american society of anesthesiology (,,,,,,
15625,,liver disease at activity,,,,,,,,,,18 - 50 years,,,,,,
15626,,c01)|cognitive impairments,,,,,,,,,,below 65 mmhg,,,,,,
15627,,condition incompatible with driving simulator,,,,,,,,,,< 25 ml/min/1.73m2|pregnant,,,,,,
15628,,painful neuropathy,,,,,,,,,,< 20ml/s.|limitation,,,,,,
15629,,renal disease)|pulmonary,,,,,,,,,,2.5 x 103/cc and 2500/μl,,,,,,
15630,,gastrointestinal fistula occurred,,,,,,,,,,≥ 5 × 10^2 copies/l,,,,,,
15631,,hhv-6,,,,,,,,,,=< 3 x uln (=,,,,,,
15632,,postpartum,,,,,,,,,,≥.5 × 10^9/l,,,,,,
15633,,orthopedic,,,,,,,,,,25 cm^2 on,,,,,,
15634,,carcinomatous meningitis.|new recurrence of osteosarcoma metastasis,,,,,,,,,,≥ grade 2.|liver,,,,,,
15635,,24-hour,,,,,,,,,,>6.4,,,,,,
15636,,hypoglycemic event,,,,,,,,,,"> 1,500 pg/ml",,,,,,
15637,,etc.)|pupil abnormality,,,,,,,,,,equal or more than 18 years,,,,,,
15638,,chronic eczema,,,,,,,,,,at least 25 milliinternational units per milliliter of urine (miu/ml,,,,,,
15639,,age|ability,,,,,,,,,,≤ 2×uln,,,,,,
15640,,skin scraping stains,,,,,,,,,,> upper limit of normal);|patients,,,,,,
15641,,organ injuries,,,,,,,,,,significant abnormal,,,,,,
15642,,good general body,,,,,,,,,,less than 45 beats per minute.||subject,,,,,,
15643,,skin ulcers|patients,,,,,,,,,,older than 18 years,,,,,,
15644,,hepatic impairments,,,,,,,,,,≥ 3 × uln|prior,,,,,,
15645,,intestinal obstruction;|patients,,,,,,,,,,≥4cm,,,,,,
15646,,associated congenital malformation,,,,,,,,,,< 100 × 109/l,,,,,,
15647,,pain syndrome,,,,,,,,,,> 92%;|total bilirubin,,,,,,
15648,,neuroendocrine prostate cancer,,,,,,,,,,≥ 1mm,,,,,,
15649,,metastatic melanoma,,,,,,,,,,< 5 x upper limit of normal,,,,,,
15650,,systemic infection|ec,,,,,,,,,,less than 18 years|unable to consent,,,,,,
15651,,judged by the investigator to potentially interfere with the subject's compliance,,,,,,,,,,≤ 125 umol/l,,,,,,
15652,,sars-cov-2.|hiv-infected,,,,,,,,,,at least 45 kg,,,,,,
15653,,drug-induced liver injury,,,,,,,,,,between 18 and 65 years|experiencing signs,,,,,,
15654,,sporadic cold sores,,,,,,,,,,>=4.|recent,,,,,,
15655,,fluid overload,,,,,,,,,,≥25 kg/m2|able,,,,,,
15656,,local symptoms of myeloma,,,,,,,,,,> 30 ng/ml,,,,,,
15657,,predialytic chronic kidney disease,,,,,,,,,,< 18 years-old|history,,,,,,
15658,,weight loss medications|currently,,,,,,,,,,maximum 60 mg/day,,,,,,
15659,,necrotizing enteritis,,,,,,,,,,>18 and <75 years||,,,,,,
15660,,peptic ulcer.||patients,,,,,,,,,,100 to 190 bpm,,,,,,
15661,,clinical findings and|nerve abnormalities,,,,,,,,,,12-21,,,,,,
15662,,etc.)|opioid addiction|patient,,,,,,,,,,<40 kg;|enrolled,,,,,,
15663,,acute hepatic failure,,,,,,,,,,at enrollment,,,,,,
15664,,pregnancy loss,,,,,,,,,,"<100,000/μl|have",,,,,,
15665,,right ventricular (rv) dysfunction,,,,,,,,,,outside the range of 90 to 140 mmhg,,,,,,
15666,,cardiac malformations,,,,,,,,,,≥ 2||,,,,,,
15667,,disease of the spine,,,,,,,,,,<=140 mm hg,,,,,,
15668,,treatment|glaucoma,,,,,,,,,,> ii,,,,,,
15669,,undesirable conditions,,,,,,,,,,≥ 3 months,,,,,,
15670,,multi-organ transplant,,,,,,,,,,between 7-12 years,,,,,,
15671,,ventilation;|acute stroke,,,,,,,,,,< 60 ml/min/1.73m^2|alt,,,,,,
15672,,musculoskeletal deformity,,,,,,,,,,18 and above|presentation,,,,,,
15673,,unresectable hcc,,,,,,,,,,more than 29 days old,,,,,,
15674,,thrombotic event,,,,,,,,,,≥18 and ≤65 years.|diagnosed,,,,,,
15675,,limb threatening,,,,,,,,,,18-75||having,,,,,,
15676,,leakage|pregnancy,,,,,,,,,,< 45 mm hg,,,,,,
15677,,visual,,,,,,,,,,least 50 kg,,,,,,
15678,,terminal disease|those,,,,,,,,,,< 2 years,,,,,,
15679,,ulcers diabetes mellitus,,,,,,,,,,<55 years,,,,,,
15680,,neck surgery|systemic,,,,,,,,,,> 160,,,,,,
15681,,hypothalamic-pituitary diseases,,,,,,,,,,"less than 15%,|2nd degree",,,,,,
15682,,cystic fibrosis,,,,,,,,,,>= 18 years|primary caregiver|access to the internet|fluent,,,,,,
15683,,non-plaque psoriasis,,,,,,,,,,≤1.0 g.|blood coagulation test standards,,,,,,
15684,,venous pressure,,,,,,,,,,≥ 1.5×109/l,,,,,,
15685,,uterine malformation,,,,,,,,,,from families,,,,,,
15686,,ischemic disorders,,,,,,,,,,≤ 1.|intention to treat,,,,,,
15687,,deficiency disorders,,,,,,,,,,≥ 10 g/l,,,,,,
15688,,polyneuropathy,,,,,,,,,,between 18 and 75 years;|subjects,,,,,,
15689,,periodontal disease detectible,,,,,,,,,,>=40 milli international,,,,,,
15690,,pseudodrusen,,,,,,,,,,iii and above,,,,,,
15691,,recurrence/persistence disease,,,,,,,,,,better than 75,,,,,,
15692,,intestinal absorption,,,,,,,,,,"18 - 60 years,|not",,,,,,
15693,,intracranial hemorrhage;|left ventricular thrombosis,,,,,,,,,,under 70 years||,,,,,,
15694,,cochlear anomaly,,,,,,,,,,hbcab test.||negative hepatitis c virus (hcv) antibody test,,,,,,
15695,,hiv.|men,,,,,,,,,,≥175×109/l,,,,,,
15696,,raynaud's syndrome,,,,,,,,,,0.0 - 6.0.|at,,,,,,
15697,,primary cancer,,,,,,,,,,< 10 %|physically able,,,,,,
15698,,placenta,,,,,,,,,,iii-iv;|unstable angina,,,,,,
15699,,autoimmune diseases;|neutrophil count,,,,,,,,,,>0.50 d of,,,,,,
15700,,p.e. £,,,,,,,,,,< 50 beats/min,,,,,,
15701,,unresectable locally advanced/metastatic,,,,,,,,,,≥18 years|ability to sign,,,,,,
15702,,cough,,,,,,,,,,1-34,,,,,,
15703,,perimeningeal metastases,,,,,,,,,,≥ 9.|patients,,,,,,
15704,,between recurrence node(s,,,,,,,,,,at least 30 days prior to the first dose,,,,,,
15705,,acute inflammatory infiltrate,,,,,,,,,,> 5x normal limit,,,,,,
15706,,age||,,,,,,,,,,less than 50 beats/min or more than 100 beats/min,,,,,,
15707,,death|severe infection,,,,,,,,,,<200,,,,,,
15708,,focus of infection,,,,,,,,,,≥ 450 msec,,,,,,
15709,,chronic debilitating,,,,,,,,,,≥ 21,,,,,,
15710,,conditions|active infection,,,,,,,,,,=< 28 days prior,,,,,,
15711,,type 2,,,,,,,,,,>= 30 ml/min/1.73 m^2 to < 45 ml/min/1.73 m^2,,,,,,
15712,,lower respiratory illness,,,,,,,,,,< 140mg/dl,,,,,,
15713,,pneumonia complications,,,,,,,,,,≥20%,,,,,,
15714,,cachexia,,,,,,,,,,18.5-30.0 kg/m^2,,,,,,
15715,,adjustment disorder,,,,,,,,,,>3 times upper normal,,,,,,
15716,,criteria for cwp,,,,,,,,,,<10 g/dl|has,,,,,,
15717,,target vegf,,,,,,,,,,>=18 years.|measurable disease,,,,,,
15718,,conjunctivitis,,,,,,,,,,long-term,,,,,,
15719,,millisievert,,,,,,,,,,7-9 points)|absence,,,,,,
15720,,vasopressor dependence,,,,,,,,,,≥100 x10^9/l.|hemoglobin ≥100 g/l,,,,,,
15721,,benign tumor|widespread lymphoma,,,,,,,,,,≥50% guideline directed doses,,,,,,
15722,,medical condition|cognitive disorders,,,,,,,,,,"> 1.40),|asymptomatic pad",,,,,,
15723,,not|pregnancy,,,,,,,,,,i or more,,,,,,
15724,,post-tubal ligation,,,,,,,,,,less than 3m,,,,,,
15725,,side;|ability,,,,,,,,,,>4 units/day)|allergy,,,,,,
15726,,outpatient exacerbation,,,,,,,,,,between 18 and 30 kg/m2|body weight,,,,,,
15727,,gastritis|pregnancy,,,,,,,,,,< 8g/l,,,,,,
15728,,tb,,,,,,,,,,≤ 60,,,,,,
15729,,cerebral complications,,,,,,,,,,27 kg/m2,,,,,,
15730,,poor tolerability,,,,,,,,,,from day 7 through 9 should,,,,,,
15731,,differ,,,,,,,,,,score <13|lower extremity trauma|a prior,,,,,,
15732,,heart failure|renal failure|cardiovascular accident|abscess or infection,,,,,,,,,,≥ 32 g/l,,,,,,
15733,,adequate organ function,,,,,,,,,,between 18 and 35 years,,,,,,
15734,,rheumatoid arthritis).|radicular symptoms consistent,,,,,,,,,,<45 kg,,,,,,
15735,,chronic constipation,,,,,,,,,,> 1.3.|tbl > 25 μmol/l,,,,,,
15736,,substantial potential,,,,,,,,,,>11 mm,,,,,,
15737,,ferromagnetic implants,,,,,,,,,,≥ 28 days,,,,,,
15738,,middle ear balance,,,,,,,,,,> 300,,,,,,
15739,,paraffin-,,,,,,,,,,>25 × 109/l,,,,,,
15740,,substance abuse treatment,,,,,,,,,,greater than or equal to 7 mm,,,,,,
15741,,motor deficit,,,,,,,,,,≥ 55 and ≤ 75 years,,,,,,
15742,,shingles,,,,,,,,,,c-ssrs).60,,,,,,
15743,,isolated plasma cell,,,,,,,,,,< 40 ml/min/1.73m2);|anticipated,,,,,,
15744,,electrical stimulation|absence of peripheral carotid,,,,,,,,,,> 60 pre-operatively,,,,,,
15745,,no metabolism,,,,,,,,,,≥ 1 year,,,,,,
15746,,tumor necrosis,,,,,,,,,,>4.2 miu/,,,,,,
15747,,"osteoporosis),|psychiatric disorders,|cancer",,,,,,,,,,18-70 years|preoperative mini-mental state examination score,,,,,,
15748,,heart failure;|thromboembolic events,,,,,,,,,,≥18 years|sars-cov-2,,,,,,
15749,,electrolyte imbalances,,,,,,,,,,< 50% and,,,,,,
15750,,localized basal cell,,,,,,,,,,>6 mm,,,,,,
15751,,3rd degree block,,,,,,,,,,< 10 disc areas (25.4 mm2)|absence,,,,,,
15752,,anatomical abnormalities,,,,,,,,,,">18 , <80 year",,,,,,
15753,,systemically free,,,,,,,,,,≥ 1500cells/mm3,,,,,,
15754,,pervasive developmental disorder,,,,,,,,,,60 ml/min/1.73 m^2,,,,,,
15755,,terminal hair regrowth,,,,,,,,,,between 3 years and 12 years 11 months|diagnosis,,,,,,
15756,,blood relatives,,,,,,,,,,>3.0 mg/dl,,,,,,
15757,,pure alcohol,,,,,,,,,,5 µm-10 µm,,,,,,
15758,,reynaud's syndrome,,,,,,,,,,> 1.5 times of the upper limit of the normal range,,,,,,
15759,,epidermal growth factor receptor (egfr) activating mutation positive,,,,,,,,,,≥18 years.|diagnosis,,,,,,
15760,,below:||intracranial pathology,,,,,,,,,,< 18.5 kg/m2)|active,,,,,,
15761,,attributable to disease,,,,,,,,,,≥ 3||unacceptable,,,,,,
15762,,cardiac disease.|clinically,,,,,,,,,,being 65 years old,,,,,,
15763,,mitral valve,,,,,,,,,,less than 40.|immunosuppressants treatment.|chronic constipation,,,,,,
15764,,type 2 diabetes mellitus.||,,,,,,,,,,0-1)|angiography,,,,,,
15765,,spondylolisthesis,,,,,,,,,,>70 years,,,,,,
15766,,severe physical illness,,,,,,,,,,≥18 years|subjects must have the,,,,,,
15767,,osteochondral defect,,,,,,,,,,below 3.0×the upper limit of normal (uln),,,,,,
15768,,viral infections,,,,,,,,,,≥ 125 beats/minute,,,,,,
15769,,year.||{common cold,,,,,,,,,,≤5 times the upper limit of,,,,,,
15770,,hemophilia,,,,,,,,,,10 to 17 years:||healthy children,,,,,,
15771,,pathology of the upper limbs,,,,,,,,,,> 10 000 ng/ml,,,,,,
15772,,"inflammatory rheumatic disorders,|need",,,,,,,,,,0-1.|expected survival time,,,,,,
15773,,autistic spectrum disorder,,,,,,,,,,from 18 to 75,,,,,,
15774,,experience mental health problems,,,,,,,,,,≥18 years|diagnosis of head and neck cancer,,,,,,
15775,,non-vertex corrected subjective,,,,,,,,,,18 to 60 years inclusive,,,,,,
15776,,common cold virus,,,,,,,,,,was<100 * 10 ^ 9/l.||exclusion,,,,,,
15777,,chronic renal disease.|mosaicism,,,,,,,,,,>3h/,,,,,,
15778,,dvcad,,,,,,,,,,over 18 years old|tumor,,,,,,
15779,,pudendal block,,,,,,,,,,<3 or >12 cm|abdominal aortic aneurysm disorders|pregnancy,,,,,,
15780,,mycobacterium tuberculosis,,,,,,,,,,50 - 100.|subject,,,,,,
15781,,hydrodissection cervical,,,,,,,,,,>60ml/kg/h,,,,,,
15782,,chronic obstructive pulmonary diseases,,,,,,,,,,18.5 ~ 27.0,,,,,,
15783,,fecal incontinence,,,,,,,,,,18+ years of age|be able,,,,,,
15784,,active disease process,,,,,,,,,,score of 24 to 68,,,,,,
15785,,neurological symptoms attributable,,,,,,,,,,equal to or more than 10mm hg,,,,,,
15786,,bidimensionally measurable disease,,,,,,,,,,12-15|volunteering to participate,,,,,,
15787,,localized prostate,,,,,,,,,,> 8.0 g/dl,,,,,,
15788,,hematologic malignancy,,,,,,,,,,18 or greater|history,,,,,,
15789,,non-transient haematological abnormalities;|renal dysfunction,,,,,,,,,,>= 55 years|eastern,,,,,,
15790,,ih,,,,,,,,,,>=90 mmhg,,,,,,
15791,,gilbert's disease.|platelets,,,,,,,,,,≥ 55 %,,,,,,
15792,,focal onset epilepsy,,,,,,,,,,≤ 25 μmol/l,,,,,,
15793,,systemic exposure,,,,,,,,,,stage iv);|the,,,,,,
15794,,liver transplant.|current,,,,,,,,,,4-5|other,,,,,,
15795,,hereditary hemorrhagic physique,,,,,,,,,,1 ml or less,,,,,,
15796,,kidney disfunction,,,,,,,,,,≤ 100mmhg|at least 10%,,,,,,
15797,,sequelae|participant,,,,,,,,,,greater than 3 months;||7,,,,,,
15798,,preoperative)|sepsis,,,,,,,,,,< 50 ng/dl,,,,,,
15799,,complaints of regurgitation,,,,,,,,,,≥ 6.|a new,,,,,,
15800,,puncture drainage,,,,,,,,,,≥30%,,,,,,
15801,,complex polypectomies,,,,,,,,,,40% alcohol,,,,,,
15802,,prolonged qtc interval,,,,,,,,,,< 33%,,,,,,
15803,,certain comorbidities,,,,,,,,,,above this threshold,,,,,,
15804,,acute problems,,,,,,,,,,below 90 x10^6|hemoglobin level,,,,,,
15805,,burn injuries,,,,,,,,,,< 14 years and > 30 years;|presence of structured physical activity programs,,,,,,
15806,,adverse drug reactions to more than one class,,,,,,,,,,18-66,,,,,,
15807,,close friends|adults,,,,,,,,,,>8 mmol/l - can,,,,,,
15808,,polycystic ovarian syndrome,,,,,,,,,,9.0 or higher,,,,,,
15809,,entity|adolescent scoring,,,,,,,,,,>500 within 2 weeks,,,,,,
15810,,foot ulcer,,,,,,,,,,outside the range of 90 to 150 millimeter of mercury,,,,,,
15811,,cholagogic,,,,,,,,,,equal to or lower than,,,,,,
15812,,sarcomas,,,,,,,,,,> -2sd or >p10|asymptomatic,,,,,,
15813,,exon 21 mutations|patients,,,,,,,,,,≥ 18years,,,,,,
15814,,adverse drug reaction,,,,,,,,,,> 18 years.|subject has provided informed,,,,,,
15815,,impairment of lung,,,,,,,,,,levels ≤ 10 times the upper limit of normal (uln),,,,,,
15816,,unresectable disease,,,,,,,,,,>18 years|ability to provide,,,,,,
15817,,brain metastases;|receiving,,,,,,,,,,less than or equal to 1.5 x uln,,,,,,
15818,,iron|acute sepsis,,,,,,,,,,18.5 to 31.9 kg/m2,,,,,,
15819,,insufficiency,,,,,,,,,,___,,,,,,
15820,,interstitial pulmonary disease,,,,,,,,,,>0.2 ng/dl,,,,,,
15821,,renal function|symptomatic congestive heart failure|unstable angina pectoris|kidney disease|uncontrolled diabetes|cystic fibrosis|fibromyalgia,,,,,,,,,,> 18|bmi > 30 kg/m2|requires,,,,,,
15822,,few pleural effusion,,,,,,,,,,≥ 38 kg/m2.|use,,,,,,
15823,,cardiovascular pulmonary,,,,,,,,,,≤ 1.5 × 109/l,,,,,,
15824,,mycosis fungoides (mf),,,,,,,,,,≥ 6.0|individuals,,,,,,
15825,,health promotion entity - eps,,,,,,,,,,"10-12,|having",,,,,,
15826,,inclusive||,,,,,,,,,,>18 years|previous diagnosis of eoe,,,,,,
15827,,aversion,,,,,,,,,,≥ 18 years|diagnosis,,,,,,
15828,,increased bleeding,,,,,,,,,,greater than 2x normal,,,,,,
15829,,mental pathology orsuspicion,,,,,,,,,,less than 3 months).|parent,,,,,,
15830,,siewert type,,,,,,,,,,score ≥ 24|physically able,,,,,,
15831,,acute hypothyroidism,,,,,,,,,,>1.5×10^9/liter,,,,,,
15832,,cardiac biomarkers,,,,,,,,,,>4%;|willing to take,,,,,,
15833,,inhibiters,,,,,,,,,,>70,,,,,,
15834,,hyperviscosity syndrome,,,,,,,,,,1.5 × 109/l,,,,,,
15835,,left atrial diameter,,,,,,,,,,≥3 months.|histologically or cytologically,,,,,,
15836,,technologies|intact cognition||,,,,,,,,,,<30 ml/min/1.73m2.|women,,,,,,
15837,,perianal disease,,,,,,,,,,less than 45/min,,,,,,
15838,,tumor not,,,,,,,,,,<100 µg/l,,,,,,
15839,,hiv infection);|patients,,,,,,,,,,greater than or equal to 55 on the,,,,,,
15840,,bowel|complete main portal vein,,,,,,,,,,0-28 days);||gestational,,,,,,
15841,,pupillary reflex present,,,,,,,,,,score or score of ≥ 35,,,,,,
15842,,long qtc syndrome,,,,,,,,,,>300 minutes,,,,,,
15843,,thoracic level,,,,,,,,,,>32 weeks regardless of birth weight,,,,,,
15844,,solid tumor,,,,,,,,,,ib,,,,,,
15845,,term,,,,,,,,,,<80 years|from,,,,,,
15846,,teaching,,,,,,,,,,greater than or equal to 1 gout flare,,,,,,
15847,,prostatic condition,,,,,,,,,,≥ lower limit of normal (lln),,,,,,
15848,,hepatic involvement,,,,,,,,,,=< 2|histologic,,,,,,
15849,,liberty|pregnant,,,,,,,,,,>=60,,,,,,
15850,,non-psychotic major depressive disorder,,,,,,,,,,lower than 30%|severe,,,,,,
15851,,psychiatric psychological,,,,,,,,,,<2.5 g/dl,,,,,,
15852,,schizotypal disorders,,,,,,,,,,"between 1,5 and 12 cm|fibroid easily recognizable",,,,,,
15853,,procedural terminology,,,,,,,,,,<90 ml/min/1.73m^2,,,,,,
15854,,left valve disease,,,,,,,,,,0 or 1|unsuitable,,,,,,
15855,,sinus tachycardia,,,,,,,,,,at least three months;||adequate,,,,,,
15856,,multi-vitamins,,,,,,,,,,≤60mm,,,,,,
15857,,disease.|patients,,,,,,,,,,< 40 kg.|participant,,,,,,
15858,,reasons;|gorlin's syndrome,,,,,,,,,,0-1|expected lifetime of not,,,,,,
15859,,auditory brainstem response,,,,,,,,,,< 21)|subthreshold,,,,,,
15860,,excessive dragon fruit,,,,,,,,,,greater than 3);|patients,,,,,,
15861,,reason|ventricular dysfunction,,,,,,,,,,over 18||,,,,,,
15862,,interstitial pneumonitis,,,,,,,,,,< 40%)|patients,,,,,,
15863,,spray,,,,,,,,,,≥ 60||individual,,,,,,
15864,,muscle hypertrophy|taking narcotics,,,,,,,,,,≥50 kg;|the volunteer,,,,,,
15865,,infection of the wound,,,,,,,,,,≥ 60.||bone marrow:||anc,,,,,,
15866,,transfusion dependence,,,,,,,,,,less than 30 days before the start of the study.||volunteers,,,,,,
15867,,small bowel resection|a,,,,,,,,,,15 years,,,,,,
15868,,systemic factors,,,,,,,,,,greater than 5.5 cm,,,,,,
15869,,normalization of,,,,,,,,,,less than 1/3 of the gland volume by,,,,,,
15870,,td)/extrapyramidal symptoms,,,,,,,,,,≥29 ml/m2,,,,,,
15871,,enterohepatic circulation,,,,,,,,,,≥ g2,,,,,,
15872,,fracture,,,,,,,,,,≥ 8g/dl|creatine clearance,,,,,,
15873,,hypersensitivity reaction,,,,,,,,,,from 100 to 125 mg/dl|glycated,,,,,,
15874,,adjuvant et,,,,,,,,,,≥45 ml/min/1.73 m2|no,,,,,,
15875,,short life expectancy,,,,,,,,,,0-15,,,,,,
15876,,observable response,,,,,,,,,,16 - 65 y,,,,,,
15877,,acute promyelocytic,,,,,,,,,,"more than or equal to 100,000 cells/mm3",,,,,,
15878,,non-study ett,,,,,,,,,,≥ 14 mg/l).|for,,,,,,
15879,,renal impact|major medical,,,,,,,,,,> 20 and < 50|ability to understand the study,,,,,,
15880,,fridericia's formula,,,,,,,,,,"18-60|diagnosed ""healthy""",,,,,,
15881,,vt / vf,,,,,,,,,,10-16 cores.|≤15mm,,,,,,
15882,,spinal malformations,,,,,,,,,,equal to 16 years of age|tolerating levels of pressure support,,,,,,
15883,,type 1 diabetes mellitus|patients,,,,,,,,,,<50%).|current,,,,,,
15884,,raynaud disease,,,,,,,,,,> grade 1 from,,,,,,
15885,,hearing loss|ear pathology,,,,,,,,,,≥19.0 kg/m2,,,,,,
15886,,glaucoma.|psychological conditions,,,,,,,,,,> 3 mg/ml,,,,,,
15887,,fibrotic changes.|uncontrolled,,,,,,,,,,<92%)|patients participating in another clinical trial,,,,,,
15888,,surgery|patients,,,,,,,,,,2 or,,,,,,
15889,,medical issues,,,,,,,,,,0 to 2|stage i-ii,,,,,,
15890,,preclude muscle,,,,,,,,,,18 - 40 years||,,,,,,
15891,,coagulation disorders).|bacterial,,,,,,,,,,18.5-28|adherence,,,,,,
15892,,deep vein thrombosis/pulmonary embolism,,,,,,,,,,"≤ 65, regardless of gender;|patients",,,,,,
15893,,kostmann syndrome,,,,,,,,,,>9%,,,,,,
15894,,somatic conditions,,,,,,,,,,-4,,,,,,
15895,,toxicities,,,,,,,,,,equal or better than 0.00,,,,,,
15896,,hepatitis c;|use of,,,,,,,,,,>400ml,,,,,,
15897,,abdominal hernia,,,,,,,,,,6 to 17 years inclusive,,,,,,
15898,,motor deficits,,,,,,,,,,<1.5x upper level of normal (uln),,,,,,
15899,,feet,,,,,,,,,,> 2.5 mg/dl,,,,,,
15900,,her2- breast cancer,,,,,,,,,,1.5×10^9/l,,,,,,
15901,,rectal wall,,,,,,,,,,>5% change,,,,,,
15902,,acute brain injury,,,,,,,,,,than or equal to 50% when,,,,,,
15903,,normal anatomy alteration,,,,,,,,,,≤1.6 mg/dl|total,,,,,,
15904,,germinal-center,,,,,,,,,,between levels i and ii,,,,,,
15905,,gastrointestinal obstruction,,,,,,,,,,≥55 years,,,,,,
15906,,functional net,,,,,,,,,,between 50.0 and 115.0 kg,,,,,,
15907,,signs of biliary obstruction.||,,,,,,,,,,at least 20 years,,,,,,
15908,,disc herniation causing s1,,,,,,,,,,>30 genes analyzed,,,,,,
15909,,familial combined hyperlipidemia,,,,,,,,,,≥18 and ≤70 years.|ability and willingness,,,,,,
15910,,pulmonary disorders,,,,,,,,,,≥ 2.8 mmol/l,,,,,,
15911,,hyperplasia,,,,,,,,,,≥45 kg,,,,,,
15912,,scc,,,,,,,,,,≥ 18 years|valid informed consent|patient information available,,,,,,
15913,,ice pick,,,,,,,,,,> 2x normal|age,,,,,,
15914,,uncontrollable infections,,,,,,,,,,≥ 90mmhg;|nyha,,,,,,
15915,,drug abuse;|systemic diseases judged by researchers,,,,,,,,,,< 30k,,,,,,
15916,,disc prolapse,,,,,,,,,,<0.1x109/l|primary cns,,,,,,
15917,,judged by the investigator to be unsuitable for continuing the research;|the subject does not adhere to the protocol,,,,,,,,,,greater than 120 mmhg,,,,,,
15918,,reversible factors;|left atrial appendage depth,,,,,,,,,,i-iii,,,,,,
15919,,criteria:||hunt-hess grade,,,,,,,,,,<10th centile,,,,,,
15920,,rth,,,,,,,,,,between 18 and 65 years,,,,,,
15921,,poor clinical control|pleural effusion,,,,,,,,,,< 12 months||•,,,,,,
15922,,hypertrophic scarring,,,,,,,,,,30 normal,,,,,,
15923,,acute pericarditis,,,,,,,,,,2-4,,,,,,
15924,,t2-t4an0m0 (ct/mr,,,,,,,,,,15-25,,,,,,
15925,,mentally handicapped.|contraindication,,,,,,,,,,1.60-1.90,,,,,,
15926,,gaming addiction|lack of,,,,,,,,,,< 40 ml/min/,,,,,,
15927,,free of disease,,,,,,,,,,≥ 18years.|ecog score,,,,,,
15928,,psychiatric disposition,,,,,,,,,,>35 inches,,,,,,
15929,,basic liver diseases,,,,,,,,,,21-45,,,,,,
15930,,signs of pneumonia,,,,,,,,,,less than 20/80,,,,,,
15931,,lewy body disease,,,,,,,,,,sign separate consent,,,,,,
15932,,cervical instability,,,,,,,,,,> 1*103,,,,,,
15933,,alcohol abuse.|moderate,,,,,,,,,,≥ 75×109/l;||biochemical examination,,,,,,
15934,,breastfeeding|substance abuse,,,,,,,,,,0-10)||,,,,,,
15935,,neck mobility)|nasal infection,,,,,,,,,,> 200 u/l,,,,,,
15936,,intracranial metastases,,,,,,,,,,< 18 years|currently pregnant|neutropenic,,,,,,
15937,,rv implantable cardiac device,,,,,,,,,,> grade 2.|hepatic insufficiency resulting,,,,,,
15938,,year|diagnosis,,,,,,,,,,6-15 months|voluntarily consented,,,,,,
15939,,sexual dysfunction,,,,,,,,,,<3000 cells/mm3|aspartate,,,,,,
15940,,lupus anticoagulants,,,,,,,,,,≥ 90mmhg,,,,,,
15941,,dermatofibrosarcoma protuberans,,,,,,,,,,≥ 1 week between each determination,,,,,,
15942,,digestive symptoms,,,,,,,,,,< 60 (ckd-epi).|systolic blood pressure,,,,,,
15943,,sclc,,,,,,,,,,35 and 43-47,,,,,,
15944,,gallbladder cancer,,,,,,,,,,between 18 and 65 years|free of pain,,,,,,
15945,,cardiovascular,,,,,,,,,,≥35 kg|study,,,,,,
15946,,cns disease|participants,,,,,,,,,,below or above 18 years|comorbidities like,,,,,,
15947,,non-melanoma carcinoma,,,,,,,,,,> 2x the,,,,,,
15948,,dental abscess,,,,,,,,,,>8% prior,,,,,,
15949,,arrthymia,,,,,,,,,,> 160 mg/dl,,,,,,
15950,,hard,,,,,,,,,,greater than or equal to 3,,,,,,
15951,,cns-2 involvement,,,,,,,,,,≥60 ml / min.|be,,,,,,
15952,,recreational use,,,,,,,,,,support.|refusal to participate|persons,,,,,,
15953,,fiducial markers,,,,,,,,,,19.0-26.0 kg/m 2 (inclusive),,,,,,
15954,,caseworker,,,,,,,,,,<100000/mm3);|severe,,,,,,
15955,,progressive cancer,,,,,,,,,,60 - 80 years,,,,,,
15956,,non-st-elevation myocardial infarction,,,,,,,,,,>23 kg/m2|hba1c %,,,,,,
15957,,solid tumor|phase 1 only,,,,,,,,,,> 1000 pg/ml|hs,,,,,,
15958,,allergy|heart disease,,,,,,,,,,4 mm or more,,,,,,
15959,,neurological lesions,,,,,,,,,,18 or older;||a,,,,,,
15960,,wilsons disease,,,,,,,,,,more than 350 µm,,,,,,
15961,,"immune disorders,|maintenance",,,,,,,,,,between 80 years old,,,,,,
15962,,metastatic cancer,,,,,,,,,,< 10 g/dl)|contraindication,,,,,,
15963,,hepatitis c virus antibodies,,,,,,,,,,<200 copies/ml obtained,,,,,,
15964,,medical condition;|patients,,,,,,,,,,= activated,,,,,,
15965,,another hp form,,,,,,,,,,≤ 450 msec,,,,,,
15966,,tracheostoma|cystic fibrosis|congestive heart failure,,,,,,,,,,>1.5x the upper limit of normal utilizing the cockcroft gault formula,,,,,,
15967,,systematic diseases,,,,,,,,,,50-85|alzheimer's disease diagnosis,,,,,,
15968,,seriously allergic,,,,,,,,,,1-2||,,,,,,
15969,,removable orthodontic appliance,,,,,,,,,,greater than 500 ms.|stage iii or higher chronic kidney disease.|history,,,,,,
15970,,"neurologic, malignancy",,,,,,,,,,younger than 18|nonpregnant,,,,,,
15971,,cholecystitis,,,,,,,,,,≤ 5 mm,,,,,,
15972,,hyperimmunized,,,,,,,,,,< 51 μmol/l,,,,,,
15973,,non-squamous cell carcinoma,,,,,,,,,,"40 or more,|provision",,,,,,
15974,,disease.|active malignancy,,,,,,,,,,1% per year,,,,,,
15975,,surgically sterile||,,,,,,,,,,0-1|absolute neutrophil count (,,,,,,
15976,,limited passive range of motion of the,,,,,,,,,,born < 37 weeks,,,,,,
15977,,cyst,,,,,,,,,,=< 50%,,,,,,
15978,,torsional ventricular tachycardia,,,,,,,,,,between 21 to 60 years|undergoing,,,,,,
15979,,abuse of alcohol,,,,,,,,,,≥ 70%|having,,,,,,
15980,,vascular invasion,,,,,,,,,,at least 12 weeks.|patients,,,,,,
15981,,hiv infection.|patients,,,,,,,,,,<3 x 109/l,,,,,,
15982,,neck,,,,,,,,,,≥ 50%;||women,,,,,,
15983,,acute salpingitis,,,,,,,,,,between 21-30|without,,,,,,
15984,,basal cell cancer,,,,,,,,,,60-90 years,,,,,,
15985,,pulpal involvement,,,,,,,,,,>45,,,,,,
15986,,platelet transfusion failure,,,,,,,,,,0-2|no,,,,,,
15987,,radical melanoma,,,,,,,,,,greater than three times the normal upper limit|patients,,,,,,
15988,,nodular pinguecula,,,,,,,,,,>15 µg/l,,,,,,
15989,,drug use disorder,,,,,,,,,,score of 3 or more,,,,,,
15990,,nonpainful disorders,,,,,,,,,,< 35/min,,,,,,
15991,,cardiac abnormality,,,,,,,,,,between 0.0 and 5.0,,,,,,
15992,,papillary muscle rupture,,,,,,,,,,between 5-12 years,,,,,,
15993,,carrying bags,,,,,,,,,,0-1;|at least one,,,,,,
15994,,bronchodilators,,,,,,,,,,≥ 3 points,,,,,,
15995,,endophthalmitis,,,,,,,,,,> 2.5 times the upper limit of normal values,,,,,,
15996,,extrahepatic metastases,,,,,,,,,,≤ 1.7 mg/dl||hepatic||bilirubin,,,,,,
15997,,respiratory illness||,,,,,,,,,,95-100.3,,,,,,
15998,,vestibulopathy,,,,,,,,,,>= 30 kg/m2|rural resident|english speaking|physician clearance to participate|able to walk,,,,,,
15999,,infectious upper airway diseases,,,,,,,,,,>21 units/week and >3/day;|reported,,,,,,
16000,,month|objective pathological performance,,,,,,,,,,ii-iv|6 min walk distance,,,,,,
16001,,third-stage copd,,,,,,,,,,≤ 3 × upper limit of normal (uln),,,,,,
16002,,renal artery occlusion,,,,,,,,,,years|pre-stroke,,,,,,
16003,,several symptoms,,,,,,,,,,18 to 26 years|playing,,,,,,
16004,,acute infectious illness,,,,,,,,,,18-38 years,,,,,,
16005,,sterilization (hysterectomy,,,,,,,,,,> 60 days from,,,,,,
16006,,shoulder problem,,,,,,,,,,15 or younger,,,,,,
16007,,criteria of dsm-5tr for psychosis,,,,,,,,,,grades i-iii|the score of mini mental state,,,,,,
16008,,unexplained weight loss,,,,,,,,,,more than 3 times the upper limit of normal,,,,,,
16009,,ptu,,,,,,,,,,< 470 msec,,,,,,
16010,,glaucoma family,,,,,,,,,,considered normal for age,,,,,,
16011,,lactating|active skin cancer,,,,,,,,,,1 to 6,,,,,,
16012,,self-injurious,,,,,,,,,,≥ stage ii,,,,,,
16013,,structural anomaly,,,,,,,,,,physician;|voluntary,,,,,,
16014,,toxic colitis,,,,,,,,,,<18 years|pregnancy|epilepsy|medication that reduces the seizure threshold,,,,,,
16015,,lactating.|heavy smokers,,,,,,,,,,< 20 or >80 years,,,,,,
16016,,liver metastases should,,,,,,,,,,<3.0 x103/μl|absolute,,,,,,
16017,,"sensory nerve action potential),|symptom duration of cts",,,,,,,,,,counts|life-threatening,,,,,,
16018,,kpa;|abnormal laboratory inspection indicators,,,,,,,,,,> 20|other,,,,,,
16019,,csc,,,,,,,,,,< 1800/mm3)|inability,,,,,,
16020,,autoimmune skin condition,,,,,,,,,,≥ 102 cm,,,,,,
16021,,hepatitis b core antibody [hbcab],,,,,,,,,,≥ 500 iu/ml.,,,,,,
16022,,device||double-barrier method,,,,,,,,,,≥ 1.|agreement,,,,,,
16023,,time.|skin disease,,,,,,,,,,</= 1.5 mg/dl|4,,,,,,
16024,,covid pneumonia,,,,,,,,,,≤2.5x normal,,,,,,
16025,,functional program.||,,,,,,,,,,2.5 g/dl).|creatinine ≤ 1.5 mg/dl,,,,,,
16026,,sinus arrest,,,,,,,,,,>12 years|obtaining informed consent from patients and/or from patients' parents,,,,,,
16027,,familial adenomatous polyposis (fap),,,,,,,,,,≤ 3.5 times uln,,,,,,
16028,,antisocial personality disorder,,,,,,,,,,1 and 2,,,,,,
16029,,internal carotid,,,,,,,,,,≥ 8.0%,,,,,,
16030,,hepatitis b (hbv) infection|participants,,,,,,,,,,between 6 and 59 months|have,,,,,,
16031,,pathogenic mutations,,,,,,,,,,>= 60%)|life expectancy,,,,,,
16032,,weeks|positive patellar compression test|pain intensity,,,,,,,,,,> 18 years|informed consent|willing to take part,,,,,,
16033,,end-organ failure conditions,,,,,,,,,,male|165 cm < x < 180,,,,,,
16034,,acne skin,,,,,,,,,,≤ 3 times uln,,,,,,
16035,,type 2 diabetics,,,,,,,,,,>= 5 days prior to study treatment,,,,,,
16036,,primary psychotic disorder,,,,,,,,,,≥ 20yrs,,,,,,
16037,,intolerance to eye drops used for pupillary dilation,,,,,,,,,,1.1 measurable target lesion;||the liver lesion,,,,,,
16038,,visible rash,,,,,,,,,,only)||under 18 years,,,,,,
16039,,exclusion criteria:||sleep apnea syndrome,,,,,,,,,,between 40 and 90 years||,,,,,,
16040,,inflammatory diseases,,,,,,,,,,>30 bmi <17,,,,,,
16041,,reproductive tract,,,,,,,,,,≥10% bsa,,,,,,
16042,,bronchial asthma|history,,,,,,,,,,">= 75,000/mm^3.||total",,,,,,
16043,,hospitalized covid-19,,,,,,,,,,<20 million motile sperm per,,,,,,
16044,,thrombocytopenia|ischemic stroke,,,,,,,,,,<140 mm hg,,,,,,
16045,,non-left main bifurcation lesion,,,,,,,,,,less than 1,,,,,,
16046,,breast feeding|woman,,,,,,,,,,>2 times the upper limits of normal,,,,,,
16047,,muscle mass,,,,,,,,,,≥ 3,,,,,,
16048,,in-situ cervical,,,,,,,,,,/ 50mg/dl,,,,,,
16049,,ductal in-situ breast cancer,,,,,,,,,,>=2).|current use,,,,,,
16050,,others:||malignant disease,,,,,,,,,,< 3 months|head injury|shift,,,,,,
16051,,good general health,,,,,,,,,,<30 g/l|blood flow,,,,,,
16052,,levels of anxiety,,,,,,,,,,< 18 years|head,,,,,,
16053,,in situ disease,,,,,,,,,,< 2.5 × uln,,,,,,
16054,,diabetes|preexisting,,,,,,,,,,greater than 200 cc initially,,,,,,
16055,,singular epileptic seizure,,,,,,,,,,≥ 30%,,,,,,
16056,,bipolar i disorder,,,,,,,,,,"0, 1,",,,,,,
16057,,light source,,,,,,,,,,>800 μg/day,,,,,,
16058,,myelodysplastic syndrome (mds),,,,,,,,,,>1500 pg/ml,,,,,,
16059,,achlorhydria,,,,,,,,,,18 years or greater.|willing and able to sign a written informed consent,,,,,,
16060,,tavi,,,,,,,,,,greater than equal to 600 pg/ml.|hospitalisation,,,,,,
16061,,mandatory.|symptoms,,,,,,,,,,> 130 beats per minute,,,,,,
16062,,cell death,,,,,,,,,,≥18 years.|a patient's,,,,,,
16063,,macular disease,,,,,,,,,,claudin 18.2 positive,,,,,,
16064,,nci ctcae,,,,,,,,,,200 mg/dl,,,,,,
16065,,disease by standard positron emission tomography,,,,,,,,,,≥ 3 mm,,,,,,
16066,,unhealed wound,,,,,,,,,,18 years or over.|patients,,,,,,
16067,,hiv||pregnant,,,,,,,,,,15 iu/ml,,,,,,
16068,,inadequate bowel cleanliness,,,,,,,,,,≤ 210 pg/ml|hematocrit,,,,,,
16069,,secondary infection,,,,,,,,,,1-3,,,,,,
16070,,visual impairment,,,,,,,,,,< 75 x103/mm3,,,,,,
16071,,primary tumor not,,,,,,,,,,examination;|agree to maintain the same skin care regimen,,,,,,
16072,,hmr,,,,,,,,,,≥ 175.|participants,,,,,,
16073,,passive range of motion,,,,,,,,,,≤ 2 mg/dl,,,,,,
16074,,regular menstrual,,,,,,,,,,30 to 70;|type 2 diabetes,,,,,,
16075,,*3)|scheduled for,,,,,,,,,,≥12mm,,,,,,
16076,,"lumbar disc herniation,||not having",,,,,,,,,,>=0.2 mg/kg/day,,,,,,
16077,,kimura disease,,,,,,,,,,year-old,,,,,,
16078,,drfs|multiple trauma,,,,,,,,,,0-18 years|the,,,,,,
16079,,dmdd,,,,,,,,,,lasting > 24 hours,,,,,,
16080,,unstable metabolic condition,,,,,,,,,,m 90 cm / f 80 cm,,,,,,
16081,,menstrual cycles,,,,,,,,,,=< 3.0 x uln|alkaline,,,,,,
16082,,intracranial tumor,,,,,,,,,,"greater than 18 years old, inclusive.|pathologically confirmed",,,,,,
16083,,diabetic neuropathy.|history of,,,,,,,,,,≥160 ml,,,,,,
16084,,substantive liver disease,,,,,,,,,,functional class iii or iv,,,,,,
16085,,primary gastrointestinal malignancy,,,,,,,,,,more than or equal to,,,,,,
16086,,hypertensive encephalopathy|hepatic encephalopathy,,,,,,,,,,trial|aged over 16,,,,,,
16087,,pancreaticoduodenal cancers,,,,,,,,,,18 to 85 years of age|unplanned ed visit,,,,,,
16088,,bilateral cataracts.|bilateral retinal vein,,,,,,,,,,> 0.38 m2.|all,,,,,,
16089,,intracranial pathology;|co-morbid disease,,,,,,,,,,< 10 x uln|serum,,,,,,
16090,,pathogenic ras mutation,,,,,,,,,,>185,,,,,,
16091,,contradicted to mri or tms,,,,,,,,,,≥ 80 cm||arterial,,,,,,
16092,,obstructive cardiomyopathy.|chronic anemia,,,,,,,,,,≥25% or the,,,,,,
16093,,alpha-1 antitrypsin deficiency,,,,,,,,,,> 250 msec,,,,,,
16094,,posterior staphyloma,,,,,,,,,,1 and ≤ 3,,,,,,
16095,,vagal reactions,,,,,,,,,,> 105,,,,,,
16096,,judged by the researcher to be unsuitable for surgery.|patients with severe,,,,,,,,,,3+ or ihc2+/in,,,,,,
16097,,iris neovascularization,,,,,,,,,,multiple myeloma;|3.according,,,,,,
16098,,frontotemporal disease,,,,,,,,,,250 ml),,,,,,
16099,,cough severity,,,,,,,,,,<3 days;|preoperative β-blocker,,,,,,
16100,,hla-a*02:05,,,,,,,,,,at least 3 mm,,,,,,
16101,,ischemia,,,,,,,,,,grade i-iii||6,,,,,,
16102,,olfactory dysfunction,,,,,,,,,,<18.5 kg/m2,,,,,,
16103,,neurodevelopmental delay,,,,,,,,,,≤ 2.5 × uln|alanine aminotransferase (alt),,,,,,
16104,,fertilized eggs,,,,,,,,,,higher than the detection limit of the analytical method,,,,,,
16105,,spinal cord injury,,,,,,,,,,50% or score,,,,,,
16106,,adenocarcinoma hpv-,,,,,,,,,,>2+)|subject experienced,,,,,,
16107,,claustrophobia|food allergies,,,,,,,,,,>= 1 week prior to study treatment|substrates of cyp3a4/5,,,,,,
16108,,winnipeg,,,,,,,,,,> 1.5 x unl associated,,,,,,
16109,,anterior choroidal,,,,,,,,,,1000 - 2500 grams|admitted,,,,,,
16110,,major stroke,,,,,,,,,,+ - 6,,,,,,
16111,,breast feeding.|in,,,,,,,,,,≤ 1.5 times the upper limit of normal value (uln),,,,,,
16112,,typhoid,,,,,,,,,,50% white american,,,,,,
16113,,"weeks,|acute cerebrovascular accident,|transfusion reaction,|severe",,,,,,,,,,"> 1,000 cells/mcl of blood.||",,,,,,
16114,,cancer in,,,,,,,,,,more than 75 years-old.|patient,,,,,,
16115,,days|preeclampsia,,,,,,,,,,more than 35 kg/m2.|patients,,,,,,
16116,,cardiac catheterization,,,,,,,,,,less than 18.0 kg/m2,,,,,,
16117,,months;|infectious diseases,,,,,,,,,,> 6 hours,,,,,,
16118,,ethnic minority,,,,,,,,,,≤1.5 x the institutional upper limit of normal (uln),,,,,,
16119,,vaccine reactions,,,,,,,,,,18 and over||,,,,,,
16120,,lower urinary tract pain,,,,,,,,,,18.5 to 30.0 kilogram per meter square (kg/m^2),,,,,,
16121,,rectal adenocarcinoma,,,,,,,,,,≥ 30|cushing,,,,,,
16122,,diseases|fresh cycle,,,,,,,,,,> 100 ml,,,,,,
16123,,metastatic disease,,,,,,,,,,not more than 1 line,,,,,,
16124,,femoral vein access,,,,,,,,,,6.5%,,,,,,
16125,,foreign body sensation,,,,,,,,,,≤ 1 or,,,,,,
16126,,bleeding lesions,,,,,,,,,,< 30 kg/m2,,,,,,
16127,,central corneas,,,,,,,,,,1-3|underwent,,,,,,
16128,,vascular insufficiency,,,,,,,,,,30.0-45.4,,,,,,
16129,,cough-variant asthma,,,,,,,,,,≤ 1.5 × institutional upper limit of normal (uln),,,,,,
16130,,amniotic fluid,,,,,,,,,,"> 20,000 x 109/l",,,,,,
16131,,hiv-negative||exclusion,,,,,,,,,,between 50-65 years,,,,,,
16132,,adjustment of their medication]|current,,,,,,,,,,< 29 ml/min/1.73m2,,,,,,
16133,,neurodegenerative disorder.|self-reported,,,,,,,,,,< 0.8,,,,,,
16134,,behavioral modification,,,,,,,,,,<70x109/l,,,,,,
16135,,alcohol overuse,,,,,,,,,,>110mmhg)|expected survival,,,,,,
16136,,dkd,,,,,,,,,,between 2.25 - 4.2 mm,,,,,,
16137,,treatment;|current active hepatitis;|hiv antibody,,,,,,,,,,<= 5mg,,,,,,
16138,,inflammatory bowel disease.|inability,,,,,,,,,,> 4.0mg/dl,,,,,,
16139,,intra-uterine growth restriction,,,,,,,,,,≥iv;|allergic to dexmedetomidine,,,,,,
16140,,alcohol abuse|regular consumption of,,,,,,,,,,0-2 points.||4,,,,,,
16141,,anaplastic lymphoma kinase (alk) fusion,,,,,,,,,,≥70 years old|attending,,,,,,
16142,,thyroiditis,,,,,,,,,,inpatient,,,,,,
16143,,vasculitis infectious diseases,,,,,,,,,,19 and 50 years,,,,,,
16144,,genital target lesion,,,,,,,,,,above 3 times the upper limit of normal,,,,,,
16145,,metal structures,,,,,,,,,,22 mm ocular.||esophagogastroduodenoscopies,,,,,,
16146,,impaired consciousness,,,,,,,,,,≥ 20 mg/100,,,,,,
16147,,acute coronary event,,,,,,,,,,≥60 years|being,,,,,,
16148,,guillain-barré syndrome.|behavioral,,,,,,,,,,≤ 8.0g/dl,,,,,,
16149,,' covid-19 disease,,,,,,,,,,between 50 and 60 the overall clinical evaluation,,,,,,
16150,,throat and neck surgery.|those assessed to have a,,,,,,,,,,> 200 ms|qrs duration,,,,,,
16151,,good condition,,,,,,,,,,0 to 1.|women,,,,,,
16152,,ventricular rhythm disorders,,,,,,,,,,under 30 kg|heparin allergy,,,,,,
16153,,vision disturbances|hematuria,,,,,,,,,,≥ 8 x 109/l||hepatic:||bilirubin ≤ 1.5 x upper limit of normal,,,,,,
16154,,neurological disorders|preexisting peripheral neuropathy|prior,,,,,,,,,,= 0).|patient able,,,,,,
16155,,irritated,,,,,,,,,,≤ 24,,,,,,
16156,,tumour for injection is located adjacent to the jugular vein).|are,,,,,,,,,,14-19 years).|participants must work,,,,,,
16157,,4|active liver disease,,,,,,,,,,less than 20/20|unable to follow visitors,,,,,,
16158,,lymphoproliferative disorder,,,,,,,,,,greater than the upper limit of normal,,,,,,
16159,,covid-19 symptoms,,,,,,,,,,thicker than 10 mm,,,,,,
16160,,pain group:||recent injury,,,,,,,,,,1 or 2|patient,,,,,,
16161,,liver cancer|scheduled,,,,,,,,,,hba1c>7.5 %,,,,,,
16162,,familial prolonged qt syndrome,,,,,,,,,,18 and 80 years old,,,,,,
16163,,gh,,,,,,,,,,at least 1 mm,,,,,,
16164,,memory complaints|demanding clinical consultation,,,,,,,,,,1 - 4||,,,,,,
16165,,leaflets;|lack of,,,,,,,,,,more than 5 folds.|pregnant ladies,,,,,,
16166,,pulp bleeding,,,,,,,,,,13.0-17.7 g/dl).|individual,,,,,,
16167,,disease that,,,,,,,,,,<3.0 cm,,,,,,
16168,,retardation,,,,,,,,,,≥18 years|informed consent,,,,,,
16169,,arterial system,,,,,,,,,,> 30kg/m².|any psychological,,,,,,
16170,,included)||definition of refractory:||no response,,,,,,,,,,≥25 mbps downloads,,,,,,
16171,,pituitary adenomas,,,,,,,,,,>= 70 ml/min/1.73 m^2||or -,,,,,,
16172,,heart surgery|oncological diseases,,,,,,,,,,≥30;|the,,,,,,
16173,,penetrating,,,,,,,,,,10g/dl,,,,,,
16174,,arthropathies,,,,,,,,,,18-25 years,,,,,,
16175,,intrahepatic lesion,,,,,,,,,,≥18 years|body mass index,,,,,,
16176,,halitosis,,,,,,,,,,<6 months 2,,,,,,
16177,,esophageal varicose veins,,,,,,,,,,> 30 mg/mmol|current,,,,,,
16178,,promotional reasons,,,,,,,,,,>12,,,,,,
16179,,health issues,,,,,,,,,,<30|female patients,,,,,,
16180,,distant metastasis;|tumors,,,,,,,,,,i - ii|patient,,,,,,
16181,,abnormal anemia,,,,,,,,,,< 50m,,,,,,
16182,,rapid atrial fibrillation,,,,,,,,,,0 to 2|10.ability to understand and willingness to sign,,,,,,
16183,,coats disease,,,,,,,,,,≥ 0.75×10^9/l,,,,,,
16184,,thin film|p. falciparum parasitemia,,,,,,,,,,4-18,,,,,,
16185,,calculated using the,,,,,,,,,,18-49 years.|mildly,,,,,,
16186,,positivity by fish,,,,,,,,,,≥ 85 mmhg|hip circumference,,,,,,
16187,,coeliac disease (cd),,,,,,,,,,<8.5 hours,,,,,,
16188,,permanently sterile,,,,,,,,,,minimum score 24,,,,,,
16189,,performing the block,,,,,,,,,,>= 12 weeks||h,,,,,,
16190,,liver function impairment|pregnancy,,,,,,,,,,> 30ml/min,,,,,,
16191,,anti angina drugs,,,,,,,,,,less than 30 times/minute,,,,,,
16192,,intestinal hypoperfusion,,,,,,,,,,<18.5 kg/m2);|intelligence,,,,,,
16193,,initial,,,,,,,,,,≥ 75 × 109/l.|eastern,,,,,,
16194,,endothelial dysfunction,,,,,,,,,,stage 3/4.|evidence,,,,,,
16195,,solid organ||age||1,,,,,,,,,,than at least,,,,,,
16196,,breast-feeding.|known allergy to study medication.|benzodiazepine,,,,,,,,,,> 35).|chronic inflammatory orthopedic disorders,,,,,,
16197,,technical assistance.|medical advice indicating,,,,,,,,,,≥ 37.3°c,,,,,,
16198,,lightheadedness,,,,,,,,,,between 18 to 75 years|normal,,,,,,
16199,,6 months|angina pectoris,,,,,,,,,,> 7 mmol,,,,,,
16200,,human epidermal growth factor receptor 2 (her2),,,,,,,,,,<50 rna copies/ml,,,,,,
16201,,cervical disc disorders|tumor|fibromyalgia|mental,,,,,,,,,,4 (ctla-4) inhibition therapy.||participants,,,,,,
16202,,distal sigmoid colon,,,,,,,,,,≥9g/dl);|liver function test,,,,,,
16203,,hypertensive urgency,,,,,,,,,,≥ 20 x 109/l f,,,,,,
16204,,peripheral neuropathy|liver disease,,,,,,,,,,≥19 years and <75,,,,,,
16205,,partial bone healing,,,,,,,,,,> 3.5 mm,,,,,,
16206,,cognitively-unimpaired,,,,,,,,,,less than 12 years old,,,,,,
16207,,"infection,|acute pancreatitis",,,,,,,,,,over 18 years||,,,,,,
16208,,secondary sclerosing cholangitis,,,,,,,,,,i-ii group|6 months to 7 years,,,,,,
16209,,water;|pulmonary edema,,,,,,,,,,greater than or equal to 2 minutes,,,,,,
16210,,urine protein.||sexually,,,,,,,,,,≥ 18 years||patients,,,,,,
16211,,paresthesia,,,,,,,,,,long term support,,,,,,
16212,,glioblastoma,,,,,,,,,,requires specific and,,,,,,
16213,,digestive tract tumors.|participants,,,,,,,,,,<59 ml/minute/1.73m2,,,,,,
16214,,pahang.|age between 20 - 65 years,,,,,,,,,,> 90 or < 50 beats per minute,,,,,,
16215,,investigator.|active bleeding disorder,,,,,,,,,,exceed the upper limit of the reference value,,,,,,
16216,,braf,,,,,,,,,,iv 2g/day,,,,,,
16217,,bacterial vaginosis,,,,,,,,,,< 24 months age,,,,,,
16218,,chronic perforation,,,,,,,,,,after 37 weeks,,,,,,
16219,,psychiatric hospitalization|active suicidal ideation,,,,,,,,,,18 to 40 kg/m^2 inclusive,,,,,,
16220,,clinician|stable disease,,,,,,,,,,less than 13 6/7 weeks,,,,,,
16221,,clusion,,,,,,,,,,less than 6 weeks,,,,,,
16222,,hcm,,,,,,,,,,18 years or older|confirmed,,,,,,
16223,,tacrolimus /mycophenolate,,,,,,,,,,≤ 5 × uln)|serum,,,,,,
16224,,caffeinated drinks,,,,,,,,,,≥ 90g/l).||note,,,,,,
16225,,dressing change.||,,,,,,,,,,0-1|for intervention arm only,,,,,,
16226,,index site,,,,,,,,,,< 0.|pregnancy|known,,,,,,
16227,,glycemia,,,,,,,,,,>18 years)|basic knowledge,,,,,,
16228,,mixed types,,,,,,,,,,>= 5.6 mmol/l(within 14 days of registration)||criteria must be,,,,,,
16229,,intraarticular hip pathology.|hip pain,,,,,,,,,,< 60);|patients,,,,,,
16230,,femoral neck fracture,,,,,,,,,,<24 hours prior to day 1 of treatment.|contraindication to mri,,,,,,
16231,,gastroschisis,,,,,,,,,,≥ 18 years|plan to obtain the majority,,,,,,
16232,,cognitive delay,,,,,,,,,,< 10 g/dl);|thrombocytopenia,,,,,,
16233,,acute cardiac condition,,,,,,,,,,greater than or equal to 5,,,,,,
16234,,sores,,,,,,,,,,18+ years|hiv-positive|hospitalized,,,,,,
16235,,radioactive tracer,,,,,,,,,,than 2cm,,,,,,
16236,,submucosal invasion,,,,,,,,,,55-75,,,,,,
16237,,those with claudication,,,,,,,,,,<50 bpm,,,,,,
16238,,delayed cutaneous reaction,,,,,,,,,,20 to 39 years,,,,,,
16239,,reverse shoulder arthroplasty,,,,,,,,,,7-30 days after injury|injury level,,,,,,
16240,,extracardiac arteriopathy,,,,,,,,,,equal and over 17,,,,,,
16241,,cardinal symptoms,,,,,,,,,,18-45 years|primipara,,,,,,
16242,,breast cancer t1-t2.|clinically n0.|macrometastasis,,,,,,,,,,> 60 or < 100 (bpm),,,,,,
16243,,renal dysfunction|patients,,,,,,,,,,>2.5×uln,,,,,,
16244,,tachycardia/heart rhythm disorders|individuals,,,,,,,,,,≥ 18 to ≤ 70 years,,,,,,
16245,,ssas,,,,,,,,,,≥ 14 mmhg,,,,,,
16246,,cycle;|malignant tumors,,,,,,,,,,grade 1 status,,,,,,
16247,,mixed aetiology,,,,,,,,,,> 3.|failure,,,,,,
16248,,immunodeficiency disease,,,,,,,,,,≥8% or hba1c,,,,,,
16249,,squamous cell carcinoma of the skin.|the,,,,,,,,,,< llod).||has positive,,,,,,
16250,,breakthrough,,,,,,,,,,> 10 mg/day,,,,,,
16251,,adjustable rings,,,,,,,,,,≥50ml/min,,,,,,
16252,,intracranial target lesion,,,,,,,,,,> 12 iu/ml,,,,,,
16253,,physical harm,,,,,,,,,,between 18 and 67 years,,,,,,
16254,,solid-organ transplant,,,,,,,,,,23 or higher,,,,,,
16255,,acute myocardial infarction.|at lowest,,,,,,,,,,< 1% marrow blasts,,,,,,
16256,,language troubles|disability,,,,,,,,,,mental disorders.||the,,,,,,
16257,,non-english speakers,,,,,,,,,,< 500 cells/µl,,,,,,
16258,,associated issues,,,,,,,,,,">= 100,000/mm^3|registration",,,,,,
16259,,immunomodulatory effects,,,,,,,,,,≥350 cells/µl,,,,,,
16260,,acute myelocytic leukemia(aml,,,,,,,,,,>250)|having,,,,,,
16261,,diabetic neuropathy,,,,,,,,,,ii-iva.|the patient,,,,,,
16262,,h02,,,,,,,,,,≥45 kg.||,,,,,,
16263,,correct,,,,,,,,,,≥ 135 g/l,,,,,,
16264,,limb.|significant renal,,,,,,,,,,≤ 2||,,,,,,
16265,,serous intercurrent illness,,,,,,,,,,>1 10^9/l|platelet count,,,,,,
16266,,pid,,,,,,,,,,> 0.676)|able,,,,,,
16267,,neurological symptoms suggestive of,,,,,,,,,,<50y|age >80y|bmi <=18 & >=30|recorded diagnosis,,,,,,
16268,,mmrp,,,,,,,,,,over eighteen years,,,,,,
16269,,hypersensitivity.||pregnant,,,,,,,,,,≤ 4|patients,,,,,,
16270,,standard chemotherapy;|relapse,,,,,,,,,,18 to 65 year,,,,,,
16271,,hereditary cancer syndromes,,,,,,,,,,18-65|having,,,,,,
16272,,diabetic cataract|underwent cataract surgery||,,,,,,,,,,<30 ml/min./1.73m2,,,,,,
16273,,tumor pain,,,,,,,,,,1 line of treatment,,,,,,
16274,,positive diagnosis,,,,,,,,,,≥ 100 × 109/l.||adequate,,,,,,
16275,,sickness|epileptic insults,,,,,,,,,,≥ 9.0 g/dl.||adequate,,,,,,
16276,,oncological pathology,,,,,,,,,,>248 db/m,,,,,,
16277,,bleeding diathesis.|the,,,,,,,,,,≤ 5 × uln);|total bilirubin (tbil),,,,,,
16278,,tympanic membrane disorders,,,,,,,,,,18 years of age,,,,,,
16279,,been menopausal,,,,,,,,,,0-1|no,,,,,,
16280,,since initial injury,,,,,,,,,,≥ 1.5×uln;|history of,,,,,,
16281,,brain metastases.|he,,,,,,,,,,discharge;|more than 40,,,,,,
16282,,collateral circulation,,,,,,,,,,13 to 19 years (inclusive),,,,,,
16283,,tunnel syndrome,,,,,,,,,,at least seven,,,,,,
16284,,modifying the pain threshold,,,,,,,,,,≥ 18.0 kg/m2,,,,,,
16285,,absorb oral medication.||additional inclusion criteria,,,,,,,,,,b-positive,,,,,,
16286,,cerebrovascular diseases,,,,,,,,,,8-16 pounds,,,,,,
16287,,withdrawn from that study)|inability to provide informed consent,,,,,,,,,,< 100×10^9 / l|patients,,,,,,
16288,,solid tumors,,,,,,,,,,between 60 and 75 y inclusive|bmi,,,,,,
16289,,ectopic pregnancy,,,,,,,,,,more than 37°c,,,,,,
16290,,loss of sense,,,,,,,,,,>1cm,,,,,,
16291,,episodes of bowel incontinence,,,,,,,,,,18 years old or above when they signed the informed consent,,,,,,
16292,,neurological disorders|or inability to understand the task,,,,,,,,,,≤ 1.5 times upper limit of normal (uln),,,,,,
16293,,illiterate|cannot pass,,,,,,,,,,<7.5 mmol/l,,,,,,
16294,,m. djamil,,,,,,,,,,16 ≤ easi,,,,,,
16295,,dietary habbits|weight stable,,,,,,,,,,> 40 kg m2,,,,,,
16296,,recurrence of leukemia,,,,,,,,,,20 - 40 mg + ezetimibe 10mg,,,,,,
16297,,cholestasis of pregnancy,,,,,,,,,,> 2.5 mm,,,,,,
16298,,end-stage cancer)|written informed consent obtained from the subject and/or the subject's legally authorized representative (lar),,,,,,,,,,21 to 75 years old|able,,,,,,
16299,,repetitive ventricular arrhythmias,,,,,,,,,,< 30mmhg,,,,,,
16300,,screening.|allergic constitution,,,,,,,,,,50 to 90 millimetre of mercury,,,,,,
16301,,anticoagulation||xii,,,,,,,,,,≤ 2|3,,,,,,
16302,,ii;|symptomatic urinary tract,,,,,,,,,,>85 g/l);||,,,,,,
16303,,myocardial infarction|insufficient mental,,,,,,,,,,< 50 × 109/l);|patients,,,,,,
16304,,angina,,,,,,,,,,< 3 months)|severe cognitive,,,,,,
16305,,criteria outlined,,,,,,,,,,less than 90 days,,,,,,
16306,,cognitively intact,,,,,,,,,,between 25 and 50 years|patients,,,,,,
16307,,amyloidosis,,,,,,,,,,does not need,,,,,,
16308,,malignancy|varices bleeding,,,,,,,,,,more than 2/4|history,,,,,,
16309,,elbow pain,,,,,,,,,,≥ 32,,,,,,
16310,,pathological origin|sudden cardiac arrest|documented,,,,,,,,,,<=140,,,,,,
16311,,technical challenges,,,,,,,,,,> 45|current use,,,,,,
16312,,orthostasis,,,,,,,,,,6000-12000u,,,,,,
16313,,diseases,,,,,,,,,,i-ii;|sign the informed consent form.||,,,,,,
16314,,chronic liver diseases,,,,,,,,,,≤ 1.5x institutional uln,,,,,,
16315,,rhinovirus,,,,,,,,,,< 18.5 kg/m2,,,,,,
16316,,premature ventricular contractions (pvcs),,,,,,,,,,> 120 beats/min,,,,,,
16317,,vascular complication,,,,,,,,,,>= 35 mg/dl,,,,,,
16318,,mild rv dysfunction,,,,,,,,,,≥40 kg/m2,,,,,,
16319,,heart rhythms,,,,,,,,,,between 18.0 and 29.9 kg/m²,,,,,,
16320,,melancholy features,,,,,,,,,,≥ 40 kg/,,,,,,
16321,,glaucoma tube shunts,,,,,,,,,,"score of more than 3,|able",,,,,,
16322,,c-cell,,,,,,,,,,<140 k/mm3|hemoglobin,,,,,,
16323,,syndrome.|active ocular conditions,,,,,,,,,,ii-iii)|stable,,,,,,
16324,,transient symptoms,,,,,,,,,,lasting <96 hours in duration,,,,,,
16325,,criteria|myocardial infarction,,,,,,,,,,between 18 months,,,,,,
16326,,renal impairment subjects||30,,,,,,,,,,18 years and older on the day of signing the informed consent.|a signed informed consent,,,,,,
16327,,drugs|acute liver disease,,,,,,,,,,between 1/1/2010,,,,,,
16328,,bone marrow leukemia,,,,,,,,,,≤ 2.5 times the upper limit of normal.|serum bilirubin ≤ 1.5 times the upper limit of normal,,,,,,
16329,,intracranial hemorrhagic diseases,,,,,,,,,,25 miu/ml,,,,,,
16330,,treatment|pulmonary disease,,,,,,,,,,≥48 mmol/mol,,,,,,
16331,,retinal,,,,,,,,,,incarceration|under 18 years,,,,,,
16332,,recreational drugs|medical treatment,,,,,,,,,,12 weeks,,,,,,
16333,,chronic hemophilia arthritis,,,,,,,,,,> 1500/mm3.|platelet count,,,,,,
16334,,thrombin time>21s,,,,,,,,,,≥ 18 years|age ≤ 75 years|hecsi ≥ 18,,,,,,
16335,,inflammatory joint disorders,,,,,,,,,,~ 30 kg/m^2|subjects,,,,,,
16336,,pancreatic head,,,,,,,,,,18 years and older|the diagnosis,,,,,,
16337,,sds,,,,,,,,,,12-17,,,,,,
16338,,good stereoscopic fundus photography|retinal thickness,,,,,,,,,,18 years and above;|(c,,,,,,
16339,,ischemic brain lesion,,,,,,,,,,<4 weeks)|current/past,,,,,,
16340,,indeterminate colitis,,,,,,,,,,<40 ml/min,,,,,,
16341,,infections causing bacteremia,,,,,,,,,,> 24h|patients,,,,,,
16342,,extradural hemorrhage,,,,,,,,,,i-iii|between,,,,,,
16343,,cushing's disease.|fracture,,,,,,,,,,≥ 600 ng,,,,,,
16344,,neurologic music,,,,,,,,,,0-3|interested,,,,,,
16345,,hypertrophic rhinitis,,,,,,,,,,between eighteen to fifty years,,,,,,
16346,,controlled psychiatric conditions,,,,,,,,,,"20,000/mm3- 50,000/mm3",,,,,,
16347,,between leukapheresis,,,,,,,,,,between 0 and 5,,,,,,
16348,,cerebellar tonsillar hernia|severe atlantoaxial dislocation|osteochondroplastica|rheumatoid arthritis|down syndrome|refurbished,,,,,,,,,,>= 60 ml/min.||participants,,,,,,
16349,,venous thromboembolic event,,,,,,,,,,18 years or older|non-anomalous singleton gestation|gestational diabetes type,,,,,,
16350,,incidental smoking,,,,,,,,,,19-75 years|symptoms,,,,,,
16351,,previews scars|infections|anemia,,,,,,,,,,65 and above|currently,,,,,,
16352,,asphyxia,,,,,,,,,,≤ 16 years,,,,,,
16353,,tumor|neurological disease,,,,,,,,,,<35 kg/m2|must,,,,,,
16354,,non-melanoma skin carcinomas,,,,,,,,,,greater than 2 times the upper limit of normal);|18,,,,,,
16355,,type of catheterization,,,,,,,,,,"21 to 65 years inclusive.|for part 1,",,,,,,
16356,,pulmonary hypertension|over,,,,,,,,,,grade 2 or higher,,,,,,
16357,,non-orthopaedic trauma.|other condition,,,,,,,,,,≥ 4.0 mm,,,,,,
16358,,medicine clinic,,,,,,,,,,6-15-month-,,,,,,
16359,,wrist fractures,,,,,,,,,,≥40 kg/,,,,,,
16360,,≥8 days|have,,,,,,,,,,18 or older|willing to provide informed consent|histologically,,,,,,
16361,,pharmacologically treated,,,,,,,,,,> 1.5 × uln.||coagulation,,,,,,
16362,,skin fragility,,,,,,,,,,equal or higher level than the,,,,,,
16363,,circulatory system,,,,,,,,,,> 60,,,,,,
16364,,reversible ischemic neurological deficit,,,,,,,,,,20 to 40 year,,,,,,
16365,,incised injury,,,,,,,,,,≥21 to 50 years,,,,,,
16366,,benign,,,,,,,,,,at least 2 ng/ml,,,,,,
16367,,more|vaginal bleeding,,,,,,,,,,> 0.3 mcg/kg/min,,,,,,
16368,,cancer therapeutic modalities,,,,,,,,,,at least 1 measurable,,,,,,
16369,,removable,,,,,,,,,,>8.5|known,,,,,,
16370,,arteriovenous bleeding,,,,,,,,,,18-30 kg/m2,,,,,,
16371,,major hepatic,,,,,,,,,,> ii|inability to speak,,,,,,
16372,,fast heart rate,,,,,,,,,,8-13 years|children whose parents/guardians,,,,,,
16373,,buccal bone wall loss,,,,,,,,,,> 45 ml/minute,,,,,,
16374,,old|abscence,,,,,,,,,,"≥ 1,500 / mm3;|platelet count",,,,,,
16375,,myocarditis|myocardial ischemia,,,,,,,,,,≥ 17,,,,,,
16376,,cautery,,,,,,,,,,<2000g).|use,,,,,,
16377,,primary caregiver.|diagnosis,,,,,,,,,,> 2+ tr|aortic valve disease,,,,,,
16378,,2:||healthy,,,,,,,,,,under 18-year,,,,,,
16379,,drug abuse|active malignancy|acute infection,,,,,,,,,,equal or more than 2 u/kg/day|total,,,,,,
16380,,squatting,,,,,,,,,,=< 1|life expectancy,,,,,,
16381,,essential hypertension,,,,,,,,,,≥192 pg/ml,,,,,,
16382,,eec g1,,,,,,,,,,>200/μl)|known,,,,,,
16383,,hearing disorder,,,,,,,,,,0 -1.||locally advanced,,,,,,
16384,,traditional chinese medicine treatment,,,,,,,,,,repair)|age 18 years,,,,,,
16385,,stage diseases,,,,,,,,,,≥ 25%,,,,,,
16386,,cerebral herniation syndrome,,,,,,,,,,=< 2.0 x uln,,,,,,
16387,,arthritis);|diagnoses,,,,,,,,,,evaluated,,,,,,
16388,,incompetent cervix,,,,,,,,,,> 18 and < 70 years|ready,,,,,,
16389,,serological immunity,,,,,,,,,,≥ 90 diastolic mmhg,,,,,,
16390,,anabolic-androgenic steroids,,,,,,,,,,+/- 10 lb,,,,,,
16391,,oncogenic pik3ca,,,,,,,,,,≥18 years 2,,,,,,
16392,,squamous cell skin cancers,,,,,,,,,,between 01 january 2022 and 31 december 2022 (population a,,,,,,
16393,,familial hyperplastic,,,,,,,,,,voiding diary.|individual gives written informed,,,,,,
16394,,criteria of the american academy of neurology||,,,,,,,,,,< 21 mm hg,,,,,,
16395,,eclampsia,,,,,,,,,,18-65|having alarm symptoms,,,,,,
16396,,juvenile dermatomyositis,,,,,,,,,,18-65 years|with,,,,,,
16397,,megacolon,,,,,,,,,,> 400 mg/dl|dialysis treatment,,,,,,
16398,,type 2 diabetes|concurrent treatment,,,,,,,,,,more than 1.1 mg/dl,,,,,,
16399,,teratogenic effects * therefore,,,,,,,,,,>20mm hg systolic,,,,,,
16400,,end organ hypoperfusion,,,,,,,,,,greater than 140,,,,,,
16401,,guillain-barré syndrome|diagnosis,,,,,,,,,,25-35 day cycle length,,,,,,
16402,,coagulation disorder|hypertensive crisis,,,,,,,,,,>grade 3,,,,,,
16403,,tongue cancer,,,,,,,,,,≥ii)|valvular heart disease,,,,,,
16404,,movement disorder,,,,,,,,,,<100 mmhg,,,,,,
16405,,stroke|intracranial hypertension,,,,,,,,,,≥35 at,,,,,,
16406,,progressive peripheral vascular disease,,,,,,,,,,minimum 50%,,,,,,
16407,,extensive intestinal resection,,,,,,,,,,long diameter ≥ 10mm,,,,,,
16408,,hae,,,,,,,,,,18 and 65 years inclusive,,,,,,
16409,,skin diseases,,,,,,,,,,</=,,,,,,
16410,,mesothelioma,,,,,,,,,,>4 times the upper limit of normal,,,,,,
16411,,psychiatric pathology.|rheumatic pathology,,,,,,,,,,</= 1.5 kg;|non continuous,,,,,,
16412,,generalized joint hypermobility,,,,,,,,,,unless,,,,,,
16413,,chronic obstructive pulmonary disease|lung,,,,,,,,,,colonic adenocarcinoma|patient 18 to 90 years,,,,,,
16414,,responsible for pain,,,,,,,,,,< 2.0 × uln)|serum,,,,,,
16415,,arterial revascularization|stroke|tia|peripheral arterial disease,,,,,,,,,,≥95 g/m2,,,,,,
16416,,pathological findings;|bone metastasis,,,,,,,,,,>3 times/week)|alcohol abuse,,,,,,
16417,,acute myocardial infarction.|traumatic brain injuries,,,,,,,,,,>= 13.0 years,,,,,,
16418,,hypoglycemia episodes,,,,,,,,,,=< 2x institutional upper limit of normal (uln),,,,,,
16419,,fistulas,,,,,,,,,,≤ 5 times institutional upper limits of normal,,,,,,
16420,,distorted nasal anatomy,,,,,,,,,,years|karnofsky,,,,,,
16421,,infection of the patient|the,,,,,,,,,,< 5.7 mm,,,,,,
16422,,sdec,,,,,,,,,,exceeding 3 times the upper limit of normal,,,,,,
16423,,third of the territory of the middle cerebral artery,,,,,,,,,,=< 2 x institutional upper limit of normal (uln),,,,,,
16424,,urticaria vasculitis,,,,,,,,,,>40 kg/,,,,,,
16425,,angiosarcomas,,,,,,,,,,"stones,|smaller than 10 mm",,,,,,
16426,,vaginal delivery|single healthy,,,,,,,,,,between 18.0-26.0 kg/m2,,,,,,
16427,,common iliac veins,,,,,,,,,,1 = 30 january 2023,,,,,,
16428,,residual cancer,,,,,,,,,,35.4-37.7 °c,,,,,,
16429,,chronic inflammatory disease,,,,,,,,,,< 190/110 mmhg,,,,,,
16430,,tuberculosis (tb),,,,,,,,,,0 to 1|adequate organ,,,,,,
16431,,oscc,,,,,,,,,,>9 had,,,,,,
16432,,student of the investigational site)|subjects,,,,,,,,,,+/- surgery,,,,,,
16433,,bilateral neck rt.|patients,,,,,,,,,,"at least 18 years,|neurologist",,,,,,
16434,,cancer / chemotherapy,,,,,,,,,,≥37.3℃/ mouth temperature ≥37.5℃);|a,,,,,,
16435,,dementia|clinical dementia rating,,,,,,,,,,<1.0 meter/sec)||,,,,,,
16436,,vision capabilities,,,,,,,,,,90 to 150 mm hg,,,,,,
16437,,homicidality|inability,,,,,,,,,,greater than or equal to 6.5%.|people can understand the research process,,,,,,
16438,,functional classification.|previous malignancy,,,,,,,,,,above 6.0%|random plasma glucose,,,,,,
16439,,cancer|patients,,,,,,,,,,<30 mls/min/1.73m2|active,,,,,,
16440,,ulcertive colitis,,,,,,,,,,15 or greater,,,,,,
16441,,seizure|liver failure|dyslipidemia|congenital coagulopathies,,,,,,,,,,< 50,,,,,,
16442,,renal disease|pregnancy,,,,,,,,,,≥40,,,,,,
16443,,renal mass core biopsy,,,,,,,,,,70 years or older,,,,,,
16444,,cardiovascular risk factors,,,,,,,,,,≥ 8 and < 20,,,,,,
16445,,secondary diabetes|conditions,,,,,,,,,,above 40 units per litre,,,,,,
16446,,psychosocial health,,,,,,,,,,2.5 g/dl)|for,,,,,,
16447,,substantial disability,,,,,,,,,,7-16 months,,,,,,
16448,,nonischemic heart disease,,,,,,,,,,≥ 0 mm|normal,,,,,,
16449,,brain tumor|patients,,,,,,,,,,between 18 and 45 years,,,,,,
16450,,squamous cell carcinoma of,,,,,,,,,,between 2-16 years,,,,,,
16451,,cardiac arrythmia,,,,,,,,,,≥12 weeks.||patients,,,,,,
16452,,immunosuppressants|neutropenia,,,,,,,,,,between 9,,,,,,
16453,,fruit juice beverages,,,,,,,,,,≥ 305,,,,,,
16454,,recorded,,,,,,,,,,≥ 3 months|at least one,,,,,,
16455,,available surgical specimens,,,,,,,,,,>= 1.5 x 10^9/l hemoglobin,,,,,,
16456,,fracture neck of the 2nd,,,,,,,,,,≤ 1.5 x institutional uln,,,,,,
16457,,somatic pathology|the,,,,,,,,,,>1.5 mm2,,,,,,
16458,,c.|active infection,,,,,,,,,,≥1.1mg/dl,,,,,,
16459,,recurrent seizures,,,,,,,,,,a or b,,,,,,
16460,,dominant lesion,,,,,,,,,,? the,,,,,,
16461,,marks,,,,,,,,,,16-30years)|male traceurs|parkour,,,,,,
16462,,clinical workflow.|diagnostic radiologists,,,,,,,,,,≥ 3.|≥10% body surface area (,,,,,,
16463,,disease;|cardiomyopathy developed,,,,,,,,,,≥ 250 mg/dl,,,,,,
16464,,local cardiologist.|women,,,,,,,,,,≥140 and <180 mmhg|at 4 weeks from,,,,,,
16465,,arrhythmic events,,,,,,,,,,< 30 kg/m2.|volunteers,,,,,,
16466,,acute psychotic symptoms,,,,,,,,,,1-3a,,,,,,
16467,,dementia,,,,,,,,,,350 mcg/min.|severe,,,,,,
16468,,icd,,,,,,,,,,">11,1 mmol/l",,,,,,
16469,,distal esophageal mucosal areas,,,,,,,,,,<18 years|if,,,,,,
16470,,hypothyroidism.|those,,,,,,,,,,worse than or equal to minus,,,,,,
16471,,nerve excision,,,,,,,,,,>=3,,,,,,
16472,,prandial insulin|pregnancy,,,,,,,,,,>100 mmhg;|stroke,,,,,,
16473,,palliative therapy||additional criteria,,,,,,,,,,35 kg/m2,,,,,,
16474,,sacroiliac syndrome,,,,,,,,,,0-1;|(e,,,,,,
16475,,non-agar-based method,,,,,,,,,,≥25.0 kg/m2,,,,,,
16476,,secondary diabetes,,,,,,,,,,greater than equal to 3,,,,,,
16477,,bladder functions,,,,,,,,,,> 90 mmhg diastolic,,,,,,
16478,,invasive cancer cells,,,,,,,,,,≥35 years,,,,,,
16479,,sarcomatoid hepatocellular carcinoma,,,,,,,,,,<3000/mm3,,,,,,
16480,,tumor dna,,,,,,,,,,8-11 years,,,,,,
16481,,intravenous iron,,,,,,,,,,> 18|ischemic stroke|pre-stroke independence|sufficient,,,,,,
16482,,high myopia,,,,,,,,,,between 3-17 years,,,,,,
16483,,chronic upper abdominal pain,,,,,,,,,,between 7.4mm,,,,,,
16484,,traumatism,,,,,,,,,,24-28 gestational weeks|singleton pregnancy|without,,,,,,
16485,,months;|the main organs function well,,,,,,,,,,18 and above who can provide,,,,,,
16486,,substance withdrawal,,,,,,,,,,8-12|not,,,,,,
16487,,cardiac color ultrasound,,,,,,,,,,15 weeks.||mentor inclusion,,,,,,
16488,,infection;|insufficient,,,,,,,,,,≤ 25 mg/dl|creatinine,,,,,,
16489,,sensory disorders,,,,,,,,,,<90 g/l;|renal,,,,,,
16490,,physically independent.||stage,,,,,,,,,,= 3mm,,,,,,
16491,,myocardial infarction);|revascularisation surgery,,,,,,,,,,more than 24h,,,,,,
16492,,hypoperfusion,,,,,,,,,,< 85|patients who do,,,,,,
16493,,evaluable disease,,,,,,,,,,fewer than 5 medications|currently,,,,,,
16494,,parkngum,,,,,,,,,,≥ 500 iu/ml,,,,,,
16495,,assessment approaches,,,,,,,,,,≤ 2.5 times the upper normal limit,,,,,,
16496,,occlusion,,,,,,,,,,less than 130mmol/l)|patients,,,,,,
16497,,psychiatric disorder.|current,,,,,,,,,,below 300 iu/ml,,,,,,
16498,,hematology abnormalities,,,,,,,,,,≥115 g/m2,,,,,,
16499,,type of seizure,,,,,,,,,,"< 100,000/µl or",,,,,,
16500,,intracranial atherosclerotic stenosis,,,,,,,,,,≤2.5 uln,,,,,,
16501,,perception of sensation,,,,,,,,,,meet,,,,,,
16502,,grem1,,,,,,,,,,class iii of 4 by,,,,,,
16503,,untreatable high blood pressure)|ascites,,,,,,,,,,≤60 ml/min/1.73 m2,,,,,,
16504,,suicidal attempts||other protocol defined exclusion criteria could apply,,,,,,,,,,50 to 100 mm hg,,,,,,
16505,,infectious diseases;|those,,,,,,,,,,greater than 1.5 times the normal value,,,,,,
16506,,primary cutaneous cd30+ t-cell lymphoproliferative disorders,,,,,,,,,,<50.000|pregnancy,,,,,,
16507,,mandibular arch,,,,,,,,,,>250 units per liter,,,,,,
16508,,screening.|renal dysfunction,,,,,,,,,,0-3,,,,,,
16509,,systemic chemotherapy|measurable disease,,,,,,,,,,less than or equal to the upper limit of the normal,,,,,,
16510,,infective keratitis,,,,,,,,,,≤ 15,,,,,,
16511,,hepatitis caused,,,,,,,,,,≤2 years,,,,,,
16512,,subcutaneous tophi,,,,,,,,,,> 60 mmhg)|stroke,,,,,,
16513,,spontaneous circulation,,,,,,,,,,= 24 g/day,,,,,,
16514,,eye pathology,,,,,,,,,,< 1.5×uln；|total bilirubin level,,,,,,
16515,,diabetes-specific complications|smoking,,,,,,,,,,over 18 years old|having attempted suicide|provide,,,,,,
16516,,refusal|contraindication,,,,,,,,,,≤ 8 cmh2o,,,,,,
16517,,colorectal sessile polyps,,,,,,,,,,upper limit of 65 years,,,,,,
16518,,functional electrical stimulation,,,,,,,,,,>= 18 years.||confirmed diagnosis,,,,,,
16519,,heart failure||(a,,,,,,,,,,≤ 30 days prior to the patient enrolment visit,,,,,,
16520,,hepatoblastoma,,,,,,,,,,≥ 18 y|legal,,,,,,
16521,,constituting,,,,,,,,,,greater than the first degree|severe hepatic,,,,,,
16522,,chronic gastroenterological disorders,,,,,,,,,,requires antibiotic therapy|patients,,,,,,
16523,,ddlps tumors,,,,,,,,,,< x3 upper limit of normal,,,,,,
16524,,acute peritonitis,,,,,,,,,,37 weeks)|fetus,,,,,,
16525,,malignant glioma,,,,,,,,,,1.5-3.0 × uln,,,,,,
16526,,eyelid abnormality,,,,,,,,,,< 60ml/g/m3,,,,,,
16527,,ectopic pregnancy hydatidiform mole,,,,,,,,,,100 mmhg,,,,,,
16528,,liver metastases from,,,,,,,,,,< 60 ml/min/1.73 m2,,,,,,
16529,,systemic therapy.|active tb,,,,,,,,,,≤ 37.5,,,,,,
16530,,dirty,,,,,,,,,,first--degree relative,,,,,,
16531,,open sores,,,,,,,,,,=<1.5 x uln,,,,,,
16532,,type 2 diabetes|bmi,,,,,,,,,,0 chronic lymphocytic leukemia,,,,,,
16533,,skin breakdown,,,,,,,,,,>= 1000/mm^3|platelet count,,,,,,
16534,,cns-3 involvement,,,,,,,,,,≥18 years|hypertension (,,,,,,
16535,,behavioral factors,,,,,,,,,,under 18 years|patients,,,,,,
16536,,rasopathy disorders,,,,,,,,,,>21|modified,,,,,,
16537,,involvement of the splenic hilar,,,,,,,,,,from 22 to 50 years,,,,,,
16538,,subjective perception questionnaires,,,,,,,,,,≥ 70.|neurologic function,,,,,,
16539,,narrow spinal canal|hemostasis abnormalities,,,,,,,,,,no older than 75 years,,,,,,
16540,,hmb,,,,,,,,,,> 42,,,,,,
16541,,disease|skin diseases,,,,,,,,,,60% or greater,,,,,,
16542,,acute advanced diseases,,,,,,,,,,"≥ 40,000 iu/wk",,,,,,
16543,,significant pressure ulcer,,,,,,,,,,25-60,,,,,,
16544,,etc.)|chronic renal disease|peripheral,,,,,,,,,,≤ 20;|unable,,,,,,
16545,,non-cancer,,,,,,,,,,>50% stenosis of the,,,,,,
16546,,deaf,,,,,,,,,,fewer than 18,,,,,,
16547,,rectal bleeding,,,,,,,,,,between 20-45 years,,,,,,
16548,,cardiogenic shock,,,,,,,,,,greater than or equal to 30,,,,,,
16549,,colorectal cancer|colorectal adenoma,,,,,,,,,,35.5 °c,,,,,,
16550,,cessation,,,,,,,,,,18-60 years.|asa,,,,,,
16551,,macroalbuminuria,,,,,,,,,,"≥18 years old,|patient",,,,,,
16552,,breast cancer.||,,,,,,,,,,< 5 points;|no,,,,,,
16553,,colonoscopy.|active colitis,,,,,,,,,,18-75 years；|histological,,,,,,
16554,,undetermined colitis|rheumatic diseases,,,,,,,,,,less than 18 years old must provide written assent,,,,,,
16555,,corneal ulcers,,,,,,,,,,0-18,,,,,,
16556,,renal damage factors,,,,,,,,,,232-1245 pg/ml,,,,,,
16557,,haaa)|megaloblastic anemia,,,,,,,,,,≥ 6.0,,,,,,
16558,,sss,,,,,,,,,,"< 220 ms,|interval between q and s waves",,,,,,
16559,,ovarian malignancy,,,,,,,,,,> 8.0mm,,,,,,
16560,,stroke|bronchial asthma,,,,,,,,,,class 4,,,,,,
16561,,active pulmonary,,,,,,,,,,≥3 episodes,,,,,,
16562,,endovascular thrombosis,,,,,,,,,,between 4 years and 18 years,,,,,,
16563,,inhibits metabolism,,,,,,,,,,18 - 60 years,,,,,,
16564,,tricuspid valve regurgitation,,,,,,,,,,=< 1.5|patients,,,,,,
16565,,hiv 1/2 antibodies,,,,,,,,,,>= 26%,,,,,,
16566,,auto-immune cytopenia,,,,,,,,,,>13|5 or more,,,,,,
16567,,chronic forms,,,,,,,,,,than 150 minutes,,,,,,
16568,,left internal thoracic artery,,,,,,,,,,≥90mmhg);|abnormal,,,,,,
16569,,inherited disorders,,,,,,,,,,15-30 years.|participants,,,,,,
16570,,chronic diabetic,,,,,,,,,,> 18 years||donors' exclusion,,,,,,
16571,,another type of,,,,,,,,,,>450 milliseconds,,,,,,
16572,,painful myofascial trigger point,,,,,,,,,,70 years,,,,,,
16573,,acute brain infarct,,,,,,,,,,> 20°,,,,,,
16574,,autoimmune complications||active disease,,,,,,,,,,<21.|participant,,,,,,
16575,,old|unilateral knee pain,,,,,,,,,,28,,,,,,
16576,,microdialysis,,,,,,,,,,stage c or,,,,,,
16577,,kidney stones,,,,,,,,,,4 years,,,,,,
16578,,diabetic gastroparesis,,,,,,,,,,between 3-6 years,,,,,,
16579,,oesophageal obstruction,,,,,,,,,,>60 ml/min/1.73 m2,,,,,,
16580,,soft tissue infection,,,,,,,,,,>11mm,,,,,,
16581,,"retinopathy,|dementia",,,,,,,,,,1x upper limit of normal,,,,,,
16582,,gi function,,,,,,,,,,6-17,,,,,,
16583,,gullet disease,,,,,,,,,,upper to 1,,,,,,
16584,,impaired elimination|known kidney,,,,,,,,,,14 -60 years|male,,,,,,
16585,,urinary tract infection.|pregnant,,,,,,,,,,18 years or older.|history,,,,,,
16586,,herpetic infection|autoimmune disorders|corneal thickness,,,,,,,,,,> 50nmol/l,,,,,,
16587,,right-lobe,,,,,,,,,,">18 years,|those",,,,,,
16588,,vaginal swab,,,,,,,,,,≤ 1.5x uln,,,,,,
16589,,rise,,,,,,,,,,<= 2 uln,,,,,,
16590,,adenocarcinoma of the appendix,,,,,,,,,,4-5|emergency surgery|patients,,,,,,
16591,,oropharyngeal swab,,,,,,,,,,at least 1 year||,,,,,,
16592,,mild autoimmune skin disorders,,,,,,,,,,< 0.7.|subject,,,,,,
16593,,fruit drinks,,,,,,,,,,over 4 cm2,,,,,,
16594,,b cell disorders,,,,,,,,,,at least 50.0 kg,,,,,,
16595,,hospitality,,,,,,,,,,impella|reliance,,,,,,
16596,,bi-polar syndrome,,,,,,,,,,1-current,,,,,,
16597,,non-elective surgery,,,,,,,,,,≥4 mm).|sufficient interarch space.|sufficient vestibular,,,,,,
16598,,gastric polyps,,,,,,,,,,0 or 1||,,,,,,
16599,,hereditary angioedema history.|subjects,,,,,,,,,,>5 times the upper limit of normal,,,,,,
16600,,temporomandibular joint internal,,,,,,,,,,18-65 years.|have,,,,,,
16601,,regular alcohol,,,,,,,,,,> 21 u/week,,,,,,
16602,,anoperineal dressings,,,,,,,,,,≥1 to <5 years-of-age,,,,,,
16603,,disease entities,,,,,,,,,,> 0.5mg/kg/day of,,,,,,
16604,,pseudomyxoma,,,,,,,,,,20-50,,,,,,
16605,,mixed density,,,,,,,,,,long-term follow-up results;|don't,,,,,,
16606,,renal cyst,,,,,,,,,,"< 20%,|ipsilateral",,,,,,
16607,,plausible cause of symptoms,,,,,,,,,,≥3 months;||7.eastern,,,,,,
16608,,physical activity|alcohol,,,,,,,,,,> 2 times the upper limit of,,,,,,
16609,,moderna,,,,,,,,,,≤ 1||,,,,,,
16610,,neurodegenerative disease.|allogeneic stem cell transplant,,,,,,,,,,1-3;|receive standard treatment,,,,,,
16611,,arteriovenous thrombotic events occurred,,,,,,,,,,> 90mmhg regardless,,,,,,
16612,,laboratory test abnormalities,,,,,,,,,,less than 0.05,,,,,,
16613,,depressive disorder)|other than mci,,,,,,,,,,greater than fifth percentile,,,,,,
16614,,cardiovascular risk factor,,,,,,,,,,>50mmhg,,,,,,
16615,,untreated)|anemia,,,,,,,,,,>12 weeks.||the function,,,,,,
16616,,cyp3a4-inductors,,,,,,,,,,>= 18 years|the study participant,,,,,,
16617,,neurodevelopmental condition,,,,,,,,,,<14|having,,,,,,
16618,,foot eczema,,,,,,,,,,lower than 50,,,,,,
16619,,brain metastases,,,,,,,,,,>/= 10 mm,,,,,,
16620,,idiopathic pd|diagnosis,,,,,,,,,,i to iii||patients,,,,,,
16621,,trachoma,,,,,,,,,,25 to 65 years,,,,,,
16622,,chinese ethnicity|[for dementia,,,,,,,,,,75 × 109/l,,,,,,
16623,,electrolyte abnormalities,,,,,,,,,,< 2+,,,,,,
16624,,neuromyotonia,,,,,,,,,,7-18,,,,,,
16625,,extensive lesions,,,,,,,,,,"≥ 100,000/mm3",,,,,,
16626,,give free,,,,,,,,,,exceeds 450 ms,,,,,,
16627,,dysarthria,,,,,,,,,,18 years or older||patients,,,,,,
16628,,papillary thyroid cancer,,,,,,,,,,< 24 months after the onset of menopause,,,,,,
16629,,provocative activities,,,,,,,,,,"<50 years old, should",,,,,,
16630,,bambini con diagnosi clinica,,,,,,,,,,<7 days|athletes,,,,,,
16631,,immune checkpoint-inhibitor therapy,,,,,,,,,,not less than 45)|alcoholism,,,,,,
16632,,third molars|no,,,,,,,,,,1 month postpartum,,,,,,
16633,,target dfu,,,,,,,,,,110 lb,,,,,,
16634,,systemic embolism|atrial myxoma|congenital heart disease|pregnant,,,,,,,,,,20 to 24 years,,,,,,
16635,,nonsterilized,,,,,,,,,,less than 80% of the predicted value,,,,,,
16636,,inflammatory breast cancer,,,,,,,,,,<1m/second,,,,,,
16637,,medical conditions|patients,,,,,,,,,,>35|known,,,,,,
16638,,rim notch,,,,,,,,,,less than 5 clearance half-life,,,,,,
16639,,diabetic ketosis,,,,,,,,,,> 150 mmhg,,,,,,
16640,,poor bpq,,,,,,,,,,females.|between 18 to 70 years old,,,,,,
16641,,spondyloarthritis,,,,,,,,,,=< 1.5 x uln|no,,,,,,
16642,,months|prostate cancer,,,,,,,,,,greater than 18,,,,,,
16643,,tumor tissue block,,,,,,,,,,18 or older|both radoiocarpal,,,,,,
16644,,drug pump,,,,,,,,,,≥3 x upper limit of normal (uln),,,,,,
16645,,immunocompromised|diagnosed with cancer,,,,,,,,,,i-ii||,,,,,,
16646,,chemotherapy|rectal cancer,,,,,,,,,,≥ 18 years to ≤ 85 years,,,,,,
16647,,gitr,,,,,,,,,,< 30 minutes,,,,,,
16648,,hidalgo,,,,,,,,,,<5x institutional uln,,,,,,
16649,,c virus infection,,,,,,,,,,less than 1 year & more than 3 years,,,,,,
16650,,malabsorption issues,,,,,,,,,,>90mmhg,,,,,,
16651,,childhood atopic dermatitis,,,,,,,,,,> 18 years.|individuals,,,,,,
16652,,recurrent vv,,,,,,,,,,≤ 1.5 x,,,,,,
16653,,occupational exposures,,,,,,,,,,> 2000/ml|serum calcium =< 12.0 mg/dl|patients,,,,,,
16654,,acute laryngitis,,,,,,,,,,more than 18|agreeing,,,,,,
16655,,early lens,,,,,,,,,,18-70 years;|hunt-hess grade iv-v,,,,,,
16656,,hemoptysis,,,,,,,,,,= 19 -37|have daily access,,,,,,
16657,,generalized myasthenia gravis,,,,,,,,,,≥ 100mg/dl,,,,,,
16658,,vertebral deformity)|allergy,,,,,,,,,,>450 milliseconds).||b,,,,,,
16659,,dysfunction of the liver,,,,,,,,,,0 - 1 documented,,,,,,
16660,,cns infection,,,,,,,,,,≤ 2 times the upper limit of normal|written informed consent,,,,,,
16661,,cirrhosis;||chronic liver disease,,,,,,,,,,"< 1,5 time the normal limit",,,,,,
16662,,weeks.|gender unlimited,,,,,,,,,,> 30 iu/l,,,,,,
16663,,neuroendocrine neoplasms recorded,,,,,,,,,,"more than 20%,|post-operative",,,,,,
16664,,coagulation disorder.|is,,,,,,,,,,2016);|relapsed,,,,,,
16665,,qtc syndrome,,,,,,,,,,≥3 different time points)|diagnosis,,,,,,
16666,,unresolved inflammation,,,,,,,,,,>10 µiu/ml,,,,,,
16667,,leptomeningeal lesions,,,,,,,,,,≤ 4cm,,,,,,
16668,,hereditary cancer syndrome,,,,,,,,,,"i-ii,|scheduled",,,,,,
16669,,good quality image,,,,,,,,,,"≥ 4,|dementia|peripheral polyneuropathy|pregnancy|chronic opioid",,,,,,
16670,,mouth wash,,,,,,,,,,more than 3 cm,,,,,,
16671,,breast ductal carcinoma in situ after radical surgery,,,,,,,,,,< 3.0x uln|bilirubin ≤1.5 x uln,,,,,,
16672,,etc.)|gastrointestinal diseases,,,,,,,,,,over18 years old|being 1st year,,,,,,
16673,,smoking /chewing,,,,,,,,,,≥2 points,,,,,,
16674,,iiic1 disease,,,,,,,,,,<5xuln,,,,,,
16675,,study variables,,,,,,,,,,≤ 5 events/hour,,,,,,
16676,,chest infiltrates,,,,,,,,,,90-130 mm hg,,,,,,
16677,,replaced left hepatic artery anatomy,,,,,,,,,,< 40||,,,,,,
16678,,compulsive disorders,,,,,,,,,,18 - 90,,,,,,
16679,,ocular condition,,,,,,,,,,≤ 50 umol/l,,,,,,
16680,,findings,,,,,,,,,,300 pg/ml,,,,,,
16681,,pulp exposure,,,,,,,,,,> 4 weeks,,,,,,
16682,,black/african american,,,,,,,,,,between 250 and 3000 hz|speak english,,,,,,
16683,,lower back|any issues around balance,,,,,,,,,,10-18|absence,,,,,,
16684,,interstitial nephritis,,,,,,,,,,< 16 kg/m2.|known,,,,,,
16685,,visually estimated stenosis,,,,,,,,,,18-49,,,,,,
16686,,large bowel obstruction,,,,,,,,,,less than 3 months|pain cause,,,,,,
16687,,unit of alcohol,,,,,,,,,,above 40||allergy,,,,,,
16688,,diplegia,,,,,,,,,,> 2 x upper limit of,,,,,,
16689,,obesity hypoventilation syndrome,,,,,,,,,,≥10 mg/ day,,,,,,
16690,,pagets disease,,,,,,,,,,over 25 kg/,,,,,,
16691,,extracorporeal circulation,,,,,,,,,,"<15,000/mm3.|patient",,,,,,
16692,,neuropathic pain|patient enrolled,,,,,,,,,,required.|at least 1,,,,,,
16693,,light for myopia control,,,,,,,,,,from 20 to 35 years,,,,,,
16694,,blood coagulopathy,,,,,,,,,,7 years,,,,,,
16695,,primary itp,,,,,,,,,,≥10/hr,,,,,,
16696,,acute obstruction,,,,,,,,,,75 x 109/l)|hemoglobin,,,,,,
16697,,therapeutic hormones,,,,,,,,,,<1.5x normal|creatinine clearance,,,,,,
16698,,corneal injury,,,,,,,,,,> 30 ml/min per,,,,,,
16699,,functional disabilities,,,,,,,,,,6-11 age,,,,,,
16700,,mm.|type 2 dm,,,,,,,,,,45%,,,,,,
16701,,neurological disease|acute disease,,,,,,,,,,raised,,,,,,
16702,,|elective noncardiac,,,,,,,,,,> 115 ms.|average,,,,,,
16703,,vascular embolism,,,,,,,,,,required.|who 0 or,,,,,,
16704,,impact absorption of oral medications.|history,,,,,,,,,,> 3 times upper limit normal,,,,,,
16705,,bipolar ii disorder,,,,,,,,,,<3/10).||exclusion criteria,,,,,,
16706,,cutaneous psoriasis,,,,,,,,,,>= 1 week prior to study treatment|patients,,,,,,
16707,,pd|prominent gait imbalance early,,,,,,,,,,requires antibiotic,,,,,,
16708,,antisocial personality,,,,,,,,,,less than 50 y.o,,,,,,
16709,,in-situ cancer,,,,,,,,,,patients||age < 55 years,,,,,,
16710,,above|non-smokers,,,,,,,,,,less than 30 ml/minute/1.73 m2,,,,,,
16711,,local anesthetics|coagulopathy|skin infection,,,,,,,,,,<200 pmol l-1,,,,,,
16712,,partial denture,,,,,,,,,,> 1.5 times higher than upper normal level|egfr,,,,,,
16713,,breast ductal carcinoma in situ,,,,,,,,,,> 250 pg/ml|chronic pain,,,,,,
16714,,gambling disorder unit,,,,,,,,,,greater than 3ng/ml|no,,,,,,
16715,,liposarcoma,,,,,,,,,,< 3.0 g/dl,,,,,,
16716,,autoimmune condition,,,,,,,,,,≤ 2|signing informed consent,,,,,,
16717,,gastric adenocarcinoma.|clinical stage ct2,,,,,,,,,,≥ 6%,,,,,,
16718,,peripheral disease,,,,,,,,,,>30 degrees,,,,,,
16719,,months.||diagnosis,,,,,,,,,,<1 year|any factor,,,,,,
16720,,idiopathic pah,,,,,,,,,,over 18|patients with,,,,,,
16721,,condom with spermicide,,,,,,,,,,> 27,,,,,,
16722,,heart transplant|recipient,,,,,,,,,,> 34,,,,,,
16723,,phobia symptoms,,,,,,,,,,≥1 symptom,,,,,,
16724,,good image quality,,,,,,,,,,≥2,,,,,,
16725,,autoimmune thrombocytopenia)||severe asthma,,,,,,,,,,≥100 mm hg,,,,,,
16726,,cardiac surgery|contraindication,,,,,,,,,,greater than 1.5 times normal,,,,,,
16727,,ductal syndrome,,,,,,,,,,≤ 2 x uln|albumin,,,,,,
16728,,abscesses|prosthetic joint infections,,,,,,,,,,less than 35 kg/m2|subjects should be able to understand the,,,,,,
16729,,rhinitis,,,,,,,,,,gingival health|patients,,,,,,
16730,,mechanical complications,,,,,,,,,,>= 1% blasts,,,,,,
16731,,acquired factors,,,,,,,,,,between 12 to 25 years,,,,,,
16732,,cardiac events|patients,,,,,,,,,,3-11 years,,,,,,
16733,,gastrointestinal bleed,,,,,,,,,,below 18 yrs|use of,,,,,,
16734,,pittsburgh sleep quality index,,,,,,,,,,between 2 and 3,,,,,,
16735,,major malformation|neuromuscular condition,,,,,,,,,,"rating scale,|diagnosed",,,,,,
16736,,microalbuminuria,,,,,,,,,,≤ 35 kg/m2,,,,,,
16737,,diseases related,,,,,,,,,,≥ 26.5 μ,,,,,,
16738,,previous bladder,,,,,,,,,,≥ 10 g/dl,,,,,,
16739,,heparin induced thrombocytopenia (hit)|contraindication,,,,,,,,,,≤ 4 years,,,,,,
16740,,systemic lupus erythematosus.|known,,,,,,,,,,10 g/dl|absolute,,,,,,
16741,,acute respiratory failure,,,,,,,,,,<1.5×109/l|platelet count,,,,,,
16742,,control gingivitis,,,,,,,,,,less than 3|prior endotracheal intubation,,,,,,
16743,,multiple endocrine neoplasia type 2 (men2),,,,,,,,,,less than 65 mmhg,,,,,,
16744,,hp culture,,,,,,,,,,at least 120 pounds.|normotensive,,,,,,
16745,,hyperthermia,,,,,,,,,,≥18 years.|minimum,,,,,,
16746,,heavy calcification,,,,,,,,,,ribociclib,,,,,,
16747,,chronic bronchitis,,,,,,,,,,younger than 2 years,,,,,,
16748,,pelvic segment disease of the ureter,,,,,,,,,,<150 x 109/l|patient,,,,,,
16749,,baseline|psoriasis area,,,,,,,,,,95 years,,,,,,
16750,,spinal cord magnetic resonance imaging.|patient affiliated,,,,,,,,,,over 18 years chinese,,,,,,
16751,,nail lichen,,,,,,,,,,less than 5 times response,,,,,,
16752,,brain tumor,,,,,,,,,,≤ 15 mm hg,,,,,,
16753,,non-hematopoietic organ system,,,,,,,,,,> 40,,,,,,
16754,,pregnancy-related,,,,,,,,,,greater than 40 copies per ml,,,,,,
16755,,severe personality disorders,,,,,,,,,,between 28 and 35 kg/m2,,,,,,
16756,,affected)|arterial blood circulation,,,,,,,,,,60-80 mmhg)|had,,,,,,
16757,,los angeles classification,,,,,,,,,,190 mg/dl,,,,,,
16758,,peripheral sensory neuropathy,,,,,,,,,,"grade ii, iii and iv",,,,,,
16759,,protrusions,,,,,,,,,,more than 30)|nmes contraindication,,,,,,
16760,,bmi,,,,,,,,,,>20 mm hg,,,,,,
16761,,basal cell skin carcinoma,,,,,,,,,,dose ≤ 10 mg daily of,,,,,,
16762,,weight gain,,,,,,,,,,< 6hrs prior to each recording session,,,,,,
16763,,juvenile idiopathic arthritis (sjia),,,,,,,,,,≥18 years.||histologically,,,,,,
16764,,oligometastatic bone disease,,,,,,,,,,>= 30 ml/min per 24 hour urine test,,,,,,
16765,,bmi)<17.5,,,,,,,,,,>= 1.5 x 109/l|platelets,,,,,,
16766,,graves' disease,,,,,,,,,,> 100 x 103/µl hemoglobin,,,,,,
16767,,high-risk neuroblastoma,,,,,,,,,,>160/100 mmhg)|pregnant,,,,,,
16768,,qtcf≥470,,,,,,,,,,less than 100 mg/dl,,,,,,
16769,,good compliance,,,,,,,,,,score of ≤ 2,,,,,,
16770,,hepatic metastasis,,,,,,,,,,> 65 mmhg,,,,,,
16771,,recanalized embolus.|presence of any of the following unequivocal cardiac sources of embolism,,,,,,,,,,≤2.5 x uln|total,,,,,,
16772,,end-tidal carbon dioxide (co2),,,,,,,,,,≥12 weeks|measurable,,,,,,
16773,,miastenic syndromes,,,,,,,,,,at least 6 weeks prior to initiation of study treatment,,,,,,
16774,,in-situ,,,,,,,,,,level ii repair)|genital hiatus,,,,,,
16775,,non-small cell lung cancer|eligible,,,,,,,,,,months;|patients,,,,,,
16776,,superficial bladder tumors;|baseline,,,,,,,,,,>140/90)|have,,,,,,
16777,,professionals:||lack of consent.||inclusion,,,,,,,,,,>155,,,,,,
16778,,rop,,,,,,,,,,>18,,,,,,
16779,,cardiac defibrillators,,,,,,,,,,"upper limit 75,",,,,,,
16780,,signs of gi bleeding,,,,,,,,,,larger than trace,,,,,,
16781,,coagulation test,,,,,,,,,,-2n1,,,,,,
16782,,phospholipase domain-containing,,,,,,,,,,18 years or older|signs,,,,,,
16783,,wheelchair.|new permobil chairs,,,,,,,,,,exceeded 1.5 times of the upper limit of normal,,,,,,
16784,,restored,,,,,,,,,,requires removal,,,,,,
16785,,syphilis infection,,,,,,,,,,>85% of predicted value,,,,,,
16786,,thoracic outlet syndrome,,,,,,,,,,< 1 year;|patients,,,,,,
16787,,atrial fibrillation ablation,,,,,,,,,,>37.5℃,,,,,,
16788,,etc.)|psychiatric pathology,,,,,,,,,,iv - vi.|renal failure,,,,,,
16789,,pd dementia,,,,,,,,,,< 60 a.u,,,,,,
16790,,vaginal dryness,,,,,,,,,,prevent testing|the patient's,,,,,,
16791,,pneumococcal disease|allergy,,,,,,,,,,6 to 18 months (180 to 540 days,,,,,,
16792,,carbetocin.|known medical disorders,,,,,,,,,,< 50 bpm.|patients,,,,,,
16793,,disseminated intravascular coagulation,,,,,,,,,,< 11 g/dl,,,,,,
16794,,pancreas disorder,,,,,,,,,,> 18 years,,,,,,
16795,,overt bowel involvement,,,,,,,,,,> 15)|moderate to high,,,,,,
16796,,main deciding factor,,,,,,,,,,at least 25 degrees,,,,,,
16797,,kidney function injury,,,,,,,,,,between 18 and 40 years,,,,,,
16798,,pre-menopausal,,,,,,,,,,>2 d);||fulfilling ≥1 of the,,,,,,
16799,,neurological diseases|color-blindness,,,,,,,,,,more than or equal to 8.0 g/dl,,,,,,
16800,,major health problems,,,,,,,,,,1 msm||under 18 years,,,,,,
16801,,immunodeficient state,,,,,,,,,,≥ 50% of the,,,,,,
16802,,peutz-jeghers syndrome,,,,,,,,,,<70 ml/min/1.73 m2,,,,,,
16803,,pneumonia|respiratory infection,,,,,,,,,,≤ 30 ml/minute/1.73 m2,,,,,,
16804,,spinal stenosis,,,,,,,,,,3-18 years；|proteinuria,,,,,,
16805,,food allergy(ies);|vegetarians;|restrained eaters,,,,,,,,,,20-50 years,,,,,,
16806,,pulmonary tuberculosis|positive xpert tb/rif,,,,,,,,,,>ii,,,,,,
16807,,shoulder replacement|shoulder,,,,,,,,,,≤1.5 x uln,,,,,,
16808,,peritoneal cancer,,,,,,,,,,< 18 years|conditions,,,,,,
16809,,mild cognitive dysfunction,,,,,,,,,,≥ 80,,,,,,
16810,,chronic disease(s);|participants,,,,,,,,,,>= 9.0 g/dl|registration,,,,,,
16811,,urinary tract infection|patients,,,,,,,,,,> 40 mmhg,,,,,,
16812,,acute neuritis,,,,,,,,,,2 through 6 years,,,,,,
16813,,findings consistent,,,,,,,,,,> 10% tumor cell positive,,,,,,
16814,,|active tuberculosis,,,,,,,,,,> 10.0 mm|proximal,,,,,,
16815,,onset ischemic stroke,,,,,,,,,,less than 100 iu/ml,,,,,,
16816,,pain-relief,,,,,,,,,,less than daily,,,,,,
16817,,months.|active urinary tract infection,,,,,,,,,,between 3.0mm to 5.5,,,,,,
16818,,gestational)|deep venous thrombosis,,,,,,,,,,"30%,|ubt 13c test value",,,,,,
16819,,distant progression,,,,,,,,,,< 15 millileters per minutes per 1.73^2 (ml/min/1.73 m^2,,,,,,
16820,,t2 mapping imaging sequences,,,,,,,,,,≥ 40 ml/min/1.73m2,,,,,,
16821,,respiratory function|alcohol overuse,,,,,,,,,,18 to ≤ 50 years.|willing to participate,,,,,,
16822,,active proctitis,,,,,,,,,,≥ 3 × upper limit of normal (uln),,,,,,
16823,,inflammatory condition,,,,,,,,,,>400 u/l|mdf <32 or >60,,,,,,
16824,,herpetic diseases,,,,,,,,,,from 18 to 70|40-60%,,,,,,
16825,,antibody-mediated diseases,,,,,,,,,,≥ 18 years|treatment,,,,,,
16826,,haematopoietic disorder,,,,,,,,,,>150,,,,,,
16827,,no measurable lesion,,,,,,,,,,greater than 30 days,,,,,,
16828,,illness|aged,,,,,,,,,,than 15 years,,,,,,
16829,,malignant tumors|10.other conditions,,,,,,,,,,12 to 22 breaths per,,,,,,
16830,,klatskin tumors,,,,,,,,,,greater than 5000ml,,,,,,
16831,,resection of the stomach,,,,,,,,,,>80 g/d,,,,,,
16832,,osa treatments|resting,,,,,,,,,,≥ 21 years,,,,,,
16833,,urinary tract infection.||patients,,,,,,,,,,< 60 ml/min/1.73,,,,,,
16834,,life expectancy|autoimmune diseases of the rheumatological type|cataract|epilepsy|glaucoma,,,,,,,,,,< 10 pmol/l).|they,,,,,,
16835,,spastic cerebral palsy|dyskinetic,,,,,,,,,,> 40g/d|chronical disease,,,,,,
16836,,diabetes|hyperemesis gravidarum,,,,,,,,,,<37w gestational age,,,,,,
16837,,primary degenerative arthritis,,,,,,,,,,<6.5%|poor blood supply to the wound,,,,,,
16838,,systemic autoimmune disease,,,,,,,,,,≤ 30 kg/m2.|willing,,,,,,
16839,,conditional incentives,,,,,,,,,,20 to 45,,,,,,
16840,,medical history|renal failure,,,,,,,,,,0-1.|expected survival,,,,,,
16841,,diagnostic arm):||acute injury,,,,,,,,,,less than 15 ml/min,,,,,,
16842,,chronic thromboembolic pulmonary embolism,,,,,,,,,,19-9|peritoneal carcinomatosis index (pci),,,,,,
16843,,distress,,,,,,,,,,≤ 8 points|signed informed consent,,,,,,
16844,,serious diseases(autoimmune disease,,,,,,,,,,>/= 15 ml)|core-infarct,,,,,,
16845,,sti)|diabetes,,,,,,,,,,> 18 years|post-stroke,,,,,,
16846,,zygomatic,,,,,,,,,,> 25 ng/ml,,,,,,
16847,,poor oral hygiene.|patients,,,,,,,,,,<45 mmhg,,,,,,
16848,,deficits,,,,,,,,,,< 35ml/min.|high,,,,,,
16849,,mass lesions,,,,,,,,,,>=grade 2).|ongoing,,,,,,
16850,,spine|glaucoma,,,,,,,,,,≥35,,,,,,
16851,,passive monitoring.||,,,,,,,,,,18-89,,,,,,
16852,,colorectal adenomas,,,,,,,,,,> 6 months;||,,,,,,
16853,,cessation counselor,,,,,,,,,,≥12 weeks.|eastern,,,,,,
16854,,randomization,,,,,,,,,,=< 2.0 × uln,,,,,,
16855,,"malignancy,|myocardial infarction",,,,,,,,,,long segment,,,,,,
16856,,chronic renal disease,,,,,,,,,,≥18 years old;|those who,,,,,,
16857,,floor muscle,,,,,,,,,,1||currently use,,,,,,
16858,,wpafb)|able,,,,,,,,,,between (18.5-25 kg /m2,,,,,,
16859,,trans-obturator tape surgery,,,,,,,,,,less than 40kg|subjects,,,,,,
16860,,remain stable,,,,,,,,,,0 to 1+ by ihc,,,,,,
16861,,specific syndrome,,,,,,,,,,≥18 years|routine diagnostic process includes,,,,,,
16862,,psychiatric disorders|if the,,,,,,,,,,< 18 years;|life expectancy,,,,,,
16863,,baseline dementia,,,,,,,,,,class iii or,,,,,,
16864,,indicators,,,,,,,,,,20-37 years.|primigravida.|28-40 week,,,,,,
16865,,autoleucel,,,,,,,,,,≥ 3mm/5min,,,,,,
16866,,medication.|hepatic insufficiency resulting,,,,,,,,,,30 to 60 years,,,,,,
16867,,elective breast cancer,,,,,,,,,,≥500 parasites/ul|diagnosis,,,,,,
16868,,glottic,,,,,,,,,,< 30|heart failure|peripheral arterial disease|active malignancies beyond,,,,,,
16869,,clotting disorder|the,,,,,,,,,,under 18 years old or over 90 years,,,,,,
16870,,chronic prostatitis,,,,,,,,,,≤ 3xuln.||participant,,,,,,
16871,,major cardiovascular disease,,,,,,,,,,people ≥18 years,,,,,,
16872,,malignant syndrome|history,,,,,,,,,,eligible.|18 years,,,,,,
16873,,psychotic disorder nos|current,,,,,,,,,,> moderate|functional,,,,,,
16874,,abdominal wall configuration,,,,,,,,,,≤80 kilograms (kg,,,,,,
16875,,clear tendency,,,,,,,,,,< 30%;|patients,,,,,,
16876,,acute constipation,,,,,,,,,,at least 33 weeks,,,,,,
16877,,quadriceps disorders,,,,,,,,,,≤33.0 kg/m2;|has,,,,,,
16878,,hpv16 genotype,,,,,,,,,,≤ 55mmol/mol,,,,,,
16879,,neurologic system(s,,,,,,,,,,3.9-6.1 mmol/l.||,,,,,,
16880,,immunocompromise,,,,,,,,,,65 and older|undergoing non-cardiac,,,,,,
16881,,neurological sequalae,,,,,,,,,,0.9 - 1.3.|patients,,,,,,
16882,,etc.).|current smokers,,,,,,,,,,<60%,,,,,,
16883,,lesions threatening,,,,,,,,,,≥18 and ≤85 years,,,,,,
16884,,chronic steroids|a physical,,,,,,,,,,2-10 years,,,,,,
16885,,autoimmune diseases;|known,,,,,,,,,,≥ 95%|adult,,,,,,
16886,,lung disease;|active hypertension,,,,,,,,,,50 years.|male,,,,,,
16887,,spontaneous breathing activity|sedation,,,,,,,,,,≥6g/,,,,,,
16888,,pulmonary vascular resistance,,,,,,,,,,≥1-point,,,,,,
16889,,acquired neurologic disease,,,,,,,,,,> 300 lbs,,,,,,
16890,,national team (licence),,,,,,,,,,<60 bpm,,,,,,
16891,,secondary cataract,,,,,,,,,,greater than,,,,,,
16892,,rbcs,,,,,,,,,,18-55 years|stable,,,,,,
16893,,type|body mass index (bmi),,,,,,,,,,≥35|history of,,,,,,
16894,,oncological diseases,,,,,,,,,,1-severe,,,,,,
16895,,cardiac condition,,,,,,,,,,≥ 2.0 ×109/l.|neutrophil,,,,,,
16896,,thyroid hormones,,,,,,,,,,>2.00 d 11,,,,,,
16897,,cardiac co-morbidities,,,,,,,,,,>= 18 years|ability to understand,,,,,,
16898,,chemoradiation|heart failure,,,,,,,,,,exceed limitations of the mr-scanner,,,,,,
16899,,controllable heart rate.|patients,,,,,,,,,,score 5 and above for,,,,,,
16900,,epithelial skin carcinoma).|for,,,,,,,,,,1-10 visible,,,,,,
16901,,physical lmitations,,,,,,,,,,1000/mm3,,,,,,
16902,,upper gastrointestinal surgery,,,,,,,,,,older than 70 yr||asa class iv,,,,,,
16903,,toxicity intolerance,,,,,,,,,,≥300 ng/l,,,,,,
16904,,indicates endometriosis lesions,,,,,,,,,,>1×103 copies /ml,,,,,,
16905,,≤3 cm diameter,,,,,,,,,,"less than 150,000 per microliter",,,,,,
16906,,promyelocytic leukemia,,,,,,,,,,>= 18 years|dizziness diagnosis,,,,,,
16907,,several comorbidities,,,,,,,,,,below or above the,,,,,,
16908,,urologic,,,,,,,,,,0-1||normal organ function,,,,,,
16909,,conjunctival pathology,,,,,,,,,,≤ 10 mg/day,,,,,,
16910,,ectopic kidney.|preoperative imaging inadequate,,,,,,,,,,> 24 in spite of treatment,,,,,,
16911,,uterine cancer in situ,,,,,,,,,,< 50 g/l);|renal impairment,,,,,,
16912,,cerebellar deficits|ability to ambulate,,,,,,,,,,"> 16,|ongoing",,,,,,
16913,,liver iron overload,,,,,,,,,,6-17 years old,,,,,,
16914,,thromboembolic disease,,,,,,,,,,between 13,,,,,,
16915,,genetic disorders;|uncontrolled diabetes (hba1c,,,,,,,,,,>= 10 g/dl,,,,,,
16916,,poor oral hygiene|uncontrolled,,,,,,,,,,105,,,,,,
16917,,urological disease,,,,,,,,,,3 - 5,,,,,,
16918,,dengue virus infection,,,,,,,,,,≤ 1.5 × uln,,,,,,
16919,,eye disorders,,,,,,,,,,=< 1.5 mg/dl,,,,,,
16920,,nivolumab.|patients,,,,,,,,,,≥ 18 years)|competent to provide,,,,,,
16921,,psychotic illnesses,,,,,,,,,,< 40 beats/min,,,,,,
16922,,fatal disease,,,,,,,,,,≥ ii,,,,,,
16923,,pain on percussion denoting apical periodontitis.|slight widening,,,,,,,,,,less than 70%.|children,,,,,,
16924,,solid tumor malignancy,,,,,,,,,,>= 13);||,,,,,,
16925,,chronic spo2<90,,,,,,,,,,equal or over 18 years|admitted,,,,,,
16926,,coagulation tests,,,,,,,,,,≤ 36˚c or ≥,,,,,,
16927,,third trimester ultrasound,,,,,,,,,,>= 9 g/l|platelets,,,,,,
16928,,abstain from taking these to the end of visit,,,,,,,,,,?',,,,,,
16929,,"foot wound,|irritation",,,,,,,,,,partial removal dentures.|tumour(s,,,,,,
16930,,aspermia,,,,,,,,,,120 ms,,,,,,
16931,,atrial tachycardia,,,,,,,,,,>18 years old,,,,,,
16932,,adenocarcinoma mixed,,,,,,,,,,< 150 000/mm3|albumin level,,,,,,
16933,,respiratory support procedures recorded,,,,,,,,,,between 20 and 70 years|continuous,,,,,,
16934,,investigator|serious adverse reaction,,,,,,,,,,2009 equation for 18 years old patients.|pregnancy|neoplasm|infections,,,,,,
16935,,left main stem (lms) disease.|patients,,,,,,,,,,≥3×uln with an r value,,,,,,
16936,,abstain from postoperative smoking|if a subject does not receive,,,,,,,,,,>18 years|paroxysmal,,,,,,
16937,,close relatives,,,,,,,,,,>3 × uln,,,,,,
16938,,ear(s)|regular fainting episodes|weight,,,,,,,,,,≥ 70 mmol/mol,,,,,,
16939,,corneal hypoesthesia,,,,,,,,,,≥ 50.|patient,,,,,,
16940,,renal metastasis.|participants,,,,,,,,,,give written,,,,,,
16941,,growth factor support,,,,,,,,,,=<3cm,,,,,,
16942,,metastatic liver disease,,,,,,,,,,">= 50,000/ul",,,,,,
16943,,months;||the main organs,,,,,,,,,,> 45 kg,,,,,,
16944,,behavioral dysfunction,,,,,,,,,,above 60 clearly,,,,,,
16945,,apical reaction,,,,,,,,,,0 day and 41 weeks,,,,,,
16946,,smvt,,,,,,,,,,between 18-55 years,,,,,,
16947,,persistent arrhythmias,,,,,,,,,,18 years or older (inclusive),,,,,,
16948,,traction,,,,,,,,,,> to +,,,,,,
16949,,primary brain tumor,,,,,,,,,,>1.5k/ul,,,,,,
16950,,otitis external|tumors,,,,,,,,,,55-75 years|right-handed,,,,,,
16951,,cuts,,,,,,,,,,value≥ 240db/m)|age≥ 18,,,,,,
16952,,cancer premenopausal,,,,,,,,,,4-1bb agonists,,,,,,
16953,,tumor crossing,,,,,,,,,,> 350 cc|urinary retention,,,,,,
16954,,including:||poor blood pressure control,,,,,,,,,,between 18 and 75 years(inclusive).|patients presenting superficial / first degree,,,,,,
16955,,non-small cell lung cancer|patients,,,,,,,,,,"≤75,000 per μl",,,,,,
16956,,pulmonary hypertension.|subject,,,,,,,,,,≥18 years|able to consent,,,,,,
16957,,thyroid pathology,,,,,,,,,,< 100 × 10^9/l,,,,,,
16958,,impaired power,,,,,,,,,,≥70 ml/min/1.73 m2,,,,,,
16959,,radiographic findings,,,,,,,,,,more than 1.2 times of the upper limit of normal value,,,,,,
16960,,junctional rhythm,,,,,,,,,,≥30 g/l||,,,,,,
16961,,multi-focus soft lens,,,,,,,,,,> 12 months|receiving,,,,,,
16962,,diabetic retinopathy,,,,,,,,,,< 50 * 109 / l,,,,,,
16963,,mycobacterial infection.|the,,,,,,,,,,=< 2.0 mg/dl|participants,,,,,,
16964,,periventricular t2 intense change,,,,,,,,,,between 10 to 18 years,,,,,,
16965,,mock,,,,,,,,,,<3.0 mg/dl|ast(sgot)/alt(sgpt,,,,,,
16966,,chronic lung disease,,,,,,,,,,less than 1 year.||patients,,,,,,
16967,,large vascular disease,,,,,,,,,,> / = 38.0 degrees celsius /100.4 degrees fahrenheit,,,,,,
16968,,-mop,,,,,,,,,,18 to 64 years,,,,,,
16969,,ariceal hemorrhage,,,,,,,,,,"≥75,000/mm",,,,,,
16970,,surgical site infection ssi,,,,,,,,,,<1 year|patient,,,,,,
16971,,severe injury,,,,,,,,,,90 or higher,,,,,,
16972,,dna,,,,,,,,,,between 18 and 40 years.|patients,,,,,,
16973,,comorbidity of syndromes,,,,,,,,,,poorly controlled,,,,,,
16974,,insomnia;|excessive alcohol,,,,,,,,,,greater than 3.0 mg/,,,,,,
16975,,peripheral pain,,,,,,,,,,50%,,,,,,
16976,,daily smoking,,,,,,,,,,>18 years|the patients must,,,,,,
16977,,recurrence for,,,,,,,,,,> 65 years old,,,,,,
16978,,partial staghorn stone,,,,,,,,,,i & ii|both genders|body mass index,,,,,,
16979,,condition related,,,,,,,,,,> 160 mmhg|diastolic blood pressure,,,,,,
16980,,hepatic functions|able,,,,,,,,,,0 - 2.|under general air,,,,,,
16981,,circulatory disorder)||for pain,,,,,,,,,,20% background muscle,,,,,,
16982,,spinal cord damage)|have,,,,,,,,,,≥ 1.5×109/l;|platelet count,,,,,,
16983,,trans-urethral resection of the prostate,,,,,,,,,,≥100 000/µl|hemoglobin ≥9.0 g/dl,,,,,,
16984,,dmmr,,,,,,,,,,=< 2|ability to read,,,,,,
16985,,immunosuppressive medications|patients,,,,,,,,,,from 7% to 11%;|overweight,,,,,,
16986,,end organ function|recovery,,,,,,,,,,> 221,,,,,,
16987,,"intrauterine device,|smoking,|chronic diseases",,,,,,,,,,<6 months prior to enrollment,,,,,,
16988,,bladder stones,,,,,,,,,,< 18 years|women,,,,,,
16989,,invasive malignancies,,,,,,,,,,between 3 and 10 years.|belonging,,,,,,
16990,,addison's,,,,,,,,,,≥ 4|quick,,,,,,
16991,,cognitive dysfunction.|join other similar clinical researchers,,,,,,,,,,≥ 5.7%,,,,,,
16992,,homeotherapy,,,,,,,,,,> 100mmhg)|pre-registration,,,,,,
16993,,malignant transformation.||,,,,,,,,,,≥ 90 g/,,,,,,
16994,,solid tumors.|histologically,,,,,,,,,,>38.5oc,,,,,,
16995,,risk-enhancing factors.|if,,,,,,,,,,>=18 years old,,,,,,
16996,,post-partum,,,,,,,,,,over 65 years;|body mass index,,,,,,
16997,,radiographic disease progression,,,,,,,,,,> 2.5 times of the upper limit of normal value,,,,,,
16998,,hepatorenal syndrome)|acute infection|pregnancy,,,,,,,,,,>1×104 copies /ml or >2000 iu/ml,,,,,,
16999,,"acute kidney injury ""aki"" risk",,,,,,,,,,> 3.0×109/l,,,,,,
17000,,nerve root compression,,,,,,,,,,0 - iiic,,,,,,
17001,,traditional therapies,,,,,,,,,,>1.5 × institutional uln||hepatic|total bilirubin,,,,,,
17002,,anterior segment infection,,,,,,,,,,cadaver donors,,,,,,
17003,,primary colon cancer,,,,,,,,,,<0.9,,,,,,
17004,,tumour from the block,,,,,,,,,,< 126,,,,,,
17005,,normal chromosomal microarray (cma),,,,,,,,,,≥18 years|willing and able to give,,,,,,
17006,,thyrotoxicosis,,,,,,,,,,=< 5 x uln.||alanine aminotransferase (,,,,,,
17007,,menstrual period)|individuals,,,,,,,,,,<0.5×10^9/l,,,,,,
17008,,duodenal adenocarcinoma,,,,,,,,,,age≥ 50 years||patients,,,,,,
17009,,compromised immune system;|patients,,,,,,,,,,less than 30%|most,,,,,,
17010,,transcriptomic profile,,,,,,,,,,≥ 100 x 109/l.|total bilirubin,,,,,,
17011,,pancreatic diseases,,,,,,,,,,"< 1,25 unl",,,,,,
17012,,retinal break,,,,,,,,,,40 years or more,,,,,,
17013,,judged by the investigator to be unsuitable for clinical trials,,,,,,,,,,≥450 ml,,,,,,
17014,,neurological evolution.|neurological diseases,,,,,,,,,,above 30 kg/m2||,,,,,,
17015,,soft tissue sarcoma|candidate,,,,,,,,,,≥18 years old|understand and communicate,,,,,,
17016,,multiple tumors,,,,,,,,,,5 degrees,,,,,,
17017,,allogeneic sct,,,,,,,,,,+ donor): pregnancy,,,,,,
17018,,cardiac autonomic reflex tests,,,,,,,,,,≤ 1.5 x uln|ast/alt,,,,,,
17019,,ss,,,,,,,,,,between 18-35,,,,,,
17020,,vertebro-basilary artery insufficiency.|patient,,,,,,,,,,"2a, 2b, 3, 4a, 4b",,,,,,
17021,,liver dysfunction,,,,,,,,,,18-30|individuals,,,,,,
17022,,disseminated lupus erythematosus.|diagnosis,,,,,,,,,,between 18 and 75 years|patients,,,,,,
17023,,minutes)|active cancer,,,,,,,,,,> 18 years)||between 10 and 24 weeks pregnancy|fluent,,,,,,
17024,,global disease activity (,,,,,,,,,,≥50 kg,,,,,,
17025,,c-ssrs,,,,,,,,,,greater than 350 lbs,,,,,,
17026,,gerstmann syndrome,,,,,,,,,,>50 ml/min/1.73m^2|persons,,,,,,
17027,,pregnancy.1|cases of,,,,,,,,,,≥ 20%;|patients,,,,,,
17028,,medically stable condition,,,,,,,,,,ear:||(1,,,,,,
17029,,autoimmune disease|no,,,,,,,,,,18-65|agree to participate,,,,,,
17030,,cutaneous melanoma,,,,,,,,,,amplification).||phase 1b/2:,,,,,,
17031,,adolescence,,,,,,,,,,≥ 35 years,,,,,,
17032,,ischemic rest,,,,,,,,,,do not,,,,,,
17033,,language barrier.|other conditions,,,,,,,,,,1 cm2,,,,,,
17034,,disorder|alcohol abuse,,,,,,,,,,≥ 60 ml/min/1.73 m^2|a,,,,,,
17035,,6 months).|chronic diseases,,,,,,,,,,between 18 years to 60 years,,,,,,
17036,,irritable bowel disease,,,,,,,,,,>2000 iu/ml|persistently,,,,,,
17037,,pneumonia|signs,,,,,,,,,,less than 30 ml/min).|previous splenectomy.|previous participation,,,,,,
17038,,older|stroke,,,,,,,,,,18 and 70,,,,,,
17039,,acute lung disease,,,,,,,,,,59 and 61,,,,,,
17040,,anti-anxiety medication,,,,,,,,,,within 18.5 kg/m2,,,,,,
17041,,ebv infection,,,,,,,,,,≥ 1.50 g/l|0.9 g/l,,,,,,
17042,,allowed.|participant,,,,,,,,,,< 6 months)|patients,,,,,,
17043,,carcinoma.|measurable disease,,,,,,,,,,score ≤ 2|international,,,,,,
17044,,4):||considered stable,,,,,,,,,,9-10 weeks|weight,,,,,,
17045,,acoustic neuroma/vestibular schwannoma,,,,,,,,,,grade2 or greater,,,,,,
17046,,fnd,,,,,,,,,,i or ii physical,,,,,,
17047,,distant metastases;|eastern cooperative oncology group performance status,,,,,,,,,,≥ 139 mm hg,,,,,,
17048,,fatigue syndrome,,,,,,,,,,<18.5 or > 30 kg,,,,,,
17049,,iron deficiency anemia,,,,,,,,,,> 10 mm;|30,,,,,,
17050,,mental handicaps,,,,,,,,,,65-85 years.|non-smoking.|english,,,,,,
17051,,intolerance,,,,,,,,,,≤1.5 × uln,,,,,,
17052,,status epilepticus|sign,,,,,,,,,,"25-60 ml/min/1,73m2",,,,,,
17053,,adenosquamous cell carcinoma,,,,,,,,,,more than one month,,,,,,
17054,,conceiving,,,,,,,,,,greater than or equal to 400 mg/dl,,,,,,
17055,,systematically healthy,,,,,,,,,,< 1% nuclear,,,,,,
17056,,black british,,,,,,,,,,≤ 90 mmhg|diastolic blood pressure,,,,,,
17057,,pathological conditions,,,,,,,,,,> 80 years,,,,,,
17058,,secondary hyperaldosteronism|those,,,,,,,,,,≥70 g/l,,,,,,
17059,,sleep disorder group,,,,,,,,,,"≥ 100,000/µl|bilirubin ≤ 1.5 x upper limit of normal",,,,,,
17060,,clinical jaundice,,,,,,,,,,6-14 mm,,,,,,
17061,,kidney disease|metformin,,,,,,,,,,0-1.|life expectancy,,,,,,
17062,,deoxyribonucleic acid,,,,,,,,,,≥ 85 mmhg,,,,,,
17063,,unstable hypertension,,,,,,,,,,< 5 times the upper limit of normal;||24h,,,,,,
17064,,bladder cancer|do,,,,,,,,,,< 20 cc/min.|gi,,,,,,
17065,,premature ovarian failure|healthy,,,,,,,,,,140 - 199 mg/dl,,,,,,
17066,,aneurysm;|significant proximal stenosis,,,,,,,,,,equal to or less than 6 months,,,,,,
17067,,laparoscopic exploration,,,,,,,,,,<50 years,,,,,,
17068,,av) block,,,,,,,,,,below 80%|in case,,,,,,
17069,,joint|preexisting ankle arthritis|previous ankle,,,,,,,,,,less than 18,,,,,,
17070,,viii,,,,,,,,,,score of 17,,,,,,
17071,,significant donor,,,,,,,,,,> 120 minutes,,,,,,
17072,,neurological disorders;|history,,,,,,,,,,21 years,,,,,,
17073,,systemic reactions,,,,,,,,,,12-18 months,,,,,,
17074,,hepatitis c;|evidence,,,,,,,,,,<40y or >50yrs||,,,,,,
17075,,renal monitoring,,,,,,,,,,< 5 years,,,,,,
17076,,systolic bp measurements,,,,,,,,,,at least 110,,,,,,
17077,,moving away from the study,,,,,,,,,,greater than 3 ng/ml.||,,,,,,
17078,,uip type,,,,,,,,,,grade 1 or below,,,,,,
17079,,rabies victim,,,,,,,,,,< 2.5 x uln *,,,,,,
17080,,hair thinning,,,,,,,,,,4-week intervals,,,,,,
17081,,type of intervention,,,,,,,,,,0-1;|concomitant,,,,,,
17082,,inflammatory bowel diseases,,,,,,,,,,"between ""restless"" (+1)",,,,,,
17083,,functional hand|in overall good health,,,,,,,,,,≤ 1.5 × uln international normalized ratio,,,,,,
17084,,mental disorders;|any condition,,,,,,,,,,≤ 1.5x upper normal,,,,,,
17085,,type 1 diabetes|older than 18,,,,,,,,,,15 ng/l,,,,,,
17086,,anomalies.|fetal macrosomia,,,,,,,,,,≥18 years|ecog performance status,,,,,,
17087,,toxicity,,,,,,,,,,100-125 mg/dl)|hba1c,,,,,,
17088,,injection|contraindication,,,,,,,,,,<18.5 kg/m2;|bio-impedance phase,,,,,,
17089,,bone defect,,,,,,,,,,> 5 times the upper limit of reference range,,,,,,
17090,,congenital defect,,,,,,,,,,≥ 200,,,,,,
17091,,schmorl's nodes,,,,,,,,,,≥ 1000/ μ,,,,,,
17092,,substantive contraindications,,,,,,,,,,> 3 times upper limit of normal,,,,,,
17093,,lentigo malign,,,,,,,,,,≥ 50%|symptoms,,,,,,
17094,,progressive neuromuscular disorder,,,,,,,,,,< 20 kg/m2|body,,,,,,
17095,,evaluation|comorbid conditions,,,,,,,,,,25-65,,,,,,
17096,,cervical spinal stenosis,,,,,,,,,,< 110mg%,,,,,,
17097,,autism spectrum disorder,,,,,,,,,,older than 3 months,,,,,,
17098,,lung metastasis,,,,,,,,,,240 mg/dl,,,,,,
17099,,chronic bowel disorders,,,,,,,,,,18-60|lumbar radiculopathy|no,,,,,,
17100,,alpha-1 noradrenergic blockers,,,,,,,,,,less than 40 kg,,,,,,
17101,,neurosensorial disorders,,,,,,,,,,^9/l. note,,,,,,
17102,,medication.|acute coronary syndrome,,,,,,,,,,≥ ctcae level,,,,,,
17103,,poor cognitive state,,,,,,,,,,more than 30 weeks,,,,,,
17104,,post-injury,,,,,,,,,,<60 mmhg);|have ≥ grade 2,,,,,,
17105,,nasal symptoms,,,,,,,,,,≥ 1500/μl,,,,,,
17106,,evaluable lesion,,,,,,,,,,identify,,,,,,
17107,,root damage,,,,,,,,,,18 - 35 mg/m2,,,,,,
17108,,systemically healthy,,,,,,,,,,<45 beats per minute,,,,,,
17109,,ak lesion,,,,,,,,,,between 20 and 60 years|written consent to participate,,,,,,
17110,,ccne1 amplified tumors,,,,,,,,,,≥ 7,,,,,,
17111,,voc)|acute chest syndrome,,,,,,,,,,between 2.3 logmar and 0.5 logmar,,,,,,
17112,,epithelioid trophoblastic tumor,,,,,,,,,,>100 mmhg,,,,,,
17113,,cardiac problems,,,,,,,,,,18 to 40 kg/m2,,,,,,
17114,,informant,,,,,,,,,,≤ 55%);|acute coronary,,,,,,
17115,,metastatic disease presented,,,,,,,,,,> 1.0 diopter|uncontrolled diabetic retinopathy|iris,,,,,,
17116,,hypercapnic acidosis,,,,,,,,,,>5%;|voluntarily signed informed,,,,,,
17117,,native hawaiian,,,,,,,,,,≥ 60 kg,,,,,,
17118,,predominantly hyperactive/,,,,,,,,,,6 months or older,,,,,,
17119,,donor site wounds,,,,,,,,,,25-35 kg/m2|stable,,,,,,
17120,,meant,,,,,,,,,,0-1.||i-4,,,,,,
17121,,significant disorder,,,,,,,,,,"<100,000/mm^3",,,,,,
17122,,chemotherapy.|hormone receptor status,,,,,,,,,,18 years to 89 years old|bone marrow transplant recipients,,,,,,
17123,,acute interstitial pneumonia|any condition,,,,,,,,,,20-35 years,,,,,,
17124,,hcw,,,,,,,,,,1 to 1.5 standard deviations below the mean for their age,,,,,,
17125,,multiple accidental trauma,,,,,,,,,,≥ 29 days and < 1 year,,,,,,
17126,,neuromotor diseases,,,,,,,,,,> 30 h / week|sufficient,,,,,,
17127,,large bowel obstruction.|judgment,,,,,,,,,,< 3 x upper limit of normal (uln),,,,,,
17128,,introducer sheath;|any condition,,,,,,,,,,< 50%|history,,,,,,
17129,,impaired glucose tolerance)|in good general health,,,,,,,,,,2.5 upper limit of normal,,,,,,
17130,,brain injury|minimal time,,,,,,,,,,< 5 seconds,,,,,,
17131,,lymphoepithelial carcinoma salivary duct carcinoma adenocarcinoma,,,,,,,,,,6 to 35 months,,,,,,
17132,,pregnancy|ability to read,,,,,,,,,,=< 3.0 x uln,,,,,,
17133,,breast feeding|unable,,,,,,,,,,missing more than 50% of their dentition or their dentition,,,,,,
17134,,clinical disease burden,,,,,,,,,,≤ 3|excessive airway mucus secretion,,,,,,
17135,,rhinitis symptoms,,,,,,,,,,<55 bpm,,,,,,
17136,,physical abnormality,,,,,,,,,,16-21 years,,,,,,
17137,,chronic infection diseases,,,,,,,,,,< 60 mm,,,,,,
17138,,endometriosis,,,,,,,,,,0 or 1;|7.take the shorter,,,,,,
17139,,multidisciplinary als clinic|currently,,,,,,,,,,=< 20 mg/day,,,,,,
17140,,chronic kidney disorders,,,,,,,,,,20 mu g/l,,,,,,
17141,,mental health problems,,,,,,,,,,> 30mm/hr,,,,,,
17142,,renal functions.|eastern,,,,,,,,,,15 cm above the anal margin,,,,,,
17143,,good's syndrome,,,,,,,,,,<1% per year,,,,,,
17144,,traumatic injury;|any,,,,,,,,,,≥ 5 mm,,,,,,
17145,,caution.|patients not,,,,,,,,,,> 1.5 times upper limit of normal,,,,,,
17146,,non-hodgkin's lymphoma,,,,,,,,,,i-iii|patients,,,,,,
17147,,months|expression,,,,,,,,,,≤ 1.5,,,,,,
17148,,eligible.|participants,,,,,,,,,,between 25 and 30 mg/kg2,,,,,,
17149,,scarification,,,,,,,,,,18.0 - 32.0 kg/m^2,,,,,,
17150,,bop,,,,,,,,,,equal to or higher than 1.5×10^9/l,,,,,,
17151,,tumor infiltrating basement,,,,,,,,,,>160 mmhg,,,,,,
17152,,nonmelanoma skin cancers,,,,,,,,,,greater than or equal to 65|self reported difficulty,,,,,,
17153,,right ventricular dysfunction,,,,,,,,,,0 or 1,,,,,,
17154,,ascites drainage,,,,,,,,,,>= 14 days after local xrt,,,,,,
17155,,material|mental retardation,,,,,,,,,,between 6-18,,,,,,
17156,,osteopo- rosis,,,,,,,,,,more than 10 units,,,,,,
17157,,irinotecan allergic reactions,,,,,,,,,,65-90 years,,,,,,
17158,,androgenetic,,,,,,,,,,9-12 years,,,,,,
17159,,compulsive overeating,,,,,,,,,,< 1 month from symptom onset,,,,,,
17160,,uncontrolled disease,,,,,,,,,,15 years.|iq ≥ 85.||,,,,,,
17161,,systemic medical condition,,,,,,,,,,> 400 mg,,,,,,
17162,,eye conditions,,,,,,,,,,between 18 and 79 years,,,,,,
17163,,polycystic ovary syndrome,,,,,,,,,,>750×109/l,,,,,,
17164,,mergency department,,,,,,,,,,grade 4|individual,,,,,,
17165,,condition;|diabetes,,,,,,,,,,positive|at least 40 years,,,,,,
17166,,ethanol,,,,,,,,,,>27,,,,,,
17167,,tumor burden,,,,,,,,,,< 20,,,,,,
17168,,traumatic cataract,,,,,,,,,,<70%;|hemoglobin,,,,,,
17169,,anemia,,,,,,,,,,1.0 g/dl,,,,,,
17170,,adrenal insufficiency,,,,,,,,,,≥ 30 times per minute|oxygen saturation,,,,,,
17171,,"systemic lupus erythematosus,||rheumatoid arthritis",,,,,,,,,,≤30 ml/min,,,,,,
17172,,hallux valgus,,,,,,,,,,60 to 190 hair/cm2|telogen,,,,,,
17173,,post stroke,,,,,,,,,,<2500 copies/ml,,,,,,
17174,,correctable factors,,,,,,,,,,<30.0 kg/m2,,,,,,
17175,,degeneration disease,,,,,,,,,,30-59 ml/min per,,,,,,
17176,,diaphragm + spermicide,,,,,,,,,,greater than or equal to (>=) 19 years,,,,,,
17177,,nail care,,,,,,,,,,between 20-50 years,,,,,,
17178,,diverticulitis,,,,,,,,,,above 97.5th percentile excludes,,,,,,
17179,,cancer treatment|haemoglobin,,,,,,,,,,≥ 60 ml/min|participants,,,,,,
17180,,partial thickness loss of dermis,,,,,,,,,,at least 9,,,,,,
17181,,cold sores,,,,,,,,,,18.0 to 35.0 kg/m2,,,,,,
17182,,plasma cell leukemia,,,,,,,,,,between 22 and 50,,,,,,
17183,,lack of norwegian skills,,,,,,,,,,>30%.|presence,,,,,,
17184,,national health,,,,,,,,,,18 years old or older|a,,,,,,
17185,,gastrointestinal malignancy|patients,,,,,,,,,,0-1;|laboratory test results,,,,,,
17186,,signs of cancer,,,,,,,,,,≥ class ii;|restrictive,,,,,,
17187,,local skin malignancy,,,,,,,,,,<60 days of abstinence,,,,,,
17188,,criteria:||diagnosis,,,,,,,,,,"greater than or equal to 30 kg/m²,|being",,,,,,
17189,,dialysis.|history of malignancy,,,,,,,,,,≥ 40,,,,,,
17190,,transient cerebral ischemic attack))|patients,,,,,,,,,,"20 - 30 years,|non-smoker,|systemically",,,,,,
17191,,type of cancer the participant,,,,,,,,,,3,,,,,,
17192,,hyper-autofluorescence,,,,,,,,,,≥ 18 years||phase,,,,,,
17193,,skin phototype,,,,,,,,,,greater than two times the laboratory upper limit of normal|abnormal kidney function,,,,,,
17194,,ponv,,,,,,,,,,under 18 years|inability to understand information for participation|refusal of participation,,,,,,
17195,,autonomic involvement,,,,,,,,,,18-65 years.|acute,,,,,,
17196,,diabetic mellitus,,,,,,,,,,≥3 months|prior to the enrollment,,,,,,
17197,,renal insufficiency status,,,,,,,,,,outside normal range or < 125 x109/l|hemoglobin,,,,,,
17198,,upper limbs,,,,,,,,,,3-9,,,,,,
17199,,≧,,,,,,,,,,≥0.5,,,,,,
17200,,"chronic kidney disease (ckd, 2012 kdigo",,,,,,,,,,1-84,,,,,,
17201,,radiation treatments|musculoskeletal disease,,,,,,,,,,10 and 18 years,,,,,,
17202,,severity|intellectual disability,,,,,,,,,,> 24 months.|other inclusion criteria,,,,,,
17203,,posttraumatic cord tethering,,,,,,,,,,>2.5 × upper limit of normal|lactating,,,,,,
17204,,acute cystitis|bladder cancer|chronic prostatitis|bladder stone|stress incontinence,,,,,,,,,,1 or more deformities,,,,,,
17205,,rectal,,,,,,,,,,>3 months after last,,,,,,
17206,,tension-type headache,,,,,,,,,,>300 pg/ml when,,,,,,
17207,,continuous alcohol abuse,,,,,,,,,,younger than 18 years|pregnancy|uterine,,,,,,
17208,,intraventricular conduction block,,,,,,,,,,<18 years old|pregnant,,,,,,
17209,,nulliparous pcos,,,,,,,,,,> 18 years|full,,,,,,
17210,,cola drinks,,,,,,,,,,≥50% of predicted level,,,,,,
17211,,cardiopulmonary bypass (cpb,,,,,,,,,,between 18 and 30|reporting at least a,,,,,,
17212,,urinary system diseases,,,,,,,,,,0 or 1|have measurable disease,,,,,,
17213,,death,,,,,,,,,,≥ 100×109cells/l,,,,,,
17214,,disc sequestration|previously treated,,,,,,,,,,0-2|patients,,,,,,
17215,,cognitive impairment|have,,,,,,,,,,< 10 ng/ml|normal renal,,,,,,
17216,,psychiatric disorder|advanced,,,,,,,,,,≤ 20 ml/min/1.73m2,,,,,,
17217,,periodontal disease;|healed bone crest,,,,,,,,,,≤1.0 times the upper limit of normal value|ast,,,,,,
17218,,bleeding diathesis|thyroid disease,,,,,,,,,,≤ 50,,,,,,
17219,,pus on aspiration|at least,,,,,,,,,,18-0010,,,,,,
17220,,medication|known intolerance,,,,,,,,,,0-1;|estimated survival time,,,,,,
17221,,erectile dysfunction.||,,,,,,,,,,<60/ min,,,,,,
17222,,irritation symptoms,,,,,,,,,,≥ 50 ml/min||from,,,,,,
17223,,primary liver cancer,,,,,,,,,,stage ii-iv,,,,,,
17224,,reflex changes,,,,,,,,,,from 40 to 50years,,,,,,
17225,,nsclc.|no,,,,,,,,,,0-2;|child-pugh score a period;|have not,,,,,,
17226,,functional performance,,,,,,,,,,14-15,,,,,,
17227,,genetic obesity,,,,,,,,,,>38.5).|vaccination <1 month before start of,,,,,,
17228,,short qt syndrome,,,,,,,,,,≥ 2ng/ml||j,,,,,,
17229,,judged in the kellgren-lawrence grade (kl grade,,,,,,,,,,older than 90 years,,,,,,
17230,,limit mobility,,,,,,,,,,> upper limit of normal [uln,,,,,,
17231,,contraception|willing,,,,,,,,,,≥ 1-year,,,,,,
17232,,mental health difficulties,,,,,,,,,,less than 15 years duration,,,,,,
17233,,acute heart failure.|major patient.|subject,,,,,,,,,,>21 mmhg,,,,,,
17234,,acute neurological condition,,,,,,,,,,under age,,,,,,
17235,,psychiatric diseases.|cognitive impairment,,,,,,,,,,from 18 to 75 years,,,,,,
17236,,cervical intraepithelial tumor,,,,,,,,,,>50 breaths per minute,,,,,,
17237,,anuria,,,,,,,,,,>100 ml or,,,,,,
17238,,paraplegia bone metastasis,,,,,,,,,,18 years and older;|have,,,,,,
17239,,primary bc,,,,,,,,,,between 2002-,,,,,,
17240,,systemic therapy.|the,,,,,,,,,,18 to 85 years|if,,,,,,
17241,,metabolic system,,,,,,,,,,less than 50% of the total score,,,,,,
17242,,mild dementia,,,,,,,,,,18-60,,,,,,
17243,,terminal disease||swallowing issues||self-reported,,,,,,,,,,less than 70,,,,,,
17244,,pulmonary lesions,,,,,,,,,,part a only||healthy psychedelic-experienced,,,,,,
17245,,systemic lymphoma,,,,,,,,,,≥ 18 years|both,,,,,,
17246,,major sickle cell,,,,,,,,,,> 3|head,,,,,,
17247,,language barriers,,,,,,,,,,6 to 12,,,,,,
17248,,columnar metaplasia,,,,,,,,,,< -2.0,,,,,,
17249,,associated rectal cancer,,,,,,,,,,are:||(oligo)metastatic disease|histologically,,,,,,
17250,,androgenetic alopecia,,,,,,,,,,"≥ 75,000/μl|hemoglobin",,,,,,
17251,,local basal cell,,,,,,,,,,100 109/l,,,,,,
17252,,supportive housing,,,,,,,,,,between 4 and 18 years.|informed consent signed by parents/guardians.||,,,,,,
17253,,ischaemic neurological,,,,,,,,,,<22 meq/l|consumption,,,,,,
17254,,hepatocellular cholangiocarcinoma,,,,,,,,,,6 months-14 years,,,,,,
17255,,hiatal hernias,,,,,,,,,,18 and above|have registered at least one,,,,,,
17256,,classification criteria,,,,,,,,,,<80 g/l,,,,,,
17257,,clinically significant illness,,,,,,,,,,basal cell,,,,,,
17258,,hypoglycemic episodes,,,,,,,,,,≥ 4 days.||,,,,,,
17259,,colorectal liver metastasis,,,,,,,,,,greater than or equal to,,,,,,
17260,,heart defect,,,,,,,,,,> 40|legal,,,,,,
17261,,micro,,,,,,,,,,stage d hf,,,,,,
17262,,mild joint disease,,,,,,,,,,30-65 years,,,,,,
17263,,diffuse rash,,,,,,,,,,± 5% of his/her,,,,,,
17264,,psychiatric conditions|patients,,,,,,,,,,≥1.5×10^9/l;|platelet count,,,,,,
17265,,traumatic bleeding,,,,,,,,,,≥30,,,,,,
17266,,inflammatory diseases of the nervous system,,,,,,,,,,>=1.5 cm,,,,,,
17267,,ppi,,,,,,,,,,18-75|ecog score,,,,,,
17268,,anatomical abnormality,,,,,,,,,,≥ uln,,,,,,
17269,,fibrolamellar carcinoma,,,,,,,,,,≥ 6 months.|subjects,,,,,,
17270,,diverticula,,,,,,,,,,>500/mm3,,,,,,
17271,,pain induced,,,,,,,,,,>20 units/week,,,,,,
17272,,prior bladder instillation,,,,,,,,,,class a,,,,,,
17273,,moderate dry eye|pregnancy,,,,,,,,,,60 to 75 years,,,,,,
17274,,active eye diseases,,,,,,,,,,i-iii).|female.|at least 18 years,,,,,,
17275,,pdr,,,,,,,,,,< 20ml/min,,,,,,
17276,,fibromyalgia syndrome,,,,,,,,,,≥18 years.|patients must be able to write,,,,,,
17277,,in-situ cervical cancer,,,,,,,,,,≥ 2 mm,,,,,,
17278,,"humanized antibodies,",,,,,,,,,,50-72|followed,,,,,,
17279,,celea pm,,,,,,,,,,> 4 times exceeding upper reference,,,,,,
17280,,comorbid endocrine system disorders,,,,,,,,,,less than 1 year|patients,,,,,,
17281,,acne scars,,,,,,,,,,≥ 5 points,,,,,,
17282,,interact,,,,,,,,,,> 2nd degree)|measurements,,,,,,
17283,,black stools,,,,,,,,,,< 30%|known,,,,,,
17284,,non-compliance,,,,,,,,,,< 7.30,,,,,,
17285,,antithrombotic,,,,,,,,,,≥60 ml/min|women,,,,,,
17286,,escre,,,,,,,,,,<18 or >85 years old|received chemotherapy,,,,,,
17287,,peritoneal carcinoma,,,,,,,,,,> 40|consciousness disorder,,,,,,
17288,,progressive multifocal leukoencephalopathy).|patients,,,,,,,,,,≥ 20uu/l).|hyperprolactinemia,,,,,,
17289,,urinary infections,,,,,,,,,,i to v of the neck,,,,,,
17290,,dermatological condition,,,,,,,,,,≥ 8g/,,,,,,
17291,,prognostic factor,,,,,,,,,,50-64)|women,,,,,,
17292,,takotsubo syndrome,,,,,,,,,,< 18 years;|pregnant,,,,,,
17293,,transient ischemic neurologic,,,,,,,,,,30 mm,,,,,,
17294,,acute substance,,,,,,,,,,≥18 years|ability and willingness to provide informed consent,,,,,,
17295,,non-investigational,,,,,,,,,,≥ 80 years,,,,,,
17296,,venous thromboembolism;|myocardial infarction,,,,,,,,,,≥4.0 × 109/l.|neutrophil count (,,,,,,
17297,,symptoms relapsed,,,,,,,,,,>350 cells/mm3,,,,,,
17298,,heart function,,,,,,,,,,= blank,,,,,,
17299,,asthma exacerbation treated,,,,,,,,,,< 2 months,,,,,,
17300,,keloid scarring,,,,,,,,,,>30%,,,,,,
17301,,criteria of the international classification of diseases 11th edition (icd-11) diagnostic criteria for mdd;|15≤,,,,,,,,,,younger than 34 weeks,,,,,,
17302,,sui symptoms,,,,,,,,,,< 10 words,,,,,,
17303,,pulmonary thromboembolism||,,,,,,,,,,< 13 years,,,,,,
17304,,type 2 diabetes defines,,,,,,,,,,≥ grade 3,,,,,,
17305,,pancreatic head malignancy,,,,,,,,,,c-reactive,,,,,,
17306,,gluten enteropathy,,,,,,,,,,>1.5 x uln per discussion,,,,,,
17307,,immunodeficiency|active infection,,,,,,,,,,18-25||,,,,,,
17308,,psychological pathology|do,,,,,,,,,,18-75 years|either gender|patients with aclf,,,,,,
17309,,antibody;|acute disease,,,,,,,,,,< 40%,,,,,,
17310,,associated toxicity,,,,,,,,,,< 1 cm,,,,,,
17311,,liver cancer,,,,,,,,,,> 0.5.|patient able to ambulate,,,,,,
17312,,perioperative,,,,,,,,,,≥ grade 2,,,,,,
17313,,dependent persons.|inability,,,,,,,,,,greater than 115,,,,,,
17314,,gastrointestinal (gi) condition,,,,,,,,,,≥ 41,,,,,,
17315,,digestive disease,,,,,,,,,,5 to 15 years born before,,,,,,
17316,,bleeding disorders|patients,,,,,,,,,,between 18 and 55 years.|having,,,,,,
17317,,limb agenesis,,,,,,,,,,18.5 to 30.||,,,,,,
17318,,malignancy.|active infection,,,,,,,,,,≥ 50 years,,,,,,
17319,,ffpe,,,,,,,,,,≥ 70 years|symptomatic severe,,,,,,
17320,,depression,,,,,,,,,,>200 pg/ml,,,,,,
17321,,increased fatigue|person,,,,,,,,,,2022-002616-24study code#,,,,,,
17322,,between luxation,,,,,,,,,,lower than 45 beats/minute,,,,,,
17323,,drainage procedures|uncontrolled,,,,,,,,,,3+,,,,,,
17324,,salivary glands,,,,,,,,,,18 years or older|willing to provide informed,,,,,,
17325,,rosacea.|have,,,,,,,,,,=> 18.0 to <= 32 kg/m2,,,,,,
17326,,acute stroke|patients,,,,,,,,,,18 to 55|elevated overall score,,,,,,
17327,,organ support,,,,,,,,,,between 45 to 59 years.|women survivors of,,,,,,
17328,,oral lesion,,,,,,,,,,≤30 ml/min/1.73 m2,,,,,,
17329,,autonomic dysfunction|skin inflammation,,,,,,,,,,1.5 times higher than the uln.||creatinine is 1.5 times higher than the uln.||hiv-infected,,,,,,
17330,,women|received covid-19 vaccine||,,,,,,,,,,0 or 1.|at least 4 months,,,,,,
17331,,syphilis detection,,,,,,,,,,less than 90 beats/min,,,,,,
17332,,recovered from the effects of surgery,,,,,,,,,,<50 copies/ml;|stable,,,,,,
17333,,depressive symptoms,,,,,,,,,,over 105 mmhg,,,,,,
17334,,addictive disorder,,,,,,,,,,>3,,,,,,
17335,,above cardiac failure,,,,,,,,,,≥ 60×109/l,,,,,,
17336,,third spacing,,,,,,,,,,equal to or less than 17|patient,,,,,,
17337,,as:||unstable angina,,,,,,,,,,≥ 130 mg/dl,,,,,,
17338,,bilateral tubal occlusion,,,,,,,,,,> 1/3mca)|patients,,,,,,
17339,,inflammatory syndrome,,,,,,,,,,score 0-1;|the main organs function normally,,,,,,
17340,,hereditary colorectal cancer syndrome,,,,,,,,,,> one year,,,,,,
17341,,calculated by cockcroft and gault formulas] - creatinine clearance,,,,,,,,,,ix,,,,,,
17342,,fetal congenital malformations,,,,,,,,,,<15 u/ml,,,,,,
17343,,neoadjuvant therapy|age,,,,,,,,,,≤ 2 x uln,,,,,,
17344,,nerve palsy|medical,,,,,,,,,,< 2.8mmol/l,,,,,,
17345,,life sustaining,,,,,,,,,,≥ 8.5 g/dl|absolute,,,,,,
17346,,mental deficiency,,,,,,,,,,<18 years|decline to participate|pregnancy|cirrhosis,,,,,,
17347,,ntg)||identical to poag,,,,,,,,,,18 to 45 years;|conform to the,,,,,,
17348,,recovered from the,,,,,,,,,,≤ 5.30 mmol/l|triglycerides,,,,,,
17349,,acute heart failure|patients,,,,,,,,,,i to iv|subject,,,,,,
17350,,digital rectal exam,,,,,,,,,,greater than 2.0,,,,,,
17351,,memory domain,,,,,,,,,,long-term treatment,,,,,,
17352,,vascular condition,,,,,,,,,,per-operative,,,,,,
17353,,congestive heart failure|hypertension,,,,,,,,,,between 50 and 70 years,,,,,,
17354,,radicular extremity pain,,,,,,,,,,"< 13,000 u/l)||according",,,,,,
17355,,tuberculous cystitis|history,,,,,,,,,,0-1|available archival formalin-fixed,,,,,,
17356,,pleural involvement,,,,,,,,,,at least 18 months,,,,,,
17357,,training,,,,,,,,,,>= 30 years old and =< 75 years,,,,,,
17358,,local infection,,,,,,,,,,>200 ml,,,,,,
17359,,dyspnea|transcutaneous oxygen saturation,,,,,,,,,,higher than or equal to 25 kg / m 2,,,,,,
17360,,thyroid disorder,,,,,,,,,,≤1.5 uln,,,,,,
17361,,calculated by the cockcroft,,,,,,,,,,score 4 or more,,,,,,
17362,,organic gastrointestinal,,,,,,,,,,< 1.4,,,,,,
17363,,polypathology,,,,,,,,,,>2|prior,,,,,,
17364,,day)|concomitant disease,,,,,,,,,,<5 years,,,,,,
17365,,spontaneous menstrual cycle,,,,,,,,,,25-40)||,,,,,,
17366,,old|bmi,,,,,,,,,,≥ 1×109/l,,,,,,
17367,,child's grade,,,,,,,,,,>= 1500/mm^3|registration,,,,,,
17368,,revascularisation of,,,,,,,,,,> 10.0 g/dl|bilirubin < 1.5 mg/dl,,,,,,
17369,,posttraumatic arthritis,,,,,,,,,,</= 5 mg,,,,,,
17370,,radiation esophagitis,,,,,,,,,,≥12 weeks;||9,,,,,,
17371,,terminal ill.|previous chemotherapy,,,,,,,,,,= 284 ml of beer,,,,,,
17372,,hemodynamic support.|participation,,,,,,,,,,>80 years|patients,,,,,,
17373,,bone marrow transplantation;|2,,,,,,,,,,score of back pain,,,,,,
17374,,vesicle cyst,,,,,,,,,,less than 8 years,,,,,,
17375,,urothelium cancer,,,,,,,,,,25 mmhg,,,,,,
17376,,psychotic disorder.|diagnosis,,,,,,,,,,greater than or equal to 25|able to participate,,,,,,
17377,,sacral plexus,,,,,,,,,,0-1.|patients should not,,,,,,
17378,,circulatory disorder,,,,,,,,,,≤ 5 x uln.|renal function,,,,,,
17379,,nervous disorders,,,,,,,,,,<35 kg/m^2||,,,,,,
17380,,chronic fatigue syndrome (m79 .7,,,,,,,,,,>= 18 kg,,,,,,
17381,,inadequate bowel preparation quality,,,,,,,,,,18-35 kg / m2,,,,,,
17382,,arteriovenous sheath,,,,,,,,,,≤ 5 uln,,,,,,
17383,,drugs abuse,,,,,,,,,,">1 year|rutherford classification of 2, 3 or 4.||",,,,,,
17384,,right coronary artery,,,,,,,,,,18 years and older|histologically,,,,,,
17385,,habit|taking berry-related supplementation,,,,,,,,,,24 to 32 days:||if,,,,,,
17386,,severe dysautonomic disease,,,,,,,,,,"> 52,5 kilograms",,,,,,
17387,,cardiac disease|positive test for hiv,,,,,,,,,,score between 83 and 23 letters,,,,,,
17388,,anamnesis,,,,,,,,,,<130 mmol/l)|dyskalemia,,,,,,
17389,,electrophoresis⎯,,,,,,,,,,22-40|bmi,,,,,,
17390,,epithelial cell skin cancer,,,,,,,,,,≤ 1.0 unl,,,,,,
17391,,liver biochemical indexes,,,,,,,,,,> 10 mmhg|at the principal investigator's discretion,,,,,,
17392,,stop-bang,,,,,,,,,,0-1 +,,,,,,
17393,,tree nuts,,,,,,,,,,> 0.75 mm,,,,,,
17394,,benign thymoma|history of thymectomy,,,,,,,,,,6/10 or more,,,,,,
17395,,move away,,,,,,,,,,≥43 mmol/mol,,,,,,
17396,,end of consolidation,,,,,,,,,,between 2.5 to 8 years,,,,,,
17397,,neurosensory deficiency,,,,,,,,,,> 5 ml/kg,,,,,,
17398,,functional mitral regurgitation,,,,,,,,,,0 or 1.|histologically,,,,,,
17399,,pregnancy|lack,,,,,,,,,,18-90,,,,,,
17400,,pathological type,,,,,,,,,,> 2.5 x uln,,,,,,
17401,,contraindicates contact lens,,,,,,,,,,from 18 to 35,,,,,,
17402,,breast feeding.|craniocerebral injury,,,,,,,,,,≤ 5%).|it,,,,,,
17403,,processes,,,,,,,,,,0-2.|subjects,,,,,,
17404,,profound numbness after,,,,,,,,,,between 18 - 70,,,,,,
17405,,non-atherothrombotic mechanism,,,,,,,,,,long-term care facility|does,,,,,,
17406,,trochleoplasty|significant osteoarthritis,,,,,,,,,,> 10 g/dl|ast(sgot)/alt(sgpt,,,,,,
17407,,hepatic vein,,,,,,,,,,≤ 1.5 x uln|serum,,,,,,
17408,,anaesthetic room,,,,,,,,,,less than 12.0mm.|participants,,,,,,
17409,,solid-tumor malignancy,,,,,,,,,,less than 22 (<22),,,,,,
17410,,colectomy,,,,,,,,,,=< 1.5 × uln,,,,,,
17411,,microangiopathy,,,,,,,,,,50-65,,,,,,
17412,,spinal inflammatory disease,,,,,,,,,,male ≥50 kg,,,,,,
17413,,tela,,,,,,,,,,between 12 and 17 years|atraumatic lower extremity pain,,,,,,
17414,,nru,,,,,,,,,,> 6 kpa)|need,,,,,,
17415,,end-organ failure,,,,,,,,,,≤ 2.5 x uln|albumin ≥,,,,,,
17416,,"""epilepsy",,,,,,,,,,45-day,,,,,,
17417,,syncopal episodes resulting,,,,,,,,,,more than 45 degrees,,,,,,
17418,,mental pathology,,,,,,,,,,4.3 or higher,,,,,,
17419,,digital workflow,,,,,,,,,,from 3 to 8 years|first,,,,,,
17420,,lumbar stabilization,,,,,,,,,,0 to 1.|expected survival,,,,,,
17421,,lost response,,,,,,,,,,≤ 450 meters,,,,,,
17422,,childbearing age.||,,,,,,,,,,0-1;||6,,,,,,
17423,,macular scarring,,,,,,,,,,9-12|have standing orders,,,,,,
17424,,sunflower,,,,,,,,,,"0, 1, 5 or 6|presence",,,,,,
17425,,secondary forms,,,,,,,,,,<150 iu/l,,,,,,
17426,,angiographic complication,,,,,,,,,,< iii.|muscle relaxant,,,,,,
17427,,acute respiratory insuffiency,,,,,,,,,,0-1;|non-squamous,,,,,,
17428,,immunodeficiency condition,,,,,,,,,,> 2 times the upper limit normal.|ecog performance status,,,,,,
17429,,primary hematologic disorder|petechiae,,,,,,,,,,<9|last a1c date occurred,,,,,,
17430,,antilymphocyte sera,,,,,,,,,,< 100 and >,,,,,,
17431,,ischemic attack|uncontrolled hypertension|unstable angina|myocardial,,,,,,,,,,"between 30 and 80 years,|no",,,,,,
17432,,total n=400,,,,,,,,,,> 0.4 mg/l,,,,,,
17433,,extraduodenal small bowel tumors,,,,,,,,,,≥7.0%)|able to,,,,,,
17434,,participation|medical condition,,,,,,,,,,less than 34,,,,,,
17435,,rheumatic,,,,,,,,,,1 or better from,,,,,,
17436,,sgc,,,,,,,,,,> 4.8 to 5.0 mmol/l,,,,,,
17437,,adverse events (ctcae) version,,,,,,,,,,18 years and above on the day of enrollment;|had,,,,,,
17438,,excessive sleepiness,,,,,,,,,,≥75 mg/day,,,,,,
17439,,passive immunization,,,,,,,,,,<50% vas reduction,,,,,,
17440,,thrombus;|uncontrolled heart failure,,,,,,,,,,< 10 ng/ml,,,,,,
17441,,myoneural disorders|congestive heart failure,,,,,,,,,,less than 18 years old|multiple,,,,,,
17442,,head injuries,,,,,,,,,,>1.5 × the upper limit of normal,,,,,,
17443,,oklahoma,,,,,,,,,,> 1.5 g/l;|platelets,,,,,,
17444,,liver injury,,,,,,,,,,>18 years and <80 years,,,,,,
17445,,impairment of immune function,,,,,,,,,,4-15 years,,,,,,
17446,,drug of abuse,,,,,,,,,,1.5×109/l);|platelet count,,,,,,
17447,,exotic citrus fruits,,,,,,,,,,>2×uln;|total bilirubin level,,,,,,
17448,,signs of ischemia,,,,,,,,,,two times by his/her,,,,,,
17449,,gastrointestinal discomfort,,,,,,,,,,greater than sinotubular junction,,,,,,
17450,,local anesthesia.|patients,,,,,,,,,,140 mmhg.|patients,,,,,,
17451,,autoimmune encephalopathy,,,,,,,,,,1.5 x 109/l,,,,,,
17452,,malignant tumors;|cohort extension of,,,,,,,,,,score 0~1,,,,,,
17453,,high-risk arrhythmias,,,,,,,,,,<18 years).|willing to allow specimens,,,,,,
17454,,bacterial endocarditis.|evidence,,,,,,,,,,=< 15 days prior to registration)|platelet count,,,,,,
17455,,large vessel vasculitis,,,,,,,,,,≥ 18 years old.|anterior stemi,,,,,,
17456,,type of tki,,,,,,,,,,≥ 30 g/l;||serum,,,,,,
17457,,malignant colonic obstruction|overall health status,,,,,,,,,,≤ 2.0 × upper limit of normal (uln),,,,,,
17458,,transfusion of red blood cells,,,,,,,,,,> grade 1.||*white,,,,,,
17459,,moderate alcohol,,,,,,,,,,18 - 30 years|confirmed,,,,,,
17460,,handling of the nss device.|subjects,,,,,,,,,,≥ 8.0 g/dl|creatinine,,,,,,
17461,,human immunodeficiency,,,,,,,,,,< 30%)|egfr < 30 ml/min/1.73m2,,,,,,
17462,,organ injury,,,,,,,,,,≥ 15 kg.|females,,,,,,
17463,,residents|critically ill,,,,,,,,,,above >5.6 mmol/l,,,,,,
17464,,≤1 cm diameter,,,,,,,,,,≥ 250 μg/g,,,,,,
17465,,medication-controlled hypertension,,,,,,,,,,lower than the pain,,,,,,
17466,,hepatitis d virus,,,,,,,,,,25 - 60 years.|fluent,,,,,,
17467,,valve heart disease,,,,,,,,,,<= 29.|history,,,,,,
17468,,svd,,,,,,,,,,from 13 years,,,,,,
17469,,tachy-atrial arrhythmias,,,,,,,,,,≥ 3 years,,,,,,
17470,,bcc)|inflammatory bowel disease|mammography,,,,,,,,,,between 12 and 18 years)|diagnosis of chd,,,,,,
17471,,child dies,,,,,,,,,,ml/min,,,,,,
17472,,infection|pregnant,,,,,,,,,,>2 times uln,,,,,,
17473,,lower extremity unilateral dvt,,,,,,,,,,≥ 18 years|documented diagnosis,,,,,,
17474,,sufficient)|no nephropathy,,,,,,,,,,above 60 min duration|informed,,,,,,
17475,,signal transduction inhibitors,,,,,,,,,,≥12 months;|understand,,,,,,
17476,,recurrence (disease progression,,,,,,,,,,less than 11g/dl|history,,,,,,
17477,,underlying diseases;|no depression,,,,,,,,,,≥ 18 years.|good understanding of the oral,,,,,,
17478,,stroke type,,,,,,,,,,18.5 to 42.0 kg/m2|willing,,,,,,
17479,,dairy intolerance,,,,,,,,,,c)|body,,,,,,
17480,,diagnosis|chronic respiratory disease,,,,,,,,,,> 2 x normal,,,,,,
17481,,leg;|hemiplegia,,,,,,,,,,>= 45 ml/min,,,,,,
17482,,myometrial invasion.||,,,,,,,,,,<7.4mm,,,,,,
17483,,lipid storage diseases,,,,,,,,,,>= 2|non-,,,,,,
17484,,retinal vein,,,,,,,,,,>5 g/l,,,,,,
17485,,pathological symptoms/,,,,,,,,,,40-85|asa,,,,,,
17486,,criteria of androgenic alopecia,,,,,,,,,,15 degrees|non-correctable,,,,,,
17487,,nationality,,,,,,,,,,<30 kg/m^2||exclusion criteria,,,,,,
17488,,difficulty communicating,,,,,,,,,,0 to < 8 years,,,,,,
17489,,mild hepatic impairment,,,,,,,,,,<36 weeks,,,,,,
17490,,abnormal clinical medical investigation;|subjects,,,,,,,,,,between 18 and 40 years.|maximal,,,,,,
17491,,impaired peristalsis,,,,,,,,,,< 20%|planning,,,,,,
17492,,target lesions amenable,,,,,,,,,,under 18 years old|having poor oral,,,,,,
17493,,bilateral appendage resection);|signed,,,,,,,,,,16 years or more,,,,,,
17494,,lifestyle consideration,,,,,,,,,,more than two years prior to study,,,,,,
17495,,cervical trauma pathology|acdf,,,,,,,,,,< 50 ml per min ethylenediaminetetraacetic acid,,,,,,
17496,,neurologic level,,,,,,,,,,≤ 200 pg/ml;|blood,,,,,,
17497,,reproductive biology,,,,,,,,,,< 60 ml / min / 1.73 m2,,,,,,
17498,,external rotation,,,,,,,,,,>90 decibels [db],,,,,,
17499,,midbrain,,,,,,,,,,6-11 months old,,,,,,
17500,,cerebrospinal fluid,,,,,,,,,,between ≤20/40,,,,,,
17501,,crown defects,,,,,,,,,,>2 mg/dl.|ecg,,,,,,
17502,,41.4 gy,,,,,,,,,,≥18 and ≤65,,,,,,
17503,,cardiovascular comorbidities,,,,,,,,,,"≥65 ,",,,,,,
17504,,impaired glucose tolerance,,,,,,,,,,<2 days/wk,,,,,,
17505,,arterial hypervascularity,,,,,,,,,,letter score,,,,,,
17506,,radiographic variables,,,,,,,,,,≤ 30 years,,,,,,
17507,,lower back,,,,,,,,,,≥ 35% predicted|ct mucus plug score,,,,,,
17508,,health supplement,,,,,,,,,,< 25 ml/min,,,,,,
17509,,intracranial tumors,,,,,,,,,,< 24 hours before randomization.|suspected,,,,,,
17510,,venous serum bicarbonate,,,,,,,,,,>45%.||hematologic:||absolute lymphocyte count,,,,,,
17511,,month.|serious infectious diseases,,,,,,,,,,at least 90 days after the procedure).||**true,,,,,,
17512,,thyroid cancer,,,,,,,,,,less than 50 beats per minute|systolic blood pressure,,,,,,
17513,,"inflammatory joint disease,|having",,,,,,,,,,≤ 3 mg/day,,,,,,
17514,,pelvic infection,,,,,,,,,,the 80%,,,,,,
17515,,significant physical abnormalities,,,,,,,,,,<60%|bmi,,,,,,
17516,,gallstones,,,,,,,,,,≥ 4).||intermediate-,,,,,,
17517,,impaired muscles,,,,,,,,,,between 18-65 years,,,,,,
17518,,acute lung disorders,,,,,,,,,,18-40 years,,,,,,
17519,,t1,,,,,,,,,,weaned <15 years||,,,,,,
17520,,pathogenic microorganism pneumonia,,,,,,,,,,older than 6 years,,,,,,
17521,,consumption of up to 10 cigarettes,,,,,,,,,,≥ 200mg/day,,,,,,
17522,,neurological diseases|previous hysterectomy,,,,,,,,,,≥10 hours per week,,,,,,
17523,,in situ squamous cell carcinoma,,,,,,,,,,> 20 years.|agreement to complete the study.||,,,,,,
17524,,ulcer disease|large hiatal,,,,,,,,,,<18 years|open wounds,,,,,,
17525,,etc.|pruritus,,,,,,,,,,18-27 kg/m2.|sufficient,,,,,,
17526,,hepatic transaminase levels,,,,,,,,,,≥7.5 mg/dl,,,,,,
17527,,contra-indication,,,,,,,,,,> 1.4 mg/dl)|psychiatric,,,,,,
17528,,coronary multivessel disease,,,,,,,,,,15 years or older|residence,,,,,,
17529,,end of intervention visit,,,,,,,,,,years|minimum 2 cm diastasis,,,,,,
17530,,general anxiety disorder,,,,,,,,,,= 450 milliliter [ml,,,,,,
17531,,risk surgical candidates,,,,,,,,,,≥ 60ml/min|serum,,,,,,
17532,,cognitive impairment.||exclusion criteria,,,,,,,,,,≤ 1.5×uln,,,,,,
17533,,wrinkle severity scale,,,,,,,,,,< 3.5mmol/l,,,,,,
17534,,systemic disorders,,,,,,,,,,upper limit of normal value,,,,,,
17535,,parkinson's disease|human immunodeficiency virus (hiv),,,,,,,,,,≤ 25,,,,,,
17536,,good,,,,,,,,,,1 year,,,,,,
17537,,verified extraduodenal tumor(-s,,,,,,,,,,1.1 criteria;|estimated,,,,,,
17538,,vasculitis,,,,,,,,,,>= 30 ml/min|eligibility criteria,,,,,,
17539,,cohort||consecutive adult,,,,,,,,,,< 70 g/l;|researchers,,,,,,
17540,,hallucinations,,,,,,,,,,≥2 points;|the subject,,,,,,
17541,,tips,,,,,,,,,,"37-41 weeks).,|american society of anaesthesiologists",,,,,,
17542,,asat,,,,,,,,,,> 1x upper limit of normal (uln),,,,,,
17543,,immune defects,,,,,,,,,,60- to 90-year,,,,,,
17544,,infection related,,,,,,,,,,0 to 3,,,,,,
17545,,nocturnal dyspnea,,,,,,,,,,<95% predicted|asthma control questionnaire (acq-7): score ≥1.5|in,,,,,,
17546,,skin diseases.|those,,,,,,,,,,18 - 65 years|capable,,,,,,
17547,,peripheral arterial circulatory disturbance,,,,,,,,,,>500ms,,,,,,
17548,,neurological disease|traumatic brain injury,,,,,,,,,,40-100 beats/min,,,,,,
17549,,natural amenorrhoea,,,,,,,,,,>18.|subject,,,,,,
17550,,sacroiliac pathology,,,,,,,,,,≥ 30 and ≤ 60 years,,,,,,
17551,,microscopy colitis,,,,,,,,,,< 4 weeks before screening,,,,,,
17552,,malfunctioning|acute infections,,,,,,,,,,=< 1.5 x upper limit of normal (uln),,,,,,
17553,,elective nasal surgeries,,,,,,,,,,≥1.0×109/l,,,,,,
17554,,dm||diagnosis of dm with,,,,,,,,,,at least 50% of time in direct patient care|availability,,,,,,
17555,,suppress ovulation,,,,,,,,,,< 60 / min)|patients,,,,,,
17556,,generalized seizures,,,,,,,,,,18 - 100 years,,,,,,
17557,,leptomeningeal disease|uncontrolled,,,,,,,,,,4-8,,,,,,
17558,,coronary bypass surgery|tall,,,,,,,,,,≤ 1.5 x unl,,,,,,
17559,,pulmonary fibrosis.|history,,,,,,,,,,<75 years old,,,,,,
17560,,cervical cancer,,,,,,,,,,> 11.1 mmol/l,,,,,,
17561,,stages,,,,,,,,,,≤ 60 bpm,,,,,,
17562,,brain lesions|for,,,,,,,,,,18 years old|over,,,,,,
17563,,intestinal bleeding,,,,,,,,,,18 or more|a,,,,,,
17564,,axial bone density,,,,,,,,,,< 0.5×10^9/l,,,,,,
17565,,hepatocellular carcinoma||,,,,,,,,,,>7gm%|less than 24h away from emergency care||,,,,,,
17566,,unstable clinical condition,,,,,,,,,,≥ 95 mmhg,,,,,,
17567,,removable partial prosthesis,,,,,,,,,,>1.1 x uln|urine protein/creatinine ratio,,,,,,
17568,,month||,,,,,,,,,,>0.30 mcg/kg/min,,,,,,
17569,,specifically dermatomyositis,,,,,,,,,,≥ 4||,,,,,,
17570,,primary cardiomyopathy,,,,,,,,,,not consenting,,,,,,
17571,,admiral nurses)|people living,,,,,,,,,,longer than 24 hours|signed general consent||,,,,,,
17572,,meningeal metastases,,,,,,,,,,≥ 50 ng/ml,,,,,,
17573,,gastrointestinal surgery|gastrostomy|known gi dysmotility,,,,,,,,,,18 and 75,,,,,,
17574,,aortic valve regurgitation.|concomitant,,,,,,,,,,grade ii or above,,,,,,
17575,,skin abscesses,,,,,,,,,,2 1/2 to 5 years|childcare program,,,,,,
17576,,pulmonary right-,,,,,,,,,,more than 3 years before date of randomization,,,,,,
17577,,unmanaged mental health disorders,,,,,,,,,,equal to 150 mmhg)|able to understand,,,,,,
17578,,essential thrombocythemia,,,,,,,,,,exhaled,,,,,,
17579,,neurofibromatosis type 1,,,,,,,,,,25 - <60 years|bmi,,,,,,
17580,,celiac disease|immune suppression|intestinal obstruction|oropharyngeal dysphagia,,,,,,,,,,18.0 to 38.0 kilogram per square meter (kg/m^2)|stable renal function,,,,,,
17581,,cardio-specific,,,,,,,,,,> 120,,,,,,
17582,,chronic gastrointestinal conditions associated,,,,,,,,,,>2.5 times the upper limit of normal (uln),,,,,,
17583,,major pathologies,,,,,,,,,,> 18.0 and < 30.0 kg/m2,,,,,,
17584,,skin rash,,,,,,,,,,below 70,,,,,,
17585,,blood sickness,,,,,,,,,,≤ 1.5 × the upper limit of normal (uln),,,,,,
17586,,musculoligamentous supporting structures,,,,,,,,,,18-39,,,,,,
17587,,chemical peel,,,,,,,,,,less than 9 g/dl.||,,,,,,
17588,,solid tumors;|at least one,,,,,,,,,,lower than 10th percentile,,,,,,
17589,,ct scan).||exclusion criteria:||hemodynamic instability,,,,,,,,,,>7.5%)|bmi ≥ 25 kg/m2||,,,,,,
17590,,judged by ultrasound,,,,,,,,,,> 35;|active oncological disease,,,,,,
17591,,multiple myeloma.||- stroke,,,,,,,,,,100×10^9/l,,,,,,
17592,,process,,,,,,,,,,0 to 1;|estimated,,,,,,
17593,,traumatic brain injury|having epilepsy,,,,,,,,,,≥ 7 mm,,,,,,
17594,,place a peripheral venous access,,,,,,,,,,< 134 or > 148 mmoll-1||women,,,,,,
17595,,psychotic disorders|self-reporting type,,,,,,,,,,less than 30 days before participating,,,,,,
17596,,co-morbidities)||,,,,,,,,,,>140,,,,,,
17597,,"communication barrier,||having",,,,,,,,,,> 18 years.|patient,,,,,,
17598,,allergic conjunctivitis,,,,,,,,,,between 0-18 years old,,,,,,
17599,,resistant hypertension,,,,,,,,,,below 6|affiliated or beneficiary,,,,,,
17600,,judged by the investigator to be unsuitable for current standard treatment,,,,,,,,,,under 18 or over 64 years old|pregnant women|disease status,,,,,,
17601,,shortening,,,,,,,,,,> 20 points|psa,,,,,,
17602,,etc.)||healthy,,,,,,,,,,scores more than 24|patients,,,,,,
17603,,coma,,,,,,,,,,>50 years,,,,,,
17604,,neurologic disease.|participant,,,,,,,,,,under 18 years old|does not,,,,,,
17605,,renal disease.|considering,,,,,,,,,,for dose,,,,,,
17606,,ischemic heart disease|diagnosis,,,,,,,,,,≥5.7%,,,,,,
17607,,eye injury,,,,,,,,,,>7/10)|severe,,,,,,
17608,,good general health.|agreement,,,,,,,,,,class 2b,,,,,,
17609,,confirmed disease,,,,,,,,,,<7.0%|uncontactable,,,,,,
17610,,us,,,,,,,,,,> 7.5|malignancy,,,,,,
17611,,month).|no infectious fever,,,,,,,,,,less than 12 months;|patients,,,,,,
17612,,extensive bilateral,,,,,,,,,,< must,,,,,,
17613,,index acs event,,,,,,,,,,stage i,,,,,,
17614,,btk inhibitors|significant,,,,,,,,,,≥ 6 months;|8,,,,,,
17615,,covid-19;|self-reported,,,,,,,,,,between 30.0 and 39.9 kg/m2||females,,,,,,
17616,,percutaneous transluminal coronary angioplasty],,,,,,,,,,less than the limit of detection,,,,,,
17617,,cardiovascular disease|peripheral neuropathy,,,,,,,,,,>2|significant,,,,,,
17618,,human immunodeficiency virus [hiv] infection,,,,,,,,,,≤ 5mm,,,,,,
17619,,challenges related,,,,,,,,,,less than 15 or more than 35 years,,,,,,
17620,,heart palpitations,,,,,,,,,,> 25 kg,,,,,,
17621,,type 1 diabetes.|unable to communicate,,,,,,,,,,22-65 years,,,,,,
17622,,emergent care,,,,,,,,,,18 to 75 years.|hba1c,,,,,,
17623,,parasitic infections,,,,,,,,,,<35%).|the participant,,,,,,
17624,,bipolar disorder|psychosis|substance,,,,,,,,,,18-80 y.o.;|more,,,,,,
17625,,major neurocognitive disorders,,,,,,,,,,≥18 years)|persistent epistaxis,,,,,,
17626,,mild pain,,,,,,,,,,≤ 75 years old,,,,,,
17627,,heart valve,,,,,,,,,,≥2cm,,,,,,
17628,,acupuncture needles.|pregnancy,,,,,,,,,,> 80 or <18|any,,,,,,
17629,,≤3.5mm.|target lesion,,,,,,,,,,≤ unl,,,,,,
17630,,mainly chronic indications,,,,,,,,,,≥12 weeks;||blood test,,,,,,
17631,,versus pathology,,,,,,,,,,below 11.0 g/dl,,,,,,
17632,,abnormal clinical significance,,,,,,,,,,20-60|volunteering,,,,,,
17633,,ophthalmological diseases,,,,,,,,,,>500 cells/yl,,,,,,
17634,,ventricular arrhythmias||active autoimmune disease,,,,,,,,,,60 years old,,,,,,
17635,,neurological status,,,,,,,,,,≥ 5%|cd19 expression,,,,,,
17636,,svt,,,,,,,,,,11.1 mmol/l,,,,,,
17637,,mi,,,,,,,,,,greater than or equal to 18 years||,,,,,,
17638,,conditions;|poor oral hygiene,,,,,,,,,,18 to 80|capable of providing informed consent,,,,,,
17639,,paraffin,,,,,,,,,,> 3x upper limit of,,,,,,
17640,,organ diseases,,,,,,,,,,>= 100 x 109/l|hemoglobin,,,,,,
17641,,scan|progressive prostate cancer,,,,,,,,,,> 2 mmol/l)|git disorders,,,,,,
17642,,modic changes,,,,,,,,,,18 years to 55 years,,,,,,
17643,,attention deficit disorder,,,,,,,,,,≥ 1.5 × 10^9/l|platelet count,,,,,,
17644,,viral hepatitis,,,,,,,,,,higher than the detection,,,,,,
17645,,auditory impairment|cognitive impairment,,,,,,,,,,older than 18 years old,,,,,,
17646,,psychotic features)|intelligence quotient<70,,,,,,,,,,27 - 35)|motivation,,,,,,
17647,,generalized pain,,,,,,,,,,≥40 ml/min/1.73m2,,,,,,
17648,,gastrointestinal anastomosis,,,,,,,,,,> 9.0 g/dl,,,,,,
17649,,hiv infection.|receive,,,,,,,,,,< 5cm,,,,,,
17650,,muffled hearing,,,,,,,,,,≥ 126 mg/dl,,,,,,
17651,,pkcs,,,,,,,,,,<5 mm,,,,,,
17652,,optic nerve head,,,,,,,,,,≥ 100 mmhg,,,,,,
17653,,keratoacanthoma,,,,,,,,,,between 18.5-30 kg/m²|subject,,,,,,
17654,,hormonal deficiencies.|known chromosomal aneuploidy,,,,,,,,,,≥65 years|bilateral dry-amd|etdrs-corrected visual acuity,,,,,,
17655,,risdiplam,,,,,,,,,,25 to 57 years.|non-smoker,,,,,,
17656,,chronic diseases|be able to read,,,,,,,,,,less than upper limit of normal (uln),,,,,,
17657,,penile-vaginal penetration.||a,,,,,,,,,,>18|radial side,,,,,,
17658,,transilluminable iris,,,,,,,,,,between 7 to 17|depression|anxiety|school refusers|eating disorders|established contact,,,,,,
17659,,deprived,,,,,,,,,,"<100,000/mm3)|severe",,,,,,
17660,,abstain from non-prescription,,,,,,,,,,between 21,,,,,,
17661,,horseback riding sessions,,,,,,,,,,≥500ms or pr interval,,,,,,
17662,,joint diseases,,,,,,,,,,>2 years.|any unresolved,,,,,,
17663,,ocular media,,,,,,,,,,male's,,,,,,
17664,,leishmaniasis,,,,,,,,,,35 or,,,,,,
17665,,abnormal retinal,,,,,,,,,,≤ 3 uln,,,,,,
17666,,gr)|pregnancy|bmi>35|acute urinary tract infections,,,,,,,,,,>3|surgery,,,,,,
17667,,metabolic diseases.|chronic pain,,,,,,,,,,5 to 16 years,,,,,,
17668,,finger extension,,,,,,,,,,≥35|current or,,,,,,
17669,,total mesolectal resection,,,,,,,,,,>= 60ml / min.||6,,,,,,
17670,,culture result|patients,,,,,,,,,,>3×109/l,,,,,,
17671,,procedures.|adverse events,,,,,,,,,,>100.000/mcl,,,,,,
17672,,intravesical dosing,,,,,,,,,,<= 1||adequate hematologic function,,,,,,
17673,,dhmc,,,,,,,,,,± 10 years,,,,,,
17674,,non-cardiac syncope,,,,,,,,,,≥18 years;|understand and voluntarily sign the written informed consent form;||study,,,,,,
17675,,kg)|medical condition,,,,,,,,,,<2 ng/dl,,,,,,
17676,,entities,,,,,,,,,,>100.5°f,,,,,,
17677,,nicotinic habits,,,,,,,,,,>3/15,,,,,,
17678,,heart valve disease|patients,,,,,,,,,,>= 90 days,,,,,,
17679,,respiratory infection,,,,,,,,,,≤6.5%,,,,,,
17680,,eosinophilic granulomatosis polyangiitis,,,,,,,,,,>1.5 mg/dl,,,,,,
17681,,clinical atherosclerotic disease,,,,,,,,,,<120 g/l.|provision of signed informed consent,,,,,,
17682,,infectious diseases.|women,,,,,,,,,,>50 ml/min/1.73 m2for,,,,,,
17683,,cough of unknown cause,,,,,,,,,,>= 16 years,,,,,,
17684,,periodontal,,,,,,,,,,scores <8|report total,,,,,,
17685,,infantile fshd|pregnancy,,,,,,,,,,i-iii|undergoing elective pelvi-ureteric,,,,,,
17686,,malignancy.|participant,,,,,,,,,,more than 15mm|cbd,,,,,,
17687,,acute asthma exacerbation,,,,,,,,,,≥90%,,,,,,
17688,,cns metastases.||14,,,,,,,,,,between 1:1.1 and 1:1.0,,,,,,
17689,,cancer therapeutics,,,,,,,,,,greater than or equal to 24.|the,,,,,,
17690,,squamous cancer)|being,,,,,,,,,,≤ 1.5 upper limit normal,,,,,,
17691,,chest pain recurs,,,,,,,,,,≥ 25kg/m2,,,,,,
17692,,tried,,,,,,,,,,t3-4,,,,,,
17693,,fluent,,,,,,,,,,more than 8.0 g/dl,,,,,,
17694,,enpp1,,,,,,,,,,< 35 kg/m2||,,,,,,
17695,,drugs.|alcohol abuse,,,,,,,,,,<12 years,,,,,,
17696,,cytogenetic abnormality,,,,,,,,,,≥ 1.5×109/l.|absolute,,,,,,
17697,,mooren ulcer,,,,,,,,,,> 15 points,,,,,,
17698,,ci612,,,,,,,,,,-2,,,,,,
17699,,institute's,,,,,,,,,,≥ 110 mmhg,,,,,,
17700,,malignant hematological diseases,,,,,,,,,,≥2 uln|white blood cell count,,,,,,
17701,,non-hodgkin lymphoma,,,,,,,,,,≥ 100mmhg;|history,,,,,,
17702,,crescentic glomerulonephritis,,,,,,,,,,65+ years).|participant,,,,,,
17703,,cervical spine issues|chronic vertigo|vestibular problems,,,,,,,,,,<g2,,,,,,
17704,,atrial fibrillation\flutter,,,,,,,,,,≥ 40 and ≤ 64 years,,,,,,
17705,,medication for menopausal symptoms|using,,,,,,,,,,>= 100 mmhg,,,,,,
17706,,achondroplasia,,,,,,,,,,or|not,,,,,,
17707,,g-6-pd deficiency,,,,,,,,,,equation).|international normalized ratio,,,,,,
17708,,mean e,,,,,,,,,,18-35|able to understand written,,,,,,
17709,,familial hypoalphalipoproteinemia|patients,,,,,,,,,,<20 years|patients,,,,,,
17710,,hypoglossal nerve stimulation,,,,,,,,,,greater than 5 kilograms (kg),,,,,,
17711,,severe esophagitis,,,,,,,,,,> 50 mg/kg;|new,,,,,,
17712,,morphologic remission,,,,,,,,,,18 and above and under,,,,,,
17713,,emphysema,,,,,,,,,,"˂50,000/μl",,,,,,
17714,,drug abuse.|pregnant,,,,,,,,,,1.5 109/l,,,,,,
17715,,diplopia,,,,,,,,,,younger than 16,,,,,,
17716,,risk of its development,,,,,,,,,,12-71 months,,,,,,
17717,,major cardiovascular diseases,,,,,,,,,,≥12 weeks|disease progression,,,,,,
17718,,organ transplantation;|concomitant diseases,,,,,,,,,,2 to 14 years,,,,,,
17719,,dermographism,,,,,,,,,,109 mm hg,,,,,,
17720,,carcinoma in situ of the cervix.|psychiatric illness,,,,,,,,,,< 2000 mg of protein,,,,,,
17721,,mild autoimmune disorders,,,,,,,,,,60 ml/min.|serum,,,,,,
17722,,interocular difference,,,,,,,,,,> 93%,,,,,,
17723,,acute eye,,,,,,,,,,45 u/l|shortening fraction,,,,,,
17724,,cases of covid-19,,,,,,,,,,≥ 1 million,,,,,,
17725,,chronic lateral epicondylitis,,,,,,,,,,< 10|sjogren's syndrome|ecog status,,,,,,
17726,,waldenströms macroglobulinemia,,,,,,,,,,>=40 ml/min,,,,,,
17727,,psychological comorbidities,,,,,,,,,,< 24 months||for more,,,,,,
17728,,intravenous bubble study,,,,,,,,,,< 30 ml/min)|any condition,,,,,,
17729,,pain relievers,,,,,,,,,,70,,,,,,
17730,,inflammatory breast cancer.|patients,,,,,,,,,,>= 20 mm,,,,,,
17731,,lymphogranuloma venereum,,,,,,,,,,less than 200/mm3,,,,,,
17732,,mental alteration,,,,,,,,,,≤ 10 mm,,,,,,
17733,,health problem,,,,,,,,,,≥ 2 times the upper limit of normal reference,,,,,,
17734,,organic gi abnormalities,,,,,,,,,,> 3.0 x 109/l,,,,,,
17735,,ihc,,,,,,,,,,6 years to less than 12 years,,,,,,
17736,,gait disorder|patients,,,,,,,,,,<41||,,,,,,
17737,,asymptomatic,,,,,,,,,,>=3|pre-frail,,,,,,
17738,,colon resection.|colorectal pathology,,,,,,,,,,higher than 21 mmhg,,,,,,
17739,,lung metastases amenable,,,,,,,,,,between 18 - 25 kg/m2|had,,,,,,
17740,,risk factor for bleeding ex,,,,,,,,,,less than 10 years,,,,,,
17741,,left heart catheterization,,,,,,,,,,<60 kg,,,,,,
17742,,convulsive seizures,,,,,,,,,,">= 100,000/ul|hemoglobin",,,,,,
17743,,chronic kidney failure,,,,,,,,,,over 20 years old,,,,,,
17744,,acute periapical abscess,,,,,,,,,,score for dry eye classification,,,,,,
17745,,type 1a,,,,,,,,,,140 - age,,,,,,
17746,,infections organ/system,,,,,,,,,,+ baby shampoo,,,,,,
17747,,coronary pneumonia plasma,,,,,,,,,,18 kg/m2,,,,,,
17748,,stable|unilateral internal carotid artery,,,,,,,,,,110-200 ms|qrs duration,,,,,,
17749,,drug pneumonia,,,,,,,,,,18-69;|male,,,,,,
17750,,ocular disease|va,,,,,,,,,,≥ 40 ml/min.|serum,,,,,,
17751,,mixed urinary incontinence|prolapse,,,,,,,,,,greater than 63mm|weight greater than or equal to 600g|ability of caretaker to understand verbal and written,,,,,,
17752,,hepatitis b virus(hbv,,,,,,,,,,< 6 months)||,,,,,,
17753,,hepatitis b virus (hbv) dna,,,,,,,,,,≥2 or more,,,,,,
17754,,cardiovascular disease;|oncological,,,,,,,,,,≥9 g/,,,,,,
17755,,known allergy,,,,,,,,,,< anb<10)|overjet more than 5 mm.|normal overbite (more than 0 mm,,,,,,
17756,,peritoneal dialysis,,,,,,,,,,<2+ or 24h,,,,,,
17757,,malignant tumors;|exclude,,,,,,,,,,less than 90 ml/min/1.73 m2,,,,,,
17758,,congenital hemophilia,,,,,,,,,,">= 1,000/ul",,,,,,
17759,,degree|gastric-bypass operation|operation planned,,,,,,,,,,<3·0×109/l,,,,,,
17760,,cardiovascular disease|pulmonary disease,,,,,,,,,,< 40 kg/m2,,,,,,
17761,,artery occlusion,,,,,,,,,,at least 3 months;||adequate major organ function:||respiratory function,,,,,,
17762,,type-1,,,,,,,,,,proper medication|age 30 to 70|ejection fraction,,,,,,
17763,,inclusive|meet the,,,,,,,,,,≤ 1|male,,,,,,
17764,,non-stroke etiology,,,,,,,,,,≥ 70 mm hg,,,,,,
17765,,breast-feeding.|females,,,,,,,,,,4-,,,,,,
17766,,tumor tissue block made,,,,,,,,,,≥ 450 ml,,,,,,
17767,,monkeypox,,,,,,,,,,≥12 weeks.|participants',,,,,,
17768,,irritable bowel syndrome (ibs),,,,,,,,,,"0,1",,,,,,
17769,,brain radiation,,,,,,,,,,antigen positive,,,,,,
17770,,mild hearing loss,,,,,,,,,,fewer than 6,,,,,,
17771,,depressive symptomatology,,,,,,,,,,>21,,,,,,
17772,,cognitive diseases,,,,,,,,,,≥ 18 years.|be,,,,,,
17773,,judged by the researcher to be inappropriate for participation in this study,,,,,,,,,,≤ 27.0 kg/m2,,,,,,
17774,,breast feeding||active bleeding,,,,,,,,,,35,,,,,,
17775,,distant metastasis|lesions,,,,,,,,,,= ger,,,,,,
17776,,called adenocarcinoma,,,,,,,,,,<8g/dl|inability,,,,,,
17777,,failure of,,,,,,,,,,= 125 ml glass,,,,,,
17778,,primary hemochromatosis,,,,,,,,,,< 1.5,,,,,,
17779,,cardiopulmonary issues,,,,,,,,,,>1.5 cm,,,,,,
17780,,crps,,,,,,,,,,>1.5 x uln|serum,,,,,,
17781,,chronic hepatitis b,,,,,,,,,,< 100 x 10^9/l|adults legally protected,,,,,,
17782,,nerves,,,,,,,,,,over 105,,,,,,
17783,,vaginal cancer,,,,,,,,,,≤ 3)|antidepressant,,,,,,
17784,,vegetarian,,,,,,,,,,grade a or c periodontitis|presence,,,,,,
17785,,parathyroid disease,,,,,,,,,,6-9 mm,,,,,,
17786,,system.|the,,,,,,,,,,less than 3 years,,,,,,
17787,,aml disease,,,,,,,,,,18-80 years,,,,,,
17788,,multi-ligament pathology|follow-up surgical procedures,,,,,,,,,,≥90 mmhg)|urine,,,,,,
17789,,urological diseases,,,,,,,,,,> 250 ml or,,,,,,
17790,,glucose homeostasis,,,,,,,,,,>40s,,,,,,
17791,,practice walking|skin lesions,,,,,,,,,,less than 30%|unstable heart,,,,,,
17792,,ppd,,,,,,,,,,<30 ml/kg|pregnant,,,,,,
17793,,clinical symptoms worsen,,,,,,,,,,13-65 years,,,,,,
17794,,sensory deficit,,,,,,,,,,18.5 - 24.9)|presence,,,,,,
17795,,femur fractures,,,,,,,,,,>38.0°c,,,,,,
17796,,colonic ibd,,,,,,,,,,<7 mmol/l,,,,,,
17797,,finger amputations||for reference,,,,,,,,,,between 6 and 21 years,,,,,,
17798,,spermatic cord block,,,,,,,,,,>2 cm,,,,,,
17799,,primary nasopharynx,,,,,,,,,,< 40 years,,,,,,
17800,,imwg criteria.||measurable disease,,,,,,,,,,> 30);|patient,,,,,,
17801,,growth factors,,,,,,,,,,≥ 2500g|age,,,,,,
17802,,pulmonale,,,,,,,,,,equal to or higher than 60% of the lower limit of normal range;|hepatic function,,,,,,
17803,,localized interstitial pneumonia,,,,,,,,,,"< 60 ml/min/1,73m²",,,,,,
17804,,brain metastasis,,,,,,,,,,≤ -2.5,,,,,,
17805,,cardiac death,,,,,,,,,,<2.0 mg/100 ml.|total bilirubin,,,,,,
17806,,positive).|positive hiv,,,,,,,,,,≥ 85);|ability to give,,,,,,
17807,,native italian speakers;|ability,,,,,,,,,,4 to <13 years,,,,,,
17808,,thoracic spine fusion surgery,,,,,,,,,,above the limit of detection,,,,,,
17809,,cardiovascular accidents,,,,,,,,,,more than 18 year.|ckd patient,,,,,,
17810,,months|cardiovascular disease,,,,,,,,,,above 25 years,,,,,,
17811,,left main visual stenosis,,,,,,,,,,>12|ren users across the united states,,,,,,
17812,,thinning of the neuro-retinal rim,,,,,,,,,,ecg,,,,,,
17813,,sibling,,,,,,,,,,>50%|diastolic dysfunction,,,,,,
17814,,chronic pelvic,,,,,,,,,,v1-v6,,,,,,
17815,,sneezing,,,,,,,,,,≤ 2×uln;|alanine aminotransferase,,,,,,
17816,,increased sensitivity to the effects,,,,,,,,,,- class,,,,,,
17817,,long covid-19,,,,,,,,,,> 100 mmhg)|patients,,,,,,
17818,,vital signs values,,,,,,,,,,≥ 8.0 g / dl;|serum,,,,,,
17819,,brain surgery|can,,,,,,,,,,≤ 5 x the upper limit of normal of the,,,,,,
17820,,drug food allergy,,,,,,,,,,scores of 18.5 to 34.9.||,,,,,,
17821,,uc)|willingness,,,,,,,,,,< 50 mm hg|no more,,,,,,
17822,,minimal consumption,,,,,,,,,,≥ 100 x 109/l,,,,,,
17823,,depressive disorder,,,,,,,,,,≥0.5×10 9 /l,,,,,,
17824,,panss,,,,,,,,,,18 and 34,,,,,,
17825,,psychiatric care|persons admitted,,,,,,,,,,≥ 100%,,,,,,
17826,,elective craniotomies,,,,,,,,,,0-2.|at least 1 measurable,,,,,,
17827,,lower limb problems,,,,,,,,,,>1.2 tbi,,,,,,
17828,,inflammatory bowel disease|history of,,,,,,,,,,< 45 ml/(min×1.73m2)|women,,,,,,
17829,,variceal hemorrhage,,,,,,,,,,> 6.5%|history of,,,,,,
17830,,infective embolism,,,,,,,,,,≥ 45 kg.||,,,,,,
17831,,asthma exacerbation,,,,,,,,,,before enrollment,,,,,,
17832,,myasthenia gravis|patients,,,,,,,,,,mg/ day,,,,,,
17833,,aids related illness,,,,,,,,,,5 through 18 years,,,,,,
17834,,leg numbness,,,,,,,,,,>30kg/m2|prediabetes|type 2,,,,,,
17835,,acute myocardial infarct,,,,,,,,,,> 1.5x upper limit);|major surgery,,,,,,
17836,,vitamin k deficiency,,,,,,,,,,< 50% of the total cnv lesion,,,,,,
17837,,egg donation plan,,,,,,,,,,≥ 18 y|written informed consent,,,,,,
17838,,lower limb power,,,,,,,,,,<40mmhg||slips assessment,,,,,,
17839,,metabolic disease|allergies,,,,,,,,,,portosystemic,,,,,,
17840,,vertical gaze paralysis,,,,,,,,,,surgeon,,,,,,
17841,,indication,,,,,,,,,,19 to 70 years old|those,,,,,,
17842,,ssr,,,,,,,,,,≥ 185 mmhg,,,,,,
17843,,skin type i-,,,,,,,,,,4-7 years.|positive,,,,,,
17844,,hellp syndrome,,,,,,,,,,> 60 ml/min/1.73,,,,,,
17845,,tissue transglutaminase,,,,,,,,,,=< 5.0 × uln,,,,,,
17846,,flc,,,,,,,,,,≥ 25kg/,,,,,,
17847,,old|presence,,,,,,,,,,from 18 to 55 years,,,,,,
17848,,prescribed pain,,,,,,,,,,between 18 and 55|matched in age,,,,,,
17849,,to.||additional exclusions,,,,,,,,,,total of 70,,,,,,
17850,,brain scan results;|refuse,,,,,,,,,,between 21 and 70 years old,,,,,,
17851,,distal intracranial carotid artery,,,,,,,,,,"≤ 40,000/μl|known",,,,,,
17852,,child c,,,,,,,,,,18 years old or older,,,,,,
17853,,clinical dementia rating scale,,,,,,,,,,ph range,,,,,,
17854,,limb circumference,,,,,,,,,,≥18 to ≤60 years||additional inclusion criteria,,,,,,
17855,,pulmonary disease|psychosomatic disorders,,,,,,,,,,12 to < 18 years,,,,,,
17856,,ulcer,,,,,,,,,,at least 12 weeks||,,,,,,
17857,,carnitine deficiency,,,,,,,,,,≥ 9.0 g/dl,,,,,,
17858,,functional vision,,,,,,,,,,≥ 15;|cognition,,,,,,
17859,,unknown hiv status|bacterial sti,,,,,,,,,,20 ml/minute,,,,,,
17860,,age)|thrombocytopenia,,,,,,,,,,< 18 years old|body mass index,,,,,,
17861,,muscle relaxant drugs,,,,,,,,,,30 to 40 years,,,,,,
17862,,malabsorptive conditions,,,,,,,,,,35+ and/or,,,,,,
17863,,urticaria,,,,,,,,,,<110 picograms per milliliter ([pg/ml,,,,,,
17864,,eteplirsen,,,,,,,,,,< age 40)|early menopause,,,,,,
17865,,body pain,,,,,,,,,,18-70 years;|body condition score,,,,,,
17866,,spine stability,,,,,,,,,,between +2.00 and +5.00 d in each eye,,,,,,
17867,,evaluating micronecrosis status|gross tumor necrosis,,,,,,,,,,<90 mm hg)|inability to provide,,,,,,
17868,,inflammatory bowel disease,,,,,,,,,,<130 mmol/l|serum osmolality <280 mosmol/kg,,,,,,
17869,,heart disease|difficulties,,,,,,,,,,≤ 3 g/day,,,,,,
17870,,hpv-related,,,,,,,,,,free triiodothyronine (ft3),,,,,,
17871,,organic cause,,,,,,,,,,>133 μmol/l,,,,,,
17872,,neurectomy,,,,,,,,,,≥ 200/µl,,,,,,
17873,,underrepresented populations,,,,,,,,,,"≤ 1,250/mm3|calculated",,,,,,
17874,,giant cell arteritis,,,,,,,,,,least 50 % of all team members should accept,,,,,,
17875,,acute major bleeding|assessment of,,,,,,,,,,>129 mgdl-1.||,,,,,,
17876,,her2-targeted therapy.||-≥,,,,,,,,,,7.0-10.0 percent,,,,,,
17877,,convalescent plasma,,,,,,,,,,> grade 3,,,,,,
17878,,anatomical locations,,,,,,,,,,less than one year|patient,,,,,,
17879,,learning disorders,,,,,,,,,,= 50kg|chronic hyperglycemia,,,,,,
17880,,nancy hospital bewteen septemnre,,,,,,,,,,scale|owns,,,,,,
17881,,alcohol drinks /week|heavy marijuana/thc,,,,,,,,,,> two,,,,,,
17882,,cardiopulmonary insufficiency,,,,,,,,,,iv|uncontrolled,,,,,,
17883,,respiratory tract infections,,,,,,,,,,at least ≥2 ng/ml above the nadir,,,,,,
17884,,lv systolic dysfunction,,,,,,,,,,≥ 18 years||,,,,,,
17885,,focus groups||adults||hispanic,,,,,,,,,,140 mg of,,,,,,
17886,,hiv seropositive status,,,,,,,,,,> 6)|minimal,,,,,,
17887,,"nephropathy,|elevated serum creatinine level",,,,,,,,,,<lnl,,,,,,
17888,,productive cough,,,,,,,,,,between 20 and 60 years|american society of anesthesiologists physical status of 1|elective,,,,,,
17889,,suicide attempt,,,,,,,,,,≥18.0 kg/m2,,,,,,
17890,,unstable cardiac function,,,,,,,,,,>70u/l|renal disease,,,,,,
17891,,cardiopulmonary,,,,,,,,,,from 80 - 92 %|o2 therapy,,,,,,
17892,,secondary chronic disease,,,,,,,,,,>160|diastolic blood pressure,,,,,,
17893,,hungarian,,,,,,,,,,"between 5,000 to 150,000 asexual parasite count/μl",,,,,,
17894,,polyhydramions,,,,,,,,,,> upper limit of normal reference range 6,,,,,,
17895,,"acute trauma,|previous surgical intervention",,,,,,,,,,< 15mm,,,,,,
17896,,other pathology,,,,,,,,,,≤ 4.0x uln,,,,,,
17897,,multiple organ failure syndrome,,,,,,,,,,>25 mm,,,,,,
17898,,hyperplenism,,,,,,,,,,"≥ 100,000/l|hemoglobin",,,,,,
17899,,contact allergies,,,,,,,,,,less than 35 kg/m2,,,,,,
17900,,gastric ulcer bleeding,,,,,,,,,,> 25 kg/m2,,,,,,
17901,,deep dry,,,,,,,,,,less than 135kg,,,,,,
17902,,consent|rv dysfunction,,,,,,,,,,<60 mm hg,,,,,,
17903,,ptcl,,,,,,,,,,24 - 36 months,,,,,,
17904,,non-metastatic disease,,,,,,,,,,> 40 units / liter,,,,,,
17905,,primary staging,,,,,,,,,,≥ 1.0 x 109/l|platelet count,,,,,,
17906,,vomiting blood,,,,,,,,,,① history,,,,,,
17907,,tuberculosis;|pneumonitis,,,,,,,,,,≥40 kg/m2.|uncontrolled,,,,,,
17908,,secondary cause of hypertension,,,,,,,,,,">/= 12 years;|diagnosis ""definite""",,,,,,
17909,,national guidelines.|for,,,,,,,,,,18 to 90 years,,,,,,
17910,,acute respiratory distress,,,,,,,,,,≥1 week,,,,,,
17911,,mucinous carcinoma,,,,,,,,,,at least 18 years when signing the informed consent|subjects with wounds,,,,,,
17912,,impairment of renal function,,,,,,,,,,booster dose,,,,,,
17913,,structural defect,,,,,,,,,,>2.00 mm,,,,,,
17914,,vascular injury,,,,,,,,,,> two times upper reference,,,,,,
17915,,somatic diseases,,,,,,,,,,≥30 =,,,,,,
17916,,emsculpt,,,,,,,,,,between 350 to 450 msec,,,,,,
17917,,dysfunction,,,,,,,,,,= or > 30 kg/m^2,,,,,,
17918,,cognitive impairment|neurological disorders,,,,,,,,,,between 2500 - 4000,,,,,,
17919,,space occupying lesions,,,,,,,,,,> 20%.|wd g3,,,,,,
17920,,terminal illness|3,,,,,,,,,,12-17 old,,,,,,
17921,,pnes|inability,,,,,,,,,,< 12 months.|patient,,,,,,
17922,,neurological disorders|organic diseases of the small,,,,,,,,,,34.2 μmol/,,,,,,
17923,,herbal preparations/medications,,,,,,,,,,< 90 mm,,,,,,
17924,,point)|mild cardiovascular disease,,,,,,,,,,between 18.5 and 25.||,,,,,,
17925,,weight loss treatment,,,,,,,,,,>4mm,,,,,,
17926,,digestive issue,,,,,,,,,,6 or older,,,,,,
17927,,parkinson,,,,,,,,,,___||o,,,,,,
17928,,endometrioid ovarian cancer,,,,,,,,,,< 22 years,,,,,,
17929,,open,,,,,,,,,,greater than or equal to 120,,,,,,
17930,,t2 flair sequence,,,,,,,,,,> 5 times the upper limit of normal (uln),,,,,,
17931,,hemispheric acute ischemic stroke;|patient,,,,,,,,,,25 to 40 years old,,,,,,
17932,,local residence;||,,,,,,,,,,"between 30,0 - 39,9 kg/",,,,,,
17933,,weight loss diet.|participate,,,,,,,,,,equal to or greater than 120,,,,,,
17934,,breastfeeding|food intolerances,,,,,,,,,,">= 1,000/mm^3|leukocytes",,,,,,
17935,,spinal anesthesia||,,,,,,,,,,= weight(kg)/ height(m)2||individuals,,,,,,
17936,,vestibular impairment,,,,,,,,,,< 1.5 times the upper limit of normal,,,,,,
17937,,rectal stenosis,,,,,,,,,,stage ii,,,,,,
17938,,abnormal lens findings,,,,,,,,,,5 times per,,,,,,
17939,,distal oesophagectomy|previous ablation therapy,,,,,,,,,,> 80%,,,,,,
17940,,recall of a,,,,,,,,,,≥ 100 × 10^9/l|hemoglobin,,,,,,
17941,,acute pulmonary thromboembolism,,,,,,,,,,20-45 years|healthy,,,,,,
17942,,severe weakness,,,,,,,,,,≥ 25 kg/m2,,,,,,
17943,,m])^2||in good health,,,,,,,,,,>10% of their body weight,,,,,,
17944,,cystic areas,,,,,,,,,,19 to 27|stable weight,,,,,,
17945,,oesophageal,,,,,,,,,,≤ 1.5 x uln.|prior,,,,,,
17946,,internal conditions,,,,,,,,,,grade ii or greater,,,,,,
17947,,cytokines;|previous,,,,,,,,,,≥1.5uln);|on dialysis,,,,,,
17948,,systemic medical diseases,,,,,,,,,,> score 19,,,,,,
17949,,flow,,,,,,,,,,>60mmhg,,,,,,
17950,,pain intensities,,,,,,,,,,9-12|have,,,,,,
17951,,hypoxic seizures,,,,,,,,,,prolonged <= 6 seconds.||,,,,,,
17952,,good dental state,,,,,,,,,,> 5 years,,,,,,
17953,,fulfilled):||gerd,,,,,,,,,,"> 30),|women",,,,,,
17954,,higher.|do not sign,,,,,,,,,,< 470 ms,,,,,,
17955,,diagnosticated cancer,,,,,,,,,,< 2.5×uln；|serum creatinine,,,,,,
17956,,archival,,,,,,,,,,0 or 1).||,,,,,,
17957,,residence making,,,,,,,,,,score is 0 or,,,,,,
17958,,urinary symptoms,,,,,,,,,,65-75 years;|complaint,,,,,,
17959,,extrarenal pathology,,,,,,,,,,more than 6 months||,,,,,,
17960,,nocturnal erectile function,,,,,,,,,,i-ii|scheduled,,,,,,
17961,,ischaemic stroke,,,,,,,,,,0-iii,,,,,,
17962,,pleural drainage)|hemodynamic instability,,,,,,,,,,90-140,,,,,,
17963,,hormonal disease,,,,,,,,,,≥18 kg,,,,,,
17964,,dexmedetomedine.|neuraxial anesthesia.|cardiovascular disease,,,,,,,,,,≥ 8g /dl;|blood biochemical indicators,,,,,,
17965,,judged by the investigators to be unsuitable for the trial.|pregnant,,,,,,,,,,less than every second,,,,,,
17966,,facial acne vulgaris,,,,,,,,,,</= 1.5 x uln,,,,,,
17967,,pulmonary tuberculosis infection,,,,,,,,,,≥ 2.5 pg/ml,,,,,,
17968,,tinea infections,,,,,,,,,,≥450 msec,,,,,,
17969,,bacterial vaginosis/candidiasis,,,,,,,,,,between post-resection tumor cavity,,,,,,
17970,,yellow fever,,,,,,,,,,<90 mm hg,,,,,,
17971,,gynaecological disease,,,,,,,,,,18 - 65 years,,,,,,
17972,,carcinoma in situ of the prostate/cervix/breast that the researchers,,,,,,,,,,between 19 and 80.|patients,,,,,,
17973,,valvular heart disease|morbid obesity|intubation difficulty|drug,,,,,,,,,,over 20 mg/l|patient,,,,,,
17974,,indicates,,,,,,,,,,≥ 3.0 × 109/l；||platelet count,,,,,,
17975,,neoplastic diseases,,,,,,,,,,≥18 years|suspected pulmonary hypertension,,,,,,
17976,,pulmonary hypertension|age,,,,,,,,,,less than 18 or more than 25,,,,,,
17977,,solid tumors.|agree to provide archived tumor tissue,,,,,,,,,,<0.8 ng/ml.|any of the following,,,,,,
17978,,selected solid tumors enrolled,,,,,,,,,,1 to <26 years,,,,,,
17979,,motor skills disorders,,,,,,,,,,5 to 60 years,,,,,,
17980,,healthy rats||,,,,,,,,,,> upper limit of normal (uln),,,,,,
17981,,malignant tumor;|presence,,,,,,,,,,> 100 mm-hg,,,,,,
17982,,unexplained fever,,,,,,,,,,<65 years|unable to consent|chronic pain medication usage,,,,,,
17983,,aortic valve|severe mitral,,,,,,,,,,≥ 1.5 × 109/l;||c.,,,,,,
17984,,delirium;|other mental,,,,,,,,,,<18|presence of autonomic nervous system diseases,,,,,,
17985,,appendiceal cancer)|peritoneal disease,,,,,,,,,,≥ 450,,,,,,
17986,,detectable hbv dna,,,,,,,,,,greater than or equal to 4/10 the 3 days,,,,,,
17987,,pain.|extensive osteosynthesis,,,,,,,,,,< 25 kg/m2||,,,,,,
17988,,"systemic diseases,|malignancy,|immunodeficiency,|infectious",,,,,,,,,,score ≥ 10,,,,,,
17989,,black,,,,,,,,,,≥2.|alk-negative,,,,,,
17990,,abstain from tobacco,,,,,,,,,,>= 60 ml/min per the cockcroft-gault formula,,,,,,
17991,,arterio-vascular malformations,,,,,,,,,,=< 5.0 x uln.|recipient,,,,,,
17992,,dementia)|physical impairment,,,,,,,,,,> 1000/µl,,,,,,
17993,,t4bnanym0,,,,,,,,,,">= 1,500 / ul|platelets",,,,,,
17994,,autoimmune hepatic disorders,,,,,,,,,,>29%,,,,,,
17995,,nodules on,,,,,,,,,,≥40 kg/m2.|subject,,,,,,
17996,,uterine fibroids,,,,,,,,,,29 days to 89 years|willing,,,,,,
17997,,shoulder joint replacement|contraindications,,,,,,,,,,= 360 ml,,,,,,
17998,,community health workers working,,,,,,,,,,≥60 ml/min;serum,,,,,,
17999,,preimplantation,,,,,,,,,,50-100,,,,,,
18000,,resting diastolic bp,,,,,,,,,,≤ 1.5 x normal range,,,,,,
18001,,t215y,,,,,,,,,,> normal range,,,,,,
18002,,5.1 type diabetes,,,,,,,,,,<30%|cardiac surgery,,,,,,
18003,,glucose tolerance,,,,,,,,,,from 18-75 years,,,,,,
18004,,limiting,,,,,,,,,,resection.||greater than or equal to 50,,,,,,
18005,,pass);|italian native,,,,,,,,,,≥ 45 ml/min/1.73m^2,,,,,,
18006,,restrictive lung disease,,,,,,,,,,greater than 15 db,,,,,,
18007,,radicular symptoms,,,,,,,,,,>50% of the total lesion,,,,,,
18008,,medical treatment||,,,,,,,,,,negligible,,,,,,
18009,,hla-e agents,,,,,,,,,,≤ 2 times uln,,,,,,
18010,,non-hydantoin,,,,,,,,,,between 18.0 and 32.0 kilograms per square meter (kg/m^2,,,,,,
18011,,autoimmune disease|concurrent,,,,,,,,,,=< 10 mg,,,,,,
18012,,cerebral palsy)|areas,,,,,,,,,,"<15 mmol/l/1,73m2.|pregnancy",,,,,,
18013,,chronic pain syndromes|chronic opioid,,,,,,,,,,60 and older,,,,,,
18014,,palpable tumor,,,,,,,,,,≥9.0 g/dl|absolute,,,,,,
18015,,inflammatory bowel disease.|active interstitial lung disease,,,,,,,,,,4 ng/ml,,,,,,
18016,,active psychosis,,,,,,,,,,more than 2kg,,,,,,
18017,,"caffeine-containing food (coffee, green tea",,,,,,,,,,greater than 350 pounds,,,,,,
18018,,poor general health status,,,,,,,,,,30 days.|intranasal,,,,,,
18019,,normal)|abnormal renal function,,,,,,,,,,>5.0 mmol/l.|unable,,,,,,
18020,,immunosuppressive drugs|symptoms of leukostasis,,,,,,,,,,≥50 x 10^9/l,,,,,,
18021,,systemic contraindications,,,,,,,,,,>2.8 mmol/l.||a,,,,,,
18022,,preventing infection,,,,,,,,,,<90 ml/min/1.73 m2,,,,,,
18023,,transient confusion,,,,,,,,,,> 5 and <14.9,,,,,,
18024,,porphyria|metastatic tumor,,,,,,,,,,≤ 200 mg/l,,,,,,
18025,,autoimmune disease.|untreated,,,,,,,,,,from 30 to 65,,,,,,
18026,,skin rash)|colitis/enteritis,,,,,,,,,,0-1).|slight,,,,,,
18027,,miscarriages.|male factor infertility,,,,,,,,,,+ high dose,,,,,,
18028,,cyclothymia,,,,,,,,,,female|over 18 years,,,,,,
18029,,urine drug abuse,,,,,,,,,,cover < 10% of body surface,,,,,,
18030,,alcohol breath,,,,,,,,,,≤ 36 months,,,,,,
18031,,criteria for psychosis,,,,,,,,,,≥ the upper limit of laboratory normal,,,,,,
18032,,hip protheses prohibit accurate mr,,,,,,,,,,< 12 years;|history,,,,,,
18033,,electrodes|traumatic brain injury|facial metal implants,,,,,,,,,,≥25 kilogram per square meter (kg/m²,,,,,,
18034,,generalized muscle weakness,,,,,,,,,,+/- dislocation)|neurologic motor deficit,,,,,,
18035,,days|medical condition,,,,,,,,,,between 50 and 80,,,,,,
18036,,chronic apical periodontitis,,,,,,,,,,>= 18 years|an,,,,,,
18037,,intestinal transit|hypersensitivity,,,,,,,,,,>16.5 g/dl)|subject,,,,,,
18038,,sociological conditions,,,,,,,,,,less than 6 months|metastases,,,,,,
18039,,neurovascular event,,,,,,,,,,i score).|grade,,,,,,
18040,,metabolic enzyme,,,,,,,,,,50-unlimited|found,,,,,,
18041,,localized infection.|who,,,,,,,,,,≥90g/l,,,,,,
18042,,partial remission,,,,,,,,,,> 10x,,,,,,
18043,,major depressive disorder.|pain,,,,,,,,,,<6 or>12 years,,,,,,
18044,,arterial cannulation,,,,,,,,,,<92% or >96%,,,,,,
18045,,migraine headaches precipitated,,,,,,,,,,>90 mm hg diastolic,,,,,,
18046,,non-ischemic cardiomyopathy|impaired,,,,,,,,,,above the baseline level of 150ppb.||,,,,,,
18047,,breast-feeding patients,,,,,,,,,,≥18 years.|ability to understand,,,,,,
18048,,refuses neoadjuvant chemotherapy,,,,,,,,,,> 30%);|history,,,,,,
18049,,rbans,,,,,,,,,,<1000 cells/l,,,,,,
18050,,acute coronary disease,,,,,,,,,,prognosis,,,,,,
18051,,brain donation,,,,,,,,,,30-65 years.|informed consent for participation,,,,,,
18052,,aortic pathology,,,,,,,,,,less than 24 hours before taking the drug,,,,,,
18053,,critical illness-related polyneuropathy,,,,,,,,,,t-score,,,,,,
18054,,glucose-6-phosphate dehydrogenase (g6pd) patients.|are,,,,,,,,,,>18 years old exclusion criteria,,,,,,
18055,,second stroke,,,,,,,,,,greater than or equal to 6.5%,,,,,,
18056,,netherton's syndrome,,,,,,,,,,b-cell hematologic malignancies,,,,,,
18057,,deep venous thrombosis.|participants,,,,,,,,,,iii-iv,,,,,,
18058,,novel coronavirus,,,,,,,,,,anc)≥1.5×10 9 /l,,,,,,
18059,,myocarditis|conditions,,,,,,,,,,score ≥60|being able to communicate,,,,,,
18060,,surgeries,,,,,,,,,,≥ 18 years;|aortic,,,,,,
18061,,chronic pulmonary disease,,,,,,,,,,between 18-35 years.|bmi,,,,,,
18062,,primary dysmenorrhea,,,,,,,,,,2 years or older,,,,,,
18063,,prostatic cancer,,,,,,,,,,> 18 years|ecog,,,,,,
18064,,other diseases are obviously,,,,,,,,,,"> 5,6 mmol/l|elevated",,,,,,
18065,,emg signal quality,,,,,,,,,,"< 1,3 mmol/l",,,,,,
18066,,primary insufficiency of the,,,,,,,,,,between 13 and 17 years|sufficient,,,,,,
18067,,metabolic dysfunction,,,,,,,,,,≤ 1.5 x uln|the patient can understand and sign the informed consent form to participate,,,,,,
18068,,neurodegenerative disorder,,,,,,,,,,18.5 - 30.0 kg/m2).|the,,,,,,
18069,,juvenile arthritis,,,,,,,,,,score of 16-20|insurance,,,,,,
18070,,ankle fracture,,,,,,,,,,>5% within 3 months prior,,,,,,
18071,,systemic disease|neck,,,,,,,,,,> 40 u/ml)|postoperative,,,,,,
18072,,complaint of urgency|those with,,,,,,,,,,> 12x109/l,,,,,,
18073,,heart failure;|the eligibility,,,,,,,,,,1-2 points,,,,,,
18074,,chemical peels,,,,,,,,,,18-65,,,,,,
18075,,hemodialysis;|other diseases,,,,,,,,,,> 2.5x,,,,,,
18076,,signs of phlebitis,,,,,,,,,,< 40 ml/min/1.73 m2,,,,,,
18077,,hepatitis b infection,,,,,,,,,,higher than 450 msec,,,,,,
18078,,suboptimal difference,,,,,,,,,,< 1 weekly stool)|chronic diarrhea,,,,,,
18079,,mammaprint,,,,,,,,,,= 0)|normal,,,,,,
18080,,extramedullary lesions,,,,,,,,,,less than 60 ml/min/1.73m2)|patients,,,,,,
18081,,diseases of the heart,,,,,,,,,,=<3cm|maximum tumor diameter,,,,,,
18082,,hepatitis c;|history,,,,,,,,,,more than three months||,,,,,,
18083,,coh,,,,,,,,,,≥ 1.5 x g/l|platelet count,,,,,,
18084,,remote monitoring system (rms),,,,,,,,,,greater than 7.1 cm,,,,,,
18085,,intracranial hemorrhage).|prior,,,,,,,,,,18-35 years,,,,,,
18086,,generalized,,,,,,,,,,between 18-65 to control,,,,,,
18087,,intracranial arteriovenous malformations,,,,,,,,,,3-4.|bone marrow transplant,,,,,,
18088,,nephrotic syndrome,,,,,,,,,,every 24 - 35 days,,,,,,
18089,,lymphoplasmacytic lymphoma,,,,,,,,,,between 90 to 140 mmhg,,,,,,
18090,,spinal deformities|not,,,,,,,,,,18-50|be,,,,,,
18091,,bleeding|active infections,,,,,,,,,,≥18 y of age,,,,,,
18092,,ility,,,,,,,,,,greater than 10,,,,,,
18093,,bowel syndrome|previous exposure,,,,,,,,,,18-80 year,,,,,,
18094,,contraindicated the use of argatroban,,,,,,,,,,0 or 1|subject,,,,,,
18095,,malignant cancers,,,,,,,,,,≥94 cm,,,,,,
18096,,surgically infertile,,,,,,,,,,at least 25 miu/ml,,,,,,
18097,,hepatitis b natural infection (hbcab positive serology,,,,,,,,,,children's hospital,,,,,,
18098,,atypical teratoid/rhabdoid tumors,,,,,,,,,,≤ 12 months;|participation,,,,,,
18099,,metabolic diseases;|had hypersensitivity,,,,,,,,,,<5,,,,,,
18100,,venous thromboembolic disease,,,,,,,,,,< 140 mmhg,,,,,,
18101,,triggers.|serious cardiovascular disease,,,,,,,,,,110 lbs),,,,,,
18102,,main involvement,,,,,,,,,,cover < 10% of body surface area,,,,,,
18103,,cerebral infarction,,,,,,,,,,less than or equal to 45 milliliters/min/1.73 m2,,,,,,
18104,,superficial skin infection,,,,,,,,,,more than 10 pounds,,,,,,
18105,,female,,,,,,,,,,> grade 0,,,,,,
18106,,parenteral antibiotics|active tuberculosis,,,,,,,,,,"<18.5 kg/m2,|allergy",,,,,,
18107,,neurological disorder|uncontrolled endocrinology disease,,,,,,,,,,eighteen,,,,,,
18108,,rapidly disease,,,,,,,,,,≤ 75 years.|subjects,,,,,,
18109,,asherman syndrome,,,,,,,,,,between 3 and 6 years|do,,,,,,
18110,,lifestyle of the volunteer.||5,,,,,,,,,,94% or lower;|be able to follow the,,,,,,
18111,,glottic squamous cell,,,,,,,,,,> b|denutrition with bmi<15kg/m2|nephrotic,,,,,,
18112,,birth|recovering,,,,,,,,,,≥ 1:80,,,,,,
18113,,chronic disease|growth failure,,,,,,,,,,<30ml/min/1.73m2,,,,,,
18114,,corneal scar,,,,,,,,,,> 1.5 × uln.||4,,,,,,
18115,,inability for fluoroscopy,,,,,,,,,,32 kg/m2,,,,,,
18116,,gi infections,,,,,,,,,,greater than 5g/l.,,,,,,
18117,,vital sign findings,,,,,,,,,,class iv hf|if,,,,,,
18118,,localised breast cancer,,,,,,,,,,0-1；|detection,,,,,,
18119,,sensation,,,,,,,,,,"3,4)|untreated periodontitis.|poor oral hygiene",,,,,,
18120,,heart problems|any condition,,,,,,,,,,≥ 500 iu / ml;hepatitis c,,,,,,
18121,,confirmed covid-19,,,,,,,,,,-mutated,,,,,,
18122,,drug dependence.|females,,,,,,,,,,≥18 and ≤50 years,,,,,,
18123,,primary lung adenocarcinoma,,,,,,,,,,> 1%,,,,,,
18124,,cardiovascular risk - documented,,,,,,,,,,≥18 years.|subject,,,,,,
18125,,local infections around,,,,,,,,,,50 to 110 beats per min.|hypertension,,,,,,
18126,,non accessible lesions,,,,,,,,,,160 mg/dl,,,,,,
18127,,asked,,,,,,,,,,higher than 90 mm hg,,,,,,
18128,,ebv virus,,,,,,,,,,between +4.00 to -9.00 (inclusive),,,,,,
18129,,uncontrolled intercurrent illness,,,,,,,,,,18 - 45||,,,,,,
18130,,erectile function,,,,,,,,,,≥ 75 × 109/l.|patients,,,,,,
18131,,hepatitis c virus|pregnancy,,,,,,,,,,from january 01,,,,,,
18132,,clubs,,,,,,,,,,less than 21 years,,,,,,
18133,,irritable mood,,,,,,,,,,<126 mg/dl;|sedentary/recreationally,,,,,,
18134,,thrombotic microangiopathy,,,,,,,,,,≥ grade d),,,,,,
18135,,streptococcal skin,,,,,,,,,,">= 100,000/mcl",,,,,,
18136,,known disorder,,,,,,,,,,18 ~ 45,,,,,,
18137,,alteration of consciousness,,,,,,,,,,between 65 and 85 at entry,,,,,,
18138,,hepatocellular carcinoma.|patients,,,,,,,,,,> 2-4 uln).|smokers,,,,,,
18139,,uncontrolled sustained,,,,,,,,,,18+|provision of verbal consent,,,,,,
18140,,thyroid reduced function,,,,,,,,,,=< 20 mg,,,,,,
18141,,resectable cancer head pancreas.|soft pancreas.|small pancreatic duct diameter.||,,,,,,,,,,18-60years old|asa class,,,,,,
18142,,local tumors,,,,,,,,,,≥21years old keeping,,,,,,
18143,,modified,,,,,,,,,,over 50 years,,,,,,
18144,,amenorrhea,,,,,,,,,,≥ 160mmhg|at least 10%,,,,,,
18145,,breast feeding.|uncontrolled medical,,,,,,,,,,>= 13,,,,,,
18146,,lack of testing supplies,,,,,,,,,,greater than 1.0 cm,,,,,,
18147,,a:||ischemic stroke,,,,,,,,,,">= 50,000/mm^3",,,,,,
18148,,ill,,,,,,,,,,≥170 mmhg,,,,,,
18149,,intestinal tract diseases,,,,,,,,,,1.5,,,,,,
18150,,asthma.|recent,,,,,,,,,,≥3 x upper limit of normal,,,,,,
18151,,multiple-gated,,,,,,,,,,above 25 apm;|use,,,,,,
18152,,diabetic nephropathy,,,,,,,,,,≤ 2.5 x uln|all,,,,,,
18153,,ovarian cystectomy,,,,,,,,,,impaired,,,,,,
18154,,cardiovascular conditions,,,,,,,,,,≥ 50%;|have sufficient understanding,,,,,,
18155,,fetoscopic cord coagulation,,,,,,,,,,> 5 × ul.|alp ≥ 1.5 × uln,,,,,,
18156,,central serous retinopathy (,,,,,,,,,,above 18 years|working,,,,,,
18157,,transfusion therapy|abnormal tcd,,,,,,,,,,< 3years.|patients,,,,,,
18158,,cardiomyopathy|uncontrolled hypertension,,,,,,,,,,<2+,,,,,,
18159,,evaluable tumor lesion.|be conscious,,,,,,,,,,b or c,,,,,,
18160,,predominantly lytic bone lesion,,,,,,,,,,<6.5%|satisfactory,,,,,,
18161,,a cancer,,,,,,,,,,more than 6 months;|female,,,,,,
18162,,compulsive alcohol abuse,,,,,,,,,,≤ 1.5xuln,,,,,,
18163,,somatic symptom,,,,,,,,,,1-2|undergoing,,,,,,
18164,,typo,,,,,,,,,,from 0 to 12 years old|nusinersen treatment|benefiting from a niv|current monitoring,,,,,,
18165,,epidural)|intracranial arterial stenosis,,,,,,,,,,between 18 and 65 years old,,,,,,
18166,,mixed squamous cell carcinoma,,,,,,,,,,between 18.5 and 29.9 kilogram per square metre,,,,,,
18167,,articipants,,,,,,,,,,≥ 18 years||ability to provide written informed consent,,,,,,
18168,,primary psychotic,,,,,,,,,,higher than the normal range,,,,,,
18169,,multifocal gbm,,,,,,,,,,20 to 40 years|presented leg,,,,,,
18170,,not read,,,,,,,,,,greater than 2.5 times the upper normal,,,,,,
18171,,ct,,,,,,,,,,18 to 55|willing and able to provide,,,,,,
18172,,primary myelofibrosis,,,,,,,,,,"0-2,|asa≤3.|at least 18 years",,,,,,
18173,,c infections,,,,,,,,,,> 450 ms|pr,,,,,,
18174,,arteriovenous thromboembolism events,,,,,,,,,,≥30 ml/min/1.73m2||elevated,,,,,,
18175,,non-loop diuretic aside from aldosterone antagonists,,,,,,,,,,<1%,,,,,,
18176,,radical radiotherapy|gleason score,,,,,,,,,,0-1|treatment,,,,,,
18177,,above pulmonary dysfunction,,,,,,,,,,< 3 × institutional uln).||the participant,,,,,,
18178,,fabry,,,,,,,,,,>2cm into the ivc from the,,,,,,
18179,,various ablations,,,,,,,,,,18 years||o exclusion criteria,,,,,,
18180,,vaccine;|current alcohol abuse,,,,,,,,,,less than 3 years|if,,,,,,
18181,,microcristalline disease,,,,,,,,,,8-< 18 years,,,,,,
18182,,symptom exacerbation,,,,,,,,,,greater than 30;|allergic,,,,,,
18183,,skin|squamous cell carcinoma,,,,,,,,,,between 40-200 u/l.|the,,,,,,
18184,,atrophic acne,,,,,,,,,,1.1/recil.||i-7,,,,,,
18185,,spinal muscular,,,,,,,,,,> 8 mg per,,,,,,
18186,,protein sequence,,,,,,,,,,≤ 140/90 mmhg,,,,,,
18187,,abdominal effusion,,,,,,,,,,positive airway pressure therapy or home,,,,,,
18188,,respiratory functions|cardiovascular diseases,,,,,,,,,,1 month to <18 years,,,,,,
18189,,sacrocolpopexy,,,,,,,,,,greater than 1000 iu/ml,,,,,,
18190,,non-surgical sterilization,,,,,,,,,,"equal or exceed 28,000 pmol/l",,,,,,
18191,,nerve damage|currently,,,,,,,,,,> 140 mm hg,,,,,,
18192,,alcohol abuse,,,,,,,,,,≥7 years,,,,,,
18193,,nasal swab,,,,,,,,,,above 160/100,,,,,,
18194,,chronic stable hepatitis,,,,,,,,,,≤ 3 s,,,,,,
18195,,pulmonary embolism|renal failure,,,,,,,,,,<50 years||,,,,,,
18196,,handling,,,,,,,,,,< 40 kg,,,,,,
18197,,botulism,,,,,,,,,,> 220 msec,,,,,,
18198,,photophobia,,,,,,,,,,≥18 years and ≤ 65 years,,,,,,
18199,,sexes.|no obvious,,,,,,,,,,>3×uln,,,,,,
18200,,medical honey,,,,,,,,,,≥20u/ml)||,,,,,,
18201,,present):||- measurable,,,,,,,,,,<1000 mg/day)|current treatment,,,,,,
18202,,influenza virus infection,,,,,,,,,,normal <60 ml/min/bsa,,,,,,
18203,,constrictive pericarditis,,,,,,,,,,"between march 01, 2014",,,,,,
18204,,herpes keratitis,,,,,,,,,,=< 2.5 uln)|patients,,,,,,
18205,,"membrane,|primiparous",,,,,,,,,,≥ 35 kg/m^2,,,,,,
18206,,cognitive difficulties.|we,,,,,,,,,,0 or 1;|informed consent signed,,,,,,
18207,,localized cancer,,,,,,,,,,less than 4 weeks from the end of the previous clinical study,,,,,,
18208,,bi-parental asthma,,,,,,,,,,<60ml/min,,,,,,
18209,,stemi type myocardial infarction,,,,,,,,,,lower than 25,,,,,,
18210,,cirt|nodal involvement,,,,,,,,,,grade ii,,,,,,
18211,,fish.|diagnosis of diseases about collagen metabolism,,,,,,,,,,18-75.||adapted,,,,,,
18212,,rbc,,,,,,,,,,>14 years|chronic,,,,,,
18213,,brainstem lesions,,,,,,,,,,> 3-times the upper limit of normal,,,,,,
18214,,ici)|myocarditis,,,,,,,,,,>= 5,,,,,,
18215,,infectious pneumonia,,,,,,,,,,≤ 3 × uln.)|oxygen saturation,,,,,,
18216,,permanent flutter|systemic disease,,,,,,,,,,≥ 30% after pre expansion,,,,,,
18217,,medication reaction,,,,,,,,,,≥ 3)|oct confirms,,,,,,
18218,,recurrant,,,,,,,,,,≥ 38.0°c [100.4ºf,,,,,,
18219,,cognizance;|body mass index,,,,,,,,,,> 35 miu/ml,,,,,,
18220,,extensive calcifications,,,,,,,,,,>30 kg 13,,,,,,
18221,,tests|normal menstrual cycles,,,,,,,,,,≤ 1.5x institutional upper limit of normal (uln),,,,,,
18222,,bipolar disorder).|self-reported,,,,,,,,,,>= 42 days,,,,,,
18223,,qt syndrome,,,,,,,,,,requiring iv,,,,,,
18224,,depression disorders,,,,,,,,,,≥ 103iu/ml,,,,,,
18225,,disabling condition,,,,,,,,,,5-9 years,,,,,,
18226,,blood losses,,,,,,,,,,14-55 from,,,,,,
18227,,localized carcinoma of the skin,,,,,,,,,,≥ 21 years.|histological,,,,,,
18228,,diseases|laboratory measures,,,,,,,,,,> 3 months|24,,,,,,
18229,,mood disorders,,,,,,,,,,less than 6 months|contraindication,,,,,,
18230,,skin care professional,,,,,,,,,,i-ii,,,,,,
18231,,cancer-related,,,,,,,,,,18.0 to 35 kilograms/square meter (kg/m2,,,,,,
18232,,seizure free,,,,,,,,,,3.0 mm,,,,,,
18233,,acute medical conditions,,,,,,,,,,outside the range of 90 to 140 millimetre(s,,,,,,
18234,,noninfectious pneumonitis,,,,,,,,,,≥3 g/dl.|ability,,,,,,
18235,,myeloproliferative disorder,,,,,,,,,,≥38,,,,,,
18236,,dietary allergies,,,,,,,,,,>3 times upper limit of normal (uln),,,,,,
18237,,stomach pain,,,,,,,,,,<2500 g,,,,,,
18238,,local regulation):||abstinence||acceptable highly effective methods,,,,,,,,,,>4 mm,,,,,,
18239,,joint contractures,,,,,,,,,,0-1 7,,,,,,
18240,,trauma exposure,,,,,,,,,,older than 14,,,,,,
18241,,pac obstruction,,,,,,,,,,more than 60 mmhg,,,,,,
18242,,human immuno deﬁciency virus (hiv) infection;|patients who had been in hospital,,,,,,,,,,"≥ 100,000/μl",,,,,,
18243,,nasal disease,,,,,,,,,,≥35 kg/,,,,,,
18244,,medical contraindications,,,,,,,,,,>18 and <85 years,,,,,,
18245,,nasal fractures,,,,,,,,,,⑧ presence,,,,,,
18246,,deep-seated,,,,,,,,,,30-40 kg/,,,,,,
18247,,signs of pulpal infection,,,,,,,,,,ii.|age,,,,,,
18248,,end-stage cancer,,,,,,,,,,1 or more new lesions;|progression,,,,,,
18249,,inflammatory bowel disease patients.||,,,,,,,,,,≥18 years and ≤75 years,,,,,,
18250,,cutaneous ageing,,,,,,,,,,">75,000/ mm3",,,,,,
18251,,contraindicate safe participation|participation,,,,,,,,,,45 to 55 years,,,,,,
18252,,oncological disease,,,,,,,,,,>200ml|unable,,,,,,
18253,,covid-19 pcr test,,,,,,,,,,<18||participating,,,,,,
18254,,urinary retention|history of stroke|an ulcer,,,,,,,,,,≥ 30 to 59 years,,,,,,
18255,,lack of understanding of the trial,,,,,,,,,,≥12 years to ≤65 years,,,,,,
18256,,cyp4v2 mutations,,,,,,,,,,≥ 21 years|able to understand the informed consent form,,,,,,
18257,,pancreatic disease,,,,,,,,,,1-3 weeks,,,,,,
18258,,end-stage renal disease|planned kidney transplantation||the expanded standard donors (ecd),,,,,,,,,,≥30ml/min,,,,,,
18259,,clinical hepatic decompensation,,,,,,,,,,greater than 3 times the upper limit of normal,,,,,,
18260,,spondyloarthropathies,,,,,,,,,,<18 or >60 years,,,,,,
18261,,stimulating factors,,,,,,,,,,n=20):||18-65 years,,,,,,
18262,,acute infarcts lesion,,,,,,,,,,<18|planned combined cases,,,,,,
18263,,bleeding tendency,,,,,,,,,,= 340 ml beer,,,,,,
18264,,parkinson's disease);|pregnancy,,,,,,,,,,zinc,,,,,,
18265,,it.|previous surgeries,,,,,,,,,,less than 4 weeks prior to study enrollment,,,,,,
18266,,acid folic deficiency,,,,,,,,,,class ii - iv,,,,,,
18267,,mental incompetence,,,,,,,,,,and|access to internet,,,,,,
18268,,chromosome abnormalities,,,,,,,,,,> 180mg/dl,,,,,,
18269,,nasal cavity cancer,,,,,,,,,,≥ 80%,,,,,,
18270,,homeopathic preparations,,,,,,,,,,30-60years|bell's palsy,,,,,,
18271,,malignant tumors;|uncontrolled pulmonary,,,,,,,,,,0 to 2|adequate,,,,,,
18272,,diverticulosis,,,,,,,,,,less than ≤ 5cm，or,,,,,,
18273,,endometrial sarcoma,,,,,,,,,,prematurely,,,,,,
18274,,alcohol withdrawal,,,,,,,,,,≤ 93%||3）pao2/fio2,,,,,,
18275,,parenchymal diseases,,,,,,,,,,1) provide,,,,,,
18276,,normal pressure,,,,,,,,,,>470ms,,,,,,
18277,,plan,,,,,,,,,,>160/100).|history,,,,,,
18278,,lupus);|recent symptoms of illness,,,,,,,,,,> 18 years||diagnosis:||histologically,,,,,,
18279,,abnormal heart,,,,,,,,,,> 2+).|anyone,,,,,,
18280,,heart rate (hr),,,,,,,,,,6 months or more,,,,,,
18281,,primary care physician,,,,,,,,,,"greater than iii,|patients",,,,,,
18282,,risk intermediaries,,,,,,,,,,18-85 year-old,,,,,,
18283,,inflammatory bowel disease.|screening,,,,,,,,,,16 or younger 2- biopsy specimens,,,,,,
18284,,tract infection.|severe anemia,,,,,,,,,,excluding,,,,,,
18285,,urinary tract hemorrhage,,,,,,,,,,1.2 mg/dl,,,,,,
18286,,congenital immunodeficiency diseases,,,,,,,,,,1-3|brunnstrom stages 1-4|fugyl meyer score limit for upper limb||,,,,,,
18287,,behavioral health,,,,,,,,,,< 1.5×10^9/l,,,,,,
18288,,fertile,,,,,,,,,,18|the patient,,,,,,
18289,,lobar microbleeds +/-cortical superficial siderosis|written informed consent||,,,,,,,,,,lactate dehydrogenase,,,,,,
18290,,excessive physical activity,,,,,,,,,,0-6|signed,,,,,,
18291,,several limit function|patients,,,,,,,,,,ii or above,,,,,,
18292,,non-sustained,,,,,,,,,,more than 10 minutes||,,,,,,
18293,,left atrial appendage thrombus|lvef,,,,,,,,,,≥ 2 years and <18,,,,,,
18294,,structural anatomy,,,,,,,,,,< 24|current,,,,,,
18295,,rectum,,,,,,,,,,18 to 75 years old,,,,,,
18296,,mnsclc,,,,,,,,,,distant metastatic disease on ct/mri scans,,,,,,
18297,,secondary atrial fibrillation,,,,,,,,,,≥ 4.0 × 10 9 / l,,,,,,
18298,,defective restorations,,,,,,,,,,>75yo,,,,,,
18299,,hemodynamic instability|cardiac,,,,,,,,,,higher than 210 g / week,,,,,,
18300,,oral allergy syndrome,,,,,,,,,,< 18 mmhg,,,,,,
18301,,etc.)|glomelular filtration rate (gfr),,,,,,,,,,≥8 at screening,,,,,,
18302,,vision ability sufficient,,,,,,,,,,score of ≥ 5,,,,,,
18303,,vertebral compression,,,,,,,,,,> stage ii,,,,,,
18304,,inflammatory rheumatic disease,,,,,,,,,,65 years|patients,,,,,,
18305,,bietti's,,,,,,,,,,> 15mm,,,,,,
18306,,monogenic diabetes,,,,,,,,,,3)bilirubin ≤ 1.5 times the upper limit of normal,,,,,,
18307,,milk products|taking lipid-lowering medications,,,,,,,,,,≥ 65 years.|patients,,,,,,
18308,,porcine products|anaphylaxis,,,,,,,,,,5 to 21,,,,,,
18309,,disease|ocular lymphoma,,,,,,,,,,> 6.5%,,,,,,
18310,,acute gout flare,,,,,,,,,,iii/iv)|elevated,,,,,,
18311,,"congestive heart failure,|the",,,,,,,,,,0-2|laboratory assessments,,,,,,
18312,,post-covid19 syndrome.|known,,,,,,,,,,from 18 to 25 years,,,,,,
18313,,stressors|positive urine drug test|contraindication,,,,,,,,,,>=0.6 bu,,,,,,
18314,,gas,,,,,,,,,,rating ≤50;|able to comply,,,,,,
18315,,restrictive cardiomyopathy|has active myocarditis,,,,,,,,,,> 180,,,,,,
18316,,hyperpigmentation,,,,,,,,,,>2 ng/ml above,,,,,,
18317,,weeks)|neck pain,,,,,,,,,,1.4 mg/dl,,,,,,
18318,,old|healthy,,,,,,,,,,between 18 and 55|french native,,,,,,
18319,,multidrug-resistant organism,,,,,,,,,,0 ~,,,,,,
18320,,or|refractory disease,,,,,,,,,,> 12 000/mm3,,,,,,
18321,,gastrointestinal (gi) disorders,,,,,,,,,,ib-iiia,,,,,,
18322,,home bilevel,,,,,,,,,,no more than 3 prior,,,,,,
18323,,hr+ mbc,,,,,,,,,,between 18.5 and 24.9 kg/m2|median nerve sensory distal latency,,,,,,
18324,,skin changes,,,,,,,,,,between 18 and 85 years|critically ill,,,,,,
18325,,consistent pain,,,,,,,,,,> 170 beats per minute,,,,,,
18326,,mate2k,,,,,,,,,,2.5 - 5 mmol/l,,,,,,
18327,,deep gray matter nuclei,,,,,,,,,,+/- preventer,,,,,,
18328,,persistent chest pain,,,,,,,,,,90 - 93%,,,,,,
18329,,heart,,,,,,,,,,18-65|to,,,,,,
18330,,progressive aphasia,,,,,,,,,,≥ 2.8 g/dl.|(pt)/inr,,,,,,
18331,,adult diabetic,,,,,,,,,,≥ 1 litre.||13,,,,,,
18332,,major organs,,,,,,,,,,> 2.0 times the upper limit of normal value,,,,,,
18333,,mild liver disease,,,,,,,,,,≥42 kg.||,,,,,,
18334,,reproductive age should,,,,,,,,,,5% cream.|subject,,,,,,
18335,,renal diseases,,,,,,,,,,26-30,,,,,,
18336,,metastatic tissue,,,,,,,,,,>8%,,,,,,
18337,,dietary modification,,,,,,,,,,<2× upper limit of normal (uln),,,,,,
18338,,ct scan.|ich,,,,,,,,,,< 110 mg/dl,,,,,,
18339,,cognitive deficit,,,,,,,,,,from 20- 35 years,,,,,,
18340,,communication barrier,,,,,,,,,,"<3,000 or >15,000|platelet count",,,,,,
18341,,active disease,,,,,,,,,,37 to 42 weeks,,,,,,
18342,,kg|hypocalcaemia|contraindications,,,,,,,,,,≥ 1500/µ l,,,,,,
18343,,breast radiation therapy|breast cancer,,,,,,,,,,"<100,000/mm3);|severe",,,,,,
18344,,middle ear infection,,,,,,,,,,scores i,,,,,,
18345,,rhegmatogenous retinal detachment,,,,,,,,,,≥18 years|patient is willing and able to give,,,,,,
18346,,multi-tracer pet scans,,,,,,,,,,0 to 2|adequate organ,,,,,,
18347,,oab dry,,,,,,,,,,≥9 g/dl.|endocrine,,,,,,
18348,,cerebrovascular disease.|patients,,,,,,,,,,<50 kg;|haemoglobin,,,,,,
18349,,high-risk,,,,,,,,,,score 3 to 4,,,,,,
18350,,adhd symptoms,,,,,,,,,,6.5,,,,,,
18351,,eaton-lambert disorders||patients,,,,,,,,,,≤ 75 years.||,,,,,,
18352,,little assistance;|ability to understand and sign informed consent.||,,,,,,,,,,above 8%|diabetes mellitus,,,,,,
18353,,ubm,,,,,,,,,,18-55 years;|ability to understand the nature,,,,,,
18354,,tumor metastasis,,,,,,,,,,fridericia's correction,,,,,,
18355,,disc herniation,,,,,,,,,,less than 1% per year,,,,,,
18356,,serious illness resulting,,,,,,,,,,<9.6 g/dl).|no,,,,,,
18357,,aids)-related illness,,,,,,,,,,< 1.5 times of the normal value.|il-13rα2,,,,,,
18358,,atopic syndrome,,,,,,,,,,>11 years old,,,,,,
18359,,seroma,,,,,,,,,,<= 1.5 x uln,,,,,,
18360,,hypovolemia|psychiatric diseases,,,,,,,,,,≤ 7 days before initial treatment.||highly effective birth control,,,,,,
18361,,local myeloma progression,,,,,,,,,,between 20 to 65 years old|bmi,,,,,,
18362,,lgl,,,,,,,,,,≥ 100/mm3||key,,,,,,
18363,,ulcers|diabetes mellitus,,,,,,,,,,more than 8%,,,,,,
18364,,portal vein tumor,,,,,,,,,,≥21|subject must have,,,,,,
18365,,colon,,,,,,,,,,from 18 to 25 kg/,,,,,,
18366,,consumption of grapefruit,,,,,,,,,,≥ 100 × 109 / l|serum bilirubin,,,,,,
18367,,ert||,,,,,,,,,,less than 30 ml/min/1.73 m2)|skin disease,,,,,,
18368,,chronic pancreatitis episode,,,,,,,,,,every 21,,,,,,
18369,,synthetic human,,,,,,,,,,at least 20 mm hg,,,,,,
18370,,real-world,,,,,,,,,,40-85 years|diagnosis,,,,,,
18371,,kidney transplant)|structural heart disease|currently,,,,,,,,,,> 40 kg/m2.|history,,,,,,
18372,,hospitalization|active infection,,,,,,,,,,<70% predicted,,,,,,
18373,,heart failure|renal failure,,,,,,,,,,<12 and >18 years,,,,,,
18374,,interstitial changes,,,,,,,,,,=< 2 × upper limit of normal (uln),,,,,,
18375,,progressive keratoconus,,,,,,,,,,1.1 via ct,,,,,,
18376,,acute coronary syndrome;|patients,,,,,,,,,,> 400 ml,,,,,,
18377,,unstable coronary artery disease,,,,,,,,,,≥ 4 years,,,,,,
18378,,is,,,,,,,,,,less than 40 kg.|pregnant,,,,,,
18379,,mf,,,,,,,,,,earlier than 35,,,,,,
18380,,available curative,,,,,,,,,,≤ 5×uln);|able to understand and sign the informed consent document.||exclusion,,,,,,
18381,,hereditary myopathy,,,,,,,,,,greater than 50% of the volume of the lesion,,,,,,
18382,,personality disorder,,,,,,,,,,18 or older|type 1 myocardial,,,,,,
18383,,elasticity,,,,,,,,,,< 3x upper limit of,,,,,,
18384,,eb-101 treatment;|the,,,,,,,,,,>31;|having,,,,,,
18385,,intraabdominal bowel calcification,,,,,,,,,,> 25 days|treatment,,,,,,
18386,,metastatic sites)||,,,,,,,,,,≥ 3.0 cm,,,,,,
18387,,episodic migraine.|the,,,,,,,,,,≥60 ml/min/1.73 m2||for,,,,,,
18388,,aortic regurgitation bundle width/left,,,,,,,,,,≥ 100 × 10 9 /l；③,,,,,,
18389,,etc.)||not,,,,,,,,,,45 min,,,,,,
18390,,vertical skeletal dysplasia,,,,,,,,,,free-floating,,,,,,
18391,,cns leukemia.||use,,,,,,,,,,less than 70 years|the,,,,,,
18392,,diffuse,,,,,,,,,,7-16,,,,,,
18393,,recurrent infections,,,,,,,,,,1.1)|be able to comply with outpatient,,,,,,
18394,,significant stenosis,,,,,,,,,,>105 mmhg,,,,,,
18395,,curatorship|patient deaf,,,,,,,,,,<80 x 109/ l,,,,,,
18396,,screening|women,,,,,,,,,,"< 150,000/microl",,,,,,
18397,,primary cad,,,,,,,,,,= 0.000||,,,,,,
18398,,mitochondrial disorders,,,,,,,,,,+- 5%,,,,,,
18399,,walking,,,,,,,,,,"<125,000 cell/mm³;|platelets < 125,000 cell/mm³|prothrombin time (pt)",,,,,,
18400,,prior treatment]|patients,,,,,,,,,,people aged,,,,,,
18401,,algorithm|bp ≥140/90 mmhg,,,,,,,,,,≥10|known secondary,,,,,,
18402,,local lesions,,,,,,,,,,< 1%.|a female,,,,,,
18403,,recurrence after radical therapy,,,,,,,,,,"<30 mls/min/1.73 m2,|history",,,,,,
18404,,stenosis of,,,,,,,,,,>18 years|-,,,,,,
18405,,symptoms,,,,,,,,,,<3 m/s,,,,,,
18406,,ipsilateral adrenal metastasis,,,,,,,,,,≥18 and ≤49 years,,,,,,
18407,,know human immunodeficiency virus (hiv),,,,,,,,,,0.2 ng/ml or higher,,,,,,
18408,,20/100,,,,,,,,,,>60 ml,,,,,,
18409,,neurological disorders beyond tbi|having,,,,,,,,,,<60 or >,,,,,,
18410,,adrenal disease,,,,,,,,,,≥ 100,,,,,,
18411,,clinical dementia rating,,,,,,,,,,≥30)|late trimester of pregnancy,,,,,,
18412,,non-routine,,,,,,,,,,above 24,,,,,,
18413,,persistent atrial,,,,,,,,,,< 60 ml per min,,,,,,
18414,,urinary tract infections|history of chronic,,,,,,,,,,>1.5× uln,,,,,,
18415,,limb ischemia,,,,,,,,,,< 30 ml/min/1.73 m^2)|pregnancy,,,,,,
18416,,irregular shaped node,,,,,,,,,,≥ 7mmol/l);|abnormal,,,,,,
18417,,worse nrs pain score,,,,,,,,,,≥ 30%|score≥ 3,,,,,,
18418,,psychotic illness,,,,,,,,,,less than 150 minutes,,,,,,
18419,,acute rhinitis|asthmatic,,,,,,,,,,≥12 weeks;|patients,,,,,,
18420,,skin breakdown induced,,,,,,,,,,< 2 visits/last,,,,,,
18421,,criteria:||critically ill,,,,,,,,,,cd1a+,,,,,,
18422,,deep brain stimulators,,,,,,,,,,< 10 pmol/h/mg,,,,,,
18423,,chronic kidney disease epidemiology collaboration).|albumin,,,,,,,,,,> 2.0 mg/dl||b.,,,,,,
18424,,prolonged qtc syndrome,,,,,,,,,,years|greater than 3 months,,,,,,
18425,,non-metastatic breast cancer|self- reported,,,,,,,,,,≥ 12 weeks.||11,,,,,,
18426,,analyses.|age|participant,,,,,,,,,,≤ 15%.|pregnant,,,,,,
18427,,posterior hemiblock,,,,,,,,,,>=30 ml/min,,,,,,
18428,,neurological deficit,,,,,,,,,,long-term care staff,,,,,,
18429,,lack of appetite,,,,,,,,,,50 ng/ml,,,,,,
18430,,cardiac repolarization abnormality,,,,,,,,,,greater than 60ml/min/1.73m2.|patients,,,,,,
18431,,cessation of breast feeding,,,,,,,,,,class ii or higher,,,,,,
18432,,chronic health problems,,,,,,,,,,no next of kin|patients,,,,,,
18433,,papillary renal cell carcinoma,,,,,,,,,,>100mmhg)|hypotension,,,,,,
18434,,psychiatric illness|self-report,,,,,,,,,,< 20 ml/min /1.73m2,,,,,,
18435,,coexistence,,,,,,,,,,≥3 nights per week,,,,,,
18436,,concurrents medical condition,,,,,,,,,,0-2.||5,,,,,,
18437,,systemic inflammation,,,,,,,,,,less than 5 days' duration,,,,,,
18438,,critical illness,,,,,,,,,,> 1.5 × uln per discussion between,,,,,,
18439,,ga,,,,,,,,,,between 18 and 65 years.|diagnosis,,,,,,
18440,,enteropathies,,,,,,,,,,18-75|asa i-iii||,,,,,,
18441,,robot-assisted,,,,,,,,,,> 50 kg|haemoglobin,,,,,,
18442,,concomitant disease,,,,,,,,,,40-70,,,,,,
18443,,internal medicine residency,,,,,,,,,,under 50 years-of-age,,,,,,
18444,,breastfeeding|very dry,,,,,,,,,,16 to 30,,,,,,
18445,,radiographic bone loss .|gingivitis,,,,,,,,,,18-70 y|ejection fraction,,,,,,
18446,,spinal cord lesions;|unclear,,,,,,,,,,25-45 years,,,,,,
18447,,cognitive behavior,,,,,,,,,,below such thresholds,,,,,,
18448,,investigator.|measurable disease,,,,,,,,,,> 10 mm diameter.|imaging findings,,,,,,
18449,,anticancer herbal remedy),,,,,,,,,,4-12 years old.|for the foveation therapy group,,,,,,
18450,,intracranial mass,,,,,,,,,,> 50 kg/m2|clinical,,,,,,
18451,,prolonged qt of immediate family members,,,,,,,,,,between 23-feb-2020,,,,,,
18452,,allogenic bone marrow,,,,,,,,,,less than 30 kg/m2,,,,,,
18453,,angioid streaks,,,,,,,,,,over 450 umol/l|signs,,,,,,
18454,,inflammatory arthropathies,,,,,,,,,,≥5 years,,,,,,
18455,,type i diabetes mellitus,,,,,,,,,,> 60 mm g,,,,,,
18456,,febrile seizures,,,,,,,,,,18 years or older;|identifying,,,,,,
18457,,aspirin|contra-indication,,,,,,,,,,2.0 ng/ml;|soft-tissue progression,,,,,,
18458,,digestive organ,,,,,,,,,,≥30 ml/min|participants,,,,,,
18459,,malignant tumors expressing fibroblast-activated,,,,,,,,,,? a response,,,,,,
18460,,gastric emptying,,,,,,,,,,> 10mmol/l),,,,,,
18461,,community dwelling,,,,,,,,,,≥ 10g/dl；liver function,,,,,,
18462,,visual impairment|known pregnancy|implanted,,,,,,,,,,<2.5,,,,,,
18463,,ct4b disease,,,,,,,,,,less than 40%,,,,,,
18464,,intradural extramedullary lesion,,,,,,,,,,"≥ 100, 109/l)|inr",,,,,,
18465,,steroids.|active infection,,,,,,,,,,"0, 1, 2",,,,,,
18466,,breathing frequence,,,,,,,,,,"greater than 25,000/mm^3",,,,,,
18467,,mechanical cause for cs,,,,,,,,,,diseased,,,,,,
18468,,cerebral tumors,,,,,,,,,,=< 50 ng/dl,,,,,,
18469,,hbsb0 thal,,,,,,,,,,0 - 21,,,,,,
18470,,spinal fractures,,,,,,,,,,less than 12 months;|the investigator judged,,,,,,
18471,,hypertension;|serous cavity effusion beyond clinical control,,,,,,,,,,longer than 4 hours each day||inclusion for child outcomes / measurement||children,,,,,,
18472,,hemochromatosis,,,,,,,,,,over 18;|ecog：0-1；|the pain score,,,,,,
18473,,diastolic ≥100 mmhg,,,,,,,,,,hbss,,,,,,
18474,,medical comorbidities,,,,,,,,,,resectable,,,,,,
18475,,medullary thyroid carcinoma,,,,,,,,,,at least 90 minutes.|18 to 80 years||,,,,,,
18476,,habitually consumes,,,,,,,,,,≥ 10 miu/ml,,,,,,
18477,,memory loss|interest,,,,,,,,,,naive,,,,,,
18478,,malignant tumour,,,,,,,,,,2-17 years,,,,,,
18479,,comorbid autism spectrum,,,,,,,,,,≥60/ml,,,,,,
18480,,central neurological diseases,,,,,,,,,,> 6 months||,,,,,,
18481,,gastrointestinal diseases.|weight loss,,,,,,,,,,0 to 2,,,,,,
18482,,local infections,,,,,,,,,,> 100mmhg,,,,,,
18483,,impaired;|pregnant,,,,,,,,,,above 3 times the normal upper limit,,,,,,
18484,,stroke)||symptomatic peripheral arterial disease,,,,,,,,,,< 12 months|ecog performance status,,,,,,
18485,,non-covid-19 authorized vaccines,,,,,,,,,,≥ 37.5°c,,,,,,
18486,,right hepatic artery.|ca,,,,,,,,,,30-40 kg/m2|stable,,,,,,
18487,,visceral bleeding,,,,,,,,,,requires assistance|cardiac disease,,,,,,
18488,,papillary disease,,,,,,,,,,≤ 24|unable,,,,,,
18489,,otherwise healthy,,,,,,,,,,1 month - 12 years,,,,,,
18490,,liver fibrosis.|participant,,,,,,,,,,18 - 75 years;|fulfilling,,,,,,
18491,,skin resurfacing,,,,,,,,,,<37 weeks|birth weight,,,,,,
18492,,medical diseases,,,,,,,,,,"over 18 years old,|having no barriers",,,,,,
18493,,pls,,,,,,,,,,between 60.0 and 100.0 kg,,,,,,
18494,,pure adenocarcinoma,,,,,,,,,,between 16-35 kg/m2|forced,,,,,,
18495,,thrombolytic therapy:||at least 1 week after medical intervention|clinically stable|body weight,,,,,,,,,,1 and 2 diabetes|any,,,,,,
18496,,vasculitis .|diagnosed hepatocellular carcinoma,,,,,,,,,,≤ 29.5|anterior,,,,,,
18497,,arterial ph,,,,,,,,,,less than or equal to 18 years,,,,,,
18498,,colon adenocarcinoma,,,,,,,,,,less than 20/25,,,,,,
18499,,discharged home safely,,,,,,,,,,equal to or higher than 90g/l,,,,,,
18500,,metastatic prostate cancer disease,,,,,,,,,,18 and 60 years).|hbsag positive,,,,,,
18501,,non-rheumatic mitral stenosis,,,,,,,,,,greater than 30,,,,,,
18502,,diseases;|participants,,,,,,,,,,≥ 18 years.|performance status,,,,,,
18503,,cheng,,,,,,,,,,≥18 years|participants must,,,,,,
18504,,urine drug screening;|patients,,,,,,,,,,> 2.5,,,,,,
18505,,dryness,,,,,,,,,,≥ 18 years old who:||are,,,,,,
18506,,simplified oral hygiene index,,,,,,,,,,> 1500 cells/mm3|creatinine ≤ 1.5 x uln,,,,,,
18507,,acute ischemic stroke symptom.||time,,,,,,,,,,12-20,,,,,,
18508,,posttraumatic facial scar||,,,,,,,,,,">30,000 cells/ml",,,,,,
18509,,-related,,,,,,,,,,>99th percentile,,,,,,
18510,,hypertensive encephalopathy,,,,,,,,,,1.00 d or,,,,,,
18511,,macrophage activation syndrome,,,,,,,,,,> 90 or < 45 beats per minute,,,,,,
18512,,barrier forms,,,,,,,,,,>250 μg/g,,,,,,
18513,,alternative communication (aac),,,,,,,,,,< 1l|severe,,,,,,
18514,,persistent pain,,,,,,,,,,"< 1,100 cel/ml.|admitted to icu",,,,,,
18515,,caries rate,,,,,,,,,,over 9 years,,,,,,
18516,,healthy obese,,,,,,,,,,<45%.|myocardial infarction,,,,,,
18517,,crohn's disease.|active,,,,,,,,,,edition.||(*5 cm<,,,,,,
18518,,angina symptoms,,,,,,,,,,tendinopathy|less than 3 months,,,,,,
18519,,hematological conditions,,,,,,,,,,≥ii,,,,,,
18520,,confirmed covid-19 infection,,,,,,,,,,> 2.5 × upper limit of normal (uln),,,,,,
18521,,illness|active infection,,,,,,,,,,≤ 1|measurable disease,,,,,,
18522,,joint injuries|having an,,,,,,,,,,> 470 msec obtained,,,,,,
18523,,plasmapheresis,,,,,,,,,,classification ii or,,,,,,
18524,,pediatrics,,,,,,,,,,between 1 and 5,,,,,,
18525,,events of alopecia,,,,,,,,,,≥18 years 3a,,,,,,
18526,,reactive hyperemia index,,,,,,,,,,<4 g/l,,,,,,
18527,,cognitive problems,,,,,,,,,,penile plaque,,,,,,
18528,,prior infections|retinal disease,,,,,,,,,,>= 1 cm,,,,,,
18529,,external root resorption,,,,,,,,,,≥ 50 cc/min,,,,,,
18530,,active enthesitis,,,,,,,,,,"≥ 1,5;|concomitant",,,,,,
18531,,rescue medicine.||,,,,,,,,,,less than the lower limit of normal,,,,,,
18532,,resolved infection,,,,,,,,,,4 to 17 years|child,,,,,,
18533,,neurological disorders;|failure,,,,,,,,,,distant metastatic disease,,,,,,
18534,,aortic valve stenosis||,,,,,,,,,,20 female,,,,,,
18535,,ventricular tachyarrhythmias,,,,,,,,,,between 18-30 kg/m2|systolic,,,,,,
18536,,disease progression by observation,,,,,,,,,,>250 nmol/l).|pregnant,,,,,,
18537,,discretion.|pregnant,,,,,,,,,,< 92%,,,,,,
18538,,malignant ascites,,,,,,,,,,≥1 and ≤9,,,,,,
18539,,exacerbation,,,,,,,,,,≤ 5 days from day 1,,,,,,
18540,,anorectal advancement flap,,,,,,,,,,between 18 and 30 kilograms per metered square,,,,,,
18541,,glycogen storage disease,,,,,,,,,,at least 80% predicted|the participant,,,,,,
18542,,corneal diseases,,,,,,,,,,>=1 cm,,,,,,
18543,,craniofacial malformations,,,,,,,,,,9-17 years voluntarily signed,,,,,,
18544,,peripheral deep vein thrombosis,,,,,,,,,,less than 50 degrees.|age,,,,,,
18545,,"neurologic, gi",,,,,,,,,,18 and 40 years,,,,,,
18546,,joint injury,,,,,,,,,,deemed not,,,,,,
18547,,non-autologous,,,,,,,,,,>0.1 msv,,,,,,
18548,,aorta aneurysm,,,,,,,,,,greater than 10 million/ml||,,,,,,
18549,,embryonal sarcoma,,,,,,,,,,at least 10,,,,,,
18550,,allogeneic bone marrow,,,,,,,,,,18-75 years|cirrhotic,,,,,,
18551,,primary glomerular disease,,,,,,,,,,greater than 30 g/day,,,,,,
18552,,level|regular menstrual cycle,,,,,,,,,,12.1 appendix 1.||,,,,,,
18553,,undiagnosed children|inadequate,,,,,,,,,,> 6 months from stroke)|they,,,,,,
18554,,anticancer therapy.|ongoing,,,,,,,,,,>1.5 × upper limit of normal,,,,,,
18555,,hyperkeratotic lesions,,,,,,,,,,> 1.5 x uln|alt,,,,,,
18556,,cognitive measure of attention,,,,,,,,,,≤0.8 ng/ml,,,,,,
18557,,points|diagnosis,,,,,,,,,,>2.0 times uln,,,,,,
18558,,slnb,,,,,,,,,,≥9.5 kpa,,,,,,
18559,,transplantation|active cancer|liver disease,,,,,,,,,,≥ 100 x109/l|haemoglobin,,,,,,
18560,,pulmonary disease|bleeding disorder,,,,,,,,,,≥ 40 mg/l|6,,,,,,
18561,,recurrence to participate.||arm,,,,,,,,,,>10,,,,,,
18562,,metastatic lesion,,,,,,,,,,≥ 30 kg/m2|patient,,,,,,
18563,,pulmonary fibrosis|uncontrollable pleural effusion,,,,,,,,,,< 90 x 10^9 / l,,,,,,
18564,,congestive heart failure|individuals,,,,,,,,,,18-25|diagnosed,,,,,,
18565,,complicated diabetes,,,,,,,,,,between 18 and 35 kg/m² inclusive.||additional inclusion criteria,,,,,,
18566,,gardner's syndrome,,,,,,,,,,< 5 times the half-life,,,,,,
18567,,malignant colorectal disease,,,,,,,,,,between 20 - 75 years|previously,,,,,,
18568,,hemorrhagic event,,,,,,,,,,per day or,,,,,,
18569,,chronic sleep disorders,,,,,,,,,,draws.||less than 2 acceptable,,,,,,
18570,,bladder-,,,,,,,,,,no more than 50% involvement of the nail area.|target toenail thickness 1.5mm,,,,,,
18571,,renal failure.|seizure disorder,,,,,,,,,,18 to 40 years;|35 to 41 weeks of pregnancy;|singleton pregnancy;|plan,,,,,,
18572,,serious anatomical damage,,,,,,,,,,> uln.|any,,,,,,
18573,,zmc fractures,,,,,,,,,,≥ 2.||patients,,,,,,
18574,,lvi,,,,,,,,,,more than 5|patients,,,,,,
18575,,pain killers,,,,,,,,,,students|age 18 years,,,,,,
18576,,shared etiology,,,,,,,,,,between 18-80,,,,,,
18577,,microcytic,,,,,,,,,,less than 1.0 standard deviation below the test score normed for age,,,,,,
18578,,devastating injuries,,,,,,,,,,≤ 40%||valve disease:||degenerative,,,,,,
18579,,type 2)|uncontrolled thyroid,,,,,,,,,,not less than 2500g,,,,,,
18580,,"asthma,|asthma exacerbation",,,,,,,,,,> 102 cm|women,,,,,,
18581,,auditory pathway damage,,,,,,,,,,≤ 5uln;|serum,,,,,,
18582,,vertebrobacillary arterial system,,,,,,,,,,< 60 years old,,,,,,
18583,,urogenital infection,,,,,,,,,,score of <2,,,,,,
18584,,parafunctional habit.|having infection,,,,,,,,,,between 19 and 24 kg/m2,,,,,,
18585,,cognitive impairment.|contraindications,,,,,,,,,,18.00-24.99 kg/m2|obese,,,,,,
18586,,mental disorders.|disturbance,,,,,,,,,,15-70years,,,,,,
18587,,breast feeding|ascitis|transjugular intrahepatic portosystemic shunt,,,,,,,,,,≤ 3 x uln,,,,,,
18588,,period;|abnormal liver function,,,,,,,,,,>20 units/week)|reported,,,,,,
18589,,t2 flair,,,,,,,,,,"≥ 1,500/mcl.|platelets",,,,,,
18590,,primary lesions,,,,,,,,,,< 0.5 or,,,,,,
18591,,ptsd symptoms,,,,,,,,,,60 or,,,,,,
18592,,tried antidepressants off-label,,,,,,,,,,codes for,,,,,,
18593,,physical incapacity,,,,,,,,,,≥ class,,,,,,
18594,,cardiotoxicity,,,,,,,,,,20 to 40 years,,,,,,
18595,,global pharmacovigilance,,,,,,,,,,≥15 mm|subject,,,,,,
18596,,cancer therapies,,,,,,,,,,between 40 - 150 kg.||,,,,,,
18597,,primary plasma cell,,,,,,,,,,between 18 to 65 years,,,,,,
18598,,pulmonary pathology,,,,,,,,,,≥18 years.||participant,,,,,,
18599,,solid organ transplantation|any other disease,,,,,,,,,,greater than the lower limits of detection of the assay.|hiv-infected,,,,,,
18600,,little,,,,,,,,,,6 and 16 years,,,,,,
18601,,traumatic brain injury)|a,,,,,,,,,,>=26)|baseline,,,,,,
18602,,chocolates,,,,,,,,,,younger than 12 years,,,,,,
18603,,blood thinning agents|known,,,,,,,,,,< 18 yrs|t3-t4 staging|unable to understand the verbal,,,,,,
18604,,hepatic diseased,,,,,,,,,,> 40 kg/m2|haemodinamic,,,,,,
18605,,falls,,,,,,,,,,+/-20%).||,,,,,,
18606,,chronic obstructive pulmonary disease)|rheumatoid arthritis of the lower extremities|severe,,,,,,,,,,0-2.|life expectancy,,,,,,
18607,,acceptable individual capable,,,,,,,,,,less than 0.1|allergy,,,,,,
18608,,lymphocytic lymphoma,,,,,,,,,,more than or equal to 50 ml/min,,,,,,
18609,,pulmonary hypertension|patient under guardianship,,,,,,,,,,3 times a week,,,,,,
18610,,sonrtip atrial pacing lead.|future,,,,,,,,,,≥ 5.7%)||previous,,,,,,
18611,,mixed cholangiocellular carcinoma|massive tumor progression,,,,,,,,,,older than 28 weeks,,,,,,
18612,,clinical laboratory abnormalities,,,,,,,,,,≥18 years|patients followed in medical oncology,,,,,,
18613,,osas,,,,,,,,,,≥16.5 kg/m2,,,,,,
18614,,ventricular tachyarrhythmia,,,,,,,,,,less than 1 year.|participation,,,,,,
18615,,mental disease,,,,,,,,,,"≤ 100,000",,,,,,
18616,,skin inflammatory conditions,,,,,,,,,,=< 2.0 mg/dl.||aspartate aminotransferase,,,,,,
18617,,resistant bacterial strains,,,,,,,,,,≥ 1.5 cm,,,,,,
18618,,interferes with the primary outcome of this research,,,,,,,,,,< 100 ml / 24,,,,,,
18619,,basal-like carcinoma,,,,,,,,,,= 3.||,,,,,,
18620,,malignant tumors|before,,,,,,,,,,≥18 and ≤75 years,,,,,,
18621,,neurologic disorders;|infections;|systemic disorders;|pregnancy,,,,,,,,,,< 27|severe chronic diseases,,,,,,
18622,,alcohol abuse.|is,,,,,,,,,,"≥18 years,|(2",,,,,,
18623,,retinitis,,,,,,,,,,">2,500g|no",,,,,,
18624,,lymphoma infiltration,,,,,,,,,,>100/mm3,,,,,,
18625,,criteria of postmenopausal,,,,,,,,,,<25%).|in the case,,,,,,
18626,,neurodermatitis -,,,,,,,,,,between i and iii);|able to understand and respond to self-report,,,,,,
18627,,repetitions,,,,,,,,,,18 years or older|up to 2 cm tear size,,,,,,
18628,,chromophobe cell carcinoma,,,,,,,,,,elevations,,,,,,
18629,,vergence,,,,,,,,,,at least 12 weeks.||is medically,,,,,,
18630,,ipsilateral breast cancer,,,,,,,,,,>7%.|uncontrolled gastric,,,,,,
18631,,lung abnormalities,,,,,,,,,,≥12 and <18 years,,,,,,
18632,,non-cancer surgery,,,,,,,,,,>20 g/d,,,,,,
18633,,multi-racial,,,,,,,,,,< 1.5 x normal|creatinine clearance,,,,,,
18634,,therapy.|seizure disorder,,,,,,,,,,<= 1.5 uln,,,,,,
18635,,documenting systolic dysfunction,,,,,,,,,,>220 ms,,,,,,
18636,,primary insertional achilles tendinopathy|platelet rich plasma (prp),,,,,,,,,,≥ 6；|the,,,,,,
18637,,renal function)|life expectancy,,,,,,,,,,25-50 years|provision of signed,,,,,,
18638,,end-ischemic dhope,,,,,,,,,,>220 mmhg,,,,,,
18639,,cyanotic congenital cardiac lesions,,,,,,,,,,>/= 11.1 mmol/l,,,,,,
18640,,diseases of the exocrine pancreas,,,,,,,,,,less than 30 %,,,,,,
18641,,squamous cell skin cancer,,,,,,,,,,between the ranges of 18.5 and 35.||,,,,,,
18642,,vascular disorders,,,,,,,,,,>2×upper limit of normal (uln),,,,,,
18643,,kidney involvement,,,,,,,,,,>1500/mm3,,,,,,
18644,,meningeal disease,,,,,,,,,,> 80 % of predicted values|oxygen saturation,,,,,,
18645,,sar,,,,,,,,,,iii - iv patient group|patients,,,,,,
18646,,antihypertensive drug.|hypertension,,,,,,,,,,> 30 db hl,,,,,,
18647,,non-epileptic psychogenic,,,,,,,,,,<100)|habitual intake,,,,,,
18648,,recurrence|acute bacterial sinusitis,,,,,,,,,,between the first anti-vegf injection,,,,,,
18649,,signs of inborn disease|infants,,,,,,,,,,more than 180 mmhg,,,,,,
18650,,lower extremity arterial bypass.|ongoing,,,,,,,,,,≥100 000/µl|hemoglobin ≥9.0 g/dl|creatinine,,,,,,
18651,,and|not,,,,,,,,,,> 25 kg/m2)|normal,,,,,,
18652,,intercurrent illness;|major surgical procedure,,,,,,,,,,less than 60|previous history,,,,,,
18653,,t1c,,,,,,,,,,greater than 6',,,,,,
18654,,lower limb ischemia criteria,,,,,,,,,,< 8mg/dl,,,,,,
18655,,progressive brain metastases,,,,,,,,,,0 - 1,,,,,,
18656,,chronic bowel disease,,,,,,,,,,fulflling these criteria,,,,,,
18657,,hepatitis c [hepc,,,,,,,,,,1500/ml,,,,,,
18658,,amblyopia|3-12 years,,,,,,,,,,5-17 years|normal,,,,,,
18659,,consent.|medical disorders,,,,,,,,,,>30 ml/min/1.73 m2,,,,,,
18660,,genotype);|symptomatic,,,,,,,,,,less than 8 years.||note,,,,,,
18661,,reinke's edema|cyst of the vocal fold|nodule of the vocal fold|polyp of the vocal fold||exclusion criteria:||previous laryngeal,,,,,,,,,,≥1.5 ×uln,,,,,,
18662,,as:||myopathy,,,,,,,,,,≥ 18 years|ability to provide,,,,,,
18663,,high bleeding risk,,,,,,,,,,18 to 80 inclusive (subjects,,,,,,
18664,,etc.;|previous,,,,,,,,,,"<1,000/mm3|hemoglobin levels",,,,,,
18665,,transient tic disorder,,,,,,,,,,> 200/,,,,,,
18666,,congenital long qt syndrome.|history of clinically significant,,,,,,,,,,1 year or more,,,,,,
18667,,field coverage,,,,,,,,,,18-70 years old,,,,,,
18668,,large ferromagnetic fragments,,,,,,,,,,≥480 ms,,,,,,
18669,,contraceptive measures;|able to communicate well,,,,,,,,,,18 years and above.|subject,,,,,,
18670,,arterial thromboembolic events,,,,,,,,,,≥55%,,,,,,
18671,,bloody stools）|arterial thrombosis,,,,,,,,,,1.5×10⁹/l - platelet count,,,,,,
18672,,solid organ transplantation.||major surgery,,,,,,,,,,> 2xuln,,,,,,
18673,,end-stage chronic renal failure|receiving chemotherapy,,,,,,,,,,≤ 1 year;|known,,,,,,
18674,,ocular disorders,,,,,,,,,,lvef≥45%|at least,,,,,,
18675,,immunodeficiency.|participant,,,,,,,,,,<12.5 cm|conversion,,,,,,
18676,,severe difficulties,,,,,,,,,,≥ 10 mg/dl,,,,,,
18677,,malignant liver placeholder,,,,,,,,,,≥18 years;|have,,,,,,
18678,,pulmonary metastases,,,,,,,,,,above 37.5,,,,,,
18679,,infectious process,,,,,,,,,,>4 points,,,,,,
18680,,iim,,,,,,,,,,between 18 and 39 years,,,,,,
18681,,familial hypercholesterolemia|bmi,,,,,,,,,,≥1000/mcl|platelet,,,,,,
18682,,salivary gland pathologies,,,,,,,,,,>= 18 years|registration,,,,,,
18683,,frontotemporal dementia,,,,,,,,,,< 4;|bmi ≤ 45;|patient willing and able to provide written informed consent,,,,,,
18684,,heart infarction,,,,,,,,,,less than (<),,,,,,
18685,,limb,,,,,,,,,,between 18.0 and 26.0 kg/m2,,,,,,
18686,,cervical disc herniation,,,,,,,,,,> 1.0 times uln.|active gastrointestinal disease,,,,,,
18687,,nuclear factor kappa-b ligand inhibitors,,,,,,,,,,"less than 100,000",,,,,,
18688,,hypoglycaemia;|subjects,,,,,,,,,,> 30kg||exclusion,,,,,,
18689,,chronic disorder,,,,,,,,,,= 12 g)|administration of another investigational product,,,,,,
18690,,comfortable using applications,,,,,,,,,,> 2.5 x unl,,,,,,
18691,,neuropsychiatric symptoms,,,,,,,,,,<3 weeks prior to the signing of informed,,,,,,
18692,,poor sleep quantity,,,,,,,,,,mainly,,,,,,
18693,,figo,,,,,,,,,,18-27.9 kg/m2,,,,,,
18694,,clear cell carcinoma,,,,,,,,,,> 90mmhg).||severe,,,,,,
18695,,physiological sleep problems,,,,,,,,,,a score,,,,,,
18696,,chronic renal failure.|substance,,,,,,,,,,18-65)|diagnosis,,,,,,
18697,,treatment modalities,,,,,,,,,,< 2 × uln,,,,,,
18698,,pulmonary dysfunction,,,,,,,,,,<400 copies/ml,,,,,,
18699,,diabetic kidney disease,,,,,,,,,,>39).|anxiety/depressive disorder,,,,,,
18700,,remote consent||,,,,,,,,,,≥ 10.0 mg/dl,,,,,,
18701,,pneumonectomy);|nutritional deficiency,,,,,,,,,,>70 g/week,,,,,,
18702,,alcohol use|no,,,,,,,,,,below 50 years,,,,,,
18703,,therapy|leukemia|lymphoma,,,,,,,,,,b-cell-like (gcb),,,,,,
18704,,axillary nodes,,,,,,,,,,<2.8 mmol/l,,,,,,
18705,,skeletal diseases,,,,,,,,,,30-49 years,,,,,,
18706,,adult epileptic,,,,,,,,,,>50,,,,,,
18707,,inhaled hormones);|suffering from mental illness;|the patient has,,,,,,,,,,18-80 years|type 2,,,,,,
18708,,.|active infection,,,,,,,,,,> 200 copies/ml)|undetectable,,,,,,
18709,,hbsag loss,,,,,,,,,,> / = 38.0 degrees celsius/100.4 degrees fahrenheit,,,,,,
18710,,gynecologic disease,,,,,,,,,,greater than 12 weeks|the,,,,,,
18711,,liver metastases.|renal function,,,,,,,,,,< 1500/ml,,,,,,
18712,,acute decompensation of hf,,,,,,,,,,between -1.00 d and -10.00 d,,,,,,
18713,,radiation ovarian irradiation).||,,,,,,,,,,less than 12 months|participation,,,,,,
18714,,aortic insufficiency|dissection aneurysm,,,,,,,,,,<60 mls/min/1.73 m2,,,,,,
18715,,local ablation|no recurrence after curative treatment of,,,,,,,,,,>2mg/dl,,,,,,
18716,,renal cell tumors,,,,,,,,,,<50 beats per minute,,,,,,
18717,,niu)|diagnosis,,,,,,,,,,≥ 5% after cr,,,,,,
18718,,high grade dysplasia,,,,,,,,,,to 18 years|pregnancy and lactation|patients,,,,,,
18719,,impact oropharyngeal,,,,,,,,,,≥ 1.5 × 10^9/l||-platelet count (,,,,,,
18720,,pharyngeal swabs,,,,,,,,,,> 40% predicted,,,,,,
18721,,structural cardiomyopathy,,,,,,,,,,<11.0g/dl|history,,,,,,
18722,,detectble disease,,,,,,,,,,≥ 18 years|symptoms of,,,,,,
18723,,noncavitated,,,,,,,,,,40-60 years|50/50,,,,,,
18724,,health coaching,,,,,,,,,,≥18 with,,,,,,
18725,,sinus lift,,,,,,,,,,< 50||caregivers:||•,,,,,,
18726,,cardiac dysrhythmia.|historical,,,,,,,,,,greater than or equal to 18 years,,,,,,
18727,,myelodysplastic syndromes (mds),,,,,,,,,,">/= 3,000/microl",,,,,,
18728,,all)/lymphoma|myelodysplasia,,,,,,,,,,≥ 43 mmol/mol|if,,,,,,
18729,,atherosclerotic lesions,,,,,,,,,,17.5 to 32.0 kilograms per square meter (kg/m^2,,,,,,
18730,,swallowing capsules,,,,,,,,,,30-65 years.||,,,,,,
18731,,hepatitis c:,,,,,,,,,,> 20 ng/l|clinically,,,,,,
18732,,gfd,,,,,,,,,,> 20% of the,,,,,,
18733,,heart rate disorder,,,,,,,,,,more than 30 days have,,,,,,
18734,,conditions like neurological conditions|any infection|tumor|spinal surgery|cognitive impairments|refusal to sign consent|patients taking,,,,,,,,,,>200 iu/ml,,,,,,
18735,,compromised bone marrow function,,,,,,,,,,>= 18 years|aml,,,,,,
18736,,cva,,,,,,,,,,<1.5×uln.||exclusion criteria,,,,,,
18737,,cardiac conduction disorders|disease,,,,,,,,,,15-30 mm,,,,,,
18738,,impaired pulmonary,,,,,,,,,,≥ 4.0×109/l,,,,,,
18739,,ptcl-nos,,,,,,,,,,≥ 40 db hl,,,,,,
18740,,product|inability,,,,,,,,,,180 or less,,,,,,
18741,,hepatic impairment||hepatic impaired,,,,,,,,,,≤ 40,,,,,,
18742,,age;|participant,,,,,,,,,,>/= 15 mm per short axis,,,,,,
18743,,limb pathologies,,,,,,,,,,>50 hours/year,,,,,,
18744,,participation|hemoglobinopathy,,,,,,,,,,≥ 100 × 109/l;||hemoglobin,,,,,,
18745,,std,,,,,,,,,,between 50-70 years.|patients,,,,,,
18746,,local allergic,,,,,,,,,,">= 100,000/mm^3|creatinine clearance",,,,,,
18747,,coagulation functions,,,,,,,,,,less than 12 weeks,,,,,,
18748,,bleeding diathesis|pregnant,,,,,,,,,,score of ≥70% or better,,,,,,
18749,,aortic mass,,,,,,,,,,20%,,,,,,
18750,,right ventricular dysfunction.|copd,,,,,,,,,,between 18.5 kg/m2,,,,,,
18751,,reactive eluate,,,,,,,,,,≥350 within 6 months of the first dose of study treatment,,,,,,
18752,,difficulty swallowing,,,,,,,,,,>= 18 years.|participant or legally,,,,,,
18753,,chronic obstructive pulmonary disease.|suspected,,,,,,,,,,<60 × 10^9 per liter [,,,,,,
18754,,pancreatic disease)||concerns,,,,,,,,,,17-28 years.||class ii,,,,,,
18755,,mean pain,,,,,,,,,,> 40|patients,,,,,,
18756,,prophylactic medications,,,,,,,,,,4-10mm,,,,,,
18757,,pathological lesions,,,,,,,,,,< 30.0 g/l|abnormalities,,,,,,
18758,,homeless shelter,,,,,,,,,,≥40ml/min,,,,,,
18759,,augmented virtual reality application,,,,,,,,,,>0.1,,,,,,
18760,,age)|body mass index,,,,,,,,,,< 13.0 years,,,,,,
18761,,mixed neuroendocrine,,,,,,,,,,"less than 400 or higher than 1,200",,,,,,
18762,,signature,,,,,,,,,,< 25 (normal weight,,,,,,
18763,,recurrent pericarditis,,,,,,,,,,egfr<60ml/min,,,,,,
18764,,administration.|medical condition,,,,,,,,,,<3 months;|received,,,,,,
18765,,aortic dissection).|rhythm disorders,,,,,,,,,,<3 years,,,,,,
18766,,congenital heart disease|syndromic,,,,,,,,,,18-45 years,,,,,,
18767,,menopausal symptoms,,,,,,,,,,under 18 years old|contraindication,,,,,,
18768,,t-lbl,,,,,,,,,,between 25 and 65 years,,,,,,
18769,,abnormalities of the pupil,,,,,,,,,,less than 30 minutes after periods,,,,,,
18770,,airway colonization,,,,,,,,,,18.0 to 32.0 kg/m2|hemoglobin a1c ≤ 6.0%|female,,,,,,
18771,,knee arthritis,,,,,,,,,,equal to 13 follicles measuring,,,,,,
18772,,"stroke,|cauda equina",,,,,,,,,,< 800 pg/ml,,,,,,
18773,,hiv-1 infection|if,,,,,,,,,,14 - 25 years.|participants,,,,,,
18774,,terminal malignancy,,,,,,,,,,> 1.3 or pt prolongation,,,,,,
18775,,arthritis|systemic lupus,,,,,,,,,,20-35|term pregnancies,,,,,,
18776,,head trauma|conditions,,,,,,,,,,"less than 6'2""",,,,,,
18777,,central neurological condition|no treatment,,,,,,,,,,above the upper limit of normal (uln),,,,,,
18778,,liver disease|patients,,,,,,,,,,0-2.|expected life,,,,,,
18779,,chronic diarrhea,,,,,,,,,,<3mm,,,,,,
18780,,patulous eustachian tube dysfunction,,,,,,,,,,0-iv,,,,,,
18781,,complaint of supra-esophageal symptoms,,,,,,,,,,older than 24 years old and above 50 years,,,,,,
18782,,castration-resistant prostate cancer,,,,,,,,,,i-iii;|bmi,,,,,,
18783,,painful condition,,,,,,,,,,80-150 mm hg systolic,,,,,,
18784,,mild problems.||exclusion criteria:||the latter means,,,,,,,,,,<= 10 following:||erythema,,,,,,
18785,,significant condition,,,,,,,,,,> 18 years|diagnosis of chronic stroke,,,,,,
18786,,accessible by surgery,,,,,,,,,,18-65|edss score ≤ 6.5|sdmt,,,,,,
18787,,antifungal,,,,,,,,,,between 7 years,,,,,,
18788,,hepatitis b virus core antibody (hbcab),,,,,,,,,,+/- chemotherapy|18 years,,,,,,
18789,,chronic renal failure|receiving chemotherapy,,,,,,,,,,below 37.5℃,,,,,,
18790,,"chronic obstructive pulmonary disease,|malignant",,,,,,,,,,≥50 mm maximum diameter|indication for evar,,,,,,
18791,,infertility,,,,,,,,,,>0.7,,,,,,
18792,,epidural disease,,,,,,,,,,less than 7 days before taking the drug,,,,,,
18793,,involuntary weight loss,,,,,,,,,,≥ 18 years|informed,,,,,,
18794,,secondary infertility,,,,,,,,,,60 kg to 100 kg.|healthy volunteers should,,,,,,
18795,,subretinal fluid seen on,,,,,,,,,,> 6 cm below the left costal margin,,,,,,
18796,,sports activities,,,,,,,,,,≥ 28 kg/m2,,,,,,
18797,,serious mental health illness,,,,,,,,,,1.1 both first-,,,,,,
18798,,lubricants.||baseline symptoms score,,,,,,,,,,less than 500ml;|ecog/who performance score,,,,,,
18799,,squamous cell carcinoma of the skin,,,,,,,,,,< 12 g/dl,,,,,,
18800,,breast cancer liver metastases,,,,,,,,,,>70% diameter stenosis,,,,,,
18801,,smokers,,,,,,,,,,6 mm or greater,,,,,,
18802,,irritable bowel syndrome|pregnancy,,,,,,,,,,3 times or higher than upper normal,,,,,,
18803,,salivary duct carcinoma,,,,,,,,,,at least,,,,,,
18804,,mood disorder,,,,,,,,,,45 mm or more,,,,,,
18805,,rectal cancer disease.|the lower margin of the tumor,,,,,,,,,,individuals ≥18 years,,,,,,
18806,,heart disease.|women,,,,,,,,,,< 25,,,,,,
18807,,mixed hepatocellular / cholangiocarcinoma,,,,,,,,,,6-month mortality,,,,,,
18808,,extra-abdominal,,,,,,,,,,18 to <40 kilograms/meter,,,,,,
18809,,"criteria for exclusion of parents from the study are:||caring for other dependent people (elderly,",,,,,,,,,,0 to 2|patients,,,,,,
18810,,rheumatism/organs,,,,,,,,,,greater than or equal to 2,,,,,,
18811,,medullary thyroid carcinoma.|presence of,,,,,,,,,,less than or equal to 80,,,,,,
18812,,microecological preparations,,,,,,,,,,between 50.0 to 90.0 kg,,,,,,
18813,,thoracic oncology staging manual|histological,,,,,,,,,,b-cell,,,,,,
18814,,local anaesthetic,,,,,,,,,,<27 kg/m2|normal,,,,,,
18815,,primary amyloidosis,,,,,,,,,,<50 copies/ml|cd4,,,,,,
18816,,gastrointestinal (gi) function,,,,,,,,,,≤ 1.5 x institutional upper limit of normal (uln),,,,,,
18817,,specific pathology,,,,,,,,,,60-120 minutes daily,,,,,,
18818,,pruriginous lesions,,,,,,,,,,≥ 0.2mv,,,,,,
18819,,organ perforation,,,,,,,,,,< 30|no orthopedic,,,,,,
18820,,cognitively,,,,,,,,,,≥ 2.0 g/dl||all,,,,,,
18821,,multiple fractures,,,,,,,,,,<1.0 sd and,,,,,,
18822,,prolonged period,,,,,,,,,,18 years to 80,,,,,,
18823,,dromo-tropic effects,,,,,,,,,,older than 50 years old,,,,,,
18824,,good health,,,,,,,,,,<50.000,,,,,,
18825,,pervasive developmental delay,,,,,,,,,,0-2|ability of the participant understand and the willingness to sign,,,,,,
18826,,emergency surgery|chronic renal failure,,,,,,,,,,20-35||,,,,,,
18827,,2 hypertension,,,,,,,,,,"less than 20,000 per microliter",,,,,,
18828,,mtrps have,,,,,,,,,,= 400 ml,,,,,,
18829,,lactation|comorbid disease,,,,,,,,,,> 18yrs|informed consent|sterile urine culture,,,,,,
18830,,psychiatric illness;|neurodegenerative pathology,,,,,,,,,,12-17 years,,,,,,
18831,,intrahepatic biliary tract,,,,,,,,,,age≥18 years；meet,,,,,,
18832,,good response,,,,,,,,,,2-3 mm,,,,,,
18833,,rhinorrhea,,,,,,,,,,age|older than 18years,,,,,,
18834,,solid component suspicious,,,,,,,,,,< 30 kg/,,,,,,
18835,,infectious disease;|patients,,,,,,,,,,less than 1.5 years.|participants,,,,,,
18836,,infective endocarditis,,,,,,,,,,<34 weeks,,,,,,
18837,,language communication difficulties,,,,,,,,,,seropositivity,,,,,,
18838,,copd exacerbation in,,,,,,,,,,>= 3.5)||metastasis confined to the,,,,,,
18839,,otherwise,,,,,,,,,,lvef<50%,,,,,,
18840,,traumatic cerebral hemorrhage,,,,,,,,,,18 years or older|ability to speak,,,,,,
18841,,non-conservative,,,,,,,,,,"≥ 5 points,|have minor",,,,,,
18842,,respiratory system diseases,,,,,,,,,,< 5400 μm (equivalent to 9,,,,,,
18843,,iron utilization disorders|patients with serum ferritin,,,,,,,,,,≥7.0%,,,,,,
18844,,mwho disease,,,,,,,,,,>3|cardiac,,,,,,
18845,,any comorbidities,,,,,,,,,,≥ 1.20 d,,,,,,
18846,,metastatic diseases,,,,,,,,,,≥75 years|benign gallbladder,,,,,,
18847,,abraded scalp,,,,,,,,,,18 and older|serious,,,,,,
18848,,functional disorder,,,,,,,,,,>140 / 90 mmhg,,,,,,
18849,,score symptoms,,,,,,,,,,3-1)|cardiovascular stability||,,,,,,
18850,,neuromyelitis optica,,,,,,,,,,>110 ms,,,,,,
18851,,chronic enteritis,,,,,,,,,,1.1 standard;|the main organ function,,,,,,
18852,,p. vivax malaria,,,,,,,,,,functional class hf,,,,,,
18853,,acute promyelocytic leukemia.|radiologically-detected,,,,,,,,,,18-60 years old,,,,,,
18854,,gingiva infection,,,,,,,,,,above a baseline,,,,,,
18855,,tuberculosis [tb],,,,,,,,,,≤1.5-fold the uln of the study site,,,,,,
18856,,comorbid anxiety disorder|those,,,,,,,,,,> 100 beats/min or < 50 beats/min,,,,,,
18857,,menstrual cycle,,,,,,,,,,12 to 18 years old,,,,,,
18858,,spleen,,,,,,,,,,< 6.5%,,,,,,
18859,,isoniazid)|poor general condition,,,,,,,,,,≥ 0.5×10^9/l,,,,,,
18860,,uterine fibroid,,,,,,,,,,a；|estimated survival,,,,,,
18861,,cognitive barriers,,,,,,,,,,n3 upper limit of normal,,,,,,
18862,,spine|peripheral nerve injury,,,,,,,,,,above the detection limit,,,,,,
18863,,suppositories,,,,,,,,,,+ 28 days|non consent,,,,,,
18864,,myopic traction macular disease,,,,,,,,,,≥ 50 ml /min,,,,,,
18865,,pituitary obesity,,,,,,,,,,18 years or older|a,,,,,,
18866,,acute adverse events,,,,,,,,,,overall patient criteria,,,,,,
18867,,sick-sinus syndrome,,,,,,,,,,≥18 to ≤65 years,,,,,,
18868,,non-squamous,,,,,,,,,,≥ 45 years,,,,,,
18869,,acute febrile infection,,,,,,,,,,unreachable,,,,,,
18870,,schistosomiasis,,,,,,,,,,1.1 with the,,,,,,
18871,,coronary arterial,,,,,,,,,,1.5 times higher than the upper limit of normal.|patients,,,,,,
18872,,cardiogenic embolism,,,,,,,,,,=< 30 ml/min,,,,,,
18873,,esophageal reflux disease,,,,,,,,,,≥ 3.0 x uln,,,,,,
18874,,1)complex fistula,,,,,,,,,,between 20 and 75 years,,,,,,
18875,,squamous cell only,,,,,,,,,,≤ al ≤ 30mm,,,,,,
18876,,allergic condition,,,,,,,,,,< 2.5x uln||,,,,,,
18877,,alcohol abuse.|active pregnancy,,,,,,,,,,between 25-36 from,,,,,,
18878,,non-ad dementia|contraindication,,,,,,,,,,i to iii,,,,,,
18879,,risk cytogenetics,,,,,,,,,,<4 weeks,,,,,,
18880,,complete remission,,,,,,,,,,> 25.0,,,,,,
18881,,ileus,,,,,,,,,,greater than 130 millimeter of mercury,,,,,,
18882,,chronic gastrointestinal conditions,,,,,,,,,,more than once per week).|inability to complete research assessments,,,,,,
18883,,uterine cervix;|decompensated heart failure,,,,,,,,,,< 30 ml/min,,,,,,
18884,,dermatological symptoms,,,,,,,,,,>= 40 ml/min,,,,,,
18885,,nyha classification);|uncontrolled hypertension,,,,,,,,,,bullosa|patient,,,,,,
18886,,hepatitis e.|presence,,,,,,,,,,global score of 0.5,,,,,,
18887,,bladder neck contracture,,,,,,,,,,single tumor,,,,,,
18888,,hematopoietic system|active cancers|acute,,,,,,,,,,9-12|do,,,,,,
18889,,mogad,,,,,,,,,,<= 2.5 x uln,,,,,,
18890,,infectious diseases|participants,,,,,,,,,,greater than 37 completed,,,,,,
18891,,limiting symptoms,,,,,,,,,,score ≤ 3;||normal hemodynamic indices:||blood cell count,,,,,,
18892,,extensive colonic resection,,,,,,,,,,>20 pack years|receipt,,,,,,
18893,,systemic hypotension,,,,,,,,,,> 8 g/dl||renal:||bun,,,,,,
18894,,chemistry panel,,,,,,,,,,shorter than 2 weeks;|years younger than 12 years,,,,,,
18895,,risk of infection,,,,,,,,,,"< 150,000 / μl|hemoglobin < 6.2 mmol/l",,,,,,
18896,,cardiac repolarization,,,,,,,,,,18 to 65,,,,,,
18897,,mental retardation,,,,,,,,,,25 years or younger,,,,,,
18898,,liver decompensating events,,,,,,,,,,>65%||,,,,,,
18899,,mass,,,,,,,,,,> 2 times the reference range.|hypersensitivity to the,,,,,,
18900,,hepatitis d,,,,,,,,,,≥ 7mm,,,,,,
18901,,local anesthetic|hypothyroidism,,,,,,,,,,≥ 20 kg.|performance status,,,,,,
18902,,hypoplastic left heart syndrome,,,,,,,,,,3-5.||,,,,,,
18903,,consumption of food,,,,,,,,,,=< 1.6,,,,,,
18904,,painful disorders,,,,,,,,,,>2.8 m/sec,,,,,,
18905,,oesophageal fistula,,,,,,,,,,at least another,,,,,,
18906,,mtbi,,,,,,,,,,< 12.0 g/dl,,,,,,
18907,,early-stage als,,,,,,,,,,< 0.9).|thrombocytopenic patients,,,,,,
18908,,rales on auscultation,,,,,,,,,,440 nmol/l,,,,,,
18909,,immune thrombocytopenia,,,,,,,,,,> 120 msec|qtcb,,,,,,
18910,,nccn risk group criteria,,,,,,,,,,>=2 cm,,,,,,
18911,,primary hepatobiliary malignancies,,,,,,,,,,≥ 100.4°f,,,,,,
18912,,sperm parameters.|known infection,,,,,,,,,,"under 100,000.|serum creatinine greater than 1.5 mg/dl.|serum",,,,,,
18913,,corneal disorders,,,,,,,,,,<70%,,,,,,
18914,,post-cricoid,,,,,,,,,,at least 12 weeks||sex,,,,,,
18915,,sports like tennis,,,,,,,,,,>g,,,,,,
18916,,nerve root,,,,,,,,,,less than 52°,,,,,,
18917,,autoimmune disorders.||,,,,,,,,,,<1 month,,,,,,
18918,,grace village,,,,,,,,,,≥ class ii,,,,,,
18919,,superficial digital flexor tendon injuries,,,,,,,,,,0-2.|estimated,,,,,,
18920,,human immunodeficiency virus [hiv,,,,,,,,,,>15 eosinophilic granulocytes per high,,,,,,
18921,,fails,,,,,,,,,,≥18 years)|will,,,,,,
18922,,lm,,,,,,,,,,<90%,,,,,,
18923,,drainage;|patients,,,,,,,,,,>6)|individuals,,,,,,
18924,,francilien,,,,,,,,,,less than or equal to 63 mm,,,,,,
18925,,acceptable disease-free,,,,,,,,,,> 3 x uln,,,,,,
18926,,demonstration of a qtc interval,,,,,,,,,,5%,,,,,,
18927,,lower extremity edema,,,,,,,,,,ii-iv ovarian,,,,,,
18928,,thyroid disease.|the,,,,,,,,,,less than 30 ml/,,,,,,
18929,,gastrointestinal oxalate absorption,,,,,,,,,,> 50ml/min/1.73m^2.|recipient,,,,,,
18930,,hf symptom decompensation,,,,,,,,,,greater than 11 years,,,,,,
18931,,non-smoking,,,,,,,,,,<2.5x10^9/l,,,,,,
18932,,retinal vascular disease than dr|refractive errors,,,,,,,,,,≤ 3000 ng/ml,,,,,,
18933,,pai-1 risk allele,,,,,,,,,,at least 3 weeks,,,,,,
18934,,formula intolerance,,,,,,,,,,>= 18|english speaking|able to comprehend,,,,,,
18935,,head and neck radiation|written informed consent,,,,,,,,,,greater than or equal to 30 kg/m2;|older,,,,,,
18936,,renal psoriasis|epidermal bullosum|other diseases,,,,,,,,,,18-65 years|diagnosis,,,,,,
18937,,other neoplasms,,,,,,,,,,≤ 30 kg/m2;|a willingness,,,,,,
18938,,chest orthostatic x-ray,,,,,,,,,,<105,,,,,,
18939,,oral ulcers,,,,,,,,,,< 40%|patient,,,,,,
18940,,maternal chronic diseases,,,,,,,,,,at least 3 months.|no more than one prior therapy,,,,,,
18941,,adenomyoma,,,,,,,,,,>2 mg/dl.|brain mri exclusion criteria,,,,,,
18942,,paget's disease,,,,,,,,,,"2,5- 4",,,,,,
18943,,monoclonal gammopathy,,,,,,,,,,functional classification.|significant screening electrocardiogram (ecg),,,,,,
18944,,cns instrumentation,,,,,,,,,,ii-iii|can perform,,,,,,
18945,,dependent,,,,,,,,,,less than 18 years.|patients,,,,,,
18946,,refractory aml,,,,,,,,,,≥18 and ≤60,,,,,,
18947,,orr,,,,,,,,,,more than 60 beats/min,,,,,,
18948,,disease-free,,,,,,,,,,over 120 kg|participation,,,,,,
18949,,sjögren syndrome,,,,,,,,,,≥ 18 years|karnofsky,,,,,,
18950,,squamous epithelial cell skin cancer,,,,,,,,,,greater than 0.0,,,,,,
18951,,n2c disease,,,,,,,,,,"≥ 1,5 × 10^9/l|platelets",,,,,,
18952,,congestive heart failure (chf) human immunodeficiency virus (hiv),,,,,,,,,,<18.5 kg/m^2,,,,,,
18953,,major depressive episode,,,,,,,,,,<18.0 or >30.0 kg/m2.||women,,,,,,
18954,,cardio-respiratory instability.|traumatic,,,,,,,,,,more than 20%,,,,,,
18955,,pregnancy|contra-indication,,,,,,,,,,≥ 4 mm,,,,,,
18956,,period;|prolonged qt syndrome,,,,,,,,,,score of < 19,,,,,,
18957,,fudr,,,,,,,,,,> 1.5 mg/dl.|received,,,,,,
18958,,paranasal sinuses,,,,,,,,,,between 45 to 90 mmhg,,,,,,
18959,,cerebrovascular damage,,,,,,,,,,> 130 mm hg,,,,,,
18960,,hepatobiliary,,,,,,,,,,interval,,,,,,
18961,,retained after,,,,,,,,,,> 100mmhg).|pre-registration,,,,,,
18962,,hypertension.|inability to administer darolutamide,,,,,,,,,,≥ 7.5%|patients,,,,,,
18963,,activated from the blood bank.|patients transferred,,,,,,,,,,≥32 kg/m^2 to ≤39.9 kg/m^2,,,,,,
18964,,er+/her2- bc,,,,,,,,,,outside of the normal laboratory defined range,,,,,,
18965,,nicotine dependence,,,,,,,,,,<11.0 g/dl,,,,,,
18966,,cyp3a4*,,,,,,,,,,>35kg/m2;|peri-incisional,,,,,,
18967,,multiple glioma metastases,,,,,,,,,,between 5 and 15 cm from the dentate,,,,,,
18968,,white matter disease,,,,,,,,,,≤ 50% gfr,,,,,,
18969,,respiratory deficit,,,,,,,,,,95% for ≥f3,,,,,,
18970,,left atrial appendage occluder,,,,,,,,,,=< 3 × uln,,,,,,
18971,,silicone|terminal medical condition,,,,,,,,,,≥ 6.5% despite,,,,,,
18972,,neurotransidal);||featured pulmonary fibrosis,,,,,,,,,,<100|orthostatic hypotension of,,,,,,
18973,,meniscus injury,,,,,,,,,,≤ 1);|sufficient,,,,,,
18974,,conditions,,,,,,,,,,≤ 2.5 x uln|inr,,,,,,
18975,,skin condition,,,,,,,,,,11-17,,,,,,
18976,,acquired disorders,,,,,,,,,,≥10 points,,,,,,
18977,,benifits,,,,,,,,,,> 18-yr to 85-yr|severe,,,,,,
18978,,crystal deposition arthritis,,,,,,,,,,male's penis enters,,,,,,
18979,,down syndrome,,,,,,,,,,>18 years old.|twin pregnancy.||,,,,,,
18980,,diabetes mellitus|exposure,,,,,,,,,,>60|able to understand,,,,,,
18981,,cancers,,,,,,,,,,least 50% diameter stenosis,,,,,,
18982,,fibrolamellar hcc,,,,,,,,,,= 40%,,,,,,
18983,,age.|eastern,,,,,,,,,,more than 40,,,,,,
18984,,musculoskeletal disease|no removable,,,,,,,,,,between 30 to 44(include,,,,,,
18985,,perianal diseases,,,,,,,,,,< 60 mm hg,,,,,,
18986,,vivo.|skin lesions,,,,,,,,,,<38℃,,,,,,
18987,,ruptured eardrum,,,,,,,,,,<= 5 x uln)|participants serologically,,,,,,
18988,,teeth,,,,,,,,,,>13.3 mmol/l|gpt>100u/l,,,,,,
18989,,genital herpes,,,,,,,,,,2.87 mg/l).|any,,,,,,
18990,,atopic keratoconjunctivitis,,,,,,,,,,below 50 %,,,,,,
18991,,communication barriers|patients,,,,,,,,,,100-140 mmhg,,,,,,
18992,,lack of support,,,,,,,,,,between 2-6|18+ years,,,,,,
18993,,pruritic dermatosis.|woman,,,,,,,,,,> 100 x 109/l iii,,,,,,
18994,,congestion,,,,,,,,,,≥2 mg/dl,,,,,,
18995,,early stage cancers,,,,,,,,,,<650)||chloroquine (cq),,,,,,
18996,,bilirubin obstruction,,,,,,,,,,0-2|registration,,,,,,
18997,,unstable condition,,,,,,,,,,score i,,,,,,
18998,,stabilized|pregnant,,,,,,,,,,≥25 on 17-item hamilton rating scale for depression,,,,,,
18999,,sedentary behavior)|depressive symptoms,,,,,,,,,,> grade 2).|participants,,,,,,
19000,,rad51c,,,,,,,,,,19-65 age range|female|bmi,,,,,,
19001,,kidney failure|pregnancy,,,,,,,,,,≥60 years|had,,,,,,
19002,,acute hemorrhagic stroke,,,,,,,,,,<50% of the total lesion,,,,,,
19003,,contraindicating intramuscular,,,,,,,,,,18 and older|enrolled,,,,,,
19004,,pleural effusions,,,,,,,,,,> 1.5 cm)|step,,,,,,
19005,,type 1 diabetes|hemoglobin,,,,,,,,,,4-18 years,,,,,,
19006,,consciousness disturbance,,,,,,,,,,between 18 and 90 years;|glasgow,,,,,,
19007,,rickets,,,,,,,,,,≥ 60;|written informed,,,,,,
19008,,distant metastatic lesion,,,,,,,,,,> 6.5 pmol/l,,,,,,
19009,,rhenium-186,,,,,,,,,,>= 500/mcl||platelets,,,,,,
19010,,left pulmonary artery,,,,,,,,,,≥150 (≥18 years old,,,,,,
19011,,type 2 diabetes.||the study eye,,,,,,,,,,=< 2.5 x institutional uln,,,,,,
19012,,tail tumors,,,,,,,,,,> 50 kg/m2|atrial,,,,,,
19013,,recurring pain,,,,,,,,,,">= 100,000/mcl||total bilirubin",,,,,,
19014,,hypertension.|inability to swallow oral medications.||darolutamide,,,,,,,,,,?,,,,,,
19015,,organ involvement related to pss,,,,,,,,,,25 or above,,,,,,
19016,,obstructed nasal,,,,,,,,,,≥ 200 ng/ml,,,,,,
19017,,thoracic surgery;|pregnant,,,,,,,,,,lower than 30%,,,,,,
19018,,cardiac pathologies,,,,,,,,,,"between 28-35 weeks of gestation,|being in appropriate weight",,,,,,
19019,,granulomatous vasculitis,,,,,,,,,,≥ 100 g/l|serum creatinine,,,,,,
19020,,tract infections,,,,,,,,,,≤ 70mmhg|at least 10%,,,,,,
19021,,completed soc,,,,,,,,,,80%,,,,,,
19022,,recruitment.|spontaneously breathing,,,,,,,,,,class iii/iv,,,,,,
19023,,nifedipine|inability,,,,,,,,,,mri.|the,,,,,,
19024,,attempted,,,,,,,,,,< 500 iu/ml|variceal status,,,,,,
19025,,metabolic disorders;|healthy,,,,,,,,,,<0.8,,,,,,
19026,,auditory condition,,,,,,,,,,>two-fold above uln,,,,,,
19027,,localized gleason 6 prostate cancer,,,,,,,,,,from 2 to 10 years.|sex,,,,,,
19028,,cd30+ ptcl,,,,,,,,,,0 - 2.|ability to understand and sign the informed,,,,,,
19029,,yukon chrome pc,,,,,,,,,,> the normal control median,,,,,,
19030,,facial acne,,,,,,,,,,> 5 mm,,,,,,
19031,,idiopathic interstitial pneumonia,,,,,,,,,,≥ 110,,,,,,
19032,,ductal carcinoma in situ of the breast after radical,,,,,,,,,,≥ 305 iu/ml)|patient,,,,,,
19033,,pancreatic cancer.|ecog performance status,,,,,,,,,,> 70 mg/dl,,,,,,
19034,,menstrual cramps,,,,,,,,,,< 5.|body mass index,,,,,,
19035,,infectious causes||guillain barre||mri,,,,,,,,,,=< 2.5 x uln|women,,,,,,
19036,,mechanism,,,,,,,,,,grade;|18-65,,,,,,
19037,,eighteen.|submucosal,,,,,,,,,,10 mg/day);|received,,,,,,
19038,,covid vaccines,,,,,,,,,,between 0-7,,,,,,
19039,,liver metastases,,,,,,,,,,≥ 10%,,,,,,
19040,,diabetes|current,,,,,,,,,,sex|between 25-55 years,,,,,,
19041,,associated sinus,,,,,,,,,,≤ 1.5 x upper limit of normal,,,,,,
19042,,inspection indicators,,,,,,,,,,≥ and < 80 years,,,,,,
19043,,ischemic heart disease,,,,,,,,,,not exceeding 10%,,,,,,
19044,,non-ischemic dilated cardiomyopathy,,,,,,,,,,< 3 g/l,,,,,,
19045,,hemodynamic findings consistent,,,,,,,,,,class iv heart failure,,,,,,
19046,,study;|ocular disorder,,,,,,,,,,more than 7 days.|tumor tissue sections,,,,,,
19047,,bipolar i,,,,,,,,,,> 80|clinical diagnosis,,,,,,
19048,,skin disease,,,,,,,,,,">150,000/mm^3|hemoglobin",,,,,,
19049,,junctional adhesion molecule,,,,,,,,,,equal to or greater,,,,,,
19050,,hemoglobin abnormalities,,,,,,,,,,> 50 ml/min.|total,,,,,,
19051,,digits,,,,,,,,,,≥ 18 and≤ 75 years,,,,,,
19052,,hcc,,,,,,,,,,greater than two-fold normal,,,,,,
19053,,cannabis|weight loss,,,,,,,,,,> 2 × uln|aspartate aminotransferase,,,,,,
19054,,atresia,,,,,,,,,,between 18 kg/m2,,,,,,
19055,,classification)|significant renal disease,,,,,,,,,,≥ 20 mmhg,,,,,,
19056,,reduced,,,,,,,,,,>= 21 years||high,,,,,,
19057,,seropositivity to hiv,,,,,,,,,,> 13mm,,,,,,
19058,,consent)|cardiogenic shock,,,,,,,,,,between 18 and 25 kg/m²||,,,,,,
19059,,urinary diseases,,,,,,,,,,under 18 years|inability to give,,,,,,
19060,,symptom of fever,,,,,,,,,,">100,000/mm3",,,,,,
19061,,behavioral concerns,,,,,,,,,,0-1.|patients,,,,,,
19062,,neutropenic,,,,,,,,,,worse than snellen,,,,,,
19063,,drug-induced interstitial lung disease,,,,,,,,,,between 19 to 40 years.|bmi,,,,,,
19064,,infection.|presence,,,,,,,,,,0-2||exclusion,,,,,,
19065,,akkanat sbf nursing,,,,,,,,,,american race|age,,,,,,
19066,,coronary artery disease (cad),,,,,,,,,,above 1.5 × uln,,,,,,
19067,,superficial venous thrombosis,,,,,,,,,,≥18 years|written informed,,,,,,
19068,,end-organ damage,,,,,,,,,,> 10|the patient's,,,,,,
19069,,lack of ability in oral intake,,,,,,,,,,<-0.88 d,,,,,,
19070,,stress urinary incontinence,,,,,,,,,,below 75%,,,,,,
19071,,skin neoplasia,,,,,,,,,,more than 50.0 kg,,,,,,
19072,,chronic allergic rhinitis,,,,,,,,,,<45 ml/min,,,,,,
19073,,aortic heart disease,,,,,,,,,,14 to 17 years,,,,,,
19074,,diabetic ulcer,,,,,,,,,,< 7 kgs,,,,,,
19075,,urgency,,,,,,,,,,under 18 years|cannot complete and understand study materials,,,,,,
19076,,vascular damage,,,,,,,,,,"<50,000 platelets per µl)|pregnancy",,,,,,
19077,,her2 ++,,,,,,,,,,between 30-60|pateint,,,,,,
19078,,adverse habits,,,,,,,,,,≤ 5 half-lives,,,,,,
19079,,shape anomaly,,,,,,,,,,140-age,,,,,,
19080,,neonatal problems,,,,,,,,,,7 to 17 years,,,,,,
19081,,substance abuse|pulse,,,,,,,,,,> 4.0ng/ml,,,,,,
19082,,intracardiac shunt,,,,,,,,,,≥45 % or below 20%.|prior,,,,,,
19083,,bleeding diathesis|patient,,,,,,,,,,>18 years.|diagnosis,,,,,,
19084,,non-steroidal anti-inflammatory drugs (nsaids) amiodarone,,,,,,,,,,≥ 60;|exclusion,,,,,,
19085,,medically inadvisable,,,,,,,,,,more than 15mm|patients,,,,,,
19086,,comorbid substance misuse,,,,,,,,,,less than 34 week of amenorrhea corrected age|birth,,,,,,
19087,,tumor necrosis factor blockers,,,,,,,,,,> 1.5 × institutional upper limit of normal,,,,,,
19088,,histologic diagnosis,,,,,,,,,,< 3 x uln,,,,,,
19089,,causing issues,,,,,,,,,,>=2||,,,,,,
19090,,rotator cuff,,,,,,,,,,>=20%,,,,,,
19091,,ulcerative colitis).|any condition,,,,,,,,,,< 1.5 x 109/l.|platelet count,,,,,,
19092,,sympathetic dysfunction,,,,,,,,,,≤ 2.5 x uln.|renal function,,,,,,
19093,,intestinal tuberculosis,,,,,,,,,,30 kg/m2,,,,,,
19094,,screening.|active infection,,,,,,,,,,≥3 months;|there should,,,,,,
19095,,chronic inflammatory demyelinating polyneuropathy,,,,,,,,,,"> 3,000/microliter",,,,,,
19096,,uncontrollable clinical problem,,,,,,,,,,≥1.5×10^9,,,,,,
19097,,ocular pain,,,,,,,,,,≥ 26,,,,,,
19098,,vascular malformation,,,,,,,,,,× 0.85/72 × serum creatinine,,,,,,
19099,,squamous cell carcinoma of the skin)|patients known,,,,,,,,,,> 37.5℃,,,,,,
19100,,active virus infection,,,,,,,,,,> normal reference value,,,,,,
19101,,these comorbidities,,,,,,,,,,<60 ml/min/1.73 m2)|positive,,,,,,
19102,,alcohol use,,,,,,,,,,>18 mm hg,,,,,,
19103,,admission|allergic reaction,,,,,,,,,,20 and 70 are eligible,,,,,,
19104,,creates,,,,,,,,,,between 0-5 years,,,,,,
19105,,congitive impairment,,,,,,,,,,≥ 10 mg/l|informed,,,,,,
19106,,papilloma,,,,,,,,,,>2.5 times,,,,,,
19107,,lymphoma/dlbcl,,,,,,,,,,< 13.0 g/dl|serum creatinine,,,,,,
19108,,mucositis,,,,,,,,,,20-45 years,,,,,,
19109,,breast feeding|are investigator site personnel,,,,,,,,,,≥18 to 95 years,,,,,,
19110,,painful diabetes neuropathy,,,,,,,,,,adults||50-90 years,,,,,,
19111,,regular menstrual cycle|vascular disease,,,,,,,,,,<60|pregnancy|currently,,,,,,
19112,,tubal ligation,,,,,,,,,,between 200/7,,,,,,
19113,,moffitt cancer center,,,,,,,,,,i-ii-iii|scheduled,,,,,,
19114,,soft tissue sarcoma of the limbs,,,,,,,,,,no more than 20mm,,,,,,
19115,,pain palliation,,,,,,,,,,greater than 90/60mmhg,,,,,,
19116,,syndromic obesity|for,,,,,,,,,,≥ 65 db hl|aided,,,,,,
19117,,iii)transverse myelitis,,,,,,,,,,≥3.0×10^9/l,,,,,,
19118,,detectable evidence of,,,,,,,,,,1-18 years.|a negative pregnancy test in,,,,,,
19119,,independence scale,,,,,,,,,,150m,,,,,,
19120,,structural brain abnormalities,,,,,,,,,,less than 8 mm,,,,,,
19121,,horizontal growth,,,,,,,,,,5.7-6.4%||ii,,,,,,
19122,,small bowel,,,,,,,,,,vegetarians;|long-term,,,,,,
19123,,stage solid tumor|progressed,,,,,,,,,,250 mg/dl,,,,,,
19124,,prophylaxis)|renal failure,,,,,,,,,,2 cm from the natal cleft.|distance,,,,,,
19125,,arad,,,,,,,,,,>90 or <60 mmhg|pulse <60 or >100,,,,,,
19126,,old;||mitral valve insufficiency,,,,,,,,,,> 1.5 cm,,,,,,
19127,,co-morbid,,,,,,,,,,18 or above,,,,,,
19128,,disease||castration-sensitive status,,,,,,,,,,disease,,,,,,
19129,,surgical complication,,,,,,,,,,january 2010,,,,,,
19130,,small molecules,,,,,,,,,,grade b,,,,,,
19131,,pulmonary arterial hypertension pulmonary arterial hypertension,,,,,,,,,,30 db or greater,,,,,,
19132,,canal sized #60,,,,,,,,,,>350 µl;|had,,,,,,
19133,,internal,,,,,,,,,,≥ 16 - 50 years,,,,,,
19134,,metastases on the ct scan,,,,,,,,,,< 1.5 × institutional unl.|albumin,,,,,,
19135,,non infectious pneumonia,,,,,,,,,,greater than or equal to 18 years of age|eligible,,,,,,
19136,,adverse health conditions,,,,,,,,,,>120 kg,,,,,,
19137,,cycles,,,,,,,,,,between 18 and 45 years.|women,,,,,,
19138,,tanning booth,,,,,,,,,,"≥2,000/mm3",,,,,,
19139,,active disorders,,,,,,,,,,> 30 kg/m2||,,,,,,
19140,,coronary bypass,,,,,,,,,,18 years or older|all,,,,,,
19141,,chronic skin problems.|seizure,,,,,,,,,,high-grade,,,,,,
19142,,left atrial diameter (,,,,,,,,,,> 30 miu/ml,,,,,,
19143,,recurrence bppv,,,,,,,,,,<15,,,,,,
19144,,brain.|uncontrolled infection,,,,,,,,,,between 1 and 8 years of age|caregiver,,,,,,
19145,,fungal respiratory disease;|there are factors,,,,,,,,,,greater than 3 months|at least one,,,,,,
19146,,epilepsy|fixed contracture,,,,,,,,,,over 20 kg/m2,,,,,,
19147,,covid infection,,,,,,,,,,between 50 and 70 years|magnetic resonance imaging verified,,,,,,
19148,,chronic gastrointestinal illness,,,,,,,,,,> 120 msec,,,,,,
19149,,acute onset neurological deficit attributable,,,,,,,,,,20-30 kg/m2||,,,,,,
19150,,bidirectional shunts.|patients,,,,,,,,,,> 18 years)|patients,,,,,,
19151,,healthy resident,,,,,,,,,,≥ 65 years;|body,,,,,,
19152,,overall involvement,,,,,,,,,,1 to 3.|body mass index,,,,,,
19153,,bone pain,,,,,,,,,,=< t2b|normal pre-radical,,,,,,
19154,,pathology of the facet joints of the involved,,,,,,,,,,≥ 1.0 x g/l,,,,,,
19155,,biochemical hyper androgenesim.|polycystic ovaries.||,,,,,,,,,,>3.38 mmol/l,,,,,,
19156,,vitiligo,,,,,,,,,,more than 70% stenosis,,,,,,
19157,,intact periodontium,,,,,,,,,,less than 29 kg/m2||,,,,,,
19158,,neurologic dysfunction,,,,,,,,,,>=15%,,,,,,
19159,,duodenal ulcer,,,,,,,,,,20-70 years|no,,,,,,
19160,,substantial bm radiation,,,,,,,,,,>10 kg,,,,,,
19161,,simple hernia,,,,,,,,,,"< 50,000 per ml",,,,,,
19162,,gastritis,,,,,,,,,,>= 75 years|eastern,,,,,,
19163,,abdominal metastasis,,,,,,,,,,≥ 400 µm,,,,,,
19164,,bladder tumour found,,,,,,,,,,≥ 70 mg/dl|patients,,,,,,
19165,,atopic dermatitis exacerbations,,,,,,,,,,> 13.9 mmol/l,,,,,,
19166,,systemic condition,,,,,,,,,,<40%|resting,,,,,,
19167,,erythrodermic psoriasis,,,,,,,,,,less than 72h ago,,,,,,
19168,,ophthalmologic diseases,,,,,,,,,,18 years or older|chronic,,,,,,
19169,,good general health.|maxillary anterior tooth,,,,,,,,,,less than 1%,,,,,,
19170,,idiopathic intracranial hypertension,,,,,,,,,,> 35)|,,,,,,
19171,,lattice degeneration,,,,,,,,,,> 175%,,,,,,
19172,,genotype mutations,,,,,,,,,,≥18 years and ≤75 years;|ecog,,,,,,
19173,,progressive neurological,,,,,,,,,,1-2|otherwise,,,,,,
19174,,intrahepatic cholangiocarcinoma,,,,,,,,,,≥ 18 years|muscle cramp,,,,,,
19175,,psychotic episode,,,,,,,,,,9-12,,,,,,
19176,,linguistic incapability,,,,,,,,,,">= 1,500/mcl.|platelets",,,,,,
19177,,epidural hematoma,,,,,,,,,,0-1;|expected survival time,,,,,,
19178,,ulcerations|acute febrile processes|diagnosis,,,,,,,,,,18 to 75 years|sufficient command of the french language to understand the instructions|no,,,,,,
19179,,non-white race,,,,,,,,,,at least 12months.|willing and able to comply with the requirements,,,,,,
19180,,mucosal intolerance,,,,,,,,,,18 to 99 years,,,,,,
19181,,thought,,,,,,,,,,c grade,,,,,,
19182,,systemic disorder,,,,,,,,,,>=50%,,,,,,
19183,,cerebellar lesion,,,,,,,,,,<95.|score,,,,,,
19184,,solid malignancy irrespective,,,,,,,,,,< 2000 iu/ml;|screening,,,,,,
19185,,periodontal health,,,,,,,,,,< 92 %,,,,,,
19186,,subtance abuse|any disease state,,,,,,,,,,above 72%,,,,,,
19187,,myopathy,,,,,,,,,,between 14-19 years,,,,,,
19188,,pustular psoriasis,,,,,,,,,,>25 kg/m2|we,,,,,,
19189,,acute mental health care,,,,,,,,,,more than uln,,,,,,
19190,,lower limb reaching performance,,,,,,,,,,≥65 years.|patients,,,,,,
19191,,spinal surgery|having,,,,,,,,,,excluded,,,,,,
19192,,pulmonary embolism.|myocardial infarction,,,,,,,,,,<0.5 or >5.0 mu/l,,,,,,
19193,,concomitant skin conditions,,,,,,,,,,14-16,,,,,,
19194,,resolution,,,,,,,,,,>50% of the respiratory events,,,,,,
19195,,renal cell carcinoma,,,,,,,,,,90 cm,,,,,,
19196,,ductal carcinoma in situ of breast);|the,,,,,,,,,,>1.7.|patients,,,,,,
19197,,difficulty collecting blood|patients,,,,,,,,,,≤ 25%).||,,,,,,
19198,,epilepsy|recent epileptic seizure,,,,,,,,,,<140/90 mmhg;|fasted glucose,,,,,,
19199,,progressive cardiogenic shock,,,,,,,,,,≤ 5 × uln,,,,,,
19200,,mrse,,,,,,,,,,≥ 300,,,,,,
19201,,cm)|duodenal stenosis|post- surgical altered anatomy|benign disease,,,,,,,,,,stage iib,,,,,,
19202,,types of cancer,,,,,,,,,,3.0-4.0,,,,,,
19203,,fructan intolerance,,,,,,,,,,> 30|or waist circumferences,,,,,,
19204,,venous access point,,,,,,,,,,≤ 45%,,,,,,
19205,,breast-feeding|any,,,,,,,,,,≤ 2.5 times the upper limit of normal value,,,,,,
19206,,"mri,|previous intolerance",,,,,,,,,,≥ 10 grams,,,,,,
19207,,"using nsaids,|pregnancy",,,,,,,,,,>45 years,,,,,,
19208,,bronchial suctioning,,,,,,,,,,>450ms,,,,,,
19209,,hereditary diseases,,,,,,,,,,> 60 cm|prior therapeutic cranial irradiation|leptomeningeal dissemination,,,,,,
19210,,angiography.|significant,,,,,,,,,,≤ 18|patients for,,,,,,
19211,,non-culprit lesions,,,,,,,,,,more than or equal to 3,,,,,,
19212,,coagulopathy)|renal failure,,,,,,,,,,long-term use,,,,,,
19213,,infection.|sgnificant abdominal ascites,,,,,,,,,,at least 33,,,,,,
19214,,completed hepatitis c directed antiviral therapy,,,,,,,,,,hcv-rna,,,,,,
19215,,myocardial infarction.|in,,,,,,,,,,0-iic,,,,,,
19216,,cds,,,,,,,,,,<100 x 109/l)|bleeding disorders,,,,,,
19217,,neurological symptoms return,,,,,,,,,,0 to 2|anticipated,,,,,,
19218,,decreased renal function,,,,,,,,,,less than or equal to 60 ml/min/1.73m^2|history,,,,,,
19219,,common adverse events,,,,,,,,,,7-11,,,,,,
19220,,prolonged symptoms,,,,,,,,,,5 to 15 years born,,,,,,
19221,,third-degree,,,,,,,,,,> 5,,,,,,
19222,,breast feeding|known allergy to the study drugs,,,,,,,,,,< 1.5 times the upper limit of,,,,,,
19223,,fatty hepatic disease,,,,,,,,,,at least 50.0 kilogram (kg),,,,,,
19224,,over||pulmonary function tests:||40% predicted,,,,,,,,,,smokers meaning,,,,,,
19225,,teeth extracted,,,,,,,,,,=< 2.|histologically,,,,,,
19226,,immunosuppressive agents;|comorbidity,,,,,,,,,,between 20- 30 years,,,,,,
19227,,urothelial cancer|refused standard therapies,,,,,,,,,,0-1|pregnancy,,,,,,
19228,,non-melanoma skin,,,,,,,,,,<1.25 x upper limit of normal.||participants,,,,,,
19229,,"neurological disease,|previous bariatric surgery,|weight loss",,,,,,,,,,20-75,,,,,,
19230,,communicating the dutch language.|written informed consent,,,,,,,,,,0-28,,,,,,
19231,,obstructive sleep apnea-hypopnea,,,,,,,,,,equal or greater than 0.7,,,,,,
19232,,ethanol (alcohol),,,,,,,,,,equal to or greater than 30 kg/m2).|hba1c greater than 5.6%;|igf-1 level,,,,,,
19233,,early manifest hd,,,,,,,,,,less than 15mm|patients,,,,,,
19234,,status|active congestive heart failure,,,,,,,,,,< 3.0 x 109/l|platelet count,,,,,,
19235,,vertebral involvement,,,,,,,,,,equal to or higher than 80g/l,,,,,,
19236,,definitive dental care,,,,,,,,,,<4 grams per liter,,,,,,
19237,,substance dependency,,,,,,,,,,between 24 and 32 weeks,,,,,,
19238,,mixed adenocarcinoma,,,,,,,,,,> 70|healthy volunteer,,,,,,
19239,,hydroelectric shock wave lithotripsy,,,,,,,,,,< 30 ml per minute);|is,,,,,,
19240,,specific diseases.|specific diseases,,,,,,,,,,>2 times upper limit of normal)|those,,,,,,
19241,,hemiplegic,,,,,,,,,,40-60 years||,,,,,,
19242,,chronic pain,,,,,,,,,,>90 to ≤120 ml/min/1.73 m2,,,,,,
19243,,posterior segment inflammation,,,,,,,,,,< 37.5°c,,,,,,
19244,,other causes of fatigue complaints,,,,,,,,,,>30.0 kg/m^2.|weight change,,,,,,
19245,,poor oral hygiene,,,,,,,,,,>/= 4 weeks,,,,,,
19246,,urosepsis|cirrhosis,,,,,,,,,,20 - 40 mg,,,,,,
19247,,risk of failure,,,,,,,,,,<2.5 cm,,,,,,
19248,,episodes of neck pain,,,,,,,,,,lasting more than 5,,,,,,
19249,,acute promyelocytic leukemia.|peripheral blast count,,,,,,,,,,① those,,,,,,
19250,,lymphoma hodgkin lymphoma,,,,,,,,,,15-26|available/consenting,,,,,,
19251,,pulmonary hypertension,,,,,,,,,,18-30years.|participants,,,,,,
19252,,guillain barre syndrome,,,,,,,,,,>5.0 mu/l,,,,,,
19253,,acute respiratory illnesses,,,,,,,,,,>3x the upper limit of normal (uln),,,,,,
19254,,intracranial infarction,,,,,,,,,,< 48 h||,,,,,,
19255,,stage)|diabetes mellitus,,,,,,,,,,≥4 mm,,,,,,
19256,,hypogonadism,,,,,,,,,,18 to 73 years,,,,,,
19257,,light perception,,,,,,,,,,< 18 years and > 140/90 mmhg,,,,,,
19258,,metabolic bone disease,,,,,,,,,,over 18 years|non-smokers|normal findings,,,,,,
19259,,laboratory abnormality including:||absolute wbc count,,,,,,,,,,between 70-25 letters,,,,,,
19260,,inner ear infections,,,,,,,,,,greater than or equal to 4).|no knee injuries.|treatment,,,,,,
19261,,head injury,,,,,,,,,,less than 12,,,,,,
19262,,traumatic ca,,,,,,,,,,between ≥ 18.0 and ≤ 32.0 kg/m2,,,,,,
19263,,abo,,,,,,,,,,< 10 mg daily,,,,,,
19264,,allograft syndrome,,,,,,,,,,≥18 years)|mri diagnosis,,,,,,
19265,,nodules,,,,,,,,,,≥ 400 mg/dl|ldl,,,,,,
19266,,need dialysis|diarrhea,,,,,,,,,,>= 180 degrees of the circumference of the vessel,,,,,,
19267,,rheumatoid factor (rf),,,,,,,,,,18-45 years|diagnosis,,,,,,
19268,,hepatopulmonary shunt,,,,,,,,,,1 to 15 year,,,,,,
19269,,exercises|exercising regularly,,,,,,,,,,"< 150,000/ml",,,,,,
19270,,autoimmune hypothyroidism,,,,,,,,,,> 1.5 ×,,,,,,
19271,,trial|active infection,,,,,,,,,,>0,,,,,,
19272,,special conditions seriously endanger the patient's health,,,,,,,,,,from racism,,,,,,
19273,,comorbidity stable,,,,,,,,,,class 4= incapacitating disease,,,,,,
19274,,central vertigo|heart failure,,,,,,,,,,1.0 x 109,,,,,,
19275,,albuminuria.|figaro-dkd,,,,,,,,,,score of 0 to 1|if,,,,,,
19276,,retinal reattachment surgery,,,,,,,,,,18 years ≤ age,,,,,,
19277,,visit|airflow obstruction,,,,,,,,,,longer than 1 month)||,,,,,,
19278,,atrophy involves,,,,,,,,,,= 28%,,,,,,
19279,,intracranial haemorrhage.|pregnancy,,,,,,,,,,≥28 g/l,,,,,,
19280,,coronary syndrome,,,,,,,,,,> 2.0 mg/dl,,,,,,
19281,,susvimo,,,,,,,,,,< 1000 mm3,,,,,,
19282,,lack of response,,,,,,,,,,< 10s|able,,,,,,
19283,,respiratory stable,,,,,,,,,,> 3 units,,,,,,
19284,,not polyps,,,,,,,,,,18 years or more.||,,,,,,
19285,,related disorders,,,,,,,,,,>=2 × uln,,,,,,
19286,,cerebral functioning impairment,,,,,,,,,,<60ml/min/1.73m^2,,,,,,
19287,,autoimmune diseases;|carriage of,,,,,,,,,,18-85 years|female sex||,,,,,,
19288,,obsolete pulmonary tuberculosis,,,,,,,,,,6 and 17 years,,,,,,
19289,,luekemia,,,,,,,,,,< 30 ml per,,,,,,
19290,,prolonged loss of consciousness,,,,,,,,,,<=5 × uln,,,,,,
19291,,cerevascular malformation,,,,,,,,,,≥ 38.5 °c,,,,,,
19292,,acquiring tb infection,,,,,,,,,,≥ 18 years|histologic diagnosis,,,,,,
19293,,unconsciousness,,,,,,,,,,≤ 2 tests,,,,,,
19294,,myasthenia gravis;|preoperative delirium,,,,,,,,,,greater than equal to 2 milligrams per liter,,,,,,
19295,,recurrence of malignant tumor;|patients,,,,,,,,,,≥ 0.5|global,,,,,,
19296,,lymphedema of the upper extremity,,,,,,,,,,1-3|scheduled surgery,,,,,,
19297,,dysgnosia neurogenic bladder,,,,,,,,,,>= 18 years|eligibility criteria,,,,,,
19298,,substance-induced,,,,,,,,,,18.5≦bmi<25.0,,,,,,
19299,,heparin-induced thrombocytopenia,,,,,,,,,,0-1;||bone marrow examination,,,,,,
19300,,anatomic asplenia,,,,,,,,,,≥ the 95th percentile,,,,,,
19301,,inferolateral wall thickness,,,,,,,,,,0-2；|child,,,,,,
19302,,hbvc+,,,,,,,,,,from 50gy to 66gy;|ecog,,,,,,
19303,,middle cerebral artery (,,,,,,,,,,less than two times the normal level.|serum follicle-stimulating hormone (fsh) levels,,,,,,
19304,,tobacco use disorder,,,,,,,,,,≤ 1.5 × uln||eligible,,,,,,
19305,,acute disseminated encephalomyelitis,,,,,,,,,,0-1.|no,,,,,,
19306,,retinitis pigmentosa,,,,,,,,,,> 5 mg/day,,,,,,
19307,,reproductive capability will need,,,,,,,,,,<1.5 x upper limit of normal (uln),,,,,,
19308,,systemic disease,,,,,,,,,,score <= 30,,,,,,
19309,,acute infection,,,,,,,,,,0,,,,,,
19310,,heat burn,,,,,,,,,,≤ 1.5 × uln;|total,,,,,,
19311,,exudative pleural effusion,,,,,,,,,,1-age,,,,,,
19312,,present ulcer,,,,,,,,,,between 25 and 65 years|the,,,,,,
19313,,gastrointestinal bleeding.|myocardial infarction,,,,,,,,,,>= 1 week prior to study treatment.|substrates of cyp3a4/5,,,,,,
19314,,degenerative dementias,,,,,,,,,,<3rd percentile,,,,,,
19315,,ecg)).|those,,,,,,,,,,18-65 years|body mass index,,,,,,
19316,,aeroallergen,,,,,,,,,,of iii or iv,,,,,,
19317,,localized tumors,,,,,,,,,,>= 10g / dl,,,,,,
19318,,severe obstruction,,,,,,,,,,<8 mmol/l,,,,,,
19319,,peroneal nerve lesions|cognitive,,,,,,,,,,40-65 years;|4,,,,,,
19320,,hip flexion limitation,,,,,,,,,,between 18 and 65 years|people classified,,,,,,
19321,,primary refractory mm|impaired cardiovascular function,,,,,,,,,,products|allergic to or,,,,,,
19322,,cardiac symptoms stable,,,,,,,,,,< 22,,,,,,
19323,,neurologic problem,,,,,,,,,,<50 ml/min;|a,,,,,,
19324,,ballana,,,,,,,,,,"7.0% to 10.0%, inclusive",,,,,,
19325,,rotatory instability after acl injury;|primary aclr cases||,,,,,,,,,,"≥ 30 kg/m^2,|have",,,,,,
19326,,verbal learning,,,,,,,,,,≥ 18 yo|sex=female|patients,,,,,,
19327,,developmental delay.||inclusion criteria,,,,,,,,,,≥90 g,,,,,,
19328,,rv/lv ratio,,,,,,,,,,between 18-60 years,,,,,,
19329,,age|arrhythmia,,,,,,,,,,lower than 35;|with,,,,,,
19330,,histopathologic changes,,,,,,,,,,<50%；|atrial fibrillation,,,,,,
19331,,radicular neurological signs|spinal deformity e.g.scoliosis,,,,,,,,,,≥ 42,,,,,,
19332,,territorial stroke,,,,,,,,,,20-45|those,,,,,,
19333,,left atrial appendage tissue,,,,,,,,,,150kg,,,,,,
19334,,vestibular schwannoma,,,,,,,,,,grades i-iii|there,,,,,,
19335,,liver cancer assessment model,,,,,,,,,,≥ 40 kg/m^2,,,,,,
19336,,anhydramnios|fetal thoracentesis,,,,,,,,,,"400-500, inclusive",,,,,,
19337,,atrial/ventricular,,,,,,,,,,> 1.5 × uln|the,,,,,,
19338,,nociceptive scrotal,,,,,,,,,,> 160 mghg,,,,,,
19339,,developmental problems beyond autism spectrum disorder,,,,,,,,,,18 years or older.|presenting,,,,,,
19340,,fainting,,,,,,,,,,>1,,,,,,
19341,,neuralgia.|recent infections,,,,,,,,,,between 50 and 90 beats per minute,,,,,,
19342,,narcotic drug abuse,,,,,,,,,,< 19,,,,,,
19343,,"heart failure,|routine",,,,,,,,,,outside the 18.0 ~ 27.0 kg/m²,,,,,,
19344,,6 months||for ehoa,,,,,,,,,,>2 times than upper normal,,,,,,
19345,,present.|for aml,,,,,,,,,,"0, 1 or 2",,,,,,
19346,,unresolved psychiatric illness,,,,,,,,,,> 2 months)|lifetime,,,,,,
19347,,lack of intelligence,,,,,,,,,,greater than 3 months,,,,,,
19348,,gastrointestinal cancer,,,,,,,,,,≤ctcae grade 1,,,,,,
19349,,hepatic dysfunction|significant kidney disease|pregnant,,,,,,,,,,<80°|individuals,,,,,,
19350,,gastrointestinal organic diseases,,,,,,,,,,under 18 or over,,,,,,
19351,,idiopathic mcas,,,,,,,,,,< 40 kg/m2|american society of anesthesiologists,,,,,,
19352,,white kidney beans.|subjects bmi,,,,,,,,,,130-154 mmhg,,,,,,
19353,,allowed.|able to see and hear sufficiently to undertake assessments,,,,,,,,,,≥ 30 ml/min per,,,,,,
19354,,episodic migraines,,,,,,,,,,below 100mmhg;|use of,,,,,,
19355,,post-orthodontic periodontal,,,,,,,,,,> 95%|subjective insufficient symptom control with ppi therapy,,,,,,
19356,,ischemic attack|peripheral arterial,,,,,,,,,,60 years or older,,,,,,
19357,,revascularisation,,,,,,,,,,≥ 5x10^6|treatment,,,,,,
19358,,chronic obstructive pulmonary disease;|any,,,,,,,,,,≤ 1.5 upper limit of normal,,,,,,
19359,,primary immunodeficiencies,,,,,,,,,,>10ⅹ109/l,,,,,,
19360,,progressive scans,,,,,,,,,,10-30%,,,,,,
19361,,target mismatch profile on,,,,,,,,,,equal to or above 6 months prior to screening,,,,,,
19362,,canines,,,,,,,,,,> than 50 units,,,,,,
19363,,acute meniscus,,,,,,,,,,> 5 mmol/l|absolute neutrophil count,,,,,,
19364,,lack of physical,,,,,,,,,,"> 1,250/mm3||the",,,,,,
19365,,biologic disease-modifying,,,,,,,,,,greater than 30%,,,,,,
19366,,regimens,,,,,,,,,,>1.5mg/dl,,,,,,
19367,,language translator,,,,,,,,,,< 2.5 g/g,,,,,,
19368,,liver cirrhosis;|alcohol abuse,,,,,,,,,,t1d)|be 19 years,,,,,,
19369,,cognitive dysfunction|progressive,,,,,,,,,,>40 iu/l,,,,,,
19370,,urethral prosthesis.|bladder neck,,,,,,,,,,≥18 years;|patients presenting to gastroenterologist,,,,,,
19371,,above|ability to read,,,,,,,,,,18-45|being,,,,,,
19372,,intravenous immune globulin,,,,,,,,,,< 2.||patients,,,,,,
19373,,multiple endocrine neoplasia,,,,,,,,,,i to iii|patients,,,,,,
19374,,gastrointestinal bleeding anesthetic drugs,,,,,,,,,,> 500iu/ml,,,,,,
19375,,nasal sinus packing,,,,,,,,,,≥ 11 g/dl,,,,,,
19376,,gastric carcinoma,,,,,,,,,,< 1% expression of,,,,,,
19377,,poor performance status,,,,,,,,,,>400 ng/ml;|tsat,,,,,,
19378,,acute gastritis,,,,,,,,,,>1.5 mg/dl|random,,,,,,
19379,,rheumatoid arthritis etc.)||medication,,,,,,,,,,"class 1,2, 3",,,,,,
19380,,plla allergy,,,,,,,,,,18-75|not,,,,,,
19381,,hyperprolactinemia,,,,,,,,,,18-70 years.|clinical,,,,,,
19382,,bleeding complication,,,,,,,,,,60% or lower,,,,,,
19383,,lack of access,,,,,,,,,,≥50 years,,,,,,
19384,,primary substance,,,,,,,,,,2 to 3 months,,,,,,
19385,,dominant polycystic kidney disease,,,,,,,,,,< 5 million/ml,,,,,,
19386,,dental condition,,,,,,,,,,greater than or equal to 2 weeks,,,,,,
19387,,bmba,,,,,,,,,,> 5 cm,,,,,,
19388,,chemical menopause,,,,,,,,,,< 6 abnormal,,,,,,
19389,,corneal ulceration,,,,,,,,,,≤2.0 mg/dl|aspartate transaminase (ast): ≤100 iu/l,,,,,,
19390,,poor sleep quality,,,,,,,,,,≥ 18 years|patient,,,,,,
19391,,eye|presence,,,,,,,,,,<300,,,,,,
19392,,full haplotype match,,,,,,,,,,25-40 years,,,,,,
19393,,preterm,,,,,,,,,,19 to 26 kg/m2,,,,,,
19394,,colorectal cancer surgery,,,,,,,,,,stage c,,,,,,
19395,,covid-19-associated,,,,,,,,,,< 60 ml/minute/1.73 m2 7,,,,,,
19396,,nonplaque forms,,,,,,,,,,≥ 2cm,,,,,,
19397,,epidermal growth factor receptor therapy,,,,,,,,,,,,,,,,
19398,,retinal toxicity,,,,,,,,,,,,,,,,
19399,,asthma controller medications,,,,,,,,,,,,,,,,
19400,,grunting).||exclusion,,,,,,,,,,,,,,,,
19401,,chronic anal fissure,,,,,,,,,,,,,,,,
19402,,vitrectomy||,,,,,,,,,,,,,,,,
19403,,cardiac ischemia,,,,,,,,,,,,,,,,
19404,,skin basal cell carcinoma,,,,,,,,,,,,,,,,
19405,,chronic thromboembolic pulmonary,,,,,,,,,,,,,,,,
19406,,chronic obstructive lung,,,,,,,,,,,,,,,,
19407,,physical activities herein described||,,,,,,,,,,,,,,,,
19408,,clinical presentation of agitation,,,,,,,,,,,,,,,,
19409,,vestibular neuritis,,,,,,,,,,,,,,,,
19410,,intrahepatic cholestasis,,,,,,,,,,,,,,,,
19411,,face masks,,,,,,,,,,,,,,,,
19412,,radiation pneumonitis,,,,,,,,,,,,,,,,
19413,,arthritis,,,,,,,,,,,,,,,,
19414,,reduced ejection fraction,,,,,,,,,,,,,,,,
19415,,neuropsychiatric conditions,,,,,,,,,,,,,,,,
19416,,cutaneous disease,,,,,,,,,,,,,,,,
19417,,etantr,,,,,,,,,,,,,,,,
19418,,amyl nitrite,,,,,,,,,,,,,,,,
19419,,third interstitial fluid,,,,,,,,,,,,,,,,
19420,,middle chest,,,,,,,,,,,,,,,,
19421,,normal wall motion,,,,,,,,,,,,,,,,
19422,,type 2)||at least one additional risk factor for heart failure:||coronary artery disease,,,,,,,,,,,,,,,,
19423,,dotatate,,,,,,,,,,,,,,,,
19424,,caries;|children,,,,,,,,,,,,,,,,
19425,,cardiovascular disease.|uncontrolled,,,,,,,,,,,,,,,,
19426,,lower extremity crps type 1 (also called rsd-reflex sympathetic dystrophy,,,,,,,,,,,,,,,,
19427,,vision problems.|medically instable patients.|balance disorders.|other musculoskeletal condition of shoulders,,,,,,,,,,,,,,,,
19428,,therapeutic products,,,,,,,,,,,,,,,,
19429,,healthy rabbits|rabbits,,,,,,,,,,,,,,,,
19430,,multi-parametric magnetic resonance imaging|gleason score≤,,,,,,,,,,,,,,,,
19431,,complete behçet's disease,,,,,,,,,,,,,,,,
19432,,blv,,,,,,,,,,,,,,,,
19433,,shoulder abduction - mrc,,,,,,,,,,,,,,,,
19434,,type-2 diabetic,,,,,,,,,,,,,,,,
19435,,colorectal polyps,,,,,,,,,,,,,,,,
19436,,clear progression,,,,,,,,,,,,,,,,
19437,,frequent bleeding,,,,,,,,,,,,,,,,
19438,,pulmonary thromboendarterectomy,,,,,,,,,,,,,,,,
19439,,cancer treatments,,,,,,,,,,,,,,,,
19440,,histologies,,,,,,,,,,,,,,,,
19441,,excessive alcohol consumption,,,,,,,,,,,,,,,,
19442,,primary immune comprised disease.|ph+ t-lbl|patients,,,,,,,,,,,,,,,,
19443,,drug allergies,,,,,,,,,,,,,,,,
19444,,blood pressure,,,,,,,,,,,,,,,,
19445,,myeloid growth factor support,,,,,,,,,,,,,,,,
19446,,osteoporosis prophylaxis,,,,,,,,,,,,,,,,
19447,,good hygiene,,,,,,,,,,,,,,,,
19448,,cohort 1(aortic stenosis):||male,,,,,,,,,,,,,,,,
19449,,neurologic disorder|poorly,,,,,,,,,,,,,,,,
19450,,parathyroid gland,,,,,,,,,,,,,,,,
19451,,lack of compliance with clinic visits,,,,,,,,,,,,,,,,
19452,,clinical symptoms of,,,,,,,,,,,,,,,,
19453,,cutaneous photosensitization,,,,,,,,,,,,,,,,
19454,,ipsilateral deep venous thrombosis,,,,,,,,,,,,,,,,
19455,,vsd)|stroke,,,,,,,,,,,,,,,,
19456,,potential effects,,,,,,,,,,,,,,,,
19457,,human immunodeficiency virus (hiv) infection.|patients who are,,,,,,,,,,,,,,,,
19458,,serious disorder,,,,,,,,,,,,,,,,
19459,,rvo,,,,,,,,,,,,,,,,
19460,,congenital abnormalities,,,,,,,,,,,,,,,,
19461,,arterial hypotension,,,,,,,,,,,,,,,,
19462,,symptoms related,,,,,,,,,,,,,,,,
19463,,optic neuropathy,,,,,,,,,,,,,,,,
19464,,6.active infection,,,,,,,,,,,,,,,,
19465,,causing voiding dysfunction.|positive prostatic urethral biopsy,,,,,,,,,,,,,,,,
19466,,rheumatoid arthritis|had,,,,,,,,,,,,,,,,
19467,,ihc 1+,,,,,,,,,,,,,,,,
19468,,unclassifiable with features,,,,,,,,,,,,,,,,
19469,,patellar pathology,,,,,,,,,,,,,,,,
19470,,prn,,,,,,,,,,,,,,,,
19471,,allergic diseases|a,,,,,,,,,,,,,,,,
19472,,liver function|men,,,,,,,,,,,,,,,,
19473,,vasovagal syncope,,,,,,,,,,,,,,,,
19474,,degenerative condition,,,,,,,,,,,,,,,,
19475,,heart catheterization,,,,,,,,,,,,,,,,
19476,,isoflavones.|blood pressure,,,,,,,,,,,,,,,,
19477,,superficial skin cancers,,,,,,,,,,,,,,,,
19478,,irritable bowel syndrome)|heart disease,,,,,,,,,,,,,,,,
19479,,coronary artery disease-related,,,,,,,,,,,,,,,,
19480,,cognitive dysfunction,,,,,,,,,,,,,,,,
19481,,health professional.|individual,,,,,,,,,,,,,,,,
19482,,corneal scarring,,,,,,,,,,,,,,,,
19483,,dsa,,,,,,,,,,,,,,,,
19484,,basal,,,,,,,,,,,,,,,,
19485,,nonalcoholic steatohepatitis,,,,,,,,,,,,,,,,
19486,,estrogen-receptor positive,,,,,,,,,,,,,,,,
19487,,coiling,,,,,,,,,,,,,,,,
19488,,pte,,,,,,,,,,,,,,,,
19489,,etc.).|bleeding disorders,,,,,,,,,,,,,,,,
19490,,allergic symptoms,,,,,,,,,,,,,,,,
19491,,colorectal adenocarcinoma,,,,,,,,,,,,,,,,
19492,,autoimmune diseases|patients,,,,,,,,,,,,,,,,
19493,,m2 segment,,,,,,,,,,,,,,,,
19494,,incisional wounds,,,,,,,,,,,,,,,,
19495,,good home care||,,,,,,,,,,,,,,,,
19496,,claims,,,,,,,,,,,,,,,,
19497,,pneumococcal infectious diseases,,,,,,,,,,,,,,,,
19498,,exposure,,,,,,,,,,,,,,,,
19499,,progressive growth,,,,,,,,,,,,,,,,
19500,,multiple allergies,,,,,,,,,,,,,,,,
19501,,substance intoxication,,,,,,,,,,,,,,,,
19502,,cardio-vascular disease,,,,,,,,,,,,,,,,
19503,,sars-cov-2;|negative qrt-pcr nucleic acid test,,,,,,,,,,,,,,,,
19504,,bowel movement,,,,,,,,,,,,,,,,
19505,,corneal disorder,,,,,,,,,,,,,,,,
19506,,normal hepatic function.||inclusion criteria,,,,,,,,,,,,,,,,
19507,,"indemnities for clinical trial higher or equal to 4500 euros,|under legal",,,,,,,,,,,,,,,,
19508,,malignancies,,,,,,,,,,,,,,,,
19509,,rectal adenocarcinoma.|adenocarcinoma,,,,,,,,,,,,,,,,
19510,,type 2 dm,,,,,,,,,,,,,,,,
19511,,diabetes mellitus type 2.|ability,,,,,,,,,,,,,,,,
19512,,post-treatment brain mri,,,,,,,,,,,,,,,,
19513,,abuse of,,,,,,,,,,,,,,,,
19514,,acute coronary syndromes,,,,,,,,,,,,,,,,
19515,,intestinal malabsorption,,,,,,,,,,,,,,,,
19516,,holter monitoring|atrial,,,,,,,,,,,,,,,,
19517,,dementia.|the,,,,,,,,,,,,,,,,
19518,,pced,,,,,,,,,,,,,,,,
19519,,chronic obstructive pulmonary disease)|pregnancy,,,,,,,,,,,,,,,,
19520,,injury|claustrophobia|lack of firm resolve,,,,,,,,,,,,,,,,
19521,,primary hematologic malignancies,,,,,,,,,,,,,,,,
19522,,cabg+valve,,,,,,,,,,,,,,,,
19523,,type 2 diabetes mellitus;|2,,,,,,,,,,,,,,,,
19524,,contraceptive measures should,,,,,,,,,,,,,,,,
19525,,therapy.|measurable disease,,,,,,,,,,,,,,,,
19526,,metastatic disease||2a,,,,,,,,,,,,,,,,
19527,,cervical spondylolisthesis,,,,,,,,,,,,,,,,
19528,,autoimmune markers,,,,,,,,,,,,,,,,
19529,,periocular infection,,,,,,,,,,,,,,,,
19530,,renal functional abnormality,,,,,,,,,,,,,,,,
19531,,crohn's disease|patients,,,,,,,,,,,,,,,,
19532,,acidity,,,,,,,,,,,,,,,,
19533,,good cardiac,,,,,,,,,,,,,,,,
19534,,ischemic disease,,,,,,,,,,,,,,,,
19535,,head and neck trauma,,,,,,,,,,,,,,,,
19536,,eye diseases,,,,,,,,,,,,,,,,
19537,,services from the physician manned,,,,,,,,,,,,,,,,
19538,,cervix carcinoma,,,,,,,,,,,,,,,,
19539,,neurological disorder(s),,,,,,,,,,,,,,,,
19540,,tumoral évaluable,,,,,,,,,,,,,,,,
19541,,acute conditions,,,,,,,,,,,,,,,,
19542,,inflammatory changes,,,,,,,,,,,,,,,,
19543,,neurological illness,,,,,,,,,,,,,,,,
19544,,gilbert's syndrome,,,,,,,,,,,,,,,,
19545,,allergic disease.|acute,,,,,,,,,,,,,,,,
19546,,disease|primary immunodeficiency,,,,,,,,,,,,,,,,
19547,,urinary incontinence surgery,,,,,,,,,,,,,,,,
19548,,metastatic lesions.|active autoimmune,,,,,,,,,,,,,,,,
19549,,covid-19;|covid-19 infection,,,,,,,,,,,,,,,,
19550,,heat intolerance,,,,,,,,,,,,,,,,
19551,,trigeminal autonomic cephalgia,,,,,,,,,,,,,,,,
19552,,acquisition scan,,,,,,,,,,,,,,,,
19553,,wegener granulomatosis,,,,,,,,,,,,,,,,
19554,,occupational therapies,,,,,,,,,,,,,,,,
19555,,bone only disease,,,,,,,,,,,,,,,,
19556,,mouse,,,,,,,,,,,,,,,,
19557,,et,,,,,,,,,,,,,,,,
19558,,whf,,,,,,,,,,,,,,,,
19559,,acute hypoxemic respiratory failure|routine assessments,,,,,,,,,,,,,,,,
19560,,grinding||cardiovascular disease|pregnancy|arthritis,,,,,,,,,,,,,,,,
19561,,rish of infection,,,,,,,,,,,,,,,,
19562,,motor vehicle,,,,,,,,,,,,,,,,
19563,,interstitial lung disease.|≥,,,,,,,,,,,,,,,,
19564,,poor expectoration,,,,,,,,,,,,,,,,
19565,,difficulty swallowing;|patients,,,,,,,,,,,,,,,,
19566,,chest deformity.|subjects,,,,,,,,,,,,,,,,
19567,,inguinal hernias,,,,,,,,,,,,,,,,
19568,,specific pathologies,,,,,,,,,,,,,,,,
19569,,screening|stroke,,,,,,,,,,,,,,,,
19570,,cis)|history,,,,,,,,,,,,,,,,
19571,,congenital metabolic disease,,,,,,,,,,,,,,,,
19572,,ampullary carcinoma,,,,,,,,,,,,,,,,
19573,,psychiatric disorder.|participant,,,,,,,,,,,,,,,,
19574,,cutaneous subsites,,,,,,,,,,,,,,,,
19575,,clinical sense,,,,,,,,,,,,,,,,
19576,,ldh,,,,,,,,,,,,,,,,
19577,,decreased haptoglobin,,,,,,,,,,,,,,,,
19578,,clotting factor deficiency,,,,,,,,,,,,,,,,
19579,,hcv ribonucleic,,,,,,,,,,,,,,,,
19580,,disease copd|male,,,,,,,,,,,,,,,,
19581,,metabolical acidosis,,,,,,,,,,,,,,,,
19582,,blood coagulation,,,,,,,,,,,,,,,,
19583,,loss of response,,,,,,,,,,,,,,,,
19584,,motor neuron disease|one or more,,,,,,,,,,,,,,,,
19585,,prosthetic valve regurgitation,,,,,,,,,,,,,,,,
19586,,visiting lumc,,,,,,,,,,,,,,,,
19587,,progressive bone deterioration.|patients bone stock,,,,,,,,,,,,,,,,
19588,,cystic lesions,,,,,,,,,,,,,,,,
19589,,terminal cancer,,,,,,,,,,,,,,,,
19590,,non-curative,,,,,,,,,,,,,,,,
19591,,lpl).|relapsed disease,,,,,,,,,,,,,,,,
19592,,myopic macular lesion,,,,,,,,,,,,,,,,
19593,,airway disease,,,,,,,,,,,,,,,,
19594,,suicide ideation ascertained,,,,,,,,,,,,,,,,
19595,,bt,,,,,,,,,,,,,,,,
19596,,permanent neurologic deficit,,,,,,,,,,,,,,,,
19597,,high quality genomic dna,,,,,,,,,,,,,,,,
19598,,htn)|ele,,,,,,,,,,,,,,,,
19599,,uterine fibroids|diameter,,,,,,,,,,,,,,,,
19600,,give consent.|symptoms,,,,,,,,,,,,,,,,
19601,,psychiatric disorders,,,,,,,,,,,,,,,,
19602,,skin dimpling,,,,,,,,,,,,,,,,
19603,,clinically;|mdd,,,,,,,,,,,,,,,,
19604,,supplemental oxygen|renal disease,,,,,,,,,,,,,,,,
19605,,autoimmune diseases;|the,,,,,,,,,,,,,,,,
19606,,asplenia.|severe,,,,,,,,,,,,,,,,
19607,,car damage|teen,,,,,,,,,,,,,,,,
19608,,opportunistic infection,,,,,,,,,,,,,,,,
19609,,high-risk tia|systemic,,,,,,,,,,,,,,,,
19610,,intramucosal carcinoma,,,,,,,,,,,,,,,,
19611,,tertiary,,,,,,,,,,,,,,,,
19612,,"etc),|serious infection",,,,,,,,,,,,,,,,
19613,,end stage chronic disease . furthermore,,,,,,,,,,,,,,,,
19614,,physical rehabilitation.||,,,,,,,,,,,,,,,,
19615,,postural hypotension (bp,,,,,,,,,,,,,,,,
19616,,atrioventricular conduction disorder|having bradycardia,,,,,,,,,,,,,,,,
19617,,metabolic pathology,,,,,,,,,,,,,,,,
19618,,irregular bowel movements,,,,,,,,,,,,,,,,
19619,,syndromic etiology,,,,,,,,,,,,,,,,
19620,,solar urticaria,,,,,,,,,,,,,,,,
19621,,short term,,,,,,,,,,,,,,,,
19622,,hemiablation,,,,,,,,,,,,,,,,
19623,,non-cardiac surgical,,,,,,,,,,,,,,,,
19624,,chronic stable heart,,,,,,,,,,,,,,,,
19625,,duodenal stent,,,,,,,,,,,,,,,,
19626,,rse,,,,,,,,,,,,,,,,
19627,,mastectomies,,,,,,,,,,,,,,,,
19628,,diabetes.|pancreatogenic diabetes,,,,,,,,,,,,,,,,
19629,,allergies,,,,,,,,,,,,,,,,
19630,,dermatologic systems|diagnosis,,,,,,,,,,,,,,,,
19631,,solid organ transplantation.|presence,,,,,,,,,,,,,,,,
19632,,intracranial ischemic stroke,,,,,,,,,,,,,,,,
19633,,positive titer response,,,,,,,,,,,,,,,,
19634,,relapsing substance use,,,,,,,,,,,,,,,,
19635,,refractory cancer,,,,,,,,,,,,,,,,
19636,,leukocyte dysfunction,,,,,,,,,,,,,,,,
19637,,pressure injury,,,,,,,,,,,,,,,,
19638,,preoperative cardiogenic shock,,,,,,,,,,,,,,,,
19639,,pathological sections show,,,,,,,,,,,,,,,,
19640,,complete punctal occlusion,,,,,,,,,,,,,,,,
19641,,etc.).|muskloskletal problems,,,,,,,,,,,,,,,,
19642,,iron overload,,,,,,,,,,,,,,,,
19643,,intraprocedural stent thrombosis,,,,,,,,,,,,,,,,
19644,,melanoma skin,,,,,,,,,,,,,,,,
19645,,bacterial labyrinthitis,,,,,,,,,,,,,,,,
19646,,test including;||very,,,,,,,,,,,,,,,,
19647,,sequential chemoradiation,,,,,,,,,,,,,,,,
19648,,idiopathic rbd,,,,,,,,,,,,,,,,
19649,,barrier,,,,,,,,,,,,,,,,
19650,,primary prostate radiation,,,,,,,,,,,,,,,,
19651,,atrial dilatation,,,,,,,,,,,,,,,,
19652,,non-adherence,,,,,,,,,,,,,,,,
19653,,carotid stenosis).|no usable home blood pressure cuff available|diagnosis of hypertension,,,,,,,,,,,,,,,,
19654,,vascular deficiency,,,,,,,,,,,,,,,,
19655,,clinical t-stage,,,,,,,,,,,,,,,,
19656,,unknown hiv status,,,,,,,,,,,,,,,,
19657,,2a6,,,,,,,,,,,,,,,,
19658,,adverse events related,,,,,,,,,,,,,,,,
19659,,cerebral,,,,,,,,,,,,,,,,
19660,,anticoagulant factors,,,,,,,,,,,,,,,,
19661,,gilbert-meulengracht syndrome,,,,,,,,,,,,,,,,
19662,,chronic organic disease,,,,,,,,,,,,,,,,
19663,,pericoronitis,,,,,,,,,,,,,,,,
19664,,mij821,,,,,,,,,,,,,,,,
19665,,hypothermia,,,,,,,,,,,,,,,,
19666,,intraepithelial lesions,,,,,,,,,,,,,,,,
19667,,period.|pregnancy,,,,,,,,,,,,,,,,
19668,,limit sleep positions,,,,,,,,,,,,,,,,
19669,,swabbing,,,,,,,,,,,,,,,,
19670,,vasovagal nature,,,,,,,,,,,,,,,,
19671,,intracranial,,,,,,,,,,,,,,,,
19672,,although,,,,,,,,,,,,,,,,
19673,,memory loss|not interested,,,,,,,,,,,,,,,,
19674,,upper ureteric stones,,,,,,,,,,,,,,,,
19675,,chronic pulmonary diseases,,,,,,,,,,,,,,,,
19676,,diabetic foot ulcer,,,,,,,,,,,,,,,,
19677,,rpgn);||8,,,,,,,,,,,,,,,,
19678,,nicotine patches,,,,,,,,,,,,,,,,
19679,,inactivity,,,,,,,,,,,,,,,,
19680,,pregnancy,,,,,,,,,,,,,,,,
19681,,classic,,,,,,,,,,,,,,,,
19682,,artificial menopause,,,,,,,,,,,,,,,,
19683,,dietary supplements|recent donation of blood,,,,,,,,,,,,,,,,
19684,,clinical effusion,,,,,,,,,,,,,,,,
19685,,autoimmune disorders);|active autoimmune disorders,,,,,,,,,,,,,,,,
19686,,structural extracardiac anomalies,,,,,,,,,,,,,,,,
19687,,evolocumab);|pregnancy,,,,,,,,,,,,,,,,
19688,,exitus,,,,,,,,,,,,,,,,
19689,,immune diseases,,,,,,,,,,,,,,,,
19690,,alteration of the dose,,,,,,,,,,,,,,,,
19691,,known hypertension,,,,,,,,,,,,,,,,
19692,,rsv,,,,,,,,,,,,,,,,
19693,,restlessness,,,,,,,,,,,,,,,,
19694,,comorbid illness|symptoms,,,,,,,,,,,,,,,,
19695,,arrythmias,,,,,,,,,,,,,,,,
19696,,intra-uterine devices,,,,,,,,,,,,,,,,
19697,,familial long qt syndrome,,,,,,,,,,,,,,,,
19698,,hypoparathyroidism,,,,,,,,,,,,,,,,
19699,,bone lesion,,,,,,,,,,,,,,,,
19700,,gastrointestinal (gi) disease,,,,,,,,,,,,,,,,
19701,,multidisciplinary team|measurable lesion,,,,,,,,,,,,,,,,
19702,,active urinary tract infection,,,,,,,,,,,,,,,,
19703,,classic hodgkin lymphoma,,,,,,,,,,,,,,,,
19704,,chronic atrophic gastritis,,,,,,,,,,,,,,,,
19705,,lymphedema,,,,,,,,,,,,,,,,
19706,,patellar knee pain,,,,,,,,,,,,,,,,
19707,,criteria.|antitumor,,,,,,,,,,,,,,,,
19708,,arterial insufficiency,,,,,,,,,,,,,,,,
19709,,chronic nsnp.|office,,,,,,,,,,,,,,,,
19710,,dermal lesions,,,,,,,,,,,,,,,,
19711,,born preterm,,,,,,,,,,,,,,,,
19712,,deep venous thrombosis (,,,,,,,,,,,,,,,,
19713,,professional competition,,,,,,,,,,,,,,,,
19714,,physical condition,,,,,,,,,,,,,,,,
19715,,phenylketonuria disease,,,,,,,,,,,,,,,,
19716,,chromosome 21,,,,,,,,,,,,,,,,
19717,,transitional cells,,,,,,,,,,,,,,,,
19718,,mitral valve regurgitation,,,,,,,,,,,,,,,,
19719,,screening|type 1 diabetes mellitus,,,,,,,,,,,,,,,,
19720,,α-thalassemia trait,,,,,,,,,,,,,,,,
19721,,ulcer perforation,,,,,,,,,,,,,,,,
19722,,coronary stenosis,,,,,,,,,,,,,,,,
19723,,acute infection diseases|endometriosis,,,,,,,,,,,,,,,,
19724,,knee menisci,,,,,,,,,,,,,,,,
19725,,leucocytes,,,,,,,,,,,,,,,,
19726,,thyroid cancer treatment,,,,,,,,,,,,,,,,
19727,,hiv).|active treatment,,,,,,,,,,,,,,,,
19728,,ultrasonic lipolysis,,,,,,,,,,,,,,,,
19729,,hemodynamic instability|unstable spinal,,,,,,,,,,,,,,,,
19730,,e.g.renal impairment,,,,,,,,,,,,,,,,
19731,,"weight loss surgery,|weight",,,,,,,,,,,,,,,,
19732,,substance abuse syndrome,,,,,,,,,,,,,,,,
19733,,target vessel tortuosity,,,,,,,,,,,,,,,,
19734,,congenital bilirubinaemia,,,,,,,,,,,,,,,,
19735,,metastatic disease.|vulvar cancer,,,,,,,,,,,,,,,,
19736,,"acute illness,|cancer|hiv|systemic inflammatory disease",,,,,,,,,,,,,,,,
19737,,corneal infiltrates,,,,,,,,,,,,,,,,
19738,,glp-1-analoga|emergency surgery|chronic,,,,,,,,,,,,,,,,
19739,,skin hypopigmentation,,,,,,,,,,,,,,,,
19740,,pulmonary disease|uncontrolled diabetes,,,,,,,,,,,,,,,,
19741,,cerebral pathology,,,,,,,,,,,,,,,,
19742,,chronic kidney disease|known,,,,,,,,,,,,,,,,
19743,,old|primary ddh||,,,,,,,,,,,,,,,,
19744,,bleeding tendencies,,,,,,,,,,,,,,,,
19745,,ventricular dysfunction,,,,,,,,,,,,,,,,
19746,,connective vascular disorders,,,,,,,,,,,,,,,,
19747,,difficulty nulling,,,,,,,,,,,,,,,,
19748,,procedure;|intracranial tumors,,,,,,,,,,,,,,,,
19749,,severe arrhythmias,,,,,,,,,,,,,,,,
19750,,constant dominant strabismus,,,,,,,,,,,,,,,,
19751,,immunodeficiency disorder,,,,,,,,,,,,,,,,
19752,,needles|pregnancy,,,,,,,,,,,,,,,,
19753,,spinal injuries,,,,,,,,,,,,,,,,
19754,,head and neck cancer,,,,,,,,,,,,,,,,
19755,,associated symptoms,,,,,,,,,,,,,,,,
19756,,respiratory motion,,,,,,,,,,,,,,,,
19757,,"psychiatric disorders|dementia,|degenerative",,,,,,,,,,,,,,,,
19758,,radiation pneumonia,,,,,,,,,,,,,,,,
19759,,dietary interventions,,,,,,,,,,,,,,,,
19760,,hereditary colon cancer,,,,,,,,,,,,,,,,
19761,,postpartum medicaid beneficiaries across the us||qualitative:||medicaid beneficiaries,,,,,,,,,,,,,,,,
19762,,ms|expanded disability status scale,,,,,,,,,,,,,,,,
19763,,convulsive disorders,,,,,,,,,,,,,,,,
19764,,generalized chronic gvhd,,,,,,,,,,,,,,,,
19765,,b-all,,,,,,,,,,,,,,,,
19766,,ischemic changes,,,,,,,,,,,,,,,,
19767,,upper gi,,,,,,,,,,,,,,,,
19768,,atypical ductal hyperplasia,,,,,,,,,,,,,,,,
19769,,primary cancers,,,,,,,,,,,,,,,,
19770,,end of pci procedure,,,,,,,,,,,,,,,,
19771,,recovery on cognition,,,,,,,,,,,,,,,,
19772,,pathologies.|patients,,,,,,,,,,,,,,,,
19773,,regular basis.|autoimmune diseases,,,,,,,,,,,,,,,,
19774,,acute lymphoblastic,,,,,,,,,,,,,,,,
19775,,chronic disease/medication altering,,,,,,,,,,,,,,,,
19776,,migraine attacks|willingness,,,,,,,,,,,,,,,,
19777,,mds,,,,,,,,,,,,,,,,
19778,,chronic pulmonary disease|patients,,,,,,,,,,,,,,,,
19779,,distress)||,,,,,,,,,,,,,,,,
19780,,pneumocystosis,,,,,,,,,,,,,,,,
19781,,bifurcation intracranial aneurysms,,,,,,,,,,,,,,,,
19782,,ulcerative colitis,,,,,,,,,,,,,,,,
19783,,osteoarthritis)|neurocognitive disorder,,,,,,,,,,,,,,,,
19784,,tumour diseases,,,,,,,,,,,,,,,,
19785,,intestinal necrosis,,,,,,,,,,,,,,,,
19786,,chronic weakness,,,,,,,,,,,,,,,,
19787,,active autoimmune disorders,,,,,,,,,,,,,,,,
19788,,deep injection of,,,,,,,,,,,,,,,,
19789,,base of tongue,,,,,,,,,,,,,,,,
19790,,hpv,,,,,,,,,,,,,,,,
19791,,superfluous organisms,,,,,,,,,,,,,,,,
19792,,diabetes mellitus|renal failure,,,,,,,,,,,,,,,,
19793,,prom,,,,,,,,,,,,,,,,
19794,,oral mycosis.||acute,,,,,,,,,,,,,,,,
19795,,hiv)-infection,,,,,,,,,,,,,,,,
19796,,disease/condition,,,,,,,,,,,,,,,,
19797,,hepatitis,,,,,,,,,,,,,,,,
19798,,hemorrhagic stroke;|tandem occlusion;|coagulation disorders,,,,,,,,,,,,,,,,
19799,,cardiothoracic,,,,,,,,,,,,,,,,
19800,,substance abuse disorder.|current ptsd,,,,,,,,,,,,,,,,
19801,,psychosocial problems,,,,,,,,,,,,,,,,
19802,,arterial hypertension|have,,,,,,,,,,,,,,,,
19803,,||i-1,,,,,,,,,,,,,,,,
19804,,"curatorship,|pregnant",,,,,,,,,,,,,,,,
19805,,respiratory diseases;|abnormal liver,,,,,,,,,,,,,,,,
19806,,neuropathy;|acute cardiovascular events,,,,,,,,,,,,,,,,
19807,,injectable lesion,,,,,,,,,,,,,,,,
19808,,rare embryonal tumors,,,,,,,,,,,,,,,,
19809,,noncompliant,,,,,,,,,,,,,,,,
19810,,uterine cancer.|severe infection,,,,,,,,,,,,,,,,
19811,,upgrade,,,,,,,,,,,,,,,,
19812,,nhl,,,,,,,,,,,,,,,,
19813,,tubular secretion,,,,,,,,,,,,,,,,
19814,,contraception|females,,,,,,,,,,,,,,,,
19815,,type 2 diabetes mellitus of,,,,,,,,,,,,,,,,
19816,,shoulder myopathy,,,,,,,,,,,,,,,,
19817,,central causes,,,,,,,,,,,,,,,,
19818,,discussion.|in countries,,,,,,,,,,,,,,,,
19819,,dependence on glucocorticoids,,,,,,,,,,,,,,,,
19820,,and|no indication,,,,,,,,,,,,,,,,
19821,,cardiac damage,,,,,,,,,,,,,,,,
19822,,nursing|substance abuse,,,,,,,,,,,,,,,,
19823,,incontinence,,,,,,,,,,,,,,,,
19824,,gastroparesis|history of scleroderma|hospitalized,,,,,,,,,,,,,,,,
19825,,underlying condition,,,,,,,,,,,,,,,,
19826,,old.|ability to read,,,,,,,,,,,,,,,,
19827,,wph,,,,,,,,,,,,,,,,
19828,,ischemic stroke|pre-stroke,,,,,,,,,,,,,,,,
19829,,health concerns,,,,,,,,,,,,,,,,
19830,,haploidentical)|donor,,,,,,,,,,,,,,,,
19831,,diabetes - hyperparathyroidism,,,,,,,,,,,,,,,,
19832,,holistic,,,,,,,,,,,,,,,,
19833,,schizoaffective disorders,,,,,,,,,,,,,,,,
19834,,retinal diagnoses,,,,,,,,,,,,,,,,
19835,,hematological events/diseases,,,,,,,,,,,,,,,,
19836,,extensive ankylosis,,,,,,,,,,,,,,,,
19837,,covid -19,,,,,,,,,,,,,,,,
19838,,antidepressant adjustment,,,,,,,,,,,,,,,,
19839,,delayed type hypersensitivity,,,,,,,,,,,,,,,,
19840,,domestic worker,,,,,,,,,,,,,,,,
19841,,professional soccer,,,,,,,,,,,,,,,,
19842,,ocular abnormality,,,,,,,,,,,,,,,,
19843,,gi ulceration,,,,,,,,,,,,,,,,
19844,,alcohol screen,,,,,,,,,,,,,,,,
19845,,chronic pulmonary embolism,,,,,,,,,,,,,,,,
19846,,coagulative disease,,,,,,,,,,,,,,,,
19847,,unstable angina;|new,,,,,,,,,,,,,,,,
19848,,iatrogenic obesity,,,,,,,,,,,,,,,,
19849,,vaginal bleeding,,,,,,,,,,,,,,,,
19850,,chl,,,,,,,,,,,,,,,,
19851,,superficial bladder carcinoma,,,,,,,,,,,,,,,,
19852,,antihypertensive drugs.|systemic diseases judged by investigators,,,,,,,,,,,,,,,,
19853,,epilepsy drugs,,,,,,,,,,,,,,,,
19854,,facial,,,,,,,,,,,,,,,,
19855,,permitted.|anti-cancer agents,,,,,,,,,,,,,,,,
19856,,hla-a*02,,,,,,,,,,,,,,,,
19857,,coagulopathy|severe renal disease,,,,,,,,,,,,,,,,
19858,,turkey's meat products,,,,,,,,,,,,,,,,
19859,,disease significantly,,,,,,,,,,,,,,,,
19860,,chemotherapy|tumor,,,,,,,,,,,,,,,,
19861,,plastic left heart) condition,,,,,,,,,,,,,,,,
19862,,decrease,,,,,,,,,,,,,,,,
19863,,nonunion,,,,,,,,,,,,,,,,
19864,,hypoxic-ischemic encephalopathy lead,,,,,,,,,,,,,,,,
19865,,electrolyte disturbances,,,,,,,,,,,,,,,,
19866,,transient ischemic attack (tia),,,,,,,,,,,,,,,,
19867,,cardiovascular disorder,,,,,,,,,,,,,,,,
19868,,acute depressive episode|bipolar disorder,,,,,,,,,,,,,,,,
19869,,s-creatinine,,,,,,,,,,,,,,,,
19870,,acute ischemia,,,,,,,,,,,,,,,,
19871,,atrial flutter,,,,,,,,,,,,,,,,
19872,,bothersome pain,,,,,,,,,,,,,,,,
19873,,autoimmune diseases.|2,,,,,,,,,,,,,,,,
19874,,local anesthesia|pregnancy,,,,,,,,,,,,,,,,
19875,,cancer of any of the indications listed,,,,,,,,,,,,,,,,
19876,,mediastinal involvement,,,,,,,,,,,,,,,,
19877,,recovered from toxicity,,,,,,,,,,,,,,,,
19878,,heel-prick screening,,,,,,,,,,,,,,,,
19879,,ethic authorities,,,,,,,,,,,,,,,,
19880,,human immunodeficiency virus infection,,,,,,,,,,,,,,,,
19881,,herniated disc,,,,,,,,,,,,,,,,
19882,,hepatic iron overload,,,,,,,,,,,,,,,,
19883,,kidney disease.|patient,,,,,,,,,,,,,,,,
19884,,dietary concerns,,,,,,,,,,,,,,,,
19885,,rejection sema-rtx,,,,,,,,,,,,,,,,
19886,,episodic migraine,,,,,,,,,,,,,,,,
19887,,"nerve damage,|being",,,,,,,,,,,,,,,,
19888,,utah,,,,,,,,,,,,,,,,
19889,,proteinuria,,,,,,,,,,,,,,,,
19890,,fetal deformities.||,,,,,,,,,,,,,,,,
19891,,lymphatic diseases,,,,,,,,,,,,,,,,
19892,,biliary tract disease,,,,,,,,,,,,,,,,
19893,,cutaneous carcinoid syndrome,,,,,,,,,,,,,,,,
19894,,ckd)|able to communicate in english.||,,,,,,,,,,,,,,,,
19895,,severe hepatic impairment,,,,,,,,,,,,,,,,
19896,,secondary hypercholesterolemia||conditions / situations,,,,,,,,,,,,,,,,
19897,,gastrointestinal ulcer,,,,,,,,,,,,,,,,
19898,,pancreatic ductal adenocarcinoma|prior treatment,,,,,,,,,,,,,,,,
19899,,critical conduit(s,,,,,,,,,,,,,,,,
19900,,psychotic,,,,,,,,,,,,,,,,
19901,,musculoskeletal pain -,,,,,,,,,,,,,,,,
19902,,major depression,,,,,,,,,,,,,,,,
19903,,heart valve prosthesis/stents,,,,,,,,,,,,,,,,
19904,,peripheral vascular diseases,,,,,,,,,,,,,,,,
19905,,intracranial vascular malformation,,,,,,,,,,,,,,,,
19906,,squamous cell carcinoma|pregnancy test,,,,,,,,,,,,,,,,
19907,,auto-immune disorders,,,,,,,,,,,,,,,,
19908,,pigmentary glaucoma,,,,,,,,,,,,,,,,
19909,,disseminated herpes simplex,,,,,,,,,,,,,,,,
19910,,build,,,,,,,,,,,,,,,,
19911,,tumors/infections,,,,,,,,,,,,,,,,
19912,,acute systemic disease,,,,,,,,,,,,,,,,
19913,,cauda equina syndrome|coagulopathy|allergic,,,,,,,,,,,,,,,,
19914,,very deep carious,,,,,,,,,,,,,,,,
19915,,pmbcl,,,,,,,,,,,,,,,,
19916,,living kidney donor transplants|patients,,,,,,,,,,,,,,,,
19917,,pilonidal sinus,,,,,,,,,,,,,,,,
19918,,multi-visceral transplant,,,,,,,,,,,,,,,,
19919,,measurable diseases,,,,,,,,,,,,,,,,
19920,,posterior cruciate ligament (pcl),,,,,,,,,,,,,,,,
19921,,pih macules,,,,,,,,,,,,,,,,
19922,,glucocorticoid,,,,,,,,,,,,,,,,
19923,,cured|skin cancer,,,,,,,,,,,,,,,,
19924,,streptococcal protein,,,,,,,,,,,,,,,,
19925,,pharmacotherapies,,,,,,,,,,,,,,,,
19926,,herpes eye infection,,,,,,,,,,,,,,,,
19927,,intracranial neoplasms,,,,,,,,,,,,,,,,
19928,,mild renal impairment,,,,,,,,,,,,,,,,
19929,,considering pregnancy,,,,,,,,,,,,,,,,
19930,,solid organ transplantation|treatment,,,,,,,,,,,,,,,,
19931,,seeing,,,,,,,,,,,,,,,,
19932,,chronic ulcerative colitis (cuc),,,,,,,,,,,,,,,,
19933,,infantile krabbe disease,,,,,,,,,,,,,,,,
19934,,hiv-related disease conditions,,,,,,,,,,,,,,,,
19935,,morrisania,,,,,,,,,,,,,,,,
19936,,available on ios14 and higher and android 8.0 and higher,,,,,,,,,,,,,,,,
19937,,disability:||health issues,,,,,,,,,,,,,,,,
19938,,chronic autoimmune condition,,,,,,,,,,,,,,,,
19939,,ttt,,,,,,,,,,,,,,,,
19940,,celiac sprue,,,,,,,,,,,,,,,,
19941,,respiratory function,,,,,,,,,,,,,,,,
19942,,parasitic infection|infection,,,,,,,,,,,,,,,,
19943,,acute liver disease,,,,,,,,,,,,,,,,
19944,,endovascular adequate occlusion,,,,,,,,,,,,,,,,
19945,,intracardiac thrombi,,,,,,,,,,,,,,,,
19946,,legal authorities,,,,,,,,,,,,,,,,
19947,,acute cause of pain,,,,,,,,,,,,,,,,
19948,,tia||,,,,,,,,,,,,,,,,
19949,,bleeding event,,,,,,,,,,,,,,,,
19950,,behavioral interventions,,,,,,,,,,,,,,,,
19951,,hyperprolactinaemia,,,,,,,,,,,,,,,,
19952,,barriers,,,,,,,,,,,,,,,,
19953,,metal allergies,,,,,,,,,,,,,,,,
19954,,oral parafunctions|2 osseointegrated dental implants,,,,,,,,,,,,,,,,
19955,,thrombocytopenia|known reaction,,,,,,,,,,,,,,,,
19956,,analgesic,,,,,,,,,,,,,,,,
19957,,epithelial ovarian carcinosarcoma,,,,,,,,,,,,,,,,
19958,,spermicide||,,,,,,,,,,,,,,,,
19959,,liver tumors,,,,,,,,,,,,,,,,
19960,,coagulation defects.|acquired immune deficiency syndrome (,,,,,,,,,,,,,,,,
19961,,perinatal patients;|active pneumonia,,,,,,,,,,,,,,,,
19962,,infections,,,,,,,,,,,,,,,,
19963,,non infectious,,,,,,,,,,,,,,,,
19964,,surgical weight loss procedures|medical conditions,,,,,,,,,,,,,,,,
19965,,gastrointestinal cancer diagnosis,,,,,,,,,,,,,,,,
19966,,criteria of the american college of rheumatology||had,,,,,,,,,,,,,,,,
19967,,medulloepithelioma,,,,,,,,,,,,,,,,
19968,,cns chloromatous disease,,,,,,,,,,,,,,,,
19969,,reproductive organs|request,,,,,,,,,,,,,,,,
19970,,prep).|any,,,,,,,,,,,,,,,,
19971,,renal dialysis;|acute,,,,,,,,,,,,,,,,
19972,,moderate hepatic impairment,,,,,,,,,,,,,,,,
19973,,cns symptoms,,,,,,,,,,,,,,,,
19974,,unresectable cholangiocarcinoma,,,,,,,,,,,,,,,,
19975,,gastrointestinal (gi) bleeding,,,,,,,,,,,,,,,,
19976,,absorption of the study drug,,,,,,,,,,,,,,,,
19977,,papillary muscle rupture);|need,,,,,,,,,,,,,,,,
19978,,unsure of pregnancy,,,,,,,,,,,,,,,,
19979,,renal chemistry,,,,,,,,,,,,,,,,
19980,,know serious disease,,,,,,,,,,,,,,,,
19981,,sleep apnea-hypopnea syndrome,,,,,,,,,,,,,,,,
19982,,cancer assisted,,,,,,,,,,,,,,,,
19983,,lower limb surgery,,,,,,,,,,,,,,,,
19984,,lung malformations,,,,,,,,,,,,,,,,
19985,,intra uterine infection,,,,,,,,,,,,,,,,
19986,,potential cancer recurrence||,,,,,,,,,,,,,,,,
19987,,urinary tract obstruction,,,,,,,,,,,,,,,,
19988,,recreational inhalants,,,,,,,,,,,,,,,,
19989,,antigenemia,,,,,,,,,,,,,,,,
19990,,condition|orthodontic braces in situ,,,,,,,,,,,,,,,,
19991,,other disease,,,,,,,,,,,,,,,,
19992,,liver disease.|systolic bp,,,,,,,,,,,,,,,,
19993,,medical pathology,,,,,,,,,,,,,,,,
19994,,pregnancy outcome,,,,,,,,,,,,,,,,
19995,,hearing,,,,,,,,,,,,,,,,
19996,,left main artery stenosis,,,,,,,,,,,,,,,,
19997,,ros1 mutation,,,,,,,,,,,,,,,,
19998,,adjuvant platinum-based,,,,,,,,,,,,,,,,
19999,,vascular disease,,,,,,,,,,,,,,,,
20000,,mechanical obstruction,,,,,,,,,,,,,,,,
20001,,resistant germ,,,,,,,,,,,,,,,,
20002,,thyroid-related diseases,,,,,,,,,,,,,,,,
20003,,complex study|unlikely,,,,,,,,,,,,,,,,
20004,,cardiopathic asthma,,,,,,,,,,,,,,,,
20005,,pancreatic abscess,,,,,,,,,,,,,,,,
20006,,localized non-melanoma skin,,,,,,,,,,,,,,,,
20007,,bleeding manifestations,,,,,,,,,,,,,,,,
20008,,pancreatic cancer treated,,,,,,,,,,,,,,,,
20009,,mca lesions,,,,,,,,,,,,,,,,
20010,,isolated mandible fractures,,,,,,,,,,,,,,,,
20011,,possible malignancy,,,,,,,,,,,,,,,,
20012,,parkinson's disease of the international movement disorders association (mds),,,,,,,,,,,,,,,,
20013,,heterozygous mutation,,,,,,,,,,,,,,,,
20014,,aortic coarctation,,,,,,,,,,,,,,,,
20015,,primary gout,,,,,,,,,,,,,,,,
20016,,child-bearing ffcd,,,,,,,,,,,,,,,,
20017,,autoimmune thyroid disease；|history,,,,,,,,,,,,,,,,
20018,,antibodies to,,,,,,,,,,,,,,,,
20019,,psychomotor disorders,,,,,,,,,,,,,,,,
20020,,pulmonary fibrosis.|leptomeningeal disease,,,,,,,,,,,,,,,,
20021,,suggesting abnormal immune function,,,,,,,,,,,,,,,,
20022,,sjögren syndrome)|intraoperative complications,,,,,,,,,,,,,,,,
20023,,multifocal tumor,,,,,,,,,,,,,,,,
20024,,neurocognitive impairment,,,,,,,,,,,,,,,,
20025,,poor perfusion,,,,,,,,,,,,,,,,
20026,,nodal lesions,,,,,,,,,,,,,,,,
20027,,neurological disease|rheumatological disease|malignant disease|previous spinal surgery,,,,,,,,,,,,,,,,
20028,,lung mass,,,,,,,,,,,,,,,,
20029,,restasis,,,,,,,,,,,,,,,,
20030,,cardiac dysfunction,,,,,,,,,,,,,,,,
20031,,venous drainage,,,,,,,,,,,,,,,,
20032,,sodium cromogicate,,,,,,,,,,,,,,,,
20033,,semantic fluency score,,,,,,,,,,,,,,,,
20034,,non-culprit-lesion stenosis,,,,,,,,,,,,,,,,
20035,,chronic illness.|history,,,,,,,,,,,,,,,,
20036,,endocrine neoplasms,,,,,,,,,,,,,,,,
20037,,left-right shunt.|previous,,,,,,,,,,,,,,,,
20038,,exceptions:||--autoimmune hypothyroidism,,,,,,,,,,,,,,,,
20039,,phenylketonuria,,,,,,,,,,,,,,,,
20040,,prolonged qt interval corrected,,,,,,,,,,,,,,,,
20041,,again,,,,,,,,,,,,,,,,
20042,,renal biopsy;|subjects,,,,,,,,,,,,,,,,
20043,,infection with,,,,,,,,,,,,,,,,
20044,,microscopic dermatopathology,,,,,,,,,,,,,,,,
20045,,flavivirus infections,,,,,,,,,,,,,,,,
20046,,psychiatric interview.|current,,,,,,,,,,,,,,,,
20047,,wall motion abnormalities,,,,,,,,,,,,,,,,
20048,,male breast cancer,,,,,,,,,,,,,,,,
20049,,clinical reference,,,,,,,,,,,,,,,,
20050,,cardiac arrest,,,,,,,,,,,,,,,,
20051,,nebulized,,,,,,,,,,,,,,,,
20052,,oral squamous cell carcinoma,,,,,,,,,,,,,,,,
20053,,velocity,,,,,,,,,,,,,,,,
20054,,former smoker|airway infection,,,,,,,,,,,,,,,,
20055,,hypercalcemia,,,,,,,,,,,,,,,,
20056,,large molecule monoclonal antibody drugs,,,,,,,,,,,,,,,,
20057,,surgery|diabetes mellitus|pregnancy||for,,,,,,,,,,,,,,,,
20058,,blindness|patients,,,,,,,,,,,,,,,,
20059,,congenital syndrome,,,,,,,,,,,,,,,,
20060,,life-threatening,,,,,,,,,,,,,,,,
20061,,daily symptoms,,,,,,,,,,,,,,,,
20062,,molar teeth planned,,,,,,,,,,,,,,,,
20063,,lower gi tract disease,,,,,,,,,,,,,,,,
20064,,target tumors,,,,,,,,,,,,,,,,
20065,,drug,,,,,,,,,,,,,,,,
20066,,≥3|underlying hypertension,,,,,,,,,,,,,,,,
20067,,trauma,,,,,,,,,,,,,,,,
20068,,stomach stagnation syndrome;|signed,,,,,,,,,,,,,,,,
20069,,former smokers.|prior lung transplants|subjects,,,,,,,,,,,,,,,,
20070,,standard contraindications,,,,,,,,,,,,,,,,
20071,,maintenance,,,,,,,,,,,,,,,,
20072,,pmn,,,,,,,,,,,,,,,,
20073,,low back pain)|unresponsiveness,,,,,,,,,,,,,,,,
20074,,etc.).|abnormalities,,,,,,,,,,,,,,,,
20075,,cervical spine disorder.||peripheral,,,,,,,,,,,,,,,,
20076,,36.|high risk pregnancy,,,,,,,,,,,,,,,,
20077,,anxiety disorders,,,,,,,,,,,,,,,,
20078,,idiopathic thrombocytopenic purpura.|7,,,,,,,,,,,,,,,,
20079,,prostate cancer|strong,,,,,,,,,,,,,,,,
20080,,blood donations,,,,,,,,,,,,,,,,
20081,,hypertensive encephalopathy.|received the following antitumor drugs,,,,,,,,,,,,,,,,
20082,,terminal illness,,,,,,,,,,,,,,,,
20083,,pulmonary hypertension||20,,,,,,,,,,,,,,,,
20084,,multiple sclerosis,,,,,,,,,,,,,,,,
20085,,ocular criteria:||co,,,,,,,,,,,,,,,,
20086,,chronic anal incontinence,,,,,,,,,,,,,,,,
20087,,hmpv disease,,,,,,,,,,,,,,,,
20088,,inner tube diameter,,,,,,,,,,,,,,,,
20089,,chronic condition susceptible,,,,,,,,,,,,,,,,
20090,,limit spine motion,,,,,,,,,,,,,,,,
20091,,abstain from the consumption of any caffeine,,,,,,,,,,,,,,,,
20092,,acne lesions,,,,,,,,,,,,,,,,
20093,,noncompliance,,,,,,,,,,,,,,,,
20094,,pregnancy|cystitis,,,,,,,,,,,,,,,,
20095,,premature ovarian,,,,,,,,,,,,,,,,
20096,,localized skin,,,,,,,,,,,,,,,,
20097,,demonstrates intact mismatch repair enzymes,,,,,,,,,,,,,,,,
20098,,calculated by the schwartz formula|conjugated,,,,,,,,,,,,,,,,
20099,,carcinomatous meningitis.|prior malignancy,,,,,,,,,,,,,,,,
20100,,corona virus disease,,,,,,,,,,,,,,,,
20101,,hiv/aids,,,,,,,,,,,,,,,,
20102,,passive knee extension degree,,,,,,,,,,,,,,,,
20103,,nodularity,,,,,,,,,,,,,,,,
20104,,included.|the,,,,,,,,,,,,,,,,
20105,,to:||nationality|mental health status|substance,,,,,,,,,,,,,,,,
20106,,autoimmune antibody,,,,,,,,,,,,,,,,
20107,,delayed toxicity|patients,,,,,,,,,,,,,,,,
20108,,breastfeeding;|4.active infection,,,,,,,,,,,,,,,,
20109,,cerebral arteries,,,,,,,,,,,,,,,,
20110,,neurosarcoidosis,,,,,,,,,,,,,,,,
20111,,tigit,,,,,,,,,,,,,,,,
20112,,lactation.|febrile illness,,,,,,,,,,,,,,,,
20113,,probiotic absorption,,,,,,,,,,,,,,,,
20114,,impaired adults.|uncontrolled,,,,,,,,,,,,,,,,
20115,,calculated by the cockcroft-gault formula,,,,,,,,,,,,,,,,
20116,,hiv)|patient,,,,,,,,,,,,,,,,
20117,,erythromyelemia,,,,,,,,,,,,,,,,
20118,,arterial vascular disease,,,,,,,,,,,,,,,,
20119,,non-circumcised,,,,,,,,,,,,,,,,
20120,,entorhinal cortex,,,,,,,,,,,,,,,,
20121,,calgary depression scale,,,,,,,,,,,,,,,,
20122,,cancer|structural abnormalities,,,,,,,,,,,,,,,,
20123,,hematopoietic system,,,,,,,,,,,,,,,,
20124,,rhythm,,,,,,,,,,,,,,,,
20125,,brain abscess,,,,,,,,,,,,,,,,
20126,,aortic root anatomy,,,,,,,,,,,,,,,,
20127,,gilbert's syndrome.|any condition,,,,,,,,,,,,,,,,
20128,,dyspnoea,,,,,,,,,,,,,,,,
20129,,good locomotion,,,,,,,,,,,,,,,,
20130,,treatment.|abnormal liver function,,,,,,,,,,,,,,,,
20131,,prostate carcinoma;|successfully completed,,,,,,,,,,,,,,,,
20132,,utp,,,,,,,,,,,,,,,,
20133,,sensory motor dysfunction,,,,,,,,,,,,,,,,
20134,,antiarrhythmic medication.)|active infection,,,,,,,,,,,,,,,,
20135,,genital infection history|serious trauma,,,,,,,,,,,,,,,,
20136,,cervical cancer in situ after,,,,,,,,,,,,,,,,
20137,,platelet disease,,,,,,,,,,,,,,,,
20138,,class|valvular heart disease,,,,,,,,,,,,,,,,
20139,,dsm-5);|insomnia symptoms,,,,,,,,,,,,,,,,
20140,,carcinoma in situ of breast.|receipt,,,,,,,,,,,,,,,,
20141,,homelessness,,,,,,,,,,,,,,,,
20142,,qtc>430ms,,,,,,,,,,,,,,,,
20143,,simple urinary tract infection,,,,,,,,,,,,,,,,
20144,,herpes zoster infection,,,,,,,,,,,,,,,,
20145,,cervical disorders,,,,,,,,,,,,,,,,
20146,,urgency urinary incontinence,,,,,,,,,,,,,,,,
20147,,somatic brca1,,,,,,,,,,,,,,,,
20148,,positive tumors,,,,,,,,,,,,,,,,
20149,,events,,,,,,,,,,,,,,,,
20150,,poor diabetes,,,,,,,,,,,,,,,,
20151,,mepa||,,,,,,,,,,,,,,,,
20152,,chronic pulmonary obstructive pulmonary disease,,,,,,,,,,,,,,,,
20153,,abnormal cardiac conduction,,,,,,,,,,,,,,,,
20154,,celecoxib).||pregnant,,,,,,,,,,,,,,,,
20155,,facial lymph nodes biopsy,,,,,,,,,,,,,,,,
20156,,liver adenoma,,,,,,,,,,,,,,,,
20157,,radiological presentation consistent,,,,,,,,,,,,,,,,
20158,,sepsis|contraindications,,,,,,,,,,,,,,,,
20159,,otitis externa,,,,,,,,,,,,,,,,
20160,,positive digital rectal,,,,,,,,,,,,,,,,
20161,,acute variceal bleed|child,,,,,,,,,,,,,,,,
20162,,carotid artery disease,,,,,,,,,,,,,,,,
20163,,chemotherapeutic drugs,,,,,,,,,,,,,,,,
20164,,dementia|pre-stroke,,,,,,,,,,,,,,,,
20165,,fulvestrant,,,,,,,,,,,,,,,,
20166,,in bladder cancer,,,,,,,,,,,,,,,,
20167,,disease of the central nervous,,,,,,,,,,,,,,,,
20168,,heart failure.|shock,,,,,,,,,,,,,,,,
20169,,impaired epithelial barrier,,,,,,,,,,,,,,,,
20170,,molar teeth,,,,,,,,,,,,,,,,
20171,,renal dysfunction|hyperthyroidism|vascular diseases|bmi>30|monoamine oxidase inhibitors,,,,,,,,,,,,,,,,
20172,,individual intolerance,,,,,,,,,,,,,,,,
20173,,chronic functional pain,,,,,,,,,,,,,,,,
20174,,atrioventricular block,,,,,,,,,,,,,,,,
20175,,active bleeding,,,,,,,,,,,,,,,,
20176,,muscle tension,,,,,,,,,,,,,,,,
20177,,symptomatic,,,,,,,,,,,,,,,,
20178,,1.5t,,,,,,,,,,,,,,,,
20179,,neurological disorders|difficulty complying,,,,,,,,,,,,,,,,
20180,,delusional disorder).|self-reported,,,,,,,,,,,,,,,,
20181,,primary diseases.|allergic to the ingredients,,,,,,,,,,,,,,,,
20182,,macular degeneration,,,,,,,,,,,,,,,,
20183,,terminal medical condition,,,,,,,,,,,,,,,,
20184,,potential malignancy,,,,,,,,,,,,,,,,
20185,,clinically detectable,,,,,,,,,,,,,,,,
20186,,hematological disorder,,,,,,,,,,,,,,,,
20187,,pneumoconiosis,,,,,,,,,,,,,,,,
20188,,nasal cannula,,,,,,,,,,,,,,,,
20189,,ductal carcinoma in situ of breast,,,,,,,,,,,,,,,,
20190,,researchers,,,,,,,,,,,,,,,,
20191,,acute myocardial infarction.|the,,,,,,,,,,,,,,,,
20192,,⑦ abnormal,,,,,,,,,,,,,,,,
20193,,consent|age,,,,,,,,,,,,,,,,
20194,,caries lesions.||,,,,,,,,,,,,,,,,
20195,,active malignancies,,,,,,,,,,,,,,,,
20196,,traditional remedies,,,,,,,,,,,,,,,,
20197,,peritoneal metastasis,,,,,,,,,,,,,,,,
20198,,gastroenteritis,,,,,,,,,,,,,,,,
20199,,epidural anaesthesia|all forms,,,,,,,,,,,,,,,,
20200,,non-smoker,,,,,,,,,,,,,,,,
20201,,transfusion-dependent,,,,,,,,,,,,,,,,
20202,,head and neck chemotherapy,,,,,,,,,,,,,,,,
20203,,psychiatric condition;|unable to tolerate the surgeries,,,,,,,,,,,,,,,,
20204,,gastric surgery;|serious illness,,,,,,,,,,,,,,,,
20205,,allele of the wfs1,,,,,,,,,,,,,,,,
20206,,diagnosed dementia,,,,,,,,,,,,,,,,
20207,,good-quality,,,,,,,,,,,,,,,,
20208,,decreased liver function,,,,,,,,,,,,,,,,
20209,,limb paralysis,,,,,,,,,,,,,,,,
20210,,renal condition,,,,,,,,,,,,,,,,
20211,,syncytial virus,,,,,,,,,,,,,,,,
20212,,cause of injury related,,,,,,,,,,,,,,,,
20213,,active bacterial infection,,,,,,,,,,,,,,,,
20214,,liver metastases.||international normalized ratio (inr),,,,,,,,,,,,,,,,
20215,,abstain from alcohol,,,,,,,,,,,,,,,,
20216,,hepatitis c.|patients,,,,,,,,,,,,,,,,
20217,,worker's compensation,,,,,,,,,,,,,,,,
20218,,ahus,,,,,,,,,,,,,,,,
20219,,chronic care,,,,,,,,,,,,,,,,
20220,,dysplastic syndrome,,,,,,,,,,,,,,,,
20221,,long qt syndrome).|require,,,,,,,,,,,,,,,,
20222,,ovarian surgery.|abnormal sexual development.|received,,,,,,,,,,,,,,,,
20223,,aesthetically unacceptable upper eyelid position,,,,,,,,,,,,,,,,
20224,,visual disturbance|congenital conditions of the cervical spine|it is of primary concern,,,,,,,,,,,,,,,,
20225,,arrhythmia - atrial fibrillation,,,,,,,,,,,,,,,,
20226,,follows:||for,,,,,,,,,,,,,,,,
20227,,thrombosed internal,,,,,,,,,,,,,,,,
20228,,morbus crohn,,,,,,,,,,,,,,,,
20229,,uncomfortable symptoms,,,,,,,,,,,,,,,,
20230,,delirium etc).|pregnancy,,,,,,,,,,,,,,,,
20231,,acute systemic infection,,,,,,,,,,,,,,,,
20232,,acute reinfection,,,,,,,,,,,,,,,,
20233,,emotional disorders;|inapplicable for this study,,,,,,,,,,,,,,,,
20234,,systemic health conditions,,,,,,,,,,,,,,,,
20235,,end stage kidney disease,,,,,,,,,,,,,,,,
20236,,corticosteroid infiltration,,,,,,,,,,,,,,,,
20237,,glucose,,,,,,,,,,,,,,,,
20238,,actively trying,,,,,,,,,,,,,,,,
20239,,sis,,,,,,,,,,,,,,,,
20240,,communication disorders|severe pregnancy complications,,,,,,,,,,,,,,,,
20241,,temporomandibular joint disease,,,,,,,,,,,,,,,,
20242,,pulmonary disease.|patients,,,,,,,,,,,,,,,,
20243,,deep submucosal,,,,,,,,,,,,,,,,
20244,,child:||chronic conditions,,,,,,,,,,,,,,,,
20245,,allergy reaction,,,,,,,,,,,,,,,,
20246,,jia,,,,,,,,,,,,,,,,
20247,,perception,,,,,,,,,,,,,,,,
20248,,intestinal type,,,,,,,,,,,,,,,,
20249,,morton's neuroma|over 18 years,,,,,,,,,,,,,,,,
20250,,partum depression,,,,,,,,,,,,,,,,
20251,,immunosuppressives,,,,,,,,,,,,,,,,
20252,,concomitant pathology,,,,,,,,,,,,,,,,
20253,,cure,,,,,,,,,,,,,,,,
20254,,type 2 diabetes of the ministry of health,,,,,,,,,,,,,,,,
20255,,primary carcinoma,,,,,,,,,,,,,,,,
20256,,inflammatory,,,,,,,,,,,,,,,,
20257,,bleaching,,,,,,,,,,,,,,,,
20258,,autoimmune skin disorders,,,,,,,,,,,,,,,,
20259,,"mental illness,|not",,,,,,,,,,,,,,,,
20260,,canal disease,,,,,,,,,,,,,,,,
20261,,subfoveal retinal fluid,,,,,,,,,,,,,,,,
20262,,left atrial volume indexed,,,,,,,,,,,,,,,,
20263,,problems|neurological diseases,,,,,,,,,,,,,,,,
20264,,suicidal ideations,,,,,,,,,,,,,,,,
20265,,physical support,,,,,,,,,,,,,,,,
20266,,colonic dysplasia,,,,,,,,,,,,,,,,
20267,,loss of viable myocardium,,,,,,,,,,,,,,,,
20268,,upper extremity occlusive peripheral vascular,,,,,,,,,,,,,,,,
20269,,fetal growth restriction|pregnancies,,,,,,,,,,,,,,,,
20270,,gastrointestinal bleeding episodes,,,,,,,,,,,,,,,,
20271,,metachronous rectal,,,,,,,,,,,,,,,,
20272,,myositis)|coronary artery disease,,,,,,,,,,,,,,,,
20273,,teeth with periodontal,,,,,,,,,,,,,,,,
20274,,neurologic diseases|claustrophobia|active malignant neoplasms|severe kidney,,,,,,,,,,,,,,,,
20275,,restored gingiva,,,,,,,,,,,,,,,,
20276,,orthodontic treatment.|healthy periodontal tissues,,,,,,,,,,,,,,,,
20277,,discharged from the ed|significant,,,,,,,,,,,,,,,,
20278,,functional deficit,,,,,,,,,,,,,,,,
20279,,cancer,,,,,,,,,,,,,,,,
20280,,right carotid artery,,,,,,,,,,,,,,,,
20281,,uterine myoma,,,,,,,,,,,,,,,,
20282,,cardiac disease.|patients,,,,,,,,,,,,,,,,
20283,,breast cancer measuring,,,,,,,,,,,,,,,,
20284,,exceptions,,,,,,,,,,,,,,,,
20285,,communication trainings,,,,,,,,,,,,,,,,
20286,,similar problems,,,,,,,,,,,,,,,,
20287,,self-harming,,,,,,,,,,,,,,,,
20288,,years|tracheal tube diameter of 5.0 mm,,,,,,,,,,,,,,,,
20289,,celiac disease|cystic fibrosis|hypothyroidism,,,,,,,,,,,,,,,,
20290,,liver diseases.|hiv,,,,,,,,,,,,,,,,
20291,,diagnosed covid-19,,,,,,,,,,,,,,,,
20292,,breast cancers|women,,,,,,,,,,,,,,,,
20293,,himself,,,,,,,,,,,,,,,,
20294,,cancer in situ,,,,,,,,,,,,,,,,
20295,,leptomeningeal carcinosis,,,,,,,,,,,,,,,,
20296,,atrial tachyarrhythmias,,,,,,,,,,,,,,,,
20297,,gastrointestinal hemorrhage,,,,,,,,,,,,,,,,
20298,,thyroid eye,,,,,,,,,,,,,,,,
20299,,primary care clinics.||exclusion,,,,,,,,,,,,,,,,
20300,,months|diagnosis,,,,,,,,,,,,,,,,
20301,,renal stones,,,,,,,,,,,,,,,,
20302,,tenderness,,,,,,,,,,,,,,,,
20303,,hemorrhagic transformation|subjects,,,,,,,,,,,,,,,,
20304,,ild)/pneumonia,,,,,,,,,,,,,,,,
20305,,tuberculosis should,,,,,,,,,,,,,,,,
20306,,unclear local recurrence,,,,,,,,,,,,,,,,
20307,,progressive diseases,,,,,,,,,,,,,,,,
20308,,end-stage cirrhosis,,,,,,,,,,,,,,,,
20309,,inflammatory bowel disease);|schizophrenia,,,,,,,,,,,,,,,,
20310,,acute ischemic stroke；|time,,,,,,,,,,,,,,,,
20311,,acid covid-19 vaccines,,,,,,,,,,,,,,,,
20312,,endocrinopathies stable,,,,,,,,,,,,,,,,
20313,,attention,,,,,,,,,,,,,,,,
20314,,close,,,,,,,,,,,,,,,,
20315,,critical condition,,,,,,,,,,,,,,,,
20316,,acute musculoskeletal injury,,,,,,,,,,,,,,,,
20317,,prolonged episodes of pain,,,,,,,,,,,,,,,,
20318,,nodular lymphocyte,,,,,,,,,,,,,,,,
20319,,ocular surgery.|systemic diseases,,,,,,,,,,,,,,,,
20320,,practice true abstinence,,,,,,,,,,,,,,,,
20321,,clinical modification [icd-9-cm,,,,,,,,,,,,,,,,
20322,,lv dysfunction|coronary anomalies,,,,,,,,,,,,,,,,
20323,,childhood asthma,,,,,,,,,,,,,,,,
20324,,meningeal involvement.|patients,,,,,,,,,,,,,,,,
20325,,narcotic substance,,,,,,,,,,,,,,,,
20326,,upper limb,,,,,,,,,,,,,,,,
20327,,venous thromboembolism,,,,,,,,,,,,,,,,
20328,,cdi,,,,,,,,,,,,,,,,
20329,,screening.|active cns lupus,,,,,,,,,,,,,,,,
20330,,grant,,,,,,,,,,,,,,,,
20331,,hereditary disorders,,,,,,,,,,,,,,,,
20332,,bcva,,,,,,,,,,,,,,,,
20333,,dorsal,,,,,,,,,,,,,,,,
20334,,endodontic considerations,,,,,,,,,,,,,,,,
20335,,"inflammatory and immune system disorders,|type i",,,,,,,,,,,,,,,,
20336,,impaired absorption of oral medication,,,,,,,,,,,,,,,,
20337,,transnasal intracranial occupancy,,,,,,,,,,,,,,,,
20338,,immunomodulating drugs|estimated glomerular filtration rate (egfr),,,,,,,,,,,,,,,,
20339,,disease recurrence,,,,,,,,,,,,,,,,
20340,,chondrosarcoma,,,,,,,,,,,,,,,,
20341,,alcohol use disorder|binge drinking,,,,,,,,,,,,,,,,
20342,,bone lesions,,,,,,,,,,,,,,,,
20343,,pain disorder,,,,,,,,,,,,,,,,
20344,,diffuse glioma,,,,,,,,,,,,,,,,
20345,,multiple endocrine neoplasia syndrome type,,,,,,,,,,,,,,,,
20346,,chronic arterial hypertension,,,,,,,,,,,,,,,,
20347,,good individual oral hygiene,,,,,,,,,,,,,,,,
20348,,intranasal/inhaled steroids,,,,,,,,,,,,,,,,
20349,,isolated congenital cardiac anomaly,,,,,,,,,,,,,,,,
20350,,distant metastasis;|patients,,,,,,,,,,,,,,,,
20351,,autoimmune disease;|patients,,,,,,,,,,,,,,,,
20352,,hepatic malignancy,,,,,,,,,,,,,,,,
20353,,clinical manifestations later,,,,,,,,,,,,,,,,
20354,,routine postnatal checkup,,,,,,,,,,,,,,,,
20355,,upper-limb neurodynamic,,,,,,,,,,,,,,,,
20356,,burning mouth syndrome,,,,,,,,,,,,,,,,
20357,,serious infections,,,,,,,,,,,,,,,,
20358,,gastrointestinal tract lesions).|refuse,,,,,,,,,,,,,,,,
20359,,internal pathologies,,,,,,,,,,,,,,,,
20360,,traditional chinese medicine and/or its analogue,,,,,,,,,,,,,,,,
20361,,cross-sectional imaging (ct or mri,,,,,,,,,,,,,,,,
20362,,hereditary thrombophilia,,,,,,,,,,,,,,,,
20363,,ultrasound.|allergy,,,,,,,,,,,,,,,,
20364,,severe pulmonary insufficiency,,,,,,,,,,,,,,,,
20365,,spread beyond the external ear(s,,,,,,,,,,,,,,,,
20366,,renal impairment||body mass index,,,,,,,,,,,,,,,,
20367,,bleeding disorders.|patients,,,,,,,,,,,,,,,,
20368,,multifocal bc,,,,,,,,,,,,,,,,
20369,,suicidal plan,,,,,,,,,,,,,,,,
20370,,untreated)|hypothyroidism,,,,,,,,,,,,,,,,
20371,,radiotherapy|hematological disorders,,,,,,,,,,,,,,,,
20372,,pregelatinized starch,,,,,,,,,,,,,,,,
20373,,congenital anomaly of the spine,,,,,,,,,,,,,,,,
20374,,coffee consumption,,,,,,,,,,,,,,,,
20375,,baumannii pneumonia,,,,,,,,,,,,,,,,
20376,,dflc,,,,,,,,,,,,,,,,
20377,,structural deformities,,,,,,,,,,,,,,,,
20378,,metastatic biliary tract cancer,,,,,,,,,,,,,,,,
20379,,right coronary,,,,,,,,,,,,,,,,
20380,,drugs|premorbid dementia,,,,,,,,,,,,,,,,
20381,,bowel like ibd,,,,,,,,,,,,,,,,
20382,,paraolfactory cortex,,,,,,,,,,,,,,,,
20383,,consisting of neck,,,,,,,,,,,,,,,,
20384,,immunosuppressant stable,,,,,,,,,,,,,,,,
20385,,necessary||,,,,,,,,,,,,,,,,
20386,,criteria)|maternal cardiac disease,,,,,,,,,,,,,,,,
20387,,tumor hemorrhage,,,,,,,,,,,,,,,,
20388,,mental disorders.|the investigator,,,,,,,,,,,,,,,,
20389,,"heart allograft,|written informed consent obtained",,,,,,,,,,,,,,,,
20390,,endometrioma,,,,,,,,,,,,,,,,
20391,,extensive adhesions,,,,,,,,,,,,,,,,
20392,,premature group:||-,,,,,,,,,,,,,,,,
20393,,subcutaneous,,,,,,,,,,,,,,,,
20394,,autonomic dysreflexia.|severe comorbidities - any condition,,,,,,,,,,,,,,,,
20395,,older|diagnosis,,,,,,,,,,,,,,,,
20396,,vascular sclerosis,,,,,,,,,,,,,,,,
20397,,vasovagal-related,,,,,,,,,,,,,,,,
20398,,nhl tumor,,,,,,,,,,,,,,,,
20399,,intracranial space-occupying lesions,,,,,,,,,,,,,,,,
20400,,pathological colonic adenocarcinoma|clinical tnm classification,,,,,,,,,,,,,,,,
20401,,jdm,,,,,,,,,,,,,,,,
20402,,alcohol abusers,,,,,,,,,,,,,,,,
20403,,acute oophoritis,,,,,,,,,,,,,,,,
20404,,hepatic disease|urinary tract infection|chorioamnionitis|intrauterine,,,,,,,,,,,,,,,,
20405,,herpes zoster vaccine;|female,,,,,,,,,,,,,,,,
20406,,proximal femur fracture,,,,,,,,,,,,,,,,
20407,,≤5 x uln,,,,,,,,,,,,,,,,
20408,,chest/abdomen,,,,,,,,,,,,,,,,
20409,,cutaneous burning,,,,,,,,,,,,,,,,
20410,,acute intestinal disease,,,,,,,,,,,,,,,,
20411,,acute pain condition||,,,,,,,,,,,,,,,,
20412,,life support,,,,,,,,,,,,,,,,
20413,,recurrent depressive disorder)|discharged,,,,,,,,,,,,,,,,
20414,,end stage treatment|people,,,,,,,,,,,,,,,,
20415,,bilateral vocal cord lesions,,,,,,,,,,,,,,,,
20416,,chronic alcoholism,,,,,,,,,,,,,,,,
20417,,fever,,,,,,,,,,,,,,,,
20418,,transient swelling would cause substantial symptoms,,,,,,,,,,,,,,,,
20419,,and|polycystic ovaries,,,,,,,,,,,,,,,,
20420,,chronic hepatitis of,,,,,,,,,,,,,,,,
20421,,human immunodeficiency virus antibody (,,,,,,,,,,,,,,,,
20422,,managing hepatitis,,,,,,,,,,,,,,,,
20423,,physically healthy,,,,,,,,,,,,,,,,
20424,,pancreatic function abnormalities,,,,,,,,,,,,,,,,
20425,,primary liver cancer of the,,,,,,,,,,,,,,,,
20426,,non severe,,,,,,,,,,,,,,,,
20427,,lymph node lesion,,,,,,,,,,,,,,,,
20428,,traumatic metal implants,,,,,,,,,,,,,,,,
20429,,gis motility disorder,,,,,,,,,,,,,,,,
20430,,fractures of hip,,,,,,,,,,,,,,,,
20431,,acute toxicities,,,,,,,,,,,,,,,,
20432,,tumor infiltrating,,,,,,,,,,,,,,,,
20433,,chronic pain conditions,,,,,,,,,,,,,,,,
20434,,fibrinogen abnormalities & deficiency,,,,,,,,,,,,,,,,
20435,,diffuse dermatological conditions,,,,,,,,,,,,,,,,
20436,,condition resulting asplenia,,,,,,,,,,,,,,,,
20437,,spinal disease,,,,,,,,,,,,,,,,
20438,,infection|severe heart failure,,,,,,,,,,,,,,,,
20439,,emergency presentation,,,,,,,,,,,,,,,,
20440,,heart block|congestive heart failure,,,,,,,,,,,,,,,,
20441,,unstable physical health,,,,,,,,,,,,,,,,
20442,,serious heart disease,,,,,,,,,,,,,,,,
20443,,juvenile polyposis,,,,,,,,,,,,,,,,
20444,,equinovarus,,,,,,,,,,,,,,,,
20445,,tachyarrhythmias,,,,,,,,,,,,,,,,
20446,,"renal disease,|frequent headaches",,,,,,,,,,,,,,,,
20447,,haematological disorders,,,,,,,,,,,,,,,,
20448,,acute ophthalmic symptoms,,,,,,,,,,,,,,,,
20449,,congential opitc abnormal,,,,,,,,,,,,,,,,
20450,,av-node disturbing medicament,,,,,,,,,,,,,,,,
20451,,progressive forms,,,,,,,,,,,,,,,,
20452,,ambulant,,,,,,,,,,,,,,,,
20453,,ankle sprain,,,,,,,,,,,,,,,,
20454,,concomitant disorder,,,,,,,,,,,,,,,,
20455,,ischemic ecg changes,,,,,,,,,,,,,,,,
20456,,traumatic spinal cord injury,,,,,,,,,,,,,,,,
20457,,nephrectomy;|presence,,,,,,,,,,,,,,,,
20458,,systemic hypertension,,,,,,,,,,,,,,,,
20459,,pre-stenotic dilation,,,,,,,,,,,,,,,,
20460,,neuraxial anesthetics;|uncorrected thrombocytopenia,,,,,,,,,,,,,,,,
20461,,serious physical diseases,,,,,,,,,,,,,,,,
20462,,disenrollment,,,,,,,,,,,,,,,,
20463,,obstructive sleep apnea hypopnea syndrome,,,,,,,,,,,,,,,,
20464,,sitagliptin treatmet,,,,,,,,,,,,,,,,
20465,,arterial rupture|family,,,,,,,,,,,,,,,,
20466,,middle school staff,,,,,,,,,,,,,,,,
20467,,indication;|clinical manifestations,,,,,,,,,,,,,,,,
20468,,tight hamstring syndrome,,,,,,,,,,,,,,,,
20469,,ocd,,,,,,,,,,,,,,,,
20470,,anticoagulants|active intravascular coagulation,,,,,,,,,,,,,,,,
20471,,environmental factors,,,,,,,,,,,,,,,,
20472,,xeroquel,,,,,,,,,,,,,,,,
20473,,united states territories|participants,,,,,,,,,,,,,,,,
20474,,pill esophagitis,,,,,,,,,,,,,,,,
20475,,antibiotics have,,,,,,,,,,,,,,,,
20476,,functional tumor,,,,,,,,,,,,,,,,
20477,,ventricular arrhythmias|contraindication,,,,,,,,,,,,,,,,
20478,,drowsiness,,,,,,,,,,,,,,,,
20479,,unrepaired abdominal injury,,,,,,,,,,,,,,,,
20480,,systemic al,,,,,,,,,,,,,,,,
20481,,periprocedural complications,,,,,,,,,,,,,,,,
20482,,condition of the feet,,,,,,,,,,,,,,,,
20483,,growth factors.|females,,,,,,,,,,,,,,,,
20484,,non-keratinizing,,,,,,,,,,,,,,,,
20485,,progressive increase in physical disability,,,,,,,,,,,,,,,,
20486,,manual muscle testing-8,,,,,,,,,,,,,,,,
20487,,emotional problems,,,,,,,,,,,,,,,,
20488,,drop arm test,,,,,,,,,,,,,,,,
20489,,weight bearing system|cognitive deficits,,,,,,,,,,,,,,,,
20490,,colon carcinoma,,,,,,,,,,,,,,,,
20491,,degenerative disc disease,,,,,,,,,,,,,,,,
20492,,structural cardiac disorders,,,,,,,,,,,,,,,,
20493,,cancer therapy.|current major psychiatric disorder,,,,,,,,,,,,,,,,
20494,,exploitations,,,,,,,,,,,,,,,,
20495,,native vessels.|patient,,,,,,,,,,,,,,,,
20496,,congenital lumbar anomaly,,,,,,,,,,,,,,,,
20497,,non-small cell lung cancer|written consent obtained,,,,,,,,,,,,,,,,
20498,,reporting consumption of alcoholic beverages|consumption,,,,,,,,,,,,,,,,
20499,,liver involvement,,,,,,,,,,,,,,,,
20500,,bowel disease,,,,,,,,,,,,,,,,
20501,,clinical insomnia symptoms,,,,,,,,,,,,,,,,
20502,,celiac disease|patient,,,,,,,,,,,,,,,,
20503,,chronic headache/migraine|the,,,,,,,,,,,,,,,,
20504,,asplenia.|short bowel syndrome,,,,,,,,,,,,,,,,
20505,,weeks|pregnancy,,,,,,,,,,,,,,,,
20506,,necrotic mandibular second,,,,,,,,,,,,,,,,
20507,,end-stage liver disease,,,,,,,,,,,,,,,,
20508,,seizures.|significant alcohol,,,,,,,,,,,,,,,,
20509,,sdc,,,,,,,,,,,,,,,,
20510,,0.75dc,,,,,,,,,,,,,,,,
20511,,asperger's syndrome,,,,,,,,,,,,,,,,
20512,,systolic bp,,,,,,,,,,,,,,,,
20513,,thyroid abnormality,,,,,,,,,,,,,,,,
20514,,myocarditis,,,,,,,,,,,,,,,,
20515,,hepatic,,,,,,,,,,,,,,,,
20516,,intercurrent conditions,,,,,,,,,,,,,,,,
20517,,hyperglycaemia,,,,,,,,,,,,,,,,
20518,,end stage renal disease|uncontrolled diabetes mellitus,,,,,,,,,,,,,,,,
20519,,cavitated lesions,,,,,,,,,,,,,,,,
20520,,vertical root fracture,,,,,,,,,,,,,,,,
20521,,critical issues,,,,,,,,,,,,,,,,
20522,,cardiac event,,,,,,,,,,,,,,,,
20523,,antiphospholipid syndrome|active bleeding|cardiogenic shock,,,,,,,,,,,,,,,,
20524,,rb-deficient,,,,,,,,,,,,,,,,
20525,,immune deficiency/immunosuppression;|diagnosed,,,,,,,,,,,,,,,,
20526,,ra,,,,,,,,,,,,,,,,
20527,,hoarseness,,,,,,,,,,,,,,,,
20528,,jugular tympanum,,,,,,,,,,,,,,,,
20529,,cases of novel,,,,,,,,,,,,,,,,
20530,,frontotemporal dementia (ftd),,,,,,,,,,,,,,,,
20531,,lymphomatous infiltration of the liver,,,,,,,,,,,,,,,,
20532,,immunologic etiology,,,,,,,,,,,,,,,,
20533,,pathological origin|sudden cardiac arrest|unprovoked,,,,,,,,,,,,,,,,
20534,,extranodal lesion,,,,,,,,,,,,,,,,
20535,,stomach ulcer,,,,,,,,,,,,,,,,
20536,,non-ambulatory,,,,,,,,,,,,,,,,
20537,,functional dyspnea/hyperventilation syndrome,,,,,,,,,,,,,,,,
20538,,metastatic disease|locoregional disease,,,,,,,,,,,,,,,,
20539,,basal cell carcinomas of the skin.|any clinically significant abnormalities,,,,,,,,,,,,,,,,
20540,,cerebrovascular events);|any,,,,,,,,,,,,,,,,
20541,,dermatitis,,,,,,,,,,,,,,,,
20542,,cardiorespiratory disease,,,,,,,,,,,,,,,,
20543,,immunodeficiency conditions,,,,,,,,,,,,,,,,
20544,,socio-economic status,,,,,,,,,,,,,,,,
20545,,infections|patients,,,,,,,,,,,,,,,,
20546,,urolithiasis|thrombophlebitis,,,,,,,,,,,,,,,,
20547,,very sick,,,,,,,,,,,,,,,,
20548,,caries-free,,,,,,,,,,,,,,,,
20549,,copd,,,,,,,,,,,,,,,,
20550,,migraine headaches.||-,,,,,,,,,,,,,,,,
20551,,cranial tumor,,,,,,,,,,,,,,,,
20552,,spinal tumor,,,,,,,,,,,,,,,,
20553,,amyloidosis|myelomatosis|monoclonal gammopathy,,,,,,,,,,,,,,,,
20554,,consent||,,,,,,,,,,,,,,,,
20555,,pelvic malignancy,,,,,,,,,,,,,,,,
20556,,high-risk hematologic malignancies,,,,,,,,,,,,,,,,
20557,,celiac disease,,,,,,,,,,,,,,,,
20558,,hypofibrinogenemia,,,,,,,,,,,,,,,,
20559,,asymptomatic brain metastases,,,,,,,,,,,,,,,,
20560,,external pressure,,,,,,,,,,,,,,,,
20561,,worse on the retina society terminology committee classification,,,,,,,,,,,,,,,,
20562,,skin sensation|anhidrosis,,,,,,,,,,,,,,,,
20563,,acute symptoms.|ppcs,,,,,,,,,,,,,,,,
20564,,hepatocyte injury type,,,,,,,,,,,,,,,,
20565,,ballooning degeneration≥1;② fibrosis,,,,,,,,,,,,,,,,
20566,,end-stage dementia,,,,,,,,,,,,,,,,
20567,,isolated limb,,,,,,,,,,,,,,,,
20568,,multidisciplinary team.|measurable lesion,,,,,,,,,,,,,,,,
20569,,cardiometabolic diseases,,,,,,,,,,,,,,,,
20570,,brugada syndrome,,,,,,,,,,,,,,,,
20571,,errors of,,,,,,,,,,,,,,,,
20572,,homozygosity,,,,,,,,,,,,,,,,
20573,,ocular lymphoma,,,,,,,,,,,,,,,,
20574,,ocular organic lesions,,,,,,,,,,,,,,,,
20575,,chronic peptic ulcer,,,,,,,,,,,,,,,,
20576,,"obstructive endometrial polyps,|irritable bowel syndrome|major abdominal",,,,,,,,,,,,,,,,
20577,,idiopathic pneumonia,,,,,,,,,,,,,,,,
20578,,esophageal squamous cell,,,,,,,,,,,,,,,,
20579,,f32.2,,,,,,,,,,,,,,,,
20580,,retinal disease.|patients,,,,,,,,,,,,,,,,
20581,,shoulder anterior dislocation,,,,,,,,,,,,,,,,
20582,,malignancy.|a helminth parasitic,,,,,,,,,,,,,,,,
20583,,nociceptive pain,,,,,,,,,,,,,,,,
20584,,tokyo guidelines|symptom onset||,,,,,,,,,,,,,,,,
20585,,persistent risk factor,,,,,,,,,,,,,,,,
20586,,hepatitis b virus dna level,,,,,,,,,,,,,,,,
20587,,complete response,,,,,,,,,,,,,,,,
20588,,fungal nail infection,,,,,,,,,,,,,,,,
20589,,heavy drinking,,,,,,,,,,,,,,,,
20590,,mandibular first,,,,,,,,,,,,,,,,
20591,,spinal cord compression;|patients,,,,,,,,,,,,,,,,
20592,,endotic tinnitus|patients,,,,,,,,,,,,,,,,
20593,,trifascicular block,,,,,,,,,,,,,,,,
20594,,grandparents,,,,,,,,,,,,,,,,
20595,,meaning minimal,,,,,,,,,,,,,,,,
20596,,teeth with,,,,,,,,,,,,,,,,
20597,,pain|tachypnea,,,,,,,,,,,,,,,,
20598,,hepatitis c infection.||gastrointestinal abnormalities,,,,,,,,,,,,,,,,
20599,,parkinson syndroma|patients,,,,,,,,,,,,,,,,
20600,,respiratory muscle strength,,,,,,,,,,,,,,,,
20601,,chronic prostatitis type,,,,,,,,,,,,,,,,
20602,,residence,,,,,,,,,,,,,,,,
20603,,multiple system atrophy,,,,,,,,,,,,,,,,
20604,,developmental deficit,,,,,,,,,,,,,,,,
20605,,clinical hepatic dysfunction,,,,,,,,,,,,,,,,
20606,,hbsag reactive,,,,,,,,,,,,,,,,
20607,,irccs policlinico san donato;|signed,,,,,,,,,,,,,,,,
20608,,gastrointestinal stromal tumour,,,,,,,,,,,,,,,,
20609,,valvular heart disease,,,,,,,,,,,,,,,,
20610,,gastric cancer peritoneal metastasis,,,,,,,,,,,,,,,,
20611,,her2 +,,,,,,,,,,,,,,,,
20612,,mmhg|pregnancy|clinical heart failure,,,,,,,,,,,,,,,,
20613,,acute myocardial ischemia,,,,,,,,,,,,,,,,
20614,,acute fracture,,,,,,,,,,,,,,,,
20615,,hallucinations|motion sickness,,,,,,,,,,,,,,,,
20616,,vertigo|legal blindness,,,,,,,,,,,,,,,,
20617,,mental handicapping condition,,,,,,,,,,,,,,,,
20618,,left main lesion,,,,,,,,,,,,,,,,
20619,,smile,,,,,,,,,,,,,,,,
20620,,nasolabial folds,,,,,,,,,,,,,,,,
20621,,hiv +,,,,,,,,,,,,,,,,
20622,,liver disease|jaundice,,,,,,,,,,,,,,,,
20623,,her2+,,,,,,,,,,,,,,,,
20624,,progressive sclerosing cholangitis,,,,,,,,,,,,,,,,
20625,,environmental - bronchospastic allergies,,,,,,,,,,,,,,,,
20626,,missing,,,,,,,,,,,,,,,,
20627,,tachycardic,,,,,,,,,,,,,,,,
20628,,carcinoid syndrome):||30,,,,,,,,,,,,,,,,
20629,,hepatic disease.|severe obesity,,,,,,,,,,,,,,,,
20630,,metastatic advanced,,,,,,,,,,,,,,,,
20631,,contact dermatitis,,,,,,,,,,,,,,,,
20632,,extremity dysfunction,,,,,,,,,,,,,,,,
20633,,adequate bone marrow reserve,,,,,,,,,,,,,,,,
20634,,systemic hypersensitivity reaction,,,,,,,,,,,,,,,,
20635,,hyperlipidemia/dyslipidemia,,,,,,,,,,,,,,,,
20636,,main artery,,,,,,,,,,,,,,,,
20637,,partial obstructions of,,,,,,,,,,,,,,,,
20638,,otosclerosis,,,,,,,,,,,,,,,,
20639,,lower gi complaints||,,,,,,,,,,,,,,,,
20640,,immune dysregulatory diseases,,,,,,,,,,,,,,,,
20641,,etc.|ocular abnormalities,,,,,,,,,,,,,,,,
20642,,drug abuse test,,,,,,,,,,,,,,,,
20643,,valgus/varus deformities,,,,,,,,,,,,,,,,
20644,,clinically prominent heart disease,,,,,,,,,,,,,,,,
20645,,akinetic,,,,,,,,,,,,,,,,
20646,,bilateral otomycosis,,,,,,,,,,,,,,,,
20647,,intracranial lesions,,,,,,,,,,,,,,,,
20648,,emergency surgical conditions|known hypersensitivity,,,,,,,,,,,,,,,,
20649,,≤200 mmhg,,,,,,,,,,,,,,,,
20650,,hydronephrosis,,,,,,,,,,,,,,,,
20651,,coagulopathy|history of chronic analgesic use|patients,,,,,,,,,,,,,,,,
20652,,colorectal resection,,,,,,,,,,,,,,,,
20653,,topical ophthalmic preparations,,,,,,,,,,,,,,,,
20654,,diabetic renal disease,,,,,,,,,,,,,,,,
20655,,retinal separation,,,,,,,,,,,,,,,,
20656,,antifungals|active primary immunodeficiency,,,,,,,,,,,,,,,,
20657,,heritable disorders,,,,,,,,,,,,,,,,
20658,,complex injuries||,,,,,,,,,,,,,,,,
20659,,measles mumps rubella,,,,,,,,,,,,,,,,
20660,,function.|inability,,,,,,,,,,,,,,,,
20661,,aphasia|pregnancy,,,,,,,,,,,,,,,,
20662,,gingival hyperplasia,,,,,,,,,,,,,,,,
20663,,acute malnutrition,,,,,,,,,,,,,,,,
20664,,tumor-directed therapy.|the,,,,,,,,,,,,,,,,
20665,,extreme mobility issues,,,,,,,,,,,,,,,,
20666,,horse-shoe shaped,,,,,,,,,,,,,,,,
20667,,respiratory support,,,,,,,,,,,,,,,,
20668,,menstrual cups,,,,,,,,,,,,,,,,
20669,,mixed involvement,,,,,,,,,,,,,,,,
20670,,skin conditions,,,,,,,,,,,,,,,,
20671,,anatomical uterine disorders,,,,,,,,,,,,,,,,
20672,,liver metastases.|adequate hematologic function,,,,,,,,,,,,,,,,
20673,,aids-defining opportunistic infection,,,,,,,,,,,,,,,,
20674,,medicine preparations,,,,,,,,,,,,,,,,
20675,,complex neurobiological,,,,,,,,,,,,,,,,
20676,,hepatic disease.|patients,,,,,,,,,,,,,,,,
20677,,tinnitus|objective tinnitus|known,,,,,,,,,,,,,,,,
20678,,evaluable neurological impairment,,,,,,,,,,,,,,,,
20679,,pancreatic pathology,,,,,,,,,,,,,,,,
20680,,arterial thrombotic,,,,,,,,,,,,,,,,
20681,,proximal subungual onychomycosis,,,,,,,,,,,,,,,,
20682,,pulmonary embolus,,,,,,,,,,,,,,,,
20683,,hepatitis b virus [hbv],,,,,,,,,,,,,,,,
20684,,vaginal inflammation,,,,,,,,,,,,,,,,
20685,,bone metabolism,,,,,,,,,,,,,,,,
20686,,mrna covid-1 vaccines,,,,,,,,,,,,,,,,
20687,,ct image,,,,,,,,,,,,,,,,
20688,,chronic tendency,,,,,,,,,,,,,,,,
20689,,ph-positive,,,,,,,,,,,,,,,,
20690,,abstain from the consumption of any alcoholic substances,,,,,,,,,,,,,,,,
20691,,refractory heart failure,,,,,,,,,,,,,,,,
20692,,poor prognosis,,,,,,,,,,,,,,,,
20693,,abnormal bleeding,,,,,,,,,,,,,,,,
20694,,ocular conditions,,,,,,,,,,,,,,,,
20695,,intestinal stenosis,,,,,,,,,,,,,,,,
20696,,urolithiasis|diabetes|thrombophlebitis,,,,,,,,,,,,,,,,
20697,,available hepatic imaging results,,,,,,,,,,,,,,,,
20698,,fungal infection|presence of any,,,,,,,,,,,,,,,,
20699,,urethral stenosis,,,,,,,,,,,,,,,,
20700,,macular oedema,,,,,,,,,,,,,,,,
20701,,hepatic diseases,,,,,,,,,,,,,,,,
20702,,ecchymosis,,,,,,,,,,,,,,,,
20703,,e deficit level|any spinal cord injury,,,,,,,,,,,,,,,,
20704,,vascular events,,,,,,,,,,,,,,,,
20705,,refractory (disease,,,,,,,,,,,,,,,,
20706,,peritoneal metastatic carcinoma,,,,,,,,,,,,,,,,
20707,,hepatitis/aspartate aminotransferase,,,,,,,,,,,,,,,,
20708,,substance addiction|antisocial personality disorder|inability to participate in group sessions|current,,,,,,,,,,,,,,,,
20709,,rheumatic heart disease,,,,,,,,,,,,,,,,
20710,,third space effusion,,,,,,,,,,,,,,,,
20711,,hiv detectable viral load,,,,,,,,,,,,,,,,
20712,,complex regional pain,,,,,,,,,,,,,,,,
20713,,needle rollers,,,,,,,,,,,,,,,,
20714,,impaired lvef,,,,,,,,,,,,,,,,
20715,,stroke /embolic events still,,,,,,,,,,,,,,,,
20716,,digoxin.|current,,,,,,,,,,,,,,,,
20717,,"milk proteins|chronic diseases,|carious lesions",,,,,,,,,,,,,,,,
20718,,serious infections should,,,,,,,,,,,,,,,,
20719,,contraindicated drug,,,,,,,,,,,,,,,,
20720,,coloboma,,,,,,,,,,,,,,,,
20721,,immunoglobulin e,,,,,,,,,,,,,,,,
20722,,thrombocytopenia|allergic reaction,,,,,,,,,,,,,,,,
20723,,esophageal adenocarcinoma pathology,,,,,,,,,,,,,,,,
20724,,"parkinson's disease),|serious",,,,,,,,,,,,,,,,
20725,,number of lesions,,,,,,,,,,,,,,,,
20726,,liver disease;|chronic kidney disease,,,,,,,,,,,,,,,,
20727,,parenchymal hematoma,,,,,,,,,,,,,,,,
20728,,osteopenia,,,,,,,,,,,,,,,,
20729,,renal impairment||a marked prolongation,,,,,,,,,,,,,,,,
20730,,pigmentary oag.|patients,,,,,,,,,,,,,,,,
20731,,intestinal obstruction;|5,,,,,,,,,,,,,,,,
20732,,malignant tumors|suffering from mental illness,,,,,,,,,,,,,,,,
20733,,dangerous arrythmia,,,,,,,,,,,,,,,,
20734,,skin gvhd,,,,,,,,,,,,,,,,
20735,,genital infection,,,,,,,,,,,,,,,,
20736,,human immunodeficiency virus(hiv,,,,,,,,,,,,,,,,
20737,,drug abusers,,,,,,,,,,,,,,,,
20738,,exogenous melatonin.|phase delay syndrome,,,,,,,,,,,,,,,,
20739,,artifact)|previous coronary artery bypass graft,,,,,,,,,,,,,,,,
20740,,vasculature,,,,,,,,,,,,,,,,
20741,,covid-infected,,,,,,,,,,,,,,,,
20742,,neurological disorder|subjects,,,,,,,,,,,,,,,,
20743,,months.|prior cystectomy,,,,,,,,,,,,,,,,
20744,,digestive disorders,,,,,,,,,,,,,,,,
20745,,heart diseases|history,,,,,,,,,,,,,,,,
20746,,rescue pain,,,,,,,,,,,,,,,,
20747,,paranasal sinus,,,,,,,,,,,,,,,,
20748,,recreational drugs|regularly,,,,,,,,,,,,,,,,
20749,,disease history;|axillary temperature,,,,,,,,,,,,,,,,
20750,,gastric diseases,,,,,,,,,,,,,,,,
20751,,excellent prognosis,,,,,,,,,,,,,,,,
20752,,southern sweden,,,,,,,,,,,,,,,,
20753,,complicated pregnancies,,,,,,,,,,,,,,,,
20754,,ptosis,,,,,,,,,,,,,,,,
20755,,injectables,,,,,,,,,,,,,,,,
20756,,local guidelines|conditions,,,,,,,,,,,,,,,,
20757,,hepatitis)|renal insufficiency,,,,,,,,,,,,,,,,
20758,,cnlc liver cancer,,,,,,,,,,,,,,,,
20759,,voluntary dementia,,,,,,,,,,,,,,,,
20760,,medical [hypogonadism],,,,,,,,,,,,,,,,
20761,,self-harm,,,,,,,,,,,,,,,,
20762,,swelling of the vestibule.|normal gingival,,,,,,,,,,,,,,,,
20763,,vulvovaginal pain,,,,,,,,,,,,,,,,
20764,,infectious conjunctivitis,,,,,,,,,,,,,,,,
20765,,deep vein thrombosis.||patients,,,,,,,,,,,,,,,,
20766,,alcohol use)|patients,,,,,,,,,,,,,,,,
20767,,structural abnormalities,,,,,,,,,,,,,,,,
20768,,abnormalities of glucose metabolism,,,,,,,,,,,,,,,,
20769,,congenital platelet disease,,,,,,,,,,,,,,,,
20770,,medication.|active infection,,,,,,,,,,,,,,,,
20771,,hepatitis b core antibody,,,,,,,,,,,,,,,,
20772,,cracking,,,,,,,,,,,,,,,,
20773,,acute burn,,,,,,,,,,,,,,,,
20774,,attention-deficit hyperactivity disorders (,,,,,,,,,,,,,,,,
20775,,shoulder resurfacing arthroplasty,,,,,,,,,,,,,,,,
20776,,auscultatory abnormalities,,,,,,,,,,,,,,,,
20777,,abnormality,,,,,,,,,,,,,,,,
20778,,fermented foods,,,,,,,,,,,,,,,,
20779,,obstetric pathology of the fpg,,,,,,,,,,,,,,,,
20780,,intestinal infection,,,,,,,,,,,,,,,,
20781,,respiratory difficulty,,,,,,,,,,,,,,,,
20782,,electronic health record,,,,,,,,,,,,,,,,
20783,,car-t cells,,,,,,,,,,,,,,,,
20784,,severe dry eye disease,,,,,,,,,,,,,,,,
20785,,hemocoagulopathy,,,,,,,,,,,,,,,,
20786,,active covid-19 infection,,,,,,,,,,,,,,,,
20787,,months)|acute pulmonary embolism,,,,,,,,,,,,,,,,
20788,,musculoskeletal symptoms,,,,,,,,,,,,,,,,
20789,,immunosuppressive disease.||known severe,,,,,,,,,,,,,,,,
20790,,oral habits.|children,,,,,,,,,,,,,,,,
20791,,"suicidal ideation),|at least 16 years",,,,,,,,,,,,,,,,
20792,,hematoma,,,,,,,,,,,,,,,,
20793,,congenital diaphragmatic hernia,,,,,,,,,,,,,,,,
20794,,symptoms suggesting pancreatitis,,,,,,,,,,,,,,,,
20795,,lipodystrophic syndromes (hiv etc,,,,,,,,,,,,,,,,
20796,,been amenorrhoeic,,,,,,,,,,,,,,,,
20797,,trehalose dihydrate,,,,,,,,,,,,,,,,
20798,,pregnancy cognitive dysfunction dementia,,,,,,,,,,,,,,,,
20799,,transient abnormal myelopoiesis,,,,,,,,,,,,,,,,
20800,,etc)|medical contraindications,,,,,,,,,,,,,,,,
20801,,visceral abscesses,,,,,,,,,,,,,,,,
20802,,antidiabetic drugs.|treatment,,,,,,,,,,,,,,,,
20803,,chronic peptic disorders,,,,,,,,,,,,,,,,
20804,,liver transplantation;|active,,,,,,,,,,,,,,,,
20805,,sinonasal,,,,,,,,,,,,,,,,
20806,,lower gastrointestinal symptoms,,,,,,,,,,,,,,,,
20807,,intestinal villous atrophy,,,,,,,,,,,,,,,,
20808,,depressed skull fracture,,,,,,,,,,,,,,,,
20809,,adhesive disease,,,,,,,,,,,,,,,,
20810,,transformation;|bilateral stroke,,,,,,,,,,,,,,,,
20811,,difficulty understanding the protocol,,,,,,,,,,,,,,,,
20812,,dyspnea symptoms,,,,,,,,,,,,,,,,
20813,,communication disorders,,,,,,,,,,,,,,,,
20814,,fibrosis stage,,,,,,,,,,,,,,,,
20815,,non-metastatic,,,,,,,,,,,,,,,,
20816,,focal brain lesion,,,,,,,,,,,,,,,,
20817,,study.||non aiddes healthy controls||-inclusion criteria,,,,,,,,,,,,,,,,
20818,,treatment resistance|eligibility,,,,,,,,,,,,,,,,
20819,,heparin-induced,,,,,,,,,,,,,,,,
20820,,enteropathies.|selective iga deficiency,,,,,,,,,,,,,,,,
20821,,head trauma resulting in loss of consciousness,,,,,,,,,,,,,,,,
20822,,chest deformities|patient,,,,,,,,,,,,,,,,
20823,,painful stimulus,,,,,,,,,,,,,,,,
20824,,humanized antibodies,,,,,,,,,,,,,,,,
20825,,hepatitis b virus surface antigen (hbsag),,,,,,,,,,,,,,,,
20826,,neoplastic fever,,,,,,,,,,,,,,,,
20827,,details|patients,,,,,,,,,,,,,,,,
20828,,pathology of keratinizing squamous cells,,,,,,,,,,,,,,,,
20829,,hypertensive encephalopathy|severe,,,,,,,,,,,,,,,,
20830,,hemodynamic conditions,,,,,,,,,,,,,,,,
20831,,hfmref,,,,,,,,,,,,,,,,
20832,,limitations,,,,,,,,,,,,,,,,
20833,,arrhythmia left ventricle ejection fractions,,,,,,,,,,,,,,,,
20834,,recovery.|lack of,,,,,,,,,,,,,,,,
20835,,first,,,,,,,,,,,,,,,,
20836,,corticosteroids|symptomatic,,,,,,,,,,,,,,,,
20837,,acute conditions.|post cellulitis,,,,,,,,,,,,,,,,
20838,,sleeping disorder,,,,,,,,,,,,,,,,
20839,,fractures|prosthetic fracture,,,,,,,,,,,,,,,,
20840,,hepatic function,,,,,,,,,,,,,,,,
20841,,vagus nerve stimulator,,,,,,,,,,,,,,,,
20842,,inflammatory arthritis condition|collagen,,,,,,,,,,,,,,,,
20843,,alcohol use.|participants,,,,,,,,,,,,,,,,
20844,,active hemorrhage,,,,,,,,,,,,,,,,
20845,,congenital cystic,,,,,,,,,,,,,,,,
20846,,communication of informed consent,,,,,,,,,,,,,,,,
20847,,lower limb fragility fractures,,,,,,,,,,,,,,,,
20848,,atrial ventricular block|cardiogenic,,,,,,,,,,,,,,,,
20849,,superficial lymph nodes,,,,,,,,,,,,,,,,
20850,,non-invasive method,,,,,,,,,,,,,,,,
20851,,tympani membrane perforation,,,,,,,,,,,,,,,,
20852,,etc.).|guillain-barre syndrome,,,,,,,,,,,,,,,,
20853,,primary pulmonary hypertension|lt,,,,,,,,,,,,,,,,
20854,,urge urinary incontinence.|associated,,,,,,,,,,,,,,,,
20855,,daytime frequency,,,,,,,,,,,,,,,,
20856,,superficial temporal,,,,,,,,,,,,,,,,
20857,,mitochondrial disease,,,,,,,,,,,,,,,,
20858,,good overall health,,,,,,,,,,,,,,,,
20859,,anosmia.|major depression,,,,,,,,,,,,,,,,
20860,,hepatotoxicity,,,,,,,,,,,,,,,,
20861,,trevicta,,,,,,,,,,,,,,,,
20862,,type 9 (pcsk9),,,,,,,,,,,,,,,,
20863,,oocyte retrieved|patients,,,,,,,,,,,,,,,,
20864,,recurrent headaches,,,,,,,,,,,,,,,,
20865,,apri,,,,,,,,,,,,,,,,
20866,,end-stage renal disease|patients,,,,,,,,,,,,,,,,
20867,,cervical in situ cancer,,,,,,,,,,,,,,,,
20868,,paranoid、antisocial personality disorder,,,,,,,,,,,,,,,,
20869,,fluorescence in situ hybridization [fish] amplified,,,,,,,,,,,,,,,,
20870,,iv;|refractory hypertension,,,,,,,,,,,,,,,,
20871,,muscle injuries,,,,,,,,,,,,,,,,
20872,,corrected vision,,,,,,,,,,,,,,,,
20873,,human t-lymphotropic virus (htlv),,,,,,,,,,,,,,,,
20874,,hereditary bleeding tendency,,,,,,,,,,,,,,,,
20875,,former,,,,,,,,,,,,,,,,
20876,,disturbances of consciousness,,,,,,,,,,,,,,,,
20877,,paroxysmal nocturnal hemoglobinuria).|creatinine,,,,,,,,,,,,,,,,
20878,,with:||mastitis|granulomatous mastitis|breast fillers,,,,,,,,,,,,,,,,
20879,,end-stage hepatic,,,,,,,,,,,,,,,,
20880,,muscle disorders,,,,,,,,,,,,,,,,
20881,,extracorporeal sepsis,,,,,,,,,,,,,,,,
20882,,focal cervical dystonia,,,,,,,,,,,,,,,,
20883,,odynophagia,,,,,,,,,,,,,,,,
20884,,use|liver cirrhosis,,,,,,,,,,,,,,,,
20885,,gsw,,,,,,,,,,,,,,,,
20886,,acute pain site of chest,,,,,,,,,,,,,,,,
20887,,hospitalization.|use,,,,,,,,,,,,,,,,
20888,,neurological complications|complications,,,,,,,,,,,,,,,,
20889,,cerebellar oculomotor abnormalities,,,,,,,,,,,,,,,,
20890,,core,,,,,,,,,,,,,,,,
20891,,typhus,,,,,,,,,,,,,,,,
20892,,singleton gestation,,,,,,,,,,,,,,,,
20893,,active cancer,,,,,,,,,,,,,,,,
20894,,tinnitus distress,,,,,,,,,,,,,,,,
20895,,chronic respiratory diseases,,,,,,,,,,,,,,,,
20896,,cns leukemia,,,,,,,,,,,,,,,,
20897,,morphological changes,,,,,,,,,,,,,,,,
20898,,postoperative distal metastasis,,,,,,,,,,,,,,,,
20899,,neurodevelopmental,,,,,,,,,,,,,,,,
20900,,seborrheic,,,,,,,,,,,,,,,,
20901,,immunodeficiency etc.).|no,,,,,,,,,,,,,,,,
20902,,rheumatic heart disease;|mechanic tricuspid valve patients;|patients,,,,,,,,,,,,,,,,
20903,,mngie disease,,,,,,,,,,,,,,,,
20904,,controlled hypertension,,,,,,,,,,,,,,,,
20905,,cashew,,,,,,,,,,,,,,,,
20906,,american|diagnosis,,,,,,,,,,,,,,,,
20907,,pregnancy plan,,,,,,,,,,,,,,,,
20908,,unresectable tumors,,,,,,,,,,,,,,,,
20909,,psychiatric disorder condition,,,,,,,,,,,,,,,,
20910,,xifo-pubic incision,,,,,,,,,,,,,,,,
20911,,systemic allergy,,,,,,,,,,,,,,,,
20912,,solid organ transplantation.|history of other malignancy,,,,,,,,,,,,,,,,
20913,,migraine,,,,,,,,,,,,,,,,
20914,,cocoa intolerance,,,,,,,,,,,,,,,,
20915,,endocrine system lesions,,,,,,,,,,,,,,,,
20916,,cognitive dysfunction|diseases,,,,,,,,,,,,,,,,
20917,,pleural effusion,,,,,,,,,,,,,,,,
20918,,proximal lobar pulmonary artery|classification of intermediate high-risk pe,,,,,,,,,,,,,,,,
20919,,homicidal ideation,,,,,,,,,,,,,,,,
20920,,bone marrow,,,,,,,,,,,,,,,,
20921,,retinal tear,,,,,,,,,,,,,,,,
20922,,abuse;|pregnant,,,,,,,,,,,,,,,,
20923,,decompressive craniectomy,,,,,,,,,,,,,,,,
20924,,eatl).|hepatosplenic t-cell lymphoma,,,,,,,,,,,,,,,,
20925,,acute myocardial infarction|pacemaker,,,,,,,,,,,,,,,,
20926,,carpal tunnel syndrome,,,,,,,,,,,,,,,,
20927,,thrombocytopenia.|documented bacteremia,,,,,,,,,,,,,,,,
20928,,deleterious effects,,,,,,,,,,,,,,,,
20929,,cancerous involvement.|patients,,,,,,,,,,,,,,,,
20930,,primary immunodeficiency syndromes,,,,,,,,,,,,,,,,
20931,,inflammatory bowel disease||no personal,,,,,,,,,,,,,,,,
20932,,right hand.|ak lesions,,,,,,,,,,,,,,,,
20933,,infection|pregnancy,,,,,,,,,,,,,,,,
20934,,blood disorders,,,,,,,,,,,,,,,,
20935,,calories,,,,,,,,,,,,,,,,
20936,,sitting systolic,,,,,,,,,,,,,,,,
20937,,right ventricular cardiomyopathy,,,,,,,,,,,,,,,,
20938,,middle ears,,,,,,,,,,,,,,,,
20939,,related pathology,,,,,,,,,,,,,,,,
20940,,ia||sex,,,,,,,,,,,,,,,,
20941,,co-administered vaccines,,,,,,,,,,,,,,,,
20942,,head and neck surgery,,,,,,,,,,,,,,,,
20943,,mild depressive symptoms,,,,,,,,,,,,,,,,
20944,,alcohol-containing beverages,,,,,,,,,,,,,,,,
20945,,kidney transplantation.|patients,,,,,,,,,,,,,,,,
20946,,metabolic dysfunction)|or,,,,,,,,,,,,,,,,
20947,,isotope,,,,,,,,,,,,,,,,
20948,,treated,,,,,,,,,,,,,,,,
20949,,restricted diffusion,,,,,,,,,,,,,,,,
20950,,hence influence deviations from standard acute care,,,,,,,,,,,,,,,,
20951,,surgical removal,,,,,,,,,,,,,,,,
20952,,sinonasal tumors,,,,,,,,,,,,,,,,
20953,,recurring infection(s,,,,,,,,,,,,,,,,
20954,,cognitive sequelae,,,,,,,,,,,,,,,,
20955,,pain disturbances,,,,,,,,,,,,,,,,
20956,,uterine cavity.||,,,,,,,,,,,,,,,,
20957,,renal conditions,,,,,,,,,,,,,,,,
20958,,striae,,,,,,,,,,,,,,,,
20959,,cerebellar deficits|any other,,,,,,,,,,,,,,,,
20960,,stenosis,,,,,,,,,,,,,,,,
20961,,uti,,,,,,,,,,,,,,,,
20962,,physical activity contraindications,,,,,,,,,,,,,,,,
20963,,left flank areas,,,,,,,,,,,,,,,,
20964,,digestive diseases,,,,,,,,,,,,,,,,
20965,,"auditory impairment,|current",,,,,,,,,,,,,,,,
20966,,treatment|acute infection,,,,,,,,,,,,,,,,
20967,,speech impairments,,,,,,,,,,,,,,,,
20968,,acute upper airway upper infection,,,,,,,,,,,,,,,,
20969,,cause|hiv-infection,,,,,,,,,,,,,,,,
20970,,mania,,,,,,,,,,,,,,,,
20971,,partial androgen insensitivity syndrome,,,,,,,,,,,,,,,,
20972,,keratinizing squamous cell carcinoma,,,,,,,,,,,,,,,,
20973,,chronic systemic diseases,,,,,,,,,,,,,,,,
20974,,primary biliary cirrhosis,,,,,,,,,,,,,,,,
20975,,"above),|male",,,,,,,,,,,,,,,,
20976,,valvular disease,,,,,,,,,,,,,,,,
20977,,acl injury,,,,,,,,,,,,,,,,
20978,,light penetration,,,,,,,,,,,,,,,,
20979,,paranoid disorder,,,,,,,,,,,,,,,,
20980,,drug sensitivity,,,,,,,,,,,,,,,,
20981,,complex congenital heart disease,,,,,,,,,,,,,,,,
20982,,hydrolic,,,,,,,,,,,,,,,,
20983,,autoimmune,,,,,,,,,,,,,,,,
20984,,microbial keratitis,,,,,,,,,,,,,,,,
20985,,painful limit,,,,,,,,,,,,,,,,
20986,,gastrointestinal (gi) issue of the upper gi tract,,,,,,,,,,,,,,,,
20987,,climbing stairs,,,,,,,,,,,,,,,,
20988,,nasopharyngeal carcinoma,,,,,,,,,,,,,,,,
20989,,rarely,,,,,,,,,,,,,,,,
20990,,pain assessment|allergy,,,,,,,,,,,,,,,,
20991,,continuous supplemental oxygen|evidence of,,,,,,,,,,,,,,,,
20992,,previous burns,,,,,,,,,,,,,,,,
20993,,asymptomatic coronary artery,,,,,,,,,,,,,,,,
20994,,qtc,,,,,,,,,,,,,,,,
20995,,acute complications||,,,,,,,,,,,,,,,,
20996,,named party,,,,,,,,,,,,,,,,
20997,,local skin cancer,,,,,,,,,,,,,,,,
20998,,cerebrovascular diseases;|gastrointestinal perforation,,,,,,,,,,,,,,,,
20999,,uc|coeliac disease,,,,,,,,,,,,,,,,
21000,,botox,,,,,,,,,,,,,,,,
21001,,recovery|associated,,,,,,,,,,,,,,,,
21002,,neuroendocrine carcinoma,,,,,,,,,,,,,,,,
21003,,pigmentary disorders,,,,,,,,,,,,,,,,
21004,,bladder,,,,,,,,,,,,,,,,
21005,,anisometropia,,,,,,,,,,,,,,,,
21006,,homosexual,,,,,,,,,,,,,,,,
21007,,mixed psychosis,,,,,,,,,,,,,,,,
21008,,difficulty collecting normal,,,,,,,,,,,,,,,,
21009,,coagulopathy|abnormal blood,,,,,,,,,,,,,,,,
21010,,epilepsy recurrence|overdose,,,,,,,,,,,,,,,,
21011,,intentional,,,,,,,,,,,,,,,,
21012,,biosimilar versions thereof,,,,,,,,,,,,,,,,
21013,,"arrest,|stroke,|comfort measures only,|unable",,,,,,,,,,,,,,,,
21014,,"acute penetrating, puncture",,,,,,,,,,,,,,,,
21015,,clinical infection,,,,,,,,,,,,,,,,
21016,,lower limb function|osteonecrosis,,,,,,,,,,,,,,,,
21017,,electrolyte eudract#,,,,,,,,,,,,,,,,
21018,,muscle stimulation,,,,,,,,,,,,,,,,
21019,,impaired renal function,,,,,,,,,,,,,,,,
21020,,spinal disorders,,,,,,,,,,,,,,,,
21021,,not clear,,,,,,,,,,,,,,,,
21022,,acute infections,,,,,,,,,,,,,,,,
21023,,delirium,,,,,,,,,,,,,,,,
21024,,panic attack,,,,,,,,,,,,,,,,
21025,,csle,,,,,,,,,,,,,,,,
21026,,chronic bronchitis;|patients,,,,,,,,,,,,,,,,
21027,,non-fluent aphasia,,,,,,,,,,,,,,,,
21028,,candidate for rts segmentectomy,,,,,,,,,,,,,,,,
21029,,persistent asthma,,,,,,,,,,,,,,,,
21030,,hematologic system disorders,,,,,,,,,,,,,,,,
21031,,traumatic injuries,,,,,,,,,,,,,,,,
21032,,alcohol abuse|is using,,,,,,,,,,,,,,,,
21033,,catatonic symptoms,,,,,,,,,,,,,,,,
21034,,nascet,,,,,,,,,,,,,,,,
21035,,cerebrovascular diseases;|any condition,,,,,,,,,,,,,,,,
21036,,non-squamous nsclc|presence,,,,,,,,,,,,,,,,
21037,,acute febrile illness,,,,,,,,,,,,,,,,
21038,,wheezing,,,,,,,,,,,,,,,,
21039,,orthopedic conditions,,,,,,,,,,,,,,,,
21040,,"muscle atrophy,|hypothyroidism,|known",,,,,,,,,,,,,,,,
21041,,benign prostate disease,,,,,,,,,,,,,,,,
21042,,cerebral ischemic seizure,,,,,,,,,,,,,,,,
21043,,acute sports,,,,,,,,,,,,,,,,
21044,,shoulder pain,,,,,,,,,,,,,,,,
21045,,t1|regular smoking,,,,,,,,,,,,,,,,
21046,,histopathological type,,,,,,,,,,,,,,,,
21047,,antifungal treatment.|known,,,,,,,,,,,,,,,,
21048,,gastric ulcer,,,,,,,,,,,,,,,,
21049,,myocardial infarction.|uncontrolled hypertension,,,,,,,,,,,,,,,,
21050,,hepatic impairment,,,,,,,,,,,,,,,,
21051,,her2 negativity.||willingness,,,,,,,,,,,,,,,,
21052,,past hbv infection,,,,,,,,,,,,,,,,
21053,,nonprogressive disease,,,,,,,,,,,,,,,,
21054,,impact on quality of life are,,,,,,,,,,,,,,,,
21055,,somatic symptoms,,,,,,,,,,,,,,,,
21056,,imidazoles,,,,,,,,,,,,,,,,
21057,,respiratory conditions,,,,,,,,,,,,,,,,
21058,,surgery.|prior glaucoma surgery.|pseudoexfoliation,,,,,,,,,,,,,,,,
21059,,erythromycin]);|significant traumatic injury,,,,,,,,,,,,,,,,
21060,,eosinophilic gastritis,,,,,,,,,,,,,,,,
21061,,judged by the investigator or sub investigator to be inappropriate to participate in this study for,,,,,,,,,,,,,,,,
21062,,acute kidney injury.|evidence,,,,,,,,,,,,,,,,
21063,,paranasal sinusitis,,,,,,,,,,,,,,,,
21064,,radio- opaque renal stone,,,,,,,,,,,,,,,,
21065,,aml|no known,,,,,,,,,,,,,,,,
21066,,months.|serious infection,,,,,,,,,,,,,,,,
21067,,psychiatric limitations;|chronic degenerative inflammatory,,,,,,,,,,,,,,,,
21068,,thereof.|sleep apnea,,,,,,,,,,,,,,,,
21069,,chest syndrome,,,,,,,,,,,,,,,,
21070,,altered renal function,,,,,,,,,,,,,,,,
21071,,homeostasis,,,,,,,,,,,,,,,,
21072,,allergic rhinitis,,,,,,,,,,,,,,,,
21073,,simple colitis clinical,,,,,,,,,,,,,,,,
21074,,hiv|history of organ,,,,,,,,,,,,,,,,
21075,,visual impairments,,,,,,,,,,,,,,,,
21076,,months.||healthy participants||healthy,,,,,,,,,,,,,,,,
21077,,teratogenic effects,,,,,,,,,,,,,,,,
21078,,gi disease|selective,,,,,,,,,,,,,,,,
21079,,systemic therapy.|breast cancer,,,,,,,,,,,,,,,,
21080,,women.|heavy smokers,,,,,,,,,,,,,,,,
21081,,gastrointestinal cancer|being,,,,,,,,,,,,,,,,
21082,,auxiliary nurses,,,,,,,,,,,,,,,,
21083,,hbsag negative||,,,,,,,,,,,,,,,,
21084,,non-invasive lesion,,,,,,,,,,,,,,,,
21085,,suicidal tendency,,,,,,,,,,,,,,,,
21086,,norms|dr,,,,,,,,,,,,,,,,
21087,,waldenström macroglobulinemia[wm,,,,,,,,,,,,,,,,
21088,,af episodes,,,,,,,,,,,,,,,,
21089,,degenerative pulp conditions,,,,,,,,,,,,,,,,
21090,,exclusion factor for study participation,,,,,,,,,,,,,,,,
21091,,chest x-ray,,,,,,,,,,,,,,,,
21092,,persistent hypoglycemia,,,,,,,,,,,,,,,,
21093,,poor compensation,,,,,,,,,,,,,,,,
21094,,intervene,,,,,,,,,,,,,,,,
21095,,serous retinopathy,,,,,,,,,,,,,,,,
21096,,memory impairment,,,,,,,,,,,,,,,,
21097,,performance;|ventilator dependence,,,,,,,,,,,,,,,,
21098,,trembling,,,,,,,,,,,,,,,,
21099,,metabolic diseases|incomplete records,,,,,,,,,,,,,,,,
21100,,malformations,,,,,,,,,,,,,,,,
21101,,acute ischemic stroke,,,,,,,,,,,,,,,,
21102,,alcohol-containing,,,,,,,,,,,,,,,,
21103,,paraesthesia,,,,,,,,,,,,,,,,
21104,,third transaminase,,,,,,,,,,,,,,,,
21105,,conditions apply:||hiv infection,,,,,,,,,,,,,,,,
21106,,transfusion reactions,,,,,,,,,,,,,,,,
21107,,iron preparations,,,,,,,,,,,,,,,,
21108,,equivalent|refusal,,,,,,,,,,,,,,,,
21109,,females.|smokers.|systemic disease,,,,,,,,,,,,,,,,
21110,,monogenic cardiovascular diseases,,,,,,,,,,,,,,,,
21111,,normal organ function,,,,,,,,,,,,,,,,
21112,,traumatic event,,,,,,,,,,,,,,,,
21113,,fluorescence in situ hybridization,,,,,,,,,,,,,,,,
21114,,hypoalbuminemia,,,,,,,,,,,,,,,,
21115,,heterosexual activity,,,,,,,,,,,,,,,,
21116,,tract related operations,,,,,,,,,,,,,,,,
21117,,older|measurable disease,,,,,,,,,,,,,,,,
21118,,kidney dysfunction|patients,,,,,,,,,,,,,,,,
21119,,skin eczema,,,,,,,,,,,,,,,,
21120,,oncogenic ret mutations,,,,,,,,,,,,,,,,
21121,,retinal migraine,,,,,,,,,,,,,,,,
21122,,autoimmune diseases.|patients,,,,,,,,,,,,,,,,
21123,,joint,,,,,,,,,,,,,,,,
21124,,temporomandibular joint disorders,,,,,,,,,,,,,,,,
21125,,chronic osteomyelitis,,,,,,,,,,,,,,,,
21126,,stable autoimmune diseases,,,,,,,,,,,,,,,,
21127,,systemic hormones,,,,,,,,,,,,,,,,
21128,,chronic illness.|spine,,,,,,,,,,,,,,,,
21129,,old.|high myopia,,,,,,,,,,,,,,,,
21130,,seborrheic blepharitis)|have eyelid abnormalities,,,,,,,,,,,,,,,,
21131,,chronic lung disease of prematurity,,,,,,,,,,,,,,,,
21132,,resection cavities,,,,,,,,,,,,,,,,
21133,,oligometastatic prostate cancer,,,,,,,,,,,,,,,,
21134,,ulcerative disease|treatment,,,,,,,,,,,,,,,,
21135,,rosacea,,,,,,,,,,,,,,,,
21136,,acute cardiac inflammation;|allergic,,,,,,,,,,,,,,,,
21137,,congestive heart failure.|unstable angina,,,,,,,,,,,,,,,,
21138,,compliance problems,,,,,,,,,,,,,,,,
21139,,professional athletes,,,,,,,,,,,,,,,,
21140,,trisomies,,,,,,,,,,,,,,,,
21141,,transient tachypnoea,,,,,,,,,,,,,,,,
21142,,oxygen,,,,,,,,,,,,,,,,
21143,,cerebellar disease,,,,,,,,,,,,,,,,
21144,,breast cancer;||,,,,,,,,,,,,,,,,
21145,,acute cholecystitis treated,,,,,,,,,,,,,,,,
21146,,lewy bodies (dlb).|cvd,,,,,,,,,,,,,,,,
21147,,septic arthritis,,,,,,,,,,,,,,,,
21148,,behavioral tasks|absolute contraindication,,,,,,,,,,,,,,,,
21149,,trying to get pregnant,,,,,,,,,,,,,,,,
21150,,left portal main branches,,,,,,,,,,,,,,,,
21151,,follows:||in situ carcinoma,,,,,,,,,,,,,,,,
21152,,ambulatory units,,,,,,,,,,,,,,,,
21153,,liver disease.|active,,,,,,,,,,,,,,,,
21154,,tuberculosis infections,,,,,,,,,,,,,,,,
21155,,healthy european,,,,,,,,,,,,,,,,
21156,,mild sleep apnea,,,,,,,,,,,,,,,,
21157,,dka,,,,,,,,,,,,,,,,
21158,,hiv infection|pregnant,,,,,,,,,,,,,,,,
21159,,baby||,,,,,,,,,,,,,,,,
21160,,complex atherosclerotic lesion,,,,,,,,,,,,,,,,
21161,,catastrophizing,,,,,,,,,,,,,,,,
21162,,acute ischemic stroke|unable,,,,,,,,,,,,,,,,
21163,,acutely suicidal,,,,,,,,,,,,,,,,
21164,,auditory neuropathy.|additional health factors,,,,,,,,,,,,,,,,
21165,,r knee osteoarthritis,,,,,,,,,,,,,,,,
21166,,access,,,,,,,,,,,,,,,,
21167,,bipolar unspecified,,,,,,,,,,,,,,,,
21168,,soft tissue infection overlying,,,,,,,,,,,,,,,,
21169,,chronic illness therapy (facit) cough item,,,,,,,,,,,,,,,,
21170,,pulmonary atresia,,,,,,,,,,,,,,,,
21171,,stroke events,,,,,,,,,,,,,,,,
21172,,vaginal delivery)||,,,,,,,,,,,,,,,,
21173,,hcv ribonucleic acid,,,,,,,,,,,,,,,,
21174,,aortic stenosis)|pulmonary hypertension||iii,,,,,,,,,,,,,,,,
21175,,hypothyroidism|any disorder,,,,,,,,,,,,,,,,
21176,,lactation.|uncontrolled diabetes,,,,,,,,,,,,,,,,
21177,,hemorrhagic disease,,,,,,,,,,,,,,,,
21178,,lumbar spine surgery,,,,,,,,,,,,,,,,
21179,,intraabdominal injuries,,,,,,,,,,,,,,,,
21180,,excessive drinking;|allergy,,,,,,,,,,,,,,,,
21181,,aica,,,,,,,,,,,,,,,,
21182,,thrombocytopenic purpura,,,,,,,,,,,,,,,,
21183,,penetrating fistula(e,,,,,,,,,,,,,,,,
21184,,resides in san diego county,,,,,,,,,,,,,,,,
21185,,congenital deficiency,,,,,,,,,,,,,,,,
21186,,failure|electrolyte abnormalities,,,,,,,,,,,,,,,,
21187,,central pathology review,,,,,,,,,,,,,,,,
21188,,chronic rhinitis,,,,,,,,,,,,,,,,
21189,,rv pacing burden,,,,,,,,,,,,,,,,
21190,,institutionalization,,,,,,,,,,,,,,,,
21191,,nasal diseases,,,,,,,,,,,,,,,,
21192,,hearing disorders,,,,,,,,,,,,,,,,
21193,,drug-induced myopathy,,,,,,,,,,,,,,,,
21194,,conditions that could affect gait,,,,,,,,,,,,,,,,
21195,,anterior prolapse,,,,,,,,,,,,,,,,
21196,,orthopedic impairments,,,,,,,,,,,,,,,,
21197,,impairment associated,,,,,,,,,,,,,,,,
21198,,photosensitive migraines,,,,,,,,,,,,,,,,
21199,,bleeding episode,,,,,,,,,,,,,,,,
21200,,mud,,,,,,,,,,,,,,,,
21201,,hypercoagulable condition|baseline study visit,,,,,,,,,,,,,,,,
21202,,subjects):||- obesity,,,,,,,,,,,,,,,,
21203,,blood fainting,,,,,,,,,,,,,,,,
21204,,acceptance,,,,,,,,,,,,,,,,
21205,,discretion,,,,,,,,,,,,,,,,
21206,,adhd medication,,,,,,,,,,,,,,,,
21207,,non-asthma control,,,,,,,,,,,,,,,,
21208,,degenerative spinal,,,,,,,,,,,,,,,,
21209,,disorder|psychosis disorder|pregnant,,,,,,,,,,,,,,,,
21210,,treated carcinoma in situ of the cervix.||have,,,,,,,,,,,,,,,,
21211,,cervical stenosis,,,,,,,,,,,,,,,,
21212,,risk of suicide;|(k,,,,,,,,,,,,,,,,
21213,,women|end stage renal disease,,,,,,,,,,,,,,,,
21214,,primary outcome,,,,,,,,,,,,,,,,
21215,,functional constipation,,,,,,,,,,,,,,,,
21216,,kidney disease;|hypersensitivity,,,,,,,,,,,,,,,,
21217,,functions of the main organs,,,,,,,,,,,,,,,,
21218,,painful,,,,,,,,,,,,,,,,
21219,,cancerous pathology.||,,,,,,,,,,,,,,,,
21220,,extra hepatic spread;|previous,,,,,,,,,,,,,,,,
21221,,authorities,,,,,,,,,,,,,,,,
21222,,arterial embolism,,,,,,,,,,,,,,,,
21223,,metastases of,,,,,,,,,,,,,,,,
21224,,sensitive mutation,,,,,,,,,,,,,,,,
21225,,systemic antitumor therapy,,,,,,,,,,,,,,,,
21226,,t2-4a,,,,,,,,,,,,,,,,
21227,,primary biliary,,,,,,,,,,,,,,,,
21228,,"von willebrand factor activity, antigen and factor 8",,,,,,,,,,,,,,,,
21229,,hepatocellular injury,,,,,,,,,,,,,,,,
21230,,functional heart disease,,,,,,,,,,,,,,,,
21231,,tumour lesions,,,,,,,,,,,,,,,,
21232,,active polypoidal lesions,,,,,,,,,,,,,,,,
21233,,wash cloth,,,,,,,,,,,,,,,,
21234,,megacolon|persisting maternal tachycardia,,,,,,,,,,,,,,,,
21235,,resting symptoms,,,,,,,,,,,,,,,,
21236,,invasive pelvic malignancy,,,,,,,,,,,,,,,,
21237,,neurotrophism 5v,,,,,,,,,,,,,,,,
21238,,acute coronary heart disease|previous,,,,,,,,,,,,,,,,
21239,,psychic disorders,,,,,,,,,,,,,,,,
21240,,extracapsular extension|prior prostate surgery|prior,,,,,,,,,,,,,,,,
21241,,risk multiple myeloma,,,,,,,,,,,,,,,,
21242,,sinus sequestration,,,,,,,,,,,,,,,,
21243,,cftr,,,,,,,,,,,,,,,,
21244,,weight-loss medications,,,,,,,,,,,,,,,,
21245,,multi-dermatomal herpes zoster,,,,,,,,,,,,,,,,
21246,,intracranial neoplasm,,,,,,,,,,,,,,,,
21247,,ten,,,,,,,,,,,,,,,,
21248,,corneal dermoid tumor,,,,,,,,,,,,,,,,
21249,,blood glucose,,,,,,,,,,,,,,,,
21250,,binocular functions|medication,,,,,,,,,,,,,,,,
21251,,arteriovenous thrombolysis,,,,,,,,,,,,,,,,
21252,,clinical researchers,,,,,,,,,,,,,,,,
21253,,primary liver,,,,,,,,,,,,,,,,
21254,,brain tissue compression;|the subject,,,,,,,,,,,,,,,,
21255,,transient ischemia,,,,,,,,,,,,,,,,
21256,,local clinical practice||,,,,,,,,,,,,,,,,
21257,,intramuscular injection|myocardial infarction,,,,,,,,,,,,,,,,
21258,,singleton pregnancies.||cephalic presentation,,,,,,,,,,,,,,,,
21259,,post-acute sequelae,,,,,,,,,,,,,,,,
21260,,pancreatic duct stenosis,,,,,,,,,,,,,,,,
21261,,"drug treatment,|endometriotic lesion",,,,,,,,,,,,,,,,
21262,,stroke;|history of congestive heart failure;|preoperative nt-probnp,,,,,,,,,,,,,,,,
21263,,fibromas,,,,,,,,,,,,,,,,
21264,,histological subtype,,,,,,,,,,,,,,,,
21265,,eating habits,,,,,,,,,,,,,,,,
21266,,impaired lung function|subjects,,,,,,,,,,,,,,,,
21267,,aortic stenosis|use of,,,,,,,,,,,,,,,,
21268,,learning disability|no,,,,,,,,,,,,,,,,
21269,,parkinson's dementia,,,,,,,,,,,,,,,,
21270,,malignant disease(s,,,,,,,,,,,,,,,,
21271,,comorbid pulmonary diseases,,,,,,,,,,,,,,,,
21272,,non-colonic ibd|children,,,,,,,,,,,,,,,,
21273,,colon cancer syndrome,,,,,,,,,,,,,,,,
21274,,lower limb lymphedema,,,,,,,,,,,,,,,,
21275,,≤12|acute ischemic stroke,,,,,,,,,,,,,,,,
21276,,icf)|pregnant,,,,,,,,,,,,,,,,
21277,,covid)-19 infection,,,,,,,,,,,,,,,,
21278,,unstably controlled hypertension,,,,,,,,,,,,,,,,
21279,,vabp,,,,,,,,,,,,,,,,
21280,,1）comorbidity,,,,,,,,,,,,,,,,
21281,,parental karyotype,,,,,,,,,,,,,,,,
21282,,"disease|hypertension,|musculoskeletal injuries",,,,,,,,,,,,,,,,
21283,,autoimmune hemolytic,,,,,,,,,,,,,,,,
21284,,type 1 diabetes|inability,,,,,,,,,,,,,,,,
21285,,non-contrast enhancing tumor areas suggesting,,,,,,,,,,,,,,,,
21286,,skin cancers;|metastatic scc,,,,,,,,,,,,,,,,
21287,,blood coagulation dysfunction,,,,,,,,,,,,,,,,
21288,,malignant solid tumors|cytopenia,,,,,,,,,,,,,,,,
21289,,congenial,,,,,,,,,,,,,,,,
21290,,upper respiratory infection,,,,,,,,,,,,,,,,
21291,,circulation,,,,,,,,,,,,,,,,
21292,,difficulty focusing,,,,,,,,,,,,,,,,
21293,,ionisation radiation,,,,,,,,,,,,,,,,
21294,,criteria of copd,,,,,,,,,,,,,,,,
21295,,sentinel attack,,,,,,,,,,,,,,,,
21296,,homozygotes,,,,,,,,,,,,,,,,
21297,,replacement therapy|stable diabetes mellitus,,,,,,,,,,,,,,,,
21298,,neurodevelopmental difficulties,,,,,,,,,,,,,,,,
21299,,multiple dental implants,,,,,,,,,,,,,,,,
21300,,extracardiac disease,,,,,,,,,,,,,,,,
21301,,collapse,,,,,,,,,,,,,,,,
21302,,transplantation|pregnant,,,,,,,,,,,,,,,,
21303,,anesthesia|lack of response,,,,,,,,,,,,,,,,
21304,,surgery.|inconcomitant exotropia.|incomitance,,,,,,,,,,,,,,,,
21305,,sepsis-3|traumatic,,,,,,,,,,,,,,,,
21306,,skin bagcer,,,,,,,,,,,,,,,,
21307,,classrooms,,,,,,,,,,,,,,,,
21308,,cognitive functions,,,,,,,,,,,,,,,,
21309,,myasthenia,,,,,,,,,,,,,,,,
21310,,menstrual period.||pregnancy,,,,,,,,,,,,,,,,
21311,,urticaria;|11 pregnant,,,,,,,,,,,,,,,,
21312,,copd|diagnosis,,,,,,,,,,,,,,,,
21313,,pathological findings,,,,,,,,,,,,,,,,
21314,,pelvic floor,,,,,,,,,,,,,,,,
21315,,ileostomies|inflammatory bowel disease|colonic optimization,,,,,,,,,,,,,,,,
21316,,corneal ulcer,,,,,,,,,,,,,,,,
21317,,clear disease,,,,,,,,,,,,,,,,
21318,,hemophiliacs,,,,,,,,,,,,,,,,
21319,,skin infections,,,,,,,,,,,,,,,,
21320,,neuropathic pain,,,,,,,,,,,,,,,,
21321,,eye|fixation threatening,,,,,,,,,,,,,,,,
21322,,study procedures.|controlled,,,,,,,,,,,,,,,,
21323,,mechanical exfoliative treatments,,,,,,,,,,,,,,,,
21324,,acoustic trauma,,,,,,,,,,,,,,,,
21325,,sperm cells,,,,,,,,,,,,,,,,
21326,,consumption of the study supplement,,,,,,,,,,,,,,,,
21327,,vagus nerve stimulation,,,,,,,,,,,,,,,,
21328,,organic psychosis.||6,,,,,,,,,,,,,,,,
21329,,functional disorder.|drug abuse,,,,,,,,,,,,,,,,
21330,,arteritis of the,,,,,,,,,,,,,,,,
21331,,ischemic thromboembolic events,,,,,,,,,,,,,,,,
21332,,multiple pregnancies,,,,,,,,,,,,,,,,
21333,,facial nerve palsy,,,,,,,,,,,,,,,,
21334,,stable mood disorders,,,,,,,,,,,,,,,,
21335,,antigens in donor stool,,,,,,,,,,,,,,,,
21336,,eye|ocular surface disease index (,,,,,,,,,,,,,,,,
21337,,|for normal,,,,,,,,,,,,,,,,
21338,,solid organ transplantation.||patient,,,,,,,,,,,,,,,,
21339,,≥5/µl,,,,,,,,,,,,,,,,
21340,,behavioral issues,,,,,,,,,,,,,,,,
21341,,primary tumors,,,,,,,,,,,,,,,,
21342,,breast feeding|history,,,,,,,,,,,,,,,,
21343,,/or carcinoma in situ after radical resection,,,,,,,,,,,,,,,,
21344,,mental confussion,,,,,,,,,,,,,,,,
21345,,pulmonary shunt|unstable heart disease|serious pulmonary disease|pregnancy,,,,,,,,,,,,,,,,
21346,,mop,,,,,,,,,,,,,,,,
21347,,oesophageal perforation,,,,,,,,,,,,,,,,
21348,,cerebral diseases,,,,,,,,,,,,,,,,
21349,,non-cns lesions,,,,,,,,,,,,,,,,
21350,,cerebral stroke,,,,,,,,,,,,,,,,
21351,,readily accessible,,,,,,,,,,,,,,,,
21352,,craniofacial syndrome,,,,,,,,,,,,,,,,
21353,,visual disturbances,,,,,,,,,,,,,,,,
21354,,psychological disorder,,,,,,,,,,,,,,,,
21355,,etc.)||newborn:||amniotic fluid stained,,,,,,,,,,,,,,,,
21356,,heart rhythm disorders.|pathology,,,,,,,,,,,,,,,,
21357,,orthopaedic injury,,,,,,,,,,,,,,,,
21358,,n3 neck disease,,,,,,,,,,,,,,,,
21359,,criteria)||colon cancer,,,,,,,,,,,,,,,,
21360,,cauda equina syndrome.|pain,,,,,,,,,,,,,,,,
21361,,chronic pain|allergy,,,,,,,,,,,,,,,,
21362,,other cancer from,,,,,,,,,,,,,,,,
21363,,lung,,,,,,,,,,,,,,,,
21364,,skin wounds,,,,,,,,,,,,,,,,
21365,,venous insufficiency,,,,,,,,,,,,,,,,
21366,,respiratory,,,,,,,,,,,,,,,,
21367,,trans,,,,,,,,,,,,,,,,
21368,,functional inability to chew,,,,,,,,,,,,,,,,
21369,,acute dento-alveolar infection,,,,,,,,,,,,,,,,
21370,,unresectable solid cancer,,,,,,,,,,,,,,,,
21371,,hepatic disease,,,,,,,,,,,,,,,,
21372,,platelet aggregation.|participant,,,,,,,,,,,,,,,,
21373,,consensus criteria,,,,,,,,,,,,,,,,
21374,,acute myeloid leukaemia,,,,,,,,,,,,,,,,
21375,,ros1 rearrangements,,,,,,,,,,,,,,,,
21376,,brain metastasis|patients,,,,,,,,,,,,,,,,
21377,,proteolytic enzymes,,,,,,,,,,,,,,,,
21378,,pyp scans,,,,,,,,,,,,,,,,
21379,,readily identifiable,,,,,,,,,,,,,,,,
21380,,orthopedic disease,,,,,,,,,,,,,,,,
21381,,food protein induced enterocolitis,,,,,,,,,,,,,,,,
21382,,agranulocytosis,,,,,,,,,,,,,,,,
21383,,anaemia,,,,,,,,,,,,,,,,
21384,,acute onset focal symptoms matching,,,,,,,,,,,,,,,,
21385,,onset of sudden sensorineural hearing loss|evidence of or previous diagnosis of,,,,,,,,,,,,,,,,
21386,,thyroid dysfunction)||patients,,,,,,,,,,,,,,,,
21387,,neonatal retinopathy,,,,,,,,,,,,,,,,
21388,,ced serology,,,,,,,,,,,,,,,,
21389,,air|liver dysfunction,,,,,,,,,,,,,,,,
21390,,≥1 of,,,,,,,,,,,,,,,,
21391,,15)|acute exacerbation,,,,,,,,,,,,,,,,
21392,,abstain from alcohol consumption,,,,,,,,,,,,,,,,
21393,,poor tolerance,,,,,,,,,,,,,,,,
21394,,neurofeedback,,,,,,,,,,,,,,,,
21395,,common cold,,,,,,,,,,,,,,,,
21396,,permanent teeth,,,,,,,,,,,,,,,,
21397,,atrioventricular block ⅱ~ⅲ degree,,,,,,,,,,,,,,,,
21398,,pupillary defect,,,,,,,,,,,,,,,,
21399,,vulnerable persons,,,,,,,,,,,,,,,,
21400,,familial genetic disease,,,,,,,,,,,,,,,,
21401,,oral hygiene.|patients,,,,,,,,,,,,,,,,
21402,,reduced corneal,,,,,,,,,,,,,,,,
21403,,nodes,,,,,,,,,,,,,,,,
21404,,alcohol dehydrogenase inhibitors (adhs),,,,,,,,,,,,,,,,
21405,,eaton-lambert syndrome,,,,,,,,,,,,,,,,
21406,,care|pregnant,,,,,,,,,,,,,,,,
21407,,systemic diseases.|those,,,,,,,,,,,,,,,,
21408,,renal pelvic stones,,,,,,,,,,,,,,,,
21409,,primary symptomatic,,,,,,,,,,,,,,,,
21410,,spastic paraplegia type 2,,,,,,,,,,,,,,,,
21411,,cervical radiculopathy,,,,,,,,,,,,,,,,
21412,,trying to become pregnant,,,,,,,,,,,,,,,,
21413,,amyotrophic lateral sclerosis.||cervical spine fracture,,,,,,,,,,,,,,,,
21414,,carcinomatous meningitis,,,,,,,,,,,,,,,,
21415,,unstable angina,,,,,,,,,,,,,,,,
21416,,muscle disability,,,,,,,,,,,,,,,,
21417,,subclinical hyperthyroidism,,,,,,,,,,,,,,,,
21418,,anatomical deformity,,,,,,,,,,,,,,,,
21419,,necessity,,,,,,,,,,,,,,,,
21420,,mental diseases,,,,,,,,,,,,,,,,
21421,,health condition,,,,,,,,,,,,,,,,
21422,,shorter);|serious infection,,,,,,,,,,,,,,,,
21423,,intraarticular fractures,,,,,,,,,,,,,,,,
21424,,osteoarthritis disease,,,,,,,,,,,,,,,,
21425,,"bleeding disorders,|did",,,,,,,,,,,,,,,,
21426,,nstemi event,,,,,,,,,,,,,,,,
21427,,disc lesion,,,,,,,,,,,,,,,,
21428,,progress from the oral lead-in phase,,,,,,,,,,,,,,,,
21429,,cardiac rhythm regulators,,,,,,,,,,,,,,,,
21430,,acute changes,,,,,,,,,,,,,,,,
21431,,preserved reproductive potential,,,,,,,,,,,,,,,,
21432,,underming wound,,,,,,,,,,,,,,,,
21433,,thoracic surgery|t1n1,,,,,,,,,,,,,,,,
21434,,covid-19 human immunoglobulin,,,,,,,,,,,,,,,,
21435,,cisgender identity,,,,,,,,,,,,,,,,
21436,,functional gastrointestinal disorder,,,,,,,,,,,,,,,,
21437,,wound,,,,,,,,,,,,,,,,
21438,,cyp1a1-inhibitors,,,,,,,,,,,,,,,,
21439,,controls);|mental illness,,,,,,,,,,,,,,,,
21440,,liver impairment)|cancer,,,,,,,,,,,,,,,,
21441,,pain perception|hemorrhagic conditions|septic conditions,,,,,,,,,,,,,,,,
21442,,peritoneum metastasis,,,,,,,,,,,,,,,,
21443,,healthcare,,,,,,,,,,,,,,,,
21444,,hct,,,,,,,,,,,,,,,,
21445,,valvular regurgitation,,,,,,,,,,,,,,,,
21446,,major liver disease,,,,,,,,,,,,,,,,
21447,,oliguric renal impairment,,,,,,,,,,,,,,,,
21448,,mixed phenotypic acute leukemia,,,,,,,,,,,,,,,,
21449,,back pain|patient,,,,,,,,,,,,,,,,
21450,,localized non-melanoma skin cancer,,,,,,,,,,,,,,,,
21451,,ocular herpes zoster,,,,,,,,,,,,,,,,
21452,,solid organ transplant|participants,,,,,,,,,,,,,,,,
21453,,crc asthma,,,,,,,,,,,,,,,,
21454,,haemostasis,,,,,,,,,,,,,,,,
21455,,cardiac resynchronization therapy|patient,,,,,,,,,,,,,,,,
21456,,structural deformity,,,,,,,,,,,,,,,,
21457,,unwilling,,,,,,,,,,,,,,,,
21458,,thrombosis/embolism,,,,,,,,,,,,,,,,
21459,,monogenic diabetes|participants,,,,,,,,,,,,,,,,
21460,,impact glycemic control,,,,,,,,,,,,,,,,
21461,,congenital hypothyroidism,,,,,,,,,,,,,,,,
21462,,sonovue,,,,,,,,,,,,,,,,
21463,,recurrent autonomic dysreflexia,,,,,,,,,,,,,,,,
21464,,amenorrhea.|chronic inflammatory condition,,,,,,,,,,,,,,,,
21465,,ocular factor,,,,,,,,,,,,,,,,
21466,,medical illness.|decisional impairment,,,,,,,,,,,,,,,,
21467,,mechanical circulatory support,,,,,,,,,,,,,,,,
21468,,chronic heart failure|patients,,,,,,,,,,,,,,,,
21469,,thyroid cancer|patients,,,,,,,,,,,,,,,,
21470,,good organ function:1).hematology,,,,,,,,,,,,,,,,
21471,,acute appendicitis,,,,,,,,,,,,,,,,
21472,,joint surgery.|acute pain,,,,,,,,,,,,,,,,
21473,,switching,,,,,,,,,,,,,,,,
21474,,focus group.||,,,,,,,,,,,,,,,,
21475,,home,,,,,,,,,,,,,,,,
21476,,abnormal behavior,,,,,,,,,,,,,,,,
21477,,intractable hf,,,,,,,,,,,,,,,,
21478,,cerebrovascular diseases.|participants,,,,,,,,,,,,,,,,
21479,,permanent discontinuation,,,,,,,,,,,,,,,,
21480,,communication impairments,,,,,,,,,,,,,,,,
21481,,prognosis,,,,,,,,,,,,,,,,
21482,,pjp,,,,,,,,,,,,,,,,
21483,,color weakness,,,,,,,,,,,,,,,,
21484,,legs consistent,,,,,,,,,,,,,,,,
21485,,bone metabolism|concomitant diseases,,,,,,,,,,,,,,,,
21486,,fecal occult,,,,,,,,,,,,,,,,
21487,,major adverse events,,,,,,,,,,,,,,,,
21488,,infections difficult,,,,,,,,,,,,,,,,
21489,,painful states,,,,,,,,,,,,,,,,
21490,,antibodies)|symptomatic,,,,,,,,,,,,,,,,
21491,,upper abdominal surgery|allergies,,,,,,,,,,,,,,,,
21492,,cholestasis,,,,,,,,,,,,,,,,
21493,,hypothermic circulatory arrest|left,,,,,,,,,,,,,,,,
21494,,gerd,,,,,,,,,,,,,,,,
21495,,tidal lavage,,,,,,,,,,,,,,,,
21496,,genetic familial,,,,,,,,,,,,,,,,
21497,,i.e.||gallbladder disease,,,,,,,,,,,,,,,,
21498,,disorder of coagulation,,,,,,,,,,,,,,,,
21499,,benign angiopathy,,,,,,,,,,,,,,,,
21500,,end stage renal disease,,,,,,,,,,,,,,,,
21501,,signing,,,,,,,,,,,,,,,,
21502,,intracranial mass|prohibitive lumbar spinal disease|enrollment,,,,,,,,,,,,,,,,
21503,,nonanaplastic thyroid cancer,,,,,,,,,,,,,,,,
21504,,left leg,,,,,,,,,,,,,,,,
21505,,traumatic brain injury|current insomnia|reliable access,,,,,,,,,,,,,,,,
21506,,scheme|pregnant,,,,,,,,,,,,,,,,
21507,,sensitivity,,,,,,,,,,,,,,,,
21508,,portal vein embolization,,,,,,,,,,,,,,,,
21509,,neurological disorders|surrent chronic pain,,,,,,,,,,,,,,,,
21510,,peripheral neurotoxicity,,,,,,,,,,,,,,,,
21511,,systemic condition|patients,,,,,,,,,,,,,,,,
21512,,brain dysfunction,,,,,,,,,,,,,,,,
21513,,cerebrovascular accident.|interventions,,,,,,,,,,,,,,,,
21514,,postpartum angiopathy,,,,,,,,,,,,,,,,
21515,,muscle diseases,,,,,,,,,,,,,,,,
21516,,smartphone|speaks,,,,,,,,,,,,,,,,
21517,,diabetic complications,,,,,,,,,,,,,,,,
21518,,permanent atrial fibrillation,,,,,,,,,,,,,,,,
21519,,carcinoma in situ of any type,,,,,,,,,,,,,,,,
21520,,co-morbidity,,,,,,,,,,,,,,,,
21521,,brain lesion,,,,,,,,,,,,,,,,
21522,,cytogenetic abnormality indicative of myelodysplasia,,,,,,,,,,,,,,,,
21523,,fetal toxicities,,,,,,,,,,,,,,,,
21524,,solid tumor malignancy.||participants,,,,,,,,,,,,,,,,
21525,,nl,,,,,,,,,,,,,,,,
21526,,all|hemorrhoidal disease,,,,,,,,,,,,,,,,
21527,,chronic pressure ulcers,,,,,,,,,,,,,,,,
21528,,tumor infiltration,,,,,,,,,,,,,,,,
21529,,donor from phase 1b,,,,,,,,,,,,,,,,
21530,,adjustment in the type,,,,,,,,,,,,,,,,
21531,,suicidal ideation|topical therapy,,,,,,,,,,,,,,,,
21532,,cryostimulation,,,,,,,,,,,,,,,,
21533,,severe heart failure,,,,,,,,,,,,,,,,
21534,,deep vein thrombosis|upper,,,,,,,,,,,,,,,,
21535,,exon19 deletion,,,,,,,,,,,,,,,,
21536,,nostril pathway,,,,,,,,,,,,,,,,
21537,,third international consensus definitions,,,,,,,,,,,,,,,,
21538,,liver metastatic,,,,,,,,,,,,,,,,
21539,,myocardial infarction attack,,,,,,,,,,,,,,,,
21540,,fixation indicated||,,,,,,,,,,,,,,,,
21541,,vascular disease|pregnancy|secondary hypertension|atrial fibrillation,,,,,,,,,,,,,,,,
21542,,cancer of the head and neck,,,,,,,,,,,,,,,,
21543,,months|colon-rectal cancer,,,,,,,,,,,,,,,,
21544,,pose a risk to the participant,,,,,,,,,,,,,,,,
21545,,nail,,,,,,,,,,,,,,,,
21546,,judged by the investigator to be unsuitable for the study;|a,,,,,,,,,,,,,,,,
21547,,organ failure;|the,,,,,,,,,,,,,,,,
21548,,versus host reaction,,,,,,,,,,,,,,,,
21549,,poor results.||,,,,,,,,,,,,,,,,
21550,,b-cell lymphoma[pmbcl,,,,,,,,,,,,,,,,
21551,,alcohol- containing products,,,,,,,,,,,,,,,,
21552,,infection occurs,,,,,,,,,,,,,,,,
21553,,qysmia,,,,,,,,,,,,,,,,
21554,,involvement of the right,,,,,,,,,,,,,,,,
21555,,t2dm||type 1 diabetes mellitus,,,,,,,,,,,,,,,,
21556,,hcc-cholangiocarcinoma,,,,,,,,,,,,,,,,
21557,,veteran,,,,,,,,,,,,,,,,
21558,,arterial diameter stenosis,,,,,,,,,,,,,,,,
21559,,sion criteria:||grandmother|self,,,,,,,,,,,,,,,,
21560,,vt)|ventricular fibrillation,,,,,,,,,,,,,,,,
21561,,urinary retention,,,,,,,,,,,,,,,,
21562,,aortic valve orifice area,,,,,,,,,,,,,,,,
21563,,distant metastasis;|were intolerant,,,,,,,,,,,,,,,,
21564,,polyarteritis nodosa,,,,,,,,,,,,,,,,
21565,,recurrence of platinum sensitive,,,,,,,,,,,,,,,,
21566,,solid malignancy,,,,,,,,,,,,,,,,
21567,,needle fainting,,,,,,,,,,,,,,,,
21568,,gastrointestinal bleed 2,,,,,,,,,,,,,,,,
21569,,iris,,,,,,,,,,,,,,,,
21570,,tumor tissue should,,,,,,,,,,,,,,,,
21571,,systemic symptoms,,,,,,,,,,,,,,,,
21572,,intravenous busulfan with documentation,,,,,,,,,,,,,,,,
21573,,presbycusis,,,,,,,,,,,,,,,,
21574,,pre-cancerous lesion,,,,,,,,,,,,,,,,
21575,,viral vascular diseases,,,,,,,,,,,,,,,,
21576,,laptop computer,,,,,,,,,,,,,,,,
21577,,lactate dehydrogenase,,,,,,,,,,,,,,,,
21578,,pathologic root resorption.||,,,,,,,,,,,,,,,,
21579,,postcentral gyri,,,,,,,,,,,,,,,,
21580,,spastic type cp|cooperate,,,,,,,,,,,,,,,,
21581,,severe allergy;|known allergy to the active ingredient,,,,,,,,,,,,,,,,
21582,,ophthalmic diseases,,,,,,,,,,,,,,,,
21583,,type 1,,,,,,,,,,,,,,,,
21584,,normal psa levels|participants,,,,,,,,,,,,,,,,
21585,,recreational activities,,,,,,,,,,,,,,,,
21586,,co-morbid disease,,,,,,,,,,,,,,,,
21587,,premature coronary artery disease,,,,,,,,,,,,,,,,
21588,,renal impaired patients||patients,,,,,,,,,,,,,,,,
21589,,ct1a stage)|regional lymphadenopathy,,,,,,,,,,,,,,,,
21590,,spinal cord embolism syndrome,,,,,,,,,,,,,,,,
21591,,refractory/relapsed,,,,,,,,,,,,,,,,
21592,,hiv)|uncontrolled intercurrent illness,,,,,,,,,,,,,,,,
21593,,cancer metastasis,,,,,,,,,,,,,,,,
21594,,covid-19 infection,,,,,,,,,,,,,,,,
21595,,"support,|have tumors",,,,,,,,,,,,,,,,
21596,,cerebral ischemic,,,,,,,,,,,,,,,,
21597,,atherosclerotic heart,,,,,,,,,,,,,,,,
21598,,investigator.|active malignancy,,,,,,,,,,,,,,,,
21599,,heart failure|anemia|hemoglobinopathy|sepsis,,,,,,,,,,,,,,,,
21600,,repetitive seizures,,,,,,,,,,,,,,,,
21601,,low back pain.|any traumatic,,,,,,,,,,,,,,,,
21602,,nontuberculous mycobacterial infection,,,,,,,,,,,,,,,,
21603,,functional somatic disorders,,,,,,,,,,,,,,,,
21604,,upper gi bleeding,,,,,,,,,,,,,,,,
21605,,bam,,,,,,,,,,,,,,,,
21606,,nocturnal symptomatic,,,,,,,,,,,,,,,,
21607,,renal organ transplantation|pregnant,,,,,,,,,,,,,,,,
21608,,glucocorticoid therapy);|concurrent malignancy,,,,,,,,,,,,,,,,
21609,,dihydropyridine sensitivity,,,,,,,,,,,,,,,,
21610,,her2-positive status,,,,,,,,,,,,,,,,
21611,,peripheral olfactory tract involvement,,,,,,,,,,,,,,,,
21612,,mild cognitive deficit,,,,,,,,,,,,,,,,
21613,,psychotic conditions tumors,,,,,,,,,,,,,,,,
21614,,hiv-status,,,,,,,,,,,,,,,,
21615,,musculoskeletal pain disorders||,,,,,,,,,,,,,,,,
21616,,fracture|inability,,,,,,,,,,,,,,,,
21617,,chronic atopic dermatitis,,,,,,,,,,,,,,,,
21618,,diabetic macular edema,,,,,,,,,,,,,,,,
21619,,unable to abstain,,,,,,,,,,,,,,,,
21620,,"instability,|pregnant athletes",,,,,,,,,,,,,,,,
21621,,abnormalities after colonoscopy,,,,,,,,,,,,,,,,
21622,,intracranial meningioma,,,,,,,,,,,,,,,,
21623,,atrial fibrillation|uncontrolled diabetes mellitus,,,,,,,,,,,,,,,,
21624,,heart attack,,,,,,,,,,,,,,,,
21625,,normal renal function,,,,,,,,,,,,,,,,
21626,,r all participants:||healthy,,,,,,,,,,,,,,,,
21627,,cancer|non-metastatic,,,,,,,,,,,,,,,,
21628,,adaptations,,,,,,,,,,,,,,,,
21629,,esophagus varices,,,,,,,,,,,,,,,,
21630,,habitrol,,,,,,,,,,,,,,,,
21631,,atraumatic c2-,,,,,,,,,,,,,,,,
21632,,dysphasia,,,,,,,,,,,,,,,,
21633,,predominantly classic,,,,,,,,,,,,,,,,
21634,,needle sickness,,,,,,,,,,,,,,,,
21635,,clti,,,,,,,,,,,,,,,,
21636,,impact on the gastrointestinal tract,,,,,,,,,,,,,,,,
21637,,unreliability||local exclusion criteria:||any,,,,,,,,,,,,,,,,
21638,,complaints|severe ocular impairments|any neurological,,,,,,,,,,,,,,,,
21639,,cough reflex,,,,,,,,,,,,,,,,
21640,,florid autoimmune diseases,,,,,,,,,,,,,,,,
21641,,organ enlargement,,,,,,,,,,,,,,,,
21642,,covid-19 human immunoglobulin treatment,,,,,,,,,,,,,,,,
21643,,immunodeficiency,,,,,,,,,,,,,,,,
21644,,fetal anomalies)|opioid tolerance,,,,,,,,,,,,,,,,
21645,,brain metastases:||prior,,,,,,,,,,,,,,,,
21646,,fixed anatomical,,,,,,,,,,,,,,,,
21647,,heart transplantation|end-stage kidney disease,,,,,,,,,,,,,,,,
21648,,formality,,,,,,,,,,,,,,,,
21649,,acute trauma|unstable physical,,,,,,,,,,,,,,,,
21650,,future weight loss procedures,,,,,,,,,,,,,,,,
21651,,intravenous (iv) contrast,,,,,,,,,,,,,,,,
21652,,pelvic pain,,,,,,,,,,,,,,,,
21653,,onset angina,,,,,,,,,,,,,,,,
21654,,orthopedic disorder,,,,,,,,,,,,,,,,
21655,,localized breast cancer,,,,,,,,,,,,,,,,
21656,,reduced ejection fractions,,,,,,,,,,,,,,,,
21657,,corneal epithelial lesions,,,,,,,,,,,,,,,,
21658,,malignant central nervous system tumors,,,,,,,,,,,,,,,,
21659,,biochemical indicators,,,,,,,,,,,,,,,,
21660,,participation|alcohol abuse,,,,,,,,,,,,,,,,
21661,,diabetets mellitus (dm),,,,,,,,,,,,,,,,
21662,,associated myositis,,,,,,,,,,,,,,,,
21663,,hypertension);|terminal disease,,,,,,,,,,,,,,,,
21664,,heavy machinery,,,,,,,,,,,,,,,,
21665,,prosthetic abutment|presence,,,,,,,,,,,,,,,,
21666,,zanubrutinib).|active bleeding,,,,,,,,,,,,,,,,
21667,,"criteria of the german ""s3 guideline non-restorative",,,,,,,,,,,,,,,,
21668,,pupillomotor.|quantified pain,,,,,,,,,,,,,,,,
21669,,failure of btk inhibitor therapy.|3),,,,,,,,,,,,,,,,
21670,,xuezhikang,,,,,,,,,,,,,,,,
21671,,alnd.|breast cancer,,,,,,,,,,,,,,,,
21672,,learning disorder,,,,,,,,,,,,,,,,
21673,,psa|patients,,,,,,,,,,,,,,,,
21674,,≥1 of the following:||stroke;|neurological,,,,,,,,,,,,,,,,
21675,,bronchiectasis,,,,,,,,,,,,,,,,
21676,,head and neck malignancies,,,,,,,,,,,,,,,,
21677,,pituitary tumors,,,,,,,,,,,,,,,,
21678,,muscular hypotonia,,,,,,,,,,,,,,,,
21679,,radio embolization|central nervous system,,,,,,,,,,,,,,,,
21680,,primary biliary cirrhosis.||pregnancy status,,,,,,,,,,,,,,,,
21681,,dysphonia,,,,,,,,,,,,,,,,
21682,,mechanically ventilated|patients,,,,,,,,,,,,,,,,
21683,,dislocation,,,,,,,,,,,,,,,,
21684,,sacral dysplasia,,,,,,,,,,,,,,,,
21685,,good-quality retinal,,,,,,,,,,,,,,,,
21686,,pneumonia took,,,,,,,,,,,,,,,,
21687,,spontaneous bleeding abnormality,,,,,,,,,,,,,,,,
21688,,distinct ak lesions,,,,,,,,,,,,,,,,
21689,,pain sensitivity,,,,,,,,,,,,,,,,
21690,,peritoneal implants|pre-registration,,,,,,,,,,,,,,,,
21691,,skeletal deformities,,,,,,,,,,,,,,,,
21692,,coronary arterial disease,,,,,,,,,,,,,,,,
21693,,acute pulmonary embolus,,,,,,,,,,,,,,,,
21694,,posttraumatic symptoms,,,,,,,,,,,,,,,,
21695,,passive smoker||,,,,,,,,,,,,,,,,
21696,,infectious disorders,,,,,,,,,,,,,,,,
21697,,eczema,,,,,,,,,,,,,,,,
21698,,diabetes symptoms,,,,,,,,,,,,,,,,
21699,,treated carcinoma,,,,,,,,,,,,,,,,
21700,,diabetes type 2|patients,,,,,,,,,,,,,,,,
21701,,diabetic retinopathy study [,,,,,,,,,,,,,,,,
21702,,refractory all disease,,,,,,,,,,,,,,,,
21703,,uws,,,,,,,,,,,,,,,,
21704,,schizophreniform disorders,,,,,,,,,,,,,,,,
21705,,hypomanic episode,,,,,,,,,,,,,,,,
21706,,restenotic chronic total occlusion,,,,,,,,,,,,,,,,
21707,,calcified lesions,,,,,,,,,,,,,,,,
21708,,orthostatic hypotension,,,,,,,,,,,,,,,,
21709,,pemphigus,,,,,,,,,,,,,,,,
21710,,target lesions,,,,,,,,,,,,,,,,
21711,,secondary lesion,,,,,,,,,,,,,,,,
21712,,thrombocytopenia.|clinically significant,,,,,,,,,,,,,,,,
21713,,loose stools,,,,,,,,,,,,,,,,
21714,,interior health authorities)|be english,,,,,,,,,,,,,,,,
21715,,straight leg raise,,,,,,,,,,,,,,,,
21716,,os,,,,,,,,,,,,,,,,
21717,,congenital anomalies.|birth asphyxia's,,,,,,,,,,,,,,,,
21718,,peripheral artery thrombosis,,,,,,,,,,,,,,,,
21719,,post-acute,,,,,,,,,,,,,,,,
21720,,embolism events,,,,,,,,,,,,,,,,
21721,,secondary cause of hypertension|anatomy,,,,,,,,,,,,,,,,
21722,,hepatic artery,,,,,,,,,,,,,,,,
21723,,periodontal disease|systemic diseases,,,,,,,,,,,,,,,,
21724,,anterior permanent tooth,,,,,,,,,,,,,,,,
21725,,former pulmonary rehabilitation,,,,,,,,,,,,,,,,
21726,,emdr,,,,,,,,,,,,,,,,
21727,,anigosarcoma,,,,,,,,,,,,,,,,
21728,,latina breast cancer,,,,,,,,,,,,,,,,
21729,,programed cell death,,,,,,,,,,,,,,,,
21730,,granulomatous diseases,,,,,,,,,,,,,,,,
21731,,instability,,,,,,,,,,,,,,,,
21732,,thymoma-associated,,,,,,,,,,,,,,,,
21733,,radiation therapy.|severe infections,,,,,,,,,,,,,,,,
21734,,characterized depressive episodé,,,,,,,,,,,,,,,,
21735,,hyper mobility,,,,,,,,,,,,,,,,
21736,,diabetes|terminal illness|myocardial infarction,,,,,,,,,,,,,,,,
21737,,myocardial infarction.|unstable angina,,,,,,,,,,,,,,,,
21738,,use)|planned,,,,,,,,,,,,,,,,
21739,,congo red,,,,,,,,,,,,,,,,
21740,,hdp,,,,,,,,,,,,,,,,
21741,,asperger syndrome,,,,,,,,,,,,,,,,
21742,,pinguecula,,,,,,,,,,,,,,,,
21743,,parents,,,,,,,,,,,,,,,,
21744,,above||exclusion criteria:||can't read,,,,,,,,,,,,,,,,
21745,,respiratory support.||,,,,,,,,,,,,,,,,
21746,,anxiety symptoms||exclusion,,,,,,,,,,,,,,,,
21747,,corrective osteotomies,,,,,,,,,,,,,,,,
21748,,gastrointestinal motility disorder,,,,,,,,,,,,,,,,
21749,,hypoparathyroidism.|patients,,,,,,,,,,,,,,,,
21750,,pupils,,,,,,,,,,,,,,,,
21751,,hirschsprung's disease,,,,,,,,,,,,,,,,
21752,,dermal fillers,,,,,,,,,,,,,,,,
21753,,permitted).|pulmonary embolism,,,,,,,,,,,,,,,,
21754,,lichen planus pilaris|presence of pruritus of the scalp,,,,,,,,,,,,,,,,
21755,,drug-related pulmonary toxicity.||significant,,,,,,,,,,,,,,,,
21756,,restrictive bariatric surger,,,,,,,,,,,,,,,,
21757,,impairment|preterm,,,,,,,,,,,,,,,,
21758,,gall bladder cancer)|her2,,,,,,,,,,,,,,,,
21759,,implantation failures,,,,,,,,,,,,,,,,
21760,,contraindicated,,,,,,,,,,,,,,,,
21761,,ecg abnormality,,,,,,,,,,,,,,,,
21762,,performed|antibiotic use,,,,,,,,,,,,,,,,
21763,,main organs dysfunctions,,,,,,,,,,,,,,,,
21764,,myelopathy,,,,,,,,,,,,,,,,
21765,,native valve,,,,,,,,,,,,,,,,
21766,,transmural scarring,,,,,,,,,,,,,,,,
21767,,hopping,,,,,,,,,,,,,,,,
21768,,non specific neck,,,,,,,,,,,,,,,,
21769,,available osteoporosis therapy,,,,,,,,,,,,,,,,
21770,,colorectal cancer.|metastatic colorectal cancer,,,,,,,,,,,,,,,,
21771,,hypocalcification hyperplasia,,,,,,,,,,,,,,,,
21772,,inflammatory lesions,,,,,,,,,,,,,,,,
21773,,recurrent events,,,,,,,,,,,,,,,,
21774,,post-menopause,,,,,,,,,,,,,,,,
21775,,thromboembolic disorder.|personal,,,,,,,,,,,,,,,,
21776,,superficial bladder cancers,,,,,,,,,,,,,,,,
21777,,breast tumors,,,,,,,,,,,,,,,,
21778,,ortic stenosis,,,,,,,,,,,,,,,,
21779,,compensatory cirrhosis,,,,,,,,,,,,,,,,
21780,,"intestinal resection,)|chronic",,,,,,,,,,,,,,,,
21781,,abdominal cramps pain ends after periods,,,,,,,,,,,,,,,,
21782,,vertebrae|low back pain,,,,,,,,,,,,,,,,
21783,,criteria consistent with international classification of headache disorders (ichd),,,,,,,,,,,,,,,,
21784,,male breast,,,,,,,,,,,,,,,,
21785,,baseline.||major depression,,,,,,,,,,,,,,,,
21786,,recreational drug,,,,,,,,,,,,,,,,
21787,,primary bronchiectasis,,,,,,,,,,,,,,,,
21788,,pregnancy|inability to tolerate,,,,,,,,,,,,,,,,
21789,,pulmonary insufficiency.|patients,,,,,,,,,,,,,,,,
21790,,smoking cessation,,,,,,,,,,,,,,,,
21791,,hematologic tumors,,,,,,,,,,,,,,,,
21792,,other)|significant mental,,,,,,,,,,,,,,,,
21793,,amount of loperamide for,,,,,,,,,,,,,,,,
21794,,partial obstruction,,,,,,,,,,,,,,,,
21795,,epilepsy|those,,,,,,,,,,,,,,,,
21796,,renal stone,,,,,,,,,,,,,,,,
21797,,life-threatening bleeding,,,,,,,,,,,,,,,,
21798,,pulmonary insufficiency,,,,,,,,,,,,,,,,
21799,,bacteriuria,,,,,,,,,,,,,,,,
21800,,myocardial ischemia;||severe cardiopulmonary,,,,,,,,,,,,,,,,
21801,,indemnities for clinical trial higher or equal to 4500 euros.||after,,,,,,,,,,,,,,,,
21802,,interstitial disease,,,,,,,,,,,,,,,,
21803,,carcinomas,,,,,,,,,,,,,,,,
21804,,isncsci,,,,,,,,,,,,,,,,
21805,,padang,,,,,,,,,,,,,,,,
21806,,decreased bowel sounds,,,,,,,,,,,,,,,,
21807,,pregnancy on,,,,,,,,,,,,,,,,
21808,,early recurrence,,,,,,,,,,,,,,,,
21809,,supervisor,,,,,,,,,,,,,,,,
21810,,malignancy.|serious infections,,,,,,,,,,,,,,,,
21811,,illegal recreational drugs,,,,,,,,,,,,,,,,
21812,,regional infections,,,,,,,,,,,,,,,,
21813,,digestive system diseases,,,,,,,,,,,,,,,,
21814,,thrombosis center,,,,,,,,,,,,,,,,
21815,,cd123,,,,,,,,,,,,,,,,
21816,,multicentric breast cancer,,,,,,,,,,,,,,,,
21817,,complex sleep apnea).|previous,,,,,,,,,,,,,,,,
21818,,mandibular setback,,,,,,,,,,,,,,,,
21819,,biliary salt diarrhea,,,,,,,,,,,,,,,,
21820,,congenital number anomaly.|patients,,,,,,,,,,,,,,,,
21821,,angiographically compromised sb,,,,,,,,,,,,,,,,
21822,,consistent facial skin status,,,,,,,,,,,,,,,,
21823,,unresectable surgical contraindications,,,,,,,,,,,,,,,,
21824,,brain injury itself,,,,,,,,,,,,,,,,
21825,,tympanic temperature,,,,,,,,,,,,,,,,
21826,,nash histological diagnosis,,,,,,,,,,,,,,,,
21827,,anticoagulated states,,,,,,,,,,,,,,,,
21828,,total lesion,,,,,,,,,,,,,,,,
21829,,ihca,,,,,,,,,,,,,,,,
21830,,infection;|uncontrolled diabetes,,,,,,,,,,,,,,,,
21831,,liver cirrhosis;|renal failure,,,,,,,,,,,,,,,,
21832,,target lesion,,,,,,,,,,,,,,,,
21833,,connective tissue disorder,,,,,,,,,,,,,,,,
21834,,cavernous hemangiomas,,,,,,,,,,,,,,,,
21835,,radioactive pneumonia,,,,,,,,,,,,,,,,
21836,,fatty liver diseases,,,,,,,,,,,,,,,,
21837,,univentricular heart,,,,,,,,,,,,,,,,
21838,,crc,,,,,,,,,,,,,,,,
21839,,allergic skin,,,,,,,,,,,,,,,,
21840,,black african,,,,,,,,,,,,,,,,
21841,,muityh associated polyposis,,,,,,,,,,,,,,,,
21842,,brain pace,,,,,,,,,,,,,,,,
21843,,strenuous activity,,,,,,,,,,,,,,,,
21844,,intracerebral haemorrhage admitted,,,,,,,,,,,,,,,,
21845,,asthenia,,,,,,,,,,,,,,,,
21846,,gastrointestinal bleeding.|patients,,,,,,,,,,,,,,,,
21847,,anemic pregnancies,,,,,,,,,,,,,,,,
21848,,laduviglusib,,,,,,,,,,,,,,,,
21849,,parkinson 's disease,,,,,,,,,,,,,,,,
21850,,treatment.|active infection,,,,,,,,,,,,,,,,
21851,,hereditary pulmonary arterial hypertension,,,,,,,,,,,,,,,,
21852,,anxiety,,,,,,,,,,,,,,,,
21853,,dominant arteriopathy,,,,,,,,,,,,,,,,
21854,,aki,,,,,,,,,,,,,,,,
21855,,schizophrenic spectrum disorder,,,,,,,,,,,,,,,,
21856,,drug absorption and metabolism,,,,,,,,,,,,,,,,
21857,,qtcf,,,,,,,,,,,,,,,,
21858,,reflux,,,,,,,,,,,,,,,,
21859,,glaucoma|infection,,,,,,,,,,,,,,,,
21860,,potential covid-19 infection,,,,,,,,,,,,,,,,
21861,,autoimmune diseases；|with,,,,,,,,,,,,,,,,
21862,,trial.||active infection,,,,,,,,,,,,,,,,
21863,,non-communicating hydrocephalus,,,,,,,,,,,,,,,,
21864,,in situ cervical/breast cancer,,,,,,,,,,,,,,,,
21865,,speech disorder,,,,,,,,,,,,,,,,
21866,,extensive periodontal therapy,,,,,,,,,,,,,,,,
21867,,large infraorbital,,,,,,,,,,,,,,,,
21868,,vitreomacular traction,,,,,,,,,,,,,,,,
21869,,hypotensive episodes,,,,,,,,,,,,,,,,
21870,,venous insufficiency c4,,,,,,,,,,,,,,,,
21871,,hematologic malignancies,,,,,,,,,,,,,,,,
21872,,pathological symptoms,,,,,,,,,,,,,,,,
21873,,arteriovenous dialysis fistula,,,,,,,,,,,,,,,,
21874,,t3 disease,,,,,,,,,,,,,,,,
21875,,bi-fascicular block,,,,,,,,,,,,,,,,
21876,,non-conjunctive regurgitant bundle,,,,,,,,,,,,,,,,
21877,,chronic hepatic disease,,,,,,,,,,,,,,,,
21878,,extensive third-degree burns,,,,,,,,,,,,,,,,
21879,,"hyperlipidemia,|known hyperthyroid disease|endocrine disorders",,,,,,,,,,,,,,,,
21880,,inoperable disease,,,,,,,,,,,,,,,,
21881,,asthmatic,,,,,,,,,,,,,,,,
21882,,staging,,,,,,,,,,,,,,,,
21883,,bags.|one-sided,,,,,,,,,,,,,,,,
21884,,syndrome).|acute intestinal obstruction,,,,,,,,,,,,,,,,
21885,,cardiovascular disease|uncontrolled hypertension,,,,,,,,,,,,,,,,
21886,,peripheral t-cell lymphoma,,,,,,,,,,,,,,,,
21887,,basal cell cancers,,,,,,,,,,,,,,,,
21888,,renal toxicity,,,,,,,,,,,,,,,,
21889,,active cancer disease|conditions,,,,,,,,,,,,,,,,
21890,,persistence of prostate cancer,,,,,,,,,,,,,,,,
21891,,pulmonary disease.|clinically,,,,,,,,,,,,,,,,
21892,,fetal anomaly,,,,,,,,,,,,,,,,
21893,,autoimmune diseases.|histories,,,,,,,,,,,,,,,,
21894,,major bleeding event,,,,,,,,,,,,,,,,
21895,,worsen,,,,,,,,,,,,,,,,
21896,,type of pathology,,,,,,,,,,,,,,,,
21897,,unresectable small cell lung carcinoma,,,,,,,,,,,,,,,,
21898,,dyslexia|normal schooling (,,,,,,,,,,,,,,,,
21899,,major seizure disorder,,,,,,,,,,,,,,,,
21900,,nicu admissions,,,,,,,,,,,,,,,,
21901,,chromogenic in situ hybridization [cish],,,,,,,,,,,,,,,,
21902,,pneumonia;|active tuberculosis infection,,,,,,,,,,,,,,,,
21903,,skin defects,,,,,,,,,,,,,,,,
21904,,amaurosis,,,,,,,,,,,,,,,,
21905,,corneal inflammation,,,,,,,,,,,,,,,,
21906,,caries,,,,,,,,,,,,,,,,
21907,,parasitic,,,,,,,,,,,,,,,,
21908,,contraception|nonsterilized,,,,,,,,,,,,,,,,
21909,,metastases on the postoperative scan.|three,,,,,,,,,,,,,,,,
21910,,behavioral impairment,,,,,,,,,,,,,,,,
21911,,hypoxaemia,,,,,,,,,,,,,,,,
21912,,non-negotiable canals|teeth,,,,,,,,,,,,,,,,
21913,,chronic disease.|patients,,,,,,,,,,,,,,,,
21914,,management.|active lung disease,,,,,,,,,,,,,,,,
21915,,neurologic deficit|the,,,,,,,,,,,,,,,,
21916,,partially controlled,,,,,,,,,,,,,,,,
21917,,points;|blood pressure,,,,,,,,,,,,,,,,
21918,,bronchial asthma,,,,,,,,,,,,,,,,
21919,,moderate exacerbation,,,,,,,,,,,,,,,,
21920,,conditions.|concurrent,,,,,,,,,,,,,,,,
21921,,allergic bronchopulmonary aspergillosis,,,,,,,,,,,,,,,,
21922,,neurodevelopmental delay|type,,,,,,,,,,,,,,,,
21923,,complex disease,,,,,,,,,,,,,,,,
21924,,skin wound,,,,,,,,,,,,,,,,
21925,,marfan syndrome)|pregnancy,,,,,,,,,,,,,,,,
21926,,generalized polyarthritis,,,,,,,,,,,,,,,,
21927,,acute attack of gout,,,,,,,,,,,,,,,,
21928,,cauda equina syndrome||progressive neurologic deficit|history of,,,,,,,,,,,,,,,,
21929,,teeth bleaching,,,,,,,,,,,,,,,,
21930,,still's disease,,,,,,,,,,,,,,,,
21931,,local conditions contraindicating cirt,,,,,,,,,,,,,,,,
21932,,minimally classic,,,,,,,,,,,,,,,,
21933,,impact onto daily activities,,,,,,,,,,,,,,,,
21934,,asas criteria||,,,,,,,,,,,,,,,,
21935,,local esophageal inflammation,,,,,,,,,,,,,,,,
21936,,suspected.|pregnant,,,,,,,,,,,,,,,,
21937,,chronic insomnia,,,,,,,,,,,,,,,,
21938,,selected target lesions,,,,,,,,,,,,,,,,
21939,,months.|pain rating,,,,,,,,,,,,,,,,
21940,,impaired liver functions,,,,,,,,,,,,,,,,
21941,,disclosure,,,,,,,,,,,,,,,,
21942,,deep burns,,,,,,,,,,,,,,,,
21943,,reporting bruxism,,,,,,,,,,,,,,,,
21944,,distal obstruction,,,,,,,,,,,,,,,,
21945,,ctcl,,,,,,,,,,,,,,,,
21946,,arteriovenous malformation,,,,,,,,,,,,,,,,
21947,,contra-indicated,,,,,,,,,,,,,,,,
21948,,henry ford orthopedic,,,,,,,,,,,,,,,,
21949,,pasc-related,,,,,,,,,,,,,,,,
21950,,diabetes|cardiovascular disease,,,,,,,,,,,,,,,,
21951,,prolonged qt syndrome|active substance use disorder|active eating disorder|porphyria|on current,,,,,,,,,,,,,,,,
21952,,chronic dialysis)|females,,,,,,,,,,,,,,,,
21953,,chronic liver impairment.(but,,,,,,,,,,,,,,,,
21954,,gastrointestinal tract surgery;|history,,,,,,,,,,,,,,,,
21955,,gilbert syndrome,,,,,,,,,,,,,,,,
21956,,pons,,,,,,,,,,,,,,,,
21957,,cerebral palsy||any patient,,,,,,,,,,,,,,,,
21958,,conscious level.|pregnancy,,,,,,,,,,,,,,,,
21959,,moles.|pregnant,,,,,,,,,,,,,,,,
21960,,degenerative spondylotic myelopathy,,,,,,,,,,,,,,,,
21961,,leiomyoma,,,,,,,,,,,,,,,,
21962,,axillary temperature,,,,,,,,,,,,,,,,
21963,,psychological instability,,,,,,,,,,,,,,,,
21964,,insulin autoimmune hypoglycemia,,,,,,,,,,,,,,,,
21965,,organic gastrointestinal disease,,,,,,,,,,,,,,,,
21966,,bevacizumab)|no assessable archival tumor tissue,,,,,,,,,,,,,,,,
21967,,obstructed defecation,,,,,,,,,,,,,,,,
21968,,periprosthetic infection,,,,,,,,,,,,,,,,
21969,,status.||drug treatment:||antihypertensive drugs,,,,,,,,,,,,,,,,
21970,,extensive facial,,,,,,,,,,,,,,,,
21971,,malignancy related to soft tissue,,,,,,,,,,,,,,,,
21972,,respiratory pathologies,,,,,,,,,,,,,,,,
21973,,serious cardiopulmonary diseases,,,,,,,,,,,,,,,,
21974,,impairment in mental status,,,,,,,,,,,,,,,,
21975,,pneumococcal pneumonia,,,,,,,,,,,,,,,,
21976,,pulpitis,,,,,,,,,,,,,,,,
21977,,4|anaplastic astrocytoma,,,,,,,,,,,,,,,,
21978,,epistaxis)|post cardiac arrest,,,,,,,,,,,,,,,,
21979,,pupillary diameter,,,,,,,,,,,,,,,,
21980,,arteriovenous malformations,,,,,,,,,,,,,,,,
21981,,cerebral ventricle|karnofsky performance status (kps),,,,,,,,,,,,,,,,
21982,,detectable hepatitis,,,,,,,,,,,,,,,,
21983,,av block|bradycardia,,,,,,,,,,,,,,,,
21984,,thoracic aortic diameters,,,,,,,,,,,,,,,,
21985,,thromboembolic pulmonary disease,,,,,,,,,,,,,,,,
21986,,infliximab,,,,,,,,,,,,,,,,
21987,,begun,,,,,,,,,,,,,,,,
21988,,poor vascular puncture conditions,,,,,,,,,,,,,,,,
21989,,extramedullary disease,,,,,,,,,,,,,,,,
21990,,physically active people who exercise vigorously,,,,,,,,,,,,,,,,
21991,,contra-,,,,,,,,,,,,,,,,
21992,,deep fascia;|ecog physical status score,,,,,,,,,,,,,,,,
21993,,syndrome|symptomatic peripheral neuropathy|systemic,,,,,,,,,,,,,,,,
21994,,meibomian gland dysfunction,,,,,,,,,,,,,,,,
21995,,brain,,,,,,,,,,,,,,,,
21996,,property destruction,,,,,,,,,,,,,,,,
21997,,hepatic decompensation|current,,,,,,,,,,,,,,,,
21998,,rasi,,,,,,,,,,,,,,,,
21999,,skin carcinomas,,,,,,,,,,,,,,,,
22000,,non-smoker||gh deficient,,,,,,,,,,,,,,,,
22001,,cancer risk physicians,,,,,,,,,,,,,,,,
22002,,disorder|active cancer,,,,,,,,,,,,,,,,
22003,,subepithelial scarring,,,,,,,,,,,,,,,,
22004,,infraspinatus,,,,,,,,,,,,,,,,
22005,,central neurological impairment,,,,,,,,,,,,,,,,
22006,,light reflex,,,,,,,,,,,,,,,,
22007,,addictive,,,,,,,,,,,,,,,,
22008,,removal;|colon resection,,,,,,,,,,,,,,,,
22009,,impairment of cognitive,,,,,,,,,,,,,,,,
22010,,enrolment|pregnant,,,,,,,,,,,,,,,,
22011,,ischemic cardiopathology,,,,,,,,,,,,,,,,
22012,,major disease,,,,,,,,,,,,,,,,
22013,,brittle bone disease,,,,,,,,,,,,,,,,
22014,,bone problems,,,,,,,,,,,,,,,,
22015,,alcohol-containing food,,,,,,,,,,,,,,,,
22016,,global rim thinning,,,,,,,,,,,,,,,,
22017,,hemorrhagic transformation,,,,,,,,,,,,,,,,
22018,,recreational drug use|current symptomatic urinary tract infection (uti),,,,,,,,,,,,,,,,
22019,,chron's disease,,,,,,,,,,,,,,,,
22020,,german language skills,,,,,,,,,,,,,,,,
22021,,chronic allergic rhinitis||allergic,,,,,,,,,,,,,,,,
22022,,choroidal neovascularization||,,,,,,,,,,,,,,,,
22023,,infiltrates,,,,,,,,,,,,,,,,
22024,,ileal involvement,,,,,,,,,,,,,,,,
22025,,muscle toxicity,,,,,,,,,,,,,,,,
22026,,stage head,,,,,,,,,,,,,,,,
22027,,solid organ transplant.||active,,,,,,,,,,,,,,,,
22028,,pose a health risk,,,,,,,,,,,,,,,,
22029,,criteria of the european society of cardiology (esc),,,,,,,,,,,,,,,,
22030,,respectively)|any contraindications,,,,,,,,,,,,,,,,
22031,,chronic of kidney,,,,,,,,,,,,,,,,
22032,,deemed unsuitable,,,,,,,,,,,,,,,,
22033,,historic,,,,,,,,,,,,,,,,
22034,,completely remission,,,,,,,,,,,,,,,,
22035,,lupus)|chronic systemic pain,,,,,,,,,,,,,,,,
22036,,systemic illness,,,,,,,,,,,,,,,,
22037,,hepatic encephalopathy.|oesophageal variceal bleeding,,,,,,,,,,,,,,,,
22038,,renal rickets.|those,,,,,,,,,,,,,,,,
22039,,cdr,,,,,,,,,,,,,,,,
22040,,limb necrosis,,,,,,,,,,,,,,,,
22041,,cutaneous toxicity involvement,,,,,,,,,,,,,,,,
22042,,functional foods,,,,,,,,,,,,,,,,
22043,,none of the exclusion criteria,,,,,,,,,,,,,,,,
22044,,colon carcinoma.|possibility of,,,,,,,,,,,,,,,,
22045,,mpn)|report,,,,,,,,,,,,,,,,
22046,,potent inducer,,,,,,,,,,,,,,,,
22047,,early onset preeclampsia,,,,,,,,,,,,,,,,
22048,,right-handed|diagnosis,,,,,,,,,,,,,,,,
22049,,distress syndrome ecmo va,,,,,,,,,,,,,,,,
22050,,feeling short of breath|loss of smell,,,,,,,,,,,,,,,,
22051,,close contact,,,,,,,,,,,,,,,,
22052,,primary brain or base of skull tumour,,,,,,,,,,,,,,,,
22053,,hepatitis b cirrhosis,,,,,,,,,,,,,,,,
22054,,sftpc,,,,,,,,,,,,,,,,
22055,,cancer treated,,,,,,,,,,,,,,,,
22056,,gliosarcoma,,,,,,,,,,,,,,,,
22057,,candidate for,,,,,,,,,,,,,,,,
22058,,cell mass,,,,,,,,,,,,,,,,
22059,,hip resurfacing,,,,,,,,,,,,,,,,
22060,,severe head trauma,,,,,,,,,,,,,,,,
22061,,mass pleural effusion,,,,,,,,,,,,,,,,
22062,,functional changes.|written informed consent,,,,,,,,,,,,,,,,
22063,,hepatitis c viral infection,,,,,,,,,,,,,,,,
22064,,ns,,,,,,,,,,,,,,,,
22065,,heart rhythm modifying disease,,,,,,,,,,,,,,,,
22066,,guillain-barré syndrome|patient,,,,,,,,,,,,,,,,
22067,,thyroid,,,,,,,,,,,,,,,,
22068,,primary dry eye,,,,,,,,,,,,,,,,
22069,,translations,,,,,,,,,,,,,,,,
22070,,hat,,,,,,,,,,,,,,,,
22071,,met.||active hcv infection,,,,,,,,,,,,,,,,
22072,,primary entry tear,,,,,,,,,,,,,,,,
22073,,anatomical pathology,,,,,,,,,,,,,,,,
22074,,gilbert's syndrome)|13,,,,,,,,,,,,,,,,
22075,,renal trauma,,,,,,,,,,,,,,,,
22076,,terminal kidney failure,,,,,,,,,,,,,,,,
22077,,instable ischemic,,,,,,,,,,,,,,,,
22078,,multifocal disease,,,,,,,,,,,,,,,,
22079,,pitaya,,,,,,,,,,,,,,,,
22080,,progressive net|prior treatment,,,,,,,,,,,,,,,,
22081,,breast-feeding.|subjects,,,,,,,,,,,,,,,,
22082,,cerebrospinal fluid (csf) cytology,,,,,,,,,,,,,,,,
22083,,infection|human immunodeficiency virus,,,,,,,,,,,,,,,,
22084,,tees,,,,,,,,,,,,,,,,
22085,,"scaling"".|have",,,,,,,,,,,,,,,,
22086,,probiotics|clinically,,,,,,,,,,,,,,,,
22087,,medical illness,,,,,,,,,,,,,,,,
22088,,immunodeficiency diseases,,,,,,,,,,,,,,,,
22089,,hiv-1 infected,,,,,,,,,,,,,,,,
22090,,laryngeal tumor,,,,,,,,,,,,,,,,
22091,,cns tumors,,,,,,,,,,,,,,,,
22092,,oncogenic ret gene fusion,,,,,,,,,,,,,,,,
22093,,retinal detachment|retinal,,,,,,,,,,,,,,,,
22094,,non-chemotherapy-induced thrombocytopenic bleeding,,,,,,,,,,,,,,,,
22095,,osteomalacia,,,,,,,,,,,,,,,,
22096,,adhd||,,,,,,,,,,,,,,,,
22097,,participants.|chronic kidney disease,,,,,,,,,,,,,,,,
22098,,primary dentition).|healthy,,,,,,,,,,,,,,,,
22099,,standard deviations sds,,,,,,,,,,,,,,,,
22100,,reduced lvef,,,,,,,,,,,,,,,,
22101,,keratokonus,,,,,,,,,,,,,,,,
22102,,fetal macrosomia,,,,,,,,,,,,,,,,
22103,,fistulotomy|active infection,,,,,,,,,,,,,,,,
22104,,aed|anoxic brain injury,,,,,,,,,,,,,,,,
22105,,dyslipidemias,,,,,,,,,,,,,,,,
22106,,underlying conditions,,,,,,,,,,,,,,,,
22107,,α1-antitrypsin deficiency,,,,,,,,,,,,,,,,
22108,,autoimmune disorder.||,,,,,,,,,,,,,,,,
22109,,severe respiratory conditions|injury,,,,,,,,,,,,,,,,
22110,,materially affects gait,,,,,,,,,,,,,,,,
22111,,screening;|regular alcohol,,,,,,,,,,,,,,,,
22112,,recovered from the effects,,,,,,,,,,,,,,,,
22113,,developmentally delayed,,,,,,,,,,,,,,,,
22114,,autoimmune-associated,,,,,,,,,,,,,,,,
22115,,esophageal mucosal infection,,,,,,,,,,,,,,,,
22116,,sars-cov-2|allergy,,,,,,,,,,,,,,,,
22117,,respiratory failure|pregnant woman|patients,,,,,,,,,,,,,,,,
22118,,detection,,,,,,,,,,,,,,,,
22119,,extrahepatic deposition of the scout dose activity,,,,,,,,,,,,,,,,
22120,,trying to be pregnant|life expectancy,,,,,,,,,,,,,,,,
22121,,overexpression of her2 protein,,,,,,,,,,,,,,,,
22122,,cerebrovascular diseases|clinical depression,,,,,,,,,,,,,,,,
22123,,hematopoietic disorders,,,,,,,,,,,,,,,,
22124,,systemic conditions,,,,,,,,,,,,,,,,
22125,,alcohol drinking,,,,,,,,,,,,,,,,
22126,,benign lung tumor,,,,,,,,,,,,,,,,
22127,,choriorapillaris,,,,,,,,,,,,,,,,
22128,,bacillus tuberculosis,,,,,,,,,,,,,,,,
22129,,intravenous-inhalation anesthesia,,,,,,,,,,,,,,,,
22130,,sarcopenic obesity,,,,,,,,,,,,,,,,
22131,,pregestational hypertension,,,,,,,,,,,,,,,,
22132,,malignant bladder,,,,,,,,,,,,,,,,
22133,,"neurological, vestibular",,,,,,,,,,,,,,,,
22134,,mesenteric ischemia,,,,,,,,,,,,,,,,
22135,,endometrial carcinoma.|uncontrolled,,,,,,,,,,,,,,,,
22136,,pcr covid-19 infection,,,,,,,,,,,,,,,,
22137,,|sperm motility,,,,,,,,,,,,,,,,
22138,,premalignant lesion,,,,,,,,,,,,,,,,
22139,,months.|able to speak and read in english||,,,,,,,,,,,,,,,,
22140,,criteria outlined by mckay et al,,,,,,,,,,,,,,,,
22141,,multivessel coronary lesions.|participants,,,,,,,,,,,,,,,,
22142,,dry eye symptoms,,,,,,,,,,,,,,,,
22143,,third interspace fluid；|patients,,,,,,,,,,,,,,,,
22144,,gastric bypass,,,,,,,,,,,,,,,,
22145,,cerebral palsy|curarization|paraplegia,,,,,,,,,,,,,,,,
22146,,personnel,,,,,,,,,,,,,,,,
22147,,pleural metastases,,,,,,,,,,,,,,,,
22148,,opioid abuse,,,,,,,,,,,,,,,,
22149,,type 2 diabetes mellitus,,,,,,,,,,,,,,,,
22150,,complicating condition,,,,,,,,,,,,,,,,
22151,,varices,,,,,,,,,,,,,,,,
22152,,severe illness,,,,,,,,,,,,,,,,
22153,,"hormonal hypersecreting adrenal mass,|symptoms",,,,,,,,,,,,,,,,
22154,,rabies infection,,,,,,,,,,,,,,,,
22155,,coagulable status,,,,,,,,,,,,,,,,
22156,,pathology laboratory.||mbc,,,,,,,,,,,,,,,,
22157,,traumatic intracerebral haemorrhage,,,,,,,,,,,,,,,,
22158,,reoperation,,,,,,,,,,,,,,,,
22159,,leukostasis,,,,,,,,,,,,,,,,
22160,,non-digestive system tumors,,,,,,,,,,,,,,,,
22161,,instrument developed,,,,,,,,,,,,,,,,
22162,,epidermal growth factor for wound healing,,,,,,,,,,,,,,,,
22163,,wall gaps,,,,,,,,,,,,,,,,
22164,,co-had,,,,,,,,,,,,,,,,
22165,,urethral conditions,,,,,,,,,,,,,,,,
22166,,abdominal fistula,,,,,,,,,,,,,,,,
22167,,uncommon tumors.|pancreatic metastasis,,,,,,,,,,,,,,,,
22168,,prolonged erection,,,,,,,,,,,,,,,,
22169,,her2 positive status,,,,,,,,,,,,,,,,
22170,,neck tumors,,,,,,,,,,,,,,,,
22171,,diseases of the pancreas,,,,,,,,,,,,,,,,
22172,,ultraviolet a1 [,,,,,,,,,,,,,,,,
22173,,enclosed infection,,,,,,,,,,,,,,,,
22174,,high cholesterol levels,,,,,,,,,,,,,,,,
22175,,non-contact sport,,,,,,,,,,,,,,,,
22176,,colorectal disease|digestive resection,,,,,,,,,,,,,,,,
22177,,getational diabetes,,,,,,,,,,,,,,,,
22178,,metastatic melanoma.|in,,,,,,,,,,,,,,,,
22179,,diagnosis);|diagnosis,,,,,,,,,,,,,,,,
22180,,cranial nerve block,,,,,,,,,,,,,,,,
22181,,high-risk contact,,,,,,,,,,,,,,,,
22182,,scan|allergy,,,,,,,,,,,,,,,,
22183,,overlap syndrome,,,,,,,,,,,,,,,,
22184,,hepatitis b reference,,,,,,,,,,,,,,,,
22185,,ecv|chronic pain,,,,,,,,,,,,,,,,
22186,,females.|postpartum,,,,,,,,,,,,,,,,
22187,,drinking episode,,,,,,,,,,,,,,,,
22188,,profound atrophy/excessive,,,,,,,,,,,,,,,,
22189,,neck|previous stroke,,,,,,,,,,,,,,,,
22190,,paroxysmal,,,,,,,,,,,,,,,,
22191,,corneal surgery|capacity,,,,,,,,,,,,,,,,
22192,,impaired motor function,,,,,,,,,,,,,,,,
22193,,distant metastases.|the,,,,,,,,,,,,,,,,
22194,,immunosuppression,,,,,,,,,,,,,,,,
22195,,h. pylori,,,,,,,,,,,,,,,,
22196,,mindful courage effectively|bmi,,,,,,,,,,,,,,,,
22197,,gvhd).|uncontrolled epilepsy,,,,,,,,,,,,,,,,
22198,,refractory to medical treatment,,,,,,,,,,,,,,,,
22199,,pneumocystis jirovecii pneumonia,,,,,,,,,,,,,,,,
22200,,multi-part studies)||exclusion criteria,,,,,,,,,,,,,,,,
22201,,end stage renal disease|parathyroid disorders|cancer,,,,,,,,,,,,,,,,
22202,,lfts,,,,,,,,,,,,,,,,
22203,,chronic ascites,,,,,,,,,,,,,,,,
22204,,skin infection wounds,,,,,,,,,,,,,,,,
22205,,intact membranes|viable,,,,,,,,,,,,,,,,
22206,,abdominal carcinomatosis.|patients,,,,,,,,,,,,,,,,
22207,,arterial tortuosity,,,,,,,,,,,,,,,,
22208,,tuberculosis (bcg),,,,,,,,,,,,,,,,
22209,,stop smoking medications,,,,,,,,,,,,,,,,
22210,,labyrinthitis,,,,,,,,,,,,,,,,
22211,,trying to become,,,,,,,,,,,,,,,,
22212,,neurological diseases|active athletes,,,,,,,,,,,,,,,,
22213,,severe dysplasia,,,,,,,,,,,,,,,,
22214,,shoulder trauma,,,,,,,,,,,,,,,,
22215,,open lesion,,,,,,,,,,,,,,,,
22216,,hiv-1-infection,,,,,,,,,,,,,,,,
22217,,dsm disorders,,,,,,,,,,,,,,,,
22218,,neoplastic disease,,,,,,,,,,,,,,,,
22219,,venous thrombosis.||plans,,,,,,,,,,,,,,,,
22220,,bisexual|be hiv,,,,,,,,,,,,,,,,
22221,,solid tumor.|physical state score,,,,,,,,,,,,,,,,
22222,,abstain from any form of,,,,,,,,,,,,,,,,
22223,,functional impairment.|participants deemed well,,,,,,,,,,,,,,,,
22224,,anatomically not resectable,,,,,,,,,,,,,,,,
22225,,hirschprung disease,,,,,,,,,,,,,,,,
22226,,urinary cytology.|patients,,,,,,,,,,,,,,,,
22227,,cryoglobulinemia,,,,,,,,,,,,,,,,
22228,,drug screen,,,,,,,,,,,,,,,,
22229,,subdural hematoma,,,,,,,,,,,,,,,,
22230,,cervical medial branche block,,,,,,,,,,,,,,,,
22231,,drainage|active gastric,,,,,,,,,,,,,,,,
22232,,debilitating symptoms,,,,,,,,,,,,,,,,
22233,,extensive dental damage,,,,,,,,,,,,,,,,
22234,,treatment.|all lesions,,,,,,,,,,,,,,,,
22235,,"chronic disease,|not",,,,,,,,,,,,,,,,
22236,,tumor lesion,,,,,,,,,,,,,,,,
22237,,tuberculosis,,,,,,,,,,,,,,,,
22238,,acute choelcystitis,,,,,,,,,,,,,,,,
22239,,) infection,,,,,,,,,,,,,,,,
22240,,lower limp infection,,,,,,,,,,,,,,,,
22241,,non-digestive system malignancies,,,,,,,,,,,,,,,,
22242,,sud)|diagnosis,,,,,,,,,,,,,,,,
22243,,neonatal intensive care (nicu) admission,,,,,,,,,,,,,,,,
22244,,gastric outlet obstruction,,,,,,,,,,,,,,,,
22245,,lactation|strenuous physical activity (,,,,,,,,,,,,,,,,
22246,,thymic malignancies|18,,,,,,,,,,,,,,,,
22247,,ligament injury etc.|non-ambulatory,,,,,,,,,,,,,,,,
22248,,ventriculoperitoneal shunt,,,,,,,,,,,,,,,,
22249,,autoimmune diseases;|history,,,,,,,,,,,,,,,,
22250,,isolated skin,,,,,,,,,,,,,,,,
22251,,non-resectable metastases,,,,,,,,,,,,,,,,
22252,,target individual,,,,,,,,,,,,,,,,
22253,,language impairment,,,,,,,,,,,,,,,,
22254,,intraoperative arrythmia,,,,,,,,,,,,,,,,
22255,,cardiac pacemaker)|tissue,,,,,,,,,,,,,,,,
22256,,e.g.suicidal ideation,,,,,,,,,,,,,,,,
22257,,leprosy,,,,,,,,,,,,,,,,
22258,,venous access.|second malignancies,,,,,,,,,,,,,,,,
22259,,primary melanoma,,,,,,,,,,,,,,,,
22260,,mood,,,,,,,,,,,,,,,,
22261,,tuberculosis;|acute fever diseases,,,,,,,,,,,,,,,,
22262,,malignant cancer diagnosis|traumatic,,,,,,,,,,,,,,,,
22263,,echocardiography;|abnormal coagulation function,,,,,,,,,,,,,,,,
22264,,old|type 1 diabetes,,,,,,,,,,,,,,,,
22265,,swallowing disorder,,,,,,,,,,,,,,,,
22266,,symptomatic disease,,,,,,,,,,,,,,,,
22267,,sleep-disordered breathing,,,,,,,,,,,,,,,,
22268,,fna|patients,,,,,,,,,,,,,,,,
22269,,obstructive lesions,,,,,,,,,,,,,,,,
22270,,immune reaction,,,,,,,,,,,,,,,,
22271,,citizens of turku|home-dwelling||,,,,,,,,,,,,,,,,
22272,,medical diagnosis|previous spine surgeries,,,,,,,,,,,,,,,,
22273,,extra-pulmonary tb infection,,,,,,,,,,,,,,,,
22274,,simultaneous kidney pancreas,,,,,,,,,,,,,,,,
22275,,cerebrovascular accident|contra-indications,,,,,,,,,,,,,,,,
22276,,delivering,,,,,,,,,,,,,,,,
22277,,interpersonal trauma,,,,,,,,,,,,,,,,
22278,,extensive scarring,,,,,,,,,,,,,,,,
22279,,systemic comorbidities,,,,,,,,,,,,,,,,
22280,,mucosal ulcers).|british isles lupus assessment group-2004 (bilag,,,,,,,,,,,,,,,,
22281,,necrotic keratin,,,,,,,,,,,,,,,,
22282,,spinal,,,,,,,,,,,,,,,,
22283,,mandibular,,,,,,,,,,,,,,,,
22284,,neurogenic orthostatic hypotension,,,,,,,,,,,,,,,,
22285,,arcapa,,,,,,,,,,,,,,,,
22286,,cerebral thrombus.|protected persons,,,,,,,,,,,,,,,,
22287,,cardinal signs,,,,,,,,,,,,,,,,
22288,,biliary tract,,,,,,,,,,,,,,,,
22289,,etc.)|known allergy,,,,,,,,,,,,,,,,
22290,,clinicians and|faculty||,,,,,,,,,,,,,,,,
22291,,endodontic failure,,,,,,,,,,,,,,,,
22292,,coagulative disorders|renal impairment|sickle cell disease|thrombotic diseases|comorbidities,,,,,,,,,,,,,,,,
22293,,epilepsy,,,,,,,,,,,,,,,,
22294,,shunts,,,,,,,,,,,,,,,,
22295,,acute illness occurring,,,,,,,,,,,,,,,,
22296,,cardiac arrhythmia,,,,,,,,,,,,,,,,
22297,,hodgkin's lymphoma,,,,,,,,,,,,,,,,
22298,,normal mean mitral,,,,,,,,,,,,,,,,
22299,,ocular histoplasmosis syndrome,,,,,,,,,,,,,,,,
22300,,gastric bleeding.|irritable bowel syndrome,,,,,,,,,,,,,,,,
22301,,present.|a main complaint,,,,,,,,,,,,,,,,
22302,,hyperthyroidism,,,,,,,,,,,,,,,,
22303,,deep brain stimulation)|conductive hearing loss,,,,,,,,,,,,,,,,
22304,,eligible.|congestive heart failure,,,,,,,,,,,,,,,,
22305,,cauda equina,,,,,,,,,,,,,,,,
22306,,immunocompromised states,,,,,,,,,,,,,,,,
22307,,comorbid cardiac disease,,,,,,,,,,,,,,,,
22308,,ligament damage,,,,,,,,,,,,,,,,
22309,,clinical condition,,,,,,,,,,,,,,,,
22310,,psychoactive substance abuse,,,,,,,,,,,,,,,,
22311,,therapy;|poorly controlled,,,,,,,,,,,,,,,,
22312,,judged by the treating physician,,,,,,,,,,,,,,,,
22313,,drugs);|active hepatitis,,,,,,,,,,,,,,,,
22314,,copd).|cardiac dysfunction,,,,,,,,,,,,,,,,
22315,,cervical tissue alteration,,,,,,,,,,,,,,,,
22316,,cowden syndome,,,,,,,,,,,,,,,,
22317,,bipolar disorder|heart disease,,,,,,,,,,,,,,,,
22318,,glomerulitis,,,,,,,,,,,,,,,,
22319,,atypical lobular hyperplasia,,,,,,,,,,,,,,,,
22320,,perthes disease,,,,,,,,,,,,,,,,
22321,,scapular pain,,,,,,,,,,,,,,,,
22322,,chronic lichenia simple,,,,,,,,,,,,,,,,
22323,,pleural adhesion,,,,,,,,,,,,,,,,
22324,,acute myeloid leukemia.|patients,,,,,,,,,,,,,,,,
22325,,thrombophilic disorders,,,,,,,,,,,,,,,,
22326,,additional risk factor for coronary artery disease|presence of microvascular disease,,,,,,,,,,,,,,,,
22327,,eye surgeries,,,,,,,,,,,,,,,,
22328,,chronic hbv infection,,,,,,,,,,,,,,,,
22329,,signs of disease,,,,,,,,,,,,,,,,
22330,,anemia|alcoholic liver disease|malabsorptive syndromes - celiac disease,,,,,,,,,,,,,,,,
22331,,criteria for hiv wasting syndrome (loss of,,,,,,,,,,,,,,,,
22332,,h. pylori infection|active smoking|ongoing,,,,,,,,,,,,,,,,
22333,,exon 14 skipping,,,,,,,,,,,,,,,,
22334,,thyroid goiter)||both,,,,,,,,,,,,,,,,
22335,,involvement of lymph nodes;|prior therapy,,,,,,,,,,,,,,,,
22336,,middle ear occlusion,,,,,,,,,,,,,,,,
22337,,urinary infection,,,,,,,,,,,,,,,,
22338,,bacterial pneumonia,,,,,,,,,,,,,,,,
22339,,deranged coagulation,,,,,,,,,,,,,,,,
22340,,non-isolated tricuspid valve surgery,,,,,,,,,,,,,,,,
22341,,tried e-cigarette,,,,,,,,,,,,,,,,
22342,,bowel disease (ibd),,,,,,,,,,,,,,,,
22343,,signet-ring cell carcinoma,,,,,,,,,,,,,,,,
22344,,lorazepam,,,,,,,,,,,,,,,,
22345,,acute brain infarction,,,,,,,,,,,,,,,,
22346,,new brain metastasis,,,,,,,,,,,,,,,,
22347,,diseases of heart,,,,,,,,,,,,,,,,
22348,,vitreous macular traction,,,,,,,,,,,,,,,,
22349,,metachronous peritoneal carcinomatosis,,,,,,,,,,,,,,,,
22350,,retinal vascular alterations,,,,,,,,,,,,,,,,
22351,,gastrointestinal mucosal cancer,,,,,,,,,,,,,,,,
22352,,carcinoma in situ of the breast/cervix,,,,,,,,,,,,,,,,
22353,,substance addiction,,,,,,,,,,,,,,,,
22354,,local regulations deviate,,,,,,,,,,,,,,,,
22355,,tract disease,,,,,,,,,,,,,,,,
22356,,aortapathy,,,,,,,,,,,,,,,,
22357,,complications；|5.pregnancy,,,,,,,,,,,,,,,,
22358,,bipolar mood disorder,,,,,,,,,,,,,,,,
22359,,pathological indications,,,,,,,,,,,,,,,,
22360,,valvular heart disease|hypertension,,,,,,,,,,,,,,,,
22361,,varicosities,,,,,,,,,,,,,,,,
22362,,arterial thrombosis,,,,,,,,,,,,,,,,
22363,,females.|children,,,,,,,,,,,,,,,,
22364,,exacerbation||for,,,,,,,,,,,,,,,,
22365,,delayed hypersensitivity reaction,,,,,,,,,,,,,,,,
22366,,neurologic diseases,,,,,,,,,,,,,,,,
22367,,neuropathy.|previous fracture/ trauma,,,,,,,,,,,,,,,,
22368,,gilbert's syndrome.||v. international ratio,,,,,,,,,,,,,,,,
22369,,rsv infection,,,,,,,,,,,,,,,,
22370,,infantile cerebral palsy,,,,,,,,,,,,,,,,
22371,,carbon monoxide (co),,,,,,,,,,,,,,,,
22372,,transient ischemic attack|prior heart,,,,,,,,,,,,,,,,
22373,,tourette's syndrome,,,,,,,,,,,,,,,,
22374,,disorder;|active gastrointestinal graft,,,,,,,,,,,,,,,,
22375,,adverse drug reactions,,,,,,,,,,,,,,,,
22376,,skin conditions favorizing infections,,,,,,,,,,,,,,,,
22377,,hyper-/hypocalcemia,,,,,,,,,,,,,,,,
22378,,screening|significant changes in lifestyle,,,,,,,,,,,,,,,,
22379,,systemic infection,,,,,,,,,,,,,,,,
22380,,unstable renal function,,,,,,,,,,,,,,,,
22381,,nose).|skin phototype,,,,,,,,,,,,,,,,
22382,,historic dysmenorrhea,,,,,,,,,,,,,,,,
22383,,crescentic collection of,,,,,,,,,,,,,,,,
22384,,abstain from recreational cannabis,,,,,,,,,,,,,,,,
22385,,urinary outflow,,,,,,,,,,,,,,,,
22386,,afl,,,,,,,,,,,,,,,,
22387,,coagulation dysfunction.|the toxicity of,,,,,,,,,,,,,,,,
22388,,neuralgi|osteoarthrosis,,,,,,,,,,,,,,,,
22389,,nivolumab.|evidence,,,,,,,,,,,,,,,,
22390,,blood stream infection,,,,,,,,,,,,,,,,
22391,,papillary thyroid microcarcinoma,,,,,,,,,,,,,,,,
22392,,glaucoma|history,,,,,,,,,,,,,,,,
22393,,male infertility,,,,,,,,,,,,,,,,
22394,,pre-gestational diabetes mellitus|multiple,,,,,,,,,,,,,,,,
22395,,intestinal metaplasia,,,,,,,,,,,,,,,,
22396,,hence,,,,,,,,,,,,,,,,
22397,,incisional glaucoma surgery,,,,,,,,,,,,,,,,
22398,,acute trauma,,,,,,,,,,,,,,,,
22399,,hematopoietic factor preparations,,,,,,,,,,,,,,,,
22400,,drug use|clinical disorders,,,,,,,,,,,,,,,,
22401,,renal insufficiency.|previous cardiac,,,,,,,,,,,,,,,,
22402,,pennsylvania,,,,,,,,,,,,,,,,
22403,,old|pleural infection,,,,,,,,,,,,,,,,
22404,,hepatitis b carriers,,,,,,,,,,,,,,,,
22405,,adverse events (ctcae) v.5.0,,,,,,,,,,,,,,,,
22406,,arterial hypotension.|hypersensitivity,,,,,,,,,,,,,,,,
22407,,abca4g1961e variant,,,,,,,,,,,,,,,,
22408,,asthma episode,,,,,,,,,,,,,,,,
22409,,myocardial infarction|previous gastro,,,,,,,,,,,,,,,,
22410,,intestinal obstruction);|those,,,,,,,,,,,,,,,,
22411,,neurological conditions,,,,,,,,,,,,,,,,
22412,,drug abuse problem,,,,,,,,,,,,,,,,
22413,,coagulation indicators,,,,,,,,,,,,,,,,
22414,,bleeding problems,,,,,,,,,,,,,,,,
22415,,radiation therapy.|unstable angina,,,,,,,,,,,,,,,,
22416,,acute coronary syndrome,,,,,,,,,,,,,,,,
22417,,hysteria|ocular surgery|amblyopia|anisometropia|strabismus|systemic disease,,,,,,,,,,,,,,,,
22418,,hypercalcemia corrected,,,,,,,,,,,,,,,,
22419,,"ezetimib,|pregnant",,,,,,,,,,,,,,,,
22420,,regurgitation,,,,,,,,,,,,,,,,
22421,,lower extremity fractures,,,,,,,,,,,,,,,,
22422,,renal osteodystrophy,,,,,,,,,,,,,,,,
22423,,inguinal hernia|patients,,,,,,,,,,,,,,,,
22424,,unsteadiness on feet,,,,,,,,,,,,,,,,
22425,,impaired functional outcomes,,,,,,,,,,,,,,,,
22426,,fpies).|diagnosis,,,,,,,,,,,,,,,,
22427,,bilateral head pain,,,,,,,,,,,,,,,,
22428,,tumor disease|acute infection,,,,,,,,,,,,,,,,
22429,,alpha-1-antitrypsin deficiency,,,,,,,,,,,,,,,,
22430,,herpetic eye disease,,,,,,,,,,,,,,,,
22431,,paroxysmal tachyarrhythmia,,,,,,,,,,,,,,,,
22432,,asthma bronchiale|exacerbation,,,,,,,,,,,,,,,,
22433,,aortic valve stenosis,,,,,,,,,,,,,,,,
22434,,pain,,,,,,,,,,,,,,,,
22435,,nsclc/,,,,,,,,,,,,,,,,
22436,,lymphadenopathy,,,,,,,,,,,,,,,,
22437,,mydriasis,,,,,,,,,,,,,,,,
22438,,rv myocardial performance,,,,,,,,,,,,,,,,
22439,,non-epilepsy neurological surgery,,,,,,,,,,,,,,,,
22440,,wall thrombosis,,,,,,,,,,,,,,,,
22441,,ivf,,,,,,,,,,,,,,,,
22442,,chronic diarrhea|peptic ulcer,,,,,,,,,,,,,,,,
22443,,pharyngitis,,,,,,,,,,,,,,,,
22444,,immunocompromised condition,,,,,,,,,,,,,,,,
22445,,left hemispatial neglect||,,,,,,,,,,,,,,,,
22446,,acute cerebral infarction,,,,,,,,,,,,,,,,
22447,,hematological disorders,,,,,,,,,,,,,,,,
22448,,-age 40,,,,,,,,,,,,,,,,
22449,,calculated risk for breast cancer,,,,,,,,,,,,,,,,
22450,,paroxysmal atrial,,,,,,,,,,,,,,,,
22451,,uncontrolled illness,,,,,,,,,,,,,,,,
22452,,applied,,,,,,,,,,,,,,,,
22453,,systemic treatment.|interstitial lung disease,,,,,,,,,,,,,,,,
22454,,hepatitis c|systemic infection,,,,,,,,,,,,,,,,
22455,,laboratory indicators,,,,,,,,,,,,,,,,
22456,,local curable cancers.|uncontrolled,,,,,,,,,,,,,,,,
22457,,radical hysterectomy,,,,,,,,,,,,,,,,
22458,,products|known osteomyelitis,,,,,,,,,,,,,,,,
22459,,secondary suicide attempt,,,,,,,,,,,,,,,,
22460,,lower limb amputation,,,,,,,,,,,,,,,,
22461,,throat/oesophagus;|mechanical obstruction of the throat accountable,,,,,,,,,,,,,,,,
22462,,covid-19 exposure,,,,,,,,,,,,,,,,
22463,,permanent visual,,,,,,,,,,,,,,,,
22464,,immune-mediated thrombocytopenia,,,,,,,,,,,,,,,,
22465,,bone metastases ap,,,,,,,,,,,,,,,,
22466,,relapsing forms,,,,,,,,,,,,,,,,
22467,,hypobetalipoproteinemia,,,,,,,,,,,,,,,,
22468,,medically compromised patients|pregnant,,,,,,,,,,,,,,,,
22469,,months;|stable disease,,,,,,,,,,,,,,,,
22470,,psychiatric interview;|at least moderate,,,,,,,,,,,,,,,,
22471,,hands bilaterally,,,,,,,,,,,,,,,,
22472,,prolonged qt syndrome.|uncontrolled,,,,,,,,,,,,,,,,
22473,,self-injurious behavior|have,,,,,,,,,,,,,,,,
22474,,judged by the investigator.|history,,,,,,,,,,,,,,,,
22475,,training|inability,,,,,,,,,,,,,,,,
22476,,hemostasis,,,,,,,,,,,,,,,,
22477,,retinal vascular occlusions,,,,,,,,,,,,,,,,
22478,,deleterious germline brca,,,,,,,,,,,,,,,,
22479,,dumping syndrome,,,,,,,,,,,,,,,,
22480,,comorbid medical disorder,,,,,,,,,,,,,,,,
22481,,bronchoalveolar lavage fluid,,,,,,,,,,,,,,,,
22482,,mrna splicing modifier,,,,,,,,,,,,,,,,
22483,,nras,,,,,,,,,,,,,,,,
22484,,pain/injury,,,,,,,,,,,,,,,,
22485,,intracranial brain lesions,,,,,,,,,,,,,,,,
22486,,malignancy.|pregnancy,,,,,,,,,,,,,,,,
22487,,prostate in situ cancer,,,,,,,,,,,,,,,,
22488,,hip replacement,,,,,,,,,,,,,,,,
22489,,mismatch repair deficient,,,,,,,,,,,,,,,,
22490,,resting periods;|able,,,,,,,,,,,,,,,,
22491,,bone defect treatment,,,,,,,,,,,,,,,,
22492,,influence hemodynamic response|presence,,,,,,,,,,,,,,,,
22493,,retinal vein occlusion (,,,,,,,,,,,,,,,,
22494,,proportion,,,,,,,,,,,,,,,,
22495,,pns procedure|shoulder pain,,,,,,,,,,,,,,,,
22496,,disease like asthma,,,,,,,,,,,,,,,,
22497,,serious head injury.|subject,,,,,,,,,,,,,,,,
22498,,third-space effusion,,,,,,,,,,,,,,,,
22499,,intracranial space,,,,,,,,,,,,,,,,
22500,,pad,,,,,,,,,,,,,,,,
22501,,conditions.|active epilepsy,,,,,,,,,,,,,,,,
22502,,norway,,,,,,,,,,,,,,,,
22503,,lymphoblastic leukemia,,,,,,,,,,,,,,,,
22504,,metolazone|inability to take oral medications|severe aortic stenosis (,,,,,,,,,,,,,,,,
22505,,completely resolved,,,,,,,,,,,,,,,,
22506,,coronary ischemia,,,,,,,,,,,,,,,,
22507,,cns malignancies,,,,,,,,,,,,,,,,
22508,,preterm labor,,,,,,,,,,,,,,,,
22509,,inflammatory spinal pain,,,,,,,,,,,,,,,,
22510,,juvenile rheumatoid arthritis (jra),,,,,,,,,,,,,,,,
22511,,internal trichiasis,,,,,,,,,,,,,,,,
22512,,medial wound,,,,,,,,,,,,,,,,
22513,,arrest,,,,,,,,,,,,,,,,
22514,,mood depressive disorder,,,,,,,,,,,,,,,,
22515,,heart failure.|an ecg,,,,,,,,,,,,,,,,
22516,,common variable immunodeficiency disease,,,,,,,,,,,,,,,,
22517,,tympanometry,,,,,,,,,,,,,,,,
22518,,neurosensory retinal detachment,,,,,,,,,,,,,,,,
22519,,gastrin-releasing peptide receptor (grpr),,,,,,,,,,,,,,,,
22520,,shoulder fracture.|body mass index,,,,,,,,,,,,,,,,
22521,,ⅳ level;|liver,,,,,,,,,,,,,,,,
22522,,surgical operations|surgeries,,,,,,,,,,,,,,,,
22523,,cognitive disorder,,,,,,,,,,,,,,,,
22524,,"mental retardation,|gmfcs level",,,,,,,,,,,,,,,,
22525,,severe constipation,,,,,,,,,,,,,,,,
22526,,visit.|asthma stability,,,,,,,,,,,,,,,,
22527,,arterial,,,,,,,,,,,,,,,,
22528,,musculoskeletal disorders like oa,,,,,,,,,,,,,,,,
22529,,functional physical limitations,,,,,,,,,,,,,,,,
22530,,cord compression,,,,,,,,,,,,,,,,
22531,,vasculopathy,,,,,,,,,,,,,,,,
22532,,sgc.|participants,,,,,,,,,,,,,,,,
22533,,alcohol drinking|male,,,,,,,,,,,,,,,,
22534,,performing an mri,,,,,,,,,,,,,,,,
22535,,need emergency,,,,,,,,,,,,,,,,
22536,,women;|mental disorders,,,,,,,,,,,,,,,,
22537,,ph-lhd,,,,,,,,,,,,,,,,
22538,,leaks,,,,,,,,,,,,,,,,
22539,,brain metastases|ecog ps score,,,,,,,,,,,,,,,,
22540,,zonular weakness,,,,,,,,,,,,,,,,
22541,,roanoke,,,,,,,,,,,,,,,,
22542,,human immunodeficiency virus (hiv) test)||a subject,,,,,,,,,,,,,,,,
22543,,lifestyle factor,,,,,,,,,,,,,,,,
22544,,solid tumors|subjects,,,,,,,,,,,,,,,,
22545,,recovered from any adverse events relating,,,,,,,,,,,,,,,,
22546,,breathing disorders,,,,,,,,,,,,,,,,
22547,,coagulation function,,,,,,,,,,,,,,,,
22548,,idiopathic rls,,,,,,,,,,,,,,,,
22549,,acute confusional state,,,,,,,,,,,,,,,,
22550,,mental dysfunction,,,,,,,,,,,,,,,,
22551,,endometrial dysplasia/carcinoma,,,,,,,,,,,,,,,,
22552,,immune deficiency diseases.||laboratory inspection,,,,,,,,,,,,,,,,
22553,,keratoconus stages,,,,,,,,,,,,,,,,
22554,,respiratory muscle pump,,,,,,,,,,,,,,,,
22555,,relapsing-remitting,,,,,,,,,,,,,,,,
22556,,consent|not regularly physically active,,,,,,,,,,,,,,,,
22557,,primary renal disease.|evidence,,,,,,,,,,,,,,,,
22558,,ground-glass opacity,,,,,,,,,,,,,,,,
22559,,immune-deficiency,,,,,,,,,,,,,,,,
22560,,semi-professional / professional,,,,,,,,,,,,,,,,
22561,,primary adrenal insufficiency,,,,,,,,,,,,,,,,
22562,,scleral buckle surgery|cases,,,,,,,,,,,,,,,,
22563,,liver cyst,,,,,,,,,,,,,,,,
22564,,bone metastases,,,,,,,,,,,,,,,,
22565,,ventricle heart disease,,,,,,,,,,,,,,,,
22566,,disorders of metabolism,,,,,,,,,,,,,,,,
22567,,tpa:||intracerebral hemorrhage,,,,,,,,,,,,,,,,
22568,,cognitive impairment|patients,,,,,,,,,,,,,,,,
22569,,hypertension)|persons,,,,,,,,,,,,,,,,
22570,,large cell carcinoma,,,,,,,,,,,,,,,,
22571,,face-to-face rehabilitation,,,,,,,,,,,,,,,,
22572,,cerebral occupying lesion;|fusiform aneurysm,,,,,,,,,,,,,,,,
22573,,takutsubo cardiomyopathy,,,,,,,,,,,,,,,,
22574,,ccd,,,,,,,,,,,,,,,,
22575,,sigmoid colon,,,,,,,,,,,,,,,,
22576,,2019;|pulmonary artery hypertension,,,,,,,,,,,,,,,,
22577,,thrombocytopenia induced,,,,,,,,,,,,,,,,
22578,,balance disturbances,,,,,,,,,,,,,,,,
22579,,lymphomatous involvement,,,,,,,,,,,,,,,,
22580,,proliferative retinopathy,,,,,,,,,,,,,,,,
22581,,student of the experimental bacteriology group,,,,,,,,,,,,,,,,
22582,,variant,,,,,,,,,,,,,,,,
22583,,biliary obstruction,,,,,,,,,,,,,,,,
22584,,chronic seizures,,,,,,,,,,,,,,,,
22585,,brain abscesses,,,,,,,,,,,,,,,,
22586,,immunosuppressive drugs|uncontrolled hypertension,,,,,,,,,,,,,,,,
22587,,metastasic cancer,,,,,,,,,,,,,,,,
22588,,modified t-cell,,,,,,,,,,,,,,,,
22589,,drip)|poor response,,,,,,,,,,,,,,,,
22590,,syndrome,,,,,,,,,,,,,,,,
22591,,medical complications,,,,,,,,,,,,,,,,
22592,,pose,,,,,,,,,,,,,,,,
22593,,heart valve diseases,,,,,,,,,,,,,,,,
22594,,colonic eosinophilia.|patients,,,,,,,,,,,,,,,,
22595,,drug pump.|skin sensitivity,,,,,,,,,,,,,,,,
22596,,smouldering mm,,,,,,,,,,,,,,,,
22597,,sll)|waldenström's macroglobulinemia,,,,,,,,,,,,,,,,
22598,,coronary ivl,,,,,,,,,,,,,,,,
22599,,michigan campus,,,,,,,,,,,,,,,,
22600,,brachial plexopathy|injection,,,,,,,,,,,,,,,,
22601,,brain metastases:|brain metastases,,,,,,,,,,,,,,,,
22602,,breast cancer carcinoma,,,,,,,,,,,,,,,,
22603,,childhood seizure,,,,,,,,,,,,,,,,
22604,,herniation disoriented patients|patients,,,,,,,,,,,,,,,,
22605,,compliance.|tempromandibular joint disorders.|disabilities,,,,,,,,,,,,,,,,
22606,,cvrx,,,,,,,,,,,,,,,,
22607,,ptsd||non-ptsd,,,,,,,,,,,,,,,,
22608,,hemorrhagic complications,,,,,,,,,,,,,,,,
22609,,ocular tumors)|reduced transparency,,,,,,,,,,,,,,,,
22610,,liver cirrhosis.|symptomatic brain metastases,,,,,,,,,,,,,,,,
22611,,hydrogels;|pregnant,,,,,,,,,,,,,,,,
22612,,acute anemia,,,,,,,,,,,,,,,,
22613,,avoiding alcohol intake,,,,,,,,,,,,,,,,
22614,,in situ breast cancer,,,,,,,,,,,,,,,,
22615,,acute glomerulopathy,,,,,,,,,,,,,,,,
22616,,covid-19 risk,,,,,,,,,,,,,,,,
22617,,vulvar tumor,,,,,,,,,,,,,,,,
22618,,drug rhinitis,,,,,,,,,,,,,,,,
22619,,diabetes mellitus|patients,,,,,,,,,,,,,,,,
22620,,hepatitis c|uncontrolled pleural effusion,,,,,,,,,,,,,,,,
22621,,immunodeficiency|active hepatitis,,,,,,,,,,,,,,,,
22622,,inadequate response/non-response,,,,,,,,,,,,,,,,
22623,,adequate dexterity,,,,,,,,,,,,,,,,
22624,,transient ischemia attack,,,,,,,,,,,,,,,,
22625,,discomfort|history of,,,,,,,,,,,,,,,,
22626,,movement disorders,,,,,,,,,,,,,,,,
22627,,irregular corneal astigmatism,,,,,,,,,,,,,,,,
22628,,carcinosis,,,,,,,,,,,,,,,,
22629,,homozygous factor ii,,,,,,,,,,,,,,,,
22630,,physician assistants,,,,,,,,,,,,,,,,
22631,,thrombotic disease,,,,,,,,,,,,,,,,
22632,,stressful event frequency,,,,,,,,,,,,,,,,
22633,,ischemic stroke,,,,,,,,,,,,,,,,
22634,,mullerian duct malformation,,,,,,,,,,,,,,,,
22635,,mental condition,,,,,,,,,,,,,,,,
22636,,cardiopulmonary abnormalities,,,,,,,,,,,,,,,,
22637,,asymptomatic infections,,,,,,,,,,,,,,,,
22638,,allergic disease,,,,,,,,,,,,,,,,
22639,,chronic intractable pain,,,,,,,,,,,,,,,,
22640,,primary aldosteronism,,,,,,,,,,,,,,,,
22641,,alxn1840,,,,,,,,,,,,,,,,
22642,,atrx,,,,,,,,,,,,,,,,
22643,,metatarsal heads,,,,,,,,,,,,,,,,
22644,,previous ca,,,,,,,,,,,,,,,,
22645,,in situ cervical cancer,,,,,,,,,,,,,,,,
22646,,bleeding diatheses.|active infection,,,,,,,,,,,,,,,,
22647,,learning difficulties|is,,,,,,,,,,,,,,,,
22648,,psychotic depression episode,,,,,,,,,,,,,,,,
22649,,pathologic root resorption,,,,,,,,,,,,,,,,
22650,,coaching,,,,,,,,,,,,,,,,
22651,,atorvastatin.|active peptic ulcer disease,,,,,,,,,,,,,,,,
22652,,accessible lesion,,,,,,,,,,,,,,,,
22653,,prolonged seizure,,,,,,,,,,,,,,,,
22654,,toxin exposure,,,,,,,,,,,,,,,,
22655,,soft tissue loss,,,,,,,,,,,,,,,,
22656,,acute hemorrhage,,,,,,,,,,,,,,,,
22657,,viral rhinitis,,,,,,,,,,,,,,,,
22658,,intestinal cavity perforation,,,,,,,,,,,,,,,,
22659,,balance problems,,,,,,,,,,,,,,,,
22660,,niu,,,,,,,,,,,,,,,,
22661,,systemic antimetabolites,,,,,,,,,,,,,,,,
22662,,hyperactive coagulation states,,,,,,,,,,,,,,,,
22663,,neurosurgery intervention done,,,,,,,,,,,,,,,,
22664,,chronic cardiac,,,,,,,,,,,,,,,,
22665,,metabolic disorders||,,,,,,,,,,,,,,,,
22666,,skin reaction,,,,,,,,,,,,,,,,
22667,,somatic comorbidities,,,,,,,,,,,,,,,,
22668,,cutaneous fistula,,,,,,,,,,,,,,,,
22669,,regular menstrual cycles,,,,,,,,,,,,,,,,
22670,,deep vertical periodontal lesions,,,,,,,,,,,,,,,,
22671,,nccrcc,,,,,,,,,,,,,,,,
22672,,thrombotic disorders,,,,,,,,,,,,,,,,
22673,,anxiety disorders inpatient unit,,,,,,,,,,,,,,,,
22674,,cystic components,,,,,,,,,,,,,,,,
22675,,cancers|prior cancer,,,,,,,,,,,,,,,,
22676,,dog-1(+)|wild type gist,,,,,,,,,,,,,,,,
22677,,electrolyte metabolism,,,,,,,,,,,,,,,,
22678,,atrial fibrillation|active pacing,,,,,,,,,,,,,,,,
22679,,pigmentation disorders,,,,,,,,,,,,,,,,
22680,,novasoy,,,,,,,,,,,,,,,,
22681,,preoperative sick sinus,,,,,,,,,,,,,,,,
22682,,old|mini-mental state examination (mmse),,,,,,,,,,,,,,,,
22683,,give consent.|upper arm vein diameter,,,,,,,,,,,,,,,,
22684,,incidental findings,,,,,,,,,,,,,,,,
22685,,acquired condition,,,,,,,,,,,,,,,,
22686,,soft tissue pathology,,,,,,,,,,,,,,,,
22687,,neuroimaging abnormality,,,,,,,,,,,,,,,,
22688,,lgd,,,,,,,,,,,,,,,,
22689,,obstructive pulmonary,,,,,,,,,,,,,,,,
22690,,hyperosmolar states,,,,,,,,,,,,,,,,
22691,,refractory hypertension,,,,,,,,,,,,,,,,
22692,,disorders,,,,,,,,,,,,,,,,
22693,,sensitivity to mph,,,,,,,,,,,,,,,,
22694,,right heart catherisation,,,,,,,,,,,,,,,,
22695,,penile disease,,,,,,,,,,,,,,,,
22696,,antimetabolites,,,,,,,,,,,,,,,,
22697,,neurological dysfunction,,,,,,,,,,,,,,,,
22698,,sbrt lesions|patients,,,,,,,,,,,,,,,,
22699,,rheumatic conditions,,,,,,,,,,,,,,,,
22700,,bladder pain syndrome,,,,,,,,,,,,,,,,
22701,,surgery|previous swallowing,,,,,,,,,,,,,,,,
22702,,premature ovarian insufficiency,,,,,,,,,,,,,,,,
22703,,myelopathy|communication problems|pregnancy,,,,,,,,,,,,,,,,
22704,,pose a risk to study personnel,,,,,,,,,,,,,,,,
22705,,liver function|patients,,,,,,,,,,,,,,,,
22706,,gastric adenocarcinoma,,,,,,,,,,,,,,,,
22707,,respiratory support procedure,,,,,,,,,,,,,,,,
22708,,viral keratitis,,,,,,,,,,,,,,,,
22709,,bladder catheter,,,,,,,,,,,,,,,,
22710,,adult obese,,,,,,,,,,,,,,,,
22711,,non-emergency surgery,,,,,,,,,,,,,,,,
22712,,resectable lesion,,,,,,,,,,,,,,,,
22713,,erectile dysfunction,,,,,,,,,,,,,,,,
22714,,psychosis;|asplenia,,,,,,,,,,,,,,,,
22715,,pulmonary thromboembolism,,,,,,,,,,,,,,,,
22716,,alternative condition,,,,,,,,,,,,,,,,
22717,,hepato-cellular carcinoma,,,,,,,,,,,,,,,,
22718,,"ischemic stroke.|adamts 13<10%,",,,,,,,,,,,,,,,,
22719,,abdominal aortic aneurysm,,,,,,,,,,,,,,,,
22720,,inadequate muscle mass,,,,,,,,,,,,,,,,
22721,,peep ≥5cmh20,,,,,,,,,,,,,,,,
22722,,multicentric castleman disease.|current active liver disease,,,,,,,,,,,,,,,,
22723,,double-barrier methods of contraception,,,,,,,,,,,,,,,,
22724,,valvular heart,,,,,,,,,,,,,,,,
22725,,familial crc,,,,,,,,,,,,,,,,
22726,,non-cardiac surgery,,,,,,,,,,,,,,,,
22727,,colon cancer diagnosis|stage,,,,,,,,,,,,,,,,
22728,,acute chest pain|elevated troponin|non-obstructive coronary,,,,,,,,,,,,,,,,
22729,,cross-reactive allergen,,,,,,,,,,,,,,,,
22730,,late-stage alzheimer's dementia,,,,,,,,,,,,,,,,
22731,,gastroesophageal reflux,,,,,,,,,,,,,,,,
22732,,early pregnancy||healthy,,,,,,,,,,,,,,,,
22733,,acute stemi,,,,,,,,,,,,,,,,
22734,,cranio-cerebral trauma,,,,,,,,,,,,,,,,
22735,,labyrinthine injury,,,,,,,,,,,,,,,,
22736,,hypercoagulability diseases,,,,,,,,,,,,,,,,
22737,,cardiac function,,,,,,,,,,,,,,,,
22738,,herbal medicine,,,,,,,,,,,,,,,,
22739,,non-cardiac cause|participation,,,,,,,,,,,,,,,,
22740,,farsi,,,,,,,,,,,,,,,,
22741,,good blood pressure control,,,,,,,,,,,,,,,,
22742,,ocular comorbidity,,,,,,,,,,,,,,,,
22743,,inflammations,,,,,,,,,,,,,,,,
22744,,spinal dysraphism,,,,,,,,,,,,,,,,
22745,,severe clinical illness,,,,,,,,,,,,,,,,
22746,,turns,,,,,,,,,,,,,,,,
22747,,myopathy|hypothyroidism|if,,,,,,,,,,,,,,,,
22748,,consciousness disorders,,,,,,,,,,,,,,,,
22749,,hla typing);|vaginal,,,,,,,,,,,,,,,,
22750,,classical trigeminal neuralgia,,,,,,,,,,,,,,,,
22751,,radiation cystitis,,,,,,,,,,,,,,,,
22752,,dyspnea of nyha functional class,,,,,,,,,,,,,,,,
22753,,anamnesis)|no accommodative,,,,,,,,,,,,,,,,
22754,,head trauma.|neoplasia.|prior neurodegenerative disease.|prior diagnosis,,,,,,,,,,,,,,,,
22755,,mild disease severity,,,,,,,,,,,,,,,,
22756,,severe diarrhea,,,,,,,,,,,,,,,,
22757,,tumor cachexia,,,,,,,,,,,,,,,,
22758,,myocardiopathy,,,,,,,,,,,,,,,,
22759,,type 1 diabetes|currently,,,,,,,,,,,,,,,,
22760,,dermatological lesions,,,,,,,,,,,,,,,,
22761,,non-small cell lung cancer,,,,,,,,,,,,,,,,
22762,,dyspareunia,,,,,,,,,,,,,,,,
22763,,conduct disorder,,,,,,,,,,,,,,,,
22764,,allergy)|narcotic dependence|women,,,,,,,,,,,,,,,,
22765,,impaired consciousness|protected persons,,,,,,,,,,,,,,,,
22766,,somatic pole/pold1,,,,,,,,,,,,,,,,
22767,,hypo,,,,,,,,,,,,,,,,
22768,,end-stage disease,,,,,,,,,,,,,,,,
22769,,lateral patellofemoral instability|tt-tg,,,,,,,,,,,,,,,,
22770,,severe sensory alterations,,,,,,,,,,,,,,,,
22771,,states,,,,,,,,,,,,,,,,
22772,,undetectable|c,,,,,,,,,,,,,,,,
22773,,surgically unresectable,,,,,,,,,,,,,,,,
22774,,non-dn,,,,,,,,,,,,,,,,
22775,,lentigo maligna (,,,,,,,,,,,,,,,,
22776,,autoimmune conditions,,,,,,,,,,,,,,,,
22777,,etc.);|surgical interventions,,,,,,,,,,,,,,,,
22778,,lung squamous carcinoma,,,,,,,,,,,,,,,,
22779,,typhoid fever,,,,,,,,,,,,,,,,
22780,,chemotherapy;|human immunodeficiency virus,,,,,,,,,,,,,,,,
22781,,soft tissue injury,,,,,,,,,,,,,,,,
22782,,pulmonary surgical procedures,,,,,,,,,,,,,,,,
22783,,regional neurological symptoms,,,,,,,,,,,,,,,,
22784,,surgical bleeding,,,,,,,,,,,,,,,,
22785,,wrist arthritis,,,,,,,,,,,,,,,,
22786,,vital bone,,,,,,,,,,,,,,,,
22787,,physically violent behaviors.|initiation,,,,,,,,,,,,,,,,
22788,,intact cervix.||group,,,,,,,,,,,,,,,,
22789,,simple calculated osteoporosis risk estimation,,,,,,,,,,,,,,,,
22790,,carbonated foods,,,,,,,,,,,,,,,,
22791,,more|current coffee drinkers,,,,,,,,,,,,,,,,
22792,,eac,,,,,,,,,,,,,,,,
22793,,cystic,,,,,,,,,,,,,,,,
22794,,cyp3a inducer,,,,,,,,,,,,,,,,
22795,,exercise intolerance,,,,,,,,,,,,,,,,
22796,,refractory shock,,,,,,,,,,,,,,,,
22797,,injectable progesterone,,,,,,,,,,,,,,,,
22798,,chronic uveitis,,,,,,,,,,,,,,,,
22799,,head/brain,,,,,,,,,,,,,,,,
22800,,thyroidal condition,,,,,,,,,,,,,,,,
22801,,kidney disease|anaemia,,,,,,,,,,,,,,,,
22802,,basal-cell carcinoma,,,,,,,,,,,,,,,,
22803,,intracranial glioblastoma multiforme,,,,,,,,,,,,,,,,
22804,,underlying infection,,,,,,,,,,,,,,,,
22805,,mgus,,,,,,,,,,,,,,,,
22806,,bifascicular,,,,,,,,,,,,,,,,
22807,,muscle,,,,,,,,,,,,,,,,
22808,,rheumatoid arthritis)|contraindication to mri|pregnancy,,,,,,,,,,,,,,,,
22809,,disseminated herpes,,,,,,,,,,,,,,,,
22810,,richter's transformation,,,,,,,,,,,,,,,,
22811,,hemodynamic stability,,,,,,,,,,,,,,,,
22812,,suicidal behavior,,,,,,,,,,,,,,,,
22813,,peritoneal signs,,,,,,,,,,,,,,,,
22814,,mood stabilization,,,,,,,,,,,,,,,,
22815,,developmental disorder,,,,,,,,,,,,,,,,
22816,,psychological symptoms related,,,,,,,,,,,,,,,,
22817,,cs.google.com/spreadsheets/d/17qj294pffmocfyleq0esvn7hlj6mob-0djcr1rl3kfk/edit?usp=sharing,,,,,,,,,,,,,,,,
22818,,cycloplegic auto refraction|intraocular pressure,,,,,,,,,,,,,,,,
22819,,multiple myeloma；|lvef≥50%；|ecog score,,,,,,,,,,,,,,,,
22820,,conscious level|patients,,,,,,,,,,,,,,,,
22821,,major cardiac abnormalities,,,,,,,,,,,,,,,,
22822,,bronchial tree toilet,,,,,,,,,,,,,,,,
22823,,trauma-related,,,,,,,,,,,,,,,,
22824,,cystic leukomalacia,,,,,,,,,,,,,,,,
22825,,hepatocellular disease,,,,,,,,,,,,,,,,
22826,,persistent erythema,,,,,,,,,,,,,,,,
22827,,tablets;|active bleeding,,,,,,,,,,,,,,,,
22828,,viral skin infection,,,,,,,,,,,,,,,,
22829,,lung nodule,,,,,,,,,,,,,,,,
22830,,heart conduction,,,,,,,,,,,,,,,,
22831,,hypertension.|other diseases,,,,,,,,,,,,,,,,
22832,,chemotherapy|chronic renal insufficiency|abdominal ascites|infection,,,,,,,,,,,,,,,,
22833,,renal functional disorder,,,,,,,,,,,,,,,,
22834,,collagenosis,,,,,,,,,,,,,,,,
22835,,resistant organisms,,,,,,,,,,,,,,,,
22836,,primary neoplasms,,,,,,,,,,,,,,,,
22837,,severe dry eye,,,,,,,,,,,,,,,,
22838,,chronic hypertensive cardiomyopathy,,,,,,,,,,,,,,,,
22839,,postural instability,,,,,,,,,,,,,,,,
22840,,chest diseases,,,,,,,,,,,,,,,,
22841,,opportunistic infections,,,,,,,,,,,,,,,,
22842,,traumatic zonulolysis,,,,,,,,,,,,,,,,
22843,,progestogen- containing,,,,,,,,,,,,,,,,
22844,,pain normal,,,,,,,,,,,,,,,,
22845,,deep orbits,,,,,,,,,,,,,,,,
22846,,neoplasms,,,,,,,,,,,,,,,,
22847,,psychiatric disorders|failure,,,,,,,,,,,,,,,,
22848,,left atrial ablation|refusal,,,,,,,,,,,,,,,,
22849,,air;|positive urine analysis,,,,,,,,,,,,,,,,
22850,,gastrointestinal malignancy|locally,,,,,,,,,,,,,,,,
22851,,oesophageal atresia,,,,,,,,,,,,,,,,
22852,,restricted positivity,,,,,,,,,,,,,,,,
22853,,motion impairment,,,,,,,,,,,,,,,,
22854,,head and neck soft tissue defect,,,,,,,,,,,,,,,,
22855,,tubular sclerosis,,,,,,,,,,,,,,,,
22856,,squamous cell carcinoma of the head and neck,,,,,,,,,,,,,,,,
22857,,inducer of metabolism,,,,,,,,,,,,,,,,
22858,,chorioamnionitis,,,,,,,,,,,,,,,,
22859,,psychological diseases,,,,,,,,,,,,,,,,
22860,,non-al amyloidosis|3,,,,,,,,,,,,,,,,
22861,,chronic nephritis.||cardiovascular,,,,,,,,,,,,,,,,
22862,,oral valganciclovir.|absence,,,,,,,,,,,,,,,,
22863,,lymphatic feature,,,,,,,,,,,,,,,,
22864,,thoracoabdominal,,,,,,,,,,,,,,,,
22865,,mmse,,,,,,,,,,,,,,,,
22866,,neurological symptoms,,,,,,,,,,,,,,,,
22867,,hiv 1/2,,,,,,,,,,,,,,,,
22868,,intestinal disease,,,,,,,,,,,,,,,,
22869,,auditive deficits,,,,,,,,,,,,,,,,
22870,,acute traumatic cervical sci,,,,,,,,,,,,,,,,
22871,,unresectable assessed by,,,,,,,,,,,,,,,,
22872,,metabolic encephalopathy,,,,,,,,,,,,,,,,
22873,,pterygium,,,,,,,,,,,,,,,,
22874,,heart failure|individuals,,,,,,,,,,,,,,,,
22875,,primary immunodeficiency disease,,,,,,,,,,,,,,,,
22876,,acute nerve lesion)|denied,,,,,,,,,,,,,,,,
22877,,conditions on the study measurement tools)|21 years old,,,,,,,,,,,,,,,,
22878,,perianal abscess,,,,,,,,,,,,,,,,
22879,,febrile illness,,,,,,,,,,,,,,,,
22880,,sjögren's,,,,,,,,,,,,,,,,
22881,,chronic obstructive pulmonary disease;|use,,,,,,,,,,,,,,,,
22882,,immunological diseases,,,,,,,,,,,,,,,,
22883,,physically able,,,,,,,,,,,,,,,,
22884,,gastric motility,,,,,,,,,,,,,,,,
22885,,narcotic addiction,,,,,,,,,,,,,,,,
22886,,omega-3 fatty acid,,,,,,,,,,,,,,,,
22887,,musculoskeletal condition,,,,,,,,,,,,,,,,
22888,,polymyositis,,,,,,,,,,,,,,,,
22889,,singleton pregnancy,,,,,,,,,,,,,,,,
22890,,stage pdac.|moffitt cancer center,,,,,,,,,,,,,,,,
22891,,bladder pain,,,,,,,,,,,,,,,,
22892,,cataracts,,,,,,,,,,,,,,,,
22893,,local treatment.||symptomatic,,,,,,,,,,,,,,,,
22894,,catalogue reference,,,,,,,,,,,,,,,,
22895,,vaccination.|history of cold,,,,,,,,,,,,,,,,
22896,,cognitive impairment,,,,,,,,,,,,,,,,
22897,,colorectal cancer tumor,,,,,,,,,,,,,,,,
22898,,scalp trauma,,,,,,,,,,,,,,,,
22899,,period|bipolar disorder,,,,,,,,,,,,,,,,
22900,,renal functional abnormality.||history,,,,,,,,,,,,,,,,
22901,,uterine cancer||a,,,,,,,,,,,,,,,,
22902,,respiratory tract (inhalation),,,,,,,,,,,,,,,,
22903,,relapsing remitting [,,,,,,,,,,,,,,,,
22904,,contraceptive pills,,,,,,,,,,,,,,,,
22905,,biliary drainage status,,,,,,,,,,,,,,,,
22906,,drugs|peripheral arterial disease,,,,,,,,,,,,,,,,
22907,,prostatic hyperplasia,,,,,,,,,,,,,,,,
22908,,motor neuron disease,,,,,,,,,,,,,,,,
22909,,uterine fibroid not responding to medical treatment,,,,,,,,,,,,,,,,
22910,,oligo-progression,,,,,,,,,,,,,,,,
22911,,unstable endocrine disease,,,,,,,,,,,,,,,,
22912,,malignant hyperthermia).|severe obstructive pulmonary,,,,,,,,,,,,,,,,
22913,,simple febrile seizures,,,,,,,,,,,,,,,,
22914,,excessive dermatochalasis,,,,,,,,,,,,,,,,
22915,,apparent difficulty communicating,,,,,,,,,,,,,,,,
22916,,adverse events [ctcae],,,,,,,,,,,,,,,,
22917,,renal denervation.|presence of,,,,,,,,,,,,,,,,
22918,,cll,,,,,,,,,,,,,,,,
22919,,metabolic functions,,,,,,,,,,,,,,,,
22920,,neurostimulators|pregnant|inability to read,,,,,,,,,,,,,,,,
22921,,underlying decay,,,,,,,,,,,,,,,,
22922,,progressive loss,,,,,,,,,,,,,,,,
22923,,lung squamous cell carcinoma,,,,,,,,,,,,,,,,
22924,,lactation|epilepsy,,,,,,,,,,,,,,,,
22925,,sleep syncope,,,,,,,,,,,,,,,,
22926,,neck disease,,,,,,,,,,,,,,,,
22927,,think you might,,,,,,,,,,,,,,,,
22928,,concerns,,,,,,,,,,,,,,,,
22929,,anterior cerebral,,,,,,,,,,,,,,,,
22930,,paget disease,,,,,,,,,,,,,,,,
22931,,interstitial lung disease.|participants,,,,,,,,,,,,,,,,
22932,,acute tonsillitis,,,,,,,,,,,,,,,,
22933,,native aortic stenosis,,,,,,,,,,,,,,,,
22934,,solid tumors|unresolved toxicities,,,,,,,,,,,,,,,,
22935,,comorbid ptsd,,,,,,,,,,,,,,,,
22936,,fludarabine + cyclophosphamide,,,,,,,,,,,,,,,,
22937,,third degree atrioventricular block)|angina,,,,,,,,,,,,,,,,
22938,,spinal abnormalities,,,,,,,,,,,,,,,,
22939,,b virus infection,,,,,,,,,,,,,,,,
22940,,diseases of the skin,,,,,,,,,,,,,,,,
22941,,delayed loss of consciousness,,,,,,,,,,,,,,,,
22942,,adnexal pathology|systemic diseases,,,,,,,,,,,,,,,,
22943,,apheresis,,,,,,,,,,,,,,,,
22944,,h2ra,,,,,,,,,,,,,,,,
22945,,her2-positive,,,,,,,,,,,,,,,,
22946,,thoracic nodal disease,,,,,,,,,,,,,,,,
22947,,"failure,|obesity,|uncompensated diabetes,|autoimmune disease",,,,,,,,,,,,,,,,
22948,,biliary duct disease,,,,,,,,,,,,,,,,
22949,,model for end-stage liver disease (meld),,,,,,,,,,,,,,,,
22950,,in situ cervical cancer.|note,,,,,,,,,,,,,,,,
22951,,acute interstitial nephritis,,,,,,,,,,,,,,,,
22952,,johnson's syndrome,,,,,,,,,,,,,,,,
22953,,unable to swallow,,,,,,,,,,,,,,,,
22954,,unstable coronary disease,,,,,,,,,,,,,,,,
22955,,painful conditions,,,,,,,,,,,,,,,,
22956,,colon cancer resection,,,,,,,,,,,,,,,,
22957,,post menopausal,,,,,,,,,,,,,,,,
22958,,infection|drug abuse,,,,,,,,,,,,,,,,
22959,,pulmonary vein,,,,,,,,,,,,,,,,
22960,,pelvic fractures,,,,,,,,,,,,,,,,
22961,,clinical manifestations of a significant neurological,,,,,,,,,,,,,,,,
22962,,fanconi anemia,,,,,,,,,,,,,,,,
22963,,curative intent.|is,,,,,,,,,,,,,,,,
22964,,familial hyperchylomicronemia,,,,,,,,,,,,,,,,
22965,,autonomic neuropathy|known diabetes,,,,,,,,,,,,,,,,
22966,,hepatitis b virus (hbv) deoxyribonucleic acid,,,,,,,,,,,,,,,,
22967,,laboratory inspection,,,,,,,,,,,,,,,,
22968,,major neurological deﬁcits,,,,,,,,,,,,,,,,
22969,,ipsilateral iliac lesions,,,,,,,,,,,,,,,,
22970,,conduction defects,,,,,,,,,,,,,,,,
22971,,normal intracranial pressure hydrocephalus,,,,,,,,,,,,,,,,
22972,,progressive mcrpc,,,,,,,,,,,,,,,,
22973,,weight loss diet,,,,,,,,,,,,,,,,
22974,,recurrence of disease,,,,,,,,,,,,,,,,
22975,,endocrine neoplasia syndrome,,,,,,,,,,,,,,,,
22976,,good organ function,,,,,,,,,,,,,,,,
22977,,cardiovascular disease|psychiatric disorders,,,,,,,,,,,,,,,,
22978,,naso-sinus,,,,,,,,,,,,,,,,
22979,,binocular myopic chorioretinal atrophy,,,,,,,,,,,,,,,,
22980,,t,,,,,,,,,,,,,,,,
22981,,infections of any type).|have,,,,,,,,,,,,,,,,
22982,,cancerous,,,,,,,,,,,,,,,,
22983,,sites of disease,,,,,,,,,,,,,,,,
22984,,rectal swab collected,,,,,,,,,,,,,,,,
22985,,hematologic relapse,,,,,,,,,,,,,,,,
22986,,infectious endocarditis,,,,,,,,,,,,,,,,
22987,,-situ cancer,,,,,,,,,,,,,,,,
22988,,local heart failure,,,,,,,,,,,,,,,,
22989,,ocular astigmatism,,,,,,,,,,,,,,,,
22990,,inflammatory skin disease,,,,,,,,,,,,,,,,
22991,,radiation-related,,,,,,,,,,,,,,,,
22992,,her2 ihc staining,,,,,,,,,,,,,,,,
22993,,excluded|rectal cancer,,,,,,,,,,,,,,,,
22994,,respiratory condition,,,,,,,,,,,,,,,,
22995,,pt010,,,,,,,,,,,,,,,,
22996,,trauma high intraoptic pressure pulmonary hypertension,,,,,,,,,,,,,,,,
22997,,breathing problems,,,,,,,,,,,,,,,,
22998,,cardiofaciocutaneous syndrome,,,,,,,,,,,,,,,,
22999,,early satiety,,,,,,,,,,,,,,,,
23000,,upper gi symptoms,,,,,,,,,,,,,,,,
23001,,posterior teeth,,,,,,,,,,,,,,,,
23002,,respiratory insufficiency,,,,,,,,,,,,,,,,
23003,,limbs.|oliguria,,,,,,,,,,,,,,,,
23004,,executive functions,,,,,,,,,,,,,,,,
23005,,impaired hepatic,,,,,,,,,,,,,,,,
23006,,old)|presence,,,,,,,,,,,,,,,,
23007,,irregular diabetes,,,,,,,,,,,,,,,,
23008,,brain injuries,,,,,,,,,,,,,,,,
23009,,c.|prior allergic reaction,,,,,,,,,,,,,,,,
23010,,neuritis optica,,,,,,,,,,,,,,,,
23011,,ffa,,,,,,,,,,,,,,,,
23012,,hereditary problems,,,,,,,,,,,,,,,,
23013,,colorectal,,,,,,,,,,,,,,,,
23014,,deep fungal infection,,,,,,,,,,,,,,,,
23015,,neurologic disease)|malignancy,,,,,,,,,,,,,,,,
23016,,healthy participants|body mass index,,,,,,,,,,,,,,,,
23017,,hammer toes,,,,,,,,,,,,,,,,
23018,,locations,,,,,,,,,,,,,,,,
23019,,mentally compromised,,,,,,,,,,,,,,,,
23020,,ocular infection,,,,,,,,,,,,,,,,
23021,,esophageal motility,,,,,,,,,,,,,,,,
23022,,dementia|diagnosis,,,,,,,,,,,,,,,,
23023,,congenital cataracts,,,,,,,,,,,,,,,,
23024,,congenital myopathies,,,,,,,,,,,,,,,,
23025,,mechanical neck pain,,,,,,,,,,,,,,,,
23026,,allergic purpura,,,,,,,,,,,,,,,,
23027,,trachomatis,,,,,,,,,,,,,,,,
23028,,myofascial pain,,,,,,,,,,,,,,,,
23029,,multisystemic disease,,,,,,,,,,,,,,,,
23030,,uncontrollable diabetes,,,,,,,,,,,,,,,,
23031,,progressive cardiovascular pathologies,,,,,,,,,,,,,,,,
23032,,rapid immune suppression,,,,,,,,,,,,,,,,
23033,,follicular variant,,,,,,,,,,,,,,,,
23034,,severe disease,,,,,,,,,,,,,,,,
23035,,serious health conditions,,,,,,,,,,,,,,,,
23036,,cerebrovascular accident|patients,,,,,,,,,,,,,,,,
23037,,radiologic evaluation|no peritonitis,,,,,,,,,,,,,,,,
23038,,decreased hepatic function,,,,,,,,,,,,,,,,
23039,,indirect effects,,,,,,,,,,,,,,,,
23040,,heads,,,,,,,,,,,,,,,,
23041,,asthma exacerbation event,,,,,,,,,,,,,,,,
23042,,trial;|poor health condition,,,,,,,,,,,,,,,,
23043,,chronic abdominal pain,,,,,,,,,,,,,,,,
23044,,growth hormone deficiency,,,,,,,,,,,,,,,,
23045,,preoperative cardiovascular instability,,,,,,,,,,,,,,,,
23046,,left coronary artery dominance,,,,,,,,,,,,,,,,
23047,,stable autoimmune thyroiditis,,,,,,,,,,,,,,,,
23048,,remaining teeth|periodontitis,,,,,,,,,,,,,,,,
23049,,person|ability,,,,,,,,,,,,,,,,
23050,,extrahepatic disease,,,,,,,,,,,,,,,,
23051,,vigilance disorders,,,,,,,,,,,,,,,,
23052,,unexpected weight loss,,,,,,,,,,,,,,,,
23053,,anxiety symptoms,,,,,,,,,,,,,,,,
23054,,been stable,,,,,,,,,,,,,,,,
23055,,lower exacerbation rate,,,,,,,,,,,,,,,,
23056,,pathological tissue biopsy)|life expectancy,,,,,,,,,,,,,,,,
23057,,joint replacement surgery)|cancer,,,,,,,,,,,,,,,,
23058,,coeliac disease|presence,,,,,,,,,,,,,,,,
23059,,severe reactions,,,,,,,,,,,,,,,,
23060,,human immunodeficiency virus (hiv) infection;|a,,,,,,,,,,,,,,,,
23061,,major mental illness,,,,,,,,,,,,,,,,
23062,,tectb,,,,,,,,,,,,,,,,
23063,,hereditary colon cancer syndrome,,,,,,,,,,,,,,,,
23064,,subgingival,,,,,,,,,,,,,,,,
23065,,substance abuse disorder,,,,,,,,,,,,,,,,
23066,,stoma,,,,,,,,,,,,,,,,
23067,,demonstrates those findings|vaccinations,,,,,,,,,,,,,,,,
23068,,brain imaging,,,,,,,,,,,,,,,,
23069,,localized disease,,,,,,,,,,,,,,,,
23070,,1)|unresectable disease,,,,,,,,,,,,,,,,
23071,,leptomeningeal metastases,,,,,,,,,,,,,,,,
23072,,rare hereditary problems of,,,,,,,,,,,,,,,,
23073,,wheelchair,,,,,,,,,,,,,,,,
23074,,periodic alcohol,,,,,,,,,,,,,,,,
23075,,amines,,,,,,,,,,,,,,,,
23076,,vasopressors|ph on arterial blood,,,,,,,,,,,,,,,,
23077,,suspected hypogonadism,,,,,,,,,,,,,,,,
23078,,reduced renal function.|patients,,,,,,,,,,,,,,,,
23079,,nondoubly-irradiated,,,,,,,,,,,,,,,,
23080,,primary malignancy.|participants,,,,,,,,,,,,,,,,
23081,,changes,,,,,,,,,,,,,,,,
23082,,intestinal oedema,,,,,,,,,,,,,,,,
23083,,endocrinopathies,,,,,,,,,,,,,,,,
23084,,intolerance of,,,,,,,,,,,,,,,,
23085,,renal impairment.|patient,,,,,,,,,,,,,,,,
23086,,acquisition,,,,,,,,,,,,,,,,
23087,,bone metastasis treatable,,,,,,,,,,,,,,,,
23088,,elbow joint pain,,,,,,,,,,,,,,,,
23089,,surgically unresectable disease,,,,,,,,,,,,,,,,
23090,,sexually transmitted,,,,,,,,,,,,,,,,
23091,,malignant bone tumors,,,,,,,,,,,,,,,,
23092,,macular edema;|perioperative complications;|congenital,,,,,,,,,,,,,,,,
23093,,infection|myocardial infarction,,,,,,,,,,,,,,,,
23094,,abrasion,,,,,,,,,,,,,,,,
23095,,diseases;|respiratory tract infection,,,,,,,,,,,,,,,,
23096,,postural deformity,,,,,,,,,,,,,,,,
23097,,unstable angina.|major surgical procedure,,,,,,,,,,,,,,,,
23098,,chronic cancer-related,,,,,,,,,,,,,,,,
23099,,helicobacter pylori,,,,,,,,,,,,,,,,
23100,,atrial fibrillation|nt pro,,,,,,,,,,,,,,,,
23101,,obstructive atherosclerosis,,,,,,,,,,,,,,,,
23102,,days|monitoring,,,,,,,,,,,,,,,,
23103,,risk prostate cancer,,,,,,,,,,,,,,,,
23104,,systemic combinational therapy,,,,,,,,,,,,,,,,
23105,,steal syndrome,,,,,,,,,,,,,,,,
23106,,cardio-circulatory assistance,,,,,,,,,,,,,,,,
23107,,blood;|hyperlipidaemia,,,,,,,,,,,,,,,,
23108,,isolated gh,,,,,,,,,,,,,,,,
23109,,internal disorders,,,,,,,,,,,,,,,,
23110,,hepatic dysfunction.|pregnancy,,,,,,,,,,,,,,,,
23111,,inflammatory gynecological conditions,,,,,,,,,,,,,,,,
23112,,associated comorbidities,,,,,,,,,,,,,,,,
23113,,cerebrospinal fluid (csf) testing,,,,,,,,,,,,,,,,
23114,,fatal bleeding episode,,,,,,,,,,,,,,,,
23115,,autoimmune neuromuscular disease,,,,,,,,,,,,,,,,
23116,,nancy,,,,,,,,,,,,,,,,
23117,,pathological processes,,,,,,,,,,,,,,,,
23118,,substance abuse.|thrombophlebitis,,,,,,,,,,,,,,,,
23119,,diverticulitis|irritable bowel syndrome|gastric,,,,,,,,,,,,,,,,
23120,,infected bronchiectasis,,,,,,,,,,,,,,,,
23121,,physical conditions,,,,,,,,,,,,,,,,
23122,,pisz genotypes,,,,,,,,,,,,,,,,
23123,,neuroendocrine,,,,,,,,,,,,,,,,
23124,,musculoskeletal injury/operation,,,,,,,,,,,,,,,,
23125,,filled teeth,,,,,,,,,,,,,,,,
23126,,hyper-ige syndromes,,,,,,,,,,,,,,,,
23127,,gestational trophoblastic,,,,,,,,,,,,,,,,
23128,,breast reduction,,,,,,,,,,,,,,,,
23129,,tumor vaccines,,,,,,,,,,,,,,,,
23130,,meniscal tear;|lack of functional,,,,,,,,,,,,,,,,
23131,,metastatic lesion accessible,,,,,,,,,,,,,,,,
23132,,hepatic functions,,,,,,,,,,,,,,,,
23133,,included|cohort,,,,,,,,,,,,,,,,
23134,,diabetes mellitus).|coronary artery disorders .|neurological disorders.|recent musculoskeletal injuries.|renal disorders.|hepatic disorders.|skin hypersensitive.|smokers,,,,,,,,,,,,,,,,
23135,,etc.)|congestive heart failure (chf),,,,,,,,,,,,,,,,
23136,,head and neck cancer|to,,,,,,,,,,,,,,,,
23137,,congestive heart failure|peptic ulcer,,,,,,,,,,,,,,,,
23138,,overt disease,,,,,,,,,,,,,,,,
23139,,circulatory disorders,,,,,,,,,,,,,,,,
23140,,hemoglobinopathies,,,,,,,,,,,,,,,,
23141,,com701,,,,,,,,,,,,,,,,
23142,,cerebral oxygen saturation,,,,,,,,,,,,,,,,
23143,,suicidal ideation.|healthy,,,,,,,,,,,,,,,,
23144,,ka|neurological dysfunction compromising,,,,,,,,,,,,,,,,
23145,,gastric variceal bleeding,,,,,,,,,,,,,,,,
23146,,skin anytime,,,,,,,,,,,,,,,,
23147,,nstemi,,,,,,,,,,,,,,,,
23148,,histologically-,,,,,,,,,,,,,,,,
23149,,emotional tension,,,,,,,,,,,,,,,,
23150,,hba1c≥8|chronic kidney disease,,,,,,,,,,,,,,,,
23151,,neurological deficits trauma|pregnancy,,,,,,,,,,,,,,,,
23152,,bep).|biochemical remission,,,,,,,,,,,,,,,,
23153,,liver metastases|negative pregnancy test||,,,,,,,,,,,,,,,,
23154,,gtn|allergy,,,,,,,,,,,,,,,,
23155,,fia,,,,,,,,,,,,,,,,
23156,,airway inflammation,,,,,,,,,,,,,,,,
23157,,neuroleukemia,,,,,,,,,,,,,,,,
23158,,alcoholism|concomitant,,,,,,,,,,,,,,,,
23159,,craniospinal rt,,,,,,,,,,,,,,,,
23160,,disease.||for bc,,,,,,,,,,,,,,,,
23161,,common mental disorder,,,,,,,,,,,,,,,,
23162,,impaired pulmonary function,,,,,,,,,,,,,,,,
23163,,weight loss medication,,,,,,,,,,,,,,,,
23164,,"cognitive competence,|additional eye problems",,,,,,,,,,,,,,,,
23165,,"diabetic foot,|neurological diseases",,,,,,,,,,,,,,,,
23166,,protease inhibitors,,,,,,,,,,,,,,,,
23167,,traditional chinese medicine therapy,,,,,,,,,,,,,,,,
23168,,past peripheral ulcer,,,,,,,,,,,,,,,,
23169,,ghat,,,,,,,,,,,,,,,,
23170,,significant alcohol,,,,,,,,,,,,,,,,
23171,,neurological complication,,,,,,,,,,,,,,,,
23172,,cervical pathologies,,,,,,,,,,,,,,,,
23173,,systolic 90mmhg|haemothorax,,,,,,,,,,,,,,,,
23174,,brain metastases|additional malignancy,,,,,,,,,,,,,,,,
23175,,upper gastrointestinal (gi),,,,,,,,,,,,,,,,
23176,,p. falciparum parasitemia,,,,,,,,,,,,,,,,
23177,,antagonists|autosomal dominant polycystic kidney disease,,,,,,,,,,,,,,,,
23178,,conduction abnormalities,,,,,,,,,,,,,,,,
23179,,sigmoidal resection|portal hypertension,,,,,,,,,,,,,,,,
23180,,mixed cellularity,,,,,,,,,,,,,,,,
23181,,unresectable factors,,,,,,,,,,,,,,,,
23182,,hodkinson mental test score,,,,,,,,,,,,,,,,
23183,,chronic pulmonary disease|collagen,,,,,,,,,,,,,,,,
23184,,electrical acupuncture,,,,,,,,,,,,,,,,
23185,,non-immune-related,,,,,,,,,,,,,,,,
23186,,glenohumeral shoulder,,,,,,,,,,,,,,,,
23187,,non-neurological solid tumors,,,,,,,,,,,,,,,,
23188,,alcohol addiction,,,,,,,,,,,,,,,,
23189,,exposure|known bleeding disorder,,,,,,,,,,,,,,,,
23190,,high-quality,,,,,,,,,,,,,,,,
23191,,auto-immune diseases,,,,,,,,,,,,,,,,
23192,,brain infection,,,,,,,,,,,,,,,,
23193,,heartburn,,,,,,,,,,,,,,,,
23194,,septic shock|diagnosis,,,,,,,,,,,,,,,,
23195,,acute episodes of illness,,,,,,,,,,,,,,,,
23196,,cmv,,,,,,,,,,,,,,,,
23197,,non-correctable causes,,,,,,,,,,,,,,,,
23198,,nicotine abuse,,,,,,,,,,,,,,,,
23199,,atrial appendage,,,,,,,,,,,,,,,,
23200,,upper extremity surgery|botulinum toxin,,,,,,,,,,,,,,,,
23201,,uncorrectable visual,,,,,,,,,,,,,,,,
23202,,paraffin-embedded,,,,,,,,,,,,,,,,
23203,,pain scores|does,,,,,,,,,,,,,,,,
23204,,bucco-sinus communication,,,,,,,,,,,,,,,,
23205,,fractures|degenerative muscular disorder,,,,,,,,,,,,,,,,
23206,,deep brain stimulation (dbs),,,,,,,,,,,,,,,,
23207,,surgery;|presence,,,,,,,,,,,,,,,,
23208,,acute polyneuropathy,,,,,,,,,,,,,,,,
23209,,interspinous process,,,,,,,,,,,,,,,,
23210,,pill,,,,,,,,,,,,,,,,
23211,,irreversible pulpitis.|normal periapical condition,,,,,,,,,,,,,,,,
23212,,hemorrhagic rash,,,,,,,,,,,,,,,,
23213,,moderate depressive symptoms,,,,,,,,,,,,,,,,
23214,,intracranial arterial thrombus,,,,,,,,,,,,,,,,
23215,,adjustment of medication requiring,,,,,,,,,,,,,,,,
23216,,retinal blindness,,,,,,,,,,,,,,,,
23217,,intestinal fistula,,,,,,,,,,,,,,,,
23218,,short bowel syndrome.|history of,,,,,,,,,,,,,,,,
23219,,angina unstable,,,,,,,,,,,,,,,,
23220,,phpt,,,,,,,,,,,,,,,,
23221,,non-primary,,,,,,,,,,,,,,,,
23222,,examination|pregnant,,,,,,,,,,,,,,,,
23223,,good general health||key,,,,,,,,,,,,,,,,
23224,,hospitalized,,,,,,,,,,,,,,,,
23225,,biochemical function,,,,,,,,,,,,,,,,
23226,,hepatocyte decompensation,,,,,,,,,,,,,,,,
23227,,autoimmune disease.|the,,,,,,,,,,,,,,,,
23228,,spondylitis,,,,,,,,,,,,,,,,
23229,,criteria|clinical dementia,,,,,,,,,,,,,,,,
23230,,obstructive physiology,,,,,,,,,,,,,,,,
23231,,hepatitis c|topical antibiotics,,,,,,,,,,,,,,,,
23232,,parathyroid hormones,,,,,,,,,,,,,,,,
23233,,sleep apnea,,,,,,,,,,,,,,,,
23234,,mellitus|cardiovascular disease,,,,,,,,,,,,,,,,
23235,,mechanical heart assistance,,,,,,,,,,,,,,,,
23236,,diabetic foot syndrome.|peripheral artery disease,,,,,,,,,,,,,,,,
23237,,steroid inhalers ok,,,,,,,,,,,,,,,,
23238,,hbv infection,,,,,,,,,,,,,,,,
23239,,basal cell skin cancer,,,,,,,,,,,,,,,,
23240,,hepatitis b virus (hbv) infection,,,,,,,,,,,,,,,,
23241,,cerebral palsy,,,,,,,,,,,,,,,,
23242,,child-bearing age|ability,,,,,,,,,,,,,,,,
23243,,oral cavity,,,,,,,,,,,,,,,,
23244,,skin diseases);|travel across,,,,,,,,,,,,,,,,
23245,,puncture-aspiration|cuff pathology,,,,,,,,,,,,,,,,
23246,,age.|hospital admissions,,,,,,,,,,,,,,,,
23247,,regional anesthesia|presence,,,,,,,,,,,,,,,,
23248,,hcv;|symptomatic,,,,,,,,,,,,,,,,
23249,,neoplastic disease.|active mycobacteria,,,,,,,,,,,,,,,,
23250,,related condition,,,,,,,,,,,,,,,,
23251,,bilateral injury,,,,,,,,,,,,,,,,
23252,,chromosomal abnormality,,,,,,,,,,,,,,,,
23253,,creatinine,,,,,,,,,,,,,,,,
23254,,dysphagia|degenerative neurological condition|severe visual impairment|severe,,,,,,,,,,,,,,,,
23255,,adverse factors,,,,,,,,,,,,,,,,
23256,,anatomically unsuitable,,,,,,,,,,,,,,,,
23257,,rheumatologic conditions,,,,,,,,,,,,,,,,
23258,,-pharyngeal swab,,,,,,,,,,,,,,,,
23259,,ckd-epi.|renal biopsy,,,,,,,,,,,,,,,,
23260,,deep intratumoral injection procedures,,,,,,,,,,,,,,,,
23261,,pregnancy|no allergy history|signed informed consent||,,,,,,,,,,,,,,,,
23262,,common carotid artery center|implantation,,,,,,,,,,,,,,,,
23263,,idiopathic abdominal pain,,,,,,,,,,,,,,,,
23264,,t2-4,,,,,,,,,,,,,,,,
23265,,medullary thyroid carcinoma.|renal impairment,,,,,,,,,,,,,,,,
23266,,head and neck,,,,,,,,,,,,,,,,
23267,,spine trauma,,,,,,,,,,,,,,,,
23268,,opacities,,,,,,,,,,,,,,,,
23269,,bladder cancer,,,,,,,,,,,,,,,,
23270,,lower limb arthroplasties,,,,,,,,,,,,,,,,
23271,,muscle weakness,,,,,,,,,,,,,,,,
23272,,genital fistula,,,,,,,,,,,,,,,,
23273,,cystoid macular edema,,,,,,,,,,,,,,,,
23274,,neurological co-morbidities,,,,,,,,,,,,,,,,
23275,,living residence,,,,,,,,,,,,,,,,
23276,,epilepsy|children,,,,,,,,,,,,,,,,
23277,,autoimmune disease|active,,,,,,,,,,,,,,,,
23278,,drug-induced pneumonitis,,,,,,,,,,,,,,,,
23279,,therapeutic paracentesis,,,,,,,,,,,,,,,,
23280,,toxic optic neuropathy,,,,,,,,,,,,,,,,
23281,,cold agglutinin syndrome,,,,,,,,,,,,,,,,
23282,,status).||women,,,,,,,,,,,,,,,,
23283,,hydrocephalus limiting,,,,,,,,,,,,,,,,
23284,,cerebral infarction;|patients,,,,,,,,,,,,,,,,
23285,,type 2 diabetes.||prior,,,,,,,,,,,,,,,,
23286,,cardiometabolic condition,,,,,,,,,,,,,,,,
23287,,suicidal thoughts,,,,,,,,,,,,,,,,
23288,,chronic minor,,,,,,,,,,,,,,,,
23289,,metastatic acc,,,,,,,,,,,,,,,,
23290,,alleles,,,,,,,,,,,,,,,,
23291,,referral,,,,,,,,,,,,,,,,
23292,,acute promyelocytic leukemia.|isolated,,,,,,,,,,,,,,,,
23293,,cts,,,,,,,,,,,,,,,,
23294,,invasive breast carcinoma,,,,,,,,,,,,,,,,
23295,,normal hepatic function:||healthy,,,,,,,,,,,,,,,,
23296,,enrollment|arrhythmia,,,,,,,,,,,,,,,,
23297,,infections in lung,,,,,,,,,,,,,,,,
23298,,corrected gestational age)|maternal,,,,,,,,,,,,,,,,
23299,,binocular best-corrected,,,,,,,,,,,,,,,,
23300,,multi gated,,,,,,,,,,,,,,,,
23301,,criteria of,,,,,,,,,,,,,,,,
23302,,anti-coagulation regimen therapy,,,,,,,,,,,,,,,,
23303,,gerd related symptoms,,,,,,,,,,,,,,,,
23304,,avds,,,,,,,,,,,,,,,,
23305,,parkinson's disease|color blindness,,,,,,,,,,,,,,,,
23306,,about to undergo,,,,,,,,,,,,,,,,
23307,,guttate psoriasis,,,,,,,,,,,,,,,,
23308,,dental pain,,,,,,,,,,,,,,,,
23309,,urothelial carcinoma|cohort,,,,,,,,,,,,,,,,
23310,,chronic diseases|cardiovascular diseases,,,,,,,,,,,,,,,,
23311,,-stage,,,,,,,,,,,,,,,,
23312,,gh receptors,,,,,,,,,,,,,,,,
23313,,urinary tract diseases|endocrine,,,,,,,,,,,,,,,,
23314,,ct|lesions outside of the designated lung areas,,,,,,,,,,,,,,,,
23315,,treatment.|active hepatitis b or,,,,,,,,,,,,,,,,
23316,,pleomorphic sarcoma,,,,,,,,,,,,,,,,
23317,,chronic hypoxic conditions,,,,,,,,,,,,,,,,
23318,,substance abuse|having,,,,,,,,,,,,,,,,
23319,,terminates spontaneously,,,,,,,,,,,,,,,,
23320,,radiologic disease,,,,,,,,,,,,,,,,
23321,,cancer|iron deficiency,,,,,,,,,,,,,,,,
23322,,recurring bronchitis,,,,,,,,,,,,,,,,
23323,,1||organ function：||kidney function,,,,,,,,,,,,,,,,
23324,,heavy menstrual bleeding,,,,,,,,,,,,,,,,
23325,,disease of the heart,,,,,,,,,,,,,,,,
23326,,gestational diabetes|24-28,,,,,,,,,,,,,,,,
23327,,functional impairment|unable,,,,,,,,,,,,,,,,
23328,,above hypertension,,,,,,,,,,,,,,,,
23329,,hereditary caa,,,,,,,,,,,,,,,,
23330,,malignant bowel obstruction,,,,,,,,,,,,,,,,
23331,,mixed.|difficulty urinating|hematuria|pregnancy|patients,,,,,,,,,,,,,,,,
23332,,materials.|females,,,,,,,,,,,,,,,,
23333,,ideation,,,,,,,,,,,,,,,,
23334,,inflammatory bowel disease;|history,,,,,,,,,,,,,,,,
23335,,history|psychotically seizures,,,,,,,,,,,,,,,,
23336,,renal transplantation|both,,,,,,,,,,,,,,,,
23337,,joint pain,,,,,,,,,,,,,,,,
23338,,inhibits ovulation,,,,,,,,,,,,,,,,
23339,,circumferential difference,,,,,,,,,,,,,,,,
23340,,ischemic heart diseases,,,,,,,,,,,,,,,,
23341,,sleep quality,,,,,,,,,,,,,,,,
23342,,brachial nerve,,,,,,,,,,,,,,,,
23343,,solid tumors|treatment,,,,,,,,,,,,,,,,
23344,,malignant mesothelioma,,,,,,,,,,,,,,,,
23345,,serious basic diseases,,,,,,,,,,,,,,,,
23346,,localized prostate cancer,,,,,,,,,,,,,,,,
23347,,visit|infectious blepharitis,,,,,,,,,,,,,,,,
23348,,crohn's,,,,,,,,,,,,,,,,
23349,,primary amyloid light chain (al),,,,,,,,,,,,,,,,
23350,,etc.)|homozygous sickle cell disease|bacterial pneumonia|hospitalization,,,,,,,,,,,,,,,,
23351,,alcoholic liver disease||,,,,,,,,,,,,,,,,
23352,,drugs|allergic,,,,,,,,,,,,,,,,
23353,,underlying comorbidities,,,,,,,,,,,,,,,,
23354,,surgery|anaemia,,,,,,,,,,,,,,,,
23355,,cardiac tamponade,,,,,,,,,,,,,,,,
23356,,viable nsgct,,,,,,,,,,,,,,,,
23357,,polyarthritis,,,,,,,,,,,,,,,,
23358,,mixed genotype,,,,,,,,,,,,,,,,
23359,,income,,,,,,,,,,,,,,,,
23360,,normal glucose tolerance,,,,,,,,,,,,,,,,
23361,,eosinophilic gastrointestinal diseases,,,,,,,,,,,,,,,,
23362,,area|concomitant auto-immune disease,,,,,,,,,,,,,,,,
23363,,untreated)|pregnancy,,,,,,,,,,,,,,,,
23364,,dystonia;|normal brain mri;|the,,,,,,,,,,,,,,,,
23365,,discriminatory factors,,,,,,,,,,,,,,,,
23366,,corticobasal syndrome,,,,,,,,,,,,,,,,
23367,,angiosarcoma,,,,,,,,,,,,,,,,
23368,,tape,,,,,,,,,,,,,,,,
23369,,disseminated herpes zoster,,,,,,,,,,,,,,,,
23370,,m.o.f syndrome,,,,,,,,,,,,,,,,
23371,,prohibitive calcification,,,,,,,,,,,,,,,,
23372,,loss of the entire,,,,,,,,,,,,,,,,
23373,,bacterial keratitis,,,,,,,,,,,,,,,,
23374,,scchn.|prior invasive,,,,,,,,,,,,,,,,
23375,,superficial bladder tumors,,,,,,,,,,,,,,,,
23376,,prostatic hyperplasia|blood dyscrasias,,,,,,,,,,,,,,,,
23377,,tortuous lesions,,,,,,,,,,,,,,,,
23378,,central cord spinal cord injury,,,,,,,,,,,,,,,,
23379,,hepatic glycogen accumulation,,,,,,,,,,,,,,,,
23380,,major fetal anomaly,,,,,,,,,,,,,,,,
23381,,neck cancer,,,,,,,,,,,,,,,,
23382,,pvc,,,,,,,,,,,,,,,,
23383,,paralytic intestinal obstruction|patients,,,,,,,,,,,,,,,,
23384,,surgical comorbidity,,,,,,,,,,,,,,,,
23385,,digestion,,,,,,,,,,,,,,,,
23386,,mood dysregulation disorder,,,,,,,,,,,,,,,,
23387,,delirious,,,,,,,,,,,,,,,,
23388,,renal pelvis carcinoma,,,,,,,,,,,,,,,,
23389,,disc herniation|those,,,,,,,,,,,,,,,,
23390,,hiv complications,,,,,,,,,,,,,,,,
23391,,myeloid malignancy,,,,,,,,,,,,,,,,
23392,,cryo-lipolysis,,,,,,,,,,,,,,,,
23393,,barthel index.|cognitive impairment,,,,,,,,,,,,,,,,
23394,,aeci,,,,,,,,,,,,,,,,
23395,,progressive neurodegenerative,,,,,,,,,,,,,,,,
23396,,gall bladder,,,,,,,,,,,,,,,,
23397,,esophageal catheterization,,,,,,,,,,,,,,,,
23398,,clinical gross dermatology,,,,,,,,,,,,,,,,
23399,,oral disabilities,,,,,,,,,,,,,,,,
23400,,replicating,,,,,,,,,,,,,,,,
23401,,digital equipment,,,,,,,,,,,,,,,,
23402,,pelvic surgery|vulnerable,,,,,,,,,,,,,,,,
23403,,organic causes,,,,,,,,,,,,,,,,
23404,,biliary tract cancer,,,,,,,,,,,,,,,,
23405,,mullerian agenesis,,,,,,,,,,,,,,,,
23406,,hyperglycemic crisis,,,,,,,,,,,,,,,,
23407,,ventricular hypertrophy,,,,,,,,,,,,,,,,
23408,,progressive cognitive decline,,,,,,,,,,,,,,,,
23409,,non-covid-19 inactivated vaccine,,,,,,,,,,,,,,,,
23410,,general condition,,,,,,,,,,,,,,,,
23411,,complicated cataract|corneal opacities,,,,,,,,,,,,,,,,
23412,,major events/changes,,,,,,,,,,,,,,,,
23413,,medical conditions failure,,,,,,,,,,,,,,,,
23414,,upper lateral incisors,,,,,,,,,,,,,,,,
23415,,hypo- albuminemia,,,,,,,,,,,,,,,,
23416,,lactic acidosis,,,,,,,,,,,,,,,,
23417,,known hypogonadism,,,,,,,,,,,,,,,,
23418,,impaired cardiac function,,,,,,,,,,,,,,,,
23419,,old;|diagnosis of ibd,,,,,,,,,,,,,,,,
23420,,of:||celiac disease,,,,,,,,,,,,,,,,
23421,,unable to tolerate to fiber especially vegetables|type 1 diabetes,,,,,,,,,,,,,,,,
23422,,medical abnormality,,,,,,,,,,,,,,,,
23423,,antitumor effects,,,,,,,,,,,,,,,,
23424,,acs,,,,,,,,,,,,,,,,
23425,,urinary diversion,,,,,,,,,,,,,,,,
23426,,achalasia,,,,,,,,,,,,,,,,
23427,,functional neurological deficit|subject,,,,,,,,,,,,,,,,
23428,,folic,,,,,,,,,,,,,,,,
23429,,schizophrenia similar condition,,,,,,,,,,,,,,,,
23430,,diseases like osteoporosis,,,,,,,,,,,,,,,,
23431,,pituitary endocrine diseases,,,,,,,,,,,,,,,,
23432,,biologic disease,,,,,,,,,,,,,,,,
23433,,dna positive,,,,,,,,,,,,,,,,
23434,,pericardial friction rubs,,,,,,,,,,,,,,,,
23435,,old|first-ever,,,,,,,,,,,,,,,,
23436,,irritable bowel syndrome/disease,,,,,,,,,,,,,,,,
23437,,photodermatitis,,,,,,,,,,,,,,,,
23438,,giant platelet syndrome,,,,,,,,,,,,,,,,
23439,,occupational risk insurer-arl.|players,,,,,,,,,,,,,,,,
23440,,liver diseases,,,,,,,,,,,,,,,,
23441,,pneumonitis,,,,,,,,,,,,,,,,
23442,,progestin-containing therapies,,,,,,,,,,,,,,,,
23443,,dependence on,,,,,,,,,,,,,,,,
23444,,health related quality of life|pregnancy,,,,,,,,,,,,,,,,
23445,,benign diseases|genitourinary cancer,,,,,,,,,,,,,,,,
23446,,third molars.||,,,,,,,,,,,,,,,,
23447,,end-stage renal disease (esrd),,,,,,,,,,,,,,,,
23448,,implanted brain stimulator)|conditions,,,,,,,,,,,,,,,,
23449,,basal cell carcinoma|acute,,,,,,,,,,,,,,,,
23450,,adenocarcinoma in situ,,,,,,,,,,,,,,,,
23451,,nsclc,,,,,,,,,,,,,,,,
23452,,disease-modifying drugs,,,,,,,,,,,,,,,,
23453,,acute hf decompensation.|optimal drug treatment,,,,,,,,,,,,,,,,
23454,,severe depression,,,,,,,,,,,,,,,,
23455,,hip oa|veterans,,,,,,,,,,,,,,,,
23456,,non diabetic,,,,,,,,,,,,,,,,
23457,,gastrointestinal surgeries,,,,,,,,,,,,,,,,
23458,,ccs,,,,,,,,,,,,,,,,
23459,,transdermal patch,,,,,,,,,,,,,,,,
23460,,third molars).||poor oral hygiene,,,,,,,,,,,,,,,,
23461,,severe anaphylactic diseases,,,,,,,,,,,,,,,,
23462,,dementia);|cardio-metabolic diseases,,,,,,,,,,,,,,,,
23463,,pulmonary vascular diseases,,,,,,,,,,,,,,,,
23464,,acquired immune function defects,,,,,,,,,,,,,,,,
23465,,cardiac insufficiency,,,,,,,,,,,,,,,,
23466,,sensitive p-gp substrates.|any,,,,,,,,,,,,,,,,
23467,,regularization of,,,,,,,,,,,,,,,,
23468,,nuclear,,,,,,,,,,,,,,,,
23469,,thoracic tumors 5th,,,,,,,,,,,,,,,,
23470,,brain trauma|patients,,,,,,,,,,,,,,,,
23471,,comorbid mental health disorder|no,,,,,,,,,,,,,,,,
23472,,hispanic|diagnosis,,,,,,,,,,,,,,,,
23473,,s best interest,,,,,,,,,,,,,,,,
23474,,tracheal damage,,,,,,,,,,,,,,,,
23475,,invasive breast cancer,,,,,,,,,,,,,,,,
23476,,dyshemoglobinemia,,,,,,,,,,,,,,,,
23477,,not exclusion criteria);|fractures around,,,,,,,,,,,,,,,,
23478,,eligibility,,,,,,,,,,,,,,,,
23479,,consent|pregnancy,,,,,,,,,,,,,,,,
23480,,squamous histology|planned,,,,,,,,,,,,,,,,
23481,,colonic stricture,,,,,,,,,,,,,,,,
23482,,myeloid neoplasms,,,,,,,,,,,,,,,,
23483,,asthma|poorly controlled asthma,,,,,,,,,,,,,,,,
23484,,therapy|active cancer,,,,,,,,,,,,,,,,
23485,,cns sarcoma.|patients,,,,,,,,,,,,,,,,
23486,,metabolic disease.|use,,,,,,,,,,,,,,,,
23487,,underlying disease,,,,,,,,,,,,,,,,
23488,,anorectal pathology,,,,,,,,,,,,,,,,
23489,,congestive heart,,,,,,,,,,,,,,,,
23490,,cardiovascular disorders.|presence,,,,,,,,,,,,,,,,
23491,,ric,,,,,,,,,,,,,,,,
23492,,intra-uterine abnormality,,,,,,,,,,,,,,,,
23493,,resting respiratory failure,,,,,,,,,,,,,,,,
23494,,abnormal symptoms,,,,,,,,,,,,,,,,
23495,,contraceptive measures,,,,,,,,,,,,,,,,
23496,,liver cirrhosis complication,,,,,,,,,,,,,,,,
23497,,third degree heart block.|any factors,,,,,,,,,,,,,,,,
23498,,liver lesions,,,,,,,,,,,,,,,,
23499,,persist from the initial,,,,,,,,,,,,,,,,
23500,,hepatitis c virus ribonucleic acid,,,,,,,,,,,,,,,,
23501,,palliative causes,,,,,,,,,,,,,,,,
23502,,vitreous haze,,,,,,,,,,,,,,,,
23503,,unsterilized,,,,,,,,,,,,,,,,
23504,,nephron loss calculated on the average of the two previous years,,,,,,,,,,,,,,,,
23505,,localized non-cns radiotherapy,,,,,,,,,,,,,,,,
23506,,etc.;|patients,,,,,,,,,,,,,,,,
23507,,venous thrombosis treatment,,,,,,,,,,,,,,,,
23508,,systemic antitumor,,,,,,,,,,,,,,,,
23509,,blood vessels,,,,,,,,,,,,,,,,
23510,,reverse)|osteoarthritis,,,,,,,,,,,,,,,,
23511,,tetralogy,,,,,,,,,,,,,,,,
23512,,care,,,,,,,,,,,,,,,,
23513,,acs)|splenic sequestration|dactylitis|requires,,,,,,,,,,,,,,,,
23514,,non-mr,,,,,,,,,,,,,,,,
23515,,m.levator scapula muscles|patients,,,,,,,,,,,,,,,,
23516,,fibrosis-4,,,,,,,,,,,,,,,,
23517,,identifiers,,,,,,,,,,,,,,,,
23518,,myocardialinfarction,,,,,,,,,,,,,,,,
23519,,cerebral circulation disorder,,,,,,,,,,,,,,,,
23520,,proven pathology,,,,,,,,,,,,,,,,
23521,,rheumatologic diseases,,,,,,,,,,,,,,,,
23522,,gastroesophageal reflux|severe,,,,,,,,,,,,,,,,
23523,,spinal cord stimulator (scs),,,,,,,,,,,,,,,,
23524,,similar patients)|positive crossmatch,,,,,,,,,,,,,,,,
23525,,metastases.|active gastrointestinal diseases,,,,,,,,,,,,,,,,
23526,,reasons.|active infection,,,,,,,,,,,,,,,,
23527,,major psychological condition,,,,,,,,,,,,,,,,
23528,,menstrual bleeding|sexually,,,,,,,,,,,,,,,,
23529,,etc.;|suffering,,,,,,,,,,,,,,,,
23530,,abnormal cervical biopsy results,,,,,,,,,,,,,,,,
23531,,ia,,,,,,,,,,,,,,,,
23532,,diameter|measurable disease,,,,,,,,,,,,,,,,
23533,,uterine diseases,,,,,,,,,,,,,,,,
23534,,hormone preparations,,,,,,,,,,,,,,,,
23535,,esophageal varices,,,,,,,,,,,,,,,,
23536,,orthostatic hypotension|use,,,,,,,,,,,,,,,,
23537,,abnormal curvature,,,,,,,,,,,,,,,,
23538,,bladder dysfunction.|children,,,,,,,,,,,,,,,,
23539,,hallucinogens,,,,,,,,,,,,,,,,
23540,,cseu la salle|ability to perform all the clinical tests,,,,,,,,,,,,,,,,
23541,,endometrial lesions;|the,,,,,,,,,,,,,,,,
23542,,major organ failure,,,,,,,,,,,,,,,,
23543,,functional extranodal involvement,,,,,,,,,,,,,,,,
23544,,recurrence to participate.||all arms:||participants,,,,,,,,,,,,,,,,
23545,,mixed invasive candida,,,,,,,,,,,,,,,,
23546,,castration sensitive prostate cancer,,,,,,,,,,,,,,,,
23547,,antitumor indications,,,,,,,,,,,,,,,,
23548,,hypercholesterolaemia,,,,,,,,,,,,,,,,
23549,,chimeric cell therapy,,,,,,,,,,,,,,,,
23550,,image,,,,,,,,,,,,,,,,
23551,,cta,,,,,,,,,,,,,,,,
23552,,incurable hnc,,,,,,,,,,,,,,,,
23553,,cancer treatment contraindicates,,,,,,,,,,,,,,,,
23554,,comorbid illicit substance use disorders,,,,,,,,,,,,,,,,
23555,,metastasis;|inability to swallow,,,,,,,,,,,,,,,,
23556,,cutaneous tumor site amenable to direct,,,,,,,,,,,,,,,,
23557,,myocardial infarction|acute coronary syndromes|stable,,,,,,,,,,,,,,,,
23558,,extensive crohn's disease,,,,,,,,,,,,,,,,
23559,,physiological dosed systemic corticosteroids,,,,,,,,,,,,,,,,
23560,,prolonged bleeding,,,,,,,,,,,,,,,,
23561,,diffusion abnormality,,,,,,,,,,,,,,,,
23562,,hyperaldosteronism,,,,,,,,,,,,,,,,
23563,,criteria|ebv-dna viral load,,,,,,,,,,,,,,,,
23564,,chronic stable angina,,,,,,,,,,,,,,,,
23565,,addictive behavior,,,,,,,,,,,,,,,,
23566,,bp,,,,,,,,,,,,,,,,
23567,,health of the patient|any physical or mental handicap,,,,,,,,,,,,,,,,
23568,,sex|sensorineural hearing loss,,,,,,,,,,,,,,,,
23569,,skin disorders,,,,,,,,,,,,,,,,
23570,,prolonged general anesthesia,,,,,,,,,,,,,,,,
23571,,squamous differentiation,,,,,,,,,,,,,,,,
23572,,obesity,,,,,,,,,,,,,,,,
23573,,tuberculosis|immunodeficiency,,,,,,,,,,,,,,,,
23574,,postoperative af,,,,,,,,,,,,,,,,
23575,,hemodynamic instability|uncorrectable coagulopathy|severe pulmonary hypertension|acute coronary syndrome|intermediate-high-risk,,,,,,,,,,,,,,,,
23576,,vision,,,,,,,,,,,,,,,,
23577,,macular retinal,,,,,,,,,,,,,,,,
23578,,serious condition,,,,,,,,,,,,,,,,
23579,,progressive multifocal leukoencephalopathy (pml),,,,,,,,,,,,,,,,
23580,,limb fractures,,,,,,,,,,,,,,,,
23581,,available values,,,,,,,,,,,,,,,,
23582,,end stage organ,,,,,,,,,,,,,,,,
23583,,severe alcohol,,,,,,,,,,,,,,,,
23584,,cardiovascular diseases|evidence,,,,,,,,,,,,,,,,
23585,,scad,,,,,,,,,,,,,,,,
23586,,α1-antitrypsin,,,,,,,,,,,,,,,,
23587,,contralateral disease,,,,,,,,,,,,,,,,
23588,,uncontrollable mental illness,,,,,,,,,,,,,,,,
23589,,spine surgery)|expected,,,,,,,,,,,,,,,,
23590,,nodes consistent,,,,,,,,,,,,,,,,
23591,,atrial septal defect,,,,,,,,,,,,,,,,
23592,,sars-cov-2,,,,,,,,,,,,,,,,
23593,,oesophageal varices|achalasia|severe,,,,,,,,,,,,,,,,
23594,,namd,,,,,,,,,,,,,,,,
23595,,muscle pain,,,,,,,,,,,,,,,,
23596,,osteonecrosis|cerebrovascular,,,,,,,,,,,,,,,,
23597,,as:||1,,,,,,,,,,,,,,,,
23598,,ovarian cancer,,,,,,,,,,,,,,,,
23599,,acute thrombophlebitis,,,,,,,,,,,,,,,,
23600,,arteriovenous thrombosis events,,,,,,,,,,,,,,,,
23601,,injectable disease,,,,,,,,,,,,,,,,
23602,,vascular dementia,,,,,,,,,,,,,,,,
23603,,chronic respiratory disease,,,,,,,,,,,,,,,,
23604,,craniotomies,,,,,,,,,,,,,,,,
23605,,nutritional habits,,,,,,,,,,,,,,,,
23606,,embolic cerebrovertebral accident,,,,,,,,,,,,,,,,
23607,,neurodevelopmental disease)|patient bearing,,,,,,,,,,,,,,,,
23608,,submissions,,,,,,,,,,,,,,,,
23609,,bleeding clotting,,,,,,,,,,,,,,,,
23610,,agents.|other malignancy,,,,,,,,,,,,,,,,
23611,,non-allergic bronchospasm,,,,,,,,,,,,,,,,
23612,,reticular changes,,,,,,,,,,,,,,,,
23613,,glucotrol,,,,,,,,,,,,,,,,
23614,,wrist problems,,,,,,,,,,,,,,,,
23615,,premature cardiovascular disease,,,,,,,,,,,,,,,,
23616,,grow factors,,,,,,,,,,,,,,,,
23617,,rectal prolapse|pelvic pain,,,,,,,,,,,,,,,,
23618,,cicatricial pemphigoid,,,,,,,,,,,,,,,,
23619,,pain below the buttock|must,,,,,,,,,,,,,,,,
23620,,tuberculosis.|requiring escalating,,,,,,,,,,,,,,,,
23621,,ocular neoplasm,,,,,,,,,,,,,,,,
23622,,prognostic medical treatment.|under,,,,,,,,,,,,,,,,
23623,,cutaneous non melanoma,,,,,,,,,,,,,,,,
23624,,apparent cause,,,,,,,,,,,,,,,,
23625,,drain,,,,,,,,,,,,,,,,
23626,,biologic therapy.|current malignancy,,,,,,,,,,,,,,,,
23627,,functional abilities,,,,,,,,,,,,,,,,
23628,,her2-positive.|treatment-naïve,,,,,,,,,,,,,,,,
23629,,arrhythmia;|(4,,,,,,,,,,,,,,,,
23630,,smoking status,,,,,,,,,,,,,,,,
23631,,"cerebral palsy,|located",,,,,,,,,,,,,,,,
23632,,extracorporeal membrane oxygenation,,,,,,,,,,,,,,,,
23633,,hearing deficit,,,,,,,,,,,,,,,,
23634,,replacement|percutaneous transluminal coronary angioplasty,,,,,,,,,,,,,,,,
23635,,culture.|patients,,,,,,,,,,,,,,,,
23636,,difficulty walking ¼ mile,,,,,,,,,,,,,,,,
23637,,infections|known,,,,,,,,,,,,,,,,
23638,,teeth marks,,,,,,,,,,,,,,,,
23639,,nutritional ketosis,,,,,,,,,,,,,,,,
23640,,metabolized cyp3a4,,,,,,,,,,,,,,,,
23641,,chorioretinopathy,,,,,,,,,,,,,,,,
23642,,hearing damage,,,,,,,,,,,,,,,,
23643,,iagnosis,,,,,,,,,,,,,,,,
23644,,cardiovascular disease.|patients,,,,,,,,,,,,,,,,
23645,,complicated allergy,,,,,,,,,,,,,,,,
23646,,herpetic keratitis,,,,,,,,,,,,,,,,
23647,,metastatic,,,,,,,,,,,,,,,,
23648,,otological infection|tympanic,,,,,,,,,,,,,,,,
23649,,impairment in cognition,,,,,,,,,,,,,,,,
23650,,sequential complex wound care procedures,,,,,,,,,,,,,,,,
23651,,allergies.|the,,,,,,,,,,,,,,,,
23652,,lower extremities injury,,,,,,,,,,,,,,,,
23653,,primary adrenal insufficiency (,,,,,,,,,,,,,,,,
23654,,dermatitis herpetiformis,,,,,,,,,,,,,,,,
23655,,cranial neuropathies,,,,,,,,,,,,,,,,
23656,,meibomian gland,,,,,,,,,,,,,,,,
23657,,menstrual,,,,,,,,,,,,,,,,
23658,,texas southwestern,,,,,,,,,,,,,,,,
23659,,gynaecological cancer,,,,,,,,,,,,,,,,
23660,,corneal scars|patients,,,,,,,,,,,,,,,,
23661,,anticholinergic properties,,,,,,,,,,,,,,,,
23662,,breast lumpectomy.||,,,,,,,,,,,,,,,,
23663,,accessory pathway|signs,,,,,,,,,,,,,,,,
23664,,lung|sepsis,,,,,,,,,,,,,,,,
23665,,schizophrenia spectrum,,,,,,,,,,,,,,,,
23666,,liver failure|renal dysfunction,,,,,,,,,,,,,,,,
23667,,type 1 diabetes mellitus;|hypothyroidism,,,,,,,,,,,,,,,,
23668,,intractable radiculopathy,,,,,,,,,,,,,,,,
23669,,vagal tension,,,,,,,,,,,,,,,,
23670,,cognitive function,,,,,,,,,,,,,,,,
23671,,cns disease,,,,,,,,,,,,,,,,
23672,,febrile seizures).|patients,,,,,,,,,,,,,,,,
23673,,hemofiltration,,,,,,,,,,,,,,,,
23674,,egfr determinations,,,,,,,,,,,,,,,,
23675,,sars,,,,,,,,,,,,,,,,
23676,,pain on percussion test.||radiographic criteria:||no sign of radiolucency,,,,,,,,,,,,,,,,
23677,,myocardial infarction|cervical spine instability,,,,,,,,,,,,,,,,
23678,,loads,,,,,,,,,,,,,,,,
23679,,skin laxity,,,,,,,,,,,,,,,,
23680,,pbmt,,,,,,,,,,,,,,,,
23681,,hepatitis b (hbsag positive,,,,,,,,,,,,,,,,
23682,,balance disorder diagnosis|uncorrected severe,,,,,,,,,,,,,,,,
23683,,and|who required ionotropic support,,,,,,,,,,,,,,,,
23684,,heart rate (,,,,,,,,,,,,,,,,
23685,,rheumatoid arthritis.|patients,,,,,,,,,,,,,,,,
23686,,head and neck malignancy,,,,,,,,,,,,,,,,
23687,,knee pain,,,,,,,,,,,,,,,,
23688,,peripheral nerve block,,,,,,,,,,,,,,,,
23689,,unrealistic expectations.|severe bruxism,,,,,,,,,,,,,,,,
23690,,musculoskeletal conditions,,,,,,,,,,,,,,,,
23691,,ca125,,,,,,,,,,,,,,,,
23692,,fecal impaction|suspicion,,,,,,,,,,,,,,,,
23693,,pfo,,,,,,,,,,,,,,,,
23694,,chronic meningitis,,,,,,,,,,,,,,,,
23695,,hormonal factors,,,,,,,,,,,,,,,,
23696,,overlapping toes,,,,,,,,,,,,,,,,
23697,,liver systems,,,,,,,,,,,,,,,,
23698,,doctor's,,,,,,,,,,,,,,,,
23699,,male participants|healthy,,,,,,,,,,,,,,,,
23700,,clinical significance,,,,,,,,,,,,,,,,
23701,,malignant arrhythmia;|ecog (eastern cooperative oncology group,,,,,,,,,,,,,,,,
23702,,anginal symptoms,,,,,,,,,,,,,,,,
23703,,liver stiffness,,,,,,,,,,,,,,,,
23704,,immunosuppression.|evidence of,,,,,,,,,,,,,,,,
23705,,compromised immune system,,,,,,,,,,,,,,,,
23706,,expansive injury,,,,,,,,,,,,,,,,
23707,,breeding,,,,,,,,,,,,,,,,
23708,,empyema,,,,,,,,,,,,,,,,
23709,,congenital immunodeficiency disorders,,,,,,,,,,,,,,,,
23710,,resident,,,,,,,,,,,,,,,,
23711,,criteria of western medicine,,,,,,,,,,,,,,,,
23712,,angular gyrus,,,,,,,,,,,,,,,,
23713,,from dysphasia,,,,,,,,,,,,,,,,
23714,,lower extremity swelling,,,,,,,,,,,,,,,,
23715,,endocrinopathies stably,,,,,,,,,,,,,,,,
23716,,epicardial coronary artery stenosis,,,,,,,,,,,,,,,,
23717,,large b-cell lymphoma,,,,,,,,,,,,,,,,
23718,,sensory impairment,,,,,,,,,,,,,,,,
23719,,hepatic disease|urinary tract,,,,,,,,,,,,,,,,
23720,,gastrointestinal disease,,,,,,,,,,,,,,,,
23721,,target car-t treatment,,,,,,,,,,,,,,,,
23722,,temporomandibular joint pain,,,,,,,,,,,,,,,,
23723,,non-syndromic clp.||,,,,,,,,,,,,,,,,
23724,,human immunodeficiency virus (hiv) antibody,,,,,,,,,,,,,,,,
23725,,non-covid-19 related,,,,,,,,,,,,,,,,
23726,,metabolic status;|injury,,,,,,,,,,,,,,,,
23727,,actively under custody of law enforcement,,,,,,,,,,,,,,,,
23728,,extensive external beam radiation therapy,,,,,,,,,,,,,,,,
23729,,breast cancer|using ai,,,,,,,,,,,,,,,,
23730,,retrosternal pain,,,,,,,,,,,,,,,,
23731,,judged by the investigator to be highly,,,,,,,,,,,,,,,,
23732,,epidermolysis,,,,,,,,,,,,,,,,
23733,,disorder|having,,,,,,,,,,,,,,,,
23734,,neurological deficit|mental retardation|anatomical deformity,,,,,,,,,,,,,,,,
23735,,lack of effective treatment.||,,,,,,,,,,,,,,,,
23736,,lactation|uncontrolled hypertension,,,,,,,,,,,,,,,,
23737,,age|inactive periodontal,,,,,,,,,,,,,,,,
23738,,humerus,,,,,,,,,,,,,,,,
23739,,interstitial lung diseases,,,,,,,,,,,,,,,,
23740,,refuses,,,,,,,,,,,,,,,,
23741,,parkinson's disease.|history,,,,,,,,,,,,,,,,
23742,,access|able to read,,,,,,,,,,,,,,,,
23743,,gib)).|presence,,,,,,,,,,,,,,,,
23744,,bone impairments,,,,,,,,,,,,,,,,
23745,,hyperosmotic hyperglycaemic non-ketotic,,,,,,,,,,,,,,,,
23746,,infection|evidence,,,,,,,,,,,,,,,,
23747,,deviated septum,,,,,,,,,,,,,,,,
23748,,sars-cov-2.||,,,,,,,,,,,,,,,,
23749,,month.|patients,,,,,,,,,,,,,,,,
23750,,diabetic hypertonic coma,,,,,,,,,,,,,,,,
23751,,human t-cell lymphoma virus (htlv)-i/ii,,,,,,,,,,,,,,,,
23752,,individual basis.|active malignancy,,,,,,,,,,,,,,,,
23753,,crack,,,,,,,,,,,,,,,,
23754,,type 1 mnv,,,,,,,,,,,,,,,,
23755,,human birth tissue.|undergone surgical procedures of either knee,,,,,,,,,,,,,,,,
23756,,motor symptoms,,,,,,,,,,,,,,,,
23757,,penile cancer,,,,,,,,,,,,,,,,
23758,,tracheal stenosis,,,,,,,,,,,,,,,,
23759,,dyslipidemia.|female,,,,,,,,,,,,,,,,
23760,,majority,,,,,,,,,,,,,,,,
23761,,intravenous thrombolysis||,,,,,,,,,,,,,,,,
23762,,carcinoid cell type,,,,,,,,,,,,,,,,
23763,,superficial diabetic ulcer,,,,,,,,,,,,,,,,
23764,,contralateral neck dissection,,,,,,,,,,,,,,,,
23765,,consistent dh response,,,,,,,,,,,,,,,,
23766,,relapsed aml,,,,,,,,,,,,,,,,
23767,,cavitiation,,,,,,,,,,,,,,,,
23768,,deformity,,,,,,,,,,,,,,,,
23769,,vital sign monitoring,,,,,,,,,,,,,,,,
23770,,cohorts,,,,,,,,,,,,,,,,
23771,,inability to tolerate,,,,,,,,,,,,,,,,
23772,,solid tumor||patient,,,,,,,,,,,,,,,,
23773,,transvaginal rectopexy,,,,,,,,,,,,,,,,
23774,,ultraviolet light sources,,,,,,,,,,,,,,,,
23775,,symptomatic hf,,,,,,,,,,,,,,,,
23776,,substance use screen,,,,,,,,,,,,,,,,
23777,,acute otitis media,,,,,,,,,,,,,,,,
23778,,renal impairment|urine protein,,,,,,,,,,,,,,,,
23779,,communication difficulties,,,,,,,,,,,,,,,,
23780,,occupational factors,,,,,,,,,,,,,,,,
23781,,other respiratory disease,,,,,,,,,,,,,,,,
23782,,good visual,,,,,,,,,,,,,,,,
23783,,hypertensive retinopathy,,,,,,,,,,,,,,,,
23784,,evans syndrome,,,,,,,,,,,,,,,,
23785,,refractory ced,,,,,,,,,,,,,,,,
23786,,congenital ichthyoses,,,,,,,,,,,,,,,,
23787,,conditions unsuitable for participation in this study,,,,,,,,,,,,,,,,
23788,,patellofemoral osteoarthritis,,,,,,,,,,,,,,,,
23789,,guillain-barre syndrome.|subjects receive,,,,,,,,,,,,,,,,
23790,,rescue laxatives,,,,,,,,,,,,,,,,
23791,,mitral stenosis|cancer,,,,,,,,,,,,,,,,
23792,,influence carbohydrate metabolism,,,,,,,,,,,,,,,,
23793,,intervention;|abnormal coagulation function,,,,,,,,,,,,,,,,
23794,,papules,,,,,,,,,,,,,,,,
23795,,clinical symptoms related,,,,,,,,,,,,,,,,
23796,,radiologic findings,,,,,,,,,,,,,,,,
23797,,injury;|acute hepatic impairment,,,,,,,,,,,,,,,,
23798,,spastic type cerebral,,,,,,,,,,,,,,,,
23799,,alcoholism;|pregnancy,,,,,,,,,,,,,,,,
23800,,cadasil - cerebral autosomal,,,,,,,,,,,,,,,,
23801,,pregnancy|psychiatric disease|alcohol,,,,,,,,,,,,,,,,
23802,,rehabilitation training|participant's parents,,,,,,,,,,,,,,,,
23803,,toxic injury,,,,,,,,,,,,,,,,
23804,,nasal cavities,,,,,,,,,,,,,,,,
23805,,coronavirus pneumonia,,,,,,,,,,,,,,,,
23806,,gi dysfunction,,,,,,,,,,,,,,,,
23807,,transmucosal height,,,,,,,,,,,,,,,,
23808,,co morbidities,,,,,,,,,,,,,,,,
23809,,spend time||,,,,,,,,,,,,,,,,
23810,,tumor bone metastasis,,,,,,,,,,,,,,,,
23811,,decreased kidney function,,,,,,,,,,,,,,,,
23812,,alcohol dependence,,,,,,,,,,,,,,,,
23813,,esophageal cancer;|pre-treatment,,,,,,,,,,,,,,,,
23814,,g6pd deficiency,,,,,,,,,,,,,,,,
23815,,significant hf,,,,,,,,,,,,,,,,
23816,,non-cardiac procedures,,,,,,,,,,,,,,,,
23817,,bronchiolitis,,,,,,,,,,,,,,,,
23818,,inoperable surgically resectable,,,,,,,,,,,,,,,,
23819,,icf);|male,,,,,,,,,,,,,,,,
23820,,parkinson's' disease,,,,,,,,,,,,,,,,
23821,,orthostatic syncope,,,,,,,,,,,,,,,,
23822,,vista-targeted therapy.|prior history of,,,,,,,,,,,,,,,,
23823,,pd)-1,,,,,,,,,,,,,,,,
23824,,/internal infection,,,,,,,,,,,,,,,,
23825,,maternal cardiac disease,,,,,,,,,,,,,,,,
23826,,insomnia symptoms,,,,,,,,,,,,,,,,
23827,,system diseases,,,,,,,,,,,,,,,,
23828,,etc.)|25 0h vit,,,,,,,,,,,,,,,,
23829,,congenital haemophilia,,,,,,,,,,,,,,,,
23830,,severe anxiety,,,,,,,,,,,,,,,,
23831,,prostate cancer treatment,,,,,,,,,,,,,,,,
23832,,historical bone marrow,,,,,,,,,,,,,,,,
23833,,guillain-barre syndrome [gbs],,,,,,,,,,,,,,,,
23834,,ischemic aetiology,,,,,,,,,,,,,,,,
23835,,renal parenchymal disease,,,,,,,,,,,,,,,,
23836,,asymptomatic brain,,,,,,,,,,,,,,,,
23837,,cortico-visual,,,,,,,,,,,,,,,,
23838,,methionyl-transfer rna,,,,,,,,,,,,,,,,
23839,,fibrovascular proliferation,,,,,,,,,,,,,,,,
23840,,cmet exon 14 skipping,,,,,,,,,,,,,,,,
23841,,reliant|assistive walking device reliant,,,,,,,,,,,,,,,,
23842,,epilepsy;|pregnant,,,,,,,,,,,,,,,,
23843,,clicking,,,,,,,,,,,,,,,,
23844,,buccal wall).|the,,,,,,,,,,,,,,,,
23845,,of||proliferative diabetic,,,,,,,,,,,,,,,,
23846,,myxofibrosarcoma,,,,,,,,,,,,,,,,
23847,,diaplegic spastic cp,,,,,,,,,,,,,,,,
23848,,uterine cervical carcinoma in situ,,,,,,,,,,,,,,,,
23849,,medical sleep disorder,,,,,,,,,,,,,,,,
23850,,excluded.)||pregnant,,,,,,,,,,,,,,,,
23851,,third degree heart block,,,,,,,,,,,,,,,,
23852,,neurotoxic chemotherapies,,,,,,,,,,,,,,,,
23853,,surgeries|active inflammatory bowel disease,,,,,,,,,,,,,,,,
23854,,skin tape,,,,,,,,,,,,,,,,
23855,,coronary thrombosis,,,,,,,,,,,,,,,,
23856,,chronic diarrhoeal disorders,,,,,,,,,,,,,,,,
23857,,saphenous vein reflux,,,,,,,,,,,,,,,,
23858,,pack,,,,,,,,,,,,,,,,
23859,,temporomandibular joint disorder.|patients,,,,,,,,,,,,,,,,
23860,,serious head trauma,,,,,,,,,,,,,,,,
23861,,high frequency seizures,,,,,,,,,,,,,,,,
23862,,symptoms of psychosis,,,,,,,,,,,,,,,,
23863,,periocular,,,,,,,,,,,,,,,,
23864,,dupilumab.|ocular disorder,,,,,,,,,,,,,,,,
23865,,ivf +,,,,,,,,,,,,,,,,
23866,,food,,,,,,,,,,,,,,,,
23867,,glioblastoma|genetic disorders,,,,,,,,,,,,,,,,
23868,,ihd,,,,,,,,,,,,,,,,
23869,,comorbidities:||(1,,,,,,,,,,,,,,,,
23870,,cancer related,,,,,,,,,,,,,,,,
23871,,tbi|intracranial abnormalities|chronic neurologic conditions,,,,,,,,,,,,,,,,
23872,,acute unidentified,,,,,,,,,,,,,,,,
23873,,lad,,,,,,,,,,,,,,,,
23874,,histological features,,,,,,,,,,,,,,,,
23875,,attention deficit,,,,,,,,,,,,,,,,
23876,,c3 nephropathy,,,,,,,,,,,,,,,,
23877,,aneurysm features,,,,,,,,,,,,,,,,
23878,,compromised left ventricular ejection fraction,,,,,,,,,,,,,,,,
23879,,drug abuse dependency disorder,,,,,,,,,,,,,,,,
23880,,hopeless tooth.|immature,,,,,,,,,,,,,,,,
23881,,lumbar disc herniation,,,,,,,,,,,,,,,,
23882,,laboratory liver profile,,,,,,,,,,,,,,,,
23883,,cns metastatic disease,,,,,,,,,,,,,,,,
23884,,microsatellite instability,,,,,,,,,,,,,,,,
23885,,primary care,,,,,,,,,,,,,,,,
23886,,factors,,,,,,,,,,,,,,,,
23887,,immunotherapy targeting pd-1,,,,,,,,,,,,,,,,
23888,,following:||borderline resectable disease,,,,,,,,,,,,,,,,
23889,,3 cancer,,,,,,,,,,,,,,,,
23890,,not the first-born child,,,,,,,,,,,,,,,,
23891,,good condition.|prior intolerance,,,,,,,,,,,,,,,,
23892,,poor exercise,,,,,,,,,,,,,,,,
23893,,reproductively capable,,,,,,,,,,,,,,,,
23894,,versus host disease,,,,,,,,,,,,,,,,
23895,,icd.||symptomatic,,,,,,,,,,,,,,,,
23896,,infectious disease;|malignancy,,,,,,,,,,,,,,,,
23897,,resectable disease,,,,,,,,,,,,,,,,
23898,,granulocytopenia,,,,,,,,,,,,,,,,
23899,,emts,,,,,,,,,,,,,,,,
23900,,nasal,,,,,,,,,,,,,,,,
23901,,chronic hepatic impairment resulted,,,,,,,,,,,,,,,,
23902,,bell's palsy,,,,,,,,,,,,,,,,
23903,,eosinophilic granulomatosis,,,,,,,,,,,,,,,,
23904,,ambulatory care,,,,,,,,,,,,,,,,
23905,,intracranial hemorrhage);|subjects,,,,,,,,,,,,,,,,
23906,,myocardial infarction;|the,,,,,,,,,,,,,,,,
23907,,malignant arrhythmia,,,,,,,,,,,,,,,,
23908,,b|be immunosuppressed (,,,,,,,,,,,,,,,,
23909,,human immunodeficiency virus (hiv) viral serology test,,,,,,,,,,,,,,,,
23910,,hypertrophic obstructive cardiomyopathy,,,,,,,,,,,,,,,,
23911,,bleeding constitution,,,,,,,,,,,,,,,,
23912,,necrotic lung disease,,,,,,,,,,,,,,,,
23913,,mio click 2p click flat,,,,,,,,,,,,,,,,
23914,,album bone marrow,,,,,,,,,,,,,,,,
23915,,elimination,,,,,,,,,,,,,,,,
23916,,transient ischemic,,,,,,,,,,,,,,,,
23917,,depression|prior brain surgery,,,,,,,,,,,,,,,,
23918,,surgical indication.|altered pain perception,,,,,,,,,,,,,,,,
23919,,infectious joint disease,,,,,,,,,,,,,,,,
23920,,cutaneous sarcoidosis,,,,,,,,,,,,,,,,
23921,,aortic valve calcification|those deemed unsuitable,,,,,,,,,,,,,,,,
23922,,hospital|hemodynamic instability,,,,,,,,,,,,,,,,
23923,,isolated motor delay,,,,,,,,,,,,,,,,
23924,,swallowing disorder|subject,,,,,,,,,,,,,,,,
23925,,ocular surgery|refusal,,,,,,,,,,,,,,,,
23926,,paralysis,,,,,,,,,,,,,,,,
23927,,incompatible with the proper conduct of the study|history of cancer|use of immune,,,,,,,,,,,,,,,,
23928,,diabetic insipidus,,,,,,,,,,,,,,,,
23929,,congenital lung abnormality,,,,,,,,,,,,,,,,
23930,,human t-cell leukemia virus (htlv),,,,,,,,,,,,,,,,
23931,,participate||,,,,,,,,,,,,,,,,
23932,,cholangitis)||vi,,,,,,,,,,,,,,,,
23933,,rheumatoid nodules,,,,,,,,,,,,,,,,
23934,,coexistent migraine,,,,,,,,,,,,,,,,
23935,,brain oedema,,,,,,,,,,,,,,,,
23936,,skin diseases)|travel across,,,,,,,,,,,,,,,,
23937,,deep brain stimulator)|is,,,,,,,,,,,,,,,,
23938,,lymphoproliferative neoplasms|had,,,,,,,,,,,,,,,,
23939,,assiut university heart hospital,,,,,,,,,,,,,,,,
23940,,children injury,,,,,,,,,,,,,,,,
23941,,consistent neurologic,,,,,,,,,,,,,,,,
23942,,crohn 's disease,,,,,,,,,,,,,,,,
23943,,duodenal-pancreatectomy surgical,,,,,,,,,,,,,,,,
23944,,screening|significant medical condition,,,,,,,,,,,,,,,,
23945,,intestinal permeability markers;|a urine collection,,,,,,,,,,,,,,,,
23946,,thrombosis,,,,,,,,,,,,,,,,
23947,,*6/*6,,,,,,,,,,,,,,,,
23948,,sebaceous epithelioma,,,,,,,,,,,,,,,,
23949,,trauma-fracture-dislocation,,,,,,,,,,,,,,,,
23950,,extra-pulmonary neuroendocrine carcinoma,,,,,,,,,,,,,,,,
23951,,alzheimer disease,,,,,,,,,,,,,,,,
23952,,reduced occupational employability medical,,,,,,,,,,,,,,,,
23953,,corneal staining,,,,,,,,,,,,,,,,
23954,,diabetes|patient,,,,,,,,,,,,,,,,
23955,,samples|tumor tissue block,,,,,,,,,,,,,,,,
23956,,release|returning,,,,,,,,,,,,,,,,
23957,,corneal neovascularization.||,,,,,,,,,,,,,,,,
23958,,canal permanent tooth,,,,,,,,,,,,,,,,
23959,,cardiovascular event,,,,,,,,,,,,,,,,
23960,,acupuncture,,,,,,,,,,,,,,,,
23961,,diabetic coma,,,,,,,,,,,,,,,,
23962,,paramedic,,,,,,,,,,,,,,,,
23963,,condition,,,,,,,,,,,,,,,,
23964,,kidney disease (ckd),,,,,,,,,,,,,,,,
23965,,rss,,,,,,,,,,,,,,,,
23966,,disclose phi||,,,,,,,,,,,,,,,,
23967,,hgb,,,,,,,,,,,,,,,,
23968,,renal disease|the,,,,,,,,,,,,,,,,
23969,,urological comorbidity,,,,,,,,,,,,,,,,
23970,,systemic allergic disease,,,,,,,,,,,,,,,,
23971,,between 01/03/2020,,,,,,,,,,,,,,,,
23972,,gynaecologic pathologies,,,,,,,,,,,,,,,,
23973,,oads,,,,,,,,,,,,,,,,
23974,,other respiratory diseases,,,,,,,,,,,,,,,,
23975,,acute myocardial infarction (ami),,,,,,,,,,,,,,,,
23976,,deep-brain stimulation (dbs),,,,,,,,,,,,,,,,
23977,,gastrointestinal infection,,,,,,,,,,,,,,,,
23978,,pc20,,,,,,,,,,,,,,,,
23979,,lips-related,,,,,,,,,,,,,,,,
23980,,consent|active autoimmune disease,,,,,,,,,,,,,,,,
23981,,|autoimmune diseases,,,,,,,,,,,,,,,,
23982,,zonular dialysis,,,,,,,,,,,,,,,,
23983,,facial palsy,,,,,,,,,,,,,,,,
23984,,male infertility factor,,,,,,,,,,,,,,,,
23985,,dka)|uncontrolled hypertension,,,,,,,,,,,,,,,,
23986,,ulna fracture,,,,,,,,,,,,,,,,
23987,,whiplash).|any red,,,,,,,,,,,,,,,,
23988,,random follow-up|persons,,,,,,,,,,,,,,,,
23989,,acute myocardial infarction|non-sinus rhythm,,,,,,,,,,,,,,,,
23990,,visceral failure,,,,,,,,,,,,,,,,
23991,,vestibular system,,,,,,,,,,,,,,,,
23992,,oncologic disorders,,,,,,,,,,,,,,,,
23993,,excessive risk,,,,,,,,,,,,,,,,
23994,,reproductive system,,,,,,,,,,,,,,,,
23995,,renal dialysis,,,,,,,,,,,,,,,,
23996,,diagnostic criteria,,,,,,,,,,,,,,,,
23997,,impairs speech comprehension e,,,,,,,,,,,,,,,,
23998,,vestibular,,,,,,,,,,,,,,,,
23999,,histology|received cancer care,,,,,,,,,,,,,,,,
24000,,vomiting,,,,,,,,,,,,,,,,
24001,,neovascular glaucoma|received oral,,,,,,,,,,,,,,,,
24002,,avna,,,,,,,,,,,,,,,,
24003,,vascular claudication,,,,,,,,,,,,,,,,
24004,,isolated extramedullary relapse;|patients,,,,,,,,,,,,,,,,
24005,,neuropathic symptoms,,,,,,,,,,,,,,,,
24006,,analyze,,,,,,,,,,,,,,,,
24007,,culture-proven,,,,,,,,,,,,,,,,
24008,,stable,,,,,,,,,,,,,,,,
24009,,extrahepatic biliary tract cancer,,,,,,,,,,,,,,,,
24010,,dietary restrictions,,,,,,,,,,,,,,,,
24011,,digital maturity,,,,,,,,,,,,,,,,
24012,,hepatitis b (hbv),,,,,,,,,,,,,,,,
24013,,disability|contra-indication,,,,,,,,,,,,,,,,
24014,,corticosteroid inhalers,,,,,,,,,,,,,,,,
24015,,non-steroidal anti-inflammatory drugs (nsaids),,,,,,,,,,,,,,,,
24016,,adverse reactions)|previously endovascular repair of the aorta|only thoracic aorta|no informed,,,,,,,,,,,,,,,,
24017,,neuroendocrine prostate cancer includes,,,,,,,,,,,,,,,,
24018,,pleural effusion;|the,,,,,,,,,,,,,,,,
24019,,stainless steel;|urethral malformation,,,,,,,,,,,,,,,,
24020,,acute stroke,,,,,,,,,,,,,,,,
24021,,pressure ulcer,,,,,,,,,,,,,,,,
24022,,periampullary carcinoma,,,,,,,,,,,,,,,,
24023,,intestinal occlusion,,,,,,,,,,,,,,,,
24024,,acute heart failure.|patients,,,,,,,,,,,,,,,,
24025,,cardiac rhythm loss,,,,,,,,,,,,,,,,
24026,,disseminated lyme disease,,,,,,,,,,,,,,,,
24027,,hepatitis c;|positive,,,,,,,,,,,,,,,,
24028,,uncontrollable cerebrovascular disease,,,,,,,,,,,,,,,,
24029,,pre-donation screening.|for,,,,,,,,,,,,,,,,
24030,,colonoscopy|adequate bowel,,,,,,,,,,,,,,,,
24031,,dietary arrangements;|patients,,,,,,,,,,,,,,,,
24032,,respiratory disease|significant renal disease|significant liver,,,,,,,,,,,,,,,,
24033,,es-sclc,,,,,,,,,,,,,,,,
24034,,carotid atheromasia,,,,,,,,,,,,,,,,
24035,,congenital immunodeficiency,,,,,,,,,,,,,,,,
24036,,retinal infarction|coronary artery,,,,,,,,,,,,,,,,
24037,,acute bleeding,,,,,,,,,,,,,,,,
24038,,hypermagnesemia,,,,,,,,,,,,,,,,
24039,,dilated heart chambers,,,,,,,,,,,,,,,,
24040,,non-interpretable recordings,,,,,,,,,,,,,,,,
24041,,congenital bone marrow failure,,,,,,,,,,,,,,,,
24042,,japanese,,,,,,,,,,,,,,,,
24043,,hypercoagulable conditions,,,,,,,,,,,,,,,,
24044,,hormonal dysfunction,,,,,,,,,,,,,,,,
24045,,above myocardial ischemia,,,,,,,,,,,,,,,,
24046,,acute crisis intervention,,,,,,,,,,,,,,,,
24047,,preoperative)|metastatic disease,,,,,,,,,,,,,,,,
24048,,hepatocyte injury type dili,,,,,,,,,,,,,,,,
24049,,states unable to comply,,,,,,,,,,,,,,,,
24050,,spine fracture,,,,,,,,,,,,,,,,
24051,,cardiac arrhythmic,,,,,,,,,,,,,,,,
24052,,immune deficiency|history of cancer,,,,,,,,,,,,,,,,
24053,,hypersensitivities,,,,,,,,,,,,,,,,
24054,,mobile technologies,,,,,,,,,,,,,,,,
24055,,consent.|contra-indication,,,,,,,,,,,,,,,,
24056,,cryo,,,,,,,,,,,,,,,,
24057,,complete wound,,,,,,,,,,,,,,,,
24058,,squamous intraepithelial lesions,,,,,,,,,,,,,,,,
24059,,prophylaxis,,,,,,,,,,,,,,,,
24060,,clinical insomnia,,,,,,,,,,,,,,,,
24061,,arachnoiditis,,,,,,,,,,,,,,,,
24062,,and|who can communicate verbally.||facilities inclusion,,,,,,,,,,,,,,,,
24063,,organ transplant|known allergy,,,,,,,,,,,,,,,,
24064,,hepato-renal,,,,,,,,,,,,,,,,
24065,,oral mucosal diseases,,,,,,,,,,,,,,,,
24066,,stevens-johnson syndrome,,,,,,,,,,,,,,,,
24067,,acute infection.|patients,,,,,,,,,,,,,,,,
24068,,prolonged qt interval,,,,,,,,,,,,,,,,
24069,,0.00d,,,,,,,,,,,,,,,,
24070,,situ)；|active hepatitis,,,,,,,,,,,,,,,,
24071,,metabolic condition,,,,,,,,,,,,,,,,
24072,,miles from cardiac rehab center,,,,,,,,,,,,,,,,
24073,,guillain-barré syndrome,,,,,,,,,,,,,,,,
24074,,squamous cells,,,,,,,,,,,,,,,,
24075,,permitted.)|pulmonary embolism,,,,,,,,,,,,,,,,
24076,,immunologic disorders,,,,,,,,,,,,,,,,
24077,,endometrial,,,,,,,,,,,,,,,,
24078,,recipients|cirrhosis,,,,,,,,,,,,,,,,
24079,,acute covid-19 episode,,,,,,,,,,,,,,,,
24080,,intrabody ferromagnetic,,,,,,,,,,,,,,,,
24081,,neonatal disease,,,,,,,,,,,,,,,,
24082,,hbsag carriers,,,,,,,,,,,,,,,,
24083,,meningiomas,,,,,,,,,,,,,,,,
24084,,biochemical failure,,,,,,,,,,,,,,,,
24085,,prion disease,,,,,,,,,,,,,,,,
24086,,external iliac,,,,,,,,,,,,,,,,
24087,,glucose-galactose,,,,,,,,,,,,,,,,
24088,,colonic,,,,,,,,,,,,,,,,
24089,,ca,,,,,,,,,,,,,,,,
24090,,asthma inhalers,,,,,,,,,,,,,,,,
24091,,chemotherapy|patients,,,,,,,,,,,,,,,,
24092,,cardiac rehabilitation,,,,,,,,,,,,,,,,
24093,,lower incisors|patients,,,,,,,,,,,,,,,,
24094,,other auto-immune diseases)|recent,,,,,,,,,,,,,,,,
24095,,electrolyte abnormalities.|proteinuria,,,,,,,,,,,,,,,,
24096,,measurements|aortic ectasia,,,,,,,,,,,,,,,,
24097,,poor controlled,,,,,,,,,,,,,,,,
24098,,chronic hepatitis need,,,,,,,,,,,,,,,,
24099,,congenital uterine abnormalities,,,,,,,,,,,,,,,,
24100,,dex,,,,,,,,,,,,,,,,
24101,,metabolic mineral storage disorders,,,,,,,,,,,,,,,,
24102,,defiant disorder,,,,,,,,,,,,,,,,
24103,,hepatocellular carcinoma.|known intolerance,,,,,,,,,,,,,,,,
24104,,major cognitive impairment,,,,,,,,,,,,,,,,
24105,,deep caries,,,,,,,,,,,,,,,,
24106,,cancer in remission,,,,,,,,,,,,,,,,
24107,,24-hour urinary oxalate,,,,,,,,,,,,,,,,
24108,,chronic diarrhoea,,,,,,,,,,,,,,,,
24109,,acute respiratory illness,,,,,,,,,,,,,,,,
24110,,proceeding,,,,,,,,,,,,,,,,
24111,,pregnancy.|maternal hiv,,,,,,,,,,,,,,,,
24112,,acute infections/diseases|regular,,,,,,,,,,,,,,,,
24113,,substance induced,,,,,,,,,,,,,,,,
24114,,parkinsonism,,,,,,,,,,,,,,,,
24115,,chest auscultation|peripheral edema,,,,,,,,,,,,,,,,
24116,,deficiency diseases,,,,,,,,,,,,,,,,
24117,,mycotic,,,,,,,,,,,,,,,,
24118,,caa,,,,,,,,,,,,,,,,
24119,,coagulation disorders.|mental,,,,,,,,,,,,,,,,
24120,,epithelial defect,,,,,,,,,,,,,,,,
24121,,old;|able to read,,,,,,,,,,,,,,,,
24122,,left common carotid artery,,,,,,,,,,,,,,,,
24123,,clinical stage,,,,,,,,,,,,,,,,
24124,,renal functions.|myelodysplastic syndromes (mds),,,,,,,,,,,,,,,,
24125,,carcinoma of the breast,,,,,,,,,,,,,,,,
24126,,contra-indication)|proven,,,,,,,,,,,,,,,,
24127,,hypertriglyceridemia,,,,,,,,,,,,,,,,
24128,,amblyopia,,,,,,,,,,,,,,,,
24129,,cardiovascular disorders.|hypertensive,,,,,,,,,,,,,,,,
24130,,tendency to decompensation,,,,,,,,,,,,,,,,
24131,,bulimia nervosa,,,,,,,,,,,,,,,,
24132,,"thyroid disorders,|adults",,,,,,,,,,,,,,,,
24133,,cauda equina neuropathy,,,,,,,,,,,,,,,,
24134,,retinal reattachment,,,,,,,,,,,,,,,,
24135,,impaired level,,,,,,,,,,,,,,,,
24136,,fragilis,,,,,,,,,,,,,,,,
24137,,pulmonary vein obstruction,,,,,,,,,,,,,,,,
24138,,hemodynamic instability,,,,,,,,,,,,,,,,
24139,,autologous cancer cell,,,,,,,,,,,,,,,,
24140,,|concussion,,,,,,,,,,,,,,,,
24141,,sci|spinal injury,,,,,,,,,,,,,,,,
24142,,prolonged loss,,,,,,,,,,,,,,,,
24143,,invasion,,,,,,,,,,,,,,,,
24144,,cold constitution,,,,,,,,,,,,,,,,
24145,,akinesia,,,,,,,,,,,,,,,,
24146,,delayed endolymphatic,,,,,,,,,,,,,,,,
24147,,tuberculosis;|active infection,,,,,,,,,,,,,,,,
24148,,cancer|refusing to participate,,,,,,,,,,,,,,,,
24149,,disease status,,,,,,,,,,,,,,,,
24150,,drug|sensitivity,,,,,,,,,,,,,,,,
24151,,non-encephalitis disorders,,,,,,,,,,,,,,,,
24152,,cardiac arrhythmias,,,,,,,,,,,,,,,,
24153,,neurologic diseases|contraction anomalies (hypotonic,,,,,,,,,,,,,,,,
24154,,brain tumors,,,,,,,,,,,,,,,,
24155,,refusal|cancer,,,,,,,,,,,,,,,,
24156,,physiology|current regular,,,,,,,,,,,,,,,,
24157,,melena,,,,,,,,,,,,,,,,
24158,,inadequate urate-lowering,,,,,,,,,,,,,,,,
24159,,sarcomatoid features,,,,,,,,,,,,,,,,
24160,,obstructive sleep apnea,,,,,,,,,,,,,,,,
24161,,renal cell carinoma,,,,,,,,,,,,,,,,
24162,,her2-negative bc,,,,,,,,,,,,,,,,
24163,,sepsis;|14,,,,,,,,,,,,,,,,
24164,,chronic regional pain,,,,,,,,,,,,,,,,
24165,,communication disorder,,,,,,,,,,,,,,,,
24166,,hepatitis b vaccination,,,,,,,,,,,,,,,,
24167,,unforeseen clinical need,,,,,,,,,,,,,,,,
24168,,patellar instability|any contraindication,,,,,,,,,,,,,,,,
24169,,seizure|botulinum toxin injection,,,,,,,,,,,,,,,,
24170,,potato starches.|surgical complications,,,,,,,,,,,,,,,,
24171,,carcinoma in situ of the bladder,,,,,,,,,,,,,,,,
24172,,arterial lesion,,,,,,,,,,,,,,,,
24173,,infectious diseases society,,,,,,,,,,,,,,,,
24174,,spinal radiculopathy,,,,,,,,,,,,,,,,
24175,,computerized executive function,,,,,,,,,,,,,,,,
24176,,mixed dementia,,,,,,,,,,,,,,,,
24177,,contemporaneous onset of the symptoms,,,,,,,,,,,,,,,,
24178,,psychical diseases,,,,,,,,,,,,,,,,
24179,,congenital thyroid disease,,,,,,,,,,,,,,,,
24180,,organic heart diseases,,,,,,,,,,,,,,,,
24181,,between puberty,,,,,,,,,,,,,,,,
24182,,dme>320,,,,,,,,,,,,,,,,
24183,,6.|treatment of lesions,,,,,,,,,,,,,,,,
24184,,individual's first,,,,,,,,,,,,,,,,
24185,,child-fathering potential,,,,,,,,,,,,,,,,
24186,,multiple rib fracture,,,,,,,,,,,,,,,,
24187,,respectively|heart failure,,,,,,,,,,,,,,,,
24188,,clinically significant.|uncontrolled hypertension,,,,,,,,,,,,,,,,
24189,,abruption,,,,,,,,,,,,,,,,
24190,,hemorrhagic syndrome,,,,,,,,,,,,,,,,
24191,,chronic disease(s,,,,,,,,,,,,,,,,
24192,,recreational iv drug use,,,,,,,,,,,,,,,,
24193,,cerebral haemodynamics;|stable,,,,,,,,,,,,,,,,
24194,,unstable cardiac arrhythmias,,,,,,,,,,,,,,,,
24195,,neurological pathologies).|non-italian education,,,,,,,,,,,,,,,,
24196,,subclinical cushing,,,,,,,,,,,,,,,,
24197,,media opacities,,,,,,,,,,,,,,,,
24198,,acquired hypogammaglobulinemia,,,,,,,,,,,,,,,,
24199,,"neck radiation,|cervical spine",,,,,,,,,,,,,,,,
24200,,frequently pericardiocentesis,,,,,,,,,,,,,,,,
24201,,technical reasons|drawings,,,,,,,,,,,,,,,,
24202,,severe covid-19 infection,,,,,,,,,,,,,,,,
24203,,prolapse,,,,,,,,,,,,,,,,
24204,,risk factors for bowel perforation,,,,,,,,,,,,,,,,
24205,,tki,,,,,,,,,,,,,,,,
24206,,adequately treated carcinoma in situ,,,,,,,,,,,,,,,,
24207,,moderate renal impairment,,,,,,,,,,,,,,,,
24208,,sebaceous adenoma,,,,,,,,,,,,,,,,
24209,,erythrema multiforme,,,,,,,,,,,,,,,,
24210,,dysfunction (mgd),,,,,,,,,,,,,,,,
24211,,her2-positive disease,,,,,,,,,,,,,,,,
24212,,infection;|mental disorders,,,,,,,,,,,,,,,,
24213,,digeorge syndrome,,,,,,,,,,,,,,,,
24214,,lugano lymphoma,,,,,,,,,,,,,,,,
24215,,covid-19,,,,,,,,,,,,,,,,
24216,,treatment.|recurrent,,,,,,,,,,,,,,,,
24217,,psychiatric issues,,,,,,,,,,,,,,,,
24218,,acute hepatitis,,,,,,,,,,,,,,,,
24219,,third space fluid accumulation,,,,,,,,,,,,,,,,
24220,,multidisciplinary spine conference review|maximum,,,,,,,,,,,,,,,,
24221,,gastrointestinal tract.|hemodynamically stable,,,,,,,,,,,,,,,,
24222,,situ|ductal carcinoma in situ,,,,,,,,,,,,,,,,
24223,,vision changes,,,,,,,,,,,,,,,,
24224,,malignant intracranial neoplasia,,,,,,,,,,,,,,,,
24225,,inductive effects,,,,,,,,,,,,,,,,
24226,,poor condition,,,,,,,,,,,,,,,,
24227,,retinal disease,,,,,,,,,,,,,,,,
24228,,kaposi,,,,,,,,,,,,,,,,
24229,,developmental defects,,,,,,,,,,,,,,,,
24230,,blood glucose disorder,,,,,,,,,,,,,,,,
24231,,pose an unacceptable risk,,,,,,,,,,,,,,,,
24232,,bloorview;|medically stable,,,,,,,,,,,,,,,,
24233,,symptoms health questionnaire,,,,,,,,,,,,,,,,
24234,,liver functions||key,,,,,,,,,,,,,,,,
24235,,relapsed ovarian cancer,,,,,,,,,,,,,,,,
24236,,pulmonary artery embolism,,,,,,,,,,,,,,,,
24237,,acute ocular disease,,,,,,,,,,,,,,,,
24238,,comorbid rheumatic disease,,,,,,,,,,,,,,,,
24239,,ureteral mucosal laceration,,,,,,,,,,,,,,,,
24240,,major morbidities compromising,,,,,,,,,,,,,,,,
24241,,extra-esophageal symptoms,,,,,,,,,,,,,,,,
24242,,heart disease;|3.pregnant,,,,,,,,,,,,,,,,
24243,,refusal|age,,,,,,,,,,,,,,,,
24244,,-situ thrombosis,,,,,,,,,,,,,,,,
24245,,esophageal varices.|patients,,,,,,,,,,,,,,,,
24246,,severe dementia,,,,,,,,,,,,,,,,
24247,,sepsis)|chronic kidney disease,,,,,,,,,,,,,,,,
24248,,lumbar spine surgery|progressive,,,,,,,,,,,,,,,,
24249,,rapid test)|clinical condition,,,,,,,,,,,,,,,,
24250,,distal forearm fracture,,,,,,,,,,,,,,,,
24251,,difficulty achieving,,,,,,,,,,,,,,,,
24252,,primary immunodeficiency disorders|immune-compromised,,,,,,,,,,,,,,,,
24253,,central serous chorioretinopathy.||healthy,,,,,,,,,,,,,,,,
24254,,bleeding episodes,,,,,,,,,,,,,,,,
24255,,ganglioneuroblastoma,,,,,,,,,,,,,,,,
24256,,neurological disease.|have,,,,,,,,,,,,,,,,
24257,,cosmetic problems.|clinical thyrotoxicosis,,,,,,,,,,,,,,,,
24258,,complaint from pain,,,,,,,,,,,,,,,,
24259,,acute kidney,,,,,,,,,,,,,,,,
24260,,mandibular protrusion,,,,,,,,,,,,,,,,
24261,,lbsl,,,,,,,,,,,,,,,,
24262,,chronic dermatological,,,,,,,,,,,,,,,,
24263,,loco-regional recurrent,,,,,,,,,,,,,,,,
24264,,nonvalvular atrial fibrillation,,,,,,,,,,,,,,,,
24265,,suspected|normal premorbid serum creatinine,,,,,,,,,,,,,,,,
24266,,ssc,,,,,,,,,,,,,,,,
24267,,intraoperative fracture,,,,,,,,,,,,,,,,
24268,,malignant tumors.|life expectancy,,,,,,,,,,,,,,,,
24269,,malignant space,,,,,,,,,,,,,,,,
24270,,bowel dysfunction,,,,,,,,,,,,,,,,
24271,,primary ciliary dyskinesia,,,,,,,,,,,,,,,,
24272,,alpha-1 antitrypsin,,,,,,,,,,,,,,,,
24273,,human serum albumin,,,,,,,,,,,,,,,,
24274,,major injury,,,,,,,,,,,,,,,,
24275,,nos,,,,,,,,,,,,,,,,
24276,,hcv infection,,,,,,,,,,,,,,,,
24277,,peit,,,,,,,,,,,,,,,,
24278,,acute oral,,,,,,,,,,,,,,,,
24279,,cardio-metabolic abnormalities,,,,,,,,,,,,,,,,
24280,,"drug allergy,|morbid obesity",,,,,,,,,,,,,,,,
24281,,fetal anomalies|contraindications,,,,,,,,,,,,,,,,
24282,,including-0.50,,,,,,,,,,,,,,,,
24283,,central vein,,,,,,,,,,,,,,,,
24284,,pathological diagnosis,,,,,,,,,,,,,,,,
24285,,aat,,,,,,,,,,,,,,,,
24286,,non-melanoma skin cancers,,,,,,,,,,,,,,,,
24287,,colic,,,,,,,,,,,,,,,,
24288,,local allergens,,,,,,,,,,,,,,,,
24289,,cardiac pacemakers|patients,,,,,,,,,,,,,,,,
24290,,liver function,,,,,,,,,,,,,,,,
24291,,nonautoimmune allergic,,,,,,,,,,,,,,,,
24292,,tractional detachments,,,,,,,,,,,,,,,,
24293,,colon resection,,,,,,,,,,,,,,,,
24294,,neurologic integrity.||participants,,,,,,,,,,,,,,,,
24295,,myocardial infactus|patient,,,,,,,,,,,,,,,,
24296,,leucopenia,,,,,,,,,,,,,,,,
24297,,binocular visual difference,,,,,,,,,,,,,,,,
24298,,"st elevation,|cardiogenic shock",,,,,,,,,,,,,,,,
24299,,joint||h. bilateral medial unicompartmental knee,,,,,,,,,,,,,,,,
24300,,rheumatoid arthritis;|the,,,,,,,,,,,,,,,,
24301,,polyarteritis,,,,,,,,,,,,,,,,
24302,,incidental epileptic seizure,,,,,,,,,,,,,,,,
24303,,generalized malignancy,,,,,,,,,,,,,,,,
24304,,chiari malformation,,,,,,,,,,,,,,,,
24305,,virus,,,,,,,,,,,,,,,,
24306,,onset of psychotic symptoms,,,,,,,,,,,,,,,,
24307,,chronic nasal obstruction,,,,,,,,,,,,,,,,
24308,,chronic total occlusion (cto),,,,,,,,,,,,,,,,
24309,,involuntary behavior,,,,,,,,,,,,,,,,
24310,,equivalent|renal function,,,,,,,,,,,,,,,,
24311,,brain stem,,,,,,,,,,,,,,,,
24312,,percutaneous transluminal coronary intervention (ptci),,,,,,,,,,,,,,,,
24313,,thinning of the corpus callosum,,,,,,,,,,,,,,,,
24314,,clozapine treatment|unable to stop treatment,,,,,,,,,,,,,,,,
24315,,av block type ii,,,,,,,,,,,,,,,,
24316,,acdf,,,,,,,,,,,,,,,,
24317,,cold skin,,,,,,,,,,,,,,,,
24318,,uneventful exposure,,,,,,,,,,,,,,,,
24319,,drug-induced pancreatitis|pseudocyst compressed gastrointestinal,,,,,,,,,,,,,,,,
24320,,old:|b-ultrasound,,,,,,,,,,,,,,,,
24321,,germline breast cancer,,,,,,,,,,,,,,,,
24322,,polytrauma.|acute cerebrovascular accident.|infection-inflammatory disease of cns,,,,,,,,,,,,,,,,
24323,,inclusive.|caucasian.|healthy,,,,,,,,,,,,,,,,
24324,,is required.|pregnancy,,,,,,,,,,,,,,,,
24325,,needle core biopsy,,,,,,,,,,,,,,,,
24326,,gastrointestinal ulcer(s),,,,,,,,,,,,,,,,
24327,,colon or,,,,,,,,,,,,,,,,
24328,,chronic bowel diseases,,,,,,,,,,,,,,,,
24329,,spinal injury association (asia) impairment scale,,,,,,,,,,,,,,,,
24330,,early signs of psychosis,,,,,,,,,,,,,,,,
24331,,immune deficiency disorders,,,,,,,,,,,,,,,,
24332,,rcd,,,,,,,,,,,,,,,,
24333,,prolonged smoking,,,,,,,,,,,,,,,,
24334,,prolonged constipation,,,,,,,,,,,,,,,,
24335,,myocarditis|effort angina,,,,,,,,,,,,,,,,
24336,,nonmodifiable bleeding,,,,,,,,,,,,,,,,
24337,,bacterial consortia,,,,,,,,,,,,,,,,
24338,,end-stage organ,,,,,,,,,,,,,,,,
24339,,orthodontic brackets||edentulous group:||inclusion,,,,,,,,,,,,,,,,
24340,,surgery|biopsy cases|incomplete outcome-data|palliative treatment,,,,,,,,,,,,,,,,
24341,,chronic functional,,,,,,,,,,,,,,,,
24342,,superficial cancer,,,,,,,,,,,,,,,,
24343,,non-menopausal,,,,,,,,,,,,,,,,
24344,,impairments,,,,,,,,,,,,,,,,
24345,,magnesium chloride hexahydrate,,,,,,,,,,,,,,,,
24346,,myocardial infarction;|hypotension;|internal malignancy,,,,,,,,,,,,,,,,
24347,,intraocular pathology,,,,,,,,,,,,,,,,
24348,,adenomas|type 1 diabetes,,,,,,,,,,,,,,,,
24349,,early feeding skill/efs,,,,,,,,,,,,,,,,
24350,,water|chronic diseases,,,,,,,,,,,,,,,,
24351,,cannula site infection,,,,,,,,,,,,,,,,
24352,,chronic health condition|english,,,,,,,,,,,,,,,,
24353,,mds on marrow examination,,,,,,,,,,,,,,,,
24354,,traction bronchiectasis,,,,,,,,,,,,,,,,
24355,,infectious disease testing,,,,,,,,,,,,,,,,
24356,,hypomania,,,,,,,,,,,,,,,,
24357,,maxillary sinus augmentation)|partial,,,,,,,,,,,,,,,,
24358,,criteria of the inflammatory bowel group of the gastroenterology branch of the chinese medical association,,,,,,,,,,,,,,,,
24359,,benign disorders,,,,,,,,,,,,,,,,
24360,,medications|renal insufficiency,,,,,,,,,,,,,,,,
24361,,liver disease|symptomatic,,,,,,,,,,,,,,,,
24362,,type 2 diabetes≥,,,,,,,,,,,,,,,,
24363,,interstitial lung disease|patients,,,,,,,,,,,,,,,,
24364,,yorkshire,,,,,,,,,,,,,,,,
24365,,vaginal health,,,,,,,,,,,,,,,,
24366,,abuse of alcohol.|the,,,,,,,,,,,,,,,,
24367,,localized skin cancers,,,,,,,,,,,,,,,,
24368,,keratinized gingiva|intact buccal bone wall|adequate plaque control (fmps ≤ 25%)|adequate bone quantity allowing,,,,,,,,,,,,,,,,
24369,,adverse reaction assessments,,,,,,,,,,,,,,,,
24370,,immunocompromised|vaginal infection,,,,,,,,,,,,,,,,
24371,,confirmed malignancy,,,,,,,,,,,,,,,,
24372,,b-cell all,,,,,,,,,,,,,,,,
24373,,muscle disease,,,,,,,,,,,,,,,,
24374,,persistent atrial fibrillation.|signed,,,,,,,,,,,,,,,,
24375,,rapid weight loss,,,,,,,,,,,,,,,,
24376,,interval.|prior malignancy,,,,,,,,,,,,,,,,
24377,,sleep apnea.|have disorders,,,,,,,,,,,,,,,,
24378,,large bowel .|cholangiocarcinoma,,,,,,,,,,,,,,,,
24379,,child cognitive impairment,,,,,,,,,,,,,,,,
24380,,incubator o2,,,,,,,,,,,,,,,,
24381,,exclusions,,,,,,,,,,,,,,,,
24382,,etc.|stroke,,,,,,,,,,,,,,,,
24383,,chronic gvhd,,,,,,,,,,,,,,,,
24384,,motor impairments,,,,,,,,,,,,,,,,
24385,,coagulation disorders|patients,,,,,,,,,,,,,,,,
24386,,ventricle dysfunction,,,,,,,,,,,,,,,,
24387,,immunosuppressive condition,,,,,,,,,,,,,,,,
24388,,covid-19 disease,,,,,,,,,,,,,,,,
24389,,chronic illness associated,,,,,,,,,,,,,,,,
24390,,mevalonate kinase deficiency,,,,,,,,,,,,,,,,
24391,,tumor-necrosis,,,,,,,,,,,,,,,,
24392,,locoregional recurrence,,,,,,,,,,,,,,,,
24393,,serous effusion,,,,,,,,,,,,,,,,
24394,,total serum bile acids,,,,,,,,,,,,,,,,
24395,,cohort b||metastatic cancers,,,,,,,,,,,,,,,,
24396,,infection|symptomatic congestive heart failure,,,,,,,,,,,,,,,,
24397,,rhabdomysarcomas,,,,,,,,,,,,,,,,
24398,,colon cancer|patient,,,,,,,,,,,,,,,,
24399,,cerebral trauma,,,,,,,,,,,,,,,,
24400,,post covid-19,,,,,,,,,,,,,,,,
24401,,epilepsy.|mental retardation,,,,,,,,,,,,,,,,
24402,,hepatitis carrier,,,,,,,,,,,,,,,,
24403,,adenocarcinoma of the lung,,,,,,,,,,,,,,,,
24404,,exertion.|pregnant,,,,,,,,,,,,,,,,
24405,,cardio,,,,,,,,,,,,,,,,
24406,,rifaximin|gastrointestinal bleeding,,,,,,,,,,,,,,,,
24407,,excessive drinking.|known allergy,,,,,,,,,,,,,,,,
24408,,encephalitis,,,,,,,,,,,,,,,,
24409,,renal disease|patients,,,,,,,,,,,,,,,,
24410,,cardiovascular surgery.|anemia,,,,,,,,,,,,,,,,
24411,,dactylitis,,,,,,,,,,,,,,,,
24412,,inflammatory rheumatic conditions,,,,,,,,,,,,,,,,
24413,,gpds)|status epilepticus resolved,,,,,,,,,,,,,,,,
24414,,chronic pruritus,,,,,,,,,,,,,,,,
24415,,sjögren's syndrome,,,,,,,,,,,,,,,,
24416,,external resorption,,,,,,,,,,,,,,,,
24417,,cardiovascular disease|active infection,,,,,,,,,,,,,,,,
24418,,gastric outlet,,,,,,,,,,,,,,,,
24419,,hepatitis c.||6.current cancer,,,,,,,,,,,,,,,,
24420,,abdominal wall,,,,,,,,,,,,,,,,
24421,,myopericarditis|thrombocytopenia,,,,,,,,,,,,,,,,
24422,,bipolar depression,,,,,,,,,,,,,,,,
24423,,antidiabetic agents.|patients,,,,,,,,,,,,,,,,
24424,,rheumatism immune system disease,,,,,,,,,,,,,,,,
24425,,infection of the hip,,,,,,,,,,,,,,,,
24426,,right ventricular infarction,,,,,,,,,,,,,,,,
24427,,tc≥1%).|previous failure,,,,,,,,,,,,,,,,
24428,,major organ dysfunction,,,,,,,,,,,,,,,,
24429,,smallpox,,,,,,,,,,,,,,,,
24430,,liver cirrhosis|had child-pugh,,,,,,,,,,,,,,,,
24431,,illness.|pregnant,,,,,,,,,,,,,,,,
24432,,neurological condition,,,,,,,,,,,,,,,,
24433,,black stool,,,,,,,,,,,,,,,,
24434,,study eye,,,,,,,,,,,,,,,,
24435,,residual macroscopic disease,,,,,,,,,,,,,,,,
24436,,total bilirubin,,,,,,,,,,,,,,,,
24437,,autistic features,,,,,,,,,,,,,,,,
24438,,herpes,,,,,,,,,,,,,,,,
24439,,mandibular condylar fracture,,,,,,,,,,,,,,,,
24440,,renal dysfunction|pregnancy,,,,,,,,,,,,,,,,
24441,,"solid organ metastases (liver, lung",,,,,,,,,,,,,,,,
24442,,developmental disability,,,,,,,,,,,,,,,,
24443,,host disease,,,,,,,,,,,,,,,,
24444,,non alcoholic fatty liver,,,,,,,,,,,,,,,,
24445,,persistent cough,,,,,,,,,,,,,,,,
24446,,reiki,,,,,,,,,,,,,,,,
24447,,mixed-type urinary incontinence,,,,,,,,,,,,,,,,
24448,,type of bottlecer,,,,,,,,,,,,,,,,
24449,,junction (gej) adenocarcinoma,,,,,,,,,,,,,,,,
24450,,rare mutations,,,,,,,,,,,,,,,,
24451,,gouty arthritis,,,,,,,,,,,,,,,,
24452,,high stress,,,,,,,,,,,,,,,,
24453,,basal septal hypertrophy,,,,,,,,,,,,,,,,
24454,,nonadenoma like dysplasia associated lesions,,,,,,,,,,,,,,,,
24455,,stork,,,,,,,,,,,,,,,,
24456,,tumour tissue collected,,,,,,,,,,,,,,,,
24457,,oropharyngeal dysphagia,,,,,,,,,,,,,,,,
24458,,abnormal coagulation profile,,,,,,,,,,,,,,,,
24459,,respiratory arrest,,,,,,,,,,,,,,,,
24460,,kidney dysfunction,,,,,,,,,,,,,,,,
24461,,neoplastic processes,,,,,,,,,,,,,,,,
24462,,sepsis,,,,,,,,,,,,,,,,
24463,,eosinophilic esophagitis,,,,,,,,,,,,,,,,
24464,,primary headache,,,,,,,,,,,,,,,,
24465,,lactating,,,,,,,,,,,,,,,,
24466,,chest tightness,,,,,,,,,,,,,,,,
24467,,pancreatic,,,,,,,,,,,,,,,,
24468,,neurologic signs,,,,,,,,,,,,,,,,
24469,,prechiasmatic field,,,,,,,,,,,,,,,,
24470,,shiga toxin +,,,,,,,,,,,,,,,,
24471,,head and neck squamous cell carcinoma (hnscc),,,,,,,,,,,,,,,,
24472,,localized squamous cell,,,,,,,,,,,,,,,,
24473,,diabetes type 2,,,,,,,,,,,,,,,,
24474,,contralateral microfocus score,,,,,,,,,,,,,,,,
24475,,hpap,,,,,,,,,,,,,,,,
24476,,retinal detachment surgery,,,,,,,,,,,,,,,,
24477,,multiple endocrine neoplasia type 2 (men 2,,,,,,,,,,,,,,,,
24478,,viral liver disease,,,,,,,,,,,,,,,,
24479,,cerebellar subtype,,,,,,,,,,,,,,,,
24480,,chronic viral illness,,,,,,,,,,,,,,,,
24481,,eating disorder,,,,,,,,,,,,,,,,
24482,,unanesthetized schirmer's test,,,,,,,,,,,,,,,,
24483,,"disease,|rash,|urticaria",,,,,,,,,,,,,,,,
24484,,occlusal,,,,,,,,,,,,,,,,
24485,,organic mental disorders,,,,,,,,,,,,,,,,
24486,,acute event associated,,,,,,,,,,,,,,,,
24487,,autologous liver,,,,,,,,,,,,,,,,
24488,,rotary vertigo,,,,,,,,,,,,,,,,
24489,,hendricks,,,,,,,,,,,,,,,,
24490,,latent tuberculosis,,,,,,,,,,,,,,,,
24491,,hepatitis c infection,,,,,,,,,,,,,,,,
24492,,auditory impairment,,,,,,,,,,,,,,,,
24493,,small meningioma,,,,,,,,,,,,,,,,
24494,,upper limb disability,,,,,,,,,,,,,,,,
24495,,local pathology,,,,,,,,,,,,,,,,
24496,,reason for anaemia,,,,,,,,,,,,,,,,
24497,,ocular disease|has read,,,,,,,,,,,,,,,,
24498,,critical covid-19,,,,,,,,,,,,,,,,
24499,,severity (cgis),,,,,,,,,,,,,,,,
24500,,end-stage renal disease)|attended a,,,,,,,,,,,,,,,,
24501,,peripheral motor neuropathy,,,,,,,,,,,,,,,,
24502,,malignant freckle moles,,,,,,,,,,,,,,,,
24503,,moribund,,,,,,,,,,,,,,,,
24504,,spinal scoliosis,,,,,,,,,,,,,,,,
24505,,color blindness,,,,,,,,,,,,,,,,
24506,,infectious gastroenteritis,,,,,,,,,,,,,,,,
24507,,drink alcohol,,,,,,,,,,,,,,,,
24508,,post-cancer therapy,,,,,,,,,,,,,,,,
24509,,gastrointestinal function,,,,,,,,,,,,,,,,
24510,,pulmonary tuberculosis;|diagnosis,,,,,,,,,,,,,,,,
24511,,functional failure,,,,,,,,,,,,,,,,
24512,,retinopathy beyond mild,,,,,,,,,,,,,,,,
24513,,starfruit,,,,,,,,,,,,,,,,
24514,,probe,,,,,,,,,,,,,,,,
24515,,nervous system tumor,,,,,,,,,,,,,,,,
24516,,significant hypertension,,,,,,,,,,,,,,,,
24517,,cocs,,,,,,,,,,,,,,,,
24518,,compensatory heart failure,,,,,,,,,,,,,,,,
24519,,age.|active cnv lesions,,,,,,,,,,,,,,,,
24520,,whz,,,,,,,,,,,,,,,,
24521,,aortic calcification,,,,,,,,,,,,,,,,
24522,,indicates iron deficiency,,,,,,,,,,,,,,,,
24523,,good health;|subjects volunteered to use covid-19 neutralizing antibody nasal spray.||,,,,,,,,,,,,,,,,
24524,,pennsylvania health system,,,,,,,,,,,,,,,,
24525,,primary canines,,,,,,,,,,,,,,,,
24526,,excessive alcohol intake,,,,,,,,,,,,,,,,
24527,,solitary plasmacytoma,,,,,,,,,,,,,,,,
24528,,covid mdt,,,,,,,,,,,,,,,,
24529,,hyperactive form,,,,,,,,,,,,,,,,
24530,,reflex deficit)|hip pain,,,,,,,,,,,,,,,,
24531,,mycobacterial infections,,,,,,,,,,,,,,,,
24532,,malignant hematologic,,,,,,,,,,,,,,,,
24533,,memory care,,,,,,,,,,,,,,,,
24534,,paralytic hip dx,,,,,,,,,,,,,,,,
24535,,uterine pathology,,,,,,,,,,,,,,,,
24536,,nitinol,,,,,,,,,,,,,,,,
24537,,oasis,,,,,,,,,,,,,,,,
24538,,partially matched,,,,,,,,,,,,,,,,
24539,,respiratory decompensation,,,,,,,,,,,,,,,,
24540,,vascular parkinsonism,,,,,,,,,,,,,,,,
24541,,general hemorrhagic diseases,,,,,,,,,,,,,,,,
24542,,challenges,,,,,,,,,,,,,,,,
24543,,heart function|eastern cooperative oncology group (ecog) performance status,,,,,,,,,,,,,,,,
24544,,hypoxic respiratory failure,,,,,,,,,,,,,,,,
24545,,drug use,,,,,,,,,,,,,,,,
24546,,in situ hybridization [ish],,,,,,,,,,,,,,,,
24547,,acute cerebrovascular disease,,,,,,,,,,,,,,,,
24548,,davf|controlateral sinus aplasia,,,,,,,,,,,,,,,,
24549,,adrenocortical hyperplasia,,,,,,,,,,,,,,,,
24550,,value;|liver disease,,,,,,,,,,,,,,,,
24551,,aids-defining,,,,,,,,,,,,,,,,
24552,,skin disorder,,,,,,,,,,,,,,,,
24553,,consultant neuro,,,,,,,,,,,,,,,,
24554,,ménière's disease,,,,,,,,,,,,,,,,
24555,,mixed histology.|ineligible,,,,,,,,,,,,,,,,
24556,,traumatic causes,,,,,,,,,,,,,,,,
24557,,cardiorespiratory symptoms,,,,,,,,,,,,,,,,
24558,,primary teeth|children,,,,,,,,,,,,,,,,
24559,,genitourinary abnormalities,,,,,,,,,,,,,,,,
24560,,"impact absorption, distribution, metabolism",,,,,,,,,,,,,,,,
24561,,drinks alcohol,,,,,,,,,,,,,,,,
24562,,diabetic foot ulcer|stalled wound/failed,,,,,,,,,,,,,,,,
24563,,colorectal cancer|patients,,,,,,,,,,,,,,,,
24564,,mixed acidosis,,,,,,,,,,,,,,,,
24565,,stemi,,,,,,,,,,,,,,,,
24566,,injections|stable hypothyroidism,,,,,,,,,,,,,,,,
24567,,upper extremity injury,,,,,,,,,,,,,,,,
24568,,mpnst,,,,,,,,,,,,,,,,
24569,,type covid-19.|initial,,,,,,,,,,,,,,,,
24570,,bilateral neck,,,,,,,,,,,,,,,,
24571,,common clinical practice|remission,,,,,,,,,,,,,,,,
24572,,intervention|spontaneous sinus,,,,,,,,,,,,,,,,
24573,,antiseptic use,,,,,,,,,,,,,,,,
24574,,sanfilippo syndrome type d disease,,,,,,,,,,,,,,,,
24575,,benign hematologic disorders,,,,,,,,,,,,,,,,
24576,,alcapa,,,,,,,,,,,,,,,,
24577,,poor image quality,,,,,,,,,,,,,,,,
24578,,gait disturbance,,,,,,,,,,,,,,,,
24579,,hepatitis c (,,,,,,,,,,,,,,,,
24580,,second opinions,,,,,,,,,,,,,,,,
24581,,caries lesion,,,,,,,,,,,,,,,,
24582,,functions,,,,,,,,,,,,,,,,
24583,,flaps,,,,,,,,,,,,,,,,
24584,,human coronavirus infection,,,,,,,,,,,,,,,,
24585,,diabetic ketoacidosis.|surgical admission,,,,,,,,,,,,,,,,
24586,,ckd-epi formula.|serum,,,,,,,,,,,,,,,,
24587,,hpv infections,,,,,,,,,,,,,,,,
24588,,acute medical illness,,,,,,,,,,,,,,,,
24589,,natural health,,,,,,,,,,,,,,,,
24590,,cns metastases,,,,,,,,,,,,,,,,
24591,,from immunodeficiency diseases,,,,,,,,,,,,,,,,
24592,,pneumonitis.|active infections,,,,,,,,,,,,,,,,
24593,,radiosensitive histologies,,,,,,,,,,,,,,,,
24594,,liver,,,,,,,,,,,,,,,,
24595,,hepatitis b positive,,,,,,,,,,,,,,,,
24596,,congenital condition,,,,,,,,,,,,,,,,
24597,,acute illness|poor,,,,,,,,,,,,,,,,
24598,,early psychosis,,,,,,,,,,,,,,,,
24599,,pcsk9 inhibitor|recent infection,,,,,,,,,,,,,,,,
24600,,alcohol consumption.|unable,,,,,,,,,,,,,,,,
24601,,feeling unwell,,,,,,,,,,,,,,,,
24602,,abetalipoproteinemia,,,,,,,,,,,,,,,,
24603,,acceptable.|pregnant,,,,,,,,,,,,,,,,
24604,,severe depressive disorder,,,,,,,,,,,,,,,,
24605,,endorectal probe,,,,,,,,,,,,,,,,
24606,,functional abnormalities,,,,,,,,,,,,,,,,
24607,,cardio-cerebrovascular diseases,,,,,,,,,,,,,,,,
24608,,insomnia,,,,,,,,,,,,,,,,
24609,,-situ carcinoma,,,,,,,,,,,,,,,,
24610,,patients|bilateral lt|absent,,,,,,,,,,,,,,,,
24611,,unresectable ovarian,,,,,,,,,,,,,,,,
24612,,chronic illnesses.|current prescription medication,,,,,,,,,,,,,,,,
24613,,epatic failure,,,,,,,,,,,,,,,,
24614,,women;|patients,,,,,,,,,,,,,,,,
24615,,shoulder instability,,,,,,,,,,,,,,,,
24616,,trna,,,,,,,,,,,,,,,,
24617,,relationships in group settings|in,,,,,,,,,,,,,,,,
24618,,early learning,,,,,,,,,,,,,,,,
24619,,cca,,,,,,,,,,,,,,,,
24620,,hiv positive.|highly allergic,,,,,,,,,,,,,,,,
24621,,colonic enema,,,,,,,,,,,,,,,,
24622,,ulcerative disease,,,,,,,,,,,,,,,,
24623,,serous adenocarcinoma histologic epithelial cell type,,,,,,,,,,,,,,,,
24624,,old|evidence,,,,,,,,,,,,,,,,
24625,,aml,,,,,,,,,,,,,,,,
24626,,migraine)|known alcohol abuse,,,,,,,,,,,,,,,,
24627,,cerebrovascular atherosclerosis,,,,,,,,,,,,,,,,
24628,,ffpe paraffin,,,,,,,,,,,,,,,,
24629,,completed infarction,,,,,,,,,,,,,,,,
24630,,stomatitis,,,,,,,,,,,,,,,,
24631,,alcoholic epilepsy,,,,,,,,,,,,,,,,
24632,,papillary bladder,,,,,,,,,,,,,,,,
24633,,other eye disease,,,,,,,,,,,,,,,,
24634,,autism recorded,,,,,,,,,,,,,,,,
24635,,electrolyte balance,,,,,,,,,,,,,,,,
24636,,medication|lactating,,,,,,,,,,,,,,,,
24637,,congenital syndromes of the craniofacial area.|anterior,,,,,,,,,,,,,,,,
24638,,type of malignancy,,,,,,,,,,,,,,,,
24639,,chronic lesions,,,,,,,,,,,,,,,,
24640,,dermatologic condition,,,,,,,,,,,,,,,,
24641,,infection|chronic pulmonary disease|congenital,,,,,,,,,,,,,,,,
24642,,suffer,,,,,,,,,,,,,,,,
24643,,immunodeficiency.||primary immune deficiencies.|human immunodeficiency virus (hiv) infection,,,,,,,,,,,,,,,,
24644,,active ulcer lesion,,,,,,,,,,,,,,,,
24645,,debilitating disease,,,,,,,,,,,,,,,,
24646,,giant intracranial,,,,,,,,,,,,,,,,
24647,,biopsiable disease,,,,,,,,,,,,,,,,
24648,,shoulder migration percentage,,,,,,,,,,,,,,,,
24649,,uterine fibroma,,,,,,,,,,,,,,,,
24650,,local allergic necrosis reaction,,,,,,,,,,,,,,,,
24651,,mental impairment,,,,,,,,,,,,,,,,
24652,,lv mass indexed,,,,,,,,,,,,,,,,
24653,,emr,,,,,,,,,,,,,,,,
24654,,mandibular defects,,,,,,,,,,,,,,,,
24655,,"surgical revascularization,|unfavourable anatomy",,,,,,,,,,,,,,,,
24656,,haemorrhagic)|upper limb weakness,,,,,,,,,,,,,,,,
24657,,hereditary hepatic diseases,,,,,,,,,,,,,,,,
24658,,cerebral vascular,,,,,,,,,,,,,,,,
24659,,muscle enzyme,,,,,,,,,,,,,,,,
24660,,myocardial infarction≤6 months prior to lymphocyte clearance,,,,,,,,,,,,,,,,
24661,,chronic dyspepsia,,,,,,,,,,,,,,,,
24662,,central venous thrombosis,,,,,,,,,,,,,,,,
24663,,avascular necrosis|gastrointestinal reflux disease,,,,,,,,,,,,,,,,
24664,,chronic medical condition||,,,,,,,,,,,,,,,,
24665,,ocular comorbidities,,,,,,,,,,,,,,,,
24666,,liver cirrhosis|white blood cells,,,,,,,,,,,,,,,,
24667,,binocular vision disorders;|previous eye surgeries,,,,,,,,,,,,,,,,
24668,,mental disabilities,,,,,,,,,,,,,,,,
24669,,impaired sensation,,,,,,,,,,,,,,,,
24670,,acute mental disorders,,,,,,,,,,,,,,,,
24671,,neurological pathologies,,,,,,,,,,,,,,,,
24672,,end-stage renal disease|standard peritoneal balance test shows,,,,,,,,,,,,,,,,
24673,,endobronchial stent,,,,,,,,,,,,,,,,
24674,,local anaphylactic,,,,,,,,,,,,,,,,
24675,,macular edema,,,,,,,,,,,,,,,,
24676,,hernia,,,,,,,,,,,,,,,,
24677,,antiphospholipid syndrome disease|thrombosis,,,,,,,,,,,,,,,,
24678,,congenital mental retardation||the,,,,,,,,,,,,,,,,
24679,,pgtcs,,,,,,,,,,,,,,,,
24680,,disease|poor oral hygiene|ıncomplete orthodontic treatment|being a smoker|working,,,,,,,,,,,,,,,,
24681,,major bowel resection,,,,,,,,,,,,,,,,
24682,,data;|vascular malformations,,,,,,,,,,,,,,,,
24683,,liver fibrosis,,,,,,,,,,,,,,,,
24684,,right heart failure,,,,,,,,,,,,,,,,
24685,,restricted,,,,,,,,,,,,,,,,
24686,,coronary revascularization);|4,,,,,,,,,,,,,,,,
24687,,type 1 diabetes mellitus,,,,,,,,,,,,,,,,
24688,,institutional pneumonia,,,,,,,,,,,,,,,,
24689,,congenital nystagmus,,,,,,,,,,,,,,,,
24690,,glioma treated,,,,,,,,,,,,,,,,
24691,,kidney disease|thyroid dysfunction,,,,,,,,,,,,,,,,
24692,,antimicrobial therapy|known allergies,,,,,,,,,,,,,,,,
24693,,corneal disease,,,,,,,,,,,,,,,,
24694,,spinal cord trauma)|lead toxicity,,,,,,,,,,,,,,,,
24695,,indicated|sarcoma,,,,,,,,,,,,,,,,
24696,,collegial validation,,,,,,,,,,,,,,,,
24697,,end-stage renal,,,,,,,,,,,,,,,,
24698,,auditory neuropathy.|deafness,,,,,,,,,,,,,,,,
24699,,cardiac arrhythmia failure,,,,,,,,,,,,,,,,
24700,,latest infection,,,,,,,,,,,,,,,,
24701,,generalised anxiety disorder,,,,,,,,,,,,,,,,
24702,,dysplasia of the,,,,,,,,,,,,,,,,
24703,,lower limb disabilities|breastfeeding,,,,,,,,,,,,,,,,
24704,,leukemia.|constitutional aplastic,,,,,,,,,,,,,,,,
24705,,growth factor therapies|abuse of drugs and/or alcohol|participation in another biomedical study,,,,,,,,,,,,,,,,
24706,,hypertension,,,,,,,,,,,,,,,,
24707,,femoropopliteal arteries|significant stenoses,,,,,,,,,,,,,,,,
24708,,liver abnormalities,,,,,,,,,,,,,,,,
24709,,|eclamptic,,,,,,,,,,,,,,,,
24710,,irritable bowel syndrome);|age,,,,,,,,,,,,,,,,
24711,,mental system diseases,,,,,,,,,,,,,,,,
24712,,hip replacements,,,,,,,,,,,,,,,,
24713,,lvh,,,,,,,,,,,,,,,,
24714,,abstain from,,,,,,,,,,,,,,,,
24715,,pacemaker|arrythmia|uncontrolled hypothyroidism,,,,,,,,,,,,,,,,
24716,,coronary,,,,,,,,,,,,,,,,
24717,,acute mesenteric ischemia,,,,,,,,,,,,,,,,
24718,,paralytic disease|patient,,,,,,,,,,,,,,,,
24719,,another etiology,,,,,,,,,,,,,,,,
24720,,hypotensive crises.|the,,,,,,,,,,,,,,,,
24721,,brain stem lesions,,,,,,,,,,,,,,,,
24722,,debilitating pulmonary disease,,,,,,,,,,,,,,,,
24723,,other,,,,,,,,,,,,,,,,
24724,,müllerian agenesis,,,,,,,,,,,,,,,,
24725,,occupational reasons,,,,,,,,,,,,,,,,
24726,,ecmo or|septic shock or|multiple organ failure|prior therapy with plasma from a recovered covid-19 patient,,,,,,,,,,,,,,,,
24727,,facial fractures,,,,,,,,,,,,,,,,
24728,,nonfebrile seizure,,,,,,,,,,,,,,,,
24729,,secondary orifices should,,,,,,,,,,,,,,,,
24730,,tuberculosis (tb,,,,,,,,,,,,,,,,
24731,,dry cough,,,,,,,,,,,,,,,,
24732,,her2 negative postmenopausal,,,,,,,,,,,,,,,,
24733,,diabetic lactic acidosis,,,,,,,,,,,,,,,,
24734,,oral prophylaxis,,,,,,,,,,,,,,,,
24735,,diseases;|bmi,,,,,,,,,,,,,,,,
24736,,human immunodeficiency virus ( hiv),,,,,,,,,,,,,,,,
24737,,interest;|allergies,,,,,,,,,,,,,,,,
24738,,neisseria gonorrhea,,,,,,,,,,,,,,,,
24739,,hypogonadism.|participant,,,,,,,,,,,,,,,,
24740,,metformin.|diabetic patients.|cancer,,,,,,,,,,,,,,,,
24741,,vocal fold paralysis|no voice,,,,,,,,,,,,,,,,
24742,,alzheimer's disease|patients,,,,,,,,,,,,,,,,
24743,,reduced mobility,,,,,,,,,,,,,,,,
24744,,erb's palsy/brachial plexus,,,,,,,,,,,,,,,,
24745,,contact lens,,,,,,,,,,,,,,,,
24746,,lactation|significant surgeries,,,,,,,,,,,,,,,,
24747,,malignant tumors;|patient,,,,,,,,,,,,,,,,
24748,,facial edema,,,,,,,,,,,,,,,,
24749,,speech problems,,,,,,,,,,,,,,,,
24750,,demyelinating disorder,,,,,,,,,,,,,,,,
24751,,occasional exposure,,,,,,,,,,,,,,,,
24752,,congenital hearing loss,,,,,,,,,,,,,,,,
24753,,tia,,,,,,,,,,,,,,,,
24754,,accreta,,,,,,,,,,,,,,,,
24755,,arterial aneurysm,,,,,,,,,,,,,,,,
24756,,somatic symptom disorder||caregiver exclusion criteria:||cognitive,,,,,,,,,,,,,,,,
24757,,up-front docetaxel,,,,,,,,,,,,,,,,
24758,,crohn's disease|recent,,,,,,,,,,,,,,,,
24759,,acute covid-19 infection;|covid-19 pneumonia,,,,,,,,,,,,,,,,
24760,,brain mri.|participants,,,,,,,,,,,,,,,,
24761,,retinal hole,,,,,,,,,,,,,,,,
24762,,breastfeeding|nausea,,,,,,,,,,,,,,,,
24763,,irregular menstrual cycle,,,,,,,,,,,,,,,,
24764,,atrioventricular node disease.|absence,,,,,,,,,,,,,,,,
24765,,sign those with,,,,,,,,,,,,,,,,
24766,,timi blood flow,,,,,,,,,,,,,,,,
24767,,inflammatory conditions.|patients,,,,,,,,,,,,,,,,
24768,,target lesions selected,,,,,,,,,,,,,,,,
24769,,criteria of emancipated minors;|pakistan,,,,,,,,,,,,,,,,
24770,,breath alcohol,,,,,,,,,,,,,,,,
24771,,sodium overload justifying the prescription of loop diuretics,,,,,,,,,,,,,,,,
24772,,liver tumor ablation,,,,,,,,,,,,,,,,
24773,,fencing,,,,,,,,,,,,,,,,
24774,,type ii diabetes mellitus,,,,,,,,,,,,,,,,
24775,,retinal angiomatous proliferation,,,,,,,,,,,,,,,,
24776,,complex regional pain syndrome (crps),,,,,,,,,,,,,,,,
24777,,normal vaginal delivery.||,,,,,,,,,,,,,,,,
24778,,intracranial pathology,,,,,,,,,,,,,,,,
24779,,anesthetic complications,,,,,,,,,,,,,,,,
24780,,type 2|gastrointestinal diseases,,,,,,,,,,,,,,,,
24781,,judged by the investigators,,,,,,,,,,,,,,,,
24782,,tmdm myalgia,,,,,,,,,,,,,,,,
24783,,systemic disease;|hiv,,,,,,,,,,,,,,,,
24784,,significant deficits,,,,,,,,,,,,,,,,
24785,,bronchoalveolar lavage fluid cytology,,,,,,,,,,,,,,,,
24786,,willis,,,,,,,,,,,,,,,,
24787,,tremor dominant disease,,,,,,,,,,,,,,,,
24788,,manic episode|is currently imprisoned,,,,,,,,,,,,,,,,
24789,,surgical events,,,,,,,,,,,,,,,,
24790,,nonautoimmune condition,,,,,,,,,,,,,,,,
24791,,mitochondrial function,,,,,,,,,,,,,,,,
24792,,hypoalbuminaemia,,,,,,,,,,,,,,,,
24793,,fits,,,,,,,,,,,,,,,,
24794,,ventricular anatomy,,,,,,,,,,,,,,,,
24795,,sperm from testes biopsy,,,,,,,,,,,,,,,,
24796,,contralateral ptosis,,,,,,,,,,,,,,,,
24797,,cancer of,,,,,,,,,,,,,,,,
24798,,colorectal endometriosis excision surgery,,,,,,,,,,,,,,,,
24799,,therapy||without bone marrow involvement,,,,,,,,,,,,,,,,
24800,,localized cancers,,,,,,,,,,,,,,,,
24801,,hepatitis b polymerase chain reaction (pcr) evaluation before,,,,,,,,,,,,,,,,
24802,,cyp2d4,,,,,,,,,,,,,,,,
24803,,occupational lung diseases,,,,,,,,,,,,,,,,
24804,,anginal equivalents,,,,,,,,,,,,,,,,
24805,,autoimmune diseases|antibiotic premedication requirement|history,,,,,,,,,,,,,,,,
24806,,brain changes|diagnosis,,,,,,,,,,,,,,,,
24807,,bladder augmentation,,,,,,,,,,,,,,,,
24808,,lens diseases,,,,,,,,,,,,,,,,
24809,,years;|documented cerebrovascular accident,,,,,,,,,,,,,,,,
24810,,myofascial pain syndrome,,,,,,,,,,,,,,,,
24811,,locomotor problems,,,,,,,,,,,,,,,,
24812,,lobular carcinoma,,,,,,,,,,,,,,,,
24813,,respiratory infection.||consent,,,,,,,,,,,,,,,,
24814,,significant reaction,,,,,,,,,,,,,,,,
24815,,myxedema,,,,,,,,,,,,,,,,
24816,,nli,,,,,,,,,,,,,,,,
24817,,interstitial cystitis,,,,,,,,,,,,,,,,
24818,,richter's syndrome,,,,,,,,,,,,,,,,
24819,,extranodal tissues,,,,,,,,,,,,,,,,
24820,,dullness to percussion,,,,,,,,,,,,,,,,
24821,,tumour (ffpe) tissue block,,,,,,,,,,,,,,,,
24822,,complete supraspinatus,,,,,,,,,,,,,,,,
24823,,peripheral oedema,,,,,,,,,,,,,,,,
24824,,ischemic heart disease;|new,,,,,,,,,,,,,,,,
24825,,localised skin cancer,,,,,,,,,,,,,,,,
24826,,double malignancy,,,,,,,,,,,,,,,,
24827,,gastrointestinal (appendectomy,,,,,,,,,,,,,,,,
24828,,hirsutism,,,,,,,,,,,,,,,,
24829,,manic episodes|severe psychological impairment|previous use,,,,,,,,,,,,,,,,
24830,,aortic stenosis;|acute endocarditis,,,,,,,,,,,,,,,,
24831,,granulomatous pathology,,,,,,,,,,,,,,,,
24832,,predominantly clear cell,,,,,,,,,,,,,,,,
24833,,nail changes,,,,,,,,,,,,,,,,
24834,,splenomegaly|massive nodes,,,,,,,,,,,,,,,,
24835,,tuberculous,,,,,,,,,,,,,,,,
24836,,create,,,,,,,,,,,,,,,,
24837,,kidney transplant|polycystic kidney diseases|chronic kidney disease,,,,,,,,,,,,,,,,
24838,,common cancer types,,,,,,,,,,,,,,,,
24839,,genetic diagnosis,,,,,,,,,,,,,,,,
24840,,apraxia,,,,,,,,,,,,,,,,
24841,,secondary sjogren's,,,,,,,,,,,,,,,,
24842,,congenital glaucoma,,,,,,,,,,,,,,,,
24843,,venipunctures.|surgical interventions,,,,,,,,,,,,,,,,
24844,,mechanical hemodynamic support|need,,,,,,,,,,,,,,,,
24845,,cardiovascular pathology,,,,,,,,,,,,,,,,
24846,,structural lung disease,,,,,,,,,,,,,,,,
24847,,polycystic kidney disease,,,,,,,,,,,,,,,,
24848,,lumbar muscle,,,,,,,,,,,,,,,,
24849,,preclude participation|lower motor neuron disease,,,,,,,,,,,,,,,,
24850,,kidney failure;|physical weakness,,,,,,,,,,,,,,,,
24851,,close friend,,,,,,,,,,,,,,,,
24852,,medically compromised children.|children,,,,,,,,,,,,,,,,
24853,,pulmonary embolism);|human immunodeficiency virus,,,,,,,,,,,,,,,,
24854,,complete left bundle branch block|hypertension,,,,,,,,,,,,,,,,
24855,,ros,,,,,,,,,,,,,,,,
24856,,in vitro fertilization,,,,,,,,,,,,,,,,
24857,,pleural drainage,,,,,,,,,,,,,,,,
24858,,candidate for heart transplantation,,,,,,,,,,,,,,,,
24859,,secondary hypothyroidism,,,,,,,,,,,,,,,,
24860,,human immunodeficiency virus antibody,,,,,,,,,,,,,,,,
24861,,community-dwelling,,,,,,,,,,,,,,,,
24862,,localized pustular psoriasis,,,,,,,,,,,,,,,,
24863,,stevens johnsons syndrome,,,,,,,,,,,,,,,,
24864,,cardiac valvular disease,,,,,,,,,,,,,,,,
24865,,radioactive nuclides,,,,,,,,,,,,,,,,
24866,,surgery.|patients,,,,,,,,,,,,,,,,
24867,,metastatic lung tumor,,,,,,,,,,,,,,,,
24868,,icd shock,,,,,,,,,,,,,,,,
24869,,large b cell lymphoma,,,,,,,,,,,,,,,,
24870,,distant organ metastases,,,,,,,,,,,,,,,,
24871,,pose increased risk for protocol participation|must,,,,,,,,,,,,,,,,
24872,,province)|chronic stroke,,,,,,,,,,,,,,,,
24873,,neurological disease|psychiatric disease|benzodiazepines,,,,,,,,,,,,,,,,
24874,,biopsy pathology,,,,,,,,,,,,,,,,
24875,,infectious colitis,,,,,,,,,,,,,,,,
24876,,pertinent excerpt,,,,,,,,,,,,,,,,
24877,,high-risk factor,,,,,,,,,,,,,,,,
24878,,intrapartum hemorrhage,,,,,,,,,,,,,,,,
24879,,radical resectable carcinoma,,,,,,,,,,,,,,,,
24880,,ria:||healthy,,,,,,,,,,,,,,,,
24881,,vertebral stenosis,,,,,,,,,,,,,,,,
24882,,ccca))|refusal,,,,,,,,,,,,,,,,
24883,,ttp|medical contraindication,,,,,,,,,,,,,,,,
24884,,atherosclerotic risk factors,,,,,,,,,,,,,,,,
24885,,basal cell skin,,,,,,,,,,,,,,,,
24886,,paraffin block,,,,,,,,,,,,,,,,
24887,,rare genetic diseases - galactose intolerance,,,,,,,,,,,,,,,,
24888,,osseous defects created,,,,,,,,,,,,,,,,
24889,,her2 directed antibodies,,,,,,,,,,,,,,,,
24890,,≥6 months|a,,,,,,,,,,,,,,,,
24891,,patellar tendinopathy,,,,,,,,,,,,,,,,
24892,,clinically uncontrollable hypertension,,,,,,,,,,,,,,,,
24893,,degenerative meniscus lesions,,,,,,,,,,,,,,,,
24894,,kidney transplantation|having,,,,,,,,,,,,,,,,
24895,,lateral fistula,,,,,,,,,,,,,,,,
24896,,rectal pathology,,,,,,,,,,,,,,,,
24897,,third stage||,,,,,,,,,,,,,,,,
24898,,severity scale||,,,,,,,,,,,,,,,,
24899,,intestinal adenoma,,,,,,,,,,,,,,,,
24900,,healthy tissues,,,,,,,,,,,,,,,,
24901,,light sensitivity condition;|loss of,,,,,,,,,,,,,,,,
24902,,projection,,,,,,,,,,,,,,,,
24903,,multipara|risky,,,,,,,,,,,,,,,,
24904,,increased liver span,,,,,,,,,,,,,,,,
24905,,uncontrolled hypercalcemia,,,,,,,,,,,,,,,,
24906,,acute ms relapse,,,,,,,,,,,,,,,,
24907,,facelift,,,,,,,,,,,,,,,,
24908,,acute hf,,,,,,,,,,,,,,,,
24909,,aneurysm,,,,,,,,,,,,,,,,
24910,,renal replacement,,,,,,,,,,,,,,,,
24911,,optic nerve disorders,,,,,,,,,,,,,,,,
24912,,target dose||,,,,,,,,,,,,,,,,
24913,,acute alcohol-associated hepatitis,,,,,,,,,,,,,,,,
24914,,radiologic investigation,,,,,,,,,,,,,,,,
24915,,heart disease||,,,,,,,,,,,,,,,,
24916,,radiation induced,,,,,,,,,,,,,,,,
24917,,ophtalmological involvement,,,,,,,,,,,,,,,,
24918,,lower limb,,,,,,,,,,,,,,,,
24919,,pvr,,,,,,,,,,,,,,,,
24920,,pneumatic retinopexy,,,,,,,,,,,,,,,,
24921,,motor vehicle accident,,,,,,,,,,,,,,,,
24922,,pelvic floor dysfunction,,,,,,,,,,,,,,,,
24923,,psychotropic drugs.|healthy,,,,,,,,,,,,,,,,
24924,,platelets transfusion-dependent,,,,,,,,,,,,,,,,
24925,,urinary calculi,,,,,,,,,,,,,,,,
24926,,contrast sensitivity,,,,,,,,,,,,,,,,
24927,,alcohol every,,,,,,,,,,,,,,,,
24928,,intraarticular injection,,,,,,,,,,,,,,,,
24929,,non-insulin dependent,,,,,,,,,,,,,,,,
24930,,conduction disorder,,,,,,,,,,,,,,,,
24931,,osteogenesis imperfecta,,,,,,,,,,,,,,,,
24932,,absorption of the drug.|uncontrolled effusion,,,,,,,,,,,,,,,,
24933,,heparin sensitivity,,,,,,,,,,,,,,,,
24934,,isolated tbl,,,,,,,,,,,,,,,,
24935,,limit visual potential,,,,,,,,,,,,,,,,
24936,,medicamentous immune-suppression,,,,,,,,,,,,,,,,
24937,,course of covid-19,,,,,,,,,,,,,,,,
24938,,chronic renal insufficiency (egfr<30)|5),,,,,,,,,,,,,,,,
24939,,physical activity,,,,,,,,,,,,,,,,
24940,,bleeding c,,,,,,,,,,,,,,,,
24941,,marfan's,,,,,,,,,,,,,,,,
24942,,acute injuries,,,,,,,,,,,,,,,,
24943,,blood coagulation disorder,,,,,,,,,,,,,,,,
24944,,lactation period|participation,,,,,,,,,,,,,,,,
24945,,intestinal cramping,,,,,,,,,,,,,,,,
24946,,pelvic effusion,,,,,,,,,,,,,,,,
24947,,version|smi,,,,,,,,,,,,,,,,
24948,,control disease,,,,,,,,,,,,,,,,
24949,,|genital tract infection,,,,,,,,,,,,,,,,
24950,,metastatic breast cancer,,,,,,,,,,,,,,,,
24951,,ultrafiltration failure,,,,,,,,,,,,,,,,
24952,,left coronary artery,,,,,,,,,,,,,,,,
24953,,former cigarette smokers,,,,,,,,,,,,,,,,
24954,,chronic systemic immune,,,,,,,,,,,,,,,,
24955,,leukemia,,,,,,,,,,,,,,,,
24956,,paradoxal diaphragm,,,,,,,,,,,,,,,,
24957,,ucla,,,,,,,,,,,,,,,,
24958,,labor,,,,,,,,,,,,,,,,
24959,,deep seated infection,,,,,,,,,,,,,,,,
24960,,lung insufficiency,,,,,,,,,,,,,,,,
24961,,post-sci/d,,,,,,,,,,,,,,,,
24962,,child.|febrile illness,,,,,,,,,,,,,,,,
24963,,irritable bowel syndrome.|clinically significant,,,,,,,,,,,,,,,,
24964,,old.|mandibular total edentulism.|presence of sufficient,,,,,,,,,,,,,,,,
24965,,spondylarthritis,,,,,,,,,,,,,,,,
24966,,obstructive pneumonia,,,,,,,,,,,,,,,,
24967,,deep brain stimulation intervention,,,,,,,,,,,,,,,,
24968,,reappearance of blasts,,,,,,,,,,,,,,,,
24969,,cerebral ischemia,,,,,,,,,,,,,,,,
24970,,macromastia,,,,,,,,,,,,,,,,
24971,,periventricular leukomalacia,,,,,,,,,,,,,,,,
24972,,largest tumor lesions,,,,,,,,,,,,,,,,
24973,,lupus anticoagulans positivity,,,,,,,,,,,,,,,,
24974,,pancreatoblastoma,,,,,,,,,,,,,,,,
24975,,periapical pathology,,,,,,,,,,,,,,,,
24976,,bladder biopsy|inability to give informed consent,,,,,,,,,,,,,,,,
24977,,poor performance status)|lack,,,,,,,,,,,,,,,,
24978,,vocal cord disorder,,,,,,,,,,,,,,,,
24979,,rt|patients,,,,,,,,,,,,,,,,
24980,,neuromyelitis optica spectrum disease,,,,,,,,,,,,,,,,
24981,,gi cancer,,,,,,,,,,,,,,,,
24982,,cars made,,,,,,,,,,,,,,,,
24983,,increased bleeding of the skin,,,,,,,,,,,,,,,,
24984,,autoimmune lymphoproliferative syndrome,,,,,,,,,,,,,,,,
24985,,customs:|habitual constipation,,,,,,,,,,,,,,,,
24986,,dentine lesions,,,,,,,,,,,,,,,,
24987,,mitral valve replacement (mvr),,,,,,,,,,,,,,,,
24988,,pain onset||2,,,,,,,,,,,,,,,,
24989,,hereditary nonpolyposis,,,,,,,,,,,,,,,,
24990,,bulimia,,,,,,,,,,,,,,,,
24991,,lower limb deformity,,,,,,,,,,,,,,,,
24992,,gilbert-.meulengracht syndrome,,,,,,,,,,,,,,,,
24993,,speaking|those,,,,,,,,,,,,,,,,
24994,,brain injuries|alcohol,,,,,,,,,,,,,,,,
24995,,schizophrenia-spectrum disorder,,,,,,,,,,,,,,,,
24996,,unstable disease,,,,,,,,,,,,,,,,
24997,,demonstrated disease,,,,,,,,,,,,,,,,
24998,,tertiary care,,,,,,,,,,,,,,,,
24999,,pulmonary disease)|current active alcohol,,,,,,,,,,,,,,,,
25000,,non-childbearing potential,,,,,,,,,,,,,,,,
25001,,etc.|immunodeficiency disease,,,,,,,,,,,,,,,,
25002,,risky pregnancy,,,,,,,,,,,,,,,,
25003,,somnolence,,,,,,,,,,,,,,,,
25004,,"disorder,|intrauterine growth retardation",,,,,,,,,,,,,,,,
25005,,serious the disease,,,,,,,,,,,,,,,,
25006,,fructose intolerance,,,,,,,,,,,,,,,,
25007,,roxithromycin)).|contra-indication,,,,,,,,,,,,,,,,
25008,,contracting tb,,,,,,,,,,,,,,,,
25009,,esophagostenosis,,,,,,,,,,,,,,,,
25010,,brain disease|magnetic resonance,,,,,,,,,,,,,,,,
25011,,cardiovascular health,,,,,,,,,,,,,,,,
25012,,variants of cns function disorder,,,,,,,,,,,,,,,,
25013,,recovered from all radiation-related,,,,,,,,,,,,,,,,
25014,,adequate absorption of,,,,,,,,,,,,,,,,
25015,,brain metastases.||patient,,,,,,,,,,,,,,,,
25016,,thromboembolic event,,,,,,,,,,,,,,,,
25017,,csami,,,,,,,,,,,,,,,,
25018,,"corticosteroids),|allergy",,,,,,,,,,,,,,,,
25019,,fridericia's,,,,,,,,,,,,,,,,
25020,,rare diseases,,,,,,,,,,,,,,,,
25021,,groups||neurobehavioral disorder,,,,,,,,,,,,,,,,
25022,,alzheimer's association,,,,,,,,,,,,,,,,
25023,,juvenile rheumatoid arthritis,,,,,,,,,,,,,,,,
25024,,gastric varices,,,,,,,,,,,,,,,,
25025,,/reaction,,,,,,,,,,,,,,,,
25026,,ptb,,,,,,,,,,,,,,,,
25027,,rheumatic arthritis,,,,,,,,,,,,,,,,
25028,,micoalbuminuria,,,,,,,,,,,,,,,,
25029,,malignant disease,,,,,,,,,,,,,,,,
25030,,patient|ability,,,,,,,,,,,,,,,,
25031,,parathyroid glands,,,,,,,,,,,,,,,,
25032,,completed penetrative,,,,,,,,,,,,,,,,
25033,,pain visual analogue scale (vas),,,,,,,,,,,,,,,,
25034,,secondary myopia,,,,,,,,,,,,,,,,
25035,,hepatic medical condition,,,,,,,,,,,,,,,,
25036,,blood dyscrasia,,,,,,,,,,,,,,,,
25037,,respiratory support|crackling,,,,,,,,,,,,,,,,
25038,,developmental defect,,,,,,,,,,,,,,,,
25039,,ct3n0)|candidates,,,,,,,,,,,,,,,,
25040,,unresectable malignancy,,,,,,,,,,,,,,,,
25041,,acpa,,,,,,,,,,,,,,,,
25042,,non-responders,,,,,,,,,,,,,,,,
25043,,proprietary chinese medicine treatment,,,,,,,,,,,,,,,,
25044,,mineral metabolism,,,,,,,,,,,,,,,,
25045,,transfusion support,,,,,,,,,,,,,,,,
25046,,consent.|sensory loss,,,,,,,,,,,,,,,,
25047,,breastfeeding.||regular smoking,,,,,,,,,,,,,,,,
25048,,hernia repairs,,,,,,,,,,,,,,,,
25049,,lack of any neurological disorders,,,,,,,,,,,,,,,,
25050,,considered stable,,,,,,,,,,,,,,,,
25051,,old;|diagnosis,,,,,,,,,,,,,,,,
25052,,follicular helper t cell phenotype||previously,,,,,,,,,,,,,,,,
25053,,abrupt deafness,,,,,,,,,,,,,,,,
25054,,corneal infection,,,,,,,,,,,,,,,,
25055,,clinical bleeding,,,,,,,,,,,,,,,,
25056,,back open,,,,,,,,,,,,,,,,
25057,,cardiac insufficiency|hiv,,,,,,,,,,,,,,,,
25058,,child-bearing potential,,,,,,,,,,,,,,,,
25059,,drinking alcohol,,,,,,,,,,,,,,,,
25060,,breast cancer|target lesion,,,,,,,,,,,,,,,,
25061,,ctx,,,,,,,,,,,,,,,,
25062,,inability to receive general anesthesia|presence,,,,,,,,,,,,,,,,
25063,,"azathioprine,|who did not",,,,,,,,,,,,,,,,
25064,,drainage management|patients,,,,,,,,,,,,,,,,
25065,,digitalis,,,,,,,,,,,,,,,,
25066,,delayed diagnosis,,,,,,,,,,,,,,,,
25067,,basal cell carcinoma,,,,,,,,,,,,,,,,
25068,,alcohol cessation,,,,,,,,,,,,,,,,
25069,,dermatomyositis,,,,,,,,,,,,,,,,
25070,,mpsih being,,,,,,,,,,,,,,,,
25071,,remain overnight,,,,,,,,,,,,,,,,
25072,,premature babies,,,,,,,,,,,,,,,,
25073,,infection);|hepatitis,,,,,,,,,,,,,,,,
25074,,carcinoma in situ,,,,,,,,,,,,,,,,
25075,,neighboring municipalities,,,,,,,,,,,,,,,,
25076,,enzyme linked immunosorbent assay (elisa,,,,,,,,,,,,,,,,
25077,,"breastfeeding,|allergy",,,,,,,,,,,,,,,,
25078,,thrombophilia,,,,,,,,,,,,,,,,
25079,,lumbar spinal disease,,,,,,,,,,,,,,,,
25080,,cerebral vascular event.|pregnancy,,,,,,,,,,,,,,,,
25081,,laboratory condition,,,,,,,,,,,,,,,,
25082,,knee joint pain,,,,,,,,,,,,,,,,
25083,,traditional medicines,,,,,,,,,,,,,,,,
25084,,being|inability,,,,,,,,,,,,,,,,
25085,,progressive cardiac,,,,,,,,,,,,,,,,
25086,,cortex,,,,,,,,,,,,,,,,
25087,,large vessel occlusion stroke,,,,,,,,,,,,,,,,
25088,,infarction|percutaneous coronary revascularization,,,,,,,,,,,,,,,,
25089,,chronic medical conditions,,,,,,,,,,,,,,,,
25090,,breast feeding.|distal subungual onychomycosis (dso),,,,,,,,,,,,,,,,
25091,,brachial plexus injury,,,,,,,,,,,,,,,,
25092,,general health,,,,,,,,,,,,,,,,
25093,,analphabetic,,,,,,,,,,,,,,,,
25094,,cardiac disease|chronic obstructive lung disease,,,,,,,,,,,,,,,,
25095,,transient ischemic attack (tia):,,,,,,,,,,,,,,,,
25096,,good general condition,,,,,,,,,,,,,,,,
25097,,metabolic factors,,,,,,,,,,,,,,,,
25098,,lymphadenopathy.|progressive lymphocytosis,,,,,,,,,,,,,,,,
25099,,chronic tactile deficits,,,,,,,,,,,,,,,,
25100,,pulmonary emboli,,,,,,,,,,,,,,,,
25101,,tablet|profound mood disorders,,,,,,,,,,,,,,,,
25102,,hospital|willingness,,,,,,,,,,,,,,,,
25103,,months|frequency,,,,,,,,,,,,,,,,
25104,,squamous skin cancer,,,,,,,,,,,,,,,,
25105,,impaired hearing,,,,,,,,,,,,,,,,
25106,,unsuitable candidate,,,,,,,,,,,,,,,,
25107,,cardiac vascular disease,,,,,,,,,,,,,,,,
25108,,identify allergy,,,,,,,,,,,,,,,,
25109,,alcoholic hepatitis,,,,,,,,,,,,,,,,
25110,,tpn,,,,,,,,,,,,,,,,
25111,,cancer.|men,,,,,,,,,,,,,,,,
25112,,critically ill,,,,,,,,,,,,,,,,
25113,,nasal spray,,,,,,,,,,,,,,,,
25114,,lift off test,,,,,,,,,,,,,,,,
25115,,ligament deficiency|present,,,,,,,,,,,,,,,,
25116,,acute coronary syndrome|acute,,,,,,,,,,,,,,,,
25117,,atypical symptoms,,,,,,,,,,,,,,,,
25118,,impaired thyroid,,,,,,,,,,,,,,,,
25119,,intolerance of the,,,,,,,,,,,,,,,,
25120,,seizure disorders,,,,,,,,,,,,,,,,
25121,,cc,,,,,,,,,,,,,,,,
25122,,hypertrophic obstructive cardiomyopathy.|metastatic,,,,,,,,,,,,,,,,
25123,,adequate organ functions,,,,,,,,,,,,,,,,
25124,,resulted,,,,,,,,,,,,,,,,
25125,,g6pd);|diagnosis,,,,,,,,,,,,,,,,
25126,,vertebrates,,,,,,,,,,,,,,,,
25127,,clonal bone marrow (bm) plasma cells,,,,,,,,,,,,,,,,
25128,,health technologies inc.,,,,,,,,,,,,,,,,
25129,,psychiatric disorder|taking pain,,,,,,,,,,,,,,,,
25130,,middle ear disease,,,,,,,,,,,,,,,,
25131,,mrcc,,,,,,,,,,,,,,,,
25132,,impaired mental,,,,,,,,,,,,,,,,
25133,,congestive heart failure|unable to provide informed consent,,,,,,,,,,,,,,,,
25134,,intellectual disorder,,,,,,,,,,,,,,,,
25135,,hepatitis b virus (hbv) antiviral therapy,,,,,,,,,,,,,,,,
25136,,index ulcer assessment:||penetrates,,,,,,,,,,,,,,,,
25137,,adjuvants,,,,,,,,,,,,,,,,
25138,,possible interaction,,,,,,,,,,,,,,,,
25139,,good general health.|clinical diagnosis,,,,,,,,,,,,,,,,
25140,,monkeypox infection,,,,,,,,,,,,,,,,
25141,,nutritionist,,,,,,,,,,,,,,,,
25142,,maternal infection,,,,,,,,,,,,,,,,
25143,,disorder|renal dysfunction,,,,,,,,,,,,,,,,
25144,,acute conjunctivitis of the eye,,,,,,,,,,,,,,,,
25145,,cutaneous horns,,,,,,,,,,,,,,,,
25146,,chronic viral hepatitis,,,,,,,,,,,,,,,,
25147,,allergy,,,,,,,,,,,,,,,,
25148,,"substance use that,",,,,,,,,,,,,,,,,
25149,,neuro-psychiatric illness,,,,,,,,,,,,,,,,
25150,,prolonged bleeding||**please note this protocol,,,,,,,,,,,,,,,,
25151,,areas,,,,,,,,,,,,,,,,
25152,,lumbar spinal,,,,,,,,,,,,,,,,
25153,,urinary lithiasis,,,,,,,,,,,,,,,,
25154,,neurocognitive disorder.|current,,,,,,,,,,,,,,,,
25155,,prohibitive risk of surgical aortic valve replacement,,,,,,,,,,,,,,,,
25156,,related conditions.|peripheral,,,,,,,,,,,,,,,,
25157,,pulmonary embolism,,,,,,,,,,,,,,,,
25158,,gestation|willingness to,,,,,,,,,,,,,,,,
25159,,liver impairments,,,,,,,,,,,,,,,,
25160,,skin folds,,,,,,,,,,,,,,,,
25161,,hypoglossal nerve stimulator,,,,,,,,,,,,,,,,
25162,,euthymic,,,,,,,,,,,,,,,,
25163,,hypokinesia,,,,,,,,,,,,,,,,
25164,,precancerous lesion,,,,,,,,,,,,,,,,
25165,,haemoptysis,,,,,,,,,,,,,,,,
25166,,regional pain syndrome,,,,,,,,,,,,,,,,
25167,,tendonitis,,,,,,,,,,,,,,,,
25168,,localized thyroid cancer,,,,,,,,,,,,,,,,
25169,,diastolic dysfunction,,,,,,,,,,,,,,,,
25170,,ecg abnormalities,,,,,,,,,,,,,,,,
25171,,major gastrointestinal surgery,,,,,,,,,,,,,,,,
25172,,tumor size,,,,,,,,,,,,,,,,
25173,,refractory to,,,,,,,,,,,,,,,,
25174,,unhealed wounds,,,,,,,,,,,,,,,,
25175,,mobility,,,,,,,,,,,,,,,,
25176,,medication)|myocardial infarction,,,,,,,,,,,,,,,,
25177,,acute cardiac ischemia,,,,,,,,,,,,,,,,
25178,,thrombocytopenia,,,,,,,,,,,,,,,,
25179,,gynecologic infection,,,,,,,,,,,,,,,,
25180,,plus lesions,,,,,,,,,,,,,,,,
25181,,forefoot deformity,,,,,,,,,,,,,,,,
25182,,recreational drugs|recent,,,,,,,,,,,,,,,,
25183,,free of,,,,,,,,,,,,,,,,
25184,,localized low-risk prostate cancer,,,,,,,,,,,,,,,,
25185,,general pain,,,,,,,,,,,,,,,,
25186,,acute early postoperative infection,,,,,,,,,,,,,,,,
25187,,hyperopia,,,,,,,,,,,,,,,,
25188,,chf,,,,,,,,,,,,,,,,
25189,,neurodevelopmental troubles strongly,,,,,,,,,,,,,,,,
25190,,hypertensive disorder,,,,,,,,,,,,,,,,
25191,,periapical disease,,,,,,,,,,,,,,,,
25192,,atiii deficiency,,,,,,,,,,,,,,,,
25193,,adult healthy,,,,,,,,,,,,,,,,
25194,,poor outcome,,,,,,,,,,,,,,,,
25195,,corneal dystrophy,,,,,,,,,,,,,,,,
25196,,hiv)|hepatitis b virus,,,,,,,,,,,,,,,,
25197,,crohns disease,,,,,,,,,,,,,,,,
25198,,gestational hypertension,,,,,,,,,,,,,,,,
25199,,homolateral shoulder dislocation,,,,,,,,,,,,,,,,
25200,,exertional hypoxemia,,,,,,,,,,,,,,,,
25201,,eye|uncontrolled glaucoma,,,,,,,,,,,,,,,,
25202,,individual egfr,,,,,,,,,,,,,,,,
25203,,pregnancy urine tests,,,,,,,,,,,,,,,,
25204,,viridian cognitive complex,,,,,,,,,,,,,,,,
25205,,bladder outflow obstruction,,,,,,,,,,,,,,,,
25206,,radiotherapy|active infectious disease|active bleeding|severe renal insufficiency,,,,,,,,,,,,,,,,
25207,,blood pregnancy testing.|cancer,,,,,,,,,,,,,,,,
25208,,sidewall,,,,,,,,,,,,,,,,
25209,,skin atrophy,,,,,,,,,,,,,,,,
25210,,cpt,,,,,,,,,,,,,,,,
25211,,target organ involvement,,,,,,,,,,,,,,,,
25212,,poems syndrome.|symptomatic,,,,,,,,,,,,,,,,
25213,,multiparous,,,,,,,,,,,,,,,,
25214,,poor drug control,,,,,,,,,,,,,,,,
25215,,poor compliance.|patients,,,,,,,,,,,,,,,,
25216,,knee oa,,,,,,,,,,,,,,,,
25217,,medial compartment of the knee,,,,,,,,,,,,,,,,
25218,,contraindicated communicable disease,,,,,,,,,,,,,,,,
25219,,peritoneal membrane cancer,,,,,,,,,,,,,,,,
25220,,local recurrence,,,,,,,,,,,,,,,,
25221,,toxic megacolon,,,,,,,,,,,,,,,,
25222,,lower limb injury,,,,,,,,,,,,,,,,
25223,,immunodeficiency infection,,,,,,,,,,,,,,,,
25224,,myc,,,,,,,,,,,,,,,,
25225,,non-tuberculosis,,,,,,,,,,,,,,,,
25226,,t1 carcinomas,,,,,,,,,,,,,,,,
25227,,disease of the central nervous system|other conditions,,,,,,,,,,,,,,,,
25228,,leptomeningeal involvement.|patients,,,,,,,,,,,,,,,,
25229,,"acute pancreatitis,|an",,,,,,,,,,,,,,,,
25230,,non,,,,,,,,,,,,,,,,
25231,,thyroid condition,,,,,,,,,,,,,,,,
25232,,local hyperthermia).|acute pain,,,,,,,,,,,,,,,,
25233,,therapy;|local lesions,,,,,,,,,,,,,,,,
25234,,benign thyroid nodule,,,,,,,,,,,,,,,,
25235,,i.e.||hiv,,,,,,,,,,,,,,,,
25236,,petersen's criteria,,,,,,,,,,,,,,,,
25237,,primary osteoarthritis of,,,,,,,,,,,,,,,,
25238,,breath,,,,,,,,,,,,,,,,
25239,,cognitive domain,,,,,,,,,,,,,,,,
25240,,sports injury,,,,,,,,,,,,,,,,
25241,,metallic ocular foreign body,,,,,,,,,,,,,,,,
25242,,non research related,,,,,,,,,,,,,,,,
25243,,limb amputations,,,,,,,,,,,,,,,,
25244,,reflex bursts,,,,,,,,,,,,,,,,
25245,,primary mds,,,,,,,,,,,,,,,,
25246,,recurrent fainting,,,,,,,,,,,,,,,,
25247,,acute covid-19,,,,,,,,,,,,,,,,
25248,,bone metastasis site;|aged,,,,,,,,,,,,,,,,
25249,,human immunodeficiency virus (hiv) virus infection,,,,,,,,,,,,,,,,
25250,,promyelocytic,,,,,,,,,,,,,,,,
25251,,diagnostic block,,,,,,,,,,,,,,,,
25252,,intracranial pressure|pregnancy,,,,,,,,,,,,,,,,
25253,,abstain from sex,,,,,,,,,,,,,,,,
25254,,aid|in general,,,,,,,,,,,,,,,,
25255,,cardiac rehab,,,,,,,,,,,,,,,,
25256,,progressive lesion,,,,,,,,,,,,,,,,
25257,,retinal functional,,,,,,,,,,,,,,,,
25258,,treatment response,,,,,,,,,,,,,,,,
25259,,chronic neurological condition,,,,,,,,,,,,,,,,
25260,,therapeutic response,,,,,,,,,,,,,,,,
25261,,disease)|meniscal rupture.|condylar,,,,,,,,,,,,,,,,
25262,,vertebral fracture,,,,,,,,,,,,,,,,
25263,,rheumatoid arthritis (,,,,,,,,,,,,,,,,
25264,,physical examination|participants,,,,,,,,,,,,,,,,
25265,,paxlovid,,,,,,,,,,,,,,,,
25266,,head trauma causing loss of consciousness,,,,,,,,,,,,,,,,
25267,,poor lifestyle habits,,,,,,,,,,,,,,,,
25268,,blood vessel puncture,,,,,,,,,,,,,,,,
25269,,type 3 neovascularization,,,,,,,,,,,,,,,,
25270,,allergic reaction.||inability,,,,,,,,,,,,,,,,
25271,,care)|participant clarification,,,,,,,,,,,,,,,,
25272,,modified t cell therapy.|active,,,,,,,,,,,,,,,,
25273,,heart failure)|acute pulmonary embolism|pneumonia,,,,,,,,,,,,,,,,
25274,,congenital long qt syndrome|symptomatic,,,,,,,,,,,,,,,,
25275,,ptsd||,,,,,,,,,,,,,,,,
25276,,positive hepatitis panel,,,,,,,,,,,,,,,,
25277,,arrhythmias.|primary cardiomyopathies|significant pulmonary disease,,,,,,,,,,,,,,,,
25278,,acute mental,,,,,,,,,,,,,,,,
25279,,distal embolizations,,,,,,,,,,,,,,,,
25280,,medical conditions:||participant,,,,,,,,,,,,,,,,
25281,,hepatitis;|renal failure,,,,,,,,,,,,,,,,
25282,,primary sclerosing cholangitis,,,,,,,,,,,,,,,,
25283,,generalized anxiety disorder,,,,,,,,,,,,,,,,
25284,,not-curative,,,,,,,,,,,,,,,,
25285,,bruxism,,,,,,,,,,,,,,,,
25286,,linguistic,,,,,,,,,,,,,,,,
25287,,condition unsuitable,,,,,,,,,,,,,,,,
25288,,under|substance abuse,,,,,,,,,,,,,,,,
25289,,medial branch block,,,,,,,,,,,,,,,,
25290,,non-reducible joint limitations,,,,,,,,,,,,,,,,
25291,,spondylosis,,,,,,,,,,,,,,,,
25292,,kidney disorder,,,,,,,,,,,,,,,,
25293,,cardiac implantable electronic device,,,,,,,,,,,,,,,,
25294,,penetrating head injury,,,,,,,,,,,,,,,,
25295,,impaired sensation.|it,,,,,,,,,,,,,,,,
25296,,hepatic impairment.|hypermagnesemia,,,,,,,,,,,,,,,,
25297,,chronic urticaria,,,,,,,,,,,,,,,,
25298,,residual lesions,,,,,,,,,,,,,,,,
25299,,app,,,,,,,,,,,,,,,,
25300,,osteogenesis,,,,,,,,,,,,,,,,
25301,,high disease burden,,,,,,,,,,,,,,,,
25302,,premenstrual symptoms,,,,,,,,,,,,,,,,
25303,,gravid,,,,,,,,,,,,,,,,
25304,,nonmelanoma skin cancer,,,,,,,,,,,,,,,,
25305,,adverse response,,,,,,,,,,,,,,,,
25306,,health-related,,,,,,,,,,,,,,,,
25307,,symptomatic myocarditis,,,,,,,,,,,,,,,,
25308,,pulp necrosis,,,,,,,,,,,,,,,,
25309,,kidney injury,,,,,,,,,,,,,,,,
25310,,chester,,,,,,,,,,,,,,,,
25311,,breastfeeding|mycobacterium tuberculosis infection,,,,,,,,,,,,,,,,
25312,,thoracic esophageal squamous cell carcinoma,,,,,,,,,,,,,,,,
25313,,endometrioid epithelial ovarian,,,,,,,,,,,,,,,,
25314,,chronic obstructive pulmonary disease;|patients,,,,,,,,,,,,,,,,
25315,,nail fungus,,,,,,,,,,,,,,,,
25316,,crc)|colorectal cancer,,,,,,,,,,,,,,,,
25317,,irrespective of p16 status,,,,,,,,,,,,,,,,
25318,,completed phase 1 of the,,,,,,,,,,,,,,,,
25319,,perennial allergic rhinitis,,,,,,,,,,,,,,,,
25320,,criteria for alopecia areata,,,,,,,,,,,,,,,,
25321,,neurological abnormalities,,,,,,,,,,,,,,,,
25322,,cerebral anoxo-ischemia,,,,,,,,,,,,,,,,
25323,,acute cardiac,,,,,,,,,,,,,,,,
25324,,free of malignancy,,,,,,,,,,,,,,,,
25325,,lower back pathology|tumor of the,,,,,,,,,,,,,,,,
25326,,sle classification criteria,,,,,,,,,,,,,,,,
25327,,behavioral problems,,,,,,,,,,,,,,,,
25328,,carbonated beverages,,,,,,,,,,,,,,,,
25329,,heart f failure,,,,,,,,,,,,,,,,
25330,,complete motor paralysis,,,,,,,,,,,,,,,,
25331,,cancer related findings,,,,,,,,,,,,,,,,
25332,,pneumonia,,,,,,,,,,,,,,,,
25333,,shock,,,,,,,,,,,,,,,,
25334,,type 2 diabetic|diagnosed,,,,,,,,,,,,,,,,
25335,,myocardial infarction|eligibility criteria,,,,,,,,,,,,,,,,
25336,,ocular dendrites,,,,,,,,,,,,,,,,
25337,,antiphospholipid syndrome-related,,,,,,,,,,,,,,,,
25338,,primary obesity surgery endoscopic (,,,,,,,,,,,,,,,,
25339,,squamous metaplasia,,,,,,,,,,,,,,,,
25340,,aids).||7,,,,,,,,,,,,,,,,
25341,,bone disease,,,,,,,,,,,,,,,,
25342,,simple urinary tract infections,,,,,,,,,,,,,,,,
25343,,criteria:||medical conditions,,,,,,,,,,,,,,,,
25344,,gilbert's syndrome|serum,,,,,,,,,,,,,,,,
25345,,permanent atrial fibrillation|pregnancy,,,,,,,,,,,,,,,,
25346,,light-smokers,,,,,,,,,,,,,,,,
25347,,ak lesions,,,,,,,,,,,,,,,,
25348,,acidosis,,,,,,,,,,,,,,,,
25349,,vulvovaginal candidiasis|8.pregnant,,,,,,,,,,,,,,,,
25350,,inflammatory myositis,,,,,,,,,,,,,,,,
25351,,breast-feeding|plans to become pregnant,,,,,,,,,,,,,,,,
25352,,associated co-morbidities|those,,,,,,,,,,,,,,,,
25353,,acute onset of chronic heart failure,,,,,,,,,,,,,,,,
25354,,myeloproliferative disorders,,,,,,,,,,,,,,,,
25355,,t2-3n0-1m0).|patients,,,,,,,,,,,,,,,,
25356,,aortic stenosis,,,,,,,,,,,,,,,,
25357,,tumor involvement,,,,,,,,,,,,,,,,
25358,,congenital qt prolongation|absolute corrected qt interval,,,,,,,,,,,,,,,,
25359,,recovered from prior toxicities,,,,,,,,,,,,,,,,
25360,,sus|type 2 diabetes,,,,,,,,,,,,,,,,
25361,,aneurysmatic,,,,,,,,,,,,,,,,
25362,,inattention symptoms,,,,,,,,,,,,,,,,
25363,,cardiac malformation,,,,,,,,,,,,,,,,
25364,,cognitive comorbidity,,,,,,,,,,,,,,,,
25365,,treatment stable,,,,,,,,,,,,,,,,
25366,,leptomeningeal involvement,,,,,,,,,,,,,,,,
25367,,ealthy controls):||available csf,,,,,,,,,,,,,,,,
25368,,sized pleural effusion,,,,,,,,,,,,,,,,
25369,,lobar frontotemporal degeneration,,,,,,,,,,,,,,,,
25370,,acute cerebrovascular accident;|previous myocardial infarction,,,,,,,,,,,,,,,,
25371,,skin ulcer symptoms,,,,,,,,,,,,,,,,
25372,,topical janus kinase,,,,,,,,,,,,,,,,
25373,,foot surgery|advanced osteoarthritis of the lower ankle joint|ulcerations,,,,,,,,,,,,,,,,
25374,,candangolândia,,,,,,,,,,,,,,,,
25375,,tendinopathy,,,,,,,,,,,,,,,,
25376,,lab reparation,,,,,,,,,,,,,,,,
25377,,autoimmune disease|interstitial lung disease|chronic hbv infection,,,,,,,,,,,,,,,,
25378,,sarcomatoid hcc,,,,,,,,,,,,,,,,
25379,,post-transplant,,,,,,,,,,,,,,,,
25380,,transdermal medicine patch,,,,,,,,,,,,,,,,
25381,,average pain,,,,,,,,,,,,,,,,
25382,,hgg,,,,,,,,,,,,,,,,
25383,,vascular malformations,,,,,,,,,,,,,,,,
25384,,htn.|uncontrolled,,,,,,,,,,,,,,,,
25385,,nci,,,,,,,,,,,,,,,,
25386,,oncolytic virus drugs,,,,,,,,,,,,,,,,
25387,,hyperhomocysteinemia,,,,,,,,,,,,,,,,
25388,,colorectal lesions,,,,,,,,,,,,,,,,
25389,,chronic otitis media,,,,,,,,,,,,,,,,
25390,,coagulopathy,,,,,,,,,,,,,,,,
25391,,functional diarrhea,,,,,,,,,,,,,,,,
25392,,constipation,,,,,,,,,,,,,,,,
25393,,parasitic infections of the gastrointestinal tract;|psychiatric diseases;|chronic inflammatory diseases of the gastrointestinal tract,,,,,,,,,,,,,,,,
25394,,quickscid-5).|liebowitz social anxiety scale,,,,,,,,,,,,,,,,
25395,,recent;|pulmonary embolism,,,,,,,,,,,,,,,,
25396,,removed)|mental health disorders,,,,,,,,,,,,,,,,
25397,,eria:||male,,,,,,,,,,,,,,,,
25398,,superficial vein thrombosis [svt],,,,,,,,,,,,,,,,
25399,,antiphospholipid syndrome).||any contraindication,,,,,,,,,,,,,,,,
25400,,refractory b cell,,,,,,,,,,,,,,,,
25401,,chronic hepatitis d virus (hdv) infection,,,,,,,,,,,,,,,,
25402,,practice providers,,,,,,,,,,,,,,,,
25403,,pathology of the central nervous system.|subjects,,,,,,,,,,,,,,,,
25404,,gej adenocarcinoma,,,,,,,,,,,,,,,,
25405,,reproductive hormones level,,,,,,,,,,,,,,,,
25406,,needle sickness.|drug abuse,,,,,,,,,,,,,,,,
25407,,splenic laceration,,,,,,,,,,,,,,,,
25408,,age|single chronic sci,,,,,,,,,,,,,,,,
25409,,hepatocellular carcinoma.|intermediate,,,,,,,,,,,,,,,,
25410,,deep bite|extraction,,,,,,,,,,,,,,,,
25411,,sinus node dysfunction,,,,,,,,,,,,,,,,
25412,,spinal cord injuries.|patients,,,,,,,,,,,,,,,,
25413,,basal-cell carcinoma of the skin,,,,,,,,,,,,,,,,
25414,,legs,,,,,,,,,,,,,,,,
25415,,mixed non-small cell,,,,,,,,,,,,,,,,
25416,,abstain from use of these medications,,,,,,,,,,,,,,,,
25417,,difficulties,,,,,,,,,,,,,,,,
25418,,completed nutritional survey record,,,,,,,,,,,,,,,,
25419,,intracranial hemorrhage.||,,,,,,,,,,,,,,,,
25420,,physical activity habits,,,,,,,,,,,,,,,,
25421,,organic thyroid,,,,,,,,,,,,,,,,
25422,,n. meningitides|household,,,,,,,,,,,,,,,,
25423,,sensitive skin areas,,,,,,,,,,,,,,,,
25424,,moxibustion smoke,,,,,,,,,,,,,,,,
25425,,congestive heart failure,,,,,,,,,,,,,,,,
25426,,native coronary arteries,,,,,,,,,,,,,,,,
25427,,neurological symptoms have recovered,,,,,,,,,,,,,,,,
25428,,mixed handedness|use of,,,,,,,,,,,,,,,,
25429,,ischaemic changes,,,,,,,,,,,,,,,,
25430,,impact on safety,,,,,,,,,,,,,,,,
25431,,rhythm disorders,,,,,,,,,,,,,,,,
25432,,ankle sprains,,,,,,,,,,,,,,,,
25433,,severe mental comorbidity,,,,,,,,,,,,,,,,
25434,,renal disease|hypoglycemia|physical,,,,,,,,,,,,,,,,
25435,,conscious level.|uncooperative patients|those,,,,,,,,,,,,,,,,
25436,,pdf,,,,,,,,,,,,,,,,
25437,,bruton's tyrosine kinase (btk) inhibitor for lymphoma|vaccination,,,,,,,,,,,,,,,,
25438,,breech,,,,,,,,,,,,,,,,
25439,,matching between healthy volunteers,,,,,,,,,,,,,,,,
25440,,demonstrates deficits,,,,,,,,,,,,,,,,
25441,,program.|ability,,,,,,,,,,,,,,,,
25442,,parp inhibitor,,,,,,,,,,,,,,,,
25443,,dependence on alcohol,,,,,,,,,,,,,,,,
25444,,naïve,,,,,,,,,,,,,,,,
25445,,plaque psoriasis,,,,,,,,,,,,,,,,
25446,,confirmed t2dm diagnosis,,,,,,,,,,,,,,,,
25447,,manic,,,,,,,,,,,,,,,,
25448,,possible hepatic impairment,,,,,,,,,,,,,,,,
25449,,post septic arthritis,,,,,,,,,,,,,,,,
25450,,impaired glucose tolerance (igt),,,,,,,,,,,,,,,,
25451,,"chronic dialysis,|acute pulmonary embolism,|transfusion",,,,,,,,,,,,,,,,
25452,,uric acid,,,,,,,,,,,,,,,,
25453,,pd).|hospitalized,,,,,,,,,,,,,,,,
25454,,tolerability issues,,,,,,,,,,,,,,,,
25455,,vasculitis.||significant mass,,,,,,,,,,,,,,,,
25456,,epithelial ovarian carcinoma,,,,,,,,,,,,,,,,
25457,,neoplastic growth,,,,,,,,,,,,,,,,
25458,,atrial diameter≥,,,,,,,,,,,,,,,,
25459,,bariatric) surgery,,,,,,,,,,,,,,,,
25460,,autoimmune disorder,,,,,,,,,,,,,,,,
25461,,qi-deficiency constitution,,,,,,,,,,,,,,,,
25462,,s-tdapt,,,,,,,,,,,,,,,,
25463,,therapy.|active viral hepatitis,,,,,,,,,,,,,,,,
25464,,diphtheria,,,,,,,,,,,,,,,,
25465,,collin syndrome,,,,,,,,,,,,,,,,
25466,,esophageal erosion.|serious illness,,,,,,,,,,,,,,,,
25467,,migraine aura,,,,,,,,,,,,,,,,
25468,,neonatal alloimmune thrombocytopenia,,,,,,,,,,,,,,,,
25469,,solid organ/tissue allogeneic,,,,,,,,,,,,,,,,
25470,,hepatic laboratory abnormalities,,,,,,,,,,,,,,,,
25471,,alcohol disorder,,,,,,,,,,,,,,,,
25472,,socio-economic background,,,,,,,,,,,,,,,,
25473,,off-medication.||exclusion,,,,,,,,,,,,,,,,
25474,,apparent dry eye,,,,,,,,,,,,,,,,
25475,,hepatic flexure)|surgical resection,,,,,,,,,,,,,,,,
25476,,inflammatory disease);|terminal illness,,,,,,,,,,,,,,,,
25477,,nonsurgical,,,,,,,,,,,,,,,,
25478,,vascular impairment,,,,,,,,,,,,,,,,
25479,,cerebral vascular disease.|patients,,,,,,,,,,,,,,,,
25480,,c3 glomerulopathy,,,,,,,,,,,,,,,,
25481,,fetal complications,,,,,,,,,,,,,,,,
25482,,chronic myeloid leukemia,,,,,,,,,,,,,,,,
25483,,cerebrovascular diseases.|systemic treatment,,,,,,,,,,,,,,,,
25484,,primary tumor.|lateral neck cysts,,,,,,,,,,,,,,,,
25485,,procedure,,,,,,,,,,,,,,,,
25486,,chronic inflammatory conditions,,,,,,,,,,,,,,,,
25487,,black cohosh,,,,,,,,,,,,,,,,
25488,,extraintestinal symptoms should,,,,,,,,,,,,,,,,
25489,,medical conditions,,,,,,,,,,,,,,,,
25490,,rare cancer,,,,,,,,,,,,,,,,
25491,,ventilatory support,,,,,,,,,,,,,,,,
25492,,cerebral embolism,,,,,,,,,,,,,,,,
25493,,inadequate cough,,,,,,,,,,,,,,,,
25494,,met:||secondary parkinsonism,,,,,,,,,,,,,,,,
25495,,transient ischemic attack);||serious cardiovascular disease,,,,,,,,,,,,,,,,
25496,,av block|drugs,,,,,,,,,,,,,,,,
25497,,quantify numbness,,,,,,,,,,,,,,,,
25498,,cardiac diseases.|able to communicate,,,,,,,,,,,,,,,,
25499,,parkinson's disease|healthy,,,,,,,,,,,,,,,,
25500,,hiv-1 positive,,,,,,,,,,,,,,,,
25501,,inability to adequately,,,,,,,,,,,,,,,,
25502,,haemorrhagic complications,,,,,,,,,,,,,,,,
25503,,complex chronic condition,,,,,,,,,,,,,,,,
25504,,nsip,,,,,,,,,,,,,,,,
25505,,partial necrosis,,,,,,,,,,,,,,,,
25506,,primary mediastinum,,,,,,,,,,,,,,,,
25507,,nocturnal hypoglycemia,,,,,,,,,,,,,,,,
25508,,tachycardia-induced,,,,,,,,,,,,,,,,
25509,,fungal infections|poor,,,,,,,,,,,,,,,,
25510,,non-castrate,,,,,,,,,,,,,,,,
25511,,adverse hypersensitivity,,,,,,,,,,,,,,,,
25512,,child,,,,,,,,,,,,,,,,
25513,,early spondyloarthropathy,,,,,,,,,,,,,,,,
25514,,psychological disturbance,,,,,,,,,,,,,,,,
25515,,familial pancreatic cancer (fpc).||exclusion criteria,,,,,,,,,,,,,,,,
25516,,sports training.||the procedure,,,,,,,,,,,,,,,,
25517,,gastrointestinal tract condition,,,,,,,,,,,,,,,,
25518,,liver biopsy.|uncontrolled hypertension,,,,,,,,,,,,,,,,
25519,,mental conditions,,,,,,,,,,,,,,,,
25520,,follows:||pulmonary embolism,,,,,,,,,,,,,,,,
25521,,mastocytosis,,,,,,,,,,,,,,,,
25522,,prescribed cancer,,,,,,,,,,,,,,,,
25523,,detectable hiv rna,,,,,,,,,,,,,,,,
25524,,months;|active infections,,,,,,,,,,,,,,,,
25525,,medically healthy,,,,,,,,,,,,,,,,
25526,,cancer;|atrial fibrillation,,,,,,,,,,,,,,,,
25527,,nuclear factor kappab ligand,,,,,,,,,,,,,,,,
25528,,early dementia,,,,,,,,,,,,,,,,
25529,,bep.|pregnant,,,,,,,,,,,,,,,,
25530,,paralytic ileus,,,,,,,,,,,,,,,,
25531,,.|metastatic lesion,,,,,,,,,,,,,,,,
25532,,progressive neurologic disease,,,,,,,,,,,,,,,,
25533,,screening|diagnosis,,,,,,,,,,,,,,,,
25534,,peripheral vascular disease)|4.serious,,,,,,,,,,,,,,,,
25535,,inguinal lymph nodes|patients,,,,,,,,,,,,,,,,
25536,,oncohematological diseases,,,,,,,,,,,,,,,,
25537,,therapy.|type 2 diabetic,,,,,,,,,,,,,,,,
25538,,post-surgical,,,,,,,,,,,,,,,,
25539,,kg|chronic viral infection,,,,,,,,,,,,,,,,
25540,,pulmonary heart disease,,,,,,,,,,,,,,,,
25541,,noncirrhotic,,,,,,,,,,,,,,,,
25542,,cardiac cerebrovascular,,,,,,,,,,,,,,,,
25543,,intraoperative bleeding,,,,,,,,,,,,,,,,
25544,,omental cake,,,,,,,,,,,,,,,,
25545,,refractory angina pectoris,,,,,,,,,,,,,,,,
25546,,lower extremity surgeries,,,,,,,,,,,,,,,,
25547,,organic diseases.|4,,,,,,,,,,,,,,,,
25548,,supplemental interbody,,,,,,,,,,,,,,,,
25549,,immunodeficiency;|severe infections,,,,,,,,,,,,,,,,
25550,,alcohol dependence disorder,,,,,,,,,,,,,,,,
25551,,corneal lesion,,,,,,,,,,,,,,,,
25552,,eosinophilic oesophagitis,,,,,,,,,,,,,,,,
25553,,2);|viral hepatitis,,,,,,,,,,,,,,,,
25554,,"psychiatric disorders,|multiple sexual partners",,,,,,,,,,,,,,,,
25555,,standardize mechanism,,,,,,,,,,,,,,,,
25556,,unmanaged diabetes,,,,,,,,,,,,,,,,
25557,,chronic cardiac arrhythmia,,,,,,,,,,,,,,,,
25558,,breast cancer;|prior treatment,,,,,,,,,,,,,,,,
25559,,non-cardiac surgery.||,,,,,,,,,,,,,,,,
25560,,ucc,,,,,,,,,,,,,,,,
25561,,lower limb ischemia,,,,,,,,,,,,,,,,
25562,,post-menopausal,,,,,,,,,,,,,,,,
25563,,tumor recurrence,,,,,,,,,,,,,,,,
25564,,medullary sponge kidney,,,,,,,,,,,,,,,,
25565,,paso,,,,,,,,,,,,,,,,
25566,,affective disorders,,,,,,,,,,,,,,,,
25567,,acute coronary artery obstruction,,,,,,,,,,,,,,,,
25568,,crrt,,,,,,,,,,,,,,,,
25569,,brain trauma|vasculitis|thyroid diseases|adrenal,,,,,,,,,,,,,,,,
25570,,her2-targeting therapy.||,,,,,,,,,,,,,,,,
25571,,ischemic,,,,,,,,,,,,,,,,
25572,,molluscum).|had,,,,,,,,,,,,,,,,
25573,,barrow,,,,,,,,,,,,,,,,
25574,,chronic digestive pathology,,,,,,,,,,,,,,,,
25575,,growth of adenoma,,,,,,,,,,,,,,,,
25576,,growth factor support.|ast,,,,,,,,,,,,,,,,
25577,,risk reduction,,,,,,,,,,,,,,,,
25578,,her2 gene amplification,,,,,,,,,,,,,,,,
25579,,4d flow,,,,,,,,,,,,,,,,
25580,,p. falciparum,,,,,,,,,,,,,,,,
25581,,poor physical infrastructure,,,,,,,,,,,,,,,,
25582,,generalized gingivitis,,,,,,,,,,,,,,,,
25583,,lumbar puncture|secondary causes,,,,,,,,,,,,,,,,
25584,,drug-induced liver disease.|model for,,,,,,,,,,,,,,,,
25585,,maxillae,,,,,,,,,,,,,,,,
25586,,orthostatic hypotension|patients,,,,,,,,,,,,,,,,
25587,,pain|deep brain stimulation,,,,,,,,,,,,,,,,
25588,,immunologically compromised,,,,,,,,,,,,,,,,
25589,,common comorbid diagnoses,,,,,,,,,,,,,,,,
25590,,look back,,,,,,,,,,,,,,,,
25591,,excreto-urinary tract,,,,,,,,,,,,,,,,
25592,,aspergillus infections,,,,,,,,,,,,,,,,
25593,,multiple pregnancy,,,,,,,,,,,,,,,,
25594,,between the stroke,,,,,,,,,,,,,,,,
25595,,muscle skeletal injury,,,,,,,,,,,,,,,,
25596,,type parenchymal hematoma,,,,,,,,,,,,,,,,
25597,,type 2 diabetes mellitus;|self-managing,,,,,,,,,,,,,,,,
25598,,flares,,,,,,,,,,,,,,,,
25599,,lack of coordination,,,,,,,,,,,,,,,,
25600,,psychiatric disorder,,,,,,,,,,,,,,,,
25601,,visit;|current infection,,,,,,,,,,,,,,,,
25602,,type ii,,,,,,,,,,,,,,,,
25603,,progressive neurological disorder,,,,,,,,,,,,,,,,
25604,,generalized dysmotility,,,,,,,,,,,,,,,,
25605,,speech impairment,,,,,,,,,,,,,,,,
25606,,b-cell malignancy,,,,,,,,,,,,,,,,
25607,,adenocarcinoma prostate|localized,,,,,,,,,,,,,,,,
25608,,pervasive developmental,,,,,,,,,,,,,,,,
25609,,parathyroid,,,,,,,,,,,,,,,,
25610,,rhabdoid tumor,,,,,,,,,,,,,,,,
25611,,esophageal varices.||,,,,,,,,,,,,,,,,
25612,,behavioral disturbances,,,,,,,,,,,,,,,,
25613,,at,,,,,,,,,,,,,,,,
25614,,continuation,,,,,,,,,,,,,,,,
25615,,cf consistent,,,,,,,,,,,,,,,,
25616,,growth chart,,,,,,,,,,,,,,,,
25617,,alcohol use|to,,,,,,,,,,,,,,,,
25618,,seizures.|tightness of the hip flexors,,,,,,,,,,,,,,,,
25619,,breast abscess,,,,,,,,,,,,,,,,
25620,,esophageal surgery.|esophageal stricture,,,,,,,,,,,,,,,,
25621,,vision loss)|able,,,,,,,,,,,,,,,,
25622,,immunity disorder,,,,,,,,,,,,,,,,
25623,,agoraphobia,,,,,,,,,,,,,,,,
25624,,type 1 myocardial infarction,,,,,,,,,,,,,,,,
25625,,homozygous familial hypercholesterolemia,,,,,,,,,,,,,,,,
25626,,f32,,,,,,,,,,,,,,,,
25627,,absorption of the study,,,,,,,,,,,,,,,,
25628,,neurocognitive problems,,,,,,,,,,,,,,,,
25629,,produce autonomic neuropathy,,,,,,,,,,,,,,,,
25630,,kyphosis,,,,,,,,,,,,,,,,
25631,,non-melanoma skin cancer,,,,,,,,,,,,,,,,
25632,,mobility;|orthodontic treatment;|dental,,,,,,,,,,,,,,,,
25633,,human epidermal growth factor,,,,,,,,,,,,,,,,
25634,,intracranial arteriovenous malformations;|those,,,,,,,,,,,,,,,,
25635,,residual malignant tumors,,,,,,,,,,,,,,,,
25636,,chronic physical disease,,,,,,,,,,,,,,,,
25637,,≥1 pgtcs,,,,,,,,,,,,,,,,
25638,,prostate cancer,,,,,,,,,,,,,,,,
25639,,drug induced,,,,,,,,,,,,,,,,
25640,,necrotizing enterocolitis,,,,,,,,,,,,,,,,
25641,,claustrophobia,,,,,,,,,,,,,,,,
25642,,preauricular lymphadenopathy,,,,,,,,,,,,,,,,
25643,,neonatal risk conditions,,,,,,,,,,,,,,,,
25644,,cardiac comorbidity,,,,,,,,,,,,,,,,
25645,,barrett's,,,,,,,,,,,,,,,,
25646,,drug use disorders,,,,,,,,,,,,,,,,
25647,,astrocytoma,,,,,,,,,,,,,,,,
25648,,nontraumatic subarachnoid hemorrhage,,,,,,,,,,,,,,,,
25649,,malabsorption syndromes|known,,,,,,,,,,,,,,,,
25650,,incipient dementia/,,,,,,,,,,,,,,,,
25651,,abuse|has cancer,,,,,,,,,,,,,,,,
25652,,necessitates,,,,,,,,,,,,,,,,
25653,,chest image,,,,,,,,,,,,,,,,
25654,,30%of bleeding,,,,,,,,,,,,,,,,
25655,,indoor oxygen saturation,,,,,,,,,,,,,,,,
25656,,left ventricular systolic dysfunction,,,,,,,,,,,,,,,,
25657,,haemodialysis|heart failure,,,,,,,,,,,,,,,,
25658,,uterine cancer|medical condition,,,,,,,,,,,,,,,,
25659,,"solid tumor,|no communication barrier|being able to communicate by phone|individuals who agree to participate",,,,,,,,,,,,,,,,
25660,,monomicrobial infection,,,,,,,,,,,,,,,,
25661,,known disease,,,,,,,,,,,,,,,,
25662,,adenocarcinoma of the prostate.|at least 1,,,,,,,,,,,,,,,,
25663,,bone marrow suppression,,,,,,,,,,,,,,,,
25664,,serious health condition,,,,,,,,,,,,,,,,
25665,,serious infection.|intercurrent illness,,,,,,,,,,,,,,,,
25666,,biological response,,,,,,,,,,,,,,,,
25667,,perfusion mismatch,,,,,,,,,,,,,,,,
25668,,pill bottles,,,,,,,,,,,,,,,,
25669,,anaesthetics|inability,,,,,,,,,,,,,,,,
25670,,congenital vwd,,,,,,,,,,,,,,,,
25671,,respiratory rate,,,,,,,,,,,,,,,,
25672,,reduce cancer risk,,,,,,,,,,,,,,,,
25673,,prescription weight loss,,,,,,,,,,,,,,,,
25674,,carotid sinus hypersensitivity,,,,,,,,,,,,,,,,
25675,,hiv-2,,,,,,,,,,,,,,,,
25676,,squamous cell skin carcinoma,,,,,,,,,,,,,,,,
25677,,cognitively impaired/,,,,,,,,,,,,,,,,
25678,,diarrhea,,,,,,,,,,,,,,,,
25679,,inflammatory bowel disorders,,,,,,,,,,,,,,,,
25680,,pain syndromes,,,,,,,,,,,,,,,,
25681,,chronic rhinosinusitis,,,,,,,,,,,,,,,,
25682,,light therapy|active infection,,,,,,,,,,,,,,,,
25683,,intra-corneal ring,,,,,,,,,,,,,,,,
25684,,heart kidney)|contraindication to renal biopsy|refusing biopsy|kidney transplant,,,,,,,,,,,,,,,,
25685,,unusual neurocognitive disorders,,,,,,,,,,,,,,,,
25686,,ventricular frequency,,,,,,,,,,,,,,,,
25687,,glp-1 ra,,,,,,,,,,,,,,,,
25688,,acute gvhd.|suitable haploidentical donor.|performance,,,,,,,,,,,,,,,,
25689,,clinical remission,,,,,,,,,,,,,,,,
25690,,feeling hypoglycemia,,,,,,,,,,,,,,,,
25691,,horizontal laryngectomy,,,,,,,,,,,,,,,,
25692,,tortuosity,,,,,,,,,,,,,,,,
25693,,neither cancer renders,,,,,,,,,,,,,,,,
25694,,familial hypercholesterolemia|pcsk9 inhibitors,,,,,,,,,,,,,,,,
25695,,alternative diagnosis,,,,,,,,,,,,,,,,
25696,,suicidal behaviors,,,,,,,,,,,,,,,,
25697,,age.|other pathologies,,,,,,,,,,,,,,,,
25698,,benign esophageal stricture,,,,,,,,,,,,,,,,
25699,,obstructive kidney disease,,,,,,,,,,,,,,,,
25700,,kidney failure.|new-borns,,,,,,,,,,,,,,,,
25701,,heterozygous of the coch gene (,,,,,,,,,,,,,,,,
25702,,cardiopulmonary disorders,,,,,,,,,,,,,,,,
25703,,biochemical recurrence of prostate cancer,,,,,,,,,,,,,,,,
25704,,transient neurological abnormalities,,,,,,,,,,,,,,,,
25705,,mental handicapping condition.||males,,,,,,,,,,,,,,,,
25706,,disease exacerbation/hospitalization,,,,,,,,,,,,,,,,
25707,,paroxysmal atrial fibrillation).|history,,,,,,,,,,,,,,,,
25708,,wrist extension,,,,,,,,,,,,,,,,
25709,,hbcab positive,,,,,,,,,,,,,,,,
25710,,epithelial ovarian cancer|affiliated,,,,,,,,,,,,,,,,
25711,,acute lymphoblastic leukemia,,,,,,,,,,,,,,,,
25712,,psychotic disorder|have,,,,,,,,,,,,,,,,
25713,,ia:||males,,,,,,,,,,,,,,,,
25714,,hepatitis c virus [hcv] infection,,,,,,,,,,,,,,,,
25715,,months|inability,,,,,,,,,,,,,,,,
25716,,ph+ disease,,,,,,,,,,,,,,,,
25717,,hospitalization.|unstable cardiac arrhythmias,,,,,,,,,,,,,,,,
25718,,normal.||exclusion,,,,,,,,,,,,,,,,
25719,,thyroid papillary carcinoma.|patients,,,,,,,,,,,,,,,,
25720,,limb disorders,,,,,,,,,,,,,,,,
25721,,end-stage,,,,,,,,,,,,,,,,
25722,,kidney injury;|patients,,,,,,,,,,,,,,,,
25723,,mustache;|pregnancy,,,,,,,,,,,,,,,,
25724,,impression,,,,,,,,,,,,,,,,
25725,,comparable gestational age,,,,,,,,,,,,,,,,
25726,,hbsag positive,,,,,,,,,,,,,,,,
25727,,core biopsy|be,,,,,,,,,,,,,,,,
25728,,pinimeningeal disease,,,,,,,,,,,,,,,,
25729,,"temporomandibular joint pathology,|individuals",,,,,,,,,,,,,,,,
25730,,communication barriers|students,,,,,,,,,,,,,,,,
25731,,4|oligodendroglioma,,,,,,,,,,,,,,,,
25732,,mental health condition(s)||inclusion,,,,,,,,,,,,,,,,
25733,,liver diseases criteria,,,,,,,,,,,,,,,,
25734,,cognitive symptoms,,,,,,,,,,,,,,,,
25735,,systemic therapies|patients,,,,,,,,,,,,,,,,
25736,,aneurysms,,,,,,,,,,,,,,,,
25737,,light chemical peels,,,,,,,,,,,,,,,,
25738,,thyroid insufficiency,,,,,,,,,,,,,,,,
25739,,metastases|severe psychiatric condition,,,,,,,,,,,,,,,,
25740,,site eczema,,,,,,,,,,,,,,,,
25741,,typhus vaccine,,,,,,,,,,,,,,,,
25742,,head trauma,,,,,,,,,,,,,,,,
25743,,limited tumors,,,,,,,,,,,,,,,,
25744,,hyperkalemic periodic paralysis.|myotonia,,,,,,,,,,,,,,,,
25745,,b cell lymphoma,,,,,,,,,,,,,,,,
25746,,intoxication,,,,,,,,,,,,,,,,
25747,,h. pylori infection,,,,,,,,,,,,,,,,
25748,,normal exercise,,,,,,,,,,,,,,,,
25749,,radiculopathies,,,,,,,,,,,,,,,,
25750,,distal embolism,,,,,,,,,,,,,,,,
25751,,leg ischemia,,,,,,,,,,,,,,,,
25752,,tracheostomy tube,,,,,,,,,,,,,,,,
25753,,major mood disorder,,,,,,,,,,,,,,,,
25754,,clinician|ability,,,,,,,,,,,,,,,,
25755,,schizotypal personality,,,,,,,,,,,,,,,,
25756,,lung disease|bmi,,,,,,,,,,,,,,,,
25757,,in-situ carcinoma,,,,,,,,,,,,,,,,
25758,,heart failure|other medical condition,,,,,,,,,,,,,,,,
25759,,blood pressure disorders,,,,,,,,,,,,,,,,
25760,,dengue,,,,,,,,,,,,,,,,
25761,,cough disorder,,,,,,,,,,,,,,,,
25762,,ahi,,,,,,,,,,,,,,,,
25763,,non-radiographic axspa,,,,,,,,,,,,,,,,
25764,,institutes,,,,,,,,,,,,,,,,
25765,,tolerating-fluid phase|patients,,,,,,,,,,,,,,,,
25766,,values|renal impairment,,,,,,,,,,,,,,,,
25767,,physical findings,,,,,,,,,,,,,,,,
25768,,aneurysm|thoracoabdominal aortic aneurysm elective,,,,,,,,,,,,,,,,
25769,,hemoglobinopathy,,,,,,,,,,,,,,,,
25770,,brain metastatic tumor,,,,,,,,,,,,,,,,
25771,,pathological criteria,,,,,,,,,,,,,,,,
25772,,depression|inability,,,,,,,,,,,,,,,,
25773,,corneal distortion,,,,,,,,,,,,,,,,
25774,,h3k27m midline,,,,,,,,,,,,,,,,
25775,,volume.|unstable angina pectoris,,,,,,,,,,,,,,,,
25776,,poor quality of,,,,,,,,,,,,,,,,
25777,,hypertension disorder,,,,,,,,,,,,,,,,
25778,,properties,,,,,,,,,,,,,,,,
25779,,recovered from all aes,,,,,,,,,,,,,,,,
25780,,postmenopausal,,,,,,,,,,,,,,,,
25781,,cps ≥1,,,,,,,,,,,,,,,,
25782,,total blindness,,,,,,,,,,,,,,,,
25783,,pulmonary disorder,,,,,,,,,,,,,,,,
25784,,spouse,,,,,,,,,,,,,,,,
25785,,neuraxial block|uncontrolled hypertension (htn),,,,,,,,,,,,,,,,
25786,,pregnancy allergy,,,,,,,,,,,,,,,,
25787,,biochemical menopause,,,,,,,,,,,,,,,,
25788,,delusions)|anxiety disorders,,,,,,,,,,,,,,,,
25789,,core symptoms,,,,,,,,,,,,,,,,
25790,,sterilization,,,,,,,,,,,,,,,,
25791,,neurological symptoms can,,,,,,,,,,,,,,,,
25792,,lifestyle modification,,,,,,,,,,,,,,,,
25793,,functional movement disorders,,,,,,,,,,,,,,,,
25794,,inflammatory gastrointestinal disorder|ongoing immunosuppression,,,,,,,,,,,,,,,,
25795,,major illness,,,,,,,,,,,,,,,,
25796,,drug-induced,,,,,,,,,,,,,,,,
25797,,exacerbation of congestive heart failure,,,,,,,,,,,,,,,,
25798,,bcc,,,,,,,,,,,,,,,,
25799,,another cancer,,,,,,,,,,,,,,,,
25800,,liver function||exclusion,,,,,,,,,,,,,,,,
25801,,dialysis|critically ill,,,,,,,,,,,,,,,,
25802,,shampoos,,,,,,,,,,,,,,,,
25803,,soft tissue condition,,,,,,,,,,,,,,,,
25804,,copper-related,,,,,,,,,,,,,,,,
25805,,recurrent infection,,,,,,,,,,,,,,,,
25806,,autoimmune esophageal disease,,,,,,,,,,,,,,,,
25807,,domestic,,,,,,,,,,,,,,,,
25808,,motor limitations|mental impairment leading,,,,,,,,,,,,,,,,
25809,,left main coronary,,,,,,,,,,,,,,,,
25810,,carcinoma in situ of the breast,,,,,,,,,,,,,,,,
25811,,clinical pregnancies,,,,,,,,,,,,,,,,
25812,,acute abdominal condition,,,,,,,,,,,,,,,,
25813,,benign tumor,,,,,,,,,,,,,,,,
25814,,nm8074,,,,,,,,,,,,,,,,
25815,,intubation|patients,,,,,,,,,,,,,,,,
25816,,adenoma-like dysplasia-associated lesions,,,,,,,,,,,,,,,,
25817,,medication occurs,,,,,,,,,,,,,,,,
25818,,old.|ability,,,,,,,,,,,,,,,,
25819,,adrenal metastatic carcinoma,,,,,,,,,,,,,,,,
25820,,extraction of the maxillary first premolars,,,,,,,,,,,,,,,,
25821,,enzymatic diagnostics,,,,,,,,,,,,,,,,
25822,,cardiovascular comorbidity,,,,,,,,,,,,,,,,
25823,,ocscc,,,,,,,,,,,,,,,,
25824,,peripheral nerve,,,,,,,,,,,,,,,,
25825,,pain symptoms,,,,,,,,,,,,,,,,
25826,,adverse reactions associated,,,,,,,,,,,,,,,,
25827,,procedures|definitive cancer,,,,,,,,,,,,,,,,
25828,,developmental dysplasia,,,,,,,,,,,,,,,,
25829,,myriad mychoice hrd test results available prior to registration.||patient,,,,,,,,,,,,,,,,
25830,,-being,,,,,,,,,,,,,,,,
25831,,fundus,,,,,,,,,,,,,,,,
25832,,inflammation,,,,,,,,,,,,,,,,
25833,,mexican,,,,,,,,,,,,,,,,
25834,,venous pooling,,,,,,,,,,,,,,,,
25835,,postpartum mental disorder,,,,,,,,,,,,,,,,
25836,,risk factors for ppd,,,,,,,,,,,,,,,,
25837,,paper questionnaire,,,,,,,,,,,,,,,,
25838,,bad general condition,,,,,,,,,,,,,,,,
25839,,local recurrence of the primary colorectal cancer;|intolerance,,,,,,,,,,,,,,,,
25840,,applications,,,,,,,,,,,,,,,,
25841,,ataxia,,,,,,,,,,,,,,,,
25842,,autoimmune disease,,,,,,,,,,,,,,,,
25843,,musculoskeletal injuries|any surgery,,,,,,,,,,,,,,,,
25844,,colorectal tumor,,,,,,,,,,,,,,,,
25845,,oral hygiene appointments,,,,,,,,,,,,,,,,
25846,,type 2 diabetes mellitus|patients,,,,,,,,,,,,,,,,
25847,,unable to tolerate venipuncture,,,,,,,,,,,,,,,,
25848,,subtypes:||follicular lymphoma,,,,,,,,,,,,,,,,
25849,,idiopathic constipation,,,,,,,,,,,,,,,,
25850,,duration of illness,,,,,,,,,,,,,,,,
25851,,gastrointestinal tract;|diagnosis,,,,,,,,,,,,,,,,
25852,,meningeal metastasis,,,,,,,,,,,,,,,,
25853,,sleep difﬁculties,,,,,,,,,,,,,,,,
25854,,relapse of,,,,,,,,,,,,,,,,
25855,,subarachnoid haemorrhage,,,,,,,,,,,,,,,,
25856,,biliary disorders,,,,,,,,,,,,,,,,
25857,,ncep-atp,,,,,,,,,,,,,,,,
25858,,suicidal ideation;|diagnosis,,,,,,,,,,,,,,,,
25859,,device|unstable cardiac disease,,,,,,,,,,,,,,,,
25860,,gastric tract problems,,,,,,,,,,,,,,,,
25861,,disease that limits life expectancy,,,,,,,,,,,,,,,,
25862,,"autoimmune diseases,|without",,,,,,,,,,,,,,,,
25863,,natural menopause,,,,,,,,,,,,,,,,
25864,,generalized anxiety,,,,,,,,,,,,,,,,
25865,,lmca stenosis,,,,,,,,,,,,,,,,
25866,,tumour slides,,,,,,,,,,,,,,,,
25867,,mantle cell lymphoma,,,,,,,,,,,,,,,,
25868,,endometrial compression,,,,,,,,,,,,,,,,
25869,,simple hysterectomy,,,,,,,,,,,,,,,,
25870,,acute type a aortic dissection combined with severe,,,,,,,,,,,,,,,,
25871,,benign prostatic,,,,,,,,,,,,,,,,
25872,,hyperthyroidism crisis,,,,,,,,,,,,,,,,
25873,,before inclusion failure,,,,,,,,,,,,,,,,
25874,,refractory cytopenia,,,,,,,,,,,,,,,,
25875,,cystic neoplasms,,,,,,,,,,,,,,,,
25876,,major affective disorder,,,,,,,,,,,,,,,,
25877,,dic,,,,,,,,,,,,,,,,
25878,,crohn's dsease,,,,,,,,,,,,,,,,
25879,,breast cancer in situ,,,,,,,,,,,,,,,,
25880,,relevant pathology,,,,,,,,,,,,,,,,
25881,,ucdccc,,,,,,,,,,,,,,,,
25882,,difficulty handling socks,,,,,,,,,,,,,,,,
25883,,≥ii)|cerebral amyloid angiopathy,,,,,,,,,,,,,,,,
25884,,exception of the,,,,,,,,,,,,,,,,
25885,,bacteremia,,,,,,,,,,,,,,,,
25886,,sexually transmitted diseases,,,,,,,,,,,,,,,,
25887,,bm,,,,,,,,,,,,,,,,
25888,,sll,,,,,,,,,,,,,,,,
25889,,orthostatic vital sign measurements,,,,,,,,,,,,,,,,
25890,,esophageal carcinoma,,,,,,,,,,,,,,,,
25891,,any)|temporomandibular joint dysfunction|neurodegenerative processes|hepatic,,,,,,,,,,,,,,,,
25892,,symptomatic bowel stricture(s,,,,,,,,,,,,,,,,
25893,,significant observation,,,,,,,,,,,,,,,,
25894,,lumbar disc hernia,,,,,,,,,,,,,,,,
25895,,france:||vulnerable populations,,,,,,,,,,,,,,,,
25896,,extensive dental plaque;|turesky modification of the,,,,,,,,,,,,,,,,
25897,,nose crease,,,,,,,,,,,,,,,,
25898,,haemophilia,,,,,,,,,,,,,,,,
25899,,progressive multifocal leuko-encephalopathy,,,,,,,,,,,,,,,,
25900,,exercise|cognitive disabilities,,,,,,,,,,,,,,,,
25901,,incurable malignancies,,,,,,,,,,,,,,,,
25902,,ventricular wall,,,,,,,,,,,,,,,,
25903,,psychological disorders,,,,,,,,,,,,,,,,
25904,,inability to swallow tablets,,,,,,,,,,,,,,,,
25905,,hypoglycemic coma,,,,,,,,,,,,,,,,
25906,,completed the process of donor eligibility,,,,,,,,,,,,,,,,
25907,,cranio-cerebral trauma|acute ear canal,,,,,,,,,,,,,,,,
25908,,autoimmune disease.|major surgical procedure,,,,,,,,,,,,,,,,
25909,,immunologically suppressed,,,,,,,,,,,,,,,,
25910,,human epidermal growth factor receptor 2(her-2,,,,,,,,,,,,,,,,
25911,,lower limb amputation|intra-articular steroid,,,,,,,,,,,,,,,,
25912,,structured physical activity,,,,,,,,,,,,,,,,
25913,,recurrence post resection,,,,,,,,,,,,,,,,
25914,,pathologies,,,,,,,,,,,,,,,,
25915,,clinical program focusing,,,,,,,,,,,,,,,,
25916,,multiple endocrine neoplasia type,,,,,,,,,,,,,,,,
25917,,acute myocardial injury,,,,,,,,,,,,,,,,
25918,,regular alcohol consumption,,,,,,,,,,,,,,,,
25919,,atrial fibrillation.|serious communication barriers,,,,,,,,,,,,,,,,
25920,,abstain from heterosexual intercourse,,,,,,,,,,,,,,,,
25921,,bat,,,,,,,,,,,,,,,,
25922,,oocytes,,,,,,,,,,,,,,,,
25923,,cap.||,,,,,,,,,,,,,,,,
25924,,terminal disease,,,,,,,,,,,,,,,,
25925,,adverse reactions,,,,,,,,,,,,,,,,
25926,,non-colorectal second,,,,,,,,,,,,,,,,
25927,,high risk pregnancy,,,,,,,,,,,,,,,,
25928,,ptk,,,,,,,,,,,,,,,,
25929,,renal dysfunction|preoperative dyspnea|contraindication,,,,,,,,,,,,,,,,
25930,,non-hepatic tumors,,,,,,,,,,,,,,,,
25931,,serious medical condition,,,,,,,,,,,,,,,,
25932,,venipuncture.||be,,,,,,,,,,,,,,,,
25933,,college london's queen's square,,,,,,,,,,,,,,,,
25934,,transcranial gunshot,,,,,,,,,,,,,,,,
25935,,birth defect,,,,,,,,,,,,,,,,
25936,,nuclear expression,,,,,,,,,,,,,,,,
25937,,mixed histologies,,,,,,,,,,,,,,,,
25938,,piercings,,,,,,,,,,,,,,,,
25939,,human immunodeficiency virus-related,,,,,,,,,,,,,,,,
25940,,competes,,,,,,,,,,,,,,,,
25941,,"wm),|lymphoplasmacytic lymphoma",,,,,,,,,,,,,,,,
25942,,systemic immune system diseases,,,,,,,,,,,,,,,,
25943,,hyperlipidemia,,,,,,,,,,,,,,,,
25944,,neurologically unstable,,,,,,,,,,,,,,,,
25945,,singleton living fetus.|previous,,,,,,,,,,,,,,,,
25946,,renal dysfunction;|hiv,,,,,,,,,,,,,,,,
25947,,medial deltoid,,,,,,,,,,,,,,,,
25948,,light therapy|female,,,,,,,,,,,,,,,,
25949,,right to left,,,,,,,,,,,,,,,,
25950,,maculopathy,,,,,,,,,,,,,,,,
25951,,endometrioid endometrial cancer,,,,,,,,,,,,,,,,
25952,,disengaged from hiv care,,,,,,,,,,,,,,,,
25953,,drug addicts|pregnancy,,,,,,,,,,,,,,,,
25954,,asymptomatic hypertension,,,,,,,,,,,,,,,,
25955,,bladder stimulator,,,,,,,,,,,,,,,,
25956,,primary osteosarcoma,,,,,,,,,,,,,,,,
25957,,pulmonary tuberculosis,,,,,,,,,,,,,,,,
25958,,immunomodulatory derivatives.|symptomatic cardiac disease,,,,,,,,,,,,,,,,
25959,,amnesia,,,,,,,,,,,,,,,,
25960,,lactate dehydrogenase (ldh),,,,,,,,,,,,,,,,
25961,,exclusion.|electrocardiographic abnormalities,,,,,,,,,,,,,,,,
25962,,lateral forearm radiographs;|complete clinical,,,,,,,,,,,,,,,,
25963,,abnormal bleeding|predictable risk of difficult intubation|body mass index,,,,,,,,,,,,,,,,
25964,,cpc,,,,,,,,,,,,,,,,
25965,,root canal treatment,,,,,,,,,,,,,,,,
25966,,good compliance.||exclusion,,,,,,,,,,,,,,,,
25967,,cardiovascular disease|no,,,,,,,,,,,,,,,,
25968,,arabic citizen,,,,,,,,,,,,,,,,
25969,,nickel,,,,,,,,,,,,,,,,
25970,,parents|a,,,,,,,,,,,,,,,,
25971,,cross-sensitivity,,,,,,,,,,,,,,,,
25972,,non-cardiac surgical procedure,,,,,,,,,,,,,,,,
25973,,impairs visual field testing.|inability to perform,,,,,,,,,,,,,,,,
25974,,following:||congestive heart failure,,,,,,,,,,,,,,,,
25975,,sequelae of pdr,,,,,,,,,,,,,,,,
25976,,blueberries,,,,,,,,,,,,,,,,
25977,,rare tumor,,,,,,,,,,,,,,,,
25978,,congestive heart failure|coronary/peripheral artery bypass graft,,,,,,,,,,,,,,,,
25979,,haemochromatosis,,,,,,,,,,,,,,,,
25980,,primary solid (irrespective of the status of the primary tumor)|patients,,,,,,,,,,,,,,,,
25981,,familial long qt syndrome.|symptomatic atrial,,,,,,,,,,,,,,,,
25982,,varicocele,,,,,,,,,,,,,,,,
25983,,immunodeficiency syndrome,,,,,,,,,,,,,,,,
25984,,gastrointestinal stromal tumor;|toxicity,,,,,,,,,,,,,,,,
25985,,actinic keratoses,,,,,,,,,,,,,,,,
25986,,thromboembolic concerns,,,,,,,,,,,,,,,,
25987,,superficial cancer of the stomach,,,,,,,,,,,,,,,,
25988,,major dysplasia,,,,,,,,,,,,,,,,
25989,,malignant disease.|pregnancy,,,,,,,,,,,,,,,,
25990,,significant,,,,,,,,,,,,,,,,
25991,,thromboembolic disorders,,,,,,,,,,,,,,,,
25992,,painful joint,,,,,,,,,,,,,,,,
25993,,staged ct1-4anxm0,,,,,,,,,,,,,,,,
25994,,leptomeningeal disease,,,,,,,,,,,,,,,,
25995,,hematologic,,,,,,,,,,,,,,,,
25996,,etc.)|continued pain,,,,,,,,,,,,,,,,
25997,,causes,,,,,,,,,,,,,,,,
25998,,main organs,,,,,,,,,,,,,,,,
25999,,coherent speech observed.|available written informed consent,,,,,,,,,,,,,,,,
26000,,measurable disease,,,,,,,,,,,,,,,,
26001,,pre-stroke disability,,,,,,,,,,,,,,,,
26002,,unilateral hydronephrosis,,,,,,,,,,,,,,,,
26003,,acute stroke|medically,,,,,,,,,,,,,,,,
26004,,2.|ability to undergo stereotactic radiotherapy,,,,,,,,,,,,,,,,
26005,,sync,,,,,,,,,,,,,,,,
26006,,nasal cavity abnormalities,,,,,,,,,,,,,,,,
26007,,dme threatening the center,,,,,,,,,,,,,,,,
26008,,coronary insufficiency,,,,,,,,,,,,,,,,
26009,,delirium dementia|hemodynamic instability,,,,,,,,,,,,,,,,
26010,,"kidney disease),|metabolic diseases|atherosclerosis|previous mi",,,,,,,,,,,,,,,,
26011,,neurological signs|history of benign paroxysmal positional vertigo|neck pain,,,,,,,,,,,,,,,,
26012,,localized skin cancer,,,,,,,,,,,,,,,,
26013,,carotid sinus,,,,,,,,,,,,,,,,
26014,,infection of hiv,,,,,,,,,,,,,,,,
26015,,signs of inflammation,,,,,,,,,,,,,,,,
26016,,multiple gestations.|multiparity.||medical disorders as:||diabetes,,,,,,,,,,,,,,,,
26017,,philips representatives,,,,,,,,,,,,,,,,
26018,,orthodontic,,,,,,,,,,,,,,,,
26019,,hcv)|hbcab,,,,,,,,,,,,,,,,
26020,,genital chlamydia,,,,,,,,,,,,,,,,
26021,,anaplastic lymphoma kinase (alk) mutation-positive,,,,,,,,,,,,,,,,
26022,,oral burning pain,,,,,,,,,,,,,,,,
26023,,fissure|anatomic malformations,,,,,,,,,,,,,,,,
26024,,previous bite,,,,,,,,,,,,,,,,
26025,,predicted|clinically stable,,,,,,,,,,,,,,,,
26026,,breast cancer.|systemic corticosteroids,,,,,,,,,,,,,,,,
26027,,ocular allergies,,,,,,,,,,,,,,,,
26028,,allogenic bone marrow transplantation,,,,,,,,,,,,,,,,
26029,,transient ischemic attack.|a,,,,,,,,,,,,,,,,
26030,,occipital nerve block,,,,,,,,,,,,,,,,
26031,,scleritis,,,,,,,,,,,,,,,,
26032,,conjunctival goblet cells,,,,,,,,,,,,,,,,
26033,,root,,,,,,,,,,,,,,,,
26034,,prolonged use,,,,,,,,,,,,,,,,
26035,,restenotic lesions,,,,,,,,,,,,,,,,
26036,,regular menstrual periods,,,,,,,,,,,,,,,,
26037,,serious oral dryness,,,,,,,,,,,,,,,,
26038,,chronic inflammation|hhv8+ dlbcl,,,,,,,,,,,,,,,,
26039,,gastrointestinal surgery disease,,,,,,,,,,,,,,,,
26040,,peripheral nerve blocks,,,,,,,,,,,,,,,,
26041,,irritations,,,,,,,,,,,,,,,,
26042,,endobronchial transbronchial,,,,,,,,,,,,,,,,
26043,,organ involvement,,,,,,,,,,,,,,,,
26044,,acute care areas,,,,,,,,,,,,,,,,
26045,,lactant,,,,,,,,,,,,,,,,
26046,,diagnose of head & neck cancer,,,,,,,,,,,,,,,,
26047,,small bowel proximal,,,,,,,,,,,,,,,,
26048,,early-stage bc,,,,,,,,,,,,,,,,
26049,,chronic physical illness,,,,,,,,,,,,,,,,
26050,,structural abnormality,,,,,,,,,,,,,,,,
26051,,acute aortic dissection,,,,,,,,,,,,,,,,
26052,,rotator cuff tear,,,,,,,,,,,,,,,,
26053,,retinopathy|diabetic maculopathy,,,,,,,,,,,,,,,,
26054,,allergic asthma allergic,,,,,,,,,,,,,,,,
26055,,autohemolytic anemia,,,,,,,,,,,,,,,,
26056,,old|pregnant,,,,,,,,,,,,,,,,
26057,,complicated hernias,,,,,,,,,,,,,,,,
26058,,corneal burns,,,,,,,,,,,,,,,,
26059,,cognitively impaired,,,,,,,,,,,,,,,,
26060,,neurocognitive disorder,,,,,,,,,,,,,,,,
26061,,pose a hazard to tissue handling.|undergoing fertility,,,,,,,,,,,,,,,,
26062,,survivorship clinic,,,,,,,,,,,,,,,,
26063,,impact on the,,,,,,,,,,,,,,,,
26064,,nephrotic,,,,,,,,,,,,,,,,
26065,,think they might,,,,,,,,,,,,,,,,
26066,,severe abdominal pain,,,,,,,,,,,,,,,,
26067,,folate deficiency,,,,,,,,,,,,,,,,
26068,,ntrk inhibitor treatment;|at least one measurable lesion,,,,,,,,,,,,,,,,
26069,,dumping,,,,,,,,,,,,,,,,
26070,,end stage,,,,,,,,,,,,,,,,
26071,,carnitine palmitoyltransferase,,,,,,,,,,,,,,,,
26072,,malignant tumors:||malignant tumors,,,,,,,,,,,,,,,,
26073,,bv,,,,,,,,,,,,,,,,
26074,,aβ antibody drugs,,,,,,,,,,,,,,,,
26075,,causes;|prior ipsilateral stroke,,,,,,,,,,,,,,,,
26076,,pathological involvement,,,,,,,,,,,,,,,,
26077,,sensitivity to methylphenidate,,,,,,,,,,,,,,,,
26078,,endocrine disorder causes,,,,,,,,,,,,,,,,
26079,,lztr1 pathogenic mutation.|participant,,,,,,,,,,,,,,,,
26080,,left ventricular,,,,,,,,,,,,,,,,
26081,,diabetic neurophathy,,,,,,,,,,,,,,,,
26082,,serotonin syndrome,,,,,,,,,,,,,,,,
26083,,cseu la salle|not,,,,,,,,,,,,,,,,
26084,,urinary diversion|active infection|untreated cancer,,,,,,,,,,,,,,,,
26085,,hip conditions,,,,,,,,,,,,,,,,
26086,,palpebral conjunctival observations,,,,,,,,,,,,,,,,
26087,,comorbid illness,,,,,,,,,,,,,,,,
26088,,scleroderma.|silicone,,,,,,,,,,,,,,,,
26089,,femoral hernia,,,,,,,,,,,,,,,,
26090,,or|chronic myelomonocytic leukemia,,,,,,,,,,,,,,,,
26091,,central neurological involvement,,,,,,,,,,,,,,,,
26092,,radically resected carcinoma,,,,,,,,,,,,,,,,
26093,,renal function||renal impairment,,,,,,,,,,,,,,,,
26094,,upper airway pathology,,,,,,,,,,,,,,,,
26095,,lack of efficacy.|participant,,,,,,,,,,,,,,,,
26096,,lack of expected doubling,,,,,,,,,,,,,,,,
26097,,cord involvement,,,,,,,,,,,,,,,,
26098,,significant alcohol abuse,,,,,,,,,,,,,,,,
26099,,autoimmune disease|diagnosis,,,,,,,,,,,,,,,,
26100,,non-infectious myocarditis,,,,,,,,,,,,,,,,
26101,,choroidal detachment.|consents,,,,,,,,,,,,,,,,
26102,,radiologically measurable lesion,,,,,,,,,,,,,,,,
26103,,congenital myasthenia syndromes,,,,,,,,,,,,,,,,
26104,,uncomplicated pyelonephritis,,,,,,,,,,,,,,,,
26105,,symptoms consistent,,,,,,,,,,,,,,,,
26106,,non-antibiotic therapy,,,,,,,,,,,,,,,,
26107,,fainting spells,,,,,,,,,,,,,,,,
26108,,cavum,,,,,,,,,,,,,,,,
26109,,bacteria,,,,,,,,,,,,,,,,
26110,,hyperthyroidism|a,,,,,,,,,,,,,,,,
26111,,metallic slivers,,,,,,,,,,,,,,,,
26112,,noninvasive bladder cancer,,,,,,,,,,,,,,,,
26113,,pcnsl,,,,,,,,,,,,,,,,
26114,,recurrence of the,,,,,,,,,,,,,,,,
26115,,matched,,,,,,,,,,,,,,,,
26116,,pik3ca,,,,,,,,,,,,,,,,
26117,,multi-inhaler triple therapy,,,,,,,,,,,,,,,,
26118,,performed.)|hypocalcemia,,,,,,,,,,,,,,,,
26119,,normal anatomy,,,,,,,,,,,,,,,,
26120,,homozygous familial hypercholesterolaemia,,,,,,,,,,,,,,,,
26121,,follicular lymphoma,,,,,,,,,,,,,,,,
26122,,infection.|uncontrolled hypertension,,,,,,,,,,,,,,,,
26123,,valvular heart disease|prosthetic cardiac valves,,,,,,,,,,,,,,,,
26124,,uvb,,,,,,,,,,,,,,,,
26125,,regional wall motion,,,,,,,,,,,,,,,,
26126,,self-prone,,,,,,,,,,,,,,,,
26127,,basal skin cancer,,,,,,,,,,,,,,,,
26128,,mentally unable to answer the questionnaire|typical kidney colic pain,,,,,,,,,,,,,,,,
26129,,capecitabine)|possess,,,,,,,,,,,,,,,,
26130,,genetic disorder|preterm deliveries,,,,,,,,,,,,,,,,
26131,,supraclavicular lymphadenopathy,,,,,,,,,,,,,,,,
26132,,nonalcoholic fatty liver disease,,,,,,,,,,,,,,,,
26133,,brca carrier,,,,,,,,,,,,,,,,
26134,,consensus statement,,,,,,,,,,,,,,,,
26135,,clinical manifestations of rd,,,,,,,,,,,,,,,,
26136,,childhood febrile,,,,,,,,,,,,,,,,
26137,,adenocarcinoma of the pancreas,,,,,,,,,,,,,,,,
26138,,rehabilitation plan,,,,,,,,,,,,,,,,
26139,,brain by imaging,,,,,,,,,,,,,,,,
26140,,acceptable||,,,,,,,,,,,,,,,,
26141,,g12r,,,,,,,,,,,,,,,,
26142,,autoimmune disorders)|enrolment,,,,,,,,,,,,,,,,
26143,,leukopenia,,,,,,,,,,,,,,,,
26144,,france intergroupe syndrome,,,,,,,,,,,,,,,,
26145,,testing center,,,,,,,,,,,,,,,,
26146,,pulmonary disease|previous treatment,,,,,,,,,,,,,,,,
26147,,benign anorectal pathology,,,,,,,,,,,,,,,,
26148,,electrolyte imbalance,,,,,,,,,,,,,,,,
26149,,prevention.|for,,,,,,,,,,,,,,,,
26150,,management|patients,,,,,,,,,,,,,,,,
26151,,black female|not,,,,,,,,,,,,,,,,
26152,,craniospinal xrt,,,,,,,,,,,,,,,,
26153,,alport syndrome-hematuria,,,,,,,,,,,,,,,,
26154,,impairment,,,,,,,,,,,,,,,,
26155,,bone marrow biopsies,,,,,,,,,,,,,,,,
26156,,hepatitis b virus (hbv) surface antigen,,,,,,,,,,,,,,,,
26157,,insomnia disorder,,,,,,,,,,,,,,,,
26158,,open skin lesions,,,,,,,,,,,,,,,,
26159,,non-infectious pneumonitis,,,,,,,,,,,,,,,,
26160,,mri scan|known pregnancy,,,,,,,,,,,,,,,,
26161,,systemic antitumor therapies,,,,,,,,,,,,,,,,
26162,,resorption|external root resorption,,,,,,,,,,,,,,,,
26163,,medical history:||liver cirrhosis,,,,,,,,,,,,,,,,
26164,,oesophageal dysplasia,,,,,,,,,,,,,,,,
26165,,ercp-es,,,,,,,,,,,,,,,,
26166,,human papilloma virus,,,,,,,,,,,,,,,,
26167,,traditional medicine,,,,,,,,,,,,,,,,
26168,,iron preparations|patients,,,,,,,,,,,,,,,,
26169,,cervical condition,,,,,,,,,,,,,,,,
26170,,polio,,,,,,,,,,,,,,,,
26171,,granulocyte,,,,,,,,,,,,,,,,
26172,,tumor growth rate,,,,,,,,,,,,,,,,
26173,,transgender men|platelet count,,,,,,,,,,,,,,,,
26174,,ankylosing spondylitis|current infection,,,,,,,,,,,,,,,,
26175,,glucose-galactose malabsorption.|patients,,,,,,,,,,,,,,,,
26176,,ulcer lesions,,,,,,,,,,,,,,,,
26177,,aml)|known leptomeningeal disease,,,,,,,,,,,,,,,,
26178,,dislocation of the hip following the installation of the tha|revision,,,,,,,,,,,,,,,,
26179,,depressed mood,,,,,,,,,,,,,,,,
26180,,neurological illnesses,,,,,,,,,,,,,,,,
26181,,acute illness|major surgery,,,,,,,,,,,,,,,,
26182,,placenta previa bleeding,,,,,,,,,,,,,,,,
26183,,intolerance of the drugs used in the study.|combined,,,,,,,,,,,,,,,,
26184,,pose an unacceptable radiation safety risk,,,,,,,,,,,,,,,,
26185,,signs of epidermal loss,,,,,,,,,,,,,,,,
26186,,better|no,,,,,,,,,,,,,,,,
26187,,ct scan,,,,,,,,,,,,,,,,
26188,,medical disorder,,,,,,,,,,,,,,,,
26189,,nonaffective psychotic disorders,,,,,,,,,,,,,,,,
26190,,infarct|complete bundle branch blocks|symptomatic arrhythmias,,,,,,,,,,,,,,,,
26191,,instruments,,,,,,,,,,,,,,,,
26192,,gastrointestinal bleeding judged,,,,,,,,,,,,,,,,
26193,,risk pregnancy,,,,,,,,,,,,,,,,
26194,,tgm1-deficient arci|clinical diagnosis,,,,,,,,,,,,,,,,
26195,,unability to undergone,,,,,,,,,,,,,,,,
26196,,post-carotid endarterectomy,,,,,,,,,,,,,,,,
26197,,upper motor neuron disease,,,,,,,,,,,,,,,,
26198,,ductal carcinoma in situ treated,,,,,,,,,,,,,,,,
26199,,good health|consent,,,,,,,,,,,,,,,,
26200,,concomitant valve surgery.||,,,,,,,,,,,,,,,,
26201,,major depression|substance abuse,,,,,,,,,,,,,,,,
26202,,upper abdominal surgery,,,,,,,,,,,,,,,,
26203,,cancer-related treatment,,,,,,,,,,,,,,,,
26204,,post-cardiac injury syndromes,,,,,,,,,,,,,,,,
26205,,clotting disorder,,,,,,,,,,,,,,,,
26206,,"organ rejection30,31",,,,,,,,,,,,,,,,
26207,,carcinoma in situ of the,,,,,,,,,,,,,,,,
26208,,growth retardation,,,,,,,,,,,,,,,,
26209,,semi-permanent prosthesis,,,,,,,,,,,,,,,,
26210,,screening|organ dysfunction,,,,,,,,,,,,,,,,
26211,,pure squamous cell carcinoma,,,,,,,,,,,,,,,,
26212,,atherosclerotic,,,,,,,,,,,,,,,,
26213,,distal radius fractures,,,,,,,,,,,,,,,,
26214,,record,,,,,,,,,,,,,,,,
26215,,limits exercise capacity,,,,,,,,,,,,,,,,
26216,,robson scoring,,,,,,,,,,,,,,,,
26217,,team-patient alliance.|life expectancy,,,,,,,,,,,,,,,,
26218,,age|participants,,,,,,,,,,,,,,,,
26219,,conjunctival hyperemia,,,,,,,,,,,,,,,,
26220,,respiratory virus infection,,,,,,,,,,,,,,,,
26221,,traumatic brain injury|metal implantations,,,,,,,,,,,,,,,,
26222,,periocular rosacea,,,,,,,,,,,,,,,,
26223,,hemoglobinuria,,,,,,,,,,,,,,,,
26224,,compliant,,,,,,,,,,,,,,,,
26225,,qualified raters assess,,,,,,,,,,,,,,,,
26226,,mixed epithelial,,,,,,,,,,,,,,,,
26227,,primary tha,,,,,,,,,,,,,,,,
26228,,head trauma associated,,,,,,,,,,,,,,,,
26229,,lenalidomide treatment|uncontrolled hypertension,,,,,,,,,,,,,,,,
26230,,uncontrolled angina,,,,,,,,,,,,,,,,
26231,,pulmonary interstitial emphysema,,,,,,,,,,,,,,,,
26232,,anticoagulants|bladder obstruction,,,,,,,,,,,,,,,,
26233,,immunologic test;|for females,,,,,,,,,,,,,,,,
26234,,situ|concomitant diseases,,,,,,,,,,,,,,,,
26235,,pulmonary eosinophilic syndromes,,,,,,,,,,,,,,,,
26236,,refractory ascites,,,,,,,,,,,,,,,,
26237,,cardiac valve surgery;|previous cardiac surgery,,,,,,,,,,,,,,,,
26238,,neurosensory toxicity,,,,,,,,,,,,,,,,
26239,,inr)|hypercalcaemia,,,,,,,,,,,,,,,,
26240,,general pathology,,,,,,,,,,,,,,,,
26241,,sessions,,,,,,,,,,,,,,,,
26242,,derived preparations,,,,,,,,,,,,,,,,
26243,,somatic pathology,,,,,,,,,,,,,,,,
26244,,migraine attacks,,,,,,,,,,,,,,,,
26245,,nonoxynol-9 lubricant,,,,,,,,,,,,,,,,
26246,,risk factor(s),,,,,,,,,,,,,,,,
26247,,primary teeth in,,,,,,,,,,,,,,,,
26248,,airway malformation,,,,,,,,,,,,,,,,
26249,,proctitis,,,,,,,,,,,,,,,,
26250,,tinnitus maskers,,,,,,,,,,,,,,,,
26251,,disorders|adhesive capsulitis syndrome,,,,,,,,,,,,,,,,
26252,,wrinkles,,,,,,,,,,,,,,,,
26253,,minimum disease,,,,,,,,,,,,,,,,
26254,,functional loss,,,,,,,,,,,,,,,,
26255,,ankylosis,,,,,,,,,,,,,,,,
26256,,flare,,,,,,,,,,,,,,,,
26257,,disease of the central nervous system|patient,,,,,,,,,,,,,,,,
26258,,diabetes type i,,,,,,,,,,,,,,,,
26259,,sputum,,,,,,,,,,,,,,,,
26260,,pancreatic metastases,,,,,,,,,,,,,,,,
26261,,tongue swelling,,,,,,,,,,,,,,,,
26262,,autoimmune-associated uveitis,,,,,,,,,,,,,,,,
26263,,skin allergies|pregnancy,,,,,,,,,,,,,,,,
26264,,stomach surgeries,,,,,,,,,,,,,,,,
26265,,retinal oxygen saturation,,,,,,,,,,,,,,,,
26266,,open wounds,,,,,,,,,,,,,,,,
26267,,primary malignant tumor,,,,,,,,,,,,,,,,
26268,,avoiding exposure,,,,,,,,,,,,,,,,
26269,,mandibular joint dysfunction/disorder|participants,,,,,,,,,,,,,,,,
26270,,acute leukemias|patients,,,,,,,,,,,,,,,,
26271,,foreign objects in both wrists.|participants must agree to adhere to the lifestyle considerations.||healthy controls,,,,,,,,,,,,,,,,
26272,,pulmonary tuberculosis.|viral,,,,,,,,,,,,,,,,
26273,,progressive neurological disease,,,,,,,,,,,,,,,,
26274,,reference,,,,,,,,,,,,,,,,
26275,,gynecological diseases,,,,,,,,,,,,,,,,
26276,,compliance issues,,,,,,,,,,,,,,,,
26277,,kras g12c mutation,,,,,,,,,,,,,,,,
26278,,liver infiltration,,,,,,,,,,,,,,,,
26279,,surgeons,,,,,,,,,,,,,,,,
26280,,acute respiratory syndrome coronavirus,,,,,,,,,,,,,,,,
26281,,congestive heart failure|diagnosed,,,,,,,,,,,,,,,,
26282,,physically disabled|smoke,,,,,,,,,,,,,,,,
26283,,5q-sma established,,,,,,,,,,,,,,,,
26284,,chemotherapy|prostate cancer,,,,,,,,,,,,,,,,
26285,,melanoma in situ (mis),,,,,,,,,,,,,,,,
26286,,individuals|not,,,,,,,,,,,,,,,,
26287,,eligible.||active infection,,,,,,,,,,,,,,,,
26288,,dysfunctions|pregnancy,,,,,,,,,,,,,,,,
26289,,transfusion of platelets|subject,,,,,,,,,,,,,,,,
26290,,mucosal involvement,,,,,,,,,,,,,,,,
26291,,"dysphagia),|known abnormality",,,,,,,,,,,,,,,,
26292,,laparoscopic frey procedure.|patients,,,,,,,,,,,,,,,,
26293,,type 2 diabetes||if,,,,,,,,,,,,,,,,
26294,,classes,,,,,,,,,,,,,,,,
26295,,confirms,,,,,,,,,,,,,,,,
26296,,skin issues,,,,,,,,,,,,,,,,
26297,,culture,,,,,,,,,,,,,,,,
26298,,traumatic brain injury,,,,,,,,,,,,,,,,
26299,,uveitis|subject,,,,,,,,,,,,,,,,
26300,,impaired fasting glucose)|a,,,,,,,,,,,,,,,,
26301,,contra-indicate,,,,,,,,,,,,,,,,
26302,,cognition problems.|children,,,,,,,,,,,,,,,,
26303,,human epidermal growth factor receptor 2 (her2) status,,,,,,,,,,,,,,,,
26304,,structural brain,,,,,,,,,,,,,,,,
26305,,bronchodilator|cough,,,,,,,,,,,,,,,,
26306,,weeks|diagnosis,,,,,,,,,,,,,,,,
26307,,personal health,,,,,,,,,,,,,,,,
26308,,dsa)|total ischemia time,,,,,,,,,,,,,,,,
26309,,obstructive sleep apnea)|(2,,,,,,,,,,,,,,,,
26310,,renal transplantation.|the,,,,,,,,,,,,,,,,
26311,,end-stage organ disease,,,,,,,,,,,,,,,,
26312,,mmhg);|inability to swallow,,,,,,,,,,,,,,,,
26313,,ii disorder,,,,,,,,,,,,,,,,
26314,,rr-tb,,,,,,,,,,,,,,,,
26315,,acute leukemia).|receipt,,,,,,,,,,,,,,,,
26316,,primary pain conditions,,,,,,,,,,,,,,,,
26317,,type of smoking,,,,,,,,,,,,,,,,
26318,,lfs 5|fitzpatrick skin,,,,,,,,,,,,,,,,
26319,,foveal ischemia,,,,,,,,,,,,,,,,
26320,,acute safety concerns,,,,,,,,,,,,,,,,
26321,,allergic hypersensitivity,,,,,,,,,,,,,,,,
26322,,neurocognitive deficit,,,,,,,,,,,,,,,,
26323,,iced,,,,,,,,,,,,,,,,
26324,,adrenal enlargement).|has,,,,,,,,,,,,,,,,
26325,,chronic neurological disorder,,,,,,,,,,,,,,,,
26326,,pruritus,,,,,,,,,,,,,,,,
26327,,autoimmune sclerosing cholangitis,,,,,,,,,,,,,,,,
26328,,major depressive syndrome,,,,,,,,,,,,,,,,
26329,,cervical trauma,,,,,,,,,,,,,,,,
26330,,right first dorsal interosseous (fdi),,,,,,,,,,,,,,,,
26331,,primary neuromuscular disease,,,,,,,,,,,,,,,,
26332,,enrollment;|active infections,,,,,,,,,,,,,,,,
26333,,academic procrastination,,,,,,,,,,,,,,,,
26334,,impaired intestinal absorption,,,,,,,,,,,,,,,,
26335,,cellulitis,,,,,,,,,,,,,,,,
26336,,pituitary dysfunction|moderate/severe,,,,,,,,,,,,,,,,
26337,,cns3 disease,,,,,,,,,,,,,,,,
26338,,gastric cancer,,,,,,,,,,,,,,,,
26339,,abnormalities of the hypothalamic pituitary-adrenal,,,,,,,,,,,,,,,,
26340,,reduced their consumption,,,,,,,,,,,,,,,,
26341,,bleeding diseases,,,,,,,,,,,,,,,,
26342,,coagulation disorder,,,,,,,,,,,,,,,,
26343,,clear bleeding tendency,,,,,,,,,,,,,,,,
26344,,maxillary incisors|patients,,,,,,,,,,,,,,,,
26345,,evaluate events,,,,,,,,,,,,,,,,
26346,,pancreatitis.|unable to swallow,,,,,,,,,,,,,,,,
26347,,disease outside,,,,,,,,,,,,,,,,
26348,,tracheal intubation.||,,,,,,,,,,,,,,,,
26349,,tumor manifestations outside,,,,,,,,,,,,,,,,
26350,,hiv might,,,,,,,,,,,,,,,,
26351,,transsphenoidal,,,,,,,,,,,,,,,,
26352,,computer);|lives,,,,,,,,,,,,,,,,
26353,,chronic kidney disease (ckd),,,,,,,,,,,,,,,,
26354,,nose bleeds,,,,,,,,,,,,,,,,
26355,,situations,,,,,,,,,,,,,,,,
26356,,problems|endocrine diseases,,,,,,,,,,,,,,,,
26357,,feverfew,,,,,,,,,,,,,,,,
26358,,acute liver injury,,,,,,,,,,,,,,,,
26359,,infectious diseases;|a,,,,,,,,,,,,,,,,
26360,,pulmonary fibrosis);|had,,,,,,,,,,,,,,,,
26361,,hepatitis b (hbsag),,,,,,,,,,,,,,,,
26362,,uterine adhesions,,,,,,,,,,,,,,,,
26363,,esophageal diseases,,,,,,,,,,,,,,,,
26364,,impulse control disorder,,,,,,,,,,,,,,,,
26365,,squamous cell carcinoma (scc),,,,,,,,,,,,,,,,
26366,,neurodegenerative movement disorders,,,,,,,,,,,,,,,,
26367,,peripheral nerve disease,,,,,,,,,,,,,,,,
26368,,extracorporeal membrane oxygenation (ecmo),,,,,,,,,,,,,,,,
26369,,complete documentation.||,,,,,,,,,,,,,,,,
26370,,acute neurological deficits,,,,,,,,,,,,,,,,
26371,,neurological disease||25,,,,,,,,,,,,,,,,
26372,,"chronic vertigo,|chronic dizziness,|presence",,,,,,,,,,,,,,,,
26373,,sputum cultures,,,,,,,,,,,,,,,,
26374,,anticipates,,,,,,,,,,,,,,,,
26375,,moca)|common comorbid disorders,,,,,,,,,,,,,,,,
26376,,hepato-renal syndrome.|disease,,,,,,,,,,,,,,,,
26377,,hf,,,,,,,,,,,,,,,,
26378,,structured suicidal ideation,,,,,,,,,,,,,,,,
26379,,weakened immune system,,,,,,,,,,,,,,,,
26380,,proxy.|known allergy,,,,,,,,,,,,,,,,
26381,,prostate intraepithelial neoplasm,,,,,,,,,,,,,,,,
26382,,orbital injury/fracture).|rash,,,,,,,,,,,,,,,,
26383,,co-existent,,,,,,,,,,,,,,,,
26384,,risk of bleeding,,,,,,,,,,,,,,,,
26385,,pacemaker implantations,,,,,,,,,,,,,,,,
26386,,controllable atrial fibrillation,,,,,,,,,,,,,,,,
26387,,hematuria,,,,,,,,,,,,,,,,
26388,,bilateral tubal ligation,,,,,,,,,,,,,,,,
26389,,needed.|if actionable,,,,,,,,,,,,,,,,
26390,,criteria of ctu affiliated studies,,,,,,,,,,,,,,,,
26391,,psychiatric comorbidity,,,,,,,,,,,,,,,,
26392,,inadequate response,,,,,,,,,,,,,,,,
26393,,pre-treatment,,,,,,,,,,,,,,,,
26394,,chest wall deformity,,,,,,,,,,,,,,,,
26395,,socket type i.,,,,,,,,,,,,,,,,
26396,,health-care,,,,,,,,,,,,,,,,
26397,,distant metastatic lesions,,,,,,,,,,,,,,,,
26398,,traditional contraindications,,,,,,,,,,,,,,,,
26399,,ethics committee,,,,,,,,,,,,,,,,
26400,,psychological factors maintaining pain,,,,,,,,,,,,,,,,
26401,,non-dominant,,,,,,,,,,,,,,,,
26402,,active infection,,,,,,,,,,,,,,,,
26403,,cavity structures,,,,,,,,,,,,,,,,
26404,,metabolic liver disease,,,,,,,,,,,,,,,,
26405,,elbow injuries,,,,,,,,,,,,,,,,
26406,,sever hypertension,,,,,,,,,,,,,,,,
26407,,pregnancy criticall illness,,,,,,,,,,,,,,,,
26408,,cancer-associated myositis,,,,,,,,,,,,,,,,
26409,,pet)|patient exposed to analgesic,,,,,,,,,,,,,,,,
26410,,depressive mood disorder,,,,,,,,,,,,,,,,
26411,,perforation,,,,,,,,,,,,,,,,
26412,,pulmonary air leaks,,,,,,,,,,,,,,,,
26413,,heavy drinker,,,,,,,,,,,,,,,,
26414,,medication interactions|hemochromatosis,,,,,,,,,,,,,,,,
26415,,unilateral involvement,,,,,,,,,,,,,,,,
26416,,abnormal uterine bleeding,,,,,,,,,,,,,,,,
26417,,episodes of facial paralysis,,,,,,,,,,,,,,,,
26418,,chronic heart disease,,,,,,,,,,,,,,,,
26419,,this.|excessive weight loss,,,,,,,,,,,,,,,,
26420,,treatment data;|patients,,,,,,,,,,,,,,,,
26421,,allergic diseases,,,,,,,,,,,,,,,,
26422,,"identifiable causes""|the",,,,,,,,,,,,,,,,
26423,,psychosis risk syndrome,,,,,,,,,,,,,,,,
26424,,good function.||other protocol,,,,,,,,,,,,,,,,
26425,,mucosal bleeding,,,,,,,,,,,,,,,,
26426,,systemic embolism,,,,,,,,,,,,,,,,
26427,,study)|pregnancy,,,,,,,,,,,,,,,,
26428,,mediolateral,,,,,,,,,,,,,,,,
26429,,autoimmune (,,,,,,,,,,,,,,,,
26430,,peripheral va,,,,,,,,,,,,,,,,
26431,,aortic dissections confined to the ascending,,,,,,,,,,,,,,,,
26432,,glucose-galactose malabsorption|women,,,,,,,,,,,,,,,,
26433,,modified t cells,,,,,,,,,,,,,,,,
26434,,cardiac risk behaviors,,,,,,,,,,,,,,,,
26435,,rheumatoid arthritis)|pregnant women|prisoners|non-english speakers,,,,,,,,,,,,,,,,
26436,,hepatomegaly,,,,,,,,,,,,,,,,
26437,,progressive disease.||a,,,,,,,,,,,,,,,,
26438,,abnormalities of heart,,,,,,,,,,,,,,,,
26439,,serious depressive condition,,,,,,,,,,,,,,,,
26440,,seconder normal pressure hydrocephalus,,,,,,,,,,,,,,,,
26441,,functional dyspepsia,,,,,,,,,,,,,,,,
26442,,ischemic events,,,,,,,,,,,,,,,,
26443,,cap-classes,,,,,,,,,,,,,,,,
26444,,immunosuppressive drugs;|human immunodeficiency virus antibody (,,,,,,,,,,,,,,,,
26445,,oxidative stress,,,,,,,,,,,,,,,,
26446,,mild symptoms,,,,,,,,,,,,,,,,
26447,,suicidal ideation portion,,,,,,,,,,,,,,,,
26448,,diagnostic radiology,,,,,,,,,,,,,,,,
26449,,employed midwives,,,,,,,,,,,,,,,,
26450,,high-intermediate,,,,,,,,,,,,,,,,
26451,,months|current urinary tract infection|recent,,,,,,,,,,,,,,,,
26452,,metastatic colorectal adenocarcinoma|pre-registration,,,,,,,,,,,,,,,,
26453,,hypoglycemia,,,,,,,,,,,,,,,,
26454,,endoscopy trainers,,,,,,,,,,,,,,,,
26455,,tamponade,,,,,,,,,,,,,,,,
26456,,anaplastic lymphoma kinase (alk) status,,,,,,,,,,,,,,,,
26457,,secondary mcas,,,,,,,,,,,,,,,,
26458,,uterine rupture,,,,,,,,,,,,,,,,
26459,,greasy tongue coating,,,,,,,,,,,,,,,,
26460,,brain metastases|any,,,,,,,,,,,,,,,,
26461,,liver function test,,,,,,,,,,,,,,,,
26462,,anastomotic leak)|incomplete tumor removal,,,,,,,,,,,,,,,,
26463,,kyphosis).|inflammatory disorders,,,,,,,,,,,,,,,,
26464,,perennial nasal,,,,,,,,,,,,,,,,
26465,,adequate for tumor classification,,,,,,,,,,,,,,,,
26466,,course of disease,,,,,,,,,,,,,,,,
26467,,hereditary cns,,,,,,,,,,,,,,,,
26468,,foreign body removal,,,,,,,,,,,,,,,,
26469,,oral hygiene|alcoholism,,,,,,,,,,,,,,,,
26470,,disease severe,,,,,,,,,,,,,,,,
26471,,glaucomatous changes,,,,,,,,,,,,,,,,
26472,,dm,,,,,,,,,,,,,,,,
26473,,traditional cryo|pregnant,,,,,,,,,,,,,,,,
26474,,pituitary hormones,,,,,,,,,,,,,,,,
26475,,antiepileptic,,,,,,,,,,,,,,,,
26476,,richter's transformation.|active bleeding,,,,,,,,,,,,,,,,
26477,,acute coronary syndrome|high-sensitivity,,,,,,,,,,,,,,,,
26478,,large serous effusion,,,,,,,,,,,,,,,,
26479,,significant dermatologic cancers,,,,,,,,,,,,,,,,
26480,,delayed allergic reactions,,,,,,,,,,,,,,,,
26481,,hypoglycaemia.|pregnant,,,,,,,,,,,,,,,,
26482,,nafld|current cancer,,,,,,,,,,,,,,,,
26483,,programs|mental impairment leading,,,,,,,,,,,,,,,,
26484,,keratoconus,,,,,,,,,,,,,,,,
26485,,hypertonic saline,,,,,,,,,,,,,,,,
26486,,treatment.|participant,,,,,,,,,,,,,,,,
26487,,local site,,,,,,,,,,,,,,,,
26488,,repeatedly,,,,,,,,,,,,,,,,
26489,,organ impairment,,,,,,,,,,,,,,,,
26490,,adrenal diseases|history of,,,,,,,,,,,,,,,,
26491,,endocrine disorders|physical handicaps,,,,,,,,,,,,,,,,
26492,,in critical condition,,,,,,,,,,,,,,,,
26493,,pcl,,,,,,,,,,,,,,,,
26494,,criteria of the immunotherapy committee of the spanish society of allergy,,,,,,,,,,,,,,,,
26495,,obstructive sleep apnea|previous bariatric surgery|diagnosis,,,,,,,,,,,,,,,,
26496,,systemic manifestations,,,,,,,,,,,,,,,,
26497,,greater emphasis,,,,,,,,,,,,,,,,
26498,,acute care unit,,,,,,,,,,,,,,,,
26499,,dental treatment.|high dental anxiety,,,,,,,,,,,,,,,,
26500,,skin test,,,,,,,,,,,,,,,,
26501,,ivus,,,,,,,,,,,,,,,,
26502,,absorb oral,,,,,,,,,,,,,,,,
26503,,covid symptoms,,,,,,,,,,,,,,,,
26504,,acquired iron overload,,,,,,,,,,,,,,,,
26505,,mixed carcinoma components,,,,,,,,,,,,,,,,
26506,,kaposi sarcoma,,,,,,,,,,,,,,,,
26507,,tumor necrosis factor inhibitors,,,,,,,,,,,,,,,,
26508,,glioma|surgical urgency,,,,,,,,,,,,,,,,
26509,,stabilized conditions,,,,,,,,,,,,,,,,
26510,,disorders|intrauterine polyps|thrombophlebitis,,,,,,,,,,,,,,,,
26511,,presence,,,,,,,,,,,,,,,,
26512,,hallux rigidus,,,,,,,,,,,,,,,,
26513,,decubitus position|extreme heart rates,,,,,,,,,,,,,,,,
26514,,organic diseases,,,,,,,,,,,,,,,,
26515,,downloadable,,,,,,,,,,,,,,,,
26516,,disability,,,,,,,,,,,,,,,,
26517,,gynecological surgery|having,,,,,,,,,,,,,,,,
26518,,or|atopic dermatitis,,,,,,,,,,,,,,,,
26519,,acute myocarditis,,,,,,,,,,,,,,,,
26520,,junction adenocarcinoma,,,,,,,,,,,,,,,,
26521,,large pericardial effusion,,,,,,,,,,,,,,,,
26522,,metastasis tissue,,,,,,,,,,,,,,,,
26523,,bipolar disorder,,,,,,,,,,,,,,,,
26524,,care);|symptomatic osteoporotic vertebral compression,,,,,,,,,,,,,,,,
26525,,sickle trait,,,,,,,,,,,,,,,,
26526,,procedural revascularisation,,,,,,,,,,,,,,,,
26527,,surgical,,,,,,,,,,,,,,,,
26528,,serious disease,,,,,,,,,,,,,,,,
26529,,optic neuropathy progression,,,,,,,,,,,,,,,,
26530,,atherosclerotic coronary artery disease (cad),,,,,,,,,,,,,,,,
26531,,posterior cruciate ligament (pcl) deficiency,,,,,,,,,,,,,,,,
26532,,stage ct4a,,,,,,,,,,,,,,,,
26533,,comorbidity,,,,,,,,,,,,,,,,
26534,,pericardial effusion,,,,,,,,,,,,,,,,
26535,,septicemia,,,,,,,,,,,,,,,,
26536,,sickle cell trait,,,,,,,,,,,,,,,,
26537,,multicentric castleman disease.|active infection,,,,,,,,,,,,,,,,
26538,,speaking,,,,,,,,,,,,,,,,
26539,,calcinosis,,,,,,,,,,,,,,,,
26540,,prolonged qt interval.|subjects,,,,,,,,,,,,,,,,
26541,,anticoagulant treatment;|systemic infection;|injection,,,,,,,,,,,,,,,,
26542,,hiv-1 infection|age,,,,,,,,,,,,,,,,
26543,,contrast enhancement,,,,,,,,,,,,,,,,
26544,,cvd|neurodegenerative disease,,,,,,,,,,,,,,,,
26545,,pathological scar formation,,,,,,,,,,,,,,,,
26546,,ever been allergic to the test drug,,,,,,,,,,,,,,,,
26547,,t2dm||,,,,,,,,,,,,,,,,
26548,,radiologic finding,,,,,,,,,,,,,,,,
26549,,disease.|receiving immunotherapy|ability,,,,,,,,,,,,,,,,
26550,,etc.|skin diseases,,,,,,,,,,,,,,,,
26551,,donate sperm from,,,,,,,,,,,,,,,,
26552,,acute gallbladder disease,,,,,,,,,,,,,,,,
26553,,corneal scars,,,,,,,,,,,,,,,,
26554,,unresectable locoregional recurrence,,,,,,,,,,,,,,,,
26555,,infectious disease committee,,,,,,,,,,,,,,,,
26556,,gastrointestinal abnormalities,,,,,,,,,,,,,,,,
26557,,complexity,,,,,,,,,,,,,,,,
26558,,suicide.|bleeding disorder,,,,,,,,,,,,,,,,
26559,,acute coronary syndrome|patients,,,,,,,,,,,,,,,,
26560,,prior arm injury,,,,,,,,,,,,,,,,
26561,,dental work)|personal,,,,,,,,,,,,,,,,
26562,,adrenal insufficiency|clinically significant,,,,,,,,,,,,,,,,
26563,,blood diseases,,,,,,,,,,,,,,,,
26564,,biopsies,,,,,,,,,,,,,,,,
26565,,therapy.||measurable lesions,,,,,,,,,,,,,,,,
26566,,hypertrophic obstructive cardiomyopathy.|history,,,,,,,,,,,,,,,,
26567,,medical condition|alcohol,,,,,,,,,,,,,,,,
26568,,gastrointestinal event,,,,,,,,,,,,,,,,
26569,,systematic disease,,,,,,,,,,,,,,,,
26570,,hematogenous metastases;|ability,,,,,,,,,,,,,,,,
26571,,hbv-dna>2×103 iu/ml,,,,,,,,,,,,,,,,
26572,,specialized care,,,,,,,,,,,,,,,,
26573,,dialysis status|persistent pruritus,,,,,,,,,,,,,,,,
26574,,rapid rise,,,,,,,,,,,,,,,,
26575,,complex retinal detachment,,,,,,,,,,,,,,,,
26576,,nerve stimulator,,,,,,,,,,,,,,,,
26577,,chronic kidney disease,,,,,,,,,,,,,,,,
26578,,cerebrovascular accidents,,,,,,,,,,,,,,,,
26579,,colorectal cancer related follow-up||age,,,,,,,,,,,,,,,,
26580,,breast feeding|(7,,,,,,,,,,,,,,,,
26581,,diseases.|venipuncture intolerance,,,,,,,,,,,,,,,,
26582,,allergic reactions,,,,,,,,,,,,,,,,
26583,,lotions,,,,,,,,,,,,,,,,
26584,,end the surgery|preoperative adjuvant therapy was given|clinical data are seriously missing,,,,,,,,,,,,,,,,
26585,,refractory to standard treatment,,,,,,,,,,,,,,,,
26586,,myocardial ischemia myocardial infarction cardiomyopathy,,,,,,,,,,,,,,,,
26587,,diabetes,,,,,,,,,,,,,,,,
26588,,systemic effects,,,,,,,,,,,,,,,,
26589,,symptomatic diseases,,,,,,,,,,,,,,,,
26590,,bacitracin|pregnant,,,,,,,,,,,,,,,,
26591,,aom,,,,,,,,,,,,,,,,
26592,,retinal vasculitis,,,,,,,,,,,,,,,,
26593,,end-stage liver failure,,,,,,,,,,,,,,,,
26594,,dysautonomia,,,,,,,,,,,,,,,,
26595,,congestive heart failure;|unstable angina,,,,,,,,,,,,,,,,
26596,,heart failure|a,,,,,,,,,,,,,,,,
26597,,recurrence lesion,,,,,,,,,,,,,,,,
26598,,isr).|≥ 2 lesions,,,,,,,,,,,,,,,,
26599,,disc diameter,,,,,,,,,,,,,,,,
26600,,congenital malformations,,,,,,,,,,,,,,,,
26601,,successfully cross,,,,,,,,,,,,,,,,
26602,,urge incontinence,,,,,,,,,,,,,,,,
26603,,contraindication,,,,,,,,,,,,,,,,
26604,,staying of the baby in the neonatal intensive care unit|34,,,,,,,,,,,,,,,,
26605,,example epilepsy,,,,,,,,,,,,,,,,
26606,,sign of hf,,,,,,,,,,,,,,,,
26607,,lateral semicircular canal (,,,,,,,,,,,,,,,,
26608,,osteomyelitis;|diabetic peripheral neuropathy;|homozygous familial hypercholesterolemia;|absolute contraindication,,,,,,,,,,,,,,,,
26609,,chronic atrial fibrillation,,,,,,,,,,,,,,,,
26610,,lower respiratory infection,,,,,,,,,,,,,,,,
26611,,recist 1.1)|able and,,,,,,,,,,,,,,,,
26612,,virginia commonwealth,,,,,,,,,,,,,,,,
26613,,alcoholism,,,,,,,,,,,,,,,,
26614,,shoulder arthroplasty,,,,,,,,,,,,,,,,
26615,,seropositivity for hiv,,,,,,,,,,,,,,,,
26616,,cuboid bone,,,,,,,,,,,,,,,,
26617,,postural orthostatic tachycardia syndrome,,,,,,,,,,,,,,,,
26618,,renal disorders,,,,,,,,,,,,,,,,
26619,,conducting test.|hearing loss,,,,,,,,,,,,,,,,
26620,,adrenal dysfunction,,,,,,,,,,,,,,,,
26621,,congenital foot deformities cognitive impairments,,,,,,,,,,,,,,,,
26622,,"localized, dermatomal herpes",,,,,,,,,,,,,,,,
26623,,months|excessive alcohol consumption,,,,,,,,,,,,,,,,
26624,,selections,,,,,,,,,,,,,,,,
26625,,renal denervation|systolic heart failure,,,,,,,,,,,,,,,,
26626,,kidney function,,,,,,,,,,,,,,,,
26627,,singleton pregnancy|age,,,,,,,,,,,,,,,,
26628,,acute condition,,,,,,,,,,,,,,,,
26629,,hypertension;||arrhythmia,,,,,,,,,,,,,,,,
26630,,acute pain measure,,,,,,,,,,,,,,,,
26631,,duodenal carcinoma,,,,,,,,,,,,,,,,
26632,,albumin supplementation,,,,,,,,,,,,,,,,
26633,,chemotherapy;|concomitant,,,,,,,,,,,,,,,,
26634,,poor behavior,,,,,,,,,,,,,,,,
26635,,liver inflammation,,,,,,,,,,,,,,,,
26636,,cohorts c4,,,,,,,,,,,,,,,,
26637,,myeloid metastases.||oligoresidual after,,,,,,,,,,,,,,,,
26638,,coagulation problems,,,,,,,,,,,,,,,,
26639,,ventricle hemorrhage,,,,,,,,,,,,,,,,
26640,,liver invasion,,,,,,,,,,,,,,,,
26641,,term neonate,,,,,,,,,,,,,,,,
26642,,herniation,,,,,,,,,,,,,,,,
26643,,stressor,,,,,,,,,,,,,,,,
26644,,anterior wall calcification of the target common femoral artery,,,,,,,,,,,,,,,,
26645,,hematologic disorders,,,,,,,,,,,,,,,,
26646,,lactation.|thyroid dysfunction.|peripheral neuropathy,,,,,,,,,,,,,,,,
26647,,diabetes mellitus|uncontrolled hypertension,,,,,,,,,,,,,,,,
26648,,isolated myc,,,,,,,,,,,,,,,,
26649,,sedentary lifestyle,,,,,,,,,,,,,,,,
26650,,continued activity of pericarditis,,,,,,,,,,,,,,,,
26651,,bloody stools,,,,,,,,,,,,,,,,
26652,,new onset angina,,,,,,,,,,,,,,,,
26653,,vital prognosis;|diagnosis,,,,,,,,,,,,,,,,
26654,,adrenal diseases,,,,,,,,,,,,,,,,
26655,,skin epithelial carcinoma,,,,,,,,,,,,,,,,
26656,,pancreatic injury,,,,,,,,,,,,,,,,
26657,,cohort 3|have,,,,,,,,,,,,,,,,
26658,,glucose-6-phosphate dehydrogenase deficiency.|patients,,,,,,,,,,,,,,,,
26659,,burkitt's lymphoma.|history,,,,,,,,,,,,,,,,
26660,,somatic mutations,,,,,,,,,,,,,,,,
26661,,heterosexually active,,,,,,,,,,,,,,,,
26662,,cytological diagnosis;|partial response (pr),,,,,,,,,,,,,,,,
26663,,months;|fertile,,,,,,,,,,,,,,,,
26664,,myocardial infarction recovery period,,,,,,,,,,,,,,,,
26665,,shoulder.|osteoporosis,,,,,,,,,,,,,,,,
26666,,esophageal cancer,,,,,,,,,,,,,,,,
26667,,glioma.|undergo glioma,,,,,,,,,,,,,,,,
26668,,inadequate distal outflow.|significant inflow disease.|acute,,,,,,,,,,,,,,,,
26669,,acute valve thrombosis,,,,,,,,,,,,,,,,
26670,,dpi,,,,,,,,,,,,,,,,
26671,,convexity,,,,,,,,,,,,,,,,
26672,,perihilar cholangiocarcinoma,,,,,,,,,,,,,,,,
26673,,motor disorder,,,,,,,,,,,,,,,,
26674,,keratinized gingiva,,,,,,,,,,,,,,,,
26675,,adenosquamous carcinoma,,,,,,,,,,,,,,,,
26676,,possible radiologic bone loss.||localized gingivitis,,,,,,,,,,,,,,,,
26677,,nasopharyngeal carcinomas,,,,,,,,,,,,,,,,
26678,,solid disease,,,,,,,,,,,,,,,,
26679,,metastatic disease||registration,,,,,,,,,,,,,,,,
26680,,urinary tract infection|gynecological cancer,,,,,,,,,,,,,,,,
26681,,lipid atrophy diabetes,,,,,,,,,,,,,,,,
26682,,early enteral nutrition||patients,,,,,,,,,,,,,,,,
26683,,permanent deformity,,,,,,,,,,,,,,,,
26684,,transplantation.||active hepatitis,,,,,,,,,,,,,,,,
26685,,goi,,,,,,,,,,,,,,,,
26686,,coeliac disease,,,,,,,,,,,,,,,,
26687,,criteria of the 1990 acr,,,,,,,,,,,,,,,,
26688,,psychiatric pathology,,,,,,,,,,,,,,,,
26689,,transitory ischemic stroke,,,,,,,,,,,,,,,,
26690,,terminal diseases,,,,,,,,,,,,,,,,
26691,,solid organ dysfunction,,,,,,,,,,,,,,,,
26692,,acute porphyria,,,,,,,,,,,,,,,,
26693,,iii)|congestive heart failure,,,,,,,,,,,,,,,,
26694,,peritoneal spread,,,,,,,,,,,,,,,,
26695,,pain developers,,,,,,,,,,,,,,,,
26696,,study|homozygosity,,,,,,,,,,,,,,,,
26697,,refractory definition,,,,,,,,,,,,,,,,
26698,,acute respiratory distress syndrome,,,,,,,,,,,,,,,,
26699,,clinical manifestations of covid-19,,,,,,,,,,,,,,,,
26700,,aortic valve disease|left ventricular ejection fraction,,,,,,,,,,,,,,,,
26701,,extrahepatic obstruction,,,,,,,,,,,,,,,,
26702,,peroneal vessels,,,,,,,,,,,,,,,,
26703,,2|metastatic disease,,,,,,,,,,,,,,,,
26704,,major depressive disorder.|have,,,,,,,,,,,,,,,,
26705,,primary immunodeficiency diseases,,,,,,,,,,,,,,,,
26706,,mucosal areas,,,,,,,,,,,,,,,,
26707,,obsessive compulsive disorder.|current,,,,,,,,,,,,,,,,
26708,,high-risk comorbidities,,,,,,,,,,,,,,,,
26709,,acne|patient,,,,,,,,,,,,,,,,
26710,,neuroglycopenic symptoms,,,,,,,,,,,,,,,,
26711,,flt3 mutations|uncontrolled bacterial,,,,,,,,,,,,,,,,
26712,,haematological disease,,,,,,,,,,,,,,,,
26713,,orthopaedic conditions,,,,,,,,,,,,,,,,
26714,,chronic inflammation,,,,,,,,,,,,,,,,
26715,,tumor histopathology should,,,,,,,,,,,,,,,,
26716,,carcinosarcoma,,,,,,,,,,,,,,,,
26717,,carcinoma in situ of the uterine cervix,,,,,,,,,,,,,,,,
26718,,neurologic disease.|the dose,,,,,,,,,,,,,,,,
26719,,as:|clinical lacunar stroke syndrome,,,,,,,,,,,,,,,,
26720,,symptomatic condition,,,,,,,,,,,,,,,,
26721,,bariatric surgery|current,,,,,,,,,,,,,,,,
26722,,leucoderma,,,,,,,,,,,,,,,,
26723,,dadih's vla,,,,,,,,,,,,,,,,
26724,,persistent reactions,,,,,,,,,,,,,,,,
26725,,women;|regular drinking history,,,,,,,,,,,,,,,,
26726,,alopecia,,,,,,,,,,,,,,,,
26727,,chronic tranquilizer,,,,,,,,,,,,,,,,
26728,,extramedullary infiltration,,,,,,,,,,,,,,,,
26729,,known infection,,,,,,,,,,,,,,,,
26730,,embolic events,,,,,,,,,,,,,,,,
26731,,liver metastases alat,,,,,,,,,,,,,,,,
26732,,endometrial cancer,,,,,,,,,,,,,,,,
26733,,chronic medical condition/s,,,,,,,,,,,,,,,,
26734,,biological cancer,,,,,,,,,,,,,,,,
26735,,pectus excavatum,,,,,,,,,,,,,,,,
26736,,non-infected,,,,,,,,,,,,,,,,
26737,,non-endometrioid histologies,,,,,,,,,,,,,,,,
26738,,reports,,,,,,,,,,,,,,,,
26739,,spanish|ability,,,,,,,,,,,,,,,,
26740,,drug instructions,,,,,,,,,,,,,,,,
26741,,antiepileptic drugs.||,,,,,,,,,,,,,,,,
26742,,hot flashes,,,,,,,,,,,,,,,,
26743,,legs into leg trays,,,,,,,,,,,,,,,,
26744,,right upper quadrant,,,,,,,,,,,,,,,,
26745,,kidney cancer,,,,,,,,,,,,,,,,
26746,,structural congenital heart defect,,,,,,,,,,,,,,,,
26747,,organ function;|pulmonary inflammation,,,,,,,,,,,,,,,,
26748,,breast cancer records,,,,,,,,,,,,,,,,
26749,,higher neuropathy,,,,,,,,,,,,,,,,
26750,,death occurred,,,,,,,,,,,,,,,,
26751,,bronchopulmonary dysplasia,,,,,,,,,,,,,,,,
26752,,medicine|chronic diseases,,,,,,,,,,,,,,,,
26753,,persistent infection,,,,,,,,,,,,,,,,
26754,,acute ischemic stroke.||,,,,,,,,,,,,,,,,
26755,,peptic ulcer disease|ability,,,,,,,,,,,,,,,,
26756,,physical dysfunction,,,,,,,,,,,,,,,,
26757,,muscle pains,,,,,,,,,,,,,,,,
26758,,lenalidomide treatment;|platelet transfusion dependent,,,,,,,,,,,,,,,,
26759,,mri|structural brain lesion,,,,,,,,,,,,,,,,
26760,,old|occasional sleep problems,,,,,,,,,,,,,,,,
26761,,anti-tumor,,,,,,,,,,,,,,,,
26762,,cardiac,,,,,,,,,,,,,,,,
26763,,assessment team member.|clinical,,,,,,,,,,,,,,,,
26764,,vaginal bleeding.|administration of live vaccine,,,,,,,,,,,,,,,,
26765,,bite.|poor oral hygiene,,,,,,,,,,,,,,,,
26766,,solid organ transplantation;|uncontrollable,,,,,,,,,,,,,,,,
26767,,+1.50d & +1.75d||be willing,,,,,,,,,,,,,,,,
26768,,sars-cov-2.|participant,,,,,,,,,,,,,,,,
26769,,arrythmia|unstable,,,,,,,,,,,,,,,,
26770,,muscle aches,,,,,,,,,,,,,,,,
26771,,guillain-barre syndrome.|alcohol,,,,,,,,,,,,,,,,
26772,,basal ganglia,,,,,,,,,,,,,,,,
26773,,in situ cancers.|concomitant treatment,,,,,,,,,,,,,,,,
26774,,gingivitis/periodontitis,,,,,,,,,,,,,,,,
26775,,relapse,,,,,,,,,,,,,,,,
26776,,cyclosporine).|present alcohol,,,,,,,,,,,,,,,,
26777,,study.|regular alcohol consumption,,,,,,,,,,,,,,,,
26778,,gender;|differentiated thyroid carcinoma (dtc),,,,,,,,,,,,,,,,
26779,,ards,,,,,,,,,,,,,,,,
26780,,inflammatory gastrointestinal disease|gastrointestinal illness,,,,,,,,,,,,,,,,
26781,,extractions,,,,,,,,,,,,,,,,
26782,,brain metastasis|active autoimmune diseases,,,,,,,,,,,,,,,,
26783,,cmpfd,,,,,,,,,,,,,,,,
26784,,fancc,,,,,,,,,,,,,,,,
26785,,feeling like you can't think,,,,,,,,,,,,,,,,
26786,,macular hole)|documented amblyopia of surgical eye,,,,,,,,,,,,,,,,
26787,,addictive disorders,,,,,,,,,,,,,,,,
26788,,hepatitis infection,,,,,,,,,,,,,,,,
26789,,involvement of the cns,,,,,,,,,,,,,,,,
26790,,endocarditis,,,,,,,,,,,,,,,,
26791,,left heart diseases,,,,,,,,,,,,,,,,
26792,,mechanical heart,,,,,,,,,,,,,,,,
26793,,myocardial infarction|with,,,,,,,,,,,,,,,,
26794,,acute coronary syndrome|target lesion,,,,,,,,,,,,,,,,
26795,,surgery|acute kidney failure,,,,,,,,,,,,,,,,
26796,,pathological feature,,,,,,,,,,,,,,,,
26797,,extracranial metastases,,,,,,,,,,,,,,,,
26798,,physical impairment,,,,,,,,,,,,,,,,
26799,,coronary vasomotor abnormalities,,,,,,,,,,,,,,,,
26800,,mixed ibs,,,,,,,,,,,,,,,,
26801,,significant illness,,,,,,,,,,,,,,,,
26802,,criteria of the american college of rheumatology,,,,,,,,,,,,,,,,
26803,,iodine allergy,,,,,,,,,,,,,,,,
26804,,benign lesions,,,,,,,,,,,,,,,,
26805,,difficulty understanding the patient)|patient,,,,,,,,,,,,,,,,
26806,,hepatitis b virus dna,,,,,,,,,,,,,,,,
26807,,axin1/2,,,,,,,,,,,,,,,,
26808,,non-opposition,,,,,,,,,,,,,,,,
26809,,ild/pneumonia,,,,,,,,,,,,,,,,
26810,,products containing dihydroepiandrostenedione,,,,,,,,,,,,,,,,
26811,,np swab taken,,,,,,,,,,,,,,,,
26812,,sarcoidosis.|age,,,,,,,,,,,,,,,,
26813,,psychological disorders|use of drugs affect central nervous system|substance abuse|chronic pain|pregnancy|seizure disorders|cardiovascular,,,,,,,,,,,,,,,,
26814,,generalized epilepsy,,,,,,,,,,,,,,,,
26815,,major ocular,,,,,,,,,,,,,,,,
26816,,v.1.1,,,,,,,,,,,,,,,,
26817,,pet from,,,,,,,,,,,,,,,,
26818,,hydrosalpinx,,,,,,,,,,,,,,,,
26819,,extra nodal lesions,,,,,,,,,,,,,,,,
26820,,cancer;|mucous carcinoma,,,,,,,,,,,,,,,,
26821,,diabetic feet,,,,,,,,,,,,,,,,
26822,,flexion contracture,,,,,,,,,,,,,,,,
26823,,imaging t stage are noted,,,,,,,,,,,,,,,,
26824,,carfilzomib-related,,,,,,,,,,,,,,,,
26825,,unresectable,,,,,,,,,,,,,,,,
26826,,acute pharyngitis,,,,,,,,,,,,,,,,
26827,,sexual orientations,,,,,,,,,,,,,,,,
26828,,residual tumor,,,,,,,,,,,,,,,,
26829,,impella cp,,,,,,,,,,,,,,,,
26830,,serous ovarian cancer,,,,,,,,,,,,,,,,
26831,,normal sensation,,,,,,,,,,,,,,,,
26832,,obstructive eustachian tube dysfunction,,,,,,,,,,,,,,,,
26833,,bleeding diathesis.|uncontrolled haemorrhage,,,,,,,,,,,,,,,,
26834,,severe features,,,,,,,,,,,,,,,,
26835,,part.||reasons,,,,,,,,,,,,,,,,
26836,,transperineal,,,,,,,,,,,,,,,,
26837,,neuroendocrine systems diseases,,,,,,,,,,,,,,,,
26838,,consent.|currently use diapers,,,,,,,,,,,,,,,,
26839,,primary liver disease,,,,,,,,,,,,,,,,
26840,,infections;|poor blood glucose,,,,,,,,,,,,,,,,
26841,,non-surgical root,,,,,,,,,,,,,,,,
26842,,judged by the investigator to be stable may be enrolled);|known hcv infection;|primary biliary,,,,,,,,,,,,,,,,
26843,,neoplasia,,,,,,,,,,,,,,,,
26844,,metastatic ln,,,,,,,,,,,,,,,,
26845,,chemotherapy.|active hemoptysis,,,,,,,,,,,,,,,,
26846,,duodenal mucosal,,,,,,,,,,,,,,,,
26847,,myelodysplasia,,,,,,,,,,,,,,,,
26848,,medial termination,,,,,,,,,,,,,,,,
26849,,sexual behavior,,,,,,,,,,,,,,,,
26850,,language difficulties,,,,,,,,,,,,,,,,
26851,,myopia defocus glasses,,,,,,,,,,,,,,,,
26852,,outcome assessments|lack of access,,,,,,,,,,,,,,,,
26853,,inflammatory breast,,,,,,,,,,,,,,,,
26854,,physical comorbidities:|active cancer,,,,,,,,,,,,,,,,
26855,,systemic lupus erythematosus,,,,,,,,,,,,,,,,
26856,,scale|women,,,,,,,,,,,,,,,,
26857,,vertebrobasilar insufficiency,,,,,,,,,,,,,,,,
26858,,adequate surgical tumor tissue,,,,,,,,,,,,,,,,
26859,,essential fatty acids,,,,,,,,,,,,,,,,
26860,,glucose-galactose malabortion|a,,,,,,,,,,,,,,,,
26861,,coagulation profiles,,,,,,,,,,,,,,,,
26862,,hemorrhage.|congestive heart failure,,,,,,,,,,,,,,,,
26863,,gastrointestinal cancer|have,,,,,,,,,,,,,,,,
26864,,antibodies)|endocrine pathology,,,,,,,,,,,,,,,,
26865,,rasopathy,,,,,,,,,,,,,,,,
26866,,massive internal,,,,,,,,,,,,,,,,
26867,,medical contraindication,,,,,,,,,,,,,,,,
26868,,salicylates,,,,,,,,,,,,,,,,
26869,,cmv infection,,,,,,,,,,,,,,,,
26870,,collateral branches;|hemodynamic instability,,,,,,,,,,,,,,,,
26871,,screener)|current psychosis,,,,,,,,,,,,,,,,
26872,,airway allergic,,,,,,,,,,,,,,,,
26873,,parturiente,,,,,,,,,,,,,,,,
26874,,prolonged qtc interval|concomitant,,,,,,,,,,,,,,,,
26875,,proteasome inhibitor,,,,,,,,,,,,,,,,
26876,,reproductive childbearing potential,,,,,,,,,,,,,,,,
26877,,pack-years|signature,,,,,,,,,,,,,,,,
26878,,immunotherapy|brain metastases connective tissue disease,,,,,,,,,,,,,,,,
26879,,pf-07081532,,,,,,,,,,,,,,,,
26880,,brain parenchymal,,,,,,,,,,,,,,,,
26881,,glucagonoma,,,,,,,,,,,,,,,,
26882,,nondisabled participants:||health issues,,,,,,,,,,,,,,,,
26883,,genders|blunt head trauma,,,,,,,,,,,,,,,,
26884,,metastases to the axillary lymph nodes,,,,,,,,,,,,,,,,
26885,,non-malignant,,,,,,,,,,,,,,,,
26886,,amount of,,,,,,,,,,,,,,,,
26887,,in,,,,,,,,,,,,,,,,
26888,,combining inhibit ovulation,,,,,,,,,,,,,,,,
26889,,mentally healthy,,,,,,,,,,,,,,,,
26890,,foundationone cdx cancer genome,,,,,,,,,,,,,,,,
26891,,specific personality disorder,,,,,,,,,,,,,,,,
26892,,or||ii,,,,,,,,,,,,,,,,
26893,,abdominal wall hernia|refusal,,,,,,,,,,,,,,,,
26894,,detectable viral infection,,,,,,,,,,,,,,,,
26895,,non rhumatic heart disease,,,,,,,,,,,,,,,,
26896,,cutaneous basal,,,,,,,,,,,,,,,,
26897,,exotropia,,,,,,,,,,,,,,,,
26898,,gastroesophageal cancer,,,,,,,,,,,,,,,,
26899,,nsai,,,,,,,,,,,,,,,,
26900,,carotid bruits,,,,,,,,,,,,,,,,
26901,,large visual field defects,,,,,,,,,,,,,,,,
26902,,avoiding lactose,,,,,,,,,,,,,,,,
26903,,menstrual period,,,,,,,,,,,,,,,,
26904,,psoriasis,,,,,,,,,,,,,,,,
26905,,mood disturbance,,,,,,,,,,,,,,,,
26906,,nonischemic causes,,,,,,,,,,,,,,,,
26907,,tonsils,,,,,,,,,,,,,,,,
26908,,mean whole mouth tpi score,,,,,,,,,,,,,,,,
26909,,degenerative lumbar disease|age,,,,,,,,,,,,,,,,
26910,,other lung diseases,,,,,,,,,,,,,,,,
26911,,intracranial lesion,,,,,,,,,,,,,,,,
26912,,natural resolution,,,,,,,,,,,,,,,,
26913,,planned|inflammatory bowel disease (ibd),,,,,,,,,,,,,,,,
26914,,infection of any aetiology,,,,,,,,,,,,,,,,
26915,,end-stage kidney disease,,,,,,,,,,,,,,,,
26916,,dependent persons|emergency procedure,,,,,,,,,,,,,,,,
26917,,axial disorder,,,,,,,,,,,,,,,,
26918,,heart conditions,,,,,,,,,,,,,,,,
26919,,soft drinks,,,,,,,,,,,,,,,,
26920,,condition.|patients,,,,,,,,,,,,,,,,
26921,,cirrhosis of the liver,,,,,,,,,,,,,,,,
26922,,local paravertebral tenderness||,,,,,,,,,,,,,,,,
26923,,significant disease,,,,,,,,,,,,,,,,
26924,,contraceptive skin patch,,,,,,,,,,,,,,,,
26925,,unresolved issues,,,,,,,,,,,,,,,,
26926,,cm.||prior checkpoint inhibitor therapy,,,,,,,,,,,,,,,,
26927,,circumferential defect,,,,,,,,,,,,,,,,
26928,,drug side effects,,,,,,,,,,,,,,,,
26929,,and||diagnosis,,,,,,,,,,,,,,,,
26930,,facial trauma,,,,,,,,,,,,,,,,
26931,,brain herniation,,,,,,,,,,,,,,,,
26932,,inflammatory myofibroblastic sarcoma,,,,,,,,,,,,,,,,
26933,,spinal cord stimulator trial,,,,,,,,,,,,,,,,
26934,,obstructive cause of od,,,,,,,,,,,,,,,,
26935,,mucinous adenocarcinoma.|dmmr,,,,,,,,,,,,,,,,
26936,,organic disease,,,,,,,,,,,,,,,,
26937,,cervical cancer in situ treated,,,,,,,,,,,,,,,,
26938,,infection herpes simplex,,,,,,,,,,,,,,,,
26939,,heart implants|require a hearing aid to hear properly|claustrophobia|metal fragments,,,,,,,,,,,,,,,,
26940,,active ulcers,,,,,,,,,,,,,,,,
26941,,metastatic brain lesion,,,,,,,,,,,,,,,,
26942,,spinal cord stimulation,,,,,,,,,,,,,,,,
26943,,endocrinological disorder,,,,,,,,,,,,,,,,
26944,,congenital long qt syndrome.|history of stroke,,,,,,,,,,,,,,,,
26945,,neurologic / seizure,,,,,,,,,,,,,,,,
26946,,drug administration.|,,,,,,,,,,,,,,,,
26947,,mild mood dysphoria,,,,,,,,,,,,,,,,
26948,,peripheral nerve pathology,,,,,,,,,,,,,,,,
26949,,heart failure|severe ventricular rhythm disorders|severe functional limitation,,,,,,,,,,,,,,,,
26950,,android operating system|being able to use a mobile application||,,,,,,,,,,,,,,,,
26951,,vsd,,,,,,,,,,,,,,,,
26952,,dysplasia-associated lesions,,,,,,,,,,,,,,,,
26953,,etc)|schizophrenia,,,,,,,,,,,,,,,,
26954,,weight loss procedure,,,,,,,,,,,,,,,,
26955,,established covid-19 disease,,,,,,,,,,,,,,,,
26956,,hcv rna,,,,,,,,,,,,,,,,
26957,,not tolerate,,,,,,,,,,,,,,,,
26958,,implantable defibrillators,,,,,,,,,,,,,,,,
26959,,normal hearing thresholds,,,,,,,,,,,,,,,,
26960,,primary diabetes,,,,,,,,,,,,,,,,
26961,,control|not,,,,,,,,,,,,,,,,
26962,,congenital long qt syndrome.|qt interval corrected,,,,,,,,,,,,,,,,
26963,,chronic dialysis|hemodynamic monitoring,,,,,,,,,,,,,,,,
26964,,cancer thrombosis,,,,,,,,,,,,,,,,
26965,,muscle strength||exclusion,,,,,,,,,,,,,,,,
26966,,either:||1,,,,,,,,,,,,,,,,
26967,,chronic disorders,,,,,,,,,,,,,,,,
26968,,extramedullary relapse,,,,,,,,,,,,,,,,
26969,,non-hdl-c levels,,,,,,,,,,,,,,,,
26970,,difficulty.|negative serum,,,,,,,,,,,,,,,,
26971,,breast-feeding|fever,,,,,,,,,,,,,,,,
26972,,ganglioma,,,,,,,,,,,,,,,,
26973,,immature,,,,,,,,,,,,,,,,
26974,,extensive abdominal,,,,,,,,,,,,,,,,
26975,,hyperemia,,,,,,,,,,,,,,,,
26976,,oligomenorrhea,,,,,,,,,,,,,,,,
26977,,respiratory disorder,,,,,,,,,,,,,,,,
26978,,fibrosis;|chronic hbv infected,,,,,,,,,,,,,,,,
26979,,human immunodeficiency virus [hiv],,,,,,,,,,,,,,,,
26980,,superficial basal cell carcinoma.|disease,,,,,,,,,,,,,,,,
26981,,thoracic lymph nodes,,,,,,,,,,,,,,,,
26982,,cerebral feeding artery,,,,,,,,,,,,,,,,
26983,,metabolic syndrome;|clinical,,,,,,,,,,,,,,,,
26984,,renal medullary carcinoma,,,,,,,,,,,,,,,,
26985,,hypercalcemia|neurodevelopmental disabilities of the lar/parent/guardian/caregiver,,,,,,,,,,,,,,,,
26986,,st john's wort.|participant,,,,,,,,,,,,,,,,
26987,,hereditary,,,,,,,,,,,,,,,,
26988,,uspi,,,,,,,,,,,,,,,,
26989,,vein thrombosis,,,,,,,,,,,,,,,,
26990,,smoldering mm|suffering from,,,,,,,,,,,,,,,,
26991,,her2,,,,,,,,,,,,,,,,
26992,,consistent infectious disease specialist care,,,,,,,,,,,,,,,,
26993,,sleep apnoea syndrome,,,,,,,,,,,,,,,,
26994,,syndrome|congenital pneumonia,,,,,,,,,,,,,,,,
26995,,multiple organ dysfunction,,,,,,,,,,,,,,,,
26996,,significant trauma,,,,,,,,,,,,,,,,
26997,,unable to undergo mri,,,,,,,,,,,,,,,,
26998,,ihc 2+,,,,,,,,,,,,,,,,
26999,,"vitreoretinal surgery,|coexisting cataract",,,,,,,,,,,,,,,,
27000,,gastroenteritis|(sub)total colectomy|obesity,,,,,,,,,,,,,,,,
27001,,brain infection disease,,,,,,,,,,,,,,,,
27002,,somatic disease,,,,,,,,,,,,,,,,
27003,,cns impairment,,,,,,,,,,,,,,,,
27004,,hydration in neck,,,,,,,,,,,,,,,,
27005,,head trauma disorders.|pregnant,,,,,,,,,,,,,,,,
27006,,chronic pain disorder,,,,,,,,,,,,,,,,
27007,,local prostate cancer,,,,,,,,,,,,,,,,
27008,,hb bart's edema,,,,,,,,,,,,,,,,
27009,,peripheral venous cannula placed,,,,,,,,,,,,,,,,
27010,,acute swallowing disorders,,,,,,,,,,,,,,,,
27011,,primary refractory mm,,,,,,,,,,,,,,,,
27012,,atrial arrhythmia,,,,,,,,,,,,,,,,
27013,,acute episode,,,,,,,,,,,,,,,,
27014,,motion sickness;|a,,,,,,,,,,,,,,,,
27015,,physiological dyspnea.||exclusion,,,,,,,,,,,,,,,,
27016,,spinal instrumentation,,,,,,,,,,,,,,,,
27017,,gastrointestinal symptoms|fap,,,,,,,,,,,,,,,,
27018,,type of diabetes,,,,,,,,,,,,,,,,
27019,,cardiac ischaemia,,,,,,,,,,,,,,,,
27020,,dna testing;|moderate,,,,,,,,,,,,,,,,
27021,,third degree atrioventricular block,,,,,,,,,,,,,,,,
27022,,serious infection,,,,,,,,,,,,,,,,
27023,,skin-sensitivity,,,,,,,,,,,,,,,,
27024,,schizophrenic illness,,,,,,,,,,,,,,,,
27025,,fundus photography,,,,,,,,,,,,,,,,
27026,,age|presentation,,,,,,,,,,,,,,,,
27027,,collagen diseases,,,,,,,,,,,,,,,,
27028,,iodine,,,,,,,,,,,,,,,,
27029,,tmd,,,,,,,,,,,,,,,,
27030,,therapy|lack of proficiency,,,,,,,,,,,,,,,,
27031,,distal popliteal,,,,,,,,,,,,,,,,
27032,,anxiolytic,,,,,,,,,,,,,,,,
27033,,endoscopic remission,,,,,,,,,,,,,,,,
27034,,hematopoietic system diseases,,,,,,,,,,,,,,,,
27035,,fxm(+)|active infection|hematologic malignancy,,,,,,,,,,,,,,,,
27036,,primary diseases,,,,,,,,,,,,,,,,
27037,,functional deficits,,,,,,,,,,,,,,,,
27038,,auto-inflammatory diseases,,,,,,,,,,,,,,,,
27039,,intact periodontium - bop,,,,,,,,,,,,,,,,
27040,,medtronic 670g,,,,,,,,,,,,,,,,
27041,,polyneuropathy|intolerance,,,,,,,,,,,,,,,,
27042,,goo symptoms,,,,,,,,,,,,,,,,
27043,,subhyaloid hemorrhage.||,,,,,,,,,,,,,,,,
27044,,mmrv,,,,,,,,,,,,,,,,
27045,,covid -19||,,,,,,,,,,,,,,,,
27046,,comfort care,,,,,,,,,,,,,,,,
27047,,early-stage disease|er/pr,,,,,,,,,,,,,,,,
27048,,carcinomatous meningitis|pregnancy,,,,,,,,,,,,,,,,
27049,,11)genetic disorders,,,,,,,,,,,,,,,,
27050,,non cirrhotic portal hypertension,,,,,,,,,,,,,,,,
27051,,lumbar echography||,,,,,,,,,,,,,,,,
27052,,hypothyroid obesity,,,,,,,,,,,,,,,,
27053,,motor disability,,,,,,,,,,,,,,,,
27054,,drainage of won|coagulopathy,,,,,,,,,,,,,,,,
27055,,marfan's syndrome,,,,,,,,,,,,,,,,
27056,,cerebral aneurysm,,,,,,,,,,,,,,,,
27057,,extrahepatic cancers,,,,,,,,,,,,,,,,
27058,,respiratory system disorders,,,,,,,,,,,,,,,,
27059,,non-mrna vaccines,,,,,,,,,,,,,,,,
27060,,frontal alopecia,,,,,,,,,,,,,,,,
27061,,poor response,,,,,,,,,,,,,,,,
27062,,anaesthesia,,,,,,,,,,,,,,,,
27063,,hepatitis c note,,,,,,,,,,,,,,,,
27064,,lifestyle habits,,,,,,,,,,,,,,,,
27065,,carcinoma in situ of cervix,,,,,,,,,,,,,,,,
27066,,pbmc,,,,,,,,,,,,,,,,
27067,,solid organ transplantation.|receipt of live attenuated vaccination,,,,,,,,,,,,,,,,
27068,,acute effects,,,,,,,,,,,,,,,,
27069,,diseases;|chronic renal failure,,,,,,,,,,,,,,,,
27070,,digital cognitive behavior therapy,,,,,,,,,,,,,,,,
27071,,obsessive-compulsory disorder,,,,,,,,,,,,,,,,
27072,,arrhythmogenic heart disease,,,,,,,,,,,,,,,,
27073,,msa,,,,,,,,,,,,,,,,
27074,,pres)).|those,,,,,,,,,,,,,,,,
27075,,gestational diabetes|patients,,,,,,,,,,,,,,,,
27076,,left atrial enlargement,,,,,,,,,,,,,,,,
27077,,heart failure)|unstable angina pectoris|cardiac arrhythmia|myocardial infarction,,,,,,,,,,,,,,,,
27078,,acute myocarditis/pericarditis,,,,,,,,,,,,,,,,
27079,,consciousness|substance abuse,,,,,,,,,,,,,,,,
27080,,metal allergy,,,,,,,,,,,,,,,,
27081,,acute exacerbation of asthma,,,,,,,,,,,,,,,,
27082,,unstabilized organ damage,,,,,,,,,,,,,,,,
27083,,metabolic joint diseases,,,,,,,,,,,,,,,,
27084,,epileptic encephalopathy,,,,,,,,,,,,,,,,
27085,,disorder related,,,,,,,,,,,,,,,,
27086,,qtcf interval,,,,,,,,,,,,,,,,
27087,,excessive volitional stool,,,,,,,,,,,,,,,,
27088,,atrophic vaginitis,,,,,,,,,,,,,,,,
27089,,related:||adenoma,,,,,,,,,,,,,,,,
27090,,congenital heart disease|newborns,,,,,,,,,,,,,,,,
27091,,extrauterine disease,,,,,,,,,,,,,,,,
27092,,stage)|chronic obstructive pulmonary disease,,,,,,,,,,,,,,,,
27093,,tumor tissue,,,,,,,,,,,,,,,,
27094,,valgus.|alterations of the cognitive state,,,,,,,,,,,,,,,,
27095,,mild depression,,,,,,,,,,,,,,,,
27096,,gingivitis,,,,,,,,,,,,,,,,
27097,,interpersonal issues,,,,,,,,,,,,,,,,
27098,,poor glycemic control,,,,,,,,,,,,,,,,
27099,,viral loads,,,,,,,,,,,,,,,,
27100,,under ultrasound|contraindication,,,,,,,,,,,,,,,,
27101,,faint,,,,,,,,,,,,,,,,
27102,,seizure disorder;|diabetes,,,,,,,,,,,,,,,,
27103,,non-invasive ventilation|patients,,,,,,,,,,,,,,,,
27104,,non-psychotic mdd,,,,,,,,,,,,,,,,
27105,,unacceptable intolerance,,,,,,,,,,,,,,,,
27106,,stroke syndrome,,,,,,,,,,,,,,,,
27107,,acute exacerbation|inpatients,,,,,,,,,,,,,,,,
27108,,reduced level,,,,,,,,,,,,,,,,
27109,,actively trying to become,,,,,,,,,,,,,,,,
27110,,tobacco.|pregnant,,,,,,,,,,,,,,,,
27111,,squamous carcinoma,,,,,,,,,,,,,,,,
27112,,hepatitis b & c,,,,,,,,,,,,,,,,
27113,,left cheek,,,,,,,,,,,,,,,,
27114,,compressive adenopathy,,,,,,,,,,,,,,,,
27115,,diabetes mellitus|low risk,,,,,,,,,,,,,,,,
27116,,atrial appendage thrombus,,,,,,,,,,,,,,,,
27117,,alcohol abuse|history of psychosis,,,,,,,,,,,,,,,,
27118,,breast disease,,,,,,,,,,,,,,,,
27119,,remain functional (fsh level<27.0 iu/,,,,,,,,,,,,,,,,
27120,,morbidity,,,,,,,,,,,,,,,,
27121,,paraplegic patients,,,,,,,,,,,,,,,,
27122,,choroidal rupture,,,,,,,,,,,,,,,,
27123,,mdrd);|negative pregnancy test,,,,,,,,,,,,,,,,
27124,,3|glioblastoma,,,,,,,,,,,,,,,,
27125,,condomless anal sex (cas),,,,,,,,,,,,,,,,
27126,,adequate ulnar collateral flow,,,,,,,,,,,,,,,,
27127,,medial temporal lobe atrophy visual assessment scale,,,,,,,,,,,,,,,,
27128,,lung neuroendocrine tumors,,,,,,,,,,,,,,,,
27129,,months.|pathologically,,,,,,,,,,,,,,,,
27130,,restless legs syndrome,,,,,,,,,,,,,,,,
27131,,therapy|refractory,,,,,,,,,,,,,,,,
27132,,osteoarthrosis,,,,,,,,,,,,,,,,
27133,,chf)|human immunodeficiency virus (,,,,,,,,,,,,,,,,
27134,,diabetes|diabetic macular edema,,,,,,,,,,,,,,,,
27135,,criminal lesion,,,,,,,,,,,,,,,,
27136,,glucose intolerance,,,,,,,,,,,,,,,,
27137,,aids)-defining illness,,,,,,,,,,,,,,,,
27138,,pregnancy women|hiv,,,,,,,,,,,,,,,,
27139,,angioneurotic edema,,,,,,,,,,,,,,,,
27140,,binocular vision abnormalities,,,,,,,,,,,,,,,,
27141,,persistence of histologically,,,,,,,,,,,,,,,,
27142,,cerebral oedema,,,,,,,,,,,,,,,,
27143,,anterior left block,,,,,,,,,,,,,,,,
27144,,cancer risk reduction,,,,,,,,,,,,,,,,
27145,,psychiatric abnormalities,,,,,,,,,,,,,,,,
27146,,pyruvate carboxylase deficiency,,,,,,,,,,,,,,,,
27147,,cardiomyopathy|patients,,,,,,,,,,,,,,,,
27148,,6s,,,,,,,,,,,,,,,,
27149,,chronic kidney disease epidemiology [,,,,,,,,,,,,,,,,
27150,,pathology related,,,,,,,,,,,,,,,,
27151,,gastrointestinal bleeding tendency,,,,,,,,,,,,,,,,
27152,,drugs|known sensitivity,,,,,,,,,,,,,,,,
27153,,unable to undergo bronchoscopy|a,,,,,,,,,,,,,,,,
27154,,refractory to their,,,,,,,,,,,,,,,,
27155,,tracheal cannula,,,,,,,,,,,,,,,,
27156,,mnv)|early amd|healthy,,,,,,,,,,,,,,,,
27157,,bleeding|bleeding,,,,,,,,,,,,,,,,
27158,,ileostoma,,,,,,,,,,,,,,,,
27159,,additionally,,,,,,,,,,,,,,,,
27160,,worker's compensation claims relating,,,,,,,,,,,,,,,,
27161,,normal hepatic function||certified,,,,,,,,,,,,,,,,
27162,,cml,,,,,,,,,,,,,,,,
27163,,recurrence of oc,,,,,,,,,,,,,,,,
27164,,ground-glass opacification,,,,,,,,,,,,,,,,
27165,,renal calculi,,,,,,,,,,,,,,,,
27166,,hepatitis b,,,,,,,,,,,,,,,,
27167,,-||,,,,,,,,,,,,,,,,
27168,,nonsense mutations,,,,,,,,,,,,,,,,
27169,,ischemic colitis,,,,,,,,,,,,,,,,
27170,,contrast media allergy,,,,,,,,,,,,,,,,
27171,,therapeutic protein preparations,,,,,,,,,,,,,,,,
27172,,end-stage renal disease|chronic haemodialysis|indwelling,,,,,,,,,,,,,,,,
27173,,endometrioid ovarian,,,,,,,,,,,,,,,,
27174,,pulmonary edema|intracranial hemorrhage,,,,,,,,,,,,,,,,
27175,,hyperleukocytosis,,,,,,,,,,,,,,,,
27176,,acute ischemic stroke；|time intervals,,,,,,,,,,,,,,,,
27177,,adequate renal function,,,,,,,,,,,,,,,,
27178,,chronic kidney disease-improved,,,,,,,,,,,,,,,,
27179,,sensitive urine pregnancy test,,,,,,,,,,,,,,,,
27180,,diseased sinus,,,,,,,,,,,,,,,,
27181,,multiple system atrophy (msa),,,,,,,,,,,,,,,,
27182,,chronic immune system,,,,,,,,,,,,,,,,
27183,,cerebellar disorders,,,,,,,,,,,,,,,,
27184,,heart failure|unstable angina|myocardial infarction,,,,,,,,,,,,,,,,
27185,,criterion e,,,,,,,,,,,,,,,,
27186,,temporomandibular joint,,,,,,,,,,,,,,,,
27187,,impulse control disorders,,,,,,,,,,,,,,,,
27188,,available|hiv|a medical condition,,,,,,,,,,,,,,,,
27189,,poor oral hygiene|plaque score,,,,,,,,,,,,,,,,
27190,,idiopathic generalized anhidrosis,,,,,,,,,,,,,,,,
27191,,deep,,,,,,,,,,,,,,,,
27192,,contraindicate intramuscular,,,,,,,,,,,,,,,,
27193,,filling defect,,,,,,,,,,,,,,,,
27194,,cerebral autosomal dominant arteriopathy,,,,,,,,,,,,,,,,
27195,,ostomy,,,,,,,,,,,,,,,,
27196,,psychosis not otherwise,,,,,,,,,,,,,,,,
27197,,rheumatoid/psoriasis,,,,,,,,,,,,,,,,
27198,,glycolic acids,,,,,,,,,,,,,,,,
27199,,urinary tract infection|history,,,,,,,,,,,,,,,,
27200,,bone progression,,,,,,,,,,,,,,,,
27201,,intracranial aneurysm,,,,,,,,,,,,,,,,
27202,,cancer diagnosis,,,,,,,,,,,,,,,,
27203,,depression symptoms,,,,,,,,,,,,,,,,
27204,,infection.|presence of another malignancies.|granulocyte count,,,,,,,,,,,,,,,,
27205,,chronic lung,,,,,,,,,,,,,,,,
27206,,in-situ bladder cancer,,,,,,,,,,,,,,,,
27207,,occluder dislocation,,,,,,,,,,,,,,,,
27208,,judged by the doctor that they do not need,,,,,,,,,,,,,,,,
27209,,limb weakness,,,,,,,,,,,,,,,,
27210,,intestinal atresia,,,,,,,,,,,,,,,,
27211,,residency,,,,,,,,,,,,,,,,
27212,,hematopoietic growth factors,,,,,,,,,,,,,,,,
27213,,teeth present|be willing,,,,,,,,,,,,,,,,
27214,,thyroid hormone|down's syndrome,,,,,,,,,,,,,,,,
27215,,violence,,,,,,,,,,,,,,,,
27216,,pfts,,,,,,,,,,,,,,,,
27217,,criteria for diseases,,,,,,,,,,,,,,,,
27218,,kidney insufficiency,,,,,,,,,,,,,,,,
27219,,high-grade serous,,,,,,,,,,,,,,,,
27220,,r latina breast cancer survivors:||be 18 years,,,,,,,,,,,,,,,,
27221,,blood clots hemophilia,,,,,,,,,,,,,,,,
27222,,unmanageable toxicity,,,,,,,,,,,,,,,,
27223,,sympotomatic penetrating diseases|contraindication,,,,,,,,,,,,,,,,
27224,,leishmania infections.|evidence,,,,,,,,,,,,,,,,
27225,,pain relief,,,,,,,,,,,,,,,,
27226,,bleeding|previous itp treatment,,,,,,,,,,,,,,,,
27227,,uni-,,,,,,,,,,,,,,,,
27228,,non-cardiac condition,,,,,,,,,,,,,,,,
27229,,permanently infertile,,,,,,,,,,,,,,,,
27230,,systolic ventricle dysfunction,,,,,,,,,,,,,,,,
27231,,haemophilus influenzae,,,,,,,,,,,,,,,,
27232,,cough frequency,,,,,,,,,,,,,,,,
27233,,chronic diseases (,,,,,,,,,,,,,,,,
27234,,cancer immunotherapy,,,,,,,,,,,,,,,,
27235,,lactation,,,,,,,,,,,,,,,,
27236,,gastroesophageal junction adenocarcinoma,,,,,,,,,,,,,,,,
27237,,distal arterial occlusion,,,,,,,,,,,,,,,,
27238,,valve disease|patients,,,,,,,,,,,,,,,,
27239,,esophageal varices|subject,,,,,,,,,,,,,,,,
27240,,bundle branch block,,,,,,,,,,,,,,,,
27241,,non-combusted,,,,,,,,,,,,,,,,
27242,,colorectal carcinogenesis,,,,,,,,,,,,,,,,
27243,,neovascularization|congenital eye abnormality|uncontrolled glaucoma|pseudoexfoliation syndrome|amblyopia|uveitis|amd,,,,,,,,,,,,,,,,
27244,,ovarian,,,,,,,,,,,,,,,,
27245,,urinary tract infections.|pregnant,,,,,,,,,,,,,,,,
27246,,signs of psychosis,,,,,,,,,,,,,,,,
27247,,sporadic,,,,,,,,,,,,,,,,
27248,,pas,,,,,,,,,,,,,,,,
27249,,contracture,,,,,,,,,,,,,,,,
27250,,laryngeal cancer,,,,,,,,,,,,,,,,
27251,,symptoms of depressive disorder,,,,,,,,,,,,,,,,
27252,,mucinous,,,,,,,,,,,,,,,,
27253,,acute hepatitis b,,,,,,,,,,,,,,,,
27254,,illness(es,,,,,,,,,,,,,,,,
27255,,aids])|active infection,,,,,,,,,,,,,,,,
27256,,aneurysmal subarachnoid hemorrhage,,,,,,,,,,,,,,,,
27257,,singles,,,,,,,,,,,,,,,,
27258,,childbearing potential,,,,,,,,,,,,,,,,
27259,,uterine bleeding,,,,,,,,,,,,,,,,
27260,,carditis,,,,,,,,,,,,,,,,
27261,,sensation of pressure,,,,,,,,,,,,,,,,
27262,,hmpv infection,,,,,,,,,,,,,,,,
27263,,dysfunction of the right ventricule - mpap>30mmhg,,,,,,,,,,,,,,,,
27264,,chronic obstructive pulmonary disease|an,,,,,,,,,,,,,,,,
27265,,age|biopsy,,,,,,,,,,,,,,,,
27266,,sinus bradycardia,,,,,,,,,,,,,,,,
27267,,covid-19 severe,,,,,,,,,,,,,,,,
27268,,urinary reproductive system,,,,,,,,,,,,,,,,
27269,,cerebral shunts,,,,,,,,,,,,,,,,
27270,,osteosarcoma,,,,,,,,,,,,,,,,
27271,,septic shock.||in,,,,,,,,,,,,,,,,
27272,,dsm5 hallucinogen use disorder,,,,,,,,,,,,,,,,
27273,,biopsy|adequate bone marrow,,,,,,,,,,,,,,,,
27274,,adverse drug reactions should,,,,,,,,,,,,,,,,
27275,,choroideremia,,,,,,,,,,,,,,,,
27276,,chronic hepatitis treated,,,,,,,,,,,,,,,,
27277,,communication disability,,,,,,,,,,,,,,,,
27278,,thrombolytic therapy;|thrombolytic therapy,,,,,,,,,,,,,,,,
27279,,isolated laminotomy,,,,,,,,,,,,,,,,
27280,,herniated,,,,,,,,,,,,,,,,
27281,,folliculitis,,,,,,,,,,,,,,,,
27282,,tumor-related fever,,,,,,,,,,,,,,,,
27283,,f50.0 anorexia nervosa,,,,,,,,,,,,,,,,
27284,,lhon,,,,,,,,,,,,,,,,
27285,,eating syndrome,,,,,,,,,,,,,,,,
27286,,unstable mental illness,,,,,,,,,,,,,,,,
27287,,extensive tumor dissemination,,,,,,,,,,,,,,,,
27288,,arteriovenous malformation.|the,,,,,,,,,,,,,,,,
27289,,right internal mammary artery) bypass,,,,,,,,,,,,,,,,
27290,,weight loss supplements,,,,,,,,,,,,,,,,
27291,,dvt)|pulmonary,,,,,,,,,,,,,,,,
27292,,hbet|cognitive problems,,,,,,,,,,,,,,,,
27293,,transient ischemic attack.||patients,,,,,,,,,,,,,,,,
27294,,polymyalgia rheumatic,,,,,,,,,,,,,,,,
27295,,general cognitive impairment,,,,,,,,,,,,,,,,
27296,,measureable disease,,,,,,,,,,,,,,,,
27297,,yersinia,,,,,,,,,,,,,,,,
27298,,neuropsychiatric disease,,,,,,,,,,,,,,,,
27299,,trauma.|no,,,,,,,,,,,,,,,,
27300,,breast cancer resistance protein (bcrp),,,,,,,,,,,,,,,,
27301,,"diabetic neuropathy,|mild",,,,,,,,,,,,,,,,
27302,,malignancies|cervical radiculopathy,,,,,,,,,,,,,,,,
27303,,diarrheal illness,,,,,,,,,,,,,,,,
27304,,uncontrolled hemorrhage,,,,,,,,,,,,,,,,
27305,,hyper-acute stroke,,,,,,,,,,,,,,,,
27306,,calculated using the 166ho scout dose,,,,,,,,,,,,,,,,
27307,,solid organ transplant|active therapy,,,,,,,,,,,,,,,,
27308,,c1d1)|uncontrolled infection,,,,,,,,,,,,,,,,
27309,,vaginal ring,,,,,,,,,,,,,,,,
27310,,coagulopathy disorders,,,,,,,,,,,,,,,,
27311,,mental health care,,,,,,,,,,,,,,,,
27312,,compromised renal,,,,,,,,,,,,,,,,
27313,,arrhythmias;|chronic infections;|thyroid dysfunction,,,,,,,,,,,,,,,,
27314,,akershus university hospital,,,,,,,,,,,,,,,,
27315,,watery diarrhea,,,,,,,,,,,,,,,,
27316,,maternal hyperthermia,,,,,,,,,,,,,,,,
27317,,disorder of the reproductive system|male,,,,,,,,,,,,,,,,
27318,,total colectomy;|other autoimmune diseases,,,,,,,,,,,,,,,,
27319,,rectal carcinoma,,,,,,,,,,,,,,,,
27320,,morphological disease,,,,,,,,,,,,,,,,
27321,,etc.);|2,,,,,,,,,,,,,,,,
27322,,stenotic lesions,,,,,,,,,,,,,,,,
27323,,child-bearing/sperm,,,,,,,,,,,,,,,,
27324,,cardiac clinical symptoms,,,,,,,,,,,,,,,,
27325,,render nasal,,,,,,,,,,,,,,,,
27326,,deep venous thromboembolism,,,,,,,,,,,,,,,,
27327,,leep,,,,,,,,,,,,,,,,
27328,,screening|significant cognitive impairment indicative,,,,,,,,,,,,,,,,
27329,,cognitive illness,,,,,,,,,,,,,,,,
27330,,vascular involvement,,,,,,,,,,,,,,,,
27331,,sfai).|failure,,,,,,,,,,,,,,,,
27332,,intestinal flora though,,,,,,,,,,,,,,,,
27333,,cholestatic liver disease,,,,,,,,,,,,,,,,
27334,,radiofrequency destruction,,,,,,,,,,,,,,,,
27335,,developmental disabilities,,,,,,,,,,,,,,,,
27336,,preclude involvement,,,,,,,,,,,,,,,,
27337,,muga)|human immunodeficiency virus,,,,,,,,,,,,,,,,
27338,,central pathology review|adequate heamatological,,,,,,,,,,,,,,,,
27339,,ophthalmological conditions,,,,,,,,,,,,,,,,
27340,,drivers.|ability,,,,,,,,,,,,,,,,
27341,,hyponatraemia,,,,,,,,,,,,,,,,
27342,,students|university staff,,,,,,,,,,,,,,,,
27343,,ms exacerbation,,,,,,,,,,,,,,,,
27344,,lactating|blind|deaf|abnormal ecg,,,,,,,,,,,,,,,,
27345,,systemic disease|heavy smokers,,,,,,,,,,,,,,,,
27346,,cancer|diagnosis,,,,,,,,,,,,,,,,
27347,,heart condition.||applicable,,,,,,,,,,,,,,,,
27348,,narp).|primary mitochondrial disease,,,,,,,,,,,,,,,,
27349,,aspects,,,,,,,,,,,,,,,,
27350,,skin plaque,,,,,,,,,,,,,,,,
27351,,progressive disease.|prior palliative radiotherapy,,,,,,,,,,,,,,,,
27352,,ischemic heart disease|patients,,,,,,,,,,,,,,,,
27353,,upper gastrointestinal ulceration,,,,,,,,,,,,,,,,
27354,,maintaining cognitive functions,,,,,,,,,,,,,,,,
27355,,"shoulder, neck",,,,,,,,,,,,,,,,
27356,,head trauma|contraindications,,,,,,,,,,,,,,,,
27357,,anterior circulation,,,,,,,,,,,,,,,,
27358,,dysfunction|chronic kidney disease,,,,,,,,,,,,,,,,
27359,,generalized seizure disorder,,,,,,,,,,,,,,,,
27360,,chronic granulomatous diseases,,,,,,,,,,,,,,,,
27361,,liver disease.|are,,,,,,,,,,,,,,,,
27362,,screening|previous cornea,,,,,,,,,,,,,,,,
27363,,metastatic malignancies,,,,,,,,,,,,,,,,
27364,,cardiomyopathy,,,,,,,,,,,,,,,,
27365,,adenocarcinoma of the stomach,,,,,,,,,,,,,,,,
27366,,hearing impairment,,,,,,,,,,,,,,,,
27367,,gastrointestinal infections,,,,,,,,,,,,,,,,
27368,,deep brain stimulator|implanted metal,,,,,,,,,,,,,,,,
27369,,chest trauma,,,,,,,,,,,,,,,,
27370,,growth factor supports,,,,,,,,,,,,,,,,
27371,,benign pancreatic disorders,,,,,,,,,,,,,,,,
27372,,lymphocytic leukemia,,,,,,,,,,,,,,,,
27373,,progressive brain,,,,,,,,,,,,,,,,
27374,,illness resolved,,,,,,,,,,,,,,,,
27375,,vascular disorder,,,,,,,,,,,,,,,,
27376,,c;|alcoholism,,,,,,,,,,,,,,,,
27377,,snhl,,,,,,,,,,,,,,,,
27378,,criteria|neoplastic disease,,,,,,,,,,,,,,,,
27379,,active cancers,,,,,,,,,,,,,,,,
27380,,rectal perforation,,,,,,,,,,,,,,,,
27381,,carious lesions,,,,,,,,,,,,,,,,
27382,,acceptable forms of birth control,,,,,,,,,,,,,,,,
27383,,alive virus vaccination,,,,,,,,,,,,,,,,
27384,,dyspnea after direct chest trauma,,,,,,,,,,,,,,,,
27385,,alcohol tests,,,,,,,,,,,,,,,,
27386,,macular dystrophies,,,,,,,,,,,,,,,,
27387,,defect.|women exposed,,,,,,,,,,,,,,,,
27388,,non-cardiac life threatening illness,,,,,,,,,,,,,,,,
27389,,psychotic depression,,,,,,,,,,,,,,,,
27390,,radiation injury,,,,,,,,,,,,,,,,
27391,,drug contraindicated,,,,,,,,,,,,,,,,
27392,,criteria of the site's screening consent,,,,,,,,,,,,,,,,
27393,,neurocognitive function,,,,,,,,,,,,,,,,
27394,,anatomical difficulties|the,,,,,,,,,,,,,,,,
27395,,lactase deficiency,,,,,,,,,,,,,,,,
27396,,non traumatic bleeding,,,,,,,,,,,,,,,,
27397,,ct2c-t3a,,,,,,,,,,,,,,,,
27398,,atheromatous disease,,,,,,,,,,,,,,,,
27399,,disease of the liver.|clinically,,,,,,,,,,,,,,,,
27400,,good-quality photographic imaging||namd subject||the,,,,,,,,,,,,,,,,
27401,,stable medical disorders,,,,,,,,,,,,,,,,
27402,,pnemonia,,,,,,,,,,,,,,,,
27403,,modic type,,,,,,,,,,,,,,,,
27404,,urinary tract infections,,,,,,,,,,,,,,,,
27405,,criteria of the diagnostic and statistical manual of mental disorder,,,,,,,,,,,,,,,,
27406,,iga.|pathogenic neuronal autoantibody positivity,,,,,,,,,,,,,,,,
27407,,involuntary psychiatric commitment,,,,,,,,,,,,,,,,
27408,,chest problems,,,,,,,,,,,,,,,,
27409,,tumor excision,,,,,,,,,,,,,,,,
27410,,drug-induced hepatotoxicity,,,,,,,,,,,,,,,,
27411,,progressive neurological deficits,,,,,,,,,,,,,,,,
27412,,peptic ulcer disease|nsaid,,,,,,,,,,,,,,,,
27413,,clinical gastrointestinal bleeding,,,,,,,,,,,,,,,,
27414,,nasal polyps,,,,,,,,,,,,,,,,
27415,,localized non-melanoma,,,,,,,,,,,,,,,,
27416,,hydroxychloroquine;||6.no response,,,,,,,,,,,,,,,,
27417,,malignant tumor;|clinical symptoms,,,,,,,,,,,,,,,,
27418,,neuropathic pain medications.|clinical laboratory values,,,,,,,,,,,,,,,,
27419,,respiratory physiotherapy,,,,,,,,,,,,,,,,
27420,,bundle branch block (bbb),,,,,,,,,,,,,,,,
27421,,day.|active smokers,,,,,,,,,,,,,,,,
27422,,multiple pregnancies|major,,,,,,,,,,,,,,,,
27423,,esophageal squamous carcinoma,,,,,,,,,,,,,,,,
27424,,h-2-receptor antagonist,,,,,,,,,,,,,,,,
27425,,arrhythmias;|noncardiac factors,,,,,,,,,,,,,,,,
27426,,alcohol abuse screener|use,,,,,,,,,,,,,,,,
27427,,"renal transplant,|the",,,,,,,,,,,,,,,,
27428,,chronic pulmonary condition,,,,,,,,,,,,,,,,
27429,,metastases,,,,,,,,,,,,,,,,
27430,,language abilities,,,,,,,,,,,,,,,,
27431,,extra-uterine disease,,,,,,,,,,,,,,,,
27432,,autoimmune diseases,,,,,,,,,,,,,,,,
27433,,unresectable cancer,,,,,,,,,,,,,,,,
27434,,isolated aortic stenosis adult,,,,,,,,,,,,,,,,
27435,,lack of cooperation,,,,,,,,,,,,,,,,
27436,,respiratory disorders,,,,,,,,,,,,,,,,
27437,,tremor symptoms,,,,,,,,,,,,,,,,
27438,,ovarian diseases,,,,,,,,,,,,,,,,
27439,,chondral lesion,,,,,,,,,,,,,,,,
27440,,cardiac repolarization abnormalities,,,,,,,,,,,,,,,,
27441,,painful symptomatology,,,,,,,,,,,,,,,,
27442,,eligible.|participants unable to undergo contrast,,,,,,,,,,,,,,,,
27443,,national prescribing,,,,,,,,,,,,,,,,
27444,,large vessel occlusion,,,,,,,,,,,,,,,,
27445,,schizoaffective disorder|patients,,,,,,,,,,,,,,,,
27446,,painful cranial neuropathy,,,,,,,,,,,,,,,,
27447,,solid component,,,,,,,,,,,,,,,,
27448,,spontaneous menstrual bleed,,,,,,,,,,,,,,,,
27449,,ring,,,,,,,,,,,,,,,,
27450,,stargardt disease,,,,,,,,,,,,,,,,
27451,,abnormal findings,,,,,,,,,,,,,,,,
27452,,complexes,,,,,,,,,,,,,,,,
27453,,unrestorable tooth,,,,,,,,,,,,,,,,
27454,,solid organ transplant.|received chemotherapy,,,,,,,,,,,,,,,,
27455,,basketball,,,,,,,,,,,,,,,,
27456,,criteria of the japan thyroid association.|tsi,,,,,,,,,,,,,,,,
27457,,prenatal infection,,,,,,,,,,,,,,,,
27458,,supine rest.|renal impairment,,,,,,,,,,,,,,,,
27459,,coad,,,,,,,,,,,,,,,,
27460,,acute kidney injury.|patients,,,,,,,,,,,,,,,,
27461,,hyperactivity disorder,,,,,,,,,,,,,,,,
27462,,subarachnoid bleeding,,,,,,,,,,,,,,,,
27463,,partial response,,,,,,,,,,,,,,,,
27464,,anaplastic lymphoma kinase（alk） fusion,,,,,,,,,,,,,,,,
27465,,subtype,,,,,,,,,,,,,,,,
27466,,knee deformity,,,,,,,,,,,,,,,,
27467,,depression in remission,,,,,,,,,,,,,,,,
27468,,substance abuse|history of,,,,,,,,,,,,,,,,
27469,,nonchildbearing potential,,,,,,,,,,,,,,,,
27470,,cerebral arteriovenous malformation,,,,,,,,,,,,,,,,
27471,,myocardial infarction|qt-related,,,,,,,,,,,,,,,,
27472,,prostatectomy;|failure,,,,,,,,,,,,,,,,
27473,,pulmonary hypertension|major surgery,,,,,,,,,,,,,,,,
27474,,corticosteroids).|neurological disorder,,,,,,,,,,,,,,,,
27475,,epo,,,,,,,,,,,,,,,,
27476,,uterine malformations,,,,,,,,,,,,,,,,
27477,,fibrosis,,,,,,,,,,,,,,,,
27478,,physical illness,,,,,,,,,,,,,,,,
27479,,candida infection,,,,,,,,,,,,,,,,
27480,,bone marrow failure disorders,,,,,,,,,,,,,,,,
27481,,impaired comprehension,,,,,,,,,,,,,,,,
27482,,primary immunodeficiency|other malignancies,,,,,,,,,,,,,,,,
27483,,communication problem,,,,,,,,,,,,,,,,
27484,,chronic obstructive pulmonary disease (copd),,,,,,,,,,,,,,,,
27485,,alimentary system,,,,,,,,,,,,,,,,
27486,,cervical disease,,,,,,,,,,,,,,,,
27487,,national health authorities,,,,,,,,,,,,,,,,
27488,,twnk,,,,,,,,,,,,,,,,
27489,,inflammatory bowel disease|acute purulent process,,,,,,,,,,,,,,,,
27490,,chronic active infection,,,,,,,,,,,,,,,,
27491,,intubation difficulties|presence,,,,,,,,,,,,,,,,
27492,,alcohol intoxication,,,,,,,,,,,,,,,,
27493,,unhealed surgical wounds,,,,,,,,,,,,,,,,
27494,,radiotherapy||active malignancies,,,,,,,,,,,,,,,,
27495,,significant pain,,,,,,,,,,,,,,,,
27496,,cardiovascular issues,,,,,,,,,,,,,,,,
27497,,metatarsalgia,,,,,,,,,,,,,,,,
27498,,acute thrombosis,,,,,,,,,,,,,,,,
27499,,end-stage cardiopulmonary disease,,,,,,,,,,,,,,,,
27500,,recurrence of prostate cancer,,,,,,,,,,,,,,,,
27501,,claudication,,,,,,,,,,,,,,,,
27502,,spinal anesthesia|disease,,,,,,,,,,,,,,,,
27503,,tumour tissue sample (,,,,,,,,,,,,,,,,
27504,,prostate cancer|cervical carcinoma,,,,,,,,,,,,,,,,
27505,,sleep-associated symptoms,,,,,,,,,,,,,,,,
27506,,plantar ulcer,,,,,,,,,,,,,,,,
27507,,underlying diseases,,,,,,,,,,,,,,,,
27508,,uln|allergic,,,,,,,,,,,,,,,,
27509,,appendages,,,,,,,,,,,,,,,,
27510,,right hand;|detectable stimulation-evoked,,,,,,,,,,,,,,,,
27511,,dosing change,,,,,,,,,,,,,,,,
27512,,multiple chemical sensitivities,,,,,,,,,,,,,,,,
27513,,hypersignals|pregnant,,,,,,,,,,,,,,,,
27514,,trying to conceive,,,,,,,,,,,,,,,,
27515,,hepatitis c rna,,,,,,,,,,,,,,,,
27516,,dacomitinb,,,,,,,,,,,,,,,,
27517,,lateral difference,,,,,,,,,,,,,,,,
27518,,adequate computer literacy,,,,,,,,,,,,,,,,
27519,,primary unilateral tka.|the,,,,,,,,,,,,,,,,
27520,,affirmative response,,,,,,,,,,,,,,,,
27521,,total sensory altering disorders,,,,,,,,,,,,,,,,
27522,,milli-international units per milliliter (miu/ml).|patients,,,,,,,,,,,,,,,,
27523,,infection of the peritoneal dialysis,,,,,,,,,,,,,,,,
27524,,sleep apnea|lack of,,,,,,,,,,,,,,,,
27525,,mature first,,,,,,,,,,,,,,,,
27526,,primary immunodeficiency disorders,,,,,,,,,,,,,,,,
27527,,attention disorder,,,,,,,,,,,,,,,,
27528,,pain responsible,,,,,,,,,,,,,,,,
27529,,acid|tested,,,,,,,,,,,,,,,,
27530,,pulmonary infection,,,,,,,,,,,,,,,,
27531,,lagevrio,,,,,,,,,,,,,,,,
27532,,psychosocial distress.||complete,,,,,,,,,,,,,,,,
27533,,chronic neuropathy,,,,,,,,,,,,,,,,
27534,,syndromic myopia,,,,,,,,,,,,,,,,
27535,,deep breathing,,,,,,,,,,,,,,,,
27536,,etc.;|patients with extreme weakness,,,,,,,,,,,,,,,,
27537,,acute heart failure,,,,,,,,,,,,,,,,
27538,,headaches,,,,,,,,,,,,,,,,
27539,,place to stay,,,,,,,,,,,,,,,,
27540,,recurrence after surgical resection,,,,,,,,,,,,,,,,
27541,,chronic condition,,,,,,,,,,,,,,,,
27542,,corrected qt interval,,,,,,,,,,,,,,,,
27543,,autoimmune thyroiditis,,,,,,,,,,,,,,,,
27544,,"malignant hyperthermia,|morbid obesity|alcohol",,,,,,,,,,,,,,,,
27545,,delusional disorders,,,,,,,,,,,,,,,,
27546,,heart allograft|written informed consent obtained,,,,,,,,,,,,,,,,
27547,,vascular risk factor (hypertension,,,,,,,,,,,,,,,,
27548,,intestinal parasitosis,,,,,,,,,,,,,,,,
27549,,alternative pathologies,,,,,,,,,,,,,,,,
27550,,normal coagulation test,,,,,,,,,,,,,,,,
27551,,neurogenic bladder collapse,,,,,,,,,,,,,,,,
27552,,teeth on implant,,,,,,,,,,,,,,,,
27553,,knee varus,,,,,,,,,,,,,,,,
27554,,cns involvement|patients,,,,,,,,,,,,,,,,
27555,,solid tumors|evidence,,,,,,,,,,,,,,,,
27556,,lymphoblastic lymphoma,,,,,,,,,,,,,,,,
27557,,nervous system disorders,,,,,,,,,,,,,,,,
27558,,bleeding,,,,,,,,,,,,,,,,
27559,,upper extremity fractures,,,,,,,,,,,,,,,,
27560,,breast feeding|refusal,,,,,,,,,,,,,,,,
27561,,aspiration,,,,,,,,,,,,,,,,
27562,,cardiac syncope,,,,,,,,,,,,,,,,
27563,,syphilis infection|evidence,,,,,,,,,,,,,,,,
27564,,chronic infections,,,,,,,,,,,,,,,,
27565,,cystic cavity,,,,,,,,,,,,,,,,
27566,,adrenal tumor,,,,,,,,,,,,,,,,
27567,,airway surgery,,,,,,,,,,,,,,,,
27568,,haemorrhage,,,,,,,,,,,,,,,,
27569,,breast-feeding.|participants,,,,,,,,,,,,,,,,
27570,,lactating|cigarette smoking,,,,,,,,,,,,,,,,
27571,,months.|dyspnea,,,,,,,,,,,,,,,,
27572,,months|cognitive impairment - unable to follow instructions|impaired hearing,,,,,,,,,,,,,,,,
27573,,schizoaffective disorder)|lifetime diagnosis,,,,,,,,,,,,,,,,
27574,,hemiplegic cerebral,,,,,,,,,,,,,,,,
27575,,congenital anosmia,,,,,,,,,,,,,,,,
27576,,hemodynamic instability|medical,,,,,,,,,,,,,,,,
27577,,hepatitis b infection|use of b cell depleting,,,,,,,,,,,,,,,,
27578,,gastric bleeding,,,,,,,,,,,,,,,,
27579,,experience shock,,,,,,,,,,,,,,,,
27580,,serious mental illness,,,,,,,,,,,,,,,,
27581,,good general health|the,,,,,,,,,,,,,,,,
27582,,sinusitis|rhinitis medicamentosa|recurrent,,,,,,,,,,,,,,,,
27583,,painful bladder syndrome,,,,,,,,,,,,,,,,
27584,,healing disorders,,,,,,,,,,,,,,,,
27585,,throat，stuffy,,,,,,,,,,,,,,,,
27586,,produce allergic,,,,,,,,,,,,,,,,
27587,,fcr,,,,,,,,,,,,,,,,
27588,,medication|inability,,,,,,,,,,,,,,,,
27589,,reaction,,,,,,,,,,,,,,,,
27590,,distant disease,,,,,,,,,,,,,,,,
27591,,alk+,,,,,,,,,,,,,,,,
27592,,right vastus lateralis muscle,,,,,,,,,,,,,,,,
27593,,anterior facial height,,,,,,,,,,,,,,,,
27594,,ct scan|high,,,,,,,,,,,,,,,,
27595,,diabetes|risk factors,,,,,,,,,,,,,,,,
27596,,skin hydration,,,,,,,,,,,,,,,,
27597,,or|doppler arterial,,,,,,,,,,,,,,,,
27598,,isolated extramedullary leukemia.|patients,,,,,,,,,,,,,,,,
27599,,extensive keloid,,,,,,,,,,,,,,,,
27600,,craniocerebral trauma,,,,,,,,,,,,,,,,
27601,,liver disease|no,,,,,,,,,,,,,,,,
27602,,upper premolars,,,,,,,,,,,,,,,,
27603,,malignant hepatic tumor,,,,,,,,,,,,,,,,
27604,,other adenovirus vector,,,,,,,,,,,,,,,,
27605,,screening.|hepatic insufficiency resulting,,,,,,,,,,,,,,,,
27606,,criteria of the international classification of icsd-3|restless legs syndrome,,,,,,,,,,,,,,,,
27607,,neuropathic corneal pain,,,,,,,,,,,,,,,,
27608,,local unfavorable intermediate,,,,,,,,,,,,,,,,
27609,,pregnant|end-stage kidney,,,,,,,,,,,,,,,,
27610,,facial trauma)|increased,,,,,,,,,,,,,,,,
27611,,major atherosclerotic cardiovascular disease||previous coronary revascularization|previous,,,,,,,,,,,,,,,,
27612,,medical hdu,,,,,,,,,,,,,,,,
27613,,foot ulcers,,,,,,,,,,,,,,,,
27614,,abnormal scarring,,,,,,,,,,,,,,,,
27615,,traumatic nerve injury,,,,,,,,,,,,,,,,
27616,,covid-19 have entered,,,,,,,,,,,,,,,,
27617,,localized squamous cell cancer of the skin,,,,,,,,,,,,,,,,
27618,,memory problems,,,,,,,,,,,,,,,,
27619,,primary coagulation disorder,,,,,,,,,,,,,,,,
27620,,dnm2 mutations,,,,,,,,,,,,,,,,
27621,,medication free,,,,,,,,,,,,,,,,
27622,,malabsorption.|active psychiatric,,,,,,,,,,,,,,,,
27623,,kidney function|severe obesity,,,,,,,,,,,,,,,,
27624,,refractory hypoxia,,,,,,,,,,,,,,,,
27625,,surgery;|invasive adenocarcinoma,,,,,,,,,,,,,,,,
27626,,ligamentous laxity,,,,,,,,,,,,,,,,
27627,,unidentified,,,,,,,,,,,,,,,,
27628,,indications|type 1 diabetes,,,,,,,,,,,,,,,,
27629,,solid organ transplant,,,,,,,,,,,,,,,,
27630,,childhood;|patients,,,,,,,,,,,,,,,,
27631,,hepatic encephalopathy;|diagnosis of,,,,,,,,,,,,,,,,
27632,,cerebral infarction.|pregnant,,,,,,,,,,,,,,,,
27633,,benign bilharzial cystitis,,,,,,,,,,,,,,,,
27634,,trauma|whiplash|degenerative changes|signs,,,,,,,,,,,,,,,,
27635,,problem drinking,,,,,,,,,,,,,,,,
27636,,mineral deficiencies,,,,,,,,,,,,,,,,
27637,,type 1 diabetes,,,,,,,,,,,,,,,,
27638,,haemorrhagic stroke,,,,,,,,,,,,,,,,
27639,,urinary tract infection;|oliguria,,,,,,,,,,,,,,,,
27640,,acupuncture syncope,,,,,,,,,,,,,,,,
27641,,aa,,,,,,,,,,,,,,,,
27642,,target lesion.|previous treatment,,,,,,,,,,,,,,,,
27643,,morphologic persistence,,,,,,,,,,,,,,,,
27644,,abuse.|pregnant,,,,,,,,,,,,,,,,
27645,,cognitive impairment|known,,,,,,,,,,,,,,,,
27646,,mindfulness meditation,,,,,,,,,,,,,,,,
27647,,elite athletes,,,,,,,,,,,,,,,,
27648,,drug hypersensitivity,,,,,,,,,,,,,,,,
27649,,health industry,,,,,,,,,,,,,,,,
27650,,sleep-related,,,,,,,,,,,,,,,,
27651,,lymphoma；|no gender limitation,,,,,,,,,,,,,,,,
27652,,judged by clinicians to be clinically significant;|subject,,,,,,,,,,,,,,,,
27653,,etc.|systemic abnormalities,,,,,,,,,,,,,,,,
27654,,suicidal tendencies;|pregnant,,,,,,,,,,,,,,,,
27655,,glenohumeral osteoarthritis,,,,,,,,,,,,,,,,
27656,,histological confirmed carcinoma,,,,,,,,,,,,,,,,
27657,,brain metastases:||note,,,,,,,,,,,,,,,,
27658,,non-retentive fecal,,,,,,,,,,,,,,,,
27659,,abdominal pain,,,,,,,,,,,,,,,,
27660,,squamous cell,,,,,,,,,,,,,,,,
27661,,tzd,,,,,,,,,,,,,,,,
27662,,nonionic contrast media,,,,,,,,,,,,,,,,
27663,,moderate brown,,,,,,,,,,,,,,,,
27664,,traumatic systemic disorder|patients,,,,,,,,,,,,,,,,
27665,,"cerebellar metastasis,|the condition",,,,,,,,,,,,,,,,
27666,,upper gastrointestinal surgery|patients,,,,,,,,,,,,,,,,
27667,,non-periodontitis,,,,,,,,,,,,,,,,
27668,,breastfeeding;|4、active infection,,,,,,,,,,,,,,,,
27669,,omega-3,,,,,,,,,,,,,,,,
27670,,acquired immunodeficiency,,,,,,,,,,,,,,,,
27671,,similar endocrine disorders,,,,,,,,,,,,,,,,
27672,,corticosteroids;|progressive neurological disease,,,,,,,,,,,,,,,,
27673,,cardiac dysfunctions,,,,,,,,,,,,,,,,
27674,,insp,,,,,,,,,,,,,,,,
27675,,psychogenic cough,,,,,,,,,,,,,,,,
27676,,physical malformation of fingers,,,,,,,,,,,,,,,,
27677,,squamous cell skin carcinomas.|non-invasive,,,,,,,,,,,,,,,,
27678,,cardiac arrhythmias.|stroke,,,,,,,,,,,,,,,,
27679,,von willebrand's disease,,,,,,,,,,,,,,,,
27680,,her2-targeted treatments,,,,,,,,,,,,,,,,
27681,,suboptimal hiv outcome,,,,,,,,,,,,,,,,
27682,,inferior turbinate hypertrophy,,,,,,,,,,,,,,,,
27683,,poor general condition,,,,,,,,,,,,,,,,
27684,,snuffing,,,,,,,,,,,,,,,,
27685,,asymptomatic ischemia,,,,,,,,,,,,,,,,
27686,,maternal disease,,,,,,,,,,,,,,,,
27687,,therapeutic toxicity,,,,,,,,,,,,,,,,
27688,,pbh,,,,,,,,,,,,,,,,
27689,,dyspepsia,,,,,,,,,,,,,,,,
27690,,localized injection site reaction,,,,,,,,,,,,,,,,
27691,,claustrophobia)|chronic renal disease,,,,,,,,,,,,,,,,
27692,,hc,,,,,,,,,,,,,,,,
27693,,hypertensive,,,,,,,,,,,,,,,,
27694,,health center,,,,,,,,,,,,,,,,
27695,,pancreas cancer.|contraindication,,,,,,,,,,,,,,,,
27696,,neuraxial blockade,,,,,,,,,,,,,,,,
27697,,systemic illness|known dementia,,,,,,,,,,,,,,,,
27698,,arrhythmia|unstable angina pectoris,,,,,,,,,,,,,,,,
27699,,peritonitis,,,,,,,,,,,,,,,,
27700,,behavioral,,,,,,,,,,,,,,,,
27701,,involuntary weight,,,,,,,,,,,,,,,,
27702,,adverse event,,,,,,,,,,,,,,,,
27703,,allergic dyspnea,,,,,,,,,,,,,,,,
27704,,urinary system,,,,,,,,,,,,,,,,
27705,,pernicious anemia,,,,,,,,,,,,,,,,
27706,,ae,,,,,,,,,,,,,,,,
27707,,neurodevelopmental disorders,,,,,,,,,,,,,,,,
27708,,breast ductal carcinoma in situ treated surgically with curative,,,,,,,,,,,,,,,,
27709,,eosinophilia,,,,,,,,,,,,,,,,
27710,,early postpartum period|premenopausal,,,,,,,,,,,,,,,,
27711,,hepatitis c,,,,,,,,,,,,,,,,
27712,,ulcerative colitis;|polyposis,,,,,,,,,,,,,,,,
27713,,infratentorial tumor,,,,,,,,,,,,,,,,
27714,,females|systolic bp,,,,,,,,,,,,,,,,
27715,,chronic neurological diseases|unwillingness,,,,,,,,,,,,,,,,
27716,,pseudoexfoliative glaucoma,,,,,,,,,,,,,,,,
27717,,gej,,,,,,,,,,,,,,,,
27718,,pressure ulcers,,,,,,,,,,,,,,,,
27719,,concentration disorders,,,,,,,,,,,,,,,,
27720,,hemiplegic cp,,,,,,,,,,,,,,,,
27721,,upper tract urothelial carcinoma,,,,,,,,,,,,,,,,
27722,,idiosyncratic reaction,,,,,,,,,,,,,,,,
27723,,e-stimulation,,,,,,,,,,,,,,,,
27724,,birth asphyxia,,,,,,,,,,,,,,,,
27725,,acute cholecystitis beyond,,,,,,,,,,,,,,,,
27726,,cryoglobulinemia|ec 10,,,,,,,,,,,,,,,,
27727,,prothrombin complex concentrate,,,,,,,,,,,,,,,,
27728,,virologic response,,,,,,,,,,,,,,,,
27729,,intracardiac thrombus,,,,,,,,,,,,,,,,
27730,,swimming,,,,,,,,,,,,,,,,
27731,,unacceptable bleeding risk,,,,,,,,,,,,,,,,
27732,,consistent pruritus,,,,,,,,,,,,,,,,
27733,,ards|administration,,,,,,,,,,,,,,,,
27734,,abdominal wall hernia,,,,,,,,,,,,,,,,
27735,,common variable immunodeficiency||history of malignancy,,,,,,,,,,,,,,,,
27736,,urinary system bleeding occurred,,,,,,,,,,,,,,,,
27737,,gold fiducial markers,,,,,,,,,,,,,,,,
27738,,visiting hq,,,,,,,,,,,,,,,,
27739,,active diseases,,,,,,,,,,,,,,,,
27740,,primary immune deficiency,,,,,,,,,,,,,,,,
27741,,celiac disease)|known renal,,,,,,,,,,,,,,,,
27742,,communication impairments limiting communication,,,,,,,,,,,,,,,,
27743,,primary immunodeficiency virus infection,,,,,,,,,,,,,,,,
27744,,impaired glucose,,,,,,,,,,,,,,,,
27745,,temporal tendinitis migraine,,,,,,,,,,,,,,,,
27746,,thoracic surgery.|known diagnosis,,,,,,,,,,,,,,,,
27747,,escc|for cholangiocarcinoma,,,,,,,,,,,,,,,,
27748,,elevation,,,,,,,,,,,,,,,,
27749,,traumatic injury|prior lumbar spinal surgery|lateral spondylolisthesis,,,,,,,,,,,,,,,,
27750,,pulmonary aspergillosis,,,,,,,,,,,,,,,,
27751,,bulky disease,,,,,,,,,,,,,,,,
27752,,malignant tumors,,,,,,,,,,,,,,,,
27753,,metastatic prostate cancer,,,,,,,,,,,,,,,,
27754,,classical hodgkin,,,,,,,,,,,,,,,,
27755,,fep,,,,,,,,,,,,,,,,
27756,,chronic renal impairment,,,,,,,,,,,,,,,,
27757,,abusers;|pregnant,,,,,,,,,,,,,,,,
27758,,intracranial metastasis,,,,,,,,,,,,,,,,
27759,,dvt/pe,,,,,,,,,,,,,,,,
27760,,her2 low should,,,,,,,,,,,,,,,,
27761,,r cancer,,,,,,,,,,,,,,,,
27762,,vegetation,,,,,,,,,,,,,,,,
27763,,adequate glucose control.|hypothyroidism provided,,,,,,,,,,,,,,,,
27764,,dry amd,,,,,,,,,,,,,,,,
27765,,hepatic porphyria,,,,,,,,,,,,,,,,
27766,,site infection,,,,,,,,,,,,,,,,
27767,,prolonged loss of,,,,,,,,,,,,,,,,
27768,,mras).|stroke,,,,,,,,,,,,,,,,
27769,,≥8;|thyroid dysfunction,,,,,,,,,,,,,,,,
27770,,macular degeneration);|patients,,,,,,,,,,,,,,,,
27771,,traumatic brain injury;|comorbidities,,,,,,,,,,,,,,,,
27772,,aphakia,,,,,,,,,,,,,,,,
27773,,macular,,,,,,,,,,,,,,,,
27774,,resected lesions,,,,,,,,,,,,,,,,
27775,,thromboembolic events|previous eyelid surgery,,,,,,,,,,,,,,,,
27776,,judged by the investigator to be inappropriate to participate in the trial for any other reason,,,,,,,,,,,,,,,,
27777,,eruptive breakdown.|restorable teeth|permanent molars,,,,,,,,,,,,,,,,
27778,,in situ prostate cancer,,,,,,,,,,,,,,,,
27779,,upper left extremity|pregnancy,,,,,,,,,,,,,,,,
27780,,characteristic findings,,,,,,,,,,,,,,,,
27781,,abnormal coagulation function,,,,,,,,,,,,,,,,
27782,,hours|presence,,,,,,,,,,,,,,,,
27783,,haematoma,,,,,,,,,,,,,,,,
27784,,neurologic issue,,,,,,,,,,,,,,,,
27785,,judged unsuitable to participate in the study,,,,,,,,,,,,,,,,
27786,,rv fractional area change,,,,,,,,,,,,,,,,
27787,,local health,,,,,,,,,,,,,,,,
27788,,eczema|any,,,,,,,,,,,,,,,,
27789,,orthostatic intolerance,,,,,,,,,,,,,,,,
27790,,aseptic osteonecrosis,,,,,,,,,,,,,,,,
27791,,t-wave morphology,,,,,,,,,,,,,,,,
27792,,skin problems,,,,,,,,,,,,,,,,
27793,,solid-pseudopapillary tumor;|known,,,,,,,,,,,,,,,,
27794,,generalized systemic disease,,,,,,,,,,,,,,,,
27795,,diarrheal illnesses,,,,,,,,,,,,,,,,
27796,,endoscopic obesity,,,,,,,,,,,,,,,,
27797,,treatment type,,,,,,,,,,,,,,,,
27798,,doctors,,,,,,,,,,,,,,,,
27799,,deep margin,,,,,,,,,,,,,,,,
27800,,hrec,,,,,,,,,,,,,,,,
27801,,skull fractures,,,,,,,,,,,,,,,,
27802,,gastrointestinal pathology,,,,,,,,,,,,,,,,
27803,,scalp pruritus,,,,,,,,,,,,,,,,
27804,,willebrand's disease,,,,,,,,,,,,,,,,
27805,,aids antibody,,,,,,,,,,,,,,,,
27806,,trauma-focused,,,,,,,,,,,,,,,,
27807,,renal transplant|use,,,,,,,,,,,,,,,,
27808,,pituitary tumors||nonfunctioning adenoma|acromegaly|prolactinoma|rathke's cleft,,,,,,,,,,,,,,,,
27809,,impaired quality,,,,,,,,,,,,,,,,
27810,,radical nephroureterectomy.|patients,,,,,,,,,,,,,,,,
27811,,skin abnormalities,,,,,,,,,,,,,,,,
27812,,of the disorder,,,,,,,,,,,,,,,,
27813,,poor oral,,,,,,,,,,,,,,,,
27814,,contraception,,,,,,,,,,,,,,,,
27815,,alone|trophic skin disorders,,,,,,,,,,,,,,,,
27816,,infection of the brain,,,,,,,,,,,,,,,,
27817,,endoscopic mucosal resection,,,,,,,,,,,,,,,,
27818,,end-organ disease)|anticoagulation use|bleeding dyscrasia|use of,,,,,,,,,,,,,,,,
27819,,invasive diseases,,,,,,,,,,,,,,,,
27820,,circulatory collapse,,,,,,,,,,,,,,,,
27821,,oppositional defiant disorder,,,,,,,,,,,,,,,,
27822,,acute symptoms|agrees to cognitive examinations,,,,,,,,,,,,,,,,
27823,,criteria patients:||dysphagic stroke,,,,,,,,,,,,,,,,
27824,,lack of ability to follow radiation safety precautions,,,,,,,,,,,,,,,,
27825,,psychotropic substance,,,,,,,,,,,,,,,,
27826,,htn controlled,,,,,,,,,,,,,,,,
27827,,isp,,,,,,,,,,,,,,,,
27828,,cerebral ischemic stroke,,,,,,,,,,,,,,,,
27829,,neural retina,,,,,,,,,,,,,,,,
27830,,t4)|distant metastases,,,,,,,,,,,,,,,,
27831,,suffers from diseases of the blood,,,,,,,,,,,,,,,,
27832,,burns,,,,,,,,,,,,,,,,
27833,,transvaginal ultrasound.||,,,,,,,,,,,,,,,,
27834,,cardiovascular disorders,,,,,,,,,,,,,,,,
27835,,medical condition,,,,,,,,,,,,,,,,
27836,,patients):||brain death,,,,,,,,,,,,,,,,
27837,,sedative use disorder,,,,,,,,,,,,,,,,
27838,,developmental disorders;|presence,,,,,,,,,,,,,,,,
27839,,chronic persistent hepatitis,,,,,,,,,,,,,,,,
27840,,conditions of the ear that may interfere with the evaluation of otomycosis,,,,,,,,,,,,,,,,
27841,,graves syndrome,,,,,,,,,,,,,,,,
27842,,splenectomy,,,,,,,,,,,,,,,,
27843,,condition|pregnant|non-habitual caffeine intake|smoker|diagnosed cardiovascular disease|beta-blockers|recent,,,,,,,,,,,,,,,,
27844,,cognitive related conditions,,,,,,,,,,,,,,,,
27845,,fahr's disease,,,,,,,,,,,,,,,,
27846,,ds8201a,,,,,,,,,,,,,,,,
27847,,"impaired renal function,|the",,,,,,,,,,,,,,,,
27848,,clinical significance need treatment,,,,,,,,,,,,,,,,
27849,,chronic hemolysis,,,,,,,,,,,,,,,,
27850,,unstable arrhythmias,,,,,,,,,,,,,,,,
27851,,mutant,,,,,,,,,,,,,,,,
27852,,chronic cardiac insufficiency,,,,,,,,,,,,,,,,
27853,,heavy,,,,,,,,,,,,,,,,
27854,,recorded hypertension,,,,,,,,,,,,,,,,
27855,,surgical problems||babies,,,,,,,,,,,,,,,,
27856,,anterior segment abnormalities|presence of ocular,,,,,,,,,,,,,,,,
27857,,c infection,,,,,,,,,,,,,,,,
27858,,multiple co-morbidities,,,,,,,,,,,,,,,,
27859,,carotid disease.|contraindication,,,,,,,,,,,,,,,,
27860,,ventilators,,,,,,,,,,,,,,,,
27861,,cataplexy,,,,,,,,,,,,,,,,
27862,,medullary thyroid carcinoma;|multiple endocrine neoplasia syndrome type,,,,,,,,,,,,,,,,
27863,,colon-rectal cancer duke's class,,,,,,,,,,,,,,,,
27864,,irregular menstrual periods,,,,,,,,,,,,,,,,
27865,,chronic kidney disease epidemiology collaboration formula)|white blood cell count,,,,,,,,,,,,,,,,
27866,,defect,,,,,,,,,,,,,,,,
27867,,fetal status,,,,,,,,,,,,,,,,
27868,,ureteral false passage,,,,,,,,,,,,,,,,
27869,,withdrawal,,,,,,,,,,,,,,,,
27870,,target occlusion,,,,,,,,,,,,,,,,
27871,,contraceptive hormones,,,,,,,,,,,,,,,,
27872,,chronic systemic disorders,,,,,,,,,,,,,,,,
27873,,cozen's test,,,,,,,,,,,,,,,,
27874,,treatment.|laboratory evidence,,,,,,,,,,,,,,,,
27875,,renal impairment||hemoglobin,,,,,,,,,,,,,,,,
27876,,pancreas infection,,,,,,,,,,,,,,,,
27877,,microvasculature,,,,,,,,,,,,,,,,
27878,,third of the crown missing|children,,,,,,,,,,,,,,,,
27879,,male condom,,,,,,,,,,,,,,,,
27880,,menorrhagia,,,,,,,,,,,,,,,,
27881,,latent tb infection,,,,,,,,,,,,,,,,
27882,,lungs,,,,,,,,,,,,,,,,
27883,,thrombotic complications,,,,,,,,,,,,,,,,
27884,,physical handicaps,,,,,,,,,,,,,,,,
27885,,ige-mediated reactions,,,,,,,,,,,,,,,,
27886,,portosystemic shunt,,,,,,,,,,,,,,,,
27887,,chronic diseases;|the,,,,,,,,,,,,,,,,
27888,,hepatitis c (hcvab),,,,,,,,,,,,,,,,
27889,,refractory aml:||a,,,,,,,,,,,,,,,,
27890,,good oral hygiene.|systemic healthy,,,,,,,,,,,,,,,,
27891,,active covid-19,,,,,,,,,,,,,,,,
27892,,infected,,,,,,,,,,,,,,,,
27893,,tumorous disease,,,,,,,,,,,,,,,,
27894,,chronic kidney disease epidemiology collaboration (ckd-epi) equation,,,,,,,,,,,,,,,,
27895,,restrictive cardiomyopathy,,,,,,,,,,,,,,,,
27896,,hbsd,,,,,,,,,,,,,,,,
27897,,acute respiratory syndrome,,,,,,,,,,,,,,,,
27898,,trauma.|drinking alcohol in quantities exceeding 10 units per week,,,,,,,,,,,,,,,,
27899,,syndrome;|huge,,,,,,,,,,,,,,,,
27900,,hf related,,,,,,,,,,,,,,,,
27901,,liver enzyme levels,,,,,,,,,,,,,,,,
27902,,her2 negative adenocarcinoma,,,,,,,,,,,,,,,,
27903,,enzyme-linked,,,,,,,,,,,,,,,,
27904,,chronic hepatic impairment,,,,,,,,,,,,,,,,
27905,,disease related,,,,,,,,,,,,,,,,
27906,,implantable electrical devices|pregnancy,,,,,,,,,,,,,,,,
27907,,mediastinal mass syndrome|admission,,,,,,,,,,,,,,,,
27908,,spontaneously menopausal,,,,,,,,,,,,,,,,
27909,,cognitive-behavioral therapy,,,,,,,,,,,,,,,,
27910,,thymic malignancy,,,,,,,,,,,,,,,,
27911,,ctcae version 5.0,,,,,,,,,,,,,,,,
27912,,inferior gluteal folds.||,,,,,,,,,,,,,,,,
27913,,deep venous thrombosis,,,,,,,,,,,,,,,,
27914,,recurrent disease should,,,,,,,,,,,,,,,,
27915,,lap lactase deficiency,,,,,,,,,,,,,,,,
27916,,breast feeding.|conditions,,,,,,,,,,,,,,,,
27917,,progressive sclerosis,,,,,,,,,,,,,,,,
27918,,anaphylaxis,,,,,,,,,,,,,,,,
27919,,medication|active substance,,,,,,,,,,,,,,,,
27920,,severe hypokinesia,,,,,,,,,,,,,,,,
27921,,severity levels,,,,,,,,,,,,,,,,
27922,,questionnaires.|inflammatory bowel disease|lactose intolerance,,,,,,,,,,,,,,,,
27923,,10 risk domain criteria,,,,,,,,,,,,,,,,
27924,,sleep apnea syndrome,,,,,,,,,,,,,,,,
27925,,chronic obstructive disease|history of,,,,,,,,,,,,,,,,
27926,,bilateral damage.|active suicidal,,,,,,,,,,,,,,,,
27927,,skin reactions|history,,,,,,,,,,,,,,,,
27928,,digestive system malignancies,,,,,,,,,,,,,,,,
27929,,chronic obstructive pulmonary disease|pregnancy,,,,,,,,,,,,,,,,
27930,,complex staghorn stones,,,,,,,,,,,,,,,,
27931,,reduced rv function,,,,,,,,,,,,,,,,
27932,,antacid,,,,,,,,,,,,,,,,
27933,,systemic scleroderma,,,,,,,,,,,,,,,,
27934,,necrosis,,,,,,,,,,,,,,,,
27935,,peripheral neuropathy)|mean qt interval corrected,,,,,,,,,,,,,,,,
27936,,tourette's,,,,,,,,,,,,,,,,
27937,,extragastric measurable lesion,,,,,,,,,,,,,,,,
27938,,apical periodontitis,,,,,,,,,,,,,,,,
27939,,gastrointestinal endoscopy|clinical diagnosis,,,,,,,,,,,,,,,,
27940,,immunosuppressive treatments|pregnancy,,,,,,,,,,,,,,,,
27941,,acute suicide risk,,,,,,,,,,,,,,,,
27942,,suicidal ideation,,,,,,,,,,,,,,,,
27943,,natural teeth,,,,,,,,,,,,,,,,
27944,,days|excessive exercise,,,,,,,,,,,,,,,,
27945,,t2-4|patients,,,,,,,,,,,,,,,,
27946,,home|cognitive impairment,,,,,,,,,,,,,,,,
27947,,apixaban|liver disease,,,,,,,,,,,,,,,,
27948,,hyperlipidemia)|unstable angina,,,,,,,,,,,,,,,,
27949,,postoperative complications|intraoperative iris manipulations,,,,,,,,,,,,,,,,
27950,,chronic cardiac insufficiency (,,,,,,,,,,,,,,,,
27951,,clonidine may enter the study,,,,,,,,,,,,,,,,
27952,,short bowel,,,,,,,,,,,,,,,,
27953,,lymphoproliferative diseases,,,,,,,,,,,,,,,,
27954,,altruistic kidney donor,,,,,,,,,,,,,,,,
27955,,autonomic dysreflexia,,,,,,,,,,,,,,,,
27956,,conjunctival symptoms,,,,,,,,,,,,,,,,
27957,,cardiovascular disease|a condition,,,,,,,,,,,,,,,,
27958,,csvd,,,,,,,,,,,,,,,,
27959,,type 1 diabetes.|recent,,,,,,,,,,,,,,,,
27960,,attr-cm,,,,,,,,,,,,,,,,
27961,,oncolytic virus,,,,,,,,,,,,,,,,
27962,,progressive metastatic castration-resistant prostate cancer,,,,,,,,,,,,,,,,
27963,,cervical lesions,,,,,,,,,,,,,,,,
27964,,speech,,,,,,,,,,,,,,,,
27965,,psychotic disorder,,,,,,,,,,,,,,,,
27966,,cerebrovascular disorders,,,,,,,,,,,,,,,,
27967,,multiple pregnancy.|known,,,,,,,,,,,,,,,,
27968,,rt,,,,,,,,,,,,,,,,
27969,,mrsa infection,,,,,,,,,,,,,,,,
27970,,solid organ transplant.||subjects,,,,,,,,,,,,,,,,
27971,,cider vinegar,,,,,,,,,,,,,,,,
27972,,coronary artery stenosis,,,,,,,,,,,,,,,,
27973,,impact on immune response,,,,,,,,,,,,,,,,
27974,,back pelvis,,,,,,,,,,,,,,,,
27975,,variceal bledding;|chronic kidney disease;|pregnancy,,,,,,,,,,,,,,,,
27976,,parkinson's,,,,,,,,,,,,,,,,
27977,,angioedema.|idiopathic urticaria,,,,,,,,,,,,,,,,
27978,,prohibitive co-payment,,,,,,,,,,,,,,,,
27979,,a)|concomitant injuries,,,,,,,,,,,,,,,,
27980,,host-versus-graft (hvg),,,,,,,,,,,,,,,,
27981,,surgically sterilized,,,,,,,,,,,,,,,,
27982,,chronic heart failure,,,,,,,,,,,,,,,,
27983,,inflammatory disease|vision impairments|orthopaedic problems,,,,,,,,,,,,,,,,
27984,,intact ovaries,,,,,,,,,,,,,,,,
27985,,cardiac comorbidities,,,,,,,,,,,,,,,,
27986,,lasting effects,,,,,,,,,,,,,,,,
27987,,peptic ulcer disease.|patients,,,,,,,,,,,,,,,,
27988,,organ system dysfunction,,,,,,,,,,,,,,,,
27989,,complex care).||,,,,,,,,,,,,,,,,
27990,,eczematous dermatitis,,,,,,,,,,,,,,,,
27991,,t2 squamous cell carcinoma of the nasal vestibule.|tumor diameter ≥1.5 cm,,,,,,,,,,,,,,,,
27992,,bone injury,,,,,,,,,,,,,,,,
27993,,breastfeeding;|hyperglycemia,,,,,,,,,,,,,,,,
27994,,congenital brain hypoplasia,,,,,,,,,,,,,,,,
27995,,food anaphylaxis,,,,,,,,,,,,,,,,
27996,,communication disorders.|in,,,,,,,,,,,,,,,,
27997,,non-speech treatment,,,,,,,,,,,,,,,,
27998,,symptoms from,,,,,,,,,,,,,,,,
27999,,refractive stability,,,,,,,,,,,,,,,,
28000,,active bacterial,,,,,,,,,,,,,,,,
28001,,recurrent fissure,,,,,,,,,,,,,,,,
28002,,regulatory bodies,,,,,,,,,,,,,,,,
28003,,sanger sequencing,,,,,,,,,,,,,,,,
28004,,right-handed,,,,,,,,,,,,,,,,
28005,,hypopharyngeal cancer,,,,,,,,,,,,,,,,
28006,,laceration wounds,,,,,,,,,,,,,,,,
28007,,associated disease,,,,,,,,,,,,,,,,
28008,,liver mass,,,,,,,,,,,,,,,,
28009,,total lymphoid irradiation.|presence,,,,,,,,,,,,,,,,
28010,,normal coagulation function,,,,,,,,,,,,,,,,
28011,,hallucinations questionnaire,,,,,,,,,,,,,,,,
28012,,psychotic spectrum disorder,,,,,,,,,,,,,,,,
28013,,renal dysfunction;|hypertension,,,,,,,,,,,,,,,,
28014,,analgesic medications;|pain,,,,,,,,,,,,,,,,
28015,,additional risk factors,,,,,,,,,,,,,,,,
28016,,autoimmune related hypothyroidism,,,,,,,,,,,,,,,,
28017,,dercum's disease,,,,,,,,,,,,,,,,
28018,,visible skin disease,,,,,,,,,,,,,,,,
28019,,hepatic decompensation,,,,,,,,,,,,,,,,
28020,,coronavirus,,,,,,,,,,,,,,,,
28021,,intravesical immunotherapy.|bladder neck,,,,,,,,,,,,,,,,
28022,,primrose,,,,,,,,,,,,,,,,
28023,,manifest neurologic progression,,,,,,,,,,,,,,,,
28024,,sleep disruptions)|alcohol,,,,,,,,,,,,,,,,
28025,,hepatic capsule invasion,,,,,,,,,,,,,,,,
28026,,screening.|chronic kidney disease,,,,,,,,,,,,,,,,
28027,,cannabis|children,,,,,,,,,,,,,,,,
28028,,écrit,,,,,,,,,,,,,,,,
28029,,solid organ transplant.|recipient,,,,,,,,,,,,,,,,
28030,,hiatal -hernia,,,,,,,,,,,,,,,,
28031,,histopathologic,,,,,,,,,,,,,,,,
28032,,early gc,,,,,,,,,,,,,,,,
28033,,previous diseases,,,,,,,,,,,,,,,,
28034,,congestive heart disease,,,,,,,,,,,,,,,,
28035,,solid tumor.||phase,,,,,,,,,,,,,,,,
28036,,cholangiocellular carcinoma,,,,,,,,,,,,,,,,
28037,,horseradish,,,,,,,,,,,,,,,,
28038,,gonb,,,,,,,,,,,,,,,,
28039,,electrocardiogram|normal echocardiography|written,,,,,,,,,,,,,,,,
28040,,germline atm,,,,,,,,,,,,,,,,
28041,,intracranial arterial stenosis,,,,,,,,,,,,,,,,
28042,,vascular endothelial growth factor receptor (vegfr) directed therapies,,,,,,,,,,,,,,,,
28043,,surgical diseases,,,,,,,,,,,,,,,,
28044,,neurological disorder|electroconvulsive therapy (ect),,,,,,,,,,,,,,,,
28045,,arterial stenosis,,,,,,,,,,,,,,,,
28046,,length discrepancy,,,,,,,,,,,,,,,,
28047,,ced symptoms,,,,,,,,,,,,,,,,
28048,,axspa,,,,,,,,,,,,,,,,
28049,,vascular variation,,,,,,,,,,,,,,,,
28050,,sports drinks,,,,,,,,,,,,,,,,
28051,,rls,,,,,,,,,,,,,,,,
28052,,periodic,,,,,,,,,,,,,,,,
28053,,astenia,,,,,,,,,,,,,,,,
28054,,"abstain from intensive muscular effort,|inability",,,,,,,,,,,,,,,,
28055,,disorder|asplenia,,,,,,,,,,,,,,,,
28056,,severe uni-,,,,,,,,,,,,,,,,
28057,,ptt,,,,,,,,,,,,,,,,
28058,,macular degeneration.||,,,,,,,,,,,,,,,,
28059,,gout||vi,,,,,,,,,,,,,,,,
28060,,surgical wounds,,,,,,,,,,,,,,,,
28061,,relapsing bppv,,,,,,,,,,,,,,,,
28062,,non-restorable,,,,,,,,,,,,,,,,
28063,,glucose-galactose malabsorption.|those,,,,,,,,,,,,,,,,
28064,,uc disease,,,,,,,,,,,,,,,,
28065,,chronic lung failure,,,,,,,,,,,,,,,,
28066,,non-cancerous pain,,,,,,,,,,,,,,,,
28067,,neuropsychiatric sle,,,,,,,,,,,,,,,,
28068,,apa,,,,,,,,,,,,,,,,
28069,,lower extremity fracture,,,,,,,,,,,,,,,,
28070,,anaplastic lymphoma kinase (alk),,,,,,,,,,,,,,,,
28071,,glycaemia,,,,,,,,,,,,,,,,
28072,,ruptured globe,,,,,,,,,,,,,,,,
28073,,complex regional pain syndrome,,,,,,,,,,,,,,,,
28074,,contraindications deformity of the ear,,,,,,,,,,,,,,,,
28075,,claustrophobic,,,,,,,,,,,,,,,,
28076,,schistocytes|severe hypertension,,,,,,,,,,,,,,,,
28077,,hepatitis d antibody，positive hepatitis e antibody，positive hepatitis b surface antigen (hbsag),,,,,,,,,,,,,,,,
28078,,knee oa symptoms,,,,,,,,,,,,,,,,
28079,,cardiovascular symptoms,,,,,,,,,,,,,,,,
28080,,ascites controlled,,,,,,,,,,,,,,,,
28081,,pneumonitis.|active infection,,,,,,,,,,,,,,,,
28082,,neoplastic,,,,,,,,,,,,,,,,
28083,,functioning of the eit device|high,,,,,,,,,,,,,,,,
28084,,renal replacement therapy)|severe liver failure,,,,,,,,,,,,,,,,
28085,,months|able to swallow,,,,,,,,,,,,,,,,
28086,,regulatory agency,,,,,,,,,,,,,,,,
28087,,medical trauma,,,,,,,,,,,,,,,,
28088,,brain tumor multidisciplinary committee,,,,,,,,,,,,,,,,
28089,,acute thrombotic venous events,,,,,,,,,,,,,,,,
28090,,pharmacological probe,,,,,,,,,,,,,,,,
28091,,carcinoma-,,,,,,,,,,,,,,,,
28092,,tmj disorder,,,,,,,,,,,,,,,,
28093,,neuromuscular disorders,,,,,,,,,,,,,,,,
28094,,prolonged unconsciousness,,,,,,,,,,,,,,,,
28095,,al)|intracranial tumor,,,,,,,,,,,,,,,,
28096,,orthostatic hypotension|participants,,,,,,,,,,,,,,,,
28097,,drug dependency,,,,,,,,,,,,,,,,
28098,,chronic renal dialysis.||18,,,,,,,,,,,,,,,,
28099,,hair loss,,,,,,,,,,,,,,,,
28100,,cardiac dysrhythmias,,,,,,,,,,,,,,,,
28101,,ductus arteriosus,,,,,,,,,,,,,,,,
28102,,spinal cord hemorrhage,,,,,,,,,,,,,,,,
28103,,physically spreading,,,,,,,,,,,,,,,,
28104,,bowen's disease,,,,,,,,,,,,,,,,
28105,,years.|nasopharyngeal carcinoma,,,,,,,,,,,,,,,,
28106,,digital ganglion cyst removal,,,,,,,,,,,,,,,,
28107,,lubricant etc.)|menstruation|pregnancy,,,,,,,,,,,,,,,,
28108,,glaucoma.|persistent toxicities,,,,,,,,,,,,,,,,
28109,,positive human immunodeficiency virus (hiv),,,,,,,,,,,,,,,,
28110,,coagulation disorder|identified,,,,,,,,,,,,,,,,
28111,,gastrointestinal (gi) abnormalities,,,,,,,,,,,,,,,,
28112,,hypercalcemia|neurodevelopmental disabilities,,,,,,,,,,,,,,,,
28113,,disease;|skin diseases,,,,,,,,,,,,,,,,
28114,,neonatal co-morbidities,,,,,,,,,,,,,,,,
28115,,invasive cancer,,,,,,,,,,,,,,,,
28116,,b-cll/sll,,,,,,,,,,,,,,,,
28117,,cns lesions,,,,,,,,,,,,,,,,
28118,,angioneurotic edema;|respiratory failure,,,,,,,,,,,,,,,,
28119,,enterocolitis,,,,,,,,,,,,,,,,
28120,,unstable cardiovascular disease.|bmi,,,,,,,,,,,,,,,,
28121,,local ovarian surgery,,,,,,,,,,,,,,,,
28122,,steatosis-inducing drugs,,,,,,,,,,,,,,,,
28123,,stereognosis,,,,,,,,,,,,,,,,
28124,,sensitivities,,,,,,,,,,,,,,,,
28125,,irregular severe,,,,,,,,,,,,,,,,
28126,,reconstructed|duplicated collecting system,,,,,,,,,,,,,,,,
28127,,internal eye,,,,,,,,,,,,,,,,
28128,,chlorhexidine gluconate,,,,,,,,,,,,,,,,
28129,,abdominal abscesses,,,,,,,,,,,,,,,,
28130,,subarachnoid hemorrhage,,,,,,,,,,,,,,,,
28131,,parasites,,,,,,,,,,,,,,,,
28132,,motility disorders,,,,,,,,,,,,,,,,
28133,,psychological medical condition,,,,,,,,,,,,,,,,
28134,,neuroma,,,,,,,,,,,,,,,,
28135,,proof distilled spirits,,,,,,,,,,,,,,,,
28136,,propofol.||no known allergy,,,,,,,,,,,,,,,,
28137,,nutritional risk,,,,,,,,,,,,,,,,
28138,,confusion,,,,,,,,,,,,,,,,
28139,,theatre|neurological disorders,,,,,,,,,,,,,,,,
28140,,nurses,,,,,,,,,,,,,,,,
28141,,hbv)||g,,,,,,,,,,,,,,,,
28142,,injectable hormones,,,,,,,,,,,,,,,,
28143,,aortic arch dissection,,,,,,,,,,,,,,,,
28144,,heart disease|patients,,,,,,,,,,,,,,,,
28145,,hereditary hemorrhagic telangiectasia,,,,,,,,,,,,,,,,
28146,,apical periodontitis|healthy,,,,,,,,,,,,,,,,
28147,,squamous epithelial carcinomas,,,,,,,,,,,,,,,,
28148,,c)|diagnosis,,,,,,,,,,,,,,,,
28149,,extremely obese,,,,,,,,,,,,,,,,
28150,,prostate cancer|neoplasia,,,,,,,,,,,,,,,,
28151,,ipsilateral axillary nodes,,,,,,,,,,,,,,,,
28152,,hypertrophic heart disease,,,,,,,,,,,,,,,,
28153,,follicular-derived,,,,,,,,,,,,,,,,
28154,,coordinating center,,,,,,,,,,,,,,,,
28155,,pathology of the maxillofacial region (benign,,,,,,,,,,,,,,,,
28156,,coagulation times,,,,,,,,,,,,,,,,
28157,,organic damage,,,,,,,,,,,,,,,,
28158,,resectable tumors,,,,,,,,,,,,,,,,
28159,,impaired by administrative or legal order,,,,,,,,,,,,,,,,
28160,,major organs function,,,,,,,,,,,,,,,,
28161,,chronic lung disease;|class,,,,,,,,,,,,,,,,
28162,,pt1-2n1,,,,,,,,,,,,,,,,
28163,,solid organ transplantation|presence,,,,,,,,,,,,,,,,
28164,,clotting factor abnormality,,,,,,,,,,,,,,,,
28165,,atlantia,,,,,,,,,,,,,,,,
28166,,cardiac event.|any,,,,,,,,,,,,,,,,
28167,,codes,,,,,,,,,,,,,,,,
28168,,conventional antipsoriatic systemic therapy,,,,,,,,,,,,,,,,
28169,,lower esophageal,,,,,,,,,,,,,,,,
28170,,intrastromal corneal ring segments,,,,,,,,,,,,,,,,
28171,,psychiatric co-morbidity,,,,,,,,,,,,,,,,
28172,,non-diabetic healthy,,,,,,,,,,,,,,,,
28173,,anaphylactic reaction|exclusion criteria,,,,,,,,,,,,,,,,
28174,,adenomatous polyps,,,,,,,,,,,,,,,,
28175,,non-fasting glucose,,,,,,,,,,,,,,,,
28176,,squamous nsclc.|tumor sample with cmet,,,,,,,,,,,,,,,,
28177,,high bleeding tendency lesions,,,,,,,,,,,,,,,,
28178,,scabies,,,,,,,,,,,,,,,,
28179,,retinal detachment,,,,,,,,,,,,,,,,
28180,,electron beam radiation,,,,,,,,,,,,,,,,
28181,,angel's,,,,,,,,,,,,,,,,
28182,,required|clinically stable,,,,,,,,,,,,,,,,
28183,,third hospital yanqing hospital,,,,,,,,,,,,,,,,
28184,,carriers,,,,,,,,,,,,,,,,
28185,,day|intention,,,,,,,,,,,,,,,,
28186,,intestinal perforation,,,,,,,,,,,,,,,,
28187,,drug-induced liver disease,,,,,,,,,,,,,,,,
28188,,menopause induced,,,,,,,,,,,,,,,,
28189,,chemotherapy|gynecologic cancer,,,,,,,,,,,,,,,,
28190,,exposed to histone deacetylase inhibitors,,,,,,,,,,,,,,,,
28191,,bradyarrhythmia,,,,,,,,,,,,,,,,
28192,,hepatolenticular degeneration,,,,,,,,,,,,,,,,
28193,,cirrhosis|annual risk of hcc,,,,,,,,,,,,,,,,
28194,,serial slides,,,,,,,,,,,,,,,,
28195,,igg4-rd,,,,,,,,,,,,,,,,
28196,,declaring himself,,,,,,,,,,,,,,,,
28197,,benign hematologic,,,,,,,,,,,,,,,,
28198,,substance-related disorders,,,,,,,,,,,,,,,,
28199,,metabolic lesion,,,,,,,,,,,,,,,,
28200,,sos)|uncontrolled,,,,,,,,,,,,,,,,
28201,,organic brain disorders,,,,,,,,,,,,,,,,
28202,,identifies,,,,,,,,,,,,,,,,
28203,,semi-permanent,,,,,,,,,,,,,,,,
28204,,disease|allergic reaction,,,,,,,,,,,,,,,,
28205,,platelet weakness,,,,,,,,,,,,,,,,
28206,,pulmonary infiltration,,,,,,,,,,,,,,,,
28207,,invading surrounding organs,,,,,,,,,,,,,,,,
28208,,urea,,,,,,,,,,,,,,,,
28209,,hepatitis b core antibody positive,,,,,,,,,,,,,,,,
28210,,barrier pregnancy,,,,,,,,,,,,,,,,
28211,,car,,,,,,,,,,,,,,,,
28212,,acute episodes,,,,,,,,,,,,,,,,
28213,,acute physiological assessment,,,,,,,,,,,,,,,,
28214,,preservative allergy|no,,,,,,,,,,,,,,,,
28215,,sickle cell anemia,,,,,,,,,,,,,,,,
28216,,chronic thromboembolic disease,,,,,,,,,,,,,,,,
28217,,diverticular stenosis,,,,,,,,,,,,,,,,
28218,,obstructive aetiology.|patients,,,,,,,,,,,,,,,,
28219,,2013)|symptoms,,,,,,,,,,,,,,,,
28220,,coronary/peripheral bypass,,,,,,,,,,,,,,,,
28221,,another malignancy,,,,,,,,,,,,,,,,
28222,,subthreshold symptoms,,,,,,,,,,,,,,,,
28223,,liver metastases).|aspartate aminotransferase,,,,,,,,,,,,,,,,
28224,,distal biliary stent dysfunction,,,,,,,,,,,,,,,,
28225,,dispatch,,,,,,,,,,,,,,,,
28226,,etc.);|a disease,,,,,,,,,,,,,,,,
28227,,"disc disease,||5-persistent",,,,,,,,,,,,,,,,
28228,,persistent adhd,,,,,,,,,,,,,,,,
28229,,human immunodefici,,,,,,,,,,,,,,,,
28230,,hospital admissions,,,,,,,,,,,,,,,,
28231,,associated abnormalities,,,,,,,,,,,,,,,,
28232,,hematology abnormality,,,,,,,,,,,,,,,,
28233,,thromboembolic,,,,,,,,,,,,,,,,
28234,,left ventricular hypertrophy,,,,,,,,,,,,,,,,
28235,,end-stage heart failure,,,,,,,,,,,,,,,,
28236,,hepatitis b-virus surface antigen (hbsag),,,,,,,,,,,,,,,,
28237,,cardiogenic pulmonary oedema|patients,,,,,,,,,,,,,,,,
28238,,sjogren's disease,,,,,,,,,,,,,,,,
28239,,affect,,,,,,,,,,,,,,,,
28240,,non-pulmonary sepsis,,,,,,,,,,,,,,,,
28241,,hyper igd syndrome,,,,,,,,,,,,,,,,
28242,,mcl)|follicular lymphoma,,,,,,,,,,,,,,,,
28243,,limb extremity,,,,,,,,,,,,,,,,
28244,,acute heart failure|,,,,,,,,,,,,,,,,
28245,,laboratory findings,,,,,,,,,,,,,,,,
28246,,developed,,,,,,,,,,,,,,,,
28247,,tolerance,,,,,,,,,,,,,,,,
28248,,large bowel surgery|inflammatory bowel disease|active,,,,,,,,,,,,,,,,
28249,,burkholderia cepacia complex,,,,,,,,,,,,,,,,
28250,,stricturing,,,,,,,,,,,,,,,,
28251,,r cancer arm,,,,,,,,,,,,,,,,
28252,,residual disease,,,,,,,,,,,,,,,,
28253,,plain,,,,,,,,,,,,,,,,
28254,,pulmonary regurgitation,,,,,,,,,,,,,,,,
28255,,pressure)|lung disease,,,,,,,,,,,,,,,,
28256,,mrkh syndrome,,,,,,,,,,,,,,,,
28257,,oa).|unilateral total knee replacement surgery recommended by orthopedics,,,,,,,,,,,,,,,,
28258,,uveal melanoma,,,,,,,,,,,,,,,,
28259,,transient ischemic attack,,,,,,,,,,,,,,,,
28260,,"discharge),|suicidal tendency",,,,,,,,,,,,,,,,
28261,,"circulation problems,|infection,|fibromyalgia",,,,,,,,,,,,,,,,
28262,,discharged from the intensive care unit|oxygen,,,,,,,,,,,,,,,,
28263,,severe pulmonary disease,,,,,,,,,,,,,,,,
28264,,non-invasive carcinoma of the,,,,,,,,,,,,,,,,
28265,,severe intellectual disability,,,,,,,,,,,,,,,,
28266,,dependence that,,,,,,,,,,,,,,,,
28267,,prolonged sitting.||,,,,,,,,,,,,,,,,
28268,,renal disease)|recent,,,,,,,,,,,,,,,,
28269,,good function,,,,,,,,,,,,,,,,
28270,,umbilical cord blood,,,,,,,,,,,,,,,,
28271,,growing||,,,,,,,,,,,,,,,,
28272,,thoracic esophageal,,,,,,,,,,,,,,,,
28273,,reconstructed||high-risk features,,,,,,,,,,,,,,,,
28274,,apathy,,,,,,,,,,,,,,,,
28275,,laryngitis,,,,,,,,,,,,,,,,
28276,,sexual orientation of the patient ensures compliance,,,,,,,,,,,,,,,,
28277,,prinzmetal's angina|any,,,,,,,,,,,,,,,,
28278,,with:|mania,,,,,,,,,,,,,,,,
28279,,inflammatory bowel syndrome,,,,,,,,,,,,,,,,
28280,,causes;|malignant neoplasm,,,,,,,,,,,,,,,,
28281,,cardiovascular causes,,,,,,,,,,,,,,,,
28282,,scrotal pain,,,,,,,,,,,,,,,,
28283,,septal,,,,,,,,,,,,,,,,
28284,,ct brain,,,,,,,,,,,,,,,,
28285,,dsrd symptoms,,,,,,,,,,,,,,,,
28286,,delay,,,,,,,,,,,,,,,,
28287,,active pulmonary diseases.|initiation,,,,,,,,,,,,,,,,
28288,,aortic dissection,,,,,,,,,,,,,,,,
28289,,impairment of level of consciousness,,,,,,,,,,,,,,,,
28290,,morbid obesity)|high,,,,,,,,,,,,,,,,
28291,,patients:||age,,,,,,,,,,,,,,,,
28292,,gastroenteropancreatic neuroendocrine tumors,,,,,,,,,,,,,,,,
28293,,gastrointestinal obstruction;|patients,,,,,,,,,,,,,,,,
28294,,organic gastrointestinal diseases,,,,,,,,,,,,,,,,
28295,,breast feeding|myocardial infarction,,,,,,,,,,,,,,,,
28296,,arteriovenous bridging after,,,,,,,,,,,,,,,,
28297,,normalized,,,,,,,,,,,,,,,,
28298,,adrenal insufficiency.|patient,,,,,,,,,,,,,,,,
28299,,lung condition,,,,,,,,,,,,,,,,
28300,,field experience|participants labeled,,,,,,,,,,,,,,,,
28301,,sporadic colorectal cancer,,,,,,,,,,,,,,,,
28302,,congenital ptosis,,,,,,,,,,,,,,,,
28303,,gout flare,,,,,,,,,,,,,,,,
28304,,nerve injury,,,,,,,,,,,,,,,,
28305,,hypertensive encephalopathy；|pregnant,,,,,,,,,,,,,,,,
28306,,anarthria,,,,,,,,,,,,,,,,
28307,,ophthalmic pathology,,,,,,,,,,,,,,,,
28308,,obstructive disease,,,,,,,,,,,,,,,,
28309,,malignant tumors;12,,,,,,,,,,,,,,,,
28310,,depigmentation,,,,,,,,,,,,,,,,
28311,,tumour necrosis factor blockers,,,,,,,,,,,,,,,,
28312,,adhesions,,,,,,,,,,,,,,,,
28313,,spinal cord abnormalities,,,,,,,,,,,,,,,,
28314,,vaginal fluid,,,,,,,,,,,,,,,,
28315,,antiglaucoma drugs)|any,,,,,,,,,,,,,,,,
28316,,generalized anxiety disorder questionnaire,,,,,,,,,,,,,,,,
28317,,suppress the immune,,,,,,,,,,,,,,,,
28318,,once bp,,,,,,,,,,,,,,,,
28319,,systemic pathology,,,,,,,,,,,,,,,,
28320,,neurologic affection,,,,,,,,,,,,,,,,
28321,,malformative pathology,,,,,,,,,,,,,,,,
28322,,ild/pneumonitis,,,,,,,,,,,,,,,,
28323,,nusinersen||,,,,,,,,,,,,,,,,
28324,,chronic dialysis therapy|new,,,,,,,,,,,,,,,,
28325,,blast,,,,,,,,,,,,,,,,
28326,,idiopathic interstitial pneumonias,,,,,,,,,,,,,,,,
28327,,external cervical resorption,,,,,,,,,,,,,,,,
28328,,cyst wall,,,,,,,,,,,,,,,,
28329,,persistent symptoms,,,,,,,,,,,,,,,,
28330,,abuse,,,,,,,,,,,,,,,,
28331,,spinal cord lesion,,,,,,,,,,,,,,,,
28332,,fetal heart disease,,,,,,,,,,,,,,,,
28333,,significant degree|cancer,,,,,,,,,,,,,,,,
28334,,eyeliner,,,,,,,,,,,,,,,,
28335,,impairment|myasthenia gravis,,,,,,,,,,,,,,,,
28336,,msh2,,,,,,,,,,,,,,,,
28337,,sleep disturbances,,,,,,,,,,,,,,,,
28338,,artificial tears|non-compliance to the study protocol,,,,,,,,,,,,,,,,
28339,,inmates,,,,,,,,,,,,,,,,
28340,,antibodies,,,,,,,,,,,,,,,,
28341,,cerebrovascular disease.|participants,,,,,,,,,,,,,,,,
28342,,anatomically narrow,,,,,,,,,,,,,,,,
28343,,related to asthma characterised,,,,,,,,,,,,,,,,
28344,,bipolar disorders,,,,,,,,,,,,,,,,
28345,,hiv infection.||a positive test,,,,,,,,,,,,,,,,
28346,,ue countries,,,,,,,,,,,,,,,,
28347,,under investigation,,,,,,,,,,,,,,,,
28348,,digital rectal,,,,,,,,,,,,,,,,
28349,,respiratory insufficiency|psychiatric disorders|pregnancy,,,,,,,,,,,,,,,,
28350,,hepatitis b virus carriers,,,,,,,,,,,,,,,,
28351,,"sexes,|respectablee pancreaticoduodenal tumors",,,,,,,,,,,,,,,,
28352,,wall hernia|diaphragmatic hernia|coagulation,,,,,,,,,,,,,,,,
28353,,humoral/b-,,,,,,,,,,,,,,,,
28354,,antiphospholipid syndrome,,,,,,,,,,,,,,,,
28355,,non-hbv infection,,,,,,,,,,,,,,,,
28356,,polymorphous adenocarcinoma,,,,,,,,,,,,,,,,
28357,,diagnostic standards for hepatitis b issued,,,,,,,,,,,,,,,,
28358,,legal blindness,,,,,,,,,,,,,,,,
28359,,extraintestinal symptoms,,,,,,,,,,,,,,,,
28360,,chest wall + supraclavicular,,,,,,,,,,,,,,,,
28361,,ovarian metastasis,,,,,,,,,,,,,,,,
28362,,squamous cell carcinoma of head and neck,,,,,,,,,,,,,,,,
28363,,potentially vulnerable,,,,,,,,,,,,,,,,
28364,,solid tumor carrying hrr,,,,,,,,,,,,,,,,
28365,,orientation,,,,,,,,,,,,,,,,
28366,,endometrial lesions,,,,,,,,,,,,,,,,
28367,,neuromuscular disease,,,,,,,,,,,,,,,,
28368,,cornealor retinal pathologies,,,,,,,,,,,,,,,,
28369,,pharyngeal anatomical abnormalities,,,,,,,,,,,,,,,,
28370,,"psychotic features,|meets diagnostic criteria",,,,,,,,,,,,,,,,
28371,,neurological comorbidity,,,,,,,,,,,,,,,,
28372,,deficiency,,,,,,,,,,,,,,,,
28373,,fracture;|asthmatic bronchitis,,,,,,,,,,,,,,,,
28374,,peripheral neuritis,,,,,,,,,,,,,,,,
28375,,sero+ children,,,,,,,,,,,,,,,,
28376,,abdomen,,,,,,,,,,,,,,,,
28377,,irls score,,,,,,,,,,,,,,,,
28378,,alpha-lipoic acid,,,,,,,,,,,,,,,,
28379,,blunted autonomic,,,,,,,,,,,,,,,,
28380,,pneumonitis.|active autoimmune disease,,,,,,,,,,,,,,,,
28381,,chronic oxygen,,,,,,,,,,,,,,,,
28382,,hepatitis e virus,,,,,,,,,,,,,,,,
28383,,tendency,,,,,,,,,,,,,,,,
28384,,unstable medical condition,,,,,,,,,,,,,,,,
28385,,stable immune thyroiditis,,,,,,,,,,,,,,,,
28386,,obtained.|the,,,,,,,,,,,,,,,,
28387,,multiple sclerosis||,,,,,,,,,,,,,,,,
28388,,skin cancer resection,,,,,,,,,,,,,,,,
28389,,hemorrhage)|postoperative complications,,,,,,,,,,,,,,,,
28390,,hepato-pancreato-biliary|referral,,,,,,,,,,,,,,,,
28391,,developmental anomalies,,,,,,,,,,,,,,,,
28392,,gallbladder disease,,,,,,,,,,,,,,,,
28393,,traumatic event exposure,,,,,,,,,,,,,,,,
28394,,chronic diseases|participants,,,,,,,,,,,,,,,,
28395,,immune-deficiency syndrome,,,,,,,,,,,,,,,,
28396,,digestive ulcer,,,,,,,,,,,,,,,,
28397,,nociplastic type||,,,,,,,,,,,,,,,,
28398,,intracranial injury,,,,,,,,,,,,,,,,
28399,,sah,,,,,,,,,,,,,,,,
28400,,preclude response,,,,,,,,,,,,,,,,
28401,,pituitary adenoma,,,,,,,,,,,,,,,,
28402,,axillary levels,,,,,,,,,,,,,,,,
28403,,choose,,,,,,,,,,,,,,,,
28404,,microcephaly,,,,,,,,,,,,,,,,
28405,,immunodeficiency state.|an,,,,,,,,,,,,,,,,
28406,,national policies,,,,,,,,,,,,,,,,
28407,,extensive bowel resection,,,,,,,,,,,,,,,,
28408,,acute liver failure,,,,,,,,,,,,,,,,
28409,,niv contraindication,,,,,,,,,,,,,,,,
28410,,aom episode,,,,,,,,,,,,,,,,
28411,,gastroesophageal reflux.|able,,,,,,,,,,,,,,,,
28412,,corticoids infiltration,,,,,,,,,,,,,,,,
28413,,dementia;|hachinski ischemia scale,,,,,,,,,,,,,,,,
28414,,non-mri compatible,,,,,,,,,,,,,,,,
28415,,level,,,,,,,,,,,,,,,,
28416,,adverse events.|active ulcers,,,,,,,,,,,,,,,,
28417,,etc.|pregnant,,,,,,,,,,,,,,,,
28418,,pneumoniae sensitive,,,,,,,,,,,,,,,,
28419,,active alcohol,,,,,,,,,,,,,,,,
28420,,iiid heart failure,,,,,,,,,,,,,,,,
28421,,seizures|ventilator dependence,,,,,,,,,,,,,,,,
28422,,co-stimulation signal;|8.serum creatinine,,,,,,,,,,,,,,,,
28423,,lower common bile duct,,,,,,,,,,,,,,,,
28424,,b- all,,,,,,,,,,,,,,,,
28425,,uln)|serum,,,,,,,,,,,,,,,,
28426,,primary diseases of the testes,,,,,,,,,,,,,,,,
28427,,breast cancer,,,,,,,,,,,,,,,,
28428,,gastrointestinal system disorders,,,,,,,,,,,,,,,,
28429,,chronic central serous chorioretinopathy,,,,,,,,,,,,,,,,
28430,,trauma related disorders,,,,,,,,,,,,,,,,
28431,,health,,,,,,,,,,,,,,,,
28432,,tumour spread,,,,,,,,,,,,,,,,
28433,,congenital nonhaemolytic hyperbilirubinemia,,,,,,,,,,,,,,,,
28434,,postoperative platinum therapy,,,,,,,,,,,,,,,,
28435,,symptomatic covid-19 cases,,,,,,,,,,,,,,,,
28436,,cor pulmonale,,,,,,,,,,,,,,,,
28437,,nocturnal pain,,,,,,,,,,,,,,,,
28438,,hepatitis b virus deoxyribonucleic acid,,,,,,,,,,,,,,,,
28439,,keratoconjunctivitis sicca,,,,,,,,,,,,,,,,
28440,,intravenous drug users|consume,,,,,,,,,,,,,,,,
28441,,indemnities,,,,,,,,,,,,,,,,
28442,,clinical instability,,,,,,,,,,,,,,,,
28443,,hemolysis,,,,,,,,,,,,,,,,
28444,,needing bowel resection,,,,,,,,,,,,,,,,
28445,,nasopharyngeal swab,,,,,,,,,,,,,,,,
28446,,regular menstrual cycle,,,,,,,,,,,,,,,,
28447,,ocular chemical injury,,,,,,,,,,,,,,,,
28448,,pose addiitonal risk,,,,,,,,,,,,,,,,
28449,,sensorineural deafness,,,,,,,,,,,,,,,,
28450,,decreased myocardial contractility,,,,,,,,,,,,,,,,
28451,,skin carcinoma,,,,,,,,,,,,,,,,
28452,,ligament injury,,,,,,,,,,,,,,,,
28453,,gilbert-meulengracht syndrome);(3,,,,,,,,,,,,,,,,
28454,,axillary staging,,,,,,,,,,,,,,,,
28455,,coronary artery disease symptoms,,,,,,,,,,,,,,,,
28456,,abnormal wave band is found in electrocardiogram;|indoor baseline blood oxygen saturation>92%;|total bilirubin,,,,,,,,,,,,,,,,
28457,,hypotermic circulation arrest,,,,,,,,,,,,,,,,
28458,,intestinal obstruction,,,,,,,,,,,,,,,,
28459,,substance abuse|participation in other clinical trials,,,,,,,,,,,,,,,,
28460,,residence in veranópolis,,,,,,,,,,,,,,,,
28461,,extensive armpit,,,,,,,,,,,,,,,,
28462,,dp,,,,,,,,,,,,,,,,
28463,,psychosomatic diseases,,,,,,,,,,,,,,,,
28464,,gynecological cancer|having internet,,,,,,,,,,,,,,,,
28465,,appendicitis,,,,,,,,,,,,,,,,
28466,,health care medicines,,,,,,,,,,,,,,,,
28467,,ectodermal dysplasia,,,,,,,,,,,,,,,,
28468,,epidermoid,,,,,,,,,,,,,,,,
28469,,diseases of the blood,,,,,,,,,,,,,,,,
28470,,hot,,,,,,,,,,,,,,,,
28471,,judged by the investigator to be likely to interfere with the accurate administration and interpretation of protocol,,,,,,,,,,,,,,,,
28472,,transient visual obscurations,,,,,,,,,,,,,,,,
28473,,infection,,,,,,,,,,,,,,,,
28474,,systemic problems,,,,,,,,,,,,,,,,
28475,,parkinson's disease hoehn,,,,,,,,,,,,,,,,
28476,,paris classification|colorectal lesions,,,,,,,,,,,,,,,,
28477,,nvaf,,,,,,,,,,,,,,,,
28478,,radical basal cell carcinoma,,,,,,,,,,,,,,,,
28479,,before covid-19 infection,,,,,,,,,,,,,,,,
28480,,physical altercations.|participants,,,,,,,,,,,,,,,,
28481,,collagen disorders,,,,,,,,,,,,,,,,
28482,,increased loads,,,,,,,,,,,,,,,,
28483,,diabetes.|treatment,,,,,,,,,,,,,,,,
28484,,bisphosphonates.|vertebral fracture,,,,,,,,,,,,,,,,
28485,,osteochondrosis,,,,,,,,,,,,,,,,
28486,,gastric outlet obstruction|abdominal fistula,,,,,,,,,,,,,,,,
28487,,acute adrenal insufficiency etc.);|adults,,,,,,,,,,,,,,,,
28488,,myocardial obstruction,,,,,,,,,,,,,,,,
28489,,acute severe infection,,,,,,,,,,,,,,,,
28490,,hypertensive disease,,,,,,,,,,,,,,,,
28491,,peripheral nerve injuries,,,,,,,,,,,,,,,,
28492,,to：||hiv infected (,,,,,,,,,,,,,,,,
28493,,early breast cancer|inability to take,,,,,,,,,,,,,,,,
28494,,hypertension|celiac disease,,,,,,,,,,,,,,,,
28495,,liver malignant tumors,,,,,,,,,,,,,,,,
28496,,myocardial infarction|known,,,,,,,,,,,,,,,,
28497,,squamous cell carcinoma of aerodigestive,,,,,,,,,,,,,,,,
28498,,lytic lesions,,,,,,,,,,,,,,,,
28499,,non compensated,,,,,,,,,,,,,,,,
28500,,hemoptysis symptoms,,,,,,,,,,,,,,,,
28501,,lower limb hemiparesis,,,,,,,,,,,,,,,,
28502,,rotator cuff tear group,,,,,,,,,,,,,,,,
28503,,surgical contraindications,,,,,,,,,,,,,,,,
28504,,anti- seizure,,,,,,,,,,,,,,,,
28505,,macrovascular tumor,,,,,,,,,,,,,,,,
28506,,clinically demonstrable,,,,,,,,,,,,,,,,
28507,,tavi complication,,,,,,,,,,,,,,,,
28508,,end organ,,,,,,,,,,,,,,,,
28509,,exception of,,,,,,,,,,,,,,,,
28510,,ocular dryness,,,,,,,,,,,,,,,,
28511,,poor ovarian response,,,,,,,,,,,,,,,,
28512,,hiv]/acquired immunodeficiency syndrome,,,,,,,,,,,,,,,,
28513,,tuberous sclerosis,,,,,,,,,,,,,,,,
28514,,major cognitive disorder,,,,,,,,,,,,,,,,
28515,,detectable hepatitis b virus,,,,,,,,,,,,,,,,
28516,,second cancers,,,,,,,,,,,,,,,,
28517,,infection|symptomatic congestive heart failure|unstable angina pectoris|cardiac,,,,,,,,,,,,,,,,
28518,,hostility,,,,,,,,,,,,,,,,
28519,,hemolysis|psoriasis,,,,,,,,,,,,,,,,
28520,,hiv-aids,,,,,,,,,,,,,,,,
28521,,acupressure,,,,,,,,,,,,,,,,
28522,,signs of hypoperfusion,,,,,,,,,,,,,,,,
28523,,paroxysmal atrial fibrillation,,,,,,,,,,,,,,,,
28524,,regurgitation of the mitral,,,,,,,,,,,,,,,,
28525,,healing,,,,,,,,,,,,,,,,
28526,,c.|hiv-infected,,,,,,,,,,,,,,,,
28527,,prosthetic joint infection,,,,,,,,,,,,,,,,
28528,,chronic alcohol,,,,,,,,,,,,,,,,
28529,,basal cell,,,,,,,,,,,,,,,,
28530,,myeloproliferative neoplasm,,,,,,,,,,,,,,,,
28531,,communication barrier and|do not volunteer,,,,,,,,,,,,,,,,
28532,,urinary fistula,,,,,,,,,,,,,,,,
28533,,percutaneous left atrial appendage occlusion,,,,,,,,,,,,,,,,
28534,,psychological symptoms,,,,,,,,,,,,,,,,
28535,,bone metastasis.|receive nasogastric tube,,,,,,,,,,,,,,,,
28536,,tense,,,,,,,,,,,,,,,,
28537,,paediatric malignancy,,,,,,,,,,,,,,,,
28538,,acute congestive heart failure,,,,,,,,,,,,,,,,
28539,,bariatric surgery|high,,,,,,,,,,,,,,,,
28540,,pelvic radiation.|patients,,,,,,,,,,,,,,,,
28541,,hiv antibody,,,,,,,,,,,,,,,,
28542,,traffic injuries|coagulation disorders,,,,,,,,,,,,,,,,
28543,,eligible.||active autoimmune disease,,,,,,,,,,,,,,,,
28544,,abnormal liver,,,,,,,,,,,,,,,,
28545,,herpes simplex infection,,,,,,,,,,,,,,,,
28546,,musculoskeletal disorder,,,,,,,,,,,,,,,,
28547,,pain management.|received,,,,,,,,,,,,,,,,
28548,,incidental,,,,,,,,,,,,,,,,
28549,,treatment)|alk rearrangements,,,,,,,,,,,,,,,,
28550,,oral ulcerations,,,,,,,,,,,,,,,,
28551,,antibodies.|infectious disease,,,,,,,,,,,,,,,,
28552,,psychiatric disease,,,,,,,,,,,,,,,,
28553,,hospitalization|diagnosis,,,,,,,,,,,,,,,,
28554,,contraceptive sponges,,,,,,,,,,,,,,,,
28555,,abnormal muscle tension,,,,,,,,,,,,,,,,
28556,,side effects,,,,,,,,,,,,,,,,
28557,,philipps dreamstation,,,,,,,,,,,,,,,,
28558,,autoimmune disease|positive human immunodeficiency virus,,,,,,,,,,,,,,,,
28559,,adjustment of dosage,,,,,,,,,,,,,,,,
28560,,study|significant,,,,,,,,,,,,,,,,
28561,,superficial eac,,,,,,,,,,,,,,,,
28562,,judged by the researchers,,,,,,,,,,,,,,,,
28563,,colpo,,,,,,,,,,,,,,,,
28564,,acute leukemia.|approval,,,,,,,,,,,,,,,,
28565,,diopter|visual,,,,,,,,,,,,,,,,
28566,,brain trauma,,,,,,,,,,,,,,,,
28567,,amplification|measurable disease,,,,,,,,,,,,,,,,
28568,,spinal cord disease;|pregnancy,,,,,,,,,,,,,,,,
28569,,virginal,,,,,,,,,,,,,,,,
28570,,her2 overexpression by,,,,,,,,,,,,,,,,
28571,,available archival tumor,,,,,,,,,,,,,,,,
28572,,colonography,,,,,,,,,,,,,,,,
28573,,attention deficit hyperactivity disorder,,,,,,,,,,,,,,,,
28574,,knee oa|candidate,,,,,,,,,,,,,,,,
28575,,gynecologic cancer,,,,,,,,,,,,,,,,
28576,,hydrogen peroxide sensitivity,,,,,,,,,,,,,,,,
28577,,cytopenia,,,,,,,,,,,,,,,,
28578,,mycobacterial species,,,,,,,,,,,,,,,,
28579,,non-fluent speakers of the english language||tt genotype,,,,,,,,,,,,,,,,
28580,,impaired organ perfusion,,,,,,,,,,,,,,,,
28581,,chronic anemia,,,,,,,,,,,,,,,,
28582,,fibrous histiocytoma,,,,,,,,,,,,,,,,
28583,,mc1r positivity,,,,,,,,,,,,,,,,
28584,,headaches|history of cancer,,,,,,,,,,,,,,,,
28585,,pca,,,,,,,,,,,,,,,,
28586,,active lesions,,,,,,,,,,,,,,,,
28587,,weeks.|symptomatic central nervous system metastases.|the toxicity of previous anti-tumor therapy,,,,,,,,,,,,,,,,
28588,,disease|not allergic,,,,,,,,,,,,,,,,
28589,,primary al amyloidosis.|major surgery,,,,,,,,,,,,,,,,
28590,,ability to read,,,,,,,,,,,,,,,,
28591,,adverse events,,,,,,,,,,,,,,,,
28592,,chronic musculoskeletal pain,,,,,,,,,,,,,,,,
28593,,drinking days,,,,,,,,,,,,,,,,
28594,,hemodynamics,,,,,,,,,,,,,,,,
28595,,spinal cord stimulators,,,,,,,,,,,,,,,,
28596,,acquired pneumonia,,,,,,,,,,,,,,,,
28597,,crohn's disease.|patients,,,,,,,,,,,,,,,,
28598,,high normal bp,,,,,,,,,,,,,,,,
28599,,drug-induced seizure,,,,,,,,,,,,,,,,
28600,,hla typing);|normal suprapubic,,,,,,,,,,,,,,,,
28601,,mild abnormalities,,,,,,,,,,,,,,,,
28602,,ischemia of the lower limbs|patient already,,,,,,,,,,,,,,,,
28603,,aortic valve stenosis|pregnant,,,,,,,,,,,,,,,,
28604,,restrictive lung diseases.|all,,,,,,,,,,,,,,,,
28605,,pleural effusion.|patients,,,,,,,,,,,,,,,,
28606,,progressive lymphadenopathy|progressive lymphocytosis,,,,,,,,,,,,,,,,
28607,,lack of diagnosis,,,,,,,,,,,,,,,,
28608,,acute sepsis,,,,,,,,,,,,,,,,
28609,,extrahepatic oligometastasis,,,,,,,,,,,,,,,,
28610,,interdental periodontal,,,,,,,,,,,,,,,,
28611,,extramedullary leukemia,,,,,,,,,,,,,,,,
28612,,primary atrial septal defect,,,,,,,,,,,,,,,,
28613,,1)clinical,,,,,,,,,,,,,,,,
28614,,terminal ill,,,,,,,,,,,,,,,,
28615,,developmental retardation,,,,,,,,,,,,,,,,
28616,,hepatitis c|known systemic hypersensitivity,,,,,,,,,,,,,,,,
28617,,negative tumors,,,,,,,,,,,,,,,,
28618,,neurological disease,,,,,,,,,,,,,,,,
28619,,impaired cardiac,,,,,,,,,,,,,,,,
28620,,multiple endocrine neoplasia type 1.|use,,,,,,,,,,,,,,,,
28621,,psychiatrically stable,,,,,,,,,,,,,,,,
28622,,nuclear medicine (pet/ct,,,,,,,,,,,,,,,,
28623,,shunt|inability,,,,,,,,,,,,,,,,
28624,,heart rate<50,,,,,,,,,,,,,,,,
28625,,first ischemic stroke,,,,,,,,,,,,,,,,
28626,,visual disorders,,,,,,,,,,,,,,,,
28627,,"cardiac comorbidity,|neurological",,,,,,,,,,,,,,,,
28628,,fibrotic interstitial lung disease,,,,,,,,,,,,,,,,
28629,,damage,,,,,,,,,,,,,,,,
28630,,recurrent ischemic stroke,,,,,,,,,,,,,,,,
28631,,guidelines|lack of,,,,,,,,,,,,,,,,
28632,,endocrinological disorders,,,,,,,,,,,,,,,,
28633,,urinary tract abnormalities|current uti|using phexxi,,,,,,,,,,,,,,,,
28634,,dizziness|visual,,,,,,,,,,,,,,,,
28635,,chronic kidney disease epidemiology collaboration (ckd-epi) hba1c,,,,,,,,,,,,,,,,
28636,,non-atherosclerotic renal artery stenosis;|pregnancy,,,,,,,,,,,,,,,,
28637,,uncorrectable hearing,,,,,,,,,,,,,,,,
28638,,liver disease|previous gastric bypass,,,,,,,,,,,,,,,,
28639,,ophthalmologic abnormality|any other condition,,,,,,,,,,,,,,,,
28640,,thoracic trauma,,,,,,,,,,,,,,,,
28641,,heterosexual,,,,,,,,,,,,,,,,
28642,,covid-19 infected,,,,,,,,,,,,,,,,
28643,,anaesthetic consultants,,,,,,,,,,,,,,,,
28644,,cardial insufficency|long term oxgenation therapy|immobility|bmi,,,,,,,,,,,,,,,,
28645,,subacute infection,,,,,,,,,,,,,,,,
28646,,unknow pregnancy status,,,,,,,,,,,,,,,,
28647,,immune dysfunction,,,,,,,,,,,,,,,,
28648,,bronchospastic disease,,,,,,,,,,,,,,,,
28649,,breast.|macroscopic intravascular invasion into,,,,,,,,,,,,,,,,
28650,,histories,,,,,,,,,,,,,,,,
28651,,significant hemorrhage,,,,,,,,,,,,,,,,
28652,,liver metastases ast,,,,,,,,,,,,,,,,
28653,,gout|active gallstone disease,,,,,,,,,,,,,,,,
28654,,opioids|allergy,,,,,,,,,,,,,,,,
28655,,chronic inflammatory diseases (ibds,,,,,,,,,,,,,,,,
28656,,neurosensory disorder,,,,,,,,,,,,,,,,
28657,,n20 cortical response,,,,,,,,,,,,,,,,
28658,,orthopedic disability,,,,,,,,,,,,,,,,
28659,,weight- loss treatment,,,,,,,,,,,,,,,,
28660,,portal lymph nodes,,,,,,,,,,,,,,,,
28661,,contraindicating canakinumab,,,,,,,,,,,,,,,,
28662,,trap sequence,,,,,,,,,,,,,,,,
28663,,squamous cell cancer,,,,,,,,,,,,,,,,
28664,,right hepatic artery anatomy,,,,,,,,,,,,,,,,
28665,,breastfeeding|infectious disease,,,,,,,,,,,,,,,,
28666,,respiratory tract infection,,,,,,,,,,,,,,,,
28667,,coagulopathic disorder,,,,,,,,,,,,,,,,
28668,,bleeding||active brain metastases,,,,,,,,,,,,,,,,
28669,,carotid stenosis,,,,,,,,,,,,,,,,
28670,,robertsonian translocation trisomy,,,,,,,,,,,,,,,,
28671,,thrombotic events)|unable,,,,,,,,,,,,,,,,
28672,,percutaneous transhepatic biliary drainage|patients,,,,,,,,,,,,,,,,
28673,,breast feeding|reliable severe malnutrition|patient,,,,,,,,,,,,,,,,
28674,,flash pulmonary edema,,,,,,,,,,,,,,,,
28675,,asd,,,,,,,,,,,,,,,,
28676,,refractory chronic cough,,,,,,,,,,,,,,,,
28677,,acute illnesses,,,,,,,,,,,,,,,,
28678,,traumatic brain injury (tbi),,,,,,,,,,,,,,,,
28679,,chronic disease|allergy,,,,,,,,,,,,,,,,
28680,,human immunodeficiency virus (hiv) infection,,,,,,,,,,,,,,,,
28681,,alveolitis,,,,,,,,,,,,,,,,
28682,,clinical dementia,,,,,,,,,,,,,,,,
28683,,metabolic disorders,,,,,,,,,,,,,,,,
28684,,creutzfeldt jakob disease,,,,,,,,,,,,,,,,
28685,,secondary obesity,,,,,,,,,,,,,,,,
28686,,thymoma,,,,,,,,,,,,,,,,
28687,,talcahuano cities|demonstrable ability,,,,,,,,,,,,,,,,
28688,,immunosuppressed patients)|inability to give informed consent,,,,,,,,,,,,,,,,
28689,,"breast cancer before,||",,,,,,,,,,,,,,,,
28690,,gy,,,,,,,,,,,,,,,,
28691,,jak2 v617f,,,,,,,,,,,,,,,,
28692,,urinary frequency,,,,,,,,,,,,,,,,
28693,,alcohol withdrawal;|presence,,,,,,,,,,,,,,,,
28694,,complex rd,,,,,,,,,,,,,,,,
28695,,understands non-infectious risks associated with fmt administration,,,,,,,,,,,,,,,,
28696,,germ cell tumors,,,,,,,,,,,,,,,,
28697,,reproductive age.||,,,,,,,,,,,,,,,,
28698,,unstable mental,,,,,,,,,,,,,,,,
28699,,incidental prostate cancer,,,,,,,,,,,,,,,,
28700,,meetings,,,,,,,,,,,,,,,,
28701,,mean diastolic blood pressure,,,,,,,,,,,,,,,,
28702,,drainage of,,,,,,,,,,,,,,,,
28703,,label|diagnosis,,,,,,,,,,,,,,,,
28704,,degenerative diseases,,,,,,,,,,,,,,,,
28705,,abdominoperineal resection,,,,,,,,,,,,,,,,
28706,,disease|residents,,,,,,,,,,,,,,,,
28707,,1-,,,,,,,,,,,,,,,,
28708,,epithelial ovarian cancer,,,,,,,,,,,,,,,,
28709,,york.|allergy,,,,,,,,,,,,,,,,
28710,,sis ≤4|not understanding the italian language|patients,,,,,,,,,,,,,,,,
28711,,cannabis dependence,,,,,,,,,,,,,,,,
28712,,non-study ett|declined,,,,,,,,,,,,,,,,
28713,,disease|symptomatic,,,,,,,,,,,,,,,,
28714,,percutaneous transluminal coronary,,,,,,,,,,,,,,,,
28715,,digestive tract disease,,,,,,,,,,,,,,,,
28716,,progressive on therapy,,,,,,,,,,,,,,,,
28717,,sinus node disease,,,,,,,,,,,,,,,,
28718,,glucose control);|mental retardation,,,,,,,,,,,,,,,,
28719,,spleen abscess,,,,,,,,,,,,,,,,
28720,,right-dominant,,,,,,,,,,,,,,,,
28721,,bronchiolitis||,,,,,,,,,,,,,,,,
28722,,neurological damage,,,,,,,,,,,,,,,,
28723,,truncus arteriosus,,,,,,,,,,,,,,,,
28724,,gastrointestinal (gi) disorder,,,,,,,,,,,,,,,,
28725,,head trauma.|the participant,,,,,,,,,,,,,,,,
28726,,successive therapeutic lines,,,,,,,,,,,,,,,,
28727,,shwannoma,,,,,,,,,,,,,,,,
28728,,ret fusion,,,,,,,,,,,,,,,,
28729,,image loss,,,,,,,,,,,,,,,,
28730,,uc,,,,,,,,,,,,,,,,
28731,,malignant tumor pathology,,,,,,,,,,,,,,,,
28732,,mandibular posterior teeth|overall,,,,,,,,,,,,,,,,
28733,,medical claim,,,,,,,,,,,,,,,,
28734,,cd22-directed therapy,,,,,,,,,,,,,,,,
28735,,another type of electrical device,,,,,,,,,,,,,,,,
28736,,canal inflammation,,,,,,,,,,,,,,,,
28737,,exercise.)||,,,,,,,,,,,,,,,,
28738,,chromosomic anomaly|fetal demise|patient under legal protection|poor understanding of the french language,,,,,,,,,,,,,,,,
28739,,parasitic infestation)|hepatocellular carcinoma||infiltrative disorders,,,,,,,,,,,,,,,,
28740,,neuropsychiatric diseases,,,,,,,,,,,,,,,,
28741,,aids,,,,,,,,,,,,,,,,
28742,,acute major vascular compromise,,,,,,,,,,,,,,,,
28743,,stickler syndrome,,,,,,,,,,,,,,,,
28744,,nervous system disease,,,,,,,,,,,,,,,,
28745,,coagulation disorders,,,,,,,,,,,,,,,,
28746,,oc,,,,,,,,,,,,,,,,
28747,,dehisced wound,,,,,,,,,,,,,,,,
28748,,hiv)|active tuberculosis,,,,,,,,,,,,,,,,
28749,,hypospadias.||,,,,,,,,,,,,,,,,
28750,,thrombus residues,,,,,,,,,,,,,,,,
28751,,"consent,|severe visual impairment",,,,,,,,,,,,,,,,
28752,,blood phobia,,,,,,,,,,,,,,,,
28753,,adverse reaction,,,,,,,,,,,,,,,,
28754,,gastrointestinal tumor surgery,,,,,,,,,,,,,,,,
28755,,elite athlete|nonsmokers|able to read,,,,,,,,,,,,,,,,
28756,,sensitive neuropathy,,,,,,,,,,,,,,,,
28757,,reduced immune,,,,,,,,,,,,,,,,
28758,,traumatic patellar dislocation|had,,,,,,,,,,,,,,,,
28759,,tumor of the type,,,,,,,,,,,,,,,,
28760,,good periodontal health,,,,,,,,,,,,,,,,
28761,,language barrier,,,,,,,,,,,,,,,,
28762,,unilateral disease,,,,,,,,,,,,,,,,
28763,,non-reader,,,,,,,,,,,,,,,,
28764,,hfov,,,,,,,,,,,,,,,,
28765,,chronic widespread pain,,,,,,,,,,,,,,,,
28766,,acute coronary syndrome;|preoperative,,,,,,,,,,,,,,,,
28767,,interstitial pneumonia,,,,,,,,,,,,,,,,
28768,,screening|anemia,,,,,,,,,,,,,,,,
28769,,conditions:||neuralgia,,,,,,,,,,,,,,,,
28770,,systolic,,,,,,,,,,,,,,,,
28771,,nicotine gum,,,,,,,,,,,,,,,,
28772,,personality dysfunction,,,,,,,,,,,,,,,,
28773,,hebrew native,,,,,,,,,,,,,,,,
28774,,nervosa|owns,,,,,,,,,,,,,,,,
28775,,organic mental syndrome,,,,,,,,,,,,,,,,
28776,,cardiovascular diseases,,,,,,,,,,,,,,,,
28777,,urination|those,,,,,,,,,,,,,,,,
28778,,hf decompensation,,,,,,,,,,,,,,,,
28779,,static compression therapy,,,,,,,,,,,,,,,,
28780,,bronchopulmonary dysplasia (bpd),,,,,,,,,,,,,,,,
28781,,squatting||,,,,,,,,,,,,,,,,
28782,,heamodiafiltration - treatment)der modtager hd- eller hæmodiafiltrationsbehandling,,,,,,,,,,,,,,,,
28783,,tumor pathology,,,,,,,,,,,,,,,,
28784,,hepatic cirrhosis,,,,,,,,,,,,,,,,
28785,,interferons,,,,,,,,,,,,,,,,
28786,,toxin treatment;|contraindication,,,,,,,,,,,,,,,,
28787,,mild traumatic injury,,,,,,,,,,,,,,,,
28788,,left side heart interventional procedures,,,,,,,,,,,,,,,,
28789,,participation muscle,,,,,,,,,,,,,,,,
28790,,inhalations|arterial hypotension,,,,,,,,,,,,,,,,
28791,,mri contraindication.|pregnancy,,,,,,,,,,,,,,,,
28792,,malaria,,,,,,,,,,,,,,,,
28793,,arrhythmia|myocardial infarction,,,,,,,,,,,,,,,,
28794,,recessive inheritance patterns,,,,,,,,,,,,,,,,
28795,,"singleton birth,|no pre-existing",,,,,,,,,,,,,,,,
28796,,profound hearing loss,,,,,,,,,,,,,,,,
28797,,rare solid tumors,,,,,,,,,,,,,,,,
28798,,subarachnoid,,,,,,,,,,,,,,,,
28799,,pre-menopausal status,,,,,,,,,,,,,,,,
28800,,sinus rhythm,,,,,,,,,,,,,,,,
28801,,chronic pain treatment,,,,,,,,,,,,,,,,
28802,,ventricular septal defect,,,,,,,,,,,,,,,,
28803,,fetal heart,,,,,,,,,,,,,,,,
28804,,-gestational diabetes,,,,,,,,,,,,,,,,
28805,,valvular heart disease|heavy,,,,,,,,,,,,,,,,
28806,,disability|previous,,,,,,,,,,,,,,,,
28807,,combined immunodeficiency,,,,,,,,,,,,,,,,
28808,,glp-1ra,,,,,,,,,,,,,,,,
28809,,lipid disorder,,,,,,,,,,,,,,,,
28810,,tumor necrosis factor alpha,,,,,,,,,,,,,,,,
28811,,t-cell,,,,,,,,,,,,,,,,
28812,,hyperthyroidism|infertility,,,,,,,,,,,,,,,,
28813,,changes in chest imaging,,,,,,,,,,,,,,,,
28814,,age;|left-handed,,,,,,,,,,,,,,,,
28815,,non-melanoma basal,,,,,,,,,,,,,,,,
28816,,emotional-behavioral disturbance,,,,,,,,,,,,,,,,
28817,,general criteria||skin conditions,,,,,,,,,,,,,,,,
28818,,qrs complex tachycardia,,,,,,,,,,,,,,,,
28819,,compressive causes,,,,,,,,,,,,,,,,
28820,,paraganglioma,,,,,,,,,,,,,,,,
28821,,increased intracranial pressure|pregnant,,,,,,,,,,,,,,,,
28822,,gastrointestinal (gi) tract illness,,,,,,,,,,,,,,,,
28823,,blance disorders,,,,,,,,,,,,,,,,
28824,,wound infiltration|nonelective procedures|pregnancy,,,,,,,,,,,,,,,,
28825,,sodium stearyl fumarate,,,,,,,,,,,,,,,,
28826,,individual,,,,,,,,,,,,,,,,
28827,,esophageal obstruction,,,,,,,,,,,,,,,,
28828,,older|self-reporting subjective cognitive complaints,,,,,,,,,,,,,,,,
28829,,main symptoms,,,,,,,,,,,,,,,,
28830,,subaxial cervical spine injuries,,,,,,,,,,,,,,,,
28831,,impaired renal function;|patients,,,,,,,,,,,,,,,,
28832,,90%|concomitant pathology,,,,,,,,,,,,,,,,
28833,,acute diarrhea)|chronic gastrointestinal disease,,,,,,,,,,,,,,,,
28834,,mental health,,,,,,,,,,,,,,,,
28835,,endothelial decompensation,,,,,,,,,,,,,,,,
28836,,pathological uip type/possible,,,,,,,,,,,,,,,,
28837,,nuclear perfusion|primary cardiologist enrolled,,,,,,,,,,,,,,,,
28838,,tuberculosis dispensary,,,,,,,,,,,,,,,,
28839,,lymphoma cells,,,,,,,,,,,,,,,,
28840,,burned,,,,,,,,,,,,,,,,
28841,,hemolytic anemias,,,,,,,,,,,,,,,,
28842,,menstrual discomfort,,,,,,,,,,,,,,,,
28843,,hypotension)|acute kidney injury,,,,,,,,,,,,,,,,
28844,,hbsoarab)|age,,,,,,,,,,,,,,,,
28845,,unmanaged hepatitis infection)|be,,,,,,,,,,,,,,,,
28846,,head or neck,,,,,,,,,,,,,,,,
28847,,to:||fatigue|alopecia|skin disorders|stable neuropathy|endocrinopathies,,,,,,,,,,,,,,,,
28848,,bacterial illness,,,,,,,,,,,,,,,,
28849,,suspiciousness,,,,,,,,,,,,,,,,
28850,,geographic region recorded,,,,,,,,,,,,,,,,
28851,,contraindicate contact lens,,,,,,,,,,,,,,,,
28852,,non-cns disease,,,,,,,,,,,,,,,,
28853,,deep brain stimulator)|cognitive disability,,,,,,,,,,,,,,,,
28854,,screening.|seizure disorder,,,,,,,,,,,,,,,,
28855,,balance impairments,,,,,,,,,,,,,,,,
28856,,participants||surgically sterilized,,,,,,,,,,,,,,,,
28857,,date);||immunosuppressive diseases,,,,,,,,,,,,,,,,
28858,,olecranon type fracture,,,,,,,,,,,,,,,,
28859,,deep-seated abscesses,,,,,,,,,,,,,,,,
28860,,adjuvant radiation,,,,,,,,,,,,,,,,
28861,,developmental deformity.|good oral,,,,,,,,,,,,,,,,
28862,,infiltrative disease,,,,,,,,,,,,,,,,
28863,,comprehensible reasons,,,,,,,,,,,,,,,,
28864,,nonsmoking,,,,,,,,,,,,,,,,
28865,,internal prolapse,,,,,,,,,,,,,,,,
28866,,decisional capacity - legal affairs tip,,,,,,,,,,,,,,,,
28867,,cardiac surgery.|pregnancy.|diseases,,,,,,,,,,,,,,,,
28868,,hemodynamic support drugs,,,,,,,,,,,,,,,,
28869,,hbv(hepatitis b virus,,,,,,,,,,,,,,,,
28870,,acute admission|patient considered by the clinical team to be very,,,,,,,,,,,,,,,,
28871,,rx,,,,,,,,,,,,,,,,
28872,,climbing,,,,,,,,,,,,,,,,
28873,,endometrial cancer.|patients,,,,,,,,,,,,,,,,
28874,,feeling coerced,,,,,,,,,,,,,,,,
28875,,polycystic ovarian morphology)|ha+od|ha+pcom|pcom+od||,,,,,,,,,,,,,,,,
28876,,physical activity modification,,,,,,,,,,,,,,,,
28877,,silica,,,,,,,,,,,,,,,,
28878,,ittp.|participant,,,,,,,,,,,,,,,,
28879,,non-cardiac disease,,,,,,,,,,,,,,,,
28880,,trophic disorders,,,,,,,,,,,,,,,,
28881,,disease|neurological deficit,,,,,,,,,,,,,,,,
28882,,upper extremity catheter-related,,,,,,,,,,,,,,,,
28883,,atrophic,,,,,,,,,,,,,,,,
28884,,breast cancer staging,,,,,,,,,,,,,,,,
28885,,alimentary tract hemorrhage,,,,,,,,,,,,,,,,
28886,,ssp,,,,,,,,,,,,,,,,
28887,,suicidal/homicidal,,,,,,,,,,,,,,,,
28888,,cognitively capable,,,,,,,,,,,,,,,,
28889,,non-reactive hiv-1 antibody,,,,,,,,,,,,,,,,
28890,,stressful events,,,,,,,,,,,,,,,,
28891,,assessments.|temporary resident,,,,,,,,,,,,,,,,
28892,,eneral study]||chronic pain,,,,,,,,,,,,,,,,
28893,,solid organ malignancy,,,,,,,,,,,,,,,,
28894,,complicated pneumonia,,,,,,,,,,,,,,,,
28895,,early-stage cervical,,,,,,,,,,,,,,,,
28896,,bilateral vestibular hypofunction,,,,,,,,,,,,,,,,
28897,,ventricle disease,,,,,,,,,,,,,,,,
28898,,isolation,,,,,,,,,,,,,,,,
28899,,interstitial lung disease;|current,,,,,,,,,,,,,,,,
28900,,neurological conditions|visual,,,,,,,,,,,,,,,,
28901,,hepatitis b.,,,,,,,,,,,,,,,,
28902,,acute inflammatory bowel disease|patients,,,,,,,,,,,,,,,,
28903,,neurological disorder,,,,,,,,,,,,,,,,
28904,,syphilis,,,,,,,,,,,,,,,,
28905,,↓ skin,,,,,,,,,,,,,,,,
28906,,allergic constitution,,,,,,,,,,,,,,,,
28907,,pulmonary enphisema,,,,,,,,,,,,,,,,
28908,,chronic coronary syndrome,,,,,,,,,,,,,,,,
28909,,autonomic abnormalities,,,,,,,,,,,,,,,,
28910,,detect infection,,,,,,,,,,,,,,,,
28911,,radiologic evidence,,,,,,,,,,,,,,,,
28912,,coronary/peripheral artery bypass,,,,,,,,,,,,,,,,
28913,,atherosclerosis;|hypersensitivity,,,,,,,,,,,,,,,,
28914,,stuffy,,,,,,,,,,,,,,,,
28915,,acute medication(s,,,,,,,,,,,,,,,,
28916,,national local laws.||,,,,,,,,,,,,,,,,
28917,,clinical supervisors supervision requirements (ontario,,,,,,,,,,,,,,,,
28918,,chronic lyme disease,,,,,,,,,,,,,,,,
28919,,know hypersensitivity,,,,,,,,,,,,,,,,
28920,,etc;||normal organ function,,,,,,,,,,,,,,,,
28921,,questionnaires,,,,,,,,,,,,,,,,
28922,,investigator|systemic active infection,,,,,,,,,,,,,,,,
28923,,acute complications,,,,,,,,,,,,,,,,
28924,,pericardial disease,,,,,,,,,,,,,,,,
28925,,percutaneous renal biopsy;|subjects,,,,,,,,,,,,,,,,
28926,,surgery|lack of,,,,,,,,,,,,,,,,
28927,,anal intraepithelial neoplasia.|an,,,,,,,,,,,,,,,,
28928,,childrearing potential,,,,,,,,,,,,,,,,
28929,,painful morton s neuroma,,,,,,,,,,,,,,,,
28930,,gastric protectors,,,,,,,,,,,,,,,,
28931,,osteoarthritis of the knee,,,,,,,,,,,,,,,,
28932,,impaired kidney graft function,,,,,,,,,,,,,,,,
28933,,psychological disability,,,,,,,,,,,,,,,,
28934,,acute head injury,,,,,,,,,,,,,,,,
28935,,cn2).|breast cancer,,,,,,,,,,,,,,,,
28936,,uc|uc disease,,,,,,,,,,,,,,,,
28937,,infantile,,,,,,,,,,,,,,,,
28938,,vision deficit,,,,,,,,,,,,,,,,
28939,,deep endometriosis,,,,,,,,,,,,,,,,
28940,,healthy|experienced menopausal,,,,,,,,,,,,,,,,
28941,,polycystic ovaries,,,,,,,,,,,,,,,,
28942,,impaired secretion,,,,,,,,,,,,,,,,
28943,,limit absorption of oral medication.|participant,,,,,,,,,,,,,,,,
28944,,urinary schistosomiasis|bladder,,,,,,,,,,,,,,,,
28945,,adenocarcinoma of the breast,,,,,,,,,,,,,,,,
28946,,endocrine diseases,,,,,,,,,,,,,,,,
28947,,inflammatory pseudotumor,,,,,,,,,,,,,,,,
28948,,chagas disease,,,,,,,,,,,,,,,,
28949,,localized prostate cancer treated,,,,,,,,,,,,,,,,
28950,,world health organization,,,,,,,,,,,,,,,,
28951,,additional anxiety problems,,,,,,,,,,,,,,,,
28952,,cns tumor,,,,,,,,,,,,,,,,
28953,,chronic hemiparesis,,,,,,,,,,,,,,,,
28954,,mycophenolic acids,,,,,,,,,,,,,,,,
28955,,severe hepatic,,,,,,,,,,,,,,,,
28956,,finger abduction in left,,,,,,,,,,,,,,,,
28957,,cardiac rhythm,,,,,,,,,,,,,,,,
28958,,immunodeficiency syndromes|known leptomeningeal metastases|active,,,,,,,,,,,,,,,,
28959,,nasal trauma,,,,,,,,,,,,,,,,
28960,,space occupying,,,,,,,,,,,,,,,,
28961,,bipolar ii,,,,,,,,,,,,,,,,
28962,,speech barrier,,,,,,,,,,,,,,,,
28963,,distant lymph node disease;|patients,,,,,,,,,,,,,,,,
28964,,diverticular disease,,,,,,,,,,,,,,,,
28965,,sapheno-femoral junction (sfj) incompetence,,,,,,,,,,,,,,,,
28966,,resectable,,,,,,,,,,,,,,,,
28967,,temporal pain,,,,,,,,,,,,,,,,
28968,,inflammatory skin conditions|active cold sores,,,,,,,,,,,,,,,,
28969,,kidney transplants.||,,,,,,,,,,,,,,,,
28970,,least stable,,,,,,,,,,,,,,,,
28971,,crion,,,,,,,,,,,,,,,,
28972,,gastrointestinal disorder(s),,,,,,,,,,,,,,,,
28973,,cross hypersensitivity,,,,,,,,,,,,,,,,
28974,,intracranial pathology;|documented pulmonary hypertension;|uncontrolled,,,,,,,,,,,,,,,,
28975,,partial thromboplastin,,,,,,,,,,,,,,,,
28976,,hepatitis b core antibody (hbcab),,,,,,,,,,,,,,,,
28977,,underlying cancer development,,,,,,,,,,,,,,,,
28978,,acute exacerbation of ipf,,,,,,,,,,,,,,,,
28979,,prolonged qt interval time,,,,,,,,,,,,,,,,
28980,,immune complexes,,,,,,,,,,,,,,,,
28981,,genetic disease|difficult congenital malformations,,,,,,,,,,,,,,,,
28982,,active seizures,,,,,,,,,,,,,,,,
28983,,locomotor injuries,,,,,,,,,,,,,,,,
28984,,myasthenia gravis,,,,,,,,,,,,,,,,
28985,,cardiac disease|untreated,,,,,,,,,,,,,,,,
28986,,csid,,,,,,,,,,,,,,,,
28987,,reactogenicity to vaccines,,,,,,,,,,,,,,,,
28988,,∙ m-2.|self-reported,,,,,,,,,,,,,,,,
28989,,cerebral svd,,,,,,,,,,,,,,,,
28990,,tiredness.|muscle,,,,,,,,,,,,,,,,
28991,,squamous cell carcinomas of the skin,,,,,,,,,,,,,,,,
28992,,spinal canal stenosis.|red,,,,,,,,,,,,,,,,
28993,,skin biopsies|use,,,,,,,,,,,,,,,,
28994,,cutting,,,,,,,,,,,,,,,,
28995,,cardiac arhythmia,,,,,,,,,,,,,,,,
28996,,mixed affinity binder for tspo ligands,,,,,,,,,,,,,,,,
28997,,chemoradiation,,,,,,,,,,,,,,,,
28998,,ultrafiltration,,,,,,,,,,,,,,,,
28999,,osteoporosis|paget's disease,,,,,,,,,,,,,,,,
29000,,isolation;|negative interaction,,,,,,,,,,,,,,,,
29001,,air;|cardiac function：left ventricular ejection fraction,,,,,,,,,,,,,,,,
29002,,tardive dyskinesia,,,,,,,,,,,,,,,,
29003,,ecgs,,,,,,,,,,,,,,,,
29004,,inferior wall myocardial infarction,,,,,,,,,,,,,,,,
29005,,ciliary muscle,,,,,,,,,,,,,,,,
29006,,inhalational injury,,,,,,,,,,,,,,,,
29007,,diabetes mellitus)|investigator discretion for safety reasons,,,,,,,,,,,,,,,,
29008,,biliary obstructive disease,,,,,,,,,,,,,,,,
29009,,colitis,,,,,,,,,,,,,,,,
29010,,hypocalcemia,,,,,,,,,,,,,,,,
29011,,ocular disorder,,,,,,,,,,,,,,,,
29012,,language barrier limiting,,,,,,,,,,,,,,,,
29013,,type 2 diabetic,,,,,,,,,,,,,,,,
29014,,anastomosis|subretinal hemorrhage,,,,,,,,,,,,,,,,
29015,,meniscal injury,,,,,,,,,,,,,,,,
29016,,life threatening,,,,,,,,,,,,,,,,
29017,,special communication needs.|pregnancy,,,,,,,,,,,,,,,,
29018,,defective intestinal absorption,,,,,,,,,,,,,,,,
29019,,uln).|excessive caffeine,,,,,,,,,,,,,,,,
29020,,admission|chronic kidney disease (ckd),,,,,,,,,,,,,,,,
29021,,lesions,,,,,,,,,,,,,,,,
29022,,diabetes - hba1c,,,,,,,,,,,,,,,,
29023,,common cognitive complaints,,,,,,,,,,,,,,,,
29024,,atopic eczema,,,,,,,,,,,,,,,,
29025,,comorbidities.|participant,,,,,,,,,,,,,,,,
29026,,resultant hemiparesis,,,,,,,,,,,,,,,,
29027,,respiratory cessation,,,,,,,,,,,,,,,,
29028,,metabolic syndrome,,,,,,,,,,,,,,,,
29029,,lung collapse,,,,,,,,,,,,,,,,
29030,,arterial hypertension||,,,,,,,,,,,,,,,,
29031,,gonadectomy.|diagnosis,,,,,,,,,,,,,,,,
29032,,radiation exposure,,,,,,,,,,,,,,,,
29033,,lower airway diseases,,,,,,,,,,,,,,,,
29034,,deep vein thrombosis|prior treatment,,,,,,,,,,,,,,,,
29035,,systemic immune-mediated illnesses,,,,,,,,,,,,,,,,
29036,,liver cell failure,,,,,,,,,,,,,,,,
29037,,cardiogenic shock;|active bleeding,,,,,,,,,,,,,,,,
29038,,retinal conditions,,,,,,,,,,,,,,,,
29039,,pancreatitis,,,,,,,,,,,,,,,,
29040,,radiotherapy.|comorbidities,,,,,,,,,,,,,,,,
29041,,bleeding disease,,,,,,,,,,,,,,,,
29042,,primary prostate cancer,,,,,,,,,,,,,,,,
29043,,prostatic adenocarcinoma,,,,,,,,,,,,,,,,
29044,,language therapist.||,,,,,,,,,,,,,,,,
29045,,etc.;|risk,,,,,,,,,,,,,,,,
29046,,weight loss interventions,,,,,,,,,,,,,,,,
29047,,mild cognitive impairment (mci),,,,,,,,,,,,,,,,
29048,,azoospermic male,,,,,,,,,,,,,,,,
29049,,mainly,,,,,,,,,,,,,,,,
29050,,vital sign|unable,,,,,,,,,,,,,,,,
29051,,right cheek,,,,,,,,,,,,,,,,
29052,,pituitaritis,,,,,,,,,,,,,,,,
29053,,spms,,,,,,,,,,,,,,,,
29054,,transaxillary thyroidectomy;|benign lesions,,,,,,,,,,,,,,,,
29055,,distal gastrectomy|american society of anesthesiologists,,,,,,,,,,,,,,,,
29056,,line,,,,,,,,,,,,,,,,
29057,,disease assessment|active infection,,,,,,,,,,,,,,,,
29058,,high disease activity,,,,,,,,,,,,,,,,
29059,,non-infectious pneumonitis/interstitial lung disease.|active,,,,,,,,,,,,,,,,
29060,,reconstruction|diagnosis,,,,,,,,,,,,,,,,
29061,,malignancies;|alcohol abusers,,,,,,,,,,,,,,,,
29062,,secondary cancer,,,,,,,,,,,,,,,,
29063,,setting.|other solid tumor,,,,,,,,,,,,,,,,
29064,,arterio,,,,,,,,,,,,,,,,
29065,,sgk,,,,,,,,,,,,,,,,
29066,,multiple sulfatase deficiency,,,,,,,,,,,,,,,,
29067,,temporomandibular joint disorders.|patients,,,,,,,,,,,,,,,,
29068,,type 2 diabetes;|glycated,,,,,,,,,,,,,,,,
29069,,"communication problem,|not",,,,,,,,,,,,,,,,
29070,,pregnancy|acute infections,,,,,,,,,,,,,,,,
29071,,chronic productive cough,,,,,,,,,,,,,,,,
29072,,benign infections,,,,,,,,,,,,,,,,
29073,,tachypnea,,,,,,,,,,,,,,,,
29074,,arthritis|enthesitis-related,,,,,,,,,,,,,,,,
29075,,continuous glucose monitoring (cgm),,,,,,,,,,,,,,,,
29076,,vestibular hypofunction,,,,,,,,,,,,,,,,
29077,,disease deemed not,,,,,,,,,,,,,,,,
29078,,rheumatic disease|doing regular exercise/sports,,,,,,,,,,,,,,,,
29079,,relapse-free,,,,,,,,,,,,,,,,
29080,,severe stenosis,,,,,,,,,,,,,,,,
29081,,deep tissue infection,,,,,,,,,,,,,,,,
29082,,cardio-thoracic surgery,,,,,,,,,,,,,,,,
29083,,weight-loss,,,,,,,,,,,,,,,,
29084,,developmentally disabled,,,,,,,,,,,,,,,,
29085,,pulmonary nodules,,,,,,,,,,,,,,,,
29086,,autoimmune diseases.|known,,,,,,,,,,,,,,,,
29087,,grade osteosarcoma,,,,,,,,,,,,,,,,
29088,,health care products,,,,,,,,,,,,,,,,
29089,,vagotomy|hemodynamic instability|structural heart,,,,,,,,,,,,,,,,
29090,,arthritis manifestations,,,,,,,,,,,,,,,,
29091,,and|behavioral problems causing,,,,,,,,,,,,,,,,
29092,,restrictive pulmonary pathology,,,,,,,,,,,,,,,,
29093,,idiopathic thrombocytopenic purpura)|patient,,,,,,,,,,,,,,,,
29094,,b-cell,,,,,,,,,,,,,,,,
29095,,abnormal clinical chemistry,,,,,,,,,,,,,,,,
29096,,abnormal orgasm,,,,,,,,,,,,,,,,
29097,,clothes)|infiltration,,,,,,,,,,,,,,,,
29098,,autoimmune disease.|8,,,,,,,,,,,,,,,,
29099,,skin irritations,,,,,,,,,,,,,,,,
29100,,hepatic insufficiency,,,,,,,,,,,,,,,,
29101,,personality disorders,,,,,,,,,,,,,,,,
29102,,porto-pulmonary syndrome,,,,,,,,,,,,,,,,
29103,,axillae,,,,,,,,,,,,,,,,
29104,,motor complications|dbs,,,,,,,,,,,,,,,,
29105,,motivation.|having bruxism,,,,,,,,,,,,,,,,
29106,,anterior cruciate ligament injury,,,,,,,,,,,,,,,,
29107,,extra-cardiac ttr amyloidosis,,,,,,,,,,,,,,,,
29108,,non-amyloid disease,,,,,,,,,,,,,,,,
29109,,cognitive impairments sufficient,,,,,,,,,,,,,,,,
29110,,optic disc drusen,,,,,,,,,,,,,,,,
29111,,hemi-neck,,,,,,,,,,,,,,,,
29112,,barrier|fitting,,,,,,,,,,,,,,,,
29113,,exposed vessels,,,,,,,,,,,,,,,,
29114,,menstrual bleeding episodes,,,,,,,,,,,,,,,,
29115,,acute inflammatory disease,,,,,,,,,,,,,,,,
29116,,skin system,,,,,,,,,,,,,,,,
29117,,thyroid disorder|depressive episode,,,,,,,,,,,,,,,,
29118,,eis,,,,,,,,,,,,,,,,
29119,,superficial skin infections,,,,,,,,,,,,,,,,
29120,,skin involvement|evidence,,,,,,,,,,,,,,,,
29121,,hypertension|diagnosis,,,,,,,,,,,,,,,,
29122,,inclusion;||for hfpef,,,,,,,,,,,,,,,,
29123,,ht,,,,,,,,,,,,,,,,
29124,,impact on fatigue.|diagnosis,,,,,,,,,,,,,,,,
29125,,primary teeth.|uncooperative child,,,,,,,,,,,,,,,,
29126,,custodial child,,,,,,,,,,,,,,,,
29127,,gynecological malignancy,,,,,,,,,,,,,,,,
29128,,anal cancer,,,,,,,,,,,,,,,,
29129,,cyanotic congenital heart disease.|patients,,,,,,,,,,,,,,,,
29130,,herpetic keratitis|human leukocyte antigen (hla) typed allograft|pregnancy,,,,,,,,,,,,,,,,
29131,,esami del sangue,,,,,,,,,,,,,,,,
29132,,common diets)|pregnancy,,,,,,,,,,,,,,,,
29133,,heart valve repair,,,,,,,,,,,,,,,,
29134,,human immunodeficiency virus (hiv),,,,,,,,,,,,,,,,
29135,,anterior uveitis.|ocular trauma resulting,,,,,,,,,,,,,,,,
29136,,ltd,,,,,,,,,,,,,,,,
29137,,autoimmune diseases.|diabetes.|hypertention,,,,,,,,,,,,,,,,
29138,,messenger ribonucleic acid,,,,,,,,,,,,,,,,
29139,,required|simultaneous bone augmentation,,,,,,,,,,,,,,,,
29140,,esophageal ph,,,,,,,,,,,,,,,,
29141,,seasonal allergic rhinitis,,,,,,,,,,,,,,,,
29142,,psychiatric disorders;|dementia,,,,,,,,,,,,,,,,
29143,,hiv|hepatitis b infection,,,,,,,,,,,,,,,,
29144,,exudate|able to tolerate,,,,,,,,,,,,,,,,
29145,,medullary disease,,,,,,,,,,,,,,,,
29146,,patellar realignment surgery,,,,,,,,,,,,,,,,
29147,,curatorship|pregnant,,,,,,,,,,,,,,,,
29148,,tortuosity of the brachiocephalic trunk,,,,,,,,,,,,,,,,
29149,,singleton pregnancy.|second trimester.|no contraindications,,,,,,,,,,,,,,,,
29150,,volume difference,,,,,,,,,,,,,,,,
29151,,reliable measurements,,,,,,,,,,,,,,,,
29152,,weight loss|participants,,,,,,,,,,,,,,,,
29153,,non-rhabdomyosarcoma,,,,,,,,,,,,,,,,
29154,,structural brain lesions,,,,,,,,,,,,,,,,
29155,,prostate neuroendocrine carcinoma,,,,,,,,,,,,,,,,
29156,,refractory myeloma,,,,,,,,,,,,,,,,
29157,,aortic valve insufficiency,,,,,,,,,,,,,,,,
29158,,mutant solid tumors,,,,,,,,,,,,,,,,
29159,,alternative syndrome,,,,,,,,,,,,,,,,
29160,,respiratory system,,,,,,,,,,,,,,,,
29161,,substance dependence,,,,,,,,,,,,,,,,
29162,,spinal cord compression,,,,,,,,,,,,,,,,
29163,,alteration of consciousness/mental state,,,,,,,,,,,,,,,,
29164,,isolated syndrome,,,,,,,,,,,,,,,,
29165,,clonal karyotypic abnormalities,,,,,,,,,,,,,,,,
29166,,weeks|spontaneous labor,,,,,,,,,,,,,,,,
29167,,inflammatory disease,,,,,,,,,,,,,,,,
29168,,maxillary sinusitis,,,,,,,,,,,,,,,,
29169,,systolic dysfunction,,,,,,,,,,,,,,,,
29170,,swallowing pills,,,,,,,,,,,,,,,,
29171,,demyelinating diseases,,,,,,,,,,,,,,,,
29172,,breastfeeding|end stage renal disease,,,,,,,,,,,,,,,,
29173,,bilateral subclavian artery stenosis,,,,,,,,,,,,,,,,
29174,,cns infections,,,,,,,,,,,,,,,,
29175,,acute promyelocytic leukaemia,,,,,,,,,,,,,,,,
29176,,factor xii,,,,,,,,,,,,,,,,
29177,,non-smoking status,,,,,,,,,,,,,,,,
29178,,acute coronary,,,,,,,,,,,,,,,,
29179,,speakers,,,,,,,,,,,,,,,,
29180,,colorectal cancer screening,,,,,,,,,,,,,,,,
29181,,acute respiratory failure;|pulmonary consolidation,,,,,,,,,,,,,,,,
29182,,oglethorpe,,,,,,,,,,,,,,,,
29183,,enhancer sequence,,,,,,,,,,,,,,,,
29184,,epidemic typhus,,,,,,,,,,,,,,,,
29185,,kidney disease);|patients,,,,,,,,,,,,,,,,
29186,,neonatal infection,,,,,,,,,,,,,,,,
29187,,locoregional disease,,,,,,,,,,,,,,,,
29188,,alcohol abuse disorder,,,,,,,,,,,,,,,,
29189,,children,,,,,,,,,,,,,,,,
29190,,dvt,,,,,,,,,,,,,,,,
29191,,required|prostate cancer,,,,,,,,,,,,,,,,
29192,,lewy bodies,,,,,,,,,,,,,,,,
29193,,bone marrow infiltration,,,,,,,,,,,,,,,,
29194,,radiation colitis,,,,,,,,,,,,,,,,
29195,,complete bowel obstruction,,,,,,,,,,,,,,,,
29196,,left bundle branch,,,,,,,,,,,,,,,,
29197,,neuropsychiatric disorders,,,,,,,,,,,,,,,,
29198,,hemorrhagic tendency.|14,,,,,,,,,,,,,,,,
29199,,syndrome).|sick sinus syndrome,,,,,,,,,,,,,,,,
29200,,endocrinologic disorders,,,,,,,,,,,,,,,,
29201,,substance abuse||for mri substudy:||inclusion,,,,,,,,,,,,,,,,
29202,,oral health,,,,,,,,,,,,,,,,
29203,,ppu,,,,,,,,,,,,,,,,
29204,,normal|ability,,,,,,,,,,,,,,,,
29205,,pituitary insufficiency);||need,,,,,,,,,,,,,,,,
29206,,hyper-/hypoparathyroidism,,,,,,,,,,,,,,,,
29207,,coronary arteries,,,,,,,,,,,,,,,,
29208,,orthostatic tachycardia,,,,,,,,,,,,,,,,
29209,,acute severe asthma,,,,,,,,,,,,,,,,
29210,,delay of the subsequent doses,,,,,,,,,,,,,,,,
29211,,parathyroid diseases,,,,,,,,,,,,,,,,
29212,,immunohistochemical staining,,,,,,,,,,,,,,,,
29213,,injection site,,,,,,,,,,,,,,,,
29214,,conversion,,,,,,,,,,,,,,,,
29215,,cerebral blood vessels,,,,,,,,,,,,,,,,
29216,,participation|pregnant,,,,,,,,,,,,,,,,
29217,,medication|known allergies,,,,,,,,,,,,,,,,
29218,,dysfunction of heart,,,,,,,,,,,,,,,,
29219,,invasive infection,,,,,,,,,,,,,,,,
29220,,thoracic rt,,,,,,,,,,,,,,,,
29221,,peptic ulcer disease,,,,,,,,,,,,,,,,
29222,,perianal hematoma)|anal stenosis,,,,,,,,,,,,,,,,
29223,,radiculopathy,,,,,,,,,,,,,,,,
29224,,medication|obstructive bowel symptoms,,,,,,,,,,,,,,,,
29225,,b12,,,,,,,,,,,,,,,,
29226,,spinal cord injuries,,,,,,,,,,,,,,,,
29227,,irregularities|amblyopia|anisometropia|coexisting ocular,,,,,,,,,,,,,,,,
29228,,other ophthalmic diseases,,,,,,,,,,,,,,,,
29229,,pembrolizumab.|patients,,,,,,,,,,,,,,,,
29230,,samples,,,,,,,,,,,,,,,,
29231,,hematopoietic abnormality,,,,,,,,,,,,,,,,
29232,,medical conditions stable,,,,,,,,,,,,,,,,
29233,,inflammatory bowel disease|crp level,,,,,,,,,,,,,,,,
29234,,cutaneous stoma;|food allergies;|recent,,,,,,,,,,,,,,,,
29235,,submucosal myoma,,,,,,,,,,,,,,,,
29236,,intracranial internal carotid artery (ica),,,,,,,,,,,,,,,,
29237,,abdominal diastasis,,,,,,,,,,,,,,,,
29238,,sebaceous adenocarcinoma,,,,,,,,,,,,,,,,
29239,,colonic diverticulitis,,,,,,,,,,,,,,,,
29240,,large intestinal ulcerations,,,,,,,,,,,,,,,,
29241,,benign strictures,,,,,,,,,,,,,,,,
29242,,joint united states/european union initiative,,,,,,,,,,,,,,,,
29243,,congenital uterine malformations,,,,,,,,,,,,,,,,
29244,,hereditary bleeding disorders,,,,,,,,,,,,,,,,
29245,,open response,,,,,,,,,,,,,,,,
29246,,vaginal infections,,,,,,,,,,,,,,,,
29247,,movement|balance,,,,,,,,,,,,,,,,
29248,,continuously normal,,,,,,,,,,,,,,,,
29249,,cardiorespiratory disorder,,,,,,,,,,,,,,,,
29250,,brain pathology,,,,,,,,,,,,,,,,
29251,,acute cerebrovascular,,,,,,,,,,,,,,,,
29252,,psychiatric history:||diagnosis,,,,,,,,,,,,,,,,
29253,,progressive marrow failure,,,,,,,,,,,,,,,,
29254,,1;|hepatocellular carcinoma,,,,,,,,,,,,,,,,
29255,,gastrointestinal ulcer disease,,,,,,,,,,,,,,,,
29256,,recurrence of marrow disease,,,,,,,,,,,,,,,,
29257,,neoplasia|chronic pancreatitis|acute pancreatitis,,,,,,,,,,,,,,,,
29258,,contraindication|brain stimulation,,,,,,,,,,,,,,,,
29259,,congenital malformations|antibiotic treatment,,,,,,,,,,,,,,,,
29260,,assessable lesion,,,,,,,,,,,,,,,,
29261,,limited.|diagnosis,,,,,,,,,,,,,,,,
29262,,inflammatory disease|congenital,,,,,,,,,,,,,,,,
29263,,drug resistant,,,,,,,,,,,,,,,,
29264,,mucosal head,,,,,,,,,,,,,,,,
29265,,physical activity|chest pain,,,,,,,,,,,,,,,,
29266,,≥1 pain,,,,,,,,,,,,,,,,
29267,,tinea,,,,,,,,,,,,,,,,
29268,,asociality,,,,,,,,,,,,,,,,
29269,,aptt,,,,,,,,,,,,,,,,
29270,,compensatory behavior,,,,,,,,,,,,,,,,
29271,,neurologic disorder,,,,,,,,,,,,,,,,
29272,,imp.|child-bearing potential,,,,,,,,,,,,,,,,
29273,,allergic reaction,,,,,,,,,,,,,,,,
29274,,significant bowel resection,,,,,,,,,,,,,,,,
29275,,alcoholic liver disease,,,,,,,,,,,,,,,,
29276,,polycythemia,,,,,,,,,,,,,,,,
29277,,judgement|borderline personality disorder,,,,,,,,,,,,,,,,
29278,,cooperated,,,,,,,,,,,,,,,,
29279,,major gastrointestinal tract surgery,,,,,,,,,,,,,,,,
29280,,a2b530,,,,,,,,,,,,,,,,
29281,,intestinal paralysis,,,,,,,,,,,,,,,,
29282,,study medications.|septicemia,,,,,,,,,,,,,,,,
29283,,ventricular septal defects|ventricular assist,,,,,,,,,,,,,,,,
29284,,effects,,,,,,,,,,,,,,,,
29285,,breast cancer (mbc,,,,,,,,,,,,,,,,
29286,,lower respiratory symptoms,,,,,,,,,,,,,,,,
29287,,brain abnormalities,,,,,,,,,,,,,,,,
29288,,"allergy,|not",,,,,,,,,,,,,,,,
29289,,gluten free,,,,,,,,,,,,,,,,
29290,,acute cholecystitis.|refusal,,,,,,,,,,,,,,,,
29291,,acute coronary syndrome|decompensated,,,,,,,,,,,,,,,,
29292,,somatic condition,,,,,,,,,,,,,,,,
29293,,brip1,,,,,,,,,,,,,,,,
29294,,normal physical examination,,,,,,,,,,,,,,,,
29295,,liver condition,,,,,,,,,,,,,,,,
29296,,unstable ischemic cardiovascular disease,,,,,,,,,,,,,,,,
29297,,vasculitic disease,,,,,,,,,,,,,,,,
29298,,non-hodgkin,,,,,,,,,,,,,,,,
29299,,brain vasculitis,,,,,,,,,,,,,,,,
29300,,needle aspiration,,,,,,,,,,,,,,,,
29301,,primary disease,,,,,,,,,,,,,,,,
29302,,stent,,,,,,,,,,,,,,,,
29303,,adequate treatment.|known hiv,,,,,,,,,,,,,,,,
29304,,extruded,,,,,,,,,,,,,,,,
29305,,non-emergent,,,,,,,,,,,,,,,,
29306,,cns arterial vasculitis,,,,,,,,,,,,,,,,
29307,,degenerative joint disease.|patients,,,,,,,,,,,,,,,,
29308,,quincke's edema,,,,,,,,,,,,,,,,
29309,,meningeal metastasis.|expected lifetime,,,,,,,,,,,,,,,,
29310,,atrial septal repair,,,,,,,,,,,,,,,,
29311,,maxillary sinus disease,,,,,,,,,,,,,,,,
